UI/LS -/: 95369245/CD 
TI/LS -/: IL-2/NN gene/NN expression/NN and/CC NF-kappa/NN B/NN activation/NN through/IN CD28/NN requires/VBZ reactive/JJ oxygen/NN production/NN by/IN 5-lipoxygenase/NN ./. 
AB/LS -/: Activation/NN of/IN the/DT CD28/NN surface/NN receptor/NN provides/VBZ a/DT major/JJ costimulatory/JJ signal/NN for/IN T/NN cell/NN activation/NN resulting/VBG in/IN enhanced/VBN production/NN of/IN interleukin-2/NN (/( IL-2/NN )/) and/CC cell/NN proliferation/NN ./. 
In/IN primary/JJ T/NN lymphocytes/NNS we/PRP show/VBP that/IN CD28/NN ligation/NN leads/VBZ to/TO the/DT rapid/JJ intracellular/JJ formation/NN of/IN reactive/JJ oxygen/NN intermediates/NNS (/( ROIs/NNS )/) which/WDT are/VBP required/VBN for/IN CD28-mediated/JJ activation/NN of/IN the/DT NF-kappa/NN B/CD28-responsive/JJ complex/NN and/CC IL-2/NN expression/NN ./. 
Delineation/NN of/IN the/DT CD28/NN signaling/NN cascade/NN was/VBD found/VBN to/TO involve/VB protein/NN tyrosine/NN kinase/NN activity/NN ,/, followed/VBN by/IN the/DT activation/NN of/IN phospholipase/NN A2/NN and/CC 5-lipoxygenase/NN ./. 
Our/PRP$ data/NNS suggest/VBP that/IN lipoxygenase/NN metabolites/NNS activate/VBP ROI/NN formation/NN which/WDT then/RB induce/VBP IL-2/NN expression/NN via/IN NF-kappa/NN B/NN activation/NN ./. 
These/DT findings/NNS should/MD be/VB useful/JJ for/IN therapeutic/JJ strategies/NNS and/CC the/DT development/NN of/IN immunosuppressants/NNS targeting/VBG the/DT CD28/NN costimulatory/NN pathway/NN ./. 
UI/LS -/: 95333264/CD 
TI/LS -/: The/DT peri-kappa/NN B/NN site/NN mediates/VBZ human/JJ immunodeficiency/NN virus/NN type/NN 2/CD enhancer/NN activation/NN in/IN monocytes/NNS but/CC not/RB in/IN T/NN cells/NNS ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus/NN type/NN 2/CD (/( HIV-2/NN )/) ,/, like/IN HIV-1/NN ,/, causes/VBZ AIDS/NN and/CC is/VBZ associated/VBN with/IN AIDS/NN cases/NNS primarily/RB in/IN West/NNP Africa/NNP ./. 
HIV-1/NN and/CC HIV-2/NN display/VBP significant/JJ differences/NNS in/IN nucleic/JJ acid/NN sequence/NN and/CC in/IN the/DT natural/JJ history/NN of/IN clinical/JJ disease/NN ./. 
Consistent/JJ with/IN these/DT differences/NNS ,/, we/PRP have/VBP previously/RB demonstrated/VBN that/IN the/DT enhancer/promoter/NN region/NN of/IN HIV-2/NN functions/VBZ quite/RB differently/RB from/IN that/DT of/IN HIV-1/NN ./. 
Whereas/IN activation/NN of/IN the/DT HIV-1/NN enhancer/NN following/VBG T-cell/NN stimulation/NN is/VBZ mediated/VBN largely/RB through/IN binding/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN to/TO two/CD adjacent/JJ kappa/NN B/NN sites/NNS in/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN ,/, activation/NN of/IN the/DT HIV-2/NN enhancer/NN in/IN monocytes/NNS and/CC T/NN cells/NNS is/VBZ dependent/JJ on/IN four/CD cis-acting/JJ elements/NNS :/: a/DT single/JJ kappa/NN B/NN site/NN ,/, two/CD purine-rich/JJ binding/VBG sites/NNS ,/, PuB1/NN and/CC PuB2/NN ,/, and/CC a/DT pets/NN site/NN ./. 
We/PRP have/VBP now/RB identified/VBN a/DT novel/JJ cis-acting/JJ element/NN within/IN the/DT HIV-2/NN enhancer/NN ,/, immediately/RB upstream/JJ of/IN the/DT kappa/NN B/NN site/NN ,/, designated/VBN peri-kappa/NN B/NN ./. 
This/DT site/NN is/VBZ conserved/VBN among/IN isolates/NNS of/IN HIV-2/NN and/CC the/DT closely/RB related/JJ simian/JJ immunodeficiency/NN virus/NN ,/, and/CC transfection/NN assays/NNS show/VBP this/DT site/NN to/TO mediate/VB HIV-2/NN enhancer/NN activation/NN following/VBG stimulation/NN of/IN monocytic/JJ but/CC not/RB T-cell/NN lines/NNS ./. 
This/DT is/VBZ the/DT first/JJ description/NN of/IN an/DT HIV-2/NN enhancer/NN element/NN which/WDT displays/VBZ such/JJ monocyte/NN specificity/NN ,/, and/CC no/DT comparable/JJ enhancer/NN element/NN has/VBZ been/VBN clearly/RB defined/VBN for/IN HIV-1/NN ./. 
While/IN a/DT nuclear/JJ factor/NN (/( s/NNS )/) from/IN both/CC peripheral/JJ blood/NN monocytes/NNS and/CC T/NN cells/NNS binds/VBZ the/DT peri-kappa/NN B/NN site/NN ,/, electrophoretic/JJ mobility/NN shift/NN assays/NNS suggest/VBP that/IN either/CC a/DT different/JJ protein/NN binds/VBZ to/TO this/DT site/NN in/IN monocytes/NNS versus/CC T/NN cells/NNS or/CC that/IN the/DT protein/NN recognizing/VBG this/DT enhancer/NN element/NN undergoes/VBZ differential/JJ modification/NN in/IN monocytes/NNS and/CC T/NN cells/NNS ,/, thus/RB supporting/VBG the/DT transfection/NN data/NNS ./. 
Further/RB ,/, while/IN specific/JJ constitutive/JJ binding/NN to/TO the/DT peri-kappa/NN B/NN site/NN is/VBZ seen/VBN in/IN monocytes/NNS ,/, stimulation/NN with/IN phorbol/NN esters/NNS induces/VBZ additional/JJ ,/, specific/JJ binding/NN ./. 
Understanding/VBG the/DT monocyte-specific/JJ function/NN of/IN the/DT peri-kappa/NN B/NN factor/NN may/MD ultimately/RB provide/VB insight/NN into/IN the/DT different/JJ role/NN monocytes/NNS and/CC T/NN cells/NNS play/VBP in/IN HIV/NN pathogenesis/NN ./. 
UI/LS -/: 95343554/CD 
TI/LS -/: E1A/NN gene/NN expression/NN induces/VBZ susceptibility/NN to/TO killing/NN by/IN NK/NN cells/NNS following/VBG immortalization/NN but/CC not/RB adenovirus/NN infection/NN of/IN human/JJ cells/NNS ./. 
AB/LS -/: Adenovirus/NN (/( Ad/NN )/) infection/NN and/CC E1A/NN transfection/NN were/VBD used/VBN to/TO model/VB changes/NNS in/IN susceptibility/NN to/TO NK/NN cell/NN killing/NN caused/VBN by/IN transient/JJ vs/CC stable/JJ E1A/NN expression/NN in/IN human/JJ cells/NNS ./. 
Only/RB stably/RB transfected/VBN target/NN cells/NNS exhibited/VBD cytolytic/JJ susceptibility/NN ,/, despite/IN expression/NN of/IN equivalent/JJ levels/NNS of/IN E1A/NN proteins/NNS in/IN Ad-infected/JJ targets/NNS ./. 
The/DT inability/NN of/IN E1A/NN gene/NN products/NNS to/TO induce/VB cytolytic/JJ susceptibility/NN during/IN infection/NN was/VBD not/RB explained/VBN by/IN an/DT inhibitory/JJ effect/NN of/IN viral/JJ infection/NN on/IN otherwise/RB susceptible/JJ target/NN cells/NNS or/CC by/IN viral/JJ gene/NN effects/NNS on/IN class/NN I/CD MHC/NN antigen/NN expression/NN on/IN target/NN cells/NNS ./. 
This/DT differential/JJ effect/NN of/IN E1A/NN expression/NN on/IN the/DT cytolytic/JJ phenotypes/NNS of/IN infected/JJ and/CC stably/RB transfected/VBN human/JJ cells/NNS suggests/VBZ that/IN human/JJ NK/NN cells/NNS provide/VBP an/DT effective/JJ immunologic/JJ barrier/NN against/IN the/DT in/FW vivo/FW survival/NN and/CC neoplastic/JJ progression/NN of/IN E1A-immortalized/JJ cells/NNS that/WDT may/MD emerge/VB from/IN the/DT reservoir/NN of/IN persistently/RB infected/JJ cells/NNS in/IN the/DT human/JJ host/NN ./. 
UI/LS -/: 95347379/CD 
TI/LS -/: Distinct/JJ signaling/NN properties/NNS identify/VBP functionally/RB different/JJ CD4/NN epitopes/NNS ./. 
AB/LS -/: The/DT CD4/NN coreceptor/NN interacts/VBZ with/IN non-polymorphic/JJ regions/NNS of/IN major/JJ histocompatibility/NN complex/NN class/NN II/CD molecules/NNS on/IN antigen-presenting/JJ cells/NNS and/CC contributes/VBZ to/TO T/NN cell/NN activation/NN ./. 
We/PRP have/VBP investigated/VBN the/DT effect/NN of/IN CD4/NN triggering/NN on/IN T/NN cell/NN activating/NN signals/NNS in/IN a/DT lymphoma/NN model/NN using/VBG monoclonal/JJ antibodies/NNS (/( mAb/NN )/) which/WDT recognize/VBP different/JJ CD4/NN epitopes/NNS ./. 
We/PRP demonstrate/VBP that/IN CD4/NN triggering/NN delivers/VBZ signals/NNS capable/JJ of/IN activating/VBG the/DT NF-AT/NN transcription/NN factor/NN which/WDT is/VBZ required/VBN for/IN interleukin-2/NN gene/NN expression/NN ./. 
Whereas/IN different/JJ anti-CD4/JJ mAb/NN or/CC HIV-1/NN gp120/NN could/MD all/DT trigger/VB activation/NN of/IN the/DT protein/NN tyrosine/NN kinases/NNS p56lck/NN and/CC p59fyn/NN and/CC phosphorylation/NN of/IN the/DT Shc/NN adaptor/NN protein/NN ,/, which/WDT mediates/VBZ signals/NNS to/TO Ras/NN ,/, they/PRP differed/VBD significantly/RB in/IN their/PRP$ ability/NN to/TO activate/VB NF-AT/NN ./. 
Lack/NN of/IN full/JJ activation/NN of/IN NF-AT/NN could/MD be/VB correlated/VBN to/TO a/DT dramatically/RB reduced/VBN capacity/NN to/TO induce/VB calcium/NN flux/NN and/CC could/MD be/VB complemented/VBN with/IN a/DT calcium/NN ionophore/NN ./. 
The/DT results/NNS identify/VBP functionally/RB distinct/JJ epitopes/NNS on/IN the/DT CD4/NN coreceptor/NN involved/VBN in/IN activation/NN of/IN the/DT Ras/protein/NN kinase/NN C/NN and/CC calcium/NN pathways/NNS ./. 
UI/LS -/: 95280913/CD 
TI/LS -/: Ligand-dependent/JJ repression/NN of/IN the/DT erythroid/JJ transcription/NN factor/NN GATA-1/NN by/IN the/DT estrogen/NN receptor/NN ./. 
AB/LS -/: High-dose/JJ estrogen/NN administration/NN induces/VBZ anemia/NN in/IN mammals/NNS ./. 
In/IN chickens/NNS ,/, estrogens/NNS stimulate/VBP outgrowth/NN of/IN bone/NN marrow-derived/JJ erythroid/JJ progenitor/NN cells/NNS and/CC delay/VBP their/PRP$ maturation/NN ./. 
This/DT delay/NN is/VBZ associated/VBN with/IN down-regulation/NN of/IN many/JJ erythroid/JJ cell-specific/JJ genes/NNS ,/, including/VBG alpha-/NN and/CC beta-globin/NN ,/, band/NN 3/CD ,/, band/NN 4.1/CD ,/, and/CC the/DT erythroid/JJ cell-specific/JJ histone/NN H5/NN ./. 
We/PRP show/VBP here/RB that/IN estrogens/NNS also/RB reduce/VBP the/DT number/NN of/IN erythroid/JJ progenitor/NN cells/NNS in/IN primary/JJ human/JJ bone/NN marrow/NN cultures/NNS ./. 
To/TO address/VB potential/JJ mechanisms/NNS by/IN which/WDT estrogens/NNS suppress/VBP erythropoiesis/NN ,/, we/PRP have/VBP examined/VBN their/PRP$ effects/NNS on/IN GATA-1/NN ,/, an/DT erythroid/JJ transcription/NN factor/NN that/WDT participates/VBZ in/IN the/DT regulation/NN of/IN the/DT majority/NN of/IN erythroid/JJ cell-specific/JJ genes/NNS and/CC is/VBZ necessary/JJ for/IN full/JJ maturation/NN of/IN erythrocytes/NNS ./. 
We/PRP demonstrate/VBP that/IN the/DT transcriptional/JJ activity/NN of/IN GATA-1/NN is/VBZ strongly/RB repressed/VBN by/IN the/DT estrogen/NN receptor/NN (/( ER/NN )/) in/IN a/DT ligand-dependent/JJ manner/NN and/CC that/IN this/DT repression/NN is/VBZ reversible/JJ in/IN the/DT presence/NN of/IN 4-hydroxytamoxifen/NN ./. 
ER-mediated/JJ repression/NN of/IN GATA-1/NN activity/NN occurs/VBZ on/IN an/DT artificial/JJ promoter/NN containing/VBG a/DT single/JJ GATA-binding/JJ site/NN ,/, as/RB well/RB as/IN in/IN the/DT context/NN of/IN an/DT intact/JJ promoter/NN which/WDT is/VBZ normally/RB regulated/VBN by/IN GATA-1/NN ./. 
GATA-1/NN and/CC ER/NN bind/VBP to/TO each/DT other/JJ in/FW vitro/FW in/IN the/DT absence/NN of/IN DNA/NN ./. 
In/IN coimmunoprecipitation/NN experiments/NNS using/VBG transfected/VBN COS/NN cells/NNS ,/, GATA-1/NN and/CC ER/NN associate/VBP in/IN a/DT ligand-dependent/JJ manner/NN ./. 
Mapping/NN experiments/NNS indicate/VBP that/IN GATA-1/NN and/CC the/DT ER/NN form/VBP at/IN least/JJS two/CD contacts/NNS ,/, which/WDT involve/VBP the/DT finger/NN region/NN and/CC the/DT N-terminal/JJ activation/NN domain/NN of/IN GATA-1/NN ./. 
We/PRP speculate/VBP that/IN estrogens/NNS exert/VBP effects/NNS on/IN erythropoiesis/NN by/IN modulating/VBG GATA-1/NN activity/NN through/IN protein-protein/JJ interaction/NN with/IN the/DT ER/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 95256242/CD 
TI/LS -/: Mouse/NN interleukin-2/NN receptor/NN alpha/NN gene/NN expression/NN ./. 
Interleukin-1/NN and/CC interleukin-2/NN control/VBP transcription/NN via/IN distinct/JJ cis-acting/JJ elements/NNS ./. 
AB/LS -/: We/PRP have/VBP shown/VBN that/IN interleukin-1/NN (/( IL-1/NN )/) and/CC IL-2/NN control/VBP IL-2/NN receptor/NN alpha/NN (/( IL-2R/NN alpha/NN )/) gene/NN transcription/NN in/IN CD4-CD8- murine/JJ T/NN lymphocyte/NN precursors/NNS ./. 
Here/RB we/PRP map/VBP the/DT cis-acting/JJ elements/NNS that/WDT mediate/VBP interleukin/NN responsiveness/NN of/IN the/DT mouse/NN IL-2R/NN alpha/NN gene/NN using/VBG a/DT thymic/JJ lymphoma-derived/JJ hybridoma/NN (/( PC60/NN )/) ./. 
The/DT transcriptional/JJ response/NN of/IN the/DT IL-2R/NN alpha/NN gene/NN to/TO stimulation/NN by/IN IL-1/NN +/CC IL-2/NN is/VBZ biphasic/JJ ./. 
IL-1/NN induces/VBZ a/DT rapid/JJ ,/, protein/NN synthesis-independent/JJ appearance/NN of/IN IL-2R/NN alpha/NN mRNA/NN that/WDT is/VBZ blocked/VBN by/IN inhibitors/NNS of/IN NF-kappa/NN B/NN activation/NN ./. 
It/PRP also/RB primes/VBZ cells/NNS to/TO become/VB IL-2/NN responsive/JJ and/CC thereby/RB prepares/VBZ the/DT second/JJ phase/NN ,/, in/IN which/WDT IL-2/NN induces/VBZ a/DT 100-fold/RB further/JJ increase/NN in/IN IL-2R/NN alpha/NN transcripts/NNS ./. 
Transient/JJ transfection/NN experiments/NNS show/VBP that/IN several/JJ elements/NNS in/IN the/DT promoter-proximal/JJ region/NN of/IN the/DT IL-2R/NN alpha/NN gene/NN contribute/VBP to/TO IL-1/NN responsiveness/NN ,/, most/RBS importantly/RB an/DT NF-kappa/NN B/NN site/NN conserved/VBN in/IN the/DT human/JJ and/CC mouse/NN gene/NN ./. 
IL-2/NN responsiveness/NN ,/, on/IN the/DT other/JJ hand/NN ,/, depends/VBZ on/IN a/DT 78-nucleotide/JJ segment/NN 1.3/CD kilobases/NNS upstream/RB of/IN the/DT major/JJ transcription/NN start/NN site/NN ./. 
This/DT segment/NN functions/VBZ as/IN an/DT IL-2-inducible/JJ enhancer/NN and/CC lies/VBZ within/IN a/DT region/NN that/WDT becomes/VBZ DNase/NN I/CD hypersensitive/JJ in/IN normal/JJ T/NN cells/NNS in/IN which/WDT IL-2R/NN alpha/NN expression/NN has/VBZ been/VBN induced/VBN ./. 
IL-2/NN responsiveness/NN requires/VBZ three/CD distinct/JJ elements/NNS within/IN the/DT enhancer/NN ./. 
Two/CD of/IN these/DT are/VBP potential/JJ binding/VBG sites/NNS for/IN STAT/NN proteins/NNS ./. 
UI/LS -/: 95338146/CD 
TI/LS -/: Hematopoietic/JJ lineage/NN commitment/NN :/: role/NN of/IN transcription/NN factors/NNS ./. 
AB/LS -/: This/DT review/NN focuses/VBZ on/IN the/DT roles/NNS of/IN transcription/NN factors/NNS in/IN hematopoietic/JJ lineage/NN commitment/NN ./. 
A/DT brief/JJ introduction/NN to/TO lineage/NN commitment/NN and/CC asymmetric/JJ cell/NN division/NN is/VBZ followed/VBN by/IN a/DT discussion/NN of/IN several/JJ methods/NNS used/VBN to/TO identify/VB transcription/NN factors/NNS important/JJ in/IN specifying/VBG hematopoietic/JJ cell/NN types/NNS ./. 
Next/RB is/VBZ presented/VBN a/DT discussion/NN of/IN the/DT use/NN of/IN embryonic/JJ stem/NN cells/NNS in/IN the/DT analysis/NN of/IN hematopoietic/JJ gene/NN expression/NN and/CC the/DT use/NN of/IN targeted/VBN gene/NN disruption/NN to/TO analyze/VB the/DT role/NN of/IN transcription/NN factors/NNS in/IN hematopoiesis/NN ./. 
Finally/RB ,/, the/DT status/NN of/IN our/PRP$ current/JJ knowledge/NN concerning/VBG the/DT roles/NNS of/IN transcription/NN factors/NNS in/IN the/DT commitment/NN to/TO erythroid/JJ ,/, myeloid/JJ and/CC lymphoid/JJ cell/NN types/NNS is/VBZ summarized/VBN ./. 
UI/LS -/: 95266275/CD 
TI/LS -/: Epstein-Barr/JJ virus/NN replicative/JJ gene/NN transcription/NN during/IN de/FW novo/FW infection/NN of/IN human/JJ thymocytes/NNS :/: simultaneous/JJ early/JJ expression/NN of/IN BZLF-1/NN and/CC its/PRP$ repressor/NN RAZ/NN ./. 
AB/LS -/: Epstein-Barr/JJ virus/NN (/( EBV/NN )/) is/VBZ known/VBN to/TO infect/VB B/NN cells/NNS and/CC epithelial/JJ cells/NNS ./. 
We/PRP and/CC others/NNS have/VBP shown/VBN that/IN EBV/NN can/MD also/RB infect/VB a/DT subset/NN of/IN thymocytes/NNS ./. 
Infection/NN of/IN thymocytes/NNS was/VBD accompanied/VBN by/IN the/DT appearance/NN of/IN linear/JJ EBV/NN genome/NN within/IN 8/CD hr/NN of/IN infection/NN ./. 
Circularization/NN of/IN the/DT EBV/NN genome/NN was/VBD not/RB detected/VBN ./. 
This/DT is/VBZ in/IN contrast/NN to/TO the/DT infection/NN in/IN B/NN cells/NNS where/WRB the/DT genome/NN can/MD circularize/VB within/IN 24/CD hr/NN of/IN infection/NN ./. 
The/DT appearance/NN of/IN the/DT BamHI/NN ZLF-1/NN gene/NN product/NN ,/, ZEBRA/NN ,/, by/IN RT-PCR/NN ,/, was/VBD observed/VBN within/IN 8/CD hr/NN of/IN infection/NN ./. 
The/DT appearance/NN of/IN a/DT novel/JJ fusion/NN transcript/NN (/( RAZ/NN )/) ,/, which/WDT comprised/VBD regions/NNS of/IN the/DT BZLF-1/NN locus/NN and/CC the/DT adjacent/JJ BRLF-1/NN locus/NN ,/, was/VBD detected/VBN by/IN RT-PCR/NN ./. 
ZEBRA/NN protein/NN was/VBD also/RB identified/VBN in/IN infected/JJ thymocytes/NNS by/IN immunoprecipitation/NN ./. 
In/IN addition/NN ,/, we/PRP demonstrated/VBD that/IN the/DT EBNA-1/NN gene/NN in/IN infected/JJ thymocytes/NNS was/VBD transcribed/VBN from/IN the/DT Fp/NN promoter/NN ,/, rather/RB than/IN from/IN the/DT Cp/Wp/NN promoter/NN which/WDT is/VBZ used/VBN in/IN latently/RB infected/JJ B/NN cells/NNS ./. 
Transcripts/NNS encoding/VBG gp350/220/NN ,/, the/DT major/JJ coat/NN protein/NN of/IN EBV/NN ,/, were/VBD identified/VBN ,/, but/CC we/PRP did/VBD not/RB find/VB any/DT evidence/NN of/IN transcription/NN from/IN the/DT LMP-2A/NN or/CC EBER-1/NN loci/NNS in/IN infected/JJ thymocytes/NNS ./. 
These/DT observations/NNS suggest/VBP that/IN de/FW novo/FW EBV/NN infection/NN of/IN thymocytes/NNS differs/VBZ from/IN infection/NN of/IN B/NN cells/NNS ./. 
The/DT main/JJ difference/NN is/VBZ that/IN with/IN thymocytes/NNS ,/, no/DT evidence/NN could/MD be/VB found/VBN that/IN the/DT virus/NN ever/RB circularizes/VBZ ./. 
Rather/RB ,/, EBV/NN remains/VBZ in/IN a/DT linear/JJ configuration/NN from/IN which/WDT replicative/JJ genes/NNS are/VBP transcribed/VBN ./. 
UI/LS -/: 95236292/CD 
TI/LS -/: Identification/NN and/CC purification/NN of/IN human/JJ Stat/NN proteins/NNS activated/VBN in/IN response/NN to/TO interleukin-2/NN ./. 
AB/LS -/: A/DT key/JJ cytokine/NN induced/VBN during/IN the/DT immune/JJ response/NN is/VBZ IL-2/NN ./. 
Following/VBG T/NN cell/NN activation/NN ,/, the/DT genes/NNS encoding/VBG IL-2/NN and/CC the/DT various/JJ chains/NNS of/IN its/PRP$ receptor/NN are/VBP transcriptionally/RB induced/VBN ./. 
In/IN turn/NN ,/, secreted/VBN IL-2/NN serves/VBZ to/TO stimulate/VB the/DT proliferation/NN and/CC differentiation/NN of/IN T/NN lymphocytes/NNS ./. 
Several/JJ recent/JJ studies/NNS have/VBP implicated/VBN Jak/NN kinases/NNS in/IN the/DT signaling/NN pathway/NN induced/VBN by/IN IL-2/NN ./. 
Following/VBG this/DT lead/NN ,/, we/PRP set/VBD out/RP to/TO identify/VB transcription/NN factors/NNS induced/VBN in/IN response/NN to/TO IL-2/NN ./. 
Human/JJ peripheral/JJ blood/NN lymphocytes/NNS were/VBD observed/VBN to/TO contain/VB several/JJ IL-2-inducible/JJ DNA/NN binding/NN activities/NNS ./. 
Similar/JJ activities/NNS were/VBD also/RB observed/VBN in/IN a/DT transformed/VBN human/JJ lymphocyte/NN line/NN ,/, termed/VBN YT/NN ./. 
We/PRP have/VBP purified/VBN these/DT activities/NNS and/CC found/VBD that/IN the/DT principal/JJ IL-2-inducible/JJ component/NN bears/VBZ significant/JJ relatedness/NN to/TO a/DT prolactin-induced/JJ transcription/NN factor/NN first/RB identified/VBN in/IN sheep/NN mammary/JJ gland/NN tissue/NN ./. 
We/PRP hypothesize/VBP that/IN activation/NN of/IN this/DT protein/NN ,/, designated/VBN hStat5/NN ,/, helps/VBZ govern/VB the/DT biological/JJ effects/NNS of/IN IL-2/NN during/IN the/DT immune/JJ response/NN ./. 
UI/LS -/: 95197524/CD 
TI/LS -/: E2F-1/NN and/CC a/DT cyclin-like/JJ DNA/NN repair/NN enzyme/NN ,/, uracil-DNA/NN glycosylase/NN ,/, provide/VBP evidence/NN for/IN an/DT autoregulatory/JJ mechanism/NN for/IN transcription/NN ./. 
AB/LS -/: The/DT cell/NN cycle-dependent/JJ transcription/NN factor/NN ,/, E2F-1/NN ,/, regulates/VBZ the/DT cyclin-like/JJ species/NNS of/IN the/DT DNA/NN repair/NN enzyme/NN uracil-DNA/NN glycosylase/NN (/( UDG/NN )/) gene/NN in/IN human/JJ osteosarcoma/NN (/( Saos-2/NN )/) cells/NNS ./. 
We/PRP demonstrate/VBP ,/, through/IN the/DT deletion/NN of/IN the/DT human/JJ UDG/NN promoter/NN sequences/NNS ,/, that/IN expression/NN of/IN E2F-1/NN activates/VBZ the/DT UDG/NN promoter/NN through/IN several/JJ E2F/NN sites/NNS ./. 
The/DT major/JJ putative/JJ downstream/JJ site/NN for/IN E2F/NN ,/, located/JJ in/IN the/DT first/JJ exon/NN ,/, serves/VBZ as/IN a/DT target/NN for/IN E2F-1/DP1/NN complex/NN binding/NN in/FW vitro/FW ./. 
We/PRP also/RB provide/VBP evidence/NN for/IN the/DT functional/JJ relationship/NN between/IN the/DT cyclin-like/JJ UDG/NN gene/NN product/NN and/CC E2F/NN ./. 
High/JJ levels/NNS of/IN UDG/NN expression/NN in/IN a/DT transient/JJ transfection/NN assay/NN result/VBP in/IN the/DT down-regulation/NN of/IN transcriptional/JJ activity/NN through/IN elements/NNS specific/JJ for/IN E2F-mediated/JJ transcription/NN ./. 
Overexpression/NN of/IN UDG/NN in/IN Saos/NN 2/CD cells/NNS was/VBD observed/VBN to/TO delay/VB growth/NN late/RB in/IN G1/NN phase/NN and/CC transiently/RB arrest/VB these/DT cells/NNS from/IN progressing/VBG into/IN the/DT S/NN phase/NN ./. 
This/DT hypothetical/JJ model/NN integrates/VBZ one/CD mechanism/NN of/IN DNA/NN repair/NN with/IN the/DT cell/NN cycle/NN control/NN of/IN gene/NN transcription/NN ,/, likely/RB through/IN E2F/NN ./. 
This/DT implicates/VBZ E2F/NN as/IN a/DT multifunctional/JJ target/NN for/IN proteins/NNS and/CC enzymes/NNS ,/, possibly/RB ,/, responsive/JJ to/TO DNA/NN damage/NN through/IN the/DT negative/JJ effect/NN of/IN UDG/NN on/IN E2F-mediated/JJ transcriptional/JJ activity/NN ./. 
UI/LS -/: 95370702/CD 
TI/LS -/: Cellular/JJ and/CC molecular/JJ mechanisms/NNS of/IN IFN-gamma/NN production/NN induced/VBN by/IN IL-2/NN and/CC IL-12/NN in/IN a/DT human/JJ NK/NN cell/NN line/NN ./. 
AB/LS -/: Interferon-gamma/NN (/( IFN-gamma/NN )/) is/VBZ an/DT important/JJ immunoregulatory/JJ protein/NN produced/VBN predominantly/RB by/IN T/NN cells/NNS and/CC large/JJ granular/JJ lymphocytes/NNS (/( LGL/NN )/) in/IN response/NN to/TO different/JJ extracellular/JJ signals/NNS ./. 
In/IN particular/JJ ,/, two/CD interleukins/NNS (/( ILs/NNS )/) ,/, IL-2/NN and/CC IL-12/NN ,/, have/VBP been/VBN shown/VBN to/TO be/VB potent/JJ inducers/NNS of/IN IFN-gamma/NN gene/NN expression/NN in/IN both/CC T/NN cells/NNS and/CC LGL/NN ./. 
Although/IN it/PRP has/VBZ been/VBN reported/VBN that/IN there/EX are/VBP some/DT T/NN cell/NN lines/NNS that/WDT produce/VBP IFN-gamma/NN in/IN response/NN to/TO IL-2/NN and/CC IL-12/NN stimulation/NN ,/, there/EX has/VBZ as/RB yet/RB been/VBN no/DT report/NN of/IN a/DT natural/JJ killer/NN (/( NK/NN )/) cell/NN line/NN that/WDT responds/VBZ in/IN a/DT similar/JJ manner/NN ./. 
In/IN this/DT report/NN we/PRP present/VBP evidence/NN that/IN the/DT cell/NN line/NN NK3.3/NN derived/VBN from/IN human/JJ NK/NN cells/NNS ,/, responds/VBZ to/TO both/CC IL-2/NN and/CC IL-12/NN ,/, as/IN measured/VBN by/IN increases/NNS in/IN IFN-gamma/NN and/CC granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) cytoplasmic/JJ mRNA/NN and/CC protein/NN expression/NN ./. 
In/IN addition/NN ,/, when/WRB used/VBN together/RB IL-2/NN and/CC IL-12/NN synergized/VBD in/IN the/DT induction/NN of/IN IFN-gamma/NN and/CC GM-CSF/NN and/CC this/DT synergy/NN was/VBD attributed/VBN to/TO an/DT increased/VBN accumulation/NN and/CC stability/NN of/IN the/DT IFN-gamma/NN and/CC GM-CSF/NN mRNAs/NNS ./. 
To/TO investigate/VB the/DT signaling/NN pathways/NNS involved/VBN in/IN the/DT gene/NN induction/NN ,/, five/CD inhibitors/NNS ,/, cyclosporin/NN A/NN (/( CsA/NN )/) ,/, transforming/VBG growth/NN factor-beta/NN ,/, cycloheximide/NN ,/, genistein/NN ,/, and/CC staurosporine/NN A/NN ,/, were/VBD used/VBN in/IN analyzing/VBG the/DT effects/NNS of/IN IL-2/NN and/CC IL-12/NN on/IN NK3.3/NN cells/NNS ./. 
The/DT results/NNS suggest/VBP that/IN activation/NN of/IN protein/NN kinase/NN C/NN ,/, but/CC not/RB new/JJ protein/NN synthesis/NN ,/, is/VBZ required/VBN for/IN IL-2/NN induction/NN of/IN IFN-gamma/NN and/CC GM-CSF/NN cytoplasmic/JJ mRNA/NN ./. 
In/IN contrast/NN ,/, IL-12/NN induction/NN of/IN IFN-gamma/NN cytoplasmic/JJ mRNA/NN appears/VBZ to/TO only/RB partially/RB depend/VB on/IN activation/NN of/IN protein/NN kinase/NN C/NN ./. 
Furthermore/RB ,/, both/CC transforming/VBG growth/NN factor-beta/NN and/CC genistein/NN ,/, a/DT tyrosine/NN kinase/NN inhibitor/NN ,/, could/MD suppress/VB IL-2/NN and/CC IL-12/NN signaling/NN but/CC CsA/NN was/VBD generally/RB inactive/JJ ./. 
It/PRP also/RB was/VBD observed/VBN that/IN suppression/NN of/IN cytokine/NN gene/NN expression/NN by/IN these/DT agents/NNS was/VBD independent/JJ of/IN the/DT inhibition/NN of/IN proliferation/NN ./. 
In/IN addition/NN ,/, IL-2/NN but/CC not/RB IL-12/NN induced/VBD nuclear/JJ factors/NNS NF-kappa/NN B/NN and/CC AP1/NN ,/, and/CC regulation/NN of/IN the/DT nuclear/JJ levels/NNS of/IN these/DT two/CD DNA/NN binding/NN protein/NN complexes/NNS is/VBZ correlated/VBN with/IN IFN-gamma/NN and/CC GM-CSF/NN gene/NN expression/NN ./. 
These/DT data/NNS indicate/VBP that/IN IL-2/NN and/CC IL-12/NN may/MD have/VB distinct/JJ signaling/NN pathways/NNS leading/VBG to/TO the/DT induction/NN of/IN IFN-gamma/NN and/CC GM-CSF/NN gene/NN expression/NN ,/, and/CC that/IN the/DT NK3.3/NN cell/NN line/NN may/MD serve/VB as/IN a/DT novel/JJ model/NN for/IN dissecting/VBG the/DT biochemical/JJ and/CC molecular/JJ events/NNS involved/VBN in/IN these/DT pathways/NNS ./. 
UI/LS -/: 95349600/CD 
TI/LS -/: A/DT functional/JJ T-cell/NN receptor/NN signaling/NN pathway/NN is/VBZ required/VBN for/IN p95vav/NN activity/NN ./. 
AB/LS -/: Stimulation/NN of/IN the/DT T-cell/NN antigen/NN receptor/NN (/( TCR/NN )/) induces/VBZ activation/NN of/IN multiple/JJ tyrosine/NN kinases/NNS ,/, resulting/VBG in/IN phosphorylation/NN of/IN numerous/JJ intracellular/JJ substrates/NNS ./. 
One/CD substrate/NN is/VBZ p95vav/NN ,/, which/WDT is/VBZ expressed/VBN exclusively/RB in/IN hematopoietic/JJ and/CC trophoblast/NN cells/NNS ./. 
It/PRP contains/VBZ a/DT number/NN of/IN structural/JJ motifs/NNS ,/, including/VBG Src/NN homology/NN 2/CD ,/, Src/NN homology/NN 3/CD ,/, and/CC pleckstrin/NN homology/NN domains/NNS and/CC a/DT putative/JJ guanine/NN nucleotide/NN exchange/NN domain/NN ./. 
The/DT role/NN of/IN p95vav/NN in/IN TCR-mediated/JJ signaling/NN processes/NNS is/VBZ unclear/JJ ./. 
Here/RB ,/, we/PRP show/VBP that/IN overexpression/NN of/IN p95vav/NN alone/RB in/IN Jurkat/NN T/NN cells/NNS leads/VBZ to/TO activation/NN of/IN the/DT nuclear/JJ factors/NNS ,/, including/VBG NFAT/NN ,/, involved/VBN in/IN interleukin-2/NN expression/NN ./. 
Furthermore/RB ,/, p95vav/NN synergizes/VBZ with/IN TCR/NN stimulation/NN in/IN inducing/VBG NFAT-/NN and/CC interleukin-2-dependent/JJ transcription/NN ./. 
In/IN contrast/NN ,/, NFAT/NN activation/NN by/IN a/DT G-protein-coupled/JJ receptor/NN is/VBZ not/RB modulated/VBN by/IN p95vav/NN overexpression/NN ,/, suggesting/VBG that/IN the/DT effect/NN is/VBZ specific/JJ to/TO the/DT TCR/NN signaling/NN pathways/NNS ./. 
Although/IN removal/NN of/IN the/DT first/JJ 67/CD amino/NN acids/NNS of/IN p95vav/NN activates/VBZ its/PRP$ transforming/NN potential/NN in/IN NIH/NN 3T3/NN cells/NNS ,/, this/DT region/NN appears/VBZ to/TO be/VB required/VBN for/IN its/PRP$ function/NN in/IN T/NN cells/NNS ./. 
We/PRP further/RB demonstrate/VBP that/IN the/DT p95vav-induced/JJ NFAT/NN activation/NN is/VBZ not/RB mimicked/VBN by/IN Ras/NN activation/NN ,/, though/IN its/PRP$ function/NN is/VBZ dependent/JJ upon/IN Ras/NN and/CC Raf/NN ./. 
Furthermore/RB ,/, the/DT activating/NN function/NN of/IN p95vav/NN is/VBZ blocked/VBN by/IN FK506/NN ,/, suggesting/VBG that/IN its/PRP$ activity/NN also/RB depends/VBZ on/IN calcineurin/NN ./. 
To/TO further/RB dissect/VB p95vav/NN involvement/NN in/IN TCR/NN signaling/NN ,/, we/PRP analyzed/VBD various/JJ Jurkat/NN mutants/NNS deficient/JJ in/IN TCR/NN signaling/NN function/NN or/CC TCR/NN expression/NN and/CC showed/VBD that/IN an/DT intact/JJ TCR/NN signaling/NN pathway/NN is/VBZ required/VBN for/IN p95vav/NN to/TO function/VB ./. 
However/RB ,/, overexpression/NN of/IN p95vav/NN does/VBZ not/RB appear/VB to/TO influence/VB TCR-induced/JJ protein/NN tyrosine/NN phosphorylation/NN or/CC increases/NNS in/IN cytoplasmic/JJ free/JJ calcium/NN ./. 
Taken/VBN together/RB ,/, our/PRP$ data/NNS suggest/VBP that/IN p95vav/NN plays/VBZ an/DT important/JJ role/NN at/IN an/DT yet/RB unidentified/JJ proximal/JJ position/NN in/IN the/DT TCR/NN signaling/NN cascade/NN ./. 
UI/LS -/: 95329717/CD 
TI/LS -/: Positive/JJ and/CC negative/JJ regulation/NN of/IN granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN promoter/NN activity/NN by/IN AML1-related/JJ transcription/NN factor/NN ,/, PEBP2/NN ./. 
AB/LS -/: The/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) gene/NN promoter/NN contains/VBZ a/DT consensus/NN sequence/NN for/IN the/DT polyomavirus/NN enhancer/NN binding-protein/NN 2/CD (/( PEBP2/NN )/) transcription/NN factor/NN ,/, which/WDT consists/VBZ of/IN alpha/NN and/CC beta/NN subunits/NNS ./. 
There/EX are/VBP at/IN least/JJS two/CD genes/NNS ,/, alpha/NN A/NN and/CC alpha/NN B/NN ,/, encoding/VBG the/DT alpha/NN subunit/NN ./. 
alpha/NN B/NN is/VBZ the/DT mouse/NN homologue/NN of/IN human/JJ AML1/NN gene/NN detected/VBN at/IN the/DT breakpoints/NNS of/IN t/NN (/( 8/CD ;/: 21/CD )/) and/CC t/NN (/( 3/CD ;/: 21/CD )/) myeloid/JJ leukemias/NNS ./. 
We/PRP examined/VBD alpha/NN A1/NN (/( an/DT alpha/NN A-gene/JJ product/NN )/) and/CC alpha/NN B1/NN and/CC alpha/NN B2/NN (/( two/CD alpha/NN B-encoded/JJ isomers/NNS )/) for/IN their/PRP$ effects/NNS on/IN the/DT GM-CSF/NN promoter/NN ./. 
PEBP2/NN alpha/NN A1/NN ,/, alpha/NN B1/NN ,/, and/CC alpha/NN B2/NN proteins/NNS bound/VBD the/DT PEBP2/NN site/NN within/IN the/DT mouse/NN GM-CSF/NN promoter/NN ./. 
PEBP2/NN alpha/NN A1/NN and/CC alpha/NN B1/NN enhanced/VBD the/DT expression/NN of/IN the/DT GM-CSF/NN promoter-driven/JJ reporter/NN plasmid/NN in/IN unstimulated/JJ and/CC 12-O-tetradecanoylphorbol/NN 13-acetate/phytohemagglutinin-stimulated/JJ human/JJ Jurkat/NN T/NN cells/NNS ./. 
In/IN contrast/NN ,/, the/DT promoter/NN activity/NN was/VBD suppressed/VBN by/IN alpha/NN B2/NN ./. 
Coexpression/NN of/IN alpha/NN B1/NN and/CC alpha/NN B2/NN showed/VBD that/IN the/DT promoter/NN activity/NN could/MD be/VB determined/VBN by/IN the/DT alpha/NN B1/alpha/NN B2/NN ratio/NN ./. 
Jurkat/NN cell/NN extract/NN contained/VBD PEBP2/NN site-binding/JJ protein/NN (/( s/NNS )/) that/WDT cross-reacted/VBD with/IN antimouse/JJ alpha/NN A1/NN antibodies/NNS ./. 
Northern/NN blot/NN analysis/NN indicated/VBD the/DT expression/NN of/IN human/JJ PEBP2/NN alpha/NN A/NN ,/, alpha/NN B/NN (/( AML1/NN )/) ,/, and/CC beta/NN genes/NNS in/IN Jurkat/NN cells/NNS ./. 
Although/IN further/JJ studies/NNS are/VBP required/VBN to/TO determine/VB the/DT precise/JJ role/NN of/IN PEBP2/NN in/IN the/DT GM-CSF/NN promoter/NN activity/NN ,/, the/DT present/JJ findings/NNS suggested/VBD the/DT importance/NN of/IN the/DT relative/JJ ratio/NN of/IN different/JJ PEBP2/NN isoforms/NNS in/IN regulating/VBG the/DT levels/NNS of/IN the/DT promoter/NN activity/NN ./. 
UI/LS -/: 96075792/CD 
TI/LS -/: IFN-gamma/NN priming/NN of/IN monocytes/NNS enhances/VBZ LPS-induced/JJ TNF/NN production/NN by/IN augmenting/VBG both/CC transcription/NN and/CC MRNA/NN stability/NN ./. 
AB/LS -/: The/DT induction/NN of/IN cytokine/NN expression/NN in/IN monocytes/NNS /macrophages/NNS by/IN bacterial/JJ endotoxin/NN or/CC lipopolysaccharide/NN is/VBZ a/DT critical/JJ ,/, highly/RB regulated/VBN host/NN defence/NN response/NN ./. 
The/DT augmentation/NN of/IN LPS/NN responses/NNS by/IN interferon/NN gamma/NN (/( IFN-gamma/NN )/) ,/, referred/VBN to/TO as/IN priming/NN ,/, is/VBZ well/RB established/VBN ./. 
However/RB ,/, the/DT mechanism/NN (/( s/NNS )/) by/IN which/WDT priming/NN occurs/VBZ is/VBZ poorly/RB defined/VBN ./. 
Using/VBG tumour/NN necrosis/NN factor/NN (/( TNF/NN )/) induction/NN as/IN a/DT model/NN ,/, experiments/NNS were/VBD designed/VBN to/TO analyse/VB in/IN detail/NN the/DT priming/NN effect/NN on/IN the/DT LPS/NN response/NN in/IN human/JJ monocytes/NNS ./. 
Priming/NN by/IN IFN-gamma/NN was/VBD primarily/RB manifested/VBN at/IN the/DT level/NN of/IN TNF/NN mRNA/NN accumulation/NN ./. 
IFN-gamma/NN pre-treatment/NN affected/VBD the/DT magnitude/NN rather/RB than/IN the/DT sensitivity/NN of/IN the/DT LPS/NN response/NN ./. 
Priming/NN occurred/VBD after/IN several/JJ hours/NNS of/IN treatment/NN ,/, and/CC the/DT primed/JJ state/NN was/VBD induced/VBN by/IN either/CC IFN-gamma/NN or/CC GM-CSF/NN ,/, but/CC not/RB M-CSF/NN ./. 
Primed/VBN monocytes/NNS transcribed/VBD TNF/NN mRNA/NN at/IN a/DT higher/JJR rate/NN than/IN freshly/RB isolated/VBN monocytes/NNS upon/IN activation/NN with/IN LPS/NN ./. 
The/DT increased/VBN transcriptional/JJ rate/NN correlated/VBD with/IN a/DT marked/JJ increase/NN in/IN nuclear/JJ factor-kappa/NN B/NN activity/NN in/IN these/DT cells/NNS as/IN determined/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN using/VBG a/DT consensus/NN NF-kappa/NN B/NN oligonucleotide/NN ./. 
An/DT additional/JJ significant/JJ finding/NN was/VBD than/IN TNF/NN mRNA/NN induced/VBN in/IN primed/VBN cells/NNS was/VBD much/RB more/RBR stable/JJ than/IN in/IN unprimed/JJ cells/NNS (/( T1/2/NN increased/VBN 6-8-fold/RB )/) ./. 
Consistent/JJ with/IN the/DT increased/VBN mRNA/NN stability/NN ,/, the/DT duration/NN of/IN mRNA/NN accumulation/NN was/VBD longer/RBR following/VBG LPS/NN stimulation/NN in/IN primed/VBN monocytes/NNS ,/, in/IN addition/NN to/TO being/VBG of/IN greater/JJR magnitude/NN ./. 
Finally/RB ,/, primed/VBN and/CC unprimed/JJ cells/NNS possessed/VBD a/DT differential/JJ sensitivity/NN to/TO the/DT kinase/NN inhibitor/NN H-89/NN ./. 
H-89/NN substantially/RB suppressed/VBD LPS-induced/JJ TNF/NN mRNA/NN accumulation/NN in/IN unprimed/JJ cells/NNS ,/, but/CC had/VBD no/DT effect/NN on/IN primed/VBN monocytes/NNS following/VBG LPS/NN stimulation/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 95280917/CD 
TI/LS -/: A/DT Myc-associated/JJ zinc/NN finger/NN protein/NN binding/NN site/NN is/VBZ one/CD of/IN four/CD important/JJ functional/JJ regions/NNS in/IN the/DT CD4/NN promoter/NN ./. 
AB/LS -/: The/DT CD4/NN promoter/NN plays/VBZ an/DT important/JJ role/NN in/IN the/DT developmental/JJ control/NN of/IN CD4/NN transcription/NN ./. 
In/IN this/DT report/NN ,/, we/PRP show/VBP that/IN the/DT minimal/JJ CD4/NN promoter/NN has/VBZ four/CD factor/NN binding/NN sites/NNS ,/, each/DT of/IN which/WDT is/VBZ required/VBN for/IN full/JJ function/NN ./. 
Using/VBG biochemical/JJ and/CC mutagenesis/NN analyses/NNS ,/, we/PRP determined/VBD that/IN multiple/JJ nuclear/JJ factors/NNS bind/VBP to/TO these/DT independent/JJ sites/NNS ./. 
We/PRP determined/VBD that/IN an/DT initiator-like/JJ sequence/NN present/JJ at/IN the/DT cap/NN site/NN and/CC an/DT Ets/NN consensus/NN sequence/NN are/VBP required/VBN for/IN full/JJ promoter/NN function/NN ./. 
We/PRP also/RB demonstrate/VBP that/IN the/DT Myc-associated/JJ zinc/NN finger/NN protein/NN (/( MAZ/NN )/) appears/VBZ to/TO be/VB the/DT predominant/JJ factor/NN binding/VBG to/TO one/CD of/IN these/DT sites/NNS ./. 
This/DT last/JJ site/NN closely/RB resembles/VBZ the/DT ME1a1/NN G3AG4AG3/NN motif/NN previously/RB shown/VBN to/TO be/VB a/DT critical/JJ element/NN in/IN the/DT P2/NN promoter/NN of/IN the/DT c-myc/NN gene/NN ./. 
We/PRP therefore/RB believe/VBP that/IN the/DT MAZ/NN transcription/NN factor/NN is/VBZ also/RB likely/JJ to/TO play/VB an/DT important/JJ role/NN in/IN the/DT control/NN of/IN developmental/JJ expression/NN of/IN the/DT CD4/NN gene/NN ./. 
UI/LS -/: 95263486/CD 
TI/LS -/: Erythropoietin/NN stimulates/VBZ transcription/NN of/IN the/DT TAL1/SCL/NN gene/NN and/CC phosphorylation/NN of/IN its/PRP$ protein/NN products/NNS ./. 
AB/LS -/: Activation/NN of/IN the/DT TAL1/NN (/( or/CC SCL/NN )/) gene/NN ,/, originally/RB identified/VBN through/IN its/PRP$ involvement/NN by/IN a/DT recurrent/JJ chromosomal/JJ translocation/NN ,/, is/VBZ the/DT most/RBS frequent/JJ molecular/JJ lesion/NN recognized/VBN in/IN T-cell/NN acute/JJ lymphoblastic/JJ leukemia/NN ./. 
The/DT protein/NN products/NNS of/IN this/DT gene/NN contain/VBP the/DT basic-helix-loop-helix/JJ motif/NN characteristic/JJ of/IN a/DT large/JJ family/NN of/IN transcription/NN factors/NNS that/WDT bind/VBP to/TO the/DT canonical/JJ DNA/NN sequence/NN CANNTG/NN as/IN protein/NN heterodimers/NNS ./. 
TAL1/NN expression/NN by/IN erythroid/JJ cells/NNS in/FW vivo/FW and/CC in/IN chemical-induced/JJ erythroleukemia/NN cell/NN lines/NNS in/FW vivo/FW suggested/VBD the/DT gene/NN might/MD regulate/VB aspects/NNS of/IN erythroid/JJ differentiation/NN ./. 
Since/IN the/DT terminal/JJ events/NNS of/IN erythropoiesis/NN are/VBP controlled/VBN by/IN the/DT glycoprotein/NN hormone/NN erythropoietin/NN (/( Epo/NN )/) ,/, we/PRP investigated/VBD whether/IN the/DT expression/NN or/CC activity/NN of/IN the/DT TAL1/NN gene/NN and/CC its/PRP$ protein/NN products/NNS were/VBD affected/VBN by/IN Epo/NN in/IN splenic/JJ erythroblasts/NNS from/IN mice/NNS infected/VBN with/IN an/DT anemia-inducing/JJ strain/NN of/IN Friend/NN virus/NN (/( FVA/NN cells/NNS )/) ./. 
Epo/NN elicited/VBD a/DT rapid/JJ ,/, dose-related/JJ increase/NN in/IN TAL1/NN mRNA/NN by/IN increasing/VBG transcription/NN of/IN the/DT gene/NN and/CC stabilizing/VBG one/CD of/IN its/PRP$ mRNAs/NNS ./. 
An/DT Epo-inducible/JJ TAL1/NN DNA/NN binding/NN activity/NN was/VBD identified/VBN in/IN FVA/NN cell/NN nuclear/JJ extracts/NNS that/WDT subsequently/RB decayed/VBD despite/IN accumulating/VBG mRNA/NN and/CC protein/NN ./. 
Induction/NN of/IN DNA/NN binding/NN activity/NN was/VBD associated/VBN temporally/RB with/IN Epo-induced/JJ phosphorylation/NN of/IN nuclear/JJ TAL1/NN protein/NN ./. 
These/DT results/NNS indicate/VBP that/IN Epo/NN acts/VBZ at/IN both/CC transcriptional/JJ and/CC posttranscriptional/JJ levels/NNS on/IN the/DT TAL1/NN locus/NN in/IN Friend/NN virus-induced/JJ erythroblasts/NNS and/CC establish/VBP a/DT link/NN between/IN Epo/NN signaling/NN mechanisms/NNS and/CC a/DT member/NN of/IN a/DT family/NN of/IN transcription/NN factors/NNS involved/VBN in/IN the/DT differentiation/NN of/IN diverse/JJ cell/NN lineages/NNS ./. 
UI/LS -/: 95397944/CD 
TI/LS -/: Nonradioactive/JJ quantification/NN of/IN glucocorticoid/NN receptor/NN expression/NN during/IN differentiation/NN of/IN human/JJ monocytic/JJ cells/NNS (/( U937/NN )/) ./. 
AB/LS -/: We/PRP describe/VBP a/DT method/NN for/IN relative/JJ quantification/NN of/IN specific/JJ mRNA/NN using/VBG a/DT nonradioactive/JJ assay/NN based/VBN on/IN DNA/NN strand/NN competition/NN between/IN identical/JJ sequences/NNS of/IN biotin-/NN and/CC fluorescein-labeled/JJ amplicon/NN (/( probe/NN )/) and/CC unlabeled/JJ amplicon/NN (/( target/NN )/) during/IN hybridization/NN ./. 
As/IN the/DT target/NN quantity/NN increased/VBD ,/, that/DT of/IN the/DT double-labeled/JJ probe/NN decreased/VBD in/IN accordance/NN with/IN the/DT mass/NN action/NN law/NN ./. 
This/DT technique/NN was/VBD successfully/RB applied/VBN to/TO evaluate/VB differences/NNS in/IN glucocorticoid/NN receptor/NN expression/NN in/IN U937/NN cells/NNS before/IN and/CC after/IN the/DT addition/NN of/IN potent/JJ differentiation/NN inducers/NNS :/: 12-O-tetradecanoylphorbol/NN 13-acetate/NN (/( TPA/NN )/) and/CC a/DT combination/NN of/IN all-trans/JJ retinoic/JJ acid/NN (/( RA/NN )/) and/CC 1,25-dihydroxyvitamin/NN D2/NN (/( VD/NN )/) ./. 
We/PRP observed/VBD that/IN TPA/NN treatment/NN was/VBD associated/VBN with/IN an/DT increase/NN in/IN specific/JJ binding/NN of/IN [3H]dexamethasone/NN and/CC up-regulation/NN of/IN GR/NN mRNA/NN while/IN no/DT enhanced/VBN GR/NN expression/NN was/VBD perceived/VBN with/IN RA/NN /VD/NN treatment/NN ./. 
UI/LS -/: 95266282/CD 
TI/LS -/: Induction/NN of/IN Sp1/NN phosphorylation/NN and/CC NF-kappa/NN B-independent/JJ HIV/NN promoter/NN domain/NN activity/NN in/IN T/NN lymphocytes/NNS stimulated/VBN by/IN okadaic/JJ acid/NN ./. 
AB/LS -/: In/IN contrast/NN to/TO the/DT purely/RB enhancer-dependent/JJ effect/NN of/IN cytokines/NNS such/JJ as/IN TNF/NN on/IN the/DT activity/NN of/IN the/DT HIV/NN regulatory/JJ region/NN (/( LTR/NN )/) ,/, we/PRP observed/VBD that/IN okadaic/JJ acid/NN (/( OKA/NN )/) activates/VBZ HIV/NN transcription/NN through/IN both/CC the/DT enhancer/NN ,/, responding/VBG to/TO the/DT factor/NN NF-kappa/NN B/NN ,/, and/CC the/DT promoter/NN domain/NN of/IN the/DT LTR/NN ./. 
The/DT inducibility/NN of/IN HIV/NN LTR-driven/JJ luciferase/NN expression/NN constructs/NNS in/IN lymphoblastoid/JJ cells/NNS stimulated/VBN by/IN OKA/NN depended/VBD on/IN both/CC functional/JJ Sp1/NN binding/NN elements/NNS and/CC the/DT ability/NN of/IN the/DT TATA/NN box/NN to/TO bind/VB the/DT protein/NN TBP/NN ./. 
In/IN both/CC transformed/VBN and/CC normal/JJ lymphocytes/NNS ,/, OKA/NN stimulation/NN induced/VBD intense/JJ phosphorylation/NN of/IN the/DT constitutively/RB expressed/VBN Sp1/NN protein/NN in/IN the/DT nucleus/NN ,/, a/DT property/NN of/IN OKA/NN not/RB shared/VBN by/IN TNF/NN ,/, phorbol/NN ester/NN ,/, or/CC PHA/NN and/CC interleukin/NN 2/CD ./. 
Responsiveness/NN of/IN LTR/NN constructs/NNS deleted/VBN of/IN kappa/NN B/NN elements/NNS to/TO HIV/NN Tat/NN expression/NN was/VBD increased/VBN upon/IN OKA/NN but/CC not/RB TNF/NN stimulation/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN SP1/NN phosphorylation/NN induced/VBN by/IN OKA/NN ,/, a/DT selective/JJ inhibitor/NN of/IN the/DT serine-threonine/JJ phosphatase/NN PP2A/NN ,/, facilitates/VBZ the/DT formation/NN of/IN a/DT transcription/NN complex/NN involving/VBG general/JJ transcription/NN factors/NNS ,/, HIV/NN Tat/NN ,/, and/CC Sp1/NN proteins/NNS ./. 
The/DT formation/NN of/IN this/DT complex/NN would/MD increase/VB ,/, independently/RB of/IN an/DT in/NN synergy/NN with/IN NF-kappa/NN B/NN ,/, the/DT low/JJ basal/JJ activity/NN of/IN the/DT HIV/NN LTR/NN observed/VBN in/IN normal/JJ T/NN lymphocytes/NNS ./. 
UI/LS -/: 95236293/CD 
TI/LS -/: The/DT role/NN of/IN shared/JJ receptor/NN motifs/NNS and/CC common/JJ Stat/NN proteins/NNS in/IN the/DT generation/NN of/IN cytokine/NN pleiotropy/NN and/CC redundancy/NN by/IN IL-2/NN ,/, IL-4/NN ,/, IL-7/NN ,/, IL-13/NN ,/, and/CC IL-15/NN ./. 
AB/LS -/: To/TO understand/VB the/DT molecular/JJ bases/NNS for/IN cytokine/NN redundancy/NN and/CC pleiotropy/NN ,/, we/PRP have/VBP compared/VBN the/DT Stat/NN proteins/NNS activated/VBN in/IN peripheral/JJ blood/NN lymphocytes/NNS (/( PBLs/NNS )/) by/IN cytokines/NNS with/IN shared/JJ and/CC distinct/JJ actions/NNS ./. 
Interleukin-2/NN (/( IL-2/NN )/) rapidly/RB activated/VBD Stat5/NN in/IN fresh/JJ PBL/NN ,/, and/CC Stat3/NN and/CC Stat5/NN in/IN preactivated/JJ PBL/NN ./. 
IL-7/NN and/CC IL-15/NN induced/VBD the/DT same/JJ complexes/NNS as/IN IL-2/NN ,/, a/DT feature/NN explained/VBN by/IN the/DT existence/NN of/IN similar/JJ tyrosine-phosphorylated/JJ motifs/NNS in/IN the/DT cytoplasmic/JJ domains/NNS of/IN IL-2R/NN beta/NN and/CC IL-7R/NN that/WDT can/MD serve/VB as/IN docking/NN sites/NNS for/IN Stat/NN proteins/NNS ./. 
IL-13/NN Induced/VBD the/DT same/JJ complexes/NNS as/IN IL-4/NN ,/, a/DT finding/NN explained/VBN by/IN our/PRP$ studies/NNS implicating/VBG IL-4R/NN as/IN a/DT shared/JJ component/NN of/IN the/DT receptors/NNS ./. 
These/DT studies/NNS demonstrate/VBP that/IN a/DT single/JJ cytokine/NN can/MD activate/VB different/JJ combinations/NNS of/IN Stat/NN proteins/NNS under/IN different/JJ physiological/JJ conditions/NNS ,/, and/CC also/RB indicate/VBP two/CD mechanisms/NNS by/IN which/WDT distinct/JJ cytokines/NNS can/MD activate/VB the/DT same/JJ Stat/NN protein/NN ./. 
UI/LS -/: 95184007/CD 
TI/LS -/: Control/NN of/IN I/NN kappa/NN B-alpha/NN proteolysis/NN by/IN site-specific/JJ ,/, signal-induced/JJ phosphorylation/NN ./. 
AB/LS -/: I/NN kappa/NN B-alpha/NN inhibits/VBZ transcription/NN factor/NN NF-kappa/NN B/NN by/IN retaining/VBG it/PRP in/IN the/DT cytoplasm/NN ./. 
Various/JJ stimuli/NNS ,/, typically/RB those/DT associated/VBN with/IN stress/NN or/CC pathogens/NNS ,/, rapidly/RB inactivate/VBP I/NN kappa/NN B-alpha/NN ./. 
This/DT liberates/VBZ NF-kappa/NN B/NN to/TO translocate/VB to/TO the/DT nucleus/NN and/CC initiate/VB transcription/NN of/IN genes/NNS important/JJ for/IN the/DT defense/NN of/IN the/DT organism/NN ./. 
Activation/NN of/IN NF-kappa/NN B/NN correlates/VBZ with/IN phosphorylation/NN of/IN I/NN kappa/NN B-alpha/NN and/CC requires/VBZ the/DT proteolysis/NN of/IN this/DT inhibitor/NN ./. 
When/WRB either/CC serine-32/NN or/CC serine-36/NN of/IN I/NN kappa/NN B-alpha/NN was/VBD mutated/VBN ,/, the/DT protein/NN did/VBD not/RB undergo/VB signal-induced/JJ phosphorylation/NN or/CC degradation/NN ,/, and/CC NF-kappa/NN B/NN could/MD not/RB be/VB activated/VBN ./. 
These/DT results/NNS suggest/VBP that/IN phosphorylation/NN at/IN one/CD or/CC both/DT of/IN these/DT residues/NNS is/VBZ critical/JJ for/IN activation/NN of/IN NF-kappa/NN B/NN ./. 
UI/LS -/: 95388524/CD 
TI/LS -/: Regulation/NN of/IN transcription/NN of/IN the/DT human/JJ erythropoietin/NN receptor/NN gene/NN by/IN proteins/NNS binding/VBG to/TO GATA-1/NN and/CC Sp1/NN motifs/NNS ./. 
AB/LS -/: Erythropoietin/NN (/( Epo/NN )/) ,/, the/DT primary/JJ regulator/NN of/IN the/DT production/NN of/IN erythroid/JJ cells/NNS ,/, acts/VBZ by/IN binding/VBG to/TO a/DT cell/NN surface/NN receptor/NN (/( EpoR/NN )/) on/IN erythroid/JJ progenitors/NNS ./. 
We/PRP used/VBD deletion/NN analysis/NN and/CC transfection/NN assays/NNS with/IN reporter/NN gene/NN constructs/NNS to/TO examine/VB the/DT transcription/NN control/NN elements/NNS in/IN the/DT 5'/JJ flanking/JJ region/NN of/IN the/DT human/JJ EpoR/NN gene/NN ./. 
In/IN erythroid/JJ cells/NNS most/JJS of/IN the/DT transcription/NN activity/NN was/VBD contained/VBN in/IN a/DT 150/CD bp/NN promoter/NN fragment/NN with/IN binding/VBG sites/NNS for/IN transcription/NN factors/NNS AP2/NN ,/, Sp1/NN and/CC the/DT erythroid-specific/JJ GATA-1/NN ./. 
The/DT 150/CD bp/NN hEpoR/NN promoter/NN exhibited/VBD high/JJ and/CC low/JJ activity/NN in/IN erythroid/JJ OCIM1/NN and/CC K562/NN cells/NNS ,/, respectively/RB ,/, reflecting/VBG the/DT high/JJ and/CC low/JJ levels/NNS of/IN constitutive/JJ hEpoR/NN expression/NN ./. 
The/DT GATA-1/NN and/CC Sp1/NN binding/NN sites/NNS in/IN this/DT promoter/NN lacking/VBG a/DT TATA/NN sequence/NN were/VBD necessary/JJ for/IN a/DT high/JJ level/NN of/IN transcription/NN activation/NN ./. 
Protein-DNA/JJ binding/NN studies/NNS suggested/VBD that/IN Sp1/NN and/CC two/CD other/JJ CCGCCC/NN binding/NN proteins/NNS from/IN erythroid/JJ and/CC non-erythroid/JJ cells/NNS could/MD bind/VB to/TO the/DT Sp1/NN binding/NN motif/NN ./. 
By/IN increasing/VBG GATA-1/NN levels/NNS via/IN co-transfection/NN ,/, we/PRP were/VBD able/JJ to/TO transactivate/VB the/DT hEpoR/NN promoter/NN in/IN K562/NN cells/NNS and/CC non-erythroid/JJ cells/NNS ,/, but/CC not/RB in/IN the/DT highly/RB active/JJ OCIM1/NN cells/NNS ,/, although/IN GATA-1/NN mRNA/NN levels/NNS were/VBD comparable/JJ in/IN OCIM1/NN and/CC K562/NN ./. 
Interestingly/RB ,/, when/WRB we/PRP mutated/VBD the/DT Sp1/NN site/NN ,/, resulting/VBG in/IN a/DT marked/JJ decrease/NN in/IN hEpoR/NN promoter/NN activity/NN ,/, we/PRP could/MD restore/VB transactivation/NN by/IN increasing/VBG GATA-1/NN levels/NNS in/IN OCIM1/NN cells/NNS ./. 
These/DT data/NNS suggest/VBP that/IN while/IN GATA-1/NN can/MD transactivate/VB the/DT EpoR/NN promoter/NN ,/, the/DT level/NN of/IN hEpoR/NN gene/NN expression/NN does/VBZ not/RB depend/VB on/IN GATA-1/NN alone/RB ./. 
Rather/RB ,/, hEpoR/NN transcription/NN activity/NN depends/VBZ on/IN coordination/NN between/IN Sp1/NN and/CC GATA-1/NN with/IN other/JJ cell-specific/JJ factors/NNS ,/, including/VBG possibly/RB other/JJ Sp1-like/JJ binding/NN proteins/NNS ,/, to/TO provide/VB high/JJ level/NN ,/, tissue-specific/JJ expression/NN ./. 
UI/LS -/: 95365382/CD 
TI/LS -/: Overexpression/NN of/IN DR-nm23/NN ,/, a/DT protein/NN encoded/VBN by/IN a/DT member/NN of/IN the/DT nm23/NN gene/NN family/NN ,/, inhibits/VBZ granulocyte/NN differentiation/NN and/CC induces/VBZ apoptosis/NN in/IN 32Dc13/NN myeloid/JJ cells/NNS ./. 
AB/LS -/: Chronic/JJ myelogenous/JJ leukemia/NN evolves/VBZ in/IN two/CD clinically/RB distinct/JJ stages/NNS :/: a/DT chronic/JJ and/CC a/DT blast/NN crisis/NN phase/NN ./. 
The/DT molecular/JJ changes/NNS associated/VBN with/IN chronic/JJ phase/NN to/TO blast/NN crisis/NN transition/NN are/VBP largely/RB unknown/JJ ./. 
We/PRP have/VBP identified/VBN a/DT cDNA/NN clone/NN ,/, DR-nm23/NN ,/, differentially/RB expressed/VBN in/IN a/DT blast-crisis/JJ cDNA/NN library/NN ,/, which/WDT has/VBZ approximately/RB 70/CD %/NN sequence/NN similarity/NN to/TO the/DT putative/JJ metastatic/JJ suppressor/NN genes/NNS ,/, nm23-H1/NN and/CC nm23-H2/NN ./. 
The/DT deduced/VBN amino/NN acid/NN sequence/NN similarity/NN to/TO the/DT proteins/NNS encoded/VBN by/IN these/DT two/CD latter/JJ genes/NNS is/VBZ approximately/RB 65/CD %/NN and/CC includes/VBZ domains/NNS and/CC amino/NN acid/NN residues/NNS (/( the/DT leucine/NN zipper-like/JJ and/CC the/DT RGD/NN domain/NN ,/, a/DT serine/NN and/CC a/DT histidine/NN residue/NN in/IN the/DT NH2-/NN and/CC in/IN the/DT COOH-terminal/JJ portion/NN of/IN the/DT protein/NN ,/, respectively/RB )/) postulated/VBN to/TO be/VB important/JJ for/IN nm23/NN function/NN ./. 
DR-nm23/NN mRNA/NN is/VBZ preferentially/RB expressed/VBN at/IN early/JJ stages/NNS of/IN myeloid/JJ differentiation/NN of/IN highly/RB purified/VBN CD34+/JJ cells/NNS ./. 
Its/PRP$ constitutive/JJ expression/NN in/IN the/DT myeloid/JJ precursor/NN 32Dc13/NN cell/NN line/NN ,/, which/WDT is/VBZ growth-factor/NN dependent/JJ for/IN both/CC proliferation/NN and/CC differentiation/NN ,/, results/VBZ in/IN inhibition/NN of/IN granulocytic/JJ differentiation/NN induced/VBN by/IN granulocyte/NN colony-stimulating/JJ factor/NN and/CC causes/VBZ apoptotic/JJ cell/NN death/NN ./. 
These/DT results/NNS are/VBP consistent/JJ with/IN a/DT role/NN for/IN DR-nm23/NN in/IN normal/JJ hematopoiesis/NN and/CC raise/VBP the/DT possibility/NN that/IN its/PRP$ overexpression/NN contributes/VBZ to/TO differentiation/NN arrest/NN ,/, a/DT feature/NN of/IN blastic/JJ transformation/NN in/IN chronic/JJ myelogenous/JJ leukemia/NN ./. 
UI/LS -/: 96032864/CD 
TI/LS -/: An/DT interferon-gamma/NN activation/NN sequence/NN mediates/VBZ the/DT transcriptional/JJ regulation/NN of/IN the/DT IgG/NN Fc/NN receptor/NN type/NN IC/NN gene/NN by/IN interferon-gamma/NN ./. 
AB/LS -/: Expression/NN of/IN the/DT IgG/NN Fc/NN receptor/NN type/NN I/CD (/( Fc/NN gamma/NN RI/NN )/) on/IN myeloid/JJ cells/NNS is/VBZ dramatically/RB increased/VBN by/IN treatment/NN with/IN interferon-gamma/NN (/( IFN-gamma/NN )/) ./. 
We/PRP observed/VBD that/IN Fc/NN gamma/NN RI/NN transcript/NN levels/NNS in/IN monoblast-like/JJ U937/NN cells/NNS were/VBD elevated/VBN within/IN 3/CD hr/NN and/CC peaked/VBD 12/CD hr/NN after/IN exposure/NN to/TO IFN-gamma/NN ./. 
Treatment/NN of/IN U937/NN with/IN IFN-gamma/NN for/IN 9/CD hr/NN in/IN the/DT presence/NN of/IN cycloheximide/NN led/VBD to/TO super-induction/NN of/IN Fc/NN gamma/NN RI/NN expression/NN ./. 
Nuclear/JJ run-on/JJ analysis/NN revealed/VBD that/IN the/DT rate/NN of/IN Fc/NN gamma/NN RI/NN transcription/NN was/VBD increased/VBN by/IN IFN-gamma/NN ./. 
Genomic/JJ sequence/NN upstream/JJ of/IN the/DT Fc/NN gamma/NN RIC/NN gene/NN was/VBD cloned/VBN and/CC subjected/VBN to/TO primer/NN extension/NN analysis/NN ,/, which/WDT demonstrated/VBD a/DT single/JJ transcription/NN initiation/NN site/NN without/IN a/DT TATA/NN box/NN ./. 
Transient/JJ transfections/NNS of/IN CAT/NN reporter/NN gene/NN constructs/NNS containing/VBG various/JJ Fc/NN gamma/NN RIC/NN promoter/NN sequences/NNS into/IN U937/NN cells/NNS revealed/VBD that/IN a/DT 20-bp/JJ region/NN surrounding/VBG the/DT transcription/NN start/NN site/NN (/( -7/CD to/TO +13/CD )/) was/VBD capable/JJ of/IN mediating/VBG transcription/NN initiation/NN and/CC that/IN an/DT IFN-gamma/NN responsive/JJ element/NN (/( GIRE/NN )/) was/VBD present/JJ within/IN 74/CD bp/NN upstream/JJ of/IN the/DT transcription/NN initiation/NN site/NN ./. 
A/DT 17-bp/JJ sequence/NN between/IN positions/NNS -51/CD and/CC -35/CD conferred/VBD IFN-gamma/NN responsiveness/NN on/IN a/DT heterologous/JJ promoter/NN ./. 
Double-stranded/JJ GIRE/NN sequence/NN ,/, but/CC not/RB a/DT scrambled/VBN sequence/NN ,/, was/VBD specifically/RB bound/VBN by/IN nuclear/JJ proteins/NNS from/IN IFN-gamma/NN treated/JJ U937/NN cells/NNS ./. 
Gel/NN shift/NN experiments/NNS further/RB showed/VBD that/IN the/DT STAT1/NN alpha/NN protein/NN bound/VBD to/TO the/DT Fc/NN gamma/NN RIC/NN GIRE/NN in/IN response/NN to/TO IFN-gamma/NN treatment/NN of/IN U937/NN cells/NNS ./. 
The/DT Fc/NN gamma/NN RIC/NN GIRE/NN is/VBZ homologous/JJ to/TO the/DT IFN-gamma/NN activation/NN sequence/NN (/( GAS/NN )/) of/IN the/DT guanylate/NN binding/NN protein/NN and/CC to/TO X/NN box/NN elements/NNS of/IN class/NN II/CD MHC/NN genes/NNS ./. 
Our/PRP$ results/NNS demonstrate/VBP that/IN transcriptional/JJ regulation/NN of/IN the/DT Fc/NN gamma/NN RIC/NN gene/NN by/IN IFN-gamma/NN involves/VBZ the/DT binding/NN of/IN STAT1/NN alpha/NN to/TO a/DT 17-bp/JJ GAS/NN homology/NN in/IN the/DT proximal/JJ promoter/NN ./. 
UI/LS -/: 95327953/CD 
TI/LS -/: Constitutively/RB activated/VBN Jak-STAT/JJ pathway/NN in/IN T/NN cells/NNS transformed/VBN with/IN HTLV-I/NN ./. 
AB/LS -/: Human/JJ T/NN cell/NN lymphotropic/JJ virus/NN I/NN (/( HTLV-I/NN )/) is/VBZ the/DT etiological/JJ agent/NN for/IN adult/JJ T/NN cell/NN leukemia/NN and/CC tropical/JJ spastic/JJ paraparesis/NN (/( also/RB termed/VBN HTLV-I-associated/JJ myelopathy/NN )/) ./. 
HTLV-I-infected/JJ peripheral/JJ blood/NN T/NN cells/NNS exhibit/VBP an/DT initial/JJ phase/NN of/IN interleukin-2/NN (/( IL-2/NN )/) -dependent/JJ growth/NN ;/: over/IN time/NN ,/, by/IN an/DT unknown/JJ mechanism/NN ,/, the/DT cells/NNS become/VBP IL-2-independent/JJ ./. 
Whereas/IN the/DT Jak/NN kinases/NNS Jak1/NN and/CC Jak3/NN and/CC the/DT signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN proteins/NNS Stat3/NN and/CC Stat5/NN are/VBP activated/VBN in/IN normal/JJ T/NN cells/NNS in/IN response/NN to/TO IL-2/NN ,/, this/DT signaling/NN pathway/NN was/VBD constitutively/RB activated/VBN in/IN HTLV-I-transformed/JJ cells/NNS ./. 
In/IN HTLV-I-infected/JJ cord/NN blood/NN lymphocytes/NNS ,/, the/DT transition/NN from/IN IL-2-dependent/JJ to/TO IL-2-independent/JJ growth/NN correlated/VBD with/IN the/DT acquisition/NN of/IN a/DT constitutively/RB activated/JJ Jak-STAT/JJ pathway/NN ,/, which/WDT suggests/VBZ that/IN this/DT pathway/NN participates/VBZ in/IN HTLV-I-mediated/JJ T/NN cell/NN transformation/NN ./. 
UI/LS -/: 95340873/CD 
TI/LS -/: Nitric/JJ oxide/NN decreases/VBZ cytokine-induced/JJ endothelial/JJ activation/NN ./. 
Nitric/JJ oxide/NN selectively/RB reduces/VBZ endothelial/JJ expression/NN of/IN adhesion/NN molecules/NNS and/CC proinflammatory/JJ cytokines/NNS ./. 
AB/LS -/: To/TO test/VB the/DT hypothesis/NN that/IN nitric/JJ oxide/NN (/( NO/NN )/) limits/VBZ endothelial/JJ activation/NN ,/, we/PRP treated/VBD cytokine-stimulated/JJ human/JJ saphenous/JJ vein/NN endothelial/JJ cells/NNS with/IN several/JJ NO/NN donors/NNS and/CC assessed/VBD their/PRP$ effects/NNS on/IN the/DT inducible/JJ expression/NN of/IN vascular/JJ cell/NN adhesion/NN molecule-1/NN (/( VCAM-1/NN )/) ./. 
In/IN a/DT concentration-dependent/JJ manner/NN ,/, NO/NN inhibited/VBD interleukin/NN (/( IL/NN )/) -1/CD alpha-stimulated/JJ VCAM-1/NN expression/NN by/IN 35-55/CD %/NN as/IN determined/VBN by/IN cell/NN surface/NN enzyme/NN immunoassays/NNS and/CC flow/NN cytometry/NN ./. 
This/DT inhibition/NN was/VBD paralleled/VBN by/IN reduced/VBN monocyte/NN adhesion/NN to/TO endothelial/JJ monolayers/NNS in/IN nonstatic/JJ assays/NNS ,/, was/VBD unaffected/JJ by/IN cGMP/NN analogues/NNS ,/, and/CC was/VBD quantitatively/RB similar/JJ after/IN stimulation/NN by/IN either/CC IL-1/NN alpha/NN ,/, IL-1/NN beta/NN ,/, IL-4/NN ,/, tumor/NN necrosis/NN factor/NN (/( TNF/NN alpha/NN )/) ,/, or/CC bacterial/JJ lipopolysaccharide/NN ./. 
NO/NN also/RB decreased/VBD the/DT endothelial/JJ expression/NN of/IN other/JJ leukocyte/NN adhesion/NN molecules/NNS (/( E-selectin/NN and/CC to/TO a/DT lesser/JJR extent/NN ,/, intercellular/JJ adhesion/NN molecule-1/NN )/) and/CC secretable/JJ cytokines/NNS (/( IL-6/NN and/CC IL-8/NN )/) ./. 
Inhibition/NN of/IN endogenous/JJ NO/NN production/NN by/IN L-N-monomethyl-arginine/NN also/RB induced/VBD the/DT expression/NN of/IN VCAM-1/NN ,/, but/CC did/VBD not/RB augment/VB cytokine-induced/JJ VCAM-1/NN expression/NN ./. 
Nuclear/JJ run-on/JJ assays/NNS ,/, transfection/NN studies/NNS using/VBG various/JJ VCAM-1/NN promoter/NN reporter/NN gene/NN constructs/NNS ,/, and/CC electrophoretic/JJ mobility/NN shift/NN assays/NNS indicated/VBD that/IN NO/NN represses/VBZ VCAM-1/NN gene/NN transcription/NN ,/, in/IN part/NN ,/, by/IN inhibiting/VBG NF-kappa/NN B/NN ./. 
We/PRP propose/VBP that/IN NO/NN 's/POS ability/NN to/TO limit/VB endothelial/JJ activation/NN and/CC inhibit/VB monocyte/NN adhesion/NN may/MD contribute/VB to/TO some/DT of/IN its/PRP$ antiatherogenic/JJ and/CC antiinflammatory/JJ properties/NNS within/IN the/DT vessel/NN wall/NN ./. 
UI/LS -/: 95280909/CD 
TI/LS -/: MIP1/NN alpha/NN nuclear/JJ protein/NN (/( MNP/NN )/) ,/, a/DT novel/JJ transcription/NN factor/NN expressed/VBN in/IN hematopoietic/JJ cells/NNS that/WDT is/VBZ crucial/JJ for/IN transcription/NN of/IN the/DT human/JJ MIP-1/NN alpha/NN gene/NN ./. 
AB/LS -/: Murine/JJ macrophage/NN inflammatory/JJ protein/NN 1/CD alpha/NN (/( MIP-1/NN alpha/NN )/) and/CC its/PRP$ human/JJ equivalent/NN (/( GOS19/NN ,/, LD78/NN ,/, or/CC AT464/NN )/) are/VBP members/NNS of/IN the/DT -C-C/NN family/NN of/IN low-molecular-weight/JJ chemokines/NNS ./. 
Secreted/VBN from/IN activated/VBN T/NN cells/NNS and/CC macrophages/NNS ,/, bone/NN marrow-derived/JJ MIP-1/NN alpha/GOS19/NN inhibits/VBZ primitive/JJ hematopoietic/JJ stem/NN cells/NNS and/CC appears/VBZ to/TO be/VB involved/VBN in/IN the/DT homeostatic/JJ control/NN of/IN stem/NN cell/NN proliferation/NN ./. 
It/PRP also/RB induces/VBZ chemotaxis/NN and/CC inflammatory/JJ responses/NNS in/IN mature/JJ cell/NN types/NNS ./. 
Therefore/RB ,/, it/PRP is/VBZ important/JJ to/TO understand/VB the/DT mechanisms/NNS which/WDT control/VBP the/DT expression/NN of/IN MIP-1/NN alpha/GOS19/NN ./. 
Previous/JJ work/NN has/VBZ shown/VBN that/IN in/IN Jurkat/NN T/NN cells/NNS ,/, a/DT set/NN of/IN widely/RB expressed/VBN transcription/NN factors/NNS (/( the/DT ICK-1/NN family/NN )/) affect/VBP the/DT GOS19/NN promoter/NN ./. 
One/CD member/NN ,/, ICK-1A/NN ,/, behaves/VBZ as/IN a/DT strong/JJ negative/JJ regulator/NN ./. 
In/IN this/DT communication/NN ,/, we/PRP provide/VBP evidence/NN that/IN the/DT pathway/NN of/IN induction/NN in/IN the/DT macrophage/NN cell/NN line/NN U937/NN is/VBZ different/JJ from/IN that/DT in/IN Jurkat/NN cells/NNS ./. 
Furthermore/RB ,/, we/PRP show/VBP that/IN the/DT ICK-1/NN binding/NN site/NN does/VBZ not/RB confer/VB negative/JJ regulation/NN in/IN U937/NN cells/NNS ./. 
We/PRP provide/VBP evidence/NN for/IN an/DT additional/JJ binding/VBG site/NN ,/, the/DT MIP-1/NN alpha/NN nuclear/JJ protein/NN (/( MNP/NN )/) site/NN ,/, which/WDT overlaps/VBZ the/DT ICK-1/NN site/NN ./. 
Interaction/NN of/IN nuclear/JJ extracts/NNS from/IN various/JJ cell/NN lines/NNS and/CC tissue/NN with/IN the/DT MNP/NN site/NN leads/VBZ to/TO the/DT formation/NN of/IN fast-migrating/JJ protein-DNA/JJ complexes/NNS with/IN similar/JJ but/CC distinct/JJ electrophoretic/JJ mobilities/NNS ./. 
A/DT mutation/NN of/IN the/DT MNP/NN site/NN which/WDT does/VBZ not/RB abrogate/VB ICK-1/NN binding/NN inactivates/VBZ the/DT GOS19.1/NN promoter/NN in/IN U937/NN cells/NNS and/CC reduces/VBZ its/PRP$ activity/NN by/IN fourfold/RB in/IN Jurkat/NN cells/NNS ./. 
We/PRP propose/VBP that/IN the/DT MNP/NN protein/NN (/( s/NNS )/) binding/VBG at/IN the/DT MNP/NN site/NN constitutes/VBZ a/DT novel/JJ transcription/NN factor/NN (/( s/NNS )/) expressed/VBN in/IN hematopoietic/JJ cells/NNS ./. 
UI/LS -/: 96055286/CD 
TI/LS -/: The/DT effect/NN of/IN Toremifene/NN on/IN the/DT expression/NN of/IN some/DT genes/NNS in/IN human/JJ mononuclear/JJ cells/NNS ./. 
AB/LS -/: Toremifene/NN exerts/VBZ multiple/JJ and/CC varied/JJ effects/NNS on/IN the/DT gene/NN expression/NN of/IN human/JJ peripheral/JJ mononuclear/JJ cells/NNS ./. 
After/IN short-term/JJ ,/, in/FW vitro/FW exposure/NN to/TO therapeutical/JJ levels/NNS ,/, distinct/JJ changes/NNS in/IN P-glycoprotein/NN ,/, steroid/NN receptors/NNS ,/, p53/NN and/CC Bcl-2/NN expression/NN take/VBP place/NN ./. 
In/IN view/NN of/IN the/DT increasing/VBG use/NN of/IN antiestrogens/NNS in/IN cancer/NN therapy/NN and/CC prevention/NN ,/, there/EX is/VBZ obvious/JJ merit/NN in/IN long-term/JJ in/FW vivo/FW studies/NNS to/TO be/VB conducted/VBN ./. 
UI/LS -/: 95337737/CD 
TI/LS -/: The/DT interleukin-5/receptor/NN interaction/NN activates/VBZ Lyn/NN and/CC Jak2/NN tyrosine/NN kinases/NNS and/CC propagates/VBZ signals/NNS via/IN the/DT Ras-Raf-1-MAP/NN kinase/NN and/CC the/DT Jak-STAT/JJ pathways/NNS in/IN eosinophils/NNS ./. 
AB/LS -/: We/PRP have/VBP shown/VBN that/IN the/DT interaction/NN of/IN interleukin/NN (/( IL/NN )/) -5/CD with/IN the/DT receptor/NN activates/VBZ Lyn/NN tyrosine/NN kinase/NN within/IN 1/CD min/NN and/CC Jak2/NN tyrosine/NN kinase/NN within/IN 1-3/CD min/NN ./. 
IL-5/NN also/RB stimulates/VBZ GTP/NN binding/VBG to/TO p21ras/NN ./. 
The/DT signal/NN is/VBZ subsequently/RB propagated/VBN through/IN the/DT activation/NN of/IN Raf-1/NN ,/, MEK/NN ,/, and/CC MAP/NN kinases/NNS as/IN shown/VBN by/IN their/PRP$ increased/VBN autophosphorylation/NN in/FW vitro/FW and/CC phosphorylation/NN in/FW situ/FW ./. 
Jak2/NN kinase/NN has/VBZ been/VBN shown/VBN to/TO phosphorylate/VB STAT/NN nuclear/JJ proteins/NNS ./. 
The/DT activation/NN of/IN STAT/NN nuclear/JJ factors/NNS was/VBD studied/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN using/VBG a/DT gamma/NN activation/NN site/NN (/( GAS/NN )/) probe/NN ./. 
We/PRP found/VBD that/IN IL-5/NN induces/VBZ two/CD GAS-binding/JJ proteins/NNS in/IN eosinophils/NNS ,/, one/CD of/IN which/WDT is/VBZ STAT1/NN ./. 
We/PRP conclude/VBP that/IN IL-5/NN induced/JJ signals/NNS are/VBP propagated/VBN through/IN two/CD distinct/JJ pathways/NNS :/: (/( 1/LS )/) Lyn/NN -->/TO Ras/NN -->/TO Raf-1/NN -->/TO MEK/NN -->/TO MAP/NN kinase/NN and/CC (/( 2/LS )/) Jak2/NN -->/TO STAT1/NN ./. 
UI/LS -/: 95266250/CD 
TI/LS -/: The/DT retinoblastoma/NN gene/NN product/NN negatively/RB regulates/VBZ transcriptional/JJ activation/NN mediated/VBN by/IN the/DT human/JJ cytomegalovirus/NN IE2/NN protein/NN ./. 
AB/LS -/: The/DT IE2/NN gene/NN product/NN of/IN human/JJ cytomegalovirus/NN (/( HCMV/NN )/) is/VBZ one/CD of/IN a/DT few/JJ viral/JJ regulatory/JJ proteins/NNS expressed/VBN immediately/RB upon/IN infection/NN of/IN the/DT host/NN cell/NN ./. 
It/PRP is/VBZ a/DT potent/JJ transcriptional/JJ activator/NN of/IN many/JJ viral/JJ and/CC cellular/JJ promoters/NNS ./. 
We/PRP found/VBD that/IN the/DT retinoblastoma/NN susceptibility/NN gene/NN product/NN (/( Rb/NN )/) dramatically/RB suppressed/VBD this/DT IE2/NN transactivation/NN of/IN various/JJ promoters/NNS ./. 
However/RB ,/, unlike/IN another/DT tumor/NN suppressor/NN protein/NN ,/, p53/NN ,/, Rb/NN did/VBD not/RB have/VB any/DT significant/JJ effect/NN on/IN basal/JJ levels/NNS of/IN transcription/NN ,/, suggesting/VBG that/IN Rb/NN specifically/RB interacts/VBZ with/IN IE2/NN rather/RB than/IN other/JJ cellular/JJ factors/NNS involved/VBN in/IN the/DT general/JJ transcription/NN machinery/NN ./. 
We/PRP found/VBD by/IN protein-affinity/JJ chromatography/NN that/IN Rb/NN in/IN nuclear/JJ extracts/NNS or/CC produced/VBN by/IN in/FW vitro/FW translation/NN directly/RB bound/VBD to/TO IE2/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN Rb/NN may/MD regulate/VB the/DT life/NN cycle/NN of/IN HCMV/NN ,/, which/WDT is/VBZ endemic/JJ in/IN the/DT human/JJ population/NN ./. 
Furthermore/RB ,/, these/DT data/NNS may/MD provide/VB new/JJ insights/NNS into/IN the/DT slow/JJ rate/NN of/IN HCMV/NN DNA/NN replication/NN in/IN cells/NNS and/CC the/DT possible/JJ involvement/NN of/IN HCMV/NN in/IN tumorigenesis/NN ./. 
UI/LS -/: 96082382/CD 
TI/LS -/: Expression/NN of/IN the/DT nucleoside/NN diphosphate/NN kinase/NN in/IN human/JJ skin/NN cancers/NNS :/: an/DT immunohistochemical/JJ study/NN ./. 
AB/LS -/: Expression/NN of/IN nucleoside/NN diphosphate/NN (/( NDP/NN )/) kinase/NN ,/, which/WDT is/VBZ homologous/JJ to/TO the/DT nm23/NN gene/NN product/NN in/IN a/DT variety/NN of/IN species/NNS ,/, has/VBZ been/VBN found/VBN to/TO be/VB inversely/RB associated/VBN with/IN metastatic/JJ potential/NN ./. 
However/RB ,/, the/DT relationship/NN remains/VBZ controversial/JJ according/VBG to/TO the/DT tumor/NN cell/NN types/NNS and/CC experimental/JJ system/NN ,/, with/IN conflicting/VBG results/NNS from/IN different/JJ research/NN groups/NNS ./. 
In/IN order/NN to/TO determine/VB whether/IN NDP/NN kinase/NN expression/NN serves/VBZ as/IN a/DT marker/NN for/IN metastatic/JJ potential/NN in/IN human/JJ skin/NN cancer/NN ,/, we/PRP assessed/VBD the/DT levels/NNS of/IN NDP/NN kinase/NN expression/NN in/IN 9/CD keratoacanthomas/NNS (/( KAs/NNS )/) ,/, 26/CD squamous/JJ cell/NN carcinomas/NNS (/( SCCs/NNS )/) ,/, and/CC 25/CD basal/JJ cell/NN carcinomas/NNS (/( BCCs/NNS )/) using/VBG immunohistochemistry/NN ./. 
The/DT expression/NN of/IN NDP/NN kinase/NN was/VBD intense/JJ in/IN KA/NN and/CC SCC/NN compared/VBN with/IN BCC/NN ./. 
However/RB ,/, the/DT difference/NN of/IN NDP/NN kinase/NN expression/NN between/IN KA/NN and/CC SCC/NN was/VBD not/RB statistically/RB significant/JJ ./. 
And/CC there/EX was/VBD no/DT statistically/RB significant/JJ difference/NN in/IN NDP/NN kinase/NN expression/NN between/IN SCC/NN with/IN metastasis/NN and/CC SCC/NN without/IN metastasis/NN ./. 
Our/PRP$ results/NNS contradict/VBP the/DT hypothesis/NN concerning/VBG the/DT possible/JJ role/NN of/IN nm23/NN gene/NN as/IN a/DT metastatic/JJ suppressor/NN gene/NN in/IN human/JJ skin/NN cancer/NN ./. 
The/DT mechanism/NN of/IN overexpression/NN in/IN various/JJ tumor/NN cell/NN types/NNS and/CC its/PRP$ biological/JJ significance/NN in/IN cutaneous/JJ carcinogenesis/NN remain/VB to/TO be/VB determined/VBN ./. 
UI/LS -/: 95362365/CD 
TI/LS -/: RB/NN and/CC a/DT novel/JJ E2F-1/NN binding/NN protein/NN in/IN MHC/NN class/NN II/CD deficient/JJ B-cell/NN lines/NNS and/CC normal/JJ IFN-gamma/NN induction/NN of/IN the/DT class/NN IL/NN transactivator/NN CIITA/NN in/IN class/NN II/CD non-inducible/JJ RB-defective/JJ tumor/NN lines/NNS ./. 
AB/LS -/: The/DT major/JJ histocompatibility/NN (/( MHC/NN )/) class/NN II/CD genes/NNS encode/VBP cell/NN surface/NN proteins/NNS that/WDT bind/VBP antigenic/JJ peptide/NN for/IN presentation/NN to/TO T-cells/NNS ./. 
The/DT class/NN II/CD proteins/NNS are/VBP expressed/VBN constitutively/RB on/IN B-cells/NNS and/CC EBV-/NN transformed/JJ B-cells/NNS ,/, and/CC are/VBP inducible/JJ by/IN IFN-gamma/NN on/IN a/DT wide/JJ variety/NN of/IN cell/NN types/NNS ./. 
Retinoblastoma/NN protein/NN (/( RB/NN )/) is/VBZ a/DT tumor/NN suppressor/NN and/CC functions/VBZ as/IN a/DT transcriptional/JJ repressor/NN by/IN binding/VBG and/CC inactivating/VBG the/DT transactivator/NN E2F-I/NN ./. 
RB-defective/JJ tumor/NN lines/NNS are/VBP non-inducible/JJ for/IN MHC/NN class/NN II/CD by/IN IFN-gamma/NN ,/, or/CC very/RB weakly/RB inducible/JJ ,/, but/CC transfection/NN of/IN 2/CD different/JJ lines/NNS with/IN RB/NN expression/NN vectors/NNS re-establishes/VBZ or/CC substantially/RB enhances/VBZ class/NN II/CD inducibility/NN ./. 
Therefore/RB ,/, we/PRP examined/VBD the/DT RB/NN status/NN of/IN a/DT series/NN of/IN B-cell/NN mutants/NNS that/WDT are/VBP defective/JJ in/IN class/NN II/CD expression/NN ,/, generated/VBN either/CC in/FW vitro/FW or/CC derived/VBN from/IN Bare/NN Lymphocyte/NN Syndrome/NN (/( BLS/NN )/) patients/NNS ./. 
Nuclear/JJ matrix-bound/JJ RB/NN was/VBD detectable/JJ in/IN all/DT cases/NNS ,/, indicating/VBG that/IN loss/NN of/IN RB/NN is/VBZ not/RB responsible/JJ for/IN decreased/VBN class/NN II/CD expression/NN in/IN these/DT lines/NNS ./. 
A/DT second/JJ E2F-I/NN binding/NN protein/NN ,/, most/RBS likely/RB DP-I/NN ,/, was/VBD also/RB apparently/RB normal/JJ in/IN both/CC class/NN II-positive/JJ and/CC -negative/JJ B-cell/NN lines/NNS ./. 
We/PRP also/RB examined/VBD the/DT IFN-gamma/NN induction/NN of/IN CIITA/NN in/IN RB-defective/JJ lines/NNS ./. 
CIITA/NN is/VBZ a/DT class/NN II/CD gene/NN transactivator/NN known/VBN to/TO be/VB defective/JJ in/IN one/CD form/NN of/IN BLS/NN and/CC to/TO be/VB required/VBN for/IN the/DT induction/NN of/IN MHC/NN class/NN II/CD by/IN IFN-gamma/NN ./. 
CIITA/NN mRNA/NN is/VBZ normally/RB inducible/JJ by/IN IFN-gamma/NN in/IN class/NN II/CD non-inducible/JJ ,/, RB-defective/JJ lines/NNS ,/, and/CC in/IN one/CD line/NN ,/, re-expression/NN of/IN RB/NN has/VBZ no/DT effect/NN on/IN CIITA/NN mRNA/NN induction/NN levels/NNS ./. 
Thus/RB ,/, the/DT block/NN in/IN MHC/NN class/NN II/CD inducibility/NN in/IN RB-defective/JJ cells/NNS is/VBZ not/RB due/JJ to/TO a/DT block/NN in/IN CIITA/NN inducibility/NN ./. 
UI/LS -/: 95365357/CD 
TI/LS -/: Interleukin/NN 12/CD induces/VBZ tyrosine/NN phosphorylation/NN and/CC activation/NN of/IN STAT4/NN in/IN human/JJ lymphocytes/NNS ./. 
AB/LS -/: Interleukin/NN 12/CD (/( IL-12/NN )/) is/VBZ an/DT important/JJ immunoregulatory/JJ cytokine/NN whose/WP$ receptor/NN is/VBZ a/DT member/NN of/IN the/DT hematopoietin/NN receptor/NN superfamily/NN ./. 
We/PRP have/VBP recently/RB demonstrated/VBN that/IN stimulation/NN of/IN human/JJ T/NN and/CC natural/JJ killer/NN cells/NNS with/IN IL-12/NN induces/VBZ tyrosine/NN phosphorylation/NN of/IN the/DT Janus/NN family/NN tyrosine/NN kinase/NN JAK2/NN and/CC Tyk2/NN ,/, implicating/VBG these/DT kinases/NNS in/IN the/DT immediate/JJ biochemical/JJ response/NN to/TO IL-12/NN ./. 
Recently/RB ,/, transcription/NN factors/NNS known/VBN as/IN STATs/NNS (/( signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN )/) have/VBP been/VBN shown/VBN to/TO be/VB tyrosine/NN phosphorylated/JJ and/CC activated/VBN in/IN response/NN to/TO a/DT number/NN of/IN cytokines/NNS that/WDT bind/VBP hematopoietin/NN receptors/NNS and/CC activate/VBP JAK/NN kinases/NNS ./. 
In/IN this/DT report/NN we/PRP demonstrate/VBP that/IN IL-12/NN induces/VBZ tyrosine/NN phosphorylation/NN of/IN a/DT recently/RB identified/VBN STAT/NN family/NN member/NN ,/, STAT4/NN ,/, and/CC show/VBP that/IN STAT4/NN expression/NN is/VBZ regulated/VBN by/IN T-cell/NN activation/NN ./. 
Furthermore/RB ,/, we/PRP show/VBP that/IN IL-12/NN stimulates/VBZ formation/NN of/IN a/DT DNA-binding/JJ complex/NN that/WDT recognizes/VBZ a/DT DNA/NN sequence/NN previously/RB shown/VBN to/TO bind/VB STAT/NN proteins/NNS and/CC that/IN this/DT complex/NN contains/VBZ STAT4/NN ./. 
These/DT data/NNS ,/, and/CC the/DT recent/JJ demonstration/NN of/IN JAK/NN phosphorylation/NN by/IN IL-12/NN ,/, identify/VBP a/DT rapid/JJ signal-transduction/JJ pathway/NN likely/JJ to/TO mediate/VB IL-12-induced/JJ gene/NN expression/NN ./. 
UI/LS -/: 96007705/CD 
TI/LS -/: Temperature-induced/JJ down-regulation/NN of/IN the/DT glucocorticoid/NN receptor/NN in/IN peripheral/JJ blood/NN mononuclear/JJ leucocyte/NN in/IN patients/NNS with/IN sepsis/NN or/CC septic/JJ shock/NN ./. 
AB/LS -/: OBJECTIVE/NN :/: Activation/NN of/IN the/DT hypothalamic-pituitary-adrenal/JJ axis/NN is/VBZ of/IN vital/JJ importance/NN during/IN critical/JJ illness/NN ./. 
We/PRP have/VBP studied/VBN the/DT adaptive/JJ mechanisms/NNS which/WDT occur/VBP at/IN the/DT level/NN of/IN the/DT glucocorticoid/NN receptor/NN in/IN glucocorticoid/NN target/NN tissues/NNS in/IN patients/NNS with/IN sepsis/NN or/CC septic/JJ shock/NN ./. 
DESIGN/NN :/: The/DT effects/NNS of/IN hypercortisolaemia/NN ,/, hyperthermia/NN and/CC cellular/JJ composition/NN on/IN number/NN of/IN glucocorticoid/NN receptors/NNS per/IN cell/NN and/CC their/PRP$ affinity/NN were/VBD evaluated/VBN ,/, both/CC in/FW vitro/FW and/CC in/FW vivo/FW ,/, in/IN peripheral/JJ blood/NN mononuclear/JJ leucocytes/NNS of/IN control/JJ subjects/NNS and/CC in/IN patients/NNS with/IN sepsis/NN or/CC septic/JJ shock/NN ./. 
SUBJECTS/NNS :/: Fifteen/CD patients/NNS (/( age/NN 25-79/CD )/) with/IN sepsis/NN or/CC septic/JJ shock/NN who/WP were/VBD admitted/VBN to/TO an/DT intensive/JJ care/NN unit/NN were/VBD studied/VBN ./. 
The/DT control/JJ group/NN consisted/VBD of/IN 24/CD healthy/JJ laboratory/NN employees/NNS ./. 
MEASUREMENTS/NNS :/: The/DT binding/NN capacity/NN and/CC affinity/NN of/IN the/DT glucocorticoid/NN receptors/NNS were/VBD measured/VBN and/CC compared/VBN to/TO clinical/JJ data/NNS and/CC the/DT plasma/NN cortisol/NN concentrations/NNS ./. 
RESULTS/NNS :/: Hypercortisolaemia/NN ,/, in/FW vitro/FW ,/, resulted/VBD in/IN a/DT decreased/VBN affinity/NN and/CC a/DT decreased/VBN binding/NN capacity/NN of/IN the/DT glucocorticoid/NN receptor/NN ./. 
In/FW vitro/FW ,/, hyperthermia/NN as/RB well/RB as/IN variations/NNS in/IN the/DT cellular/JJ composition/NN did/VBD not/RB influence/VB the/DT glucocorticoid/NN receptor/NN ./. 
In/FW vivo/FW ,/, there/EX was/VBD no/DT change/NN in/IN the/DT number/NN of/IN receptors/NNS per/IN cell/NN in/IN patients/NNS with/IN sepsis/NN or/CC septic/JJ shock/NN as/IN compared/VBN to/TO healthy/JJ controls/NNS ./. 
However/RB ,/, a/DT decreased/VBN affinity/NN of/IN the/DT glucocorticoid/NN receptor/NN was/VBD observed/VBN ./. 
There/EX was/VBD a/DT weak/JJ but/CC significant/JJ negative/JJ correlation/NN between/IN body/NN temperature/NN and/CC the/DT number/NN of/IN glucocorticoid/NN receptors/NNS in/IN the/DT patient/NN group/NN ./. 
There/EX was/VBD no/DT relation/NN between/IN circulating/VBG cortisol/NN concentrations/NNS and/CC glucocorticoid/NN receptor/NN affinity/NN and/CC number/NN ./. 
CONCLUSIONS/NNS :/: There/EX is/VBZ no/DT obvious/JJ regulation/NN of/IN the/DT number/NN of/IN glucocorticoid/NN receptors/NNS by/IN plasma/NN cortisol/NN concentrations/NNS in/FW vivo/FW ./. 
The/DT decreased/VBN affinity/NN of/IN the/DT glucocorticoid/NN receptor/NN together/RB with/IN the/DT negative/JJ correlation/NN between/IN hyperthermia/NN and/CC the/DT number/NN of/IN glucocorticoid/NN receptors/NNS in/IN patients/NNS with/IN sepsis/NN or/CC septic/JJ shock/NN suggest/VBP that/IN hypothalamic-pituitary-adrenal/JJ axis/NN activation/NN during/IN critical/JJ illness/NN is/VBZ accompanied/VBN by/IN peripheral/JJ adaptation/NN in/IN glucocorticoid/NN receptor/NN number/NN and/CC affinity/NN ./. 
UI/LS -/: 95332324/CD 
TI/LS -/: Integrin-mediated/JJ tyrosine/NN phosphorylation/NN and/CC cytokine/NN message/NN induction/NN in/IN monocytic/JJ cells/NNS ./. 
A/DT possible/JJ signaling/NN role/NN for/IN the/DT Syk/NN tyrosine/NN kinase/NN ./. 
AB/LS -/: Activation/NN of/IN cytoplasmic/JJ tyrosine/NN kinases/NNS is/VBZ an/DT important/JJ aspect/NN of/IN signal/NN transduction/NN mediated/VBN by/IN integrins/NNS ./. 
In/IN the/DT human/JJ monocytic/JJ cell/NN line/NN THP-1/NN ,/, either/CC integrin-dependent/JJ cell/NN adhesion/NN to/TO fibronectin/NN or/CC ligation/NN of/IN beta/NN 1/CD integrins/NNS with/IN antibodies/NNS causes/VBZ a/DT rapid/JJ and/CC intense/JJ tyrosine/NN phosphorylation/NN of/IN two/CD sets/NNS of/IN proteins/NNS of/IN about/RB 65-75/CD and/CC 120-125/CD kDa/NN ./. 
In/IN addition/NN ,/, integrin/NN ligation/NN leads/VBZ to/TO nuclear/JJ translocation/NN of/IN the/DT p50/NN and/CC p65/NN subunits/NNS of/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN ,/, to/TO activation/NN of/IN a/DT reporter/NN gene/NN driven/VBN by/IN a/DT promoter/NN containing/VBG NF-kappa/NN B/NN sites/NNS ,/, and/CC to/TO increased/VBN levels/NNS of/IN mRNAs/NNS for/IN immediate-early/JJ genes/NNS ,/, including/VBG the/DT cytokine/NN interleukin/NN (/( IL/NN )/) -1/CD beta/NN ./. 
The/DT tyrosine/NN kinase/NN inhibitors/NNS genistein/NN and/CC herbimycin/NN A/NN block/VBP both/CC integrin-mediated/JJ tyrosine/NN phosphorylation/NN and/CC increases/NNS in/IN IL-1/NN beta/NN message/NN levels/NNS ,/, indicating/VBG a/DT causal/JJ relationship/NN between/IN the/DT two/CD events/NNS ./. 
The/DT components/NNS tyrosine/NN phosphorylated/VBN subsequent/JJ to/TO cell/NN adhesion/NN include/VBP paxillin/NN ,/, pp125FAK/NN ,/, and/CC the/DT SH2/NN domain/NN containing/VBG tyrosine/NN kinase/NN Syk/NN ./. 
In/IN contrast/NN ,/, integrin/NN ligation/NN with/IN antibodies/NNS induces/VBZ tyrosine/NN phosphorylation/NN of/IN Syk/NN but/CC not/RB of/IN FAK/NN or/CC paxillin/NN ./. 
In/IN adhering/JJ cells/NNS ,/, pre-treatment/NN with/IN cytochalasin/NN D/NN suppresses/VBZ tyrosine/NN phosphorylation/NN of/IN FAK/NN and/CC paxillin/NN but/CC not/RB of/IN Syk/NN ,/, while/IN IL-1/NN beta/NN message/NN induction/NN is/VBZ unaffected/JJ ./. 
These/DT observations/NNS indicate/VBP that/IN the/DT Syk/NN tyrosine/NN kinase/NN may/MD be/VB an/DT important/JJ component/NN of/IN an/DT integrin/NN signaling/NN pathway/NN in/IN monocytic/JJ cells/NNS ,/, leading/VBG to/TO activation/NN of/IN NF-kappa/NN B/NN and/CC to/TO increased/VBN levels/NNS of/IN cytokine/NN messages/NNS ./. 
UI/LS -/: 96065933/CD 
TI/LS -/: Inhibition/NN of/IN dexamethasone/NN binding/NN to/TO human/JJ glucocorticoid/NN receptor/NN by/IN New/NN World/NN primate/JJ cell/NN extracts/NNS ./. 
AB/LS -/: To/TO determine/VB if/IN New/NN World/NN primates/NNS express/VBP an/DT inhibitor/NN that/WDT influences/VBZ glucocorticoid/NN receptor/NN (/( GR/NN )/) binding/NN characteristics/NNS ,/, we/PRP examined/VBD [3H]dexamethasone/NN binding/NN in/IN cytosol/NN prepared/VBN from/IN B95-8/NN lymphoid/JJ cells/NNS ,/, derived/VBN from/IN the/DT cotton/NN top/NN tamarin/NN (/( Saguinus/FW oedipus/FW )/) ,/, in/IN combination/NN with/IN cytosol/NN prepared/VBN from/IN human/JJ or/CC rat/NN tissues/NNS ./. 
B95-8/NN cytosol/NN inhibited/VBD specific/JJ binding/NN of/IN [3H]dexamethasone/NN (/( P/NN </JJR 0.01/CD )/) when/WRB mixed/VBN with/IN cytosol/NN prepared/VBN from/IN either/CC a/DT human/JJ lymphoid/JJ cell/NN line/NN (/( HL/NN )/) or/CC rat/NN thymus/NN ./. 
The/DT inhibitory/JJ activity/NN was/VBD heat/NN labile/JJ and/CC trypsin/NN sensitive/JJ ./. 
Peak/JJ inhibitory/JJ activity/NN was/VBD found/VBN in/IN the/DT 150-200/CD kd/NN fractions/NNS after/IN Sephacryl/NN G-200/NN ultrafiltration/NN ./. 
Scatchard/NN analysis/NN of/IN [3H]dexamethasone/NN binding/NN using/VBG mixed/JJ cytosol/NN showed/VBD a/DT diminished/VBN GR/NN apparent/JJ binding/NN affinity/NN when/WRB compared/VBN to/TO HL/NN cytosol/NN ./. 
Kinetic/JJ studies/NNS using/VBG mixed/JJ cytosol/NN indicated/VBD that/IN B95-8/NN cytosol/NN did/VBD not/RB affect/VB the/DT apparent/JJ dissociation/NN rate/NN of/IN [3H]dexamethasone/NN ./. 
These/DT data/NNS demonstrate/VBP that/IN B95-8/NN cells/NNS contain/VBP a/DT competitive/JJ inhibitor/NN that/WDT prevents/VBZ binding/NN of/IN dexamethasone/NN to/TO its/PRP$ cognate/JJ receptor/NN ./. 
UI/LS -/: 95392577/CD 
TI/LS -/: Disruption/NN of/IN a/DT GATA/NN motif/NN in/IN the/DT Duffy/NN gene/NN promoter/NN abolishes/VBZ erythroid/JJ gene/NN expression/NN in/IN Duffy-negative/JJ individuals/NNS ./. 
AB/LS -/: The/DT mRNA/NN for/IN the/DT Duffy/NN blood/NN group/NN antigen/NN ,/, the/DT erythrocyte/NN receptor/NN for/IN the/DT Plasmodium/NN vivax/NN malaria/NN parasite/NN ,/, has/VBZ recently/RB been/VBN cloned/VBN and/CC shown/VBN to/TO encode/VB a/DT widely/RB expressed/VBN chemokine/NN receptor/NN ./. 
Here/RB ,/, we/PRP show/VBP that/IN the/DT Duffy/NN antigen/chemokine/NN receptor/NN gene/NN (/( DARC/NN )/) is/VBZ composed/VBN of/IN a/DT single/JJ exon/NN and/CC that/IN most/JJS Duffy-negative/JJ blacks/NNS carry/VBP a/DT silent/JJ FY*B/NN allele/NN with/IN a/DT single/JJ T/NN to/TO C/NN substitution/NN at/IN nucleotide/NN -46/CD ./. 
This/DT mutation/NN impairs/VBZ the/DT promoter/NN activity/NN in/IN erythroid/JJ cells/NNS by/IN disrupting/VBG a/DT binding/VBG site/NN for/IN the/DT GATA1/NN erythroid/JJ transcription/NN factor/NN ./. 
With/IN the/DT recent/JJ characterization/NN of/IN the/DT FY*A/NN and/CC FY*B/NN alleles/NNS ,/, these/DT findings/NNS provide/VBP the/DT molecular/JJ basis/NN of/IN the/DT Duffy/NN blood/NN group/NN system/NN and/CC an/DT explanation/NN for/IN the/DT erythroid-specific/JJ repression/NN of/IN the/DT DARC/NN gene/NN in/IN Duffy-negative/JJ individuals/NNS ./. 
UI/LS -/: 95287633/CD 
TI/LS -/: Activation/NN of/IN pp90rsk/NN and/CC early/JJ growth/NN response-1/NN gene/NN expression/NN by/IN pokeweed/NN mitogen/NN in/IN human/JJ B/NN cells/NNS ./. 
AB/LS -/: The/DT present/JJ studies/NNS have/VBP examined/VBN the/DT effects/NNS of/IN pokeweed/NN mitogen/NN (/( PWM/NN )/) on/IN the/DT induction/NN of/IN early/JJ growth/NN response-1/NN gene/NN (/( EGR-1/NN )/) in/IN normal/JJ human/JJ B/NN cells/NNS ./. 
PWM/NN regulates/VBZ EGR-1/NN gene/NN expression/NN by/IN both/CC transcriptional/JJ and/CC post-transcriptional/JJ mechanisms/NNS ./. 
Transient/JJ transfection/NN assays/NNS with/IN EGR-1/NN promoter/NN fragments/NNS linked/VBN to/TO the/DT chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) gene/NN demonstrated/VBD that/IN PWM/NN induced/JJ EGR-1/NN transcription/NN is/VBZ conferred/VBN by/IN the/DT CArG/NN motif/NN (/( C/NN C[AT]6GG/NN )/) in/IN the/DT EGR-1/NN promoter/NN ./. 
The/DT results/NNS further/RB demonstrated/VBD the/DT activation/NN of/IN S6/NN kinase/NN (/( pp90rsk/NN )/) ,/, evidenced/VBN by/IN phosphorylation/NN of/IN S6/NN and/CC serum/NN response/NN factor/NN (/( SRF/NN )/) peptides/NNS ,/, in/IN PWM/NN treated/JJ B/NN cells/NNS ./. 
Taken/VBN together/RB ,/, these/DT findings/NNS suggest/VBP that/IN PWM/NN is/VBZ able/JJ to/TO initiate/VB an/DT intracytoplasmic/JJ signalling/NN cascade/NN and/CC EGR-1/NN induction/NN in/IN normal/JJ human/JJ B/NN cells/NNS ./. 
UI/LS -/: 95337734/CD 
TI/LS -/: A/DT conserved/VBN motif/NN in/IN the/DT promoters/NNS of/IN several/JJ cytokines/NNS expressed/VBN by/IN human/JJ Th2-type/JJ lymphocytes/NNS ./. 
AB/LS -/: We/PRP have/VBP recently/RB found/VBN a/DT novel/JJ conserved/VBN motif/NN in/IN the/DT promoters/NNS of/IN several/JJ T-cell-expressed/JJ cytokines/NNS [/( human/JJ interleukin-2/NN ,/, -4/CD ,/, -5/CD and/CC -13/CD and/CC human/JJ and/CC mouse/NN granulocyte/macrophage-colony/NN stimulating/JJ factor/NN (/( GM-CSF/NN )/) ]/) ./. 
It/PRP contains/VBZ a/DT core/NN sequence/NN CTTGG/NN .../: CCAAG/NN which/WDT is/VBZ present/JJ as/IN part/NN of/IN larger/JJR palindromic/JJ sequences/NNS in/IN each/DT gene/NN ./. 
This/DT suggest/VBP that/IN they/PRP may/MD interact/VB with/IN a/DT new/JJ family/NN of/IN trans-acting/JJ factors/NNS ./. 
In/IN transfection/NN assays/NNS ,/, the/DT human/JJ GM-CSF/NN element/NN has/VBZ a/DT strong/JJ positive/JJ effect/NN on/IN the/DT expression/NN of/IN a/DT reporter/NN gene/NN by/IN the/DT human/JJ T/NN cell/NN line/NN Jurkat/NN J6/NN upon/IN stimulation/NN ./. 
In/IN DNA/NN mobility/NN shift/NN assays/NNS ,/, this/DT sequence/NN can/MD give/VB either/CC six/CD different/JJ specific/JJ bands/NNS which/WDT are/VBP competed/VBN out/RP by/IN different/JJ parts/NNS of/IN the/DT sequence/NN or/CC one/CD specific/JJ band/NN which/WDT is/VBZ competed/VBN out/RP by/IN each/DT of/IN the/DT inverted/VBN repeats/NNS ,/, depending/VBG on/IN the/DT reconstitution/NN conditions/NNS ./. 
In/IN different/JJ genes/NNS ,/, the/DT core/NN sequences/NNS are/VBP separated/VBN by/IN integer/NN numbers/NNS of/IN helical/JJ turns/NNS ./. 
Considering/VBG the/DT strong/JJ positive/JJ regulatory/JJ effect/NN of/IN this/DT element/NN and/CC its/PRP$ presence/NN in/IN several/JJ T-cell-expressed/JJ cytokine/NN genes/NNS ,/, it/PRP may/MD be/VB crucial/JJ to/TO the/DT coordinated/VBN expression/NN of/IN these/DT cytokines/NNS in/IN T/NN helper/NN cells/NNS ./. 
UI/LS -/: 95221892/CD 
TI/LS -/: cDNA/NN cloning/NN of/IN a/DT NGFI-B/nur77-related/JJ transcription/NN factor/NN from/IN an/DT apoptotic/JJ human/JJ T/NN cell/NN line/NN ./. 
AB/LS -/: A/DT human/JJ T/NN lymphoid/JJ cell/NN line/NN ,/, PEER/NN ,/, dies/VBZ by/IN apoptosis/NN in/IN the/DT presence/NN of/IN PMA/NN and/CC calcium/NN ionophore/NN ./. 
A/DT new/JJ gene/NN ,/, TINUR/NN ,/, was/VBD cloned/VBN from/IN apoptotic/JJ PEER/NN cells/NNS ./. 
The/DT expression/NN of/IN the/DT TINUR/NN gene/NN is/VBZ induced/VBN within/IN 1/CD h/NN after/IN the/DT cross-linking/NN of/IN the/DT T/NN cell/NN Ag/NN receptor/NN complex/NN ./. 
TINUR/NN belongs/VBZ to/TO the/DT NGFI-B/nur77/NN family/NN of/IN the/DT steroid/NN receptor/NN superfamily/NN and/CC is/VBZ an/DT orphan/NN receptor/NN ./. 
TINUR/NN binds/VBZ to/TO the/DT same/JJ DNA/NN sequence/NN as/IN NGFI-B/nur77/NN ./. 
We/PRP also/RB propose/VBP that/IN the/DT NGFI-B/nur77/NN family/NN can/MD be/VB classified/VBN into/IN two/CD subtypes/NNS ./. 
UI/LS -/: 95202809/CD 
TI/LS -/: Aspirin/NN inhibits/VBZ nuclear/JJ factor-kappa/NN B/NN mobilization/NN and/CC monocyte/NN adhesion/NN in/IN stimulated/VBN human/JJ endothelial/JJ cells/NNS ./. 
AB/LS -/: BACKGROUND/NN :/: The/DT induction/NN of/IN vascular/JJ cell/NN adhesion/NN molecule-1/NN (/( VCAM-1/NN )/) and/CC E-selectin/NN by/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNF/NN )/) is/VBZ mediated/VBN by/IN mobilization/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ./. 
Since/IN salicylates/NNS have/VBP been/VBN reported/VBN to/TO inhibit/VB NF-kappa/NN B/NN activation/NN by/IN preventing/VBG the/DT degradation/NN of/IN its/PRP$ inhibitor/NN I/NN kappa/NN B/NN ,/, we/PRP studied/VBD a/DT potential/JJ inhibition/NN of/IN this/DT pathway/NN by/IN acetylsalicylate/NN (/( aspirin/NN )/) in/IN human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS (/( HUVECs/NNS )/) ./. 
METHODS/NNS AND/CC RESULTS/NNS :/: Gel-shift/JJ analyses/NNS demonstrated/VBD dose-dependent/JJ inhibition/NN of/IN TNF-induced/JJ NF-kappa/NN B/NN mobilization/NN by/IN aspirin/NN at/IN concentrations/NNS ranging/VBG from/IN 1/CD to/TO 10/CD mmol/L/NN ./. 
Induction/NN of/IN VCAM-1/NN and/CC E-selectin/NN surface/NN expression/NN by/IN TNF/NN was/VBD dose-dependently/RB reduced/VBN by/IN aspirin/NN over/IN the/DT same/JJ range/NN ,/, while/IN induction/NN of/IN intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN )/) was/VBD hardly/RB affected/VBN ./. 
Aspirin/NN appeared/VBD to/TO prevent/VB VCAM-1/NN transcription/NN ,/, since/IN it/PRP dose-dependently/RB inhibited/VBD induction/NN of/IN VCAM-1/NN mRNA/NN by/IN TNF/NN ./. 
As/IN a/DT functional/JJ consequence/NN ,/, adhesion/NN of/IN U937/NN monocytes/NNS to/TO TNF-stimulated/JJ HUVECs/NNS was/VBD markedly/RB reduced/VBN by/IN aspirin/NN due/JJ to/TO suppression/NN of/IN VCAM-1/NN and/CC E-selectin/NN upregulation/NN ./. 
These/DT effects/NNS of/IN aspirin/NN were/VBD not/RB related/JJ to/TO the/DT inhibition/NN of/IN cyclooxygenase/NN activity/NN ,/, since/IN indomethacin/NN was/VBD ineffective/JJ ./. 
CONCLUSIONS/NNS :/: Our/PRP$ data/NNS suggest/VBP that/IN aspirin/NN inhibits/VBZ NF-kappa/NN B/NN mobilization/NN ,/, induction/NN of/IN VCAM-1/NN and/CC E-selectin/NN ,/, and/CC subsequent/JJ monocyte/NN adhesion/NN in/IN endothelial/JJ cells/NNS stimulated/VBN by/IN TNF/NN ,/, thereby/RB providing/VBG an/DT additional/JJ mechanism/NN for/IN therapeutic/JJ effects/NNS of/IN aspirin/NN ./. 
UI/LS -/: 95355456/CD 
TI/LS -/: Activation/NN of/IN NF-kappa/NN B/NN by/IN phosphatase/NN inhibitors/NNS involves/VBZ the/DT phosphorylation/NN of/IN I/NN kappa/NN B/NN alpha/NN at/IN phosphatase/NN 2A-sensitive/JJ sites/NNS ./. 
AB/LS -/: Activation/NN of/IN NF-kappa/NN B/NN by/IN various/JJ cellular/JJ stimuli/NNS involves/VBZ the/DT phosphorylation/NN and/CC subsequent/JJ degradation/NN of/IN its/PRP$ inhibitor/NN ,/, I/NN kappa/NN B/NN alpha/NN ,/, although/IN the/DT underlying/VBG mechanism/NN remains/VBZ unclear/JJ ./. 
In/IN the/DT present/JJ study/NN ,/, the/DT role/NN of/IN serine/threonine/NN phosphatases/NNS in/IN the/DT regulation/NN of/IN I/NN kappa/NN B/NN alpha/NN phosphorylation/NN was/VBD investigated/VBN ./. 
Our/PRP$ studies/NNS demonstrate/VBP that/IN incubation/NN of/IN human/JJ T/NN cells/NNS with/IN low/JJ concentrations/NNS (/( approximately/RB 1-5/CD nM/NN )/) of/IN calyculin/NN A/NN or/CC okadaic/JJ acid/NN ,/, potent/JJ inhibitors/NNS of/IN protein/NN phosphatase/NN type/NN 1/CD (/( PP-1/NN )/) and/CC type/NN 2A/NN (/( PP-2A/NN )/) ,/, induces/VBZ the/DT phosphorylation/NN of/IN I/NN kappa/NN B/NN alpha/NN even/RB in/IN the/DT absence/NN of/IN any/DT cellular/JJ stimulus/NN ./. 
This/DT action/NN of/IN the/DT phosphatase/NN inhibitors/NNS ,/, which/WDT is/VBZ associated/VBN with/IN the/DT activation/NN of/IN the/DT RelA.p50/NN NF-kappa/NN B/NN heterodimer/NN ,/, is/VBZ not/RB affected/VBN by/IN agents/NNS that/WDT block/VBP the/DT induction/NN of/IN I/NN kappa/NN B/NN alpha/NN phosphorylation/NN by/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) ./. 
Furthermore/RB ,/, the/DT phosphorylated/VBN I/NN kappa/NN B/NN alpha/NN from/IN calyculin/NN A-treated/JJ cells/NNS ,/, but/CC not/RB that/DT from/IN TNF-alpha-stimulated/JJ cells/NNS ,/, is/VBZ sensitive/JJ to/TO PP-2A/NN in/FW vitro/FW ,/, suggesting/VBG the/DT existence/NN of/IN fundamental/JJ differences/NNS in/IN the/DT phosphorylation/NN of/IN I/NN kappa/NN B/NN alpha/NN induced/VBN by/IN the/DT two/CD different/JJ NF-kappa/NN B/NN inducers/NNS ./. 
However/RB ,/, induction/NN of/IN I/NN kappa/NN B/NN alpha/NN phosphorylation/NN by/IN both/CC TNF-alpha/NN and/CC the/DT phosphatase/NN inhibitors/NNS is/VBZ associated/VBN with/IN the/DT subsequent/JJ degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN ./. 
We/PRP further/RB demonstrate/VBP that/IN TNF-alpha-/NN and/CC calyculin/NN A-induced/JJ I/NN kappa/NN B/NN alpha/NN degradation/NN exhibits/VBZ similar/JJ but/CC not/RB identical/JJ sensitivities/NNS to/TO a/DT proteasome/JJ inhibitor/NN ./. 
Together/RB ,/, these/DT results/NNS suggest/VBP that/IN phosphorylation/NN of/IN I/NN kappa/NN B/NN alpha/NN ,/, mediated/VBN through/IN both/CC the/DT TNF-alpha-inducible/JJ and/CC the/DT PP-2A-opposing/JJ kinases/NNS ,/, may/MD serve/VB to/TO target/NN I/NN kappa/NN B/NN alpha/NN for/IN proteasome-mediated/JJ degradation/NN ./. 
UI/LS -/: 95365343/CD 
TI/LS -/: Sp1/NN functions/VBZ in/IN a/DT chromatin-dependent/JJ manner/NN to/TO augment/VB human/JJ alpha-globin/NN promoter/NN activity/NN ./. 
AB/LS -/: The/DT 5'/JJ flanking/JJ region/NN of/IN the/DT human/JJ alpha-globin/NN gene/NN is/VBZ highly/RB G + C/NN rich/JJ and/CC contains/VBZ multiple/JJ copies/NNS of/IN the/DT consensus/NN sequence/NN for/IN the/DT Sp1/NN binding/NN site/NN ./. 
We/PRP investigated/VBD the/DT role/NN of/IN this/DT G + C-rich/JJ region/NN in/IN augmenting/VBG alpha-globin/NN promoter/NN activity/NN in/IN the/DT presence/NN of/IN the/DT far-upstream/JJ alpha-globin/NN enhancer/NN ,/, HS-40/NN ./. 
We/PRP show/VBP that/IN in/IN transiently/RB transfected/VBN erythroid/JJ cells/NNS ,/, deletion/NN of/IN the/DT alpha-globin/NN G + C-rich/JJ 5'/JJ flanking/JJ region/NN has/VBZ no/DT effect/NN on/IN alpha-globin/NN promoter/NN activity/NN ./. 
However/RB ,/, upon/IN stable/JJ integration/NN into/IN chromatin/NN ,/, deletion/NN of/IN this/DT region/NN causes/VBZ a/DT nearly/RB 90/CD %/NN decrease/NN in/IN promoter/NN activity/NN compared/VBN with/IN expression/NN from/IN an/DT alpha-globin/NN promoter/NN retaining/VBG this/DT region/NN ./. 
These/DT results/NNS suggest/VBP that/IN the/DT alpha-globin/NN G + C-rich/JJ 5'/JJ flanking/JJ region/NN augments/VBZ alpha-globin/NN promoter/NN activity/NN in/IN a/DT chromatin-dependent/JJ manner/NN ./. 
We/PRP further/RB show/VBP that/IN this/DT G + C-rich/JJ region/NN is/VBZ required/VBN for/IN the/DT activation/NN of/IN alpha-globin/NN gene/NN expression/NN during/IN erythroid/JJ differentiation/NN ./. 
Finally/RB ,/, we/PRP show/VBP by/IN both/CC footprint/NN analysis/NN and/CC functional/JJ assays/NNS that/IN the/DT ability/NN of/IN the/DT G + C-rich/JJ region/NN to/TO increase/VB alpha-globin/NN promoter/NN activity/NN from/IN a/DT stably/RB integrated/VBN alpha-globin/NN gene/NN is/VBZ mediated/VBN by/IN its/PRP$ multiple/JJ binding/VBG sites/NNS for/IN the/DT transcription/NN factor/NN Sp1/NN ./. 
UI/LS -/: 95363078/CD 
TI/LS -/: Costimulation/NN of/IN human/JJ CD4+/JJ T/NN cells/NNS with/IN LFA-3/NN and/CC B7/NN induce/VBP distinct/JJ effects/NNS on/IN AP-1/NN and/CC NF-kappa/NN B/NN transcription/NN factors/NNS ./. 
AB/LS -/: We/PRP have/VBP earlier/RBR shown/VBN that/IN stimulation/NN of/IN human/JJ CD4+/JJ T/NN cells/NNS with/IN SEA/NN presented/VBN on/IN Chinese/JJ hamster/NN ovary/NN (/( CHO/NN )/) -DR/NN transfectants/NNS coexpressing/VBG either/CC B7/NN or/CC LFA-3/NN resulted/VBD in/IN distinct/JJ cytokine/NN profiles/NNS ./. 
We/PRP now/RB demonstrate/VBP that/IN B7/NN ,/, but/CC not/RB LFA-3/NN ,/, strongly/RB costimulated/VBD IL-2/NN transcription/NN and/CC mRNA/NN expression/NN in/IN CD4+/JJ T/NN cells/NNS ./. 
Maximal/JJ increase/NN in/IN IL-2/NN transcription/NN was/VBD recorded/VBN with/IN CHO-DR/B7/LFA-3/NN ,/, suggesting/VBG a/DT cooperative/JJ effect/NN of/IN B7/NN and/CC LFA-3/NN at/IN the/DT transcriptional/JJ level/NN ./. 
Gel-shift/JJ analysis/NN demonstrated/VBD that/IN stimulation/NN of/IN CD4+/JJ T/NN cells/NNS with/IN CHO-DR/NN and/CC staphylococcal/JJ enterotoxin/NN A/NN was/VBD sufficient/JJ to/TO induce/VB significant/JJ amounts/NNS of/IN NF-kappa/NN B/NN binding/NN proteins/NNS ,/, whereas/IN induction/NN of/IN AP-1/NN binding/NN proteins/NNS required/VBD costimulation/NN ./. 
LFA-3/NN induced/VBD moderate/JJ levels/NNS of/IN AP-1/NN ,/, but/CC did/VBD not/RB influence/VB the/DT levels/NNS of/IN NF-kappa/NN B/NN ,/, while/IN B7/NN costimulation/NN strongly/RB induced/VBD both/CC AP-1/NN and/CC substantially/RB enhanced/VBN NF-kappa/NN B/NN binding/NN proteins/NNS ./. 
The/DT CHO-DR/B7/LFA-3triple/JJ transfectant/NN induced/VBD a/DT further/JJ increase/NN in/IN AP-1/NN and/CC NF-kappa/NN B/NN binding/NN proteins/NNS compared/VBN with/IN the/DT double/JJ transfectants/NNS ./. 
The/DT level/NN of/IN Oct-1/NN binding/NN proteins/NNS remained/VBD similar/JJ in/IN all/DT samples/NNS ./. 
Super-shift/JJ analysis/NN revealed/VBD that/IN the/DT NF-kappa/NN B/NN complex/NN of/IN costimulated/VBN CD4+/JJ T/NN cells/NNS contained/VBD large/JJ amounts/NNS of/IN p50/NN ,/, substantial/JJ amounts/NNS of/IN p65/NN ,/, and/CC marginal/JJ levels/NNS of/IN c-Rel/NN proteins/NNS ./. 
The/DT AP-1/NN binding/NN proteins/NNS contained/VBD c-Jun/NN ,/, Jun-D/NN ,/, and/CC Fra-1/NN ,/, but/CC marginal/JJ amounts/NNS of/IN Jun-B/NN and/CC c-Fos/NN ./. 
Our/PRP$ results/NNS indicate/VBP distinct/JJ effects/NNS of/IN B7/NN and/CC LFA-3/NN costimulation/NN on/IN the/DT activity/NN of/IN AP-1/NN and/CC NF-kappa/NN B/NN ./. 
These/DT may/MD partly/RB account/VB for/IN the/DT differential/JJ effects/NNS of/IN B7/NN and/CC LFA-3/NN costimulation/NN on/IN IL-2/NN expression/NN ./. 
UI/LS -/: 95336453/CD 
TI/LS -/: The/DT Ah/NN receptor/NN recognizes/VBZ DNA/NN binding/NN sites/NNS for/IN the/DT B/NN cell/NN transcription/NN factor/NN ,/, BSAP/NN :/: a/DT possible/JJ mechanism/NN for/IN dioxin-mediated/JJ alteration/NN of/IN CD19/NN gene/NN expression/NN in/IN human/JJ B/NN lymphocytes/NNS ./. 
AB/LS -/: 2,3,7,8-tetrachlorodibenzo-p-dioxin/NN (/( TCDD/NN )/) inhibits/VBZ murine/JJ and/CC human/JJ B/NN lymphocyte/NN immunoglobulin/NN production/NN through/IN an/DT unknown/JJ mechanism/NN ./. 
This/DT study/NN investigated/VBD the/DT effect/NN of/IN TCDD/NN on/IN expression/NN of/IN the/DT CD19/NN gene/NN in/IN a/DT human/JJ B/NN lymphocyte/NN cell/NN line/NN ./. 
Northern/NN blot/NN analysis/NN showed/VBD that/IN TCDD/NN treatment/NN decreased/VBD steady/JJ state/NN levels/NNS of/IN CD19/NN mRNA/NN by/IN 67/CD %/NN in/IN the/DT IM-9/NN cell/NN line/NN ./. 
Using/VBG a/DT gel/NN mobility/NN shift/NN assay/NN ,/, we/PRP identified/VBD a/DT DNA-binding/NN complex/NN in/IN IM-9/NN nuclear/JJ extracts/NNS that/WDT by/IN several/JJ criteria/NNS appears/VBZ to/TO be/VB the/DT Ah/NN receptor/NN ./. 
In/IN addition/NN ,/, the/DT Ah/NN receptor/NN complex/NN recognized/VBD a/DT DNA/NN binding/NN site/NN for/IN B/NN cell/NN lineage-specific/JJ activator/NN protein/NN (/( BSAP/NN )/) in/IN the/DT promoter/NN region/NN of/IN the/DT human/JJ CD19/NN gene/NN which/WDT is/VBZ similar/JJ to/TO the/DT consensus/NN Ah/NN receptor/NN DNA/NN binding/NN site/NN ./. 
These/DT results/NNS suggest/VBP that/IN the/DT AhR/NN could/MD interfere/VB with/IN BSAP-stimulated/JJ CD19/NN gene/NN transcription/NN by/IN competition/NN for/IN a/DT common/JJ DNA/NN binding/NN site/NN ./. 
UI/LS -/: 95337142/CD 
TI/LS -/: Inhibitory/JJ action/NN of/IN nm23/NN proteins/NNS on/IN induction/NN of/IN erythroid/JJ differentiation/NN of/IN human/JJ leukemia/NN cells/NNS ./. 
AB/LS -/: We/PRP recently/RB identified/VBD a/DT differentiation/NN inhibitory/JJ factor/NN (/( I-factor/NN )/) in/IN mouse/NN myeloid/JJ leukemia/NN M1/NN cells/NNS as/IN a/DT murine/JJ homolog/NN of/IN the/DT human/JJ nm23-H2/NN gene/NN product/NN ./. 
nm23/NN genes/NNS encode/VBP proteins/NNS that/WDT participate/VBP in/IN tumor/NN metastasis/NN regulation/NN and/CC in/IN various/JJ fundamental/JJ cellular/JJ processes/NNS ,/, although/IN their/PRP$ mechanisms/NNS of/IN action/NN are/VBP still/RB unknown/JJ ./. 
Although/IN all/DT nm23/NN proteins/NNS contain/VBP nucleoside/NN diphosphate/NN (/( NDP/NN )/) kinase/NN activity/NN ,/, it/PRP has/VBZ not/RB been/VBN established/VBN that/IN the/DT enzyme/NN activity/NN mediated/VBD the/DT various/JJ functions/NNS of/IN nm23/NN proteins/NNS ./. 
In/IN the/DT present/JJ experiment/NN ,/, we/PRP examined/VBD the/DT effect/NN of/IN nm23/NN proteins/NNS on/IN various/JJ differentiation/NN induction/NN systems/NNS of/IN human/JJ leukemic/JJ cells/NNS including/VBG HL-60/NN ,/, U937/NN ,/, HEL/S/NN ,/, KU812F/NN ,/, K562/NN ,/, and/CC HEL/NN cells/NNS ./. 
Native/JJ human/JJ erythrocyte/NN NDP/NN kinase/NN protein/NN inhibited/VBD the/DT induction/NN of/IN erythroid/JJ differentiation/NN of/IN HEL/NN ,/, KU812/NN and/CC K562/NN cells/NNS ,/, but/CC not/RB the/DT induction/NN of/IN monocytic/JJ or/CC granulocytic/JJ differentiation/NN of/IN HL-60/NN ,/, U937/NN and/CC HEL/S/NN cells/NNS ./. 
The/DT erythroid/JJ differentiation/NN of/IN HEL/NN cells/NNS was/VBD inhibited/VBN by/IN recombinant/JJ human/JJ nm23-H1/NN ,/, -H2/NN ,/, mouse/NN nm23-M1/NN ,/, and/CC -M2/NN proteins/NNS ./. 
Moreover/RB ,/, both/CC the/DT mutant/JJ nm23-H2His/NN protein/NN and/CC truncated/VBN nm23-H2/NN protein/NN containing/VBG N-terminal/JJ (/( 1-60/CD )/) peptide/NN ,/, which/WDT do/VBP not/RB have/VB NDP/NN kinase/NN activity/NN ,/, also/RB inhibited/VBD erythroid/JJ differentiation/NN of/IN HEL/NN cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN (/( 1/LS )/) the/DT differentiation/NN inhibitory/JJ activity/NN of/IN I-factor/nm23/NN protein/NN is/VBZ not/RB restricted/JJ to/TO monocytic/JJ differentiation/NN of/IN M1/NN cells/NNS ,/, (/( 2/LS )/) the/DT inhibitory/JJ activity/NN is/VBZ exhibited/VBN without/IN species/NNS specificity/NN ,/, and/CC (/( 3/LS )/) the/DT differentiation/NN inhibitory/JJ activity/NN of/IN the/DT nm23/NDP/NN kinase/NN protein/NN is/VBZ independent/JJ of/IN its/PRP$ enzyme/NN activity/NN and/CC requires/VBZ the/DT presence/NN of/IN N-terminal/JJ peptides/NNS ./. 
UI/LS -/: 95355137/CD 
TI/LS -/: Lipopolysaccharide-induced/JJ E-selectin/NN expression/NN requires/VBZ continuous/JJ presence/NN of/IN LPS/NN and/CC is/VBZ inhibited/VBN by/IN bactericidal/permeability-increasing/JJ protein/NN ./. 
AB/LS -/: Endothelial/JJ cells/NNS stimulated/VBN by/IN LPS/NN express/VBP E-selectin/NN ,/, which/WDT plays/VBZ an/DT important/JJ role/NN in/IN mediating/VBG neutrophil/NN adhesion/NN during/IN inflammation/NN ./. 
E-selectin/NN is/VBZ induced/VBN within/IN 1-2/CD h/NN ,/, peaks/VBZ at/IN 4-6/CD h/NN ,/, and/CC gradually/RB returns/VBZ to/TO basal/JJ level/NN by/IN 24/CD h/NN ./. 
rBPI21/NN ,/, a/DT recombinant/JJ N-terminal/JJ fragment/NN of/IN human/JJ bactericidal/permeability-increasing/JJ protein/NN (/( BPI/NN )/) ,/, inhibited/VBD LPS-induced/JJ E-selectin/NN expression/NN when/WRB added/VBN at/IN the/DT same/JJ time/NN as/IN ,/, and/CC up/IN to/TO 6/CD h/NN after/IN ,/, LPS/NN ./. 
Delayed/VBN administration/NN of/IN rBPI21/NN also/RB affected/VBD LPS-mediated/JJ activation/NN of/IN the/DT nuclear/JJ factor/NN ,/, NF-kappa/NN B/NN ./. 
Two/CD to/TO 4/CD h/NN following/VBG LPS/NN addition/NN to/TO endothelial/JJ cells/NNS ,/, when/WRB NF-kappa/NN B/NN was/VBD already/RB activated/VBN ,/, addition/NN of/IN rBPI21/NN resulted/VBD in/IN marked/JJ reduction/NN of/IN NF-kappa/NN B/NN detectable/JJ at/IN 4/CD or/CC 6/CD h/NN ./. 
These/DT results/NNS indicate/VBP that/IN endothelial/JJ activation/NN requires/VBZ continuous/JJ presence/NN of/IN LPS/NN ,/, and/CC rBPI21/NN acts/VBZ to/TO reverse/VB LPS-mediated/JJ endothelial/JJ activation/NN by/IN interrupting/VBG the/DT on-going/JJ LPS/NN signal/NN ./. 
UI/LS -/: 95279882/CD 
TI/LS -/: GM-CSF/NN and/CC IL-2/NN share/VBP common/JJ control/NN mechanisms/NNS in/IN response/NN to/TO costimulatory/JJ signals/NNS in/IN T/NN cells/NNS ./. 
AB/LS -/: Antigen/NN complexed/VBN with/IN major/JJ histocompatibility/NN complex/NN class/NN I/CD or/CC II/CD molecules/NNS on/IN the/DT surface/NN of/IN antigen/NN presenting/NN cells/NNS interacts/VBZ with/IN the/DT T/NN cell/NN receptor/NN (/( TCR/NN )/) on/IN the/DT surface/NN of/IN T/NN cells/NNS and/CC initiates/VBZ an/DT activation/NN cascade/NN ./. 
So/RB called/VBN costimulatory/JJ signals/NNS ,/, mediated/VBN by/IN other/JJ cell/NN surface/NN interactions/NNS or/CC soluble/JJ cytokines/NNS produced/VBN by/IN antigen/NN presenting/NN cells/NNS ,/, are/VBP also/RB required/VBN for/IN complete/JJ T/NN cell/NN activation/NN ./. 
High/JJ levels/NNS of/IN cytokine/NN gene/NN expression/NN in/IN T/NN cells/NNS also/RB required/VBD both/CC TCR/NN and/CC costimulatory/JJ signals/NNS ./. 
The/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN requires/VBZ sequences/NNS in/IN the/DT promoter/NN as/RB well/RB as/IN a/DT powerful/JJ enhancer/NN located/JJ 3kb/RB upstream/RB to/TO respond/VB to/TO TCR-like/JJ signals/NNS ./. 
These/DT promoter/NN and/CC enhancer/NN regions/NNS are/VBP mainly/RB activated/VBN by/IN the/DT transcription/NN factor/NN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) ./. 
The/DT activation/NN of/IN NFAT/NN by/IN TCR/NN signals/NNS has/VBZ been/VBN well/RB described/VBN for/IN interleukin-2/NN (/( IL-2/NN )/) and/CC IL-4/NN gene/NN transcription/NN in/IN T/NN cells/NNS ./. 
Costimulatory/JJ signals/NNS ,/, such/JJ as/IN activation/NN of/IN the/DT CD28/NN cell/NN surface/NN molecule/NN on/IN T/NN cells/NNS ,/, lead/VBP to/TO activation/NN through/IN a/DT distinct/JJ region/NN of/IN the/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) promoter/NN ./. 
This/DT region/NN is/VBZ termed/VBN the/DT CK-1/NN or/CC CD28RE/NN and/CC appears/VBZ to/TO bind/VB specific/JJ members/NNS of/IN the/DT NF-kappa/NN B/NN family/NN of/IN transcription/NN factors/NNS ./. 
Human/JJ T/NN leukemia/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) infects/VBZ T/NN cells/NNS and/CC can/MD lead/VB to/TO increase/VB GM-CSF/NN expression/NN ./. 
We/PRP have/VBP found/VBN that/IN the/DT HTLV-1/NN transactivator/NN protein/NN ,/, tax/NN ,/, acts/VBZ as/IN a/DT costimulatory/JJ signal/NN for/IN GM-CSF/NN and/CC IL-2/NN gene/NN transcription/NN ,/, in/IN that/IN it/PRP can/MD cooperate/VB with/IN TCR/NN signals/NNS to/TO mediate/VB high/JJ level/NN gene/NN expression/NN ./. 
Tax/NN activates/VBZ the/DT GM-CSF/NN promoter/NN through/IN the/DT CK-1/CD28RE/NN region/NN and/CC also/RB activates/VBZ nuclear/JJ factor-kappa/NN B/NN binding/VBG to/TO this/DT region/NN ./. 
However/RB ,/, other/JJ transcription/NN factors/NNS or/CC coactivators/NNS of/IN NF-kappa/NN B/NN are/VBP required/VBN for/IN tax/NN activation/NN but/CC these/DT remain/VBP to/TO be/VB identified/VBN ./. 
The/DT CK-1/CD28RE/NN of/IN GM-CSF/NN shows/VBZ a/DT high/JJ degree/NN of/IN similarity/NN to/TO the/DT IL-2/NN CD28RE/NN and/CC the/DT IL-3/NN gene/NN also/RB contains/VBZ a/DT related/JJ region/NN ./. 
This/DT observation/NN ,/, together/RB with/IN the/DT fact/NN that/IN both/CC GM-CSF/NN and/CC IL-2/NN respond/VBP to/TO TCR/NN signals/NNS via/IN NFAT/NN ,/, implies/VBZ a/DT high/JJ degree/NN of/IN conservation/NN in/IN the/DT regulation/NN of/IN cytokine/NN gene/NN expression/NN in/IN T/NN cells/NNS ./. 
UI/LS -/: 95309632/CD 
TI/LS -/: Danazol/NN decreases/VBZ transcription/NN of/IN estrogen/NN receptor/NN gene/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: 1./LS Administration/NN of/IN danazol/NN for/IN over/IN one/CD month/NN reduced/VBD the/DT levels/NNS of/IN estrogen/NN receptor/NN (/( ER/NN )/) and/CC its/PRP$ mRNA/NN to/TO approximately/RB 50/CD and/CC 20/CD %/NN ,/, respectively/RB in/IN monocytes/NNS ./. 
2./LS Danazol/NN did/VBD not/RB alter/VB the/DT degradation/NN rate/NN of/IN ER/NN mRNA/NN in/IN monocytes/NNS ./. 
3./LS Danazol/NN decreased/VBD the/DT transcription/NN rate/NN of/IN ER/NN gene/NN to/TO approximately/RB 50/CD %/NN in/IN monocytes/NNS in/IN a/DT run-on/JJ assay/NN ./. 
4./LS Danazol/NN may/MD release/VB estrogen/NN predominance/NN via/IN the/DT reduction/NN of/IN transcription/NN for/IN ER/NN gene/NN ,/, which/WDT leads/VBZ to/TO the/DT reduction/NN of/IN ER/NN mRNA/NN and/CC ER/NN expressions/NNS in/IN monocytes/NNS ./. 
UI/LS -/: 95221870/CD 
TI/LS -/: Functional/JJ characterization/NN of/IN novel/JJ IL-2/NN transcriptional/JJ inhibitors/NNS ./. 
AB/LS -/: IL-2-mediated/JJ T/NN cell/NN proliferation/NN is/VBZ a/DT critical/JJ early/JJ event/NN in/IN the/DT inflammatory/JJ process/NN ./. 
Formation/NN of/IN the/DT NFAT-1/NN transcriptional/JJ complex/NN on/IN the/DT IL-2/NN promoter/NN is/VBZ essential/JJ for/IN IL-2/NN transcription/NN ./. 
Using/VBG a/DT cell/NN line/NN that/WDT is/VBZ stably/RB transfected/VBN with/IN a/DT trimer/NN of/IN the/DT NFAT-1/NN regulatory/JJ element/NN linked/VBN to/TO a/DT lac-Z/NN reporter/NN gene/NN ,/, we/PRP screened/VBD for/IN inhibitors/NNS of/IN NFAT-1-mediated/JJ beta-galactosidase/NN activity/NN ./. 
WIN/NN 61058/CD and/CC WIN/NN 53071/CD were/VBD identified/VBN as/IN microM/NN inhibitors/NNS ./. 
These/DT compounds/NNS also/RB inhibited/VBD beta-galactosidase/NN mRNA/NN levels/NNS ./. 
Similar/JJ inhibition/NN of/IN NFAT-1-mediated/JJ gene/NN expression/NN was/VBD observed/VBN in/IN a/DT second/JJ cell/NN line/NN ,/, which/WDT is/VBZ stably/RB transfected/VBN with/IN NFAT-1/NN regulatory/JJ elements/NNS linked/VBN to/TO the/DT reporter/NN gene/NN for/IN sCD8/NN ./. 
At/IN 10/CD microM/NN ,/, both/DT compounds/NNS inhibited/VBD IL-2/NN mRNA/NN and/CC protein/NN levels/NNS in/IN the/DT NFAT-1-linked/JJ lac-Z/NN transfectants/NNS ,/, and/CC in/IN human/JJ lymphocytes/NNS ./. 
Both/DT compounds/NNS inhibited/VBD the/DT mixed/JJ lymphocyte/NN reaction/NN ,/, and/CC this/DT inhibition/NN was/VBD reversed/VBN by/IN exogenous/JJ IL-2/NN ./. 
WIN/NN 53071/CD inhibited/VBD IL-2/NN production/NN induced/VBN in/IN the/DT calcium-dependent/JJ PMA/NN and/CC ionomycin/NN pathway/NN ./. 
Conversely/RB ,/, calcium-independent/JJ anti-CD28/JJ Ab/NN and/CC PMA-induced/JJ IL-2/NN production/NN was/VBD resistant/JJ ./. 
Both/DT compounds/NNS altered/VBD the/DT NFAT-1/NN transcriptional/JJ complex/NN ,/, causing/VBG its/PRP$ retarded/VBN mobility/NN on/IN gels/NNS ./. 
By/IN these/DT functional/JJ criteria/NNS ,/, we/PRP believe/VBP we/PRP have/VBP identified/VBN two/CD structurally/RB distinct/JJ ,/, novel/JJ inhibitors/NNS of/IN NFAT-1-mediated/JJ transcription/NN ./. 
UI/LS -/: 95221386/CD 
TI/LS -/: Transcriptional/JJ regulation/NN of/IN the/DT vacuolar/JJ H(+)-ATPase/NN B2/NN subunit/NN gene/NN in/IN differentiating/VBG THP-1/NN cells/NNS ./. 
AB/LS -/: Monocyte-macrophage/JJ differentiation/NN was/VBD used/VBN as/IN a/DT model/NN system/NN for/IN studying/VBG gene/NN regulation/NN of/IN the/DT human/JJ vacuolar/NN H(+)-ATPase/NN (/( V-ATPase/NN )/) ./. 
We/PRP examined/VBD mRNA/NN levels/NNS of/IN various/JJ V-ATPase/NN subunits/NNS during/IN differentiation/NN of/IN both/CC native/JJ monocytes/NNS and/CC the/DT cell/NN line/NN THP-1/NN ,/, and/CC found/VBD that/IN transcriptional/JJ and/CC post-transcriptional/JJ mechanisms/NNS could/MD account/VB for/IN increases/NNS in/IN cell/NN V-ATPase/NN content/NN ./. 
From/IN nuclear/JJ runoff/JJ experiments/NNS ,/, we/PRP found/VBD that/IN one/CD subunit/NN in/IN particular/JJ ,/, the/DT B2/NN isoform/NN (/( Mr/NN =/JJ 56,000/CD )/) ,/, was/VBD amplified/VBN primarily/RB by/IN transcriptional/JJ means/NNS ./. 
We/PRP have/VBP begun/VBN to/TO examine/VB the/DT structure/NN of/IN the/DT B2/NN subunit/NN promoter/NN region/NN ./. 
Isolation/NN and/CC sequencing/NN of/IN the/DT first/JJ exon/NN and/CC 5'-flanking/JJ region/NN of/IN this/DT gene/NN reveal/VBP a/DT TATA-less/JJ promoter/NN with/IN a/DT high/JJ G/NN +/CC C/NN content/NN ./. 
Primer/NN extension/NN and/CC ribonuclease/NN protection/NN analyses/NNS indicate/VBP a/DT single/JJ major/JJ transcriptional/JJ start/NN site/NN ./. 
We/PRP transfected/VBD promoter-luciferase/NN reporter/NN plasmids/NNS into/IN THP-1/NN cells/NNS to/TO define/VB sequences/NNS that/WDT mediate/VBP transcriptional/JJ control/NN during/IN monocyte/NN differentiation/NN ./. 
We/PRP found/VBD that/IN sequences/NNS downstream/RB from/IN the/DT transcriptional/JJ start/NN site/NN were/VBD sufficient/JJ to/TO confer/VB increased/VBN expression/NN during/IN THP-1/NN differentiation/NN ./. 
DNase/NN I/CD footprinting/NN and/CC sequence/NN analysis/NN revealed/VBD the/DT existence/NN of/IN multiple/JJ AP2/NN and/CC Sp1/NN binding/NN sites/NNS in/IN the/DT 5'-untranslated/JJ and/CC proximal/JJ coding/VBG regions/NNS ./. 
UI/LS -/: 96089572/CD 
TI/LS -/: Synergy/NN between/IN signal/NN transduction/NN pathways/NNS is/VBZ obligatory/JJ for/IN expression/NN of/IN c-fos/NN in/IN B/NN and/CC T/NN cell/NN lines/NNS :/: implication/NN for/IN c-fos/NN control/NN via/IN surface/NN immunoglobulin/NN and/CC T/NN cell/NN antigen/NN receptors/NNS ./. 
AB/LS -/: Expression/NN of/IN the/DT protooncogene/NN c-fos/NN is/VBZ controlled/VBN by/IN three/CD main/JJ regulatory/JJ pathways/NNS involving/VBG kinase/NN C/NN ,/, cAMP/NN ,/, and/CC calcium/NN ./. 
Kinase/NN C/NN mediates/VBZ its/PRP$ effects/NNS via/IN phosphorylation/NN of/IN serum/NN response/NN factor/NN (/( SRF/NN )/) which/WDT interacts/VBZ with/IN the/DT serum/NN response/NN element/NN (/( SRE/NN )/) ;/: cAMP/NN and/CC calcium/NN mediate/VBP their/PRP$ effects/NNS via/IN phosphorylation/NN of/IN CREB/NN (/( cAMP/NN regulatory/JJ element/NN binding/NN protein/NN )/) presumably/RB by/IN activation/NN of/IN a/DT protein/NN kinase/NN A/NN or/CC calmodulin-regulated/JJ kinase/NN ./. 
We/PRP have/VBP examined/VBN the/DT function/NN of/IN these/DT elements/NNS in/IN Burkitt/NN 's/POS lymphoma/NN cells/NNS (/( Ramos/NN and/CC Daudi/NN )/) as/RB well/RB as/IN a/DT T/NN lymphocytic/JJ cell/NN line/NN (/( Jurkat/NN )/) ./. 
We/PRP have/VBP found/VBN that/IN stimulation/NN of/IN any/DT one/CD of/IN these/DT pathways/NNS alone/RB has/VBZ little/JJ or/CC no/DT effect/NN on/IN c-fos/NN induction/NN ./. 
However/RB ,/, kinase/NN C/NN activation/NN (/( PMA/NN stimulation/NN )/) combined/VBN with/IN either/CC cAMP/NN (/( forskolin/NN plus/CC MIX/NN )/) or/CC calcium/NN stimulation/NN (/( ionophore/NN )/) leads/VBZ to/TO greatly/RB enhanced/VBN c-fos/NN induction/NN ./. 
By/IN contrast/NN ,/, cAMP/NN in/IN the/DT presence/NN of/IN calcium/NN shows/VBZ no/DT synergy/NN in/IN c-fos/NN induction/NN ./. 
Okadaic/JJ acid/NN augments/VBZ PMA-/NN as/RB well/RB as/IN calcium-mediated/JJ activation/NN of/IN c-fos/NN ,/, and/CC has/VBZ little/JJ or/CC no/DT effect/NN when/WRB combined/VBN with/IN cAMP/NN ./. 
The/DT main/JJ difference/NN between/IN Ramos/NN (/( B/NN cells/NNS )/) and/CC Jurkat/NN (/( T/NN cells/NNS )/) in/IN the/DT regulation/NN of/IN c-fos/NN is/VBZ that/IN cAMP/NN plus/CC calcium/NN is/VBZ strongly/RB synergistic/JJ in/IN Jurkat/NN and/CC is/VBZ without/IN effect/NN in/IN Ramos/NN ./. 
Analysis/NN of/IN AP-1/NN activity/NN using/VBG gel/NN mobility/NN shift/NN assays/NNS confirms/VBZ that/IN the/DT requirements/NNS for/IN synergy/NN in/IN c-fos/NN mRNA/NN induction/NN are/VBP paralleled/VBN by/IN requirements/NNS for/IN synergy/NN in/IN induction/NN of/IN AP-1/NN activity/NN ./. 
Signaling/NN in/IN B/NN cells/NNS due/JJ to/TO anti-Ig/JJ stimulation/NN involves/VBZ both/CC kinase/NN C/NN activation/NN and/CC release/NN of/IN intracellular/JJ calcium/NN ,/, and/CC results/VBZ in/IN c-fos/NN mRNA/NN induction/NN ./. 
Our/PRP$ results/NNS indicate/VBP that/IN synergy/NN between/IN the/DT kinase/NN C/NN activation/NN and/CC calcium/NN is/VBZ needed/VBN for/IN efficient/JJ c-fos/NN induction/NN since/IN neither/DT of/IN these/DT two/CD alone/RB induces/VBZ c-fos/NN well/RB ./. 
That/IN synergy/NN of/IN signaling/NN pathways/NNS is/VBZ relevant/JJ for/IN the/DT anti-Ig/JJ induction/NN of/IN c-fos/NN is/VBZ supported/VBN by/IN the/DT fact/NN that/IN cAMP-inducing/JJ agents/NNS and/CC okadaic/JJ acid/NN further/RB enhance/VBP anti-Ig/JJ induction/NN of/IN c-fos/NN ./. 
These/DT results/NNS suggest/VBP that/IN cell-specific/JJ patterns/NNS of/IN synergy/NN are/VBP an/DT essential/JJ feature/NN for/IN c-fos/NN induction/NN and/CC may/MD be/VB relevant/JJ for/IN c-fos/NN control/NN through/IN B/NN and/CC T/NN cell/NN antigen/NN receptors/NNS ./. 
UI/LS -/: 95363089/CD 
TI/LS -/: Multiple/JJ signals/NNS are/VBP required/VBN for/IN function/NN of/IN the/DT human/JJ granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN gene/NN promoter/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: The/DT human/JJ granulocyte-macrophage/JJ CSF/NN (/( GM-CSF/NN )/) gene/NN is/VBZ expressed/VBN in/IN T/NN cells/NNS in/IN response/NN to/TO TCR/NN activation/NN that/WDT can/MD be/VB mimicked/VBN by/IN treatment/NN of/IN the/DT cells/NNS with/IN PMA/NN and/CC Ca2+/NN ionophore/NN ./. 
The/DT gene/NN contains/VBZ a/DT proximal/JJ functional/JJ promoter/NN region/NN (/( -620/CD to/TO +34/CD )/) ,/, as/RB well/RB as/IN a/DT powerful/JJ enhancer/NN located/JJ 3/CD kb/NN upstream/RB ,/, both/DT of/IN which/WDT are/VBP involved/VBN in/IN the/DT response/NN of/IN the/DT gene/NN to/TO TCR/NN activation/NN ./. 
The/DT proximal/JJ promoter/NN contains/VBZ a/DT region/NN termed/VBN CLEO/NN (/( -54/CD to/TO -31/CD )/) that/WDT consists/VBZ of/IN a/DT purine-rich/JJ element/NN abutting/VBG an/DT activator/NN protein-1/NN (/( AP-1/NN )/) -like/JJ site/NN ,/, as/RB well/RB as/IN an/DT upstream/JJ nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) site/NN (/( -85/CD to/TO -76/CD )/) and/CC a/DT CK-1/NN element/NN (/( -101/CD to/TO -92/CD )/) ./. 
We/PRP show/VBP in/IN this/DT work/NN that/IN mutations/NNS in/IN either/CC the/DT purine-rich/JJ region/NN of/IN the/DT CLEO/NN element/NN or/CC the/DT NF-kappa/NN B/NN site/NN result/VBP in/IN reduced/VBN PMA/Ca2+/NN activation/NN of/IN a/DT 620-bp/JJ human/JJ GM-CSF/NN promoter-/NN luciferase/NN reporter/NN construct/NN in/IN Jurkat/NN T/NN cells/NNS by/IN 65/CD %/NN and/CC 50/CD %/NN ,/, respectively/RB ./. 
The/DT major/JJ inducible/JJ protein/NN complex/NN that/WDT binds/VBZ to/TO the/DT human/JJ CLEO/NN (/( hCLEO/NN )/) element/NN is/VBZ an/DT AP-1-like/JJ complex/NN that/WDT is/VBZ inducible/JJ by/IN PMA/NN alone/RB ,/, but/CC shows/VBZ increased/VBN binding/NN in/IN response/NN to/TO PMA/NN together/RB with/IN Ca2+/NN ionophore/NN ./. 
Although/IN the/DT binding/NN of/IN this/DT complex/NN is/VBZ not/RB cyclosporin-sensitive/JJ ,/, promoter/NN induction/NN is/VBZ inhibited/VBN by/IN cyclosporin/NN treatment/NN ./. 
A/DT second/JJ weak/JJ inducible/JJ complex/NN resembling/VBG nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) was/VBD also/RB observed/VBN binding/VBG to/TO the/DT hCLEO/NN region/NN ./. 
By/IN using/VBG recombinant/JJ proteins/NNS ,/, we/PRP confirmed/VBD that/IN AP-1/NN ,/, NF-ATp/NN ,/, and/CC a/DT higher/JJR order/NN NF-ATp/NN /AP-1/NN complex/NN could/MD all/DT form/VB with/IN the/DT hCLEO/NN element/NN ,/, and/CC we/PRP have/VBP also/RB defined/VBN the/DT sequence/NN requirements/NNS for/IN binding/NN of/IN each/DT of/IN these/DT complexes/NNS ./. 
We/PRP found/VBD that/IN expression/NN of/IN a/DT constitutively/RB active/JJ form/NN of/IN calcineurin/NN could/MD substitute/VB for/IN Ca2+/NN ionophore/NN and/CC synergize/VB with/IN PMA/NN to/TO activate/VB the/DT GM-CSF/NN promoter/NN ,/, and/CC conversely/RB that/IN mutant-activated/JJ Ras/NN could/MD substitute/VB for/IN PMA/NN and/CC cooperate/VB with/IN Ca2+/NN ionophore/NN ./. 
Co-expression/NN of/IN Ras/NN and/CC calcineurin/NN ,/, however/RB ,/, did/VBD not/RB activate/VB the/DT GM-CSF/NN promoter/NN ,/, but/CC required/VBD the/DT additional/JJ expression/NN of/IN NF-kappa/NN B/NN p65/NN ./. 
These/DT results/NNS imply/VBP that/IN at/IN least/JJS three/CD signals/NNS are/VBP required/VBN to/TO activate/VB the/DT GM-CSF/NN proximal/JJ promoter/NN ,/, and/CC that/IN the/DT signals/NNS impinge/VBP on/IN distinct/JJ transcription/NN factors/NNS that/WDT bind/VBP to/TO the/DT hCLEO/NN and/CC NF-kappa/NN B/NN regions/NNS of/IN the/DT promoter/NN ./. 
UI/LS -/: 95363073/CD 
TI/LS -/: IL-10/NN induces/VBZ the/DT tyrosine/NN phosphorylation/NN of/IN tyk2/NN and/CC Jak1/NN and/CC the/DT differential/JJ assembly/NN of/IN STAT1/NN alpha/NN and/CC STAT3/NN complexes/NNS in/IN human/JJ T/NN cells/NNS and/CC monocytes/NNS ./. 
AB/LS -/: IL-10/NN affects/VBZ monocytes/NNS and/CC T/NN cells/NNS by/IN driving/VBG the/DT progression/NN of/IN immune/JJ responsiveness/NN such/IN that/IN Th2/NN lymphocyte-mediated/JJ effects/NNS predominate/VBP ./. 
In/IN this/DT report/NN ,/, we/PRP show/VBP that/IN in/IN monocytes/NNS and/CC T/NN cells/NNS IL-10/NN stimulates/VBZ tyrosine/NN phosphorylation/NN of/IN the/DT signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN ,/, STAT1/NN alpha/NN and/CC STAT3/NN ,/, in/IN a/DT differential/JJ manner/NN such/IN that/IN the/DT relative/JJ formation/NN of/IN homo-/JJ and/CC heterodimers/NNS varies/VBZ between/IN the/DT two/CD cell/NN types/NNS ./. 
Moreover/RB ,/, monocytes/NNS express/VBP a/DT novel/JJ IL-10-stimulated/JJ STAT/NN protein/NN with/IN an/DT M(r)/NN of/IN 70/CD kDa/NN that/WDT is/VBZ recognized/VBN by/IN the/DT anti-STAT3/JJ Ab/NN but/CC is/VBZ not/RB observed/VBN in/IN T/NN cells/NNS ./. 
IL-10/NN treatment/NN of/IN both/CC T/NN cells/NNS and/CC monocytes/NNS results/VBZ in/IN the/DT ligand-induced/JJ tyrosine/NN phosphorylation/NN of/IN tyk2/NN and/CC Jak1/NN ,/, but/CC not/RB Jak2/NN or/CC Jak3/NN ./. 
Selective/JJ modulation/NN of/IN immune/JJ responsiveness/NN by/IN IL-10/NN in/IN cells/NNS such/JJ as/IN monocytes/NNS and/CC T/NN cells/NNS may/MD result/VB in/IN part/NN from/IN the/DT differential/JJ activation/NN of/IN STAT/NN protein/NN pairs/NNS ./. 
UI/LS -/: 97253017/CD 
TI/LS -/: Use/NN of/IN new/JJ biologic/JJ markers/NNS in/IN the/DT ovulation/NN induction/NN ./. 
AB/LS -/: Biological/JJ markers/NNS of/IN ovulation/NN ,/, after/IN a/DT great/JJ in/IN the/DT past/NN ,/, have/VBP been/VBN fallen/VBN into/IN disuse/NN for/IN the/DT large/JJ diffusion/NN of/IN biochemical/JJ and/CC biophysical/JJ ones/NNS ./. 
However/RB ,/, the/DT real/JJ effect/NN of/IN hormones/NNS involved/VBN in/IN ovulation/NN is/VBZ expressed/VBN by/IN biological/JJ modifications/NNS on/IN target/NN tissues/NNS ./. 
To/TO explore/VB the/DT modifications/NNS of/IN not/RB reproductive/JJ target/NN tissues/NNS as/IN ovulation/NN markers/NNS we/PRP studied/VBD the/DT behaviour/NN of/IN Albuminemia/NN ,/, Platelet/NN Factor/NN IV/CD (/( as/IN indicator/NN of/IN Platelet/NN Aggregation/NN )/) ,/, Type/NN II/CD estrogenic/JJ receptors/NNS in/IN 42/CD ovulation/NN induced/JJ women/NNS ,/, undergoing/VBG our/PRP$ observation/NN ./. 
33/CD of/IN them/PRP had/VBD ovulation/NN and/CC 9/CD developed/VBD a/DT LUF/NN syndrome/NN ,/, constituting/VBG two/CD biological/JJ models/NNS of/IN an/DT opposite/JJ situation/NN for/IN the/DT three/CD markers/NNS observed/VBN ./. 
All/PDT the/DT markers/NNS considered/VBN were/VBD sufficiently/RB sensitive/JJ ,/, but/CC among/IN them/PRP ,/, Platelet/NN Factor/NN IV/CD was/VBD the/DT most/RBS reliable/JJ to/TO the/DT hormonal/JJ ovulatory/JJ situation/NN ./. 
UI/LS -/: 95279790/CD 
TI/LS -/: Abnormal/JJ regulation/NN of/IN the/DT IL-2/NN promoter/NN in/IN lpr/NN CD4-CD8- T/NN lymphocytes/NNS results/VBZ in/IN constitutive/JJ expression/NN of/IN a/DT novel/JJ nuclear/JJ factor/NN of/IN activated/VBN T/NN cells-binding/JJ factor/NN ./. 
AB/LS -/: The/DT inert/JJ quality/NN of/IN MRL-Ipr/Ipr/NN (/( Ipr/NN )/) peripheral/JJ CD4-CD8-/JJ (/( CD4-8-/NN )/) T/NN cells/NNS manifests/VBZ primarily/RB as/IN an/DT inability/NN to/TO proliferate/VB or/CC produce/VB IL-2/NN in/IN response/NN to/TO TCR/NN or/CC mitogenic/JJ stimulation/NN ./. 
Yet/RB these/DT same/JJ cells/NNS do/VBP initiate/VB early/JJ TCR-mediated/JJ signaling/NN events/NNS ,/, such/JJ as/IN generation/NN of/IN inositol/JJ phosphates/NNS and/CC increased/VBN intracellular/JJ calcium/NN ./. 
They/PRP also/RB display/VBP constitutively/RB high/JJ levels/NNS of/IN p59fyn/NN and/CC CD3/NN zeta/NN tyrosine/NN phosphorylation/NN ./. 
The/DT generation/NN of/IN second/JJ messengers/NNS in/IN T/NN cells/NNS normally/RB leads/VBZ to/TO downstream/JJ signaling/NN that/WDT results/VBZ in/IN transcriptional/JJ activation/NN of/IN the/DT IL-2/NN gene/NN ./. 
We/PRP ,/, therefore/RB ,/, compared/VBD the/DT activation/NN state/NN of/IN the/DT IL-2/NN gene/NN promoter/NN region/NN in/IN freshly/RB isolated/VBN and/CC stimulated/VBN Ipr/NN CD4-8-T/NN cells/NNS with/IN that/DT of/IN normal/JJ T/NN lymphocytes/NNS ./. 
Levels/NNS of/IN the/DT octamer/NN ,/, NF-kappa/NN B/NN (/( p50-p65/NN heterodimer/NN )/) ,/, and/CC AP-1/NN transcriptional/JJ factors/NNS are/VBP constitutively/RB elevated/VBN in/IN freshly/RB isolated/VBN Ipr/NN CD4-8-T/NN cells/NNS ,/, consistent/JJ with/IN the/DT activated/VBN phenotype/NN of/IN these/DT cells/NNS ./. 
Upon/IN stimulation/NN with/IN mitogens/NNS ,/, formation/NN of/IN the/DT transactivating/VBG complex/NN ,/, nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) ,/, occurs/VBZ with/IN normal/JJ kinetics/NNS in/IN Ipr/NN CD4-8-T/NN cells/NNS ./. 
Yet/RB ,/, the/DT levels/NNS of/IN the/DT activating/VBG NF-AT/NN complex/NN never/RB reach/VBP those/DT observed/VBN in/IN similarly/RB stimulated/VBN normal/JJ T/NN cells/NNS ./. 
Furthermore/RB ,/, nuclear/JJ extracts/NNS from/IN Ipr/NN CD4-8-T/NN cells/NNS display/VBP high/JJ levels/NNS of/IN a/DT novel/JJ specific/JJ binding/NN activity/NN at/IN the/DT NF-AT/NN site/NN ,/, which/WDT is/VBZ present/JJ at/IN much/JJ lower/JJR levels/NNS in/IN freshly/RB isolated/VBN normal/JJ T/NN lymphocytes/NNS ./. 
Upon/IN mitogenic/JJ stimulation/NN ,/, the/DT binding/NN activity/NN of/IN the/DT novel/JJ NF-AT-binding/JJ factor/NN is/VBZ rapidly/RB down-regulated/VBN in/IN normal/JJ T/NN cells/NNS ,/, but/CC persists/VBZ at/IN high/JJ levels/NNS in/IN Ipr/NN CD4-8-T/NN cells/NNS ./. 
These/DT two/CD abnormalities/NNS at/IN the/DT NF-AT/NN site/NN provide/VBP a/DT potential/JJ mechanism/NN to/TO account/VB for/IN the/DT defect/NN in/IN IL-2/NN production/NN from/IN Ipr/NN CD4-8-T/NN cells/NNS ./. 
UI/LS -/: 95316714/CD 
TI/LS -/: Cross-linking/NN of/IN CD30/NN induces/VBZ HIV/NN expression/NN in/IN chronically/RB infected/JJ T/NN cells/NNS ./. 
AB/LS -/: CD30/NN ,/, a/DT member/NN of/IN the/DT tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) receptor/NN family/NN ,/, is/VBZ expressed/VBN constitutively/RB on/IN the/DT surface/NN of/IN the/DT human/JJ T/NN cell/NN line/NN ACH-2/NN ,/, which/WDT is/VBZ chronically/RB infected/VBN with/IN human/JJ immunodeficiency/NN virus/NN type-1/NN (/( HIV/NN )/) -1/CD ./. 
We/PRP demonstrate/VBP that/IN cross-linking/JJ CD30/NN with/IN an/DT anti-CD30-specific/JJ monoclonal/JJ antibody/NN ,/, which/WDT mimics/VBZ the/DT described/VBN biological/JJ activities/NNS of/IN the/DT CD30/NN ligand/NN (/( CD30L/NN )/) ,/, results/VBZ in/IN HIV/NN expression/NN ./. 
CD30/NN cross-linking/NN does/VBZ not/RB alter/VB proliferation/NN of/IN ACH-2/NN cells/NNS and/CC the/DT induction/NN of/IN HIV/NN expression/NN is/VBZ not/RB mediated/VBN by/IN endogenous/JJ TNF/NN alpha/beta/NN ./. 
Furthermore/RB ,/, cross-linking/NN of/IN CD30/NN leads/VBZ to/TO NF-kappa/NN B/NN activation/NN and/CC enhanced/VBN HIV/NN transcription/NN ./. 
Thus/RB ,/, CD30-CD30L/JJ interactions/NNS mediate/VBP the/DT induction/NN of/IN HIV/NN expression/NN by/IN a/DT kappa/NN B-dependent/JJ pathway/NN that/WDT is/VBZ independent/JJ of/IN TNF/NN ./. 
This/DT mechanism/NN may/MD be/VB important/JJ in/IN the/DT activation/NN of/IN HIV/NN expression/NN from/IN latently/RB infected/JJ CD4+/JJ T/NN cells/NNS ,/, especially/RB in/IN lymphoid/JJ organs/NNS where/WRB cell/NN to/TO cell/NN contact/NN is/VBZ conducive/JJ to/TO receptor-ligand/JJ interactions/NNS ./. 
UI/LS -/: 95269137/CD 
TI/LS -/: Human/JJ MHC/NN class/NN II/CD gene/NN transcription/NN directed/VBN by/IN the/DT carboxyl/NN terminus/NN of/IN CIITA/NN ,/, one/CD of/IN the/DT defective/JJ genes/NNS in/IN type/NN II/CD MHC/NN combined/JJ immune/JJ deficiency/NN ./. 
AB/LS -/: Type/NN II/CD major/JJ histocompatibility/NN complex/NN combined/JJ immune/JJ deficiency/NN (/( type/NN II/CD MHC/NN CID/NN or/CC bare/JJ lymphocyte/NN syndrome/NN )/) is/VBZ a/DT congenital/JJ immunodeficiency/NN disease/NN characterized/VBN by/IN absent/JJ MHC/NN class/NN II/CD expression/NN ./. 
Four/CD distinct/JJ complementation/NN groups/NNS have/VBP been/VBN identified/VBN ./. 
Recently/RB ,/, the/DT defective/JJ gene/NN in/IN group/NN II/CD type/NN II/CD MHC/NN CID/NN has/VBZ been/VBN isolated/VBN and/CC termed/VBN CIITA/NN ./. 
Here/RB ,/, we/PRP demonstrate/VBP that/IN CIITA/NN is/VBZ an/DT MHC/NN class/NN II/CD gene-specific/JJ transcription/NN activator/NN ./. 
The/DT transcription/NN activation/NN function/NN is/VBZ provided/VBN by/IN the/DT N-terminal/JJ acidic/JJ domain/NN (/( amino/NN acids/NNS 26-137/CD )/) ,/, which/WDT is/VBZ experimentally/RB exchangeable/JJ with/IN a/DT heterologous/JJ viral/JJ transcription-activating/JJ domain/NN ./. 
The/DT specificity/NN of/IN CIITA/NN for/IN three/CD major/JJ MHC/NN class/NN II/CD genes/NNS ,/, DR/NN ,/, DQ/NN and/CC DP/NN ,/, is/VBZ mediated/VBN by/IN its/PRP$ remaining/VBG C-terminal/JJ residues/NNS (/( amino/NN acids/NNS 317-1130/CD )/) ./. 
The/DT transactivation/NN of/IN multiple/JJ cis/JJ elements/NNS ,/, especially/RB S/NN and/CC X2/NN ,/, of/IN the/DT DR/NN alpha/NN proximal/JJ promoter/NN in/IN group/NN II/CD CID/NN cells/NNS is/VBZ CIITA/NN dependent/JJ ./. 
Since/IN CIITA/NN overexpression/NN in/IN normal/JJ cells/NNS did/VBD not/RB increase/VB class/NN II/CD expression/NN ,/, we/PRP propose/VBP that/IN initiation/NN of/IN CIITA/NN expression/NN serves/VBZ as/IN the/DT on-off/JJ switch/NN ,/, while/IN availability/NN of/IN downstream/JJ interactor/NN (/( s/NNS )/) limits/VBZ transcription/NN ./. 
UI/LS -/: 95256455/CD 
TI/LS -/: Monocyte/NN tethering/NN by/IN P-selectin/NN regulates/VBZ monocyte/NN chemotactic/JJ protein-1/NN and/CC tumor/NN necrosis/NN factor-alpha/NN secretion/NN ./. 
Signal/NN integration/NN and/CC NF-kappa/NN B/NN translocation/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: Adhesion/NN molecules/NNS that/WDT tether/VBP circulating/VBG leukocytes/NNS to/TO endothelial/JJ cells/NNS may/MD also/RB transduce/VB or/CC modulate/VB outside-in/JJ signals/NNS for/IN cellular/JJ activation/NN ,/, providing/VBG an/DT initial/JJ regulatory/JJ point/NN in/IN the/DT inflammatory/JJ response/NN ./. 
Adhesion/NN of/IN human/JJ monocytes/NNS to/TO P-selectin/NN ,/, the/DT most/RBS rapidly/RB expressed/VBN endothelial/JJ tethering/NN factor/NN ,/, increased/VBD the/DT secretion/NN of/IN monocyte/NN chemotactic/JJ protein-1/NN (/( MCP-1/NN )/) and/CC tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) by/IN the/DT leukocytes/NNS when/WRB they/PRP were/VBD stimulated/VBN with/IN platelet-activating/JJ factor/NN ./. 
Increased/VBN cytokine/NN secretion/NN was/VBD specifically/RB inhibited/VBN by/IN G1/NN ,/, an/DT anti-P-selectin/JJ mAb/NN that/WDT prevents/VBZ P-selectin/NN from/IN binding/VBG to/TO its/PRP$ ligand/NN (/( P-selectin/NN glycoprotein/NN ligand-1/NN )/) on/IN myeloid/JJ cells/NNS ./. 
Moreover/RB ,/, tethering/NN by/IN P-selectin/NN specifically/RB enhanced/VBD nuclear/JJ translocation/NN of/IN nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ,/, a/DT transcription/NN factor/NN required/VBN for/IN expression/NN of/IN MCP-1/NN ,/, TNF-alpha/NN ,/, and/CC other/JJ immediate-early/JJ genes/NNS ./. 
These/DT results/NNS demonstrate/VBP that/IN P-selectin/NN ,/, through/IN its/PRP$ ligands/NNS on/IN monocytes/NNS ,/, may/MD locally/RB regulate/VB cytokine/NN secretion/NN in/IN inflamed/JJ tissues/NNS ./. 
UI/LS -/: 95238333/CD 
TI/LS -/: Functional/JJ roles/NNS of/IN in/FW vivo/FW footprinted/VBN DNA/NN motifs/NNS within/IN an/DT alpha-globin/NN enhancer/NN ./. 
Erythroid/JJ lineage/NN and/CC developmental/JJ stage/NN specificities/NNS ./. 
AB/LS -/: Transcriptional/JJ regulation/NN of/IN the/DT human/JJ alpha-like/JJ globin/NN genes/NNS ,/, embryonic/JJ zeta/NN 2/CD and/CC adult/JJ alpha/NN ,/, during/IN erythroid/JJ development/NN is/VBZ mediated/VBN by/IN a/DT distal/JJ enhancer/NN ,/, HS-40/NN ./. 
Previous/JJ protein-DNA/JJ binding/NN studies/NNS have/VBP shown/VBN that/IN HS-40/NN consists/VBZ of/IN multiple/JJ nuclear/JJ factor/NN binding/NN motifs/NNS that/WDT are/VBP occupied/VBN in/FW vivo/FW in/IN an/DT erythroid/JJ lineage-/NN and/CC developmental/JJ stage-specific/JJ manner/NN ./. 
We/PRP have/VBP systematically/RB analyzed/VBN the/DT functional/JJ roles/NNS of/IN these/DT factor/NN binding/NN motifs/NNS of/IN HS-40/NN by/IN site-directed/JJ mutagenesis/NN and/CC transient/JJ expression/NN assay/NN in/IN erythroid/JJ cell/NN cultures/NNS ./. 
Three/CD of/IN these/DT HS-40/NN enhancer/NN motifs/NNS ,/, 5'NF-E2/AP1/NN ,/, GT/NN II/CD ,/, and/CC GATA-1(c)/NN ,/, positively/RB regulate/VBP the/DT zeta/NN 2-globin/NN promoter/NN activity/NN in/IN embryonic/fetal/JJ erythroid/JJ K562/NN cells/NNS and/CC the/DT adult/JJ alpha-globin/NN promoter/NN activity/NN in/IN adult/JJ erythroid/JJ MEL/NN cells/NNS ./. 
On/IN the/DT other/JJ hand/NN ,/, the/DT 3'NF-E2/AP1/NN motif/NN is/VBZ able/JJ to/TO exert/VB both/CC positive/JJ and/CC negative/JJ regulatory/JJ effects/NNS on/IN the/DT zeta/NN 2-globin/NN promoter/NN activity/NN in/IN K562/NN cells/NNS ,/, and/CC this/DT dual/JJ function/NN appears/VBZ to/TO be/VB modulated/VBN through/IN differential/JJ binding/NN of/IN the/DT ubiquitous/JJ AP1/NN factors/NNS and/CC the/DT erythroid-enriched/JJ NF-E2/NN factor/NN ./. 
Mutation/NN in/IN the/DT GATA-1(d)/NN motif/NN ,/, which/WDT exhibits/VBZ an/DT adult/JJ erythroid-specific/JJ genomic/JJ footprint/NN ,/, decreases/VBZ the/DT HS-40/NN enhancer/NN function/NN in/IN dimethyl/JJ sulfoxide-induced/JJ MEL/NN cells/NNS but/CC not/RB in/IN K562/NN cells/NNS ./. 
These/DT studies/NNS have/VBP defined/VBN the/DT regulatory/JJ roles/NNS of/IN the/DT different/JJ HS-40/NN motifs/NNS ./. 
The/DT remarkable/JJ correlation/NN between/IN genomic/JJ footprinting/NN data/NNS and/CC the/DT mutagenesis/NN results/NNS also/RB suggests/VBZ that/IN the/DT erythroid/JJ lineage-/NN and/CC developmental/JJ stage-specific/JJ regulation/NN of/IN human/JJ alpha-like/JJ globin/NN promoters/NNS is/VBZ indeed/RB modulated/VBN by/IN stable/JJ binding/NN of/IN specific/JJ nuclear/JJ factors/NNS in/FW vivo/FW ./. 
UI/LS -/: 95221342/CD 
TI/LS -/: Nitric/JJ oxide-stimulated/JJ guanine/NN nucleotide/NN exchange/NN on/IN p21ras/NN ./. 
AB/LS -/: The/DT protooncogene/NN p21ras/NN ,/, a/DT monomeric/JJ G/NN protein/NN family/NN member/NN ,/, plays/VBZ a/DT critical/JJ role/NN in/IN converting/VBG extracellular/JJ signals/NNS into/IN intracellular/JJ biochemical/JJ events/NNS ./. 
Here/RB ,/, we/PRP report/VBP that/IN nitric/JJ oxide/NN (/( NO/NN )/) activates/VBZ p21ras/NN in/IN human/JJ T/NN cells/NNS as/IN evidenced/VBN by/IN an/DT increase/NN in/IN GTP-bound/JJ p21ras/NN ./. 
In/FW vitro/FW studies/NNS using/VBG pure/JJ recombinant/JJ p21ras/NN demonstrate/VBP that/IN the/DT activation/NN is/VBZ direct/JJ and/CC reversible/JJ ./. 
Circular/JJ dichroism/NN analysis/NN reveals/VBZ that/IN NO/NN induces/VBZ a/DT profound/JJ conformational/JJ change/NN in/IN p21ras/NN in/IN association/NN with/IN GDP/GTP/NN exchange/NN ./. 
The/DT mechanism/NN of/IN activation/NN is/VBZ due/JJ to/TO S-nitrosylation/NN of/IN a/DT critical/JJ cysteine/NN residue/NN which/WDT stimulates/VBZ guanine/NN nucleotide/NN exchange/NN ./. 
Furthermore/RB ,/, we/PRP demonstrate/VBP that/IN p21ras/NN is/VBZ essential/JJ for/IN NO-induced/JJ downstream/JJ signaling/NN ,/, such/JJ as/IN NF-kappa/NN B/NN activation/NN ,/, and/CC that/IN endogenous/JJ NO/NN can/MD activate/VB p21ras/NN in/IN the/DT same/JJ cell/NN ./. 
These/DT studies/NNS identify/VBP p21ras/NN as/IN a/DT target/NN of/IN the/DT same/JJ cell/NN ./. 
These/DT studies/NNS identify/VBP p21ras/NN as/IN a/DT target/NN of/IN NO/NN in/IN T/NN cells/NNS and/CC suggest/VBP that/IN NO/NN activates/VBZ p21ras/NN by/IN an/DT action/NN which/WDT mimics/VBZ that/DT of/IN guanine/NN nucleotide/NN exchange/NN factors/NNS ./. 
UI/LS -/: 95394020/CD 
TI/LS -/: Interleukin-2/NN promoter/NN activity/NN in/IN Epstein-Barr/JJ virus-transformed/JJ B/NN lymphocytes/NNS is/VBZ controlled/VBN by/IN nuclear/JJ factor-chi/NN B/NN ./. 
AB/LS -/: The/DT regulation/NN of/IN interleukin/NN (/( IL/NN )/) -2/CD gene/NN expression/NN has/VBZ been/VBN investigated/VBN mainly/RB in/IN T/NN lymphocytes/NNS ,/, the/DT predominant/JJ producers/NNS of/IN IL-2/NN ./. 
However/RB ,/, B/NN cells/NNS can/MD also/RB synthesize/VB IL-2/NN ./. 
In/IN the/DT present/JJ study/NN we/PRP analyzed/VBD the/DT control/NN of/IN IL-2/NN promoter/NN activity/NN in/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) -transformed/JJ B/NN cell/NN clones/NNS which/WDT are/VBP capable/JJ of/IN secreting/VBG IL-2/NN at/IN a/DT low/JJ level/NN after/IN stimulation/NN with/IN phorbol/NN 12-myristate/NN 13-acetate/NN and/CC the/DT Ca2+/NN ionophore/NN ionomycin/NN ./. 
Transient/JJ transfections/NNS using/VBG reporter/NN constructs/NNS with/IN multiples/NNS of/IN transcription/NN factor/NN binding/NN sites/NNS from/IN the/DT IL-2/NN promoter/NN [/( distal/JJ nuclear/JJ factor/NN (/( NF/NN )/) -AT/NN ,/, proximal/JJ NF-AT/NN ,/, AP-1/Octamer/NN (/( UPS/NN )/) or/CC NF-chi/NN B/NN (/( TCEd/NN )/) sites/NNS ]/) were/VBD performed/VBN ./. 
In/IN EBV-transformed/JJ B/NN clones/NNS ,/, the/DT chi/NN B/NN site/NN exerted/VBD the/DT strongest/JJS inducible/JJ activity/NN ;/: the/DT NF-AT/NN binding/NN sites/NNS showed/VBD either/CC no/DT or/CC only/RB weak/JJ activity/NN compared/VBN to/TO Jurkat/NN T/NN cells/NNS ./. 
An/DT IL-2/NN promoter/NN bearing/VBG a/DT defective/JJ NF-chi/NN B/NN site/NN was/VBD completely/RB inactive/JJ in/IN EBV-transformed/NN B/NN cells/NNS ,/, while/IN it/PRP still/RB had/VBD activity/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
In/IN seven/CD EBV-B/NN cell/NN clones/NNS or/CC lines/NNS differing/VBG in/IN their/PRP$ capacity/NN to/TO secrete/VB IL-2/NN ,/, the/DT activity/NN of/IN the/DT IL-2/NN promoter/NN correlated/VBD well/RB with/IN the/DT status/NN of/IN IL-2/NN secretion/NN ./. 
Similarly/RB ,/, a/DT human/JJ immunodeficiency/NN virus/NN promoter/NN ,/, whose/WP$ activity/NN is/VBZ controlled/VBN through/IN chi/NN B/NN factors/NNS ,/, was/VBD found/VBN to/TO be/VB active/JJ in/IN the/DT IL-2/NN producing/NN EBV-B/NN cells/NNS ,/, but/CC inactive/JJ in/IN the/DT non-IL-2-producing/JJ cells/NNS ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS using/VBG protein/NN extracts/NNS from/IN EBV-B/NN cells/NNS and/CC the/DT IL-2/NN NF-chi/NN B/NN probe/NN revealed/VBD the/DT constitutive/JJ generation/NN of/IN chi/NN B/NN complexes/NNS in/IN IL-2-secreting/NN cells/NNS consisting/VBG mainly/RB of/IN heterodimeric/JJ p50/p65/NN complexes/NNS ./. 
A/DT weaker/JJR chi/NN B/NN complex/JJ formation/NN and/CC faster-migrating/JJ complexes/NNS were/VBD detected/VBN in/IN non-IL-2-secreting/JJ cells/NNS ./. 
These/DT results/NNS demonstrate/VBP that/IN the/DT IL-2/NN NF-chi/NN B/NN site/NN is/VBZ indispensable/JJ for/IN the/DT activity/NN of/IN the/DT IL-2/NN promoter/NN in/IN EBV-transformed/JJ B/NN cells/NNS ,/, whereas/IN other/JJ transcription/NN factors/NNS appear/VBP to/TO be/VB less/RBR important/JJ for/IN IL-2/NN expression/NN in/IN these/DT cells/NNS ./. 
UI/LS -/: 95363069/CD 
TI/LS -/: Latent/JJ membrane/NN protein-1/NN induces/VBZ cyclin/NN D2/NN expression/NN ,/, pRb/NN hyperphosphorylation/NN ,/, and/CC loss/NN of/IN TGF-beta/NN 1-mediated/JJ growth/NN inhibition/NN in/IN EBV-positive/JJ B/NN cells/NNS ./. 
AB/LS -/: The/DT normal/JJ cell/NN cycle/NN is/VBZ regulated/VBN by/IN several/JJ molecules/NNS ,/, such/JJ as/IN the/DT tumor-suppressor/JJ protein/NN pRb/NN ,/, the/DT G1/NN cyclins/NNS ,/, the/DT cyclin-dependent/JJ kinases/NNS ,/, and/CC their/PRP$ inhibitors/NNS ./. 
These/DT regulators/NNS are/VBP targeted/VBN by/IN negative/JJ growth/NN regulatory/JJ signals/NNS ,/, such/JJ as/IN that/DT provided/VBN by/IN TGF-beta/NN ./. 
Here/RB ,/, we/PRP show/VBP that/IN the/DT presence/NN of/IN either/CC wild-type/JJ EBV/NN or/CC its/PRP$ transforming/VBG latent/JJ membrane/NN protein-1/NN (/( LMP-1/NN )/) results/VBZ in/IN the/DT loss/NN of/IN TGF-beta/NN 1-mediated/JJ growth/NN inhibition/NN in/IN human/JJ B/NN cells/NNS ./. 
Chemical/JJ cross-linking/NN with/IN 125I-labeled/JJ TGF-beta/NN 1/CD showed/VBD an/DT essentially/RB normal/JJ TGF-beta/NN receptor/NN profile/NN in/IN EBV-positive/JJ and/CC EBV-negative/JJ Burkitt/NN 's/POS lymphoma/NN cell/NN lines/NNS ,/, and/CC these/DT receptors/NNS were/VBD shown/VBN to/TO be/VB functional/JJ in/IN transducing/VBG signals/NNS ,/, as/IN evidenced/VBN by/IN the/DT TGF-beta/NN 1-mediated/JJ modulation/NN of/IN junB/NN gene/NN expression/NN ./. 
However/RB ,/, TGF-beta/NN 1/CD did/VBD not/RB induce/VB dephosphorylation/NN of/IN pRb/NN in/IN EBV/NN (/( or/CC LMP-1/NN )/) -positive/JJ cells/NNS as/IN opposed/VBN to/TO EBV/JJ -negative/JJ cells/NNS ,/, suggesting/VBG a/DT dichotomy/NN in/IN the/DT TGF-beta/NN 1/CD signaling/NN pathway/NN leading/VBG to/TO separable/JJ gene/NN regulatory/JJ and/CC growth/NN inhibitory/JJ responses/NNS ./. 
Furthermore/RB ,/, LMP-1/NN was/VBD found/VBN to/TO induce/VB the/DT expression/NN of/IN cyclin/NN D2/NN ;/: normal/JJ B/NN cells/NNS or/CC EBV-negative/JJ Burkitt/NN 's/POS lymphoma/NN cells/NNS do/VBP not/RB express/VB D-type/JJ cyclins/NNS ./. 
Taken/VBN together/RB ,/, these/DT data/NNS point/VBP to/TO a/DT potential/JJ mechanism/NN underlying/VBG EBV-mediated/JJ B/NN cell/NN transformation/NN whereby/WRB constitutive/JJ induction/NN of/IN key/JJ cell/NN cycle/NN regulators/NNS by/IN LMP-1/NN can/MD lead/VB to/TO pRb/NN hyperphosphorylation/NN and/CC uncontrolled/JJ cell/NN proliferation/NN ./. 
UI/LS -/: 95355533/CD 
TI/LS -/: Does/VBZ thyroidectomy/NN ,/, radioactive/JJ iodine/NN therapy/NN ,/, or/CC antithyroid/JJ drug/NN treatment/NN alter/VB reactivity/NN of/IN patients/NNS '/POS T/NN cells/NNS to/TO epitopes/NNS of/IN thyrotropin/NN receptor/NN in/IN autoimmune/JJ thyroid/NN diseases/NNS ?/. 
AB/LS -/: The/DT effect/NN of/IN treatment/NN on/IN thyroid/NN antibody/NN production/NN and/CC T/NN cell/NN reactivity/NN to/TO thyroid/NN antigens/NNS was/VBD studied/VBN in/IN 15/CD patients/NNS with/IN Graves/NN '/POS disease/NN (/( GD/NN )/) before/IN and/CC after/IN thyroidectomy/NN ,/, 19/CD patients/NNS with/IN GD/NN before/IN and/CC after/IN radioactive/JJ iodine/NN (/( RAI/NN )/) therapy/NN ,/, and/CC 9/CD patients/NNS maintained/VBD euthyroid/JJ on/IN antithyroid/JJ drugs/NNS (/( ATD/NN )/) ./. 
Twenty/CD subjects/NNS matched/JJ for/IN age/NN and/CC sex/NN without/IN known/JJ thyroid/NN disease/NN served/VBD as/IN controls/NNS ./. 
In/IN GD/NN patients/NNS ,/, the/DT responses/NNS of/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NN )/) and/CC TSH/NN receptor/NN (/( TSHR/NN )/) -specific/JJ T/NN cell/NN lines/NNS to/TO recombinant/JJ human/JJ TSHR/NN extracellular/JJ domain/NN ,/, thyroglobulin/NN ,/, and/CC TSHR/NN peptides/NNS were/VBD examined/VBN on/IN the/DT day/NN of/IN surgery/NN or/CC RAI/NN therapy/NN (/( day/NN 0/CD )/) and/CC also/RB 6-8/CD weeks/NNS and/CC 3-6/CD months/NNS thereafter/RB ./. 
Reactivity/NN to/TO TSHR/NN peptides/NNS before/IN surgery/NN was/VBD heterogeneous/JJ and/CC spanned/VBD the/DT entire/JJ extracellular/JJ domain/NN ./. 
Six/CD to/TO 8/CD weeks/NNS after/IN subtotal/JJ thyroidectomy/NN ,/, the/DT number/NN of/IN patients/NNS '/POS PBMC/NN responding/VBG to/TO any/DT peptide/NN and/CC the/DT average/JJ number/NN of/IN recognized/VBN peptides/NNS decreased/VBD ./. 
A/DT further/JJ decrease/NN in/IN the/DT T/NN cell/NN reactivity/NN to/TO TSHR/NN peptides/NNS was/VBD observed/VBN 3-6/CD months/NNS after/IN surgery/NN ./. 
The/DT responses/NNS of/IN PBMC/NN from/IN Graves/NN '/POS patients/NNS before/IN RAI/NN therapy/NN were/VBD less/JJR than/IN those/DT in/IN the/DT presurgical/JJ group/NN ./. 
Six/CD to/TO 8/CD weeks/NNS after/IN RAI/NN therapy/NN ,/, the/DT number/NN of/IN patients/NNS responding/VBG to/TO any/DT peptide/NN and/CC the/DT average/JJ number/NN of/IN recognized/VBN peptides/NNS increased/VBD ./. 
Three/CD to/TO 6/CD months/NNS after/IN RAI/NN ,/, T/NN cell/NN responses/NNS to/TO TSHR/NN peptides/NNS were/VBD less/JJR than/IN those/DT 6-8/CD weeks/NNS after/IN RAI/NN therapy/NN ,/, but/CC still/RB higher/JJR than/IN the/DT values/NNS on/IN day/NN 0/CD ./. 
Responses/NNS of/IN PBMC/NN from/IN patients/NNS with/IN GD/NN ,/, maintained/VBD euthyroid/JJ on/IN ATD/NN ,/, were/VBD lower/JJR than/IN those/DT before/IN surgery/NN or/CC RAI/NN therapy/NN ./. 
The/DT reactivity/NN of/IN T/NN cell/NN lines/NNS in/IN different/JJ groups/NNS reflected/VBD a/DT pattern/NN similar/JJ to/TO PBMC/NN after/IN treatment/NN ./. 
TSHR/NN antibody/NN and/CC microsomal/JJ antibody/NN levels/NNS decreased/VBD after/IN surgery/NN ,/, but/CC increased/VBD after/IN RAI/NN therapy/NN ./. 
The/DT difference/NN in/IN the/DT number/NN of/IN recognized/VBN peptides/NNS by/IN patients/NNS '/POS PBMC/NN before/IN RAI/NN and/CC surgery/NN may/MD reflect/VB the/DT effect/NN of/IN long/JJ term/NN therapy/NN with/IN ATD/NN in/IN the/DT patients/NNS before/IN RAI/NN vs./CC the/DT shorter/JJR period/NN in/IN patients/NNS before/IN surgery/NN ./. 
The/DT decreased/VBN T/NN cell/NN reactivity/NN to/TO thyroid/NN antigens/NNS after/IN thyroidectomy/NN could/MD be/VB the/DT result/NN of/IN removal/NN of/IN a/DT major/JJ part/NN of/IN the/DT thyroid/NN gland/NN or/CC redistribution/NN of/IN suppressor-inducer/JJ T/NN cells/NNS ./. 
The/DT increased/VBN T/NN cell/NN response/NN after/IN RAI/NN therapy/NN is/VBZ probably/RB epitope/NN specific/JJ ,/, rather/RB than/IN a/DT response/NN to/TO the/DT whole/JJ TSHR/NN molecule/NN ./. 
Synchronous/JJ recognition/NN of/IN peptides/NNS 158-176/CD and/CC 248-263/CD is/VBZ important/JJ for/IN the/DT development/NN of/IN GD/NN ,/, and/CC the/DT loss/NN of/IN recognition/NN of/IN one/CD of/IN these/DT epitopes/NNS may/MD be/VB an/DT early/JJ sign/NN of/IN immune/JJ remission/NN and/CC a/DT predictor/NN of/IN euthyroidism/NN ./. 
UI/LS -/: 96030053/CD 
TI/LS -/: Circumvention/NN of/IN tolerance/NN for/IN the/DT nuclear/JJ T/NN cell/NN protein/NN TCF-1/NN by/IN immunization/NN of/IN TCF-1/NN knock-out/JJ mice/NNS ./. 
AB/LS -/: Molecular/JJ events/NNS that/WDT underlie/VBP the/DT well-defined/JJ phenotypic/JJ changes/NNS of/IN the/DT differentiating/VBG thymocyte/NN are/VBP poorly/RB understood/VBN ./. 
A/DT candidate/NN gene/NN to/TO control/VB thymocyte/NN differentiation/NN ,/, T/NN cell/NN factor-1/NN (/( TCF-1/NN )/) */SYM encodes/VBZ a/DT DNA-binding/JJ protein/NN ./. 
Its/PRP$ mRNA/NN expression/NN pattern/NN is/VBZ complex/JJ during/IN embryogenesis/NN ,/, yet/RB restricted/JJ to/TO lymphocytes/NNS postnatally/RB ./. 
Expression/NN studies/NNS on/IN TCF-1/NN protein/NN have/VBP been/VBN hampered/VBN by/IN the/DT difficulty/NN to/TO raise/VB antibodies/NNS due/JJ to/TO extreme/JJ evolutionary/JJ conservation/NN ./. 
TCF-1/NN knock-out/JJ mice/NNS ,/, generated/VBN recently/RB in/IN our/PRP$ laboratory/NN ,/, have/VBP strongly/RB decreased/VBN numbers/NNS of/IN thymocytes/NNS ,/, but/CC are/VBP otherwise/RB normal/JJ ./. 
We/PRP have/VBP used/VBN these/DT mice/NNS to/TO generate/VB anti-TCF-1/NN antibodies/NNS ./. 
By/IN immunization/NN with/IN a/DT recombinant/JJ fusion/NN protein/NN ,/, we/PRP show/VBP that/IN TCF-1/NN knock-out/JJ mice/NNS readily/RB yield/VBP antiserum/NN titers/NNS against/IN human/JJ and/CC mouse/NN TCF-1/NN protein/NN ./. 
Wild-type/JJ littermates/NNS remain/VBP unresponsive/JJ to/TO TCF-1/NN while/IN they/PRP mount/VBP a/DT high-titer/JJ antibody/NN response/NN to/TO the/DT fusion/NN protein/NN ,/, Maltose/NN Binding/NN Protein/NN (/( MBP/NN )/) ./. 
Subsequently/RB ,/, TCF-1-specific/JJ hybridomas/NNS could/MD be/VB prepared/VBN from/IN the/DT spleens/NNS of/IN immunized/VBN knock-out/JJ mice/NNS ./. 
This/DT study/NN illustrates/VBZ the/DT almost/RB complete/JJ tolerance/NN of/IN mice/NNS for/IN human/JJ TCF-1/NN and/CC demonstrates/VBZ that/IN this/DT tolerance/NN is/VBZ readily/RB broken/VBN by/IN gene/NN knock-out/NN ./. 
Furthermore/RB ,/, the/DT usefulness/NN of/IN knock-out/JJ mice/NNS for/IN the/DT generation/NN of/IN monoclonal/JJ antibodies/NNS against/IN the/DT gene/NN product/NN of/IN interest/NN is/VBZ underscored/VBN ./. 
UI/LS -/: 95286632/CD 
TI/LS -/: The/DT transcription/NN factor/NN ,/, Nm23H2/NN ,/, binds/VBZ to/TO and/CC activates/VBZ the/DT translocated/VBN c-myc/NN allele/NN in/IN Burkitt/NN 's/POS lymphoma/NN ./. 
AB/LS -/: We/PRP have/VBP identified/VBN an/DT in/FW vivo/FW footprint/NN over/IN the/DT PuF/NN site/NN on/IN the/DT translocated/VBN c-myc/NN allele/NN in/IN Burkitt/NN 's/POS lymphoma/NN cells/NNS ./. 
The/DT PuF/NN site/NN on/IN the/DT silent/JJ normal/JJ c-myc/NN allele/NN was/VBD unoccupied/JJ ./. 
We/PRP demonstrated/VBD by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN ,/, electrophoretic/JJ mobility/NN shift/NN assay/NN with/IN antibody/NN ,/, UV/NN cross-linking/NN followed/VBN by/IN SDS-gel/NN electrophoresis/NN ,/, and/CC Western/NN analysis/NN that/IN Nm23H2/NN in/IN B/NN cell/NN nuclear/JJ extracts/NNS bound/VBD to/TO the/DT c-myc/NN PuF/NN site/NN ./. 
Transfection/NN experiments/NNS with/IN c-myc/NN promoter/NN constructs/NNS in/IN both/CC DHL-9/NN and/CC Raji/NN cells/NNS revealed/VBD that/IN the/DT PuF/NN site/NN functioned/VBD as/IN a/DT positive/JJ regulatory/JJ element/NN in/IN B/NN cells/NNS with/IN a/DT drop/NN in/IN activity/NN with/IN mutation/NN of/IN this/DT site/NN ./. 
Access/NN to/TO this/DT site/NN is/VBZ blocked/VBN in/IN the/DT normal/JJ silent/JJ c-myc/NN allele/NN ;/: these/DT data/NNS suggest/VBP that/IN the/DT Nm23H2/NN protein/NN is/VBZ involved/VBN in/IN deregulation/NN of/IN the/DT translocated/VBN c-myc/NN allele/NN in/IN Burkitt/NN 's/POS lymphoma/NN cells/NNS ./. 
UI/LS -/: 95279435/CD 
TI/LS -/: Identification/NN of/IN two/CD novel/JJ regulatory/JJ elements/NNS within/IN the/DT 5'-untranslated/JJ region/NN of/IN the/DT human/JJ A/NN gamma-globin/NN gene/NN ./. 
AB/LS -/: Interaction/NN between/IN the/DT stage/NN selector/NN element/NN (/( SSE/NN )/) in/IN the/DT proximal/JJ gamma-globin/NN promoter/NN and/CC hypersensitivity/NN site/NN 2/CD in/IN the/DT locus/NN control/NN region/NN partly/RB mediates/VBZ the/DT competitive/JJ silencing/NN of/IN the/DT beta-globin/NN promoter/NN in/IN the/DT fetal/JJ developmental/JJ stage/NN ./. 
We/PRP have/VBP now/RB demonstrated/VBN that/IN a/DT second/JJ SSE-like/JJ element/NN in/IN the/DT 5'-untranslated/JJ region/NN of/IN the/DT gamma-gene/NN also/RB contributes/VBZ to/TO this/DT competitive/JJ silencing/NN of/IN the/DT beta-gene/NN ./. 
Utilizing/VBG transient/JJ transfection/NN assays/NNS in/IN the/DT fetal/JJ erythroid/JJ cell/NN line/NN ,/, K562/NN ,/, we/PRP have/VBP shown/VBN that/IN the/DT core/NN enhancer/NN of/IN hypersensitivity/NN site/NN 2/CD can/MD preferentially/RB interact/VB with/IN the/DT proximal/JJ gamma-promoter/NN in/IN the/DT absence/NN of/IN the/DT SSE/NN ,/, completely/RB silencing/VBG a/DT linked/VBN beta-promoter/NN ./. 
Mutation/NN of/IN a/DT 20-base/JJ pair/NN sequence/NN of/IN the/DT gamma-gene/NN 5'-untranslated/JJ region/NN (/( UTR/NN )/) led/VBD to/TO derepression/NN of/IN beta-promoter/NN activity/NN ./. 
A/DT marked/JJ activation/NN of/IN gamma-promoter/NN activity/NN was/VBD also/RB observed/VBN with/IN this/DT mutation/NN ,/, suggesting/VBG the/DT presence/NN of/IN a/DT repressor/NN ./. 
Fine/JJ mutagenesis/NN dissected/VBD these/DT activities/NNS to/TO different/JJ regions/NNS of/IN the/DT 5'-UTR/NN ./. 
The/DT stage/NN selector/NN activity/NN was/VBD localized/VBN to/TO a/DT region/NN centered/JJ on/IN nucleotides/NNS +13/CD to/TO +15/CD ./. 
Electromobility/NN shift/NN assays/NNS utilizing/VBG this/DT sequence/NN demonstrated/VBD binding/NN of/IN a/DT fetal/JJ and/CC erythroid-specific/JJ protein/NN ./. 
The/DT repressor/NN activity/NN of/IN the/DT 5'-UTR/NN was/VBD localized/VBN to/TO tandem/JJ GATA-like/JJ sites/NNS ,/, which/WDT appear/VBP to/TO bind/VB a/DT complex/NN of/IN two/CD proteins/NNS ,/, one/CD of/IN which/WDT is/VBZ the/DT erythroid/JJ transcription/NN factor/NN GATA-1/NN ./. 
These/DT results/NNS indicate/VBP that/IN the/DT 5'-UTR/NN of/IN the/DT gamma-gene/NN contains/VBZ sequences/NNS that/WDT may/MD be/VB important/JJ for/IN its/PRP$ transcriptional/JJ and/CC developmental/JJ regulation/NN ./. 
UI/LS -/: 95257963/CD 
TI/LS -/: Coupling/NN of/IN a/DT signal/NN response/NN domain/NN in/IN I/NN kappa/NN B/NN alpha/NN to/TO multiple/JJ pathways/NNS for/IN NF-kappa/NN B/NN activation/NN ./. 
AB/LS -/: The/DT eukaryotic/JJ transcription/NN factor/NN NF-kappa/NN B/NN plays/VBZ a/DT central/JJ role/NN in/IN the/DT induced/VBN expression/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD and/CC in/IN many/JJ aspects/NNS of/IN the/DT genetic/JJ program/NN mediating/VBG normal/JJ T-cell/NN activation/NN and/CC growth/NN ./. 
The/DT nuclear/JJ activity/NN of/IN NF-kappa/NN B/NN is/VBZ tightly/RB regulated/VBN from/IN the/DT cytoplasmic/JJ compartment/NN by/IN an/DT inhibitory/JJ subunit/NN called/VBN I/NN kappa/NN B/NN alpha/NN ./. 
This/DT cytoplasmic/JJ inhibitor/NN is/VBZ rapidly/RB phosphorylated/VBN and/CC degraded/VBN in/IN response/NN to/TO a/DT diverse/JJ set/NN of/IN NF-kappa/NN B-inducing/JJ agents/NNS ,/, including/VBG T-cell/NN mitogens/NNS ,/, proinflammatory/JJ cytokines/NNS ,/, and/CC viral/JJ transactivators/NNS such/JJ as/IN the/DT Tax/NN protein/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD ./. 
To/TO explore/VB these/DT I/NN kappa/NN B/NN alpha-dependent/JJ mechanisms/NNS for/IN NF-kappa/NN B/NN induction/NN ,/, we/PRP identified/VBD novel/JJ mutants/NNS of/IN I/NN kappa/NN B/NN alpha/NN that/WDT uncouple/VBP its/PRP$ inhibitory/JJ and/CC signal-transducing/JJ functions/NNS in/IN human/JJ T/NN lymphocytes/NNS ./. 
Specifically/RB ,/, removal/NN of/IN the/DT N-terminal/JJ 36/CD amino/NN acids/NNS of/IN I/NN kappa/NN B/NN alpha/NN failed/VBD to/TO disrupt/VB its/PRP$ ability/NN to/TO form/VB latent/JJ complexes/NNS with/IN NF-kappa/NN B/NN in/IN the/DT cytoplasm/NN ./. 
However/RB ,/, this/DT deletion/NN mutation/NN prevented/VBD the/DT induced/VBN phosphorylation/NN ,/, degradative/JJ loss/NN ,/, and/CC functional/JJ release/NN of/IN I/NN kappa/NN B/NN alpha/NN from/IN NF-kappa/NN B/NN in/IN Tax-expressing/JJ cells/NNS ./. 
Alanine/NN substitutions/NNS introduced/VBN at/IN two/CD serine/NN residues/NNS positioned/JJ within/IN this/DT N-terminal/JJ regulatory/JJ region/NN of/IN I/NN kappa/NN B/NN alpha/NN also/RB yielded/VBD constitutive/JJ repressors/NNS that/WDT escaped/VBD from/IN Tax-induced/JJ turnover/NN and/CC that/WDT potently/RB inhibited/VBD immune/JJ activation/NN pathways/NNS for/IN NF-kappa/NN B/NN induction/NN ,/, including/VBG those/DT initiated/VBN from/IN antigen/NN and/CC cytokine/NN receptors/NNS ./. 
In/IN contrast/NN ,/, introduction/NN of/IN a/DT phosphoserine/NN mimetic/JJ at/IN these/DT sites/NNS rectified/VBD this/DT functional/JJ defect/NN ,/, a/DT finding/NN consistent/JJ with/IN a/DT causal/JJ linkage/NN between/IN the/DT phosphorylation/NN status/NN and/CC proteolytic/JJ stability/NN of/IN this/DT cytoplasmic/JJ inhibitor/NN ./. 
Together/RB ,/, these/DT in/FW vivo/FW studies/NNS define/VBP a/DT critical/JJ signal/NN response/NN domain/NN in/IN I/NN kappa/NN B/NN alpha/NN that/WDT coordinately/RB controls/VBZ the/DT biologic/JJ activities/NNS of/IN I/NN kappa/NN B/NN alpha/NN and/CC NF-kappa/NN B/NN in/IN response/NN to/TO viral/JJ and/CC immune/JJ stimuli/NNS ./. 
UI/LS -/: 95255485/CD 
TI/LS -/: Growth/NN regulation/NN and/CC cellular/JJ changes/NNS during/IN differentiation/NN of/IN human/JJ prostatic/JJ cancer/NN LNCaP/NN cells/NNS as/IN induced/VBN by/IN T/NN lymphocyte/JJ -conditioned/JJ medium/NN ./. 
AB/LS -/: Human/JJ prostatic/JJ epithelial/JJ cells/NNS from/IN an/DT androgen-dependent/JJ LNCaP/NN cell/NN line/NN were/VBD examined/VBN in/IN response/NN to/TO conditioned/JJ medium/NN (/( CM/NN )/) derived/VBN from/IN phytohemagglutinin/NN (/( PHA/NN )/) -stimulated/JJ lymphocytes/NNS ./. 
Addition/NN of/IN CM/NN caused/VBD a/DT greater/JJR than/IN 70/CD %/NN reduction/NN of/IN cell/NN proliferation/NN by/IN cell/NN counting/NN and/CC cell/NN cycle/NN ./. 
These/DT cells/NNS showed/VBD G1/NN phase/NN arrest/NN and/CC the/DT clonogenicity/NN was/VBD reduced/VBN ./. 
The/DT growth-modulating/JJ effect/NN was/VBD dose-dependent/JJ and/CC not/RB due/JJ to/TO cell/NN lysis/NN or/CC apoptosis/NN ./. 
The/DT binding/NN of/IN androgen/NN to/TO androgen/NN receptor/NN on/IN these/DT cells/NNS showed/VBD approximately/RB 50/CD %/NN reduction/NN ,/, underlining/VBG a/DT proliferation/NN reduction/NN mechanism/NN ./. 
The/DT prostate-specific/JJ antigen/NN (/( PSA/NN )/) was/VBD downregulated/VBN to/TO approximately/RB 75/CD %/NN during/IN the/DT process/NN ./. 
Cell/NN morphology/NN showed/VBD dendritic/JJ processes/NNS extending/VBG from/IN cytoplasm/NN and/CC other/JJ neuroendocrine/JJ cell/NN characteristics/NNS ./. 
The/DT expression/NN of/IN several/JJ cytoskeleton/NN and/CC intracellular/JJ proteins/NNS increased/VBD as/IN determined/VBN by/IN immunostaining/NN on/IN slides/NNS and/CC by/IN ELISA/NN procedures/NNS ./. 
These/DT included/VBD vimentin/NN ,/, correlating/VBG to/TO cell/NN shape/NN changes/NNS ,/, cytokeratins/NNS 8/CD and/CC 18/CD ,/, associated/VBN with/IN differentiated/VBN cell/NN types/NNS of/IN prostate/NN epithelia/NN ,/, and/CC neuron-specific/JJ enolase/NN and/CC serotonin/NN ,/, associated/VBN with/IN neuroendocrine/JJ cells/NNS ./. 
From/IN these/DT cellular/JJ changes/NNS ,/, we/PRP can/MD infer/VB that/IN the/DT cell/NN growth/NN was/VBD modulated/VBN along/IN with/IN induction/NN of/IN terminal/JJ differentiation/NN ./. 
Activated/VBN T/NN cells/NNS were/VBD demonstrated/VBN to/TO be/VB important/JJ in/IN providing/VBG the/DT modulating/NN activity/NN ./. 
This/DT growth/NN modulator/NN was/VBD semipurified/VBN and/CC had/VBD an/DT estimated/VBN molecular/JJ weight/NN 13,000/CD to/TO 24,000/CD Da/NN ./. 
The/DT activity/NN was/VBD determined/VBN to/TO be/VB distinct/JJ from/IN TGF/NN ,/, TNF/NN ,/, and/CC some/DT commonly/RB known/JJ lymphokines/NNS ./. 
The/DT interaction/NN between/IN lymphoid/JJ and/CC prostatic/JJ cells/NNS in/IN growth/NN and/CC development/NN is/VBZ described/VBN ./. 
UI/LS -/: 95229576/CD 
TI/LS -/: Platelet-activating/JJ factor/NN stimulates/VBZ transcription/NN of/IN the/DT heparin-binding/JJ epidermal/JJ growth/NN factor-like/JJ growth/NN factor/NN in/IN monocytes/NNS ./. 
Correlation/NN with/IN an/DT increased/VBN kappa/NN B/NN binding/NN activity/NN ./. 
AB/LS -/: Human/JJ peripheral/JJ blood/NN monocytes/NNS responded/VBD to/TO stimulation/NN of/IN platelet-activating/JJ factor/NN (/( PAF/NN )/) with/IN up-regulation/NN of/IN the/DT transcript/NN for/IN heparin-binding/JJ epidermal/JJ growth/NN factor-like/JJ growth/NN factor/NN (/( HB-EGF/NN )/) ,/, a/DT potent/JJ mitogen/NN for/IN vascular/JJ smooth/JJ muscle/NN cells/NNS ./. 
This/DT function/NN of/IN PAF/NN was/VBD observed/VBN at/IN nanomolar/JJ concentrations/NNS of/IN the/DT ligand/NN ,/, starting/VBG at/IN 30/CD min/NN after/IN stimulation/NN ./. 
The/DT PAF-induced/JJ up-regulation/NN of/IN HB-EGF/NN mRNA/NN was/VBD accompanied/VBN by/IN an/DT increase/NN in/IN kappa/NN B/NN binding/NN activity/NN ./. 
These/DT functions/NNS of/IN PAF/NN appeared/VBD to/TO be/VB mediated/VBN through/IN the/DT cell/NN surface/NN PAF/NN receptors/NNS ,/, as/IN two/CD PAF/NN receptor/NN antagonists/NNS ,/, WEB/NN 2086/CD and/CC L-659/NN ,/, 989/CD ,/, blocked/VBD both/CC the/DT up-regulation/NN of/IN HB-EGF/NN mRNA/NN and/CC kappa/NN B/NN binding/NN activity/NN induced/VBN by/IN PAF/NN ./. 
The/DT antagonists/NNS ,/, however/RB ,/, had/VBD no/DT effect/NN on/IN phorbol/NN ester-induced/JJ up-regulation/NN of/IN HB-EGF/NN mRNA/NN and/CC kappa/NN B/NN binding/NN activity/NN ./. 
Pretreatment/NN of/IN monocytes/NNS with/IN pertussis/NN toxin/NN inhibited/VBD these/DT functions/NNS of/IN PAF/NN ,/, whereas/IN cholera/NN toxin/NN had/VBD no/DT inhibitory/JJ effect/NN ./. 
Pyrrolidine/NN dithiocarbamate/NN ,/, an/DT inhibitor/NN for/IN NF-kappa/NN B/NN activation/NN ,/, markedly/RB reduced/VBD PAF-stimulated/JJ kappa/NN B/NN binding/NN activity/NN as/RB well/RB as/IN up-regulation/NN of/IN HB-EGF/NN mRNA/NN ./. 
These/DT results/NNS suggest/VBP a/DT potential/JJ role/NN of/IN PAF/NN in/IN HB-EGF/NN expression/NN and/CC provide/VBP evidence/NN that/IN this/DT stimulation/NN may/MD occur/VB through/IN increased/VBN kappa/NN B/NN binding/NN activity/NN ./. 
UI/LS -/: 95197681/CD 
TI/LS -/: Mapping/NN of/IN the/DT interaction/NN site/NN of/IN the/DT defective/JJ transcription/NN factor/NN in/IN the/DT class/NN II/CD major/JJ histocompatibility/NN complex/NN mutant/JJ cell/NN line/NN clone-13/NN to/TO the/DT divergent/JJ X2-box/NN ./. 
AB/LS -/: We/PRP have/VBP previously/RB described/VBN a/DT mutant/JJ B/NN lymphoblastoid/JJ cell/NN line/NN ,/, Clone-13/NN ,/, that/WDT expresses/VBZ HLA-DQ/NN in/IN the/DT absence/NN of/IN HLA-DR/NN and/CC -DP/NN ./. 
Several/JJ criteria/NNS indicated/VBD that/IN the/DT defect/NN in/IN this/DT cell/NN line/NN influences/VBZ the/DT activity/NN of/IN an/DT isotype-specific/JJ transcription/NN factor/NN ./. 
Indeed/RB ,/, transient/JJ transfection/NN of/IN HLA-DRA/NN and/CC DQB/NN reporter/NN constructs/NNS indicated/VBD that/IN the/DT affected/VBN factor/NN operates/VBZ via/IN cis-elements/NNS located/JJ between/IN -141/CD base/NN pairs/NNS and/CC the/DT transcription/NN initiation/NN site/NN ./. 
A/DT series/NN of/IN hybrid/NN DRA/DQB/NN reporter/NN constructs/NNS was/VBD generated/VBN to/TO further/JJ map/VB the/DT relevant/JJ cis-elements/NNS in/IN this/DT system/NN ./. 
Insertion/NN of/IN oligonucleotides/NNS spanning/VBG the/DT DQB/NN X-box/NN (/( but/CC not/RB the/DT DQB-W/NN region/NN or/CC the/DT DQB/NN Y-box/NN )/) upstream/JJ of/IN -141/CD in/IN a/DT DRA/NN reporter/NN plasmid/NN rescued/VBD expression/NN to/TO nearly/RB wild-type/JJ levels/NNS ./. 
Substitution/NN promoters/NNS were/VBD then/RB generated/VBN where/WRB the/DT entire/JJ X-box/NN ,/, or/CC only/RB the/DT X1-/NN or/CC X2-boxes/NNS of/IN HLA-DRA/NN were/VBD replaced/VBN with/IN the/DT analogous/JJ regions/NNS of/IN HLA-DQB/NN ./. 
The/DT DQB/NN X2-box/NN was/VBD able/JJ to/TO restore/VB expression/NN to/TO the/DT silent/JJ DRA/NN reporter/NN construct/NN ./. 
Moreover/RB ,/, replacement/NN of/IN the/DT DQB/NN X2-box/NN with/IN the/DT DRA/NN X2-box/NN markedly/RB diminished/VBD the/DT activity/NN of/IN the/DT DQB/NN promoter/NN in/IN the/DT mutant/JJ cell/NN ./. 
None/NN of/IN the/DT hybrid/NN reporter/NN constructs/NNS were/VBD defective/JJ when/WRB transfected/VBN into/IN the/DT wild-type/JJ ,/, HLA-DR/-DQ/NN positive/JJ parental/JJ cell/NN line/NN ,/, Jijoye/NN ./. 
These/DT studies/NNS suggest/VBP that/IN the/DT divergent/JJ X2-box/NN of/IN the/DT class/NN II/CD major/JJ histocompatibility/NN complex/NN promoters/NNS plays/VBZ an/DT important/JJ role/NN in/IN influencing/VBG differential/JJ expression/NN of/IN the/DT human/JJ class/NN II/CD isotypes/NNS ./. 
UI/LS -/: 95373165/CD 
TI/LS -/: Restoration/NN of/IN the/DT Epstein-Barr/JJ virus/NN ZEBRA/NN protein/NN 's/POS capacity/NN to/TO disrupt/VB latency/NN by/IN the/DT addition/NN of/IN heterologous/JJ activation/NN regions/NNS ./. 
AB/LS -/: The/DT ZEBRA/NN protein/NN has/VBZ a/DT unique/JJ biological/JJ function/NN among/IN herpesviral/JJ proteins/NNS ./. 
It/PRP is/VBZ responsible/JJ for/IN the/DT disruption/NN of/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) latency/NN and/CC the/DT induction/NN of/IN the/DT lytic/JJ cycle/NN ./. 
ZEBRA/NN is/VBZ a/DT bZIP/NN transcriptional/JJ activator/NN which/WDT binds/VBZ as/IN a/DT dimer/NN to/TO 7-bp/JJ response/NN elements/NNS within/IN EBV/NN promoters/NNS and/CC is/VBZ directly/RB involved/VBN in/IN the/DT stimulation/NN of/IN virus/NN replication/NN at/IN the/DT EBV/NN lytic/JJ origin/NN ./. 
We/PRP have/VBP employed/VBN the/DT ZEBRA/EBV/NN biological/JJ system/NN to/TO test/VB whether/IN a/DT heterologous/JJ activation/NN domain/NN can/MD substitute/VB for/IN another/DT activation/NN domain/NN (/( the/DT ZEBRA/NN domain/NN )/) ./. 
The/DT ZEBRA/NN activation/NN region/NN was/VBD replaced/VBN with/IN the/DT potent/JJ acid/NN activation/NN region/NN from/IN the/DT herpes/NN simplex/JJ virus/NN VP16/NN protein/NN or/CC with/IN the/DT activation/NN region/NN of/IN the/DT EBV/NN R/NN protein/NN ./. 
Both/DT chimeras/NNS were/VBD found/VBN to/TO transactivate/VB model/NN and/CC native/JJ promoters/NNS at/IN equivalent/JJ or/CC better/JJR levels/NNS than/IN ZEBRA/NN itself/PRP ./. 
Activation/NN was/VBD not/RB target-/NN or/CC cell-type/NN dependent/JJ ,/, nor/CC was/VBD it/PRP dependent/JJ on/IN the/DT presence/NN of/IN virus/NN ./. 
These/DT activation/NN domains/NNS restored/VBD ZEBRA/NN 's/POS ability/NN to/TO induce/VB early/JJ antigen/NN and/CC to/TO stimulate/VB origin/NN replication/NN to/TO levels/NNS that/WDT were/VBD equal/JJ to/TO or/CC greater/JJR than/IN those/DT of/IN wild/JJ type/NN ./. 
These/DT studies/NNS suggest/VBP that/IN the/DT specificities/NNS of/IN some/DT of/IN the/DT known/JJ biological/JJ functions/NNS of/IN ZEBRA/NN are/VBP not/RB dependent/JJ upon/IN the/DT nature/NN of/IN the/DT activation/NN domain/NN present/JJ within/IN ZEBRA/NN ./. 
UI/LS -/: 95362854/CD 
TI/LS -/: Interleukin/NN 4/CD activates/VBZ a/DT signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( Stat/NN )/) protein/NN which/WDT interacts/VBZ with/IN an/DT interferon-gamma/NN activation/NN site-like/JJ sequence/NN upstream/RB of/IN the/DT I/NN epsilon/NN exon/NN in/IN a/DT human/JJ B/NN cell/NN line/NN ./. 
Evidence/NN for/IN the/DT involvement/NN of/IN Janus/NN kinase/NN 3/CD and/CC interleukin-4/NN Stat/NN ./. 
AB/LS -/: Germ/NN line/NN C/NN transcripts/NNS can/MD be/VB induced/VBN by/IN IL-4/NN in/IN the/DT human/JJ B/NN cell/NN line/NN ,/, BL-2/NN ./. 
Utilizing/VBG a/DT IFN-gamma/NN activation/NN site-like/JJ DNA/NN sequence/NN element/NN located/JJ upstream/RB of/IN the/DT I/NN epsilon/NN exon/NN ,/, we/PRP demonstrated/VBD by/IN gel/NN mobility/NN shift/NN assays/NNS that/IN IL-4/NN induced/VBD a/DT binding/NN activity/NN in/IN the/DT cytosol/NN and/CC nucleus/NN of/IN BL-2/NN cells/NNS ./. 
This/DT factor/NN was/VBD designated/VBN IL-4/NN NAF/NNS (/( IL-4-induced/JJ nuclear-activating/JJ factors/NNS )/) and/CC was/VBD identified/VBN as/IN a/DT tyrosine/NN phosphoprotein/NN ,/, which/WDT translocates/VBZ from/IN the/DT cytosol/NN to/TO the/DT nucleus/NN upon/IN IL-4/NN treatment/NN ./. 
Because/IN these/DT are/VBP the/DT characteristics/NNS of/IN a/DT signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( Stat/NN )/) protein/NN ,/, we/PRP determined/VBD whether/IN antibodies/NNS to/TO Stat/NN proteins/NNS will/MD interfere/VB with/IN gel/NN mobility/NN shift/NN and/CC found/VBD that/IN antibodies/NNS to/TO IL-4/NN Stat/NN ,/, also/RB known/VBN as/IN Stat6/NN ,/, but/CC not/RB antibodies/NNS to/TO other/JJ Stat/NN proteins/NNS ,/, interfere/VBP with/IN the/DT formation/NN of/IN the/DT IL-4/NN NAF/NN complex/NN ./. 
Congruous/JJ with/IN the/DT involvement/NN of/IN a/DT Stat/NN protein/NN ,/, IL-4/NN induced/VBD robust/JJ Janus/NN kinase/NN 3/CD (/( JAK3/NN )/) activity/NN in/IN BL-2/NN cells/NNS ./. 
Cotransfection/NN of/IN JAK3/NN with/IN IL-4/NN Stat/NN into/IN COS-7/NN cells/NNS produced/VBD an/DT intracellular/JJ activity/NN which/WDT bound/VBD the/DT same/JJ IFN-gamma/NN activation/NN site-like/JJ sequence/NN and/CC comigrated/VBD with/IN IL-4/NN NAF/NN in/IN electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
These/DT results/NNS show/VBP that/IN IL-4/NN NAF/NN is/VBZ IL-4/NN Stat/NN ,/, which/WDT is/VBZ activated/VBN by/IN JAK3/NN in/IN response/NN to/TO IL-4/NN receptor/NN engagement/NN ./. 
UI/LS -/: 95329724/CD 
TI/LS -/: Does/VBZ activation/NN of/IN the/DT TAL1/NN gene/NN occur/VB in/IN a/DT majority/NN of/IN patients/NNS with/IN T-cell/NN acute/JJ lymphoblastic/JJ leukemia/NN ?/. A/DT pediatric/JJ oncology/NN group/NN study/NN ./. 
AB/LS -/: Almost/RB 25/CD %/NN of/IN patients/NNS with/IN T-cell/NN acute/JJ lymphoblastic/JJ leukemia/NN (/( T-ALL/NN )/) have/VBP tumor-specific/JJ rearrangements/NNS of/IN the/DT TAL1/NN gene/NN ./. 
Although/IN TAL1/NN expression/NN has/VBZ not/RB been/VBN observed/VBN in/IN normal/JJ lymphocytes/NNS ,/, TAL1/NN gene/NN products/NNS are/VBP readily/RB detected/VBN in/IN leukemic/JJ cells/NNS that/WDT harbor/VBP a/DT rearranged/VBN TAL1/NN allele/NN ./. 
Hence/RB ,/, it/PRP has/VBZ been/VBN proposed/VBN that/IN ectopic/JJ expression/NN of/IN TAL1/NN promotes/VBZ the/DT development/NN of/IN T-ALL/NN ./. 
In/IN this/DT report/NN ,/, we/PRP show/VBP that/IN TAL1/NN is/VBZ expressed/VBN in/IN the/DT leukemic/JJ cells/NNS of/IN most/JJS patients/NNS with/IN T-ALL/NN ,/, including/VBG many/JJ that/WDT do/VBP not/RB display/VB an/DT apparent/JJ TAL1/NN gene/NN alteration/NN ./. 
A/DT polymorphic/JJ dinucleotide/NN repeat/NN in/IN the/DT transcribed/VBN sequences/NNS of/IN TAL1/NN was/VBD used/VBN to/TO determine/VB the/DT allele/NN specificity/NN of/IN TAL1/NN transcription/NN in/IN primary/JJ T-ALL/NN cells/NNS ./. 
Monoallelic/JJ expression/NN of/IN TAL1/NN was/VBD observed/VBN in/IN the/DT leukemic/JJ cells/NNS of/IN all/DT patients/NNS (/( 8/CD of/IN 8/CD )/) bearing/VBG a/DT TAL1/NN gene/NN rearrangement/NN ./. 
In/IN the/DT leukemic/JJ cells/NNS of/IN patients/NNS without/IN detectable/JJ TAL1/NN rearrangements/NNS ,/, TAL1/NN transcription/NN occurred/VBD in/IN either/CC a/DT monoallelic/JJ (/( 3/CD of/IN 7/CD patients/NNS )/) or/CC a/DT biallelic/JJ (/( 4/CD of/IN 7/CD patients/NNS )/) fashion/NN ./. 
Thus/RB ,/, TAL1/NN activation/NN in/IN these/DT patients/NNS may/MD result/VB from/IN subtle/JJ alterations/NNS in/IN cis-acting/JJ regulatory/JJ sequences/NNS (/( affecting/VBG expression/NN of/IN a/DT single/JJ TAL1/NN allele/NN )/) or/CC changes/NNS in/IN trans-acting/JJ factors/NNS that/WDT control/VBP TAL1/NN transcription/NN (/( affecting/VBG expression/NN of/IN both/DT TAL1/NN alleles/NNS )/) ./. 
UI/LS -/: 95374911/CD 
TI/LS -/: Expression/NN of/IN erythroid-specific/JJ genes/NNS in/IN acute/JJ megakaryoblastic/JJ leukaemia/NN and/CC transient/JJ myeloproliferative/JJ disorder/NN in/IN Down/NN 's/POS syndrome/NN ./. 
AB/LS -/: Acute/JJ megakaryoblastic/JJ leukaemia/NN (/( M7/NN )/) and/CC transient/JJ myeloproliferative/JJ disorder/NN in/IN Down/NN 's/POS syndrome/NN (/( TMD/NN )/) are/VBP characterized/VBN by/IN rapid/JJ growth/NN of/IN abnormal/JJ blast/NN cells/NNS which/WDT express/VBP megakaryocytic/JJ markers/NNS ./. 
To/TO clarify/VB properties/NNS of/IN the/DT blast/NN cells/NNS in/IN M7/NN and/CC TMD/NN cases/NNS ,/, we/PRP examined/VBD erythroid/JJ markers/NNS expression/NN in/IN blasts/NNS from/IN six/CD cases/NNS with/IN M7/NN and/CC seven/CD cases/NNS with/IN TMD/NN in/IN this/DT study/NN ./. 
Erythroid-specific/JJ mRNAs/NNS encoding/VBG gamma-globin/NN and/CC erythroid/JJ delta-aminolevulinate/JJ synthase/NN were/VBD found/VBN to/TO be/VB expressed/VBN in/IN blasts/NNS from/IN most/JJS of/IN these/DT cases/NNS ,/, indicating/VBG that/IN majorities/NNS of/IN the/DT blasts/NNS in/IN M7/NN and/CC TMD/NN cases/NNS have/VBP erythroid/JJ and/CC megakaryocytic/JJ phenotypes/NNS ./. 
We/PRP also/RB found/VBD that/IN mRNAs/NNS encoding/VBG GATA-1/NN and/CC GATA-2/NN are/VBP expressed/VBN in/IN all/DT these/DT cases/NNS ./. 
These/DT results/NNS suggest/VBP that/IN M7/NN blasts/NNS and/CC TMD/NN blasts/NNS correspond/VBP to/TO the/DT erythroid/megakaryocytic/JJ bipotential/JJ progenitor/NN cells/NNS ./. 
UI/LS -/: 95308691/CD 
TI/LS -/: Expression/NN of/IN Ah/NN receptor/NN (/( TCDD/NN receptor/NN )/) during/IN human/JJ monocytic/JJ differentiation/NN ./. 
AB/LS -/: We/PRP have/VBP previously/RB found/VBN a/DT high/JJ expression/NN of/IN human/JJ Ah/NN receptor/NN (/( TCDD/NN receptor/NN )/) mRNA/NN in/IN peripheral/JJ blood/NN cells/NNS of/IN individuals/NNS ./. 
In/IN this/DT paper/NN ,/, the/DT expression/NN of/IN this/DT gene/NN in/IN blood/NN cells/NNS was/VBD first/RB investigated/VBN in/IN fractions/NNS of/IN nucleated/JJ cells/NNS ,/, revealing/VBG predominant/JJ expression/NN of/IN the/DT Ah/NN receptor/NN gene/NN in/IN the/DT monocyte/NN fraction/NN ./. 
Then/RB the/DT expression/NN levels/NNS of/IN AhR/NN mRNA/NN in/IN various/JJ hematopoietic/JJ cell/NN lines/NNS were/VBD examined/VBN together/RB with/IN those/DT of/IN Arnt/NN and/CC P450IA1/NN ./. 
AhR/NN was/VBD expressed/VBN at/IN high/JJ levels/NNS in/IN monocytoid/JJ U937/NN ,/, THP1/NN ,/, and/CC HEL/S/NN cells/NNS ,/, and/CC at/IN moderate/JJ levels/NNS in/IN promyelocytic/JJ HL60/NN cells/NNS and/CC erythroblastic/JJ HEL/NN cells/NNS ./. 
However/RB ,/, it/PRP was/VBD not/RB detected/VBN in/IN lymphoid/JJ cells/NNS MOLT4/NN (/( T/NN cell/NN )/) and/CC BALL1/NN (/( B/NN cell/NN )/) ,/, nor/CC in/IN K562/NN erythroblasts/NNS ./. 
Furthermore/RB ,/, a/DT specific/JJ induction/NN of/IN AhR/NN during/IN monocytic/JJ differentiation/NN was/VBD investigated/VBN in/IN HL60/NN and/CC HEL/NN cells/NNS ./. 
HL60/NN cells/NNS were/VBD induced/VBN to/TO differentiate/VB toward/IN monocytes-macrophages/NNS by/IN incubation/NN with/IN phorbol/NN ester/NN ,/, showing/VBG a/DT 5-/CD to/TO 2-fold/JJ increase/NN of/IN AhR/NN mRNA/NN ./. 
The/DT incubation/NN with/IN transforming/VBG growth/NN factor/NN beta/NN 1/CD and/CC 1/CD alpha,25-dihydroxyvitamin/NN D3/NN resulted/VBD in/IN a/DT 5-/CD to/TO 7-fold/JJ increase/NN of/IN AhR/NN mRNA/NN ./. 
The/DT HEL/NN cells/NNS also/RB exhibited/VBD a/DT similar/JJ elevation/NN of/IN AhR/NN mRNA/NN level/NN ,/, when/WRB they/PRP had/VBD differentiated/VBN toward/IN monocyte-macrophage/JJ cells/NNS by/IN these/DT combined/JJ inducers/NNS ,/, but/CC little/JJ change/NN in/IN the/DT mRNA/NN level/NN was/VBD observed/VBN when/WRB the/DT cells/NNS were/VBD induced/VBN to/TO differentiate/VB into/IN other/JJ cell/NN types/NNS ./. 
Treatment/NN of/IN the/DT differentiated/VBN HL60/NN cells/NNS with/IN 3-methylcholanthrene/NN ,/, a/DT ligand/NN of/IN AhR/NN ,/, induced/VBD the/DT expression/NN of/IN the/DT P450IA1/NN gene/NN ./. 
These/DT results/NNS indicated/VBD that/IN expression/NN of/IN AhR/NN mRNA/NN was/VBD significantly/RB induced/VBN during/IN monocytic/JJ differentiation/NN and/CC that/IN the/DT differentiated/VBN cells/NNS were/VBD responsive/JJ to/TO xenobiotics/NNS ./. 
Our/PRP$ results/NNS suggest/VBP that/IN AhR/NN may/MD play/VB an/DT important/JJ role/NN in/IN the/DT function/NN of/IN monocytes/NNS and/CC also/RB in/IN the/DT eventual/JJ activation/NN of/IN environmental/JJ carcinogens/NNS ./. 
UI/LS -/: 95261059/CD 
TI/LS -/: Neutrophils/NNS and/CC monocytes/NNS express/VBP high/JJ levels/NNS of/IN PU.1/NN (/( Spi-1/NN )/) but/CC not/RB Spi-B/NN ./. 
AB/LS -/: PU.1/NN (/( the/DT Spi-1/NN oncogene/NN )/) and/CC Spi-B/NN are/VBP closely/RB related/JJ members/NNS of/IN the/DT ets/NN transcription/NN factor/NN family/NN ,/, sharing/VBG similar/JJ DNA/NN binding/NN specificities/NNS mediated/VBN by/IN similar/JJ DNA/NN binding/NN domains/NNS ./. 
PU.1/NN and/CC Spi-B/NN have/VBP been/VBN previously/RB described/VBN as/IN being/VBG predominantly/RB expressed/VBN coordinately/RB in/IN macrophages/NNS and/CC B/NN cells/NNS ,/, but/CC their/PRP$ expression/NN in/IN early/JJ hematopoietic/JJ stages/NNS and/CC during/IN the/DT course/NN of/IN myeloid/JJ differentiation/NN to/TO monocytes/NNS and/CC macrophages/NNS or/CC to/TO neutrophils/NNS has/VBZ not/RB been/VBN extensively/RB investigated/VBN ./. 
Here/RB ,/, we/PRP report/VBP that/IN PU.1/NN mRNA/NN is/VBZ upregulated/VBN during/IN myeloid/JJ differentiation/NN of/IN human/JJ purified/VBN CD34+/JJ cells/NNS and/CC murine/JJ multipotential/JJ FDCP-mix/NN A4/NN cells/NNS ,/, suggesting/VBG that/IN PU.1/NN is/VBZ upregulated/VBN as/IN an/DT early/JJ event/NN during/IN differentiation/NN of/IN multipotential/JJ progenitor/NN cells/NNS ./. 
PU.1/NN expression/NN is/VBZ maintained/JJ at/IN stable/JJ levels/NNS during/IN differentiation/NN of/IN myeloid/JJ cell/NN lines/NNS U937/NN and/CC HL-60/NN to/TO monocytic/JJ and/CC neutrophilic/JJ cells/NNS ./. 
PU.1/NN is/VBZ expressed/VBN at/IN highest/JJS levels/NNS in/IN mature/JJ human/JJ monocytes/NNS and/CC human/JJ peripheral/JJ blood/NN neutrophils/NNS ./. 
In/IN contrast/NN to/TO PU.1/NN ,/, significant/JJ levels/NNS of/IN Spi-B/NN mRNA/NN and/CC protein/NN are/VBP found/VBN only/RB in/IN some/DT B-cell/NN lines/NNS and/CC spleen/NN but/CC are/VBP not/RB found/VBN in/IN myeloid/JJ cell/NN lines/NNS ,/, neutrophils/NNS ,/, or/CC macrophages/NNS ./. 
In/FW vitro/FW translated/VBN Spi-B/NN protein/NN can/MD bind/VB to/TO PU.1/NN binding/NN sites/NNS in/IN myeloid/JJ promoters/NNS and/CC transactivate/VB these/DT promoters/NNS in/IN nonmyeloid/JJ cells/NNS ./. 
Therefore/RB ,/, although/IN PU.1/NN and/CC Spi-B/NN may/MD bind/VB to/TO similar/JJ DNA/NN control/NN elements/NNS and/CC have/VBP redundancy/NN of/IN transactivation/NN function/NN in/FW vitro/FW ,/, the/DT lack/NN of/IN significant/JJ levels/NNS of/IN Spi-B/NN in/IN myeloid/JJ cells/NNS makes/VBZ it/PRP unlikely/JJ that/IN Spi-B/NN plays/VBZ a/DT significant/JJ role/NN in/IN myeloid/JJ lineage/NN development/NN and/CC gene/NN expression/NN ./. 
In/IN contrast/NN ,/, PU.1/NN is/VBZ expressed/VBN at/IN high/JJ levels/NNS not/RB only/RB in/IN monocytes/NNS and/CC macrophages/NNS but/CC also/RB in/IN neutrophils/NNS ,/, indicating/VBG that/IN PU.1/NN can/MD activate/VB gene/NN expression/NN in/IN both/DT major/JJ myeloid/JJ lineages/NNS ./. 
UI/LS -/: 95244883/CD 
TI/LS -/: Identification/NN of/IN a/DT major/JJ positive/JJ regulatory/JJ element/NN located/JJ 5'/JJ to/TO the/DT human/JJ zeta-globin/NN gene/NN ./. 
AB/LS -/: The/DT function/NN of/IN the/DT zeta-globin/NN promoter/NN was/VBD studied/VBN using/VBG a/DT series/NN of/IN zeta-globin/NN promoter/NN deletion/NN constructs/NNS to/TO drive/VB luciferase/NN expression/NN in/IN transiently/RB transfected/VBN human/JJ erythroleukemia/NN cells/NNS ./. 
The/DT promoters/NNS were/VBD used/VBN without/IN enhancers/NNS ,/, or/CC with/IN enhancers/NNS derived/VBN from/IN the/DT beta-globin/NN locus/NN control/NN region/NN and/CC the/DT alpha-globin/NN HS-40/NN enhancer/NN ./. 
When/WRB transfected/VBN into/IN K562/NN cells/NNS ,/, which/WDT express/VBP zeta-globin/NN ,/, comparable/JJ amounts/NNS of/IN activity/NN were/VBD obtained/VBN from/IN the/DT -557/CD and/CC -417/CD zeta-luciferase/NN constructs/NNS and/CC the/DT alpha-luciferase/NN constructs/NNS when/WRB no/DT enhancers/NNS or/CC the/DT alpha-globin/NN locus/NN enhancers/NNS were/VBD used/VBN ./. 
When/WRB the/DT constructs/NNS were/VBD transfected/VBN into/IN OCIM1/NN cells/NNS ,/, which/WDT do/VBP not/RB express/VB zeta-globin/NN ,/, the/DT zeta-globin/NN promoters/NNS were/VBD at/IN best/RB 20/CD %/NN as/IN active/JJ as/IN the/DT alpha-globin/NN promoters/NNS ./. 
When/WRB sequences/NNS from/IN -417/CD to/TO -207/CD 5'/JJ to/TO the/DT zeta-globin/NN mRNA/NN cap/NN site/NN were/VBD deleted/VBN ,/, up/IN to/TO 95/CD %/NN of/IN the/DT zeta-globin/NN promoter/NN activity/NN was/VBD lost/VBN in/IN K562/NN cells/NNS ./. 
Reinsertion/NN of/IN these/DT sequences/NNS into/IN zeta-luciferase/NN constructs/NNS missing/VBG the/DT -417/CD to/TO -207/CD region/NN showed/VBD that/IN the/DT sequences/NNS lack/VBP classical/JJ enhancer/NN activity/NN ./. 
Point/NN mutation/NN of/IN a/DT GATA-1/NN site/NN at/IN -230/CD reduced/VBD promoter/NN activity/NN by/IN 37/CD %/NN ./. 
Point/NN mutation/NN of/IN a/DT CCACC/NN site/NN at/IN -240/CD had/VBD no/DT effect/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS indicated/VBD that/IN the/DT -230/CD GATA-1/NN site/NN has/VBZ a/DT relatively/RB low/JJ affinity/NN for/IN GATA-1/NN ./. 
These/DT experiments/NNS show/VBP the/DT presence/NN of/IN a/DT strong/JJ positive-acting/JJ element/NN ,/, located/JJ between/IN -417/CD and/CC -207/CD bp/NN 5'/JJ to/TO the/DT zeta-globin/NN mRNA/NN cap/NN site/NN ,/, is/VBZ necessary/JJ for/IN high-level/JJ promoter/NN activity/NN in/IN K562/NN cells/NNS ./. 
This/DT element/NN requires/VBZ GATA-1/NN and/CC additional/JJ unknown/JJ factors/NNS for/IN maximal/JJ activity/NN ./. 
UI/LS -/: 95247773/CD 
TI/LS -/: Analysis/NN of/IN the/DT role/NN of/IN protein/NN kinase/NN C-alpha/NN ,/, -epsilon/NN ,/, and/CC -zeta/NN in/IN T/NN cell/NN activation/NN ./. 
AB/LS -/: T/NN cells/NNS express/VBP multiple/JJ isotypes/NNS of/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) and/CC although/IN it/PRP is/VBZ well/RB accepted/VBN that/IN PKCs/NNS have/VBP an/DT important/JJ role/NN in/IN T/NN cell/NN activation/NN ,/, little/JJ is/VBZ known/VBN about/IN the/DT function/NN of/IN individual/JJ PKC/NN isotypes/NNS ./. 
To/TO address/VB this/DT issue/NN ,/, mutationally/RB active/JJ PKC-alpha/NN ,/, -epsilon/NN ,/, or/CC -zeta/NN have/VBP been/VBN transfected/VBN into/IN T/NN cells/NNS and/CC the/DT consequences/NNS for/IN T/NN cell/NN activation/NN determined/VBN ./. 
p21ras/NN plays/VBZ an/DT essential/JJ role/NN in/IN T/NN cell/NN activation/NN ./. 
Accordingly/RB ,/, the/DT effects/NNS of/IN the/DT constitutively/RB active/JJ PKCs/NNS were/VBD compared/VBN to/TO the/DT effects/NNS of/IN mutationally/RB activated/VBN p21ras/NN ./. 
The/DT data/NNS indicate/VBP that/IN PKC-epsilon/NN and/CC ,/, to/TO a/DT lesser/JJR extent/NN PKC-alpha/NN but/CC not/RB -zeta/NN ,/, can/MD regulate/VB the/DT transcription/NN factors/NNS AP-1/NN and/CC nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT-1/NN )/) ./. 
The/DT ability/NN of/IN PKC-epsilon/NN to/TO induce/VB transactivation/NN of/IN NF-AT-1/NN and/CC AP-1/NN was/VBD similar/JJ to/TO the/DT stimulatory/JJ effect/NN of/IN a/DT constitutively/RB activated/VBN p21ras/NN ./. 
PKC-epsilon/NN ,/, but/CC not/RB PKC-alpha/NN nor/CC activated/JJ p21ras/NN ,/, was/VBD able/JJ to/TO induce/VB NF-KB/NN activity/NN ./. 
Phorbol/NN esters/NNS induce/VBP expression/NN of/IN CD69/NN whereas/IN none/NN of/IN the/DT activated/VBN PKC/NN isotypes/NNS tested/VBN were/VBD able/JJ to/TO have/VB this/DT effect/NN ./. 
Activated/VBN Src/NN and/CC p21ras/NN were/VBD able/JJ to/TO induce/VB CD69/NN expression/NN ./. 
These/DT results/NNS indicate/VBP selective/JJ functions/NNS for/IN different/JJ PKC/NN isotypes/NNS in/IN T/NN cells/NNS ./. 
Moreover/RB ,/, the/DT data/NNS comparing/VBG the/DT effects/NNS of/IN activated/VBN Ras/NN and/CC PKC/NN mutants/NNS suggest/VBP that/IN PKC-alpha/NN ,/, p21ras/NN ,/, and/CC PKC-epsilon/NN are/VBP not/RB positioned/JJ linearly/RB on/IN a/DT single/JJ signal/NN transduction/NN pathway/NN ./. 
UI/LS -/: 95204946/CD 
TI/LS -/: Differences/NNS in/IN binding/NN of/IN glucocorticoid/NN receptor/NN to/TO DNA/NN in/IN steroid-resistant/JJ asthma/NN ./. 
AB/LS -/: Although/IN glucocorticosteroids/NNS are/VBP a/DT very/RB effective/JJ treatment/NN for/IN asthma/NN and/CC other/JJ chronic/JJ inflammatory/JJ diseases/NNS ,/, a/DT small/JJ proportion/NN of/IN patients/NNS are/VBP resistant/JJ to/TO their/PRP$ therapeutic/JJ effects/NNS ./. 
The/DT molecular/JJ mechanism/NN for/IN this/DT steroid/NN resistance/NN is/VBZ unclear/JJ ./. 
Steroid/NN resistance/NN can/MD not/RB be/VB explained/VBN by/IN pharmacokinetic/JJ mechanisms/NNS ,/, by/IN a/DT defect/NN in/IN the/DT binding/NN of/IN steroids/NNS to/TO glucocorticoid/NN receptors/NNS ,/, nor/CC by/IN defective/JJ nuclear/JJ translocation/NN of/IN this/DT receptor/NN ,/, thereby/RB suggesting/VBG that/IN the/DT molecular/JJ abnormality/NN lies/VBZ distal/JJ to/TO nuclear/JJ translocation/NN ./. 
We/PRP examined/VBD the/DT ability/NN of/IN nuclear/JJ translocated/VBN glucocorticoid/NN receptors/NNS to/TO bind/VB to/TO their/PRP$ DNA/NN binding/NN sites/NNS (/( GRE/NN )/) using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS in/IN PBMC/NN from/IN patients/NNS with/IN steroid-sensitive/JJ and/CC steroid-resistant/JJ asthma/NN ./. 
The/DT binding/NN of/IN the/DT glucocorticoid/NN receptor/NN to/TO DNA/NN in/IN these/DT patients/NNS was/VBD also/RB studied/VBN using/VBG Scatchard/NN analysis/NN ./. 
Dexamethasone/NN induced/VBD a/DT significant/JJ rapid/JJ and/CC sustained/JJ twofold/JJ increase/NN in/IN GRE/NN binding/NN in/IN PBMCs/NNS from/IN steroid-sensitive/JJ asthmatic/JJ patients/NNS and/CC nonasthmatic/JJ individuals/NNS ,/, but/CC this/DT was/VBD markedly/RB reduced/VBN in/IN steroid-resistant/JJ asthmatic/JJ patients/NNS ./. 
Scatchard/NN analysis/NN of/IN glucocorticoid/NN receptor-GRE/NN binding/NN showed/VBD no/DT change/NN in/IN binding/NN affinity/NN but/CC did/VBD show/VB a/DT reduced/VBN number/NN of/IN receptors/NNS available/JJ for/IN DNA/NN binding/NN in/IN the/DT steroid-resistant/JJ patients/NNS ./. 
These/DT results/NNS suggest/VBP that/IN the/DT ability/NN of/IN the/DT glucocorticoid/NN receptor/NN to/TO bind/VB to/TO GRE/NN is/VBZ impaired/JJ in/IN steroid-resistant/JJ patients/NNS because/IN of/IN a/DT reduced/VBN number/NN of/IN receptors/NNS available/JJ for/IN binding/VBG to/TO DNA/NN ./. 
UI/LS -/: 95195208/CD 
TI/LS -/: Interleukin-5/NN signaling/NN in/IN human/JJ eosinophils/NNS involves/VBZ JAK2/NN tyrosine/NN kinase/NN and/CC Stat1/NN alpha/NN ./. 
AB/LS -/: Signaling/NN by/IN a/DT wide/JJ variety/NN of/IN cytokines/NNS ,/, including/VBG interferons/NNS ,/, interleukins/NNS ,/, and/CC growth/NN factors/NNS ,/, involves/VBZ activation/NN of/IN JAK/NN kinases/NNS and/CC Stat/NNS (/( Signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN )/) proteins/NNS ./. 
At/IN present/NN ,/, not/RB much/RB is/VBZ known/VBN about/IN the/DT molecular/JJ mechanisms/NNS by/IN which/WDT interleukin-5/NN (/( IL-5/NN )/) exerts/VBZ its/PRP$ diverse/JJ biologic/JJ effects/NNS ./. 
Human/JJ eosinophils/NNS are/VBP one/CD of/IN the/DT most/RBS important/JJ target/NN cells/NNS for/IN IL-5/NN and/CC were/VBD used/VBN here/RB to/TO study/VB IL-5/NN signaling/NN in/IN a/DT primary/JJ human/JJ cell/NN ./. 
IL-5/NN induced/VBD rapid/JJ and/CC transient/JJ tyrosine/NN phosphorylation/NN of/IN JAK2/NN ./. 
Moreover/RB ,/, IL-5/NN induced/VBD at/IN least/JJS two/CD DNA-binding/JJ complexes/NNS ,/, using/VBG nuclear/JJ extracts/NNS from/IN normal/JJ human/JJ eosinophils/NNS and/CC the/DT IL-6/interferon-gamma/NN response/NN element/NN of/IN the/DT ICAM-1/NN promoter/NN (/( ICAM-1/NN pIRE/NN )/) in/IN an/DT electromobility/NN shift/NN assay/NN ./. 
From/IN supershift/NN experiments/NNS it/PRP was/VBD concluded/VBN that/IN one/CD DNA-binding/JJ complex/NN contained/VBD Stat1/NN alpha/NN ,/, probably/RB as/IN a/DT homodimer/NN ./. 
Both/DT DNA-binding/JJ complexes/NNS were/VBD inhibited/VBN by/IN a/DT phosphotyrosine/NN antibody/NN (/( 4G10/NN )/) ,/, suggesting/VBG that/IN tyrosine/NN phosphorylation/NN is/VBZ required/VBN for/IN complex/NN formation/NN ./. 
IL-3/NN and/CC granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN induced/VBD ,/, similar/JJ to/TO IL-5/NN ,/, two/CD DNA-binding/JJ complexes/NNS in/IN human/JJ eosinophils/NNS ,/, including/VBG Stat1/NN alpha/NN ./. 
These/DT data/NNS show/VBP for/IN the/DT first/JJ time/NN that/IN molecular/JJ mechanisms/NNS of/IN IL-5/NN signaling/NN in/IN human/JJ eosinophils/NNS involve/VBP members/NNS of/IN the/DT JAK/NN kinase/NN family/NN as/RB well/RB as/IN members/NNS of/IN the/DT Stat/NN family/NN ./. 
UI/LS -/: 95373132/CD 
TI/LS -/: Infection/NN and/CC replication/NN of/IN Tat- human/JJ immunodeficiency/NN viruses/NNS :/: genetic/JJ analyses/NNS of/IN LTR/NN and/CC tat/NN mutations/NNS in/IN primary/JJ and/CC long-term/JJ human/JJ lymphoid/JJ cells/NNS ./. 
AB/LS -/: Tat/NN is/VBZ an/DT essential/JJ regulatory/JJ protein/NN for/IN the/DT replication/NN of/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) ./. 
Mutations/NNS in/IN the/DT tat/NN gene/NN have/VBP been/VBN shown/VBN to/TO block/VB HIV/NN replication/NN in/IN human/JJ T/NN cells/NNS ./. 
Several/JJ studies/NNS have/VBP established/VBN that/IN Tat/NN releases/VBZ an/DT elongation/NN block/NN to/TO the/DT transcription/NN of/IN HIV/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ;/: however/RB ,/, it/PRP is/VBZ not/RB known/VBN whether/IN this/DT mechanism/NN alone/RB is/VBZ sufficient/JJ to/TO explain/VB the/DT block/NN to/TO HIV/NN replication/NN in/IN human/JJ T/NN cells/NNS when/WRB Tat/NN is/VBZ absent/JJ ./. 
It/PRP is/VBZ possible/JJ that/IN Tat/NN is/VBZ also/RB needed/VBN for/IN other/JJ functions/NNS during/IN HIV/NN replication/NN ./. 
To/TO test/VB these/DT hypotheses/NNS ,/, we/PRP studied/VBD several/JJ tat/NN mutants/NNS ,/, including/VBG two/CD stop/NN codon/NN mutants/NNS and/CC one/CD deletion/NN mutant/NN using/VBG replication-competent/JJ HIV-1/NN constructs/NNS carrying/VBG wild-type/JJ or/CC mutant/JJ LTRs/NNS with/IN modifications/NNS in/IN the/DT NF-kappa/NN B/NN and/or/CC Sp1/NN binding/NN sites/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP show/VBP that/IN Tat- HIV-1/NN with/IN wild-type/JJ LTRs/NNS can/MD replicate/VB in/IN HeLa/NN cells/NNS ,/, and/CC the/DT virus/NN produced/VBN from/IN HeLa/NN cells/NNS can/MD infect/VB primary/JJ peripheral/JJ blood/NN lymphocytes/NNS and/CC macrophages/NNS ./. 
It/PRP was/VBD found/VBN that/IN the/DT propagation/NN of/IN the/DT Tat/NN mutants/NNS containing/VBG wild-type/JJ LTRs/NNS was/VBD less/RBR efficient/JJ than/IN that/DT of/IN the/DT LTR-modified/JJ Tat/NN mutants/NNS ./. 
Large/JJ amounts/NNS of/IN viral/JJ RNA/NN and/CC particles/NNS were/VBD synthesized/VBN in/IN infections/NNS established/VBN using/VBG the/DT tat/NN mutants/NNS that/WDT contain/VBP modified/VBN LTRs/NNS ./. 
However/RB ,/, this/DT efficient/JJ propagation/NN of/IN the/DT LTR-modified/JJ tat/NN mutants/NNS was/VBD restricted/JJ to/TO some/DT lymphoid/JJ cell/NN lines/NNS that/WDT have/VBP been/VBN transformed/VBN with/IN other/JJ viruses/NNS ./. 
Thus/RB ,/, despite/IN its/PRP$ essential/JJ role/NN for/IN releasing/VBG an/DT elongation/NN block/NN ,/, Tat/NN is/VBZ not/RB otherwise/RB absolutely/RB required/VBN for/IN synthesis/NN of/IN full-length/JJ HIV/NN transcripts/NNS and/CC assembly/NN of/IN virus/NN particles/NNS ./. 
Direct/JJ sequencing/NN of/IN the/DT viral/JJ genomes/NNS and/CC reinfection/NN kinetics/NNS showed/VBD no/DT evidence/NN of/IN wild-type/JJ reversion/NN even/RB after/IN prolonged/JJ infection/NN with/IN the/DT Tat-virus/NN ./. 
The/DT implications/NNS for/IN in/FW vivo/FW HIV-1/NN replication/NN and/CC potential/JJ application/NN of/IN this/DT system/NN to/TO the/DT study/NN of/IN alternative/JJ Tat/NN function/NN are/VBP discussed/VBN ./. 
UI/LS -/: 95355848/CD 
TI/LS -/: Functional/JJ roles/NNS of/IN the/DT transcription/NN factor/NN Oct-2A/NN and/CC the/DT high/JJ mobility/NN group/NN protein/NN I/Y/NN in/IN HLA-DRA/NN gene/NN expression/NN ./. 
AB/LS -/: The/DT class/NN II/CD major/JJ histocompatibility/NN complex/NN gene/NN HLA-DRA/NN is/VBZ expressed/VBN in/IN B/NN cells/NNS ,/, activated/VBN T/NN lymphocytes/NNS ,/, and/CC in/IN antigen-presenting/JJ cells/NNS ./. 
In/IN addition/NN ,/, HLA-DRA/NN gene/NN expression/NN is/VBZ inducible/JJ in/IN a/DT variety/NN of/IN cell/NN types/NNS by/IN interferon-gamma/NN (/( IFN-gamma/NN )/) ./. 
Here/RB we/PRP show/VBP that/IN the/DT lymphoid-specific/JJ transcription/NN factor/NN Oct-2A/NN plays/VBZ a/DT critical/JJ role/NN in/IN HLA-DRA/NN gene/NN expression/NN in/IN class/NN II-positive/JJ B/NN cell/NN lines/NNS ,/, and/CC that/IN the/DT high/JJ mobility/NN group/NN protein/NN (/( HMG/NN )/) I/Y/NN binds/VBZ to/TO multiple/JJ sites/NNS within/IN the/DT DRA/NN promoter/NN ,/, including/VBG the/DT Oct-2A/NN binding/NN site/NN ./. 
Coexpression/NN of/IN HMG/NN I/Y/NN and/CC Oct-2/NN in/IN cell/NN lines/NNS lacking/VBG Oct-2/NN results/VBZ in/IN high/JJ levels/NNS of/IN HLA-DRA/NN gene/NN expression/NN ,/, and/CC in/FW vitro/FW DNA-binding/JJ studies/NNS reveal/VBP that/IN HMG/NN I/Y/NN stimulates/VBZ Oct-2A/NN binding/NN to/TO the/DT HLA-DRA/NN promoter/NN ./. 
Thus/RB ,/, Oct-2A/NN and/CC HMG/NN I/Y/NN may/MD synergize/VB to/TO activate/VB HLA-DRA/NN expression/NN in/IN B/NN cells/NNS ./. 
By/IN contrast/NN ,/, Oct-2A/NN is/VBZ not/RB involved/VBN in/IN the/DT IFN-gamma/NN induction/NN of/IN the/DT HLA-DRA/NN gene/NN in/IN HeLa/NN cells/NNS ,/, but/CC antisense/JJ HMG/NN I/Y/NN dramatically/RB decreases/VBZ the/DT level/NN of/IN induction/NN ./. 
We/PRP conclude/VBP that/IN distinct/JJ sets/NNS of/IN transcription/NN factors/NNS are/VBP involved/VBN in/IN the/DT two/CD modes/NNS of/IN HLA-DRA/NN expression/NN ,/, and/CC that/IN HMG/NN I/Y/NN may/MD be/VB important/JJ for/IN B/NN cell-specific/JJ expression/NN ,/, and/CC is/VBZ essential/JJ for/IN IFN-gamma/NN induction/NN ./. 
UI/LS -/: 95329723/CD 
TI/LS -/: Heterogeneous/JJ expression/NN of/IN Epstein-Barr/JJ virus/NN latent/JJ proteins/NNS in/IN endemic/JJ Burkitt/NN 's/POS lymphoma/NN ./. 
AB/LS -/: Epstein-Barr/JJ virus/NN (/( EBV/NN )/) -infected/JJ cells/NNS may/MD sustain/VB three/CD distinct/JJ forms/NNS of/IN virus/NN latency/NN ./. 
In/IN lymphoblastoid/JJ cell/NN lines/NNS ,/, six/CD EBV-encoded/JJ nuclear/JJ antigens/NNS (/( EBNA1/NN ,/, 2/CD ,/, 3A/NN ,/, 3B/NN ,/, 3C/NN ,/, -LP/NN )/) ,/, three/CD latent/JJ membrane/NN proteins/NNS (/( LMP1/NN ,/, 2A/NN ,/, 2B/NN )/) ,/, and/CC two/CD nuclear/JJ RNAs/NNS (/( EBERs/NNS )/) are/VBP expressed/VBN ./. 
This/DT form/NN of/IN latency/NN ,/, termed/VBN latency/NN III/CD ,/, is/VBZ also/RB encountered/VBN in/IN some/DT posttransplant/JJ lymphoproliferative/JJ disorders/NNS ./. 
In/IN EBV-positive/JJ cases/NNS of/IN Hodgkin/NN 's/POS disease/NN ,/, the/DT EBERs/NNS ,/, EBNA1/NN ,/, and/CC the/DT LMPs/NNS are/VBP expressed/VBN (/( latency/NN II/CD )/) ,/, whereas/IN in/IN Burkitt/NN 's/POS lymphoma/NN (/( BL/NN )/) only/RB the/DT EBERs/NNS and/CC EBNA1/NN have/VBP been/VBN detected/VBN (/( latency/NN I/NN )/) ./. 
We/PRP have/VBP studied/VBN the/DT expression/NN of/IN EBV/NN proteins/NNS in/IN 17/CD cases/NNS of/IN EBV-positive/JJ endemic/JJ BL/NN by/IN immunohistology/NN ./. 
Expression/NN of/IN LMP1/NN was/VBD seen/VBN in/IN variable/JJ proportions/NNS of/IN tumor/NN cells/NNS in/IN two/CD cases/NNS and/CC EBNA2/NN was/VBD detected/VBN in/IN some/DT tumor/NN cells/NNS in/IN three/CD other/JJ cases/NNS ./. 
Also/RB ,/, the/DT BZLF1/NN trans-activator/NN protein/NN was/VBD expressed/VBN in/IN a/DT few/JJ tumor/NN cells/NNS in/IN 6/CD cases/NNS ,/, indicating/VBG entry/NN into/IN the/DT lytic/JJ cycle/NN ./. 
A/DT phenotypic/JJ drift/NN from/IN latency/NN I/NN to/TO latency/NN III/CD has/VBZ been/VBN observed/VBN previously/RB in/IN some/DT BL/NN cell/NN lines/NNS ./. 
Our/PRP$ results/NNS suggest/VBP that/IN a/DT similar/JJ phenomenon/NN may/MD occur/VB in/IN BL/NN in/FW vivo/FW and/CC indicate/VBP that/IN the/DT operational/JJ definition/NN of/IN EBV/NN latencies/NNS is/VBZ not/RB easily/RB applied/VBN to/TO human/JJ tumors/NNS ./. 
UI/LS -/: 95325614/CD 
TI/LS -/: The/DT activation/NN of/IN the/DT Jak-STAT/JJ 1/CD signaling/NN pathway/NN by/IN IL-5/NN in/IN eosinophils/NNS ./. 
AB/LS -/: The/DT intracellular/JJ signal/NN transduction/NN of/IN IL-5/NN in/IN eosinophils/NNS is/VBZ unknown/JJ ./. 
The/DT objective/NN of/IN this/DT study/NN was/VBD to/TO investigate/VB the/DT involvement/NN of/IN the/DT newly/RB discovered/VBN Jak-STAT/JJ pathway/NN in/IN the/DT IL-5/NN signal/NN transduction/NN mechanism/NN ./. 
Eosinophils/NNS were/VBD purified/VBN from/IN peripheral/JJ blood/NN by/IN discontinuous/JJ Percoll/NN gradients/NNS and/CC stimulated/VBN with/IN IL-5/NN ./. 
The/DT involvement/NN of/IN Jak/NN 2/CD was/VBD investigated/VBN by/IN immunoprecipitation/NN followed/VBN by/IN immunoblotting/VBG for/IN tyrosine/NN phosphorylation/NN ./. 
The/DT activation/NN of/IN Jak/NN 2/CD was/VBD studied/VBN by/IN autophosphorylation/NN of/IN the/DT immunoprecipitated/VBN kinase/NN ./. 
Jak/NN 2/CD was/VBD tyrosine/NN phosphorylated/JJ within/IN 1/CD to/TO 3/CD min/NN after/IN stimulation/NN of/IN eosinophils/NNS with/IN IL-5/NN ./. 
Further/RB ,/, the/DT immunoprecipitated/VBN Jak/NN 2/CD obtained/VBN from/IN IL-5-stimulated/JJ cells/NNS underwent/VBD autophosphorylation/NN ./. 
Jak/NN 2/CD coprecipitated/VBD with/IN the/DT beta-subunit/NN of/IN the/DT IL-5/NN receptor/NN ,/, suggesting/VBG a/DT physical/JJ association/NN of/IN the/DT kinase/NN with/IN the/DT receptor/NN ./. 
The/DT nuclear/JJ factor/NN STAT-1/NN (/( p91/NN )/) was/VBD investigated/VBN by/IN immunoprecipitation/NN followed/VBN by/IN immunoblotting/VBG for/IN tyrosine/NN phosphorylation/NN ./. 
STAT-1/NN was/VBD tyrosine/NN phosphorylated/JJ within/IN 15/CD min/NN of/IN IL-5/NN stimulation/NN ./. 
The/DT presence/NN of/IN STAT-1/NN in/IN the/DT nuclear/JJ extract/NN was/VBD studied/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
IL-5/NN induced/VBD two/CD proteins/NNS that/WDT bound/VBD to/TO the/DT gamma-activating/JJ sequence/NN ./. 
In/IN the/DT presence/NN of/IN an/DT anti-STAT-1/JJ Ab/NN ,/, the/DT band/NN was/VBD supershifted/VBN ./. 
Thus/RB ,/, we/PRP demonstrated/VBD that/IN IL-5/NN activated/VBD the/DT Jak/NN 2-STAT/NN 1/CD signaling/NN pathway/NN in/IN eosinophils/NNS ./. 
We/PRP speculate/VBP that/IN the/DT Jak/NN 2-STAT/NN 1/CD pathway/NN may/MD be/VB involved/VBN in/IN the/DT activation/NN of/IN IL-5-inducible/JJ genes/NNS in/IN eosinophils/NNS ./. 
UI/LS -/: 95298682/CD 
TI/LS -/: Reduced/VBN mitogenic/JJ stimulation/NN of/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS as/IN a/DT prognostic/JJ parameter/NN for/IN the/DT course/NN of/IN breast/NN cancer/NN :/: a/DT prospective/JJ longitudinal/JJ study/NN ./. 
AB/LS -/: Immunosuppression/NN has/VBZ been/VBN often/RB associated/VBN with/IN the/DT course/NN of/IN malignant/JJ diseases/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, the/DT proliferation/NN of/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMCs/NNS )/) in/IN response/NN to/TO mitogenic/JJ stimulation/NN with/IN phytohaemagglutinin/NN (/( PHA/NN )/) was/VBD assessed/VBN prospectively/RB in/IN 90/CD patients/NNS with/IN stage/NN I-III/CD breast/NN cancer/NN ./. 
Whereas/IN PHA-induced/JJ proliferation/NN of/IN PBMCs/NNS derived/VBN from/IN patients/NNS with/IN breast/NN cancer/NN preoperatively/RB was/VBD significantly/RB decreased/VBN when/WRB compared/VBN with/IN data/NNS obtained/VBN in/IN healthy/JJ control/JJ individuals/NNS (/( P/NN </JJR 0.001/CD )/) ,/, the/DT degree/NN of/IN the/DT defect/NN in/IN PHA-induced/JJ proliferation/NN of/IN PBMCs/NNS depended/VBD upon/IN the/DT tumour/NN burden/NN as/IN manifested/VBN by/IN tumour/NN size/NN and/CC axillary/NN lymph/NN node/NN involvement/NN (/( P/NN </JJR 0.003/CD in/IN each/DT case/NN )/) ./. 
PHA-induced/JJ proliferation/NN of/IN PBMCs/NNS dropped/VBD significantly/RB in/IN patients/NNS who/WP received/VBD adjuvant/JJ chemotherapy/NN consisting/VBG of/IN cyclophosphamide/NN ,/, methotrexate/NN and/CC fluorouracil/NN (/( CMF/NN )/) after/IN an/DT observation/NN period/NN of/IN 6/CD months/NNS (/( P/NN </JJR 0.01/CD )/) ,/, but/CC not/RB in/IN patients/NNS under/IN adjuvant/JJ treatment/NN with/IN tamoxifen/NN only/RB ./. 
After/IN an/DT additional/JJ 6/CD months/NNS (/( i.e./FW 12/CD months/NNS after/IN surgery/NN )/) ,/, PHA-induced/JJ proliferation/NN of/IN PBMCs/NNS was/VBD similar/JJ in/IN patients/NNS after/IN adjuvant/JJ chemotherapy/NN with/IN CMF/NN and/CC in/IN those/DT receiving/VBG continued/JJ adjuvant/JJ tamoxifen/NN treatment/NN (/( P/NN >/JJR 0.1/CD )/) ,/, but/CC in/IN all/DT patients/NNS still/RB significantly/RB decreased/VBD as/IN compared/VBN with/IN healthy/JJ controls/NNS (/( P/NN </JJR 0.001/CD )/) ./. 
When/WRB data/NNS obtained/VBN preoperatively/RB and/CC after/IN 12/CD months/NNS were/VBD compared/VBN ,/, it/PRP was/VBD found/VBN that/IN out/RB of/IN 23/CD patients/NNS whose/WP$ PBMCs/NNS had/VBD experienced/VBN a/DT drop/NN in/IN their/PRP$ PHA-induced/JJ proliferation/NN ,/, 14/CD (/( 61/CD %/NN )/) had/VBD developed/VBN metastatic/JJ disease/NN within/IN the/DT subsequent/JJ 24/CD months/NNS (/( i.e./FW 36/CD months/NNS after/IN surgery/NN )/) ./. 
In/IN contrast/NN ,/, out/RB of/IN 59/CD patients/NNS whose/WP$ PBMCs/NNS showed/VBD an/DT increase/NN in/IN their/PRP$ PHA-induced/JJ proliferation/NN within/IN the/DT first/JJ 12/CD months/NNS after/IN surgery/NN ,/, only/RB one/CD (/( 2/CD %/NN )/) presented/VBD with/IN disease/NN progression/NN ./. 
We/PRP thus/RB conclude/VBP that/IN PHA-induced/JJ proliferation/NN of/IN PBMCs/NNS derived/VBN from/IN patients/NNS with/IN breast/NN cancer/NN depends/VBZ upon/IN the/DT tumour/NN load/NN and/CC is/VBZ a/DT good/JJ clinical/JJ predictor/NN for/IN the/DT further/JJ course/NN of/IN the/DT disease/NN ./. 
UI/LS -/: 95248083/CD 
TI/LS -/: Activation/NN of/IN transcription/NN by/IN binding/NN of/IN NF-E1/NN (/( YY1/NN )/) to/TO a/DT newly/RB identified/VBN element/NN in/IN the/DT first/JJ exon/NN of/IN the/DT human/JJ DR/NN alpha/NN gene/NN ./. 
AB/LS -/: A/DT previously/RB unrecognized/JJ element/NN ,/, located/JJ downstream/RB of/IN the/DT start/NN site/NN of/IN transcription/NN in/IN the/DT first/JJ exon/NN of/IN the/DT DR/NN alpha/NN gene/NN ,/, has/VBZ been/VBN defined/VBN that/WDT enhances/VBZ promoter/NN activity/NN up/IN to/TO eightfold/JJ in/IN a/DT position-dependent/JJ manner/NN ./. 
Mutations/NNS in/IN this/DT DNA-binding/JJ site/NN abolished/VBD binding/NN of/IN a/DT nuclear/JJ factor/NN in/IN human/JJ B/NN cell/NN nuclear/JJ extract/NN and/CC decreased/VBD the/DT activity/NN of/IN the/DT DR/NN alpha/NN promoter/NN to/TO a/DT basal/JJ level/NN ./. 
Significant/JJ sequence/NN homology/NN of/IN this/DT element/NN was/VBD found/VBN in/IN the/DT DNA/NN of/IN the/DT DR/NN beta/NN ,/, DP/NN alpha/NN and/CC -beta/NN ,/, and/CC DQ/NN alpha/NN genes/NNS ,/, always/RB located/JJ downstream/RB of/IN the/DT transcriptional/JJ start/NN site/NN ./. 
The/DT nuclear/JJ factor/NN binds/VBZ to/TO the/DT DR/NN alpha/NN and/CC DP/NN alpha/NN element/NN but/CC not/RB to/TO the/DT element/NN in/IN the/DT DQ/NN alpha/NN gene/NN ./. 
It/PRP was/VBD identified/VBN as/IN NF-E1/NN (/( YY1/NN )/) ./. 
This/DT protein/NN ,/, previously/RB identified/VBN by/IN its/PRP$ binding/NN to/TO the/DT Ig/NN kappa/NN 3'/JJ enhancer/NN and/CC the/DT Ig/NN heavy/JJ chain/NN mu/NN E1/NN site/NN ,/, thus/RB also/RB appears/VBZ to/TO be/VB quite/RB important/JJ in/IN the/DT regulation/NN of/IN MHC/NN class/NN II/CD gene/NN expression/NN ./. 
UI/LS -/: 95222739/CD 
TI/LS -/: Transcriptional/JJ activity/NN of/IN core/NN binding/NN factor-alpha/NN (/( AML1/NN )/) and/CC beta/NN subunits/NNS on/IN murine/JJ leukemia/NN virus/NN enhancer/NN cores/NNS ./. 
AB/LS -/: Core/NN binding/NN factor/NN (/( CBF/NN )/) ,/, also/RB known/VBN as/IN polyomavirus/NN enhancer-binding/JJ protein/NN 2/CD and/CC SL3/NN enhancer/NN factor/NN 1/CD ,/, is/VBZ a/DT mammalian/JJ transcription/NN factor/NN that/WDT binds/VBZ to/TO an/DT element/NN termed/VBN the/DT core/NN within/IN the/DT enhancers/NNS of/IN the/DT murine/JJ leukemia/NN virus/NN family/NN of/IN retroviruses/NNS ./. 
The/DT core/NN elements/NNS of/IN the/DT SL3/NN virus/NN are/VBP important/JJ genetic/JJ determinants/NNS of/IN the/DT ability/NN of/IN this/DT virus/NN to/TO induce/VB T-cell/NN lymphomas/NNS and/CC the/DT transcriptional/JJ activity/NN of/IN the/DT viral/JJ long/JJ terminal/JJ repeat/NN in/IN T/NN lymphocytes/NNS ./. 
CBF/NN consists/VBZ of/IN two/CD subunits/NNS ,/, a/DT DNA/NN binding/NN subunit/NN ,/, CBF/NN alpha/NN ,/, and/CC a/DT second/JJ subunit/NN ,/, CBF/NN beta/NN ,/, that/WDT stimulates/VBZ the/DT DNA/NN binding/NN activity/NN of/IN CBF/NN alpha/NN ./. 
One/CD of/IN the/DT genes/NNS that/WDT encodes/VBZ a/DT CBF/NN alpha/NN subunit/NN is/VBZ AML1/NN ,/, also/RB called/VBN Cbf/NN alpha/NN 2/CD ./. 
This/DT locus/NN is/VBZ rearranged/VBN by/IN chromosomal/JJ translocations/NNS in/IN human/JJ myeloproliferative/JJ disorders/NNS and/CC leukemias/NNS ./. 
An/DT exogenously/RB expressed/VBN Cbf/NN alpha/NN 2-encoded/JJ subunit/NN (/( CBF/NN alpha/NN 2-451/CD )/) stimulated/VBD transcription/NN from/IN the/DT SL3/NN enhancer/NN in/IN P19/NN and/CC HeLa/NN cells/NNS ./. 
Activity/NN was/VBD mediated/VBN through/IN the/DT core/NN elements/NNS ./. 
Three/CD different/JJ isoforms/NNS of/IN CBF/NN beta/NN were/VBD also/RB tested/VBN for/IN transcriptional/JJ activity/NN on/IN the/DT SL3/NN enhancer/NN ./. 
The/DT longest/JJS form/NN ,/, CBF/NN beta-187/NN ,/, increased/VBD the/DT transcriptional/JJ stimulation/NN by/IN CBF/NN alpha/NN 2-451/CD twofold/JJ in/IN HeLa/NN cells/NNS ,/, although/IN it/PRP had/VBD no/DT effect/NN in/IN P19/NN cells/NNS ./. 
Transcriptional/JJ activation/NN by/IN CBF/NN beta/NN required/VBD binding/NN to/TO the/DT CBF/NN alpha/NN subunit/NN ,/, as/IN a/DT form/NN of/IN CBF/NN beta/NN that/WDT lacked/VBD binding/NN ability/NN ,/, CBF/NN beta-148/NN ,/, failed/VBD to/TO increase/VB activity/NN ./. 
These/DT results/NNS indicated/VBD that/IN at/IN least/JJS in/IN certain/JJ cell/NN types/NNS ,/, the/DT maximum/NN activity/NN of/IN CBF/NN required/VBD both/DT subunits/NNS ./. 
They/PRP also/RB provided/VBD support/NN for/IN the/DT hypothesis/NN that/IN CBF/NN is/VBZ a/DT factor/NN in/IN T/NN lymphocytes/NNS that/WDT is/VBZ responsible/JJ for/IN recognition/NN of/IN the/DT SL3/NN cores/NNS ./. 
We/PRP also/RB examined/VBD whether/IN CBF/NN could/MD distinguish/VB a/DT 1-bp/JJ difference/NN between/IN the/DT enhancer/NN core/NN of/IN SL3/NN and/CC the/DT core/NN of/IN the/DT nonleukemogenic/JJ virus/NN ,/, Akv/NN ./. 
This/DT difference/NN strongly/RB affects/VBZ transcription/NN in/IN T/NN cells/NNS and/CC leukemogenicity/NN of/IN SL3/NN ./. 
However/RB ,/, no/DT combination/NN of/IN CBF/NN alpha/NN and/CC CBF/NN beta/NN subunits/NNS that/WDT we/PRP tested/VBD was/VBD able/JJ to/TO distinguish/VB the/DT 1-bp/JJ difference/NN in/IN transcription/NN assays/NNS ./. 
Thus/RB ,/, a/DT complete/JJ understanding/NN of/IN how/WRB T/NN cells/NNS recognize/VBP the/DT SL3/NN core/NN remains/VBZ to/TO be/VB elucidated/VBN ./. 
UI/LS -/: 95238477/CD 
TI/LS -/: Interleukin/NN (/( IL/NN )/) -10/CD inhibits/VBZ nuclear/JJ factor/NN kappa/NN B/NN (/( NF/NN kappa/NN B/NN )/) activation/NN in/IN human/JJ monocytes/NNS ./. 
IL-10/NN and/CC IL-4/NN suppress/VBP cytokine/NN synthesis/NN by/IN different/JJ mechanisms/NNS ./. 
AB/LS -/: Our/PRP$ previous/JJ studies/NNS in/IN human/JJ monocytes/NNS have/VBP demonstrated/VBN that/IN interleukin/NN (/( IL/NN )/) -10/CD inhibits/VBZ lipopolysaccharide/NN (/( LPS/NN )/) -stimulated/JJ production/NN of/IN inflammatory/JJ cytokines/NNS ,/, IL-1/NN beta/NN ,/, IL-6/NN ,/, IL-8/NN ,/, and/CC tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) -alpha/NN by/IN blocking/VBG gene/NN transcription/NN ./. 
Using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS (/( EMSA/NN )/) ,/, we/PRP now/RB show/VBP that/IN ,/, in/IN monocytes/NNS stimulated/VBN with/IN LPS/NN or/CC TNF/NN alpha/NN ,/, IL-10/NN inhibits/VBZ nuclear/JJ stimulation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF/NN kappa/NN B/NN )/) ,/, a/DT transcription/NN factor/NN involved/VBN in/IN the/DT expression/NN of/IN inflammatory/JJ cytokine/NN genes/NNS ./. Several/JJ other/JJ transcription/NN factors/NNS including/VBG NF-IL-6/NN ,/, AP-1/NN ,/, AP-2/NN ,/, GR/NN ,/, CREB/NN ,/, Oct-1/NN ,/, and/CC Sp-1/NN are/VBP not/RB affected/VBN by/IN IL-10/NN ./. 
This/DT selective/JJ inhibition/NN by/IN IL-10/NN of/IN NF/NN kappa/NN B/NN activation/NN occurs/VBZ rapidly/RB and/CC in/IN a/DT dose-dependent/JJ manner/NN and/CC correlates/VBZ well/RB with/IN IL-10/NN 's/POS cytokine/NN synthesis/NN inhibitory/JJ activity/NN in/IN terms/NNS of/IN both/CC kinetics/NNS and/CC dose/NN responsiveness/NN ./. 
Furthermore/RB ,/, compounds/NNS such/JJ as/IN tosylphenylalanyl/NN chloromethyl/NN ketone/NN and/CC pyrrolidinedithiocarbamate/NN that/WDT are/VBP known/VBN to/TO selectively/RB inhibit/VB NF/NN kappa/NN B/NN activation/NN block/VBP cytokine/NN gene/NN transcription/NN in/IN LPS-stimulated/JJ monocytes/NNS ./. 
Taken/VBN together/RB ,/, these/DT results/NNS suggest/VBP that/IN inhibition/NN of/IN NF/NN kappa/NN B/NN activation/NN may/MD be/VB an/DT important/JJ mechanism/NN for/IN IL-10/NN suppression/NN of/IN cytokine/NN gene/NN transcription/NN in/IN human/JJ monocytes/NNS ./. 
IL-4/NN ,/, another/DT cytokine/NN that/WDT inhibits/VBZ cytokine/NN mRNA/NN accumulation/NN in/IN monocytes/NNS ,/, shows/VBZ little/JJ inhibitory/JJ effect/NN on/IN LPS-induced/JJ NF/NN kappa/NN B/NN activation/NN ./. 
Further/RB examination/NN reveals/VBZ that/IN ,/, unlike/IN IL-10/NN ,/, IL-4/NN enhances/VBZ mRNA/NN degradation/NN and/CC does/VBZ not/RB suppress/VB cytokine/NN gene/NN transcription/NN ./. 
These/DT data/NNS indicate/VBP that/IN IL-10/NN and/CC IL-4/NN inhibit/VBP cytokine/NN production/NN by/IN different/JJ mechanisms/NNS ./. 
UI/LS -/: 95190988/CD 
TI/LS -/: LMP-1/NN activates/VBZ NF-kappa/NN B/NN by/IN targeting/VBG the/DT inhibitory/JJ molecule/NN I/NN kappa/NN B/NN alpha/NN ./. 
AB/LS -/: LMP-1/NN ,/, an/DT Epstein-Barr/JJ virus/NN membrane/NN protein/NN expressed/VBN during/IN latent/JJ infection/NN ,/, has/VBZ oncogenic/JJ properties/NNS ,/, as/IN judged/VBN from/IN its/PRP$ ability/NN to/TO transform/VB B/NN lymphocytes/NNS and/CC rodent/JJ fibroblasts/NNS ./. 
LMP-1/NN induces/VBZ the/DT expression/NN of/IN bcl2/NN ,/, an/DT oncogene/NN which/WDT protects/VBZ cells/NNS from/IN apoptosis/NN ,/, as/RB well/RB as/IN of/IN genes/NNS encoding/VBG other/JJ proteins/NNS involved/VBN in/IN cell/NN regulation/NN and/CC growth/NN control/NN ./. 
The/DT mechanisms/NNS by/IN which/WDT LMP-1/NN upregulates/VBZ these/DT proteins/NNS is/VBZ unknown/JJ ,/, but/CC it/PRP is/VBZ plausible/JJ that/IN LMP-1/NN modifies/VBZ signal/NN transduction/NN pathways/NNS that/WDT result/VBP in/IN the/DT activation/NN of/IN one/CD or/CC more/JJR transcription/NN factors/NNS that/WDT ultimately/RB regulate/VBP transcription/NN of/IN oncogenic/JJ genes/NNS ./. 
NF-kappa/NN B/NN ,/, a/DT transcription/NN factor/NN controlling/VBG the/DT expression/NN of/IN genes/NNS involved/VBN in/IN cell/NN activation/NN and/CC growth/NN control/NN ,/, has/VBZ been/VBN shown/VBN to/TO be/VB activated/VBN by/IN LMP-1/NN ./. 
The/DT mechanism/NN (/( s/NNS )/) regulating/VBG this/DT activation/NN remains/VBZ unknown/JJ ./. 
Our/PRP$ data/NNS indicate/VBP that/IN increased/VBN NF-kappa/NN B/NN DNA/NN binding/NN and/CC functional/JJ activity/NN are/VBP present/JJ in/IN B-lymphoid/JJ cells/NNS stably/RB or/CC transiently/RB expressing/VBG LMP-1/NN ./. 
I/NN kappa/NN B/NN alpha/NN is/VBZ selectively/RB modified/VBN in/IN LMP-1-expressing/JJ B/NN cells/NNS ./. 
A/DT phosphorylated/JJ form/NN of/IN I/NN kappa/NN B/NN alpha/NN and/CC increased/VBN protein/NN turnover-degradation/NN correlate/VBP with/IN increased/VBN NF-kappa/NN B/NN nuclear/JJ translocation/NN ./. 
This/DT results/VBZ in/IN increased/VBN transcription/NN of/IN NF-kappa/NN B-dependent-genes/NNS ,/, including/VBG those/DT encoding/VBG p105/NN and/CC I/NN kappa/NN B/NN alpha/NN (/( MAD3/NN )/) ./. 
These/DT results/NNS indicate/VBP that/IN LMP-1/NN activates/VBZ NF-kappa/NN B/NN in/IN B-cell/NN lines/NNS by/IN targeting/VBG I/NN kappa/NN B/NN alpha/NN ./. 
Identification/NN of/IN the/DT pathways/NNS activated/VBN by/IN LMP-1/NN to/TO result/VB in/IN posttranslational/JJ modifications/NNS of/IN I/NN kappa/NN B/NN alpha/NN will/MD aid/VB in/IN determining/VBG the/DT role/NN of/IN this/DT virus-host/JJ cell/NN protein/NN interaction/NN in/IN Epstein-Barr/JJ virus-mediated/JJ oncogenesis/NN ./. 
UI/LS -/: 95197545/CD 
TI/LS -/: Identification/NN of/IN human/JJ TR2/NN orphan/NN receptor/NN response/NN element/NN in/IN the/DT transcriptional/JJ initiation/NN site/NN of/IN the/DT simian/JJ virus/NN 40/CD major/JJ late/JJ promoter/NN [/( published/VBN erratum/NN appears/VBZ in/IN J/NNP Biol/NNP Chem/NNP 1995/CD Nov/NNP 3/CD ;/: 270/CD (/( 44/CD )/) :/: 26721/CD ]/) 
AB/LS -/: A/DT DNA/NN response/NN element/NN (/( TR2RE-SV40/NN )/) for/IN the/DT TR2/NN orphan/NN receptor/NN ,/, a/DT member/NN of/IN the/DT steroid-thyroid/JJ hormone/NN receptor/NN superfamily/NN ,/, has/VBZ been/VBN identified/VBN in/IN the/DT simian/JJ virus/NN 40/CD (/( SV40/NN )/) +55/CD region/NN (/( nucleotide/NN numbers/NNS 368-389/CD ,/, 5'-GTTAAGGTTCGTAGGTCATGGA-3'/NN )/) ./. 
Electrophoretic/JJ mobility/NN shift/NN assay/NN ,/, using/VBG in/FW vitro/FW translated/VBN TR2/NN orphan/NN receptor/NN with/IN a/DT molecular/JJ mass/NN of/IN 67/CD kilodaltons/NNS ,/, showed/VBD a/DT specific/JJ binding/NN with/IN high/JJ affinity/NN (/( dissociation/NN constant/NN =/JJ 9/CD nM/NN )/) for/IN this/DT DNA/NN sequence/NN ./. 
DNA-swap/NN experiments/NNS using/VBG chloramphenicol/NN acetyl-transferase/NN assay/NN demonstrated/VBD that/IN androgen/NN can/MD suppress/VB the/DT transcriptional/JJ activities/NNS of/IN SV40/NN early/JJ promoter/NN via/IN the/DT interaction/NN between/IN this/DT TR2RE-SV40/NN and/CC the/DT chimeric/JJ receptor/NN AR/TR2/AR/NN with/IN the/DT DNA-binding/JJ domain/NN of/IN the/DT TR2/NN orphan/NN receptor/NN flanked/VBN by/IN the/DT N-terminal/JJ and/CC androgen-binding/JJ domains/NNS of/IN the/DT androgen/NN receptor/NN ./. 
In/IN addition/NN ,/, this/DT TR2RE-SV40/NN can/MD function/VB as/IN a/DT repressor/NN to/TO suppress/VB the/DT transcriptional/JJ activities/NNS of/IN both/CC SV40/NN early/JJ and/CC late/JJ promoters/NNS ./. 
Together/RB ,/, these/DT data/NNS suggest/VBP the/DT TR2RE-SV40/NN may/MD represent/VB the/DT first/JJ identified/VBN natural/JJ DNA/NN response/NN element/NN for/IN the/DT TR2/NN orphan/NN receptor/NN that/WDT may/MD function/VB as/IN a/DT repressor/NN for/IN the/DT SV40/NN gene/NN expression/NN ./. 
UI/LS -/: 95161757/CD 
TI/LS -/: Detection/NN of/IN the/DT chromosome/NN 16/CD CBF/NN beta-MYH11/NN fusion/NN transcript/NN in/IN myelomonocytic/JJ leukemias/NNS ./. 
AB/LS -/: Karyotypic/JJ detection/NN of/IN chromosomal/JJ 16/CD abnormalities/NNS classically/RB associated/VBN with/IN AML/NN M4Eo/NN can/MD be/VB difficult/JJ ./. 
Characterization/NN of/IN the/DT two/CD genes/NNS involved/VBN in/IN the/DT inv(16)(p13q22)/NN ,/, CBF/NN beta/NN and/CC MYH11/NN ,/, has/VBZ allowed/VBN the/DT detection/NN of/IN fusion/NN transcripts/NNS by/IN reverse-transcriptase/NN polymerase/NN chain/NN reaction/NN (/( RT-PCR/NN )/) ./. 
We/PRP have/VBP analyzed/VBN CBF/NN beta-MYH11/NN fusion/NN transcripts/NNS by/IN RT-PCR/NN in/IN myelomonocytic/JJ leukemias/NNS ,/, with/IN or/CC without/IN eosinophilia/NN ,/, to/TO determine/VB whether/IN their/PRP$ presence/NN correlates/VBZ with/IN morphology/NN ./. 
Fifty-three/CD cases/NNS (/( 11/CD AML/NN M4Eo/NN ;/: 1/CD AML/NN M4/NN with/IN atypical/JJ abnormal/JJ eosinophils/NNS (/( AML/NN M4/NN "/`` Eo/NN "/'' )/) ;/: 29/CD AML/NN M4/NN ;/: 8/CD AML/NN M5/NN ;/: 3/CD CMML/NN ;/: and/CC 1/CD AML/NN M2/NN with/IN eosinophilia/NN )/) were/VBD analyzed/VBN ./. 
All/DT 11/CD typical/JJ AML/NN M4Eo/NN were/VBD CBF/NN beta-MYH11/NN positive/JJ ./. 
The/DT single/JJ case/NN of/IN AML/NN M4/NN with/IN distinctive/JJ eosinophil/NN abnormalities/NNS was/VBD negative/JJ by/IN karyotype/NN ,/, RT-PCR/NN and/CC fluorescent/JJ in/FW situ/FW hybridization/NN (/( FISH/NN )/) ./. 
Three/CD of/IN 29/CD (/( 10/CD %/NN )/) AML/NN M4/NN without/IN abnormal/JJ eosinophils/NNS were/VBD CBF/NN beta-MYH11/NN positive/JJ ,/, 1/CD of/IN which/WDT did/VBD not/RB show/VB any/DT apparent/JJ chromosome/NN 16/CD abnormalities/NNS by/IN classical/JJ metaphase/NN analysis/NN (/( 2/CD not/RB tested/VBN )/) ./. 
Both/DT cases/NNS tested/VBN also/RB showed/VBD MYH11/NN genomic/JJ rearrangement/NN ./. 
None/NN of/IN the/DT other/JJ leukemias/NNS were/VBD RT-PCR/NN positive/JJ ./. 
Follow-up/NN of/IN three/CD patient/NN showed/VBD residual/JJ positivity/NN in/IN apparent/JJ complete/JJ remission/NN ./. 
These/DT data/NNS show/VBP that/IN CBF/NN beta-MYH11/NN fusion/NN transcripts/NNS occur/VBP not/RB only/RB in/IN the/DT vast/JJ majority/NN of/IN typical/JJ AML/NN M4Eo/NN ,/, but/CC also/RB in/IN approximately/RB 10/CD %/NN of/IN AML/NN M4/NN without/IN eosinophilic/JJ abnormalities/NNS ,/, a/DT much/RB higher/JJR incidence/NN than/IN the/DT sporadic/JJ reports/NNS of/IN chromosome/NN 16/CD abnormalities/NNS in/IN AML/NN M4/NN would/MD suggest/VB ./. 
Taken/VBN together/RB with/IN the/DT detection/NN of/IN CBF/NN beta-MYH11transcripts/NNS in/IN the/DT absence/NN of/IN apparent/JJ chromosome/NN 16/CD abnormalities/NNS by/IN classical/JJ banding/NN techniques/NNS ,/, these/DT data/NNS show/VBP that/IN additional/JJ screening/NN by/IN either/CC RT-PCR/NN or/CC FISH/NN should/MD be/VB performed/VBN in/IN all/DT AML/NN M4/NN ,/, regardless/RB of/IN morphologic/JJ features/NNS ,/, to/TO allow/VB accurate/JJ evaluation/NN of/IN the/DT prognostic/JJ importance/NN of/IN this/DT fusion/NN transcript/NN ./. 
UI/LS -/: 95163587/CD 
TI/LS -/: HIV-1/NN Tat/NN potentiates/VBZ TNF-induced/JJ NF-kappa/NN B/NN activation/NN and/CC cytotoxicity/NN by/IN altering/VBG the/DT cellular/JJ redox/NN state/NN ./. 
AB/LS -/: This/DT study/NN demonstrates/VBZ that/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) Tat/NN protein/NN amplifies/VBZ the/DT activity/NN of/IN tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) ,/, a/DT cytokine/NN that/WDT stimulates/VBZ HIV-1/NN replication/NN through/IN activation/NN of/IN NF-kappa/NN B/NN ./. 
In/IN HeLa/NN cells/NNS stably/RB transfected/VBN with/IN the/DT HIV-1/NN tat/NN gene/NN (/( HeLa-tat/JJ cells/NNS )/) ,/, expression/NN of/IN the/DT Tat/NN protein/NN enhanced/VBD both/CC TNF-induced/JJ activation/NN of/IN NF-kappa/NN B/NN and/CC TNF-mediated/JJ cytotoxicity/NN ./. 
A/DT similar/JJ potentiation/NN of/IN TNF/NN effects/NNS was/VBD observed/VBN in/IN Jurkat/NN T/NN cells/NNS and/CC HeLa/NN cells/NNS treated/VBN with/IN soluble/JJ Tat/NN protein/NN ./. 
TNF-mediated/JJ activation/NN of/IN NF-kappa/NN B/NN and/CC cytotoxicity/NN involves/VBZ the/DT intracellular/JJ formation/NN of/IN reactive/JJ oxygen/NN intermediates/NNS ./. 
Therefore/RB ,/, Tat-mediated/JJ effects/NNS on/IN the/DT cellular/JJ redox/NN state/NN were/VBD analyzed/VBN ./. 
In/IN both/CC T/NN cells/NNS and/CC HeLa/NN cells/NNS HIV-1/NN Tat/NN suppressed/VBD the/DT expression/NN of/IN Mn-dependent/JJ superoxide/NN dismutase/NN (/( Mn-SOD/NN )/) ,/, a/DT mitochondrial/JJ enzyme/NN that/WDT is/VBZ part/NN of/IN the/DT cellular/JJ defense/NN system/NN against/IN oxidative/JJ stress/NN ./. 
Thus/RB ,/, Mn-SOD/NN RNA/NN protein/NN levels/NNS and/CC activity/NN were/VBD markedly/RB reduced/VBN in/IN the/DT presence/NN of/IN Tat/NN ./. 
Decreased/VBN Mn-SOD/NN expression/NN was/VBD associated/VBN with/IN decreased/VBN levels/NNS of/IN glutathione/NN and/CC a/DT lower/JJR ratio/NN of/IN reduced/VBN :/: oxidized/VBN glutathione/NN ./. 
A/DT truncated/VBN Tat/NN protein/NN (/( Tat1-72/CD )/) ,/, known/VBN to/TO transactivate/VB the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ,/, no/RB longer/RBR affected/VBD Mn-SOD/NN expression/NN ,/, the/DT cellular/JJ redox/NN state/NN or/CC TNF-mediated/JJ cytotoxicity/NN ./. 
Thus/RB ,/, our/PRP$ experiments/NNS demonstrate/VBP that/IN the/DT C-terminal/JJ region/NN of/IN HIV-1/NN Tat/NN is/VBZ required/VBN to/TO suppress/VB Mn-SOD/NN expression/NN and/CC to/TO induce/VB pro-oxidative/JJ conditions/NNS reflected/VBN by/IN a/DT drop/NN in/IN reduced/VBN glutathione/NN (/( GSH/NN )/) and/CC the/DT GSH/NN :/: oxidized/VBN GSH/NN (/( GSSG/NN )/) ratio/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 95261816/CD 
TI/LS -/: The/DT use/NN of/IN glucocorticoids/NNS in/IN acute/JJ lymphoblastic/JJ leukemia/NN of/IN childhood/NN ./. 
Molecular/JJ ,/, cellular/JJ ,/, and/CC clinical/JJ considerations/NNS ./. 
AB/LS -/: Glucocorticoids/NNS have/VBP been/VBN included/VBN in/IN almost/RB all/DT treatment/NN regimens/NNS for/IN childhood/NN acute/JJ lymphoblastic/JJ leukemia/NN for/IN decades/NNS ./. 
However/RB ,/, optimal/JJ agents/NNS ,/, doses/NNS ,/, and/or/CC schedules/NNS have/VBP yet/RB to/TO be/VB defined/VBN despite/IN extensive/JJ clinical/JJ application/NN ./. 
New/JJ data/NNS on/IN the/DT pharmacokinetics/NNS ,/, pharmacodynamics/NNS ,/, and/CC molecular/JJ mechanisms/NNS of/IN action/NN of/IN glucocorticoids/NNS have/VBP suggested/VBN alternative/JJ approaches/NNS in/IN ALL/NN ./. 
These/DT suggest/VBP that/IN prolonged/JJ ,/, i.e./FW 28/CD day/NN ,/, glucocorticoid/NN therapy/NN may/MD be/VB unnecessary/JJ as/IN exposure/NN to/TO glucocorticoid/NN induces/VBZ down-regulation/NN of/IN glucocorticoid/NN receptors/NNS ./. 
Dexamethasone/NN may/MD be/VB superior/JJ to/TO prednisone/NN in/IN conventional/JJ equi-effective/JJ doses/NNS ./. 
Blast/NN sensitivity/NN to/TO glucocorticoids/NNS correlates/VBZ closely/RB with/IN sensitivity/NN to/TO other/JJ ,/, putatively/RB non-cross-resisting/JJ agents/NNS and/CC with/IN outcome/NN after/IN multi-agent/JJ therapy/NN ,/, suggesting/VBG overlapping/JJ mechanisms/NNS of/IN action/NN ,/, and/CC focusing/VBG attention/NN on/IN the/DT determinants/NNS of/IN the/DT threshold/NN for/IN apoptosis/NN ./. 
Increasing/VBG success/NN in/IN the/DT treatment/NN of/IN childhood/NN acute/JJ lymphoblastic/JJ leukemia/NN has/VBZ led/VBN to/TO increasing/VBG awareness/NN of/IN avascular/JJ necrosis/NN of/IN bone/NN as/IN a/DT potentially/RB disabling/JJ sequela/NN of/IN glucocorticoid/NN therapy/NN ,/, especially/RB in/IN adolescent/JJ and/CC young/JJ adult/JJ patients/NNS ./. 
UI/LS -/: 95074873/CD 
TI/LS -/: Epstein-Barr/JJ virus/NN nuclear/JJ protein/NN 2/CD transactivation/NN of/IN the/DT latent/JJ membrane/NN protein/NN 1/CD promoter/NN is/VBZ mediated/VBN by/IN J/NN kappa/NN and/CC PU.1/NN ./. 
AB/LS -/: Expression/NN of/IN the/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) latent/JJ membrane/NN protein/NN 1/CD (/( LMP-1/NN )/) oncogene/NN is/VBZ regulated/VBN by/IN the/DT EBV/NN nuclear/JJ protein/NN 2/CD (/( EBNA-2/NN )/) transactivator/NN ./. 
EBNA-2/NN is/VBZ known/VBN to/TO interact/VB with/IN the/DT cellular/JJ DNA-binding/JJ protein/NN J/NN kappa/NN and/CC is/VBZ recruited/VBN to/TO promoters/NNS containing/VBG the/DT GTGGGAA/NN J/NN kappa/NN recognition/NN sequence/NN ./. 
The/DT minimal/JJ EBNA-2-responsive/JJ LMP-1/NN promoter/NN includes/VBZ one/CD J/NN kappa-binding/JJ site/NN ,/, and/CC we/PRP now/RB show/VBP that/IN mutation/NN of/IN that/DT site/NN ,/, such/JJ that/IN J/NN kappa/NN can/MD not/RB bind/VB ,/, reduces/VBZ EBNA-2/NN responsiveness/NN by/IN 60/CD %/NN ./. 
To/TO identify/VB other/JJ factors/NNS which/WDT interact/VBP with/IN the/DT LMP-1/NN EBNA-2/NN response/NN element/NN (/( E2RE/NN )/) ,/, a/DT -236/-145/JJ minimal/JJ E2RE/NN was/VBD used/VBN as/IN a/DT probe/NN in/IN an/DT electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
The/DT previously/RB characterized/VBN factors/NNS J/NN kappa/NN ,/, PU.1/NN ,/, and/CC AML1/NN bind/VBP to/TO the/DT LMP-1/NN E2RE/NN ,/, along/IN with/IN six/CD other/JJ unidentified/JJ factors/NNS (/( LBF2/NN to/TO LBF7/NN )/) ./. 
Binding/VBG sites/NNS were/VBD mapped/VBN for/IN each/DT factor/NN ./. 
LBF4/NN is/VBZ B-/NN and/CC T-cell/NN specific/JJ and/CC recognizes/VBZ the/DT PU.1/NN GGAA/NN core/NN sequence/NN as/IN shown/VBN by/IN methylation/NN interference/NN ./. 
LBF4/NN has/VBZ a/DT molecular/JJ mass/NN of/IN 105/CD kDa/NN and/CC is/VBZ probably/RB unrelated/JJ to/TO PU.1/NN ./. 
LBF2/NN was/VBD found/VBN only/RB in/IN epithelial/JJ cell/NN lines/NNS ,/, whereas/IN LBF3/NN ,/, LBF5/NN ,/, LBF6/NN ,/, and/CC LBF7/NN were/VBD not/RB cell/NN type/NN specific/JJ ./. 
Mutations/NNS of/IN the/DT AML1-/NN or/CC LBF4-binding/JJ sites/NNS had/VBD no/DT effect/NN on/IN EBNA-2/NN transactivation/NN ,/, whereas/IN mutation/NN of/IN the/DT PU.1-binding/JJ site/NN completely/RB eliminated/VBD EBNA-2/NN responses/NNS ./. 
A/DT gst-EBNA-2/NN fusion/NN protein/NN specifically/RB depleted/VBD PU.1/NN from/IN nuclear/JJ extracts/NNS and/CC bound/VBD in/FW vitro/FW translated/VBN PU.1/NN ,/, providing/VBG biochemical/JJ evidence/NN for/IN a/DT direct/JJ EBNA-2-PU.1/JJ interaction/NN ./. 
Thus/RB ,/, EBNA-2/NN transactivation/NN of/IN the/DT LMP-1/NN promoter/NN is/VBZ dependent/JJ on/IN interaction/NN with/IN at/IN least/JJS two/CD distinct/JJ sequence-specific/JJ DNA-binding/JJ proteins/NNS ,/, J/NN kappa/NN and/CC PU.1/NN ./. 
LBF3/NN ,/, LBF5/NN ,/, LBF6/NN ,/, or/CC LBF7/NN may/MD also/RB be/VB involved/VBN ,/, since/IN their/PRP$ binding/VBG sites/NNS also/RB contribute/VBP to/TO EBNA-2/NN responsiveness/NN ./. 
UI/LS -/: 96094166/CD 
TI/LS -/: Lymphocyte/NN glucocorticoid/NN receptor/NN :/: predictor/NN of/IN sertraline/NN response/NN in/IN adolescent/JJ major/JJ depressive/JJ disorder/NN (/( MDD/NN )/) ./. 
AB/LS -/: Major/JJ depressive/JJ disorder/NN (/( MDD/NN )/) in/IN adolescents/NNS demonstrates/VBZ resistance/NN to/TO tricyclic/JJ antidepressants/NNS and/CC absence/NN of/IN hypercortisolemia/NN ./. 
The/DT efficacy/NN of/IN serotonin/NN reuptake/NN inhibitors/NNS (/( SRIs/NNS )/) is/VBZ uncertain/JJ ,/, and/CC response/NN predictors/NNS are/VBP unavailable/JJ ./. 
Abnormal/JJ fast/JJ feedback/NN and/CC negative/JJ feedback/NN of/IN the/DT hypothalamic-pituitary-adrenal/JJ axis/NN implicates/VBZ a/DT dampened/JJ limbic-hippocampal/JJ glucocorticoid/NN type/NN II/CD receptor/NN (/( GCII/NN )/) ./. 
We/PRP hypothesized/VBD that/IN lymphocyte/NN GCII/NN is/VBZ altered/VBN in/IN adolescent/JJ MDD/NN and/CC could/MD serve/VB as/IN a/DT marker/NN for/IN response/NN to/TO SRIs/NNS ./. 
In/IN an/DT open-label/JJ study/NN ,/, adolescents/NNS (/( n/NN =/JJ 20/CD )/) meeting/VBG DSM-III-R/NN criteria/NNS for/IN MDD/NN showed/VBD baseline/NN lymphocyte/NN GCII/NN sites/NNS per/IN cell/NN (/( sites/cell/NNS )/) values/NNS of/IN 793/CD +/-/CC 106/CD versus/CC 2/CD ,/, 563/CD +/-/CC 499/CD (/( +/-/CC SEM/NN )/) for/IN matched/VBN controls/NNS (/( n/NN =/JJ 18/CD )/) (/( t/NN =/JJ 3.5/CD ;/: df/NN =/JJ 36/CD ;/: p/NN </JJR .001/CD )/) ./. 
GCII/NN was/VBD bimodally/RB distributed/VBN ,/, with/IN SRI/NN responders/NNS differing/VBG from/IN nonresponders/NNS (/( t/NN =/JJ 3.9/CD ;/: df/NN =/JJ 14/CD ;/: p/NN </JJR .001/CD )/) ./. 
GCII/NN accurately/RB classified/VBD 90/CD percent/NN of/IN sertraline/NN responders/NNS and/CC 80/CD percent/NN of/IN nonresponders/NNS ./. 
Only/RB SRI/NN responders/NNS showed/VBD GCII/NN sites/cell/NNS upregulated/VBN after/IN 6/CD weeks/NNS of/IN treatment/NN (/( t/NN =/JJ 2.1/CD ,/, df/NN =/JJ 10/CD ;/: p/NN </JJR .05/CD )/) ./. 
UI/LS -/: 95074049/CD 
TI/LS -/: The/DT role/NN of/IN NFATp/NN in/IN cyclosporin/NN A-sensitive/JJ tumor/NN necrosis/NN factor-alpha/NN gene/NN transcription/NN ./. 
AB/LS -/: The/DT tumor/NN necrosis/NN factor-alpha/NN (/( TNF/NN alpha/NN )/) gene/NN is/VBZ an/DT immediate/JJ early/JJ gene/NN in/IN activated/VBN T/NN cells/NNS ,/, in/IN that/IN it/PRP is/VBZ rapidly/RB induced/VBN without/IN a/DT requirement/NN for/IN protein/NN synthesis/NN ./. 
Maximal/JJ induction/NN of/IN TNF/NN alpha/NN mRNA/NN can/MD be/VB induced/VBN by/IN treatment/NN of/IN T/NN cells/NNS with/IN calcium/NN ionophores/NNS alone/RB ,/, via/IN a/DT calcineurin-dependent/JJ process/NN that/WDT is/VBZ blocked/VBN by/IN cyclosporin/NN A/NN ./. 
We/PRP have/VBP previously/RB identified/VBN a/DT promoter/NN element/NN ,/, kappa/NN 3/CD ,/, that/WDT is/VBZ required/VBN for/IN calcium-stimulated/JJ ,/, cyclosporin/NN A-sensitive/JJ induction/NN of/IN the/DT TNF/NN alpha/NN gene/NN in/IN activated/VBN T/NN cells/NNS ./. 
Here/RB ,/, we/PRP demonstrate/VBP that/IN the/DT kappa/NN 3/CD binding/NN factor/NN contains/VBZ NFATp/NN ,/, a/DT cyclosporin-sensitive/JJ DNA-binding/JJ protein/NN required/VBN for/IN interleukin-2/NN gene/NN transcription/NN ./. 
NFATp/NN binds/VBZ to/TO two/CD sites/NNS within/IN the/DT kappa/NN 3/CD element/NN ,/, and/CC occupancy/NN of/IN both/DT sites/NNS is/VBZ required/VBN for/IN TNF/NN alpha/NN gene/NN induction/NN ./. 
Thus/RB ,/, although/IN the/DT kappa/NN 3/CD element/NN has/VBZ little/JJ sequence/NN similarity/NN to/TO other/JJ NFATp-binding/JJ sites/NNS ,/, it/PRP appears/VBZ to/TO function/VB as/IN a/DT cyclosporin-sensitive/JJ promoter/NN element/NN in/IN T/NN cells/NNS by/IN virtue/NN of/IN its/PRP$ ability/NN to/TO bind/VB NFATp/NN ./. 
The/DT involvement/NN of/IN NFATp/NN in/IN transcriptional/JJ activation/NN of/IN both/DT the/DT interleukin-2/NN and/CC TNF/NN alpha/NN genes/NNS suggests/VBZ that/IN this/DT factor/NN plays/VBZ an/DT important/JJ role/NN in/IN the/DT coordinate/JJ induction/NN of/IN multiple/JJ cytokine/NN genes/NNS ,/, starting/VBG at/IN the/DT earliest/JJS stages/NNS of/IN T/NN cell/NN activation/NN ./. 
UI/LS -/: 95197720/CD 
TI/LS -/: Regulation/NN and/CC specificity/NN of/IN MNDA/NN expression/NN in/IN monocytes/NNS ,/, macrophages/NNS ,/, and/CC leukemia/B/NN lymphoma/NN cell/NN lines/NNS ./. 
AB/LS -/: The/DT expression/NN of/IN the/DT human/JJ myeloid/JJ cell/NN nuclear/JJ differentiation/NN antigen/NN (/( MNDA/NN )/) was/VBD observed/VBN specifically/RB in/IN cells/NNS of/IN the/DT granulocyte-macrophage/JJ lineage/NN in/IN our/PRP$ earlier/JJR reports/NNS ./. 
The/DT specificity/NN of/IN MNDA/NN expression/NN for/IN cells/NNS in/IN the/DT granulocyte-macrophage/NN lineage/NN was/VBD reexamined/VBN in/IN cell/NN lines/NNS established/VBN from/IN patients/NNS with/IN Philadelphia/NN chromosome-positive/JJ chronic/JJ myeloid/JJ leukemia/NN ./. 
Cell/NN lines/NNS that/WDT expressed/VBD MNDA/NN exhibited/VBD myeloid/JJ cell/NN features/NNS and/CC granulocyte/NN or/CC monocyte/NN differentiation/NN could/MD be/VB induced/VBN in/FW vitro/FW ,/, while/IN cell/NN lines/NNS exhibiting/VBG properties/NNS of/IN very/RB early/JJ stage/NN cells/NNS or/CC multipotential/JJ cells/NNS did/VBD not/RB express/VB MNDA/NN ./. 
Cells/NNS originating/VBG from/IN cases/NNS of/IN Burkitt/NN 's/POS lymphoma/NN were/VBD negative/JJ ./. 
By/IN contrast/NN ,/, three/CD lymphoblastoid/JJ cell/NN lines/NNS (/( immortalized/VBN in/FW vitro/FW with/IN Epstein-Barr/JJ virus/NN )/) were/VBD weakly/RB positive/JJ and/CC MNDA/NN was/VBD up-regulated/VBN by/IN interferon-alpha/NN (/( IFN-alpha/NN )/) treatment/NN ./. 
As/IN we/PRP reported/VBD previously/RB ,/, MNDA/NN mRNA/NN level/NN in/IN adherent/JJ monocytes/NNS is/VBZ elevated/VBN by/IN IFN-alpha/NN ;/: in/IN this/DT study/NN ,/, we/PRP further/RB assessed/VBD MNDA/NN expression/NN in/IN in/FW vitro/FW monocyte-derived/JJ macrophages/NNS ./. 
Three/CD additional/JJ agents/NNS (/( endotoxin/NN ,/, phytohemagglutinin/NN ,/, and/CC phorbol/NN ester/NN )/) and/CC other/JJ conditions/NNS that/WDT affect/VBP function/NN ,/, cytokine/NN production/NN ,/, differentiation/NN ,/, and/or/CC growth/NN of/IN monocytes/NNS were/VBD examined/VBN for/IN their/PRP$ ability/NN to/TO alter/VB MNDA/NN expression/NN ./. 
The/DT results/NNS varied/VBD with/IN the/DT agent/NN ,/, cell/NN type/NN ,/, and/CC stage/NN of/IN differentiation/NN ./. 
Changes/NNS in/IN MNDA/NN expression/NN occurred/VBD slowly/RB (/( hours/NNS to/TO days/NNS )/) ,/, suggesting/VBG that/IN MNDA/NN could/MD mediate/VB changes/NNS realized/VBN over/IN a/DT long/JJ period/NN ./. 
The/DT results/NNS also/RB reveal/VBP a/DT discordance/NN in/IN certain/JJ MNDA/NN positive/JJ cells/NNS between/IN steady-state/JJ levels/NNS or/CC changes/NNS in/IN levels/NNS of/IN protein/NN and/CC mRNA/NN indicating/VBG that/IN the/DT regulation/NN of/IN MNDA/NN expression/NN occurs/VBZ at/IN more/JJR than/IN one/CD point/NN ./. 
Changes/NNS in/IN MNDA/NN expression/NN are/VBP consistent/JJ with/IN a/DT role/NN in/IN opposing/VBG macrophage/NN differentiation/NN and/CC activation/NN of/IN monocytes/macrophages/NNS ./. 
UI/LS -/: 95053891/CD 
TI/LS -/: DNA-binding/JJ studies/NNS of/IN the/DT Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD (/( EBNA-2/NN )/) :/: evidence/NN for/IN complex/JJ formation/NN by/IN latent/JJ membrane/NN protein/NN gene/NN promoter-binding/JJ proteins/NNS in/IN EBNA-2-positive/JJ cell/NN lines/NNS ./. 
AB/LS -/: The/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) nuclear/JJ antigen/NN 2/CD (/( EBNA-2/NN )/) protein/NN is/VBZ essential/JJ for/IN the/DT immortalization/NN of/IN human/JJ primary/JJ B/NN cells/NNS by/IN EBV/NN ./. 
EBNA-2/NN trans-activates/VBZ cellular/JJ and/CC viral/JJ genes/NNS like/IN CD23/NN ,/, c-fgr/NN ,/, latent/JJ membrane/NN protein/NN 1/CD (/( LMP1/NN )/) and/CC terminal/JJ protein/NN 1/CD (/( TP1/NN )/) ./. 
Trans-activation/NN of/IN the/DT TP1/NN promoter/NN and/CC of/IN the/DT BamHI/NN C/NN promoter/NN has/VBZ already/RB been/VBN investigated/VBN in/IN detail/NN and/CC appears/VBZ to/TO be/VB mediated/VBN via/IN protein-protein/JJ interactions/NNS and/CC not/RB by/IN direct/JJ binding/NN of/IN EBNA-2/NN type/NN A/NN (/( of/IN EBV/NN type/NN 1/CD )/) to/TO the/DT DNA/NN ./. 
EBNA-2/NN is/VBZ able/JJ to/TO trans-activate/VB the/DT expression/NN of/IN the/DT LMP/NN gene/NN in/IN several/JJ cell/NN lines/NNS ./. 
Various/JJ reports/NNS have/VBP delineated/VBN the/DT cis-acting/JJ elements/NNS of/IN the/DT LMP/NN promoter/NN through/IN which/WDT EBNA-2/NN mediates/VBZ trans-activation/NN ./. 
To/TO determine/VB whether/IN EBNA-2/NN also/RB trans-activates/VBZ the/DT LMP/NN promoter/NN by/IN protein-protein/JJ interactions/NNS ,/, we/PRP performed/VBD a/DT series/NN of/IN gel/NN retardation/NN assays/NNS and/CC competition/NN experiments/NNS with/IN LMP/NN promoter/NN fragments/NNS of/IN different/JJ sizes/NNS ./. 
We/PRP determined/VBD that/IN the/DT protein-binding/JJ region/NN on/IN the/DT LMP/NN promoter/NN was/VBD within/IN a/DT 42/CD bp/NN fragment/NN encompassing/VBG nucleotides/NNS -135/CD to/TO -176/CD relative/JJ to/TO the/DT LMP/NN transcriptional/JJ start/NN site/NN ./. 
None/NN of/IN the/DT DNA/NN fragments/NNS investigated/VBN indicated/VBD interaction/NN of/IN EBNA-2/NN with/IN the/DT DNA/NN via/IN protein-protein/JJ interactions/NNS ./. 
No/DT significant/JJ differences/NNS between/IN EBNA-2-positive/JJ and/CC EBNA-2-negative/JJ nuclear/JJ extracts/NNS could/MD be/VB seen/VBN in/IN the/DT gel/NN retardation/NN assay/NN under/IN conditions/NNS that/WDT clearly/RB showed/VBD binding/NN of/IN EBNA-2A/NN to/TO the/DT TP1/NN promoter/NN ./. 
However/RB ,/, analysis/NN of/IN sucrose/NN gradient/NN fractions/NNS in/IN the/DT gel/NN retardation/NN assay/NN provided/VBD evidence/NN that/IN the/DT LMP/NN promoter-binding/JJ proteins/NNS form/VBP a/DT complex/NN of/IN higher/JJR M(r)/NN in/IN EBNA-2-positive/JJ cell/NN extracts/NNS ./. 
These/DT complexes/NNS were/VBD destroyed/VBN by/IN detergent/NN ./. 
We/PRP deduce/VBP from/IN these/DT results/NNS that/IN EBNA-2-positive/JJ cells/NNS might/MD indeed/RB contain/VB specific/JJ complexes/NNS bound/VBN to/TO the/DT LMP/NN promoter/NN which/WDT are/VBP ,/, however/RB ,/, too/RB labile/JJ to/TO be/VB detected/VBN in/IN a/DT standard/JJ gel/NN retardation/NN assay/NN ./. 
UI/LS -/: 95015835/CD 
TI/LS -/: Simultaneous/JJ activation/NN of/IN Ig/NN and/CC Oct-2/NN synthesis/NN and/CC reduction/NN of/IN surface/NN MHC/NN class/NN II/CD expression/NN by/IN IL-6/NN ./. 
AB/LS -/: Terminal/JJ differentiation/NN of/IN B/NN cells/NNS to/TO plasma/NN cells/NNS in/FW vivo/FW is/VBZ characterized/VBN by/IN secretion/NN of/IN Ig/NN and/CC extinction/NN of/IN MHC/NN class/NN II/CD expression/NN on/IN the/DT cell/NN surface/NN ./. 
We/PRP show/VBP that/IN IL-6/NN signaling/NN leads/VBZ to/TO marked/JJ increases/NNS in/IN the/DT synthesis/NN and/CC secretion/NN of/IN Ig/NN in/IN clonal/JJ human/JJ B/NN cell/NN lines/NNS and/CC newly/RB isolated/VBN polyclonal/JJ B/NN lymphocytes/NNS in/FW vitro/FW ./. 
The/DT IL-6-induced/JJ cells/NNS resemble/VBP plasma/NN cells/NNS in/IN ultrastructure/NN and/CC in/IN reduced/VBN expression/NN of/IN surface/NN MHC/NN class/NN II/CD ./. 
Enhanced/VBN Ig/NN synthesis/NN is/VBZ a/DT result/NN of/IN coordinated/VBN transcriptional/JJ activation/NN of/IN Ig/NN genes/NNS without/IN promoter/NN or/CC isotype/NN specificity/NN ,/, and/CC differential/JJ accumulation/NN of/IN the/DT mRNA/NN encoding/VBG the/DT secreted/VBN form/NN of/IN Ig/NN heavy/JJ chain/NN ./. 
It/PRP is/VBZ saturable/JJ and/CC subject/JJ to/TO negative/JJ control/NN when/WRB IL-6/NN stimulation/NN is/VBZ prolonged/JJ ./. 
Coordinate/JJ with/IN temporal/JJ changes/NNS in/IN Ig/NN synthesis/NN ,/, the/DT DNA-binding/JJ activity/NN and/CC the/DT synthesis/NN of/IN the/DT B/NN cell-enriched/JJ transcription/NN factor/NN Oct-2/NN are/VBP regulated/VBN ./. 
Thus/RB ,/, differentiation/NN of/IN B/NN cells/NNS with/IN IL-6/NN in/FW vitro/FW recapitulates/VBZ the/DT hallmarks/NNS of/IN terminal/JJ B/NN differentiation/NN in/FW vivo/FW ;/: Oct-2/NN may/MD have/VB a/DT role/NN in/IN this/DT process/NN ./. 
UI/LS -/: 95127210/CD 
TI/LS -/: T-cell/NN functional/JJ regions/NNS of/IN the/DT human/JJ IL-3/NN proximal/JJ promoter/NN ./. 
AB/LS -/: The/DT human/JJ interleukin-3/NN (/( IL-3/NN )/) gene/NN is/VBZ expressed/VBN almost/RB exclusively/RB in/IN activated/VBN T/NN cells/NNS ./. 
Its/PRP$ expression/NN is/VBZ regulated/VBN at/IN both/CC the/DT transcriptional/JJ and/CC post-transcriptional/JJ level/NN ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN treatment/NN of/IN Jurkat/NN T/NN cells/NNS with/IN phytohemaglutinin/NN (/( PHA/NN )/) and/CC the/DT phorbol/NN ester/NN ,/, PMA/NN ,/, activated/VBD transcription/NN initiation/NN from/IN the/DT IL-3/NN gene/NN ./. 
To/TO define/VB the/DT regions/NNS of/IN the/DT gene/NN required/VBN for/IN transcription/NN activation/NN ,/, we/PRP generated/VBD a/DT series/NN of/IN reporter/NN constructs/NNS containing/VBG different/JJ regions/NNS of/IN the/DT IL-3/NN gene/NN 5'/JJ and/CC 3'/JJ flanking/JJ sequences/NNS ./. 
Both/CC positive/JJ and/CC negative/JJ regulatory/JJ elements/NNS were/VBD identified/VBN in/IN the/DT proximal/JJ 5'/JJ flanking/JJ region/NN of/IN the/DT IL-3/NN gene/NN ./. 
The/DT promoter/NN region/NN between/IN -173/CD and/CC -60/CD contained/VBD the/DT strongest/JJS activating/VBG elements/NNS ./. 
The/DT transcription/NN factor/NN AP-1/NN could/MD bind/VB to/TO this/DT positive/JJ activator/NN region/NN of/IN the/DT promoter/NN ./. 
We/PRP also/RB examined/VBD the/DT function/NN of/IN the/DT IL-3/NN CK-1/CK-2/NN elements/NNS that/WDT are/VBP present/JJ in/IN many/JJ cytokine/NN genes/NNS and/CC found/VBD that/IN they/PRP acted/VBD as/IN a/DT repressor/NN of/IN basal/JJ level/NN expression/NN when/WRB cloned/VBN upstream/RB of/IN a/DT heterologous/JJ promoter/NN but/CC were/VBD also/RB inducible/JJ by/IN PMA/PHA/NN ./. 
UI/LS -/: 95166251/CD 
TI/LS -/: Expression/NN of/IN the/DT Runt/NN domain-encoding/JJ PEBP2/NN alpha/NN genes/NNS in/IN T/NN cells/NNS during/IN thymic/JJ development/NN ./. 
AB/LS -/: The/DT PEBP2/NN alpha/NN A/NN and/CC PEBP2/NN alpha/NN B/NN genes/NNS encode/VBP the/DT DNA-binding/JJ subunit/NN of/IN a/DT murine/NN transcription/NN factor/NN ,/, PEBP2/NN ,/, which/WDT is/VBZ implicated/VBN as/IN a/DT T-cell-specific/JJ transcriptional/JJ regulator/NN ./. 
These/DT two/CD related/JJ genes/NNS share/VBP the/DT evolutionarily/RB conserved/VBN region/NN encoding/VBG the/DT Runt/NN domain/NN ./. 
PEBP2/NN alpha/NN B/NN is/VBZ the/DT murine/NN counterpart/NN of/IN human/JJ AML1/NN ,/, which/WDT is/VBZ located/JJ at/IN the/DT breakpoints/NNS of/IN the/DT 8;21/NN and/CC 3;21/NN chromosome/NN translocations/NNS associated/VBN with/IN acute/JJ myeloid/JJ leukemia/NN ./. 
Northern/NN (/( RNA/NN )/) blots/NNS of/IN various/JJ adult/JJ mouse/NN tissues/NNS revealed/VBD that/IN the/DT levels/NNS of/IN expression/NN of/IN both/DT genes/NNS were/VBD most/RBS prominent/JJ in/IN the/DT thymus/NN ./. 
Furthermore/RB ,/, transcripts/NNS of/IN PEBP2/NN alpha/NN A/NN and/CC mouse/NN AML1/PEBP2/NN alpha/NN B/NN were/VBD detected/VBN in/IN T/NN lymphocytes/NNS in/IN the/DT thymuses/NNS from/IN day/NN 16/CD embryos/NNS and/CC newborns/NNS ,/, as/RB well/RB as/IN 4-week-old/JJ adult/JJ mice/NNS ,/, by/IN in/FW situ/FW hybridization/NN ./. 
The/DT expression/NN of/IN the/DT genes/NNS persisted/VBD in/IN peripheral/JJ lymph/NN nodes/NNS of/IN adult/JJ mice/NNS ./. 
The/DT transcripts/NNS were/VBD detected/VBN in/IN all/PDT the/DT CD4-/JJ CD8-/JJ ,/, CD4+/JJ CD8+/JJ ,/, CD4+/JJ CD8-/JJ ,/, and/CC CD4-/JJ CD8+/JJ cell/NN populations/NNS ./. 
The/DT results/NNS indicated/VBD that/IN both/DT genes/NNS are/VBP expressed/VBN in/IN T/NN cells/NNS throughout/IN their/PRP$ development/NN ,/, supporting/VBG the/DT notion/NN that/IN PEBP2/NN is/VBZ a/DT T-cell-specific/JJ transcription/NN factor/NN ./. 
Transcripts/NNS of/IN mouse/NN AML1/PEBP2/NN alpha/NN B/NN were/VBD also/RB detected/VBN in/IN day/NN 12/CD fetal/JJ hematopoietic/JJ liver/NN and/CC in/IN the/DT bone/NN marrow/NN cells/NNS of/IN newborn/JJ mice/NNS ./. 
The/DT implication/NN of/IN mouse/NN AML1/PEBP2/NN alpha/NN B/NN expression/NN in/IN hematopoietic/JJ cells/NNS other/JJ than/IN those/DT of/IN T-cell/NN lineage/NN is/VBZ discussed/VBN in/IN relation/NN to/TO myeloid/JJ leukemogenesis/NN ./. 
UI/LS -/: 95168272/CD 
TI/LS -/: Effects/NNS of/IN glucocorticoids/NNS on/IN transcription/NN factor/NN activation/NN in/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
AB/LS -/: Glucocorticoids/NNS have/VBP an/DT inhibitory/JJ effect/NN on/IN inflammatory/JJ and/CC immune/JJ responses/NNS ,/, and/CC this/DT may/MD be/VB through/IN the/DT modulation/NN of/IN transcription/NN factor/NN binding/VBG to/TO DNA/NN ./. 
The/DT interaction/NN of/IN the/DT transcription/NN factors/NNS ,/, activator/NN protein-1/NN (/( AP-1/NN )/) ,/, nuclear/JJ factor/NN kappa/NN B/NN (/( NF/NN kappa/NN B/NN )/) ,/, and/CC cAMP-responsive/JJ element/NN binding/NN protein/NN (/( CREB/NN )/) with/IN DNA/NN and/CC glucocorticoid/NN receptors/NNS (/( GR/NN )/) was/VBD analyzed/VBN in/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS by/IN gel/NN mobility/NN shift/NN assays/NNS ./. 
TNF-alpha/NN ,/, IL-1/NN beta/NN and/CC phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) treatment/NN increased/VBD AP-1/NN and/CC NF/NN kappa/NN B/NN DNA/NN binding/NN by/IN up/RB to/TO 200/CD %/NN but/CC decreased/VBD CREB/NN binding/NN (/( 38/CD %/NN )/) over/IN a/DT 60-min/JJ time/NN course/NN ./. 
Dexamethasone/NN produced/VBD a/DT rapid/JJ and/CC sustained/JJ increase/NN in/IN glucocorticoid/NN response/NN element/NN binding/NN and/CC a/DT concomitant/JJ 40-50/CD %/NN decrease/NN in/IN AP-1/NN ,/, NF/NN kappa/NN B/NN ,/, and/CC CREB/NN DNA/NN binding/NN that/WDT was/VBD blocked/VBN by/IN combined/JJ dexamethasone/NN and/CC cytokine/NN or/CC PMA/NN treatment/NN ./. 
These/DT latter/JJ effects/NNS were/VBD due/JJ to/TO increases/NNS in/IN the/DT nuclear/JJ localization/NN of/IN GR/NN ,/, not/RB to/TO reduced/VBN amounts/NNS of/IN the/DT other/JJ transcription/NN factors/NNS ./. 
This/DT suggests/VBZ that/IN in/IN these/DT cells/NNS GR/NN within/IN the/DT nucleus/NN interacts/VBZ with/IN cytokine-stimulated/JJ transcription/NN factors/NNS by/IN the/DT process/NN of/IN cross/JJ coupling/NN ./. 
This/DT may/MD be/VB an/DT important/JJ molecular/JJ site/NN of/IN steroid/NN action/NN ./. 
UI/LS -/: 95263289/CD 
TI/LS -/: Differential/JJ induction/NN of/IN the/DT NF-AT/NN complex/NN during/IN restimulation/NN and/CC the/DT induction/NN of/IN T-cell/NN anergy/NN ./. 
AB/LS -/: Stimulation/NN of/IN human/JJ CD4+/JJ T-cell/NN clones/NNS through/IN the/DT T-cell/NN receptor/NN (/( TcR/NN )/) by/IN high/JJ doses/NNS of/IN specific/JJ peptide/NN results/VBZ in/IN the/DT induction/NN of/IN a/DT long-lived/JJ state/NN of/IN nonresponsiveness/NN that/WDT has/VBZ been/VBN called/VBN anergy/NN ./. 
During/IN the/DT induction/NN of/IN anergy/NN ,/, T/NN cells/NNS are/VBP phenotypically/RB similar/JJ to/TO cells/NNS responding/VBG to/TO an/DT immunogenic/JJ stimulus/NN ./. 
The/DT amount/NN of/IN TcR/NN at/IN the/DT cell/NN surface/NN is/VBZ downmodulated/VBN ,/, whereas/IN the/DT CD2/NN and/CC CD25/NN receptors/NNS are/VBP increased/VBN ./. 
When/WRB restimulated/VBN ,/, however/RB ,/, anergic/JJ T/NN cells/NNS fail/VBP to/TO up-regulate/VB transcription/NN of/IN the/DT IL-2/NN gene/NN and/CC in/IN consequence/NN do/VBP not/RB produce/VB IL-2/NN ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP compared/VBN the/DT ability/NN of/IN various/JJ transcription/NN factors/NNS to/TO bind/VB to/TO their/PRP$ appropriate/JJ site/NN on/IN DNA/NN ./. 
Factors/NNS were/VBD isolated/VBN from/IN the/DT nuclei/NNS of/IN T/NN cells/NNS that/WDT were/VBD in/IN the/DT induction/NN phase/NN of/IN anergy/NN or/CC were/VBD undergoing/VBG activation/NN ./. 
The/DT pattern/NN of/IN binding/NN activity/NN in/IN restimulated/VBN T/NN cells/NNS is/VBZ consistent/JJ with/IN the/DT pattern/NN that/WDT has/VBZ previously/RB been/VBN shown/VBN to/TO regulate/VB T-cell-specific/JJ expression/NN of/IN the/DT IL-2/NN and/CC the/DT beta/NN chain/NN of/IN the/DT TcR/NN genes/NNS ./. 
The/DT measured/VBN binding/NN to/TO a/DT TCF-1/NN site/NN is/VBZ the/DT same/JJ in/IN the/DT nuclei/NNS of/IN resting/VBG ,/, activated/VBN ,/, and/CC anergized/VBN cells/NNS ./. 
The/DT inducible/JJ factors/NNS NK-kappa/NN B/NN ,/, beta/NN E2/NN ,/, CD28RC/NN ,/, and/CC AP-1/NN are/VBP not/RB expressed/VBN in/IN resting/VBG cells/NNS and/CC are/VBP twofold/RB lower/RBR in/IN anergized/VBN as/IN compared/VBN with/IN activated/VBN cells/NNS ./. 
In/IN contrast/NN ,/, anergic/JJ T/NN cells/NNS express/VBP approximately/RB eightfold/RB lower/JJR amounts/NNS of/IN NF-AT/NN ,/, a/DT member/NN of/IN the/DT class/NN of/IN inducible/JJ factors/NNS that/WDT regulates/VBZ IL-2/NN gene/NN transcription/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 96126094/CD 
TI/LS -/: The/DT number/NN of/IN glucocorticoid/NN receptors/NNS in/IN peripheral/JJ human/JJ lymphocytes/NNS is/VBZ elevated/VBN by/IN a/DT zinc/NN containing/VBG trace/NN element/NN preparation/NN ./. 
AB/LS -/: A/DT trace/NN element/NN preparation/NN (/( Beres/NN Drops/NN Plus/NN ,/, BDP/NN )/) elevates/VBZ the/DT number/NN of/IN glucocorticoid/NN receptors/NNS (/( gcR/NN )/) in/IN peripheral/JJ lymphocytes/NNS isolated/VBN both/CC from/IN healthy/JJ blood/NN donors/NNS and/CC rheumatoid/JJ arthritis/NN patients/NNS ./. 
This/DT enhancement/NN by/IN BDP/NN was/VBD found/VBN either/CC for/IN constitutive/JJ expression/NN of/IN gcRs/NNS or/CC in/IN experiments/NNS when/WRB the/DT lymphocytes/NNS were/VBD stimulated/VBN by/IN interleukin/NN (/( IL/NN )/) -6/CD ./. 
There/EX was/VBD no/DT significant/JJ effect/NN of/IN BDP/NN on/IN IL-1/NN and/CC tumour/NN necrosis/NN factor/NN alpha/NN (/( TNF/NN alpha/NN )/) -induced/JJ changes/NNS of/IN gcRs/NNS ./. 
The/DT effect/NN of/IN BDP/NN was/VBD greatly/RB dependent/JJ on/IN the/DT presence/NN of/IN Zn++/NN ions/NNS in/IN the/DT preparation/NN ,/, since/IN the/DT augmenting/VBG effect/NN was/VBD abolished/VBN if/IN BDP/NN did/VBD not/RB contain/VB zinc/NN ./. 
UI/LS -/: 96063336/CD 
TI/LS -/: The/DT DNA/NN and/CC steroid/NN binding/NN domains/NNS of/IN the/DT glucocorticoid/NN receptor/NN are/VBP not/RB altered/VBN in/IN mononuclear/JJ cells/NNS of/IN treated/VBN CLL/NN patients/NNS ./. 
AB/LS -/: The/DT aim/NN of/IN this/DT study/NN was/VBD to/TO investigate/VB whether/IN mutations/NNS in/IN the/DT glucocorticoid/NN receptor/NN could/MD account/VB for/IN the/DT increasing/VBG unresponsiveness/NN of/IN patients/NNS with/IN chronic/JJ lymphatic/JJ leukemia/NN (/( CLL/NN )/) to/TO combination/NN chemotherapy/NN ./. 
The/DT receptor/NN was/VBD tested/VBN immunocytochemically/RB ,/, in/IN steroid/NN binding/NN assays/NNS ,/, and/CC by/IN a/DT mutation/NN screening/NN (/( denaturing/VBG gradient/NN gel/NN electrophoresis/NN )/) of/IN the/DT receptor-cDNA/NN ./. 
The/DT receptor/NN concentration/NN ,/, as/IN measured/VBN by/IN staining/VBG and/CC steroid/NN binding/NN test/NN ,/, varied/VBD considerably/RB but/CC showed/VBD no/DT clear/JJ correlation/NN to/TO clinical/JJ response/NN ./. 
Using/VBG a/DT highly/RB sensitive/JJ mutation/NN screening/NN assay/NN of/IN the/DT DNA-/NN and/CC the/DT steroid-binding/JJ region/NN ,/, none/NN of/IN the/DT treated/VBN patients/NNS revealed/VBD any/DT mutation/NN ,/, suggesting/VBG that/IN the/DT glucocorticoid/NN receptor/NN in/IN the/DT CLL/NN patients/NNS tested/VBN is/VBZ not/RB altered/VBN in/IN these/DT domains/NNS ./. 
In/IN one/CD individual/NN who/WP had/VBD not/RB been/VBN treated/VBN before/IN analysis/NN a/DT silent/JJ mutation/NN was/VBD found/VBN in/IN one/CD receptor/NN allele/NN ./. 
The/DT results/NNS suggest/VBP that/IN mechanisms/NNS other/JJ than/IN altered/JJ ligand/NN or/CC DNA/NN binding/NN of/IN the/DT receptor/NN may/MD be/VB responsible/JJ for/IN the/DT lack/NN of/IN response/NN to/TO chemotherapy/NN ./. 
This/DT conclusion/NN is/VBZ discussed/VBN in/IN relation/NN to/TO the/DT mechanism/NN of/IN corticoid/NN resistance/NN in/IN mouse/NN and/CC human/JJ lymphoma/NN cells/NNS in/IN culture/NN ./. 
UI/LS -/: 95116336/CD 
TI/LS -/: An/DT AP1/NN binding/NN site/NN upstream/JJ of/IN the/DT kappa/NN immunoglobulin/NN intron/NN enhancer/NN binds/VBZ inducible/JJ factors/NNS and/CC contributes/VBZ to/TO expression/NN ./. 
AB/LS -/: Expression/NN of/IN the/DT kappa/NN immunoglobulin/NN light/JJ chain/NN gene/NN requires/VBZ developmental-/JJ and/CC tissue-specific/JJ regulation/NN by/IN trans-acting/JJ factors/NNS which/WDT interact/VBP with/IN two/CD distinct/JJ enhancer/NN elements/NNS ./. 
A/DT new/JJ protein-DNA/JJ interaction/NN has/VBZ been/VBN identified/VBN upstream/RB of/IN the/DT intron/NN enhancer/NN ,/, within/IN the/DT matrix-associated/JJ region/NN of/IN the/DT J-C/JJ intron/NN ./. 
The/DT binding/NN activity/NN is/VBZ greatly/RB inducible/JJ in/IN pre-B/JJ cells/NNS by/IN bacterial/JJ lipopolysaccharide/NN and/CC interleukin-1/NN but/CC specific/JJ complexes/NNS are/VBP found/VBN at/IN all/DT stages/NNS of/IN B/NN cell/NN development/NN tested/VBN ./. 
The/DT footprinted/VBN binding/VBG site/NN is/VBZ homologous/JJ to/TO the/DT consensus/NN AP1/NN motif/NN ./. 
The/DT protein/NN components/NNS of/IN this/DT complex/NN are/VBP specifically/RB competed/VBN by/IN an/DT AP1/NN consensus/NN motif/NN and/CC were/VBD shown/VBN by/IN supershift/NN to/TO include/VB c-Jun/NN and/CC c-Fos/NN ,/, suggesting/VBG that/IN this/DT binding/VBG site/NN is/VBZ an/DT AP1/NN motif/NN and/CC that/IN the/DT Jun/NN and/CC Fos/NN families/NNS of/IN transcription/NN factors/NNS play/VBP a/DT role/NN in/IN the/DT regulation/NN of/IN the/DT kappa/NN light/JJ chain/NN gene/NN ./. 
Mutation/NN of/IN the/DT AP1/NN motif/NN in/IN the/DT context/NN of/IN the/DT intron/NN enhancer/NN was/VBD shown/VBN to/TO decrease/VB enhancer-mediated/JJ activation/NN of/IN the/DT promoter/NN in/IN both/CC pre-B/JJ cells/NNS induced/VBN with/IN LPS/NN and/CC constitutive/JJ expression/NN in/IN mature/JJ B/NN cells/NNS ./. 
UI/LS -/: 95036290/CD 
TI/LS -/: Distinct/JJ DNase-I/NN hypersensitive/JJ sites/NNS are/VBP associated/VBN with/IN TAL-1/NN transcription/NN in/IN erythroid/JJ and/CC T-cell/NN lines/NNS ./. 
AB/LS -/: The/DT tal-1/NN gene/NN ,/, frequently/RB activated/VBN in/IN human/JJ T-cell/NN acute/JJ lymphoblastic/JJ leukemia/NN (/( T-ALL/NN )/) ,/, is/VBZ expressed/VBN in/IN the/DT erythroid/JJ ,/, megakaryocytic/JJ ,/, and/CC mast/NN cell/NN lineages/NNS during/IN normal/JJ hematopoiesis/NN ./. 
To/TO gain/VB further/JJ insight/NN into/IN the/DT molecular/JJ mechanisms/NNS that/WDT control/VBP tal-1/NN expression/NN ,/, we/PRP investigated/VBD tal-1/NN chromatin/NN structure/NN in/IN erythroid/megakaryocytic/JJ cell/NN lines/NNS and/CC in/IN T-cell/NN lines/NNS either/CC with/IN or/CC without/IN tal-1/NN rearrangements/NNS ./. 
Tal-1/NN transcription/NN was/VBD shown/VBN to/TO be/VB monoallelic/JJ in/IN Jurkat/NN ,/, a/DT T-cell/NN line/NN that/WDT expresses/VBZ tal-1/NN in/IN the/DT absence/NN of/IN apparent/JJ genomic/JJ alteration/NN of/IN the/DT locus/NN ./. 
Methylation/NN studies/NNS indicated/VBD that/IN the/DT tal-15/NN '/POS GC-rich/JJ region/NN behaves/VBZ like/IN a/DT CpG/NN island/NN ,/, hypomethylated/VBN in/IN normal/JJ cells/NNS ,/, and/CC methylated/VBN de/FW novo/FW on/IN transcriptionally/RB inactive/JJ alleles/NNS in/IN established/JJ cell/NN lines/NNS ./. 
Five/CD major/JJ DNase-I/NN hypersensitive/JJ sites/NNS (/( HS/NN )/) were/VBD mapped/VBN in/IN the/DT tal-1/NN locus/NN ./. 
HS/NN I/CD ,/, IV/CD ,/, and/CC V/CD were/VBD exclusively/RB observed/VBN in/IN the/DT erythroid/megakaryocytic/JJ cell/NN lines/NNS that/WDT express/VBP tal-1/NN from/IN the/DT promoters/NNS 1a/NN and/CC 1b/NN ./. 
HS/NN II/CD was/VBD weak/JJ in/IN hematopoietic/JJ cell/NN lines/NNS ,/, absent/JJ in/IN Hela/NN ,/, and/CC greatly/RB enhanced/VBN in/IN Jurkat/NN ,/, suggesting/VBG that/IN this/DT region/NN might/MD be/VB implicated/VBN in/IN the/DT cis-activation/NN of/IN tal-1/NN promoter/NN 1b/NN in/IN this/DT cell/NN line/NN ./. 
HS/NN III/CD was/VBD weak/JJ in/IN HEL/NN and/CC Jurkat/NN ,/, and/CC greatly/RB enhanced/VBN in/IN DU528/NN ,/, a/DT T-cell/NN line/NN that/WDT bears/VBZ a/DT t (1;14)/NN and/CC initiates/VBZ tal-1/NN transcription/NN within/IN exon/NN 4/CD ./. 
These/DT results/NNS suggest/VBP that/IN distinct/JJ regulatory/JJ elements/NNS are/VBP associated/VBN with/IN the/DT use/NN of/IN the/DT different/JJ tal-1/NN promoters/NNS ./. 
UI/LS -/: 95050523/CD 
TI/LS -/: Erythropoietin-dependent/JJ induction/NN of/IN hemoglobin/NN synthesis/NN in/IN a/DT cytokine-dependent/JJ cell/NN line/NN M-TAT/NN ./. 
AB/LS -/: M-TAT/NN is/VBZ a/DT cytokine-dependent/JJ cell/NN line/NN with/IN the/DT potential/NN to/TO differentiate/VB along/IN the/DT erythroid/JJ and/CC megakaryocytic/JJ lineages/NNS ./. 
We/PRP cultured/VBD M-TAT/NN cells/NNS long/JJ term/NN (/( >/JJR 1/CD year/NN )/) in/IN the/DT continuous/JJ presence/NN of/IN erythropoietin/NN (/( EPO/NN )/) ,/, granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) ,/, or/CC stem/NN cell/NN factor/NN (/( SCF/NN )/) ./. 
These/DT long/JJ term/NN cultures/NNS are/VBP referred/VBN to/TO as/IN M-TAT/EPO/NN ,/, M-TAT/GM-CSF/NN ,/, and/CC M-TAT/SCF/NN cells/NNS ,/, respectively/RB ./. 
Hemoglobin/NN concentration/NN and/CC gamma-globin/NN and/CC erythroid/JJ delta-aminolevulinate/JJ synthase/NN mRNA/NN levels/NNS were/VBD significantly/RB higher/JJR in/IN M-TAT/EPO/NN cells/NNS than/IN in/IN M-TAT/GM-CSF/NN cells/NNS ./. 
When/WRB the/DT supplemented/VBN cytokine/NN was/VBD switched/VBN from/IN GM-CSF/NN to/TO EPO/NN ,/, hemoglobin/NN synthesis/NN in/IN M-TAT/GM-CSF/NN cells/NNS increased/VBD rapidly/RB (/( within/IN 5/CD h/NN )/) ,/, and/CC the/DT level/NN of/IN GATA-1/NN mRNA/NN increased/VBD ./. 
In/IN contrast/NN ,/, the/DT addition/NN of/IN GM-CSF/NN to/TO the/DT M-TAT/EPO/NN cell/NN culture/NN decreased/VBD the/DT amount/NN of/IN hemoglobin/NN ,/, even/RB in/IN the/DT presence/NN of/IN EPO/NN ,/, indicating/VBG that/IN the/DT EPO/NN signal/NN for/IN erythroid/JJ differentiation/NN is/VBZ suppressed/VBN by/IN GM-CSF/NN ./. 
Thus/RB ,/, erythroid/JJ development/NN of/IN M-TAT/NN cells/NNS is/VBZ promoted/VBN by/IN EPO/NN and/CC suppressed/VBN by/IN GM-CSF/NN ./. 
These/DT results/NNS support/VBP the/DT hypothesis/NN that/IN EPO/NN actively/RB influences/VBZ the/DT programming/NN of/IN gene/NN expression/NN required/VBN for/IN erythroid/JJ progenitor/NN cell/NN differentiation/NN ./. 
UI/LS -/: 95014458/CD 
TI/LS -/: The/DT role/NN of/IN cellular/JJ transcription/NN factor/NN E2F/NN in/IN the/DT regulation/NN of/IN cdc2/NN mRNA/NN expression/NN and/CC cell/NN cycle/NN control/NN of/IN human/JJ hematopoietic/JJ cells/NNS ./. 
AB/LS -/: cdc2/NN mRNA/NN transcripts/NNS were/VBD detected/VBN in/IN immature/JJ bone/NN marrow/NN cells/NNS and/CC became/VBD undetectable/JJ along/IN with/IN differentiation/NN ./. 
Peripheral/JJ blood/NN resting/NN cells/NNS did/VBD not/RB express/VB cdc2/NN mRNA/NN ,/, but/CC it/PRP was/VBD induced/VBN in/IN T-lymphocytes/NNS when/WRB the/DT cells/NNS reentered/VBD the/DT cell/NN cycle/NN in/IN response/NN to/TO specific/JJ mitogens/NNS ./. 
In/IN contrast/NN ,/, cdc2/NN mRNA/NN could/MD not/RB be/VB induced/VBN in/IN granulocytes/NNS and/CC monocytes/NNS even/RB after/IN the/DT culture/NN with/IN the/DT appropriate/JJ stimulants/NNS ./. 
In/IN order/NN to/TO investigate/VB the/DT mechanism/NN of/IN the/DT regulation/NN of/IN cdc2/NN mRNA/NN expression/NN in/IN hematopoietic/JJ cells/NNS ,/, we/PRP isolated/VBD the/DT 5'-flanking/JJ sequence/NN of/IN the/DT cdc2/NN gene/NN and/CC found/VBD the/DT putative/JJ E2F/NN binding/NN site/NN at/IN the/DT position/NN of/IN nucleotides/NNS -124/CD to/TO -117/CD ./. 
The/DT binding/NN of/IN E2F/NN at/IN this/DT region/NN was/VBD detected/VBN by/IN a/DT gel-retardation/NN assay/NN and/CC DNaseI/NN footprinting/NN in/IN phytohemagglutinin-stimulated/JJ T-lymphocytes/NNS ,/, which/WDT was/VBD coincident/JJ with/IN the/DT expression/NN of/IN cdc2/NN mRNA/NN ./. 
E2F/NN binding/NN was/VBD not/RB observed/VBN in/IN both/CC granulocytes/NNS and/CC monocytes/NNS ./. 
Transient/JJ chloramphenicol/NN acetyltransferase/NN assay/NN revealed/VBD that/IN the/DT region/NN containing/VBG E2F/NN binding/NN site/NN had/VBD a/DT strong/JJ promoter/NN activity/NN ,/, and/CC introduction/NN of/IN the/DT mutation/NN at/IN the/DT E2F/NN binding/NN site/NN resulted/VBD in/IN a/DT significant/JJ loss/NN of/IN the/DT activity/NN ./. 
E2F-1/NN and/CC DP-1/NN mRNAs/NNS were/VBD not/RB detectable/JJ in/IN granulocytes/NNS ,/, monocytes/NNS and/CC resting/VBG T-lymphocytes/NNS but/CC were/VBD induced/VBN after/IN the/DT mitogenic/JJ stimulation/NN of/IN T-lymphocytes/NNS ./. 
The/DT induction/NN of/IN E2F/NN activity/NN preceded/VBD the/DT appearance/NN of/IN cdc2/NN mRNA/NN ,/, which/WDT is/VBZ consistent/JJ with/IN the/DT role/NN of/IN E2F/NN in/IN the/DT regulation/NN of/IN cdc2/NN mRNA/NN expression/NN ./. 
These/DT results/NNS suggest/VBP that/IN cdc2/NN mRNA/NN expression/NN is/VBZ related/JJ to/TO the/DT cell/NN cycling/NN of/IN normal/JJ human/JJ hematopoietic/JJ cells/NNS and/CC that/IN E2F/NN plays/VBZ some/DT roles/NNS in/IN the/DT regulation/NN of/IN its/PRP$ expression/NN ./. 
UI/LS -/: 95151358/CD 
TI/LS -/: Association/NN of/IN alterations/NNS in/IN NF-kappa/NN B/NN moieties/NNS with/IN HIV/NN type/NN 1/CD proviral/JJ latency/NN in/IN certain/JJ monocytic/JJ cells/NNS ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) replication/NN is/VBZ controlled/VBN by/IN a/DT complex/JJ array/NN of/IN virally/RB encoded/VBN and/CC cellular/JJ proteins/NNS ./. 
A/DT wide/JJ spectrum/NN of/IN levels/NNS of/IN HIV-1/NN expression/NN have/VBP been/VBN demonstrated/VBN in/IN various/JJ cells/NNS ,/, both/CC in/IN cell/NN culture/NN and/CC in/FW vivo/FW ./. 
Molecular/JJ mechanisms/NNS leading/VBG to/TO restricted/JJ HIV-1/NN replication/NN may/MD differ/VB between/IN certain/JJ cell/NN types/NNS ./. 
It/PRP is/VBZ now/RB demonstrated/VBN that/IN HIV-1/NN proviral/JJ latency/NN in/IN the/DT monocytic/JJ cell/NN line/NN U1/NN ,/, in/IN which/WDT only/RB extremely/RB low/JJ levels/NNS of/IN HIV-1/NN expression/NN are/VBP detected/VBN in/IN the/DT baseline/NN unstimulated/JJ state/NN ,/, is/VBZ associated/VBN with/IN alterations/NNS in/IN nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) moieties/NNS demonstrated/VBN in/IN these/DT cells/NNS by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS (/( EMSAs/NNS )/) and/CC in/FW situ/FW UV/NN cross-linking/JJ studies/NNS ./. 
A/DT predominance/NN of/IN p50/NN NF-kappa/NN B/NN moieties/NNS and/CC possibly/RB p50/NN homodimers/NNS or/CC closely/RB related/JJ species/NNS ,/, rather/RB than/IN the/DT p50-p56/NN heterodimer/NN of/IN NF-kappa/NN B/NN that/WDT is/VBZ the/DT predominant/JJ NF-kappa/NN B/NN species/NNS in/IN most/JJS T/NN lymphocytic/JJ and/CC monocytic/JJ cells/NNS ,/, is/VBZ demonstrated/VBN in/IN the/DT nuclei/NNS of/IN U1/NN cells/NNS ./. 
This/DT pattern/NN of/IN NF-kappa/NN B-related/JJ moieties/NNS differs/VBZ from/IN the/DT latently/RB infected/JJ T/NN lymphocytic/JJ cell/NN line/NN ACH-2/NN ,/, and/CC from/IN the/DT U937/NN monocytic/JJ line/NN ,/, the/DT parental/JJ cell/NN line/NN of/IN the/DT U1/NN cellular/JJ clone/NN ./. 
As/IN such/JJ ,/, these/DT data/NNS suggest/VBP that/IN different/JJ proximal/JJ mechanisms/NNS may/MD lead/VB to/TO restricted/JJ HIV-1/NN replication/NN in/IN various/JJ cell/NN types/NNS ./. 
UI/LS -/: 95199654/CD 
TI/LS -/: [/( Regulation/NN of/IN transcription/NN of/IN the/DT interleukin-2/NN gene/NN in/IN B-lymphocytes/NNS ]/) 
AB/LS -/: Since/IN most/JJS B/NN cell/NN clones/NNS immortalized/VBN with/IN EBV/NN virus/NN can/MD be/VB induced/VBN to/TO produce/VB interleukin-2/NN ,/, a/DT typical/JJ T/NN cell/NN cytokine/NN ,/, we/PRP studied/VBD the/DT role/NN of/IN different/JJ elements/NNS of/IN the/DT IL-2/NN promoter/NN in/IN such/JJ clones/NNS by/IN transfection/NN ./. 
It/PRP was/VBD found/VBN ,/, in/IN particular/JJ ,/, that/IN the/DT element/NN TCEd/NN ,/, which/WDT binds/VBZ the/DT transcription/NN factor/NN NF-kB/NN ,/, is/VBZ very/RB active/JJ in/IN all/DT three/CD B/NN clones/NNS tested/VBN ./. 
This/DT element/NN has/VBZ no/DT activity/NN in/IN T/NN cells/NNS of/IN the/DT Jurkat/NN line/NN ./. 
The/DT NFATd/NN element/NN ,/, which/WDT binds/VBZ the/DT transcription/NN factor/NN NFAT-1/NN and/CC is/VBZ very/RB active/JJ in/IN T/NN cells/NNS ,/, is/VBZ only/RB weakly/RB active/JJ in/IN one/CD B/NN clone/NN and/CC not/RB at/IN all/DT in/IN another/DT ./. 
Different/JJ elements/NNS thus/RB contribute/VBP to/TO IL-2/NN promoter/NN activity/NN in/IN different/JJ cells/NNS ./. 
UI/LS -/: 95156575/CD 
TI/LS -/: Regulation/NN of/IN I/NN kappa/NN B/NN alpha/NN and/CC p105/NN in/IN monocytes/NNS and/CC macrophages/NNS persistently/RB infected/VBN with/IN human/JJ immunodeficiency/NN virus/NN ./. 
AB/LS -/: The/DT mechanisms/NNS regulating/VBG human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) persistence/NN in/IN human/JJ monocytes/macrophages/NNS are/VBP partially/RB understood/VBN ./. 
Persistent/JJ HIV/NN infection/NN of/IN U937/NN monocytic/JJ cells/NNS results/VBZ in/IN NF-kappa/NN B/NN activation/NN ./. 
Whether/IN virus-induced/JJ NF-kappa/NN B/NN activation/NN is/VBZ a/DT mechanism/NN that/WDT favors/VBZ continuous/JJ viral/JJ replication/NN in/IN macrophages/NNS remains/VBZ unknown/JJ ./. 
To/TO further/RB delineate/VB the/DT molecular/JJ mechanisms/NNS involved/VBN in/IN the/DT activation/NN of/IN NF-kappa/NN B/NN in/IN HIV-infected/JJ monocytes/NNS and/CC macrophages/NNS ,/, we/PRP have/VBP focused/VBN on/IN the/DT regulation/NN of/IN the/DT I/NN kappa/NN B/NN molecules/NNS ./. 
First/RB ,/, we/PRP show/VBP that/IN persistent/JJ HIV/NN infection/NN results/VBZ in/IN the/DT activation/NN of/IN NF-kappa/NN B/NN not/RB only/RB in/IN monocytic/JJ cells/NNS but/CC also/RB in/IN macrophages/NNS ./. 
In/IN HIV-infected/JJ cells/NNS ,/, I/NN kappa/NN B/NN alpha/NN protein/NN levels/NNS are/VBP decreased/VBN secondary/JJ to/TO enhanced/VBN protein/NN degradation/NN ./. 
This/DT parallels/VBZ the/DT increased/VBN I/NN kappa/NN B/NN alpha/NN synthesis/NN secondary/JJ to/TO increased/VBN I/NN kappa/NN B/NN alpha/NN gene/NN transcription/NN ,/, i.e./FW ,/, increased/VBN RNA/NN and/CC transcriptional/JJ activity/NN of/IN its/PRP$ promoter-enhancer/NN ./. 
Another/DT protein/NN with/IN I/NN kappa/NN B/NN function/NN ,/, p105/NN ,/, is/VBZ also/RB modified/VBN in/IN HIV-infected/JJ cells/NNS :/: p105/NN and/CC p50/NN steady-state/JJ protein/NN levels/NNS are/VBP increased/VBN as/IN a/DT result/NN of/IN increased/VBN synthesis/NN and/CC proteolytic/JJ processing/NN of/IN p105/NN ./. 
Transcriptional/JJ activity/NN of/IN p105/NN is/VBZ also/RB increased/VBN in/IN infected/JJ cells/NNS and/CC is/VBZ also/RB mediated/VBN by/IN NF-kappa/NN B/NN through/IN a/DT specific/JJ kappa/NN B/NN motif/NN ./. 
These/DT results/NNS demonstrate/VBP the/DT existence/NN of/IN a/DT triple/JJ autoregulatory/JJ loop/NN in/IN monocytes/NNS and/CC macrophages/NNS involving/VBG HIV/NN ,/, p105/NN and/CC p50/NN ,/, and/CC MAD3/NN ,/, with/IN the/DT end/NN result/NN of/IN persistent/JJ NF-kappa/NN B/NN activation/NN and/CC viral/JJ persistence/NN ./. 
Furthermore/RB ,/, persistent/JJ HIV/NN infection/NN of/IN monocytes/NNS and/CC macrophages/NNS provides/VBZ a/DT useful/JJ model/NN with/IN which/WDT to/TO study/VB concomitant/JJ modifications/NNS of/IN different/JJ I/NN kappa/NN B/NN molecules/NNS ./. 
UI/LS -/: 95163578/CD 
TI/LS -/: Glucocorticoid-induced/JJ apoptosis/NN of/IN human/JJ leukemic/JJ cells/NNS is/VBZ caused/VBN by/IN the/DT repressive/JJ function/NN of/IN the/DT glucocorticoid/NN receptor/NN ./. 
AB/LS -/: Induction/NN of/IN apoptosis/NN in/IN lymphocytes/NNS ,/, which/WDT may/MD account/VB for/IN the/DT therapeutic/JJ effects/NNS of/IN glucocorticoids/NNS in/IN various/JJ diseases/NNS including/VBG leukemia/NN ,/, depends/VBZ on/IN the/DT glucocorticoid/NN receptor/NN ./. 
However/RB ,/, the/DT events/NNS leading/VBG from/IN the/DT activated/VBN receptor/NN to/TO cell/NN lysis/NN are/VBP not/RB understood/VBN ./. 
A/DT prevailing/VBG hypothesis/NN postulates/VBZ induction/NN of/IN so-called/JJ '/`` lysis/NN genes/NNS '/'' by/IN the/DT activated/VBN receptor/NN ./. 
In/IN this/DT study/NN ,/, we/PRP show/VBP that/IN an/DT activation-deficient/JJ glucocorticoid/NN receptor/NN mutant/NN is/VBZ as/RB effective/JJ as/IN the/DT wild-type/JJ receptor/NN in/IN repression/NN of/IN AP-1/NN activity/NN ,/, inhibition/NN of/IN interleukin-2/NN production/NN ,/, inhibition/NN of/IN c-myc/NN expression/NN and/CC induction/NN of/IN apoptosis/NN ./. 
Furthermore/RB ,/, we/PRP show/VBP that/IN retinoic/JJ acid/NN can/MD also/RB induce/VB apoptosis/NN in/IN these/DT cells/NNS through/IN the/DT retinoic/JJ acid/NN receptor/NN ,/, whose/WP$ repressive/JJ functions/NNS but/CC not/RB target/NN site/NN specificity/NN ,/, are/VBP similar/JJ to/TO those/DT of/IN the/DT glucocorticoid/NN receptor/NN ./. 
Therefore/RB ,/, the/DT primary/JJ effect/NN of/IN the/DT receptor/NN in/IN glucocorticoid-mediated/JJ apoptosis/NN correlates/VBZ with/IN transcriptional/JJ repression/NN rather/RB than/IN activation/NN and/CC could/MD be/VB mediated/VBN by/IN interference/NN with/IN other/JJ transcription/NN factors/NNS required/VBN for/IN cell/NN survival/NN ./. 
UI/LS -/: 95260531/CD 
TI/LS -/: HIV/NN type/NN 1/CD protease/NN activation/NN of/IN NF-kappa/NN B/NN within/IN T/NN lymphoid/JJ cells/NNS ./. 
AB/LS -/: NF-kappa/NN B/NN is/VBZ a/DT nuclear/JJ protein/NN of/IN the/DT rel/NN oncogene/NN family/NN capable/JJ of/IN enhancing/VBG transcription/NN of/IN several/JJ cellular/JJ genes/NNS ,/, including/VBG IL-2/NN and/CC the/DT IL-2/NN receptor/NN ,/, and/CC viral/JJ genes/NNS transcribed/VBN from/IN the/DT HIV-1/NN LTR/NN ./. 
It/PRP has/VBZ been/VBN reported/VBN that/IN HIV-1/NN protease/NN may/MD cleave/VB the/DT NF-kappa/NN B/NN precursor/NN to/TO its/PRP$ active/JJ form/NN in/FW vitro/FW ./. 
In/IN this/DT study/NN the/DT effects/NNS of/IN HIV/NN protease/NN on/IN NF-kappa/NN B/NN precursor/NN activation/NN were/VBD examined/VBN in/IN Jurkat/NN T/NN cells/NNS by/IN introducing/VBG a/DT protease/NN expression/NN vector/NN into/IN the/DT cells/NNS ./. 
Increased/VBN NF-kappa/NN B/NN activity/NN was/VBD observed/VBN and/CC this/DT increased/VBN activity/NN was/VBD blocked/VBN by/IN a/DT specific/JJ inhibitor/NN of/IN the/DT viral/JJ protease/NN ./. 
Viral/JJ transcription/NN ,/, as/IN measured/VBN using/VBG LTR-CAT/JJ assays/NNS ,/, was/VBD only/RB slightly/RB enhanced/VBN in/IN the/DT HIV-protease/NN expressing/JJ cells/NNS ,/, while/IN secretion/NN of/IN IL-2/NN and/CC expression/NN of/IN the/DT IL-2/NN receptor/NN were/VBD not/RB affected/VBN ./. 
The/DT limited/JJ activation/NN of/IN NF-kappa/NN B/NN by/IN HIV/NN protease/NN appears/VBZ unlikely/JJ to/TO have/VB a/DT significant/JJ effect/NN on/IN virus/NN expression/NN or/CC T/NN cell/NN function/NN ./. 
UI/LS -/: 95074854/CD 
TI/LS -/: Inhibition/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD replication/NN by/IN a/DT Tat-activated/JJ ,/, transduced/VBN interferon/NN gene/NN :/: targeted/VBN expression/NN to/TO human/JJ immunodeficiency/NN virus/NN type/NN 1-infected/JJ cells/NNS ./. 
AB/LS -/: We/PRP have/VBP examined/VBN the/DT feasibility/NN of/IN using/VBG interferon/NN (/( IFN/NN )/) gene/NN transfer/NN as/IN a/DT novel/JJ approach/NN to/TO anti-human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) therapy/NN in/IN this/DT study/NN ./. 
To/TO limit/VB expression/NN of/IN a/DT transduced/VBN HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) -IFNA2/NN (/( the/DT new/JJ approved/JJ nomenclature/NN for/IN IFN/NN genes/NNS is/VBZ used/VBN throughout/IN this/DT article/NN )/) hybrid/NN gene/NN to/TO the/DT HIV-1-infected/JJ cells/NNS ,/, HIV-1/NN LTR/NN was/VBD modified/VBN ./. 
Deletion/NN of/IN the/DT NF-kappa/NN B/NN elements/NNS of/IN the/DT HIV-1/NN LTR/NN significantly/RB inhibited/VBD Tat-mediated/JJ transactivation/NN in/IN T-cell/NN lines/NNS ,/, as/RB well/RB as/IN in/IN a/DT monocyte/NN line/NN ,/, U937/NN ./. 
Replacement/NN of/IN the/DT NF-kappa/NN B/NN elements/NNS in/IN the/DT HIV-1/NN LTR/NN by/IN a/DT DNA/NN fragment/NN derived/VBN from/IN the/DT 5'-flanking/JJ region/NN of/IN IFN-stimulated/JJ gene/NN 15/CD (/( ISG15/NN )/) ,/, containing/VBG the/DT IFN-stimulated/JJ response/NN element/NN ,/, partially/RB restored/VBD Tat-mediated/JJ activation/NN of/IN LTR/NN in/IN T/NN cells/NNS as/RB well/RB as/IN in/IN monocytes/NNS ./. 
Insertion/NN of/IN this/DT chimeric/JJ promoter/NN (/( ISG15/NN LTR/NN )/) upstream/JJ of/IN the/DT human/JJ IFNA2/NN gene/NN directed/VBD high/JJ levels/NNS of/IN IFN/NN synthesis/NN in/IN Tat-expressing/JJ cells/NNS ,/, while/IN this/DT promoter/NN was/VBD not/RB responsive/JJ to/TO tumor/NN necrosis/NN factor/NN alpha-mediated/JJ activation/NN ./. 
ISG15-LTR-IFN/JJ hybrid/NN gene/NN inserted/VBN into/IN the/DT retrovirus/NN vector/NN was/VBD transduced/VBN into/IN Jurkat/NN and/CC U937/NN cells/NNS ./. 
Selected/VBN transfected/VBN clones/NNS produced/VBD low/JJ levels/NNS of/IN IFN/NN A/NN (/( IFNA/NN )/) constitutively/RB ,/, and/CC their/PRP$ abilities/NNS to/TO express/VB interleukin-2/NN and/CC interleukin-2/NN receptor/NN upon/IN stimulation/NN with/IN phytohemagglutinin/NN and/CC phorbol/NN myristate/NN acetate/NN were/VBD retained/VBN ./. 
Enhancement/NN of/IN IFNA/NN synthesis/NN observed/VBN upon/IN HIV-1/NN infection/NN resulted/VBD in/IN significant/JJ inhibition/NN of/IN HIV-1/NN replication/NN for/IN a/DT period/NN of/IN at/IN least/JJS 30/CD days/NNS ./. 
Virus/NN isolated/VBN from/IN IFNA-producing/JJ cells/NNS was/VBD able/JJ to/TO replicate/VB in/IN the/DT U937/NN cells/NNS but/CC did/VBD not/RB replicate/VB efficiently/RB in/IN U937/NN cells/NNS transduced/VBN with/IN the/DT IFNA/NN gene/NN ./. 
These/DT results/NNS suggest/VBP that/IN targeting/VBG IFN/NN synthesis/NN to/TO HIV-1-infected/JJ cells/NNS is/VBZ an/DT attainable/JJ goal/NN and/CC that/IN autocrine/NN IFN/NN synthesis/NN results/VBZ in/IN a/DT long-lasting/JJ and/CC permanent/JJ suppression/NN of/IN HIV-1/NN replication/NN ./. 
UI/LS -/: 96000378/CD 
TI/LS -/: Chromosomal/JJ localization/NN of/IN two/CD KOX/NN zinc/NN finger/NN genes/NNS on/IN chromosome/NN bands/NNS 7q21-q22/NN ./. 
AB/LS -/: Human/JJ cDNAs/NNS encoding/VBG Kruppel-type/JJ zinc/NN finger/NN domains/NNS ,/, designated/VBN KOX/NN 1-32/CD ,/, have/VBP been/VBN cloned/VBN from/IN human/JJ T/NN lymphocyte/NN cell/NN line/NN libraries/NNS ./. 
We/PRP report/VBP here/RB the/DT regional/JJ localizations/NNS by/IN in/FW situ/FW hybridization/NN of/IN KOX/NN 18/CD and/CC KOX/NN 25/CD on/IN chromosome/NN bands/NNS 7q21q22/NN ./. 
Pulse-field/JJ gel/NN electrophoresis/NN (/( PFGE/NN )/) analysis/NN showed/VBD that/IN these/DT genes/NNS are/VBP physically/RB located/JJ within/IN a/DT DNA/NN fragment/NN of/IN 250/CD kb/NN ./. 
The/DT genes/NNS KOX/NN 4/CD and/CC KOX/NN 9/CD ,/, mapped/VBN on/IN chromosome/NN 8q24/NN ,/, were/VBD found/VBN to/TO be/VB located/JJ within/IN a/DT DNA/NN fragment/NN of/IN 450/CD kb/NN ./. 
From/IN the/DT present/JJ and/CC previous/JJ data/NNS ,/, eighteen/CD different/JJ KOX/NN genes/NNS have/VBP been/VBN located/JJ at/IN least/JJS two/CD by/IN two/CD within/IN nine/CD DNA/NN fragments/NNS of/IN 200/CD to/TO 580/CD kb/NN ./. 
UI/LS -/: 95088506/CD 
TI/LS -/: Influence/NN of/IN age/NN on/IN the/DT production/NN of/IN Fos/NN and/CC Jun/NN by/IN influenza/NN virus-exposed/JJ T/NN cells/NNS ./. 
AB/LS -/: This/DT study/NN investigated/VBD age-related/JJ T/NN cell/NN responses/NNS after/IN in/FW vitro/FW exposure/NN to/TO influenza/NN A/NN virus/NN ./. 
Mononuclear/JJ leukocytes/NNS from/IN young/JJ or/CC elderly/JJ persons/NNS were/VBD sham-exposed/VBN or/CC exposed/VBN to/TO influenza/NN virus/NN for/IN 1/CD ,/, 24/CD ,/, and/CC 72/CD h/NN ./. 
Immunofluorescent/JJ staining/NN and/CC flow/NN cytometric/JJ analysis/NN were/VBD then/RB used/VBN to/TO detect/VB T/NN cells/NNS producing/VBG the/DT transcriptional/JJ regulating/NN proteins/NNS Fos/NN and/CC Jun/NN ./. 
Fewer/JJR virus-exposed/JJ cells/NNS from/IN elderly/JJ donors/NNS stained/VBN for/IN Fos/NN and/CC Jun/NN at/IN each/DT data/NNS point/NN compared/VBD with/IN cells/NNS from/IN young/JJ donors/NNS ./. 
Flow/NN cytometric/JJ analysis/NN also/RB showed/VBD that/IN at/IN 72/CD h/NN of/IN virus/NN exposure/NN fewer/JJR T/NN cells/NNS from/IN the/DT elderly/JJ produced/VBD interferon-gamma/NN (/( IFN-gamma/NN )/) ,/, suggesting/VBG a/DT link/NN between/IN the/DT magnitude/NN of/IN the/DT Fos/NN and/CC Jun/NN and/CC IFN-gamma/NN responses/NNS ./. 
Thus/RB ,/, failure/NN of/IN virus-exposed/JJ T/NN cells/NNS to/TO produce/VB Fos/NN and/CC Jun/NN could/MD contribute/VB to/TO the/DT increase/NN in/IN illness/NN due/JJ to/TO influenza/NN virus/NN in/IN the/DT elderly/JJ ./. 
UI/LS -/: 95194613/CD 
TI/LS -/: The/DT regulation/NN of/IN HIV/NN by/IN retinoic/JJ acid/NN correlates/VBZ with/IN cellular/JJ expression/NN of/IN the/DT retinoic/JJ acid/NN receptors/NNS ./. 
AB/LS -/: OBJECTIVES/NNS :/: To/TO analyze/VB the/DT effect/NN of/IN retinoic/JJ acids/NNS (/( RA/NNS )/) on/IN HIV-1/NN expression/NN and/CC correlate/VB this/DT effect/NN with/IN expression/NN levels/NNS of/IN RA/NN receptors/NNS (/( RARs/NNS )/) in/IN T-lymphoid/JJ and/CC monocytoid/JJ cell/NN lines/NNS ./. 
DESIGN/NN AND/CC METHODS/NNS :/: The/DT effect/NN of/IN all-trans/JJ and/CC 9-cis/JJ RA/NN on/IN HIV-1/NN production/NN in/IN T-lymphoid/JJ (/( H9/NN ,/, CEM/NN )/) and/CC monocytoid/JJ (/( U937/NN ,/, THP-1/NN )/) cell/NN lines/NNS was/VBD measured/VBN during/IN acute/JJ and/CC chronic/JJ infection/NN ./. 
The/DT expression/NN levels/NNS of/IN human/JJ RAR/NN alpha/NN (/( hRAR/NN alpha/NN ,/, receptor/NN for/IN all-trans/JJ RA/NN )/) and/CC the/DT human/JJ retinoid-X/NN receptor/NN alpha/NN (/( hRXR/NN alpha/NN receptor/NN for/IN 9-cis/JJ RA/NN )/) were/VBD determined/VBN by/IN Northern/NN blot/NN analysis/NN ./. 
RESULTS/NNS :/: Both/CC all-trans/JJ and/CC 9-cis/JJ RA/NN inhibited/VBD virus/NN replication/NN in/IN HIV-1/NN IIIB-infected/JJ monocytoid/JJ cells/NNS ,/, in/IN the/DT presence/NN and/CC absence/NN of/IN the/DT co-stimulatory/JJ agent/NN phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) ./. 
The/DT retinoids/NNS had/VBD weak/JJ or/CC no/DT stimulatory/JJ effects/NNS on/IN HIV/NN production/NN by/IN T-cell/NN lines/NNS ./. 
HIV/NN production/NN by/IN PMA-stimulated/JJ T-cell/NN lines/NNS was/VBD inhibited/VBN by/IN these/DT retinoids/NNS ./. 
The/DT 9-cis/JJ RA/NN was/VBD generally/RB more/RBR effective/JJ than/IN all-trans/JJ RA/NN in/IN inhibiting/VBG HIV/NN production/NN and/CC in/IN combination/NN generally/RB more/RBR effective/JJ than/IN the/DT single/JJ agents/NNS alone/RB ./. 
Human/JJ RAR/NN alpha/NN was/VBD expressed/VBN in/IN H9/NN ,/, U937/NN and/CC THP-1/NN cells/NNS ,/, but/CC almost/RB undetectable/JJ in/IN CEM/NN cells/NNS ./. 
Human/JJ RXR/NN alpha/NN was/VBD significantly/RB expressed/VBN in/IN U937/NN and/CC THP-1/NN cells/NNS ,/, weakly/RB expressed/VBN in/IN H9/NN cells/NNS and/CC not/RB detectable/JJ in/IN CEM/NN cells/NNS ./. 
After/IN stimulation/NN by/IN PMA/NN ,/, RXR/NN alpha/NN expression/NN increased/VBD in/IN H9/NN and/CC U937/NN cells/NNS but/CC not/RB in/IN CEM/NN cells/NNS ./. 
Human/JJ RAR/NN alpha/NN expression/NN was/VBD unchanged/JJ in/IN H9/NN and/CC CEM/NN cells/NNS ,/, and/CC elevated/VBD in/IN U937/NN cells/NNS ,/, after/IN PMA/NN stimulation/NN ./. 
CONCLUSION/NN :/: The/DT effect/NN of/IN RA/NN on/IN HIV-1/NN expression/NN was/VBD cell-type-dependent/JJ and/CC partially/RB correlated/VBN with/IN cellular/JJ expression/NN of/IN RARs/NNS ./. 
Endogenous/JJ or/CC exogenously/RB administered/VBN RA/NN may/MD have/VB a/DT significant/JJ role/NN in/IN HIV/NN regulation/NN ./. 
UI/LS -/: 95047083/CD 
TI/LS -/: Functions/NNS of/IN glutathione/NN and/CC glutathione/NN disulfide/NN in/IN immunology/NN and/CC immunopathology/NN ./. 
AB/LS -/: Even/RB a/DT moderate/JJ increase/NN in/IN the/DT cellular/JJ cysteine/NN supply/NN elevates/VBZ the/DT intracellular/JJ glutathione/NN (/( GSH/NN )/) and/CC glutathione/NN disulfide/NN (/( GSSG/NN )/) levels/NNS and/CC potentiates/VBZ immunological/JJ functions/NNS of/IN lymphocytes/NNS in/FW vitro/FW ./. 
At/IN low/JJ GSSG/NN levels/NNS ,/, T/NN cells/NNS can/MD not/RB optimally/RB activate/VB the/DT immunologically/RB important/JJ transcription/NN factor/NN NF/NN kappa/NN B/NN ,/, whereas/IN high/JJ GSSG/NN levels/NNS inhibit/VBP the/DT DNA/NN binding/NN activity/NN of/IN NF/NN kappa/NN B/NN ./. 
The/DT effects/NNS of/IN GSSG/NN are/VBP antagonized/VBN by/IN reduced/VBN thioredoxin/NN (/( TRX/NN )/) ./. 
As/IN the/DT protein/NN tyrosine/NN kinase/NN activities/NNS p56lck/NN and/CC p59fyn/NN are/VBP activated/VBN in/IN intact/JJ cells/NNS by/IN hydrogen/NN peroxide/NN ,/, they/PRP are/VBP likely/JJ targets/NNS for/IN GSSG/NN action/NN ./. 
These/DT redox-regulated/JJ enzymes/NNS trigger/VBP signal/NN cascades/NNS for/IN NF/NN kappa/NN B/NN activation/NN and/CC transduce/VBP signals/NNS from/IN the/DT T/NN cell/NN antigen/NN receptor/NN ,/, from/IN CD4/NN and/CC CD8/NN molecules/NNS ,/, and/CC from/IN the/DT IL-2/NN receptor/NN beta-chain/NN ./. 
The/DT effector/NN phase/NN of/IN cytotoxic/JJ T/NN cell/NN responses/NNS and/CC IL-2-dependent/JJ functions/NNS are/VBP inhibited/VBN even/RB by/IN a/DT partial/JJ depletion/NN of/IN the/DT intracellular/JJ GSH/NN pool/NN ./. 
As/IN signal/NN transduction/NN is/VBZ facilitated/VBN by/IN prooxidant/JJ conditions/NNS ,/, we/PRP propose/VBP that/IN the/DT well-known/JJ immunological/JJ consequences/NNS of/IN GSH/NN depletion/NN ultimately/RB may/MD be/VB results/NNS of/IN the/DT accompanying/VBG GSSG/NN deficiency/NN ./. 
As/IN HIV-infected/JJ patients/NNS and/CC SIV-infected/JJ rhesus/NN macaques/NNS have/VBP ,/, on/IN the/DT average/NN ,/, significantly/RB decreased/VBN plasma/NN cyst/NN (/( e/NN )/) ine/NN and/CC intracellular/JJ GSH/NN levels/NNS ,/, we/PRP also/RB hypothesize/VBP that/IN AIDS/NN may/MD be/VB the/DT consequence/NN of/IN a/DT GSSG/NN deficiency/NN as/RB well/RB ./. 
UI/LS -/: 95007565/CD 
TI/LS -/: T/NN cells/NNS from/IN renal/JJ cell/NN carcinoma/NN patients/NNS exhibit/VBP an/DT abnormal/JJ pattern/NN of/IN kappa/NN B-specific/JJ DNA-binding/JJ activity/NN :/: a/DT preliminary/JJ report/NN ./. 
AB/LS -/: Recent/JJ data/NNS suggest/VBP that/IN the/DT poor/JJ induction/NN of/IN a/DT T-cell/NN response/NN to/TO human/JJ renal/JJ cell/NN carcinoma/NN (/( RCC/NN )/) may/MD be/VB related/JJ to/TO alterations/NNS in/IN signal/NN transduction/NN pathways/NNS ./. 
We/PRP report/VBP that/IN T/NN cells/NNS from/IN RCC/NN patients/NNS have/VBP two/CD alterations/NNS in/IN kappa/NN B/NN motif-specific/JJ DNA-binding/JJ activity/NN ./. 
The/DT first/JJ alteration/NN involves/VBZ the/DT constitutive/JJ expression/NN of/IN substantial/JJ kappa/NN B-binding/JJ activity/NN in/IN nuclear/JJ extracts/NNS ,/, which/WDT was/VBD observed/VBN in/IN the/DT electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
The/DT magnitude/NN of/IN kappa/NN B/NN activity/NN in/IN unstimulated/JJ patient/NN T/NN cells/NNS was/VBD similar/JJ to/TO that/DT observed/VBN in/IN T/NN cells/NNS from/IN normal/JJ individuals/NNS that/WDT had/VBD been/VBN activated/VBN in/FW vitro/FW ./. 
On/IN the/DT basis/NN of/IN Western/NN blotting/NN experiments/NNS using/VBG antibodies/NNS to/TO kappa/NN B/Rel/NN family/NN proteins/NNS ,/, the/DT kappa/NN B-binding/NN activity/NN constitutively/RB expressed/VBN in/IN T/NN cells/NNS from/IN RCC/NN patients/NNS is/VBZ composed/VBN mostly/RB of/IN the/DT NF-kappa/NN B1/NN (/( p50/NN )/) subunit/NN ./. 
The/DT second/JJ abnormality/NN in/IN kappa/NN B-binding/JJ activity/NN in/IN T/NN cells/NNS from/IN these/DT patients/NNS is/VBZ that/IN RelA/NN ,/, a/DT member/NN of/IN the/DT Rel/NN homology/NN family/NN which/WDT is/VBZ part/NN of/IN the/DT normal/JJ NF-kappa/NN B/NN complex/NN ,/, was/VBD not/RB induced/VBN in/IN the/DT nucleus/NN following/VBG activation/NN ./. 
Western/NN blotting/NN analysis/NN did/VBD not/RB detect/VB any/DT RelA/NN in/IN nuclear/JJ extracts/NNS either/CC before/IN or/CC after/IN stimulation/NN of/IN T/NN cells/NNS ./. 
The/DT altered/JJ kappa/NN B-binding/JJ activity/NN in/IN T/NN cells/NNS from/IN RCC/NN patients/NNS may/MD impair/VB their/PRP$ capacity/NN to/TO respond/VB normally/RB to/TO various/JJ stimuli/NNS ./. 
UI/LS -/: 96091353/CD 
TI/LS -/: Hemoglobin/NN switching/NN in/IN humans/NNS is/VBZ accompanied/VBN by/IN changes/NNS in/IN the/DT ratio/NN of/IN the/DT transcription/NN factors/NNS ,/, GATA-1/NN and/CC SP1/NN ./. 
AB/LS -/: BACKGROUND/NN :/: Understanding/VBG the/DT mechanism/NN of/IN developmental/JJ regulation/NN of/IN hemoglobin/NN switching/NN has/VBZ scientific/JJ as/RB well/RB as/IN clinical/JJ relevance/NN because/IN of/IN the/DT influence/NN of/IN fetal/JJ hemoglobin/NN (/( HbF/NN )/) production/NN in/IN adulthood/NN on/IN the/DT clinical/JJ manifestation/NN of/IN thalassemia/NN and/CC sickle/NN cell/NN anemia/NN ./. 
We/PRP have/VBP previously/RB found/VBN that/IN the/DT normal/JJ developmental/JJ patterns/NNS of/IN globin/NN gene/NN expression/NN are/VBP recapitulated/VBN in/IN an/DT experimental/JJ system/NN of/IN primary/JJ cultures/NNS that/WDT support/VBP differentiation/NN of/IN erythroid/JJ progenitors/NNS ./. 
We/PRP further/RB found/VBD that/IN high/JJ activities/NNS of/IN the/DT transcriptional/JJ activators/NNS ,/, GATA-1/NN and/CC SP1/NN ,/, are/VBP associated/VBN with/IN normal/JJ adult/JJ erythroid/JJ differentiation/NN ./. 
MATERIALS/NNS AND/CC METHODS/NNS :/: In/IN the/DT present/JJ work/NN ,/, we/PRP have/VBP studied/VBN ,/, the/DT activities/NNS of/IN GATA-1/NN and/CC SP1/NN during/IN differentiation/NN of/IN cultured/VBN erythroid/JJ progenitors/NNS derived/VBN from/IN cord/NN blood/NN and/CC from/IN fetal/JJ livers/NNS ,/, as/RB well/RB as/IN from/IN beta/NN zero-thalassemia/JJ patients/NNS ./. 
RESULTS/NNS :/: The/DT results/NNS showed/VBD high/JJ GATA-1/NN binding/NN activity/NN and/CC very/RB low/JJ SP1/NN activity/NN in/IN the/DT fetal/JJ liver/NN cultures/NNS ./. 
This/DT pattern/NN was/VBD in/IN contrast/NN to/TO cultures/NNS derived/VBN from/IN normal/JJ adult/JJ peripheral/JJ blood/NN ,/, in/IN which/WDT both/CC GATA-1/NN and/CC SP1/NN activities/NNS were/VBD high/JJ ./. 
Cord/NN blood/NN cultures/NNS showed/VBD an/DT additive/JJ combination/NN of/IN "/`` adult/JJ "/'' and/CC "/`` fetal/JJ "/'' patterns/NNS ./. 
The/DT progenitors/NNS derived/VBN from/IN a/DT beta/NN zero-thalassemia/JJ patient/NN with/IN high/JJ HbF/NN production/NN showed/VBD "/`` fetal/JJ "/'' pattern/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, in/IN cultures/NNS of/IN 2/CD beta/NN zero-thalassemia/JJ patients/NNS without/IN high/JJ HbF/NN ,/, "/`` adult/JJ "/'' pattern/NN was/VBD observed/VBN ./. 
CONCLUSIONS/NNS :/: In/IN the/DT present/JJ work/NN ,/, we/PRP show/VBP that/IN human/JJ fetal/JJ and/CC adult/JJ erythroid/JJ progenitors/NNS are/VBP distinct/JJ in/IN their/PRP$ transcription/NN factors/NNS ,/, and/CC that/IN the/DT commitment/NN to/TO fetal/JJ or/CC adult/JJ program/NN occurs/VBZ at/IN a/DT very/RB early/JJ differentiation/NN stage/NN ./. 
Our/PRP$ studies/NNS also/RB demonstrate/VBP that/IN under/IN anemic/JJ stress/NN ,/, recruitment/NN of/IN fetal/JJ progenitors/NNS may/MD occur/VB in/IN adulthood/NN ./. 
UI/LS -/: 95166259/CD 
TI/LS -/: Transcription-independent/JJ turnover/NN of/IN I/NN kappa/NN B/NN alpha/NN during/IN monocyte/NN adherence/NN :/: implications/NNS for/IN a/DT translational/JJ component/NN regulating/VBG I/NN kappa/NN B/NN alpha/MAD-3/NN mRNA/NN levels/NNS ./. 
AB/LS -/: We/PRP identified/VBD I/NN kappa/NN B/NN alpha/MAD-3/NN as/IN an/DT immediate-early/JJ gene/NN in/IN human/JJ monocytes/NNS that/WDT is/VBZ expressed/VBN in/IN response/NN to/TO a/DT variety/NN of/IN signals/NNS ,/, including/VBG adhesion/NN ,/, lipopolysaccharide/NN ,/, and/CC phorbol/NN myristate/NN acetate/NN ./. 
Within/IN 5/CD min/NN of/IN monocyte/NN adhesion/NN ,/, the/DT level/NN of/IN the/DT I/NN kappa/NN B/NN alpha/NN protein/NN is/VBZ markedly/RB diminished/VBN but/CC is/VBZ rapidly/RB replaced/VBN in/IN a/DT cycloheximide-sensitive/JJ manner/NN within/IN 20/CD min/NN ./. 
Accompanying/VBG the/DT rapid/JJ turnover/NN of/IN the/DT I/NN kappa/NN B/NN alpha/NN protein/NN is/VBZ simultaneous/JJ translocation/NN of/IN NF-kappa/NN B-related/JJ transcription/NN factors/NNS to/TO nuclei/NNS of/IN adhered/JJ monocytes/NNS ./. 
The/DT demonstration/NN that/IN NF-kappa/NN B/NN can/MD regulate/VB I/NN kappa/NN B/NN alpha/MAD-3/NN gene/NN transcription/NN in/IN other/JJ cell/NN types/NNS suggested/VBD that/IN the/DT rapid/JJ increase/NN in/IN steady-state/JJ I/NN kappa/NN B/NN alpha/MAD-3/NN mRNA/NN levels/NNS we/PRP observed/VBD within/IN 30/CD min/NN of/IN monocyte/NN adherence/NN would/MD result/VB from/IN NF-kappa/NN B-dependent/JJ transcriptional/JJ stimulation/NN of/IN the/DT I/NN kappa/NN B/NN alpha/MAD-3/NN gene/NN ./. 
Nuclear/JJ run-on/JJ analyses/NNS indicated/VBD that/IN ,/, instead/RB ,/, while/IN several/JJ immediate-early/JJ cytokine/NN genes/NNS ,/, such/JJ as/IN the/DT interleukin/NN 1/CD beta/NN (/( IL-1/NN beta/NN )/) gene/NN ,/, were/VBD transcriptionally/RB activated/VBN during/IN monocyte/NN adhesion/NN ,/, the/DT rate/NN of/IN I/NN kappa/NN B/NN alpha/MAD-3/NN gene/NN transcription/NN remained/VBD constant/JJ ./. 
The/DT adherence-dependent/JJ increase/NN in/IN I/NN kappa/NN B/NN alpha/MAD-3/NN mRNA/NN levels/NNS was/VBD also/RB not/RB a/DT consequence/NN of/IN mRNA/NN stabilization/NN events/NNS ./. 
Interestingly/RB ,/, while/IN increases/NNS in/IN both/CC IL-1/NN beta/NN and/CC I/NN kappa/NN B/NN alpha/MAD-3/NN mRNA/NN levels/NNS were/VBD detected/VBN in/IN nuclei/NNS of/IN adherent/JJ monocytes/NNS ,/, cytoplasmic/JJ levels/NNS of/IN IL-1/NN beta/NN mRNA/NN increased/VBN during/IN adherence/NN whereas/IN those/DT of/IN I/NN kappa/NN B/NN alpha/MAD-3/NN mRNA/NN did/VBD not/RB ./. 
Taken/VBN together/RB ,/, our/PRP$ data/NNS suggest/VBP that/IN two/CD interactive/JJ mechanisms/NNS regulate/VBP monocytic/JJ I/NN kappa/NN B/NN alpha/MAD-3/NN mRNA/NN levels/NNS ./. 
We/PRP propose/VBP that/IN adherent/JJ monocytes/NNS regulate/VBP nuclear/JJ processing/NN (/( or/CC decay/NN )/) of/IN I/NN kappa/NN B/NN alpha/MAD-3/NN mRNA/NN ,/, thereby/RB increasing/VBG mRNA/NN levels/NNS without/IN stimulating/VBG I/NN kappa/NN B/NN alpha/MAD-3/NN gene/NN transcription/NN ./. 
Moreover/RB ,/, since/IN inhibition/NN of/IN protein/NN synthesis/NN leads/VBZ to/TO accumulation/NN of/IN I/NN kappa/NN B/NN alpha/MAD-3/NN mRNA/NN without/IN stimulating/VBG I/NN kappa/NN B/NN alpha/MAD-3/NN gene/NN transcription/NN ,/, we/PRP suggest/VBP that/IN low/JJ cytoplasmic/JJ levels/NNS of/IN I/NN kappa/NN B/NN alpha/MAD-3/NN mRNA/NN are/VBP maintained/VBN by/IN a/DT translation-dependent/JJ degradation/NN mechanism/NN ./. 
UI/LS -/: 95124333/CD 
TI/LS -/: Distinct/JJ roles/NNS of/IN the/DT molecular/JJ chaperone/NN hsp90/NN in/IN modulating/VBG dioxin/NN receptor/NN function/NN via/IN the/DT basic/JJ helix-loop-helix/JJ and/CC PAS/NN domains/NNS ./. 
AB/LS -/: The/DT intracellular/JJ dioxin/NN receptor/NN mediates/VBZ signal/NN transduction/NN by/IN dioxin/NN and/CC functions/VBZ as/IN a/DT ligand-activated/JJ transcription/NN factor/NN ./. 
It/PRP contains/VBZ a/DT basic/JJ helix-loop-helix/JJ (/( bHLH/JJ )/) motif/NN contiguous/JJ with/IN a/DT Per-Arnt-Sim/NN (/( PAS/NN )/) homology/NN region/NN ./. 
In/IN extracts/NNS from/IN nonstimulated/JJ cells/NNS the/DT receptor/NN is/VBZ recovered/VBN in/IN an/DT inducible/JJ cytoplasmic/JJ form/NN associated/VBN with/IN the/DT 90-kDa/JJ heat/NN shock/NN protein/NN (/( hsp90/NN )/) ,/, a/DT molecular/JJ chaperone/NN ./. 
We/PRP have/VBP reconstituted/VBN ligand-dependent/JJ activation/NN of/IN the/DT receptor/NN to/TO a/DT DNA-binding/JJ form/NN by/IN using/VBG the/DT dioxin/NN receptor/NN and/CC its/PRP$ bHLH-PAS/JJ partner/NN factor/NN Arnt/NN expressed/VBN by/IN in/FW vitro/FW translation/NN in/IN reticulocyte/JJ lysate/NN ./. 
Deletion/NN of/IN the/DT PAS/NN domain/NN of/IN the/DT receptor/NN resulted/VBD in/IN constitutive/JJ dimerization/NN with/IN Arnt/NN ./. 
In/IN contrast/NN ,/, this/DT receptor/NN mutant/NN showed/VBD low/JJ levels/NNS of/IN xenobiotic/JJ response/NN element-binding/JJ activity/NN ,/, indicating/VBG that/IN the/DT PAS/NN domain/NN may/MD be/VB important/JJ for/IN DNA-binding/JJ affinity/NN and/or/CC specificity/NN of/IN the/DT receptor/NN ./. 
It/PRP was/VBD not/RB possible/JJ to/TO reconstitute/VB dioxin/NN receptor/NN function/NN with/IN proteins/NNS expressed/VBN in/IN wheat/NN germ/NN lysate/NN ./. 
In/IN line/NN with/IN these/DT observations/NNS ,/, reticulocyte/NN lysate/NN but/CC not/RB wheat/NN germ/NN lysate/NN promoted/VBD the/DT association/NN of/IN de/FW novo/FW synthesized/VBN dioxin/NN receptor/NN with/IN hsp90/NN ./. 
At/IN least/JJS two/CD distinct/JJ domains/NNS of/IN the/DT receptor/NN mediated/VBD interaction/NN with/IN hsp90/NN :/: the/DT ligand-binding/JJ domain/NN located/JJ within/IN the/DT PAS/NN region/NN and/CC ,/, surprisingly/RB ,/, the/DT bHLH/JJ domain/NN ./. 
Whereas/IN ligand-binding/JJ activity/NN correlated/VBD with/IN association/NN with/IN hsp90/NN ,/, bHLH-hsp90/JJ interaction/NN appeared/VBD to/TO be/VB important/JJ for/IN DNA-binding/JJ activity/NN but/CC not/RB for/IN dimerization/NN of/IN the/DT receptor/NN ./. 
Several/JJ distinct/JJ roles/NNS for/IN hsp90/NN in/IN modulating/VBG dioxin/NN receptor/NN function/NN are/VBP therefore/RB likely/JJ :/: correct/JJ folding/NN of/IN the/DT ligand-binding/JJ domain/NN ,/, interference/NN with/IN Arnt/NN heterodimerization/NN ,/, and/CC folding/NN of/IN a/DT DNA-binding/JJ conformation/NN of/IN the/DT bHLH/JJ domain/NN ./. 
Thus/RB ,/, the/DT dioxin/NN receptor/NN system/NN provides/VBZ a/DT complex/JJ and/CC interesting/JJ model/NN of/IN the/DT regulation/NN of/IN transcription/NN factors/NNS by/IN hsp90/NN ./. 
UI/LS -/: 95236467/CD 
TI/LS -/: Induction/NN of/IN transcription/NN factors/NNS in/IN human/JJ T/NN lymphocytes/NNS by/IN aspirin-like/JJ drugs/NNS ./. 
AB/LS -/: Aspirin-like/JJ drugs/NNS (/( ALD/NN )/) induce/VBP calcium/NN mobilization/NN ,/, an/DT essential/JJ component/NN of/IN T/NN cell/NN activation/NN ,/, but/CC do/VBP not/RB induce/VB the/DT biosynthesis/NN of/IN IL-2/NN ./. 
To/TO understand/VB the/DT extent/NN to/TO which/WDT ALD/NN may/MD mimic/VB mitogenic/JJ stimulation/NN ,/, we/PRP studied/VBD cytoplasmic/JJ and/CC nuclear/JJ signaling/NN steps/NNS in/IN ALD-treated/JJ T/NN cells/NNS ./. 
We/PRP found/VBD that/IN ALD/NN induce/VBP a/DT transient/JJ activation/NN of/IN protein/NN kinase/NN (/( PKC/NN )/) but/CC have/VBP no/DT effect/NN (/( in/IN comparison/NN to/TO anti-CD3/JJ antibodies/NNS )/) on/IN protein/NN tyrosine/NN phosphorylation/NN nor/CC on/IN PCL/NN gamma/NN 1/CD tyrosine/NN phosphorylation/NN ./. 
ALD-induced/JJ calcium/NN mobilization/NN and/CC PKC/NN activation/NN are/VBP independent/JJ of/IN tyrosine/NN protein/NN kinase/NN activity/NN as/IN shown/VBN by/IN the/DT lack/NN of/IN effect/NN of/IN herbimycin/NN ,/, a/DT tyrosine-protein/JJ kinase-specific/JJ inhibitor/NN ./. 
Although/IN we/PRP detected/VBD no/DT IL-2/NN mRNA/NN in/IN ALD-treated/JJ cells/NNS ,/, the/DT nuclei/NNS of/IN these/DT cells/NNS contain/VBP proteins/NNS capable/JJ of/IN binding/VBG to/TO three/CD regulatory/JJ sequences/NNS in/IN the/DT IL-2/NN promoter/NN region/NN :/: NFAT/NN ,/, NF/NN kappa/NN B/NN ,/, and/CC AP-1/NN ./. 
These/DT binding/NN activities/NNS are/VBP expressed/VBN only/RB in/IN activated/VBN T/NN cells/NNS ./. 
The/DT expression/NN of/IN AP-1/NN depended/VBD on/IN calcium/NN mobilization/NN and/CC PKC/NN activation/NN ./. 
These/DT data/NNS suggest/VBP that/IN ALD/NN cause/VBP transient/JJ but/CC significant/JJ changes/NNS in/IN T/NN cell/NN transmembrane/NN signaling/NN ,/, although/IN some/DT events/NNS induced/VBN by/IN stimulation/NN with/IN anti-CD3/JJ antibodies/NNS are/VBP not/RB induced/VBN by/IN ALD/NN ./. 
The/DT signal/NN is/VBZ transmitted/VBN to/TO the/DT nucleus/NN and/CC induces/VBZ DNA-binding/JJ activity/NN by/IN several/JJ transcription/NN factors/NNS ./. 
However/RB ,/, the/DT ALD/NN stimulus/NN is/VBZ not/RB capable/JJ of/IN causing/VBG complete/JJ T/NN cell/NN activation/NN ./. 
UI/LS -/: 95145550/CD 
TI/LS -/: Protein/NN kinase/NN C/NN is/VBZ not/RB a/DT downstream/JJ effector/NN of/IN p21ras/NN in/IN activated/VBN T/NN cells/NNS ./. 
AB/LS -/: The/DT aim/NN of/IN this/DT present/JJ study/NN was/VBD to/TO investigate/VB the/DT role/NN of/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) ,/, downstream/JJ of/IN p21ras/NN ,/, in/IN activating/VBG interleukin-2/NN (/( IL-2/NN )/) gene/NN expression/NN ./. 
It/PRP has/VBZ been/VBN reported/VBN that/IN PKC/NN is/VBZ an/DT effector/NN of/IN p21ras/NN in/IN T/NN cells/NNS ./. 
Data/NNS is/VBZ presented/VBN ,/, using/VBG the/DT potent/JJ and/CC selective/JJ PKC/NN inhibitor/NN Ro/NN 31-8425/CD and/CC transient/JJ expression/NN of/IN a/DT constitutively/RB active/JJ ras/NN mutant/JJ ,/, which/WDT clearly/RB shows/VBZ that/IN PKC/NN is/VBZ not/RB downstream/JJ of/IN p21ras/NN in/IN the/DT induction/NN of/IN NF-AT/NN and/CC AP-1/NN transcriptional/JJ activity/NN and/CC in/IN the/DT expression/NN of/IN IL-2/NN in/IN human/JJ Jurkat/NN T/NN cells/NNS ./. 
Reporter/NN gene/NN experiments/NNS demonstrated/VBD that/IN NF-kappa/NN B/NN transcriptional/JJ activity/NN is/VBZ not/RB affected/VBN by/IN expression/NN of/IN activated/VBN p21ras/NN ./. 
The/DT signaling/NN pathways/NNS involving/VBG PKC/NN activation/NN ,/, calcium/NN mobilization/NN and/CC ras/NN activation/NN combine/VBP to/TO provide/VB the/DT necessary/JJ components/NNS for/IN production/NN of/IN IL-2/NN during/IN T/NN cell/NN activation/NN ./. 
UI/LS -/: 95110353/CD 
TI/LS -/: The/DT C-terminus/NN of/IN the/DT B/NN cell/NN activator/NN Oct-2/NN functions/VBZ as/IN an/DT activation/NN domain/NN in/IN yeast/NN ./. 
AB/LS -/: Oct-1/NN and/CC Oct-2/NN are/VBP human/JJ transcriptional/JJ activators/NNS that/WDT bind/VBP to/TO the/DT same/JJ DNA/NN element/NN but/CC activate/VBP distinct/JJ sets/NNS of/IN genes/NNS ./. 
We/PRP expressed/VBD these/DT factors/NNS in/IN S. cerevisiae/FW and/CC observed/VBD greater/JJR than/IN 5-fold/JJ stimulation/NN of/IN a/DT lacZ/NN reporter/NN gene/NN only/RB with/IN Oct-2/NN ./. 
Transfer/NN of/IN the/DT Oct-2/NN C-terminal/JJ domain/NN onto/IN either/CC Oct-1/NN (/( Oct1.2/NN )/) or/CC a/DT nonactivating/JJ DNA-binding/JJ domain/NN from/IN GAL4/NN created/VBD activators/NNS capable/JJ of/IN greater/JJR than/IN 15/CD and/CC 10-fold/JJ stimulation/NN of/IN activity/NN ,/, respectively/RB ./. 
Thus/RB ,/, the/DT C-terminus/NN of/IN Oct-2/NN is/VBZ sufficient/JJ to/TO confer/VB activation/NN potential/NN to/TO nonactive/JJ DNA-binding/JJ fragments/NNS in/IN yeast/NN ./. 
UI/LS -/: 95072469/CD 
TI/LS -/: Glucocorticoid-induced/JJ apoptosis/NN of/IN lymphoid/JJ cells/NNS ./. 
AB/LS -/: The/DT induction/NN of/IN cell/NN death/NN in/IN lymphoid/JJ cells/NNS by/IN glucocorticoids/NNS is/VBZ one/CD of/IN the/DT earliest/JJS and/CC most/JJS thoroughly/RB studied/VBN models/NNS of/IN apoptosis/NN ./. 
Although/IN the/DT exact/JJ mechanism/NN by/IN which/WDT apoptosis/NN occurs/VBZ in/IN lymphocytes/NNS is/VBZ unknown/JJ many/JJ biochemical/JJ and/CC molecular/JJ changes/NNS have/VBP been/VBN shown/VBN to/TO occur/VB in/IN these/DT cells/NNS in/IN response/NN to/TO glucocorticoids/NNS ./. 
The/DT role/NN of/IN chromatin/NN degradation/NN and/CC endonucleases/NNS in/IN the/DT apoptotic/JJ process/NN has/VBZ been/VBN closely/RB studied/VBN ,/, as/RB well/RB as/IN the/DT involvement/NN of/IN several/JJ oncogenes/NNS in/IN glucocorticoid-induced/JJ cell/NN lysis/NN ./. 
In/IN addition/NN ,/, the/DT clinical/JJ importance/NN of/IN glucocorticoid-induced/JJ apoptosis/NN in/IN the/DT treatment/NN of/IN lymphoid/JJ neoplasms/NNS has/VBZ recently/RB received/VBN increased/VBN attention/NN ./. 
UI/LS -/: 95104296/CD 
TI/LS -/: Interleukin-2/NN induces/VBZ tyrosine/NN phosphorylation/NN and/CC nuclear/JJ translocation/NN of/IN stat3/NN in/IN human/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: An/DT early/RB biochemical/JJ event/NN associated/VBN with/IN T/NN cell/NN activation/NN through/IN the/DT interleukin-2/NN receptor/NN (/( IL-2R/NN )/) is/VBZ tyrosine/NN phosphorylation/NN of/IN several/JJ intracellular/JJ substrates/NNS ./. 
The/DT exact/JJ mechanism/NN by/IN which/WDT IL-2/NN regulates/VBZ transcription/NN of/IN different/JJ genes/NNS is/VBZ presently/RB unknown/JJ ./. 
Here/RB ,/, we/PRP report/VBP that/IN stimulation/NN through/IN the/DT IL-2R/NN induced/JJ tyrosine/NN phosphorylation/NN and/CC subsequent/JJ nuclear/JJ translocation/NN of/IN stat3/NN ,/, a/DT newly/RB identified/VBN member/NN of/IN the/DT signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STAT/NN )/) family/NN of/IN proteins/NNS ./. 
In/IN contrast/NN ,/, stat1/NN proteins/NNS were/VBD not/RB tyrosine/NN phosphorylated/JJ after/IN IL-2/NN ligation/NN ,/, whereas/IN tyrosine-phosphorylated/JJ stat1/NN proteins/NNS (/( 91/CD and/CC 84/CD kDa/NN proteins/NNS )/) were/VBD translocated/VBN to/TO the/DT nucleus/NN following/NN interferon-gamma/NN treatment/NN of/IN HeLa/NN cells/NNS ./. 
Apart/RB from/IN stat3/NN ,/, another/DT cytoplasmic/JJ protein/NN was/VBD tyrosine/NN phosphorylated/JJ and/CC subsequently/RB translocated/VBN to/TO the/DT nucleus/NN in/IN response/NN to/TO IL-2/NN ./. 
This/DT protein/NN had/VBD an/DT apparent/JJ molecular/JJ mass/NN of/IN 84/CD kDa/NN and/CC was/VBD not/RB recognized/VBN by/IN stat3/NN or/CC stat1/NN mAb/NN or/CC antisera/NNS ./. 
Since/IN IL-2/NN induced/JJ nuclear/JJ translocation/NN of/IN the/DT 84/CD kDa/NN protein/NN and/CC stat3/NN followed/VBD identical/JJ kinetics/NNS ,/, p84/NN is/VBZ a/DT candidate/NN for/IN a/DT new/JJ ,/, yet/RB undefined/JJ ,/, member/NN of/IN the/DT STAT/NN family/NN ./. 
Taken/VBN together/RB ,/, we/PRP report/VBP that/DT IL-2/NN induces/VBZ tyrosine/NN phosphorylation/NN and/CC subsequent/JJ nuclear/JJ translocation/NN of/IN stat3/NN and/CC an/DT as/IN yet/RB undefined/JJ 84-kDa/JJ protein/NN in/IN antigen-specific/JJ human/JJ T/NN cell/NN lines/NNS ./. 
UI/LS -/: 95021266/CD 
TI/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD Tax/NN activation/NN of/IN NF-kappa/NN B/Rel/NN involves/VBZ phosphorylation/NN and/CC degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN and/CC RelA/NN (/( p65/NN )/) -mediated/JJ induction/NN of/IN the/DT c-rel/JJ gene/NN ./. 
AB/LS -/: The/DT tax/NN gene/NN product/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) is/VBZ a/DT potent/JJ transcriptional/JJ activator/NN that/WDT both/CC stimulates/VBZ viral/JJ gene/NN expression/NN and/CC activates/VBZ an/DT array/NN of/IN cellular/JJ genes/NNS involved/VBN in/IN T-cell/NN growth/NN ./. 
Tax/NN acts/VBZ indirectly/RB by/IN inducing/VBG or/CC modifying/VBG the/DT action/NN of/IN various/JJ host/NN transcription/NN factors/NNS ,/, including/VBG members/NNS of/IN the/DT NF-kappa/NN B/Rel/NN family/NN of/IN enhancer-binding/JJ proteins/NNS ./. 
In/IN resting/VBG T/NN cells/NNS ,/, many/JJ of/IN these/DT NF-kappa/NN B/Rel/NN factors/NNS are/VBP sequestered/VBN in/IN the/DT cytoplasm/NN by/IN various/JJ ankyrin-rich/JJ inhibitory/JJ proteins/NNS ,/, including/VBG I/NN kappa/NN B/NN alpha/NN ./. 
HTLV-I/NN Tax/NN expression/NN leads/VBZ to/TO the/DT constitutive/JJ nuclear/JJ expression/NN of/IN biologically/RB active/JJ NF-kappa/NN B/NN and/CC c-Rel/NN complexes/NNS ;/: however/RB ,/, the/DT biochemical/JJ mechanism/NN (/( s/NNS )/) underlying/VBG this/DT response/NN remains/VBZ poorly/RB understood/VBN ./. 
In/IN this/DT study/NN ,/, we/PRP demonstrate/VBP that/IN Tax-stimulated/JJ nuclear/JJ expression/NN of/IN NF-kappa/NN B/NN in/IN both/CC HTLV-I-infected/JJ and/CC Tax-transfected/JJ human/JJ T/NN cells/NNS is/VBZ associated/VBN with/IN the/DT phosphorylation/NN and/CC rapid/JJ proteolytic/JJ degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN ./. 
In/IN contrast/NN to/TO prior/JJ in/FW vitro/FW studies/NNS ,/, at/IN least/JJS a/DT fraction/NN of/IN the/DT phosphorylated/JJ form/NN of/IN I/NN kappa/NN B/NN alpha/NN remains/VBZ physically/RB associated/VBN with/IN the/DT NF-kappa/NN B/NN complex/NN in/FW vivo/FW but/CC is/VBZ subject/JJ to/TO rapid/JJ degradation/NN ,/, thereby/RB promoting/VBG the/DT nuclear/JJ translocation/NN of/IN the/DT active/JJ NF-kappa/NN B/NN complex/NN ./. 
We/PRP further/RB demonstrate/VBP that/IN Tax/NN induction/NN of/IN nuclear/JJ c-Rel/NN expression/NN is/VBZ activated/VBN by/IN the/DT RelA/NN (/( p65/NN )/) subunit/NN of/IN NF-kappa/NN B/NN ,/, which/WDT activates/VBZ transcription/NN of/IN the/DT c-rel/JJ gene/NN through/IN an/DT intrinsic/JJ kappa/NN B/NN enhancer/NN element/NN ./. 
In/IN normal/JJ cells/NNS ,/, the/DT subsequent/JJ accumulation/NN of/IN nuclear/JJ c-Rel/NN acts/VBZ to/TO inhibit/VB its/PRP$ own/JJ continued/JJ production/NN ,/, indicating/VBG the/DT presence/NN of/IN an/DT autoregulatory/JJ loop/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 95009960/CD 
TI/LS -/: Activation/NN of/IN NF-kappa/NN B/NN in/FW vivo/FW is/VBZ regulated/VBN by/IN multiple/JJ phosphorylations/NNS ./. 
AB/LS -/: The/DT activation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) in/IN intact/JJ cells/NNS is/VBZ mechanistically/RB not/RB well/RB understood/JJ ./. 
Therefore/RB we/PRP investigated/VBD the/DT modifications/NNS imposed/VBN on/IN NF-kappa/NN B/I/NN kappa/NN B/NN components/NNS following/VBG stimulation/NN and/CC show/VBP that/IN the/DT final/JJ step/NN of/IN NF-kappa/NN B/NN induction/NN in/FW vivo/FW involves/VBZ phosphorylation/NN of/IN several/JJ members/NNS of/IN the/DT NF-kappa/NN B/I/NN kappa/NN B/NN protein/NN families/NNS ./. 
In/IN HeLa/NN cells/NNS as/RB well/RB as/IN in/IN B/NN cells/NNS ,/, TNF-alpha/NN rapidly/RB induced/VBD nuclear/JJ translocation/NN primarily/RB of/IN p50-p65/NN ,/, but/CC not/RB of/IN c-rel/NN ./. 
Both/CC NF-kappa/NN B/NN precursors/NNS and/CC I/NN kappa/NN B/NN alpha/NN became/VBD strongly/RB phosphorylated/VBN with/IN the/DT same/JJ kinetics/NNS ./. 
In/IN addition/NN to/TO the/DT inducible/JJ phosphorylation/NN after/IN stimulation/NN ,/, B/NN lymphocytes/NNS containing/VBG constitutive/JJ nuclear/JJ NF-kappa/NN B/NN revealed/VBD constitutively/RB phosphorylated/VBN p65/NN and/CC I/NN kappa/NN B/NN alpha/NN ./. 
Phosphorylation/NN was/VBD accompanied/VBN by/IN induced/VBN processing/NN of/IN the/DT precursors/NNS p100/NN and/CC p105/NN and/CC by/IN degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN ./. 
As/IN an/DT in/FW vitro/FW model/NN we/PRP show/VBP that/IN phosphorylation/NN of/IN p105/NN impedes/VBZ its/PRP$ ability/NN to/TO interact/VB with/IN NF-kappa/NN B/NN ,/, as/IN has/VBZ been/VBN shown/VBN before/IN for/IN I/NN kappa/NN B/NN alpha/NN ./. 
Surprisingly/RB ,/, even/RB p65/NN ,/, but/CC not/RB c-rel/NN ,/, was/VBD phosphorylated/VBN after/IN induction/NN in/FW vivo/FW ,/, suggesting/VBG that/IN TNF-alpha/NN selectively/RB activates/VBZ only/RB specific/JJ NF-kappa/NN B/NN heteromers/NNS and/CC that/IN modifications/NNS regulate/VBP not/RB only/JJ I/NN kappa/NN B/NN molecules/NNS but/CC also/RB NF-kappa/NN B/NN molecules/NNS ./. 
In/IN fact/NN ,/, cellular/JJ NF-kappa/NN B/NN activity/NN was/VBD phosphorylation-dependent/JJ and/CC the/DT DNA/NN binding/NN activity/NN of/IN p65-containing/JJ NF-kappa/NN B/NN was/VBD enhanced/VBN by/IN phosphorylation/NN in/FW vitro/FW ./. 
Furthermore/RB ,/, we/PRP found/VBD that/IN the/DT induction/NN by/IN hydrogen/NN peroxide/NN of/IN NF-kappa/NN B/NN translocation/NN to/TO the/DT nucleus/NN ,/, which/WDT is/VBZ assumed/VBN to/TO be/VB triggered/VBN by/IN reactive/JJ oxygen/NN intermediates/NNS ,/, also/RB coincided/VBD with/IN incorporation/NN of/IN phosphate/NN into/IN the/DT same/JJ subunits/NNS that/WDT were/VBD modified/VBN after/IN stimulation/NN by/IN TNF-alpha/NN ./. 
Thus/RB ,/, phosphorylation/NN appears/VBZ to/TO be/VB a/DT general/JJ mechanism/NN for/IN activation/NN of/IN NF-kappa/NN B/NN in/FW vivo/FW ./. 
UI/LS -/: 95191179/CD 
TI/LS -/: Treatment/NN of/IN HL60/NN cells/NNS with/IN various/JJ combinations/NNS of/IN retinoids/NNS and/CC 1/CD alpha/NN ,/, 25/CD dihydroxyvitamin/NN D3/NN results/VBZ in/IN differentiation/NN towards/IN neutrophils/NNS or/CC monocytes/NNS or/CC a/DT failure/NN to/TO differentiate/VB and/CC apoptosis/NN ./. 
AB/LS -/: It/PRP is/VBZ well/RB documented/VBN that/IN treatment/NN of/IN serum-grown/JJ HL60/NN cells/NNS with/IN 10(-7)/CD M/NN all-trans/JJ retinoic/JJ acid/NN (/( all-trans/JJ RA/NN )/) induces/VBZ neutrophil/NN differentiation/NN ,/, whereas/IN treatment/NN with/IN 10(-7)/CD M/NN 1/CD alpha/NN ,/, 25/CD dihydroxyvitamin/NN D3/NN (/( D3/NN )/) induces/VBZ differentiation/NN towards/IN monocytes/NNS ./. 
In/IN recent/JJ investigations/NNS ,/, using/VBG serum-free/JJ grown/JJ HL60/NN cells/NNS ,/, we/PRP observed/VBD that/IN all-trans/JJ RA/NN ,/, at/IN 10(-7)/CD M/NN ,/, did/VBD not/RB induce/VB neutrophil/NN differentiation/NN and/CC that/IN all-trans/JJ RA/NN ,/, at/IN 10(-8)/CD M/NN ,/, reduced/VBD the/DT D3/NN concentration/NN required/VBN for/IN monocyte/NN differentiation/NN to/TO 5/CD x/NN 10(-9)/CD M/NN ./. 
In/IN this/DT study/NN ,/, co-operative/JJ interactions/NNS between/IN all-trans/JJ and/CC 9-cis/JJ RA/NN and/CC D3/NN which/WDT promote/VBP neutrophil/NN and/CC monocyte/NN differentiation/NN of/IN HL60/NN cells/NNS have/VBP been/VBN analysed/VBN in/IN detail/NN ./. 
Treatment/NN of/IN serum-free/JJ grown/JJ HL60/NN cells/NNS with/IN 5/CD x/NN 10(-7)/CD M/NN all-trans/JJ RA/NN or/CC 9-cis/JJ RA/NN resulted/VBD in/IN sub-optimal/JJ neutrophil/NN differentiation/NN (/( up/RB to/TO 25/CD %/NN mature/JJ cells/NNS )/) ./. 
As/IN shown/VBN for/IN all-trans/JJ RA/NN ,/, 9-cis/JJ RA/NN cooperated/VBD with/IN D3/NN to/TO promote/VB monocyte/NN differentiation/NN ./. 
Culture/NN of/IN HL60/NN cells/NNS in/IN 5/CD x/NN 10(-7)/CD M/NN 9-cis/JJ RA/NN together/RB with/IN a/DT wide/JJ range/NN of/IN concentrations/NNS of/IN D3/NN resulted/VBD in/IN promotion/NN of/IN neutrophil/NN differentiation/NN at/IN 10(-15)-10(-12)/CD D3/NN ,/, a/DT failure/NN to/TO differentiate/VB and/CC apoptosis/NN at/IN 10(-11)-10(-10)/CD M/NN D3/NN ,/, followed/VBN by/IN co-operativity/NN between/IN 9-cis/JJ RA/NN and/CC 5/CD x/NN 10(-9)/CD M/NN D3/NN in/IN inducing/VBG monocyte/NN differentiation/NN in/IN the/DT absence/NN of/IN neutrophil/NN differentiation/NN ./. 
Similar/JJ results/NNS were/VBD obtained/VBN when/WRB HL60/NN cells/NNS were/VBD treated/VBN with/IN 5/CD x/NN 10(-7)/CD all-trans/JJ RA/NN together/RB with/IN a/DT wide/JJ range/NN of/IN concentrations/NNS of/IN D3/NN ./. 
Cross/NN titration/NN analyses/NNS of/IN the/DT effects/NNS of/IN 9-cis/JJ RA/NN and/CC D3/NN on/IN HL60/NN cell/NN differentiation/NN were/VBD undertaken/VBN to/TO determine/VB the/DT boundaries/NNS of/IN the/DT concentrations/NNS of/IN each/DT agent/NN ,/, alone/RB and/CC in/IN combination/NN ,/, that/WDT give/VBP rise/NN to/TO optimal/JJ neutrophil/NN and/CC monocyte/NN differentiation/NN of/IN HL60/NN cells/NNS ./. 
The/DT observed/VBN cooperativities/NNS between/IN either/CC 9-cis/JJ RA/NN or/CC all-trans/JJ RA/NN and/CC D3/NN have/VBP important/JJ implications/NNS for/IN the/DT use/NN of/IN combinations/NNS of/IN these/DT agents/NNS in/IN differentiation/NN therapy/NN ./. 
UI/LS -/: 95278601/CD 
TI/LS -/: Isolation/NN of/IN differentially/RB expressed/VBN sequence/NN tags/NNS from/IN steroid-responsive/JJ cells/NNS using/VBG mRNA/NN differential/JJ display/NN ./. 
AB/LS -/: Transcriptional/JJ control/NN of/IN steroid-regulated/JJ gene/NN networks/NNS by/IN nuclear/JJ receptor/NN proteins/NNS results/VBZ in/IN the/DT coordinate/NN expression/NN of/IN a/DT limited/JJ number/NN of/IN target/NN genes/NNS ./. 
Although/IN much/JJ is/VBZ known/VBN about/IN the/DT structure/NN and/CC function/NN of/IN steroid/NN receptors/NNS ,/, relatively/RB few/JJ cell-specific/JJ steroid-regulated/JJ genes/NNS have/VBP been/VBN isolated/VBN and/CC characterized/VBN ./. 
In/IN this/DT paper/NN we/PRP describe/VBP results/NNS using/VBG mRNA/NN differential/JJ display/NN reverse/JJ transcriptase/NN PCR/NN (/( DDPCR/NN )/) to/TO identify/VB and/CC isolate/VB short/JJ cDNA/NN sequence/NN tags/NNS from/IN thymocyte/NN and/CC prostate/NN cells/NNS under/IN various/JJ hormone/NN conditions/NNS ./. 
Using/VBG this/DT technique/NN we/PRP have/VBP isolated/VBN several/JJ differentially/RB expressed/VBN sequence/NN tags/NNS (/( DESTs/NNS )/) from/IN the/DT mouse/NN thymocyte/NN cell/NN line/NN WEHI/IN 7.2/CD ./. 
Two/CD of/IN these/DT DESTs/NNS ,/, GIG10/NN and/CC GIG18/NN ,/, are/VBP rapidly/RB induced/VBN by/IN dexamethasone/NN within/IN 2/CD h/NN of/IN treatment/NN ./. 
GIG10/NN is/VBZ a/DT novel/JJ sequence/NN and/CC GIG18/NN is/VBZ the/DT mouse/NN homologue/NN of/IN a/DT human/JJ expressed/VBN sequence/NN tag/NN isolated/VBN from/IN activated/VBN B/NN lymphocytes/NNS ./. 
We/PRP also/RB used/VBD DDPCR/NN to/TO isolate/VB DESTs/NNS from/IN androgen-modulated/JJ rat/NN ventral/JJ prostate/NN tissue/NN ,/, one/CD of/IN which/WDT we/PRP characterized/VBD and/CC found/VBD to/TO correspond/VB to/TO the/DT 3'/JJ end/NN of/IN prostatic/JJ spermine/NN binding/NN protein/NN mRNA/NN ,/, a/DT known/JJ androgen-regulated/JJ gene/NN ./. 
Modifications/NNS of/IN the/DT original/JJ DDPCR/NN protocol/NN ,/, which/WDT we/PRP found/VBD can/MD potentially/RB decrease/VB the/DT frequency/NN of/IN isolating/VBG false-positive/JJ DESTs/NNS ,/, are/VBP described/VBN and/CC the/DT merits/NNS of/IN DDPCR/NN ,/, relative/JJ to/TO other/JJ differential/JJ cDNA/NN cloning/NN strategies/NNS ,/, are/VBP discussed/VBN ./. 
UI/LS -/: 95123097/CD 
TI/LS -/: Activation/NN of/IN human/JJ thymocytes/NNS after/IN infection/NN by/IN EBV/NN ./. 
AB/LS -/: The/DT discovery/NN of/IN EBV/NN in/IN certain/JJ T/NN cell/NN malignancies/NNS and/CC the/DT expression/NN of/IN the/DT EBV/NN receptor/NN ,/, CR2/CD21/NN ,/, on/IN a/DT population/NN of/IN immature/JJ thymocytes/NNS ,/, T/NN lymphoblastoid/JJ cell/NN lines/NNS ,/, and/CC childhood/NN acute/JJ T/NN lymphoblastic/JJ leukemia/NN cells/NNS suggested/VBD that/IN EBV-receptor/NN interactions/NNS on/IN T/NN cells/NNS may/MD be/VB of/IN importance/NN ./. 
We/PRP have/VBP shown/VBN that/IN ,/, within/IN the/DT thymus/NN ,/, a/DT population/NN of/IN large/JJ ,/, immature/JJ cells/NNS expresses/VBZ CD21/NN ./. 
EBV/NN altered/VBD the/DT activation/NN responses/NNS of/IN immature/JJ thymocytes/NNS in/FW vitro/FW ./. 
Triggering/VBG through/IN CD2/NN is/VBZ mitogenic/JJ for/IN mature/JJ ,/, but/CC not/RB immature/JJ ,/, T/NN cells/NNS ./. 
However/RB ,/, during/IN infection/NN by/IN EBV/NN ,/, ligation/NN of/IN CD2/NN caused/VBD thymocytes/NNS to/TO proliferate/VB in/IN the/DT absence/NN of/IN exogenous/JJ cytokines/NNS ./. 
This/DT function/NN was/VBD a/DT result/NN of/IN the/DT interaction/NN of/IN EBV/NN with/IN its/PRP$ receptor/NN ,/, CD21/NN ,/, but/CC was/VBD caused/VBN by/IN infection/NN rather/RB than/IN surface/NN signaling/NN ,/, because/IN neither/CC specific/JJ mAb/NN nor/CC the/DT P3HR-1/NN strain/NN of/IN virus/NN mimicked/VBD the/DT effect/NN of/IN B95-8/NN ./. 
Immature/JJ thymocytes/NNS were/VBD infected/VBN by/IN EBV/NN ,/, as/IN determined/VBN by/IN the/DT internalization/NN of/IN the/DT viral/JJ genome/NN and/CC its/PRP$ transcriptional/JJ activity/NN ./. 
Consistent/JJ with/IN the/DT activity/NN of/IN B95-8/NN ,/, EBNA-2/NN transcripts/NNS were/VBD identified/VBN within/IN infected/JJ thymocyte/NN populations/NNS ./. 
In/IN addition/NN ,/, components/NNS of/IN the/DT viral/JJ replicative/NN pathway/NN were/VBD expressed/VBN during/IN infection/NN of/IN thymocytes/NNS ./. 
These/DT components/NNS included/VBD transcription/NN of/IN BZLF-1/NN ,/, an/DT early/JJ gene/NN that/WDT characterizes/VBZ EBV-infected/JJ B/NN cells/NNS after/IN disruption/NN of/IN latency/NN ./. 
A/DT second/JJ transcript/NN was/VBD identified/VBN as/IN encoding/VBG the/DT recently/RB characterized/VBD RAZ/NN ,/, which/WDT also/RB is/VBZ associated/VBN with/IN replicative/JJ infection/NN ./. 
The/DT consequences/NNS of/IN EBV/NN infection/NN of/IN T/NN cells/NNS at/IN an/DT early/JJ stage/NN of/IN differentiation/NN may/MD lead/VB to/TO failure/NN of/IN normal/JJ T/NN cell/NN repertoire/NN development/NN ,/, autoimmunity/NN ,/, or/CC malignancy/NN ./. 
UI/LS -/: 95222176/CD 
TI/LS -/: Effects/NNS of/IN intranasal/JJ glucocorticoids/NNS on/IN endogenous/JJ glucocorticoid/NN peripheral/JJ and/CC central/JJ function/NN ./. 
AB/LS -/: Glucocorticoids/NNS are/VBP among/IN the/DT most/RBS potent/JJ antiinflammatory/JJ agents/NNS that/WDT can/MD be/VB used/VBN in/IN the/DT treatment/NN of/IN rhinitis/NN ./. 
Their/PRP$ mechanisms/NNS of/IN action/NN are/VBP multiple/JJ and/CC complex/JJ and/CC a/DT number/NN of/IN reports/NNS describe/VBP significant/JJ systemic/JJ effects/NNS of/IN locally/RB administered/VBN glucocorticoids/NNS ./. 
In/IN order/NN to/TO evaluate/VB the/DT short-term/JJ systemic/JJ effects/NNS of/IN intranasally/RB administered/VBN glucocorticoids/NNS ,/, 14/CD normal/JJ healthy/JJ subjects/NNS were/VBD treated/VBN with/IN two/CD doses/NNS of/IN either/CC budesonide/NN (/( BUD/NN )/) or/CC fluticasone/NN propionate/NN (/( FP/NN )/) for/IN 2/CD weeks/NNS ./. 
Before/IN treatment/NN ,/, at/IN regular/JJ intervals/NNS during/IN the/DT treatment/NN ,/, 1/CD week/NN and/CC finally/RB 6/CD weeks/NNS after/IN termination/NN of/IN treatment/NN ,/, the/DT effects/NNS on/IN glucocorticoid/NN receptor/NN (/( GR/NN )/) and/CC methallothionein/NN (/( MTIIa/NN )/) mRNA/NN expression/NN levels/NNS were/VBD examined/VBN in/IN peripheral/JJ lymphocytes/NNS using/VBG a/DT solution/NN hybridization/NN assay/NN ./. 
Serum/NN cortisol/NN ,/, osteocalcin/NN and/CC urinary/JJ cortisol/NN levels/NNS were/VBD also/RB determined/VBN ./. 
An/DT insulin/NN tolerance/NN test/NN (/( ITT/NN )/) was/VBD performed/VBN at/IN the/DT end/NN of/IN the/DT second/JJ week/NN of/IN treatment/NN and/CC at/IN the/DT end/NN of/IN the/DT 6-week/JJ washout/NN period/NN with/IN no/DT statistically/RB significant/JJ change/NN in/IN cortisol/NN response/NN ./. 
In/IN peripheral/JJ lymphocytes/NNS ,/, GR/NN mRNA/NN levels/NNS were/VBD significantly/RB down-regulated/VBN ./. 
MTIIa/NN mRNA/NN levels/NNS increased/VBD significantly/RB ./. 
Serum/NN osteocalcin/NN decreased/VBD significantly/RB during/IN treatment/NN with/IN both/CC BUD/NN and/CC FP/NN ./. 
Serum/NN cortisol/NN decreased/VBD after/IN 1/CD week/NN of/IN treatment/NN whereas/IN urinary/JJ cortisol/NN was/VBD not/RB affected/VBN until/IN the/DT second/JJ week/NN of/IN treatment/NN ./. 
In/IN conclusion/NN ,/, intranasal/JJ glucocorticoids/NNS at/IN clinically/RB recommended/VBN doses/NNS have/VBP not/RB only/RB significant/JJ systemic/JJ effects/NNS on/IN adrenal/JJ function/NN ,/, but/CC also/RB have/VBP an/DT effect/NN on/IN specific/JJ gene/NN expression/NN in/IN peripheral/JJ lymphocytes/NNS ./. 
These/DT effects/NNS are/VBP receptor-dependent/JJ ,/, reversible/JJ ,/, and/CC according/VBG to/TO serum/NN and/CC urinary/JJ cortisol/NN levels/NNS and/CC ITT/NN ,/, leave/VBP the/DT hypothalamic-pituitary-adrenal/JJ function/NN intact/JJ ./. 
Finally/RB ,/, these/DT short-term/JJ systemic/JJ effects/NNS were/VBD not/RB associated/VBN with/IN any/DT of/IN the/DT noticeable/JJ side-effects/NNS usually/RB observed/VBN during/IN long-term/JJ treatment/NN with/IN glucocorticoids/NNS ./. 
UI/LS -/: 95145523/CD 
TI/LS -/: Biphasic/JJ control/NN of/IN nuclear/JJ factor-kappa/NN B/NN activation/NN by/IN the/DT T/NN cell/NN receptor/NN complex/NN :/: role/NN of/IN tumor/NN necrosis/NN factor/NN alpha/NN ./. 
AB/LS -/: The/DT regulation/NN of/IN nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN activation/NN by/IN the/DT T/NN cell/NN receptor/NN (/( TcR/NN )/) /CD3/NN complex/NN in/IN primary/JJ human/JJ T/NN cells/NNS has/VBZ been/VBN studied/VBN at/IN various/JJ times/NNS after/IN activation/NN ./. 
Only/RB p50/NN NF-kappa/NN B/NN protein/NN bound/VBD the/DT kappa/NN B/NN element/NN of/IN interleukin-2/NN receptor/NN (/( IL-2R/NN )/) alpha/NN chain/NN promoter/NN on/IN resting/VBG T/NN cells/NNS ./. 
However/RB ,/, immediately/RB after/IN TcR/CD3/NN cross-linking/JJ (/( after/IN approximately/RB 1/CD h/NN ;/: immediate/JJ )/) binding/NN of/IN p50.p65/NN heterodimers/NNS was/VBD observed/VBN ./. 
p50.c-rel/NN heterodimers/NNS were/VBD also/RB detected/VBN bound/VBN to/TO this/DT sequence/NN at/IN early/JJ time/NN points/NNS (/( 7-16/CD h/NN ;/: early/RB )/) ,/, and/CC both/DT remained/VBD active/JJ at/IN later/JJR time/NN points/NNS (/( 40/CD h/NN ;/: late/RB )/) after/IN activation/NN ./. 
This/DT regulation/NN takes/VBZ place/NN mainly/RB at/IN the/DT level/NN of/IN nuclear/JJ translocation/NN of/IN p65/NN and/CC c-rel/NN ,/, at/IN immediate/JJ and/CC early/JJ time/NN points/NNS ./. 
Activation/NN also/RB induced/VBD c-rel/NN and/CC p105/p50/NN mRNA/NN synthesis/NN ,/, but/CC not/RB p65/NN mRNA/NN whose/WP$ expression/NN was/VBD constitutive/JJ ./. 
Interestingly/RB ,/, all/PDT those/DT early/JJ and/CC late/JJ events/NNS ,/, but/CC not/RB the/DT immediate/JJ ones/NNS ,/, were/VBD inhibited/VBN by/IN a/DT neutralizing/VBG anti-tumor/JJ necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) monoclonal/JJ antibody/NN ./. 
Similarly/RB ,/, cycloheximide/NN prevented/VBD the/DT p65/NN and/CC c-rel/NN translocation/NN and/CC consequent/JJ formation/NN of/IN active/JJ binding/NN heterodimers/NNS ,/, at/IN early/JJ and/CC late/JJ times/NNS ./. 
Cyclosporin/NN A/NN impaired/VBD not/RB only/RB early/JJ and/CC late/JJ ,/, but/CC also/RB immediate/JJ events/NNS ;/: however/RB ,/, addition/NN of/IN TNF-alpha/NN prevented/VBD all/DT inhibition/NN ./. 
These/DT results/NNS indicate/VBP that/IN the/DT regulation/NN of/IN NF-kappa/NN B/NN activation/NN during/IN T/NN cell/NN activation/NN by/IN TcR/CD3/NN signals/NNS is/VBZ biphasic/JJ :/: TcR/CD3/NN triggers/VBZ its/PRP$ immediate/JJ translocation/NN ,/, which/WDT is/VBZ transient/JJ if/IN no/DT TNF-alpha/NN is/VBZ present/JJ ./. 
TNF-alpha/NN ,/, therefore/RB ,/, emerges/VBZ as/IN the/DT main/JJ factor/NN responsible/JJ for/IN a/DT second/JJ phase/NN of/IN NF-kappa/NN B/NN regulation/NN ,/, controlling/VBG both/CC translocation/NN of/IN p65/NN and/CC c-rel/NN ,/, and/CC new/JJ mRNA/NN synthesis/NN for/IN c-rel/NN and/CC p105/p50/NN ./. 
UI/LS -/: 95110287/CD 
TI/LS -/: The/DT transcription/NN factor/NN Sp1/NN is/VBZ required/VBN for/IN induction/NN of/IN the/DT murine/JJ GM-CSF/NN promoter/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: The/DT cis-acting/JJ region/NN ,/, GM-kappa/NN B/GC-box/NN (/( positions/NNS -95/CD and/CC -73/CD )/) ,/, within/IN the/DT murine/NN GM-CSF/NN gene/NN promoter/NN is/VBZ required/VBN for/IN maximal/JJ induction/NN by/IN stimulation/NN with/IN phorbol-12-myristate/NN acetate/NN (/( PMA/NN )/) and/CC calcium/NN ionophore/NN (/( A23187/NN )/) in/IN T/NN cells/NNS ./. 
GM-kappa/NN B/NN defines/VBZ a/DT binding/VBG site/NN for/IN NF-kappa/NN B/NN ,/, and/CC GC-box/NN defines/VBZ a/DT binding/VBG site/NN for/IN three/CD (/( A1/NN ,/, A2/NN ,/, B/NN )/) constitutive/JJ proteins/NNS ./. 
We/PRP report/VBP here/RB that/IN three/CD copies/NNS of/IN the/DT GC-box/NN can/MD functionally/RB compensate/VB for/IN the/DT GM-kappa/NN B/GC-box/NN region/NN ,/, suggesting/VBG that/IN the/DT GC-motif/NN can/MD function/VB independently/RB of/IN the/DT GM-kappa/NN B/NN motif/NN ./. 
The/DT major/JJ GC-box/NN binding/NN activity/NN A1/NN was/VBD purified/VBN and/CC identified/VBN as/IN the/DT transcription/NN factor/NN Sp1/NN ./. 
We/PRP show/VBP that/IN depletion/NN of/IN Sp1/NN (/( A1/NN )/) from/IN nuclear/JJ extracts/NNS specifically/RB decreases/VBZ in/FW vitro/FW transcription/NN activity/NN on/IN GM-CSF/NN templates/NNS ./. 
Since/IN the/DT human/JJ GM-CSF/NN promoter/NN has/VBZ a/DT base/NN difference/NN within/IN the/DT GC-box/NN ,/, we/PRP speculate/VBP that/IN this/DT may/MD explain/VB why/WRB the/DT human/JJ promoter/NN is/VBZ weak/JJ and/CC that/IN an/DT upstream/JJ enhancer/NN is/VBZ required/VBN for/IN the/DT induction/NN of/IN the/DT human/JJ GM-CSF/NN gene/NN ./. 
UI/LS -/: 95059073/CD 
TI/LS -/: A/DT factor/NN that/WDT regulates/VBZ the/DT class/NN II/CD major/JJ histocompatibility/NN complex/NN gene/NN DPA/NN is/VBZ a/DT member/NN of/IN a/DT subfamily/NN of/IN zinc/NN finger/NN proteins/NNS that/WDT includes/VBZ a/DT Drosophila/FW developmental/JJ control/NN protein/NN ./. 
AB/LS -/: A/DT novel/JJ DNA/NN sequence/NN element/NN termed/VBN the/DT J/NN element/NN involved/VBN in/IN the/DT regulated/VBN expression/NN of/IN class/NN II/CD major/JJ histocompatibility/NN complex/NN genes/NNS was/VBD recently/RB described/VBN ./. 
To/TO study/VB this/DT element/NN and/CC its/PRP$ role/NN in/IN class/NN II/CD gene/NN regulation/NN further/RB ,/, a/DT cDNA/NN library/NN was/VBD screened/VBN with/IN oligonucleotide/NN probes/NNS containing/VBG both/CC the/DT S/NN element/NN and/CC the/DT nearby/JJ J/NN element/NN of/IN the/DT human/JJ DPA/NN gene/NN ./. 
Several/JJ DNA/NN clones/NNS were/VBD obtained/VBN by/IN this/DT procedure/NN ,/, one/CD of/IN which/WDT ,/, clone/NN 18/CD ,/, is/VBZ reported/VBN and/CC characterized/VBN here/RB ./. 
It/PRP encodes/VBZ a/DT protein/NN predicted/VBN to/TO contain/VB 688/CD amino/NN acid/NN residues/NNS ,/, including/VBG 11/CD zinc/NN finger/NN motifs/NNS of/IN the/DT C2H2/NN type/NN in/IN the/DT C-terminal/JJ region/NN ,/, that/WDT are/VBP Kruppel-like/JJ in/IN the/DT conservation/NN of/IN the/DT H/C/NN link/NN sequence/NN connecting/VBG them/PRP ./. 
The/DT 160/CD N-terminal/JJ amino/NN acids/NNS in/IN the/DT nonfinger/JJ region/NN of/IN clone/NN 18/CD are/VBP highly/RB homologous/JJ with/IN similar/JJ regions/NNS of/IN several/JJ other/JJ human/JJ ,/, mouse/NN ,/, and/CC Drosophila/FW sequences/NNS ,/, defining/VBG a/DT subfamily/NN of/IN Kruppel-like/JJ zinc/NN finger/NN proteins/NNS termed/VBN TAB/NN (/( tramtrack/NN [/( ttk/NN ]/) -associated/JJ box/NN )/) here/RB ./. 
One/CD of/IN the/DT Drosophila/FW sequences/NNS ,/, ttk/NN ,/, is/VBZ a/DT developmental/JJ control/NN gene/NN ,/, while/IN a/DT second/JJ does/VBZ not/RB contain/VB a/DT zinc/NN finger/NN region/NN but/CC encodes/VBZ a/DT structure/NN important/JJ in/IN oocyte/NN development/NN ./. 
An/DT acidic/JJ activation/NN domain/NN is/VBZ located/JJ between/IN the/DT N-terminal/JJ conserved/JJ region/NN of/IN clone/NN 18/CD and/CC its/PRP$ zinc/NN fingers/NNS ./. 
This/DT protein/NN appears/VBZ to/TO require/VB both/CC the/DT S/NN and/CC J/NN elements/NNS ,/, which/WDT are/VBP separated/VBN by/IN 10/CD bp/NN for/IN optimal/JJ binding/NN ./. 
Antisense/JJ cDNA/NN to/TO clone/NN 18/CD inhibited/VBD the/DT expression/NN of/IN a/DT reporter/NN construct/NN containing/VBG the/DT DPA/NN promoter/NN ,/, indicating/VBG its/PRP$ functional/JJ importance/NN in/IN the/DT expression/NN of/IN this/DT class/NN II/CD gene/NN ./. 
UI/LS -/: 95062301/CD 
TI/LS -/: Separation/NN of/IN oxidant-initiated/JJ and/CC redox-regulated/JJ steps/NNS in/IN the/DT NF-kappa/NN B/NN signal/NN transduction/NN pathway/NN ./. 
AB/LS -/: Studies/NNS presented/VBN here/RB show/VBP that/IN overall/JJ NF-kappa/NN B/NN signal/NN transduction/NN begins/VBZ with/IN a/DT parallel/JJ series/NN of/IN stimuli-specific/JJ pathways/NNS through/IN which/WDT cytokines/NNS (/( tumor/NN necrosis/NN factor/NN alpha/NN )/) ,/, oxidants/NNS (/( hydrogen/NN peroxide/NN and/CC mitomycin/NN C/NN )/) ,/, and/CC phorbol/NN ester/NN (/( phorbol/NN 12-myristate/NN 13-acetate/NN )/) individually/RB initiate/VBP signaling/NN ./. 
These/DT initial/JJ pathways/NNS culminate/VBP in/IN a/DT common/JJ pathway/NN through/IN which/WDT all/DT of/IN the/DT stimulating/VBG agents/NNS ultimately/RB signal/VBP NF-kappa/NN B/NN activation/NN ./. 
We/PRP distinguish/VBP the/DT stimuli-specific/JJ pathways/NNS by/IN showing/VBG that/IN the/DT oxidative/JJ stimuli/NNS trigger/VBP NF-kappa/NN B/NN activation/NN in/IN only/RB one/CD of/IN two/CD human/JJ T-cell/NN lines/NNS (/( Wurzburg/NN but/CC not/RB Jurkat/NN )/) ,/, whereas/IN tumor/NN necrosis/NN factor/NN alpha/NN and/CC phorbol/NN 12-myristate/NN 13-acetate/NN readily/RB stimulate/VBP in/IN both/DT lines/NNS ./. 
We/PRP propose/VBP the/DT common/JJ pathway/NN as/IN the/DT simplest/JJS way/NN of/IN accounting/NN for/IN the/DT common/JJ requirements/NNS and/CC properties/NNS of/IN the/DT signaling/NN pathway/NN ./. 
We/PRP include/VBP a/DT redox-regulatory/JJ mechanism/NN (/( s/NNS )/) in/IN this/DT common/JJ pathway/NN to/TO account/VB for/IN the/DT previously/RB demonstrated/VBN redox/NN regulation/NN of/IN NF-kappa/NN B/NN activation/NN in/IN Jurkat/NN cells/NNS (/( in/IN which/WDT oxidants/NNS do/VBP n't/RB activate/VB NF-kappa/NN B/NN )/) ;/: we/PRP put/VBP tyrosine/NN phosphorylation/NN in/IN the/DT common/JJ pathway/NN by/IN showing/VBG that/IN kinase/NN activity/NN (/( inhibitable/JJ by/IN herbimycin/NN A/NN and/CC tyrphostin/NN 47/CD )/) is/VBZ required/VBN for/IN NF-kappa/NN B/NN activation/NN by/IN all/DT stimuli/NNS tested/VBN in/IN both/DT cell/NN lines/NNS ./. 
Since/IN internal/JJ sites/NNS of/IN oxidant/NN production/NN have/VBP been/VBN shown/VBN to/TO play/VB a/DT key/JJ role/NN in/IN the/DT cytokine-stimulated/JJ activation/NN of/IN NF-kappa/NN B/NN ,/, and/CC since/IN tyrosine/NN kinase/NN and/CC phosphatase/NN activities/NNS are/VBP known/VBN to/TO be/VB altered/VBN by/IN oxidants/NNS ,/, these/DT findings/NNS suggest/VBP that/IN intracellular/JJ redox/NN status/NN controls/VBZ NF-kappa/NN B/NN activation/NN by/IN regulating/VBG tyrosine/NN phosphorylation/NN event/NN (/( s/NNS )/) within/IN the/DT common/JJ step/NN of/IN the/DT NF-kappa/NN B/NN signal/NN transduction/NN pathway/NN ./. 
UI/LS -/: 95178839/CD 
TI/LS -/: Deleted/JJ chromosome/NN 20/CD from/IN a/DT patient/NN with/IN Alagille/NN syndrome/NN isolated/VBN in/IN a/DT cell/NN hybrid/NN through/IN leucine/NN transport/NN selection/NN :/: study/NN of/IN three/CD candidate/NN genes/NNS ./. 
AB/LS -/: Alagille/NN syndrome/NN (/( AGS/NN )/) is/VBZ a/DT well-defined/JJ genetic/JJ entity/NN assigned/VBN to/TO the/DT short/JJ arm/NN of/IN Chromosome/NN (/( Chr/NN )/) 20/CD by/IN a/DT series/NN of/IN observations/NNS of/IN AGS/NN patients/NNS associated/VBN with/IN microdeletions/NNS in/IN this/DT region/NN ./. 
By/IN fusing/VBG lymphoblastoid/JJ cells/NNS of/IN an/DT AGS/NN patient/NN that/WDT exhibited/VBD a/DT microdeletion/NN in/IN the/DT short/JJ arm/NN of/IN Chr/NN 20/CD encompassing/NN bands/NNS p11.23/NN to/TO p12.3/VB with/IN rodent/JJ thermosensitive/JJ mutant/JJ cells/NNS (/( CHOtsH1-1/NN )/) deficient/JJ in-leucyl-tRNA/JJ synthetase/NN ,/, we/PRP isolated/VBD a/DT somatic/JJ cell/NN hybrid/NN segregating/VBG the/DT deleted/JJ human/JJ Chr/NN 20/CD ./. 
This/DT hybrid/NN clone/NN ,/, designated/VBN NR2/NN ,/, was/VBD characterized/VBN by/IN several/JJ methods/NNS ,/, including/VBG PCR/NN ,/, with/IN eight/CD pairs/NNS of/IN oligonucleotides/NNS mapped/VBN to/TO Chr/NN 20/CD :/: D20S5/NN ,/, D20S41/NN ,/, D20S42/NN ,/, D20S56/NN ,/, D20S57/NN ,/, D20S58/NN ,/, adenosine/NN deaminase/NN (/( ADA/NN )/) ,/, and/CC Prion/NN protein/NN (/( PRIP/NN )/) ;/: Restriction/NN Fragment/NN Length/NN Polymorphism/NN (/( RFLP/NN )/) analyses/NNS with/IN four/CD genomic/JJ anonymous/JJ probes/NNS (/( D20S5/NN ,/, cD3H12/NN ,/, D20S17/NN ,/, D20S18/NN )/) ;/: and/CC fluorescent/JJ in/FW situ/FW hybridization/NN (/( FISH/NN )/) with/IN total/JJ human/JJ DNA/NN and/CC D20Z1/NN ,/, a/DT sequence/NN specific/JJ to/TO the/DT human/JJ Chr/NN 20/CD centromere/NN ,/, as/IN probes/NNS ./. 
The/DT NR2/NN hybrid/NN allowed/VBD us/PRP to/TO exclude/VB three/CD candidate/NN genes/NNS for/IN AGS/NN :/: hepatic/JJ nuclear/JJ factor/NN 3/CD beta/NN (/( HNF3/NN beta/NN )/) ,/, paired/JJ box/NN 1/CD (/( PAX1/NN )/) ,/, and/CC cystatin/NN C/NN (/( CST3/NN )/) as/IN shown/VBN by/IN their/PRP$ localization/NN outside/JJ of/IN the/DT deletion/NN ./. 
The/DT NR2/NN hybrid/NN is/VBZ a/DT powerful/JJ tool/NN for/IN the/DT mapping/NN of/IN new/JJ probes/NNS of/IN this/DT region/NN ,/, as/RB well/RB as/IN for/IN obtaining/VBG new/JJ informative/JJ probes/NNS specific/JJ for/IN the/DT deletion/NN by/IN subtractive/JJ cloning/NN of/IN the/DT region/NN ./. 
Such/JJ markers/NNS will/MD be/VB useful/JJ for/IN linkage/NN analysis/NN and/CC screening/NN of/IN cDNA/NN libraries/NNS ./. 
UI/LS -/: 95016439/CD 
TI/LS -/: Positive/JJ and/CC negative/JJ regulation/NN of/IN the/DT composite/JJ octamer/NN motif/NN of/IN the/DT interleukin/NN 2/CD enhancer/NN by/IN AP-1/NN ,/, Oct-2/NN ,/, and/CC retinoic/JJ acid/NN receptor/NN ./. 
AB/LS -/: The/DT differentiating/VBG agent/NN retinoic/JJ acid/NN (/( RA/NN )/) has/VBZ been/VBN previously/RB reported/VBN to/TO interfere/VB with/IN 12-O-tetradecanoyl-phorbol-13-acetate/NN (/( TPA/NN )/) /Ca(2+)-induced/JJ signals/NNS for/IN the/DT regulation/NN of/IN the/DT -96/CD to/TO -66-bp/JJ octamer/NN motif/NN found/VBN in/IN the/DT enhancer/NN for/IN the/DT interleukin/NN (/( IL/NN )/) -2/CD gene/NN ,/, which/WDT encodes/VBZ a/DT major/JJ T/NN lymphocyte/NN growth/NN factor/NN ./. 
The/DT IL-2/NN octamer/NN motif/NN is/VBZ a/DT composite/JJ cis-element/NN which/WDT binds/VBZ Oct-1/NN and/CC Oct-2/NN as/RB well/RB as/IN a/DT TPA/Ca(2+)-inducible/JJ nuclear/JJ factor/NN ,/, previously/RB termed/VBN octamer-associated/JJ protein/NN (/( OAP40/CD )/) ./. 
We/PRP show/VBP here/RB that/IN Oct-2/NN ,/, despite/IN the/DT presence/NN of/IN an/DT active/JJ transcriptional/JJ activation/NN domain/NN ,/, requires/VBZ TPA/Ca(2+)-induced/JJ signals/NNS to/TO strongly/RB transactivate/VB the/DT IL-2/NN octamer/NN motif/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
This/DT Oct-2-dependent/JJ transactivation/NN is/VBZ inhibited/VBN by/IN RA/NN ./. 
The/DT presence/NN of/IN an/DT intact/JJ COOH-terminal/JJ domain/NN of/IN Oct-2/NN contributes/VBZ to/TO both/CC TPA/Ca(2+)-induced/JJ transactivation/NN and/CC the/DT RA-mediated/JJ repression/NN ./. 
We/PRP also/RB show/VBP that/IN both/CC Fos/NN and/CC Jun/NN components/NNS of/IN the/DT AP-1/NN factors/NNS participate/VBP in/IN the/DT OAP40/NN complex/NN ./. 
Furthermore/RB ,/, transfected/VBN c-jun/NN ,/, jun-B/NN ,/, jun-D/NN ,/, c-fos/NN ,/, or/CC Fos-B/NN expression/NN vectors/NNS partially/RB substitute/VBP for/IN TPA/NN and/CC Ca2+/NN and/CC cooperate/VBP with/IN Oct-2/NN for/IN the/DT transactivation/NN of/IN the/DT combined/JJ OAP/octamer/NN cis-element/NN ./. 
Mutations/NNS of/IN the/DT genuine/JJ octamer-binding/JJ site/NN abrogate/VBP both/CC the/DT binding/NN of/IN Oct-1/NN and/CC Oct-2/NN and/CC the/DT TPA/Ca(2+)-induced/JJ transactivation/NN of/IN the/DT OAP/octamer/NN motif/NN ./. 
OAP/NN confers/VBZ to/TO Oct-2/NN responsivity/NN to/TO both/CC TPA/Ca2+/NN and/CC RA/NN ,/, since/IN specific/JJ mutations/NNS of/IN the/DT AP-1/OAP-bindingsite/NN significantly/RB reduce/VBP the/DT transactivation/NN by/IN Oct-2/NN in/IN response/NN to/TO TPA/NN and/CC Ca2+/NN and/CC abolish/VBP the/DT inhibition/NN by/IN RA/NN ./. 
Furthermore/RB ,/, retinoic/JJ acid/NN receptor/NN (/( RAR/NN )/) alpha/NN is/VBZ able/JJ to/TO inhibit/VB in/FW vitro/FW the/DT formation/NN of/IN the/DT complex/NN between/IN the/DT nuclear/JJ AP-1/OAP/NN and/CC its/PRP$ specific/JJ binding/VBG site/NN ,/, resulting/VBG in/IN the/DT interference/NN with/IN Oct-2-dependent/JJ cis-regulatory/JJ function/NN of/IN this/DT AP-1/NN element/NN ./. 
Therefore/RB ,/, we/PRP propose/VBP that/IN the/DT TPA/calcium-activatedAP-1/OAP/NN element/NN is/VBZ the/DT main/JJ target/NN of/IN positive/JJ or/CC negative/JJ regulatory/JJ signals/NNS influencing/VBG the/DT IL-2/NN octamer/NN motif/NN ,/, through/IN synergism/NN with/IN Oct-2/NN and/CC antagonism/NN by/IN RAR/NN ./. 
UI/LS -/: 95190013/CD 
TI/LS -/: Missense/NN mutation/NN in/IN exon/NN 7/CD of/IN the/DT common/JJ gamma/NN chain/NN gene/NN causes/VBZ a/DT moderate/JJ form/NN of/IN X-linked/JJ combined/JJ immunodeficiency/NN ./. 
AB/LS -/: Clinical/JJ and/CC immunologic/JJ features/NNS of/IN a/DT recently/RB recognized/VBN X-linked/JJ combined/JJ immunodeficiency/NN disease/NN (/( XCID/NN )/) suggested/VBD that/IN XCID/NN and/CC X-linked/JJ severe/JJ combined/JJ immunodeficiency/NN (/( XSCID/NN )/) might/MD arise/VB from/IN different/JJ genetic/JJ defects/NNS ./. 
The/DT recent/JJ discovery/NN of/IN mutations/NNS in/IN the/DT common/JJ gamma/NN chain/NN (/( gamma/NN c/NN )/) gene/NN ,/, a/DT constituent/NN of/IN several/JJ cytokine/NN receptors/NNS ,/, in/IN XSCID/NN provided/VBD an/DT opportunity/NN to/TO test/VB directly/RB whether/IN a/DT previously/RB unrecognized/JJ mutation/NN in/IN this/DT same/JJ gene/NN was/VBD responsible/JJ for/IN XCID/NN ./. 
The/DT status/NN of/IN X/NN chromosome/NN inactivation/NN in/IN blood/NN leukocytes/NNS from/IN obligate/JJ carriers/NNS of/IN XCID/NN was/VBD determined/VBN from/IN the/DT polymorphic/JJ ,/, short/JJ tandem/JJ repeats/NNS (/( CAG/NN )/) ,/, in/IN the/DT androgen/NN receptor/NN gene/NN ,/, which/WDT also/RB contains/VBZ a/DT methylation-sensitive/JJ HpaII/NN site/NN ./. 
As/IN in/IN XSCID/NN ,/, X-chromosome/NN inactivation/NN in/IN obligate/JJ carriers/NNS of/IN XCID/NN was/VBD nonrandom/JJ in/IN T/NN and/CC B/NN lymphocytes/NNS ./. 
In/IN addition/NN ,/, X/NN chromosome/NN inactivation/NN in/IN PMNs/NNS was/VBD variable/JJ ./. 
Findings/NNS from/IN this/DT analysis/NN prompted/VBD sequencing/NN of/IN the/DT gamma/NN c/NN gene/NN in/IN this/DT pedigree/NN ./. 
A/DT missense/NN mutation/NN in/IN the/DT region/NN coding/VBG for/IN the/DT cytoplasmic/JJ portion/NN of/IN the/DT gamma/NN c/NN gene/NN was/VBD found/VBN in/IN three/CD affected/VBN males/NNS but/CC not/RB in/IN a/DT normal/JJ brother/NN ./. 
Therefore/RB ,/, this/DT point/NN mutation/NN in/IN the/DT gamma/NN c/NN gene/NN leads/VBZ to/TO a/DT less/RBR severe/JJ degree/NN of/IN deficiency/NN in/IN cellular/JJ and/CC humoral/JJ immunity/NN than/IN that/DT seen/VBN in/IN XSCID/NN ./. 
UI/LS -/: 95152043/CD 
TI/LS -/: Posttranscriptional/JJ regulation/NN of/IN macrophage/NN tissue/NN factor/NN expression/NN by/IN antioxidants/NNS ./. 
AB/LS -/: Tissue/NN factor/NN (/( TF/NN )/) expression/NN by/IN cells/NNS of/IN monocyte/macrophage/NN lineage/NN represents/VBZ an/DT important/JJ mechanism/NN underlying/VBG the/DT initiation/NN of/IN fibrin/NN deposition/NN at/IN sites/NNS of/IN extravascular/JJ inflammation/NN ./. 
Recent/JJ evidence/NN suggests/VBZ a/DT role/NN for/IN oxidant/JJ stress/NN in/IN the/DT signalling/NN pathway/NN of/IN various/JJ cell/NN types/NNS by/IN virtue/NN of/IN its/PRP$ ability/NN to/TO induce/VB DNA/NN binding/NN of/IN various/JJ transcription/NN factors/NNS ,/, including/VBG nuclear/JJ factor/NN kappa/NN B/NN and/CC AP-1/NN ./. 
The/DT effect/NN of/IN antioxidant/JJ treatment/NN on/IN lipopolysaccharide/NN (/( LPS/NN )/) -induced/JJ TF/NN expression/NN was/VBD examined/VBN in/IN murine/NN peritoneal/JJ macrophages/NNS and/CC human/JJ monocytes/NNS ./. 
Both/CC pyrrolidine/NN dithiocarbamate/NN ,/, an/DT oxidant/JJ scavenger/NN ,/, and/CC N-acetyl-cysteine/NN ,/, a/DT precursor/NN of/IN the/DT endogenous/JJ antioxidant/JJ glutathione/NN ,/, inhibited/VBD stimulation/NN of/IN macrophage/NN procoagulant/NN activity/NN by/IN LPS/NN ./. 
Northern/NN blot/NN analysis/NN showed/VBD that/IN neither/DT of/IN these/DT agents/NNS reduced/VBD LPS-stimulated/JJ TF/NN mRNA/NN accumulation/NN ,/, thereby/RB suggesting/VBG a/DT posttranscriptional/JJ mechanism/NN for/IN the/DT effect/NN ./. 
Immunofluorescence/NN studies/NNS of/IN human/JJ monocytes/NNS using/VBG polyclonal/JJ anti-TF/JJ antibody/NN showed/VBD that/IN N-acetyl-cysteine/NN treatment/NN prevented/VBD the/DT characteristic/JJ plasmalemmal/JJ localization/NN of/IN TF/NN antigen/NN that/WDT occurs/VBZ in/IN response/NN to/TO LPS/NN ./. 
Western/NN blot/NN analysis/NN showed/VBD that/IN N-acetyl-cysteine/NN reduced/VBD the/DT accumulation/NN of/IN the/DT 47-kD/JJ mature/JJ glycoprotein/NN in/IN LPS-treated/JJ cells/NNS ,/, a/DT finding/NN consistent/JJ with/IN the/DT results/NNS of/IN the/DT immunofluorescence/NN studies/NNS ./. 
Furthermore/RB ,/, these/DT conditions/NNS did/VBD not/RB result/VB in/IN an/DT accumulation/NN of/IN the/DT less/RBR mature/JJ forms/NNS of/IN TF/NN ./. 
When/WRB considered/VBN together/RB ,/, these/DT data/NNS suggest/VBP that/IN antioxidants/NNS exert/VBP their/PRP$ effects/NNS by/IN impairing/VBG translation/NN and/or/CC by/IN causing/VBG degradation/NN of/IN newly/RB translated/VBN protein/NN ./. 
The/DT effect/NN of/IN antioxidants/NNS on/IN tumor/NN necrosis/NN factor/NN appeared/VBD to/TO be/VB species/NNS specific/JJ ,/, with/IN no/DT effect/NN on/IN LPS-induced/JJ tumor/NN necrosis/NN factor/NN in/IN murine/NN cells/NNS ,/, but/CC with/IN inhibition/NN in/IN human/JJ monocytes/NNS ./. 
The/DT posttranscriptional/JJ effect/NN of/IN antioxidants/NNS on/IN TF/NN expression/NN data/NNS suggests/VBZ a/DT novel/JJ mechanism/NN whereby/WRB these/DT agents/NNS might/MD modulate/VB monocyte/macrophage/NN activation/NN ./. 
UI/LS -/: 95115141/CD 
TI/LS -/: Characterization/NN of/IN the/DT CD48/NN gene/NN demonstrates/VBZ a/DT positive/JJ element/NN that/WDT is/VBZ specific/JJ to/TO Epstein-Barr/JJ virus-immortalized/JJ B-cell/NN lines/NNS and/CC contains/VBZ an/DT essential/JJ NF-kappa/NN B/NN site/NN ./. 
AB/LS -/: Epstein-Barr/JJ virus/NN (/( EBV/NN )/) infection/NN of/IN mature/JJ ,/, resting/VBG B/NN cells/NNS drives/VBZ them/PRP to/TO become/VB lymphoblasts/NNS expressing/VBG high/JJ levels/NNS of/IN cell/NN surface/NN molecules/NNS ,/, such/JJ as/IN CD48/NN ,/, characteristically/RB expressed/VBN on/IN normal/JJ activated/VBN B/NN cells/NNS ./. 
Here/RB ,/, we/PRP report/VBP on/IN the/DT identification/NN of/IN an/DT enhancer/NN element/NN in/IN the/DT CD48/NN gene/NN which/WDT reproducibly/RB confers/VBZ strong/JJ transcriptional/JJ activity/NN only/RB in/IN EBV-positive/JJ B-lymphoblastoid/JJ cell/NN lines/NNS ./. 
The/DT element/NN is/VBZ not/RB activated/VBN upon/IN infection/NN of/IN established/JJ EBV-negative/JJ B-cell/NN lines/NNS ,/, indicating/VBG that/IN EBV/NN fails/VBZ to/TO drive/VB these/DT cells/NNS to/TO a/DT fully/RB lymphoblastoid/JJ phenotype/NN ./. 
An/DT NF-kappa/NN B/NN binding/NN site/NN is/VBZ an/DT essential/JJ component/NN of/IN the/DT element/NN but/CC alone/RB is/VBZ not/RB sufficient/JJ to/TO account/VB for/IN the/DT activity/NN or/CC the/DT specificity/NN of/IN the/DT element/NN ./. 
We/PRP have/VBP detected/VBN a/DT specific/JJ nuclear/JJ protein/NN complex/NN that/WDT binds/VBZ to/TO the/DT element/NN and/CC show/VBP that/IN NF-kappa/NN B1/NN (/( p50/NN )/) is/VBZ a/DT part/NN of/IN this/DT complex/NN ./. 
The/DT EBV-encoded/JJ latent/JJ membrane/NN protein/NN 1/CD is/VBZ capable/JJ of/IN transactivating/VBG the/DT isolated/VBN CD48/NN NF-kappa/NN B/NN site/NN but/CC not/RB the/DT intact/JJ element/NN ,/, suggesting/VBG that/IN the/DT latent/JJ membrane/NN protein/NN 1-driven/JJ activation/NN of/IN NF-kappa/NN B/Rel/NN must/MD interact/VB with/IN other/JJ regulatory/JJ pathways/NNS to/TO control/VB expression/NN of/IN cellular/JJ genes/NNS as/IN EBV/NN drives/VBZ resting/VBG B/NN cells/NNS into/IN the/DT cell/NN cycle/NN ./. 
UI/LS -/: 95347767/CD 
TI/LS -/: Thapsigargin/NN induces/VBZ IL-2/NN receptor/NN alpha-chain/NN in/IN human/JJ peripheral/JJ and/CC Jurkat/NN T/NN cells/NNS via/IN a/DT protein/NN kinase/NN C-independent/JJ mechanism/NN ./. 
AB/LS -/: Thapsigargin/NN (/( TG/NN )/) ,/, an/DT inhibitor/NN of/IN Ca(2+)-ATPase/NN ,/, depletes/VBZ intracellular/JJ Ca2+/NN stores/NNS and/CC induces/VBZ a/DT sustained/JJ Ca2+/NN influx/NN without/IN altering/VBG phosphatidyl/JJ inositol/NN levels/NNS ./. 
TG/NN plus/CC phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) but/CC not/RB TG/NN alone/RB induced/VBD IL-2/NN in/IN Jurkat/NN T/NN cells/NNS ,/, suggesting/VBG that/IN TG/NN had/VBD no/DT effect/NN on/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) ./. 
However/RB ,/, TG/NN induced/VBD increases/NNS in/IN IL-2R/NN alpha/NN protein/NN as/RB well/RB as/IN IL-2R/NN alpha/NN mRNA/NN in/IN Jurkat/NN T/NN cells/NNS in/IN a/DT dose-dependent/JJ manner/NN ./. 
A/DT similar/JJ increase/NN in/IN IL-2R/NN alpha/NN by/IN TG/NN was/VBD also/RB observed/VBN in/IN human/JJ peripheral/JJ T/NN cells/NNS ./. 
Further/RB ,/, like/IN PMA/NN ,/, TG/NN markedly/RB induced/VBD NF/NN kappa/NN B/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
However/RB ,/, TG/NN and/CC PMA/NN exhibited/VBD a/DT synergistic/JJ action/NN on/IN IL-2R/NN alpha/NN expression/NN ,/, suggesting/VBG that/IN TG/NN and/CC PMA/NN induce/VBP IL-2R/NN alpha/NN through/IN distinct/JJ pathways/NNS ./. 
PMA-/NN but/CC not/RB TG-induced/JJ IL-2R/NN alpha/NN is/VBZ inhibited/VBN by/IN the/DT PKC/NN inhibitor/NN H7/NN ,/, whereas/IN TG-/NN but/CC not/RB PMA-induced/JJ IL-2R/NN alpha/NN was/VBD inhibited/VBN by/IN cholera/NN toxin/NN ,/, forskolin/NN and/CC 1/CD ,/, 9-dideoxy/JJ forskolin/NN ./. 
In/IN toto/NN ,/, these/DT results/NNS suggest/VBP that/IN TG/NN induces/VBZ IL-2R/NN alpha/NN in/IN human/JJ T/NN cells/NNS through/IN a/DT PKC-independent/JJ pathway/NN ./. 
UI/LS -/: 95311627/CD 
TI/LS -/: Physiological/JJ concentration/NN of/IN estradiol/NN inhibits/VBZ polymorphonuclear/JJ leukocyte/NN chemotaxis/NN via/IN a/DT receptor/NN mediated/JJ system/NN ./. 
AB/LS -/: Estrogen/NN exhibits/VBZ a/DT variety/NN of/IN actions/NNS ,/, including/VBG immuno-modulatory/JJ effects/NNS ,/, in/FW vivo/FW and/CC in/FW vitro/FW ./. 
The/DT mechanism/NN by/IN which/WDT estrogen/NN exerts/VBZ its/PRP$ anti-inflammatory/JJ effect/NN is/VBZ not/RB yet/RB understood/VBN ./. 
We/PRP investigated/VBD the/DT possible/JJ mechanisms/NNS of/IN estradiol/NN acting/VBG via/IN the/DT polymorphonuclear/JJ leukocytes/NNS (/( PMNs/NNS )/) ,/, which/WDT are/VBP important/JJ in/IN the/DT immune/JJ response/NN ./. 
The/DT agent/NN ,/, 17/CD beta-estradiol/NN ,/, but/CC not/RB 17/CD alpha-estradiol/NN ,/, significantly/RB reduced/VBD PMNs/NNS chemotaxis/NN to/TO FMLP/NN in/IN a/DT dose-dependent/JJ manner/NN (/( control/NN vs/CC estrogen/NN 10(-10)-(-6)/CD M/NN ,/, P/NN </JJR 0.05/CD )/) ./. 
Physiological/JJ concentrations/NNS of/IN estradiol/NN significantly/RB reduced/VBD the/DT chemotaxis/NN of/IN PMNs/NNS (/( 10(-10)/CD mol/NN )/) ./. 
Pre-incubation/NN with/IN clomiphene/NN or/CC tamoxifen/NN which/WDT are/VBP estrogen/NN receptor/NN antagonists/NNS ,/, eliminated/VBD the/DT inhibitory/JJ effect/NN of/IN 17/CD beta-estradiol/NN on/IN the/DT chemotaxis/NN of/IN PMNs/NNS ,/, restoring/VBG it/PRP to/TO the/DT control/JJ level/NN ./. 
These/DT observations/NNS suggest/VBP that/IN 17/CD beta-estradiol/NN suppressed/VBD the/DT chemotaxis/NN of/IN PMNs/NNS by/IN a/DT receptor-dependent/JJ mechanism/NN ./. 
In/IN addition/NN ,/, the/DT level/NN of/IN estradiol/NN in/IN human/JJ plasma/NN ,/, which/WDT PMNs/NNS were/VBD drawn/VBN ,/, showed/VBD a/DT close/JJ ,/, inverse/JJ correlation/NN with/IN the/DT PMNs/NNS chemotaxis/NN to/TO FMLP/NN (/( r/NN =/JJ -0.821/CD p/NN </JJR 0.001/CD )/) ./. 
Estrogen/NN may/MD modify/VB the/DT activity/NN of/IN neutrophils/NNS during/IN the/DT normal/JJ menstrual/JJ cycle/NN ,/, not/RB only/RB during/IN pregnancy/NN ,/, and/CC influence/NN inflammation/NN ./. 
UI/LS -/: 95107991/CD 
TI/LS -/: Identification/NN of/IN the/DT TCL1/NN gene/NN involved/VBN in/IN T-cell/NN malignancies/NNS ./. 
AB/LS -/: The/DT TCL1/NN locus/NN on/IN chromosome/NN 14q32.1/NN is/VBZ frequently/RB involved/VBN in/IN chromosomal/JJ translocations/NNS and/CC inversions/NNS with/IN one/CD of/IN the/DT T-cell/NN receptor/NN loci/NNS in/IN human/JJ T-cell/NN leukemias/NNS and/CC lymphomas/NNS ./. 
The/DT chromosome/NN 14/CD region/NN translocated/VBN or/CC rearranged/VBN involves/VBZ approximately/RB 350/CD kb/NN of/IN DNA/NN at/IN chromosome/NN band/NN 14q32.1/NN ./. 
Within/IN this/DT region/NN we/PRP have/VBP identified/VBN a/DT gene/NN coding/VBG for/IN a/DT 1.3-kb/JJ transcript/NN ,/, expressed/VBN only/RB in/IN restricted/JJ subsets/NNS of/IN cells/NNS within/IN the/DT lymphoid/JJ lineage/NN and/CC expressed/VBN at/IN high/JJ levels/NNS in/IN leukemic/JJ cells/NNS carrying/VBG a/DT t(14;14)/NN (q11;q32)/NN chromosome/NN translocation/NN or/CC a/DT inv(14)(q11;q32)/NN chromosome/NN inversion/NN ./. 
The/DT cognate/JJ cDNA/NN sequence/NN reveals/VBZ an/DT open/JJ reading/NN frame/NN of/IN 342/CD nt/NN encoding/VBG a/DT protein/NN of/IN 14/CD kDa/NN ./. 
The/DT TCL1/NN gene/NN sequence/NN ,/, which/WDT ,/, to/TO our/PRP$ knowledge/NN ,/, shows/VBZ no/DT sequence/NN homology/NN with/IN other/JJ human/JJ genes/NNS ,/, is/VBZ preferentially/RB expressed/VBN early/RB in/IN T-/NN and/CC B-lymphocyte/NN differentiation/NN ./. 
UI/LS -/: 95059037/CD 
TI/LS -/: Identification/NN of/IN a/DT region/NN which/WDT directs/VBZ the/DT monocytic/JJ activity/NN of/IN the/DT colony-stimulating/JJ factor/NN 1/CD (/( macrophage/NN colony-stimulating/JJ factor/NN )/) receptor/NN promoter/NN and/CC binds/VBZ PEBP2/CBF/NN (/( AML1/NN )/) ./. 
AB/LS -/: The/DT receptor/NN for/IN the/DT macrophage/NN colony-stimulating/JJ factor/NN (/( or/CC colony-stimulating/JJ factor/NN 1/CD [/( CSF-1/NN ]/) )/) is/VBZ expressed/VBN from/IN different/JJ promoters/NNS in/IN monocytic/JJ cells/NNS and/CC placental/JJ trophoblasts/NNS ./. 
We/PRP have/VBP demonstrated/VBN that/IN the/DT monocyte-specific/JJ expression/NN of/IN the/DT CSF-1/NN receptor/NN is/VBZ regulated/VBN at/IN the/DT level/NN of/IN transcription/NN by/IN a/DT tissue-specific/JJ promoter/NN whose/WP$ activity/NN is/VBZ stimulated/VBN by/IN the/DT monocyte/B-cell-specific/JJ transcription/NN factor/NN PU.1/NN (/( D.-E.Zhang/NNP ,/, C.J.Hetherington/NNP ,/, H.-M.Chen/NNP ,/, and/CC D.G.Tenen/NNP ,/, Mol/NNP .Cell./NNP Biol./NNP 14/CD :/: 373-381/CD ,/, 1994/CD )/) ./. 
Here/RB we/PRP report/VBP that/IN the/DT tissue/NN specificity/NN of/IN this/DT promoter/NN is/VBZ also/RB mediated/VBN by/IN sequences/NNS in/IN a/DT region/NN II/CD (/( bp/NN -88/CD to/TO - 59/CD )/) ,/, which/WDT lies/VBZ 10/CD bp/NN upstream/RB from/IN the/DT PU.1-binding/JJ site/NN ./. 
When/WRB analyzed/VBN by/IN DNase/NN footprinting/NN ,/, region/NN II/CD was/VBD protected/VBN preferentially/RB in/IN monocytic/JJ cells/NNS ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS confirmed/VBD that/IN region/NN II/CD interacts/VBZ specifically/RB with/IN nuclear/JJ proteins/NNS from/IN monocytic/JJ cells/NNS ./. 
Two/CD gel/NN shift/NN complexes/NNS (/( Mono/NN A/NN and/CC Mono/NN B/NN )/) were/VBD formed/VBN with/IN separate/JJ sequence/NN elements/NNS within/IN this/DT region/NN ./. 
Competition/NN and/CC supershift/NN experiments/NNS indicate/VBP that/IN Mono/NN B/NN contains/VBZ a/DT member/NN of/IN the/DT polyomavirus/NN enhancer-binding/JJ protein/NN 2/core-binding/JJ factor/NN (/( PEBP2/CBF/NN )/) family/NN ,/, which/WDT includes/VBZ the/DT AML1/NN gene/NN product/NN ,/, while/IN Mono/NN A/NN is/VBZ a/DT distinct/JJ complex/NN preferentially/RB expressed/VBN in/IN monocytic/JJ cells/NNS ./. 
Promoter/NN constructs/NNS with/IN mutations/NNS in/IN these/DT sequence/NN elements/NNS were/VBD no/RB longer/RBR expressed/VBN specifically/RB in/IN monocytes/NNS ./. 
Furthermore/RB ,/, multimerized/JJ region/NN II/CD sequence/NN elements/NNS enhanced/VBD the/DT activity/NN of/IN a/DT heterologous/JJ thymidine/NN kinase/NN promoter/NN in/IN monocytic/JJ cells/NNS but/CC not/RB other/JJ cell/NN types/NNS tested/VBN ./. 
These/DT results/NNS indicate/VBP that/IN the/DT monocyte/B-cell-specific/JJ transcription/NN factor/NN PU.1/NN and/CC the/DT Mono/NN A/NN and/CC Mono/NN B/NN protein/NN complexes/NNS act/VBP in/IN concert/NN to/TO regulate/VB monocyte-specific/JJ transcription/NN of/IN the/DT CSF-1/NN receptor/NN ./. 
UI/LS -/: 95077537/CD 
TI/LS -/: Pyrrolidine/NN dithiocarbamate/NN ,/, a/DT potent/JJ inhibitor/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) activation/NN ,/, prevents/VBZ apoptosis/NN in/IN human/JJ promyelocytic/JJ leukemia/NN HL-60/NN cells/NNS and/CC thymocytes/NNS ./. 
AB/LS -/: We/PRP examined/VBD the/DT effect/NN of/IN pyrrolidine/NN dithiocarbamate/NN (/( PDTC/NN )/) ,/, which/WDT potently/RB blocks/VBZ the/DT activation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ,/, on/IN the/DT induction/NN of/IN apoptosis/NN by/IN a/DT variety/NN of/IN agents/NNS ./. 
Treatment/NN of/IN a/DT human/JJ promyelocytic/JJ leukemia/NN cell/NN line/NN ,/, HL-60/NN ,/, with/IN 10/CD micrograms/mL/NNS etoposide/NN or/CC 2/CD microM/NN 1-beta-D-arabinofuranosylcytosine/NN induced/VBD NF-kappa/NN B/NN activation/NN within/IN 1/CD hr/NN and/CC subsequently/RB caused/VBD apoptosis/NN within/IN 3-4/JJ hr/NN ./. 
The/DT simultaneous/JJ addition/NN of/IN 50-500/CD microM/NN PDTC/NN with/IN these/DT agents/NNS blocked/VBD NF-kappa/NN B/NN activation/NN and/CC completely/RB abrogated/VBD both/CC morphologically/RB apoptotic/JJ changes/NNS and/CC internucleosomal/JJ DNA/NN fragmentation/NN for/IN up/RB to/TO 6/CD hr/NN ./. 
However/RB ,/, PDTC/NN failed/VBD to/TO inhibit/VB the/DT endonuclease/NN activity/NN contained/VBN in/IN the/DT whole/JJ cell/NN lysates/NNS ./. 
The/DT inhibitory/JJ effect/NN of/IN PDTC/NN was/VBD also/RB observed/VBN in/IN etoposide-/NN and/CC dexamethasone-induced/JJ apoptosis/NN in/IN human/JJ thymocytes/NNS at/IN a/DT concentration/NN of/IN 1-10/CD microM/NN ./. 
Since/IN PDTC/NN has/VBZ both/CC antioxidant/NN and/CC metal-ion/JJ chelating/NN activities/NNS ,/, we/PRP tested/VBD the/DT effects/NNS of/IN N-acetyl-L-cysteine/NN (/( NAC/NN )/) (/( antioxidant/JJ )/) or/CC o-phenanthroline/NN (/( OP/NN )/) (/( metal-ion/JJ chelator/NN )/) on/IN the/DT induction/NN of/IN apoptosis/NN ./. 
Pretreatment/NN of/IN HL-60/NN cells/NNS or/CC thymocytes/NNS with/IN 100-500/CD microM/NN OP/NN for/IN 2/CD hr/NN ,/, but/CC not/RB 10-60/CD mM/NN NAC/NN ,/, suppressed/VBD subsequent/JJ occurrence/NN of/IN apoptosis/NN induced/VBN by/IN etoposide/NN ./. 
These/DT results/NNS suggest/VBP that/IN the/DT activation/NN of/IN NF-kappa/NN B/NN plays/VBZ an/DT important/JJ role/NN in/IN the/DT apoptotic/JJ process/NN of/IN human/JJ hematopoietic/JJ cells/NNS ./. 
UI/LS -/: 95151640/CD 
TI/LS -/: Overexpression/NN of/IN protein/NN kinase/NN C-zeta/NN stimulates/VBZ leukemic/JJ cell/NN differentiation/NN ./. 
AB/LS -/: A/DT function/NN for/IN protein/NN kinase/NN C-zeta/NN (/( PKC-zeta/NN )/) ,/, a/DT member/NN of/IN the/DT phorbol/NN ester/NN nonresponsive/JJ atypical/JJ protein/NN kinase/NN C/NN subfamily/NN ,/, in/IN modulating/VBG differentiation/NN was/VBD examined/VBN in/IN the/DT leukemic/JJ U937/NN cell/NN ./. 
Transfected/VBN U937/NN cells/NNS stably/RB overexpressing/VBG PKC-zeta/NN displayed/VBD a/DT longer/RBR doubling/JJ time/NN ,/, lower/JJR saturation/NN density/NN at/IN confluency/NN ,/, and/CC an/DT increase/NN in/IN adherence/NN to/TO plastic/JJ as/IN compared/VBN to/TO control/JJ cells/NNS ./. 
PKC-zeta/NN cells/NNS expressed/VBD a/DT more/RBR differentiated/VBN phenotype/NN as/IN assessed/VBN by/IN changes/NNS in/IN morphology/NN ,/, surface/NN antigen/NN expression/NN ,/, and/CC lysosomal/JJ enzyme/NN activities/NNS and/CC were/VBD distinct/JJ from/IN parental/JJ U937/NN cells/NNS stimulated/VBN to/TO differentiate/VB by/IN exposure/NN to/TO phorbol/NN esters/NNS ./. 
In/IN contrast/NN to/TO parental/JJ U937/NN cells/NNS ,/, PKC-zeta/NN cells/NNS constitutively/RB expressed/VBD mRNA/NN transcripts/NNS for/IN c-jun/NN and/CC a/DT low/JJ mobility/NN AP-1/NN binding/NN activity/NN ./. 
Thus/RB ,/, PKC-zeta/NN overexpression/NN stimulates/VBZ a/DT type/NN of/IN phenotypic/JJ differentiation/NN that/WDT differs/VBZ significantly/RB from/IN maturation/NN occurring/VBG upon/IN activation/NN of/IN other/JJ PKC/NN subfamilies/NNS induced/VBN by/IN phorbol/NN ester/NN treatment/NN ./. 
Increased/VBN expression/NN of/IN the/DT c-jun/NN protooncogene/NN and/CC an/DT increase/NN in/IN AP-1/NN binding/NN activity/NN in/IN PKC-zeta/NN cells/NNS provides/VBZ a/DT potential/JJ mechanism/NN for/IN explaining/VBG the/DT altered/JJ differentiation/NN status/NN of/IN this/DT cell/NN ./. 
UI/LS -/: 95016436/CD 
TI/LS -/: A/DT family/NN of/IN serine/NN proteases/NNS expressed/VBN exclusively/RB in/IN myelo-monocytic/JJ cells/NNS specifically/RB processes/VBZ the/DT nuclear/JJ factor-kappa/NN B/NN subunit/NN p65/NN in/FW vitro/FW and/CC may/MD impair/VB human/JJ immunodeficiency/NN virus/NN replication/NN in/IN these/DT cells/NNS ./. 
AB/LS -/: Two/CD groups/NNS of/IN U937/NN promonocytic/JJ cells/NNS were/VBD obtained/VBN by/IN limiting/VBG dilution/NN cloning/NN which/WDT differed/VBD strikingly/RB in/IN their/PRP$ ability/NN to/TO support/VB human/JJ immunodeficiency/NN virus/NN 1/CD (/( HIV-1/NN )/) replication/NN ./. 
"/`` Plus/JJ "/'' clones/NNS replicated/VBD the/DT virus/NN efficiently/RB ,/, whereas/IN "/`` minus/JJ "/'' clones/NNS did/VBD not/RB ./. 
We/PRP examined/VBD these/DT clones/NNS for/IN differences/NNS in/IN nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN activity/NN which/WDT might/MD account/VB for/IN the/DT observed/VBN phenomenon/NN ./. 
Stimulation/NN of/IN plus/CC clones/NNS liberated/VBD the/DT classical/JJ p50-p65/NN complex/NN from/IN cytoplasmic/JJ pools/NNS ,/, whereas/IN minus/JJ clones/NNS produced/VBD an/DT apparently/RB novel/JJ ,/, faster-migrating/JJ complex/NN ,/, as/IN judged/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ./. 
It/PRP is/VBZ surprising/JJ that/IN the/DT faster-migrating/JJ complex/NN was/VBD composed/VBN also/RB of/IN p50/NN and/CC p65/NN ./. 
However/RB ,/, the/DT p65/NN subunit/NN was/VBD COOH-terminally/RB truncated/VBN ,/, as/IN shown/VBN by/IN immunoprecipitation/NN ./. 
The/DT truncation/NN resulted/VBD from/IN limited/JJ proteolysis/NN of/IN p65/NN during/IN cellular/JJ extraction/NN which/WDT released/VBD particular/JJ lysosomal/JJ serine/NN proteases/NNS ,/, such/JJ as/IN elastase/NN ,/, cathepsin/NN G/NN ,/, and/CC proteinase/NN 3/CD ./. 
These/DT specific/JJ proteases/NNS are/VBP coordinately/RB expressed/VBN and/CC were/VBD present/JJ exclusively/RB in/IN the/DT minus/JJ U937/NN clones/NNS ,/, but/CC not/RB in/IN the/DT plus/JJ clones/NNS ,/, as/IN demonstrated/VBN in/IN the/DT case/NN of/IN cathepsin/NN G/NN ./. 
In/IN addition/NN ,/, these/DT proteases/NNS were/VBD detected/VBN in/IN certain/JJ subclones/NNS of/IN THP-1/NN and/CC HL-60/NN cells/NNS and/CC in/IN primary/JJ monocytes/NNS ,/, in/IN each/DT case/NN correlating/VBG with/IN the/DT truncated/VBN from/IN of/IN p65/NN ./. 
We/PRP demonstrate/VBP in/FW vitro/FW cleavage/NN of/IN p65/NN by/IN purified/VBN elastase/NN and/CC cathepsin/NN G/NN ./. 
It/PRP is/VBZ possible/JJ that/IN particular/JJ serine/NN proteases/NNS may/MD have/VB inhibiting/NN effects/NNS on/IN the/DT replication/NN of/IN HIV-1/NN in/IN myelo-monocytic/JJ cells/NNS ./. 
The/DT data/NNS also/RB demonstrate/VBP that/IN special/JJ precautions/NNS must/MD be/VB taken/VBN when/WRB making/VBG extracts/NNS from/IN myelo-monocytic/JJ cells/NNS ./. 
UI/LS -/: 95186362/CD 
TI/LS -/: A/DT germline/NN TaqI/NN restriction/NN fragment/NN length/NN polymorphism/NN in/IN the/DT progesterone/NN receptor/NN gene/NN in/IN ovarian/JJ carcinoma/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: Clinical/JJ outcome/NN in/IN ovarian/JJ carcinoma/NN is/VBZ predicted/VBN by/IN progesterone/NN receptor/NN status/NN ,/, indicating/VBG an/DT endocrine/JJ aspect/NN to/TO this/DT disease/NN ./. 
Peripheral/JJ leucocyte/NN genomic/JJ DNAs/NNS were/VBD obtained/VBN from/IN 41/CD patients/NNS with/IN primary/JJ ovarian/JJ carcinoma/NN and/CC 83/CD controls/NNS from/IN Ireland/NNP ,/, as/RB well/RB as/IN from/IN 26/CD primary/JJ ovarian/JJ carcinoma/NN patients/NNS and/CC 101/CD controls/NNS in/IN Germany/NNP ./. 
Southern/NN analysis/NN using/VBG a/DT human/JJ progesterone/NN receptor/NN (/( hPR/NN )/) cDNA/NN probe/NN identified/VBD a/DT germline/NN TaqI/NN restriction/NN fragment/NN length/NN polymorphism/NN (/( RFLP/NN )/) defined/VBN by/IN two/CD alleles/NNS :/: T1/NN ,/, represented/VBN by/IN a/DT 2.7/CD kb/NN fragment/NN ;/: and/CC T2/NN ,/, represented/VBN by/IN a/DT 1.9/CD kb/NN fragment/NN and/CC characterised/VBN by/IN an/DT additional/JJ TaqI/NN restriction/NN site/NN with/IN respect/NN to/TO T1/NN ./. 
An/DT over-representation/NN of/IN T2/NN in/IN ovarian/JJ cancer/NN patients/NNS compared/VBN with/IN controls/NNS in/IN the/DT pooled/JJ Irish/German/NNP population/NN (/( P/NN </JJR 0.025/CD )/) was/VBD observed/VBN ./. 
A/DT difference/NN (/( P/NN </JJR 0.02/CD )/) in/IN the/DT distribution/NN of/IN the/DT RFLP/NN genotypes/NNS between/IN Irish/NNP and/CC German/NNP control/JJ populations/NNS was/VBD also/RB observed/VBN ./. 
The/DT allele/NN distributions/NNS could/MD not/RB be/VB shown/VBN to/TO differ/VB significantly/RB from/IN Hardy-Weinberg/JJ distribution/NN in/IN any/DT subgroup/NN ./. 
Using/VBG hPR/NN cDNA/NN region-specific/JJ probes/NNS ,/, the/DT extra/JJ TaqI/NN restriction/NN site/NN was/VBD mapped/VBN to/TO intron/NN G/NN of/IN the/DT hPR/NN gene/NN ./. 
UI/LS -/: 95163103/CD 
TI/LS -/: OBF-1/NN ,/, a/DT novel/JJ B/NN cell-specific/JJ coactivator/NN that/WDT stimulates/VBZ immunoglobulin/NN promoter/NN activity/NN through/IN association/NN with/IN octamer-binding/JJ proteins/NNS ./. 
AB/LS -/: Recent/JJ biochemical/JJ and/CC genetic/JJ studies/NNS indicate/VBP that/IN in/IN addition/NN to/TO the/DT octamer-binding/JJ proteins/NNS Oct-1/NN and/CC Oct-2/NN ,/, other/JJ B/NN cell/NN components/NNS are/VBP required/VBN for/IN lymphoid-restricted/JJ ,/, octamer/NN site-mediated/JJ immunoglobulin/NN gene/NN promoter/NN activity/NN ./. 
Using/VBG a/DT genetic/JJ screen/NN in/IN yeast/NN ,/, we/PRP have/VBP isolated/VBN B/NN cell-derived/JJ cDNAs/NNS encoding/JJ Oct-binding/JJ factor/NN 1/CD (/( OBF-1/NN )/) ,/, a/DT novel/JJ protein/NN that/WDT specifically/RB associates/VBZ with/IN Oct-1/NN and/CC Oct-2/NN ./. 
Biochemical/JJ studies/NNS demonstrate/VBP that/IN OBF-1/NN has/VBZ no/DT intrinsic/JJ DNA-binding/JJ activity/NN and/CC recognizes/VBZ the/DT POU/NN domains/NNS of/IN Oct-1/NN and/CC Oct-2/NN ,/, but/CC not/RB those/DT of/IN Oct-4/NN and/CC Oct-6/NN ./. 
The/DT OBF-1/NN mRNA/NN is/VBZ expressed/VBN in/IN a/DT highly/RB cell-specific/JJ manner/NN ,/, being/VBG most/RBS abundant/JJ in/IN B/NN cells/NNS and/CC essentially/RB absent/JJ in/IN most/JJS of/IN the/DT other/JJ cells/NNS or/CC tissues/NNS tested/VBN ./. 
Furthermore/RB ,/, expression/NN of/IN OBF-1/NN in/IN HeLa/NN cells/NNS selectively/RB stimulates/VBZ the/DT activity/NN of/IN a/DT natural/JJ immunoglobulin/NN promoter/NN in/IN an/DT octamer/NN site-dependent/JJ manner/NN ./. 
Thus/RB ,/, OBF-1/NN has/VBZ all/PDT the/DT properties/NNS expected/VBN for/IN a/DT B/NN cell-specific/JJ transcriptional/JJ coactivator/NN protein/NN ./. 
UI/LS -/: 95301128/CD 
TI/LS -/: Modulation/NN of/IN transcription/NN factor/NN NF/NN kappa/NN B/NN activity/NN by/IN intracellular/JJ glutathione/NN levels/NNS and/CC by/IN variations/NNS of/IN the/DT extracellular/JJ cysteine/NN supply/NN ./. 
AB/LS -/: HIV-infected/JJ individuals/NNS and/CC SIV-infected/JJ rhesus/NN macaques/NNS have/VBP ,/, on/IN the/DT average/NN ,/, decreased/VBN plasma/NN cysteine/NN and/CC cystine/NN concentrations/NNS and/CC decreased/VBN intracellular/JJ glutathione/NN levels/NNS ./. 
We/PRP now/RB show/VBP that/IN a/DT depletion/NN of/IN intracellular/JJ glutathione/NN in/IN a/DT human/JJ T/NN cell/NN line/NN (/( Molt-4/NN )/) inhibits/VBZ the/DT activation/NN and/CC nuclear/JJ translocation/NN of/IN the/DT transcription/NN factor/NN NF/NN kappa/NN B/NN ,/, whereas/IN incubation/NN with/IN increasing/VBG extracellular/JJ concentrations/NNS of/IN cysteine/NN inhibits/VBZ the/DT DNA-binding/JJ and/CC transactivating/JJ activity/NN of/IN NF/NN kappa/NN B/NN ./. 
Because/IN inhibition/NN of/IN DNA-binding/JJ activity/NN is/VBZ associated/VBN with/IN increasing/VBG intracellular/JJ glutathione/NN disulfide/NN levels/NNS and/CC GSSG/NN can/MD be/VB shown/VBN to/TO inhibit/VB the/DT DNA-binding/JJ activity/NN directly/RB in/IN cell-free/JJ systems/NNS ,/, our/PRP$ studies/NNS suggest/VBP that/IN GSSG/NN is/VBZ a/DT physiologically/RB relevant/JJ inhibitor/NN in/IN intact/JJ cells/NNS also/RB ./. 
NF/NN kappa/NN B/NN controls/VBZ many/JJ immunologically/RB important/JJ genes/NNS ,/, so/RB our/PRP$ studies/NNS suggest/VBP that/IN the/DT immune/JJ system/NN may/MD be/VB sensitive/JJ not/RB only/RB against/IN a/DT cysteine/NN and/CC glutathione/NN deficiency/NN but/CC also/RB against/IN an/DT excess/NN of/IN cysteine/NN ./. 
UI/LS -/: 95138118/CD 
TI/LS -/: Two/CD distinct/JJ signalling/NN pathways/NNS are/VBP involved/VBN in/IN the/DT control/NN of/IN the/DT biphasic/JJ junB/NN transcription/NN induced/VBN by/IN interleukin-6/NN in/IN the/DT B/NN cell/NN hybridoma/NN 7TD1/NN ./. 
AB/LS -/: We/PRP have/VBP measured/VBN the/DT level/NN of/IN junB/NN mRNA/NN in/IN the/DT B/NN hybridoma/NN cell/NN line/NN 7TD1/NN ,/, under/IN interleukin-6/NN (/( IL-6/NN )/) stimulation/NN ./. 
IL-6/NN increases/VBZ junB/NN mRNA/NN in/IN a/DT biphasic/JJ fashion/NN ./. 
The/DT first/JJ early-induced/JJ peak/NN was/VBD transient/JJ and/CC likely/RB corresponds/VBZ to/TO the/DT well/RB documented/VBN typical/JJ junB/NN mRNA/NN ,/, stimulated/VBN in/IN response/NN to/TO numerous/JJ growth/NN factors/NNS ,/, including/VBG IL-6/NN ./. 
At/IN variance/NN ,/, the/DT second/JJ peak/NN which/WDT has/VBZ never/RB been/VBN reported/VBN previously/RB ,/, lasted/VBD several/JJ hours/NNS ./. 
As/IN a/DT consequence/NN of/IN its/PRP$ effect/NN on/IN junB/NN mRNA/NN ,/, IL-6/NN stimulated/VBD ,/, in/IN a/DT biphasic/JJ fashion/NN ,/, the/DT nuclear/JJ accumulation/NN of/IN the/DT JunB/NN protein/NN ./. 
In/IN this/DT study/NN ,/, we/PRP demonstrated/VBD that/IN IL-6/NN regulation/NN occurred/VBD exclusively/RB at/IN the/DT transcriptional/JJ level/NN and/CC that/IN the/DT bimodal/JJ increase/NN of/IN junB/NN mRNA/NN and/CC JunB/NN protein/NN can/MD be/VB accounted/VBN for/IN by/IN a/DT biphasic/JJ stimulation/NN of/IN junB/NN transcription/NN ./. 
Furthermore/RB ,/, our/PRP$ data/NNS point/VBP to/TO two/CD major/JJ differences/NNS between/IN the/DT mechanism/NN of/IN control/NN of/IN the/DT early/JJ and/CC the/DT late/JJ IL-6-induced/JJ junB/NN transcription/NN waves/NNS ./. 
First/RB ,/, cycloheximide/NN strongly/RB potentiated/VBD the/DT transcription/NN of/IN the/DT second/JJ wave/NN ,/, whereas/IN it/PRP failed/VBD to/TO affect/VB the/DT early-induced/JJ burst/NN ./. 
Second/RB ,/, tyrphostin/NN ,/, a/DT tyrosine/NN kinase/NN inhibitor/NN ,/, impaired/VBD the/DT expression/NN of/IN the/DT first/JJ but/CC not/RB the/DT second/JJ junB/NN mRNA/NN peak/NN ./. 
Conversely/RB ,/, genistein/NN ,/, another/DT tyrosine/NN kinase/NN inhibitor/NN ,/, totally/RB abolished/VBD the/DT expression/NN of/IN the/DT second/JJ peak/NN of/IN junB/NN mRNA/NN whereas/IN it/PRP did/VBD not/RB affect/VB the/DT expression/NN of/IN the/DT first/JJ peak/NN ./. 
Altogether/RB these/DT data/NNS indicate/VBP that/IN ,/, in/IN 7TD1/NN cells/NNS ,/, IL-6/NN controls/VBZ junB/NN transcription/NN in/IN a/DT biphasic/JJ fashion/NN by/IN means/NNS of/IN two/CD separate/JJ transduction/NN pathways/NNS ./. 
UI/LS -/: 95235452/CD 
TI/LS -/: A/DT newly/RB established/JJ megakaryoblastic/erythroid/JJ cell/NN line/NN that/WDT differentiates/VBZ to/TO red/JJ cells/NNS in/IN the/DT presence/NN of/IN erythropoietin/NN and/CC produces/VBZ platelet-like/JJ particles/NNS ./. 
AB/LS -/: In/IN August/NNP ,/, 1992/CD ,/, we/PRP established/VBD a/DT leukemic/JJ cell/NN line/NN (/( NS-Meg/NN )/) from/IN a/DT patient/NN in/IN megakaryoblastic/JJ transformation/NN of/IN Philadelphia/NN chromosome-positive/JJ chronic/JJ myeloid/JJ leukemia/NN ./. 
The/DT NS-Meg/NN cells/NNS were/VBD positive/JJ for/IN alpha-naphthyl/JJ acetate/NN esterase/NN and/CC periodic/JJ acid-Schiff/NN (/( PAS/NN )/) staining/NN and/CC for/IN surface/NN CD4/NN ,/, CD7/NN ,/, CD13/NN ,/, CD34/NN ,/, CD41a/NN ,/, and/CC glycophorin/NN A/NN antigens/NNS ./. 
Ultrastructurally/RB ,/, the/DT cells/NNS had/VBD alpha-granules/NNS ,/, demarcation/NN membranes/NNS ,/, and/CC platelet/NN peroxidase/NN activity/NN ./. 
The/DT NS-Meg/NN cells/NNS spontaneously/RB produced/VBD platelet-like/JJ particles/NNS which/WDT contained/VBD alpha-granules/NNS ,/, mitochondria/NN and/CC dense/JJ bodies/NNS ,/, strongly/RB suggesting/VBG platelet/NN production/NN ./. 
Erythropoietin/NN (/( Epo/NN )/) ,/, granulocyte/macrophage/JJ colony/NN stimulating/NN factor/NN (/( GM-CSF/NN )/) ,/, and/CC interleukin/NN 3/CD (/( IL-3/NN )/) promoted/VBD the/DT growth/NN of/IN NS-Meg/NN cells/NNS ./. 
Phorbol-12-myristate-13-acetate/NN increased/VBD the/DT expression/NN of/IN both/CC CD41a/NN and/CC CD61/NN antigens/NNS ./. 
Ten-day/JJ exposure/NN to/TO Epo/NN induced/VBD mature/JJ erythroblasts/NNS and/CC red/JJ cells/NNS ./. 
These/DT benzidine-positive/JJ cells/NNS were/VBD positive/JJ for/IN hemoglobin/NN F/NN staining/NN ./. 
Untreated/JJ NS-Meg/NN cells/NNS expressed/VBD mRNA/NN for/IN the/DT Epo/NN receptor/NN (/( EpoR/NN )/) ,/, for/IN GATA-1/NN ,/, and/CC for/IN alpha/NN 1/CD ,/, alpha/NN 2/CD and/CC gamma/NN globin/NN genes/NNS ./. 
These/DT results/NNS indicate/VBP that/IN NS-Meg/NN cells/NNS undergo/VBP terminal/JJ differentiation/NN of/IN both/CC megakaryocytic/JJ and/CC erythroid/JJ lineages/NNS ./. 
This/DT cell/NN line/NN should/MD be/VB a/DT very/RB useful/JJ tool/NN for/IN the/DT investigation/NN of/IN both/CC megakaryocytic/JJ and/CC erythroid/JJ maturation/NN ./. 
UI/LS -/: 95081587/CD 
TI/LS -/: Differential/JJ regulation/NN of/IN proto-oncogenes/NNS c-jun/NN and/CC c-fos/NN in/IN T/NN lymphocytes/NNS activated/VBN through/IN CD28/NN ./. 
AB/LS -/: The/DT T/NN cell/NN surface/NN molecule/NN CD28/NN binds/VBZ to/TO ligands/NNS on/IN accessory/JJ cells/NNS and/CC APCs/NNS ,/, playing/VBG an/DT important/JJ costimulatory/JJ role/NN in/IN the/DT response/NN of/IN T/NN cells/NNS to/TO Ags/NN ./. 
Our/PRP$ knowledge/NN of/IN the/DT intracellular/JJ signaling/NN pathways/NNS coupled/VBN to/TO this/DT receptor/NN is/VBZ incomplete/JJ ./. 
In/IN addition/NN to/TO activation/NN of/IN phospholipase/NN C/NN gamma/NN 1/CD ,/, ligation/NN of/IN this/DT receptor/NN also/RB seems/VBZ to/TO activate/VB a/DT calcium-independent/JJ ,/, CD28-specific/JJ pathway/NN ./. 
In/IN this/DT paper/NN ,/, we/PRP report/VBP that/IN cross-linking/NN of/IN CD28/NN (/( but/CC not/RB CD2/NN ,/, CD5/NN ,/, LFA-1/NN ,/, or/CC CD7/NN )/) leads/VBZ to/TO an/DT elevation/NN of/IN c-jun/NN mRNA/NN ,/, with/IN only/RB minimal/JJ activation/NN of/IN c-fos/NN expression/NN ./. 
CD28-dependent/JJ induction/NN of/IN c-jun/NN expression/NN requires/VBZ protein/NN tyrosine/NN kinase/NN activity/NN ,/, but/CC does/VBZ not/RB depend/VB on/IN activation/NN of/IN a/DT phorbol/NN ester-responsive/JJ protein/NN kinase/NN C/NN or/CC elevation/NN of/IN cytosolic/JJ calcium/NN ./. 
Furthermore/RB ,/, CD28-dependent/JJ elevation/NN of/IN c-jun/NN mRNA/NN does/VBZ not/RB appear/VB to/TO be/VB mediated/VBN at/IN the/DT level/NN of/IN mRNA/NN stability/NN ./. 
A/DT mechanism/NN is/VBZ suggested/VBN whereby/WRB expression/NN of/IN c-jun/NN and/CC junB/NN ,/, in/IN the/DT absence/NN of/IN members/NNS of/IN the/DT fos/NN family/NN ,/, can/MD prevent/VB inappropriate/JJ activation/NN of/IN T/NN cells/NNS caused/VBN by/IN ligation/NN of/IN CD28/NN in/IN the/DT absence/NN of/IN a/DT specific/JJ antigenic/JJ stimulus/NN ./. 
UI/LS -/: 95056004/CD 
TI/LS -/: Enhanced/VBN responsiveness/NN to/TO nuclear/JJ factor/NN kappa/NN B/NN contributes/VBZ to/TO the/DT unique/JJ phenotype/NN of/IN simian/JJ immunodeficiency/NN virus/NN variant/NN SIVsmmPBj14/NN ./. 
AB/LS -/: Infection/NN with/IN a/DT variant/NN of/IN simian/JJ immunodeficiency/NN virus/NN ,/, SIVsmmPBj14/NN ,/, leads/VBZ to/TO severe/JJ acute/JJ disease/NN in/IN macaques/NNS ./. 
This/DT study/NN was/VBD designed/VBN to/TO investigate/VB the/DT functional/JJ significance/NN of/IN previously/RB described/VBN mutations/NNS in/IN the/DT viral/JJ long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) and/CC to/TO elucidate/VB their/PRP$ contribution/NN to/TO the/DT unique/JJ phenotype/NN of/IN SIVsmmPBj14/NN ./. 
LTR-directed/JJ transcription/NN was/VBD measured/VBN by/IN using/VBG luciferase/NN reporter/NN constructs/NNS that/WDT were/VBD transiently/RB transfected/VBN into/IN cultured/VBN cells/NNS ./. 
In/IN a/DT wide/JJ range/NN of/IN cell/NN types/NNS ,/, the/DT basal/JJ transcriptional/JJ activity/NN of/IN the/DT LTR/NN from/IN SIVsmmPBj14/NN was/VBD found/VBN to/TO be/VB 2-/CD to/TO 4.5-fold/RB higher/JJR than/IN that/DT of/IN an/DT LTR/NN from/IN a/DT non-acutely/JJ pathogenic/JJ strain/NN ./. 
These/DT LTRs/NNS differ/VBP by/IN five/CD point/NN mutations/NNS and/CC a/DT 22-bp/JJ duplication/NN in/IN SIVsmmPBj14/NN ,/, which/WDT includes/VBZ a/DT nuclear/JJ factor/NN kappa/NN B/NN (/( NF/NN kappa/NN B/NN )/) site/NN ./. 
Transcriptional/JJ differences/NNS between/IN these/DT LTRs/NNS were/VBD further/RB enhanced/VBN by/IN two-/CD to/TO threefold/RB upon/IN treatment/NN of/IN cells/NNS with/IN phorbol/NN ester/NN or/CC tumor/NN necrosis/NN factor/NN alpha/NN or/CC by/IN cotransfection/NN with/IN plasmids/NNS expressing/VBG NF/NN kappa/NN B/NN subunits/NNS ./. 
Mutagenesis/NN studies/NNS ,/, and/CC the/DT use/NN of/IN a/DT reporter/NN construct/NN containing/VBG an/DT enhancerless/JJ promoter/NN ,/, indicate/VBP that/IN these/DT transcriptional/JJ effects/NNS are/VBP due/JJ principally/RB to/TO the/DT 22-bp/JJ sequence/NN duplication/NN and/CC the/DT NF/NN kappa/NN B/NN site/NN contained/VBN within/IN it/PRP ./. 
Finally/RB ,/, infectious/JJ virus/NN stocks/NNS that/WDT were/VBD isogenic/JJ except/IN for/IN the/DT LTR/NN were/VBD generated/VBN ./. 
The/DT LTR/NN from/IN SIVsmmPBj14/NN was/VBD found/VBN to/TO confer/VB an/DT increase/NN in/IN the/DT kinetics/NNS of/IN virus/NN replication/NN in/IN cultured/VBN cells/NNS ./. 
Inclusion/NN of/IN this/DT LTR/NN in/IN recombinant/JJ SIVs/NNS also/RB resulted/VBD in/IN a/DT two-/CD to/TO threefold/JJ rise/NN in/IN the/DT extent/NN of/IN cellular/JJ proliferation/NN that/WDT was/VBD induced/VBN in/IN quiescent/JJ simian/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
These/DT studies/NNS are/VBP consistent/JJ with/IN the/DT hypothesis/NN that/IN LTR/NN mutations/NNS assist/VBP SIVsmmPBj14/NN in/IN responding/VBG efficiently/RB to/TO cellular/JJ stimulation/NN and/CC allow/VBP it/PRP to/TO replicate/VB to/TO high/JJ titers/NNS during/IN the/DT acute/JJ phase/NN of/IN viral/JJ infection/NN ./. 
UI/LS -/: 95091657/CD 
TI/LS -/: Constitutive/JJ nuclear/JJ NF-kappa/NN B/NN in/IN cells/NNS of/IN the/DT monocyte/NN lineage/NN ./. 
AB/LS -/: In/IN monocytes/NNS ,/, the/DT nuclear/JJ factor/NN NF-kappa/NN B/NN has/VBZ been/VBN invoked/VBN as/IN an/DT important/JJ transcription/NN factor/NN in/IN the/DT expression/NN of/IN cytokine/NN genes/NNS ,/, of/IN cell-surface/JJ receptors/NNS and/CC in/IN the/DT expression/NN of/IN human/JJ immunodeficiency/NN virus/NN ./. 
In/IN such/JJ cells/NNS ,/, DNA/NN binding/NN activity/NN of/IN NF-kappa/NN B/NN can/MD be/VB detected/VBN without/IN intentional/JJ stimulation/NN ./. 
In/IN our/PRP$ studies/NNS ,/, cells/NNS of/IN the/DT human/JJ monocytic/JJ line/NN Mono/NN Mac/NN 6/CD ,/, cultured/VBN in/IN medium/NN containing/VBG fetal-calf/JJ serum/NN and/CC low/JJ levels/NNS of/IN lipopolysaccharide/NN (/( LPS/NN )/) ,/, also/RB exhibit/VBP such/JJ '/`` constitutive/JJ '/'' NF-kappa/NN B/NN ,/, as/IN demonstrated/VBN by/IN mobility-shift/JJ analysis/NN of/IN nuclear/JJ extracts/NNS ./. 
This/DT nuclear/JJ NF-kappa/NN B/NN was/VBD still/RB present/JJ when/WRB contaminant/JJ LPS/NN was/VBD removed/VBN by/IN ultrafiltration/NN and/CC when/WRB serum/NN was/VBD omitted/VBN ./. 
Protein-DNA/JJ complexes/NNS of/IN constitutive/JJ NF-kappa/NN B/NN are/VBP similar/JJ in/IN mobility/NN to/TO the/DT LPS-induced/JJ NF-kappa/NN B/NN and/CC both/DT are/VBP recognized/VBN by/IN an/DT antibody/NN specific/JJ to/TO the/DT p50/NN subunit/NN of/IN NF-kappa/NN B/NN ./. 
By/IN contrast/NN ,/, treatment/NN of/IN cells/NNS with/IN pyrrolidine/NN dithiocarbamate/NN (/( PDTC/NN )/) will/MD only/RB block/VB LPS-induced/JJ NF-kappa/NN B/NN ,/, but/CC not/RB the/DT constitutive/JJ binding/VBG protein/NN ./. 
Using/VBG LPS-free/JJ and/CC serum-free/JJ conditions/NNS ,/, constitutive/JJ NF-kappa/NN B/NN can/MD be/VB detected/VBN in/IN different/JJ cell/NN lines/NNS of/IN the/DT monocytic/JJ lineage/NN (/( HL60/NN ,/, U937/NN ,/, THP-1/NN ,/, Mono/NN Mac/NN 1/CD and/CC Mono/NN Mac/NN 6/CD )/) ,/, but/CC not/RB in/IN Molt/NN 4/CD T/NN cells/NNS or/CC K562/NN stem/NN cells/NNS ./. 
When/WRB ordered/VBN according/VBG to/TO stage/NN of/IN maturation/NN ,/, the/DT amount/NN of/IN constitutive/JJ NF-kappa/NN B/NN was/VBD not/RB increased/VBN in/IN more/RBR mature/JJ cell/NN lines/NNS ./. 
Furthermore/RB ,/, when/WRB inducing/VBG differentiation/NN in/IN Mono/NN Mac/NN 6/CD cells/NNS ,/, with/IN vitamin/NN D3/NN ,/, no/DT change/NN in/IN constitutive/JJ or/CC inducible/JJ NF-kappa/NN B/NN can/MD be/VB detected/VBN ./. 
Analysis/NN of/IN primary/JJ cells/NNS revealed/VBD substantial/JJ constitutive/JJ NF-kappa/NN B-binding/JJ activity/NN in/IN blood/NN monocytes/NNS ,/, pleural/JJ macrophages/NNS and/CC alveolar/JJ macrophages/NNS ./. 
The/DT constitutive/JJ NF-kappa/NN B/NN appears/VBZ to/TO be/VB functionally/RB active/JJ ,/, since/IN a/DT low/JJ level/NN of/IN tumour/NN necrosis/NN factor/NN (/( TNF/NN )/) transcript/NN is/VBZ detectable/JJ in/IN monocytes/NNS ,/, and/CC this/DT level/NN can/MD be/VB increased/VBN by/IN blocking/VBG transcript/NN degradation/NN using/VBG cycloheximide/NN ./. 
The/DT level/NN of/IN constitutive/JJ NF-kappa/NN B/NN in/IN these/DT cells/NNS is/VBZ variable/JJ and/CC is/VBZ frequently/RB found/VBN to/TO be/VB lower/JJR in/IN the/DT more/RBR mature/JJ macrophages/NNS ./. 
Constitutive/JJ NF-kappa/NN B/NN was/VBD not/RB maintained/VBN by/IN autocrine/JJ action/NN of/IN cytokines/NNS TNF/NN ,/, interleukin/NN 6/CD ,/, interleukin/NN 10/CD ,/, granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN or/CC macrophage/NN colony-stimulating/JJ factor/NN ,/, since/IN neutralizing/VBG antibodies/NNS did/VBD not/RB reduce/VB constitutive/JJ DNA-binding/JJ activity/NN ./. 
Furthermore/RB ,/, blockade/NN of/IN prostaglandin/NN or/CC leukotriene/NN biosynthesis/NN did/VBD not/RB affect/VB constitutive/JJ NF-kappa/NN B/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 400/CD WORDS/NNS )/) 
UI/LS -/: 95036334/CD 
TI/LS -/: Steel/NN factor/NN affects/VBZ SCL/NN expression/NN during/IN normal/JJ erythroid/JJ differentiation/NN ./. 
AB/LS -/: Steel/NN factor/NN is/VBZ one/CD of/IN the/DT growth/NN factors/NNS that/WDT controls/VBZ the/DT proliferation/NN and/CC differentiation/NN of/IN hematopoietic/JJ cells/NNS and/CC SCL/NN ,/, also/RB known/VBN as/IN Tcl-5/NN or/CC Tal-1/NN ,/, is/VBZ a/DT transcription/NN factor/NN involved/VBN in/IN erythropoiesis/NN ./. 
In/IN this/DT report/NN ,/, we/PRP studied/VBD the/DT role/NN of/IN SCL/NN in/IN the/DT proliferation/NN of/IN human/JJ peripheral/JJ blood/NN burst-forming/JJ unit-erythroid/NN (/( BFU-E/NN )/) and/CC the/DT effects/NNS of/IN Steel/NN factor/NN on/IN SCL/NN expression/NN in/IN proliferating/VBG erythroid/JJ cells/NNS ./. 
BFU-E-derived/JJ colonies/NNS increase/VBP progressively/RB in/IN size/NN ,/, as/IN determined/VBN by/IN cell/NN number/NN ,/, from/IN day/NN 7/CD to/TO day/NN 14/CD of/IN culture/NN ,/, with/IN the/DT greatest/JJS increase/NN in/IN colony/NN size/NN (/( 10-fold/JJ expansion/NN )/) occurring/VBG between/IN day/NN 7/CD and/CC day/NN 10/CD ./. 
SCL/NN protein/NN levels/NNS in/IN BFU-E-derived/JJ cells/NNS were/VBD highest/JJS in/IN day/NN 7/CD cells/NNS and/CC decreased/VBD progressively/RB from/IN day/NN 7/CD to/TO day/NN 14/CD of/IN culture/NN ,/, suggesting/VBG an/DT association/NN of/IN SCL/NN with/IN erythroid/JJ proliferation/NN ./. 
In/IN contrast/NN ,/, SCL/NN mRNA/NN levels/NNS did/VBD not/RB decrease/VB significantly/RB between/IN day/NN 7/CD and/CC day/NN 14/CD cells/NNS ,/, suggesting/VBG that/IN posttranscriptional/JJ mechanisms/NNS are/VBP largely/RB responsible/JJ for/IN the/DT decrease/NN in/IN SCL/NN protein/NN observed/VBN ./. 
The/DT role/NN of/IN SCL/NN in/IN Steel/NN factor-induced/JJ erythroid/JJ proliferation/NN was/VBD then/RB examined/VBN ./. 
In/IN BFU-E-derived/JJ colonies/NNS cultured/VBN with/IN Steel/NN factor/NN ,/, colony/NN size/NN was/VBD significantly/RB increased/VBN compared/VBN to/TO control/NN ./. 
In/IN day/NN 7/CD and/CC day/NN 10/CD erythroid/JJ precursors/NNS cultured/VBN with/IN Steel/NN factor/NN ,/, SCL/NN protein/NN was/VBD increased/VBN significantly/RB compared/VBN to/TO control/NN ./. 
The/DT increase/NN in/IN SCL/NN protein/NN levels/NNS in/IN early/JJ erythroid/JJ precursors/NNS stimulated/VBD with/IN Steel/NN factor/NN suggests/VBZ one/CD mechanism/NN through/IN which/WDT Steel/NN factor/NN may/MD enhance/VB normal/JJ erythroid/JJ proliferation/NN ./. 
SCL/NN mRNA/NN levels/NNS assessed/VBN by/IN Northern/NN blot/NN in/IN day/NN 7/CD cells/NNS did/VBD not/RB increase/VB significantly/RB in/IN response/NN to/TO Steel/NN factor/NN stimulation/NN ,/, suggesting/VBG that/IN posttranscriptional/JJ mechanisms/NNS may/MD also/RB be/VB important/JJ in/IN the/DT increase/NN in/IN SCL/NN protein/NN observed/VBN in/IN response/NN to/TO Steel/NN ./. 
UI/LS -/: 95015010/CD 
TI/LS -/: C/EBP/NN beta/NN regulation/NN of/IN the/DT tumor/NN necrosis/NN factor/NN alpha/NN gene/NN ./. 
AB/LS -/: Activated/VBN macrophages/NNS contribute/VBP to/TO chronic/JJ inflammation/NN by/IN the/DT secretion/NN of/IN cytokines/NNS and/CC proteinases/NNS ./. 
Tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF/NN alpha/NN )/) is/VBZ particularly/RB important/JJ in/IN this/DT process/NN because/IN of/IN its/PRP$ ability/NN to/TO regulate/VB other/JJ inflammatory/JJ mediators/NNS in/IN an/DT autocrine/JJ and/CC paracrine/JJ fashion/NN ./. 
The/DT mechanism/NN (/( s/NNS )/) responsible/JJ for/IN the/DT cell/NN type-specific/JJ regulation/NN of/IN TNF/NN alpha/NN is/VBZ not/RB known/VBN ./. 
We/PRP present/VBP data/NNS to/TO show/VB that/IN the/DT expression/NN of/IN TNF/NN alpha/NN is/VBZ regulated/VBN by/IN the/DT transcription/NN factor/NN C/EBP/NN beta/NN (/( NF-IL6/NN )/) ./. 
C/EBP/NN beta/NN activated/VBD the/DT TNF/NN alpha/NN gene/NN promoter/NN in/IN cotransfection/NN assays/NNS and/CC bound/VBD to/TO it/PRP at/IN a/DT site/NN which/WDT failed/VBD to/TO bind/VB the/DT closely/RB related/JJ protein/NN C/EBP/NN alpha/NN ./. 
Finally/RB ,/, a/DT dominant-negative/JJ version/NN of/IN C/EBP/NN beta/NN blocked/VBD TNF/NN alpha/NN promoter/NN activation/NN in/IN myeloid/JJ cells/NNS ./. 
Our/PRP$ results/NNS implicate/VBP C/EBP/NN beta/NN as/IN an/DT important/JJ regulator/NN of/IN TNF/NN alpha/NN by/IN myelomonocytic/JJ cells/NNS ./. 
UI/LS -/: 95173590/CD 
TI/LS -/: Calcium/calmodulin-dependent/JJ protein/NN kinase/NN II/CD downregulates/VBZ both/CC calcineurin/NN and/CC protein/NN kinase/NN C-mediated/JJ pathways/NNS for/IN cytokine/NN gene/NN transcription/NN in/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: Engagement/NN of/IN the/DT T/NN cell/NN receptor/NN for/IN antigen/NN activates/VBZ phospholipase/NN C/NN resulting/VBG in/IN an/DT increase/NN in/IN intracellular/JJ free/JJ calcium/NN concentration/NN (/( [Ca2+]i/NN )/) and/CC activation/NN of/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) ./. 
Increased/VBN [Ca2+]i/NN activates/VBZ Ca2+/calmodulin-dependent/JJ kinases/NNS including/VBG the/DT multifunctional/JJ Ca2+/calmodulin-dependent/JJ protein/NN kinase/NN II/CD (/( CaM-K/NN II/CD )/) ,/, as/RB well/RB as/IN calcineurin/NN ,/, a/DT type/NN 2B/NN protein/NN phosphatase/NN ./. 
Recent/JJ studies/NNS have/VBP identified/VBN calcineurin/NN as/IN a/DT key/JJ enzyme/NN for/IN interleukin/NN (/( IL/NN )/) -2/CD and/CC IL-4/NN promoter/NN activation/NN ./. 
However/RB ,/, the/DT role/NN of/IN CaM-K/NN II/CD remains/VBZ unknown/JJ ./. 
We/PRP have/VBP used/VBN mutants/NNS of/IN these/DT kinases/NNS and/CC phosphatases/NNS (/( gamma/NN B*CaM-K/NN and/CC delta/NN CaM-AI/NN ,/, respectively/RB )/) to/TO explore/VB their/PRP$ relative/JJ role/NN in/IN cytokine/NN gene/NN transcription/NN and/CC their/PRP$ interactions/NNS with/IN PKC-dependent/JJ signaling/NN systems/NNS ./. 
gamma/NN B*CaM-K/NN and/CC delta/NN CaM-AI/NN ,/, known/VBN to/TO exhibit/VB constitutive/JJ Ca(2+)-independent/JJ activity/NN ,/, were/VBD cotransfected/VBN (/( alone/RB or/CC in/IN combination/NN )/) in/IN Jurkat/NN T/NN cells/NNS with/IN a/DT plasmid/NN containing/VBG the/DT intact/JJ IL-2/NN promoter/NN driving/VBG the/DT expression/NN of/IN the/DT chloramphenicol/NN acetyltransferase/NN reporter/NN gene/NN ./. 
Cotransfection/NN of/IN gamma/NN B*CaM-K/NN with/IN the/DT IL-2/NN promoter/NN construct/NN downregulated/VBD its/PRP$ transcription/NN in/IN response/NN to/TO stimulation/NN with/IN ionomycin/NN and/CC phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) ./. 
The/DT inhibitory/JJ effect/NN of/IN CaM-K/NN II/CD on/IN IL-2/NN promoter/NN was/VBD associated/VBN with/IN decreased/VBN transcription/NN of/IN its/PRP$ AP-1/NN and/CC NF-AT/NN transactivating/NN pathways/NNS ./. 
Under/IN the/DT same/JJ conditions/NNS ,/, delta/NN CaM-AI/NN superinduced/VBD IL-2/NN promoter/NN activity/NN (/( approximately/RB twofold/JJ increase/NN )/) ./. 
When/WRB both/DT mutants/NNS were/VBD used/VBN in/IN combination/NN ,/, gamma/NN B*CaM-K/NN inhibited/VBD the/DT induction/NN of/IN the/DT IL-2/NN promoter/NN by/IN delta/NN CaM-AI/NN ./. 
Similar/JJ results/NNS were/VBD obtained/VBN when/WRB a/DT construct/NN containing/VBG the/DT IL-4/NN promoter/NN also/RB was/VBD used/VBN ./. 
gamma/NN B*CaM-K/NN also/RB downregulated/VBD the/DT activation/NN of/IN AP-1/NN in/IN response/NN to/TO transfection/NN with/IN a/DT constitutively/RB active/JJ mutant/NN of/IN PKC/NN or/CC stimulation/NN with/IN PMA/NN ./. 
These/DT results/NNS suggest/VBP that/IN CaM-K/NN II/CD may/MD exert/VB negative/JJ influences/NNS on/IN cytokine/NN gene/NN transcription/NN in/IN human/JJ T/NN cells/NNS ,/, and/CC provide/VBP preliminary/JJ evidence/NN for/IN negative/JJ cross-talk/NN with/IN the/DT calcineurin-/NN and/CC PKC-dependent/JJ signaling/NN systems/NNS ./. 
UI/LS -/: 95130292/CD 
TI/LS -/: Induction/NN of/IN ICAM-1/NN and/CC LFA-3/NN by/IN Tax1/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD and/CC mechanism/NN of/IN down-regulation/NN of/IN ICAM-1/NN or/CC LFA-1/NN in/IN adult-T-cell-leukemia/JJ cell/NN lines/NNS ./. 
AB/LS -/: The/DT present/JJ study/NN was/VBD undertaken/VBN to/TO determine/VB the/DT role/NN of/IN HTLV-I/NN TaxI/NN in/IN the/DT up-regulation/NN of/IN ICAM-I/NN and/CC LFA-3/NN in/IN human/JJ T/NN cells/NNS transformed/VBN with/IN HTLV-I/NN and/CC the/DT mechanism/NN of/IN down-regulation/NN of/IN ICAM-I/NN and/CC LFA-I/NN in/IN ATL-derived/JJ cell/NN lines/NNS ./. 
Induction/NN of/IN TaxI/NN in/IN a/DT human/JJ T-cell/NN line/NN Jurkat/NN carrying/VBG the/DT TaxI/NN gene/NN under/IN the/DT metallothionein/NN promoter/NN led/VBD to/TO increases/NNS in/IN mRNA/NN and/CC surface/NN expression/NN of/IN ICAM-I/NN ./. 
The/DT response/NN of/IN LFA-3/NN to/TO TaxI/NN induction/NN was/VBD ,/, on/IN the/DT other/JJ hand/NN ,/, relatively/RB slow/JJ and/CC weak/JJ ,/, and/CC might/MD be/VB indirect/JJ ./. 
Transactivation/NN of/IN the/DT ICAM-I/NN promoter/NN by/IN TaxI/NN was/VBD further/RB shown/VBN by/IN co-transfection/NN of/IN a/DT CAT/NN reporter/NN construct/NN with/IN the/DT ICAM-I/NN promoter/NN and/CC a/DT plasmid/NN expressing/VBG TaxI/NN ./. 
The/DT mechanism/NN of/IN down-regulation/NN of/IN ICAM-I/NN or/CC LFA-I/NN in/IN 4/CD ATL/NN cell/NN lines/NNS was/VBD next/RB examined/VBN ./. 
ICAM-I/NN mRNA/NN was/VBD quite/RB low/JJ in/IN MT-I/NN ,/, but/CC no/DT genomic/JJ changes/NNS were/VBD found/VBN ./. 
The/DT CAT/NN reporter/NN with/IN the/DT ICAM-I/NN promoter/NN was/VBD inactive/JJ in/IN MT-I/NN ./. 
Finally/RB ,/, combined/JJ treatment/NN of/IN MT-I/NN with/IN 5-azacytidine/NN and/CC IFN-gamma/NN induced/VBD re-expression/NN of/IN ICAM-I/NN ./. 
Collectively/RB ,/, (/( a/DT )/) transcriptional/JJ factor/NN (/( s/NNS )/) necessary/JJ for/IN expression/NN of/IN ICAM-I/NN gene/NN may/MD be/VB repressed/VBN in/IN MT-I/NN through/IN DNA/NN methylation/NN ./. 
Three/CD other/JJ ATL/NN cell/NN lines/NNS (/( TL-OmI/NN ,/, H582/NN ,/, HuT102/NN )/) were/VBD found/VBN to/TO have/VB little/JJ mRNA/NN for/IN the/DT LFA-I/NN beta/NN chain/NN (/( CD18/NN )/) ./. 
H582/NN and/CC HuT102/NN were/VBD also/RB negative/JJ for/IN the/DT LFA-I/NN alpha/NN chain/NN (/( CDIIa/NN )/) mRNA/NN ./. 
No/DT genomic/JJ changes/NNS were/VBD found/VBN ,/, and/CC a/DT CAT/NN reporter/NN gene/NN with/IN the/DT CD18/NN promoter/NN was/VBD inactive/JJ in/IN the/DT 3/CD of/IN them/PRP ,/, again/RB suggesting/VBG lack/NN of/IN (/( a/DT )/) transcriptional/JJ factor/NN (/( s/NNS )/) necessary/JJ for/IN CD18/NN expression/NN ./. 
UI/LS -/: 95287902/CD 
TI/LS -/: Infection/NN with/IN Theileria/FW annulata/FW induces/VBZ expression/NN of/IN matrix/NN metalloproteinase/NN 9/CD and/CC transcription/NN factor/NN AP-1/NN in/IN bovine/JJ leucocytes/NNS ./. 
AB/LS -/: Theileria/FW annulata/FW infects/VBZ bovine/JJ leucocytes/NNS and/CC results/VBZ in/IN their/PRP$ reversible/JJ transformation/NN such/IN that/IN they/PRP become/VBP immortalised/VBN and/CC metastatic/JJ ./. 
The/DT present/JJ study/NN describes/VBZ parasite-induced/JJ changes/NNS in/IN host/NN cell/NN gene/NN expression/NN which/WDT have/VBP a/DT direct/JJ bearing/NN on/IN this/DT transformation/NN process/NN ./. 
T./FW annulata-infected/JJ leucocytes/NNS produce/VBP a/DT number/NN of/IN novel/JJ metalloproteinase/NN activities/NNS ./. 
One/CD of/IN these/DT ,/, previously/RB called/VBN B1/NN ,/, is/VBZ a/DT 97-kDa/JJ protein/NN which/WDT is/VBZ secreted/VBN in/IN large/JJ amounts/NNS and/CC has/VBZ been/VBN purified/VBN from/IN protein-free/JJ ,/, conditioned/JJ medium/NN ./. 
An/DT antiserum/NN to/TO this/DT enzyme/NN was/VBD used/VBN to/TO isolate/VB a/DT cDNA/NN clone/NN ./. 
The/DT predicted/VBN protein/NN sequence/NN of/IN B1/NN is/VBZ 81/CD %/NN identical/JJ to/TO human/JJ matrix/NN metalloproteinase/NN 9/CD (/( MMP9/NN )/) ,/, demonstrating/VBG that/IN it/PRP is/VBZ the/DT bovine/JJ homologue/NN of/IN this/DT enzyme/NN ./. 
RNAase/NN protection/NN assays/NNS demonstrated/VBD that/IN the/DT MMP9/NN activity/NN ,/, unique/JJ to/TO infected/JJ cells/NNS ,/, is/VBZ due/JJ to/TO increased/VBN MMP9/NN mRNA/NN levels/NNS ./. 
We/PRP also/RB assayed/VBD the/DT levels/NNS of/IN transcription/NN factor/NN AP-1/NN and/CC demonstrated/VBD that/IN it/PRP was/VBD constitutively/RB present/JJ in/IN increased/VBN amounts/NNS in/IN Theileria-infected/JJ cells/NNS ./. 
In/IN addition/NN we/PRP assayed/VBD the/DT level/NN of/IN mRNA/NN encoding/VBG c-Fos/NN ,/, a/DT common/JJ component/NN of/IN AP-1/NN and/CC observed/VBD that/IN it/PRP was/VBD indeed/RB up-regulated/VBN in/IN infected/JJ cells/NNS ./. 
Since/IN AP-1/NN is/VBZ implicated/VBN in/IN the/DT control/NN of/IN the/DT cell/NN cycle/NN ,/, and/CC MMP9/NN can/MD confer/VB metastatic/JJ properties/NNS ,/, these/DT results/NNS are/VBP of/IN considerable/JJ significance/NN with/IN respect/NN to/TO the/DT transformed/VBN phenotype/NN induced/VBN by/IN Theileria/FW infection/NN ./. 
UI/LS -/: 95129555/CD 
TI/LS -/: B-cell/NN proliferation/NN and/CC induction/NN of/IN early/JJ G1-regulating/JJ proteins/NNS by/IN Epstein-Barr/JJ virus/NN mutants/NNS conditional/JJ for/IN EBNA2/NN ./. 
AB/LS -/: Infection/NN of/IN primary/JJ B-lymphocytes/NNS by/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) leads/VBZ to/TO growth/NN transformation/NN of/IN these/DT B-cells/NNS in/FW vitro/FW ./. 
EBV/NN nuclear/JJ antigen/NN 2/CD (/( EBNA2/NN )/) ,/, one/CD of/IN the/DT first/JJ genes/NNS expressed/VBN after/IN EBV/NN infection/NN of/IN B-cells/NNS ,/, is/VBZ a/DT transcriptional/JJ activator/NN of/IN viral/JJ and/CC cellular/JJ genes/NNS and/CC is/VBZ essential/JJ for/IN the/DT transforming/VBG potential/NN of/IN the/DT virus/NN ./. 
We/PRP generated/VBD conditional/JJ EBV/NN mutants/NNS by/IN expressing/VBG EBNA2/NN as/IN chimeric/JJ fusion/NN protein/NN with/IN the/DT hormone/NN binding/NN domain/NN of/IN the/DT estrogen/NN receptor/NN on/IN the/DT genetic/JJ background/NN of/IN the/DT virus/NN ./. 
Growth/NN transformation/NN of/IN primary/JJ normal/JJ B-cells/NNS by/IN mutant/JJ virus/NN resulted/VBD in/IN estrogen-dependent/JJ lymphoblastoid/JJ cell/NN lines/NNS expressing/VBG the/DT chimeric/JJ EBNA2/NN protein/NN ./. 
In/IN the/DT absence/NN of/IN estrogen/NN about/RB half/NN of/IN the/DT cells/NNS enter/VBP a/DT quiescent/JJ non-proliferative/JJ state/NN whereas/IN the/DT others/NNS die/VBP by/IN apoptosis/NN ./. 
EBNA2/NN is/VBZ thus/RB required/VBN not/RB only/RB for/IN initiation/NN but/CC also/RB for/IN maintenance/NN of/IN transformation/NN ./. 
Growth/NN arrest/NN occurred/VBD at/IN G1/NN and/CC G2/NN stages/NNS of/IN the/DT cell/NN cycle/NN ,/, indicating/VBG that/IN functional/JJ EBNA2/NN is/VBZ required/VBN at/IN different/JJ restriction/NN points/NNS of/IN the/DT cell/NN cycle/NN ./. 
Growth/NN arrest/NN is/VBZ reversible/JJ for/IN G1/G0/NN cells/NNS as/IN indicated/VBN by/IN the/DT sequential/JJ accumulation/NN and/CC modification/NN of/IN cell/NN cycle/NN regulating/NN proteins/NNS ./. 
EBV/NN induces/VBZ the/DT same/JJ cell/NN cycle/NN regulating/NN proteins/NNS as/IN polyclonal/JJ stimuli/NNS in/IN primary/JJ B-cells/NNS ./. 
These/DT data/NNS suggest/VBP that/IN EBV/NN is/VBZ using/VBG a/DT common/JJ pathway/NN for/IN B-cell/NN activation/NN bypassing/VBG the/DT requirement/NN for/IN antigen/NN ,/, T-cell/NN signals/NNS and/CC growth/NN factors/NNS ./. 
UI/LS -/: 95234639/CD 
TI/LS -/: IL-1/NN receptor/NN and/CC TCR/NN signals/NNS synergize/VBP to/TO activate/VB NF-kappa/NN B-mediated/JJ gene/NN transcription/NN ./. 
AB/LS -/: Previous/JJ studies/NNS have/VBP demonstrated/VBN that/IN IL-1/NN receptor/NN (/( IL-1R/NN )/) -/: and/CC TCR-initiated/JJ signals/NNS can/MD interact/VB synergistically/RB to/TO increase/VB the/DT rate/NN of/IN transcription/NN of/IN several/JJ lymphokine/NN and/CC lymphokine/NN receptor/NN genes/NNS during/IN the/DT competence/NN phase/NN of/IN the/DT activation/NN program/NN in/IN T/NN helper/NN lymphocytes/NNS ./. 
In/IN this/DT report/NN we/PRP describe/VBP how/WRB signals/NNS initiated/VBN through/IN the/DT type/NN I/CD IL-1R/NN interact/VBP with/IN signals/NNS from/IN the/DT antigen/NN receptor/NN to/TO synergistically/RB augment/VB the/DT transactivating/NN properties/NNS of/IN NF-kappa/NN B/NN ./. 
The/DT synergistic/JJ antigen/NN receptor/NN initiated/JJ signals/NNS are/VBP mediated/VBN through/IN protein/NN kinase/NN C/NN because/IN they/PRP can/MD be/VB mimicked/VBN by/IN the/DT phorbol/NN ester/NN ,/, 12-O-tetradecanoylphorbol-13-acetate/NN ,/, but/CC not/RB with/IN calcium/NN ionophores/NNS ;/: and/CC are/VBP staurosporine/NN sensitive/JJ but/CC cyclosporine/NN resistant/JJ ./. 
Gel/NN shift/NN analyses/NNS demonstrate/VBP that/IN NF-kappa/NN B/NN nuclear/JJ translocation/NN is/VBZ stimulated/VBN primarily/RB by/IN IL-1/NN rather/RB than/IN by/IN antigen/NN receptor/NN signals/NNS ./. 
Western/NN blot/NN and/CC phosphorylation/NN analyses/NNS demonstrate/VBP that/IN the/DT synergistic/JJ effect/NN on/IN NF-kappa/NN B/NN functional/JJ activity/NN is/VBZ independent/JJ of/IN I/NN kappa/NN B/NN alpha/NN (/( MAD3/NN )/) -NF-kappa/NN B/NN dissociation/NN in/IN the/DT cytosol/NN and/CC is/VBZ not/RB associated/VBN with/IN I/NN kappa/NN B/NN nuclear/JJ translocation/NN ./. 
The/DT IL-1-induced/JJ NF-kappa/NN B/NN DNA/NN nuclear/JJ localization/NN is/VBZ transient/JJ and/CC can/MD be/VB prolonged/JJ either/CC by/IN an/DT antigen/NN receptor-initiated/JJ signal/NN or/CC by/IN inhibiting/VBG protein/NN synthesis/NN ./. 
These/DT results/NNS suggest/VBP that/IN IL-1/NN induces/VBZ both/CC NF-kappa/NN B/NN nuclear/JJ translocation/NN and/CC the/DT synthesis/NN of/IN a/DT protein/NN (/( s/NNS )/) responsible/JJ for/IN terminating/VBG NF-kappa/NN B-DNA/NN interaction/NN in/IN the/DT nucleus/NN ./. 
Antigen/NN receptor/NN signals/NNS prolong/VBP NF-kappa/NN B-DNA/NN interaction/NN ,/, probably/RB by/IN functionally/RB antagonizing/VBG the/DT IL-1-inducedsynthesis/NN of/IN a/DT protein/NN (/( s/NNS )/) responsible/JJ for/IN the/DT transient/JJ NF-kappa/NN B-DNA/NN interaction/NN and/CC consequently/RB synergistically/RB enhance/VBP IL-1-induced/JJ NF-kappa/NN B-dependent/JJ gene/NN transcription/NN ./. 
UI/LS -/: 95121921/CD 
TI/LS -/: Identification/NN of/IN the/DT promoter/NN region/NN of/IN chicken/NN anemia/NN virus/NN (/( CAV/NN )/) containing/VBG a/DT novel/JJ enhancer-like/JJ element/NN ./. 
AB/LS -/: The/DT single/JJ promoter/NN region/NN in/IN the/DT cloned/VBN genome/NN [/( Noteborn/NNP et/FW al./FW ,/, J./NNP Virol./NNP 65/CD (/( 1991/CD )/) 3131-3139/CD ]/) of/IN chicken/NN anemia/NN virus/NN (/( CAV/NN )/) in/IN chicken/NN T-cells/NNS was/VBD analysed/JJ via/IN CAT/NN assays/NNS ./. 
A/DT unique/JJ region/NN containing/VBG four/CD or/CC five/CD near-perfect/JJ direct/JJ repeats/NNS (/( DR/NN )/) of/IN 21/CD bp/NN with/IN one/CD 12-bp/JJ insert/NN was/VBD proven/VBN to/TO be/VB the/DT main/JJ transcription-activation/JJ element/NN ,/, with/IN enhancer-like/JJ characteristics/NNS ./. 
PCR/NN studies/NNS revealed/VBD that/IN CAV/NN isolates/NNS from/IN across/IN the/DT world/NN all/DT contained/VBD this/DT promoter/NN sequence/NN ./. 
Electrophoretic/JJ mobility-shift/JJ assays/NNS (/( EMSA/NN )/) showed/VBD that/IN individual/JJ DR/NN units/NNS ,/, as/RB well/RB as/IN the/DT 12-bp/JJ insert/NN ,/, can/MD bind/VB to/TO nuclear/JJ factors/NNS of/IN chicken/NN T-cells/NNS ./. 
Competition/NN assays/NNS revealed/VBD that/IN the/DT DR/NN units/NNS bound/VBD to/TO factors/NNS other/JJ than/IN the/DT 12-bp/JJ insert/NN ./. 
A/DT synthetic/JJ oligodeoxyribonucleotide/NN containing/VBG an/DT SP1-box/NN (/( 5'-GGGCGG/NN )/) could/MD compete/VB with/IN factors/NNS binding/VBG to/TO the/DT 12-bp/JJ insert/NN ./. 
Purified/VBN human/JJ SP1/NN was/VBD shown/VBN to/TO have/VB very/RB strong/JJ affinity/NN for/IN the/DT 12-bp/JJ insert/NN ./. 
UI/LS -/: 95053781/CD 
TI/LS -/: Functional/JJ Myc-Max/NN heterodimer/NN is/VBZ required/VBN for/IN activation-induced/JJ apoptosis/NN in/IN T/NN cell/NN hybridomas/NNS ./. 
AB/LS -/: T/NN cell/NN hybridomas/NNS respond/VBP to/TO activation/NN signals/NNS by/IN undergoing/VBG apoptotic/JJ cell/NN death/NN ,/, and/CC this/DT is/VBZ likely/RB to/TO represent/VB comparable/JJ events/NNS related/JJ to/TO tolerance/NN induction/NN in/IN immature/JJ and/CC mature/JJ T/NN cells/NNS in/FW vivo/FW ./. 
Previous/JJ studies/NNS using/VBG antisense/JJ oligonucleotides/NNS implicated/VBD the/DT c-Myc/NN protein/NN in/IN the/DT phenomenon/NN of/IN activation-induced/JJ apoptosis/NN ./. 
This/DT role/NN for/IN c-Myc/NN in/IN apoptosis/NN is/VBZ now/RB confirmed/VBN in/IN studies/NNS using/VBG a/DT dominant/JJ negative/JJ form/NN of/IN its/PRP$ heterodimeric/JJ binding/NN partner/NN ,/, Max/NN ,/, which/WDT we/PRP show/VBP here/RB inhibits/VBZ activation-induced/JJ apoptosis/NN ./. 
Further/RB ,/, coexpression/NN of/IN a/DT reciprocally/RB mutant/JJ Myc/NN protein/NN capable/JJ of/IN forming/VBG functional/JJ heterodimers/NNS with/IN the/DT mutant/JJ Max/NN can/MD compensate/VB for/IN the/DT dominant/JJ negative/JJ activity/NN and/CC restore/VB activation-induced/JJ apoptosis/NN ./. 
These/DT results/NNS imply/VBP that/IN Myc/NN promotes/VBZ activation-induced/JJ apoptosis/NN by/IN obligatory/JJ heterodimerization/NN with/IN Max/NN ,/, and/CC therefore/RB ,/, by/IN regulating/VBG gene/NN transcription/NN ./. 
UI/LS -/: 95065655/CD 
TI/LS -/: Epstein-Barr/JJ virus/NN SM/NN protein/NN ./. 
AB/LS -/: The/DT protein/NN products/NNS of/IN the/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) BMLF1/NN open/JJ reading/NN frame/NN have/VBP been/VBN characterized/VBN in/IN the/DT early/JJ productive/JJ cycle/NN in/IN B95-8/NN and/CC Akata/NN cells/NNS ./. 
The/DT SM/NN protein/NN derived/VBN from/IN the/DT spliced/VBN RNA/NN joining/VBG BSLF2/NN to/TO BMLF1/NN is/VBZ much/RB the/DT most/RBS abundant/JJ protein/NN ./. 
SM/NN is/VBZ a/DT phosphoprotein/NN in/IN EBV-infected/JJ cells/NNS and/CC can/MD be/VB phosphorylated/VBN in/FW vitro/FW with/IN casein/NN kinase/NN II/CD (/( CKII/NN )/) ./. 
Computer/NN analysis/NN of/IN the/DT SM/NN protein/NN sequence/NN showed/VBD a/DT C/NN terminal/JJ section/NN of/IN SM/NN to/TO be/VB related/JJ to/TO genome/NN positional/JJ homologues/NNS of/IN four/CD other/JJ herpesviruses/NNS and/CC revealed/VBD consensus/NN CKII/NN sites/NNS near/JJ the/DT N/NN termini/NNS of/IN the/DT EBV/NN SM/NN protein/NN ,/, the/DT herpes/NN simplex/JJ virus/NN (/( HSV/NN )/) ICP27/NN protein/NN and/CC the/DT herpesvirus/NN saimiri/NNS (/( HVS/NNS )/) open/JJ reading/NN frame/NN 57/CD protein/NN ./. 
Site-directed/JJ mutagenesis/NN of/IN the/DT consensus/NN CKII/NN site/NN in/IN EBV/NN SM/NN greatly/RB reduced/VBD the/DT in/FW vitro/FW phosphorylation/NN of/IN SM/NN by/IN CKII/NN ./. 
The/DT mechanism/NN of/IN transactivation/NN by/IN BMLF1/NN proteins/NNS has/VBZ been/VBN controversial/JJ but/CC SM/NN was/VBD shown/VBN to/TO transactivate/VB gene/NN expression/NN from/IN a/DT CAT/NN reporter/NN construct/NN by/IN increasing/VBG the/DT amount/NN of/IN cytoplasmic/JJ CAT/NN mRNA/NN ./. 
Mutagenesis/NN of/IN the/DT CKII/NN site/NN in/IN SM/NN made/VBD no/DT difference/NN to/TO the/DT transactivation/NN in/IN this/DT transient/JJ transfection/NN assay/NN ./. 
UI/LS -/: 95015876/CD 
TI/LS -/: Inducible/JJ binding/NN to/TO the/DT c-fos/NN serum/NN response/NN element/NN during/IN T/NN cell/NN activation/NN is/VBZ regulated/VBN by/IN a/DT phosphotyrosine-containing/JJ protein/NN ./. 
AB/LS -/: The/DT proto-oncogene/NN c-fos/NN is/VBZ an/DT immediate-early/JJ gene/NN ,/, and/CC one/CD of/IN the/DT first/JJ genes/NNS transcribed/VBN after/IN stimulation/NN of/IN most/JJS cells/NNS with/IN a/DT variety/NN of/IN ligands/NNS ./. 
Fos/NN expression/NN may/MD be/VB a/DT pivotal/JJ event/NN in/IN converting/VBG ligand-receptor/JJ interactions/NNS at/IN the/DT membrane/NN into/IN functional/JJ modulation/NN of/IN cell/NN phenotype/NN ./. 
The/DT serum/NN response/NN element/NN (/( SRE/NN )/) in/IN the/DT c-fos/NN regulatory/JJ region/NN participates/VBZ in/IN induction/NN of/IN transcription/NN by/IN various/JJ growth/NN factors/NNS and/CC by/IN phorbol/NN esters/NNS and/CC subsequent/JJ squelching/NN of/IN transcription/NN ./. 
We/PRP show/VBP that/IN an/DT inducible/JJ protein/NN complex/NN (/( Band/NN A/NN )/) binds/VBZ to/TO SRE/NN DNA/NN within/IN 10/CD min/NN after/IN mitogenic/JJ stimulation/NN of/IN human/JJ PBL-T/NN ,/, and/CC becomes/VBZ nondetectable/JJ by/IN 60/CD min/NN ./. 
Band/NN A/NN contains/VBZ the/DT serum/NN response/NN factor/NN plus/CC additional/JJ factor/NN (/( s/NNS )/) ./. 
A/DT protein/NN that/WDT is/VBZ phosphorylated/VBN on/IN a/DT tyrosine/NN residue/NN in/IN resting/VBG PBL-T/NN suppresses/VBZ binding/NN of/IN a/DT component/NN of/IN Band/NN A/NN to/TO the/DT SRE/NN motif/NN ./. 
Upon/IN stimulation/NN of/IN the/DT cells/NNS ,/, this/DT protein/NN no/RB longer/RBR prevents/VBZ binding/NN of/IN DNA/NN by/IN Band/NN A/NN ,/, and/CC suppression/NN of/IN binding/NN is/VBZ restored/VBN within/IN 30/CD min/NN ./. 
The/DT phosphorylated/VBN tyrosine/NN residue/NN itself/PRP is/VBZ important/JJ for/IN the/DT protein-protein/JJ interaction/NN ./. 
UI/LS -/: 95010257/CD 
TI/LS -/: In/FW vivo/FW modification/NN of/IN major/JJ histocompatibility/NN complex/NN class/NN II/CD DRA/NN promoter/NN occupancy/NN mediated/VBN by/IN the/DT AIR-1/NN trans-activator/NN ./. 
AB/LS -/: RJ/NN 2.2.5/CD is/VBZ a/DT human/JJ B/NN cell/NN mutant/NN derived/VBN from/IN the/DT Burkitt/NN lymphoma/NN Raji/NN cell/NN which/WDT is/VBZ defective/JJ in/IN the/DT AIR-1/NN locus/NN function/NN ./. 
This/DT locus/NN encodes/VBZ a/DT transcriptional/JJ trans-activator/NN required/VBN for/IN the/DT constitutive/JJ expression/NN of/IN major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II/CD genes/NNS ./. 
Here/RB we/PRP show/VBP ,/, by/IN in/FW vivo/FW DNase/NN I/CD footprinting/NN ,/, that/IN the/DT AIR-1/NN locus/NN defect/NN correlates/VBZ with/IN changes/NNS in/IN the/DT DRA/NN promoter/NN occupancy/NN ./. 
Interestingly/RB ,/, reexpression/NN of/IN human/JJ MHC/NN class/NN II/CD genes/NNS in/IN RJ/NN 2.2.5/CD x/NN mouse/NN spleen/NN cell/NN hybrids/NNS is/VBZ associated/VBN with/IN partial/JJ reversion/NN of/IN DRA/NN promoter/NN occupancy/NN to/TO the/DT Raji/NN pattern/NN ./. 
DRA/NN promoter/NN occupancy/NN in/IN other/JJ class/NN II-negative/JJ B/NN cell/NN lines/NNS ,/, derived/VBN from/IN patients/NNS with/IN bare/JJ lymphocyte/NN syndrome/NN ,/, is/VBZ drastically/RB different/JJ from/IN the/DT one/NN observed/VBN in/IN RJ/NN 2.2.5/CD and/CC Raji/NN cells/NNS ./. 
Moreover/RB ,/, the/DT use/NN of/IN the/DT DNase/NN I/CD as/IN an/DT in/FW vivo/FW footprinting/NN agent/NN reveals/VBZ that/IN the/DT patients/NNS '/POS cell/NN lines/NNS do/VBP not/RB display/VB a/DT completely/RB "/`` bare/JJ promoter/NN "/'' as/IN previously/RB reported/VBN using/VBG dimethyl/JJ sulfate/NN as/IN the/DT footprinting/NN agent/NN ./. 
Thus/RB ,/, the/DT use/NN of/IN DNase/NN I/CD allowed/VBD us/PRP ,/, for/IN the/DT first/JJ time/NN ,/, to/TO correlate/VB the/DT AIR-1/NN locus/NN defect/NN with/IN class/NN II/CD promoter/NN occupancy/NN alterations/NNS and/CC distinguish/VB these/DT alterations/NNS from/IN the/DT ones/NNS observed/VBN in/IN phenotypically/RB similar/JJ but/CC genetically/RB distinct/JJ MHC/NN class/NN II-negative/JJ cells/NNS ./. 
UI/LS -/: 95166264/CD 
TI/LS -/: Regulation/NN of/IN cell-type-specific/JJ interleukin-2/NN receptor/NN alpha-chain/NN gene/NN expression/NN :/: potential/JJ role/NN of/IN physical/JJ interactions/NNS between/IN Elf-1/NN ,/, HMG-I(Y)/NN ,/, and/CC NF-kappa/NN B/NN family/NN proteins/NNS ./. 
AB/LS -/: The/DT interleukin/NN 2/CD receptor/NN alpha-chain/NN (/( IL-2R/NN alpha/NN )/) gene/NN is/VBZ rapidly/RB and/CC potently/RB induced/VBN in/IN T/NN cells/NNS in/IN response/NN to/TO mitogenic/JJ stimuli/NNS ./. 
Previously/RB ,/, an/DT inducible/JJ enhancer/NN between/IN nucleotides/NNS -299/CD and/CC -228/CD that/WDT contains/VBZ NF-kappa/NN B/NN and/CC CArG/NN motifs/NNS was/VBD identified/VBN ./. 
We/PRP now/RB report/VBP the/DT characterization/NN of/IN a/DT second/JJ essential/JJ positive/JJ regulatory/JJ element/NN located/JJ between/IN nucleotides/NNS -137/CD and/CC -64/CD that/WDT binds/VBZ Elf-1/NN and/CC HMG-I(Y)/NN ./. 
This/DT element/NN had/VBD maximal/JJ activity/NN in/IN lymphoid/JJ cells/NNS ,/, paralleling/VBG the/DT cell/NN type/NN specificity/NN of/IN Elf-1/NN expression/NN ./. 
Transcription/NN from/IN the/DT IL-2R/NN alpha/NN promoter/NN was/VBD inhibited/VBN when/WRB either/CC the/DT Elf-1/NN or/CC the/DT HMG-I(Y)/NN binding/NN site/NN was/VBD mutated/VBN ./. 
Coexpression/NN of/IN both/DT proteins/NNS activated/VBD transcription/NN of/IN the/DT -137/CD to/TO -64/CD element/NN in/IN COS-7/NN cells/NNS ./. 
Elf-1/NN physically/RB associated/VBD with/IN HMG-I/NN and/CC with/IN NF-kappa/NN B/NN p50/NN and/CC c-Rel/NN in/FW vitro/FW ,/, suggesting/VBG that/IN protein-protein/JJ interactions/NNS might/MD functionally/RB coordinate/VB the/DT actions/NNS of/IN the/DT upstream/JJ and/CC downstream/JJ positive/JJ regulatory/JJ elements/NNS ./. 
This/DT is/VBZ the/DT first/JJ report/NN of/IN a/DT physical/JJ interaction/NN between/IN an/DT Ets/NN family/NN member/NN and/CC NF-kappa/NN B/NN family/NN proteins/NNS ./. 
These/DT findings/NNS provide/VBP significant/JJ new/JJ insights/NNS into/IN the/DT protein-protein/JJ and/CC protein-DNA/JJ interactions/NNS that/WDT regulate/VBP cell-type-specific/JJ and/CC inducible/JJ IL-2R/NN alpha/NN gene/NN expression/NN and/CC also/RB have/VBP implications/NNS for/IN other/JJ genes/NNS regulated/VBN by/IN Elf-1/NN and/CC NF-kappa/NN B/NN family/NN proteins/NNS ./. 
UI/LS -/: 95169271/CD 
TI/LS -/: Isolation/NN of/IN cDNA/NN clones/NNS for/IN 42/CD different/JJ Kruppel-related/JJ zinc/NN finger/NN proteins/NNS expressed/VBN in/IN the/DT human/JJ monoblast/NN cell/NN line/NN U-937/NN ./. 
AB/LS -/: To/TO study/VB the/DT complexity/NN and/CC structural/JJ characteristics/NNS of/IN zinc/NN finger/NN proteins/NNS expressed/VBN during/IN human/JJ hematopoiesis/NN and/CC to/TO isolate/VB novel/JJ regulators/NNS of/IN blood/NN cell/NN development/NN ,/, a/DT degenerate/JJ oligonucleotide/NN probe/NN specific/JJ for/IN a/DT consensus/NN zinc/NN finger/NN peptide/NN domain/NN was/VBD used/VBN to/TO isolate/VB 63/CD cDNA/NN clones/NNS for/IN Kruppel-related/JJ zinc/NN finger/NN genes/NNS from/IN the/DT human/JJ monoblast/NN cell/NN line/NN U-937/NN ./. 
By/IN extensive/JJ nucleotide/NN sequence/NN and/CC Northern/NN blot/NN analysis/NN ,/, these/DT cDNA/NN clones/NNS were/VBD found/VBN to/TO originate/VB from/IN approximately/RB 42/CD different/JJ genes/NNS (/( HZF/NN 1-42/CD )/) of/IN which/WDT only/RB 8/CD have/VBP previously/RB been/VBN described/VBN ./. 
Northern/NN blot/NN analysis/NN showed/VBD that/IN a/DT majority/NN of/IN these/DT genes/NNS were/VBD expressed/VBN at/IN comparable/JJ levels/NNS in/IN U-937/NN and/CC HeLa/NN cells/NNS ./. 
The/DT large/JJ number/NN of/IN individual/JJ genes/NNS represented/VBN among/IN the/DT 63/CD clones/NNS and/CC their/PRP$ apparent/JJ non-cell-type-specific/JJ expression/NN suggest/VBP that/IN the/DT majority/NN of/IN the/DT Kruppel-related/JJ zinc/NN finger/NN genes/NNS are/VBP likely/JJ to/TO be/VB expressed/VBN in/IN most/JJS human/JJ tissues/NNS ./. 
In/IN contrast/NN ,/, some/DT of/IN the/DT genes/NNS displayed/VBD a/DT restricted/JJ expression/NN pattern/NN ,/, indicating/VBG that/IN they/PRP represent/VBP potential/JJ regulators/NNS of/IN monocyte/NN differentiation/NN or/CC proliferation/NN ./. 
Detailed/JJ structural/JJ analysis/NN of/IN the/DT first/JJ 12/CD cDNAs/NNS (/( HZF/NN 1-10/CD )/) and/CC a/DT partial/JJ characterization/NN of/IN HZF/NN 11-42/CD revealed/VBD that/IN a/DT common/JJ feature/NN of/IN human/JJ Kruppel-related/JJ zinc/NN finger/NN proteins/NNS is/VBZ the/DT presence/NN of/IN tandem/JJ arrays/NNS of/IN zinc/NN fingers/NNS ranging/VBG in/IN number/NN from/IN 3/CD to/TO over/IN 20/CD that/WDT are/VBP preferentially/RB located/JJ in/IN the/DT carboxy-terminal/JJ regions/NNS of/IN the/DT proteins/NNS ./. 
In/IN addition/NN ,/, several/JJ novel/JJ KRAB-containing/JJ zinc/NN finger/NN genes/NNS and/CC a/DT novel/JJ conserved/VBN sequence/NN element/NN were/VBD identified/VBN ./. 
UI/LS -/: 95276747/CD 
TI/LS -/: CAG/NN repeat/NN length/NN variation/NN in/IN sperm/NN from/IN a/DT patient/NN with/IN Kennedy/NN 's/POS disease/NN ./. 
AB/LS -/: Using/VBG a/DT modified/VBN sperm/NN typing/NN protocol/NN ,/, the/DT mutation/NN frequency/NN of/IN the/DT CAG/NN repeat/NN region/NN at/IN the/DT androgen/NN receptor/NN locus/NN has/VBZ been/VBN measured/VBN using/VBG a/DT rare/JJ semen/NN sample/NN from/IN an/DT individual/NN with/IN spinal/JJ and/CC bulbar/JJ muscular/JJ atrophy/NN (/( SBMA/NN )/) ./. 
Among/IN 258/CD X/NN chromosome-containing/JJ sperm/NN ,/, 19/CD %/NN had/VBD a/DT repeat/NN number/NN equal/JJ to/TO the/DT donor/NN 's/POS somatic/JJ DNA/NN (/( 47/CD repeats/NNS )/) ,/, 66/CD %/NN were/VBD expansions/NNS and/CC 15/CD %/NN were/VBD contractions/NNS ./. 
The/DT average/JJ expansion/NN was/VBD 2.7/CD repeats/NNS ./. 
More/JJR than/IN half/NN of/IN the/DT expansions/NNS involved/VBD one/CD or/CC two/CD repeats/NNS ;/: the/DT largest/JJS was/VBD 11/CD repeats/NNS ./. 
68/CD %/NN of/IN the/DT contractions/NNS were/VBD also/RB one/CD or/CC two/CD repeats/NNS but/CC six/CD (/( 16/CD %/NN )/) were/VBD very/RB large/JJ (/( 12-25/CD repeats/NNS )/) ./. 
One/CD contraction/NN generated/VBD an/DT allele/NN in/IN an/DT intermediate/JJ size/NN range/NN (/( 33-39/CD repeats/NNS )/) ./. 
Such/JJ alleles/NNS have/VBP not/RB been/VBN observed/VBN among/IN more/JJR than/IN 900/CD normal/JJ and/CC SBMA/NN X-chromosomes/NNS that/WDT have/VBP been/VBN examined/VBN ./. 
Comparison/NN of/IN the/DT SBMA/NN sperm/NN typing/NN results/NNS with/IN mutation/NN frequency/NN data/NNS on/IN normal/JJ alleles/NNS supports/VBZ the/DT hypothesis/NN that/IN trinucleotide/NN repeat/NN expansions/NNS may/MD have/VB a/DT different/JJ molecular/JJ origin/NN than/IN contractions/NNS ./. 
UI/LS -/: 96146856/CD 
TI/LS -/: Aspirin-like/JJ drugs/NNS can/MD protect/VB human/JJ T/NN lymphocytes/NNS against/IN benzoquinone/NN cytotoxicity/NN :/: evidence/NN for/IN a/DT NAD(P)H:quinone/NN reductase-dependent/JJ mechanism/NN ./. 
AB/LS -/: Benzene/NN toxicity/NN towards/IN lymphocytes/NNS is/VBZ thought/VBN to/TO be/VB mediated/VBN by/IN metabolites/NNS of/IN benzene/NN including/VBG benzoquinone/NN (/( BQ/NN )/) ./. 
NAD(P)H:quinone/NN reductase/NN (/( QR/NN )/) is/VBZ known/VBN to/TO protect/VB against/IN BQ/NN toxicity/NN ./. 
The/DT expression/NN of/IN the/DT QR/NN gene/NN is/VBZ regulated/VBN by/IN the/DT transcription/NN factor/NN AP-1/NN ./. 
We/PRP had/VBD previously/RB found/VBN that/IN aspirin-like/JJ drugs/NNS (/( ALD/NN )/) induce/VBP AP-1/NN in/IN human/JJ T/NN lymphocytes/NNS ./. 
It/PRP was/VBD therefore/RB hypothesized/VBN that/IN ALD/NN would/MD protect/VB lymphocytes/NNS against/IN BQ/NN toxicity/NN by/IN inducing/VBG QR/NN ./. 
Molt-4/NN cells/NNS (/( M4/NN )/) ,/, a/DT human/JJ T/NN lymphocyte/NN cell/NN line/NN ,/, were/VBD incubated/VBN with/IN different/JJ concentrations/NNS of/IN two/CD ALD/NN ,/, flurbiprofen/NN and/CC sodium/NN diclofenac/NN ,/, and/CC then/RB exposed/VBN to/TO BQ/NN ./. 
Toxicity/NN was/VBD measured/VBN by/IN viability/NN (/( trypan/NN blue/JJ exclusion/NN )/) ./. 
Both/DT drugs/NNS protected/VBD the/DT cells/NNS against/IN BQ/NN cytotoxicity/NN in/IN a/DT dose-dependent/JJ manner/NN ,/, e.g./FW ,/, sodium/NN diclofenac/NN at/IN 15/CD microM/NN reduced/VBD the/DT fraction/NN of/IN BQ-treated/JJ dead/JJ cells/NNS by/IN 70/CD %/NN ./. 
ALDs/NNS induced/VBD QR/NN activity/NN in/IN the/DT M4/NN cells/NNS in/IN the/DT same/JJ range/NN of/IN concentrations/NNS that/WDT protected/VBD the/DT cells/NNS against/IN BQ/NN toxicity/NN ./. 
The/DT protective/JJ effect/NN of/IN ALD/NN was/VBD significantly/RB reduced/VBN by/IN dicoumarol/NN ,/, a/DT QR-specific/JJ inhibitor/NN ./. 
Since/IN human/JJ T/NN cells/NNS and/CC T/NN cell/NN lines/NNS do/VBP not/RB metabolize/VB arachidonic/JJ acid/NN ,/, our/PRP$ data/NNS suggest/VBP that/IN ALD/NN can/MD protect/VB human/JJ T/NN lymphocytes/NNS against/IN a/DT metabolite/NN of/IN benzene/NN by/IN induction/NN of/IN QR/NN activity/NN ./. 
UI/LS -/: 96071057/CD 
TI/LS -/: Correlation/NN of/IN differentiation-inducing/JJ activity/NN of/IN retinoids/NNS on/IN human/JJ leukemia/NN cell/NN lines/NNS HL-60/NN and/CC NB4/NN ./. 
AB/LS -/: Retinoids/NNS ,/, including/VBG all-trans-retinoic/JJ acid/NN ,/, its/PRP$ isomers/NNS ,/, and/CC fifty/CD synthetic/JJ retinoids/NNS (/( retinobenzoic/JJ acids/NNS )/) ,/, were/VBD tested/VBN for/IN differentiation-inducing/JJ activity/NN on/IN human/JJ leukemia/NN cell/NN lines/NNS HL-60/NN and/CC NB4/NN ./. 
A/DT good/JJ linear/NN correlation/NN ,/, with/IN an/DT r/NN value/NN of/IN 0.91/CD ,/, between/IN the/DT ED50/NN values/NNS for/IN the/DT differentiation-inducing/JJ activity/NN towards/IN HL-60/NN cells/NNS and/CC that/DT towards/IN NB4/NN cells/NNS was/VBD found/VBN ./. 
UI/LS -/: 95100937/CD 
TI/LS -/: Platelet-activating/JJ factor/NN (/( PAF/NN )/) positively/RB auto-regulates/VBZ the/DT expression/NN of/IN human/JJ PAF/NN receptor/NN transcript/NN 1/CD (/( leukocyte-type/NN )/) through/IN NF-kappa/NN B/NN ./. 
AB/LS -/: The/DT human/JJ platelet-activating/JJ factor/NN receptor/NN (/( PAFR/NN )/) gene/NN is/VBZ transcribed/VBN by/IN two/CD distinct/JJ promoters/NNS (/( promoter/NN 1/CD and/CC promoter/NN 2/CD )/) to/TO generate/VB two/CD transcripts/NNS (/( designated/VBN as/IN PAFR/NN transcript/NN 1/CD and/CC PAFR/NN transcript/NN 2/CD )/) ,/, though/IN their/PRP$ open/JJ reading/NN frames/NNS are/VBP identical/JJ ./. 
By/IN primer/NN extension/NN analysis/NN to/TO discriminate/VB two/CD transcripts/NNS ,/, we/PRP found/VBD that/IN the/DT levels/NNS of/IN PAFR/NN transcript/NN 1/CD (/( leukocyte-type/NN )/) ,/, but/CC not/RB PAFR/NN transcript/NN 2/CD (/( tissue-type/NN )/) ,/, are/VBP upregulated/VBN by/IN PAF/NN as/RB well/RB as/IN by/IN 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) in/IN the/DT human/JJ stomach/NN cancer/NN cell/NN line/NN (/( JR-St/NN cells/NNS )/) which/WDT expresses/VBZ both/CC functional/JJ PAFR/NN transcript/NN 1/CD and/CC PAFR/NN transcript/NN 2/CD endogenously/RB ./. 
Functional/JJ analysis/NN of/IN the/DT promoter/NN 1/CD with/IN a/DT transient/JJ expression/NN assay/NN using/VBG chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) gene/NN as/IN a/DT reporter/NN showed/VBD that/IN both/CC PAF/NN and/CC TPA/NN activated/VBD the/DT promoter/NN 1/CD but/CC not/RB the/DT deleted/JJ promoter/NN lacking/VBG the/DT three/CD consensus/NN binding/NN sites/NNS for/IN NF-kappa/NN B/NN located/JJ from/IN -571/CD bp/NN to/TO -459/CD bp/NN ./. 
These/DT findings/NNS suggest/VBP a/DT molecular/JJ mechanism/NN of/IN positive/JJ regulation/NN of/IN PAFR/NN gene/NN expression/NN by/IN PAF/NN through/IN NF-kappa/NN B/NN ,/, possibly/RB by/IN a/DT phosphorylation/NN reaction/NN involving/VBG protein/NN kinase/NN C/NN by/IN PAF/NN ./. 
UI/LS -/: 95053740/CD 
TI/LS -/: One/CD gene/NN ,/, two/CD transcripts/NNS :/: isolation/NN of/IN an/DT alternative/JJ transcript/NN encoding/VBG for/IN the/DT autoantigen/NN La/SS-B/NN from/IN a/DT cDNA/NN library/NN of/IN a/DT patient/NN with/IN primary/JJ Sjogrens/NN '/POS syndrome/NN ./. 
AB/LS -/: A/DT cDNA/NN library/NN was/VBD prepared/VBN from/IN peripheral/JJ blood/NN lymphocytes/NNS of/IN an/DT autoimmune/JJ patient/NN with/IN primary/JJ Sjogrens/NN '/POS syndrome/NN ./. 
The/DT cDNA/NN library/NN was/VBD screened/VBN with/IN the/DT patients/NNS own/JJ autoimmune/JJ serum/NN being/VBG monospecific/JJ for/IN the/DT nuclear/JJ autoantigen/NN La/SS-B/NN ./. 
Thereby/RB an/DT alternative/JJ type/NN of/IN La/NN mRNA/NN was/VBD identified/VBN that/WDT differed/VBD from/IN the/DT known/JJ La/NN mRNA/NN due/JJ to/TO an/DT exchange/NN of/IN the/DT exon/NN 1/CD ./. 
Sequencing/NN of/IN the/DT genomic/JJ region/NN between/IN the/DT exons/NNS 1/CD and/CC 2/CD showed/VBD that/IN the/DT alternative/JJ 5'-end/NN is/VBZ a/DT part/NN of/IN the/DT intron/NN ./. 
In/IN addition/NN ,/, the/DT presence/NN of/IN an/DT alternative/JJ promoter/NN site/NN ,/, which/WDT exists/VBZ within/IN the/DT intron/NN downstream/JJ of/IN the/DT exon/NN 1/CD ,/, became/VBD evident/JJ ./. 
In/IN consequence/NN ,/, the/DT alternative/JJ La/NN mRNA/NN is/VBZ the/DT result/NN of/IN a/DT promoter/NN switching/NN combined/VBN with/IN an/DT alternative/JJ splicing/NN mechanism/NN ./. 
In/IN the/DT intron/NN ,/, further/JJ transcription/NN factor/NN binding/NN sites/NNS ,/, including/VBG a/DT NF-kappa/NN B/NN element/NN ,/, were/VBD identified/VBN leading/VBG to/TO the/DT suggestion/NN that/IN the/DT expression/NN of/IN the/DT gene/NN encoding/VBG for/IN the/DT nuclear/JJ autoantigen/NN La/SS-B/NN alters/VBZ in/IN dependence/NN on/IN disease/NN conditions/NNS ./. 
UI/LS -/: 95052601/CD 
TI/LS -/: Cross-linking/JJ CD40/NN on/IN B/NN cells/NNS rapidly/RB activates/VBZ nuclear/JJ factor-kappa/NN B/NN ./. 
AB/LS -/: The/DT B/NN cell-associated/JJ surface/NN molecule/NN CD40/NN functions/VBZ to/TO regulate/VB B/NN cell/NN responses/NNS ./. 
Cross-linking/JJ CD40/NN on/IN B/NN cells/NNS can/MD lead/VB to/TO homotypic/JJ cell/NN adhesion/NN ,/, IL-6/NN production/NN ,/, and/CC ,/, in/IN combination/NN with/IN cytokines/NNS ,/, to/TO Ig/NN isotype/NN switching/NN ./. 
Tyrosine/NN kinase/NN activity/NN is/VBZ increased/VBN shortly/RB after/IN engagement/NN of/IN this/DT receptor/NN ./. 
Little/JJ is/VBZ known/VBN about/IN how/WRB the/DT very/RB early/JJ events/NNS induced/VBN by/IN CD40/NN cross-linking/NN link/VBP to/TO cellular/JJ responses/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP demonstrate/VBP that/IN nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN and/CC NF-kappa/NN B-like/JJ transcription/NN factors/NNS are/VBP activated/VBN after/IN cross-linking/JJ CD40/NN on/IN resting/VBG human/JJ tonsillar/JJ B/NN cells/NNS and/CC on/IN B/NN cell/NN lines/NNS ./. 
The/DT activation/NN is/VBZ rapid/JJ and/CC is/VBZ mediated/VBN through/IN a/DT tyrosine/NN kinase-dependent/JJ pathway/NN ./. 
The/DT complexes/NNS detected/VBN in/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS contain/VBP p50/NN ,/, p65/NN (/( RelA/NN )/) ,/, c-Rel/NN ,/, and/CC most/RBS likely/RB other/JJ components/NNS ./. 
By/IN using/VBG transient/JJ transfection/NN assays/NNS ,/, we/PRP found/VBD that/IN cross-linking/JJ CD40/NN supports/VBZ NF-kappa/NN B-dependent/JJ gene/NN expression/NN ./. 
Our/PRP$ results/NNS define/VBP the/DT NF-kappa/NN B/NN system/NN as/IN an/DT intermediate/JJ event/NN in/IN CD40/NN signaling/NN and/CC suggest/VBP that/IN the/DT CD40/NN pathway/NN can/MD influence/VB the/DT expression/NN of/IN B/NN cell-associated/JJ genes/NNS with/IN NF-kappa/NN B/NN consensus/NN sites/NNS ./. 
UI/LS -/: 95014473/CD 
TI/LS -/: Protease/NN inhibitors/NNS block/VBP lipopolysaccharide/NN induction/NN of/IN tissue/NN factor/NN gene/NN expression/NN in/IN human/JJ monocytic/JJ cells/NNS by/IN preventing/VBG activation/NN of/IN c-Rel/p65/NN heterodimers/NNS ./. 
AB/LS -/: Tissue/NN factor/NN (/( TF/NN )/) is/VBZ expressed/VBN rapidly/RB by/IN human/JJ monocytes/NNS exposed/VBN to/TO bacterial/JJ endotoxin/NN (/( lipopolysaccharide/NN ,/, or/CC LPS/NN )/) ./. 
Transcriptional/JJ regulation/NN is/VBZ mediated/VBN by/IN binding/NN of/IN c-Rel/p65/NN heterodimers/NNS to/TO a/DT kappa/NN B-like/JJ site/NN in/IN the/DT TF/NN promoter/NN ./. 
Nuclear/JJ translocation/NN of/IN cytosolic/JJ c-Rel/p65/NN heterodimers/NNS and/CC other/JJ members/NNS of/IN the/DT NF-kappa/NN B/Rel/NN family/NN requires/VBZ dissociation/NN and/CC proteolytic/JJ degradation/NN of/IN the/DT inhibitor/NN protein/NN ,/, I/NN kappa/NN B/NN alpha/NN ./. 
The/DT protease/NN inhibitors/NNS N/NN alpha-tosylphenylalanyl/JJ chloromethyl/NN ketone/NN (/( TPCK/NN )/) and/CC N/NN alpha-tosyl-L-lysine/NN chloromethyl/NN ketone/NN (/( TLCK/NN )/) block/VBP activation/NN of/IN NF-kappa/NN B/Rel/NN proteins/NNS by/IN preventing/VBG degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN ./. 
To/TO determine/VB if/IN TPCK/NN and/CC TLCK/NN inhibited/VBD LPS/NN induction/NN of/IN TF/NN expression/NN ,/, freshly/RB isolated/VBN human/JJ monocytes/NNS and/CC monocytic/JJ THP-1/NN cells/NNS were/VBD pretreated/VBN with/IN these/DT inhibitors/NNS for/IN 30/CD min/NN before/IN LPS/NN stimulation/NN ./. 
Both/CC TPCK/NN and/CC TLCK/NN inhibited/VBD LPS/NN induction/NN of/IN TF/NN protein/NN ,/, TF/NN mRNA/NN and/CC TF/NN promoter/NN activity/NN in/IN a/DT dose-dependent/JJ manner/NN ./. 
These/DT inhibitors/NNS specifically/RB prevented/VBD degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN and/CC nuclear/JJ translocation/NN of/IN c-Rel/p65/NN heterodimers/NNS ./. 
In/IN contrast/NN ,/, TPCK/NN and/CC TLCK/NN did/VBD not/RB block/VB induction/NN of/IN an/DT immediate-early/JJ gene/NN encoding/VBG the/DT transcription/NN factor/NN ,/, Egr-1/NN ./. 
Taken/VBN together/RB ,/, these/DT data/NNS indicated/VBD that/IN inhibiting/VBG nuclear/JJ translocation/NN of/IN c-Rel/p65/NN heterodimers/NNS prevented/VBD LPS/NN induction/NN of/IN TF/NN gene/NN transcription/NN in/IN monocytic/JJ cells/NNS ./. 
UI/LS -/: 95152321/CD 
TI/LS -/: 1,25-Dihydroxyvitamin/NN D3/NN receptors/NNS in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS from/IN patients/NNS with/IN primary/JJ and/CC secondary/JJ hyperparathyroidism/NN ./. 
AB/LS -/: A/DT decreased/VBN number/NN of/IN calcitriol/NN (/( 1,25(OH)2D3/NN )/) receptors/NNS has/VBZ been/VBN observed/VBN in/IN parathyroid/JJ glands/NNS of/IN uremic/JJ animals/NNS ./. 
In/IN humans/NNS ,/, studies/NNS carried/VBN out/RP in/IN surgically/RB removed/VBN parathyroid/JJ glands/NNS have/VBP shown/VBN that/IN calcitriol/NN binding/NN is/VBZ higher/JJR in/IN primary/JJ than/IN in/IN secondary/JJ hyperparathyroidism/NN ./. 
Since/IN specific/JJ receptors/NNS for/IN calcitriol/NN have/VBP been/VBN described/VBN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NN )/) ,/, we/PRP have/VBP investigated/VBN the/DT specific/JJ uptake/NN of/IN 3H-labelled/JJ 1,25(OH)2D3/NN in/IN PBMC/NN of/IN 12/CD women/NNS with/IN primary/JJ hyperparathyroidism/NN (/( PHP/NN )/) ,/, 8/CD women/NNS with/IN hyperparathyroidism/NN secondary/JJ to/TO chronic/JJ renal/JJ failure/NN (/( SH/NN )/) ,/, 9/CD women/NNS with/IN renal/JJ transplant/NN (/( RT/NN )/) ,/, and/CC 23/CD healthy/JJ women/NNS ./. 
The/DT median/JJ dissociation/NN constant/NN (/( Kd/NN )/) was/VBD similar/JJ in/IN all/DT three/CD groups/NNS of/IN patients/NNS and/CC in/IN healthy/JJ women/NNS (/( mean/NN +/-/CC S.D./NN (/( range/NN )/) :/: PHP/NN ,/, 1.2/CD +/-/CC 1.0/CD (/( 0.2-4/CD )/) x/CC 10(-10)/CD M/NN ;/: SH/NN ,/, 0.6/CD +/-/CC 0.4/CD (/( 0.2-1.2/CD )/) x/CC 10(-10)/CD M/NN ;/: RT/NN ,/, 1.1/CD +/-/CC 0.5/CD (/( 0.4-1.9/CD )/) x/CC 10(-10)/CD M/NN ;/: controls/NNS ,/, 1.0/CD +/-/CC 0.6/CD (/( 0.3-2.6/CD )/) x/CC 10(-10)/CD M/NN )/) ./. However/RB ,/, the/DT maximal/JJ binding/NN capacity/NN (/( Nmax/NN )/) was/VBD significantly/RB enhanced/VBN in/IN PHP/NN (/( 3.9/CD +/-/CC 1.9/CD (/( 1.3-7.6/CD )/) fmol/10(7)/NN cells/NNS vs./CC 2.3/CD +/-/CC 0.9/CD (/( 1.1-4.4/CD )/) fmol/10(7)/NN cells/NNS in/IN controls/NNS ;/: P/NN =/JJ 0.0006/CD )/) and/CC decreased/VBN in/IN SH/NN (/( 0.8/CD +/-/CC 0.5/CD (/( 0.2-1.6/CD )/) fmol/10(7)/NN cells/NNS vs./CC 2.3/CD +/-/CC 0.9/CD (/( 1.1-4.4/CD )/) fmol/10(7)/NN cells/NNS in/IN controls/NNS ;/: P/NN =/JJ 0.0001/CD )/) ,/, whereas/IN no/DT changes/NNS were/VBD seen/VBN in/IN RT/NN (/( 2.3/CD +/-/CC 0.7/CD (/( 1.2-3.3/CD )/) fmol/10(7)/NN cells/NNS vs./CC 2.3/CD +/-/CC 0.9/CD (/( 1.1-4.4/CD )/) fmol/10(7)/NN cells/NNS in/IN controls/NNS )/) ./. 
In/IN three/CD patients/NNS with/IN PHP/NN who/WP were/VBD subjected/VBN to/TO parathyroidectomy/NN ,/, the/DT calcitriol/NN number/NN came/VBD down/RB to/TO normal/JJ ./. 
Changes/NNS of/IN calcitriol/NN receptors/NNS in/IN primary/JJ and/CC secondary/JJ hyperparathyroidism/NN could/MD magnify/VB the/DT consequences/NNS of/IN disturbances/NNS in/IN serum/NN concentration/NN of/IN calcitriol/NN itself/PRP and/CC might/MD play/VB an/DT important/JJ role/NN in/IN the/DT development/NN of/IN secondary/JJ hyperparathyroidism/NN in/IN uremia/NN ./. 
UI/LS -/: 94361146/CD 
TI/LS -/: The/DT severe/JJ phenotype/NN of/IN females/NNS with/IN tiny/JJ ring/NN X/NN chromosomes/NNS is/VBZ associated/VBN with/IN inability/NN of/IN these/DT chromosomes/NNS to/TO undergo/VB X/NN inactivation/NN ./. 
AB/LS -/: Mental/JJ retardation/NN and/CC a/DT constellation/NN of/IN congenital/JJ malformations/NNS not/RB usually/RB associated/VBN with/IN Turner/NN syndrome/NN are/VBP seen/VBN in/IN some/DT females/NNS with/IN a/DT mosaic/JJ 45,X/46,X,r(X)/NN karyotype/NN ./. 
Studies/NNS of/IN these/DT females/NNS show/VBP that/IN the/DT XIST/NN locus/NN on/IN their/PRP$ tiny/JJ ring/NN X/NN chromosomes/NNS is/VBZ either/CC not/RB present/JJ or/CC not/RB expressed/VBN ./. 
As/IN XIST/NN transcription/NN is/VBZ well/RB correlated/VBN with/IN inactivation/NN of/IN the/DT X/NN chromosome/NN in/IN female/JJ somatic/JJ cells/NNS and/CC spermatogonia/NN ,/, nonexpression/NN of/IN the/DT locus/NN even/RB when/WRB it/PRP is/VBZ present/JJ suggests/VBZ that/IN these/DT chromosomes/NNS are/VBP transcriptionally/RB active/JJ ./. 
We/PRP examined/VBD the/DT transcriptional/JJ activity/NN of/IN ring/NN X/NN chromosomes/NNS lacking/VBG XIST/NN expression/NN (/( XISTE-/JJ )/) ,/, from/IN three/CD females/NNS with/IN severe/JJ phenotypes/NNS ./. 
The/DT two/CD tiny/JJ ring/NN X/NN chromosomes/NNS studied/VBN with/IN an/DT antibody/NN specific/JJ for/IN the/DT acetylated/VBN isoforms/NNS of/IN histone/NN H4/NN marking/VBG transcribed/VBN chromatin/NN domains/NNS were/VBD labeled/VBN at/IN a/DT level/NN consistent/JJ with/IN their/PRP$ being/VBG active/JJ ./. 
We/PRP also/RB examined/VBD tow/NN of/IN the/DT XISTE-/JJ ring/NN chromosomes/NNS to/TO determine/VB whether/IN genes/NNS that/WDT are/VBP normally/RB silent/JJ on/IN an/DT inactive/JJ X/NN are/VBP expressed/VBN from/IN these/DT chromosomes/NNS ./. 
Analyses/NNS of/IN hybrid/NN cells/NNS show/VBP that/IN TIMP/NN ,/, ZXDA/NN ,/, and/CC ZXDB/NN loci/NNS on/IN the/DT proximal/JJ short/JJ arm/NN ,/, and/CC AR/NN and/CC PHKA1/NN loci/NNS on/IN the/DT long/JJ arm/NN ,/, are/VBP well/RB expressed/VBN from/IN the/DT tiny/JJ ring/NN X/NN chromosome/NN lacking/VBG XIST/NN DNA/NN ./. 
Studies/NNS of/IN the/DT ring/NN chromosome/NN that/WDT has/VBZ XIST/NN DNA/NN but/CC does/VBZ not/RB transcribe/VB it/PRP show/VBP that/IN its/PRP$ AR/NN allele/NN is/VBZ transcribed/VBN along/IN with/IN the/DT one/NN on/IN the/DT normal/JJ X/NN allele/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 94347089/CD 
TI/LS -/: Inhibition/NN of/IN activation/NN of/IN transcription/NN factor/NN AP-1/NN by/IN CD28/NN signalling/NN in/IN human/JJ T-cells/NNS ./. 
AB/LS -/: Co-stimulation/NN of/IN T-lymphocytes/NNS by/IN T-cell/NN receptor/NN (/( TcR/NN )/) occupancy/NN and/CC activation/NN of/IN the/DT CD28/NN surface/NN molecule/NN results/VBZ in/IN enhanced/VBN proliferation/NN and/CC interleukin/NN 2/CD (/( IL-2/NN )/) production/NN ./. 
The/DT increase/NN in/IN IL-2/NN gene/NN expression/NN triggered/VBN by/IN CD28/NN involves/VBZ a/DT kappa/NN B-like/JJ sequence/NN in/IN the/DT 5'-regulatory/JJ region/NN of/IN the/DT IL-2/NN promoter/NN ,/, called/VBN CD28-responsive/JJ element/NN ./. 
Stimulation/NN of/IN T-cells/NNS by/IN agonistic/JJ anti-CD28/JJ antibodies/NNS in/IN conjunction/NN with/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) -/: or/CC TcR-derived/JJ signals/NNS induces/VBZ the/DT enhanced/VBN activation/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN ./. 
Here/RB we/PRP report/VBP that/IN CD28/NN engagement/NN ,/, however/RB ,/, exerts/VBZ opposite/JJ effects/NNS on/IN the/DT transcription/NN factor/NN AP-1/NN ./. 
Whereas/IN anti-CD28/NN together/RB with/IN PMA/NN increased/VBD the/DT DNA/NN binding/NN and/CC trans-activation/NN activity/NN of/IN NF-kappa/NN B/NN ,/, PMA-induced/JJ activation/NN of/IN AP-1/NN was/VBD significantly/RB suppressed/VBN ./. 
The/DT inhibitory/JJ effect/NN exerted/VBN by/IN anti-CD28/NN was/VBD observed/VBN at/IN the/DT level/NN of/IN DNA/NN binding/NN as/RB well/RB as/IN in/IN functional/JJ reporter-gene/JJ assays/NNS ./. 
These/DT results/NNS suggest/VBP that/IN the/DT two/CD transcription/NN factors/NNS are/VBP independently/RB regulated/VBN and/CC may/MD perform/VB different/JJ functions/NNS during/IN T-cell/NN activation/NN ./. 
UI/LS -/: 95187990/CD 
TI/LS -/: HIV-1/NN Nef/NN leads/VBZ to/TO inhibition/NN or/CC activation/NN of/IN T/NN cells/NNS depending/VBG on/IN its/PRP$ intracellular/JJ localization/NN ./. 
AB/LS -/: Nef/NN of/IN primate/JJ lentiviruses/NNS is/VBZ required/VBN for/IN viremia/NN and/CC progression/NN to/TO AIDS/NN in/IN monkeys/NNS ./. 
Negative/JJ ,/, positive/JJ ,/, and/CC no/DT effects/NNS of/IN Nef/NN have/VBP also/RB been/VBN reported/VBN on/IN viral/JJ replication/NN in/IN cells/NNS ./. 
To/TO reconcile/VB these/DT observations/NNS ,/, we/PRP expressed/VBD a/DT hybrid/NN CD8-Nef/NN protein/NN in/IN Jurkat/NN cells/NNS ./. 
Two/CD opposite/JJ phenotypes/NNS were/VBD found/VBN ,/, which/WDT depended/VBD on/IN the/DT intracellular/JJ localization/NN of/IN Nef/NN ./. 
Expressed/VBN in/IN the/DT cytoplasm/NN or/CC on/IN the/DT cell/NN surface/NN ,/, the/DT chimera/NN inhibited/VBD or/CC activated/VBD early/JJ signaling/NN events/NNS from/IN the/DT T/NN cell/NN antigen/NN receptor/NN ./. 
Activated/VBN Jurkat/NN cells/NNS died/VBD by/IN apoptosis/NN ,/, and/CC only/RB cells/NNS with/IN mutated/VBN nef/NN genes/NNS expressing/VBG truncated/VBN Nefs/NNS survived/VBD ,/, which/WDT rendered/VBD Nef/NN nonfunctional/JJ ./. 
These/DT mutations/NNS paralleled/VBD those/DT in/IN other/JJ viral/JJ strains/NNS passaged/VBN in/FW vitro/FW ./. 
Not/RB only/RB do/VBP these/DT positional/JJ effects/NNS of/IN Nef/NN reconcile/VB diverse/JJ phenotypes/NNS of/IN Nef/NN and/CC suggest/VB a/DT role/NN for/IN its/PRP$ N-terminal/JJ myristylation/NN ,/, but/CC they/PRP also/RB explain/VBP effects/NNS of/IN Nef/NN in/IN HIV/NN infection/NN and/CC progression/NN to/TO AIDS/NN ./. 
UI/LS -/: 94253152/CD 
TI/LS -/: An/DT intricate/JJ arrangement/NN of/IN binding/VBG sites/NNS for/IN the/DT Ets/NN family/NN of/IN transcription/NN factors/NNS regulates/VBZ activity/NN of/IN the/DT alpha/NN 4/CD integrin/NN gene/NN promoter/NN ./. 
AB/LS -/: alpha/NN 4/CD integrins/NNS mediate/VBP cell-cell/JJ and/CC cell-extracellular/JJ matrix/NN interactions/NNS that/WDT are/VBP critical/JJ for/IN maturation/NN and/CC function/NN of/IN the/DT immune/JJ system/NN as/RB well/RB as/IN differentiation/NN of/IN skeletal/JJ muscle/NN ./. 
Here/RB we/PRP examine/VBP molecular/JJ mechanisms/NNS controlling/VBG the/DT pattern/NN of/IN alpha/NN 4/CD expression/NN ./. 
The/DT activity/NN of/IN constructs/NNS containing/VBG 5'/JJ deletion/NN mutants/NNS of/IN the/DT alpha/NN 4/CD gene/NN promoter/NN was/VBD compared/VBN in/IN transfection/NN assays/NNS into/IN cell/NN lines/NNS that/WDT express/VBP alpha/NN 4/CD and/CC cell/NN lines/NNS that/WDT do/VBP not/RB ./. 
The/DT sequence/NN between/IN position/NN -42/CD and/CC -76/CD base/NN pairs/NNS (/( bp/NN )/) was/VBD required/VBN for/IN efficient/JJ transcription/NN in/IN cells/NNS that/WDT express/VBP alpha/NN 4/CD ,/, but/CC it/PRP showed/VBD no/DT activity/NN in/IN HeLa/NN cells/NNS ,/, which/WDT do/VBP not/RB express/VB alpha/NN 4/CD ./. 
Three/CD binding/VBG sites/NNS for/IN the/DT Ets/NN family/NN of/IN transcription/NN factors/NNS are/VBP found/VBN in/IN this/DT region/NN :/: two/CD adjacent/JJ sites/NNS at/IN positions/NNS -50/CD and/CC -54/CD bp/NN and/CC a/DT more/RBR 5'/JJ site/NN at/IN position/NN -67/CD bp/NN ./. 
Using/VBG a/DT series/NN of/IN constructs/NNS containing/VBG deletions/NNS and/CC mutations/NNS in/IN this/DT region/NN ,/, we/PRP found/VBD that/IN the/DT 3'-most/JJ site/NN alone/RB was/VBD sufficient/JJ for/IN binding/VBG GA-binding/JJ protein/NN alpha/NN (/( GABP/NN alpha/NN )/) /GABP/NN beta/NN and/CC for/IN a/DT low/JJ level/NN of/IN transcriptional/JJ activation/NN ./. 
When/WRB all/DT three/CD sites/NNS were/VBD present/JJ ,/, a/DT second/JJ complex/NN "/`` a/NN "/'' was/VBD detected/VBN ,/, which/WDT contains/VBZ an/DT unknown/JJ member/NN of/IN the/DT Ets/NN family/NN ./. 
Formation/NN of/IN complex/JJ a/NN was/VBD cell-type/NN specific/JJ and/CC correlated/VBD with/IN a/DT high/JJ level/NN of/IN transcription/NN ./. 
Deletion/NN of/IN the/DT 5'-most/JJ Ets/NN site/NN had/VBD no/DT effect/NN on/IN binding/NN to/TO GABP/NN alpha/GABP/NN beta/NN ,/, but/CC it/PRP eliminated/VBD a/NN ./. 
Concomitant/JJ with/IN this/DT loss/NN of/IN a/NN ,/, a/DT new/JJ Ets-1-containing/JJ complex/NN "/`` c/NN "/'' appeared/VBD ./. 
Complex/NN c/NN substituted/VBD efficiently/RB for/IN complex/NN a/NN in/IN transcriptional/JJ activation/NN ./. 
We/PRP conclude/VBP that/IN although/IN neither/DT of/IN the/DT two/CD 5'-most/JJ Ets/NN sites/NNS alone/RB binds/VBZ nuclear/JJ protein/NN ,/, they/PRP appear/VBP to/TO act/VB as/IN modulators/NNS which/WDT control/VBP the/DT pattern/NN of/IN Ets/NN proteins/NNS that/WDT bind/VBP the/DT alpha/NN 4/CD gene/NN promoter/NN ./. 
This/DT arrangement/NN of/IN Ets/NN sites/NNS ,/, coupled/VBN with/IN the/DT tissue-/NN and/CC developmental-/JJ specific/JJ expression/NN of/IN Ets/NN members/NNS ,/, likely/RB play/VBP a/DT key/JJ role/NN in/IN defining/VBG the/DT pattern/NN of/IN alpha/NN 4/CD integrin/NN ./. 
UI/LS -/: 95011022/CD 
TI/LS -/: Mechanism/NN of/IN antiandrogen/JJ action/NN :/: conformational/JJ changes/NNS of/IN the/DT receptor/NN ./. 
AB/LS -/: Androgen/NN receptor/NN mRNA/NN was/VBD translated/VBN in/FW vitro/FW ,/, and/CC androgen-/NN and/CC antiandrogen-bound/JJ receptor/NN complexes/NNS were/VBD studied/VBN using/VBG limited/JJ proteolytic/JJ digestion/NN by/IN trypsin/NN ./. 
Partial/JJ proteolysis/NN of/IN androgen-bound/JJ receptor/NN protein/NN resulted/VBD in/IN a/DT 29-kDa/JJ proteolysis-resisting/JJ fragment/NN ,/, whereas/IN antiandrogen/JJ binding/NN stabilised/VBD a/DT 35-kDa/JJ fragment/NN ./. 
Both/DT fragments/NNS contain/VBP the/DT entire/JJ ligand/NN binding/NN domain/NN ,/, and/CC the/DT 35-kDa/JJ fragment/NN extended/VBD into/IN the/DT hinge/NN region/NN of/IN the/DT receptor/NN ./. 
Several/JJ antiandrogens/NNS show/VBP agonistic/JJ properties/NNS for/IN a/DT mutated/VBN androgen/NN receptor/NN (/( LNCaP/NN cell/NN variant/NN )/) ;/: trypsin/NN digestion/NN of/IN antiandrogen-bound/JJ mutated/VBN receptor/NN also/RB resulted/VBD in/IN a/DT 29-kDa/JJ fragment/NN ./. 
Our/PRP$ results/NNS point/VBP to/TO an/DT important/JJ difference/NN between/IN antiandrogens/NNS and/CC antagonists/NNS of/IN other/JJ steroid/NN hormone/NN receptors/NNS ./. 
Antiandrogens/NNS result/VBP in/IN protection/NN of/IN both/CC the/DT hinge/NN region/NN and/CC C-terminus/NN of/IN the/DT androgen/NN receptor/NN agonist/NN proteolytic/JJ attack/NN ,/, whereas/IN other/JJ studies/NNS showed/VBD that/IN antiestrogens/NNS and/CC antiprogestagens/NNS expose/VBP the/DT C-terminal/JJ end/NN of/IN the/DT ligand/NN binding/NN domain/NN of/IN their/PRP$ respective/JJ receptors/NNS to/TO protease/NN ./. 
Differences/NNS in/IN conformation/NN of/IN the/DT hinge/NN region/NN distinguish/VBP androgen-bound/JJ from/IN antiandrogen-bound/JJ receptor/NN complexes/NNS ,/, which/WDT represents/VBZ an/DT important/JJ feature/NN of/IN antiandrogen/JJ action/NN ./. 
UI/LS -/: 94209877/CD 
TI/LS -/: Activation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN in/IN human/JJ neuroblastoma/NN cell/NN lines/NNS ./. 
AB/LS -/: The/DT nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) is/VBZ a/DT eukaryotic/JJ transcription/NN factor/NN ./. 
In/IN B/NN cells/NNS and/CC macrophages/NNS it/PRP is/VBZ constitutively/RB present/JJ in/IN cell/NN nuclei/NNS ,/, whereas/IN in/IN many/JJ other/JJ cell/NN types/NNS ,/, NF-kappa/NN B/NN translocates/VBZ from/IN cytosol/NN to/TO nucleus/NN as/IN a/DT result/NN of/IN transduction/NN by/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF/NN alpha/NN )/) ,/, phorbol/NN ester/NN ,/, and/CC other/JJ polyclonal/JJ signals/NNS ./. 
Using/VBG neuroblastoma/NN cell/NN lines/NNS as/IN models/NNS ,/, we/PRP have/VBP shown/VBN that/IN in/IN neural/JJ cells/NNS NF-kappa/NN B/NN was/VBD present/JJ in/IN the/DT cytosol/NN and/CC translocated/VBD into/IN nuclei/NNS as/IN a/DT result/NN of/IN TNF/NN alpha/NN treatment/NN ./. 
The/DT TNF/NN alpha-activated/JJ NF-kappa/NN B/NN was/VBD transcriptionally/RB functional/JJ ./. 
NF-kappa/NN B/NN activation/NN by/IN TNF/NN alpha/NN was/VBD not/RB correlated/VBN with/IN cell/NN differentiation/NN or/CC proliferation/NN ./. 
However/RB ,/, reagents/NNS such/JJ as/IN nerve/NN growth/NN factor/NN (/( NGF/NN )/) and/CC the/DT phorbol/NN ester/NN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) ,/, which/WDT induce/VBP phenotypical/JJ differentiation/NN of/IN the/DT SH-SY5Y/NN neuroblastoma/NN cell/NN line/NN ,/, activated/VBD NF-kappa/NN B/NN ,/, but/CC only/RB in/IN that/DT particular/JJ cell/NN line/NN ./. 
In/IN a/DT NGF-responsive/JJ rat/NN pheochromocytoma/NN cell/NN line/NN ,/, PC12/NN ,/, PMA/NN activated/VBD NF-kappa/NN B/NN ,/, whereas/IN NGF/NN did/VBD not/RB ./. 
In/IN other/JJ neuroblastoma/NN cell/NN lines/NNS ,/, such/JJ as/IN SK-N-Be(2)/NN ,/, the/DT lack/NN of/IN PMA/NN induction/NN of/IN differentiation/NN was/VBD correlated/VBN with/IN the/DT lack/NN of/IN NF-kappa/NN B/NN activation/NN ./. 
We/PRP found/VBD ,/, moreover/RB ,/, that/IN in/IN SK-N-Be(2)/NN cells/NNS protein/NN kinase/NN C/NN (/( PKC/NN )/) enzymatic/JJ activity/NN was/VBD much/RB lower/JJR compared/VBN with/IN that/DT in/IN a/DT control/JJ cell/NN line/NN and/CC that/IN the/DT low/JJ PKC/NN enzymatic/JJ activity/NN was/VBD due/JJ to/TO low/JJ PKC/NN protein/NN expression/NN ./. 
NF-kappa/NN B/NN was/VBD not/RB activated/VBN by/IN retinoic/JJ acid/NN ,/, which/WDT induced/VBD morphological/JJ differentiation/NN of/IN all/PDT the/DT neuroblastoma/NN cell/NN lines/NNS used/VBN in/IN the/DT present/JJ study/NN ./. 
Thus/RB ,/, NF-kappa/NN B/NN activation/NN was/VBD not/RB required/VBN for/IN neuroblastoma/NN cell/NN differentiation/NN ./. 
Furthermore/RB ,/, the/DT results/NNS obtained/VBN with/IN TNF/NN alpha/NN proved/VBD that/IN NF-kappa/NN B/NN activation/NN was/VBD not/RB sufficient/JJ for/IN induction/NN of/IN neuroblastoma/NN differentiation/NN ./. 
UI/LS -/: 94217726/CD 
TI/LS -/: ERP/NN ,/, a/DT new/JJ member/NN of/IN the/DT ets/NN transcription/NN factor/oncoprotein/NN family/NN :/: cloning/VBG ,/, characterization/NN ,/, and/CC differential/JJ expression/NN during/IN B-lymphocyte/NN development/NN ./. 
AB/LS -/: The/DT ets/NN gene/NN family/NN encodes/VBZ a/DT group/NN of/IN proteins/NNS which/WDT function/VBP as/IN transcription/NN factors/NNS under/IN physiological/JJ conditions/NNS and/CC ,/, if/IN aberrantly/RB expressed/VBN ,/, can/MD cause/VB cellular/JJ transformation/NN ./. 
We/PRP have/VBP recently/RB identified/VBN two/CD regulatory/JJ elements/NNS in/IN the/DT murine/NN immunoglobulin/NN heavy-chain/JJ (/( IgH/NN )/) enhancer/NN ,/, pi/NN and/CC microB/NN ,/, which/WDT exhibit/VBP striking/JJ similarity/NN to/TO binding/VBG sites/NNS for/IN ets-related/JJ proteins/NNS ./. 
To/TO identify/VB ets-related/JJ transcriptional/JJ regulators/NNS expressed/VBN in/IN pre-B/JJ lymphocytes/NNS that/WDT may/MD interact/VB with/IN either/CC the/DT pi/NN or/CC the/DT microB/NN site/NN ,/, we/PRP have/VBP used/VBN a/DT PCR/NN approach/NN with/IN degenerate/JJ oligonucleotides/NNS encoding/VBG conserved/VBN sequences/NNS in/IN all/DT members/NNS of/IN the/DT ets/NN family/NN ./. 
We/PRP have/VBP cloned/VBN the/DT gene/NN for/IN a/DT new/JJ ets-related/JJ transcription/NN factor/NN ,/, ERP/NN (/( ets-related/JJ protein/NN )/) ,/, from/IN the/DT murine/NN pre-B/JJ cell/NN line/NN BASC/NN 6C2/NN and/CC from/IN mouse/NN lung/NN tissue/NN ./. 
The/DT ERP/NN protein/NN contains/VBZ a/DT region/NN of/IN high/JJ homology/NN with/IN the/DT ETS/NN DNA-binding/JJ domain/NN common/JJ to/TO all/DT members/NNS of/IN the/DT ets/NN transcription/NN factor/oncoprotein/NN family/NN ./. 
Three/CD additional/JJ smaller/JJR regions/NNS show/VBP homology/NN to/TO the/DT ELK-1/NN and/CC SAP-1/NN genes/NNS ,/, a/DT subgroup/NN of/IN the/DT ets/NN gene/NN family/NN that/WDT interacts/VBZ with/IN the/DT serum/NN response/NN factor/NN ./. 
Full-length/JJ ERP/NN expresses/VBZ only/RB negligible/JJ DNA-binding/JJ activity/NN by/IN itself/PRP ./. 
Removal/NN of/IN the/DT carboxy/NN terminus/NN enables/VBZ ERP/NN to/TO interact/VB with/IN a/DT variety/NN of/IN ets-binding/NN sites/NNS including/VBG the/DT E74/NN site/NN ,/, the/DT IgH/NN enhancer/NN pi/NN site/NN ,/, and/CC the/DT lck/NN promoter/NN ets/NN site/NN ,/, suggesting/VBG a/DT carboxy-terminal/JJ negative/JJ regulatory/JJ domain/NN ./. 
At/IN least/JJS three/CD ERP-related/JJ transcripts/NNS are/VBP expressed/VBN in/IN a/DT variety/NN of/IN tissues/NNS ./. 
However/RB ,/, within/IN the/DT B-cell/NN lineage/NN ,/, ERP/NN is/VBZ highly/RB expressed/VBN primarily/RB at/IN early/JJ stages/NNS of/IN B-lymphocyte/NN development/NN ,/, and/CC expression/NN declines/VBZ drastically/RB upon/IN B-cell/NN maturation/NN ,/, correlating/VBG with/IN the/DT enhancer/NN activity/NN of/IN the/DT IgH/NN pi/NN site/NN ./. 
These/DT data/NNS suggest/VBP that/IN ERP/NN might/MD play/VB a/DT role/NN in/IN B-cell/NN development/NN and/CC in/IN IgH/NN gene/NN regulation/NN ./. 
UI/LS -/: 94281746/CD 
TI/LS -/: Gene/NN for/IN a/DT tissue-specific/JJ transcriptional/JJ activator/NN (/( EBF/NN or/CC Olf-1/NN )/) ,/, expressed/VBN in/IN early/JJ B/NN lymphocytes/NNS ,/, adipocytes/NNS ,/, and/CC olfactory/JJ neurons/NNS ,/, is/VBZ located/JJ on/IN human/JJ chromosome/NN 5/CD ,/, band/NN q34/NN ,/, and/CC proximal/JJ mouse/NN chromosome/NN 11/CD ./. 
AB/LS -/: Murine/NN B/NN lymphocytes/NNS ,/, adipocytes/NNS ,/, and/CC olfactory/JJ neurons/NNS contain/VBP a/DT DNA-binding/NN protein/NN that/WDT participates/VBZ in/IN the/DT regulation/NN of/IN genes/NNS encoding/VBG tissue-specific/JJ components/NNS of/IN signal/NN transduction/NN ./. 
Purification/NN and/CC cloning/NN of/IN this/DT protein/NN ,/, termed/VBN early/RB B-cell/NN factor/NN (/( EBF/NN )/) ,/, from/IN murine/NN B/NN lymphocytes/NNS and/CC independent/JJ cloning/NN of/IN a/DT protein/NN ,/, termed/VBN Olf-1/NN ,/, from/IN olfactory/JJ neuronal/JJ cells/NNS revealed/VBD virtual/JJ complete/JJ amino/NN acid/NN sequence/NN identity/NN between/IN these/DT proteins/NNS ./. 
As/IN a/DT first/JJ step/NN towards/IN identifying/VBG a/DT human/JJ genetic/JJ disorder/NN or/CC mouse/NN mutation/NN for/IN which/WDT EBF/NN could/MD be/VB a/DT candidate/NN gene/NN ,/, we/PRP have/VBP chromosomally/RB mapped/VBN the/DT corresponding/JJ locus/NN in/IN both/DT species/NNS ./. 
By/IN Southern/NN hybridization/NN analyses/NNS of/IN somatic/JJ cell/NN hybrid/NN panels/NNS with/IN murine/NN cDNA/NN probe/NN ,/, fluorescence/NN chromosomal/JJ in/FW situ/FW hybridization/NN (/( FISH/NN )/) of/IN human/JJ genomic/JJ clones/NNS ,/, and/CC analysis/NN of/IN recombinant/JJ inbred/JJ mouse/NN strains/NNS ,/, we/PRP have/VBP found/VBN single/JJ sites/NNS for/IN EBF/NN homologous/JJ sequences/NNS on/IN human/JJ Chromosome/NN (/( Chr/NN )/) 5/CD ,/, band/NN q34/NN ,/, and/CC on/IN proximal/JJ mouse/NN Chr/NN 11/CD ,/, in/IN an/DT evolutionarily/RB conserved/VBN region/NN ./. 
UI/LS -/: 94183204/CD 
TI/LS -/: Calcineurin/NN activates/VBZ transcription/NN from/IN the/DT GM-CSF/NN promoter/NN in/IN synergy/NN with/IN either/CC protein/NN kinase/NN C/NN or/CC NF-kappa/NN B/AP-1/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Two/CD cis-acting/JJ elements/NNS GM-kappa/NN B/GC-box/NN and/CC CLE0/NN ,/, of/IN the/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) gene/NN are/VBP required/VBN for/IN maximal/JJ induction/NN in/IN Jurkat/NN T/NN cells/NNS by/IN costimulation/NN with/IN phorbol-12-myristate/NN acetate/NN (/( PMA/NN )/) and/CC Ca2+/NN ionophore/NN (/( A23187/NN )/) ./. 
The/DT GM-kappa/NN B/NN sequence/NN is/VBZ recognized/VBN by/IN NF-kappa/NN B/NN ,/, which/WDT is/VBZ mainly/RB induced/VBN by/IN PMA/NN ./. 
The/DT CLE0/NN sequence/NN interacts/VBZ with/IN factors/NNS ,/, related/JJ to/TO a/DT PMA-induced/JJ AP-1/NN and/CC a/DT PMA/A23187-induced/JJ NF-AT/NN ./. 
We/PRP examined/VBD whether/IN signal/NN transducing/NN components/NNS in/IN T/NN cells/NNS can/MD activate/VB transcription/NN of/IN the/DT GM-CSF/NN gene/NN ./. 
Cotransfection/NN of/IN NF-kappa/NN B/NN (/( p50/p65/NN )/) -/: or/CC AP-1/NN (/( c-Jun/c-Fos/NN )/) -/: expression/NN vectors/NNS into/IN Jurkat/NN cells/NNS with/IN a/DT luciferase/NN reporter/NN containing/VBG the/DT GM-CSF/NN promoter/NN did/VBD not/RB stimulate/VB transcription/NN from/IN the/DT GM-CSF/NN promoter/NN ./. 
In/IN contrast/NN ,/, cotransfection/NN with/IN a/DT combination/NN of/IN NF-kappa/NN B/NN and/CC AP-1/NN significantly/RB augmented/VBD transcription/NN from/IN the/DT GM-CSF/NN promoter/NN containing/VBG the/DT GM-kappa/NN B/GC-box/NN and/CC the/DT CLE0/NN (/( AP-1/NF-AT/NN )/) ./. 
Expression/NN of/IN a/DT constitutively/RB active/JJ calcineurin/NN (/( CN/NN )/) ,/, a/DT Ca2+/calmodulin-dependent/JJ protein/NN phosphatase/NN ,/, potentiated/VBD by/IN two/CD fold/NN the/DT transcriptional/JJ activation/NN by/IN NF-kappa/NN B/AP-1/NN ./. 
Both/CC constitutively/RB active/JJ forms/NNS of/IN CN/NN and/CC protein/NN kinase/NN C/NN (/( PKC/NN )/) synergistically/RB activated/VBD transcription/NN from/IN the/DT GM-CSF/NN promoter/NN ./. 
These/DT results/NNS suggest/VBP that/IN cooperation/NN among/IN NF-kappa/NN B-/NN ,/, AP-1-/NN and/CC NF-AT-binding/JJ sequences/NNS is/VBZ required/VBN for/IN induction/NN of/IN the/DT GM-CSF/NN gene/NN through/IN PKC-/NN and/CC Ca2+-signaling/JJ pathways/NNS downstream/RB of/IN T/NN cell/NN activation/NN ./. 
UI/LS -/: 94285937/CD 
TI/LS -/: Nonpituitary/JJ human/JJ prolactin/NN gene/NN transcription/NN is/VBZ independent/JJ of/IN Pit-1/NN and/CC differentially/RB controlled/VBN in/IN lymphocytes/NNS and/CC in/IN endometrial/JJ stroma/NN ./. 
AB/LS -/: Expression/NN of/IN the/DT human/JJ PRL/NN (/( hPRL/NN )/) gene/NN in/IN extrapituitary/JJ sites/NNS such/JJ as/IN the/DT uterus/NN (/( decidualized/VBN endometrial/JJ stroma/NN and/CC myometrium/NN )/) and/CC cells/NNS of/IN the/DT hematopoietic/JJ lineage/NN is/VBZ directed/VBN by/IN an/DT alternative/JJ promoter/NN which/WDT is/VBZ located/JJ approximately/RB 6/CD kilobases/NNS (/( kb/NN )/) upstream/RB of/IN the/DT pituitary-specific/JJ start/NN site/NN ./. 
In/IN order/NN to/TO delineate/VB the/DT tissue-specific/JJ mechanisms/NNS governing/VBG the/DT control/NN of/IN nonpituitary/JJ PRL/NN gene/NN expression/NN ,/, we/PRP have/VBP cloned/VBN and/CC sequenced/VBN 3/CD kb/NN 5'-flanking/JJ DNA/NN of/IN the/DT upstream/JJ decidual/lymphoid/JJ (/( dPRL/NN )/) promoter/NN ./. 
Based/VBN on/IN sequence/NN homology/NN we/PRP identified/VBD two/CD binding/VBG motifs/NNS for/IN Pit-1/NN and/CC seven/CD half-sites/NNS for/IN glucocorticoid/NN receptor/progesterone/NN receptor/NN (/( PR/NN )/) binding/NN ./. 
We/PRP focused/VBD our/PRP$ studies/NNS on/IN the/DT role/NN of/IN Pit-1/NN and/CC of/IN PR/NN as/IN potential/JJ transcriptional/JJ regulators/NNS ,/, since/IN the/DT POU/NN domain/NN protein/NN Pit-1/NN is/VBZ essential/JJ in/IN the/DT control/NN of/IN pituitary/JJ PRL/NN expression/NN ,/, and/CC progesterone/NN induces/VBZ decidual/JJ transformation/NN of/IN the/DT endometrial/JJ stroma/NN ,/, a/DT differentiation/NN process/NN during/IN which/WDT the/DT decidual/JJ PRL/NN gene/NN is/VBZ activated/VBN ./. 
We/PRP demonstrate/VBP in/IN a/DT variety/NN of/IN cell/NN types/NNS ,/, including/VBG lymphocytes/NNS and/CC endometrial/JJ stroma/NN ,/, that/IN Pit-1/NN is/VBZ not/RB involved/VBN in/IN the/DT regulation/NN of/IN dPRL/NN promoter/reporter/NN gene/NN constructs/NNS carrying/VBG 3/CD kb/NN 5'-flanking/JJ DNA/NN ./. 
Our/PRP$ experiments/NNS also/RB show/VBP that/IN activated/VBN PR/NN does/VBZ not/RB confer/VB direct/JJ transcriptional/JJ control/NN on/IN the/DT dPRL/NN promoter/NN ./. 
When/WRB we/PRP compared/VBD the/DT activity/NN of/IN the/DT transfected/VBN dPRL/NN promoter/NN in/IN PRL-secreting/JJ and/CC nonsecreting/JJ lymphoid/JJ cells/NNS ,/, we/PRP found/VBD that/IN the/DT 3/CD kb/NN 5'-flanking/JJ region/NN of/IN the/DT dPRL/NN promoter/NN did/VBD not/RB contain/VB elements/NNS restricting/VBG expression/NN to/TO only/RB those/DT lymphocytes/NNS that/WDT produce/VBP PRL/NN but/CC allowed/VBD expression/NN of/IN fusion/NN reporter/NN genes/NNS irrespective/JJ of/IN the/DT status/NN of/IN the/DT endogenous/JJ PRL/NN gene/NN ./. 
This/DT was/VBD in/IN sharp/JJ contrast/NN to/TO endometrial/JJ cells/NNS where/WRB 3/CD kb/NN 5'-flanking/JJ DNA/NN conferred/VBD strong/JJ transcriptional/JJ activation/NN on/IN the/DT dPRL/NN promoter/NN in/IN decidualized/VBN endometrial/JJ stromal/JJ cells/NNS actively/RB secreting/VBG PRL/NN ,/, but/CC did/VBD not/RB allow/VB transcription/NN in/IN undifferentiated/JJ non-PRL-secreting/JJ endometrial/JJ stromal/JJ cells/NNS ./. 
Activation/NN of/IN the/DT dPRL/NN promoter/NN construct/NN in/IN these/DT undifferentiated/JJ cells/NNS could/MD however/RB be/VB induced/VBN by/IN the/DT addition/NN of/IN cAMP/NN ,/, in/IN the/DT absence/NN of/IN progesterone/NN ,/, suggesting/VBG that/IN a/DT signal/NN transduced/VBN through/IN the/DT cAMP/NN signaling/NN pathway/NN is/VBZ a/DT primary/JJ inducer/NN of/IN decidual/JJ PRL/NN gene/NN expression/NN ./. 
UI/LS -/: 94365323/CD 
TI/LS -/: Signals/NNS and/CC nuclear/JJ factors/NNS that/WDT regulate/VBP the/DT expression/NN of/IN interleukin-4/NN and/CC interleukin-5/NN genes/NNS in/IN helper/NN T/NN cells/NNS ./. 
AB/LS -/: Mouse/NN thymoma/NN line/NN EL-4/NN cells/NNS produce/VBP cytokines/NNS such/JJ as/IN interleukin/NN (/( IL/NN )/) -2/CD ,/, IL-3/NN ,/, IL-4/NN ,/, IL-10/NN ,/, and/CC granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN in/IN response/NN to/TO phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) ./. 
EL-4/NN cells/NNS also/RB produce/VBP low/JJ levels/NNS of/IN IL-5/NN when/WRB stimulated/VBN by/IN PMA/NN alone/RB ;/: however/RB ,/, cAMP/NN greatly/RB augments/VBZ PMA-dependent/JJ IL-5/NN production/NN ./. 
A/DT transient/JJ transfection/NN assay/NN revealed/VBD that/IN two/CD signals/NNS ,/, PMA/NN and/CC cAMP/NN ,/, are/VBP required/VBN for/IN optimal/JJ activation/NN of/IN the/DT IL-5/NN promoter/NN ./. 
In/IN contrast/NN ,/, cAMP/NN almost/RB completely/RB inhibited/VBD the/DT PMA-dependent/JJ activation/NN of/IN the/DT endogenous/JJ IL-2/NN gene/NN ,/, as/RB well/RB as/IN the/DT transfected/VBN IL-2/NN promoter/NN ./. 
These/DT results/NNS indicate/VBP that/IN the/DT IL-5/NN gene/NN is/VBZ positively/RB regulated/VBN by/IN cAMP/NN in/IN a/DT manner/NN opposite/JJ to/TO that/DT for/IN the/DT IL-2/NN gene/NN ./. 
One/CD of/IN the/DT nuclear/JJ factors/NNS (/( NFs/NNS )/) that/WDT regulates/VBZ the/DT response/NN of/IN the/DT IL-5/NN promoter/NN to/TO cAMP/NN and/CC PMA/NN has/VBZ properties/NNS similar/JJ to/TO NF/NN for/IN activated/VBN t/NN cell/NN ./. 
The/DT P/NN sequence/NN of/IN the/DT IL-4/NN gene/NN ,/, defined/VBN as/IN a/DT responsive/JJ element/NN for/IN PMA/NN and/CC calcium/NN ionophore/NN (/( A23187/NN )/) ,/, shares/VBZ sequence/NN similarity/NN with/IN the/DT NF/NN kappa/NN B/NN and/CC the/DT NF-activated/JJ T/NN cell/NN binding/NN sites/NNS ./. 
We/PRP attempted/VBD to/TO determine/VB whether/IN NF(P)/NN ,/, a/DT nuclear/JJ factor/NN specific/JJ for/IN the/DT P/NN sequence/NN ,/, is/VBZ related/JJ to/TO NF-kappa/NN B/NN and/CC nuclear/JJ factor/NN for/IN activated/VBN T/NN cell/NN (/( NF-AT/NN )/) ./. 
In/IN electromobility/NN shift/NN assays/NNS both/CC NF-kappa/NN B/NN (/( P65/NN or/CC P65/P50/NN heterodimer/NN )/) and/CC NF-AT/NN bound/VBD to/TO the/DT P/NN sequence/NN ./. 
However/RB ,/, sequence/NN specificity/NN of/IN NF-AT/NN was/VBD more/RBR similar/JJ to/TO that/DT of/IN NF(P)/NN ,/, and/CC only/RB a/DT small/JJ amount/NN of/IN P65/NN was/VBD detected/VBN in/IN NF(P)/NN ./. 
These/DT results/NNS indicate/VBP that/IN a/DT component/NN or/CC components/NNS of/IN NF-AT/NN have/VBP the/DT potential/NN to/TO reconstitute/VB NF(P)/NN ,/, whereas/IN NF-kappa/NN B/NN alone/RB does/VBZ not/RB account/VB for/IN NF(P)/NN in/IN Jurkat/NN crude/JJ extract/NN ./. 
Taken/VBN together/RB ,/, these/DT results/NNS suggest/VBP that/IN NF-AT-like/JJ factors/NNS are/VBP involved/VBN in/IN the/DT regulation/NN of/IN IL-4/NN and/CC IL-5/NN genes/NNS ./. 
UI/LS -/: 94339116/CD 
TI/LS -/: Solution/NN structure/NN of/IN a/DT POU-specific/JJ homeodomain/NN :/: 3D-NMR/NN studies/NNS of/IN human/JJ B-cell/NN transcription/NN factor/NN Oct-2/NN ./. 
AB/LS -/: The/DT POU/NN DNA-binding/JJ motif/NN defines/VBZ a/DT conserved/VBN family/NN of/IN eukaryotic/JJ transcription/NN factors/NNS involved/VBN in/IN regulation/NN of/IN gene/NN expression/NN ./. 
This/DT bipartite/JJ motif/NN consists/VBZ of/IN an/DT N-terminal/JJ POU-specific/JJ domain/NN (/( POUs/NNS )/) ,/, a/DT flexible/JJ linker/NN ,/, and/CC a/DT C-terminal/JJ POU-specific/JJ homeodomain/NN (/( POUHD/NN )/) ./. 
Here/RB we/PRP describe/VBP the/DT solution/NN structure/NN of/IN a/DT POU-specific/JJ homeodomain/NN ./. 
An/DT NMR/NN model/NN is/VBZ obtained/VBN from/IN Oct-2/NN ,/, a/DT human/JJ B-cell/NN specific/JJ transcription/NN factor/NN which/WDT participates/VBZ in/IN the/DT regulation/NN of/IN immunoglobulin/NN genes/NNS ./. 
A/DT fragment/NN of/IN Oct-2/NN containing/NN POUHD/NN and/CC an/DT adjoining/JJ linker/NN was/VBD expressed/VBN in/IN Escherichia/FW coli/FW and/CC characterized/VBN by/IN three-dimensional/JJ nuclear/JJ magnetic/JJ resonance/NN (/( 3D-NMR/NN )/) spectroscopy/NN ./. 
Complete/JJ 1H/NN and/CC 15N/NN resonance/NN assignment/NN of/IN the/DT POUHD/NN moiety/NN is/VBZ presented/VBN ./. 
The/DT POUHD/NN solution/NN structure/NN ,/, as/IN calculated/VBN by/IN distance/NN geometry/NN and/CC simulated/JJ annealing/NN (/( DG/SA/NN )/) ,/, is/VBZ similar/JJ to/TO that/DT of/IN canonical/JJ homeodomains/NNS ./. 
A/DT salient/JJ difference/NN between/IN solution/NN and/CC crystal/JJ structures/NNS is/VBZ observed/VBN in/IN the/DT C-terminal/JJ segment/NN of/IN alpha-helix/JJ 3/CD (/( the/DT HTH/NN recognition/NN helix/NN )/) ,/, which/WDT is/VBZ not/RB well/RB ordered/VBN in/IN solution/NN ./. 
Because/IN this/DT segment/NN presumably/RB folds/VBZ upon/IN specific/JJ DNA/NN binding/NN ,/, its/PRP$ flexibility/NN in/IN solution/NN may/MD reduce/VB the/DT intrinsic/JJ DNA/NN affinity/NN of/IN POUHD/NN in/IN the/DT absence/NN of/IN POUs/NNS ./. 
UI/LS -/: 94303183/CD 
TI/LS -/: NF-kappa/NN B-dependent/JJ and/CC -independent/JJ pathways/NNS of/IN HIV/NN activation/NN in/IN a/DT chronically/RB infected/JJ T/NN cell/NN line/NN ./. 
AB/LS -/: J/NN delta/NN K/NN cells/NNS were/VBD isolated/VBN as/IN a/DT chronically/RB infected/JJ survivor/NN cell/NN line/NN ,/, following/VBG infection/NN of/IN Jurkat/NN CD4+/JJ T/NN cells/NNS with/IN dl-NF/NN ,/, a/DT mutated/VBN strain/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) containing/VBG a/DT deletion/NN of/IN the/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) NF-kappa/NN B/NN sites/NNS ./. 
J/NN delta/NN K/NN cells/NNS exhibited/VBD very/RB low/JJ levels/NNS of/IN constitutive/JJ HIV/NN production/NN ./. 
HIV-1/NN expression/NN was/VBD activated/VBN from/IN J/NN delta/NN K/NN cells/NNS by/IN treatment/NN with/IN phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) ,/, sodium/NN butyrate/NN (/( NaB/NN )/) ,/, or/CC hexamethylene/NN bisacetamide/NN (/( HMBA/NN )/) ,/, but/CC not/RB tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) ,/, confirming/VBG the/DT role/NN of/IN NF-kappa/NN B/NN in/IN mediating/VBG TNF-alpha/NN induction/NN of/IN HIV/NN transcription/NN ./. 
The/DT strong/JJ induction/NN of/IN HIV/NN expression/NN by/IN NaB/NN or/CC HMBA/NN in/IN J/NN delta/NN K/NN cells/NNS clearly/RB demonstrates/VBZ the/DT existence/NN of/IN NF-kappa/NN B-independent/JJ mechanisms/NNS of/IN HIV/NN activation/NN in/IN chronically/RB infected/JJ cells/NNS ./. 
J/NN delta/NN K/NN cells/NNS may/MD provide/VB a/DT useful/JJ model/NN for/IN characterizing/VBG NF-kappa/NN B-independent/JJ transcriptional/JJ activation/NN of/IN the/DT HIV/NN LTR/NN ./. 
UI/LS -/: 94265262/CD 
TI/LS -/: JNK/NN is/VBZ involved/VBN in/IN signal/NN integration/NN during/IN costimulation/NN of/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: T/NN lymphocyte/NN activation/NN and/CC interleukin-2/NN (/( IL-2/NN )/) production/NN require/VBP at/IN least/JJS two/CD signals/NNS ,/, generated/VBN by/IN phorbol/NN ester/NN (/( TPA/NN )/) and/CC Ca2+/NN ionophore/NN or/CC costimulation/NN of/IN the/DT T/NN cell/NN receptor/NN (/( TCR/NN )/) and/CC the/DT CD28/NN auxiliary/NN receptor/NN ./. 
We/PRP investigated/VBD how/WRB these/DT stimuli/NNS affect/VBP mitogen/NN activated/JJ protein/NN (/( MAP/NN )/) kinases/NNS ./. 
Full/JJ activation/NN of/IN the/DT MAP/NN kinases/NNS that/WDT phosphorylate/VBP the/DT Jun/NN activation/NN domain/NN ,/, JNK1/NN and/CC JNK2/NN ,/, required/VBD costimulation/NN of/IN T/NN cells/NNS with/IN either/CC TPA/NN and/CC Ca2+/NN ionophore/NN or/CC antibodies/NNS to/TO TCR/NN and/CC CD28/NN ./. 
Alone/RB ,/, each/DT stimulus/NN resulted/VBD in/IN little/JJ or/CC no/DT activation/NN ./. 
Similar/JJ to/TO its/PRP$ effect/NN on/IN IL-2/NN induction/NN ,/, cyclosporin/NN A/NN (/( CsA/NN )/) inhibited/VBD the/DT synergistic/JJ activation/NN of/IN JNK/NN ,/, and/CC a/DT competitive/JJ inhibitor/NN of/IN Jun/NN phosphorylation/NN by/IN JNK/NN inhibited/VBD IL-2/NN promoter/NN activation/NN ./. 
By/IN contrast/NN ,/, the/DT MAP/NN kinases/NNS ERK1/NN and/CC ERK2/NN were/VBD fully/RB activated/VBN by/IN TPA/NN or/CC TCR/NN stimulation/NN and/CC were/VBD not/RB affected/VBN by/IN Ca2+/NN ,/, CD28/NN ,/, or/CC CsA/NN ./. 
Hence/RB ,/, integration/NN of/IN signals/NNS that/WDT lead/VBP to/TO T/NN cell/NN activation/NN occurs/VBZ at/IN the/DT level/NN of/IN JNK/NN activation/NN ./. 
UI/LS -/: 95023587/CD 
TI/LS -/: Inhibition/NN of/IN rat/NN splenocyte/NN proliferation/NN with/IN methylprednisolone/NN :/: in/FW vivo/FW effect/NN of/IN liposomal/JJ formulation/NN ./. 
AB/LS -/: The/DT effect/NN of/IN a/DT liposomal/JJ formulation/NN of/IN methylprednisolone/NN (/( MPL/NN )/) on/IN the/DT inhibition/NN of/IN lymphocyte/NN proliferation/NN in/IN spleen/NN cells/NNS was/VBD investigated/VBN following/VBG IV/CD dosing/NN in/IN rats/NNS ./. 
Liposomes/NNS do/VBP not/RB alter/VB the/DT suppressive/JJ action/NN of/IN MPL/NN when/WRB placed/VBN in/IN lymphocyte/NN culture/NN ./. 
Rat/NN splenocytes/NNS were/VBD found/VBN to/TO have/VB greater/JJR sensitivity/NN to/TO MPL/NN (/( EC50/NN =/JJ 7.9/CD nM/NN )/) than/IN do/VBP human/JJ peripheral/JJ blood/NN lymphocytes/NNS (/( EC50/NN =/JJ 28/CD nM/NN )/) ./. 
In/FW vivo/FW studies/NNS in/IN rats/NNS utilized/VBD 2/CD mg/kg/NN IV/CD bolus/NN doses/NNS of/IN liposomal/JJ MPL/NN compared/VBN to/TO drug/NN in/IN solution/NN ./. 
Animals/NNS were/VBD sacrificed/VBN at/IN various/JJ times/NNS post-dosing/JJ until/IN 120/CD h/NN ,/, spleen/NN was/VBD excised/VBN and/CC ,/, after/IN incubation/NN of/IN lymphocytes/NNS with/IN PHA/NN ,/, splenocyte/NN blastogenic/JJ responses/NNS were/VBD assessed/VBN by/IN measuring/VBG cellular/JJ incorporation/NN of/IN 3H-thymidine/NN ./. 
The/DT suppressive/JJ effect/NN of/IN liposomal/JJ MPL/NN in/IN comparison/NN with/IN free/JJ drug/NN was/VBD significantly/RB prolonged/JJ (/( >/JJR 120/CD h/NN vs/CC </JJR 18/CD h/NN )/) ./. 
Inhibition/NN effects/NNS versus/CC time/NN were/VBD described/VBN by/IN a/DT pharmacodynamic/JJ model/NN using/VBG MPL/NN concentrations/NNS in/IN plasma/NN as/IN an/DT input/NN function/NN ./. 
A/DT nonlinear/JJ relationship/NN was/VBD found/VBN between/IN suppression/NN of/IN splenocyte/NN proliferation/NN and/CC the/DT concentration/NN of/IN bound/VBN glucocorticoid/NN receptors/NNS in/IN spleen/NN ./. 
Only/RB partial/JJ receptor/NN occupancy/NN accompanied/VBD complete/JJ lymphocyte/NN suppression/NN ./. 
The/DT suppression/NN of/IN endogenous/JJ corticosterone/NN in/IN plasma/NN for/IN both/DT treatments/NNS was/VBD similar/JJ with/IN values/NNS from/IN L-MPL/NN rats/NNS returning/VBG to/TO baseline/NN after/IN 24/CD h/NN ./. 
These/DT results/NNS demonstrate/VBP enhanced/VBN efficacy/NN of/IN local/JJ immunosuppression/NN by/IN targeting/VBG spleen/NN with/IN liposomal/JJ MPL/NN ./. 
UI/LS -/: 94217690/CD 
TI/LS -/: Function/NN of/IN NF-kappa/NN B/Rel/NN binding/NN sites/NNS in/IN the/DT major/JJ histocompatibility/NN complex/NN class/NN II/CD invariant/JJ chain/NN promoter/NN is/VBZ dependent/JJ on/IN cell-specific/JJ binding/NN of/IN different/JJ NF-kappa/NN B/Rel/NN subunits/NNS ./. 
AB/LS -/: The/DT promoter/NN of/IN the/DT human/JJ major/JJ histocompatibility/NN complex/NN class/NN II-associated/JJ invariant-chain/JJ gene/NN (/( Ii/NN )/) contains/VBZ two/CD NF-kappa/NN B/Rel/NN binding/VBG sites/NNS located/JJ at/IN -109/CD to/TO -118/CD (/( Ii/NN kappa/NN B-1/NN )/) and/CC -163/CD to/TO -172/CD (/( Ii/NN kappa/NN B-2/NN )/) from/IN the/DT transcription/NN start/NN site/NN ./. 
We/PRP report/VBP here/RB that/IN the/DT differential/JJ function/NN of/IN each/DT of/IN these/DT NF-kappa/NN B/Rel/NN sites/NNS in/IN several/JJ distinct/JJ cell/NN types/NNS depends/VBZ on/IN cell-specific/JJ binding/NN of/IN NF-kappa/NN B/Rel/NN transcription/NN factors/NNS ./. 
Ii/NN kappa/NN B-1/NN is/VBZ a/DT positive/JJ regulatory/JJ element/NN in/IN B-cell/NN lines/NNS and/CC in/IN the/DT Ii-expressing/JJ T-cell/NN line/NN ,/, H9/NN ,/, but/CC acts/VBZ as/IN a/DT negative/JJ regulatory/JJ element/NN in/IN myelomonocytic/JJ and/CC glia/NN cell/NN lines/NNS ./. 
In/FW vivo/FW protein-DNA/JJ contacts/NNS are/VBP detectable/JJ at/IN Ii/NN kappa/NN B-1/NN in/IN cell/NN lines/NNS in/IN which/WDT this/DT site/NN is/VBZ functional/JJ as/IN either/CC a/DT positive/JJ or/CC negative/JJ regulator/NN ./. 
Electrophoretic/JJ mobility/NN supershift/NN assays/NNS determine/VBP that/IN members/NNS of/IN the/DT NF-kappa/NN B/Rel/NN family/NN of/IN transcription/NN factors/NNS can/MD bind/VB to/TO this/DT site/NN in/FW vitro/FW and/CC that/IN DNA-binding/JJ complexes/NNS that/WDT contain/VBP p50/NN ,/, p52/NN ,/, p65/NN ,/, and/CC cRel/NN correlate/VBP with/IN positive/JJ regulation/NN whereas/IN the/DT presence/NN of/IN p50/NN correlates/VBZ with/IN negative/JJ regulation/NN ./. 
Ii/NN kappa/NN B-2/NN is/VBZ a/DT site/NN of/IN positive/JJ regulation/NN in/IN B-cell/NN lines/NNS and/CC a/DT site/NN of/IN negative/JJ regulation/NN in/IN H9/NN T/NN cells/NNS ,/, myelomonocytic/JJ ,/, and/CC glial/JJ cell/NN lines/NNS ./. 
In/FW vivo/FW occupancy/NN of/IN this/DT site/NN is/VBZ observed/VBN only/RB in/IN the/DT H9/NN T-cell/NN line/NN ./. 
Again/RB ,/, in/FW vitro/FW supershift/NN studies/NNS indicate/VBP that/IN the/DT presence/NN of/IN p50/NN ,/, p52/NN ,/, p65/NN ,/, and/CC cRel/NN correlates/VBZ with/IN positive/JJ function/NN whereas/IN the/DT presence/NN of/IN only/JJ p50/NN and/CC p52/NN correlates/VBZ with/IN negative/JJ function/NN ./. 
This/DT differential/JJ binding/NN of/IN specific/JJ NF-kappa/NN B/Rel/NN subunits/NNS is/VBZ likely/JJ to/TO mediate/VB the/DT disparate/JJ functions/NNS of/IN these/DT two/CD NF-kappa/NN B/Rel/NN binding/NN sites/NNS ./. 
UI/LS -/: 94338593/CD 
TI/LS -/: Epstein-Barr/JJ virus/NN (/( EBV/NN )/) replicative/JJ gene/NN expression/NN in/IN tumour/NN cells/NNS of/IN AIDS-related/JJ non-Hodgkin/JJ 's/POS lymphoma/NN in/IN relation/NN to/TO CD4/NN cell/NN number/NN and/CC antibody/NN titres/NNS to/TO EBV/NN ./. 
AB/LS -/: OBJECTIVE/NN :/: To/TO determine/VB whether/IN activation/NN of/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) replication/NN in/IN tumour/NN cells/NNS of/IN AIDS-related/JJ non-Hodgkin/JJ 's/POS lymphoma/NN (/( ARNHL/NN )/) is/VBZ correlated/VBN with/IN CD4+/JJ cell/NN counts/NNS and/CC influences/VBZ antibody/NN response/NN to/TO EBV/NN [/( anti-Z/JJ Epstein-Barr/JJ replicative/JJ activator/NN (/( ZEBRA/NN )/) ,/, anti-early/JJ antigen/NN (/( EA/NN )/) ,/, anti-viral/JJ capsid/NN antigen/NN (/( VCA/NN )/) ]/) ./. 
DESIGN/NN :/: Retrospective/JJ study/NN based/VBN on/IN immunohistochemistry/NN and/CC in/FW situ/FW hybridization/NN to/TO detect/VB EBV/NN replicative/JJ gene/NN products/NNS in/IN tissue/NN samples/NNS from/IN patients/NNS affected/VBN by/IN ARNHL/NN and/CC correlation/NN with/IN CD4+/JJ cell/NN counts/NNS and/CC results/NNS of/IN EBV/NN serology/NN (/( including/VBG anti-ZEBRA/JJ activity/NN )/) in/IN sera/NNS from/IN the/DT same/JJ patients/NNS ./. 
METHODS/NNS :/: Seventeen/CD out/IN of/IN 22/CD cases/NNS of/IN ARNHL/NN were/VBD selected/VBN for/IN the/DT presence/NN of/IN EBV/NN [/( Epstein-Barr/JJ early/JJ region/NN (/( EBER/NN )/) RNA-positive/JJ ]/) ./. 
Immunohistochemistry/NN was/VBD performed/VBN with/IN anti-ZEBRA/JJ ,/, anti-EA-restricted/JJ ,/, anti-VCA/JJ antibodies/NNS and/CC in/FW situ/FW hybridization/NN with/IN BHLF1/NotI/NN oligoprobes/NNS on/IN tumour/NN samples/NNS ./. 
Results/NNS were/VBD statistically/RB correlated/VBN with/IN those/DT of/IN CD4+/JJ cell/NN counts/NNS (/( 17/CD out/IN of/IN 17/CD )/) and/CC with/IN anti-EBV/JJ antibody/NN titres/NNS (/( 13/CD out/IN of/IN 17/CD )/) assessed/VBN using/VBG standard/JJ immunofluorescence/NN method/NN and/CC enzyme-linked/JJ immunosorbent/JJ assay/NN procedure/NN using/VBG recombinant/JJ ZEBRA/NN protein/NN and/CC synthetic/JJ peptides/NNS as/IN antigens/NNS ./. 
RESULTS/NNS :/: BZLF1/NN (/( ZEBRA/NN )/) or/CC early/JJ gene/NN products/NNS (/( EA-R/NN and/CC EA-D/BHLF1/NotI/NN )/) were/VBD detected/VBN in/IN a/DT small/JJ proportion/NN (/( </JJR 0.01-5/CD %/NN )/) of/IN tumour/NN cells/NNS in/IN eight/CD of/IN these/DT 17/CD cases/NNS by/IN immunohistochemistry/NN and/CC in/FW situ/FW hybridization/NN ./. 
Demonstration/NN of/IN replicative/JJ gene/NN expression/NN did/VBD not/RB correlate/VB with/IN either/CC low/JJ CD4+/JJ cell/NN counts/NNS (/( P/NN >/JJR 0.05/CD )/) or/CC anti-EBV/JJ antibody/NN titres/NNS (/( P/NN >/JJR 0.05/CD )/) ./. 
Anti-ZEBRA/JJ activity/NN was/VBD not/RB significantly/RB increased/VBN in/IN patients/NNS affected/VBN with/IN ARNHL/NN ,/, the/DT cells/NNS of/IN which/WDT expressed/VBD replicative/JJ gene/NN products/NNS (/( P/NN >/JJR 0.05/CD )/) ./. 
CONCLUSION/NN :/: The/DT degree/NN of/IN immunodeficiency/NN does/VBZ not/RB clearly/RB enhance/VB replicative/JJ gene/NN expression/NN in/IN tumour/NN cells/NNS of/IN ARNHL/NN ./. 
EBV/NN serology/NN ,/, including/VBG anti-ZEBRA/JJ activity/NN ,/, is/VBZ not/RB a/DT reliable/JJ tool/NN for/IN predicting/VBG the/DT occurrence/NN of/IN such/JJ proliferations/NNS ./. 
UI/LS -/: 94289333/CD 
TI/LS -/: Effects/NNS of/IN prostaglandin/NN E2/NN on/IN Th0-type/JJ human/JJ T/NN cell/NN clones/NNS :/: modulation/NN of/IN functions/NNS of/IN nuclear/JJ proteins/NNS involved/VBN in/IN cytokine/NN production/NN ./. 
AB/LS -/: The/DT effects/NNS of/IN prostaglandin/NN E2/NN (/( PGE2/NN )/) on/IN cytokine/NN production/NN and/CC proliferation/NN of/IN the/DT CD4+/JJ human/JJ helper/NN T/NN cell/NN clone/NN SP-B21/NN were/VBD investigated/VBN ./. 
In/IN cells/NNS stimulated/VBN with/IN anti-CD3/JJ mAb/NN ,/, PGE2/NN inhibited/VBD cell/NN proliferation/NN and/CC the/DT production/NN of/IN all/PDT the/DT cytokines/NNS examined/VBN ./. 
Addition/NN of/IN rIL-2/NN fully/RB restored/VBD the/DT proliferative/JJ response/NN and/CC partially/RB restored/VBD the/DT production/NN of/IN IL-4/NN and/CC IL-5/NN ,/, but/CC not/RB that/DT of/IN other/JJ cytokines/NNS ./. 
In/IN contrast/NN ,/, in/IN cells/NNS stimulated/VBN with/IN phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) /A23187/NN ,/, PGE2/NN enhanced/VBD the/DT production/NN of/IN IL-4/NN and/CC IL-5/NN ,/, and/CC only/RB partially/RB inhibited/VBD the/DT production/NN of/IN other/JJ cytokines/NNS ./. 
Therefore/RB ,/, the/DT effects/NNS of/IN PGE2/NN vary/VBP depending/VBG on/IN the/DT mode/NN of/IN T/NN cell/NN activation/NN ,/, and/CC the/DT IL-4/NN and/CC IL-5/NN are/VBP regulated/VBN differently/RB from/IN other/JJ cytokines/NNS ./. 
In/IN a/DT mobility/NN shift/NN assay/NN ,/, only/RB the/DT NF-kappa/NN B/NN (/( p50/p50/NN )/) homodimer/NN was/VBD observed/VBN in/IN a/DT complex/NN formed/VBN with/IN the/DT kappa/NN B/NN sequence/NN in/IN unstimulated/JJ SP-B21/NN cells/NNS ./. 
When/WRB cells/NNS were/VBD stimulated/VBN with/IN anti-CD3/JJ mAb/NN or/CC PMA/A23187/NN ,/, a/DT complex/NN formation/NN of/IN NF-kappa/NN B/NN (/( p50/p65/NN )/) heterodimer/NN with/IN the/DT kappa/NN B/NN sequence/NN was/VBD induced/VBN ./. 
Interestingly/RB ,/, PGE2/NN or/CC di-butyryl/NN (/( Bt2/NN )/) cAMP/NN abolished/VBD the/DT binding/NN of/IN NF-kappa/NN B/NN (/( p50/p65/NN )/) heterodimer/NN to/TO the/DT kappa/NN B/NN sequence/NN in/IN cells/NNS stimulated/VBN with/IN anti-CD3/JJ mAb/NN but/CC not/RB with/IN PMA/A23187/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN the/DT target/NN of/IN PGE2/NN action/NN is/VBZ a/DT component/NN in/IN the/DT signal/NN transduction/NN pathway/NN leading/VBG to/TO the/DT activation/NN of/IN protein/NN kinase/NN C/NN ./. 
However/RB ,/, the/DT inhibition/NN of/IN the/DT T/NN cell/NN activation/NN signals/NNS by/IN PGE2/NN is/VBZ selective/JJ ./. 
PGE2/NN enhanced/VBD the/DT complex/NN formation/NN with/IN NF-AT/NN ,/, AP-1/NN and/CC CLE0/NN sequences/NNS when/WRB the/DT cells/NNS were/VBD activated/VBN by/IN either/CC anti-CD3/JJ mAb/NN or/CC PMA/A23187/NN stimulation/NN ./. 
It/PRP seems/VBZ therefore/RB that/IN PGE2/NN ,/, by/IN elevating/VBG cAMP/NN levels/NNS ,/, interferes/VBZ with/IN the/DT activation/NN pathway/NN for/IN NF-kappa/NN B/NN but/CC not/RB for/IN NF-AT/NN ,/, AP-1/NN or/CC CLE0/NN binding/NN protein/NN ./. 
UI/LS -/: 94183209/CD 
TI/LS -/: Characterization/NN of/IN NF(P)/NN ,/, the/DT nuclear/JJ factor/NN that/WDT interacts/VBZ with/IN the/DT regulatory/JJ P/NN sequence/NN (/( 5'-CGAAAATTTCC-3'/NN )/) of/IN the/DT human/JJ interleukin-4/NN gene/NN :/: relationship/NN to/TO NF-kappa/NN B/NN and/CC NF-AT/NN ./. 
AB/LS -/: The/DT P/NN sequence/NN of/IN the/DT human/JJ interleukin-4/NN (/( IL-4/NN )/) gene/NN ,/, which/WDT was/VBD defined/VBN as/IN a/DT responsive/JJ element/NN for/IN phorbol/NN 12-myristate/NN 13-acetate/NN and/CC calcium/NN ionophore/NN (/( A23187/NN )/) in/IN Jurkat/NN T/NN cells/NNS ,/, shares/VBZ sequence/NN similarity/NN with/IN the/DT NF-kappa/NN B/NN and/CC the/DT NF-AT/NN binding/NN sites/NNS ./. 
We/PRP examined/VBD whether/IN NF(P)/NN ,/, a/DT nuclear/JJ factor/NN specific/JJ for/IN the/DT P/NN sequence/NN ,/, is/VBZ related/JJ to/TO NF-kappa/NN B/NN and/CC NF-AT/NN ./. 
NF-kappa/NN B/NN (/( P65/NN or/CC P65/P50/NN heterodimer/NN )/) bound/VBD to/TO the/DT P/NN sequence/NN in/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS (/( EMSA/NN )/) and/CC activated/VBD transcription/NN through/IN the/DT P/NN sequence/NN when/WRB expression/NN plasmids/NNS were/VBD cotransfected/VBN with/IN P/NN sequence-driven/JJ reporter/NN plasmids/NNS in/IN Jurkat/NN T/NN cells/NNS ./. 
In/IN EMSAs/NNS ,/, NF(P)/NN binding/NN was/VBD inhibited/VBN by/IN the/DT unlabeled/JJ NF-AT/NN binding/NN site/NN but/CC not/RB by/IN the/DT unlabeled/JJ AP1/NN binding/NN site/NN and/CC purified/VBN NF-AT/NN contained/VBD an/DT activity/NN that/WDT bound/VBD to/TO the/DT P/NN sequence/NN ./. 
Both/CC mobility/NN shift/NN and/CC sequence/NN specificity/NN of/IN NF-AT/NN were/VBD similar/JJ to/TO those/DT of/IN NF(P)/NN and/CC only/RB a/DT small/JJ amount/NN of/IN P65/NN was/VBD detected/VBN in/IN NF(P)/NN in/IN crude/JJ nuclear/JJ extracts/NNS ./. 
These/DT results/NNS indicate/VBP that/IN the/DT component/NN (/( s/NNS )/) of/IN NF-AT/NN has/VBZ the/DT potential/NN to/TO reconstitute/VB NF(P)/NN whereas/IN NF-kappa/NN B/NN alone/RB can/MD not/RB account/VB for/IN NF(P)/NN in/IN crude/JJ extracts/NNS ./. 
Unlike/IN NF-AT/NN ,/, NF(P)/NN does/VBZ not/RB contain/VB AP1/NN as/IN its/PRP$ DNA/NN binding/NN component/NN ./. 
UI/LS -/: 94289294/CD 
TI/LS -/: Activation/NN of/IN early/JJ growth/NN response/NN 1/CD gene/NN transcription/NN and/CC pp90rsk/NN during/IN induction/NN of/IN monocytic/JJ differentiation/NN ./. 
AB/LS -/: The/DT present/JJ work/NN has/VBZ studied/VBN mechanisms/NNS responsible/JJ for/IN induction/NN of/IN early/JJ growth/NN response/NN 1/CD (/( EGR-1/NN )/) gene/NN expression/NN during/IN monocytic/JJ differentiation/NN of/IN U-937/NN myeloid/JJ leukemia/NN cells/NNS ./. 
Differentiation/NN of/IN U-937/NN cells/NNS with/IN 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) ,/, an/DT activator/NN of/IN the/DT serine/threonine/NN protein/NN kinase/NN C/NN ,/, was/VBD associated/VBN with/IN transcriptional/JJ activation/NN of/IN EGR-1/NN promoter-reporter/JJ constructs/NNS ./. 
The/DT EGR-1/NN promoter/NN contains/VBZ six/CD CC(A/T)6GG/NN (/( CArG/NN )/) motifs/NNS ./. 
The/DT two/CD 5'-most/JJ distal/JJ CArG/NN sequences/NNS conferred/VBD TPA/NN inducibility/NN ./. 
In/IN contrast/NN ,/, there/EX was/VBD little/JJ effect/NN of/IN TPA/NN on/IN EGR-1/NN transcription/NN in/IN a/DT TPA-resistant/JJ U-937/NN cell/NN variant/NN ,/, designated/VBN TUR/NN ./. 
Treatment/NN of/IN both/CC U-937/NN and/CC TUR/NN cells/NNS with/IN okadaic/JJ acid/NN ,/, an/DT inhibitor/NN of/IN serine/threonine/NN protein/NN phosphatases/NNS 1/CD and/CC 2A/NN ,/, was/VBD associated/VBN with/IN induction/NN of/IN monocytic/JJ differentiation/NN and/CC EGR-1/NN transcription/NN through/IN the/DT 5'-most/JJ CArG/NN element/NN ./. 
Since/IN these/DT findings/NNS supported/VBD the/DT involvement/NN of/IN serine/threonine/NN protein/NN phosphorylation/NN in/IN the/DT regulation/NN of/IN EGR-1/NN expression/NN ,/, we/PRP studied/VBD activation/NN of/IN the/DT 40S/NN ribosomal/JJ protein/NN S6/NN serine/threonine/NN kinases/NNS ,/, pp70S6K/NN and/CC pp90rsk/NN ./. 
Although/IN both/DT kinases/NNS participate/VBP in/IN regulating/VBG cell/NN growth/NN ,/, there/EX was/VBD no/DT detectable/JJ activation/NN of/IN pp70S6K/NN during/IN TPA-/NN or/CC okadaic/JJ acid-induced/JJ monocytic/JJ differentiation/NN ./. 
Moreover/RB ,/, rapamycin/NN ,/, an/DT inhibitor/NN of/IN pp70S6K/NN activation/NN ,/, had/VBD no/DT effect/NN on/IN induction/NN of/IN EGR-1/NN expression/NN ./. 
In/IN contrast/NN ,/, analysis/NN of/IN pp90rsk/NN activity/NN by/IN phosphorylation/NN of/IN a/DT peptide/NN derived/VBN from/IN S6/NN protein/NN demonstrated/VBD stimulation/NN of/IN this/DT kinase/NN in/IN TPA-treated/JJ U-937/NN ,/, and/CC not/RB TUR/NN ,/, cells/NNS ./. 
Okadaic/JJ acid/NN treatment/NN of/IN both/DT cell/NN types/NNS was/VBD associated/VBN with/IN activation/NN of/IN pp90rsk/NN ./. 
UI/LS -/: 95001805/CD 
TI/LS -/: Antioxidants/NNS inhibit/VBP monocyte/NN adhesion/NN by/IN suppressing/VBG nuclear/JJ factor-kappa/NN B/NN mobilization/NN and/CC induction/NN of/IN vascular/JJ cell/NN adhesion/NN molecule-1/NN in/IN endothelial/JJ cells/NNS stimulated/VBN to/TO generate/VB radicals/NNS ./. 
AB/LS -/: Cell/NN adhesion/NN to/TO endothelial/JJ cells/NNS stimulated/VBN by/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNF/NN )/) is/VBZ due/JJ to/TO induction/NN of/IN surface/NN receptors/NNS ,/, such/JJ as/IN vascular/JJ cell/NN adhesion/NN molecule-1/NN (/( VCAM-1/NN )/) ./. 
The/DT antioxidant/JJ pyrrolidine/NN dithiocarbamate/NN (/( PDTC/NN )/) specifically/RB inhibits/VBZ activation/NN of/IN nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ./. 
Since/IN kappa/NN B/NN motifs/NNS are/VBP present/JJ in/IN VCAM-1/NN and/CC intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN )/) promoters/NNS ,/, we/PRP used/VBD PDTC/NN to/TO study/VB the/DT regulatory/JJ mechanisms/NNS of/IN VCAM-1/NN and/CC ICAM-1/NN induction/NN and/CC subsequent/JJ monocyte/NN adhesion/NN in/IN TNF-treated/JJ human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS (/( HUVECs/NNS )/) ./. 
PDTC/NN or/CC N-acetylcysteine/NN dose/NN dependently/RB reduced/VBD TNF-induced/JJ VCAM-1/NN but/CC not/RB ICAM-1/NN surface/NN protein/NN (/( also/RB in/IN human/JJ umbilical/JJ arterial/JJ endothelial/JJ cells/NNS )/) and/CC mRNA/NN expression/NN (/( by/IN 70/CD %/NN at/IN 100/CD mumol/L/NN PDTC/NN )/) in/IN HUVECs/NNS as/IN assessed/VBN by/IN flow/NN cytometry/NN and/CC polymerase/NN chain/NN reaction/NN ./. 
Gel-shift/JJ analysis/NN in/IN HUVECs/NNS demonstrated/VBD that/IN PDTC/NN prevented/VBD NF-kappa/NN B/NN mobilization/NN by/IN TNF/NN ,/, suggesting/VBG that/IN only/RB VCAM-1/NN induction/NN was/VBD controlled/VBN by/IN NF-kappa/NN B/NN ./. 
Since/IN HUVECs/NNS released/VBD superoxide/NN anions/NNS in/IN response/NN to/TO TNF/NN ,/, and/CC H2O2/NN induces/VBZ VCAM-1/NN ,/, PDTC/NN may/MD act/VB as/IN a/DT radical/JJ scavenger/NN ./. 
Although/IN ICAM-1/NN induction/NN was/VBD unaffected/JJ ,/, inhibitors/NNS of/IN NADPH/NN oxidase/NN (/( apocynin/NN )/) or/CC cytochrome/NN P-450/NN (/( SKF525a/NN )/) suppressed/VBD VCAM-1/NN induction/NN by/IN TNF/NN ,/, revealing/VBG that/IN several/JJ radical-generating/JJ systems/NNS are/VBP involved/VBN in/IN its/PRP$ regulation/NN ./. 
PDTC/NN ,/, apocynin/NN ,/, or/CC SKF525a/NN decreased/VBD adhesion/NN of/IN monocytic/JJ U937/NN cells/NNS to/TO TNF-treated/VBN HUVECs/NNS (/( by/IN 75/CD %/NN at/IN 100/CD mumol/L/NN PDTC/NN )/) ./. 
Inhibition/NN by/IN anti-VCAM-1/JJ monoclonal/JJ antibody/NN 1G11/NN indicated/VBD that/IN U937/NN adhesion/NN was/VBD VCAM-1/NN dependent/JJ and/CC suppression/NN by/IN antioxidants/NNS was/VBD due/JJ to/TO reduced/VBN VCAM-1/NN induction/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 94344126/CD 
TI/LS -/: Displacement/NN of/IN an/DT E-box-binding/JJ repressor/NN by/IN basic/JJ helix-loop-helix/JJ proteins/NNS :/: implications/NNS for/IN B-cell/NN specificity/NN of/IN the/DT immunoglobulin/NN heavy-chain/JJ enhancer/NN ./. 
AB/LS -/: The/DT activity/NN of/IN the/DT immunoglobulin/NN heavy-chain/JJ (/( IgH/NN )/) enhancer/NN is/VBZ restricted/VBN to/TO B/NN cells/NNS ,/, although/IN it/PRP binds/VBZ both/CC B-cell-restricted/JJ and/CC ubiquitous/JJ transcription/NN factors/NNS ./. 
Activation/NN of/IN the/DT enhancer/NN in/IN non-B/JJ cells/NNS upon/IN overexpression/NN of/IN the/DT basic/JJ helix-loop-helix/JJ (/( bHLH/JJ )/) protein/NN E2A/NN appears/VBZ to/TO be/VB mediated/VBN not/RB only/RB by/IN the/DT binding/NN of/IN E2A/NN to/TO its/PRP$ cognate/JJ E/NN box/NN but/CC also/RB by/IN the/DT resulting/VBG displacement/NN of/IN a/DT repressor/NN from/IN that/DT same/JJ site/NN ./. 
We/PRP have/VBP identified/VBN a/DT "/`` two-handed/JJ "/'' zinc/NN finger/NN protein/NN ,/, denoted/VBN ZEB/NN ,/, the/DT DNA-binding/JJ specificity/NN of/IN which/WDT mimics/VBZ that/DT of/IN the/DT cellular/JJ repressor/NN ./. 
By/IN employing/VBG a/DT derivative/JJ E/NN box/NN that/WDT binds/VBZ ZEB/NN but/CC not/RB E2A/NN ,/, we/PRP have/VBP shown/VBN that/IN the/DT repressor/NN is/VBZ active/JJ in/IN B/NN cells/NNS and/CC the/DT IgH/NN enhancer/NN is/VBZ silenced/VBN in/IN the/DT absence/NN of/IN binding/NN competition/NN by/IN bHLH/JJ proteins/NNS ./. 
Hence/RB ,/, we/PRP propose/VBP that/IN a/DT necessary/JJ prerequisite/NN of/IN enhancer/NN activity/NN is/VBZ the/DT B-cell-specific/JJ displacement/NN of/IN a/DT ZEB-like/JJ repressor/NN by/IN bHLH/JJ proteins/NNS ./. 
UI/LS -/: 94329809/CD 
TI/LS -/: Inhibition/NN of/IN NF-kappa/NN B/NN by/IN sodium/NN salicylate/NN and/CC aspirin/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: The/DT transcription/NN factor/NN nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) is/VBZ critical/JJ for/IN the/DT inducible/JJ expression/NN of/IN multiple/JJ cellular/JJ and/CC viral/JJ genes/NNS involved/VBN in/IN inflammation/NN and/CC infection/NN including/VBG interleukin-1/NN (/( IL-1/NN )/) ,/, IL-6/NN ,/, and/CC adhesion/NN molecules/NNS ./. 
The/DT anti-inflammatory/JJ drugs/NNS sodium/NN salicylate/NN and/CC aspirin/NN inhibited/VBD the/DT activation/NN of/IN NF-kappa/NN B/NN ,/, which/WDT further/RB explains/VBZ the/DT mechanism/NN of/IN action/NN of/IN these/DT drugs/NNS ./. 
This/DT inhibition/NN prevented/VBD the/DT degradation/NN of/IN the/DT NF-kappa/NN B/NN inhibitor/NN ,/, I/NN kappa/NN B/NN ,/, and/CC therefore/RB NF-kappa/NN B/NN was/VBD retained/VBN in/IN the/DT cytosol/NN ./. 
Sodium/NN salicylate/NN and/CC aspirin/NN also/RB inhibited/VBD NF-kappa/NN B-dependent/JJ transcription/NN from/IN the/DT Ig/NN kappa/NN enhancer/NN and/CC the/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) in/IN transfected/VBN T/NN cells/NNS ./. 
UI/LS -/: 95152420/CD 
TI/LS -/: Effects/NNS of/IN the/DT antisense/JJ myb/NN expression/NN on/IN hemin-/NN and/CC erythropoietin-induced/JJ erythroid/JJ differentiation/NN of/IN K562/NN cells/NNS ./. 
AB/LS -/: In/IN order/NN to/TO elucidate/VB the/DT role/NN of/IN c-myb/NN gene/NN in/IN erythroid/JJ differentiation/NN of/IN K562/NN cell/NN induced/VBN by/IN hemin/NN (/( Hm/NN )/) and/CC erythropoietin/NN (/( Epo/NN )/) ,/, we/PRP constructed/VBD recombinant/JJ plasmid/NN that/WDT could/MD produce/VB antisense/JJ myb/NN RNA/NN after/IN induction/NN with/IN dexamethasone/NN ./. 
During/IN treatment/NN with/IN Hm/NN ,/, K562/NN cells/NNS constitutively/RB expressed/VBD c-myb/NN mRNA/NN ,/, and/CC 50/CD %/NN of/IN them/PRP began/VBD to/TO synthesize/VB hemoglobin/NN (/( Hb/NN )/) ./. 
Expression/NN of/IN antisense/JJ myb/NN RNA/NN reduced/VBD the/DT amount/NN of/IN c-myb/NN mRNA/NN ,/, and/CC the/DT percentage/NN of/IN Hb-synthesizing/JJ cells/NNS was/VBD decreased/VBN to/TO 20/CD %/NN ./. 
In/IN the/DT presence/NN of/IN Epo/NN ,/, c-myb/NN mRNA/NN declined/VBD and/CC 20/CD %/NN of/IN K562/NN cells/NNS synthesized/VBD Hb/NN regardless/JJ of/IN antisense/JJ myb/NN RNA/NN expression/NN ./. 
It/PRP is/VBZ suggested/VBN that/IN constitutive/JJ expression/NN of/IN c-myb/NN mRNA/NN is/VBZ necessary/JJ for/IN Hm-induced/JJ differentiation/NN ,/, and/CC that/IN a/DT decrease/NN in/IN the/DT amount/NN of/IN c-myb/NN mRNA/NN induced/VBN by/IN antisense/JJ myb/NN RNA/NN expression/NN suppresses/VBZ Hm-induced/JJ differentiation/NN ./. 
The/DT amount/NN of/IN c-myb/NN mRNA/NN in/IN K562/NN cells/NNS was/VBD reduced/VBN during/IN the/DT differentiation/NN induced/VBN by/IN Epo/NN ./. 
Expression/NN of/IN GATA-1/NN mRNA/NN was/VBD almost/RB constant/JJ during/IN Hm-induced/JJ differentiation/NN ,/, but/CC increased/VBD during/IN Epo/NN treatment/NN ./. 
It/PRP is/VBZ supposed/VBN that/IN the/DT mechanism/NN of/IN Hm-induced/JJ differentiation/NN is/VBZ distinguished/VBN from/IN that/DT of/IN Epo-induced/JJ differentiation/NN in/IN K562/NN cells/NNS ./. 
UI/LS -/: 94259822/CD 
TI/LS -/: Prenatal/JJ immune/JJ challenge/NN alters/VBZ the/DT hypothalamic-pituitary-adrenocortical/JJ axis/NN in/IN adult/JJ rats/NNS ./. 
AB/LS -/: We/PRP investigated/VBD whether/IN non-abortive/JJ maternal/JJ infections/NNS would/MD compromise/VB fetal/JJ brain/NN development/NN and/CC alter/VB hypothalamic-pituitary-adrenocortical/JJ (/( HPA/NN )/) axis/NN functioning/VBG when/WRB adult/JJ ./. 
To/TO study/VB putative/JJ teratogenic/JJ effects/NNS of/IN a/DT T/NN cell-mediated/JJ immune/JJ response/NN versus/CC an/DT endotoxic/JJ challenge/NN ,/, 10-d-pregnant/JJ rats/NNS received/VBD a/DT single/JJ intraperitoneal/JJ injection/NN of/IN 5/CD x/NN 10/CD (/( 8/CD )/) human/JJ red/JJ blood/NN cells/NNS (/( HRBC/NN )/) or/CC gram-negative/JJ bacterial/JJ endotoxin/NN (/( Escherichia/FW coli/FW LPS/NN :/: 30/CD micrograms/kg/NNS )/) ./. 
The/DT adult/JJ male/JJ progeny/NN (/( 3/CD mo/NN old/JJ )/) of/IN both/DT experimental/JJ groups/NNS showed/VBD increased/VBN basal/JJ plasma/NN corticosterone/NN levels/NNS ./. 
In/IN addition/NN ,/, after/IN novelty/NN stress/NN the/DT HRBC/NN group/NN ,/, but/CC not/RB the/DT LPS/NN group/NN ,/, showed/VBD increased/VBN ACTH/NN and/CC corticosterone/NN levels/NNS ./. 
Both/DT groups/NNS showed/VBD substantial/JJ decreases/NNS in/IN mineralocorticoid/NN (/( MR/NN )/) and/CC glucocorticoid/NN receptor/NN (/( GR/NN )/) levels/NNS in/IN the/DT hippocampus/NN ,/, a/DT limbic/JJ brain/NN structure/NN critical/JJ for/IN HPA/NN axis/NN regulation/NN ,/, whereas/IN GR/NN concentrations/NNS in/IN the/DT hypothalamus/NN were/VBD unchanged/JJ and/CC in/IN anterior/JJ pituitary/NN were/VBD slightly/RB increased/VBN ./. 
HRBC/NN and/CC LPS/NN indeed/RB stimulated/VBD the/DT maternal/JJ immune/JJ system/NN as/IN revealed/VBN by/IN specific/JJ anti-HRBC/JJ antibody/NN production/NN and/CC enhanced/VBD IL-1/NN beta/NN mRNA/NN expression/NN in/IN splenocytes/NNS ,/, respectively/RB ./. 
This/DT study/NN demonstrates/VBZ that/IN a/DT T/NN cell-mediated/JJ immune/JJ response/NN as/RB well/RB as/IN an/DT endotoxic/JJ challenge/NN during/IN pregnancy/NN can/MD induce/VB anomalies/NNS in/IN HPA/NN axis/NN function/NN in/IN adulthood/NN ./. 
Clinically/RB ,/, it/PRP may/MD be/VB postulated/VBN that/IN disturbed/JJ fetal/JJ brain/NN development/NN due/JJ to/TO prenatal/JJ immune/JJ challenge/NN increases/VBZ the/DT vulnerability/NN to/TO develop/VB mental/JJ illness/NN involving/VBG inadequate/JJ responses/NNS to/TO stress/NN ./. 
UI/LS -/: 95003681/CD 
TI/LS -/: A/DT low/JJ NM23.H1/NN gene/NN expression/NN identifying/VBG high/JJ malignancy/NN human/JJ melanomas/NNS ./. 
AB/LS -/: The/DT NM23/NN gene/NN has/VBZ been/VBN proposed/VBN as/IN a/DT metastasis-suppressor/JJ gene/NN ,/, and/CC its/PRP$ use/NN has/VBZ been/VBN suggested/VBN as/IN prognostic/JJ factor/NN ./. 
NM23/NN was/VBD identified/VBN in/IN a/DT system/NN of/IN murine/NN melanoma/NN cell/NN lines/NNS ,/, in/IN which/WDT an/DT inverse/JJ relationship/NN was/VBD found/VBN between/IN NM23/CD expression/NN and/CC metastatic/JJ ability/NN ./. 
In/IN a/DT human/JJ malignant/JJ melanoma/NN study/NN NM23/NN expression/NN was/VBD found/VBN to/TO be/VB significantly/RB lower/JJR in/IN metastases/NNS that/WDT developed/VBD less/JJR than/IN 24/CD months/NNS after/IN diagnosis/NN of/IN the/DT primary/JJ tumours/NNS ./. 
The/DT present/JJ paper/NN studies/VBZ the/DT expression/NN of/IN the/DT NM23.H1/NN gene/NN in/IN cell/NN lines/NNS which/WDT derive/VBP from/IN primary/JJ or/CC metastatic/JJ human/JJ malignant/JJ melanomas/NNS in/IN relation/NN to/TO staging/NN ,/, infiltration/NN degree/NN ,/, lymphocytic/JJ infiltration/NN ,/, cell/NN morphology/NN ,/, cell/NN pigmentation/NN ,/, karyotype/NN ,/, and/CC disease-free/JJ survival/NN ./. 
The/DT level/NN of/IN mRNA/NN expression/NN of/IN the/DT NM23/NN gene/NN is/VBZ significantly/RB lower/JJR in/IN cell/NN lines/NNS that/WDT derive/VBP from/IN more/JJR infiltrating/VBG primary/JJ melanomas/NNS than/IN in/IN cell/NN lines/NNS obtained/VBN from/IN less/RBR infiltrating/JJ tumours/NNS ./. 
Moreover/RB ,/, cell/NN lines/NNS derived/VBN from/IN tumours/NNS of/IN patients/NNS with/IN a/DT disease-free/JJ survival/NN of/IN more/JJR than/IN 24/CD months/NNS (/( 24-58/CD months/NNS )/) express/VBP the/DT NM23/NN gene/NN at/IN higher/JJR levels/NNS than/IN cell/NN lines/NNS obtained/VBN from/IN melanomas/NNS of/IN patients/NNS with/IN a/DT disease-free/JJ survival/NN of/IN less/JJR than/IN 24/CD months/NNS (/( 6-15/CD months/NNS )/) ./. 
UI/LS -/: 94209654/CD 
TI/LS -/: Activation/NN of/IN a/DT novel/JJ serine/threonine/NN kinase/NN that/WDT phosphorylates/VBZ c-Fos/NN upon/IN stimulation/NN of/IN T/NN and/CC B/NN lymphocytes/NNS via/IN antigen/NN and/CC cytokine/NN receptors/NNS ./. 
AB/LS -/: Ligation/NN of/IN Ag/NN receptors/NNS in/IN T/NN and/CC B/NN lymphocytes/NNS initiates/VBZ signal/NN transduction/NN cascades/NNS which/WDT alter/VBP the/DT expression/NN of/IN genes/NNS that/WDT regulate/VBP cellular/JJ proliferation/NN and/CC differentiation/NN ./. 
The/DT transmission/NN of/IN signals/NNS from/IN the/DT membrane/NN to/TO the/DT nucleus/NN is/VBZ mediated/VBN principally/RB through/IN the/DT action/NN of/IN protein/NN tyrosine/NN and/CC serine/threonine/NN kinases/NNS ./. 
We/PRP have/VBP identified/VBN and/CC characterized/VBN a/DT novel/JJ serine/threonine/NN kinase/NN that/WDT phosphorylated/VBD the/DT proto-oncogene/NN product/NN ,/, c-Fos/NN ,/, and/CC is/VBZ termed/VBN Fos/NN kinase/NN ./. 
Fos/NN kinase/NN was/VBD rapidly/RB activated/VBN after/IN ligation/NN of/IN the/DT CD3/NN and/CC CD2/NN receptors/NNS in/IN Jurkat/NN and/CC normal/JJ human/JJ T/NN lymphocytes/NNS and/CC in/IN response/NN to/TO IL-6/NN and/CC anti-IgM/NN in/IN the/DT human/JJ B/NN cell/NN lines/NNS AF10/NN and/CC Ramos/NN ,/, respectively/RB ./. 
The/DT phorbol/NN ester/NN ,/, PMA/NN ,/, was/VBD also/RB a/DT potent/JJ inducer/NN of/IN Fos/NN kinase/NN activity/NN in/IN all/DT of/IN the/DT above/JJ populations/NNS ,/, suggesting/VBG that/IN PKC/NN plays/VBZ a/DT role/NN in/IN the/DT regulation/NN of/IN this/DT enzyme/NN ./. 
Fos/NN kinase/NN phosphorylates/VBZ c-Fos/NN at/IN a/DT site/NN near/JJ the/DT C-terminus/NN ,/, as/RB well/RB as/IN a/DT peptide/NN derived/VBN from/IN this/DT region/NN (/( residues/NNS 359-370/CD ,/, RKGSSSNEPSSD/NN )/) ,/, and/CC Fos/NN peptide/NN competitively/RB inhibited/VBD c-Fos/NN phosphorylation/NN ./. 
Fos/NN kinase/NN was/VBD shown/VBN to/TO be/VB distinct/JJ from/IN other/JJ identified/VBN serine/threonine/NN kinases/NNS ,/, including/VBG protein/NN kinase/NN A/NN ,/, protein/NN kinase/NN C/NN ,/, casein/NN kinase/NN II/CD ,/, MAP/NN kinases/NNS ,/, p70S6K/NN and/CC p90RSK/NN ./. 
Fos/NN kinase/NN was/VBD purified/VBN by/IN anion/NN exchange/NN chromatography/NN and/CC exhibited/VBD an/DT apparent/JJ M(r)/NN =/JJ 65,000/CD and/CC isoelectric/JJ point/NN =/JJ 6.1/CD ./. 
Fos/NN kinase/NN may/MD play/VB a/DT role/NN in/IN transcriptional/JJ regulation/NN through/IN its/PRP$ capacity/NN to/TO phosphorylate/VB c-Fos/NN at/IN a/DT site/NN required/VBN for/IN expression/NN of/IN the/DT transcriptional/JJ transrepressive/JJ activity/NN of/IN this/DT molecule/NN ./. 
Moreover/RB ,/, its/PRP$ rapid/JJ activation/NN suggests/VBZ it/PRP may/MD have/VB a/DT wider/JJR role/NN within/IN signal/NN transduction/NN cascades/NNS in/IN lymphocytes/NNS ./. 
UI/LS -/: 94202265/CD 
TI/LS -/: Antigenic/JJ specificities/NNS of/IN human/JJ CD4+/JJ T-cell/NN clones/NNS recovered/VBD from/IN recurrent/JJ genital/JJ herpes/NN simplex/JJ virus/NN type/NN 2/CD lesions/NNS ./. 
AB/LS -/: Lesions/NNS resulting/VBG from/IN recurrent/JJ genital/JJ herpes/NN simplex/JJ virus/NN (/( HSV/NN )/) infection/NN are/VBP characterized/VBN by/IN infiltration/NN of/IN CD4+/JJ lymphocytes/NNS ./. 
We/PRP have/VBP investigated/VBN the/DT antigenic/JJ specificity/NN of/IN 47/CD HSV-specific/JJ CD4+/JJ T-cell/NN clones/NNS recovered/VBN from/IN the/DT HSV-2/NN buttock/NN and/CC thigh/NN lesions/NNS of/IN five/CD patients/NNS ./. 
Clones/NNS with/IN proliferative/JJ responses/NNS to/TO recombinant/JJ truncated/VBN glycoprotein/NN B/NN (/( gB/NN )/) or/CC gD/NN of/IN HSV-2/NN or/CC purified/VBN natural/JJ gC/NN of/IN HSV-2/NN comprised/VBD a/DT minority/NN of/IN the/DT total/JJ number/NN of/IN HSV-specific/JJ clones/NNS isolated/VBN from/IN lesions/NNS ./. 
The/DT gC2-/NN and/CC gD2-specific/JJ CD4+/JJ clones/NNS had/VBD cytotoxic/JJ activity/NN ./. 
The/DT approximate/JJ locations/NNS of/IN the/DT HSV-2/NN genes/NNS encoding/VBG HSV-2/NN type-specific/JJ CD4+/JJ antigens/NNS have/VBP been/VBN determined/VBN by/IN using/VBG HSV-1/NN x/NN HSV-2/NN intertypic/JJ recombinant/JJ virus/NN and/CC include/VBP the/DT approximate/JJ map/NN regions/NNS 0.30/CD to/TO 0.46/CD ,/, 0.59/CD to/TO 0.67/CD ,/, 0.67/CD to/TO 0.73/CD ,/, and/CC 0.82/CD to/TO 1.0/CD units/NNS ./. 
The/DT antigenic/JJ specificity/NN of/IN an/DT HLA/NN DQ2-restricted/JJ ,/, HSV-2/NN type-specific/JJ T-cell/NN clone/NN was/VBD mapped/VBN to/TO amino/NN acids/NNS 425/CD to/TO 444/CD of/IN VP16/NN of/IN HSV-2/NN by/IN sequential/JJ use/NN of/IN an/DT intertypic/JJ recombinant/JJ virus/NN containing/VBG VP16/NN of/IN HSV-2/NN in/IN an/DT HSV-1/NN background/NN ,/, recombinant/JJ VP16/NN fusion/NN proteins/NNS ,/, and/CC synthetic/JJ peptides/NNS ./. 
Each/DT of/IN the/DT remaining/VBG four/CD patients/NNS also/RB yielded/VBD at/IN least/JJS one/CD type-specific/JJ T-cell/NN clone/NN reactive/JJ with/IN an/DT HSV-2/NN epitope/NN mapping/VBG to/TO approximately/RB 0.67/CD to/TO 0.73/CD map/NN units/NNS ./. 
The/DT antigenic/JJ specificities/NNS of/IN lesion-derived/JJ CD4+/JJ T-cell/NN clones/NNS are/VBP quite/RB diverse/JJ and/CC include/VBP at/IN least/JJS 10/CD epitopes/NNS ./. 
Human/JJ T-cell/NN clones/NNS reactive/JJ with/IN gC/NN and/CC VP16/NN are/VBP reported/VBN here/RB for/IN the/DT first/JJ time/NN ./. 
UI/LS -/: 95001542/CD 
TI/LS -/: Marked/JJ basophilia/NN in/IN acute/JJ promyelocytic/JJ leukaemia/NN treated/VBN with/IN all-trans/JJ retinoic/JJ acid/NN :/: molecular/JJ analysis/NN of/IN the/DT cell/NN origin/NN of/IN the/DT basophils/NNS ./. 
AB/LS -/: We/PRP report/VBP a/DT patient/NN with/IN acute/JJ promyelocytic/JJ leukaemia/NN who/WP developed/VBD marked/JJ basophilia/NN during/IN all-trans/JJ retinoic/JJ acid/NN treatment/NN ./. 
We/PRP studied/VBD genomic/JJ DNA/NN and/CC RNA/NN extracted/VBN from/IN the/DT patient/NN 's/POS peripheral/JJ leucocytes/NNS in/IN order/NN to/TO determine/VB the/DT origin/NN of/IN the/DT basophils/NNS ./. 
The/DT RAR/NN alpha/NN rearranged/JJ band/NN in/IN the/DT Southern/NN blot/NN analysis/NN and/CC a/DT chimaeric/JJ product/NN of/IN PML-RAR/JJ alpha/NN by/IN polymerase/NN chain/NN reaction/NN were/VBD strongly/RB visible/JJ before/IN ATRA/NN treatment/NN ,/, but/CC at/IN the/DT time/NN of/IN maximal/JJ basophilia/NN both/DT of/IN them/PRP were/VBD markedly/RB diminished/VBN ./. 
These/DT findings/NNS suggest/VBP that/IN the/DT basophils/NNS which/WDT appeared/VBD during/IN the/DT ATRA/NN treatment/NN are/VBP reactive/JJ in/IN nature/NN rather/RB than/IN a/DT leukaemic/JJ clone/NN ./. 
UI/LS -/: 94181565/CD 
TI/LS -/: Activation/NN of/IN the/DT interleukin/NN 6/CD gene/NN by/IN Mycobacterium/NN tuberculosis/NN or/CC lipopolysaccharide/NN is/VBZ mediated/VBN by/IN nuclear/JJ factors/NNS NF-IL6/NN and/CC NF-kappa/NN B/NN [/( published/VBN erratum/NN appears/VBZ in/IN Proc/NNP Natl/NN Acad/NNP Sci/NNP U/NNP S/NNP A/NNP 1995/CD Apr/NN 11/CD ;/: 92/CD (/( 8/CD )/) :/: 3632/CD ]/) 
AB/LS -/: The/DT host/NN response/NN to/TO Mycobacterium/NN tuberculosis/NN includes/VBZ granuloma/NN formation/NN at/IN sites/NNS of/IN infection/NN and/CC systemic/JJ symptoms/NNS ./. 
Cytokines/NNS have/VBP been/VBN identified/VBN by/IN immunohistochemistry/NN in/IN granulomas/NNS in/IN animal/NN models/NNS of/IN bacillus/FW Calmette-Guerin/FW (/( BCG/NN )/) infection/NN and/CC are/VBP released/VBN by/IN mononuclear/JJ phagocytes/NNS upon/IN stimulation/NN by/IN mycobacterial/JJ proteins/NNS ./. 
In/IN this/DT regard/NN ,/, the/DT cytokine/NN interleukin/NN 6/CD (/( IL-6/NN )/) may/MD play/VB a/DT role/NN in/IN the/DT clinical/JJ manifestations/NNS and/CC pathological/JJ events/NNS of/IN tuberculosis/NN infection/NN ./. 
We/PRP have/VBP demonstrated/VBN that/IN lipoarabinomannan/NN (/( LAM/NN )/) from/IN the/DT mycobacterial/JJ cell/NN wall/NN ,/, which/WDT was/VBD virtually/RB devoid/JJ of/IN lipopolysaccharide/NN (/( LPS/NN )/) ,/, stimulated/VBD mononuclear/JJ phagocytes/NNS to/TO release/VB IL-6/NN in/IN a/DT dose-response/JJ manner/NN ./. 
LAM/NN and/CC LPS/NN were/VBD potent/JJ inducers/NNS of/IN IL-6/NN gene/NN expression/NN in/IN peripheral/JJ blood/NN monocytes/NNS ./. 
Both/CC LAM-/NN and/CC LPS-inducible/JJ IL-6/NN promoter/NN activity/NN was/VBD localized/JJ to/TO a/DT DNA/NN fragment/NN ,/, positions/NNS -158/CD to/TO -49/CD ,/, by/IN deletion/NN analysis/NN and/CC chloramphenicol/NN acetyltransferase/NN assay/NN ./. 
Two/CD nuclear/JJ factor/NN NF-IL6/NN (/( positions/NNS -153/CD to/TO -145/CD and/CC -83/CD to/TO -75/CD )/) and/CC one/CD nuclear/JJ factor/NN NF-kappa/NN B/NN (/( positions/NNS -72/CD to/TO -63/CD )/) motifs/NNS are/VBP present/JJ within/IN this/DT fragment/NN ./. 
Site-directed/JJ mutagenesis/NN of/IN one/CD or/CC more/JJR of/IN these/DT motifs/NNS within/IN the/DT IL-6/NN promoter/NN demonstrated/VBD that/IN each/DT has/VBZ positive/JJ regulatory/JJ activity/NN and/CC that/IN they/PRP could/MD act/VB in/IN a/DT function-/NN and/CC orientation-independent/JJ manner/NN ./. 
Deletion/NN of/IN all/DT three/CD elements/NNS abolished/VBD inducibility/NN of/IN IL-6/NN promoter/NN activity/NN by/IN both/CC LAM/NN and/CC LPS/NN ./. 
We/PRP conclude/VBP that/IN the/DT NF-IL6/NN and/CC NF-kappa/NN B/NN sites/NNS mediate/VBP IL-6/NN induction/NN in/IN response/NN to/TO both/CC LPS/NN and/CC LAM/NN ,/, acting/VBG as/IN bacterial/JJ or/CC mycobacterial/JJ response/NN elements/NNS ./. 
UI/LS -/: 94375892/CD 
TI/LS -/: Regulation/NN of/IN CD14/NN expression/NN during/IN monocytic/JJ differentiation/NN induced/VBN with/IN 1/CD alpha,25-dihydroxyvitamin/NN D3/NN ./. 
AB/LS -/: CD14/NN ,/, a/DT monocyte/macrophage/NN receptor/NN for/IN the/DT complex/NN of/IN LPS/NN and/CC LPS/NN binding/NN protein/NN ,/, is/VBZ a/DT differentiation/NN marker/NN for/IN the/DT monocyte/macrophage/NN lineage/NN ./. 
We/PRP have/VBP analyzed/VBN the/DT regulation/NN of/IN CD14/NN expression/NN during/IN 1/CD alpha,25-dihydroxyvitamin/NN D3/NN (/( VitD3/NN )/) -induced/JJ monocytic/JJ differentiation/NN ./. 
Using/VBG FACS/NN ,/, Northern/NN blotting/NN ,/, and/CC nuclear/JJ run-on/JJ analyses/NNS ,/, we/PRP demonstrate/VBP that/IN the/DT up-regulation/NN of/IN CD14/NN expression/NN during/IN monocytic/JJ cell/NN maturation/NN is/VBZ regulated/VBN mainly/RB at/IN the/DT level/NN of/IN gene/NN transcription/NN ,/, and/CC that/IN new/JJ protein/NN synthesis/NN is/VBZ required/VBN for/IN CD14/NN induction/NN ./. 
We/PRP have/VBP recently/RB cloned/VBN the/DT CD14/NN 5'/JJ upstream/JJ sequence/NN and/CC demonstrated/VBD its/PRP$ tissue-specific/JJ promoter/NN activity/NN ./. 
Using/VBG stable/JJ transfection/NN of/IN the/DT monocytoid/JJ U937/NN cell/NN line/NN with/IN a/DT series/NN of/IN deletion/NN mutants/NNS of/IN the/DT CD14/NN 5'/JJ upstream/JJ sequence/NN coupled/VBN to/TO a/DT reporter/NN gene/NN construct/NN ,/, we/PRP show/VBP that/IN bp/NN -128/CD to/TO -70/CD is/VBZ the/DT critical/JJ region/NN for/IN the/DT induction/NN of/IN CD14/NN expression/NN ./. 
This/DT region/NN contains/VBZ two/CD binding/VBG sites/NNS for/IN the/DT Sp1/NN transcription/NN factor/NN ./. 
A/DT 3-bp/JJ mutation/NN at/IN the/DT distal/JJ Sp1-binding/JJ site/NN not/RB only/RB eliminates/VBZ Sp1/NN interaction/NN ,/, but/CC also/RB abolishes/VBZ most/JJS of/IN the/DT VitD3/NN induction/NN of/IN CD14/NN expression/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN analysis/NN does/VBZ not/RB detect/VB a/DT direct/JJ interaction/NN of/IN the/DT CD14/NN distal/JJ Sp1-binding/JJ site/NN with/IN the/DT vitamin/NN D3/NN receptor/NN and/CC its/PRP$ partner/NN ,/, the/DT retinoid/NN X/NN receptor/NN ./. 
These/DT data/NNS demonstrate/VBP that/IN VitD3/NN induces/VBZ CD14/NN indirectly/RB through/IN some/DT intermediary/JJ factor/NN ,/, and/CC suggest/VBP a/DT critical/JJ role/NN for/IN Sp1/NN in/IN this/DT process/NN ./. 
UI/LS -/: 94344108/CD 
TI/LS -/: DNA-binding/JJ and/CC transcriptional/JJ regulatory/JJ properties/NNS of/IN hepatic/JJ leukemia/NN factor/NN (/( HLF/NN )/) and/CC the/DT t(17;19)/NN acute/JJ lymphoblastic/JJ leukemia/NN chimera/NN E2A-HLF/JJ ./. 
AB/LS -/: The/DT t(17;19)/NN translocation/NN in/IN acute/JJ lymphoblastic/JJ leukemias/NNS results/VBZ in/IN creation/NN of/IN E2A-hepatic/JJ leukemia/NN factor/NN (/( HLF/NN )/) chimeric/JJ proteins/NNS that/WDT contain/VBP the/DT DNA-binding/JJ and/CC protein/NN dimerization/NN domains/NNS of/IN the/DT basic/JJ leucine/NN zipper/NN (/( bZIP/NN )/) protein/NN HLF/NN fused/VBN to/TO a/DT portion/NN of/IN E2A/NN proteins/NNS with/IN transcriptional/JJ activation/NN properties/NNS ./. 
An/DT in/FW vitro/FW binding/VBG site/NN selection/NN procedure/NN was/VBD used/VBN to/TO determine/VB DNA/NN sequences/NNS preferentially/RB bound/VBN by/IN wild-type/JJ HLF/NN and/CC chimeric/JJ E2A-HLF/JJ proteins/NNS isolated/VBN from/IN various/JJ t(17;19)-bearing/JJ leukemias/NNS ./. 
All/DT were/VBD found/VBN to/TO selectively/RB bind/VB the/DT consensus/NN sequence/NN 5'-GTTACGTAAT-3'/NN with/IN high/JJ affinity/NN ./. 
Wild-type/JJ and/CC chimeric/JJ HLF/NN proteins/NNS also/RB bound/VBD closely/RB related/JJ sites/NNS identified/VBN previously/RB for/IN bZIP/NN proteins/NNS of/IN both/CC the/DT proline-/NN and/CC acidic/JJ amino/NN acid-rich/JJ (/( PAR/NN )/) and/CC C/EBP/NN subfamilies/NNS ;/: however/RB ,/, E2A-HLF/JJ proteins/NNS were/VBD significantly/RB less/JJR tolerant/JJ of/IN certain/JJ deviations/NNS from/IN the/DT HLF/NN consensus/NN binding/NN site/NN ./. 
These/DT differences/NNS were/VBD directly/RB attributable/JJ to/TO loss/NN of/IN an/DT HLF/NN ancillary/NN DNA-binding/JJ domain/NN in/IN all/DT E2A-HLF/JJ chimeras/NNS and/CC were/VBD further/RB exacerbated/JJ by/IN a/DT zipper/NN mutation/NN in/IN one/CD isolate/NN ./. 
Both/CC wild-type/JJ and/CC chimeric/JJ HLF/NN proteins/NNS displayed/VBD transcriptional/JJ activator/NN properties/NNS in/IN lymphoid/JJ and/CC nonlymphoid/JJ cells/NNS on/IN reporter/NN genes/NNS containing/VBG HLF/NN or/CC C/EBP/NN consensus/NN binding/NN sites/NNS ./. 
But/CC on/IN reporter/NN genes/NNS with/IN nonoptimal/JJ binding/VBG sites/NNS ,/, their/PRP$ transcriptional/JJ properties/NNS diverged/VBD and/CC E2A-HLF/JJ competitively/RB inhibited/VBD activation/NN by/IN wild-type/JJ PAR/NN proteins/NNS ./. 
These/DT findings/NNS establish/VBP a/DT spectrum/NN of/IN binding/VBG site-specific/JJ transcriptional/JJ properties/NNS for/IN E2A-HLF/JJ which/WDT may/MD preferentially/RB activate/VB expression/NN of/IN select/JJ subordinate/JJ genes/NNS as/IN a/DT homodimer/NN and/CC potentially/RB antagonize/VB expression/NN of/IN others/NNS through/IN heteromeric/JJ interactions/NNS ./. 
UI/LS -/: 94327655/CD 
TI/LS -/: ZAP-70/NN tyrosine/NN kinase/NN ,/, CD45/NN ,/, and/CC T/NN cell/NN receptor/NN involvement/NN in/IN UV-/NN and/CC H2O2-induced/JJ T/NN cell/NN signal/NN transduction/NN ./. 
AB/LS -/: Several/JJ mammalian/JJ responses/NNS to/TO UV/NN irradiation/NN ,/, including/VBG the/DT activation/NN of/IN NF-kappa/NN B/NN ,/, are/VBP believed/VBN to/TO involve/VB tyrosine/NN phosphorylation/NN ./. 
UV/NN irradiation/NN and/CC H2O2/NN treatment/NN of/IN T/NN lymphocytes/NNS induce/VBP protein/NN tyrosine/NN phosphorylation/NN and/CC Ca2+/NN signals/NNS similar/JJ to/TO those/DT observed/VBN following/VBG biological/JJ stimulation/NN ./. 
We/PRP have/VBP examined/VBN the/DT role/NN of/IN cell/NN surface/NN molecules/NNS in/IN these/DT responses/NNS ./. 
Normal/JJ T/NN lymphocytes/NNS whose/WP$ surface/NN expression/NN of/IN CD3/NN was/VBD depleted/VBN showed/VBD impaired/JJ UV-induced/JJ tyrosine/NN phosphorylation/NN and/CC Ca2+/NN signals/NNS ./. 
Similarly/RB ,/, Jurkat/NN T/NN cell/NN lines/NNS deficient/JJ in/IN CD3/NN or/CC CD45/NN expression/NN also/RB gave/VBD impaired/JJ UV/NN responses/NNS ./. 
However/RB ,/, all/PDT these/DT cell/NN types/NNS still/RB gave/VBD strong/JJ Ca2+/NN and/CC tyrosine/NN phosphorylation/NN responses/NNS to/TO H2O2/NN ./. 
The/DT T/NN cell/NN tyrosine/NN kinase/NN ZAP-70/NN was/VBD found/VBN to/TO be/VB highly/RB responsive/JJ to/TO UV/NN and/CC H2O2/NN treatment/NN ./. 
ZAP-70/NN responsiveness/NN to/TO UV/NN required/VBD expression/NN of/IN both/CC CD3/NN and/CC CD45/NN ,/, whereas/IN only/JJ CD3/NN was/VBD required/VBN for/IN the/DT response/NN to/TO H2O2/NN ./. 
UV-induced/JJ activation/NN of/IN NF-kappa/NN B/NN was/VBD blocked/VBN by/IN CD3/NN depletion/NN ,/, indicating/VBG the/DT importance/NN of/IN such/JJ cell/NN surface/NN molecules/NNS in/IN biological/JJ responses/NNS to/TO UV/NN ./. 
In/IN nonlymphoid/JJ cells/NNS ,/, the/DT epidermal/JJ growth/NN factor/NN receptor/NN displayed/VBD increased/VBN tyrosine/NN phosphorylation/NN within/IN seconds/NNS of/IN UV/NN irradiation/NN ./. 
These/DT results/NNS suggest/VBP that/IN UV-induced/JJ signal/NN transduction/NN is/VBZ mediated/VBN via/IN cell/NN surface/NN receptors/NNS that/WDT normally/RB respond/VBP to/TO biological/JJ stimulation/NN ,/, whereas/IN H2O2/NN is/VBZ able/JJ to/TO partially/RB bypass/VB this/DT requirement/NN ./. 
UI/LS -/: 94330935/CD 
TI/LS -/: Inhibition/NN of/IN the/DT differentiation/NN of/IN human/JJ myeloid/JJ cell/NN lines/NNS by/IN redox/NN changes/NNS induced/VBN through/IN glutathione/NN depletion/NN ./. 
AB/LS -/: We/PRP have/VBP investigated/VBN the/DT effect/NN of/IN redox/NN changes/NNS in/FW vivo/FW on/IN the/DT differentiation/NN of/IN two/CD human/JJ myeloid/JJ cell/NN lines/NNS ,/, HL-60/NN and/CC KG-1/NN ./. 
The/DT glutathione-depleting/JJ agent/NN diethyl/NN maleate/NN (/( DEM/NN )/) prevented/VBD the/DT development/NN of/IN differentiated/VBN features/NNS in/IN response/NN to/TO phorbol/NN esters/NNS ,/, including/VBG adherence/NN of/IN the/DT cells/NNS to/TO plastic/JJ surfaces/NNS and/CC repression/NN of/IN the/DT myeloperoxidase/NN and/CC CD34/NN genes/NNS ./. 
Moreover/RB ,/, DEM/NN abolished/VBD phorbol/NN 12-myristate/NN 13-acetate-induced/JJ activation/NN of/IN the/DT transcription/NN factors/NNS AP-1/NN and/CC Egr-1/NN ,/, suggesting/VBG that/IN inhibition/NN of/IN differentiation/NN may/MD be/VB due/JJ ,/, at/IN least/JJS in/IN part/NN ,/, to/TO redox/NN modifications/NNS of/IN these/DT proteins/NNS ./. 
UI/LS -/: 94254835/CD 
TI/LS -/: Lipopolysaccharide/NN induction/NN of/IN tissue/NN factor/NN gene/NN expression/NN in/IN monocytic/JJ cells/NNS is/VBZ mediated/VBN by/IN binding/NN of/IN c-Rel/p65/NN heterodimers/NNS to/TO a/DT kappa/NN B-like/JJ site/NN ./. 
AB/LS -/: Exposure/NN of/IN monocytic/JJ cells/NNS to/TO bacterial/JJ lipopolysaccharide/NN (/( LPS/NN )/) activates/VBZ the/DT NF-kappa/NN B/Rel/NN family/NN of/IN proteins/NNS and/CC leads/VBZ to/TO the/DT rapid/JJ induction/NN of/IN inflammatory/JJ gene/NN products/NNS ,/, including/VBG tissue/NN factor/NN (/( TF/NN )/) ./. 
TF/NN is/VBZ the/DT primary/JJ cellular/JJ initiator/NN of/IN the/DT coagulation/NN protease/NN cascades/NNS ./. 
Here/RB we/PRP report/VBP the/DT characterization/NN of/IN a/DT nuclear/JJ complex/NN from/IN human/JJ monocytic/JJ cells/NNS that/WDT bound/VBD to/TO a/DT kappa/NN B-like/JJ site/NN ,/, 5'-CGGAGTTTCC-3'/NN ,/, in/IN the/DT 5'-flanking/JJ region/NN of/IN the/DT human/JJ TF/NN gene/NN ./. 
This/DT nuclear/JJ complex/NN was/VBD activated/VBN by/IN LPS/NN with/IN kinetics/NNS that/WDT preceded/VBD induction/NN of/IN the/DT TF/NN gene/NN ./. 
In/FW vitro/FW binding/NN studies/NNS demonstrated/VBD that/IN the/DT TF/NN site/NN bound/VBD translated/VBN c-Rel/NN and/CC p65/NN homodimers/NNS but/CC not/RB p50/p65/NN heterodimers/NNS or/CC p50/NN homodimers/NNS ./. 
Base-pair/JJ substitutions/NNS in/IN the/DT TF/NN site/NN indicated/VBD that/IN the/DT presence/NN of/IN a/DT cytosine/NN at/IN position/NN 1/CD precluded/VBD binding/NN of/IN NF-kappa/NN B/NN ./. 
In/IN fact/NN ,/, under/IN low-ionic-strength/JJ conditions/NNS ,/, the/DT TF/NN complex/NN did/VBD not/RB migrate/VB with/IN translated/VBN p50/p65/NN dimers/NNS but/CC instead/RB comigrated/VBD with/IN c-Rel/p65/NN dimers/NNS ./. 
Antibodies/NNS against/IN the/DT NF-kappa/NN B/NN and/CC Rel/NN proteins/NNS and/CC UV/NN cross-linking/JJ studies/NNS revealed/VBD the/DT presence/NN of/IN c-Rel/NN and/CC p65/NN and/CC the/DT absence/NN of/IN p50/NN in/IN the/DT TF/NN complex/NN and/CC further/RB showed/VBD that/IN c-Rel/p65/NN heterodimers/NNS selectively/RB bound/VBD to/TO the/DT TF/NN kappa/NN B-like/JJ site/NN ./. 
Functional/JJ studies/NNS indicated/VBD that/IN the/DT TF/NN site/NN conferred/VBD LPS/NN inducibility/NN on/IN a/DT heterologous/JJ promoter/NN and/CC was/VBD transactivated/VBN by/IN c-Rel/NN or/CC p65/NN ./. 
Taken/VBN together/RB ,/, our/PRP$ results/NNS demonstrated/VBD that/IN binding/NN of/IN c-Rel/p65/NN heterodimers/NNS to/TO a/DT novel/JJ kappa/NN B-like/JJ site/NN mediated/VBD LPS/NN induction/NN of/IN TF/NN gene/NN expression/NN in/IN monocytic/JJ cells/NNS ./. 
UI/LS -/: 94246160/CD 
TI/LS -/: Inhibition/NN of/IN T/NN cell/NN activation/NN by/IN the/DT extracellular/JJ matrix/NN protein/NN tenascin/NN ./. 
AB/LS -/: Tenascin/NN (/( TN/NN )/) is/VBZ an/DT extracellular/JJ matrix/NN protein/NN that/WDT is/VBZ expressed/VBN widely/RB in/IN the/DT fetus/NN and/CC sparingly/RB in/IN the/DT adult/NN ,/, but/CC reappears/VBZ at/IN high/JJ levels/NNS in/IN certain/JJ areas/NNS of/IN tissue/NN insult/NN such/JJ as/IN tumor/NN matrices/NNS and/CC sites/NNS of/IN wound/NN healing/NN ./. 
We/PRP show/VBP here/RB that/IN soluble/JJ TN/NN inhibits/VBZ proliferation/NN of/IN human/JJ T/NN cells/NNS in/IN response/NN to/TO alpha/NN CD3/NN Ab/NN co-/NN immobilized/VBN with/IN the/DT extracellular/JJ matrix/NN protein/NN fibronectin/NN (/( FN/NN )/) ./. 
TN/NN also/RB inhibits/VBZ proliferation/NN driven/VBN by/IN alpha/NN CD3/IL-2/NN or/CC by/IN phorbol/NN ester/IL-2/NN ,/, and/CC it/PRP prevents/VBZ high/JJ level/NN induction/NN of/IN IL-2R/NN ./. 
The/DT presence/NN of/IN TN/NN in/IN culture/NN medium/NN does/VBZ not/RB detectably/RB alter/VB the/DT pattern/NN of/IN tyrosine/NN phosphorylation/NN resulting/VBG from/IN T/NN cell/NN triggering/VBG with/IN alpha/NN CD3/NN ,/, but/CC at/IN later/JJR time/NN points/NNS prevents/VBZ the/DT appearance/NN of/IN functional/JJ NF-AT1/NN transcription/NN factor/NN complexes/NNS in/IN T/NN cell/NN nuclear/JJ extracts/NNS ./. 
These/DT findings/NNS are/VBP consistent/JJ with/IN the/DT postulated/VBN role/NN for/IN TN/NN as/IN a/DT natural/JJ antagonist/NN to/TO FN/NN action/NN ,/, and/CC suggest/VBP that/IN T/NN cell/NN responses/NNS occurring/VBG at/IN tissue/NN sites/NNS in/IN which/WDT TN/NN is/VBZ expressed/VBN could/MD be/VB influenced/VBN by/IN its/PRP$ presence/NN ./. 
UI/LS -/: 94202312/CD 
TI/LS -/: Human/JJ immunodeficiency/NN virus/NN type/NN 1/CD Nef/NN protein/NN down-regulates/VBZ transcription/NN factors/NNS NF-kappa/NN B/NN and/CC AP-1/NN in/IN human/JJ T/NN cells/NNS in/FW vitro/FW after/IN T-cell/NN receptor/NN stimulation/NN ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) negative/JJ factor/NN (/( Nef/NN )/) has/VBZ been/VBN shown/VBN to/TO down-regulate/VB the/DT transcription/NN factors/NNS NF-kappa/NN B/NN and/CC AP-1/NN in/FW vitro/FW ./. 
To/TO define/VB the/DT mechanism/NN of/IN action/NN of/IN the/DT Nef/NN protein/NN ,/, the/DT signal/NN transduction/NN pathways/NNS which/WDT may/MD be/VB affected/VBN in/IN T/NN cells/NNS by/IN constitutive/JJ expression/NN of/IN the/DT nef/NN gene/NN were/VBD examined/VBN ./. 
Stimulation/NN of/IN T/NN cells/NNS with/IN tumor/NN necrosis/NN factor/NN ,/, interleukin-1/NN ,/, or/CC lipopolysaccharide/NN resulted/VBD in/IN the/DT recruitment/NN of/IN transcriptional/JJ factors/NNS to/TO a/DT similar/JJ level/NN whether/IN or/CC not/RB the/DT cells/NNS expressed/VBD the/DT nef/NN gene/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, stimulation/NN of/IN T/NN cells/NNS by/IN mitogens/NNS or/CC antibodies/NNS to/TO the/DT T-cell/NN receptor/NN (/( TCR/NN )/) -CD3/NN complex/NN resulted/VBD in/IN the/DT down-regulation/NN of/IN transcriptional/JJ factors/NNS NF-kappa/NN B/NN and/CC AP-1/NN in/IN cells/NNS expressing/VBG the/DT nef/NN gene/NN compared/VBN with/IN cells/NNS not/RB expressing/VBG the/DT nef/NN gene/NN ./. 
Because/IN the/DT Nef/NN protein/NN does/VBZ not/RB affect/VB the/DT surface/NN expression/NN of/IN the/DT CD3-TCR/NN complex/NN ,/, we/PRP conclude/VBP that/IN the/DT Nef/NN protein/NN down-regulates/VBZ the/DT transcriptional/JJ factors/NNS NF-kappa/NN B/NN and/CC AP-1/NN in/IN T/NN cells/NNS in/FW vitro/FW through/IN an/DT effect/NN on/IN the/DT TCR-dependent/JJ signal/NN transduction/NN pathway/NN ./. 
UI/LS -/: 94235006/CD 
TI/LS -/: Effects/NNS of/IN alpha-lipoic/JJ acid/NN and/CC dihydrolipoic/JJ acid/NN on/IN expression/NN of/IN proto-oncogene/NN c-fos/NN ./. 
AB/LS -/: The/DT transcription/NN factor/NN AP-1/NN is/VBZ an/DT important/JJ human/JJ mediator/NN of/IN the/DT cellular/JJ response/NN to/TO serum/NN ,/, growth/NN factors/NNS ,/, and/CC phorbol/NN esters/NNS such/JJ as/IN 12-O-tetradecanoyl-phorbol-13/NN acetate/NN (/( TPA/NN )/) ./. 
The/DT AP-1/NN complex/NN consists/VBZ of/IN distinct/JJ protein/NN heterodimers/NNS encoded/VBN by/IN the/DT proto-oncogene/NN c-fos/NN and/CC c-jun/NN mRNA/NN whose/WP$ gene/NN expression/NN can/MD be/VB induced/VBN by/IN TPA/NN ,/, cyclic/JJ AMP/NN and/CC growth/NN factors/NNS ./. 
Recent/JJ findings/NNS suggest/VBP an/DT involvement/NN of/IN reactive/JJ oxygen/NN species/NNS in/IN the/DT pathway/NN of/IN TPA/NN and/CC protein/NN kinase/NN C/NN leading/VBG to/TO expression/NN of/IN c-fos/NN and/CC c-jun/NN mRNA/NN ./. 
To/TO investigate/VB the/DT role/NN of/IN reactive/JJ oxygen/NN species/NNS we/PRP studied/VBD the/DT effects/NNS of/IN alpha-lipoic/JJ acid/NN and/CC dihydrolipoic/JJ acid/NN (/( natural/JJ thiol/NN antioxidants/NNS )/) on/IN the/DT expression/NN of/IN c-fos/NN mRNA/NN in/IN human/JJ Jurkat/NN T/NN cells/NNS ./. 
When/WRB cells/NNS were/VBD preincubated/VBN with/IN dihydrolipoic/JJ acid/NN (/( 0.2/CD mM/NN )/) the/DT expression/NN of/IN c-fos/NN mRNA/NN was/VBD suppressed/VBN at/IN 30/CD min/NN after/IN stimulation/NN of/IN TPA/NN (/( 0.5/CD microM/NN )/) whereas/IN in/IN the/DT case/NN of/IN preincubation/NN of/IN alpha-lipoic/JJ acid/NN (/( 0.2/CD microM/NN )/) ,/, the/DT expression/NN was/VBD enhanced/VBN at/IN 30/CD min/NN ./. 
These/DT studies/NNS support/VBP the/DT idea/NN that/IN superoxide/NN anion/NN radical/NN plays/VBZ a/DT role/NN in/IN the/DT expression/NN of/IN c-fos/NN mRNA/NN ./. 
UI/LS -/: 94347465/CD 
TI/LS -/: Appraisal/NN of/IN potential/JJ therapeutic/JJ index/NN of/IN antioxidants/NNS on/IN the/DT basis/NN of/IN their/PRP$ in/FW vitro/FW effects/NNS on/IN HIV/NN replication/NN in/IN monocytes/NNS and/CC interleukin/NN 2-induced/JJ lymphocyte/NN proliferation/NN ./. 
AB/LS -/: Antioxidant/JJ molecules/NNS have/VBP been/VBN suggested/VBN to/TO be/VB of/IN therapeutic/JJ value/NN in/IN the/DT treatment/NN of/IN HIV-infected/JJ patients/NNS ./. 
To/TO evaluate/VB this/DT possibility/NN ,/, we/PRP examined/VBD in/FW vitro/FW the/DT effects/NNS of/IN two/CD types/NNS of/IN antioxidant/JJ molecules/NNS in/IN terms/NNS of/IN inhibition/NN of/IN HIV/NN replication/NN in/IN monocytes/NNS ,/, one/CD of/IN the/DT main/JJ reservoirs/NNS of/IN HIV/NN ,/, and/CC also/RB in/IN terms/NNS of/IN modulation/NN of/IN the/DT immune/JJ competence/NN as/IN measured/VBN by/IN PBMC/NN proliferation/NN ./. 
We/PRP tested/VBD the/DT effects/NNS of/IN BHA/NN ,/, a/DT phenolic/JJ ,/, lipid-soluble/JJ ,/, chain-breaking/JJ antioxidant/NN ,/, and/CC NAC/NN ,/, a/DT known/JJ glutathione/NN precursor/NN with/IN some/DT direct/JJ free-radical/JJ scavenging/NN properties/NNS as/RB well/RB ,/, on/IN the/DT regulation/NN of/IN HIV-1/NN expression/NN in/IN latently/RB infected/JJ U1/NN cells/NNS and/CC in/IN productively/RB and/CC chronically/RB infected/JJ U937/NN cells/NNS ./. 
Both/DT antioxidants/NNS inhibited/VBD TNF-/NN or/CC PMA-induced/JJ NF-kappa/NN B/NN activity/NN in/IN U1/NN cells/NNS ,/, as/RB well/RB as/IN the/DT sustained/JJ NF-kappa/NN B/NN activity/NN permanently/RB induced/VBN by/IN the/DT virus/NN itself/PRP in/IN chronically/RB HIV-infected/JJ U937/NN cells/NNS ./. 
This/DT resulted/VBD in/IN only/RB a/DT partial/JJ inhibition/NN of/IN TNF-/NN or/CC PMA-induced/JJ HIV/NN replication/NN in/IN U1/NN cells/NNS ,/, and/CC no/DT detectable/JJ effect/NN on/IN HIV/NN replication/NN in/IN chronically/RB infected/JJ U937/NN cells/NNS ./. 
This/DT may/MD be/VB the/DT first/JJ limitation/NN to/TO potential/JJ antiviral/JJ effects/NNS of/IN antioxidant/JJ therapies/NNS ./. 
Another/DT limitation/NN is/VBZ that/IN antioxidant/JJ concentrations/NNS high/JJ enough/RB to/TO block/VB NK-kappa/NN B/NN activation/NN were/VBD shown/VBN to/TO have/VB a/DT suppressive/JJ effect/NN on/IN immune/JJ functions/NNS in/FW vitro/FW ,/, because/IN NAC/NN and/CC BHA/NN blocked/VBD IL-2-induced/JJ PBMC/NN proliferation/NN ./. 
These/DT data/NNS warrant/VBP prudence/NN in/IN the/DT design/NN of/IN antioxidant-based/JJ therapies/NNS aimed/VBN at/IN suppressing/VBG HIV/NN replication/NN ./. 
UI/LS -/: 94169380/CD 
TI/LS -/: Isolation/NN and/CC characterization/NN of/IN gelatinase/NN granules/NNS from/IN human/JJ neutrophils/NNS ./. 
AB/LS -/: We/PRP recently/RB confirmed/VBD the/DT existence/NN of/IN gelatinase/NN granules/NNS as/IN a/DT subpopulation/NN of/IN peroxidase-negative/JJ granules/NNS by/IN double-labeling/JJ immunogold/JJ electron/NN microscopy/NN on/IN intact/JJ cells/NNS and/CC by/IN subcellular/JJ fractionation/NN ./. 
Further/JJ characterization/NN of/IN gelatinase/NN granules/NNS has/VBZ been/VBN hampered/VBN by/IN poor/JJ separation/NN of/IN specific/JJ and/CC gelatinase/NN granules/NNS on/IN both/CC two-layer/JJ Percoll/NN gradients/NNS and/CC sucrose/NN gradients/NNS ./. 
We/PRP have/VBP developed/VBN a/DT three-layer/JJ Percoll/NN density/NN gradient/NN that/WDT allows/VBZ separation/NN of/IN the/DT different/JJ granules/NNS and/CC vesicles/NNS from/IN human/JJ neutrophils/NNS ;/: in/IN particular/JJ ,/, it/PRP allows/VBZ separation/NN of/IN specific/JJ and/CC gelatinase/NN granules/NNS ./. 
This/DT allows/VBZ us/PRP to/TO characterize/VB these/DT two/CD granule/NN populations/NNS with/IN regard/NN to/TO their/PRP$ content/NN of/IN membrane/NN proteins/NNS ,/, which/WDT become/VBP incorporated/VBN into/IN the/DT plasma/NN membrane/NN during/IN exocytosis/NN ./. 
We/PRP found/VBD that/IN gelatinase/NN granules/NNS ,/, defined/VBN as/IN peroxidase-negative/JJ granules/NNS containing/VBG gelatinase/NN but/CC lacking/VBG lactoferrin/NN ,/, contain/VBP 50/CD %/NN of/IN total/JJ cell/NN gelatinase/NN ,/, with/IN the/DT remaining/VBG residing/NN in/IN specific/JJ granules/NNS ./. 
Furthermore/RB ,/, we/PRP found/VBD that/IN 20/CD %/NN to/TO 25/CD %/NN of/IN both/DT the/DT adhesion/NN protein/NN Mac-1/NN and/CC the/DT NADPH-oxidase/NN component/NN cytochrome/NN b558/NN is/VBZ localized/JJ in/IN gelatinase/NN granules/NNS ./. 
Although/IN no/DT qualitative/JJ difference/NN was/VBD observed/VBN between/IN specific/JJ granules/NNS and/CC gelatinase/NN granules/NNS with/IN respect/NN to/TO cytochrome/NN b558/NN and/CC Mac-1/NN ,/, stimulation/NN of/IN the/DT neutrophil/NN with/IN FMLP/NN resulted/VBD in/IN a/DT selective/JJ mobilization/NN of/IN the/DT least/RBS dense/JJ peroxidase-negative/JJ granules/NNS ,/, ie/FW ,/, gelatinase/NN granules/NNS ,/, which/WDT ,/, in/IN concert/NN with/IN secretory/JJ vesicles/NNS ,/, furnish/VBP the/DT plasma/NN membrane/NN with/IN Mac-1/NN and/CC cytochrome/NN b558/NN ./. 
This/DT shows/VBZ that/IN gelatinase/NN granules/NNS are/VBP functionally/RB important/JJ relative/JJ to/TO specific/JJ granules/NNS in/IN mediating/VBG early/JJ inflammatory/JJ responses/NNS ./. 
UI/LS -/: 95014190/CD 
TI/LS -/: Regulation/NN of/IN interleukin-2/NN receptor/NN alpha/NN chain/NN expression/NN and/CC nuclear/JJ factor.kappa/NN B/NN activation/NN by/IN protein/NN kinase/NN C/NN in/IN T/NN lymphocytes/NNS ./. 
Autocrine/NN role/NN of/IN tumor/NN necrosis/NN factor/NN alpha/NN ./. 
AB/LS -/: The/DT regulation/NN of/IN interleukin-2/NN receptor/NN alpha/NN chain/NN (/( IL-2R/NN alpha/NN )/) expression/NN and/CC nuclear/JJ factor/NN (/( NF/NN )/) activation/NN by/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) in/IN resting/VBG T/NN cells/NNS ,/, has/VBZ been/VBN studied/VBN ./. 
Treatment/NN of/IN human/JJ resting/VBG T/NN cells/NNS with/IN phorbol/NN esters/NNS strongly/RB induced/VBD the/DT expression/NN of/IN IL-2R/NN alpha/NN and/CC the/DT activation/NN of/IN NF.kappa/NN B/NN ./. 
This/DT activation/NN was/VBD due/JJ to/TO the/DT translocation/NN of/IN p65/NN and/CC c-Rel/NN NF.kappa/NN B/NN proteins/NNS from/IN cytoplasmic/JJ stores/NNS to/TO the/DT nucleus/NN ,/, where/WRB they/PRP bound/VBD the/DT kappa/NN B/NN sequence/NN of/IN the/DT IL-2R/NN alpha/NN promoter/NN either/CC as/IN p50.p65/NN or/CC as/IN p50.c-Rel/NN heterodimers/NNS ./. 
Interestingly/RB ,/, all/DT of/IN those/DT events/NNS were/VBD largely/RB indirect/JJ and/CC mediated/VBN by/IN endogenously/RB secreted/VBN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF/NN alpha/NN )/) ,/, as/IN they/PRP were/VBD strongly/RB inhibited/VBN by/IN a/DT neutralizing/VBG anti-TNF/JJ alpha/NN monoclonal/JJ antibody/NN ./. 
Furthermore/RB ,/, cyclosporin/NN A/NN ,/, which/WDT blocked/VBD TNF/NN alpha/NN production/NN induced/VBN by/IN PKC/NN ,/, strongly/RB inhibited/VBD IL-2R/NN alpha/NN and/CC NF.kappa/NN B/NN activation/NN ./. 
The/DT addition/NN of/IN either/CC TNF/NN alpha/NN or/CC IL-2/NN partially/RB recovered/VBD cyclosporin/NN A-induced/JJ IL-2R/NN alpha/NN inhibition/NN ,/, but/CC only/RB TNF/NN alpha/NN completely/RB recovered/VBD NF.kappa/NN B/NN activation/NN ./. 
Those/DT results/NNS indicate/VBP that/IN ,/, in/IN resting/VBG T/NN cells/NNS ,/, PKC/NN activation/NN has/VBZ only/RB a/DT triggering/VBG role/NN ,/, whereas/IN the/DT endogenously/RB secreted/VBN TNF/NN alpha/NN plays/VBZ an/DT essential/JJ role/NN in/IN the/DT quantitative/JJ control/NN of/IN the/DT expression/NN of/IN IL-2R/NN alpha/NN chain/NN or/CC NF.kappa/NN B/NN activation/NN ./. 
UI/LS -/: 94340810/CD 
TI/LS -/: Superantigens/NNS activate/VBP HIV-1/NN gene/NN expression/NN in/IN monocytic/JJ cells/NNS ./. 
AB/LS -/: Binding/NN of/IN superantigens/NNS to/TO MHC/NN class/NN II/CD molecules/NNS results/VBZ in/IN transduction/NN of/IN biochemical/JJ signals/NNS leading/VBG to/TO cellular/JJ activation/NN and/CC gene/NN expression/NN ./. 
We/PRP demonstrate/VBP that/IN the/DT staphylococcal/JJ superantigens/NNS toxic/JJ shock/NN syndrome/NN toxin-1/NN (/( TSST-1/NN )/) and/CC staphylococcal/JJ enterotoxin/NN A/NN (/( SEA/NN )/) activate/VBP HIV-1-LTR-driven/JJ transcription/NN of/IN chloramphenicol/NN acetyl/NN transferase/NN in/IN the/DT human/JJ monocytic/JJ cell/NN line/NN THP-1/NN ./. 
Induction/NN of/IN HIV-1-LTR-driven/JJ transcription/NN in/IN THP-1/NN cells/NNS by/IN superantigens/NNS was/VBD associated/VBN with/IN the/DT induction/NN of/IN nuclear/JJ factor-kappa/NN B/NN DNA-binding/JJ activity/NN ./. 
Superantigens/NNS also/RB increased/VBD viral/JJ protein/NN secretion/NN from/IN the/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor-pretreated/JJ chronically/RB infected/JJ human/JJ monocytic/JJ cell/NN line/NN U1/NN ./. 
Induction/NN of/IN HIV-1/NN gene/NN expression/NN in/IN monocytic/JJ cells/NNS by/IN superantigens/NNS occurred/VBD via/IN tumor/NN necrosis/NN factor-alpha-dependent/JJ and/CC -independent/JJ mechanisms/NNS ./. 
Our/PRP$ results/NNS suggest/VBP that/IN superantigens/NNS and/CC other/JJ MHC/NN class/NN II/CD ligands/NNS may/MD activate/VB HIV-1/NN gene/NN expression/NN in/IN monocytes/macrophages/NNS ./. 
UI/LS -/: 94327512/CD 
TI/LS -/: Mitogen/NN activation/NN of/IN human/JJ peripheral/JJ T/NN lymphocytes/NNS induces/VBZ the/DT formation/NN of/IN new/JJ cyclic/JJ AMP/NN response/NN element-binding/JJ protein/NN nuclear/JJ complexes/NNS ./. 
AB/LS -/: A/DT large/JJ body/NN of/IN evidence/NN indicates/VBZ that/IN experimental/JJ agents/NNS which/WDT raise/VBP cellular/JJ cAMP/NN levels/NNS inhibit/VBP T/NN cell/NN growth/NN and/CC division/NN ./. 
By/IN contrast/NN ,/, many/JJ studies/NNS have/VBP reported/VBN that/IN mitogen/NN activation/NN of/IN T/NN cells/NNS increases/VBZ cAMP/NN levels/NNS ,/, implying/VBG a/DT positive/JJ physiological/JJ role/NN for/IN cAMP/NN in/IN the/DT activation/NN process/NN ./. 
In/IN the/DT present/JJ study/NN we/PRP demonstrate/VBP that/IN mitogen/NN activation/NN of/IN human/JJ peripheral/JJ T/NN lymphocytes/NNS induces/VBZ nuclear/JJ factors/NNS that/WDT form/VBP complexes/NNS with/IN cyclic/JJ AMP/NN response/NN element-binding/JJ protein/NN (/( CREB/NN )/) ./. 
Four/CD complexes/NNS are/VBP identified/VBN by/IN the/DT electrophoretic/JJ mobility/NN shift/NN assay/NN ,/, two/CD of/IN which/WDT are/VBP induced/VBN by/IN mitogen/NN activation/NN ./. 
All/DT four/CD complexes/NNS contain/VBP CREB/NN and/CC are/VBP bound/VBN to/TO the/DT cAMP/NN response/NN element/NN (/( CRE/NN )/) core/NN sequence/NN (/( TGACGTCA/NN )/) ,/, as/IN indicated/VBN by/IN antibody/NN and/CC oligonucleotide/NN competition/NN experiments/NNS ./. 
Binding/NN of/IN the/DT four/CD complexes/NNS to/TO CRE/NN is/VBZ prevented/VBN by/IN dephosphorylation/NN of/IN nuclear/JJ extracts/NNS and/CC is/VBZ restored/VBN by/IN rephosphorylation/NN with/IN cAMP-dependent/JJ protein/NN kinase/NN or/CC endogenous/JJ kinases/NNS ./. 
Similar/JJ complexes/NNS are/VBP detected/VBN in/IN nuclear/JJ extracts/NNS of/IN Jurkat/NN cells/NNS ./. 
Mitogen/NN induction/NN of/IN the/DT electrophoretic/JJ mobility/NN shift/NN assay/NN complexes/NNS is/VBZ not/RB accounted/VBN for/IN by/IN protein/NN phosphorylation/NN or/CC by/IN induction/NN of/IN CREB/NN ./. 
Rather/RB ,/, the/DT data/NNS indicate/VBP that/IN mitogen/NN increases/VBZ the/DT levels/NNS of/IN a/DT nuclear/JJ factor/NN (/( s/NNS )/) that/WDT dimerizes/VBZ with/IN CREB/NN ./. 
Induction/NN of/IN new/JJ CREB/NN complexes/NNS implies/VBZ a/DT physiological/JJ role/NN for/IN cAMP/NN in/IN mitogen/NN activation/NN of/IN T/NN lymphocytes/NNS ./. 
UI/LS -/: 94314962/CD 
TI/LS -/: Alpha-tocopherol/NN inhibits/VBZ agonist-induced/JJ monocytic/JJ cell/NN adhesion/NN to/TO cultured/VBN human/JJ endothelial/JJ cells/NNS ./. 
AB/LS -/: Antioxidants/NNS have/VBP been/VBN proposed/VBN to/TO be/VB anti-atherosclerotic/JJ agents/NNS ;/: however/RB ,/, the/DT mechanisms/NNS underlying/VBG their/PRP$ beneficial/JJ effects/NNS are/VBP poorly/RB understood/VBN ./. 
We/PRP have/VBP examined/VBN the/DT effect/NN of/IN alpha-tocopherol/NN (/( alpha-tcp/NN )/) on/IN one/CD cellular/JJ event/NN in/IN atherosclerotic/JJ plaque/NN development/NN ,/, monocyte/NN adhesion/NN to/TO stimulated/VBN endothelial/JJ cells/NNS (/( ECs/NNS )/) ./. 
Human/JJ umbilical/JJ vein/NN ECs/NNS were/VBD pretreated/VBN with/IN alpha-tcp/NN before/IN stimulation/NN with/IN known/JJ agonists/NNS of/IN monocyte/NN adhesion/NN :/: IL-1/NN (/( 10/CD ng/ml/NN )/) ,/, LPS/NN (/( 10/CD ng/ml/NN )/) ,/, thrombin/IN (/( 30/CD U/ml/NN )/) ,/, or/CC PMA/NN (/( 10/CD nM/NN )/) ./. 
Agonist-induced/JJ monocytic/JJ cell/NN adhesion/NN ,/, but/CC not/RB basal/JJ adhesion/NN ,/, was/VBD inhibited/VBN in/IN a/DT time-/NN and/CC concentration-dependent/JJ manner/NN by/IN alpha-tcp/NN ./. 
The/DT IC50/NN of/IN alpha-tcp/NN on/IN an/DT IL-1-induced/JJ response/NN was/VBD 45/CD microM/NN ./. 
The/DT inhibition/NN correlated/VBD with/IN a/DT decrease/NN in/IN steady/JJ state/NN levels/NNS of/IN E-selectin/NN mRNA/NN and/CC cell/NN surface/NN expression/NN of/IN E-selectin/NN which/WDT is/VBZ consistent/JJ with/IN the/DT ability/NN of/IN a/DT monoclonal/JJ antibody/NN to/TO E-selectin/NN to/TO inhibit/VB monocytic/JJ cell/NN adhesion/NN in/IN this/DT system/NN ./. 
Probucol/NN (/( 50/CD microM/NNS )/) and/CC N-acetylcysteine/NN (/( 20/CD mM/NN )/) also/RB inhibited/VBD agonist-induced/JJ monocytic/JJ cell/NN adhesion/NN ;/: whereas/IN ,/, several/JJ other/JJ antioxidants/NNS had/VBD no/DT significant/JJ effect/NN ./. 
Protein/NN kinase/NN C/NN (/( PKC/NN )/) does/VBZ not/RB appear/VB to/TO play/VB a/DT role/NN in/IN the/DT alpha-tcp/NN effect/NN since/IN no/DT suppression/NN of/IN phosphorylation/NN of/IN PKC/NN substrates/NNS was/VBD observed/VBN ./. 
Activation/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN is/VBZ reported/VBN to/TO be/VB necessary/JJ but/CC not/RB sufficient/JJ for/IN E-selectin/NN expression/NN in/IN EC/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS failed/VBD to/TO show/VB an/DT alpha-tcp-induced/JJ decrease/NN in/IN activation/NN of/IN this/DT transcription/NN factor/NN after/IN cytokine/NN stimulation/NN ./. 
It/PRP has/VBZ been/VBN hypothesized/VBN that/IN alpha-tcp/NN acts/VBZ as/IN an/DT anti-atherosclerotic/JJ molecule/NN by/IN inhibiting/VBG generation/NN of/IN oxidized/VBN LDL/NN --/: a/DT putative/JJ triggering/VBG molecule/NN in/IN the/DT atherosclerotic/JJ process/NN ./. 
Our/PRP$ results/NNS point/VBP to/TO a/DT novel/JJ alternative/NN mechanism/NN of/IN action/NN of/IN alpha-tcp/NN ./. 
UI/LS -/: 94246743/CD 
TI/LS -/: Central/JJ nervous/JJ system-derived/JJ cells/NNS express/VBP a/DT kappa/NN B-binding/JJ activity/NN that/WDT enhances/VBZ human/JJ immunodeficiency/NN virus/NN type/NN 1/CD transcription/NN in/FW vitro/FW and/CC facilitates/VBZ TAR-independent/JJ transactivation/NN by/IN Tat/NN ./. 
AB/LS -/: The/DT Tat/NN protein/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) is/VBZ a/DT potent/JJ activator/NN of/IN long/JJ terminal/JJ repeat-directed/JJ transcription/NN ./. 
While/IN in/IN most/JJS cell/NN types/NNS ,/, activation/NN requires/VBZ interaction/NN of/IN Tat/NN with/IN the/DT unusual/JJ transcription/NN element/NN TAR/NN ,/, astrocytic/JJ glial/JJ cells/NNS support/VBP TAR-independent/JJ transactivation/NN of/IN HIV-1/NN transcription/NN by/IN Tat/NN ./. 
This/DT alternative/JJ pathway/NN of/IN Tat/NN activation/NN is/VBZ mediated/VBN by/IN the/DT viral/JJ enhancer/NN ,/, a/DT kappa/NN B/NN domain/NN capable/JJ of/IN binding/VBG the/DT prototypical/JJ form/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) present/JJ in/IN many/JJ cell/NN types/NNS ,/, including/VBG T/NN lymphocytes/NNS ./. 
Tat/NN transactivation/NN mediated/VBN by/IN the/DT kappa/NN B/NN domain/NN is/VBZ sufficient/JJ to/TO allow/VB replication/NN of/IN TAR-deleted/JJ mutant/JJ HIV-1/NN in/IN astrocytes/NNS ./. 
The/DT present/JJ study/NN demonstrates/VBZ the/DT existence/NN of/IN kappa/NN B-specific/JJ binding/NN factors/NNS present/JJ in/IN human/JJ glial/JJ astrocytes/NNS that/WDT differ/VBP from/IN prototypical/JJ NF-kappa/NN B/NN ./. 
The/DT novel/JJ astrocyte-derived/JJ kappa/NN B-binding/NN activity/NN is/VBZ retained/VBN on/IN an/DT HIV-1/NN Tat/NN affinity/NN column/NN ,/, while/IN prototypical/JJ NF-kappa/NN B/NN from/IN Jurkat/NN T/NN cells/NNS is/VBZ not/RB ./. 
In/FW vitro/FW transcription/NN studies/NNS demonstrate/VBP that/IN astrocyte-derived/JJ kappa/NN B-binding/JJ factors/NNS activate/VBP transcription/NN of/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN and/CC that/IN this/DT activation/NN is/VBZ dependent/JJ on/IN the/DT kappa/NN B/NN domain/NN ./. 
Moreover/RB ,/, TAR-independent/JJ transactivation/NN of/IN HIV-1/NN transcription/NN is/VBZ reproduced/VBN in/FW vitro/FW in/IN an/DT astrocyte/NN factor-dependent/JJ manner/NN which/WDT correlates/VBZ with/IN kappa/NN B-binding/JJ activity/NN ./. 
The/DT importance/NN of/IN the/DT central/JJ nervous/JJ system-enriched/JJ kappa/NN B/NN transcription/NN factor/NN in/IN the/DT regulation/NN of/IN HIV-1/NN expression/NN is/VBZ discussed/VBN ./. 
UI/LS -/: 94259178/CD 
TI/LS -/: Human/JJ interleukin-13/NN activates/VBZ the/DT interleukin-4-dependent/JJ transcription/NN factor/NN NF-IL4/NN sharing/VBG a/DT DNA/NN binding/NN motif/NN with/IN an/DT interferon-gamma-induced/JJ nuclear/JJ binding/VBG factor/NN ./. 
AB/LS -/: The/DT effects/NNS of/IN interleukin-13/NN (/( IL-13/NN )/) and/CC interleukin-4/NN (/( IL-4/NN )/) on/IN cellular/JJ functions/NNS were/VBD shown/VBN to/TO be/VB quite/RB similar/JJ ./. 
We/PRP provide/VBP evidence/NN that/IN in/IN monocytes/NNS as/RB well/RB as/IN in/IN T/NN lymphocytes/NNS both/CC IL-4/NN and/CC IL-13/NN activate/VBP the/DT same/JJ recently/RB identified/VBN transcription/NN factor/NN NF-IL4/NN which/WDT binds/VBZ to/TO the/DT specific/JJ responsive/JJ element/NN IL-4RE/NN ./. 
In/IN addition/NN ,/, we/PRP show/VBP that/IN a/DT nuclear/JJ factor/NN activated/VBN by/IN interferon-gamma/NN also/RB interacts/VBZ with/IN the/DT IL-4RE/NN ./. 
It/PRP differs/VBZ from/IN NF-IL4/NN in/IN the/DT electrophoretic/JJ mobility/NN of/IN the/DT complex/NN with/IN DNA/NN ,/, in/IN its/PRP$ DNA-binding/JJ specificity/NN and/CC in/IN the/DT proteins/NNS interacting/VBG with/IN the/DT DNA/NN sequence/NN ./. 
Sensitivity/NN against/IN various/JJ enzyme/NN inhibitors/NNS suggests/VBZ that/IN components/NNS of/IN the/DT signal/NN transduction/NN pathway/NN are/VBP shared/VBN by/IN all/DT three/CD cytokines/NNS ./. 
UI/LS -/: 94202306/CD 
TI/LS -/: Encephalomyocarditis/NN virus/NN internal/JJ ribosomal/JJ entry/NN site/NN RNA-protein/JJ interactions/NNS ./. 
AB/LS -/: Translational/JJ initiation/NN of/IN encephalomyocarditis/NN virus/NN (/( EMCV/NN )/) mRNA/NN occurs/VBZ by/IN ribosomal/JJ entry/NN into/IN the/DT 5'/NN nontranslated/JJ region/NN of/IN the/DT EMCV/NN mRNA/NN ,/, rather/RB than/IN by/IN ribosomal/JJ scanning/NN ./. 
Internal/JJ ribosomal/JJ binding/NN requires/VBZ a/DT cis-acting/JJ element/NN termed/VBN the/DT internal/JJ ribosomal/JJ entry/NN site/NN (/( IRES/NN )/) ./. 
IRES/NNS elements/NNS have/VBP been/VBN proposed/VBN to/TO be/VB involved/VBN in/IN the/DT translation/NN of/IN picornavirus/NN mRNAs/NNS and/CC some/DT cellular/JJ mRNAs/NNS ./. 
Internal/JJ ribosome/NN binding/NN likely/RB requires/VBZ the/DT interaction/NN of/IN trans-acting/JJ factors/NNS that/WDT recognize/VBP both/CC the/DT mRNA/NN and/CC the/DT ribosomal/JJ complex/NN ./. 
Five/CD cellular/JJ proteins/NNS (/( p52/NN ,/, p57/NN ,/, p70/NN ,/, p72/NN ,/, and/CC p100/NN )/) cross-link/VBP the/DT EMCV/NN IRES/NN or/CC fragments/NNS of/IN the/DT IRES/NN ./. 
For/IN one/CD of/IN these/DT proteins/NNS ,/, p57/NN ,/, binding/VBG to/TO the/DT IRES/NN correlates/VBZ with/IN translation/NN ./. 
Recently/RB ,/, p57/NN was/VBD identified/VBN to/TO be/VB very/RB similar/JJ ,/, if/IN not/RB identical/JJ ,/, to/TO polypyrimidine/NN tract-binding/JJ protein/NN ./. 
On/IN the/DT basis/NN of/IN cross-linking/JJ results/NNS with/IN 21/CD different/JJ EMCV/NN IRES/NN fragments/NNS and/CC cytoplasmic/JJ HeLa/NN extract/NN or/CC rabbit/NN reticulocyte/NN lysate/NN as/IN the/DT source/NN of/IN polypeptides/NNS ,/, consensus/NN binding/NN sites/NNS for/IN p52/NN ,/, p57/NN ,/, p70/NN ,/, and/CC p100/NN are/VBP proposed/VBN ./. 
It/PRP is/VBZ suggested/VBN that/IN each/DT of/IN these/DT proteins/NNS recognizes/VBZ primarily/RB a/DT structural/JJ feature/NN of/IN the/DT RNA/NN rather/RB than/IN a/DT specific/JJ sequence/NN ./. 
UI/LS -/: 94216261/CD 
TI/LS -/: A/DT novel/JJ heterodimerization/NN partner/NN for/IN thyroid/NN hormone/NN receptor/NN ./. 
Peroxisome/NN proliferator-activated/JJ receptor/NN ./. 
AB/LS -/: Retinoid-like/JJ receptors/NNS play/VBP a/DT central/JJ role/NN in/IN hormonal/JJ responses/NNS by/IN forming/VBG heterodimers/NNS with/IN other/JJ nuclear/JJ hormone/NN receptors/NNS ./. 
In/IN this/DT study/NN we/PRP have/VBP identified/VBN the/DT peroxisome/NN proliferator-activated/JJ receptor/NN (/( PPAR/NN )/) as/IN a/DT new/JJ thyroid/NN hormone/NN receptor/NN (/( THR/NN )/) auxiliary/JJ nuclear/JJ protein/NN ,/, heterodimerizing/VBG with/IN THR/NN in/IN solution/NN ./. 
Although/IN these/DT heterodimers/NNS do/VBP not/RB recognize/VB a/DT classical/JJ thyroid/NN hormone/NN response/NN element/NN (/( TRE/NN )/) characterized/VBN by/IN direct/JJ repeat/NN separated/VBN by/IN four/CD nucleotides/NNS (/( DR+4/NN )/) ,/, PPAR/NN behaves/VBZ as/IN a/DT dominant/JJ negative/JJ regulator/NN of/IN thyroid/NN hormone/NN (/( TH/NN )/) action/NN ./. 
However/RB ,/, a/DT TH-dependent/JJ positive/JJ effect/NN is/VBZ elicited/VBN by/IN selective/JJ interaction/NN of/IN the/DT THR/NN beta-PPAR/NN but/CC not/RB the/DT THR/NN alpha-PPAR/NN heterodimer/NN with/IN a/DT novel/JJ TRE/NN (/( DR+2/NN )/) ./. 
The/DT critical/JJ region/NN of/IN THR/NN beta/NN was/VBD mapped/VBN to/TO 3/CD amino/NN acids/NNS in/IN the/DT distal/JJ box/NN of/IN the/DT DNA/NN binding/NN domain/NN ./. 
Hence/RB ,/, PPAR/NN can/MD positively/RB or/CC negatively/RB influence/VB TH/NN action/NN depending/VBG on/IN TRE/NN structure/NN and/CC THR/NN isotype/NN ./. 
UI/LS -/: 94200898/CD 
TI/LS -/: Comparison/NN of/IN retinoic/JJ acid/NN and/CC phorbol/NN myristate/NN acetate/NN as/IN inducers/NNS of/IN monocytic/JJ differentiation/NN ./. 
AB/LS -/: Several/JJ human/JJ myeloid/JJ leukemia/NN cell/NN lines/NNS growing/VBG in/FW vitro/FW can/MD be/VB induced/VBN to/TO differentiate/VB to/TO more/RBR mature/JJ monocyte/macrophage-like/JJ cells/NNS by/IN treatment/NN with/IN protein/NN kinase/NN C-activating/JJ phorbol/NN esters/NNS ,/, such/JJ as/IN PMA/NN ./. 
In/IN addition/NN to/TO PMA/NN ,/, cells/NNS of/IN the/DT THP-1/NN myeloid/JJ leukemia/NN cell/NN line/NN acquire/VBP macrophage-like/JJ characteristics/NNS after/IN treatment/NN with/IN all-trans/JJ retinoic/JJ acid/NN (/( RA/NN )/) ./. 
To/TO analyze/VB the/DT signal/NN transduction/NN mechanisms/NNS induced/VBN by/IN RA/NN ,/, we/PRP first/RB compared/VBD the/DT effects/NNS of/IN PMA/NN and/CC RA/NN on/IN the/DT expression/NN of/IN genes/NNS which/WDT are/VBP known/VBN to/TO be/VB regulated/VBN during/IN monocytic/JJ differentiation/NN ./. 
Both/CC RA/NN and/CC PMA/NN effectively/RB down-regulated/VBD c-myc/NN expression/NN ,/, while/IN c-myb/NN expression/NN decreased/VBD only/RB after/IN PMA/NN treatment/NN ./. 
Expression/NN of/IN the/DT beta/NN 2-integrin/JJ genes/NNS ,/, CD11a/NN and/CC CD11b/NN ,/, was/VBD clearly/RB increased/VBN after/IN both/DT of/IN these/DT treatments/NNS ./. 
Their/PRP$ effects/NNS on/IN the/DT src-family/NN tyrosine/NN kinase/NN genes/NNS were/VBD different/JJ :/: hck/NN expression/NN was/VBD similarly/RB induced/VBN by/IN these/DT agents/NNS but/CC lyn/NN expression/NN was/VBD stronger/JJR and/CC more/RBR rapid/JJ after/IN RA/NN treatment/NN ./. 
RA/NN also/RB enhanced/VBD lyn/NN mRNA/NN production/NN rapidly/RB in/IN HL-60/NN ,/, indicating/VBG that/IN the/DT activation/NN of/IN lyn/NN gene/NN expression/NN is/VBZ common/JJ in/IN monocytic/JJ and/CC granulocytic/JJ maturation/NN of/IN myeloid/JJ leukemia/NN cells/NNS ./. 
To/TO examine/VB whether/IN the/DT AP-1/NN enhancer/NN activity/NN is/VBZ involved/VBN in/IN RA-induced/JJ monocytic/JJ differentiation/NN ,/, THP-1/NN cells/NNS were/VBD transiently/RB transfected/VBN with/IN a/DT chloramphenicol/NN acetyl/NN transferase/NN (/( CAT/NN )/) -reporter/NN gene/NN containing/VBG 5/CD copies/NNS of/IN the/DT AP-1/NN binding/NN sites/NNS ./. 
In/IN contrast/NN to/TO PMA/NN ,/, RA/NN did/VBD not/RB induce/VB any/DT CAT/NN activity/NN in/IN these/DT cells/NNS ,/, thus/RB suggesting/VBG that/IN the/DT RA-induced/JJ changes/NNS in/IN the/DT expression/NN of/IN those/DT genes/NNS described/VBN above/IN were/VBD not/RB dependent/JJ on/IN the/DT AP-1/NN enhancer/NN activity/NN ./. 
UI/LS -/: 95011572/CD 
TI/LS -/: An/DT active/JJ v-abl/JJ protein/NN tyrosine/NN kinase/NN blocks/VBZ immunoglobulin/NN light-chain/JJ gene/NN rearrangement/NN ./. 
AB/LS -/: Lymphoid/JJ cells/NNS transformed/VBN by/IN Abelson/NN murine/NN leukemia/NN virus/NN have/VBP provided/VBN one/CD of/IN the/DT classic/JJ models/NNS for/IN study/NN of/IN early/JJ B-cell/NN development/NN and/CC immunoglobulin/NN rearrangement/NN ./. 
Most/JJS of/IN these/DT cells/NNS have/VBP rearranged/VBN their/PRP$ heavy-chain/JJ locus/NN but/CC not/RB their/PRP$ light/JJ chain/NN genes/NNS ,/, suggesting/VBG that/IN an/DT active/JJ v-abl/JJ protein/NN interferes/VBZ with/IN this/DT differentiation/NN step/NN ./. 
To/TO test/VB this/DT hypothesis/NN ,/, light-chain/JJ gene/NN structure/NN was/VBD examined/VBN in/IN pre-B/JJ cells/NNS transformed/VBN by/IN temperature-sensitive/JJ mutants/NNS of/IN the/DT Abelson/NN virus/NN and/CC in/IN derivatives/NNS that/WDT survive/VBP at/IN the/DT nonpermissive/JJ temperature/NN because/IN they/PRP express/VBP a/DT human/JJ BCL-2/NN gene/NN ./. 
Our/PRP$ studies/NNS reveal/VBP that/IN inactivation/NN of/IN the/DT v-abl/JJ protein/NN tyrosine/NN kinase/NN triggers/NNS high-frequency/VBP rearrangement/NN of/IN kappa/NN and/CC lambda/NN light-chain/JJ genes/NNS ./. 
These/DT events/NNS are/VBP accompanied/VBN by/IN marked/JJ increases/NNS in/IN the/DT expression/NN of/IN RAG-1/NN and/CC RAG-2/NN RNAs/NNS ./. 
These/DT increases/NNS occur/VBP in/IN the/DT absence/NN of/IN protein/NN synthesis/NN but/CC are/VBP dependent/JJ on/IN inactivation/NN of/IN the/DT v-abl/JJ protein/NN tyrosine/NN kinase/NN ./. 
As/IN documented/VBN in/IN the/DT accompanying/VBG paper/NN (/( Klug/NN et/FW al./FW ,/, this/DT issue/NN )/) ,/, an/DT active/JJ v-abl/JJ protein/NN also/RB suppresses/VBZ the/DT activity/NN of/IN NF-kappa/NN B/rel/NN and/CC expression/NN controlled/VBN by/IN the/DT kappa/NN intron/NN enhancer/NN ./. 
Together/RB these/DT data/NNS demonstrate/VBP that/IN the/DT v-abl/JJ protein/NN specifically/RB interferes/VBZ with/IN light-chain/JJ gene/NN rearrangement/NN by/IN suppressing/VBG at/IN least/JJS two/CD pathways/NNS essential/JJ for/IN this/DT stage/NN of/IN B-cell/NN differentiation/NN and/CC suggest/VBP that/IN tyrosine/NN phosphorylation/NN is/VBZ important/JJ in/IN regulating/VBG RAG/NN gene/NN expression/NN ./. 
UI/LS -/: 94376879/CD 
TI/LS -/: Calcium/NN signalling/NN in/IN T/NN cells/NNS stimulated/VBN by/IN a/DT cyclophilin/NN B-binding/JJ protein/NN ./. 
AB/LS -/: The/DT immunosuppressant/JJ drug/NN cyclosporin/NN A/NN blocks/VBZ a/DT calcium-dependent/JJ signal/NN from/IN the/DT T-cell/NN receptor/NN (/( TCR/NN )/) that/WDT normally/RB leads/VBZ to/TO T-cell/NN activation/NN ./. 
When/WRB bound/VBN to/TO cyclophilin/NN ,/, cyclosporin/NN A/NN binds/VBZ and/CC inactivates/VBZ the/DT key/JJ signalling/NN intermediate/JJ calcineurin/NN ./. 
To/TO identify/VB potential/JJ cellular/JJ homologues/NNS of/IN cyclosporin/NN A/NN that/WDT might/MD regulate/VB calcium/NN signalling/NN ,/, we/PRP have/VBP cloned/VBN human/JJ genes/NNS encoding/VBG cyclophilin/NN B-binding-proteins/NNS using/VBG the/DT yeast/NN two-hybrid/JJ system/NN ./. 
One/CD gene/NN product/NN ,/, when/WRB overexpressed/VBN in/IN Jurkat/NN T/NN cells/NNS ,/, specifically/RB induced/VBD transcription/NN from/IN the/DT interleukin-2/NN enhancer/NN ,/, by/IN activating/VBG the/DT T-cell-specific/JJ transcription/NN factors/NNS NF-AT/NN and/CC NF-IL2A/NN ./. 
This/DT protein/NN ,/, termed/VBN calcium-signal/JJ modulating/NN cyclophilin/NN ligand/NN (/( CAML/NN )/) ,/, acts/VBZ downstream/RB of/IN the/DT TCR/NN and/CC upstream/RB of/IN calcineurin/NN by/IN causing/VBG an/DT influx/NN of/IN calcium/NN ./. 
CAML/NN appears/VBZ to/TO be/VB a/DT new/JJ participant/NN in/IN the/DT calcium-signal/JJ transduction/NN pathway/NN ,/, implicating/VBG cyclophilin/NN B/NN in/IN calcium/NN signalling/NN ,/, even/RB in/IN the/DT absence/NN of/IN cyclosporin/NN ./. 
UI/LS -/: 95162017/CD 
TI/LS -/: Expression/NN and/CC genomic/JJ configuration/NN of/IN GM-CSF/NN ,/, IL-3/NN ,/, M-CSF/NN receptor/NN (/( C-FMS/NN )/) ,/, early/JJ growth/NN response/NN gene-1/NN (/( EGR-1/NN )/) and/CC M-CSF/NN genes/NNS in/IN primary/JJ myelodysplastic/JJ syndromes/NNS ./. 
AB/LS -/: Peripheral/JJ blood/NN mononuclear/JJ cells/NNS from/IN seventeen/CD patients/NNS with/IN primary/JJ myelodysplastic/JJ syndromes/NNS (/( MDS/NN )/) in/IN advanced/JJ stage/NN were/VBD enriched/JJ for/IN blasts/NNS and/CC tested/VBN for/IN (/( 1/LS )/) karyotype/NN ,/, (/( 2/LS )/) genomic/JJ configuration/NN and/CC (/( 3/LS )/) expression/NN of/IN IL-3/NN ,/, GM-CSF/NN ,/, FMS/NN and/CC EGR-1/NN genes/NNS which/WDT are/VBP all/DT located/JJ on/IN the/DT long/JJ arm/NN of/IN chromosome/NN 5/CD ./. 
The/DT expression/NN of/IN the/DT M-CSF/NN gene/NN ,/, that/WDT has/VBZ been/VBN recently/RB reassigned/VBN to/TO the/DT short/JJ arm/NN of/IN chromosome/NN 1/CD (/( lp/NN )/) ,/, was/VBD also/RB investigated/VBN ./. 
Aims/NNS of/IN the/DT study/NN were/VBD to/TO (/( 1/LS )/) assess/VB the/DT potential/JJ role/NN of/IN the/DT expression/NN of/IN these/DT genes/NNS in/IN the/DT maintenance/NN and/CC expansion/NN of/IN the/DT neoplastic/JJ clones/NNS and/CC (/( 2/LS )/) search/VB for/IN constitutional/JJ losses/NNS or/CC rearrangements/NNS of/IN one/CD allele/NN followed/VBN by/IN a/DT deletion/NN of/IN the/DT second/JJ allele/NN of/IN the/DT same/JJ genes/NNS in/IN the/DT leukemic/JJ cells/NNS ./. 
The/DT latter/JJ issue/NN was/VBD investigated/VBN by/IN comparing/VBG ,/, in/IN 8/CD cases/NNS ,/, constitutive/JJ DNA/NN from/IN skin/NN fibroblasts/NNS with/IN leukemic/JJ DNA/NN ./. 
Eleven/CD of/IN the/DT 17/CD patients/NNS had/VBD abnormal/JJ karyotypes/NNS ./. 
The/DT M-CSF/NN gene/NN was/VBD expressed/VBN in/IN 6/CD cases/NNS and/CC the/DT FMS/NN and/CC the/DT EGR-1/NN genes/NNS were/VBD expressed/VBN in/IN 2/CD of/IN the/DT latter/JJ cases/NNS ./. 
An/DT autocrine/JJ mechanism/NN of/IN growth/NN could/MD be/VB hypothesized/VBN only/RB for/IN the/DT 2/CD patients/NNS whose/WP$ cells/NNS expressed/VBD both/CC the/DT M-CSF/NN and/CC FMS/NN genes/NNS ./. 
No/DT germline/NN changes/NNS or/CC rearrangements/NNS were/VBD observed/VBN in/IN any/DT of/IN the/DT genes/NNS studied/VBN ./. 
Thus/RB ,/, deregulation/NN of/IN genes/NNS encoding/VBG for/IN certain/JJ hemopoietic/JJ growth/NN factors/NNS or/CC receptors/NNS does/VBZ not/RB seem/VB to/TO represent/VB a/DT major/JJ mechanism/NN of/IN MDS/NN progression/NN ./. 
UI/LS -/: 94327547/CD 
TI/LS -/: A/DT novel/JJ human/JJ homeobox/NN gene/NN distantly/RB related/JJ to/TO proboscipedia/NN is/VBZ expressed/VBN in/IN lymphoid/JJ and/CC pancreatic/JJ tissues/NNS ./. 
AB/LS -/: A/DT novel/JJ human/JJ homeobox/NN gene/NN ,/, HB9/NN ,/, was/VBD isolated/VBN from/IN a/DT cDNA/NN library/NN prepared/VBN from/IN in/FW vitro/FW stimulated/VBN human/JJ tonsil/NN B/NN lymphocytes/NNS and/CC from/IN a/DT human/JJ genomic/JJ library/NN ./. 
The/DT HB9/NN gene/NN is/VBZ composed/VBN of/IN 3/CD exons/NNS spread/VBN over/IN 6/CD kilobases/NNS of/IN DNA/NN ./. 
An/DT open/JJ reading/NN frame/NN of/IN 1206/CD nucleotides/NNS is/VBZ in/IN frame/NN with/IN a/DT diverged/JJ homeodomain/NN ./. 
The/DT predicted/VBN HB9/NN protein/NN has/VBZ a/DT molecular/JJ mass/NN of/IN 41/CD kilodaltons/NNS and/CC is/VBZ enriched/JJ for/IN alanine/NN ,/, glycine/NN ,/, and/CC leucine/NN ./. 
The/DT HB9/NN homeodomain/NN is/VBZ most/RBS similar/JJ to/TO that/DT of/IN the/DT Drosophila/FW melanogaster/FW homeobox/NN gene/NN proboscipedia/NN ./. 
Northern/NN blot/NN analysis/NN of/IN poly(A)/NN RNA/NN purified/VBN from/IN the/DT human/JJ B/NN cell/NN line/NN RPMI/NN 8226/CD and/CC from/IN activated/VBN T/NN cells/NNS revealed/VBD a/DT major/JJ mRNA/NN transcript/NN of/IN 2.2/CD kilobases/NNS ./. 
Similar/JJ analysis/NN of/IN poly(A)/NN RNA/NN from/IN a/DT variety/NN of/IN adult/JJ tissues/NNS demonstrated/VBD HB9/NN transcripts/NNS in/IN pancreas/NN ,/, small/JJ intestine/NN ,/, and/CC colon/NN ./. 
Reverse/JJ transcriptase-polymerase/JJ chain/NN reaction/NN was/VBD used/VBN to/TO examine/VB HB9/NN RNA/NN transcripts/NNS in/IN hematopoietic/JJ cell/NN lines/NNS ./. 
HB9/NN RNA/NN transcripts/NNS were/VBD most/RBS prevalent/JJ in/IN several/JJ human/JJ B/NN cell/NN lines/NNS and/CC K562/NN cells/NNS ./. 
In/IN addition/NN ,/, transcripts/NNS were/VBD detected/VBN in/IN RNA/NN prepared/VBN from/IN tonsil/NN B/NN cells/NNS and/CC in/FW situ/FW hybridization/NN studies/NNS localized/VBD them/PRP in/IN the/DT germinal/JJ center/NN region/NN of/IN adult/JJ tonsil/NN ./. 
These/DT findings/NNS suggest/VBP the/DT involvement/NN of/IN HB9/NN in/IN regulating/VBG gene/NN transcription/NN in/IN lymphoid/JJ and/CC pancreatic/JJ tissues/NNS ./. 
UI/LS -/: 94267876/CD 
TI/LS -/: Human/JJ immunodeficiency/NN virus/NN type/NN 1/CD Tat/NN upregulates/VBZ interleukin-2/NN secretion/NN in/IN activated/VBN T/NN cells/NNS ./. 
AB/LS -/: Dysregulation/NN of/IN cytokines/NNS secreted/VBN by/IN T/NN cells/NNS may/MD play/VB an/DT important/JJ role/NN in/IN the/DT pathogenesis/NN of/IN AIDS/NN ./. 
To/TO investigate/VB the/DT effects/NNS of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) Tat/NN on/IN interleukin-2/NN (/( IL-2/NN )/) expression/NN ,/, we/PRP used/VBD IL-2/NN promoter-chloramphenicol/JJ acetyltransferase/NN constructs/NNS and/CC IL-2-secreting/JJ Jurkat/NN T/NN cells/NNS as/IN a/DT model/NN system/NN ./. 
Transient/JJ expression/NN of/IN HIV-1/NN Tat/NN induced/VBD a/DT five-/CD to/TO eightfold/JJ increase/NN in/IN IL-2/NN promoter/NN activity/NN in/IN Jurkat/NN T/NN cells/NNS stimulated/VBN with/IN phytohemagglutinin/NN and/CC phorbol/NN myristate/NN acetate/NN ./. 
IL-2/NN secretion/NN was/VBD increased/VBN more/JJR than/IN twofold/RB in/IN both/CC Jurkat/NN T/NN cells/NNS and/CC primary/JJ T/NN cells/NNS stimulated/VBN by/IN extracellular/JJ HIV-1/NN Tat/NN protein/NN ./. 
Analysis/NN of/IN mRNA/NN suggested/VBD that/IN Tat/NN exerts/VBZ its/PRP$ effect/NN on/IN IL-2/NN primarily/RB at/IN the/DT transcriptional/JJ level/NN ./. 
The/DT NF-kappa/NN B/NN site/NN at/IN positions/NNS -206/CD to/TO -195/CD of/IN the/DT IL-2/NN promoter/NN was/VBD required/VBN but/CC not/RB sufficient/JJ for/IN the/DT Tat/NN effect/NN ./. 
The/DT Tat-mediated/JJ increase/NN in/IN IL-2/NN promoter/NN activity/NN could/MD selectively/RB be/VB blocked/VBN by/IN antisense/JJ tat/NN or/CC -/: unlike/IN the/DT analogous/JJ effect/NN of/IN human/JJ T-cell/NN lymphotropic/JJ virus/NN type/NN 1/CD Tax/NN -/: by/IN cyclosporin/NN A/NN ./. 
The/DT observed/VBN increase/NN in/IN IL-2/NN levels/NNS might/MD facilitate/VB virus/NN spread/VBN from/IN or/CC to/TO T/NN cells/NNS ./. 
Furthermore/RB ,/, it/PRP might/MD contribute/VB to/TO the/DT hypergammaglobulinemia/NN or/CC ,/, together/RB with/IN other/JJ cytokines/NNS found/VBN to/TO be/VB dysregulated/VBN ,/, the/DT T-helper/NN cell/NN dysfunctions/NNS observed/VBN in/IN AIDS/NN patients/NNS ./. 
UI/LS -/: 94240241/CD 
TI/LS -/: Activation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN in/IN human/JJ lymphoblastoid/JJ cells/NNS by/IN low-dose/JJ ionizing/VBG radiation/NN ./. 
AB/LS -/: Nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) is/VBZ a/DT pleiotropic/JJ transcription/NN factor/NN which/WDT is/VBZ involved/VBN in/IN the/DT transcriptional/JJ regulation/NN of/IN several/JJ specific/JJ genes/NNS ./. 
Recent/JJ reports/NNS demonstrated/VBD that/IN ionizing/VBG radiation/NN in/IN the/DT dose/NN range/NN of/IN 2-50/CD Gy/NN results/VBZ in/IN expression/NN of/IN NF-kappa/NN B/NN in/IN human/JJ KG-1/NN myeloid/JJ leukemia/NN cells/NNS and/CC human/JJ B-lymphocyte/NN precursor/NN cells/NNS ;/: the/DT precise/JJ mechanism/NN involved/VBN and/CC the/DT significance/NN are/VBP not/RB yet/RB known/VBN ./. 
The/DT present/JJ report/NN demonstrates/VBZ that/IN even/RB lower/JJR doses/NNS of/IN ionizing/VBG radiation/NN ,/, 0.25-2.0/CD Gy/NN ,/, are/VBP capable/JJ of/IN inducing/VBG expression/NN of/IN NF-kappa/NN B/NN in/IN EBV-transformed/JJ 244B/NN human/JJ lymphoblastoid/JJ cells/NNS ./. 
These/DT results/NNS are/VBP in/IN a/DT dose/NN range/NN where/WRB the/DT viability/NN of/IN the/DT cells/NNS remains/VBZ very/RB high/JJ ./. 
After/IN exposure/NN to/TO 137Cs/NN gamma/NN rays/NNS at/IN a/DT dose/NN rate/NN of/IN 1.17/CD Gy/min/NN ,/, a/DT maximum/NN in/IN expression/NN of/IN NF-kappa/NN B/NN was/VBD seen/VBN at/IN 8/CD h/NN after/IN a/DT 0.5-Gy/JJ exposure/NN ./. 
Time-course/JJ studies/NNS revealed/VBD a/DT biphasic/JJ time-dependent/JJ expression/NN after/IN 0.5-/CD ,/, 1-/CD and/CC 2-Gy/JJ exposures/NNS ./. 
However/RB ,/, for/IN each/DT time/NN examined/VBN ,/, the/DT expression/NN of/IN NF-kappa/NN B/NN was/VBD maximum/NN after/IN the/DT 0.5-Gy/JJ exposure/NN ./. 
The/DT expression/NN of/IN the/DT p50/NN and/CC p65/NN NF-kappa/NN B/NN subunits/NNS was/VBD also/RB shown/VBN to/TO be/VB regulated/VBN differentially/RB after/IN exposures/NNS to/TO 1.0/CD and/CC 2.0/CD Gy/NN ./. 
UI/LS -/: 94240138/CD 
TI/LS -/: Alternative/JJ splicing/NN of/IN RNA/NN transcripts/NNS encoded/VBN by/IN the/DT murine/NN p105/NN NF-kappa/NN B/NN gene/NN generates/VBZ I/NN kappa/NN B/NN gamma/NN isoforms/NNS with/IN different/JJ inhibitory/JJ activities/NNS ./. 
AB/LS -/: The/DT gene/NN encoding/VBG the/DT 105-kDa/JJ protein/NN (/( p105/NN )/) precursor/NN of/IN the/DT p50/NN subunit/NN of/IN transcription/NN factor/NN NF-kappa/NN B/NN also/RB encodes/VBZ a/DT p70/NN I/NN kappa/NN B/NN protein/NN ,/, I/NN kappa/NN B/NN gamma/NN ,/, which/WDT is/VBZ identical/JJ to/TO the/DT C-terminal/JJ 607/CD amino/NN acids/NNS of/IN p105/NN ./. 
Here/RB we/PRP show/VBP that/IN alternative/JJ RNA/NN splicing/NN generates/VBZ I/NN kappa/NN B/NN gamma/NN isoforms/NNS with/IN properties/NNS different/JJ from/IN those/DT of/IN p70/NN ./. 
One/CD 63-kDa/JJ isoform/NN ,/, termed/VBN I/NN kappa/NN B/NN gamma-1/NN ,/, which/WDT lacks/VBZ 59/CD amino/NN acids/NNS C-terminal/JJ to/TO ankyrin/NN repeat/NN 7/CD ,/, has/VBZ a/DT novel/JJ 35-amino/NN acid/NN C/NN terminus/NN encoded/VBN by/IN an/DT alternative/JJ reading/NN frame/NN of/IN the/DT p105/NN gene/NN ./. 
A/DT 55-kDa/JJ isoform/NN ,/, I/NN kappa/NN B/NN gamma-2/NN ,/, lacks/VBZ the/DT 190/CD C-terminal/JJ amino/NN acids/NNS of/IN p70I/NN kappa/NN B/NN gamma/NN ./. 
In/IN contrast/NN to/TO p70Ikappa/NN B/NN gamma/NN ,/, which/WDT is/VBZ a/DT cytoplasmic/JJ protein/NN ,/, I/NN kappa/NN B/NN gamma-1/NN is/VBZ found/VBN in/IN both/CC the/DT cytoplasm/NN and/CC nucleus/NN ,/, whereas/IN I/NN kappa/NN B/NN gamma-2/NN is/VBZ predominantly/RB nuclear/JJ ./. 
The/DT I/NN kappa/NN B/NN gamma/NN isoforms/NNS also/RB display/VBP differences/NNS in/IN specificity/NN and/CC affinity/NN for/IN Rel/NF-kappa/NN B/NN proteins/NNS ./. 
While/IN p70I/NN kappa/NN B/NN gamma/NN inhibits/VBZ p50-/NN ,/, p65-/NN ,/, and/CC c-Rel-mediated/JJ transactivation/NN and/or/CC DNA/NN binding/NN ,/, both/CC I/NN kappa/NN B/NN gamma-1/NN and/CC I/NN kappa/NN B/NN gamma-2/NN are/VBP specific/JJ for/IN p50/NN and/CC have/VBP different/JJ affinities/NNS for/IN this/DT subunit/NN ./. 
The/DT absence/NN in/IN I/NN kappa/NN B/NN gamma-1/NN and/CC I/NN kappa/NN B/NN gamma-2/NN of/IN a/DT protein/NN kinase/NN A/NN site/NN whose/WP$ phosphorylation/NN modulates/VBZ p70I/NN kappa/NN B/NN gamma/NN inhibitory/JJ activity/NN suggests/VBZ that/IN alternative/JJ RNA/NN splicing/NN may/MD be/VB used/VBN to/TO generate/VB I/NN kappa/NN B/NN gamma/NN isoforms/NNS that/WDT respond/VBP differently/RB to/TO intracellular/JJ signals/NNS ./. 
UI/LS -/: 94375000/CD 
TI/LS -/: Structure/NN and/CC expression/NN of/IN the/DT human/JJ GATA3/NN gene/NN ./. 
AB/LS -/: GATA3/NN ,/, a/DT member/NN of/IN the/DT GATA/NN family/NN that/WDT is/VBZ abundantly/RB expressed/VBN in/IN the/DT T-lymphocyte/NN lineage/NN ,/, is/VBZ thought/VBN to/TO participate/VB in/IN T-cell/NN receptor/NN gene/NN activation/NN through/IN binding/NN to/TO enhancers/NNS ./. 
To/TO understand/VB GATA3/NN gene/NN regulation/NN ,/, we/PRP cloned/VBD the/DT human/JJ gene/NN and/CC the/DT 5'/NN end/NN of/IN the/DT mouse/NN GATA3/NN gene/NN ./. 
We/PRP show/VBP that/IN the/DT human/JJ GATA3/NN gene/NN contains/VBZ six/CD exons/NNS distributed/VBN over/IN 17/CD kb/NN of/IN DNA/NN ./. 
The/DT two/CD human/JJ GATA3/NN zinc/NN fingers/NNS are/VBP encoded/VBN by/IN two/CD separate/JJ exons/NNS highly/RB conserved/VBN with/IN those/DT of/IN GATA1/NN ,/, but/CC no/DT other/JJ structural/JJ homologies/NNS between/IN these/DT two/CD genes/NNS can/MD be/VB found/VBN ./. 
The/DT human/JJ and/CC mouse/NN GATA3/NN transcription/NN units/NNS start/VBP at/IN a/DT major/JJ initiation/NN site/NN ./. 
The/DT promoter/NN sequence/NN analysis/NN of/IN these/DT two/CD genes/NNS revealed/VBD that/IN they/PRP are/VBP embedded/JJ within/IN a/DT CpG/NN island/NN and/CC share/VBP structural/JJ features/NNS often/RB found/VBN in/IN the/DT promoters/NNS of/IN housekeeping/JJ genes/NNS ./. 
Finally/RB ,/, we/PRP show/VBP that/IN a/DT DNA/NN fragment/NN containing/VBG the/DT human/JJ GATA3/NN transcription/NN unit/NN ,/, 3/CD kb/NN upstream/RB from/IN the/DT initiation/NN site/NN and/CC 4/CD kb/NN downstream/RB from/IN the/DT polyadenylation/NN site/NN ,/, displays/VBZ T-cell/NN specificity/NN ./. 
UI/LS -/: 94209308/CD 
TI/LS -/: Characterization/NN of/IN the/DT human/JJ gene/NN encoding/NN LBR/NN ,/, an/DT integral/JJ protein/NN of/IN the/DT nuclear/JJ envelope/NN inner/JJ membrane/NN ./. 
AB/LS -/: We/PRP have/VBP characterized/VBN the/DT human/JJ gene/NN encoding/NN LBR/NN ,/, an/DT integral/JJ protein/NN of/IN the/DT nuclear/JJ envelope/NN inner/JJ membrane/NN ./. 
Restriction/NN mapping/NN shows/VBZ that/IN the/DT transcription/NN unit/NN spans/VBZ approximately/RB 35/CD kilobases/NNS ./. 
A/DT transcription/NN start/NN site/NN is/VBZ located/JJ approximately/RB 4/CD kilobases/NNS 5'/NN to/TO the/DT translation/NN initiation/NN codon/NN ,/, and/CC an/DT RNA/NN splice/NN of/IN 3863/CD bases/NNS occurs/VBZ in/IN the/DT 5'-untranslated/JJ region/NN to/TO generate/VB mature/JJ HeLa/NN cell/NN mRNA/NN ./. 
5'/NN to/TO the/DT identified/VBN transcription/NN start/NN site/NN are/VBP two/CD CCAAT/NN sequences/NNS and/CC potential/JJ recognition/NN sites/NNS for/IN several/JJ transcription/NN factors/NNS including/VBG Sp1/NN ,/, AP-1/NN ,/, AP-2/NN ,/, and/CC NF-kB/NN ./. 
There/EX are/VBP 13/CD protein/NN coding/NN exons/NNS in/IN the/DT LBR/NN gene/NN ./. 
LBR/NN 's/POS nucleoplasmic/JJ domain/NN is/VBZ encoded/VBN by/IN exons/NNS 1-4/CD ,/, and/CC its/PRP$ hydrophobic/JJ domain/NN ,/, with/IN eight/CD putative/JJ transmembrane/NN segments/NNS ,/, is/VBZ encoded/VBN by/IN exons/NNS 5-13/CD ./. 
The/DT hydrophobic/JJ domain/NN is/VBZ homologous/JJ to/TO three/CD yeast/NN polypeptides/NNS ,/, suggesting/VBG that/IN this/DT higher/JJR eukaryotic/JJ gene/NN could/MD have/VB evolved/VBN from/IN recombination/NN between/IN a/DT gene/NN that/WDT encoded/VBD a/DT soluble/JJ nuclear/JJ protein/NN and/CC a/DT membrane/NN protein/NN gene/NN similar/JJ to/TO those/DT in/IN yeast/NN ./. 
These/DT results/NNS are/VBP the/DT first/JJ to/TO demonstrate/VB the/DT structural/JJ organization/NN of/IN a/DT vertebrate/JJ gene/NN encoding/VBG an/DT integral/JJ membrane/NN protein/NN of/IN the/DT nuclear/JJ envelope/NN that/WDT may/MD be/VB a/DT member/NN of/IN a/DT family/NN of/IN polypeptides/NNS conserved/VBN in/IN evolution/NN ./. 
UI/LS -/: 94185011/CD 
TI/LS -/: Retinoic/JJ acid-induced/JJ expression/NN of/IN CD38/NN antigen/NN in/IN myeloid/JJ cells/NNS is/VBZ mediated/VBN through/IN retinoic/JJ acid/NN receptor-alpha/NN ./. 
AB/LS -/: CD38/NN is/VBZ a/DT leukocyte/NN differentiation/NN antigen/NN that/WDT has/VBZ been/VBN thought/VBN to/TO be/VB a/DT phenotypic/JJ marker/NN of/IN different/JJ subpopulations/NNS of/IN T-/NN and/CC B-lymphocytes/NNS ./. 
In/IN myeloid/JJ cells/NNS ,/, CD38/NN is/VBZ expressed/VBN during/IN early/JJ stages/NNS of/IN differentiation/NN ./. 
Virtually/RB no/DT information/NN is/VBZ available/JJ on/IN regulation/NN and/CC functions/NNS of/IN CD38/NN ./. 
Recently/RB we/PRP reported/VBD that/IN all-trans-retinoic/JJ acid/NN (/( ATRA/NN )/) is/VBZ a/DT potent/JJ and/CC highly/RB specific/JJ inducer/NN of/IN CD38/NN expression/NN in/IN human/JJ promyelocytic/JJ leukemia/NN cells/NNS ./. 
Here/RB we/PRP report/VBP that/IN ATRA-induced/JJ expression/NN of/IN CD38/NN antigen/NN in/IN myeloid/JJ cells/NNS is/VBZ mediated/VBN through/IN retinoic/JJ acid-alpha/NN receptor/NN (/( RAR/NN alpha/NN )/) ./. 
ATRA/NN failed/VBD to/TO induce/VB CD38/NN expression/NN in/IN a/DT mutant/JJ subclone/NN of/IN the/DT HL-60/NN myeloid/JJ leukemia/NN cell/NN line/NN (/( designated/VBN HL-60R/NN )/) that/WDT is/VBZ relatively/RB resistant/JJ to/TO ATRA-induced/JJ granulocytic/JJ differentiation/NN ./. 
Retroviral/JJ vector-mediated/JJ transduction/NN of/IN RA/NN receptor/NN (/( RAR/NN alpha/NN )/) into/IN this/DT HL-60R/NN subclone/NN completely/RB restored/VBD the/DT sensitivity/NN of/IN these/DT cells/NNS to/TO ATRA/NN in/IN terms/NNS of/IN their/PRP$ ability/NN to/TO express/VB CD38/NN ./. 
In/IN contrast/NN ,/, CD38/NN expression/NN was/VBD not/RB inducible/JJ by/IN ATRA/NN in/IN HL-60R/NN cells/NNS ,/, transfected/VBN with/IN a/DT functional/JJ RAR/NN beta/NN ,/, RAR/NN gamma/NN ,/, or/CC RXR/NN alpha/NN receptor/NN ./. 
Induction/NN of/IN CD38/NN in/IN acute/JJ promyelocytic/JJ and/CC acute/JJ myeloblastic/JJ leukemia/NN cells/NNS was/VBD independent/JJ of/IN ATRA-induced/JJ cytodifferentiation/NN ./. 
Following/VBG culture/NN with/IN ATRA/NN ,/, increased/VBN CD38/NN protein/NN levels/NNS were/VBD also/RB observed/VBN in/IN normal/JJ CD34+/JJ bone/NN marrow/NN cells/NNS ,/, but/CC not/RB on/IN normal/JJ circulating/VBG granulocytes/NNS ./. 
From/IN these/DT results/NNS ,/, we/PRP conclude/VBP that/IN CD38/NN is/VBZ ATRA/NN inducible/JJ in/IN myeloid/JJ leukemia/NN cells/NNS and/CC normal/JJ CD34+/JJ bone/NN marrow/NN cells/NNS ./. 
This/DT effect/NN is/VBZ independent/JJ of/IN differentiation/NN and/CC is/VBZ mediated/VBN by/IN RAR/NN alpha/NN in/IN HL-60/NN cells/NNS ,/, suggesting/VBG a/DT similar/JJ role/NN for/IN RAR/NN alpha/NN in/IN CD38/NN expression/NN in/IN other/JJ hematopoietic/JJ cells/NNS ./. 
UI/LS -/: 94242719/CD 
TI/LS -/: Some/DT antioxidants/NNS inhibit/VBP ,/, in/IN a/DT co-ordinate/JJ fashion/NN ,/, the/DT production/NN of/IN tumor/NN necrosis/NN factor-alpha/NN ,/, IL-beta/NN ,/, and/CC IL-6/NN by/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
AB/LS -/: Some/DT antioxidants/NNS ,/, including/VBG butylated/VBN hydroxyanisole/NN (/( BHA/NN )/) ,/, tetrahydropapaveroline/NN (/( THP/NN )/) ,/, nordihydroguiauretic/JJ acid/NN ,/, and/CC 10,11-dihydroxyaporphine/NN (/( DHA/NN )/) ,/, were/VBD found/VBN to/TO be/VB potent/JJ inhibitors/NNS of/IN the/DT production/NN of/IN tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) -alpha/NN ,/, IL-1/NN beta/NN ,/, and/CC IL-6/NN by/IN human/JJ peripheral/JJ blood/NN mononuclear/NN cells/NNS (/( PBMC/NN )/) stimulated/VBN by/IN lipopolysaccharide/NN (/( LPS/NN )/) (/( IC50s/NN in/IN the/DT low/JJ micromolar/JJ range/NN )/) ./. 
Inhibition/NN of/IN cytokine/NN production/NN was/VBD gene/NN selective/JJ and/CC not/RB due/JJ to/TO general/JJ effects/NNS on/IN protein/NN synthesis/NN ./. 
Inhibition/NN of/IN cytokine/NN production/NN by/IN PBMC/NN was/VBD observed/VBN also/RB when/WRB other/JJ inducers/NNS were/VBD used/VBN (/( staphylococci/NNS ,/, silica/NN ,/, zymosan/NN )/) ./. 
Much/RB higher/JJR concentrations/NNS of/IN other/JJ antioxidants/NNS --/: including/VBG ascorbic/JJ acid/NN ,/, trolox/NN ,/, alpha-tocopherol/NN ,/, butylated/VBN hydroxytoluene/NN ,/, and/CC the/DT 5-lipoxygenase/JJ inhibitor/NN zileuton/NN --/: did/VBD not/RB affect/VB the/DT production/NN of/IN these/DT cytokines/NNS ./. 
The/DT active/JJ compounds/NNS did/VBD not/RB inhibit/VB IL-1-induced/JJ production/NN of/IN IL-6/NN in/IN fibroblasts/NNS ,/, showing/VBG the/DT cell/NN selectivity/NN of/IN the/DT effect/NN ./. 
Antioxidant-mediated/JJ inhibition/NN of/IN cytokine/NN production/NN was/VBD correlated/JJ with/IN low/JJ levels/NNS of/IN the/DT corresponding/JJ messenger/NN RNAs/NNS ./. 
Nuclear/JJ run-on/JJ experiments/NNS showed/VBD that/IN THP/NN inhibited/VBD transcription/NN of/IN the/DT IL-1/NN beta/NN gene/NN ./. 
THP/NN decreased/VBD the/DT concentration/NN of/IN the/DT transcription/NN factors/NNS NF-kappa/NN B/NN and/CC AP-1/NN detected/VBN in/IN nuclear/JJ extracts/NNS of/IN PBMC/NN cultured/VBN in/IN the/DT presence/NN or/CC absence/NN of/IN LPS/NN ./. 
THP/NN and/CC DHA/NN markedly/RB decreased/VBD the/DT levels/NNS of/IN TNF-alpha/NN and/CC IL-1/NN beta/NN in/IN the/DT circulation/NN of/IN mice/NNS following/VBG LPS/NN injection/NN ./. 
Thus/RB antioxidants/NNS vary/VBP widely/RB in/IN potency/NN as/IN inhibitors/NNS of/IN the/DT activation/NN of/IN transcription/NN factors/NNS and/CC of/IN the/DT transcription/NN of/IN genes/NNS for/IN pro-inflammatory/JJ cytokines/NNS ./. 
Coordinate/JJ inhibition/NN of/IN the/DT transcription/NN of/IN genes/NNS for/IN inflammatory/JJ cytokines/NNS could/MD provide/VB a/DT strategy/NN for/IN therapy/NN of/IN diseases/NNS with/IN inflammatory/JJ pathogenesis/NN and/CC for/IN septic/JJ shock/NN ./. 
UI/LS -/: 94367369/CD 
TI/LS -/: An/DT interleukin-4-induced/JJ transcription/NN factor/NN :/: IL-4/NN Stat/NN ./. 
AB/LS -/: Interleukin-4/NN (/( IL-4/NN )/) is/VBZ an/DT immunomodulatory/JJ cytokine/NN secreted/VBN by/IN activated/VBN T/NN lymphocytes/NNS ,/, basophils/NNS ,/, and/CC mast/JJ cells/NNS ./. 
It/PRP plays/VBZ an/DT important/JJ role/NN in/IN modulating/VBG the/DT balance/NN of/IN T/NN helper/NN (/( Th/NN )/) cell/NN subsets/NNS ,/, favoring/VBG expansion/NN of/IN the/DT Th2/NN lineage/NN relative/JJ to/TO Th1/NN ./. 
Imbalance/NN of/IN these/DT T/NN lymphocyte/NN subsets/NNS has/VBZ been/VBN implicated/VBN in/IN immunological/JJ diseases/NNS including/VBG allergy/NN ,/, inflammation/NN ,/, and/CC autoimmune/JJ disease/NN ./. 
IL-4/NN may/MD mediate/VB its/PRP$ biological/JJ effects/NNS ,/, at/IN least/JJS in/IN part/NN ,/, by/IN activating/VBG a/DT tyrosine-phosphorylated/JJ DNA/NN binding/NN protein/NN ./. 
This/DT protein/NN has/VBZ now/RB been/VBN purified/VBN and/CC its/PRP$ encoding/JJ gene/NN cloned/VBN ./. 
Examination/NN of/IN the/DT primary/JJ amino/NN acid/NN sequence/NN of/IN this/DT protein/NN indicates/VBZ that/IN it/PRP is/VBZ a/DT member/NN of/IN the/DT signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( Stat/NN )/) family/NN of/IN DNA/NN binding/NN proteins/NNS ,/, hereby/RB designated/VBN IL-4/NN Stat/NN ./. 
Study/NN of/IN the/DT inhibitory/JJ activities/NNS of/IN phosphotyrosine-containing/JJ peptides/NNS derived/VBN from/IN the/DT intracellular/JJ domain/NN of/IN the/DT IL-4/NN receptor/NN provided/VBD evidence/NN for/IN direct/JJ coupling/NN of/IN receptor/NN and/CC transcription/NN factor/NN during/IN the/DT IL-4/NN Stat/NN activation/NN cycle/NN ./. 
Such/JJ observations/NNS indicate/VBP that/IN IL-4/NN Stat/NN has/VBZ the/DT same/JJ functional/JJ domain/NN for/IN both/CC receptor/NN coupling/NN and/CC dimerization/NN ./. 
UI/LS -/: 95134788/CD 
TI/LS -/: Evaluation/NN of/IN the/DT respiratory/JJ epithelium/NN of/IN normals/NNS and/CC individuals/NNS with/IN cystic/JJ fibrosis/NN for/IN the/DT presence/NN of/IN adenovirus/NN E1a/NN sequences/NNS relevant/JJ to/TO the/DT use/NN of/IN E1a- adenovirus/NN vectors/NNS for/IN gene/NN therapy/NN for/IN the/DT respiratory/JJ manifestations/NNS of/IN cystic/JJ fibrosis/NN ./. 
AB/LS -/: Lung/NN disease/NN associated/VBN with/IN disorders/NNS such/JJ as/IN cystic/JJ fibrosis/NN (/( CF/NN )/) may/MD be/VB amenable/JJ to/TO somatic/JJ gene/NN therapy/NN in/IN which/WDT there/EX is/VBZ delivery/NN of/IN the/DT normal/JJ gene/NN directly/RB to/TO the/DT respiratory/JJ epithelium/NN using/VBG E1a- adenovirus/NN (/( Ad/NN )/) type/NN 2-/CD or/CC 5-based/JJ vectors/NNS ./. 
For/IN safety/NN reasons/NNS ,/, the/DT Ad/NN vectors/NNS are/VBP rendered/VBN replication/NN deficient/JJ by/IN deletion/NN of/IN the/DT E1a/NN region/NN ./. 
Because/IN there/EX is/VBZ the/DT theoretical/JJ possibility/NN of/IN an/DT E1a- replication-deficient/JJ vector/NN replicating/VBG as/IN a/DT result/NN of/IN recombination/NN or/CC complementation/NN with/IN Ad/NN 2/5/CD E1a/NN sequences/NNS present/JJ in/IN the/DT target/NN cell/NN ,/, this/DT study/NN is/VBZ directed/VBN toward/IN evaluating/VBG respiratory/NN epithelium/NN of/IN normals/NNS and/CC individuals/NNS with/IN CF/NN for/IN the/DT presence/NN of/IN E1a/NN sequences/NNS ./. 
Using/VBG Ad/NN 2/5/CD E1a-specific/JJ primers/NNS and/CC the/DT polymerase/NN chain/NN reaction/NN to/TO evaluate/VB DNA/NN recovered/VBN from/IN freshly/RB isolated/VBN nasal/NN and/CC bronchial/JJ epithelium/NN recovered/VBN by/IN brushing/NN ,/, E1a/NN sequences/NNS were/VBD detected/VBN in/IN respiratory/JJ epithelium/NN of/IN 19/CD of/IN 91/CD normals/NNS (/( 21/CD %/NN )/) ./. 
In/IN the/DT E1a-positive/JJ samples/NNS ,/, the/DT average/NN of/IN E1a/NN copy/NN number/NN was/VBD 55/CD +/-/CC 18/10(3)/CD recovered/VBN cells/NNS ./. 
In/IN CF/NN individuals/NNS ,/, 7/CD of/IN 52/CD (/( 13/CD %/NN )/) had/VBD detectable/JJ E1a/NN sequences/NNS in/IN the/DT respiratory/JJ epithelium/NN ,/, with/IN E1a/NN copy/NN number/NN in/IN the/DT positive/JJ samples/NNS of/IN 80/CD +/-/CC 21/10(3)/CD recovered/VBN cells/NNS ./. 
These/DT results/NNS demonstrate/VBP that/IN there/EX are/VBP detectable/JJ Ad/NN 2/5/CD E1a/NN sequences/NNS in/IN the/DT respiratory/JJ epithelium/NN of/IN a/DT small/JJ percentage/NN of/IN normals/NNS and/CC individuals/NNS with/IN CF/NN ./. 
Because/IN of/IN the/DT theoretical/JJ potential/NN of/IN such/JJ sequences/NNS supporting/VBG replication/NN of/IN E1a-Ad/NN vectors/NNS ,/, human/JJ gene/NN therapy/NN protocols/NNS for/IN CF/NN utilizing/VBG such/JJ vectors/NNS should/MD consider/VB evaluating/VBG study/NN individuals/NNS for/IN the/DT presence/NN of/IN Ad/NN 2/5/CD E1a/NN sequences/NNS in/IN the/DT respiratory/JJ epithelium/NN ./. 
UI/LS -/: 94341725/CD 
TI/LS -/: Leiomyosarcoma/NN of/IN the/DT vulva/NN :/: report/NN of/IN a/DT case/NN ./. 
AB/LS -/: A/DT 52-year-old/JJ female/JJ presented/VBN with/IN a/DT progressively/RB enlarging/VBG vulvar/JJ mass/NN ./. 
Pathological/JJ evaluation/NN revealed/VBD a/DT high-grade/JJ vulvar/JJ leiomyosarcoma/NN ./. 
Immunohistochemical/JJ and/CC ultrastructural/JJ studies/NNS were/VBD performed/VBN to/TO support/VB the/DT diagnosis/NN ./. 
In/IN an/DT effort/NN to/TO better/RBR understand/VB the/DT biology/NN of/IN this/DT tumor/NN additional/JJ immunohistochemical/JJ studies/NNS for/IN the/DT protein/NN product/NN of/IN p53/NN tumor/NN suppressor/NN gene/NN and/CC estrogen/NN receptor/NN expression/NN by/IN tumor/NN cells/NNS ,/, as/RB well/RB as/IN the/DT type/NN of/IN immune/JJ cells/NNS infiltrating/VBG the/DT tumor/NN were/VBD performed/VBN ./. 
Tumor/NN cells/NNS showed/VBD an/DT overexpression/NN of/IN p53/NN protein/NN and/CC were/VBD estrogen/NN receptor-positive/JJ ./. 
Macrophages/NNS and/CC T/NN and/CC B/NN lymphocytes/NNS infiltrated/VBD the/DT tumor/NN in/IN moderate/JJ numbers/NNS with/IN occasional/JJ lymphoid/JJ aggregate/NN formation/NN ./. 
This/DT study/NN is/VBZ the/DT first/JJ attempt/NN to/TO better/RBR understand/VB the/DT biology/NN of/IN these/DT tumors/NNS ./. 
UI/LS -/: 94267706/CD 
TI/LS -/: Stimulation/NN of/IN HIV/NN replication/NN in/IN mononuclear/JJ phagocytes/NNS by/IN leukemia/NN inhibitory/JJ factor/NN ./. 
AB/LS -/: This/DT study/NN examined/VBD the/DT effects/NNS of/IN leukemia/NN inhibitory/JJ factor/NN (/( LIF/NN )/) on/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) replication/NN in/IN mononuclear/JJ phagocytes/NNS (/( MNP/NNS )/) ./. 
LIF/NN induced/VBD a/DT dose-dependent/JJ increase/NN in/IN p24/NN antigen/NN production/NN in/IN the/DT chronically/RB infected/JJ promonocytic/JJ cell/NN line/NN U1/NN ./. 
The/DT magnitude/NN and/CC time/NN kinetics/NNS of/IN the/DT LIF/NN effects/NNS were/VBD similar/JJ to/TO interleukin/NN 1/CD (/( IL-1/NN )/) ,/, IL-6/NN ,/, and/CC tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) ,/, other/JJ cytokines/NNS known/VBN to/TO induce/VB HIV/NN replication/NN in/IN this/DT cell/NN line/NN ./. 
To/TO characterize/VB mechanisms/NNS responsible/JJ for/IN these/DT LIF/NN effects/NNS ,/, levels/NNS of/IN HIV/NN mRNA/NN ,/, activation/NN of/IN the/DT DNA/NN binding/NN protein/NN nuclear/JJ factor/NN (/( NF/NN )/) -kB/NN ,/, signal/NN transduction/NN pathways/NNS ,/, and/CC potential/JJ interactions/NNS with/IN other/JJ cytokines/NNS were/VBD analyzed/VBN ./. 
LIF/NN increased/VBD steady-state/JJ levels/NNS of/IN HIV/NN mRNA/NN at/IN 2.0/CD ,/, 4.3/CD ,/, and/CC 9.2/CD kB/NN ./. 
This/DT was/VBD detectable/JJ by/IN 24/CD h/NN and/CC persisted/VBD until/IN 72/CD h/NN ./. 
The/DT DNA/NN binding/NN protein/NN NF-kB/NN is/VBZ a/DT central/JJ mediator/NN in/IN cytokine/NN activation/NN of/IN HIV/NN transcription/NN ./. 
NF-kB/NN levels/NNS were/VBD higher/JJR in/IN unstimulated/JJ U1/NN cells/NNS as/IN compared/VBN to/TO the/DT parent/NN cell/NN line/NN U937/NN ./. 
In/IN both/DT cell/NN lines/NNS LIF/NN increased/VBD NF-kB/NN activity/NN ./. 
Induction/NN of/IN NF-kB/NN and/CC HIV/NN replication/NN by/IN cytokines/NNS are/VBP at/IN least/JJS in/IN part/NN dependent/JJ on/IN reactive/JJ oxygen/NN intermediates/NNS ./. 
The/DT oxygen/NN radical/JJ scavenger/NN N-acetyl-L-cysteine/NN ,/, but/CC not/RB an/DT inhibitor/NN of/IN nitric/JJ oxide/NN synthase/NN ,/, inhibited/VBD LIF-induced/JJ HIV/NN replication/NN ./. 
LIF/NN induces/VBZ the/DT production/NN of/IN other/JJ cytokines/NNS in/IN monocytes/NNS but/CC its/PRP$ effects/NNS on/IN HIV/NN replication/NN were/VBD not/RB inhibited/VBN by/IN antibodies/NNS to/TO IL-1/NN ,/, TNF/NN ,/, or/CC IL-6/NN ./. 
These/DT results/NNS identify/VBP LIF/NN as/IN a/DT stimulus/NN of/IN HIV/NN replication/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 94375097/CD 
TI/LS -/: Mechanisms/NNS involved/VBN in/IN the/DT inhibition/NN of/IN growth/NN of/IN a/DT human/JJ B/NN lymphoma/NN cell/NN line/NN ,/, B104/NN ,/, by/IN anti-MHC/JJ class/NN II/CD antibodies/NNS ./. 
AB/LS -/: The/DT mechanisms/NNS involved/VBN in/IN the/DT inhibition/NN of/IN growth/NN of/IN a/DT human/JJ B/NN lymphoma/NN cell/NN line/NN ,/, B104/NN ,/, by/IN anti-MHC/JJ class/NN II/CD antibodies/NNS (/( Ab/NNS )/) were/VBD compared/VBN with/IN those/DT in/IN anti-IgM/JJ Ab-induced/JJ B104/NN growth/NN inhibition/NN ./. 
Two/CD anti-MHC/JJ class/NN II/CD Ab/NNS ,/, L227/NN and/CC 2.06/CD ,/, inhibited/VBD the/DT growth/NN of/IN B104/NN cells/NNS ,/, although/IN 2.06/CD ,/, but/CC not/RB L227/NN ,/, needed/VBD to/TO be/VB further/RBR cross-linked/VBN with/IN a/DT goat/NN anti-mouse/JJ IgG/NN Ab/NN (/( GAM/NN )/) to/TO show/VB the/DT effect/NN ./. 
L227/NN induced/VBD an/DT increase/NN in/IN intracellular/JJ free/JJ Ca2+/NN concentration/NN (/( [Ca2+]i/NN )/) from/IN the/DT intracellular/JJ pool/NN and/CC little/JJ or/CC no/DT protein/NN tyrosine/NN phosphorylation/NN ,/, phosphatidyl/JJ inositol/NN turnover/NN ,/, or/CC expression/NN of/IN Egr-1/NN mRNA/NN ,/, whereas/IN 2.06/CD plus/CC GAM/NN induced/VBD an/DT increase/NN in/IN [Ca2+]i/NN from/IN both/CC the/DT intracellular/JJ and/CC ,/, in/IN particular/JJ ,/, the/DT extracellular/JJ pools/NNS ./. 
The/DT inhibition/NN of/IN B104/NN cell/NN growth/NN induced/VBN by/IN anti-MHC/JJ class/NN II/CD Ab/NNS was/VBD Ca(2+)-independent/JJ and/CC not/RB inhibited/VBN by/IN actinomycin/JJ D/NN or/CC cyclosporin/NN A/NN ,/, and/CC cell/NN cycle/NN arrest/NN at/IN the/DT G2/M/NN interphase/NN was/VBD not/RB observed/VBN ./. 
These/DT features/NNS are/VBP very/RB different/JJ from/IN those/DT observed/VBN in/IN B104/NN cell/NN death/NN induced/VBN by/IN anti-IgM/JJ Ab/NNS ./. 
Neither/DT DNA/NN fragmentation/NN nor/CC the/DT morphology/NN of/IN apoptosis/NN was/VBD observed/VBN ./. 
These/DT findings/NNS demonstrate/VBP that/IN cross-linking/NN of/IN MHC/NN class/NN II/CD molecules/NNS transduced/VBD the/DT negative/JJ signals/NNS through/IN intracellular/JJ mechanisms/NNS different/JJ from/IN those/DT present/JJ in/IN the/DT cross-linking/NN of/IN surface/NN IgM/NN ./. 
UI/LS -/: 94230451/CD 
TI/LS -/: Functional/JJ block/NN for/IN 1/CD alpha,25-dihydroxyvitamin/NN D3-mediated/JJ gene/NN regulation/NN in/IN human/JJ B/NN lymphocytes/NNS ./. 
AB/LS -/: Elements/NNS necessary/JJ for/IN the/DT steroid/NN hormone/NN 1/CD alpha,25-dihydroxyvitamin/NN D3/NN (/( 1/CD alpha,25-(OH)2D3/NN )/) to/TO induce/VB a/DT biological/JJ response/NN include/VBP the/DT presence/NN of/IN specific/JJ intracellular/JJ receptors/NNS (/( vitamin/NN D3/NN receptors/NNS (/( VDR/NNS )/) )/) and/CC modulation/NN of/IN gene/NN expression/NN via/IN hormone-activated/JJ receptor/NN binding/VBG to/TO regulatory/JJ regions/NNS of/IN target/NN genes/NNS ./. 
These/DT parameters/NNS were/VBD examined/VBN in/IN normal/JJ and/CC Epstein-Barr/JJ virus-immortalized/JJ human/JJ B/NN cells/NNS and/CC compared/VBN with/IN 1/CD alpha,25-(OH)2D3-responsive/NN cells/NNS of/IN the/DT T/NN and/CC monocytic/JJ lineages/NNS ./. 
Although/IN resting/VBG tonsillar/JJ B/NN cells/NNS did/VBD not/RB express/VB VDR/NN mRNA/NN ,/, activation/NN of/IN these/DT cells/NNS with/IN interleukin-4/NN induced/VBD VDR/NN in/IN the/DT absence/NN of/IN exogenously/RB supplemented/VBN 1/CD alpha,25-(OH)2D3/NN ./. 
As/IN indicators/NNS of/IN hormone-mediated/JJ gene/NN regulation/NN we/PRP analyzed/VBD modulation/NN of/IN CD23/NN ,/, a/DT common/JJ B/NN cell/monocyte/NN surface/NN antigen/NN ,/, and/CC 24-hydroxylase/NN ./. 
1/CD alpha,25-(OH)2D3/NN inhibited/VBD CD23/NN expression/NN in/IN U937/NN cells/NNS ,/, yet/RB failed/VBD to/TO modulate/VB CD23/NN expression/NN in/IN B/NN cells/NNS ./. 
Furthermore/RB ,/, 1/CD alpha,25-(OH)2D3/NN induced/VBD 24-hydroxylase/NN mRNA/NN expression/NN and/CC metabolic/JJ activity/NN in/IN both/CC U937/NN cells/NNS and/CC lectin-activated/JJ T/NN cells/NNS ,/, yet/RB failed/VBD to/TO induce/VB 24-hydroxylase/NN mRNA/NN or/CC its/PRP$ metabolic/JJ activity/NN in/IN B/NN cells/NNS ./. 
These/DT findings/NNS suggest/VBP that/IN although/IN human/JJ B/NN lymphocytes/NNS can/MD express/VB VDR/NN mRNA/NN and/CC protein/NN ,/, they/PRP exhibit/VBP a/DT functional/JJ block/NN for/IN vitamin/NN D-dependent/JJ gene/NN regulation/NN ./. 
UI/LS -/: 94331553/CD 
TI/LS -/: Positive/JJ and/CC negative/JJ regulation/NN of/IN IL-2/NN gene/NN expression/NN :/: role/NN of/IN multiple/JJ regulatory/JJ sites/NNS ./. 
AB/LS -/: Interleukin/NN 2/CD (/( IL-2/NN )/) is/VBZ an/DT important/JJ lymphokine/NN required/VBN in/IN the/DT process/NN of/IN T/NN cell/NN activation/NN ,/, proliferation/NN ,/, clonal/JJ expansion/NN and/CC differentiation/NN ./. 
The/DT IL-2/NN gene/NN displays/VBZ both/CC T/NN cell/NN specific/JJ and/CC inducible/JJ expression/NN :/: it/PRP is/VBZ only/RB expressed/VBN in/IN CD4+/JJ T/NN cells/NNS after/IN antigenic/JJ or/CC mitogenic/JJ stimulation/NN ./. 
Several/JJ cis-acting/JJ regulatory/JJ sites/NNS are/VBP required/VBN for/IN induction/NN of/IN the/DT IL-2/NN gene/NN after/IN stimulation/NN ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP analysed/VBN the/DT function/NN of/IN these/DT cis-acting/JJ regulatory/JJ sites/NNS in/IN the/DT context/NN of/IN the/DT native/JJ IL-2/NN enhancer/NN and/CC promoter/NN sequence/NN ./. 
The/DT results/NNS of/IN this/DT study/NN suggest/VBP that/IN the/DT NFAT/NN (/( -276/CD to/TO -261/CD )/) ,/, the/DT distal/JJ octamer/NN (/( -256/CD to/TO -248/CD )/) and/CC the/DT proximal/JJ octamer/NN (/( -75/CD to/TO -66/CD )/) sites/NNS not/RB only/RB act/VBP as/IN enhancers/NNS of/IN IL-2/NN gene/NN transcription/NN in/IN the/DT presence/NN of/IN cellular/JJ stimulation/NN ,/, but/CC also/RB have/VBP a/DT silencing/JJ effect/NN on/IN IL-2/NN gene/NN expression/NN in/IN resting/VBG cells/NNS ./. 
Two/CD other/JJ sites/NNS display/VBP disparate/JJ effects/NNS on/IN IL-2/NN gene/NN expression/NN in/IN different/JJ T/NN leukemia/NN cell/NN lines/NNS :/: the/DT distal/JJ purine/NN box/NN (/( -291/CD to/TO -277/CD )/) and/CC the/DT proximal/JJ purine/NN box/NN sites/NNS (/( -145/CD to/TO -128/CD )/) ./. 
Finally/RB ,/, the/DT AP-1/NN (/( -186/CD to/TO -176/CD )/) and/CC the/DT kappa/NN B/NN sites/NNS (/( -206/CD to/TO -195/CD )/) respond/VBP to/TO different/JJ cellular/JJ activation/NN in/IN EL4/NN cells/NNS ./. 
The/DT AP-1/NN site/NN mediated/VBD the/DT response/NN to/TO PMA/NN stimulation/NN while/IN the/DT kappa/NN B/NN site/NN responded/VBD to/TO IL-1/NN stimulation/NN ./. 
These/DT data/NNS suggest/VBP that/IN the/DT regulation/NN of/IN IL-2/NN gene/NN expression/NN is/VBZ a/DT complex/JJ process/NN and/CC multiple/JJ cis-acting/JJ regulatory/JJ sites/NNS interact/VBP to/TO exert/VB different/JJ effects/NNS in/IN T/NN cells/NNS representative/JJ of/IN alternative/JJ stages/NNS of/IN differentiation/NN ./. 
UI/LS -/: 94209322/CD 
TI/LS -/: Sp1/NN is/VBZ a/DT critical/JJ factor/NN for/IN the/DT monocytic/JJ specific/JJ expression/NN of/IN human/JJ CD14/NN ./. 
AB/LS -/: CD14/NN is/VBZ a/DT membrane/NN glycoprotein/NN expressed/VBN specifically/RB on/IN monocytes/NNS and/CC macrophages/NNS ,/, and/CC its/PRP$ expression/NN is/VBZ markedly/RB increased/VBN during/IN the/DT process/NN of/IN monocyte/NN differentiation/NN ./. 
In/IN order/NN to/TO study/VB CD14/NN gene/NN regulation/NN ,/, the/DT human/JJ CD14/NN gene/NN was/VBD cloned/VBN from/IN a/DT partial/JJ EcoRI/NN digested/JJ chromosome/NN 5/CD library/NN ./. 
A/DT 5.5-kilobase/JJ genomic/JJ clone/NN contained/VBD the/DT full-length/JJ CD14/NN coding/NN sequence/NN and/CC 4.2/CD kilobases/NNS of/IN 5'-upstream/JJ sequence/NN ./. 
One/CD major/JJ and/CC one/CD minor/JJ transcription/NN start/NN site/NN were/VBD identified/VBN 101/CD and/CC 130/CD base/NN pairs/NNS (/( bp/NN )/) upstream/RB ,/, respectively/RB ,/, from/IN the/DT protein/NN translation/NN start/NN ATG/NN ./. 
A/DT DNA/NN fragment/NN containing/VBG 128/CD bp/NN of/IN upstream/JJ sequence/NN had/VBD strong/JJ ,/, monocyte-specific/JJ promoter/NN activity/NN in/IN the/DT CD14/NN positive/JJ monocytic/JJ cell/NN line/NN Mono/NN Mac/NN 6/CD as/IN compared/VBN to/TO the/DT nonmonocytic/JJ cell/NN lines/NNS HeLa/NN and/CC REX/NN ./. 
Four/CD regions/NNS in/IN this/DT DNA/NN fragment/NN interact/VBP with/IN nuclear/JJ proteins/NNS isolated/VBN from/IN monocytic/JJ cells/NNS ./. 
The/DT Sp1/NN transcription/NN factor/NN bound/VBD to/TO three/CD different/JJ regions/NNS in/IN the/DT CD14/NN promoter/NN ./. 
Mutation/NN of/IN the/DT major/JJ Sp1/NN binding/NN site/NN (/( -110/CD bp/NN )/) decreased/VBD tissue-specific/JJ promoter/NN activity/NN ,/, and/CC these/DT results/NNS ,/, together/RB with/IN transactivation/NN experiments/NNS ,/, demonstrate/VBP that/IN Sp1/NN plays/VBZ a/DT critical/JJ role/NN in/IN the/DT tissue-specific/JJ expression/NN of/IN CD14/NN in/IN monocytic/JJ cells/NNS ./. 
CD14/NN Sp1/NN site/NN oligonucleotides/NNS bound/VBD preferentially/RB to/TO a/DT 105-kDa/JJ Sp1/NN species/NNS ,/, which/WDT is/VBZ present/JJ in/IN higher/JJR relative/JJ levels/NNS in/IN monocytic/JJ than/IN non-monocytic/JJ cells/NNS ,/, suggesting/VBG that/IN modification/NN of/IN Sp1/NN ,/, such/JJ as/IN phosphorylation/NN ,/, may/MD explain/VB how/WRB the/DT Sp1/NN site/NN mediates/VBZ monocytic/JJ specific/JJ promoter/NN activity/NN ./. 
UI/LS -/: 94179250/CD 
TI/LS -/: The/DT interleukin-8/NN AP-1/NN and/CC kappa/NN B-like/JJ sites/NNS are/VBP genetic/JJ end/NN targets/NNS of/IN FK506-sensitive/JJ pathway/NN accompanied/VBN by/IN calcium/NN mobilization/NN ./. 
AB/LS -/: FK506/NN ,/, an/DT immunosuppressant/NN ,/, inhibits/VBZ the/DT production/NN of/IN several/JJ cytokines/NNS in/IN T/NN lymphocytes/NNS ./. 
We/PRP observed/VBD that/IN FK506/NN suppressed/VBD the/DT transcription/NN of/IN a/DT chemotactic/JJ cytokine/NN ,/, interleukin-8/NN (/( IL-8/NN )/) in/IN a/DT human/JJ T/NN cell/NN line/NN ,/, Jurkat/NN cells/NNS ,/, activated/VBN by/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) and/CC calcium/NN (/( Ca2+/NN )/) ionophore/NN (/( ionomycin/NN )/) ./. 
By/IN deleted/JJ and/CC mutated/VBN analysis/NN of/IN the/DT IL-8/NN promoters/NNS ,/, the/DT AP-1/NN and/CC kappa/NN B-like/JJ sites/NNS were/VBD identified/VBN as/IN the/DT responsive/JJ elements/NNS for/IN PMA/NN and/CC ionomycin/NN ./. 
FK506/NN suppressed/VBD the/DT transcriptions/NNS through/IN the/DT AP-1/NN or/CC kappa/NN B-like/JJ sites/NNS induced/VBN by/IN PMA/NN plus/CC Ca(2+)-mobilizing/NN agents/NNS ,/, but/CC not/RB those/DT induced/VBN by/IN Ca(2+)-independent/NN stimuli/NNS ./. 
In/IN gel/NN retardation/NN analysis/NN ,/, FK506/NN had/VBD little/JJ effect/NN on/IN the/DT binding/NN to/TO the/DT AP-1/NN site/NN of/IN PMA/ionomycin-induced/JJ nuclear/JJ factors/NNS ,/, which/WDT were/VBD recognized/VBN with/IN anti-JunD/JJ or/CC c-Fos/NN antibody/NN ./. 
In/IN contrast/NN ,/, FK506/NN or/CC EGTA/NN (/( Ca2+/NN chelator/NN )/) similarly/RB affected/VBD the/DT formation/NN of/IN kappa/NN B-like/JJ site/NN binding/NN complexes/NNS ,/, which/WDT were/VBD not/RB recognized/VBN by/IN any/DT antibodies/NNS against/IN the/DT human/JJ Rel/NN family/NN proteins/NNS (/( c-Rel/NN ,/, p65/NN ,/, p50/NN ,/, and/CC p49/NN )/) ./. 
Furthermore/RB ,/, we/PRP confirmed/VBD the/DT previous/JJ report/NN that/IN FK506/NN suppressed/VBD the/DT PMA/ionomycin-induced/JJ activation/NN through/IN authentic/JJ kappa/NN B/NN site/NN of/IN immunoglobulin/NN (/( Ig/NN )/) gene/NN ,/, to/TO which/WDT NF-kappa/NN B/NN binding/NN was/VBD also/RB decreased/VBN by/IN FK506/NN ,/, indicating/VBG that/IN both/CC IL-8/NN kappa/NN B-like/JJ site/NN and/CC Ig/NN kappa/NN B/NN site/NN are/VBP FK506-sensitive/JJ in/IN spite/NN of/IN the/DT difference/NN of/IN binding/JJ factors/NNS ./. 
Our/PRP$ results/NNS indicate/VBP that/IN not/RB only/RB the/DT reported/VBN IL-2/NN NF-AT/NN and/CC NFIL-2A/NN sites/NNS and/CC Ig/NN kappa/NN B/NN site/NN ,/, but/CC also/RB the/DT IL-8/NN AP-1/NN and/CC kappa/NN B-like/JJ sites/NNS are/VBP terminals/NNS of/IN FK506-sensitive/JJ pathway/NN involving/VBG Ca2+/NN mobilization/NN ./. 
UI/LS -/: 94190839/CD 
TI/LS -/: Androgen/NN binding/NN sites/NNS in/IN peripheral/JJ human/JJ mononuclear/JJ leukocytes/NNS of/IN healthy/JJ males/NNS and/CC females/NNS ./. 
AB/LS -/: Androgen/NN binding/NN sites/NNS have/VBP been/VBN identified/VBN in/IN circulating/VBG human/JJ mononuclear/JJ leukocytes/NNS of/IN healthy/JJ donors/NNS of/IN both/DT sexes/NNS ./. 
Cells/NNS were/VBD separated/VBN from/IN blood/NN samples/NNS on/IN a/DT Ficoll/NN gradient/NN and/CC incubated/VBN with/IN different/JJ concentrations/NNS of/IN [3H]testosterone/NN in/IN the/DT presence/NN or/CC absence/NN of/IN a/DT 400-fold/JJ excess/NN of/IN unlabelled/JJ testosterone/NN ./. 
Binding/NN data/NNS were/VBD derived/VBN from/IN Scatchard/NN analysis/NN ./. 
The/DT binding/VBG sites/NNS fulfil/VBP the/DT required/JJ criteria/NNS for/IN specific/JJ steroid/NN binding/NN sites/NNS however/RB differ/VBP somewhat/RB from/IN the/DT classic/JJ androgen/NN receptors/NNS from/IN genital/JJ skin/NN fibroblast/NN :/: in/IN fertile/JJ adult/JJ males/NNS (/( n/NN =/JJ 20/CD )/) the/DT binding/VBG sites/NNS showed/VBD (/( 1/LS )/) a/DT high/JJ affinity/NN for/IN testosterone/NN (/( 1.32/CD +/-/JJ 0.49/CD nM/NN ;/: mean/NN +/-/JJ SD/NN )/) ,/, (/( 2/LS )/) a/DT saturable/JJ capacity/NN (/( 184/CD +/-/JJ 52/CD binding/VBG sites/NNS per/IN cell/NN ;/: mean/NN +/-/JJ SD/NN )/) ,/, and/CC (/( 3/LS )/) a/DT characteristic/JJ competitive/JJ binding/NN profile/NN for/IN other/JJ steroid/NN hormones/NNS (/( relative/JJ binding/NN affinities/NNS :/: testosterone/NN =/JJ dihydrotestosterone/NN >/JJR 17/CD beta-estradiol/NN >/JJR progesterone/NN ,/, whereas/IN aldosterone/NN ,/, 17-hydroxy-progesterone/NN and/CC cortisol/NN did/VBD not/RB compete/VB appreciably/RB )/) ./. 
Furthermore/RB the/DT number/NN of/IN binding/VBG sites/NNS determined/VBN using/VBG [3H]dihydrotestosterone/NN ,/, [3H]RU-1881/NN ,/, or/CC [3H]testosterone/NN were/VBD comparable/JJ ./. 
This/DT raises/VBZ the/DT possibility/NN that/IN androgen/NN receptors/NNS in/IN peripheral/JJ mononuclear/JJ leukocytes/NNS differ/VBP from/IN those/DT in/IN genital/JJ skin/NN fibroblasts/NNS ./. 
There/EX was/VBD no/DT apparent/JJ correlation/NN between/IN serum/NN testosterone/NN concentrations/NNS and/CC androgen/NN binding/NN sites/NNS ./. 
In/IN fertile/JJ women/NNS remarkable/JJ changes/NNS in/IN androgen/NN binding/NN sites/NNS were/VBD seen/VBN in/IN the/DT course/NN of/IN the/DT menstrual/JJ cycle/NN ,/, with/IN a/DT significant/JJ increase/NN in/IN the/DT immediate/JJ preovulatory/JJ period/NN ./. 
The/DT presence/NN of/IN androgen/NN receptors/NNS in/IN peripheral/JJ mononuclear/JJ leukocytes/NNS provides/VBZ for/IN the/DT first/JJ time/NN the/DT experimental/JJ basis/NN for/IN an/DT hypothesis/NN of/IN direct/JJ ,/, receptor-mediated/JJ effects/NNS of/IN androgens/NNS on/IN mature/JJ immunocompetent/JJ cells/NNS ./. 
The/DT immunological/JJ implications/NNS of/IN these/DT results/NNS are/VBP discussed/VBN ./. 
UI/LS -/: 94358417/CD 
TI/LS -/: Induction/NN of/IN IL-8/NN expression/NN in/IN T/NN cells/NNS uses/VBZ the/DT CD28/NN costimulatory/JJ pathway/NN ./. 
AB/LS -/: IL-8/NN ,/, a/DT potent/JJ chemotactic/JJ factor/NN for/IN neutrophil/NN granulocytes/NNS and/CC lymphocytes/NNS ,/, is/VBZ a/DT proinflammatory/JJ cytokine/NN secreted/VBN by/IN a/DT variety/NN of/IN cell/NN types/NNS ,/, including/VBG T/NN cells/NNS ./. 
Stimulation/NN of/IN the/DT CD28/NN cell/NN surface/NN molecule/NN delivers/VBZ costimulatory/JJ signals/NNS essential/JJ for/IN lymphokine/NN production/NN in/IN activated/VBN T/NN cells/NNS via/IN a/DT conserved/VBN sequence/NN element/NN found/VBN in/IN the/DT promoter/NN of/IN several/JJ lymphokine/NN genes/NNS ./. 
Anti-CD28-stimulated/JJ T/NN cells/NNS produced/VBD significant/JJ amounts/NNS of/IN IL-8/NN ;/: additionally/RB ,/, costimulation/NN with/IN anti-CD3/JJ and/CC anti-CD28/JJ Abs/NNS resulted/VBD in/IN a/DT synergistic/JJ induction/NN of/IN IL-8/NN secretion/NN ./. 
Sequence/NN homology/NN ,/, single/JJ nucleotide/JJ mutations/NNS ,/, and/CC anti-CD28/JJ Ab/NN stimulation/NN studies/NNS established/VBD that/IN the/DT NF-kappa/NN B-like/JJ sequence/NN in/IN the/DT promoter/NN of/IN the/DT IL-8/NN gene/NN functioned/VBD as/IN a/DT CD28/NN response/NN element/NN ./. 
Furthermore/RB ,/, cyclosporin/NN A/NN ,/, but/CC not/RB rapamycin/NN ,/, blocked/VBD the/DT synergistic/JJ induction/NN of/IN IL-8/NN expression/NN achieved/VBN with/IN anti-CD3/JJ and/CC anti-CD28/JJ costimulation/NN ./. 
The/DT involvement/NN of/IN a/DT CD28/NN response/NN element/NN in/IN the/DT induction/NN of/IN IL-8/NN expression/NN in/IN activated/VBN T/NN cells/NNS may/MD provide/VB new/JJ insights/NNS into/IN the/DT pathogenesis/NN and/CC persistence/NN of/IN immune/JJ disorders/NNS characterized/VBN by/IN increased/VBN levels/NNS of/IN IL-8/NN ,/, such/JJ as/IN psoriasis/NN and/CC rheumatoid/NN arthritis/NN ./. 
UI/LS -/: 95032566/CD 
TI/LS -/: MHC/NN class/NN II/CD signaling/NN in/IN B-cell/NN activation/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: The/DT cognate/JJ interaction/NN between/IN T/NN cells/NNS and/CC antigen-presenting/JJ cells/NNS (/( APCs/NNS )/) ,/, mediated/VBN by/IN major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II/CD molecules/NNS ,/, results/VBZ in/IN the/DT delivery/NN of/IN activation/NN signals/NNS to/TO the/DT APC/NN ./. 
These/DT signals/NNS contribute/VBP to/TO the/DT expression/NN of/IN co-stimulatory/JJ activity/NN by/IN APCs/NNS and/CC have/VBP important/JJ consequences/NNS for/IN cell/NN effector/NN function/NN ./. 
MHC/NN class/NN II/CD molecules/NNS also/RB serve/VBP as/IN receptors/NNS for/IN B-cell/NN stimulation/NN by/IN microbial/JJ superantigens/NNS ./. 
In/IN this/DT review/NN ,/, Paul/NN Scholl/NN and/CC Raif/NN Geha/NN discuss/VBP recent/JJ advances/NNS in/IN our/PRP$ understanding/NN of/IN mechanisms/NNS of/IN MHC/NN class/NN II/CD signaling/NN and/CC analyse/VBP their/PRP$ role/NN in/IN human/JJ B-cell/NN activation/NN ./. 
UI/LS -/: 94331016/CD 
TI/LS -/: Effects/NNS of/IN glucocorticoids/NNS in/IN rheumatoid/JJ arthritis/NN ./. 
Diminished/VBN glucocorticoid/NN receptors/NNS do/VBP not/RB result/VB in/IN glucocorticoid/NN resistance/NN ./. 
AB/LS -/: OBJECTIVE/NN ./. 
Lymphocytes/NNS of/IN patients/NNS with/IN rheumatoid/JJ arthritis/NN (/( RA/NN )/) have/VBP diminished/VBN receptor/NN density/NN ;/: thus/RB ,/, patients/NNS with/IN RA/NN should/MD show/VB partial/JJ resistance/NN to/TO glucocorticoids/NNS ./. 
We/PRP investigated/VBD the/DT glucocorticoid/NN sensitivity/NN of/IN lymphocytes/NNS in/IN RA/NN patients/NNS compared/VBN with/IN healthy/JJ subjects/NNS ./. 
METHODS/NNS ./. 
We/PRP determined/VBD the/DT effects/NNS of/IN glucocorticoids/NNS on/IN lymphocyte/NN proliferation/NN and/CC cytokine/NN release/NN ./. 
RESULTS/NNS ./. 
Proliferation/NN and/CC cytokine/NN release/NN were/VBD inhibited/VBN in/IN RA/NN patients/NNS to/TO the/DT same/JJ extent/NN as/IN in/IN healthy/JJ controls/NNS ./. 
CONCLUSION/NN ./. 
Diminished/VBN receptor/NN density/NN in/IN RA/NN patients/NNS does/VBZ not/RB result/VB in/IN glucocorticoid/NN resistance/NN ./. 
UI/LS -/: 95031992/CD 
TI/LS -/: Arrested/VBN development/NN :/: understanding/VBG v-abl/NN ./. 
AB/LS -/: The/DT protein/NN tyrosine/NN kinase/NN activity/NN of/IN the/DT v-abl/NN oncogene/NN has/VBZ been/VBN demonstrated/VBN to/TO subvert/VB the/DT normal/JJ second/JJ messenger/NN systems/NNS used/VBN by/IN lymphoid/JJ cells/NNS for/IN growth/NN and/CC differentiation/NN ./. 
Transformation/NN of/IN bone/NN marrow/NN with/IN the/DT Abelson/NN murine/NN leukemia/NN virus/NN results/VBZ in/IN the/DT appearance/NN of/IN B/NN cell/NN lineage/NN cells/NNS arrested/VBN at/IN the/DT pre-B/JJ cell/NN stage/NN ./. 
Recent/JJ reports/NNS have/VBP characterized/VBN these/DT cells/NNS expressing/VBG high/JJ v-abl/NN kinase/NN activity/NN as/IN deficient/JJ in/IN detectable/JJ NF-kappaB/NN DNA/NN binding/NN activity/NN and/CC low/JJ level/NN RAG/NN gene/NN expression/NN ./. 
These/DT observations/NNS suggest/VBP that/IN v-abl/NN may/MD be/VB inhibiting/VBG the/DT differentiation/NN of/IN B/NN cells/NNS by/IN blocking/VBG these/DT two/CD crucial/JJ elements/NNS in/IN the/DT maturation/NN pathway/NN ./. 
UI/LS -/: 94318550/CD 
TI/LS -/: Corticosteroid/NN receptors/NNS in/IN lymphocytes/NNS :/: a/DT possible/JJ marker/NN of/IN brain/NN involution/NN ?/. 
AB/LS -/: A/DT similarity/NN has/VBZ recently/RB been/VBN found/VBN between/IN the/DT regulation/NN of/IN corticosteroid/NN receptors/NNS in/IN brain/NN and/CC in/IN lymphoid/JJ tissue/NN ./. 
We/PRP have/VBP studied/VBN the/DT regulation/NN of/IN corticosteroid/NN receptors/NNS in/IN human/JJ mononuclear/JJ leukocytes/NNS as/IN a/DT possible/JJ marker/NN of/IN brain/NN involution/NN ./. 
Type/NN I/CD corticosteroid/NN receptors/NNS are/VBP down/RB regulated/VBN by/IN excess/NN of/IN mineralocorticoids/NNS (/( primary/JJ and/CC secondary/JJ hyperaldosteronism/NN ,/, pseudohyperaldosteronism/NN )/) and/CC of/IN glucocorticoids/NNS (/( Cushing/NN 's/POS syndrome/NN )/) ./. Type/NN II/CD corticosteroid/NN receptors/NNS are/VBP not/RB reduced/VBN by/IN excess/NN of/IN endogenous/JJ corticosteroids/NNS (/( Cushing/NN 's/POS syndrome/NN )/) ./. 
In/IN normal/JJ adults/NNS there/EX is/VBZ a/DT direct/JJ significant/JJ correlation/NN between/IN plasma/NN cortisol/NN and/CC Type/NN I/CD and/CC between/IN plasma/NN cortisol/NN and/CC Type/NN II/CD receptors/NNS in/IN mononuclear/JJ leukocytes/NNS ,/, while/IN in/IN Cushing/NN 's/POS syndrome/NN the/DT correlation/NN is/VBZ inverse/JJ between/IN plasma/NN cortisol/NN at/IN 8/CD a.m./RB and/CC Type/NN II/CD receptors/NNS ./. 
In/IN an/DT aged/JJ population/NN the/DT mean/JJ numbers/NNS of/IN Type/NN I/CD and/CC of/IN Type/NN II/CD receptors/NNS are/VBP lower/JJR and/CC plasma/NN cortisol/NN is/VBZ higher/JJR than/IN in/IN adult/JJ controls/NNS ,/, but/CC the/DT increase/NN of/IN plasma/NN cortisol/NN is/VBZ not/RB followed/VBN by/IN a/DT clinical/JJ picture/NN of/IN hypercorticism/NN ./. 
Corticosteroid/NN Type/NN I/CD and/CC Type/NN II/CD receptors/NNS are/VBP inversely/RB correlated/VBN with/IN age/NN ./. 
After/IN dexamethasone/NN suppression/NN (/( 1/CD mg/NN at/IN 11/CD p.m./NN )/) Type/NN I/CD receptors/NNS always/RB decrease/VBP in/IN controls/NNS while/IN the/DT response/NN of/IN Type/NN II/CD is/VBZ not/RB homogeneous/JJ ./. 
In/IN an/DT aged/JJ group/NN of/IN patients/NNS ,/, both/DT receptors/NNS are/VBP reduced/VBN by/IN dexamethasone/NN ./. 
We/PRP conclude/VBP that/IN the/DT decrease/NN with/IN age/NN of/IN corticosteroid/NN receptors/NNS is/VBZ possibly/RB related/JJ to/TO a/DT physiological/JJ involution/NN of/IN corticosteroid/NN receptors/NNS and/CC that/IN this/DT reduction/NN does/VBZ increase/VB plasma/NN cortisol/NN concentration/NN ,/, without/IN affecting/VBG the/DT glucocorticoid/NN effector/NN mechanism/NN ./. 
UI/LS -/: 94238904/CD 
TI/LS -/: All-trans/JJ retinoic/JJ acid/NN and/CC 1/CD alpha,25-dihydroxyvitamin/NN D3/NN co-operate/VBP to/TO promote/VB differentiation/NN of/IN the/DT human/JJ promyeloid/JJ leukemia/NN cell/NN line/NN HL60/NN to/TO monocytes/NNS ./. 
AB/LS -/: A/DT basis/NN for/IN differentiation/NN therapy/NN of/IN leukemias/NNS is/VBZ provided/VBN by/IN knowledge/NN of/IN agents/NNS which/WDT induce/VBP specific/JJ lineage/NN maturation/NN ./. 
All-trans/JJ retinoic/JJ acid/NN (/( RA/NN )/) induces/VBZ differentiation/NN of/IN HL60/NN cells/NNS to/TO neutrophils/NNS and/CC is/VBZ used/VBN to/TO treat/VB acute/JJ promyelocytic/JJ leukemia/NN ./. 
We/PRP observed/VBD that/IN RA/NN did/VBD not/RB induced/VBN neutrophil/NN differentiation/NN in/IN serum-free/JJ grown/VBN HL60/NN cells/NNS whereas/IN 50/CD nM/NN 1/CD alpha,25-dihydroxyvitamin/NN D3/NN (/( D3/NN )/) induced/VBD maximal/JJ monocyte/NN differentiation/NN ./. 
Increasing/VBG RA/NN concentrations/NNS reduced/VBD the/DT D3/NN concentration/NN required/VBN for/IN monocyte/NN differentiation/NN ./. 
Cells/NNS treated/VBN with/IN 5/CD nM/NN D3/NN showed/VBD little/JJ response/NN ,/, but/CC differentiated/VBD maximally/RB with/IN 5/CD nM/NN D3/NN and/CC 10/CD nM/NN RA/NN ./. 
The/DT D3/NN analogs/NNS MC903/NN ,/, EB1089/NN and/CC KH1060/NN were/VBD more/JJR potent/JJ inducers/NNS of/IN monocyte/NN differentiation/NN ./. 
The/DT extent/NN to/TO which/WDT analog/NN activity/NN was/VBD increased/VBN after/IN cotreatment/NN with/IN RA/NN was/VBD inversely/RB related/JJ to/TO potency/NN ./. 
Twenty-four/CD hour/NN treatment/NN with/IN 10/CD nM/NN RA/NN primed/VBD cells/NNS for/IN response/NN to/TO 5/CD nM/NN D3/NN ;/: the/DT reverse/NN sequence/NN being/VBG ineffective/JJ ./. 
Priming/VBG with/IN 10/CD nM/NN RA/NN ,/, or/CC subsequent/JJ treatment/NN with/IN D3/NN (/( 5/CD nM/NN )/) ,/, did/VBD not/RB alter/VB expression/NN of/IN mRNAs/NNS encoding/VBG receptors/NNS for/IN D3/NN (/( VDR/NN )/) ,/, RA/NN (/( RAR/NN alpha/NN )/) or/CC 9-CIS/JJ RA/NN (/( RXR/NN alpha/NN ,/, beta/NN ,/, gamma/NN )/) ./. 
That/IN RA/NN promotes/VBZ both/CC neutrophil/NN and/CC monocyte/NN differentiation/NN has/VBZ implications/NNS for/IN the/DT use/NN of/IN RA/NN and/CC D3/NN in/IN treatment/NN of/IN leukemias/NNS and/CC provides/VBZ insight/NN into/IN mechanisms/NNS whereby/WRB RAR/NN ,/, VDR/NN and/CC RXR/NN facilitate/VBP monocyte/NN differentiation/NN ./. 
UI/LS -/: 95012031/CD 
TI/LS -/: [/( An/DT overexpression/NN of/IN retinoic/JJ acid/NN receptor/NN alpha/NN blocks/VBZ myeloid/JJ cell/NN differentiation/NN at/IN the/DT promyelocyte/JJ stage/NN ]/) 
AB/LS -/: Retinoic/JJ acid/NN (/( RA/NN )/) ,/, a/DT vitamin/NN A/NN derivative/JJ ,/, exerts/VBZ a/DT wide/JJ range/NN of/IN biological/JJ effects/NNS related/JJ to/TO cell/NN proliferation/NN and/CC differentiation/NN ./. 
The/DT pleiotropic/JJ effects/NNS of/IN RA/NN are/VBP thought/VBN to/TO be/VB mediated/VBN through/IN specific/JJ nuclear/JJ RA/NN receptors/NNS (/( RARs/NNS )/) ./. 
RARs/NNS are/VBP members/NNS of/IN the/DT steroid/thyroid/NN hormone/NN receptor/NN superfamily/NN and/CC exhibit/VBP a/DT molecular/JJ structure/NN that/WDT possess/VBP discrete/JJ DNA-binding/JJ and/CC RA/NN (/( ligand/NN )/) -binding/JJ domains/NNS ./. 
In/IN hematopoietic/JJ system/NN ,/, RA/NN and/CC RARs/NNS ,/, predominantly/RB RAR/NN alpha/NN may/MD play/VB key/JJ roles/NNS for/IN the/DT proliferation/NN and/CC differentiation/NN of/IN hematopoietic/JJ progenitors/NNS ./. 
However/RB ,/, it/PRP is/VBZ currently/RB unknown/JJ how/WRB RA/NN and/CC RARs/NNS are/VBP involved/VBN in/IN regulating/VBG normal/JJ hematopoietic/JJ differentiation/NN ./. 
To/TO make/VB clear/JJ the/DT roles/NNS of/IN RA/NN and/CC RAR/NN alpha/NN in/IN the/DT normal/JJ hematopoiesis/NN ,/, I/PRP have/VBP introduced/VBN the/DT construct/NN of/IN human/JJ RAR/NN alpha/NN (/( hRAR/NN alpha/NN )/) into/IN murine/NN bone/NN marrow/NN cells/NNS with/IN retroviral/JJ vector/NN ,/, and/CC selected/VBN infected/JJ cells/NNS with/IN drug/NN resistant/JJ marker/NN (/( Neo(r)/NN )/) cultured/VBN on/IN the/DT stroma/NN cell/NN line/NN (/( PA6-neo/JJ )/) ,/, and/CC analyzed/VBN the/DT behavior/NN of/IN infected/JJ cells/NNS ./. 
All/DT of/IN procedure/NN were/VBD done/VBN in/FW vitro/FW ./. 
Most/JJS cells/NNS infected/VBN with/IN hRAR/NN alpha/NN exhibited/VBD promyelocytic/JJ morphology/NN and/CC were/VBD thought/VBN to/TO be/VB blocked/VBN at/IN the/DT promyelocytic/JJ stage/NN in/IN their/PRP$ myeloid/JJ differentiation/NN ./. 
Furthermore/RB ,/, these/DT immature/JJ cells/NNS differentiated/VBD terminally/RB into/IN mature/JJ granulocytes/NNS by/IN adding/VBG with/IN RA/NN (/( 10/CD (/( -6/CD )/) M/NN )/) ./. 
RAR/NN alpha/NN infected/JJ cells/NNS were/VBD also/RB able/JJ to/TO differentiate/VB into/IN mature/JJ macrophages/NNS in/IN the/DT both/CC of/IN long/JJ term/NN culture/NN and/CC IL3/NN colony/NN ./. 
These/DT observations/NNS suggest/VBP that/IN an/DT overexpression/NN of/IN RAR/NN alpha/NN alone/RB is/VBZ effective/JJ to/TO suppress/VB myeloid/JJ cell/NN differentiation/NN and/CC RAR/NN alpha/NN plays/VBZ a/DT crucial/JJ role/NN in/IN the/DT terminal/JJ differentiation/NN of/IN myeloid/JJ precursors/NNS ./. 
The/DT system/NN described/VBN here/RB may/MD serve/VB as/IN a/DT model/NN for/IN studying/VBG the/DT the/DT essential/JJ genes/NNS for/IN differentiation/NN of/IN normal/JJ bone/NN marrow/NN cells/NNS ./. 
UI/LS -/: 94216500/CD 
TI/LS -/: Hypoxic/JJ induction/NN of/IN interleukin-8/NN gene/NN expression/NN in/IN human/JJ endothelial/JJ cells/NNS ./. 
AB/LS -/: Because/IN leukocyte-mediated/JJ tissue/NN damage/NN is/VBZ an/DT important/JJ component/NN of/IN the/DT pathologic/JJ picture/NN in/IN ischemia/reperfusion/NN ,/, we/PRP have/VBP sought/VBN mechanisms/NNS by/IN which/WDT PMNs/NNS are/VBP directed/VBN into/IN hypoxic/JJ tissue/NN ./. 
Incubation/NN of/IN human/JJ endothelial/JJ cells/NNS (/( ECs/NNS )/) in/IN hypoxia/NN ,/, PO2/NN approximately/RB 14-18/CD Torr/NN ,/, led/VBD to/TO time-dependent/JJ release/NN of/IN IL-8/NN antigen/NN into/IN the/DT conditioned/JJ medium/NN ;/: this/DT was/VBD accompanied/VBN by/IN increased/VBN chemotactic/JJ activity/NN for/IN PMNs/NNS ,/, blocked/VBN by/IN antibody/NN to/TO IL-8/NN ./. 
Production/NN of/IN IL-8/NN by/IN hypoxic/JJ ECs/NNS occurred/VBD concomitantly/RB with/IN both/DT increased/VBN levels/NNS of/IN IL-8/NN mRNA/NN ,/, based/VBN on/IN polymerase/NN chain/NN reaction/NN analysis/NN ,/, and/CC increased/VBN IL-8/NN transcription/NN ,/, based/VBN on/IN nuclear/JJ run-on/JJ assays/NNS ./. 
Northern/JJ analysis/NN of/IN mRNA/NN from/IN hypoxic/JJ ECs/NNS also/RB demonstrated/VBD increased/VBN levels/NNS of/IN mRNA/NN for/IN macrophage/NN chemotactic/NN protein-1/NN ,/, another/DT member/NN of/IN the/DT chemokine/NN superfamily/NN of/IN proinflammatory/JJ cytokines/NNS ./. 
IL-8/NN gene/NN induction/NN was/VBD associated/VBN with/IN the/DT presence/NN of/IN increased/VBN binding/NN activity/NN in/IN nuclear/JJ extracts/NNS from/IN hypoxic/JJ ECs/NNS for/IN the/DT NF-kB/NN site/NN ./. 
Studies/NNS with/IN human/JJ umbilical/JJ vein/NN segments/NNS exposed/VBN to/TO hypoxia/NN also/RB demonstrated/VBD increased/VBN elaboration/NN of/IN IL-8/NN antigen/NN compared/VBN with/IN normoxic/JJ controls/NNS ./. 
In/IN mice/NNS exposed/VBN to/TO hypoxia/NN (/( PO2/NN approximately/RB 30-40/CD Torr/NN )/) ,/, there/EX was/VBD increased/VBN pulmonary/JJ leukostasis/NN ,/, as/IN evidenced/VBN by/IN increased/VBN myeloperoxidase/NN activity/NN in/IN tissue/NN homogenates/NNS ./. 
In/IN parallel/NN ,/, increased/VBN levels/NNS of/IN transcripts/NNS for/IN IP-10/NN ,/, a/DT murine/NN homologue/NN in/IN the/DT chemokine/NN family/NN related/JJ to/TO IL-8/NN ,/, were/VBD observed/VBN in/IN hypoxic/JJ lung/NN tissue/NN ./. 
Taken/VBN together/RB ,/, these/DT data/NNS suggest/VBP that/IN hypoxia/NN constitutes/VBZ a/DT stimulus/NN for/IN leukocyte/NN chemotaxis/NN and/CC tissue/NN leukostasis/NN ./. 
UI/LS -/: 94179241/CD 
TI/LS -/: Thrombin/NN and/CC thrombin/NN receptor/NN agonist/NN peptide/NN induce/VBP early/JJ events/NNS of/IN T/NN cell/NN activation/NN and/CC synergize/VBP with/IN TCR/NN cross-linking/NN for/IN CD69/NN expression/NN and/CC interleukin/NN 2/CD production/NN ./. 
AB/LS -/: Thrombin/NN stimulation/NN of/IN the/DT T/NN leukemic/JJ cell/NN line/NN Jurkat/NN induced/VBD a/DT transient/JJ increase/NN in/IN [Ca2+]i/NN ./. 
Proteolytic/JJ activity/NN of/IN the/DT enzyme/NN was/VBD required/VBN for/IN this/DT effect/NN since/IN diisopropyl/NN fluorophosphate-thrombin/NN failed/VBD to/TO increase/VB [Ca2+]i/NN ./. 
Furthermore/RB ,/, hirudin/NN and/CC anti-thrombin/NN III/CD inhibited/VBD the/DT thrombin-induced/JJ [Ca2+]i/NN rise/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
A/DT synthetic/JJ thrombin/NN receptor/NN agonist/NN peptide/NN (/( TRP/NN )/) of/IN 7/CD residues/NNS (/( SFLLRNP/NN )/) was/VBD found/VBN to/TO be/VB as/RB effective/JJ as/IN thrombin/NN for/IN [Ca2+]i/NN mobilization/NN ,/, and/CC both/DT agonists/NNS induced/VBD Ca2+/NN release/NN exclusively/RB from/IN internal/JJ stores/NNS ./. 
Thrombin/NN stimulated/VBD tyrosine/NN phosphorylation/NN of/IN several/JJ proteins/NNS of/IN molecular/JJ mass/NN 40/CD ,/, 42/CD ,/, 70/CD ,/, 120/CD ,/, and/CC 130/CD kDa/NN ./. 
There/EX was/VBD a/DT good/JJ correlation/NN between/IN thrombin-induced/JJ tyrosine/NN phosphorylation/NN of/IN the/DT latter/JJ three/CD proteins/NNS and/CC Ca2+/NN mobilization/NN ./. 
Thrombin/NN and/CC TRP/NN also/RB caused/VBD translocation/NN of/IN protein/NN kinase/NN C/NN from/IN the/DT cytosol/NN to/TO the/DT plasma/NN membrane/NN ./. 
As/IN a/DT likely/JJ consequence/NN of/IN these/DT events/NNS ,/, thrombin/NN activated/VBD the/DT nuclear/JJ factor/NN NF-kB/NN ./. 
Several/JJ cell/NN lines/NNS of/IN hematopoietic/JJ origin/NN including/VBG the/DT leukemic/JJ T/NN cell/NN line/NN HPB.ALL/NN and/CC the/DT erythroleukemic/JJ cell/NN line/NN K562/NN were/VBD responsive/JJ to/TO thrombin/NN ,/, whereas/IN others/NNS such/JJ as/IN THP1/NN ,/, a/DT myelomonocytic/JJ cell/NN line/NN ,/, and/CC BL2/NN ,/, a/DT Burkitt/NN lymphoma/NN were/VBD refractory/JJ to/TO thrombin/NN or/CC TRP/NN stimulation/NN ./. 
The/DT magnitude/NN of/IN the/DT thrombin/NN response/NN in/IN the/DT different/JJ cell/NN types/NNS paralleled/VBD the/DT expression/NN of/IN the/DT thrombin/NN receptor/NN mRNA/NN ./. 
We/PRP found/VBD that/IN activation/NN of/IN Jurkat/NN T/NN cells/NNS by/IN a/DT combination/NN of/IN phytohemagglutinin/NN and/CC phorbol/NN 12-myristate/NN 13-acetate/NN led/VBD to/TO a/DT dramatic/JJ inhibition/NN of/IN thrombin/NN receptor/NN mRNA/NN expression/NN and/CC to/TO a/DT concomitant/JJ loss/NN of/IN the/DT thrombin/NN response/NN ./. 
Finally/RB ,/, we/PRP demonstrate/VBP that/IN thrombin/NN and/CC TRP/NN enhanced/VBD CD69/NN expression/NN and/CC interleukin/NN 2/CD production/NN induced/VBN by/IN T/NN cell/NN receptor/NN cross-linking/NN in/IN both/CC Jurkat/NN T/NN cells/NNS and/CC peripheral/JJ blood/NN lymphocytes/NNS ./. 
These/DT findings/NNS highlight/VBP the/DT role/NN of/IN thrombin/NN as/IN a/DT potential/JJ regulator/NN of/IN T/NN lymphocyte/NN activation/NN ./. 
UI/LS -/: 94172207/CD 
TI/LS -/: Stress/NN response/NN of/IN senescent/JJ T/NN lymphocytes/NNS :/: reduced/VBN hsp70/NN is/VBZ independent/JJ of/IN the/DT proliferative/JJ block/NN ./. 
AB/LS -/: Senescent/JJ human/JJ T/NN lymphocyte/NN cultures/NNS are/VBP unable/JJ to/TO undergo/VB proliferation/NN ,/, but/CC show/VBP no/DT difference/NN from/IN early/JJ passage/NN cells/NNS in/IN cytotoxic/JJ function/NN or/CC surface/NN antigenic/JJ profile/NN ./. 
A/DT second/JJ feature/NN of/IN senescent/JJ T/NN cells/NNS is/VBZ the/DT dramatic/JJ reduction/NN in/IN hsp70/NN production/NN in/IN response/NN to/TO heat/NN shock/NN ./. 
This/DT decline/NN is/VBZ associated/VBN with/IN a/DT decrease/NN in/IN binding/NN of/IN nuclear/JJ extracts/NNS to/TO the/DT consensus/NN heat/NN shock/NN element/NN ./. 
Interestingly/RB ,/, the/DT progressive/JJ decline/NN in/IN the/DT heat/NN shock/NN response/NN of/IN cultured/VBD T/NN cells/NNS correlates/VBZ with/IN the/DT percent/JJ proliferative/JJ life/NN span/NN completed/VBN rather/RB than/IN with/IN the/DT actual/JJ proliferative/JJ activity/NN at/IN the/DT time/NN of/IN heat/NN shock/NN ./. 
This/DT suggests/VBZ that/IN for/IN senescent/JJ T/NN cells/NNS the/DT reduced/VBN ability/NN to/TO respond/VB to/TO heat/NN shock/NN by/IN producing/VBG hsp70/NN ,/, although/IN possibly/RB lying/VBG at/IN the/DT level/NN of/IN transcriptional/JJ control/NN ,/, may/MD nevertheless/RB be/VB unrelated/JJ to/TO the/DT reduced/VBN DNA/NN synthesis/NN or/CC the/DT diminished/VBN proliferative/NN activity/NN also/RB manifested/VBN by/IN these/DT cells/NNS ./. 
UI/LS -/: 94358411/CD 
TI/LS -/: Involvement/NN of/IN phospholipase/NN D/NN in/IN the/DT activation/NN of/IN transcription/NN factor/NN AP-1/NN in/IN human/JJ T/NN lymphoid/JJ Jurkat/NN cells/NNS ./. 
AB/LS -/: The/DT induction/NN of/IN the/DT AP-1/NN transcription/NN factor/NN has/VBZ been/VBN ascribed/VBN to/TO the/DT early/JJ events/NNS leading/VBG to/TO T/NN lymphocyte/NN activation/NN ./. 
We/PRP have/VBP examined/VBN the/DT possibility/NN that/IN stimulation/NN of/IN phospholipase/NN D/NN (/( PLD/NN )/) may/MD regulate/VB activation/NN of/IN transcription/NN factor/NN AP-1/NN in/IN human/JJ T/NN cells/NNS by/IN transfecting/VBG human/JJ T/NN lymphocyte/NN Jurkat/NN cells/NNS with/IN a/DT plasmid/NN containing/VBG an/DT AP-1/NN enhancer/NN element/NN and/CC a/DT chloramphenicol/NN acetyltransferase/NN reporter/NN gene/NN ./. 
We/PRP have/VBP detected/VBN activatable/JJ PLD/NN in/IN Jurkat/NN cells/NNS ,/, and/CC we/PRP have/VBP found/VBN that/IN addition/NN of/IN phosphatidic/JJ acid/NN (/( PA/NN )/) ,/, the/DT physiologic/JJ product/NN of/IN PLD/NN action/NN on/IN phospholipids/NNS ,/, is/VBZ rapidly/RB incorporated/VBN into/IN Jurkat/NN cells/NNS and/CC leads/VBZ to/TO activation/NN of/IN transcription/NN factor/NN AP-1/NN ./. 
Treatment/NN of/IN Jurkat/NN cells/NNS with/IN anti-CD3/JJ mAb/NN activated/VBD both/CC PLD/NN and/CC transcription/NN factor/NN AP-1/NN ./. 
Wortmannin/NN ,/, an/DT inhibitor/NN of/IN receptor-coupled/JJ PLD/NN activation/NN ,/, blocked/VBD the/DT anti-CD3-induced/JJ increases/NNS in/IN both/CC PLD/NN activity/NN and/CC AP-1/NN enhancer/NN activity/NN ./. 
We/PRP found/VBD a/DT good/JJ correlation/NN in/IN the/DT transfected/VBN cells/NNS between/IN PLD/NN activation/NN and/CC induction/NN of/IN AP-1/NN enhancer/NN activity/NN under/IN different/JJ experimental/JJ conditions/NNS ./. 
Furthermore/RB ,/, ethanol/NN ,/, an/DT inhibitor/NN of/IN the/DT PLD/NN pathway/NN ,/, blocked/VBD the/DT anti-CD3-stimulated/JJ AP-1/NN enhancer/NN activity/NN ./. 
However/RB ,/, this/DT anti-CD3-mediated/JJ response/NN was/VBD not/RB inhibited/VBN by/IN neomycin/NN ,/, an/DT inhibitor/NN of/IN phosphoinositide/JJ hydrolysis/NN ./. 
The/DT increases/NNS in/IN AP-1/NN enhancer/NN activity/NN induced/VBN by/IN PA/NN or/CC anti-CD3/JJ mAb/NN were/VBD efficiently/RB abrogated/VBN by/IN the/DT presence/NN of/IN propranolol/NN ,/, an/DT inhibitor/NN of/IN PA/NN phosphohydrolase/NN and/CC protein/NN kinase/NN C/NN (/( PKC/NN )/) ./. 
Furthermore/RB ,/, the/DT PA-/NN and/CC the/DT anti-CD3-induced/JJ increases/NNS in/IN AP-1/NN enhancer/NN activity/NN were/VBD blocked/VBN by/IN the/DT presence/NN of/IN PKC/NN inhibitors/NNS or/CC by/IN PKC/NN down-regulation/NN ./. 
These/DT data/NNS indicate/VBP that/IN PLD/NN stimulation/NN can/MD activate/VB the/DT transcription/NN factor/NN AP-1/NN in/IN T/NN lymphocytes/NNS ,/, and/CC suggest/VBP that/IN the/DT induction/NN of/IN AP-1/NN enhancer/NN factor/NN activity/NN by/IN PA/NN is/VBZ mediated/VBN via/IN PKC/NN stimulation/NN ,/, either/CC through/IN a/DT direct/JJ activating/NN effect/NN of/IN PA/NN or/CC through/IN PA-derived/JJ diacylglycerol/NN formation/NN ./. 
These/DT data/NNS also/RB provide/VBP evidence/NN for/IN a/DT role/NN of/IN PLD-derived/JJ lipids/NNS in/IN the/DT induction/NN of/IN AP-1/NN enhancer/NN activity/NN resulting/VBG from/IN stimulation/NN of/IN the/DT TCR/CD3/NN complex/NN ,/, suggesting/VBG that/IN increased/VBN PLD/NN activity/NN can/MD play/VB an/DT important/JJ role/NN in/IN T/NN lymphocyte/NN activation/NN ./. 
UI/LS -/: 94335073/CD 
TI/LS -/: Upregulation/NN of/IN bcl-2/NN by/IN the/DT Epstein-Barr/JJ virus/NN latent/JJ membrane/NN protein/NN LMP1/NN :/: a/DT B-cell-specific/JJ response/NN that/WDT is/VBZ delayed/VBN relative/JJ to/TO NF-kappa/NN B/NN activation/NN and/CC to/TO induction/NN of/IN cell/NN surface/NN markers/NNS ./. 
AB/LS -/: An/DT ability/NN of/IN the/DT Epstein-Barr/JJ virus/NN latent/JJ membrane/NN protein/NN LMP1/NN to/TO enhance/VB the/DT survival/NN of/IN infected/JJ B/NN cells/NNS through/IN upregulation/NN of/IN the/DT bcl-2/NN oncogene/NN was/VBD first/RB suggested/VBN by/IN experiments/NNS involving/VBG gene/NN transfection/NN and/CC the/DT selection/NN of/IN stable/JJ LMP1+/JJ clones/NNS (/( S.Henderson/NNP ,/, M./NNP Rowe/NNP ,/, C.Gregory/NNP ,/, F.Wang/NNP ,/, E.Kieff/NNP ,/, and/CC A.Rickinson/NNP ,/, Cell/NNP 65/CD :/: 1107-1115/CD ,/, 1991/CD )/) ./. 
However/RB ,/, it/PRP was/VBD not/RB possible/JJ to/TO ascertain/VB whether/IN Bcl-2/NN upregulation/NN was/VBD a/DT specific/JJ consequence/NN of/IN LMP1/NN expression/NN or/CC an/DT artifact/NN of/IN the/DT selection/NN procedure/NN whereby/WRB rare/JJ Bcl-2+/JJ cells/NNS already/RB present/JJ in/IN the/DT starting/VBG population/NN might/MD best/RBS be/VB able/JJ to/TO tolerate/VB the/DT potentially/RB toxic/JJ effects/NNS of/IN LMP1/NN ./. 
We/PRP therefore/RB reexamined/VBD this/DT issue/NN by/IN using/VBG two/CD different/JJ experimental/JJ approaches/NNS that/WDT allowed/VBD LMP1-induced/JJ effects/NNS to/TO be/VB monitored/VBN immediately/RB following/VBG expression/NN of/IN the/DT viral/JJ protein/NN and/CC in/IN the/DT absence/NN of/IN selective/JJ pressures/NNS ;/: activation/NN of/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN and/CC upregulation/NN of/IN the/DT cell/NN adhesion/NN molecule/NN ICAM-1/NN were/VBD used/VBN as/IN early/JJ indices/NNS of/IN LMP1/NN function/NN ./. 
In/IN the/DT first/JJ approach/NN ,/, stable/JJ clones/NNS of/IN two/CD B-cell/NN lines/NNS carrying/VBG an/DT LMP1/NN gene/NN under/IN the/DT control/NN of/IN an/DT inducible/JJ metallothionein/NN promoter/NN were/VBD induced/VBN to/TO express/VB LMP1/NN in/IN all/DT cells/NNS ./. 
Activation/NN of/IN NK-kappa/NN B/NN and/CC upregulation/NN of/IN ICAM-1/NN occurred/VBD within/IN 24/CD h/NN and/CC were/VBD followed/VBN at/IN 48/CD to/TO 72/CD h/NN by/IN upregulation/NN of/IN Bcl-2/NN ./. 
In/IN the/DT second/JJ approach/NN ,/, we/PRP tested/VBD the/DT generality/NN of/IN this/DT phenomenon/NN by/IN transiently/RB expressing/VBG LMP1/NN from/IN a/DT strong/JJ constitutively/RB active/JJ promoter/NN in/IN a/DT range/NN of/IN different/JJ cell/NN types/NNS ./. 
All/DT six/CD B-cell/NN lines/NNS tested/VBN showed/VBD NF-kappa/NN B/NN activation/NN in/IN response/NN to/TO LMP1/NN expression/NN ,/, and/CC this/DT was/VBD followed/VBN in/IN five/CD of/IN six/CD lines/NNS by/IN expression/NN of/IN ICAM-1/NN and/CC Bcl-2/NN ./. 
In/IN the/DT same/JJ experiments/NNS ,/, all/DT three/CD non-B-cell/JJ lines/NNS showed/VBD NF-kappa/NN B/NN activation/NN and/CC ICAM-1/NN upregulation/NN but/CC never/RB any/DT effect/NN upon/IN Bcl-2/NN ./. 
We/PRP therefore/RB conclude/VBP that/IN Bcl-2/NN upregulation/NN is/VBZ part/NN of/IN the/DT panoply/NN of/IN cellular/JJ changes/NNS induced/VBN by/IN LMP1/NN but/CC that/IN the/DT effect/NN is/VBZ cell/NN type/NN specific/JJ ./. 
Our/PRP$ data/NNS also/RB suggest/VBP that/IN whilst/IN NF-kappa/NN B/NN may/MD be/VB an/DT essential/JJ component/NN of/IN LMP1/NN signal/NN transduction/NN ,/, other/JJ cell-specific/JJ factors/NNS may/MD be/VB required/VBN to/TO effect/VB some/DT functions/NNS of/IN the/DT viral/JJ protein/NN ./. 
UI/LS -/: 94313679/CD 
TI/LS -/: Long-term/JJ inositol/NN phosphate/NN release/NN ,/, but/CC not/RB tyrosine/NN kinase/NN activity/NN ,/, correlates/VBZ with/IN IL-2/NN secretion/NN and/CC NF-AT/NN induction/NN in/IN anti-CD3-activated/JJ peripheral/JJ human/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT cascade/NN of/IN events/NNS within/IN the/DT first/JJ few/JJ minutes/NNS of/IN T/NN cell/NN stimulation/NN has/VBZ been/VBN well/RB characterized/VBN ./. 
Although/IN many/JJ second/JJ messengers/NNS have/VBP been/VBN shown/VBN to/TO be/VB necessary/JJ and/CC sufficient/JJ for/IN T/NN cell/NN activation/NN in/IN a/DT number/NN of/IN model/NN systems/NNS ,/, the/DT rate-limiting/JJ step/NN in/IN peripheral/JJ T/NN cells/NNS has/VBZ not/RB been/VBN demonstrated/VBN ./. 
To/TO model/VB effective/JJ versus/CC ineffective/JJ CD3-mediated/JJ stimulation/NN in/IN peripheral/JJ T/NN cells/NNS ,/, we/PRP used/VBD two/CD anti-CD3/JJ mAbs/NNS that/WDT differ/VBP in/IN their/PRP$ ability/NN to/TO stimulate/VB purified/VBN T/NN cells/NNS :/: OKT3/NN ,/, which/WDT causes/VBZ early/JJ second/JJ messenger/NN generation/NN but/CC is/VBZ unable/JJ to/TO activate/VB T/NN cells/NNS without/IN a/DT second/JJ signal/NN ,/, and/CC 64.1/CD ,/, which/WDT stimulates/VBZ T/NN cell/NN proliferation/NN on/IN its/PRP$ own/JJ ./. 
We/PRP found/VBD that/IN tyrosine/NN kinase/NN activity/NN was/VBD similar/JJ for/IN both/DT mAbs/NNS over/IN a/DT period/NN of/IN hours/NNS ./. 
However/RB ,/, the/DT inositol/NN phosphate/NN response/NN was/VBD stronger/JJR for/IN 64.1/CD than/IN for/IN OKT3/NN ./. 
To/TO tie/VB these/DT events/NNS to/TO gene/NN activation/NN ,/, we/PRP measured/VBD NF-kappa/NN B/NN and/CC NF-AT/NN activity/NN in/IN the/DT nucleus/NN after/IN anti-CD3/JJ stimulation/NN ./. 
Both/DT stimuli/NNS induced/VBD the/DT appearance/NN of/IN the/DT NF-kappa/NN B/NN components/NNS (/( c-Rel/NN ,/, p65/NN (/( RelA/NN )/) ,/, and/CC p50/NN (/( NF-kappa/NN B1/NN )/) )/) and/CC NF-kappa/NN B/NN DNA/NN binding/NN activity/NN in/IN the/DT nucleus/NN ./. 
However/RB ,/, only/RB 64.1/CD induced/VBD NF-AT/NN in/IN the/DT nucleus/NN ,/, correlating/VBG with/IN its/PRP$ ability/NN to/TO activate/VB T/NN cells/NNS ./. 
Thus/RB ,/, NF-AT/NN induction/NN and/CC IL-2/NN secretion/NN were/VBD correlated/VBN with/IN the/DT levels/NNS of/IN inositol/NN phosphate/NN release/NN but/CC not/RB with/IN gross/JJ levels/NNS of/IN tyrosine/NN kinase/NN activity/NN induced/VBN late/RB following/VBG the/DT response/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, NF-kappa/NN B/NN induction/NN and/CC IL-2/NN receptor/NN expression/NN occurred/VBD even/RB with/IN the/DT smaller/JJR second/JJ messenger/NN response/NN generated/VBN by/IN OKT3/NN ./. 
UI/LS -/: 94289707/CD 
TI/LS -/: HLA-DR-/JJ ,/, CD33+/JJ ,/, CD56+/JJ ,/, CD16-/JJ myeloid/natural/JJ killer/NN cell/NN acute/JJ leukemia/NN :/: a/DT previously/RB unrecognized/JJ form/NN of/IN acute/JJ leukemia/NN potentially/RB misdiagnosed/JJ as/IN French-American-British/JJ acute/JJ myeloid/JJ leukemia-M3/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: We/PRP have/VBP identified/VBN and/CC characterized/VBN a/DT previously/RB unrecognized/JJ form/NN of/IN acute/JJ leukemia/NN that/WDT shares/VBZ features/NNS of/IN both/CC myeloid/JJ and/CC natural/JJ killer/NN (/( NK/NN )/) cells/NNS ./. 
From/IN a/DT consecutive/JJ series/NN of/IN 350/CD cases/NNS of/IN adult/JJ de/FW novo/FW acute/JJ myeloid/JJ leukemia/NN (/( AML/NN )/) ,/, we/PRP identified/VBD 20/CD cases/NNS (/( 6/CD %/NN )/) with/IN a/DT unique/JJ immunophenotype/NN :/: CD33+/JJ ,/, CD56+/JJ ,/, CD11a+/JJ ,/, CD13lo/JJ ,/, CD15lo/JJ ,/, CD34+/-/JJ ,/, HLA-DR-/JJ ,/, CD16-/JJ ./. 
Multicolor/JJ flow/NN cytometric/JJ assays/NNS confirmed/VBD the/DT coexpression/NN of/IN myeloid/JJ (/( CD33/NN ,/, CD13/NN ,/, CD15/NN )/) and/CC NK/NN cell-associated/JJ (/( CD56/NN )/) antigens/NNS in/IN each/DT case/NN ,/, whereas/IN reverse/NN transcription/NN polymerase/NN chain/NN reaction/NN (/( RT-PCR/NN )/) assays/NNS confirmed/VBD the/DT identity/NN of/IN CD56/NN (/( neural/JJ cell/NN adhesion/NN molecule/NN )/) in/IN leukemic/JJ blasts/NNS ./. 
Although/IN two/CD cases/NNS expressed/VBD CD4/NN ,/, no/DT case/NN expressed/VBD CD2/NN ,/, CD3/NN ,/, or/CC CD8/NN and/CC no/DT case/NN showed/VBD clonal/JJ rearrangement/NN of/IN genes/NNS encoding/VBG the/DT T-cell/NN receptor/NN (/( TCR/NN beta/NN ,/, gamma/NN ,/, delta/NN )/) ./. 
Leukemic/JJ blasts/NNS in/IN the/DT majority/NN of/IN cases/NNS shared/VBD unique/JJ morphologic/JJ features/NNS (/( deeply/RB invaginated/JJ nuclear/JJ membranes/NNS ,/, scant/JJ cytoplasm/NN with/IN fine/JJ azurophilic/JJ granularity/NN ,/, and/CC finely/RB granular/JJ Sudan/NN black/JJ B/NN and/CC myeloperoxidase/NN cytochemical/JJ reactivity/NN )/) that/WDT were/VBD remarkably/RB similar/JJ to/TO those/DT of/IN acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) ;/: particularly/RB the/DT microgranular/JJ variant/NN (/( FAB/NN AML-M3v/NN )/) ./. 
However/RB ,/, all/DT 20/CD cases/NNS lacked/VBD the/DT t(15;17)/NN and/CC 17/CD cases/NNS tested/VBN lacked/VBD the/DT promyelocytic/retinoic/JJ acid/NN receptor/NN alpha/NN (/( RAR/NN alpha/NN )/) fusion/NN transcript/NN in/IN RT-PCR/NN assays/NNS ;/: 12/CD cases/NNS had/VBD 46,XX/NN or/CC 46,XY/NN karyotypes/NNS ,/, whereas/IN 2/CD cases/NNS had/VBD abnormalities/NNS of/IN chromosome/NN 17q/NN :/: 1/CD with/IN del(17)(q25)/NN and/CC the/DT other/JJ with/IN t(11;17)(q23;q21)/NN and/CC the/DT promyelocytic/JJ leukemia/NN zinc/NN finger/RAR/NN alpha/NN fusion/NN transcript/NN ./. 
All/DT cases/NNS tested/VBN (/( 6/20/CD )/) ,/, including/VBG the/DT case/NN with/IN t(11;17)/NN ,/, failed/VBD to/TO differentiate/VB in/FW vitro/FW in/IN response/NN to/TO all-trans/JJ retinoic/JJ acid/NN (/( ATRA/NN )/) ,/, suggesting/VBG that/IN these/DT cases/NNS may/MD account/VB for/IN some/DT APLs/NNS that/WDT have/VBP not/RB shown/VBN a/DT clinical/JJ response/NN to/TO ATRA/NN ./. 
Four/CD of/IN 6/CD cases/NNS tested/VBN showed/VBD functional/JJ NK/NN cell-mediated/JJ cytotoxicity/NN ,/, suggesting/VBG a/DT relationship/NN between/IN these/DT unique/JJ CD33+/JJ ,/, CD56+/JJ ,/, CD16-/JJ acute/JJ leukemias/NNS and/CC normal/JJ CD56+/JJ ,/, CD16-/JJ NK/NN precursor/NN cells/NNS ./. 
Using/VBG a/DT combination/NN of/IN panning/NN and/CC multiparameter/NN flow/NN cytometric/JJ sorting/NN ,/, we/PRP identified/VBD a/DT normal/JJ CD56+/JJ ,/, CD33+/JJ ,/, CD16-/JJ counterpart/NN cell/NN at/IN a/DT frequency/NN of/IN 1/CD %/NN to/TO 2/CD %/NN in/IN the/DT peripheral/JJ blood/NN of/IN healthy/JJ individuals/NNS ./. 
Our/PRP$ studies/NNS suggest/VBP that/IN this/DT form/NN of/IN acute/JJ leukemia/NN may/MD arise/VB from/IN transformation/NN of/IN a/DT precursor/NN cell/NN common/JJ to/TO both/CC the/DT myeloid/JJ and/CC NK/NN cell/NN lineages/NNS ;/: thus/RB we/PRP propose/VBP the/DT designation/NN myeloid/NK/JJ acute/JJ leukemia/NN ./. 
Recognition/NN of/IN this/DT new/JJ leukemic/JJ entity/NN will/MD be/VB important/JJ in/IN distinguishing/VBG these/DT ATRA-nonresponsive/JJ cases/NNS from/IN ATRA-responsive/JJ true/JJ APL/NN ./. 
UI/LS -/: 94312466/CD 
TI/LS -/: IL-4/NN down-regulates/VBZ IL-2-/NN ,/, IL-3-/NN ,/, and/CC GM-CSF-induced/JJ cytokine/NN gene/NN expression/NN in/IN peripheral/JJ blood/NN monocytes/NNS ./. 
AB/LS -/: IL-4/NN ,/, a/DT product/NN of/IN the/DT T-helper/NN 0/CD (/( Th0/NN )/) and/CC 2/CD (/( Th2/NN )/) subset/NN ,/, was/VBD originally/RB described/VBN as/IN a/DT B-cell/NN stimulatory/JJ factor/NN and/CC has/VBZ subsequently/RB been/VBN found/VBN to/TO suppress/VB IL-1/NN alpha/NN ,/, IL-1/NN beta/NN ,/, IL-6/NN ,/, IL-8/NN ,/, and/CC TNF-alpha/NN gene/NN expression/NN in/IN monocytes/NNS stimulated/VBN with/IN LPS/NN ,/, and/CC to/TO upregulate/VB IL-1/NN receptor/NN antagonist/NN (/( IL1-RA/NN )/) gene/NN expression/NN ./. 
In/IN this/DT study/NN we/PRP investigated/VBD the/DT effect/NN of/IN IL-4/NN on/IN the/DT expression/NN of/IN cytokine/NN genes/NNS in/IN monocytes/NNS evoked/VBN by/IN other/JJ T-helper/NN cell/NN cytokines/NNS :/: IL-2/NN ,/, IL-3/NN ,/, and/CC GM-CSF/NN ./. 
IL-4/NN down-regulated/VBD mRNA/NN accumulation/NN of/IN the/DT proinflammatory/JJ cytokines/NNS IL-1/NN beta/NN ,/, IL-8/NN ,/, and/CC TNF-alpha/NN in/IN monocytes/NNS stimulated/VBN with/IN IL-2/NN ,/, IL-3/NN ,/, and/CC GM-CSF/NN ./. 
IL-4/NN also/RB suppressed/VBD the/DT IL-2-induced/JJ IL-6/NN mRNA/NN expression/NN ./. 
Temporal/JJ analysis/NN of/IN the/DT IL-4/NN down-regulatory/JJ effect/NN on/IN the/DT IL-2-/NN ,/, IL-3-/NN ,/, or/CC GM-CSF-induced/JJ proinflammatory/JJ cytokine/NN gene/NN expression/NN in/IN monocytes/NNS provided/VBD evidence/NN that/IN IL-4/NN acts/VBZ predominantly/RB on/IN the/DT post-transcriptional/JJ level/NN ./. 
This/DT was/VBD supported/VBN by/IN the/DT observation/NN that/IN the/DT down-regulatory/JJ capacity/NN of/IN IL-4/NN appeared/VBD to/TO be/VB dependent/JJ on/IN de/FW novo/FW protein/NN synthesis/NN ./. 
IL-4/NN did/VBD not/RB exert/VB significant/JJ influence/NN on/IN the/DT induction/NN of/IN expression/NN of/IN IL-1-RA/NN or/CC various/JJ CSFs/NNS by/IN IL-2/NN ,/, IL-3/NN ,/, and/CC GM-CSF/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 94238882/CD 
TI/LS -/: Induction/NN of/IN proto-oncogene/NN and/CC cytokine/NN expression/NN in/IN human/JJ peripheral/JJ blood/NN monocytes/NNS and/CC the/DT monocytic/JJ cell/NN line/NN THP-1/NN after/IN stimulation/NN with/IN mycoplasma-derived/JJ material/NN MDHM/NN ./. 
AB/LS -/: Mycoplasma/NN fermentans-derived/JJ high-molecular-weight/JJ material/NN (/( MDHM/NN )/) was/VBD originally/RB described/VBN to/TO induce/VB differentiation/NN of/IN murine/NN thymocytes/NNS to/TO cytolytic/JJ effector/NN T-cells/NNS by/IN stimulating/VBG IL-6/NN release/NN from/IN adherent/JJ cells/NNS ./. 
This/DT study/NN shows/VBZ that/IN human/JJ peripheral/JJ blood/NN monocytes/NNS (/( PBMo/NN )/) also/RB respond/VBP to/TO MDHM/NN with/IN increases/NNS in/IN IL-1/NN beta/NN ,/, IL-6/NN and/CC TNF/NN alpha/NN expression/NN ,/, both/CC at/IN the/DT mRNA/NN and/CC protein/NN level/NN ./. 
The/DT induced/VBN expression/NN of/IN IL-1/NN beta/NN and/CC TNF/NN alpha/NN mRNA/NN in/IN the/DT monocytic/JJ THP-1/NN cell/NN line/NN increased/VBD as/RB quickly/RB as/IN in/IN primary/JJ cells/NNS ./. 
In/IN contrast/NN to/TO PBMo/NN ,/, THP-1/NN and/CC 14/CD other/JJ monocytic/myeloid/JJ leukemia-derived/JJ cell/NN lines/NNS did/VBD not/RB secrete/VB measurable/JJ amounts/NNS of/IN the/DT cytokines/NNS upon/IN treatment/NN with/IN MDHM/NN ./. 
IL-1/NN beta/NN and/CC IL-6/NN genes/NNS contain/VBP AP-1/NN binding/NN sites/NNS as/IN regulatory/JJ elements/NNS ,/, the/DT AP-1/NN protein/NN being/VBG composed/VBN of/IN c-jun/NN and/CC c-fos/NN gene/NN products/NNS ./. 
In/IN THP-1/NN cells/NNS c-jun/NN mRNA/NN expression/NN increased/VBD after/IN incubation/NN with/IN MDHM/NN while/IN positive/JJ c-fos/NN expression/NN remained/VBD unaffected/JJ ./. 
Although/IN these/DT data/NNS suggest/VBP AP-1/NN regulated/VBD cytokine/NN mRNA/NN expression/NN ,/, results/NNS from/IN PBMo/NN are/VBP not/RB in/IN accordance/NN with/IN this/DT notion/NN ./. 
In/IN the/DT primary/JJ cells/NNS MDHM-induced/JJ elevation/NN of/IN cytokine/NN mRNA/NN levels/NNS was/VBD preceded/VBN by/IN a/DT downregulation/NN of/IN c-fos/NN expression/NN while/IN positive/JJ c-jun/NN expression/NN was/VBD not/RB modulated/VBN ./. 
c-myc/NN mRNA/NN expression/NN ,/, constitutively/RB high/JJ in/IN THP-1/NN cells/NNS ,/, was/VBD induced/VBN in/IN MDHM-stimulated/JJ PBMo/NN ./. 
In/IN conclusion/NN ,/, MDHM-stimulated/JJ induction/NN of/IN cytokine/NN mRNA/NN expression/NN was/VBD accompanied/VBN by/IN different/JJ proto-oncogene/NN responses/NNS in/IN PBMo/NN and/CC THP-1/NN cells/NNS ./. 
These/DT differences/NNS may/MD represent/VB different/JJ regulatory/JJ pathways/NNS of/IN the/DT two/CD cell/NN systems/NNS ./. 
Alternatively/RB ,/, these/DT data/NNS support/VBP the/DT notion/NN that/IN neither/CC AP-1/NN nor/CC the/DT c-myc/NN protein/NN are/VBP involved/VBN in/IN the/DT MDHM-induced/JJ increase/NN in/IN IL-1/NN beta/NN ,/, IL-6/NN or/CC TNF/NN alpha/NN mRNA/NN levels/NNS ./. 
Furthermore/RB ,/, the/DT present/JJ results/NNS demonstrate/VBP clearly/RB that/IN mycoplasma/NN products/NNS can/MD have/VB a/DT profound/JJ impact/NN on/IN the/DT activation/NN status/NN of/IN eukaryotic/JJ cells/NNS ./. 
UI/LS -/: 95003956/CD 
TI/LS -/: Novel/JJ membrane/NN receptors/NNS for/IN aldosterone/NN in/IN human/JJ lymphocytes/NNS :/: a/DT 50/CD kDa/NN protein/NN on/IN SDS-PAGE/NN ./. 
AB/LS -/: Fast/JJ in/FW vitro/FW effects/NNS of/IN aldosterone/NN on/IN the/DT Na+/H(+)-exchanger/NN ,/, inositoltrisphosphate/NN generation/NN and/CC corresponding/VBG specific/JJ binding/NN to/TO plasma/NN membranes/NNS at/IN Kd-values/NNS of/IN approximately/RB 0.1/CD nM/NN have/VBP been/VBN found/VBN in/IN human/JJ mononuclear/JJ leukocytes/NNS and/CC vascular/JJ smooth/JJ muscle/NN cells/NNS ./. 
The/DT novel/JJ aldosterone/NN membrane/NN receptor/NN was/VBD analyzed/VBN on/IN SDS-PAGE/NN after/IN labeling/VBG of/IN microsomal/JJ membranes/NNS from/IN human/JJ mononuclear/JJ leukocytes/NNS with/IN a/DT [125I]-aldosterone-derivative/NN by/IN use/NN of/IN BASED/NN as/IN a/DT photoactivatable/JJ crosslinker/NN ./. 
Binding/NN of/IN 1/CD nM/NN [125I]-aldosterone/NN was/VBD found/VBN at/IN a/DT molecular/JJ weight/NN of/IN approximately/RB 50/CD kDa/NN which/WDT was/VBD absent/JJ with/IN 1/CD microM/NN cold/JJ aldosterone/NN ,/, but/CC not/RB cortisol/NN in/IN the/DT binding/VBG media/NNS ./. 
This/DT aldosterone-selectivity/NN is/VBZ typical/JJ and/CC discriminatory/JJ for/IN the/DT new/JJ aldosterone/NN membrane/NN receptor/NN ./. 
Solubilization/NN of/IN the/DT receptor/NN protein/NN from/IN membranes/NNS by/IN high/JJ salt/NN concentrations/NNS (/( 1/CD M/NN NaCl/NN ,/, 1/CD mM/NN EDTA/NN )/) was/VBD not/RB achieved/VBN ./. 
It/PRP ,/, thus/RB ,/, appears/VBZ as/IN an/DT integral/JJ membrane/NN protein/NN ./. 
Dithiothreitol/NN ,/, a/DT sulfhydryl/NN agent/NN ,/, does/VBZ not/RB reduce/VB specific/JJ aldosterone/NN binding/NN indicating/VBG the/DT absence/NN of/IN SH-groups/NNS in/IN the/DT binding/NN domain/NN or/CC sensitive/JJ structures/NNS of/IN the/DT receptors/NNS ./. 
The/DT results/NNS are/VBP the/DT first/JJ to/TO characterize/VB the/DT novel/JJ membrane/NN receptor/NN for/IN aldosterone/NN with/IN regard/NN to/TO molecular/JJ weight/NN and/CC basic/JJ properties/NNS ./. 
These/DT findings/NNS and/CC other/JJ related/JJ results/NNS are/VBP reviewed/VBN here/RB ./. 
UI/LS -/: 94187105/CD 
TI/LS -/: A/DT transcriptional/JJ regulatory/JJ element/NN is/VBZ associated/VBN with/IN a/DT nuclease-hypersensitive/JJ site/NN in/IN the/DT pol/NN gene/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD ./. 
AB/LS -/: Analysis/NN of/IN the/DT chromatin/NN organization/NN of/IN the/DT integrated/VBN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) genome/NN has/VBZ previously/RB revealed/VBN a/DT major/JJ constitutive/JJ DNase/NN I-hypersensitive/JJ site/NN associated/VBN with/IN the/DT pol/NN gene/NN (/( E/NNP ./. Verdin/NNP ,/, J/NNP ./. Virol/NNP ./. 65/CD :/: 6790-6799/CD ,/, 1991/CD )/) ./. 
In/IN the/DT present/JJ report/NN ,/, high-resolution/JJ mapping/NN of/IN this/DT site/NN with/IN DNase/NN I/CD and/CC micrococcal/JJ nuclease/NN identified/VBD a/DT nucleosome-free/JJ region/NN centered/VBN around/IN nucleotides/NNS (/( nt/NNS )/) 4490/CD to/TO 4766/CD ./. 
A/DT 500-bp/JJ fragment/NN encompassing/VBG this/DT hypersensitive/JJ site/NN (/( nt/NNS 4481/CD to/TO 4982/CD )/) exhibited/VBD transcription-enhancing/JJ activity/NN (/( two-/CD to/TO threefold/JJ )/) when/WRB it/PRP was/VBD cloned/VBN in/IN its/PRP$ natural/JJ position/NN with/IN respect/NN to/TO the/DT HIV-1/NN promoter/NN after/IN transient/JJ transfection/NN in/IN U937/NN and/CC CEM/NN cells/NNS ./. 
Using/VBG in/FW vitro/FW footprinting/NN and/CC gel/NN shift/NN assays/NNS ,/, we/PRP have/VBP identified/VBN four/CD distinct/JJ binding/VBG sites/NNS for/IN nuclear/JJ proteins/NNS within/IN this/DT positive/JJ regulatory/JJ element/NN ./. 
Site/NN B/NN (/( nt/NNS 4519/CD to/TO 4545/CD )/) specifically/RB bound/VBD four/CD distinct/JJ nuclear/JJ protein/NN complexes/NNS :/: a/DT ubiquitous/JJ factor/NN ,/, a/DT T-cell-specific/JJ factor/NN ,/, a/DT B-cell-specific/JJ factor/NN ,/, and/CC the/DT monocyte/macrophage-/NN and/CC B-cell-specific/JJ transcription/NN factor/NN PU.1/Spi-1/NN ./. 
In/IN most/JJS HIV-1/NN isolates/NNS in/IN which/WDT this/DT PU/NN box/NN was/VBD not/RB conserved/VBN ,/, it/PRP was/VBD replaced/VBN by/IN a/DT binding/VBG site/NN for/IN the/DT related/JJ factor/NN Ets1/NN ./. 
Factors/NNS binding/VBG to/TO site/NN C/NN (/( nt/NNS 4681/CD to/TO 4701/CD )/) had/VBD a/DT DNA-binding/JJ specificity/NN similar/JJ to/TO that/DT of/IN factors/NNS binding/VBG to/TO site/NN B/NN ,/, except/IN for/IN PU.1/Spi-1/NN ./. 
A/DT GC/NN box/NN containing/VBG a/DT binding/VBG site/NN for/IN Sp1/NN was/VBD identified/VBN (/( nt/NNS 4623/CD to/TO 4631/CD )/) ./. 
Site/NN D/NN (/( nt/NNS 4816/CD to/TO 4851/CD )/) specifically/RB bound/VBD a/DT ubiquitously/RB expressed/VBN factor/NN ./. 
These/DT results/NNS identify/VBP a/DT transcriptional/JJ regulatory/JJ element/NN associated/VBN with/IN a/DT nuclease-hypersensitive/JJ site/NN in/IN the/DT pol/NN gene/NN of/IN HIV-1/NN and/CC suggest/VBP that/IN its/PRP$ activity/NN may/MD be/VB controlled/VBN by/IN a/DT complex/JJ interplay/NN of/IN cis-regulatory/JJ elements/NNS ./. 
UI/LS -/: 94194029/CD 
TI/LS -/: Expression/NN of/IN v-src/NN in/IN T/NN cells/NNS correlates/VBZ with/IN nuclear/JJ expression/NN of/IN NF-kappa/NN B/NN ./. 
AB/LS -/: NF-kappa/NN B/NN is/VBZ a/DT rapidly/RB inducible/JJ transcriptional/JJ activator/NN that/WDT responds/VBZ to/TO a/DT variety/NN of/IN signals/NNS and/CC influences/VBZ the/DT expression/NN of/IN many/JJ genes/NNS involved/VBN in/IN the/DT immune/JJ response/NN ./. 
Protein/NN tyrosine/NN kinases/NNS transmit/VBP signals/NNS from/IN cytokine/NN and/CC immune/JJ receptors/NNS ./. 
Very/RB little/JJ information/NN exists/VBZ linking/VBG these/DT two/CD important/JJ classes/NNS of/IN signaling/VBG molecules/NNS ./. 
We/PRP now/RB demonstrate/VBP that/IN v-src/NN expression/NN correlates/VBZ with/IN nuclear/JJ expression/NN of/IN a/DT kappa/NN B/NN binding/NN complex/NN similar/JJ to/TO that/DT induced/VBN by/IN phorbol/NN ester/NN and/CC ionomycin/NN ,/, as/IN detected/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN using/VBG a/DT variety/NN of/IN kappa/NN B/NN sites/NNS ./. 
This/DT complex/NN was/VBD blocked/VBN by/IN the/DT tyrosine/NN kinase/NN inhibitor/NN ,/, herbimycin/NN A/NN ./. 
The/DT v-src-induced/JJ complex/NN comprised/VBD the/DT p50/NN and/CC p65/NN components/NNS of/IN NF-kappa/NN B/NN ,/, as/IN determined/VBN by/IN supershift/NN and/CC immunoblot/NN analysis/NN ./. 
As/IN a/DT functional/JJ correlate/NN of/IN this/DT finding/NN ,/, transient/JJ co-transfection/NN of/IN HIV-1/NN LTR/NN reporter/NN constructs/NNS in/IN a/DT different/JJ T/NN cell/NN line/NN demonstrated/VBD that/IN v-src/NN activated/VBD this/DT promoter/NN in/IN a/DT kappa/NN B-dependent/JJ manner/NN ./. 
We/PRP found/VBD that/IN transactivation/NN of/IN the/DT HIV-1/NN LTR/NN by/IN v-src/NN was/VBD more/RBR sensitive/JJ to/TO mutations/NNS of/IN the/DT proximal/NN ,/, rather/RB than/IN the/DT distal/JJ ,/, kappa/NN B/NN element/NN ./. 
The/DT implications/NNS for/IN T/NN cell/NN receptor/NN signaling/NN and/CC HIV-1/NN gene/NN expression/NN are/VBP considered/VBN ./. 
UI/LS -/: 94167865/CD 
TI/LS -/: trans-activation/NN of/IN the/DT HIV/NN promoter/NN by/IN a/DT cDNA/NN and/CC its/PRP$ genomic/JJ clones/NNS of/IN human/JJ herpesvirus-6/NN ./. 
AB/LS -/: Human/JJ herpesvirus/NN 6/CD (/( HHV-6/NN )/) is/VBZ a/DT lymphotropic/JJ herpesvirus/NN ,/, and/CC in/FW vitro/FW ,/, it/PRP can/MD productively/RB infect/VB human/JJ CD4+/JJ T/NN cells/NNS as/IN HIV-1/NN ./. 
Co-infection/NN of/IN T/NN cells/NNS by/IN HIV-1/NN and/CC HHV-6/NN can/MD lead/VB to/TO both/CC activation/NN of/IN the/DT HIV-1/NN promoter/NN and/CC acceleration/NN of/IN the/DT cytopathic/JJ effects/NNS ./. 
An/DT HHV-6/NN (/( GS/NN )/) cDNA/NN clone/NN ,/, pCD41/NN ,/, encoding/VBG for/IN a/DT 41-kDa/JJ nuclear/JJ protein/NN was/VBD identified/VBN and/CC characterized/VBN previously/RB (/( Chang/NNP and/CC Balachandran/NNP ,/, J./NNP Virol/NNP ./. 65/CD ,/, 2884-2894/CD and/CC 7085/CD ,/, 1991/CD )/) ./. 
Sequence/NN analyses/NNS show/VBP that/IN this/DT protein/NN has/VBZ significant/JJ homology/NN with/IN the/DT human/JJ cytomegalovirus/NN UL44/NN gene/NN coding/VBG for/IN the/DT ICP36/NN family/NN of/IN early-late-class/JJ phosphoprotein/NN ./. 
Using/VBG this/DT cDNA/NN as/IN the/DT probe/NN ,/, a/DT 3.8-kb/JJ EcoRI/NN genomic/JJ fragment/NN encoding/VBG the/DT HHV-6/NN (/( GS/NN )/) P41/NN was/VBD cloned/VBN and/CC designated/VBN as/IN pGD41/NN ./. 
When/WRB cotransfected/VBN with/IN the/DT HIV/NN LTR/NN CAT/NN into/IN CV-1/NN cells/NNS ,/, both/CC the/DT pCD41/NN and/CC pGD41/NN clones/NNS trans-activated/VBD the/DT HIV/NN LTR/NN ./. 
Sequence/NN analyses/NNS of/IN pCD41/NN indicate/VBP that/IN there/EX are/VBP two/CD potential/JJ open/JJ reading/NN frames/NNS (/( ORFs/NNS )/) ,/, A/NN and/CC B/NN ,/, which/WDT are/VBP homologous/JJ to/TO the/DT ORFs/NNS found/VBN in/IN the/DT genomic/JJ clone/NN pGD41/NN ./. 
Deletion/NN constructs/NNS of/IN the/DT pCD41/NN clone/NN demonstrated/VBD that/IN ORF-A/NN was/VBD critical/JJ for/IN the/DT HIV/NN LTR/NN activation/NN ./. 
Deletion/NN analyses/NNS of/IN the/DT pCD41/NN ORF-A/NN and/CC the/DT use/NN of/IN promoter/NN constructs/NNS further/RB mapped/VBD an/DT internal/JJ functional/JJ promoter/NN within/IN the/DT pCD41/NN sequence/NN that/WDT can/MD direct/VB the/DT synthesis/NN of/IN the/DT trans-activating/JJ protein/NN ./. 
By/IN using/VBG HIV/NN LTR/NN deletion/NN mutants/NNS ,/, the/DT NF-kappa/NN B/NN binding/NN sites/NNS were/VBD found/VBN to/TO be/VB critical/JJ for/IN response/NN to/TO the/DT pCD41/NN trans-activation/NN ./. 
UI/LS -/: 94350980/CD 
TI/LS -/: CD14-mediated/JJ translocation/NN of/IN nuclear/JJ factor-kappa/NN B/NN induced/VBN by/IN lipopolysaccharide/NN does/VBZ not/RB require/VB tyrosine/NN kinase/NN activity/NN ./. 
AB/LS -/: During/IN the/DT course/NN of/IN serious/JJ bacterial/JJ infections/NNS ,/, lipopolysaccharide/NN (/( LPS/NN )/) is/VBZ believed/VBN to/TO interact/VB with/IN macrophage/NN receptors/NNS ,/, resulting/VBG in/IN the/DT generation/NN of/IN inflammatory/JJ mediators/NNS and/CC systemic/JJ symptoms/NNS including/VBG hemodynamic/JJ instability/NN and/CC shock/NN ./. 
CD14/NN ,/, a/DT glycosylphosphatidylinositol-linked/JJ antigen/NN ,/, functions/VBZ as/IN an/DT LPS/NN signaling/NN receptor/NN ./. 
A/DT critical/JJ issue/NN concerns/VBZ the/DT mechanism/NN by/IN which/WDT CD14/NN ,/, which/WDT has/VBZ no/DT transmembrane/NN domain/NN ,/, transduces/VBZ its/PRP$ signal/NN following/VBG LPS/NN binding/NN ./. 
Recently/RB ,/, investigators/NNS have/VBP hypothesized/VBN that/IN CD14-mediated/JJ signaling/NN is/VBZ effected/VBN through/IN a/DT receptor-associated/JJ tyrosine/NN kinase/NN (/( TK/NN )/) ,/, suggesting/VBG a/DT multicomponent/JJ receptor/NN model/NN of/IN LPS/NN signaling/NN ./. 
Wild-type/JJ Chinese/JJ hamster/NN ovary/NN (/( CHO/NN )/) -K1/NN cells/NNS can/MD be/VB activated/VBN by/IN endotoxin/NN to/TO release/VB arachidonate/NN following/VBG transfection/NN with/IN human/JJ CD14/NN (/( CHO/CD14/NN )/) ./. 
Nuclear/JJ translocation/NN of/IN cytosolic/JJ NF-kappa/NN B/NN is/VBZ correlated/VBN with/IN a/DT number/NN of/IN LPS-inducible/JJ responses/NNS ./. 
We/PRP sought/VBD to/TO determine/VB if/IN this/DT pathway/NN were/VBD present/JJ in/IN CHO/CD14/NN cells/NNS and/CC to/TO elucidate/VB the/DT relationship/NN of/IN NF-kappa/NN B/NN activation/NN to/TO the/DT CD14/NN receptor/NN system/NN ./. 
LPS-stimulated/JJ translocation/NN of/IN NF-kappa/NN B/NN in/IN CHO/CD14/NN cells/NNS resembled/VBD the/DT same/JJ response/NN in/IN the/DT murine/NN macrophage-like/JJ cell/NN line/NN RAW/NN 264.7/CD ./. 
Protein/NN synthesis/NN inhibitors/NNS and/CC corticosteroids/NNS ,/, which/WDT suppress/VBP arachidonate/NN release/NN and/CC the/DT synthesis/NN of/IN proinflammatory/JJ cytokines/NNS ,/, had/VBD no/DT effect/NN on/IN translocation/NN of/IN NF-kappa/NN B/NN in/IN CHO/CD14/NN or/CC RAW/NN 264.7/CD cells/NNS ,/, demonstrating/VBG that/IN NF-kappa/NN B/NN translocation/NN is/VBZ an/DT early/JJ event/NN ./. 
Although/IN TK/NN activity/NN was/VBD consistently/RB observed/VBN by/IN immunoblotting/VBG extracts/NNS from/IN activated/VBN RAW/NN 264.7/CD cells/NNS ,/, LPS-induced/JJ phosphotyrosine/NN residues/NNS were/VBD not/RB observed/VBN from/IN similarly/RB treated/VBN CHO/CD14/NN cells/NNS ./. 
Furthermore/RB ,/, the/DT TK/NN inhibitors/NNS herbimycin/NN A/NN and/CC genistein/NN failed/VBD to/TO inhibit/VB translocation/NN of/IN NF-kappa/NN B/NN in/IN CHO/CD14/NN or/CC RAW/NN 264.7/CD cells/NNS ,/, although/IN both/DT of/IN these/DT agents/NNS inhibited/VBD LPS-induced/JJ TK/NN activity/NN in/IN RAW/NN 264.7/CD cells/NNS ./. 
These/DT results/NNS imply/VBP that/IN TK/NN activity/NN is/VBZ not/RB obligatory/JJ for/IN CD14-mediated/JJ signal/JJ transduction/NN to/TO occur/VB in/IN response/NN to/TO LPS/NN ./. 
UI/LS -/: 94354848/CD 
TI/LS -/: Signals/NNS transduced/VBN through/IN the/DT CD4/NN molecule/NN on/IN T/NN lymphocytes/NNS activate/VBP NF-kappa/NN B/NN ./. 
AB/LS -/: We/PRP have/VBP demonstrated/VBN that/IN native/JJ envelope/NN glycoproteins/NNS of/IN HIV-1/NN ,/, gp160/NN can/MD induce/VB activation/NN of/IN the/DT transcription/NN factor/NN ,/, NF-kappa/NN B/NN ./. 
The/DT stimulatory/JJ effects/NNS of/IN gp160/NN are/VBP mediated/VBN through/IN the/DT CD4/NN molecule/NN ,/, since/IN pretreatment/NN with/IN soluble/JJ CD4/NN abrogates/VBZ its/PRP$ activity/NN ./. 
The/DT gp160-induced/JJ NF-kappa/NN B/NN complex/NN consists/VBZ of/IN p65/NN ,/, p50/NN and/CC c-rel/NN proteins/NNS ./. 
The/DT stimulatory/JJ effect/NN of/IN gp160/NN on/IN NF-kappa/NN B/NN activation/NN is/VBZ protein/NN synthesis/NN independent/JJ ,/, is/VBZ dependent/JJ upon/IN protein/NN tyrosine/NN phosphorylation/NN ,/, and/CC abrogated/VBN by/IN inhibitors/NNS of/IN protein/NN kinase/NN C/NN ./. 
The/DT gp160-mediated/JJ activation/NN of/IN NF-kappa/NN B/NN in/IN CD4/NN positive/JJ T/NN cells/NNS may/MD be/VB involved/VBN in/IN biological/JJ effects/NNS ,/, e.g./FW ,/, enhanced/VBN HIV/NN replication/NN ,/, hypergammaglobulinemia/NN ,/, increased/VBN cytokine/NN secretion/NN ,/, hypercellularity/NN in/IN bone/NN marrow/NN and/CC apoptosis/NN ./. 
UI/LS -/: 95081342/CD 
TI/LS -/: No/DT evidence/NN for/IN the/DT expression/NN of/IN the/DT progesterone/NN receptor/NN on/IN peripheral/JJ blood/NN lymphocytes/NNS during/IN pregnancy/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: The/DT expression/NN of/IN the/DT progesterone/NN receptor/NN in/IN human/JJ peripheral/JJ blood/NN lymphocytes/NNS was/VBD analysed/VBN ,/, using/VBG an/DT enzyme/NN linked/JJ immunosorbent/JJ assay/NN (/( Abbott/NN PgR-EIA/NN monoclonal/JJ )/) ,/, in/IN order/NN to/TO evaluate/VB its/PRP$ prognostic/JJ character/NN in/IN the/DT context/NN of/IN spontaneous/JJ abortion/NN ./. 
Cytosols/NNS were/VBD prepared/VBN from/IN lymphocytes/NNS of/IN 24/CD healthy/JJ pregnant/JJ women/NNS (/( 11/CD first/JJ ,/, 10/CD second/JJ and/CC three/CD third/JJ trimester/NN )/) ,/, seven/CD healthy/JJ non-pregnant/JJ women/NNS ,/, nine/CD women/NNS with/IN recurrent/JJ spontaneous/JJ abortion/NN ,/, and/CC six/CD healthy/JJ men/NNS ./. 
In/IN addition/NN ,/, a/DT human/JJ breast/NN carcinoma/NN cell/NN line/NN (/( ZR-75-1/NN )/) ,/, which/WDT expresses/VBZ the/DT progesterone/NN receptor/NN ,/, was/VBD analysed/VBN throughout/RB ./. 
The/DT ZR-75-1/NN cell/NN line/NN showed/VBD an/DT expression/NN of/IN 642/CD fmol/mg/NN whereas/IN lymphocytes/NNS of/IN pregnant/JJ women/NNS showed/VBD an/DT expression/NN </JJR or/CC =/JJ 4/CD fmol/mg/NN ./. 
Lymphocytes/NNS of/IN non-pregnant/JJ women/NNS ,/, women/NNS with/IN threatened/VBN pre-term/JJ delivery/NN ,/, and/CC men/NNS showed/VBD equivalent/JJ levels/NNS :/: 3/CD +/-/CC 1/CD ,/, 3/CD +/-/CC 2/CD and/CC 5/CD +/-/CC 4/CD fmol/mg/NN respectively/RB ./. 
These/DT results/NNS show/VBP that/IN there/EX is/VBZ no/DT evidence/NN of/IN specific/JJ expression/NN of/IN the/DT progesterone/NN receptor/NN in/IN pregnancy/NN and/CC exclude/VBP any/DT prognostic/JJ character/NN in/IN spontaneous/JJ abortion/NN ./. 
A/DT role/NN for/IN the/DT progesterone/NN receptor/NN in/IN the/DT mechanism/NN of/IN the/DT known/JJ effect/NN of/IN progesterone/NN on/IN peripheral/JJ blood/NN lymphocytes/NNS is/VBZ also/RB excluded/VBN ./. 
UI/LS -/: 94274683/CD 
TI/LS -/: Tolerance/NN to/TO lipopolysaccharide/NN involves/VBZ mobilization/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN with/IN predominance/NN of/IN p50/NN homodimers/NNS ./. 
AB/LS -/: Stimulation/NN of/IN the/DT human/JJ monocytic/JJ cell/NN line/NN Mono/NN Mac/NN 6/CD with/IN lipopolysaccharide/NN (/( LPS/NN )/) leads/VBZ to/TO rapid/JJ and/CC transient/JJ expression/NN of/IN cytokines/NNS like/IN tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) ./. 
When/WRB such/JJ cells/NNS are/VBP precultured/VBN for/IN 2/CD days/NNS with/IN a/DT low/JJ dose/NN of/IN LPS/NN (/( 20/CD ng/ml/NN )/) followed/VBN by/IN stimulation/NN with/IN a/DT high/JJ dose/NN of/IN LPS/NN (/( 1/CD microgram/ml/NN )/) ,/, expression/NN of/IN the/DT TNF/NN gene/NN is/VBZ minimal/JJ ,/, i.e./FW the/DT cells/NNS are/VBP tolerant/JJ ./. 
In/IN nuclear/JJ run-on/JJ analysis/NN ,/, such/JJ tolerant/JJ cells/NNS show/VBP only/RB a/DT low/JJ degree/NN of/IN transcription/NN ,/, indicating/VBG that/IN tolerance/NN operates/VBZ at/IN or/CC upstream/RB of/IN the/DT transcription/NN level/NN ./. 
The/DT CD14/NN LPS/NN receptor/NN is/VBZ ,/, however/RB ,/, up-regulated/VBN (/( not/RB down-regulated/VBN )/) in/IN tolerant/JJ cells/NNS ,/, and/CC LPS/NN can/MD ,/, in/IN fact/NN ,/, still/RB lead/VB to/TO activation/NN of/IN tolerant/JJ cells/NNS as/IN evidenced/VBN by/IN mobilization/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ./. 
Resolution/NN of/IN the/DT NF-kappa/NN B/NN complex/NN in/IN gel/NN shift/NN analysis/NN shows/VBZ that/IN the/DT binding/VBG protein/NN ,/, mobilized/VBN in/IN naive/JJ Mono/NN Mac/NN 6/CD cells/NNS ,/, consists/VBZ mainly/RB of/IN p50-p65/NN heterodimers/NNS ,/, while/IN in/IN tolerant/JJ cells/NNS ,/, the/DT p50/NN homodimer/NN is/VBZ predominant/JJ ./. 
This/DT increase/NN in/IN p50/NN homodimers/NNS coincides/VBZ with/IN an/DT increase/NN in/IN p105/NN mRNA/NN ,/, suggestive/JJ of/IN a/DT transcriptional/JJ up-regulation/NN of/IN p50/NN ./. 
Reporter/NN gene/NN analysis/NN reveals/VBZ that/IN the/DT NF-kappa/NN B/NN complex/NN mobilized/VBN in/IN tolerant/JJ cells/NNS is/VBZ functionally/RB inactive/JJ in/IN that/IN NF-kappa/NN B-dependent/JJ luciferase/NN constructs/NNS containing/VBG the/DT human/JJ immunodeficiency/NN virus/NN long/JJ terminal/JJ repeat/NN or/CC the/DT TNF/NN 5'-region/NN show/VBP only/RB minimal/JJ transactivation/NN after/IN LPS/NN stimulation/NN ./. 
Similar/JJ to/TO Mono/NN Mac/NN 6/CD cells/NNS ,/, primary/JJ blood/NN monocytes/NNS ,/, when/WRB precultured/VBN with/IN a/DT low/JJ dose/NN of/IN LPS/NN ,/, also/RB become/VBP tolerant/JJ and/CC produce/VBP little/JJ TNF/NN after/IN LPS/NN stimulation/NN ./. 
The/DT tolerant/JJ blood/NN monocytes/NNS also/RB up-regulate/VBP CD14/NN ,/, and/CC they/PRP mobilize/VBP NF-kappa/NN B/NN with/IN a/DT predominance/NN of/IN p50/NN homodimers/NNS ./. 
Taken/VBN together/RB ,/, these/DT results/NNS demonstrate/VBP that/IN tolerance/NN to/TO LPS/NN is/VBZ determined/VBN by/IN post-receptor/JJ mechanisms/NNS that/WDT involve/VBP an/DT altered/JJ composition/NN of/IN the/DT NF-kappa/NN B/NN complex/NN ./. 
UI/LS -/: 94278430/CD 
TI/LS -/: Analysis/NN of/IN Oct2-isoform/JJ expression/NN in/IN lipopolysaccharide-stimulated/JJ B/NN lymphocytes/NNS ./. 
AB/LS -/: Oct2-isoform/JJ expression/NN in/IN splenic/JJ B/NN cells/NNS stimulated/VBN with/IN lipopolysaccharide/NN or/CC lipopolysaccharide/NN plus/CC phorbol-di-butyrate/NN was/VBD analysed/VBN by/IN cDNA/NN cloning/NN ./. 
The/DT frequency/NN of/IN Oct2-positive/JJ clones/NNS was/VBD 1/15,000/CD in/IN both/DT libraries/NNS ./. 
Two/CD new/JJ isoforms/NNS were/VBD found/VBN that/WDT generate/VBP novel/JJ amino-/NN or/CC carboxy-terminal/JJ sequences/NNS ./. 
An/DT isoform/NN lacking/VBG exon/NN 11/CD destroyed/VBD the/DT carboxy-terminal/JJ leucin-zipper/NN region/NN and/CC introduced/VBD a/DT frame/NN shift/NN creating/VBG a/DT novel/JJ ,/, proline-rich/JJ carboxy/NN terminus/NN ./. 
A/DT new/JJ exon/NN containing/VBG a/DT highly/RB basic/JJ region/NN (/( 4c/NN )/) was/VBD characterized/VBN ,/, between/IN exons/NNS 4/CD and/CC 5/CD ./. 
This/DT exon/NN was/VBD inserted/VBN between/IN glutamine-rich/JJ regions/NNS 2/CD and/CC 3/CD ,/, carboxy/JJ terminal/NN of/IN a/DT tentative/JJ leucine-zipper/NN structure/NN ./. 
In/IN addition/NN ,/, a/DT new/JJ combination/NN isoform/NN containing/VBG Oct2a/NN 's/POS amino/NN terminal/JJ insert/NN (/( exon/NN 7a/NN )/) and/CC Oct2b/NN 's/POS carboxy/NN terminal/JJ insert/NN (/( exon/NN 13/CD )/) was/VBD found/VBN that/WDT created/VBD a/DT novel/JJ large/JJ isoform/NN ,/, Oct2ab/NN ./. 
More/RBR frequent/JJ use/NN of/IN the/DT classical/JJ Oct2a/NN and/CC Oct2b/NN isoforms/NNS was/VBD observed/VBN in/IN the/DT lipopolysaccharide-stimulated/JJ B/NN cells/NNS ,/, while/IN a/DT preference/NN for/IN the/DT Oct2ab/NN and/CC Oct2ba/NN isoforms/NNS was/VBD observed/VBN in/IN lipopolysaccharide/NN plus/CC phorbol-di-butyrate-treated/JJ cells/NNS ./. 
UI/LS -/: 94217708/CD 
TI/LS -/: Positive/JJ regulators/NNS of/IN the/DT lineage-specific/JJ transcription/NN factor/NN GATA-1/NN in/IN differentiating/JJ erythroid/JJ cells/NNS ./. 
AB/LS -/: The/DT zinc/NN finger/NN transcription/NN factor/NN GATA-1/NN is/VBZ a/DT major/JJ regulator/NN of/IN gene/NN expression/NN in/IN erythroid/JJ ,/, megakaryocyte/NN ,/, and/CC mast/NN cell/NN lineages/NNS ./. 
GATA-1/NN binds/VBZ to/TO WGATAR/NN consensus/NN motifs/NNS in/IN the/DT regulatory/JJ regions/NNS of/IN virtually/RB all/DT erythroid/JJ cell-specific/JJ genes/NNS ./. 
Analyses/NNS with/IN cultured/VBN cells/NNS and/CC cell-free/JJ systems/NNS have/VBP provided/VBN strong/JJ evidence/NN that/IN GATA-1/NN is/VBZ involved/VBN in/IN control/NN of/IN globin/NN gene/NN expression/NN during/IN erythroid/JJ differentiation/NN ./. 
Targeted/VBN mutagenesis/NN of/IN the/DT GATA-1/NN gene/NN in/IN embryonic/JJ stem/NN cells/NNS has/VBZ demonstrated/VBN its/PRP$ requirement/NN in/IN normal/JJ erythroid/JJ development/NN ./. 
Efficient/JJ rescue/NN of/IN the/DT defect/NN requires/VBZ an/DT intact/JJ GATA/NN element/NN in/IN the/DT distal/JJ promoter/NN ,/, suggesting/VBG autoregulatory/JJ control/NN of/IN GATA-1/NN transcription/NN ./. 
To/TO examine/VB whether/IN GATA-1/NN expression/NN involves/VBZ additional/JJ regulatory/JJ factors/NNS or/CC is/VBZ maintained/VBN entirely/RB by/IN an/DT autoregulatory/JJ loop/NN ,/, we/PRP have/VBP used/VBN a/DT transient/JJ heterokaryon/NN system/NN to/TO test/VB the/DT ability/NN of/IN erythroid/JJ factors/NNS to/TO activate/VB the/DT GATA-1/NN gene/NN in/IN nonerythroid/JJ nuclei/NNS ./. 
We/PRP show/VBP here/RB that/IN proerythroblasts/NNS and/CC mature/JJ erythroid/JJ cells/NNS contain/VBP a/DT diffusible/JJ activity/NN (/( TAG/NN )/) capable/JJ of/IN transcriptional/JJ activation/NN of/IN GATA-1/NN and/CC that/IN this/DT activity/NN decreases/VBZ during/IN the/DT terminal/JJ differentiation/NN of/IN erythroid/JJ cells/NNS ./. 
Nuclei/NNS from/IN GATA-1-mutant/JJ embryonic/JJ stem/NN cells/NNS can/MD still/RB be/VB reprogrammed/VBN to/TO express/VB their/PRP$ globin/NN genes/NNS in/IN erythroid/JJ heterokaryons/NNS ,/, indicating/VBG that/IN de/FW novo/FW induction/NN of/IN GATA-1/NN is/VBZ not/RB required/VBN for/IN globin/NN gene/NN activation/NN following/VBG cell/NN fusion/NN ./. 
UI/LS -/: 95000924/CD 
TI/LS -/: Role/NN of/IN HIV-1/NN Nef/NN expression/NN in/IN activation/NN pathways/NNS in/IN CD4+/JJ T/NN cells/NNS ./. 
AB/LS -/: The/DT role/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN (/( HIV-1/NN )/) Nef/NN protein/NN in/IN T/NN cell/NN activation/NN pathways/NNS was/VBD investigated/VBN using/VBG a/DT Jurkat/NN CD4+/JJ cell/NN line/NN stably/RB transfected/VBN with/IN a/DT Nef/NN expression/NN vector/NN ./. 
Secretion/NN of/IN IL-2/NN and/CC TNF-alpha/NN ,/, surface/NN expression/NN of/IN IL-2R/NN ,/, and/CC DNA-binding/JJ activity/NN of/IN NF-kappa/NN B/NN and/CC AP-1/NN (/( Fos/Jun/NN )/) complex/NN in/IN response/NN to/TO phorbol/NN myristate/NN acetate/NN ,/, TNF-alpha/NN ,/, or/CC immobilized/VBN antibodies/NNS to/TO CD3/NN were/VBD monitored/VBN ./. 
These/DT parameters/NNS were/VBD not/RB modified/VBN by/IN Nef/NN expression/NN in/IN Jurkat/NN cells/NNS ,/, whereas/IN stimulation/NN with/IN the/DT same/JJ stimuli/NNS resulted/VBD in/IN partial/JJ inhibition/NN of/IN LTR/NN activation/NN in/IN Nef+/JJ Jurkat/NN cells/NNS ./. 
This/DT inhibition/NN was/VBD not/RB mediated/VBN through/IN Nef/NN phosphorylation/NN on/IN Thr-15/NN or/CC GTP-binding/JJ activity/NN because/IN mutations/NNS in/IN critical/JJ sites/NNS did/VBD not/RB alter/VB this/DT inhibition/NN ./. 
Analysis/NN of/IN truncated/VBN LTRs/NNS confirmed/VBD that/IN inhibition/NN of/IN LTR/NN activation/NN was/VBD not/RB mediated/VBN through/IN NF-kappa/NN B-binding/JJ activity/NN but/CC through/IN the/DT region/NN containing/VBG the/DT negative/JJ responding/VBG elements/NNS (/( NREs/NNS )/) ./. 
These/DT results/NNS suggest/VBP that/IN Nef/NN downmodulates/VBZ LTR/NN activation/NN without/IN significantly/RB inhibiting/VBG the/DT capacity/NN of/IN T/NN cells/NNS to/TO respond/VB to/TO immunological/JJ activations/NNS ./. 
UI/LS -/: 94338582/CD 
TI/LS -/: Tat-binding/JJ protein/NN 7/CD is/VBZ a/DT subunit/NN of/IN the/DT 26S/NN protease/NN ./. 
AB/LS -/: Subunit/NN 6/CD (/( S6/NN )/) ,/, an/DT integral/JJ component/NN of/IN the/DT 26S/NN protease/NN from/IN human/JJ erythrocytes/NNS ,/, has/VBZ been/VBN studied/VBN by/IN SDS-PAGE/NN ,/, peptide/NN mapping/NN and/CC sequence/NN analysis/NN ./. 
S6/NN was/VBD cleaved/VBN with/IN CNBr/NN and/CC three/CD internal/JJ peptides/NNS were/VBD sequenced/VBN ./. 
A/DT comparison/NN with/IN known/JJ proteins/NNS in/IN Genbank/NNP revealed/VBD that/IN all/DT three/CD S6/NN peptides/NNS match/VBP the/DT predicted/VBN sequence/NN of/IN TBP7/NN ,/, Tat-binding/JJ protein/NN 7/CD ./. 
Based/VBN on/IN peptide/NN matches/NNS covering/VBG more/JJR than/IN 10/CD %/NN of/IN the/DT TBP7/NN sequence/NN ,/, and/CC the/DT fact/NN that/IN the/DT migration/NN of/IN S6/NN on/IN SDS-PAGE/NN is/VBZ consistent/JJ with/IN the/DT estimated/VBN molecular/JJ mass/NN for/IN TBP7/NN ,/, we/PRP conclude/VBP that/IN subunit/NN 6/CD of/IN the/DT 26S/NN protease/NN is/VBZ TBP7/NN ./. 
UI/LS -/: 94184956/CD 
TI/LS -/: Hypoxia/NN causes/VBZ the/DT activation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN through/IN the/DT phosphorylation/NN of/IN I/NN kappa/NN B/NN alpha/NN on/IN tyrosine/NN residues/NNS ./. 
AB/LS -/: The/DT response/NN of/IN mammalian/JJ cells/NNS to/TO stress/NN is/VBZ controlled/VBN by/IN transcriptional/JJ regulatory/JJ proteins/NNS such/JJ as/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) to/TO induce/VB a/DT wide/JJ variety/NN of/IN early/JJ response/NN genes/NNS ./. 
In/IN this/DT report/NN ,/, we/PRP show/VBP that/IN exposure/NN of/IN cells/NNS to/TO hypoxia/NN (/( 0.02/CD %/NN O2/CD )/) results/VBZ in/IN I/NN kappa/NN B/NN alpha/NN degradation/NN ,/, increased/VBN NF-kappa/NN B/NN DNA/NN binding/NN activity/NN ,/, and/CC transactivation/NN of/IN a/DT reporter/NN gene/NN construct/NN containing/VBG two/CD NF-kappa/NN B/NN DNA/NN binding/NN sites/NNS ./. 
Pretreatment/NN of/IN cells/NNS with/IN protein/NN tyrosine/NN kinase/NN inhibitors/NNS and/CC the/DT dominant/JJ negative/JJ allele/NN of/IN c-Raf-1/NN (/( Raf/NN 301/CD )/) inhibited/VBD I/NN kappa/NN B/NN alpha/NN degradation/NN ,/, NF-kappa/NN B/NN binding/NN ,/, and/CC transactivation/NN of/IN kappa/NN B/NN reporter/NN constructs/NNS by/IN hypoxia/NN ./. 
To/TO demonstrate/VB a/DT direct/JJ link/NN between/IN changes/NNS in/IN the/DT phosphorylation/NN pattern/NN of/IN I/NN kappa/NN B/NN alpha/NN with/IN NF-kappa/NN B/NN activation/NN ,/, we/PRP immunoprecipitated/VBD I/NN kappa/NN B/NN alpha/NN after/IN varying/VBG times/NNS of/IN hypoxic/JJ exposure/NN and/CC found/VBD that/IN its/PRP$ tyrosine/NN phosphorylation/NN status/NN increased/VBD during/IN hypoxic/JJ exposure/NN ./. 
Inhibition/NN of/IN the/DT transfer/NN of/IN tyrosine/NN phosphoryl/NN groups/NNS onto/IN I/NN kappa/NN B/NN alpha/NN prevented/VBD I/NN kappa/NN B/NN alpha/NN degradation/NN and/CC NF-kappa/NN B/NN binding/NN ./. 
In/IN comparison/NN to/TO other/JJ activators/NNS of/IN NF-kappa/NN B/NN such/JJ as/IN phorbol/NN myristate/NN acetate/NN or/CC tumor/NN necrosis/NN factor/NN ,/, we/PRP did/VBD not/RB detect/VB changes/NNS in/IN the/DT tyrosine/NN phosphorylation/NN status/NN of/IN I/NN kappa/NN B/NN alpha/NN following/VBG treatment/NN with/IN either/DT of/IN these/DT agents/NNS ./. 
These/DT results/NNS suggest/VBP that/IN tyrosine/NN phosphorylation/NN of/IN I/NN kappa/NN B/NN alpha/NN during/IN hypoxia/NN is/VBZ an/DT important/JJ proximal/JJ step/NN which/WDT precedes/VBZ its/PRP$ dissociation/NN and/CC degradation/NN from/IN NF-kappa/NN B/NN ./. 
UI/LS -/: 94151007/CD 
TI/LS -/: Overproduction/NN of/IN NFKB2/NN (/( lyt-10/NN )/) and/CC c-Rel/NN :/: a/DT mechanism/NN for/IN HTLV-I/NN Tax-mediated/JJ trans-activation/NN via/IN the/DT NF-kappa/NN B/NN signalling/NN pathway/NN ./. 
AB/LS -/: Molecular/JJ ,/, biochemical/JJ and/CC epidemiological/JJ evidence/NN implicate/VBP HTLV-I/NN as/IN an/DT etiologic/JJ agent/NN of/IN adult/JJ T/NN cell/NN leukemia/NN (/( ATL/NN )/) ./. 
The/DT Tax/NN protein/NN of/IN HTLV-I/NN ,/, a/DT positive/JJ transcriptional/JJ activator/NN of/IN HTLV-I/NN gene/NN expression/NN ,/, is/VBZ a/DT viral/JJ oncogene/NN that/WDT also/RB increases/VBZ transcription/NN of/IN cellular/JJ genes/NNS including/VBG GM-CSF/NN ,/, IL-2R/NN alpha/NN and/CC IL-2/NN ./. 
One/CD of/IN the/DT cellular/JJ targets/NNS of/IN the/DT trans-activating/JJ effects/NNS of/IN Tax/NN is/VBZ the/DT NF-kappa/NN B/Rel/NN family/NN of/IN transcription/NN factors/NNS ,/, pleiotropic/JJ regulators/NNS of/IN immunoregulatory/JJ ,/, cytokine/NN and/CC viral/JJ gene/NN expression/NN ./. 
In/IN this/DT report/NN ,/, we/PRP demonstrate/VBP that/IN NFKB2/NN (/( lyt-10/NN )/) and/CC c-Rel/NN are/VBP overexpressed/VBN in/IN HTLV-I/NN infected/JJ and/CC Tax-expressing/JJ cells/NNS and/CC ,/, together/RB ,/, account/VBP for/IN the/DT majority/NN of/IN the/DT constitutive/JJ NF-kappa/NN B/NN binding/NN activity/NN in/IN these/DT cells/NNS before/IN and/CC after/IN PMA/NN stimulation/NN ./. 
Most/RBS importantly/RB ,/, we/PRP show/VBP a/DT Tax-dependent/JJ correlation/NN between/IN expression/NN of/IN NFKB2/NN (/( p100/NN )/) and/CC processing/NN to/TO the/DT DNA/NN binding/NN NFKB2/NN (/( p52/NN )/) form/NN ,/, induction/NN of/IN c-Rel/NN ,/, and/CC trans-activation/NN of/IN NF-kappa/NN B-mediated/JJ gene/NN expression/NN ./. 
Furthermore/RB ,/, the/DT NFKB2/NN precursor/NN is/VBZ physically/RB associated/VBN with/IN c-Rel/NN and/CC with/IN Tax/NN in/NN HTLV-I/NN infected/JJ cells/NNS ./. 
We/PRP propose/VBP that/IN NFKB2/NN synthesis/NN and/CC processing/NN allows/VBZ continuous/JJ nuclear/JJ expression/NN of/IN an/DT otherwise/RB cytoplasmic/JJ protein/NN and/CC ,/, in/IN conjunction/NN with/IN overexpression/NN of/IN c-Rel/NN ,/, NFKB2/NN alters/VBZ the/DT NF-kappa/NN B/NN signalling/NN pathway/NN and/CC contributes/VBZ to/TO leukemic/JJ transformation/NN of/IN T/NN cells/NNS by/IN HTLV-I/NN ./. 
UI/LS -/: 94129004/CD 
TI/LS -/: Retinoic/JJ acid/NN downmodulates/VBZ erythroid/JJ differentiation/NN and/CC GATA1/NN expression/NN in/IN purified/VBN adult-progenitor/JJ culture/NN ./. 
AB/LS -/: All-trans/JJ retinoic/JJ acid/NN (/( RA/NN )/) is/VBZ an/DT important/JJ morphogen/NN in/IN vertebrate/NN development/NN ,/, a/DT normal/JJ constituent/NN in/IN human/JJ adult/JJ blood/NN and/CC is/VBZ also/RB involved/VBN in/IN the/DT control/NN of/IN cell/NN growth/NN and/CC differentiation/NN in/IN acute/JJ promyelocytic/JJ leukemia/NN ./. 
We/PRP have/VBP examined/VBN the/DT effects/NNS of/IN RA/NN on/IN normal/JJ hematopoiesis/NN by/IN using/VBG early/JJ hematopoietic/JJ progenitor/NN cells/NNS (/( HPC/NN )/) stringently/RB purified/VBN from/IN adult/JJ peripheral/JJ blood/NN ./. 
In/IN clonogenetic/JJ fetal/JJ calf/NN serum-supplemented/JJ (/( FCS+/JJ )/) or/CC -nonsupplemented/JJ (/( FCS-/JJ )/) culture/NN treated/VBN with/IN saturating/JJ levels/NNS of/IN interleukin-3/NN (/( IL-3/NN )/) granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) and/CC erythropoietin/NN (/( Ep/NN )/) (/( combined/VBN with/IN c-kit/NN ligand/NN in/IN FCS(-)-culture/JJ conditions/NNS )/) ,/, RA/NN induces/VBZ a/DT dramatic/JJ dose-dependent/JJ shift/NN from/IN erythroid/JJ to/TO granulomonocytic/JJ colony/NN formation/NN ,/, the/DT latter/JJ colonies/NNS being/VBG essentially/RB represented/VBN by/IN granulocytic/JJ clones/NNS ./. 
This/DT shift/NN is/VBZ apparently/RB not/RB caused/VBN by/IN a/DT recruitment/NN phenomenon/NN ,/, because/IN in/IN FCS+/JJ culture/NN ,/, the/DT total/JJ number/NN of/IN colonies/NNS is/VBZ not/RB significantly/RB modified/VBN by/IN RA/NN addition/NN ./. 
In/IN FCS-/JJ liquid-suspension/NN culture/NN supplemented/VBN with/IN saturating/JJ Ep/NN level/NN and/CC low-dose/JJ IL-3/GM-CSF/NN ,/, adult/JJ HPC/NN undergo/VBP unilineage/JJ erythropoietic/JJ differentiation/NN :/: Here/RB again/RB ,/, treatment/NN with/IN high-dose/JJ RA/NN induces/VBZ a/DT shift/NN from/IN the/DT erythroid/JJ to/TO granulocytic/JJ differentiation/NN pathway/NN ./. 
Studies/NNS on/IN RA/NN time-response/JJ or/CC pulse/NN treatment/NN in/IN semisolid/JJ or/CC liquid/JJ culture/NN show/VBP that/IN early/JJ RA/NN addition/NN is/VBZ most/RBS effective/JJ ,/, thus/RB indicating/VBG that/IN early/JJ but/CC not/RB late/JJ HPC/NN are/VBP sensitive/JJ to/TO its/PRP$ action/NN ./. 
We/PRP then/RB analyzed/VBD the/DT expression/NN of/IN the/DT master/NN GATA1/NN gene/NN ,/, which/WDT encodes/VBZ a/DT finger/NN transcription/NN factor/NN required/VBN for/IN normal/JJ erythroid/JJ development/NN ;/: addition/NN of/IN RA/NN to/TO HPC/NN stimulated/VBN into/IN unilineage/JJ erythropoietic/JJ differentiation/NN in/IN liquid/JJ culture/NN caused/VBD a/DT virtually/RB complete/JJ inhibition/NN of/IN GATA1/NN mRNA/NN induction/NN ./. 
These/DT results/NNS indicate/VBP that/IN RA/NN directly/RB inhibits/VBZ the/DT erythroid/JJ differentiation/NN program/NN at/IN the/DT level/NN of/IN early/JJ adult/JJ HPC/NN ,/, and/CC may/MD lead/VB to/TO a/DT shift/NN from/IN the/DT erythroid/JJ to/TO granulocytic/JJ differentiation/NN pathway/NN ./. 
This/DT phenomenon/NN is/VBZ correlated/VBN with/IN inhibition/NN of/IN GATA1/NN induction/NN in/IN the/DT early/JJ stages/NNS of/IN erythropoietic/JJ differentiation/NN ./. 
UI/LS -/: 94134077/CD 
TI/LS -/: Induction/NN of/IN phosphatidylinositol/NN turnover/NN and/CC EGR-1/NN mRNA/NN expression/NN by/IN crosslinking/VBG of/IN surface/NN IgM/NN and/CC IgD/NN in/IN the/DT human/JJ B/NN cell/NN line/NN B104/NN ./. 
AB/LS -/: We/PRP have/VBP previously/RB shown/VBN that/IN a/DT human/JJ B/NN lymphoma/NN cell/NN line/NN ,/, B104/NN ,/, expressed/VBD surface/NN IgM/NN (/( sIgM/NN )/) and/CC surface/NN IgD/NN (/( sIgD/NN )/) ,/, and/CC that/IN crosslinking/VBG of/IN sIgM/NN and/CC sIgD/NN by/IN anti-IgM/JJ antibody/NN (/( Ab/NN )/) and/CC anti-IgD/JJ Ab/NN ,/, respectively/RB ,/, induced/VBD Ca2+/NN influx/NN to/TO almost/RB the/DT same/JJ degree/NN ,/, whereas/IN only/RB sIgM-crosslinking/NN caused/VBD B104/NN cell/NN death/NN ./. 
Here/RB ,/, we/PRP investigated/VBD the/DT accumulation/NN of/IN cyclic/JJ AMP/NN (/( cAMP/NN )/) ,/, the/DT hydrolysis/NN of/IN inositol/NN phosphates/NNS ,/, protein/NN kinase/NN C/NN (/( PKC/NN )/) activity/NN and/CC the/DT induction/NN of/IN Egr-1/NN and/CC c-fos/NN mRNA/NN expression/NN by/IN sIgM-/NN and/CC sIgD-crosslinking/NN to/TO examine/VB differences/NNS in/IN the/DT signals/NNS mediated/VBN through/IN sIgM/NN and/CC sIgD/NN in/IN B104/NN cells/NNS ./. 
Both/CC sIgM-/NN and/CC sIgD-crosslinking/NN with/IN antibodies/NNS induced/VBD elevation/NN of/IN cAMP/NN levels/NNS ,/, phosphatidylinositol/NN turnover/NN ,/, PKC/NN activation/NN and/CC expression/NN of/IN Egr-1/NN and/CC c-fos/NN mRNA/NN ,/, although/IN sIgM-crosslinking/NN was/VBD more/RBR effective/JJ than/IN sIgD-crosslinking/NN ,/, presumably/RB due/JJ to/TO the/DT higher/JJR expression/NN of/IN sIgM/NN than/IN of/IN sIgD/NN ./. 
Egr-1/NN mRNA/NN expression/NN induced/VBN by/IN sIgM-/NN and/CC sIgD-crosslinking/NN was/VBD inhibited/VBN by/IN H7/NN ,/, erbstatin/NN and/CC genistein/NN ,/, but/CC not/RB by/IN HA1004/NN ./. 
Erbstatin/NN and/CC genistein/NN inhibited/VBD the/DT sIg-crosslinking-induced/JJ Egr-1/NN mRNA/NN expression/NN in/IN a/DT dose-dependent/JJ manner/NN parallel/JJ to/TO that/WDT observed/VBN in/IN the/DT inhibition/NN of/IN sIg-crosslinking-induced/JJ protein/NN tyrosine/NN phosphorylation/NN ./. 
Phorbol/NN myristate/NN acetate/NN induced/VBD Egr-1/NN mRNA/NN expression/NN but/CC forskolin/NN and/CC dibutyryl/NN cyclic/JJ AMP/NN did/VBD not/RB ./. 
These/DT findings/NNS suggest/VBP that/IN the/DT Egr-1/NN mRNA/NN activating/NN signals/NNS through/IN sIgM/NN and/CC sIgD/NN are/VBP protein/NN tyrosine/NN kinase-/NN and/CC PKC-dependent/JJ ,/, but/CC protein/NN kinase/NN A-independent/JJ ./. 
Cyclosporin/NN A/NN (/( CsA/NN )/) and/CC FK506/NN rescued/VBD B104/NN cells/NNS from/IN death/NN induced/VBN by/IN anti-IgM/JJ Ab/NN ,/, but/CC did/VBD not/RB affect/VB the/DT expression/NN of/IN Egr-1/NN and/CC c-fos/NN mRNA/NN ,/, showing/VBG that/IN CsA/NN and/CC FK506/NN affect/VBP signal/NN transducers/NNS differently/RB from/IN or/CC downstream/RB to/TO these/DT molecules/NNS ./. 
The/DT difference/NN in/IN signals/NNS transduced/VBN through/IN sIgM/NN and/CC sIgD/NN in/IN B104/NN cells/NNS is/VBZ discussed/VBN ./. 
UI/LS -/: 94166578/CD 
TI/LS -/: Direct/JJ exposure/NN to/TO 2,3,7,8-tetrachlorodibenzo-p-dioxin/NN (/( TCDD/NN )/) increases/VBZ infectivity/NN of/IN human/JJ erythrocytes/NNS to/TO a/DT malarial/JJ parasite/NN ./. 
AB/LS -/: Direct/JJ exposure/NN to/TO 10/CD nM/NN 2,3,7,8-TCDD/NN caused/VBD a/DT 75/CD %/NN increase/NN and/CC a/DT 2-fold/JJ increase/NN in/IN the/DT infectivity/NN of/IN isolated/VBN human/JJ erythrocytes/NNS to/TO P./FW falciparum/FW after/IN 48/CD hours/NNS when/WRB the/DT parasites/NNS were/VBD in/IN an/DT unsynchronized/JJ or/CC synchronized/JJ state/NN of/IN growth/NN ,/, respectively/RB ./. 
Treatment/NN of/IN human/JJ erythrocytes/NNS with/IN 10/CD microM/NN sodium/NN orthovanadate/NN (/( NaOV/NN )/) ,/, an/DT inhibitor/NN of/IN plasma/NN membrane/NN Ca-ATPase/NN and/CC phosphotyrosine/NN phosphatase/NN ,/, decreased/VBD parasitemia/NN by/IN 30/CD %/NN ./. 
Co-treatment/NN of/IN RBCs/NNS with/IN TCDD/NN and/CC NaOV/NN completely/RB blocked/VBD the/DT TCDD-induced/JJ increase/NN in/IN parasitemia/NN ./. 
Because/IN erythrocytes/NNS are/VBP anucleated/JJ ,/, these/DT results/NNS are/VBP discussed/VBN as/IN evidence/NN for/IN biochemical/JJ changes/NNS by/IN TCDD/NN without/IN requiring/VBG the/DT activation/NN of/IN gene/NN products/NNS ./. 
UI/LS -/: 94314370/CD 
TI/LS -/: Evidence/NN for/IN a/DT trans-acting/JJ activator/NN function/NN regulating/VBG the/DT expression/NN of/IN the/DT human/JJ CD5/NN antigen/NN ./. 
AB/LS -/: Interspecies/JJ somatic/JJ cell/NN hybrids/NNS were/VBD generated/VBN by/IN fusing/VBG the/DT mouse/NN T-lymphoma/NN cell/NN line/NN ,/, BW5147/NN ,/, with/IN normal/JJ human/JJ T/NN lymphocytes/NNS at/IN different/JJ stages/NNS of/IN differentiation/NN ./. 
Thymocytes/NNS ,/, activated/VBN peripheral/JJ T/NN lymphocytes/NNS ,/, or/CC an/DT activated/VBN T-cell/NN clone/NN were/VBD used/VBN as/IN human/JJ partners/NNS ,/, respectively/RB ,/, in/IN three/CD independent/JJ fusions/NNS ./. 
Irrespective/JJ of/IN the/DT human/JJ cell/NN partner/NN used/VBN for/IN fusion/NN ,/, a/DT certain/JJ number/NN of/IN hybrids/NNS lost/VBD CD5/NN surface/NN expression/NN over/IN a/DT period/NN of/IN time/NN in/IN culture/NN ./. 
Analysis/NN at/IN the/DT phenotype/NN and/CC genetic/JJ level/NN showed/VBD that/IN lack/NN of/IN CD5/NN expression/NN was/VBD due/JJ neither/CC to/TO segregation/NN of/IN human/JJ autosome/NN 11/CD ,/, on/IN which/WDT the/DT CD5/NN gene/NN has/VBZ been/VBN mapped/VBN ,/, nor/CC to/TO deletion/NN of/IN the/DT CD5/NN structural/JJ gene/NN ./. 
Furthermore/RB ,/, loss/NN of/IN CD5/NN surface/NN expression/NN correlated/VBD with/IN the/DT absence/NN of/IN specific/JJ mRNA/NN ./. 
Since/IN these/DT hybrids/NNS preferentially/RB segregate/VBP human/JJ chromosomes/NNS ,/, these/DT results/NNS indicate/VBP the/DT existence/NN of/IN a/DT non-syntenic/JJ trans-active/JJ locus/NN ,/, or/CC loci/NNS ,/, positively/RB controlling/VBG the/DT expression/NN of/IN the/DT human/JJ CD5/NN gene/NN ./. 
UI/LS -/: 97113352/CD 
TI/LS -/: Induction/NN of/IN the/DT CD11b/NN gene/NN during/IN activation/NN of/IN the/DT monocytic/JJ cell/NN line/NN U937/NN requires/VBZ a/DT novel/JJ nuclear/JJ factor/NN MS-2/NN [/( published/VBN erratum/NN appears/VBZ in/IN J/NNP Immunol/NNP 1999/CD Jul/NNP 15/CD ;/: 163/CD (/( 2/CD )/) :/: 1091/CD ]/) 
AB/LS -/: The/DT differentiation/NN of/IN myeloid/JJ precursors/NNS into/IN mature/JJ myelomonocytic/JJ cells/NNS is/VBZ characterized/VBN by/IN the/DT induction/NN of/IN the/DT gene/NN encoding/VBG the/DT beta2/NN integrin/NN CD11b/NN ./. 
The/DT transcription/NN factors/NNS Sp1/NN and/CC PU.1/NN prime/VBP the/DT CD11b/NN promoter/NN ,/, but/CC the/DT nature/NN of/IN the/DT factors/NNS responsible/JJ for/IN its/PRP$ inducible/JJ expression/NN are/VBP unknown/JJ ./. 
In/IN addition/NN to/TO the/DT CD11b/NN gene/NN ,/, the/DT homologous/JJ genes/NNS encoding/VBG CD11a/NN and/CC CD11c/NN also/RB exhibit/VBP inducible/JJ expression/NN during/IN myeloid/JJ differentiation/NN ./. 
Therefore/RB ,/, we/PRP compared/VBD the/DT nucleotide/JJ sequences/NNS of/IN the/DT CD11a/NN ,/, CD11b/NN ,/, and/CC CD11c/NN gene/NN promoters/NNS to/TO identify/VB common/JJ elements/NNS that/WDT might/MD contribute/VB to/TO inducible/JJ expression/NN ./. 
This/DT analysis/NN identified/VBD one/CD such/JJ element/NN repeated/VBN four/CD times/NNS within/IN the/DT CD11b/NN promoter/NN ./. 
Mutation/NN of/IN these/DT elements/NNS indicated/VBD that/IN two/CD ,/, MS-2beta/NN and/CC MS-2gamma/NN ,/, are/VBP critical/JJ to/TO the/DT induction/NN of/IN the/DT CD11b/NN gene/NN during/IN differentiation/NN of/IN the/DT pro-monocytic/JJ cell/NN line/NN U937/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS indicate/VBP that/IN MS-2beta/NN and/CC MS-2gamma/NN interact/VBP with/IN nuclear/JJ factors/NNS that/WDT are/VBP induced/VBN during/IN U937/NN differentiation/NN ./. 
These/DT factors/NNS are/VBP detected/VBN at/IN the/DT time/NN the/DT CD11b/NN promoter/NN is/VBZ activated/VBN ./. 
The/DT molecular/JJ mass/NN of/IN these/DT factors/NNS is/VBZ approximately/RB 28/CD kDa/NN ,/, and/CC their/PRP$ DNA/NN binding/NN characteristics/NNS are/VBP indistinguishable/JJ from/IN those/DT of/IN the/DT novel/JJ nuclear/JJ factor/NN MS-2/NN ./. 
Taken/VBN together/RB ,/, our/PRP$ data/NNS indicate/VBP that/IN MS-2/NN mediates/VBZ induction/NN of/IN the/DT CD11b/NN gene/NN as/IN cells/NNS of/IN the/DT monocytic/JJ lineage/NN mature/VBP ./. 
The/DT presence/NN of/IN multiple/JJ potential/JJ binding/VBG sites/NNS for/IN MS-2/NN in/IN the/DT promoter/NN regions/NNS of/IN a/DT wide/JJ range/NN of/IN genes/NNS expressed/VBN in/IN mature/JJ myeloid/JJ cells/NNS suggests/VBZ this/DT factor/NN plays/VBZ a/DT general/JJ role/NN in/IN myeloid/JJ differentiation/NN ./. 
UI/LS -/: 97127169/CD 
TI/LS -/: Acetylsalicylic/JJ acid/NN and/CC sodium/NN salicylate/NN inhibit/VBP LPS-induced/JJ NF-kappa/NN B/c-Rel/NN nuclear/JJ translocation/NN ,/, and/CC synthesis/NN of/IN tissue/NN factor/NN (/( TF/NN )/) and/CC tumor/NN necrosis/NN factor/NN alfa/NN (/( TNF-alpha/NN )/) in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: We/PRP have/VBP investigated/VBN the/DT effects/NNS of/IN acetylsalicylic/JJ acid/NN and/CC sodium/NN salicylate/NN on/IN the/DT LPS-induced/JJ synthesis/NN of/IN the/DT pro-coagulant/JJ protein/NN tissue/NN factor/NN (/( TF/NN )/) and/CC the/DT pro-inflammatory/JJ protein/NN tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) ,/, as/RB well/RB as/IN the/DT prostaglandin/NN PGE2/NN in/IN human/JJ monocytes/NNS ./. 
Both/DT drugs/NNS dose-dependently/RB inhibited/VBD LPS-induced/JJ TF/NN and/CC TNF-alpha/NN synthesis/NN at/IN the/DT mRNA/NN and/CC the/DT protein/NN level/NN ,/, and/CC reduced/VBD PGE2/NN production/NN ./. 
As/IN evidenced/VBN by/IN electro/NN mobility/NN shift/NN assay/NN (/( EMSA/NN )/) and/CC the/DT use/NN of/IN a/DT NF-kappa/NN B/NN prototypic/JJ probe/NN ,/, these/DT drugs/NNS probably/RB exert/VBP their/PRP$ inhibitory/JJ effects/NNS by/IN interference/NN with/IN the/DT nuclear/JJ translocation/NN of/IN NF-kappa/NN B/c-Rel/NN proteins/NNS ./. 
These/DT data/NNS may/MD expand/VB the/DT understanding/NN of/IN the/DT anti-thrombotic/JJ and/CC anti-inflammatory/JJ effects/NNS of/IN these/DT drugs/NNS when/WRB activation/NN of/IN monocytes/NNS occurs/VBZ ./. 
UI/LS -/: 97074532/CD 
TI/LS -/: Interferon/NN augments/VBZ PML/NN and/CC PML/RAR/NN alpha/NN expression/NN in/IN normal/JJ myeloid/JJ and/CC acute/JJ promyelocytic/JJ cells/NNS and/CC cooperates/VBZ with/IN all-trans/JJ retinoic/JJ acid/NN to/TO induce/VB maturation/NN of/IN a/DT retinoid-resistant/JJ promyelocytic/JJ cell/NN line/NN ./. 
AB/LS -/: The/DT PML/NN gene/NN is/VBZ fused/VBN to/TO the/DT retinoic/JJ acid/NN receptor/NN alpha/NN gene/NN (/( RAR/NN alpha/NN )/) in/IN the/DT acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) 15/CD ;/: 17/CD translocation/NN ./. 
PML/NN is/VBZ expressed/VBN in/IN diverse/JJ tissues/NNS and/CC cell/NN lines/NNS and/CC localized/JJ in/IN the/DT nucleus/NN with/IN a/DT typical/JJ speckled/JJ pattern/NN ./. 
In/IN the/DT bone/NN marrow/NN ,/, it/PRP is/VBZ preferentially/RB expressed/VBN in/IN myeloid/JJ cells/NNS ./. 
PML/NN appears/VBZ to/TO be/VB transcriptionally/RB regulated/VBN by/IN class/NN I/CD and/CC II/CD interferons/NNS ,/, which/WDT raises/VBZ the/DT possibility/NN that/IN interferons/NNS modulate/VBP the/DT function/NN and/CC growth/NN and/CC differentiation/NN potential/NN of/IN normal/JJ myeloid/JJ cells/NNS and/CC precursors/NNS by/IN activating/VBG PML-dependent/JJ pathways/NNS ./. 
Similarly/RB ,/, interferons/NNS could/MD act/VB on/IN APL/NN cells/NNS ,/, alone/RB or/CC in/IN combination/NN with/IN all-trans/JJ retinoic/JJ acid/NN (/( RA/NN )/) ,/, especially/RB if/IN the/DT PML/RAR/NN alpha/NN fusion/NN transcript/NN that/WDT results/VBZ from/IN the/DT t(15; 17)/NN is/VBZ induced/VBN by/IN interferon/NN ./. 
We/PRP report/VBP here/RB that/IN PML/NN is/VBZ expressed/VBN at/IN low/JJ levels/NNS or/CC not/RB expressed/VBN in/IN normal/JJ circulating/VBG human/JJ monocytes/NNS ,/, lymphocytes/NNS ,/, and/CC polymorphonucleate/JJ cells/NNS ,/, but/CC is/VBZ markedly/RB induced/VBN by/IN interferon/NN ;/: that/IN PML/NN and/CC PML/RAR/NN alpha/NN expression/NN is/VBZ augmented/VBN by/IN interferon/NN in/IN the/DT NB4/NN APL/NN cell/NN line/NN ,/, which/WDT carries/VBZ the/DT t(15; 17)/NN ,/, and/CC in/IN APL/NN blasts/NNS from/IN patients/NNS ;/: that/IN interferon/NN inhibits/VBZ growth/NN and/CC survival/NN of/IN NB4/NN APL/NN cells/NNS in/IN cooperation/NN with/IN RA/NN ;/: that/IN interferons/NNS alone/RB have/VBP minimal/JJ maturation/NN effect/NN on/IN NB4/NN cells/NNS ;/: and/CC ,/, finally/RB ,/, that/IN interferon/NN gamma/NN ,/, but/CC not/RB alpha/NN or/CC beta/NN ,/, induces/VBZ maturation/NN and/CC growth/NN suppression/NN of/IN NB4/NN cells/NNS with/IN de/FW novo/FW retinoid/NN resistance/NN ,/, and/CC partially/RB restores/VBZ RA/NN response/NN ./. 
UI/LS -/: 97107281/CD 
TI/LS -/: Effects/NNS of/IN Ara-C/NN on/IN neutral/JJ sphingomyelinase/NN and/CC mitogen-/NN and/CC stress-activated/JJ protein/NN kinases/NNS in/IN T-lymphocyte/NN cell/NN lines/NNS ./. 
AB/LS -/: Neutral/JJ sphingomyelinase/NN (/( SMase/NN )/) can/MD be/VB activated/VBN by/IN extracellular/JJ signals/NNS to/TO produce/VB ceramide/NN ,/, which/WDT may/MD affect/VB mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) activities/NNS ./. 
Neutral/JJ SMase/NN activity/NN was/VBD assessed/VBN in/IN membranes/NNS from/IN Jurkat/NN ,/, a/DT human/JJ T-cell/NN line/NN ,/, and/CC EL4/NN ,/, a/DT murine/JJ T-cell/NN line/NN ./. 
Ara-C/NN activated/VBD SMase/NN with/IN 10/CD minutes/NNS in/IN both/CC Jurkat/NN and/CC EL4/NN cells/NNS ,/, while/IN phorbol/NN ester/NN (/( PMA/NN )/) had/VBD no/DT effect/NN ./. 
PMA/NN ,/, but/CC not/RB Ara-C/NN or/CC ceramides/NNS ,/, activated/VBD ERK/NN MAPKS/NNS ,/, in/IN Jurkat/NN and/CC EL4/NN ./. 
PMA/NN acted/VBD synergistically/RB with/IN ionomycin/NN to/TO activate/VB JNK/NN MAPKs/NNS in/IN Jurkat/NN and/CC EL4/NN within/IN 10/CD minutes/NNS ./. 
Ara-C/NN activated/VBD JNKs/NNS only/RB after/IN prolonged/JJ incubation/NN (/( 90-120/CD minutes/NNS )/) ./. 
Thus/RB ,/, ceramide/NN is/VBZ not/RB a/DT positive/JJ signal/NN for/IN ERK/NN activation/NN in/IN T-cell/NN lines/NNS ./. 
The/DT effects/NNS of/IN Ara-C/NN on/IN JNK/NN activity/NN may/MD be/VB mediated/VBN through/IN secondary/JJ response/NN pathways/NNS ./. 
UI/LS -/: 97048062/CD 
TI/LS -/: Comparative/JJ analysis/NN identifies/VBZ conserved/VBN tumor/NN necrosis/NN factor/NN receptor-associated/JJ factor/NN 3/CD binding/NN sites/NNS in/IN the/DT human/JJ and/CC simian/JJ Epstein-Barr/JJ virus/NN oncogene/NN LMP1/NN ./. 
AB/LS -/: Nonhuman/JJ primates/NNS are/VBP naturally/RB infected/VBN with/IN a/DT B-lymphotropic/JJ herpesvirus/NN closely/RB related/JJ to/TO Epstein-Barr/JJ virus/NN (/( EBV/NN )/) ./. 
These/DT simian/JJ EBV/NNS share/VBP considerable/JJ genetic/JJ ,/, biologic/JJ ,/, and/CC epidemiologic/JJ features/NNS with/IN human/JJ EBV/NN ,/, including/VBG virus-induced/JJ tumorigenesis/NN ./. 
However/RB ,/, latent/JJ ,/, transformation-associated/JJ viral/JJ genes/NNS demonstrate/VBP marked/JJ sequence/NN divergence/NN among/IN species/NNS despite/IN the/DT conserved/VBN functions/NNS ./. 
We/PRP have/VBP cloned/VBN the/DT latent/JJ membrane/NN protein/NN 1/CD (/( LMP1/NN )/) homologs/NNS from/IN the/DT simian/JJ EBV/NN naturally/RB infecting/VBG baboons/NNS (/( cercopithicine/NN herpesvirus/NN 12/CD ,/, herpesvirus/NN papio/NN )/) and/CC rhesus/NN monkeys/NNS (/( cercopithicine/NN herpesvirus/NN 15/CD )/) for/IN a/DT comparative/JJ study/NN with/IN the/DT human/JJ EBV/NN oncogene/NN ./. 
The/DT transmembrane/NN domains/NNS are/VBP well/RB conserved/VBN ,/, but/CC there/EX is/VBZ striking/JJ sequence/NN divergence/NN of/IN the/DT carboxy-terminal/JJ cytoplasmic/JJ domain/NN essential/JJ for/IN B-cell/NN immortalization/NN and/CC interaction/NN with/IN the/DT tumor/NN necrosis/NN factor/NN receptor/NN signaling/NN pathway/NN ./. 
Nevertheless/RB ,/, the/DT simian/JJ EBV/NN LMP1s/NNS retain/VBP most/JJS functions/NNS in/IN common/NN with/IN EBV/NN LMP1/NN ,/, including/VBG the/DT ability/NN to/TO induce/VB NF-(kappa)B/NN activity/NN in/IN human/JJ cells/NNS ,/, to/TO bind/VB the/DT tumor/NN necrosis/NN factor-associated/JJ factor/NN 3/CD (/( TRAF3/NN )/) in/FW vitro/FW ,/, and/CC to/TO induce/VB expression/NN of/IN tumor/NN necrosis/NN factor-responsive/JJ genes/NNS ,/, such/JJ as/IN ICAM1/NN ,/, in/IN human/JJ B/NN lymphocytes/NNS ./. 
Multiple/JJ TRAF3/NN binding/NN sites/NNS containing/VBG a/DT PXQXT/S/NN core/NN sequence/NN can/MD be/VB identified/VBN in/IN the/DT simian/JJ EBV/NN LMP1s/NNS by/IN an/DT in/FW vitro/FW binding/NN assay/NN ./. 
A/DT PXQXT/S-containing/JJ sequence/NN is/VBZ also/RB present/JJ in/IN the/DT cytoplasmic/JJ domain/NN of/IN the/DT Hodgkin/NN 's/POS disease/NN marker/NN ,/, CD30/NN ,/, and/CC binds/VBZ TRAF3/NN in/FW vitro/FW ./. 
The/DT last/JJ 13/CD amino/NN acids/NNS containing/VBG a/DT PXQXT/S/NN sequence/NN are/VBP highly/RB conserved/VBN in/IN human/JJ and/CC simian/JJ EBV/NN LMP1/NN but/CC do/VBP not/RB bind/VB TRAF3/NN ,/, suggesting/VBG a/DT distinct/JJ role/NN for/IN this/DT conserved/VBN region/NN of/IN LMP1/NN ./. 
The/DT conserved/VBN TRAF3/NN binding/NN sites/NNS in/IN LMP1/NN and/CC the/DT CD30/NN Hodgkin/NN 's/POS disease/NN marker/NN provides/VBZ further/JJ evidence/NN that/IN a/DT TRAF3-mediated/JJ signal/NN transduction/NN pathway/NN may/MD be/VB important/JJ in/IN malignant/JJ transformation/NN ./. 
UI/LS -/: 97056026/CD 
TI/LS -/: Chromosome/NN 1/CD aneusomy/NN with/IN 1p36/NN under-representation/NN is/VBZ related/JJ to/TO histologic/JJ grade/NN ,/, DNA/NN aneuploidy/NN ,/, high/JJ c-erb/NN B-2/NN and/CC loss/NN of/IN bcl-2/NN expression/NN in/IN ductal/JJ breast/NN carcinoma/NN ./. 
AB/LS -/: Chromosome/NN 1/CD abnormalities/NNS with/IN loss/NN of/IN 1p36/NN have/VBP been/VBN investigated/VBN in/IN 95/CD breast-cancer/NN samples/NNS by/IN means/NNS of/IN a/DT dual-target/JJ fluorescence/NN in-situ/FW hybridization/NN (/( FISH/NN )/) technique/NN using/VBG the/DT pUC/NN 1.77/CD and/CC p1-79/NN probes/NNS ,/, specific/JJ for/IN the/DT 1q12/NN and/CC 1p36/NN regions/NNS ,/, respectively/RB ./. 
Abnormalities/NNS for/IN one/CD or/CC both/DT probes/NNS were/VBD detected/VBN in/IN 83/95/CD samples/NNS ./. 
Relative/JJ 1p36/NN under-representation/NN was/VBD found/VBN in/IN 79/95/CD ./. 
The/DT clinical/JJ relevance/NN of/IN these/DT alterations/NNS was/VBD studied/VBN by/IN comparing/VBG the/DT FISH/NN results/NNS with/IN several/JJ parameters/NNS currently/RB used/VBN in/IN breast-cancer/JJ pathology/NN ./. 
Distinct/JJ patterns/NNS of/IN chromosome/NN 1/CD abnormalities/NNS were/VBD found/VBN among/IN the/DT histologic/JJ types/NNS of/IN breast/NN carcinoma/NN ./. 
Lobular/JJ or/CC mucinous/JJ samples/NNS showed/VBD few/JJ or/CC no/DT alterations/NNS ,/, whereas/IN most/JJS ductal/JJ samples/NNS had/VBD high/JJ chromosome/NN 1/CD polysomy/NN with/IN under-representation/NN of/IN 1p36/NN ./. 
In/IN ductal/JJ carcinomas/NNS ,/, chromosome/NN 1/CD alterations/NNS increased/VBD with/IN histologic/JJ grade/NN ,/, DNA/NN aneuploidy/NN ,/, loss/NN of/IN bcl-2/NN and/CC high/JJ c-erb/NN B-2/NN expression/NN ./. 
These/DT associations/NNS were/VBD found/VBN to/TO be/VB statistically/RB significant/JJ ./. 
No/DT correlation/NN between/IN chromosome/NN 1/CD alterations/NNS and/CC nuclear/JJ grade/NN ,/, age/NN ,/, size/NN ,/, lymph-node/JJ involvement/NN ,/, hormonal/JJ receptor/NN presence/NN ,/, proliferation/NN activity/NN or/CC p53/NN protein/NN expression/NN was/VBD detected/VBN ./. 
These/DT results/NNS indicate/VBP the/DT utility/NN of/IN this/DT FISH/NN technique/NN for/IN a/DT better/JJR definition/NN of/IN the/DT biological/JJ characteristics/NNS of/IN ductal/JJ carcinomas/NNS ./. 
UI/LS -/: 94140841/CD 
TI/LS -/: G(Anh)MTetra/NN ,/, a/DT natural/JJ bacterial/JJ cell/NN wall/NN breakdown/NN product/NN ,/, induces/VBZ interleukin-1/NN beta/NN and/CC interleukin-6/NN expression/NN in/IN human/JJ monocytes/NNS ./. 
A/DT study/NN of/IN the/DT molecular/JJ mechanisms/NNS involved/VBN in/IN inflammatory/JJ cytokine/NN expression/NN [/( published/VBN erratum/NN appears/VBZ in/IN J/NNP Biol/NNP Chem/NNP 1994/CD Jun/NNP 17/CD ;/: 269/CD (/( 24/CD )/) :/: 16983/CD ]/) 
AB/LS -/: It/PRP is/VBZ believed/VBN that/IN induction/NN of/IN cytokine/NN expression/NN by/IN bacterial/JJ cell/NN wall/NN components/NNS plays/VBZ a/DT role/NN in/IN the/DT development/NN and/CC course/NN of/IN sepsis/NN ./. 
However/RB ,/, most/JJS attention/NN has/VBZ been/VBN focused/VBN on/IN lipopolysaccharide/NN (/( LPS/NN )/) ./. 
We/PRP studied/VBD the/DT ability/NN of/IN N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D- isoglutamyl-m-diaminopimelyl-D-alanine/NN (/( G(Anh)MTetra/NN )/) ,/, a/DT naturally/RB occurring/VBG breakdown/NN product/NN of/IN peptidoglycan/NN that/WDT is/VBZ produced/VBN by/IN soluble/JJ lytic/JJ transglycosylase/NN of/IN Escherichia/FW coli/FW ,/, to/TO induce/VB cytokine/NN expression/NN in/IN human/JJ monocytes/NNS ./. 
G(Anh)MTetra/NN was/VBD found/VBN to/TO strongly/RB induce/VB interleukin/NN (/( IL/NN )/) -1/CD beta/NN and/CC IL-6/NN mRNA/NN expression/NN after/IN 2/CD h/NN and/CC IL-1/NN beta/NN and/CC IL-6/NN protein/NN secretion/NN after/IN 48/CD h/NN of/IN activation/NN ./. 
The/DT increase/NN in/IN mRNA/NN accumulation/NN was/VBD at/IN least/JJS partly/RB due/JJ to/TO an/DT increase/NN in/IN the/DT transcription/NN rates/NNS of/IN the/DT respective/JJ genes/NNS and/CC was/VBD accompanied/VBN by/IN a/DT strong/JJ induction/NN of/IN nuclear/JJ factor-kappa/NN B/NN and/CC activator/NN protein-1/NN transcription/NN factor/NN expression/NN ./. 
Experiments/NNS using/VBG inhibitors/NNS of/IN protein/NN kinase/NN C/NN ,/, protein/NN kinase/NN A/NN ,/, and/CC tyrosine/NN kinase-dependent/JJ pathways/NNS revealed/VBD that/IN G(Anh)MTetra-induced/JJ IL-1/NN beta/NN and/CC IL-6/NN mRNA/NN expression/NN involves/VBZ activation/NN of/IN an/DT H7-inhibitable/JJ pathway/NN ./. 
By/IN using/VBG the/DT protein/NN synthesis/NN inhibitor/NN cycloheximide/NN ,/, it/PRP was/VBD shown/VBN that/IN G(Anh)MTetra-induced/JJ IL-6/NN mRNA/NN expression/NN depends/VBZ on/IN the/DT synthesis/NN of/IN new/JJ protein/NN ,/, whereas/IN G(Anh)MTetra-induced/JJ IL-1/NN beta/NN mRNA/NN accumulation/NN does/VBZ not/RB ./. 
When/WRB responses/NNS to/TO G(Anh)MTetra/NN were/VBD compared/VBN with/IN those/DT to/TO LPS/NN and/CC muramyldipeptide/NN (/( MDP/NN )/) ,/, it/PRP was/VBD found/VBN that/IN the/DT optimal/JJ response/NN to/TO G(Anh)MTetra/NN induction/NN was/VBD similar/JJ to/TO that/DT of/IN LPS/NN but/CC significantly/RB higher/JJR than/IN the/DT response/NN to/TO MDP/NN ./. 
Furthermore/RB ,/, maximal/JJ G(Anh)MTetra-induced/JJ IL-1/NN beta/NN and/CC IL-6/NN mRNA/NN expression/NN could/MD be/VB enhanced/VBN by/IN co-stimulation/NN with/IN LPS/NN or/CC MDP/NN ,/, suggesting/VBG that/IN different/JJ receptors/NNS and/or/CC transduction/NN pathways/NNS were/VBD involved/VBN ./. 
These/DT results/NNS indicate/VBP that/IN G(Anh)MTetra/NN induces/VBZ IL-1/NN beta/NN and/CC IL-6/NN expression/NN in/IN human/JJ monocytes/NNS suggesting/VBG a/DT possible/JJ role/NN for/IN G(Anh)MTetra/NN in/IN the/DT release/NN of/IN cytokines/NNS during/IN sepsis/NN ./. 
UI/LS -/: 94110603/CD 
TI/LS -/: Increased/VBN proliferation/NN ,/, cytotoxicity/NN ,/, and/CC gene/NN expression/NN after/IN stimulation/NN of/IN human/JJ peripheral/JJ blood/NN T/NN lymphocytes/NNS through/IN a/DT surface/NN ganglioside/NN (/( GD3/NN )/) [/( published/VBN erratum/NN appears/VBZ in/IN J/NNP Immunol/NNP 1994/CD Jul/NNP 15/CD ;/: 153/CD (/( 2/CD )/) :/: 910/CD ]/) 
AB/LS -/: Previous/JJ studies/NNS have/VBP suggested/VBN that/IN gangliosides/NNS have/VBP an/DT important/JJ role/NN in/IN cell/NN signaling/NN and/CC recognition/NN ./. 
However/RB ,/, their/PRP$ specific/JJ function/NN in/IN these/DT processes/NNS has/VBZ not/RB been/VBN clearly/RB defined/VBN ./. 
A/DT mAb/NN ,/, R24/NN ,/, that/WDT reacts/VBZ specifically/RB with/IN a/DT cell/NN surface/NN ganglioside/NN (/( GD3/NN )/) has/VBZ been/VBN demonstrated/VBN to/TO stimulate/VB proliferation/NN of/IN T/NN cells/NNS derived/VBN from/IN human/JJ peripheral/JJ blood/NN ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP investigated/VBN the/DT mechanisms/NNS by/IN which/WDT the/DT R24/NN mAb/NN affects/VBZ T/NN cell/NN functions/NNS ./. 
We/PRP have/VBP observed/VBN that/IN the/DT R24/NN mAb/NN stimulates/VBZ GD3+/JJ T/NN cell/NN proliferation/NN ,/, cytotoxicity/NN ,/, and/CC surface/NN marker/NN expression/NN of/IN IL-2R/NN alpha-chain/NN ,/, IL-2R/NN beta-chain/NN ,/, HLA-DR/NN ,/, CD11a/NN ,/, and/CC CD11c/NN ./. 
Additionally/RB ,/, IFN-gamma/NN activity/NN but/CC not/RB IL-1/NN ,/, IL-2/NN ,/, or/CC IL-4/NN activity/NN was/VBD present/JJ in/IN culture/NN supernatants/NNS 72/CD h/NN after/IN R24/NN stimulation/NN ./. 
In/IN some/DT donors/NNS ,/, increased/VBN IL-6/NN and/CC TNF-alpha/NN activity/NN also/RB was/VBD detected/VBN after/IN R24/NN treatment/NN ./. 
Furthermore/RB ,/, R24/NN treatment/NN resulted/VBD in/IN translocation/NN of/IN c-rel/NN ,/, but/CC little/JJ or/CC no/DT NF/NN kappa/NN B/NN p50/NN or/CC p65/NN ,/, from/IN the/DT cytoplasm/NN to/TO the/DT nucleus/NN and/CC an/DT increase/NN of/IN NF/NN kappa/NN B/NN binding/NN complexes/NNS containing/VBG c-rel/NN and/CC p50/NN ./. 
This/DT treatment/NN also/RB caused/VBD increased/VBN tyrosine/NN phosphorylation/NN of/IN specific/JJ protein/NN substrates/NNS ./. 
R24-stimulated/JJ increases/NNS in/IN proliferation/NN ,/, cytotoxicity/NN ,/, and/CC cell/NN surface/NN protein/NN expression/NN could/MD be/VB blocked/VBN by/IN cyclosporin/NN and/CC staurosporin/NN ,/, indicating/VBG that/IN cyclophilin/calcineurin/NN and/CC protein/NN kinase/NN C/NN may/MD be/VB involved/VBN in/IN the/DT R24/NN signaling/NN pathway/NN ./. 
Additionally/RB ,/, herbimycin/NN A/NN ,/, a/DT tyrosine/NN kinase/NN inhibitor/NN ,/, blocked/VBD the/DT R24-stimulated/JJ increase/NN in/IN proliferation/NN but/CC not/RB cytotoxicity/NN at/IN concentrations/NNS consistent/JJ with/IN specificity/NN for/IN tyrosine/NN kinases/NNS ./. 
These/DT results/NNS suggest/VBP that/IN multiple/JJ biochemical/JJ pathways/NNS are/VBP involved/VBN in/IN the/DT activation/NN of/IN human/JJ T/NN cells/NNS by/IN R24/NN ./. 
UI/LS -/: 94214477/CD 
TI/LS -/: Genes/NNS encoding/VBG general/JJ initiation/NN factors/NNS for/IN RNA/NN polymerase/NN II/CD transcription/NN are/VBP dispersed/VBN in/IN the/DT human/JJ genome/NN ./. 
AB/LS -/: General/JJ transcription/NN factors/NNS are/VBP required/VBN for/IN accurate/JJ initiation/NN of/IN transcription/NN by/IN RNA/NN polymerase/NN II/CD ./. 
Human/JJ cDNAs/NNS encoding/VBG subunits/NNS of/IN these/DT factors/NNS have/VBP been/VBN cloned/VBN and/CC sequenced/VBN ./. 
Using/VBG fluorescence/NN in/FW situ/FW hybridization/NN (/( FISH/NN )/) ,/, we/PRP show/VBP here/RB that/IN the/DT genes/NNS encoding/VBG the/DT TATA-box/NN binding/NN protein/NN (/( TBP/NN )/) ,/, TFIIB/NN ,/, TFIIE/NN alpha/NN ,/, TFIIE/NN beta/NN ,/, RAP30/NN ,/, RAP74/NN and/CC the/DT 62/CD kDa/NN subunit/NN ,/, of/IN TFIIH/NN are/VBP located/JJ at/IN the/DT human/JJ chromosomal/JJ bands/NNS 6q26-27/NN ,/, 1p21-22/NN ,/, 3q21-24/NN ,/, 8p12/NN ,/, 13q14/NN ,/, 19p13.3/NN and/CC 11p14-15.1/NN ,/, respectively/RB ./. 
This/DT dispersed/JJ localization/NN of/IN a/DT group/NN of/IN functionally/RB related/JJ gene/NN provides/VBZ insights/NNS into/IN the/DT molecular/JJ mechanism/NN of/IN human/JJ genome/NN evolution/NN and/CC their/PRP$ possible/JJ involvement/NN in/IN human/JJ diseases/NNS ./. 
UI/LS -/: 96063079/CD 
TI/LS -/: BCL-6/NN and/CC the/DT molecular/JJ pathogenesis/NN of/IN B-cell/NN lymphoma/NN ./. 
AB/LS -/: The/DT results/NNS presented/VBN identify/VBP the/DT first/JJ genetic/JJ lesion/NN associated/VBN with/IN DLCL/NN ,/, the/DT most/RBS clinically/RB relevant/JJ form/NN of/IN NHL/NN ./. 
Although/IN no/DT proof/NN yet/RB exists/VBZ of/IN a/DT role/NN for/IN these/DT lesions/NNS in/IN DLCL/NN pathogenesis/NN ,/, the/DT feature/NN of/IN the/DT BCL-6/NN gene/NN product/NN ,/, its/PRP$ specific/JJ pattern/NN of/IN expression/NN in/IN B/NN cells/NNS ,/, and/CC the/DT clustering/NN of/IN lesions/NNS disrupting/VBG its/PRP$ regulatory/JJ domain/NN strongly/RB suggest/VBP that/IN deregulation/NN of/IN BCL-6/NN expression/NN may/MD contribute/VB to/TO DLCL/NN development/NN ./. 
A/DT more/RBR precise/JJ definition/NN of/IN the/DT role/NN of/IN BCL-6/NN in/IN normal/JJ and/CC neoplastic/JJ B-cell/NN development/NN is/VBZ the/DT goal/NN of/IN ongoing/JJ study/NN of/IN transgenic/JJ mice/NNS engineered/VBN either/CC to/TO express/VB BCL-6/NN under/IN heterologous/JJ promoters/NNS or/CC lacking/VBG BCL-6/NN function/NN due/JJ to/TO targeted/VBN deletions/NNS ./. 
In/IN addition/NN to/TO contributing/VBG to/TO the/DT understanding/NN of/IN DLCL/NN pathogenesis/NN ,/, the/DT identification/NN of/IN BCL-6/NN lesions/NNS may/MD have/VB relevant/JJ clinical/JJ implications/NNS ./. 
DLCL/NN represent/VBP a/DT heterogeneous/JJ group/NN of/IN neoplasms/NNS which/WDT are/VBP treated/VBN homogeneously/RB despite/IN the/DT fact/NN that/IN only/RB 50/CD %/NN of/IN patients/NNS experience/VBP long-term/JJ disease-free/JJ survival/NN (/( Schneider/NNP et/FW al./FW 1990/CD )/) ./. 
The/DT fact/NN that/IN BCL-6/NN rearrangements/NNS identify/VBP biologically/RB and/CC clinically/RB distinct/JJ subsets/NNS of/IN DLCL/NN suggests/VBZ that/IN these/DT lesions/NNS may/MD be/VB useful/JJ as/IN markers/NNS in/IN selection/NN of/IN differential/JJ therapeutic/JJ strategies/NNS based/VBN on/IN different/JJ risk/NN groups/NNS ./. 
Furthermore/RB ,/, the/DT BCL-6/NN rearrangements/NNS can/MD be/VB used/VBN to/TO identify/VB and/CC monitor/VB the/DT malignant/JJ clone/NN with/IN sensitive/JJ PCR-based/JJ techniques/NNS ./. 
Since/IN clinical/JJ remission/NN has/VBZ been/VBN observed/VBN in/IN a/DT significant/JJ fraction/NN of/IN DLCL/NN cases/NNS ,/, these/DT markers/NNS may/MD serve/VB as/IN critical/JJ tools/NNS for/IN sensitive/JJ monitoring/NN of/IN minimal/JJ residual/JJ disease/NN and/CC early/JJ diagnosis/NN of/IN relapse/NN (/( Gribben/NNP et/FW al./FW 1993/CD )/) ./. 
UI/LS -/: 97175006/CD 
TI/LS -/: Pancreatic/JJ development/NN and/CC maturation/NN of/IN the/DT islet/NN B/NN cell/NN ./. 
Studies/NNS of/IN pluripotent/JJ islet/NN cultures/NNS ./. 
AB/LS -/: Pancreas/NN organogenesis/NN is/VBZ a/DT highly/RB regulated/VBN process/NN ,/, in/IN which/WDT two/CD anlage/NNS|FW evaginate/VBP from/IN the/DT primitive/JJ gut/NN ./. 
They/PRP later/RB fuse/VBP ,/, and/CC ,/, under/IN the/DT influence/NN of/IN the/DT surrounding/VBG mesenchyme/NN ,/, the/DT mature/JJ organ/NN develops/VBZ ,/, being/VBG mainly/RB composed/VBN of/IN ductal/JJ ,/, exocrine/JJ and/CC endocrine/JJ compartments/NNS ./. 
Early/JJ buds/NNS are/VBP characterized/VBN by/IN a/DT branching/VBG morphogenesis/NN of/IN the/DT ductal/JJ epithelium/NN from/IN which/WDT endocrine/JJ and/CC exocrine/JJ precursor/NN cells/NNS bud/VBP to/TO eventually/RB form/VB the/DT two/CD other/JJ compartments/NNS ./. 
The/DT three/CD compartments/NNS are/VBP thought/VBN to/TO be/VB of/IN common/JJ endodermal/JJ origin/NN ;/: in/IN contrast/NN to/TO earlier/JJR hypotheses/NNS ,/, which/WDT suggested/VBD that/IN the/DT endocrine/JJ compartment/NN was/VBD of/IN neuroectodermal/JJ origin/NN ./. 
It/PRP is/VBZ thus/RB generally/RB believed/VBN that/IN the/DT pancreatic/JJ endocrine-lineage/NN possesses/VBZ the/DT ability/NN to/TO mature/VB along/IN a/DT differentiation/NN pathway/NN that/WDT shares/VBZ many/JJ characteristics/NNS with/IN those/DT of/IN neuronal/JJ differentiation/NN ./. 
During/IN recent/JJ years/NNS ,/, studies/NNS of/IN insulin-gene/JJ regulation/NN and/CC ,/, in/IN particular/JJ ,/, the/DT tissue-specific/JJ transcriptional/JJ control/NN of/IN insulin-gene/JJ activity/NN have/VBP provided/VBN information/NN on/IN pancreas/NN development/NN in/IN general/JJ ./. 
The/DT present/JJ review/NN summarizes/VBZ these/DT findings/NNS ,/, with/IN a/DT special/JJ focus/NN on/IN our/PRP$ own/JJ studies/NNS on/IN pluripotent/JJ endocrine/JJ cultures/NNS of/IN rat/NN pancreas/NN ./. 
UI/LS -/: 97128276/CD 
TI/LS -/: Octamer/NN independent/JJ activation/NN of/IN transcription/NN from/IN the/DT kappa/NN immunoglobulin/NN germline/NN promoter/NN ./. 
AB/LS -/: Previous/JJ analyses/NNS of/IN immunoglobulin/NN V/JJ region/NN promoters/NNS has/VBZ led/VBN to/TO the/DT discovery/NN of/IN a/DT common/JJ octamer/NN motif/NN which/WDT is/VBZ functionally/RB important/JJ in/IN the/DT tissue-specific/JJ and/CC developmentally/RB regulated/VBN transcriptional/JJ activation/NN of/IN immunoglobulin/NN genes/NNS ./. 
The/DT germline/NN promoters/NNS (/( Ko/NN )/) located/JJ upstream/RB of/IN the/DT J/JJ region/NN gene/NN segments/NNS of/IN the/DT kappa/NN locus/NN also/RB contain/VBP an/DT octamer/NN motif/NN (/( containing/VBG a/DT single/JJ base/NN pair/NN mutation/NN and/CC referred/VBN to/TO as/IN the/DT variant/JJ octamer/NN )/) which/WDT has/VBZ been/VBN shown/VBN previously/RB to/TO bind/VB Oct-1/NN and/CC Oct-2/NN transcription/NN factors/NNS in/FW vitro/FW ./. 
To/TO further/RB elucidate/VB the/DT role/NN of/IN this/DT variant/JJ octamer/NN motif/NN in/IN the/DT regulation/NN of/IN germline/NN transcription/NN from/IN the/DT unrearranged/JJ kappa/NN locus/NN ,/, we/PRP have/VBP quantitated/VBN the/DT relative/JJ binding/NN affinity/NN of/IN Oct-1/NN and/CC Oct-2/NN for/IN the/DT variant/JJ octamer/NN motif/NN and/CC determined/VBD the/DT functional/JJ role/NN of/IN this/DT octamer/NN motif/NN in/IN transcriptional/JJ activation/NN ./. 
We/PRP find/VBP that/IN ,/, although/IN the/DT variant/JJ octamer/NN motif/NN binds/VBZ Oct-1/NN and/CC Oct-2/NN in/FW vitro/FW with/IN 5-fold/JJ lower/JJR affinity/NN than/IN the/DT consensus/NN octamer/NN motif/NN ,/, mutation/NN of/IN the/DT variant/JJ octamer/NN motif/NN to/TO either/CC a/DT consensus/NN octamer/NN or/CC non-octamer/JJ motif/NN has/VBZ no/DT effect/NN on/IN transcriptional/JJ activation/NN from/IN the/DT germline/NN promoter/NN ./. 
We/PRP also/RB find/VBP significant/JJ differences/NNS in/IN activation/NN of/IN germline/NN and/CC V/JJ region/NN promoters/NNS by/IN kappa/NN enhancers/NNS ./. 
Our/PRP$ results/NNS suggest/VBP that/IN the/DT germline/NN promoters/NNS and/CC V/JJ region/NN promoters/NNS differ/VBP in/IN their/PRP$ dependence/NN on/IN octamer/NN for/IN activation/NN and/CC respond/VBP differently/RB to/TO enhancer/NN activation/NN ./. 
These/DT findings/NNS have/VBP important/JJ implications/NNS in/IN regulation/NN of/IN germline/NN transcription/NN as/RB well/RB as/IN concomitant/JJ activation/NN of/IN the/DT V-J/JJ recombination/NN of/IN the/DT kappa/NN light/JJ chain/NN locus/NN ./. 
UI/LS -/: 97074543/CD 
TI/LS -/: Generation/NN of/IN CD1+RelB+/JJ dendritic/JJ cells/NNS and/CC tartrate-resistant/JJ acid/NN phosphatase-positive/JJ osteoclast-like/JJ multinucleated/JJ giant/JJ cells/NNS from/IN human/JJ monocytes/NNS ./. 
AB/LS -/: We/PRP previously/RB showed/VBD that/IN granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) and/CC macrophage/NN colony-stimulating/JJ factor/NN (/( M-CSF/NN )/) stimulate/VBP the/DT differentiation/NN of/IN human/JJ monocytes/NNS into/IN two/CD phenotypically/RB distinct/JJ types/NNS of/IN macrophages/NNS ./. 
However/RB ,/, in/FW vivo/FW ,/, not/RB only/RB CSF/NN but/CC also/RB many/JJ other/JJ cytokines/NNS are/VBP produced/VBN under/IN various/JJ conditions/NNS ./. 
Those/DT cytokines/NNS may/MD modulate/VB the/DT differentiation/NN of/IN monocytes/NNS by/IN CSFs/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP showed/VBD that/IN CD14+/JJ adherent/JJ human/JJ monocytes/NNS can/MD differentiate/VB into/IN CD1+relB+/JJ dendritic/JJ cells/NNS (/( DC/NN )/) by/IN the/DT combination/NN of/IN GM-CSF/NN plus/CC interleukin-4/NN (/( IL-4/NN )/) and/CC that/IN they/PRP differentiate/VBP into/IN tartrate-resistant/JJ acid/NN phosphatase/NN (/( TRAP/NN )/) -positive/JJ osteoclast-like/JJ multinucleated/JJ giant/JJ cells/NNS (/( MGC/NN )/) by/IN the/DT combination/NN of/IN M-CSF/NN plus/CC IL-4/NN ./. 
However/RB ,/, the/DT monocyte-derived/JJ DC/NN were/VBD not/RB terminally/RB differentiated/VBN cells/NNS ;/: they/PRP could/MD still/RB convert/VB to/TO macrophages/NNS in/IN response/NN to/TO M-CSF/NN ./. 
Tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) stimulated/VBD the/DT terminal/JJ differentiation/NN of/IN the/DT DC/NN by/IN downregulating/VBG the/DT expression/NN of/IN the/DT M-CSF/NN receptor/NN ,/, cfms/NN mRNA/NN ,/, and/CC aborting/VBG the/DT potential/NN to/TO convert/VB to/TO macrophages/NNS ./. 
In/IN contrast/NN to/TO IL-4/NN ,/, interferon-gamma/NN (/( IFN-gamma/NN )/) had/VBD no/DT demonstrable/JJ effect/NN on/IN the/DT differentiation/NN of/IN monocytes/NNS ./. 
Rather/RB ,/, IFN-gamma/NN antagonized/VBD the/DT effect/NN of/IN IL-4/NN and/CC suppressed/VBD the/DT DC/NN and/CC MGC/NN formation/NN induced/VBN by/IN GM-CSF/NN +/CC IL-4/NN and/CC M-CSF/NN +/CC IL-4/NN ,/, respectively/RB ./. 
Taken/VBN together/RB ,/, these/DT results/NNS provide/VBP a/DT new/JJ aspect/NN to/TO our/PRP$ knowledge/NN of/IN monocyte/NN differentiation/NN and/CC provide/VBP evidence/NN that/IN human/JJ monocytes/NNS are/VBP flexible/JJ in/IN their/PRP$ differentiation/NN potential/NN and/CC are/VBP precursors/NNS not/RB only/RB of/IN macrophages/NNS but/CC also/RB of/IN CD1+relB+DC/NN and/CC TRAP-positive/JJ MGC/NN ./. 
Such/PDT a/DT diverse/JJ pathway/NN of/IN monocyte/NN differentiation/NN may/MD constitute/VB one/CD of/IN the/DT basic/JJ mechanisms/NNS of/IN immune/JJ regulation/NN ./. 
UI/LS -/: 97177471/CD 
TI/LS -/: The/DT NF-kappa/NN B/NN inhibitor/NN ,/, tepoxalin/NN ,/, suppresses/VBZ surface/NN expression/NN of/IN the/DT cell/NN adhesion/NN molecules/NNS CD62E/NN ,/, CD11b/CD18/NN and/CC CD106/NN ./. 
AB/LS -/: Tepoxalin/NN ,/, a/DT dual/JJ enzyme/NN inhibitor/NN of/IN cyclooxygenase/NN and/CC 5-lipoxygenase/NN has/VBZ been/VBN shown/VBN to/TO inhibit/VB T-cell/NN activation/NN ./. 
Its/PRP$ immunosuppressive/JJ property/NN is/VBZ distinct/JJ from/IN cyclosporin/NN because/IN only/RB tepoxalin/NN ,/, but/CC not/RB cyclosporin/NN ,/, suppresses/VBZ NF-kappa/NN B/NN activation/NN ./. 
Here/RB we/PRP report/VBP that/IN tepoxalin/NN selectively/RB inhibits/VBZ intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN ,/, CD54/NN )/) /MAC-1/NN (/( CD11b/CD18/NN )/) dependent/JJ adhesion/NN of/IN polymorphonuclear/JJ cells/NNS to/TO IL-1/NN activated/JJ human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS ./. 
The/DT mechanism/NN of/IN inhibition/NN is/VBZ related/JJ to/TO the/DT surface/NN expression/NN of/IN several/JJ cell/NN adhesion/NN molecules/NNS ./. 
Flow/NN cytometry/NN analyses/NNS on/IN cultured/VBN cells/NNS that/WDT were/VBD treated/VBN with/IN tepoxalin/NN or/CC antisense/JJ oligonucleotides/NNS to/TO the/DT P65/p50/NN subunit/NN of/IN NF-kappa/NN B/NN ,/, and/CC then/RB stimulated/VBN with/IN PMA/NN ,/, revealed/VBD a/DT reduced/VBN expression/NN of/IN CD11b/CD18/NN on/IN monocytic/JJ HL60/NN cells/NNS ,/, and/CC endothelial/JJ adhesion/NN molecule-1/NN (/( CD62E/NN )/) and/CC vascular/JJ adhesion/NN molecule-1/NN (/( CD106/NN )/) on/IN human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS ./. 
Expression/NN of/IN other/JJ adhesion/NN molecules/NNS such/JJ as/IN lymphocyte/NN function/NN associated-antigen-1/NN (/( CD11a/CD18/NN )/) and/CC CD54/NN were/VBD unaffected/JJ ./. 
Tepoxalin/NN also/RB inhibited/VBD the/DT secretion/NN of/IN a/DT NF-kappa/NN B/NN regulated/JJ chemokine/NN ,/, IL-8/NN ,/, a/DT known/JJ inducer/NN of/IN CD11b/CD18/NN expression/NN ./. 
Thus/RB the/DT suppression/NN of/IN CD11b/CD18/NN expression/NN by/IN tepoxalin/NN may/MD involve/VB IL-8/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN by/IN inhibiting/VBG NF-kappa/NN B/NN activation/NN ,/, surface/NN expression/NN of/IN several/JJ adhesion/NN molecules/NNS can/MD be/VB modulated/VBN and/CC that/IN tepoxalin/NN may/MD be/VB useful/JJ in/IN treating/VBG selected/VBN adhesion/NN mediated/JJ events/NNS such/JJ as/IN leukocyte/NN migration/NN or/CC atherosclerotic/JJ plaque/NN formation/NN ./. 
UI/LS -/: 97066958/CD 
TI/LS -/: Characterization/NN of/IN a/DT CD43/leukosialin-mediated/JJ pathway/NN for/IN inducing/VBG apoptosis/NN in/IN human/JJ T-lymphoblastoid/JJ cells/NNS ./. 
AB/LS -/: The/DT monoclonal/JJ antibody/NN (/( mAb/NN )/) J393/NN induces/VBZ apoptosis/NN in/IN Jurkat/NN T-cells/NNS ./. 
NH2-terminal/JJ amino/NN acid/NN sequence/NN analysis/NN identified/VBD the/DT 140-kDa/JJ surface/NN antigen/NN for/IN mAb/NN J393/NN as/IN CD43/leukosialin/NN ,/, the/DT major/JJ sialoglycoprotein/NN of/IN leukocytes/NNS ./. 
While/IN Jurkat/NN cells/NNS co-expressed/VBD two/CD discrete/JJ cell-surface/JJ isoforms/NNS of/IN CD43/NN ,/, recognized/VBN by/IN mAb/NN J393/NN and/CC mAb/NN G10-2/NN ,/, respectively/RB ,/, only/RB J393/CD43/NN signaled/VBD apoptosis/NN ./. 
J393/CD43/NN was/VBD found/VBN to/TO be/VB hyposialylated/VBN ,/, bearing/VBG predominantly/RB O-linked/JJ monosaccharide/NN glycans/NNS ,/, whereas/IN G10-2/CD43/NN bore/VBD complex/JJ sialylated/VBN tetra-/JJ and/CC hexasaccharide/NN chains/NNS ./. 
Treatment/NN with/IN soluble/JJ ,/, bivalent/JJ mAb/NN J393/NN killed/VBD 25-50/CD %/NN of/IN the/DT cell/NN population/NN ,/, while/IN concomitant/JJ engagement/NN of/IN either/CC the/DT CD3.TcR/NN complex/NN or/CC the/DT integrins/NNS CD18/NN and/CC CD29/NN significantly/RB potentiated/VBD this/DT effect/NN ./. 
Treatment/NN of/IN Jurkat/NN cells/NNS with/IN mAb/NN J393/NN induced/VBD tyrosine/NN phosphorylation/NN of/IN specific/JJ protein/NN substrates/NNS that/WDT underwent/VBD hyperphosphorylation/NN upon/IN antigen/NN receptor/NN costimulation/NN ./. 
Tyrosine/NN kinase/NN inhibition/NN by/IN herbimycin/NN A/NN diminished/VBD J393/CD43-mediated/JJ apoptosis/NN ,/, whereas/IN inhibition/NN of/IN phosphotyrosine/NN phosphatase/NN activity/NN by/IN bis(maltolato)oxovanadium-IV/NN enhanced/VBD cell/NN death/NN ./. 
Signal/NN transduction/NN through/IN tyrosine/NN kinase/NN activation/NN may/MD lead/VB to/TO altered/JJ gene/NN expression/NN ,/, as/IN J393/CD43/NN ligation/NN prompted/VBD decreases/NNS in/IN the/DT nuclear/JJ localization/NN of/IN the/DT transcriptional/JJ regulatory/JJ protein/NN NF-kappaB/NN and/CC proteins/NNS binding/VBG the/DT interferon-inducible/JJ regulatory/JJ element/NN ./. 
Since/IN peripheral/JJ blood/NN T-lymphocytes/NNS express/VBP cryptic/JJ epitopes/NNS for/IN mAb/NN J393/NN ,/, these/DT findings/NNS demonstrate/VBP the/DT existence/NN of/IN a/DT tightly/RB regulated/VBN CD43-mediated/JJ pathway/NN for/IN inducing/VBG apoptosis/NN in/IN human/JJ T-cell/NN lineages/NNS ./. 
UI/LS -/: 97103140/CD 
TI/LS -/: Sterol/NN dependent/JJ LDL-receptor/NN gene/NN transcription/NN in/IN lymphocytes/NNS from/IN normal/JJ and/CC CML/NN patients/NNS ./. 
AB/LS -/: Sterol/NN regulatory/JJ element/NN (/( SRE/NN )/) has/VBZ been/VBN recognized/VBN to/TO regulate/VB various/JJ key/JJ genes/NNS coding/VBG for/IN especially/RB low/JJ density/NN lipoprotein/NN (/( LDL/NN )/) -receptor/NN ,/, 3-hydroxy-3-methylglutaryl/NN coenzyme/NN A/NN (/( HMG-CoA/NN )/) reductase/NN and/CC HMG-CoA/NN synthase/NN known/VBN to/TO play/VB a/DT crucial/JJ role/NN in/IN the/DT cholesterol/NN feedback/NN mechanism/NN ./. 
The/DT deranged/JJ cholesterol/NN feedback/NN mechanism/NN has/VBZ been/VBN widely/RB recognised/VBN in/IN initiation/NN as/RB well/RB as/IN progression/NN of/IN various/JJ types/NNS of/IN cancers/NNS including/VBG chronic/JJ myeloid/JJ leukaemia/NN (/( CML/NN )/) ./. 
Consequently/RB ,/, the/DT present/JJ study/NN was/VBD addressed/VBN to/TO understand/VB this/DT phenomenon/NN and/CC revealed/VBD the/DT existence/NN of/IN a/DT unique/JJ 47/CD kDa/NN protein/NN factor/NN having/VBG affinity/NN for/IN this/DT SRE/NN sequence/NN in/IN lymphocytes/NNS from/IN normal/JJ subjects/NNS as/RB well/RB as/IN its/PRP$ absence/NN in/IN lymphocytes/NNS from/IN untreated/JJ CML/NN patients/NNS ./. 
However/RB ,/, this/DT factor/NN appeared/VBD when/WRB the/DT CML/NN patients/NNS achieved/VBD complete/JJ haematological/JJ remission/NN (/( CHR/NN )/) through/IN alpha-interferon/NN therapy/NN ./. 
Further/RB ,/, an/DT inverse/NN relationship/NN was/VBD also/RB observed/VBN between/IN sterol/NN modulated/JJ LDL-receptor/NN gene/NN transcription/NN and/CC the/DT binding/NN affinity/NN of/IN this/DT 47/CD kDa/NN factor/NN to/TO the/DT SRE/NN sequence/NN ./. 
Based/VBN upon/IN these/DT results/NNS we/PRP propose/VBP that/IN alpha-interferon/NN through/IN its/PRP$ receptor/NN initiates/VBZ phosphatidic/JJ acid/NN dependent/JJ signalling/NN which/WDT in/IN turn/NN regulates/VBZ the/DT affinity/NN of/IN 47/CD kDa/NN sterol/NN regulatory/JJ element/NN binding/NN factor/NN as/RB well/RB as/IN LDL-receptor/NN gene/NN transcription/NN in/IN lymphocytes/NNS from/IN CML/NN patients/NNS ./. 
UI/LS -/: 94285936/CD 
TI/LS -/: Multiple/JJ prolactin-responsive/JJ elements/NNS mediate/VBP G1/NN and/CC S/NN phase/NN expression/NN of/IN the/DT interferon/NN regulatory/JJ factor-1/NN gene/NN ./. 
AB/LS -/: The/DT interferon/NN regulatory/JJ factor-1/NN (/( IRF-1/NN )/) gene/NN is/VBZ both/CC an/DT immediate-early/JJ G1/NN phase/NN gene/NN and/CC an/DT S/NN phase/NN gene/NN inducible/JJ by/IN PRL/NN in/IN rat/NN Nb2/NN T/NN lymphocytes/NNS ./. 
To/TO understand/VB the/DT mechanism/NN by/IN which/WDT PRL/NN regulates/VBZ the/DT biphasic/JJ expression/NN of/IN IRF-1/NN ,/, we/PRP cloned/VBD the/DT rat/NN IRF-1/NN gene/NN and/CC functionally/RB characterized/VBD the/DT IRF-1/NN promoter/NN ./. 
Upon/IN transfection/NN into/IN Nb2/NN T/NN cells/NNS ,/, 1.7/CD kilobases/NNS (/( kb/NN )/) of/IN IRF-1/NN 5'-flanking/JJ DNA/NN linked/VBN to/TO a/DT chloramphenicol/NN acetyl/JJ|NN transferase/NN (/( CAT/NN )/) reporter/NN gene/NN mediated/VBD a/DT 30-fold/JJ induction/NN of/IN CAT/NN enzyme/NN activity/NN in/IN response/NN to/TO 24/CD h/NN of/IN PRL/NN stimulation/NN ./. 
Deletion/NN mutants/NNS containing/VBG 1.3/CD ,/, 0.6/CD ,/, and/CC 0.2/CD kb/NN 5'-flanking/JJ DNA/NN were/VBD incrementally/RB less/RBR transcriptionally/RB active/JJ ,/, although/IN 0.2/CD kb/NN still/RB mediated/VBD a/DT 12-fold/JJ induction/NN by/IN PRL/NN ./. 
The/DT sequence/NN between/IN -1.7/CD and/CC -0.2/CD kb/NN linked/VBN to/TO a/DT heterologous/JJ thymidine/NN kinase/NN promoter/NN failed/VBD to/TO respond/VB to/TO PRL/NN stimulation/NN ,/, suggesting/VBG that/IN the/DT activity/NN of/IN upstream/JJ PRL/NN response/NN elements/NNS may/MD require/VB an/DT interaction/NN with/IN promoter-proximal/JJ elements/NNS ./. 
By/IN assaying/VBG CAT/NN enzyme/NN activity/NN across/IN a/DT 24-h/JJ PRL/NN induction/NN time/NN course/NN ,/, we/PRP were/VBD able/JJ to/TO assign/VB G1/NN vs./CC S/NN phase/NN PRL/NN responses/NNS of/IN the/DT IRF-1/NN gene/NN to/TO different/JJ regions/NNS of/IN the/DT IRF-1/NN 5'-flanking/JJ and/CC promoter/NN DNA/NN ./. 
The/DT 0.2-kb/JJ IRF-CAT/NN construct/NN was/VBD induced/VBN by/IN PRL/NN stimulation/NN during/IN the/DT G1/NN phase/NN of/IN the/DT cell/NN cycle/NN ./. 
In/IN contrast/NN ,/, the/DT 1.7-kb/JJ IRF-CAT/NN construct/NN was/VBD inducible/JJ by/IN PRL/NN during/IN both/CC G1/NN and/CC S/NN phase/NN of/IN the/DT cell/NN cycle/NN ./. 
Hence/RB ,/, the/DT PRL-induced/JJ biphasic/JJ expression/NN of/IN the/DT IRF-1/NN gene/NN appears/VBZ to/TO be/VB controlled/VBN by/IN separate/JJ PRL-responsive/JJ elements/NNS :/: elements/NNS in/IN the/DT first/JJ 0.2/CD kb/NN of/IN the/DT IRF-1/NN promoter/NN region/NN act/VBP during/IN early/JJ activation/NN ,/, and/CC elements/NNS between/IN 0.2/CD and/CC 1.7/CD kb/NN act/VBP in/IN concert/NN with/IN the/DT proximal/JJ 0.2-kb/JJ region/NN during/IN S/NN phase/NN progression/NN ./. 
UI/LS -/: 94120719/CD 
TI/LS -/: Regulation/NN of/IN the/DT BZLF1/NN promoter/NN of/IN Epstein-Barr/JJ virus/NN by/IN second/JJ messengers/NNS in/IN anti-immunoglobulin-treated/JJ B/NN cells/NNS ./. 
AB/LS -/: Initiation/NN of/IN the/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) lytic/JJ cycle/NN is/VBZ dependent/JJ on/IN the/DT transcription/NN of/IN the/DT BZLF1/NN gene/NN ./. 
The/DT BZLF1/NN gene/NN promoter/NN (/( Zp/NN )/) was/VBD activated/VBN by/IN crosslinking/NN of/IN cell/NN surface/NN immunoglobulin/NN (/( Ig/NN )/) with/IN anti-Ig/JJ antibody/NN in/IN B/NN cells/NNS ,/, even/RB in/IN the/DT absence/NN of/IN other/JJ viral/JJ genes/NNS ./. 
We/PRP identified/VBD several/JJ anti-Ig/JJ response/NN elements/NNS within/IN Zp/NN ,/, which/WDT were/VBD originally/RB defined/VBN as/IN 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) response/NN elements/NNS (/( ZI/NN repeats/NNS and/CC ZII/NN ,/, an/DT AP-1-like/JJ domain/NN )/) ./. 
Since/IN anti-Ig/JJ crosslinking/NN leads/VBZ to/TO activation/NN of/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) and/CC an/DT increase/NN in/IN intracellular/JJ calcium/NN level/NN ,/, Zp/NN was/VBD tested/VBN for/IN the/DT response/NN to/TO these/DT cellular/JJ factors/NNS ./. 
Treatment/NN with/IN calcium/NN ionophore/NN A23187/NN increased/VBD Zp/NN activity/NN ./. 
When/WRB the/DT calcium/NN ionophore/NN was/VBD used/VBN in/IN conjunction/NN with/IN TPA/NN ,/, a/DT PKC/NN activator/NN ,/, the/DT Zp/NN induction/NN was/VBD synergistically/RB enhanced/VBN ./. 
1-(5-Isoquinolinyl sulfonyl)-2-methylpiperazine/NN ,/, an/DT inhibitor/NN of/IN PKC/NN ,/, inhibited/VBD the/DT anti-Ig/JJ inducibility/NN of/IN Zp/NN ./. 
Calmodulin/NN antagonists/NNS ,/, compound/NN R24571/NN and/CC trifluoperazine/NN ,/, blocked/VBD the/DT Zp/NN activation/NN with/IN anti-Ig/NN ./. 
These/DT findings/NNS suggest/VBP that/IN Zp/NN responds/VBZ directly/RB to/TO changes/NNS in/IN the/DT activity/NN of/IN both/CC PKC/NN and/CC calcium/calmodulin-dependent/JJ protein/NN kinase/NN ./. 
Requirement/NN of/IN tyrosine/NN kinase/NN activation/NN for/IN the/DT anti-Ig-mediated/JJ Zp/NN activation/NN was/VBD also/RB demonstrated/VBN through/IN the/DT use/NN of/IN the/DT tyrosine/NN kinase/NN inhibitor/NN herbimycin/NN ./. 
These/DT cellular/JJ gene/NN regulatory/JJ molecules/NNS induced/VBN with/IN anti-Ig/NN may/MD cooperatively/RB play/VB an/DT important/JJ part/NN in/IN achieving/VBG efficient/JJ EBV/NN activation/NN as/IN seen/VBN with/IN anti-Ig/JJ treatment/NN in/IN B/NN cells/NNS ./. 
UI/LS -/: 94118533/CD 
TI/LS -/: The/DT SCL/NN protein/NN displays/VBZ cell-specific/JJ heterogeneity/NN in/IN size/NN ./. 
AB/LS -/: SCL/NN protein/NN production/NN was/VBD examined/VBN in/IN a/DT variety/NN of/IN hemopoietic/JJ cell/NN lines/NNS by/IN immunoblotting/VBG using/VBG specific/JJ polyclonal/JJ antisera/NNS ./. 
SCL/NN protein/NN was/VBD detected/VBN in/IN erythroid/JJ ,/, megakaryocyte/NN ,/, mast/NN and/CC early/JJ myeloid/JJ cell/NN lines/NNS ,/, as/RB well/RB as/IN in/IN several/JJ lymphoid/JJ leukemia/NN cell/NN lines/NNS which/WDT are/VBP known/VBN to/TO harbor/VB SCL/NN gene/NN rearrangements/NNS ./. 
In/IN most/JJS cell/NN lines/NNS ,/, proteins/NNS of/IN molecular/JJ weight/NN 49/CD and/CC 44/CD kDa/NN were/VBD found/VBN ,/, however/RB two/CD myeloid/JJ cell/NN lines/NNS expressed/VBD only/RB lower/JJR molecular/JJ weight/NN species/NNS of/IN 24/CD and/CC 22/CD kDa/NN ./. 
This/DT size/NN discrepancy/NN appeared/VBD to/TO be/VB due/JJ to/TO cell-specific/JJ translational/JJ regulation/NN ,/, since/IN overexpression/NN of/IN a/DT retrovirally/RB transfected/VBN SCL/NN gene/NN yielded/VBD the/DT higher/JJR molecular/JJ weight/NN forms/NNS in/IN most/JJS cell/NN lines/NNS (/( GP+E-86/NN ,/, AT2.5/NN ,/, M1/NN )/) but/CC only/RB the/DT 22/CD kDa/NN form/NN in/IN the/DT myeloid/JJ cell/NN line/NN ,/, WEHI-3B/D+/NN ./. 
Overexpression/NN of/IN full-length/JJ SCL/NN protein/NN in/IN the/DT lymphoid/JJ cell/NN lines/NNS ,/, SupT1/NN and/CC Raji/NN ,/, did/VBD not/RB alter/VB cell/NN phenotype/NN and/CC there/EX was/VBD no/DT evidence/NN for/IN autoregulation/NN of/IN SCL/NN transcription/NN ./. 
The/DT restricted/JJ pattern/NN of/IN SCL/NN protein/NN synthesis/NN is/VBZ consistent/JJ with/IN the/DT restricted/JJ expression/NN of/IN SCL/NN mRNA/NN documented/VBN previously/RB ./. 
In/IN addition/NN ,/, the/DT present/JJ results/NNS indicate/VBP that/IN SCL/NN protein/NN size/NN was/VBD determined/VBN by/IN regulation/NN of/IN translation/NN in/IN a/DT cell-specific/JJ manner/NN ./. 
UI/LS -/: 94290489/CD 
TI/LS -/: Description/NN and/CC functional/JJ implications/NNS of/IN a/DT novel/JJ mutation/NN in/IN the/DT sex-determining/JJ gene/NN SRY/NN ./. 
AB/LS -/: The/DT sex-determining/JJ gene/NN SRY/NN was/VBD screened/VBN for/IN molecular/JJ alteration/NN in/IN an/DT XY/NN sex-reversed/JJ female/NN by/IN single-strand/JJ conformation/NN polymorphism/NN (/( SSCP/NN )/) technique/NN ./. 
An/DT A-to-G/JJ transition/NN was/VBD detected/VBN which/WDT leads/VBZ to/TO an/DT exchange/NN of/IN a/DT tyrosine/NN by/IN a/DT cysteine/NN in/IN the/DT SRY/NN protein/NN ./. 
The/DT affected/VBN tyrosine/NN residue/NN located/JJ at/IN the/DT C/NN terminus/NN of/IN the/DT DNA/NN binding/NN protein/NN is/VBZ evolutionarily/RB strongly/RB conserved/VBN among/IN the/DT members/NNS of/IN the/DT HMG/NN box/NN containing/VBG proteins/NNS ./. 
Using/VBG gel/NN shift/NN assay/NN and/CC peptide/NN synthesis/NN such/PDT a/DT mutation/NN is/VBZ shown/VBN to/TO abolish/VB the/DT SRY/NN protein/NN DNA/NN binding/NN ability/NN ./. 
The/DT involvement/NN of/IN this/DT particular/JJ amino/NN acid/NN in/IN the/DT binding/NN specificity/NN is/VBZ also/RB discussed/VBN ./. 
UI/LS -/: 94107268/CD 
TI/LS -/: Induction/NN of/IN tyrosine/NN phosphorylation/NN and/CC T-cell/NN activation/NN by/IN vanadate/NN peroxide/NN ,/, an/DT inhibitor/NN of/IN protein/NN tyrosine/NN phosphatases/NNS ./. 
AB/LS -/: Rapid/JJ tyrosine/NN phosphorylation/NN of/IN key/JJ cellular/JJ proteins/NNS is/VBZ a/DT crucial/JJ event/NN in/IN the/DT transduction/NN of/IN activation/NN signals/NNS to/TO T-lymphocytes/NNS ./. 
The/DT regulatory/JJ role/NN of/IN protein/NN tyrosine/NN phosphatases/NNS (/( PTPases/NNS )/) in/IN this/DT process/NN was/VBD explored/VBN by/IN studying/VBG the/DT effects/NNS of/IN a/DT powerful/JJ PTPase/NN inhibitor/NN ,/, vanadate/NN peroxide/NN (/( pervanadate/NN )/) ,/, on/IN the/DT activation/NN cascade/NN of/IN Jurkat/NN human/JJ leukaemic/JJ T-cells/NNS ./. 
Pervanadate/NN induced/VBD activation/NN of/IN the/DT tyrosine/NN kinases/NNS lck/NN and/CC fyn/NN (/( 4-/CD and/CC 3-fold/JJ respectively/RB )/) and/CC a/DT dramatic/JJ increase/NN in/IN tyrosine/NN phosphorylation/NN of/IN cellular/JJ proteins/NNS ,/, notably/RB phospholipase/NN C/NN gamma/NN 1/CD ./. 
After/IN this/DT event/NN ,/, we/PRP observed/VBD a/DT rise/NN in/IN intracellular/JJ Ca2+/NN concentration/NN ,/, corresponding/VBG to/TO an/DT influx/NN ./. 
This/DT effect/NN required/VBD surface/NN expression/NN of/IN the/DT CD45/NN PTPase/NN and/CC was/VBD not/RB observed/VBN in/IN CD45-deficient/JJ variants/NNS of/IN Jurkat/NN cells/NNS ./. 
In/IN the/DT CD45-negative/JJ variant/NN ,/, the/DT effect/NN of/IN pervanadate/NN on/IN tyrosine/NN phosphorylation/NN was/VBD globally/RB decreased/VBN and/CC some/DT phosphorylated/VBN substrates/NNS were/VBD specifically/RB missing/JJ ./. 
Pervanadate/NN also/RB stimulated/VBD transcription/NN of/IN the/DT c-fos/NN gene/NN and/CC accumulation/NN of/IN its/PRP$ mRNA/NN as/RB well/RB as/IN several/JJ other/JJ hallmarks/NNS of/IN T-lymphocyte/NN activation/NN such/JJ as/IN surface/NN expression/NN of/IN the/DT CD69/NN antigen/NN and/CC the/DT interleukin/NN 2/CD receptor/NN alpha-chain/NN (/( CD25/NN )/) ./. 
Pervanadate/NN synergized/VBD with/IN signals/NNS delivered/VBN by/IN T-cell/NN antigen/NN receptor/NN engagement/NN or/CC by/IN a/DT phorbol/NN ester/NN to/TO induce/VB interleukin/NN 2/CD production/NN ./. 
Pervanadate/NN activated/VBD NF-kappa/NN B/NN ,/, as/IN shown/VBN by/IN an/DT increase/NN in/IN DNA-binding/JJ activity/NN of/IN this/DT transcription/NN factor/NN ./. 
We/PRP thus/RB conclude/VBP that/IN PTPases/NNS play/VBP a/DT crucial/JJ role/NN in/IN the/DT negative/JJ regulation/NN of/IN signal/NN transduction/NN culminating/VBG in/IN T-lymphocyte/NN activation/NN ./. 
Moreover/RB ,/, induction/NN of/IN tyrosine/NN phosphorylation/NN appears/VBZ sufficient/JJ per/FW se/FW to/TO initiate/VB a/DT complete/JJ activation/NN programme/NN ./. 
UI/LS -/: 97113313/CD 
TI/LS -/: Activation/NN of/IN nuclear/JJ factor-kappaB/NN via/IN T/NN cell/NN receptor/NN requires/VBZ a/DT Raf/NN kinase/NN and/CC Ca2+/NN influx/NN ./. 
Functional/JJ synergy/NN between/IN Raf/NN and/CC calcineurin/NN ./. 
AB/LS -/: Signals/NNS transduced/VBN via/IN the/DT TCR/NN activate/VBP the/DT transcription/NN factor/NN nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) ,/, which/WDT ,/, in/IN turn/NN ,/, is/VBZ critical/JJ to/TO the/DT transcriptional/JJ induction/NN of/IN many/JJ genes/NNS important/JJ for/IN the/DT proliferation/NN and/CC expression/NN of/IN a/DT differentiated/VBN phenotype/NN ./. 
Treatment/NN of/IN T/NN cells/NNS with/IN the/DT protein/NN kinase/NN C/NN activator/NN PMA/NN in/IN combination/NN with/IN Ca2+/NN ionophores/NNS mimics/VBZ this/DT process/NN ,/, and/CC the/DT two/CD agents/NNS are/VBP often/RB substituted/VBN for/IN TCR/NN stimulation/NN ,/, bypassing/VBG the/DT TCR/NN ./. 
Here/RB we/PRP identify/VBP intracellular/JJ signaling/VBG components/NNS involved/VBN in/IN activation/NN of/IN NF-kappaB/NN following/VBG TCR/NN stimulation/NN ./. 
TCR/NN signaling/NN was/VBD triggered/VBN by/IN treating/VBG Jurkat/NN T/NN cells/NNS with/IN PHA/NN or/CC anti-CD3/JJ Abs/NNS ,/, and/CC NF-kappaB/NN activation/NN was/VBD monitored/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS and/or/CC by/IN kappaB-dependent/JJ reporter/NN assays/NNS ./. 
Contrary/JJ to/TO the/DT idea/NN that/IN protein/NN kinase/NN C/NN is/VBZ involved/VBN in/IN TCR-mediated/JJ activation/NN of/IN NF-kappaB/NN ,/, high/JJ doses/NNS of/IN staurosporine/NN did/VBD not/RB interfere/VB with/IN activation/NN of/IN NF-kappaB/NN by/IN PHA/NN ,/, while/IN the/DT same/JJ dose/NN of/IN staurosporine/NN completely/RB blocked/VBD activation/NN by/IN PMA/NN ./. 
PHA-induced/JJ kappaB-dependent/JJ reporter/NN activity/NN was/VBD ,/, however/RB ,/, effectively/RB blocked/VBN by/IN a/DT dominant/JJ negative/JJ form/NN of/IN Raf-1/NN ,/, suggesting/VBG a/DT critical/JJ role/NN for/IN a/DT Raf/NN kinase/NN ./. 
The/DT TCR-mediated/JJ activation/NN of/IN NF-kappaB/NN was/VBD also/RB dependent/JJ on/IN a/DT Ca2+/NN influx/NN ,/, because/IN the/DT Ca2+/NN channel/NN blocker/NN ,/, SK&F/NN 96365/CD ,/, as/RB well/RB as/IN other/JJ agents/NNS that/WDT prevented/VBD the/DT Ca2+/NN influx/NN ,/, inhibited/VBD NF-kappaB/NN activation/NN ./. 
Cotransfection/NN of/IN a/DT constitutively/RB active/JJ form/NN of/IN calcineurin/NN largely/RB substituted/VBD for/IN the/DT Ca2+/NN requirement/NN and/CC reversed/VBD the/DT blockade/NN by/IN SK&F/NN 96365/CD ./. 
Consistent/JJ with/IN these/DT observations/NNS ,/, coexpression/NN of/IN constitutively/RB active/JJ forms/NNS of/IN Raf-1/NN and/CC calcineurin/NN synergistically/RB induced/VBD kappaB-dependent/JJ reporter/NN activity/NN ,/, suggesting/VBG a/DT physiologically/RB relevant/JJ functional/JJ interaction/NN between/IN the/DT kinase/NN and/CC the/DT phosphatase/NN ./. 
UI/LS -/: 97126060/CD 
TI/LS -/: Synergistic/JJ interactions/NNS between/IN overlapping/VBG binding/VBG sites/NNS for/IN the/DT serum/NN response/NN factor/NN and/CC ELK-1/NN proteins/NNS mediate/VBP both/CC basal/JJ enhancement/NN and/CC phorbol/NN ester/NN responsiveness/NN of/IN primate/JJ cytomegalovirus/NN major/JJ immediate-early/JJ promoters/NNS in/IN monocyte/NN and/CC T-lymphocyte/NN cell/NN types/NNS ./. 
AB/LS -/: Cytomegalovirus/NN (/( CMV/NN )/) infection/NN is/VBZ nonpermissive/JJ or/CC persistent/JJ in/IN many/JJ lymphoid/JJ and/CC myeloid/JJ cell/NN types/NNS but/CC can/MD be/VB activated/VBN in/IN differentiated/VBN macrophages/NNS ./. 
We/PRP have/VBP shown/VBN elsewhere/RB that/IN both/CC the/DT major/JJ immediate-early/JJ gene/NN (/( MIE/NN )/) and/CC lytic/JJ cycle/NN infectious/JJ progeny/NN virus/NN expression/NN can/MD be/VB induced/VBN in/IN otherwise/JJ nonpermissive/JJ monocyte-like/JJ U-937/NN cell/NN cultures/NNS infected/VBN with/IN either/CC human/JJ CMV/NN (/( HCMV/NN )/) or/CC simian/JJ CMV/NN (/( SCMV/NN )/) by/IN treatment/NN with/IN the/DT phorbol/NN ester/NN 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) ./. 
Two/CD multicopy/JJ basal/JJ enhancer/NN motifs/NNS within/IN the/DT SCMV/NN MIE/NN enhancer/NN ,/, namely/RB ,/, 11/CD copies/NNS of/IN the/DT 16-bp/JJ cyclic/JJ AMP/NN response/NN element/NN (/( CRE/NN )/) and/CC 3/CD copies/NNS of/IN novel/JJ 17-bp/JJ serum/NN response/NN factor/NN (/( SRF/NN )/) binding/NN sites/NNS referred/VBN to/TO as/IN the/DT SNE/NN (/( SRF/NFkappaB-like/JJ element/NN )/) ,/, as/RB well/RB as/IN four/CD classical/JJ NFkappaB/NN sites/NNS within/IN the/DT HCMV/NN version/NN ,/, contribute/VBP to/TO TPA/NN responsiveness/NN in/IN transient/JJ assays/NNS in/IN monocyte/NN and/CC T-cell/NN types/NNS ./. 
The/DT SCMV/NN SNE/NN sites/NNS contain/VBP potential/JJ overlapping/VBG core/NN recognition/NN binding/NN motifs/NNS for/IN SRF/NN ,/, Rel/NFkappaB/NN ,/, ETS/NN ,/, and/CC YY1/NN class/NN transcription/NN factors/NNS but/CC fail/VBP to/TO respond/VB to/TO either/CC serum/NN or/CC tumor/NN necrosis/NN factor/NN alpha/NN ./. 
Therefore/RB ,/, to/TO evaluate/VB the/DT mechanism/NN of/IN TPA/NN responsiveness/NN of/IN the/DT SNE/NN motifs/NNS and/CC of/IN a/DT related/JJ 16-bp/JJ SEE/NN (/( SRF/ETS/NN element/NN )/) motif/NN found/VBN in/IN the/DT HCMV/NN and/CC chimpanzee/NN CMV/NN MIE/NN enhancers/NNS ,/, we/PRP have/VBP examined/VBN the/DT functional/JJ responses/NNS and/CC protein/NN binding/NN properties/NNS of/IN multimerized/JJ wild-type/JJ and/CC mutant/JJ elements/NNS added/VBN upstream/RB to/TO the/DT SCMV/NN MIE/NN or/CC simian/JJ virus/NN 40/CD minimal/JJ promoter/NN regions/NNS in/IN the/DT U-937/NN ,/, K-562/NN ,/, HL-60/NN ,/, THP-1/NN ,/, and/CC Jurkat/NN cell/NN lines/NNS ./. 
Unlike/IN classical/JJ NFkappaB/NN sites/NNS ,/, neither/CC the/DT SNE/NN nor/CC the/DT SEE/NN motif/NN responded/VBD to/TO phosphatase/NN inhibition/NN by/IN okadaic/JJ acid/NN ./. 
However/RB ,/, the/DT TPA/NN responsiveness/NN of/IN both/DT CMV/NN elements/NNS proved/VBD to/TO involve/VB synergistic/JJ interactions/NNS between/IN the/DT core/NN SRF/NN binding/NN site/NN (/( CCATATATGG/NN )/) and/CC the/DT adjacent/JJ inverted/VBN ETS/NN binding/NN motifs/NNS (/( TTCC/NN )/) ,/, which/WDT correlated/VBD directly/RB with/IN formation/NN of/IN a/DT bound/VBN tripartite/JJ complex/NN containing/VBG both/CC the/DT cellular/JJ SRF/NN and/CC ELK-1/NN proteins/NNS ./. 
This/DT protein/NN complex/NN was/VBD more/RBR abundant/JJ in/IN U-937/NN ,/, K-562/NN ,/, and/CC HeLa/NN cell/NN extracts/NNS than/IN in/IN Raji/NN ,/, HF/NN ,/, BALB/c/NN 3T3/NN ,/, or/CC HL-60/NN cells/NNS ,/, but/CC the/DT binding/NN activity/NN was/VBD altered/VBN only/RB twofold/RB after/IN TPA/NN treatment/NN ./. 
A/DT 40-fold/JJ stimulation/NN of/IN chloramphenicol/JJ acetyltransferase/NN activity/NN mediated/VBN by/IN four/CD tandem/JJ repeats/NNS of/IN the/DT SNE/NN could/MD be/VB induced/VBN within/IN 2/CD h/NN (/( and/CC up/RB to/TO 250-fold/JJ within/IN 6/CD h/NN )/) after/IN addition/NN of/IN TPA/NN in/IN DNA-transfected/JJ U-937/NN cells/NNS ,/, indicating/VBG that/IN the/DT stimulation/NN appeared/VBD likely/JJ to/TO be/VB a/DT true/JJ protein/NN kinase/NN C-mediated/JJ signal/NN transduction/NN event/NN rather/RB than/IN a/DT differentiation/NN response/NN ./. 
Slight/JJ differences/NNS in/IN the/DT sequence/NN of/IN the/DT core/NN SRF/NN binding/NN site/NN compared/VBN with/IN that/DT of/IN the/DT classical/JJ c-Fos/NN promoter/NN serum/NN response/NN element/NN ,/, together/RB with/IN differences/NNS in/IN the/DT spacing/NN between/IN the/DT SRF/NN and/CC ETS/NN motifs/NNS ,/, appear/VBP to/TO account/VB for/IN the/DT inability/NN of/IN the/DT SCMV/NN SNEs/NNS to/TO respond/VB to/TO serum/NN induction/NN ./. 
UI/LS -/: 97069862/CD 
TI/LS -/: T-cell-directed/JJ TAL-1/NN expression/NN induces/VBZ T-cell/NN malignancies/NNS in/IN transgenic/JJ mice/NNS ./. 
AB/LS -/: The/DT TAL-1/NN gene/NN specifies/VBZ for/IN a/DT basic/JJ domain-helix-loop-helix/JJ protein/NN ,/, which/WDT is/VBZ involved/VBN in/IN the/DT control/NN of/IN normal/JJ hematopoiesis/NN ./. 
In/IN human/JJ pathology/NN ,/, the/DT TAL-1/NN gene/NN product/NN is/VBZ expressed/VBN in/IN a/DT high/JJ percentage/NN of/IN T-cell/NN acute/JJ lymphoblastic/JJ leukemias/NNS in/IN the/DT pediatric/JJ age/NN range/NN ;/: however/RB ,/, it/PRP has/VBZ not/RB been/VBN established/VBN whether/IN the/DT expression/NN has/VBZ a/DT causal/JJ role/NN in/IN oncogenesis/NN ./. 
In/IN this/DT report/NN ,/, we/PRP describe/VBP the/DT phenotype/NN of/IN mouse/NN transgenic/JJ lines/NNS obtained/VBN by/IN inducing/VBG tal-1/NN protein/NN expression/NN in/IN lymphoid/JJ tissues/NNS using/VBG the/DT LCK/NN promoter/NN ./. 
The/DT survival/NN rate/NN of/IN tal-1/NN transgenic/JJ animals/NNS was/VBD much/RB lower/JJR as/IN compared/VBN with/IN control/NN mice/NNS ./. 
Histopathological/JJ analysis/NN revealed/VBD lymphomas/NNS of/IN T-cell/NN type/NN ,/, often/RB comprising/VBG a/DT minor/JJ B-cell/NN component/NN ./. 
Some/DT mice/NNS showed/VBD marked/JJ splenic/JJ lymphocyte/NN depletion/NN ./. 
Primary/JJ lymphocyte/NN cultures/NNS showed/VBD partial/JJ independence/NN from/IN exogenous/JJ growth/NN stimuli/NNS and/CC increased/VBD resistance/NN to/TO low-serum/JJ apoptosis/NN ./. 
To/TO further/RB unravel/VB the/DT tal-1/NN oncogenic/JJ potential/NN ,/, a/DT strain/NN of/IN tal-1/NN transgenic/JJ mice/NNS was/VBD crossbred/VBN with/IN p53-/-/JJ mice/NNS ;/: the/DT survival/NN rate/NN in/IN these/DT animals/NNS was/VBD reduced/VBN by/IN more/JJR than/IN one-half/NN when/WRB compared/VBN with/IN that/DT of/IN tal-1/NN mice/NNS ,/, and/CC histopathological/JJ analysis/NN revealed/VBD exclusively/RB T-cell/NN lymphomas/NNS ./. 
These/DT data/NNS indicate/VBP that/IN TAL-1/NN ,/, expressed/VBN in/IN T/NN cells/NNS ,/, is/VBZ per/FW se/FW a/DT potent/JJ oncogene/NN ,/, which/WDT may/MD exert/VB a/DT key/JJ leukemogenetic/JJ role/NN in/IN the/DT majority/NN of/IN T-cell/NN acute/JJ lymphoblastic/JJ leukemias/NNS ./. 
UI/LS -/: 97087515/CD 
TI/LS -/: Tissue/NN and/CC cell-type/JJ specific/JJ expression/NN of/IN the/DT tuberous/JJ sclerosis/NN gene/NN ,/, TSC2/NN ,/, in/IN human/JJ tissues/NNS ./. 
AB/LS -/: TSC2/NN is/VBZ a/DT gene/NN on/IN chromosome/NN 16p13.3/NN associated/VBN with/IN the/DT autosomal/JJ dominant/JJ neurocutaneous/JJ disorder/NN ,/, tuberous/JJ sclerosis/NN complex/NN (/( TSC/NN )/) ./. 
By/IN using/VBG a/DT partial/JJ nucleotide/JJ sequence/NN from/IN the/DT cloned/VBN TSC2/NN and/CC polymerase/NN chain/NN reaction/NN methodology/NN ,/, we/PRP constructed/VBD a/DT digoxigenin-labeled/JJ complementary/JJ DNA/NN probe/NN to/TO examine/VB TSC2/NN gene/NN expression/NN in/IN autopsy-/NN or/CC biopsy-derived/JJ human/JJ tissues/NNS by/IN in/FW situ/FW hybridization/NN ./. 
TSC2/NN messenger/NN RNA/NN was/VBD widely/RB expressed/VBN in/IN various/JJ cell/NN types/NNS throughout/IN the/DT body/NN ,/, including/VBG epithelia/NN ,/, lymphocytes/NNS ,/, and/CC cells/NNS with/IN endocrine/JJ functions/NNS ,/, e.g./FW ,/, adrenal/JJ cortex/NN and/CC anterior/JJ pituitary/NN ./. 
It/PRP was/VBD prominently/RB and/CC selectively/RB (/( within/IN the/DT central/JJ nervous/JJ system/NN )/) expressed/VBN in/IN pyramidal/JJ cells/NNS of/IN the/DT cerebral/JJ cortex/NN and/CC other/JJ motor/NN neurons/NNS ,/, e.g./FW ,/, in/IN spinal/JJ cord/NN and/CC brainstem/NN nuclei/NNS ./. 
Visceral/JJ TSC2/NN expression/NN was/VBD comparable/JJ in/IN autopsy/NN tissues/NNS from/IN patients/NNS with/IN and/CC without/IN TSC/NN ;/: TSC2/NN messenger/NN RNA/NN expression/NN was/VBD most/RBS prominent/JJ in/IN cells/NNS with/IN a/DT rapid/JJ mitotic/JJ rate/NN and/CC turnover/NN ,/, e.g./FW ,/, epithelia/NN and/CC lymphocytes/NNS ,/, with/IN central/JJ nervous/JJ system/NN pyramidal/JJ cells/NNS and/CC other/JJ neurons/NNS being/VBG an/DT obvious/JJ exception/NN ,/, and/or/CC in/IN cells/NNS with/IN important/JJ secretory/transport/NN functions/NNS ./. 
This/DT widespread/JJ expression/NN of/IN the/DT TSC2/NN gene/NN supports/VBZ the/DT view/NN that/IN it/PRP encodes/VBZ a/DT protein/NN vital/JJ to/TO cell/NN growth/NN and/CC metabolism/NN or/CC one/CD that/WDT functions/VBZ as/IN a/DT tumor/growth/NN suppressor/NN ./. 
UI/LS -/: 97047773/CD 
TI/LS -/: Apoptosis/NN signaling/NN pathways/NNS in/IN normal/JJ T/NN cells/NNS :/: differential/JJ activity/NN of/IN Bcl-2/NN and/CC IL-1beta-converting/JJ enzyme/NN family/NN protease/NN inhibitors/NNS on/IN glucocorticoid-/NN and/CC Fas-mediated/JJ cytotoxicity/NN ./. 
AB/LS -/: Fas-mediated/JJ apoptosis/NN plays/VBZ an/DT important/JJ role/NN in/IN regulating/VBG the/DT immune/JJ response/NN in/IN peripheral/JJ T/NN cells/NNS ./. 
Restimulation/NN of/IN T/NN cell/NN blasts/NNS up-regulates/VBZ Fas/NN and/CC Fas/NN ligand/NN expression/NN ,/, with/IN subsequent/JJ interaction/NN leading/VBG to/TO cell/NN death/NN ./. 
Overexpression/NN of/IN Bcl-2/NN in/IN tumor/NN cells/NNS blocks/VBZ apoptosis/NN induced/VBN by/IN many/JJ stimuli/NNS ,/, but/CC inhibition/NN of/IN Fas-mediated/JJ killing/NN has/VBZ not/RB been/VBN consistently/RB observed/VBN ./. 
To/TO examine/VB the/DT behavior/NN of/IN Bcl-2/NN in/IN normal/JJ cells/NNS ,/, T/NN cell/NN blasts/NNS were/VBD transiently/RB transfected/VBN with/IN Bcl-2/NN and/CC related/JJ gene/NN products/NNS to/TO determine/VB the/DT effect/NN on/IN apoptotic/JJ signaling/NN ./. 
Transient/JJ overexpression/NN of/IN Bcl-2/NN in/IN mouse/NN and/CC human/JJ T/NN cell/NN blasts/NNS did/VBD not/RB block/VB Fas-mediated/JJ apoptosis/NN ,/, whereas/IN etoposide-/NN and/CC glucocorticoid-induced/JJ cytotoxicity/NN was/VBD potently/RB inhibited/VBN ./. 
Expression/NN of/IN Bcl-xL/NN and/CC adenovirus/NN E1B/NN 19K/NN did/VBD not/RB interfere/VB with/IN anti-Fas/JJ killing/NN ./. 
In/IN contrast/NN ,/, interleukin-1beta-converting/JJ enzyme/NN family/NN protease/NN inhibitors/NNS Ac-DEVD-CHO/NN and/CC CrmA/NN blocked/VBD Fas-mediated/JJ apoptosis/NN ./. 
These/DT results/NNS suggest/VBP that/IN peripheral/JJ T/NN cells/NNS use/VBP distinct/JJ apoptosis/NN signaling/NN pathways/NNS with/IN differential/JJ sensitivity/NN to/TO Bcl-2/NN and/CC interleukin-1beta-converting/JJ enzyme/NN family/NN protease/NN inhibitors/NNS ./. 
Since/IN T/NN cells/NNS normally/RB express/VBP Bcl-2/NN and/CC Bcl-xL/NN following/VBG activation/NN ,/, their/PRP$ inability/NN to/TO block/VB Fas-mediated/JJ apoptosis/NN may/MD allow/VB for/IN the/DT elimination/NN of/IN self-reactive/JJ cells/NNS and/CC the/DT appropriate/JJ regulation/NN of/IN immune/JJ responses/NNS ./. 
UI/LS -/: 94284067/CD 
TI/LS -/: Increased/VBN interleukin/NN 2/CD transcription/NN in/IN murine/JJ lymphocytes/NNS by/IN ciprofloxacin/NN ./. 
AB/LS -/: The/DT fluoroquinolone/JJ|NN antibiotic/JJ ,/, ciprofloxacin/NN (/( cipro/NN )/) ,/, induces/VBZ hyperproduction/NN of/IN interleukin/NN 2/CD (/( IL-2/NN )/) and/CC interferon-gamma/NN (/( IFN-gamma/NN )/) in/IN stimulated/VBN human/JJ peripheral/JJ blood/NN lymphocytes/NNS ./. 
In/IN this/DT investigation/NN an/DT enhanced/VBN and/CC prolonged/JJ IL-2/NN and/CC IL-2/NN mRNA/NN response/NN was/VBD also/RB detected/VBN in/IN both/CC stimulated/VBN (/( T/NN cell/NN mitogens/NNS or/CC alloantigens/NNS )/) murine/JJ splenocytes/NNS and/CC in/IN the/DT stimulated/VBN murine/JJ T/NN cell/NN line/NN EL-4/NN in/IN the/DT presence/NN of/IN ciprofloxacin/NN (/( 5-80/CD micrograms/ml/NN )/) as/IN compared/VBN to/TO control/NN cells/NNS without/IN antibiotics/NNS ./. 
However/RB ,/, in/IN contrast/NN to/TO human/JJ lymphocytes/NNS ,/, IFN-gamma/NN production/NN was/VBD inhibited/VBN and/CC IFN-gamma/NN mRNA/NN levels/NNS were/VBD unaffected/JJ at/IN 24/CD h/NN and/CC only/RB slightly/RB upregulated/VBN at/IN 48/CD and/CC 72/CD h/NN of/IN culture/NN in/IN murine/JJ splenocytes/NNS incubated/VBN with/IN cipro/NN (/( 20/CD micrograms/ml/NNS )/) ./. 
EL-4/NN cells/NNS were/VBD transfected/VBN with/IN a/DT plasmid/NN containing/VBG the/DT IL-2/NN promoter/NN and/CC enhancer/NN region/NN linked/VBN to/TO the/DT chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) reporter/NN gene/NN ./. 
Analysis/NN of/IN CAT/NN activity/NN revealed/VBD that/IN cipro/NN enhanced/VBD IL-2/NN gene/NN induction/NN ./. 
In/IN addition/NN ,/, EL-4/NN cells/NNS incubated/VBN with/IN ciprofloxacin/NN showed/VBD an/DT early/JJ peak/NN and/CC more/RBR activated/VBN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT-1/NN )/) as/IN compared/VBN to/TO control/NN cells/NNS without/IN antibiotics/NNS ./. 
Cipro/NN did/VBD not/RB affect/VB the/DT nuclear/JJ transcription/NN factors/NNS AP-1/NN or/CC NFIL-2A/NN ./. 
Taken/VBN together/RB ,/, cipro/NN inhibited/VBD IFN-gamma/NN synthesis/NN ,/, but/CC enhanced/VBD IL-2/NN production/NN in/IN murine/JJ lymphocytes/NNS by/IN means/NNS of/IN influencing/VBG NFAT-1/NN and/CC causing/VBG an/DT increased/VBN IL-2/NN transcription/NN ./. 
UI/LS -/: 94119088/CD 
TI/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD Tax/NN associates/VBZ with/IN and/CC is/VBZ negatively/RB regulated/VBN by/IN the/DT NF-kappa/NN B2/NN p100/NN gene/NN product/NN :/: implications/NNS for/IN viral/JJ latency/NN ./. 
AB/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) is/VBZ the/DT etiologic/JJ agent/NN of/IN the/DT adult/JJ T-cell/NN leukemia/NN ,/, an/DT aggressive/JJ and/CC often/RB fatal/JJ malignancy/NN of/IN activated/VBN human/JJ CD4/NN T/NN cells/NNS ./. 
HTLV-I/NN encodes/VBZ an/DT essential/JJ 40-kDa/JJ protein/NN termed/VBN Tax/NN that/WDT not/RB only/RB transactivates/VBZ the/DT long/JJ terminal/JJ repeat/NN of/IN this/DT retrovirus/NN but/CC also/RB induces/VBZ an/DT array/NN of/IN cellular/JJ genes/NNS ./. 
Tax-mediated/JJ transformation/NN of/IN T/NN cells/NNS likely/RB involves/VBZ the/DT deregulated/VBN expression/NN of/IN various/JJ cellular/JJ genes/NNS that/WDT normally/RB regulate/VBP lymphocyte/NN growth/NN produced/VBN by/IN altered/JJ activity/NN of/IN various/JJ endogenous/JJ host/NN transcription/NN factors/NNS ./. 
In/IN particular/JJ ,/, Tax/NN is/VBZ capable/JJ of/IN modulating/VBG the/DT expression/NN or/CC activity/NN of/IN various/JJ host/NN transcription/NN factors/NNS ,/, including/VBG members/NNS of/IN the/DT NF-kappa/NN B/Rel/NN and/CC CREB/ATF/NN families/NNS ,/, as/RB well/RB as/IN the/DT cellular/JJ factors/NNS HEB-1/NN and/CC p67SRF/NN ./. 
An/DT additional/JJ distinguishing/JJ characteristic/NN of/IN HTLV-I/NN infection/NN is/VBZ the/DT profound/JJ state/NN of/IN viral/JJ latency/NN that/WDT is/VBZ present/JJ in/IN circulating/VBG primary/JJ leukemic/JJ T/NN cells/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP demonstrate/VBP that/IN HTLV-I/NN Tax/NN can/MD physically/RB associate/VB with/IN p100/NN ,/, the/DT product/NN of/IN the/DT Rel-related/JJ NF-kappa/NN B2/NN gene/NN ,/, both/CC in/IN transfected/VBN cells/NNS and/CC in/IN HTLV-I-infected/JJ leukemic/JJ T-cell/NN lines/NNS ./. 
Furthermore/RB ,/, the/DT physical/JJ interaction/NN of/IN Tax/NN with/IN p100/NN leads/VBZ to/TO the/DT inhibition/NN of/IN Tax-induced/JJ activation/NN of/IN the/DT HTLV-I/NN and/CC human/JJ immunodeficiency/NN virus/NN type/NN 1/CD long/JJ terminal/JJ repeats/NNS ,/, reflecting/VBG p100-mediated/JJ cytoplasmic/JJ sequestration/NN of/IN the/DT normally/RB nuclearly/RB expressed/VBN Tax/NN protein/NN ./. 
In/IN contrast/NN ,/, a/DT mutant/NN of/IN Tax/NN that/WDT selectively/RB fails/VBZ to/TO activate/VB nuclear/JJ NF-kappa/NN B/NN expression/NN does/VBZ not/RB associate/VB with/IN p100/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 94110361/CD 
TI/LS -/: Rhabdomyosarcomas/NNS do/VBP not/RB contain/VB mutations/NNS in/IN the/DT DNA/NN binding/NN domains/NNS of/IN myogenic/JJ transcription/NN factors/NNS ./. 
AB/LS -/: Skeletal/JJ myogenesis/NN is/VBZ regulated/VBN by/IN a/DT group/NN of/IN transcription/NN factors/NNS (/( MyoD/NN ,/, myogenin/NN ,/, myf5/NN ,/, and/CC myf6/NN )/) that/WDT are/VBP "/`` basic/JJ helix-loop-helix/JJ "/'' proteins/NNS that/WDT bind/VBP to/TO the/DT promoters/NNS of/IN muscle-specific/JJ genes/NNS and/CC promote/VBP their/PRP$ expression/NN ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN after/IN a/DT mutation/NN of/IN Leu122/NN to/TO Arg/NN the/DT DNA/NN binding/NN basic/JJ domain/NN of/IN MyoD/NN confers/VBZ c-myc-like/JJ functional/JJ characteristics/NNS to/TO the/DT protein/NN ./. 
In/IN this/DT study/NN we/PRP used/VBD single-strand/JJ conformation/NN polymorphism/NN analysis/NN to/TO determine/VB whether/IN such/JJ mutations/NNS occur/VBP naturally/RB in/IN rhabdomyosarcomas/NNS ./. 
We/PRP have/VBP found/VBN that/IN the/DT basic/JJ domains/NNS of/IN all/PDT the/DT myogenic/JJ factors/NNS remain/VBP unaltered/JJ in/IN rhabdomyosarcomas/NNS ./. 
Selection/NN against/IN such/JJ mutations/NNS may/MD be/VB the/DT result/NN of/IN functional/JJ redundancy/NN of/IN these/DT myogenic/JJ transcription/NN factors/NNS ./. 
UI/LS -/: 94280766/CD 
TI/LS -/: Function/NN and/CC activation/NN of/IN NF-kappa/NN B/NN in/IN the/DT immune/JJ system/NN ./. 
AB/LS -/: NF-kappa/NN B/NN is/VBZ a/DT ubiquitous/JJ transcription/NN factor/NN ./. 
Nevertheless/RB ,/, its/PRP$ properties/NNS seem/VBP to/TO be/VB most/RBS extensively/RB exploited/VBN in/IN cells/NNS of/IN the/DT immune/JJ system/NN ./. 
Among/IN these/DT properties/NNS are/VBP NF-kappa/NN B/NN 's/POS rapid/JJ posttranslational/JJ activation/NN in/IN response/NN to/TO many/JJ pathogenic/JJ signals/NNS ,/, its/PRP$ direct/JJ participation/NN in/IN cytoplasmic/nuclear/JJ signaling/NN ,/, and/CC its/PRP$ potency/NN to/TO activate/VB transcription/NN of/IN a/DT great/JJ variety/NN of/IN genes/NNS encoding/VBG immunologically/RB relevant/JJ proteins/NNS ./. 
In/IN vertebrates/NNS ,/, five/CD distinct/JJ DNA/NN binding/NN subunits/NNS are/VBP currently/RB known/VBN which/WDT might/MD extensively/RB heterodimerize/VB ,/, thereby/RB forming/VBG complexes/NNS with/IN distinct/JJ transcriptional/JJ activity/NN ,/, DNA/NN sequence/NN specificity/NN ,/, and/CC cell/NN type-/NN and/CC cell/NN stage-specific/JJ distribution/NN ./. 
The/DT activity/NN of/IN DNA/NN binding/NN NF-kappa/NN B/NN dimers/NNS is/VBZ tightly/RB controlled/VBN by/IN accessory/NN proteins/NNS called/VBN I/NN kappa/NN B/NN subunits/NNS of/IN which/WDT there/EX are/VBP also/RB five/CD different/JJ species/NNS currently/RB known/VBN in/IN vertebrates/NNS ./. 
I/NN kappa/NN B/NN proteins/NNS inhibit/VBP DNA/NN binding/NN and/CC prevent/VBP nuclear/JJ uptake/NN of/IN NF-kappa/NN B/NN complexes/NNS ./. 
An/DT exception/NN is/VBZ the/DT Bcl-3/NN protein/NN which/WDT in/IN addition/NN can/MD function/VB as/IN a/DT transcription/NN activating/NN subunit/NN in/IN th/DT nucleus/NN ./. 
Other/JJ I/NN kappa/NN B/NN proteins/NNS are/VBP rather/RB involved/VBN in/IN terminating/VBG NF-kappa/NN B/NN 's/POS activity/NN in/IN the/DT nucleus/NN ./. 
The/DT intracellular/JJ events/NNS that/WDT lead/VBP to/TO the/DT inactivation/NN of/IN I/NN kappa/NN B/NN ,/, i.e./FW the/DT activation/NN of/IN NF-kappa/NN B/NN ,/, are/VBP complex/JJ ./. 
They/PRP involve/VBP phosphorylation/NN and/CC proteolytic/JJ reactions/NNS and/CC seem/VBP to/TO be/VB controlled/VBN by/IN the/DT cells/NNS '/POS redox/NN status/NN ./. 
Interference/NN with/IN the/DT activation/NN or/CC activity/NN of/IN NF-kappa/NN B/NN may/MD be/VB beneficial/JJ in/IN suppressing/VBG toxic/septic/JJ shock/NN ,/, graft-vs-host/JJ reactions/NNS ,/, acute/JJ inflammatory/JJ reactions/NNS ,/, acute/JJ phase/NN response/NN ,/, and/CC radiation/NN damage/NN ./. 
The/DT inhibition/NN of/IN NF-kappa/NN B/NN activation/NN by/IN antioxidants/NNS and/CC specific/JJ protease/NN inhibitors/NNS may/MD provide/VB a/DT pharmacological/JJ basis/NN for/IN interfering/VBG with/IN these/DT acute/JJ processes/NNS ./. 
UI/LS -/: 99035056/CD 
TI/LS -/: Lack/NN of/IN T-cell-mediated/JJ recognition/NN of/IN the/DT fusion/NN region/NN of/IN the/DT pml/RAR-alpha/NN hybrid/NN protein/NN by/IN lymphocytes/NNS of/IN acute/JJ promyelocytic/JJ leukemia/NN patients/NNS ./. 
AB/LS -/: In/IN previous/JJ studies/NNS ,/, it/PRP was/VBD shown/VBN that/IN the/DT fusion/NN region/NN of/IN the/DT pml/RAR-alpha/NN protein/NN ,/, expressed/VBN by/IN acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) cells/NNS ,/, can/MD be/VB specifically/RB recognized/VBN in/FW vitro/FW by/IN donor/NN (/( D./NNP E./NNP )/) CD4/NN T/NN cells/NNS in/IN a/DT HLA/NN class/NN II/CD DR11-restricted/JJ fashion/NN ./. 
We/PRP present/VBP here/RB the/DT results/NNS on/IN the/DT recognition/NN of/IN several/JJ pml/RAR-alpha/NN peptides/NNS by/IN APL/NN patients/NNS expressing/VBG HLA/NN DR11/NN ./. 
The/DT in/FW vitro/FW immunization/NN of/IN peripheral/JJ blood/NN lymphocytes/NNS from/IN four/CD patients/NNS in/IN remission/NN (/( S.R./NNP ,/, F.R./NNP ,/, M.M./NNP ,/, P./NNP G./NNP )/) with/IN BCR1/25/NN ,/, a/DT 25-mer/NN pml/RAR-alpha/NN ,/, did/VBD not/RB elicit/VB either/CC a/DT polyclonal/JJ or/CC a/DT clonal/JJ immune/JJ response/NN specific/JJ to/TO the/DT peptide/NN ./. 
We/PRP then/RB generated/VBD new/JJ donor/NN anti-pml/RAR-alpha/JJ CD4(+)/JJ T-cell/NN clones/NNS ./. 
These/DT clones/NNS were/VBD tested/VBN for/IN their/PRP$ recognition/NN of/IN BCR1/25/NN ./. 
One/CD clone/NN (/( C3/5/NN ,/, CD3(+)/JJ ,/, CD4(+)/JJ ,/, CD8(-)/JJ )/) was/VBD selected/VBN for/IN further/JJ analysis/NN ./. 
Clone/NN C3/5/NN showed/VBD specific/JJ proliferation/NN ,/, cytotoxicity/NN ,/, and/CC cytokine/NN (/( tumor/NN necrosis/NN factor/NN alpha/NN ,/, granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN )/) production/NN when/WRB challenged/VBN with/IN autologous/JJ lymphoblastic/JJ cell/NN lines/NNS pulsed/VBN with/IN peptide/NN BCR1/25/NN ./. 
C3/5/NN cells/NNS developed/VBD specific/JJ proliferation/NN and/CC cytotoxicity/NN when/WRB challenged/VBN with/IN peptide-pulsed/JJ lymphoblastic/JJ cell/NN lines/NNS and/CC peripheral/JJ blood/NN lymphocytes/NNS from/IN the/DT four/CD DR11(+)/JJ APL/NN patients/NNS ./. 
APL/NN blasts/NNS ,/, available/JJ only/RB from/IN patients/NNS F.R./NNP and/CC P.G./NNP ,/, were/VBD not/RB lysed/VBN by/IN C3/5/NN and/CC were/VBD unable/JJ to/TO present/VB peptide/NN BCR1/25/NN ./. 
Incubation/NN of/IN APL/NN cells/NNS with/IN IFN-gamma/NN failed/VBD to/TO induce/VB HLA/NN class/NN II/CD molecules/NNS and/CC recognition/NN by/IN the/DT C3/5/NN clone/NN ./. 
Since/IN APL/NN cells/NNS do/VBP not/RB express/VB HLA/NN class/NN II/CD molecules/NNS ,/, we/PRP tested/VBD in/IN two/CD donors/NNS (/( D.E./NNP and/CC C.H.R./NNP )/) and/CC in/IN patients/NNS S.R./NN and/CC P.G./NN whether/CC the/DT use/NN of/IN 9-mer/NN peptides/NNS (/( BCR1/9/NN )/) would/MD generate/VB a/DT CD8/HLA/NN class/NN I-restricted/JJ response/NN ./. 
No/DT peptide-specific/JJ T-cell/NN line/NN or/CC clone/NN could/MD be/VB generated/VBN from/IN both/CC donors/NNS and/CC patients/NNS ./. 
These/DT findings/NNS are/VBP discussed/VBN in/IN relation/NN to/TO possible/JJ therapeutic/JJ approaches/NNS to/TO the/DT immunotherapy/NN of/IN APL/NN ./. 
UI/LS -/: 97112990/CD 
TI/LS -/: The/DT proximal/JJ regulatory/JJ element/NN of/IN the/DT interferon-gamma/NN promoter/NN mediates/VBZ selective/JJ expression/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Interferon-gamma/NN (/( IFN-gamma/NN )/) is/VBZ produced/VBN by/IN natural/JJ killer/NN cells/NNS and/CC certain/JJ subsets/NNS of/IN T/NN cells/NNS ,/, but/CC the/DT basis/NN for/IN its/PRP$ selective/JJ expression/NN is/VBZ unknown/JJ ./. 
Within/IN the/DT region/NN between/IN -108/CD and/CC -40/CD base/NN pairs/NNS of/IN the/DT IFN-gamma/NN promoter/NN are/VBP two/CD conserved/VBN and/CC essential/JJ regulatory/JJ elements/NNS ,/, which/WDT confer/VBP activation-specific/JJ expression/NN in/IN T/NN cells/NNS ./. 
This/DT report/NN describes/VBZ studies/NNS indicating/VBG that/IN the/DT most/RBS proximal/JJ of/IN these/DT two/CD regulatory/JJ elements/NNS is/VBZ an/DT important/JJ determinant/NN of/IN its/PRP$ restricted/JJ expression/NN ./. 
The/DT proximal/JJ element/NN is/VBZ a/DT composite/JJ site/NN that/WDT binds/VBZ members/NNS of/IN the/DT CREB/ATF/NN ,/, AP-1/NN ,/, and/CC octamer/NN families/NNS of/IN transcription/NN factors/NNS ./. 
Jun/NN is/VBZ essential/JJ for/IN activation-induced/JJ transcription/NN and/CC binds/VBZ preferably/RB as/IN a/DT heterodimer/NN with/IN ATF-2/NN ./. 
In/IN contrast/NN ,/, CREB/NN appears/VBZ to/TO dampen/VB transcription/NN from/IN this/DT element/NN ./. 
The/DT CpG/NN dinucleotide/NN in/IN this/DT element/NN is/VBZ selectively/RB methylated/VBN in/IN Th2/NN T/NN cells/NNS and/CC other/JJ cells/NNS that/WDT do/VBP not/RB express/VB IFN-gamma/NN ,/, and/CC methylation/NN markedly/RB reduces/VBZ transcription/NN factor/NN binding/NN ./. 
As/IN a/DT target/NN for/IN DNA/NN methylation/NN and/CC for/IN binding/NN of/IN transcription/NN factors/NNS that/WDT mediate/VBP or/CC impede/VBP transcription/NN ,/, this/DT element/NN appears/VBZ to/TO play/VB a/DT central/JJ role/NN in/IN controlling/VBG IFN-gamma/NN expression/NN ./. 
UI/LS -/: 97098712/CD 
TI/LS -/: CD40/NN ,/, but/CC not/RB lipopolysaccharide/NN and/CC anti-IgM/JJ stimulation/NN of/IN primary/JJ B/NN lymphocytes/NNS ,/, leads/VBZ to/TO a/DT persistent/JJ nuclear/JJ accumulation/NN of/IN RelB/NN ./. 
AB/LS -/: In/IN this/DT study/NN we/PRP analyzed/VBD the/DT effect/NN of/IN CD40/NN stimulation/NN on/IN the/DT activity/NN and/CC nuclear/JJ appearance/NN of/IN Rel/nuclear/NN factor/NN kappaB/NN (/( NF-kappaB/NN )/) factors/NNS in/IN primary/JJ murine/JJ B/NN lymphocytes/NNS ./. 
We/PRP show/VBP that/IN triggering/NN of/IN CD40/NN signaling/NN pathway/NN (/( s/NNS )/) by/IN CD40/NN ligands/NNS expressed/VBN on/IN L/NN cells/NNS led/VBD to/TO strong/JJ activation/NN of/IN an/DT NF-kappaB-controlled/JJ beta-globin/NN reporter/NN gene/NN in/IN primary/JJ B/NN lymphocytes/NNS from/IN transgenic/JJ mice/NNS ./. 
Analyses/NNS of/IN nuclear/JJ translocation/NN of/IN individual/JJ members/NNS of/IN Rel/NN proteins/NNS after/IN CD40/NN induction/NN of/IN primary/JJ B/NN cells/NNS showed/VBD a/DT strong/JJ and/CC long-lasting/JJ accumulation/NN of/IN RelB/NN and/CC ,/, less/RBR pronounced/JJ ,/, of/IN c-Rel/NN ./. 
LPS/NN stimulation/NN did/VBD not/RB give/VB rise/NN to/TO a/DT persistent/JJ nuclear/JJ accumulation/NN of/IN RelB/NN and/CC c-Rel/NN ,/, whereas/IN nuclear/JJ c-Rel/NN ,/, but/CC not/RB RelB/NN ,/, accumulated/VBD after/IN B/NN cell/NN receptor/NN stimulation/NN ./. 
CD40/NN induced/VBD not/RB only/RB nuclear/JJ translocation/NN but/CC also/RB de/FW novo/FW synthesis/NN of/IN RelB/NN RNA/NN and/CC protein/NN ./. 
S107/NN plasmacytoma/NN cells/NNS ,/, which/WDT express/VBP CD40/NN but/CC are/VBP defective/JJ for/IN the/DT nuclear/JJ appearance/NN of/IN p50/p65-NF-kappaB/NN ,/, do/VBP not/RB express/VB RelB/NN after/IN CD40/NN stimulation/NN ./. 
In/IN S107/NN cells/NNS stably/RB transfected/VBN with/IN relB/NN genes/NNS ,/, stimulation/NN of/IN nuclear/JJ RelB/NN translocation/NN by/IN CD40/NN was/VBD observed/VBN ./. 
These/DT results/NNS indicate/VBP that/IN stimulation/NN of/IN CD40/NN signaling/NN pathways/NNS exerts/VBZ a/DT long-lasting/JJ stimulatory/JJ effect/NN on/IN both/CC the/DT transcription/NN and/CC nuclear/JJ translocation/NN of/IN RelB/NN ./. 
Since/IN LPS/NN and/CC anti-IgM/NN were/VBD unable/JJ to/TO activate/VB RelB/NN ,/, CD40/NN appears/VBZ to/TO trigger/VB a/DT special/JJ program/NN of/IN gene/NN expression/NN involved/VBN in/IN the/DT proliferation/NN and/or/CC differentiation/NN of/IN B/NN lymphocytes/NNS ./. 
UI/LS -/: 97067175/CD 
TI/LS -/: Identification/NN and/CC characterization/NN of/IN a/DT leukocyte-specific/JJ component/NN of/IN the/DT nuclear/JJ body/NN ./. 
AB/LS -/: The/DT nuclear/JJ body/NN (/( NB/NN )/) is/VBZ a/DT cellular/JJ organelle/NN that/WDT is/VBZ involved/VBN in/IN the/DT pathogenesis/NN of/IN acute/JJ promyelocytic/JJ leukemia/NN and/CC viral/JJ infection/NN ./. 
The/DT NB/NN is/VBZ also/RB a/DT target/NN of/IN antibodies/NNS in/IN the/DT serum/NN of/IN patients/NNS with/IN the/DT autoimmune/JJ disease/NN primary/JJ biliary/JJ cirrhosis/NN ./. 
In/IN this/DT study/NN ,/, serum/NN from/IN a/DT patient/NN with/IN primary/JJ biliary/JJ cirrhosis/NN was/VBD used/VBN to/TO identify/VB a/DT cDNA/NN encoding/VBG a/DT novel/JJ component/NN of/IN the/DT NB/NN ,/, a/DT 140-kDa/JJ protein/NN designated/VBN Sp140/NN ./. 
The/DT predicted/VBN amino/NN acid/NN sequence/NN of/IN the/DT amino-terminal/JJ portion/NN of/IN Sp140/NN was/VBD similar/JJ to/TO Sp100/NN ,/, a/DT previously/RB identified/VBN NB/NN protein/NN ./. 
The/DT carboxyl/JJ portion/NN of/IN Sp140/NN contained/VBD a/DT zinc-finger/JJ domain/NN and/CC a/DT bromodomain/NN ,/, motifs/NNS that/WDT are/VBP present/JJ in/IN proteins/NNS regulating/VBG gene/NN transcription/NN ./. 
High/JJ levels/NNS of/IN Sp140/NN mRNA/NN were/VBD detected/VBN in/IN human/JJ spleen/NN and/CC peripheral/JJ blood/NN leukocytes/NNS ,/, but/CC not/RB other/JJ human/JJ tissues/NNS ./. 
The/DT level/NN of/IN SP140/NN mRNA/NN in/IN myeloid/JJ precursor/NN cell/NN lines/NNS HL60/NN and/CC NB4/NN markedly/RB increased/VBD in/IN response/NN to/TO chemically/RB induced/VBN cellular/JJ differentiation/NN ./. 
Immunohistochemical/JJ techniques/NNS were/VBD used/VBN to/TO demonstrate/VB that/IN SP140/NN localized/VBD to/TO the/DT NB/NN in/IN differentiated/VBN HL60/NN and/CC NB4/NN cells/NNS ./. 
The/DT location/NN of/IN Sp140/NN in/IN the/DT NB/NN ,/, and/CC expression/NN of/IN this/DT gene/NN in/IN cells/NNS involved/VBN in/IN host/NN defense/NN ,/, suggest/VBP that/IN Sp140/NN may/MD be/VB involved/VBN in/IN the/DT pathogenesis/NN of/IN acute/JJ promyelocytic/JJ leukemia/NN and/CC viral/JJ infection/NN ./. 
UI/LS -/: 97083588/CD 
TI/LS -/: Regulation/NN of/IN cytokine/NN and/CC cytokine/NN receptor/NN expression/NN by/IN glucocorticoids/NNS ./. 
AB/LS -/: Glucocorticoids/NNS (/( GCS/NNS )/) profoundly/RB inhibit/VBP several/JJ aspects/NNS of/IN T/NN cell/NN immunity/NN largely/RB through/IN inhibition/NN of/IN cytokine/NN expression/NN at/IN the/DT transcriptional/JJ and/CC posttranscriptional/JJ levels/NNS ./. 
GCS/NNS were/VBD also/RB reported/VBN to/TO act/VB indirectly/RB by/IN inducing/VBG transforming/VBG growth/NN factor-beta/NN expression/NN ,/, which/WDT in/IN turn/NN blocks/VBZ T/NN cell/NN immunity/NN ./. 
In/IN exerting/VBG their/PRP$ antiproliferative/JJ effects/NNS ,/, GCS/NNS diffuse/VBP into/IN target/NN cells/NNS where/WRB they/PRP bind/VBP their/PRP$ cytoplasmic/JJ receptor/NN ,/, which/WDT in/IN turn/NN translocates/VBZ to/TO the/DT nucleus/NN where/WRB it/PRP inhibits/VBZ transcription/NN of/IN cytokine/NN genes/NNS through/IN direct/JJ binding/NN to/TO the/DT glucocorticoid/NN response/NN elements/NNS (/( GRE/NN )/) ,/, which/WDT are/VBP located/JJ in/IN the/DT promoter/NN region/NN of/IN cytokine/NN genes/NNS or/CC ,/, alternatively/RB ,/, through/IN antagonism/NN of/IN the/DT action/NN of/IN transcription/NN factors/NNS required/VBN for/IN optimal/JJ transcriptional/JJ activation/NN ./. 
In/IN contrast/NN to/TO their/PRP$ inhibitory/JJ effects/NNS on/IN cytokine/NN expression/NN ,/, GCS/NNS up-regulate/VBP cytokine/NN receptor/NN expression/NN that/WDT correlates/VBZ with/IN enhanced/VBN cytokine/NN effects/NNS on/IN target/NN cells/NNS ./. 
In/IN this/DT review/NN ,/, we/PRP summarize/VBP the/DT current/JJ state/NN of/IN knowledge/NN of/IN the/DT mechanism/NN of/IN action/NN of/IN GCS/NNS ,/, including/VBG the/DT phenomenon/NN of/IN steroid-induced/JJ rebound/NN ,/, which/WDT ensues/VBZ upon/IN GCS/NNS withdrawal/NN ./. 
UI/LS -/: 97047769/CD 
TI/LS -/: Isolation/NN and/CC characterization/NN of/IN murine/JJ fra-1/NN :/: induction/NN mediated/VBN by/IN CD40/NN and/CC surface/NN Ig/NN is/VBZ protein/NN kinase/NN C/NN dependent/JJ ./. 
AB/LS -/: The/DT murine/JJ fra-1/NN gene/NN ,/, encoding/VBG Fos-related/JJ Ag/NN 1/CD ,/, was/VBD isolated/VBN from/IN a/DT splenic/JJ cDNA/NN library/NN and/CC sequenced/VBN ./. 
Murine/JJ|NN fra-1/NN was/VBD highly/RB homologous/JJ to/TO rat/NN and/CC human/JJ fra-1/NN ./. 
Oligonucleotide/NN primers/NNS based/VBN on/IN the/DT murine/JJ sequence/NN were/VBD used/VBN to/TO construct/VB a/DT quantitative/JJ reverse/NN transcription-PCR/NN assay/NN for/IN gene/NN expression/NN ./. 
B/NN lymphocyte/NN stimulation/NN via/IN both/CC CD40/NN and/CC surface/NN Ig/NN (/( sIg/NN )/) receptors/NNS substantially/RB induced/VBD fra-1/NN expression/NN ,/, and/CC for/IN both/DT receptors/NNS ,/, induction/NN was/VBD protein/NN kinase/NN C/NN (/( PKC/NN )/) dependent/JJ ./. 
This/DT contrasts/VBZ with/IN induction/NN of/IN c-fos/NN by/IN both/CC CD40/NN and/CC sIg/NN ,/, which/WDT is/VBZ PKC/NN independent/JJ and/CC indicates/VBZ that/IN CD40/NN is/VBZ capable/JJ of/IN signaling/VBG through/IN PKC/NN or/CC a/DT closely/RB related/JJ kinase/NN ./. 
Induction/NN of/IN fra-1/NN following/VBG engagement/NN of/IN CD40/NN did/VBD not/RB require/VB protein/NN synthesis/NN ,/, suggesting/VBG that/IN the/DT PKC-dependent/JJ linkage/NN between/IN CD40/NN and/CC fra-1/NN is/VBZ direct/JJ ./. 
CD40-mediated/JJ fra-1/NN induction/NN did/VBD require/VB tyrosine/NN kinase/NN activity/NN ./. 
These/DT results/NNS demonstrate/VBP that/IN CD40/NN ,/, like/IN sIg/NN ,/, may/MD employ/VB PKC/NN in/IN producing/VBG select/JJ outcomes/NNS ,/, that/IN individual/JJ B/NN cell/NN receptors/NNS may/MD signal/VB downstream/JJ events/NNS via/IN both/CC PKC-dependent/JJ and/CC PKC-independent/JJ pathways/NNS ,/, and/CC that/IN multiple/JJ signal/NN transduction/NN pathways/NNS may/MD be/VB used/VBN to/TO activate/VB the/DT expression/NN of/IN closely/RB related/JJ genes/NNS ./. 
UI/LS -/: 94281402/CD 
TI/LS -/: Pentoxifylline/NN for/IN the/DT treatment/NN of/IN infection/NN with/IN human/JJ immunodeficiency/NN virus/NN ./. 
AB/LS -/: Cytokine/NN dysregulation/NN in/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) infection/NN has/VBZ been/VBN documented/VBN in/IN numerous/JJ studies/NNS and/CC has/VBZ been/VBN cited/VBN as/IN an/DT important/JJ component/NN in/IN the/DT pathogenesis/NN of/IN this/DT retroviral/JJ infection/NN ./. 
Pharmacological/JJ modification/NN of/IN cytokine/NN dysregulation/NN ,/, therefore/RB ,/, has/VBZ been/VBN suggested/VBN as/IN a/DT therapeutic/JJ modality/NN for/IN HIV-1/NN infection/NN ./. 
Dr./NNP Dezube/NNP of/IN Beth/NNP Israel/NNP Hospital/NNP (/( Boston/NNP )/) concisely/RB reviews/VBZ the/DT state/NN of/IN our/PRP$ knowledge/NN regarding/VBG the/DT effects/NNS of/IN pentoxifylline/NN on/IN expression/NN of/IN tumor/NN necrosis/NN factor-alpha/NN ,/, a/DT cytokine/NN known/VBN to/TO influence/VB HIV-1/NN replication/NN and/CC to/TO play/VB a/DT possible/JJ role/NN in/IN the/DT clinical/JJ manifestations/NNS of/IN advanced/JJ infection/NN with/IN this/DT virus/NN ./. 
Pentoxifylline/NN ,/, a/DT trisubstituted/JJ xanthine/NN derivative/NN ,/, has/VBZ been/VBN used/VBN to/TO decrease/VB blood/NN viscosity/NN and/CC is/VBZ reasonably/RB well/RB tolerated/VBN by/IN most/JJS recipients/NNS of/IN the/DT drug/NN ./. 
Results/NNS of/IN preliminary/JJ studies/NNS ,/, many/JJ of/IN which/WDT were/VBD conducted/VBN by/IN Dr./NNP Dezube/NNP ,/, suggest/VBP that/IN use/NN of/IN this/DT agent/NN in/IN combination/NN with/IN antiretroviral/JJ compounds/NNS may/MD prove/VB useful/JJ in/IN the/DT treatment/NN of/IN patients/NNS with/IN HIV-1/NN infection/NN ./. 
UI/LS -/: 94119067/CD 
TI/LS -/: Activation/NN of/IN the/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN promoter/NN in/IN T/NN cells/NNS requires/VBZ cooperative/JJ binding/NN of/IN Elf-1/NN and/CC AP-1/NN transcription/NN factors/NNS ./. 
AB/LS -/: The/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) gene/NN has/VBZ been/VBN studied/VBN extensively/RB as/IN a/DT model/NN system/NN of/IN transcriptional/JJ induction/NN during/IN T-lymphocyte/NN activation/NN ./. 
The/DT GM-CSF/NN gene/NN is/VBZ not/RB expressed/VBN in/IN resting/VBG peripheral/JJ blood/NN T/NN cells/NNS but/CC is/VBZ rapidly/RB induced/VBN at/IN the/DT transcriptional/JJ level/NN following/VBG activation/NN through/IN the/DT cell/NN surface/NN T-cell/NN receptor/NN ./. 
A/DT highly/RB conserved/VBN 19-bp/JJ element/NN located/JJ immediately/RB 5'/JJ of/IN the/DT human/JJ GM-CSF/NN TATA/NN box/NN (/( bp/NN -34/CD to/TO -52/CD )/) ,/, herein/RB called/VBN purine/NN box/NN 1/CD (/( PB1/NN )/) ,/, has/VBZ been/VBN shown/VBN to/TO bind/VB a/DT T-cell/NN nuclear/JJ protein/NN complex/NN and/CC to/TO be/VB required/VBN for/IN transcriptional/JJ induction/NN of/IN the/DT GM-CSF/NN gene/NN following/VBG T-cell/NN activation/NN ./. 
The/DT PB1/NN sequence/NN motif/NN is/VBZ highly/RB conserved/VBN in/IN both/CC human/JJ and/CC murine/JJ GM-CSF/NN genes/NNS ./. 
In/IN this/DT report/NN ,/, we/PRP demonstrate/VBP that/IN the/DT PB1/NN element/NN alone/RB confers/VBZ inducibility/NN on/IN a/DT heterologous/JJ promoter/NN following/VBG transfection/NN into/IN human/JJ Jurkat/NN T/NN cells/NNS ./. 
In/IN addition/NN ,/, we/PRP identify/VBP a/DT major/JJ PB1/NN nuclear/JJ protein-binding/JJ complex/NN that/WDT is/VBZ not/RB present/JJ in/IN resting/VBG peripheral/JJ blood/NN T/NN cells/NNS but/CC is/VBZ rapidly/RB induced/VBN following/VBG T-cell/NN activation/NN ./. 
Sequence/NN analysis/NN revealed/VBD that/IN PB1/NN is/VBZ composed/VBN of/IN adjacent/JJ binding/VBG sites/NNS for/IN Ets/NN and/CC AP-1/NN transcription/NN factors/NNS ./. 
In/FW vitro/FW mutagenesis/NN experiments/NNS demonstrated/VBD that/IN both/CC the/DT Ets/NNS and/CC AP-1/NN sites/NNS are/VBP required/VBN for/IN binding/NN of/IN the/DT inducible/JJ PB1/NN nuclear/JJ protein/NN complex/NN and/CC for/IN the/DT transcriptional/JJ activity/NN of/IN this/DT element/NN and/CC the/DT GM-CSF/NN promoter/NN in/IN activated/VBN T/NN cells/NNS ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 94110342/CD 
TI/LS -/: Steroid-resistant/JJ asthma/NN ./. 
Cellular/JJ mechanisms/NNS contributing/VBG to/TO inadequate/JJ response/NN to/TO glucocorticoid/NN therapy/NN ./. 
AB/LS -/: The/DT current/JJ study/NN examined/VBD whether/IN alterations/NNS in/IN glucocorticoid/NN receptor/NN (/( GR/NN )/) binding/NN contribute/VBP to/TO poor/JJ response/NN to/TO glucocorticoid/NN therapy/NN in/IN asthma/NN ./. 
29/CD asthma/NN patients/NNS with/IN forced/VBN expiratory/JJ volume/NN in/IN 1/CD s/NN (/( FEV1/NN )/) </JJR 70/CD %/NN predicted/VBN were/VBD studied/VBN ./. 
Patients/NNS were/VBD classified/VBN as/IN steroid/NN sensitive/JJ (/( SS/JJ )/) if/IN their/PRP$ morning/NN FEV1/NN increased/VBD >/RBR 30/CD %/NN after/IN a/DT 1-wk/JJ course/NN of/IN oral/JJ prednisone/NN 20/CD mg/NN twice/RB daily/RB and/CC steroid/NN resistant/JJ (/( SR/JJ )/) if/IN they/PRP failed/VBD to/TO increase/VB >/RBR 15/CD %/NN ./. 
PBMC/NN obtained/VBN from/IN these/DT two/CD groups/NNS ,/, 17/CD SR/JJ and/CC 12/CD SS/JJ ,/, as/RB well/RB as/IN 12/CD normal/JJ controls/NNS were/VBD analyzed/VBN ./. SR/JJ patients/NNS had/VBD two/CD distinguishable/JJ GR/NN binding/NN abnormalities/NNS :/: 15/CD of/IN the/DT 17/CD SR/JJ patients/NNS demonstrated/VBD a/DT significantly/RB reduced/VBN GR/NN binding/NN affinity/NN ,/, as/IN compared/VBN with/IN SS/JJ patients/NNS (/( P/NN =/JJ 0.0001/CD )/) and/CC normal/JJ controls/NNS (/( P/NN =/JJ 0.0001/CD )/) ./. 
This/DT defect/NN was/VBD localized/JJ to/TO T/NN cells/NNS and/CC reverted/VBD to/TO normal/JJ after/IN 48/CD h/NN in/IN culture/NN media/NNS ./. 
However/RB ,/, incubation/NN with/IN a/DT combination/NN of/IN IL-2/NN and/CC IL-4/NN sustained/VBD this/DT abnormality/NN ./. 
The/DT other/JJ two/CD SR/JJ patients/NNS had/VBD an/DT abnormally/RB low/JJ GR/NN number/NN with/IN normal/JJ binding/NN affinity/NN that/WDT was/VBD not/RB limited/VBN to/TO T/NN cells/NNS ./. 
Furthermore/RB ,/, GR/NN number/NN failed/VBD to/TO normalize/VB after/IN incubation/NN in/IN media/NNS alone/RB or/CC IL-2/NN and/CC IL-4/NN ./. 
Therefore/RB ,/, SR/JJ asthma/NN may/MD be/VB due/JJ to/TO more/JJR than/IN one/CD abnormality/NN ,/, the/DT majority/NN related/JJ to/TO a/DT reversible/JJ cytokine-induced/JJ reduction/NN in/IN GR/NN binding/NN affinity/NN and/CC the/DT second/JJ related/JJ to/TO an/DT irreversible/JJ reduction/NN in/IN GR/NN number/NN ./. 
These/DT findings/NNS may/MD have/VB important/JJ implications/NNS for/IN the/DT design/NN of/IN alternative/JJ treatment/NN approaches/NNS for/IN recalcitrant/JJ asthma/NN ./. 
UI/LS -/: 95072277/CD 
TI/LS -/: Prevalence/NN of/IN aneuploidy/NN ,/, overexpressed/JJ ER/NN ,/, and/CC overexpressed/JJ EGFR/NN in/IN random/JJ breast/NN aspirates/NNS of/IN women/NNS at/IN high/JJ and/CC low/JJ risk/NN for/IN breast/NN cancer/NN ./. 
AB/LS -/: Breast/NN tissue/NN biomarkers/NNS which/WDT accurately/RB predict/VBP breast/NN cancer/NN development/NN within/IN a/DT 10/CD year/NN period/NN in/IN high/JJ risk/NN women/NNS are/VBP needed/VBN but/CC currently/RB not/RB available/JJ ./. 
We/PRP initiated/VBD this/DT study/NN to/TO determine/VB 1/LS )/) the/DT prevalence/NN of/IN one/CD or/CC more/JJR breast/NN tissue/NN abnormalities/NNS in/IN a/DT group/NN of/IN women/NNS at/IN high/JJ risk/NN for/IN breast/NN cancer/NN ,/, and/CC 2/LS )/) if/IN the/DT prevalence/NN of/IN biomarker/NN abnormalities/NNS is/VBZ greater/JJR in/IN high/JJ risk/NN than/IN in/IN low/JJ risk/NN women/NNS ./. 
Eligible/JJ high/JJ risk/NN women/NNS were/VBD those/DT with/IN a/DT first/JJ degree/NN relative/NN with/IN breast/NN cancer/NN ,/, prior/JJ breast/NN cancer/NN ,/, or/CC precancerous/JJ mastopathy/NN ./. 
Low/JJ risk/NN women/NNS were/VBD those/DT without/IN these/DT or/CC other/JJ major/JJ identifiable/JJ risk/NN factors/NNS ./. 
Ductal/JJ cells/NNS were/VBD obtained/VBN via/IN random/JJ fine/JJ needle/NN aspirations/NNS and/CC cytologically/RB classified/VBN ./. 
Biomarkers/NNS included/VBD DNA/NN ploidy/NN ,/, estrogen/NN receptor/NN (/( ER/NN )/) ,/, and/CC epidermal/JJ growth/NN factor/NN receptor/NN (/( EGFR/NN )/) ./. 
The/DT prevalence/NN of/IN DNA/NN aneuploidy/NN was/VBD 30/CD %/NN ,/, overexpression/NN of/IN ER/NN 10/CD %/NN ,/, and/CC overexpression/NN of/IN EGFR/NN 35/CD %/NN ,/, in/IN the/DT 206/CD high/JJ risk/NN women/NNS whose/WP$ median/JJ 10/CD year/NN Gail/NN risk/NN (/( projected/VBN probability/NN )/) of/IN developing/VBG breast/NN cancer/NN was/VBD 4.5/CD %/NN ./. 
The/DT prevalence/NN of/IN aneuploidy/NN and/CC overexpressed/JJ EGFR/NN was/VBD significantly/RB higher/JJR in/IN the/DT high/JJ risk/NN women/NNS than/IN in/IN the/DT 25/CD low/JJ risk/NN controls/NNS (/( p/NN </JJR 0.002/CD )/) ,/, whose/WP$ median/JJ 10/CD year/NN Gail/NN risk/NN was/VBD 0.7/CD %/NN ./. 
The/DT difference/NN in/IN the/DT prevalence/NN of/IN ER/NN overexpression/NN between/IN high/JJ and/CC low/JJ risk/NN groups/NNS was/VBD not/RB statistically/RB significant/JJ (/( p/NN =/JJ 0.095/CD )/) ./. 
This/DT may/MD be/VB due/JJ to/TO the/DT low/JJ prevalence/NN of/IN overexpressed/JJ ER/NN and/CC the/DT small/JJ number/NN of/IN controls/NNS ./. 
A/DT significant/JJ difference/NN was/VBD noted/VBN in/IN the/DT prevalence/NN of/IN one/CD or/CC more/JJR abnormal/JJ biomarkers/NNS between/IN the/DT high/JJ risk/NN and/CC low/JJ risk/NN women/NNS (/( p/NN </JJR 0.001/CD )/) ./. 
A/DT large/JJ prospective/JJ trial/NN is/VBZ needed/VBN to/TO determine/VB if/IN one/CD or/CC more/JJR of/IN these/DT biomarkers/NNS ,/, is/VBZ predictive/JJ of/IN breast/NN cancer/NN development/NN ./. 
UI/LS -/: 98128482/CD 
TI/LS -/: Inhibition/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN subunit/NN p65/NN mRNA/NN accumulation/NN in/IN lipopolysaccharide-stimulated/JJ human/JJ monocytic/JJ cells/NNS treated/VBN with/IN sodium/NN salicylate/NN ./. 
AB/LS -/: Lipopolysaccharide/NN is/VBZ one/CD of/IN the/DT most/RBS potent/JJ trigger/NN substances/NNS for/IN monocytes/NNS and/CC macrophages/NNS causing/VBG secretion/NN of/IN inflammatory/JJ mediators/NNS such/JJ as/IN tumor/NN necrosis/NN factor/NN and/CC interleukin-1/NN ./. 
The/DT nature/NN of/IN the/DT nuclear/JJ factors/NNS involved/VBN in/IN regulation/NN of/IN these/DT cytokine/NN genes/NNS is/VBZ still/RB unknown/JJ ./. 
Nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN ;/: heterodimer/NN of/IN p50/NN and/CC p65/NN )/) proteins/NNS have/VBP been/VBN suggested/VBN to/TO play/VB an/DT important/JJ role/NN in/IN gene/NN transcription/NN of/IN inflammatory/JJ mediators/NNS when/WRB monocytes/NNS are/VBP stimulated/VBN with/IN lipopolysaccharide/NN ./. 
Nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS such/JJ as/IN salicylates/NNS have/VBP been/VBN used/VBN to/TO treat/VB symptoms/NNS of/IN inflammation/NN ,/, and/CC a/DT new/JJ mechanism/NN of/IN drug/NN action/NN was/VBD suggested/VBN recently/RB ./. 
Salicylates/NNS have/VBP been/VBN shown/VBN to/TO inhibit/VB lipopolysaccharide-induced/JJ gene/NN transcription/NN via/IN inhibition/NN of/IN NF-kappa/NN B/NN activation/NN by/IN preventing/VBG the/DT degradation/NN of/IN NF-kappa/NN B/NN inhibitor/NN "/`` I/NN kappa/NN B/NN "/'' ,/, blocking/VBG the/DT translocation/NN of/IN NF-kappa/NN B/NN into/IN the/DT nuclear/JJ compartment/NN ./. 
However/RB ,/, the/DT nature/NN of/IN the/DT subunit/NN involved/VBN in/IN this/DT mechanism/NN has/VBZ not/RB been/VBN defined/VBN ./. 
To/TO examine/VB the/DT mechanisms/NNS by/IN which/WDT salicylates/NNS affect/VBP cytokine/NN gene/NN transcription/NN ,/, the/DT amount/NN of/IN active/JJ and/CC inactive/JJ NF-kappa/NN B/NN and/CC NF-kappa/NN B/NN mRNA/NN ,/, in/IN Porphyromonas/NN gingivalis/NN lipopolysaccharide-stimulated/JJ human/JJ monocytic/JJ cells/NNS was/VBD assessed/VBN ./. 
High/JJ doses/NNS of/IN sodium/NN salicylate/NN suppressed/VBD NF-kappa/NN B/NN p65/NN mRNA/NN accumulation/NN ,/, resulting/VBG in/IN suppression/NN of/IN total/JJ NF-kappa/NN B/NN ,/, p50/NN on/IN tissue/NN oligonucleotide/NN had/VBD no/DT effects/NNS on/IN lipopolysaccharide-induced/JJ NF-kappa/NN B/NN activation/NN ./. 
The/DT data/NNS demonstrate/VBP that/IN the/DT p65/NN subunit/NN of/IN NF-kappa/NN B/NN is/VBZ inhibited/VBN by/IN salicylate/NN treatment/NN and/CC highlight/VBP the/DT role/NN of/IN salicylate/NN in/IN the/DT control/NN of/IN gene/NN expression/NN of/IN inflammatory/JJ mediators/NNS ./. 
UI/LS -/: 97131617/CD 
TI/LS -/: Glucocorticoid-mediated/JJ inhibition/NN of/IN RANTES/NN expression/NN in/IN human/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT chemokine/NN RANTES/NN has/VBZ been/VBN implicated/VBN in/IN the/DT pathogenesis/NN of/IN allergic/JJ inflammatory/JJ diseases/NNS including/VBG asthma/NN and/CC rhinitis/NN which/WDT are/VBP frequently/RB treated/VBN with/IN glucocorticoids/NNS ./. 
We/PRP observed/VBD that/IN dexamethasone/NN dramatically/RB inhibited/VBD RANTES/NN mRNA/NN expression/NN dose/NN dependently/RB in/IN anti-CD3/NN activated/JJ Hut-78/NN T/NN cells/NNS and/CC human/JJ PBMCs/NNS ./. 
Inhibition/NN of/IN RANTES/NNS expression/NN did/VBD not/RB appear/VB to/TO be/VB secondary/JJ to/TO IL-2/NN inhibition/NN and/CC required/VBD binding/VBG to/TO the/DT intracellular/JJ glucocorticoid/NN receptor/NN ./. 
The/DT down-regulation/NN of/IN RANTES/NN expression/NN by/IN glucocorticoids/NNS in/IN T/NN cells/NNS may/MD directly/RB contribute/VB to/TO the/DT efficacy/NN of/IN these/DT agents/NNS in/IN suppressing/VBG cellular/JJ infiltration/NN and/CC to/TO their/PRP$ anti-inflammatory/JJ properties/NNS ./. 
UI/LS -/: 97098688/CD 
TI/LS -/: Association/NN of/IN TRAF1/NN ,/, TRAF2/NN ,/, and/CC TRAF3/NN with/IN an/DT Epstein-Barr/JJ virus/NN LMP1/NN domain/NN important/JJ for/IN B-lymphocyte/NN transformation/NN :/: role/NN in/IN NF-kappaB/NN activation/NN ./. 
AB/LS -/: The/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) transforming/VBG protein/NN LMP1/NN appears/VBZ to/TO be/VB a/DT constitutively/RB activated/VBN tumor/NN necrosis/NN factor/NN receptor/NN (/( TNFR/NN )/) on/IN the/DT basis/NN of/IN an/DT intrinsic/JJ ability/NN to/TO aggregate/VB in/IN the/DT plasma/NN membrane/NN and/CC an/DT association/NN of/IN its/PRP$ cytoplasmic/JJ carboxyl/NN terminus/NN (/( CT/NN )/) with/IN TNFR-associated/JJ factors/NNS (/( TRAFs/NNS )/) ./. 
We/PRP now/RB show/VBP that/IN in/IN EBV-transformed/JJ B/NN lymphocytes/NNS most/JJS of/IN TRAF1/NN or/CC TRAF3/NN and/CC 5/CD %/NN of/IN TRAF2/NN are/VBP associated/VBN with/IN LMP1/NN and/CC that/IN most/JJS of/IN LMP1/NN is/VBZ associated/VBN with/IN TRAF1/NN or/CC TRAF3/NN ./. 
TRAF1/NN ,/, TRAF2/NN ,/, and/CC TRAF3/NN bind/VBP to/TO a/DT single/JJ site/NN in/IN the/DT LMP1/NN CT/NN corresponding/VBG to/TO amino/NN acids/NNS (/( aa/NNS )/) 199/CD to/TO 214/CD ,/, within/IN a/DT domain/NN which/WDT is/VBZ important/JJ for/IN B-lymphocyte/NN growth/NN transformation/NN (/( aa/NNS 187/CD to/TO 231/CD )/) ./. 
Further/JJ deletional/JJ and/CC alanine/NN mutagenesis/NN analyses/NNS and/CC comparison/NN with/IN TRAF/NN binding/NN sequences/NNS in/IN CD40/NN ,/, in/IN CD30/NN ,/, and/CC in/IN the/DT LMP1/NN of/IN other/JJ lymphycryptoviruses/NNS provide/VBP the/DT first/JJ evidence/NN that/IN PXQXT/S/NN is/VBZ a/DT core/NN TRAF/NN binding/NN motif/NN ./. 
The/DT negative/JJ effects/NNS of/IN point/NN mutations/NNS in/IN the/DT LMP1(1-231)/NN core/NN TRAF/NN binding/NN motif/NN on/IN TRAF/NN binding/NN and/CC NF-kappaB/NN activation/NN genetically/RB link/VBP the/DT TRAFs/NNS to/TO LMP1(1-231)-mediated/JJ NF-kappaB/NN activation/NN ./. 
NF-kappaB/NN activation/NN by/IN LMP1(1-231)/NN is/VBZ likely/JJ to/TO be/VB mediated/VBN by/IN TRAF1/TRAF2/NN heteroaggregates/NNS since/IN TRAF1/NN is/VBZ unique/JJ among/IN the/DT TRAFs/NNS in/IN coactivating/VBG NF-kappaB/NN with/IN LMP1(1-231)/NN ,/, a/DT TRAF2/NN dominant-negative/JJ mutant/NN can/MD block/VB LMP1(1-231)-mediated/JJ NF-kappaB/NN activation/NN as/RB well/RB as/IN TRAF1/NN coactivation/NN ,/, and/CC 30/CD %/NN of/IN TRAF2/NN is/VBZ associated/VBN with/IN TRAF1/NN in/IN EBV-transformed/JJ B/NN cells/NNS ./. 
TRAF3/NN is/VBZ a/DT negative/JJ modulator/NN of/IN LMP1(1-231)-mediated/JJ NF-kappaB/NN activation/NN ./. 
Surprisingly/RB ,/, TRAF1/NN ,/, -2/CD ,/, or/CC -3/CD does/VBZ not/RB interact/VB with/IN the/DT terminal/JJ LMP1/NN CT/NN aa/NNS 333/CD to/TO 386/CD which/WDT can/MD independently/RB mediate/VBP NF-kappaB/NN activation/NN ./. 
The/DT constitutive/JJ association/NN of/IN TRAFs/NNS with/IN LMP1/NN through/IN the/DT aa/NNS 187/CD to/TO 231/CD domain/NN which/WDT is/VBZ important/JJ in/IN NF-kappaB/NN activation/NN and/CC primary/JJ B-lymphocyte/NN growth/NN transformation/NN implicates/VBZ TRAF/NN aggregation/NN in/IN LMP1/NN signaling/NN ./. 
UI/LS -/: 97064186/CD 
TI/LS -/: Lack/NN of/IN IL-12/NN signaling/NN in/IN human/JJ allergen-specific/JJ Th2/NN cells/NNS ./. 
AB/LS -/: IL-12/NN is/VBZ a/DT powerful/JJ skewer/NN of/IN CD4+/JJ T/NN cell/NN responses/NNS toward/IN the/DT Th1/NN phenotype/NN by/IN inducing/VBG IFN-gamma/NN production/NN in/IN naive/JJ Th/NN cells/NNS ./. 
In/IN the/DT present/JJ study/NN we/PRP addressed/VBD the/DT question/NN of/IN whether/IN IL-12/NN can/MD reverse/VB established/JJ Th2/NN responses/NNS into/IN Th1/Th0/NN responses/NNS by/IN inducing/VBG IFN-gamma/NN production/NN in/IN memory/NN Th2/NN cells/NNS ./. 
To/TO this/DT aim/NN ,/, allergen-specific/JJ CD4+/JJ T/NN cell/NN clones/NNS (/( TCC/NN )/) were/VBD generated/VBN from/IN the/DT peripheral/JJ blood/NN of/IN three/CD atopic/JJ patients/NNS ,/, and/CC their/PRP$ cytokine/NN profiles/NNS were/VBD analyzed/VBN ./. 
The/DT majority/NN of/IN these/DT TCC/NN exhibited/VBD a/DT strongly/RB polarized/VBN Th2/NN cytokine/NN profile/NN ,/, and/CC the/DT production/NN of/IN IFN-gamma/NN could/MD not/RB be/VB induced/VBN by/IN exogenous/JJ IL-12/NN ./. 
Only/RB those/DT TCC/NN with/IN low/JJ IFN-gamma/NN levels/NNS in/IN the/DT absence/NN of/IN IL-12/NN responded/VBD to/TO IL-12/NN by/IN additional/JJ enhancement/NN of/IN IFN-gamma/NN production/NN ./. 
The/DT IL-12/NN nonresponsiveness/NN of/IN the/DT Th2/NN clones/NNS was/VBD further/RBR evident/JJ by/IN the/DT total/JJ lack/NN of/IN IL-12-induced/JJ phosphorylation/NN of/IN STAT4/NN (/( signal/NN transducer/NN and/CC activator/NN of/IN transcription-4/NN )/) ,/, a/DT transcription/NN factor/NN that/WDT is/VBZ typically/RB involved/VBN in/IN IL-12/NN signaling/NN ./. 
Consequently/RB ,/, IL-12/NN also/RB failed/VBD to/TO induce/VB the/DT DNA-binding/JJ activity/NN of/IN STAT4-containing/JJ complexes/NNS in/IN the/DT nuclei/NNS of/IN these/DT Th2/NN clones/NNS ./. 
All/DT TCC/NN expressed/VBD equal/JJ levels/NNS of/IN the/DT low-affinity/JJ IL-12R/NN beta1/NN subunit/NN ./. 
Our/PRP$ results/NNS indicate/VBP that/IN human/JJ allergen-specific/JJ Th/NN cells/NNS with/IN strongly/RB polarized/VBN Th2/NN cytokine/NN profiles/NNS do/VBP not/RB respond/VB to/TO IL-12/NN and/CC ,/, therefore/RB ,/, can/MD not/RB be/VB induced/VBN to/TO produce/VB IFN-gamma/NN ./. 
The/DT apparent/JJ high/JJ frequency/NN of/IN IL-12-nonresponsive/JJ Th/NN cells/NNS within/IN the/DT allergen-specific/JJ populations/NNS in/IN atopic/JJ patients/NNS predicts/VBZ a/DT limited/JJ skewing/JJ potential/NN of/IN IL-12/NN in/IN the/DT case/NN of/IN established/JJ Th2/NN responses/NNS ,/, but/CC only/RB affecting/VBG newly/RB recruited/VBN naive/JJ Th/NN cells/NNS ./. 
UI/LS -/: 97081192/CD 
TI/LS -/: Cloning/NN and/CC expression/NN of/IN the/DT Epstein-Barr/JJ virus-encoded/JJ dUTPase/NN :/: patients/NNS with/IN acute/JJ ,/, reactivated/VBN or/CC chronic/JJ virus/NN infection/NN develop/VBP antibodies/NNS against/IN the/DT enzyme/NN ./. 
AB/LS -/: The/DT gene/NN encoding/VBG the/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) -specific/JJ dUTPase/NN was/VBD amplified/VBN from/IN virus/NN DNA/NN by/IN PCR/NN ./. 
The/DT active/JJ enzyme/NN was/VBD expressed/VBN in/IN Escherichia/FW coli/FW and/CC in/IN insect/NN cells/NNS as/IN a/DT non-fusion/JJ protein/NN ./. 
The/DT protein/NN from/IN E./FW coli/FW specifically/RB converted/VBD dUTP/NN to/TO dUMP/NN and/CC did/VBD not/RB react/VB with/IN other/JJ dNTPs/NNS or/CC NTPs/NNS ./. 
Preliminary/JJ experiments/NNS yielded/VBD a/DT Km/NN value/NN of/IN about/RB 0.8/CD microM/NN for/IN dUTP/NN ./. 
MAbs/NNS against/IN the/DT dUTPase/NN reacted/VBD with/IN a/DT protein/NN of/IN approximately/RB 31/CD kDa/NN in/IN 12-O-tetradecanoyl-phorbol-13-acetate/NN (/( TPA/NN )/) -stimulated/JJ B/NN cells/NNS harbouring/VBG either/CC type/NN 1/CD or/CC type/NN 2/CD EBV/NN ./. 
The/DT protein/NN was/VBD found/VBN in/IN untreated/JJ cells/NNS at/IN low/JJ levels/NNS ,/, whereas/IN induction/NN of/IN the/DT lytic/JJ replication/NN cycle/NN by/IN TPA/NN treatment/NN or/CC by/IN providing/VBG the/DT immediate/JJ early/JJ transactivator/NN BZLF1/NN in/IN trans/NN resulted/VBD in/IN increased/VBN expression/NN ./. 
We/PRP demonstrated/VBD that/IN the/DT virus/NN dUTPase/NN isolated/VBN from/IN EBV-infected/JJ cells/NNS is/VBZ a/DT phosphoprotein/NN ./. 
The/DT protein/NN expressed/VBN in/IN insect/NN cells/NNS was/VBD used/VBN to/TO test/VB for/IN the/DT presence/NN of/IN specific/JJ antibodies/NNS in/IN sera/NN from/IN normal/JJ ,/, healthy/JJ carriers/NNS and/CC from/IN patients/NNS with/IN various/JJ diseases/NNS ./. 
While/IN the/DT sera/NN of/IN EBV-negative/JJ individuals/NNS (/( 0/3/CD )/) or/CC healthy/JJ carriers/NNS (/( 0/33/CD )/) did/VBD not/RB contain/VB detectable/JJ levels/NNS of/IN antibodies/NNS ,/, patients/NNS with/IN mononucleosis/NN (/( 5/18/CD )/) ,/, chronic/JJ EBV/NN infection/NN (/( 2/7/CD )/) ,/, EBV/NN reactivation/NN (/( 7/20/CD )/) and/CC human/JJ immunodeficiency/NN virus/NN infection/NN (/( 5/24/CD )/) showed/VBD elevated/JJ antibody/NN titres/NNS against/IN the/DT enzyme/NN ./. 
This/DT indicated/VBD that/IN the/DT dUTPase/NN is/VBZ expressed/VBN during/IN EBV/NN replication/NN and/CC reactivation/NN ./. 
The/DT enzyme/NN might/MD therefore/RB be/VB a/DT potential/JJ target/NN for/IN drug/NN therapy/NN under/IN conditions/NNS of/IN active/JJ DNA/NN replication/NN ./. 
UI/LS -/: 97047764/CD 
TI/LS -/: The/DT catalytic/JJ domain/NN of/IN pp56(lck)/NN ,/, but/CC not/RB its/PRP$ regulatory/JJ domain/NN ,/, is/VBZ sufficient/JJ for/IN inducing/VBG IL-2/NN production/NN ./. 
AB/LS -/: The/DT lymphoid/JJ src/NN kinase/NN pp56(lck)/NN has/VBZ been/VBN shown/VBN to/TO be/VB essential/JJ for/IN the/DT induction/NN of/IN different/JJ T/NN lymphocyte/NN responses/NNS ,/, including/VBG CD4-mediated/JJ enhancement/NN of/IN Ag-induced/JJ T/NN cell/NN activation/NN ,/, early/JJ T/NN cell/NN differentiation/NN ,/, induction/NN of/IN IL-2/NN production/NN ,/, and/CC cytotoxicity/NN ./. 
It/PRP is/VBZ assumed/VBN that/IN pp56(lck)/NN acts/VBZ on/IN these/DT processes/NNS by/IN phosphorylating/VBG substrates/NNS ./. 
However/RB ,/, it/PRP has/VBZ been/VBN recently/RB reported/VBN that/IN the/DT NH2/NN regulatory/JJ domain/NN is/VBZ sufficient/JJ to/TO mediate/VB CD4/NN accessory/JJ function/NN ./. 
In/IN this/DT report/NN we/PRP address/VBP the/DT contribution/NN of/IN the/DT regulatory/JJ and/CC catalytic/JJ domains/NNS of/IN pp56(lck)/NN to/TO another/DT function/NN of/IN this/DT enzyme/NN independent/JJ of/IN CD4/NN :/: TCR-induced/JJ IL-2/NN production/NN ./. 
Two/CD pp56(lck)/NN mutants/NNS lacking/VBG either/CC the/DT entire/JJ catalytic/JJ domain/NN or/CC the/DT entire/JJ NH2/NN regulatory/JJ domain/NN were/VBD generated/VBN ,/, and/CC their/PRP$ abilities/NNS to/TO trigger/VB transactivation/NN of/IN the/DT TCR-regulated/JJ nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) region/NN of/IN the/DT IL-2/NN promoter/NN were/VBD compared/VBN ./. 
Only/RB the/DT catalytic/JJ ,/, but/CC not/RB the/DT NH2/NN regulatory/JJ ,/, domain/NN of/IN pp56(lck)/NN was/VBD able/JJ to/TO induce/VB NF-AT/NN region/NN transactivation/NN on/IN its/PRP$ own/JJ and/CC to/TO cooperate/VB with/IN other/JJ intracellular/JJ signals/NNS to/TO trigger/VB this/DT response/NN ./. 
Moreover/RB ,/, the/DT catalytic/JJ domain/NN of/IN pp56(lck)/NN was/VBD able/JJ to/TO induce/VB IL-2/NN cytokine/NN production/NN to/TO an/DT extent/NN similar/JJ to/TO that/DT of/IN wild-type/JJ pp56(lck)/NN ./. 
We/PRP conclude/VBP that/IN different/JJ domains/NNS of/IN the/DT pp56(lck)/NN molecule/NN contribute/VBP to/TO regulate/VB distinct/JJ biologic/JJ functions/NNS ./. 
In/IN fact/NN ,/, while/IN the/DT NH2/NN regulatory/JJ domain/NN is/VBZ sufficient/JJ to/TO mediate/VB CD4/NN accessory/JJ function/NN ,/, we/PRP show/VBP here/RB that/IN the/DT catalytic/JJ domain/NN of/IN pp56(lck)/NN is/VBZ sufficient/JJ for/IN induction/NN of/IN IL-2/NN production/NN ,/, mimicking/VBG TCR/NN ligation/NN ./. 
UI/LS -/: 95104037/CD 
TI/LS -/: [/( The/DT changes/NNS in/IN glucocorticoid/NN receptors/NNS in/IN peripheral/JJ leukocytes/NNS in/IN asthmatic/JJ subjects/NNS ]/) 
AB/LS -/: The/DT number/NN of/IN glucocorticoid/NN receptors/NNS (/( GCR/NN )/) in/IN peripheral/JJ leukocytes/NNS was/VBD determined/VBN by/IN radioligand-binding/JJ assay/NN in/IN extrinsic/JJ and/CC intrinsic/JJ asthmatics/NNS ./. 
Their/PRP$ corresponding/JJ plasma/NN cortisol/NN levels/NNS were/VBD assessed/VBN ./. 
The/DT results/NNS showed/VBD that/IN the/DT average/JJ number/NN of/IN GCR/NN in/IN asthmatics/NNS was/VBD significantly/RB lower/JJR than/IN that/DT in/IN healthy/JJ subjects/NNS (/( P/NN </JJR 0.01/CD )/) ,/, and/CC there/EX was/VBD a/DT linear/JJ correlation/NN between/IN the/DT number/NN of/IN GCR/NN and/CC the/DT course/NN of/IN asthma/NN ./. 
Besides/RB ,/, there/EX was/VBD also/RB a/DT linear/JJ correlation/NN between/IN the/DT number/NN of/IN GCR/NN and/CC the/DT age/NN of/IN the/DT initial/JJ attack/NN of/IN asthma/NN ./. 
No/DT difference/NN in/IN plasma/NN cortisol/NN level/NN was/VBD found/VBN between/IN asthmatics/NNS and/CC healthy/JJ subjects/NNS ./. 
These/DT findings/NNS suggest/VBP that/IN there/EX is/VBZ no/DT primary/JJ and/CC general/JJ impairment/NN of/IN glucocorticoid/NN metabolism/NN in/IN the/DT asthmatics/NNS ,/, but/CC the/DT number/NN of/IN GCR/NN in/IN the/DT asthmatics/NNS is/VBZ lower/JJR than/IN that/DT in/IN healthy/JJ controls/NNS ./. 
The/DT decrease/NN of/IN the/DT number/NN of/IN GCR/NN in/IN asthmatics/NNS ,/, we/PRP think/VBP ,/, is/VBZ related/JJ to/TO heredity/NN and/CC repeated/VBN attacks/NNS of/IN asthma/NN ./. 
UI/LS -/: 94249033/CD 
TI/LS -/: Novel/JJ aldosterone/NN receptors/NNS :/: specificity-conferring/JJ mechanism/NN at/IN the/DT level/NN of/IN the/DT cell/NN membrane/NN ./. 
AB/LS -/: Functional/JJ studies/NNS in/IN extra-renal/JJ ,/, nonepithelial/JJ cells/NNS such/JJ as/IN smooth/JJ muscle/NN cells/NNS and/CC more/RBR recently/RB circulating/VBG human/JJ lymphocytes/NNS have/VBP provided/VBN increasing/VBG evidence/NN that/IN aldosterone/NN produces/VBZ not/RB only/RB classical/JJ genomic/JJ effects/NNS ,/, but/CC also/RB rapid/JJ non-genomic/JJ effects/NNS on/IN transmembrane/NN electrolyte/NN movements/NNS ./. 
These/DT involve/VBP activation/NN of/IN the/DT sodium/proton-exchanger/NN of/IN the/DT cell/NN membrane/NN at/IN very/RB low/JJ ,/, physiological/JJ concentrations/NNS of/IN aldosterone/NN with/IN an/DT acute/JJ onset/NN within/IN 1-2/CD minutes/NNS ./. 
A/DT second/JJ messenger/NN cascade/NN involved/VBN is/VBZ the/DT inositol-1,4,5-trisphosphate/calcium/NN pathway/NN which/WDT responds/VBZ over/IN the/DT same/JJ rapid/JJ time/NN course/NN ./. 
Such/JJ changes/NNS clearly/RB can/MD not/RB be/VB explained/VBN by/IN genomic/JJ mechanisms/NNS ,/, which/WDT are/VBP responsible/JJ for/IN later/JJ effects/NNS than/IN the/DT membrane-related/JJ rapid/JJ responses/NNS ./. 
In/IN addition/NN to/TO its/PRP$ rapid/JJ time/NN course/NN the/DT unique/JJ characteristics/NNS of/IN this/DT new/JJ pathway/NN for/IN steroid/NN action/NN include/VBP a/DT 10000-fold/JJ selectivity/NN for/IN aldosterone/NN over/IN cortisol/NN and/CC the/DT ineffectiveness/NN of/IN spironolactones/NNS ,/, classical/JJ mineralocorticoid/NN antagonists/NNS ,/, as/IN antagonists/NNS of/IN the/DT response/NN ./. 
Subsequently/RB binding/VBG sites/NNS have/VBP been/VBN demonstrated/VBN in/IN the/DT plasma/NN membrane/NN of/IN human/JJ lymphocytes/NNS which/WDT show/VBP pharmacological/JJ (/( aldosterone/NN specificity/NN )/) and/CC kinetic/JJ (/( high/JJ turnover/NN )/) properties/NNS identical/JJ with/IN those/DT of/IN the/DT rapid/JJ aldosterone/NN effects/NNS in/IN the/DT same/JJ cells/NNS ./. 
SDS-PAGE/NN analysis/NN of/IN the/DT receptor/NN protein/NN has/VBZ shown/VBN a/DT molecular/JJ weight/NN of/IN approximately/RB 50/CD kD/NN ./. 
The/DT present/JJ paper/NN reviews/VBZ the/DT data/NNS supporting/VBG a/DT new/JJ ,/, two-step/JJ model/NN for/IN non-genomic/JJ and/CC genomic/JJ aldosterone/NN effects/NNS ./. 
It/PRP also/RB suggests/VBZ a/DT novel/JJ specificity-conferring/JJ mechanism/NN for/IN mineralocorticoid/NN action/NN at/IN the/DT membrane/NN level/NN ./. 
UI/LS -/: 94088534/CD 
TI/LS -/: The/DT macrophage/NN transcription/NN factor/NN PU.1/NN directs/VBZ tissue-specific/JJ expression/NN of/IN the/DT macrophage/NN colony-stimulating/JJ factor/NN receptor/NN ./. 
AB/LS -/: The/DT macrophage/NN colony-stimulating/JJ factor/NN (/( M-CSF/NN )/) receptor/NN is/VBZ expressed/VBN in/IN a/DT tissue-specific/JJ fashion/NN from/IN two/CD distinct/JJ promoters/NNS in/IN monocytes/macrophages/NNS and/CC the/DT placenta/NN ./. 
In/IN order/NN to/TO further/RB understand/VB the/DT transcription/NN factors/NNS which/WDT play/VBP a/DT role/NN in/IN the/DT commitment/NN of/IN multipotential/JJ progenitors/NNS to/TO the/DT monocyte/macrophage/NN lineage/NN ,/, we/PRP have/VBP initiated/VBN an/DT investigation/NN of/IN the/DT factors/NNS which/WDT activate/VBP the/DT M-CSF/NN receptor/NN very/RB early/RB during/IN the/DT monocyte/NN differentiation/NN process/NN ./. 
Here/RB we/PRP demonstrate/VBP that/IN the/DT human/JJ monocytic/JJ M-CSF/NN receptor/NN promoter/NN directs/VBZ reporter/NN gene/NN activity/NN in/IN a/DT tissue-specific/JJ fashion/NN ./. 
Since/IN one/CD of/IN the/DT few/JJ transcription/NN factors/NNS which/WDT have/VBP been/VBN implicated/VBN in/IN the/DT regulation/NN of/IN monocyte/NN genes/NNS is/VBZ the/DT macrophage-/NN and/CC B-cell-specific/JJ PU.1/NN transcription/NN factor/NN ,/, we/PRP investigated/VBD whether/IN PU.1/NN binds/VBZ and/CC activates/VBZ the/DT M-CSF/NN receptor/NN promoter/NN ./. 
Here/RB we/PRP demonstrate/VBP that/IN both/CC in/FW vitro-translated/VBN PU.1/NN and/CC PU.1/NN from/IN nuclear/JJ extracts/NNS bind/VBP to/TO a/DT specific/JJ site/NN in/IN the/DT M-CSF/NN receptor/NN promoter/NN just/RB upstream/JJ from/IN the/DT major/JJ transcription/NN initiation/NN site/NN ./. 
Mutations/NNS in/IN this/DT site/NN which/WDT eliminate/VB PU.1/NN binding/NN decrease/VBP M-CSF/NN receptor/NN promoter/NN activity/NN significantly/RB in/IN macrophage/JJ cell/NN lines/NNS only/RB ./. 
Furthermore/RB ,/, PU.1/NN transactivates/VBZ the/DT M-CSF/NN receptor/NN promoter/NN in/IN nonmacrophage/JJ cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN PU.1/NN plays/VBZ a/DT major/JJ role/NN in/IN macrophage/NN gene/NN regulation/NN and/CC development/NN by/IN directing/VBG the/DT expression/NN of/IN a/DT receptor/NN for/IN a/DT key/JJ macrophage/NN growth/NN factor/NN ./. 
UI/LS -/: 94101543/CD 
TI/LS -/: Increased/VBN natural/JJ killer/NN cell/NN activity/NN correlates/VBZ with/IN low/JJ or/CC negative/JJ expression/NN of/IN the/DT HER-2/neu/NN oncogene/NN in/IN patients/NNS with/IN breast/NN cancer/NN ./. 
AB/LS -/: BACKGROUND/NN ./. 
Increased/VBN expression/NN of/IN the/DT HER-2/neu/NN oncogene/NN in/IN breast/NN cancer/NN correlates/VBZ with/IN decreased/VBN estrogen/NN receptor/NN concentration/NN and/CC seems/VBZ to/TO be/VB an/DT important/JJ prognostic/JJ factor/NN ./. 
The/DT authors/NNS investigated/VBD whether/IN there/EX is/VBZ a/DT correlation/NN between/IN HER-2/neu/NN expression/NN and/CC immunologic/JJ parameters/NNS representing/VBG tumor/NN defense/NN in/IN patients/NNS with/IN breast/NN cancer/NN ./. 
METHOD/NN ./. 
A/DT Western/JJ|NN blot/NN analysis/NN was/VBD used/VBN to/TO investigate/VB HER-2/neu/NN expression/NN ,/, whereas/IN a/DT chromium-release/NN assay/NN using/VBG the/DT K562/NN cell/NN line/NN as/IN target/NN was/VBD used/VBN to/TO measure/VB natural/JJ killer/NN (/( NK/NN )/) cell/NN activity/NN ./. 
RESULTS/NNS ./. 
In/IN patients/NNS with/IN breast/NN cancer/NN ,/, NK/NN cell/NN activity/NN was/VBD significantly/RB higher/JJR compared/VBN with/IN patients/NNS with/IN benign/JJ tumors/NNS (/( P/NN =/JJ 0.006/CD )/) or/CC healthy/JJ control/NN subjects/NNS (/( P/NN =/JJ 0.002/CD )/) ./. 
Moreover/RB ,/, 23.3/CD %/NN of/IN patients/NNS with/IN breast/NN cancer/NN showed/VBD an/DT overexpression/NN of/IN HER-2/neu/NN protein/NN ./. 
Within/IN this/DT group/NN of/IN patients/NNS ,/, NK/NN cell/NN activity/NN was/VBD significantly/RB lower/JJR (/( 45.6/CD +/-/CC 16.1/CD %/NN )/) compared/VBN with/IN the/DT group/NN with/IN no/DT HER-2/neu/NN overexpression/NN (/( 57.3/CD +/-/CC 11.0/CD %/NN )/) ./. 
NK/NN cell/NN activity/NN did/VBD not/RB increase/VB in/IN patients/NNS with/IN HER-2/neu/NN overexpression/NN ./. 
Thus/RB ,/, there/EX was/VBD a/DT statistically/RB significant/JJ correlation/NN of/IN cytolytic/JJ effector/NN cell/NN function/NN with/IN HER-2/neu/NN expression/NN of/IN the/DT tumor/NN (/( P/NN =/JJ 0.003/CD )/) ,/, and/CC HER-2/neu/NN overexpression/NN correlated/VBD with/IN a/DT negative/JJ estrogen/NN receptor/NN status/NN (/( P/NN =/JJ 0.005/CD )/) ./. 
CONCLUSION/NN ./. 
These/DT data/NNS add/VBP further/JJ evidence/NN to/TO previous/JJ observations/NNS from/IN the/DT authors/NNS '/POS laboratory/NN that/IN certain/JJ tumor/NN characteristics/NNS may/MD be/VB associated/VBN with/IN reactions/NNS of/IN the/DT host/NN with/IN breast/NN cancer/NN ./. 
UI/LS -/: 98048869/CD 
TI/LS -/: [/( The/DT value/NN of/IN the/DT clinical/JJ test/NN of/IN glucocorticoid/NN receptors/NNS of/IN peripheral/JJ blood/NN leukocytes/NNS in/IN patients/NNS with/IN chronic/JJ pulmonary/JJ heart/NN disease/NN ]/) 
AB/LS -/: In/IN order/NN to/TO inquire/VB into/IN the/DT functional/JJ state/NN of/IN adrenal/JJ cortex/NN in/IN patients/NNS with/IN pulmonary/JJ heart/NN disease/NN ,/, the/DT number/NN of/IN glucocorticoid/NN receptors/NNS (/( GCR/NN )/) of/IN peripheral/JJ blood/NN leukocytes/NNS in/IN patients/NNS with/IN chronic/JJ pulmonary/JJ heart/NN disease/NN was/VBD determined/VBN with/IN radioligand-binding/JJ assay/NN and/CC the/DT corresponding/JJ plasma/NN cortisol/NN levels/NNS were/VBD assessed/VBN with/IN radioimmune/JJ assays/NNS ./. 
The/DT results/NNS showed/VBD that/IN the/DT number/NN of/IN GCR/NN in/IN the/DT patients/NNS was/VBD significantly/RB reduced/VBN (/( P/NN </JJR 0.01/CD )/) and/CC it/PRP was/VBD increased/VBN when/WRB their/PRP$ health/NN state/NN was/VBD improved/VBN ./. 
However/RB ,/, it/PRP was/VBD still/RB lower/JJR than/IN that/DT in/IN healthy/JJ subjects/NNS (/( P/NN </JJR 0.01/CD )/) ./. 
The/DT number/NN of/IN GCR/NN in/IN the/DT patients/NNS was/VBD greatly/RB increased/VBN when/WRB these/DT patients/NNS were/VBD treated/VBN with/IN oxygen/NN (/( P/NN </JJR 0.01/CD )/) ./. 
No/DT difference/NN in/IN plasma/NN cortisol/NN was/VBD found/VBN between/IN the/DT patients/NNS and/CC the/DT healthy/JJ subjects/NNS (/( P/NN >/JJR 0.05/CD )/) ./. 
These/DT results/NNS indicate/VBP that/IN the/DT function/NN of/IN adrenal/JJ cortex/NN may/MD be/VB improved/VBN by/IN the/DT compensation/NN mechanism/NN of/IN the/DT patients/NNS ,/, but/CC the/DT lower/JJR GCR/NN number/NN was/VBD the/DT result/NN of/IN lacking/NN of/IN oxygen/NN in/IN the/DT patients/NNS ./. 
The/DT number/NN of/IN GCR/NN may/MD be/VB improved/VBN by/IN inhalation/NN of/IN oxygen/NN ./. 
Therefore/RB oxygen/NN therapy/NN is/VBZ helpful/JJ in/IN raising/VBG the/DT activity/NN of/IN glucocorticoid/NN receptors/NNS and/CC controlling/VBG the/DT development/NN of/IN the/DT disease/NN ./. 
UI/LS -/: 97140237/CD 
TI/LS -/: Signaling/NN via/IN IL-2/NN and/CC IL-4/NN in/IN JAK3-deficient/JJ severe/JJ combined/JJ immunodeficiency/NN lymphocytes/NNS :/: JAK3-dependent/JJ and/CC independent/JJ pathways/NNS ./. 
AB/LS -/: Both/CC IL-2/NN and/CC IL-4/NN bind/VBP to/TO receptors/NNS containing/VBG the/DT common/JJ gamma/NN chain/NN and/CC JAK3/NN ./. 
Although/IN JAK3/NN is/VBZ required/VBN for/IN proper/JJ lymphoid/JJ development/NN ,/, the/DT precise/JJ roles/NNS of/IN this/DT kinase/NN in/IN IL-2/NN and/CC IL-4/NN signaling/NN in/IN lymphocytes/NNS have/VBP not/RB been/VBN defined/VBN ./. 
Here/RB ,/, we/PRP have/VBP studied/VBN IL-2/NN and/CC IL-4/NN signaling/NN in/IN B/NN cell/NN lines/NNS lacking/VBG JAK3/NN ./. 
Although/IN IL-2-induced/JJ phosphorylation/NN of/IN IL-2R/NN beta/NN ,/, JAK1/NN ,/, and/CC STAT5/NN all/DT required/VBN the/DT presence/NN of/IN JAK3/NN ,/, IL-4-mediated/JJ phosphorylation/NN of/IN JAK1/NN ,/, STAT6/NN ,/, and/CC insulin/NN receptor/NN substrates/NNS 1/CD and/CC 2/CD did/VBD not/RB ./. 
However/RB ,/, IL-4-induced/JJ effects/NNS were/VBD clearly/RB improved/VBN following/VBG JAK3/NN expression/NN ./. 
These/DT data/NNS indicate/VBP that/IN IL-4/NN signaling/NN occurs/VBZ in/IN the/DT absence/NN of/IN of/IN JAK3/NN ,/, but/CC is/VBZ comparatively/RB inefficient/JJ ./. 
These/DT findings/NNS may/MD help/VB in/RP understanding/VBG the/DT pathogenesis/NN of/IN the/DT immunodeficiency/NN that/WDT occurs/VBZ with/IN mutations/NNS of/IN JAK3/NN and/CC may/MD suggest/VB a/DT mechanism/NN for/IN the/DT pleiotropic/JJ effects/NNS of/IN IL-4/NN ./. 
UI/LS -/: 97098661/CD 
TI/LS -/: Elf-1/NN and/CC Stat5/NN bind/VBP to/TO a/DT critical/JJ element/NN in/IN a/DT new/JJ enhancer/NN of/IN the/DT human/JJ interleukin-2/NN receptor/NN alpha/NN gene/NN [/( published/VBN erratum/NN appears/VBZ in/IN Mol/NNP Cell/NNP Biol/NNP 1997/CD Apr/NNP ;/: 17/CD (/( 4/CD )/) :/: 2351/CD ]/) 
AB/LS -/: The/DT interleukin/NN 2/CD receptor/NN alpha-chain/NN (/( IL-2R/NN alpha/NN )/) gene/NN is/VBZ a/DT key/JJ regulator/NN of/IN lymphocyte/NN proliferation/NN ./. 
IL-2R/NN alpha/NN is/VBZ rapidly/RB and/CC potently/RB induced/VBN in/IN T/NN cells/NNS in/IN response/NN to/TO mitogenic/JJ stimuli/NNS ./. 
Interleukin/NN 2/CD (/( IL-2/NN )/) stimulates/VBZ IL-2R/NN alpha/NN ./. 
transcription/NN ,/, thereby/RB amplifying/VBG expression/NN of/IN its/PRP$ own/JJ high-affinity/NN receptor/NN ./. 
IL-2R/NN alpha/NN transcription/NN is/VBZ at/IN least/JJS in/IN part/NN controlled/VBN by/IN two/CD positive/JJ regulatory/JJ regions/NNS ,/, PRRI/NN and/CC PRRII/NN ./. 
PRRI/NN is/VBZ an/DT inducible/JJ proximal/JJ enhancer/NN ,/, located/JJ between/IN nucleotides/NNS -276/CD and/CC -244/CD ,/, which/WDT contains/VBZ NF-kappaB/NN and/CC SRE/CArG/NN motifs/NNS ./. 
PRRII/NN is/VBZ a/DT T-cell-specific/JJ enhancer/NN ,/, located/JJ between/IN nucleotides/NNS -137/CD and/CC -64/CD ,/, which/WDT binds/VBZ the/DT T-cell-specific/JJ Ets/NN protein/NN Elf-1/NN and/CC HMG-I(Y)/NN proteins/NNS ./. 
However/RB ,/, none/NN of/IN these/DT proximal/JJ regions/NNS account/VBP for/IN the/DT induction/NN of/IN IL-2R/NN alpha/NN transcription/NN by/IN IL-2/NN ./. 
To/TO find/VB new/JJ regulatory/JJ regions/NNS of/IN the/DT IL-2R/NN alpha/NN gene/NN ,/, 8.5/CD kb/NN of/IN the/DT 5'/JJ end/NN noncoding/JJ sequence/NN of/IN the/DT IL-2R/NN alpha/NN gene/NN have/VBP been/VBN sequenced/VBN ./. 
We/PRP identified/VBD an/DT 86-nucleotide/JJ fragment/NN that/WDT is/VBZ 90/CD %/NN identical/JJ to/TO the/DT recently/RB characterized/VBN murine/JJ IL-2-responsive/JJ element/NN (/( mIL-2rE/NN )/) ./. 
This/DT putative/JJ human/JJ IL-2rE/NN ,/, designated/VBN PRRIII/NN ,/, confers/VBZ IL-2/NN responsiveness/NN on/IN a/DT heterologous/JJ promoter/NN ./. 
PRRIII/NN contains/VBZ a/DT Stat/NN protein/NN binding/NN site/NN that/WDT overlaps/VBZ with/IN an/DT EBS/NN motif/NN (/( GASd/EBSd/NN )/) ./. 
These/DT are/VBP essential/JJ for/IN IL-2/NN inducibility/NN of/IN PRRIII/CAT/NN reporter/NN constructs/NNS ./. 
IL-2/NN induced/VBD the/DT binding/NN of/IN Stat5a/NN and/CC b/NN proteins/NNS to/TO the/DT human/JJ GASd/NN element/NN ./. 
To/TO confirm/VB the/DT physiological/JJ relevance/NN of/IN these/DT findings/NNS ,/, we/PRP carried/VBD out/RP in/FW vivo/FW footprinting/NN experiments/NNS which/WDT showed/VBD that/IN stimulation/NN of/IN IL-2R/NN alpha/NN expression/NN correlated/VBD with/IN occupancy/NN of/IN the/DT GASd/NN element/NN ./. 
Our/PRP$ data/NNS demonstrate/VBP a/DT major/JJ role/NN of/IN the/DT GASd/EBSd/NN element/NN in/IN IL-2R/NN alpha/NN regulation/NN and/CC suggest/VBP that/IN the/DT T-cell-specific/JJ Elf-1/NN factor/NN can/MD serve/VB as/IN a/DT transcriptional/JJ repressor/NN ./. 
UI/LS -/: 97081063/CD 
TI/LS -/: Signal/NN transduction/NN by/IN DR3/NN ,/, a/DT death/NN domain-containing/JJ receptor/NN related/JJ to/TO TNFR-1/NN and/CC CD95/NN ./. 
AB/LS -/: Tumor/NN necrosis/NN factor/NN receptor-1/NN (/( TNFR-1/NN )/) and/CC CD95/NN (/( also/RB called/VBN Fas/NN or/CC APO-1/NN )/) are/VBP cytokine/NN receptors/NNS that/WDT engage/VBP the/DT apoptosis/NN pathway/NN through/IN a/DT region/NN of/IN intracellular/JJ homology/NN ,/, designated/VBD the/DT "/`` death/NN domain/NN ./. "/'' Another/DT death/NN domain-containing/NN member/NN of/IN the/DT TNFR/NN family/NN ,/, death/NN receptor/NN 3/CD (/( DR3/NN )/) ,/, was/VBD identified/VBN and/CC was/VBD shown/VBN to/TO induce/VB both/CC apoptosis/NNS and/CC activation/NN of/IN nuclear/JJ factor/NN kappaB/NN ./. 
Expression/NN of/IN DR3/NN appears/VBZ to/TO be/VB restricted/JJ to/TO tissues/NNS enriched/VBN in/IN lymphocytes/NNS ./. 
DR3/NN signal/NN transduction/NN is/VBZ mediated/VBN by/IN a/DT complex/NN of/IN intracellular/JJ signaling/VBG molecules/NNS including/VBG TRADD/NN ,/, TRAF2/NN ,/, FADD/NN ,/, and/CC FLICE/NN ./. 
Thus/RB ,/, DR3/NN likely/RB plays/VBZ a/DT role/NN in/IN regulating/VBG lymphocyte/NN homeostasis/NN ./. 
UI/LS -/: 97080592/CD 
TI/LS -/: Differential/JJ nuclear/JJ localization/NN of/IN p50/NN ,/, p52/NN ,/, and/CC RelB/NN proteins/NNS in/IN human/JJ accessory/JJ cells/NNS of/IN the/DT immune/JJ response/NN in/FW situ/FW ./. 
AB/LS -/: The/DT Rel/NF-kappa/NN B/NN proteins/NNS ,/, p50/NN ,/, p52/NN ,/, p65/NN ,/, c-Rel/NN ,/, and/CC RelB/NN ,/, constitute/VBP a/DT family/NN of/IN transcription/NN factors/NNS involved/VBN in/IN the/DT positive/JJ regulation/NN of/IN a/DT variety/NN of/IN genes/NNS during/IN the/DT immune/JJ response/NN ./. 
Recently/RB ,/, it/PRP has/VBZ been/VBN shown/VBN that/IN RelB/NN knockout/JJ|NN mice/NNS have/VBP no/DT dendritic/JJ cells/NNS (/( DC/NN )/) ./. 
An/DT overexpression/NN of/IN p50/NN has/VBZ been/VBN described/VBN in/IN follicular/JJ dendritic/JJ cells/NNS (/( FDC/NN )/) ./. 
A/DT constitutive/JJ NF-kappa/NN B/NN activity/NN has/VBZ been/VBN reported/VBN in/IN mature/JJ macrophages/NNS ./. 
This/DT led/VBD to/TO the/DT hypothesis/NN that/IN some/DT of/IN the/DT Rel/NF-kappa/NN B/NN proteins/NNS were/VBD key/JJ nuclear/JJ factors/NNS in/IN functions/NNS of/IN accessory/JJ cells/NNS of/IN the/DT immune/JJ response/NN ./. 
Therefore/RB ,/, we/PRP investigated/VBD in/FW situ/FW the/DT nuclear/JJ localization/NN of/IN Rel/NF-kappa/NN B/NN proteins/NNS in/IN accessory/JJ cells/NNS of/IN the/DT immune/JJ system/NN by/IN immunohistochemistry/NN and/CC double/JJ labeling/NN by/IN immunofluorescence/NN from/IN five/CD normal/JJ human/JJ tonsils/NNS and/CC five/CD lymph/NN nodes/NNS with/IN follicular/JJ hyperplasia/NN ./. 
Nuclear/JJ p65/NN and/CC c-Rel/NN proteins/NNS were/VBD found/VBN in/IN all/DT cell/NN types/NNS including/VBG lymphocytes/NNS ./. 
In/IN germinal/JJ centers/NNS GC/NN ,/, p50/NN ,/, p52/NN ,/, and/CC RelB/NN were/VBD found/VBN in/IN the/DT nuclei/NNS of/IN FDC/NN only/RB and/CC were/VBD not/RB detected/VBN in/IN the/DT nuclei/NNS of/IN CD68+/JJ cells/NNS ./. 
In/IN T/NN cell/NN areas/NNS ,/, p50/NN ,/, p52/NN ,/, and/CC RelB/NN were/VBD found/VBN in/IN the/DT nuclei/NNS of/IN HLA-DR+/JJ cells/NNS with/IN an/DT antigen-presenting/JJ cell/NN (/( APC/NN )/) morphology/NN ./. 
p52/NN and/CC RelB/NN were/VBD detected/VBN in/IN the/DT nuclei/NNS in/IN both/CC CD1a+/JJ and/CC CD68+/JJ cells/NNS from/IN the/DT T/NN cell/NN area/NN ,/, whereas/IN p50/NN was/VBD found/VBN only/RB in/IN CD68-/JJ and/CC CD1a-cells/NNS ./. 
Cells/NNS with/IN nuclear/JJ p50/NN were/VBD negative/JJ for/IN the/DT CD38/NN ,/, CD20/NN and/CC CD2/NN markers/NNS ./. 
These/DT results/NNS show/VBP that/IN ,/, physiologically/RB ,/, high/JJ levels/NNS of/IN nuclear/JJ of/IN p50/NN ,/, p52/NN and/CC RelB/NN are/VBP restricted/JJ to/TO accessory/JJ cells/NNS of/IN the/DT immune/JJ system/NN ,/, which/WDT include/VBP FDC/NN in/IN GC/NN ,/, and/CC DC/NN and/CC macrophages/NNS in/IN the/DT T/NN cell/NN zone/NN ,/, that/IN specialized/VBN scavenger/NN macrophages/NNS from/IN GC/NN do/VBP not/RB have/VB detectable/JJ levels/NNS of/IN p52/NN and/CC RelB/NN ,/, whereas/IN macrophages/NNS from/IN the/DT T/NN cell/NN area/NN ,/, known/VBN to/TO present/VB the/DT antigen/NN to/TO T/NN cells/NNS ,/, do/VBP have/VB both/CC nuclear/JJ p52/NN and/CC RelB/NN ,/, and/CC that/IN in/IN the/DT T/NN cell/NN zone/NN ,/, p52/NN and/CC RelB/NN are/VBP located/JJ in/IN nuclei/NNS of/IN both/DT CD1a+/JJ ,/, CD68+/JJ or/CC both/DT ,/, cells/NNS APC/NN ,/, whereas/IN p50/NN is/VBZ restricted/JJ to/TO CD1a-/NN and/CC CD68- APC/NN ./. 
The/DT different/JJ patterns/NNS of/IN p50/NN ,/, p52/NN and/CC RelB/NN protein/NN nuclear/JJ localization/NN may/MD provide/VB insight/NN into/IN their/PRP$ different/JJ roles/NNS during/IN the/DT immune/JJ response/NN in/FW vivo/FW ./. 
UI/LS -/: 97047763/CD 
TI/LS -/: Tyrosines/NNS 113/CD ,/, 128/CD ,/, and/CC 145/CD of/IN SLP-76/NN are/VBP required/VBN for/IN optimal/JJ augmentation/NN of/IN NFAT/NN promoter/NN activity/NN ./. 
AB/LS -/: SLP-76/NN (/( SH2/NN domain/NN leukocyte/NN protein/NN of/IN 76/CD kDa/NN )/) is/VBZ a/DT recently/RB identified/VBN substrate/NN of/IN the/DT TCR-stimulated/JJ protein/NN tyrosine/NN kinases/NNS that/WDT functions/VBZ in/IN the/DT signal/NN transduction/NN cascade/NN linking/VBG the/DT TCR/NN with/IN IL-2/NN gene/NN expression/NN ./. 
In/IN this/DT report/NN ,/, we/PRP demonstrate/VBP that/IN engagement/NN of/IN the/DT TCR/NN results/VBZ in/IN tyrosine/NN phosphorylation/NN of/IN SLP-76/NN in/IN its/PRP$ amino-terminal/JJ acidic/JJ region/NN ./. 
Two/CD tyrosines/NNS (/( Y113/NN and/CC Y128/NN )/) fall/VBP within/IN an/DT identical/JJ five/CD amino-acid/JJ motif/NN and/CC are/VBP shown/VBN to/TO be/VB phosphorylated/VBN upon/IN TCR/NN ligation/NN ./. 
Although/IN mutation/NN of/IN either/CC Y113/NN and/CC Y128/NN has/VBZ a/DT minimal/JJ effect/NN on/IN SLP-76/NN function/NN ,/, mutation/NN of/IN both/DT residues/NNS decreases/VBZ significantly/RB the/DT ability/NN of/IN SLP-76/NN to/TO promote/VB T/NN cell/NN activation/NN ./. 
A/DT third/JJ tyrosine/NN within/IN the/DT amino-terminal/JJ region/NN (/( Y145/NN )/) appears/VBZ to/TO be/VB the/DT most/RBS important/JJ for/IN optimal/JJ SLP-76/NN function/NN ,/, as/IN altering/VBG it/PRP alone/RB to/TO phenylalanine/NN has/VBZ a/DT potent/JJ impact/NN on/IN SLP-76/NN augmentation/NN of/IN NFAT/NN promoter/NN activity/NN ./. 
UI/LS -/: 94148994/CD 
TI/LS -/: Human/JJ interferon/NN regulatory/JJ factor/NN 2/CD gene/NN ./. 
Intron-exon/JJ organization/NN and/CC functional/JJ analysis/NN of/IN 5'-flanking/JJ region/NN ./. 
AB/LS -/: Interferon/NN regulatory/JJ factor/NN 2/CD (/( IRF-2/NN )/) is/VBZ a/DT transcriptional/JJ regulatory/JJ protein/NN that/WDT terminates/VBZ interferon/NN beta/NN expression/NN initiated/VBN by/IN interferon/NN regulatory/JJ factor/NN 1/CD ./. 
In/IN this/DT study/NN ,/, we/PRP isolated/VBD the/DT genomic/JJ DNA/NN for/IN human/JJ IRF-2/NN gene/NN ,/, determined/VBD the/DT intron-exon/JJ structure/NN of/IN the/DT human/JJ IRF-2/NN gene/NN ,/, mapped/VBD the/DT major/JJ transcription/NN initiation/NN site/NN ,/, identified/VBD a/DT number/NN of/IN potential/JJ regulatory/JJ elements/NNS in/IN the/DT 5'-flanking/JJ region/NN ,/, and/CC localized/VBD the/DT IRF-2/NN gene/NN on/IN human/JJ chromosome/NN 4/CD ./. 
The/DT IRF-2/NN promoter/NN region/NN contains/VBZ a/DT CpG/NN island/NN ,/, with/IN several/JJ GC/NN boxes/NNS ,/, a/DT putative/JJ NF-kappa/NN B-binding/JJ site/NN ,/, and/CC a/DT CAAT/NN box/NN ,/, but/CC no/DT TATA/NN box/NN ./. 
When/WRB the/DT promoter/NN region/NN was/VBD linked/VBN with/IN a/DT heterologous/JJ reporter/NN gene/NN ,/, we/PRP found/VBD that/IN the/DT promoter/NN region/NN is/VBZ inducible/JJ by/IN both/CC interferons/NNS (/( interferon-alpha/NN and/CC -gamma/NN )/) and/CC interferon/NN regulatory/JJ factor/NN 1/CD ./. 
The/DT region/NN which/WDT induced/VBD these/DT inductions/NNS was/VBD identified/VBN as/IN being/VBG confined/VBN to/TO 40/CD nucleotides/NNS 5'/JJ to/TO the/DT major/JJ transcriptional/JJ initiation/NN site/NN by/IN testing/VBG a/DT series/NN of/IN clones/NNS with/IN truncated/VBN promoter/NN of/IN IRF-2/NN ./. 
This/DT region/NN contains/VBZ elements/NNS which/WDT are/VBP shared/VBN with/IN the/DT transcriptional/JJ enhancers/NNS of/IN other/JJ genes/NNS including/VBG interferon/NN regulatory/JJ factor/NN 1/CD ,/, interferon/NN beta/NN ,/, and/CC interferon-inducible/JJ genes/NNS ./. 
These/DT data/NNS suggest/VBP that/IN interferon/NN regulatory/JJ factor/NN 1/CD not/RB only/RB triggers/VBZ the/DT activation/NN of/IN the/DT interferon/NN signal/NN transduction/NN pathway/NN ,/, but/CC also/RB may/MD play/VB a/DT role/NN in/IN limiting/VBG the/DT duration/NN of/IN this/DT response/NN by/IN activating/VBG the/DT transcription/NN of/IN IRF-2/NN ./. 
UI/LS -/: 94230583/CD 
TI/LS -/: Interferon/NN alpha/NN selectively/RB affects/VBZ expression/NN of/IN the/DT human/JJ myeloid/JJ cell/NN nuclear/JJ differentiation/NN antigen/NN in/IN late/JJ stage/NN cells/NNS in/IN the/DT monocytic/JJ but/CC not/RB the/DT granulocytic/JJ lineage/NN ./. 
AB/LS -/: The/DT human/JJ myeloid/JJ cell/NN nuclear/JJ differentiation/NN antigen/NN (/( MNDA/NN )/) is/VBZ expressed/VBN constitutively/RB in/IN cells/NNS of/IN the/DT myeloid/JJ lineage/NN ,/, appearing/VBG in/IN myeloblast/JJ cells/NNS in/IN some/DT cases/NNS of/IN acute/JJ myeloid/JJ leukemia/NN and/CC consistently/RB being/VBG detected/VBN in/IN promyelocyte/JJ stage/NN cells/NNS as/RB well/RB as/IN in/IN all/DT later/JJR stage/NN cells/NNS including/VBG peripheral/JJ blood/NN monocytes/NNS and/CC granulocytes/NNS ./. 
The/DT human/JJ myeloid/JJ leukemia/NN cell/NN lines/NNS ,/, HL-60/NN ,/, U937/NN ,/, and/CC THP-1/NN ,/, express/VBP similar/JJ levels/NNS of/IN immunochemically/RB detectable/JJ MNDA/NN ./. 
Although/IN ,/, the/DT level/NN of/IN MNDA/NN mRNA/NN in/IN primary/JJ monocytes/NNS is/VBZ very/RB low/JJ it/PRP was/VBD up-regulated/VBN at/IN 6/CD h/NN following/VBG the/DT addition/NN of/IN interferon/NN alpha/NN ./. 
The/DT effect/NN of/IN interferon/NN alpha/NN on/IN the/DT MNDA/NN mRNA/NN is/VBZ also/RB observed/VBN in/IN the/DT cell/NN lines/NNS HL-60/NN ,/, U937/NN ,/, and/CC THP-1/NN ./. 
The/DT MNDA/NN mRNA/NN level/NN in/IN primary/JJ granulocytes/NNS was/VBD unaffected/JJ by/IN addition/NN of/IN interferon/NN alpha/NN and/CC other/JJ agents/NNS including/VBG interferon/NN gamma/NN ,/, endotoxin/NN ,/, poly (I).poly (C)/NN ,/, and/CC FMLP/NN ./. 
The/DT MNDA/NN mRNA/NN level/NN in/IN the/DT myeloid/JJ cell/NN lines/NNS was/VBD also/RB unaffected/JJ by/IN the/DT latter/JJ four/CD agents/NNS ./. 
Induction/NN of/IN differentiation/NN in/IN the/DT myeloid/JJ cell/NN lines/NNS with/IN phorbol/NN ester/NN induces/VBZ monocyte/NN differentiation/NN which/WDT was/VBD accompanied/VBN by/IN a/DT decrease/NN in/IN MNDA/NN mRNA/NN level/NN ./. 
This/DT reduced/JJ level/NN of/IN mRNA/NN could/MD then/RB be/VB elevated/JJ with/IN subsequent/JJ interferon/NN alpha/NN treatment/NN ./. 
The/DT effects/NNS of/IN phorbol/NN ester/NN on/IN MNDA/NN mRNA/NN appeared/VBD to/TO be/VB associated/VBN with/IN induced/VBN differentiation/NN since/IN inhibiting/VBG cell/NN proliferation/NN did/VBD not/RB alter/VB the/DT level/NN of/IN MNDA/NN mRNA/NN and/CC cell/NN cycle/NN variation/NN in/IN MNDA/NN mRNA/NN levels/NNS were/VBD not/RB observed/VBN ./. 
The/DT ability/NN of/IN interferon/NN alpha/NN to/TO up-regulate/VB MNDA/NN mRNA/NN in/IN phorbol/NN ester/NN treated/JJ myeloid/JJ cell/NN lines/NNS is/VBZ consistent/JJ with/IN the/DT observations/NNS made/VBN in/IN primary/JJ monocytes/NNS ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 94076456/CD 
TI/LS -/: Involvement/NN of/IN transcription/NN factor/NN YB-1/NN in/IN human/JJ T-cell/NN lymphotropic/JJ virus/NN type/NN I/CD basal/JJ gene/NN expression/NN ./. 
AB/LS -/: Sequences/NNS which/WDT control/VBP basal/JJ human/JJ T-cell/NN lymphotropic/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) transcription/NN likely/RB play/VB an/DT important/JJ role/NN in/IN initiation/NN and/CC maintenance/NN of/IN virus/NN replication/NN ./. 
We/PRP previously/RB identified/VBD and/CC analyzed/VBD a/DT 45-nucleotide/JJ sequence/NN (/( downstream/JJ regulatory/JJ element/NN 1/CD [/( DRE/NN 1/CD ]/) )/) ,/, +195/CD to/TO +240/CD ,/, at/IN the/DT boundary/NN of/IN the/DT R/U5/NN region/NN of/IN the/DT long/JJ terminal/JJ repeat/NN which/WDT is/VBZ required/VBN for/IN HTLV-I/NN basal/JJ transcription/NN ./. 
We/PRP identified/VBD a/DT protein/NN ,/, p37/NN ,/, which/WDT specifically/RB bound/VBD to/TO DRE/NN 1/CD ./. 
An/DT affinity/NN column/NN fraction/NN ,/, containing/VBG p37/NN ,/, stimulated/VBD HTLV-I/NN transcription/NN approximately/RB 12-fold/RB in/FW vitro/FW ./. 
We/PRP now/RB report/VBP the/DT identification/NN of/IN a/DT cDNA/NN clone/NN (/( 15B-7/NN )/) ,/, from/IN a/DT Jurkat/NN expression/NN library/NN ,/, that/WDT binds/VBZ specifically/RB to/TO the/DT DRE/NN 1/CD regulatory/JJ sequence/NN ./. 
Binding/NN of/IN the/DT cDNA/NN fusion/NN protein/NN ,/, similarly/RB to/TO the/DT results/NNS obtained/VBN with/IN purified/VBN Jurkat/NN protein/NN ,/, was/VBD decreased/VBN by/IN introduction/NN of/IN site-specific/JJ mutations/NNS in/IN the/DT DRE/NN 1/CD regulatory/JJ sequence/NN ./. 
In/FW vitro/FW transcription/NN and/CC translation/NN of/IN 15B-7/NN cDNA/NN produced/VBD a/DT fusion/NN protein/NN which/WDT bound/VBD specifically/RB to/TO the/DT HTLV-I/NN +195/CD to/TO +240/CD oligonucleotide/NN ./. 
The/DT partial/JJ cDNA/NN encodes/VBZ a/DT protein/NN which/WDT is/VBZ homologous/JJ to/TO the/DT C-terminal/JJ 196/CD amino/NN acids/NNS of/IN the/DT 36-kDa/JJ transcription/NN factor/NN ,/, YB-1/NN ./. 
Cotransfection/NN of/IN a/DT YB-1/NN expression/NN plasmid/NN increases/VBZ HTLV-I/NN basal/JJ transcription/NN approximately/RB 14-fold/RB in/IN Jurkat/NN T/NN lymphocytes/NNS ./. 
On/IN the/DT basis/NN of/IN the/DT molecular/JJ weight/NN ,/, DNA-binding/JJ characteristics/NNS ,/, and/CC in/FW vivo/FW transactivation/NN activity/NN ,/, we/PRP suggest/VBP that/IN the/DT previously/RB identified/VBN DRE/NN 1-binding/JJ protein/NN ,/, p37/NN ,/, is/VBZ YB-1/NN ./. 
UI/LS -/: 95201644/CD 
TI/LS -/: Changes/NNS in/IN triiodothyronine/NN (/( T3/NN )/) mononuclear/JJ leukocyte/NN receptor/NN kinetics/NNS after/IN T3/NN administration/NN and/CC multiple/JJ cold-air/JJ exposures/NNS ./. 
AB/LS -/: Repeated/VBN cold-air/JJ exposures/NNS increase/VBP human/JJ triiodothyronine/NN (/( T3/CD )/) plasma/NN clearance/NN rates/NNS ./. 
To/TO study/VB the/DT response/NN of/IN the/DT nuclear/JJ T3/NN receptor/NN (/( NT3R/NN )/) in/IN this/DT condition/NN ,/, binding/VBG characteristics/NNS were/VBD analyzed/VBN in/IN human/JJ mononuclear/JJ leukocytes/NNS (/( MNL/NN )/) ./. 
In/IN addition/NN ,/, we/PRP supplemented/VBD one/CD group/NN of/IN individuals/NNS with/IN a/DT daily/RB oral/JJ replacement/NN dose/NN of/IN T3/NN to/TO isolate/VB the/DT influence/NN of/IN serum/NN thyroxine/NN (/( T4/NN )/) and/CC thyrotropin/NN (/( TSH/NN )/) levels/NNS on/IN receptor/NN kinetics/NNS ./. 
The/DT subjects/NNS were/VBD exposed/VBN to/TO cold/JJ air/NN (/( 4/CD degrees/NNS C/NN )/) twice/d/RB ,/, 30/CD min/exposure/NN ,/, for/IN a/DT total/NN of/IN 80/CD exposures/NNS ./. 
The/DT T3-subjects/NNS received/VBD placebo/NN [/( n/NN =/JJ 8/CD ]/) and/CC the/DT T3/NN +/JJ subjects/NNS received/VBD T3/CD (/( 30/CD micrograms/d/NN )/) [/( n/NN =/JJ 8/CD ]/) in/IN a/DT double-blind/JJ fashion/NN ./. 
Mononuclear/JJ leukocytes/NNS were/VBD isolated/VBN from/IN peripheral/JJ blood/NN before/IN the/DT cold/JJ exposure/NN and/CC drug/NN regimen/NNS began/VBD ,/, and/CC then/RB after/IN every/DT 20/CD exposures/NNS ./. 
The/DT dissociation/NN constant/NN (/( Kd/NN )/) and/CC maximum/NN binding/NN capacity/NN (/( MBC/NN )/) of/IN the/DT NT3R/NN values/NNS were/VBD log/NN transformed/VBN to/TO minimize/VB between-subject/JJ variability/NN ./. 
In/IN the/DT T3+/JJ group/NN ,/, serum/NN total/VBP thyroxine/NN (/( TT4/NN )/) ,/, free/JJ T4/NN (/( FT4/NN )/) ,/, and/CC TSH/NN were/VBD approx/RB 50/CD %/NN lower/JJR than/IN both/CC basal/JJ and/CC T3-values/NNS ./. 
The/DT log10Kd/NN increased/VBD 0.304/CD +/-/CC 0.139/CD (/( p/NN </JJR 0.04/CD )/) and/CC the/DT log10MBC/NN increased/VBD 0.49/CD +/-/CC 0.10/CD (/( p/NN </JJR 0.001/CD )/) in/IN the/DT T3+/JJ subjects/NNS compared/VBN to/TO baseline/NN ./. 
This/DT change/NN in/IN MBC/NN represents/VBZ a/DT 311/CD %/NN increase/NN in/IN the/DT MBC/NN over/IN baseline/NN and/CC a/DT fivefold/JJ increase/NN over/IN placebo-treated/JJ subjects/NNS ./. 
The/DT T3-group/NN showed/VBD no/DT change/NN in/IN MBC/NN over/IN the/DT study/NN ./. 
These/DT results/NNS describe/VBP for/IN the/DT first/JJ time/NN the/DT rapid/JJ modulation/NN of/IN the/DT NT3R/NN in/IN response/NN to/TO the/DT combined/JJ influence/NN of/IN cold/JJ exposure/NN and/CC reduced/VBN circulating/VBG T4/NN and/CC TSH/NN ./. 
UI/LS -/: 97115684/CD 
TI/LS -/: HIV-1/NN LTR/NN activity/NN in/IN human/JJ CD40-activated/JJ B/NN lymphocytes/NNS is/VBZ dependent/JJ on/IN NF-kappaB/NN ./. 
AB/LS -/: CD40-stimulated/JJ human/JJ B/NN lymphocytes/NNS are/VBP highly/RB permissive/JJ to/TO a/DT productive/JJ infection/NN by/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD ./. 
In/IN these/DT cells/NNS ,/, nuclear/JJ factors/NNS involved/VBN in/IN activation/NN of/IN the/DT HIV-1/NN LTR/NN ,/, which/WDT contains/VBZ the/DT transcriptional/JJ control/NN elements/NNS of/IN the/DT virus/NN ,/, are/VBP unknown/JJ ./. 
Transient/JJ expression/NN assays/NNS with/IN plasmids/NNS containing/VBG deleted/VBN parts/NNS of/IN the/DT LTR/NN region/NN linked/VBN to/TO a/DT reporter/NN gene/NN showed/VBD that/IN the/DT NF-kappaB/NN binding/NN site/NN was/VBD essential/JJ for/IN HIV-1/NN LTR/NN activity/NN in/IN CD40-stimulated/JJ B/NN lymphocytes/NNS ./. 
In/IN addition/NN ,/, electrophoretic/JJ mobility/NN shift/NN and/CC supershift/NN assays/NNS revealed/VBD that/IN important/JJ NF-kappaB/NN binding/NN activity/NN composed/VBN of/IN at/IN least/JJS p50/NN ,/, p65/NN ,/, and/CC c-Rel/NN NF-kappaB/NN subunits/NNS was/VBD present/JJ in/IN nuclei/NNS of/IN CD40-stimulated/JJ B/NN cells/NNS ./. 
These/DT results/NNS confirm/VBP at/IN a/DT molecular/JJ level/NN the/DT ability/NN of/IN HIV-1/NN to/TO replicate/VB in/IN B/NN cells/NNS and/CC that/IN this/DT activity/NN is/VBZ strongly/RB associated/VBN with/IN NF-kappaB/NN ./. 
UI/LS -/: 97138090/CD 
TI/LS -/: Sequence/NN analysis/NN and/CC expression/NN in/IN cultured/VBN lymphocytes/NNS of/IN the/DT human/JJ FOSB/NN gene/NN (/( G0S3/NN )/) ./. 
AB/LS -/: G0S3/NN is/VBZ a/DT member/NN of/IN a/DT set/NN of/IN putative/JJ G0/G1/NN switch/NN regulatory/JJ genes/NNS (/( G0S/NN genes/NNS )/) selected/VBN by/IN screening/VBG cDNA/NN libraries/NNS prepared/VBN from/IN human/JJ blood/NN mononuclear/JJ cells/NNS cultured/VBN for/IN 2/CD hr/NN with/IN lectin/NN and/CC cycloheximide/NN ./. 
The/DT sequence/NN shows/VBZ high/JJ homology/NN with/IN the/DT murine/JJ FOSB/NN gene/NN ,/, which/WDT encodes/VBZ a/DT component/NN of/IN the/DT AP1/NN transcriptional/JJ regulator/NN ./. 
Comparison/NN of/IN cDNA/NN and/CC genomic/JJ sequences/NNS reveals/VBZ a/DT 4-exon/JJ structure/NN characteristic/JJ of/IN the/DT FOS/NN family/NN of/IN genes/NNS ./. 
Freshly/RB isolated/VBN cells/NNS show/VBP high/JJ levels/NNS of/IN FOSB/G0S3/NN and/CC FOS/G0S7/NN mRNAs/NNS ,/, which/WDT decline/VBP rapidly/RB during/IN incubation/NN in/IN culture/NN medium/NN ./. 
The/DT kinetics/NNS of/IN expression/NN suggest/VBP that/IN the/DT high/JJ initial/JJ levels/NNS are/VBP caused/VBN by/IN the/DT isolation/NN procedure/NN ,/, and/CC do/VBP not/RB reflect/VB constitutive/JJ expression/NN ./. 
In/IN cells/NNS preincubated/VBN for/IN a/DT day/NN ,/, levels/NNS of/IN FOS/NN mRNA/NN reach/VBP a/DT maximum/NN 20/CD min/NN after/IN the/DT addition/NN of/IN lectin/NN and/CC decline/VBP to/TO control/NN levels/NNS over/IN the/DT next/JJ 3/CD hr/NN ./. 
Levels/NNS of/IN FOSB/NN mRNA/NN reach/VBP a/DT maximum/JJ 40/CD min/NN after/IN the/DT addition/NN of/IN lectin/NN and/CC decline/VBP to/TO control/NN levels/NNS over/IN the/DT next/JJ 6/CD hr/NN ./. 
In/IN freshly/RB isolated/VBN cells/NNS ,/, both/CC FOS/NNS and/CC FOSB/NN mRNAs/NNS increase/VBP dramatically/RB in/IN response/NN to/TO the/DT protein/NN synthesis/NN inhibitor/NN cycloheximide/NN ./. 
In/IN preincubated/JJ cells/NNS ,/, the/DT cycloheximide/NN response/NN is/VBZ decreased/VBN ,/, especially/RB in/IN the/DT case/NN of/IN FOSB/NN ./. 
These/DT differences/NNS in/IN expression/NN of/IN FOS/NN and/CC FOSB/NN suggest/VBP different/JJ roles/NNS and/CC regulation/NN ./. 
Regions/NNS of/IN low/JJ base/NN order-dependent/JJ stem-loop/JJ potential/NN in/IN the/DT region/NN of/IN the/DT gene/NN are/VBP defined/VBN ./. 
These/DT indicate/VBP where/WRB base/NN order/NN has/VBZ been/VBN adapted/VBN for/IN purposes/NNS other/JJ than/IN stem-loop/JJ stability/NN (/( e.g./FW ,/, encoding/VBG proteins/NNS or/CC gene/NN regulation/NN )/) ./. 
Regions/NNS of/IN low/JJ potential/NN in/IN a/DT 68.5-kb/JJ genomic/JJ segment/NN containing/VBG the/DT FOSB/NN gene/NN suggest/VBP that/IN the/DT potential/NN may/MD help/VB locate/VB genes/NNS in/IN uncharted/JJ DNA/NN sequences/NNS ./. 
UI/LS -/: 97051521/CD 
TI/LS -/: Susceptibility/NN to/TO natural/JJ killer/NN cells/NNS and/CC down/JJ regulation/NN of/IN MHC/NN class/NN I/CD expression/NN in/IN adenovirus/NN 12/CD transformed/VBN cells/NNS are/VBP regulated/VBN by/IN different/JJ E1A/NN domains/NNS ./. 
AB/LS -/: All/DT human/JJ adenoviruses/NNS transform/VBP rodent/JJ cells/NNS in/FW vitro/FW ,/, but/CC only/RB cells/NNS transformed/VBN by/IN serotypes/NNS belonging/VBG to/TO subgroups/NNS A/NN (/( Ad12/NN )/) and/CC B/NN (/( Ad3/NN )/) are/VBP tumorigenic/JJ for/IN immunocompetent/JJ animals/NNS ./. 
In/IN these/DT cells/NNS ,/, the/DT expression/NN of/IN MHC-class/NN I/CD antigens/NNS is/VBZ repressed/VBN and/CC might/MD allow/VB them/PRP to/TO escape/VB from/IN recognition/NN by/IN cytotoxic/JJ T/NN lymphocytes/NNS (/( CTL/NN )/) and/CC to/TO develop/VB in/IN tumor/NN ./. 
Furthermore/RB ,/, these/DT cell/NN lines/NNS appear/VBP resistant/JJ to/TO lysis/NN by/IN natural/JJ killer/NN (/( NK/NN )/) cells/NNS ./. 
To/TO determine/VB the/DT E1A/NN domain/NN (/( s/NNS )/) responsible/JJ for/IN these/DT properties/NNS several/JJ cell/NN lines/NNS were/VBD created/VBN by/IN transforming/VBG baby/NN rat/NN kidney/NN (/( BRK/NN )/) cells/NNS with/IN a/DT set/NN of/IN plasmids/NNS expressing/VBG different/JJ Ad2/Ad12/NN hybrid/NN E1A/NN gene/NN products/NNS ./. 
The/DT MHC/NN class/NN 1/CD gene/NN expression/NN was/VBD inhibited/VBN in/IN cells/NNS expressing/VBG the/DT Ad12/NN 13S/NN mRNA/NN product/NN and/CC in/IN cells/NNS transformed/VBN with/IN Ad2/Ad12/NN hybrid/NN E1A/NN gene/NN product/NN harboring/VBG the/DT C-terminal/JJ part/NN of/IN the/DT conserved/VBN region/NN (/( CR/NN )/) 3/CD of/IN Ad12/NN ./. 
Susceptibility/NN of/IN these/DT transformed/VBN cell/NN lines/NNS to/TO NK/NN cells/NNS was/VBD determined/VBN by/IN cytolytic/JJ assays/NNS ./. 
The/DT results/NNS obtained/VBD suggest/VBP that/IN two/CD Ad12/NN E1A/NN domains/NNS are/VBP required/VBN to/TO induce/VB resistance/NN of/IN the/DT cell/NN lines/NNS to/TO NK/NN cells/NNS ./. 
UI/LS -/: 97088634/CD 
TI/LS -/: Cell/NN specific/JJ expression/NN of/IN human/JJ Bruton/NN 's/POS agammaglobulinemia/NN tyrosine/NN kinase/NN gene/NN (/( Btk/NN )/) is/VBZ regulated/VBN by/IN Sp1-/NN and/CC Spi-1/PU.1-family/NN members/NNS ./. 
AB/LS -/: Bruton/NN 's/POS agammaglobulinemia/NN tyrosine/NN kinase/NN (/( Btk/NN )/) is/VBZ a/DT cytoplasmic/JJ tyrosine/NN kinase/NN involved/VBN in/IN the/DT human/JJ disease/NN X-linked/JJ agammaglobulinemia/NN (/( XLA/NN )/) ./. 
The/DT gene/NN is/VBZ expressed/VBN in/IN all/DT hematopoietic/JJ cells/NNS with/IN the/DT exception/NN of/IN T-cells/NNS and/CC plasma/NN cells/NNS ./. 
For/IN this/DT expression/NN pattern/NN the/DT first/JJ 280/CD bp/NN upstream/JJ of/IN the/DT major/JJ transcriptional/JJ start/NN site/NN seems/VBZ to/TO be/VB sufficient/JJ ./. 
In/FW vitro/FW footprinting/NN analysis/NN within/IN this/DT part/NN of/IN the/DT promoter/NN revealed/VBD two/CD Sp1/NN binding/NN sites/NNS as/RB well/RB as/IN a/DT PU-box/NN ./. 
The/DT transcription/NN factor/NN Spi-1/PU.1/NN as/RB well/RB as/IN the/DT closely/RB related/JJ factor/NN Spi-B/NN bound/VBD to/TO the/DT PU-box/NN in/IN B-cells/NNS ./. 
In/IN the/DT erythroleukemia/NN cell/NN line/NN K562/NN ,/, due/IN to/TO the/DT absence/NN of/IN Spi-B/NN ,/, only/RB PU.1/NN bound/VBD to/TO the/DT Btk/NN promoter/NN ./. 
Mutation/NN of/IN either/DT site/NN reduced/VBD the/DT expression/NN in/IN transient/JJ transfection/NN experiments/NNS ./. 
However/RB ,/, mutation/NN of/IN the/DT PU/NN box/NN had/VBD no/DT effect/NN in/IN the/DT T-cell/NN line/NN Jurkat/NN ,/, where/WRB none/NN of/IN the/DT Spi-1/NN family/NN members/NNS is/VBZ expressed/VBN ./. 
In/IN addition/NN Spi-B/NN as/RB well/RB as/IN PU.1/NN were/VBD able/JJ to/TO transactivate/VB Btk/NN expression/NN ./. 
In/IN fetal/JJ liver/NN of/IN PU.1-/-/JJ mice/NNS ,/, which/WDT lack/VBP lymphoid/JJ and/CC myeloid/JJ cells/NNS ,/, expression/NN of/IN Btk/NN was/VBD reduced/VBN two-/CD to/TO threefold/RB but/CC not/RB abolished/VBN ./. 
Collectively/RB this/DT study/NN shows/VBZ that/IN expression/NN of/IN the/DT Btk/NN gene/NN is/VBZ regulated/VBN by/IN the/DT combined/JJ action/NN of/IN Sp1-/NN and/CC PU.1-family/NN members/NNS ./. 
UI/LS -/: 97079135/CD 
TI/LS -/: T/NN cell/NN response/NN to/TO Epstein-Barr/JJ virus/NN transactivators/NNS in/IN chronic/JJ rheumatoid/JJ arthritis/NN ./. 
AB/LS -/: Rheumatoid/JJ arthritis/NN is/VBZ a/DT multistep/JJ disorder/NN associated/VBN with/IN autoimmune/JJ features/NNS of/IN yet/RB unknown/JJ etiology/NN ./. 
Implication/NN of/IN viruses/NNS such/JJ as/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) in/IN rheumatoid/JJ arthritis/NN pathogenesis/NN has/VBZ been/VBN suspected/VBN on/IN the/DT basis/NN of/IN several/JJ indirect/JJ observations/NNS ,/, but/CC thus/RB far/RB ,/, a/DT direct/JJ link/NN between/IN EBV/NN and/CC rheumatoid/JJ arthritis/NN has/VBZ not/RB been/VBN provided/VBN ./. 
Here/RB we/PRP show/VBP that/IN a/DT large/JJ fraction/NN of/IN T/NN cells/NNS infiltrating/VBG affected/VBN joints/NNS from/IN a/DT patient/NN with/IN chronic/JJ rheumatoid/JJ arthritis/NN recognizes/VBZ two/CD EBV/NN transactivators/NNS (/( BZLF1/NN and/CC BMLF1/NN )/) in/IN a/DT major/JJ histocompatibility/NN complex-restricted/JJ fashion/NN ./. 
Responses/NNS to/TO these/DT EBV/NN antigens/NNS by/IN synovial/JJ lymphocytes/NNS from/IN several/JJ other/JJ chronic/JJ rheumatoid/JJ arthritis/NN patients/NNS were/VBD readily/RB detectable/JJ ./. 
Thus/RB these/DT results/NNS suggest/VBP a/DT direct/JJ contribution/NN of/IN EBV/NN to/TO chronic/JJ rheumatoid/JJ arthritis/NN pathogenesis/NN ./. 
They/PRP also/RB demonstrate/VBP for/IN the/DT first/JJ time/NN the/DT occurrence/NN of/IN T/NN cell/NN responses/NNS against/IN EBV/NN transactivating/VBG factors/NNS ,/, which/WDT might/MD be/VB central/JJ in/IN the/DT control/NN of/IN virus/NN reactivation/NN ./. 
UI/LS -/: 97045131/CD 
TI/LS -/: CD14-mediated/JJ signal/NN pathway/NN of/IN Porphyromonas/NN gingivalis/NN lipopolysaccharide/NN in/IN human/JJ gingival/JJ fibroblasts/NNS ./. 
AB/LS -/: Lipopolysaccharide/NN (/( LPS/NN )/) induces/VBZ expression/NN of/IN inflammatory/JJ cytokines/NNS in/IN monocytes/macrophages/NNS via/IN CD14/NN ,/, one/CD of/IN the/DT LPS/NN receptors/NNS ,/, which/WDT is/VBZ expressed/VBN predominantly/RB in/IN these/DT cells/NNS ./. 
It/PRP has/VBZ been/VBN demonstrated/VBN that/IN Porphyromonas/NN gingivalis/NN LPS/NN (/( P-LPS/NN )/) also/RB is/VBZ able/JJ to/TO induce/VB inflammatory/JJ cytokines/NNS in/IN human/JJ gingival/JJ fibroblasts/NNS ./. 
Therefore/RB ,/, it/PRP is/VBZ important/JJ to/TO determine/VB whether/IN CD14/NN is/VBZ expressed/VBN in/IN gingival/JJ fibroblasts/NNS and/CC to/TO define/VB the/DT P-LPS-mediated/JJ signal-transducing/JJ mechanism/NN in/IN the/DT cells/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP observed/VBD unexpectedly/RB by/IN immunohistochemical/JJ ,/, Western/JJ|NN blotting/NN (/( immunoblotting/NN )/) ,/, and/CC Northern/NN (/( RNA/NN )/) blotting/NN assays/NNS that/IN CD14/NN is/VBZ expressed/VBN at/IN high/JJ density/NN in/IN human/JJ gingival/JJ fibroblasts/NNS ./. 
P-LPS-induced/JJ expression/NN of/IN the/DT monocyte/NN chemoattractant/NN protein/NN 1/CD (/( MCP-1/NN )/) gene/NN in/IN the/DT cells/NNS was/VBD inhibited/VBN markedly/RB by/IN treatment/NN with/IN anti-human/JJ CD14/NN antibody/NN and/CC was/VBD completely/RB inhibited/VBN by/IN herbimycin/NN A/NN ,/, a/DT potent/JJ inhibitor/NN of/IN tyrosine/NN kinase/NN ./. 
The/DT inhibitor/NN also/RB dramatically/RB inhibited/VBD monocyte/NN chemotactic/JJ activity/NN of/IN and/CC MCP-1/NN production/NN by/IN the/DT cells/NNS ./. 
Furthermore/RB ,/, P-LPS-induced/JJ expression/NN of/IN the/DT MCP-1/JJ gene/NN in/IN the/DT cells/NNS also/RB was/VBD blocked/VBN by/IN inhibitors/NNS of/IN two/CD transcription/NN factors/NNS ,/, i.e./FW ,/, curcumin/NN ,/, an/DT inhibitor/NN of/IN AP-1/NN ,/, and/CC pyrolidine/NN dithiocarbamate/NN ,/, an/DT inhibitor/NN of/IN NF-kappaB/NN ./. 
Both/DT inhibitors/NNS inhibited/VBD monocyte/NN chemotactic/JJ activity/NN in/IN the/DT culture/NN supernatant/JJ of/IN P-LPS-treated/JJ cells/NNS ./. 
Gel/NN shift/NN mobility/NN assay/NN showed/VBD stimulation/NN of/IN the/DT AP-1/NN and/CC NF-kappaB/NN contents/NNS in/IN P-LPS-treated/JJ cells/NNS ./. 
This/DT study/NN is/VBZ the/DT first/JJ to/TO demonstrate/VB the/DT expression/NN of/IN CD14/NN in/IN human/JJ gingival/JJ fibroblasts/NNS and/CC to/TO show/VB that/IN the/DT signal-transducing/JJ pathway/NN of/IN P-LPS/NN in/IN the/DT cells/NNS is/VBZ mediated/VBN by/IN CD14/NN ./. 
UI/LS -/: 94149008/CD 
TI/LS -/: rel/NN Is/VBZ rapidly/RB tyrosine-phosphorylated/JJ following/VBG granulocyte-colony/JJ stimulating/NN factor/NN treatment/NN of/IN human/JJ neutrophils/NNS ./. 
AB/LS -/: Stimulation/NN of/IN neutrophils/NNS with/IN granulocyte-colony/JJ stimulating/NN factor/NN (/( G-CSF/NN )/) results/VBZ in/IN an/DT enhanced/VBN respiratory/JJ burst/NN ,/, prolonged/JJ survival/NN ,/, and/CC increased/VBN tumor/NN cell/NN killing/NN ./. 
The/DT effects/NNS of/IN G-CSF/NN are/VBP mediated/VBN by/IN binding/VBG to/TO specific/JJ ,/, high/JJ affinity/NN receptors/NNS ./. 
G-CSF/NN receptors/NNS lack/VBP intrinsic/JJ tyrosine/NN kinase/NN activity/NN ,/, but/CC activation/NN of/IN the/DT receptor/NN results/VBZ in/IN the/DT rapid/JJ induction/NN of/IN tyrosine/NN kinase/NN activity/NN ./. 
Antiphosphotyrosine/JJ immunoblots/NNS of/IN whole/JJ cell/NN lysates/NNS prepared/VBN from/IN neutrophils/NNS show/VBP that/IN the/DT G-CSF/NN rapidly/RB induces/VBZ prominent/JJ tyrosine/NN phosphorylation/NN of/IN a/DT protein/NN of/IN a/DT relative/JJ molecular/JJ mass/NN of/IN 80/CD kDa/NN ./. 
Using/VBG monospecific/JJ antibodies/NNS ,/, the/DT 80-kDa/JJ tyrosine-phosphorylated/JJ protein/NN has/VBZ been/VBN shown/VBN to/TO be/VB p80c-rel/NN ,/, a/DT proto-oncogene/NN belonging/VBG to/TO a/DT family/NN of/IN transcriptional/JJ regulators/NNS which/WDT include/VBP NF-kB/NN ./. 
The/DT induction/NN of/IN tyrosine/NN phosphorylation/NN of/IN p80c-rel/NN was/VBD unique/JJ to/TO G-CSF/NN in/IN that/IN granulocyte-macrophage/JJ colony/NN stimulating/NN factor/NN which/WDT also/RB stimulates/VBZ neutrophils/NNS and/CC induces/VBZ tyrosine/NN phosphorylation/NN does/VBZ not/RB result/VB in/IN tyrosine/NN phosphorylation/NN of/IN p80c-rel/NN ./. 
The/DT consequences/NNS of/IN p80c-rel/NN tyrosine/NN phosphorylation/NN are/VBP not/RB yet/RB known/VBN ;/: however/RB ,/, tyrosine-phosphorylated/JJ p80c-rel/NN is/VBZ capable/JJ of/IN binding/VBG to/TO DNA/NN ,/, and/CC G-CSF/NN stimulation/NN results/VBZ in/IN an/DT increase/NN in/IN the/DT amount/NN of/IN p80c-rel/NN which/WDT binds/VBZ to/TO DNA/NN ./. 
These/DT results/NNS demonstrate/VBP that/IN one/CD of/IN the/DT first/JJ biochemical/JJ events/NNS which/WDT occurs/VBZ in/IN neutrophils/NNS following/VBG G-CSF/NN stimulation/NN ,/, activation/NN of/IN a/DT tyrosine/NN kinase/NN ,/, leads/VBZ directly/RB to/TO the/DT tyrosine/NN phosphorylation/NN of/IN p80c-rel/NN ./. 
Thus/RB ,/, the/DT tyrosine/NN kinase/NN activated/VBN by/IN G-CSF/NN appears/VBZ to/TO directly/RB transduce/VB a/DT signal/NN to/TO a/DT protein/NN which/WDT functions/VBZ as/IN a/DT transcriptional/JJ regulator/NN ./. 
UI/LS -/: 94224239/CD 
TI/LS -/: Patterns/NN of/IN Pan/NN expression/NN and/CC role/NN of/IN Pan/NN proteins/NNS in/IN endocrine/NN cell/NN type-specific/JJ complex/JJ formation/NN ./. 
AB/LS -/: The/DT Pan/NN gene/NN encodes/VBZ at/IN least/JJS two/CD distinct/JJ transcripts/NNS ,/, Pan-1/NN and/CC Pan-2/NN (/( also/RB known/VBN as/IN E47/NN and/CC E12/NN ,/, respectively/RB )/) ,/, by/IN the/DT mechanism/NN of/IN alternative/JJ RNA/NN splicing/NN ./. 
Northern/JJ blot/NN analyses/NNS performed/VBN on/IN rat/NN and/CC mouse/NN tissues/NNS have/VBP detected/VBN ubiquitously/RB expressed/VBN Pan/NN transcripts/NNS ,/, but/CC the/DT abundance/NN ,/, distribution/NN ,/, and/CC form/NN of/IN Pan/NN proteins/NNS have/VBP not/RB been/VBN clearly/RB defined/VBN ./. 
Studies/NNS of/IN cell/NN lines/NNS representing/VBG endocrine/NN ,/, fibroblast/NN ,/, and/CC lymphoid/JJ lineages/NNS using/VBG polyclonal/JJ antisera/NNS to/TO detect/VB E2A/NN proteins/NNS have/VBP suggested/VBN that/IN significant/JJ E2A/NN protein/NN expression/NN is/VBZ restricted/JJ to/TO B-lymphocytes/NNS ./. 
We/PRP have/VBP developed/VBN a/DT monoclonal/JJ antibody/NN ,/, Yae/NN ,/, which/WDT is/VBZ specific/JJ for/IN Pan/E2A/NN proteins/NNS ,/, and/CC have/VBP used/VBN the/DT Yae/NN antibody/NN to/TO examine/VB a/DT variety/NN of/IN endocrine/JJ and/CC nonendocrine/JJ cell/NN lineages/NNS for/IN differences/NNS in/IN Pan/E2A/NN protein/NN expression/NN ,/, subcellular/JJ localization/NN ,/, and/CC heteromeric/JJ complex/JJ formation/NN ./. 
In/IN contrast/NN to/TO previous/JJ results/NNS obtained/VBN using/VBG polyclonal/JJ antiseras/NN to/TO detect/VB Pan/E2A/NN proteins/NNS ,/, we/PRP report/VBP comparable/JJ levels/NNS of/IN Pan/NN proteins/NNS in/IN GH/PRL-/NN and/CC insulin-producing/JJ ,/, B-/NN and/CC T-lymphocyte/NN cells/NNS ./. 
IEF-1/NN ,/, a/DT pancreatic/JJ beta-cell/NN type-specific/JJ complex/NN believed/VBN to/TO regulate/VB insulin/NN expression/NN ,/, is/VBZ demonstrated/VBN to/TO consist/VB of/IN at/IN least/JJS two/CD distinct/JJ species/NNS ,/, one/CD of/IN which/WDT does/VBZ not/RB contain/VB Pan/NN molecules/NNS ./. 
Although/IN it/PRP has/VBZ been/VBN postulated/VBN that/IN pituitary/JJ endocrine/JJ cells/NNS and/CC pancreatic/JJ endocrine/NN beta-cells/NNS share/VBP identical/JJ Pan/E2A/NN complexes/NNS ,/, native-Western/JJ|NN analyses/NNS of/IN pituitary/JJ and/CC endocrine/JJ beta-cells/NNS detect/VBP Pan/NN proteins/NNS in/IN distinct/JJ cell/NN type-specific/JJ complexes/NNS ./. 
UI/LS -/: 94075814/CD 
TI/LS -/: Visualization/NN of/IN the/DT endogenous/JJ NF-kappa/NN B/NN p50/NN subunit/NN in/IN the/DT nucleus/NN of/IN follicular/JJ dendritic/JJ cells/NNS in/IN germinal/JJ centers/NNS ./. 
AB/LS -/: NF-kappa/NN B/NN ,/, a/DT 50/CD kDa/65/CD kDa/NN (/( p50/p65/NN )/) heterodimer/NN ,/, is/VBZ a/DT ubiquitous/JJ transcription/NN factor/NN involved/VBN in/IN the/DT positive/JJ regulation/NN of/IN various/JJ immune/JJ genes/NNS ./. 
The/DT aim/NN of/IN this/DT study/NN was/VBD to/TO determine/VB whether/IN NF-kappa/NN B/NN is/VBZ related/JJ to/TO a/DT particular/JJ cell/NN type/NN and/or/CC differentiation/NN step/NN during/IN immunopoiesis/NN ./. 
Using/VBG in/FW situ/FW hybridization/NN on/IN sections/NNS from/IN non/JJ HIV/NN hyperplastic/JJ lymph/NN nodes/NNS ,/, we/PRP found/VBD that/IN the/DT gene/NN of/IN the/DT 105/CD kDa/NN precursor/NN of/IN p50/NN was/VBD overexpressed/VBN in/IN the/DT light/JJ zone/NN of/IN germinal/JJ centers/NNS ,/, with/IN a/DT network/NN aspect/NN ,/, which/WDT suggested/VBD the/DT involvement/NN of/IN follicular/JJ dendritic/JJ cells/NNS (/( FDC/NN )/) ./. 
By/IN immunohistochemistry/NN ,/, p50/NN protein/NN was/VBD detected/VBN in/IN the/DT cytoplasm/NN and/CC nucleus/NN of/IN FDC/NN ,/, confirming/VBG the/DT involvement/NN of/IN FDC/NN ./. 
Furthermore/RB ,/, p50/NN protein/NN was/VBD detected/VBN in/IN the/DT cytoplasm/NN of/IN all/DT lymphocytes/NNS ./. 
Thus/RB ,/, we/PRP focused/VBD our/PRP$ study/NN on/IN isolated/VBN FDC/NN clusters/NNS from/IN normal/JJ tonsils/NNS ./. 
As/IN showed/VBN on/IN tissue/NN sections/NNS ,/, we/PRP detected/VBD the/DT p50/NN in/IN both/CC cytoplasm/NN and/CC nucleus/NN of/IN FDC/NN ./. 
Nuclei/NNS of/IN lymphocytes/NNS from/IN FDC/NN clusters/NNS were/VBD negative/JJ ./. 
We/PRP next/RB studied/VBD p65/NN and/CC c-Rel/NN protein/NN expression/NN in/IN FDC/NN clusters/NNS ./. 
p65/NN was/VBD detected/VBN in/IN the/DT cytoplasm/NN of/IN FDC/NN ,/, whereas/IN nuclei/NNS were/VBD negative/JJ ./. 
Furthermore/RB ,/, p65/NN was/VBD detected/VBN in/IN the/DT nuclei/NNS of/IN some/DT lymphocytes/NNS ./. 
c-Rel/NN protein/NN was/VBD detected/VBN only/RB in/IN the/DT cytoplasm/NN of/IN lymphocytes/NNS and/CC not/RB in/IN the/DT nucleus/NN and/CC cytoplasm/NN of/IN FDC/NN ./. 
Our/PRP$ results/NNS indicated/VBD that/IN ,/, in/IN the/DT context/NN of/IN T/NN cell-dependent/JJ B/NN cell/NN immunopoiesis/NN occurring/VBG in/IN FDC/NN clusters/NNS ,/, p50/NN is/VBZ mainly/RB related/JJ to/TO FDC/NN with/IN a/DT massive/JJ overexpression/NN in/IN the/DT nuclei/NNS ,/, whereas/IN p65/NN is/VBZ expressed/VBN in/IN a/DT scattered/VBN manner/NN in/IN the/DT nuclei/NNS of/IN lymphocytes/NNS and/CC c-Rel/NN protein/NN exclusively/RB in/IN the/DT cytoplasm/NN of/IN lymphocytes/NNS from/IN FDC/NN clusters/NNS ./. 
These/DT results/NNS suggested/VBD that/IN the/DT two/CD subunits/NNS of/IN NF-kappa/NN B/NN and/CC the/DT c-Rel/NN protein/NN have/VBP different/JJ roles/NNS in/IN different/JJ cell/NN types/NNS during/IN B/NN cell/NN immunopoiesis/NN ./. 
UI/LS -/: 95193668/CD 
TI/LS -/: Cloning/NN and/CC characterization/NN of/IN NF-ATc/NN and/CC NF-ATp/NN :/: the/DT cytoplasmic/JJ components/NNS of/IN NF-AT/NN ./. 
AB/LS -/: Present/JJ evidence/NN indicates/VBZ a/DT pathway/NN of/IN signal/NN transmission/NN in/IN T/NN cells/NNS that/WDT is/VBZ outlined/VBN in/IN figure/NN 1/CD ./. 
The/DT elevation/NN in/IN intracellular/JJ calcium/NN that/WDT is/VBZ induced/VBN by/IN interactions/NNS at/IN the/DT antigen/NN receptor/NN leads/VBZ to/TO the/DT activation/NN of/IN the/DT calcium-dependent/JJ phosphatase/NN calcineurin/NN ./. 
This/DT in/IN turn/NN leads/VBZ to/TO the/DT nuclear/JJ association/NN of/IN the/DT cytosolic/JJ component/NN of/IN NF-ATc/NN ./. 
The/DT activation/NN of/IN calcineurin/NN and/CC the/DT nuclear/JJ import/NN of/IN NF-ATc/NN can/MD both/DT be/VB blocked/VBN by/IN cyclosporin/NN A/NN or/CC FK506/NN in/IN complex/NN with/IN their/PRP$ respective/JJ immunophilins/NNS ./. 
Once/RB in/IN the/DT nucleus/NN ,/, NF-ATc/NN interacts/VBZ with/IN NF-ATn/NN to/TO form/VB an/DT active/JJ transcriptional/JJ complex/NN ./. 
NF-ATn/NN is/VBZ a/DT ubiquitous/JJ protein/NN ,/, can/MD be/VB synthesized/VBN in/IN response/NN to/TO PMA/NN ,/, and/CC has/VBZ many/JJ similarities/NNS to/TO AP-1/NN ./. 
The/DT mechanism/NN by/IN which/WDT NF-ATc/NN enters/VBZ the/DT nucleus/NN is/VBZ unknown/JJ ,/, and/CC although/IN it/PRP appears/VBZ to/TO require/VB calcineurin/NN ,/, NF-ATc/NN has/VBZ not/RB yet/RB been/VBN shown/VBN to/TO be/VB an/DT in/FW vivo/FW substrate/NN of/IN calcineurin/NN ./. 
Alternative/JJ mechanisms/NNS include/VBP the/DT possibility/NN that/IN NF-ATc/NN operates/VBZ on/IN some/DT cytoplasmic/JJ anchor/NN or/CC that/IN other/JJ proteins/NNS that/WDT are/VBP controlled/VBN by/IN calcineurin/NN carry/VBP out/RP the/DT nuclear/JJ import/NN of/IN NF-ATc/NN ./. 
Although/IN NF-ATp/NN copurifies/VBZ with/IN NF-ATc/NN ,/, there/EX is/VBZ as/RB yet/RB no/DT understanding/NN of/IN how/WRB NF-ATp/NN is/VBZ functioning/VBG in/FW vivo/FW ./. 
Now/RB that/IN these/DT proteins/NNS are/VBP purified/VBN and/CC cloned/VBN ,/, the/DT major/JJ goals/NNS will/MD be/VB to/TO understand/VB their/PRP$ role/NN and/CC the/DT roles/NNS of/IN other/JJ family/NN members/NNS in/IN thymic/JJ development/NN ./. 
UI/LS -/: 97175274/CD 
TI/LS -/: Induction/NN of/IN vascular/JJ cell/NN adhesion/NN molecule-1/NN by/IN low-density/JJ lipoprotein/NN ./. 
AB/LS -/: Low-density/JJ lipoprotein/NN (/( LDL/NN )/) is/VBZ a/DT well-established/JJ risk/NN factor/NN for/IN atherosclerosis/NN ./. 
When/WRB endothelial/JJ cells/NNS are/VBP incubated/VBN with/IN this/DT lipoprotein/NN in/IN pathophysiologic/JJ amounts/NNS ,/, the/DT cells/NNS are/VBP activated/VBN ./. 
Among/IN the/DT documented/VBN cellular/JJ responses/NNS to/TO LDL/NN is/VBZ increased/VBN recruitment/NN of/IN monocytes/NNS ,/, which/WDT are/VBP believed/VBN to/TO play/VB a/DT major/JJ role/NN in/IN promoting/VBG intimal/JJ plaque/NN formation/NN ./. 
The/DT findings/NNS presented/VBN here/RB link/VB an/DT atheogenic/JJ lipoprotein/NN ,/, LDL/NN ,/, with/IN the/DT induction/NN of/IN an/DT adhesion/NN molecule/NN important/JJ in/IN atherogenesis/NN Human/JJ LDL/NN induces/VBZ the/DT vascular/JJ cell/NN adhesion/NN molecule-1/NN (/( VCAM-1/NN )/) transcriptionally/RB with/IN an/DT increase/NN in/IN mRNA/NN levels/NNS through/IN activation/NN of/IN the/DT VCAM/NN promoter/NN ./. 
This/DT effect/NN is/VBZ blocked/VBN by/IN anti-VCAM/JJ antibodies/NNS ./. 
After/IN a/DT 2-day/JJ incubation/NN in/IN LDL/NN ,/, the/DT binding/NN of/IN NF-kappa/NN B/NN ,/, which/WDT is/VBZ believed/VBN to/TO be/VB a/DT key/JJ oxidative-stress/JJ sensor/NN for/IN VCAM/NN regulation/NN ,/, remains/VBZ at/IN basal/JJ level/NN ./. 
In/IN contrast/NN ,/, the/DT binding/NN activities/NNS of/IN AP-1/NN and/CC GATA/NN ,/, on/IN the/DT other/JJ hand/NN ,/, are/VBP increased/VBN by/IN LDL/NN ./. 
Thus/RB ,/, a/DT component/NN of/IN LDL-enhanced/JJ endothelial/JJ recruitment/NN of/IN monocytes/NNS is/VBZ attributed/VBN to/TO VCAM-1/JJ expression/NN ,/, which/WDT appears/VBZ to/TO be/VB mediated/VBN through/IN AP-1/NN and/CC GATA/NN ./. 
These/DT data/NNS identify/VBP LDL/NN as/IN a/DT VCAM-inducer/NN possibly/RB distinct/JJ from/IN cytokines/NNS and/CC endotoxin/NN ./. 
UI/LS -/: 97132074/CD 
TI/LS -/: Involvement/NN of/IN nuclear/JJ factor-kappa/NN B/NN activation/NN in/IN IgE/NN synthesis/NN in/IN human/JJ B/NN cells/NNS ./. 
AB/LS -/: Nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) is/VBZ a/DT transcription/NN factor/NN that/WDT binds/VBZ to/TO the/DT consensus/NN DNA/NN sequence/NN in/IN the/DT cis-acting/JJ elements/NNS of/IN various/JJ genes/NNS ./. 
Although/IN NF-kappa/NN B/NN activates/VBZ the/DT expression/NN of/IN many/JJ genes/NNS involved/VBN in/IN immune/JJ and/CC inflammatory/JJ responses/NNS ,/, little/JJ is/VBZ known/VBN about/IN the/DT role/NN of/IN NF-kappa/NN B/NN activation/NN in/IN the/DT induction/NN of/IN IgE/NN synthesis/NN in/IN human/JJ B/NN cells/NNS ./. 
Therefore/RB we/PRP first/RB examined/VBD the/DT participation/NN of/IN NF-kappa/NN B/NN in/IN germline/NN C/NN epsilon/NN transcription/NN in/IN a/DT human/JJ Burkitt/NN lymphoma/NN B/NN cell/NN line/NN ,/, DND39/NN ./. 
Stimulation/NN of/IN DND39/NN cells/NNS with/IN IL-4/NN or/CC anti-CD40/JJ monoclonal/JJ antibody/NN (/( mAb/NN )/) activated/VBD phosphatidylinositol/NN 3-kinase/NN and/CC subsequently/RB induced/VBD nuclear/JJ expression/NN of/IN NF-kappa/NN B/NN ,/, which/WDT was/VBD identified/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ./. 
n-Acetyl-L-cysteine/NN (/( NAC/NN )/) ,/, a/DT potent/JJ antioxidant/NN ,/, blocked/VBD NF-kappa/NN B/NN activation/NN caused/VBN by/IN IL-4/NN and/CC by/IN anti-CD40/JJ mAb/NN ./. 
Although/IN inhibition/NN of/IN IL-4-driven/JJ germline/NN C/NN epsilon/NN transcription/NN by/IN NAC/NN was/VBD not/RB sufficient/JJ ,/, the/DT agent/NN remarkably/RB diminished/VBD anti-CD40/JJ mAb-mediated/JJ up-regulation/NN of/IN germline/NN C/NN epsilon/NN transcription/NN ./. 
Second/RB ,/, we/PRP studied/VBD the/DT effect/NN of/IN NAC/NN on/IN IgE/NN synthesis/NN in/IN human/JJ normal/JJ B/NN cells/NNS costimulated/VBN with/IN IL-4/NN and/CC anti-CD40/JJ mAb/NN ./. 
NAC/NN was/VBD effective/JJ in/IN inhibiting/VBG mature/JJ C/NN epsilon/NN transcription/NN and/CC IgE/NN synthesis/NN in/IN the/DT T/NN cell-independent/JJ culture/NN system/NN ./. 
However/RB ,/, NAC/NN did/VBD not/RB significantly/RB affect/VB the/DT spontaneous/JJ production/NN of/IN IgE/NN by/IN atopic/JJ B/NN cells/NNS ./. 
These/DT results/NNS indicate/VBP that/IN NF-kappa/NN B/NN activity/NN is/VBZ commonly/RB inducible/JJ in/IN DND39/NN cells/NNS by/IN IL-4/NN and/CC anti-CD40/JJ mAb/NN and/CC suggest/VBP that/IN NF-kappa/NN B/NN sensitive/JJ to/TO NAC/NN may/MD play/VB a/DT role/NN in/IN regulating/VBG IgE/NN synthesis/NN in/IN B/NN cells/NNS ./. 
UI/LS -/: 97083501/CD 
TI/LS -/: Prostaglandin/NN E2/NN induction/NN of/IN binding/NN activity/NN to/TO CRE/NN and/CC AP-2/NN elements/NNS in/IN human/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: Prostaglandins/NNP of/IN the/DT E/NN series/NNS are/VBP immunomodulatory/JJ agents/NNS which/WDT exert/VBP inhibitory/JJ as/RB well/RB as/IN stimulatory/JJ effects/NNS on/IN a/DT variety/NN of/IN immune/JJ responses/NNS ./. 
Since/IN it/PRP is/VBZ known/VBN that/IN PGE2/NN is/VBZ able/JJ to/TO increase/VB cAMP/NN levels/NNS ,/, we/PRP investigated/VBD whether/IN it/PRP can/MD affect/VB gene/NN expression/NN through/IN the/DT activation/NN of/IN the/DT transcription/NN factors/NNS which/WDT bind/VBP enhancer/NN elements/NNS in/IN the/DT promoter/NN regions/NNS of/IN cAMP-regulated/JJ genes/NNS ./. 
Using/VBG electrophoretic/JJ mobility/NN shift/NN assay/NN ,/, we/PRP demonstrated/VBD that/IN a/DT short/JJ treatment/NN of/IN human/JJ T/NN lymphocytes/NNS with/IN PGE2/NN induces/VBZ specific/JJ binding/NN activity/NN to/TO CRE/NN and/CC AP-2/NN ,/, but/CC not/RB AP-1/NN ,/, DNA/NN elements/NNS ./. 
Since/IN the/DT okadaic/JJ acid/NN ,/, a/DT potent/JJ protein/NN phosphatase/NN inhibitor/NN ,/, prolongs/VBZ the/DT induction/NN of/IN the/DT binding/NN activity/NN ,/, phosphorylation/NN events/NNS are/VBP likely/JJ to/TO occur/VB ./. 
This/DT activity/NN seems/VBZ to/TO be/VB due/JJ to/TO increased/VBN cAMP/NN levels/NNS because/IN forskolin/NN and/CC IBMX/NN mimic/VBP the/DT effects/NNS of/IN PGE2/NN ./. 
More/RBR interestingly/RB ,/, transfection/NN experiments/NNS with/IN CRE-CAT/NN plasmide/NN show/VBP that/IN PGE2/NN activates/VBZ the/DT transcription/NN of/IN a/DT CRE-containing/NN promoter/NN ./. 
These/DT data/NNS support/VBP the/DT positive/JJ role/NN for/IN PGE2/NN on/IN some/DT immune/JJ functions/NNS ./. 
UI/LS -/: 97060432/CD 
TI/LS -/: Nasal/JJ NK-/NN and/CC T-cell/NN lymphomas/NNS share/VBP the/DT same/JJ type/NN of/IN Epstein-Barr/JJ virus/NN latency/NN as/IN nasopharyngeal/JJ carcinoma/NN and/CC Hodgkin/NN 's/POS disease/NN ./. 
AB/LS -/: Nasal/JJ T/NK-cell/JJ lymphomas/NNS can/MD be/VB further/RBR separated/VBN into/IN those/DT of/IN natural/JJ killer/NN (/( NK/NN )/) cell/NN lineage/NN or/CC of/IN T-cell/NN lineage/NN ,/, with/IN differences/NNS in/IN cellular/JJ phenotype/NN ,/, T-cell/NN receptor/NN (/( TcR/NN )/) gene/NN rearrangement/NN and/CC TcR/NN transcript/NN expression/NN ./. 
Both/CC NK-/NN and/CC T-cell/NN subtypes/NNS are/VBP closely/RB associated/VBN with/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) ./. 
In/IN this/DT study/NN ,/, EBV/NN gene/NN expression/NN was/VBD determined/VBN in/IN 23/CD cases/NNS of/IN nasal/JJ lymphoma/NN (/( NL/NN )/) by/IN in/FW situ/FW hybridisation/NN (/( ISH/NN )/) ,/, reverse/JJ transcriptase-polymerase/NN chain/NN reaction/NN (/( RT-PCR/NN )/) and/CC immunohistochemistry/NN (/( IH/NN )/) ./. 
Of/IN the/DT 23/CD cases/NNS ,/, 19/CD were/VBD classified/VBN as/IN NK-cell/NN and/CC 4/CD as/IN T-cell/NN tumours/NNS ./. 
ISH/NN for/IN EBV-encoded/JJ small/JJ non-polyadenylated/JJ RNAs/NNS showed/VBD that/IN all/DT cases/NNS ,/, whether/IN NK/NN or/CC T/NN ,/, harboured/VBD EBV/NN in/IN virtually/RB all/DT tumour/NN cells/NNS ./. 
RT-PCR/NN demonstrated/VBD that/IN NL/NN of/IN both/DT subtypes/NNS expressed/VBD EBNAI/NN of/IN the/DT QUK/NN splice/NN pattern/NN ,/, the/DT latent/JJ membrane/NN proteins/NNS ,/, LMP1/NN and/CC 2/CD and/CC the/DT BamHI/NN A/NN rightward/JJ transcripts/NNS in/IN the/DT absence/NN of/IN EBNA2/NN mRNAs/NNS ,/, compatible/JJ with/IN the/DT latency/NN type/NN II/CD pattern/NN ./. 
In/IN addition/NN ,/, analysis/NN of/IN EBV/NN protein/NN expression/NN by/IN IH/NN revealed/VBD a/DT heterogeneous/JJ pattern/NN of/IN EBV/NN gene/NN expression/NN at/IN the/DT single-cell/NN level/NN consisting/VBG of/IN both/CC LMP1+/JJ and/CC LMP1-tumour/NN cells/NNS ,/, suggesting/VBG a/DT mixture/NN of/IN latency/NN I/CD and/CC II/CD ./. 
Although/IN 2/CD early/JJ lytic/JJ transcripts/NNS ,/, BZLF1/NN and/CC BHRF1/NN ,/, were/VBD also/RB detected/VBN in/IN 13/CD and/CC 10/CD cases/NNS ,/, respectively/RB ,/, the/DT lack/NN of/IN ZEBRA/NN staining/NN in/IN any/DT case/NN indicates/VBZ that/IN these/DT lytic/JJ transcripts/NNS are/VBP most/RBS likely/RB expressed/VBN by/IN rare/JJ cells/NNS in/IN the/DT biopsies/NNS entering/VBG lytic/JJ cycle/NN ./. 
The/DT viral/JJ transcriptional/JJ pattern/NN similar/JJ to/TO that/DT of/IN nasopharyngeal/JJ carcinoma/NN and/CC Hodgkin/NN 's/POS disease/NN suggests/VBZ that/IN EBV/NN can/MD exploit/VB common/JJ regulatory/JJ mechanisms/NNS for/IN gene/NN transcription/NN in/IN diverse/JJ host/NN cell/NN types/NNS ./. 
Down-regulation/NN of/IN immunogenic/JJ proteins/NNS (/( EBNA2-EBNA6/NN )/) in/IN nasal/JJ lymphoma/NN may/MD enable/VB tumour/NN cells/NNS to/TO evade/VB host/NN cytotoxic/JJ T-cell/NN surveillance/NN ./. 
UI/LS -/: 97070945/CD 
TI/LS -/: Potent/JJ gene/NN regulatory/JJ and/CC antiproliferative/JJ activities/NNS of/IN 20-methyl/JJ analogues/NNS of/IN 1,25/CD dihydroxyvitamin/NN D3/NN ./. 
AB/LS -/: The/DT biological/JJ active/JJ form/NN of/IN vitamin/NN D3/NN ,/, 1,25-dihydroxyvitamin/NN D3/NN (/( VD/NN )/) ,/, regulates/VBZ cellular/JJ growth/NN and/CC differentiation/NN ./. 
This/DT provides/VBZ the/DT hormone/NN with/IN an/DT interesting/JJ therapeutic/JJ potential/NN ./. 
However/RB ,/, hypercalcemia/NN is/VBZ a/DT side/JJ effect/NN ,/, which/WDT is/VBZ caused/VBN by/IN VD/NN 's/POS classical/JJ action/NN ,/, the/DT regulation/NN of/IN calcium/NN homeostasis/NN ./. 
This/DT made/VBD the/DT need/NN for/IN VD/NN analogues/NNS with/IN selectively/RB increased/VBN cell/NN regulatory/JJ properties/NNS ./. 
Studies/NNS with/IN 20-epi/JJ|NN analogues/NNS pointed/VBD out/RP the/DT importance/NN of/IN the/DT carbon-20/NN position/NN and/CC led/VBD to/TO the/DT development/NN of/IN 20-methyl/NN derivatives/NNS of/IN VD/NN ./. 
In/IN this/DT report/NN the/DT biological/JJ properties/NNS of/IN the/DT compounds/NNS ZK161422/NN and/CC ZK157202/NN ,/, which/WDT are/VBP 20-methyl-/NN and/CC 20-methyl-23-eneanalogues/NN ,/, respectively/RB ,/, have/VBP been/VBN analyzed/VBN in/IN comparison/NN with/IN VD/NN ./. 
Both/DT compounds/NNS show/VBP about/IN 2-fold/RB lower/JJR affinity/NN to/TO the/DT VD/NN receptor/NN (/( VDR/NN )/) than/IN VD/NN ./. 
However/RB ,/, compared/VBN to/TO VD/NN ,/, their/PRP$ antiproliferative/JJ effect/NN is/VBZ up/RB to/TO 30-fold/RB higher/JJR on/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS and/CC even/RB up/RB to/TO 300-fold/RB higher/JJR on/IN human/JJ breast/NN cancer/NN MCF-7/NN cells/NNS ./. 
Whereas/IN the/DT hypercalcemic/JJ effect/NN for/IN ZK157202/NN is/VBZ also/RB increased/VBN 10-fold/RB ,/, ZK161422/NN has/VBZ the/DT same/JJ calcium-mobilizing/JJ potency/NN as/IN VD/NN ./. 
Moreover/RB ,/, ZK161422/NN ,/, but/CC not/RB ZK157202/NN ,/, showed/VBD preference/NN for/IN gene/NN activation/NN from/IN a/DT promoter/NN carrying/VBG a/DT VD/NN response/NN element/NN with/IN a/DT palindromic/JJ arrangement/NN of/IN two/CD hexameric/JJ receptor/NN binding/NN sites/NNS spaced/VBN by/IN 9/CD nucleotides/NNS (/( IP9/NN )/) rather/RB than/IN for/IN activation/NN from/IN a/DT response/NN element/NN formed/VBN by/IN a/DT direct/JJ repeat/NN spaced/VBN by/IN 3/CD nucleotides/NNS (/( DR3/NN )/) ./. 
This/DT observation/NN supports/VBZ a/DT model/NN ,/, in/IN which/WDT promoter/NN selectivity/NN reflects/VBZ the/DT selectively/RB increased/VBN antiproliferative/JJ effect/NN of/IN VD/NN analogues/NNS ./. 
UI/LS -/: 97042487/CD 
TI/LS -/: Calcium-dependent/JJ immediate-early/JJ gene/NN induction/NN in/IN lymphocytes/NNS is/VBZ negatively/RB regulated/VBN by/IN p21Ha-ras/NN ./. 
AB/LS -/: The/DT induction/NN of/IN immediate-early/JJ (/( IE/JJ )/) response/NN genes/NNS ,/, such/JJ as/IN egr-1/NN ,/, c-fos/NN ,/, and/CC c-jun/NN ,/, occurs/VBZ rapidly/RB after/IN the/DT activation/NN of/IN T/NN lymphocytes/NNS ./. 
The/DT process/NN of/IN activation/NN involves/VBZ calcium/NN mobilization/NN ,/, activation/NN of/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) ,/, and/CC phosphorylation/NN of/IN tyrosine/NN kinases/NNS ./. 
p21(ras)/NN ,/, a/DT guanine/NN nucleotide/NN binding/NN factor/NN ,/, mediates/VBZ T-cell/NN signal/NN transduction/NN through/IN PKC-dependent/JJ and/CC PKC-independent/JJ pathways/NNS ./. 
The/DT involvement/NN of/IN p21(ras)/NN in/IN the/DT regulation/NN of/IN calcium-dependent/JJ signals/NNS has/VBZ been/VBN suggested/VBN through/IN analysis/NN of/IN its/PRP$ role/NN in/IN the/DT activation/NN of/IN NF-AT/NN ./. 
We/PRP have/VBP investigated/VBN the/DT inductions/NNS of/IN the/DT IE/JJ genes/NNS in/IN response/NN to/TO calcium/NN signals/NNS in/IN Jurkat/NN cells/NNS (/( in/IN the/DT presence/NN of/IN activated/VBN p21(ras)/NN )/) and/CC their/PRP$ correlated/VBN consequences/NNS ./. 
The/DT expression/NN of/IN activated/VBN p21(ras)/NN negatively/RB regulated/VBD the/DT induction/NN of/IN IE/JJ genes/NNS by/IN calcium/NN ionophore/NN ./. 
This/DT inhibition/NN of/IN calcium-activated/JJ IE/JJ gene/NN induction/NN was/VBD reversed/VBN by/IN treatment/NN with/IN cyclosporin/NN A/NN ,/, suggesting/VBG the/DT involvement/NN of/IN calcineurin/NN in/IN this/DT regulation/NN ./. 
A/DT later/JJ result/NN of/IN inhibition/NN of/IN this/DT activation/NN pathway/NN by/IN p21(ras)/NN was/VBD down-regulation/NN of/IN the/DT activity/NN of/IN the/DT transcription/NN factor/NN AP-1/NN and/CC subsequent/JJ coordinate/JJ reductions/NNS in/IN IL-2/NN gene/NN expression/NN and/CC protein/NN production/NN ./. 
These/DT results/NNS suggest/VBP that/IN p2l(ras)/NN is/VBZ an/DT essential/JJ mediator/NN in/IN generating/VBG not/RB only/RB positive/JJ but/CC also/RB negative/JJ modulatory/JJ mechanisms/NNS controlling/VBG the/DT competence/NN of/IN T/NN cells/NNS in/IN response/NN to/TO inductive/JJ stimulations/NNS ./. 
UI/LS -/: 94155850/CD 
TI/LS -/: Calcineurin/NN acts/VBZ in/IN synergy/NN with/IN PMA/NN to/TO inactivate/VB I/NN kappa/NN B/MAD3/NN ,/, an/DT inhibitor/NN of/IN NF-kappa/NN B/NN ./. 
AB/LS -/: The/DT interleukin-2/NN (/( IL-2/NN )/) promoter/NN consists/VBZ of/IN several/JJ independent/JJ T/NN cell/NN receptor/NN (/( TcR/NN )/) responsive/JJ elements/NNS ./. 
The/DT induction/NN of/IN promoters/NNS dependent/JJ on/IN these/DT elements/NNS is/VBZ inhibitable/JJ by/IN the/DT immunosuppressants/NNS cyclosporin/NN A/NN (/( CsA/NN )/) and/CC tacrolimus/NN (/( FK-506/NN )/) ./. 
Calcineurin/NN ,/, a/DT Ca2+/calmodulin-dependent/JJ protein/NN phosphatase/NN ,/, is/VBZ the/DT FK-506-/NN and/CC CsA-sensitive/JJ enzyme/NN required/VBN for/IN TcR/NN mediated/JJ activation/NN of/IN the/DT IL-2/NN promoter/NN ./. 
We/PRP report/VBP that/IN a/DT constitutively/RB active/JJ form/NN of/IN calcineurin/NN partially/RB substitutes/VBZ for/IN the/DT Ca2+/NN co-stimulus/NN required/VBN to/TO activate/VB the/DT IL-2/NN promoter/NN elements/NNS IL-2A/NN (/( which/WDT binds/VBZ the/DT factors/NNS OAP/NN and/CC Oct-1/NN )/) and/CC IL-2E/NN (/( which/WDT binds/VBZ NF-AT/NN )/) ,/, and/CC completely/RB substitutes/VBZ for/IN the/DT Ca2+/NN co-stimulus/NN required/VBN to/TO stimulate/VB an/DT NF-kappa/NN B-dependent/JJ element/NN ./. 
Calcineurin/NN stimulates/VBZ the/DT NF-kappa/NN B/NN element/NN by/IN enhancing/VBG inactivation/NN of/IN I/NN kappa/NN B/MAD3/NN ,/, an/DT inhibitor/NN of/IN NF-kappa/NN B/NN ,/, thereby/RB increasing/VBG the/DT amount/NN of/IN nuclear/JJ NF-kappa/NN B/NN DNA/NN binding/NN activity/NN ./. 
These/DT data/NNS provide/VBP the/DT first/JJ demonstration/NN in/FW vivo/FW that/IN activation/NN of/IN a/DT protein/NN phosphatase/NN can/MD inactivate/VB I/NN kappa/NN B/NN ,/, and/CC suggest/VBP one/CD possible/JJ explanation/NN for/IN mechanism-based/JJ toxicities/NNS associated/VBN with/IN FK-506/NN and/CC CsA/NN by/IN demonstrating/VBG that/IN these/DT drugs/NNS can/MD inhibit/VB the/DT calcineurin-dependent/JJ activation/NN of/IN a/DT virtually/RB ubiquitous/JJ transcription/NN factor/NN ./. 
UI/LS -/: 94193110/CD 
TI/LS -/: Detection/NN of/IN minimal/JJ residual/JJ disease/NN in/IN a/DT patient/NN with/IN acute/JJ promyelocytic/JJ leukemia/NN by/IN RT-PCR/NN :/: necessity/NN of/IN chemotherapy/NN following/VBG ATRA/NN therapy/NN ./. 
AB/LS -/: The/DT PML/RAR/NN alpha/NN fusion/NN gene/NN resulting/VBG from/IN the/DT t (15;17)/NN translocation/NN is/VBZ a/DT specific/JJ marker/NN for/IN acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) ./. 
We/PRP examined/VBD bone/NN marrow/NN cells/NNS by/IN reverse/JJ transcriptase-polymerase/NN chain/NN reaction/NN (/( RT-PCR/NN )/) to/TO detect/VB residual/JJ PML/RAR/NN alpha/NN mRNA-containing/JJ cells/NNS following/VBG treatment/NN with/IN all-trans/JJ retinoic/JJ acid/NN (/( ATRA/NN )/) and/CC cytotoxic/JJ chemotherapy/NN in/IN a/DT patient/NN with/IN APL/NN ./. 
This/DT RT-PCR/NN assay/NN can/MD detect/VB one/CD leukemic/JJ cell/NN in/IN 10(2)/CD normal/JJ cells/NNS in/FW vitro/FW ./. 
We/PRP show/VBP that/IN PML/RAR/NN alpha/NN mRNA/NN was/VBD still/RB detectable/JJ despite/IN clinical/JJ remission/NN following/VBG ATRA/NN treatment/NN ,/, but/CC undetectable/JJ following/VBG consolidation/NN with/IN chemotherapy/NN ./. 
These/DT data/NNS show/VBP that/IN this/DT technique/NN is/VBZ useful/JJ for/IN the/DT identification/NN of/IN minimal/JJ residual/JJ disease/NN in/NN patients/NNS with/IN APL/NN and/CC that/IN cytotoxic/JJ chemotherapy/NN following/VBG ATRA/NN therapy/NN is/VBZ required/VBN for/IN the/DT elimination/NN of/IN APL/NN cells/NNS ./. 
UI/LS -/: 94266606/CD 
TI/LS -/: Glucocorticoid-mediated/JJ inhibition/NN of/IN interleukin-2/NN receptor/NN alpha/NN and/CC -beta/NN subunit/NN expression/NN by/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: To/TO determine/VB the/DT mechanism/NN of/IN glucocorticoid/NN (/( GC/NN )/) -mediated/JJ inhibition/NN of/IN T/NN cell/NN functions/NNS ,/, the/DT effect/NN of/IN dexamethasone/NN (/( DM/NN )/) on/IN T/NN cell/NN proliferation/NN and/CC interleukin-2/NN receptor/NN (/( IL-2R/NN )/) generation/NN were/VBD studied/VBN ./. 
Dexamethasone/NN inhibited/VBD IL-2-induced/JJ T/NN cell/NN proliferation/NN by/IN 30/CD %/NN -88/CD %/NN ,/, relative/JJ to/TO its/PRP$ concentration/NN within/IN the/DT cultures/NNS ./. 
The/DT effect/NN of/IN DM/NN on/IN expression/NN of/IN IL-2R/NN alpha/NN (/( Tac/NN ,/, p55/NN ,/, CD25/NN )/) and/CC beta/NN (/( p75/NN )/) genes/NNS in/IN activated/VBN T/NN cells/NNS was/VBD examined/VBN next/RB ./. 
In/IN T/NN cells/NNS stimulated/VBN with/IN purified/VBN phytohemagglutinin/NN (/( PHA-p/NN )/) and/CC 4/CD beta-phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) addition/NN of/IN DM/NN to/TO the/DT cultures/NNS resulted/VBD in/IN a/DT 60/CD %/NN reduction/NN in/IN IL-2R/NN alpha/NN and/CC a/DT 30/CD %/NN reduction/NN in/IN IL-2R/NN beta/NN membrane/NN expression/NN compared/VBN to/TO T/NN cells/NNS cultured/VBN in/IN the/DT absence/NN of/IN DM/NN (/( p/NN </JJR 0.01/CD )/) ./. 
Inhibition/NN of/IN membrane/NN IL-2R/NN alpha/NN and/CC IL-2R/NN beta/NN expression/NN by/IN 10(-6)/CD M/NN DM/NN was/VBD partially/RB reversible/JJ by/IN recombinant/JJ human/JJ IL-2/NN (/( rhIL-2/NN )/) ./. 
By/IN Northern/JJ|NN blot/NN analysis/NN ,/, DM/NN caused/VBD a/DT comparable/JJ decrease/NN in/IN IL-2R/NN alpha/NN and/CC in/IN IL-2R/NN beta/NN mRNA/NN levels/NNS to/TO membrane/NN receptor/NN expression/NN in/IN mitogen-stimulated/JJ T/NN cells/NNS ./. 
By/IN in/FW vitro/FW transcription/NN assays/NNS ,/, DM/NN regulated/VBD IL-2R/NN alpha/NN gene/NN expression/NN at/IN a/DT transcriptional/JJ level/NN while/IN transcription/NN of/IN IL-2R/NN beta/NN gene/NN was/VBD unaffected/VBN by/IN DM/NN ./. 
The/DT mechanism/NN of/IN action/NN of/IN DM/NN on/IN IL-2R/NN alpha/NN transcription/NN was/VBD examined/VBN by/IN determining/VBG the/DT mRNA/NN levels/NNS of/IN the/DT p50/NN subunit/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ,/, a/DT transcription/NN factor/NN that/WDT stimulates/VBZ IL-2R/NN alpha/NN gene/NN expression/NN ./. 
The/DT data/NNS indicate/VBP that/IN 10(-6)/CD M/NN DM/NN increased/VBD T/NN cell/NN p50/NN NF-kappa/NN B/NN mRNA/NN levels/NNS by/IN four-fold/JJ compared/VBN to/TO the/DT levels/NNS obtained/VBN in/IN the/DT absence/NN of/IN DM/NN ./. 
Further/RB ,/, the/DT level/NN of/IN nuclear/JJ proteins/NNS capable/JJ of/IN binding/VBG to/TO the/DT NF-kappa/NN B/NN sites/NNS in/IN activated/VBN T/NN cells/NNS increased/VBD in/IN response/NN to/TO DM/NN ./. 
In/IN sum/NN ,/, DM/NN regulates/VBZ T/NN cell/NN membrane/NN expression/NN of/IN IL-2R/NN by/IN more/JJR than/IN one/CD molecular/JJ mechanism/NN ./. 
UI/LS -/: 95154979/CD 
TI/LS -/: Alteration/NN of/IN structural/JJ order/NN of/IN human/JJ erythrocyte/NN ghost/NN membrane/NN by/IN glucocorticoids/NNS and/CC the/DT influence/NN of/IN the/DT glucocorticoid/NN receptor/NN antagonist/NN RU/NN 486/CD ./. 
AB/LS -/: High-dose/JJ pulse/NN glucocorticoid/NN therapy/NN has/VBZ been/VBN used/VBN successfully/RB in/IN the/DT clinic/NN in/IN severe/JJ pathological/JJ conditions/NNS for/IN about/RB 20/CD years/NNS ./. 
The/DT mode/NN of/IN glucocorticoid/NN action/NN after/IN administration/NN of/IN such/JJ megadoses/NNS is/VBZ inexplicable/JJ up/RP to/TO now/RB ./. 
It/PRP is/VBZ supposed/VBN that/IN some/DT effects/NNS may/MD be/VB due/JJ to/TO membrane/NN alterations/NNS ./. 
In/IN the/DT present/JJ in-vitro/FW experiments/NNS the/DT effect/NN of/IN dexamethasone/NN ,/, of/IN further/JJ glucocorticoids/NNS ,/, and/CC of/IN the/DT glucocorticoid/NN receptor/NN antagonist/NN RU/NN 486/CD ,/, on/IN structural/JJ order/NN of/IN human/JJ erythrocyte/NN ghost/NN membranes/NNS was/VBD investigated/VBN by/IN determining/VBG the/DT steady-state/JJ fluorescence/NN anisotropy/NN of/IN diphenylhexatriene/NN (/( DPH/NN )/) ./. 
Dexamethasone/NN was/VBD found/VBN to/TO induce/VB a/DT significant/JJ decrease/NN in/IN membrane/NN structural/JJ order/NN at/IN concentrations/NNS of/IN about/RB 10(-6)/CD M/NN in/IN a/DT concentration-dependent/JJ manner/NN ./. 
We/PRP found/VBD a/DT correlation/NN between/IN the/DT uptake/NN of/IN dexamethasone/NN by/IN the/DT ghost/NN membranes/NNS and/CC the/DT decrease/NN in/IN the/DT structural/JJ order/NN ./. 
The/DT other/JJ glucocorticoids/NNS tested/VBN ,/, methylprednisolone/NN and/CC corticosterone/NN ,/, were/VBD also/RB effective/JJ at/IN concentrations/NNS of/IN 10(-5)/CD M/NN or/CC greater/JJR ./. 
We/PRP observed/VBD no/DT change/NN in/IN membrane/NN structural/JJ order/NN with/IN RU/NN 486/CD up/IN to/TO a/DT concentration/NN of/IN 10(-4)/CD M/NN ./. 
However/RB ,/, simultaneous/JJ incubation/NN of/IN RU/NN 486/CD with/IN dexamethasone/NN caused/VBD a/DT distinct/JJ interference/NN of/IN RU/NN 486/CD with/IN dexamethasone/NN ./. 
Thus/RB ,/, the/DT glucocorticoid-induced/JJ membrane/NN perturbation/NN ,/, the/DT possibility/NN to/TO inhibit/VB it/PRP by/IN RU/NN 486/CD ,/, and/CC the/DT inactivity/NN of/IN the/DT structurally/RB related/JJ progesterone/NN ,/, refer/VBP to/TO relatively/RB specific/JJ binding/VBG sites/NNS for/IN the/DT glucocorticoids/NNS in/IN the/DT membrane/NN of/IN erythrocyte/NN ghosts/NNS ./. 
UI/LS -/: 97115792/CD 
TI/LS -/: Mutation/NN of/IN tyrosines/NNS 492/493/CD in/IN the/DT kinase/NN domain/NN of/IN ZAP-70/NN affects/VBZ multiple/JJ T-cell/NN receptor/NN signaling/NN pathways/NNS ./. 
AB/LS -/: The/DT protein-tyrosine/JJ kinase/NN ZAP-70/NN is/VBZ implicated/VBN ,/, together/RB with/IN the/DT Src/NN kinase/NN p56(lck)/NN ,/, in/IN controlling/VBG the/DT early/JJ steps/NNS of/IN the/DT T-cell/NN antigen/NN receptor/NN (/( TCR/NN )/) signaling/NN cascade/NN ./. 
To/TO help/VB elucidate/VB further/RBR the/DT mechanism/NN by/IN which/WDT ZAP-70/NN regulates/VBZ these/DT initial/JJ events/NNS ,/, we/PRP used/VBD a/DT dominant-negative/JJ mutant/NN approach/NN ./. 
We/PRP overexpressed/VBD in/IN the/DT Jurkat/NN T-cell/NN line/NN ZAP-70/NN mutated/VBN on/IN Tyr-492/NN and/CC Tyr-493/NN in/IN the/DT putative/JJ regulatory/JJ loop/NN of/IN its/PRP$ kinase/NN domain/NN ./. 
This/DT mutant/NN inhibited/VBD TCR-induced/JJ activation/NN of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS by/IN interfering/VBG with/IN both/CC intracellular/JJ calcium/NN increase/NN and/CC Ras-regulated/JJ activation/NN of/IN extracellular/JJ signal-regulated/JJ kinases/NNS ./. 
Moreover/RB ,/, TCR-induced/JJ phosphorylation/NN of/IN pp36-38/NN ,/, thought/VBN to/TO play/VB a/DT role/NN upstream/RB of/IN these/DT pathways/NNS ,/, was/VBD found/VBN to/TO be/VB reduced/VBN ./. 
In/IN contrast/NN ,/, overexpression/NN of/IN wild-type/JJ ZAP-70/NN induced/VBD constitutive/JJ activation/NN of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS ./. 
The/DT ZAP-70/NN mutant/NN studied/VBN here/RB could/MD be/VB phosphorylated/VBN on/IN tyrosine/NN when/WRB associated/VBN to/TO the/DT TCR/NN zeta/NN chain/NN and/CC was/VBD able/JJ to/TO bind/VB p56(lck)/NN ./. 
This/DT result/NN demonstrates/VBZ that/IN Tyr-492/NN and/CC Tyr-493/NN are/VBP not/RB responsible/JJ for/IN the/DT Src/NN homology/NN domain/NN 2-mediated/JJ association/NN of/IN p56(lck)/NN with/IN ZAP-70/NN ./. 
Our/PRP$ data/NNS are/VBP most/RBS consistent/JJ with/IN a/DT model/NN in/IN which/WDT recruitment/NN to/TO the/DT TCR/NN allows/VBZ ZAP-70/NN autophosphorylation/NN and/CC binding/NN to/TO p56(lck)/NN ,/, which/WDT in/IN turn/NN phosphorylates/VBZ Tyr-492/NN and/or/CC Tyr-493/NN with/IN consequent/JJ up-regulation/NN of/IN the/DT ZAP-70/NN kinase/NN activity/NN ./. 
ZAP-70/NN will/MD then/RB be/VB able/JJ to/TO effectively/RB control/VB phosphorylation/NN of/IN its/PRP$ substrates/NNS and/CC lead/VB to/TO gene/NN activation/NN ./. 
UI/LS -/: 97132051/CD 
TI/LS -/: Effects/NNS of/IN glucocorticoids/NNS on/IN lymphocyte/NN activation/NN in/IN patients/NNS with/IN steroid-sensitive/JJ and/CC steroid-resistant/JJ asthma/NN ./. 
AB/LS -/: BACKGROUND/NN :/: Glucocorticoids/NNS are/VBP important/JJ medications/NNS used/VBN to/TO control/VB the/DT airway/NN inflammation/NN associated/VBN with/IN asthma/NN ./. 
Synthetic/JJ glucocorticoids/NNS vary/VBP in/IN their/PRP$ binding/NN affinity/NN for/IN the/DT glucocorticoid/NN receptor/NN (/( GCR/NN )/) ./. 
METHODS/NNS :/: We/PRP compared/VBD hydrocortisone/NN ,/, beclomethasone/NN dipropionate/NN ,/, triamcinolone/NN acetonide/NN ,/, flunisolide/NN ,/, and/CC budesonide/NN with/IN regard/NN to/TO their/PRP$ capacity/NN to/TO inhibit/VB phytohemagglutinin-induced/JJ peripheral/JJ blood/NN mononuclear/JJ cell/NN proliferation/NN from/IN six/CD patients/NNS with/IN steroid-sensitive/JJ asthma/NN and/CC seven/CD patients/NNS with/IN steroid-resistant/JJ asthma/NN ./. 
Peripheral/JJ blood/NN mononuclear/JJ cell/NN GCR/NN binding/NN affinities/NNS for/IN dexamethasone/NN and/CC budesonide/NN were/VBD also/RB determined/VBN for/IN both/DT patient/NN groups/NNS by/IN using/VBG a/DT radioligand/NN binding/NN assay/NN and/CC Scatchard/NN analysis/NN ./. 
RESULTS/NNS :/: Dose-dependent/JJ inhibition/NN was/VBD demonstrated/VBN for/IN all/DT glucocorticoids/NNS in/IN both/DT patient/NN groups/NNS ,/, with/IN the/DT steroid-resistant/JJ group/NN requiring/VBG approximately/RB 2/CD log-fold/JJ more/JJR glucocorticoids/NNS for/IN an/DT equivalent/JJ degree/NN of/IN inhibition/NN ./. 
The/DT mean/NN concentrations/NNS necessary/JJ to/TO cause/VB 50/CD %/NN inhibition/NN of/IN lymphocyte/NN proliferation/NN (/( IC50s/NNS )/) for/IN the/DT steroid-sensitive/JJ group/NN ranged/VBD from/IN 2/CD x/CC 10(-10)/CD mol/L/NN for/IN budesonide/NN to/TO 7/CD x/CC 10(-8)/CD mol/L/NN for/IN hydrocortisone/NN ,/, whereas/IN the/DT mean/NN IC50s/NNS for/IN the/DT steroid-resistant/JJ group/NN ranged/VBD from/IN approximately/RB 2/CD x/CC 10(-8)/CD mol/L/NN for/IN budesonide/NN to/TO greater/JJR than/IN 10(-6)/CD mol/L/NN for/IN hydrocortisone/NN ./. 
In/IN addition/NN ,/, a/DT significant/JJ correlation/NN was/VBD noted/VBN between/IN the/DT degree/NN of/IN inhibition/NN of/IN lymphocyte/NN proliferation/NN (/( IC50/NN )/) and/CC the/DT binding/NN affinity/NN of/IN dexamethasone/NN to/TO the/DT GCR/NN ./. 
Patients/NNS with/IN steroid-resistant/JJ asthma/NN have/VBP been/VBN shown/VBN to/TO have/VB a/DT reduced/VBN GCR/NN binding/NN affinity/NN ./. 
The/DT GCR/NN binding/NN affinity/NN for/IN budesonide/NN was/VBD significantly/RB higher/JJR in/IN both/DT groups/NNS (/( i.e./FW ,/, lower/JJR dissociation/NN constant/NN )/) than/IN that/DT obtained/VBN for/IN dexamethasone/NN ./. 
CONCLUSION/NN :/: These/DT data/NNS suggest/VBP that/IN glucocorticoids/NNS such/JJ as/IN budesonide/NN ,/, by/IN virtue/NN of/IN their/PRP$ high/JJ GCR/NN binding/NN affinities/NNS and/CC greater/JJR ability/NN to/TO suppress/VB lymphocyte/NN proliferation/NN ,/, may/MD therefore/RB be/VB beneficial/JJ in/IN the/DT management/NN of/IN difficult-to-control/JJ asthma/NN ./. 
UI/LS -/: 97128814/CD 
TI/LS -/: Characterization/NN of/IN the/DT murine/JJ cyclin-dependent/JJ kinase/NN inhibitor/NN gene/NN p27Kip1/NN ./. 
AB/LS -/: The/DT cyclin-dependent/JJ kinase/NN inhibitor/NN p27Kip1/NN plays/VBZ an/DT important/JJ role/NN in/IN regulating/VBG cell-cycle/JJ progression/NN ./. 
p27Kip1/NN directly/RB inhibits/VBZ the/DT catalytic/JJ activity/NN of/IN cyclin/cdks/NNS (/( cyclin-dependent/JJ kinase/NN )/) complexes/NNS and/or/CC interferes/VBZ physically/RB with/IN cyclin/cdks/NN activation/NN by/IN CAK/NN ./. 
Interestingly/RB ,/, the/DT expression/NN level/NN of/IN p27Kip1/NN mRNA/NN was/VBD maximal/JJ in/IN resting/VBG Go/NN T-cells/NNS and/CC rapidly/RB declined/VBD following/VBG anti-CD3/JJ activation/NN ./. 
We/PRP report/VBP here/RB the/DT cloning/NN of/IN p27Kip1/NN gene/NN from/IN murine/JJ genomic/JJ DNA/NN and/CC the/DT functional/JJ analysis/NN of/IN the/DT promoter/NN of/IN the/DT p27Kip1/NN gene/NN ./. 
The/DT gene/NN consists/VBZ of/IN at/IN least/JJS three/CD exons/NNS and/CC spans/NNS more/RBR than/IN 5.6/CD kb/NN of/IN DNA/NN ./. 
Primer/NN extension/NN and/CC nuclease/NN S1/NN protection/NN analysis/NN revealed/VBD two/CD major/JJ transcription/NN initiation/NN sites/NNS ./. 
The/DT promoter/NN region/NN lacked/VBD a/DT TATA/NN box/NN but/CC contained/VBD potential/JJ binding/VBG sites/NNS for/IN the/DT transcriptional/JJ factors/NNS including/VBG two/CD Sp1/NN ,/, CRE/NN ,/, Myb/NN and/CC NFkB/NN located/JJ at/IN positions/NNS -153/CD ,/, -178/CD ,/, -286/CD ,/, -875/CD ,/, and/CC -1011/CD ,/, respectively/RB ./. 
To/TO analyze/VB the/DT regulatory/JJ mechanisms/NNS controlling/VBG p27Kip1/NN gene/NN expression/NN ,/, we/PRP characterized/VBD the/DT 5'-flanking/JJ region/NN from/IN nt/NN -1609/CD to/TO +178/CD ./. 
The/DT -326/CD to/TO -615/CD region/NN contained/VBD positive/JJ regulatory/JJ elements/NNS ./. 
UI/LS -/: 97182951/CD 
TI/LS -/: Nuclear/JJ NF-ATp/NN is/VBZ a/DT hallmark/NN of/IN unstimulated/JJ B/NN cells/NNS from/IN B-CLL/NN patients/NNS ./. 
AB/LS -/: B/NN lymphocytes/NNS from/IN the/DT peripheral/JJ blood/NN of/IN patients/NNS with/IN chronic/JJ lymphocytic/JJ leukaemia/NN (/( CLL/NN )/) were/VBD analysed/VBN for/IN the/DT nuclear/JJ presence/NN and/CC DNA/NN binding/NN of/IN a/DT panel/NN of/IN transcription/NN factors/NNS which/WDT are/VBP involved/VBN in/IN the/DT gene/NN control/NN of/IN lymphoid/JJ cells/NNS ./. 
The/DT following/JJ transcription/NN factors/NNS were/VBD studied/VBN :/: the/DT Octamer/NN factors/NNS Oct-1/NN and/CC Oct-2/NN ,/, members/NNS of/IN the/DT AP-1/NN factor/NN family/NN ,/, NF-AT/NN factors/NNS ,/, in/IN particular/JJ NF-ATp/NN ,/, and/CC members/NNS of/IN the/DT Rel/NF-kB/NN family/NN ./. 
We/PRP show/VBP that/IN the/DT constitutive/JJ nuclear/JJ translocation/NN of/IN NF-ATp/NN ,/, a/DT member/NN of/IN the/DT growing/VBG family/NN of/IN NF-AT/NN factors/NNS ,/, is/VBZ a/DT hallmark/NN of/IN nonstimulated/JJ B/NN cells/NNS from/IN CLL/NN patients/NNS that/WDT distinguishes/VBZ B-CLL/NN cells/NNS from/IN '/`` normal/JJ '/'' B/NN lymphocytes/NNS ./. 
Constitutive/JJ nuclear/JJ appearance/NN was/VBD also/RB observed/VBN for/IN NF-kB2/p52/NN ./. 
Constitutive/JJ binding/NN of/IN further/JJ factor/NN proteins/NNS to/TO DNA/NN ,/, such/JJ as/IN JunD/NN ,/, c-Fos/NN and/CC FosB/NN ,/, was/VBD detected/VBN in/IN several/JJ patients/NNS whereas/IN the/DT localisation/NN and/CC DNA/NN binding/NN of/IN other/JJ factors/NNS such/JJ as/IN c-Jun/NN ,/, RelA/p65/NN and/CC c-Rel/NN was/VBD unaltered/JJ ./. 
It/PRP is/VBZ remarkable/JJ that/IN in/IN B-CLL/JJ cells/NNS the/DT nuclear/JJ appearance/NN and/CC DNA/NN binding/NN of/IN specific/JJ transcription/NN factors/NNS is/VBZ dramatically/RB affected/JJ whereas/IN other/JJ members/NNS of/IN the/DT same/JJ factor/NN family/NN remained/VBD unaltered/JJ in/IN these/DT leukemic/JJ cells/NNS ./. 
It/PRP remains/VBZ to/TO be/VB shown/VBN which/WDT molecular/JJ events/NNS lead/VBP to/TO the/DT specific/JJ '/`` pre-activation/NN '/'' ,/, i.e./FW 
constitutive/JJ nuclear/JJ translocation/NN and/CC DNA/NN binding/NN ,/, of/IN these/DT members/NNS of/IN NF-AT/NN ,/, NF-kB/NN and/CC AP-1/NN factor/NN families/NNS ./. 
UI/LS -/: 97069908/CD 
TI/LS -/: Naive/JJ (/( CD45RA+/JJ )/) T/NN lymphocytes/NNS are/VBP more/RBR sensitive/JJ to/TO oxidative/JJ stress-induced/JJ signals/NNS than/IN memory/NN (/( CD45RO+/JJ )/) cells/NNS ./. 
AB/LS -/: Formation/NN of/IN reactive/JJ oxygen/NN intermediates/NNS (/( ROI/NN )/) after/IN oxidative/JJ stress/NN has/VBZ been/VBN shown/VBN to/TO be/VB an/DT activation/NN signal/NN for/IN T/NN lymphocytes/NNS ,/, e.g./FW ,/, expression/NN of/IN IL-2/NN and/CC its/PRP$ receptor/NN are/VBP induced/VBN ./. 
These/DT ROI-induced/JJ effects/NNS can/MD ,/, to/TO a/DT large/JJ extent/NN ,/, be/VB attributed/VBN to/TO the/DT activation/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN ./. 
Now/RB we/PRP have/VBP examined/VBN whether/IN naive/JJ and/CC memory/NN T/NN lymphocytes/NNS differ/VBP in/IN their/PRP$ sensitivity/NN to/TO ROI-mediated/JJ signals/NNS ./. 
When/WRB CD45RA+/JJ (/( naive/JJ )/) and/CC CD45RO+/JJ (/( memory/NN )/) T/NN lymphocytes/NNS were/VBD directly/RB stimulated/VBN with/IN H2O2/NN ,/, NF-kappaB/NN nuclear/JJ translocation/NN was/VBD stronger/JJR in/IN naive/JJ cells/NNS than/IN in/IN memory/NN cells/NNS and/CC it/PRP could/MD be/VB induced/VBN with/IN lower/JJR doses/NNS ./. 
The/DT composition/NN of/IN the/DT induced/VBN nuclear/JJ NF-kappaB/NN (/( levels/NNS of/IN p50/NN and/CC RelA/NN proteins/NNS )/) was/VBD similar/JJ in/IN these/DT cell/NN types/NNS ./. 
The/DT magnitude/NN and/CC kinetics/NNS of/IN intracellular/JJ ROI/NN were/VBD similar/JJ ,/, suggesting/VBG that/IN there/EX were/VBD no/DT differences/NNS in/IN ROI-forming/JJ mechanisms/NNS or/CC antioxidative/JJ capacities/NNS ./. 
The/DT probable/JJ regulatory/JJ point/NN was/VBD the/DT cytoplasmic/JJ IkappaB/NN inhibitor/NN :/: in/IN CD45RA+/JJ cells/NNS ,/, H2O2/NN caused/VBD a/DT more/RBR profound/JJ depression/NN in/IN the/DT levels/NNS of/IN IkappaB/NN alpha/NN ./. 
These/DT findings/NNS indicate/VBP that/IN T/NN cells/NNS representing/VBG different/JJ activation/NN and/or/CC differentiation/NN stages/NNS can/MD be/VB differentially/RB responsive/JJ to/TO ROI-mediated/JJ signals/NNS ./. 
UI/LS -/: 97048170/CD 
TI/LS -/: Rapid/JJ shuttling/NN of/IN NF-AT/NN in/IN discrimination/NN of/IN Ca2+/NN signals/NNS and/CC immunosuppression/NN ./. 
AB/LS -/: Cells/NNS need/VBP to/TO distinguish/VB between/IN transient/JJ Ca2+/NN signals/NNS that/WDT induce/VBP events/NNS such/JJ as/IN muscle/NN contraction/NN ,/, secretion/NN ,/, adhesion/NN and/CC synaptic/JJ transmission/NN ,/, and/CC sustained/JJ Ca2+/NN signals/NNS that/WDT are/VBP involved/VBN in/IN cell/NN proliferation/NN and/CC differentiation/NN ./. 
The/DT latter/JJ class/NN of/IN events/NNS is/VBZ blocked/VBN in/IN lymphocytes/NNS by/IN the/DT immunosuppressive/JJ drugs/NNS cyclosporin/NN A/NN and/CC FK506/NN ,/, which/WDT inhibit/VBP calcineurin/NN ,/, a/DT Ca2+-activated/JJ serine/threonine/NN phosphatase/NN necessary/JJ for/IN the/DT nuclear/JJ import/NN of/IN NF-AT/NN transcription/NN factors/NNS ./. 
Here/RB we/PRP report/VBP that/IN sustained/JJ high/JJ concentrations/NNS of/IN Ca2+/NN ,/, but/CC not/RB transient/JJ pulses/NNS ,/, are/VBP required/VBN to/TO maintain/VB NF-AT/NN transcription/NN factors/NNS in/IN the/DT nucleus/NN ,/, where/WRB they/PRP participate/VBP in/IN Ca2+-dependent/JJ induction/NN of/IN genes/NNS required/VBN for/IN lymphocyte/NN activation/NN and/CC proliferation/NN ./. 
Furthermore/RB ,/, overexpression/NN and/CC constitutive/JJ nuclear/JJ localization/NN of/IN NF-AT/NN ,/, but/CC not/RB Jun/NN ,/, Fos/NN ,/, NF-kappaB/NN ,/, Oct/NN or/CC Ets/NN family/NN members/NNS ,/, renders/VBZ the/DT interleukin-2/NN enhancer/NN in/IN Jurkat/NN T/NN lymphocytes/NNS resistant/JJ to/TO FK506/NN and/CC cyclosporin/NN A/NN ./. 
Thus/RB a/DT primary/JJ effect/NN of/IN these/DT immunosuppressive/JJ reagents/NNS is/VBZ to/TO control/VB the/DT subcellular/JJ localization/NN of/IN the/DT NF-AT/NN family/NN of/IN transcription/NN factors/NNS ./. 
UI/LS -/: 94151327/CD 
TI/LS -/: Autoregulation/NN of/IN the/DT NF-kappa/NN B/NN transactivator/NN RelA/NN (/( p65/NN )/) by/IN multiple/JJ cytoplasmic/JJ inhibitors/NNS containing/VBG ankyrin/NN motifs/NNS ./. 
AB/LS -/: RelA/NN (/( p65/NN )/) functions/VBZ as/IN the/DT critical/JJ transactivating/VBG component/NN of/IN the/DT heterodimeric/JJ p50-p65/NN NF-kappa/NN B/NN complex/NN and/CC contains/VBZ a/DT high-affinity/JJ binding/VBG site/NN for/IN its/PRP$ cytoplasmic/JJ inhibitor/NN ,/, I/NN kappa/NN B/NN alpha/NN ./. 
After/IN cellular/JJ activation/NN ,/, I/NN kappa/NN B/NN alpha/NN is/VBZ rapidly/RB degraded/VBN in/IN concert/NN with/IN the/DT induced/VBN nuclear/JJ translocation/NN of/IN NF-kappa/NN B/NN ./. 
The/DT present/JJ study/NN demonstrates/VBZ that/IN tumor/NN necrosis/NN factor/NN alpha-induced/JJ degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN in/IN human/JJ T/NN cells/NNS is/VBZ preceded/VBN by/IN its/PRP$ rapid/JJ phosphorylation/NN in/FW vivo/FW ./. 
However/RB ,/, these/DT effects/NNS on/IN I/NN kappa/NN B/NN alpha/NN result/VBP in/IN nuclear/JJ mobilization/NN of/IN only/RB a/DT fraction/NN of/IN the/DT entire/JJ cytoplasmic/JJ pool/NN of/IN RelA/NN ./. 
Subsequent/JJ studies/NNS have/VBP revealed/VBN that/IN (/( i/LS )/) cytoplasmic/JJ RelA/NN is/VBZ stably/RB associated/VBN not/RB only/RB with/IN I/NN kappa/NN B/NN alpha/NN but/CC also/RB with/IN other/JJ ankyrin/NN motif-rich/JJ proteins/NNS including/VBG the/DT products/NNS of/IN the/DT NF-kappa/NN B2/NN (/( p100/NN )/) and/CC NF-kappa/NN B1/NN (/( p105/NN )/) genes/NNS ;/: (/( ii/LS )/) in/IN contrast/NN to/TO RelA-I/NN kappa/NN B/NN alpha/NN ,/, RelA-p100/NN cytoplasmic/JJ complexes/NNS are/VBP not/RB dissociated/VBN following/VBG tumor/NN necrosis/NN factor/NN alpha/NN activation/NN ;/: (/( iii/LS )/) p100/NN functions/VBZ as/IN a/DT potent/JJ inhibitor/NN of/IN RelA-mediated/JJ transcription/NN in/FW vivo/FW ;/: (/( iv/LS )/) the/DT interaction/NN of/IN RelA/NN and/CC p100/NN involves/VBZ the/DT conserved/VBN Rel/NN homology/NN domain/NN of/IN both/DT proteins/NNS but/CC not/RB the/DT nuclear/JJ localization/NN signal/NN of/IN RelA/NN ,/, which/WDT is/VBZ required/VBN for/IN I/NN kappa/NN B/NN alpha/NN binding/NN ;/: (/( v/LS )/) p100/NN inhibition/NN of/IN RelA/NN function/NN requires/VBZ the/DT C-terminal/JJ ankyrin/NN motif/NN domain/NN ,/, which/WDT mediates/VBZ cytoplasmic/JJ retention/NN of/IN RelA/NN ;/: and/CC (/( vi/LS )/) as/IN observed/VBN with/IN I/PRP kappa/NN B/NN alpha/NN ,/, nuclear/JJ RelA/NN stimulates/VBZ p100/NN mRNA/NN and/CC protein/NN expression/NN ./. 
These/DT findings/NNS thus/RB reveal/VBP the/DT presence/NN of/IN a/DT second/JJ inducible/JJ autoregulated/JJ inhibitory/JJ pathway/NN that/WDT helps/VBZ ensure/VB the/DT rapid/JJ but/CC transient/JJ action/NN of/IN nuclear/JJ NF-kappa/NN B/NN ./. 
UI/LS -/: 94132650/CD 
TI/LS -/: Effects/NNS of/IN CD45/NN on/IN NF-kappa/NN B/NN ./. 
Implications/NNS for/IN replication/NN of/IN HIV-1/NN ./. 
AB/LS -/: Increased/VBN levels/NNS of/IN replication/NN of/IN the/DT HIV/NN type/NN 1/CD are/VBP observed/VBN after/IN the/DT activation/NN of/IN infected/JJ T/NN cells/NNS through/IN the/DT TCR/NN ./. 
However/RB ,/, anti-CD45/JJ antibodies/NNS inhibit/VBP these/DT effects/NNS in/IN cells/NNS from/IN infected/JJ individuals/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD interrelationships/NNS between/IN CD45/NN and/CC HIV-1/NN further/RB ./. 
We/PRP measured/VBD effects/NNS on/IN the/DT HIV-1/NN LTR/NN in/IN T/NN cell/NN lines/NNS that/WDT were/VBD stimulated/VBN with/IN antibodies/NNS against/IN CD45/NN and/CC in/IN those/DT that/WDT lacked/VBD the/DT expression/NN of/IN CD45/NN on/IN their/PRP$ surfaces/NNS ./. 
First/RB ,/, anti-CD45/JJ antibodies/NNS did/VBD not/RB affect/VB basal/JJ but/CC decreased/VBD activated/JJ levels/NNS of/IN expression/NN from/IN the/DT HIV-1/NN LTR/NN ./. 
Second/RB ,/, T/NN cells/NNS ,/, which/WDT lack/VBP CD45/NN and/CC can/MD not/RB signal/VB via/IN the/DT TCR/NN ,/, supported/VBD higher/JJR levels/NNS of/IN viral/JJ replication/NN and/CC gene/NN expression/NN ./. 
This/DT was/VBD due/JJ to/TO the/DT presence/NN of/IN active/JJ NF-kappa/NN B/NN complexes/NNS in/IN the/DT nucleus/NN of/IN CD45-T/NN cells/NNS ./. 
Additionally/RB ,/, infected/JJ T/NN cells/NNS displayed/VBD lower/JJR levels/NNS of/IN CD45/NN on/IN their/PRP$ surfaces/NNS ./. 
Thus/RB ,/, CD45/NN plays/VBZ an/DT active/JJ role/NN in/IN the/DT physiology/NN of/IN T/NN cells/NNS and/CC in/IN the/DT replication/NN of/IN HIV-1/NN ./. 
UI/LS -/: 94243031/CD 
TI/LS -/: Calcineurin/NN potentiates/VBZ activation/NN of/IN the/DT granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN gene/NN in/IN T/NN cells/NNS :/: involvement/NN of/IN the/DT conserved/VBN lymphokine/NN element/NN 0/CD ./. 
AB/LS -/: Granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) and/CC interleukin-2/NN (/( IL-2/NN )/) are/VBP produced/VBN by/IN stimulation/NN with/IN phorbol-12-myristate/NN acetate/NN (/( PMA/NN )/) and/CC calcium/NN ionophore/NN (/( A23187/NN )/) in/IN human/JJ T/NN cell/NN leukemia/NN Jurkat/NN cells/NNS ./. 
The/DT expression/NN of/IN GM-CSF/NN and/CC IL-2/NN is/VBZ inhibited/VBN by/IN immunosuppressive/JJ drugs/NNS such/JJ as/IN cyclosporin/NN A/NN (/( CsA/NN )/) and/CC FK506/NN ./. 
Earlier/JJR studies/NNS on/IN the/DT IL-2/NN gene/NN expression/NN showed/VBD that/IN overexpression/NN of/IN calcineurin/NN (/( CN/NN )/) ,/, a/DT Ca2+/calmodulin-dependent/JJ protein/NN phosphatase/NN ,/, can/MD stimulate/VB transcription/NN from/IN the/DT IL-2/NN promoter/NN through/IN the/DT NF-AT-binding/JJ site/NN ./. 
In/IN this/DT study/NN ,/, we/PRP obtained/VBD evidence/NN that/IN transfection/NN of/IN the/DT cDNAs/NNS for/IN CN/NN A/NN (/( catalytic/JJ )/) and/CC CN/NN B/NN (/( regulatory/JJ )/) subunits/NNS also/RB augments/VBZ transcription/NN from/IN the/DT GM-CSF/NN promoter/NN and/CC recovers/VBZ the/DT transcription/NN inhibited/VBN by/IN CsA/NN ./. 
The/DT constitutively/RB active/JJ type/NN of/IN the/DT CN/NN A/NN subunit/NN ,/, which/WDT lacks/VBZ the/DT auto-inhibitory/JJ and/CC calmodulin-binding/JJ domains/NNS ,/, acts/VBZ in/IN synergy/NN with/IN PMA/NN to/TO activate/VB transcription/NN from/IN the/DT GM-CSF/NN promoter/NN ./. 
We/PRP also/RB found/VBD that/IN the/DT active/JJ CN/NN partially/RB replaces/VBZ calcium/NN ionophore/NN in/IN synergy/NN with/IN PMA/NN to/TO induce/VB expression/NN of/IN endogenous/JJ GM-CSF/NN and/CC IL-2/NN ./. 
By/IN multimerizing/VBG the/DT regulatory/JJ elements/NNS of/IN the/DT GM-CSF/NN promoter/NN ,/, we/PRP found/VBD that/IN one/CD of/IN the/DT target/NN sites/NNS for/IN the/DT CN/NN action/NN is/VBZ the/DT conserved/VBN lymphokine/NN element/NN 0/CD (/( CLE0/NN )/) ,/, located/JJ at/IN positions/NNS between/IN -54/CD and/CC -40/CD ./. 
Mobility/NN shift/NN assays/NNS showed/VBD that/IN the/DT CLE0/NN sequence/NN has/VBZ an/DT AP1-binding/JJ site/NN and/CC is/VBZ associated/VBN with/IN an/DT NF-AT-like/JJ factor/NN ,/, termed/VBN NF-CLE0/NN gamma/NN ./. 
NF-CLE0/NN gamma/NN binding/NN is/VBZ induced/VBN by/IN PMA/A23187/NN and/CC is/VBZ inhibited/VBN by/IN treatment/NN with/IN CsA/NN ./. 
These/DT results/NNS suggest/VBP that/IN CN/NN is/VBZ involved/VBN in/IN the/DT coordinated/VBN induction/NN of/IN the/DT GM-CSF/NN and/CC IL-2/NN genes/NNS and/CC that/IN the/DT CLE0/NN sequence/NN of/IN the/DT GM-CSF/NN gene/NN is/VBZ a/DT functional/JJ analogue/NN of/IN the/DT NF-AT-binding/JJ site/NN in/IN the/DT IL-2/NN promoter/NN ,/, which/WDT mediates/VBZ signals/NNS downstream/RB of/IN T/NN cell/NN activation/NN ./. 
UI/LS -/: 95127261/CD 
TI/LS -/: Alternate/JJ immune/JJ system/NN targets/VBZ for/IN TCDD/NN :/: lymphocyte/NN stem/NN cells/NNS and/CC extrathymic/JJ T-cell/NN development/NN ./. 
AB/LS -/: We/PRP here/RB summarize/VBP evidence/NN that/IN thymic/JJ atrophy/NN induced/VBN by/IN 2,3,7,8-tetrachlorodibenzo-p-dioxin/NN (/( TCDD/NN )/) can/MD be/VB mediated/VBN ,/, at/IN least/JJS in/IN part/NN ,/, by/IN damage/NN to/TO extrathymic/JJ T-cell/NN precursors/NNS in/IN bone/NN marrow/NN and/CC fetal/JJ liver/NN ./. 
This/DT atrophy/NN induction/NN does/VBZ not/RB involve/VB apoptotic/JJ mechanisms/NNS in/IN thymocytes/NNS affected/VBN by/IN the/DT bcl-2/NN proto-oncogene/NN ./. 
TCDD/NN mediates/VBZ atrophy/NN induction/NN through/IN its/PRP$ specific/JJ receptor/NN (/( the/DT AhR/NN )/) and/CC not/RB through/IN effects/NNS on/IN the/DT estrogen/NN receptor/NN ./. 
Both/CC TCDD/NN and/CC estradiol/NN induce/VBP extrathymic/JJ T-cell/NN differentiation/NN in/IN the/DT liver/NN ./. 
These/DT extrathymic/JJ T-cell/NN populations/NNS include/VBP cells/NNS expressing/VBG elevated/JJ levels/NNS of/IN V/NN beta/NN T-cell/NN receptors/NNS that/WDT are/VBP normally/RB deleted/VBN in/IN thymic/JJ development/NN ./. 
UI/LS -/: 97152553/CD 
TI/LS -/: Identification/NN of/IN Bcd/NN ,/, a/DT novel/JJ proto-oncogene/NN expressed/VBN in/IN B-cells/NNS ./. 
AB/LS -/: A/DT novel/JJ B-cell/NN derived/JJ (/( Bcd/NN )/) oncogene/NN has/VBZ been/VBN isolated/VBN from/IN the/DT peripheral/JJ blood/NN lymphocytes/NNS of/IN one/CD B-cell/NN chronic/JJ lymphocytic/JJ leukemia/NN (/( B-CLL/NN )/) patient/NN using/VBG DNA/NN transfer/NN and/CC a/DT mouse/NN tumorigenicity/NN assay/NN ./. 
The/DT Bcd/NN proto-oncogene/NN was/VBD activated/VBN by/IN a/DT truncation/NN in/IN the/DT 5'/JJ UTR/NN ./. 
It/PRP predicts/VBZ for/IN two/CD open/JJ reading/NN frames/NNS (/( ORFs/NNS )/) ./. 
ORF1/NN consists/VBZ of/IN 240/CD bp/NN that/WDT would/MD encode/VB 80/CD amino/NN acids/NNS ,/, while/IN the/DT major/JJ ORF2/NN consists/VBZ of/IN 648/CD bp/NN capable/JJ of/IN coding/VBG for/IN 216/CD amino/NN acids/NNS ./. 
Predicted/VBN peptide/NN sequence/NN of/IN ORF2/NN contained/VBD a/DT zinc/NN finger/NN domain/NN which/WDT showed/VBD significant/JJ homology/NN to/TO GC/NN box/NN binding/NN proteins/NNS BTEB2/NN and/CC SP1/NN ./. 
Transfection/NN of/IN an/DT expression/NN vector/NN containing/VBG ORF2/NN but/CC not/RB full/JJ length/NN cDNA/NN was/VBD able/JJ to/TO transform/VB NIH3T3/NN cells/NNS and/CC induce/VB tumors/NNS in/IN nude/JJ mice/NNS ./. 
Bcd/NN mRNA/NN transcripts/NNS of/IN </JJR or/CC =/JJ 2.6/CD kb/NN were/VBD selectively/RB expressed/VBN in/IN PBL/NN and/CC testis/NN of/IN healthy/JJ individuals/NNS ./. 
Within/IN the/DT PBL/NN ,/, Bcd/NN gene/NN expression/NN was/VBD restricted/JJ to/TO CD19+/JJ B-cells/NNS and/CC absent/JJ from/IN CD14+/JJ monocytes/NNS and/CC T-cells/NNS ./. 
Bcd/NN transcripts/NNS were/VBD detected/VBN in/IN all/DT normal/JJ PBL/NN samples/NNS tested/VBN but/CC not/RB in/IN several/JJ malignant/JJ human/JJ B-cell/NN lines/NNS and/CC not/RB in/IN 50/CD %/NN of/IN B-cells/NNS from/IN B-CLL/NN patients/NNS ./. 
However/RB ,/, stimulation/NN of/IN B-cells/NNS from/IN B-CLL/NN patients/NNS under/IN conditions/NNS which/WDT induced/VBD differentiation/NN into/IN plasma/NN cells/NNS was/VBD associated/VBN with/IN induction/NN of/IN Bcd/NN gene/NN expression/NN ./. 
The/DT Bcd/NN gene/NN may/MD therefore/RB play/VB an/DT important/JJ role/NN in/IN B-cell/NN growth/NN and/CC development/NN ./. 
UI/LS -/: 97131823/CD 
TI/LS -/: A/DT novel/JJ SP-1/NN site/NN in/IN the/DT human/JJ interleukin-1/NN beta/NN promoter/NN confers/VBZ preferential/JJ transcriptional/JJ activity/NN in/IN keratinocytes/NNS ./. 
AB/LS -/: To/TO investigate/VB the/DT mechanisms/NNS of/IN transcriptional/JJ activation/NN of/IN interleukin-1beta/NN (/( IL-1beta/NN )/) in/IN non-monocytic/JJ cells/NNS ,/, we/PRP constructed/VBD a/DT series/NN of/IN reporter/NN plasmids/NNS with/IN the/DT bacterial/JJ chloramphenicol/NN acetyltransferase/NN gene/NN linked/VBN to/TO various/JJ parts/NNS of/IN the/DT human/JJ IL-1beta/NN promoter/NN and/CC performed/VBD transient/JJ transfection/NN experiments/NNS ./. 
We/PRP identified/VBD a/DT promoter/NN segment/NN that/WDT activates/VBZ transcription/NN most/RBS efficiently/RB in/IN keratinocytes/NNS ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS (/( EMSA/NN )/) with/IN a/DT 43-mer/NN oligonucleotide/NN derived/VBN from/IN the/DT functionally/RB identified/VBN cis-acting/JJ element/NN revealed/VBD specific/JJ complexes/NNS ./. 
By/IN competition/NN analysis/NN with/IN transcription/NN factor/NN consensus/NN sequence/NN oligonucleotides/NNS and/CC by/IN immunosupershift/NN ,/, transcription/NN factor/NN SP-1/NN or/CC a/DT closely/RB related/JJ protein/NN was/VBD shown/VBN to/TO bind/VBP to/TO this/DT regulatory/JJ element/NN ./. 
The/DT closest/JJS match/NN to/TO the/DT known/VBN SP-1/NN consensus/NN sequence/NN within/IN the/DT respective/JJ region/NN is/VBZ a/DT TCCCCTCCCCT/NN motif/NN ./. 
Mutation/NN of/IN this/DT motif/NN almost/RB completely/RB ,/, and/CC specifically/RB ,/, abolished/VBD the/DT binding/NN of/IN two/CD low-mobility/JJ complexes/NNS and/CC led/VBD to/TO a/DT 95/CD %/NN decrease/NN of/IN constitutive/JJ transcriptional/JJ activation/NN of/IN a/DT reporter/NN construct/NN IL-1beta/NN (/( -170/+108/CD )/) ./. 
Likewise/RB ,/, activation/NN of/IN this/DT reporter/NN construct/NN by/IN tumor/NN necrosis/NN factor-alpha/NN depended/VBD on/IN the/DT SP-1/NN site/NN ./. 
These/DT observations/NNS suggest/VBP that/IN a/DT so-far-unrecognized/JJ SP-1/NN site/NN in/IN the/DT human/JJ IL-1beta/NN promoter/NN may/MD participate/VB in/IN the/DT transcriptional/JJ regulation/NN of/IN this/DT gene/NN in/IN keratinocytes/NNS ./. 
UI/LS -/: 97108656/CD 
TI/LS -/: Expression/NN of/IN Egr-1/NN correlates/VBZ with/IN the/DT transformed/VBN phenotype/NN and/CC the/DT type/NN of/IN viral/JJ latency/NN in/IN EBV/NN genome/NN positive/JJ lymphoid/JJ cell/NN lines/NNS ./. 
AB/LS -/: In/IN this/DT paper/NN we/PRP have/VBP investigated/VBN the/DT role/NN of/IN Egr-1/NN in/IN B/NN cell/NN growth/NN regulation/NN by/IN examining/VBG the/DT gene/NN expression/NN in/IN a/DT panel/NN of/IN B/NN cell/NN lines/NNS ,/, including/VBG both/CC EBV/NN genome/NN negative/JJ and/CC EBV/NN carrying/VBG cell/NN lines/NNS ./. 
Egr-1/NN expression/NN correlates/VBZ with/IN the/DT cellular/JJ phenotype/NN and/CC the/DT specific/JJ pattern/NN of/IN viral/JJ latency/NN established/VBN within/IN the/DT individual/JJ cell/NN lines/NNS ./. 
Thus/RB ,/, constitutive/JJ activation/NN of/IN Egr-1/NN gene/NN is/VBZ invariably/RB associated/VBN with/IN unrestricted/JJ expression/NN of/IN viral/JJ latent/JJ genes/NNS in/IN all/DT group/NN III/CD EBV/NN genome/NN carrying/VBG cell/NN lines/NNS ./. 
In/IN contrast/NN ,/, Egr-1/NN expression/NN is/VBZ abrogated/VBN in/IN group/NN I/NN Burkitt/NN tumor/NN cells/NNS ,/, irrespective/JJ of/IN the/DT EBV/NN genome/NN carrying/NN status/NN ./. 
Activated/VBN viral/JJ gene/NN expression/NN associated/VBN with/IN phenotypic/JJ conversion/NN of/IN group/NN I/NN cell/NN lines/NNS in/IN to/TO group/NN II/CD or/CC III/CD restores/VBZ the/DT Egr-1/NN gene/NN expression/NN ./. 
Several/JJ forms/NNS of/IN EGR-1/JJ protein/NN are/VBP found/VBN within/IN the/DT different/JJ groups/NNS of/IN cell/NN lines/NNS ,/, and/CC the/DT binding/NN activity/NN to/TO DNA/NN consensus/NN sequences/NNS was/VBD investigated/VBN ./. 
Finally/RB ,/, time/NN course/NN analysis/NN of/IN Egr-1/NN expression/NN during/IN the/DT early/JJ steps/NNS of/IN EBV/NN infection/NN in/FW vitro/FW demonstrated/VBD that/IN Egr-1/NN is/VBZ upregulated/VBN within/IN minutes/NNS from/IN the/DT initial/JJ interaction/NN with/IN the/DT B/NN lymphocyte/NN ./. 
UI/LS -/: 97182946/CD 
TI/LS -/: Expression/NN of/IN erythroid-specific/JJ genes/NNS in/IN megakaryoblastic/JJ disorders/NNS ./. 
AB/LS -/: Currently/RB available/JJ data/NNS indicate/VBP that/IN erythroid/JJ and/CC megakaryocytic/JJ differentiation/NN pathways/NNS are/VBP closely/RB related/JJ to/TO each/DT other/JJ ,/, and/CC there/EX may/MD exist/VB progenitor/NN cells/NNS common/JJ to/TO those/DT two/CD lineages/NNS may/MD exist/VB ./. 
Acute/JJ megakaryoblastic/JJ leukemia/NN (/( AML-M7/NN )/) and/CC transient/JJ myeloproliferative/JJ disorder/NN in/IN Down/NN 's/POS syndrome/NN (/( TMD/NN )/) are/VBP characterized/VBN by/IN rapid/JJ growth/NN of/IN abnormal/JJ blast/NN cells/NNS which/WDT express/VBP megakaryocytic/JJ markers/NNS ./. 
These/DT blast/NN cells/NNS express/VBP lineage-specific/JJ transcription/NN factors/NNS such/JJ as/IN GATA-1/NN common/JJ to/TO these/DT lineages/NNS and/CC frequently/RB express/VBP erythroid-specific/JJ mRNAs/NNS such/JJ as/IN gamma-globin/NN and/CC erythroid/JJ delta-aminolevulinate/NN synthase/NN (/( ALAS-E/NN )/) ,/, indicating/VBG that/IN most/JJS of/IN the/DT blasts/NNS in/IN M7/NN and/CC TMD/NN cases/NNS have/VBP erythroid/JJ and/CC megakaryocytic/JJ phenotypes/NNS ./. 
These/DT results/NNS suggest/VBP that/IN blasts/NNS in/IN M7/NN and/CC TMD/NN may/MD correspond/VB to/TO progenitors/NNS of/IN both/CC erythroid/JJ and/CC megakaryocytic/JJ lineages/NNS ./. 
UI/LS -/: 97066996/CD 
TI/LS -/: Stat3/NN recruitment/NN by/IN two/CD distinct/JJ ligand-induced/JJ ,/, tyrosine-phosphorylated/JJ docking/NN sites/NNS in/IN the/DT interleukin-10/NN receptor/NN intracellular/JJ domain/NN ./. 
AB/LS -/: Recent/JJ work/NN has/VBZ shown/VBN that/IN IL-10/NN induces/VBZ activation/NN of/IN the/DT JAK-STAT/NN signaling/NN pathway/NN ./. 
To/TO define/VB the/DT mechanism/NN underlying/VBG signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) protein/NN recruitment/NN to/TO the/DT interleukin/NN 10/CD (/( IL-10/NN )/) receptor/NN ,/, the/DT STAT/NN proteins/NNS activated/VBN by/IN IL-10/NN in/IN different/JJ cell/NN populations/NNS were/VBD first/RB defined/VBN using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS ./. 
In/IN all/DT cells/NNS tested/VBN ,/, IL-10/NN activated/VBD Stat1/NN and/CC Stat3/NN and/CC induced/VBD the/DT formation/NN of/IN three/CD distinct/JJ DNA/NN binding/NN complexes/NNS that/WDT contained/VBD different/JJ combinations/NNS of/IN these/DT two/CD transcription/NN factors/NNS ./. 
IL-10/NN also/RB activated/VBD Stat5/NN in/IN Ba/F3/NN cells/NNS that/IN stably/RB expressed/VBD the/DT murine/JJ IL-10/NN receptor/NN ./. 
Using/VBG a/DT structure-function/JJ mutagenesis/NN approach/NN ,/, two/CD tyrosine/NN residues/NNS (/( Tyr427/NN and/CC Tyr477/NN )/) in/IN the/DT intracellular/JJ domain/NN of/IN the/DT murine/JJ IL-10/NN receptor/NN were/VBD found/VBN to/TO be/VB redundantly/RB required/VBN for/IN receptor/NN function/NN and/CC for/IN activation/NN of/IN Stat3/NN but/CC not/RB for/IN Stat1/NN or/CC Stat5/NN ./. 
Twelve/CD amino/NN acid/NN peptides/NNS encompassing/VBG either/DT of/IN these/DT two/CD tyrosine/NN residues/NNS in/IN phosphorylated/JJ form/NN coprecipitated/VBD Stat3/NN but/CC not/RB Stat1/NN and/CC blocked/VBD IL-10-induced/JJ Stat3/NN phosphorylation/NN in/IN a/DT cell-free/JJ system/NN ./. 
In/IN contrast/NN ,/, tyrosine-phosphorylated/JJ peptides/NNS containing/VBG Tyr374/NN or/CC Tyr396/NN did/VBD not/RB interact/VB with/IN Stat3/NN or/CC block/VB Stat3/NN activation/NN ./. 
These/DT data/NNS demonstrate/VBP that/IN Stat3/NN but/CC not/RB Stat1/NN or/CC Stat5/NN is/VBZ directly/RB recruited/VBN to/TO the/DT ligand-activated/JJ IL-10/NN receptor/NN by/IN binding/VBG to/TO specific/JJ but/CC redundant/JJ receptor/NN intracellular/JJ domain/NN sequences/NNS containing/VBG phosphotyrosine/NN ./. 
This/DT study/NN thus/RB supports/VBZ the/DT concept/NN that/IN utilization/NN of/IN distinct/JJ STAT/NN proteins/NNS by/IN different/JJ cytokine/NN receptors/NNS is/VBZ dependent/JJ on/IN the/DT expression/NN of/IN particular/JJ ligand-activatable/JJ ,/, tyrosine-containing/JJ STAT/NN docking/NN sites/NNS in/IN receptor/NN intracellular/JJ domains/NNS ./. 
UI/LS -/: 97057230/CD 
TI/LS -/: Silencing/NN of/IN human/JJ fetal/JJ globin/NN expression/NN is/VBZ impaired/JJ in/IN the/DT absence/NN of/IN the/DT adult/JJ beta-globin/IN gene/NN activator/NN protein/NN EKLF/NN ./. 
AB/LS -/: Globin/NN genes/NNS are/VBP subject/JJ to/TO tissue-specific/JJ and/CC developmental/JJ stage-specific/JJ regulation/NN ./. 
A/DT switch/NN from/IN human/JJ fetal/JJ (/( gamma/NN )/) -to/TO adult/JJ (/( beta/NN )/) -globin/NN expression/NN occurs/VBZ within/IN erythroid/JJ precursor/JJ cells/NNS of/IN the/DT adult/JJ lineage/NN ./. 
Previously/RB we/PRP and/CC others/NNS showed/VBD by/IN targeted/VBN gene/NN disruption/NN that/IN the/DT zinc/NN finger/NN gene/NN ,/, erythroid/JJ Kruppel-like/JJ factor/NN (/( EKLF/NN )/) ,/, is/VBZ required/VBN for/IN expression/NN of/IN the/DT beta-globin/NN gene/NN in/IN mice/NNS ,/, presumably/RB through/IN interaction/NN with/IN a/DT high-affinity/JJ binding/VBG site/NN in/IN the/DT proximal/JJ promoter/NN ./. 
To/TO examine/VB the/DT role/NN of/IN EKLF/NN in/IN the/DT developmental/JJ regulation/NN of/IN the/DT human/JJ gamma-globin/NN gene/NN we/PRP interbred/VBD EKLF/NN heterozygotes/NNS (/( +/-/CC )/) with/IN mice/NNS harboring/VBG a/DT human/JJ beta-globin/NN yeast/NN artificial/JJ chromosome/NN transgene/NN ./. 
We/PRP find/VBP that/IN in/IN the/DT absence/NN of/IN EKLF/NN ,/, while/IN human/JJ beta-globin/NN expression/NN is/VBZ dramatically/RB reduced/VBN ,/, gamma-globin/NN transcripts/NNS are/VBP elevated/JJ approximately/RB 5-fold/RB ./. 
Impaired/JJ silencing/NN of/IN gamma-globin/NN expression/NN identifies/VBZ EKLF/NN as/IN the/DT first/JJ transcription/NN factor/NN participating/VBG quantitatively/RB in/IN the/DT gamma-globin/NN to/TO beta-globin/NN switch/NN ./. 
Our/PRP$ findings/NNS are/VBP compatible/JJ with/IN a/DT competitive/JJ model/NN of/IN switching/NN in/IN which/WDT EKLF/NN mediates/VBZ an/DT adult/JJ stage-specific/JJ interaction/NN between/IN the/DT beta-globin/NN gene/NN promoter/NN and/CC the/DT locus/NN control/NN region/NN that/WDT excludes/VBZ the/DT gamma-globin/NN gene/NN ./. 
UI/LS -/: 97135341/CD 
TI/LS -/: Stimulation/NN of/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS by/IN zinc/NN and/CC related/JJ cations/NNS ./. 
AB/LS -/: Zinc/NN is/VBZ an/DT important/JJ trace/NN element/NN for/IN immune/JJ function/NN ./. 
Here/RB ,/, we/PRP show/VBP that/IN zinc/NN addition/NN in/IN a/DT serum-/NN and/CC lipopolysaccharide-free/JJ cell/NN culture/NN system/NN leads/VBZ to/TO significantly/RB enhanced/JJ levels/NNS of/IN interleukin/NN 1/CD beta/NN (/( IL-1/NN beta/NN )/) and/CC tumour/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) and/CC to/TO expression/NN of/IN the/DT corresponding/JJ mRNA/NN in/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NN )/) ./. 
Structurally/RB related/JJ divalent/JJ cations/NNS like/IN cobalt/NN ,/, nickel/NN ,/, and/CC mercury/NN also/RB partially/RB increase/VBP monokine/NN secretion/NN but/CC to/TO a/DT much/RB lower/JJR and/CC thus/RB insignificant/JJ extent/NN ./. 
They/PRP fail/VBP to/TO induce/VB mRNA/NN of/IN TNF-alpha/NN after/IN 3/CD h/NN of/IN culture/NN ./. 
Therefore/RB ,/, monokine/NN induction/NN is/VBZ a/DT zinc-specific/JJ effect/NN influenced/VBN by/IN the/DT physicochemical/JJ properties/NNS of/IN the/DT ion/NN ./. 
Confirmation/NN of/IN the/DT unique/JJ significance/NN of/IN zinc/NN for/IN immune/JJ function/NN provides/VBZ a/DT better/JJR understanding/NN of/IN the/DT mechanisms/NNS of/IN specific/JJ zinc-mediated/JJ immune/JJ modulation/NN ./. 
UI/LS -/: 96437028/CD 
TI/LS -/: E3/NN ,/, a/DT hematopoietic-specific/JJ transcript/NN directly/RB regulated/VBN by/IN the/DT retinoic/JJ acid/NN receptor/NN alpha/NN ./. 
AB/LS -/: Retinoic/JJ acid/NN (/( RA/NN )/) -induced/JJ maturation/NN mediated/VBN by/IN the/DT retinoic/JJ acid/NN receptor/NN alpha/NN (/( RAR/NN alpha/NN )/) has/VBZ been/VBN implicated/VBN in/IN myeloid/JJ development/NN ./. 
We/PRP have/VBP used/VBN differential/JJ hybridization/NN analysis/NN of/IN a/DT cDNA/NN library/NN constructed/VBN from/IN the/DT murine/JJ RA-inducible/JJ MPRO/NN promyelocyte/NN cell/NN line/NN to/TO identify/VB immediate-early/JJ genes/NNS induced/VBN by/IN RA/NN during/IN granulocytic/JJ differentiation/NN ./. 
E3/NN ,/, one/CD of/IN nine/CD sequences/NNS identified/VBN ,/, was/VBD upregulated/VBN in/IN an/DT immediate-early/JJ manner/NN ,/, with/IN transcript/NN levels/NNS peaking/VBG after/IN 60/CD minutes/NNS exposure/NN to/TO RA/NN ./. 
E3/NN transcripts/NNS were/VBD RA-inducible/JJ in/IN HL60/NN cells/NNS ,/, but/CC not/RB in/IN an/DT RA-resistant/JJ subclone/NN ,/, HL60R/NN ,/, that/WDT harbors/VBZ a/DT mutated/VBN RAR/NN alpha/NN gene/NN ./. 
However/RB ,/, when/WRB HL60R/NN cells/NNS were/VBD transduced/VBN with/IN a/DT functional/JJ copy/NN of/IN the/DT RAR/NN alpha/NN gene/NN ,/, RA/NN induced/VBD a/DT 10-fold/JJ increase/NN in/IN E3/NN mRNA/NN levels/NNS ./. 
E3/NN transcripts/NNS are/VBP present/JJ in/IN the/DT myeloid/JJ ,/, B-lymphoid/JJ ,/, and/CC erythroid/JJ lineages/NNS ,/, absent/JJ in/IN nonhematopoietic/JJ cells/NNS ,/, and/CC encode/VBP a/DT highly/RB hydrophobic/JJ ,/, potentially/RB phosphorylated/VBN polypeptide/NN of/IN unknown/JJ function/NN with/IN significant/JJ homology/NN to/TO a/DT putative/JJ protein/NN expressed/VBN in/IN myeloid/JJ cells/NNS ./. 
The/DT murine/JJ E3/NN promoter/NN harbors/VBZ a/DT single/JJ bipartite/JJ retinoic/JJ acid/NN response/NN element/NN which/WDT in/IN transient/NN transfection/NN assays/NNS conferred/VBD RA/NN sensitivity/NN ./. 
These/DT results/NNS indicate/VBP that/IN E3/NN is/VBZ a/DT hematopoietic-specific/JJ gene/NN that/WDT is/VBZ an/DT immediate/JJ target/NN for/IN the/DT activated/VBN RAR/NN alpha/NN during/IN myelopoiesis/NN ./. 
UI/LS -/: 96399059/CD 
TI/LS -/: Multifactor/JJ cis-dominant/JJ negative/JJ regulation/NN of/IN IL-2/NN gene/NN expression/NN in/IN anergized/VBN T/NN cells/NNS ./. 
AB/LS -/: The/DT molecular/JJ mechanism/NN underlying/VBG IL-2/NN transcriptional/JJ blockade/NN in/IN anergic/JJ T/NN cell/NN clones/NNS is/VBZ not/RB fully/RB understood/VBN ./. 
To/TO examine/VB whether/IN an/DT active/JJ negative/JJ regulatory/JJ process/NN occurs/VBZ ,/, we/PRP created/VBD a/DT reporter/NN construct/NN containing/VBG as/IN an/DT enhancer/NN four/CD copies/NNS of/IN the/DT NF-AT/NN site/NN and/CC one/CD copy/NN of/IN the/DT octamer/NN site/NN (/( 4X/NN NF-AT-Oct/NN )/) ./. 
This/DT construct/NN was/VBD only/RB slightly/RB reduced/VBN (/( 1.3-fold/RB )/) in/IN its/PRP$ expression/NN when/WRB stimulated/VBN under/IN anergic/JJ conditions/NNS ,/, while/IN a/DT whole/JJ mouse/NN IL-2/NN enhancer/NN construct/NN showed/VBD a/DT reduction/NN of/IN 4.3-fold/JJ ./. 
Addition/NN of/IN the/DT -176/CD to/TO -96/CD sequence/NN to/TO the/DT 4X/NN NF-AT-Oct/NN construct/NN did/VBD not/RB impart/VB the/DT ability/NN to/TO be/VB affected/VBN by/IN anergy/NN ,/, but/CC addition/NN of/IN the/DT -236/CD to/TO -96/CD sequence/NN did/VBD ,/, demonstrating/VBG that/IN anergy/NN is/VBZ an/DT active/JJ inhibitory/JJ process/NN and/CC that/IN more/JJR than/IN the/DT presence/NN of/IN the/DT -150/CD AP-1/NN binding/NN site/NN (/( -152/CD to/TO -147/CD )/) is/VBZ required/VBN to/TO mediate/VB the/DT effect/NN ./. 
Mutational/JJ studies/NNS of/IN the/DT -236/CD to/TO -96/CD sequence/NN indicated/VBD that/IN the/DT presence/NN of/IN both/CC the/DT -130/CD AP-1-like/JJ site/NN (/( -187/CD to/TO -181/CD )/) and/CC the/DT -150/CD proximal/JJ AP-1/NN site/NN were/VBD necessary/JJ to/TO observe/VB anergy/NN ./. 
Because/IN the/DT -180/CD site/NN is/VBZ not/RB required/VBN for/IN trans-activation/NN ,/, it/PRP was/VBD possible/JJ to/TO confirm/VB by/IN mutation/NN in/IN the/DT normal/JJ mouse/NN IL-2/NN enhancer/NN that/IN this/DT site/NN is/VBZ absolutely/RB essential/JJ for/IN anergy/NN induction/NN ./. 
The/DT simplest/JJS model/NN to/TO explain/VB these/DT results/NNS is/VBZ that/IN anergy/NN is/VBZ mediated/VBN by/IN a/DT complex/NN of/IN multiple/JJ transcription/NN factors/NNS that/WDT exert/VBP a/DT cis-acting/JJ dominant/JJ negative/JJ regulatory/JJ effect/NN on/IN the/DT trans-activation/NN of/IN the/DT IL-2/NN gene/NN ./. 
UI/LS -/: 96409274/CD 
TI/LS -/: Severe/JJ combined/JJ immunodeficiency/NN due/IN to/TO defective/JJ binding/NN of/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS in/IN T/NN lymphocytes/NNS of/IN two/CD male/JJ siblings/NNS ./. 
AB/LS -/: Peripheral/JJ blood/NN lymphocytes/NNS (/( PBL/NN )/) and/CC alloreactive/JJ T/NN cell/NN lines/NNS of/IN two/CD male/JJ infants/NNS born/VBN to/TO consanguinous/JJ parents/NNS and/CC presenting/VBG with/IN severe/JJ combined/JJ immunodeficiency/NN (/( SCID/NN )/) showed/VBD a/DT pronounced/JJ deficiency/NN in/IN T/NN cell/NN activation/NN ./. 
Although/IN phenotypically/RB normal/JJ ,/, the/DT proliferative/JJ response/NN of/IN the/DT childrens/NNS '/POS T/NN cells/NNS was/VBD strongly/RB reduced/VBN but/CC could/MD be/VB improved/VBN by/IN the/DT addition/NN of/IN interleukin-2/NN (/( IL-2/NN )/) ./. 
Furthermore/RB both/DT childrens/NNS '/POS T/NN cells/NNS were/VBD unable/JJ to/TO produce/VB the/DT cytokines/NNS IL-2/NN ,/, interferon-gamma/NN (/( IFN-gamma/NN )/) ,/, IL-4/NN and/CC tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) ./. 
This/DT multiple/JJ cytokine/NN production/NN deficiency/NN could/MD not/RB be/VB restored/VBN by/IN IL-2/NN or/CC co-stimulatory/JJ signals/NNS provided/VBN by/IN antigen-presenting/JJ cells/NNS (/( APC/NN )/) ./. 
Moreover/RB ,/, mRNA/NN for/IN IL-2/NN and/CC IFN-gamma/NN could/MD not/RB be/VB detected/VBN ./. 
In/IN contrast/NN ,/, expression/NN of/IN the/DT activation-dependent/JJ cell/NN surface/NN markers/NNS CD25/NN and/CC CD69/NN was/VBD within/IN normal/JJ limits/NNS ./. 
To/TO determine/VB whether/IN the/DT functional/JJ defect/NN of/IN the/DT patients/NNS '/POS T/NN cells/NNS was/VBD due/JJ to/TO the/DT absence/NN or/CC abnormal/JJ binding/NN of/IN transcription/NN factors/NNS involved/VBN in/IN cytokine/NN gene/NN expression/NN ,/, electrophoretic/JJ mobility/NN shift/NN assays/NNS were/VBD used/VBN to/TO examine/VB the/DT DNA/NN binding/NN of/IN AP-1/NN ,/, Oct/NN ,/, CREB/NN ,/, SP1/NN ,/, NF-kappa/NN B/NN and/CC the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) to/TO their/PRP$ respective/JJ response/NN elements/NNS in/IN the/DT promoter/NN of/IN the/DT IL-2/NN gene/NN ./. 
Whereas/IN AP-1/NN ,/, NF-kappa/NN B/NN ,/, Oct/NN ,/, CREB/NN and/CC SP1/NN displayed/VBD normal/JJ binding/NN activities/NNS in/IN nuclear/JJ extracts/NNS ,/, the/DT binding/NN of/IN NF-AT/NN to/TO its/PRP$ IL-2/NN promoter/NN response/NN element/NN was/VBD barely/RB detectable/JJ both/CC before/IN and/CC after/IN T/NN cell/NN stimulation/NN ./. 
Our/PRP$ results/NNS strongly/RB suggest/VBP that/IN this/DT NF-AT/DNA/NN binding/NN defect/NN is/VBZ responsible/JJ for/IN the/DT multiple/JJ cytokine/NN deficiency/NN and/CC the/DT SCID/NN phenotype/NN observed/VBN in/IN the/DT two/CD infant/JJ brothers/NNS ./. 
UI/LS -/: 96323085/CD 
TI/LS -/: oriP/NN is/VBZ essential/JJ for/IN EBNA/NN gene/NN promoter/NN activity/NN in/IN Epstein-Barr/JJ virus-immortalized/JJ lymphoblastoid/JJ cell/NN lines/NNS ./. 
AB/LS -/: During/IN Epstein-Barr/JJ virus/NN latent/JJ infection/NN of/IN B/NN lymphocytes/NNS in/FW vitro/FW ,/, six/CD viral/JJ nuclear/JJ antigens/NNS (/( EBNAs/NN )/) are/VBP expressed/VBN from/IN one/CD of/IN two/CD promoters/NNS ,/, Cp/NN or/CC Wp/NN ,/, whose/WP$ activities/NNS are/VBP mutually/RB exclusive/JJ ./. 
Upon/IN infection/NN ,/, Wp/NN is/VBZ initially/RB active/JJ ,/, followed/VBN by/IN a/DT switch/NN to/TO Cp/NN for/IN the/DT duration/NN of/IN latency/NN ./. 
In/IN this/DT study/NN ,/, the/DT region/NN upstream/JJ of/IN Cp/NN was/VBD analyzed/VBN for/IN the/DT presence/NN of/IN cis/NN elements/NNS involved/VBN in/IN regulating/VBG the/DT activities/NNS of/IN the/DT EBNA/NN gene/NN promoters/NNS in/IN established/JJ in/FW vitro/FW immortalized/VBN lymphoblastoid/JJ cell/NN lines/NNS (/( LCLs/NNS )/) ./. 
It/PRP was/VBD determined/VBN that/IN oriP/NN ,/, the/DT origin/NN for/IN episomal/JJ maintenance/NN during/IN latency/NN ,/, is/VBZ essential/JJ for/IN efficient/JJ transcription/NN initiation/NN from/IN either/CC Cp/NN or/CC Wp/NN in/IN LCLs/NN ,/, as/RB well/RB as/IN in/IN some/DT Burkitt/NN 's/POS lymphoma/NN cell/NN lines/NNS ./. 
Deletion/NN of/IN the/DT EBNA2-dependent/JJ enhancer/NN located/JJ upstream/RB of/IN Cp/NN resulted/VBD in/IN a/DT ca./FW two-/CD to/TO fivefold/JJ reduction/NN in/IN Cp/NN activity/NN in/IN the/DT LCLs/NNS assayed/VBN ./. 
More/RBR extensive/JJ deletion/NN of/IN sequences/NNS upstream/JJ of/IN Cp/NN ,/, including/VBG the/DT EBNA2-dependent/JJ enhancer/NN ,/, resulted/VBD in/IN nearly/RB complete/JJ loss/NN of/IN Cp/NN activity/NN ./. 
This/DT loss/NN of/IN activity/NN was/VBD shown/VBN to/TO correlate/VB with/IN deletion/NN of/IN two/CD CCAAT/NN boxes/NNS ,/, a/DT proximal/JJ CCAAT/NN box/NN located/JJ at/IN bp/NN -61/CD to/TO -65/CD and/CC a/DT distal/JJ CCAAT/NN box/NN located/JJ at/IN bp/NN -253/CD to/TO -257/CD ,/, upstream/RB of/IN Cp/NN ./. 
Site-directed/JJ mutagenesis/NN of/IN these/DT cis/NN elements/NNS demonstrated/VBD that/IN Cp/NN activity/NN is/VBZ highly/RB dependent/JJ on/IN the/DT presence/NN of/IN a/DT properly/RB positioned/VBN CCAAT/NN box/NN ,/, with/IN the/DT dependence/NN on/IN the/DT distal/JJ CCAAT/NN box/NN apparent/JJ only/RB when/WRB the/DT proximal/JJ CCAAT/NN box/NN was/VBD deleted/VBN or/CC mutated/VBN ./. 
Deletion/NN of/IN the/DT glucocorticoid/NN response/NN elements/NNS located/JJ at/IN ca./FW bp/NN -850/CD upstream/RB of/IN Cp/NN did/VBD not/RB result/VB in/IN a/DT significant/JJ loss/NN in/IN activity/NN ./. 
In/IN general/JJ ,/, deletions/NNS which/WDT diminished/VBD Cp/JJ activity/NN resulted/VBD in/IN induction/NN of/IN Wp/JJ activity/NN ,/, consistent/JJ with/IN suppression/NN of/IN Wp/JJ activity/NN by/IN transcriptional/JJ interference/NN from/IN Cp/NN ./. 
The/DT identification/NN of/IN oriP/NN and/CC the/DT EBNA2-dependent/JJ enhancer/NN as/IN the/DT major/JJ positive/JJ cis/NN elements/NNS involved/VBN in/IN regulating/VBG Cp/JJ activity/NN in/IN LCL/NN suggests/VBZ that/IN EBNA/NN gene/NN transcription/NN is/VBZ largely/RB autoregulated/VBN by/IN EBNA/NN 1/CD and/CC EBNA/NN 2/CD ./. 
UI/LS -/: 96324890/CD 
TI/LS -/: Protein-tyrosine/JJ kinase/NN activation/NN is/VBZ required/VBN for/IN lipopolysaccharide/NN induction/NN of/IN interleukin/NN 1beta/NN and/CC NFkappaB/NN activation/NN ,/, but/CC not/RB NFkappaB/NN nuclear/JJ translocation/NN ./. 
AB/LS -/: In/IN human/JJ monocytes/NNS ,/, interleukin/NN 1beta/NN protein/NN production/NN and/CC steady/JJ state/NN mRNA/NN levels/NNS are/VBP increased/VBN in/IN response/NN to/TO lipopolysaccharide/NN ,/, predominantly/RB as/IN a/DT result/NN of/IN increased/VBN transcription/NN of/IN the/DT interleukin/NN 1beta/NN gene/NN ./. 
Expression/NN of/IN interleukin/NN 1beta/NN and/CC other/JJ cytokines/NNS ,/, such/JJ as/IN interleukin/NN 6/CD and/CC tumor/NN necrosis/NN factor/NN alpha/NN ,/, has/VBZ been/VBN shown/VBN to/TO be/VB dependent/JJ on/IN the/DT activation/NN of/IN the/DT transcription/NN factor/NN ,/, NFkappaB/NN ./. 
Since/IN recent/JJ studies/NNS have/VBP shown/VBN that/IN lipopolysaccharide-induced/JJ tyrosine/NN kinase/NN activation/NN is/VBZ not/RB required/VBN for/IN NFkappaB/NN nuclear/JJ translocation/NN ,/, we/PRP sought/VBD to/TO determine/VB whether/IN NFkappaB/NN translocated/VBN in/IN the/DT absence/NN of/IN tyrosine/NN kinase/NN activity/NN was/VBD active/JJ in/IN stimulating/VBG transcription/NN ./. 
We/PRP have/VBP found/VBN that/IN ,/, in/IN the/DT human/JJ pro-monocytic/JJ cell/NN line/NN ,/, THP-1/NN ,/, the/DT lipopolysaccharide-induced/JJ expression/NN of/IN interleukin/NN 1beta/NN is/VBZ dependent/JJ on/IN tyrosine/NN kinase/NN activation/NN ./. 
Tyrosine/NN kinases/NNS are/VBP not/RB required/VBN for/IN lipopolysaccharide-mediated/JJ nuclear/JJ translocation/NN of/IN NFkappaB/NN ./. 
However/RB ,/, in/IN the/DT absence/NN of/IN tyrosine/NN kinase/NN activity/NN ,/, the/DT ability/NN of/IN NFkappaB/NN to/TO stimulate/VB transcription/NN is/VBZ impaired/JJ ./. 
This/DT inhibition/NN of/IN transcription/NN is/VBZ specific/JJ for/IN NFkappaB/NN ;/: in/IN the/DT absence/NN of/IN tyrosine/NN kinase/NN activity/NN ,/, AP-1-dependent/JJ transcription/NN is/VBZ enhanced/VBN ./. 
These/DT results/NNS suggest/VBP that/IN ,/, while/IN lipopolysaccharide-induced/JJ expression/NN of/IN inflammatory/JJ mediators/NNS requires/VBZ tyrosine/NN kinase/NN activity/NN ,/, tyrosine/NN kinase/NN activity/NN is/VBZ not/RB obligatory/JJ for/IN lipopolysaccharide/NN signal/NN transduction/NN ./. 
UI/LS -/: 96357043/CD 
TI/LS -/: Chronic/JJ human/JJ immunodeficiency/NN virus/NN type/NN 1/CD infection/NN of/IN myeloid/JJ cells/NNS disrupts/VBZ the/DT autoregulatory/JJ control/NN of/IN the/DT NF-kappaB/Rel/NN pathway/NN via/IN enhanced/VBN IkappaBalpha/NN degradation/NN ./. 
AB/LS -/: Productive/JJ human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) infection/NN causes/VBZ sustained/JJ NF-kappaB/NN DNA-binding/JJ activity/NN in/IN chronically/RB infected/VBN monocytic/JJ cells/NNS ./. 
A/DT direct/JJ temporal/JJ correlation/NN exists/VBZ between/IN HIV/NN infection/NN and/CC the/DT appearance/NN of/IN NF-kappaB/NN DNA-binding/JJ activity/NN in/IN myelomonoblastic/JJ PLB-985/NN cells/NNS ./. 
To/TO examine/VB the/DT molecular/JJ basis/NN of/IN constitutive/JJ NF-kappaB/NN DNA-binding/JJ activity/NN in/IN HIV1 -infected/JJ cells/NNS ,/, we/PRP analyzed/VBD the/DT phosphorylation/NN and/CC turnover/NN of/IN IkappaBalpha/NN protein/NN ,/, the/DT activity/NN of/IN the/DT double-stranded/JJ RNA-dependent/JJ protein/NN kinase/NN (/( PKR/NN )/) and/CC the/DT intracellular/JJ levels/NNS of/IN NF-kappaB/NN subunits/NNS in/IN the/DT PLB-985/NN and/CC U937/NN myeloid/JJ cell/NN models/NNS ./. 
HIV-1/NN infection/NN resulted/VBD in/IN constitutive/JJ ,/, low-level/JJ expression/NN of/IN type/NN 1/CD interferon/NN (/( IFN/NN )/) at/IN the/DT mRNA/NN level/NN ./. 
Constitutive/JJ PKR/NN activity/NN was/VBD also/RB detected/VBN in/IN HIV-1-infected/JJ cells/NNS as/IN a/DT result/NN of/IN low-level/JJ IFN/NN production/NN ,/, since/IN the/DT addition/NN of/IN anti-IFN-alpha/beta/JJ antibody/NN to/TO the/DT cells/NNS decreased/VBD PKR/NN expression/NN ./. 
Furthermore/RB ,/, the/DT analysis/NN of/IN IkappaBalpha/NN turnover/NN demonstrated/VBD an/DT increased/VBN degradation/NN of/IN IkappaBalpha/NN in/IN HIV-1-infected/JJ cells/NNS that/WDT may/MD account/VB for/IN the/DT constitutive/JJ DNA/NN binding/NN activity/NN ./. 
A/DT dramatic/JJ increase/NN in/IN the/DT intracellular/JJ levels/NNS of/IN NF-kappaB/NN subunits/NNS c-Rel/NN and/CC NF-kappaB2/NN p100/NN and/CC a/DT moderate/JJ increase/NN in/IN NF-kappaB2/NN p52/NN and/CC RelA/NN (/( p65/NN )/) were/VBD detected/VBN in/IN HIV-1-infected/JJ cells/NNS ,/, whereas/IN NF-kappaB1/NN p105/p50/NN levels/NNS were/VBD not/RB altered/VBN relative/JJ to/TO the/DT levels/NNS in/IN uninfected/JJ cells/NNS ./. 
We/PRP suggest/VBP that/IN HIV-1/NN infection/NN of/IN myeloid/JJ cells/NNS induces/VBZ IFN/NN production/NN and/CC PKR/NN activity/NN ,/, which/WDT in/IN turn/NN contribute/VBP to/TO enhanced/VBN IkappaBalpha/NN phosphorylation/NN and/CC subsequent/JJ degradation/NN ./. 
Nuclear/JJ translocation/NN of/IN NF-kappaB/NN subunits/NNS may/MD ultimately/RB increase/VB the/DT intracellular/JJ pool/NN of/IN NF-kappaB/IkappaBalpha/NN by/IN an/DT autoregulatory/JJ mechanism/NN ./. 
Enhanced/VBN turnover/NN of/IN IkappaBalpha/NN and/CC the/DT accumulation/NN of/IN NF-kappaB/Rel/NN proteins/NNS may/MD contribute/VB to/TO the/DT chronically/RB activated/JJ state/NN of/IN HIV-1-infected/JJ cells/NNS ./. 
UI/LS -/: 96291858/CD 
TI/LS -/: The/DT c-Jun/NN delta-domain/NN inhibits/VBZ neuroendocrine/NN promoter/NN activity/NN in/IN a/DT DNA/NN sequence-/NN and/CC pituitary-specific/JJ manner/NN ./. 
AB/LS -/: The/DT transcription/NN and/CC transformation/NN activity/NN of/IN c-Jun/NN is/VBZ governed/VBN by/IN a/DT 27-amino/JJ acid/NN regulatory/JJ motif/NN ,/, labeled/VBN the/DT delta-domain/NN ,/, which/WDT is/VBZ deleted/VBN in/IN v-Jun/NN ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN c-Jun/NN is/VBZ a/DT potent/JJ inhibitor/NN of/IN the/DT rat/NN prolactin/NN (/( rPRL/NN )/) promoter/NN activity/NN induced/VBN by/IN either/DT oncogenic/JJ Ras/NN or/CC phorbol/NN esters/NNS ./. 
Here/RB ,/, we/PRP have/VBP characterized/VBN the/DT structural/JJ and/CC cell-specific/JJ requirements/NNS for/IN this/DT c-Jun/NN inhibitory/JJ response/NN ,/, and/CC we/PRP show/VBP that/IN this/DT c-Jun/NN inhibitory/JJ response/NN mapped/VBD to/TO the/DT rPRL/NN footprint/NN II/CD repressor/NN site/NN ,/, was/VBD pituitary-specific/JJ and/CC required/VBD the/DT c-Jun/NN delta-domain/NN ./. 
Moreover/RB ,/, alteration/NN of/IN any/DT one/CD of/IN these/DT features/NNS (/( e.g./FW ,/, cis-element/NN ,/, trans-factor/NN ,/, or/CC cell-specific/JJ background/NN )/) switched/VBD c-Jun/NN to/TO a/DT transcriptional/JJ activator/NN of/IN the/DT rPRL/NN promoter/NN ./. 
In/IN HeLa/NN nonpituitary/JJ cells/NNS ,/, c-Jun/NN alone/RB activated/VBD the/DT rPRL/NN promoter/NN via/IN the/DT most/RBS proximal/JJ GHF-1/Pit-1/NN binding/NN site/NN ,/, footprint/NN I/NN ,/, and/CC synergized/VBD with/IN GHF-1/NN ./. 
Finally/RB ,/, recombinant/JJ GHF-1/NN interacted/VBD directly/RB with/IN c-Jun/NN but/CC not/RB c-Fos/NN proteins/NNS ./. 
These/DT data/NNS provide/VBP important/JJ fundamental/JJ insights/NNS into/IN the/DT molecular/NN mechanisms/NNS by/IN which/WDT the/DT c-Jun/NN delta-domain/NN functions/VBZ as/IN a/DT modulatory/JJ switch/NN and/CC further/RB imply/VBP that/IN the/DT functional/JJ role/NN of/IN c-Jun/NN is/VBZ dictated/VBN by/IN cell-specific/JJ influences/NNS and/CC the/DT delta-domain/JJ motif/NN ./. 
UI/LS -/: 96290415/CD 
TI/LS -/: Retinoic/JJ acid/NN activates/VBZ interferon/NN regulatory/JJ factor-1/JJ gene/NN expression/NN in/IN myeloid/JJ cells/NNS ./. 
AB/LS -/: All-trans-retinoic/JJ acid/NN (/( ATRA/NN )/) is/VBZ the/DT drug/NN of/IN choice/NN in/IN the/DT treatment/NN of/IN acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) ./. 
ATRA/NN induces/VBZ both/CC in/FW vitro/FW and/CC in/FW vivo/FW differentiation/NN of/IN APL/NN cells/NNS into/IN mature/JJ granulocytes/NNS ./. 
However/RB ,/, the/DT molecular/JJ mechanisms/NNS involved/VBN in/IN ATRA-dependent/JJ growth/NN inhibition/NN and/CC cellular/JJ differentiation/NN are/VBP not/RB presently/RB understood/VBN ./. 
The/DT NB4/NN cell/NN line/NN ,/, which/WDT is/VBZ derived/VBN from/IN the/DT bone/NN marrow/NN of/IN a/DT patient/NN with/IN APL/NN during/IN relapse/NN ,/, can/MD be/VB used/VBN as/IN a/DT model/JJ system/NN to/TO study/VB the/DT growth/NN and/CC differentiation/NN of/IN APL/NN cells/NNS ./. 
Because/IN interferon/NN (/( IFN/NN )/) regulatory/JJ factors/NNS (/( IRF-1/NN and/CC IRF-2/NN )/) and/CC other/JJ IFN-inducible/JJ gene/NN products/NNS regulate/VBP cell/NN growth/NN ,/, we/PRP analyzed/VBD the/DT effects/NNS of/IN ATRA/NN on/IN the/DT expression/NN of/IN these/DT genes/NNS ./. 
We/PRP show/VBP that/IN ATRA/NN directly/RB activates/VBZ IRF-1/NN gene/NN expression/NN ,/, followed/VBN by/IN activation/NN of/IN IRF-2/NN and/CC 2'-5'/JJ oligoadenylate/NN synthetase/NN (/( OAS/NN )/) gene/NN expression/NN with/IN slower/JJR kinetics/NNS ./. 
In/IN addition/NN to/TO NB4/NN cells/NNS ,/, ATRA/NN also/RB activated/VBD IRF-1/NN gene/NN expression/NN in/IN HL-60/NN ,/, U937/NN ,/, and/CC THP-1/NN cells/NNS ,/, which/WDT all/DT respond/VBP to/TO ATRA/NN by/IN growth/NN inhibition/NN ./. 
A/DT more/JJR than/IN additive/JJ increase/NN in/IN IRF-1/NN gene/NN expression/NN was/VBD seen/VBN with/IN ATRA/NN and/CC IFN-gamma/NN in/IN NB4/NN cells/NNS ./. 
ATRA/NN did/VBD not/RB activate/VB nuclear/JJ factor/NN kappa/NN B/NN or/CC signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) activation/NN pathways/NNS ,/, suggesting/VBG that/IN an/DT alternate/JJ mechanism/NN is/VBZ involved/VBN in/IN IRF-1/NN gene/NN activation/NN ./. 
The/DT ATRA-induced/JJ expression/NN of/IN IRF-1/NN ,/, an/DT activator/NN of/IN transcription/NN and/CC repressor/NN of/IN transformation/NN ,/, may/MD be/VB one/CD of/IN the/DT molecular/JJ mechanisms/NNS of/IN ATRA-induced/JJ growth/NN inhibition/NN ,/, and/CC the/DT basis/NN for/IN the/DT synergistic/JJ actions/NNS of/IN ATRA/NN and/CC IFNs/NN in/IN myeloid/JJ leukemia/NN cells/NNS ./. 
UI/LS -/: 96251346/CD 
TI/LS -/: Recombinant/JJ NFAT1/NN (/( NFATp/NN )/) is/VBZ regulated/VBN by/IN calcineurin/NN in/IN T/NN cells/NNS and/CC mediates/VBZ transcription/NN of/IN several/JJ cytokine/NN genes/NNS ./. 
AB/LS -/: Transcription/NN factors/NNS of/IN the/DT NFAT/NN family/NN play/VBP a/DT key/JJ role/NN in/IN the/DT transcription/NN of/IN cytokine/NN genes/NNS and/CC other/JJ genes/NNS during/IN the/DT immune/JJ response/NN ./. 
We/PRP have/VBP identified/VBN two/CD new/JJ isoforms/NNS of/IN the/DT transcription/NN factor/NN NFAT1/NN (/( previously/RB termed/VBN NFATp/NN )/) that/WDT are/VBP the/DT predominant/JJ isoforms/NNS expressed/VBN in/IN murine/JJ and/CC human/JJ T/NN cells/NNS ./. 
When/WRB expressed/VBN in/IN Jurkat/NN T/NN cells/NNS ,/, recombinant/JJ NFAT1/NN is/VBZ regulated/VBN ,/, as/IN expected/VBN ,/, by/IN the/DT calmodulin-dependent/JJ phosphatase/NN calcineurin/NN ,/, and/CC its/PRP$ function/NN is/VBZ inhibited/VBN by/IN the/DT immunosuppressive/JJ agent/NN cyclosporin/NN A/NN (/( CsA/NN )/) ./. 
Transactivation/NN by/IN recombinant/JJ NFAT1/NN in/IN Jurkat/NN T/NN cells/NNS requires/VBZ dual/JJ stimulation/NN with/IN ionomycin/NN and/CC phorbol/NN 12-myristate/NN 13-acetate/NN ;/: this/DT activity/NN is/VBZ potentiated/VBN by/IN coexpression/NN of/IN constitutively/RB active/JJ calcineurin/NN and/CC is/VBZ inhibited/VBN by/IN CsA/NN ./. 
Immunocytochemical/JJ analysis/NN indicates/VBZ that/IN recombinant/JJ NFAT1/NN localizes/VBZ in/IN the/DT cytoplasm/NN of/IN transiently/RB transfected/VBN T/NN cells/NNS and/CC translocates/VBZ into/IN the/DT nucleus/NN in/IN a/DT CsA-sensitive/JJ manner/NN following/VBG ionomycin/NN stimulation/NN ./. 
When/WRB expressed/VBN in/IN COS/NN cells/NNS ,/, however/RB ,/, NFAT1/NN is/VBZ capable/JJ of/IN transactivation/NN ,/, but/CC it/PRP is/VBZ not/RB regulated/VBN correctly/RB :/: its/PRP$ subcellular/JJ localization/NN and/CC transcriptional/JJ function/NN are/VBP not/RB affected/VBN by/IN stimulation/NN of/IN the/DT COS/NN cells/NNS with/IN ionomycin/NN and/CC phorbol/NN 12-myristate/NN 13-acetate/NN ./. 
Recombinant/JJ NFAT1/NN can/MD mediate/VB transcription/NN of/IN the/DT interleukin-2/NN ,/, interleukin-4/NN ,/, tumor/NN necrosis/NN factor/NN alpha/NN ,/, and/CC granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN promoters/NNS in/IN T/NN cells/NNS ,/, suggesting/VBG that/IN NFAT1/NN contributes/VBZ to/TO the/DT CsA-sensitive/JJ transcription/NN of/IN these/DT genes/NNS during/IN the/DT immune/JJ response/NN ./. 
UI/LS -/: 97011146/CD 
TI/LS -/: Human/JJ TAFII/NN 105/CD is/VBZ a/DT cell/NN type-specific/JJ TFIID/NN subunit/NN related/JJ to/TO hTAFII130/NN ./. 
AB/LS -/: We/PRP previously/RB characterized/VBD Drosophila/NN and/CC human/JJ TAF/NN subunits/NNS that/WDT make/VBP up/RP the/DT core/NN TFIID/NN complex/NN found/VBN in/IN all/DT cells/NNS ./. 
Here/RB ,/, we/PRP report/VBP that/IN differentiated/VBN B/NN cells/NNS contain/VBP a/DT novel/JJ substoichiometric/JJ TAF/NN of/IN 105/CD kDa/NN not/RB found/VBN associated/VBN with/IN TFIID/NN isolated/VBN from/IN other/JJ cell/NN types/NNS ./. 
The/DT cDNA/NN encoding/NN hTAFII105/NN reveals/VBZ a/DT highly/RB conserved/VBN C-terminal/JJ domain/NN shared/VBN by/IN hTAFII130/NN and/CC oTAFII110/NN ,/, while/IN the/DT N-terminal/JJ coactivator/NN domain/NN has/VBZ diverged/VBN significantly/RB ./. 
All/DT cells/NNS tested/VBN express/VBP TAFII105/NN mRNA/NN ,/, but/CC only/RB B/NN cells/NNS contain/VBP significant/JJ levels/NNS of/IN protein/NN associated/VBN with/IN TFIID/NN ./. 
Transient/JJ overexpression/NN of/IN hTAFII105/NN selectively/RB squelches/VBZ the/DT transcription/NN of/IN some/DT genes/NNS in/IN B/NN cells/NNS ./. 
These/DT properties/NNS suggest/VBP that/IN TAFII105/NN is/VBZ a/DT cell/NN type-specific/JJ subunit/NN of/IN TFIID/NN that/WDT may/MD be/VB responsible/JJ for/IN mediating/VBG transcription/NN by/IN a/DT subset/NN of/IN activators/NNS in/IN B/NN cells/NNS ./. 
UI/LS -/: 96437048/CD 
TI/LS -/: Interstitial/JJ deletion/NN constitutes/VBZ the/DT major/JJ mechanism/NN for/IN loss/NN of/IN heterozygosity/NN on/IN chromosome/NN 20q/NN in/IN polycythemia/NN vera/NN ./. 
AB/LS -/: An/DT acquired/VBN deletion/NN of/IN the/DT long/JJ arm/NN of/IN chromosome/NN 20/CD is/VBZ a/DT recurrent/JJ abnormality/NN in/IN myeloproliferative/JJ disorders/NNS ,/, particularly/RB polycythemia/NN vera/NN and/CC myelodysplastic/JJ syndromes/NNS ./. 
The/DT association/NN of/IN 20q/NN deletions/NNS with/IN myeloid/JJ "/`` stem/NN cell/NN "/'' disorders/NNS suggests/VBZ that/IN the/DT deletions/NNS mark/VBP the/DT site/NN of/IN one/CD or/CC more/JJR genes/NNS ,/, loss/NN or/CC inactivation/NN of/IN which/WDT plays/VBZ a/DT role/NN in/IN the/DT regulation/NN of/IN normal/JJ hematopoietic/JJ progenitors/NNS ./. 
We/PRP have/VBP recently/RB performed/VBN a/DT detailed/JJ molecular/JJ analysis/NN of/IN 20q/JJ deletions/NNS in/IN peripheral/JJ blood/NN (/( PB/NN )/) granulocytes/NNS and/CC defined/VBN a/DT commonly/RB deleted/VBN region/NN of/IN 16/CD to/TO 21/CD centimorgan/NN (/( cM/NN )/) ./. 
To/TO further/RBR reduce/VB the/DT size/NN of/IN the/DT common/JJ deleted/VBN region/NN we/PRP have/VBP searched/VBN for/IN small/JJ deletions/NNS or/CC mitotic/JJ recombination/NN events/NNS ,/, neither/DT of/IN which/WDT would/MD be/VB detected/VBN by/IN conventional/JJ cytogenetics/NNS ./. 
We/PRP have/VBP studied/VBN 48/CD patients/NNS with/IN polycythemia/NN vera/NN and/CC four/CD patients/NNS with/IN idiopathic/JJ myelofibrosis/NN ./. 
In/IN each/DT case/NN ,/, cytogenetic/JJ analysis/NN had/VBD either/RB failed/VBN or/CC had/VBD shown/VBN no/DT abnormalities/NNS of/IN chromosome/NN 20/CD ./. 
Seventeen/CD microsatellite/NN markers/NNS that/WDT span/VBP the/DT common/JJ deleted/VBN region/NN were/VBD used/VBN to/TO search/VB for/IN loss/NN of/IN heterozygosity/NN in/IN granulocyte/NN DNA/NN ./. 
No/DT instance/NN of/IN microsatellite/NN instability/NN was/VBD observed/VBN in/IN a/DT total/NN of/IN 880/CD comparisons/NNS of/IN granulocyte/NN and/CC T-cell/NN DNA/NN ./. 
Granulocyte/NN DNA/NN from/IN four/CD patients/NNS exhibited/VBD allele/NN loss/NN on/IN 20q/NN ./. 
In/IN each/DT case/NN the/DT allele/NN loss/NN was/VBD caused/VBN by/IN an/DT interstitial/JJ deletion/NN because/IN heterozygosity/NN at/IN distal/JJ markers/NNS was/VBD retained/VBN and/CC because/IN quantitative/JJ Southern/NN blotting/NN demonstrated/VBD hemizygosity/NN ./. 
Loss/NN of/IN heterozygosity/NN in/IN PB/NN granulocytes/NNS would/MD be/VB masked/VBN by/IN the/DT presence/NN of/IN significant/JJ numbers/NNS of/IN normal/JJ granulocytes/NNS not/RB derived/VBN from/IN the/DT malignant/JJ clone/NN ./. 
Therefore/RB ,/, the/DT human/JJ androgen/NN receptor/NN assay/NN (/( HUMARA/NN )/) was/VBD used/VBN to/TO determine/VB granulocyte/NN clonality/NN ./. 
In/IN 21/CD of/IN 27/CD informative/JJ female/NN patients/NNS the/DT majority/NN of/IN the/DT granulocytes/NNS were/VBD clonally/RB derived/VBN ./. 
In/IN 5/CD patients/NNS the/DT granulocytes/NNS appeared/VBD polyclonal/JJ and/CC in/IN 1/CD patient/NN unilateral/JJ X/NN inactivation/NN was/VBD observed/VBN in/IN both/CC granulocytes/NNS and/CC T/JJ cells/NNS ./. 
These/DT results/NNS show/VBP that/IN ,/, in/IN the/DT vast/JJ majority/NN of/IN patients/NNS presented/VBN here/RB ,/, the/DT failure/NN to/TO detect/VB loss/NN of/IN heterozygosity/NN can/MD not/RB be/VB attributed/VBN to/TO the/DT presence/NN of/IN normal/JJ polyclonal/JJ granulocytes/NNS ./. 
Our/PRP$ results/NNS therefore/RB show/VBP that/IN allele/NN loss/NN on/IN chromosome/NN 20q/NN in/IN polycythemia/NN vera/NN does/VBZ not/RB commonly/RB involve/VB mitotic/JJ recombination/NN or/CC chromosome/NN loss/NN and/CC that/IN microsatellite/NN instability/NN is/VBZ a/DT rare/JJ event/NN in/IN this/DT disorder/NN ./. 
UI/LS -/: 96420243/CD 
TI/LS -/: Interleukin-6/NN promotes/VBZ multiple/JJ myeloma/NN cell/NN growth/NN via/IN phosphorylation/NN of/IN retinoblastoma/NN protein/NN ./. 
AB/LS -/: Interleukin-6/NN (/( IL-6/NN )/) mediates/VBZ autocrine/NN and/CC paracrine/NN growth/NN of/IN multiple/JJ myeloma/NN (/( MM/NN )/) cells/NNS and/CC inhibits/VBZ tumor/NN cell/NN apoptosis/NN ./. 
Abnormalities/NNS of/IN retinoblastoma/NN protein/NN (/( pRB/NN )/) and/CC mutations/NNS of/IN RB/NN gene/NN have/VBP been/VBN reported/VBN in/IN up/IN to/TO 70/CD %/NN of/IN MM/NN patients/NNS and/CC 80/CD %/NN of/IN MM-derived/JJ cell/NN lines/NNS ./. 
Because/IN dephosphorylated/VBN (/( activated/VBN )/) pRB/NN blocks/VBZ transition/NN from/IN G1/NN to/TO S/NN phase/NN of/IN the/DT cell/NN cycle/NN whereas/IN phosphorylated/VBN (/( inactivated/VBN )/) pRB/NN releases/VBZ this/DT growth/NN arrest/NN ,/, we/PRP characterized/VBD the/DT role/NN of/IN pRB/NN in/IN IL-6-mediated/JJ MM/NN cell/NN growth/NN ./. 
Both/CC phosphorylated/VBN and/CC dephosphorylated/VBN pRB/NN were/VBD expressed/VBN in/IN all/DT serum-starved/JJ MM/NN patient/NN cells/NNS and/CC MM-derived/JJ cell/NN lines/NNS ,/, but/CC pRB/NN was/VBD predominantly/RB in/IN its/PRP$ phosphorylated/JJ form/NN ./. 
In/IN MM/NN cells/NNS that/WDT proliferated/VBD in/IN response/NN to/TO IL-6/NN ,/, exogenous/JJ IL-6/NN downregulated/VBD dephosphorylated/VBN pRB/NN and/CC decreased/VBD dephosphorylated/VBN pRB-E2F/NN complexes/NNS ./. 
Importantly/RB ,/, culture/NN of/IN MM/NN cells/NNS with/IN RB/NN antisense/JJ ,/, but/CC not/RB RB/NN sense/NN ,/, oligonucleotide/NN (/( ODN/NN )/) triggered/VBD IL-6/NN secretion/NN and/CC proliferation/NN in/IN MM/NN cells/NNS ;/: however/RB ,/, proliferation/NN was/VBD only/RB partially/RB inhibited/VBN by/IN neutralizing/VBG anti-IL-6/JJ monoclonal/JJ antibody/NN (/( MoAb/NN )/) ./. 
In/IN contrast/NN to/TO MM/NN cells/NNS ,/, normal/JJ splenic/JJ B/NN cells/NNS express/VBP dephosphorylated/VBN pRB/NN ./. 
Although/IN CD40/NN ligand/NN (/( CD40L/NN )/) triggers/VBZ a/DT shift/NN from/IN dephosphorylated/VBN to/TO phosphorylated/VBN pRB/NN and/CC proliferation/NN of/IN B/NN cells/NNS ,/, the/DT addition/NN of/IN exogenous/JJ IL-6/NN to/TO CD40L-treated/JJ B/NN cells/NNS does/VBZ not/RB alter/VB either/CC pRB/NN or/CC proliferation/NN ,/, as/IN observed/VBN in/IN MM/NN cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN phosphorylated/VBN pRB/NN is/VBZ constitutively/RB expressed/VBN in/IN MM/JJ cells/NNS and/CC that/IN IL-6/NN further/RB shifts/VBZ pRB/NN from/IN its/PRP$ dephosphorylated/JJ to/TO its/PRP$ phosphorylated/JJ form/NN ,/, thereby/RB promoting/VBG MM/NN cell/NN growth/NN via/IN two/CD mechanisms/NNS ;/: by/IN decreasing/VBG the/DT amount/NN of/IN E2F/NN bound/VBN by/IN dephosphorylated/VBN pRB/NN due/IN to/TO reduced/VBN dephosphorylated/VBN pRB/NN ,/, thereby/RB releasing/VBG growth/NN arrest/NN ;/: and/CC by/IN upregulating/VBG IL-6/NN secretion/NN by/IN MM/NN cells/NNS and/CC related/JJ IL-6-mediated/JJ autocrine/JJ tumor/NN cell/NN growth/NN ./. 
UI/LS -/: 97026428/CD 
TI/LS -/: Soluble/JJ factors/NNS secreted/VBN by/IN activated/VBN T-lymphocytes/NNS modulate/VBP the/DT transcription/NN of/IN the/DT immunosuppressive/JJ cytokine/NN TGF-beta/NN 2/CD in/IN glial/JJ cells/NNS ./. 
AB/LS -/: Coordination/NN of/IN the/DT immune/JJ response/NN to/TO injury/NN or/CC disease/NN in/IN the/DT brain/NN is/VBZ postulated/VBN to/TO involve/VB bi-directional/JJ discourse/NN between/IN the/DT immune/JJ system/NN and/CC the/DT central/JJ nervous/JJ system/NN ./. 
This/DT cross/JJ communication/NN involves/VBZ soluble/JJ mediators/NNS ,/, including/VBG various/JJ growth/NN factors/NNS ,/, cytokines/NNS ,/, and/CC neuropeptides/NNS ./. 
In/IN this/DT report/NN ,/, we/PRP demonstrate/VBP that/IN the/DT supernatant/NN from/IN activated/VBN T-lymphocytes/NNS is/VBZ able/JJ to/TO induce/VB the/DT transcription/NN of/IN a/DT potent/JJ cytokine/NN ,/, TGF-beta/NN 2/CD in/IN glial/JJ cells/NNS ./. 
The/DT activating/VBG stimulus/NN invokes/VBZ signaling/NN mechanisms/NNS distinct/JJ from/IN known/JJ kinase/NN or/CC protease/NN pathways/NNS ./. 
Activation/NN of/IN TGF-beta/NN 2/CD transcription/NN correlates/VBZ with/IN the/DT loss/NN of/IN binding/NN activity/NN for/IN an/DT 80/CD kDA/NN glial/JJ labile/NN repressor/NN protein/NN ,/, GLRP/NN ,/, to/TO a/DT responsive/JJ region/NN within/IN the/DT TFG-beta/NN 2/CD promoter/NN ./. 
Although/IN GLRP/NN shares/VBZ some/DT characteristics/NNS with/IN the/DT inducible/JJ transcription/NN factor/NN AP-1/NN ,/, it/PRP appears/VBZ to/TO be/VB distinct/JJ from/IN known/JJ AP-1/NN family/NN members/NNS ./. 
These/DT data/NNS along/IN with/IN previous/JJ observations/NNS demonstrating/VBG the/DT potent/JJ immunosuppressive/JJ activity/NN of/IN TGF-beta/NN 2/CD ,/, support/VBP a/DT model/NN for/IN a/DT feedback/NN mechanism/NN between/IN the/DT activated/VBN T-lymphocytes/NNS and/CC astrocytes/NNS via/IN TGF-beta/NN 2/CD to/TO regulate/VB the/DT immune/JJ response/NN ./. 
UI/LS -/: 96323103/CD 
TI/LS -/: Various/JJ modes/NNS of/IN basic/JJ helix-loop-helix/JJ protein-mediated/JJ regulation/NN of/IN murine/JJ leukemia/NN virus/NN transcription/NN in/IN lymphoid/JJ cell/NN lines/NNS ./. 
AB/LS -/: The/DT transcriptionally/RB regulatory/JJ regions/NNS of/IN the/DT lymphomagenic/JJ Akv/NN and/CC SL3-3/NN murine/JJ leukemia/NN retroviruses/NNS (/( MLVs/NNS )/) contain/VBP two/CD types/NNS of/IN E-box/NN consensus/NN motifs/NNS ,/, CAGATG/NN ./. 
One/CD type/NN ,/, EA/S/NN ,/, is/VBZ located/JJ in/IN the/DT upstream/JJ promoter/NN region/NN ,/, and/CC the/DT other/JJ ,/, E/NN (/( gre/NN )/) ,/, is/VBZ located/JJ in/IN a/DT tandem/JJ repeat/NN with/IN enhancer/NN properties/NNS ./. 
We/PRP have/VBP examined/VBN the/DT requirements/NNS of/IN the/DT individual/JJ E-boxes/NNS in/IN MLV/NN transcriptional/JJ regulation/NN ./. 
In/IN lymphoid/JJ cell/NN lines/NNS only/RB ,/, the/DT E/NN (/( gre/NN )/) -binding/JJ protein/NN complexes/NNS included/VBD ALF1/NN or/CC HEB/NN and/CC E2A/NN basic/JJ helix-loop-helix/JJ proteins/NNS ./. 
Ectopic/JJ ALF1/NN and/CC E2A/NN proteins/NNS required/VBD intact/JJ E/NN (/( gre/NN )/) motifs/NNS for/IN mediating/VBG transcriptional/JJ activation/NN ./. 
ALF1/NNP transactivated/VBD transcription/NN of/IN Akv/NN MLV/NN through/IN the/DT two/CD E/NN (/( gre/NN )/) motifs/NNS equally/RB ,/, whereas/IN E2A/NN protein/NN required/VBD the/DT promoter-proximal/JJ E/NN (/( gre/NN )/) motif/NN ./. 
In/IN T-/NN and/CC B-cell/NN lines/NNS ,/, the/DT E/NN (/( gre/NN )/) motifs/NNS were/VBD of/IN major/JJ importance/NN for/IN Akv/NN MLV/NN transcriptional/JJ activity/NN ,/, while/IN the/DT EA/S/NN motif/NN had/VBD some/DT effect/NN ./. 
In/IN contrast/NN ,/, neither/CC E/NN (/( gre/NN )/) nor/CC EA/S/NN motifs/NNS contributed/VBD pronouncedly/RB to/TO Akv/NN MLV/NN transcription/NN in/IN NIH/NN 3T3/NN cells/NNS lacking/VBG DNA-binding/JJ ALF1/NN or/CC HEB/NN and/CC E2A/NN proteins/NNS ./. 
The/DT Id1/NN protein/NN was/VBD found/VBN to/TO repress/VB ALF1/NN activity/NN in/FW vitro/FW and/CC in/FW vivo/FW ./. 
Moreover/RB ,/, ectopic/JJ Id1/NN repressed/VBD E/NN (/( gre/NN )/) -directed/JJ but/CC not/RB EA/S-directed/JJ MLV/NN transcription/NN in/IN lymphoid/JJ cell/NN lines/NNS ./. 
In/IN conclusion/NN ,/, E/NN (/( gre/NN )/) motifs/NNS and/CC interacting/VBG basic/JJ helix-loop-helix/JJ proteins/NNS are/VBP important/JJ determinants/NNS for/IN MLV/NN transcriptional/JJ activity/NN in/IN lymphocytic/JJ cell/NN lines/NNS ./. 
UI/LS -/: 96320558/CD 
TI/LS -/: Reversal/NN of/IN apoptosis/NN by/IN the/DT leukaemia-associated/JJ E2A-HLF/NN chimaeric/JJ transcription/NN factor/NN ./. 
AB/LS -/: The/DT E2A-HLF/NN (/( for/IN hepatic/JJ leukaemia/NN factor/NN )/) fusion/NN gene/NN ,/, formed/VBN by/IN action/NN of/IN the/DT t(17;19) (q22;p13)/NN chromosomal/JJ translocation/NN ,/, drives/VBZ the/DT leukaemic/JJ transformation/NN of/IN early/JJ B-cell/NN precursors/NNS ,/, but/CC the/DT mechanism/NN of/IN this/DT activity/NN remains/VBZ unknown/JJ ./. 
Here/RB we/PRP report/VBP that/IN human/JJ leukaemia/NN cells/NNS carrying/VBG the/DT translocation/NN t(17;19)/NN rapidly/RB died/VBD by/IN apoptosis/NN when/WRB programmed/VBN to/TO express/VB a/DT dominant-negative/JJ suppressor/NN of/IN the/DT fusion/NN protein/NN E2A-HLF/NN ,/, indicating/VBG that/IN the/DT chimaeric/JJ oncoprotein/NN probably/RB affects/VBZ cell/NN survival/NN rather/RB than/IN cell/NN growth/NN ./. 
Moreover/RB ,/, when/WRB introduced/VBN into/IN murine/JJ pro-B/JJ lymphocytes/NNS ,/, the/DT oncogenic/JJ E2A-HLF/NN fusion/NN protein/NN reversed/VBD both/CC interleukin-3-dependent/JJ and/CC p53-mediated/JJ apoptosis/NN ./. 
The/DT close/JJ homology/NN of/IN the/DT basic/JJ region/leucine/NN zipper/NN (/( bZIP/NN )/) DNA-binding/JJ and/CC dimerization/NN domain/NN of/IN HLF/NN to/TO that/DT of/IN the/DT CES-2/NN cell-death/NN specification/NN protein/NN of/IN Caenorhabditis/NN elegans/NNS suggests/VBZ a/DT model/NN of/IN leukaemogenesis/NN in/IN which/WDT E2A-HLF/NN blocks/VBZ an/DT early/JJ step/NN within/IN an/DT evolutionarily/RB conserved/VBN cell-death/NN pathway/NN ./. 
UI/LS -/: 96369636/CD 
TI/LS -/: The/DT role/NN of/IN early/JJ growth/NN response/NN gene/NN 1/CD (/( egr-1/NN )/) in/IN regulation/NN of/IN the/DT immune/JJ response/NN ./. 
AB/LS -/: The/DT induction/NN of/IN immediate/JJ early/JJ genes/NNS in/IN cells/NNS of/IN the/DT immune/JJ system/NN is/VBZ critical/JJ to/TO determining/VBG the/DT ultimate/JJ outcome/NN of/IN exposure/NN to/TO antigen/NN ./. 
The/DT importance/NN of/IN many/JJ of/IN these/DT genes/NNS relates/VBZ to/TO the/DT role/NN their/PRP$ transcription/NN factor/NN products/NNS play/VBP in/IN dictating/VBG patterns/NNS of/IN expression/NN of/IN downstream/JJ ,/, function-related/JJ genes/NNS ./. 
Evidence/NN from/IN several/JJ systems/NNS indicates/VBZ that/IN the/DT immediate/JJ early/JJ gene/NN ,/, egr-1/NN may/MD be/VB of/IN particular/JJ importance/NN in/IN the/DT immune/JJ system/NN ./. 
Recently/RB ,/, the/DT egr-1/NN promoter/NN has/VBZ been/VBN shown/VBN to/TO be/VB highly/RB responsive/JJ to/TO the/DT diverse/JJ biochemical/JJ signals/NNS generated/VBN by/IN antigen/NN and/CC cytokines/NNS in/IN cells/NNS of/IN the/DT immune/JJ system/NN ./. 
Furthermore/RB ,/, an/DT important/JJ role/NN for/IN egr-1/NN in/IN determining/VBG the/DT differentiation/NN pathway/NN of/IN myeloid/JJ cell/NN precursors/NNS has/VBZ been/VBN recently/RB elaborated/VBN ./. 
Finally/RB ,/, potential/JJ targets/NNS of/IN regulation/NN by/IN the/DT zinc-finger/NN transcription/NN factor/NN encoded/VBN by/IN egr-1/NN include/VBP the/DT interleukin-2/NN ,/, CD44/NN ,/, ICAM-1/NN ,/, and/CC tumor/NN necrosis/NN factor/NN genes/NNS ./. 
The/DT role/NN of/IN egr-1/NN in/IN regulation/NN of/IN the/DT immune/JJ response/NN will/MD be/VB discussed/VBN in/IN the/DT context/NN of/IN these/DT recent/JJ studies/NNS ./. 
UI/LS -/: 96353908/CD 
TI/LS -/: Peptide/NN vaccination/NN can/MD lead/VB to/TO enhanced/VBN tumor/NN growth/NN through/IN specific/JJ T-cell/NN tolerance/NN induction/NN ./. 
AB/LS -/: Vaccination/NN with/IN synthetic/JJ peptides/NNS representing/VBG cytotoxic/JJ T/NN lymphocyte/NN (/( CTL/NN )/) epitopes/NNS can/MD lead/VB to/TO a/DT protective/JJ CTL-mediated/JJ immunity/NN against/IN tumors/NNS or/CC viruses/NNS ./. 
We/PRP now/RB report/VBP that/IN vaccination/NN with/IN a/DT CTL/NN epitope/NN derived/VBN from/IN the/DT human/JJ adenovirus/NN type/NN 5/CD E1A-region/NN (/( Ad5E1A234-243/NN )/) ,/, which/WDT can/MD serve/VB as/IN a/DT target/NN for/IN tumor-eradicating/JJ CTL/NN ,/, enhances/VBZ rather/RB than/IN inhibits/VBZ the/DT growth/NN of/IN Ad5E1A-expressing/JJ tumors/NNS ./. 
This/DT adverse/JJ effect/NN of/IN peptide/NN vaccination/NN was/VBD rapidly/RB evoked/VBN ,/, required/VBD low/JJ doses/NNS of/IN peptide/NN (/( 10/CD micrograms/NNS )/) ,/, and/CC was/VBD achieved/VBN by/IN a/DT mode/NN of/IN peptide/NN delivery/NN that/WDT induces/VBZ protective/JJ T-cell-mediated/JJ immunity/NN in/IN other/JJ models/NNS ./. 
Ad5E1A-specific/JJ CTL/NN activity/NN could/MD no/RB longer/RB be/VB isolated/VBN from/IN mice/NNS after/IN injection/NN of/IN Ad5E1A-peptide/NN ,/, indicating/VBG that/IN tolerization/NN of/IN Ad5E1A-specific/JJ CTL/NN activity/NN causes/VBZ the/DT enhanced/VBN tumor/NN outgrowth/NN ./. 
In/IN contrast/NN to/TO peptide/NN vaccination/NN ,/, immunization/NN with/IN adenovirus/NN ,/, expressing/VBG Ad5E1A/NN ,/, induced/VBD Ad5E1A-specific/JJ immunity/NN and/CC prevented/VBD the/DT outgrowth/NN of/IN Ad5E1A-expressing/JJ tumors/NNS ./. 
These/DT results/NNS show/VBP that/IN immunization/NN with/IN synthetic/JJ peptides/NNS can/MD lead/VB to/TO the/DT elimination/NN of/IN anti-tumor/JJ CTL/NN responses/NNS ./. 
These/DT findings/NNS are/VBP important/JJ for/IN the/DT design/NN of/IN safe/JJ peptide-based/JJ vaccines/NNS against/IN tumors/NNS ,/, allogeneic/JJ organ/NN transplants/NNS ,/, and/CC T-cell-mediated/JJ autoimmune/JJ diseases/NNS ./. 
UI/LS -/: 96344715/CD 
TI/LS -/: [/( NGFI-B/nur77/NN family/NN involved/VBN in/IN T-cell/NN apoptosis/NN ]/) 
AB/LS -/: NGFI-B/nur77/NN is/VBZ a/DT member/NN of/IN the/DT steroid/NN receptor/NN superfamily/NN ./. 
NGFI-B/nur77/NN and/CC its/PRP$ related/JJ genes/NNS constitute/VBP a/DT family/NN and/CC the/DT NGFI-B/nur77/NN family/NN consists/VBZ of/IN three/CD subtypes/NNS ,/, named/VBN nur77/NN alpha/NN ,/, nur77/NN beta/NN ,/, nur77/NN gamma/NN ./. 
We/PRP cloned/VBD human/JJ nur77/NN beta/NN cDNA/NN ,/, called/VBN TINUR/NN ./. 
Although/IN NGFI-B/nur77/NN is/VBZ essential/JJ for/IN TCR-mediated/JJ apoptosis/NN in/IN T-cell/NN hybridomas/NNS ,/, the/DT reports/NNS on/IN nur77/NN knock-out/JJ mice/NNS and/CC nur77/NN dominant/JJ negative/JJ transgenic/JJ mice/NNS suggest/VBP that/IN there/EX is/VBZ a/DT functional/JJ redundancy/NN among/IN NGFI-B/nur77/NN family/NN ./. 
NGFI-B/nur77/NN binds/VBZ to/TO the/DT response/NN element/NN by/IN monomer/NN or/CC heterodimer/NN with/IN retinoid/NN X/NN receptor/NN (/( RXR/NN )/) ./. 
Assuming/VBG that/IN 9-cis-retinoic/JJ acid/NN (/( 9-cis-RA/NN )/) inhibits/VBZ TCR-mediated/JJ apoptosis/NN ,/, nur77/NNS may/MD cause/VB apoptosis/NN by/IN monomer/NN in/IN the/DT absence/NN of/IN 9-cis-RA/NN and/CC may/MD inhibit/VB apoptosis/NN by/IN heterodimer/NN with/IN RXR/NN in/IN the/DT presence/NN of/IN 9-cis-RA/NN ./. 
UI/LS -/: 96272884/CD 
TI/LS -/: Glucocorticoids/NNS and/CC interferon-alpha/NN in/IN the/DT acquired/VBN immunodeficiency/NN syndrome/NN ./. 
AB/LS -/: Some/DT patients/NNS with/IN acquired/VBN immunodeficiency/NN syndrome/NN (/( AIDS/NN )/) develop/VBP glucocorticoid/NN resistance/NN characterized/VBN by/IN low/JJ receptor/NN affinity/NN (/( Kd/NN )/) for/IN glucocorticoids/NNS in/IN mononuclear/JJ ,/, cells/NNS and/CC high/JJ values/NNS of/IN ACTH/NN and/CC cortisol/NN ./. 
As/IN glucocorticoids/NNS regulate/VBP interferon-alpha/NN (/( IFN/NN alpha/NN )/) production/NN ,/, we/PRP hypothesized/VBD that/IN IFN/NN alpha/NN ,/, a/DT cytokine/NN produced/VBN predominantly/RB by/IN monocytes/NNS in/IN AIDS/NN ,/, should/MD be/VB increased/VBN in/IN cortisol-resistant/JJ AIDS/NN ,/, attributing/VBG the/DT lack/NN of/IN cortisol/NN inhibition/NN to/TO IFN/NN alpha/NN production/NN ./. 
Therefore/RB ,/, we/PRP examined/VBD glucocorticoid/NN receptor/NN characteristics/NNS on/IN monocytes/NNS by/IN [3H]dexamethasone/NN binding/NN and/CC measured/VBD IFN/NN alpha/NN ,/, cortisol/NN ,/, and/CC ACTH/NN in/IN AIDS/NN patients/NNS with/IN (/( AIDS-GR/NN )/) or/CC without/IN glucocorticoid/NN resistance/NN (/( AIDS-C/NN )/) and/CC controls/NNS (/( C/NN )/) ./. 
Monocytes/NNS of/IN AIDS-GR/NN patients/NNS had/VBD a/DT receptor/NN Kd/NN of/IN 10.5/CD +/-/CC 4.2/CD nmol/L/NN that/WDT was/VBD higher/JJR than/IN that/DT in/IN the/DT AIDS-C/NN group/NN (/( 2.9/CD +/-/CC 0.8/CD nmol/L/NN )/) and/CC normal/JJ subjects/NNS (/( 2.0/CD +/-/CC 0.8/CD nmol/L/NN ;/: P/NN </JJR 0.01/CD )/) ./. 
IFN/NN alpha/NN levels/NNS were/VBD increased/VBN in/IN the/DT AIDS-GR/NN group/NN (/( 17/CD +/-/CC 6/CD vs./CC 
4/CD +/-/CC 1/CD U/mL/NN in/IN the/DT AIDS-C/NN group/NN and/CC 2/CD +/-/CC 0.5/CD U/mL/NN in/IN the/DT C/NN group/NN ;/: P/NN </JJR 0.01/CD )/) ./. 
Correlations/NNS were/VBD found/VBN between/IN plasma/NN IFN/NN alpha/NN and/CC receptor/NN Kd/NN on/IN monocytes/NNS of/IN AIDS-GR/NN (/( r/NN =/JJ 0.77/CD )/) and/CC between/IN IFN/NN alpha/NN and/CC plasma/NN cortisol/NN in/IN the/DT same/JJ group/NN (/( r/NN =/JJ 0.74/CD )/) ./. 
The/DT poly(I)-poly(C)-induced/JJ IFN/NN alpha/NN production/NN by/IN monocytes/NNS was/VBD inhibited/VBN by/IN glucocorticoids/NNS in/IN the/DT C/NN and/CC AIDS-C/NN groups/NNS (/( approximately/RB 80/CD %/NN inhibition/NN in/IN both/DT groups/NNS )/) ;/: the/DT effect/NN was/VBD reversed/VBN by/IN the/DT receptor/NN antagonist/NN RU-38486/NN ./. 
By/IN contrast/NN ,/, glucocorticoids/NNS failed/VBD to/TO inhibit/VB IFNalpha/NN production/NN from/IN AIDS-GR/NN monocytes/NNS (/( approximately/RB 20/CD %/NN inhibition/NN )/) ./. 
In/IN conclusion/NN ,/, elevated/JJ IFN/NN alpha/NN levels/NNS in/IN AIDS-GR/NN may/MD be/VB due/JJ to/TO the/DT lack/NN of/IN inhibitory/JJ effect/NN of/IN cortisol/NN on/IN IFN/NN alpha/NN production/NN due/IN to/TO cortisol/JJ resistance/NN in/IN monocytes/NNS 
UI/LS -/: 96421639/CD 
TI/LS -/: JNK/NN (/( c-Jun/NN NH2-terminal/JJ kinase/NN )/) is/VBZ a/DT target/NN for/IN antioxidants/NNS in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: AP-1/NN has/VBZ been/VBN shown/VBN to/TO behave/VB as/IN a/DT redox-sensitive/JJ transcription/NN factor/NN that/WDT can/MD be/VB activated/VBN by/IN both/CC oxidant/JJ and/CC antioxidant/JJ stimuli/NNS ./. 
However/RB ,/, the/DT mechanisms/NNS involved/VBN in/IN the/DT activation/NN of/IN AP-1/NN by/IN antioxidants/NNS are/VBP largely/RB unknown/JJ ./. 
In/IN this/DT study/NN we/PRP show/VBP that/IN the/DT structurally/RB unrelated/JJ antioxidant/JJ agents/NNS pyrrolidine/NN dithiocarbamate/NN (/( PDTC/NN )/) ,/, butylated/VBN hydroxyanisole/NN ,/, and/CC Nacetylcysteine/NN activated/VBD JNK/NN (/( c-Jun/NN NH2-terminal/JJ kinase/NN )/) in/IN Jurkat/NN T/NN cells/NNS ./. 
This/DT activation/NN differed/VBD substantially/RB from/IN that/DT mediated/VBN by/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) and/CC Ca2+/NN ionophore/NN or/CC produced/VBN by/IN costimulation/NN with/IN antibodies/NNS against/IN the/DT T/NN cell/NN receptor-CD3/NN complex/NN and/CC to/TO CD28/NN ./. 
The/DT activation/NN of/IN JNK/NN by/IN classical/JJ T/NN cell/NN stimuli/NNS was/VBD transient/JJ ,/, whereas/IN that/DT mediated/VBN by/IN PDTC/NN and/CC butylated/VBN hydroxyanisole/NN (/( but/CC not/RB N-acetylcysteine/NN )/) was/VBD sustained/JJ ./. 
The/DT kinetics/NNS of/IN JNK/NN activation/NN correlated/VBD with/IN the/DT expression/NN of/IN c-jun/NN which/WDT was/VBD transient/JJ after/IN stimulation/NN with/IN PMA/NN plus/CC ionophore/NN and/CC prolonged/VBD in/IN response/NN to/TO PDTC/NN ,/, which/WDT also/RB transiently/RB induced/VBD c-fos/NN ./. 
In/IN addition/NN ,/, JNK/NN activation/NN by/IN PMA/NN plus/CC ionophore/NN was/VBD sensitive/JJ to/TO inhibitors/NNS of/IN signaling/NN pathways/NNS involving/VBG Ca2+/NN ,/, protein/NN kinase/NN C/NN ,/, and/CC tyrosine/NN phosphorylation/NN ,/, which/WDT failed/VBD to/TO inhibit/VB the/DT activation/NN mediated/VBN by/IN PDTC/NN ./. 
Transfection/NN of/IN trans-dominant/JJ negative/JJ expression/NN vectors/NNS of/IN ras/NN and/CC raf/NN ,/, together/RB with/IN AP-1-dependent/JJ reporter/NN constructs/NNS ,/, as/RB well/RB as/IN Western/NN blot/NN analysis/NN using/VBG anti-ERK/JJ (/( extracellular/JJ signal-regulated/JJ kinase/NN )/) antibodies/NNS ,/, indicated/VBD that/IN the/DT Ras/Raf/ERK/NN pathway/NN did/VBD not/RB appear/VB to/TO mediate/VB the/DT effect/NN of/IN the/DT antioxidant/NN ./. 
However/RB ,/, the/DT combined/JJ treatment/NN with/IN PDTC/NN and/CC PMA/NN ,/, two/CD agents/NNS that/WDT synergize/VBP on/IN AP-1/NN activation/NN ,/, resulted/VBD in/IN the/DT persistent/JJ phosphorylation/NN of/IN ERK-2/NN ./. 
In/IN conclusion/NN ,/, our/PRP$ results/NNS identify/VBP JNK/NN as/IN a/DT target/NN of/IN antioxidant/JJ agents/NNS which/WDT can/MD be/VB regulated/VBN differentially/RB under/IN oxidant/JJ and/CC antioxidant/JJ conditions/NNS ./. 
UI/LS -/: 97132479/CD 
TI/LS -/: [/( Molecular/JJ mechanisms/NNS of/IN age-related/JJ lymphocyte/NN dysfunction/NN ]/) 
AB/LS -/: Aging/NN is/VBZ classically/RB accompanied/VBN by/IN a/DT dysregulation/NN of/IN the/DT immunologic/JJ machinery/NN ./. 
As/IN a/DT consequence/NN ,/, the/DT immune/JJ response/NN developed/VBN in/IN senescent/JJ organisms/NNS is/VBZ usually/RB inappropriate/JJ ,/, often/RB inefficient/JJ ,/, sometimes/RB aberrant/JJ ,/, and/CC potentially/RB detrimental/JJ ./. 
The/DT age-associated/JJ immune/JJ dysfunction/NN may/MD be/VB implicated/VBN to/TO some/DT degree/NN in/IN the/DT extreme/JJ susceptibility/NN of/IN the/DT elderly/JJ to/TO infection/NN and/CC neoplasia/NN and/CC may/MD even/RB participate/VB in/IN various/JJ aspects/NNS of/IN senescence/NN ./. 
The/DT current/JJ understanding/NN of/IN the/DT molecular/JJ mechanisms/NNS underlying/VBG immunosenescence/NN is/VBZ still/RB fragmentary/JJ ./. 
The/DT most/RBS extensively/RB studied/VBN phenomenon/NN is/VBZ the/DT progressive/JJ decline/NN in/IN the/DT proliferative/JJ capacities/NNS of/IN T/NN lymphocytes/NNS with/IN aging/NN ./. 
The/DT loss/NN of/IN proliferative/JJ potential/NN in/IN response/NN to/TO antigenic/JJ challenge/NN is/VBZ a/DT characteristic/JJ feature/NN of/IN immune/JJ senescence/NN ./. 
It/PRP is/VBZ directly/RB implicated/VBN in/IN the/DT emergence/NN of/IN the/DT age-related/JJ immune/JJ deficiency/NN ./. 
The/DT purpose/NN of/IN this/DT review/NN is/VBZ to/TO show/VB how/WRB the/DT accumulation/NN of/IN various/JJ biochemical/JJ lesions/NNS with/IN advancing/VBG age/NN leads/VBZ to/TO the/DT failure/NN of/IN a/DT critical/JJ cell/NN function/NN ,/, namely/RB the/DT activation-induced/JJ lymphocyte/NN proliferation/NN ./. 
The/DT biochemical/JJ modifications/NNS responsible/JJ for/IN the/DT defect/NN in/IN transduction/NN and/CC execution/NN of/IN the/DT proliferative/JJ signal/NN are/VBP analyzed/VBN as/IN a/DT function/NN of/IN age/NN ./. 
The/DT multiple/JJ alterations/NNS observed/VBN on/IN the/DT various/JJ biochemical/JJ pathways/NNS may/MD appear/VB as/IN a/DT consequence/NN of/IN a/DT unique/JJ deleterious/JJ mechanism/NN more/RBR fundamentally/RB related/JJ to/TO the/DT process/NN of/IN senescence/NN such/JJ as/IN the/DT inability/NN to/TO cope/VB with/IN oxidative/JJ stress/NN ./. 
UI/LS -/: 96413305/CD 
TI/LS -/: Induction/NN of/IN bcl-2/NN expression/NN by/IN phosphorylated/VBN CREB/NN proteins/NNS during/IN B-cell/NN activation/NN and/CC rescue/NN from/IN apoptosis/NN ./. 
AB/LS -/: Engagement/NN of/IN surface/NN immunoglobulin/NN on/IN mature/JJ B/NN cells/NNS leads/VBZ to/TO rescue/NN from/IN apoptosis/NN and/CC to/TO proliferation/NN ./. 
Levels/NNS of/IN bcl-2/NN mRNA/NN and/CC protein/NN increase/VBP with/IN cross-linking/NN of/IN surface/NN immunoglobulin/NN ./. 
We/PRP have/VBP located/JJ the/DT major/JJ positive/JJ regulatory/JJ region/NN for/IN control/NN of/IN bcl-2/NN expression/NN in/IN B/NN cells/NNS in/IN the/DT 5'-flanking/JJ region/NN ./. 
The/DT positive/JJ region/NN can/MD be/VB divided/VBN into/IN an/DT upstream/JJ and/CC a/DT downstream/JJ regulatory/JJ region/NN ./. 
The/DT downstream/JJ regulatory/JJ region/NN contains/VBZ a/DT cyclic/JJ AMP-responsive/JJ element/NN (/( CRE/NN )/) ./. 
We/PRP show/VBP by/IN antibody/NN supershift/NN experiments/NNS and/CC UV/NN cross-linking/NN followed/VBN by/IN denaturing/VBG polyacrylamide/NN gel/NN electrophoresis/NN that/IN both/CC CREB/NN and/CC ATF/NN family/NN members/NNS bind/VBP to/TO this/DT region/NN in/FW vitro/FW ./. 
Mutations/NNS of/IN the/DT CRE/NN site/NN that/WDT result/VBP in/IN loss/NN of/IN CREB/NN binding/NN also/RB lead/VBP to/TO loss/NN of/IN functional/JJ activity/NN of/IN the/DT bcl-2/NN promoter/NN in/IN transient-transfection/NN assays/NNS ./. 
The/DT presence/NN of/IN an/DT active/JJ CRE/NN site/NN in/IN the/DT bcl-2/NN promoter/NN implies/VBZ that/IN the/DT regulation/NN of/IN bcl-2/NN expression/NN is/VBZ linked/VBN to/TO a/DT signal/NN transduction/NN pathway/NN in/IN B/NN cells/NNS ./. 
Treatment/NN of/IN the/DT mature/JJ B-cell/NN line/NN BAL-17/NN with/IN either/CC anti-immunoglobulin/JJ M/NN or/CC phorbol/NN 12-myristate/NN 13-acetate/NN leads/VBZ to/TO an/DT increase/NN in/IN bcl-2/NN expression/NN that/WDT is/VBZ mediated/VBN by/IN the/DT CRE/NN site/NN ./. 
Treatment/NN of/IN the/DT more/RBR immature/JJ B-cell/NN line/NN ,/, Ramos/NN ,/, with/IN phorbol/NN esters/NNS rescues/VBZ the/DT cells/NNS from/IN calcium-dependent/JJ apoptosis/NN ./. 
bcl-2/NN expression/NN is/VBZ increased/VBN following/VBG phorbol/NN ester/NN treatment/NN ,/, and/CC the/DT increased/VBN expression/NN is/VBZ dependent/JJ on/IN the/DT CRE/NN site/NN ./. 
These/DT stimuli/NNS result/VBP in/IN phosphorylation/NN of/IN CREB/NN at/IN serine/NN 133/CD ./. 
The/DT phosphorylation/NN of/IN CREB/NN that/WDT results/VBZ in/IN activation/NN is/VBZ mediated/VBN by/IN protein/NN kinase/NN C/NN rather/RB than/IN by/IN protein/NN kinase/NN A/NN ./. 
Although/IN the/DT CRE/NN site/NN is/VBZ necessary/JJ ,/, optimal/JJ induction/NN of/IN bcl-2/NN expression/NN requires/VBZ participation/NN of/IN the/DT upstream/JJ regulatory/JJ element/NN ,/, suggesting/VBG that/IN phosphorylation/NN of/IN CREB/NN alters/VBZ its/PRP$ interaction/NN with/IN the/DT upstream/JJ regulatory/JJ element/NN ./. 
The/DT CRE/NN site/NN in/IN the/DT bcl-2/NN promoter/NN appears/VBZ to/TO play/VB a/DT major/JJ role/NN in/IN the/DT induction/NN of/IN bcl-2/NN expression/NN during/IN the/DT activation/NN of/IN mature/JJ B/NN cells/NNS and/CC during/IN the/DT rescue/NN of/IN immature/JJ B/NN cells/NNS from/IN apoptosis/NN ./. 
It/PRP is/VBZ possible/JJ that/IN the/DT CRE/NN site/NN is/VBZ responsible/JJ for/IN induction/NN of/IN bcl-2/NN expression/NN in/IN other/JJ cell/NN types/NNS ,/, particularly/RB those/DT in/IN which/WDT protein/NN kinase/NN C/NN is/VBZ involved/VBN ./. 
UI/LS -/: 96404971/CD 
TI/LS -/: Characterization/NN of/IN the/DT human/JJ myeloid/JJ cell/NN nuclear/JJ differentiation/NN antigen/NN gene/NN promoter/NN ./. 
AB/LS -/: MNDA/NN (/( myeloid/JJ cell/NN nuclear/JJ differentiation/NN antigen/NN )/) is/VBZ an/DT interferon/NN alpha/NN regulated/VBN nuclear/JJ protein/NN expressed/VBN only/RB in/IN cells/NNS of/IN the/DT human/JJ myelomonocytic/JJ lineage/NN ./. 
To/TO identify/VB mechanisms/NNS responsible/JJ for/IN this/DT lineage-specific/JJ and/CC interferon-regulated/JJ expression/NN ,/, the/DT 5'/JJ flanking/JJ sequence/NN of/IN the/DT gene/NN has/VBZ been/VBN characterized/VBN ./. 
Two/CD interferon-stimulated/JJ response/NN elements/NNS (/( ISRE/NN )/) flank/VBP a/DT multiple/JJ transcription/NN start/NN site/NN region/NN identifying/VBG MNDA/NN as/IN a/DT TATA-less/JJ interferon-regulated/JJ gene/NN ./. 
Other/JJ DNA/NN elements/NNS present/JJ include/VBP a/DT cluster/NN of/IN Myb/NN sites/NNS ,/, several/JJ Ets/NNS ,/, an/DT Ets/NN related/JJ PU.1/NN site/NN and/CC an/DT Sp1/NN site/NN located/JJ within/IN 600/CD bp/NN of/IN the/DT transcription/NN start/NN sites/NNS ./. 
In/IN addition/NN ,/, DNA/NN methylation/NN was/VBD revealed/VBN as/IN one/CD of/IN the/DT possible/JJ factors/NNS in/IN establishing/VBG MNDA/NN expression/NN ./. 
The/DT 5'/JJ flanking/JJ sequence/NN has/VBZ promoter/NN activity/NN which/WDT is/VBZ elevated/VBN by/IN interferon/NN alpha/NN ./. 
The/DT findings/NNS indicate/VBP that/IN MNDA/NN expression/NN is/VBZ regulated/VBN by/IN mechanisms/NNS similar/JJ to/TO other/JJ myelomonocytic/JJ cell/NN specific/JJ genes/NNS and/CC genes/NNS up-regulated/VBN by/IN interferon/NN alpha/NN ./. 
UI/LS -/: 96409256/CD 
TI/LS -/: Abnormality/NN of/IN Oct-1/NN DNA/NN binding/NN in/IN T/NN cells/NNS from/IN Sjogren/NN 's/POS syndrome/NN patients/NNS ./. 
AB/LS -/: Primary/JJ Sjogren/NN 's/POS syndrome/NN (/( SS/NN )/) is/VBZ an/DT autoimmune/JJ rheumatic/JJ disease/NN characterized/VBN by/IN T/NN cell/NN hypoactivity/NN ./. 
To/TO understand/VB the/DT diminished/VBN T/NN cell/NN response/NN to/TO activation/NN signals/NNS ,/, we/PRP measured/VBD nucleoprotein/NN DNA-binding/JJ activities/NNS regulating/VBG gene/NN expression/NN during/IN T/NN cell/NN activation/NN using/VBG the/DT electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
Peripheral/JJ blood/NN lymphocytes/NNS from/IN 9/19/CD SS/NN patients/NNS were/VBD found/VBN to/TO be/VB defective/JJ in/IN their/PRP$ ability/NN to/TO bind/VB an/DT october/NN sequence/NN (/( Oct-1/NN )/) ./. 
This/DT Oct-1-binding/JJ phenotype/NN remained/VBD stable/JJ in/IN culture/NN for/IN up/IN to/TO 3/CD days/NNS prior/RB to/TO activation/NN ./. 
This/DT abnormality/NN was/VBD not/RB seen/VBN in/IN resting/VBG T/NN cells/NNS nor/CC T/NN cells/NNS from/IN patients/NNS with/IN systemic/JJ lupus/NN erythematosus/NN ,/, rheumatoid/JJ arthritis/NN (/( RA/NN )/) ,/, or/CC SS/NN accompanied/VBN by/IN RA/NN ./. 
The/DT SS/NN Oct-1/NN DNA-binding/JJ abnormality/NN correlated/VBD significantly/RB with/IN an/DT inability/NN of/IN cells/NNS to/TO exit/VB the/DT Gzero/G1/NN cell/NN cycle/NN phase/NN when/WRB stimulated/VBN in/FW vitro/FW ./. 
Importantly/RB ,/, nucleoprotein/NN extracts/NNS showing/VBG decreased/VBN DNA-binding/JJ activity/NN had/VBD normal/JJ amounts/NNS of/IN Oct-1/NN proteins/NNS as/IN determined/VBN by/IN immunoprecipitation/NN ,/, implying/VBG a/DT functional/JJ defect/NN in/IN the/DT Oct-1/NN protein/NN ./. 
Moreover/RB ,/, defective/JJ DNA/NN binding/NN was/VBD corrected/VBN by/IN treatment/NN with/IN acid/NN phosphatase/NN ./. 
UI/LS -/: 96355439/CD 
TI/LS -/: Characterization/NN of/IN a/DT new/JJ isoform/NN of/IN the/DT NFAT/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS )/) gene/NN family/NN member/NN NFATc/NN [/( published/VBN erratum/NN appears/VBZ in/IN J/NNP Biol/NNP Chem/NNP 1996/CD Dec/NNP 27/CD ;/: 271/CD (/( 52/CD )/) :/: 33705/CD ]/) 
AB/LS -/: The/DT cyclosporin/NN A/NN (/( CsA/NN )/) /FK506-sensitive/JJ nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) plays/VBZ a/DT key/JJ role/NN in/IN the/DT inducible/JJ expression/NN of/IN cytokine/NN genes/NNS in/IN T/NN cells/NNS ./. 
Although/IN NFAT/NN has/VBZ been/VBN recently/RB shown/VBN to/TO be/VB inducible/JJ in/IN several/JJ non-T/JJ immune/JJ cells/NNS ,/, the/DT NFAT/NN gene/NN family/NN members/NNS characterized/VBN to/TO date/NN have/VBP been/VBN isolated/VBN only/RB from/IN T/NN cells/NNS ./. 
To/TO further/RBR characterize/VB NFAT/NN function/NN in/IN human/JJ B/NN cells/NNS and/CC to/TO demonstrate/VB cytokine/NN gene/NN specificity/NN of/IN NFAT/NN proteins/NNS ,/, we/PRP report/VBP here/RB the/DT isolation/NN and/CC characterization/NN of/IN a/DT cDNA/NN clone/NN from/IN the/DT Raji/NN B/NN cell/NN line/NN ./. 
The/DT cDNA/NN clone/NN encodes/VBZ a/DT new/JJ isoform/NN ,/, NFATc.beta/NN ,/, of/IN the/DT NFAT/NN gene/NN family/NN member/NN NFATc/NN (/( designated/VBN here/RB NFATc.alpha/NN )/) ./. 
The/DT amino/NN acid/NN sequence/NN of/IN NFATc.beta/NN differs/VBZ from/IN that/DT of/IN NFATc/NN ./. 
alpha/NN in/IN the/DT first/JJ NH2-terminal/JJ 29/CD residues/NNS and/CC contains/VBZ an/DT additional/JJ region/NN of/IN 142/CD residues/NNS at/IN the/DT COOH/NN terminus/NN ./. 
Northern/NN analysis/NN using/VBG a/VBG probe/NN encompassing/VBG a/DT common/JJ region/NN of/IN both/DT isoforms/NNS showed/VBD two/CD mRNA/NN species/NNS of/IN 2.7/CD and/CC 4.5/CD kilobase/NN pairs/NNS ,/, while/IN an/DT NFATc.beta-specific/JJ probe/NN detected/VBD only/RB the/DT 4.5-kilobase/NN pair/NN mRNA/NN which/WDT was/VBD preferentially/RB expressed/VBN in/IN the/DT spleen/NN ./. 
Transient/JJ expression/NN of/IN NFATc.beta/NN was/VBD capable/JJ of/IN activating/VBG an/DT interleukin-2/NN NFAT-driven/JJ reporter/NN gene/NN in/IN stimulated/VBN Jurkat/NN cells/NNS in/IN a/DT CsA-sensitive/JJ manner/NN ./. 
However/RB ,/, NFATc.beta/NN neither/CC bound/VBD to/TO the/DT kappa3/NN element/NN (/( an/DT NFAT-binding/JJ site/NN )/) in/IN the/DT tumor/NN necrosis/NN factor-alpha/NN promoter/NN nor/CC activated/VBD the/DT tumor/NN necrosis/NN factor-alpha/NN promoter/NN in/IN cotransfection/NN assays/NN ./. 
These/DT data/NNS suggest/VBP that/IN different/JJ members/NNS or/CC isoforms/NNS of/IN NFAT/NN gene/NN family/NN may/MD regulate/VB inducible/JJ expression/NN of/IN different/JJ cytokine/NN genes/NNS ./. 
UI/LS -/: 97031819/CD 
TI/LS -/: Regulation/NN of/IN interferon-gamma/NN gene/NN expression/NN ./. 
AB/LS -/: Interferon-gamma/NN (/( IFN-gamma/NN )/) ,/, also/RB known/VBN as/IN type/NN II/CD interferon/NN ,/, is/VBZ an/DT important/JJ immunoregulatory/JJ gene/NN that/WDT has/VBZ multiple/JJ effects/NNS on/IN the/DT development/NN ,/, maturation/NN ,/, and/CC function/NN of/IN the/DT immune/JJ system/NN ./. 
IFN-gamma/NN mRNA/NN and/CC protein/NN are/VBP expressed/VBN predominantly/RB by/IN T/NN cells/NNS and/CC large/JJ granular/JJ lymphocytes/NNS .==================== The/DT IFN-gamma/ mRNA/NN is/VBZ induced/inhibited/VBN in/IN these/DT cell/NN types/NNS by/IN a/DT wide/JJ variety/NN of/IN extracellular/JJ signals/NNS ,/, thus/RB implicating/VBG a/DT number/NN of/IN diverse,/JJ yet/RB convergent/JJ signal/NN transduction/NN pathways/NNS in/IN its/PRP$ transcriptional/JJ control/NN .==================== In/IN this/DT review/NN ,/, I/PRP describe/VBP how/WRB DNA/NN methylation/NN and/CC specific/JJ DNA/NN binding/NN proteins/NNS may/MD regulate/VB transcription/NN of/IN the/DT IFN-gamma/NN gene/NN in/IN response/NN to/TO extracellular/JJ signals/NNS ./. 
UI/LS -/: 96358388/CD 
TI/LS -/: Transcriptional/JJ analysis/NN of/IN Epstein-Barr/JJ virus/NN gene/NN expression/NN in/IN EBV-positive/JJ gastric/JJ carcinoma/NN :/: unique/JJ viral/JJ latency/NN in/IN the/DT tumour/NN cells/NNS ./. 
AB/LS -/: Although/IN case-oriented/JJ evidence/NN for/IN an/DT association/NN of/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) with/IN gastric/JJ carcinoma/NN has/VBZ been/VBN accumulating/VBG recently/RB ,/, the/DT interaction/NN (/( s/NNS )/) between/IN EBV/NN and/CC gastric/JJ epithelial/NN cells/NNS is/are/VBP|VBZ largely/RB unknown/JJ ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD seven/CD EBV-positive/JJ gastric/JJ carcinoma/NN tissues/NNS for/IN viral/JJ gene/NN expression/NN at/IN the/DT mRNA/NN level/NN ,/, from/IN which/WDT studies/NNS on/IN the/DT EBV/NN oncogenicity/NN in/IN human/JJ epithelial/JJ cells/NNS will/MD benefit/VB ./. 
Reverse/JJ transcription-PCR/NN analysis/NN showed/VBD that/IN all/DT seven/CD EBV-positive/JJ tumour/NN tissues/NNS constitutively/RB expressed/VBD EBV/NN nuclear/JJ antigen/NN (/( EBNA/NN )/) 1/CD mRNA/NN ,/, but/CC not/RB EBNA2/NN mRNA/NN ./. 
The/DT EBNA/NN transcription/NN was/VBD initiated/VBN from/IN one/CD of/IN three/CD EBNA/NN promoters/NNS ,/, Qp/NN :/: by/IN contrast/NN ,/, both/CC Cp/NN and/CC Wp/NN were/VBD silent/JJ ,/, thus/RB resulting/VBG in/IN the/DT lack/NN of/IN EBNA2/NN mRNA/NN ./. 
Latent/JJ membrane/NN protein/NN (/( LMP/NN )/) 2A/NN mRNA/NN was/VBD detected/VBN in/IN three/CD of/IN seven/CD cases/NNS ;/: however/RB ,/, neither/CC LMP1/NN nor/CC LMP2B/NN mRNA/NN was/VBD detected/VBN in/IN any/DT of/IN the/DT tumours/NNS tested/VBN ./. 
Transcripts/NNS from/IN the/DT BamHI-A/NN region/NN of/IN the/DT viral/JJ genome/NN were/VBD detectable/JJ in/IN all/DT cases/NNS ./. 
BZLF1/NN mRNA/NN and/CC the/DT product/NN ,/, an/DT immediate-early/JJ gene/NN for/IN EBV/NN replication/NN ,/, was/VBD not/RB expressed/VBN in/IN any/DT of/IN them/PRP ,/, thereby/RB suggesting/VBG that/IN the/DT tumour/JJ cells/NNS carried/VBD EBV/NN genomes/NNS in/IN a/DT tightly/RB latent/JJ form/NN ./. 
These/DT findings/NNS further/RB extended/VBD our/PRP$ previous/JJ data/NNS regarding/VBG EBV/NN latency/NN in/IN gastric/JJ carcinoma/NN cells/NNS at/IN the/DT protein/NN level/NN ,/, and/CC have/VBP affirmed/VBN that/IN the/DT programme/NN of/IN viral/JJ gene/NN expression/NN in/IN the/DT tumour/NN more/RBR closely/RB resembles/VBZ '/`` latency/NN I/CD '/'' represented/VBN by/IN Burkitt/NN 's/POS lymphoma/NN than/IN '/`` latency/NN II/CD '/'' represented/VBN by/IN the/DT majority/NN of/IN nasopharyngeal/JJ carcinomas/NNS ./. 
UI/LS -/: 96289501/CD 
TI/LS -/: Characterization/NN of/IN Grb2-binding/JJ proteins/NNS in/IN human/JJ platelets/NNS activated/VBN by/IN Fc/NN gamma/NN RIIA/NN cross-linking/NN ./. 
AB/LS -/: Glutathione-S-transferase/NN (/( GST/NN )/) -Grb2/NN fusion/NN proteins/NNS have/VBP been/VBN used/VBN to/TO identify/VB the/DT potential/JJ role/NN of/IN Grb2-binding/JJ proteins/NNS in/IN platelet/NN activation/NN by/IN the/DT platelet/NN low-affinity/NN IgG/NN receptor/NN ,/, Fc/NN gamma/NN RIIA/NN ./. 
Two/CD tyrosine/NN phosphoproteins/NNS of/IN 38/CD and/CC 63/CD kD/NN bind/VBP to/TO the/DT SH2/NN domain/NN of/IN Grb2/NN following/VBG Fc/NN gamma/NN RIIA/NN stimulation/NN of/IN platelets/NNS ./. 
Both/DT are/VBP located/JJ in/IN the/DT particulate/JJ fraction/NN following/VBG platelet/NN activation/NN and/CC are/VBP also/RB able/JJ to/TO bind/VB to/TO a/DT GST-construct/NN containing/VBG the/DT SH2/NN and/CC SH3/NN domains/NNS of/IN phospholipase/NN C/NN gamma/NN 1/CD ./. 
p38/NN also/RB forms/VBZ a/DT complex/NN with/IN the/DT tyrosine/NN kinase/NN csk/NN in/IN stimulated/VBN cells/NNS and/CC is/VBZ a/DT substrate/NN for/IN the/DT kinase/NN ./. 
The/DT SH3/NN domains/NNS of/IN Grb2/NN form/VBP a/DT stable/JJ complex/NN with/IN SOS1/NN and/CC two/CD proteins/NNS of/IN 75/CD kD/NN and/CC 120/CD kD/NN ,/, which/WDT undergo/VBP tyrosine/NN phosphorylation/NN in/IN Fc/NN gamma/NN RIIA/NN stimulated/JJ cells/NNS ./. 
The/DT 75-kD/JJ protein/NN is/VBZ recognized/VBN by/IN antibodies/NNS to/TO SLP-76/NN ,/, which/WDT has/VBZ recently/RB been/VBN isolated/VBN from/IN T/NN cells/NNS and/CC sequenced/VBN ./. 
Tyrosine/NN phosphorylation/NN of/IN p38/NN and/CC p63/NN is/VBZ also/RB observed/VBN in/IN platelets/NNS stimulated/VBN by/IN the/DT tyrosine/NN kinase-linked/JJ receptor/NN agonist/NN collagen/NN and/CC by/IN the/DT G/NN protein-coupled/JJ receptor/NN agonist/NN thrombin/NN ,/, although/IN phosphorylation/NN of/IN SLP-76/NN is/VBZ only/RB observed/VBN in/IN collagen-stimulated/JJ platelets/NNS ./. 
p38/NN and/CC p63/NN may/MD provide/VB a/DT docking/NN site/NN for/IN Grb2/NN ,/, thereby/RB linking/VBG Grb2/NN SH3-binding/JJ proteins/NNS SOS1/NN ,/, SLP-76/NN ,/, and/CC p120/NN to/TO downstream/JJ signalling/NN events/NNS ./. 
UI/LS -/: 96295969/CD 
TI/LS -/: Constitutive/JJ expression/NN of/IN specific/JJ interferon/NN isotypes/NNS in/IN peripheral/JJ blood/NN leukocytes/NNS from/IN normal/JJ individuals/NNS and/CC in/IN promonocytic/JJ U937/NN cells/NNS ./. 
AB/LS -/: Constitutive/JJ expression/NN of/IN IFN-alpha5/NN and/CC IFN-beta/NN was/VBD detected/VBN in/IN different/JJ lymphoid/JJ cells/NNS including/VBG peripheral/JJ blood/NN mononuclear/JJ cells/NNS from/IN normal/JJ individuals/NNS following/VBG amplification/NN of/IN IFN/NN mRNA/NN by/IN reverse/JJ transcriptase-polymerase/NN chain/NN reaction/NN and/CC direct/JJ sequencing/NN of/IN the/DT amplified/VBN product/NN ./. 
The/DT activated/JJ form/NN of/IN the/DT interferon-induced/JJ transcription/NN factor/NN complex/NN ISGF3/NN was/VBD also/RB detected/VBN in/IN nuclear/JJ extracts/NNS from/IN uninduced/JJ cells/NNS ./. 
Culture/NN supernatants/NNS from/IN uninduced/JJ U937/NN cells/NNS were/VBD also/RB found/VBN to/TO activate/VB an/DT ISRE/NN cloned/VBN upstream/RB of/IN the/DT luciferase/NN reporter/NN gene/NN ,/, indicating/VBG the/DT presence/NN of/IN endogenous/JJ IFN/NN activity/NN equivalent/JJ to/TO approximately/RB 0.3/CD to/TO 0.5/CD IU/mL/NN ./. 
This/DT endogenous/JJ IFN/NN was/VBD also/RB shown/VBN to/TO play/VB a/DT role/NN in/IN maintaining/VBG the/DT basal/JJ level/NN of/IN expression/NN of/IN the/DT major/JJ histocompatibility/NN class/NN I/CD genes/NNS in/IN lymphoid/JJ cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN IFN-alpha5/NN and/CC IFN-beta/NN are/VBP produced/VBN at/IN low/JJ levels/NNS in/IN normal/JJ tissues/NNS and/CC play/VBP an/DT important/JJ role/NN in/IN the/DT regulation/NN of/IN cell/NN function/NN and/CC in/IN the/DT maintenance/NN of/IN homeostasis/NN ./. 
UI/LS -/: 97051821/CD 
TI/LS -/: An/DT IL-2/NN response/NN element/NN in/IN the/DT human/JJ IL-2/NN receptor/NN alpha/NN chain/NN promoter/NN is/VBZ a/DT composite/JJ element/NN that/WDT binds/VBZ Stat5/NN ,/, Elf-1/NN ,/, HMG-I(Y) and/CC a/DT GATA/NN family/NN protein/NN ./. 
AB/LS -/: Expression/NN of/IN the/DT human/JJ interleukin-2/NN (/( IL-2/NN )/) receptor/NN alpha/NN chain/NN gene/NN is/VBZ potently/RB upregulated/VBN by/IN its/PRP$ own/JJ ligand/NN ,/, IL-2/NN ./. 
In/IN this/DT study/NN ,/, we/PRP characterize/VBP an/DT essential/JJ upstream/JJ IL-2/NN response/NN element/NN that/WDT contains/VBZ both/CC consensus/NN and/CC non-consensus/JJ GAS/NN motifs/NNS ,/, two/CD putative/JJ Ets/NN binding/NN sites/NNS (/( EBS/NN )/) ,/, one/CD of/IN which/WDT overlaps/VBZ the/DT consensus/NN GAS/NN motif/NN ,/, and/CC a/DT GATA/NN motif/NN ,/, which/WDT overlaps/VBZ the/DT non-consensus/JJ GAS/NN motif/NN ./. 
We/PRP demonstrate/VBP that/IN although/IN the/DT individual/JJ components/NNS of/IN this/DT element/NN do/VBP not/RB respond/VB to/TO IL-2/NN ,/, together/RB they/PRP form/VBP a/DT composite/JJ element/NN capable/JJ of/IN conferring/VBG IL-2/NN responsiveness/NN to/TO a/DT heterologous/JJ promoter/NN ./. 
Multiple/JJ factors/NNS including/VBG Stat5/NN ,/, Elf-1/NN ,/, HMG-I(Y)/NN and/CC GATA/NN family/NN proteins/NNS bind/VBP to/TO the/DT IL-2/NN response/NN element/NN and/CC mutation/NN of/IN any/DT one/CD of/IN these/DT binding/VBG sites/NNS diminishes/VBZ the/DT activity/NN of/IN this/DT element/NN ./. 
An/DT unidentified/JJ Ets/NN family/NN protein/NN binds/VBZ to/TO the/DT EBS/NN overlapping/VBG the/DT consensus/NN GAS/NN motif/NN and/CC appears/VBZ to/TO negatively/RB regulate/VB the/DT human/JJ IL-2R/NN alpha/NN promoter/NN ./. 
Thus/RB ,/, IL-2-induced/JJ IL-2R/NN alpha/NN promoter/NN activity/NN requires/VBZ a/DT complex/JJ upstream/JJ element/NN ,/, which/WDT appears/VBZ to/TO contain/VB binding/VBG sites/NNS for/IN both/CC positive/JJ and/CC negative/JJ regulatory/JJ factors/NNS ./. 
UI/LS -/: 97119289/CD 
TI/LS -/: Lymphocytes/NNS from/IN CML/NN patients/NNS lack/VBP a/DT 47/CD kDa/NN factor/NN having/VBG affinity/NN for/IN a/DT genomic/JJ sterol/NN regulatory/JJ sequence/NN ./. 
AB/LS -/: Deranged/VBN cellular/JJ cholesterol/NN homeostasis/NN has/VBZ been/VBN widely/RB recognized/VBN in/IN the/DT initiation/NN as/RB well/RB as/IN progression/NN of/IN various/JJ types/NNS of/IN cancers/NNS including/VBG chronic/JJ myeloid/JJ leukaemia/NN (/( CML/NN )/) ./. 
Since/IN the/DT human/JJ genomic/JJ sterol/NN regulatory/JJ element/NN (/( SRE/NN )/) has/VBZ been/VBN shown/VBN to/TO regulate/VB various/JJ key/JJ genes/NNS involved/VBN in/IN this/DT phenomenon/NN ,/, the/DT present/JJ study/NN revealed/VBD the/DT existence/NN of/IN a/DT unique/JJ 47/CD kDa/NN protein/NN factor/NN having/VBG affinity/NN for/IN this/DT SRE/JJ sequence/NN in/IN lymphocytes/NNS from/IN normal/JJ subjects/NNS ,/, as/RB well/RB as/IN its/PRP$ absence/NN in/IN lymphocytes/NNS from/IN untreated/JJ CML/NN patients/NNS ./. 
However/RB ,/, this/DT factor/NN appeared/VBD when/WRB these/DT CML/NN patients/NNS achieved/VBD complete/JJ haematological/JJ remission/NN (/( CHR/NN )/) through/IN alpha-interferon/NN therapy/NN ./. 
Furthermore/RB ,/, an/DT inverse/JJ relationship/NN was/VBD also/RB observed/VBN between/IN the/DT LDL/NN receptor/NN gene/NN expression/NN at/IN the/DT transcriptional/JJ level/NN and/CC the/DT binding/NN affinity/NN of/IN this/DT 47/CD kDa/NN protein/NN factor/NN to/TO the/DT SRE/NN sequence/NN ./. 
Based/VBN upon/IN these/DT results/NNS we/PRP propose/VBP that/IN this/DT factor/NN may/MD have/VB a/DT role/NN in/IN pathophysiology/NN of/IN chronic/JJ myeloid/JJ leukaemia/NN ./. 
UI/LS -/: 96413292/CD 
TI/LS -/: Cloning/NN and/CC characterization/NN of/IN the/DT beta/NN subunit/NN of/IN human/JJ proximal/JJ sequence/NN element-binding/JJ transcription/NN factor/NN and/CC its/PRP$ involvement/NN in/IN transcription/NN of/IN small/JJ nuclear/JJ RNA/NN genes/NNS by/IN RNA/NN polymerases/NNS II/CD and/CC III/CD ./. 
AB/LS -/: The/DT proximal/JJ sequence/NN element/NN (/( PSE/NN )/) -binding/JJ transcription/NN factor/NN (/( PTF/NN )/) ,/, which/WDT binds/VBZ the/DT PSE/NN of/IN both/CC RNA/NN polymerase/NN II-/NN and/CC RNA/NN polymerase/NN III-transcribed/JJ mammalian/JJ small/JJ nuclear/JJ RNA/NN (/( snRNA/NN )/) genes/NNS ,/, is/VBZ essential/JJ for/IN their/PRP$ transcription/NN ./. 
We/PRP previously/RB reported/VBD the/DT purification/NN of/IN human/JJ PTF/NN ,/, a/DT complex/NN of/IN four/CD subunits/NNS ,/, and/CC the/DT molecular/JJ cloning/NN and/CC characterization/NN of/IN PTF/NN gamma/NN and/CC delta/NN subunits/NNS ./. 
Here/RB we/PRP describe/VBP the/DT isolation/NN and/CC expression/NN of/IN a/DT cDNA/NN encoding/VBG PTF/NN beta/NN ,/, as/RB well/RB as/IN functional/JJ studies/NNS using/VBG anti-PTF/JJ beta/NN antibodies/NNS ./. 
Native/JJ PTF/NN beta/NN ,/, in/IN either/CC protein/NN fractions/NNS or/CC a/DT PTF-Oct-1-DNA/NN complex/NN ,/, can/MD be/VB recognized/VBN by/IN polyclonal/JJ antibodies/NNS raised/VBN against/IN recombinant/JJ PTF/NN beta/NN ./. 
Immunodepletion/NN studies/NNS show/VBP that/IN PTF/NN beta/NN is/VBZ required/VBN for/IN transcription/NN of/IN both/DT classes/NNS of/IN snRNA/NN genes/NNS in/FW vitro/FW ./. 
In/IN addition/NN ,/, immunoprecipitation/NN analyses/NNS demonstrate/VBP that/IN substantial/JJ and/CC similar/JJ molar/JJ amounts/NNS of/IN TATA-binding/JJ protein/NN (/( TBP/NN )/) and/CC TFIIIB90/NN can/MD weakly/RB associate/VBP with/IN PTF/NN at/IN low/JJ salt/NN conditions/NNS ,/, but/CC this/DT association/NN is/VBZ dramatically/RB reduced/VBN at/IN high/JJ salt/NN concentrations/NNS ./. 
Along/IN with/IN our/PRP$ previous/JJ demonstration/NN of/IN both/DT physical/JJ interactions/NNS between/IN PTF/NN gamma/NN //: PTF/NN delta/NN and/CC TBP/NN and/CC the/DT involvement/NN of/IN TFIIIB90/NN in/IN the/DT transcription/NN of/IN class/NN III/CD snRNA/NN genes/NNS ,/, these/DT results/NNS are/VBP consistent/JJ with/IN the/DT notion/NN that/IN a/DT TBP-containing/JJ complex/NN related/JJ to/TO TFIIIB/NN is/VBZ required/VBN for/IN the/DT transcription/NN of/IN class/NN III/CD snRNA/NN genes/NNS ,/, and/CC acts/VBZ through/IN weak/JJ interaction/NN with/IN the/DT four-subunit/JJ PTF/NN ./. 
UI/LS -/: 96397543/CD 
TI/LS -/: Attenuated/VBN function/NN of/IN a/DT variant/JJ form/NN of/IN the/DT helix-loop-helix/JJ protein/NN ,/, Id-3/NN ,/, generated/VBN by/IN an/DT alternative/JJ splicing/NN mechanism/NN ./. 
AB/LS -/: The/DT Id/NN family/NN of/IN helix-loop-helix/JJ proteins/NNS function/VBP as/IN negative/JJ regulators/NNS of/IN DNA/NN binding/NN ,/, basic/JJ helix-loop-helix/JJ proteins/NNS in/IN the/DT regulation/NN of/IN cell/NN growth/NN and/CC differentiation/NN ./. 
We/PRP report/VBP here/RB on/IN the/DT identification/NN of/IN a/DT 17/CD kDa/NN variant/NN of/IN the/DT 14/CD kDa/NN Id-3/NN protein/NN termed/VBN Id-3L/NN (/( long/JJ version/NN )/) which/WDT possesses/VBZ a/DT unique/JJ 60/CD amino/NN acid/NN carboxy-terminus/NN generated/VBN by/IN read/VBN through/IN of/IN a/DT '/`` coding/VBG intron/NN '/'' and/CC alternative/JJ splicing/NN ./. 
Northern/NN analysis/NN revealed/VBD expression/NN of/IN a/DT minor/JJ 1.1/CD kb/NN Id-3L/NN transcript/NN together/RB with/IN the/DT predominant/JJ 0.95/CD kb/NN Id-3/NN transcript/NN in/IN the/DT majority/NN of/IN adult/JJ human/JJ tissues/NNS analysed/VBN ./. 
The/DT variant/JJ Id-3L/NN protein/NN is/VBZ functionally/RB distinguishable/JJ from/IN conventional/JJ Id-3/NN since/IN in/IN in/FW vitro/FW DNA/NN mobility/NN shift/NN assays/NNS ,/, it/PRP was/VBD greatly/RB impaired/JJ in/IN its/PRP$ ability/NN to/TO abrogate/VB binding/NN of/IN the/DT basic/JJ helix-loop-helix/JJ protein/NN ,/, E47/NN ,/, to/TO an/DT E/NN box/NN recognition/NN sequence/NN ./. 
UI/LS -/: 96406504/CD 
TI/LS -/: Tyloxapol/NN inhibits/VBZ NF-kappa/NN B/NN and/CC cytokine/NN release/NN ,/, scavenges/VBZ HOCI/NN ,/, and/CC reduces/VBZ viscosity/NN of/IN cystic/JJ fibrosis/NN sputum/NN ./. 
AB/LS -/: Cystic/JJ fibrosis/NN (/( CF/NN )/) patients/NNS develop/VB progressive/JJ cytokine-mediated/JJ inflammatory/JJ lung/NN disease/NN ,/, with/IN abundant/JJ production/NN of/IN thick/JJ ,/, tenacious/JJ ,/, protease-/NN and/CC oxidant-rich/JJ purulent/JJ airway/NN secretions/NNS that/WDT are/VBP difficult/JJ to/TO clear/VB even/RB with/IN physiotherapy/NN ./. 
In/IN the/DT search/NN for/IN a/DT potential/JJ treatment/NN ,/, we/PRP have/VBP tested/VBN tyloxapol/NN ,/, an/DT alkylaryl/NN polyether/JJ alcohol/NN polymer/NN detergent/NN previously/RB used/VBN as/IN a/DT mucolytic/JJ agent/NN in/IN adult/JJ chronic/JJ bronchitis/NN ./. 
Tyloxapol/NN inhibits/VBZ activation/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor-kappa/NN B/NN (/( NK-kappa/NN B/NN )/) ,/, reduces/VBZ resting/VBG secretion/NN of/IN the/DT cytokine/NN interleukin-8/NN (/( IL-8/NN )/) in/IN cultured/VBN human/JJ monocytes/NNS ,/, and/CC inhibits/VBZ lipopolysaccharide/NN (/( LPS/NN )/) -stimulated/JJ release/NN of/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) ,/, IL-1/NN beta/NN ,/, IL-6/NN ,/, IL-8/NN ,/, granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) ,/, and/CC the/DT eiconsanoids/NNS thromboxane/NN A2/NN and/CC leukotriene/NN B4/NN (/( LTB4/NN )/) ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN tyloxapol/NN is/VBZ a/DT potent/JJ antioxidant/NN for/IN hydroxyl/NN radicals/NNS (/( OH/NN )/) ./. 
Tyloxapol/NN (/( 0.05/CD to/TO 0.1/CD %/NN wt/vol/NN )/) effectively/RB scavenges/VBZ the/DT oxidant/JJ hypochlorous/JJ acid/NN (/( HOCl/NN ;/: 1/CD to/TO 7.5/CD mM/NN )/) in/FW vitro/FW ,/, and/CC protects/VBZ from/IN HOCl-mediated/JJ lung/NN injury/NN in/IN rats/NNS ./. 
Tyloxapol/NN also/RB reduces/VBZ the/DT viscosity/NN of/IN CF/NN sputum/NN (/( from/IN 463/CD +/-/CC 133/CD to/TO 128/CD +/-/CC 52/CD centipoise/NN )/) ./. 
We/PRP conclude/VBP that/IN tyloxapol/NN is/VBZ potentially/RB useful/JJ as/IN a/DT new/JJ antiinflammatory/JJ therapy/NN for/IN CF/NN lung/NN disease/NN ,/, and/CC could/MD possibly/RB promote/VB clearance/NN of/IN secretions/NNS in/IN the/DT CF/NN airway/NN ./. 
UI/LS -/: 96355428/CD 
TI/LS -/: Elevated/JJ cyclic/JJ AMP/NN inhibits/VBZ NF-kappaB-mediated/JJ transcription/NN in/IN human/JJ monocytic/JJ cells/NNS and/CC endothelial/JJ cells/NNS ./. 
AB/LS -/: The/DT NF-kappaB/Rel/NN family/NN of/IN transcription/NN factors/NNS regulates/VBZ the/DT inducible/JJ expression/NN of/IN many/JJ genes/NNS in/IN activated/VBN human/JJ monocytes/NNS and/CC endothelial/JJ cells/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD the/DT molecular/JJ mechanism/NN by/IN which/WDT agents/NNS that/WDT elevate/VBP intracellular/JJ cAMP/NN inhibit/VBP the/DT expression/NN of/IN the/DT tumor/NN necrosis/NN factor/NN alpha/NN (/( TNFalpha/NN )/) ,/, tissue/NN factor/NN ,/, endothelial/JJ leukocyte/NN adhesion/NN molecule-1/NN ,/, and/CC vascular/JJ cell/NN adhesion/NN molecule-1/NN genes/NNS ./. 
Both/CC forskolin/NN and/CC dibutyryl/NN cAMP/NN ,/, which/WDT elevate/VBP intracellular/JJ cAMP/NN by/IN independent/JJ mechanisms/NNS ,/, inhibited/VBD TNFalpha/NN and/CC tissue/NN factor/NN expression/NN at/IN the/DT level/NN of/IN transcription/NN ./. 
Induction/NN of/IN NF-kappaB-dependent/JJ gene/NN expression/NN in/IN transiently/RB transfected/VBN human/JJ monocytic/JJ THP-1/NN cells/NNS and/CC human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS was/VBD inhibited/VBN by/IN elevated/JJ cAMP/NN and/CC by/IN overexpression/NN of/IN the/DT catalytic/JJ subunit/NN of/IN protein/NN kinase/NN A/NN (/( PKA/NN )/) ./. 
Elevated/JJ cAMP/NN did/VBD not/RB prevent/VB nuclear/JJ translocation/NN of/IN p50/p65/NN and/CC c-Rel/p65/NN heterodimers/NNS ,/, decrease/VB nuclear/JJ translocation/NN of/IN p65/NN ,/, or/CC significantly/RB modify/VB TNFalpha-induced/JJ phosphorylation/NN of/IN p65/NN ./. 
Functional/JJ studies/NNS demonstrated/VBD that/IN transcriptional/JJ activation/NN of/IN a/DT plasmid/NN containing/VBG multimerized/JJ kappaB/NN sites/NNS by/IN p65/NN was/VBD inhibited/VBN by/IN agents/NNS that/IN elevate/VBP cAMP/NN and/CC by/IN overexpression/NN of/IN the/DT catalytic/JJ subunit/NN of/IN PKA/NN ./. 
This/DT study/NN indicates/VBZ that/IN activation/NN of/IN PKA/NN reduces/VBZ the/DT induction/NN of/IN a/DT distinct/JJ set/NN of/IN genes/NNS in/IN monocytes/NNS and/CC endothelial/JJ cells/NNS by/IN inhibiting/VBG NF-kappaB-mediated/JJ transcription/NN ./. 
UI/LS -/: 97024837/CD 
TI/LS -/: Molecular/JJ mechanisms/NNS of/IN steroid/NN action/NN :/: a/DT novel/JJ type/NN of/IN cross-talk/NN between/IN glucocorticoids/NNS and/CC NF-kappa/NN B/NN transcription/NN factors/NNS ./. 
AB/LS -/: Despite/IN the/DT widespread/JJ use/NN of/IN glucocorticoids/NNS in/IN the/DT treatment/NN of/IN diseases/NNS characterized/VBN by/IN inflammation/NN ,/, the/DT molecular/JJ mechanism/NN (/( s/NNS )/) by/IN which/WDT these/DT hormones/NNS exert/VBP this/DT beneficial/JJ effect/NN in/IN patients/NNS with/IN asthma/NN remains/VBZ to/TO be/VB elucidated/VBN ./. 
Therefore/RB ,/, we/PRP have/VBP studied/VBN the/DT transcriptional/JJ regulation/NN of/IN intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN )/) as/IN adhesion/NN molecules/NNS are/VBP likely/JJ to/TO play/VB a/DT causal/JJ role/NN in/IN inflammation/NN in/IN promoting/VBG cell-cell/JJ and/CC cell-matrix/JJ interactions/NNS ./. 
We/PRP observed/VBD that/IN in/IN a/DT monocytic/JJ (/( U937/NN )/) and/CC a/DT bronchial/JJ epithelial/NN (/( H292/NN )/) cell-line/JJ dexamethasone/NN strongly/RB suppressed/VBD basal/JJ and/CC induced/VBN ICAM-1/NN expression/NN ./. 
Subsequent/JJ analysis/NN of/IN the/DT human/JJ ICAM-1/NN promoter/NN has/VBZ revealed/VBN that/IN both/CC 12-O-tetradecanoylphorbol/NN 13-acetate/NN (/( TPA/NN )/) and/CC tumour/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) upregulate/VBP ICAM-1/NN expression/NN through/IN the/DT presence/NN of/IN a/DT nuclear/JJ factor/NN (/( NF-kappa/NN B/NN )/) target/NN sequence/NN (/( TGGAAATTCC/NN )/) ./. 
No/DT glucocorticoid/NN recognition/NN sequences/NNS are/VBP present/JJ in/IN this/DT promoter/NN region/NN and/CC dexamethasone/NN is/VBZ still/RB able/JJ to/TO repress/VB transcription/NN when/WRB the/DT multimerized/JJ NF-kappa/NN B/NN sequence/NN is/VBZ transactivated/VBN by/IN TNF-alpha/NN upon/IN transfection/NN in/IN 293/CD cells/NNS ./. 
We/PRP propose/VBP that/IN direct/JJ interaction/NN between/IN the/DT glucocorticoid/NN receptor/NN and/CC nuclear/JJ factor-kappa/NN B/NN factors/NNS is/VBZ at/IN least/JJS a/DT partial/JJ explanation/NN for/IN the/DT effects/NNS of/IN this/DT hormone/NN in/IN inflammatory/JJ diseases/NNS ./. 
UI/LS -/: 96330347/CD 
TI/LS -/: Abnormalities/NNS of/IN p16/NN ,/, p15/NN and/CC CDK4/NN genes/NNS in/IN recurrent/JJ malignant/JJ astrocytomas/NNS ./. 
AB/LS -/: Abnormalities/NNS in/IN the/DT p16/NN ,/, p15/NN and/CC CDK4/NN genes/NNS that/WDT regulate/VBP transition/NN through/IN the/DT G1/NN phase/NN of/IN the/DT cell/NN cycle/NN have/VBP been/VBN implicated/VBN in/IN the/DT malignant/JJ progression/NN of/IN astrocytomas/NNS ./. 
The/DT results/NNS of/IN the/DT present/JJ study/NN demonstrate/VBP that/IN dysfunction/NN of/IN these/DT genes/NNS also/RB occurs/VBZ during/IN recurrence/NN of/IN glial/JJ tumors/NNS that/WDT were/VBD highly/RB malignant/JJ at/IN first/JJ presentation/NN ./. 
Analysis/NN of/IN 10/CD matched/VBN pairs/NNS of/IN high/JJ grade/NN malignant/JJ astrocytomas/NNS and/CC their/PRP$ subsequent/JJ recurrences/NNS identified/VBD three/CD distinct/JJ groups/NNS ./. 
The/DT primary/JJ and/CC recurrent/JJ tumors/NNS in/IN Group/NN A/NN did/VBD not/RB show/VB structural/JJ alterations/NNS in/IN the/DT p16/NN ,/, p15/NN or/CC CDK4/NN genes/NNS ,/, whereas/IN homozygous/JJ codeletion/NN of/IN p16/NN and/CC p15/NN was/VBD observed/VBN in/IN both/CC primary/JJ and/CC recurrent/JJ tumors/NNS in/IN Group/NN B/NN ./. 
The/DT primary/JJ tumors/NNS in/IN Group/NN C/NN had/VBD a/DT normal/JJ profile/NN of/IN p16/NN ,/, p15/NN and/CC CDK4/NN at/IN presentation/NN ./. 
Upon/IN recurrence/NN ,/, however/RB ,/, the/DT tumors/NNS sustained/VBD either/CC deletion/NN of/IN p16/NN alone/RB or/CC codeletion/NN of/IN both/CC p16/NN and/CC p15/NN or/CC amplification/NN of/IN CDK4/NN ./. 
Analysis/NN of/IN the/DT molecular/JJ differences/NNS between/IN primary/JJ anaplastic/JJ astrocytomas/glioblastomas/NNS and/CC their/PRP$ subsequent/JJ recurrences/NNS ,/, which/WDT are/VBP clinically/RB indistinguishable/JJ ,/, may/MD provide/VB better/JJR therapeutic/JJ options/NNS for/IN treatment/NN ./. 
UI/LS -/: 96293454/CD 
TI/LS -/: BCL-6/NN ,/, a/DT POZ/zinc-finger/NN protein/NN ,/, is/VBZ a/DT sequence-specific/JJ transcriptional/JJ repressor/NN ./. 
AB/LS -/: Approximately/RB 40/CD %/NN of/IN diffuse/JJ large/JJ cell/NN lymphoma/NN are/VBP associated/VBN with/IN chromosomal/JJ translocations/NNS that/WDT deregulate/VBP the/DT expression/NN of/IN the/DT BCL6/NN gene/NN by/IN juxtaposing/VBG heterologous/JJ promoters/NNS to/TO the/DT BCL-6/NN coding/NN domain/NN ./. 
The/DT BCL6/NN gene/NN encodes/VBZ a/DT 95-kDa/JJ protein/NN containing/VBG six/CD C-terminal/JJ zinc-finger/NN motifs/NNS and/CC an/DT N-terminal/JJ POZ/NN domain/NN ,/, suggesting/VBG that/IN it/PRP may/MD function/VB as/IN a/DT transcription/NN factor/NN ./. 
By/IN using/VBG a/DT DNA/NN sequence/NN selected/VBN for/IN its/PRP$ ability/NN to/TO bind/VB recombinant/JJ BCL-6/NN in/FW vitro/FW ,/, we/PRP show/VBP here/RB that/IN BCL-6/NN is/VBZ present/JJ in/IN DNA-binding/JJ complexes/NNS in/IN nuclear/JJ extracts/NNS from/IN various/JJ B-cell/NN lines/NNS ./. 
In/IN transient/JJ transfectin/NN experiments/NNS ,/, BCL6/NN can/MD repress/VB transcription/NN from/IN promoters/NNS linked/VBN to/TO its/PRP$ DNA/NN target/NN sequence/NN and/CC this/DT activity/NN is/VBZ dependent/JJ upon/IN specific/JJ DNA-binding/NN and/CC the/DT presence/NN of/IN an/DT intact/JJ N-terminal/JJ half/NN of/IN the/DT protein/NN ./. 
We/PRP demonstrate/VBP that/IN this/DT part/NN of/IN the/DT BCL6/NN molecule/NN contains/VBZ an/DT autonomous/JJ transrepressor/NN domain/NN and/CC that/IN two/CD noncontiguous/JJ regions/NNS ,/, including/VBG the/DT POZ/NN motif/NN ,/, mediate/VBP maximum/JJ transrepressive/JJ activity/NN ./. 
These/DT results/NNS indicate/VBP that/IN the/DT BCL-6/NN protein/NN can/MD function/VB as/IN a/DT sequence-specific/JJ transcriptional/JJ repressor/NN and/CC have/VBP implications/NNS for/IN the/DT role/NN of/IN BCL6/NN in/IN normal/JJ lymphoid/JJ development/NN and/CC lymphomagenesis/NN ./. 
UI/LS -/: 96285641/CD 
TI/LS -/: Signals/NNS leading/VBG to/TO the/DT activation/NN of/IN NF-kappa/NN B/NN transcription/NN factor/NN are/VBP stronger/JJR in/IN neonatal/JJ than/IN adult/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT molecular/JJ background/NN of/IN the/DT defects/NNS in/IN the/DT immune/JJ reactivity/NN of/IN human/JJ neonates/NNS has/VBZ not/RB been/VBN fully/RB elucidated/VBN ./. 
As/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN has/VBZ a/DT central/JJ role/NN in/IN the/DT control/NN of/IN transcription/NN of/IN several/JJ genes/NNS involved/VBN in/IN immune/JJ and/CC inflammatory/JJ responses/NNS ,/, the/DT authors/NNS have/VBP analysed/VBN the/DT activation/NN of/IN NF-kappa/NN B/NN in/IN human/JJ umbilical/JJ cord/NN T/NN lymphocytes/NNS ./. 
The/DT activity/NN was/VBD tested/VBN by/IN quantitating/VBG the/DT nuclear/JJ proteins/NNS binding/VBG to/TO an/DT oligonucleotide/NN containing/VBG the/DT consensus/NN kappa/NN B/NN binding/NN sequence/NN (/( electrophoretic/JJ mobility/NN shift/NN assay/NN )/) ./. 
The/DT data/NNS obtained/VBN demonstrate/VBP that/IN phorbol/NN dibutyrate/calcium/NN ionophore/NN A23187/NN (/( PDBu/iono/NN )/) combination/NN induced/VBD a/DT clearly/RB higher/JJR nuclear/JJ translocation/NN of/IN NF-kappa/NN B/NN in/IN neonatal/JJ than/IN adult/JJ T/NN cells/NNS ./. 
This/DT higher/JJR NF-kappa/NN B/NN activity/NN was/VBD restricted/JJ to/TO the/DT CD4+/JJ T-cell/NN subset/NN ./. 
Analysis/NN of/IN the/DT nuclear/JJ extracts/NNS with/IN antibodies/NNS directed/VBN against/IN the/DT major/JJ components/NNS of/IN NF-kappa/NN B/NN the/DT p50/NN and/CC RelA/NN (/( p65/NN )/) proteins/NNS ,/, indicated/VBD that/IN the/DT composition/NN of/IN NF-kappa/NN B/NN was/VBD similar/JJ in/IN neonatal/JJ and/CC adult/JJ cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN neonatal/JJ T/NN cells/NNS are/VBP exposed/VBN to/TO oxidative/JJ stress-inducing/JJ signals/NNS during/IN delivery/NN and/or/CC are/VBP inherently/RB more/RBR sensitive/JJ to/TO NF-kappa/NN B/NN activating/NN signals/NNS than/IN adult/JJ T/NN cells/NNS ./. 
UI/LS -/: 97028169/CD 
TI/LS -/: Dual/JJ action/NN of/IN retinoic/JJ acid/NN on/IN human/JJ embryonic/fetal/JJ hematopoiesis/NN :/: blockade/NN of/IN primitive/JJ progenitor/NN proliferation/NN and/CC shift/NN from/IN multipotent/erythroid/monocytic/JJ to/TO granulocytic/JJ differentiation/NN program/NN ./. 
AB/LS -/: In/IN preliminary/JJ studies/NNS ,/, we/PRP have/VBP analyzed/VBN the/DT hematopoietic/JJ growth/NN factor/NN (/( HGF/NN )/) requirement/NN of/IN hematopoietic/JJ progenitor/NN cells/NNS (/( HPCs/NNS )/) purified/VBN from/IN embryonic-fetal/JJ liver/NN (/( FL/NN )/) and/CC grown/VBN in/IN fetal/JJ calf/NN serum-supplemented/JJ (/( FCS+/NN )/) clonogenic/JJ culture/NN ./. 
The/DT key/JJ role/NN of/IN erythropoietin/NN (/( Epo/NN )/) for/IN colony/NN formation/NN by/IN early/JJ erythroid/JJ progenitors/NNS (/( burst-forming/JJ units-erythroid/JJ [/( BFU-E/NN ]/) )/) has/VBZ been/VBN confirmed/VBN ./. 
Furthermore/RB ,/, in/IN the/DT absence/NN of/IN exogenous/JJ HGFs/NNS ,/, FL/NN monocytic/JJ progenitors/NNS (/( colony-forming/JJ unit/NN monocyte/NN [/( CFU-M/NN ]/) )/) generate/VBP large/JJ colonies/NNS exclusively/RB composed/VBN of/IN monocytes-macrophages/NNS ;/: these/DT colonies/NNS are/VBP absent/JJ in/IN FCS-/NN clonogenic/JJ culture/NN ./. 
On/IN this/DT basis/NN ,/, we/PRP have/VBP investigated/VBN the/DT role/NN of/IN all-trans/JJ retinoic/JJ acid/NN (/( ATRA/NN )/) and/CC its/PRP$ isomer/NN 9-cis/JJ RA/NN in/IN FL/NN hematopoiesis/NN ./. 
Both/DT compounds/NNS modulate/VBP the/DT growth/NN of/IN purified/VBN FL/NN HPCs/NNS ,/, which/WDT show/VBP a/DT dose-dependent/JJ shift/NN from/IN mixed/erythroid/monocytic/JJ to/TO granulocytic/JJ colony/NN formation/NN ./. 
Studies/NNS on/IN unicellular/JJ and/CC paired/JJ daughter/NN cell/NN culture/NN unequivocally/RB indicate/VBP that/IN the/DT shift/NN is/VBZ mediated/VBN by/IN modulation/NN of/IN the/DT HPC/NN differentiation/NN program/NN to/TO the/DT granulopoietic/JJ pathway/NN (/( rather/RB than/IN RA-induced/JJ down-modulation/NN of/IN multipotent//JJ erythroid/monocytic/JJ HPC/NN growth/NN coupled/VBN with/IN recruitment/NN of/IN granulocytic/JJ HPCs/NNS )/) ./. 
ATRA/NN and/CC 9-cis/JJ RA/NN also/RB exert/VBP their/PRP$ effect/NN on/IN the/DT proliferation/NN of/IN primitive/JJ HPCs/NNS (/( high-proliferative/JJ potential/JJ colony-forming/JJ cells/NNS [/( HPP-CFCs/NNS ]/) )/) and/CC putative/JJ hematopoietic/JJ stem/NN cells/NNS (/( HSCs/NNS ;/: assayed/VBN in/IN Dexter-type/JJ long-term/JJ culture/NN )/) ./. 
High/JJ concentrations/NNS of/IN either/DT compound/NN (/( 1/LS )/) drastically/RB reduced/VBD the/DT number/NN of/IN primary/JJ HPP-CFC/NN colonies/NNS and/CC totally/RB abolished/VBD their/PRP$ recloning/VBG capacity/NN and/CC (/( 2/LS )/) inhibited/VBD HSC/NN proliferation/NN ./. 
It/PRP is/VBZ crucial/JJ that/IN these/DT results/NNS mirror/VBP recent/JJ observations/NNS indicating/VBG that/IN murine/JJ adult/JJ HPCs/NNS transduced/VBN with/IN dominant/JJ negative/JJ ATRA/NN receptor/NN (/( RAR/NN )/) gene/NN are/VBP immortalized/VBN and/CC show/VBP a/DT selective/JJ blockade/NN of/IN granulocytic/JJ differentiation/NN ./. 
Altogether/RB ,/, these/DT results/NNS suggest/VBP that/IN ATRA/9-cis/NN RA/NN may/MD play/VB a/DT key/JJ role/NN in/IN FL/NN hematopoiesis/NN via/IN a/DT dual/JJ effect/NN hypothetically/RB mediated/VBN by/IN interaction/NN with/IN the/DT RAR/RXR/NN heterodimer/NN ,/, ie/FW ,/, inhibition/NN of/IN HSC//NN primitive/JJ HPC/NN proliferation/NN and/CC induction/NN of/IN CFU-GEMM//NN BFU-E/CFU-M/NN shift/NN from/IN the/DT multipotent/erythroid/monocytic/JJ to/TO the/DT granulocytic-neutrophilic/JJ differentiation/NN program/NN ./. 
UI/LS -/: 97118356/CD 
TI/LS -/: Dexamethasone/NN suppression/NN test/NN :/: corticosteroid/NN receptors/NNS regulation/NN in/IN mononuclear/JJ leukocytes/NNS of/IN young/JJ and/CC aged/JJ subjects/NNS ./. 
AB/LS -/: The/DT dexamethasone/NN suppression/NN test/NN (/( DST/NN )/) is/VBZ considered/VBN an/DT indicator/NN of/IN the/DT function/NN of/IN the/DT adrenal/JJ pituitary/JJ axis/NN ./. 
The/DT effect/NN of/IN the/DT steroid/NN is/VBZ mediated/VBN by/IN its/PRP$ binding/NN to/TO corticosteroid/NN receptors/NNS ./. 
We/PRP previously/RB suggested/VBD that/IN the/DT measurement/NN of/IN corticosteroid/NN receptors/NNS in/IN lymphocytes/NNS is/VBZ an/DT index/NN of/IN an/DT analogous/JJ pattern/NN in/IN brain/NN ./. 
In/IN the/DT present/JJ study/NN ,/, corticosteroid/NN Type/NN I/CD and/CC Type/NN II/CD receptors/NNS in/IN mononuclear/JJ leukocytes/NNS were/VBD measured/VBN in/IN 10/CD elderly/JJ subjects/NNS and/CC in/IN 9/CD young/JJ adults/NNS ,/, before/IN and/CC after/IN overnight/JJ DST/NN (/( 1/CD mg/NN )/) ./. 
Receptors/NNS were/VBD measured/VBN by/IN radioreceptor/NN assay/NN ./. 
In/IN all/PDT the/DT subjects/NNS ,/, dexamethasone/NN was/VBD able/JJ to/TO suppress/VB plasma/NN cortisol/NN ./. 
The/DT number/NN of/IN Type/NN I/CD and/CC Type/NN II/CD receptors/NNS before/IN the/DT test/NN was/VBD lower/JJR in/IN elderly/JJ subjects/NNS than/IN in/IN adults/NNS ./. 
In/IN the/DT control/NN group/NN ,/, dexamethasone/NN produced/VBD a/DT significant/JJ depression/NN of/IN Type/NN I/CD receptors/NNS (/( from/IN 267/CD +/-/CC 72/CD to/TO 169/CD +/-/CC 71/CD receptors/NNS per/IN cell/NN )/) ,/, which/WDT can/MD be/VB interpreted/VBN as/IN a/DT primary/JJ involvement/NN of/IN Type/NN I/CD receptors/NNS in/IN the/DT response/NN to/TO dexamethasone/NN ;/: Type/NN II/CD receptors/NNS decreased/VBD in/IN half/PDT the/DT subjects/NNS (/( from/IN 2849/CD +/-/CC 703/CD to/TO 2345/CD +/-/CC 569/CD receptors/NNS per/IN cell/NN )/) ./. 
In/IN elderly/JJ healthy/JJ subjects/NNS ,/, Type/NN II/CD receptors/NNS were/VBD also/RB significantly/RB decreased/VBN (/( from/IN 1796/CD +/-/CC 671/CD to/TO 720/CD +/-/CC 345/CD )/) ./. 
We/PRP suggest/VBP that/IN in/IN young/JJ subjects/NNS Type/NN II/CD receptors/NNS are/VBP initially/RB up-regulated/VBN by/IN dexamethasone/NN ,/, and/CC then/RB down-regulated/VBN ,/, while/IN in/RB aged/JJ subjects/NNS an/DT up-regulation/NN can/MD not/RB be/VB achieved/VBN ,/, as/IN suggested/VBN by/IN the/DT higher/JJR values/NNS of/IN plasma/NN cortisol/NN usually/RB found/VBN in/IN aging/VBG subjects/NNS ./. 
UI/LS -/: 96413288/CD 
TI/LS -/: Analysis/NN of/IN the/DT ligand-binding/JJ domain/NN of/IN human/JJ retinoic/JJ acid/NN receptor/NN alpha/NN by/IN site-directed/JJ mutagenesis/NN ./. 
AB/LS -/: Three/CD subtypes/NNS of/IN retinoic/JJ acid/NN receptors/NNS (/( RAR/NN )/) ,/, termed/VBN RAR/NN alpha/NN ,/, RAR/NN beta/NN ,/, and/CC RAR/NN gamma/NN ,/, have/VBP been/VBN described/VBN ./. 
They/PRP are/VBP composed/VBN of/IN different/JJ structural/JJ domains/NNS ,/, including/VBG distinct/JJ domains/NNS for/IN DNA/NN and/CC ligand/NN binding/NN ./. 
RARs/NNS specifically/RB bind/VBP all-trans-retinoic/JJ acid/NN (/( RA/NN )/) ,/, 9-cis-RA/NN ,/, and/CC retinoid/JJ analogs/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD the/DT functional/JJ role/NN of/IN cysteine/NN and/CC arginine/NN residues/NNS in/IN the/DT ligand-binding/JJ domain/NN of/IN hRAR/NN alpha/NN (/( hRAR/NN alpha-LBD/NN ,/, amino/NN acids/NNS 154/CD to/TO 462/CD )/) ./. 
All/DT conserved/VBN cysteine/NN and/CC arginine/NN residues/NNS in/IN this/DT domain/NN were/VBD mutated/VBN by/IN site-directed/JJ mutagenesis/NN ,/, and/CC the/DT mutant/JJ proteins/NNS were/VBD characterized/VBN by/IN blocking/VBG reactions/NNS ,/, ligand-binding/JJ experiments/NNS ,/, transactivation/NN assays/NNS ,/, and/CC protease/NN mapping/NN ./. 
Changes/NNS of/IN any/DT cysteine/JJ residue/NN of/IN the/DT hRAR/NN alpha-LBD/NN had/VBD no/DT significant/JJ influence/NN on/IN the/DT binding/NN of/IN all-trans/JJ RA/NN or/CC 9-cis/JJ RA/NN ./. 
Interestingly/RB ,/, residue/JJ C-235/NN is/VBZ specifically/RB important/JJ in/IN antagonist/NN binding/NN ./. 
With/IN respect/NN to/TO arginine/NN residues/NNS ,/, only/RB the/DT two/CD single/JJ mutations/NNS of/IN R-276/NN and/CC R-394/NN to/TO alanine/NN showed/VBD a/DT dramatic/JJ decrease/NN of/IN agonist/NN and/CC antagonist/NN binding/NN whereas/IN the/DT R272A/NN mutation/NN showed/VBD only/RB a/DT slight/JJ effect/NN ./. 
For/IN all/DT other/JJ arginine/NN mutations/NNS ,/, no/DT differences/NNS in/IN affinity/NN were/VBD detectable/JJ ./. 
The/DT two/CD mutations/NNS R217A/NN and/CC R294A/NN caused/VBD an/DT increased/VBN binding/NN efficiency/NN for/IN antagonists/NNS but/CC no/DT change/NN in/IN agonist/NN binding/NN ./. 
From/IN these/DT results/NNS ,/, we/PRP can/MD conclude/VB that/IN electrostatic/JJ interactions/NNS of/IN retinoids/NNS with/IN the/DT RAR/NN alpha-LBD/NN play/VBP a/DT significant/JJ role/NN in/IN ligand/NN binding/NN ./. 
In/IN addition/NN ,/, antagonists/NNS show/VBP distinctly/RB different/JJ requirements/NNS for/IN efficient/JJ binding/NN ,/, which/WDT may/MD contribute/VB to/TO their/PRP$ interference/NN in/IN the/DT ligand-inducible/JJ transactivation/NN function/NN of/IN RAR/NN alpha/NN ./. 
UI/LS -/: 96397528/CD 
TI/LS -/: IL4/NN and/CC IL13/NN receptors/NNS share/VBP the/DT gamma/NN c/NN chain/NN and/CC activate/VBP STAT6/NN ,/, STAT3/NN and/CC STAT5/NN proteins/NNS in/IN normal/JJ human/JJ B/NN cells/NNS ./. 
AB/LS -/: IL13/NN induces/VBZ the/DT same/JJ biological/JJ effects/NNS as/IN IL4/NN in/IN normal/JJ human/JJ B/NN cells/NNS ./. 
We/PRP show/VBP that/IN as/IN in/IN the/DT IL4R/NN complex/NN ,/, both/CC IL4R/NN alpha/NN and/CC IL2R/NN gamma/NN c/NN are/VBP components/NNS of/IN the/DT IL13R/NN and/CC that/IN both/DT cytokines/NNS induced/VBD STAT6/NN ,/, STAT3/NN and/CC STAT5/NN activation/NN in/IN B/NN cells/NNS ./. 
In/IN spite/NN of/IN this/DT similar/JJ downstream/JJ signalling/NN ,/, IL4/NN and/CC IL13/NN used/VBD a/DT different/JJ set/NN of/IN Janus/NN kinases/NNS :/: IL13/NN is/VBZ unable/JJ to/TO activate/VB JAK1/NN and/CC JAK3/NN ./. 
UI/LS -/: 96387353/CD 
TI/LS -/: Calcineurin/NN mutants/NNS render/VBP T/NN lymphocytes/NNS resistant/JJ to/TO cyclosporin/NN A/NN ./. 
AB/LS -/: The/DT immunosuppressants/NNS cyclosporin/NN A/NN (/( CsA/NN )/) and/CC FK506/NN have/VBP been/VBN widely/RB used/VBN to/TO prevent/VB and/CC treat/VB graft/NN rejection/NN after/IN human/JJ organ/NN and/CC tissue/NN transplantations/NNS ./. 
CsA/NN and/CC FK506/NN associate/VBP with/IN intracellular/JJ binding/VBG proteins/NNS (/( i.e./FW ,/, CsA/NN with/IN cyclophilin/NN A/NN and/CC FK506/NN with/IN FKBP12/NN )/) to/TO form/VB protein/drug/NN complexes/NNS that/WDT suppress/VBP the/DT immune/JJ system/NN by/IN preventing/VBG activation/NN of/IN T/NN cells/NNS in/IN response/NN to/TO antigen/NN presentation/NN ./. 
The/DT common/JJ target/NN of/IN CsA/NN and/CC FK506/NN is/VBZ calcineurin/NN ,/, a/DT Ca2+/calmodulin-regulated/JJ ,/, serine/threonine-specific/JJ protein/NN phosphatase/NN that/WDT regulates/VBZ the/DT nuclear/JJ import/NN of/IN a/DT transcription/NN factor/NN ,/, NF-AT/NN ,/, required/VBN for/IN expression/NN of/IN T/NN cell/NN activation/NN genes/NNS ./. 
In/IN previous/JJ studies/NNS ,/, we/PRP identified/VBD calcineurin/NN mutations/NNS that/WDT block/VBP binding/NN by/IN the/DT cyclophilin/NN A/CsA/NN or/CC FKBP12/FK506/NN complexes/NNS and/CC thereby/RB render/VBP yeast/NN cells/NNS resistant/JJ to/TO the/DT antifungal/JJ effects/NNS of/IN CsA/NN or/CC FK506/NN ./. 
In/IN this/DT report/NN ,/, we/PRP demonstrate/VBP that/IN the/DT corresponding/JJ mutations/NNS in/IN murine/JJ calcineurin/NN render/VBP the/DT T/NN cell/NN receptor/NN signal/NN transduction/NN cascade/NN CsA/NN resistant/JJ in/IN human/JJ Jurkat/NN T/NN cells/NNS ./. 
Our/PRP$ findings/NNS support/VBP the/DT recently/RB determined/VBN calcineurin/NN X-ray/NN crystal/NN structure/NN ,/, provide/VBP evidence/NN that/IN calcineurin/NN is/VBZ the/DT only/RB CsA-sensitive/JJ component/NN limiting/VBG signaling/NN from/IN the/DT T/NN cell/NN receptor/NN to/TO the/DT nucleus/NN ,/, and/CC suggest/VBP a/DT means/NN to/TO render/VB cells/NNS and/CC tissues/NNS resistant/JJ to/TO the/DT toxic/JJ side/JJ effects/NNS of/IN CsA/NN and/CC FK506/NN ./. 
UI/LS -/: 96392389/CD 
TI/LS -/: Epstein-Barr/JJ viral/JJ latency/NN is/VBZ disrupted/VBN by/IN the/DT immediate-early/JJ BRLF1/NN protein/NN through/IN a/DT cell-specific/JJ mechanism/NN ./. 
AB/LS -/: Epstein-Barr/JJ virus/NN (/( EBV/NN )/) ,/, the/DT causative/JJ agent/NN of/IN infectious/JJ mononucleosis/NN ,/, is/VBZ a/DT human/JJ herpesvirus/NN associated/VBN with/IN epithelial/JJ cell/NN malignancies/NNS (/( nasopharyngeal/JJ carcinoma/NN )/) as/RB well/RB as/IN B-cell/NN malignancies/NNS ./. 
Understanding/VBG how/WRB viral/JJ latency/NN is/VBZ disrupted/VBN is/VBZ a/DT central/JJ issue/NN in/IN herpesvirus/JJ biology/NN ./. 
Epithelial/JJ cells/NNS are/VBP the/DT major/JJ site/NN of/IN lytic/JJ EBV/NN replication/NN within/IN the/DT human/JJ host/NN ,/, and/CC viral/JJ reactivation/NN occurs/VBZ in/IN EBV-associated/JJ nasopharyngeal/JJ carcinomas/NNS ./. 
It/PRP is/VBZ known/VBN that/IN expression/NN of/IN a/DT single/JJ viral/JJ immediate-early/JJ protein/NN ,/, BZLF1/NN ,/, is/VBZ sufficient/JJ to/TO initiate/VB the/DT switch/NN from/IN latent/JJ to/TO lytic/JJ infection/NN in/IN B/NN cells/NNS ./. 
Cellular/JJ regulation/NN of/IN BZLF1/NN transcription/NN is/VBZ therefore/RB thought/VBN to/TO play/VB a/DT key/JJ role/NN in/IN regulating/VBG the/DT stringency/NN of/IN viral/JJ latency/NN ./. 
Here/RB we/PRP show/VBP that/IN ,/, unexpectedly/RB ,/, expression/NN of/IN another/DT viral/JJ immediate-early/JJ protein/NN ,/, BRLF1/NN ,/, can/MD disrupt/VB viral/JJ latency/NN in/IN an/DT epithelial/JJ cell-specific/JJ fashion/NN ./. 
Therefore/RB ,/, the/DT mechanisms/NNS leading/VBG to/TO disruption/NN of/IN EBV/NN latency/NN appear/VBP to/TO be/VB cell-type/NN specific/JJ ./. 
UI/LS -/: 97024832/CD 
TI/LS -/: Eosinophil/NN priming/NN by/IN cytokines/NNS :/: from/IN cellular/JJ signal/NN to/TO in/FW vivo/FW modulation/NN ./. 
AB/LS -/: Eosinophils/NNS play/VBP an/DT important/JJ role/NN in/IN the/DT effector/NN phase/NN of/IN allergic/JJ inflammation/NN ./. 
This/DT review/NN will/MD focus/VB on/IN the/DT conversion/NN of/IN the/DT unprimed/JJ eosinophil/NN phenotype/NN in/IN the/DT peripheral/JJ blood/NN of/IN normal/JJ individuals/NNS to/TO the/DT primed/JJ phenotype/NN found/VBN in/IN the/DT peripheral/JJ blood/NN and/CC tissues/NNS of/IN allergic/JJ patients/NNS ,/, a/DT phenomenon/NN called/VBN priming/NN ./. 
Recent/JJ data/NNS on/IN the/DT signals/NNS initiated/VBN after/IN cytokine/NN receptor/NN activation/NN on/IN eosinophils/NNS will/MD be/VB reviewed/VBN ./. 
UI/LS -/: 96338163/CD 
TI/LS -/: CTL/NN recognition/NN of/IN an/DT altered/JJ peptide/NN associated/VBN with/IN asparagine/NN bond/NN rearrangement/NN ./. 
Implications/NNS for/IN immunity/NN and/CC vaccine/NN design/NN ./. 
AB/LS -/: The/DT extent/NN to/TO which/WDT peptides/NNS containing/VBG chemically/RB and/CC post-translationally/RB modified/VBN amino/NN acid/NN side/JJ chains/NNS are/VBP recognized/VBN by/IN primed/JJ CTL/NN has/VBZ not/RB been/VBN clearly/RB defined/VBN ./. 
We/PRP report/VBP on/IN the/DT CTL/NN recognition/NN of/IN a/DT MHC/NN class/NN I-restricted/JJ peptide/NN containing/VBG a/DT cyclized/JJ asparagine/NN (/( succinimide/NN )/) residue/NN ./. 
This/DT modification/NN of/IN the/DT asparagine/NN side/JJ chain/NN is/VBZ a/DT common/JJ intermediate/JJ structure/NN during/IN deamidation/NN ,/, isomerization/NN ,/, and/CC bond/NN rearrangements/NNS of/IN amide-containing/JJ amino/NN acids/NNS and/CC also/RB occurs/VBZ as/IN a/DT side/JJ reaction/NN in/IN peptide/NN synthesis/NN ./. 
The/DT CTL/NN specifically/RB recognized/VBD the/DT succinimide-containing/JJ peptide/NN showing/VBG only/RB weak/JJ cross-reactivity/NN at/IN high/JJ concentrations/NNS of/IN the/DT parent/NN peptide/NN containing/VBG unmodified/JJ asparagine/NN ./. 
Similarly/RB ,/, CTL/NN raised/VBN against/IN the/DT parent/NN peptide/NN did/VBD not/RB recognize/VB the/DT succinimide/JJ derivative/NN of/IN this/DT peptide/NN ./. 
Naturally/RB processed/VBN forms/NNS of/IN these/DT structures/NNS are/VBP likely/JJ to/TO occur/VB given/VBN the/DT importance/NN and/CC frequency/NN of/IN deamidation/NN both/CC in/FW vitro/FW and/CC in/FW vivo/FW ./. 
Moreover/RB ,/, since/IN succinimide/NN intermediates/NNS of/IN deamidated/VBN peptides/NNS can/MD occasionally/RB be/VB very/RB stable/JJ ,/, these/DT peptides/NNS have/VBP the/DT potential/NN to/TO act/VB as/IN altered/JJ self-Ags/NNS with/IN significant/JJ implications/NNS for/IN autoimmunity/NN ./. 
In/IN addition/NN ,/, unwanted/JJ and/CC potentially/RB hazardous/JJ specificities/NNS may/MD be/VB elicited/VBN when/WRB using/VBG synthetic/JJ peptides/NNS in/IN subunit/NN vaccines/NNS in/IN which/WDT succinimide/NN residues/NNS may/MD form/VB spontaneously/RB during/IN storage/NN or/CC chemical/JJ synthesis/NN ./. 
UI/LS -/: 96279126/CD 
TI/LS -/: A/DT 3'/JJ -->/TO 5'/JJ XPB/NN helicase/NN defect/NN in/IN repair/transcription/NN factor/NN TFIIH/NN of/IN xeroderma/NN pigmentosum/NN group/NN B/NN affects/VBZ both/CC DNA/NN repair/NN and/CC transcription/NN ./. 
AB/LS -/: XPB/NN is/VBZ a/DT subunit/NN of/IN the/DT basal/JJ transcription/NN factor/NN TFIIH/NN ,/, which/WDT is/VBZ also/RB involved/VBN in/IN nucleotide/NN excision/NN repair/NN (/( NER/NN )/) and/CC potentially/RB in/IN cell/NN cycle/NN regulation/NN ./. 
A/DT frameshift/NN mutation/NN in/IN the/DT 3'-end/NN of/IN the/DT XPB/NN gene/NN is/VBZ responsible/JJ for/IN a/DT concurrence/NN of/IN two/CD disorders/NNS :/: xeroderma/NN pigmentosum/NN (/( XP/NN )/) and/CC Cockayne/NN 's/POS syndrome/NN (/( CS/NN )/) ./. 
We/PRP have/VBP isolated/VBN TFIIH/NN from/IN cells/NNS derived/VBN from/IN a/DT patient/NN (/( XP11BE/NN )/) who/WP carries/VBZ this/DT frameshift/NN mutation/NN (/( TFIIHmut/NN )/) and/CC from/IN the/DT mother/NN of/IN this/DT patient/NN (/( TFIIHwt/NN )/) to/TO determine/VB the/DT biochemical/JJ consequences/NNS of/IN the/DT mutation/NN ./. 
Although/IN identical/JJ in/IN composition/NN and/CC stoichiometry/NN to/TO TFIIHwt/NN ,/, TFIIHmut/NN shows/VBZ a/DT reduced/VBN 3'/JJ -->/TO 5'/JJ XPB/NN helicase/NN activity/NN ./. 
A/DT decrease/NN in/IN helicase/NN and/CC DNA-dependent/JJ ATPase/NN activities/NNS was/VBD also/RB observed/VBN with/IN the/DT mutated/VBN recombinant/JJ XPB/NN protein/NN ./. 
The/DT XPB/NN mutation/NN causes/VBZ a/DT severe/JJ NER/NN defect/NN ./. 
In/IN addition/NN ,/, we/PRP provide/VBP evidence/NN for/IN a/DT decrease/NN in/IN basal/JJ transcription/NN activity/NN in/FW vitro/FW ./. 
The/DT latter/JJ defect/NN may/MD provide/VB an/DT explanation/NN for/IN many/JJ of/IN the/DT XP/NN and/CC CS/NN symptoms/NNS that/WDT are/VBP difficult/JJ to/TO rationalize/VB based/VBN solely/RB on/IN an/DT NER/NN defect/NN ./. 
Thus/RB ,/, this/DT work/NN presents/VBZ the/DT first/JJ detailed/JJ analysis/NN of/IN a/DT naturally/RB occurring/VBG mutation/NN in/IN a/DT basal/JJ transcription/NN factor/NN and/CC supports/VBZ the/DT concept/NN that/IN the/DT combined/JJ XP/CS/NN clinical/JJ entity/NN is/VBZ actually/RB the/DT result/NN of/IN a/DT combined/JJ transcription/repair/NN deficiency/NN ./. 
UI/LS -/: 96305203/CD 
TI/LS -/: The/DT Ets/NN protein/NN Spi-B/NN is/VBZ expressed/VBN exclusively/RB in/IN B/NN cells/NNS and/CC T/NN cells/NNS during/IN development/NN ./. 
AB/LS -/: Spi-B/NN and/CC PU.1/NN are/VBP hematopoietic-specific/JJ transcription/NN factors/NNS that/WDT constitute/VBP a/DT subfamily/NN of/IN the/DT Ets/NN family/NN of/IN DNA-binding/JJ proteins/NNS ./. 
Here/RB we/PRP show/VBP that/IN contrary/JJ to/TO previous/JJ reports/NNS ,/, PU.1/NN and/CC Spi-B/NN have/VBP very/RB different/JJ expression/NN patterns/NNS ./. 
PU.1/NN is/VBZ expressed/VBN at/IN high/JJ levels/NNS in/IN B/NN cells/NNS ,/, mast/NN cells/NNS ,/, megakaryocytes/NNS ,/, macrophages/NNS ,/, neutrophils/NNS ,/, and/CC immature/JJ erythroid/JJ cells/NNS and/CC at/IN lower/JJR levels/NNS in/IN mature/JJ erythrocytes/NNS ./. 
PU.1/NN is/VBZ completely/RB absent/JJ from/IN peripheral/JJ T/NN cells/NNS and/CC most/JJS T/JJ cell/NN lines/NNS based/VBN on/IN sensitive/JJ RT-PCR/NN assays/NNS ./. 
In/IN contrast/NN ,/, Spi-B/NN is/VBZ expressed/VBN exclusively/RB in/IN lymphoid/JJ cells/NNS and/CC can/MD be/VB detected/VBN in/IN early/JJ fetal/JJ thymus/NN and/CC spleen/NN ./. 
In/FW situ/FW hybridizations/NNS of/IN adult/JJ murine/JJ tissues/NNS demonstrate/VBP Spi-B/NN mRNA/NN in/IN the/DT medulla/NN of/IN the/DT thymus/NN ,/, the/DT white/JJ pulp/NN of/IN the/DT spleen/NN ,/, and/CC the/DT germinal/JJ centers/NNS of/IN lymph/NN nodes/NNS ./. 
Spi-B/JJ expression/NN is/VBZ very/RB abundant/JJ in/IN B/NN cells/NNS and/CC both/CC Spi-B/NN mRNA/NN and/CC protein/NN are/VBP detected/VBN in/IN some/DT T/NN cells/NNS ./. 
In/FW situ/FW hybridization/NN and/CC Northern/NN blot/NN analysis/NN suggest/VBP that/IN Spi-B/NN gene/NN expression/NN increases/VBZ during/IN B/NN cell/NN maturation/NN and/CC decreases/VBZ during/IN T/NN cell/NN maturation/NN ./. 
Gel-retardation/JJ experiments/NNS show/VBP that/IN Spi-B/NN can/MD bind/VB to/TO all/DT putative/JJ PU.1/NN binding/NN sites/NNS ,/, but/CC do/VBP not/RB reveal/VB any/DT preferred/JJ Spi-B/NN binding/NN site/NN ./. 
Finally/RB ,/, both/CC PU.1/NN and/CC Spi-B/NN function/VBP as/IN transcriptional/JJ activators/NNS of/IN the/DT immunoglobulin/JJ light-chain/NN enhancer/NN E/NN lambda/NN 2.4/CD when/WRB coexpressed/VBN with/IN Pip/NN (/( PU.1-interaction/JJ partner/NN )/) in/IN NIH-3T3/NN cells/NNS ./. 
Taken/VBN together/RB ,/, these/DT data/NNS suggest/VBP that/IN differences/NNS in/IN patterns/NNS of/IN expression/NN between/IN Spi-B/NN and/CC PU.1/NN distinguish/VBP the/DT function/NN of/IN each/DT protein/NN during/IN development/NN of/IN the/DT immune/JJ system/NN ./. 
UI/LS -/: 97025459/CD 
TI/LS -/: A/DT critical/JJ role/NN of/IN Sp1-/NN and/CC Ets-related/JJ transcription/NN factors/NNS in/IN maintaining/VBG CTL-specific/JJ expression/NN of/IN the/DT mouse/NN perforin/NN gene/NN ./. 
AB/LS -/: This/DT study/NN was/VBD designed/VBN to/TO determine/VB the/DT potential/JJ cis-elements/NNS involved/VBN in/IN transcriptional/JJ regulation/NN of/IN the/DT mouse/NN perforin/NN gene/NN ./. 
DNase/NN I/CD hypersensitive/JJ site/NN (/( DHS/NN )/) mapping/NN revealed/VBD that/IN the/DT perforin/NN locus/NN contained/VBD six/CD DHS/NN within/IN 7.0/CD kb/NN of/IN the/DT 5'/JJ upstream/JJ sequence/NN (/( -7.0/CD kb/NN )/) and/CC two/CD DHS/NN in/IN intron/NN 2/CD ./. 
The/DT six/CD 5'/JJ upstream/JJ and/CC one/CD intronic/JJ DHS/NN were/VBD detected/VBN in/IN only/RB perforin-expressing/JJ lymphocytes/NNS ./. 
Chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) activities/NNS directed/VBN by/IN 5'/JJ upstream/JJ promoter/NN were/VBD detected/VBN preferentially/RB in/IN perforin-expressing/JJ cell/NN lines/NNS ./. 
A/DT construct/NN termed/VBN PFP5a/NN containing/VBG -795/CD bp/NN exhibited/VBD the/DT highest/JJS CAT/NN activity/NN ,/, and/CC PFP9a20/NN containing/VBG only/RB -73/CD bp/NN also/RB produced/VBD significantly/RB high/JJ CAT/NN activity/NN in/IN CTLL-R8/NN cells/NNS ./. 
The/DT proximal/JJ region/NN in/IN PFP9a20/NN contained/VBD two/CD potential/JJ Sp1/NN binding/NN sites/NNS (/( GC/NN box/NN and/CC GT/NN box/NN )/) and/CC one/CD Ets/NN binding/NN site/NN (/( EBS/NN )/) ./. 
Electrophoretic/JJ mobility/NN shift/NN assay/NN showed/VBD that/IN each/DT of/IN the/DT cis-elements/NNS bound/VBD specific/JJ protein/NN factors/NNS ./. 
When/WRB single-point/JJ mutation/NN was/VBD introduced/VBN to/TO each/DT GC/NN box/NN ,/, EBS/NN ,/, and/CC GT/NN box/NN in/IN PFP9a20/NN ,/, at/IN least/JJS 3-fold/RB less/JJR CAT/NN activity/NN was/VBD observed/VBN in/IN CTLL-R8/NN cells/NNS ./. 
To/TO confirm/VB the/DT importance/NN of/IN the/DT three/CD cis-acting/JJ elements/NNS in/IN the/DT perforin/NN gene/NN expression/NN ,/, point/NN mutation/NN was/VBD introduced/VBN again/RB to/TO each/DT proximal/JJ GC/NN box/NN ,/, EBS/NN ,/, and/CC GT/NN box/NN of/IN PFP5a/NN ./. 
The/DT point/NN mutations/NNS resulted/VBD in/IN a/DT 2.5-/CD to/TO 3-fold/JJ reduction/NN of/IN CAT/NN activity/NN ./. 
The/DT results/NNS suggest/VBP that/IN a/DT combination/NN of/IN the/DT three/CD proximal/JJ cis-acting/JJ elements/NNS may/MD constitute/VB a/DT minimal/JJ region/NN responsible/JJ for/IN CTL-specific/JJ expression/NN of/IN perforin/NN ./. 
UI/LS -/: 97083787/CD 
TI/LS -/: The/DT Oct-2/NN transcription/NN factor/NN ./. 
AB/LS -/: The/DT Oct-2/NN transcription/NN factor/NN is/VBZ a/DT member/NN of/IN the/DT POU/NN (/( Pit-Oct-Unc/NN )/) family/NN of/IN transcription/NN factors/NNS and/CC is/VBZ expressed/VBN only/RB in/IN B/NN lymphocytes/NNS and/CC in/IN neuronal/JJ cells/NNS but/CC not/RB in/IN other/JJ cell/NN types/NNS ./. 
The/DT primary/JJ RNA/NN transcript/NN of/IN the/DT gene/NN is/VBZ subject/JJ to/TO alternative/JJ splicing/NN to/TO yield/VB different/JJ variants/NNS which/WDT can/MD either/CC activate/VBP or/CC repress/VBP gene/NN expression/NN ./. 
The/DT forms/NNS produced/VBN in/IN B/NN lymphocytes/NNS have/VBP a/DT predominantly/RB activating/JJ effect/NN on/IN gene/NN expression/NN whereas/IN those/DT produced/VBN in/IN neuronal/JJ cells/NNS have/VBP a/DT predominantly/RB inhibitory/JJ effect/NN and/CC can/MD repress/VB the/DT expression/NN of/IN both/CC the/DT herpes/NN simplex/NN virus/NN immediate-early/JJ genes/NNS and/CC the/DT cellular/JJ tyrosine/NN hydroxylase/NN gene/NN ./. 
Thus/RB Oct-2/NN plays/VBZ an/DT important/JJ role/NN in/IN the/DT regulation/NN of/IN cellular/JJ gene/NN expression/NN in/IN both/CC B/NN cells/NNS and/CC neuronal/JJ cells/NNS as/RB well/RB as/IN in/IN the/DT control/NN of/IN viral/JJ latency/NN ./. 
UI/LS -/: 96413274/CD 
TI/LS -/: Cell-type-specific/JJ regulation/NN of/IN the/DT human/JJ tumor/NN necrosis/NN factor/NN alpha/NN gene/NN in/IN B/NN cells/NNS and/CC T/NN cells/NNS by/IN NFATp/NN and/CC ATF-2/JUN/NN ./. 
AB/LS -/: The/DT human/JJ tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) gene/NN is/VBZ one/CD of/IN the/DT earliest/JJS genes/NNS transcribed/VBN after/IN the/DT stimulation/NN of/IN a/DT B/NN cell/NN through/IN its/PRP$ antigen/NN receptor/NN or/CC via/IN the/DT CD-40/NN pathway/NN ./. 
In/IN both/DT cases/NNS ,/, induction/NN of/IN TNF-alpha/NN gene/NN transcription/NN can/MD be/VB blocked/VBN by/IN the/DT immunosuppressants/NNS cyclosporin/NN A/NN and/CC FK506/NN ,/, which/WDT suggested/VBD a/DT role/NN for/IN the/DT NFAT/NN family/NN of/IN proteins/NNS in/IN the/DT regulation/NN of/IN the/DT gene/NN in/IN B/NN cells/NNS ./. 
Furthermore/RB ,/, in/IN T/NN cells/NNS ,/, two/CD molecules/NNS of/IN NFATp/NN bind/VBP to/TO the/DT TNF-alpha/NN promoter/NN element/NN kappa/NN 3/CD in/NN association/NN with/IN ATF-2/NN and/CC Jun/NN proteins/NNS bound/VBN to/TO an/DT immediately/RB adjacent/JJ cyclic/JJ AMP/NN response/NN element/NN (/( CRE/NN )/) site/NN ./. 
Here/RB ,/, using/VBG the/DT murine/JJ B-cell/NN lymphoma/NN cell/NN line/NN A20/NN ,/, we/PRP show/VBP that/IN the/DT TNF-alpha/NN gene/NN is/VBZ regulated/VBN in/IN a/DT cell-type-specific/JJ manner/NN ./. 
In/IN A20/NN B/NN cells/NNS ,/, the/DT TNF-alpha/NN gene/NN is/VBZ not/RB regulated/VBN by/IN NFATp/NN bound/VBN to/TO the/DT kappa/NN 3/CD element/NN ./. 
Instead/RB ,/, ATF-2/NN and/CC Jun/NN proteins/NNS bind/VBP to/TO the/DT composite/JJ kappa/NN 3/CRE/NN site/NN and/CC NFATp/NN binds/VBZ to/TO a/DT newly/RB identified/VBN second/JJ NFAT/NN site/NN centered/JJ at/IN -76/CD nucleotides/NNS relative/JJ to/TO the/DT TNF-alpha/NN transcription/NN start/NN site/NN ./. 
This/DT new/JJ site/NN plays/VBZ a/DT critical/JJ role/NN in/IN the/DT calcium-mediated/JJ ,/, cyclosporin/NN A-sensitive/JJ induction/NN of/IN TNF-alpha/NN in/IN both/CC A20/NN B/NN cells/NNS and/CC Ar-5/NN cells/NNS ./. 
Consistent/JJ with/IN these/DT results/NNS ,/, quantitative/JJ DNase/NN footprinting/NN of/IN the/DT TNF-alpha/NN promoter/NN using/VBG increasing/VBG amounts/NNS of/IN recombinant/JJ NFATp/NN demonstrated/VBD that/IN the/DT -76/CD site/NN binds/VBZ to/TO NFATp/NN with/IN a/DT higher/JJR affinity/NN than/IN the/DT kappa/NN 3/CD site/NN ./. 
Two/CD other/JJ previously/RB unrecognized/JJ NFATp-binding/JJ sites/NNS in/IN the/DT proximal/JJ TNF-alpha/NN promoter/NN were/VBD also/RB identified/VBN by/IN this/DT analysis/NN ./. 
Thus/RB ,/, through/IN the/DT differential/JJ use/NN of/IN the/DT same/JJ promoter/NN element/NN ,/, the/DT composite/JJ kappa/NN 3/CRE/NN site/NN ,/, the/DT TNF-alpha/NN gene/NN is/VBZ regulated/VBN in/IN a/DT cell-type-specific/JJ manner/NN in/IN response/NN to/TO the/DT same/JJ extracellular/JJ signal/NN ./. 
UI/LS -/: 96382512/CD 
TI/LS -/: Activation/NN of/IN Stat/NN 5b/NN in/IN erythroid/JJ progenitors/NNS correlates/VBZ with/IN the/DT ability/NN of/IN ErbB/NN to/TO induce/VB sustained/JJ cell/NN proliferation/NN ./. 
AB/LS -/: Self/NN renewal/NN of/IN normal/JJ erythroid/JJ progenitors/NNS is/VBZ induced/VBN by/IN the/DT receptor/NN tyrosine/NN kinase/NN c-ErbB/NN ,/, whereas/IN other/JJ receptors/NNS (/( c-Kit/Epo-R/NNS )/) regulate/VBP erythroid/JJ differentiation/NN ./. 
To/TO address/VB possible/JJ mechanisms/NNS that/WDT could/MD explain/VB this/DT selective/JJ activity/NN of/IN c-ErbB/NN ,/, we/PRP analyzed/VBD the/DT ability/NN of/IN these/DT receptors/NNS to/TO activate/VB the/DT different/JJ members/NNS of/IN the/DT Stat/NN transcription/NN factor/NN family/NN ./. 
Ligand/NN activation/NN of/IN c-ErbB/NN induced/VBD the/DT tyrosine/NN phosphorylation/NN ,/, DNA-binding/NN ,/, and/CC reporter/NN gene/NN transcription/NN of/IN Stat/NN 5b/NN in/IN erythroblasts/NNS ./. 
In/IN contrast/NN ,/, ligand/NN activation/NN of/IN c-Kit/NN was/VBD unable/JJ to/TO induce/VB any/DT of/IN these/DT effects/NNS in/IN the/DT same/JJ cells/NNS ./. 
Activation/NN of/IN the/DT erythropoietin/NN receptor/NN caused/VBD specific/JJ DNA-binding/NN of/IN Stat/NN 5b/NN ,/, but/CC failed/VBD to/TO induce/VB reporter/NN gene/NN transcription/NN ./. 
These/DT biochemical/JJ findings/NNS correlate/VBP perfectly/RB with/IN the/DT selective/JJ ability/NN of/IN c-ErbB/NN to/TO cause/VB sustained/JJ self/NN renewal/NN in/IN erythroid/JJ progenitors/NNS ./. 
UI/LS -/: 96355009/CD 
TI/LS -/: Defective/JJ transcription/NN of/IN the/DT IL-2/NN gene/NN is/VBZ associated/VBN with/IN impaired/JJ expression/NN of/IN c-Fos/NN ,/, FosB/NN ,/, and/CC JunB/NN in/IN anergic/JJ T/NN helper/NN 1/CD cells/NNS ./. 
AB/LS -/: Anergic/JJ CD4+/JJ Th/NN cells/NNS do/VBP not/RB produce/VB IL-2/NN when/WRB challenged/VBN with/IN Ag-pulsed/JJ accessory/JJ cells/NNS because/IN of/IN a/DT transcriptional/JJ defect/NN ./. 
In/IN this/DT work/NN ,/, we/PRP report/VBP that/IN these/DT anergic/JJ T/NN cells/NNS are/VBP defective/JJ in/IN their/PRP$ ability/NN to/TO up-regulate/VB protein/NN binding/NN and/CC transactivation/NN at/IN two/CD critical/JJ IL-2/NN DNA/NN enhancer/NN elements/NNS :/: NF-AT/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS ;/: a/DT sequence/NN that/WDT binds/VBZ a/DT heterotrimeric/JJ NFATp/NN ,/, Fos/NN ,/, and/CC Jun/NN protein/NN complex/NN )/) and/CC Activator/NN Protein-1/NN (/( AP-1/NN )/) (/( that/WDT binds/VBZ Fos/NN and/CC Jun/NN heterodimers/NNS )/) ./. 
Western/NN blot/NN analysis/NN of/IN nuclear/JJ extracts/NNS showed/VBD that/IN the/DT impaired/JJ DNA-protein/NN interactions/NNS in/IN anergic/JJ T/NN cells/NNS were/VBD associated/VBN with/IN poor/JJ expression/NN of/IN the/DT inducible/JJ AP-1/NN family/NN members/NNS c-Fos/NN ,/, FosB/NN ,/, and/CC JunB/NN ./. 
However/RB ,/, the/DT reduced/VBN expression/NN of/IN these/DT proteins/NNS was/VBD not/RB the/DT result/NN of/IN a/DT global/JJ TCR/CD3-signaling/JJ defect/NN because/IN CD3/NN cross-linking/NN induced/VBD an/DT equivalent/JJ increase/NN in/IN intracellular-free/JJ calcium/NN ions/NNS ,/, as/RB well/RB as/IN NFATp/NN dephosphorylation/NN ,/, translocation/NN to/TO the/DT nucleus/NN ,/, and/CC DNA/NN binding/NN in/IN both/CC normal/JJ and/CC anergic/JJ T/NN cells/NNS ./. 
Thus/RB ,/, defective/JJ IL-2/NN gene/NN transcription/NN appears/VBZ to/TO be/VB due/JJ ,/, at/IN least/JJS in/IN part/NN ,/, to/TO a/DT selective/JJ block/NN in/IN the/DT expression/NN of/IN the/DT AP-1/NN Fos/NN and/CC Jun/NN family/NN members/NNS in/IN anergic/JJ T/NN cells/NNS ./. 
UI/LS -/: 96365473/CD 
TI/LS -/: Sequence-specific/JJ DNA/NN binding/NN of/IN the/DT B-cell-specific/JJ coactivator/NN OCA-B/NN ./. 
AB/LS -/: B-cell-specific/JJ transcription/NN of/IN immunoglobulin/NN genes/NNS is/VBZ mediated/VBN by/IN the/DT interaction/NN of/IN a/DT POU/NN domain/NN containing/VBG transcription/NN factor/NN Oct-1/NN or/CC Oct-2/NN ,/, with/IN the/DT B-cell-specific/JJ coactivator/NN OCA-B/NN (/( Bob-1/NN ,/, OBF-1/NN )/) and/CC a/DT prototype/NN octamer/NN element/NN ./. 
We/PRP find/VBP that/IN OCA-B/NN binds/VBZ DNA/NN directly/RB in/IN the/DT major/JJ groove/NN between/IN the/DT two/CD subdomains/NNS of/IN the/DT POU/NN domain/NN ,/, requiring/VBG both/CC an/DT A/NN at/IN the/DT fifth/JJ position/NN of/IN the/DT octamer/NN element/NN and/CC contact/NN with/IN the/DT POU/NN domain/NN ./. 
An/DT amino-terminal/JJ fragment/NN of/IN OCA-B/NN binds/VBZ the/DT octamer/NN site/NN in/IN the/DT absence/NN of/IN a/DT POU/NN domain/NN with/IN the/DT same/JJ sequence/NN specificity/NN ./. 
Coactivator/NN OCA-B/NN may/MD undergo/VB a/DT POU-dependent/JJ conformational/JJ change/NN that/WDT exposes/VBZ its/PRP$ amino/NN terminus/NN ,/, allowing/VBG it/PRP to/TO recognize/VB specific/JJ DNA/NN sequences/NNS in/IN the/DT major/JJ groove/NN within/IN the/DT binding/VBG site/NN for/IN Oct-1/NN or/CC Oct-2/NN ./. 
The/DT recognition/NN of/IN both/CC the/DT POU/NN domain/NN and/CC the/DT octamer/NN sequence/NN by/IN OCA-B/NN provides/VBZ a/DT mechanism/NN for/IN differential/JJ regulation/NN of/IN octamer/NN sites/NNS containing/VBG genes/NNS by/IN the/DT ubiquitous/JJ factor/NN Oct-1/NN ./. 
UI/LS -/: 97016536/CD 
TI/LS -/: Uneven/JJ X/NN inactivation/NN in/IN a/DT female/JJ monozygotic/JJ twin/JJ pair/NN with/IN Fabry/NN disease/NN and/CC discordant/JJ expression/NN of/IN a/DT novel/JJ mutation/NN in/IN the/DT alpha-galactosidase/NN A/NN gene/NN ./. 
AB/LS -/: We/PRP describe/VBP two/CD female/JJ monozygotic/JJ (/( MZ/JJ )/) twins/NNS heterozygous/JJ for/IN Fabry/NN disease/NN ,/, an/DT X/NN linked/VBN disorder/NN resulting/VBG from/IN the/DT deficient/JJ activity/NN of/IN alpha-galactosidase/NN A/NN ./. 
While/IN one/CD of/IN the/DT twins/NNS was/VBD clinically/RB affected/VBN ,/, the/DT other/JJ was/VBD asymptomatic/JJ ./. 
Enzymatic/JJ assay/NN of/IN alpha-galactosidase/NN in/IN blood/NN leucocytes/NNS ,/, skin/NN fibroblasts/NNS ,/, Epstein-Barr/JJ virus/NN transformed/VBD lymphoid/JJ cell/NN lines/NNS ,/, and/CC hair/NN follicles/NNS of/IN the/DT twins/NNS and/CC their/PRP$ parents/NNS confirmed/VBD the/DT heterozygous/JJ status/NN of/IN the/DT twins/NNS and/CC indicated/VBD that/IN Fabry/NN disease/NN had/VBD occurred/VBN as/IN a/DT result/NN of/IN a/DT de/FW novo/FW mutation/NN ./. 
The/DT son/NN of/IN the/DT unaffected/JJ twin/NN sister/NN was/VBD shown/VBN to/TO be/VB hemizygous/JJ ./. 
Molecular/JJ analysis/NN of/IN the/DT alpha-galactosidase/NN A/NN gene/NN permitted/VBD the/DT identification/NN of/IN an/DT as/RB yet/RB undescribed/JJ point/NN mutation/NN at/IN position/NN 10182/CD of/IN exon/NN 5/CD which/WDT causes/VBZ an/DT Asp/NN to/TO Asn/NN substitution/NN at/IN codon/NN 231/CD ./. 
Single/JJ strand/NN conformation/NN polymorphism/NN (/( SSCP/NN )/) analysis/NN again/RB showed/VBD the/DT heterozygous/JJ status/NN of/IN the/DT twins/NNS and/CC a/DT normal/JJ pattern/NN in/IN their/PRP$ parents/NNS ./. 
The/DT basis/NN for/IN the/DT discordant/JJ expression/NN of/IN this/DT d/FW novo/FW mutation/NN in/IN the/DT twins/NNS was/VBD investigated/VBN by/IN studying/VBG their/PRP$ X/NN inactivation/NN status/NN ./. 
Analysis/NN of/IN the/DT inactive/JJ X/NN specific/JJ methylation/NN at/IN the/DT androgen/NN receptor/NN gene/NN showed/VBD unbalanced/JJ inactivation/NN in/IN the/DT twins/NNS '/POS fibroblasts/NNS and/CC in/IN opposite/JJ directions/NNS ./. 
While/IN the/DT maternally/RB derived/VBN X/NN chromosome/NN was/VBD preferentially/RB active/JJ in/IN the/DT asymptomatic/JJ twin/NN ,/, the/DT paternal/JJ X/NN chromosome/NN was/VBD active/JJ in/IN the/DT other/JJ ,/, affected/VBN twin/NN and/CC was/VBD found/VBN in/IN her/PRP$ hemizygotic/JJ nephew/NN ./. 
These/DT data/NNS suggest/VBP that/IN the/DT paternal/JJ X/NN chromosome/NN carries/VBZ the/DT de/FW novo/FW alpha-galactosidase/NN A/NN mutation/NN and/CC that/IN uneven/JJ X/NN inactivation/NN is/VBZ the/DT underlying/VBG mechanism/NN for/IN disease/NN expression/NN in/IN this/DT novel/JJ female/NN MZ/JJ twin/NN pair/NN ./. 
This/DT is/VBZ the/DT first/JJ documented/VBN case/NN of/IN female/JJ twins/NNS discordant/JJ for/IN Fabry/NN disease/NN ./. 
UI/LS -/: 96315681/CD 
TI/LS -/: Precise/JJ alignment/NN of/IN sites/NNS required/VBN for/IN mu/NN enhancer/NN activation/NN in/IN B/NN cells/NNS ./. 
AB/LS -/: The/DT lymphocyte-specific/JJ immunoglobulin/NN mu/NN heavy-chain/JJ gene/NN intronic/JJ enhancer/NN is/VBZ regulated/VBN by/IN multiple/JJ nuclear/JJ factors/NNS ./. 
The/DT previously/RB defined/VBN minimal/JJ enhancer/NN containing/VBG the/DT muA/NN ,/, muE3/NN ,/, and/CC muB/NN sites/NNS is/VBZ transactivated/VBN by/IN a/DT combination/NN of/IN the/DT ETS-domain/NN proteins/NNS PU.1/NN and/CC Ets-1/NN in/IN nonlymphoid/JJ cells/NNS ./. 
The/DT core/NN GGAAs/NNS of/IN the/DT muA/NN and/CC muB/NN sites/NNS are/VBP separated/VBN by/IN 30/CD nucleotides/NNS ,/, suggesting/VBG that/IN ETS/NNS proteins/NNS bind/VBP to/TO these/DT sites/NNS from/IN these/DT same/JJ side/NN of/IN the/DT DNA/NN helix/NN ./. 
We/PRP tested/VBD the/DT necessity/NN for/IN appropriate/JJ spatial/JJ alignment/NN of/IN these/DT elements/NNS by/IN using/VBG mutated/VBN enhancers/NNS with/IN altered/JJ spacings/NNS ./. 
A/DT 4-/CD or/CC 10-bp/JJ insertion/NN between/IN muE3/NN and/CC muB/NN inactivated/VBD the/DT mu/NN enhancer/NN in/IN S194/NN plasma/NN cells/NNS but/CC did/VBD not/RB affect/VB in/FW vitro/FW binding/NN of/IN Ets-1/NN ,/, PU.1/NN ,/, or/CC the/DT muE3-binding/JJ protein/NN TFE3/NN ,/, alone/RB or/CC in/IN pairwise/JJ combinations/NNS ./. 
Circular/JJ permutation/NN and/CC phasing/NN analyses/NNS demonstrated/VBD that/IN PU.1/NN binding/NN but/CC not/RB TFE3/NN or/CC Ets-1/NN bends/VBZ mu/NN enhancer/NN DNA/NN toward/IN the/DT major/JJ groove/NN ./. 
We/PRP propose/VBP that/IN the/DT requirement/NN for/IN precise/JJ spacing/NN of/IN the/DT muA/NN and/CC muB/NN elements/NNS is/VBZ due/JJ in/IN part/NN to/TO a/DT directed/JJ DNA/NN bend/NN induced/VBN by/IN PU.1/NN ./. 
UI/LS -/: 97108276/CD 
TI/LS -/: [/( Cortisone-resistant/JJ bronchial/JJ asthma/NN ]/) 
AB/LS -/: There/EX is/VBZ general/JJ agreement/NN on/IN the/DT inflammatory/JJ pathogenesis/NN of/IN bronchial/JJ asthma/NN :/: an/DT accumulation/NN of/IN activated/VBN eosinophils/NNS ,/, degranulated/VBN mast/NN cells/NNS ,/, T/NN lymphocytes/NNS and/CC in/IN very/RB severe/JJ forms/NNS ,/, granulocytes/NNS has/VBZ constantly/RB been/VBN found/VBN in/IN the/DT bronchial/JJ mucosa/NN ./. 
In/IN allergic/JJ bronchial/JJ asthma/NN ,/, inflammation/NN seems/VBZ to/TO be/VB orchestrated/VBN predominantly/RB by/IN a/DT subset/NN of/IN T/NN lymphocytes/NNS ,/, with/IN a/DT phenotype/NN similar/JJ to/TO the/DT Th2/NN subset/NN able/JJ to/TO produce/VB IL-4/NN and/CC IL-5/NN ./. 
Although/IN corticosteroids/NNS are/VBP the/DT most/RBS potent/JJ therapeutic/JJ agents/NNS used/VBN for/IN this/DT disease/NN ,/, their/PRP$ anti-inflammatory/JJ effect/NN differs/VBZ from/IN patient/NN to/TO patient/NN ./. 
Some/DT criteria/NNS which/WDT can/MD be/VB used/VBN to/TO define/VB steroid-resistant/JJ bronchial/JJ asthma/NN are/VBP listed/VBN here/RB ./. 
This/DT review/NN analyzes/VBZ various/JJ molecular/JJ alterations/NNS responsible/JJ for/IN the/DT deficient/JJ response/NN to/TO corticosteroid/NN treatment/NN observed/VBN in/IN steroid-resistant/JJ bronchial/JJ asthmatic/JJ subjects/NNS ./. 
New/JJ knowledge/NN on/IN the/DT mechanism/NN of/IN steroid/NN resistance/NN may/MD have/VB important/JJ implications/NNS for/IN the/DT treatment/NN of/IN chronic/JJ asthma/NN and/CC other/JJ diseases/NNS ./. 
UI/LS -/: 96305196/CD 
TI/LS -/: Mechanisms/NNS of/IN transactivation/NN by/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells-1/NNS ./. 
AB/LS -/: Nuclear/JJ factor/NN of/IN activated/VBN T/NN cells-family/NN proteins/NNS (/( NFAT1/NFATp/NN ,/, NFATc/NN ,/, NFAT3/NN ,/, and/CC NFAT4/NFATx/NFATc3/NN )/) play/VBP a/DT key/JJ role/NN in/IN the/DT transcription/NN of/IN cytokine/NN genes/NNS and/CC other/JJ genes/NNS during/IN the/DT immune/JJ response/NN ./. 
We/PRP have/VBP defined/VBN the/DT mechanisms/NNS of/IN transactivation/NN by/IN NFAT1/NN ./. 
NFAT1/NNP possesses/VBZ two/CD transactivation/NN domains/NNS whose/WP$ sequences/NNS are/VBP not/RB conserved/VBN in/IN the/DT other/JJ NFAT-family/NN proteins/NNS ,/, and/CC a/DT conserved/VBN DNA-binding/JJ domain/NN that/WDT mediates/VBZ the/DT recruitment/NN of/IN cooperating/VBG nuclear/JJ transcription/NN factors/NNS even/RB when/WRB it/PRP is/VBZ expressed/VBN in/IN the/DT absence/NN of/IN other/JJ regions/NNS of/IN the/DT protein/NN ./. 
The/DT activity/NN of/IN the/DT NH2-terminal/JJ transactivation/NN domain/NN is/VBZ modulated/VBN by/IN an/DT adjacent/JJ regulatory/JJ region/NN that/WDT contains/VBZ several/JJ conserved/VBN sequence/NN motifs/NNS represented/VBN only/RB in/IN the/DT NFAT/NN family/NN ./. 
Our/PRP$ results/NNS emphasize/VBP the/DT multiple/JJ levels/NNS at/IN which/WDT NFAT-dependent/JJ transactivation/NN is/VBZ regulated/VBN ,/, and/CC predict/VBP significant/JJ differences/NNS in/IN the/DT architecture/NN of/IN cooperative/JJ transcription/NN complexes/NNS containing/VBG different/JJ NFAT-family/NN proteins/NNS ./. 
UI/LS -/: 97025433/CD 
TI/LS -/: Induction/NN of/IN activator/NN protein/NN (/( AP/NN )/) -1/CD and/CC nuclear/JJ factor-kappaB/NN by/IN CD28/NN stimulation/NN involves/VBZ both/CC phosphatidylinositol/NN 3-kinase/NN and/CC acidic/JJ sphingomyelinase/NN signals/NNS ./. 
AB/LS -/: A/DT major/JJ obstacle/NN in/IN understanding/VBG the/DT signaling/NN events/NNS that/WDT follow/VBP CD28/NN receptor/NN ligation/NN arises/VBZ from/IN the/DT fact/NN that/IN CD28/NN acts/VBZ as/IN a/DT costimulus/NN to/TO TCR/NN engagement/NN ,/, making/VBG it/PRP difficult/JJ to/TO assess/VB the/DT relative/JJ contribution/NN of/IN CD28/NN signals/NNS as/IN distinct/JJ from/IN those/DT of/IN the/DT TCR/NN ./. 
To/TO overcome/VB this/DT problem/NN ,/, we/PRP have/VBP exploited/VBN the/DT observation/NN that/IN activated/VBN human/JJ T/NN cell/NN blasts/NNS can/MD be/VB stimulated/VBN via/IN the/DT CD28/NN surface/NN molecule/NN in/IN the/DT absence/NN of/IN antigenic/JJ challenge/NN ;/: thus/RB ,/, we/PRP have/VBP been/VBN able/JJ to/TO observe/VB the/DT response/NN of/IN normal/JJ T/NN cells/NNS to/TO CD28/NN activation/NN in/IN isolation/NN ./. 
Using/VBG this/DT system/NN ,/, we/PRP observed/VBD that/IN CD28/NN stimulation/NN by/IN B7-transfected/JJ CHO/NN cells/NNS induced/VBD a/DT proliferative/JJ response/NN in/IN T/NN cells/NNS that/WDT was/VBD not/RB accompanied/VBN by/IN measurable/JJ IL-2/NN production/NN ./. 
However/RB ,/, subsequent/JJ analysis/NN of/IN transcription/NN factor/NN generation/NN revealed/VBD that/IN B7/NN stimulation/NN induced/VBD both/CC activator/NN protein-1/NN (/( AP-1/NN )/) and/CC nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) complexes/NNS ,/, but/CC not/RB NF-AT/NN ./. 
In/IN contrast/NN ,/, engagement/NN of/IN the/DT TCR/NN by/IN class/NN II/CD MHC/superantigen/NN ,/, either/CC with/IN or/CC without/IN CD28/NN ligation/NN ,/, resulted/VBD in/IN the/DT induction/NN of/IN NF-AT/NN ,/, AP-1/NN ,/, and/CC NF-kappaB/NN as/RB well/RB as/IN IL-2/NN production/NN ./. 
Using/VBG selective/JJ inhibitors/NNS ,/, we/PRP investigated/VBD the/DT signaling/NN pathways/NNS involved/VBN in/IN the/DT CD28-mediated/JJ induction/NN of/IN AP-1/NN and/CC NF-kappaB/NN ./. 
This/DT revealed/VBD that/IN NF-kappaB/NN generation/NN was/VBD sensitive/JJ to/TO chloroquine/NN ,/, an/DT inhibitor/NN of/IN acidic/JJ sphingomyelinase/NN ,/, but/CC not/RB to/TO the/DT phosphatidylinositol/NN 3-kinase/NN inhibitor/NN ,/, wortmannin/NN ./. 
In/IN contrast/NN ,/, AP-1/NN generation/NN was/VBD inhibited/VBN by/IN wortmannin/NN and/CC was/VBD also/RB variably/RB sensitive/JJ to/TO chloroquine/NN ./. 
These/DT data/NNS suggest/VBP that/IN in/IN activated/VBN normal/JJ T/NN cells/NNS ,/, CD28-derived/JJ signals/NNS can/MD stimulate/VB proliferation/NN at/IN least/JJS in/IN part/NN via/IN NF-kappaB/NN and/CC AP-1/NN generation/NN ,/, and/CC that/IN this/DT response/NN uses/VBZ both/CC acidic/JJ sphingomyelinase/NN and/CC phosphatidylinositol/NN 3-kinase-linked/JJ pathways/NNS ./. 
UI/LS -/: 97061522/CD 
TI/LS -/: Presence/NN of/IN a/DT variant/JJ form/NN of/IN the/DT estrogen/NN receptor/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS from/IN normal/JJ individuals/NNS and/CC lupus/NN patients/NNS ./. 
AB/LS -/: Estrogen/NN may/MD participate/VB in/IN the/DT pathogenesis/NN of/IN systemic/JJ lupus/NN erythematosus/NN (/( SLE/NN )/) via/IN its/PRP$ intracellular/JJ receptor/NN ./. 
To/TO investigate/VB the/DT presence/NN of/IN various/JJ isoforms/NNS of/IN the/DT estrogen/NN receptor/NN (/( ER/NN )/) in/IN SLE/NN we/PRP isolated/VBD RNA/NN from/IN mononuclear/JJ cells/NNS of/IN lupus/NN patients/NNS and/CC normal/JJ controls/NNS ./. 
Using/VBG RT-PCR/NN we/PRP were/VBD able/JJ to/TO identify/VB both/CC the/DT full/JJ length/NN wild-type/JJ form/NN and/CC an/DT isoform/NN of/IN the/DT ER/NN which/WDT precisely/RB lacks/VBZ exon/NN V/NN in/IN both/CC patient/NN and/CC normal/JJ individuals/NNS ./. 
Our/PRP$ results/NNS ,/, although/IN limited/JJ ,/, suggest/VBP that/IN normal/JJ individuals/NNS can/MD express/VB both/CC the/DT wild-type/JJ and/CC truncated/VBN version/NN at/IN the/DT same/JJ time/NN ,/, whereas/IN lupus/NN patients/NNS only/RB express/VBP either/CC the/DT wild-type/JJ or/CC the/DT truncated/VBN ER/NN ./. 
This/DT finding/NN may/MD lead/VB to/TO a/DT better/JJR understanding/NN of/IN the/DT reasons/NNS for/IN the/DT prevalence/NN of/IN lupus/NN in/IN females/NNS and/CC of/IN the/DT estrogenic/JJ effects/NNS on/IN SLE/NN disease/NN activity/NN ./. 
UI/LS -/: 96413262/CD 
TI/LS -/: Regulation/NN of/IN sialoadhesin/NN expression/NN on/IN rat/NN macrophages/NNS ./. 
Induction/NN by/IN glucocorticoids/NNS and/CC enhancement/NN by/IN IFN-beta/NN ,/, IFN-gamma/NN ,/, IL-4/NN ,/, and/CC lipopolysaccharide/NN ./. 
AB/LS -/: Sialoadhesin/NN is/VBZ a/DT macrophage-restricted/JJ member/NN of/IN the/DT Ig/NN superfamily/NN that/WDT mediates/VBZ adhesion/NN with/IN lymphoid/JJ and/CC myeloid/JJ cells/NNS ./. 
It/PRP is/VBZ expressed/VBN on/IN a/DT subpopulation/NN of/IN macrophages/NNS in/IN lymphoid/JJ tissues/NNS and/CC in/IN chronic/JJ inflammation/NN (/( e.g./FW ,/, during/IN autoimmune/JJ diseases/NNS )/) ./. 
We/PRP have/VBP studied/VBN the/DT regulation/NN of/IN sialoadhesin/NN expression/NN in/FW vitro/FW and/CC show/VBP that/IN glucocorticoids/NNS (/( GC/NNS )/) induce/VBP sialoadhesin/NN expression/NN on/IN freshly/RB isolated/VBN rat/NN macrophages/NNS and/CC the/DT rat/NN macrophage/NN cell/NN line/NN R2/NN ./. 
The/DT cytokines/NNS IFN-beta/NN ,/, IFN-gamma/NN ,/, IL-4/NN ,/, and/CC LPS/NN ,/, although/IN unable/JJ to/TO induce/VB sialoadhesin/NN expression/NN by/IN themselves/PRP ,/, were/VBD able/JJ to/TO enhance/VB GC-mediated/JJ induction/NN of/IN sialoadhesin/NN ./. 
Sialoadhesin/NN expression/NN was/VBD functional/JJ as/IN shown/VBN by/IN cell/NN adhesion/NN assays/NNS with/IN human/JJ RBCs/NNS ./. 
Northern/NN blotting/VBG experiments/NNS indicated/VBD that/IN regulation/NN predominantly/RB occurred/VBD at/IN the/DT mRNA/NN level/NN ./. 
Comparison/NN of/IN the/DT different/JJ combinations/NNS of/IN GC/NN and/CC cytokines/LPS/NNS revealed/VBD differences/NNS in/IN the/DT level/NN of/IN GC-dependent/JJ enhancement/NN of/IN sialoadhesin/NN expression/NN ,/, with/IN IFN-beta/NN and/CC IL-4/NN being/VBG more/RBR potent/JJ than/IN IFN-gamma/NN and/CC LPS/NN ./. 
Moreover/RB ,/, the/DT effects/NNS of/IN IFN-gamma/NN and/CC LPS/NN could/MD be/VB reproduced/VBN by/IN priming/NN ,/, whereas/IN IFN-beta/NN and/CC IL-4/NN were/VBD required/VBN simultaneously/RB with/IN GC/NN ./. 
The/DT regulation/NN of/IN sialoadhesin/NN expression/NN was/VBD mediated/VBN by/IN the/DT GC/NN receptor/NN ,/, and/CC not/RB by/IN mineralocorticoid/NN receptor/NN ,/, as/IN shown/VBN by/IN inhibition/NN experiments/NNS with/IN specific/JJ antagonists/NNS ./. 
Finally/RB ,/, it/PRP is/VBZ demonstrated/VBN that/IN macrophages/NNS in/IN the/DT adrenal/JJ gland/NN ,/, the/DT major/JJ site/NN of/IN endogenous/JJ GC/NN production/NN ,/, express/VBP sialoadhesin/NN ./. 
This/DT study/NN demonstrates/VBZ that/IN GC/NN act/VBP as/IN a/DT primary/JJ inducer/NN of/IN sialoadhesin/NN expression/NN on/IN rat/NN macrophages/NNS ,/, and/CC that/IN the/DT response/NN can/MD be/VB enhanced/VBN by/IN IFN-beta/NN ,/, T/NN cell-derived/JJ cytokines/NNS ,/, or/CC LPS/NN ./. 
UI/LS -/: 96382507/CD 
TI/LS -/: Apoptosis/NN mediated/VBN by/IN HIV/NN protease/NN is/VBZ preceded/VBN by/IN cleavage/NN of/IN Bcl-2/NN ./. 
AB/LS -/: Expression/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV/NN )/) protease/NN in/IN cultured/VBN cells/NNS leads/VBZ to/TO apoptosis/NN ,/, preceded/VBN by/IN cleavage/NN of/IN bcl-2/NN ,/, a/DT key/JJ negative/JJ regulator/NN of/IN cell/NN death/NN ./. 
In/IN contrast/NN ,/, a/DT high/JJ level/NN of/IN bcl-2/NN protects/VBZ cells/NNS in/FW vitro/FW and/CC in/FW vivo/FW from/IN the/DT viral/JJ protease/NN and/CC prevents/VBZ cell/NN death/NN following/VBG HIV/NN infection/NN of/IN human/JJ lymphocytes/NNS ,/, while/IN reducing/VBG the/DT yields/NNS of/IN viral/JJ structural/JJ proteins/NNS ,/, infectivity/NN ,/, and/CC tumor/NN necrosis/NN factor/NN alpha/NN ./. 
We/PRP present/VBP a/DT model/NN for/IN HIV/NN replication/NN in/IN which/WDT the/DT viral/JJ protease/NN depletes/VBZ the/DT infected/JJ cells/NNS of/IN bcl-2/NN ,/, leading/VBG to/TO oxidative/JJ stress-dependent/JJ activation/NN of/IN NF/NN kappa/NN B/NN ,/, a/DT cellular/JJ factor/NN required/VBN for/IN HIV/NN transcription/NN ,/, and/CC ultimately/RB to/TO cell/NN death/NN ./. 
Purified/VBN bcl-2/NN is/VBZ cleaved/VBN by/IN HIV/NN protease/NN between/IN phenylalanine/NN 112/CD and/CC alanine/NN 113/CD ./. 
The/DT results/NNS suggest/VBP a/DT new/JJ option/NN for/IN HIV/NN gene/NN therapy/NN ;/: bcl-2/NN muteins/NNS that/WDT have/VBP noncleavable/JJ alterations/NNS surrounding/VBG the/DT HIV/NN protease/NN cleavage/NN site/NN ./. 
UI/LS -/: 96354999/CD 
TI/LS -/: Alpha/NN 4/CD beta/NN 1/CD (/( CD49d/CD29/NN )/) integrin/NN costimulation/NN of/IN human/JJ T/NN cells/NNS enhances/VBZ transcription/NN factor/NN and/CC cytokine/NN induction/NN in/IN the/DT absence/NN of/IN altered/JJ sensitivity/NN to/TO anti-CD3/NN stimulation/NN ./. 
AB/LS -/: The/DT integrin/NN alpha/NN 4/CD beta/NN 1/CD can/MD provide/VB a/DT costimulus/NN to/TO induce/VB IL-2/NN secretion/NN and/CC IL-2R/NN expression/NN leading/VBG to/TO enhanced/VBN proliferation/NN of/IN purified/VBN ,/, peripheral/JJ blood/NN T/NN cells/NNS ./. 
Similar/JJ to/TO expression/NN of/IN IL-2/NN ,/, we/PRP demonstrated/VBD that/IN recombinant/JJ vascular-cell/NN adhesion/NN molecule-1/NN ,/, when/WRB co-immobilized/VBN with/IN anti-CD3/NN mAb/NN ,/, significantly/RB enhanced/VBD the/DT induction/NN of/IN transcription/NN factors/NNS NF-AT/NN ,/, AP-1/NN ,/, and/CC NF-kappa/NN B/NN as/IN determined/VBN by/IN electromobility/NN shift/NN assays/NNS ./. 
alpha/NN 4/CD beta/NN 1/CD ligation/NN alone/RB had/VBD no/DT effect/NN on/IN transcription/NN factor/NN binding/NN ./. 
The/DT requirements/NNS for/IN induction/NN of/IN transcription/NN factors/NNS reflected/VBD the/DT requirements/NNS for/IN the/DT secretion/NN of/IN multiple/JJ cytokines/NNS ,/, including/VBG IL-2/NN ,/, TNF-alpha/NN ,/, IFN-gamma/NN ,/, and/CC granulocyte/NN macrophage-CSF/NN ./. 
In/IN contrast/NN to/TO freshly/RB isolated/VBN T/NN cells/NNS ,/, in/FW vitro-cultured/JJ T/NN cells/NNS did/VBD not/RB require/VB costimulation/NN for/IN cytokine/NN secretion/NN in/IN response/NN to/TO anti-CD3/NN alone/RB ./. 
Comparison/NN of/IN the/DT dose/NN response/NN to/TO anti-CD3/NN stimulation/NN demonstrated/VBD that/IN half-maximal/JJ induction/NN of/IN IL-2/NN was/VBD achieved/VBN using/VBG the/DT same/JJ dose/NN of/IN anti-CD3/NN for/IN both/CC freshly/RB isolated/VBN and/CC cultured/VBN T/NN cells/NNS ./. 
Furthermore/RB ,/, the/DT dose/NN of/IN OKT3/NN required/VBN to/TO achieve/VB half-maximal/JJ activation/NN was/VBD the/DT same/JJ using/VBG PMA/NN or/CC different/JJ concentrations/NNS of/IN alpha/NN 4/CD beta/NN 1/CD ligands/NNS ./. 
Therefore/RB ,/, costimulation/NN by/IN alpha/NN 4/CD beta/NN 1/CD ligands/NNS was/VBD not/RB due/JJ to/TO stabilization/NN of/IN the/DT interaction/NN of/IN the/DT cells/NNS with/IN its/PRP$ substrate/NN ./. 
We/PRP conclude/VBP ,/, rather/RB ,/, that/IN alpha/NN 4/CD beta/NN 1/CD in/IN freshly/RB isolated/VBN T/NN cells/NNS delivers/VBZ a/DT distinct/JJ signal/NN that/WDT synergizes/VBZ early/RB with/IN signals/NNS initiated/VBN by/IN TCR/CD3/NN ligation/NN to/TO induce/VB DNA/NN binding/NN of/IN multiple/JJ transcription/NN factors/NNS required/VBN for/IN cytokine/NN gene/NN induction/NN ./. 
UI/LS -/: 96322738/CD 
TI/LS -/: Inhibition/NN of/IN T/NN lymphocyte/NN activation/NN by/IN cAMP/NN is/VBZ associated/VBN with/IN down-regulation/NN of/IN two/CD parallel/JJ mitogen-activated/JJ protein/NN kinase/NN pathways/NNS ,/, the/DT extracellular/JJ signal-related/JJ kinase/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN ./. 
AB/LS -/: The/DT induction/NN of/IN T/NN cell/NN proliferation/NN requires/VBZ signals/NNS from/IN the/DT TCR/NN and/CC a/DT co-receptor/NN molecule/NN ,/, such/JJ as/IN CD28/NN ,/, that/WDT activate/VBP parallel/JJ and/CC partially/RB cross-reactive/JJ signaling/NN pathways/NNS ./. 
These/DT pathways/NNS are/VBP disrupted/VBN by/IN agonists/NNS that/WDT utilize/VBP adenylate/NN cyclase/NN and/CC cAMP-dependent/JJ protein/NN kinase/NN A/NN (/( PKA/NN )/) ./. 
We/PRP found/VBD that/IN the/DT adenylate/NN cyclase/NN activator/NN ,/, forskolin/NN ,/, inhibits/VBZ anti-CD3-induced/JJ shift/NN in/IN Lck/NN electrophoretic/JJ mobility/NN ,/, suggesting/VBG an/DT intervention/NN at/IN the/DT TCR-coupled/JJ phosphoinositide/JJ turnover/NN that/WDT precedes/VBZ the/DT activation/NN of/IN PKC/NN ./. 
The/DT shift/NN of/IN Lck/NN following/VBG direct/JJ PKC/NN activation/NN by/IN 12-O-tetradecanoyl/NN phorbol/NN 13-acetate/NN ,/, which/WDT bypasses/VBZ early/JJ receptor-triggered/JJ biochemical/JJ events/NNS ,/, is/VBZ insensitive/JJ to/TO forskolin/NN ./. 
Nevertheless/RB ,/, forskolin/NN also/RB inhibits/VBZ PKC/NN downstream/JJ events/NNS ,/, such/JJ as/IN c-jun/NN expression/NN ,/, which/WDT is/VBZ critical/JJ for/IN the/DT activation/NN process/NN of/IN T/NN cells/NNS ./. 
To/TO further/RB analyze/VB potential/JJ cross/NN points/NNS between/IN positively/RB and/CC negatively/RB regulating/VBG signaling/NN pathways/NNS in/IN T/NN cells/NNS ,/, we/PRP tested/VBD the/DT effects/NNS of/IN activators/NNS of/IN the/DT adenylate/NN cyclase/NN or/CC PKA/NN on/IN two/CD parallel/JJ mitogen-activated/JJ protein/NN kinase/NN signaling/NN pathways/NNS mediated/VBN by/IN extracellular/JJ signal-regulated/JJ kinase/NN (/( ERK/NN )/) and/CC c-Jun/NN N-terminal/JJ kinase/NN ./. 
Using/VBG a/DT PKC-specific/JJ inhibitor/NN ,/, GF109203X/NN ,/, or/CC PKC-depleted/JJ T/NN cells/NNS ,/, we/PRP found/VBD that/IN a/DT large/JJ part/NN of/IN the/DT anti-CD3-induced/JJ ERK/NN activation/NN is/VBZ PKC/NN dependent/JJ ./. 
Both/CC PKC-dependent/JJ and/CC -independent/JJ activation/NN of/IN ERK/NN were/VBD sensitive/JJ to/TO inhibition/NN by/IN forskolin/NN or/CC a/DT cell-permeable/JJ cAMP/NN analogue/NN ,/, dbcAMP/NN ./. 
Furthermore/RB ,/, the/DT effect/NN of/IN 12-O-tetradecanoyl/NN phorbol/NN 13-acetate/NN and/CC ionomycin/NN ,/, which/WDT synergized/VBD to/TO fully/RB activate/VB c-Jun/NN N-terminal/JJ kinase/NN ,/, was/VBD also/RB sensitive/JJ to/TO inhibition/NN by/IN forskolin/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN PKA/NN inhibits/VBZ T/NN cell/NN activation/NN by/IN interfering/VBG with/IN multiple/JJ events/NNS along/IN the/DT two/CD signaling/NN pathways/NNS operating/VBG downstream/RB of/IN the/DT TCR/NN and/CC the/DT CD28/NN co-receptor/NN molecules/NNS ./. 
UI/LS -/: 97006605/CD 
TI/LS -/: Transcriptional/JJ and/CC posttranscriptional/JJ regulation/NN of/IN erythroid/JJ gene/NN expression/NN in/IN anthracycline-induced/JJ differentiation/NN of/IN human/JJ erythroleukemic/JJ cells/NNS ./. 
AB/LS -/: Aclacinomycin/NN (/( ACLA/NN )/) and/CC doxorubicin/NN (/( DOX/NN )/) were/VBD used/VBN at/IN subtoxic/JJ concentrations/NNS to/TO induce/VB erythroid/JJ differentiation/NN in/IN the/DT human/JJ leukemic/JJ cell/NN line/NN K562/NN ./. 
Cell/NN hemoglobinization/NN was/VBD accompanied/VBN by/IN the/DT increased/VBN expression/NN of/IN genes/NNS encoding/VBG gamma-globin/NN and/CC porphobilinogen/NN deaminase/NN (/( PBGD/NN )/) ,/, an/DT enzyme/NN of/IN heme/NN synthesis/NN ./. 
By/IN using/VBG run-on/JJ assays/NNS ,/, ACLA/NN was/VBD shown/VBN to/TO induce/VB an/DT enhancement/NN of/IN the/DT transcription/NN of/IN erythroid/JJ genes/NNS ,/, including/VBG gamma-globin/NN ,/, PBGD/NN ,/, erythropoietin/NN receptor/NN ,/, and/CC GATA-1/NN transcription/NN factor/NN ./. 
In/IN contrast/NN ,/, in/IN DOX-treated/JJ cells/NNS ,/, the/DT transcription/NN rate/NN of/IN these/DT genes/NNS was/VBD unchanged/JJ in/IN comparison/NN with/IN control/NN cells/NNS ./. 
In/IN addition/NN ,/, inhibition/NN of/IN mRNA/NN synthesis/NN with/IN actinomycin/NN D/NN indicated/VBD that/IN DOX/NN induced/VBD an/DT increased/VBN stability/NN of/IN PBGD/NN and/CC GATA-1/NN mRNAs/NNS ,/, whereas/IN ACLA/NN did/VBD not/RB affect/VB the/DT half-lives/NNS of/IN these/DT mRNAs/NNS ./. 
Because/IN the/DT increase/NN in/IN erythroid/JJ mRNA/NN steady-state/NN level/NN in/IN anthracycline-treated/JJ cells/NNS was/VBD inhibited/VBN by/IN cycloheximide/NN ,/, this/DT suggests/VBZ that/IN transcriptional/JJ activation/NN in/IN ACLA-treated/JJ cells/NNS and/CC mRNA/NN stabilization/NN in/IN DOX-treated/JJ cells/NNS were/VBD dependent/JJ on/IN de/FW novo/FW protein/NN synthesis/NN ./. 
Finally/RB ,/, GATA-1/NN protein/NN level/NN was/VBD shown/VBN to/TO be/VB increased/VBN in/IN ACLA-treated/JJ but/CC not/RB in/IN DOX-treated/JJ cells/NNS ./. 
These/DT two/CD anthracyclines/NNS ,/, although/IN closely/RB related/JJ in/IN their/PRP$ structures/NNS ,/, appeared/VBD to/TO act/VB as/IN differentiation/NN inducers/NNS by/IN distinct/JJ mechanisms/NNS ./. 
Indeed/RB ,/, erythroid/JJ gene/NN expression/NN was/VBD demonstrated/VBN to/TO be/VB regulated/VBN transcriptionally/RB by/IN ACLA/NN and/CC mainly/RB posttranscriptionally/RB by/IN DOX/NN ./. 
UI/LS -/: 96320605/CD 
TI/LS -/: Interleukin-7/NN signaling/NN in/IN human/JJ B/NN cell/NN precursor/NN acute/JJ lymphoblastic/JJ leukemia/NN cells/NNS and/CC murine/JJ BAF3/NN cells/NNS involves/VBZ activation/NN of/IN STAT1/NN and/CC STAT5/NN mediated/VBN via/IN the/DT interleukin-7/NN receptor/NN alpha/NN chain/NN ./. 
AB/LS -/: Interleukin-7/NN (/( IL-7/NN )/) stimulates/VBZ the/DT proliferation/NN of/IN normal/JJ and/CC leukemic/JJ B/NN and/CC T/NN cell/NN precursors/NNS and/CC T/NN lymphocytes/NNS ./. 
Activation/NN of/IN the/DT JAK/STAT/NN pathway/NN has/VBZ been/VBN implicated/VBN in/IN IL-7R/NN signaling/NN ./. 
We/PRP investigated/VBD which/WDT STAT/NN complexes/NNS are/VBP formed/VBN upon/IN stimulation/NN of/IN B/NN cell/NN precursor/NN acute/JJ lymphoblastic/JJ leukemia/NN (/( BCP-ALL/NN )/) cells/NNS with/IN IL-7/NN ./. 
Gel/NN retardation/NN assays/NNS with/IN STAT-binding/JJ oligonucleotides/NNS showed/VBD that/IN IL-7/NN induces/VBZ the/DT formation/NN of/IN two/CD major/JJ STAT/NN complexes/NNS in/IN BCP-ALL/NN cells/NNS ./. 
Supershifts/NNS with/IN anti-STAT/JJ antibodies/NNS identified/VBD these/DT as/IN STAT1/NN and/CC STAT5/NN complexes/NNS ./. 
This/DT pattern/NN of/IN STAT/NN activation/NN was/VBD seen/VBN in/IN all/DT BCP-ALL/NN cases/NNS that/WDT respond/VBP to/TO IL-7/NN in/IN proliferation/NN assays/NNS ./. 
IL-7/NN also/RB induced/VBD STAT/DNA/NN binding/NN in/IN BCP-ALL/NN cases/NNS that/WDT failed/VBD to/TO proliferate/VB in/IN response/NN to/TO IL-7/NN ,/, suggesting/VBG that/IN the/DT ability/NN of/IN IL-7R/NN to/TO activate/VB the/DT JAK/STAT/NN pathway/NN per/FW se/FW is/VBZ not/RB sufficient/JJ for/IN proliferation/NN induction/NN ./. 
To/TO determine/VB the/DT contribution/NN of/IN the/DT cytoplasmic/JJ domain/NN of/IN the/DT IL-7/NN receptor/NN alpha/NN chain/NN (/( IL-7R/NN alpha/NN )/) to/TO activation/NN of/IN STAT/NN proteins/NNS ,/, transfectants/NNS of/IN the/DT murine/JJ pro-B/NN cell/NN line/NN BAF3/NNS were/VBD made/VBN that/WDT express/NN chimeric/JJ receptors/NNS consisting/VBG of/IN the/DT extracellular/JJ domain/NN of/IN human/JJ granulocyte/NN colony-stimulating/JJ factor/NN receptor/NN (/( G-CSF-R/NN )/) and/CC the/DT transmembrane/NN and/CC intracellular/JJ domains/NNS of/IN human/JJ IL-7R/NN alpha/NN ./. 
Activation/NN of/IN the/DT chimeric/JJ G-CSF-R/IL-7R/NN alpha/NN with/IN G-CSF/NN resulted/VBD in/IN a/DT full/JJ proliferative/JJ response/NN and/CC induced/VBD the/DT phosphorylation/NN of/IN JAK1/NN but/CC not/RB JAK2/NN ./. 
Major/JJ STAT/NN complexes/NNS activated/VBN by/IN G-CSF-R/IL-7R/NN alpha/NN contained/VBD STAT1/NN or/CC STAT5/NN ,/, while/IN some/DT formation/NN of/IN STAT3-containing/JJ complexes/NNS was/VBD also/RB seen/VBN ./. 
These/DT findings/NNS establish/VBP that/IN STAT1/NN and/CC STAT5/NN ,/, and/CC possibly/RB STAT3/NN ,/, are/VBP activated/VBN upon/IN stimulation/NN of/IN precursor/JJ B/NN cells/NNS with/IN IL-7/NN ./. 
The/DT data/NNS further/RB indicate/VBP that/IN the/DT IL-7R/NN alpha/NN chains/NNS are/VBP directly/RB involved/VBN in/IN the/DT activation/NN of/IN JAKs/NNS and/CC STATs/NNS and/CC have/VB a/DT major/JJ role/NN in/IN proliferative/JJ signaling/NN in/IN precursor/NN B/NN cells/NNS ./. 
UI/LS -/: 97025698/CD 
TI/LS -/: Stimulation/NN of/IN human/JJ lymphocyte/NN proliferation/NN and/CC CD40/NN antigen/NN expression/NN by/IN phosphorothioate/NN oligonucleotides/NNS complementary/JJ to/TO hepatitis/NN B/NN virus/NN genome/NN ./. 
AB/LS -/: We/PRP have/VBP studied/VBN the/DT proliferation/NN and/CC CD40/NN antigen/NN expression/NN of/IN lymphocytes/NNS ,/, and/CC the/DT cytotoxicity/NN to/TO monocytes/NNS ,/, of/IN antisense/JJ phosphorothioate/NN oligodeoxynucleotides/NNS complementary/JJ to/TO the/DT SP/NN II/CD promoter/NN of/IN HBV/NN mRNA/NN (/( sequence/NN I/NN )/) and/CC the/DT X/NN gene/NN (/( sequence/NN II/CD )/) in/IN patients/NNS with/IN chronic/JJ hepatitis/NN B/NN ./. 
The/DT oligo/JJ sequence/NN I/NN stimulated/VBD proliferation/NN of/IN both/CC T/NN and/CC ,/, to/TO a/DT lesser/JJR extent/NN ,/, B/NN cells/NNS ./. 
The/DT percentage/NN of/IN cells/NNS expressing/VBG CD40/NN in/IN T/NN and/CC B/NN cell/NN co-cultures/NNS increased/VBD from/IN 4.2/CD %/NN to/TO 13.8/CD %/NN after/IN oligo/JJ stimulation/NN in/IN patients/NNS ,/, while/IN it/PRP increased/VBD form/NN 4.7/CD %/NN to/TO 48.6/CD %/NN in/IN healthy/JJ controls/NNS ./. 
The/DT sense/NN sequence/NN (/( sequence/NN III/CD )/) of/IN the/DT X/NN gene/NN also/RB enhanced/VBD the/DT expression/NN of/IN CD40/NN antigen/NN in/IN patients/NNS with/IN hepatitis/NN B/NN ./. 
The/DT proportion/NN of/IN CD40/NN cells/NNS (/( 26/CD %/NN )/) in/IN a/DT resting/VBG B-cell/NN preparation/NN from/IN hepatitis/NN B/NN patients/NNS decreased/VBD to/TO zero/CD after/IN a/DT 5-day/JJ culture/NN with/IN sequence/NN I/NN ,/, but/CC IgG/NN levels/NNS in/IN the/DT culture/NN supernatant/NN increased/VBD ./. 
The/DT cytotoxic/JJ properties/NNS of/IN monocytes/NNS were/VBD not/RB influenced/VBN by/IN the/DT oligos/NNS ./. 
These/DT findings/NNS indicate/VBP that/IN antisense/JJ oligos/NNS against/IN hepatitis/NN B/NN virus/NN (/( HBV/NN )/) have/VBP mitogenic/JJ effects/NNS on/IN the/DT proliferation/NN of/IN human/JJ lymphocytes/NNS in/IN a/DT non-specific/JJ manner/NN and/CC may/MD activate/VB T/NN cells/NNS to/TO express/VB CD40/NN antigen/NN ./. 
UI/LS -/: 96305192/CD 
TI/LS -/: Activation/NN protein/NN 1-dependent/JJ transcriptional/JJ activation/NN of/IN interleukin/NN 2/CD gene/NN by/IN Ca2+/calmodulin/NN kinase/NN type/NN IV/Gr/NN ./. 
AB/LS -/: The/DT Ca2+/calmodulin-dependent/JJ protein/NN kinase/NN (/( CaMK/NN )/) type/NN IV/Gr/NN is/VBZ selectively/RB expressed/VBN in/IN T/NN lymphocytes/NNS and/CC is/VBZ activated/VBN after/IN signaling/VBG via/IN the/DT T/NN cell/NN antigen/NN receptor/NN (/( TCR/NN )/) ,/, indicating/VBG that/IN it/PRP mediates/VBZ some/DT of/IN the/DT Ca(2+)-dependent/JJ transcriptional/JJ events/NNS that/WDT follow/VBP TCR/NN engagement/NN ./. 
Here/RB we/PRP show/VBP that/IN CaMKIV/Gr/NN induces/VBZ the/DT transcription/NN factor/NN activation/NN protein/NN 1/CD (/( AP-1/NN )/) alone/RB or/CC in/IN synergy/NN with/IN T/NN cell/NN mitogens/NNS and/CC with/IN the/DT p21ras/NN oncoprotein/NN ./. 
CaMKIV//NN Gr/NN signaling/NN is/VBZ associated/VBN with/IN transcriptional/JJ activation/NN of/IN c-fos/NN but/CC is/VBZ independent/JJ of/IN p21ras/NN or/CC calcineurin/NN ./. 
AP-1/NN is/VBZ an/DT integral/JJ component/NN of/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) transcriptional/JJ complex/NN ,/, which/WDT is/VBZ required/VBN for/IN interleukin/NN 2/CD gene/NN expression/NN in/IN T/NN cells/NNS ./. 
We/PRP demonstrate/VBP that/IN CaMKIV/Gr/NN reconstitutes/VBZ the/DT capacity/NN of/IN the/DT cytosolic/JJ component/NN of/IN NFAT/NN to/TO direct/VB transcription/NN from/IN NFAT/NN sites/NNS in/IN non-T/NN cells/NNS ./. 
These/DT results/NNS reveal/VBP a/DT central/JJ role/NN for/IN CaMKIV/Gr/NN as/IN a/DT Ca(2+)-regulated/JJ activator/NN of/IN gene/NN transcription/NN in/IN T/NN lymphocytes/NNS ./. 
UI/LS -/: 97025427/CD 
TI/LS -/: IL-12-induced/JJ activation/NN of/IN NK/NN and/CC T/NN cells/NNS occurs/VBZ in/IN the/DT absence/NN of/IN immediate-early/JJ activation/NN gene/NN expression/NN ./. 
AB/LS -/: The/DT responses/NNS of/IN lymphocytes/NNS to/TO IL-2/NN and/CC IL-12/NN ,/, involving/VBG proliferation/NN ,/, differentiation/NN ,/, and/CC cytokine/NN production/NN ,/, are/VBP only/RB partially/RB overlapping/VBG ,/, and/CC may/MD depend/VB on/IN induced/VBN differential/JJ expression/NN of/IN specific/JJ sets/NNS of/IN genes/NNS ./. 
Using/VBG reverse-transcription/JJ PCR/NN differential/JJ display/NN ,/, we/PRP isolated/VBD an/DT mRNA/NN species/NNS expressed/VBN in/IN IL-2-/NN but/CC not/RB IL-12-stimulated/JJ NK/NN cells/NNS ./. 
This/DT was/VBD identified/VBN as/IN the/DT mRNA/NN encoding/VBG the/DT transcription/NN factor/NN egr-1/NN ,/, which/WDT is/VBZ expressed/VBN with/IN fast/JJ kinetics/NNS in/IN T/NN and/CC NK/NN cells/NNS upon/IN IL-2/NN ,/, but/CC not/RB IL-12/NN ,/, stimulation/NN ./. 
Analysis/NN of/IN the/DT accumulation/NN of/IN mRNA-encoding/JJ members/NNS of/IN the/DT AP-1/NN transcription/NN factor/NN family/NN demonstrated/VBD that/IN c-fos/NN and/CC junB/NN are/VBP also/RB expressed/VBN upon/IN stimulation/NN of/IN NK/NN and/CC T/NN cells/NNS with/IN IL-2/NN ,/, but/CC not/RB IL-12/NN ,/, whereas/IN expression/NN of/IN c-jun/NN and/CC junD/NN is/VBZ not/RB modified/VBN by/IN either/DT cytokine/NN ./. 
Accordingly/RB ,/, increased/VBN AP-1/NN DNA-binding/JJ activity/NN and/CC AP-1-dependent/JJ transcriptional/JJ activity/NN were/VBD detected/VBN exclusively/RB in/IN IL-2-stimulated/JJ cells/NNS ./. 
Analysis/NN of/IN the/DT expression/NN of/IN genes/NNS reported/VBN to/TO regulate/VB cytokine-induced/JJ proliferation/NN demonstrated/VBD that/IN both/CC IL-2/NN and/CC IL-12/NN induce/VBP c-myc/NN mRNA/NN accumulation/NN in/IN NK/NN and/CC T/NN cells/NNS ,/, whereas/IN only/RB IL-2/NN induces/VBZ bcl-2/NN expression/NN ./. 
Our/PRP$ data/NNS provide/VBP the/DT first/JJ demonstration/NN that/IN IL-12-mediated/JJ activation/NN of/IN T/NN and/CC NK/NN cells/NNS does/VBZ not/RB involve/VB expression/NN of/IN members/NNS of/IN the/DT immediate-early/JJ activation/NN genes/NNS family/NN (/( egr-1/NN ,/, c-fos/NN ,/, and/CC junB/NN )/) ,/, AP-1/NN transcriptional/JJ activity/NN ,/, or/CC bcl-2/NN expression/NN ./. 
This/DT indicates/VBZ that/IN functional/JJ differences/NNS observed/VBN in/IN IL-2-/NN and/CC IL-12-stimulated/JJ cells/NNS may/MD depend/VB ,/, at/IN least/JJS in/IN part/NN ,/, on/IN differential/JJ gene/NN regulation/NN ./. 
UI/LS -/: 97054663/CD 
TI/LS -/: Active/JJ suppression/NN of/IN the/DT class/NN II/CD transactivator-encoding/JJ AIR-1/NN locus/NN is/VBZ responsible/JJ for/IN the/DT lack/NN of/IN major/JJ histocompatibility/NN complex/NN class/NN II/CD gene/NN expression/NN observed/VBN during/IN differentiation/NN from/IN B/NN cells/NNS to/TO plasma/NN cells/NNS ./. 
AB/LS -/: In/IN this/DT study/NN the/DT genetic/JJ control/NN of/IN major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II/CD gene/NN expression/NN during/IN the/DT transition/NN from/IN B/NN cell/NN to/TO plasma/NN cell/NN has/VBZ been/VBN analyzed/VBN ./. 
Class/NN II/CD molecules/NNS are/VBP not/RB expressed/VBN in/IN plasma/NN cells/NNS because/IN of/IN an/DT active/JJ suppression/NN resulting/VBG in/IN the/DT abrogation/NN of/IN class/NN II/CD gene/NN transcription/NN ./. 
We/PRP show/VBP here/RB that/IN the/DT plasma/NN cell-specific/JJ repressor/NN function/NN ,/, designated/VBN SIR/NN (/( suppressor/NN of/IN immune/JJ response/NN genes/NNS )/) ,/, does/VBZ not/RB act/VB directly/RB on/IN the/DT transcription/NN of/IN class/NN II/CD genes/NNS ,/, but/CC instead/RB on/IN the/DT transcription/NN of/IN the/DT AIR-1/NN gene/NN ,/, whose/WP$ product/NN ,/, the/DT class/NN II/CD transactivator/NN (/( CIITA/NN )/) ,/, is/VBZ fundamental/JJ for/IN the/DT regulation/NN of/IN the/DT constitutive/JJ and/CC inducible/JJ expression/NN of/IN MHC/NN class/NN II/CD genes/NNS ./. 
This/DT was/VBD unambiguously/RB demonstrated/VBN by/IN the/DT fact/NN that/IN plasmacytoma/NN x/NN B/NN cell/NN hybrids/NNS carrying/VBG an/DT AIR-1/NN locus/NN derived/VBN from/IN CIITA-expressing/JJ cells/NNS do/VBP not/RB express/VB CIITA-specific/JJ transcripts/NNS ./. 
Transfection/NN of/IN a/DT cDNA/NN containing/VBG the/DT human/JJ CIITA/NN coding/NN sequence/NN under/IN the/DT control/NN of/IN an/DT heterologous/JJ promoter/NN restores/VBZ expression/NN of/IN human/JJ MHC/NN class/NN II/CD genes/NNS in/IN the/DT hybrids/NNS and/CC is/VBZ responsible/JJ for/IN de/FW novo/FW expression/NN of/IN mouse/NN MHC/NN class/NN II/CD genes/NNS in/IN both/CC the/DT mouse/NN plasmacytoma/NN cell/NN line/NN and/CC the/DT hybrids/NNS ./. 
These/DT results/NNS confirm/VBP and/CC extend/VBP the/DT notion/NN of/IN the/DT functional/JJ conservation/NN of/IN the/DT AIR-1/JJ gene/NN product/NN across/IN species/NNS barriers/NNS ./. 
Interestingly/RB ,/, in/IN CIITA-transfected/JJ cell/NN hybrids/NNS ,/, cell/NN surface/NN expression/NN of/IN the/DT human/JJ HLA-DQ/NN heterodimer/NN was/VBD not/RB observed/VBN ./. 
This/DT result/NN was/VBD not/RB attributable/JJ to/TO lack/NN of/IN HLA-DQ/NN alpha/NN or/CC -DQ/NN beta/NN transcription/NN ,/, because/IN both/DT transcripts/NNS were/VBD present/JJ in/IN the/DT CIITA-transfected/JJ hybrids/NNS ,/, although/IN at/IN reduced/VBN levels/NNS ./. 
These/DT findings/NNS further/RB support/VBP our/PRP$ previous/JJ observations/NNS on/IN the/DT distinct/JJ regulation/NN of/IN expression/NN of/IN the/DT human/JJ HLA-DQ/NN class/NN II/CD subset/NN ,/, which/WDT may/MD be/VB thus/RB controlled/VBN at/IN the/DT posttranscriptional/JJ level/NN by/IN a/DT CIITA-independent/JJ mechanism/NN ./. 
UI/LS -/: 96413233/CD 
TI/LS -/: Requirements/NNS for/IN induction/NN of/IN vitamin/NN D-mediated/JJ gene/NN regulation/NN in/IN normal/JJ human/JJ B/NN lymphocytes/NNS ./. 
AB/LS -/: Mature/JJ human/JJ lymphocytes/NNS are/VBP unique/JJ targets/NNS of/IN 1/CD alpha,25-dihydroxyvitamin/NN D3/NN (/( 1/CD alpha,25(OH)2D3/NN )/) in/IN that/IN vitamin/NN D/NN receptors/NNS (/( VDR/NN )/) are/VBP not/RB constitutively/RB expressed/VBN ,/, and/CC specific/JJ cellular/JJ activation/NN signals/NNS are/VBP required/VBN for/IN both/DT the/DT up-regulation/NN of/IN VDR/NN and/CC establishment/NN of/IN reactivity/NN to/TO the/DT lipophilic/JJ ligand/NN ./. 
Treatment/NN of/IN B/NN lymphocytes/NNS with/IN the/DT cytokine/NN IL-4/NN (/( IL-4/NN )/) ,/, in/IN the/DT absence/NN of/IN prior/JJ activation/NN ,/, induces/VBZ a/DT weak/JJ up-regulation/NN of/IN VDR/NN expression/NN but/CC fails/VBZ to/TO generate/VB vitamin/NN D-responsive/JJ element/NN (/( VDRE/NN )/) -reactive/JJ nuclear/JJ protein/NN complexes/NNS or/CC to/TO initiate/VB the/DT genomic/JJ transcription/NN of/IN 25-hydroxyvitamin/NN D3/NN 24-hydroxylase/NN ./. 
Stimulation/NN of/IN B/NN lymphocytes/NNS by/IN either/CC ligation/NN of/IN CD40/NN Ag/NN or/CC cross-linking/VBG the/DT Ig/NN receptor/NN is/VBZ also/RB insufficient/JJ to/TO render/VB B/NN lymphocytes/NNS responsive/JJ to/TO 1/CD alpha,25(OH)2D3/NN ./. 
However/RB ,/, this/DT apparent/JJ lack/NN of/IN response/NN to/TO the/DT secosterol/NN can/MD be/VB overcome/VBN by/IN stimulation/NN of/IN B/NN lymphocytes/NNS with/IN a/DT combination/NN of/IN these/DT cellular/JJ activation/NN signals/NNS ,/, which/WDT are/VBP sufficient/JJ to/TO lead/VB to/TO G1/NN cell/NN cycle/NN progression/NN ./. 
In/IN the/DT presence/NN of/IN 1/CD alpha,25(OH)2D3/NN ,/, cellular/JJ activation/NN associated/VBN with/IN stimulation/NN of/IN such/PDT a/DT progression/NN appears/VBZ to/TO be/VB sufficient/JJ for/IN the/DT up-regulation/NN of/IN VDR/NN message/NN and/CC protein/NN and/CC necessary/JJ for/IN the/DT establishment/NN of/IN VDRE/NN binding/NN complexes/NNS and/CC the/DT induction/NN of/IN 24-hydroxylase/NN message/NN ./. 
Furthermore/RB ,/, biologic/JJ functions/NNS are/VBP modulated/VBN ,/, in/IN that/IN the/DT hormone/NN inhibits/VBZ proliferation/NN in/IN a/DT subset/NN of/IN the/DT activated/VBN B/NN cells/NNS ./. 
These/DT observations/NNS suggest/VBP that/IN reactivity/NN to/TO 1/CD alpha,25(OH)2D3/NN is/VBZ tightly/RB regulated/VBN in/IN B/NN lymphocytes/NNS ,/, requiring/VBG specific/JJ signals/NNS for/IN its/PRP$ initiation/NN ./. 
UI/LS -/: 96382503/CD 
TI/LS -/: Cross/NN talk/NN between/IN cell/NN death/NN and/CC cell/NN cycle/NN progression/NN :/: BCL-2/NN regulates/VBZ NFAT-mediated/JJ activation/NN ./. 
AB/LS -/: BCL-2-deficient/JJ T/NN cells/NNS demonstrate/VBP accelerated/VBN cell/NN cycle/NN progression/NN and/CC increased/VBN apoptosis/NN following/VBG activation/NN ./. 
Increasing/VBG the/DT levels/NNS of/IN BCL-2/NN retarded/VBD the/DT G0/NN -->/TO S/NN transition/NN ,/, sustained/VBD the/DT levels/NNS of/IN cyclin-dependent/JJ kinase/NN inhibitor/NN p27Kip1/NN ,/, and/CC repressed/VBD postactivation/NN death/NN ./. 
Proximal/JJ signal/NN transduction/NN events/NNS and/CC immediate/JJ early/JJ gene/NN transcription/NN were/VBD unaffected/JJ ./. 
However/RB ,/, the/DT transcription/NN and/CC synthesis/NN of/IN interleukin/NN 2/CD and/CC other/JJ delayed/VBN early/JJ cytokines/NNS were/VBD markedly/RB attenuated/VBN by/IN BCL-2/NN ./. 
In/IN contrast/NN ,/, a/DT cysteine/NN protease/NN inhibitor/NN that/WDT also/RB blocks/VBZ apoptosis/NN had/VBD no/DT substantial/JJ affect/NN upon/IN cytokine/NN production/NN ./. 
InterleUkin/NN 2/CD expression/NN requires/VBZ several/JJ transcription/NN factors/NNS of/IN which/WDT nuclear/JJ translocation/NN of/IN NFAT/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS )/) and/CC NFAT-mediated/JJ transactivation/NN were/VBD impaired/VBN by/IN BCL-2/NN ./. 
Thus/RB ,/, select/JJ genetic/JJ aberrations/NNS in/IN the/DT apoptotic/JJ pathway/NN reveal/VBP a/DT cell/NN autonomous/JJ coregulation/NN of/IN activation/NN ./. 
UI/LS -/: 96347533/CD 
TI/LS -/: Interaction/NN of/IN the/DT human/JJ T-cell/NN lymphotropic/JJ virus/NN type/NN 1/CD tax/NN transactivator/NN with/IN transcription/NN factor/NN IIA/NN ./. 
AB/LS -/: The/DT Tax/NN protein/NN of/IN human/JJ T-cell/NN lymphotropic/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) is/VBZ a/DT 40-kDa/JJ transcriptional/JJ activator/NN which/WDT is/VBZ critical/JJ for/IN HTLV-1/NN gene/NN regulation/NN and/CC virus-induced/JJ cellular/JJ transformation/NN ./. 
Tax/NN is/VBZ localized/JJ to/TO the/DT DNA/NN through/IN its/PRP$ interaction/NN with/IN the/DT site-specific/JJ activators/NNS cyclic/JJ AMP-responsive/JJ element-binding/JJ protein/NN ,/, NF-kappaB/NN ,/, and/CC serum/NN response/NN factor/NN ./. 
It/PRP has/VBZ been/VBN suggested/VBN that/IN the/DT recruitment/NN of/IN Tax/NN to/TO the/DT DNA/NN positions/VBZ Tax/NN for/IN interaction/NN with/IN the/DT basal/JJ transcriptional/JJ machinery/NN ./. 
On/IN the/DT basis/NN of/IN several/JJ independent/JJ assays/NNS ,/, we/PRP now/RB report/VBP a/DT physical/JJ and/CC functional/JJ interaction/NN between/IN Tax/NN and/CC the/DT transcription/NN factor/NN ,/, TFIIA/NN ./. 
First/RB ,/, Tax/NN was/VBD found/VBN to/TO interact/VB with/IN the/DT 35-kDa/JJ (/( alpha/NN )/) subunit/NN of/IN TFIIA/NN in/IN the/DT yeast/NN two-hybrid/JJ interaction/NN system/NN ./. 
Importantly/RB ,/, two/CD previously/RB characterized/VBN mutants/NNS with/IN point/NN mutations/NNS in/IN Tax/NN ,/, M32/NN (/( Y196A/NN ,/, K197S/NN )/) and/CC M41/NN (/( H287A/NN ,/, P288S/NN )/) ,/, which/WDT were/VBD shown/VBN to/TO be/VB defective/JJ in/IN Tax-activated/JJ transcription/NN were/VBD unable/JJ to/TO interact/VB with/IN TFIIA/NN in/IN this/DT assay/NN ./. 
Second/RB ,/, a/DT glutathione-S-transferase/NN (/( GST/NN )/) affinity-binding/JJ assay/NN showed/VBD that/IN the/DT interaction/NN of/IN holo-TFIIA/NN with/IN GST-Tax/NN was/VBD 20-fold/RB higher/JJR than/IN that/DT observed/VBN with/IN either/CC the/DT GST-Tax/NN M32/NN activation/NN mutant/NN or/CC the/DT GST/NN control/NN ./. 
Third/RB ,/, a/DT coimmunoprecipitation/NN assay/NN showed/VBD that/IN in/IN HTLV-1-infected/JJ human/JJ T/NN lymphocytes/NNS ,/, Tax/NN and/CC TFIIA/NN were/VBD associated/VBN ./. 
Finally/RB ,/, TFIIA/NN facilitates/NNS Tax/NN transactivation/NN in/FW vitro/FW and/CC in/FW vivo/FW ./. 
In/FW vitro/FW transcription/NN studies/NNS showed/VBD reduced/VBN levels/NNS of/IN Tax-activated/JJ transcription/NN in/IN cell/NN extracts/NNS depleted/VBN of/IN TFIIA/NN ./. 
In/IN addition/NN ,/, transfection/NN of/IN human/JJ T/NN lymphocytes/NNS with/IN TFIIA/NN expression/NN vectors/NNS enhanced/VBD Tax-activated/JJ transcription/NN of/IN an/DT HTLV-1/NN long/JJ terminal/JJ repeat-chloramphenicol/NN acetyltransferase/NN reporter/NN construct/NN ./. 
Our/PRP$ study/NN suggests/VBZ that/IN the/DT interaction/NN of/IN Tax/NN with/IN the/DT transcription/NN factor/NN TFIIA/NN may/MD play/VB a/DT role/NN in/IN Tax-mediated/JJ transcriptional/JJ activation/NN ./. 
UI/LS -/: 96322726/CD 
TI/LS -/: Inhibition/NN of/IN transcription/NN factor/NN Stat1/NN activity/NN in/IN mononuclear/JJ cell/NN cultures/NNS and/CC T/NN cells/NNS by/IN the/DT cyclic/JJ AMP/NN signaling/NN pathway/NN ./. 
AB/LS -/: Activation/NN of/IN T/NN cells/NNS results/VBZ in/IN a/DT cascade/NN of/IN gene/NN activation/NN and/CC subsequent/JJ proliferation/NN and/CC differentiation/NN into/IN effector/NN phenotypes/NNS ./. 
The/DT regulation/NN of/IN transcription/NN factors/NNS belonging/VBG to/TO the/DT signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) family/NN was/VBD analyzed/VBN in/IN PHA-activated/JJ mononuclear/JJ cells/NNS and/CC in/IN purified/VBN T/NN cells/NNS activated/VBN by/IN cross-linking/JJ cell/NN surface/NN CD3/NN ./. 
Cell/NN activation/NN resulted/VBD in/IN a/DT delayed/VBN induction/NN of/IN STAT/NN DNA-binding/JJ activity/NN ,/, which/WDT was/VBD sustained/JJ for/IN several/JJ days/NNS ,/, was/VBD composed/VBN predominantly/RB of/IN Stat1/NN and/CC Stat3/NN ,/, and/CC was/VBD blocked/VBN by/IN cycloheximide/NN and/CC actinomycin/NN D/NN ./. 
Increased/VBN Stat1/NN and/CC Stat3/NN mRNA/NN and/CC protein/NN levels/NNS were/VBD detected/VBN ,/, respectively/RB 4/CD and/CC 24/CD h/NN after/IN activation/NN ./. 
Stimulation/NN of/IN the/DT cAMP/NN signal/NN transduction/NN pathway/NN ,/, which/WDT skews/VBZ cytokine/NN production/NN toward/IN a/DT Th2/NN pattern/NN ,/, resulted/VBD in/IN the/DT preferential/JJ suppression/NN of/IN Stat1/NN activity/NN ./. 
cAMP/NN inhibited/VBD the/DT induction/NN of/IN expression/NN of/IN IL-2/NN receptor/NN components/NNS ,/, but/CC did/VBD not/RB inhibit/VB IL-4/NN receptor/NN alpha-chain/NN and/CC CD69/NN expression/NN or/CC the/DT induction/NN of/IN activator/NN protein/NN 1/CD transcription/NN factors/NNS ./. 
cAMP/NN signaling/NN inhibited/VBD Stat1/NN at/IN several/JJ different/JJ levels/NNS ,/, including/VBG suppression/NN of/IN DNA/NN binding/NN and/CC down-regulation/NN of/IN Stat1/NN protein/NN and/CC mRNA/NN levels/NNS ./. 
Our/PRP$ results/NNS demonstrate/VBP the/DT regulation/NN of/IN STAT/NN activity/NN by/IN a/DT signaling/NN pathway/NN that/WDT regulates/VBZ the/DT T/NN cell/NN functional/JJ phenotype/NN and/CC is/VBZ distinct/JJ from/IN the/DT cytokine-activated/JJ Janus/NN kinase-STAT/NN signaling/NN pathway/NN ./. 
UI/LS -/: 97006603/CD 
TI/LS -/: Suppression/NN of/IN c-jun/NN by/IN antisense/JJ oligonucleotides/NNS inhibits/VBZ cell/NN adhesion/NN but/CC not/RB respiratory/JJ burst/NN during/IN phorbol/NN ester-induced/JJ differentiation/NN of/IN U937/NN human/JJ monoblastic/JJ cells/NNS ./. 
AB/LS -/: We/PRP studied/VBD the/DT role/NN of/IN the/DT immediate/JJ early/JJ gene/NN c-jun/NN in/IN cell/NN proliferation/NN and/CC phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) -induced/JJ differentiation/NN in/IN U937/NN human/JJ monoblastic/JJ cells/NNS ,/, using/VBG c-jun-specific/JJ antisense/JJ (/( AS/JJ )/) phosphorothioate/NN oligonucleotides/NNS ./. 
In/IN selecting/VBG the/DT most/RBS specific/JJ and/CC potent/JJ oligonucleotide/JJ sequence/NN ,/, we/PRP performed/VBD extensive/JJ analyses/NNS for/IN the/DT binding/NN specificity/NN between/IN all/DT candidates/NNS of/IN c-jun/NN AS/JJ oligonucleotides/NNS and/CC the/DT whole/JJ sequences/NNS in/IN GenBank/NN database/NN ,/, using/VBG a/DT computer/NN program/NN ./. 
Among/IN the/DT 20/CD selected/VBN oligonucleotides/NNS ,/, two/CD potent/JJ 15-mer/JJ|NN AS/JJ oligonucleotides/NNS (/( C-JUN/NN AS/JJ oligonucleotides/NNS )/) exhibited/VBD significant/JJ inhibition/NN of/IN cell/NN growth/NN in/IN a/DT dose-dependent/JJ manner/NN between/IN 2/CD and/CC 10/CD microM/NN ./. 
Reverse/JJ transcription-PCR/NN and/CC Western/NN blot/NN analysis/NN demonstrated/VBD that/IN 10/CD microM/NN of/IN C-JUN/NN AS/JJ oligonucleotides/NNS reduced/VBD c-jun/NN expression/NN at/IN both/CC the/DT mRNA/NN and/CC protein/NN levels/NNS ./. 
More/RBR importantly/RB ,/, C-JUN/NN AS/JJ oligonucleotides/NNS showed/VBD distinct/JJ effects/NNS on/IN two/CD markers/NNS of/IN PMA-induced/JJ differentiation/NN ;/: the/DT C-JUN/NN AS/JJ oligonucleotides/NNS inhibited/VBD cell/NN adhesion/NN ,/, whereas/IN they/PRP did/VBD not/RB affect/VB another/DT marker/NN of/IN differentiation/NN ,/, respiratory/JJ burst/NN (/( measured/VBN by/IN nitro/NN blue/JJ tetrazolium/NN reduction/NN assay/NN )/) ./. 
These/DT results/NNS suggest/VBP a/DT critical/JJ role/NN of/IN c-jun/NN in/IN both/CC cell/NN proliferation/NN and/CC PMA-induced/JJ cell/NN adhesion/NN but/CC not/RB in/IN PMA-induced/JJ respiratory/JJ burst/NN in/IN U937/NN cells/NNS ./. 
UI/LS -/: 96320604/CD 
TI/LS -/: Effects/NNS of/IN IL-10/NN and/CC IL-4/NN on/IN LPS-induced/JJ transcription/NN factors/NNS (/( AP-1/NN ,/, NF-IL6/NN and/CC NF-kappa/NN B/NN )/) which/WDT are/VBP involved/VBN in/IN IL-6/NN regulation/NN ./. 
AB/LS -/: Interleukin-10/NN (/( IL-10/NN )/) ,/, like/IN IL-4/NN ,/, is/VBZ known/VBN to/TO inhibit/VB cytokine/NN expression/NN in/IN activated/VBN human/JJ monocytes/NNS ./. 
We/PRP showed/VBD that/IN both/CC IL-10/NN and/CC IL-4/NN inhibit/VBP LPS-induced/JJ IL-6/NN mRNA/NN and/CC protein/NN expression/NN by/IN inhibiting/VBG the/DT transcription/NN rate/NN of/IN the/DT IL-6/NN gene/NN ./. 
The/DT strong/JJ inhibition/NN of/IN the/DT IL-6/NN transcription/NN rate/NN prompted/VBD us/PRP to/TO study/VB the/DT effect/NN of/IN IL-10/NN and/CC IL-4/NN on/IN the/DT expression/NN of/IN transcription/NN factors/NNS ./. 
We/PRP questioned/VBD whether/IN or/CC not/RB IL-10/NN and/CC IL-4/NN affected/VBD the/DT expression/NN of/IN transcription/NN factors/NNS that/WDT are/VBP known/VBN to/TO be/VB involved/VBN in/IN the/DT control/NN of/IN the/DT IL-6/NN transcription/NN rate/NN ,/, namely/RB activator/NN protein-1/NN (/( AP-1/NN )/) ,/, nuclear/JJ factor/NN IL-6/NN (/( NF-IL6/NN )/) ,/, and/CC nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappaB/NN )/) ./. 
In/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS (/( EMSAs/NNS )/) we/PRP showed/VBD that/IN IL-10/NN and/CC IL-4/NN inhibited/VBD LPS-induced/JJ AP-1/NN binding/NN activity/NN ./. 
The/DT inhibiting/JJ effect/NN of/IN IL-4/NN was/VBD slightly/RB more/RBR pronounced/JJ than/IN that/DT of/IN IL-10/NN ./. 
Downregulation/NN of/IN LPS-induced/JJ AP-1/NN was/VBD accompanied/VBN ,/, and/CC thus/RB possibly/RB explained/VBN ,/, by/IN a/DT reduced/VBN expression/NN at/IN mRNA/NN level/NN of/IN the/DT two/CD major/JJ components/NNS of/IN the/DT AP-1/NN complex/NN ,/, namely/RB c-fos/NN and/CC c-jun/NN as/IN determined/VBN by/IN Northern/NN experiments/NNS ./. 
Binding/NN activity/NN of/IN NF-IL6/NN was/VBD also/RB strongly/RB inhibited/VBN by/IN IL-4/NN whereas/IN IL-10/NN showed/VBD no/DT effect/NN ./. 
NF-IL6/NN mRNA/NN levels/NNS were/VBD not/RB affected/VBN by/IN IL-10/NN or/CC IL-4/NN ,/, suggesting/VBG that/IN IL-4/NN affects/VBZ binding/NN activity/NN of/IN preexisting/VBG NF-IL6/NN ./. 
Neither/CC IL-10/NN nor/CC IL-4/NN inhibited/VBD LPS-induced/JJ NF-kappa/NN B/NN binding/NN activity/NN ./. 
In/IN agreement/NN with/IN this/DT finding/NN ,/, Northern/NN experiments/NNS where/WRB p65/NN and/CC p105/NN mRNA/NN levels/NNS were/VBD determined/VBN ,/, demonstrated/VBD that/IN expression/NN of/IN these/DT components/NNS of/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN were/VBD not/RB affected/VBN by/IN IL-10/NN or/CC IL-4/NN ./. 
Furthermore/RB ,/, neither/CC IL-10/NN nor/CC IL-4/NN showed/VBD any/DT effect/NN on/IN I-kappa/NN B/NN mRNA/NN expression/NN as/IN determined/VBN by/IN Northern/NN experiments/NNS ./. 
Thus/RB ,/, IL-10/NN and/CC IL-4/NN similarly/RB affect/VBP IL-6/NN expression/NN ./. 
However/RB ,/, for/IN IL-4/NN this/DT was/VBD accompanied/VBN with/IN a/DT reduction/NN of/IN AP-1/NN and/CC NF-IL6/NN binding/NN activity/NN whereas/IN IL-10/NN only/RB inhibited/VBD AP-1/NN binding/NN activity/NN ./. 
UI/LS -/: 96405269/CD 
TI/LS -/: Regulation/NN of/IN GM-CSF/NN gene/NN transcription/NN by/IN core-binding/JJ factor/NN ./. 
AB/LS -/: GM-CSF/NN gene/NN activation/NN in/IN T/NN cells/NNS is/VBZ known/VBN to/TO involve/VB the/DT transcription/NN factors/NNS nuclear/JJ factor-kappa/NN B/NN ,/, AP-1/NN ,/, NFAT/NN ,/, and/CC Sp1/NN ./. 
Here/RB we/PRP demonstrate/VBP that/IN the/DT human/JJ GM-CSF/NN promoter/NN and/CC enhancer/NN also/RB encompass/VBP binding/VBG sites/NNS for/IN core-binding/JJ factor/NN (/( CBF/NN )/) ./. 
Significantly/RB ,/, the/DT CBF/NN sites/NNS are/VBP in/IN each/DT case/NN contained/VBN within/IN the/DT minimum/JJ essential/JJ core/NN regions/NNS required/VBN for/IN inducible/JJ activation/NN of/IN transcription/NN ./. 
Furthermore/RB ,/, these/DT core/NN regions/NNS of/IN the/DT enhancer/NN and/CC promoter/NN each/DT encompass/VBP closely/RB linked/VBN binding/VBG sites/NNS for/IN CBF/NN ,/, AP-1/NN ,/, and/CC NFATp/NN ./. 
The/DT GM-CSF/NN promoter/NN CBF/NN site/NN TGTGGTCA/NN is/VBZ located/JJ 51/CD bp/NN upstream/RB of/IN the/DT transcription/NN start/NN site/NN and/CC also/RB overlaps/VBZ a/DT YY-1/NN binding/NN site/NN ./. 
A/DT 2-bp/JJ mutation/NN within/IN the/DT CBF/NN site/NN resulted/VBD in/IN a/DT 2-3-fold/JJ decrease/NN in/IN the/DT activities/NNS of/IN both/CC a/DT 69-bp/JJ proximal/JJ promoter/NN fragment/NN and/CC a/DT 627-bp/JJ full-length/NN promoter/NN fragment/NN ./. 
Stepwise/JJ deletions/NNS into/IN the/DT proximal/JJ promoter/NN also/RB revealed/VBD that/IN the/DT CBF/NN site/NN ,/, but/CC not/RB the/DT YY-1/NN site/NN ,/, was/VBD required/VBN for/IN efficient/JJ induction/NN of/IN transcriptional/JJ activation/NN ./. 
The/DT AML1/NN and/CC CBF/NN beta/NN genes/NNS that/WDT encode/VBP CBF/NN each/DT have/VBP the/DT ability/NN to/TO influence/VB cell/NN growth/NN and/CC differentiation/NN and/CC have/VBP been/VBN implicated/VBN as/IN proto-oncogenes/NNS in/IN acute/JJ myeloid/JJ leukemia/NN ./. 
This/DT study/NN adds/VBZ GM-CSF/NN to/TO a/DT growing/VBG list/NN of/IN cytokines/NNS and/CC receptors/NNS that/WDT are/VBP regulated/VBN by/IN CBF/NN and/CC which/WDT control/VBP the/DT growth/NN ,/, differentiation/NN ,/, and/CC activation/NN of/IN hemopoietic/JJ cells/NNS ./. 
The/DT GM-CSF/NN locus/NN may/MD represent/VB one/CD of/IN several/JJ target/NN genes/NNS that/WDT are/VBP dysregulated/VBN in/IN acute/JJ myeloid/JJ leukemia/NN ./. 
UI/LS -/: 96264685/CD 
TI/LS -/: Sublethal/JJ levels/NNS of/IN oxidative/JJ stress/NN stimulate/VBP transcriptional/JJ activation/NN of/IN c-jun/NN and/CC suppress/VBP IL-2/NN promoter/NN activation/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
AB/LS -/: Sublethal/JJ levels/NNS of/IN oxidative/JJ stress/NN are/VBP well/RB known/VBN to/TO alter/VB T/NN cell/NN functional/JJ responses/NNS ,/, but/CC the/DT underlying/JJ mechanisms/NNS are/VBP unknown/JJ ./. 
The/DT current/JJ study/NN examined/VBD the/DT effects/NNS of/IN oxidative/JJ stress/NN on/IN transcriptional/JJ activities/NNS mediated/VBN by/IN c-Fos/c-Jun/NN AP-1/NN and/CC the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) ./. 
The/DT present/JJ results/NNS show/VBP that/IN Jurkat/NN T/NN cells/NNS acutely/RB exposed/VBN to/TO micromolar/JJ concentrations/NNS of/IN H2O2/NN exhibit/VBP substantial/JJ increases/NNS in/IN AP-1/NN binding/NN activity/NN and/CC the/DT expression/NN of/IN c-jun/NN but/CC not/RB c-fos/NN mRNA/NN ./. 
The/DT preferential/JJ induction/NN of/IN c-jun/NN by/IN H2O2/NN did/VBD not/RB represent/VB redox/NN stabilization/NN of/IN mRNA/NN transcripts/NNS ,/, and/CC oxidative/JJ signals/NNS closely/RB resembled/VBD PHA/PMA/NN stimulation/NN by/IN effectively/RB transactivating/VBG the/DT full/JJ length/NN c-jun/NN promoter/NN via/IN the/DT proximal/JJ jun1/NN tumor/NN promoter-responsive/JJ element/NN (/( TRE/NN )/) -like/JJ promoter/NN element/NN ./. 
Similarly/RB ,/, the/DT complexes/NNS binding/VBG the/DT consensus/NN AP-1/NN TRE/NN and/CC jun/NN TRE-like/JJ motifs/NNS in/IN cells/NNS exposed/VBN to/TO oxidative/JJ signals/NNS or/CC PHA/PMA/NN were/VBD indistinguishable/JJ ,/, being/VBG composed/VBN of/IN c-Fos/NN ,/, c-Jun/NN ,/, and/CC JunD/NN ./. 
However/RB ,/, PHA/PMA/NN but/CC not/RB oxidative/JJ signals/NNS induced/VBD the/DT coordinate/JJ activation/NN of/IN reporter/NN constructs/NNS containing/VBG the/DT AP-1-TRE/NN ,/, NF-AT/NN ,/, and/CC IL-2/NN promoter/NN regions/NNS along/IN with/IN IL-2/NN mRNA/NN expression/NN ./. 
Furthermore/RB ,/, sublethal/JJ levels/NNS of/IN H2O2/NN actively/RB suppressed/VBD the/DT transcriptional/JJ activation/NN of/IN NF-AT/NN and/CC IL-2/NN reporters/NNS as/RB well/RB as/IN the/DT expression/NN of/IN IL-2/NN mRNA/NN in/IN cells/NNS stimulated/VBN with/IN PHA/PMA/NN ./. 
Gel/NN shift/NN analysis/NN revealed/VBD that/IN oxidative/JJ suppression/NN of/IN NF-AT/NN represented/VBD inhibition/NN in/IN the/DT early/JJ generation/NN of/IN NFAT/NN complexes/NNS rather/RB than/IN the/DT binding/NN of/IN preformed/JJ NF-AT/NN complexes/NNS ./. 
These/DT results/NNS suggest/VBP that/IN oxidative/JJ signals/NNS can/MD positively/RB and/CC negatively/RB regulate/VB T/NN cell/NN transcriptional/JJ events/NNS and/CC that/IN changes/NNS in/IN cellular/JJ redox/NN can/MD uncouple/VB AP-1/NN regulation/NN of/IN c-jun/NN from/IN transcriptional/JJ up-regulation/NN of/IN IL-2/NN via/IN NF-AT/NN ./. 
UI/LS -/: 97032774/CD 
TI/LS -/: Inorganic/JJ lead/NN activates/VBZ NF-kappa/NN B/NN in/IN primary/JJ human/JJ CD4+/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: Inorganic/JJ lead/NN (/( Pb/NN )/) is/VBZ a/DT ubiquitous/JJ environmental/JJ contaminant/NN that/WDT produces/VBZ a/DT variety/NN of/IN effects/NNS on/IN humoral/JJ and/CC cell/NN mediated/JJ immune/JJ responses/NNS ./. 
The/DT underlying/VBG molecular/JJ mechanism/NN for/IN Pb/NN 's/POS complex/JJ effects/NNS on/IN the/DT immune/JJ system/NN remain/VBP obscure/JJ ./. 
Many/JJ of/IN Pb/NN 's/POS effects/NNS on/IN the/DT immune/JJ system/NN could/MD be/VB explained/VBN through/IN activation/NN of/IN the/DT transcription/NN factor/NN ,/, NF-kappa/NN B/NN ./. 
NF-kappa/NN B/NN is/VBZ critical/JJ for/IN T/NN lymphocyte/NN function/NN and/CC is/VBZ a/DT strong/JJ inducer/NN of/IN HIV-LTR/NN activation/NN ./. 
We/PRP demonstrate/VBP that/IN Pb/NN at/IN physiologically/RB relevant/JJ concentrations/NNS activates/VBZ NF-kappa/NN B/NN in/IN primary/JJ human/JJ CD4+/JJ T/NN lymphocytes/NNS ./. 
Pb-induced/JJ activation/NN of/IN NF-kappa/NN B/NN is/VBZ blocked/VBN by/IN antibodies/NNS for/IN p65/NN and/CC p50/NN subunits/NNS but/CC not/RB cRel/NN ,/, indicating/VBG that/IN the/DT p65/NN :/: p50/NN heterodimer/NN (/( NF-kappa/NN B/NN )/) is/VBZ involved/VBN ./. 
Functional/JJ activation/NN of/IN gene/NN expression/NN by/IN Pb/NN was/VBD confirmed/VBN using/VBG primary/JJ CD4+/JJ T/NN cells/NNS transfected/VBN with/IN an/DT NF-kappa/NN B/NN dependent/JJ reporter/NN gene/NN construct/NN ./. 
Pb/NN did/VBD not/RB activate/VB NF-kappa/NN B/NN in/IN 4/CD different/JJ T/NN cell/NN lines/NNS ,/, suggesting/VBG that/IN lymphoid/JJ cell/NN lines/NNS may/MD not/RB be/VB reliable/JJ surrogates/NNS for/IN the/DT study/NN of/IN transcriptional/JJ activation/NN in/IN human/JJ T/NN cells/NNS ./. 
These/DT data/NNS suggest/VBP that/IN NF-kappa/NN B/NN may/MD be/VB an/DT important/JJ molecular/JJ mediator/NN of/IN Pb-induced/JJ immunotoxicity/NN ./. 
UI/LS -/: 97054651/CD 
TI/LS -/: Tyrosine/NN kinase/NN and/CC cAMP-dependent/JJ protein/NN kinase/NN activities/NNS in/IN CD40-activated/JJ human/JJ B/NN lymphocytes/NNS ./. 
AB/LS -/: In/FW vitro/FW ,/, human/JJ B/NN lymphocytes/NNS undergo/VBP long-term/JJ proliferation/NN when/WRB activated/VBN through/IN CD40/NN ,/, a/DT protein/NN expressed/VBN on/IN their/PRP$ cell/NN surface/NN ./. 
The/DT nature/NN of/IN CD40-dependent/JJ signals/NNS in/IN proliferating/VBG fresh/JJ human/JJ Epstein-Barr/JJ virus-negative/JJ B/NN lymphocytes/NNS is/VBZ currently/RB unknown/JJ ./. 
In/IN this/DT study/NN ,/, a/DT CD40-dependent/JJ B/NN cell/NN culture/NN system/NN was/VBD used/VBN to/TO examine/VB the/DT role/NN of/IN different/JJ signal/NN transduction/NN elements/NNS ./. 
Protein/NN kinase/NN C/NN (/( PKC/NN )/) depletion/NN generated/VBN by/IN a/DT long-term/JJ phorbol/NN 12/CD myristate/NN 13-acetate/NN treatment/NN had/VBD weak/JJ effects/NNS on/IN proliferation/NN ./. 
Rather/RB ,/, tyrosine/NN phosphorylation/NN was/VBD shown/VBN to/TO be/VB directly/RB involved/VBN in/IN mediating/VBG CD40-dependent/JJ signals/NNS ./. 
The/DT use/NN of/IN the/DT protein/NN tyrosine/NN kinase/NN (/( PTK/NN )/) -specific/JJ inhibitor/NN herbimycin/NN A/NN dramatically/RB decreased/VBD cellular/JJ proliferation/NN without/IN altering/VBG the/DT activity/NN of/IN the/DT human/JJ immunodeficiency/NN virus-1/NN long/JJ terminal/JJ repeat/NN (/( HIV-1/NN LTR/NN )/) ,/, a/DT promoter/NN largely/RB dependent/JJ on/IN the/DT binding/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF- kappa/NN B/NN )/) ./. 
In/IN contrast/NN ,/, the/DT cAMP-dependent/JJ protein/NN kinase/NN specific/JJ inhibitor/NN H-89/NN totally/RB inhibited/VBD HIV-1/NN LTR/NN activity/NN at/IN a/DT concentration/NN as/RB low/JJ as/IN 100/CD nM/NN without/IN affecting/VBG cellular/JJ proliferation/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assay/NN (/( EMSA/NN )/) and/CC supershift/NN assay/NN using/VBG an/DT NF-kappa/NN B/NN binding/NN sequence/NN from/IN the/DT kappa/NN light/JJ chain/NN as/IN a/DT probe/NN ,/, revealed/VBD that/IN both/CC p65/NNS (/( RelA/NN )/) and/CC c-Rel/NN were/VBD present/JJ in/IN CD40-stimulated/JJ B/NN cells/NNS ./. 
While/IN PKC/NN depletion/NN did/VBD not/RB alter/VB the/DT NF-kappa/NN B/NN level/NN ,/, treatment/NN of/IN B/NN lymphocytes/NNS with/IN H-89/NN or/CC herbimycin/NN A/NN provoked/VBD a/DT decrease/NN in/IN the/DT NF-kappa/NN B/NN level/NN ./. 
These/DT observations/NNS establish/VBP the/DT importance/NN of/IN different/JJ signal/NN transducing/NN pathways/NNS leading/VBG to/TO CD40/NN activation/NN of/IN B/NN lymphocytes/NNS ./. 
UI/LS -/: 97050805/CD 
TI/LS -/: Interferons/NNS induce/VBP normal/JJ and/CC aberrant/JJ retinoic-acid/NN receptors/NNS type/NN alpha/NN in/IN acute/JJ promyelocytic/JJ leukemia/NN cells/NNS :/: potentiation/NN of/IN the/DT induction/NN of/IN retinoid-dependent/JJ differentiation/NN markers/NNS ./. 
AB/LS -/: Treatment/NN of/IN the/DT acute/JJ promyelocytic/JJ (/( APL/NN )/) cell/NN line/NN NB4/NN with/IN interferon/NN alpha/NN (/( IFN/NN (/( alpha/NN )/) )/) ,/, as/RB well/RB as/IN IFN/NN (/( beta/NN )/) and/CC gamma/NN ,/, results/VBZ in/IN an/DT increased/VBN expression/NN of/IN the/DT transcripts/NNS coding/VBG for/IN retinoic-acid/JJ receptor/NN type/NN alpha/NN (/( RAR/NN (/( alpha/NN )/) )/) and/CC the/DT leukemia-specific/JJ retinoic/JJ acid/NN receptor/NN PML-RAR/NN ./. 
Transcriptional/JJ induction/NN of/IN the/DT RAR/NN (/( alpha/NN )/) and/CC PML-RAR/NN mRNAs/NNS is/VBZ rapid/JJ and/CC it/PRP is/VBZ parallelled/VBN by/IN an/DT increase/NN in/IN the/DT corresponding/JJ proteins/NNS ./. 
Up-regulation/NN of/IN RAR/NN (/( alpha/NN )/) and/CC PML-RAR/NN gene/NN expression/NN by/IN IFN/NN (/( alpha/NN )/) is/VBZ accompanied/VBN by/IN a/DT strong/JJ potentiation/NN in/IN the/DT induction/NN of/IN 2/CD retinoid-dependent/JJ granulocytic/JJ markers/NNS ,/, i.e./FW ,/, granulocyte-colony-stimulating/JJ factor/NN receptor/NN mRNA/NN and/CC leukocyte/NN alkaline/NN phosphatase/NN ./. 
However/RB ,/, IFN/NN (/( alpha/NN )/) does/VBZ not/RB have/VB any/DT effects/NNS on/IN the/DT retinoid-dependent/JJ regulation/NN of/IN the/DT myeloid/JJ surface/NN markers/NNS CD11b/NN and/CC CD33/NN ./. 
The/DT IFN-dependent/JJ increase/NN in/IN RAR/NN (/( alpha/NN )/) levels/NNS and/CC the/DT enhancing/JJ effect/NN of/IN the/DT cytokine/NN on/IN retinoid-dependent/JJ granulocytic/JJ markers/NNS expression/NN may/MD be/VB a/DT characteristic/NN of/IN PML-RAR/NN positive/JJ cells/NNS ,/, since/IN the/DT phenomena/NNS are/VBP not/RB observed/VBN in/IN HL-60/NN promyelocytes/NNS ./. 
Interferons/NNS as/RB well/RB as/IN retinoids/NNS inhibit/VBP the/DT growth/NN of/IN NB4/NN cells/NNS ,/, although/IN the/DT 2/CD classes/NNS of/IN compounds/NNS do/VBP not/RB significantly/RB interact/VBP in/IN terms/NNS of/IN anti-proliferative/JJ activity/NN ./. 
These/DT results/NNS suggest/VBP the/DT possible/JJ use/NN of/IN combinations/NNS between/IN IFNs/NNS and/CC retinoic/JJ acid/NN in/IN the/DT cyto-differentiating/JJ treatment/NN of/IN APL/NN patients/NNS ./. 
UI/LS -/: 97058563/CD 
TI/LS -/: Modulatory/JJ effects/NNS of/IN glucocorticoids/NNS and/CC catecholamines/NNS on/IN human/JJ interleukin-12/NN and/CC interleukin-10/NN production/NN :/: clinical/JJ implications/NNS ./. 
AB/LS -/: Interleukin-12/NN (/( IL-12/NN )/) is/VBZ a/DT key/JJ inducer/NN of/IN differentiation/NN of/IN uncommitted/JJ T/NN helper/NN (/( TH/NN )/) cells/NNS toward/IN the/DT TH1/NN phenotype/NN ,/, which/WDT regulates/VBZ cellular/JJ immunity/NN ,/, whereas/IN IL-10/NN inhibits/VBZ TH1/NN functions/NNS and/CC potentiates/VBZ TH2-regulated/JJ responses/NNS (/( i.e./FW ,/, humoral/JJ immunity/NN )/) ./. 
To/TO examine/VB the/DT potential/JJ effects/NNS of/IN stress/NN on/IN TH1/TH2/NN balance/NN ,/, we/PRP studied/VBD the/DT ability/NN of/IN three/CD prototype/NN stress/NN hormones/NNS -/: dexamethasone/NN (/( a/DT synthetic/JJ glucocorticoid/NN )/) and/CC the/DT catecholamines/NNS norepinephrine/NN and/CC epinephrine/NN -/: to/TO alter/VB the/DT production/NN of/IN IL-12/NN (/( p70/NN )/) and/CC IL-10/NN induced/VBN by/IN bacterial/JJ lipopolysaccharide/NN (/( LPS/NN )/) in/IN human/JJ whole/JJ blood/NN ./. 
Dexamethasone/NN inhibited/VBD LPS-induced/JJ bioactive/JJ IL-12/NN production/NN in/IN a/DT dose-dependent/JJ fashion/NN and/CC at/IN physiologically/RB relevant/JJ concentrations/NNS ;/: it/PRP had/VBD no/DT effect/NN on/IN IL-10/NN secretion/NN ./. 
The/DT glucocorticoid-induced/JJ reduction/NN of/IN IL-12/NN production/NN was/VBD antagonized/VBN by/IN RU/NN 486/CD ,/, a/DT glucocorticoid-receptor/JJ antagonist/NN ,/, suggesting/VBG that/IN it/PRP was/VBD mediated/VBN by/IN the/DT glucocorticoid/NN receptor/NN ./. 
Norepinephrine/NN and/CC epinephrine/NN also/RB suppressed/VBD IL-12/NN production/NN in/IN a/DT dose-dependent/JJ fashion/NN and/CC at/IN physiological/JJ concentrations/NNS ;/: both/DT catecholamines/NNS ,/, however/RB ,/, dose-dependently/RB increased/VBD the/DT production/NN of/IN IL-10/NN ./. 
The/DT effects/NNS of/IN either/DT catecholamine/NN on/IN IL-12/NN or/CC IL-10/NN secretion/NN were/VBD blocked/VBN completely/RB by/IN propranolol/NN ,/, a/DT beta-adrenoreceptor/JJ antagonist/NN ,/, indicating/VBG that/IN they/PRP were/VBD mediated/VBN by/IN the/DT beta-adrenergic/JJ receptor/NN ./. 
These/DT findings/NNS suggest/VBP that/IN the/DT central/JJ nervous/JJ system/NN may/MD regulate/VB IL-12/NN and/CC IL-10/NN secretion/NN and/CC ,/, hence/RB ,/, TH1/TH2/NN balance/NN via/IN the/DT peripheral/JJ end-effectors/NNS of/IN the/DT stress/NN system/NN ./. 
Thus/RB ,/, stress/NN may/MD cause/VB a/DT selective/JJ suppression/NN of/IN TH1/NN functions/NNS and/CC a/DT shift/NN toward/IN a/DT TH2/NN cytokine/NN pattern/NN rather/RB than/IN generalized/JJ TH/NN suppression/NN ./. 
The/DT TH1-to-TH2/JJ shift/NN may/MD be/VB responsible/JJ for/IN the/DT stress-induced/JJ susceptibility/NN of/IN the/DT organism/NN to/TO certain/JJ infections/NNS ./. 
Through/IN the/DT same/JJ or/CC a/DT reciprocal/JJ mechanism/NN ,/, states/NNS associated/VBN with/IN chronic/JJ hyperactivity/NN or/CC hypoactivity/NN of/IN the/DT stress/NN system/NN might/MD influence/VB the/DT susceptibility/NN of/IN an/DT individual/NN to/TO certain/JJ autoimmune/JJ ,/, allergic/JJ ,/, infectious/JJ ,/, or/CC neoplastic/JJ diseases/NNS ./. 
UI/LS -/: 96355899/CD 
TI/LS -/: Activation/NN of/IN human/JJ monocytic/JJ cells/NNS by/IN Treponema/FW pallidum/FW and/CC Borrelia/FW burgdorferi/FW lipoproteins/NNS and/CC synthetic/JJ lipopeptides/NNS proceeds/VBZ via/IN a/DT pathway/NN distinct/JJ from/IN that/DT of/IN lipopolysaccharide/NN but/CC involves/VBZ the/DT transcriptional/JJ activator/NN NF-kappa/NN B/NN ./. 
AB/LS -/: There/EX is/VBZ increasing/VBG evidence/NN that/IN lipoproteins/NNS of/IN Treponema/FW pallidum/FW and/CC Borrelia/FW burgdorferi/FW are/VBP key/JJ inflammatory/JJ mediators/NNS during/IN syphilis/NN and/CC Lyme/NN disease/NN ./. 
A/DT principal/JJ objective/NN of/IN the/DT present/JJ study/NN was/VBD to/TO identify/VB more/RBR precisely/RB similarities/NNS and/CC divergences/NNS among/IN lipopolysaccharide/NN (/( LPS/NN )/) -/: and/CC lipoprotein-lipopeptide-induced/JJ immune/JJ cell/NN signaling/NN events/NNS ./. 
Like/IN LPS/NN ,/, purified/VBN native/JJ B./FW burgdorferi/FW OspA/NN and/CC synthetic/JJ analogs/NNS of/IN OspA/NN ,/, OspB/NN ,/, and/CC two/CD T./FW pallidum/FW lipoproteins/NNS (/( Tpp47/NN and/CC Tpp17/NN )/) all/DT induced/VBD NF-kappa/NN B/NN translocation/NN in/IN THP-1/NN human/JJ monocytoid/NN cells/NNS ./. 
Acylation/NN of/IN OspA/NN and/CC the/DT synthetic/JJ peptides/NNS was/VBD requisite/JJ for/IN cell/NN activation/NN ./. 
Polymyxin/NN B/NN abrogated/VBD only/RB the/DT response/NN to/TO LPS/NN ./. 
By/IN using/VBG 70Z/3-derived/JJ pre-B-cell/NN lines/NNS either/CC lacking/VBG or/CC expressing/VBG human/JJ CD14/NN (/( the/DT LPS/NN receptor/NN )/) ,/, it/PRP was/VBD observed/VBN that/IN expression/NN of/IN human/JJ CD14/NN imparted/VBD responsiveness/NN to/TO LPS/NN but/CC not/RB to/TO OspA/NN or/CC spirochetal/JJ lipopeptides/NNS (/( assessed/VBN by/IN induction/NN of/IN NF-kappa/NN B/NN and/CC expression/NN of/IN surface/NN immunoglobulin/NN M/NN )/) ./. 
Finally/RB ,/, the/DT biological/JJ relevance/NN of/IN the/DT observation/NN that/IN T./FW pallidum/FW lipoproteins-lipopeptides/NNS induce/VBP both/CC NF-kappa/NN B/NN and/CC cytokine/NN production/NN in/IN monocytes/NNS was/VBD supported/VBN by/IN the/DT ability/NN of/IN the/DT synthetic/JJ analogs/NNS to/TO promote/VB human/JJ immunodeficiency/NN virus/NN replication/NN in/IN chronically/RB infected/JJ U1/NN monocytoid/NN cells/NNS ;/: these/DT observations/NNS also/RB suggest/VBP a/DT potential/JJ mechanism/NN whereby/WRB a/DT syphilitic/JJ chancre/NN can/MD serve/VB as/IN a/DT cofactor/NN for/IN human/JJ immunodeficiency/NN virus/NN transmission/NN ./. 
The/DT combined/JJ data/NNS lend/VBP additional/JJ support/NN to/TO the/DT proposal/NN that/IN spirochetal/JJ lipoproteins/NNS and/CC LPS/NN initiate/VBP monocyte/NN activation/NN via/IN different/JJ cell/NN surface/NN events/NNS but/CC that/IN the/DT signaling/NN pathways/NNS ultimately/RB converge/VBP to/TO produce/VB qualitatively/RB similar/JJ cellular/JJ responses/NNS ./. 
UI/LS -/: 96329578/CD 
TI/LS -/: LYSP100-associated/JJ nuclear/JJ domains/NNS (/( LANDs/NNS )/) :/: description/NN of/IN a/DT new/JJ class/NN of/IN subnuclear/JJ structures/NNS and/CC their/PRP$ relationship/NN to/TO PML/NN nuclear/JJ bodies/NNS ./. 
AB/LS -/: The/DT PML/NN gene/NN is/VBZ fused/VBN to/TO the/DT retinoic/JJ acid/NN receptor/NN alpha/NN (/( RAR/NN alpha/NN )/) gene/NN in/IN t(15;17)/NN acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) ,/, creating/VBG a/DT PML-RAR/NN alpha/NN fusion/NN oncoprotein/NN ./. 
The/DT PML/NN gene/NN product/NN has/VBZ been/VBN localized/JJ to/TO subnuclear/JJ dot-like/JJ structures/NNS variously/RB termed/VBN PODs/NNS ,/, ND10s/NNS ,/, Kr/NN bodies/NNS ,/, or/CC PML/NN nuclear/JJ bodies/NNS (/( PML/NN NBs/NNS )/) ./. 
The/DT present/JJ study/NN describes/VBZ the/DT cloning/NN of/IN a/DT lymphoid-restricted/JJ gene/NN ,/, LYSP100/NN ,/, that/WDT is/VBZ homologous/JJ to/TO another/DT protein/NN that/WDT localizes/VBZ to/TO PML/NN NBs/NNS ,/, SP100/NN ./. 
In/IN addition/NN to/TO SP100/NN homology/NN regions/NNS ,/, one/CD LYSP100/NN cDNA/NN isoform/NN contains/VBZ a/DT bromodomain/NN and/CC a/DT PHD/TTC/NN domain/NN ,/, which/WDT are/VBP present/JJ in/IN a/DT variety/NN of/IN transcriptional/JJ regulatory/JJ proteins/NNS ./. 
By/IN immunofluorescence/NN ,/, LYSP100/NN was/VBD localized/JJ to/TO nuclear/JJ dots/NNS that/WDT were/VBD surprisingly/RB largely/RB nonoverlapping/JJ with/IN PML/NN NBs/NNS ./. 
However/RB ,/, a/DT minority/NN of/IN LYSP100/NN nuclear/JJ dots/NNS exactly/RB colocalized/VBD with/IN PML/NN and/CC SP100/NN ./. 
We/PRP term/VBP the/DT LYSP100/NN structures/NNS "/`` LANDs/NNS ,/, "/'' for/IN LYSP100-associated/JJ nuclear/JJ domains/NNS ./. 
Although/IN LYSP100/NN is/VBZ expressed/VBN only/RB in/IN lymphoid/JJ cells/NNS ,/, LANDs/NNS could/MD be/VB visualized/VBN in/IN HeLa/NN cells/NNS by/IN transfection/NN of/IN a/DT LYSP100/NN cDNA/NN ./. 
Immunoelectron/NN microscopy/NN revealed/VBD LANDs/NNS to/TO be/VB globular/JJ ,/, electron-dense/JJ structures/NNS morphologically/RB distinct/JJ from/IN the/DT annular/JJ structures/NNS characteristic/JJ of/IN PML/NN NBs/NNS ./. 
LANDs/NNS were/VBD most/RBS often/RB found/VBN in/IN the/DT nucleoplasm/NN ,/, but/CC were/VBD also/RB found/VBN at/IN the/DT nuclear/JJ membrane/NN and/CC in/IN the/DT cytoplasm/NN ,/, suggesting/VBG that/IN these/DT structures/NNS may/MD traffic/VBP between/IN the/DT cytoplasm/NN and/CC the/DT nucleus/NN ./. 
By/IN double-immunogold/JJ labeling/NN of/IN PML/NN and/CC LYSP100/NN ,/, some/DT LANDs/NNS were/VBD shown/VBN to/TO contain/VB both/CC PML/NN and/CC LYSP100/NN ./. 
Thus/RB ,/, PML/NN is/VBZ localized/JJ to/TO a/DT second/JJ subnuclear/JJ domain/NN that/WDT is/VBZ morphologically/RB and/CC biochemically/RB distinct/JJ from/IN PML/NN NBs/NNS ./. 
UI/LS -/: 97000328/CD 
TI/LS -/: Transcriptional/JJ control/NN of/IN steroid-regulated/JJ apoptosis/NN in/IN murine/JJ thymoma/NN cells/NNS ./. 
AB/LS -/: Early/JJ studies/NNS in/IN murine/JJ T/NN cell/NN lines/NNS indicated/VBD that/IN transcriptional/JJ transactivation/NN functions/NNS encoded/VBN in/IN the/DT glucocorticoid/NN receptor/NN (/( GR/NN )/) N-terminal/JJ domain/NN are/VBP required/VBN for/IN glucocorticoid-mediated/JJ apoptosis/NN ./. 
However/RB ,/, more/RBR recent/JJ studies/NNS in/IN human/JJ T/NN cell/NN lines/NNS have/VBP suggested/VBN that/IN the/DT N-terminal/JJ domain/NN is/VBZ not/RB necessary/JJ for/IN steroid-regulated/JJ apoptosis/NN and/CC that/IN GR-mediated/JJ transrepression/NN may/MD be/VB the/DT more/RBR critical/JJ mechanism/NN ./. 
To/TO better/RBR understand/VB the/DT contribution/NN of/IN the/DT GR/NN N-terminal/JJ transactivation/NN domain/NN in/IN mediating/VBG murine/JJ thymocyte/NN apoptosis/NN ,/, we/PRP stably/RB transfected/VBD GR/NN ,/, GR/NN variants/NNS ,/, and/CC the/DT androgen/NN receptor/NN (/( AR/NN )/) into/IN receptor-negative/JJ S49/NN murine/JJ thymoma/NN cells/NNS ./. 
GR/NN expression/NN levels/NNS were/VBD shown/VBN to/TO be/VB rate-limiting/JJ for/IN initiating/VBG the/DT apoptotic/JJ pathway/NN ,/, and/CC a/DT positive/JJ correlation/NN between/IN steroid/NN sensitivity/NN and/CC GR-mediated/JJ induction/NN of/IN an/DT integrated/VBN mouse/NN mammary/JJ tumor/NN virus/NN (/( MMTV/NN )/) LTR/NN reporter/NN gene/NN was/VBD observed/VBN ./. 
Analysis/NN of/IN GR/NN chimeric/JJ receptors/NNS containing/VBG the/DT potent/JJ VP16/NN and/CC E1A/NN viral/JJ transactivation/NN domains/NNS in/IN place/NN of/IN the/DT GR/NN N/NN terminus/NN revealed/VBD that/IN even/RB low/JJ level/NN expression/NN of/IN these/DT receptors/NNS resulted/VBD in/IN both/CC enhanced/VBN steroid/NN sensitivity/NN and/CC MMTV/NN induction/NN ,/, thus/RB supporting/VBG a/DT role/NN for/IN transactivation/NN in/IN apoptosis/NN ./. 
In/IN contrast/NN ,/, we/PRP found/VBD that/IN AR/NN can/MD initiate/VB apoptosis/NN in/IN S49/NN cells/NNS after/IN treatment/NN with/IN 5/CD alpha-dihydrotestosterone/NN ,/, despite/IN its/PRP$ relative/JJ inability/NN to/TO induce/VB high/JJ level/NN expression/NN of/IN MMTV/NN ./. 
To/TO investigate/VB this/DT further/RBR ,/, we/PRP examined/VBD the/DT steroid-regulated/JJ expression/NN of/IN an/DT endogenous/JJ thymocyte-specific/JJ gene/NN called/VBN GIG18/NN ./. 
We/PRP found/VBD that/IN GIG18/NN was/VBD rapidly/RB induced/VBN to/TO comparable/JJ levels/NNS by/IN both/CC AR/NN and/CC GR/NN ,/, demonstrating/VBG that/IN AR/NN can/MD indeed/RB function/VB as/IN a/DT transcriptional/JJ activator/NN in/IN S49/NN cells/NNS and/CC ,/, moreover/RB ,/, that/IN GIG18/NN induction/NN may/MD be/VB a/DT marker/NN of/IN early/JJ apoptotic/JJ events/NNS in/IN steroid-treated/JJ cells/NNS ./. 
Taken/VBN together/RB ,/, these/DT results/NNS support/VBP our/PRP$ conclusion/NN that/IN transcriptional/JJ transactivation/NN is/VBZ a/DT necessary/JJ signaling/NN component/NN of/IN S49/NN cell/NN apoptosis/NN ,/, although/IN an/DT additional/JJ role/NN for/IN GR-mediated/JJ transrepression/NN can/MD not/RB be/VB excluded/VBN ./. 
UI/LS -/: 96324400/CD 
TI/LS -/: Multiple/JJ p21ras/NN effector/NN pathways/NNS regulate/VBP nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS ./. 
AB/LS -/: The/DT transcription/NN factor/NN ,/, Nuclear/JJ Factor/NN of/IN Activated/VBN T/NN cells/NNS (/( NFAT/NN )/) is/VBZ a/DT major/JJ target/NN for/IN p21ras/NN and/CC calcium/NN signalling/NN pathways/NNS in/IN the/DT IL-2/NN gene/NN and/CC is/VBZ induced/VBN by/IN p21ras/NN signals/NNS acting/VBG in/IN synergy/NN with/IN calcium/calcineurin/NN signals/NNS ./. 
One/CD p21ras/NN effector/NN pathway/NN involves/VBZ the/DT MAP/NN kinase/NN ERK-2/NN ,/, and/CC we/PRP have/VBP examined/VBN its/PRP$ role/NN in/IN NFAT/NN regulation/NN ./. 
Expression/NN of/IN dominant/JJ negative/JJ MAPKK-1/NN prevents/VBZ NFAT/NN induction/NN ./. 
Constitutively/RB active/JJ MAPKK-1/NN fully/RB activates/VBZ ERK-2/NN and/CC the/DT transcription/NN factor/NN Elk-1/NN ,/, but/CC does/VBZ not/RB substitute/VB for/IN activated/VBN p21ras/NN and/CC synergize/VBP with/IN calcium/calcineurin/NN signals/NNS to/TO induce/VB NFAT/NN ./. 
Expression/NN of/IN dominant/JJ negative/JJ N17Rac/NN also/RB prevents/VBZ TCR/NN and/CC p21ras/NN activation/NN of/IN NFAT/NN ,/, but/CC without/IN interfering/VBG with/IN the/DT ERK-2/NN pathway/NN ./. 
The/DT transcriptional/JJ activity/NN of/IN the/DT NFAT/NN binding/NN site/NN is/VBZ mediated/VBN by/IN a/DT complex/NN comprising/VBG a/DT member/NN of/IN the/DT NFAT/NN group/NN and/CC AP-1/NN family/NN proteins/NNS ./. 
The/DT induction/NN of/IN AP-1/NN by/IN p21ras/NN also/RB requires/VBZ Rac-1/NN function/NN ./. 
Activated/VBN Rac-1/NN could/MD mimic/VB activated/VBN p21ras/NN to/TO induce/VB AP-1/NN but/CC not/RB to/TO induce/VB NFAT/NN ./. 
Moreover/RB ,/, the/DT combination/NN of/IN activated/VBN MAPKK-1/NN and/CC Rac-1/NN could/MD not/RB substitute/VB for/IN activated/VBN p21ras/NN and/CC synergize/VB with/IN calcium/NN signals/NNS to/TO induce/VB NFAT/NN ./. 
Thus/RB ,/, p21ras/NN regulation/NN of/IN NFAT/NN in/IN T/NN cells/NNS requires/VBZ the/DT activity/NN of/IN multiple/JJ effector/NN pathways/NNS including/VBG those/DT regulated/VBN by/IN MAPKK-1/ERK-2/NN and/CC Rac-1/NN ./. 
UI/LS -/: 96388957/CD 
TI/LS -/: Retinoid/NN differentiation/NN therapy/NN in/IN promyelocytic/JJ leukemia/NN ./. 
AB/LS -/: Acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) is/VBZ a/DT specific/JJ type/NN of/IN acute/JJ myeloid/JJ leukemia/NN characterized/VBN by/IN the/DT morphology/NN of/IN the/DT blast/NN cells/NNS ,/, a/DT specific/JJ t(15;17)/NN translocation/NN ,/, and/CC risks/NNS of/IN definite/JJ coagulopathy/NN ./. 
Recently/RB this/DT leukemia/NN was/VBD further/RB characterized/VBN by/IN an/DT exquisite/JJ sensitivity/NN to/TO all-trans/JJ retinoic/JJ acid/NN 's/POS differentiation/NN effect/NN and/CC the/DT production/NN of/IN a/DT fusion/NN gene/NN altering/VBG the/DT gene/NN of/IN RARalpha/NN and/CC a/DT novel/JJ gene/NN PML/NN ./. 
In/FW vivo/FW differentiation/NN therapy/NN with/IN retinoids/NNS in/IN APL/NN patients/NNS follows/VBZ strict/JJ guidelines/NNS related/JJ both/CC to/TO the/DT APL/NN cell/NN and/CC the/DT biodisposal/NN of/IN all-trans/JJ retinoic/JJ acid/NN ./. 
UI/LS -/: 96264681/CD 
TI/LS -/: Differential/JJ utilization/NN of/IN Janus/NN kinase-signal/JJ transducer/NN activator/NN of/IN transcription/NN signaling/NN pathways/NNS in/IN the/DT stimulation/NN of/IN human/JJ natural/JJ killer/NN cells/NNS by/IN IL-2/NN ,/, IL-12/NN ,/, and/CC IFN-alpha/NN ./. 
AB/LS -/: IL-2-/NN ,/, IL-12-/NN ,/, and/CC IFN-alpha-mediated/JJ signaling/NN pathways/NNS were/VBD analyzed/VBN in/IN primary/JJ NK/NN cells/NNS and/CC in/IN the/DT NK3.3/NN cell/NN line/NN ./. 
Gel/NN mobility/NN shift/NN and/CC immunoprecipitation/NN analyses/NNS revealed/VBD that/IN in/IN addition/NN to/TO activating/VBG STAT3/NN (/( signal/NN transducer/NN and/CC activator/NN of/IN transcription-3/NN )/) and/CC STAT5/NN ,/, IL-2/NN induced/VBD tyrosine/NN and/CC serine/NN phosphorylation/NN of/IN STAT1/NN alpha/NN ,/, which/WDT formed/VBD IFN-gamma-activated/JJ sequence-binding/NN complexes/NNS by/IN itself/PRP and/CC with/IN STAT3/NN ./. 
Although/IN IL-2/NN and/CC IFN-alpha/NN activated/VBD STAT1/NN alpha/NN and/CC STAT5/NN ,/, IL-2/NN predominantly/RB activated/VBN STAT5/NN ,/, while/IN IFN-alpha/NN predominantly/RB activated/VBD STAT1/NN alpha/NN ./. 
IL-2/NN induced/VBD less/RBR STAT1/NN alpha/NN activation/NN and/CC IFN-alpha/NN induced/VBD greater/JJR STAT5/NN activation/NN in/IN NK3.3/NN cells/NNS compared/VBN with/IN preactivated/JJ primary/JJ NK/NN cells/NNS ./. 
In/IN NK3.3/NN cells/NNS ,/, IL-2/NN induced/VBD comparable/JJ formation/NN of/IN c-fos/NN promoter/NN sis-inducible/JJ element/NN IFN-gamma-activated/JJ sequence-binding/NN complexes/NNS containing/VBG STAT3/NN alone/RB with/IN complexes/NNS containing/VBG STAT3/NN and/CC STAT1/NN alpha/NN ,/, while/IN in/IN preactivated/JJ primary/JJ NK/NN cells/NNS ,/, it/PRP preferentially/RB induced/VBD complexes/NNS containing/VBG STAT3/NN and/CC STAT1/NN alpha/NN ./. 
Thus/RB ,/, signaling/NN in/IN NK3.3/NN cells/NNS is/VBZ not/RB always/RB identical/JJ with/IN that/DT in/IN primary/JJ NK/NN cells/NNS ./. 
In/IN contrast/NN to/TO IL-2/NN and/CC IFN-alpha/NN ,/, IL-12/NN induced/VBD strong/JJ tyrosine/NN phosphorylation/NN of/IN STAT4/NN and/CC variable/JJ weak/JJ phosphorylation/NN of/IN STAT3/NN ./. 
However/RB ,/, supershift/NN analyses/NNS using/VBG the/DT c-fos/NN promoter/NN sis-inducible/JJ element/NN probe/NN showed/VBD that/IN IL-12/NN activated/VBD STAT4/NN ,/, STAT1/NN alpha/NN ,/, and/CC STAT3/NN ,/, and/CC induced/VBD complexes/NNS containing/VBG STAT4/NN only/RB ,/, STAT4/NN with/IN STAT1/NN alpha/NN ,/, STAT3/NN with/IN STAT1/NN alpha/NN ,/, or/CC STAT1/NN alpha/NN only/RB in/IN preactivated/JJ primary/JJ NK/NN cells/NNS ./. 
STAT1/NN alpha/NN activation/NN by/IN IL-12/NN correlated/VBD with/IN increased/VBN phosphorylation/NN of/IN serine/NN ,/, but/CC not/RB tyrosine/NN ./. 
Finally/RB ,/, IL-2/NN induced/VBD tyrosine/NN phosphorylation/NN of/IN JAK1/NN and/CC JAK3/NN ,/, while/IN IL-12/NN induced/VBD phosphorylation/NN of/IN JAK2/NN and/CC TYK2/NN in/IN both/CC preactivated/JJ primary/JJ NK/NN and/CC NK3.3/NN cells/NNS ./. 
Differential/JJ phosphorylation/NN and/CC consequent/JJ differential/JJ activation/NN of/IN both/CC separate/JJ and/CC overlapping/JJ STAT/NN proteins/NNS by/IN IL-2/NN ,/, IL-12/NN ,/, and/CC IFN-alpha/NN may/MD provide/VB a/DT molecular/JJ basis/NN for/IN the/DT similarities/NNS and/CC differences/NNS in/IN the/DT actions/NNS of/IN these/DT cytokines/NNS on/IN NK/NN cells/NNS ./. 
UI/LS -/: 97025418/CD 
TI/LS -/: The/DT suppression/NN of/IN T/NN cell/NN function/NN and/CC NF(kappa)B/NN expression/NN by/IN serine/NN protease/NN inhibitors/NNS is/VBZ blocked/VBN by/IN N-acetylcysteine/NN ./. 
AB/LS -/: Direct/JJ evidence/NN that/IN N-acetylcysteine/NN (/( NAC/NN )/) enhances/VBZ the/DT immune/JJ response/NN of/IN peripheral/JJ blood/NN T/NN cells/NNS at/IN the/DT level/NN of/IN NF(kappa)B/NN is/VBZ presented/VBN ./. 
In/IN addition/NN ,/, NAC/NN blocks/VBZ the/DT suppression/NN of/IN T/NN cell/NN mitogenesis/NN and/CC cytokine/NN production/NN by/IN protease/NN inhibitors/NNS such/JJ as/IN N-tosylphenylalanine/NN chloromethyl/NN ketone/NN (/( TPCK/NN )/) ./. 
The/DT proliferative/JJ responses/NNS of/IN purified/VBN CD4+/JJ or/CC CD8+/JJ T/NN cells/NNS are/VBP suppressed/VBN more/RBR strongly/RB by/IN TPCK/NN when/WRB anti-CD28/NN rather/RB than/IN the/DT phorbol/NN ester/NN PMA/NN is/VBZ used/VBN as/IN the/DT mitogenic/JJ coactivator/NN ./. 
Cytokine/NN (/( IL-2/NN ,/, IL-6/NN ,/, INF-gamma/NN )/) production/NN is/VBZ inhibited/VBN 95-100/CD %/NN by/IN concentrations/NNS of/IN TPCK/NN that/WDT totally/RB suppress/VB the/DT mitogenesis/NN of/IN CD4+/JJ or/CC CD8+/JJ cells/NNS ./. 
Using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, we/PRP find/VBP that/IN TPCK/NN virtually/RB abolishes/VBZ (/( to/TO less/JJR than/IN 1/CD %/NN )/) the/DT levels/NNS of/IN NF(kappa)B/NN (/( but/CC not/RB Oct-1/NN )/) found/VBN in/IN nuclear/JJ and/CC whole/JJ cell/NN extracts/NNS of/IN activated/VBN T/NN cells/NNS ./. 
Strikingly/RB ,/, the/DT immunosuppressive/JJ effects/NNS of/IN TPCK/NN are/VBP blocked/VBN when/WRB T/NN cells/NNS are/VBP pretreated/VBN for/IN 15/CD min/NN with/IN 5/CD mM/NN NAC/NN ./. 
NAC/NN not/RB only/RB blocks/VBZ the/DT effect/NN of/IN TPCK/NN but/CC enhances/VBZ mitogenesis/NN and/CC cytokine/NN production/NN (/( >/JJR 2.5-fold/RB in/IN some/DT cases/NNS )/) upon/IN activation/NN of/IN unsuppressed/JJ T/NN cells/NNS ./. 
Our/PRP$ data/NNS support/VBP the/DT notion/NN that/IN NF/NN (/( kappa/NN )/) B/NN and/CC I/NN (/( kappa/NN )/) B/NN proteases/NNS play/VBP obligate/JJ roles/NNS in/IN T/NN cell/NN activation/NN and/CC mitogenesis/NN ,/, roles/NNS that/WDT are/VBP enhanced/VBN significantly/RB by/IN NAC/NN ./. 
UI/LS -/: 97017504/CD 
TI/LS -/: Signaling/NN by/IN IL-2/NN and/CC related/JJ cytokines/NNS :/: JAKs/NNS ,/, STATs/NNS ,/, and/CC relationship/NN to/TO immunodeficiency/NN ./. 
AB/LS -/: Cytokines/NNS that/WDT bind/VBP to/TO the/DT interleukin-2/NN (/( IL-2/NN )/) receptor/NN common/JJ gamma/NN chain/NN (/( gamma/NN c/NN )/) ,/, including/VBG IL-2/NN ,/, IL-4/NN ,/, IL-7/NN ,/, IL-9/NN ,/, and/CC IL-15/NN ,/, are/VBP important/JJ for/IN the/DT growth/NN and/CC differentiation/NN of/IN T/NN and/CC B/NN lymphocytes/NNS ,/, natural/JJ killer/NN cells/NNS ,/, macrophages/NNS ,/, and/CC monoctyes/NNS ./. 
These/DT cytokines/NNS have/VBP overlapping/VBG biological/JJ effects/NNS that/WDT in/IN part/NN result/VBP from/IN the/DT use/NN of/IN the/DT shared/VBN receptor/NN subunit/NN gamma/NN c/NN ./. 
Recently/RB it/PRP has/VBZ become/VBN clear/JJ that/IN these/DT cytokines/NNS activate/VBP a/DT number/NN of/IN important/JJ intracellular/JJ signaling/VBG molecules/NNS ,/, including/VBG the/DT Janus/NN kinases/NNS JAK1/NN and/CC JAK3/NN and/CC members/NNS of/IN the/DT transcription/NN factor/NN family/NN of/IN signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STATs/NNS )/) ./. 
The/DT discovery/NN of/IN these/DT signaling/NN pathways/NNS has/VBZ led/VBN to/TO important/JJ new/JJ insights/NNS into/IN their/PRP$ role/NN in/IN lymphocyte/NN maturation/NN ,/, as/IN it/PRP has/VBZ emerged/VBN that/IN mutations/NNS in/IN the/DT genes/NNS encoding/VBG both/CC gamma/NN c/NN and/CC JAK3/NN result/VBP in/IN similar/JJ forms/NNS of/IN severe/JJ combined/JJ immunodeficiency/NN (/( SCID/NN )/) ./. 
In/IN this/DT review/NN we/PRP examine/VBP the/DT structure/NN and/CC function/NN of/IN cytokine/NN receptors/NNS and/CC the/DT signaling/NN pathways/NNS involved/VBN in/IN their/PRP$ regulation/NN of/IN gene/NN expression/NN ./. 
Furthermore/RB ,/, we/PRP discuss/VBP recent/JJ advances/NNS that/WDT have/VBP led/VBN to/TO a/DT better/JJR understanding/NN of/IN how/WRB cytokines/NNS elicit/VBP intracellular/JJ responses/NNS ,/, as/RB well/RB as/IN their/PRP$ role/NN in/IN normal/JJ lymphoid/JJ development/NN ./. 
UI/LS -/: 96427516/CD 
TI/LS -/: Cytomegalovirus/NN modulates/VBZ interleukin-6/NN gene/NN expression/NN ./. 
AB/LS -/: Complications/NNS after/IN lung/NN transplantation/NN include/VBP the/DT development/NN of/IN rejection/NN and/CC an/DT increased/VBN incidence/NN of/IN infection/NN ,/, particularly/RB with/IN cytomegalovirus/NN (/( CMV/NN )/) ./. 
Several/JJ recent/JJ studies/NNS have/VBP suggested/VBN that/IN interleukin/NN (/( IL/NN )/) -6/CD may/MD be/VB used/VBN to/TO detect/VB both/CC infection/NN and/CC rejection/NN after/IN lung/NN transplantation/NN ./. 
In/IN addition/NN ,/, IL-6/NN may/MD play/VB a/DT role/NN in/IN the/DT development/NN of/IN bronchiolitis/NN obliterans/NNS after/IN transplantation/NN ./. 
Because/IN CMV/NN is/VBZ also/RB associated/VBN with/IN the/DT development/NN of/IN bronchiolitis/NN obliterans/NNS after/IN transplantation/NN ,/, we/PRP determined/VBD whether/IN CMV/NN induces/VBZ IL-6/NN gene/NN expression/NN ./. 
We/PRP demonstrated/VBD that/IN CMV/NN infection/NN increased/VBD both/CC IL-6/NN protein/NN and/CC mRNA/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
We/PRP also/RB demonstrated/VBD that/IN the/DT CMV/NN immediate/JJ early/JJ 1/CD gene/NN product/NN increased/VBD expression/NN of/IN the/DT IL-6/NN promoter/NN ./. 
This/DT effect/NN of/IN the/DT CMV/NN immediate/JJ early/JJ 1/CD gene/NN product/NN was/VBD dependent/JJ upon/IN the/DT presence/NN of/IN specific/JJ transcription/NN factor/NN binding/NN sites/NNS in/IN the/DT IL-6/NN promoter/NN ./. 
These/DT studies/NNS demonstrate/VBP that/IN CMV/NN may/MD be/VB an/DT important/JJ cofactor/NN in/IN the/DT development/NN of/IN rejection/NN and/CC infection/NN after/IN transplantation/NN through/IN its/PRP$ effects/NNS on/IN IL-6/NN ./. 
UI/LS -/: 97031178/CD 
TI/LS -/: Vitamin/NN D3-/NN and/CC retinoic/JJ acid-induced/JJ monocytic/JJ differentiation/NN :/: interactions/NNS between/IN the/DT endogenous/JJ vitamin/NN D3/NN receptor/NN ,/, retinoic/JJ acid/NN receptors/NNS ,/, and/CC retinoid/NN X/NN receptors/NNS in/IN U-937/NN cells/NNS ./. 
AB/LS -/: Retinoic/JJ acid/NN (/( RA/NN )/) and/CC 1,25/CD alpha-dihydroxycholecalciferol/NN (/( VitD3/NN )/) are/VBP potent/JJ regulators/NNS of/IN hematopoletic/JJ differentiation/NN ./. 
Yet/RB ,/, little/JJ is/VBZ known/VBN as/IN to/TO how/WRB the/DT RA/NN and/CC VitD3/NN receptor/NN network/NN operates/VBZ in/IN hematopoietic/JJ cells/NNS ,/, and/CC whether/IN receptor/NN interactions/NNS can/MD explain/VB the/DT interplay/NN between/IN the/DT RA-/NN and/CC VitD3-signaling/JJ pathways/NNS during/IN differentiation/NN ./. 
Therefore/RB ,/, we/PRP analyzed/VBD the/DT expression/NN ,/, DNA/NN binding/NN ,/, and/CC transcriptional/JJ activity/NN of/IN the/DT endogenous/JJ RA/NN and/CC VitD3/NN receptors/NNS [/( retinoic/JJ acid/NN receptors/NNS (/( RARs/NNS )/) ,/, retinoid/NN X/NN receptors/NNS (/( RXRs/NNS )/) ,/, and/CC VitD3/NN receptor/NN (/( VDR/NN )/) ]/) in/IN the/DT U-937/NN cell/NN line/NN ,/, in/IN which/WDT RA/NN and/CC VitD3/NN induce/VBP distinct/JJ monocytic/JJ differentiation/NN pathways/NNS ./. 
VitD3/NN induction/NN resulted/VBD in/IN the/DT formation/NN of/IN VDR/RXR/NN DNA-binding/JJ complexes/NNS on/IN both/CC VitD3/NN response/NN elements/NNS and/CC RA/NN response/NN elements/NNS (/( RAREs/NNS )/) ./. 
However/RB ,/, transcriptional/JJ activation/NN was/VBD only/RB observed/VBN from/IN a/DT VitD3/NN response/NN element-driven/JJ reporter/NN construct/NN ./. 
Several/JJ DNA-binding/JJ complexes/NNS were/VBD detected/VBN on/IN RAREs/NNS in/IN undifferentiated/JJ cells/NNS ./. 
Stimulation/NN by/IN RA/NN resulted/VBD in/IN increased/VBN RAR/NN beta/RXR/NN DNA/NN binding/NN ,/, activated/VBN RARE-dependent/JJ transcription/NN ,/, and/CC increased/VBN expression/NN of/IN RAR-beta/NN ./. 
Concomitant/JJ stimulation/NN by/IN VitD3/NN inhibited/VBD the/DT RA-stimulated/JJ formation/NN of/IN RAR/NN beta/RXR/NN heterodimers/NNS ,/, favoring/VBG VDR/RXR/NN binding/NN to/TO the/DT RARE/NN ./. 
Also/RB ,/, VitD3/NN inhibited/VBD the/DT expression/NN of/IN CD23/NN and/CC CD49f/NN ,/, characteristic/JJ markers/NNS of/IN retinoid-induced/JJ U-937/NN cell/NN differentiation/NN ./. 
In/IN contrast/NN ,/, neither/CC the/DT RA-stimulated/JJ ,/, RARE-mediated/JJ transcription/NN nor/CC the/DT induced/VBN RAR-beta/NN expression/NN was/VBD suppressed/VBN by/IN VitD3/NN ,/, suggesting/VBG that/IN VitD3/NN selectively/RB inhibited/VBD the/DT retinoid-induced/JJ differentiation/NN program/NN but/CC not/RB the/DT RARE-mediated/JJ signal/NN ./. 
These/DT results/NNS demonstrate/VBP a/DT complex/JJ role/NN for/IN VitD3/NN in/IN modifying/VBG the/DT retinoid/NN differentiation/NN pathway/NN and/CC may/MD have/VB implications/NNS for/IN differentiation-inducing/JJ therapy/NN of/IN hematopoietic/JJ tumors/NNS ./. 
UI/LS -/: 96323172/CD 
TI/LS -/: The/DT human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD posttranscriptional/JJ trans-activator/NN Rex/NN contains/VBZ a/DT nuclear/JJ export/NN signal/NN ./. 
AB/LS -/: The/DT Rex/NN protein/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD is/VBZ required/VBN for/IN the/DT nuclear/JJ export/NN of/IN unspliced/JJ viral/JJ mRNA/NN and/CC ,/, therefore/RB ,/, for/IN virus/NN replication/NN ./. 
In/IN this/DT manuscript/NN ,/, we/PRP demonstrate/VBP that/IN Rex/NN shuttles/VBZ between/IN the/DT nucleus/NN and/CC the/DT cytoplasm/NN and/CC that/IN its/PRP$ activation/NN domain/NN constitutes/VBZ a/DT nuclear/JJ export/NN signal/NN that/WDT specifies/VBZ efficient/JJ transport/NN to/TO the/DT cytoplasm/NN ./. 
These/DT findings/NNS are/VBP consistent/JJ with/IN a/DT model/NN for/IN Rex-mediated/JJ trans-activation/NN in/IN which/WDT Rex-viral/JJ mRNA/NN complexes/NNS are/VBP targeted/VBN for/IN nuclear/JJ export/NN by/IN the/DT direct/JJ action/NN of/IN the/DT activation/NN domain/NN ./. 
UI/LS -/: 96329553/CD 
TI/LS -/: Granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN preferentially/RB activates/VBZ the/DT 94-kD/JJ STAT5A/NN and/CC an/DT 80-kD/JJ STAT5A/NN isoform/NN in/IN human/JJ peripheral/JJ blood/NN monocytes/NNS ./. 
AB/LS -/: Granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) induces/VBZ immediate/JJ effects/NNS in/IN monocytes/NNS by/IN activation/NN of/IN the/DT Janus/NN kinase/NN (/( JAK2/NN )/) and/CC STAT/NN transcription/NN factor/NN (/( STAT5/NN )/) pathway/NN ./. 
Recent/JJ studies/NNS have/VBP identified/VBN homologues/NNS of/IN STAT5/NN ,/, STAT5A/NN ,/, and/CC STAT5B/NN ,/, as/RB well/RB as/IN lower/JJR molecular/JJ weight/NN variants/NNS of/IN STAT5/NN ./. 
To/TO define/VB the/DT activation/NN of/IN the/DT STAT5/NN homologues/NNS and/CC lower/JJR molecular/JJ weight/NN variant/NN in/IN human/JJ monocytes/NNS and/CC monocytes/NNS differentiated/VBN into/IN macrophages/NNS by/IN culture/NN in/IN macrophage-CSF/NN (/( M-CSF/NN )/) ,/, we/PRP measured/VBD the/DT GM-CSF/NN induced/JJ tyrosine/NN phosphorylation/NN of/IN STAT5A/NN ,/, STAT5B/NN ,/, and/CC any/DT lower/JJR molecular/JJ weight/NN STAT5/NN isoforms/NNS ./. 
Freshly/RB isolated/VBN monocytes/NNS expressed/VBD 94-kD/JJ STAT5A/NN ,/, 92-kD/JJ STAT5B/NN ,/, and/CC an/DT 80-kD/JJ STAT5A/NN molecule/NN ./. 
Whereas/IN 94-kD/JJ STAT5A/NN was/VBD clearly/RB tyrosine/NN phosphorylated/JJ and/CC bound/VBD to/TO the/DT enhancer/NN element/NN ,/, the/DT gamma/NN response/NN region/NN (/( GRR/NN )/) ,/, of/IN the/DT Fc/NN gamma/NN RI/NN gene/NN ,/, substantially/RB less/JJR tyrosine/NN phosphorylated/JJ STAT5B/NN bound/VBD to/TO the/DT immobilized/JJ GRR/NN element/NN ./. 
Macrophages/NNS lost/VBD their/PRP$ ability/NN to/TO express/VB the/DT 80-kD/JJ STAT5A/NN protein/NN ,/, but/CC retained/VBD their/PRP$ ability/NN to/TO activate/VB STAT5A/NN ./. 
STAT5A-STAT5A/JJ|NN homodimers/NNS and/CC STAT5A-STAT5B/NN heterodimers/NNS formed/VBD in/IN response/NN to/TO GM-CSF/NN ./. 
Therefore/RB ,/, activation/NN of/IN STAT5A/NN predominates/VBZ compared/VBN to/TO STAT5B/NN when/WRB assayed/VBN by/IN direct/JJ immunoprecipitation/NN and/CC by/IN evaluation/NN of/IN bound/VBN STATs/NNS to/TO immobilized/JJ GRR/NN ./. 
Selective/JJ activation/NN of/IN STAT5/NN homologues/NNS in/IN addition/NN to/TO generation/NN of/IN lower/JJR molecular/JJ isoforms/NNS may/MD provide/VB specificity/NN and/CC control/NN to/TO genes/NNS expressed/VBN in/IN response/NN to/TO cytokines/NNS such/JJ as/IN GM-CSF/NN ./. 
UI/LS -/: 96374456/CD 
TI/LS -/: Translocation/NN (/( 3/CD ;/: 14/CD )/) (/( q27/NN ;/: q11/NN )/) :/: a/DT new/JJ variant/JJ translocation/NN in/IN a/DT patient/NN with/IN non-Hodgkin/JJ|NN 's/POS lymphoma/NN of/IN B-cell/NN type/NN with/IN BCL6/NN rearrangement/NN ./. 
AB/LS -/: We/PRP report/VBP a/DT 65-year-old/JJ woman/NN with/IN non-Hodgkin/JJ|NN 's/POS lymphoma/NN (/( NHL/NN )/) carrying/VBG a/DT t(3;14)(q27;q11)/NN and/CC BCL6/NN rearrangement/NN in/IN the/DT affected/VBN cells/NNS ./. 
She/PRP had/VBD generalized/VBN lymphadenopathy/NN and/CC the/DT bone/NN marrow/NN was/VBD infiltrated/VBN by/IN lymphoma/NN cells/NNS at/IN presentation/NN ./. 
Histological/JJ diagnosis/NN was/VBD "/`` malignant/JJ lymphoma/NN ,/, diffuse/JJ ,/, large/JJ cell/NN "/'' type/NN according/VBG to/TO an/DT International/NNP Working/NNP Formulation/NNP ./. 
Chromosome/NN analysis/NN revealed/VBD a/DT t(3;14)(q27;q11)/NN ,/, which/WDT is/VBZ a/DT new/JJ variant/JJ translocation/NN of/IN t(3;14) (q27;q32)/NN ./. 
Southern/NN blot/NN analysis/NN showed/VBD rearrangement/NN of/IN BCL6/NN ,/, JH/NN ,/, and/CC TCR/NN beta/NN but/CC not/RB of/IN TCR/NN delta/NN ./. 
Cosmid/NN probe/NN of/IN BCL6/NN hybridized/VBD to/TO 14q11/NN and/CC 3q27/NN by/IN fluorescence/NN in/FW situ/FW hybridization/NN (/( FISH/NN )/) ./. 
Although/IN the/DT band/NN 14q11/NN is/VBZ a/DT locus/NN of/IN T-cell/NN receptor/NN alpha-/NN and/CC delta-chains/NNS (/( TCR/NN alpha/delta/NN )/) ,/, lymphoma/NN cells/NNS expressed/VBD B-cell/NN ,/, IgGk/NN phenotype/NN ./. 
The/DT findings/NNS suggest/VBP that/IN a/DT novel/JJ proto-oncogene/NN in/IN the/DT vicinity/NN of/IN TCR/NN alpha/delta/NN is/VBZ involved/VBN in/IN this/DT translocation/NN ./. 
UI/LS -/: 96353916/CD 
TI/LS -/: Transgenic/JJ expression/NN of/IN PML/RARalpha/NN impairs/VBZ myelopoiesis/NN ./. 
AB/LS -/: The/DT translocation/NN found/VBN in/IN acute/JJ promyelocytic/JJ leukemia/NN rearranges/VBZ the/DT promyelocytic/JJ leukemia/NN gene/NN (/( PML/NN )/) on/IN chromosome/NN 15/CD with/IN the/DT retinoic/JJ acid/NN receptor/NN alpha/NN (/( RARalpha/NN )/) on/IN chromosome/NN 17/CD ./. 
This/DT yields/VBZ a/DT fusion/NN transcript/NN ,/, PML/RARalpha/NN ,/, a/DT transcription/NN factor/NN with/IN reported/VBN dominant/JJ negative/JJ functions/NNS in/IN the/DT absence/NN of/IN hormone/NN ./. 
Clinical/JJ remissions/NNS induced/VBN with/IN all-trans/JJ retinoic/JJ acid/NN (/( RA/NN )/) treatment/NN in/IN acute/JJ promyelocytic/JJ leukemia/NN are/VBP linked/VBN to/TO PML/RARalpha/NN expression/NN in/IN leukemic/JJ cells/NNS ./. 
To/TO evaluate/VB the/DT PML/RARalpha/NN role/NN in/IN myelopoiesis/PRP$ ,/, transgenic/JJ mice/NNS expressing/VBG PML/RARalpha/NN were/VBD engineered/VBN ./. 
A/DT full-length/JJ PML/RARalpha/NN cDNA/NN driven/VBN by/IN the/DT CD11b/NN promoter/NN was/VBD expressed/VBN in/IN transgenic/JJ mice/NNS ./. 
Expression/NN was/VBD confirmed/VBN in/IN the/DT bone/NN marrow/NN with/IN a/DT reverse/JJ transcription/NN PCR/NN assay/NN ./. 
Basal/JJ total/JJ white/JJ blood/NN cell/NN and/CC granulocyte/NN counts/NNS did/VBD not/RB appreciably/RB differ/VB between/IN PML/RARalpha/NN transgenic/JJ and/CC control/NN mice/NNS ./. 
Cell/NN sorter/NN analysis/NN of/IN CD11b+/JJ bone/NN marrow/NN cells/NNS revealed/VBD similar/JJ CD11b+/JJ populations/NNS in/IN transgenic/JJ and/CC control/NN mice/NNS ./. 
However/RB ,/, in/FW vitro/FW clonal/JJ growth/NN assays/NNS performed/VBN on/IN peripheral/JJ blood/NN from/IN transgenic/JJ versus/CC control/NN mice/NNS revealed/VBD a/DT marked/JJ reduction/NN of/IN myeloid/JJ progenitors/NNS ,/, especially/RB in/IN those/DT responding/VBG to/TO granulocyte/ macrophage/NN colony-stimulating/JJ factor/NN ./. 
Granulocyte/macrophage/NN colony-stimulating/JJ factor/NN and/CC kit/NN ligand/NN cotreatment/NN did/VBD not/RB overcome/VB this/DT inhibition/NN ./. 
Impaired/JJ myelopoiesis/NN in/FW vivo/FW was/VBD shown/VBN by/IN stressing/VBG these/DT mice/NNS with/IN sublethal/JJ irradiation/NN ./. 
Following/VBG irradiation/NN ,/, PML/RARalpha/NN transgenic/JJ mice/NNS ,/, as/IN compared/VBN with/IN controls/NNS ,/, more/RBR rapidly/RB depressed/VBD peripheral/JJ white/JJ blood/NN cell/NN and/CC granulocyte/NN counts/NNS ./. 
As/IN expected/VBN ,/, nearly/RB all/DT control/NN mice/NNS (/( 94.4/CD %/NN )/) survived/VBD irradiation/NN ,/, yet/CC this/DT irradiation/NN was/VBD lethal/JJ to/TO 45.8/CD %/NN of/IN PML/RARalpha/NN transgenic/JJ mice/NNS ./. 
Lethality/NN was/VBD associated/VBN with/IN more/RBR severe/JJ leukopenia/NN in/IN transgenic/JJ versus/CC control/NN mice/NNS ./. 
Retinoic/JJ acid/NN treatment/NN of/IN irradiated/JJ PML/RARalpha/NN mice/NNS enhanced/VBD granulocyte/NN recovery/NN ./. 
These/DT data/NNS suggest/VBP that/IN abnormal/JJ myelopoiesis/NN due/IN to/TO PML/RARalpha/NN expression/NN is/VBZ an/DT early/JJ event/NN in/IN oncogenic/JJ transformation/NN ./. 
UI/LS -/: 96320521/CD 
TI/LS -/: C/EBP/NN activators/NNS are/VBP required/VBN for/IN HIV-1/NN replication/NN and/CC proviral/JJ induction/NN in/IN monocytic/JJ cell/NN lines/NNS ./. 
AB/LS -/: Previous/JJ work/NN has/VBZ shown/VBN that/IN C/EBP/NN sites/NNS and/CC C/EBP/NN transcriptional/JJ activators/NNS are/VBP necessary/JJ for/IN HIV-1/NN LTR/NN activity/NN in/IN monocytes/macrophages/NNS ./. 
We/PRP have/VBP investigated/VBN the/DT role/NN that/WDT C/EBP/NN proteins/NNS play/VBP in/IN induction/NN and/CC replication/NN of/IN HIV-1/NN ./. 
Ectopic/JJ expression/NN of/IN the/DT dominant/JJ negative/JJ C/EBP/NN protein/NN LIP/NN inhibited/VBD HIV-1/NN mRNA/NN and/CC virus/NN production/NN in/IN activated/VBN U1/NN cells/NNS ,/, demonstrating/VBG that/IN C/EBP/NN proteins/NNS are/VBP required/VBN for/IN provirus/NN induction/NN ./. 
U1/NN lines/NNS overexpressing/VBG C/EBP/NN activator/NN NF-IL-6/NN produced/VBD more/JJR viral/JJ mRNA/NN and/CC virus/NN particles/NNS following/VBG cellular/JJ activation/NN than/IN control/NN lines/NNS ,/, demonstrating/VBG that/IN C/EBP/NN proteins/NNS are/VBP limiting/VBG for/IN virus/NN transcription/NN ./. 
HIV-1/NN harboring/NN mutations/NNS within/IN two/CD C/EBP/NN sites/NNS were/VBD crippled/VBN in/IN their/PRP$ ability/NN to/TO replicate/VB in/IN U937/NN promonocytic/JJ cells/NNS ,/, indicating/VBG that/IN these/DT sites/NNS are/VBP required/VBN for/IN replication/NN ./. 
These/DT data/NNS identify/VBP C/EBP/NN proteins/NNS as/IN regulators/NNS of/IN HIV-1/NN expression/NN in/IN monocytes/macrophages/NNS ./. 
UI/LS -/: 96256807/CD 
TI/LS -/: Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD and/CC latent/JJ membrane/NN protein/NN independently/RB transactivate/VBP p53/NN through/IN induction/NN of/IN NF-kappaB/NN activity/NN ./. 
AB/LS -/: B-cell/NN immortalization/NN by/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) is/VBZ dependent/JJ on/IN permanent/JJ control/NN of/IN the/DT cellular/JJ processes/NNS which/WDT normally/RB regulate/VB cell/NN division/NN and/CC apoptosis/NN ,/, functions/NNS possessed/VBN by/IN p53/NN in/IN a/DT number/NN of/IN normal/JJ cell/NN types/NNS ./. 
In/IN studies/NNS initiated/VBN to/TO evaluate/VB relationships/NNS between/IN EBV/NN latent/JJ genes/NNS and/CC p53/NN ,/, p53/NN levels/NNS were/VBD found/VBN to/TO increase/VB approximately/RB 10-fold/RB 4/CD to/TO 5/CD days/NNS after/IN EBV/NN infection/NN of/IN purified/VBN resting/VBG human/JJ B/NN cells/NNS ;/: the/DT induced/VBN p53/NN was/VBD transcriptionally/RB active/JJ ./. 
Latent/JJ membrane/NN protein/NN 1/CD and/CC ,/, to/TO a/DT lesser/JJR extent/NN ,/, EBV/NN nuclear/JJ antigen/NN 2/CD mediated/VBD the/DT increase/NN in/IN p53/NN levels/NNS via/IN activation/NN of/IN the/DT NF-kappaB/NN transcription/NN factor/NN ./. 
UI/LS -/: 96278851/CD 
TI/LS -/: Cooperation/NN between/IN core/NN binding/NN factor/NN and/CC adjacent/JJ promoter/NN elements/NNS contributes/VBZ to/TO the/DT tissue-specific/JJ expression/NN of/IN interleukin-3/NN ./. 
AB/LS -/: Tissue-specific/JJ expression/NN of/IN interleukin-3/NN (/( IL-3/NN )/) is/VBZ mediated/VBN via/IN cis-acting/JJ elements/NNS located/JJ within/IN 315/CD base/NN pairs/NNS of/IN the/DT transcription/NN start/NN ./. 
This/DT is/VBZ achieved/VBN in/IN part/NN through/IN the/DT positive/JJ activities/NNS of/IN the/DT AP-1/NN and/CC Elf-1/NN sites/NNS in/IN the/DT IL-3/NN promoter/NN ./. 
The/DT contribution/NN to/TO T/NN cell-specific/JJ expression/NN by/IN other/JJ promoter/NN sites/NNS was/VBD assessed/VBN in/IN a/DT transient/JJ expression/NN assay/NN with/IN IL-3/NN promoter/NN constructs/NNS linked/VBN to/TO a/DT luciferase/NN gene/NN ,/, focusing/VBG initially/RB on/IN the/DT core/NN binding/NN factor/NN (/( CBF/NN )/) site/NN ,/, which/WDT is/VBZ footprinted/JJ in/FW vivo/FW upon/IN T/NN cell/NN activation/NN ./. 
Activity/NN of/IN the/DT CBF/NN site/NN is/VBZ shown/VBN to/TO be/VB critically/RB dependent/JJ on/IN the/DT adjacent/JJ activator/NN site/NN Act-1/CD ./. 
Together/RB the/DT Act-1/NN and/CC CBF/NN sites/NNS form/VBP a/DT functional/JJ unit/NN (/( AC/NN unit/NN )/) with/IN dual/JJ activity/NN ./. 
The/DT AC/NN unit/NN is/VBZ demonstrated/VBN to/TO enhance/VB basal/JJ activity/NN of/IN promoters/NNS both/CC in/IN fibroblasts/NNS and/CC T/NN cells/NNS ./. 
This/DT activity/NN is/VBZ further/RB inducible/JJ in/IN activated/VBN T/NN cells/NNS ,/, but/CC not/RB in/IN fibroblasts/NNS ./. 
In/IN addition/NN to/TO the/DT already/RB identified/VBN NIP/NN repressor/NN site/NN ,/, evidence/NN is/VBZ presented/VBN for/IN a/DT second/JJ repressor/NN region/NN that/WDT restricts/VBZ promoter/NN activity/NN in/IN fibroblasts/NNS ./. 
Finally/RB ,/, a/DT novel/JJ positive/JJ regulatory/JJ element/NN has/VBZ been/VBN mapped/VBN in/IN the/DT IL-3/NN promoter/NN between/IN nucleotide/NN -180/CD and/CC -210/CD that/WDT leads/VBZ to/TO increased/VBN expression/NN in/IN T/NN cells/NNS ./. 
Together/RB these/DT results/NNS demonstrate/VBP that/IN T/NN cell/NN expression/NN of/IN IL-3/NN is/VBZ not/RB specified/VBN by/IN the/DT activity/NN of/IN a/DT single/JJ tissue-specific/JJ element/NN ,/, but/CC instead/RB involves/VBZ multiple/JJ interacting/VBG elements/NNS that/WDT provide/VBP both/CC specific/JJ positive/JJ regulation/NN in/IN T/NN cells/NNS and/CC specific/JJ negative/JJ regulation/NN in/IN fibroblasts/NNS ./. 
UI/LS -/: 96247631/CD 
TI/LS -/: Modulation/NN of/IN the/DT expression/NN of/IN the/DT IFN-gamma/NN receptor/NN beta-chain/NN controls/VBZ responsiveness/NN to/TO IFN-gamma/NN in/IN human/JJ peripheral/JJ blood/NN T/NN cells/NNS ./. 
AB/LS -/: IFN-gamma/NN has/VBZ potent/JJ antiproliferative/JJ and/CC apoptotic/JJ effects/NNS in/IN T/NN cells/NNS that/WDT are/VBP important/JJ in/IN determining/VBG T/NN cell/NN development/NN and/CC polarized/VBN differentiation/NN ./. 
Therefore/RB ,/, any/DT event/NN that/WDT enables/VBZ T/NN cells/NNS to/TO become/VB less/RBR responsive/JJ to/TO IFN- gamma/NN may/MD potentially/RB alter/VB immune/JJ responsiveness/NN to/TO Ag/NN ./. 
In/IN this/DT work/NN ,/, we/PRP show/VBP that/IN human/JJ peripheral/JJ blood/NN T/NN cells/NNS that/WDT are/VBP stimulated/VBN through/IN the/DT TCR/NN and/CC expanded/VBN with/IN IL-2/NN are/VBP unresponsive/JJ to/TO IFN-gamma/NN ,/, as/IN determined/VBN by/IN a/DT lack/NN of/IN activation/NN of/IN jak/NN kinases/NNS and/CC the/DT transcription/NN factor/NN ,/, STAT1/NN (/( alpha/NN )/) ,/, a/DT signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN ./. 
This/DT nonresponsiveness/NN occurs/VBZ because/IN of/IN a/DT lack/NN of/IN expression/NN of/IN the/DT beta- chain/NN (/( accessory/JJ factor/NN )/) of/IN the/DT IFN-gamma/NN receptor/NN ,/, while/IN at/IN the/DT same/JJ time/NN maintaining/VBG IFN-gamma/NN receptor/NN alpha-chain/NN expression/NN ./. 
Expression/NN of/IN the/DT beta-chain/NN can/MD be/VB restored/VBN by/IN secondary/JJ TCR/NN ligation/NN or/CC PMA/NN treatment/NN ./. 
T/NN cell/NN blasts/NNS treated/VBN with/IN PMA/NNS are/VBP now/RB responsive/JJ to/TO IFN-gamma/NN ./. 
When/WRB freshly/RB isolated/VBN ,/, highly/RB enriched/VBN|JJ (/( >/JJR 98/CD %/NN )/) T/NN cells/NNS are/VBP examined/VBN for/IN IFN-gamma/NN responsiveness/NN ;/: these/DT cells/NNS can/MD respond/VB to/TO IFN-gamma/NN and/CC express/VB beta-chain/NN ./. 
Therefore/RB ,/, as/IN T/NN cells/NNS progress/VBP from/IN primary/JJ TCR/NN activation/NN through/IN IL-2-dependent/JJ proliferation/NN ,/, followed/VBN by/IN secondary/JJ TCR/NN stimulation/NN ,/, their/PRP$ responsiveness/NN to/TO IFN-gamma/NN varies/VBZ ,/, and/CC this/DT may/MD affect/VB their/PRP$ ability/NN to/TO participate/VB in/IN an/DT ongoing/JJ immune/JJ response/NN ./. 
UI/LS -/: 96211859/CD 
TI/LS -/: Age-related/JJ decreases/NNS in/IN IL-2/NN production/NN by/IN human/JJ T/NN cells/NNS are/VBP associated/VBN with/IN impaired/JJ activation/NN of/IN nuclear/JJ transcriptional/JJ factors/NNS AP-1/NN and/CC NF-AT/NN ./. 
AB/LS -/: Although/IN transcriptional/JJ factors/NNS AP-1/NN and/CC nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) are/VBP important/JJ for/IN the/DT normal/JJ induction/NN of/IN IL-2/NN ,/, it/PRP is/VBZ unknown/JJ if/IN the/DT age-related/JJ decline/NN in/IN IL-2/NN production/NN by/IN activated/VBN human/JJ T/NN cells/NNS may/MD be/VB associated/VBN with/IN aberrancies/NNS in/IN transcriptional/JJ regulatory/JJ proteins/NNS ./. 
In/IN the/DT current/JJ studies/NNS ,/, IL-2/NN production/NN by/IN T/NN cells/NNS from/IN elderly/JJ (/( mean/NN 78/CD years/NNS )/) and/CC young/JJ (/( mean/NN 37/CD years/NNS )/) humans/NNS was/VBD measured/VBN in/IN cultures/NNS stimulated/VBN with/IN PHA/NN ,/, PHA/NN plus/CC PMA/NN ,/, crosslinked/VBN anti-CD3/JJ mAB/NN OKT3/NN plus/CC PMA/NN ,/, or/CC PMA/NN plus/CC ionomycin/NN ./. 
Substantial/JJ decreases/NNS of/IN IL-2/NN production/NN were/VBD observed/VBN for/IN cell/NN cultures/NNS from/IN 7/CD of/IN 12/CD elderly/JJ individuals/NNS in/IN response/NN to/TO the/DT different/JJ stimuli/NNS ,/, whereas/IN the/DT levels/NNS of/IN IL-2/NN produced/VBN by/IN stimulated/VBN T/NN cells/NNS from/IN other/JJ elderly/JJ individuals/NNS were/VBD equivalent/JJ to/TO those/DT observed/VBN for/IN stimulated/VBN T/NN cells/NNS of/IN young/JJ subjects/NNS ./. 
Analyses/NNS of/IN nuclear/JJ extracts/NNS by/IN electrophoretic/JJ DNA/NN mobility/NN shift/NN assays/NNS showed/VBD that/IN decreased/VBN IL-2/NN production/NN by/IN stimulated/VBN T/NN cells/NNS of/IN elderly/JJ individuals/NNS was/VBD closely/RB associated/VBN with/IN impairments/NNS in/IN the/DT activation/NN of/IN both/CC AP-1/NN and/CC NF-AT/NN ./. 
By/IN contrast/NN ,/, T/NN cells/NNS from/IN elderly/JJ subjects/NNS with/IN normal/JJ levels/NNS of/IN IL-2/NN production/NN exhibited/VBD normal/JJ activation/NN of/IN AP-1/NN and/CC NF-AT/NN ./. 
In/IN addition/NN ,/, the/DT results/NNS of/IN competition/NN experiments/NNS analyzing/VBG the/DT normal/JJ components/NNS of/IN NF-AT/NN showed/VBD that/IN the/DT age-related/JJ reductions/NNS in/IN stimulus-dependent/JJ NF-AT/NN complexes/NNS corresponded/VBD to/TO the/DT slow/JJ migrating/VBG complexes/NNS that/WDT were/VBD composed/VBN of/IN c-Fos/c-Jun/NN AP-1/NN ./. 
The/DT resting/JJ and/CC stimulated/JJ levels/NNS of/IN NF/NN kappa/NN B/NN were/VBD reduced/VBN in/IN T/NN cells/NNS from/IN certain/JJ elderly/JJ individuals/NNS ;/: however/RB ,/, alterations/NNS of/IN NF/NN kappa/NN B/NN did/VBD not/RB correlate/VB with/IN changes/NNS in/IN IL-2/NN expression/NN ./. 
Thus/RB ,/, these/DT results/NNS show/VBP that/IN age-related/JJ impairments/NNS in/IN the/DT activation/NN of/IN AP-1/NN and/CC NF-AT/NN are/VBP closely/RB associated/VBN with/IN decreased/VBN expression/NN of/IN IL-2/NN and/CC further/RB suggest/VBP that/IN aberrancies/NNS in/IN the/DT signaling/NN pathways/NNS important/JJ for/IN the/DT induction/NN of/IN transcriptionally/RB active/JJ c-Fos/c-Jun/NN AP-1/NN may/MD contribute/VB to/TO the/DT impaired/JJ activation/NN of/IN NF-AT/NN ./. 
UI/LS -/: 96183254/CD 
TI/LS -/: IL-13/NN induces/VBZ phosphorylation/NN and/CC activation/NN of/IN JAK2/NN Janus/NN kinase/NN in/IN human/JJ colon/NN carcinoma/NN cell/NN lines/NNS :/: similarities/NNS between/IN IL-4/NN and/CC IL-13/NN signaling/NN ./. 
AB/LS -/: We/PRP have/VBP recently/RB reported/VBN that/IN IL-13R/NN may/MD share/VB a/DT component/NN with/IN IL-4R/NN ./. Here/RB we/PRP report/VBP that/IN both/CC IL-4/NN and/CC IL-13/NN share/VBP signaling/NN events/NNS in/IN human/JJ colon/NN carcinoma/NN cell/NN lines/NNS (/( HT-29/NN and/CC WiDr/NN )/) ./. 
IL-13/NN caused/VBD rapid/JJ phosphorylation/NN of/IN the/DT three/CD out/IN of/IN four/CD members/NNS of/IN the/DT known/JJ Janus/NN family/NN of/IN kinases/NNS (/( JAKs/NNS )/) ./. 
We/PRP show/VBP that/IN JAK2/NN kinase/NN is/VBZ rapidly/RB phosphorylated/VBN and/CC activated/VBN in/IN response/NN to/TO IL-13/NN ./. 
Within/IN 1/CD min/NN of/IN activation/NN ,/, JAK2/NN was/VBD phosphorylated/VBN ,/, and/CC peaked/VBD in/IN 10/CD min/NN ./. 
In/IN addition/NN ,/, IL-13/NN phosphorylated/VBD insulin/NN response/NN substrate-1/NN ,/, IL-4R/NN p140/NN ,/, JAK1/NN ,/, and/CC Tyk2/NN ,/, but/CC not/RB JAK3/NN kinase/NN ./. 
IL-4/NN also/RB stimulated/VBD all/DT three/CD kinases/NNS and/CC substrates/NNS ,/, but/CC unlike/IN in/IN immune/JJ cells/NNS ,/, IL-4/NN did/VBD not/RB involve/VB JAK3/NN activation/NN for/IN its/PRP$ signaling/NN in/IN colon/NN cancer/NN cell/NN lines/NNS ./. 
Furthermore/RB ,/, JAK2/NN associated/VBN with/IN the/DT IL-4R/NN p140/NN before/IN and/CC after/IN stimulation/NN with/IN IL-13/NN ./. 
Both/CC IL-13/NN and/CC IL-4/NN induced/VBD phosphorylation/NN of/IN IL-4/NN STAT/NN (/( STAT6/NN )/) but/CC not/RB STAT1/NN ,/, STAT3/NN ,/, or/CC STAT5/NN ./. 
125I-IL-13/NN did/VBD not/RB bind/VB to/TO colon/NN cancer/NN cell/NN lines/NNS ,/, but/CC unlabeled/JJ IL-13/NN competed/VBD for/IN the/DT binding/NN of/IN 125I-IL-4/NN ./. 
Our/PRP$ data/NNS suggest/VBP that/IN IL-13/NN utilizes/VBZ IL-4R/NN and/CC its/PRP$ signaling/NN pathway/NN ,/, and/CC JAK2/NN may/MD play/VB an/DT important/JJ role/NN in/IN the/DT function/NN of/IN IL-4R/NN and/CC IL-13R/NN in/IN colon/NN cancer/NN cells/NNS ./. 
UI/LS -/: 96180219/CD 
TI/LS -/: Differential/JJ regulation/NN of/IN IL-6/NN gene/NN transcription/NN and/CC expression/NN by/IN IL-4/NN and/CC IL-10/NN in/IN human/JJ monocytic/JJ cell/NN lines/NNS ./. 
AB/LS -/: IL-4/NN and/CC IL-10/NN inhibit/VBP the/DT cytokine/NN production/NN and/CC mRNA/NN expression/NN by/IN monocytes/macrophages/NNS ./. 
To/TO investigate/VB the/DT molecular/JJ mechanism/NN of/IN the/DT inhibitory/JJ effect/NN on/IN transcriptional/JJ or/CC post-transcriptional/JJ regulation/NN of/IN IL-6/NN gene/NN expression/NN by/IN IL-4/NN and/CC IL-10/NN ,/, we/PRP studied/VBD IL-6/NN production/NN ,/, expression/NN level/NN of/IN IL-6/NN mRNA/NN ,/, IL-6/NN promoter/NN activity/NN ,/, transcriptional/JJ activity/NN of/IN NF-kappaB/NN and/CC NF-IL-6/NN ,/, and/CC IL-6/NN mRNA/NN stability/NN in/IN human/JJ monocytic/JJ cell/NN lines/NNS ,/, THP-1/NN and/CC U937/NN ,/, stimulated/VBN by/IN PMA/NN and/CC LPS/NN in/IN the/DT absence/NN or/CC the/DT presence/NN of/IN IL-4/NN or/CC IL-10/NN ./. 
Both/CC IL-4/NN and/CC IL-10/NN were/VBD seen/VBN to/TO inhibit/VB IL-6/NN production/NN and/CC the/DT expression/NN of/IN IL-6/NN mRNA/NN in/IN both/DT monocytic/JJ cell/NN lines/NNS studied/VBN ./. 
In/IN chloramphenicol/NN acetyltransferase/NN assays/NNS ,/, utilizing/VBG the/DT transient/JJ transfection/NN of/IN a/DT chloramphenicol/NN acetyltransferase/NN reporter/NN plasmid/NN containing/VBG the/DT IL-6/NN gene/NN promoter/NN ,/, IL-4/NN ,/, but/CC not/RB IL-10/NN ,/, suppressed/VBD the/DT transcriptional/JJ activity/NN of/IN the/DT IL-6/NN gene/NN promoter/NN stimulated/VBN by/IN PMA/NN and/CC LPS/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS showed/VBD that/IN IL-4/NN ,/, but/CC not/RB IL-10/NN ,/, inhibited/VBD nuclear/JJ NF-kappaB/NN activity/NN ,/, and/CC that/IN IL-4/NN and/CC IL-10/NN did/VBD not/RB affect/VB NF-IL-6/NN activity/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, IL-10/NN enhanced/VBD the/DT degradation/NN of/IN IL-6/NN mRNA/NN in/IN a/DT mRNA/NN stability/NN assay/NN ./. 
These/DT results/NNS suggest/VBP that/IN IL-4/NN may/MD inhibit/VB the/DT transcription/NN of/IN the/DT IL-6/NN gene/NN by/IN affecting/VBG NF-kappaB/NN binding/NN activity/NN ,/, while/IN IL-10/NN may/MD inhibit/VB the/DT IL-6/NN mRNA/NN levels/NNS post-transcriptionally/RB ,/, without/IN suppressing/VBG promoter/NN activity/NN ./. 
Therefore/RB ,/, we/PRP conclude/VBP that/IN IL-4/NN and/CC IL-10/NN inhibit/VBP IL-6/NN production/NN by/IN different/JJ mechanisms/NNS in/IN human/JJ monocytic/JJ cell/NN lines/NNS ./. 
UI/LS -/: 96205960/CD 
TI/LS -/: Activation/NN of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS in/IN a/DT cyclosporin/NN A-resistant/JJ pathway/NN ./. 
AB/LS -/: The/DT mechanism/NN of/IN action/NN of/IN the/DT immunosuppressive/JJ drug/NN cyclosporin/NN A/NN (/( CsA/NN )/) is/VBZ the/DT inactivation/NN of/IN the/DT Ca2+/calmodulin-dependent/JJ serine-threonine/NN phosphatase/NN calcineurin/NN by/IN the/DT drug-immunophilin/JJ complex/NN ./. 
Inactive/JJ calcineurin/NN is/VBZ unable/JJ to/TO activate/VB the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) ,/, a/DT transcription/NN factor/NN required/VBN for/IN expression/NN of/IN the/DT interleukin/NN 2/CD (/( IL-2/NN )/) gene/NN ./. 
IL-2/NN production/NN by/IN CsA-treated/JJ cells/NNS is/VBZ therefore/RB dramatically/RB reduced/VBN ./. 
We/PRP demonstrate/VBP here/RB ,/, however/RB ,/, that/IN NFAT/NN can/MD be/VB activated/VBN ,/, and/CC significant/JJ levels/NNS of/IN IL-2/NN can/MD be/VB produced/VBN by/IN the/DT CsA-resistant/JJ CD28-signaling/JJ pathway/NN ./. 
In/IN transient/JJ transfection/NN assays/NNS ,/, both/CC multicopy/JJ NFAT-/NN and/CC IL-2/NN promoter-beta-galactosidase/NN reporter/NN gene/NN constructs/NNS could/MD be/VB activated/VBN by/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) /alpha-CD28/NN stimulation/NN ,/, and/CC this/DT activation/NN was/VBD resistant/JJ to/TO CsA/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assay/NN showed/VBD the/DT induction/NN of/IN a/DT CsA-resistant/JJ NFAT/NN complex/NN in/IN the/DT nuclear/JJ extracts/NNS of/IN peripheral/JJ blood/NN T/NN cells/NNS stimulated/VBN with/IN PMA/NN plus/CC alphaCD28/NN ./. 
Peripheral/JJ blood/NN T/NN cells/NNS stimulated/VBN with/IN PMA/alphaCD28/NN produced/VBD IL-2/NN in/IN the/DT presence/NN of/IN CsA/NN ./. 
Collectively/RB ,/, these/DT data/NNS suggest/VBP that/IN NFAT/NN can/MD be/VB activated/VBN and/CC IL-2/NN can/MD be/VB produced/VBN in/IN a/DT calcineurin/NN independent/JJ manner/NN ./. 
UI/LS -/: 96186497/CD 
TI/LS -/: Effects/NNS of/IN interleukin-10/NN on/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cell/NN responses/NNS to/TO Cryptococcus/NN neoformans/NNS ,/, Candida/NN albicans/NNS ,/, and/CC lipopolysaccharide/NN ./. 
AB/LS -/: Deactivation/NN of/IN mononuclear/JJ phagocytes/NNS is/VBZ critical/JJ to/TO limit/VB the/DT inflammatory/JJ response/NN but/CC can/MD be/VB detrimental/JJ in/IN the/DT face/NN of/IN progressive/JJ infection/NN ./. 
We/PRP compared/VBD the/DT effects/NNS of/IN the/DT deactivating/VBG cytokine/NN interleukin/NN 10/CD (/( IL-10/NN )/) on/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cell/NN (/( PBMC/NN )/) responses/NNS to/TO lipopolysaccharide/NN (/( LPS/NN )/) ,/, Cryptococcus/NN neoformans/NNS ,/, and/CC Candida/NN albicans/NNS ./. 
IL-10/NN effected/VBD dose-dependent/JJ inhibition/NN of/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) release/NN in/IN PBMC/NN stimulated/VBN by/IN LPS/NN and/CC C./FW neoformans/FW ,/, with/IN significant/JJ inhibition/NN seen/VBN with/IN 0.1/CD U/ml/NN and/CC greater/JJR than/IN 90/CD %/NN inhibition/NN noted/VBN with/IN 10/CD U/ml/NN ./. 
In/IN contrast/NN ,/, even/RB at/IN doses/NNS as/RB high/JJ as/IN 100/CD U/ml/NN ,/, IL-10/NN inhibited/VBD TNF-alpha/NN release/NN in/IN response/NN to/TO C./FW albicans/FW by/IN only/RB 50/CD %/NN ./. 
IL-10/NN profoundly/RB inhibited/VBD release/NN of/IN IL-1beta/NN from/IN PBMC/NN stimulated/VBN by/IN all/DT three/CD stimuli/NNS ./. 
TNF-alpha/NN mRNA/NN and/CC release/NN was/VBD inhibited/VBN even/RB if/IN IL-10/NN was/VBD added/VBN up/RP to/TO 8/CD h/NN after/IN cryptococcal/JJ stimulation/NN ./. 
In/IN contrast/NN ,/, inhibition/NN of/IN IL-1/NN beta/NN mRNA/NN was/VBD of/IN lesser/JJR magnitude/NN and/CC occurred/VBD only/RB when/WRB IL-10/NN was/VBD added/VBN within/IN 2/CD h/NN of/IN cryptococcal/JJ stimulation/NN ./. 
IL-10/NN inhibited/VBD translocation/NN of/IN NF-kappaB/NN in/IN response/NN to/TO LPS/NN but/CC not/RB the/DT fungal/JJ stimuli/NNS ./. 
All/DT three/CD stimuli/NNS induced/VBD IL-10/NN production/NN in/IN PBMC/NN ,/, although/IN over/IN 10-fold/RB less/JJR IL-10/NN was/VBD released/VBN in/IN response/NN to/TO C./FW neoformans/FW compared/VBN with/IN LPS/NN and/CC C./NN albicans/NNS ./. 
Thus/RB ,/, while/IN IL-10/NN has/VBZ deactivating/VBG effects/NNS on/IN PBMC/NN responses/NNS to/TO all/DT three/CD stimuli/NNS ,/, disparate/JJ stimulus-/NN and/CC response-specific/JJ patterns/NNS of/IN deactivation/NN are/VBP seen/VBN ./. 
Inhibition/NN by/IN IL-10/NN of/IN proinflammatory/JJ cytokine/NN release/NN appears/VBZ to/TO occur/VB at/IN the/DT level/NN of/IN gene/NN transcription/NN for/IN TNF-alpha/NN and/CC both/CC transcriptionally/RB and/CC posttranscriptionally/RB for/IN IL-1beta/NN ./. 
UI/LS -/: 96173754/CD 
TI/LS -/: Characterization/NN and/CC purification/NN of/IN a/DT protein/NN kinase/NN C/NN substrate/NN in/IN human/JJ B/NN cells/NNS ./. 
Identification/NN as/IN lymphocyte-specific/JJ protein/NN 1/CD (/( LSP1/NN )/) ./. 
AB/LS -/: Incubation/NN of/IN B-chronic/JJ lymphocytic/JJ leukemia/NN (/( B-CLL/NN )/) cells/NNS with/IN phorbol/NN esters/NNS resulted/VBD in/IN the/DT phosphorylation/NN of/IN two/CD major/JJ PKC/NN substrates/NNS ,/, MARCKS/NN (/( myristoylated/VBN ,/, alanine-rich/JJ C/NN kinase/NN substrate/NN )/) and/CC MRP/NN (/( MARCKS-related/JJ protein/NN )/) ,/, and/CC of/IN a/DT third/JJ protein/NN ,/, with/IN an/DT apparent/JJ m.w./NN of/IN 60,000/CD that/WDT was/VBD the/DT most/RBS prominent/JJ protein/NN kinase/NN C/NN substrate/NN in/IN these/DT cells/NNS ./. 
p60/NN phosphorylation/NN was/VBD time/NN and/CC PMA/NN dose/NN dependent/JJ ,/, and/CC was/VBD induced/VBN by/IN cell-permeable/JJ diacylglycerol/NN ,/, but/CC not/RB by/IN inactive/JJ phorbol/NN esters/NNS ./. 
Two-dimensional/JJ electrophoretic/JJ analysis/NN of/IN the/DT protein/NN phosphorylation/NN pattern/NN from/IN the/DT B/NN cell/NN line/NN CESS/NN demonstrated/VBD the/DT identity/NN between/IN the/DT p60/NN protein/NN expressed/VBN in/IN this/DT cell/NN line/NN and/CC that/DT expressed/VBN in/IN B-CLL/NN cells/NNS ./. 
p60/NN was/VBD purified/VBN from/IN CESS/NN cells/NNS and/CC peptide/NN microsequencing/NN of/IN this/DT protein/NN revealed/VBD that/IN it/PRP was/VBD lymphocyte-specific/JJ protein/NN 1/CD (/( LSP1/NN )/) ,/, that/WDT is/VBZ here/RB characterized/VBN as/IN the/DT most/RBS prominent/JJ protein/NN kinase/NN C/NN substrate/JJ in/IN B/NN cells/NNS ./. 
UI/LS -/: 96230713/CD 
TI/LS -/: Transcription/NN factors/NNS of/IN T/NN and/CC B/NN lymphocytes/NNS --/: basic/JJ research/NN and/CC clinical/JJ perspectives/NNS for/IN gastroenterology/NN ./. 
AB/LS -/: Tissue/NN specific/JJ regulation/NN of/IN gene/NN expression/NN by/IN transcription/NN factors/NNS is/VBZ a/DT fascinating/JJ new/JJ field/NN in/IN molecular/JJ immunology/NN ./. 
This/DT review/NN summarizes/VBZ data/NNS on/IN specific/JJ regulation/NN of/IN promoters/NNS and/CC enhancers/NNS by/IN nuclear/JJ trans-acting/JJ factors/NNS in/IN lymphocytes/NNS ./. 
The/DT structural/JJ classes/NNS of/IN transcription/NN factors/NNS are/VBP described/VBN and/CC basic/JJ methods/NNS for/IN detection/NN and/CC analysis/NN of/IN transcription/NN factors/NNS are/VBP detailed/VBN ./. 
Furthermore/RB ,/, the/DT most/RBS important/JJ trans-acting/JJ factors/NNS of/IN T/NN and/CC B/NN lymphocytes/NNS (/( e.g./FW NF-kB/NN ,/, NF-AT/NN and/CC STAT/NN families/NNS )/) and/CC their/PRP$ functional/JJ importance/NN are/VBP described/VBN ./. 
Several/JJ methods/NNS for/IN specific/JJ down-regulation/NN of/IN transcription/NN factors/NNS are/VBP shown/VBN that/IN may/MD be/VB relevant/JJ to/TO treatment/NN of/IN human/JJ disease/NN ./. 
The/DT data/NNS are/VBP discussed/VBN with/IN regard/NN to/TO their/PRP$ potential/JJ clinical/JJ relevance/NN for/IN gastroenterology/NN ./. 
UI/LS -/: 96147310/CD 
TI/LS -/: Selective/JJ effects/NNS of/IN DNA/NN damaging/NN agents/NNS on/IN HIV/NN long/JJ terminal/JJ repeat/NN activation/NN and/CC virus/NN replication/NN in/FW vitro/FW ./. 
AB/LS -/: Much/JJ attention/NN has/VBZ recently/RB focused/VBN on/IN the/DT observation/NN that/IN UV/NN light/NN can/MD activate/VB the/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) of/IN the/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) ./. 
Although/IN the/DT mechanism/NN of/IN LTR/NN activation/NN remains/VBZ obscure/JJ ,/, several/JJ lines/NNS of/IN investigation/NN have/VBP suggested/VBN that/IN it/PRP is/VBZ a/DT result/NN of/IN activation/NN of/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN (/( s/NNS )/) following/VBG signaling/NN events/NNS related/JJ to/TO generalized/VBN DNA/NN damage/NN ./. 
In/IN this/DT report/NN ,/, we/PRP present/VBP data/NNS demonstrating/NN that/IN HIV/NN LTR/NN activation/NN is/VBZ not/RB a/DT general/JJ consequence/NN of/IN cellular/JJ DNA/NN damage/NN ,/, but/CC rather/RB a/DT process/NN unique/JJ to/TO specific/JJ genotoxic/JJ stimuli/NNS ,/, and/CC that/IN it/PRP does/VBZ not/RB necessarily/RB depend/VB on/IN activation/NN of/IN NF-kappa/NN B/NN ./. 
Furthermore/RB ,/, we/PRP demonstrate/VBP that/IN several/JJ of/IN these/DT agents/NNS can/MD significantly/RB increase/VB HIV/NN replication/NN and/CC accelerate/VB CD4-positive/JJ lymphocyte/NN cytotoxicity/NN in/FW vitro/FW ./. 
These/DT findings/NNS ,/, therefore/RB ,/, could/MD have/VB clinical/JJ significance/NN to/TO AIDS/NN patients/NNS with/IN malignancies/NNS who/WP are/VBP undergoing/VBG radiotherapy/NN and/CC chemotherapy/NN ./. 
UI/LS -/: 96278844/CD 
TI/LS -/: Receptors/NNS for/IN interleukin/NN (/( IL/NN )/) -10/CD and/CC IL-6-type/JJ cytokines/NNS use/VBP similar/JJ signaling/NN mechanisms/NNS for/IN inducing/NN transcription/NN through/IN IL-6/NN response/NN elements/NNS ./. 
AB/LS -/: The/DT cytoplasmic/JJ domain/NN of/IN the/DT receptor/NN for/IN interleukin/NN 10/CD (/( IL-10R/NN )/) contains/VBZ two/CD box/NN 3/CD sequence/NN motifs/NNS that/WDT have/VBP been/VBN identified/VBN in/IN the/DT signal-transducing/JJ receptor/NN subunits/NNS for/IN IL-6-type/JJ cytokines/NNS and/CC noted/VBN to/TO be/VB required/VBN for/IN activating/VBG STAT3/NN and/CC inducing/VBG transcription/NN through/IN IL-6-responsive/JJ elements/NNS ./. 
To/TO determine/VB whether/IN the/DT IL-10R/NN has/VBZ signaling/NN functions/NNS similar/JJ to/TO IL-6R/NN in/IN cells/NNS normally/RB expressing/VBG these/DT receptors/NNS ,/, leukocytes/NNS of/IN the/DT B-/NN ,/, T-/NN ,/, and/CC NK-cell/NN lineages/NNS were/VBD treated/VBN with/IN either/DT cytokine/NN ./. 
Both/DT cytokines/NNS activated/VBD factors/NNS that/WDT bound/VBD to/TO the/DT sis-inducible/JJ element/NN and/CC included/VBD STAT1/NN and/CC STAT3/NN ./. 
The/DT cell/NN response/NN to/TO IL-10/NN characteristically/RB differed/VBN from/IN that/DT to/TO IL-2/IL-15/NN ,/, IL-4/NN ,/, and/CC interferon/NN gamma/NN ./. 
The/DT signaling/NN capabilities/NNS of/IN the/DT IL-10R/NN for/IN activating/VBG specific/JJ STAT/NN proteins/NNS and/CC inducing/VBG gene/NN transcription/NN were/VBD defined/VBN by/IN reconstitution/NN of/IN receptor/NN functions/NNS in/IN transfected/VBN tissue/NN culture/NN cells/NNS ./. 
COS-1/NN cells/NNS ,/, co-expressing/VBG the/DT human/JJ IL-10R/NN and/CC individual/JJ STAT/NN proteins/NNS ,/, confirmed/VBD a/DT preference/NN of/IN the/DT IL-10R/NN for/IN STAT3/NN and/CC STAT1/NN ./. 
Unlike/IN many/JJ hematopoietin/NN receptors/NNS ,/, the/DT IL-10R/NN did/VBD not/RB detectably/RB activate/VB STAT5/NN ./. 
The/DT IL-10R/NN ,/, together/RB with/IN reporter/NN gene/NN constructs/NNS containing/VBG different/JJ IL-6-responsive/JJ gene/NN elements/NNS ,/, reconstituted/VBD in/IN hepatoma/NN cells/NNS an/DT induction/NN of/IN transcription/NN by/IN IL-10/NN that/WDT was/VBD comparable/JJ to/TO that/DT by/IN IL-6/NN ./. 
This/DT regulation/NN could/MD not/RB be/VB appreciably/RB modified/VBN by/IN enhanced/VBN expression/NN of/IN STAT/NN proteins/NNS ./. 
The/DT similar/JJ actions/NNS of/IN IL-10R/NN and/CC IL-6R/NN on/IN the/DT induction/NN of/IN endogenous/JJ IL-6-responsive/JJ genes/NNS were/VBD demonstrated/VBN in/IN hepatoma/NN cells/NNS stably/RB expressing/VBG the/DT IL-10R/NN ./. 
These/DT receptor/NN functions/NNS required/VBD the/DT presence/NN of/IN the/DT box/NN 3/CD motifs/NNS ,/, as/IN shown/VBN by/IN the/DT analysis/NN of/IN the/DT mouse/NN IL-10R/NN constructs/NNS containing/VBG progressively/RB truncated/VBN cytoplasmic/JJ domains/NNS ./. 
The/DT data/NNS demonstrate/VBP that/IN the/DT IL-10R/NN ,/, unlike/IN other/JJ members/NNS of/IN the/DT interferon/NN receptor/NN family/NN ,/, is/VBZ highly/RB effective/JJ in/IN recruiting/VBG the/DT signaling/NN pathways/NNS of/IN IL-6-type/JJ cytokine/NN receptors/NNS ./. 
UI/LS -/: 96247643/CD 
TI/LS -/: Induction/NN of/IN CIITA/NN and/CC modification/NN of/IN in/FW vivo/FW HLA-DR/NN promoter/NN occupancy/NN in/IN normal/JJ thymic/JJ epithelial/JJ cells/NNS treated/VBN with/IN IFN-gamma/NN :/: similarities/NNS and/CC distinctions/NNS with/IN respect/NN to/TO HLA-DR-constitutive/JJ B/NN cells/NNS ./. 
AB/LS -/: In/IN this/DT study/NN ,/, the/DT IFN-gamma/NN induction/NN of/IN MHC/NN class/NN II/CD gene/NN expression/NN in/IN primary/JJ cultures/NNS of/IN thymic/JJ epithelial/JJ cells/NNS (/( TEC/NN )/) was/VBD analyzed/VBN ./. 
This/DT cellular/JJ system/NN offers/VBZ the/DT advantage/NN that/IN MHC/NN class/NN II/CD induction/NN is/VBZ studied/VBN in/IN a/DT "/`` physiologic/JJ "/'' cell/NN lineage/NN that/WDT ,/, as/IN a/DT result/NN of/IN this/DT expression/NN within/IN the/DT thymus/NN ,/, is/VBZ thought/VBN to/TO participate/VB to/TO the/DT selection/NN and/CC maturation/NN of/IN the/DT T/NN cells/NNS ./. 
It/PRP was/VBD found/VBN that/IN the/DT MHC/NN class/NN II/CD gene/NN expression/NN was/VBD associated/VBN with/IN the/DT de/FW novo/FW transcription/NN of/IN the/DT gene/NN encoding/VBG the/DT CIITA/NN trans-activator/NN ,/, a/DT crucial/JJ MHC/NN class/NN II/CD gene/NN regulatory/JJ factor/NN ./. 
Furthermore/RB ,/, the/DT anatomy/NN of/IN interaction/NN between/IN the/DT MHC/NN class/NN II/CD DRA/NN promoter/NN and/CC corresponding/JJ binding/VBG factors/NNS was/VBD analyzed/VBN by/IN in/FW vivo/FW DNAse/NN I/NN footprint/NN ./. 
It/PRP was/VBD found/VBN that/IN treatment/NN with/IN IFN-gamma/NN induces/VBZ changes/NNS in/IN the/DT occupancy/NN of/IN the/DT DRA/NN gene/NN regulatory/JJ sequences/NNS by/IN nuclear/JJ factors/NNS ./. 
The/DT resulting/VBG occupancy/NN displays/VBZ strong/JJ similarities/NNS with/IN the/DT one/CD observed/VBN in/IN the/DT MHC/NN class/NN II-constitutive/JJ B/NN cells/NNS ,/, represented/VBN by/IN both/CC the/DT Burkitt/NN lymphoma/NN line/NN Raji/NN and/CC normal/JJ tonsil- derived/JJ B/NN cells/NNS ./. 
However/RB ,/, some/DT peculiar/JJ differences/NNS were/VBD observed/VBN between/IN the/DT TEC/NN ,/, either/CC IFN-gamma-induced/JJ or/CC not/RB ,/, and/CC the/DT constitutive/JJ B/NN cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN both/CC common/JJ mechanisms/NNS ,/, such/JJ as/IN the/DT one/CD mediated/VBN by/IN the/DT CIITA/NN trans-activator/NN ,/, and/CC distinct/JJ tissue-specific/JJ constraints/NNS contribute/VBP to/TO the/DT transcriptional/JJ control/NN of/IN constitutive/JJ and/CC IFN-gamma-induced/JJ MHC/NN class/NN II/CD gene/NN expression/NN ./. 
UI/LS -/: 96212948/CD 
TI/LS -/: Inhibitory/JJ effect/NN of/IN E3330/NN ,/, a/DT novel/JJ quinone/NN derivative/JJ able/JJ to/TO suppress/VB tumor/NN necrosis/NN factor-alpha/NN generation/NN ,/, on/IN activation/NN of/IN nuclear/JJ factor-kappa/NN B/NN ./. 
AB/LS -/: (2E)-3-[5-(2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl)]-2-nonyl-2- propenoic/JJ acid/NN (/( E3330/NN )/) ,/, is/VBZ a/DT novel/JJ agent/NN with/IN hepatoprotective/JJ activity/NN ./. 
We/PRP report/VBP the/DT effect/NN of/IN E3330/NN on/IN transcriptional/JJ activation/NN of/IN tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) -alpha/NN gene/NN and/CC on/IN nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN activation/NN ./. 
Nuclear/JJ run-on/JJ experiments/NNS showed/VBD that/IN E3330/NN decreases/VBZ transcriptional/JJ activation/NN of/IN TNF-alpha/NN gene/NN induced/VBN by/IN lipopolysaccharide/NN (/( LPS/NN )/) stimulation/NN in/IN human/JJ peripheral/JJ monocytes/NNS ./. 
To/TO investigate/VB the/DT inhibitory/JJ mechanisms/NNS ,/, we/PRP constructed/VBD a/DT secreted-type/JJ placental/JJ alkaline/NN phosphatase/NN (/( PLAP/NN )/) reporter/NN gene/NN whose/WP$ transcription/NN is/VBZ controlled/VBN by/IN a/DT 1.4-kb/JJ human/JJ TNF-alpha/NN promoter/NN ./. 
A/DT stable/JJ transformant/NN of/IN the/DT PLAP/NN reporter/NN gene/NN derived/VBN from/IN human/JJ monocytic/JJ cell/NN line/NN showed/VBD very/RB little/JJ activity/NN on/IN the/DT promoter/NN before/IN stimulation/NN ,/, whereas/IN LPS/NN stimulation/NN led/VBD to/TO a/DT dramatic/JJ increase/NN in/IN PLAP/NN activity/NN ./. 
E3330/NN inhibited/VBD this/DT induced/VBN promoter/NN activity/NN in/IN a/DT dose-dependent/JJ manner/NN ./. 
There/EX are/VBP four/CD putative/JJ NF-kappa/NN B/NN binding/NN sites/NNS (/( kappa/NN B-1/NN ,/, kappa/NN B-2/NN ,/, kappa/NN B-3/NN ,/, kappa/NN B-4/NN )/) in/IN human/JJ TNF-alpha/NN promoter/NN ./. 
By/IN using/VBG mutated/VBN promoter-PLAP/JJ|NN plasmids/NNS ,/, we/PRP established/VBD that/IN these/DT NF-kappa/NN B/NN sites/NNS were/VBD necessary/JJ for/IN induction/NN of/IN TNF-alpha/NN transcription/NN on/IN stimulation/NN with/IN LPS/NN ./. 
A/DT gel/NN retardation/NN experiment/NN with/IN synthetic/JJ double-stranded/JJ oligonucleotides/NNS showed/VBD that/IN activated/VBN NF-kappa/NN B/NN consisting/VBG of/IN p50/p65/NN heterodimer/NN bound/VBN to/TO all/DT four/CD putative/JJ NF-kappa/NN B/NN DNA/NN probes/NNS ,/, suggesting/VBG that/IN all/DT four/CD putative/JJ NF-kappa/NN B/NN recognition/NN sites/NNS play/VBP an/DT important/JJ role/NN in/IN inducible/JJ TNF-alpha/NN expression/NN ./. 
E3330/NN decreased/VBD activated/VBN NF-kappa/NN B/NN in/IN nuclei/NNS ,/, suggesting/VBG that/IN E3330/NN inhibits/VBZ NF-kappa/NN B/NN activation/NN and/or/CC translocation/NN of/IN the/DT nuclei/NNS ./. 
Western/NN blotting/NN analysis/NN with/IN anti-I/JJ kappa/NN B-alpha/NN antibody/NN indicated/VBD that/IN E3330/NN inhibited/VBD degradation/NN of/IN I/NN kappa/NN B-alpha/NN ,/, which/WDT is/VBZ an/DT inhibitory/JJ protein/NN of/IN NF-kappa/NN B/NN ,/, in/IN LPS-stimulated/JJ monocytes/NNS ./. 
E3330/NN may/MD suppress/VB the/DT production/NN of/IN active/JJ oxygen/NN species/NNS serving/VBG as/IN common/JJ messengers/NNS to/TO activate/VB NF-kappa/NN B/NN ./. 
UI/LS -/: 96203119/CD 
TI/LS -/: C-terminal/JJ activating/VBG and/CC inhibitory/JJ domains/NNS determine/VBP the/DT transactivation/NN potential/NN of/IN BSAP/NN (/( Pax-5/NN )/) ,/, Pax-2/NN and/CC Pax-8/NN ./. 
AB/LS -/: Pax-5/NN encodes/VBZ the/DT transcription/NN factor/NN BSAP/NN which/WDT plays/VBZ an/DT essential/JJ role/NN in/IN early/JJ B/NN cell/NN development/NN and/CC midbrain/JJ patterning/NN ./. 
In/IN this/DT study/NN we/PRP have/VBP analysed/VBN the/DT structural/JJ requirements/NNS for/IN transcriptional/JJ activation/NN by/IN BSAP/NN ./. 
In/FW vitro/FW mutagenesis/NN and/CC transient/JJ transfection/NN experiments/NNS indicate/VBP that/IN the/DT C-terminal/JJ serine/threonine/proline-rich/JJ region/NN of/IN BSAP/NN contains/VBZ a/DT potent/JJ transactivation/NN domain/NN of/IN 55/CD amino/NN acids/NNS which/WDT is/VBZ active/JJ from/IN promoter/NN and/CC enhancer/NN positions/NNS ./. 
This/DT transactivation/NN domain/NN was/VBD found/VBN to/TO be/VB inactivated/VBN by/IN a/DT naturally/RB occurring/VBG frameshift/NN mutation/NN in/IN one/CD PAX-5/NN allele/NN of/IN the/DT acute/JJ lymphoblastic/JJ leukemia/NN cell/NN line/NN REH/NN ./. 
The/DT function/NN of/IN the/DT transactivation/NN domain/NN is/VBZ negatively/RB regulated/VBN by/IN adjacent/JJ sequences/NNS from/IN the/DT extreme/JJ C-terminus/NN ./. 
The/DT activating/VBG and/CC inhibitory/JJ domains/NNS function/VBP together/RB as/IN an/DT independent/JJ regulatory/JJ module/NN in/IN different/JJ cell/NN types/NNS as/IN shown/VBN by/IN fusion/NN to/TO the/DT GAL4/NN DNA/NN binding/NN domain/NN ./. 
The/DT same/JJ arrangement/NN of/IN positively/RB and/CC negatively/RB acting/VBG sequences/NNS has/VBZ been/VBN conserved/VBN in/IN the/DT mammalian/JJ Pax-2/NN and/CC Pax-8/NN ,/, the/DT zebrafish/NN Pax-b/NN as/RB well/RB as/IN the/DT sea/NN urchin/NN Pax-258/NN proteins/NNS ./. 
These/DT data/NNS demonstrate/VBP that/IN the/DT transcriptional/JJ competence/NN of/IN a/DT subfamily/NN of/IN Pax/NN proteins/NNS is/VBZ determined/VBN by/IN a/DT C-terminal/JJ regulatory/JJ module/NN composed/VBN of/IN activating/VBG and/CC inhibitory/JJ sequences/NNS ./. 
UI/LS -/: 96198610/CD 
TI/LS -/: Second/JJ messenger/NN up-regulation/NN of/IN androgen/NN receptor/NN gene/NN transcription/NN is/VBZ absent/JJ in/IN androgen/NN insensitive/JJ human/JJ prostatic/JJ carcinoma/NN cell/NN lines/NNS ,/, PC-3/NN and/CC DU-145/NN ./. 
AB/LS -/: A/DT theoretical/JJ pathway/NN of/IN transcriptional/JJ regulation/NN of/IN the/DT androgen/NN receptor/NN (/( AR/NN )/) gene/NN is/VBZ via/IN a/DT cAMP/NN response/NN element/NN (/( CRE/NN )/) present/JJ in/IN its/PRP$ promoter/NN region/NN (/( -508/CD to/TO -501/CD )/) ./. 
After/IN 20/CD h/NN of/IN stimulation/NN with/IN 8-bromo-cAMP/NN ,/, AR/NN mRNA/NN was/VBD upregulated/VBN in/IN LNCaP/NN but/CC not/RB in/IN either/CC PC-3/NN or/CC DU-145/NN cell/NN lines/NNS ./. 
We/PRP have/VBP demonstrated/VBN that/IN the/DT level/NN of/IN CRE/NN binding/NN protein/NN (/( CREB/NN )/) was/VBD the/DT same/JJ in/IN all/DT cell/NN lines/NNS and/CC that/IN the/DT putative/JJ AR-CRE/NN forms/VBZ specific/JJ and/CC compatible/JJ protein/NN interactions/NNS with/IN CREB/NN ./. 
The/DT ability/NN to/TO regulate/VB AR/NN gene/NN transcription/NN via/IN the/DT second/JJ messenger/NN pathway/NN is/VBZ lost/VBN in/IN the/DT PC-3/NN and/CC DU-145/NN cell/NN lines/NNS ./. 
This/DT may/MD be/VB an/DT important/JJ primary/JJ mechanism/NN of/IN androgen/NN insensitivity/NN in/IN prostate/NN cancer/NN ./. 
UI/LS -/: 96205972/CD 
TI/LS -/: Structural/JJ and/CC functional/JJ characterization/NN of/IN the/DT human/JJ CD36/NN gene/NN promoter/NN :/: identification/NN of/IN a/DT proximal/JJ PEBP2/CBF/NN site/NN ./. 
AB/LS -/: CD36/NN is/VBZ a/DT cell/NN surface/NN glycoprotein/NN composed/VBN of/IN a/DT single/JJ polypeptide/NN chain/NN ,/, which/WDT interacts/VBZ with/IN thrombospondin/NN ,/, collagens/NNS type/NN I/CD and/CC IV/CD ,/, oxidized/VBN low/JJ density/NN lipoprotein/NN ,/, fatty/JJ acids/NNS ,/, anionic/JJ phospholipids/NNS ,/, and/CC erythrocytes/NNS parasitized/VBN with/IN Plasmodium/NN falciparum/NN ./. 
Its/PRP$ expression/NN is/VBZ restricted/JJ to/TO a/DT few/JJ cell/NN types/NNS ,/, including/VBG monocyte/macrophages/NNS ./. 
In/IN these/DT cells/NNS ,/, CD36/NN is/VBZ involved/VBN in/IN phagocytosis/NN of/IN apoptotic/JJ cells/NNS ,/, and/CC foam/NN cell/NN formation/NN by/IN uptake/NN of/IN oxidized/VBN low/JJ density/NN lipoprotein/NN ./. 
To/TO study/VB the/DT molecular/JJ mechanisms/NNS that/WDT control/VBP the/DT transcription/NN of/IN the/DT CD36/NN gene/NN in/IN monocytic/JJ cells/NNS we/PRP have/VBP isolated/VBN and/CC analyzed/VBN the/DT CD36/NN promoter/NN ./. 
Transient/JJ expression/NN experiments/NNS of/IN 5'-deletion/JJ fragments/NNS of/IN the/DT CD36/NN promoter/NN coupled/VBN to/TO luciferase/NN demonstrated/VBD that/IN as/RB few/JJ as/IN 158/CD base/NN pairs/NNS upstream/JJ from/IN the/DT transcription/NN initiation/NN site/NN were/VBD sufficient/JJ to/TO direct/VB the/DT monocyte-specific/JJ transcription/NN of/IN the/DT reporter/NN gene/NN ./. 
Within/IN the/DT above/JJ region/NN ,/, the/DT fragment/NN spanning/NN nucleotides/NNS -158/CD to/TO -90/CD was/VBD required/VBN for/IN optimal/JJ transcription/NN in/IN monocytic/JJ cells/NNS ./. 
Biochemical/JJ analysis/NN of/IN the/DT region/NN -158/-90/CD revealed/VBN a/DT binding/VBG site/NN for/IN transcription/NN factors/NNS of/IN the/DT polyomavirus/NN enhancer-binding/JJ protein/NN 2/core-binding/JJ factor/NN (/( PEBP2/CBF/NN )/) family/NN at/IN position/NN -103/CD ./. 
Disruption/NN of/IN the/DT PEBP2/CBF/NN site/NN markedly/RB diminished/VBD the/DT role/NN of/IN the/DT PEBP2/CBF/NN factors/NNS in/IN the/DT constitutive/JJ transcription/NN of/IN the/DT CD36/NN gene/NN ./. 
The/DT involvement/NN of/IN members/NNS of/IN the/DT PEBP2/CBF/NN family/NN in/IN chromosome/NN translocations/NNS associated/VBN with/IN acute/JJ myeloid/JJ leukemia/NN ,/, and/CC in/IN the/DT transcriptional/JJ regulation/NN of/IN the/DT myeloid-specific/JJ genes/NNS encoding/VBG for/IN myeloperoxidase/NN ,/, elastase/NN ,/, and/CC the/DT colony-stimulating/JJ factor/NN receptor/NN ,/, highlights/VBZ the/DT relevance/NN of/IN the/DT regulation/NN of/IN the/DT CD36/NN gene/NN promoter/NN in/IN monocytic/JJ cells/NNS by/IN members/NNS of/IN the/DT PEBP2/CBF/NN family/NN ./. 
UI/LS -/: 96228347/CD 
TI/LS -/: HLA-DQB1/NN codon/NN 57/CD is/VBZ critical/JJ for/IN peptide/NN binding/NN and/CC recognition/NN ./. 
AB/LS -/: The/DT association/NN of/IN specific/JJ HLA-DQ/NN alleles/NNS with/IN autoimmunity/NN is/VBZ correlated/VBN with/IN discrete/JJ polymorphisms/NNS in/IN the/DT HLA-DQ/NN sequence/NN that/WDT are/VBP localized/VBN within/IN sites/NNS suitable/JJ for/IN peptide/NN recognition/NN ./. 
The/DT polymorphism/NN at/IN residue/NN 57/CD of/IN the/DT DQB1/NN polypeptide/NN is/VBZ of/IN particular/JJ interest/NN since/IN it/PRP may/MD play/VB a/DT major/JJ structural/JJ role/NN in/IN the/DT formation/NN of/IN a/DT salt/NN bridge/NN structure/NN at/IN one/CD end/NN of/IN the/DT peptide-binding/JJ cleft/NN of/IN the/DT DQ/NN molecules/NNS ./. 
This/DT polymorphism/NN at/IN residue/NN 57/CD is/VBZ a/DT recurrent/JJ feature/NN of/IN HLA-DQ/NN evolution/NN ,/, occurring/VBG in/IN multiple/JJ distinct/JJ allelic/JJ families/NNS ,/, which/WDT implies/VBZ a/DT functional/JJ selection/NN for/IN maintaining/VBG variation/NN at/IN this/DT position/NN in/IN the/DT class/NN II/CD molecule/NN ./. 
We/PRP directly/RB tested/VBD the/DT amino/NN acid/NN polymorphism/NN at/IN this/DT site/NN as/IN a/DT determinant/NN for/IN peptide/NN binding/NN and/CC for/IN antigen-specific/JJ T/NN cell/NN stimulation/NN ./. 
We/PRP found/VBD that/IN a/DT single/JJ Ala/NN -->/TO Asp/NN amino/NN acid/NN 57/CD substitution/NN in/IN an/DT HLA-DQ3.2/NN molecule/NN regulated/VBD binding/NN of/IN an/DT HSV-2/NN VP-16-derived/JJ peptide/NN ./. 
A/DT complementary/JJ single-residue/NN substitution/NN in/IN the/DT peptide/NN abolished/VBD its/PRP$ binding/NN to/TO DQ3.2/NN and/CC converted/VBD it/PRP to/TO a/DT peptide/NN that/WDT can/MD bind/VB to/TO DQ3.1/NN and/CC DQ3.3/NN Asp-57-positive/JJ MHC/NN molecules/NNS ./. 
These/DT binding/NN studies/NNS were/VBD paralleled/VBN by/IN specific/JJ T/NN cell/NN recognition/NN of/IN the/DT class/NN II-peptide/NN complex/NN ,/, in/IN which/WDT the/DT substituted/VBN peptide/NN abolished/VBD T/NN cell/NN reactivity/NN ,/, which/WDT was/VBD directed/VBN to/TO the/DT DQ3.2-peptide/NN complex/NN ,/, whereas/IN the/DT same/JJ T/NN cell/NN clone/NN recognized/VBD the/DT substituted/VBN peptide/NN presented/VBN by/IN DQ3.3/NN ,/, a/DT class/NN II/CD restriction/NN element/NN differing/VBG from/IN DQ3.2/NN only/RB at/IN residue/NN 57/CD ./. 
This/DT structural/JJ and/CC functional/JJ complementarity/NN for/IN residue/NN 57/CD and/CC a/DT specific/JJ peptide/NN residue/NN identifies/VBZ this/DT interaction/NN as/IN a/DT key/JJ controlling/VBG determinant/NN of/IN restricted/JJ recognition/NN in/IN HLA-DQ-specific/JJ immune/JJ response/NN ./. 
UI/LS -/: 96182305/CD 
TI/LS -/: Autocrine/NN activation/NN by/IN interferon-gamma/NN of/IN STAT/NN factors/NNS following/VBG T/NN cell/NN activation/NN ./. 
AB/LS -/: The/DT activation/NN of/IN T/NN cells/NNS requires/VBZ engagement/NN of/IN the/DT T/NN cell/NN receptor/CD3/NN complex/NN and/CC co-stimulatory/JJ molecules/NNS ,/, and/CC results/VBZ in/IN the/DT triggering/NN of/IN several/JJ signaling/NN pathways/NNS which/WDT lead/VBP rapidly/RB to/TO the/DT nuclear/JJ translocation/NN of/IN several/JJ transcription/NN factors/NNS ,/, such/JJ as/IN nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN and/CC NF-AT/NN ./. 
A/DT result/NN of/IN this/DT activation/NN process/NN is/VBZ the/DT induction/NN of/IN a/DT number/NN of/IN genes/NNS ,/, including/VBG those/DT encoding/VBG cytokines/NNS such/JJ as/IN interleukin-2/NN ,/, tumor/NN necrosis/NN factor-alpha/NN ,/, and/CC interferon/NN (/( IFN/NN )/) -gamma/NN which/WDT have/VBP important/JJ immunoregulatory/JJ effects/NNS ./. 
We/PRP report/VBP here/RB that/IN a/DT DNA-binding/JJ factor/NN containing/VBG STAT1/NN also/RB becomes/VBZ activated/JJ in/IN human/JJ peripheral/JJ blood/NN T/NN lymphocytes/NNS or/CC Jurkat/NN cells/NNS ,/, although/IN not/RB until/IN 1-2/CD h/NN after/IN stimulation/NN ./. 
Activation/NN is/VBZ delayed/VBN a/DT further/JJ 1-2/CD hr/NN when/WRB mononuclear/JJ cell/NN cultures/NNS are/VBP stimulated/VBN by/IN an/DT antigen/NN which/WDT requires/VBZ processing/NN ./. 
Appearance/NN of/IN the/DT STAT1/NN factor/NN is/VBZ significantly/RB reduced/VBN in/IN the/DT presence/NN of/IN cyclosporin/NN A/NN ,/, and/CC blocked/VBN by/IN cycloheximide/NN ,/, indicating/VBG that/IN its/PRP$ activation/NN is/VBZ dependent/JJ upon/IN a/DT protein/NN (/( s/NNS )/) synthesized/VBN in/IN response/NN to/TO initial/JJ signaling/NN events/NNS ./. 
Neutralizing/VBG antiserum/NN against/IN IFN-gamma/NN ,/, but/CC not/RB other/JJ cytokines/NNS tested/VBN ,/, blocked/VBD activation/NN of/IN the/DT factor/NN almost/RB completely/RB ,/, and/CC IFN-gamma/NN was/VBD found/VBN in/IN the/DT culture/NN supernatants/NNS of/IN stimulated/VBN cells/NNS at/IN levels/NNS at/IN which/WDT recombinant/JJ IFN-gamma/NN could/MD activate/VB the/DT factor/NN in/IN naive/JJ cells/NNS ./. 
Therefore/RB ,/, a/DT STAT1/NN transcription/NN factor/NN is/VBZ activated/VBN by/IN IFN-gamma/NN synthesized/VBN and/CC released/VBN upon/IN stimulation/NN of/IN T/NN lymphocyte/NN populations/NNS ./. 
While/IN Jurkat/NN cells/NNS both/CC secrete/VBP and/CC respond/VBP to/TO IFN-gamma/NN in/IN an/DT autocrine/NN loop/NN ,/, it/PRP seems/VBZ likely/JJ that/IN the/DT responding/VBG cells/NNS may/MD differ/VB from/IN those/DT synthesizing/VBG this/DT cytokine/NN in/IN the/DT mononuclear/JJ cell/NN cultures/NNS in/IN the/DT light/NN of/IN the/DT recent/JJ report/NN that/IN Th1/NN cells/NNS lack/VBP the/DT IFN-gamma/NN receptor/NN chain/NN necessary/JJ for/IN activation/NN of/IN STAT1/NN (/( Pernis/NNP ,/, A./NNP ,/, Gupta/NNP ,/, S./NNP ,/, Gollob/NNP ,/, K.J./NNP ,/, Garfein/NNP ,/, E./NNP ,/, Coffman/NNP ,/, R.L./NNP ,/, Schindler/NNP ,/, C./NNP ,/, and/CC Rothman/NNP ,/, P./NNP ,/, Science/NNP 1995/CD ./. 269/CD :/: 245/CD )/) ./. 
UI/LS -/: 96373868/CD 
TI/LS -/: Absence/NN of/IN T-cell-/NN and/CC B-cell-specific/JJ transcription/NN factors/NNS TCF-1/NN ,/, GATA-3/NN ,/, and/CC BSAP/NN in/IN Hodgkin/NN 's/POS Reed-Sternberg/NN cells/NNS ./. 
AB/LS -/: Based/VBN on/IN the/DT presence/NN of/IN T/NN cell/NN receptor-beta/NN (/( TcR-beta/NN )/) gene/NN rearrangements/NNS in/IN L428/NN and/CC HDLM-1/NN cells/NNS ,/, the/DT expression/NN of/IN CD2/NN in/IN HDLM-1/NN cells/NNS ,/, and/CC the/DT presence/NN of/IN immunoglobulin/NN heavy-chain/NN (/( IgH/NN )/) gene/NN rearrangement/NN in/IN KM-H2/NN cells/NNS ,/, some/DT researchers/NNS have/VBP concluded/VBN that/IN these/DT long-term/JJ cell/NN lines/NNS derived/VBN from/IN patients/NNS with/IN Hodgkin/NN 's/POS disease/NN are/VBP lymphoid/JJ in/IN nature/NN ./. 
The/DT information/NN obtained/VBN from/IN these/DT cell/NN lines/NNS has/VBZ also/RB been/VBN used/VBN in/IN arguments/NNS for/IN a/DT lymphoid/JJ origin/NN of/IN H-RS/NN cells/NNS in/IN tissue/NN despite/IN the/DT frequent/JJ absence/NN of/IN lymphoid/JJ markers/NNS and/CC Ig/TcR/NN gene/NN rearrangements/NNS in/IN these/DT cells/NNS ./. 
We/PRP questioned/VBD whether/IN one/PRP can/MD use/VB the/DT limited/JJ expression/NN of/IN lymphoid/JJ markers/NNS or/CC the/DT limited/JJ gene/NN rearrangement/NN to/TO conclude/VB that/IN H-RS/NN cells/NNS have/VBP a/DT lymphoid/JJ origin/NN ,/, because/IN these/DT markers/NNS may/MD be/VB aberrant/JJ in/IN tumor/NN cells/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD the/DT expression/NN of/IN two/CD T-cell-specific/JJ transcription/NN factors/NNS (/( TCF-1/NN and/CC GATA-3/NN )/) and/CC one/CD B-cell-specific/JJ transcription/NN factor/NN (/( BSAP/NN )/) in/IN cultured/VBN H-RS/NN cells/NNS by/IN using/VBG a/DT gel/NN mobility/NN shift/NN assay/NN ./. 
The/DT sensitivity/NN and/CC specificity/NN of/IN this/DT assay/NN for/IN determination/NN of/IN cell/NN lineage/NN have/VBP been/VBN established/VBN in/IN a/DT large/JJ number/NN of/IN cultured/VBN human/JJ and/CC murine/JJ cell/NN lines/NNS ./. 
All/DT three/CD types/NNS of/IN H-RS/NN cell/NN lines/NNS were/VBD consistently/RB negative/JJ for/IN BSAP/NN ,/, TCF-1/NN ,/, and/CC GATA-3/NN ./. 
The/DT absence/NN of/IN GATA-3/NN was/VBD confirmed/VBN in/IN H-RS/NN cells/NNS in/IN tissues/NNS by/IN an/DT in/FW situ/FW hybridization/NN technique/NN ./. 
Virtually/RB all/DT B-cell/NN lines/NNS ,/, with/IN the/DT exception/NN of/IN some/DT myeloma/NN cell/NN lines/NNS ,/, are/VBP positive/JJ for/IN BSAP/NN ,/, which/WDT is/VBZ the/DT transcription/NN factor/NN for/IN promoters/NNS for/IN several/JJ B-cell/NN markers/NNS ,/, including/VBG VpreB1/NN ,/, lambda/NN 5/CD ,/, CD19/NN ,/, and/CC CD20/NN ./. 
All/DT T-cell/NN lines/NNS tested/VBN were/VBD positive/JJ for/IN TCF-1/NN and/CC GATA-3/NN ,/, which/WDT are/VBP the/DT transcription/NN factors/NNS for/IN promoters/NNS for/IN several/JJ T-cell-restricted/JJ markers/NNS ,/, including/VBG CD2/NN ,/, CD3/NN ,/, TcR/NN ,/, and/CC lck/NN ./. 
The/DT absence/NN of/IN BSAP/NN ,/, TCF-1/NN ,/, and/CC GATA-3/NN clearly/RB indicates/VBZ an/DT underlying/JJ difference/NN between/IN H-RS/NN cells/NNS and/CC lymphoid/JJ cells/NNS ./. 
UI/LS -/: 96144322/CD 
TI/LS -/: MEK1/NN and/CC the/DT extracellular/JJ signal-regulated/JJ kinases/NNS are/VBP required/VBN for/IN the/DT stimulation/NN of/IN IL-2/NN gene/NN transcription/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: TCR/NN engagement/NN stimulates/VBZ the/DT activation/NN of/IN the/DT protein/NN kinase/NN Raf-1/NN ./. 
Active/JJ Raf-1/NN phosphorylates/VBZ and/CC activates/VBZ the/DT mitogen-activated/JJ protein/NN (/( MAP/NN )/) kinase/extracellular/JJ signal-regulated/JJ kinase/NN kinase/NN 1/CD (/( MEK1/NN )/) ,/, which/WDT in/IN turn/NN phosphorylates/VBZ and/CC activates/VBZ the/DT MAP/NN kinases/extracellular/JJ signal/NN regulated/JJ kinases/NNS ,/, ERK1/NN and/CC ERK2/NN ./. 
Raf-1/NN activity/NN promotes/VBZ IL-2/NN production/NN in/IN activated/VBN T/NN lymphocytes/NNS ./. 
Therefore/RB ,/, we/PRP sought/VBD to/TO determine/VB whether/IN MEK1/NN and/CC ERK/NN activities/NNS also/RB stimulate/VBP IL-2/NN gene/NN transcription/NN ./. 
Expression/NN of/IN constitutively/RB active/JJ Raf-1/NN or/CC MEK1/NN in/IN Jurkat/NN T/NN cells/NNS enhanced/VBD the/DT stimulation/NN of/IN IL-2/NN promoter-driven/JJ transcription/NN stimulated/VBN by/IN a/DT calcium/NN ionophore/NN and/CC PMA/NN ,/, and/CC together/RB with/IN a/DT calcium/NN ionophore/NN the/DT expression/NN of/IN each/DT protein/NN was/VBD sufficient/JJ to/TO stimulate/VB NF-AT/NN activity/NN ./. 
Expression/NN of/IN MEK1-interfering/JJ mutants/NNS inhibited/VBD the/DT stimulation/NN of/IN IL-2/NN promoter-driven/JJ transcription/NN and/CC blocked/VBD the/DT ability/NN of/IN constitutively/RB active/JJ Ras/NN and/CC Raf-1/NN to/TO costimulate/VB NF-AT/NN activity/NN with/IN a/DT calcium/NN ionophore/NN ./. 
Expression/NN of/IN the/DT MAP/NN kinase-specific/JJ phosphatase/NN ,/, MKP-1/NN ,/, which/WDT blocks/VBZ ERK/NN activation/NN ,/, inhibited/VBD IL-2/NN promoter/NN and/CC NF-AT-driven/JJ transcription/NN stimulated/VBN by/IN a/DT calcium/NN ionophore/NN and/CC PMA/NN ,/, and/CC in/IN addition/NN ,/, MKP-1/NN neutralized/VBD the/DT transcriptional/JJ enhancement/NN caused/VBN by/IN active/JJ Raf-1/NN and/CC MEK1/NN expression/NN ./. 
We/PRP conclude/VBP that/IN the/DT MAP/NN kinase/NN signal/NN transduction/NN pathway/NN consisting/VBG of/IN Raf-1/NN ,/, MEK1/NN ,/, and/CC ERK1/NN and/CC ERK2/NN functions/VBZ in/IN the/DT stimulation/NN IL-2/NN gene/NN transcription/NN in/IN activated/VBN T/NN lymphocytes/NNS ./. 
UI/LS -/: 96279111/CD 
TI/LS -/: Multiple/JJ transcription/NN factors/NNS are/VBP required/VBN for/IN activation/NN of/IN human/JJ interleukin/NN 9/CD gene/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: The/DT genetic/JJ elements/NNS and/CC regulatory/JJ mechanisms/NNS responsible/JJ for/IN human/JJ interleukin/NN 9/CD (/( IL-9/NN )/) gene/NN expression/NN in/IN a/DT human/JJ T/NN cell/NN leukemia/NN virus/NN type/NN I-transformed/JJ human/JJ T/NN cell/NN line/NN ,/, C5MJ2/NN ,/, were/VBD investigated/VBN ./. 
We/PRP demonstrated/VBD that/IN IL-9/NN gene/NN expression/NN is/VBZ controlled/VBN ,/, at/IN least/JJS in/IN part/NN ,/, by/IN transcriptional/JJ activation/NN ./. 
Transient/JJ expression/NN of/IN the/DT luciferase/NN reporter/NN gene/NN linked/VBN to/TO serially/RB deleted/VBN sequences/NNS of/IN the/DT 5'-flanking/JJ region/NN of/IN the/DT IL-9/NN gene/NN has/VBZ revealed/VBN several/JJ positive/JJ and/CC negative/JJ regulatory/JJ elements/NNS involved/VBN in/IN the/DT basal/JJ and/CC inducible/JJ expression/NN of/IN the/DT IL-9/NN gene/NN in/IN C5MJ2/NN cells/NNS ./. 
An/DT AP-1/NN site/NN at/IN -146/CD to/TO -140/CD was/VBD shown/VBN to/TO be/VB involved/VBN in/IN the/DT expression/NN of/IN the/DT IL-9/NN gene/NN ./. 
A/DT proximal/JJ region/NN between/IN -46/CD and/CC -80/CD was/VBD identified/VBN as/IN the/DT minimum/JJ sequence/NN for/IN the/DT basal/JJ and/CC inducible/JJ expression/NN of/IN the/DT IL-9/NN gene/NN in/IN C5MJ2/NN cells/NNS ./. 
Within/IN this/DT region/NN ,/, an/DT NF-kappaB/NN site/NN at/IN -59/CD to/TO -50/CD and/CC its/PRP$ adjacent/JJ 20-base/JJ pair/NN upstream/JJ sequence/NN were/VBD demonstrated/VBN to/TO play/VB a/DT critical/JJ role/NN for/IN the/DT IL-9/NN promoter/NN activity/NN ./. 
DNA-protein/JJ binding/NN studies/NNS indicated/VBD that/IN NF-kappaB/NN ,/, c-Jun/NN ,/, and/CC potentially/RB novel/JJ proteins/NNS (/( around/IN 35/CD kDa/NN )/) can/MD bind/VB to/TO this/DT important/JJ sequence/NN ./. 
Mutations/NNS at/IN different/JJ sites/NNS within/IN this/DT proximal/JJ promoter/NN region/NN abolished/VBD the/DT promoter/NN activity/NN as/RB well/RB as/IN the/DT DNA/NN binding/NN ./. 
Taken/VBN together/RB ,/, these/DT results/NNS suggest/VBP that/IN the/DT cooperation/NN of/IN different/JJ transcription/NN factors/NNS is/VBZ essential/JJ for/IN IL-9/NN gene/NN expression/NN in/IN T/NN cells/NNS ./. 
UI/LS -/: 96278909/CD 
TI/LS -/: DNA/NN triplex/NN formation/NN selectively/RB inhibits/VBZ granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN gene/NN expression/NN in/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: Granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) is/VBZ a/DT hemopoietic/JJ growth/NN factor/NN that/WDT is/VBZ expressed/VBN in/IN activated/VBN T/NN cells/NNS ,/, fibroblasts/NNS ,/, macrophages/NNS ,/, and/CC endothelial/JJ cells/NNS ./. 
Although/IN GM-CSF/NN does/VBZ not/RB appear/VB to/TO be/VB essential/JJ for/IN normal/JJ hemopoiesis/NN ,/, overexpression/NN of/IN GM-CSF/NN has/VBZ been/VBN implicated/VBN in/IN the/DT pathogenesis/NN of/IN some/DT diseases/NNS such/JJ as/IN myeloid/JJ leukemia/NN and/CC chronic/JJ inflammation/NN ./. 
An/DT NF-kappaB/Rel/NN binding/NN site/NN within/IN the/DT GM-CSF/NN promoter/NN ,/, termed/VBN the/DT kappaB/NN element/NN appears/VBZ to/TO be/VB important/JJ for/IN controlling/VBG expression/NN in/IN reporter/NN gene/NN assays/NNS in/IN response/NN to/TO a/DT number/NN of/IN stimuli/NNS in/IN T/NN cells/NNS ./. 
We/PRP investigated/VBD oligonucleotide-directed/JJ triple/JJ helix/NN formation/NN across/IN this/DT regulatory/JJ sequence/NN as/IN a/DT potential/JJ tool/NN to/TO inhibit/VB GM-CSF/NN gene/NN transcription/NN ./. 
A/DT 15-base/NN oligonucleotide/NN ,/, GM3/NN ,/, was/VBD targeted/VBN to/TO a/DT purine-rich/JJ region/NN in/IN the/DT GM-CSF/NN proximal/JJ promoter/NN ,/, which/WDT overlaps/VBZ the/DT kappaB/NN element/NN ./. 
Gel/NN mobility/NN shift/NN assays/NNS and/CC DNase/NN I/CD footprinting/NN demonstrated/VBD that/IN GM3/NN formed/VBD a/DT sequence-specific/JJ collinear/NN triplex/NN with/IN its/PRP$ double-stranded/JJ DNA/NN target/NN ./. 
Triplex/JJ formation/NN by/IN GM3/NN blocked/VBD recombinant/JJ and/CC nuclear/JJ NF-kappaB/NN proteins/NNS binding/VBG to/TO the/DT GM-CSF/NN element/NN ./. 
GM3/NN also/RB caused/VBD selective/JJ inhibition/NN of/IN the/DT human/JJ T-cell/NN lymphotrophic/JJ virus-1/NN Tax/NN transactivator-induced/JJ luciferase/NN activity/NN from/IN a/DT reporter/NN construct/NN driven/VBN by/IN the/DT GM-CSF/NN promoter/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
Finally/RB ,/, GM3/NN greatly/RB reduced/VBD the/DT concentration/NN of/IN endogenous/JJ GM-CSF/NN mRNA/NN induced/VBN by/IN different/JJ stimuli/NNS in/IN Jurkat/NN T/NN cells/NNS but/CC did/VBD not/RB affect/VB interleukin/NN 3/CD mRNA/NN levels/NNS in/IN the/DT same/JJ cells/NNS ./. 
We/PRP conclude/VBP that/IN the/DT kappaB/NN element/NN in/IN the/DT GM-CSF/NN promoter/NN plays/VBZ a/DT central/JJ role/NN in/IN the/DT transcriptional/JJ activation/NN of/IN the/DT endogenous/JJ GM-CSF/NN gene/NN ./. 
Colinear/JJ triplex/NN formation/NN acts/VBZ as/IN a/DT selective/JJ transcriptional/JJ repressor/NN of/IN the/DT GM-CSF/NN gene/NN and/CC may/MD have/VB potential/JJ therapeutic/JJ application/NN in/IN cases/NNS of/IN undesirable/JJ overexpression/NN of/IN this/DT protein/NN ./. 
UI/LS -/: 96221559/CD 
TI/LS -/: Reversible/JJ differentiation/NN of/IN human/JJ monoblastic/JJ leukemia/NN U937/NN cells/NNS by/IN ML-9/NN ,/, an/DT inhibitor/NN of/IN myosin/JJ light/JJ chain/NN kinase/NN ./. 
AB/LS -/: Human/JJ monoblastic/JJ leukemia/NN U937/NN cells/NNS are/VBP induced/VBN to/TO differentiate/VB into/IN monocytes/NNS and/CC macrophages/NNS by/IN various/JJ agents/NNS ./. 
We/PRP have/VBP shown/VBN that/IN 1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine/NN hydrochloride/NN (/( ML-9/NN )/) ,/, an/DT inhibitor/NN of/IN myosin/JJ light/JJ chain/NN kinase/NN ,/, induces/VBZ differentiation/NN of/IN monocytoid/NN leukemia/NN cell/NN lines/NNS U937/NN and/CC THP-1/NN but/CC not/RB of/IN myeloblastic/JJ leukemic/JJ ML-1/NN cell/NN or/CC erythroleukemia/NN K562/NN cells/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP further/RB analyzed/VBD the/DT effect/NN of/IN ML-9/NN in/IN comparison/NN with/IN that/DT of/IN 1/CD alpha, 25-dihydroxyvitamin/NN D3/NN (/( VD3/NN )/) a/DT typical/JJ inducer/NN of/IN monocytic/JJ differentiation/NN ./. 
ML-9/NN induced/VBD nitroblue/JJ tetrazolium/NN (/( NBT/NN )/) -reducing/JJ activity/NN of/IN U937/NN cell/NN more/RBR rapidly/RB than/IN VD3/NN :/: This/DT differentiation/NN marker/NN was/VBD induced/VBN significantly/RB after/IN incubation/NN with/IN ML-9/NN and/CC VD3/NN for/IN 4/CD hours/NNS and/CC 1/CD day/NN ,/, respectively/RB ./. 
ML-9/NN also/RB induced/VBD alpha-naphthyl/JJ acetate/NN esterase/NN (/( ANAE/NN )/) activity/NN ,/, another/DT monocytic/JJ differentiation/NN marker/NN ,/, more/JJR rapidly/RB than/IN VD3/NN ./. 
The/DT maximum/JJ levels/NNS of/IN these/DT markers/NNS induced/VBN by/IN ML-9/NN were/VBD comparable/JJ to/TO those/DT induced/VBN by/IN VD3/NN ,/, but/CC after/IN removal/NN of/IN ML-9/NN from/IN the/DT medium/NN by/IN washing/VBG the/DT cells/NNS ,/, the/DT expressions/NNS of/IN theses/DT markers/NNS decreased/VBD within/IN 4/CD hours/NNS and/CC reached/VBD basal/JJ levels/NNS in/IN 1/CD day/NN ,/, indicating/VBG that/IN ML-9/NN 's/POS induction/NN of/IN expression/NN of/IN differentiation-associated/JJ phenotypes/NNS was/VBD reversible/JJ ./. 
The/DT growth/NN inhibition/NN of/IN U937/NN cells/NNS by/IN ML-9/NN was/VBD also/RB reversible/JJ ./. 
Similar/JJ effects/NNS were/VBD observed/VBN in/IN another/DT line/NN of/IN human/JJ monoblastic/JJ cells/NNS ,/, THP-1/NN ./. 
ML-9/NN had/VBD little/JJ or/CC no/DT effect/NN on/IN the/DT morphology/NN of/IN U937/NN cells/NNS but/CC increased/VBD the/DT expression/NN of/IN monocyte-macrophage/JJ lineage-associated/JJ surface/NN antigen/NN ,/, CD14/NN ,/, to/TO some/DT extent/NN ./. 
Irreversible/JJ terminal/JJ differentiation/NN induced/VBN by/IN VD3/NN is/VBZ associated/VBN with/IN down/JJ regulation/NN of/IN the/DT expression/NN of/IN c-myc/NN and/CC upregulation/NN of/IN the/DT expression/NN of/IN c-fos/NN and/CC c-jun/NN ,/, but/CC ML-9/NN did/VBD not/RB affect/VB the/DT expression/NN of/IN these/DT oncogenes/NNS appreciably/RB ./. 
ML-9-induced/JJ differentiation/NN was/VBD also/RB reversible/JJ when/WRB the/DT cells/NNS were/VBD cultured/VBN with/IN cultured/VBN with/IN ML-9/NN plus/CC an/DT anti-cancer/JJ drug/NN such/JJ as/IN 1-beta-D-arabino-furanosylcytosine/NN or/CC daunomycin/NN ./. 
it/PRP became/VBD irreversible/JJ ,/, however/RB ,/, upon/IN simultaneous/JJ treatment/NN with/IN dexamethasone/NN and/CC transforming/VBG growth/NN factor-beta/NN 1/CD (/( TGF-beta/NN 1/CD )/) ,/, which/WDT did/VBD not/RB induce/VB differentiation/NN of/IN U937/NN cells/NNS but/CC caused/VBD growth/NN arrest/NN of/IN the/DT cells/NNS in/IN the/DT G0/G1/NN phase/NN of/IN the/DT cell/NN cycle/NN ./. 
These/DT results/NNS suggest/VBP that/IN ML-9/NN should/MD be/VB useful/JJ for/IN studying/VBG the/DT mechanisms/NNS of/IN monocytic/JJ differentiation/NN ./. 
UI/LS -/: 96194562/CD 
TI/LS -/: Modulation/NN of/IN endogenous/JJ IL-1/NN beta/NN and/CC IL-1/NN receptor/NN antagonist/NN results/VBZ in/IN opposing/JJ effects/NNS on/IN HIV/NN expression/NN in/IN chronically/RB infected/JJ monocytic/JJ cells/NNS ./. 
AB/LS -/: A/DT proportion/NN of/IN HIV-infected/JJ individuals/NNS experience/VBP episodes/NNS of/IN localized/JJ or/CC systemic/JJ bacterial/JJ infections/NNS caused/VBN by/IN Gram-negative/JJ bacteria/NNS ./. 
Many/JJ of/IN the/DT clinical/JJ side/JJ effects/NNS of/IN these/DT infections/NNS are/VBP associated/VBN with/IN the/DT production/NN of/IN proinflammatory/JJ cytokines/NNS ,/, which/WDT are/VBP induced/VBN primarily/RB by/IN LPS/NN ,/, a/DT constituent/NN of/IN the/DT bacterial/JJ cell/NN wall/NN of/IN Gram-negative/JJ bacteria/NNS ./. 
The/DT present/JJ study/NN examines/VBZ the/DT mechanisms/NNS involved/VBN in/IN LPS-mediated/JJ induction/NN of/IN HIV/NN expression/NN in/IN U1/NN cells/NNS ,/, a/DT promonocytic/JJ cell/NN line/NN chronically/RB infected/VBN with/IN HIV/NN ./. 
Stimulation/NN of/IN U1/NN cells/NNS by/IN LPS/NN alone/RB induced/VBD minimal/JJ levels/NNS of/IN HIV/NN expression/NN ,/, which/WDT was/VBD significantly/RB enhanced/VBN by/IN granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) ./. 
Costimulation/NN of/IN U1/NN cells/NNS with/IN LPS/NN plus/CC GM-CSF/NN resulted/VBD in/IN the/DT accumulation/NN of/IN steady-state/JJ levels/NNS of/IN HIV/NN RNA/NN ;/: however/RB ,/, only/RB a/DT weak/JJ induction/NN of/IN HIV/NN long/JJ terminal/JJ repeat-driven/JJ transcription/NN ,/, which/WDT was/VBD not/RB associated/VBN with/IN the/DT activation/NN of/IN the/DT cellular/JJ transcription/NN factor/NN nuclear/JJ factor-kappa/NN B/NN ,/, was/VBD noted/VBN ./. 
Costimulation/NN of/IN cells/NNS with/IN LPS/NN plus/CC GM-CSF/NN induced/VBD the/DT production/NN of/IN proinflammatory/JJ cytokines/NNS ,/, IL-8/NN ,/, IL-1/NN beta/NN and/CC IL-6/NN ,/, but/CC not/RB TNF-alpha/NN ./. 
IL-1/NN receptor/NN antagonist/NN (/( ra/NN )/) inhibited/VBD LPS/NN enhancement/NN of/IN HIV/NN expression/NN in/IN GM-CSF-stimulated/JJ cells/NNS ,/, suggesting/VBG that/IN endogenous/JJ IL-1/NN was/VBD involved/VBN in/IN LPS-mediated/JJ viral/JJ production/NN ./. 
In/IN this/DT regard/NN ,/, anti-inflammatory/JJ cytokines/NNS inhibited/VBD LPS/NN plus/CC GM-CSF-stimulated/JJ HIV/NN expression/NN ,/, and/CC this/DT effect/NN closely/RB correlated/VBD with/IN inhibition/NN of/IN IL-1/NN beta/NN release/NN and/CC ,/, in/IN particular/JJ ,/, with/IN up-regulation/NN of/IN endogenous/JJ IL-1ra/NN production/NN ./. 
Thus/RB ,/, the/DT balance/NN between/IN an/DT endogenously/RB produced/VBN viral/JJ inducer/NN (/( IL-1/NN beta/NN )/) and/CC an/DT inhibitor/NN (/( IL-1ra/NN )/) may/MD represent/VB an/DT important/JJ pathway/NN leading/VBG to/TO modulation/NN of/IN HIV/NN expression/NN from/IN monocytic/JJ cells/NNS ./. 
UI/LS -/: 96183228/CD 
TI/LS -/: Herpesvirus/NN saimiri/NN immortalized/VBD gamma/NN delta/NN T/NN cell/NN line/NN activated/VBN by/IN IL-12/NN ./. 
AB/LS -/: IL-12/NN is/VBZ a/DT novel/JJ heterodimeric/JJ cytokine/NN important/JJ for/IN the/DT regulation/NN and/CC differentiation/NN of/IN lymphocytes/NNS and/CC NK/NN cells/NNS ./. 
Like/IN other/JJ cytokines/NNS ,/, IL-12/NN mediates/VBZ its/PRP$ biologic/JJ activity/NN through/IN high-affinity/JJ receptors/NNS expressed/VBN on/IN responsive/JJ cells/NNS ./. 
To/TO date/NN ,/, a/DT large/JJ number/NN of/IN receptors/NNS for/IN IL-12/NN have/VBP been/VBN found/VBN only/RB on/IN PBMC/NN following/VBG activation/NN with/IN PHA/NN or/CC IL-2/NN ./. 
To/TO gain/VB further/JJ knowledge/NN of/IN the/DT IL-12R/NN complex/NN and/CC the/DT IL-12/NN signal/NN transduction/NN pathway/NN in/IN cytotoxic/JJ T/NN cells/NNS ,/, we/PRP studied/VBD a/DT number/NN of/IN human/JJ T/NN cell/NN lines/NNS that/WDT had/VBD been/VBN transformed/VBN to/TO permanent/JJ growth/NN with/IN Herpesvirus/NN saimiri/NN ,/, an/DT oncogenic/JJ virus/NN of/IN nonhuman/JJ primates/NNS ./. 
This/DT paper/NN reports/VBZ the/DT expression/NN of/IN IL-12R/NN on/IN a/DT human/JJ gamma/NN delta/NN T/NN cell/NN line/NN that/WDT responds/VBZ to/TO IL-12/NN with/IN enhanced/VBN cytolytic/JJ activity/NN and/CC increased/VBN expression/NN of/IN cytolytic/JJ effector/NN molecules/NNS granzyme/NN B/NN and/CC perforin/NN ./. 
Using/VBG these/DT T/NN cells/NNS as/IN a/DT model/NN of/IN IL-12/NN signal/NN transduction/NN ,/, we/PRP confirmed/VBD that/IN these/DT events/NNS involve/VBP members/NNS of/IN the/DT Janus/NN kinase/NN family/NN of/IN nonreceptor/NN tyrosine/NN kinases/NNS JAK2/NN ,/, TYK2/NN ,/, and/CC signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN 4/CD ./. 
UI/LS -/: 96338485/CD 
TI/LS -/: Regulation/NN of/IN gene/NN expression/NN at/IN early/JJ stages/NNS of/IN B-cell/NN and/CC T-cell/NN differentiation/NN ./. 
AB/LS -/: The/DT expression/NN of/IN distinct/JJ sets/NNS of/IN genes/NNS at/IN different/JJ stages/NNS of/IN B-lymphocyte/NN and/CC T-lymphocyte/NN differentiation/NN is/VBZ controlled/VBN at/IN the/DT level/NN of/IN transcription/NN ./. 
A/DT number/NN of/IN recent/JJ studies/NNS have/VBP described/VBN interactions/NNS between/IN transcription/NN factors/NNS in/IN lymphocytes/NNS that/WDT provide/VBP new/JJ insights/NNS into/IN mechanisms/NNS regulating/VBG gene/NN expression/NN ./. 
These/DT mechanisms/NNS include/VBP the/DT assembly/NN of/IN higher/JJR order/NN nucleoprotein/NN complexes/NNS and/CC other/JJ protein-protein/JJ interactions/NNS that/WDT enhance/VBP the/DT functional/JJ specificity/NN of/IN transcriptional/JJ regulators/NNS in/IN lymphocytes/NNS ./. 
UI/LS -/: 96226351/CD 
TI/LS -/: Identification/NN of/IN a/DT human/JJ LIM-Hox/NN gene/NN ,/, hLH-2/NN ,/, aberrantly/RB expressed/VBN in/IN chronic/JJ myelogenous/JJ leukaemia/NN and/CC located/JJ on/IN 9q33-34.1/NN ./. 
AB/LS -/: We/PRP describe/VBP the/DT isolation/NN of/IN human/JJ LH-2/NN ,/, a/DT putative/JJ transcription/NN factor/NN containing/VBG two/CD cysteine-rich/JJ regions/NNS (/( LIM/NN domains/NNS )/) and/CC a/DT homeobox/NN (/( Hox/NN )/) DNA-binding/JJ domain/NN ./. 
High/JJ levels/NNS of/IN hLH-2/NN expression/NN were/VBD observed/VBN in/IN all/DT cases/NNS of/IN chronic/JJ myelogenous/JJ leukaemia/NN (/( CML/NN )/) tested/VBN ,/, regardless/RB of/IN disease/NN status/NN ./. 
hLH-2/NN was/VBD mapped/VBN to/TO chromosome/NN 9Q33-34.1/NN ,/, in/IN the/DT same/JJ region/NN as/IN the/DT reciprocal/JJ translocation/NN that/WDT creates/VBZ the/DT BCR-ABL/NN chimera/NN of/IN the/DT Philadelphia/NN chromosome/NN (/( Ph/NN '/'' )/) ,/, the/DT hallmark/NN of/IN CML/NN ;/: hLH-2/NN was/VBD retained/VBN on/IN the/DT derivative/JJ 9/CD chromosome/NN and/CC is/VBZ therefore/RB centromeric/JJ of/IN c-ABL/NN ./. 
The/DT proximity/NN of/IN hLH-2/NN to/TO the/DT breakpoint/NN on/IN chromosome/NN 9/CD raises/VBZ the/DT possibility/NN of/IN cis-activation/NN by/IN the/DT t(9;22)(q34;q11)/NN translocation/NN ./. 
In/IN addition/NN to/TO finding/VBG hLH-2/NN expression/NN in/IN all/DT cases/NNS of/IN CML/NN ,/, expression/NN was/VBD observed/VBN in/IN lymphoid/JJ malignancies/NNS and/CC myeloid/JJ cell/NN lines/NNS ,/, but/CC not/RB in/IN primary/JJ cases/NNS of/IN acute/JJ myelogenous/JJ leukaemia/NN ./. 
The/DT role/NN of/IN hLH-2/NN in/IN the/DT development/NN or/CC progression/NN of/IN leukaemia/NN is/VBZ not/RB known/VBN ./. 
However/RB ,/, hLH-2/NN may/MD prove/VB useful/JJ as/IN a/DT marker/NN of/IN CML/NN for/IN monitoring/VBG residual/JJ disease/NN ./. 
UI/LS -/: 96235996/CD 
TI/LS -/: Lymphoid/JJ cell/NN resistance/NN to/TO glucocorticoids/NNS in/IN HIV/NN infection/NN ./. 
AB/LS -/: In/IN humans/NNS infected/VBN with/IN the/DT HIV-1/NN virus/NN there/EX may/MD be/VB a/DT disproportionate/JJ severity/NN of/IN signs/NNS and/CC symptoms/NNS of/IN illness/NN compared/VBN to/TO the/DT fraction/NN of/IN CD4+/JJ infected/JJ T-lymphoid/NN cells/NNS ./. 
In/IN part/NN ,/, this/DT may/MD be/VB due/JJ to/TO altered/JJ intercellular/JJ signalling/NN systems/NNS and/CC intracellular/JJ signal/NN transduction/NN ./. 
Glucocorticoids/NNS are/VBP well/RB known/JJ for/IN their/PRP$ effects/NNS on/IN the/DT vitality/NN and/CC function/NN of/IN lymphoid/JJ cells/NNS ./. 
Patients/NNS with/IN HIV/NN infections/NNS often/RB show/VBP elevated/JJ circulating/JJ levels/NNS of/IN cortisol/NN ,/, suggesting/VBG some/DT misfunction/NN in/IN the/DT regulatory/JJ systems/NNS that/WDT maintain/VBP the/DT levels/NNS of/IN this/DT critical/JJ hormone/NN ./. 
At/IN the/DT cellular/JJ level/NN ,/, it/PRP is/VBZ known/VBN that/IN both/CC acute/JJ HIV/NN infection/NN and/CC glucocorticoids/NNS can/MD cause/VB apoptotic/JJ cell/NN death/NN in/IN thymic/JJ lymphocytes/NNS ./. 
However/RB ,/, chronically/RB HIV-infected/JJ cells/NNS appear/VBP to/TO be/VB resistant/JJ to/TO glucocorticoid-evoked/JJ cell/NN death/NN ./. 
Glucocorticoid/NN receptor-ligand/NN binding/NN studies/NNS on/IN patients/NNS '/POS cells/NNS have/VBP shown/VBN reduced/VBN affinity/NN between/IN the/DT receptor/NN binding/NN sites/NNS and/CC test/NN steroids/NNS ./. 
In/FW vitro/FW ,/, chronically/RB HIV-infected/JJ cells/NNS of/IN the/DT lymphoid/JJ CEM/NN line/NN displayed/VBD resistance/NN to/TO glucocorticoid-induced/JJ apoptosis/NN ./. 
These/DT cells/NNS showed/VBD reduced/VBN numbers/NNS of/IN binding/VBG sites/NNS with/IN little/JJ alteration/NN in/IN apparent/JJ affinity/NN between/IN ligand/NN and/CC receptor/NN ./. 
Thus/RB it/PRP appears/VBZ that/IN there/EX may/MD often/RB be/VB malfunction/NN of/IN the/DT normal/JJ glucocorticoid/NN response/NN in/IN HIV-infected/JJ cells/NNS probably/RB due/JJ to/TO altered/JJ interactions/NNS between/IN the/DT glucocorticoid/NN receptor/NN and/CC its/PRP$ hormone/NN ./. 
Such/JJ alterations/NNS may/MD have/VB clinical/JJ consequences/NNS ,/, including/VBG the/DT possibility/NN of/IN a/DT relatively/RB longer/JJR life/NN span/NN of/IN infected/JJ CD4+/JJ T-lymphocytes/NNS ,/, as/RB well/RB as/IN systemic/JJ effects/NNS of/IN chronically/RB elevated/JJ cortisol/NN level/NN ./. 
UI/LS -/: 96216725/CD 
TI/LS -/: Abundant/JJ expression/NN of/IN erythroid/JJ transcription/NN factor/NN P45/NN NF-E2/NN mRNA/NN in/IN human/JJ peripheral/JJ granurocytes/NNS ./. 
AB/LS -/: Transcription/NN factor/NN NF-E2/NN is/VBZ crucial/JJ for/IN regulation/NN of/IN erythroid-specific/JJ gene/NN expression/NN ./. 
p45/NN subunit/NN of/IN NF-E2/NN contains/VBZ a/DT basic-leucine/NN zipper/NN domain/NN and/CC dimerizes/VBZ with/IN the/DT small/JJ Maf/NN family/NN protein/NN to/TO form/VB functional/JJ NF-E2/NN complex/NN ./. 
While/IN p45/NN expression/NN was/VBD shown/VBN to/TO be/VB restricted/JJ to/TO erythroid/JJ cells/NNS ,/, megakaryocytes/NNS and/CC mast/NN cells/NNS in/IN hematopoietic/JJ lineage/NN ,/, we/PRP found/VBD in/IN this/DT study/NN that/IN p45/NN mRNA/NN is/VBZ abundantly/RB transcribed/VBN in/IN the/DT granulocyte/NN fraction/NN of/IN human/JJ peripheral/JJ blood/NN cells/NNS ./. 
As/IN neutrophils/NNS occupy/VBP approximately/RB 92/CD %/NN of/IN the/DT cells/NNS in/IN granulocyte/NN fraction/NN of/IN human/JJ peripheral/JJ blood/NN cells/NNS ./. 
As/IN neutrophils/NNS occupy/VBP approximately/RB 92/CD %/NN of/IN the/DT cells/NNS in/IN this/DT fraction/NN ,/, the/DT cells/NNS expressing/VBG p45/NN is/VBZ most/RBS likely/JJ to/TO be/VB neutrophils/NNS ./. 
p45/NN mRNA/NN is/VBZ also/RB expressed/VBN in/IN HL-60/NN promyelocytes/NNS ,/, albeit/IN the/DT expression/NN level/NN is/VBZ much/RB lower/JJR than/IN that/DT of/IN the/DT granulocyte/NN fraction/NN ./. 
HL-60/NN cells/NNS were/VBD found/VBN to/TO express/VB mafK/NN mRNA/NN ,/, indicating/VBG the/DT presence/NN of/IN genuine/JJ NF-E2/NN complex/NN in/IN the/DT cells/NNS ./. 
Although/IN p45/NN mRNA/NN is/VBZ transcribed/VBN from/IN two/CD different/JJ promoters/NNS ,/, aNF-E2/NN promoter/NN and/CC fNF-E2/NN promoter/NN ,/, in/IN erythroid/JJ and/CC megakaryocytic/JJ lineage/NN cells/NNS ,/, p45/NN mRNA/NN is/VBZ transcribed/VBN only/RB from/IN aNF-E2/NN promoter/NN ./. 
The/DT expression/NN of/IN p45/NN megakaryocytic/JJ lineage/NN cells/NNS ,/, p45/NN mRNA/NN is/VBZ transcribed/VBN only/RB from/IN aNF-E2/NN promoter/NN ./. 
The/DT expression/NN of/IN p45/NN mRNA/NN in/IN the/DT neutrophils/NNS declined/VBD rapidly/RB after/IN transfer/NN of/IN the/DT cells/NNS to/TO in/FW vitro/FW culture/NN and/CC G-CSF/NN could/MD not/RB sustain/VB the/DT expression/NN from/IN the/DT down-regulation/NN ,/, suggesting/VBG the/DT E2/NN may/MD also/RB participate/VB in/IN the/DT regulation/NN of/IN neutrophil-specific/JJ gene/NN expression/NN ./. 
UI/LS -/: 96195546/CD 
TI/LS -/: Expression/NN of/IN c-fos/NN and/CC c-jun/NN proteins/NNS and/CC AP-1/NN binding/NN activity/NN during/IN cell/NN cycle/NN progression/NN of/IN HL60/NN cells/NNS and/CC phytohemagglutinin-stimulated/JJ lymphocytes/NNS ./. 
AB/LS -/: The/DT protein/NN products/NNS of/IN the/DT c-fos/NN (/( p62c-fos/NN )/) and/CC c-jun/NN (/( p39c-jun/NN )/) genes/NNS are/VBP members/NNS of/IN the/DT AP-1/NN transcription/NN factor/NN family/NN and/CC are/VBP thought/VBN to/TO play/VB important/JJ roles/NNS in/IN the/DT regulation/NN of/IN gene/NN expression/NN during/IN the/DT cell/NN cycle/NN ./. 
Most/JJS studies/NNS on/IN the/DT expression/NN of/IN these/DT proteins/NNS in/IN relation/NN to/TO the/DT cell/NN cycle/NN have/VBP been/VBN performed/VBN at/IN the/DT mRNA/NN level/NN ,/, and/CC therefore/RB do/VB not/RB give/VB direct/JJ information/NN about/IN the/DT presence/NN of/IN the/DT proteins/NNS during/IN the/DT cell/NN cycle/NN ./. 
We/PRP have/VBP used/VBN Western/NN blotting/NN to/TO investigate/VB the/DT presence/NN of/IN these/DT proteins/NNS during/IN the/DT cell/NN cycles/NNS of/IN two/CD different/JJ cellular/JJ systems/NNS :/: a/DT continuously/RB growing/VBG myeloid/JJ leukemic/JJ cell/NN line/NN ,/, HL60/NN ,/, and/CC normal/JJ cells/NNS stimulated/VBN into/IN cycle/NN ,/, phyto- hemagglutinin/NN (/( PHA/NN )/) -stimulated/JJ normal/JJ human/JJ peripheral/JJ blood/NN lymphocytes/NNS (/( PBL/NN )/) ./. 
The/DT binding/NN activity/NN of/IN transcription/NN factor/NN AP-1/NN ,/, which/WDT consists/VBZ of/IN dimers/NNS of/IN Fos/NN and/CC Jun/NN family/NN proteins/NNS ,/, was/VBD also/RB studied/VBN using/VBG a/DT gel/NN shift/NN assay/NN ./. 
We/PRP found/VBD nuclear/JJ p62c-fos/NN ,/, p39c-jun/NN ,/, and/CC AP-1/NN binding/NN activity/NN throughout/IN the/DT cell/NN cycle/NN both/CC in/IN HL60/NN cells/NNS and/CC in/IN PHA-stimulated/JJ PBL/NN ,/, and/CC we/PRP postulate/VBP that/IN these/DT proteins/NNS are/VBP required/VBN throughout/IN the/DT cell/NN cycle/NN and/CC not/RB transiently/RB in/IN the/DT G0/NN to/TO G1/NN transition/NN as/IN previous/JJ mRNA/NN studies/NNS have/VBP indicated/VBN ./. 
We/PRP demonstrated/VBD an/DT uncoupling/NN of/IN AP-1/NN binding/NN activity/NN from/IN p62c-fos/NN ,/, and/CC p39c-jun/NN AP-1/NN activity/NN was/VBD expressed/VBN more/RBR strongly/RB in/IN the/DT G1-/NN and/CC G2/M-phase/NN enriched/JJ samples/NNS than/IN in/IN the/DT S-phase/NN enriched/JJ samples/NNS of/IN HL60/NN cells/NNS ,/, while/IN levels/NNS of/IN nuclear/JJ p62c-fos/NN and/CC p39c-jun/NN were/VBD constant/JJ ./. 
Nuclei/NNS of/IN unstimulated/JJ PBL/NN from/IN different/JJ donors/NNS expressed/VBD p62c-fos/NN and/CC p39c-jun/NN ,/, but/CC AP-1/NN was/VBD not/RB detected/VBN in/IN the/DT majority/NN of/IN samples/NNS ./. 
Following/VBG PHA/NN stimulation/NN of/IN PBL/NN ,/, the/DT increase/NN in/IN AP-1/NN activity/NN was/VBD delayed/VBN with/IN respect/NN to/TO the/DT augmentation/NN of/IN p39c-jun/NN expression/NN ./. 
We/PRP also/RB observed/VBD that/IN cytoplasmic/JJ p62c-fos/NN and/CC p39c-jun/NN were/VBD present/JJ in/IN HL60/NN cells/NNS and/CC PHA-stimulated/JJ PBL/NN ./. 
However/RB ,/, no/DT cytoplasmic/JJ p62c-fos/NN was/VBD detected/VBN in/IN unstimulated/JJ PBL/NN ,/, although/IN in/IN some/DT cases/NNS cytoplasmic/JJ p39c-jun/NN was/VBD detected/VBN ,/, suggesting/VBG that/IN subcellular/JJ compartmentalization/NN of/IN these/DT proteins/NNS may/MD occur/VB under/IN certain/JJ circumstances/NNS ./. 
UI/LS -/: 96279101/CD 
TI/LS -/: Octamer/NN binding/NN factors/NNS and/CC their/PRP$ coactivator/NN can/MD activate/VB the/DT murine/JJ PU.1/NN (/( spi-1/NN )/) promoter/NN ./. 
AB/LS -/: PU.1/NN (/( spi-1/NN )/) ,/, a/DT member/NN of/IN the/DT Ets/NN transcription/NN factor/NN family/NN ,/, is/VBZ predominantly/RB expressed/VBN in/IN myeloid/JJ and/CC B/NN cells/NNS ,/, activates/VBZ many/JJ B/NN cell/NN and/CC myeloid/JJ genes/NNS ,/, and/CC is/VBZ critical/JJ for/IN development/NN of/IN both/DT of/IN these/DT lineages/NNS ./. 
Our/PRP$ previous/JJ studies/NNS (/( Chen/NNP ,/, H.M./NNP ,/, Ray-Gallet/NNP ,/, D./NNP ,/, Zhang/NNP ,/, P./NNP ,/, Hetherington/NNP ,/, C.J./NNP ,/, Gonzalez/NNP ,/, D.A./NNP ,/, Zhang/NNP ,/, D.-E./NNP ,/, Moreau-Gachelin/NNP ,/, F./NNP ,/, and/CC Tenen/NNP ,/, D.G./NNP (/( 1995/CD )/) Oncogene/NN 11/CD ,/, 1549-1560/CD )/) demonstrate/VBP that/IN the/DT PU.1/NN promoter/NN directs/VBZ cell/NN type-specific/JJ reporter/NN gene/NN expression/NN in/IN myeloid/JJ cell/NN lines/NNS ,/, and/CC that/IN PU.1/NN activates/VBZ its/PRP$ own/JJ promoter/NN in/IN an/DT autoregulatory/JJ loop/NN ./. 
Here/RB we/PRP show/VBP that/IN the/DT murine/JJ PU.1/NN promoter/NN is/VBZ also/RB specifically/RB and/CC highly/RB functional/JJ in/IN B/NN cell/NN lines/NNS as/RB well/RB ./. 
Oct-1/NN and/CC Oct-2/NN can/MD bind/VB specifically/RB to/TO a/DT site/NN at/IN base/NN pair/NN -55/CD in/FW vitro/FW ,/, and/CC this/DT site/NN is/VBZ specifically/RB protected/VBN in/IN B/NN cells/NNS in/FW vivo/FW ./. 
We/PRP also/RB demonstrate/VBP that/IN two/CD other/JJ sites/NNS contribute/VBP to/TO promoter/NN activity/NN in/IN B/NN cells/NNS ;/: an/DT Sp1/NN binding/NN site/NN adjacent/JJ to/TO the/DT octamer/NN site/NN ,/, and/CC the/DT PU.1/NN autoregulatory/NN site/NN ./. 
Finally/RB ,/, we/PRP show/VBP that/IN the/DT B/NN cell/NN coactivator/NN OBF-1/Bob1/OCA-B/NN is/VBZ only/RB expressed/VBN in/IN B/NN cells/NNS and/CC not/RB in/IN myeloid/JJ cells/NNS ,/, and/CC that/IN OBF-1/Bob1/OCA-B/NN can/MD transactivate/VB the/DT PU.1/NN promoter/NN in/IN HeLa/NN and/CC myeloid/JJ cells/NNS ./. 
This/DT B/NN cell/NN restricted/JJ coactivator/NN may/MD be/VB responsible/JJ for/IN the/DT B/NN cell/NN specific/JJ expression/NN of/IN PU.1/NN mediated/VBN by/IN the/DT octamer/NN site/NN ./. 
UI/LS -/: 96239599/CD 
TI/LS -/: Inhibition/NN of/IN p105/NN processing/NN by/IN NF-kappaB/NN proteins/NNS in/IN transiently/RB transfected/VBN cells/NNS ./. 
AB/LS -/: Regulation/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN involves/VBZ proteasome-mediated/JJ processing/NN of/IN the/DT NF-kappaB1/NN p105/NN precursor/NN protein/NN ,/, which/WDT generates/VBZ the/DT p50/NN subunit/NN of/IN NF-kappaB/NN ./. 
The/DT processing/NN of/IN p105/NN occurs/VBZ constitutively/RB in/FW vivo/FW but/CC can/MD be/VB markedly/RB enhanced/VBN by/IN various/JJ cellular/JJ activation/NN agents/NNS ,/, although/IN the/DT underlying/JJ regulatory/JJ mechanism/NN is/VBZ not/RB yet/RB clear/JJ ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP demonstrate/VBP that/IN signal-mediated/JJ induction/NN of/IN p105/NN processing/NN in/IN human/JJ T/NN cells/NNS is/VBZ associated/VBN with/IN de/FW novo/FW synthesis/NN of/IN this/DT precursor/JJ protein/NN ./. 
Transient/JJ transfection/NN studies/NNS performed/VBN in/IN COS7/NN cells/NNS revealed/VBD that/IN the/DT newly/RB synthesized/VBN p105/NN protein/NN appears/VBZ to/TO be/VB more/RBR rapidly/RB processed/VBN compared/VBN to/TO its/PRP$ accumulated/VBN form/NN that/WDT is/VBZ already/RB associated/VBN with/IN the/DT processed/VBN product/NN p50/NN ./. 
Interestingly/RB ,/, the/DT processing/NN rate/NN of/IN p105/NN is/VBZ markedly/RB inhibited/VBN in/IN cells/NNS co-transfected/VBN with/IN p50/NN or/CC other/JJ NF-kappaB/NN subunits/NNS ,/, including/VBG RelA/NN and/CC c-Rel/NN ,/, that/WDT physically/RB interact/VBP with/IN p105/NN ./. 
These/DT findings/NNS suggest/VBP that/IN the/DT processing/NN of/IN p105/NN is/VBZ subject/JJ to/TO negative/JJ regulation/NN by/IN the/DT various/JJ NF-kappaB/NN subunits/NNS ./. 
We/PRP further/RBR demonstrate/VB that/IN p105/NN undergoes/VBZ degradation/NN in/IN lipopolysaccharide-stimulated/JJ human/JJ monocytic/JJ cells/NNS ./. 
However/RB ,/, the/DT inducible/JJ degradation/NN of/IN p105/NN is/VBZ not/RB coupled/VBN with/IN the/DT generation/NN of/IN p50/NN ./. 
Together/RB ,/, these/DT studies/NNS demonstrate/VBP that/IN the/DT processing/NN and/CC inducible/JJ degradation/NN of/IN p105/NN are/VBP differentially/RB regulated/VBN ./. 
UI/LS -/: 96189121/CD 
TI/LS -/: Identification/NN of/IN an/DT inducible/JJ regulator/NN of/IN c-myb/NN expression/NN during/IN T-cell/NN activation/NN ./. 
AB/LS -/: Resting/VBG T/NN cells/NNS express/VBP very/RB low/JJ levels/NNS of/IN c-Myb/NN protein/NN ./. 
During/IN T-cell/NN activation/NN ,/, c-myb/NN expression/NN is/VBZ induced/VBN and/CC much/JJ of/IN the/DT increase/NN in/IN expression/NN occurs/VBZ at/IN the/DT transcriptional/JJ level/NN ./. 
We/PRP identified/VBD a/DT region/NN of/IN the/DT c-myb/NN 5'/JJ flanking/JJ sequence/NN that/WDT increased/VBD c-myb/NN expression/NN during/IN T-cell/NN activation/NN ./. 
In/FW vivo/FW footprinting/NN by/IN ligation-mediated/JJ PCR/NN was/VBD performed/VBN to/TO correlate/VB in/FW vivo/FW protein/NN binding/NN with/IN functional/JJ activity/NN ./. 
A/DT protein/NN footprint/NN was/VBD visible/JJ over/IN this/DT region/NN of/IN the/DT c-myb/NN 5'/JJ flanking/JJ sequence/NN in/IN activated/VBN T/NN cells/NNS but/CC not/RB in/IN unactivated/JJ T/NN cells/NNS ./. 
An/DT electrophoretic/JJ mobility/NN shift/NN assay/NN (/( EMSA/NN )/) with/IN nuclear/JJ extract/NN from/IN activated/VBN T/NN cells/NNS and/CC an/DT oligonucleotide/NN of/IN this/DT binding/VBG site/NN demonstrated/VBD a/DT new/JJ protein-DNA/JJ complex/NN ,/, referred/VBN to/TO as/IN CMAT/NN for/IN c-myb/NN in/IN activated/VBN T/NN cells/NNS ;/: this/DT complex/NN was/VBD not/RB present/JJ in/IN unactivated/JJ T/NN cells/NNS ./. 
Because/IN the/DT binding/VBG site/NN showed/VBD some/DT sequence/NN similarity/NN with/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) binding/NN site/NN ,/, we/PRP compared/VBD the/DT kinetics/NNS of/IN induction/NN of/IN the/DT two/CD binding/VBG complexes/NNS and/CC the/DT molecular/JJ masses/NNS of/IN the/DT two/CD proteins/NNS ./. 
Studies/NNS of/IN the/DT kinetics/NNS of/IN induction/NN showed/VBD that/IN the/DT NFAT/NN EMSA/NN binding/NN complex/NN appeared/VBD earlier/RBR than/IN the/DT CMAT/NN complex/NN ./. 
The/DT NFAT/NN protein/NN migrated/VBD more/RBR slowly/RB in/IN a/DT sodium/NN dodecyl/NN sulfate-polyacrylamide/JJ gel/NN than/IN the/DT CMAT/NN protein/NN did/VBD ./. 
In/IN addition/NN ,/, an/DT antibody/NN against/IN NFAT/NN did/VBD not/RB cross-react/VB with/IN the/DT CMAT/NN protein/NN ./. 
The/DT appearance/NN of/IN the/DT CMAT/NN binding/NN complex/NN was/VBD inhibited/VBN by/IN both/CC cyclosporin/NN A/NN and/CC rapamycin/NN ./. 
The/DT CMAT/NN protein/NN appears/VBZ to/TO be/VB a/DT novel/JJ inducible/JJ protein/NN involved/VBN in/IN the/DT regulation/NN of/IN c-myb/NN expression/NN during/IN T-cell/NN activation/NN ./. 
UI/LS -/: 96210575/CD 
TI/LS -/: CNI-1493/NN inhibits/VBZ monocyte/macrophage/JJ tumor/NN necrosis/NN factor/NN by/IN suppression/NN of/IN translation/NN efficiency/NN ./. 
AB/LS -/: Tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) mediates/VBZ a/DT wide/JJ variety/NN of/IN disease/NN states/NNS including/VBG septic/JJ shock/NN ,/, acute/JJ and/CC chronic/JJ inflammation/NN ,/, and/CC cachexia/NN ./. 
Recently/RB ,/, a/DT multivalent/JJ guanylhydrazone/NN (/( CNI-1493/NN )/) developed/VBN as/IN an/DT inhibitor/NN of/IN macrophage/NN activation/NN was/VBD shown/VBN to/TO suppress/VB TNF/NN production/NN and/CC protect/NN against/IN tissue/NN inflammation/NN and/CC endotoxin/NN lethality/NN [/( Bianchi/NNP ,/, M./NNP ,/, Ulrich/NNP ,/, P./NNP ,/, Bloom/NNP ,/, O./NNP ,/, Meistrell/NNP ,/, M./NNP ,/, Zimmerman/NNP ,/, G.A./NNP ,/, Schmidtmayerova/NNP ,/, H./NNP ,/, Bukrinsky/NNP ,/, M./NNP ,/, Donnelley/NNP ,/, T./NNP ,/, Bucala/NNP ,/, R./NNP ,/, Sherry/NNP ,/, B./NNP ,/, Manogue/NNP ,/, K.R./NNP ,/, Tortolani/NNP ,/, A.J./NNP ,/, Cerami/NNP ,/, A./NNP &/CC Tracey/NNP ,/, K.J./NNP (/( 1995/CD )/) Mol.Med.1/NNP ,/, 254-266/CD ,/, and/CC Bianchi/NNP ,/, M./NNP ,/, Bloom/NNP ,/, O./NNP ,/, Raabe/NNP ,/, T./NNP ,/, Cohen/NNP ,/, P./NNP S./NNP ,/, Chesney/NNP ,/, J./NNP ,/, Sherry/NNP ,/, B./NNP ,/, Schmidtmayerova/NNP ,/, H./NNP ,/, Zhang/NNP ,/, X./NNP ,/, Bukrinsky/NNP ,/, M./NNP ,/, Ulrich/NNP ,/, P./NNP ,/, Cerami/NNP ,/, A./NNP &/CC Tracey/NNP ,/, J./NNP (/( 1996/CD )/) J.Exp.Med./NNP ,/, in/IN press/NN ]/) ./. 
We/PRP have/VBP now/RB elucidated/VBN the/DT mechanism/NN by/IN which/WDT CNI-1493/NN inhibits/VBZ macrophage/NN TNF/NN synthesis/NN and/CC show/VBP here/RB that/IN it/PRP acts/VBZ through/IN suppression/NN of/IN TNF/NN translation/NN efficiency/NN ./. 
CNI-1493/NN blocked/VBD neither/CC the/DT lipopolysaccharide/NN (/( LPS/NN )/) -induced/JJ increases/NNS in/IN the/DT expression/NN of/IN TNF/NN mRNA/NN nor/CC the/DT translocation/NN of/IN nuclear/JJ factor/NN NF-kappa/NN B/NN to/TO the/DT nucleus/NN in/IN macrophages/NNS activated/VBN by/IN 15/CD min/NN of/IN LPS/NN stimulation/NN ,/, indicating/VBG that/IN CNI-1493/NN does/VBZ not/RB interfere/VB with/IN early/JJ NF-kappa/NN B-mediated/JJ transcriptional/JJ regulation/NN of/IN TNF/NN ./. 
However/RB ,/, synthesis/NN of/IN the/DT 26-kDa/JJ membrane/NN form/NN of/IN TNF/NN was/VBD effectively/RB blocked/VBN by/IN CNI-1493/NN ./. 
Further/RB evidence/NN for/IN the/DT translational/JJ suppression/NN of/IN TNF/NN is/VBZ given/VBN by/IN experiments/NNS using/VBG chloram-phenicol/NN acetyltransferase/NN (/( CAT/NN )/) constructs/VBZ containing/VBG elements/NNS of/IN the/DT TNF/NN gene/NN that/WDT are/VBP involved/VBN in/IN TNF/NN translational/JJ regulation/NN ./. 
Both/CC the/DT 5'/JJ and/CC 3'/JJ untranslated/JJ regions/NNS of/IN the/DT TNF/NN gene/NN were/VBD required/VBN to/TO elicit/VB maximal/JJ translational/JJ suppression/NN by/IN CNI-1493/NN ./. 
Identification/NN of/IN the/DT molecular/JJ target/NN through/IN which/WDT CNI- 1493/NN inhibits/VBZ TNF/NN translation/NN should/MD provide/VB insight/NN into/IN the/DT regulation/NN of/IN macrophage/NN activation/NN and/CC mechanisms/NNS of/IN inflammation/NN ./. 
UI/LS -/: 96198880/CD 
TI/LS -/: Soluble/JJ tumor/NN necrosis/NN factor/NN receptors/NNS inhibit/VBP phorbol/NN myristate/NN acetate/NN and/CC cytokine-induced/JJ HIV-1/NN expression/NN chronically/RB infected/JJ U1/NN cells/NNS ./. 
AB/LS -/: Recombinant/JJ human/JJ tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) binding/NN protein-1/NN (/( r-h/JJ TBP-1/NN )/) and/CC recombinant/JJ human/JJ soluble/JJ dimeric/JJ TNF/NN receptor/NN (/( rhu/JJ TNFR/NN :/: Fc/NN )/) were/VBD used/VBN to/TO determine/VB the/DT relative/JJ contributions/NNS of/IN TNF/NN to/TO phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) and/CC cytokine-induced/JJ human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) replication/NN in/IN chronically/RB infected/JJ cell/NN lines/NNS ./. 
Treatment/NN of/IN HIV-1-infected/JJ promonocytic/JJ U1/NN cells/NNS with/IN r-h-TBP-1/NN or/CC rhu/JJ TNFR/NN :/: Fc/NN reduced/VBD PMA-induced/JJ HIV-1/NN p24/NN antigen/NN production/NN in/IN a/DT concentration-dependent/JJ manner/NN ,/, with/IN a/DT maximal/JJ inhibition/NN of/IN approximately/RB 90/CD %/NN ./. 
Maximal/JJ inhibition/NN of/IN p24/NN antigen/NN production/NN in/IN T-lymphocytic/JJ ACH-2/NN cells/NNS was/VBD 47/CD %/NN with/IN r-hTBP-1/NN and/CC 42/CD %/NN with/IN rhu/JJ TNFR/NN :/: Fc/NN ./. 
r-hTBP-1/NN and/CC rhu/NN TNFR/NN :/: Fc/NN also/RB decreased/VBD p24/NN antigen/NN synthesized/VBN by/IN U1/NN cells/NNS in/IN response/NN to/TO other/JJ stimuli/NNS ,/, including/VBG phytohemagglutinin/NN (/( PHA/NN )/) -induced/JJ supernatant/NN ,/, granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN ,/, interleukin-6/NN ,/, and/CC TNF/NN ./. 
Addition/NN of/IN r-hTBP-1/NN to/TO U1/NN cells/NNS during/IN the/DT last/JJ 4/CD h/NN of/IN a/DT 24/CD h/NN incubation/NN with/IN PMA/NN still/RB inhibited/VBD p24/NN antigen/NN production/NN by/IN 15/CD %/NN ./. 
U1/NN cells/NNS stimulated/VBN with/IN 10/CD (/( -7/CD )/) M/NN PMA/NN released/VBD approximately/RB 1/CD ng/ml/NN endogenous/JJ TBP-1/NN with/IN an/DT initial/JJ peak/NN observed/VBN at/IN 1/CD h/NN and/CC a/DT second/JJ peak/NN at/IN 24/CD h/NN after/IN PMA/NN stimulation/NN ./. 
r-hTBP-1/NN also/RB partially/RB reversed/VBD inhibition/NN of/IN U1/NN cellular/JJ proliferation/NN caused/VBN by/IN PMA/NN ./. 
Both/CC r-hTBP-1/NN and/CC rhu/JJ TNFR/NN :/: Fc/NN blocked/VBD PMA/NN induction/NN of/IN nuclear/JJ factor/NN (/( NK/NN )/) - kappa/NN B/NN DNA-binding/JJ activity/NN in/IN U1/NN cells/NNS in/IN association/NN with/IN decreases/NNS in/IN HIV-1/NN replication/NN ./. 
We/PRP conclude/VBP that/IN soluble/JJ TNF/NN receptors/NNS can/MD inhibit/VB stimuli-induced/JJ HIV-1/NN expression/NN and/CC NK- kappa/NN B/NN DNA-binding/JJ activity/NN in/IN chronically/RB infected/JJ U1/NN cells/NNS ./. 
UI/LS -/: 96239534/CD 
TI/LS -/: Transcriptional/JJ activation/NN of/IN RNA/NN polymerase/NN III-dependent/JJ genes/NNS by/IN the/DT human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD tax/NN protein/NN ./. 
AB/LS -/: The/DT human/JJ T-cell/NN leukemia/NN virus-encoded/JJ tax/NN protein/NN is/VBZ a/DT potent/JJ activator/NN of/IN many/JJ viral/JJ and/CC cellular/JJ genes/NNS transcribed/VBN by/IN RNA/NN polymerase/NN II/CD ./. 
We/PRP find/VBP that/IN both/CC chromatin/NN and/CC cell/NN extracts/NNS derived/VBN from/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1-infected/JJ human/JJ T/NN lymphocytes/NNS support/VBP higher/JJR levels/NNS of/IN 5S/NN rRNA/NN and/CC tRNA/NN gene/NN transcription/NN than/IN chromatin/NN or/CC extracts/NNS from/IN uninfected/JJ T/NN lymphocytes/NNS ./. 
The/DT viral/JJ protein/NN Tax/NN was/VBD likely/JJ responsible/JJ for/IN this/DT higher/JJR level/NN of/IN class/NN II/CD gene/NN transcription/NN ,/, as/IN purified/VBN Tax/NN was/VBD found/VBN to/TO stimulate/VB both/DT genes/NNS when/WRB added/VBN to/TO the/DT uninfected/JJ cell/NN extract/NN or/CC in/IN reconstituted/VBN systems/NNS ./. 
Both/CC limiting-component/JJ transcription/NN assays/NNS and/CC DNA/NN binding/NN assays/NNS identified/VBD the/DT class/NN III/CD gene/NN transcription/NN factor/NN TFIIIB/NN as/IN the/DT principle/NN target/NN of/IN Tax/NN activity/NN ./. 
Surprisingly/RB ,/, we/PRP find/VBP that/IN Tax/NN increases/VBZ the/DT effective/JJ concentration/NN of/IN active/JJ TFIIIB/NN molecules/NNS ./. 
These/DT data/NNS suggest/VBP that/IN Tax/NN stimulates/VBZ RNA/NN polymerase/NN III-dependent/JJ gene/NN expression/NN by/IN accelerating/VBG the/DT rate/NN and/or/CC extent/NN of/IN transcription/NN initiation/NN complex/NN assembly/NN ./. 
UI/LS -/: 96184651/CD 
TI/LS -/: Expression/NN of/IN Retinoid/NN X/NN Receptor/NN alpha/NN is/VBZ increased/VBN upon/IN monocytic/JJ cell/NN differentiation/NN ./. 
AB/LS -/: 1/CD alpha, 25-Dihydroxyvitamin/NN D3/NN (/( VD/NN )/) is/VBZ a/DT potent/JJ inducer/NN of/IN monocytic/JJ differentiation/NN of/IN both/CC normal/JJ and/CC leukemic/JJ cells/NNS ./. 
Its/PRP$ effects/NNS are/VBP mediated/VBN by/IN its/PRP$ nuclear/JJ receptor/NN (/( VDR/NN )/) ./. 
Efficient/JJ gene/NN activation/NN requires/VBZ the/DT heterodimerization/NN of/IN VDR/NN with/IN Retinoid/NN X/NN Receptors/NNS (/( RXR/NN )/) ./. 
In/IN the/DT present/JJ study/NN using/VBG specific/JJ antibodies/NNS ,/, we/PRP analyzed/VBD the/DT expression/NN of/IN the/DT RXR/NN alpha/NN protein/NN in/IN blood/NN mononuclear/JJ cells/NNS from/IN acute/JJ myeloid/JJ patients/NNS (/( AML/NN )/) (/( 10/CD cases/NNS )/) and/CC from/IN myelomonocytic/JJ cell/NN lines/NNS arrested/VBN at/IN different/JJ stages/NNS of/IN differentiation/NN ./. 
We/PRP observed/VBD that/IN the/DT RXR/NN alpha/NN expression/NN increased/VBD during/IN myelomonocytic/JJ differentiation/NN ,/, since/IN the/DT highest/JJS levels/NNS were/VBD found/VBN in/IN AML/NN samples/NNS and/CC in/IN myelomonocytic/JJ cell/NN lines/NNS having/VBG the/DT highest/JJS amounts/NNS of/IN monocytic/JJ precursors/NNS ./. 
We/PRP also/RB demonstrated/VBD that/IN fresh/JJ leukemic/JJ cells/NNS ,/, whatever/WDT their/PRP$ stage/NN of/IN differentiation/NN ,/, as/RB well/RB as/IN myelomonocytic/JJ cell/NN lines/NNS ,/, respond/VB to/TO VD/NN by/IN an/DT increase/NN in/IN RXR/NN alpha/NN levels/NNS ./. 
Combinations/NNS of/IN all-trans/JJ retinoic/JJ acid/NN (/( RA/NN )/) and/CC VD/NN ,/, in/IN some/DT cases/NNS ,/, increased/VBD this/DT effect/NN ./. 
This/DT response/NN suggests/VBZ the/DT involvement/NN of/IN RXR/NN alpha/NN in/IN monocytic/JJ differentiation/NN upon/IN VD/NN treatment/NN ./. 
UI/LS -/: 96202516/CD 
TI/LS -/: Expression/NN of/IN p13MTCP1/NN is/VBZ restricted/JJ to/TO mature/VB T-cell/NN proliferations/NNS with/IN t(X;14)/NN translocations/NNS ./. 
AB/LS -/: T-cell/NN prolymphocytic/JJ leukemia/NN (/( T-PLL/NN )/) ,/, a/DT rare/JJ form/NN of/IN mature/JJ T-cell/NN leukemias/NNS ,/, and/CC ataxia/NN telangiectasia/NN clonal/JJ proliferation/NN ,/, a/DT related/JJ condition/NN occurring/NN in/IN patients/NNS suffering/VBG from/IN ataxia/NN telangiectasia/NN ,/, have/VBP been/VBN associated/VBN to/TO translocations/NNS involving/VBG the/DT 14q32.1/NN or/CC Xq28/NN regions/NNS ,/, where/WRB are/VBP located/JJ the/DT TCL1/NN and/CC MTCP1/NN putative/JJ oncogenes/NNS ,/, respectively/RB ./. 
The/DT MTCP1/NN gene/NN is/VBZ involved/VBN in/IN the/DT t(X;14)(q28;q11)/NN translocation/NN associated/VBN with/IN these/DT T-cell/NN proliferations/NNS ./. 
Alternative/JJ splicing/NN generates/VBZ type/NN A/NN and/CC B/NN transcripts/NNS that/WDT potentially/RB encode/VBP two/CD entirely/RB distinct/JJ proteins/NNS ;/: type/NN A/NN transcripts/NNS code/VBP for/IN a/DT small/JJ mitochondrial/JJ protein/NN ,/, p8MTCP1/NN ,/, and/CC type/NN B/NN transcripts/NNS ,/, containing/VBG an/DT additional/JJ open/NN reading/NN frame/NN ,/, may/MD code/VBP for/IN 107/CD amino-acid/JJ protein/NN ,/, p13MTCP1/NN ./. 
The/DT recently/RB cloned/VBN TCL1/NN gene/NN ,/, also/RB involved/VBN in/IN translocations/NNS and/CC inversions/NNS associated/VBN with/IN T-cell/NN proliferations/NNS ,/, codes/VBZ for/IN a/DT 14-kD/JJ protein/NN that/WDT displays/VBZ significant/JJ homology/NN with/IN p13MTCP1/NN ./. 
We/PRP have/VBP generated/VBN rabbit/NN antisera/NNS against/IN this/DT putative/JJ p13MTCP1/NN protein/NN and/CC screened/VBN for/IN expression/NN of/IN p13MTCP1/NN normal/JJ lymphoid/JJ tissues/NNS and/CC 33/CD cases/NNS of/IN immature/JJ and/CC mature/JJ lymphoid/JJ T-cell/NN proliferations/NNS using/VBG a/DT sensitive/JJ Western/NN blot/NN assay/NN ./. 
We/PRP also/RB investigated/VBD the/DT MTCP1/NN locus/NN configuration/NN by/IN Southern/NN blot/NN analysis/NN ./. 
The/DT p13MTCP1/NN protein/NN was/VBD detected/VBN in/IN the/DT three/CD T-cell/NN proliferations/NNS with/IN MTCP1/NN rearrangements/NNS because/IN of/IN t(X;14)/NN translocations/NNS ,/, but/CC neither/CC in/IN normal/JJ resting/VBG and/CC activated/VBN lymphocytes/NNS nor/CC in/IN the/DT other/JJ T-cell/NN leukemias/NNS ./. 
Our/PRP$ data/NNS support/VBP the/DT hypothesis/NN that/IN p13MTCP1/NN and/CC p14TCL1/NN form/VBP a/DT new/JJ protein/NN family/NN that/WDT plays/VBZ a/DT key/JJ role/NN in/IN the/DT pathogenesis/NN of/IN T-PLL/NN and/CC related/JJ conditions/NNS ./. 
UI/LS -/: 96223984/CD 
TI/LS -/: Preassociation/NN of/IN STAT1/NN with/IN STAT2/NN and/CC STAT3/NN in/IN separate/JJ signalling/NN complexes/NNS prior/RB to/TO cytokine/NN stimulation/NN ./. 
AB/LS -/: A/DT variety/NN of/IN cytokines/NNS and/CC growth/NN factors/NNS act/VBP through/IN an/DT induction/NN of/IN gene/NN expression/NN mediated/VBN by/IN a/DT family/NN of/IN latent/JJ transcription/NN factors/NNS called/VBN STAT/NN (/( signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN )/) proteins/NNS ./. 
Ligand-induced/JJ tyrosine/NN phosphorylation/NN of/IN the/DT STATs/NNS promotes/VBZ their/PRP$ homodimer/NN and/CC heterodimer/NN formation/NN and/CC subsequent/JJ nuclear/JJ translocation/NN ./. 
We/PRP demonstrate/VBP here/RB that/IN STAT/NN protein/NN heterocomplexes/NNS exist/VBP prior/RB to/TO cytokine/NN treatment/NN ./. 
When/WRB unstimulated/JJ HeLa/NN cells/NNS are/VBP ruptured/VBN in/IN hypotonic/JJ buffer/NN without/IN salt/NN or/CC detergent/NN ,/, immunoadsorption/NN of/IN either/CC STAT1/NN or/CC STAT2/NN from/IN the/DT resulting/VBG cytosol/NN yields/VBZ coimmunoadsorption/NN of/IN the/DT other/JJ STAT/NN protein/NN ./. 
Similarly/RB ,/, STAT1-STAT3/NN heterocomplexes/NNS are/VBP coimmunoadsorbed/VBN from/IN hypotonic/JJ cytosol/NN ./. 
STAT1/NN and/CC STAT2/NN or/CC STAT1/NN and/CC STAT3/NN translated/VBN in/IN reticulocyte/NN lysate/NN spontaneously/RB form/VBP heterocomplexes/NNS when/WRB the/DT translation/NN lysates/NNS are/VBP mixed/VBN at/IN 0/CD degrees/NNS C/NN ./. 
Our/PRP$ data/NNS suggest/VBP that/IN interferon-alpha/NN /beta-induced/JJ tyrosine/NN phosphorylation/NN increases/VBZ the/DT stability/NN of/IN a/DT preexisting/JJ ,/, latent/JJ ,/, STAT1-STAT2/JJ signaling/NN complex/NN ./. 
Newly/RB translated/VBN STAT1/NN binds/VBZ in/IN equilibrium/NN fashion/NN to/TO STAT2/NN and/CC STAT3/NN ,/, but/CC we/PRP show/VBP that/IN STAT2/NN and/CC STAT3/NN exist/VBP in/IN separate/JJ heterocomplexes/NNS with/IN STAT1/NN ,/, consistent/JJ with/IN a/DT model/NN in/IN which/WDT STAT1/NN contains/VBZ a/DT common/JJ binding/VBG site/NN for/IN other/JJ STAT/NN proteins/NNS ./. 
UI/LS -/: 96195539/CD 
TI/LS -/: Interferon-gamma/NN modulates/VBZ the/DT lipopolysaccharide-induced/JJ expression/NN of/IN AP-1/NN and/CC NF-kappa/NN B/NN at/IN the/DT mRNA/NN and/CC protein/NN level/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: Interferon-gamma/NN (/( IFN-gamma/NN )/) modulates/VBZ the/DT expression/NN of/IN several/JJ cytokines/NNS by/IN human/JJ monocytes/NNS at/IN the/DT transcriptional/JJ level/NN ./. 
In/IN view/NN of/IN these/DT findings/NNS ,/, we/PRP analyzed/VBD the/DT effects/NNS of/IN IFN-gamma/NN on/IN the/DT expression/NN of/IN different/JJ transcription/NN factors/NNS in/IN activated/VBN human/JJ monocytes/NNS ./. 
Priming/NN of/IN human/JJ monocytes/NNS with/IN IFN-gamma/NN resulted/VBD in/IN the/DT down/JJ regulation/NN of/IN c-fos/NN and/CC c-jun/NN mRNA/NN in/IN response/NN to/TO stimulation/NN with/IN lipopolysaccharide/NN (/( LPS/NN )/) compared/VBN to/TO the/DT effects/NNS of/IN LPS/NN alone/RB ./. 
Not/RB only/RB was/VBD this/DT effect/NN observed/VBN at/IN the/DT mRNA/NN level/NN ,/, but/CC activator/NN protein-1/NN (/( AP-1/NN )/) DNA/NN binding/NN capacity/NN was/VBD affected/VBN as/RB well/RB ,/. A/DT strong/JJ reduction/NN was/VBD observed/VBN in/IN the/DT LPS-induced/JJ DNA-binding/JJ activity/NN of/IN AP-1/NN in/IN the/DT presence/NN of/IN IFN-gamma/NN ./. 
LPS-stimulated/JJ monocytes/NNS showed/VBD an/DT increased/VBN expression/NN of/IN p105/NN mRNA/NN ,/, the/DT precursor/NN of/IN the/DT p50/NN subunit/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ,/, while/IN no/DT effect/NN was/VBD noticed/VBN on/IN the/DT expression/NN of/IN p65/NN mRNA/NN ./. 
In/IN contrast/NN ,/, IFN-gamma/NN priming/NN did/VBD not/RB affect/VB the/DT expression/NN of/IN p105/NN transcripts/NNS but/CC enhanced/VBD the/DT expression/NN of/IN p65/NN mRNA/NN (/( two-fold/RB )/) ./. 
Priming/VBG with/IN IFN-gamma/NN followed/VBN by/IN LPS/NN stimulation/NN resulted/VBD in/IN a/DT further/JJ increase/NN in/IN the/DT expression/NN of/IN p65/NN mRNA/NN ./. 
This/DT was/VBD due/JJ to/TO an/DT increase/NN in/IN the/DT half-life/NN of/IN p65/NN mRNA/NN (/( 75/CD vs/CC 150/CD minutes/NNS )/) ./. 
Electrophoretic/JJ mobility/NN shift/VB assays/NNS (/( EMSAs/NNS )/) demonstrated/VBD that/IN unstimulated/JJ monocytes/NNS predominantly/RB expressed/VBD p50/NN NF-kappa/NN B/NN ./. 
Stimulation/NN with/IN LPS/NN or/CC IFN-gamma/NN resulted/VBD in/IN the/DT expression/NN of/IN p50/NN and/CC p65/NN subunits/NNS ,/, while/IN the/DT combination/NN of/IN IFN-gamma/NN plus/CC LPS/NN caused/VBD a/DT further/JJ increase/NN in/IN the/DT expression/NN of/IN NF-kappa/NN B/NN ./. 
With/IN Western/NN blotting/NN ,/, it/PRP was/VBD shown/VBN that/IN nuclear/JJ extracts/NNS from/IN monocytes/NNS contained/VBD p50/NN and/CC p65/NN protein/NN in/IN response/NN to/TO LPS/NN and/CC IFN-gamma/NN stimulation/NN ./. 
However/RB ,/, the/DT combined/JJ stimulation/NN did/VBD not/RB result/VB in/IN enhanced/VBN p50/NN and/CC p65/NN protein/NN expression/NN ./. 
The/DT effects/NNS of/IN IFN-gamma/NN on/IN the/DT transcription/NN factors/NNS were/VBD specific/JJ ,/, since/IN no/DT change/NN was/VBD observed/VBN in/IN the/DT expression/NN of/IN NF-IL-6/NN or/CC I/NN kappa/NN B/NN alpha/NN ,/, the/DT inhibitor/NN of/IN NF-kappa/NN B/NN ./. 
We/PRP conclude/VBP that/IN the/DT effects/NNS of/IN IFN-gamma/NN on/IN the/DT expression/NN of/IN the/DT transcription/NN factors/NNS AP-1/NN and/CC NF-kappa/NN B/NN may/MD be/VB important/JJ for/IN the/DT modulatory/JJ effects/NNS of/IN IFN-gamma/NN on/IN the/DT cytokine/NN expression/NN in/IN activated/VBN human/JJ monocytes/NNS ./. 
UI/LS -/: 96268712/CD 
TI/LS -/: HIV-1/NN tat/NN induces/VBZ the/DT expression/NN of/IN a/DT new/JJ hematopoietic/JJ cell-specific/JJ transcription/NN factor/NN and/CC downregulates/VBZ MIP-1/NN alpha/NN gene/NN expression/NN in/IN activated/VBN T-cells/NNS ./. 
AB/LS -/: MIP-1/NN alpha/NN is/VBZ a/DT secreted/VBN chemokine/NN which/WDT can/MD inhibit/VB hematopoietic/JJ stem/NN cells/NNS and/CC modulate/VB inflammatory/JJ responses/NNS ./. 
It/PRP is/VBZ also/RB an/DT inhibitor/NN of/IN HIV/NN replication/NN in/IN CD8+/JJ T-cells/NNS ./. 
The/DT expression/NN of/IN MIP-1/NN alpha/NN is/VBZ induced/VBN during/IN cellular/JJ activation/NN of/IN CD4+/JJ T-cells/NNS and/CC monocytes/NNS ./. 
It/PRP is/VBZ also/RB expressed/VBN in/IN transformed/VBN B-cells/NNS ./. 
We/PRP have/VBP previously/RB identified/VBN a/DT new/JJ transcription/NN factor/NN family/NN (/( the/DT MNP/NN family/NN )/) whose/WP$ expression/NN is/VBZ crucial/JJ for/IN the/DT induction/NN of/IN MIP-1/NN alpha/NN transcription/NN during/IN cellular/JJ activation/NN and/CC in/IN transformed/VBN B/NN cells/NNS ./. 
Monocytes/NNS and/CC transformed/VBN B-cells/NNS normally/RB express/VBP MNP-1/NN strongly/RB and/CC MNP-2/NN weakly/RB ,/, while/IN T-cells/NNS strongly/RB express/VBP only/RB MNP-2/NN ./. 
Recently/RB ,/, we/PRP reported/VBD that/IN HIV-1/NN tat/NN downregulates/VBZ MIP-1/NN alpha/NN expression/NN in/IN Jurkat/NN T-cells/NNS ./. 
In/IN this/DT report/NN we/PRP show/VBP induction/NN of/IN MNP-1/NN in/IN Jurkat/NN T-cells/NNS expressing/VBG HIV-1/NN tat/NN ./. 
Expression/NN of/IN neither/CC HTLV-1/NN tax/NN in/IN Jurkat/NN T-cells/NNS nor/CC EBV/NN in/IN B-cells/NNS had/VBD any/DT effect/NN on/IN MNP-1/NN or/CC MNP-2/NN expression/NN ,/, showing/VBG that/IN the/DT effect/NN is/VBZ specific/JJ for/IN HIV-1/NN tat/NN ./. 
We/PRP propose/VBP that/IN HIV-1/NN tat/NN may/MD inhibit/VB MIP-1/NN alpha/NN expression/NN by/IN inducing/VBG MNP-1/NN expression/NN in/IN T-cells/NNS ,/, probably/RB by/IN either/CC competing/VBG with/IN MNP-2/NN for/IN binding/NN to/TO the/DT MIP-1/NN alpha/NN promoter/NN or/CC by/IN sequestering/VBG it/PRP into/IN inactive/JJ forms/NNS ./. 
UI/LS -/: 97233191/CD 
TI/LS -/: Differentiation/NN of/IN T-helper/NN lymphocytes/NNS :/: selective/JJ regulation/NN by/IN members/NNS of/IN the/DT STAT/NN family/NN of/IN transcription/NN factors/NNS ./. 
AB/LS -/: Interleukin-4/NN (/( IL-4/NN )/) and/CC interleukin-12/NN (/( IL-12/NN )/) control/VBP the/DT differentiation/NN of/IN T-helper/NN cells/NNS ./. 
Here/RB we/PRP summarize/VBP studies/NNS which/WDT investigate/VBP the/DT mechanism/NN by/IN which/WDT these/DT cytokines/NNS selectively/RB reprogramme/VBP gene/NN expression/NN in/IN T-lymphocytes/NNS ./. 
Cytokine/NN stimulation/NN leads/VBZ to/TO the/DT phosphorylation/NN of/IN specific/JJ tyrosine/NN residues/NNS within/IN the/DT intracellular/JJ domain/NN of/IN the/DT corresponding/JJ cytokine/NN receptor/NN ./. 
These/DT phosphotyrosines/NNS serve/VBP as/IN docking/NN sites/NNS for/IN latent/JJ ,/, cytoplasmic/JJ transcription/NN factors/NNS known/VBN as/IN signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( Stat/NN )/) proteins/NNS ./. 
Receptor/Stat/NN interaction/NN is/VBZ mediated/VBN by/IN the/DT src/NN homology/NN 2/CD (/( SH2/NN )/) domain/NN of/IN the/DT corresponding/JJ Stat/NN protein/NN ./. 
Although/IN Stat/NN binding/VBG to/TO the/DT intracellular/JJ domain/NN of/IN the/DT cytokine/NN receptor/NN strongly/RB depends/VBZ on/IN the/DT phosphotyrosine/NN residue/NN ,/, the/DT recruitment/NN of/IN a/DT specific/JJ Stat/NN protein/NN is/VBZ dictated/VBN by/IN amino/NN acid/NN residues/NNS C-terminal/JJ to/TO the/DT phosphotyrosine/NN ./. 
Specific/JJ docking/NN sites/NNS within/IN individual/JJ cytokine/NN receptors/NNS have/VBP been/VBN identified/VBN for/IN almost/RB all/DT Stat/NN proteins/NNS ./. 
The/DT direct/JJ coupling/NN between/IN cytokine/NN receptor/NN and/CC transcription/NN factor/NN helps/VBZ to/TO explain/VB how/WRB different/JJ cytokines/NNS elicit/VBP distinct/JJ patterns/NNS of/IN gene/NN expression/NN ./. 
UI/LS -/: 96189110/CD 
TI/LS -/: Role/NN of/IN EGR1/NN in/IN regulation/NN of/IN stimulus-dependent/JJ CD44/NN transcription/NN in/IN B/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT immediate-early/JJ gene/NN egr-1/NN encodes/VBZ a/DT transcription/NN factor/NN (/( EGR1/NN )/) that/WDT links/VBZ B-cell/NN antigen/NN receptor/NN (/( BCR/NN )/) signals/NNS to/TO downstream/JJ activation/NN events/NNS through/IN the/DT regulation/NN of/IN previously/RB unidentified/JJ target/NN genes/NNS ./. 
Here/RB we/PRP identify/VBP the/DT gene/NN encoding/VBG the/DT lymphocyte/NN homing/NN and/CC migration/NN protein/NN CD44/NN as/IN a/DT target/NN of/IN EGR1/NN regulation/NN in/IN B/NN cells/NNS ./. 
BCR-induced/JJ increases/NNS in/IN CD44/NN mRNA/NN expression/NN and/CC transcription/NN levels/NNS are/VBP shown/VBN to/TO occur/VB in/IN EGR1-expressing/JJ but/CC not/RB in/IN nonexpressing/JJ subclones/NNS of/IN the/DT B-cell/NN line/NN WEHI-231/NN ./. 
Kinetics/NNS of/IN egr-1/NN transcription/NN and/CC the/DT appearance/NN of/IN nuclear/JJ EGR1/NN protein/NN precede/VBP CD44/NN induction/NN and/CC occur/VB within/IN 30/CD min/NN after/IN stimulation/NN in/IN the/DT EGR1-expressing/JJ subclone/NN ./. 
A/DT single/JJ EGR1/NN binding/NN motif/NN is/VBZ demonstrated/VBN at/IN bp/NN -301/CD of/IN the/DT human/JJ CD44/NN promoter/NN ./. 
Cotransfection/NN of/IN a/DT CD44/NN promoter-chloramphenicol/JJ acetyltransferase/NN reporter/NN construct/NN with/IN an/DT egr-1/NN expression/NN vector/NN resulted/VBD in/IN a/DT 6.5-/CD to/TO 8.5-fold/JJ induction/NN of/IN transcriptional/JJ activity/NN relative/JJ to/TO an/DT empty/JJ expression/NN vector/NN ./. 
The/DT EGR1/NN binding/NN motif/NN was/VBD shown/VBN to/TO be/VB necessary/JJ for/IN stimulus-induced/JJ expression/NN of/IN a/DT CD44/NN promoter-chloramphenicol/JJ acetyltransferase/NN reporter/NN construct/NN in/IN nontransformed/JJ B/NN lymphocytes/NNS and/CC was/VBD required/VBN for/IN transactivation/NN by/IN an/DT EGR1/NN expression/NN vector/NN in/IN a/DT B-cell/NN line/NN ./. 
These/DT studies/NNS identify/VBP EGR1/NN as/IN an/DT intermediary/JJ linking/VBG BCR-derived/JJ signals/NNS to/TO the/DT induction/NN of/IN CD44/NN ./. 
The/DT relevance/NN of/IN these/DT molecular/JJ events/NNS to/TO BCR/NN signal/NN transduction/NN and/CC antigen-stimulated/JJ B-cell-mediated/JJ immune/JJ responses/NNS is/VBZ discussed/VBN ./. 
UI/LS -/: 96200169/CD 
TI/LS -/: Involvement/NN of/IN intracellular/JJ Ca2+/NN in/IN oxidant-induced/JJ NF-kappa/NN B/NN activation/NN ./. 
AB/LS -/: In/IN human/JJ Jurkat/NN T/NN cells/NNS and/CC its/PRP$ subclone/NN Wurzburg/NN cells/NNS oxidant/NN challenge/NN elevated/VBD [Ca2+]i/NN by/IN mobilizing/VBG Ca2+/NN from/IN intracellular/JJ stores/NNS ./. 
In/IN Jurkat/NN cells/NNS this/DT effect/NN was/VBD rapid/JJ and/CC transient/JJ ,/, but/CC in/IN Wurzburg/NN cells/NNS the/DT response/NN was/VBD slow/JJ and/CC sustained/JJ ./. 
H2O2-induced/JJ NF-kappaB/NN activation/NN in/IN Wurzburg/NN cells/NNS was/VBD not/RB influenced/VBN by/IN the/DT presence/NN of/IN extracellular/JJ EGTA/NN but/CC was/VBD totally/RB inhibited/VBN in/IN cells/NNS that/WDT were/VBD loaded/VBN with/IN esterified/VBN EGTA/NN ./. 
In/IN Jurkat/NN cells/NNS that/WDT are/VBP not/RB sensitive/JJ to/TO H2O2-induced/JJ NF-kappaB/NN activation/NN ,/, H2O2/NN potentiated/VBD NF-kappaB/NN activation/NN in/IN the/DT presence/NN of/IN sustained/JJ high/JJ [Ca2+]i/NN following/VBG thapsigargin/NN treatment/NN ./. 
NF-kappaB/NN regulatory/JJ effect/NN of/IN alpha-lipoate/NN and/CC N-acetylcysteine/NN appeared/VBD to/TO be/VB ,/, at/IN least/JJS in/IN part/NN ,/, due/JJ to/TO their/PRP$ ability/NN to/TO stabilize/VB elevation/NN of/IN [Ca2+]i/NN following/VBG oxidant/NN challenge/NN ./. 
Results/NNS of/IN this/DT study/NN indicate/VBP that/IN a/DT sustained/JJ elevated/JJ [Ca2+]i/NN is/VBZ a/DT significant/JJ factor/NN in/IN oxidant-induced/JJ NF-kappaB/NN activation/NN ./. 
UI/LS -/: 96184802/CD 
TI/LS -/: Transactivation/NN of/IN the/DT interleukin-1alpha/NN promoter/NN by/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD and/CC type/NN II/CD Tax/NN proteins/NNS ./. 
AB/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) -infected/JJ T-cell/NN lines/NNS constitutively/RB produce/VBP high/JJ levels/NNS of/IN interleukin-1alpha/NN (/( IL-1alpha/NN )/) ./. 
To/TO analyze/VB the/DT mechanisms/NNS that/WDT lead/VBP to/TO the/DT expression/NN of/IN IL-1alpha/NN in/IN HTLV-I-infected/JJ cell/NN lines/NNS ,/, we/PRP studied/VBD regulatory/JJ regions/NNS of/IN the/DT human/JJ IL-1alpha/NN promoter/NN involved/VBN in/IN activation/NN of/IN the/DT IL-1alpha/NN gene/NN ./. 
IL-1alpha/NN promoter/NN constructs/NNS drive/VBP transcription/NN of/IN the/DT chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) reporter/NN gene/NN in/IN HTLV-I-positive/JJ MT-2/NN cells/NNS ,/, which/WDT constitutively/RB produce/VBP IL-1alpha/NN ./. 
In/IN a/DT cotransfection/NN assay/NN ,/, the/DT Tax/NN protein/NN of/IN both/CC HTLV-I/NN and/CC HTLV-II/NN specifically/RB activated/VBD transcription/NN from/IN the/DT IL-1alpha/NN promoter/NN in/IN an/DT uninfected/JJ Jurkat/NN cell/NN line/NN ./. 
A/DT mutant/JJ Tax/NN protein/NN deficient/JJ in/IN transactivation/NN of/IN genes/NNS by/IN the/DT nuclear/JJ factor/NN (/( NF/NN )/) -kappaB/NN pathway/NN was/VBD unable/JJ to/TO induce/VB transcriptional/JJ activity/NN of/IN IL-1alpha/NN promoter-CAT/JJ|NN constructs/NNS ,/, but/CC was/VBD rescued/VBN by/IN exogenous/JJ provision/NN of/IN p65/p50/NN NF-kappaB/NN ./. 
We/PRP found/VBD that/IN two/CD IL-1alpha/NN kappaB-like/JJ sites/NNS (/( positions/NNS -1,065/CD to/TO -1,056/CD and/CC +646/CD to/TO +655/CD )/) specifically/RB formed/VBD a/DT complex/JJ with/IN NF-kappaB-containing/JJ nuclear/JJ extract/NN from/IN MT-2/NN cells/NNS and/CC that/IN NF-kappaB/NN bound/VBD with/IN higher/JJR affinity/NN to/TO the/DT 3'/JJ NF-kappaB/NN binding/NN site/NN than/IN to/TO the/DT 5'/JJ NF-kappaB/NN site/NN ./. 
Moreover/RB ,/, deletion/NN of/IN either/CC 5'/JJ or/CC 3'/JJ NF-kappaB/NN sites/NNS reduced/VBD IL-1alpha/NN promoter/NN activity/NN in/IN MT-2/NN cells/NNS and/CC transactivation/NN of/IN the/DT IL-1alpha/NN promoter/NN by/IN exogenous/JJ NF-kappaB/NN and/CC Tax/NN in/IN Jurkat/NN cells/NNS ./. 
These/DT data/NNS suggest/VBP a/DT general/JJ role/NN for/IN Tax/NN induction/NN of/IN IL-1alpha/NN gene/NN transcription/NN by/IN the/DT NF-kappaB/NN pathway/NN ./. 
Expression/NN of/IN IL-1alpha/NN by/IN HTLV-I/NN productively/RB infected/JJ cells/NNS may/MD be/VB important/JJ in/IN the/DT hypercalcemia/NN ,/, osteolytic/JJ bone/NN lesions/NNS ,/, neutrophilia/NN ,/, elevation/NN of/IN C-reactive/JJ protein/NN ,/, and/CC fever/NN frequently/RB seen/VBN in/IN patients/NNS with/IN HTLV-I-induced/JJ adult/JJ T-cell/NN leukemia/lymphoma/NN ./. 
UI/LS -/: 96239524/CD 
TI/LS -/: The/DT myeloid-cell-specific/JJ c-fes/NN promoter/NN is/VBZ regulated/VBN by/IN Sp1/NN ,/, PU.1/NN ,/, and/CC a/DT novel/JJ transcription/NN factor/NN ./. 
AB/LS -/: The/DT protein/NN product/NN of/IN the/DT c-fps/fes/NN (/( c-fes/NN )/) proto-oncogene/NN has/VBZ been/VBN implicated/VBN in/IN the/DT normal/JJ development/NN of/IN myeloid/JJ cells/NNS (/( macrophages/NNS and/CC neutrophils/NNS )/) ./. 
mRNA/NN for/IN c-fes/NN has/VBZ been/VBN detected/VBN exclusively/RB in/IN myeloid/JJ cells/NNS and/CC vascular/JJ endothelial/JJ cells/NNS in/IN adult/JJ mammals/NNS ./. 
Although/IN a/DT 13-kilobase-pair/NN (/( kb/NN )/) human/JJ c-fes/NN transgene/NN exhibits/VBZ high/JJ levels/NNS of/IN expression/NN in/IN mice/NNS ,/, the/DT sequences/NNS that/WDT confer/VBP myeloid-cell-specific/JJ expression/NN of/IN the/DT human/JJ c-fes/NN gene/NN have/VBP not/RB been/VBN defined/VBN ./. 
Transient-transfection/NN experiments/NNS demonstrated/VBD that/IN plasmids/NNS containing/VBG 446/CD bp/NN of/IN c-fes/NN 5'-flanking/JJ sequences/NNS linked/VBN to/TO a/DT luciferase/NN reporter/NN gene/NN were/VBD active/JJ exclusively/RB in/IN myeloid/JJ cells/NNS ./. 
No/DT other/JJ DNA/NN element/NN within/IN the/DT 13-kb/JJ human/JJ c-fes/NN locus/NN contained/VBD positive/JJ cis-acting/JJ elements/NNS ,/, with/IN the/DT exception/NN of/IN a/DT weakly/RB active/JJ region/NN within/IN the/DT 3'-flanking/JJ sequences/NNS ./. 
DNase/NN I/CD footprinting/NN assays/NNS revealed/VBD four/CD distinct/JJ sites/NNS that/WDT bind/VBP myeloid/JJ nuclear/JJ proteins/NNS (/( -408/CD to/TO -386/CD ,/, -293/CD to/TO -254/CD ,/, -76/CD to/TO -65/CD ,/, and/CC -34/CD to/TO +3/CD )/) ./. 
However/RB ,/, the/DT first/JJ two/CD footprints/NNS resided/VBD in/IN sequences/NNS that/WDT were/VBD largely/RB dispensable/JJ for/IN transient/JJ activity/NN ./. 
Plasmids/NNS containing/VBG 151/CD bp/NN of/IN 5'-flanking/JJ sequences/NNS confer/VBP myeloid-cell-specific/JJ gene/NN expression/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN analyses/NNS demonstrated/VBD that/IN the/DT 151-bp/JJ region/NN contains/VBZ nuclear/JJ protein/NN binding/NN sites/NNS for/IN Sp1/NN ,/, PU.1/NN ,/, and/or/CC Elf-1/NN ,/, and/CC a/DT novel/JJ factor/NN ./. 
This/DT unidentified/JJ factor/NN binds/VBZ immediately/RB 3'/JJ of/IN the/DT PU.1/Elf-1/JJ|NN sites/NNS and/CC appears/VBZ to/TO be/VB myeloid/JJ cell/NN specific/JJ ./. 
Mutation/NN of/IN the/DT PU.1/Elf-1/JJ|NN site/NN or/CC the/DT 3'/JJ site/NN (/( FP4-3'/NN )/) within/IN the/DT context/NN of/IN the/DT c-fes/NN promoter/NN resulted/VBD in/IN substantially/RB reduced/VBN activity/NN in/IN transient/JJ transfections/NNS ./. 
Furthermore/RB ,/, transient-cotransfection/JJ|NN assay/NN demonstrated/VBD that/IN PU.1/NN (/( and/CC not/RB Elf-1/NN )/) can/MD transactivate/VB the/DT c-fes/NN promoter/NN in/IN nonmyeloid/JJ cell/NN lines/NNS ./. 
We/PRP conclude/VBP that/IN the/DT human/JJ c-fes/NN gene/NN contains/VBZ a/DT strong/JJ myeloid-cell-specific/JJ promoter/NN that/WDT is/VBZ regulated/VBN by/IN Sp1/NN ,/, PU.1/NN ,/, and/CC a/DT novel/JJ transcription/NN factor/NN ./. 
UI/LS -/: 96310948/CD 
TI/LS -/: IL-10/NN inhibits/VBZ nuclear/JJ factor-kappa/NN B/Rel/NN nuclear/JJ activity/NN in/IN CD3-stimulated/JJ human/JJ peripheral/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: IL-10/NN markedly/RB reduces/VBZ nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/Rel/NN nuclear/JJ activity/NN induced/VBN in/IN PBMC/NN by/IN stimulation/NN with/IN the/DT anti-CD3/JJ mAb/NN OKT3/NN ./. 
The/DT inhibition/NN is/VBZ exerted/VBN specifically/RB on/IN the/DT NF-kappa/NN B/Rel/NN activation/NN induced/VBN by/IN mAb/NN OKT3/NN ,/, and/CC not/RB that/DT produced/VBN by/IN PMA/NN ./. 
As/IN judged/VBN by/IN supershifting/VBG the/DT DNA-protein/JJ complexes/NNS with/IN Abs/NN recognizing/VBG specific/JJ components/NNS of/IN the/DT NF-kappa/NN B/Rel/NN protein/NN family/NN ,/, the/DT p50/p65/NN (/( Rel/NN A/NN )/) heterodimeric/JJ form/NN of/IN NF-kappa/NN B/NN is/VBZ primarily/RB affected/VBN ./. 
The/DT maximal/JJ effect/NN is/VBZ observed/VBN at/IN the/DT IL-10/NN concentration/NN of/IN 20/CD U/ml/NN ./. 
IL-10/NN inhibitory/JJ activity/NN is/VBZ exerted/VBN on/IN T/NN lymphocytes/NNS and/CC is/VBZ mediated/VBN by/IN monocytes/NNS ./. 
Indeed/RB ,/, monocytes/NNS pretreated/VBN with/IN IL-10/NN are/VBP able/JJ so/RB inhibit/VBP NF-kappa/NN B/NN nuclear/JJ activity/NN in/IN purified/VBN T/NN lymphocytes/NNS stimulated/VBN with/IN OKT3/NN ./. 
Soluble/JJ factors/NNS do/VBP not/RB appear/VB to/TO be/VB involved/VBN in/IN the/DT mechanism/NN of/IN inhibition/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, the/DT up-regulation/NN of/IN CD80/NN Ag/NN ,/, found/VBN on/IN monocytes/NNS obtained/VBN from/IN PBMC/NN incubated/VBN with/IN OKT3/NN ,/, is/VBZ not/RB detected/VBN after/IN addition/NN of/IN IL-10/NN ,/, and/CC the/DT anti-CD28/JJ mAb/NN CLB-CD28/1/NN restores/VBZ the/DT NF-kappa/NN B/Rel/NN nuclear/JJ activity/NN in/IN IL-10-inhibited/JJ lymphocytes/NNS ./. 
Therefore/RB ,/, the/DT NF-kappa/NN B/Rel/NN inhibition/NN might/MD be/VB ascribed/VBN to/TO a/DT lack/NN of/IN cooperation/NN between/IN accessory/NN cells/NNS and/CC T/NN lymphocytes/NNS ,/, resulting/VBG from/IN down-regulation/NN of/IN a/DT costimulatory/JJ molecule/NN ,/, such/JJ as/IN CD80/NN ,/, produced/VBN by/IN IL-10/NN on/IN activated/VBN monocytes/NNS ./. 
Our/PRP$ results/NNS demonstrate/VBP that/IN IL-10/NN can/MD inhibit/VB the/DT induction/NN of/IN NF-kappa/NN B/Rel/NN nuclear/JJ activity/NN in/IN CD3-stimulated/JJ T/NN lymphocytes/NNS ./. 
Since/IN inappropriate/JJ activation/NN of/IN kappa/NN B-driven/JJ genes/NNS has/VBZ a/DT physiopathologic/JJ role/NN in/IN a/DT number/NN of/IN diseases/NNS ,/, such/JJ as/IN HIV/NN infection/NN ,/, our/PRP$ findings/NNS support/VBP the/DT possibility/NN of/IN using/VBG this/DT cytokine/NN to/TO suppress/VB an/DT undesirable/JJ activation/NN of/IN these/DT transcription/NN factors/NNS ./. 
UI/LS -/: 96202514/CD 
TI/LS -/: Expression/NN of/IN A-myb/NN ,/, but/CC not/RB c-myb/NN and/CC B-myb/NN ,/, is/VBZ restricted/JJ to/TO Burkitt/NN 's/POS lymphoma/NN ,/, sIg+/NN B-acute/JJ lymphoblastic/JJ leukemia/NN ,/, and/CC a/DT subset/NN of/IN chronic/JJ lymphocytic/JJ leukemias/NNS ./. 
AB/LS -/: The/DT A-myb/NN gene/NN encodes/VBZ a/DT transcription/NN factor/NN that/WDT is/VBZ related/JJ both/CC functionally/RB and/CC structurally/RB to/TO the/DT v-myb/NN oncogene/NN ./. 
Following/VBG our/PRP$ observations/NNS that/IN A-myb/NN is/VBZ expressed/VBN in/IN a/DT restricted/JJ subset/NN of/IN normal/JJ mature/JJ human/JJ B/NN lymphocytes/NNS ,/, with/IN the/DT phenotype/NN CD38+/NN ,/, CD39-/NN ,/, slgM-/JJ ,/, we/PRP have/VBP now/RB investigated/VBN the/DT pattern/NN of/IN A-myb/NN expression/NN in/IN neoplastic/JJ B/NN cells/NNS representating/VBG the/DT whole/JJ spectrum/NN of/IN B-cell/NN differentiation/NN and/CC compared/VBD it/PRP to/TO that/DT of/IN c-myb/NN and/CC B-myb/NN ./. 
In/IN a/DT panel/NN of/IN 32/CD B-cell/NN lines/NNS ,/, A-myb/NN was/VBD very/RB strongly/RB expressed/VBN in/IN most/JJS Burkitt/NN 's/POS lymphoma/NN (/( BL/NN )/) cell/NN lines/NNS ,/, but/CC weak/JJ or/CC negative/JJ in/IN 2/CD pre-B/NN acute/JJ lymphoblastic/JJ leukemia/NN (/( ALL/NN )/) ,/, 4/CD non-Hodgkin/JJ 's/POS lymphoma/NN (/( NHL/NN )/) ,/, 6/CD Epstein-Barr/JJ virus-immortalized/JJ lymphoblastoid/JJ cell/NN lines/NNS ,/, and/CC 6/CD myeloma/NN lines/NNS ./. 
Protein/NN expression/NN paralleled/VBD that/DT of/IN the/DT RNA/NN ./. 
We/PRP have/VBP also/RB investigated/VBN A-myb/NN expression/NN in/IN 49/CD fresh/JJ cases/NNS of/IN B/NN leukemias/NN ./. 
Among/IN 24/CD ALL/NN ,/, 6/CD were/VBD of/IN the/DT null/JJ and/CC 11/CD of/IN the/DT common/JJ type/NN and/CC all/DT these/DT were/VBD negative/JJ for/IN A-myb/NN expression/NN ;/: on/IN the/DT other/JJ hand/NN ,/, all/DT 7/CD B-ALL/NN cases/NNS (/( slg+/JJ )/) ,/, as/RB well/RB as/IN one/CD fresh/JJ BL/NN case/NN with/IN bone/NN marrow/NN infiltration/NN ,/, expressed/VBD A-myb/NN ./. 
A-myb/NN was/VBD undetectable/JJ in/IN 4/CD prolymphocytic/JJ leukemias/NNS (/( PLL/NN )/) but/CC was/VBD strongly/RB expressed/VBN in/IN 5/20/CD (/( 25/CD %/NN )/) of/IN chronic/JJ lymphocytic/JJ leukemia/NN (/( CLL/NN )/) samples/NNS ./. 
In/IN the/DT latter/JJ A-myb/NN did/VBD not/RB correlate/VB with/IN phenotype/NN or/CC clinical/JJ stage/NN ./. 
Finally/RB ,/, we/PRP have/VBP studied/VBN the/DT progression/NN of/IN one/CD case/NN of/IN CLL/NN into/IN Richter/NN 's/POS syndrome/NN and/CC have/VBP found/VBN that/IN the/DT Richter/NN 's/POS cells/NNS expressed/VBD about/RB 25-fold/RB less/JJR A-myb/NN RNA/NN than/IN the/DT CLL/NN cells/NNS from/IN the/DT same/JJ patient/NN ./. The/DT pattern/NN of/IN c-myb/NN and/CC B-myb/NN was/VBD clearly/RB distinct/JJ from/IN that/DT of/IN A-myb/NN ./. 
C-myb/NN and/CC B-myb/NN were/VBD expressed/VBN in/IN all/DT neoplastic/JJ groups/NNS ,/, except/IN in/IN CLL/NN cells/NNS ./. 
Thus/RB ,/, A-myb/NN expression/NN ,/, unlike/IN that/DT of/IN c-myb/NN and/CC B-myb/NN ,/, is/VBZ restricted/JJ to/TO a/DT subset/NN of/IN B-cell/NN neoplasias/NN (/( in/IN particular/JJ BL/NN and/CC slg+B-ALL/NN )/) representative/NN of/IN a/DT specific/JJ stage/NN of/IN B-cell/NN differentiation/NN ./. 
This/DT expression/NN may/NN in/IN part/NN reflect/VBP expression/NN of/IN A-myb/NN by/IN the/DT normal/JJ germinal/JJ center/NN B/NN cells/NNS that/WDT are/VBP the/DT normal/JJ counterpart/NN of/IN these/DT transformed/VBN B/NN cells/NNS ./. 
The/DT data/NNS presented/VBN strongly/RB support/VBP a/DT role/NN for/IN this/DT transcription/NN factor/NN in/IN B-cell/NN differentiation/NN and/CC perhaps/RB in/IN B-cell/NN transformation/NN in/IN some/DT neoplasias/NNS ./. 
UI/LS -/: 96216453/CD 
TI/LS -/: Granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN stimulates/VBZ JAK2/NN signaling/NN pathway/NN and/CC rapidly/RB activates/VBZ p93fes/NN ,/, STAT1/NN p91/NN ,/, and/CC STAT3/NN p92/NN in/IN polymorphonuclear/JJ leukocytes/NNS ./. 
AB/LS -/: Granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) ,/, supports/VBZ proliferation/NN ,/, differentiation/NN ,/, and/CC functional/JJ activation/NN of/IN hemopoietic/JJ cells/NNS by/IN its/PRP$ interaction/NN with/IN a/DT heterodimeric/JJ receptor/NN ./. 
Although/IN GM-CSF/NN receptor/NN is/VBZ devoid/JJ of/IN tyrosine/NN kinase/NN enzymatic/JJ activity/NN ,/, GM-CSF-induced/JJ peripheral/JJ blood/NN polymorphonuclear/JJ leukocytes/NNS (/( PMN/NN )/) functional/JJ activation/NN is/VBZ mediated/VBN by/IN the/DT phosphorylation/NN of/IN a/DT large/JJ number/NN of/IN intracellular/JJ signaling/NN molecules/NNS ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN JAK2/NN becomes/VBZ tyrosine-phosphorylated/JJ in/IN response/NN to/TO GM-CSF/NN in/IN PMN/NN ./. 
In/IN the/DT present/JJ study/NN we/PRP demonstrate/VBP that/IN also/RB the/DT signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STAT/NN )/) family/NN members/NNS STAT1/NN p91/NN and/CC STAT3/NN p92/NN and/CC the/DT product/NN of/IN the/DT c-fps/fes/NN protooncogene/NN become/VBN tyrosine-phosphorylated/JJ upon/IN GM-CSF/NN stimulation/NN and/CC physically/RB associated/VBN with/IN both/CC GM-CSF/NN receptor/NN beta/NN common/JJ subunit/NN and/CC JAK2/NN ./. 
Moreover/RB GM-CSF/NN was/VBD able/JJ to/TO induce/VB JAK2/NN and/CC p93fes/NN catalytic/JJ activity/NN ./. 
We/PRP also/RB demonstrate/VBP that/IN the/DT association/NN of/IN the/DT GM-CSF/NN receptor/NN beta/NN common/JJ subunit/NN with/IN JAK2/NN is/VBZ ligand-dependent/JJ ./. 
Finally/RB we/PRP demonstrate/VBP that/IN GM-CSF/NN induces/VBZ a/DT DNA-binding/JJ complex/NN that/WDT contains/VBZ both/CC p91/NN and/CC p92/NN ./. 
These/DT results/NNS identify/VBP a/DT new/JJ signal/NN transduction/NN pathway/NN activated/VBN by/IN GM-CSF/NN and/CC provide/VBP a/DT mechanism/NN for/IN rapid/JJ activation/NN of/IN gene/NN expression/NN in/IN GM-CSF-stimulated/JJ PMN/NN ./. 
UI/LS -/: 96226013/CD 
TI/LS -/: Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD (/( EBNA2/NN )/) -oestrogen/NN receptor/NN fusion/NN proteins/NNS complement/VBP the/DT EBNA2-deficient/JJ Epstein-Barr/JJ virus/NN strain/NN P3HR1/NN in/IN transformation/NN of/IN primary/JJ B/NN cells/NNS but/CC suppress/VBP growth/NN of/IN human/JJ B/NN cell/NN lymphoma/NN lines/NNS ./. 
AB/LS -/: To/TO develop/VB a/DT transformation/NN system/NN with/IN a/DT conditional/JJ Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD (/( EBNA2/NN )/) gene/NN ,/, we/PRP fused/VBD the/DT hormone/NN binding/NN domain/NN of/IN the/DT oestrogen/NN receptor/NN to/TO the/DT N/NN or/CC C/NN terminus/NN of/IN EBNA2/NN ./. 
In/IN promoter/NN transactivation/NN as/RB well/RB as/IN primary/JJ B/NN cell/NN transformation/NN assays/NNS these/DT chimeric/JJ EBNA2/NN proteins/NNS are/VBP able/JJ to/TO substitute/VB for/IN wild-type/JJ EBNA2/NN in/IN the/DT presence/NN of/IN oestrogen/NN ./. 
Here/RB we/PRP provide/VBP evidence/NN that/IN this/DT transformation/NN is/VBZ the/DT result/NN of/IN double/JJ infection/NN of/IN a/DT cell/NN with/IN two/CD virions/NNS ,/, the/DT P3HR1/NN virus/NN genome/NN and/CC a/DT mini-EBV/NN plasmid/NN carrying/VBG the/DT chimeric/JJ EBNA2/NN gene/NN ./. 
Unexpectedly/RB ,/, expression/NN of/IN the/DT same/JJ EBNA2-oestrogen/NN receptor/NN fusion/NN protein/NN in/IN established/JJ human/JJ B/NN cell/NN lymphoma/NN lines/NNS resulted/VBD in/IN growth/NN retardation/NN or/CC growth/NN arrest/NN upon/IN the/DT addition/NN of/IN oestrogen/NN ./. 
By/IN titrating/VBG the/DT oestrogen/NN concentration/NN in/IN these/DT stably/RB transfected/VBN cells/NNS ,/, the/DT growth/NN retarding/NN and/CC the/DT transactivating/VBG function/NN of/IN the/DT chimeric/JJ proteins/NNS could/MD not/RB be/VB dissociated/VBN ./. 
We/PRP propose/VBP that/IN growth/NN inhibition/NN of/IN established/JJ B/NN cell/NN lymphoma/NN lines/NNS is/VBZ a/DT novel/JJ function/NN of/IN EBNA2/NN which/WDT has/VBZ not/RB been/VBN detected/VBN in/IN the/DT absence/NN of/IN an/DT inducible/JJ system/NN ./. 
It/PRP remains/VBZ open/JJ whether/IN the/DT growth/NN retarding/NN property/NN of/IN the/DT EBNA2-oestrogen/JJ|NN receptor/NN fusion/NN protein/NN in/IN B/NN cell/NN lymphoma/NN lines/NNS is/VBZ due/JJ to/TO unphysiologically/RB high/JJ expression/NN of/IN the/DT chimeric/JJ protein/NN or/CC to/TO interference/NN with/IN a/DT cellular/JJ programme/NN driving/VBG proliferation/NN in/IN these/DT cell/NN lines/NNS ./. 
UI/LS -/: 96278973/CD 
TI/LS -/: Tissue-specific/JJ activity/NN of/IN the/DT gammac/NN chain/NN gene/NN promoter/NN depends/VBZ upon/IN an/DT Ets/NN binding/NN site/NN and/CC is/VBZ regulated/VBN by/IN GA-binding/JJ protein/NN ./. 
AB/LS -/: The/DT gammac/NN chain/NN is/VBZ a/DT subunit/NN of/IN multiple/JJ cytokine/NN receptors/NNS (/( interleukin/NN (/( IL/NN )/) -2/CD ,/, IL-4/NN ,/, IL-7/NN ,/, IL-9/NN ,/, and/CC IL-15/NN )/) ,/, the/DT expression/NN of/IN which/WDT is/VBZ restricted/JJ to/TO hematopoietic/JJ lineages/NNS ./. 
A/DT defect/NN in/IN gammac/NN leads/VBZ to/TO the/DT X-linked/JJ severe/JJ combined/JJ immunodeficiency/NN characterized/VBN by/IN a/DT block/NN in/IN T/NN cell/NN differentiation/NN ./. 
In/IN order/NN to/TO better/RB characterize/VB the/DT human/JJ gammac/NN promoter/NN and/CC define/VB the/DT minimal/JJ tissue-specific/JJ promoter/NN region/NN ,/, progressive/JJ 5'-deletion/JJ constructs/NNS of/IN a/DT segment/NN extending/VBG 1053/CD base/NN pairs/NNS upstream/RB of/IN the/DT major/JJ transcription/NN start/NN site/NN were/VBD generated/VBN and/CC tested/VBN for/IN promoter/NN activity/NN in/IN various/JJ hematopoietic/JJ and/CC nonhematopoietic/JJ cell/NN types/NNS ./. 
The/DT -1053/+34/CD construct/NN allowed/VBD promoter/NN activity/NN only/RB in/IN cells/NNS of/IN hematopoietic/JJ origin/NN ,/, and/CC tissue/NN specificity/NN was/VBD conserved/VBN in/IN all/DT other/JJ constructs/NNS tested/VBN ./. 
The/DT region/NN downstream/JJ of/IN -90/CD appeared/VBD critical/JJ for/IN basal/JJ promoter/NN activity/NN ./. 
It/PRP contains/VBZ two/CD potential/JJ Ets/NN binding/NN sites/NNS conserved/VBN in/IN the/DT murine/JJ gammac/NN promoter/NN gene/NN ,/, one/CD of/IN which/WDT was/VBD found/VBN essential/JJ for/IN functional/JJ promoter/NN activity/NN as/IN determined/VBN by/IN mutational/JJ analysis/NN ./. 
The/DT functional/JJ Ets/NN binding/NN site/NN was/VBD found/VBN to/TO bind/VB Ets/NN family/NN proteins/NNS ,/, principally/RB GA-binding/JJ protein/NN and/CC Elf-1/NN and/CC could/MD be/VB transactivated/VBN by/IN GABPalpha/NN and/CC -beta/NN synergistically/RB ./. 
These/DT results/NNS indicate/VBP that/IN ,/, as/IN already/RB reported/VBN for/IN the/DT IL2Rbeta/NN promoter/NN ,/, GA-binding/JJ protein/NN is/VBZ an/DT essential/JJ component/NN of/IN gammac/NN basal/JJ promoter/NN activity/NN ./. 
Although/IN GABP/NN expression/NN is/VBZ not/RB restricted/JJ to/TO the/DT hematopoietic/JJ lineage/NN ,/, its/PRP$ interaction/NN with/IN other/JJ specific/JJ factors/NNS may/MD contribute/VB to/TO the/DT tissue-specific/JJ expression/NN of/IN the/DT gammac/NN gene/NN ./. 
UI/LS -/: 97047122/CD 
TI/LS -/: Detection/NN of/IN intracellular/JJ signal/NN transduction/NN molecules/NNS in/IN PBMC/NN from/IN rhesus/NN macaques/NNS and/CC sooty/JJ mangabeys/NNS ./. 
AB/LS -/: One/CD of/IN the/DT manifestations/NNS of/IN human/JJ HIV-1/NN and/CC nonhuman/JJ primate/JJ SIV/NN infection/NN that/WDT lead/VBP to/TO disease/NN is/VBZ reasoned/VBN to/TO be/VB secondary/JJ to/TO generalized/VBN T-cell/NN dysfunction/NN ./. 
The/DT molecular/JJ mechanisms/NNS associated/VBN with/IN the/DT T-cell/NN dysfunction/NN remain/VBP to/TO be/VB elucidated/VBN ./. 
To/TO address/VB this/DT issue/NN ,/, we/PRP sought/VBD to/TO utilize/VB the/DT nonhuman/JJ primate/JJ model/NN to/TO study/VB intracellular/JJ signaling/NN events/NNS in/IN cells/NNS from/IN disease-susceptible/JJ rhesus/NN macaques/NNS and/CC disease-resistant/JJ sooty/JJ mangabeys/NNS ./. 
Because/IN relatively/RB little/JJ is/VBZ known/VBN about/IN these/DT events/NNS in/IN nonhuman/JJ primates/NNS ,/, our/PRP$ laboratory/NN defined/VBD optimal/JJ conditions/NNS ,/, reagents/NNS ,/, and/CC assays/NNS for/IN the/DT study/NN of/IN signal/NN transduction/NN events/NNS in/IN cells/NNS from/IN nonhuman/JJ primates/NNS ./. 
The/DT protein/NN phosphorylation/NN patterns/NNS in/IN the/DT two/CD monkeys/NNS exhibited/VBD quantitative/JJ ,/, qualitative/JJ ,/, and/CC kinetic/JJ differences/NNS ./. 
Antibodies/NNS to/TO Stat6/NN detected/VBD a/DT unique/JJ band/NN in/IN macaque/JJ cell/NN lysates/NNS ./. 
This/DT band/NN is/VBZ markedly/RB decreased/VBN human/JJ cell/NN lysates/NNS and/CC never/RB seen/VBN in/IN mangabey/JJ cell/NN lysates/NNS ./. 
Detection/NN of/IN various/JJ other/JJ intracellular/JJ signaling/NN proteins/NNS is/VBZ also/RB described/VBN ./. 
UI/LS -/: 96189099/CD 
TI/LS -/: Genetic/JJ characterization/NN of/IN transactivation/NN of/IN the/DT human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD promoter/NN :/: Binding/NN of/IN Tax/NN to/TO Tax-responsive/JJ element/NN 1/CD is/VBZ mediated/VBN by/IN the/DT cyclic/JJ AMP-responsive/JJ members/NNS of/IN the/DT CREB/ATF/NN family/NN of/IN transcription/NN factors/NNS ./. 
AB/LS -/: To/TO achieve/VB a/DT better/JJR understanding/NN of/IN the/DT mechanism/NN of/IN transactivation/NN by/IN Tax/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD Tax-responsive/JJ element/NN 1/CD (/( TRE-1/NN )/) ,/, we/PRP developed/VBD a/DT genetic/JJ approach/NN with/IN Saccharomyces/NN cerevisiae/NN ./. 
We/PRP constructed/VBD a/DT yeast/NN reporter/NN strain/NN containing/VBG the/DT lacZ/NN gene/NN under/IN the/DT control/NN of/IN the/DT CYC1/NN promoter/NN associated/VBN with/IN three/CD copies/NNS of/IN TRE-1/NN ./. 
Expression/NN of/IN either/CC the/DT cyclic/JJ AMP/NN response/NN element-binding/NN protein/NN (/( CREB/NN )/) or/CC CREB/NN fused/VBN to/TO the/DT GAL4/NN activation/NN domain/NN (/( GAD/NN )/) in/IN this/DT strain/NN did/VBD not/RB modify/VB the/DT expression/NN of/IN the/DT reporter/NN gene/NN ./. 
Tax/NN alone/RB was/VBD also/RB inactive/JJ ./. 
However/RB ,/, expression/NN of/IN the/DT reporter/NN gene/NN was/VBD induced/VBN by/IN coexpression/NN of/IN Tax/NN and/CC CREB/NN ./. 
This/DT effect/NN was/VBD stronger/JJR with/IN the/DT GAD-CREB/NN fusion/NN protein/NN ./. 
Analysis/NN of/IN different/JJ CREB/NN mutants/NNS with/IN this/DT genetic/JJ system/NN indicated/VBD that/IN the/DT C-terminal/JJ 92/CD amino/NN acid/NN residues/NNS ,/, which/WDT include/VBP the/DT basic/JJ domain/NN and/CC the/DT leucine/NN zipper/NN ,/, are/VBP necessary/JJ and/CC sufficient/JJ to/TO mediate/VB transactivation/NN by/IN Tax/NN ./. 
To/TO identify/VB cellular/JJ proteins/NNS binding/VBG to/TO TRE-1/NN in/IN a/DT Tax-dependent/JJ manner/NN ,/, this/DT strain/NN was/VBD also/RB used/VBN to/TO screen/VB a/DT library/NN of/IN human/JJ cDNAs/NNS fused/VBN to/TO GAD/NN ./. 
Of/IN five/CD positive/JJ clones/NNS isolated/VBN from/IN 0.75/CD x/CC 10(6)/CD yeast/NN colonies/NNS ,/, four/CD were/VBD members/NNS of/IN the/DT CREB/activating/JJ transcription/NN factor/NN (/( ATF/NN )/) family/NN :/: CREB/NN ,/, two/CD isoforms/NNS of/IN the/DT cyclic/JJ AMP-responsive/JJ element/NN modulator/NN (/( CREM/NN )/) ,/, and/CC ATF-1/NN ./. 
Interestingly/RB ,/, these/DT three/CD proteins/NNS can/MD be/VB phosphorylated/VBN by/IN protein/NN kinase/NN A/NN and/CC thus/RB form/VB a/DT particular/JJ subgroup/NN within/IN the/DT CREB/ATF/NN family/NN ./. 
Expression/NN of/IN ATF-2/NN in/IN S./FW cerevisiae/FW did/VBD not/RB activate/VB TRE-1/NN in/IN the/DT presence/NN of/IN Tax/NN ./. 
This/DT shows/VBZ that/IN in/IN a/DT eukaryotic/JJ nucleus/NN ,/, Tax/NN specifically/RB interacts/VBZ with/IN the/DT basic/JJ domain-leucine/JJ zipper/NN region/NN of/IN ATF-1/NN ,/, CREB/NN ,/, and/CC CREM/NN ./. 
The/DT fifth/JJ clone/NN identified/VBN in/IN this/DT screening/NN corresponded/VBD to/TO the/DT Ku/NN autoantigen/NN p70/NN subunit/NN ./. 
When/WRB fused/VBN to/TO GAD/NN ,/, the/DT C-terminal/JJ region/NN of/IN Ku/NN was/VBD able/JJ to/TO activate/VB transcription/NN via/IN TRE-1/NN but/CC this/DT activation/NN was/VBD not/RB dependent/JJ on/IN Tax/NN ./. 
UI/LS -/: 96185499/CD 
TI/LS -/: A/DT mammalian/JJ histone/NN deacetylase/NN related/JJ to/TO the/DT yeast/NN transcriptional/JJ regulator/NN Rpd3p/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: Trapoxin/NN is/VBZ a/DT microbially/RB derived/VBN cyclotetrapeptide/NN that/WDT inhibits/VBZ histone/NN deacetylation/NN in/FW vivo/FW and/CC causes/VBZ mammalian/JJ cells/NNS to/TO arrest/VB in/IN the/DT cell/NN cycle/NN ./. 
A/DT trapoxin/NN affinity/NN matrix/NN was/VBD used/VBN to/TO isolate/VB two/CD nuclear/JJ proteins/NNS that/WDT copurified/VBD with/IN histone/NN deacetylase/NN activity/NN ./. 
Both/DT proteins/NNS were/VBD identified/VBN by/IN peptide/NN microsequencing/NN ,/, and/CC a/DT complementary/JJ DNA/NN encoding/VBG the/DT histone/NN deacetylase/NN catalytic/JJ subunit/NN (/( HD1/NN )/) was/VBD cloned/VBN from/IN a/DT human/JJ Jurkat/NN T/NN cell/NN library/NN ./. 
As/IN the/DT predicted/VBN protein/NN is/VBZ very/RB similar/JJ to/TO the/DT yeast/NN transcriptional/JJ regulator/NN Rpd3p/NN ,/, these/DT results/NNS support/VBP a/DT role/NN for/IN histone/NN deacetylase/NN as/IN a/DT key/JJ regulator/NN of/IN eukaryotic/JJ transcription/NN ./. 
UI/LS -/: 96184791/CD 
TI/LS -/: Coexpression/NN of/IN the/DT interleukin-13/NN and/CC interleukin-4/NN genes/NNS correlates/VBZ with/IN their/PRP$ physical/JJ linkage/NN in/IN the/DT cytokine/NN gene/NN cluster/NN on/IN human/JJ chromosome/NN 5q23-31/NN ./. 
AB/LS -/: Interleukin-13/NN (/( IL-13/NN )/) and/CC IL-4/NN are/VBP cytokines/NNS produced/VBN by/IN T/NN cells/NNS that/WDT are/VBP encoded/VBN by/IN the/DT q23-31/NN region/NN of/IN human/JJ chromosome/NN 5/CD ./. 
To/TO investigate/VB the/DT regulation/NN of/IN IL-13/NN gene/NN expression/NN by/IN T/NN cells/NNS ,/, we/PRP isolated/VBD and/CC sequenced/VBD the/DT human/JJ IL-13/NN gene/NN ,/, analyzed/VBD its/PRP$ 5'-flanking/JJ region/NN for/IN potential/JJ transcriptional/JJ activation/NN elements/NNS ,/, and/CC examined/VBD its/PRP$ expression/NN in/IN nontransformed/JJ T-lineage/NN cell/NN populations/NNS ./. 
The/DT human/JJ IL-13/NN gene/NN was/VBD located/JJ 12.5-kb/JJ upstream/RB of/IN the/DT IL-4/NN gene/NN and/CC 2-kb/JJ downstream/RB of/IN a/DT CpG/NN island/NN ./. 
The/DT IL-13/NN gene/NN 5'/JJ flank/JJ region/NN included/VBD a/DT segment/NN with/IN sequence/NN homology/NN to/TO P/NN elements/NNS of/IN the/DT IL-4/NN promoter/NN involved/VBN in/IN transcriptional/JJ activation/NN in/IN T/NN cells/NNS ./. 
Mutation/NN of/IN the/DT IL-13/NN P/NN element/NN site/NN significantly/RB reduced/VBD IL-13/NN promoter/NN activity/NN in/IN response/NN to/TO T-cell/NN activation/NN ./. 
Oligonucleotides/NNS containing/VBG the/DT IL-13/NN or/CC IL-4/NN P/NN element/NN sites/NNS specifically/RB bound/VBD the/DT transcriptional/JJ activator/NN protein/NN ,/, nuclear/JJ factor-activated/JJ T/NN cells/NNS ,/, preformed/JJ (/( NF-ATp/NN )/) ,/, when/WRB incubated/VBN with/IN nuclear/JJ protein/NN extracts/NNS from/IN activated/VBN T/NN cells/NNS ./. 
Similar/JJ to/TO IL-4/NN ,/, IL-13/NN mRNA/NN expression/NN was/VBD highest/JJS in/IN T-cell/NN populations/NNS enriched/VBN for/IN cells/NNS that/WDT had/VBD previously/RB been/VBN primed/VBN in/FW vivo/FW or/CC in/FW vitro/FW ,/, indicating/VBG that/IN priming/NN increases/VBZ the/DT expression/NN of/IN the/DT IL-13/NN and/CC IL-4/NN genes/NNS in/IN a/DT coordinate/JJ manner/NN ./. 
Because/IN the/DT primed/VBN T/NN cells/NNS contain/VBP higher/JJR levels/NNS of/IN nuclear/JJ NF-ATp/NN ,/, capable/JJ of/IN binding/VBG to/TO P/NN elements/NNS of/IN the/DT IL-4/NN and/CC IL-13/NN promoters/NNS ,/, than/IN do/VBP freshly-isolated/JJ T/NN cells/NNS ,/, the/DT NF-AT-binding/JJ P/NN elements/NNS are/VBP attractive/JJ candidates/NNS to/TO mediate/VB the/DT coordinate/JJ expression/NN of/IN these/DT two/CD cytokine/NN genes/NNS ./. 
UI/LS -/: 96239496/CD 
TI/LS -/: Inhibition/NN of/IN alpha/NN interferon/NN but/CC not/RB gamma/VB interferon/NN signal/NN transduction/NN by/IN phorbol/NN esters/NNS is/VBZ mediated/VBN by/IN a/DT tyrosine/NN phosphatase/NN ./. 
AB/LS -/: Previous/JJ studies/NNS have/VBP indicated/VBN that/IN the/DT expression/NN of/IN viral/JJ oncoproteins/NNS ,/, cell/NN transformation/NN ,/, or/CC phorbol/NN ester/NN treatment/NN of/IN cells/NNS can/MD inhibit/VB alpha/beta/NN interferon/NN (/( IFN-alpha/beta/NN )/) -induced/JJ gene/NN expression/NN ./. 
The/DT mechanisms/NNS by/IN which/WDT these/DT promoters/NNS of/IN cell/NN growth/NN exert/VB their/PRP$ inhibitory/JJ effects/NNS vary/VBP ,/, but/CC in/IN most/JJS instances/NNS they/PRP involve/VBP a/DT disruption/NN of/IN the/DT IFN-alpha/beta-induced/JJ transcription/NN complex/NN ISGF3/NN such/JJ that/IN the/DT DNA-binding/JJ component/NN of/IN this/DT complex/NN (/( the/DT 48-kDa/JJ ISGF3gamma/NN protein/NN )/) does/VBZ not/RB bind/VB to/TO the/DT interferon-stimulated/JJ response/NN element/NN (/( ISRE/NN )/) ./. 
In/IN this/DT report/NN ,/, we/PRP demonstrated/VBD that/IN phorbol/NN ester/NN treatment/NN of/IN human/JJ peripheral/JJ blood/NN monocytes/NNS dramatically/RB inhibits/VBZ activation/NN of/IN IFN-alpha/B-stimulated/JJ early/JJ response/NN genes/NNS but/CC by/IN a/DT mechanism/NN which/WDT does/VBZ not/RB involve/VB abrogation/NN of/IN the/DT ISRE/NN binding/NN of/IN ISGF3gamma/NN ./. 
Phorbol/NN ester/NN treatment/NN of/IN monocytes/NNS inhibited/VBD IFN/NN alpha-stimulated/JJ tyrosine/NN phosphorylation/NN of/IN the/DT transcription/NN factors/NNS Stat1alpha/NN ,/, Stat2/NN ,/, and/CC Stat3/NN and/CC of/IN the/DT tyrosine/NN kinase/NN Tyk2/NN but/CC had/VBD no/DT effect/NN on/IN IFN-gamma/NN activation/NN of/IN Stat1alpha/NN ./. 
IFNalpha-stimulated/JJ tyrosine/NN phosphorylation/NN of/IN Jak1/NN and/CC the/DT alpha/NN subunit/NN of/IN the/DT IFN-alpha/NN receptor/NN were/VBD unaffected/JJ by/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) ./. 
Moreover/RB ,/, PMA/NN caused/VBD the/DT dephosphorylation/NN of/IN Tyk2/NN but/CC not/RB of/IN Jak1/NN ,/, which/WDT was/VBD activated/VBN by/IN IFN/NN ./. 
Pretreatment/NN of/IN cells/NNS with/IN vanadate/NN prevented/VBD the/DT effects/NNS of/IN PMA/NN with/IN regard/NN to/TO PMA-induced/JJ Tyk2/NN dephosphorylation/NN ./. 
These/DT observations/NNS suggest/VBP that/IN PMA/NN exerts/VBZ its/PRP$ inhibitory/JJ effects/NNS by/IN activation/NN of/IN a/DT tyrosine/NN phosphatase/NN which/WDT selectively/RB regulates/VBZ Tyk2/NN but/CC not/RB Jak1/NN activity/NN ./. 
UI/LS -/: 96214987/CD 
TI/LS -/: Transcriptional/JJ regulation/NN of/IN the/DT interleukin-2/NN gene/NN in/IN normal/JJ human/JJ peripheral/JJ blood/NN T/NN cells/NNS ./. 
Convergence/NN of/IN costimulatory/JJ signals/NNS and/CC differences/NNS from/IN transformed/VBN T/NN cells/NNS ./. 
AB/LS -/: To/TO study/VB transcriptional/JJ regulation/NN in/IN normal/JJ human/JJ T/NN cells/NNS ,/, we/PRP have/VBP optimized/VBN conditions/NNS for/IN transient/JJ transfection/NN ./. 
Interleukin-2/NN (/( IL-2/NN )/) promoter-reporter/JJ gene/NN behavior/NN closely/RB parallels/VBZ the/DT endogenous/JJ gene/NN in/IN response/NN to/TO T/NN cell/NN receptor/NN and/CC costimulatory/JJ signals/NNS ./. 
As/IN assessed/VBN with/IN mutagenized/VBN promoters/NNS ,/, the/DT most/RBS important/JJ IL-2/NN cis-regulatory/JJ elements/NNS in/IN normal/JJ T/NN cells/NNS are/VBP the/DT proximal/JJ AP-1/NN site/NN and/CC the/DT NF- kappaB/NN site/NN ./. 
Both/CC primary/JJ activation/NN ,/, with/IN phytohemagglutinin/NN or/CC antibodies/NNS to/TO CD3/NN ,/, and/CC costimulation/NN ,/, provided/VBN by/IN pairs/NNS of/IN CD2/NN antibodies/NNS or/CC B7-positive/JJ (/( B/NN cells/NNS )/) or/CC B7-negative/JJ (/( endothelial/NN )/) accessory/JJ cells/NNS ,/, are/VBP mediated/VBN through/IN the/DT same/JJ cis-elements/NNS ./. 
Interestingly/RB ,/, the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cell/NN sites/NNS are/VBP much/RB less/RBR important/JJ in/IN normal/JJ T/NN cells/NNS than/IN in/IN Jurkat/NN T/NN cells/NNS ./. 
We/PRP conclude/VBP that/IN IL-2/NN transcriptional/JJ regulation/NN differs/VBZ in/IN tumor/NN cell/NN lines/NNS compared/VBN with/IN normal/JJ T/NN cells/NNS and/CC that/IN different/JJ costimulatory/JJ signals/NNS converge/VBP on/IN the/DT same/JJ cis-elements/NNS in/IN the/DT IL-2/NN promoter/NN ./. 
UI/LS -/: 96202494/CD 
TI/LS -/: The/DT RAR-RXR/JJ as/RB well/RB as/IN the/DT RXR-RXR/JJ pathway/NN is/VBZ involved/VBN in/IN signaling/NN growth/NN inhibition/NN of/IN human/JJ CD34+/JJ erythroid/JJ progenitor/NN cells/NNS ./. 
AB/LS -/: Previous/JJ studies/NNS have/VBP shown/VBN that/IN retinoic/JJ acid/NN (/( RA/NN )/) ,/, similar/JJ to/TO tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) ,/, can/MD act/VB as/IN a/DT bifunctional/JJ regulator/NN of/IN the/DT growth/NN of/IN bone/NN marrow/NN progenitors/NNS ,/, in/IN that/IN it/PRP can/MD stimulate/VB granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) -/: or/CC interleukin-3/NN (/( IL-3/NN )/) -induced/JJ GM/NN colony/NN formation/NN ,/, but/CC potently/RB inhibit/VBP G-CSF-induced/JJ growth/NN ./. 
The/DT present/JJ study/NN ,/, using/VBG highly/RB enriched/VBN human/JJ CD34+/JJ as/RB well/RB as/IN Lin- murine/JJ bone/NN marrow/NN progenitor/NN cells/NNS ,/, demonstrates/VBZ a/DT potent/JJ inhibitory/JJ effect/NN of/IN 9-cis-RA/NN on/IN burst-forming/JJ unit-erythroid/JJ (/( BFU-E/NN )/) colony/NN formation/NN regardless/RB of/IN the/DT cytokine/NN stimulating/NN growth/NN ./. 
Specifically/RB ,/, 9-cis-RA/NN potently/RB inhibited/VBD the/DT growth/NN of/IN BFU-E/NN response/NN to/TO erythropoietin/NN (/( Epo/NN )/) (/( 100/CD %/NN )/) ,/, stem/NN cell/NN factor/NN (/( SCF/NN )/) +/CC Epo/NN (/( 92/CD %/NN )/) ,/, IL-3/NN +/CC Epo/NN (/( 97/CD %/NN )/) ,/, IL-4/NN +/CC Epo/NN (/( 88/CD %/NN )/) ,/, and/CC IL-9/NN +/CC Epo/NN (/( 100/CD %/NN )/) ./. 
Erythroid/JJ colony/NN growth/NN was/VBD also/RB inhibited/VBN when/WRB CD34+/JJ progenitors/NNS were/VBD seeded/VBN at/IN one/CD cell/NN per/IN well/NN ,/, suggesting/VBG a/DT direct/JJ action/NN of/IN RA/NN ./. 
Using/VBG synthetic/JJ ligands/NNS to/TO retinoic/JJ acid/NN receptors/NNS (/( RARs/NNS )/) and/CC retinoid/NN X/NN receptors/NNS (/( RXRs/NNS )/) that/WDT selectively/RB bind/VBP and/CC activate/VBP RAR-RXR/NN or/CC RXR-RXR/JJ dimers/NNS ,/, respectively/RB ,/, we/PRP dissected/VBD the/DT involvement/NN of/IN the/DT two/CD retinoid/NN response/NN pathways/NNS in/IN the/DT regulation/NN of/IN normal/JJ myeloid/JJ and/CC erythroid/JJ progenitor/NN cell/NN growth/NN ./. 
Transactivation/NN studies/NNS showed/VBD that/IN both/CC the/DT RAR/NN (/( Ro/NN 13-7410/CD )/) and/CC RXR/NN (/( Ro/NN 25-6603/CD and/CC Ro/NN 25-7386/CD )/) ligands/NNS were/VBD highly/RB selective/JJ at/IN 100/CD nmol/L/NN ./. 
At/IN this/DT concentration/NN ,/, Ro/NN 13-7410/CD potently/RB inhibited/VBD G-CSF-stimulated/JJ myeloid/JJ as/RB well/RB as/IN SCF/NN +/CC Epo-induced/JJ erythroid/JJ colony/NN growth/NN ./. 
At/IN the/DT same/JJ concentration/NN ,/, Ro/NN 25-6603/CD and/CC Ro/NN 25-7386/CD had/VBD little/JJ or/CC no/DT effect/NN on/IN G-CSF-induced/JJ colony/NN formation/NN ,/, whereas/IN they/PRP inhibited/VBD 75/CD %/NN and/CC 53/CD %/NN ,/, respectively/RB ,/, of/IN SCF/NN +/CC Epo-stimulated/JJ BFU-E/NN colony/NN growth/NN ./. 
Thus/RB ,/, the/DT RAR-RXR/JJ response/NN pathway/NN can/MD signal/VB growth/NN inhibition/NN of/IN normal/JJ bone/NN marrow/NN myeloid/JJ and/CC erythroid/JJ progenitor/NN cells/NNS ./. 
In/IN addition/NN ,/, we/PRP demonstrate/VBP a/DT unique/JJ involvement/NN of/IN the/DT RXR-RXR/JJ pathway/NN in/IN mediating/VBG growth/NN inhibition/NN of/IN erythroid/JJ but/CC not/RB myeloid/JJ progenitor/NN cells/NNS ./. 
UI/LS -/: 96190069/CD 
TI/LS -/: AM580/NN ,/, a/DT stable/JJ benzoic/JJ derivative/NN of/IN retinoic/JJ acid/NN ,/, has/VBZ powerful/JJ and/CC selective/JJ cyto-differentiating/JJ effects/NNS on/IN acute/JJ promyelocytic/JJ leukemia/NN cells/NNS ./. 
AB/LS -/: All-trans/JJ retinoic/JJ acid/NN (/( ATRA/NN )/) is/VBZ successfully/RB used/VBN in/IN the/DT cyto-differentiating/JJ treatment/NN of/IN acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) ./. 
Paradoxically/RB ,/, APL/NN cells/NNS express/VBP PML-RAR/NN ,/, an/DT aberrant/JJ form/NN of/IN the/DT retinoic/JJ acid/NN receptor/NN type/NN alpha/NN (/( RAR/NN alpha/NN )/) derived/VBN from/IN the/DT leukemia-specific/JJ t(15;17)/NN chromosomal/NN translocation/NN ./. 
We/PRP show/VBP here/RB that/IN AM580/NN ,/, a/DT stable/JJ retinobenzoic/JJ derivative/NN originally/RB synthesized/VBN as/IN a/DT RAR/NN alpha/NN agonist/NN ,/, is/VBZ a/DT powerful/JJ inducer/NN of/IN granulocytic/JJ maturation/NN in/IN NB4/NN ,/, an/DT APL-derived/JJ cell/NN line/NN ,/, and/CC in/IN freshly/RB isolated/VBN APL/NN blasts/NNS ./. 
After/IN treatment/NN of/IN APL/NN cells/NNS with/IN AM580/NN either/CC alone/RB or/CC in/IN combination/NN with/IN granulocyte/NN colony-stimulating/JJ factor/NN (/( G-CSF/NN )/) ,/, the/DT compound/NN induces/VBZ granulocytic/JJ maturation/NN ,/, as/IN assessed/VBN by/IN determination/NN of/IN the/DT levels/NNS of/IN leukocyte/NN alkaline/NN phosphatase/NN ,/, CD11b/NN ,/, CD33/NN ,/, and/CC G-CSF/NN receptor/NN mRNA/NN ,/, at/IN concentrations/NNS that/WDT are/VBP 10-/CD to/TO 100-fold/RB lower/JJR than/IN those/DT of/IN ATRA/NN necessary/JJ to/TO produce/VB similar/JJ effects/NNS ./. 
By/IN contrast/NN ,/, AM580/NN is/VBZ not/RB effective/JJ as/IN ATRA/NN in/IN modulating/VBG the/DT expression/NN of/IN these/DT differentiation/NN markers/NNS in/IN the/DT HL-60/NN cell/NN line/NN and/CC in/IN freshly/RB isolated/VBN granulocytes/NNS obtained/VBN from/IN the/DT peripheral/JJ blood/NN of/IN chronic/JJ myelogenous/JJ leukemia/NN patients/NNS during/IN the/DT stable/JJ phase/NN of/IN the/DT disease/NN ./. 
In/IN NB4/NN cells/NNS ,/, two/CD other/JJ synthetic/JJ nonselective/JJ RAR/NN ligands/NNS are/VBP capable/JJ of/IN inducing/VBG LAP/NN as/RB much/JJ as/IN AM580/NN ,/, whereas/IN RAR/NN beta-/NN or/CC RAR/NN gamma-specific/JJ ligands/NNS are/VBP totally/RB ineffective/JJ ./. 
These/DT results/NNS show/VBP that/IN AM580/NN is/VBZ more/RBR powerful/JJ than/IN ATRA/NN in/IN modulating/VBG the/DT expression/NN of/IN differentiation/NN antigens/NNS only/RB in/IN cells/NNS in/IN which/WDT PML-RAR/NN is/VBZ present/JJ ./. 
Binding/NN experiments/NNS ,/, using/VBG COS-7/NN cells/NNS transiently/RB transfected/VBN with/IN PML-RAR/NN and/CC the/DT normal/JJ RAR/NN alpha/NN ,/, show/VBP that/IN AM580/NN has/VBZ a/DT lower/JJR affinity/NN than/IN ATRA/NN for/IN both/DT receptors/NNS ./. 
However/RB ,/, in/IN the/DT presence/NN of/IN PML-RAR/NN ,/, the/DT synthetic/JJ retinoid/NN is/VBZ a/DT much/RB better/JJR transactivator/NN of/IN retinoic/JJ acid-responsive/JJ element-containing/JJ promoters/NNS than/IN the/DT natural/JJ retinoid/NN ,/, whereas/IN ,/, in/IN the/DT presence/NN of/IN RAR/NN alpha/NN ,/, AM580/NN and/CC ATRA/NN have/VBP similar/JJ activity/NN ./. 
This/DT may/MD explain/VB the/DT strong/JJ cyto-differentiating/JJ potential/NN of/IN AM580/NN in/IN PML-RAR-containing/JJ leukemic/JJ cells/NNS ./. 
UI/LS -/: 96146497/CD 
TI/LS -/: Inhibition/NN of/IN vitamin/NN D/NN receptor-retinoid/JJ|NN X/NN receptor-vitamin/JJ|NN D/NN response/NN element/NN complex/JJ formation/NN by/IN nuclear/JJ extracts/NNS of/IN vitamin/NN D-resistant/JJ New/NN World/NN primate/JJ cells/NNS ./. 
AB/LS -/: Most/JJS New/NN World/NN primate/NN (/( NWP/NN )/) genera/NN evolved/VBD to/TO require/VB high/JJ circulating/JJ levels/NNS of/IN steroid/NN hormones/NNS and/CC vitamin/NN D/NN ./. 
We/PRP hypothesized/VBD that/IN an/DT intracellular/JJ vitamin/NN D/NN binding/NN protein/NN (/( IDBP/NN )/) ,/, present/JJ in/IN both/CC nuclear/JJ and/CC cytoplasmic/JJ fractions/NNS of/IN NWP/NN cells/NNS ,/, or/CC another/DT protein/NN (/( s/NNS )/) may/MD cause/VB or/CC contribute/VB to/TO the/DT steroid/NN hormone-resistant/JJ state/NN in/IN NWP/NN by/IN disruption/NN of/IN the/DT receptor/NN dimerization/NN process/NN and/or/CC by/IN interference/NN of/IN receptor/NN complex/NN binding/VBG to/TO the/DT consensus/NN response/NN elements/NNS present/JJ in/IN the/DT enhancer/NN regions/NNS of/IN steroid-responsive/JJ genes/NNS ./. 
We/PRP employed/VBD electromobility/NN shift/NN assay/NN (/( EMSA/NN )/) to/TO screen/VB for/IN the/DT presence/NN of/IN proteins/NNS capable/JJ of/IN binding/VBG to/TO the/DT vitamin/NN D/NN response/NN element/NN (/( VDRE/NN )/) ./. 
Nuclear/JJ and/CC post-nuclear/JJ extracts/NNS were/VBD prepared/VBN from/IN two/CD B-lymphoblastoid/JJ cell/NN lines/NNS known/VBN to/TO be/VB representative/JJ of/IN the/DT vitamin/NN D-resistant/JJ and/CC wild/JJ type/NN phenotypes/NNS ,/, respectively/RB ./. 
The/DT extracts/NNS were/VBD compared/VBN for/IN their/PRP$ ability/NN to/TO retard/VB the/DT migration/NN of/IN radiolabeled/VBN double/JJ stranded/JJ oligomers/NNS representative/NN of/IN the/DT VDREs/NNS of/IN the/DT human/JJ osteocalcin/NN and/CC the/DT mouse/NN osteopontin/NN gene/NN promoters/NNS ./. 
A/DT specific/JJ ,/, retarded/JJ band/NN containing/VBG VDR-RXR/NN was/VBD identified/VBN when/WRB wild/JJ type/NN cell/NN but/CC not/RB when/WRB vitamin/NN D-resistant/JJ cell/NN nuclear/JJ extract/NN was/VBD used/VBN in/IN the/DT binding/NN reaction/NN with/IN either/DT probe/NN ./. 
In/IN addition/NN ,/, vitamin/NN D-resistant/JJ cell/NN nuclear/JJ extract/NN contained/VBD a/DT protein/NN (/( s/NNS )/) which/WDT was/VBD bound/VBN specifically/RB to/TO the/DT VDRE/NN and/CC was/VBD capable/JJ of/IN completely/RB inhibiting/VBG VDR-RXR-VDRE/JJ|NN complex/NN formation/NN ;/: these/DT effects/NNS were/VBD not/RB demonstrated/VBN with/IN nuclear/JJ extract/NN from/IN the/DT wild/JJ type/NN cell/NN line/NN or/CC with/IN the/DT post-nuclear/JJ extract/NN of/IN the/DT vitamin/NN D-resistant/JJ cell/NN line/NN ./. 
We/PRP conclude/VBP that/IN a/DT VDRE-binding/JJ protein/NN (/( s/NNS )/) ,/, distinct/JJ from/IN IDBP/NN and/CC present/JJ in/IN nuclear/JJ extract/NN of/IN cells/NNS from/IN a/DT prototypical/JJ vitamin/NN D-resistant/JJ NWP/NN ,/, is/VBZ capable/JJ of/IN inhibiting/VBG normal/JJ VDR-RXR/NN heterodimer/NN binding/VBG to/TO the/DT VDRE/NN ./. 
UI/LS -/: 96247530/CD 
TI/LS -/: BCL-6/NN expression/NN during/IN B-cell/NN activation/NN ./. 
AB/LS -/: Translocations/NNS involving/VBG the/DT BCL-6/NN gene/NN are/VBP common/JJ in/IN the/DT diffuse/JJ large/JJ cell/NN subtype/NN of/IN non-Hodgkin/JJ 's/POS lymphoma/NN ./. 
Invariably/RB ,/, the/DT BCL-6/NN coding/NN region/NN is/VBZ intact/JJ ,/, but/CC its/PRP$ 5'/JJ untranslated/JJ region/NN is/VBZ replaced/VBN with/IN sequences/NNS from/IN the/DT translocation/NN partner/NN ./. 
The/DT present/JJ study/NN shows/VBZ that/IN BCL-6/NN expression/NN is/VBZ regulated/VBN in/IN lymphocytes/NNS during/IN mitogenic/JJ stimulation/NN ./. 
Resting/VBG B/NN and/CC T/NN lymphocytes/NNS contain/VBP high/JJ levels/NNS of/IN BCL-6/NN mRNA/NN ./. 
Stimulation/NN of/IN mouse/NN B/NN cells/NNS with/IN anti-IgM/JJ or/CC IgD/NN antibodies/NNS ,/, bacterial/JJ lipopolysaccharide/NN ,/, phorbol/NN 12-myristate/NN 13-acetate/NN plus/CC ionomycin/NN ,/, or/CC CD40/NN ligand/NN led/VBD to/TO a/DT five-fold/JJ to/TO 35-fold/JJ decrease/NN in/IN BCL-6/NN mRNA/NN levels/NNS ./. 
Similar/JJ downregulation/NN of/IN BCL-6/NN mRNA/NN was/VBD seen/VBN in/IN human/JJ B/NN cells/NNS stimulated/VBN with/IN Staphylococcus/FW aureus/FW plus/CC interleukin-2/NN or/CC anti-IgM/JJ antibodies/NNS and/CC in/IN human/JJ T/NN lymphocytes/NNS stimulated/VBN with/IN phytohemagglutinin/NN ./. 
BCL-6/NN mRNA/NN levels/NNS began/VBD to/TO decrease/VB 8/CD to/TO 16/CD hours/NNS after/IN stimulation/NN ,/, before/IN cells/NNS entered/VBD S/NN phase/NN ./. 
Although/IN polyclonal/JJ activation/NN of/IN B/NN cells/NNS in/FW vitro/FW invariably/RB decreased/VBD BCL-6/NN MRNA/NN expression/NN ,/, activated/VBN B/NN cells/NNS from/IN human/JJ germinal/JJ centers/NNS expressed/VBD BCL-6/NN mRNA/NN at/IN levels/NNS comparable/JJ to/TO the/DT levels/NNS in/IN resting/VBG B/NN cells/NNS ./. 
Despite/IN these/DT similar/JJ mRNA/NN levels/NNS ,/, BCL-6/NN protein/NN expression/NN was/VBD threefold/RB to/TO 34-fold/RB higher/JJR in/IN germinal/JJ center/NN B/NN cells/NNS than/IN in/IN resting/VBG B/NN cells/NNS ,/, suggesting/VBG that/IN BCL-6/NN protein/NN levels/NNS are/VBP controlled/VBN by/IN translational/JJ or/CC posttranslational/JJ mechanisms/NNS ./. 
These/DT observations/NNS suggest/VBP that/IN the/DT germinal/JJ center/NN reaction/NN provides/VBZ unique/JJ activation/NN signals/NNS to/TO B/NN cells/NNS that/WDT allow/VBP for/IN continued/JJ ,/, high-level/JJ BCL-6/NN expression/NN ./. 
UI/LS -/: 96440214/CD 
TI/LS -/: DNA-binding/JJ phosphoproteins/NNS induced/VBN after/IN T/NN cell/NN activation/NN :/: effects/NNS of/IN cyclosporin/NN A/NN ./. 
AB/LS -/: To/TO define/VB novel/JJ proteins/NNS involved/VBN in/IN the/DT early/JJ transcriptional/JJ response/NN during/IN the/DT activation/NN of/IN human/JJ T/NN lymphocytes/NNS ,/, we/PRP used/VBD a/DT high-resolution/JJ ,/, two-dimensional/JJ gel/NN electrophoresis/NN system/NN to/TO identify/VB nuclear/JJ ,/, deoxyribonucleic/JJ acid/NN (/( DNA/NN )/) binding/NN proteins/NNS exhibiting/VBG rapid/JJ changes/NNS in/IN phosphorylation/NN following/VBG cell/NN stimulation/NN ./. 
We/PRP identified/VBD 18/CD nuclear/JJ proteins/NNS whose/WP$ phosphorylation/NN level/NN changed/VBD more/JJR than/IN 5-fold/RB upon/IN activation/NN ./. 
Of/IN these/DT ,/, 11/CD were/VBD found/VBN to/TO possess/VB DNA-binding/JJ properties/NNS ./. 
The/DT 11/CD phosphoproteins/NNS with/IN DNA-binding/JJ activity/NN ,/, along/IN with/IN 4/CD others/NNS ,/, were/VBD analyzed/VBN further/RB ./. 
Phosphoamino/NN acid/NN analysis/NN revealed/VBD several/JJ sets/NNS of/IN proteins/NNS with/IN different/JJ phosphorylated/VBN residues/NNS Kinetic/JJ analysis/NN of/IN the/DT phosphorylation/NN of/IN the/DT selected/VBN proteins/NNS was/VBD performed/VBN and/CC revealed/VBD a/DT complex/JJ group/NN of/IN transient/JJ and/CC sustained/JJ responses/NNS to/TO cell/NN activation/NN ./. 
Finally/RB ,/, the/DT activation-induced/JJ changes/NNS in/IN one/CD set/NN of/IN phosphoproteins/NNS were/VBD dramatically/RB inhibited/VBN by/IN cyclosporin/NN A/NN ./. 
We/PRP suggest/VBP that/IN these/DT phosphoproteins/NNS may/MD be/VB directly/RB involved/VBN in/IN regulating/VBG the/DT transcriptional/JJ response/NN to/TO cellular/JJ activation/NN by/IN external/JJ stimuli/NNS ./. 
UI/LS -/: 96189089/CD 
TI/LS -/: Inactivation/NN of/IN IkappaBbeta/NN by/IN the/DT tax/NN protein/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD :/: a/DT potential/JJ mechanism/NN for/IN constitutive/JJ induction/NN of/IN NF-kappaB/NN ./. 
AB/LS -/: In/IN resting/VBG T/NN lymphocytes/NNS ,/, the/DT transcription/NN factor/NN NF-kappaB/NN is/VBZ sequestered/VBN in/IN the/DT cytoplasm/NN via/IN interactions/NNS with/IN members/NNS of/IN the/DT I/NN kappa/NN B/NN family/NN of/IN inhibitors/NNS ,/, including/VBG IkappaBalpha/NN and/CC IkappaBbeta/NN ./. 
During/IN normal/JJ T-cell/NN activation/NN ,/, IkappaBalpha/NN is/VBZ rapidly/RB phosphorylated/VBN ,/, ubiquitinated/VBN ,/, and/CC degraded/VBN by/IN the/DT 26S/NN proteasome/NN ,/, thus/RB permitting/VBG the/DT release/NN of/IN functional/JJ NF-kappaB/NN ./. 
In/IN contrast/NN to/TO its/PRP$ transient/JJ pattern/NN of/IN nuclear/JJ induction/NN during/IN an/DT immune/JJ response/NN ,/, NF-kappaB/NN is/VBZ constitutively/RB activated/VBN in/IN cells/NNS expressing/VBG the/DT Tax/NN transforming/NN protein/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-1/NN )/) ./. 
Recent/JJ studies/NNS indicate/VBP that/IN HTLV-1/NN Tax/NN targets/VBZ IkappaBalpha/NN to/TO the/DT ubiquitin-proteasome/JJ pathway/NN ./. 
However/RB ,/, it/PRP remains/VBZ unclear/JJ how/WRB this/DT viral/JJ protein/NN induces/VBZ a/DT persistent/JJ rather/RB than/IN transient/JJ NF-kappaB/NN response/NN ./. 
In/IN this/DT report/NN ,/, we/PRP provide/VBP evidence/NN that/IN in/IN addition/NN to/TO acting/VBG on/IN IkappaBalpha/NN ,/, Tax/NN stimulates/VBZ the/DT turnover/NN Of/IN IkappaBbeta/NN via/IN a/DT related/JJ targeting/NN mechanism/NN ./. 
Like/IN IkappaBalpha/NN ,/, Tax-mediated/JJ breakdown/NN of/IN IkappaBbeta/NN in/IN transfected/VBN T/NN lymphocytes/NNS is/VBZ blocked/VBN either/CC by/IN cell-permeable/JJ proteasome/NN inhibitors/NNS or/CC by/IN mutation/NN Of/IN IkappaBbeta/NN at/IN two/CD serine/NN residues/NNS present/JJ within/IN its/PRP$ N-terminal/JJ region/NN ./. 
Despite/IN the/DT dual/JJ specificity/NN of/IN HTLV-1/NN Tax/NN for/IN IkappaBalpha/NN and/CC IkappaBbeta/NN at/IN the/DT protein/NN level/NN ,/, Tax/NN selectively/RB stimulates/VBZ NF-kappaB-directed/JJ transcription/NN of/IN the/DT IkappaBalpha/NN gene/NN ./. 
Consequently/RB ,/, IkappaBbeta/NN protein/NN expression/NN is/VBZ chronically/RB downregulated/VBN in/IN HTLV-1-infected/JJ T/NN lymphocytes/NNS ./. 
These/DT findings/NNS with/IN IkappaBbeta/NN provide/VBP a/DT potential/JJ mechanism/NN for/IN the/DT constitutive/JJ activation/NN of/IN NF-kappaB/NN in/IN Tax-expressing/JJ cells/NNS ./. 
UI/LS -/: 96201643/CD 
TI/LS -/: The/DT role/NN of/IN p16/NN in/IN the/DT E2F-dependent/JJ thymidine/NN kinase/NN regulation/NN ./. 
AB/LS -/: The/DT role/NN of/IN alterations/NNS of/IN the/DT MTS1/NN tumor/NN suppressor/NN gene/NN on/IN chromosome/NN 9p21/NN ,/, which/WDT encodes/VBZ p16/NN ,/, the/DT inhibitor/NN of/IN cyclin-dependent-kinase-4/NN and/CC 6/CD ,/, in/IN tumorigenesis/NN is/VBZ not/RB yet/RB clear/JJ ./. 
Phosphorylation/NN of/IN the/DT retinoblastoma/NN protein/NN by/IN cyclin-dependent/JJ kinases/NNS 4/CD and/CC 6/CD prevents/VBZ its/PRP$ interaction/NN with/IN the/DT transcription/NN factor/NN E2F/NN ,/, which/WDT subsequently/RB promotes/VBZ the/DT expression/NN of/IN S/NN phase/NN regulated/JJ genes/NNS ,/, such/JJ as/IN thymidine/NN kinase/NN ./. 
Although/IN a/DT role/NN of/IN p16/NN in/IN this/DT regulation/NN has/VBZ been/VBN presumed/VBN ,/, there/EX is/VBZ no/DT proof/NN so/RB far/RB that/IN loss/NN of/IN this/DT tumor/NN suppressor/NN gene/NN really/RB affects/VBZ E2F-mediated/JJ regulations/NNS ./. 
We/PRP investigated/VBD the/DT regulation/NN of/IN thymidine/NN kinase/NN in/IN phytohemagglutinin-stimulated/JJ normal/JJ human/JJ lymphocytes/NNS and/CC in/IN the/DT p16-negative/JJ human/JJ acute/JJ lymphoblastic/JJ leukemia/NN cell/NN lines/NNS ,/, MOLT-4/NN and/CC CEM/NN ./. 
Compared/VBN to/TO normal/JJ lymphocytes/NNS ,/, MOLT-4/NN and/CC CEM/NN cells/NNS exhibited/VBD an/DT altered/JJ cell/NN cycle/NN regulation/NN of/IN thymidine/NN kinase/NN ,/, a/DT much/RB higher/JJR intracellular/JJ activity/NN of/IN this/DT enzyme/NN ,/, and/CC higher/JJR thymidine/NN kinase/NN mRNA/NN expression/NN ./. 
Transient/JJ expression/NN of/IN p16/NN in/IN normal/JJ human/JJ lymphocytes/NNS caused/VBD arrest/NN in/IN G1/NN ,/, but/CC was/VBD without/IN effect/NN on/IN the/DT cell/NN growth/NN of/IN MOLT-4/NN and/CC CEM/NN cells/NNS ,/, although/IN all/DT of/IN them/PRP express/VBP functional/JJ retinoblastoma/NN protein/NN ./. 
Nevertheless/RB ,/, in/IN the/DT two/CD leukemia/NN cell/NN lines/NNS transient/JJ overexpression/NN of/IN p16/NN reestablished/VBD the/DT normal/JJ regulation/NN of/IN thymidine/NN kinase/NN ,/, paralleled/VBN by/IN an/DT increase/NN of/IN the/DT underphosphorylated/JJ form/NN of/IN retinoblastoma/NN protein/NN and/CC decrease/NN of/IN free/JJ E2F/NN bound/VBD to/TO its/PRP$ motif/NN in/IN the/DT thymidine/NN kinase/NN promoter/NN ./. 
We/PRP demonstrate/VBP that/IN loss/NN of/IN p16/NN causes/VBZ upregulation/NN of/IN this/DT DNA/NN precursor/NN pathway/NN enzyme/NN via/IN activation/NN of/IN E2F/NN by/IN a/DT mechanism/NN involving/VBG retinoblastoma/NN protein/NN ./. 
UI/LS -/: 96224113/CD 
TI/LS -/: Interactions/NNS of/IN a/DT transcriptional/JJ activator/NN in/IN the/DT env/NN gene/NN of/IN the/DT mouse/NN mammary/JJ tumor/NN virus/NN with/IN activation-dependent/JJ ,/, T/NN cell-specific/JJ transacting/VBG factors/NNS ./. 
AB/LS -/: The/DT mouse/NN mammary/JJ tumor/NN virus/NN env/NN gene/NN contains/VBZ a/DT transcriptional/JJ activator/NN (/( META/NN )/) that/WDT can/MD control/VB transcription/NN of/IN the/DT adjacent/JJ long/JJ terminal/JJ repeat/NN region/NN ./. 
Transcriptional/JJ control/NN by/IN META/NN parallels/VBZ that/DT of/IN several/JJ lymphokine/NN genes/NNS ,/, being/VBG specific/JJ to/TO T/NN cells/NNS ,/, dependent/JJ on/IN their/PRP$ activation/NN ,/, and/CC inhibited/VBN by/IN the/DT immunosuppressive/JJ drug/NN cyclosporine/NN (/( CsA/NN )/) ./. 
DNase/NN I/CD footprinting/NN indicated/VBD that/IN nuclear/JJ factors/NNS from/IN activated/VBN T/NN lymphocytes/NNS bound/VBD a/DT promoter-proximal/JJ site/NN ,/, META(P)/NN ,/, and/CC a/DT promoter-distal/JJ site/NN ,/, META(D+)/NN ,/, within/IN the/DT 400-base/JJ pair/NN META/NN region/NN ./. 
Nuclear/JJ factors/NNS from/IN unstimulated/JJ ,/, but/CC not/RB from/IN activated/VBN cells/NNS ,/, bound/VBD a/DT site/NN ,/, META(D-)/NN ,/, adjacent/JJ to/TO META(D+)/NN ./. 
META(D+)/NN directed/VBD transcription/NN of/IN a/DT linked/VBN luciferase/NN gene/NN ,/, and/CC gel/NN shift/NN analysis/NN revealed/VBD binding/NN of/IN inducible/JJ ,/, CsA-sensitive/JJ T/NN cell/NN factors/NNS ,/, in/IN parallel/NN with/IN transfection/NN results/NNS ./. 
Authentic/JJ NFAT/NN and/CC NF-kappaB/NN targets/NNS did/VBD not/RB compete/VB for/IN the/DT META(D+)/NN binding/NN factor/NN (/( s/NNS )/) ./. 
The/DT SV40/NN core/NN sequence/NN competed/VBD for/IN META(D+)/NN binding/NN factors/NNS ,/, but/CC META(D+)/NN failed/VBD to/TO compete/VB for/IN the/DT complexes/NNS obtained/VBN with/IN the/DT SV40/NN probe/NN ./. 
Our/PRP$ results/NNS ,/, taken/VBN together/RB ,/, indicate/VBP that/IN META(D+)/NN is/VBZ a/DT novel/JJ transcriptional/JJ enhancer/NN element/NN that/WDT is/VBZ similar/JJ in/IN its/PRP$ cell-type/JJ specificity/NN ,/, activation/NN dependence/NN ,/, and/CC CsA/NN sensitivity/NN to/TO the/DT NFAT/NN element/NN ./. 
It/PRP may/MD be/VB relevant/JJ to/TO the/DT role/NN of/IN MMTV/NN in/IN expression/NN of/IN Mls/NN antigens/NNS or/CC the/DT induction/NN of/IN T/NN cell/NN lymphomas/NNS ./. 
UI/LS -/: 96239482/CD 
TI/LS -/: A/DT novel/JJ interferon/NN regulatory/JJ factor/NN family/NN transcription/NN factor/NN ,/, ICSAT/Pip/LSIRF/NN ,/, that/WDT negatively/RB regulates/VBZ the/DT activity/NN of/IN interferon-regulated/JJ genes/NNS ./. 
AB/LS -/: We/PRP have/VBP isolated/VBN a/DT novel/JJ cDNA/NN clone/NN encoding/NN interferon/NN (/( IFN/NN )/) consensus/NN sequence-binding/JJ protein/NN in/IN adult/JJ T-cell/NN leukemia/NN cell/NN line/NN or/CC activated/VBN T/NN cells/NNS (/( ICSAT/NN )/) ;/: this/DT protein/NN is/VBZ the/DT human/JJ homolog/NN of/IN the/DT recently/RB cloned/VBN Pip/LSIRF/NN ./. 
ICSAT/NN is/VBZ structurally/RB most/RBS closely/RB related/JJ to/TO the/DT previously/RB cloned/VBN ICSBP/NN ,/, a/DT member/NN of/IN the/DT IFN/NN regulatory/JJ factor/NN (/( IRF/NN )/) family/NN of/IN proteins/NNS that/WDT binds/VBZ to/TO interferon/NN consensus/NN sequences/NNS (/( ICSs/NNS )/) found/VBN in/IN many/JJ promoters/NNS of/IN the/DT IFN-regulated/JJ genes/NNS ./. 
Among/IN T-cell/NN lines/NNS investigated/VBN ,/, ICSAT/NN was/VBD abundantly/RB expressed/VBN in/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) -infected/JJ T/NN cells/NNS ./. 
When/WRB the/DT HTLV-1/NN tax/NN gene/NN was/VBD expressed/VBN or/CC phorbol/NN myristake/NN acetate-A23187/NN stimulation/NN was/VBD used/VBN ,/, ICSAT/NN expression/NN was/VBD induced/VBN in/IN Jurkat/NN cells/NNS which/WDT otherwise/RB do/VBP not/RB express/VB ICSAT/NN ./. 
When/WRB the/DT binding/NN of/IN ICSAT/NN to/TO four/CD different/JJ ICSs/NNS was/VBD tested/VBN ,/, the/DT relative/JJ differences/NNS in/IN binding/NN affinities/NNS for/IN those/DT ICSs/NNS were/VBD determined/VBN ./. 
To/TO study/VB the/DT functional/JJ role/NN of/IN ICSAT/NN ,/, we/PRP performed/VBD cotransfection/NN experiments/NNS with/IN the/DT human/JJ embryonal/JJ carcinoma/NN cell/NN line/NN N-Tera2/NN ./. 
ICSAT/NN was/VBD demonstrated/VBN to/TO possess/VB repressive/JJ function/NN over/IN the/DT gene/NN activation/NN induced/VBN by/IN IFN/NN stimulation/NN or/CC by/IN IRF-1/NN cotransfection/NN ./. 
Such/JJ repressive/JJ function/NN is/VBZ similar/JJ to/TO that/DT seen/VBN in/IN IRF-2/NN or/CC ICSBP/NN ./. 
However/RB ,/, we/PRP have/VBP found/VBN that/IN ICSAT/NN has/VBZ a/DT different/JJ repressive/JJ effect/NN from/IN that/DT of/IN IRF-2/NN or/CC ICSBP/NN in/IN some/DT IFN-responsive/JJ reporter/NN constructs/NNS ./. 
These/DT results/NNS suggest/VBP that/IN a/DT novel/JJ mechanism/NN of/IN gene/NN regulation/NN by/IN "/`` differential/JJ repression/NN "/'' is/VBZ used/VBN by/IN multiple/JJ members/NNS of/IN repressor/NN proteins/NNS with/IN different/JJ repressive/JJ effects/NNS on/IN the/DT IFN-responsive/JJ genes/NNS ./. 
UI/LS -/: 97077077/CD 
TI/LS -/: Regulation/NN of/IN [Ca2+]i/NN rise/NN activated/VBN by/IN doxepin-sensitive/JJ H1-histamine/JJ receptors/NNS in/IN Jurkat/NN cells/NNS ,/, cloned/VBN human/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: To/TO clarify/VB the/DT presence/NN of/IN histamine/NN receptor/NN and/CC its/PRP$ transmembrane/JJ mechanism/NN in/IN human/JJ T/NN lymphocytes/NNS ,/, we/PRP investigated/VBD the/DT effects/NNS of/IN agonists/NNS or/CC antagonists/NNS of/IN histamine/NN receptor/NN subtypes/NNS and/CC bacterial/JJ toxins/NNS on/IN intracellular/JJ concentration/NN of/IN Ca2+/NN [Ca2+]i/NN )/) ,/, [3H]pyrilamine/NN binding/NN and/CC c-fos/NN mRNA/NN expression/NN in/IN Jurkat/NN cells/NNS ,/, cloned/VBN human/JJ T/NN lymphocytes/NNS ./. 
H1-agonists/NNS (/( histamine/NN and/CC 2-methylhistamine/NN )/) caused/VBD a/DT transient/JJ rise/NN of/IN [Ca2+]/NN ,/, and/CC H1-antagonists/NNS (/( pyrilamine/NN and/CC doxepin/NN )/) inhibited/VBD the/DT histamine-induced/JJ [Ca2+]i/NN rise/NN more/RBR potently/RB than/IN the/DT H2-antagonist/NN (/( cimetidine/NN )/) on/IN the/DT H3-antagonist/NN (/( impromidine/NN )/) ./. 
Binding/NN parameters/NNS of/IN [3H]pyrilamine/NN binding/NN were/VBD Kd/NN =/JJ 5.53/CD nM/NN and/CC Bmax/NN =/JJ 2/CD ,/, 647/CD sites/cell/NNS ./. 
Pretreatment/NN with/IN B.pertussis/FW ,/, V.cholera./FW or/CC C.botulinum/FW toxin/NN did/VBD not/RB influence/VB histamine-induced/JJ [Ca2+]i/NN rise/NN ./. 
Western/NN Blot/NN analysis/NN using/VBG antibodies/NNS against/IN subunits/NNS of/IN GTP-binding/JJ proteins/NNS indicated/VBD that/IN Gq/G11/NN richly/RB existed/VBD in/IN Jurkat/NN cells/NNS ./. 
Histamine/NN induced/VBD mRNA/NN expression/NN of/IN an/DT immediate/JJ early/JJ gene/NN c-fos/NN ./. 
Pretreatment/NN with/IN a/DT protein/NN kinase/NN C/NN activator/NN ,/, phorbol/NN 12-myristate/NN 13-acetate/NN ,/, caused/VBD almost/RB complete/JJ inhibition/NN of/IN histamine-induced/JJ [Ca2+]i/NN rise/NN ,/, but/CC did/VBD not/RB do/VB so/RB by/IN activators/NNS of/IN cAMP-/NN and/CC cGMP-dependent/JJ protein/NN kinases/NNS ./. 
UI/LS -/: 96202489/CD 
TI/LS -/: STAT-related/JJ transcription/NN factors/NNS are/VBP constitutively/RB activated/VBN in/IN peripheral/JJ blood/NN cells/NNS from/IN acute/JJ leukemia/NN patients/NNS ./. 
AB/LS -/: A/DT signal/NN transduction/NN pathway/NN activated/VBN by/IN many/JJ cytokines/NNS has/VBZ recently/RB been/VBN elaborated/VBN ./. 
The/DT JAK/NN kinases/NNS and/CC the/DT signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STAT/NN )/) factors/NNS have/VBP been/VBN found/VBN to/TO be/VB essential/JJ components/NNS ./. 
In/IN this/DT report/NN ,/, we/PRP describe/VBP the/DT presence/NN of/IN constitutively/RB activated/VBN STAT/NN factors/NNS in/IN peripheral/JJ blood/NN cells/NNS from/IN patients/NNS with/IN acute/JJ leukemia/NN ./. 
We/PRP used/VBD oligonucleotide/JJ probes/NNS from/IN the/DT beta-casein/NN and/CC IRF-1/NN gene/NN promoters/NNS and/CC the/DT ISRE/NN probe/NN to/TO detect/VB STAT/NN proteins/NNS in/IN nuclear/JJ extracts/NNS from/IN acute/JJ leukemia/NN cells/NNS in/IN bandshift/NN assays/NNS ./. 
Specific/JJ DNA/NN protein/NN complex/NN formation/NN was/VBD observed/VBN with/IN the/DT probes/NNS from/IN the/DT beta-casein/NN and/CC IRF-1/NN gene/NN promoters/NNS ,/, but/CC not/RB with/IN the/DT ISRE/NN oligonucleotide/NN probe/NN ,/, when/WRB cell/NN extracts/NNS from/IN acute/JJ lymphoblastic/JJ leukemia/NN (/( ALL/NN )/) and/CC acute/JJ myeloid/JJ leukemia/NN (/( AML/NN )/) were/VBD investigated/VBN ./. 
We/PRP used/VBD nonradioactive/JJ oligonucleotides/NNS as/IN competitors/NNS to/TO show/VB the/DT specificity/NN of/IN the/DT complex/NN formation/NN ./. 
Specific/JJ antibodies/NNS directed/VBN against/IN the/DT individual/JJ STAT/NN proteins/NNS were/VBD used/VBN in/IN supershift/NN experiments/NNS ./. 
STAT5-/NN and/CC STAT1-related/JJ factors/NNS were/VBD detected/VBN in/IN ALL/NN and/CC STAT1-/NN ,/, STAT3-/NN ,/, and/CC STAT5-related/JJ proteins/NNS were/VBD present/JJ in/IN nuclear/JJ cell/NN extracts/NNS from/IN AML/NN ./. 
Since/IN the/DT cells/NNS were/VBD not/RB treated/VBN with/IN cytokines/NNS before/IN the/DT nuclear/JJ proteins/NNS were/VBD extracted/VBN ,/, we/PRP conclude/VBP that/IN these/DT factors/NNS are/VBP constitutively/RB activated/VBN in/FW vivo/FW ./. 
It/PRP is/VBZ likely/JJ that/IN the/DT constitutive/JJ activation/NN of/IN STAT/NN proteins/NNS is/VBZ a/DT part/NN of/IN the/DT events/NNS of/IN leukemogenesis/NN ./. 
UI/LS -/: 96194904/CD 
TI/LS -/: An/DT element/NN upstream/JJ from/IN the/DT human/JJ delta-globin-encoding/JJ gene/NN specifically/RB enhances/VBZ beta-globin/JJ reporter/NN gene/NN expression/NN in/IN murine/JJ erythroleukemia/NN cells/NNS ./. 
AB/LS -/: We/PRP have/VBP previously/RB shown/VBN that/IN a/DT DNA-binding/JJ factor/NN specific/JJ to/TO adult/JJ hematopoietic/JJ cells/NNS (/( polypryrimidine-binding/JJ factor/NN ,/, PYBF/NN )/) binds/VBZ to/TO a/DT pyrimidine-rich/JJ region/NN 1/CD kb/NN upstream/JJ from/IN the/DT human/JJ delta-globin-encoding/JJ gene/NN (/( HBD/NN )/) ./. 
The/DT developmental/JJ stage-specificity/NN of/IN PYBF/NN and/CC the/DT location/NN of/IN its/PRP$ binding/VBG site/NN between/IN the/DT fetal/JJ and/CC adult/JJ beta-globin/NN (/( HBB/NN )/) -like/JJ genes/NNS suggest/VBP that/IN PBYF/NN and/CC its/PRP$ binding/VBG site/NN may/MD function/VB in/IN fetal-to-adult/JJ globin/NN gene/NN switching/NN ./. 
Here/RB ,/, we/PRP describe/VBP the/DT effect/NN of/IN 383-bp/JJ (/( delta383/NN )/) and/CC 99-bp/JJ (/( delta99/NN )/) sequences/NNS containing/VBG the/DT PYBF-binding/JJ site/NN on/IN transcription/NN from/IN various/JJ globin/NN and/CC non-globin/JJ promoters/NNS ,/, using/VBG a/DT transient/JJ assay/NN with/IN the/DT cat/NN reporter/NN gene/NN in/IN murine/JJ erythroleukemia/NN (/( MEL/NN )/) cells/NNS ,/, a/DT cell/NN line/NN with/IN abundant/JJ PYBF/NN activity/NN ./. 
We/PRP show/VBP that/IN both/CC delta383/NN and/CC delta99/NN specifically/RB enhance/VBP expression/NN of/IN cat/NN for/IN plasmids/NNS containing/VBG a/DT human/JJ adult/JJ globin/NN (/( HBB/NN )/) promoter/NN ,/, whereas/IN expression/NN of/IN similar/JJ constructs/NNS using/VBG human/JJ fetal/JJ (/( A/NN gamma-/NN )/) globin/NN (/( HBG1/NN )/) or/CC simian/JJ virus/NN 40/CD (/( SV40/NN )/) promoters/NNS is/VBZ not/RB enhanced/VBN ./. 
The/DT results/NNS suggest/VBP that/IN PYBF/NN and/CC the/DT pyrimidine-rich/JJ region/NN upstream/JJ from/IN HBD/NN can/MD specifically/RB enhance/VB HBB/NN transcription/NN in/IN adult/JJ erythroid/JJ cells/NNS ./. 
UI/LS -/: 96163492/CD 
TI/LS -/: Translocation/NN breakpoints/NNS in/IN three/CD patients/NNS with/IN campomelic/JJ dysplasia/NN and/CC autosomal/JJ sex/NN reversal/JJ map/NN more/JJR than/IN 130/CD kb/NN from/IN SOX9/NN ./. 
AB/LS -/: Campomelic/JJ dysplasia/NN (/( CMPD1/NN )/) and/CC autosomal/JJ XY/NN sex/NN reversal/JJ (/( SRA1/NN )/) are/VBP caused/VBN by/IN mutations/NNS in/IN the/DT SRY-related/JJ gene/NN SOX9/NN on/IN 17q/NN ./. 
Unexpectedly/RB ,/, the/DT 17q/NN breakpoints/NNS in/IN four/CD CMPD1/NN translocation/NN cases/NNS previously/RB analyzed/VBN by/IN us/PRP and/CC others/NNS map/VBP 50/CD kb/NN or/CC more/JJR from/IN SOX9/NN ./. 
Here/RB ,/, we/PRP present/VBP clinical/JJ ,/, cytogenetic/JJ ,/, and/CC molecular/JJ data/NNS from/IN a/DT new/JJ CMPD1/SRA1/NN patient/NN with/IN t(6;17)(q14;q24)/NN ./. 
Fluorescence/NN in/FW situ/FW hybridization/NN has/VBZ shown/VBN that/IN the/DT 17q/NN breakpoint/NN in/IN this/DT case/NN maps/VBZ to/TO the/DT same/JJ region/NN as/IN the/DT breakpoints/NNS in/IN the/DT other/JJ translocation/NN cases/NNS ,/, at/IN least/JJS 130/CD kb/NN from/IN SOX9/NN ./. 
Likewise/RB ,/, the/DT breakpoints/NNS in/IN two/CD of/IN the/DT previously/RB described/VBN cases/NNS also/RB map/VBP more/JJR than/IN 130/CD kb/NN and/CC ,/, as/IN shown/VBN by/IN pulsed/JJ field/NN gel/NN electrophoresis/NN analysis/NN ,/, at/IN most/JJS 400/CD kb/NN or/CC 690/CD kb/NN from/IN SOX9/NN ./. 
By/IN using/VBG a/DT SOX9/NN coding/NN sequence/NN polymorphism/NN ,/, expression/NN of/IN both/DT SOX9/NN alleles/NNS has/VBZ been/VBN demonstrated/VBN by/IN the/DT reverse/JJ transcriptase/NN polymerase/NN chain/NN reaction/NN in/IN lymphoblastoid/JJ cells/NNS from/IN one/CD of/IN the/DT translocation/NN cases/NNS ./. 
UI/LS -/: 96264628/CD 
TI/LS -/: An/DT alternatively/RB spliced/VBN isoform/NN of/IN the/DT Spi-B/NN transcription/NN factor/NN ./. 
AB/LS -/: Spi-B/NN is/VBZ an/DT Ets/NN transcription/NN factor/NN related/JJ to/TO the/DT oncoprotein/NN Spi-1/PU.1/NN and/CC highly/RB expressed/VBN in/IN B/NN lymphoid/JJ cells/NNS ./. 
The/DT Ets/NN proteins/NNS share/VBP a/DT conserved/VBN Ets/NN domain/NN that/WDT mediates/VBZ specific/JJ DNA/NN binding/NN ./. 
Spi-B/NN binds/VBZ DNA/NN sequences/NNS containing/VBG a/DT core/NN 5'-GGAA-3'/NN and/CC activates/VBZ transcription/NN through/IN this/DT motif/NN ./. 
Up/IN to/TO date/NN ,/, the/DT biological/JJ function/NN of/IN Spi-B/NN remains/VBZ unknown/JJ ./. 
Here/RB ,/, we/PRP describe/VBP the/DT characterization/NN of/IN an/DT alternatively/RB spliced/VBN variant/NN of/IN Spi-B/NN ,/, named/VBN deltaSpi-B/NN ,/, which/WDT has/VBZ lost/VBN the/DT Ets/NN domain/NN ./. 
In/IN B/NN lymphoid/JJ cells/NNS ,/, deltaspi-B/NN and/CC spi-B/NN mRNAs/NNS were/VBD present/JJ simultaneously/RB in/IN a/DT ratio/NN of/IN around/IN 10/CD %/NN ./. 
DeltaSpi-B/NN product/NN was/VBD not/RB able/JJ to/TO bind/VB DNA/NN and/CC was/VBD recovered/VBN in/IN cytoplasmic/JJ cellular/JJ extracts/NNS ./. 
We/PRP raise/VBP the/DT hypothesis/NN that/IN delta/NN Spi-B/NN might/MD affect/VB Spi-B/NN function/NN by/IN recruiting/VBG factors/NNS involved/VBN in/IN Spi-B/NN activity/NN ./. 
UI/LS -/: 96281903/CD 
TI/LS -/: Binding/NN and/CC cooperative/JJ interactions/NNS between/IN two/CD B/NN cell-specific/JJ transcriptional/JJ coactivators/NNS ./. 
AB/LS -/: The/DT class/NN II/CD transactivator/NN (/( CIITA/NN )/) and/CC B/NN cell/NN octamer-binding/JJ protein/NN 1/octamer-binding/JJ factor/NN 1/Oct/NN coactivator/NN from/IN B/NN cells/NNS (/( Bob1/OBF-1/OCA-B/NN )/) represent/VBP two/CD B/NN cell-specific/JJ transcriptional/JJ coactivators/NNS ./. 
CIITA/NN and/CC Bob1/NN interact/VBP with/IN proteins/NNS that/WDT bind/VBP to/TO conserved/VBN upstream/JJ sequences/NNS in/IN promoters/NNS of/IN class/NN II/CD major/JJ histocompatibility/NN genes/NNS and/CC octamer-binding/JJ transcription/NN factors/NNS Oct-1/NN and/CC Oct-2/NN ,/, respectively/RB ./. 
Both/CC CIITA/NN and/CC Bob1/NN increase/VBP the/DT expression/NN from/IN the/DT DRA/NN promoter/NN ,/, which/WDT is/VBZ a/DT prototypic/JJ class/NN II/CD promoter/NN ./. 
Moreover/RB ,/, in/IN the/DT presence/NN of/IN CIITA/NN ,/, interactions/NNS between/IN class/NN II/CD promoters/NNS and/CC Bob1/NN are/VBP independent/JJ of/IN the/DT octamer-binding/JJ site/NN ./. 
Using/VBG in/FW vivo/FW and/CC in/FW vitro/FW binding/NN assays/NNS ,/, we/PRP confirm/VBP that/IN Bob1/NN binds/VBZ to/TO CIITA/NN ./. 
Thus/RB ,/, CIITA/NN not/RB only/RB activates/VBZ the/DT expression/NN of/IN class/NN II/CD genes/NNS but/CC recruits/VBZ another/DT B/NN cell-specific/JJ coactivator/NN to/TO increase/VB transcriptional/JJ activity/NN of/IN class/NN II/CD promoters/NNS in/IN B/NN cells/NNS ./. 
UI/LS -/: 96186742/CD 
TI/LS -/: Efficient/JJ transcription/NN and/CC replication/NN of/IN simian/JJ immunodeficiency/NN virus/NN in/IN the/DT absence/NN of/IN NF-kappaB/NN and/CC Sp1/NN binding/NN elements/NNS ./. 
AB/LS -/: Ten/CD mutants/NNS of/IN the/DT simian/JJ immunodeficiency/NN virus/NN (/( SIV/NN )/) SIVmac239/NN bearing/VBG deletions/NNS (/( delta/JJ|NNS )/) or/CC substitutions/NNS (/( subst/JJ|NNS )/) in/IN the/DT NF-kappaB/NN and/or/CC Sp1/NN binding/NN elements/NNS were/VBD created/VBN ,/, and/CC the/DT replicative/JJ capacities/NNS of/IN the/DT mutants/NNS were/VBD analyzed/VBN ./. 
All/DT mutants/NNS ,/, including/VBG one/CD extensively/RB mutagenized/VBN strain/NN entirely/RB missing/VBG the/DT NF-kappaB/NN and/CC four/CD Spl/NN binding/NN elements/NNS ,/, replicated/VBN with/IN wild-type/JJ kinetics/NNS and/CC to/TO a/DT wild-type/JJ level/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cell/NN cultures/NNS in/IN 50/CD to/TO 100/CD %/NN of/IN the/DT experiments/NNS ./. 
One/CD group/NN of/IN mutants/NNS replicated/VBN very/RB similarly/RB to/TO SIVmac239/NN in/IN kinetics/NN and/CC yield/NN in/IN CEMxl74/NN cells/NNS (/( 2xNFKappaB/NN >/JJ or/CC =/JJ SlVmac239/NN approximately/RB deltaNFkappaB/NN approximately/RB deltaSpl234/NN approximately/RB substNFkappaB/NN approximately/RB substSpl2/NN approximately/RB substSp23/NN )/) ,/, while/IN a/DT second/JJ group/NN replicated/VBD with/IN delayed/VBN or/CC slightly/RB delayed/VBN kinetics/NN in/IN CEMxl74/NN cells/NNS (/( SIVmac239/NN >/JJ substSp34/NN >/JJ deltaNFkappaBdeltaSpl234/NN approximately/RB deltaNFkappaBdeltaSp1/NN >/JJ substSpl234/NN )/) ./. 
Reversions/NNS or/CC additional/JJ mutations/NNS were/VBD not/RB detected/VBN in/IN the/DT U3/NN and/CC R/NN regions/NNS of/IN proviral/JJ DNA/NN from/IN CEMxl74/NN cells/NNS infected/VBN with/IN the/DT SIVmac239/NN mutants/NNS ./. 
Similar/JJ results/NNS were/VBD obtained/VBN when/WRB mutants/NNS of/IN SIVmacMER/NN (/( a/DT macrophage-competent/JJ derivative/NN of/IN SIVmac239/NN )/) were/VBD tested/VBN in/IN peripheral/JJ blood/NN mononuclear/JJ cell/NN and/CC CEMx174/NN cultures/NNS ./. 
However/RB ,/, the/DT growth/NN of/IN most/JJ mutated/VBN viruses/NNS was/VBD suppressed/VBN in/IN primary/JJ rhesus/NN monkey/NN alveolar/JJ macrophages/NNS (/( SIVmacMER/NN approximately/RB 2xNFkappaB/NN approximately/RB substNFkappaB/NN >/JJ deltaNFkappaB/NN >/JJ deltaNFkappaBdeltaSpl234approximately/RB deltaNFkappaBdeltaSpl/NN >/JJ deltaSpl234/NN approximately/RB substSpl2/NN >/JJ substSp23/NN approximately/RB substSp34/NN approximately/RB substSpl234/NN >/JJ or/CC =/JJ SIVmac239/NN )/) ./. 
Thus/RB ,/, changes/NNS in/IN the/DT Sp1/NN binding/NN sites/NNS had/VBD the/DT most/RBS dramatic/JJ effects/NNS on/IN SIVmac/NN replication/NN in/IN primary/JJ macrophage/NN cultures/NNS ./. 
Analysis/NN of/IN long/JJ terminal/JJ repeat-driven/JJ secreted/VBN alkaline/NN phosphatase/NN activity/NN in/IN transient/JJ assays/NNS showed/VBD that/IN ,/, unlike/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD ,/, the/DT SIV/NN long/JJ terminal/JJ repeat/NN possesses/VBZ an/DT enhancer/NN region/NN just/RB upstream/RB of/IN the/DT NF-kappaB/NN element/NN which/WDT maintains/VBZ significant/JJ levels/NNS of/IN basal/JJ transcription/NN in/IN the/DT absence/NN of/IN NF-kappaB/NN and/CC Sp1/NN sites/NNS ./. 
This/DT region/NN is/VBZ responsive/JJ to/TO transactivation/NN by/IN Tat/NN ./. 
In/IN addition/NN ,/, the/DT SIV/NN TATA/NN box/NN was/VBD shown/VBN to/TO be/VB stronger/JJR than/IN that/DT of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD ./. 
Therefore/RB ,/, the/DT surprisingly/RB high/JJ replicative/JJ capacity/NN of/IN NF-kappaB/NN and/CC Sp1/NN binding/NN site/NN mutants/NNS of/IN SIVmac/NN is/VBZ due/JJ to/TO unique/JJ features/NNS or/CC the/DT enhancer/promoter/NN region/NN ./. 
UI/LS -/: 96195006/CD 
TI/LS -/: cAMP/NN inducibility/NN of/IN transcriptional/JJ repressor/NN ICER/NN in/IN developing/VBG and/CC mature/JJ human/JJ T/NN lymphocytes/NNS [/( published/VBN erratum/NN appears/VBZ in/IN Proc/NNP Natl/NNP Acad/NNP Sci/NNP U/NNP S/NNP A/NNP 1996/CD Jul/NNP 23/CD ;/: 93/CD (/( 15/CD )/) :/: 8154/CD ]/) 
AB/LS -/: Stimulation/NN of/IN the/DT cAMP-dependent/JJ signaling/NN pathway/NN exerts/VBZ an/DT inhibitory/JJ effect/NN on/IN the/DT proliferation/NN and/CC effector/NN functions/NNS of/IN T/NN cells/NNS ./. 
The/DT ability/NN of/IN T/NN cells/NNS to/TO form/VB high/JJ intracellular/JJ levels/NNS of/IN cAMP/NN is/VBZ acquired/VBN during/IN development/NN in/IN the/DT human/JJ thymus/NN and/CC is/VBZ retained/VBN by/IN the/DT majority/NN of/IN mature/JJ peripheral/JJ T/NN lymphocytes/NNS ./. 
Here/RB we/PRP show/VBP that/IN elevated/JJ cAMP/NN levels/NNS in/IN T/NN cells/NNS correlate/VBP with/IN the/DT expression/NN of/IN the/DT potent/JJ transcriptional/JJ repressor/NN ICER/NN (/( inducible/JJ cAMP/NN early/JJ repressor/NN )/) previously/RB described/VBN in/IN the/DT hypothalamic-pituitary-gonadal/JJ axis/NN ./. 
Further/RB ,/, in/IN transcriptional/JJ assays/NNS in/FW vivo/FW ,/, ICER/NN inhibits/VBZ calcineurin-mediated/JJ expression/NN of/IN the/DT interleukin/NN 2/CD promoter/NN as/RB well/RB as/IN Tax-mediated/JJ transactivation/NN of/IN the/DT human/JJ T-lymphotropic/JJ virus/NN type/NN I/CD (/( HTLV-I/NN )/) promoter/NN ./. 
Thus/RB ,/, the/DT induction/NN of/IN ICER/NN in/IN T/NN cells/NNS may/MD play/VB an/DT important/JJ role/NN in/IN the/DT cAMP-induced/JJ quiescence/NN and/CC the/DT persistent/JJ latency/NN of/IN HTLV-I/NN ./. 
UI/LS -/: 96224055/CD 
TI/LS -/: A/DT hydrophobic/JJ domain/NN of/IN Ca2+-modulating/JJ cyclophilin/NN ligand/NN modulates/VBZ calcium/NN influx/NN signaling/NN in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: Ca2+-modulating/JJ cyclophilin/NN ligand/NN (/( CAML/NN )/) was/VBD originally/RB described/VBN as/IN a/DT cyclophilin/NN B-binding/JJ protein/NN whose/WP$ overexpression/NN in/IN T/NN cells/NNS causes/VBZ a/DT rise/NN in/IN intracellular/JJ calcium/NN ,/, thus/RB activating/VBG transcription/NN factors/NNS responsible/JJ for/IN the/DT early/JJ immune/JJ response/NN ./. 
As/IN reported/VBN here/RB ,/, structure-function/JJ analysis/NN of/IN the/DT CAML/NN gene/NN in/IN Jurkat/NN T/NN cells/NNS indicates/VBZ that/IN two/CD of/IN CAML/NN 's/POS putative/JJ membrane-spanning/JJ domains/NNS are/VBP necessary/JJ and/CC sufficient/JJ for/IN the/DT modulation/NN of/IN intracellular/JJ calcium/NN ./. 
We/PRP propose/VBP that/IN the/DT hydrophobic/JJ C-terminal/JJ tail/NN of/IN CAML/NN forms/VBZ its/PRP$ effector/NN domain/NN ,/, thus/RB implicating/VBG the/DT N-terminal/JJ hydrophilic/JJ domain/NN in/IN a/DT regulatory/JJ role/NN ./. 
These/DT findings/NNS define/VBP a/DT novel/JJ protein/NN motif/NN that/WDT functions/VBZ in/IN intracellular/JJ calcium/NN signaling/NN ./. 
UI/LS -/: 96183906/CD 
TI/LS -/: The/DT Epstein-Barr/JJ virus-encoded/JJ nuclear/JJ antigen/NN EBNA-5/NN accumulates/VBZ in/IN PML-containing/JJ bodies/NNS ./. 
AB/LS -/: EBNA-5/NN is/VBZ one/CD of/IN the/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) -encoded/JJ nuclear/JJ proteins/NNS required/VBN for/IN immortalization/NN of/IN human/JJ B/NN lymphocytes/NNS ./. 
In/IN the/DT nuclei/NNS of/IN EBV-transformed/JJ lymphoblastoid/JJ cell/NN lines/NNS EBNA-5/NN is/VBZ preferentially/RB targetted/VBN to/TO distinct/JJ nuclear/JJ foci/NNS ./. 
Previously/RB we/PRP have/VBP shown/VBN (/( W.Q./NNP Jiang/NNP ,/, L.Szekely/NNP ,/, V.Wendel-Hansen/NNP ,/, N.Ringertz/NNP ,/, G.Klein/NNP ,/, and/CC A./NNP Rosen/NNP ,/, Exp.Cell/NNP Res/NNP ./. 
UI/LS -/: 96201015/CD 
TI/LS -/: A/DT new/JJ variant/JJ translocation/NN in/IN acute/JJ promyelocytic/JJ leukaemia/NN :/: molecular/JJ characterization/NN and/CC clinical/JJ correlation/NN ./. 
AB/LS -/: Translocation/NN t(15;17)(q22;q21)/NN is/VBZ an/DT acquired/VBN clonal/JJ cytogenetic/JJ change/NN present/JJ in/IN almost/RB all/DT cases/NNS of/IN acute/JJ promelocytic/JJ leukemia/NN (/( APL/NN )/) ./. 
The/DT molecular/JJ genetic/JJ basis/NN of/IN the/DT translocation/NN supports/VBZ its/PRP$ integral/JJ role/NN in/IN pathogenesis/NN ./. 
We/PRP describe/VBP a/DT patient/NN with/IN APL/NN in/IN whom/WP the/DT leukaemic/JJ clone/NN was/VBD characterized/VBN by/IN a/DT true/JJ variant/NN of/IN the/DT classical/JJ t(15;17)/NN ./. 
The/DT patient/NN whose/WP$ disease/NN had/VBD numerous/JJ atypical/JJ clinical/JJ features/NNS ,/, had/VBD t(11;17)(q13;121)/NN ./. 
The/DT chromosome/NN 17/CD breakpoint/NN was/VBD localized/JJ to/TO intron/NN 2/CD of/IN RARA/NN by/IN Southern/NN blotting/NN ,/, and/CC there/EX was/VBD no/DT evidence/NN at/IN the/DT molecular/JJ level/NN for/IN rearrangement/NN at/IN PML/NN locus/NN ./. 
These/DT data/NNS ,/, along/IN with/IN previous/JJ reports/NNS of/IN rare/JJ variant/JJ translocations/NNS in/IN APL/NN ,/, indicate/VBP that/IN while/IN dysregulation/NN of/IN RARA/NN by/IN gene/NN fusion/NN may/MD be/VB essential/JJ for/IN the/DT APL/NN phenotype/NN ,/, the/DT particular/JJ fusion/NN partner/NN may/MD determine/VB clinicopathological/JJ aspects/NNS ,/, including/VBG presentation/NN ,/, response/NN to/TO treatment/NN with/IN all-trans/JJ retinoic/JJ acid/NN (/( ATRA/NN )/) ,/, and/CC prognosis/NN ./. 
This/DT heterogeneity/NN suggests/VBZ that/IN the/DT variant/JJ fusion/NN partners/NNS of/IN RARA/NN in/IN APL/NN encode/VBP factors/NNS with/IN properties/NNS both/CC common/JJ to/TO and/CC distinct/JJ from/IN those/DT of/IN PML/NN ./. 
Investigation/NN of/IN these/DT factors/NNS promises/VBZ to/TO shed/VB light/NN on/IN the/DT complex/JJ development/NN pathways/NNS involved/VBN in/IN the/DT regulation/NN of/IN haematopoiesis/NN ./. 
UI/LS -/: 96182568/CD 
TI/LS -/: A/DT model/NN of/IN latent/JJ adenovirus/NN 5/CD infection/NN in/IN the/DT guinea/NN pig/NN (/( Cavia/NN porcellus/NN )/) ./. 
AB/LS -/: A/DT model/NN of/IN adenovirus/NN 5/CD (/( Ad5/NN )/) infection/NN was/VBD developed/VBN in/IN guinea/NN pigs/NNS to/TO begin/VB to/TO study/VB its/PRP$ role/NN in/IN the/DT pathogenesis/NN of/IN peripheral/JJ lung/NN inflammation/NN ./. 
Forty/CD animals/NNS were/VBD inoculated/VBN intranasally/RB with/IN 10(7.0)/CD pfu/NN of/IN Ad5/animal/NN ,/, and/CC 15/CD animals/NNS inoculated/VBN with/IN sterile/JJ culture/NN media/NNS served/VBD as/IN controls/NNS ./. 
Viral/JJ titres/NNS were/VBD 10(4.4)/CD ,/, 10(6.1)/CD ,/, 10(5.2)/CD ,/, and/CC 10(2.9)/CD pfu/animal/NN ,/, on/IN days/NNS 1/CD ,/, 3/CD ,/, 4/CD ,/, and/CC 7/CD after/IN infection/NN ,/, respectively/RB ./. 
In/FW situ/FW hybridization/NN to/TO viral/JJ DNA/NN and/CC immunocytochemistry/NN for/IN Ad5/NN E1A/NN protein/NN localized/VBD the/DT virus/NN to/TO airway/NN and/CC alveolar/JJ epithelial/JJ cells/NNS ./. 
Histologic/JJ examination/NN showed/VBD an/DT extensive/JJ inflammatory/JJ cell/NN infiltration/NN around/IN the/DT airways/NNS ,/, with/IN epithelial/JJ necrosis/NN and/CC an/DT alveolar/JJ exudate/NN that/WDT caused/VBD localized/JJ|VBN alveolar/JJ collapse/NN in/IN the/DT infected/JJ areas/NNS ./. 
Immunocytochemistry/NN identified/VBD the/DT cells/NNS in/IN the/DT infiltrate/NN as/IN cytotoxic/JJ T/NN cells/NNS ./. 
Although/IN all/DT animals/NNS 20/CD and/CC 47/CD days/NNS after/IN infection/NN had/VBD seroconverted/VBN to/TO Ad5/NN ,/, virus/NN was/VBD not/RB detected/VBN in/IN these/DT groups/NNS either/CC by/IN viral/JJ plaque/NN assay/NN or/CC in/FW situ/FW hybridization/NN ./. 
Ad5/NN E1A/NN DNA/NN was/VBD detected/VBN by/IN polymerase/NN chain/NN reaction/NN in/IN five/CD of/IN six/CD animals/NNS 20/CD days/NNS after/IN infection/NN and/CC in/IN five/CD of/IN five/CD animals/NNS 47/CD days/NNS after/IN infection/NN ./. 
In/IN these/DT same/JJ animals/NNS ,/, E1A/NN protein/NN was/VBD detected/VBN 20/CD days/NNS after/IN infection/NN in/IN two/CD and/CC 47/CD days/NNS after/IN infection/NN in/IN one/CD while/IN persistent/JJ bronchiolitis/NN was/VBD observed/VBN in/IN four/CD and/CC three/CD animals/NNS 20/CD and/CC 47/CD days/NNS after/IN infection/NN ,/, respectively/RB ./. 
These/DT results/NNS demonstrate/VBP that/IN the/DT guinea/NN pig/NN provides/VBZ a/DT useful/JJ model/NN to/TO study/VB the/DT role/NN of/IN Ad5/NN infection/NN in/IN chronic/JJ airway/NN inflammation/NN ./. 
UI/LS -/: 96190579/CD 
TI/LS -/: Cyclic/JJ AMP-responsive/JJ element-dependent/JJ activation/NN of/IN Epstein-Barr/JJ virus/NN zebra/NN promoter/NN by/IN human/JJ herpesvirus/NN 6/CD ./. 
AB/LS -/: We/PRP have/VBP recently/RB shown/VBN that/IN infection/NN of/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) genome-positive/JJ B/NN cells/NNS by/IN human/JJ herpesvirus/NN 6/CD (/( HHV-6/NN )/) results/VBZ in/IN the/DT expression/NN of/IN the/DT immediate-early/JJ EBV/NN Zebra/NN gene/NN ,/, followed/VBN by/IN virus/NN replication/NN (/( L.Flamand/NNP ,/, I.Stefanescu/NNP ,/, D.V.Ablashi/NNP ,/, and/CC J.Menezes/NNP ,/, J.Virol.67/NNP :/: 6768-6777/CD ,/, 1993/CD )/) ./. 
Here/RB we/PRP show/VBP that/IN HHV-6/NN upregulates/VBZ Zebra/NN gene/NN transcription/NN through/IN a/DT cyclic/JJ AMP-responsive/JJ element/NN (/( CRE/NN )/) located/JJ within/IN the/DT Zebra/NN promoter/NN (/( Zp/NN )/) ./. 
Using/VBG human/JJ B-/NN or/CC T-cell/NN lines/NNS transfected/VBN with/IN ZpCat/NN reporter/NN gene/NN constructs/NNS ,/, we/PRP demonstrate/VBP that/IN a/DT region/NN designated/VBN the/DT ZII/NN domain/NN of/IN Zp/NN is/VBZ the/DT target/NN of/IN HHV-6/NN transactivation/NN ./. 
Mutation/NN of/IN the/DT consensus/NN AP-1/CRE/NN site/NN within/IN ZII/NN abolished/VBD the/DT inducibility/NN of/IN Zp/NN by/IN HHV-6/NN ,/, whereas/IN positioning/NN of/IN the/DT ZII/NN domain/JJ upstream/JJ of/IN the/DT beta-globin/NN minimal/JJ promoter/NN conferred/VBD responsiveness/NN following/VBG HHV-6/NN infection/NN ./. 
Binding/NN of/IN these/DT factors/NNS to/TO ZII/NN was/VBD prevented/VBN by/IN oligonucleotides/NNS containing/VBG CRE/NN but/CC not/RB by/IN AP-1/NN consensus/NN sequences/NNS ./. 
Antibodies/NNS against/IN CRE-binding/JJ (/( CREB/NN )/) protein/NN but/CC not/RB against/IN c-Fos/NN or/CC c-Jun/NN were/VBD able/JJ to/TO supershift/VB the/DT DNA-protein/JJ complex/NN ,/, identifying/VBG the/DT nature/NN of/IN the/DT transcription/NN factor/NN which/WDT binds/VBZ to/TO ZII/NN as/IN a/DT member/NN of/IN the/DT CREB/NN family/NN of/IN proteins/NNS ./. 
Finally/RB ,/, transfection/NN of/IN CREB/NN protein/NN and/CC protein/NN kinase/NN A/NN expression/NN vectors/NNS were/VBD found/VBN to/TO activate/VB Zp/NN in/IN Jurkat/NN cells/NNS ,/, suggesting/VBG that/IN phosphorylated/JJ form/NN of/IN CREB/NN protein/NN can/MD play/VB a/DT determining/JJ role/NN in/IN the/DT EBV/NN reactivation/NN process/NN ./. 
UI/LS -/: 96190675/CD 
TI/LS -/: Regulation/NN of/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS in/IN stably/RB transfected/VBN Jurkat/NN cell/NN clones/NNS ./. 
AB/LS -/: Two/CD Jurkat/NN cell/NN clones/NNS have/VBP been/VBN stably/RB transfected/VBN with/IN a/DT reporter/NN vector/NN for/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) ./. 
Upon/IN stimulation/NN ,/, they/PRP express/VBP high/JJ levels/NNS of/IN secreted/VBN heat/NN stable/JJ placental/JJ alkaline/NN phosphatase/NN ./. 
With/IN these/DT clones/NNS ,/, we/PRP demonstrated/VBD that/IN NFAT/NN activation/NN induced/VBN by/IN phorbol/NN 12-myristate/NN 13-acetate/NN and/CC ionomycin/NN was/VBD inhibited/VBN by/IN both/CC cyclosporin/NN A/NN (/( CsA/NN )/) (/( IC50/NN =/JJ 8/CD nM/NN )/) and/CC FK506/NN (/( IC50/NN =/JJ 160/CD pM/NN )/) ,/, presumably/RB by/IN inhibition/NN of/IN calcineurin/NN activity/NN ./. 
Selective/JJ phosphatase/NN inhibitors/NNS for/IN protein/NN phosphatase/NN 1/CD (/( PP1/NN )/) and/CC 2A/NN (/( PP2A/NN )/) that/WDT do/VBP not/RB inhibit/VB calcineurin/NN ,/, such/JJ as/IN okadaic/JJ acid/NN and/CC calyculin/NN A/NN ,/, also/RB inhibited/VBD NFAT/NN activation/NN with/IN IC50s/NN of/IN 87/CD nM/NN and/CC 4/CD nM/NN ,/, respectively/RB ,/, suggesting/VBG that/IN okadaic/JJ acid/NN and/CC related/JJ inhibitors/NNS may/MD block/VB NFAT/NN activation/NN through/IN the/DT inhibition/NN of/IN PP1/NN ,/, instead/RB of/IN PP2A/NN ./. 
NFAT/NN activation/NN was/VBD also/RB inhibited/VBN by/IN agents/NNS that/WDT increase/VBP cAMP/NN concentrations/NNS such/JJ as/IN dibutyryl/JJ cAMP/NN ,/, forskolin/NN and/CC prostaglandin/NN E2/NN ./. 
These/DT stable/JJ Jurkat/NN cell/NN clones/NNS provide/VBP a/DT convenient/JJ and/CC sensitive/JJ tool/NN to/TO study/VB NFAT/NN regulation/NN ./. 
UI/LS -/: 96152682/CD 
TI/LS -/: Glucocorticoids/NNS induced/VBD down-regulation/NN of/IN glucocorticoid/NN receptor/NN mRNA/NN expression/NN in/IN asthma/NN ./. 
AB/LS -/: Although/IN their/PRP$ precise/JJ mechanism/NN of/IN action/NN remains/VBZ to/TO be/VB elucidated/VBN ,/, glucocorticoids/NNS represent/VBP the/DT most/RBS effective/JJ therapy/NN in/IN the/DT treatment/NN of/IN asthma/NN ./. 
Interactions/NNS between/IN the/DT glucocorticoid/NN receptor/NN and/CC the/DT AP-1/NN complex/NN have/VBP been/VBN shown/VBN to/TO regulate/VB the/DT transcription/NN of/IN some/DT genes/NNS ,/, including/VBG glucocorticoid/NN receptor/NN itself/PRP ./. 
The/DT aim/NN of/IN the/DT present/JJ study/NN was/VBD to/TO compare/VB the/DT expression/NN of/IN mRNA/NN for/IN glucocorticoid/NN receptor/NN in/IN human/JJ blood/NN monocytes/NNS obtained/VBN from/IN seven/CD unstable/JJ untreated/JJ asthmatic/JJ patients/NNS who/WP were/VBD subsequently/RB treated/VBN with/IN high/JJ doses/NNS of/IN parenteral/JJ corticosteroid/NN (/( methyl/NN prednisolone/NN 120/CD mg/day/NN )/) for/IN 10/CD days/NNS ./. 
mRNA/NN expression/NN was/VBD identified/VBN after/IN RNA/NN extraction/NN using/VBG RNAzol/NN and/CC analysed/VBN after/IN reverse/JJ transcriptase/NN ,/, by/IN polymerase/NN chain/NN reaction/NN using/VBG a/DT semiquantitative/JJ competitive/JJ hybridization/NN assay/NN ./. 
All/DT asthmatic/JJ patients/NNS showed/VBD an/DT improvement/NN in/IN their/PRP$ FEV1/NN values/NNS after/IN corticosteroid/NN treatment/NN (/( per/IN cent/NN of/IN predicted/VBN value/NN 68.28/CD +/-/CC 4.93/CD versus/CC 95.57/CD +/-/CC 6.41/CD ,/, P/NN </JJR 0.02/CD )/) ,/, and/CC a/DT significant/JJ decrease/NN for/IN glucocorticoid/NN receptor/NN mRNA/NN expression/NN (/( P/NN </JJR 0.02/CD )/) was/VBD observed/VBN in/IN their/PRP$ monocytes/NNS ./. 
This/DT is/VBZ the/DT first/JJ report/NN of/IN an/DT ex/FW vivo/FW down-regulation/NN for/IN the/DT glucocorticoid/NN receptor/NN mRNA/NN expression/NN ,/, following/VBG corticosteroid/NN treatment/NN ./. 
UI/LS -/: 96278836/CD 
TI/LS -/: Mapping/NN of/IN the/DT transcriptional/JJ repression/NN domain/NN of/IN the/DT lymphoid-specific/JJ transcription/NN factor/NN oct-2A/NN ./. 
AB/LS -/: The/DT lymphoid-specific/JJ transcription/NN factor/NN Oct-2a/NN is/VBZ implicated/VBN in/IN B/NN cell-specific/JJ transcriptional/JJ activity/NN via/IN the/DT octamer/NN motif/NN ./. 
Structure/function/JJ|NN analysis/NN of/IN various/JJ Oct-2a/NN effector/NN regions/NNS in/IN the/DT context/NN of/IN the/DT GAL4/NN DNA-binding/JJ domain/NN revealed/VBD that/IN Oct-2a/NN contains/VBZ two/CD functionally/RB different/JJ activation/NN domains/NNS at/IN the/DT N/NN and/CC the/DT C/NN termini/NNS ./. 
The/DT transcriptional/JJ activity/NN of/IN both/DT domains/NNS is/VBZ strongly/RB potentiated/VBN by/IN interactions/NNS with/IN distinct/JJ B/NN cell-specific/JJ coactivators/NNS ./. 
Recently/RB ,/, we/PRP have/VBP identified/VBN a/DT repression/NN domain/NN located/JJ within/IN the/DT N/NN terminus/NN of/IN Oct-2a/NN (/( amino/NN acids/NNS 2-99/CD )/) ./. 
When/WRB this/DT domain/NN was/VBD transferred/VBN to/TO a/DT potent/JJ activator/NN ,/, transcription/NN was/VBD strongly/RB inhibited/VBN ./. 
In/IN this/DT study/NN we/PRP present/VBP a/DT deletion/NN analysis/NN of/IN the/DT N-terminal/JJ region/NN of/IN Oct-2a/NN to/TO determine/VB the/DT minimal/JJ repression/NN domain/NN ./. 
We/PRP identified/VBD a/DT stretch/NN of/IN 23/CD amino/NN acids/NNS ,/, rich/JJ in/IN serine/NN and/CC threonine/NN residues/NNS ,/, which/WDT was/VBD responsible/JJ for/IN most/JJS of/IN the/DT repression/NN activity/NN ./. 
We/PRP show/VBP that/IN repression/NN is/VBZ strongly/RB dependent/JJ on/IN the/DT type/NN of/IN enhancer/NN present/JJ in/IN the/DT reporter/NN plasmid/NN as/RB well/RB as/IN on/IN the/DT cell/NN line/NN tested/VBN ./. 
The/DT possibility/NN that/IN Oct-2a/NN can/MD act/VB as/IN an/DT activator/NN and/or/CC a/DT repressor/NN may/MD have/VB important/JJ consequences/NNS for/IN the/DT function/NN of/IN Oct-2a/NN in/IN B/NN cell/NN differentiation/NN and/CC other/JJ developmental/JJ processes/NNS ./. 
UI/LS -/: 96247664/CD 
TI/LS -/: Opposing/JJ effects/NNS of/IN glucocorticoids/NNS on/IN the/DT rate/NN of/IN apoptosis/NN in/IN neutrophilic/JJ and/CC eosinophilic/JJ granulocytes/NNS ./. 
AB/LS -/: Eosinophils/NNS and/CC neutrophils/NNS are/VBP closely/RB related/JJ ,/, terminally/RB differentiated/VBN cells/NNS that/WDT in/FW vitro/FW undergo/VBP constitutive/JJ cell/NN death/NN by/IN apoptosis/NN ./. 
The/DT onset/NN of/IN apoptosis/NN in/IN both/DT cell/NN types/NNS can/MD be/VB delayed/VBN by/IN hemopoietins/NNS and/CC inflammatory/JJ mediators/NNS ./. 
Although/IN there/EX have/VBP been/VBN a/DT number/NN of/IN reports/NNS demonstrating/VBG that/IN glucocorticoids/NNS (/( in/IN particular/JJ dexamethasone/NN )/) antagonize/VBP the/DT eosinophil/NN life-prolonging/JJ effects/NNS of/IN hemopoietins/NNS ,/, direct/JJ effects/NNS of/IN dexamethasone/NN on/IN eosinophil/NN apoptosis/NN have/VBP not/RB been/VBN documented/VBN ./. 
In/IN this/DT study/NN we/PRP examined/VBD the/DT direct/JJ effects/NNS of/IN glucocorticoids/NNS on/IN eosinophil/NN and/CC neutrophil/NN apoptosis/NN in/IN light/NN of/IN their/PRP$ common/JJ therapeutic/JJ use/NN as/IN anti-inflammatory/JJ and/CC anti-allergic/hypereosinophilic/JJ agents/NNS ./. 
We/PRP found/VBD that/IN treatment/NN with/IN dexamethasone/NN induced/VBD eosinophil/NN apoptosis/NN ./. 
In/IN contrast/NN ,/, dexamethasone/NN was/VBD a/DT potent/JJ inhibitor/NN of/IN neutrophil/NN apoptosis/NN ./. 
The/DT effect/NN of/IN dexamethasone/NN on/IN both/DT cell/NN types/NNS was/VBD mediated/VBN through/IN the/DT glucocorticoid/NN receptor/NN ,/, i.e./FW ,/, it/PRP was/VBD abolished/VBN by/IN the/DT glucocorticoid/NN receptor/NN antagonist/NN RU38486/NN ./. 
This/DT is/VBZ the/DT first/JJ description/NN of/IN an/DT agent/NN that/WDT promotes/VBZ eosinophil/NN apoptosis/NN while/IN inhibiting/VBG neutrophil/NN apoptosis/NN ,/, and/CC thus/RB presents/VBZ a/DT novel/JJ approach/NN to/TO the/DT study/NN of/IN control/NN of/IN apoptosis/NN in/IN these/DT closely/RB related/JJ cell/NN types/NNS as/RB well/RB as/IN increases/VBZ our/PRP$ understanding/NN of/IN the/DT clinical/JJ action/NN of/IN glucocorticoids/NNS in/IN inflammation/NN ./. 
UI/LS -/: 96186719/CD 
TI/LS -/: Permanent/JJ occupancy/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD enhancer/NN by/IN NF-kappa/NN B/NN is/VBZ needed/VBN for/IN persistent/JJ viral/JJ replication/NN in/IN monocytes/NNS ./. 
AB/LS -/: This/DT work/NN aimed/VBD to/TO ascertain/VB the/DT role/NN of/IN kappaB-responsive/JJ elements/NNS of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) enhancer/NN not/RB only/RB in/IN early/JJ initiation/NN but/CC also/RB in/IN long-term/JJ maintenance/NN of/IN proviral/JJ transcription/NN in/IN cells/NNS of/IN the/DT monocytic/JJ lineage/NN ./. 
For/IN this/DT purpose/NN ,/, we/PRP used/VBD three/CD main/JJ approaches/NNS ./. 
The/DT first/JJ was/VBD to/TO abruptly/RB terminate/VB tumor/NN necrosis/NN factor-induced/JJ NF-kappaB/NN binding/VBG to/TO the/DT enhancer/NN sequences/NNS in/IN U1/NN monocytic/JJ cells/NNS ,/, using/VBG a/DT short/JJ pulse/NN of/IN exogenous/JJ tumor/NN necrosis/NN factor/NN ./. 
This/DT resulted/VBD in/IN concomitant/JJ decrease/NN in/IN nuclear/JJ NF-kappaB/NN DNA-binding/JJ activity/NN and/CC endogenous/JJ long/JJ terminal/JJ repeat/NN transcriptional/JJ activity/NN ./. 
The/DT second/JJ was/VBD to/TO suppress/VB the/DT permanent/JJ NF-kappaB/NN translocation/NN induced/VBN by/IN HIV-1/NN replication/NN itself/PRP in/IN chronically/RB infected/JJ U937/NN cells/NNS ,/, using/VBG a/DT specific/JJ proteasome/NN inhibitor/NN (/( Z-LLL-H/NN )/) ./. 
As/RB early/RB as/IN 2/CD h/NN after/IN addition/NN of/IN the/DT inhibitor/NN to/TO the/DT culture/NN medium/NN ,/, there/EX was/VBD an/DT inhibition/NN of/IN both/CC constitutive/JJ activation/NN of/IN NF-kappaB/NN and/CC HIV-1/NN genome/NN expression/NN ./. 
The/DT third/JJ approach/NN was/VBD to/TO monitor/VB the/DT replication/NN competence/NN in/IN U937/NN cells/NNS of/IN an/DT infectious/JJ HIV-1/NN provirus/NN carrying/VBG point/NN mutations/NNS in/IN the/DT kappaB-responsive/JJ elements/NNS of/IN both/DT long/JJ terminal/JJ repeats/NNS ./. 
Compared/VBN with/IN its/PRP$ wild-type/JJ counterpart/NN ,/, this/DT mutated/VBN provirus/NN showed/VBD a/DT profoundly/RB decreased/VBN ,/, Z-LLL-H-insensitive/JJ transcriptional/JJ and/CC replicative/JJ activity/NN in/IN U937/NN monocytes/NNS ./. 
Together/RB ,/, our/PRP$ results/NNS indicate/VBP that/IN occupancy/NN of/IN the/DT viral/JJ enhancer/NN by/IN NF-kappaB/NN (/( p50/p65/NN )/) heterodimers/NNS is/VBZ required/VBN for/IN ongoing/JJ transcription/NN of/IN integrated/VBN HIV/NN provirus/NN in/IN monocytes/NNS ,/, even/RB in/IN cells/NNS chronically/RB infected/VBN and/CC permanently/RB producing/VBG functional/JJ HIV/NN Tat/NN protein/NN ./. 
Thus/RB ,/, the/DT ability/NN of/IN HIV-1/NN replication/NN to/TO activate/VB NF-kappaB/NN is/VBZ crucial/JJ to/TO the/DT intense/JJ self-perpetuated/JJ viral/JJ transcription/NN observed/VBN in/IN cells/NNS of/IN the/DT monocytic/JJ lineage/NN ./. 
UI/LS -/: 96194982/CD 
TI/LS -/: Rel-deficient/JJ T/NN cells/NNS exhibit/VBP defects/NNS in/IN production/NN of/IN interleukin/NN 3/CD and/CC granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN ./. 
AB/LS -/: The/DT c-rel/NN protooncogene/NN encodes/VBZ a/DT subunit/NN of/IN the/DT NF-kappa/NN B-like/JJ family/NN of/IN transcription/NN factors/NNS ./. 
Mice/NNS lacking/VBG Rel/NN are/VBP defective/JJ in/IN mitogenic/JJ activation/NN of/IN B/NN and/CC T/NN lymphocytes/NNS and/CC display/VBP impaired/JJ humoral/JJ immunity/NN ./. 
In/IN an/DT attempt/NN to/TO identify/VB changes/NNS in/IN gene/NN expression/NN that/WDT accompany/VBP the/DT T-cell/NN stimulation/NN defects/NNS associated/VBN with/IN the/DT loss/NN of/IN Rel/NN ,/, we/PRP have/VBP examined/VBN the/DT expression/NN of/IN cell/NN surface/NN activation/NN markers/NNS and/CC cytokine/NN production/NN in/IN mitogen-stimulated/JJ Rel-/-/JJ T/NN cells/NNS ./. 
The/DT expression/NN of/IN cell/NN surface/NN markers/NNS including/VBG the/DT interleukin/NN 2/CD receptor/NN alpha/NN (/( IL-2R/NN alpha/NN )/) chain/NN (/( CD25/NN )/) ,/, CD69/NN and/CC L-selectin/NN (/( CD62/NN )/) is/VBZ normal/JJ in/IN mitogen-activated/JJ Rel-/-/JJ T/NN cells/NNS ,/, but/CC cytokine/NN production/NN is/VBZ impaired/JJ ./. 
In/IN Rel-/-/JJ splenic/JJ T/NN cell/NN cultures/NNS stimulated/VBN with/IN phorbol/NN 12-myristate/NN 13-acetate/NN and/CC ionomycin/NN ,/, the/DT levels/NNS of/IN IL-3/NN ,/, IL-5/NN ,/, granulocyte- macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) ,/, tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) ,/, and/CC gamma/NN interferon/NN (/( IFN-gamma/NN )/) were/VBD only/RB 2-/CD to/TO 3-fold/RB lower/JJR compared/VBN with/IN normal/JJ T/NN cells/NNS ./. 
In/IN contrast/NN ,/, anti-CD3/JJ|NN and/CC anti-CD28/JJ|NN stimulated/JJ Rel-/-/JJ T/NN cells/NNS ,/, which/WDT fail/VBP to/TO proliferate/VB ,/, make/VBP little/JJ or/CC no/DT detectable/JJ cytokines/NNS ./. 
Exogenous/JJ IL-2/NN ,/, which/WDT restitutes/VBZ the/DT proliferative/JJ response/NN of/IN the/DT anti-CD3-/JJ|NN and/CC anti-CD28-treated/JJ Rel-/-/JJ T/NN cells/NNS ,/, restores/VBZ production/NN of/IN IL-5/NN ,/, TNF-alpha/NN ,/, and/CC IFN-gamma/NN ,/, but/CC not/RB IL-3/NN and/CC GM-CSF/NN expression/NN to/TO approximately/RB normal/JJ levels/NNS ./. 
In/IN contrast/NN to/TO mitogen-activated/JJ Rel-/-/JJ T/NN cells/NNS ,/, lipopolysaccharide-stimulated/JJ Rel-/-/JJ macrophages/NNS produce/VBP higher/JJR than/IN normal/JJ levels/NNS of/IN GM-CSF/NN ./. 
These/DT findings/NNS establish/VBP that/IN Rel/NN can/MD function/VB as/IN an/DT activator/NN or/CC repressor/NN of/IN gene/NN expression/NN and/CC is/VBZ required/VBN by/IN T/NN lymphocytes/NNS for/IN production/NN of/IN IL-3/NN and/CC GM-CSF/NN ./. 
UI/LS -/: 96215235/CD 
TI/LS -/: Nuclear/JJ appearance/NN of/IN a/DT factor/NN that/WDT binds/VBZ the/DT CD28/NN response/NN element/NN within/IN the/DT interleukin-2/NN enhancer/NN correlates/VBZ with/IN interleukin-2/NN production/NN ./. 
AB/LS -/: Activation/NN of/IN T/NN lymphocytes/NNS requires/VBZ the/DT combined/JJ signaling/NN of/IN the/DT T/NN cell/NN receptor/NN and/CC costimulatory/JJ molecules/NNS such/JJ as/IN CD28/NN ./. 
The/DT ability/NN of/IN T/NN cells/NNS to/TO produce/VB interleukin-2/NN (/( IL-2/NN )/) is/VBZ a/DT critical/JJ control/NN point/NN in/IN T/NN lymphocyte/NN activation/NN ./. 
The/DT IL-2/NN enhancer/NN contains/VBZ a/DT functional/JJ motif/NN named/VBN CD28/NN response/NN element/NN (/( CD28RE/NN )/) that/WDT serves/VBZ a/DT role/NN as/IN a/DT target/NN for/IN mitogenic/JJ T/NN cell/NN activation/NN signals/NNS ./. 
The/DT CD28RE/NN sequence/NN reveals/VBZ similarity/NN to/TO the/DT consensus/NN kappaB/NN binding/NN motif/NN ./. 
Here/RB we/PRP demonstrate/VBP that/IN CD28RE/NN binds/VBZ an/DT inducible/JJ protein/NN with/IN a/DT molecular/JJ mass/NN of/IN approximately/RB 35/CD kDa/NN called/VBN nuclear/JJ factor/NN of/IN mitogenic-activated/JJ T/NN cells/NNS (/( NF-MATp35/NN )/) that/WDT is/VBZ clearly/RB different/JJ from/IN the/DT known/JJ NF- kappaB/Rel/NN family/NN members/NNS ./. 
Induction/NN of/IN NF-MATp35/NN was/VBD shown/VBN to/TO depend/VB on/IN de/FW novo/FW protein/NN synthesis/NN and/CC was/VBD restricted/JJ to/TO T/NN cells/NNS that/WDT received/VBD a/DT mitogenic/JJ combination/NN of/IN T/NN cell/NN stimuli/NNS ,/, not/RB necessarily/RB including/VBG CD28/NN signaling/NN ./. 
Nonmitogenic/JJ T/NN cell/NN stimulation/NN did/VBD not/RB result/VB in/IN appearance/NN of/IN NF-MATp35/NN ./. 
These/DT results/NNS indicate/VBP that/IN mitogenic/JJ combinations/NNS of/IN T/NN cell/NN activation/NN signals/NNS are/VBP integrated/VBN at/IN the/DT level/NN of/IN NF-MATp35/NN induction/NN ./. 
Similar/JJ to/TO its/PRP$ effect/NN on/IN IL-2/NN production/NN ,/, cyclosporin/NN A/NN inhibited/VBD the/DT induction/NN of/IN NF-MATp35/NN ./. 
Taken/VBN together/RB ,/, these/DT data/NNS demonstrate/VBP that/IN the/DT nuclear/JJ appearance/NN of/IN NF-MATp35/NN shows/VBZ excellent/JJ correlation/NN with/IN IL-2/NN production/NN ,/, which/WDT is/VBZ a/DT unique/JJ characteristic/NN among/IN nuclear/JJ factors/NNS implicated/VBN in/IN the/DT control/NN of/IN IL-2/NN gene/NN expression/NN ./. 
UI/LS -/: 96201628/CD 
TI/LS -/: Transcriptional/JJ basis/NN for/IN hyporesponsiveness/NN of/IN the/DT human/JJ inducible/JJ nitric/JJ oxide/NN synthase/NN gene/NN to/TO lipopolysaccharide/interferon-gamma/NN ./. 
AB/LS -/: The/DT work/NN reported/VBN here/RB resolves/VBZ ,/, at/IN the/DT level/NN of/IN gene/NN regulation/NN ,/, the/DT controversy/NN as/IN to/TO whether/IN or/CC not/RB human/JJ monocytes/macrophages/NNS can/MD produce/VB nitric/JJ oxide/NN (/( NO/NN )/) when/WRB stimulated/VBN with/IN lipopolysaccharide/NN (/( LPS/NN )/) ,/, with/IN or/CC without/IN co-stimulation/NN by/IN interferon-gamma/NN (/( IFN-gamma/NN )/) ./. 
Studies/NNS included/VBD structural/JJ comparison/NN of/IN the/DT promoters/NNS for/IN human/JJ and/CC mouse/NN inducible/JJ NO/NN synthase/NN (/( iNOS/NN )/) genes/NNS ,/, transfection/NN and/CC assay/NN of/IN human/JJ and/CC mouse/NN iNOS/NN promoter/NN regions/NNS in/IN response/NN to/TO LPS/NN +/-/CC IFN-gamma/NN ,/, and/CC electrophoretic/JJ mobility/NN shift/NN assays/NNS of/IN kappa/NN B/NN response/NN elements/NNS ./. 
Two/CD explanations/NNS for/IN hyporesponsiveness/NN of/IN the/DT human/JJ iNOS/NN promoter/NN to/TO LPS/NN +/-/CC IFN-gamma/NN were/VBD found/VBN :/: (/( 1/LS )/) multiple/JJ inactivating/VBG nucleotide/JJ substitutions/NNS in/IN the/DT human/JJ counterpart/NN of/IN the/DT enhancer/NN element/NN that/WDT has/VBZ been/VBN shown/VBN to/TO regulate/VB LPS/IFN-gamma/NN induced/JJ expression/NN of/IN the/DT mouse/NN iNOS/NN gene/NN ;/: and/CC (/( 2/LS )/) and/CC absence/NN of/IN one/CD or/CC more/JJR nuclear/JJ factors/NNS in/IN human/JJ macrophages/NNS (/( e.g./FW ,/, an/DT LPS-inducible/JJ nuclear/JJ factor-kappa/NN B/Rel/NN complex/NN )/) ,/, that/WDT is/VBZ (/( are/VBP )/) required/VBN for/IN maximal/JJ expression/NN of/IN the/DT gene/NN ./. 
The/DT importance/NN of/IN resolution/NN of/IN this/DT controversy/NN is/VBZ that/IN future/JJ research/NN in/IN this/DT area/NN should/MD be/VB directed/VBN toward/IN the/DT understanding/NN of/IN alternative/JJ mechanisms/NNS that/WDT can/MD result/VB in/IN the/DT successful/JJ production/NN of/IN NO/NN ./. 
UI/LS -/: 96341625/CD 
TI/LS -/: X/NN inactivation/NN analysis/NN in/IN a/DT female/NN with/IN hypomelanosis/NN of/IN Ito/NN associated/VBN with/IN a/DT balanced/JJ X/NN ;/: 17/CD translocation/NN :/: evidence/NN for/IN functional/JJ disomy/NN of/IN Xp/NN ./. 
AB/LS -/: X/NN inactivation/NN analysis/NN was/VBD performed/VBN on/IN normal/JJ and/CC hypopigmented/JJ skin/NN samples/NNS obtained/VBN from/IN a/DT female/NN with/IN hypomelanosis/NN of/IN Ito/NN associated/VBN with/IN a/DT balanced/JJ whole/JJ arm/NN X/NN ;/: 17/CD translocation/NN ./. 
Severe/JJ skewing/NN of/IN X/NN inactivation/NN resulting/VBG in/IN inactivity/NN of/IN the/DT intact/JJ X/NN was/VBD found/VBN in/IN blood/NN and/CC cultures/NNS of/IN both/DT types/NNS of/IN skin/NN ,/, but/CC analysis/NN of/IN DNA/NN prepared/VBN directly/RB from/IN hypopigmented/JJ skin/NN showed/VBD significant/JJ inactivation/NN of/IN the/DT translocated/VBN X/NN ,/, inconsistent/JJ with/IN the/DT usual/JJ mechanism/NN of/IN phenotypic/JJ expression/NN in/IN X/NN ;/: autosome/JJ translocations/NNS ./. 
In/IN addition/NN ,/, dual/JJ colour/NN FISH/NN analysis/NN using/VBG centromere/NN specific/JJ probes/NNS for/IN chromosomes/NNS X/NN and/CC 17/CD showed/VBD that/IN the/DT breakpoints/NNS on/IN both/DT chromosomes/NNS lie/VBP within/IN the/DT alphoid/JJ arrays/NNS ,/, making/VBG interruption/NN of/IN a/DT locus/NN on/IN either/DT chromosome/NN unlikely/JJ ./. 
While/IN partial/JJ variable/JJ monosomy/NN of/IN loci/NNS on/IN chromosome/NN 17p/NN can/MD not/RB be/VB excluded/VBN as/IN contributing/VBG to/TO the/DT phenotype/NN in/IN this/DT patient/NN ,/, it/PRP is/VBZ argued/VBN that/IN the/DT major/JJ likely/JJ factor/NN is/VBZ partial/JJ functional/JJ disomy/NN of/IN sequences/NNS on/IN Xp/NN in/IN cell/NN lineages/NNS that/WDT have/VBP failed/VBN to/TO inactivate/VB the/DT intact/JJ X/NN chromosome/NN ./. 
UI/LS -/: 96190573/CD 
TI/LS -/: Identification/NN of/IN a/DT herpesvirus/NN Saimiri/NN cis-acting/JJ DNA/NN fragment/NN that/WDT permits/VBZ stable/JJ replication/NN of/IN episomes/NNS in/IN transformed/VBN T/NN cells/NNS ./. 
AB/LS -/: Herpesvirus/NN saimiri/NN is/VBZ a/DT lymphotropic/JJ herpesvirus/NN capable/JJ of/IN immortalizing/VBG and/CC transforming/VBG T/NN cells/NNS both/CC in/FW vitro/FW and/CC in/FW vivo/FW ./. 
Immortalized/VBN and/CC transformed/VBN T/NN cells/NNS harbor/VBP several/JJ copies/NNS of/IN the/DT viral/JJ genome/NN as/IN a/DT persisting/VBG|JJ genome/NN ./. 
The/DT mapping/NN of/IN the/DT cis-acting/JJ genetic/JJ cis-acting/JJ segment/NN (/( oriP/NN )/) required/VBN for/IN viral/JJ episomal/JJ maintenance/NN is/VBZ reported/VBN here/RB ./. 
Viral/JJ DNA/NN fragments/NNS that/WDT potentially/RB contain/VBP oriP/NN were/VBD cloned/VBN into/IN a/DT plasmid/NN that/WDT contains/VBZ the/DT hygromycin/NN resistance/NN gene/NN ./. 
After/IN several/JJ round/NN of/IN subcloning/NN followed/VBN by/IN transfection/NN ,/, oriP/NN was/VBD mapped/VBN to/TO a/DT 1.955-kb/JJ viral/JJ segment/NN ./. 
This/DT viral/JJ fragment/NN permits/VBZ stable/JJ plasmid/NN replication/NN without/IN deletion/NN or/CC rearrangement/NN as/RB well/RB as/IN episomal/JJ maintenance/NN without/IN integration/NN or/CC recombination/NN ./. 
The/DT function/NN of/IN oriP/NN depends/VBZ on/IN a/DT trans-acting/JJ factor/NN (/( s/NNS )/) encoded/VBN by/IN the/DT viral/JJ genome/NN ./. 
The/DT 1.955-kb/JJ viral/JJ segment/NN includes/VBZ a/DT dyad/JJ symmetry/NN region/NN located/JJ between/IN two/CD small/JJ nuclear/JJ RNA/NN genes/NNS and/CC is/VBZ located/JJ upstream/RB of/IN the/DT dihydrofolate/JJ reductase/NN gene/NN homolog/NN ./. 
Therefore/RB ,/, this/DT oriP/NN contains/VBZ novel/JJ elements/NNS distinct/JJ from/IN those/DT of/IN other/JJ DNA/NN viruses/NNS ./. 
UI/LS -/: 96165503/CD 
TI/LS -/: In/FW vivo/FW anergized/VBN CD4+/JJ T/NN cells/NNS express/VBP perturbed/VBN AP-1/NN and/CC NF-kappa/NN B/NN transcription/NN factors/NNS ./. 
AB/LS -/: Anergy/NN is/VBZ a/DT major/JJ mechanism/NN to/TO ensure/VB antigen-specific/JJ tolerance/NN in/IN T/NN lymphocytes/NNS in/IN the/DT adult/NN ./. 
In/FW vivo/FW ,/, anergy/NN has/VBZ mainly/RB been/VBN studied/VBN at/IN the/DT cellular/JJ level/NN ./. 
In/IN this/DT study/NN ,/, we/PRP used/VBD the/DT T-cell-activating/JJ superantigen/NN staphylococcal/NN enterotoxin/NN A/NN (/( SEA/NN )/) to/TO investigate/VB molecular/JJ mechanisms/NNS of/IN T-lymphocyte/NN anergy/NN in/FW vivo/FW ./. 
Injection/NN of/IN SEA/NN to/TO adult/JJ mice/NNS activates/VBZ CD4+/JJ T/NN cells/NNS expressing/VBG certain/JJ T-cell/NN receptor/NN (/( TCR/NN )/) variable/JJ region/NN beta-chain/IN families/NNS and/CC induces/VBZ strong/JJ and/CC rapid/JJ production/NN of/IN interleukin/NN 2/CD (/( IL-2/NN )/) ./. 
In/IN contrast/NN ,/, repeated/JJ injections/NNS of/IN SEA/NN cause/VBP CD4+/JJ T-cell/NN deletion/NN and/CC anergy/NN in/IN the/DT remaining/VBG CD4+/JJ T/NN cells/NNS ,/, characterized/VBN by/IN reduced/VBN expression/NN of/IN IL-2/NN at/IN mRNA/NN and/CC protein/NN levels/NNS ./. 
We/PRP analyzed/VBD expression/NN of/IN AP-1/NN ,/, NF-kappa/NN B/NN ,/, NF-AT/NN ,/, and/CC octamer/NN binding/NN transcription/NN factors/NNS ,/, which/WDT are/VBP known/VBN to/TO be/VB involved/VBN in/IN the/DT regulation/NN of/IN IL-2/NN gene/NN promoter/NN activity/NN ./. 
Large/JJ amounts/NNS of/IN AP-1/NN and/CC NF-kappa/NN B/NN and/CC significant/JJ quantities/NNS of/IN NF-AT/NN were/VBD induced/VBN in/IN SEA-activated/JJ CD4+/JJ spleen/NN T/NN cells/NNS ,/, whereas/IN Oct-1/NN and/CC Oct-2/NN DNA/NN binding/NN activity/NN was/VBD similar/JJ in/IN both/CC resting/VBG and/CC activated/VBN T/NN cells/NNS ./. 
In/IN contrast/NN ,/, anergic/JJ CD4+/JJ T/NN cells/NNS contained/VBD severely/RB reduced/VBN levels/NNS of/IN AP-1/NN and/CC Fos/Jun-containing/JJ NF-AT/NN complexes/NNS but/CC expressed/VBD significant/JJ amounts/NNS of/IN NF-kappa/NN B/NN and/CC Oct/NN binding/NN proteins/NNS after/IN SEA/NN stimulation/NN ./. 
Resolution/NN of/IN the/DT NF-kappa/NN B/NN complex/NN demonstrated/VBD predominant/JJ expression/NN of/IN p50-p65/JJ|NN heterodimers/NNS in/IN activated/VBN CD4+/JJ T/NN cells/NNS ,/, while/IN anergic/JJ cells/NNS mainly/RB expressed/VBD the/DT transcriptionally/RB inactive/JJ p50/NN homodimer/NN ./. 
These/DT alterations/NNS of/IN transcription/NN factors/NNS are/VBP likely/JJ to/TO be/VB responsible/JJ for/IN repression/NN of/IN IL-2/NN in/IN anergic/JJ T/NN cells/NNS ./. 
UI/LS -/: 96151964/CD 
TI/LS -/: Fas/NN ligation/NN induces/VBZ apoptosis/NN and/CC Jun/NN kinase/NN activation/NN independently/RB of/IN CD45/NN and/CC Lck/NN in/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: Stimulation/NN through/IN the/DT Fas/APO-1/JJ|NN receptor/NN results/NNS in/IN apoptosis/NN through/IN an/DT incompletely/RB characterized/VBN signaling/NN pathway/NN ./. 
More/JJR is/VBZ known/VBN regarding/VBG signal/NN transduction/NN events/NNS that/WDT occur/VBP after/IN ligation/NN of/IN the/DT T-cell/NN antigen/NN receptor/NN (/( TCR/NN )/) ./. 
It/PRP has/VBZ been/VBN shown/VBN that/IN TCR/NN stimulation/NN requires/VBZ both/CC the/DT membrane/NN tyrosine/NN phosphatase/NN ,/, CD45/NN ,/, and/CC the/DT Src-family/JJ kinase/NN ,/, Lck/NN ,/, to/TO result/VB in/IN cellular/JJ activation/NN ./. 
Although/IN prior/JJ studies/NNS suggest/VBP a/DT role/NN for/IN protein/NN tyrosine/NN kinases/NNS and/CC phosphatases/NNS in/IN Fas/NN signaling/NN ,/, we/PRP report/VBP here/RB that/IN Fas/NN ligation/NN induces/VBZ apoptosis/NN in/IN T/NN cells/NNS deficient/JJ in/IN either/CC CD45/NN or/CC Lck/NN ./. 
Further/RB ,/, in/IN normal/JJ and/CC CD45-/NN or/CC Lck-deficient/JJ cell/NN lines/NNS ,/, Fas/NN stimulation/NN results/VBZ in/IN activation/NN of/IN Jun/NN kinase/NN (/( JNK/NN )/) ,/, a/DT proposed/JJ mediator/NN of/IN stress/NN activation/NN pathways/NNS ./. 
Previous/JJ studies/NNS have/VBP also/RB demonstrated/VBN a/DT role/NN for/IN endogenous/JJ ceramide/NN release/NN in/IN Fas-mediated/JJ apoptosis/NN ./. 
We/PRP show/VBP that/IN stimulation/NN with/IN a/DT synthetic/JJ ceramide/NN analog/NN results/VBZ in/IN JNK/NN activation/NN as/RB well/RB as/IN apoptosis/NN ,/, suggesting/VBG ceramide/NN release/NN occurs/VBZ proximal/JJ to/TO JNK/NN activation/NN in/IN Fas/NN signaling/NN ./. 
Our/PRP$ data/NNS suggest/VBP that/IN although/IN CD45/NN and/CC Lck/NN are/VBP not/RB required/VBN for/IN Fas/NN signaling/NN ,/, JNK/NN activation/NN may/MD play/VB an/DT important/JJ role/NN transducing/VBG distal/JJ signals/NNS that/WDT lead/VBP to/TO apoptosis/NN after/IN Fas/NN ligation/NN ./. 
UI/LS -/: 96278860/CD 
TI/LS -/: Globin/NN gene/NN switching/NN ./. 
In/FW vivo/FW protein-DNA/JJ interactions/NNS of/IN the/DT human/JJ beta-globin/NN locus/NN in/IN erythroid/JJ cells/NNS expressing/VBG the/DT fetal/JJ or/CC the/DT adult/JJ globin/NN gene/NN program/NN ./. 
AB/LS -/: To/TO characterize/VB the/DT protein-DNA/JJ interactions/NNS important/JJ for/IN the/DT developmental/JJ control/NN of/IN the/DT human/JJ beta-globin/NN locus/NN ,/, we/PRP analyzed/VBD by/IN in/FW vivo/FW dimethyl/NN sulfate/JJ footprinting/NN erythroid/JJ cells/NNS expressing/VBG either/CC the/DT fetal/JJ or/CC the/DT adult/JJ globin/NN developmental/JJ program/NN ./. 
In/IN the/DT locus/NN control/NN region/NN (/( LCR/NN )/) of/IN the/DT beta-globin/NN locus/NN ,/, in/FW vivo/FW footprints/NNS on/IN NF-E2/NN (/( or/CC AP-1/NN )/) and/CC GATA-1/NN motifs/NNS remained/VBD the/DT same/JJ regardless/RB of/IN whether/IN the/DT fetal/JJ or/CC the/DT adult/JJ globin/NN genes/NNS are/VBP expressed/VBN ./. 
In/IN contrast/NN ,/, in/FW vivo/FW footprints/NNS on/IN GT/NN (/( CACCC/NN )/) motifs/NNS differed/VBD between/IN the/DT cells/NNS expressing/VBG the/DT fetal/JJ or/CC the/DT adult/JJ globin/NN program/NN ./. 
In/IN promoter/NN regions/NNS ,/, the/DT actively/RB transcribed/VBN genes/NNS demonstrated/VBD extensive/JJ and/CC consistent/JJ footprints/NNS over/IN the/DT canonical/JJ elements/NNS ,/, such/JJ as/IN CACCC/NN and/CC CCAAT/NN motifs/NNS ./. 
The/DT adult/JJ globin/NN expressing/NN cells/NNS displayed/VBD more/RBR extensive/JJ footprints/NNS than/IN the/DT fetal/JJ globin/NN expressing/NN cells/NNS in/IN the/DT 3'/JJ regulatory/JJ sequences/NNS of/IN both/CC the/DT Agamma-/NN and/CC the/DT beta-globin/NN genes/NNS ,/, suggesting/VBG a/DT role/NN of/IN these/DT 3'/JJ elements/NNS in/IN beta-globin/NN gene/NN expression/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN the/DT bulk/NN of/IN protein-DNA/JJ interactions/NNS that/WDT underlies/VBZ the/DT developmental/JJ control/NN of/IN globin/NN genes/NNS takes/VBZ place/NN in/IN the/DT gamma-/NN and/CC beta-globin/NN gene/NN promoters/NNS ,/, and/CC that/IN GT/NN motifs/NNS of/IN the/DT beta-globin/NN locus/NN LCR/NN may/MD play/VB a/DT role/NN in/IN the/DT developmental/JJ regulation/NN of/IN human/JJ beta-globin/NN gene/NN expression/NN ,/, perhaps/RB by/IN increasing/VBG the/DT probability/NN of/IN interaction/NN of/IN the/DT LCR/NN holocomplex/NN with/IN the/DT fetal/JJ or/CC the/DT adult/JJ globin/NN gene/NN ./. 
UI/LS -/: 96247660/CD 
TI/LS -/: Antisense/JJ inhibition/NN of/IN vitamin/NN D/NN receptor/NN expression/NN induces/VBZ apoptosis/NN in/IN monoblastoid/JJ U937/NN cells/NNS ./. 
AB/LS -/: The/DT active/JJ vitamin/NN D3/NN metabolite/NN 1,25-dihydroxycholecalciferol/NN (/( 1,25(OH)2D3/NN )/) acts/VBZ as/IN an/DT antiproliferative/JJ and/CC differentiating/VBG agent/NN for/IN the/DT monoblastoid/JJ cell/NN line/NN U937/NN and/CC as/IN an/DT important/JJ immunologic/JJ mediator/NN implicated/VBN particularly/RB in/IN the/DT function/NN of/IN cells/NNS belonging/VBG to/TO the/DT monocyte/macrophage/NN lineage/NN ./. 
These/DT effects/NNS are/VBP controlled/VBN by/IN the/DT vitamin/NN D/NN receptor/NN (/( VDR/NN )/) ,/, a/DT member/NN of/IN the/DT steroid/NN hormone/NN receptor/NN family/NN ./. 
The/DT objective/NN of/IN this/DT study/NN was/VBD to/TO develop/VB U937/NN transfectants/NNS expressing/VBG antisense/JJ VDR/NN mRNA/NN ,/, and/CC to/TO use/VB these/DT to/TO examine/VB the/DT role/NN of/IN 1,25(OH)2D3-VDR/JJ interaction/NN in/IN this/DT lineage/NN ./. 
A/DT 2-kb/JJ VDR/NN cDNA/NN insert/NN (/( including/VBG the/DT complete/JJ VDR/NN coding/NN region/NN )/) was/VBD cloned/VBN in/IN an/DT antisense/JJ orientation/NN into/IN the/DT EBV/NN episomal/NN vector/NN pMEP4/NN under/IN the/DT control/NN of/IN an/DT inducible/JJ promoter/NN and/CC transfected/VBN into/IN U937/NN ./. 
The/DT resultant/JJ cell/NN line/NN ,/, DH42/NN ,/, was/VBD hygromycin/NN resistant/JJ ,/, contained/VBD VDR/NN cDNA/NN ,/, expressed/VBD fewer/JJR VDRs/NNS than/IN controls/NNS ,/, and/CC showed/VBD a/DT substantial/JJ decrease/NN in/IN antiproliferative/JJ response/NN to/TO 1,25(OH)2D3/NN ./. 
However/RB ,/, 1,25(OH)2D3/NN increased/VBD the/DT number/NN of/IN cells/NNS expressing/VBG macrophage/NN cell/NN surface/NN Ags/NN ,/, including/VBG CD14/NN and/CC CD11b/NN ./. 
A/DT subpopulation/NN of/IN smaller/JJR cells/NNS did/VBD not/RB express/VB the/DT differentiation/NN markers/NNS after/IN cadmium/NN stimulation/NN ./. 
Cell/NN cycle/NN analysis/NN showed/VBD shifts/NNS in/IN the/DT distribution/NN of/IN cells/NNS from/IN G1/NN to/TO S/NN phase/NN ,/, which/WDT were/VBD more/RBR pronounced/JJ after/IN cadmium/NN treatment/NN ./. 
A/DT considerable/JJ proportion/NN of/IN cells/NNS were/VBD outside/IN the/DT cycle/NN and/CC DNA/NN fragmentation/NN confirmed/VBD apoptosis/NN ./. 
Thus/RB ,/, the/DT functional/JJ outcome/NN of/IN the/DT VDR/NN antisense/JJ transfection/NN suggests/VBZ that/IN in/IN the/DT myelomonocytic/JJ lineage/NN ,/, VDR/NN expression/NN may/MD act/VB as/IN a/DT protective/JJ mechanism/NN against/IN programmed/VBN cell/NN death/NN ./. 
UI/LS -/: 96208140/CD 
TI/LS -/: Human/JJ T/NN lymphotropic/JJ virus-I/NN infection/NN of/IN human/JJ T/NN lymphocytes/NNS induces/VBZ expression/NN of/IN the/DT beta-galactoside-binding/JJ lectin/NN ,/, galectin-3/NN ./. 
AB/LS -/: Animal/NN lectins/NNS play/VBP important/JJ roles/NNS in/IN a/DT variety/NN of/IN biological/JJ processes/NNS via/IN their/PRP$ recognition/NN of/IN glycoconjugates/NNS ./. 
Galectin-3/NN is/VBZ a/DT beta-galactoside-binding/JJ lectin/NN previously/RB designated/VBN as/IN epsilon/NN BP/NN (/( IgE-binding/JJ protein/NN )/) ,/, CBP35/NN ,/, Mac-2/NN ,/, L-29/NN ,/, and/CC L-34/NN ,/, and/CC its/PRP$ expression/NN has/VBZ been/VBN associated/VBN with/IN various/JJ physiological/JJ and/CC pathological/JJ processes/NNS ,/, including/VBG cell/NN growth/NN ,/, tumor/NN transformation/NN ,/, and/CC metastasis/NN ./. 
Galectin-3/NN is/VBZ widely/RB distributed/VBN in/IN various/JJ tissues/NNS and/CC cell/NN types/NNS and/CC is/VBZ expressed/VBN in/IN many/JJ leukocytes/NNS ,/, with/IN the/DT notable/JJ exception/NN of/IN B/NN and/CC T/NN lymphocytes/NNS ./. 
We/PRP now/RB report/VBP that/IN galectin-3/NN is/VBZ abundantly/RB expressed/VBN in/IN a/DT number/NN of/IN human/JJ T/NN lymphotropic/JJ virus/NN (/( HTLV/NN )/) -I-infected/JJ human/JJ T/NN cell/NN lines/NNS ,/, including/VBG F6T/NN ,/, HUT/NN 102/CD ,/, K3T/NN ,/, MT-2/NN ,/, and/CC SLB-I/NN ,/, but/CC is/VBZ not/RB expressed/VBN in/IN non-HTLV-I-infected/JJ T/NN cell/NN lines/NNS such/JJ as/IN Jurkat/NN ,/, CEM/NN ,/, and/CC MOLT-4/NN ./. 
In/IN addition/NN ,/, the/DT galectin-3/NN level/NN was/VBD markedly/RB increased/VBN in/IN human/JJ thymocytes/NNS after/IN infection/NN with/IN HTLV-I/NN as/IN compared/VBN with/IN uninfected/JJ thymocytes/NNS ./. 
The/DT up-regulation/NN of/IN galectin-3/NN expression/NN appeared/VBD to/TO correlate/VB well/RB with/IN HTLV-I/NN gene/NN expression/NN ,/, as/IN undetectable/JJ or/CC very/RB low/JJ levels/NNS of/IN galectin-3/NN were/VBD found/VBN in/IN the/DT S1T/NN and/CC ATL-1K/NN cell/NN lines/NNS ,/, which/WDT are/VBP nonproductively/RB infected/VBN with/IN HTLV-I/NN ./. 
In/IN co-transfection/NN experiments/NNS ,/, the/DT galectin-3/NN promoter/NN was/VBD significantly/RB up-regulated/VBN by/IN expression/NN vectors/NNS encoding/VBG the/DT 40-kd/JJ Tax/NN protein/NN ,/, a/DT potent/JJ transactivator/NN in/IN HTLV-I/NN ./. 
Analysis/NN of/IN various/JJ Tax/NN mutants/NNS suggested/VBD that/IN galectin-3/NN promoter/NN induction/NN is/VBZ dependent/JJ on/IN activation/NN of/IN the/DT cyclic-AMP-responsive/JJ element/NN binding/NN protein/activation/NN transcription/NN factor/NN family/NN of/IN transcription/NN factors/NNS and/CC ,/, to/TO a/DT lesser/JJR extent/NN ,/, nuclear/JJ factor-kappa/NN B/Rel/NN induction/NN ./. 
Transfection/NN of/IN human/JJ promonocytic/JJ U-937/NN cells/NNS with/IN an/DT HTLV-I/NN Tax/NN expression/NN vector/NN induced/VBD galectin-3/NN expression/NN in/IN this/DT cell/NN line/NN ./. 
Functionally/RB ,/, galectin-3/NN was/VBD shown/VBN to/TO activate/VBP interleukin-2/NN production/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
Together/RB ,/, these/DT findings/NNS raise/VBP the/DT possibility/NN that/IN HTLV-I/NN Tax/NN production/NN induces/VBZ the/DT transcription/NN and/CC subsequent/JJ synthesis/NN and/CC secretion/NN of/IN galectin-3/NN ,/, which/WDT in/IN turn/NN may/MD further/RB activate/VB these/DT T/NN cells/NNS and/CC contribute/VB to/TO the/DT altered/JJ properties/NNS of/IN cell/NN growth/NN found/VBN in/IN adult/JJ T/NN cell/NN leukemia/NN induced/VBN by/IN HTLV-I/NN ./. 
UI/LS -/: 96194689/CD 
TI/LS -/: Monocytic/JJ cell/NN type-specific/JJ transcriptional/JJ induction/NN of/IN collagenase/NN ./. 
AB/LS -/: Interstitial/JJ collagenase/NN (/( MMP-1/NN )/) ,/, a/DT metalloproteinase/NN produced/VBN by/IN resident/JJ and/CC inflammatory/JJ cells/NNS during/IN connective/JJ tissue/NN turnover/NN ,/, cleaves/VBZ type/NN I/CD collagen/NN fibrils/NNS ./. 
This/DT catalytic/JJ event/NN is/VBZ rate/NN limiting/VBG in/IN remodeling/NN of/IN tissues/NNS rich/JJ in/IN fibrillar/JJ collagen/NN such/JJ as/IN the/DT skin/NN and/CC lungs/NNS ./. 
The/DT regulation/NN of/IN collagenase/NN expression/NN is/VBZ cell-type/NN specific/JJ ;/: bacterial/JJ LPS/NN and/CC zymosan/NN ,/, a/DT yeast/NN cell/NN wall/NN derivative/NN ,/, are/VBP potent/JJ inducers/NNS of/IN collagenase/NN expression/NN in/IN macrophages/NNS ,/, but/CC do/VBP not/RB alter/VB fibroblast/NN collagenase/NN expression/NN ./. 
Since/IN promoter/NN elements/NNS controlling/VBG collagenase/NN transcription/NN in/IN monocytic/JJ cells/NNS have/VBP not/RB been/VBN previously/RB defined/VBN ,/, we/PRP sought/VBD to/TO delineate/VB responsive/JJ cis-acting/JJ elements/NNS of/IN the/DT collagenase/NN promoter/NN in/IN transiently/RB transfected/VBN human/JJ (/( U937/NN )/) and/CC murine/JJ (/( J774/NN )/) monocytic/JJ cell/NN lines/NNS ./. 
Deletion/NN constructs/NNS containing/VBG as/RB little/JJ as/IN 72/CD bp/NN of/IN 5' -flanking/JJ sequence/NN of/IN the/DT collagenase/NN promoter/NN were/VBD sufficient/JJ for/IN LPS-/NN or/CC zymosan-mediated/JJ transcriptional/JJ induction/NN ,/, whereas/IN phorbol/NN inducibility/NN exhibited/VBD an/DT absolute/JJ requirement/NN for/IN upstream/JJ elements/NNS including/VBG the/DT polyoma/NN enhancer/NN A-binding/JJ protein-3/NN site/NN (/( -83/CD to/TO -91/CD )/) and/CC TTCA/NN sequence/NN (/( -102/CD to/TO -105/CD )/) in/IN both/CC monocytic/JJ cells/NNS and/CC fibroblasts/NNS ./. 
Mutagenesis/NN of/IN the/DT activator/NN protein-1/NN [/( AP-1/NN ]/) site/NN at/IN -72/CD abolished/VBD basal/JJ promoter/NN activity/NN and/CC LPS/zymosan/NN inducibility/NN ,/, while/IN mutagenesis/NN of/IN an/DT NF-kappaB-like/JJ site/NN at/IN -20/CD to/TO -10/CD had/VBD no/DT effect/NN ./. 
Nuclear/JJ extracts/NNS from/IN LPS-/NN and/CC zymosan-treated/JJ cells/NNS showed/VBD strong/JJ AP-1/NN activity/NN by/IN gel-shift/JJ analysis/NN ,/, and/CC supershift/NN analysis/NN showed/VBD the/DT AP-1/NN complexes/NNS contained/VBD specific/JJ members/NNS of/IN both/CC the/DT jun/NN and/CC fos/NN gene/NN families/NNS ./. 
These/DT data/NNS indicate/VBP that/IN ,/, in/IN contrast/NN to/TO most/JJS LPS/NN effects/NNS ,/, AP-1/NN ,/, but/CC not/RB nuclear/JJ factor-kappaB/NN ,/, mediates/VBZ LPS/NN induction/NN of/IN collagenase/NN transcription/NN in/IN macrophagelike/JJ cells/NNS ./. 
Furthermore/RB ,/, as/IN compared/VBN to/TO regulation/NN by/IN phorbol/NN ester/NN ,/, collagenase/NN induction/NN in/IN monocytic/JJ cells/NNS by/IN cell/NN wall/NN derivatives/NNS of/IN bacteria/NNS or/CC yeast/NN is/VBZ largely/RB independent/JJ of/IN upstream/JJ promoter/NN sequences/NNS ./. 
UI/LS -/: 96181482/CD 
TI/LS -/: Activation/NN of/IN c-Jun/NN N-terminal/JJ kinase/NN in/IN bacterial/JJ lipopolysaccharide-stimulated/JJ macrophages/NNS ./. 
AB/LS -/: Activation/NN of/IN macrophages/NNS by/IN bacterial/JJ lipopolysaccharide/NN (/( LPS/NN )/) induces/VBZ transcription/NN of/IN genes/NNS that/WDT encode/VBP for/IN proinflammatory/JJ regulators/NNS of/IN the/DT immune/JJ response/NN ./. 
Previous/JJ work/NN has/VBZ suggested/VBN that/IN activation/NN of/IN the/DT transcription/NN factor/NN activator/NN protein/NN 1/CD (/( AP-1/NN )/) is/VBZ one/CD LPS-induced/JJ event/NN that/WDT mediates/VBZ this/DT response/NN ./. 
Consistent/JJ with/IN this/DT notion/NN ,/, we/PRP found/VBD that/IN LPS/NN stimulated/VBD AP-1-mediated/JJ transcription/NN of/IN a/DT transfected/VBN reporter/NN gene/NN in/IN the/DT murine/JJ macrophage/NN cell/NN line/NN RAW/NN 264.7/CD ./. 
As/IN AP-1/NN activity/NN is/VBZ regulated/VBN in/IN part/NN by/IN activation/NN of/IN the/DT c-Jun/NN N-terminal/JJ kinase/NN (/( JNK/NN )/) ,/, which/WDT phosphorylates/VBZ and/CC subsequently/RB increases/VBZ the/DT transcriptional/JJ activity/NN of/IN c-Jun/NN ,/, we/PRP examined/VBD whether/IN LPS/NN treatment/NN of/IN macrophages/NNS resulted/VBD in/IN activation/NN of/IN this/DT kinase/NN ./. 
LPS/NN treatment/NN of/IN RAW/NN 264.7/CD cells/NNS ,/, murine/JJ bone/NN marrow-derived/JJ macrophages/NNS ,/, and/CC the/DT human/JJ monocyte/NN cell/NN line/NN THP-1/NN resulted/VBD in/IN rapid/JJ activation/NN of/IN the/DT p46/NN and/CC p54/NN isoforms/NNS of/IN JNK/NN ./. 
Treatment/NN with/IN wild-type/JJ and/CC rough/JJ mutant/JJ forms/NNS of/IN LPS/NN and/CC synthetic/JJ lipid/NN A/NN resulted/VBD in/IN JNK/NN activation/NN ,/, while/IN pretreatment/NN with/IN the/DT tyrosine/NN kinase/NN inhibitor/NN herbimycin/NN A/NN inhibited/VBD this/DT response/NN ./. 
Binding/NN of/IN LPS-LPS/NN binding/NN protein/NN (/( LBP/NN )/) complexes/NNS to/TO CD14/NN ,/, a/DT surface/NN receptor/NN that/WDT mediates/VBZ many/JJ LPS/NN responses/NNS ,/, was/VBD found/VBN to/TO be/VB crucial/JJ ,/, as/IN pretreatment/NN of/IN THP-1/NN cells/NNS with/IN the/DT monoclonal/JJ antibody/NN 60b/NN ,/, which/WDT blocks/VBZ this/DT binding/NN ,/, inhibited/VBD JNK/NN activation/NN ./. 
These/DT results/NNS suggest/VBP that/IN LPS/NN activation/NN of/IN JNK/NN in/IN monocyte/macrophage/JJ|NN cells/NNS is/VBZ a/DT CD14-/NN and/CC protein/NN tyrosine/NN phosphorylation-dependent/JJ event/NN that/WDT may/MD mediate/VB the/DT early/JJ activation/NN of/IN AP-1/NN in/IN regulating/VBG LPS-triggered/JJ gene/NN induction/NN ./. 
UI/LS -/: 96186978/CD 
TI/LS -/: Surfactant/NN suppresses/VBZ NF-kappa/NN B/NN activation/NN in/IN human/JJ monocytic/JJ cells/NNS ./. 
AB/LS -/: In/IN addition/NN to/TO biophysical/JJ properties/NNS ,/, pulmonary/JJ surfactant/NN has/VBZ immunomodulatory/JJ activity/NN ./. 
We/PRP previously/RB demonstrated/VBD that/IN both/CC synthetic/JJ (/( Exosurf/NN )/) and/CC modified/VBN natural/JJ surfactant/NN (/( Survanta/NN )/) downregulated/VBD endotoxin-stimulated/JJ inflammatory/JJ c/NN ytokine/NN mRNA/NN levels/NNS and/CC protein/NN products/NNS (/( tumor/NN necrosis/NN factor-alpha/NN [/( TNF/NN ]/) ,/, interleukin-1-beta/NN [/( IL-1/NN ]/) ,/, interleukin-6/NN [/( IL-6/NN ]/) )/) in/IN human/JJ alveolar/NN macrophages/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP report/VBP that/IN both/CC Exosurf/NN and/CC Survanta/NN suppress/VBP TNF/NN mRNA/NN and/CC secretion/NN (/( 85/CD +/-/CC 4/CD %/NN mean/NN percent/NN inhibition/NN +/-/CC SEM/NN by/IN Exosurf/NN ;/: 71/CD +/-/CC 6/CD %/NN by/IN Survanta/NN )/) by/IN endotoxin-stimulated/JJ THP-1/NN ,/, a/DT human/JJ monocytic/JJ cell/NN line/NN ./. 
Because/IN surfactant/NN downregulated/VBD inflammatory/JJ cytokine/NN production/NN similarly/RB in/IN both/CC normal/JJ human/JJ alveolar/JJ macrophages/NNS and/CC the/DT THP-1/NN cell/NN line/NN ,/, we/PRP used/VBD this/DT cell/NN line/NN to/TO investigate/VB whether/IN surfactant/JJ affected/VBN transcriptional/JJ mechanisms/NNS ./. 
Specifically/RB ,/, we/PRP examined/VBD nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) activation/NN because/IN it/PRP is/VBZ crucial/JJ in/IN transcriptional/JJ regulation/NN of/IN many/JJ inflammatory/JJ cytokine/NN genes/NNS including/VBG TNF/NN ,/, IL-1/NN ,/, and/CC IL-6/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS showed/VBD that/IN both/DT surfactants/NNS decreased/VBD activation/NN of/IN NF-kappa/NN B/NN ./. 
The/DT presence/NN of/IN both/CC p65/NN and/CC p50/NN NF-kappa/NN B/NN components/NNS in/IN LPS-activated/JJ THP-1/NN cells/NNS was/VBD confirmed/VBN by/IN specific/JJ antibody/NN induction/NN of/IN supershifts/NNS in/IN mobility/NN assays/NNS ./. 
These/DT results/NNS are/VBP the/DT first/JJ to/TO suggest/VB that/IN surfactant/NN 's/POS suppressive/JJ effects/NNS on/IN inflammatory/JJ cytokine/NN production/NN may/MD involve/VB transcriptional/JJ regulation/NN through/IN inhibition/NN of/IN NF-kappa/NN B/NN activation/NN ./. 
UI/LS -/: 96228299/CD 
TI/LS -/: A/DT cell/NN type-specific/JJ enhancer/NN in/IN the/DT human/JJ B7.1/NN gene/NN regulated/VBN by/IN NF-kappaB/NN ./. 
AB/LS -/: The/DT costimulatory/JJ molecule/NN B7.1/NN provides/VBZ a/DT second/JJ signal/NN critical/JJ for/IN T/NN cell/NN activation/NN ./. 
The/DT distribution/NN of/IN this/DT integral/JJ membrane/NN protein/NN is/VBZ restricted/JJ to/TO certain/JJ tissues/NNS where/WRB its/PRP$ level/NN of/IN expression/NN is/VBZ modulated/VBN by/IN multiple/JJ exogenous/JJ stimuli/NNS ./. 
To/TO identify/VB the/DT molecular/JJ basis/NN for/IN specificity/NN and/CC inducibility/NN ,/, the/DT chromatin/NN configuration/NN of/IN the/DT human/JJ B7.1/NN gene/NN was/VBD examined/VBN in/IN intact/JJ nuclei/NNS from/IN various/JJ cell/NN types/NNS ./. 
The/DT identification/NN of/IN a/DT tissue-specific/JJ deoxyribonuclease/NN I/CD hypersensitive/JJ site/NN approximately/RB 3kb/JJ upstream/JJ of/IN the/DT transcription/NN start/NN site/NN led/VBD to/TO the/DT characterization/NN of/IN a/DT cell/NN type-specific/JJ enhancer/NN region/NN ./. 
This/DT 183-bp/JJ region/NN was/VBD both/CC cell/NN type/NN specific/JJ and/CC responsive/JJ to/TO two/CD distinct/JJ stimuli/NNS ,/, lipopolysaccharide/NN and/CC dibutyryl/NN cAMP/NN ,/, known/VBN to/TO regulate/VB B7.1/NN expression/NN ./. 
Deletional/JJ and/CC site-directed/JJ mutagenesis/NN revealed/VBD the/DT presence/NN of/IN multiple/JJ functionally/RB critical/JJ cis/NN elements/NNS within/IN this/DT region/NN ,/, one/CD of/IN which/WDT was/VBD a/DT nuclear/JJ factor/NN (/( NF/NN )/) -kappaB/NN consensus/NN sequence/NN ./. 
In/IN B7.1-positive/JJ B/NN cells/NNS ,/, this/DT element/NN bound/VBD several/JJ members/NNS of/IN the/DT NF-kappaB/NN family/NN ,/, transcription/NN factors/NNS already/RB implicated/VBN in/IN signal/NN transduction/NN pathways/NNS relevant/JJ to/TO B7.1/NN expression/NN ./. 
This/DT is/VBZ the/DT first/JJ description/NN ,/, to/TO our/PRP$ knowledge/NN ,/, of/IN regulatory/JJ elements/NNS that/WDT control/VBP expression/NN of/IN a/DT gene/NN encoding/VBG a/DT B7/NN costimulatory/JJ molecule/NN ./. 
UI/LS -/: 96214919/CD 
TI/LS -/: Ubiquitinylation/NN of/IN transcription/NN factors/NNS c-Jun/NN and/CC c-Fos/NN using/VBG reconstituted/VBN ubiquitinylating/VBG enzymes/NNS ./. 
AB/LS -/: Recombinant/JJ c-Jun/NN and/CC c-Fos/NN were/VBD ubiquitinylated/VBN by/IN the/DT ubiquitin/NN carrier/NN enzymes/NNS E214K/NN ,/, E220K/NN ,/, or/CC E232K/NN in/IN the/DT presence/NN of/IN the/DT ubiquitin-activating/JJ enzyme/NN ,/, E1/NN ./. 
Addition/NN of/IN ubiquitin/NN protein/NN ligase/NN E3/NN substantially/RB enhanced/VBD the/DT E214K-mediated/JJ ubiquitinylation/NN of/IN c-Jun/NN and/CC c-Fos/NN ./. 
Truncated/VBN c-Jun/NN and/CC c-Fos/NN mutant/JJ proteins/NNS including/VBG wbJun/NN and/CC wbFos/NN were/VBD also/RB ubiquitinylated/VBN under/IN the/DT same/JJ conditions/NNS ,/, suggesting/VBG the/DT sites/NNS of/IN ubiquitinylation/NN are/VBP located/JJ within/IN the/DT dimerization/NN and/CC DNA/NN binding/NN domains/NNS of/IN c-Jun/NN and/CC c-Fos/NN ./. 
The/DT E3-dependent/JJ ubiquitinylation/NN of/IN c-Jun/NN was/VBD inhibited/VBN upon/IN the/DT heterodimerization/NN of/IN c-Jun/NN with/IN c-Fos/NN ./. 
Further/IN addition/NN of/IN E220K/NN significantly/RB enhanced/VBD ubiquitinylation/NN of/IN c-Jun/NN in/IN the/DT heterodimer/NN suggesting/VBG a/DT regulatory/JJ role/NN of/IN E220K/NN ./. 
Polyubiquitinylated/VBN c-Jun/NN ,/, wbFos/NN ,/, and/CC wbJun/NN ,/, but/CC not/RB E220K-ubiquitinylated/JJ c-Jun/NN ,/, were/VBD readily/RB degraded/VBN by/IN the/DT ATP-dependent/JJ 26/CD S/NN multicatalytic/JJ proteases/NNS ./. 
These/DT results/NNS suggest/VBP that/IN the/DT temporal/JJ control/NN of/IN c-Jun/NN and/CC c-Fos/NN may/MD be/VB regulated/VBN through/IN the/DT ubiquitinylation/NN pathways/NNS ,/, and/CC the/DT ubiquitinylation/NN of/IN c-Jun/NN and/CC c-Fos/NN may/MD in/IN turn/NN be/VB regulated/VBN in/IN response/NN to/TO the/DT heterodimerization/NN between/IN them/PRP and/CC the/DT cooperation/NN between/IN E220K/NN and/CC E3/NN mediated/JJ polyubiquitinylation/NN ./. 
UI/LS -/: 97021709/CD 
TI/LS -/: Cloning/NN and/CC characterization/NN of/IN the/DT murine/JJ B-cell/NN specific/JJ transcriptional/JJ coactivator/NN Bob1/NN ./. 
AB/LS -/: From/IN a/DT murine/JJ B-cell/NN cDNA-library/NN we/PRP have/VBP cloned/VBN a/DT cDNA/NN encoding/VBG the/DT murine/JJ B-cell/NN specific/JJ coactivator/NN mBob1/NN ./. 
The/DT protein/NN is/VBZ the/DT murine/JJ homologue/NN to/TO the/DT recently/RB described/VBN human/JJ coactivator/NN Bob1/NN (/( hBob1/NN )/) ,/, also/RB referred/VBN to/TO as/IN OBF-1/NN or/CC OCA-B/NN ./. 
We/PRP have/VBP also/RB characterized/VBN the/DT genomic/JJ mBob1/NN clone/NN ./. 
Analysis/NN of/IN its/PRP$ intron-exon/JJ structure/NN has/VBZ allowed/VBN identification/NN of/IN a/DT C-terminal/JJ splice/NN variant/NN ./. 
mBob1/NN is/VBZ B-cell/NN restricted/JJ ,/, and/CC is/VBZ found/VBN in/IN all/DT B-cell/NN lines/NNS representing/VBG different/JJ stages/NNS of/IN B-cell/NN differentiation/NN ./. 
mBob1/NN interacts/VBZ with/IN the/DT octamer/NN transcription/NN factors/NNS Oct-1/NN and/CC Oct-2/NN and/CC stimulates/VBZ transcription/NN mediated/VBN by/IN these/DT factors/NNS ./. 
UI/LS -/: 96144358/CD 
TI/LS -/: HIV/NN glycoprotein/NN 120/CD enhances/VBZ intercellular/JJ adhesion/NN molecule-1/NN gene/NN expression/NN in/IN glial/JJ cells/NNS ./. 
Involvement/NN of/IN Janus/NN kinase/signal/JJ|NN transducer/NN and/CC activator/NN of/IN transcription/NN and/CC protein/NN kinase/NN C/NN signaling/NN pathways/NNS ./. 
AB/LS -/: It/PRP is/VBZ well/RB established/VBN that/IN the/DT two/CD major/JJ glial/JJ cells/NNS in/IN the/DT central/JJ nervous/JJ system/NN (/( CNS/NN )/) ,/, astrocytes/NNS and/CC microglia/NN ,/, are/VBP key/JJ participants/NNS in/IN mediating/VBG the/DT neurologic/JJ dysfunction/NN associated/VBN with/IN HIV/NN infection/NN of/IN the/DT CNS/NN ./. 
In/IN this/DT study/NN ,/, we/PRP investigated/VBD the/DT ability/NN of/IN the/DT major/JJ envelope/NN glycoprotein/NN of/IN HIV/NN ,/, glycoprotein/NN 120/CD (/( gp120/NN )/) ,/, to/TO regulate/VB intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN )/) expression/NN in/IN glial/JJ cells/NNS ,/, because/IN ICAM-1/NN is/VBZ important/JJ in/IN mediating/VBG immune/JJ responsiveness/NN in/IN the/DT CNS/NN ,/, facilitating/VBG entry/NN of/IN HIV-infected/JJ cells/NNS into/IN the/DT CNS/NN ,/, and/CC promoting/VBG syncytia/NN formation/NN ./. 
Our/PRP$ results/NNS indicate/VBP that/IN gp120/NN enhances/VBZ ICAM-1/NN gene/NN expression/NN in/IN primary/JJ rat/NN astrocytes/NNS ,/, primary/JJ human/JJ astrocytes/NNS ,/, a/DT human/JJ astroglioma/NN cell/NN line/NN CRT/NN ,/, and/CC primary/JJ rat/NN microglia/NNS ./. 
The/DT signal/NN transduction/NN events/NNS involved/VBN in/IN gp120-mediated/JJ enhancement/NN of/IN ICAM-1/NN appear/VBP to/TO involve/VB activation/NN of/IN both/CC protein/NN kinase/NN C/NN and/CC tyrosine/NN kinase/NN ,/, because/IN inhibitors/NNS of/IN protein/NN kinase/NN C/NN and/CC tyrosine/NN kinase/NN abrogate/VBP gp120-mediated/JJ ICAM-1/NN expression/NN in/IN both/CC astrocytes/NNS and/CC microglia/NNS ./. 
Moreover/RB ,/, gp120/NN induces/VBZ tyrosine/NN phosphorylation/NN of/IN signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT-1/NN alpha/NN )/) as/RB well/RB as/IN the/DT Janus/NN kinase/NN (/( JAK2/NN )/) in/IN glial/JJ cells/NNS ./. 
We/PRP also/RB demonstrate/VBP that/IN gp120-mediated/JJ ICAM-1/NN expression/NN has/VBZ functional/JJ significance/NN ,/, as/IN it/PRP enhances/VBZ the/DT ability/NN of/IN monocytic/JJ cells/NNS to/TO bind/VB to/TO gp120-stimulated/JJ human/JJ astrocytes/NNS in/IN an/DT ICAM-1/beta/NN 2/CD integrin-dependent/JJ fashion/NN ./. 
These/DT results/NNS provide/VBP new/JJ insights/NNS into/IN how/WRB gp120/NN can/MD influence/VB the/DT involvement/NN of/IN glial/JJ cells/NNS in/IN the/DT pathogenesis/NN of/IN AIDS/NN dementia/JJ|NN complex/NN ./. 
UI/LS -/: 96133016/CD 
TI/LS -/: IL-10/NN cooperates/VBZ with/IN TNF-alpha/NN to/TO activate/VB HIV-1/NN from/IN latently/RB and/CC acutely/RB infected/JJ cells/NNS of/IN monocyte/macrophage/NN lineage/NN ./. 
AB/LS -/: IL-10/NN is/VBZ elevated/JJ in/IN HIV-1-infected/JJ individuals/NNS and/CC has/VBZ been/VBN implicated/VBN in/IN disease/NN progression/NN ./. 
In/IN this/DT study/NN ,/, we/PRP investigated/VBD the/DT effects/NNS of/IN IL-10/NN on/IN the/DT activation/NN of/IN HIV-1/NN from/IN infected/JJ monocytes/NNS and/CC macrophages/NNS ./. 
Although/IN IL-10/NN alone/RB did/VBD not/RB induce/VB HIV-1/NN replication/NN ,/, in/IN the/DT presence/NN of/IN TNF-alpha/NN ,/, IL-10/NN markedly/RB enhanced/VBD virion/NN production/NN from/IN a/DT chronically/RB infected/JJ promonocytic/JJ cell/NN line/NN (/( U1/NN )/) and/CC in/IN acutely/RB infected/JJ monocyte-derived/JJ macrophages/NNS ./. 
Neutralizing/VBG mAbs/NNS to/TO IL-10/NN and/CC TNF-alpha/NN indicated/VBD that/IN both/DT cytokines/NNS were/VBD essential/JJ for/IN the/DT induction/NN and/CC were/VBD required/VBN to/TO generate/VB a/DT synergistic/JJ increase/NN in/IN virus/NN expression/NN ./. 
The/DT effects/NNS of/IN the/DT two/CD cytokines/NNS were/VBD distinguishable/JJ functionally/RB since/IN pretreatment/NN with/IN TNF-alpha/NN attenuated/VBD the/DT cytokine/NN cooperativity/NN ,/, while/IN pretreatment/NN with/IN IL-10/NN potentiated/VBD their/PRP$ cooperativity/NN ,/, suggesting/VBG that/IN IL-10/NN and/CC TNF-alpha/NN play/VBP different/JJ roles/NNS in/IN the/DT activation/NN of/IN virus/NN ./. 
Northern/JJ|NN blot/NN analysis/NN as/RB well/RB as/IN Ab/NN blocking/NN and/CC cytokine/NN secretion/NN studies/NNS indicated/VBD that/IN the/DT induction/NN of/IN either/CC endogenous/JJ TNF-alpha/NN or/CC IL-10/NN was/VBD not/RB involved/VBN in/IN the/DT cooperativity/NN ,/, nor/CC was/VBD an/DT up-regulation/NN of/IN TNF-alpha/NN receptors/NNS ./. 
In/IN combination/NN with/IN TNF-alpha/NN ,/, IL-10/NN stimulated/VBD activating/VBG protein-1/NN (/( AP-1/NN )/) and/CC nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN binding/NN activities/NNS and/CC cooperated/VBD to/TO increase/VB HIV-1/NN steady-state/JJ mRNA/NN levels/NNS and/CC enhance/VB long/JJ terminal/JJ repeat-directed/JJ transcription/NN through/IN activation/NN of/IN the/DT NF-kappa/NN B/NN binding/NN sites/NNS ,/, suggesting/VBG the/DT IL-10/NN effect/NN occurs/VBZ at/IN least/JJS in/IN part/NN at/IN the/DT transcriptional/JJ level/NN ./. 
These/DT results/NNS indicate/VBP that/IN IL-10/NN ,/, in/IN addition/NN to/TO down-regulating/VBG the/DT cellular/JJ immune/JJ response/NN to/TO HIV-1/NN ,/, may/MD also/RB play/VB a/DT role/NN in/IN TNF-alpha-mediated/JJ activation/NN of/IN HIV-1/NN replication/NN in/IN the/DT monocyte/macrophage/JJ|NN lineage/NN ./. 
UI/LS -/: 96390735/CD 
TI/LS -/: Interaction/NN of/IN HTLV-I/NN Tax/NN with/IN the/DT human/JJ proteasome/NN :/: implications/NNS for/IN NF-kappa/NN B/NN induction/NN ./. 
AB/LS -/: The/DT human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) has/VBZ been/VBN etiologically/RB associated/VBN with/IN the/DT development/NN of/IN the/DT adult/JJ T-cell/NN leukemia/NN (/( ATL/NN )/) as/RB well/RB as/IN degenerative/JJ neurologic/JJ syndrome/NN termed/VBN tropical/JJ spastic/JJ paraparesis/NN (/( TSP/NN )/) ./. 
HTLV-I/NN encodes/VBZ a/DT potent/JJ transactivator/NN protein/NN termed/VBN Tax/NN that/WDT appears/VBZ to/TO play/VB an/DT important/JJ role/NN in/IN the/DT process/NN of/IN T-cell/NN immortalization/NN ./. 
Even/RB though/IN the/DT mechanisms/NNS by/IN which/WDT Tax/NN induces/VBZ transformation/NN are/VBP still/RB unknown/JJ ,/, it/PRP seems/VBZ likely/JJ that/IN the/DT ability/NN of/IN Tax/NN to/TO alter/VB the/DT expression/NN of/IN many/JJ cellular/JJ genes/NNS plays/VBZ an/DT important/JJ part/NN in/IN this/DT process/NN ./. 
Tax/NN does/VBZ not/RB bind/VB directly/RB to/TO DNA/NN but/CC rather/RB deregulates/VBZ the/DT activity/NN of/IN cellular/JJ transcription/NN factors/NNS ./. 
One/CD family/NN of/IN host/NN transcription/NN factors/NNS whose/WP$ activity/NN is/VBZ altered/VBN by/IN Tax/NN includes/VBZ NF-kappa/NN B/Rel/NN ./. 
These/DT transcription/NN factors/NNS are/VBP post-transcriptionally/RB regulated/VBN by/IN their/PRP$ assembly/NN with/IN a/DT second/JJ family/NN of/IN inhibitory/JJ proteins/NNS termed/VBN I/NN kappa/NN B/NN that/WDT serve/VBP to/TO sequester/VB the/DT NF-kappa/NN B/Rel/NN complexes/NNS in/IN the/DT cytoplasm/NN ./. 
Upon/IN cellular/JJ activation/NN ,/, I/NN kappa/NN B/NN alpha/NN is/VBZ phosphorylated/VBN ,/, polyubiquitinated/VBN ,/, and/CC degraded/VBN in/IN the/DT proteasome/NN ./. 
This/DT proteolytic/JJ event/NN liberates/VBZ NF-kappa/NN B/NN ,/, permitting/VBG its/PRP$ rapid/JJ translocation/NN into/IN the/DT nucleus/NN where/WRB it/PRP binds/VBZ to/TO its/PRP$ cognate/JJ enhancer/NN elements/NNS ./. 
Similarly/RB ,/, the/DT p105/NN precursor/NN of/IN the/DT NF-kappa/NN B/NN p50/NN subunit/NN is/VBZ also/RB post-translationally/RB processed/VBN in/IN the/DT proteasome/NN ./. 
The/DT mechanisms/NNS by/IN which/WDT Tax/NN activates/VBZ NF-kappa/NN B/NN remain/VBP unclear/JJ ,/, and/CC findings/NNS presented/VBN in/IN the/DT literature/NN are/VBP often/RB controversial/JJ ./. 
We/PRP identified/VBD a/DT physical/JJ interaction/NN between/IN Tax/NN and/CC the/DT HsN3/NN subunit/NN of/IN the/DT human/JJ proteasome/NN ./. 
This/DT raises/VBZ the/DT intriguing/JJ possibility/NN that/IN physical/JJ association/NN of/IN the/DT HsN3/NN proteasome/NN subunit/NN with/IN HTLV-I/NN Tax/NN coupled/VBN with/IN the/DT independent/JJ interaction/NN of/IN Tax/NN with/IN either/CC p100/NN or/CC p65-I/NN kappa/NN B/NN alpha/NN targets/VBZ these/DT cytoplasmic/JJ NF-kappa/NN B/Rel/NN complexes/NNS to/TO the/DT proteasome/NN for/IN processing/NN ./. 
UI/LS -/: 96136023/CD 
TI/LS -/: Immunophenotype/NN of/IN intraductal/JJ carcinoma/NN ./. 
AB/LS -/: OBJECTIVE/NN --/: Mammography/NN and/CC breast-conserving/JJ therapy/NN have/VBP focused/VBN attention/NN on/IN the/DT classification/NN of/IN intraductal/JJ carcinoma/NN (/( IDC/NN )/) and/CC emphasized/VBN the/DT prognostic/JJ importance/NN of/IN comedo/NN versus/CC noncomedo/JJ variants/NNS ./. 
We/PRP used/VBD histochemical/JJ markers/NNS to/TO define/VB the/DT immunophenotype/NN of/IN 43/CD IDCs/NNS with/IN respect/NN to/TO comedo/NN versus/CC noncomedo/JJ status/NN and/CC patterns/NNS of/IN angiogenesis/NN ./. 
RESULTS/NNS --/: Reactions/NNS in/IN comedo/NN carcinomas/NNS were/VBD significantly/RB negative/JJ for/IN estrogen/NN receptor/NN and/CC progesterone/NN receptor/NN ,/, and/CC positive/JJ for/IN p53/NN and/CC HER-2/neu/NN more/RBR often/RB than/IN the/DT noncomedo/JJ variant/NN ./. 
All/DT seven/CD IDCs/NNS associated/VBN with/IN Paget/NN 's/POS disease/NN showed/VBD positive/JJ reactions/NNS for/IN HER-2/neu/NN ./. 
Basement/NN membrane/NN immunoreactivity/NN for/IN type/NN IV/CD collagen/NN and/CC laminin/NN was/VBD discontinuous/JJ in/IN most/JJS examples/NNS of/IN IDC/NN regardless/RB of/IN type/NN ,/, with/IN a/DT trend/NN toward/IN more/RBR intense/JJ staining/NN in/IN comedo/NN than/IN in/IN noncomedo/JJ carcinomas/NNS ./. 
Periductal/JJ angiogenesis/NN was/VBD not/RB significantly/RB related/JJ to/TO the/DT type/NN of/IN IDC/NN but/CC was/VBD more/RBR pronounced/JJ with/IN comedo/NN carcinomas/NNS ./. 
CONCLUSIONS/NNS --/: These/DT observations/NNS indicate/VBP that/IN there/EX are/VBP immunophenotypic/JJ correlates/NNS to/TO the/DT current/JJ structural/JJ classification/NN of/IN IDC/NN ./. 
The/DT immunophenotype/NN of/IN IDC/NN is/VBZ helpful/JJ in/IN subclassifying/VBG an/DT IDC/NN and/CC could/MD prove/VB useful/JJ as/IN a/DT prognostic/JJ indicator/NN for/IN local/JJ control/NN in/IN patients/NNS treated/VBN by/IN breast-conserving/JJ therapy/NN ./. 
UI/LS -/: 99415908/CD 
TI/LS -/: Inhibition/NN of/IN protein/NN phosphatase/NN 2A/NN induces/VBZ serine/threonine/JJ|NN phosphorylation/NN ,/, subcellular/JJ redistribution/NN ,/, and/CC functional/JJ inhibition/NN of/IN STAT3/NN ./. 
AB/LS -/: Signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STATs/NNS )/) are/VBP rapidly/RB phosphorylated/VBN on/IN tyrosine/NN residues/NNS in/IN response/NN to/TO cytokine/NN and/CC growth/NN factor/NN stimulation/NN of/IN cell/NN surface/NN receptors/NNS ./. 
STATs/NNS hereafter/RB are/VBP translocated/VBN to/TO the/DT nucleus/NN where/WRB they/PRP act/VBP as/IN transcription/NN factors/NNS ./. 
Recent/JJ reports/NNS suggest/VBP that/IN serine/NN phosphorylation/NN of/IN STATs/NNS also/RB is/VBZ involved/VBN in/IN the/DT regulation/NN of/IN STAT-mediated/JJ gene/NN transcription/NN ./. 
Here/RB ,/, we/PRP studied/VBD the/DT role/NN of/IN serine/threonine/JJ|NN phosphatases/NNS in/IN STAT3/NN signaling/NN in/IN human/JJ antigen-specific/JJ CD4(+)/JJ T/NN cell/NN lines/NNS and/CC cutaneous/JJ T/NN cell/NN lymphoma/NN lines/NNS ,/, expressing/VBG a/DT constitutively/RB activated/VBN STAT3/NN ./. 
We/PRP show/VBP that/IN an/DT inhibitor/NN of/IN protein/NN phosphatases/NNS (/( PPs/NNS )/) PP1/PP2A/NN ,/, calyculin/NN A/NN ,/, induces/VBZ (/( i/LS )/) phosphorylation/NN of/IN STAT3/NN on/IN serine/NN and/CC threonine/NN residues/NNS ,/, (/( ii/LS )/) inhibition/NN of/IN STAT3/NN tyrosine/NN phosphorylation/NN and/CC DNA/NN binding/NN activity/NN ,/, and/CC (/( iii/LS )/) relocation/NN of/IN STAT3/NN from/IN the/DT nucleus/NN to/TO the/DT cytoplasm/NN ./. 
Similar/JJ results/NNS were/VBD obtained/VBN with/IN other/JJ PP2A/NN inhibitors/NNS (/( okadaic/JJ acid/NN ,/, endothall/NN thioanhydride/NN )/) but/CC not/RB with/IN inhibitors/NNS of/IN PP1/NN (/( tautomycin/NN )/) or/CC PP2B/NN (/( cyclosporine/NN A/NN )/) ./. 
Pretreatment/NN with/IN the/DT broad/JJ serine/threonine/JJ|NN kinase/NN inhibitor/NN staurosporine/NN partly/RB blocked/VBD the/DT calyculin/NN A-induced/JJ STAT3/NN phosphorylation/NN ,/, whereas/IN inhibitors/NNS of/IN serine/threonine/NN kinases/NNS ,/, such/JJ as/IN mitogen-activated/JJ protein/NN kinase-1/NN extracellular-regulated/JJ kinase-kinase/NN ,/, mitogen-activated/JJ protein/NN p38/NN kinase/NN ,/, and/CC phosphatidylinositol/NN 3-kinase/NN ,/, did/VBD not/RB ./. 
In/IN conclusion/NN ,/, we/PRP provide/VBP evidence/NN that/IN PP2A/NN plays/VBZ a/DT crucial/JJ role/NN in/IN the/DT regulation/NN of/IN STAT3/NN phosphorylation/NN and/CC subcellular/JJ distribution/NN in/IN T/NN cells/NNS ./. 
Moreover/RB ,/, our/PRP$ findings/NNS suggest/VBP that/IN the/DT level/NN of/IN STAT3/NN phosphorylation/NN is/VBZ balanced/JJ between/IN a/DT staurosporine-sensitive/JJ kinase/NN (/( s/NNS )/) and/CC PP2A/NN ./. 
UI/LS -/: 99401563/CD 
TI/LS -/: Polyamines/NNS in/IN human/JJ breast/NN cancer/NN and/CC its/PRP$ relations/NNS to/TO classical/JJ prognostic/JJ features/NNS :/: clinical/JJ implications/NNS ./. 
AB/LS -/: Experimental/JJ evidence/NN suggest/VBP an/DT important/JJ role/NN of/IN polyamines/NNS in/IN breast/NN cancer/NN development/NN ./. 
Polyamines/NNS have/VBP been/VBN determined/VBN in/IN tissue/NN and/CC erythrocyte/NN samples/NNS from/IN 100/CD patients/NNS with/IN primary/JJ invasive/JJ breast/NN cancer/NN and/CC 30/CD patients/NNS with/IN fibroadenomas/NNS ./. 
Statistical/JJ analysis/NN was/VBD performed/VBN in/IN order/NN to/TO determine/VB the/DT prognostic/JJ value/NN of/IN the/DT polyamine/NN patterns/NNS of/IN tumor/NN tissues/NNS and/CC erythrocytes/NNS in/IN comparison/NN with/IN clinical/JJ and/CC histological/JJ prognostic/JJ factors/NNS ./. 
In/IN malignant/JJ tissues/NNS ,/, polyamine/NN levels/NNS were/VBD significantly/RB higher/JJR than/IN in/IN benign/JJ tissues/NNS ./. 
They/PRP correlated/VBD with/IN markers/NNS of/IN tumor/NN aggressivity/NN (/( axillary/JJ node/NN involvement/NN and/CC especially/RB with/IN markers/NNS of/IN high/JJ mitotic/JJ rate/NN as/IN Ki-67/NN staining/NN ,/, histological/JJ grade/NN )/) ./. 
No/DT correlation/NN was/VBD found/VBN between/IN estrogen/NN and/CC progesterone/NN status/NN ,/, tumor/NN size/NN and/CC polyamine/NN concentrations/NNS ./. 
Erythrocyte/NN polyamines/NNS levels/NNS were/VBD identical/JJ between/IN cancer/NN patients/NNS and/CC controls/NNS ./. 
The/DT knowledge/NN of/IN the/DT polyamine/NN pattern/NN in/IN breast/NN cancer/NN could/MD become/VB useful/JJ in/IN clinical/JJ practice/NN particularly/RB if/IN polyamine/NN metabolism/NN is/VBZ targeted/VBN as/IN a/DT therapeutic/JJ approach/NN ./. 
UI/LS -/: 99382334/CD 
TI/LS -/: Signal/NN transduction/NN pathways/NNS triggered/VBN by/IN the/DT FcepsilonRIIb/NN receptor/NN (/( CD23/NN )/) in/IN human/JJ monocytes/NNS lead/VBP to/TO nuclear/JJ factor-kappaB/NN activation/NN ./. 
AB/LS -/: BACKGROUND/NN :/: Alveolar/JJ macrophages/NNS play/VBP a/DT key/JJ role/NN in/IN the/DT initiation/NN of/IN the/DT inflammatory/JJ reaction/NN of/IN allergic/JJ asthma/NN ./. 
Alveolar/JJ macrophages/NNS and/CC peripheral/JJ blood/NN monocytes/NNS are/VBP activated/VBN when/WRB IgE/allergen/JJ|NN immune/JJ complexes/NNS bind/VBP to/TO the/DT CD23/NN receptor/NN ,/, which/WDT leads/VBZ to/TO the/DT production/NN of/IN inflammatory/JJ cytokines/NNS ./. 
OBJECTIVE/NN :/: We/PRP sought/VBD to/TO investigate/VB the/DT molecular/JJ mechanisms/NNS regulating/VBG this/DT early/JJ inflammatory/JJ response/NN ./. 
We/PRP have/VBP focused/VBN on/IN the/DT study/NN of/IN the/DT signal/NN transduction/NN pathways/NNS triggered/VBN by/IN CD23/NN in/IN human/JJ monocytes/NNS and/CC the/DT promonocytic/JJ cell/NN line/NN U937/NN ./. 
METHODS/NNS :/: CD23/NN was/VBD cross-linked/VBN in/IN human/JJ monocytes/NNS and/CC U937/NN cells/NNS with/IN IgE/NN immune/JJ complexes/NNS ./. 
Surface/NN expression/NN of/IN CD23/NN was/VBD determined/VBN by/IN FACS/NN analysis/NN ./. 
Transcription/NN factor/NN activation/NN and/CC gene/NN transcription/NN were/VBD studied/VBN by/IN gel-shift/JJ assays/NNS and/CC Northern/JJ|NN blot/NN analysis/NN ,/, respectively/RB ./. 
IkappaBalpha/NN phosphorylation/NN and/CC degradation/NN was/VBD analyzed/VBN by/IN Western/JJ|NN blot/NN ./. 
RESULTS/NNS :/: Nuclear/JJ factor/NN (/( NF/NN )/) -kappaB/NN is/VBZ the/DT main/JJ transcription/NN factor/NN involved/VBN in/IN the/DT gene/NN activation/NN that/WDT follows/VBZ CD23/NN cross-linking/NN in/IN monocytes/NNS ./. 
CD23-induced/JJ NF-kappaB/NN is/VBZ a/DT heterodimer/NN composed/VBN of/IN p65/p50/JJ|NN subunits/NNS ./. 
NF-kappaB/NN nuclear/JJ translocation/NN is/VBZ secondary/JJ to/TO the/DT phosphorylation/NN and/CC subsequent/JJ degradation/NN of/IN the/DT NF-kappaB/NN inhibitory/JJ molecule/NN IkappaBalpha/NN ./. 
Tyrosine/NN kinase-dependent/JJ ,/, and/CC not/RB protein/NN kinase/NN C-dependent/JJ ,/, pathways/NNS mediate/VBP CD23-triggered/JJ NF-kappaB/NN activation/NN but/CC do/VBP not/RB participate/VB in/IN the/DT direct/JJ phosphorylation/NN of/IN IkappaBalpha/NN ./. 
IkappaBalpha/NN degradation/NN and/CC NF-kappaB/NN nuclear/JJ translocation/NN correlate/VBP with/IN transcriptional/JJ activation/NN of/IN the/DT inflammatory/JJ cytokines/NNS TNF-alpha/NN and/CC IL-1beta/NN ./. 
CONCLUSIONS/NNS :/: NF-kappaB/NN is/VBZ the/DT main/JJ transcription/NN factor/NN involved/VBN in/IN the/DT signal/NN transduction/NN pathway/NN of/IN CD23/NN in/IN monocytes/NNS ./. 
UI/LS -/: 99369911/CD 
TI/LS -/: Suppression/NN of/IN TNFalpha-mediated/JJ NFkappaB/NN activity/NN by/IN myricetin/NN and/CC other/JJ flavonoids/NNS through/IN downregulating/VBG the/DT activity/NN of/IN IKK/NN in/IN ECV304/NN cells/NNS ./. 
AB/LS -/: Flavonoids/NNS are/VBP a/DT group/NN of/IN naturally-occurring/JJ phenolic/JJ compounds/NNS in/IN the/DT plant/NN kingdom/NN ,/, and/CC many/JJ flavonoids/NNS are/VBP found/VBN with/IN vascular/JJ protective/JJ properties/NNS ./. 
Nevertheless/RB how/WRB the/DT protective/JJ response/NN is/VBZ exerted/VBN by/IN flavonoids/NNS is/VBZ not/RB well/RB characterized/VBN ./. 
In/IN view/NN of/IN the/DT nuclear/JJ factor-kappaB/NN (/( NFkappaB/NN )/) may/MD play/VB a/DT central/JJ role/NN in/IN the/DT initiation/NN of/IN atherosclerosis/NN ,/, prevention/NN of/IN the/DT activation/NN of/IN NFkappaB/NN represents/VBZ an/DT important/JJ role/NN in/IN protecting/VBG vascular/JJ injury/NN ./. 
In/IN this/DT study/NN ,/, the/DT effects/NNS of/IN flavonoids/NNS on/IN NFkappaB/inhibitor-kappaB/NN (/( IkappaB/NN )/) system/NN in/IN ECV304/NN cells/NNS activated/VBN with/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNFalpha/NN )/) were/VBD examined/VBN ./. 
We/PRP investigated/VBD the/DT inhibitory/JJ action/NN of/IN six/CD flavonoids/NNS on/IN IkappaB/NN kinase/NN (/( IKK/NN )/) activity/NN ,/, an/DT enzyme/NN recently/RB found/VBN to/TO phosphorylate/VB critical/JJ serine/NN residues/NNS of/IN IkappaB/NN for/IN degradation/NN ./. 
Of/IN six/CD flavonoids/NNS tested/VBN ,/, myricetin/NN was/VBD found/VBN to/TO strongly/RB inhibit/VB IKK/NN kinase/NN activity/NN ,/, and/CC prevent/VB the/DT degradation/NN of/IN IkappaBalpha/NN and/CC IkappaBbeta/NN in/IN activated/VBN endothelial/JJ cells/NNS ./. 
Furthermore/RB ,/, myricetin/NN was/VBD also/RB found/VBN to/TO inhibit/VB NFkappaB/NN activity/NN correlated/VBN with/IN suppression/NN of/IN monocyte/NN adhesion/NN to/TO ECV304/NN cells/NNS ./. 
Therefore/RB we/PRP conclude/VBP that/IN flavonoids/NNS may/MD be/VB of/IN therapeutic/JJ value/NN for/IN vascular/JJ disease/NN through/IN down/JJ regulation/NN of/IN NFkappaB/IkappaB/NN system/NN ./. 
Copyright/NN 1999/CD Wiley-Liss/NNP ,/, Inc/NNP ./. 
UI/LS -/: 99362923/CD 
TI/LS -/: Bcl-2-mediated/JJ drug/NN resistance/NN :/: inhibition/NN of/IN apoptosis/NN by/IN blocking/VBG nuclear/JJ factor/NN of/IN activated/VBN T/NN lymphocytes/NNS (/( NFAT/NN )/) -induced/JJ Fas/NN ligand/NN transcription/NN ./. 
AB/LS -/: Bcl-2/NN inhibits/VBZ apoptosis/NN induced/VBN by/IN a/DT variety/NN of/IN stimuli/NNS ,/, including/VBG chemotherapy/NN drugs/NNS and/CC glucocorticoids/NNS ./. 
It/PRP is/VBZ generally/RB accepted/VBN that/IN Bcl-2/NN exerts/VBZ its/PRP$ antiapoptotic/JJ effects/NNS mainly/RB by/IN dimerizing/VBG with/IN proapoptotic/JJ members/NNS of/IN the/DT Bcl-2/NN family/NN such/JJ as/IN Bax/NN and/CC Bad/NN ./. 
However/RB ,/, the/DT mechanism/NN of/IN the/DT antiapoptotic/JJ effects/NNS is/VBZ unclear/JJ ./. 
Paclitaxel/NN and/CC other/JJ drugs/NNS that/WDT disturb/VBP microtubule/NN dynamics/NNS kill/VBP cells/NNS in/IN a/DT Fas/Fas/NN ligand/NN (/( FasL/NN )/) -dependent/JJ manner/NN ;/: antibody/NN to/TO FasL/NN inhibits/VBZ paclitaxel-induced/JJ apoptosis/NN ./. 
We/PRP have/VBP found/VBN that/IN Bcl-2/NN overexpression/NN leads/VBZ to/TO the/DT prevention/NN of/IN chemotherapy/NN (/( paclitaxel/NN )/) -induced/JJ expression/NN of/IN FasL/NN and/CC blocks/VBZ paclitaxel-induced/JJ apoptosis/NN ./. 
The/DT mechanism/NN of/IN this/DT effect/NN is/VBZ that/IN Bcl-2/NN prevents/VBZ the/DT nuclear/JJ translocation/NN of/IN NFAT/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T/NN lymphocytes/NNS ,/, a/DT transcription/NN factor/NN activated/VBN by/IN microtubule/JJ damage/NN )/) by/IN binding/VBG and/CC sequestering/VBG calcineurin/NN ,/, a/DT calcium-dependent/JJ phosphatase/NN that/WDT must/MD dephosphorylate/VB NFAT/NN to/TO move/VB to/TO the/DT nucleus/NN ./. 
Without/IN NFAT/NN nuclear/JJ translocation/NN ,/, the/DT FasL/NN gene/NN is/VBZ not/RB transcribed/VBN ./. 
Thus/RB ,/, it/PRP appears/VBZ that/IN paclitaxel/NN and/CC other/JJ drugs/NNS that/WDT disturb/VBP microtubule/JJ function/NN kill/VBP cells/NNS at/IN least/JJS in/IN part/NN through/IN the/DT induction/NN of/IN FasL/NN ./. 
Furthermore/RB ,/, Bcl-2/NN antagonizes/VBZ drug-induced/JJ apoptosis/NN by/IN inhibiting/VBG calcineurin/NN activation/NN ,/, blocking/VBG NFAT/NN nuclear/JJ translocation/NN ,/, and/CC preventing/VBG FasL/NN expression/NN ./. 
The/DT effects/NNS of/IN Bcl-2/NN can/MD be/VB overcome/VBN ,/, at/IN least/JJS partially/RB ,/, through/IN phosphorylation/NN of/IN Bcl-2/NN ./. 
Phosphorylated/VBN Bcl-2/NN can/MD not/RB bind/VB calcineurin/NN ,/, and/CC NFAT/NN activation/NN ,/, FasL/NN expression/NN ,/, and/CC apoptosis/NN can/MD occur/VB after/IN Bcl-2/NN phosphorylation/NN ./. 
UI/LS -/: 99353321/CD 
TI/LS -/: MHC-peptide/NN ligand/NN interactions/NNS establish/VB a/DT functional/JJ threshold/NN for/IN antigen-specific/JJ T/NN cell/NN recognition/NN ./. 
AB/LS -/: Antigen-specific/JJ T/NN cell/NN recognition/NN is/VBZ dependent/JJ on/IN the/DT functional/JJ density/NN of/IN the/DT TCR-ligand/NN ,/, which/WDT consists/VBZ of/IN specific/JJ MHC/NN molecules/NNS and/CC a/DT specifically/RB bound/VBN peptide/NN ./. 
We/PRP have/VBP examined/VBN the/DT influence/NN of/IN the/DT affinity/NN and/CC concentration/NN of/IN exogenous/JJ peptide/NN and/CC the/DT density/NN of/IN specific/JJ MHC/NN molecules/NNS on/IN the/DT proliferation/NN of/IN a/DT CD4+/JJ ,/, DQA1*0501/DQB1*0201/NN (/( DQ2.1/NN )/) -restricted/JJ ,/, HSV-2-specific/JJ T/NN cell/NN clone/NN ./. 
Using/VBG antigen/JJ peptide/NN analogs/NNS with/IN different/JJ mutations/NNS of/IN known/JJ DQ2-anchor/NN residues/NNS ,/, T/NN cell/NN response/NN was/VBD reduced/VBN in/IN an/DT peptide-affinity/NN and/CC - concentration/NN specific/JJ manner/NN ./. 
The/DT decrease/NN using/VBG weaker/JJR binding/NN peptides/NNS was/VBD gradual/JJ as/IN stimulation/NN with/IN a/DT peptide/NN with/IN intermediate/JJ affinity/NN yielded/VBD intermediate/JJ T/NN cell/NN proliferation/NN and/CC the/DT poorest/JJ binding/NN peptide/NN induced/VBD an/DT even/RB weaker/JJR T/NN cell/NN response/NN ./. 
MHC/NN class/NN II/CD density/NN on/IN the/DT APC/NN was/VBD modified/VBN using/VBG DQ2/NN homo-/JJ and/CC heterozygous/JJ B-LCLs/NNS as/IN APCs/NNS ,/, however/RB this/DT variation/NN of/IN MHC/NN concentration/NN had/VBD no/DT effect/NN on/IN T/NN cell/NN proliferation/NN ./. 
We/PRP interpret/VB this/DT as/IN a/DT reflection/NN of/IN a/DT low/JJ threshold/NN for/IN activation/NN of/IN the/DT T/NN cell/NN clone/NN ,/, in/IN which/WDT peptide-MHC/JJ avidity/NN is/VBZ the/DT over-riding/JJ determinant/NN of/IN the/DT strength/NN of/IN ligand/NN signal/NN ./. 
UI/LS -/: 99336784/CD 
TI/LS -/: Regulatory/JJ effects/NNS of/IN interleukin-11/NN during/IN acute/JJ lung/NN inflammatory/JJ injury/NN ./. 
AB/LS -/: The/DT role/NN of/IN interleukin-11/NN (/( IL-11/NN )/) was/VBD evaluated/VBN in/IN the/DT IgG/NN immune/JJ complex/NN model/NN of/IN acute/JJ lung/NN injury/NN in/IN rats/NNS ./. 
IL-11/NN mRNA/NN and/CC protein/NN were/VBD both/DT up-regulated/VBN during/IN the/DT course/NN of/IN this/DT inflammatory/JJ response/NN ./. 
Exogenously/RB administered/VBN IL-11/NN substantially/RB reduced/VBD ,/, in/IN a/DT dose-dependent/JJ manner/NN ,/, the/DT intrapulmonary/JJ accumulation/NN of/IN neutrophils/NNS and/CC the/DT lung/NN vascular/JJ leak/NN of/IN albumin/NN ./. 
These/DT in/FW vivo/FW anti-inflammatory/JJ effects/NNS of/IN IL-11/NN were/VBD associated/VBN with/IN reduced/VBN NF-kappaB/NN activation/NN in/IN lung/NN ,/, reduced/VBD levels/NNS of/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) in/IN bronchoalveolar/JJ lavage/NN (/( BAL/NN )/) fluids/NNS ,/, and/CC diminished/VBD up-regulation/NN of/IN lung/NN vascular/JJ ICAM-1/NN ./. 
It/PRP is/VBZ interesting/JJ that/IN IL-11/NN did/VBD not/RB affect/VB BAL/NN fluid/JJ content/NN of/IN the/DT CXC/NN chemokines/NNS ,/, macrophage/NN inflammatory/JJ protein-2/NN (/( MIP-2/NN )/) and/CC cytokine-inducible/JJ neutrophil/NN chemoattractant/NN (/( CINC/NN )/) ;/: the/DT presence/NN of/IN IL-11/NN did/VBD not/RB affect/VB these/DT chemokines/NNS ./. 
However/RB ,/, BAL/NN content/NN of/IN C5a/NN was/VBD reduced/VBN by/IN IL-11/NN ./. 
These/DT data/NNS indicate/VBP that/IN IL-11/NN is/VBZ a/DT regulatory/JJ cytokine/NN in/IN the/DT lung/NN and/CC that/IN ,/, like/IN other/JJ members/NNS of/IN this/DT family/NN ,/, its/PRP$ anti-inflammatory/JJ properties/NNS appear/VBP to/TO be/VB linked/VBN to/TO its/PRP$ suppression/NN of/IN NF-kappaB/NN activation/NN ,/, diminished/VBN production/NN of/IN TNF-alpha/NN ,/, and/CC reduced/VBN up-regulation/NN of/IN lung/NN vascular/JJ ICAM-1/NN ./. 
UI/LS -/: 96141062/CD 
TI/LS -/: Thrombopoietin/NN induces/VBZ tyrosine/NN phosphorylation/NN of/IN Stat3/NN and/CC Stat5/NN in/IN human/JJ blood/NN platelets/NNS ./. 
AB/LS -/: Thrombopoietin/NN is/VBZ known/VBN to/TO be/VB essential/JJ for/IN megakaryocytopoiesis/NN and/CC thrombopoiesis/NN ./. 
Recently/RB ,/, we/PRP and/CC others/NNS have/VBP shown/VBN that/IN thrombopoietin/NN induces/VBZ rapid/JJ tyrosine/NN phosphorylation/NN of/IN Jak2/NN and/CC other/JJ proteins/NNS in/IN human/JJ platelets/NNS and/CC BaF3/NN cells/NNS ,/, genetically/RB engineered/VBN to/TO express/VB c-Mpl/NN ,/, a/DT receptor/NN for/IN thrombopoietin/NN ./. 
The/DT Jak/NN family/NN of/IN tyrosine/NN kinases/NNS are/VBP known/VBN to/TO mediate/VB some/DT of/IN the/DT effects/NNS of/IN cytokines/NNS or/CC hematopoietic/JJ growth/NN factors/NNS by/IN recruitment/NN and/CC tyrosine/NN phosphorylation/NN of/IN a/DT variety/NN of/IN Stat/NN (/( signal/JJ transducers/NNS and/CC activators/NNS of/IN transcription/NN )/) proteins/NNS ./. 
Hence/RB ,/, we/PRP have/VBP investigated/VBN whether/IN Stat/NN proteins/NNS are/VBP present/JJ in/IN platelets/NNS and/CC ,/, if/IN so/RB ,/, whether/IN they/PRP become/VBP tyrosine/NN phosphorylated/JJ in/IN response/NN to/TO thrombopoietin/NN ./. 
We/PRP immunologically/RB identified/VBD Stat1/NN ,/, Stat2/NN ,/, Stat3/NN ,/, and/CC Stat5/NN in/IN human/JJ platelet/NN lysates/NNS ./. 
Thrombopoietin/IN induced/VBD tyrosine/NN phosphorylation/NN of/IN Stat3/NN and/CC Stat5/NN in/IN these/DT cells/NNS ./. 
Thrombopoietin/NN also/RB induced/VBD tyrosine/NN phosphorylation/NN of/IN Stat3/NN and/CC Stat5/NN in/IN FDCP-2/NN cells/NNS genetically/RB engineered/VBN to/TO constitutively/RB express/VB human/JJ c-Mpl/NN ./. 
Thus/RB ,/, our/PRP$ data/NNS indicate/VBP that/IN Stat3/NN and/CC Stat5/NN may/MD be/VB involved/VBN in/IN signal/NN transduction/NN after/IN ligand/NN binding/NN to/TO c-Mpl/NN and/CC that/IN this/DT event/NN may/MD have/VB a/DT role/NN in/IN megakaryopoiesis/thrombopoiesis/JJ|NN or/CC possibly/RB a/DT mature/JJ platelet/NN function/NN such/JJ as/IN aggregation/NN ./. 
UI/LS -/: 96405332/CD 
TI/LS -/: Mechanisms/NNS that/WDT contribute/VBP to/TO the/DT development/NN of/IN lymphoid/JJ malignancies/NNS :/: roles/NNS for/IN genetic/JJ alterations/NNS and/CC cytokine/NN production/NN ./. 
AB/LS -/: Recent/JJ studies/NNS have/VBP defined/VBN genetic/JJ alterations/NNS commonly/RB associated/VBN with/IN transformed/VBN lymphocytes/NNS ./. 
This/DT review/NN suggests/VBZ roles/NNS for/IN these/DT alterations/NNS in/IN the/DT development/NN of/IN lymphoid/JJ neoplasms/NNS ./. 
Damage/NN to/TO the/DT genes/NNS encoding/VBG proteins/NNS that/WDT function/VBP in/IN intracellular/JJ signaling/NN ,/, transcription/NN ,/, or/CC regulation/NN of/IN the/DT cell/NN cycle/NN has/VBZ been/VBN identified/VBN and/CC linked/VBN at/IN varying/VBG degrees/NNS to/TO the/DT progression/NN of/IN certain/JJ lymphoid/JJ malignancies/NNS ./. 
An/DT understanding/NN of/IN the/DT mechanistic/JJ consequences/NNS following/VBG such/JJ genetic/JJ alterations/NNS is/VBZ essential/JJ to/TO an/DT understanding/NN of/IN the/DT development/NN of/IN these/DT lymphoid/JJ neoplasms/NNS ./. 
In/IN contrast/NN ,/, it/PRP is/VBZ also/RB becoming/VBG clear/JJ that/IN the/DT dysregulated/VBN expression/NN of/IN proteins/NNS that/WDT are/VBP not/RB genetically/RB altered/VBN can/MD also/RB contribute/VB to/TO the/DT progression/NN of/IN lymphoid/JJ malignancies/NNS ./. 
One/CD such/JJ example/NN is/VBZ the/DT excessive/JJ expression/NN of/IN "/`` normal/JJ "/'' lymphokines/NNS of/IN cytokines/NNS which/WDT accompanies/VBZ many/JJ lymphoproliferative/JJ diseases/NNS ./. 
The/DT dysregulated/VBN expression/NN of/IN cytokines/NNS during/IN malignancy/NN can/MD result/VB in/IN the/DT augmentation/NN of/IN growth/NN of/IN transformed/VBN lymphocytes/NNS ,/, as/RB well/RB as/IN an/DT alteration/NN of/IN the/DT anti-tumor/JJ immune/JJ response/NN ./. 
The/DT latter/JJ mechanism/NN is/VBZ especially/RB important/JJ because/IN evasion/NN of/IN the/DT impending/JJ immune/JJ response/NN is/VBZ a/DT prerequisite/NN for/IN the/DT progression/NN of/IN lymphoproliferative/JJ diseases/NNS ./. 
Taken/VBN together/RB ,/, this/DT review/NN supports/VBZ the/DT notion/NN that/IN the/DT development/NN of/IN lymphoid/JJ malignancies/NNS is/VBZ multifactorial/JJ ,/, involving/VBG genetic/JJ alterations/NNS as/RB well/RB as/IN dysregulated/VBN cytokine/NN expression/NN ./. 
UI/LS -/: 96108879/CD 
TI/LS -/: Dehydroepiandrosterone/NN modulation/NN of/IN lipopolysaccharide-stimulated/JJ monocyte/NN cytotoxicity/NN ./. 
AB/LS -/: Dehydroepiandrosterone/NN (/( DHEA/NN )/) ,/, the/DT predominant/JJ androgen/NN secreted/VBN by/IN the/DT adrenal/JJ cortex/NN ,/, can/MD be/VB converted/VBN to/TO both/CC potent/JJ androgens/NNS and/CC estrogens/NNS ./. 
In/IN addition/NN to/TO its/PRP$ role/NN as/IN a/DT precursor/NN for/IN other/JJ steroid/NN hormones/NNS ,/, DHEA/NN has/VBZ been/VBN proposed/VBN to/TO play/VB an/DT important/JJ role/NN in/IN immunity/NN ./. 
This/DT study/NN has/VBZ investigated/VBN DHEA/NN modulation/NN of/IN LPS-induced/JJ monocyte/NN cytotoxicity/NN ./. 
Cytotoxicity/NN markers/NNS assessed/VBN include/VBP tumor/NN cell/NN killing/NN ,/, IL-1/NN secretion/NN ,/, reactive/JJ oxygen/NN intermediate/JJ release/NN ,/, nitric/JJ oxide/NN synthetase/NN activity/NN as/IN measured/VBN by/IN the/DT release/NN of/IN reactive/JJ nitrogen/NN intermediates/NNS ,/, complement/NN receptor-1/NN cell/NN surface/NN protein/NN ,/, and/CC TNF-alpha/NN protein/NN presence/NN ./. 
Monocytes/NNS stimulated/VBN with/IN LPS/NN concentrations/NNS of/IN 1.0/CD micrograms/ml/NNS displayed/VBD the/DT above/JJ cytotoxic/JJ markers/NNS ,/, whereas/IN monocytes/NNS stimulated/VBN with/IN DHEA/NN alone/RB or/CC with/IN LPS/NN at/IN a/DT lower/JJR concentration/NN of/IN 0.2/CD ng/ml/NN did/VBD not/RB ./. 
However/RB ,/, when/WRB used/VBN simultaneously/RB ,/, DHEA/NN and/CC LPS/NN 0.2/CD ng/ml/NN displayed/VBD a/DT synergistic/JJ effect/NN on/IN monocyte/NN cytotoxicity/NN against/IN cancerous/JJ cell/NN lines/NNS ,/, IL-1/NN secretion/NN ,/, reactive/JJ nitrogen/NN intermediate/JJ release/NN ,/, complement/NN receptor-1/NN cell-surface/NN protein/NN ,/, and/CC TNF-alpha/NN protein/NN to/TO levels/NNS comparable/JJ with/IN levels/NNS obtained/VBN using/VBG LPS/NN 1.0/CD microgram/ml/NN ./. 
Finally/RB ,/, Scatchard/NN plot/NN analysis/NN demonstrated/VBD the/DT presence/NN of/IN a/DT DHEA/NN receptor/NN in/IN monocytes/NNS ,/, suggesting/VBG that/IN DHEA/NN effects/NNS on/IN LPS-stimulated/JJ monocytes/NNS are/VBP mediated/VBN through/IN a/DT receptor-dependent/JJ process/NN ./. 
UI/LS -/: 99415939/CD 
TI/LS -/: Interferons/NNS inhibit/VBP activation/NN of/IN STAT6/NN by/IN interleukin/NN 4/CD in/IN human/JJ monocytes/NNS by/IN inducing/VBG SOCS-1/NN gene/NN expression/NN ./. 
AB/LS -/: Interferons/NNS (/( IFNs/NNS )/) inhibit/VBP induction/NN by/IN IL-4/NN of/IN multiple/JJ genes/NNS in/IN human/JJ monocytes/NNS ./. 
However/RB ,/, the/DT mechanism/NN by/IN which/WDT IFNs/NNS mediate/VBP this/DT inhibition/NN has/VBZ not/RB been/VBN defined/VBN ./. 
IL-4/NN activates/VBZ gene/NN expression/NN by/IN inducing/VBG tyrosine/NN phosphorylation/NN ,/, homodimerization/NN ,/, and/CC nuclear/JJ translocation/NN of/IN the/DT latent/JJ transcription/NN factor/NN ,/, STAT6/NN (/( signal/JJ transducer/NN and/CC activator/NN of/IN transcription-6/NN )/) ./. 
STAT6-responsive/JJ elements/NNS are/VBP characteristically/RB present/JJ in/IN the/DT promoters/NNS of/IN IL-4-inducible/JJ genes/NNS ./. 
Because/IN STAT6/NN activation/NN is/VBZ essential/JJ for/IN IL-4-induced/JJ gene/NN expression/NN ,/, we/PRP examined/VBD the/DT ability/NN of/IN type/NN I/CD and/CC type/NN II/CD IFNs/NNS to/TO regulate/VB activation/NN of/IN STAT6/NN by/IN IL-4/NN in/IN primary/JJ human/JJ monocytes/NNS ./. 
Pretreatment/NN of/IN monocytes/NNS with/IN IFN-beta/NN or/CC IFN-gamma/NN ,/, but/CC not/RB IL-1/NN ,/, IL-2/NN ,/, macrophage/NN colony-stimulating/JJ factor/NN ,/, granulocyte/macrophage/JJ colony-stimulating/JJ factor/NN ,/, IL-6/NN ,/, or/CC transforming/VBG growth/NN factor/IN beta/NN suppressed/VBD activation/NN of/IN STAT6/NN by/IN IL-4/NN ./. 
This/DT inhibition/NN was/VBD associated/VBN with/IN decreased/VBN tyrosine/NN phosphorylation/NN and/CC nuclear/JJ translocation/NN of/IN STAT6/NN and/CC was/VBD not/RB evident/JJ unless/IN the/DT cells/NNS were/VBD preincubated/VBN with/IN IFN/NN for/IN at/IN least/JJS 1/CD hr/NN before/IN IL-4/NN stimulation/NN ./. 
Furthermore/RB ,/, inhibition/NN by/IN IFN/NN could/MD be/VB blocked/VBN by/IN cotreatment/NN with/IN actinomycin/NN D/NN and/CC correlated/VBN temporally/RB with/IN induction/NN of/IN the/DT JAK/STAT/NN inhibitory/JJ gene/NN ,/, SOCS-1/NN ./. 
Forced/VBN expression/NN of/IN SOCS-1/NN in/IN a/DT macrophage/JJ cell/NN line/NN ,/, RAW264/NN ,/, markedly/RB suppressed/VBD trans-activation/NN of/IN an/DT IL-4-inducible/JJ reporter/NN as/RB well/RB as/IN IL-6-/NN and/CC IFN-gamma-induced/JJ reporter/NN gene/NN activity/NN ./. 
These/DT findings/NNS demonstrate/VBP that/IN IFNs/NNS inhibit/VBP IL-4-induced/JJ activation/NN of/IN STAT6/NN and/CC STAT6-dependent/JJ gene/NN expression/NN ,/, at/IN least/JJS in/IN part/NN ,/, by/IN inducing/VBG expression/NN of/IN SOCS-1/NN ./. 
UI/LS -/: 99406823/CD 
TI/LS -/: An/DT activation-responsive/JJ element/NN in/IN single/JJ C/NN motif-1/lymphotactin/JJ|NN promoter/NN is/VBZ a/DT site/NN of/IN constitutive/JJ and/CC inducible/JJ DNA-protein/JJ interactions/NNS involving/VBG nuclear/JJ factor/NN of/IN activated/VBN T/NN cell/NN ./. 
AB/LS -/: Single/JJ C/NN motif-1/NN (/( SCM-1/NN )/) /lymphotactin/NN is/VBZ a/DT C-type/JJ chemokine/NN whose/WP$ expression/NN is/VBZ activation/NN dependent/JJ ,/, cyclosporin/NN A/NN sensitive/JJ and/CC restricted/JJ to/TO CD8+/JJ T/NN cells/NNS ,/, double-negative/JJ thymocytes/NNS ,/, gammadelta-type/JJ T/NN cells/NNS ,/, and/CC NK/NN cells/NNS ./. 
In/IN humans/NNS ,/, there/EX are/VBP two/CD highly/RB homologous/JJ genes/NNS encoding/VBG SCM-1alpha/NN and/CC SCM-1beta/NN ./. 
Here/RB we/PRP examined/VBD the/DT regulatory/JJ mechanism/NN of/IN the/DT SCM-1/NN genes/NNS ./. 
The/DT luciferase/NN reporter/NN gene/NN under/IN the/DT control/NN of/IN the/DT 5'/JJ flanking/JJ region/NN of/IN 0.7/CD kb/NN was/VBD strongly/RB induced/VBN upon/IN activation/NN with/IN anti-CD3/NN or/CC PHA/NN plus/CC PMA/NN only/RB in/IN SCM-1-producer/JJ T/NN cell/NN lines/NNS through/IN a/DT cyclosporin/NN A-sensitive/JJ mechanism/NN ./. 
An/DT element/NN termed/VBN E1/NN located/JJ at/IN -108/CD to/TO -95/CD nt/NN relative/JJ to/TO the/DT major/JJ transcription/NN start/NN site/NN was/VBD found/VBN to/TO be/VB critical/JJ for/IN the/DT promoter/NN activity/NN ./. 
In/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS using/VBG the/DT E1/NN oligonucleotide/NN as/IN probe/NN ,/, nuclear/JJ extracts/NNS from/IN unstimulated/JJ T/NN and/CC B/NN cell/NN lines/NNS formed/VBD a/DT constitutive/JJ complex/NN termed/VBN complex/NN I/NN ,/, while/IN nuclear/JJ extracts/NNS from/IN stimulated/VBN SCM-1-producer/NN T/NN cell/NN lines/NNS formed/VBD a/DT higher/JJR mobility/NN complex/NN termed/VBN complex/NN II/CD with/IN a/DT concomitant/JJ decrease/NN in/IN complex/NN I/CD ./. 
The/DT shift/NN from/IN complex/NN I/CD to/TO complex/NN II/CD seen/VBN only/RB in/IN SCM-1-producer/JJ T/NN cell/NN lines/NNS upon/IN activation/NN was/VBD completely/RB suppressed/VBN by/IN cyclosporin/NN A/NN ./. 
Both/DT complexes/NNS were/VBD critically/RB dependent/JJ on/IN the/DT NF-AT/NN core/NN sequence/NN TTTCC/NN in/IN the/DT E1/NN element/NN and/CC were/VBD partially/RB supershifted/VBN by/IN anti-NF-ATp/NN ./. 
One-hybrid/NN assays/NNS in/IN yeast/NN isolated/VBD NF-ATp/NN as/IN an/DT E1/NN binding/NN protein/NN ,/, and/CC transfection/NN of/IN NF-ATp/NN into/IN T/NN and/CC B/NN cell/NN lines/NNS strongly/RB enhanced/VBD the/DT activation-dependent/JJ SCM-1/NN promoter/NN activity/NN ./. 
Collectively/RB ,/, a/DT unique/JJ mechanism/NN involving/VBG NF-ATp/NN appears/VBZ to/TO regulate/VB the/DT cell/NN type-specific/JJ and/CC activation-dependent/JJ expression/NN of/IN the/DT SCM-1/NN genes/NNS ./. 
UI/LS -/: 99384376/CD 
TI/LS -/: Dopamine/NN stimulates/VBZ expression/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD via/IN NF-kappaB/NN in/IN cells/NNS of/IN the/DT immune/JJ system/NN ./. 
AB/LS -/: Recent/JJ studies/NNS have/VBP reported/VBN that/IN lymphocytes/NNS produce/VBP ,/, transport/VBP and/CC bind/VBP dopamine/NN present/JJ in/IN plasma/NN ./. 
However/RB ,/, the/DT action/NN of/IN dopamine/NN on/IN HIV-1/NN gene/NN expression/NN in/IN cells/NNS of/IN the/DT immune/JJ system/NN has/VBZ not/RB yet/RB been/VBN examined/VBN ./. 
Here/RB ,/, we/PRP have/VBP investigated/VBN the/DT regulation/NN of/IN HIV-1/NN expression/NN by/IN dopamine/NN in/IN Jurkat/NN T/NN cells/NNS and/CC in/IN primary/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NN )/) ./. 
HIV-1/NN replication/NN was/VBD increased/VBN by/IN dopamine/NN ,/, which/WDT correlated/VBD with/IN the/DT increased/VBN levels/NNS of/IN HIV-1/NN transactivation/NN ./. 
Our/PRP$ transient/JJ expression/NN data/NNS revealed/VBD that/IN dopamine/NN stimulated/VBD transcription/NN through/IN the/DT NF-kappaB/NN element/NN present/JJ in/IN the/DT long/JJ terminal/JJ repeat/NN ./. 
The/DT importance/NN of/IN NF-kappaB/NN sites/NNS was/VBD confirmed/VBN by/IN using/VBG vectors/NNS containing/VBG wild-type/JJ or/CC mutant/JJ kappaB/NN sites/NNS in/IN a/DT heterologous/JJ promoter/NN ./. 
Consistent/JJ with/IN the/DT role/NN of/IN NF-kappaB/NN in/IN mediating/VBG dopamine/NN responsiveness/NN ,/, the/DT proteasome/NN inhibitor/NN MG132/NN abolished/VBD dopamine-induced/JJ transcriptional/JJ activation/NN ./. 
We/PRP further/RB explored/VBD the/DT effect/NN of/IN dopamine/NN in/IN the/DT presence/NN of/IN phorbol/NN esters/NNS or/CC tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) known/VBN to/TO activate/VB NF-kappaB/NN ./. 
The/DT combination/NN of/IN dopamine/NN and/CC TNF-alpha/NN led/VBD to/TO a/DT stimulation/NN of/IN HIV-1/NN transcription/NN and/CC replication/NN ./. 
However/RB ,/, in/IN contrast/NN with/IN TNF-alpha/NN ,/, dopamine/NN treatment/NN did/VBD not/RB affect/VB NF-kappaB/NN DNA/NN binding/NN activity/NN nor/CC the/DT concentrations/NNS of/IN p50/NN ,/, p65/NN and/CC IkappaB-alpha/NN proteins/NNS ,/, which/WDT suggests/VBZ a/DT distinct/JJ NF-kappaB/NN activation/NN mechanism/NN ./. 
These/DT results/NNS reveal/VBP a/DT new/JJ link/NN between/IN the/DT dopamine/NN system/NN ,/, cytokine/NN signaling/NN pathway/NN and/CC regulation/NN of/IN gene/NN expression/NN via/IN the/DT involvement/NN of/IN NF-kappaB/NN in/IN T/NN cells/NNS and/CC PBMC/NN ./. 
UI/LS -/: 99372175/CD 
TI/LS -/: [/( Hormonal/JJ metabolic/JJ status/NN in/IN breast/NN cancer/NN patients/NNS after/IN conservative/JJ surgery/NN :/: comparison/NN with/IN known/JJ prognostic/JJ criteria/NNS ]/) 
AB/LS -/: Body/NN weight/NN ,/, body/NN mass/NN index/NN ,/, body/NN fat/NN ,/, lean/JJ body/NN mass/NN ,/, blood-glucose/NN ,/, cholesterol/NN ,/, HDL-cholesterol/NN ,/, triglyceride/NN ,/, beta-lipoproteins/NNS ,/, insulin/NN ,/, gonadotropin/NN ,/, estradiol/NN ,/, testosterone/NN ,/, SHBG/NN ,/, T3/NN ,/, T4/NN and/CC TSH/NN levels/NNS as/RB well/RB as/IN estradiol/NN and/CC progesterone/NN receptor/NN levels/NNS in/IN excised/VBN tumor/NN were/VBD studied/VBN in/IN 40/CD patients/NNS with/IN breast/NN cancer/NN prior/RB to/TO conservative/JJ treatment/NN ./. 
Said/NN anthropometric/NN ,/, metabolic/JJ and/CC hormonal/JJ parameters/NNS were/VBD compared/VBN with/IN the/DT index/NN of/IN lymphocytic/JJ infiltration/NN of/IN tumor/NN selected/VBN as/IN a/DT prognostic/JJ factor/NN ./. 
A/DT significant/JJ correlation/NN between/IN high/JJ lymphocytic/JJ infiltration/NN (/( 2.5/CD points/NNS )/) ,/, low/JJ body/NN mass/NN and/CC fat/NN was/VBD identified/VBN ./. 
Also/RB ,/, smoking/NN contributed/VBD to/TO loss/NN of/IN body/NN mass/NN and/CC fat/NN ;/: however/RB ,/, it/PRP caused/VBD lymphocytic/JJ infiltration/NN to/TO rise/VB ./. 
Moderate/JJ body/NN mass/NN ,/, relatively/RB low/JJ fat/JJ level/NN and/CC positive/JJ receptor/NN status/NN are/VBP among/IN factors/NNS of/IN good/JJ prognosis/NN in/IN breast/NN cancer/NN of/IN early/JJ stages/NNS ./. 
UI/LS -/: 99360752/CD 
TI/LS -/: Selective/JJ DNA-binding/JJ activity/NN of/IN interleukin-10-stimulated/JJ STAT/NN molecules/NNS in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: It/PRP has/VBZ been/VBN demonstrated/VBN that/IN interferon-gamma/NN (/( IFN-gamma/NN )/) and/CC interleukin-10/NN (/( IL-10/NN )/) have/VBP various/JJ reverse/JJ effects/NNS on/IN macrophages/NNS ;/: however/RB ,/, the/DT molecular/JJ mechanism/NN of/IN this/DT difference/NN has/VBZ not/RB been/VBN fully/RB understood/VBN ./. 
In/IN this/DT study/NN ,/, we/PRP analyzed/VBD the/DT binding/VBG activity/NN of/IN IL-10-/NN and/CC IFN-gamma-activated/JJ STAT/NN molecules/NNS to/TO two/CD kinds/NNS of/IN GAS-motif/NN sequences/NNS ./. 
IL-10-activated/JJ STAT1/NN could/MD bind/VB to/TO the/DT GAS-motif/JJ sequence/NN in/IN the/DT promoter/NN region/NN of/IN the/DT Fcgamma/NN receptor/NN ,/, but/CC not/RB to/TO that/DT in/IN the/DT promoter/JJ region/NN of/IN the/DT COX-2/NN gene/NN ,/, whereas/IN IFN-gamma-activated/JJ STAT1/NN and/CC STAT5/NN could/MD bind/VB to/TO both/DT sequences/NNS ./. 
IL-10/NN inhibited/VBD IFN-gamma-induced/JJ STAT/NN activation/NN without/IN newly/RB synthesized/VBN protein/NN ./. 
We/PRP further/RB demonstrated/VBD that/IN aspirin/NN ,/, but/CC not/RB dexamethasone/NN ,/, suppressed/VBD IFN-gamma-induced/JJ STAT/NN activation/NN ./. 
Taken/VBN together/RB ,/, these/DT results/NNS suggest/VBP that/IN IL-10-activated/JJ STAT1/NN has/VBZ a/DT specificity/NN in/IN binding/VBG to/TO the/DT GAS-motif/JJ sequences/NNS ,/, whereas/IN IFN-gamma-activated/JJ STAT1/NN and/CC STAT5/NN have/VBP a/DT broader/JJR spectrum/NN in/IN binding/VBG to/TO the/DT GAS-motif/JJ|NN sequences/NNS ./. 
This/DT may/MD explain/VB the/DT difference/NN between/IN IL-10/NN and/CC IFN-gamma/NN in/IN biological/JJ activity/NN ,/, and/CC the/DT inhibitory/JJ effect/NN of/IN IL-10/NN on/IN IFN-gamma/NN activities/NNS ./. 
UI/LS -/: 99353322/CD 
TI/LS -/: Peptide/NN binding/NN affinity/NN and/CC pH/NN variation/NN establish/VBP functional/JJ thresholds/NNS for/IN activation/NN of/IN HLA-DQ-restricted/JJ T/NN cell/NN recognition/NN ./. 
AB/LS -/: Peptides/NNS derived/VBN from/IN the/DT HSV-2/NN VP16/NN protein/NN were/VBD utilized/VBN for/IN studies/NNS of/IN peptide/NN binding/VBG to/TO DQ0302/NN molecules/NNS and/CC T/NN cell/NN activation/NN at/IN both/CC neutral/JJ and/CC acidic/JJ pH/NN ./. 
The/DT native/JJ peptide/NN VP16/NN 430-444/CD contains/VBZ an/DT Asp/NN at/IN position/NN 442/CD ,/, binds/VBZ to/TO DQ0302/NN strongly/RB ,/, with/IN a/DT Kd/NN value/NN of/IN 50nM/NN at/IN acidic/JJ pH/NN and/CC very/RB weakly/RB ,/, with/IN a/DT Kd/NN value/NN of/IN greater/JJR than/IN 10/CD microM/NN at/IN neutral/JJ pH/NN ./. 
A/DT truncated/VBN version/NN of/IN 430-444/CD ,/, i.e./FW ,/, VP16/NN 433-442/CD ,/, binds/VBZ with/IN an/DT affinity/NN 10-fold/RB lower/JJR compared/VBN to/TO 430-444/CD at/IN acidic/JJ pH/NN ,/, and/CC binding/NN at/IN neutral/JJ pH/NN was/VBD barely/RB detectable/JJ ./. 
The/DT homologous/JJ peptide/NN 430-444,442A/NN has/VBZ an/DT Asp/NN to/TO Ala/NN substitution/NN at/IN position/NN 442/CD and/CC binds/VBZ to/TO DQ0302/NN with/IN a/DT Kd/NN similar/JJ to/TO 433-442/CD ./. 
The/DT short/JJ truncated/VBN analog/NN 433-442A/NN binds/VBZ very/RB poorly/RB at/IN both/CC acidic/JJ and/CC neutral/JJ pH/NN ./. 
Both/CC the/DT wild/JJ type/NN 430-444/CD and/CC 433-442/CD peptides/NNS stimulated/VBD a/DT HSV-specific/JJ T/NN cell/NN clone/NN after/IN a/DT brief/JJ incubation/NN with/IN antigen/NN presenting/NN cells/NNS (/( APC/NN )/) expressing/VBG DQ0302/NN at/IN acidic/JJ pH/NN ./. 
Much/RB higher/JJR concentrations/NNS of/IN wild/JJ type/NN peptides/NNS were/VBD needed/VBN to/TO activate/VB T/NN cells/NNS at/IN neutral/JJ pH/NN ./. 
In/IN contrast/NN ,/, APC/NN pulsed/JJ with/IN Ala-substituted/JJ peptides/NNS 430-444,442A/NN or/CC 433-442A/NN at/IN neutral/JJ pH/NN failed/VBD to/TO stimulate/VB the/DT T/NN cell/NN clone/NN ,/, while/IN APC/NN pulsed/JJ at/IN acidic/JJ pH/NN and/CC subsequently/RB washed/VBN led/VBD to/TO successful/JJ T/NN cell/NN activation/NN ./. 
The/DT Ala-substituted/JJ peptide/NN was/VBD recognized/VBN by/IN the/DT T/NN cell/NN clone/NN at/IN neutral/JJ pH/NN only/RB when/WRB it/PRP was/VBD present/JJ in/IN the/DT APC/NN culture/NN throughout/IN the/DT stimulation/NN process/NN ./. 
While/IN the/DT MHC-peptide/JJ|NN complexes/NNS formed/VBN with/IN the/DT native/JJ peptide/NN are/VBP stable/JJ ,/, complexes/NNS formed/VBN with/IN the/DT Ala-substituted/JJ peptide/NN had/VBD a/DT functional/JJ t1/2/NN of/IN less/JJR than/IN 4/CD hr/NN at/IN neutral/JJ pH/NN ./. 
UI/LS -/: 99336788/CD 
TI/LS -/: ETS/NN transcription/NN factors/NNS regulate/VBP an/DT enhancer/NN activity/NN in/IN the/DT third/JJ intron/NN of/IN TNF-alpha/NN ./. 
AB/LS -/: We/PRP describe/VBP an/DT enhancer/NN site/NN in/IN the/DT third/JJ intron/NN of/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) ./. 
A/DT reporter/NN construct/NN containing/VBG the/DT 5'-flanking/JJ region/NN of/IN the/DT mouse/NN TNF-alpha/NN gene/NN displayed/VBD weak/JJ activity/NN when/WRB transfected/VBN into/IN RAW264.7/NN macrophage-like/JJ cells/NNS ./. 
The/DT addition/NN of/IN the/DT third/JJ intron/NN of/IN TNF-alpha/NN to/TO this/DT construct/NN resulted/VBD in/IN an/DT enhancement/NN of/IN CAT/NN protein/NN ./. 
This/DT enhancement/NN was/VBD eliminated/VBN if/IN a/DT conserved/VBN 20-bp/JJ sequence/NN was/VBD removed/VBN from/IN the/DT intron/NN or/CC if/IN a/DT dominant-negative/JJ ets-binding/JJ factor/NN was/VBD co-transfected/VBN with/IN the/DT reporter/NN gene/NN ./. 
Mutations/NNS of/IN this/DT site/NN that/WDT destroyed/VBD potential/JJ ets/NN transcription/NN factor/NN binding/NN sites/NNS had/VBD reduced/VBN transcriptional/JJ activity/NN ./. 
The/DT major/JJ transcription/NN factor/NN that/WDT bound/VBD to/TO the/DT oligonucleotide/NN was/VBD confirmed/VBN to/TO be/VB GABP/NN by/IN supershift/NN and/CC competition/NN analysis/NN ./. 
In/IN RAW264.7/NN cells/NNS ,/, the/DT binding/NN was/VBD constitutive/JJ ,/, however/RB ,/, in/IN bone/NN marrow-derived/JJ macrophages/NNS binding/NN activity/NN was/VBD shown/VBN to/TO be/VB interferon-gamma/NN inducible/JJ ./. 
This/DT may/MD imply/VB a/DT role/NN for/IN ets/NN transcription/NN factors/NNS in/IN the/DT production/NN of/IN TNF-alpha/NN ./. 
UI/LS -/: 96140436/CD 
TI/LS -/: E2F-1/NN blocks/VBZ terminal/JJ differentiation/NN and/CC causes/VBZ proliferation/NN in/IN transgenic/JJ megakaryocytes/NNS ./. 
AB/LS -/: The/DT transcription/NN factor/NN E2F-1/NN plays/VBZ a/DT central/JJ role/NN in/IN the/DT cell/NN cycle/NN through/IN its/PRP$ ability/NN to/TO activate/VB genes/NNS involved/VBN in/IN cell/NN division/NN ./. 
E2F-1/NN activity/NN is/VBZ regulated/VBN by/IN a/DT number/NN of/IN proteins/NNS ,/, including/VBG the/DT retinoblastoma/NN susceptibility/NN gene/NN product/NN ,/, cyclin-dependent/JJ kinases/NNS ,/, and/CC their/PRP$ inhibitors/NNS ,/, proteins/NNS that/WDT have/VBP been/VBN implicated/VBN in/IN the/DT control/NN of/IN certain/JJ developmental/JJ processes/NNS ./. 
To/TO investigate/VB a/DT potential/JJ role/NN of/IN E2F-1/NN in/IN differentiation/NN ,/, we/PRP assayed/VBD the/DT ability/NN of/IN megakaryocytes/NNS to/TO form/VB platelets/NNS in/IN an/DT in/FW vivo/FW transgenic/JJ model/NN ./. 
E2F-1/NN expression/NN in/IN megakaryocytes/NNS blocked/VBD differentiation/NN during/IN maturation/NN ,/, resulting/VBG in/IN severe/JJ thrombocytopenia/NN ./. 
Ultrastructural/JJ analysis/NN of/IN megakaryocytes/NNS revealed/VBD abnormal/JJ development/NN characterized/VBN by/IN hyperdemarcation/NN of/IN cytoplasmic/JJ membranes/NNS and/CC reduced/VBN numbers/NNS of/IN alpha/NN granules/NNS ./. 
Administration/NN of/IN megakaryocyte/NN growth/NN and/CC development/NN factor/NN or/CC interleukin/NN 6/CD could/MD not/RB overcome/VB the/DT differentiation/NN block/NN ./. 
Additionally/RB ,/, E2F-1/NN caused/VBD massive/JJ megakaryocyte/NN accumulation/NN in/IN both/CC normal/JJ and/CC ectopic/JJ sites/NNS ,/, first/RB evident/JJ in/IN E15/CD embryonic/JJ liver/NN ./. 
Furthermore/RB ,/, significant/JJ apoptosis/NN was/VBD observed/VBN in/IN transgenic/JJ megakaryocytes/NNS ./. 
These/DT data/NNS indicate/VBP that/IN E2F-1/NN can/MD prevent/VB terminal/JJ differentiation/NN ,/, probably/RB through/IN its/PRP$ cell/NN cycle-stimulatory/JJ activity/NN ./. 
UI/LS -/: 96132964/CD 
TI/LS -/: Polymorphic/JJ nucleotides/NNS within/IN the/DT human/JJ IL-4/NN promoter/NN that/WDT mediate/VBP overexpression/NN of/IN the/DT gene/NN ./. 
AB/LS -/: Atopy/NN ,/, which/WDT predisposes/VBZ individuals/NNS to/TO develop/VB asthma/NN ,/, severe/JJ systemic/JJ anaphylaxis/NN ,/, and/CC atopic/JJ dermatitis/NN ,/, is/VBZ usually/RB associated/VBN with/IN dramatically/RB elevated/JJ total/JJ serum/NN IgE/NN levels/NNS and/CC is/VBZ thought/VBN to/TO be/VB controlled/VBN by/IN a/DT major/JJ susceptibility/NN gene/NN and/CC multiple/JJ minor/JJ susceptibility/NN genes/NNS ./. 
A/DT recent/JJ sib-pair/JJ|NN analysis/NN revealed/VBD a/DT tight/JJ linkage/NN between/IN markers/NNS on/IN 5q31.1/NN and/CC a/DT major/JJ susceptibility/NN gene/NN controlling/VBG total/JJ serum/NN IgE/NN levels/NNS ./. 
Due/IN to/TO its/PRP$ location/NN within/IN this/DT cluster/NN and/CC its/PRP$ biologic/JJ role/NN in/IN Ig/NN class/NN switching/NN and/CC Th2/NN cell/NN differentiation/NN ,/, the/DT IL-4/NN gene/NN has/VBZ emerged/VBN as/IN one/CD major/JJ candidate/NN for/IN the/DT atopy/NN gene/NN ./. 
In/IN one/CD model/NN ,/, polymorphisms/NNS within/IN IL-4/NN regulatory/JJ elements/NNS might/MD result/VB in/IN overexpression/NN of/IN the/DT gene/NN ,/, amplifying/VBG Th2/NN cell/NN differentiation/NN and/CC class/NN switching/NN to/TO IgE/NN ./. 
In/IN support/NN of/IN this/DT model/NN ,/, we/PRP report/VBP that/IN the/DT human/JJ IL-4/NN promoter/NN exists/VBZ in/IN multiple/JJ allelic/JJ forms/NNS that/WDT exhibit/VBP distinct/JJ transcriptional/JJ activities/NNS in/IN IL-4-positive/JJ T/NN cells/NNS ./. 
A/DT particular/JJ allele/NN has/VBZ an/DT unusually/RB high/JJ transcriptional/JJ activity/NN ./. 
A/DT nucleotide/JJ substitution/NN within/IN a/DT recently/RB described/VBN OAP40/NN element/NN located/JJ just/RB upstream/RB of/IN an/DT NF-AT/NN site/NN (/( P/NN sequence/NN )/) appears/VBZ to/TO be/VB largely/RB responsible/JJ for/IN the/DT increased/VBN promotor/NN strength/NN of/IN this/DT particular/JJ allelic/JJ form/NN of/IN the/DT IL-4/NN promoter/NN ./. 
In/IN EMSAs/NNS ,/, this/DT substitution/NN results/VBZ in/IN a/DT markedly/RB enhanced/VBN affinity/NN for/IN sequence-specific/JJ complexes/NNS exhibiting/VBG an/DT AP-1/NN specificity/NN ./. 
The/DT identification/NN of/IN allelic/JJ nucleotides/NNS ,/, which/WDT results/VBZ in/IN overexpression/NN of/IN the/DT IL-4/NN gene/NN ,/, provides/VBZ specific/JJ targets/NNS for/IN a/DT comprehensive/JJ screening/NN of/IN atopic/JJ and/CC nonatopic/JJ individuals/NNS and/CC may/MD provide/VB a/DT clue/NN for/IN genetic/JJ predisposition/NN for/IN atopy/NN ./. 
UI/LS -/: 96389043/CD 
TI/LS -/: Evidence/NN for/IN lowered/JJ induction/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN in/IN activated/VBN human/JJ T/NN lymphocytes/NNS during/IN aging/NN ./. 
AB/LS -/: Transcription/NN factor/NN NF/NN kappa/NN B/NN (/( nuclear/JJ factor/NN kappa/NN B/NN )/) is/VBZ induced/VBN in/IN T/NN lymphocytes/NNS from/IN young/JJ individuals/NNS following/VBG activation/NN with/IN a/DT variety/NN of/IN stimuli/NNS including/VBG anti-CD3/NN ,/, phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) ,/, and/CC tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) ./. 
In/IN contrast/NN ,/, activated/VBN T/NN lymphocytes/NNS from/IN older/JJR individuals/NNS show/VBP a/DT significant/JJ reduction/NN in/IN the/DT induction/NN of/IN NF/NN kappa/NN B/NN in/IN response/NN to/TO the/DT same/JJ stimuli/NNS ./. 
The/DT age-related/JJ decline/NN in/IN induction/NN of/IN NF/NN kappa/NN B/NN could/MD not/RB be/VB attributed/VBN to/TO alteration/NN in/IN the/DT composition/NN of/IN subunits/NNS ,/, p50/NN and/CC p65/NN were/VBD found/VBN to/TO be/VB the/DT predominant/JJ subunits/NNS of/IN induced/VBN NF/NN kappa/NN B/NN in/IN T/NN cells/NNS from/IN young/JJ as/RB well/RB as/IN elderly/JJ donors/NNS ./. 
Furthermore/RB ,/, similar/JJ levels/NNS of/IN NF/NN kappa/NN B/NN were/VBD found/VBN in/IN the/DT cytosols/NNS of/IN unactivated/JJ T/NN cells/NNS from/IN both/CC young/JJ and/CC elderly/JJ donors/NNS suggesting/VBG that/IN precursor/NN levels/NNS of/IN NF/NN kappa/NN B/NN remain/VBP unaltered/JJ during/IN aging/NN ./. 
These/DT results/NNS suggest/VBP that/IN an/DT age-associated/JJ decline/NN in/IN the/DT induction/NN of/IN NF/NN kappa/NN B/NN in/IN activated/VBN T/NN cells/NNS from/IN elderly/JJ individuals/NNS may/MD be/VB attributable/JJ to/TO altered/JJ regulation/NN of/IN the/DT inhibitor/NN ,/, I/NN kappa/NN B/NN ,/, and/CC may/MD play/VB an/DT important/JJ role/NN in/IN immune/JJ dysregulation/NN accompanying/VBG aging/NN ./. 
UI/LS -/: 96141969/CD 
TI/LS -/: Inhibition/NN of/IN lipopolysaccharide-induced/JJ monocyte/NN interleukin-1/NN receptor/NN antagonist/NN synthesis/NN by/IN cortisol/NN :/: involvement/NN of/IN the/DT mineralocorticoid/NN receptor/NN ./. 
AB/LS -/: Glucocorticoids/NNS ,/, as/IN a/DT part/NN of/IN their/PRP$ physiological/JJ role/NN in/IN the/DT control/NN of/IN inflammatory/JJ and/CC immune/JJ processes/NNS ,/, suppress/VBP the/DT expression/NN of/IN interleukin-1/NN (/( IL-1/NN )/) and/CC other/JJ cytokines/NNS ./. 
Human/JJ monocyte/NN IL-1/NN receptor/NN antagonist/NN (/( IL-1ra/NN )/) messenger/NN ribonucleic/NN acid/NN (/( mRNA/NN )/) expression/NN and/CC protein/NN secretion/NN are/VBP inhibited/VBN by/IN dexamethasone/NN ./. 
We/PRP have/VBP now/RB further/RB studied/VBN the/DT regulation/NN of/IN IL-1ra/NN by/IN the/DT major/JJ physiological/JJ human/JJ glucocorticoid/NN ,/, cortisol/NN ./. 
We/PRP found/VBD that/IN cortisol/NN incubation/NN induced/VBD a/DT decrease/NN in/IN IL-1ra/NN mRNA/NN expression/NN and/CC a/DT significant/JJ inhibition/NN of/IN IL-1ra/NN protein/NN secretion/NN in/IN cell/NN cultures/NNS of/IN human/JJ peripheral/JJ monocytes/NNS stimulated/VBN with/IN the/DT bacterial/JJ endotoxin/NN lipopolysaccharide/NN (/( LPS/NN )/) ./. 
Oral/JJ administration/NN of/IN 276/CD mumol/NN cortisol/NN to/TO normal/JJ subjects/NNS also/RB decreased/VBD LPS-induced/JJ IL-1ra/NN synthesis/NN in/IN cultured/VBN monocytes/NNS ./. 
By/IN coincubating/VBG the/DT monocytes/NNS with/IN either/CC the/DT mineralocorticoid/NN antagonist/NN spironolactone/NN or/CC the/DT glucocorticoid/NN receptor/NN antagonist/NN RU/NN 38486/CD ,/, the/DT in/FW vitro/FW cortisol-induced/JJ inhibition/NN of/IN LPS-stimulated/JJ IL-1ra/NN secretion/NN was/VBD partially/RB reversed/VBN ./. 
The/DT mineralocorticoid/NN aldosterone/NN exerted/VBD a/DT significant/JJ decrease/NN in/IN LPS-induced/JJ monocyte/NN IL-1ra/NN secretion/NN in/FW vitro/FW ,/, which/WDT was/VBD blocked/VBN by/IN coincubation/NN with/IN spironolactone/NN ./. 
In/IN addition/NN ,/, the/DT expression/NN of/IN mineralocorticoid/NN receptor/NN mRNA/NN in/IN human/JJ monocytes/NNS was/VBD observed/VBN by/IN PCR/NN of/IN reversed/VBN transcribed/VBN RNA/NN ./. 
Our/PRP$ results/NNS further/RB indicate/VBP that/IN corticosteroids/NNS physiologically/RB control/VBP the/DT IL-1/IL-1ra/JJ|NN system/NN during/IN inflammatory/JJ or/CC immune/JJ processes/NNS ./. 
Moreover/RB ,/, we/PRP provide/VBP evidence/NN that/IN ,/, in/IN addition/NN to/TO a/DT glucocorticoid/NN receptor-mediated/JJ effect/NN ,/, the/DT mineralocorticoid/NN receptor/NN is/VBZ involved/VBN in/IN the/DT inhibition/NN of/IN monocyte/NN IL-1ra/NN secretion/NN by/IN cortisol/NN ./. 
UI/LS -/: 99412333/CD 
TI/LS -/: Target/NN structures/NNS of/IN the/DT CD8(+)-T-cell/NN response/NN to/TO human/JJ cytomegalovirus/NN :/: the/DT 72-kilodalton/JJ major/JJ immediate-early/JJ protein/NN revisited/VBN ./. 
AB/LS -/: Cell-mediated/JJ immunity/NN plays/VBZ an/DT essential/JJ role/NN in/IN the/DT control/NN of/IN infection/NN with/IN the/DT human/JJ cytomegalovirus/NN (/( HCMV/NN )/) ./. 
However/RB ,/, only/RB a/DT few/JJ CD8(+)-T-cell/NN epitopes/NNS are/VBP known/VBN ,/, with/IN the/DT majority/NN being/VBG contained/VBN in/IN the/DT pp65/NN phosphoprotein/NN ,/, which/WDT is/VBZ believed/VBN to/TO dominate/VB the/DT CD8(+)-T-cell/NN response/NN to/TO HCMV/NN ./. 
Here/RB ,/, we/PRP have/VBP readdressed/VBN the/DT issue/NN of/IN CD8(+)/JJ T/NN cells/NNS specific/JJ for/IN the/DT 72-kDa/JJ major/JJ immediate-early/JJ protein/NN (/( IE-1/NN )/) ,/, which/WDT is/VBZ nonstructural/JJ but/CC is/VBZ found/VBN very/RB early/RB and/CC throughout/IN the/DT replicative/JJ cycle/NN ./. 
Using/VBG a/DT novel/JJ flow-cytometric/JJ assay/NN ,/, we/PRP were/VBD able/JJ to/TO identify/VB CD8(+)-T-cell/NN epitopes/NNS (/( by/IN IE-1/NN peptide-specific/JJ induction/NN of/IN cytokine/NN synthesis/NN )/) and/CC simultaneously/RB measure/VB the/DT frequency/NN of/IN cells/NNS directed/VBN against/IN them/PRP ./. 
For/IN this/DT purpose/NN ,/, 81/CD pentadecamer/NN peptides/NNS covering/VBG the/DT complete/JJ 491-amino-acid/NN sequence/NN of/IN IE-1/NN were/VBD tested/VBN on/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS of/IN anti-HCMV/NN immunoglobulin/NN G-seropositive/JJ donors/NNS ./. 
At/IN least/JJS 10/CD new/JJ epitopes/NNS were/VBD identified/VBN ,/, and/CC the/DT fine/NN specificity/NN and/CC presenting/JJ HLA/NN molecule/NN of/IN the/DT first/JJ of/IN them/PRP was/VBD determined/VBN ./. 
The/DT frequencies/NNS of/IN CD8(+)/JJ T/NN cells/NNS directed/VBN against/IN IE-1/NN were/VBD similar/JJ to/TO those/DT directed/VBN against/IN pp65/NN in/IN donors/NNS tested/VBN with/IN known/JJ pp65-derived/JJ peptides/NNS ./. 
Importantly/RB ,/, additional/JJ testing/NN of/IN a/DT corresponding/JJ set/NN of/IN peptides/NNS covering/VBG the/DT complete/JJ sequence/NN of/IN pp65/NN on/IN 10/CD of/IN these/DT donors/NNS identified/VBD individuals/NNS whose/WP$ CD8(+)/JJ T/NN cells/NNS recognized/VBD IE-1/NN but/CC not/RB pp65/NN and/CC vice/RB versa/RB ,/, clearly/RB illustrating/VBG that/IN either/DT protein/NN may/MD be/VB a/DT major/JJ target/NN ./. 
In/IN summary/NN ,/, our/PRP$ results/NNS suggest/VBP that/IN IE-1/NN is/VBZ far/RB more/RBR important/JJ as/IN a/DT CD8(+)-T-cell/NN target/NN than/IN current/JJ opinion/NN suggests/VBZ ./. 
UI/LS -/: 99400649/CD 
TI/LS -/: E1A/NN oncogene/NN induction/NN of/IN cellular/JJ susceptibility/NN to/TO killing/NN by/IN cytolytic/JJ lymphocytes/NNS through/IN target/NN cell/NN sensitization/NN to/TO apoptotic/JJ injury/NN ./. 
AB/LS -/: E1A/NN oncogene/NN expression/NN increases/VBZ mammalian/JJ cell/NN susceptibility/NN to/TO lysis/NN by/IN cytolytic/JJ lymphocytes/NNS (/( CLs/NNS )/) at/IN a/DT stage/NN in/IN this/DT intercellular/JJ interaction/NN that/WDT is/VBZ independent/JJ of/IN cell/NN surface/NN recognition/NN events/NNS ./. 
Since/IN CLs/NN can/MD induce/VB either/CC apoptotic/JJ or/CC necrotic/JJ cell/NN death/NN ,/, we/PRP asked/VBD whether/IN E1A/NN sensitization/NN to/TO injury-induced/JJ apoptosis/NN is/VBZ sufficient/JJ to/TO explain/VB E1A-induced/JJ cytolytic/JJ susceptibility/NN ./. 
Mouse/NN ,/, rat/NN ,/, hamster/NN ,/, and/CC human/JJ cells/NNS that/WDT were/VBD rendered/VBN cytolytic/JJ susceptible/JJ by/IN E1A/NN were/VBD also/RB sensitized/VBN to/TO CL-induced/JJ and/CC chemically/RB induced/VBN apoptosis/NN ./. 
In/IN contrast/NN ,/, E1A-positive/JJ cells/NNS were/VBD no/DT more/RBR susceptible/JJ to/TO injury-induced/JJ necrosis/NN than/IN E1A-negative/JJ cells/NNS ./. 
Similar/JJ to/TO induction/NN of/IN cytolytic/JJ susceptibility/NN and/CC in/IN contrast/NN to/TO other/JJ E1A/NN activities/NNS ,/, cellular/JJ sensitization/NN to/TO chemically/RB induced/VBN apoptosis/NN depended/VBD on/IN high-level/JJ E1A/NN oncoprotein/NN expression/NN ./. 
Loss/NN of/IN both/CC cytolytic/JJ susceptibility/NN and/CC sensitization/NN to/TO chemically/RB induced/VBN apoptosis/NN was/VBD coselected/VBN during/IN in/FW vivo/FW selection/NN of/IN E1A-positive/JJ sarcoma/NN cells/NNS for/IN increased/VBN tumorigenicity/NN ./. 
Furthermore/RB ,/, E1A/NN mutant/JJ proteins/NNS that/WDT can/MD not/RB bind/VB the/DT cellular/JJ transcriptional/JJ coactivator/NN ,/, p300/NN ,/, and/CC that/WDT fail/VBP to/TO induce/VB cytolytic/JJ susceptibility/NN also/RB failed/VBD to/TO sensitize/VB cells/NNS to/TO injury-induced/JJ apoptosis/NN ./. 
These/DT data/NNS indicate/VBP that/IN E1A/NN induces/VBZ susceptibility/NN to/TO killer/NN cell-induced/JJ lysis/NN through/IN sensitization/NN of/IN cells/NNS to/TO injury-induced/JJ apoptosis/NN ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99380601/CD 
TI/LS -/: TCL1/NN oncogene/NN expression/NN in/IN AIDS-related/JJ lymphomas/NNS and/CC lymphoid/JJ tissues/NNS ./. 
AB/LS -/: AIDS-related/JJ non-Hodgkin/JJ 's/POS lymphoma/NN (/( AIDS/NN NHL/NN )/) comprises/VBZ a/DT diverse/JJ and/CC heterogeneous/JJ group/NN of/IN high-grade/JJ B/NN cell/NN tumors/NNS ./. 
Certain/JJ classes/NNS of/IN AIDS/NN NHL/NN are/VBP associated/VBN with/IN alterations/NNS in/IN oncogenes/NNS or/CC tumor-suppressor/JJ genes/NNS or/CC infections/NNS by/IN oncogenic/JJ herpesviruses/NNS ./. 
However/RB ,/, the/DT clinically/RB significant/JJ class/NN of/IN AIDS/NN NHL/NN designated/JJ immunoblastic/JJ lymphoma/NN plasmacytoid/NN (/( AIDS/NN IBLP/NN )/) lacks/VBZ any/DT consistent/JJ genetic/JJ alterations/NNS ./. 
We/PRP identified/VBD the/DT TCL1/NN oncogene/NN from/IN a/DT set/NN of/IN AIDS/NN IBLP-associated/JJ cDNA/NN fragments/NNS generated/VBN by/IN subtractive/JJ hybridization/NN with/IN non-AIDS/JJ IBLP/NN ./. 
Aberrant/JJ TCL1/NN expression/NN has/VBZ been/VBN implicated/VBN in/IN T/NN cell/NN leukemia/lymphoma/JJ|NN development/NN ,/, and/CC its/PRP$ expression/NN also/RB has/VBZ been/VBN seen/VBN in/IN many/JJ established/JJ B/NN cell/NN tumor/NN lines/NNS ./. 
However/RB ,/, TCL1/NN expression/NN has/VBZ not/RB been/VBN reported/VBN in/IN AIDS/NN NHL/NN ./. 
We/PRP find/VBP that/IN TCL1/NN is/VBZ expressed/VBN in/IN the/DT majority/NN of/IN AIDS/NN IBLP/NN tumors/NNS examined/VBN ./. 
TCL1/NN protein/NN expression/NN is/VBZ restricted/JJ to/TO tumor/NN cells/NNS in/IN AIDS/NN IBLP/NN tissue/NN samples/NNS analyzed/VBN with/IN immunohistochemical/JJ staining/NN ./. 
Hyperplastic/JJ lymph/NN node/NN and/CC tonsil/NN also/RB exhibit/VBP strong/JJ TCL1/NN protein/NN expression/NN in/IN mantle/NN zone/NN B/NN cells/NNS and/CC in/IN rare/JJ interfollicular/JJ zone/NN cells/NNS ,/, whereas/IN follicle-center/JJ B/NN cells/NNS (/( centroblasts/NNS and/CC centrocytes/NNS )/) show/VBP weaker/JJR expression/NN ./. 
These/DT results/NNS establish/VBP TCL1/NN as/IN the/DT most/RBS prevalent/JJ of/IN all/DT of/IN the/DT surveyed/VBN oncogenes/NNS associated/VBN with/IN AIDS/NN IBLP/NN ./. 
They/PRP also/RB indicate/VBP that/IN abundant/JJ TCL1/NN expression/NN in/IN quiescent/JJ mantle/NN zone/NN B/NN cells/NNS is/VBZ down-regulated/VBN in/IN activated/VBN germinal/JJ center/NN follicular/JJ B/NN cells/NNS in/IN parallel/NN to/TO the/DT known/JJ expression/NN pattern/NN of/IN BCL-2/NN ./. 
High-level/JJ expression/NN in/IN nonproliferating/JJ B/NN cells/NNS suggests/VBZ that/IN TCL1/NN may/MD function/VB in/IN protecting/VBG naive/JJ preactivated/JJ B/NN cells/NNS from/IN apoptosis/NN ./. 
UI/LS -/: 99369980/CD 
TI/LS -/: IL-2-independent/JJ activation/NN and/CC proliferation/NN in/IN human/JJ T/NN cells/NNS induced/VBN by/IN CD28/NN ./. 
AB/LS -/: Although/IN the/DT role/NN of/IN CD28/NN in/IN T/NN cell/NN costimulation/NN is/VBZ firmly/RB established/VBN ,/, the/DT mechanisms/NNS by/IN which/WDT it/PRP exerts/VBZ its/PRP$ costimulatory/JJ actions/NNS are/VBP less/RBR clear/JJ ./. 
In/IN many/JJ circumstances/NNS it/PRP is/VBZ difficult/JJ to/TO distinguish/VB the/DT effects/NNS of/IN CD28/NN from/IN subsequent/JJ actions/NNS of/IN cytokines/NNS ,/, such/JJ as/IN IL-2/NN ,/, on/IN T/NN cell/NN proliferation/NN ./. 
Here/RB ,/, we/PRP report/VBP a/DT model/NN of/IN CD28/NN costimulation/NN using/VBG PMA/NN plus/CC the/DT natural/JJ ligand/NN CD80/NN that/WDT resulted/VBD in/IN very/RB limited/JJ stimulation/NN of/IN IL-2/NN ,/, as/IN evidenced/VBN by/IN both/CC cytokine/NN production/NN and/CC IL-2/NN promoter/NN stimulation/NN ./. 
Promoter/NN assays/NNS revealed/VBD CD28-dependent/JJ effects/NNS on/IN both/CC NF-kappaB/NN and/CC AP-1/NN ,/, but/CC not/RB on/IN NF-AT/NN or/CC the/DT intact/JJ IL-2/NN promoter/NN ./. 
In/IN addition/NN ,/, T/NN cell/NN proliferation/NN was/VBD completely/RB resistant/JJ to/TO the/DT actions/NNS of/IN the/DT immunosuppressant/JJ cyclosporin/NN A/NN (/( CsA/NN )/) ./. 
Moreover/RB T/NN cell/NN proliferation/NN was/VBD unaffected/JJ by/IN the/DT addition/NN of/IN blocking/VBG Abs/NNS to/TO both/CC IL-2/NN and/CC the/DT IL-2/NN receptor/NN ,/, demonstrating/VBG that/IN this/DT form/NN of/IN costimulation/NN by/IN CD28/NN was/VBD independent/JJ of/IN IL-2/NN ./. 
We/PRP also/RB investigated/VBD the/DT effects/NNS of/IN stimulating/VBG T/NN cell/NN blasts/NNS with/IN CD80/NN alone/RB and/CC found/VBD that/IN there/EX was/VBD a/DT limited/JJ requirement/NN for/IN IL-2/NN in/IN this/DT system/NN ./. 
We/PRP conclude/VBP that/IN CD28/NN costimulation/NN can/MD cause/VB substantial/JJ T/NN cell/NN proliferation/NN in/IN the/DT absence/NN of/IN IL-2/NN ,/, which/WDT is/VBZ driven/VBN by/IN a/DT soluble/JJ factor/NN independent/JJ of/IN NF-AT/NN transactivation/NN ./. 
UI/LS -/: 99362759/CD 
TI/LS -/: The/DT Epstein-Barr/JJ virus/NN latency/NN BamHI-Q/NN promoter/NN is/VBZ positively/RB regulated/VBN by/IN STATs/NNS and/CC Zta/NN interference/NN with/IN JAK/STAT/JJ|NN activation/NN leads/VBZ to/TO loss/NN of/IN BamHI-Q/NN promoter/NN activity/NN ./. 
AB/LS -/: In/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) -associated/JJ tumors/NNS in/IN nonimmunocompromised/JJ patients/NNS ,/, EBV/NN gene/NN expression/NN is/VBZ highly/RB restricted/JJ ./. 
EBV-encoded/JJ nuclear/JJ antigen/NN (/( EBNA/NN )/) -1/CD is/VBZ expressed/VBN ,/, whereas/IN the/DT immunogenic/JJ and/CC proliferative/JJ EBNAs/NNS are/VBP not/RB ./. 
This/DT pattern/NN of/IN EBNA/NN expression/NN is/VBZ generated/VBN by/IN usage/NN of/IN the/DT BamHI-Q/NN promoter/NN (/( Qp/NN )/) ./. 
We/PRP have/VBP determined/VBN that/IN the/DT JAK/STAT/JJ|NN pathway/NN positively/RB regulates/VBZ Qp/NN activity/NN ./. 
In/IN transient-transfection/JJ|NN assays/NNS ,/, a/DT Qp-CAT/NN reporter/NN was/VBD activated/VBN by/IN cotransfected/VBN JAK-1/NN and/CC by/IN treatment/NN of/IN cells/NNS with/IN the/DT cytokine/NN IL-6/NN ./. 
The/DT ability/NN of/IN Qp/NN to/TO bind/VB signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) proteins/NNS was/VBD directly/RB demonstrated/VBN by/IN electrophoretic/JJ mobility-shift/JJ|NN assay/NN ,/, and/CC mutation/NN of/IN potential/JJ STAT-binding/JJ sites/NNS reduced/VBD Qp/NN responsiveness/NN to/TO Janus/NN kinase/NN (/( JAK/NN )/) -1/CD ./. 
Consistent/JJ with/IN a/DT role/NN for/IN STATs/NNS in/IN Qp/NN function/NN ,/, Qp/NN using/VBG Burkitt/NN 's/POS lymphoma/NN Rael/NN cells/NNS and/CC cultured/VBN nasopharyngeal/NN carcinoma/NN (/( NPC/NN )/) cells/NNS contained/VBD nuclear/JJ STAT/NN protein/NN ./. 
We/PRP investigated/VBD whether/IN the/DT inability/NN to/TO maintain/VB EBV-positive/JJ NPC/NN cell/NN lines/NNS in/IN culture/NN was/VBD related/JJ to/TO Qp/NN activity/NN ./. 
Passaging/NN of/IN the/DT NPC/NN cell/NN line/NN HK666/NN led/VBD to/TO activation/NN of/IN expression/NN of/IN BZLF1/NN ,/, which/WDT encodes/VBZ Zta/NN and/CC loss/NN of/IN Qp/NN function/NN ./. 
Transient/JJ expression/NN assays/NNS linked/VBD Zta/NN expression/NN to/TO the/DT down-regulation/NN of/IN Qp/NN ./. 
Cotransfection/NN of/IN Zta/NN reduced/VBD Qp/NN activity/NN in/IN reporter/NN assays/NNS ./. 
This/DT negative/JJ regulation/NN required/VBD Zta/NN DNA-binding/JJ activity/NN ./. 
We/PRP provide/VBP evidence/NN that/IN Zta/NN up-regulation/NN of/IN p53/NN leads/VBZ to/TO p53-mediated/JJ interference/NN with/IN JAK/STAT/JJ|NN activation/NN of/IN Qp/NN ./. 
The/DT data/NNS imply/VBP that/IN JAK/STAT/JJ|NN signaling/NN has/VBZ a/DT role/NN in/IN EBV-associated/JJ malignancies/NNS ./. 
UI/LS -/: 99356019/CD 
TI/LS -/: Reactive/JJ oxygen/NN intermediate-release/NN of/IN fibre-exposed/JJ monocytes/NNS increases/VBZ inflammatory/JJ cytokine-mRNA/JJ level/NN ,/, protein/NN tyrosine/NN kinase/NN and/CC NF-kappaB/NN activity/NN in/IN co-cultured/VBN bronchial/JJ epithelial/JJ cells/NNS (/( BEAS-2B/NN )/) ./. 
AB/LS -/: Some/DT pulmonary/JJ diseases/NNS like/IN bronchitis/NN or/CC asthma/NN bronchiale/NN are/VBP mediated/VBN by/IN inflammatory/JJ mechanisms/NNS in/IN bronchial/JJ epithelial/JJ cells/NNS ./. 
Alveolar/JJ macrophages/NNS are/VBP located/JJ directly/RB in/IN the/DT surrounding/NN of/IN these/DT cells/NNS ,/, so/IN that/IN we/PRP suppose/VBP an/DT interaction/NN between/IN epithelial/JJ cells/NNS and/CC macrophages/NNS regarding/VBG to/TO the/DT release/NN of/IN inflammatory/JJ mediators/NNS ./. 
For/IN measuring/VBG the/DT contribution/NN of/IN macrophages/NNS to/TO the/DT release/NN of/IN inflammatory/JJ mediators/NNS by/IN bronchial/JJ epithelial/JJ cells/NNS ,/, we/PRP established/VBD an/DT in/FW vitro/FW model/NN of/IN co-cultured/VBN blood/NN monocytes/NNS (/( BM/NNS )/) and/CC BEAS-2B/NN cells/NNS in/IN a/DT transwell/NN system/NN (/( Costar/NN )/) ./. 
BM/NNS were/VBD exposed/VBN to/TO Chrysotile/NN B/NN and/CC soot/NN particle/NN FR/NN 101/CD in/IN a/DT concentration/NN of/IN 100/CD microg/10/NN (/( 6/CD )/) cells/NNS ./. 
After/IN up/RB to/TO 90/CD min/NN exposure/NN time/NN ELISA/NN ,/, EMSA/NN (/( electromobility/NN shift/NN assay/NN )/) and/CC RT-PCR/NN were/VBD used/VBN to/TO measure/VB protein/NN tyrosine/NN kinase/NN activity/NN ,/, protein/NN activity/NN of/IN NF-kappaB/NN and/CC cytokine/NN (/( IL-1beta/NN ,/, IL-6/NN ,/, TNF-alpha/NN )/) specific/JJ mRNA/NN levels/NNS in/IN BEAS-2B/NN cells/NNS ./. 
We/PRP observed/VBD an/DT increase/NN in/IN protein/NN tyrosine/NN kinase/NN activity/NN (/( up/RB to/TO 1.8/CD +/-/CC 0.5-fold/JJ )/) and/CC NF-kappaB/NN protein/NN activity/NN in/IN BEAS-2B/NN cells/NNS after/IN particle/NN or/CC fibre/JJ exposure/NN of/IN co-cultured/VBN BM/NNS ./. 
Consecutive/JJ IL-1beta-/NN ,/, IL-6-/NN and/CC TNF-alpha-mRNA/NN were/VBD elevated/JJ (/( up/RB to/TO 1.9/CD +/-/CC 0.58-fold/JJ )/) ./. 
Protein/NN tyrosine/NN kinase/NN activity/NN ,/, NF-kappaB/NN activity/NN ,/, and/CC the/DT synthesis/NN of/IN cytokine-specific/JJ mRNA/NN were/VBD inhibited/VBN by/IN antioxidants/NNS ./. 
These/DT data/NNS suggest/VBP a/DT ROI-dependent/JJ NF-kappaB/NN mediated/VBD transcription/NN of/IN inflammatory/JJ cytokines/NNS in/IN bronchial/JJ epithelial/JJ cells/NNS ./. 
UI/LS -/: 96431382/CD 
TI/LS -/: Suppression/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN long/JJ terminal/JJ repeat/NN by/IN CD8+/JJ T/NN cells/NNS is/VBZ dependent/JJ on/IN the/DT NFAT-1/NN element/NN ./. 
AB/LS -/: CD8+/JJ T/NN lymphocytes/NNS of/IN HIV-1/NN infected/JJ individuals/NNS produce/VBP a/DT soluble/JJ factor/NN that/WDT efficiently/RB suppresses/VBZ HIV-1/NN replication/NN at/IN the/DT transcriptional/JJ level/NN ./. 
We/PRP show/VBP here/RB that/IN the/DT response/NN of/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) to/TO mitogenic/JJ or/CC Tat-mediated/JJ activation/NN is/VBZ sensitive/JJ to/TO the/DT suppressive/JJ action/NN of/IN a/DT Herpesvirus/NN saimiri/NN (/( HVS/NN )/) -transformed/JJ CD8+/JJ T/NN cell/NN clone/NN from/IN an/DT HIV-infected/JJ individual/JJ and/CC supernatants/NNS from/IN CD8+/JJ T/NN cells/NNS of/IN HIV-1-infected/JJ asymptomatic/JJ subjects/NNS (/( CD4+/JJ >/JJR 350/microliters/NNS )/) ./. 
Mutagenesis/NN of/IN NF/NN kappa/NN B/NN or/CC Sp-1/NN elements/NNS within/IN the/DT LTR/NN resulted/VBD in/IN no/DT change/NN in/IN the/DT ability/NN of/IN CD8+/JJ T/NN cell/NN supernatants/NNS to/TO inhibit/VB Tat-/NN or/CC mitogen-mediated/JJ LTR/NN transcription/NN ./. 
However/RB ,/, the/DT response/NN to/TO HIV-1/NN Tat/NN by/IN a/DT LTR/NN in/IN which/WDT the/DT interleukin/NN (/( IL/NN )/) -2/CD homology/NN NFAT-1/NN region/NN was/VBD mutated/VBN resulted/VBD in/IN almost/RB complete/JJ elimination/NN of/IN suppression/NN by/IN CD8+/JJ T/NN cells/NNS ./. 
This/DT was/VBD not/RB observed/VBN when/WRB the/DT NFAT-1/NN mutant/JJ LTR/NN was/VBD activated/VBN by/IN mitogen/NN ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN gene/NN expression/NN directed/VBN by/IN the/DT HIV-1/NN NF/NN kappa/NN B/NN elements/NNS is/VBZ inhibited/VBN by/IN CD8+/JJ cell-derived/JJ supernatants/NNS (/( Copeland/NNP et/FW al./FW ,/, AIDS/NNP Res/NNP Hum/NNP Retroviruses/NNP ,/, 1995/CD ;/: 11/CD :/: 1321-1326/CD )/) ./. 
Taken/VBN together/RB ,/, these/DT observations/NNS suggest/VBP that/IN mitogenic/JJ activation/NN ,/, mediated/VBN primarily/RB through/IN the/DT NF/NN kappa/NN B/NN enhancer/NN ,/, is/VBZ susceptible/JJ to/TO CD8-mediated/JJ inhibition/NN ,/, however/RB ,/, inhibition/NN of/IN Tat-mediated/JJ activation/NN may/MD rely/VB upon/IN a/DT different/JJ pathway/NN that/WDT is/VBZ NFAT-1/NN dependent/JJ ./. 
UI/LS -/: 96136291/CD 
TI/LS -/: Inhibition/NN of/IN NF-kappa/NN B/NN activation/NN in/IN human/JJ T-cell/NN lines/NNS by/IN anetholdithiolthione/NN ./. 
AB/LS -/: Nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN is/VBZ a/DT redox/NN sensitive/JJ cytosolic/JJ transcription/NN factor/NN ./. 
Redox/NN regulation/NN of/IN NF-kappa/NN B/NN has/VBZ been/VBN implicated/VBN in/IN the/DT activation/NN of/IN the/DT human/JJ immuno-deficiency/NN virus/NN (/( HIV/NN )/) ./. 
Therefore/RB ,/, inhibition/NN of/IN NF-kappa/NN B/NN activation/NN may/MD be/VB an/DT effective/JJ strategy/NN for/IN acquired/VBN immunodeficiency/NN syndrome/NN therapy/NN ./. 
Anetholdithiolthione/NN (/( ADT/NN ,/, 5-[p-methoxyphenyl]-3H-1,2-dithiol-3-thione/NN )/) is/VBZ an/DT antioxidant/NN which/WDT has/VBZ been/VBN used/VBN to/TO protect/VB against/IN acetaminophen-/NN and/CC CCl4-induced/JJ hepatotoxicity/NN ,/, lipid/NN peroxidation/NN ,/, radiation/NN injury/NN ,/, and/CC also/RB has/VBZ been/VBN used/VBN clinically/RB as/IN an/DT anti-choleretic/JJ agent/NN ./. 
The/DT present/JJ study/NN examined/VBD the/DT effect/NN of/IN ADT/NN pretreatment/NN on/IN NF-kappa/NN B/NN activation/NN in/IN response/NN to/TO a/DT variety/NN of/IN stimuli/NNS such/JJ as/IN H2O2/NN ,/, phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) or/CC tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF/NN alpha/NN )/) ./. 
PMA/NN and/CC TNF/NN alpha/NN induced/JJ activation/NN of/IN (/( NF/NN )/) -kappa/NN B/NN in/IN human/JJ Jurkat/NN T-cells/NNS was/VBD partially/RB inhibited/VBN by/IN ADT/NN (/( 0.1/CD mM/NN )/) pretreatment/NN ./. 
ADT/NN (/( 0.1/CD mM/NN )/) also/RB inhibited/VBD H2O2/NN induced/JJ activation/NN of/IN the/DT transcription/NN factor/NN in/IN the/DT peroxide/NN sensitive/JJ human/JJ Wurzburg/NN T-cells/NNS ./. 
Furthermore/RB ,/, ADT/NN treated/JJ Wurzburg/NN cells/NNS had/VBD significantly/RB higher/JJR glutathione/NN levels/NNS as/IN compared/VBN with/IN untreated/JJ cells/NNS ./. 
H2O2/NN induced/JJ lipid/NN peroxidation/NN in/IN Wurzburg/NN cells/NNS was/VBD remarkably/RB inhibited/VBN by/IN ADT/NN pretreatment/NN ./. 
ADT/NN ,/, a/DT pro-glutathione/NN antioxidant/NN ,/, was/VBD observed/VBN to/TO be/VB capable/JJ of/IN modulating/VBG NF-kappa/NN B/NN activation/NN ./. 
UI/LS -/: 96320762/CD 
TI/LS -/: Involvement/NN of/IN tyrosine/NN phosphorylation/NN in/IN endothelial/JJ adhesion/NN molecule/NN induction/NN ./. 
AB/LS -/: Induction/NN of/IN endothelial/JJ adhesion/NN molecules/NNS by/IN the/DT cytokine/NN tumor/NN necrosis/NN factor-alpha/NN (/( TNF/NN )/) can/MD occur/VB independently/RB of/IN protein/NN kinase/NN C/NN and/CC activation/NN of/IN a/DT protein/NN tyrosine/NN kinase/NN (/( PTK/NN )/) has/VBZ recently/RB been/VBN implicated/VBN in/IN the/DT upregulation/NN of/IN vascular/JJ cell/NN adhesion/NN molecule/NN 1/CD (/( VCAM-1/NN )/) by/IN interleukin-4/NN (/( IL-4/NN )/) on/IN endothelial/JJ cells/NNS ./. 
We/PRP demonstrate/VBP that/IN the/DT PTK/NN inhibitors/NNS herbimycin/NN A/NN or/CC genistein/NN suppress/VBP induction/NN of/IN endothelial/JJ VCAM-1/NN and/CC E-selectin/NN ,/, as/RB well/RB as/IN subsequent/JJ monocytic/JJ cell/NN adhesion/NN to/TO endothelial/JJ cells/NNS stimulated/VBN by/IN TNF/NN ./. 
Inhibition/NN studies/NNS indicate/VBP that/IN specific/JJ tyrosine/NN phosphorylation/NN following/VBG PTK/NN activation/NN is/VBZ involved/VBN in/IN the/DT mobilization/NN of/IN the/DT transcription/NN factor/NN ,/, nuclear/JJ factor/NN kappa/NN B/NN ,/, and/CC VCAM-1/NN mRNA/NN expression/NN ./. 
This/DT may/MD have/VB implications/NNS for/IN pathophysiological/JJ conditions/NNS that/WDT involve/VBP the/DT upregulation/NN of/IN these/DT molecules/NNS (/( e.g./FW inflammation/NN and/CC atherosclerosis/NN )/) ./. 
UI/LS -/: 96099434/CD 
TI/LS -/: Protein/NN kinase/NN C-zeta/NN mediates/VBZ NF-kappa/NN B/NN activation/NN in/IN human/JJ immunodeficiency/NN virus-infected/JJ monocytes/NNS ./. 
AB/LS -/: The/DT molecular/NN mechanisms/NNS regulating/VBG human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) persistence/NN in/IN a/DT major/JJ cell/NN reservoir/NN such/JJ as/IN the/DT macrophage/NN remain/VBP unknown/JJ ./. 
NF-kappa/NN B/NN is/VBZ a/DT transcription/NN factor/NN involved/VBN in/IN the/DT regulation/NN of/IN the/DT HIV/NN long/JJ terminal/JJ repeat/NN and/CC is/VBZ selectively/RB activated/VBN following/VBG HIV/NN infection/NN of/IN human/JJ macrophages/NNS ./. 
Although/IN little/JJ information/NN as/IN to/TO what/WP signal/NN transduction/NN pathways/NNS mediate/VBP NF-kappa/NN B/NN activation/NN in/IN monocytes-macrophages/NNS is/VBZ available/JJ ,/, our/PRP$ previous/JJ work/NN indicated/VBD that/IN classical/JJ protein/NN kinase/NN C/NN (/( PKC/NN )/) isoenzymes/NNS were/VBD not/RB involved/VBN in/IN the/DT HIV-mediated/JJ NF-kappa/NN B/NN activation/NN ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP focused/VBN on/IN atypical/JJ PKC/NN isoenzymes/NNS ./. 
PKC-zeta/NN belongs/VBZ to/TO this/DT family/NN and/CC is/VBZ known/VBN to/TO be/VB an/DT important/JJ step/NN in/IN NF-kappa/NN B/NN activation/NN in/IN other/JJ cell/NN systems/NNS ./. 
Immunoblotting/NN experiments/NNS with/IN U937/NN cells/NNS demonstrate/VBP that/IN PKC-zeta/NN is/VBZ present/JJ in/IN these/DT cells/NNS ,/, and/CC its/PRP$ expression/NN can/MD be/VB downmodulated/VBN by/IN antisense/JJ oligonucleotides/NNS (/( AO/NN )/) ./. 
The/DT HIV-mediated/JJ NF-kappa/NN B/NN activation/NN is/VBZ selectively/RB reduced/VBN by/IN AO/NN to/TO PKC-zeta/NN ./. 
In/IN addition/NN ,/, cotransfection/NN of/IN a/DT negative/JJ dominant/JJ molecule/NN of/IN PKC-zeta/NN (/( PKC-zeta/NN mut/NN )/) with/IN NF-kappa/NN B-dependent/JJ reporter/NN genes/NNS selectively/RB inhibits/VBZ the/DT HIV-/NN but/CC not/RB phorbol/NN myristate/NN acetate-/NN or/CC lipopolysaccharide-mediated/JJ activation/NN of/IN NF-kappa/NN B/NN ./. 
That/IN PKC-zeta/NN is/VBZ specific/JJ in/IN regulating/VBG NF-kappa/NN B/NN is/VBZ concluded/VBN from/IN the/DT inability/NN of/IN PKC-zeta/NN (/( mut/NN )/) to/TO interfere/VB with/IN the/DT basal/JJ or/CC phorbol/NN myristate/NN acetate-inducible/JJ CREB-/NN or/CC AP1-dependent/JJ transcriptional/JJ activity/NN ./. 
Lastly/RB ,/, we/PRP demonstrate/VBP a/DT selective/JJ inhibition/NN of/IN p24/NN production/NN by/IN HIV-infected/JJ human/JJ macrophages/NNS when/WRB treated/VBN with/IN AO/NN to/TO PKC-zeta/NN ./. 
Altogether/RB ,/, these/DT results/NNS suggest/VBP that/IN atypical/JJ PKC/NN isoenzymes/NNS ,/, including/VBG PKC-zeta/NN ,/, participate/VBP in/IN the/DT signal/NN transduction/NN pathways/NNS by/IN which/WDT HIV/NN infection/NN results/VBZ in/IN the/DT activation/NN of/IN NF-kappa/NN B/NN in/IN human/JJ monocytic/JJ cells/NNS and/CC macrophages/NNS ./. 
UI/LS -/: 99412310/CD 
TI/LS -/: Induction/NN of/IN Bcl-x/NN (/( L/NN )/) expression/NN by/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD Tax/NN through/IN NF-kappaB/NN in/IN apoptosis-resistant/JJ T-cell/NN transfectants/NNS with/IN Tax/NN ./. 
AB/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) Tax/NN is/VBZ thought/VBN to/TO play/VB a/DT pivotal/JJ role/NN in/IN immortalization/NN of/IN T/NN cells/NNS ./. 
We/PRP have/VBP recently/RB shown/VBN that/IN the/DT expression/NN of/IN Tax/NN protected/VBD the/DT mouse/NN T-cell/NN line/NN CTLL-2/NN against/IN apoptosis/NN induced/VBN by/IN interleukin-2/NN (/( IL-2/NN )/) deprivation/NN and/CC converted/VBD its/PRP$ growth/NN from/IN being/VBG IL-2/NN dependent/JJ to/TO being/VBG IL-2/NN independent/JJ ./. 
In/IN this/DT study/NN ,/, we/PRP demonstrate/VBP that/IN constitutive/JJ expression/NN of/IN bcl-xl/NN but/CC not/RB bcl-2/NN ,/, bcl-xs/NN ,/, bak/NN ,/, bad/NN ,/, or/CC bax/NN was/VBD associated/VBN with/IN apoptosis/JJ resistance/NN after/IN IL-2/NN deprivation/NN in/IN CTLL-2/NN cells/NNS that/WDT expressed/VBD Tax/NN ./. 
Transient-transfection/JJ assays/NNS showed/VBD that/IN bcl-x/NN promoter/NN was/VBD transactivated/VBN by/IN wild-type/JJ Tax/NN ./. 
Similar/JJ effects/NNS were/VBD observed/VBN in/IN mutant/JJ Tax/NN retaining/VBG transactivating/NN ability/NN through/IN NF-kappaB/NN ./. 
Deletion/NN or/CC substitution/NN of/IN a/DT putative/JJ NF-kappaB/NN binding/NN site/NN identified/VBN in/IN the/DT bcl-x/NN promoter/NN significantly/RB decreased/VBD Tax-induced/JJ transactivation/NN ./. 
This/DT NF-kappaB-like/JJ element/NN was/VBD able/JJ to/TO form/VB a/DT complex/NN with/IN NF-kappaB/NN family/NN proteins/NNS in/FW vitro/FW ./. 
Furthermore/RB ,/, Tax-induced/JJ transactivation/NN of/IN the/DT bcl-x/NN promoter/NN was/VBD also/RB diminished/VBN by/IN the/DT mutant/JJ IkappaBalpha/NN ,/, which/WDT specifically/RB inhibits/VBZ NF-kappaB/NN activity/NN ./. 
Our/PRP$ findings/NNS suggest/VBP that/IN constitutive/JJ expression/NN of/IN Bcl-x/NN (/( L/NN )/) induced/VBN by/IN Tax/NN through/IN the/DT NF-kappaB/NN pathway/NN contributes/VBZ to/TO the/DT inhibition/NN of/IN apoptosis/NN in/IN CTLL-2/NN cells/NNS after/IN IL-2/NN deprivation/NN ./. 
UI/LS -/: 99398660/CD 
TI/LS -/: The/DT beta-globin/NN promoter/NN is/VBZ important/JJ for/IN recruitment/NN of/IN erythroid/JJ Kruppel-like/JJ factor/NN to/TO the/DT locus/NN control/NN region/NN in/IN erythroid/JJ cells/NNS ./. 
AB/LS -/: Erythroid/JJ Kruppel-like/JJ factor/NN (/( EKLF/NN )/) ,/, which/WDT binds/VBZ to/TO the/DT CACCC/NN box/NN in/IN the/DT beta-globin/NN promoter/NN ,/, is/VBZ required/VBN for/IN the/DT expression/NN of/IN the/DT beta-globin/NN gene/NN in/IN adult/JJ erythroid/JJ cells/NNS ./. 
It/PRP was/VBD recently/RB demonstrated/VBN that/IN EKLF/NN is/VBZ also/RB required/VBN for/IN the/DT activity/NN of/IN the/DT beta-globin/NN locus/NN control/NN region/NN (/( LCR/NN )/) 5'HS3/NN ./. 
Some/DT evidence/NN suggests/VBZ that/IN the/DT LCR/NN and/CC the/DT beta-globin/NN promoter/NN interact/NN in/IN adult/JJ erythroid/JJ cells/NNS ,/, and/CC the/DT network/NN of/IN protein-protein/JJ interactions/NNS that/WDT exists/VBZ between/IN these/DT two/CD elements/NNS may/MD regulate/VB how/WRB EKLF/NN is/VBZ recruited/VBN to/TO the/DT LCR/NN ./. 
In/IN this/DT report/NN ,/, we/PRP use/VBP the/DT PIN*POINT/JJ|NN assay/NN to/TO study/VB the/DT role/NN of/IN the/DT promoter/NN on/IN the/DT recruitment/NN of/IN EKLF/NN to/TO 5'HS2/NN and/CC 5'HS3/NN of/IN the/DT LCR/NN ./. 
We/PRP find/VBP that/IN recruitment/NN of/IN EKLF/NN to/TO 5'HS2/NN requires/VBZ the/DT TATA/NN box/NN ,/, but/CC recruitment/NN to/TO 5'HS3/NN depends/VBZ on/IN the/DT CACCC/NN and/CC TATA/NN boxes/NNS of/IN the/DT beta-globin/NN promoter/NN ./. 
Furthermore/RB ,/, recruitment/NN of/IN EKLF/NN to/TO 5'HS3/NN only/RB occurred/VBD in/IN beta-globin-expressing/JJ murine/JJ erythroid/JJ leukemia/NN cells/NNS ,/, whereas/IN recruitment/NN of/IN EKLF/NN to/TO 5'HS2/NN occurred/VBD in/IN both/CC gamma-globin-expressing/JJ K562/NN cells/NNS and/CC murine/JJ erythroid/JJ leukemia/NN cells/NNS ./. 
Unlike/IN EKLF/NN ,/, Sp1/NN ,/, which/WDT also/RB binds/VBZ to/TO CACCC/NN boxes/NNS ,/, is/VBZ not/RB recruited/VBN to/TO 5'HS3/NN ./. 
We/PRP have/VBP also/RB examined/VBN how/WRB one/CD 5'HS/NN affects/VBZ the/DT recruitment/NN of/IN EKLF/NN to/TO another/DT 5'HS/NN ./. 
We/PRP have/VBP found/VBN that/IN the/DT recruitment/NN of/IN EKLF/NN to/TO 5'HS3/NN depends/VBZ on/IN the/DT presence/NN of/IN 5'HS2/NN in/IN cis/NN ,/, but/CC the/DT recruitment/NN to/TO 5'HS2/NN does/VBZ not/RB depend/VB on/IN 5'HS3/NN ./. 
Based/VBN on/IN these/DT results/NNS ,/, we/PRP present/VBP a/DT model/NN that/WDT illustrates/VBZ how/WRB EKLF/NN may/MD be/VB recruited/VBN to/TO the/DT beta-globin/NN locus/NN ./. 
UI/LS -/: 99380273/CD 
TI/LS -/: Estrogen/NN decreases/VBZ TNF/NN gene/NN expression/NN by/IN blocking/VBG JNK/NN activity/NN and/CC the/DT resulting/VBG production/NN of/IN c-Jun/NN and/CC JunD/NN ./. 
AB/LS -/: Central/JJ to/TO the/DT bone-sparing/JJ effect/NN of/IN estrogen/NN (/( E/NN (/( 2/CD )/) )/) is/VBZ its/PRP$ ability/NN to/TO block/VB the/DT monocytic/JJ production/NN of/IN the/DT osteoclastogenic/JJ cytokine/NN TNF-alpha/NN (/( TNF/NN )/) ./. 
However/RB ,/, the/DT mechanism/NN by/IN which/WDT E/NN (/( 2/CD )/) downregulates/VBZ TNF/NN production/NN is/VBZ presently/RB unknown/JJ ./. 
Transient/JJ transfection/NN studies/NNS in/IN HeLa/NN cells/NNS ,/, an/DT E/NN (/( 2/CD )/) receptor-negative/JJ line/NN ,/, suggest/VBP that/IN E/NN (/( 2/CD )/) inhibits/VBZ TNF/NN gene/NN expression/NN through/IN an/DT effect/NN mediated/VBN by/IN estrogen/NN receptor/NN beta/NN (/( ERbeta/NN )/) ./. 
We/PRP also/RB report/VBP that/IN in/IN RAW/NN 264.7/CD cells/NNS ,/, an/DT E/NN (/( 2/CD )/) receptor-positive/JJ murine/JJ monocytic/JJ line/NN ,/, E/NN (/( 2/CD )/) downregulates/VBZ cytokine-induced/JJ TNF/NN gene/NN expression/NN by/IN decreasing/VBG the/DT activity/NN of/IN the/DT Jun/NN NH(2)-terminal/JJ kinase/NN (/( JNK/NN )/) ./. 
The/DT resulting/VBG diminished/VBN phosphorylation/NN of/IN c-Jun/NN and/CC JunD/NN at/IN their/PRP$ NH(2)-termini/NNS decreases/VBZ the/DT ability/NN of/IN these/DT nuclear/JJ proteins/NNS to/TO autostimulate/VB the/DT expression/NN of/IN the/DT c-Jun/NN and/CC JunD/NN genes/NNS ,/, thus/RB leading/VBG to/TO lower/JJR production/NN of/IN c-Jun/NN and/CC JunD/NN ./. 
The/DT consequent/JJ decrease/NN in/IN the/DT nuclear/JJ levels/NNS of/IN c-Jun/NN and/CC JunD/NN leads/VBZ to/TO diminished/VBN binding/NN of/IN c-Jun/c-Fos/NN and/CC JunD/c-Fos/NN heterodimers/NNS to/TO the/DT AP-1/NN consensus/NN sequence/NN in/IN the/DT TNF/NN promoter/NN and/CC ,/, thus/RB ,/, to/TO decreased/VBN transactivation/NN of/IN the/DT TNF/NN gene/NN ./. 
UI/LS -/: 99369970/CD 
TI/LS -/: Cutting/JJ edge/NN :/: TCR/NN stimulation/NN by/IN antibody/NN and/CC bacterial/JJ superantigen/NN induces/VBZ Stat3/NN activation/NN in/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: Recent/JJ data/NNS show/VBP that/IN TCR/CD3/JJ stimulation/NN induces/VBZ activation/NN of/IN Stat5/NN in/IN murine/JJ T/NN cells/NNS ./. 
Here/RB ,/, we/PRP show/VBP that/IN CD3/NN ligation/NN by/IN mAb/NN and/CC Staphylococcal/JJ enterotoxin/NN (/( SE/NN )/) induce/VBP a/DT rapid/JJ ,/, gradually/RB accumulating/VBG ,/, long-lasting/JJ tyrosine/NN ,/, and/CC serine/NN phosphorylation/NN of/IN Stat3/NN (/( but/CC not/RB Stat5/NN )/) in/IN allogen-specific/JJ human/JJ CD4+/JJ T/NN cell/NN lines/NNS ./. 
In/IN contrast/NN ,/, IL-2/NN induces/VBZ a/DT rapid/JJ and/CC transient/JJ tyrosine/NN and/CC serine/NN phosphorylation/NN of/IN Stat3/NN ./. 
Compared/VBN with/IN IL-2/NN ,/, CD3/NN ligation/NN induces/VBZ a/DT delayed/VBN Stat3/NN binding/VBG to/TO oligonucleotide/NN probes/NNS from/IN the/DT ICAM-1/NN and/CC IL-2R/NN alpha/NN promoter/NN ./. 
CD3-mediated/JJ activation/NN of/IN Stat3/NN is/VBZ almost/RB completely/RB inhibited/VBN by/IN a/DT Src/NN kinase/NN inhibitor/NN (/( PP1/NN )/) ,/, whereas/IN IL-2-induced/JJ Stat3/NN activation/NN is/VBZ unaffected/JJ ./. 
In/IN conclusion/NN ,/, we/PRP show/VBP that/IN CD3/NN ligation/NN by/IN mAb/NN and/CC SE/NN triggers/VBZ a/DT rapid/JJ ,/, PP1-sensitive/JJ tyrosine/NN and/CC serine/NN phosphorylation/NN of/IN Stat3/NN in/IN human/JJ CD4+/JJ T/NN cells/NNS ./. 
Moreover/RB ,/, we/PRP provide/VBP evidence/NN that/IN TCR/CD3/JJ and/CC IL-2/NN induce/VBP Stat3/NN activation/NN via/IN distinct/JJ signaling/NN pathways/NNS ./. 
UI/LS -/: 99362737/CD 
TI/LS -/: Distinctive/JJ gene/NN expression/NN patterns/NNS in/IN human/JJ mammary/JJ epithelial/JJ cells/NNS and/CC breast/NN cancers/NNS ./. 
AB/LS -/: cDNA/NN microarrays/NNS and/CC a/DT clustering/NN algorithm/NN were/VBD used/VBN to/TO identify/VB patterns/NNS of/IN gene/NN expression/NN in/IN human/JJ mammary/JJ epithelial/JJ cells/NNS growing/VBG in/IN culture/NN and/CC in/IN primary/JJ human/JJ breast/NN tumors/NNS ./. 
Clusters/NNS of/IN coexpressed/VBN genes/NNS identified/VBN through/IN manipulations/NNS of/IN mammary/JJ epithelial/JJ cells/NNS in/FW vitro/FW also/RB showed/VBD consistent/JJ patterns/NNS of/IN variation/NN in/IN expression/NN among/IN breast/NN tumor/NN samples/NNS ./. 
By/IN using/VBG immunohistochemistry/NN with/IN antibodies/NNS against/IN proteins/NNS encoded/VBN by/IN a/DT particular/JJ gene/NN in/IN a/DT cluster/NN ,/, the/DT identity/NN of/IN the/DT cell/NN type/NN within/IN the/DT tumor/NN specimen/NN that/WDT contributed/VBD the/DT observed/VBN gene/NN expression/NN pattern/NN could/MD be/VB determined/VBN ./. 
Clusters/NNS of/IN genes/NNS with/IN coherent/JJ expression/NN patterns/NNS in/IN cultured/VBN cells/NNS and/CC in/IN the/DT breast/NN tumors/NNS samples/NNS could/MD be/VB related/JJ to/TO specific/JJ features/NNS of/IN biological/JJ variation/NN among/IN the/DT samples/NNS ./. 
Two/CD such/JJ clusters/NNS were/VBD found/VBN to/TO have/VB patterns/NNS that/WDT correlated/VBD with/IN variation/NN in/IN cell/NN proliferation/NN rates/NNS and/CC with/IN activation/NN of/IN the/DT IFN-regulated/JJ signal/NN transduction/NN pathway/NN ,/, respectively/RB ./. 
Clusters/NNS of/IN genes/NNS expressed/VBN by/IN stromal/JJ cells/NNS and/CC lymphocytes/NNS in/IN the/DT breast/NN tumors/NNS also/RB were/VBD identified/VBN in/IN this/DT analysis/NN ./. 
These/DT results/NNS support/VBP the/DT feasibility/NN and/CC usefulness/NN of/IN this/DT systematic/JJ approach/NN to/TO studying/VBG variation/NN in/IN gene/NN expression/NN patterns/NNS in/IN human/JJ cancers/NNS as/IN a/DT means/NN to/TO dissect/VB and/CC classify/VB solid/JJ tumors/NNS ./. 
UI/LS -/: 99355592/CD 
TI/LS -/: PPARgamma/NN activation/NN induces/VBZ the/DT expression/NN of/IN the/DT adipocyte/NN fatty/JJ acid/NN binding/NN protein/NN gene/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: The/DT peroxisome-proliferator/NN activated/JJ receptor/NN gamma/NN (/( PPARgamma/NN )/) ,/, a/DT member/NN of/IN the/DT nuclear/JJ receptor/NN superfamily/NN of/IN ligand/NN activated/JJ transcription/NN factors/NNS ,/, plays/VBZ a/DT key/JJ role/NN in/IN the/DT anti-diabetic/JJ actions/NNS of/IN the/DT thiazolidinediones/NNS (/( TZDs/NNS )/) ./. 
PPARgamma/NN induces/VBZ the/DT expression/NN of/IN many/JJ genes/NNS involved/VBN in/IN lipid/NN anabolism/NN ,/, including/VBG the/DT adipocyte/NN fatty/JJ acid/NN binding/NN protein/NN (/( aP2/NN )/) ,/, and/CC is/VBZ a/DT key/JJ regulator/NN of/IN adipocyte/JJ differentiation/NN ./. 
PPARgamma/NN is/VBZ also/RB expressed/VBN in/IN hematopoietic/JJ cells/NNS and/CC is/VBZ up-regulated/VBN in/IN activated/VBN monocytes/macrophages/NNS ./. 
Activation/NN of/IN PPARgamma/NN may/MD play/VB a/DT role/NN in/IN the/DT induction/NN of/IN differentiation/NN of/IN macrophages/NNS to/TO foam/NN cells/NNS that/WDT are/VBP associated/VBN with/IN atherosclerotic/JJ lesions/NNS ./. 
We/PRP report/VBP that/IN both/CC natural/JJ and/CC synthetic/JJ PPARgamma/NN agonists/NNS induce/VBP time-/NN and/CC dose-dependent/JJ increases/NNS in/IN aP2/NN mRNA/NN in/IN both/CC primary/JJ human/JJ monocytes/NNS and/CC the/DT monocytic/JJ cell/NN line/NN ,/, THP-1/NN ./. 
These/DT data/NNS suggest/VBP that/IN PPARgamma/NN activation/NN may/MD play/VB a/DT role/NN in/IN monocyte/NN differentiation/NN and/CC function/VB analogous/JJ to/TO its/PRP$ well-characterized/JJ role/NN in/IN adipocytes/NNS ./. 
UI/LS -/: 96139448/CD 
TI/LS -/: Identification/NN of/IN a/DT physical/JJ interaction/NN between/IN calcineurin/NN and/CC nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFATp/NN )/) ./. 
AB/LS -/: In/IN T/NN lymphocytes/NNS ,/, the/DT calcium/calmodulin-dependent/JJ serine/threonine/JJ|NN phosphatase/NN ,/, calcineurin/NN ,/, plays/VBZ a/DT pivotal/JJ role/NN in/IN transducing/VBG membrane-associated/JJ signals/NNS to/TO the/DT nucleus/NN ./. 
One/CD of/IN the/DT putative/JJ targets/NNS of/IN calcineurin/NN is/VBZ the/DT pre-existing/JJ ,/, cytosolic/JJ component/NN of/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFATp/NN ;/: also/RB referred/VBN to/TO as/IN NFAT1/NN )/) ,/, which/WDT is/VBZ one/CD of/IN several/JJ transcription/NN factors/NNS required/VBN for/IN the/DT expression/NN of/IN interleukin/NN 2/CD ./. 
Inhibition/NN of/IN calcineurin/NN by/IN the/DT immunosuppressive/JJ drugs/NNS cyclosporin/NN A/NN and/CC FK506/NN prevents/VBZ dephosphorylation/NN of/IN NFATp/NN and/CC its/PRP$ translocation/NN to/TO the/DT nucleus/NN ./. 
However/RB ,/, a/DT physical/JJ interaction/NN between/IN calcineurin/NN and/CC NFATp/NN has/VBZ not/RB been/VBN demonstrated/VBN ./. 
Here/RB we/PRP demonstrate/VBP the/DT binding/NN of/IN NFATp/NN from/IN lysates/NNS of/IN T/NN cells/NNS to/TO immobilized/VBN calcineurin/NN ./. 
Stimulation/NN of/IN T/NN cells/NNS with/IN calcium/NN ionophore/NN induced/VBD a/DT shift/NN in/IN the/DT molecular/JJ weight/NN of/IN NFATp/NN that/WDT is/VBZ due/JJ to/TO its/PRP$ dephosphorylation/NN ./. 
This/DT dephosphorylation/NN was/VBD inhibited/VBN by/IN treatment/NN of/IN T/NN cells/NNS with/IN cyclosporin/NN A/NN or/CC FK506/NN prior/JJ to/TO stimulation/NN ./. 
Of/IN note/NN ,/, both/CC the/DT phosphorylated/JJ and/CC the/DT dephosphorylated/JJ form/NN of/IN NFATp/NN bound/VBD to/TO calcineurin/NN ./. 
Furthermore/RB ,/, the/DT binding/NN of/IN both/DT forms/NNS of/IN NFATp/NN to/TO calcineurin/NN was/VBD inhibited/VBN by/IN pretreatment/NN of/IN calcineurin/NN with/IN a/DT complex/NN of/IN FK506/NN and/CC its/PRP$ ligand/NN FKBP12/NN ./. 
Taken/VBN together/RB these/DT data/NNS strongly/RB suggest/VBP a/DT direct/JJ interaction/NN of/IN calcineurin/NN with/IN NFATp/NN and/CC that/IN this/DT interaction/NN does/VBZ not/RB depend/VB upon/IN the/DT phosphorylation/NN sites/NNS of/IN NFATp/NN affected/VBN by/IN activation/NN ./. 
UI/LS -/: 96176764/CD 
TI/LS -/: Cross-linking/JJ CD40/NN on/IN B/NN cells/NNS preferentially/RB induces/VBZ stress-activated/JJ protein/NN kinases/NNS rather/RB than/IN mitogen-activated/JJ protein/NN kinases/NNS ./. 
AB/LS -/: The/DT B/NN cell-associated/VBD surface/NN molecule/NN CD40/NN plays/VBZ a/DT key/JJ role/NN in/IN T/NN cell-dependent/JJ B/NN cell/NN maturation/NN ,/, as/IN individuals/NNS with/IN defects/NNS in/IN either/CC CD40/NN or/CC its/PRP$ ligand/NN are/VBP impaired/JJ in/IN immunoglobulin/NN isotype/NN class/NN switching/NN and/CC germinal/JJ center/NN formation/NN ./. 
CD40/NN signaling/NN activates/VBZ downstream/JJ effectors/NNS ,/, including/VBG the/DT tyrosine/NN protein/NN kinase/NN ,/, Lyn/NN ,/, the/DT phosphatidylinositol-3-kinase/NN (/( PI-3/NN kinase/NN )/) ,/, and/CC the/DT transcription/NN factor/NN ,/, NF-kappa/NN B/NN ./. 
In/IN this/DT study/NN ,/, we/PRP demonstrate/VBP that/IN stress-activated/JJ protein/NN kinases/NNS (/( SAPK/NN )/) are/VBP activated/VBN after/IN CD40/NN cross-linking/NN on/IN various/JJ B/NN cell/NN lines/NNS or/CC human/JJ tonsillar/JJ|NN B/NN cells/NNS ./. 
The/DT activation/NN is/VBZ rapid/JJ and/CC transient/JJ and/CC is/VBZ mediated/VBN through/IN a/DT cyclosporin/NN A-insensitive/JJ pathway/NN ./. 
Furthermore/RB ,/, this/DT signaling/NN pathway/NN appears/VBZ not/RB to/TO rely/VB on/IN protein/NN kinase/NN C/NN ./. 
While/IN CD40/NN ligation/NN strongly/RB activates/VBZ the/DT SAPKs/NNS (/( up/RB to/TO 25-fold/JJ )/) ,/, it/PRP does/VBZ not/RB affect/VB members/NNS of/IN the/DT mitogen-activated/JJ protein/NN kinase/NN family/NN (/( MAPK/NN ;/: ERK1/NN and/CC ERK2/NN )/) ./. 
Consistent/JJ with/IN these/DT data/NNS ,/, CD40/NN signals/NNS up-regulate/VBP c-jun/NN but/CC not/RB c-fos/NN mRNA/NN and/CC alter/VBP the/DT transcription/NN factor/NN ATF2/NN but/CC not/RB the/DT Raf-1/NN protein/NN ./. 
In/IN summary/NN ,/, CD40/NN signaling/NN preferentially/RB induces/VBZ SAPK/NN but/CC not/RB MAPK/NN ./. 
UI/LS -/: 96317173/CD 
TI/LS -/: Stimulation/NN of/IN the/DT T-cell/NN antigen/NN receptor-CD3/JJ|NN complex/NN signaling/NN pathway/NN by/IN the/DT tyrosine/NN phosphatase/NN inhibitor/NN pervanadate/NN is/VBZ mediated/VBN by/IN inhibition/NN of/IN CD45/NN :/: evidence/NN for/IN two/CD interconnected/JJ Lck/Fyn-/NN or/CC zap-70-dependent/JJ signaling/NN pathways/NNS ./. 
AB/LS -/: The/DT tyrosine/NN phosphatase/NN specific/JJ inhibitor/NN pervanadate/NN is/VBZ a/DT potent/JJ activator/NN of/IN T/NN lymphocytes/NNS through/IN induction/NN of/IN tyrosine/NN phosphorylation/NN and/CC downstream/JJ events/NNS of/IN the/DT activation/NN cascade/NN ./. 
Using/VBG CD45-/NN or/CC CD3-negative/JJ variants/NNS of/IN the/DT Jurkat/NN leukemic/JJ T-cell/NN line/NN we/PRP show/VBP that/IN the/DT different/JJ biochemical/JJ events/NNS induced/VBN by/IN pervanadate/NN appeared/VBD to/TO be/VB dependent/JJ on/IN the/DT presence/NN at/IN the/DT cell/NN surface/NN of/IN either/CC CD45/NN or/CC CD3/NN ./. 
CD45-dependent/JJ events/NNS such/JJ as/IN tyrosine/NN phosphorylation/NN of/IN Shc/NN ,/, activation/NN of/IN nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ,/, activator/NN protein-1/NN (/( AP-1/NN )/) ,/, transcription/NN factors/NNS ,/, and/CC stimulation/NN of/IN interleukin-2/NN (/( IL-2/NN )/) promoter/NN and/CC of/IN CD69/NN and/CC CD25/NN surface/NN expression/NN paralleled/VBD activation/NN of/IN the/DT tyrosine/NN kinases/NNS lck/NN and/CC fyn/NN ./. 
By/IN contrast/NN ,/, stimulation/NN of/IN calcium/NN influx/NN ,/, a/DT CD3-dependent/JJ event/NN ,/, paralleled/VBD zap-70/NN activation/NN ./. 
The/DT data/NNS demonstrate/VBP that/IN the/DT T-cell/NN antigen/NN receptor-CD3/JJ|NN (/( TcR-CD3/JJ|NN )/) complex/NN is/VBZ functionally/RB linked/VBN to/TO two/CD different/JJ protein/NN tyrosine/NN kinase/NN (/( PTK/NN )/) modules/NNS with/IN separate/JJ specific/JJ functions/NNS and/CC that/IN CD45/NN may/MD be/VB an/DT important/JJ regulator/NN of/IN this/DT coupling/NN ./. 
UI/LS -/: 99427884/CD 
TI/LS -/: Vitamin/NN D/NN analogs/NNS ,/, 20-Epi-22-oxa-24a,26a,27a,-trihomo-1alpha,25(OH)2-/NN vitamin/NN D3/NN ,/, 1,24(OH)2-22-ene-24-cyclopropyl-vitamin/NN D3/NN and/CC 1alpha,25(OH)2-lumisterol3/NN prime/JJ NB4/NN leukemia/NN cells/NNS for/IN monocytic/JJ differentiation/NN via/IN nongenomic/JJ signaling/NN pathways/NNS ,/, involving/VBG calcium/NN and/CC calpain/NN ./. 
AB/LS -/: Side-chain/NN modified/JJ vitamin/NN D/NN analogs/NNS including/VBG 20-Epi-22-oxa-24a,26a,27a-trihomo-1alpha,2/NN 5-dihydroxyvitamin/NN D3/NN (/( KH1060/NN )/) ,/, and/CC 1,24-dihydroxy-22-ene-24-cyclopropyl-vitamin/NN D3/NN (/( MC903/NN )/) were/VBD originally/RB designed/VBN to/TO aid/VB in/IN the/DT treatment/NN of/IN hyperproliferative/JJ disorders/NNS including/VBG psoriasis/NN and/CC cancer/NN ./. 
Here/RB we/PRP demonstrate/VBP that/IN these/DT analogs/NNS ,/, as/RB well/RB as/IN the/DT 6-cis-locked/JJ conformer/NN ,/, 1alpha,25-dihydroxy-lumisterol3/NN (/( JN/NN )/) prime/JJ NB4/NN cells/NNS for/IN monocytic/JJ differentiation/NN ./. 
Previously/RB ,/, the/DT action/NN of/IN MC903/NN and/CC KH1060/NN was/VBD presumed/VBN to/TO be/VB mediated/VBN by/IN the/DT nuclear/JJ vitamin/NN D/NN receptor/NN (/( VDRnuc/NN )/) ./. 
Differentiation/NN in/IN response/NN to/TO all/DT analogs/NNS was/VBD shown/VBN to/TO be/VB inhibited/VBN by/IN 1beta,25-dihydroxyvitamin/NN D3/NN (/( HL/NN )/) ,/, the/DT antagonist/NN to/TO the/DT nongenomic/JJ activities/NNS of/IN 1,25D3/NN ./. 
These/DT data/NNS suggest/VBP that/IN although/IN MC903/NN and/CC KH1060/NN may/MD bind/VB the/DT VDRnuc/NN ,/, that/IN the/DT differentiative/JJ activities/NNS of/IN these/DT agents/NNS requires/VBZ nongenomic/JJ signaling/NN pathways/NNS ./. 
Here/RB we/PRP show/VBP that/IN 1alpha,25(OH)2-d5-previtamin/NN D3/NN (/( HF/NN )/) ,/, JN/NN ,/, KH1060/NN ,/, and/CC MC903/NN induce/VBP expression/NN of/IN PKC/NN alpha/NN and/CC PKC/NN delta/NN and/CC translocation/NN of/IN both/DT isoforms/NNS to/TO the/DT particulate/JJ fraction/NN ,/, and/CC PKC/NN alpha/NN to/TO the/DT nuclear/JJ fraction/NN ./. 
The/DT full/JJ differentiation/NN response/NN with/IN combinations/NNS of/IN analogs/NNS and/CC TPA/NN was/VBD inhibited/VBN 50/CD %/NN by/IN the/DT membrane/NN permeable/JJ Ca2+/NN chelator/NN ,/, 1,2-bis(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic/JJ acid/NN (/( BAPTA-AM/NN )/) or/CC calpain/JJ inhibitor/NN I/NN ./. 
These/DT data/NNS demonstrate/VBP that/IN intracellular/JJ free/JJ calcium/NN and/CC the/DT calcium-dependent/JJ protease/NN ,/, calpain/NN play/VBP critical/JJ roles/NNS in/IN monocytic/JJ differentiation/NN ./. 
Intracellular/JJ calcium/NN appears/VBZ to/TO be/VB most/RBS critical/JJ in/IN the/DT 1,25D3-priming/JJ stage/NN of/IN differentiation/NN ,/, while/IN calpain/NN is/VBZ essential/JJ in/IN the/DT TPA/NN maturation/NN response/NN ./. 
UI/LS -/: 99408303/CD 
TI/LS -/: Neutrophil/NN maturation/NN and/CC the/DT role/NN of/IN retinoic/JJ acid/NN ./. 
AB/LS -/: Neutrophil/NN maturation/NN occurs/VBZ in/IN well/RB defined/VBN morphological/JJ stages/NNS that/WDT correlate/VBP with/IN the/DT acquisition/NN of/IN molecular/JJ markers/NNS associated/VBN with/IN neutrophil/NN function/NN ./. 
A/DT variety/NN of/IN factors/NNS are/VBP known/VBN to/TO play/VB a/DT role/NN in/IN terminal/JJ neutrophil/NN maturation/NN ,/, including/VBG the/DT vitamin/NN A/NN derivative/NN ,/, retinoic/JJ acid/NN ./. 
Retinoic/JJ acid/NN can/MD directly/RB modulate/VB gene/NN expression/NN via/IN binding/VBG to/TO its/PRP$ nuclear/JJ receptors/NNS ,/, which/WDT can/MD ,/, in/IN turn/NN ,/, activate/VBP transcription/NN of/IN target/NN genes/NNS ./. 
A/DT role/NN for/IN retinoic/JJ acid/NN during/IN neutrophil/NN maturation/NN has/VBZ been/VBN suggested/VBN from/IN a/DT variety/NN of/IN sources/NNS ./. Here/RB we/PRP present/VBP a/DT review/NN of/IN the/DT mechanism/NN of/IN retinoic/JJ acid/NN receptor/NN action/NN and/CC the/DT major/JJ evidence/NN showing/VBG that/IN normal/JJ retinoid/NN signaling/NN is/VBZ required/VBN for/IN neutrophil/NN maturation/NN ./. 
UI/LS -/: 99393322/CD 
TI/LS -/: Human/JJ T-cell/NN lymphotrophic/JJ virus/NN type-I/JJ tax/NN gene/NN induces/VBZ secretion/NN of/IN human/JJ macrophage/NN inflammatory/JJ protein-1alpha/NN ./. 
AB/LS -/: Human/JJ T-cell/NN lymphotropic/JJ virus/NN I/NN (/( HTLV-I/NN )/) encodes/VBZ for/IN a/DT 40-kDa/JJ protein/NN ,/, Tax/NN ,/, which/WDT is/VBZ important/JJ for/IN the/DT immortalization/NN of/IN T/NN cells/NNS ./. 
Tax/NN has/VBZ been/VBN shown/VBN to/TO transactivate/VB several/JJ cellular/JJ genes/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP show/VBP that/IN MIP-1alpha/NN is/VBZ selectively/RB expressed/VBN and/CC secreted/VBN in/IN the/DT tax/NN transfected/JJ Jurkat/NN cell/NN line/NN upon/IN mitogen/NN stimulation/NN ./. 
Expression/NN of/IN MIP-1alpha-R/NN mRNA/NN in/IN these/DT cells/NNS suggests/VBZ an/DT autocrine/JJ role/NN for/IN this/DT chemokine/NN in/IN HTLV-I/NN infected/JJ T-cells/NNS ./. 
Induced/VBN MIP-1alpha/NN expression/NN and/CC secretion/NN in/IN PMA/PHA/NN stimulated/JJ tax/NN transfected/JJ cells/NNS correlate/VBP with/IN the/DT noninduction/NN of/IN MNP-1/NN transcription/NN factor/NN ,/, which/WDT is/VBZ intimately/RB involved/VBN in/IN downmodulating/VBG the/DT MIP-1alpha/NN gene/NN ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99376409/CD 
TI/LS -/: Dendritic/JJ cells/NNS and/CC the/DT pathogenesis/NN of/IN rheumatoid/JJ arthritis/NN ./. 
AB/LS -/: Rheumatoid/JJ arthritis/NN (/( RA/NN )/) is/VBZ a/DT chronic/JJ autoimmune/JJ inflammatory/JJ disease/NN in/IN which/WDT unknown/JJ arthrogenic/JJ autoantigen/NN is/VBZ presented/VBN to/TO CD4+/JJ T/NN cells/NNS ./. 
The/DT strong/JJ association/NN of/IN the/DT disease/NN with/IN an/DT epitope/NN within/IN the/DT HLA-DR/NN chain/NN shared/VBN between/IN various/JJ alleles/NNS of/IN HLA-DR4/NN and/CC DR1/NN emphasizes/VBZ the/DT importance/NN of/IN antigen/JJ presentation/NN ./. 
This/DT immune/JJ response/NN predominantly/RB occurs/VBZ in/IN the/DT synovial/NN tissue/NN and/CC fluid/NN of/IN the/DT joints/NNS and/CC autoreactive/JJ T/NN cells/NNS are/VBP readily/RB demonstrable/JJ in/IN both/CC the/DT synovial/JJ compartment/NN and/CC blood/NN ./. 
Circulating/VBG dendritic/JJ cells/NNS (/( DC/NN )/) are/VBP phenotypically/RB and/CC functionally/RB identical/JJ with/IN normal/JJ peripheral/JJ blood/NN (/( PB/NN )/) DC/NN ./. 
In/IN the/DT synovial/JJ tissue/NN ,/, fully/RB differentiated/VBN perivascular/JJ DC/NN are/VBP found/VBN in/IN close/JJ association/NN with/IN T/NN cells/NNS and/CC with/IN B/NN cell/NN follicles/NNS ,/, sometimes/RB containing/VBG follicular/JJ DC/NN ./. 
These/DT perivascular/JJ DC/NN migrate/VBP across/IN the/DT activated/VBN endothelium/NN from/IN blood/NN and/CC receive/VBP differentiative/JJ signals/NNS within/IN the/DT joint/NN from/IN monocyte-derived/JJ cytokines/NNS and/CC CD40-ligand+/JJ T/NN cells/NNS ./. 
In/IN the/DT SF/NN ,/, DC/NN manifest/VBP an/DT intermediate/JJ phenotype/NN ,/, similar/JJ to/TO that/DT of/IN monocyte-derived/JJ DC/NN in/FW vitro/FW ./. 
Like/IN a/DT delayed-type/JJ hypersensitivity/NN response/NN ,/, the/DT rheumatoid/JJ synovium/NN represents/VBZ an/DT effector/NN site/NN ./. 
DC/NN at/IN many/JJ effector/NN sites/NNS have/VBP a/DT characteristic/JJ pattern/NN of/IN infiltration/NN and/CC differentiation/NN ./. 
It/PRP is/VBZ important/JJ to/TO note/VB that/IN the/DT effector/NN response/NN is/VBZ not/RB self-limiting/JJ in/IN RA/NN autoimmune/JJ inflammation/NN ./. 
In/IN this/DT article/NN ,/, we/PRP argue/VBP that/IN the/DT presentation/NN of/IN self-antigen/NN by/IN DC/NN and/CC by/IN autoantibody-producing/JJ B/NN cells/NNS is/VBZ critical/JJ for/IN the/DT perpetuation/NN of/IN the/DT autoimmune/JJ response/NN ./. 
Permanently/RB arresting/VBG this/DT ongoing/JJ immune/JJ response/NN with/IN either/CC pharmaceutical/JJ agents/NNS or/CC immunotherapy/NN is/VBZ a/DT major/JJ challenge/NN for/IN immunology/NN ./. 
UI/LS -/: 99370197/CD 
TI/LS -/: Thymocyte-thymic/JJ epithelial/NN cell/NN interaction/NN leads/VBZ to/TO high-level/JJ replication/NN of/IN human/JJ immunodeficiency/NN virus/NN exclusively/RB in/IN mature/JJ CD4(+)/JJ CD8(-)/JJ CD3(+)/JJ thymocytes/NNS :/: a/DT critical/JJ role/NN for/IN tumor/NN necrosis/NN factor/NN and/CC interleukin-7/NN ./. 
AB/LS -/: This/DT work/NN aims/VBZ at/IN identifying/VBG the/DT thymocyte/NN subpopulation/NN able/JJ to/TO support/VB human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) replication/NN under/IN the/DT biological/JJ stimuli/NNS of/IN the/DT thymic/JJ microenvironment/NN ./. 
In/IN this/DT report/NN we/PRP demonstrate/VBP that/IN interaction/NN with/IN thymic/JJ epithelial/JJ cells/NNS (/( TEC/NN )/) induces/VBZ a/DT high-level/JJ replication/NN of/IN the/DT T-tropic/JJ primary/JJ isolate/JJ HIV-1/NN (/( B-LAIp/NN )/) exclusively/RB in/IN the/DT mature/JJ CD4(+)/JJ CD8(-)/JJ CD3(+)/JJ thymocytes/NNS ./. 
Tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) and/CC interleukin-7/NN (/( IL-7/NN )/) ,/, secreted/VBN during/IN this/DT interaction/NN ,/, are/VBP critical/JJ cytokines/NNS for/IN HIV/NN long/JJ terminal/JJ repeat/NN transactivation/NN through/IN NF-kappaB-dependent/JJ activation/NN ./. 
TNF/NN is/VBZ the/DT major/JJ inducer/NN of/IN NF-kappaB/NN and/CC particularly/RB of/IN the/DT p50-p65/JJ|NN complex/NN ,/, whereas/IN IL-7/NN acts/VBZ as/IN a/DT cofactor/NN by/IN sustaining/VBG the/DT expression/NN of/IN the/DT p75/NN TNF/NN receptor/NN ./. 
The/DT requirement/NN for/IN TNF/NN is/VBZ further/RBR confirmed/VBN by/IN the/DT observation/NN that/IN the/DT inability/NN of/IN the/DT intermediate/JJ CD4(+)/JJ CD8(-)/JJ CD3(-)/JJ thymocytes/NNS to/TO replicate/VB the/DT virus/NN is/VBZ associated/VBN with/IN a/DT defect/NN in/IN TNF/NN production/NN during/IN their/PRP$ interaction/NN with/IN TEC/NN and/CC correlates/VBZ with/IN the/DT absence/NN of/IN nuclear/JJ NF-kappaB/NN activity/NN in/IN these/DT freshly/RB isolated/VBN thymocytes/NNS ./. 
Addition/NN of/IN exogenous/JJ TNF/NN to/TO the/DT intermediate/JJ thymocyte/NN cultures/NNS induces/VBZ NF-kappaB/NN activity/NN and/CC is/VBZ sufficient/JJ to/TO promote/VB HIV/NN replication/NN in/IN the/DT cocultures/NNS with/IN TEC/NN ./. 
The/DT other/JJ major/JJ subpopulation/NN expressing/VBG the/DT CD4/NN receptor/NN ,/, namely/RB ,/, the/DT double-positive/JJ (/( DP/NN )/) CD4(+)/JJ CD8(+)/JJ CD3(+/-)/JJ thymocytes/NNS ,/, despite/IN the/DT entry/NN of/IN the/DT virus/NN ,/, do/VBP not/RB produce/VB a/DT significant/JJ level/NN of/IN virus/NN ,/, presumably/RB because/IN they/PRP are/VBP unresponsive/JJ to/TO TNF/NN and/CC IL-7/NN ./. 
Together/RB ,/, these/DT data/NNS suggest/VBP that/IN in/FW vivo/FW ,/, despite/IN an/DT efficient/JJ entry/NN of/IN the/DT virus/NN in/IN all/PDT the/DT CD4(+)/JJ subpopulations/NNS ,/, a/DT high/JJ viral/JJ load/NN may/MD be/VB generated/VBN exclusively/RB within/IN the/DT mature/JJ CD4(+)/JJ CD8(-)/JJ CD3(+)/JJ subset/NN of/IN thymocytes/NNS ./. 
However/RB ,/, under/IN conditions/NNS of/IN inflammatory/JJ response/NN after/IN infection/NN ,/, TNF/NN might/MD also/RB be/VB present/JJ in/IN the/DT intermediate/JJ thymocyte/NN compartment/NN ,/, leading/VBG to/TO efficient/JJ HIV/NN replication/NN in/IN these/DT cells/NNS ./. 
UI/LS -/: 99362723/CD 
TI/LS -/: NF-kappaB-mediated/JJ up-regulation/NN of/IN Bcl-x/NN and/CC Bfl-1/A1/NN is/VBZ required/VBN for/IN CD40/NN survival/NN signaling/VBG in/IN B/NN lymphocytes/NNS ./. 
AB/LS -/: Activation/NN of/IN CD40/NN is/VBZ essential/JJ for/IN thymus-dependent/JJ humoral/JJ immune/JJ responses/NNS and/CC rescuing/VBG B/NN cells/NNS from/IN apoptosis/NN ./. 
Many/JJ of/IN the/DT effects/NNS of/IN CD40/NN are/VBP believed/VBN to/TO be/VB achieved/VBN through/IN altered/JJ gene/NN expression/NN ./. 
In/IN addition/NN to/TO Bcl-x/NN ,/, a/DT known/JJ CD40-regulated/JJ antiapoptotic/JJ molecule/NN ,/, we/PRP identified/VBD a/DT related/JJ antiapoptotic/JJ molecule/NN ,/, A1/Bfl-1/NN ,/, as/IN a/DT CD40-inducible/JJ gene/NN ./. 
Inhibition/NN of/IN the/DT NF-kappaB/NN pathway/NN by/IN overexpression/NN of/IN a/DT dominant-active/JJ inhibitor/NN of/IN NF-kappaB/NN abolished/VBD CD40-induced/JJ up-regulation/NN of/IN both/CC the/DT Bfl-1/NN and/CC Bcl-x/NN genes/NNS and/CC also/RB eliminated/VBD the/DT ability/NN of/IN CD40/NN to/TO rescue/VB Fas-induced/JJ cell/NN death/NN ./. 
Within/IN the/DT upstream/JJ promoter/NN region/NN of/IN Bcl-x/NN ,/, a/DT potential/JJ NF-kappaB-binding/JJ sequence/NN was/VBD found/VBN to/TO support/VB NF-kappaB-dependent/JJ transcriptional/JJ activation/NN ./. 
Furthermore/RB ,/, expression/NN of/IN physiological/JJ levels/NNS of/IN Bcl-x/NN protected/VBD B/NN cells/NNS from/IN Fas-mediated/JJ apoptosis/NN in/IN the/DT absence/NN of/IN NF-kappaB/NN signaling/NN ./. 
Thus/RB ,/, our/PRP$ results/NNS suggest/VBP that/IN CD40-mediated/JJ cell/NN survival/NN proceeds/VBZ through/IN NF-kappaB-dependent/JJ up-regulation/NN of/IN Bcl-2/NN family/NN members/NNS ./. 
UI/LS -/: 99353876/CD 
TI/LS -/: Stimulation/NN of/IN neutrophil/NN interleukin-8/NN production/NN by/IN eosinophil/NN granule/NN major/JJ basic/JJ protein/NN ./. 
AB/LS -/: We/PRP evaluated/VBD the/DT ability/NN of/IN eosinophil/NN granule/NN major/JJ basic/JJ protein/NN (/( MBP/NN )/) to/TO stimulate/VB interleukin/NN (/( IL/NN )/) -8/CD production/NN by/IN neutrophils/NNS ./. 
MBP/NN over/IN the/DT concentration/NN range/NN of/IN 0.1/CD to/TO 10/CD microM/NN stimulated/VBD the/DT release/NN of/IN up/RB to/TO approximately/RB 8/CD ng/ml/NN IL-8/NN ./. 
Incubation/NN with/IN 2/CD microM/NN MBP/NN showed/VBD that/IN ,/, after/IN a/DT 1/CD h/NN lag/NN ,/, the/DT level/NN of/IN IL-8/NN release/NN increased/VBD with/IN time/NN for/IN approximately/RB 10/CD h/NN ./. 
At/IN the/DT 2/CD microM/NN concentration/NN ,/, eosinophil/NN cationic/NN protein/NN ,/, eosinophil-derived/JJ neurotoxin/NN ,/, and/CC eosinophil/NN peroxidase/NN did/VBD not/RB stimulate/VB significant/JJ levels/NNS of/IN IL-8/NN production/NN ./. 
MBP/NN stimulated/VBD 2-fold/JJ increases/NNS in/IN IL-8/NN messenger/NN RNA/NN (/( mRNA/NN )/) after/IN 1/CD and/CC 3/CD h/NN of/IN incubation/NN ,/, which/WDT were/VBD blocked/VBN by/IN pretreatment/NN with/IN actinomycin/NN D/NN ./. 
However/RB ,/, stimulation/NN with/IN MBP/NN did/VBD not/RB produce/VB an/DT increase/NN in/IN the/DT binding/NN activity/NN of/IN nuclear/JJ factor/NN (/( NF/NN )/) -kappaB/NN or/CC activator/NN protein-1/NN ./. 
No/DT NF-IL-6/NN binding/NN activity/NN was/VBD detected/VBN in/IN the/DT same/JJ nuclear/JJ extracts/NNS ./. 
In/IN addition/NN ,/, stimulation/NN with/IN MBP/NN prolonged/VBD the/DT stability/NN of/IN IL-8/NN mRNA/NN ./. 
MBP/NN also/RB induced/VBD transient/JJ increases/NNS in/IN mRNA/NN for/IN macrophage/NN inflammatory/JJ protein/NN (/( MIP/NN )/) -1alpha/NN and/CC MIP-1beta/NN ,/, but/CC did/VBD not/RB stimulate/VB the/DT release/NN of/IN either/DT chemokine/NN ./. 
These/DT findings/NNS indicate/VBP that/IN MBP/NN is/VBZ selective/JJ among/IN the/DT eosinophil/NN granule/NN proteins/NNS as/IN a/DT stimulus/NN for/IN neutrophil/NN IL-8/NN release/NN and/CC ,/, further/RB ,/, that/IN stimulation/NN of/IN neutrophil/NN IL-8/NN release/NN by/IN MBP/NN involves/VBZ both/CC transcriptional/JJ and/CC posttranscriptional/JJ regulation/NN ./. 
We/PRP postulate/VBP that/IN MBP-induced/JJ release/NN of/IN IL-8/NN by/IN neutrophils/NNS may/MD contribute/VB to/TO the/DT pathophysiology/NN of/IN acute/JJ asthma/NN and/CC other/JJ inflammatory/JJ lung/NN diseases/NNS ./. 
UI/LS -/: 96152904/CD 
TI/LS -/: Expression/NN of/IN either/CC the/DT TCL1/NN oncogene/NN ,/, or/CC transcripts/NNS from/IN its/PRP$ homologue/NN MTCP1/c6.1B/NN ,/, in/IN leukaemic/JJ and/CC non-leukaemic/JJ T/NN cells/NNS from/IN ataxia/NN telangiectasia/NN patients/NNS ./. 
AB/LS -/: Patients/NNS with/IN the/DT recessively/RB inherited/VBN disorder/NN ataxia/NN telangiectasia/NN (/( A-T/NN )/) have/VBP a/DT high/JJ level/NN of/IN specific/JJ chromosome/NN translocations/NNS which/WDT can/MD be/VB easily/RB observed/VBN in/IN peripheral/JJ T/NN cells/NNS and/CC show/VB a/DT greatly/RB increased/VBN predisposition/NN to/TO leukaemia/lymphoma/NN ,/, mainly/RB of/IN T/NN cell/NN origin/NN ./. 
Some/DT translocation/NN cells/NNS proliferate/VBP into/IN a/DT large/JJ clone/NN and/CC may/MD develop/VB into/IN T/NN cell/NN prolymphocytic/NN leukaemia/NN (/( T-PLL/NN )/) ./. 
By/IN the/DT time/NN of/IN diagnosis/NN of/IN T-PLL/NN ,/, the/DT clone/NN contains/VBZ many/JJ more/JJR genetic/JJ changes/NNS in/IN the/DT form/NN of/IN additional/JJ translocations/NNS ./. 
T-PLL/NN is/VBZ also/RB seen/VBN in/IN non-A-T/JJ individuals/NNS where/WRB expression/NN of/IN either/CC TCL1/NN (/( at/IN 14q32/NN )/) or/CC the/DT c6.1B/MTCP1/NN A1/NN transcript/NN (/( at-Xq28/NN )/) has/VBZ been/VBN demonstrated/VBN in/IN just/RB a/DT few/JJ instances/NNS ./. 
We/PRP show/VBP here/RB ,/, that/IN expression/NN of/IN TCL1/NN occurs/VBZ in/IN leukaemic/JJ T/NN cells/NNS from/IN A-T/NN patients/NNS with/IN chromosome/NN 14/CD rearrangements/NNS ./. 
Expression/NN of/IN TCL1/NN also/RB occurs/VBZ in/IN the/DT preleukaemic/JJ clone/NN cells/NNS of/IN A-T/NN patients/NNS containing/VBG the/DT primary/JJ translocation/NN alone/RB ./. 
Some/DT expression/NN of/IN TCL1/NN could/MD also/RB be/VB detected/VBN in/IN randomly/RB selected/VBN A-T/JJ patients/NNS without/IN large/JJ cytogenetic/JJ clones/NNS and/CC without/IN any/DT evidence/NN of/IN leukaemic/JJ change/NN ./. 
We/PRP also/RB show/VBP that/IN expression/NN of/IN the/DT B1/NN transcript/NN from/IN a/DT second/JJ gene/NN ,/, MTCP1/NN ,/, occurred/VBD at/IN a/DT relatively/RB high/JJ level/NN only/RB in/IN two/CD T-PLL/NN tumours/NNS from/IN A-T/NN patients/NNS with/IN t(X;14)/NN translocations/NNS whereas/IN the/DT MTCP1/A1/NN transcript/NN is/VBZ much/RB more/RBR widely/RB expressed/VBN in/IN both/CC tumour/NN and/CC non/JJ tumour/NN cells/NNS of/IN A-T/NN and/CC non-A-T/JJ individuals/NNS ./. 
UI/LS -/: 97195004/CD 
TI/LS -/: [/( Correlation/NN of/IN lymphocytic/JJ infiltration/NN of/IN tumor/NN tissue/NN with/IN the/DT hormonal/JJ and/CC metabolic/JJ state/NN in/IN patients/NNS with/IN breast/NN cancer/NN ]/) 
AB/LS -/: Lymphocyte/NN infiltration/NN of/IN tumor/NN was/VBD studied/VBN vis-a-vis/FW hormone/NN metabolic/JJ status/NN ,/, tumor/NN tissue/NN hormone/NN sensitivity/NN and/CC tobacco/NN smoking/NN ,/, in/IN 113/CD breast/NN cancer/NN patients/NNS ,/, aged/JJ 25-77/CD ./. 
On/IN the/DT average/NN ,/, no/DT correlation/NN was/VBD established/VBN between/IN degree/NN of/IN lymphocyte/NN infiltration/NN in/IN breast/NN tumor/NN and/CC age/NN and/CC menopause/NN onset/NN ./. 
In/IN smoking/NN menopausal/JJ patients/NNS ,/, lymphocyte/NN infiltration/NN was/VBD found/VBN to/TO be/VB higher/JJR than/IN in/IN non-smokers/NNS (/( p/NN </JJR 0.05/CD )/) ./. 
There/EX was/VBD a/DT direct/JJ correlation/NN between/IN the/DT rate/NN of/IN lymphocyte/NN infiltration/NN and/CC the/DT level/NN of/IN progesterone/NN receptors/NNS in/IN tumor/NN ./. 
Some/DT subgroups/NNS displayed/VBD a/DT direct/JJ correlation/NN between/IN infiltration/NN and/CC sex-binding/JJ globulin/NN ,/, cholesterol/NN ,/, luteinizing/JJ|VBG hormone/NN in/IN blood/NN ,/, and/CC lean/JJ body/NN mass/NN ./. 
It/PRP was/VBD matched/VBN by/IN an/DT inverse/JJ correlation/NN between/IN lymphocyte/NN infiltration/NN and/CC blood-thyroid/JJ hormone/NN concentration/NN ,/, urine/NN catecholamines/NNS and/CC free/JJ cortisol/NN excretion/NN and/CC fat/lean/JJ body/NN mass/NN ratio/NN ./. 
Considering/VBG the/DT abovesaid/VBN as/RB well/RB as/IN the/DT lymphocyte/NN ability/NN to/TO perform/VB the/DT dual/JJ function/NN of/IN immunocytes/NNS and/CC hormonocytes/NNS ,/, it/PRP is/VBZ suggested/VBN that/IN the/DT results/NNS may/MD be/VB used/VBN in/IN both/CC the/DT study/NN of/IN lymphocyte/NN infiltration/NN and/CC research/NN in/IN means/NNS of/IN its/PRP$ control/NN ./. 
UI/LS -/: 96303658/CD 
TI/LS -/: Gene/NN transcription/NN through/IN activation/NN of/IN G-protein-coupled/JJ chemoattractant/NN receptors/NNS ./. 
AB/LS -/: Receptors/NNS for/IN leukocyte/JJ chemoattractants/NNS ,/, including/VBG chemokines/NNS ,/, are/VBP traditionally/RB considered/VBN to/TO be/VB responsible/JJ for/IN the/DT activation/NN of/IN special/JJ leukocyte/JJ functions/NNS such/JJ as/IN chemotaxis/NN ,/, degranulation/NN ,/, and/CC the/DT release/NN of/IN superoxide/NN anions/NNS ./. 
Recently/RB ,/, these/DT G-protein-coupled/JJ serpentine/NN receptors/NNS have/VBP been/VBN found/VBN to/TO transduce/VB signals/NNS leading/VBG to/TO gene/NN transcription/NN and/CC translation/NN in/IN leukocytes/NNS ./. 
Transcription/NN factors/NNS ,/, such/JJ as/IN NF/NN kappa/NN B/NN and/CC AP-1/NN ,/, are/VBP activated/VBN upon/IN stimulation/NN of/IN the/DT cells/NNS with/IN several/JJ chemoattractants/NNS at/IN physiologically/RB relevant/JJ concentrations/NNS ./. 
Activation/NN of/IN transcription/NN factors/NNS through/IN these/DT receptors/NNS involves/VBZ G-protein/NN coupling/NN and/CC the/DT activation/NN of/IN protein/NN kinases/NNS ./. 
The/DT underlying/JJ signaling/NN pathways/NNS appear/VBP to/TO be/VB different/JJ from/IN those/DT utilized/VBN by/IN TNF-alpha/NN ,/, a/DT better/RBR characterized/VBN cytokine/NN that/WDT induces/VBZ the/DT transcription/NN of/IN immediate-early/JJ genes/NNS ./. 
Chemoattractants/NNS stimulate/VBP the/DT expression/NN of/IN several/JJ inflammatory/JJ cytokines/NNS and/CC chemokines/NNS ,/, which/WDT in/IN turn/NN may/MD activate/VB their/PRP$ respective/JJ receptors/NNS and/CC initiate/VB an/DT autocrine/JJ regulatory/JJ mechanism/NN for/IN persistent/JJ cytokine/NN and/CC chemokine/NN gene/NN expression/NN ./. 
UI/LS -/: 99428687/CD 
TI/LS -/: Affinity-driven/JJ peptide/NN selection/NN of/IN an/DT NFAT/NN inhibitor/NN more/RBR selective/JJ than/IN cyclosporin/NN A/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: The/DT flow/NN of/IN information/NN from/IN calcium-mobilizing/JJ receptors/NNS to/TO nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) -dependent/JJ genes/NNS is/VBZ critically/RB dependent/JJ on/IN interaction/NN between/IN the/DT phosphatase/NN calcineurin/NN and/CC the/DT transcription/NN factor/NN NFAT/NN ./. 
A/DT high-affinity/JJ calcineurin-binding/JJ peptide/NN was/VBD selected/VBN from/IN combinatorial/JJ peptide/NN libraries/NNS based/VBN on/IN the/DT calcineurin/NN docking/NN motif/NN of/IN NFAT/NN ./. 
This/DT peptide/NN potently/RB inhibited/VBD NFAT/NN activation/NN and/CC NFAT-dependent/JJ expression/NN of/IN endogenous/JJ cytokine/NN genes/NNS in/IN T/NN cells/NNS ,/, without/IN affecting/VBG the/DT expression/NN of/IN other/JJ cytokines/NNS that/WDT require/VBP calcineurin/NN but/CC not/RB NFAT/NN ./. 
Substitution/NN of/IN the/DT optimized/VBN peptide/NN sequence/NN into/IN the/DT natural/JJ calcineurin/NN docking/NN site/NN increased/VBD the/DT calcineurin/NN responsiveness/NN of/IN NFAT/NN ./. 
Compounds/NNS that/WDT interfere/VBP selectively/RB with/IN the/DT calcineurin-NFAT/JJ interaction/NN without/IN affecting/VBG calcineurin/NN phosphatase/NN activity/NN may/MD be/VB useful/JJ as/IN therapeutic/JJ agents/NNS that/WDT are/VBP less/RBR toxic/JJ than/IN current/JJ drugs/NNS ./. 
UI/LS -/: 99410810/CD 
TI/LS -/: 9-cis/JJ|NN retinoic/JJ acid/NN induces/VBZ monocyte/NN chemoattractant/NN protein-1/NN secretion/NN in/IN human/JJ monocytic/JJ THP-1/NN cells/NNS ./. 
AB/LS -/: Monocyte/NN migration/NN and/CC activation/NN are/VBP regulated/VBN by/IN monocyte/NN chemoattractant/NN protein-1/NN (/( MCP-1/NN )/) ./. 
Prior/JJ studies/NNS have/VBP shown/VBN MCP-1/NN expression/NN is/VBZ modulated/VBN by/IN a/DT variety/NN of/IN ligands/NNS that/WDT act/VBP through/IN extracellular/JJ receptors/NNS ./. 
In/IN the/DT current/JJ study/NN ,/, we/PRP show/VBP 9-cis/JJ|NN retinoic/JJ acid/NN (/( RA/NN )/) ,/, a/DT ligand/NN for/IN the/DT nuclear/JJ hormone/NN receptor/NN retinoid/NN X/NN receptor/NN (/( RXR/NN )/) and/CC retinoic/JJ acid/NN receptor/NN (/( RAR/NN )/) ,/, markedly/RB induces/VBZ the/DT expression/NN of/IN MCP-1/NN ./. 
In/IN human/JJ THP-1/NN monocytic/JJ leukemia/NN cells/NNS cultured/VBN with/IN RA/NN (/( 0.05/CD to/TO 500/CD nmol/L/NN )/) ,/, MCP-1/NN expression/NN was/VBD induced/VBN rapidly/RB ,/, significantly/RB ,/, and/CC dose-dependently/RB by/IN as/RB much/JJ as/IN 165-fold/RB ./. 
MCP-1/NN RNA/NN level/NN was/VBD also/RB increased/VBN in/IN RA-treated/JJ cells/NNS ./. 
Expression/NN of/IN PPARgamma/NN ,/, a/DT heterodimer/NN partner/NN of/IN RXR/NN ,/, is/VBZ also/RB markedly/RB induced/VBN by/IN RA/NN in/IN THP-1/NN cells/NNS ./. 
However/RB ,/, BRL49653/NN ,/, a/DT PPARgamma/NN ligand/NN ,/, failed/VBD to/TO induce/VB MCP-1/NN secretion/NN either/CC alone/RB or/CC to/TO modify/VB the/DT expression/NN level/NN induced/VBN by/IN RA/NN ./. 
In/IN contrast/NN ,/, BRL49653/NN significantly/RB increased/VBD MCP-1/NN (/( biotinylated/VBN MCP-1/NN )/) binding/VBG to/TO THP-1/NN cells/NNS ,/, whereas/IN RA/NN had/VBD no/DT effect/NN ./. 
Other/JJ peroxisome/JJ proliferator/NN activated/JJ receptor/NN (/( PPAR/NN )/) ligands/NNS ,/, 15d-PGJ/NN (/( 2/CD )/) and/CC troglitazone/NN (/( PPARgamma/NN )/ ,/, Wy14/NN ,/, 643/CD (/( PPARalpha/NN )/) ,/, and/CC PD195599/NN (/( PPARbeta/NN )/) inhibited/VBD the/DT induction/NN of/IN MCP-1/NN by/IN RA/NN ./. 
RA/NN 's/POS effect/NN on/IN MCP-1/NN expression/NN in/IN human/JJ elutriated/VBN monocytes/NNS were/VBD similar/JJ to/TO that/DT observed/VBN in/IN the/DT THP-1/NN cells/NNS ./. 
These/DT studies/NNS identify/VBP RA/NN as/IN a/DT nuclear/JJ signal/NN for/IN MCP-1/NN induction/NN in/IN undifferentiated/JJ human/JJ monocytic/JJ cells/NNS ./. 
These/DT studies/NNS also/RB suggest/VBP monocyte/NN MCP-1/NN expression/NN induced/VBN through/IN RA/NN may/MD modulate/VB cell/NN migration/NN ./. 
UI/LS -/: 99388640/CD 
TI/LS -/: Classification/NN of/IN IVS1-10T/NN -->/TO C/NN as/IN a/DT polymorphism/NN of/IN BRCA1/NN ./. 
AB/LS -/: Mutations/NNS inactivating/VBG the/DT tumor/NN suppressor/NN gene/NN BRCA1/NN may/MD be/VB responsible/JJ for/IN disease/NN for/IN up/RB to/TO 80/CD %/NN of/IN familial/JJ ovarian/JJ cancer/NN cases/NNS ./. 
In/IN this/DT syndrome/NN ,/, tumorigenesis/NN classically/RB initiates/VBZ from/IN an/DT inherited/VBN mutation/NN in/IN one/CD allele/NN followed/VBN by/IN somatic/JJ deletion/NN of/IN the/DT normal/JJ allele/NN ./. 
Sequencing/NN of/IN BRCA1/NN amplified/VBN from/IN genomic/JJ DNA/NN of/IN lymphocytes/NNS and/CC microdissected/VBN ovarian/JJ tumor/NN cells/NNS of/IN a/DT familial/JJ ovarian/JJ cancer/NN patient/NN revealed/VBD three/CD ,/, rare/JJ heterozygous/NN DNA/NN variations/NNS (/( 2418delA/NN ,/, 233G/NN -->/TO A/NN ,/, and/CC IVS1-10T/NN -->/TO C/NN )/) in/IN both/CC tumor/NN and/CC constitutional/JJ (/( lymphocyte/NN )/) DNA/NN ./. 
Thus/RB ,/, both/DT copies/NNS of/IN BRCA1/NN were/VBD retained/VBN in/IN tumor/NN ./. 
Haplotype/NN analysis/NN of/IN the/DT patient/NN and/CC four/CD siblings/NNS assigned/VBD 2418delA/NN to/TO one/CD copy/NN of/IN BRCA1/NN and/CC 233G/NN -->/TO A/NN and/CC IVS1-10T/NN -->/TO C/NN to/TO the/DT other/JJ ./. 
The/DT DNA/NN change/NN ,/, 2418delA/NN ,/, is/VBZ considered/VBN a/DT mutation/NN that/WDT inactivated/VBD one/CD BRCA1/NN allele/NN because/IN it/PRP caused/VBD a/DT frameshift/NN and/CC generation/NN of/IN a/DT premature/JJ stop/NN codon/NN ,/, resulting/VBG in/IN synthesis/NN of/IN a/DT truncated/VBN peptide/NN as/IN evidenced/VBN by/IN an/DT in/FW vitro/FW protein/NN truncation/NN test/NN ./. 
The/DT DNA/NN variation/NN ,/, 233G/NN -->/TO A/NN ,/, does/VBZ not/RB result/VB in/IN an/DT amino/NN acid/NN change/NN ,/, and/CC is/VBZ considered/VBN a/DT benign/JJ polymorphism/NN ./. 
IVS1-10T/NN -->/TO C/NN is/VBZ a/DT unique/JJ BRCA1/NN change/NN that/WDT occurs/VBZ in/IN the/DT last/JJ nucleotide/NN of/IN a/DT consensus/NN sequence/NN for/IN a/DT branch/NN site/NN critical/JJ for/IN RNA/NN splicing/NN ./. 
Therefore/RB ,/, we/PRP investigated/VBD whether/IN IVS1-10T/NN -->/TO C/NN deleteriously/RB affected/VBD BRCA1/NN splicing/NN or/CC expression/NN ,/, and/CC thereby/RB inactivated/VBD the/DT other/JJ BRCA1/NN allele/NN ./. 
Using/VBG the/DT technique/NN of/IN reverse/JJ transcription-polymerase/JJ|NN chain/NN reaction/NN (/( PCR/NN )/) with/IN RNA/NN isolated/VBN from/IN lymphoid/JJ cell/NN lines/NNS of/IN the/DT patient/NN and/CC of/IN controls/NNS ,/, no/DT evidence/NN was/VBD found/VBN that/IN IVS1-10TC/NN abnormally/RB disrupted/VBD mRNA/NN splicing/NN or/CC caused/VBD the/DT absence/NN of/IN BRCA1/NN mRNA/NN ./. 
Thus/RB ,/, IVS1-10T/NN -->/TO C/NN is/VBZ not/RB harmful/JJ to/TO BRCA1/NN function/NN ,/, and/CC is/VBZ classified/VBN a/DT benign/JJ polymorphism/NN ./. 
Retention/NN of/IN the/DT normal/JJ BRCA1/NN allele/NN in/IN the/DT tumor/NN with/IN the/DT heterozygous/JJ germline/NN BRCA1/NN mutation/NN ,/, 2418delA/NN ,/, indicated/VBD that/IN mutational/JJ inactivation/NN of/IN both/DT BRCA1/NN alleles/NNS was/VBD not/RB required/VBN for/IN tumorigenesis/NN ./. 
It/PRP is/VBZ possible/JJ that/IN the/DT normal/JJ allele/NN may/MD be/VB functionally/RB inactivated/VBN by/IN a/DT nonmutational/JJ mechanism/NN ./. 
UI/LS -/: 99376397/CD 
TI/LS -/: Myb-transformed/JJ hematopoietic/JJ cells/NNS as/IN a/DT model/NN for/IN monocyte/NN differentiation/NN into/IN dendritic/JJ cells/NNS and/CC macrophages/NNS ./. 
AB/LS -/: Immune/JJ induction/NN is/VBZ effected/VBN through/IN the/DT interaction/NN of/IN antigen-presenting/JJ cells/NNS with/IN specific/JJ receptors/NNS on/IN the/DT surface/NN of/IN thymus-derived/JJ lymphocytes/NNS ./. 
Cells/NNS most/RBS able/JJ to/TO ingest/VB ,/, process/NN ,/, and/CC present/VB antigen/NN appear/VBP to/TO be/VB related/JJ to/TO the/DT mononuclear/JJ phagocyte/neutrophil/NN series/NN ./. 
For/IN example/NN dendritic/JJ cells/NNS (/( DC/NN )/) can/MD be/VB found/VBN in/IN colonies/NNS of/IN GM-CSF-responsive/JJ bone/NN marrow/NN cells/NNS ,/, and/CC under/IN experimental/JJ conditions/NNS are/VBP routinely/RB expanded/VBN as/IN a/DT population/NN in/FW vitro/FW from/IN GM-CSF-responsive/JJ progenitor/NN cells/NNS ./. 
To/TO address/VB the/DT question/NN of/IN DC/NN lineage/NN and/CC to/TO determine/VB what/WP genes/NNS are/VBP involved/VBN in/IN lineage/NN commitment/NN ,/, we/PRP have/VBP generated/VBN a/DT series/NN of/IN GM-CSF-responsive/JJ cell/NN lines/NNS that/WDT can/MD be/VB induced/VBN to/TO differentiate/VB in/IN a/DT homogeneous/JJ manner/NN in/FW vitro/FW ./. 
The/DT cloned/VBN cell/NN lines/NNS are/VBP derived/VBN from/IN 12-day/JJ fetal/JJ liver/NN and/CC are/VBP transformed/VBN with/IN a/DT truncated/VBN form/NN of/IN c-myb/NN ,/, which/WDT lacks/VBZ the/DT normal/JJ autoregulatory/JJ sequences/NNS ./. 
As/RB far/RB as/IN we/PRP know/VBP ,/, these/DT myb-transformed/JJ hemopoi-etic/JJ cells/NNS (/( MTHC/NN )/) differ/VBP from/IN normal/JJ only/RB in/IN the/DT unregulated/JJ expression/NN of/IN myb/NN ,/, a/DT gene/NN whose/WP$ expression/NN is/VBZ obligatory/JJ for/IN proliferation/NN of/IN hemopoietic/JJ cells/NNS ./. 
MTHC/NN in/IN the/DT presence/NN of/IN TNF-alpha/NN and/CC IL-4/NN will/MD differentiate/VB into/IN cells/NNS that/WDT have/VBP many/JJ of/IN the/DT properties/NNS of/IN macrophages/NNS ./. 
When/WRB the/DT same/JJ MTHC/NN lines/NNS are/VBP exposed/VBN to/TO TNF-alpha/NN in/IN combination/NN with/IN IFN-gamma/NN ,/, the/DT cells/NNS instead/RB become/VBP DC/NN ./. 
The/DT differentiated/VBN DC/NN are/VBP potent/JJ presenters/NNS of/IN antigen/NN in/IN mixed/JJ lymphocyte/NN reactions/NNS and/CC of/IN soluble/JJ antigen/NN to/TO specific/JJ T/NN cell/NN lines/NNS ./. 
Thus/RB ,/, cells/NNS with/IN the/DT properties/NNS of/IN both/CC macrophages/NNS and/CC DC/NN can/MD be/VB derived/VBN from/IN a/DT single/JJ type/NN of/IN GM-CSF-responsive/JJ progenitor/NN cell/NN ./. 
We/PRP have/VBP used/VBN this/DT MTHC/NN system/NN to/TO analyze/VB differences/NNS in/IN gene/NN expression/NN as/IN the/DT cells/NNS mature/VBP along/IN the/DT DC/NN and/CC macrophage/NN pathways/NNS ./. 
A/DT distinctive/JJ pattern/NN of/IN differentially/RB expressed/VBN cDNAs/NNS is/VBZ evident/JJ where/WRB macrophage-specific/JJ cDNAs/NNS are/VBP homologous/JJ to/TO genes/NNS encoding/VBG cytoskeletal/JJ and/CC cell-surface/JJ proteins/NNS ,/, whereas/IN the/DT DC-specific/JJ cDNAs/NNS are/VBP homologous/JJ to/TO signaling/NN ,/, chemokine/NN ,/, and/CC IFN-gamma-inducible/JJ genes/NNS ./. 
We/PRP discuss/VBP the/DT utility/NN of/IN MTHC/NN in/IN analyzing/VBG the/DT relationships/NNS between/IN DC/NN and/CC macrophages/NNS ,/, and/CC suggest/VB that/IN DC/NN and/CC macrophages/NNS represent/VBP extreme/JJ phenotypes/NNS in/IN a/DT spectrum/NN of/IN antigen/NN handling/NN cells/NNS that/WDT are/VBP somewhat/RB interchangeable/JJ ,/, depending/VBG on/IN their/PRP$ immediate/JJ environment/NN ./. 
UI/LS -/: 99369860/CD 
TI/LS -/: The/DT Legionella/NN pneumophila/NN rpoS/NN gene/NN is/VBZ required/VBN for/IN growth/NN within/IN Acanthamoeba/NN castellanii/NN ./. 
AB/LS -/: To/TO investigate/VB regulatory/JJ networks/NNS in/IN Legionella/NN pneumophila/NN ,/, the/DT gene/NN encoding/VBG the/DT homolog/NN of/IN the/DT Escherichia/FW coli/FW stress/NN and/CC stationary-phase/NN sigma/NN factor/NN RpoS/NN was/VBD identified/VBN by/IN complementation/NN of/IN an/DT E./FW coli/FW rpoS/NN mutation/NN ./. 
An/DT open/JJ reading/NN frame/NN that/WDT is/VBZ approximately/RB 60/CD %/NN identical/JJ to/TO the/DT E./FW coli/FW rpoS/NN gene/NN was/VBD identified/VBN ./. 
Western/JJ|NN blot/NN analysis/NN showed/VBD that/IN the/DT level/NN of/IN L./FW pneumophila/FW RpoS/NN increased/VBD in/IN stationary/JJ phase/NN ./. 
An/DT insertion/NN mutation/NN was/VBD constructed/VBN in/IN the/DT rpoS/NN gene/NN on/IN the/DT chromosome/NN of/IN L./FW pneumophila/FW ,/, and/CC the/DT ability/NN of/IN this/DT mutant/JJ strain/NN to/TO survive/VB various/JJ stress/NN conditions/NNS was/VBD assayed/VBN and/CC compared/VBN with/IN results/NNS for/IN the/DT wild-type/JJ strain/NN ./. 
Both/CC the/DT mutant/JJ and/CC wild-type/JJ strains/NNS were/VBD more/RBR resistant/JJ to/TO stress/NN when/WRB in/IN stationary/JJ phase/NN than/IN when/WRB in/IN the/DT logarithmic/JJ phase/NN of/IN growth/NN ./. 
This/DT finding/NN indicates/VBZ that/IN L./FW pneumophila/FW RpoS/NN is/VBZ not/RB required/VBN for/IN a/DT stationary-phase-dependent/JJ resistance/NN to/TO stress/NN ./. 
Although/IN the/DT mutant/JJ strain/NN was/VBD able/JJ to/TO kill/VB HL-60-/NN and/CC THP-1-derived/JJ macrophages/NNS ,/, it/PRP could/MD not/RB replicate/VB within/IN a/DT protozoan/NN host/NN ,/, Acanthamoeba/NN castellanii/NN ./. 
These/DT data/NNS suggest/VBP that/IN L./FW pneumophila/FW possesses/VBZ a/DT growth/NN phase-dependent/JJ resistance/NN to/TO stress/NN that/WDT is/VBZ independent/JJ of/IN RpoS/NN control/NN and/CC that/IN RpoS/NN likely/RB regulates/VBZ genes/NNS that/WDT enable/VBP it/PRP to/TO survive/VB in/IN the/DT environment/NN within/IN protozoa/NN ./. 
Our/PRP$ data/NNS indicate/VBP that/IN the/DT role/NN of/IN rpoS/NN in/IN L./NN pneumophila/NN is/VBZ very/RB different/JJ from/IN what/WP has/VBZ previously/RB been/VBN reported/VBN for/IN E./FW coli/FW rpoS/NN ./. 
UI/LS -/: 99357094/CD 
TI/LS -/: Monoallelic/JJ expression/NN of/IN Pax5/NN :/: a/DT paradigm/NN for/IN the/DT haploinsufficiency/NN of/IN mammalian/JJ Pax/NN genes/NNS ?/. 
AB/LS -/: It/PRP is/VBZ generally/RB assumed/VBN that/IN most/JJS mammalian/JJ genes/NNS are/VBP transcribed/VBN from/IN both/DT alleles/NNS ./. 
Hence/RB ,/, the/DT diploid/JJ state/NN of/IN the/DT genome/NN offers/VBZ the/DT advantage/NN that/IN a/DT loss-of-function/JJ mutation/NN in/IN one/CD allele/NN can/MD be/VB compensated/VBN for/IN by/IN the/DT remaining/VBG wild-type/JJ allele/NN of/IN the/DT same/JJ gene/NN ./. 
Indeed/RB ,/, the/DT vast/JJ majority/NN of/IN human/JJ disease/NN syndromes/NNS and/CC engineered/VBN mutations/NNS in/IN the/DT mouse/NN genome/NN are/VBP recessive/JJ ,/, indicating/VBG that/IN recessiveness/NN is/VBZ the/DT '/`` default/NN '/'' state/NN ./. 
However/RB ,/, a/DT minority/NN of/IN genes/NNS are/VBP semi-dominant/JJ ,/, as/IN heterozygous/JJ loss-of-function/JJ mutation/NN in/IN these/DT genes/NNS leads/VBZ to/TO phenotypic/JJ abnormalities/NNS ./. 
This/DT condition/NN ,/, known/VBN as/IN haploinsufficiency/NN ,/, has/VBZ been/VBN described/VBN for/IN five/CD of/IN the/DT nine/CD mammalian/JJ Pax/NN genes/NNS ,/, which/WDT are/VBP associated/VBN with/IN mouse/NN developmental/JJ mutants/NNS and/CC human/JJ disease/NN syndromes/NNS ./. 
Recently/RB we/PRP have/VBP reported/VBN that/IN the/DT Pax5/NN gene/NN is/VBZ subject/JJ to/TO allele-specific/JJ regulation/NN during/IN B/NN cell/NN development/NN ./. 
Pax5/NN is/VBZ predominantly/RB transcribed/VBN from/IN only/RB one/CD of/IN its/PRP$ two/CD alleles/NNS in/IN early/JJ B-lymphoid/JJ progenitors/NNS and/CC mature/JJ B/NN cells/NNS ,/, while/IN it/PRP transiently/RB switches/VBZ to/TO a/DT biallelic/JJ mode/NN of/IN transcription/NN in/IN pre-B/NN and/CC immature/JJ B/NN cells/NNS ./. 
As/IN a/DT consequence/NN ,/, B-lymphoid/JJ tissues/NNS are/VBP mosaic/JJ with/IN regard/NN to/TO the/DT transcribed/VBN allele/NN ,/, and/CC heterozygous/JJ mutation/NN of/IN Pax5/NN therefore/RB results/VBZ in/IN deletion/NN of/IN B/NN lymphocytes/NNS expressing/VBG only/RB the/DT mutant/JJ allele/NN ./. 
The/DT allele-specific/JJ regulation/NN of/IN Pax5/NN raises/VBZ the/DT intriguing/JJ possibility/NN that/IN monoallelic/JJ expression/NN may/MD also/RB be/VB the/DT mechanism/NN causing/VBG the/DT haploinsufficiency/NN of/IN other/JJ Pax/NN genes/NNS ./. 
In/IN this/DT review/NN ,/, we/PRP discuss/VBP different/JJ models/NNS accounting/VBG for/IN the/DT haploinsufficiency/NN of/IN mammalian/JJ Pax/NN genes/NNS ,/, provide/VBP further/JJ evidence/NN in/IN support/NN of/IN the/DT allele-specific/JJ regulation/NN of/IN Pax5/NN and/CC discuss/VBP the/DT implication/NN of/IN these/DT findings/NNS in/IN the/DT context/NN of/IN the/DT recent/JJ literature/NN describing/VBG the/DT stochastic/JJ and/CC monoallelic/JJ activation/NN of/IN other/JJ hematopoietic/JJ genes/NNS ./. 
UI/LS -/: 99352259/CD 
TI/LS -/: Activation/NN of/IN STAT5/NN by/IN IL-4/NN relies/VBZ on/IN Janus/NN kinase/NN function/NN but/CC not/RB on/IN receptor/NN tyrosine/NN phosphorylation/NN ,/, and/CC can/MD contribute/VB to/TO both/CC cell/NN proliferation/NN and/CC gene/NN regulation/NN ./. 
AB/LS -/: We/PRP have/VBP investigated/VBN mechanisms/NNS and/CC consequences/NNS of/IN STAT5/NN activation/NN through/IN the/DT human/JJ IL-4/NN receptor/NN (/( IL-4R/NN )/) ./. 
By/IN functionally/RB expressing/VBG receptor/NN mutants/NNS in/IN the/DT murine/JJ pro-B/JJ cell/NN line/NN Ba/F3/NN ,/, we/PRP could/MD show/VB that/IN phosphorylated/VBN tyrosine/NN residues/NNS within/IN the/DT IL-4R/NN alpha/NN chain/NN are/VBP dispensable/JJ for/IN IL-4-induced/JJ STAT5/NN activity/NN ./. 
However/RB ,/, disruption/NN of/IN a/DT membrane-proximal/JJ proline-rich/JJ sequence/NN motif/NN (/( '/`` box1/NN '/'' )/) in/IN either/DT subunit/NN of/IN the/DT bipartite/JJ IL-4R/NN abolished/VBD not/RB only/RB ligand-induced/JJ tyrosine/NN phosphorylation/NN of/IN Janus/NN kinases/NNS JAK1/NN and/CC JAK3/NN ,/, but/CC also/RB IL-4-triggered/JJ activation/NN of/IN STAT5/NN and/CC concomitant/JJ cell/NN proliferation/NN ./. 
A/DT dominant-negative/JJ version/NN of/IN STAT5b/NN ,/, but/CC not/RB of/IN STAT5a/NN ,/, interfered/VBD with/IN IL-4-induced/JJ DNA/NN synthesis/NN in/IN Ba/F3/NN cells/NNS ,/, suggesting/VBG an/DT involvement/NN of/IN STAT5b/NN in/IN the/DT control/NN of/IN cell/NN proliferation/NN through/IN IL-4R/NN ./. 
Reporter/NN gene/NN experiments/NNS finally/RB showed/VBD that/IN transcription/NN from/IN promoters/NNS of/IN STAT5/NN target/NN genes/NNS can/MD be/VB specifically/RB induced/VBN by/IN challenging/VBG cells/NNS with/IN IL-4/NN ,/, and/CC that/IN both/CC STAT5a/NN and/CC STAT5b/NN can/MD contribute/VB to/TO IL-4-triggered/JJ transcriptional/JJ control/NN ./. 
UI/LS -/: 96144699/CD 
TI/LS -/: Inhibition/NN of/IN NF-AT/NN signal/NN transduction/NN events/NNS by/IN a/DT dominant-negative/JJ form/NN of/IN calcineurin/NN ./. 
AB/LS -/: An/DT inhibitory/JJ ,/, "/`` dominant-negative/JJ ,/, "/'' form/NN of/IN the/DT calcineurin/NN catalytic/JJ (/( A/NN )/) subunit/NN was/VBD prepared/VBN ,/, which/WDT lacks/VBZ the/DT calmodulin-binding/JJ domain/NN ,/, autoinhibitory/JJ domain/NN and/CC most/JJS of/IN its/PRP$ catalytic/JJ core/NN but/CC possesses/VBZ the/DT regulatory/JJ (/( B/NN )/) subunit/NN binding/NN domain/NN ./. 
When/WRB tested/VBN for/IN its/PRP$ ability/NN to/TO block/VB calcineurin-dependent/JJ signaling/NN in/IN Jurkat/NN cells/NNS ,/, expression/NN of/IN this/DT "/`` B-subunit/JJ knock-out/JJ "/'' (/( BKO/NN )/) construct/NN suppressed/VBD reporter/NN gene/NN activity/NN driven/VBN by/IN NF-AT/NN ,/, the/DT pivotal/JJ promoter/NN element/NN for/IN interleukin/NN (/( IL/NN )/) -2/CD gene/NN induction/NN ./. 
Immunoprecipitation/NN of/IN epitope-labeled/JJ BKO/NN demonstrated/VBD for/IN the/DT formation/NN of/IN a/DT tight/JJ complex/NN with/IN endogenous/JJ B/NN subunit/NN in/IN Jurkat/NN cells/NNS ,/, consistent/JJ with/IN an/DT inhibitory/JJ mechanism/NN that/WDT involves/VBZ the/DT sequestration/NN of/IN the/DT B/NN subunit/NN ./. 
Furthermore/RB ,/, the/DT sharply/RB reduced/VBN NF-AT/NN activity/NN produced/VBN by/IN co-transfecting/VBG BKO/NN could/MD be/VB "/`` rescued/VBN "/'' by/IN overexpression/NN of/IN transfected/VBN B/NN subunit/NN ,/, suggesting/VBG that/IN depletion/NN of/IN this/DT subunit/NN was/VBD responsible/JJ for/IN the/DT inhibition/NN ./. 
These/DT data/NNS suggest/VBP the/DT potential/JJ utility/NN of/IN agents/NNS that/WDT disrupt/VBP calcineurin-mediated/JJ signal/NN transduction/NN pathways/NNS by/IN blocking/VBG formation/NN of/IN the/DT catalytically/RB active/JJ dimer/NN of/IN calcineurin/NN A/NN and/CC B/NN subunits/NNS ./. 
UI/LS -/: 97171572/CD 
TI/LS -/: Evaluation/NN of/IN monoclonal/JJ anti-D/JJ reagents/NNS using/VBG D/NN variant/JJ cells/NNS ./. 
AB/LS -/: Monoclonal/JJ anti-D/JJ antibodies/NNS submitted/VBN to/TO the/DT Third/NNP Monoclonal/NNP International/NNP Workshop/NNP were/VBD evaluated/VBN against/IN a/DT number/NN of/IN D/NN variant/JJ cells/NNS using/VBG standard/JJ serological/JJ techniques/NNS ./. 
The/DT monoclonal/JJ antibodies/NNS were/VBD able/JJ to/TO discriminate/VB between/IN the/DT cells/NNS of/IN Categories/NNS Va/NN ,/, VI/NN and/CC DFR/NN but/CC not/RB Category/NN III/CD cells/NNS ./. 
Cells/NNS within/IN each/DT category/NN did/VBD not/RB give/VB any/DT aberrant/JJ results/NNS ./. 
The/DT Rh/NN :/: 33/CD cells/NNS behaved/VBD as/IN normal/JJ Rh/NN (/( D/NN )/) positive/JJ cells/NNS ./. 
UI/LS -/: 96262594/CD 
TI/LS -/: Interleukin/NN 10/CD induced/JJ c-fos/NN expression/NN in/IN human/JJ B/NN cells/NNS by/IN activation/NN of/IN divergent/JJ protein/NN kinases/NNS ./. 
AB/LS -/: IL-10/NN is/VBZ a/DT potent/JJ mediator/NN of/IN human/JJ B/NN cell/NN growth/NN and/CC plasma/NN cell/NN formation/NN ./. 
However/RB ,/, signal/NN transduction/NN of/IN IL-10/NN in/IN B/NN cells/NNS is/VBZ poorly/RB understood/VBN ./. 
In/IN this/DT study/NN the/DT effect/NN of/IN IL-10/NN on/IN the/DT expression/NN of/IN the/DT protooncogene/NN c-fos/NN was/VBD investigated/VBN ,/, because/IN Fos/NN plays/VBZ a/DT potential/JJ role/NN in/IN the/DT regulation/NN of/IN B/NN cell/NN proliferation/NN and/CC differentiation/NN ./. 
B/NN cells/NNS were/VBD purified/VBN from/IN buffy/JJ coat/NN preparations/NNS of/IN healthy/JJ blood/NN donors/NNS by/IN positive/JJ selection/NN using/VBG an/DT anti/JJ CD20/NN monoclonal/JJ antibody/NN and/CC a/DT MiniMACS/NN separation/NN unit/NN ./. 
B/NN cells/NNS were/VBD prestimulated/VBN with/IN SAC/NN for/IN 48/CD hrs/NNS ./. 
Then/RB ,/, cells/NNS were/VBD incubated/VBN with/IN medium/NN or/CC IL-10/NN (/( 100/CD ng/ml/NN )/) for/IN 10/CD to/TO 120/CD min/NN ./. 
RNA/NN was/VBD extracted/VBN by/IN phenol/chloroform/NN and/CC c-fos/NN expression/NN was/VBD analyzed/VBN by/IN PCR/NN assisted/JJ mRNA/NN assay/NN ./. 
A/DT significant/JJ 2-4/CD fold/JJ increase/NN of/IN c-fos/NN expression/NN was/VBD observed/VBN within/IN 30/CD min/NN of/IN stimulation/NN with/IN IL-10/NN (/( p/NN </JJR 0.01/CD )/) ./. 
After/IN 2/CD hrs/NNS c-fos/NN expression/NN declined/VBD to/TO basal/JJ levels/NNS ./. 
The/DT effect/NN of/IN IL-10/NN was/VBD dose-dependent/JJ with/IN a/DT maximum/NN stimulation/NN using/VBG 100/CD ng/ml/NN of/IN IL-10/NN ./. 
The/DT IL-10/NN effect/NN on/IN c-fos/NN expression/NN was/VBD not/RB blocked/VBN by/IN polymyxin/NN B/NN ./. 
Using/VBG the/DT tyrosine/NN kinase/NN inhibitor/NN genistein/NN (/( 10/CD microM/NN )/) a/DT complete/JJ inhibition/NN of/IN IL-10/NN induced/JJ c-fos/NN expression/NN was/VBD observed/VBN ./. 
In/IN addition/NN ,/, H-7/NN (/( 10/CD microM/NN )/) ,/, a/DT specific/JJ inhibitor/NN of/IN serine/threonine/NN kinases/NNS ,/, significantly/RB blocked/VBD IL-10/NN mediated/JJ c-fos/NN expression/NN (/( p/NN </JJR 0.05/CD )/) ./. 
In/IN conclusion/NN ,/, these/DT data/NNS show/VBP that/IN IL-10/NN induces/VBZ c-fos/NN expression/NN in/IN human/JJ B-cells/NNS by/IN activation/NN of/IN tyrosine/NN and/CC serine/threonine/NN kinases/NNS ./. 
Since/IN this/DT is/VBZ the/DT first/JJ report/NN on/IN IL-10/NN induced/JJ signal/NN transduction/NN ,/, these/DT data/NNS may/MD help/VB to/TO identify/VB the/DT intracellular/JJ mechanisms/NNS by/IN which/WDT IL-10/NN stimulates/VBZ human/JJ B-cells/NNS ./. 
UI/LS -/: 99419787/CD 
TI/LS -/: Immunocytochemical/JJ analysis/NN of/IN MNDA/NN in/IN tissue/NN sections/NNS and/CC sorted/VBN normal/JJ bone/NN marrow/NN cells/NNS documents/VBZ expression/NN only/RB in/IN maturing/VBG normal/JJ and/CC neoplastic/JJ myelomonocytic/JJ cells/NNS and/CC a/DT subset/NN of/IN normal/JJ and/CC neoplastic/JJ B/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT human/NN myeloid/NN cell/NN nuclear/JJ differentiation/NN antigen/NN (/( MNDA/NN )/) is/VBZ a/DT nuclear/JJ antigen/NN known/VBN to/TO be/VB expressed/VBN in/IN mature/JJ myelomonocytic/JJ cell/NN lines/NNS ./. 
An/DT extensive/JJ immunocytochemical/JJ evaluation/NN of/IN fixed/JJ tissues/NNS confirmed/VBD MNDA/NN expression/NN in/IN normal/JJ maturing/VBG granulocytes/NNS and/CC monocytes/NNS and/CC in/IN acute/JJ nonlymphocytic/JJ leukemias/NNS and/CC chronic/JJ myelogenous/JJ leukemia/NN ./. 
MNDA/NN was/VBD not/RB detected/VBN in/IN normal/JJ tissue/NN histiocytes/NNS but/CC was/VBD found/VBN in/IN activated/VBN macrophages/NNS and/CC foreign/JJ body/NN giant/JJ cells/NNS associated/VBN with/IN inflammation/NN ./. 
Flow/NN cytometric/JJ cell/NN sorting/NN of/IN normal/JJ bone/NN marrow/NN established/VBD that/IN MNDA/NN is/VBZ initially/RB expressed/VBN in/IN myeloid/JJ blast/NN cells/NNS ./. 
Examination/NN of/IN lymphoid/JJ tissues/NNS showed/VBD a/DT low/JJ level/NN of/IN expression/NN in/IN a/DT population/NN of/IN normal/JJ mande/NN B/NN lymphocytes/NNS but/CC not/RB in/IN germinal/JJ center/NN cells/NNS or/CC plasma/NN cells/NNS ./. 
A/DT subset/NN of/IN B/NN cell/NN neoplasms/NNS expressing/VBG MNDA/NN included/VBD hairy/JJ cell/NN leukemia/NN ,/, parafollicular/JJ (/( monocytoid/JJ )/) B/NN cell/NN lymphoma/NN ,/, mantle/NN cell/NN lymphoma/NN ,/, and/CC small/JJ lymphocytic/JJ lymphoma/NN ./. 
Cell/NN sorting/NN of/IN normal/JJ bone/NN marrow/NN showed/VBD MNDA/NN expression/NN in/IN CD20+/CD10-/CD5-/JJ B/NN cells/NNS ./. 
MNDA/NN was/VBD not/RB detected/VBN in/IN other/JJ normal/JJ bone/NN marrow/NN or/CC all/DT other/JJ nonhematopoietic/JJ cells/NNS ./. 
The/DT hematopoietic/JJ cell-specific/JJ pattern/NN of/IN MNDA/NN expression/NN was/VBD elucidated/VBN through/IN a/DT comprehensive/JJ analysis/NN of/IN normal/JJ and/CC neoplastic/JJ tissues/NNS ,/, and/CC the/DT results/NNS provide/VBP further/JJ evidence/NN of/IN the/DT coexpression/NN of/IN B-/NN and/CC myeloid/JJ cell/NN markers/NNS in/IN neoplastic/JJ B/NN cells/NNS and/CC identify/VBP a/DT normal/JJ B/NN cell/NN population/NN that/WDT might/MD be/VB related/JJ to/TO the/DT cell/NN of/IN origin/NN of/IN a/DT subset/NN of/IN B/NN cell/NN neoplasms/NNS ./. 
UI/LS -/: 99410809/CD 
TI/LS -/: Peroxisome/NN proliferator-activated/JJ receptor/NN activators/NNS target/VBP human/JJ endothelial/JJ cells/NNS to/TO inhibit/VB leukocyte-endothelial/JJ cell/NN interaction/NN ./. 
AB/LS -/: An/DT early/JJ event/NN in/IN acute/JJ and/CC chronic/JJ inflammation/NN and/CC associated/VBN diseases/NNS such/JJ as/IN atherosclerosis/NN and/CC rheumatoid/JJ arthritis/NN is/VBZ the/DT induced/VBN expression/NN of/IN specific/JJ adhesion/NN molecules/NNS on/IN the/DT surface/NN of/IN endothelial/JJ cells/NNS (/( ECs/NNS )/) ,/, which/WDT subsequently/RB bind/VBP leukocytes/NNS ./. 
Peroxisome/NN proliferator-activated/JJ receptors/NNS (/( PPARs/NNS )/) ,/, members/NNS of/IN the/DT nuclear/JJ receptor/NN superfamily/NN of/IN transcription/NN factors/NNS ,/, are/VBP activated/VBN by/IN fatty/JJ acid/JJ metabolites/NNS ,/, peroxisome/NN proliferators/NNS ,/, and/CC thiazolidinediones/NNS and/CC are/VBP now/RB recognized/VBN as/RB important/JJ mediators/NNS in/IN the/DT inflammatory/JJ response/NN ./. 
Whether/IN PPAR/NN activators/NNS influence/VBP the/DT inflammatory/JJ responses/NNS of/IN ECs/NNS is/VBZ unknown/JJ ./. 
We/PRP show/VBP that/IN the/DT PPAR/NN activators/NNS 15-deoxy-Delta/NN (/( 12/CD ,/, 14/CD )/) -prostaglandin/NN J/NN (/( 2/CD )/) (/( 15d-PGJ/NN (/( 2/CD )/) )/) ,/, Wyeth/NN 14643/CD ,/, ciglitazone/NN ,/, and/CC troglitazone/NN ,/, but/CC not/RB BRL/NN 49653/CD ,/, partially/RB inhibit/VBP the/DT induced/VBN expression/NN of/IN vascular/JJ cell/NN adhesion/NN molecule-1/NN (/( VCAM-1/NN )/) ,/, as/IN measured/VBN by/IN ELISA/NN ,/, and/CC monocyte/NN binding/VBG to/TO human/JJ aortic/JJ endothelial/JJ cells/NNS (/( HAECs/NNS )/) activated/VBN by/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) or/CC lipopolysaccharide/NN ./. 
The/DT "/`` natural/JJ "/'' PPAR/NN activator/NN 15d-PGJ/NN (/( 2/CD )/) had/VBD the/DT greatest/JJS potency/NN and/CC was/VBD the/DT only/RB tested/VBN molecule/NN capable/JJ of/IN partially/RB inhibiting/VBG the/DT induced/VBN expression/NN of/IN E-selectin/NN and/CC neutrophil-like/JJ HL60/NN cell/NN binding/VBG to/TO PMA-activated/JJ HAECs/NNS ./. 
Intracellular/JJ adhesion/NN molecule-1/NN induction/NN by/IN PMA/NN was/VBD unaffected/JJ by/IN any/DT of/IN the/DT molecules/NNS tested/VBN ./. 
Both/CC PPAR-alpha/NN and/CC PPAR-gamma/NN mRNAs/NNS were/VBD detected/VBN in/IN HAECs/NNS by/IN using/VBG reverse/JJ transcription-polymerase/JJ|NN chain/NN reaction/NN and/CC a/DT ribonuclease/NN protection/NN assay/NN ;/: however/RB ,/, we/PRP have/VBP yet/RB to/TO determine/VB which/WDT ,/, if/IN any/DT ,/, of/IN the/DT PPARs/NNS are/VBP mediating/VBG this/DT process/NN ./. 
These/DT results/NNS suggest/VBP that/IN certain/JJ PPAR/NN activators/NNS may/MD help/VB limit/VB chronic/JJ inflammation/NN mediated/VBN by/IN VCAM-1/NN and/CC monocytes/NNS without/IN affecting/VBG acute/JJ inflammation/NN mediated/VBN by/IN E-selectin/NN and/CC neutrophil/JJ binding/NN ./. 
UI/LS -/: 99388007/CD 
TI/LS -/: Dephosphorylation/NN of/IN ZAP-70/NN and/CC inhibition/NN of/IN T/NN cell/NN activation/NN by/IN activated/VBN SHP1/NN ./. 
AB/LS -/: Studies/NNS with/IN motheaten/NN mice/NNS ,/, which/WDT lack/VBP the/DT SHP1/NN protein/NN tyrosine/NN phosphatase/NN ,/, indicate/VBP that/IN this/DT enzyme/NN plays/VBZ an/DT important/JJ negative/JJ role/NN in/IN T/NN cell/NN antigen/NN receptor/NN (/( TCR/NN )/) signaling/NN ./. 
The/DT physiological/JJ substrates/NNS for/IN SHP1/NN in/IN T/NN lymphocytes/NNS ,/, however/RB ,/, have/VBP remained/VBN unclear/JJ or/CC controversial/JJ ./. 
To/TO define/VB these/DT targets/NNS for/IN SHP1/NN we/PRP have/VBP compared/VBN the/DT effects/NNS of/IN constitutively/RB active/JJ and/CC inactive/JJ mutants/NNS of/IN SHP1/NN on/IN TCR/NN signaling/NN ./. 
Expression/NN of/IN wild-type/JJ SHP1/NN had/VBD a/DT very/RB small/JJ effect/NN on/IN the/DT TCR-induced/JJ tyrosine/NN phosphorylation/NN of/IN ZAP-70/NN and/CC Syk/NN ,/, even/RB when/WRB SHP1/NN was/VBD overexpressed/VBN 20 - 100-fold/RB over/IN endogenous/JJ SHP1/NN ./. 
Inactive/JJ SHP1-D421A/NN and/CC wild-type/JJ SHP2/NN were/VBD without/IN effects/NNS ./. 
Constitutively/RB active/JJ SHP1-DeltaSH2/NN had/VBD a/DT more/RBR pronounced/JJ effect/NN on/IN ZAP-70/NN and/CC Syk/NN ,/, even/RB when/WRB expressed/VBN at/IN near/JJ physiological/JJ levels/NNS ./. 
SHP1-DeltaSH2/NN also/RB inhibited/VBD events/NNS downstream/JJ of/IN ZAP-70/NN and/CC Syk/NN ,/, such/JJ as/IN activation/NN of/IN the/DT mitogen-activated/JJ protein/NN kinase/NN Erk2/NN and/CC the/DT transcriptional/JJ activation/NN of/IN the/DT interleukin-2/NN gene/NN ./. 
In/IN contrast/NN ,/, a/DT constitutively/RB active/JJ SHP2-DeltaSH2/NN had/VBD no/DT statistically/RB significant/JJ effect/NN (/( although/IN it/PRP caused/VBD a/DT slight/JJ augmentation/NN in/IN some/DT individual/JJ experiments/NNS )/) ./. 
None/NN of/IN the/DT constructs/NNS influenced/VBD the/DT anti-CD3-induced/JJ tyrosine/NN phosphorylation/NN of/IN the/DT TCR/NN zeta-chain/NN or/CC phospholipase/NN Cgamma1/NN ,/, indicating/VBG that/IN Src/NN family/NN kinase/NN function/NN was/VBD intact/JJ ./. 
Taken/VBN together/RB ,/, our/PRP$ findings/NNS support/VBP the/DT notion/NN that/IN ZAP-70/NN and/CC Syk/NN can/MD be/VB direct/JJ substrates/NNS for/IN SHP1/NN in/IN intact/JJ cells/NNS ./. 
However/RB ,/, the/DT two/CD SH2/NN domains/NNS of/IN SHP1/NN did/VBD not/RB facilitate/VB its/PRP$ recognition/NN of/IN ZAP-70/NN and/CC Syk/NN as/IN substrates/NNS in/IN intact/JJ cells/NNS ./. 
Therefore/RB ,/, we/PRP suggest/VBP that/IN SHP1/NN is/VBZ not/RB actively/RB recruited/VBN to/TO inhibit/VB TCR/NN signaling/NN induced/VBN by/IN ligation/NN of/IN this/DT receptor/NN alone/RB ./. 
Instead/RB ,/, we/PRP propose/VBP that/IN ligation/NN of/IN a/DT distinct/JJ inhibitory/JJ receptor/NN leads/VBZ to/TO the/DT recruitment/NN of/IN SHP1/NN via/IN its/PRP$ SH2/NN domains/NNS ,/, activation/NN of/IN SHP1/NN and/CC subsequently/RB inhibition/NN of/IN TCR/NN signals/NNS if/IN the/DT inhibitory/JJ receptor/NN is/VBZ juxtaposed/VBN to/TO the/DT TCR/NN ./. 
UI/LS -/: 99379868/CD 
TI/LS -/: Immune/JJ responses/NNS to/TO adenoviruses/NNS :/: viral/JJ evasion/NN mechanisms/NNS and/CC their/PRP$ implications/NNS for/IN the/DT clinic/NN ./. 
AB/LS -/: Adenoviruses/NNS encode/VBP proteins/NNS that/WDT block/VBP responses/NNS to/TO interferons/NNS ,/, intrinsic/JJ cellular/JJ apoptosis/NN ,/, killing/NN by/IN CD8(+)/JJ cytotoxic/JJ T/NN lymphocytes/NNS and/CC killing/NN by/IN the/DT death/NN ligands/NNS TNF/NN ,/, Fas/NN ligand/NN and/CC TRAIL/NN ./. 
The/DT viral/JJ proteins/NNS are/VBP believed/VBN to/TO prolong/VB acute/JJ and/CC persistent/JJ adenovirus/NN infections/NNS ./. 
The/DT proteins/NNS may/MD prove/VB useful/JJ in/IN protecting/VBG adenovirus/NN gene/NN therapy/NN vectors/NNS and/CC transplanted/VBN cells/NNS from/IN the/DT immune/JJ system/NN ./. 
UI/LS -/: 99369690/CD 
TI/LS -/: C/EBPbeta/NN and/CC GATA-1/NN synergistically/RB regulate/VBP activity/NN of/IN the/DT eosinophil/NN granule/NN major/JJ basic/JJ protein/NN promoter/NN :/: implication/NN for/IN C/EBPbeta/NN activity/NN in/IN eosinophil/NN gene/NN expression/NN ./. 
AB/LS -/: Eosinophil/NN granule/NN major/JJ basic/JJ protein/NN (/( MBP/NN )/) is/VBZ expressed/VBN exclusively/RB in/IN eosinophils/NNS and/CC basophils/NNS in/IN hematopoietic/JJ cells/NNS ./. 
In/IN our/PRP$ previous/JJ study/NN ,/, we/PRP demonstrated/VBD a/DT major/JJ positive/JJ regulatory/JJ role/NN for/IN GATA-1/NN and/CC a/DT negative/JJ regulatory/JJ role/NN for/IN GATA-2/NN in/IN MBP/NN gene/NN transcription/NN ./. 
Further/RB analysis/NN of/IN the/DT MBP/NN promoter/NN region/NN identified/VBD a/DT C/EBP/NN (/( CCAAT/enhancer-binding/JJ protein/NN )/) consensus/NN binding/NN site/NN 6/CD bp/NN upstream/JJ of/IN the/DT functional/JJ GATA-binding/JJ site/NN in/IN the/DT MBP/NN gene/NN ./. 
In/IN the/DT cell/NN line/NN HT93A/NN ,/, which/WDT is/VBZ capable/JJ of/IN differentiating/VBG towards/IN both/CC the/DT eosinophil/NN and/CC neutrophil/NN lineages/NNS in/IN response/NN to/TO retinoic/JJ acid/NN (/( RA/NN )/) ,/, C/EBPalpha/NN mRNA/NN expression/NN decreased/VBD significantly/RB concomitant/JJ with/IN eosinophilic/JJ and/CC neutrophilic/JJ differentiation/NN ,/, whereas/IN C/EBPbeta/NN expression/NN was/VBD markedly/RB increased/VBN ./. 
Electrophoretic/JJ mobility/NN shift/VB assays/NNS (/( EMSAs/NNS )/) showed/VBD that/IN recombinant/JJ C/EBPbeta/NN protein/NN could/MD bind/VB to/TO the/DT potential/JJ C/EBP-binding/JJ site/NN (/( bp/NN -90/CD to/TO -82/CD )/) in/IN the/DT MBP/NN promoter/NN ./. 
Furthermore/RB ,/, we/PRP have/VBP demonstrated/VBN that/IN both/CC C/EBPbeta/NN and/CC GATA-1/NN can/MD bind/VB simultaneously/RB to/TO the/DT C/EBP-/NN and/CC GATA-binding/JJ sites/NNS in/IN the/DT MBP/NN promoter/NN ./. 
To/TO determine/VB the/DT functionality/NN of/IN both/CC the/DT C/EBP-/NN and/CC GATA-binding/JJ sites/NNS ,/, we/PRP analyzed/VBD whether/IN C/EBPbeta/NN and/CC GATA-1/NN can/MD stimulate/VB the/DT MBP/NN promoter/NN in/IN the/DT C/EBPbeta/NN and/CC GATA-1/NN negative/JJ Jurkat/NN T-cell/NN line/NN ./. 
Cotransfection/NN with/IN C/EBPbeta/NN and/CC GATA-1/NN expression/NN vectors/NNS produced/VBD a/DT 5-fold/JJ increase/NN compared/VBN with/IN cotransfection/NN with/IN the/DT C/EBPbeta/NN or/CC GATA-1/NN expression/NN vectors/NNS individually/RB ./. 
In/IN addition/NN ,/, GST/NN pull-down/JJ experiments/NNS demonstrated/VBD a/DT physical/JJ interaction/NN between/IN human/JJ GATA-1/NN and/CC C/EBPbeta/NN ./. 
Expression/NN of/IN FOG/NN (/( riend/NN ATA/NN )/) ,/, which/WDT binds/VBZ to/TO GATA-1/NN and/CC acts/VBZ as/IN a/DT cofactor/NN for/IN GATA-binding/JJ proteins/NNS ,/, decreased/VBD transactivation/NN activity/NN of/IN GATA-1/NN for/IN the/DT MBP/NN promoter/NN in/IN a/DT dose-dependent/JJ manner/NN ./. 
Our/PRP$ results/NNS provide/VBP the/DT first/JJ evidence/NN that/IN both/CC GATA-1/NN and/CC C/EBPbeta/NN synergistically/RB transactivate/VBP the/DT promoter/NN of/IN an/DT eosinophil-specific/JJ granule/NN protein/NN gene/NN and/CC that/IN FOG/NN may/MD act/VB as/IN a/DT negative/JJ cofactor/NN for/IN the/DT eosinophil/NN lineage/NN ,/, unlike/IN its/PRP$ positively/RB regulatory/JJ function/NN for/IN the/DT erythroid/JJ and/CC megakaryocyte/NN lineages/NNS ./. 
UI/LS -/: 99357809/CD 
TI/LS -/: Tissue-specific/JJ regulation/NN of/IN the/DT ecto-5'-nucleotidase/JJ|NN promoter/NN ./. 
Role/NN of/IN the/DT camp/NN response/NN element/NN site/NN in/IN mediating/VBG repression/NN by/IN the/DT upstream/JJ regulatory/JJ region/NN ./. 
AB/LS -/: We/PRP have/VBP isolated/VBN the/DT 5'/JJ region/NN of/IN the/DT ecto-5'-nucleotidase/JJ (/( low/JJ K/NN (/( m/NN )/) 5'-NT/JJ|NN )/) gene/NN and/CC established/VBD that/IN a/DT 969-base/JJ pair/NN (/( bp/NN )/) fragment/NN confers/VBZ cell-specific/JJ expression/NN of/IN a/DT CAT/NN reporter/NN gene/NN that/WDT correlates/VBZ with/IN the/DT expression/NN of/IN endogenous/JJ ecto-5'-NT/JJ|NN mRNA/NN and/CC enzymatic/JJ activity/NN ./. 
A/DT 768-bp/JJ upstream/JJ negative/JJ regulatory/JJ region/NN has/VBZ been/VBN identified/VBN that/WDT conferred/VBD lymphocyte-specific/JJ negative/JJ regulation/NN in/IN a/DT heterologous/JJ system/NN with/IN a/DT 244-bp/JJ deoxycytidine/NN kinase/NN core/NN promoter/NN ./. 
DNase/NN I/CD footprinting/NN identified/VBD several/JJ protected/JJ areas/NNS including/VBG Sp1/NN ,/, Sp1/AP-2/NN ,/, and/CC cAMP/NN response/NN element/NN (/( CRE/NN )/) binding/NN sites/NNS within/IN the/DT 201-bp/JJ core/NN promoter/NN region/NN and/CC Sp1/NN ,/, NRE-2a/NN ,/, TCF-1/LEF-1/NN ,/, and/CC Sp1/NF-AT/NN binding/NN sites/NNS in/IN the/DT upstream/JJ regulatory/JJ region/NN ./. 
Whereas/IN the/DT CRE/NN site/NN was/VBD essential/JJ in/IN mediating/VBG the/DT negative/JJ activity/NN of/IN the/DT upstream/JJ regulatory/JJ region/NN in/IN Jurkat/NN but/CC not/RB in/IN HeLa/NN cells/NNS ,/, mutation/NN of/IN the/DT Sp1/AP-2/NN site/NN decreased/VBD promoter/NN activity/NN in/IN both/DT cell/NN lines/NNS ./. 
Electrophoretic/JJ mobility/NN shift/NN assay/NN analysis/NN of/IN proteins/NNS binding/VBG to/TO the/DT CRE/NN site/NN identified/VBD both/CC ATF-1/NN and/CC ATF-2/NN in/IN Jurkat/NN cells/NNS ./. 
Finally/RB ,/, phorbol/NN 12-myristate/NN 13-acetate/NN increased/VBD the/DT activity/NN of/IN both/CC the/DT core/NN and/CC the/DT 969-bp/JJ promoter/NN fragments/NNS ,/, and/CC this/DT increase/NN was/VBD abrogated/VBN by/IN mutations/NNS at/IN the/DT CRE/NN site/NN ./. 
In/IN summary/NN ,/, we/PRP have/VBP identified/VBN a/DT tissue-specific/JJ regulatory/JJ region/NN 5'/JJ of/IN the/DT ecto-5'-NT/JJ|NN core/NN promoter/NN that/WDT requires/VBZ the/DT presence/NN of/IN a/DT functional/JJ CRE/NN site/NN within/IN the/DT basal/JJ promoter/NN for/IN its/PRP$ suppressive/JJ activity/NN ./. 
UI/LS -/: 99348033/CD 
TI/LS -/: Extracellular/JJ signal-regulated/JJ protein/NN kinase/NN (/( ERK/NN )/) -dependent/JJ and/CC ERK-independent/JJ pathways/NNS target/VBP STAT3/NN on/IN serine-727/NN in/IN human/JJ neutrophils/NNS stimulated/VBN by/IN chemotactic/JJ factors/NNS and/CC cytokines/NNS ./. 
AB/LS -/: STAT3/NN (/( signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN 3/CD )/) is/VBZ a/DT latent/JJ transcription/NN factor/NN that/WDT is/VBZ activated/VBN by/IN tyrosine/NN phosphorylation/NN (/( Tyr-705/NN )/) in/IN cells/NNS stimulated/VBN with/IN cytokines/NNS or/CC growth/NN factors/NNS ./. 
Recent/JJ studies/NNS suggest/VBP that/IN one/CD or/CC more/JJR cytoplasmic/JJ serine/NN kinases/NNS also/RB phosphorylate/VBP STAT3/NN and/CC are/VBP necessary/JJ for/IN maximal/JJ gene/NN activation/NN ./. 
Here/RB we/PRP demonstrate/VBP ,/, with/IN a/DT site-specific/JJ antibody/NN ,/, that/IN STAT3/NN is/VBZ phosphorylated/VBN on/IN Ser-727/NN in/IN human/JJ neutrophils/NNS stimulated/VBN with/IN chemotactic/JJ factors/NNS (/( N-formyl-methionyl-leucyl-phenylalanine/NN and/CC complement/NN C5a/NN )/) ,/, cytokines/NNS [/( granulocyte/macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) and/CC granulocyte/NN colony-stimulating/JJ factor/NN (/( G-CSF/NN )/) ]/) ,/, or/CC a/DT protein/NN kinase/NN C/NN activator/NN (/( PMA/NN )/) ./. 
(2-Amino-3'-methoxyphenyl)oxanaphthalen-4-one/NN (/( PD/NN 98059/CD )/) ,/, an/DT inhibitor/NN of/IN extracellular/JJ signal-regulated/JJ protein/NN kinase/NN (/( ERK/NN )/) activation/NN ,/, blocked/VBD the/DT serine/JJ phosphorylation/NN of/IN STAT3/NN induced/VBN by/IN chemotactic/JJ factors/NNS or/CC PMA/NN ./. 
The/DT drug/NN was/VBD less/JJR effective/JJ on/IN cytokines/NNS :/: it/PRP virtually/RB abolished/VBD the/DT response/NN to/TO GM-CSF/NN that/WDT occurred/VBD 5/CD min/NN after/IN stimulation/NN but/CC only/RB partly/RB decreased/VBD those/DT at/IN 15-30/CD min/NN and/CC did/VBD not/RB appreciably/RB alter/VB responses/NNS to/TO G-CSF/NN regardless/RB of/IN incubation/NN time/NN ./. 
1-(5-Isoquinolinylsulphonyl)-2-methylpiperazine/NN dihydrochloride/NN (/( H7/NN )/) ,/, an/DT inhibitor/NN of/IN a/DT putative/JJ STAT3/NN serine/NN kinase/NN ,/, and/CC 4-(4-fluorophenyl)-2-(4-methylsulphinylphenyl)-5-(4-pyridyl) 1H-imidazole/NN (/( SB/NN 203580/CD )/) ,/, an/DT inhibitor/NN of/IN p38/NN mitogen-activated/JJ protein/NN (/( MAP/NN )/) kinase/NN ,/, did/VBD not/RB dampen/VB any/DT of/IN these/DT serine/NN phosphorylation/NN responses/NNS ./. 
We/PRP propose/VBP that/IN neutrophils/NNS use/VBP both/CC ERK-dependent/JJ and/CC ERK-independent/JJ pathways/NNS to/TO phosphorylate/VB Ser-727/NN on/IN STAT3/NN ./. 
The/DT former/JJ pathway/NN is/VBZ recruited/VBN by/IN all/DT ERK-activating/JJ stimuli/NNS ,/, whereas/IN the/DT latter/JJ pathway/NN uses/VBZ an/DT undefined/JJ serine/NN kinase/NN and/CC is/VBZ recruited/VBN selectively/RB by/IN cytokines/NNS ./. 
UI/LS -/: 96178227/CD 
TI/LS -/: GATA/NN transcription/NN factors/NNS associate/VBP with/IN a/DT novel/JJ class/NN of/IN nuclear/JJ bodies/NNS in/IN erythroblasts/NNS and/CC megakaryocytes/NNS ./. 
AB/LS -/: The/DT nuclear/JJ distribution/NN of/IN GATA/NN transcription/NN factors/NNS in/IN murine/JJ haemopoietic/JJ cells/NNS was/VBD examined/VBN by/IN indirect/JJ immunofluorescence/NN ./. 
Specific/JJ bright/JJ foci/NNS of/IN GATA-1/NN fluorescence/NN were/VBD observed/VBN in/IN erythroleukaemia/NN cells/NNS and/CC primary/JJ murine/JJ erythroblasts/NNS and/CC megakaryocytes/NNS ,/, in/IN addition/NN to/TO diffuse/VB nucleoplasmic/JJ localization/NN ./. 
These/DT foci/NNS ,/, which/WDT were/VBD preferentially/RB found/VBN adjacent/JJ to/TO nucleoli/JJ or/CC at/IN the/DT nuclear/JJ periphery/NN ,/, did/VBD not/RB represent/VB sites/NNS of/IN active/JJ transcription/NN or/CC binding/NN of/IN GATA-1/NN to/TO consensus/NN sites/NNS in/IN the/DT beta-globin/NN loci/NNS ./. 
Immunoelectron/NN microscopy/NN demonstrated/VBD the/DT presence/NN of/IN intensely/RB labelled/VBN structures/NNS likely/JJ to/TO represent/VB the/DT GATA-1/NN foci/NNS seen/VBN by/IN immunofluorescence/NN ./. 
The/DT GATA-1/NN nuclear/JJ bodies/NNS differed/VBN from/IN previously/RB described/VBN nuclear/JJ structures/NNS and/CC there/EX was/VBD no/DT co-localization/NN with/IN nuclear/JJ antigens/NNS involved/VBN in/IN RNA/NN processing/NN or/CC other/JJ ubiquitous/JJ (/( Spl/NN ,/, c-Jun/NN and/CC TBP/NN )/) or/CC haemopoietic/JJ (/( NF-E2/NN )/) transcription/NN factors/NNS ./. 
Interestingly/RB ,/, GATA-2/NN and/CC GATA-3/NN proteins/NNS also/RB localized/VBD to/TO the/DT same/JJ nuclear/JJ bodies/NNS in/IN cell/NN lines/NNS co-expressing/VBG GATA-1/NN and/CC -2/CD or/CC GATA-1/NN and/CC -3/CD gene/NN products/NNS ./. 
This/DT pattern/NN of/IN distribution/NN is/VBZ ,/, thus/RB far/RB ,/, unique/JJ to/TO the/DT GATA/NN transcription/NN factors/NNS and/CC suggests/VBZ a/DT protein-protein/JJ interaction/NN with/IN other/JJ components/NNS of/IN the/DT nuclear/JJ bodies/NNS via/IN the/DT GATA/NN zinc/NN finger/NN domain/NN ./. 
UI/LS -/: 97126580/CD 
TI/LS -/: Energy/NN substrates/NNS ,/, hormone/NN responses/NNS and/CC glucocorticoid/NN binding/NN in/IN lymphocytes/NNS during/IN intense/JJ physical/JJ exercise/NN in/IN humans/NNS following/VBG phosphocreatine/JJ administration/NN ./. 
AB/LS -/: Eight/CD healthy/JJ untrained/JJ male/JJ volunteers/NNS pedalled/VBD a/DT cycle/NN ergometer/NN according/VBG to/TO two/CD exercise/NN protocols/NNS :/: the/DT first/JJ involved/VBD step-wise/RB increasing/VBG physical/JJ exercise/NN to/TO maximal/JJ (/( MPE/NN )/) ;/: the/DT second/JJ involved/VBD prolonged/JJ (/( 35/CD min/NN )/) submaximal/JJ physical/JJ exercise/NN (/( PPE/NN )/) at/IN 70/CD %/NN of/IN the/DT individual/NN 's/POS maximal/JJ oxygen/NN uptake/NN ./. 
Each/DT volunteer/NN performed/VBD these/DT exercise/NN twice/RB ,/, following/VBG either/CC an/DT intravenous/JJ injection/NN of/IN phosphocreatine/JJ (/( PCr/NN )/) or/CC a/DT placebo/NN of/IN an/DT isotonic/JJ NaCl/NN solution/NN ./. 
Anaerobic/JJ threshold/NN (/( AT/NN )/) was/VBD determined/VBN from/IN the/DT point/NN of/IN departure/NN of/IN the/DT ventilatory/JJ response/NN from/IN linearity/NN and/CC from/IN the/DT sudden/JJ increase/NN in/IN venous/JJ blood/NN lactate/NN concentrations/NNS during/IN MPE/NN ./. 
After/IN exercise/NN following/VBG placebo/NN administration/NN we/PRP observed/VBD increases/NNS in/IN concentrations/NNS of/IN blood/NN substrates/NNS ,/, plasma/NN adrenocorticotropin/NN (/( ACTH/NN )/) ,/, growth/NN hormone/NN and/CC cortisol/NN and/CC in/IN the/DT number/NN of/IN glucocorticoid/NN receptors/NNS in/IN lymphocytes/NNS without/IN changes/NNS in/IN the/DT dissociation/NN constant/NN ./. 
Intravenous/JJ administration/NN of/IN PCr/NN (/( starting/VBG 1/CD day/NN before/IN exercise/NN )/) led/VBD to/TO an/DT increase/NN in/IN the/DT total/JJ workload/NN (/( on/IN average/NN by/IN 5.8/CD %/NN )/) and/CC in/IN AT/NN (/( on/IN average/NN by/IN 6.8/CD %/NN )/) during/IN MPE/NN and/CC to/TO a/DT better/JJR tolerance/NN of/IN exercise/NN during/IN PPE/NN ./. 
Following/VBG PCr/NN administration/NN we/PRP observed/VBD lower/JJR blood/NN lactate/NN concentrations/NNS and/CC different/JJ patterns/NNS of/IN some/DT enzyme/NN activities/NNS ,/, less/RBR pronounced/JJ changes/NNS in/IN plasma/NN ACTH/NN and/CC cortisol/NN concentrations/NNS and/CC in/IN glucocorticoid/NN binding/NN in/IN lymphocytes/NNS ,/, but/CC no/DT changes/NNS in/IN plasma/NN growth/NN hormone/NN concentrations/NNS compared/VBN to/TO the/DT placebo/NN ./. 
The/DT results/NNS showed/VBD that/IN intense/JJ physical/JJ exercise/NN led/VBD not/RB only/RB to/TO increases/NNS in/IN blood/NN hormone/NN concentrations/NNS but/CC also/RB to/TO an/DT increase/NN in/IN the/DT density/NN of/IN glucocorticoid/NN receptors/NNS in/IN lymphocytes/NNS ./. 
Intravenous/JJ PCr/NN injection/NN led/VBD to/TO smaller/JJR changes/NNS in/IN ACTH/NN and/CC cortisol/NN concentrations/NNS as/RB well/RB as/IN to/TO a/DT lower/JJR activation/NN of/IN glucocorticoid/NN binding/NN in/IN lymphocytes/NNS ./. 
UI/LS -/: 96209427/CD 
TI/LS -/: Putative/JJ steroid/NN binding/NN domain/NN of/IN the/DT human/JJ mineralocorticoid/NN receptor/NN ,/, expressed/VBN in/IN E./FW coli/FW in/IN the/DT presence/NN of/IN heat/NN shock/NN proteins/NNS shows/VBZ typical/JJ native/JJ receptor/NN characteristics/NNS ./. 
AB/LS -/: Domain/NN E/NN ,/, considered/VBN as/IN the/DT putative/JJ hormone/NN binding/NN domain/NN (/( HBD/NN )/) of/IN the/DT human/JJ mineralocorticoid/NN receptor/NN (/( hMR/NN )/) was/VBD expressed/VBN in/IN Escherichia/FW coli/FW as/IN a/DT fusion/NN protein/NN with/IN either/CC maltose/NN binding/NN protein/NN (/( MBP/NN )/) or/CC glutathione/NN S-transferase/NN (/( GST/NN )/) ./. 
These/DT bacterially-produced/JJ MR/NN constructs/NNS had/VBD no/DT steroid/NN binding/NN activity/NN per/FW se/FW ./. 
In/IN fact/NN ,/, heat/NN shock/NN protein/NN association/NN (/( hsp/NN )/) is/VBZ required/VBN for/IN high/JJ affinity/NN ligand-binding/NN of/IN the/DT MR/NN ./. 
After/IN incubation/NN of/IN purified/VBN MBP-/NN or/CC GST-HBD/NN with/IN rabbit/NN reticulocyte/NN lysate/NN ,/, known/VBN to/TO be/VB rich/JJ in/IN heat/NN shock/NN proteins/NNS ,/, we/PRP obtained/VBD saturable/JJ binding/NN of/IN [3H]aldosterone/NN ./. 
The/DT Kd/NN value/NN for/IN aldosterone/NN was/VBD 0.3/CD nM/NN and/CC the/DT Bmax/NN =/VBD 32/CD pmol/mg/NN ./. 
Hormone/NN binding/NN specificity/NN was/VBD assessed/VBN by/IN competition/NN studies/NNS with/IN various/JJ steroid/NN ligands/NNS ./. 
Sucrose/NN gradient/NN assays/NNS performed/VBN with/IN [3H]aldosterone-MBP-HBD/NN revealed/VBD complex/NN sedimenting/VBG at/IN 8.3S/NN and/CC 4.9S/NN with/IN [3H]progesterone-MBP-HBD/NN ./. 
Western-blot/JJ analysis/NN of/IN the/DT sedimentation/NN peak/NN showed/VBD the/DT concomitant/JJ presence/NN of/IN MBP-HBD/NN by/IN a/DT monoclonal/JJ anti-MBP/JJ antibody/NN ,/, and/CC hsp90/NN by/IN a/DT monoclonal/JJ anti-hsp/JJ antibody/NN ./. 
Moreover/RB ,/, following/VBG incubation/NN with/IN the/DT anti-rabbit/JJ hsp90/NN monoclonal/JJ antibody/NN the/DT sedimenting/NN gradient/NN showed/VBD a/DT 10.4S/NN sedimenting/NN complex/NN ./. 
These/DT analyses/NNS demonstrated/VBD that/IN the/DT [3H]aldosterone/NN -MBP-HBD/NN complex/NN is/VBZ at/IN least/JJS associated/VBN with/IN hsp90/NN in/IN reticulocyte/NN lysate/NN and/CC that/IN the/DT HBD/NN of/IN hMR/NN is/VBZ sufficient/JJ to/TO bind/VB hsp90/NN ./. 
Deletions/NNS of/IN a/DT relatively/RB short/JJ amino-/NN (/( 729-766/CD )/) or/CC carboxy-terminal/JJ (/( 940-984/CD )/) region/NN of/IN the/DT HBD/NN fragment/NN eliminated/VBD all/DT steroid-binding/JJ properties/NNS ./. 
Overall/RB ,/, these/DT results/NNS indicate/VBP that/IN the/DT integrity/NN of/IN domain/NN E/NN is/VBZ necessary/JJ and/CC sufficient/JJ to/TO bind/VB steroid/NN ligands/NNS ,/, agonists/NNS or/CC antagonists/NNS ,/, with/IN characteristics/NNS similar/JJ to/TO the/DT entire/JJ native/JJ MR/NN ./. 
UI/LS -/: 99423690/CD 
TI/LS -/: Renal/JJ cell/NN carcinoma-derived/JJ gangliosides/NNS suppress/VBP nuclear/JJ factor-kappaB/NN activation/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Activation/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor-kappaB/NN (/( NFkappaB/NN )/) is/VBZ impaired/JJ in/IN T/NN cells/NNS from/IN patients/NNS with/IN renal/JJ cell/NN carcinomas/NNS (/( RCCs/NNS )/) ./. 
In/IN circulating/VBG T/NN cells/NNS from/IN a/DT subset/NN of/IN patients/NNS with/IN RCCs/NNS ,/, the/DT suppression/NN of/IN NFkappaB/NN binding/NN activity/NN is/VBZ downstream/JJ from/IN the/DT stimulus-induced/JJ degradation/NN of/IN the/DT cytoplasmic/JJ factor/NN IkappaBalpha/NN ./. 
Tumor-derived/JJ soluble/JJ products/NNS from/IN cultured/VBN RCC/NN explants/NNS inhibit/VBP NFkappaB/NN activity/NN in/IN T/NN cells/NNS from/IN healthy/JJ volunteers/NNS ,/, despite/IN a/DT normal/JJ level/NN of/IN stimulus-induced/JJ IkappaBalpha/NN degradation/NN in/IN these/DT cells/NNS ./. 
The/DT inhibitory/JJ agent/NN has/VBZ several/JJ features/NNS characteristic/JJ of/IN a/DT ganglioside/NN ,/, including/VBG sensitivity/NN to/TO neuraminidase/NN but/CC not/RB protease/NN treatment/NN ;/: hydrophobicity/NN ;/: and/CC molecular/JJ weight/NN less/JJR than/IN 3/CD kDa/NN ./. 
Indeed/RB ,/, we/PRP detected/VBD gangliosides/NNS in/IN supernatants/NNS from/IN RCC/NN explants/NNS and/CC not/RB from/IN adjacent/JJ normal/JJ kidney/NN tissue/NN ./. 
Gangliosides/NNS prepared/VBN from/IN RCC/NN supernatants/NNS ,/, as/RB well/RB as/IN the/DT purified/VBN bovine/NN gangliosides/NNS G/NN (/( m1/NN )/) and/CC G/NN (/( d1a/NN )/) ,/, suppressed/VBD NFkappaB/NN binding/NN activity/NN in/IN T/NN cells/NNS and/CC reduced/VBD expression/NN of/IN the/DT cytokines/NNS IL-2/NN and/CC IFN-gamma/NN ./. 
Taken/VBN together/RB ,/, our/PRP$ findings/NNS suggest/VBP that/IN tumor-derived/JJ gangliosides/NNS may/MD blunt/VB antitumor/JJ immune/JJ responses/NNS in/IN patients/NNS with/IN RCCs/NNS ./. 
UI/LS -/: 99408727/CD 
TI/LS -/: Nuclear/JJ factor-kappaB-dependent/JJ induction/NN of/IN interleukin-8/NN gene/NN expression/NN by/IN tumor/NN necrosis/NN factor/NN alpha/NN :/: evidence/NN for/IN an/DT antioxidant/JJ sensitive/JJ activating/NN pathway/NN distinct/JJ from/IN nuclear/JJ translocation/NN ./. 
AB/LS -/: Tumor/NN necrosis/NN factor/NN alpha/NN (/( TNFalpha/NN )/) is/VBZ a/DT pluripotent/JJ activator/NN of/IN inflammation/NN by/IN inducing/VBG a/DT proinflammatory/JJ cytokine/NN cascade/NN ./. 
This/DT phenomenon/NN is/VBZ mediated/VBN ,/, in/IN part/NN ,/, through/IN inducible/JJ expression/NN of/IN the/DT CXC/NN chemokine/NN ,/, interleukin-8/NN (/( IL-8/NN )/) ./. 
In/IN this/DT study/NN ,/, we/PRP investigate/VBP the/DT role/NN of/IN TNFalpha-inducible/JJ reactive/JJ oxygen/NN species/NNS (/( ROS/NN )/) in/IN IL-8/NN expression/NN by/IN "/`` monocyte-like/JJ "/'' U937/NN histiocytic/JJ lymphoma/NN cells/NNS ./. 
TNFalpha/NN is/VBZ a/DT rapid/JJ activator/NN of/IN IL-8/NN gene/NN expression/NN by/IN U937/NN ,/, producing/VBG a/DT 50-fold/JJ induction/NN of/IN mRNA/NN within/IN 1/CD hour/NN of/IN treatment/NN ./. 
In/IN gene/NN transfection/NN assays/NNS ,/, the/DT effect/NN of/IN TNFalpha/NN requires/VBZ the/DT presence/NN of/IN an/DT inducible/JJ nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) (/( Rel/NN A/NN )/) binding/NN site/NN in/IN the/DT IL-8/NN promoter/NN ./. 
TNFalpha/NN treatment/NN induces/VBZ a/DT rapid/JJ translocation/NN of/IN the/DT 65/CD kD/NN transcriptional/JJ activator/NN NF-kappaB/NN subunit/NN ,/, Rel/NN A/NN ,/, whose/WP$ binding/NN in/IN the/DT nucleus/NN occurs/VBZ before/IN changes/NNS in/IN intracellular/JJ ROS/NN ./. 
Pretreatment/NN (/( or/CC up/IN to/TO 15/CD minutes/NNS posttreatment/NN )/) relative/JJ to/TO TNFalpha/NN with/IN the/DT antioxidant/JJ dimethyl/NN sulfoxide/NN (/( DMSO/NN )/) (/( 2/CD %/NN [/( vol/vol/NN ]/) )/) blocks/VBZ 80/CD %/NN of/IN NF-kappaB-dependent/JJ transcription/NN ./. 
Surprisingly/RB ,/, however/RB ,/, DMSO/NN has/VBZ no/DT effect/NN on/IN inducible/JJ Rel/NN A/NN binding/NN ./. 
Similar/JJ selective/JJ effects/NNS on/IN NF-kappaB/NN transcription/NN are/VBP seen/VBN with/IN the/DT unrelated/JJ antioxidants/NNS ,/, N-acetylcysteine/NN (/( NAC/NN )/) and/CC vitamin/NN C/NN ./. 
These/DT data/NNS indicate/VBP that/IN TNFalpha/NN induces/VBZ a/DT delayed/VBN ROS-dependent/JJ signalling/NN pathway/NN that/WDT is/VBZ required/VBN for/IN NF-kappaB/NN transcriptional/JJ activation/NN and/CC is/VBZ separable/JJ from/IN that/DT required/VBN for/IN its/PRP$ nuclear/JJ translocation/NN ./. 
Further/RB definition/NN of/IN this/DT pathway/NN will/MD yield/VB new/JJ insights/NNS into/IN inflammation/NN initiated/VBN by/IN TNFalpha/NN signalling/NN ./. 
UI/LS -/: 99394774/CD 
TI/LS -/: Gender/NN and/CC vascular/JJ reactivity/NN ./. 
AB/LS -/: Estrogen/NN receptors/NNS are/VBP found/VBN on/IN vascular/JJ endothelial/JJ and/CC smooth/VB muscle/NN cells/NNS ;/: their/PRP$ expression/NN is/VBZ influenced/VBN by/IN exposure/NN to/TO the/DT hormone/NN ./. 
Estrogen/NN receptors/NNS influence/VBP non-genomic/JJ events/NNS ,/, which/WDT are/VBP rapid/JJ in/IN onset/NN and/CC genomic/JJ events/NNS ,/, which/WDT are/VBP longer/RBR acting/NN responses/NNS ./. 
Estrogens/NNS affect/VBP vascular/JJ tone/NN indirectly/RB by/IN modulating/VBG release/NN of/IN endothelium-derived/JJ vasoactive/JJ factors/NNS and/CC directly/RB by/IN modulating/VBG intracellular/JJ calcium/NN in/IN vascular/JJ smooth/NN muscle/NN cells/NNS ./. 
Estrogens/NNS indirectly/RB affect/VBP thrombotic/JJ events/NNS and/CC inflammation/NN by/IN altering/VBG platelet/NN aggregation/NN and/CC leukocyte/NN adherence/NN and/CC migration/NN ,/, respectively/RB ./. 
Estrogens/NNS also/RB influence/VBP production/NN of/IN mitogens/NNS which/WDT ,/, when/WRB released/VBN at/IN sites/NNS of/IN vascular/JJ injury/NN ,/, affect/VBP vascular/JJ remodeling/NN ./. 
Although/IN estrogens/NNS initiate/VBP vascular/JJ responses/NNS ,/, genomic/JJ sex/NN may/MD influence/VB and/or/CC limit/VB expression/NN of/IN estrogen/NN receptors/NNS and/CC therefore/RB actions/NNS of/IN sex/NN steroid/NN hormones/NNS throughout/IN the/DT vasculature/NN ./. 
UI/LS -/: 99374665/CD 
TI/LS -/: Induction/NN of/IN a/DT functional/JJ vitamin/NN D/NN receptor/NN in/IN all-trans-retinoic/JJ acid-induced/JJ monocytic/JJ differentiation/NN of/IN M2-type/JJ leukemic/JJ blast/NN cells/NNS ./. 
AB/LS -/: Different/JJ types/NNS of/IN acute/JJ myeloid/JJ leukemia/NN blast/NN cells/NNS were/VBD induced/VBN to/TO differentiate/VB in/FW vitro/FW with/IN all-trans-retinoic/JJ acid/NN (/( ATRA/NN )/) and/CC vitamin/NN D3/NN (/( VD/NN )/) ./. 
M0/M1/NN leukemic/JJ cells/NNS are/VBP not/RB sensitive/JJ to/TO differentiating/VBG agents/NNS ,/, whereas/IN M3/NN leukemic/JJ cells/NNS are/VBP induced/VBN to/TO undergo/VB granulocytic/JJ differentiation/NN after/IN ATRA/NN treatment/NN but/CC are/VBP not/RB sensitive/JJ to/TO VD/NN ./. 
M2/NN leukemic/JJ blast/NN cells/NNS behave/VBP differently/RB because/IN they/PRP undergo/VBP monocytic/JJ differentiation/NN with/IN both/DT the/DT differentiation/NN inducers/NNS ./. 
To/TO gain/VB some/DT insight/NN into/IN the/DT maturation/NN of/IN M2-type/JJ leukemic/JJ cells/NNS ,/, we/PRP studied/VBD the/DT molecular/JJ mechanisms/NNS underlying/VBG monocytic/JJ differentiation/NN induced/VBN by/IN ATRA/NN and/CC VD/NN in/IN spontaneous/JJ M2/NN blast/NN cells/NNS as/RB well/RB as/IN in/IN Kasumi-1/NN cells/NNS (/( an/DT acute/JJ myeloid/JJ leukemia/NN M2-type/JJ cell/NN line/NN )/) ./. 
Our/PRP$ results/NNS indicate/VBP that/IN ATRA/NN as/RB well/RB as/IN VD/NN efficiently/RB increases/VBZ the/DT nuclear/JJ abundance/NN of/IN VD/NN receptor/NN (/( VDR/NN )/) and/CC promotes/VBZ monocytic/JJ differentiation/NN ./. 
VDR/NN is/VBZ functionally/RB active/JJ in/IN ATRA-treated/JJ Kasumi-1/NN cells/NNS because/IN it/PRP efficiently/RB heterodimerizes/VBZ with/IN retinoid/NN X/NN receptor/NN ,/, binds/VBZ to/TO a/DT DR3-type/JJ vitamin/NN D-responsive/JJ element/NN ,/, and/CC activates/VBZ the/DT transcription/NN of/IN a/DT vitamin/NN D-responsive/JJ element-regulated/JJ reporter/NN gene/NN ./. 
Consistent/JJ with/IN these/DT findings/NNS ,/, VD-responsive/JJ genes/NNS are/VBP induced/VBN by/IN ATRA/NN treatment/NN of/IN Kasumi-1/NN cells/NNS ,/, suggesting/VBG that/IN the/DT genetic/JJ program/NN underlying/VBG monocytic/JJ differentiation/NN is/VBZ activated/VBN ./. 
The/DT molecular/JJ mechanism/NN by/IN which/WDT ATRA/NN increases/VBZ the/DT nuclear/JJ abundance/NN of/IN a/DT functional/JJ VDR/NN is/VBZ still/RB unknown/JJ ,/, but/CC our/PRP$ data/NNS clearly/RB indicate/VBP that/IN the/DT M2/NN leukemic/JJ cell/NN context/NN is/VBZ only/RB permissive/JJ of/IN monocytic/JJ differentiation/NN ./. 
UI/LS -/: 99367411/CD 
TI/LS -/: Protein/NN kinase/NN C/NN and/CC calcineurin/NN synergize/VBP to/TO activate/VB IkappaB/NN kinase/NN and/CC NF-kappaB/NN in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT nuclear/JJ factor/NN of/IN kappaB/NN (/( NF-kappaB/NN )/) is/VBZ a/DT ubiquitous/JJ transcription/NN factor/NN that/WDT is/VBZ key/JJ in/IN the/DT regulation/NN of/IN the/DT immune/JJ response/NN and/CC inflammation/NN ./. 
T/NN cell/NN receptor/NN (/( TCR/NN )/) cross-linking/NN is/VBZ in/IN part/NN required/VBN for/IN activation/NN of/IN NF-kappaB/NN ,/, which/WDT is/VBZ dependent/JJ on/IN the/DT phosphorylation/NN and/CC degradation/NN of/IN IkappaBalpha/NN ./. 
By/IN using/VBG Jurkat/NN and/CC primary/JJ human/JJ T/NN lymphocytes/NNS ,/, we/PRP demonstrate/VBP that/IN the/DT simultaneous/JJ activation/NN of/IN two/CD second/JJ messengers/NNS of/IN the/DT TCR-initiated/JJ signal/NN transduction/NN ,/, protein/NN kinase/NN C/NN (/( PKC/NN )/) and/CC calcineurin/NN ,/, results/VBZ in/IN the/DT synergistic/JJ activation/NN of/IN the/DT IkappaBalpha/NN kinase/NN (/( IKK/NN )/) complex/NN but/CC not/RB of/IN another/DT putative/JJ IkappaBalpha/NN kinase/NN ,/, p90/NN (/( rsk/NN )/) ./. 
We/PRP also/RB demonstrate/VBP that/IN the/DT IKK/NN complex/NN ,/, but/CC not/RB p90/NN (/( rsk/NN )/) ,/, is/VBZ responsible/JJ for/IN the/DT in/FW vivo/FW phosphorylation/NN of/IN IkappaBalpha/NN mediated/VBN by/IN the/DT co-activation/NN of/IN PKC/NN and/CC calcineurin/NN ./. 
Each/DT second/JJ messenger/NN is/VBZ necessary/JJ ,/, as/IN inhibition/NN of/IN either/DT one/CD reverses/VBZ the/DT activation/NN of/IN the/DT IKK/NN complex/NN and/CC IkappaBalpha/NN phosphorylation/NN in/FW vivo/FW ./. 
Overexpression/NN of/IN dominant/JJ negative/JJ forms/NNS of/IN IKKalpha/NN and/CC -beta/NN demonstrates/VBZ that/IN only/JJ IKKbeta/NN is/VBZ the/DT target/NN for/IN PKC/NN and/CC calcineurin/NN ./. 
These/DT results/NNS indicate/VBP that/IN within/IN the/DT TCR/CD3/NN signal/NN transduction/NN pathway/NN both/CC PKC/NN and/CC calcineurin/NN are/VBP required/VBN for/IN the/DT effective/JJ activation/NN of/IN the/DT IKK/NN complex/NN and/CC NF-kappaB/NN in/IN T/NN lymphocytes/NNS ./. 
UI/LS -/: 99354925/CD 
TI/LS -/: Diminished/VBN responses/NNS to/TO IL-13/NN by/IN human/JJ monocytes/NNS differentiated/VBN in/FW vitro/FW :/: role/NN of/IN the/DT IL-13Ralpha1/NN chain/NN and/CC STAT6/NN ./. 
AB/LS -/: The/DT primary/JJ IL-13/NN receptor/NN complex/NN on/IN human/JJ monocytes/NNS is/VBZ believed/VBN to/TO be/VB a/DT heterodimer/NN comprised/VBN of/IN the/DT IL-4R/NN alpha/NN chain/NN and/CC the/DT IL-2R/NN gamma/NN chain/NN (/( gamma(c)/NN )/) -like/JJ molecule/NN ,/, IL-13R/NN alpha1/NN ./. 
mRNA/NN levels/NNS for/IN IL-13R/NN alpha1/NN ,/, but/CC not/RB IL-4R/NN alpha/NN ,/, were/VBD markedly/RB decreased/VBN in/IN in/FW vitro/FW monocyte-derived/JJ macrophages/NNS (/( MDMac/NN )/) ,/, and/CC with/IN increasing/VBG time/NN of/IN monocytes/NNS in/IN culture/NN correlated/VBN with/IN the/DT loss/NN of/IN IL-13/NN regulation/NN of/IN lipopolysaccharide-induced/JJ TNF-alpha/NN production/NN ./. 
Analysis/NN of/IN cell/NN lines/NNS Daudi/NN and/CC THP-1/NN that/WDT differentially/RB express/VBP gamma(c)/NN and/CC IL-13R/NN alpha1/NN showed/VBD that/IN IL-13/NN can/MD activate/VB STAT6/NN in/IN IL-13R/NN alpha1-positive/JJ THP-1/NN cells/NNS but/CC not/RB in/IN gamma(c)-positive/JJ ,/, IL-13R/NN alpha1-negative/JJ Daudi/NN cells/NNS ./. 
IL-13/NN activation/NN of/IN STAT6/NN was/VBD reduced/VBN in/IN MDMac/NN which/WDT was/VBD associated/VBN with/IN diminished/VBN IL-13-induced/JJ expression/NN of/IN CD23/NN and/CC MHC/NN class/NN II/CD ./. 
However/RB ,/, with/IN reduced/VBN IL-13R/NN alpha1/NN expression/NN and/CC low/JJ nuclear/JJ STAT6/NN activity/NN ,/, some/DT IL-13-induced/JJ responses/NNS were/VBD unaltered/JJ in/IN magnitude/NN in/IN MDMac/NN ./. 
In/IN the/DT absence/NN of/IN functional/JJ IL-13R/NN alpha1/NN and/CC gamma(c)/NN ,/, IL-13/NN must/MD signal/VB through/IN an/DT alternative/JJ receptor/NN complex/NN on/IN MDMac/NN ./. 
Experiments/NNS with/IN a/DT blocking/VBG antibody/NN to/TO IL-4R/NN alpha/NN showed/VBD that/IN this/DT chain/NN remains/VBZ an/DT essential/JJ component/NN of/IN the/DT IL-13/NN receptor/NN complex/NN on/IN MDMac/NN ./. 
UI/LS -/: 99343400/CD 
TI/LS -/: The/DT p53/NN paradox/NN in/IN the/DT pathogenesis/NN of/IN tumor/NN progression/NN ./. 
AB/LS -/: Recent/JJ evidence/NN suggests/VBZ that/IN the/DT p53/NN molecule/NN appears/VBZ in/IN two/CD different/JJ forms/NNS :/: the/DT mutant/JJ p53/NN that/WDT stimulates/VBZ tumor/NN progression/NN ,/, and/CC wild/JJ type/NN p53/NN that/WDT inhibits/VBZ tumor/NN progression/NN ./. 
In/IN addition/NN ,/, it/PRP has/VBZ been/VBN established/VBN that/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) can/MD activate/VB the/DT expression/NN of/IN wild/JJ type/NN p53/NN in/IN concert/NN with/IN the/DT nuclear/JJ transcription/NN factor/NN ,/, NF-kappa/NN B/NN ./. 
Both/CC TNF-alpha/NN and/CC NF-kappa/NN B/NN are/VBP also/RB involved/VBN in/IN the/DT stimulation/NN of/IN the/DT pathway/NN that/WDT leads/VBZ to/TO the/DT expression/NN of/IN major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN I/CD molecules/NNS and/CC ,/, hence/RB ,/, antigen/NN presentation/NN to/TO the/DT T/NN cells/NNS ./. 
In/IN this/DT paper/NN we/PRP shall/MD advance/VB the/DT hypothesis/NN that/IN :/: (/( i/LS )/) TNF-alpha/NN indirectly/RB controls/VBZ immune/JJ surveillance/NN ;/: and/CC (/( ii/LS )/) TNF-alpha/NN controls/VBZ DNA/NN repair/NN and/CC tumor/NN suppression/NN through/IN the/DT regulation/NN of/IN wild/JJ type/NN p53/NN ./. 
Thus/RB ,/, it/PRP is/VBZ hypothesized/VBN that/IN elevated/JJ TNF-alpha/NN is/VBZ primarily/RB responsible/JJ for/IN promoting/VBG tumor/NN progression/NN ./. 
UI/LS -/: 96141087/CD 
TI/LS -/: The/DT promoter/NN and/CC 5'/JJ flanking/JJ sequences/NNS controlling/VBG human/JJ B29/NN gene/NN expression/NN ./. 
AB/LS -/: The/DT product/NN of/IN the/DT B-cell-specific/JJ B29/NN gene/NN (/( B29/NN ,/, Ig/NN beta/NN ,/, CD79b/NN )/) is/VBZ essential/JJ for/IN Ig-mediated/JJ B-cell/NN activation/NN via/IN the/DT B-cell/NN antigen/NN receptor/NN complex/NN (/( BCR/NN )/) on/IN human/JJ and/CC murine/JJ B/NN lymphocytes/NNS ./. 
To/TO better/RBR understand/VB the/DT regulation/NN of/IN this/DT pivotal/JJ gene/NN ,/, we/PRP have/VBP analyzed/VBN the/DT human/JJ genomic/JJ DNA/NN sequence/NN upstream/RB of/IN the/DT B29/NN ATG/NN start/VBP codon/NN for/IN transcriptional/JJ control/NN activity/NN ./. 
The/DT human/JJ B29/NN gene/NN lacks/VBZ either/CC a/DT TATA/NN or/CC a/DT CAAT/NN box/NN and/CC transcription/NN is/VBZ initiated/VBN at/IN multiple/JJ sites/NNS ./. 
The/DT minimal/JJ promoter/NN of/IN the/DT human/JJ B29/NN gene/NN is/VBZ contained/VBN within/IN a/DT 193-bp/JJ region/NN 5'/JJ of/IN these/DT multiple/JJ start/NN sites/NNS ./. 
This/DT minimal/JJ promoter/NN exhibits/VBZ B-cell-specific/JJ activity/NN and/CC contains/VBZ SP1/NN ,/, ETS/NN ,/, OCT/NN ,/, and/CC IKAROS/LYF-1/NN transcription/NN factor/NN motifs/NNS ./. 
All/DT these/DT motifs/NNS are/VBP strikingly/RB conserved/VBN in/IN sequence/NN and/CC placement/NN relative/JJ to/TO the/DT previously/RB characterized/VBN murine/JJ B29/NN promoter/NN ./. 
Additional/JJ upstream/JJ gene/NN segments/NNS dramatically/RB affected/VBD B29/NN minimal/JJ promoter/NN activity/NN ./. 
A/DT newly/RB identified/VBN motif/NN called/VBN the/DT B29/NN conserved/VBN sequence/NN (/( BCS/NN )/) ,/, found/VBN upstream/RB of/IN both/CC human/JJ and/CC murine/JJ B29/NN promoters/NNS ,/, appears/VBZ to/TO stimulate/VB B29/NN transcription/NN through/IN a/DT novel/JJ mechanism/NN ./. 
A/DT single/JJ BCS/NN had/VBD little/JJ effect/NN either/CC on/IN the/DT minimal/JJ B29/NN promoter/NN or/CC on/IN a/DT heterologous/JJ promoter/NN ./. 
Instead/RB ,/, the/DT BCS/NN stimulated/VBD transcription/NN by/IN counteracting/VBG 5'/JJ negative/JJ regulatory/JJ DNA/NN sequences/NNS that/WDT block/VBP the/DT activity/NN of/IN the/DT B29/NN minimal/JJ promoter/NN in/IN its/PRP$ absence/NN ./. 
These/DT findings/NNS indicate/VBP that/IN B29/NN gene/NN expression/NN is/VBZ controlled/VBN by/IN the/DT complex/JJ interplay/NN of/IN positive/JJ and/CC negative/JJ regulatory/JJ elements/NNS ./. 
UI/LS -/: 97119542/CD 
TI/LS -/: A/DT novel/JJ immunosuppressive/JJ factor/NN in/IN bovine/JJ colostrum/NN blocks/VBZ activation/NN of/IN the/DT interleukin/NN 2/CD gene/NN enhancer/NN at/IN the/DT NFAT/NN site/NN ./. 
AB/LS -/: A/DT factor/NN in/IN bovine/JJ colostrum/NN (/( colostrum/NN inhibitory/JJ factor/NN ,/, CIF/NN )/) inhibits/VBZ interleukin/NN 2/CD (/( IL2/NN )/) production/NN in/IN activated/JJ T/NN helper/NN cells/NNS by/IN blocking/VBG the/DT accumulation/NN of/IN IL2/NN mRNA/NN ./. 
To/TO determine/VB whether/IN CIF/NN blocks/VBZ at/IN the/DT level/NN of/IN IL2/NN transcription/NN ,/, we/PRP introduced/VBD reporter/NN plasmids/NNS into/IN the/DT human/JJ T/NN leukemia/NN cell/NN line/NN Jurkat/NN by/IN transient/JJ transfection/NN ./. 
These/DT contained/VBD the/DT luciferase/NN gene/NN under/IN the/DT control/NN of/IN either/CC the/DT human/JJ IL2/NN upstream/JJ enhancer/NN region/NN (/( segments/NNS -326/CD to/TO +45/CD )/) or/CC three/CD repeats/NNS of/IN the/DT NFAT/NN element/NN contained/VBN within/IN it/PRP (/( segments/NNS -255/CD to/TO -285/CD )/) ./. 
Expression/NN of/IN luciferase/NN in/IN these/DT cells/NNS was/VBD induced/VBN by/IN phorbol/NN myristate/NN acetate/NN plus/CC a/DT calcium/NN ionophore/NN ./. 
CIF/NN inhibited/VBD induction/NN of/IN either/DT construct/NN as/IN did/VBD cyclosporine/NN ,/, which/WDT is/VBZ known/VBN to/TO block/VB activation/NN of/IN the/DT NFAT/NN element/NN ./. 
CIF/NN failed/VBD to/TO inhibit/VB several/JJ other/JJ enhancer/NN elements/NNS ./. 
The/DT NFAT-controlled/JJ luciferase/NN gene/NN system/NN distinguishes/VBZ CIF/NN from/IN other/JJ T/NN cell/NN inhibitory/JJ activities/NNS present/JJ in/IN colostrum/NN ,/, in/IN particular/JJ ,/, TGF/NN beta/NN 1/CD and/CC TGF/NN beta/NN 2/CD and/CC the/DT glucocorticoids/NNS ./. 
Stably/RB transfected/VBN Jurkat/NN cells/NNS behaved/VBD similarly/RB to/TO the/DT transiently/RB transfected/VBN ones/NNS with/IN respect/NN to/TO inhibition/NN by/IN CIF/NN and/CC cyclosporine/NN ./. 
The/DT NFAT-luc/JJ|NN assay/NN is/VBZ a/DT useful/JJ technique/NN for/IN the/DT rapid/JJ ,/, sensitive/JJ measurement/NN of/IN CIF/NN or/CC other/JJ immunosuppressants/NNS with/IN a/DT similar/JJ mode/NN of/IN action/NN ./. 
UI/LS -/: 96215633/CD 
TI/LS -/: Heat/NN shock/NN induces/VBZ HIV-1/NN replication/NN in/IN chronically/RB infected/JJ promyelocyte/JJ cell/NN line/NN OM10.1/NN ./. 
AB/LS -/: A/DT long/JJ period/NN of/IN clinical/JJ latency/NN before/IN development/NN of/IN symptoms/NNS is/VBZ characteristic/JJ of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) infection/NN ./. 
OM10.1/NN ,/, a/DT promyelocyte/JJ cell/NN line/NN latently/RB infected/VBN with/IN HIV-1/NN ,/, has/VBZ been/VBN developed/VBN as/IN a/DT model/NN for/IN studying/VBG the/DT mechanism/NN of/IN viral/JJ latency/NN and/CC the/DT activation/NN of/IN virus/NN expression/NN ./. 
We/PRP found/VBD that/IN this/DT latently/RB infected/JJ cell/NN line/NN with/IN heat/NN shock/NN at/IN 42/CD degrees/NNS C/NN for/IN 2/CD h/NN resulted/VBD in/IN a/DT high/JJ level/NN of/IN HIV-1/NN production/NN without/IN addition/NN of/IN any/DT cytokines/NNS ./. 
The/DT mechanism/NN of/IN activation/NN was/VBD analyzed/VBN by/IN using/VBG anti-TNF-alpha/JJ antibody/NN and/CC various/JJ inhibitors/NNS ./. 
Although/IN the/DT TNF-alpha/NN level/NN in/IN culture/NN supernatants/NNS was/VBD below/IN the/DT sensitivity/NN of/IN an/DT ELISA/NN assay/NN system/NN ,/, addition/NN of/IN anti-TNF-alpha/JJ antibody/NN in/IN culture/NN medium/NN could/MD partially/RB suppress/VB the/DT heat/NN shock/NN induced/JJ HIV-1/NN production/NN ./. 
Staurosporine/NN (/( PKC/NN inhibitor/NN )/) ,/, pentoxifylline/NN (/( NF-kappa/NN B/NN inhibitor/NN )/) ,/, and/CC Ro5-3335/NN (/( HIV-1/NN Tat/NN inhibitor/NN )/) also/RB inhibited/VBD significantly/RB the/DT heat/NN shock/NN induced/JJ virus/NN activation/NN ./. 
In/IN particular/JJ ,/, staurosporine/NN achieved/VBD approximately/RB 90/CD %/NN inhibition/NN of/IN the/DT HIV-1/NN antigen/NN expression/NN in/IN heat/NN shock-treated/JJ OM10.1/NN at/IN a/DT non-toxic/JJ concentration/NN ./. 
Although/IN the/DT mechanism/NN of/IN HIV-1/NN activation/NN with/IN heat/NN shock/NN has/VBZ not/RB been/VBN fully/RB elucidated/VBN yet/RB ,/, it/PRP is/VBZ presumed/VBN PKC/NN plays/VBZ an/DT important/JJ role/NN in/IN HIV-1/NN activation/NN ./. 
Thus/RB ,/, the/DT present/JJ observations/NNS will/MD provide/VB a/DT further/JJ insight/NN into/IN the/DT pathogenesis/NN of/IN HIV-1/NN infections/NNS ./. 
UI/LS -/: 99423672/CD 
TI/LS -/: Activation/NN of/IN the/DT CDC42/NN effector/NN N-WASP/NN by/IN the/DT Shigella/NN flexneri/NN IcsA/NN protein/NN promotes/VBZ actin/NN nucleation/NN by/IN Arp2/3/NN complex/NN and/CC bacterial/JJ actin-based/JJ motility/NN ./. 
AB/LS -/: To/TO propel/VB itself/PRP in/IN infected/JJ cells/NNS ,/, the/DT pathogen/NN Shigella/NN flexneri/NN subverts/VBZ the/DT Cdc42-controlled/JJ machinery/NN responsible/JJ for/IN actin/NN assembly/NN during/IN filopodia/NN formation/NN ./. 
Using/VBG a/DT combination/NN of/IN bacterial/JJ motility/NN assays/NNS in/IN platelet/NN extracts/NNS with/IN Escherichia/FW coli/FW expressing/VBG the/DT Shigella/NN IcsA/NN protein/NN and/CC in/FW vitro/FW analysis/NN of/IN reconstituted/VBN systems/NNS from/IN purified/VBN proteins/NNS ,/, we/PRP show/VBP here/RB that/IN the/DT bacterial/JJ protein/NN IcsA/NN binds/VBZ N-WASP/NN and/CC activates/VBZ it/PRP in/IN a/DT Cdc42-like/JJ fashion/NN ./. 
Dramatic/JJ stimulation/NN of/IN actin/NN assembly/NN is/VBZ linked/VBN to/TO the/DT formation/NN of/IN a/DT ternary/JJ IcsA-N-WASP-Arp2/3/NN complex/NN ,/, which/WDT nucleates/VBZ actin/NN polymerization/NN ./. 
The/DT Arp2/3/NN complex/NN is/VBZ essential/JJ in/IN initiation/NN of/IN actin/NN assembly/NN and/CC Shigella/NN movement/NN ,/, as/IN previously/RB observed/VBN for/IN Listeria/NN monocytogenes/NNS ./. 
Activation/NN of/IN N-WASP/NN by/IN IcsA/NN unmasks/VBZ two/CD domains/NNS acting/VBG together/RB in/IN insertional/JJ actin/NN polymerization/NN ./. 
The/DT isolated/VBN COOH-terminal/JJ domain/NN of/IN N-WASP/NN containing/VBG a/DT verprolin-homology/JJ region/NN ,/, a/DT cofilin-homology/JJ sequence/NN ,/, and/CC an/DT acidic/JJ terminal/JJ segment/NN (/( VCA/NN )/) interacts/VBZ with/IN G-actin/NN in/IN a/DT unique/JJ profilin-like/JJ functional/JJ fashion/NN ./. 
Hence/RB ,/, when/WRB N-WASP/NN is/VBZ activated/VBN ,/, its/PRP$ COOH-terminal/JJ domain/NN feeds/VBZ barbed/VBN|JJ end/NN growth/NN of/IN filaments/NNS and/CC lowers/VBZ the/DT critical/JJ concentration/NN at/IN the/DT bacterial/JJ surface/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, the/DT NH(2)-terminal/JJ domain/NN of/IN N-WASP/NN interacts/VBZ with/IN F-actin/NN ,/, mediating/VBG the/DT attachment/NN of/IN the/DT actin/NN tail/NN to/TO the/DT bacterium/NN surface/NN ./. 
VASP/NN is/VBZ not/RB involved/VBN in/IN Shigella/NN movement/NN ,/, and/CC the/DT function/NN of/IN profilin/NN does/VBZ not/RB require/VB its/PRP$ binding/NN to/TO proline-rich/JJ regions/NNS ./. 
UI/LS -/: 99409030/CD 
TI/LS -/: c-Maf/NN induces/VBZ monocytic/JJ differentiation/NN and/CC apoptosis/NN in/IN bipotent/JJ myeloid/JJ progenitors/NNS ./. 
AB/LS -/: The/DT transcriptional/JJ mechanisms/NNS that/WDT drive/VBP colony-forming/JJ unit/NN granulocyte-macrophage/JJ (/( CFU-GM/NN )/) myeloid/JJ progenitors/NNS to/TO differentiate/VB into/IN cells/NNS of/IN either/CC the/DT granulocytic/JJ or/CC monocytic/JJ lineage/NN are/VBP not/RB fully/RB understood/VBN ./. 
We/PRP have/VBP shown/VBN that/IN the/DT c-Maf/NN and/CC c-Myb/NN transcription/NN factors/NNS physically/RB interact/VBP in/IN myeloid/JJ cells/NNS to/TO form/VB inhibitory/JJ complexes/NNS that/WDT hinder/VBP transactivation/NN of/IN c-Myb/NN target/NN genes/NNS through/IN direct/JJ binding/NN to/TO Myb/NN consensus/NN sites/NNS ./. 
These/DT complexes/NNS arise/VBP in/IN a/DT developmentally/RB regulated/VBN pattern/NN ,/, peaking/VBG at/IN the/DT promyelocyte/JJ stage/NN ,/, or/CC in/IN cell/NN model/NN systems/NNS ,/, appearing/VBG soon/RB after/IN the/DT induction/NN of/IN monocytic/JJ differentiation/NN ./. 
We/PRP wished/VBD to/TO determine/VB if/IN this/DT developmentally/RB related/JJ interaction/NN is/VBZ a/DT consequence/NN of/IN myeloid/JJ differentiation/NN or/CC an/DT intrinsic/JJ differentiating/VBG stimulus/NN ./. 
Because/IN the/DT elevated/JJ Myb/NN :/: Maf/NN status/NN seen/VBN in/IN differentiating/VBG cells/NNS can/MD be/VB recapitulated/VBN by/IN overexpression/NN of/IN c-Maf/NN in/IN myeloid/JJ cell/NN lines/NNS ,/, we/PRP inducibly/RB expressed/VBD the/DT c-Maf/NN cDNA/NN in/IN 2/CD bipotent/JJ human/JJ myeloid/JJ progenitor/NN cells/NNS ./. 
Elevated/JJ levels/NNS of/IN c-Maf/NN protein/NN led/VBD to/TO marked/JJ increases/NNS in/IN Myb/NN :/: Maf/NN complexes/NNS and/CC the/DT accumulation/NN of/IN monocyte/macrophage/JJ|NN cells/NNS ,/, followed/VBN by/IN eventual/JJ programmed/VBN cell/NN death/NN ./. 
Analysis/NN of/IN targets/NNS that/WDT could/MD mediate/VB these/DT phenotypic/JJ changes/NNS indicated/VBD that/IN c-Maf/NN likely/RB plays/VBZ a/DT key/JJ role/NN in/IN myeloid/JJ cell/NN development/NN through/IN dual/JJ mechanisms/NNS ;/: inhibition/NN of/IN a/DT select/JJ set/NN of/IN c-Myb/NN regulated/JJ targets/NNS ,/, such/JJ as/IN Bcl-2/NN and/CC CD13/APN/NN ,/, coupled/VBN with/IN the/DT activation/NN of/IN as/RB yet/RB undefined/JJ differentiation-promoting/JJ genes/NNS ./. 
UI/LS -/: 99386942/CD 
TI/LS -/: AML1/NN (/( CBFalpha2/NN )/) cooperates/VBZ with/IN B/NN cell-specific/JJ activating/VBG protein/NN (/( BSAP/PAX5/NN )/) in/IN activation/NN of/IN the/DT B/NN cell-specific/JJ BLK/NN gene/NN promoter/NN ./. 
AB/LS -/: AML1/NN plays/VBZ a/DT critical/JJ role/NN during/IN hematopoiesis/NN and/CC chromosomal/JJ translocations/NNS involving/VBG AML1/NN are/VBP commonly/RB associated/VBN with/IN different/JJ forms/NNS of/IN leukemia/NN ,/, including/VBG pre-B/JJ acute/JJ lymphoblastic/JJ leukemia/NN ./. 
To/TO understand/VB the/DT function/NN of/IN AML1/NN during/IN B/NN cell/NN differentiation/NN ,/, we/PRP analyzed/VBD regulatory/JJ regions/NNS of/IN B/NN cell-specific/JJ genes/NNS for/IN potential/JJ AML1-binding/JJ sites/NNS and/CC have/VBP identified/VBN a/DT putative/JJ AML1-binding/JJ site/NN in/IN the/DT promoter/NN of/IN the/DT B/NN cell-specific/JJ tyrosine/NN kinase/NN gene/NN ,/, blk/NN ./. 
Gel/NN mobility/NN shift/NN assays/NNS and/CC transient/JJ transfection/NN assays/NNS demonstrate/VBP that/IN AML1/NN binds/VBZ specifically/RB to/TO this/DT site/NN in/IN the/DT blk/NN promoter/NN and/CC this/DT binding/VBG site/NN is/VBZ important/JJ for/IN blk/NN promoter/NN activity/NN ./. 
Furthermore/RB ,/, in/FW vitro/FW binding/NN analysis/NN revealed/VBD that/IN the/DT AML1/NN runt/NN DNA-binding/NN domain/NN physically/RB interacts/VBZ with/IN the/DT paired/JJ DNA-binding/JJ domain/NN of/IN BSAP/NN ,/, a/DT B/NN cell-specific/JJ transcription/NN factor/NN ./. 
BSAP/NN has/VBZ been/VBN shown/VBN previously/RB to/TO be/VB important/JJ for/IN B/NN cell-specific/JJ regulation/NN of/IN the/DT blk/NN gene/NN ./. 
Physical/JJ interaction/NN of/IN AML1/NN with/IN BSAP/NN correlates/VBZ with/IN functional/JJ cooperativity/NN in/IN transfection/NN studies/NNS where/WRB AML1/NN and/CC BSAP/NN synergistically/RB activate/VBP blk/NN promoter/NN transcription/NN by/IN more/JJR than/IN 50-fold/JJ ./. 
These/DT results/NNS demonstrate/VBP physical/JJ and/CC functional/JJ interactions/NNS between/IN AML1/NN and/CC BSAP/NN and/CC suggest/VB that/IN AML1/NN is/VBZ an/DT important/JJ factor/NN for/IN regulating/VBG a/DT critical/JJ B/NN cell-specific/JJ gene/NN ,/, blk/NN ./. 
UI/LS -/: 99377310/CD 
TI/LS -/: Transcriptional/JJ inhibition/NN by/IN interleukin-6/NN of/IN the/DT class/NN A/NN macrophage/NN scavenger/NN receptor/NN in/IN macrophages/NNS derived/VBN from/IN human/JJ peripheral/JJ monocytes/NNS and/CC the/DT THP-1/NN monocytic/JJ cell/NN line/NN ./. 
AB/LS -/: Expression/NN of/IN the/DT class/NN A/NN macrophage/NN scavenger/NN receptor/NN (/( MSR/NN )/) contributes/VBZ to/TO the/DT uptake/NN of/IN modified/VBN low/JJ density/NN lipoproteins/NNS (/( LDL/NN )/) by/IN macrophages/NNS and/CC transformation/NN of/IN these/DT cells/NNS into/IN lipid-laden/JJ foam/NN cells/NNS ,/, which/WDT characterize/VBP atherosclerosis/NN ./. 
Many/JJ environmental/JJ factors/NNS ,/, in/IN particular/JJ ,/, proinflammatory/JJ cytokines/NNS and/CC growth/NN factors/NNS ,/, can/MD exert/VB regulatory/JJ effects/NNS on/IN MSR/NN expression/NN ,/, whereas/IN intracellular/JJ accumulation/NN of/IN cholesterol/NN itself/PRP does/VBZ not/RB influence/VB MSR/JJ levels/NNS to/TO any/DT considerable/JJ extent/NN ./. 
In/IN the/DT present/JJ study/NN ,/, by/IN using/VBG an/DT in/FW vitro/FW model/NN ,/, we/PRP examined/VBD whether/IN stimulation/NN with/IN interleukin-6/NN (/( IL-6/NN )/) ,/, an/DT immunoregulatory/JJ ,/, multipotential/JJ cytokine/NN ,/, modulates/VBZ the/DT expression/NN and/CC activities/NNS of/IN the/DT MSR/NN in/IN macrophages/NNS ./. 
When/WRB treated/VBN with/IN IL-6/NN ,/, macrophages/NNS derived/VBN from/IN peripheral/JJ monocytes/NNS and/CC phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) -differentiated/JJ THP-1/NN monocytic/JJ cells/NNS showed/VBD significantly/RB reduced/VBN uptake/NN and/or/CC binding/NN of/IN the/DT MSR/NN ligand/NN ,/, acetylated/VBN LDL/NN ./. 
This/DT effect/NN was/VBD paralleled/VBN by/IN a/DT reduction/NN in/IN the/DT expression/NN of/IN MSR/NN protein/NN and/CC mRNA/NN ./. 
Analysis/NN of/IN MSR/NN promoter/NN activity/NN in/IN THP-1/NN cells/NNS transfected/VBN with/IN an/DT MSR/NN promoter-reporter/JJ gene/NN construct/NN demonstrated/VBD decreased/VBN activity/NN of/IN the/DT MSR/NN promoter/NN in/IN IL-6-treated/JJ THP-1/NN macrophages/NNS ./. 
Electrophoretic/JJ mobility/NN gel/NN shift/NN assay/NN also/RB showed/VBD a/DT reduction/NN in/IN the/DT binding/NN of/IN a/DT transcription/NN factor/NN to/TO the/DT MSR/NN promoter/NN AP-1/ets/NN elements/NNS in/IN IL-6-treated/JJ cells/NNS ./. 
Thus/RB ,/, exposure/NN to/TO IL-6/NN may/MD inhibit/VB expression/NN of/IN the/DT class/NN A/NN MSR/NN in/IN differentiated/VBN macrophages/NNS at/IN transcriptional/JJ levels/NNS ./. 
This/DT result/NN suggests/VBZ that/IN this/DT cytokine/NN may/MD modulate/VB foam/NN cell/NN formation/NN during/IN atherogenesis/NN ./. 
UI/LS -/: 99364624/CD 
TI/LS -/: Retinoblastoma/NN protein/NN expression/NN leads/VBZ to/TO reduced/VBN Oct-1/NN DNA/NN binding/NN activity/NN and/CC enhances/VBZ interleukin-8/NN expression/NN ./. 
AB/LS -/: Tumor/NN cell/NN lines/NNS with/IN a/DT defective/JJ retinoblastoma/NN gene/NN are/VBP unable/JJ to/TO transcribe/VB the/DT HLA/NN class/NN II/CD genes/NNS in/IN response/NN to/TO IFN-gamma/NN treatment/NN ,/, and/CC reconstitution/NN of/IN functional/JJ Rb/NN rescues/VBZ IFN-gamma-induced/JJ class/NN II/CD gene/NN expression/NN ./. 
However/RB ,/, the/DT molecular/JJ mechanism/NN of/IN Rb/NN rescue/NN of/IN the/DT class/NN II/CD genes/NNS is/VBZ unknown/JJ ./. 
We/PRP have/VBP examined/VBN the/DT effect/NN of/IN Rb/NN expression/NN on/IN the/DT activation/NN of/IN the/DT promoter/NN for/IN HLA-DRA/NN ,/, the/DT prototype/NN class/NN II/CD gene/NN ./. 
Oct-1/NN ,/, a/DT POU/NN domain/NN transcription/NN factor/NN ,/, was/VBD identified/VBN as/IN a/DT repressor/NN of/IN HLA-DRA/NN promoter/NN activity/NN in/IN the/DT Rb-defective/JJ cells/NNS ./. 
Rb/NN expression/NN led/VBD to/TO phosphorylation/NN of/IN Oct-1/NN ,/, thus/RB relieving/VBG its/PRP$ repressive/JJ effect/NN ./. 
Oct-1/NN has/VBZ also/RB been/VBN shown/VBN to/TO repress/VB interleukin/NN 8/CD promoter/NN activity/NN ./. 
Consistent/JJ with/IN reduced/VBN levels/NNS of/IN Oct-1/NN DNA/NN binding/NN activity/NN in/IN the/DT Rb-transformed/JJ cell/NN lines/NNS ,/, interleukin/NN 8/CD expression/NN is/VBZ higher/JJR in/IN these/DT cell/NN lines/NNS ./. 
UI/LS -/: 99357867/CD 
TI/LS -/: Cell/NN activation/NN and/CC apoptosis/NN by/IN bacterial/JJ lipoproteins/NNS through/IN toll-like/JJ receptor-2/NN ./. 
AB/LS -/: Apoptosis/NN is/VBZ implicated/VBN in/IN the/DT generation/NN and/CC resolution/NN of/IN inflammation/NN in/IN response/NN to/TO bacterial/JJ pathogens/NNS ./. 
All/DT bacterial/JJ pathogens/NNS produce/VBP lipoproteins/NNS (/( BLPs/NNS )/) ,/, which/WDT trigger/VBP the/DT innate/JJ immune/JJ response/NN ./. 
BLPs/NNS were/VBD found/VBN to/TO induce/VB apoptosis/NN in/IN THP-1/NN monocytic/JJ cells/NNS through/IN human/JJ Toll-like/JJ receptor-2/NN (/( hTLR2/NN )/) ./. 
BLPs/NNS also/RB initiated/VBD apoptosis/NN in/IN an/DT epithelial/JJ cell/NN line/NN transfected/VBN with/IN hTLR2/NN ./. 
In/IN addition/NN ,/, BLPs/NNS stimulated/VBD nuclear/JJ factor-kappaB/NN ,/, a/DT transcriptional/JJ activator/NN of/IN multiple/JJ host/NN defense/NN genes/NNS ,/, and/CC activated/VBD the/DT respiratory/JJ burst/NN through/IN hTLR2/NN ./. 
Thus/RB ,/, hTLR2/NN is/VBZ a/DT molecular/JJ link/NN between/IN microbial/JJ products/NNS ,/, apoptosis/NN ,/, and/CC host/NN defense/NN mechanisms/NNS ./. 
UI/LS -/: 99344098/CD 
TI/LS -/: Possible/JJ differences/NNS in/IN the/DT mechanism/NN (/( s/NNS )/) of/IN action/NN of/IN different/JJ glucocorticoid/NN hormone/NN compounds/NNS ./. 
AB/LS -/: Different/JJ glucocorticoid/NN hormones/NNS (/( GCH/NN )/) show/VBP differences/NNS in/IN the/DT intensity/NN and/CC in/IN the/DT kinetics/NNS of/IN their/PRP$ immunomodulating/JJ activity/NN ./. 
The/DT mechanism/NN (/( s/NNS )/) of/IN action/NN of/IN GCH/NN is/VBZ under/IN investigation/NN ,/, but/CC is/VBZ has/VBZ been/VBN noted/VBN that/IN they/PRP exert/VBP immune/JJ activity/NN via/IN the/DT genomic/JJ pathway/NN ./. 
We/PRP have/VBP studied/VBN the/DT effects/NNS of/IN prednisone/NN (/( PDN/NN )/) ,/, deflazacort/NN (/( DFC/NN )/) ,/, and/CC dexamethasone/NN (/( DXM/NN )/) on/IN the/DT production/NN of/IN cytokines/NNS (/( IL-2/NN ,/, IL-6/NN ,/, TNF-alpha/NN ,/, IL-10/NN )/) by/IN peripheral/JJ T/NN lymphocytes/NNS ,/, and/CC the/DT effects/NNS on/IN the/DT inhibition/NN of/IN NF-kB/NN DNA/NN binding/NN activity/NN by/IN activated/JJ Jurkat/NN cell/NN line/NN ./. 
The/DT data/NNS obtained/VBN show/VBP that/IN the/DT three/CD GCH/NN molecules/NNS exert/VBP an/DT immunosuppression/NN on/IN cytokine/NN production/NN by/IN T/NN lymphocytes/NNS and/CC a/DT strong/JJ decrease/NN in/IN the/DT nuclear/JJ translocation/NN of/IN NF-kB/NN in/IN Jurkat/NN cells/NNS ;/: moreover/RB ,/, (/( a/LS )/) not/RB all/PDT the/DT cytokines/NNS investigated/VBN were/VBD affected/VBN ,/, and/CC not/RB with/IN the/DT same/JJ intensity/NN ,/, by/IN the/DT three/CD GCH/NN and/CC (/( b/LS )/) DXM/NN inhibited/VBD the/DT binding/VBG activity/NN of/IN NF-kB/NN less/CC than/IN that/DT of/IN DFC/NN and/CC PDN/NN ./. 
These/DT data/NNS are/VBP in/IN agreement/NN with/IN the/DT concept/NN that/IN different/JJ GCH/NN compounds/NNS might/MD differ/VB in/IN their/PRP$ binding/NN and/CC affinity/NN properties/NNS ,/, tissue-specific/JJ metabolism/NN ,/, and/CC interaction/NN with/IN transcription/NN factor/NN ./. 
UI/LS -/: 96141065/CD 
TI/LS -/: Distinctive/JJ expression/NN pattern/NN of/IN the/DT BCL-6/NN protein/NN in/IN nodular/JJ lymphocyte/NN predominance/NN Hodgkin/NN 's/POS disease/NN ./. 
AB/LS -/: The/DT BCL-6/NN gene/NN encoding/VBG a/DT nuclear-located/JJ Kruppel-type/JJ zinc/NN finger/NN protein/NN is/VBZ rearranged/VBN in/IN about/RB 30/CD %/NN diffuse/JJ large/JJ B-cell/NN lymphomas/NNS and/CC is/VBZ expressed/VBN predominantly/RB in/IN normal/JJ germinal/JJ center/NN B/NN cells/NNS and/CC related/JJ lymphomas/NNS ./. 
These/DT findings/NNS suggest/VBP that/IN BCL-6/NN may/MD play/VB a/DT role/NN in/IN regulating/VBG differentiation/NN of/IN normal/JJ germinal/JJ center/NN B/NN cells/NNS and/CC that/IN its/PRP$ deregulated/VBN expression/NN caused/VBN by/IN rearrangements/NNS may/MD contribute/VB to/TO lymphomagenesis/NN ./. 
This/DT prompted/VBD us/PRP to/TO investigate/VB the/DT expression/NN of/IN the/DT BCL-6/NN protein/NN in/IN Hodgkin/NN 's/POS disease/NN (/( HD/NN )/) ,/, focusing/VBG on/IN the/DT nodular/JJ lymphocyte/NN predominance/NN subtype/NN (/( NLPHD/NN )/) ,/, which/WDT differs/VBZ from/IN classical/JJ HD/NN by/IN virtue/NN of/IN the/DT B-cell/NN nature/NN of/IN the/DT malignant/JJ cell/NN population/NN (/( so-called/JJ L/NN &/CC H/NN cells/NNS )/) and/CC its/PRP$ relationship/NN with/IN germinal/JJ centers/NNS ./. 
Forty-one/CD HD/NN samples/NNS (/( 19/CD NLPHD/NN ,/, 12/CD nodular/JJ sclerosis/NN ,/, and/CC 10/CD mixed/JJ cellularity/NN )/) were/VBD immunostained/VBN with/IN the/DT monoclonal/JJ antibodies/NNS PG-B6/NN and/CC PG-B6p/NN that/WDT react/VBP with/IN a/DT fixative-sensitive/JJ and/CC a/DT formalin-resistant/JJ epitope/NN on/IN the/DT aminoterminal/JJ region/NN of/IN the/DT BCL-6/NN gene/NN product/NN ,/, respectively/RB ./. 
Strong/JJ nuclear/JJ positivity/NN for/IN the/DT BCL-6/NN protein/NN was/VBD detected/VBN in/IN tumor/NN (/( L/NN &/CC H/NN )/) cells/NNS in/IN all/DT cases/NNS of/IN NLPHD/NN ./. 
In/IN contrast/NN ,/, BCL-6/NN was/VBD expressed/VBN only/RB in/IN a/DT small/JJ percentage/NN of/IN Hodgkin/NN and/CC Reed-Sternberg/NN cells/NNS in/IN about/RB 30/CD %/NN of/IN classical/JJ HD/NN cases/NNS ./. 
Notably/RB ,/, the/DT nuclei/NNS of/IN reactive/JJ CD3+/CD4+/JJ T/NN cells/NNS nearby/JJ to/TO and/CC rosetting/VBG around/IN L/NN &/CC H/NN cells/NNS in/IN NLPHD/NN were/VBD also/RB strongly/RB BCL-6+/JJ ,/, but/CC lacked/VBD CD40/NN ligand/NN (/( CD40L/NN )/) expression/NN ./. 
This/DT staining/NN pattern/NN clearly/RB differed/VBD from/IN that/DT of/IN classical/JJ HD/NN ,/, whose/WP$ cellular/JJ background/NN was/VBD made/VBN up/IN of/IN CD3+/CD4+/JJ T/NN cells/NNS showing/VBG the/DT BCL-6-/CD40L/JJ +/JJ phenotype/NN ./. 
These/DT results/NNS further/RBR support/VBP the/DT concept/NN that/IN NLPHD/NN is/VBZ an/DT histogenetically/RB distinct/JJ ,/, B-cell-derived/JJ subtype/NN of/IN HD/NN and/CC suggest/VBP a/DT role/NN for/IN BCL-6/NN in/IN its/PRP$ development/NN ./. 
UI/LS -/: 97005399/CD 
TI/LS -/: Selenium-mediated/JJ inhibition/NN of/IN transcription/NN factor/NN NF-kappa/NN B/NN and/CC HIV-1/NN LTR/NN promoter/NN activity/NN ./. 
AB/LS -/: The/DT eukaryotic/JJ transcription/NN factor/NN NF-kappa/NN B/NN is/VBZ involved/VBN in/IN the/DT inducible/JJ expression/NN of/IN various/JJ inflammatory/JJ genes/NNS as/RB well/RB as/IN in/IN HIV-1/NN replication/NN ./. 
Activation/NN of/IN NF-kappa/NN B/NN is/VBZ induced/VBN by/IN prooxidants/NNS and/CC several/JJ stimuli/NNS eliciting/VBG oxidative/JJ stress/NN ,/, such/JJ as/IN cytokines/NNS ,/, lipopolysaccharide/NN ,/, UV/NN irradiation/NN and/CC other/JJ mediators/NNS ./. 
Various/JJ antioxidants/NNS inhibit/VBP NF-kappa/NN B/NN activation/NN in/IN response/NN to/TO these/DT stimuli/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP investigated/VBN the/DT effects/NNS of/IN selenium/NN ,/, an/DT integral/JJ component/NN of/IN glutathione/NN peroxidase/NN (/( GPX/NN )/) ,/, on/IN NF-kappa/NN B/NN activation/NN ./. 
In/IN selenium-deprived/JJ Jurkat/NN and/CC ESb-L/NN T/NN lymphocytes/NNS ,/, supplementation/NN of/IN selenium/NN led/VBD to/TO a/DT substantial/JJ increase/NN of/IN GPX/NN activity/NN ./. 
Analysis/NN of/IN DNA/NN binding/NN revealed/VBD that/IN NF-kappa/NN B/NN activation/NN in/IN response/NN to/TO TNF/NN was/VBD significantly/RB inhibited/VBN under/IN these/DT conditions/NNS ./. 
Likewise/RB ,/, reporter/NN gene/NN assays/NNS using/VBG luciferase/NN constructs/NNS driven/VBN by/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN showed/VBD a/DT dose-dependent/JJ inhibition/NN of/IN NF-kappa/NN B/NN controlled/JJ gene/NN expression/NN by/IN selenium/NN ./. 
The/DT effects/NNS of/IN selenium/NN were/VBD specific/JJ for/IN NF-kappa/NN B/NN ,/, since/IN the/DT activity/NN of/IN the/DT transcription/NN factor/NN AP-1/NN was/VBD not/RB suppressed/VBN ./. 
These/DT data/NNS suggest/VBP that/IN selenium/NN supplementation/NN may/MD be/VB used/VBN to/TO modulate/VB the/DT expression/NN of/IN NF-kappa/NN B/NN target/NN genes/NNS and/CC HIV-1/NN ./. 
UI/LS -/: 96184185/CD 
TI/LS -/: The/DT involvement/NN of/IN p23/NN ,/, hsp90/NN ,/, and/CC immunophilins/NNS in/IN the/DT assembly/NN of/IN progesterone/NN receptor/NN complexes/NNS ./. 
AB/LS -/: To/TO better/RBR understand/VB the/DT assembly/NN mechanism/NN for/IN the/DT progesterone/NN receptor/NN (/( PR/NN )/) ,/, we/PRP have/VBP developed/VBN cell-free/JJ systems/NNS for/IN studying/VBG interactions/NNS of/IN PR/NN ,/, hsp90/NN ,/, and/CC other/JJ associated/VBN proteins/NNS ./. 
When/WRB PR/NN is/VBZ incubated/VBN in/IN rabbit/NN reticulocyte/NN lysate/NN ,/, its/PRP$ association/NN with/IN hsp90/NN ,/, hsp70/NN ,/, the/DT three/CD immunophilins/JJ FKBP54/NN ,/, FKBP52/NN and/CC CyP-40/NN ,/, and/CC with/IN p23/NN is/VBZ observed/VBN ./. 
These/DT interactions/NNS require/VBP ATP/Mg2+/NN and/CC when/WRB ATP/NN is/VBZ limiting/VBG the/DT PR/NN complex/NN is/VBZ altered/VBN to/TO one/CD containing/VBG the/DT proteins/NNS p60/NN and/CC p48/NN ,/, but/CC lacking/VBG immunophilins/NNS and/CC p23/NN ./. 
We/PRP have/VBP studied/VBN two/CD pre-formed/JJ hsp90/NN complexes/NNS that/WDT may/MD participate/VB in/IN the/DT assembly/NN of/IN PR/NN complexes/NNS ./. 
One/CD contains/VBZ hsp90/NN bound/VBN to/TO hsp70/NN and/CC p60/NN and/CC this/DT complex/NN forms/VBZ spontaneously/RB in/IN the/DT absence/NN of/IN ATP/NN ./. 
A/DT second/JJ complex/NN contains/VBZ hsp90/NN bound/VBN to/TO p23/NN plus/CC the/DT three/CD immunophilins/NNS and/CC some/DT hsp70/NN ./. 
The/DT formation/NN of/IN this/DT complex/NN requires/VBZ ATP/NN ./. 
In/IN further/JJ studies/NNS we/PRP have/VBP shown/VBN that/IN purified/VBN hsp90/NN can/MD bind/VB to/TO purified/VBN p23/NN and/CC this/DT interaction/NN requires/VBZ both/CC ATP/NN and/CC molybdate/NN ./. 
This/DT explains/VBZ ,/, in/IN part/NN ,/, the/DT known/JJ effects/NNS of/IN ATP/NN and/CC molybdate/NN on/IN assembly/NN of/IN PR/NN complexes/NNS ./. 
UI/LS -/: 99415656/CD 
TI/LS -/: Increased/VBN IkappaB/NN expression/NN and/CC diminished/VBN nuclear/JJ NF-kappaB/NN in/IN human/JJ mononuclear/JJ cells/NNS following/VBG hydrocortisone/NN injection/NN ./. 
AB/LS -/: We/PRP have/VBP recently/RB demonstrated/VBN that/IN hydrocortisone/NN and/CC other/JJ glucocorticoids/NNS inhibit/VBP reactive/JJ oxygen/NN species/NNS (/( ROS/NN )/) generation/NN by/IN mononuclear/JJ (/( MNC/NN )/) and/CC polymorphonuclear/JJ leucocytes/NNS (/( PMNL/NN )/) ./. 
Since/IN NF-kappaB/IkappaB/JJ|NN system/NN regulates/VBZ the/DT transcription/NN of/IN proinflammatory/JJ genes/NNS ,/, including/VBG those/DT responsible/JJ for/IN ROS/NN generation/NN ,/, we/PRP tested/VBD the/DT hypothesis/NN that/IN hydrocortisone/NN may/MD stimulate/VB IkappaB/NN production/NN thus/RB inhibiting/VBG NF-kappaB/NN translocation/NN from/IN the/DT cytosol/NN into/IN the/DT nucleus/NN in/IN MNC/NN ,/, in/FW vivo/FW ./. 
One/CD hundred/CD milligram/NN of/IN hydrocortisone/NN was/VBD injected/VBN intravenously/RB into/IN 4/CD normal/JJ subjects/NNS ./. 
Blood/NN samples/NNS were/VBD obtained/VBN prior/JJ to/TO the/DT injection/NN and/CC at/IN 1/CD ,/, 2/CD ,/, 4/CD ,/, 8/CD and/CC 24/CD hr/NN after/IN the/DT injection/NN ./. 
Nuclear/JJ extracts/NNS and/CC total/JJ cell/NN lysates/NNS were/VBD prepared/VBN from/IN MNC/NN by/IN standard/JJ techniques/NNS ./. 
IkappaB/NN levels/NNS in/IN MNC/NN homogenates/NNS increased/VBD at/IN 1/CD hr/NN ,/, peaked/VBD at/IN 2-4/CD hr/NN ,/, started/VBD to/TO decrease/VB at/IN 8/CD hr/NN ,/, and/CC returned/VBD to/TO baseline/NN levels/NNS at/IN 24/CD hr/NN ./. 
NF-kappaB/NN in/IN MNC/NN nuclear/JJ extracts/NNS decreased/VBD at/IN 1/CD hr/NN ,/, reached/VBD a/DT nadir/NN at/IN 4/CD hr/NN ,/, gradually/RB increased/VBD at/IN 8/CD hr/NN and/CC returned/VBD back/RB to/TO baseline/NN levels/NNS at/IN 24/CD hr/NN ./. 
The/DT total/JJ protein/NN content/NN of/IN NF-kappaB/NN subunit/NN (/( P65/NN )/) in/IN MNC/NN lysates/NNS also/RB showed/VBD a/DT decrease/NN following/VBG hydrocortisone/NN injection/NN ./. 
This/DT decrease/NN was/VBD observed/VBN at/IN 2/CD hr/NN ,/, reached/VBD a/DT nadir/NN at/IN 4/CD hr/NN ,/, and/CC returned/VBD to/TO baseline/NN levels/NNS at/IN 24/CD hr/NN ./. 
ROS/NN generation/NN inhibition/NN paralleled/VBD NF-kappaB/NN levels/NNS in/IN the/DT nucleus/NN ./. 
It/PRP was/VBD inhibited/VBN at/IN 1/CD hr/NN ,/, reached/VBD a/DT nadir/NN at/IN 2-4/CD hr/NN ,/, started/VBD to/TO increase/VB at/IN 8/CD hr/NN ,/, and/CC returned/VBD to/TO basal/JJ levels/NNS at/IN 24/CD hr/NN ./. 
Our/PRP$ data/NNS demonstrate/VBP that/IN hydrocortisone/NN induces/VBZ IkappaB/NN and/CC suppresses/VBZ NF-kappaB/NN expression/NN in/IN MNC/NN in/IN parallel/NN ./. 
IkappaB/NN further/RB reduces/VBZ the/DT translocation/NN of/IN NF-kappaB/NN into/IN the/DT nucleus/NN thus/RB preventing/VBG the/DT expression/NN of/IN proinflammatory/JJ genes/NNS ./. 
UI/LS -/: 99406845/CD 
TI/LS -/: Glucocorticoids/NNS induce/VBP apoptosis/NN in/IN human/JJ monocytes/NNS :/: potential/JJ role/NN of/IN IL-1/NN beta/NN ./. 
AB/LS -/: Glucocorticoids/NNS (/( GC/NN )/) are/VBP potent/JJ anti-inflammatory/JJ and/CC immunosuppressive/JJ agents/NNS that/WDT act/VBP on/IN a/DT variety/NN of/IN immune/JJ cells/NNS ,/, including/VBG monocytes/NNS and/CC macrophages/NNS ./. 
However/RB ,/, the/DT exact/JJ cellular/JJ mechanisms/NNS underlying/VBG this/DT anti-inflammatory/JJ capacity/NN are/VBP still/RB unknown/JJ ./. 
In/IN our/PRP$ study/NN ,/, we/PRP determined/VBD the/DT induction/NN of/IN apoptosis/NN by/IN GC/NN in/IN human/JJ monocytes/NNS ./. 
Peripheral/JJ blood/NN monocytes/NNS were/VBD isolated/VBN by/IN density/NN centrifugation/NN methods/NNS with/IN a/DT purity/NN of/IN >/JJR 90/CD %/NN and/CC were/VBD cultured/VBN in/IN RPMI/NN 1640/CD medium/NN ./. 
Monocyte/NN apoptosis/NN was/VBD determined/VBN by/IN four/CD independent/JJ methods/NNS ,/, including/VBG annexin-V/JJ staining/NN ,/, TUNEL/NN ,/, DNA-laddering/NN ,/, and/CC typical/JJ morphology/NN by/IN means/NNS of/IN transmission/NN electron/NN microscopy/NN ./. 
TNF-alpha/NN and/CC IL-1beta/NN were/VBD measured/VBN by/IN ELISA/NN ./. 
GC/NN receptor/NN was/VBD blocked/VBN with/IN mifepristone/NN ./. 
Caspase/NN 3/CD was/VBD inhibited/VBN with/IN caspase-3/NN inhibitor/NN (/( DEVD-CHO/NN )/) ./. 
Stimulation/NN with/IN different/JJ GC/NN at/IN therapeutic/JJ concentrations/NNS resulted/VBD in/IN monocyte/NN apoptosis/NN in/IN a/DT time-/NN and/CC dose-dependent/JJ manner/NN ./. 
Necrosis/NN was/VBD excluded/VBN by/IN propidium/NN iodide/NN staining/NN ./. 
Proinflammatory/JJ cytokines/NNS such/JJ as/IN IL-1beta/NN and/CC TNF-alpha/NN were/VBD down-regulated/VBN by/IN GC/NN treatment/NN ./. 
Continuous/JJ treatment/NN of/IN monocytes/NNS with/IN IL-1beta/NN ,/, but/CC not/RB with/IN TNF-alpha/NN ,/, could/MD almost/RB completely/RB prevent/VB GC-induced/JJ cell/NN death/NN ./. 
The/DT addition/NN of/IN mifepristone/NN or/CC caspase-3/NN inhibitor/NN could/MD partially/RB abrogate/VB GC-induced/JJ apoptosis/NN as/RB well/RB as/IN GC-induced/JJ inhibition/NN of/IN IL-1beta/NN ./. 
This/DT is/VBZ the/DT first/JJ study/NN to/TO demonstrate/VB induction/NN of/IN apoptosis/NN by/IN GC/NN in/IN human/JJ monocytes/NNS ./. 
GC-induced/JJ monocyte/NN apoptosis/NN may/MD be/VB partially/RB mediated/VBN through/IN effects/NNS on/IN IL-1beta/NN production/NN ./. 
It/PRP is/VBZ conceivable/JJ that/IN GC/NN exert/VBP their/PRP$ anti-inflammatory/JJ capacity/NN in/IN various/JJ diseases/NNS ,/, at/IN least/JJS in/IN part/NN ,/, by/IN the/DT induction/NN of/IN apoptosis/NN in/IN monocytes/NNS ./. 
UI/LS -/: 99386936/CD 
TI/LS -/: Differential/JJ effects/NNS of/IN lipopolysaccharide/NN and/CC tumor/NN necrosis/NN factor/NN on/IN monocytic/JJ IkappaB/NN kinase/NN signalsome/JJ activation/NN and/CC IkappaB/NN proteolysis/NN ./. 
AB/LS -/: The/DT inflammatory/JJ mediators/NNS lipopolysaccharide/NN (/( LPS/NN )/) and/CC tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) are/VBP potent/JJ activators/NNS of/IN NF-kappaB/NN ./. 
This/DT study/NN compared/VBD the/DT effect/NN of/IN these/DT stimuli/NNS on/IN endogenous/JJ IkappaB/NN kinase/NN (/( IKK/NN )/) signalsome/JJ activation/NN and/CC IkappaB/NN phosphorylation/proteolysis/NN in/IN human/JJ monocytic/JJ cells/NNS and/CC investigated/VBD the/DT role/NN of/IN the/DT signalsome/JJ proteins/NNS IKK-alpha/NN ,/, IKK-beta/NN ,/, NF-kappaB-inducing/JJ kinase/NN (/( NIK/NN )/) ,/, IKK-gamma/NN (/( NF-kappaB/NN essential/JJ modulator/NN )/) ,/, and/CC IKK/NN complex-associated/JJ protein/NN ./. 
Kinase/NN assays/NNS showed/VBD that/IN TNF/NN elicited/VBD a/DT rapid/JJ but/CC short-lived/JJ induction/NN of/IN IKK/NN activity/NN with/IN a/DT 3-fold/JJ greater/JJR effect/NN on/IN IKK-alpha/NN than/IN on/IN IKK-beta/NN ,/, peaking/VBG at/IN 5/CD min/NN ./. 
In/IN contrast/NN ,/, LPS/NN predominantly/RB stimulated/VBD IKK-beta/NN activity/NN ,/, which/WDT slowly/RB increased/VBD ,/, peaking/VBG at/IN 30/CD min/NN ./. 
A/DT second/JJ peak/NN was/VBD observed/VBN at/IN a/DT later/JJ time/NN point/NN following/VBG LPS/NN stimulation/NN ,/, which/WDT consisted/VBD of/IN both/CC IKK-alpha/NN and/CC -beta/NN activity/NN ./. 
The/DT endogenous/JJ levels/NNS of/IN the/DT signalsome/JJ components/NNS were/VBD unaffected/JJ by/IN stimulation/NN ./. 
Furthermore/RB ,/, our/PRP$ studies/NNS showed/VBD association/NN of/IN the/DT IKK-alpha/beta/NN heterodimer/NN with/IN NIK/NN ,/, IkappaB-alpha/NN and/CC -epsilon/NN in/IN unstimulated/JJ cells/NNS ./. 
Exposure/NN to/TO LPS/NN or/CC TNF/NN led/VBD to/TO differential/JJ patterns/NNS of/IN IkappaB-alpha/NN and/CC IkappaB-epsilon/NN disappearance/NN from/IN and/CC reassembly/NN with/IN the/DT signalsome/JJ ,/, whereas/IN IKK-alpha/NN ,/, IKK-beta/NN ,/, and/CC NIK/NN remained/VBD complex-associated/JJ ./. 
NIK/NN can/MD not/RB phosphorylate/VB IkappaB-alpha/NN directly/RB ,/, but/CC it/PRP appears/VBZ to/TO be/VB a/DT functionally/RB important/JJ subunit/NN ,/, because/IN mutated/VBN NIK/NN inhibited/VBD stimulus-induced/JJ kappaB-dependent/JJ transcription/NN more/JJR effectively/RB than/IN mutated/VBN IKK-alpha/NN or/CC -beta/NN ./. 
Overexpression/NN of/IN IKK/NN complex-associated/JJ protein/NN inhibited/VBD stimulus-mediated/JJ transcription/NN ,/, whereas/IN NF-kappaB/NN essential/JJ modulator/NN enhanced/VBD it/PRP ./. 
The/DT understanding/NN of/IN LPS-/NN and/CC TNF-induced/JJ signaling/NN may/MD allow/VB the/DT development/NN of/IN specific/JJ strategies/NNS to/TO treat/VB sepsis-associated/JJ disease/NN ./. 
UI/LS -/: 99371288/CD 
TI/LS -/: Tumor/NN necrosis/NN factor/NN alpha/NN decreases/VBZ ,/, and/CC interleukin-10/NN increases/VBZ ,/, the/DT sensitivity/NN of/IN human/JJ monocytes/NNS to/TO dexamethasone/NN :/: potential/JJ regulation/NN of/IN the/DT glucocorticoid/NN receptor/NN ./. 
AB/LS -/: Resistance/NN to/TO glucocorticoid/NN therapy/NN has/VBZ been/VBN observed/VBN in/IN patients/NNS with/IN autoimmune/inflammatory/JJ diseases/NNS and/CC may/MD be/VB related/JJ to/TO the/DT inflammatory/JJ process/NN itself/PRP ./. 
The/DT aim/NN of/IN this/DT study/NN was/VBD to/TO examine/VB the/DT ability/NN of/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNFalpha/NN ,/, a/DT proinflammatory/JJ cytokine/NN )/) and/CC interleukin/NN (/( IL/NN )/) -10/CD (/( an/DT anti-inflammatory/JJ cytokine/NN )/) to/TO differentially/RB regulate/VB the/DT sensitivity/NN of/IN human/JJ monocytes/macrophages/NNS to/TO glucocorticoids/NNS ./. 
To/TO accomplish/VB this/DT ,/, we/PRP first/RB analyzed/VBD the/DT pattern/NN of/IN TNFalpha/NN and/CC IL-10/NN inhibition/NN by/IN dexamethasone/NN in/IN LPS-stimulated/JJ whole-blood/JJ cell/NN cultures/NNS ./. 
Second/RB ,/, we/PRP studied/VBD the/DT modulation/NN of/IN the/DT sensitivity/NN of/IN these/DT cells/NNS to/TO dexamethasone/NN by/IN preincubation/NN with/IN TNFalpha/NN or/CC IL-10/NN and/CC measurement/NN of/IN LPS-stimulated/JJ IL-6/NN secretion/NN ./. 
In/IN addition/NN ,/, we/PRP evaluated/VBD the/DT effect/NN of/IN dexamethasone/NN on/IN phorbolmyristate-acetate-stimulated/JJ IL-1/NN receptor/NN antagonist/NN secretion/NN by/IN the/DT human/JJ monocytic/JJ cell/NN line/NN U937/NN ./. 
Finally/RB ,/, we/PRP investigated/VBD whether/IN the/DT modulation/NN of/IN corticosensitivity/NN in/IN TNFalpha-/NN and/CC IL-10-pretreated/JJ U937/NN cells/NNS was/VBD related/JJ to/TO a/DT change/NN of/IN the/DT glucocorticoid/NN receptor/NN concentration/NN and/CC affinity/NN ./. 
Dexamethasone/NN had/VBD different/JJ effects/NNS on/IN LPS-induced/JJ TNFalpha/NN and/CC IL-10/NN secretion/NN ;/: whereas/IN it/PRP suppressed/VBD TNFalpha/NN in/IN a/DT dose-dependent/JJ fashion/NN ,/, its/PRP$ effect/NN on/IN IL-10/NN secretion/NN was/VBD biphasic/JJ ,/, producing/VBG stimulation/NN at/IN lower/JJR ,/, and/CC inhibition/NN at/IN higher/JJR doses/NNS ./. 
The/DT concentration/NN of/IN LPS/NN employed/VBN influenced/VBD the/DT effect/NN of/IN dexamethasone/NN on/IN IL-10/NN secretion/NN (/( P/NN </JJR 0.001/CD )/) ./. 
Pretreatment/NN with/IN TNFalpha/NN diminished/VBD ,/, and/CC with/IN IL-10/NN improved/VBD ,/, the/DT ability/NN of/IN dexamethasone/NN to/TO suppress/VB IL-6/NN secretion/NN in/IN whole-blood/JJ cell/NN cultures/NNS (/( P/NN </JJR 0.01/CD for/IN both/DT )/) and/CC to/TO enhance/VB IL-1/NN receptor/NN antagonist/NN secretion/NN by/IN U937/NN cells/NNS (/( P/NN </JJR 0.05/CD for/IN both/DT )/) ./. 
TNFalpha/NN decreased/VBD (/( P/NN </JJR 0.001/CD )/) ,/, while/IN IL-10/NN increased/VBD (/( P/NN </JJR 0.001/CD )/) ,/, the/DT concentration/NN of/IN dexamethasone/NN binding/NN sites/NNS in/IN these/DT cells/NNS ,/, with/IN no/DT discernible/JJ effect/NN on/IN their/PRP$ binding/NN affinity/NN ./. 
We/PRP conclude/VBP that/IN glucocorticoids/NNS differentially/RB modulate/VBP TNFalpha/NN and/CC IL-10/NN secretion/NN by/IN human/JJ monocytes/NNS in/IN a/DT LPS/NN dose-dependent/JJ fashion/NN and/CC that/IN the/DT sensitivity/NN of/IN these/DT cells/NNS to/TO glucocorticoids/NNS is/VBZ altered/VBN by/IN TNFalpha/NN or/CC IL-10/NN pretreatment/NN ;/: TNFalpha/NN blocks/VBZ their/PRP$ effects/NNS ,/, whereas/IN IL-10/NN acts/VBZ synergistically/RB with/IN glucocorticoids/NNS ./. 
This/DT is/VBZ accompanied/VBN by/IN opposite/JJ glucocorticoid/NN receptor/NN changes/NNS ,/, respectively/RB opposing/VBG and/CC favoring/VBG glucocorticoid/NN actions/NNS ./. 
This/DT study/NN suggests/VBZ that/IN the/DT pattern/NN of/IN pro-/antiinflammatory/JJ cytokine/NN secretion/NN may/MD alter/VB the/DT response/NN of/IN patients/NNS to/TO glucocorticoid/NN therapy/NN ./. 
UI/LS -/: 99361939/CD 
TI/LS -/: Block/NN of/IN granulocytic/JJ differentiation/NN of/IN 32Dcl3/NN cells/NNS by/IN AML1/ETO/NN (/( MTG8/NN )/) but/CC not/RB by/IN highly/RB expressed/VBN Bcl-2/NN ./. 
AB/LS -/: The/DT chimeric/JJ gene/NN ,/, AML1/ETO/NN (/( MTG8/NN )/) ,/, generated/VBN in/IN t(8;21)/NN acute/JJ myeloid/JJ leukemia/NN enhances/VBZ the/DT expression/NN of/IN Bcl-2/NN ./. 
To/TO evaluate/VB whether/IN this/DT enhancement/NN is/VBZ the/DT primary/JJ role/NN of/IN AML1/ETO/NN in/IN leukemogenesis/NN ,/, effects/NNS of/IN over-expression/NN of/IN Bcl-2/NN in/IN the/DT murine/JJ myeloid/JJ precursor/NN cell/NN line/NN ,/, 32Dcl3/NN ,/, were/VBD examined/VBN ./. 
When/WRB 32Dcl3/NN cells/NNS expressing/VBG exogenous/JJ Bcl-2/NN were/VBD induced/VBN to/TO differentiate/VB ,/, the/DT onset/NN of/IN morphological/JJ differentiation/NN was/VBD delayed/VBN ./. 
However/RB ,/, even/RB the/DT cells/NNS expressing/VBG very/RB high/JJ levels/NNS of/IN exogenous/JJ Bcl-2/NN eventually/RB underwent/VBD differentiation/NN without/IN a/DT significant/JJ decrease/NN in/IN the/DT synthesis/NN of/IN Bcl-2/NN ./. 
On/IN the/DT contrary/NN ,/, 32Dcl3/NN cells/NNS stably/RB expressing/VBG AML1/ETO/NN were/VBD completely/RB resistant/JJ to/TO differentiation/NN and/CC continued/VBD to/TO grow/VB in/IN the/DT presence/NN of/IN G-CSF/NN ./. 
These/DT results/NNS are/VBP consistent/JJ with/IN the/DT interpretation/NN that/IN stimulation/NN of/IN Bcl-2/NN expression/NN is/VBZ not/RB the/DT primary/JJ target/NN of/IN AML1/ETO/NN ./. 
UI/LS -/: 99357866/CD 
TI/LS -/: Host/NN defense/NN mechanisms/NNS triggered/VBN by/IN microbial/JJ lipoproteins/NNS through/IN toll-like/JJ receptors/NNS ./. 
AB/LS -/: The/DT generation/NN of/IN cell-mediated/JJ immunity/NN against/IN many/JJ infectious/JJ pathogens/NNS involves/VBZ the/DT production/NN of/IN interleukin-12/NN (/( IL-12/NN )/) ,/, a/DT key/JJ signal/NN of/IN the/DT innate/JJ immune/JJ system/NN ./. 
Yet/RB ,/, for/IN many/JJ pathogens/NNS ,/, the/DT molecules/NNS that/WDT induce/VBP IL-12/NN production/NN by/IN macrophages/NNS and/CC the/DT mechanisms/NNS by/IN which/WDT they/PRP do/VBP so/RB remain/VB undefined/JJ ./. 
Here/RB it/PRP is/VBZ shown/VBN that/IN microbial/JJ lipoproteins/NNS are/VBP potent/JJ stimulators/NNS of/IN IL-12/NN production/NN by/IN human/JJ macrophages/NNS ,/, and/CC that/IN induction/NN is/VBZ mediated/VBN by/IN Toll-like/JJ receptors/NNS (/( TLRs/NNS )/) ./. 
Several/JJ lipoproteins/NNS stimulated/VBD TLR-dependent/JJ transcription/NN of/IN inducible/JJ nitric/JJ oxide/NN synthase/NN and/CC the/DT production/NN of/IN nitric/JJ oxide/NN ,/, a/DT powerful/JJ microbicidal/NN pathway/NN ./. 
Activation/NN of/IN TLRs/NN by/IN microbial/JJ lipoproteins/NNS may/MD initiate/VB innate/JJ defense/NN mechanisms/NNS against/IN infectious/JJ pathogens/NNS ./. 
UI/LS -/: 99343785/CD 
TI/LS -/: Abnormal/JJ NF-kappa/NN B/NN activity/NN in/IN T/NN lymphocytes/NNS from/IN patients/NNS with/IN systemic/JJ lupus/NN erythematosus/NN is/VBZ associated/VBN with/IN decreased/VBN p65-RelA/NN protein/NN expression/NN ./. 
AB/LS -/: Numerous/JJ cellular/JJ and/CC biochemical/JJ abnormalities/NNS in/IN immune/JJ regulation/NN have/VBP been/VBN described/VBN in/IN patients/NNS with/IN systemic/JJ lupus/NN erythematosus/NN (/( SLE/NN )/) ,/, including/VBG surface/NN Ag/NN receptor-initiated/JJ signaling/NN events/NNS and/CC lymphokine/JJ production/NN ./. 
Because/IN NF-kappa/NN B/NN contributes/VBZ to/TO the/DT transcription/NN of/IN numerous/JJ inflammatory/JJ genes/NNS and/CC has/VBZ been/VBN shown/VBN to/TO be/VB a/DT molecular/JJ target/NN of/IN antiinflammatory/JJ drugs/NNS ,/, we/PRP sought/VBD to/TO characterize/VB the/DT functional/JJ role/NN of/IN the/DT NF-kappa/NN B/NN protein/NN complex/NN in/IN lupus/JJ|NN T/NN cells/NNS ./. 
Freshly/RB isolated/VBN T/NN cells/NNS from/IN lupus/NN patients/NNS ,/, rheumatoid/JJ arthritis/NN (/( RA/NN )/) patients/NNS ,/, and/CC normal/JJ individuals/NNS were/VBD activated/VBN physiologically/RB via/IN the/DT TCR/NN with/IN anti-CD3/JJ and/CC anti-CD28/JJ Abs/NNS to/TO assess/VB proximal/JJ membrane/NN signaling/NN ,/, and/CC with/IN PMA/NN and/CC a/DT calcium/NN ionophore/NN (/( A23187/NN )/) to/TO bypass/VB membrane-mediated/JJ signaling/NN events/NNS ./. 
We/PRP measured/VBD the/DT NF-kappa/NN B/NN binding/NN activity/NN in/IN nuclear/JJ extracts/NNS by/IN gel/NN shift/NN analysis/NN ./. 
When/WRB compared/VBN with/IN normal/JJ cells/NNS ,/, the/DT activation/NN of/IN NF-kappa/NN B/NN activity/NN in/IN SLE/NN patients/NNS was/VBD significantly/RB decreased/VBN in/IN SLE/NN ,/, but/CC not/RB in/IN RA/NN ,/, patients/NNS ./. 
NF-kappa/NN B/NN binding/NN activity/NN was/VBD absent/JJ in/IN several/JJ SLE/NN patients/NNS who/WP were/VBD not/RB receiving/VBG any/DT medication/NN ,/, including/VBG corticosteroids/NNS ./. 
Also/RB ,/, NF-kappa/NN B/NN activity/NN remained/VBD absent/JJ in/IN follow-up/JJ studies/NNS ./. 
In/IN supershift/NN experiments/NNS using/VBG specific/JJ Abs/NNS ,/, we/PRP showed/VBD that/IN ,/, in/IN the/DT group/NN of/IN SLE/NN patients/NNS who/WP displayed/VBD undetectable/JJ NF-kappa/NN B/NN activity/NN ,/, p65/NN complexes/NNS were/VBD not/RB formed/VBN ./. 
Finally/RB ,/, immunoblot/NN analysis/NN of/IN nuclear/JJ extracts/NNS showed/VBD decreased/VBN or/CC absent/JJ p65/NN protein/NN levels/NNS ./. 
As/IN p65/NN complexes/NNS are/VBP transcriptionally/RB active/JJ in/IN comparison/NN to/TO the/DT p50/NN homodimer/NN ,/, this/DT novel/JJ finding/NN may/MD provide/VB insight/NN on/IN the/DT origin/NN of/IN abnormal/JJ cytokine/NN or/CC other/JJ gene/NN transcription/NN in/IN SLE/NN patients/NNS ./. 
UI/LS -/: 99323953/CD 
TI/LS -/: Signaling/NN events/NNS induced/VBN by/IN lipopolysaccharide-activated/JJ toll-like/JJ receptor/NN 2/CD ./. 
AB/LS -/: Human/JJ Toll-like/JJ receptor/NN 2/CD (/( TLR2/NN )/) is/VBZ a/DT signaling/NN receptor/NN that/WDT responds/VBZ to/TO LPS/NN and/CC activates/VBZ NF-kappaB/NN ./. 
Here/RB ,/, we/PRP investigate/VBP further/RBR the/DT events/NNS triggered/VBN by/IN TLR2/NN in/IN response/NN to/TO LPS/NN ./. 
We/PRP show/VBP that/IN TLR2/NN associates/NNS with/IN the/DT high-affinity/JJ LPS/NN binding/NN protein/NN membrane/NN CD14/NN to/TO serve/VB as/IN an/DT LPS/NN receptor/NN complex/NN ,/, and/CC that/IN LPS/NN treatment/NN enhances/VBZ the/DT oligomerization/NN of/IN TLR2/NN ./. 
Concomitant/JJ with/IN receptor/NN oligomerization/NN ,/, the/DT IL-1R-associated/JJ kinase/NN (/( IRAK/NN )/) is/VBZ recruited/VBN to/TO the/DT TLR2/NN complex/NN ./. 
Intracellular/JJ deletion/NN variants/NNS of/IN TLR2/NN lacking/VBG C-terminal/JJ 13/CD or/CC 141/CD aa/NN fail/VBP to/TO recruit/VB IRAK/NN ,/, which/WDT is/VBZ consistent/JJ with/IN the/DT inability/NN of/IN these/DT mutants/NNS to/TO transmit/VB LPS/NN cellular/JJ signaling/NN ./. 
Moreover/RB ,/, both/DT deletion/NN mutants/NNS could/MD still/RB form/VB complexes/NNS with/IN wild-type/JJ TLR2/NN and/CC act/VB in/IN a/DT dominant-negative/JJ (/( DN/JJ )/) fashion/NN to/TO block/VB TLR2-mediated/JJ signal/NN transduction/NN ./. 
DN/JJ constructs/NNS of/IN myeloid/JJ differentiation/NN protein/NN ,/, IRAK/NN ,/, TNF/NN receptor-associated/JJ factor/NN 6/CD ,/, and/CC NF-kappaB-inducing/JJ kinase/NN ,/, when/WRB coexpressed/VBN with/IN TLR2/NN ,/, abrogate/VBP TLR2-mediated/JJ NF-kappaB/NN activation/NN ./. 
These/DT results/NNS reveal/VBP a/DT conserved/VBN signaling/NN pathway/NN for/IN TLR2/NN and/CC IL-1Rs/NNS and/CC suggest/VBP a/DT molecular/JJ mechanism/NN for/IN the/DT inhibition/NN of/IN TLR2/NN by/IN DN/JJ variants/NNS ./. 
UI/LS -/: 99308622/CD 
TI/LS -/: Tyrphostin/NN AG-490/NN inhibits/VBZ cytokine-mediated/JJ JAK3/STAT5a/b/NN signal/NN transduction/NN and/CC cellular/JJ proliferation/NN of/IN antigen-activated/JJ human/JJ T/NN cells/NNS ./. 
AB/LS -/: Janus/NN kinase/NN 3/CD (/( JAK3/NN )/) is/VBZ a/DT cytoplasmic/JJ tyrosine/NN kinase/NN required/VBN for/IN T/NN cell/NN development/NN and/CC activated/VBN by/IN cytokines/NNS that/WDT utilize/VBP the/DT interleukin-2/NN (/( IL-2/NN )/) receptor/NN common/JJ gamma/NN chain/NN (/( gamma(c)/NN )/) ./. 
Genetic/JJ inactivation/NN of/IN JAK3/NN is/VBZ manifested/VBN as/IN severe/JJ combined/JJ immunodeficiency/NN disease/NN (/( SCID/NN )/) in/IN humans/NNS and/CC mice/NNS ./. 
These/DT findings/NNS have/VBP suggested/VBN that/IN JAK3/NN represents/VBZ a/DT pharmacological/JJ target/NN to/TO control/VB certain/JJ lymphoid-derived/JJ diseases/NNS ./. 
Here/RB we/PRP provide/VBP novel/JJ evidence/NN that/IN AG-490/NN potently/RB inhibits/VBZ the/DT autokinase/NN activity/NN of/IN JAK3/NN and/CC tyrosine/NN phosphorylation/NN and/CC DNA/NN binding/NN of/IN signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN 5a/NN and/CC 5b/NN (/( STAT5a/b/NN )/) ./. 
Similar/JJ inhibitory/JJ effects/NNS were/VBD observed/VBN with/IN other/JJ cytokines/NNS that/WDT use/VBP gamma(c)/NN ./. 
AG-490/NN also/RB inhibited/VBD IL-2-mediated/JJ proliferative/JJ growth/NN in/IN human/JJ T/NN cells/NNS with/IN an/DT IC50)/NN =/JJ 25/CD microM/NN that/WDT was/VBD partially/RB recoverable/JJ ./. 
Moreover/RB ,/, we/PRP demonstrate/VBP that/IN this/DT inhibitor/NN prevented/VBD tetanus/NN toxoid/NN antigen-specific/JJ T/NN cell/NN proliferation/NN and/CC expansion/NN but/CC failed/VBD to/TO block/VB activation/NN of/IN Zap70/NN or/CC p56Lck/NN after/IN anti-CD3/JJ stimulation/NN of/IN human/JJ T/NN cells/NNS ./. 
Taken/VBN together/RB ,/, these/DT findings/NNS suggest/VBP that/IN AG-490/NN inhibits/VBZ the/DT JAK3-mediated/JJ Type/NN II/CD signaling/NN pathway/NN but/CC not/RB the/DT T/NN cell/NN receptor-derived/JJ Type/NN I/CD pathway/NN and/CC possesses/VBZ therapeutic/JJ potential/NN for/IN T/NN cell-derived/JJ pathologies/NNS such/JJ as/IN graft-versus-host/JJ disease/NN ,/, allergy/NN ,/, and/CC autoimmune/JJ disorders/NNS ./. 
UI/LS -/: 99298510/CD 
TI/LS -/: C/EBP/NN beta/NN in/IN rheumatoid/JJ arthritis/NN :/: correlation/NN with/IN inflammation/NN ,/, not/RB disease/NN specificity/NN ./. 
AB/LS -/: Rheumatoid/JJ arthritis/NN synovial/JJ tissue/NN was/VBD examined/VBN and/CC compared/VBN with/IN osteoarthritis/NN tissue/NN for/IN the/DT presence/NN of/IN the/DT nuclear/JJ transcription/NN factor/NN C/EBP/NN beta/NN (/( NF-IL-6/NN )/) ./. 
The/DT region/NN (/( lining/JJ or/CC sublining/JJ )/) ,/, cell/NN type/NN ,/, and/CC subcellular/JJ distribution/NN (/( cytoplasmic/JJ or/CC nuclear/JJ )/) of/IN the/DT expression/NN of/IN C/EBP/NN beta/NN was/VBD characterized/VBN ./. 
Rheumatoid/JJ arthritis/NN synovial/JJ fluid/NN and/CC blood/NN and/CC normal/JJ peripheral/JJ blood/NN were/VBD also/RB examined/VBN ./. 
C/EBP/NN beta/NN was/VBD detected/VBN in/IN the/DT synovial/JJ lining/NN and/CC in/IN sublining/JJ cells/NNS of/IN synovial/JJ tissue/NN from/IN patients/NNS with/IN both/CC rheumatoid/JJ and/CC osteoarthritis/NN ./. 
A/DT significant/JJ (/( P/NN </JJR 0.001/CD and/CC </JJR 0.05/CD ,/, respectively/RB )/) increase/NN in/IN the/DT percentage/NN of/IN cells/NNS with/IN nuclear/JJ staining/NN was/VBD seen/VBN in/IN the/DT lining/JJ layer/NN ,/, compared/VBN to/TO cells/NNS in/IN the/DT sublining/JJ region/NN ,/, in/IN rheumatoid/NN and/CC osteoarthritis/NN ./. 
In/IN both/DT diseases/NNS a/DT strong/JJ correlation/NN (/( r/NN =/JJ 0.79/CD ,/, P/NN </JJR 0.001/CD )/) was/VBD observed/VBN between/IN the/DT percentage/NN of/IN cells/NNS in/IN the/DT synovial/JJ lining/NN that/WDT were/VBD positive/JJ for/IN nuclear/JJ C/EBP/NN beta/NN and/CC lining/JJ cell/NN depth/NN ./. 
Two-color/JJ immunohistochemistry/NN demonstrated/VBD that/IN both/CC macrophages/NNS and/CC fibroblast-like/JJ synoviocytes/NNS were/VBD positive/JJ for/IN nuclear/JJ C/EBP/NN beta/NN ./. 
The/DT presence/NN of/IN C/EBP/NN beta/NN was/VBD confirmed/VBN by/IN immunohistochemistry/NN and/CC Western/NN blot/NN analysis/NN with/IN isolated/VBN synovial/JJ fibroblasts/NNS ./. 
Nuclear/JJ C/EBP/NN beta/NN was/VBD also/RB detected/VBN in/IN rheumatoid/JJ synovial/JJ fluid/NN monocytes/macrophages/NNS ,/, but/CC not/RB in/IN lymphocytes/NNS or/CC neutrophils/NNS ./. 
Western/NN blot/NN analysis/NN confirmed/VBD the/DT presence/NN of/IN C/EBP/NN beta/NN in/IN these/DT cells/NNS ./. 
The/DT intensity/NN of/IN C/EBP/NN beta/NN staining/NN was/VBD greater/JJR (/( P/NN </JJR 0.001/CD )/) in/IN synovial/JJ fluid/NN monocytes/NNS than/IN in/IN those/DT from/IN normal/JJ or/CC rheumatoid/JJ peripheral/JJ blood/NN ./. 
In/IN conclusion/NN ,/, the/DT enhanced/VBN nuclear/JJ staining/NN for/IN C/EBP/NN beta/NN in/IN the/DT synovial/JJ lining/NN ,/, compared/VBN to/TO the/DT sublining/NN ,/, suggesting/VBG activation/NN in/IN the/DT lining/NN ,/, and/CC the/DT positive/JJ correlation/NN of/IN lining/JJ layer/NN depth/NN with/IN the/DT percentage/NN of/IN cells/NNS in/IN the/DT lining/JJ positive/JJ for/IN nuclear/JJ C/EBP/NN beta/NN ,/, suggest/VBP a/DT potential/JJ role/NN for/IN C/EBP/NN beta/NN in/IN chronic/JJ inflammation/NN ./. 
The/DT regulation/NN of/IN the/DT production/NN or/CC activity/NN of/IN C/EBP/NN beta/NN ,/, to/TO inhibit/VB inflammatory/JJ mediator/NN expression/NN by/IN synovial/JJ macrophages/NNS and/CC fibroblasts/NNS ,/, offers/VBZ a/DT novel/JJ approach/NN to/TO therapeutic/JJ intervention/NN ./. 
UI/LS -/: 99292681/CD 
TI/LS -/: Direct/JJ interaction/NN of/IN hematopoietic/JJ transcription/NN factors/NNS PU.1/NN and/CC GATA-1/NN :/: functional/JJ antagonism/NN in/IN erythroid/JJ cells/NNS ./. 
AB/LS -/: Malignant/JJ transformation/NN usually/RB inhibits/VBZ terminal/JJ cell/NN differentiation/NN but/CC the/DT precise/JJ mechanisms/NNS involved/VBN are/VBP not/RB understood/VBN ./. 
PU.1/NN is/VBZ a/DT hematopoietic-specific/JJ Ets/NN family/NN transcription/NN factor/NN that/WDT is/VBZ required/VBN for/IN development/NN of/IN some/DT lymphoid/JJ and/CC myeloid/JJ lineages/NNS ./. 
PU.1/NN can/MD also/RB act/VB as/IN an/DT oncoprotein/NN as/IN activation/NN of/IN its/PRP$ expression/NN in/IN erythroid/JJ precursors/NNS by/IN proviral/JJ insertion/NN or/CC transgenesis/NN causes/VBZ erythroleukemias/NNS in/IN mice/NNS ./. 
Restoration/NN of/IN terminal/JJ differentiation/NN in/IN the/DT mouse/NN erythroleukemia/NN (/( MEL/NN )/) cells/NNS requires/VBZ a/DT decline/NN in/IN the/DT level/NN of/IN PU.1/NN ,/, indicating/VBG that/IN PU.1/NN can/MD block/VB erythroid/JJ differentiation/NN ./. 
Here/RB we/PRP investigate/VBP the/DT mechanism/NN by/IN which/WDT PU.1/NN interferes/VBZ with/IN erythroid/JJ differentiation/NN ./. 
We/PRP find/VBP that/IN PU.1/NN interacts/VBZ directly/RB with/IN GATA-1/NN ,/, a/DT zinc/NN finger/NN transcription/NN factor/NN required/VBN for/IN erythroid/JJ differentiation/NN ./. 
Interaction/NN between/IN PU.1/NN and/CC GATA-1/NN requires/VBZ intact/JJ DNA-binding/JJ domains/NNS in/IN both/DT proteins/NNS ./. 
PU.1/NN represses/VBZ GATA-1-mediated/JJ transcriptional/JJ activation/NN ./. 
Both/CC the/DT DNA/NN binding/NN and/CC transactivation/NN domains/NNS of/IN PU.1/NN are/VBP required/VBN for/IN repression/NN and/CC both/DT domains/NNS are/VBP also/RB needed/VBN to/TO block/VB terminal/JJ differentiation/NN in/IN MEL/NN cells/NNS ./. 
We/PRP also/RB show/VBP that/IN ectopic/JJ expression/NN of/IN PU.1/NN in/IN Xenopus/NN embryos/NNS is/VBZ sufficient/JJ to/TO block/VB erythropoiesis/NN during/IN normal/JJ development/NN ./. 
Furthermore/RB ,/, introduction/NN of/IN exogenous/JJ GATA-1/NN in/IN both/CC MEL/NN cells/NNS and/CC Xenopus/NN embryos/NNS and/CC explants/NNS relieves/VBZ the/DT block/NN to/TO erythroid/JJ differentiation/NN imposed/VBN by/IN PU.1/NN ./. 
Our/PRP$ results/NNS indicate/VBP that/IN the/DT stoichiometry/NN of/IN directly/RB interacting/VBG but/CC opposing/VBG transcription/NN factors/NNS may/MD be/VB a/DT crucial/JJ determinant/NN governing/VBG processes/NNS of/IN normal/JJ differentiation/NN and/CC malignant/JJ transformation/NN ./. 
UI/LS -/: 99288085/CD 
TI/LS -/: IL-12/NN induces/VBZ IFN/NN regulating/NN factor-1/NN (/( IRF-1/NN )/) gene/NN expression/NN in/IN human/JJ NK/NN and/CC T/NN cells/NNS ./. 
AB/LS -/: IL-12/NN is/VBZ a/DT critical/JJ immunoregulatory/JJ cytokine/NN that/WDT promotes/VBZ cell-mediated/JJ immune/JJ responses/NNS and/CC the/DT differentiation/NN of/IN naive/JJ CD4+/JJ cells/NNS to/TO Th1/NN cells/NNS ;/: however/RB ,/, relatively/RB few/JJ IL-12/NN target/NN genes/NNS have/VBP been/VBN identified/VBN ./. 
To/TO better/RBR clarify/VB the/DT molecular/JJ basis/NN of/IN IL-12/NN action/NN ,/, we/PRP set/VBD out/RP to/TO characterize/VB genes/NNS up-regulated/VBN by/IN IL-12/NN ,/, first/RB by/IN contrasting/VBG IL-12-/NN and/CC IFN-alpha-inducible/JJ genes/NNS ./. 
We/PRP identified/VBD several/JJ genes/NNS up-regulated/VBN by/IN IL-12/NN ,/, namely/RB ,/, MIP-1alpha/NN ,/, MIP-1beta/NN ,/, IL-1RA/NN ,/, and/CC IFN/NN regulatory/JJ factor-1/NN (/( IRF-1/NN )/) ./. 
IRF-1/NN is/VBZ a/DT transcription/NN factor/NN regulated/VBN by/IN IFNs/NN that/WDT is/VBZ also/RB essential/JJ for/IN Th1/NN responses/NNS ./. 
We/PRP demonstrated/VBD that/IN IL-12/NN directly/RB up-regulates/VBZ IRF-1/NN to/TO the/DT same/JJ extent/NN as/IN IFN-alpha/NN in/IN normal/JJ human/JJ T/NN cells/NNS and/CC in/IN NK/NN cells/NNS ./. 
We/PRP showed/VBD that/IN IL-12/NN had/VBD a/DT direct/JJ effect/NN on/IN IRF-1/NN ,/, an/DT effect/NN not/RB mediated/VBN indirectly/RB by/IN the/DT induction/NN of/IN IFN-gamma/NN production/NN ./. 
Furthermore/RB ,/, IL-2/NN and/CC IL-12/NN synergistically/RB induced/VBD IRF-1/NN ,/, whereas/IN IFN-alpha/NN and/CC IL-12/NN did/VBD not/RB ./. 
The/DT participation/NN of/IN STAT4/NN in/IN the/DT regulation/NN of/IN IRF-1/NN was/VBD demonstrated/VBN in/IN two/CD ways/NNS ./. 
First/RB ,/, STAT4/NN was/VBD required/VBN for/IN the/DT IL-12-dependent/JJ transactivation/NN of/IN an/DT IRF-1/NN reporter/NN construct/NN ,/, and/CC second/RB ,/, STAT4/NN binding/VBG to/TO the/DT IRF-1/NN promoter/NN was/VBD shown/VBN using/VBG EMSA/NN ./. 
In/IN contrast/NN to/TO IL-12/NN ,/, no/DT up-regulation/NN of/IN IRF-1/NN was/VBD found/VBN in/IN IL-4-stimulated/JJ cells/NNS ,/, and/CC IL-4/NN did/VBD not/RB block/VB IL-12-dependent/JJ up-regulation/NN of/IN IRF-1/NN ./. 
Therefore/RB ,/, IRF-1/NN may/MD be/VB an/DT important/JJ contributor/NN to/TO IL-12/NN signaling/NN ,/, and/CC we/PRP speculate/VBP that/IN the/DT defective/JJ IL-12/NN responses/NNS seen/VBN in/IN IRF-1-/-/JJ mice/NNS might/MD be/VB attributable/JJ ,/, in/IN part/NN ,/, to/TO the/DT absence/NN of/IN this/DT transcription/NN factor/NN ./. 
UI/LS -/: 99279130/CD 
TI/LS -/: Targeted/VBN remodeling/NN of/IN human/JJ beta-globin/NN promoter/NN chromatin/NN structure/NN produces/VBZ increased/VBN expression/NN and/CC decreased/VBN silencing/NN ./. 
AB/LS -/: The/DT chromatin/NN structure/NN of/IN the/DT human/JJ beta-globin/NN gene/NN locus/NN assumes/VBZ a/DT transcriptionally-active/JJ conformation/NN in/IN erythroid/JJ cells/NNS ./. 
One/CD feature/NN of/IN this/DT chromatin/NN reorganization/NN is/VBZ the/DT formation/NN of/IN DNase/NN 1/CD hypersensitive/JJ sites/NNS in/IN the/DT regions/NNS of/IN active/JJ globin/NN gene/NN promoters/NNS ./. 
This/DT reorganization/NN requires/VBZ the/DT globin/NN locus/NN control/NN region/NN and/CC is/VBZ associated/VBN with/IN normal/JJ expression/NN of/IN the/DT beta-like/JJ globin/NN genes/NNS ./. 
To/TO determine/VB whether/IN it/PRP is/VBZ possible/JJ to/TO artificially/RB enhance/VB the/DT opening/NN of/IN the/DT chromatin/NN structure/NN of/IN a/DT minimal/JJ beta-globin/NN promoter/NN ,/, we/PRP placed/VBD a/DT 101bp/JJ ,/, erythroid-specific/JJ DNase/NN 1/CD hypersensitive/JJ site-forming/JJ element/NN (/( HSFE/NN )/) immediately/RB upstream/JJ of/IN the/DT beta-globin/NN promoter/NN and/CC gene/NN ./. 
This/DT element/NN includes/VBZ binding/VBG sites/NNS for/IN NF-E2/NN ,/, AP-1/NN ,/, GATA-1/NN and/CC Sp-1/NN ./. 
Constructs/NNS were/VBD stably/RB transfected/VBN into/IN murine/JJ erythroleukemia/NN cells/NNS and/CC promoter/NN chromatin/NN structure/NN and/CC gene/NN expression/NN were/VBD analyzed/VBN ./. 
The/DT HSFE/NN induced/VBD an/DT area/NN of/IN enhanced/VBN DNase/NN 1/CD hypersensitivity/NN extending/VBG from/IN the/DT transcriptional/JJ start/NN site/NN to/TO -300bp/NN of/IN the/DT artificial/JJ promoter/NN and/CC significantly/RB increased/VBD the/DT proportion/NN of/IN beta-globin/NN promoters/NNS in/IN an/DT open/JJ chromatin/NN configuration/NN ./. 
This/DT remodeling/NN of/IN promoter/NN chromatin/NN structure/NN resulted/VBD in/IN 3-fold/JJ increases/NNS in/IN beta-globin/NN gene/NN transcription/NN and/CC induction/NN ,/, and/CC inhibited/VBD long-term/JJ beta-globin/NN gene/NN silencing/NN ./. 
These/DT results/NNS indicate/VBP that/IN a/DT relatively/RB small/JJ cis-acting/JJ element/NN is/VBZ able/JJ to/TO enhance/VB remodeling/NN of/IN promoter/NN chromatin/NN structure/NN resulting/VBG in/IN increased/VBN beta-globin/NN gene/NN expression/NN ./. 
UI/LS -/: 99261844/CD 
TI/LS -/: Regulation/NN of/IN low/JJ shear/NN flow-induced/JJ HAEC/NNS VCAM-1/NN expression/NN and/CC monocyte/NN adhesion/NN ./. 
AB/LS -/: We/PRP recently/RB reported/VBD that/IN prolonged/JJ exposure/NN of/IN human/JJ aortic/JJ endothelial/JJ cells/NNS (/( HAEC/NNS )/) to/TO low/JJ shear/NN stress/NN flow/NN patterns/NNS is/VBZ associated/VBN with/IN a/DT sustained/JJ increase/NN in/IN the/DT activated/JJ form/NN of/IN the/DT transcriptional/JJ regulator/NN nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) ./. 
Here/RB we/PRP investigate/VBP the/DT hypothesis/NN that/IN low/JJ shear-induced/JJ activation/NN of/IN NF-kappaB/NN is/VBZ responsible/JJ for/IN enhanced/VBN expression/NN of/IN vascular/JJ cell/NN adhesion/NN molecule/NN (/( VCAM-1/NN )/) resulting/VBG in/IN augmented/JJ endothelial/JJ cell-monocyte/NN (/( EC-Mn/NN )/) adhesion/NN and/CC that/IN this/DT activation/NN is/VBZ dependent/JJ on/IN intracellular/JJ oxidant/JJ activity/NN ./. 
Before/IN exposure/NN to/TO low/JJ shear/NN (/( 2/CD dyn/cm2/NN )/) for/IN 6/CD h/NN ,/, HAEC/NNS were/VBD preincubated/VBN with/IN or/CC without/IN the/DT antioxidants/NNS pyrrolidine/NN dithiocarbamate/NN (/( PDTC/NN )/) or/CC N-acetyl-L-cysteine/NN (/( NAC/NN )/) ./. 
PDTC/NN strongly/RB inhibited/VBD low/JJ shear-induced/JJ activation/NN of/IN NF-kappaB/NN ,/, expression/NN of/IN VCAM-1/NN ,/, and/CC EC-Mn/NN adhesion/NN ./. 
Paradoxically/RB ,/, NAC/NN exerted/VBD a/DT positive/JJ effect/NN on/IN low/JJ shear-induced/JJ VCAM-1/NN expression/NN and/CC EC-Mn/NN adhesion/NN and/CC only/RB slightly/RB downregulated/JJ NF-kappaB/NN activation/NN ./. 
However/RB ,/, cytokine-induced/JJ NF-kappaB/NN activation/NN and/CC VCAM-1/NN expression/NN are/VBP blocked/VBN by/IN both/CC PDTC/NN and/CC NAC/NN ./. 
These/DT data/NNS suggest/VBP that/IN NF-kappaB/NN plays/VBZ a/DT key/JJ role/NN in/IN low/JJ shear-induced/JJ VCAM-1/NN expression/NN and/CC that/IN pathways/NNS mediating/VBG low/JJ shear-/NN and/CC cytokine-induced/JJ EC-Mn/NN adhesion/NN may/MD be/VB differentially/RB regulated/VBN ./. 
UI/LS -/: 99255395/CD 
TI/LS -/: Nuclear/JJ factor-90/NN of/IN activated/VBN T-cells/NNS :/: A/DT double-stranded/JJ RNA-binding/JJ protein/NN and/CC substrate/NN for/IN the/DT double-stranded/JJ RNA-dependent/JJ protein/NN kinase/NN ,/, PKR/NN ./. 
AB/LS -/: NFAT/NN transcription/NN factors/NNS play/VBP a/DT central/JJ role/NN in/IN initiating/VBG T-cell/NN activation/NN through/IN the/DT induction/NN of/IN immediate-early/JJ T-cell/NN specific/JJ genes/NNS including/VBG interleukin-2/NN (/( IL-2/NN )/) ./. 
NFAT/NN transcription/NN factors/NNS bind/VBP to/TO a/DT sequence/NN in/IN the/DT IL-2/NN enhancer/NN known/VBN as/IN the/DT antigen/NN receptor/NN response/NN element/NN 2/CD (/( ARRE-2/NN )/) ./. 
Multiple/JJ proteins/NNS exhibiting/VBG ARRE-2/NN binding/NN activity/NN have/VBP been/VBN isolated/VBN ,/, including/VBG a/DT heterodimer/NN from/IN stimulated/VBN T-cell/NN nuclear/JJ extracts/NNS consisting/VBG of/IN Mr/NN =/JJ 90/CD 000/CD (/( NF90/NN )/) and/CC Mr/NN =/JJ 45/CD 000/CD (/( NF45/NN )/) subunits/NNS ./. 
The/DT subunits/NNS of/IN this/DT heterodimer/NN have/VBP been/VBN cloned/VBN ,/, and/CC NF90/NN was/VBD found/VBN to/TO encode/VB a/DT protein/NN containing/VBG two/CD domains/NNS that/WDT are/VBP predicted/VBN to/TO form/VB motifs/NNS capable/JJ of/IN binding/VBG to/TO double-stranded/JJ RNA/NN ./. 
Using/VBG in/FW vitro/FW translated/VBN polypeptides/NNS ,/, we/PRP have/VBP demonstrated/VBN that/IN NF90/NN specifically/RB binds/VBZ to/TO double-stranded/JJ RNA/NN ./. 
Furthermore/RB ,/, NF90/NN was/VBD phosphorylated/VBN in/IN a/DT double-stranded/JJ RNA-dependent/JJ manner/NN likely/RB by/IN the/DT interferon-induced/JJ ,/, double-stranded/JJ RNA-dependent/JJ protein/NN kinase/NN ,/, PKR/NN ./. 
The/DT NF90/NN protein/NN was/VBD found/VBN to/TO be/VB expressed/VBN not/RB only/RB in/IN T-cells/NNS ,/, but/CC also/RB in/IN nonimmune/JJ HeLa/NN cells/NNS ./. 
In/IN HeLa/NN cells/NNS ,/, the/DT protein/NN was/VBD almost/RB exclusively/RB localized/JJ to/TO the/DT ribosome/NN salt/NN wash/NN fraction/NN of/IN cell/NN lysates/NNS ./. 
UI/LS -/: 99252077/CD 
TI/LS -/: NF-kappaB/NN activation/NN is/VBZ required/VBN for/IN C5a-induced/JJ interleukin-8/NN gene/NN expression/NN in/IN mononuclear/JJ cells/NNS ./. 
AB/LS -/: C5a/NN ,/, a/DT potent/JJ peptide/NN chemoattractant/NN ,/, stimulates/VBZ interleukin-8/NN (/( IL-8/NN )/) secretion/NN from/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NNS )/) ./. 
Experiments/NNS were/VBD conducted/VBN to/TO understand/VB the/DT mechanisms/NNS for/IN C5a-induced/JJ IL-8/NN production/NN ,/, which/WDT was/VBD 14-fold/JJ greater/JJR than/IN that/DT in/IN unstimulated/JJ cells/NNS by/IN 2/CD hours/NNS ./. 
IL-8/NN secretion/NN was/VBD accompanied/VBN by/IN accumulation/NN of/IN IL-8/NN mRNA/NN in/IN the/DT cytosol/NN and/CC by/IN nuclear/JJ expression/NN of/IN a/DT kappaB/NN DNA/NN binding/NN activity/NN within/IN 30/CD minutes/NNS ./. 
AP-1/NN but/CC not/RB NF-IL-6/NN DNA/NN binding/NN activity/NN was/VBD also/RB detected/VBN in/IN C5a-stimulated/JJ PBMC/NNS ;/: however/RB ,/, its/PRP$ delayed/VBN expression/NN (/( maximal/JJ at/IN 4/CD hours/NNS )/) suggested/VBD a/DT less/RBR important/JJ role/NN in/IN the/DT rapid/JJ production/NN of/IN IL-8/NN ./. 
The/DT correlation/NN between/IN C5a-induced/JJ kappaB/NN binding/NN activity/NN and/CC IL-8/NN gene/NN expression/NN was/VBD examined/VBN in/IN the/DT RAW264.7/NN macrophage/NN cells/NNS using/VBG reporter/NN genes/NNS directed/VBN by/IN the/DT kappaB/NN sequence/NN from/IN IkappaBalpha/NN and/CC IL-8/NN promoter/NN regions/NNS ./. 
C5a-induced/JJ reporter/NN gene/NN expression/NN was/VBD abolished/VBN by/IN introducing/VBG mutations/NNS into/IN the/DT kappaB/NN sites/NNS and/CC by/IN coexpression/NN of/IN a/DT dominant/JJ negative/JJ IkappaBalpha/NN construct/NN resistant/JJ to/TO agonist-induced/JJ phosphorylation/NN ./. 
Pertussis/NN toxin/NN ,/, which/WDT ADP-ribosylates/VBZ the/DT Gi/NN proteins/NNS known/VBN to/TO couple/VB to/TO the/DT C5a/NN receptor/NN ,/, produced/VBD minimal/JJ inhibition/NN of/IN C5a-induced/JJ IL-8/NN expression/NN and/CC had/VBD little/JJ effect/NN on/IN C5a-induced/JJ calcium/NN mobilization/NN in/IN RAW264.7/NN cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN NF-kappaB/NN activation/NN is/VBZ required/VBN for/IN C5a-induced/JJ IL-8/NN gene/NN expression/NN and/CC that/IN this/DT response/NN is/VBZ mediated/VBN primarily/RB through/IN a/DT pertussis/NN toxin-insensitive/JJ pathway/NN ./. 
UI/LS -/: 99246501/CD 
TI/LS -/: Increased/VBN glucocorticoid/NN receptor/NN beta/NN in/IN airway/NN cells/NNS of/IN glucocorticoid-insensitive/JJ asthma/NN ./. 
AB/LS -/: Glucocorticoid/NN (/( GC/NN )/) -insensitive/JJ asthma/NN is/VBZ a/DT challenging/JJ clinical/JJ problem/NN that/WDT can/MD be/VB associated/VBN with/IN life-threatening/JJ disease/NN progression/NN ./. 
The/DT molecular/JJ basis/NN of/IN GC/NN insensitivity/NN is/VBZ unknown/JJ ./. 
Alternative/JJ splicing/NN of/IN the/DT GC/NN receptor/NN (/( GCR/NN )/) pre-mRNA/NN generates/VBZ a/DT second/JJ GCR/NN ,/, termed/VBN GCRbeta/NN ,/, which/WDT does/VBZ not/RB bind/VB GC/NN but/CC antagonizes/VBZ the/DT transactivating/NN activity/NN of/IN the/DT classic/JJ GCR/NN ./. 
Thus/RB increased/VBN expression/NN of/IN GCRbeta/NN could/MD account/VB for/IN glucocorticoid/NN insensitivity/NN ./. 
Bronchoalveolar/JJ lavage/NN (/( BAL/NN )/) cells/NNS and/CC peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NNS )/) were/VBD examined/VBN for/IN GCRbeta/NN immunoreactivity/NN using/VBG a/DT GCRbeta-specific/JJ antibody/NN by/IN immunohistochemical/JJ staining/NN ./. 
Cell/NN localization/NN of/IN GCRbeta/NN expression/NN was/VBD performed/VBN using/VBG a/DT double/JJ immunostaining/JJ technique/NN ./. 
Patients/NNS with/IN GC-insensitive/JJ asthma/NN expressed/VBD a/DT significantly/RB higher/JJR number/NN of/IN GCRbeta-immunoreactive/JJ cells/NNS in/IN their/PRP$ BAL/NN and/CC peripheral/JJ blood/NN than/IN GC-sensitive/JJ asthmatics/NNS or/CC normal/JJ control/JJ subjects/NNS ./. 
Furthermore/RB ,/, GCRbeta/NN expression/NN in/IN GC-insensitive/JJ asthma/NN was/VBD particularly/RB high/JJ in/IN airway/NN T/NN cells/NNS ,/, which/WDT are/VBP thought/VBN to/TO play/VB a/DT major/JJ role/NN in/IN the/DT pathogenesis/NN of/IN asthma/NN ./. 
We/PRP also/RB examined/VBD the/DT expression/NN of/IN GCRbeta/NN in/IN specimens/NNS from/IN the/DT airways/NNS of/IN patients/NNS with/IN chronic/JJ bronchitis/NN ./. 
In/IN chronic/JJ bronchitis/NN ,/, few/JJ cells/NNS were/VBD GCRbeta-positive/JJ and/CC their/PRP$ numbers/NNS did/VBD not/RB differ/VB significantly/RB from/IN normal/JJ control/JJ subjects/NNS ./. 
We/PRP conclude/VBP that/IN GC-insensitive/JJ asthma/NN is/VBZ associated/VBN with/IN increased/VBN expression/NN of/IN GCRbeta/NN in/IN airway/NN T/NN cells/NNS ./. 
UI/LS -/: 99323972/CD 
TI/LS -/: Activation/NN of/IN the/DT Janus/NN kinase/NN 3-STAT5a/NN pathway/NN after/IN CD40/NN triggering/NN of/IN human/JJ monocytes/NNS but/CC not/RB of/IN resting/VBG B/NN cells/NNS ./. 
AB/LS -/: CD40/CD40/NN ligand/NN interactions/NNS play/VBP a/DT key/JJ role/NN in/IN the/DT immune/JJ responses/NNS of/IN B/NN lymphocytes/NNS ,/, monocytes/NNS ,/, and/CC dendritic/JJ cells/NNS ./. 
The/DT signal/NN transduction/NN events/NNS triggered/VBN by/IN cross-linking/NN of/IN the/DT CD40/NN receptor/NN have/VBP been/VBN widely/RB studied/VBN in/IN B/NN cell/NN lines/NNS ,/, but/CC little/JJ is/VBZ known/VBN about/IN signaling/NN following/VBG CD40/NN stimulation/NN of/IN monocytes/NNS and/CC resting/VBG tonsillar/JJ B/NN cells/NNS ./. 
Therefore/RB ,/, we/PRP studied/VBD the/DT CD40/NN pathway/NN in/IN highly/RB purified/VBN human/JJ monocytes/NNS and/CC resting/VBG B/NN cells/NNS ./. 
After/IN CD40/NN triggering/NN ,/, a/DT similar/JJ activation/NN of/IN the/DT NF-kappaB/NN (/( but/CC not/RB of/IN the/DT AP-1/NN )/) transcription/NN factor/NN complex/NN occurred/VBD in/IN both/DT cell/NN preparations/NNS ./. 
However/RB ,/, the/DT components/NNS of/IN the/DT NF-kappaB/NN complexes/NNS were/VBD different/JJ in/IN monocytes/NNS and/CC B/NN cells/NNS ,/, because/IN p50/NN is/VBZ part/NN of/IN the/DT NF-kappaB/NN complex/NN induced/VBN by/IN CD40/NN triggering/NN in/IN both/CC monocytes/NNS and/CC B/NN cells/NNS ,/, whereas/IN p65/NN was/VBD only/RB induced/VBN in/IN B/NN cells/NNS ./. In/IN contrast/NN ,/, although/IN the/DT Janus/NN kinase/NN 3/CD tyrosine/NN kinase/NN was/VBD associated/VBN with/IN CD40/NN molecules/NNS in/IN both/CC monocytes/NNS and/CC resting/VBG B/NN cells/NNS ,/, Janus/NN kinase/NN 3/CD phosphorylation/NN induction/NN was/VBD observed/VBN only/RB in/IN CD40-activated/JJ monocytes/NNS ,/, with/IN subsequent/JJ induction/NN of/IN STAT5a/NN DNA/NN binding/NN activity/NN in/IN the/DT nucleus/NN ./. 
These/DT results/NNS suggest/VBP that/IN the/DT activation/NN signals/NNS in/IN human/JJ B/NN cells/NNS and/CC monocytes/NNS differ/VBP following/VBG CD40/NN stimulation/NN ./. 
This/DT observation/NN is/VBZ consistent/JJ with/IN the/DT detection/NN of/IN normal/JJ CD40-induced/JJ monocyte/NN activation/NN in/IN patients/NNS with/IN CD40/NN ligand+/JJ hyper/NN IgM/NN syndrome/NN in/IN whom/WP a/DT defect/NN in/IN CD40-induced/JJ B/NN cell/NN activation/NN has/VBZ been/VBN reported/VBN ./. 
UI/LS -/: 99310626/CD 
TI/LS -/: Genetic/JJ evidence/NN for/IN an/DT additional/JJ factor/NN required/VBN for/IN erythropoietin-induced/JJ signal/NN transduction/NN ./. 
AB/LS -/: Erythropoietin/NN (/( EPO/NN )/) and/CC its/PRP$ receptor/NN (/( EPOR/NN )/) are/VBP required/VBN for/IN the/DT development/NN of/IN mature/JJ erythrocytes/NNS ./. 
After/IN binding/NN of/IN ligand/NN ,/, the/DT EPOR/NN activates/VBZ a/DT variety/NN of/IN signaling/NN pathways/NNS that/WDT ultimately/RB control/VBP cellular/JJ proliferation/NN ,/, survival/NN ,/, and/CC specific/JJ gene/NN expression/NN ./. 
Although/IN erythroid/JJ progenitors/NNS appear/VBP to/TO be/VB the/DT principal/JJ EPO-responsive/JJ cell/NN type/NN in/FW vivo/FW due/JJ to/TO the/DT restricted/JJ expression/NN of/IN the/DT EPOR/NN ,/, many/JJ growth/NN factor-dependent/JJ cell/NN lines/NNS expressing/VBG the/DT EPOR/NN can/MD respond/VB to/TO EPO/NN by/IN activating/VBG many/JJ or/CC all/DT of/IN these/DT pathways/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP have/VBP identified/VBN a/DT cellular/JJ context/NN (/( the/DT interleukin-2/NN [/( IL-2/NN ]/) -dependent/JJ HT-2/NN line/NN )/) in/IN which/WDT the/DT EPO/NN stimulation/NN of/IN the/DT EPOR/NN fails/VBZ to/TO support/VB cellular/JJ proliferation/NN ,/, STAT-5/NN induction/NN ,/, or/CC MAPK/NN activation/NN ,/, despite/IN efficient/JJ phosphorylation/NN of/IN the/DT EPOR/NN and/CC JAK2/NN and/CC inhibition/NN of/IN apoptosis/NN after/IN withdrawal/NN of/IN IL-2/NN ./. 
Interestingly/RB ,/, when/WRB we/PRP fused/VBD HT-2/NN cells/NNS expressing/VBG the/DT EPOR/NN with/IN Ba/F3/NN cells/NNS in/IN a/DT complementation/NN assay/NN ,/, the/DT resulting/VBG hybridomas/NN proliferated/VBD and/CC potently/RB activated/VBD STAT-5/NN and/CC MAPK/NN in/IN response/NN to/TO EPO/NN ./. 
These/DT data/NNS indicate/VBP that/IN an/DT unidentified/JJ cellular/JJ factor/NN is/VBZ needed/VBN to/TO mediate/VB signaling/NN by/IN the/DT EPOR/NN ./. 
Moreover/RB ,/, Ba/F3/NN cells/NNS apparently/RB express/VBP this/DT factor/NN (/( s/NNS )/) and/CC somatic/JJ fusions/NNS can/MD ,/, therefore/RB ,/, confer/VB EPO-responsiveness/NN to/TO HT-2/NN cells/NNS that/WDT lack/VBP this/DT factor/NN ./. 
UI/LS -/: 99300859/CD 
TI/LS -/: Novel/JJ therapies/NNS for/IN inflammatory/JJ bowel/NN disease/NN ./. 
AB/LS -/: Looking/VBG back/RB at/IN successes/NNS and/CC failures/NNS in/IN newer/JJR approaches/NNS to/TO treating/VBG IBD/NN ,/, it/PRP is/VBZ tempting/JJ --/: although/IN still/RB difficult/JJ --/: to/TO draw/VB conclusions/NNS about/IN pathogenesis/NN ./. 
When/WRB a/DT therapy/NN proves/VBZ effective/JJ ,/, do/VBP clinicians/NNS truly/RB know/VB how/WRB it/PRP works/VBZ ?/. Even/RB with/IN a/DT therapy/NN as/IN specific/JJ as/IN anti-TNF/JJ antibody/NN ,/, it/PRP is/VBZ not/RB clear/JJ if/IN the/DT benefit/NN is/VBZ attributable/JJ to/TO simple/JJ binding/NN and/CC clearance/NN of/IN TNF-alpha/NN or/CC to/TO binding/NN on/IN the/DT cell/NN surface/NN and/CC subsequent/JJ deletion/NN of/IN the/DT activated/VBN macrophage/NN ./. 
When/WRB a/DT drug/NN appears/VBZ to/TO be/VB less/RBR effective/JJ than/IN preclinical/JJ models/NNS suggest/VBP ,/, can/MD failures/NNS in/IN effectiveness/NN from/IN delivery/NN or/CC dosing/NN be/VB differentiated/VBN ?/. The/DT disappointing/JJ results/NNS of/IN clinical/JJ trials/NNS with/IN IL-10/NN --/: so/RB at/IN odds/NNS with/IN the/DT prediction/NN of/IN benefit/NN from/IN animal/NN models/NNS --/: bring/VBP into/IN question/NN the/DT validity/NN of/IN those/DT models/NNS as/RB well/RB as/IN the/DT soundness/NN of/IN design/NN of/IN the/DT clinical/JJ trials/NNS on/IN which/WDT efficacy/NN of/IN IL-10/NN is/VBZ judged/VBN ./. 
The/DT variability/NN of/IN response/NN even/RB to/TO the/DT most/RBS narrowly/RB targeted/VBN agents/NNS suggests/VBZ that/IN these/DT diseases/NNS are/VBP far/RB more/RBR heterogeneous/JJ in/IN humans/NNS than/IN in/IN their/PRP$ murine/JJ counterparts/NNS ./. 
Clinicians/NNS are/VBP only/RB just/RB beginning/VBG to/TO recognize/VB subclinical/JJ markers/NNS of/IN response/NN ,/, and/CC it/PRP may/MD soon/RB be/VB possible/JJ to/TO predict/VB response/NN on/IN the/DT basis/NN of/IN genetic/JJ composition/NN ./. 
For/IN the/DT moment/NN ,/, however/RB ,/, the/DT field/NN of/IN pharmacogenetics/NNS is/VBZ embryonic/JJ ./. 
Challenges/NNS in/IN developing/VBG new/JJ therapeutic/JJ strategies/NNS include/VBP not/RB only/RB identifying/VBG novel/JJ agents/NNS ,/, but/CC also/RB improving/VBG the/DT definitions/NNS of/IN clinical/JJ endpoints/NNS and/CC defining/VBG efficacy/NN at/IN the/DT biologic/JJ level/NN ./. 
Only/RB through/IN considered/VBN evaluation/NN of/IN clinical/JJ evidence/NN may/MD clinicians/NNS determine/VB which/WDT therapies/NNS should/MD remain/VB novelties/NNS and/CC which/WDT should/MD become/VB an/DT accepted/VBN part/NN of/IN the/DT armamentarium/NN ./. 
UI/LS -/: 99292715/CD 
TI/LS -/: Potent/NN and/CC stable/JJ attenuation/NN of/IN live-HIV-1/NN by/IN gain/NN of/IN a/DT proteolysis-resistant/JJ inhibitor/NN of/IN NF-kappaB/NN (/( IkappaB-alphaS32/36A/NN )/) and/CC the/DT implications/NNS for/IN vaccine/NN development/NN ./. 
AB/LS -/: Live-attenuated/JJ human/JJ immunodeficiency/NN viruses/NNS (/( HIVs/NNS )/) are/VBP candidates/NNS for/IN Acquired/VBN Immunodeficiency/NN Syndrome/NN (/( AIDS/NN )/) vaccine/NN ./. 
Based/VBN on/IN the/DT simian/JJ immunodeficiency/NN virus/NN (/( SIV/NN )/) model/NN for/IN AIDS/NN ,/, loss-of-function/NN (/( e.g./FW deletion/NN of/IN accessory/NN genes/NNS such/JJ as/IN nef/NN )/) has/VBZ been/VBN forwarded/VBN as/IN a/DT primary/JJ approach/NN for/IN creating/VBG enfeebled/JJ ,/, but/CC replication-competent/JJ ,/, HIV-1/SIV/NN ./. 
Regrettably/RB ,/, recent/JJ evidence/NN suggests/VBZ that/IN loss-of-function/NN alone/RB is/VBZ not/RB always/RB sufficient/JJ to/TO prevent/VB the/DT emergence/NN of/IN virulent/JJ mutants/NNS ./. 
New/NN strategies/NNS that/WDT attenuate/VBP via/IN mechanisms/NNS distinct/JJ from/IN loss-of-function/NN are/VBP needed/VBN for/IN enhancing/VBG the/DT safety/NN phenotype/NN of/IN viral/JJ genome/NN ./. 
Here/RB ,/, we/PRP propose/VBP gain-of-function/NN to/TO be/VB used/VBN simultaneously/RB with/IN loss-of-function/NN as/IN a/DT novel/JJ approach/NN for/IN attenuating/VBG HIV-1/NN ./. 
We/PRP have/VBP constructed/VBN an/DT HIV-1/NN genome/NN carrying/VBG the/DT cDNA/NN of/IN a/DT proteolysis-resistant/JJ nuclear/JJ factor-kappaB/NN inhibitor/NN (/( IkappaB-alphaS32/36A/NN )/) in/IN the/DT nef/NN region/NN ./. 
HIV-1/NN expressing/VBG IkappaB-alphaS32/36A/NN down-regulates/VBZ viral/JJ expression/NN and/CC is/VBZ highly/RB attenuated/VBN in/IN both/CC Jurkat/NN and/CC peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
We/PRP provide/VBP formal/JJ proof/NN that/IN the/DT phenotypic/JJ and/CC attenuating/NN characteristics/NNS of/IN IkappaB-alphaS32/36A/NN permit/VBP its/PRP$ stable/JJ maintenance/NN in/IN a/DT live/JJ ,/, replicating/VBG HIV-1/NN despite/IN 180/CD days/NNS of/IN forced/JJ ex/FW vivo/FW passaging/NN in/IN tissue/NN culture/NN ./. 
As/IN compared/VBN with/IN other/JJ open-reading/JJ frames/NNS embedded/JJ into/IN HIV/SIV/NN genome/NN ,/, this/DT degree/NN of/IN stability/NN is/VBZ unprecedented/JJ ./. 
Thus/RB ,/, IkappaB-alphaS32/36A/NN offers/VBZ proof-of-principle/NN that/IN artifactually/RB gained/VBN functions/NNS ,/, when/WRB used/VBN to/TO attenuate/VB the/DT replication/NN of/IN live/JJ HIV-1/NN ,/, can/MD be/VB stable/JJ ./. 
These/DT findings/NNS illustrate/VBP gain-of-function/NN as/IN a/DT feasible/JJ strategy/NN for/IN developing/VBG safer/JJR live-attenuated/JJ HIVs/NNS to/TO be/VB tested/VBN as/IN candidates/NNS for/IN AIDS/NN vaccine/NN ./. 
UI/LS -/: 99288090/CD 
TI/LS -/: Multiple/JJ NF-ATc/NN isoforms/NNS with/IN individual/JJ transcriptional/JJ properties/NNS are/VBP synthesized/VBN in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT transcription/NN factor/NN NF-ATc/NN that/WDT controls/VBZ gene/NN expression/NN in/IN T/NN lymphocytes/NNS and/CC embryonic/JJ cardiac/JJ cells/NNS is/VBZ expressed/VBN in/IN three/CD prominent/JJ isoforms/NNS ./. 
This/DT is/VBZ due/JJ to/TO alternative/JJ splice/polyadenylation/NN events/NNS that/WDT lead/VBP to/TO the/DT predominant/JJ synthesis/NN of/IN two/CD long/JJ isoforms/NNS in/IN naive/JJ T/NN cells/NNS and/CC a/DT shorter/JJR NF-ATc/NN isoform/NN in/IN effector/NN T/NN cells/NNS ./. 
Whereas/IN the/DT previously/RB described/VBN isoform/NN NF-ATc/A/NN contains/VBZ a/DT relatively/RB short/JJ C/NN terminus/NN ,/, the/DT longer/JJR isoforms/NNS ,/, B/NN and/CC C/NN ,/, span/VBP extra/JJ C-terminal/JJ peptides/NNS of/IN 128/CD and/CC 246/CD aa/NN ,/, respectively/RB ./. 
We/PRP show/VBP here/RB that/IN in/IN addition/NN to/TO the/DT strong/JJ N-terminal/JJ trans-activation/NN domain/NN ,/, TAD-A/NN ,/, which/WDT is/VBZ common/JJ to/TO all/DT three/CD NF-ATc/NN isoforms/NNS ,/, NF-ATc/C/NN contains/VBZ a/DT second/JJ trans-activation/NN domain/NN ,/, TAD-B/NN ,/, in/IN its/PRP$ C-terminal/JJ peptide/NN ./. 
Various/JJ stimuli/NNS of/IN T/NN cells/NNS that/WDT induce/VBP the/DT activity/NN of/IN TAD-A/NN also/RB enhance/VBP the/DT activity/NN of/IN TAD-B/NN ,/, but/CC ,/, unlike/IN TAD-A/NN ,/, TAD-B/NN remains/VBZ unphosphorylated/JJ by/IN protein/NN from/IN 12-O-tetradecanoyl/NN 12-phorbol/NN 13-acetate-stimulated/JJ T/NN cells/NNS ./. 
The/DT shorter/JJR C-terminal/JJ peptide/NN of/IN isoform/NN NF-ATc/B/NN exerts/VBZ a/DT suppressive/JJ transcriptional/JJ effect/NN ./. 
These/DT properties/NNS of/IN NF-ATc/B/NN and/CC -C/NN might/MD be/VB of/IN importance/NN for/IN gene/NN regulation/NN in/IN naive/JJ T/NN lymphocytes/NNS in/IN which/WDT NF-ATc/B/NN and-/CC C/NN are/VBP predominantly/RB synthesized/VBN ./. 
UI/LS -/: 99282915/CD 
TI/LS -/: Selection/NN and/CC long-term/JJ persistence/NN of/IN reactive/JJ CTL/NN clones/NNS during/IN an/DT EBV/NN chronic/JJ response/NN are/VBP determined/VBN by/IN avidity/NN ,/, CD8/NN variable/JJ contribution/NN compensating/VBG for/IN differences/NNS in/IN TCR/NN affinities/NNS ./. 
AB/LS -/: Recent/JJ studies/NNS have/VBP suggested/VBN that/IN the/DT diversity/NN of/IN TCR/NN repertoire/NN after/IN primary/JJ immunization/NN is/VBZ conserved/VBN in/IN memory/NN T/NN cells/NNS and/CC that/IN a/DT progressive/JJ narrowing/NN of/IN this/DT repertoire/NN may/MD take/VB place/NN during/IN recall/NN infections/NNS ./. 
It/PRP now/RB remains/VBZ to/TO be/VB investigated/VBN which/WDT parameters/NNS determine/VBP the/DT repertoire/NN of/IN the/DT memory/NN response/NN and/CC possibly/RB restrict/VB its/PRP$ diversity/NN after/IN subsequent/JJ antigenic/JJ challenges/NNS ./. 
To/TO address/VB this/DT question/NN ,/, we/PRP took/VBD advantage/NN of/IN a/DT panel/NN of/IN CD8+/JJ T/NN cell/NN clones/NNS from/IN the/DT joint/NN of/IN a/DT rheumatoid/JJ arthritis/NN patient/NN and/CC selected/VBD for/IN their/PRP$ reactivity/NN against/IN a/DT single/JJ MHC/peptide/NN complex/NN ./. 
Characterization/NN of/IN both/DT TCR/NN chains/NNS documented/VBD a/DT great/JJ diversity/NN among/IN those/DT clones/NNS and/CC the/DT persistence/NN of/IN clonotypes/NNS over/IN a/DT 2-yr/JJ period/NN ./. 
Strikingly/RB ,/, despite/IN the/DT observed/VBN repertoire/NN heterogeneity/NN ,/, all/DT clones/NNS displayed/VBD a/DT narrow/JJ range/NN of/IN MHC/peptide/NN density/NN requirements/NNS in/IN cytotoxicity/NN assays/NNS (/( ED50/NN between/IN 9/CD and/CC 36/CD nM/NN )/) ./. 
TCR/NN affinities/NNS were/VBD then/RB indirectly/RB estimated/VBN by/IN blocking/VBG CD8/NN interaction/NN with/IN an/DT anti-CD8/JJ mAb/NN ./. 
We/PRP found/VBD a/DT wide/JJ range/NN of/IN TCR/NN affinities/NNS among/IN the/DT different/JJ clonotypes/NNS that/WDT segregated/VBD with/IN Vbeta/NN usage/NN ./. 
We/PRP thus/RB propose/VBP that/IN during/IN an/DT in/FW vivo/FW chronic/JJ response/NN ,/, a/DT narrow/JJ range/NN of/IN avidity/NN of/IN the/DT TCR-CD8/NN complex/NN conditions/VBZ long-term/JJ clonotype/NN persistence/NN ,/, and/CC that/IN the/DT level/NN of/IN CD8/NN contribution/NN is/VBZ adjusted/VBN to/TO keep/VB clonotypes/NNS with/IN variable/JJ TCR/NN affinities/NNS within/IN this/DT avidity/NN window/NN ./. 
UI/LS -/: 99263020/CD 
TI/LS -/: Nuclear/JJ localization/NN and/CC formation/NN of/IN beta-catenin-lymphoid/JJ enhancer/NN factor/NN 1/CD complexes/NNS are/VBP not/RB sufficient/JJ for/IN activation/NN of/IN gene/NN expression/NN ./. 
AB/LS -/: In/IN response/NN to/TO activation/NN of/IN the/DT Wnt/NN signaling/NN pathway/NN ,/, beta-catenin/NN accumulates/VBZ in/IN the/DT nucleus/NN ,/, where/WRB it/PRP cooperates/VBZ with/IN LEF/TCF/NN (/( for/IN lymphoid/JJ enhancer/NN factor/NN and/CC T-cell/NN factor/NN )/) transcription/NN factors/NNS to/TO activate/VB gene/NN expression/NN ./. 
The/DT mechanisms/NNS by/IN which/WDT beta-catenin/NN undergoes/VBZ this/DT shift/NN in/IN location/NN and/CC participates/VBZ in/IN activation/NN of/IN gene/NN transcription/NN are/VBP unknown/JJ ./. 
We/PRP demonstrate/VBP here/RB that/IN beta-catenin/NN can/MD be/VB imported/VBN into/IN the/DT nucleus/NN independently/RB of/IN LEF/TCF/NN binding/NN ,/, and/CC it/PRP may/MD also/RB be/VB exported/VBN from/IN nuclei/NNS ./. 
We/PRP have/VBP introduced/VBN a/DT small/JJ deletion/NN within/IN beta-catenin/JJ (/( Delta19/NN )/) that/WDT disrupts/VBZ binding/NN to/TO LEF-1/NN ,/, E-cadherin/NN ,/, and/CC APC/NN but/CC not/RB axin/NN ./. 
This/DT Delta19/NN beta-catenin/NN mutant/NN localizes/VBZ to/TO the/DT nucleus/NN because/IN it/PRP may/MD not/RB be/VB efficiently/RB sequestered/VBN in/IN the/DT cytoplasm/NN ./. 
The/DT nuclear/JJ localization/NN of/IN Delta19/NN definitively/RB demonstrates/VBZ that/IN the/DT mechanisms/NNS by/IN which/WDT beta-catenin/NN localizes/VBZ in/IN the/DT nucleus/NN are/VBP completely/RB independent/JJ of/IN LEF/TCF/NN factors/NNS ./. 
beta-Catenin/NN and/CC LEF-1/NN complexes/NNS can/MD activate/VB reporter/NN gene/NN expression/NN in/IN a/DT transformed/VBN T-lymphocyte/NN cell/NN line/NN (/( Jurkat/NN )/) but/CC not/RB in/IN normal/JJ T/NN lymphocytes/NNS ,/, even/RB though/IN both/DT factors/NNS are/VBP nuclear/JJ ./. 
Thus/RB ,/, localization/NN of/IN both/DT factors/NNS to/TO the/DT nucleus/NN is/VBZ not/RB sufficient/JJ for/IN activation/NN of/IN gene/NN expression/NN ./. 
Excess/JJ beta-catenin/NN can/MD squelch/VB reporter/NN gene/NN activation/NN by/IN LEF-1-beta-catenin/NN complexes/NNS but/CC not/RB activation/NN by/IN the/DT transcription/NN factor/NN VP16/NN ./. 
Taken/VBN together/RB ,/, these/DT data/NNS suggest/VBP that/IN a/DT third/JJ component/NN is/VBZ necessary/JJ for/IN gene/NN activation/NN and/CC that/IN this/DT third/JJ component/NN may/MD vary/VB with/IN cell/NN type/NN ./. 
UI/LS -/: 99257180/CD 
TI/LS -/: Control/NN of/IN lymphocyte/NN development/NN by/IN the/DT Ikaros/NN gene/NN family/NN ./. 
AB/LS -/: Lymphoid/JJ cell/NN differentiation/NN relies/VBZ on/IN precisely/RB orchestrated/VBN gene/NN activation/NN and/CC repression/NN events/NNS ./. 
Gene/NN targeting/NN studies/NNS have/VBP demonstrated/VBN crucial/JJ roles/NNS for/IN the/DT transcription/NN factors/NNS Ikaros/NN and/CC Aiolos/NN in/IN regulating/VBG multiple/JJ stages/NNS of/IN B/NN and/CC T/NN cell/NN development/NN ./. 
Recent/JJ experiments/NNS suggest/VBP that/IN Ikaros/NN and/CC Aiolos/NN set/VBP B/NN cell/NN antigen-receptor/NN (/( BCR/NN )/) -/: and/CC TCR-mediated/JJ signaling/NN thresholds/NNS and/CC that/IN the/DT molecules/NNS exist/VBP within/IN T/NN cells/NNS in/IN nuclear/JJ complexes/NNS that/WDT contain/VBP nucleosome/JJ remodeling/NN and/CC histone/NN deacetylase/NN activities/NNS ./. 
UI/LS -/: 99252081/CD 
TI/LS -/: Transcriptional/JJ targeting/NN of/IN retroviral/JJ vectors/NNS to/TO the/DT erythroblastic/JJ progeny/NN of/IN transduced/VBN hematopoietic/JJ stem/NN cells/NNS ./. 
AB/LS -/: Targeted/VBN expression/NN to/TO specific/JJ tissues/NNS or/CC cell/NN lineages/NNS is/VBZ a/DT necessary/JJ feature/NN of/IN a/DT gene/NN therapy/NN vector/NN for/IN many/JJ clinical/JJ applications/NNS ,/, such/JJ as/IN correction/NN of/IN hemoglobinopathies/NNS or/CC thalassemias/NNS by/IN transplantation/NN of/IN genetically/RB modified/VBN hematopoietic/JJ stem/NN cells/NNS ./. 
We/PRP developed/VBD retroviral/JJ vectors/NNS in/IN which/WDT the/DT constitutive/JJ viral/JJ enhancer/NN in/IN the/DT U3/NN region/NN of/IN the/DT 3'/JJ LTR/NN is/VBZ replaced/VBN by/IN an/DT autoregulatory/JJ enhancer/NN of/IN the/DT erythroid-specific/JJ GATA-1/NN transcription/NN factor/NN gene/NN ./. 
The/DT replaced/VBN enhancer/NN is/VBZ propagated/VBN to/TO the/DT 5'/JJ LTR/NN upon/IN integration/NN into/IN the/DT target/NN cell/NN genome/NN ./. 
The/DT modified/VBN vectors/NNS were/VBD used/VBN to/TO transduce/VB human/JJ hematopoietic/JJ cell/NN lines/NNS ,/, cord/NN blood-derived/JJ CD34(+)/JJ stem/progenitor/NN cells/NNS ,/, and/CC murine/JJ bone/NN marrow/NN repopulating/VBG stem/NN cells/NNS ./. 
The/DT expression/NN of/IN appropriate/JJ reporter/NN genes/NNS (/( triangle/NN upLNGFR/NN ,/, EGFP/NN )/) was/VBD analyzed/VBN in/IN the/DT differentiated/VBN progeny/NN of/IN transduced/VBN stem/NN cells/NNS in/FW vitro/FW ,/, in/IN liquid/JJ culture/NN as/RB well/RB as/IN in/IN clonogenic/JJ assay/NN ,/, and/CC in/FW vivo/FW ,/, after/IN bone/NN marrow/NN transplantation/NN in/IN lethally/RB irradiated/JJ mice/NNS ./. 
The/DT GATA-1/NN autoregulatory/JJ enhancer/NN effectively/RB restricts/VBZ the/DT expression/NN of/IN the/DT LTR-driven/JJ proviral/JJ transcription/NN unit/NN to/TO the/DT erythroblastic/JJ progeny/NN of/IN both/CC human/JJ progenitors/NNS and/CC mouse-repopulating/JJ stem/NN cells/NNS ./. 
Packaging/NN of/IN viral/JJ particles/NNS ,/, integration/NN into/IN the/DT target/NN genome/NN ,/, and/CC stability/NN of/IN the/DT integrated/JJ provirus/NN are/VBP not/RB affected/VBN by/IN the/DT LTR/NN modification/NN ./. 
Enhancer/NN replacement/NN is/VBZ therefore/RB an/DT effective/JJ strategy/NN to/TO target/VB expression/NN of/IN a/DT retroviral/JJ transgene/NN to/TO a/DT specific/JJ progeny/NN of/IN transduced/VBN hematopoietic/JJ stem/NN cells/NNS ./. 
UI/LS -/: 99244237/CD 
TI/LS -/: Regulation/NN of/IN Fas/NN ligand/NN expression/NN and/CC cell/NN death/NN by/IN apoptosis-linked/JJ gene/NN 4/CD ./. 
AB/LS -/: Programmed/VBN cell/NN death/NN is/VBZ a/DT process/NN required/VBN for/IN the/DT normal/JJ development/NN of/IN an/DT organism/NN ./. 
One/CD of/IN the/DT best/JJS understood/VBN apoptotic/JJ pathways/NNS occurs/VBZ in/IN T/NN lymphocytes/NNS and/CC is/VBZ mediated/VBN by/IN Fas/Fas/NN ligand/NN (/( FasL/NN )/) interaction/NN ./. 
During/IN studies/NNS of/IN apoptosis/NN induced/VBN by/IN T/NN cell-receptor/NN engagement/NN ,/, we/PRP identified/VBD ALG-4F/NN ,/, a/DT truncated/VBN transcript/NN that/WDT prevents/VBZ T/NN cell-receptor-induced/JJ FasL/NN upregulation/NN and/CC cell/NN death/NN ./. 
Overexpression/NN of/IN full-length/JJ ALG-4/NN induced/VBD transcription/NN of/IN FasL/NN and/CC ,/, consequently/RB ,/, apoptosis/NN ./. 
These/DT results/NNS indicate/VBP that/IN ALG-4/NN is/VBZ necessary/JJ and/CC sufficient/JJ for/IN FasL/NN expression/NN ./. 
Fas/FasL/NN interaction/NN initiates/VBZ cell/NN death/NN in/IN many/JJ other/JJ systems/NNS ,/, and/CC its/PRP$ dysregulation/NN is/VBZ a/DT mechanism/NN by/IN which/WDT several/JJ pathologic/JJ conditions/NNS arise/VBP ./. 
Understanding/VBG the/DT molecular/JJ mechanisms/NNS of/IN FasL/NN regulation/NN could/MD be/VB very/RB useful/JJ in/IN elucidating/VBG how/WRB these/DT diseases/NNS develop/VBP and/CC in/IN identifying/VBG potential/JJ therapeutic/JJ targets/NNS ./. 
UI/LS -/: 99340272/CD 
TI/LS -/: The/DT Epstein-Barr/JJ virus/NN oncoprotein/NN latent/JJ membrane/NN protein/NN 1/CD engages/VBZ the/DT tumor/NN necrosis/NN factor/NN receptor-associated/JJ proteins/NNS TRADD/NN and/CC receptor-interacting/JJ protein/NN (/( RIP/NN )/) but/CC does/VBZ not/RB induce/VB apoptosis/NN or/CC require/VB RIP/NN for/IN NF-kappaB/NN activation/NN ./. 
AB/LS -/: A/DT site/NN in/IN the/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) transforming/NN protein/NN LMP1/NN that/WDT constitutively/RB associates/VBZ with/IN the/DT tumor/NN necrosis/NN factor/NN receptor/NN 1/CD (/( TNFR1/NN )/) -associated/JJ death/NN domain/NN protein/NN TRADD/NN to/TO mediate/VB NF-kappaB/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN activation/NN is/VBZ critical/JJ for/IN long-term/JJ lymphoblastoid/JJ cell/NN proliferation/NN ./. 
We/PRP now/RB find/VBP that/IN LMP1/NN signaling/NN through/IN TRADD/NN differs/VBZ from/IN TNFR1/NN signaling/NN through/IN TRADD/NN ./. 
LMP1/NN needs/VBZ only/RB 11/CD amino/NN acids/NNS to/TO activate/VB NF-kappaB/NN or/CC synergize/VB with/IN TRADD/NN in/IN NF-kappaB/NN activation/NN ,/, while/IN TNFR1/NN requires/VBZ approximately/RB 70/CD residues/NNS ./. 
Further/RB ,/, LMP1/NN does/VBZ not/RB require/VB TRADD/NN residues/NNS 294/CD to/TO 312/CD for/IN NF-kappaB/NN activation/NN ,/, while/IN TNFR1/NN requires/VBZ TRADD/NN residues/NNS 296/CD to/TO 302/CD ./. 
LMP1/NN is/VBZ partially/RB blocked/VBN for/IN NF-kappaB/NN activation/NN by/IN a/DT TRADD/NN mutant/NN consisting/VBG of/IN residues/NNS 122/CD to/TO 293/CD ./. 
Unlike/IN TNFR1/NN ,/, LMP1/NN can/MD interact/VB directly/RB with/IN receptor-interacting/JJ protein/NN (/( RIP/NN )/) and/CC stably/RB associates/VBZ with/IN RIP/NN in/IN EBV-transformed/JJ lymphoblastoid/JJ cell/NN lines/NNS ./. 
Surprisingly/RB ,/, LMP1/NN does/VBZ not/RB require/VB RIP/NN for/IN NF-kappaB/NN activation/NN ./. 
Despite/IN constitutive/JJ association/NN with/IN TRADD/NN or/CC RIP/NN ,/, LMP1/NN does/VBZ not/RB induce/VB apoptosis/NN in/IN EBV-negative/JJ Burkitt/NN lymphoma/NN or/CC human/JJ embryonic/JJ kidney/NN 293/CD cells/NNS ./. 
These/DT results/NNS add/VBP a/DT different/JJ perspective/NN to/TO the/DT molecular/JJ interactions/NNS through/IN which/WDT LMP1/NN ,/, TRADD/NN ,/, and/CC RIP/NN participate/VBP in/IN B-lymphocyte/NN activation/NN and/CC growth/NN ./. 
UI/LS -/: 99323946/CD 
TI/LS -/: Inhibition/NN of/IN NF-kappa/NN B/NN activity/NN in/IN human/JJ T/NN lymphocytes/NNS induces/VBZ caspase-dependent/JJ apoptosis/NN without/IN detectable/JJ activation/NN of/IN caspase-1/NN and/CC -3/CD ./. 
AB/LS -/: NF-kappa/NN B/NN is/VBZ involved/VBN in/IN the/DT transcriptional/JJ control/NN of/IN various/JJ genes/NNS that/WDT act/VBP as/IN extrinsic/JJ and/CC intrinsic/JJ survival/NN factors/NNS for/IN T/NN cells/NNS ./. 
Our/PRP$ findings/NNS show/VBP that/IN suppression/NN of/IN NF-kappa/NN B/NN activity/NN with/IN cell-permeable/JJ SN50/NN peptide/NN ,/, which/WDT masks/VBZ the/DT nuclear/JJ localization/NN sequence/NN of/IN NF-kappa/NN B1/NN dimers/NNS and/CC prevents/VBZ their/PRP$ nuclear/JJ localization/NN ,/, induces/VBZ apoptosis/NN in/IN resting/VBG normal/JJ human/JJ PBL/NN ./. 
Inhibition/NN of/IN NF-kappa/NN B/NN resulted/VBD in/IN the/DT externalization/NN of/IN phosphatidylserine/NN ,/, induction/NN of/IN DNA/NN breaks/NNS ,/, and/CC morphological/JJ changes/NNS consistent/JJ with/IN apoptosis/NN ./. 
DNA/NN fragmentation/NN was/VBD efficiently/RB blocked/VBN by/IN the/DT caspase/NN inhibitor/NN Z-VAD-fmk/NN and/CC partially/RB blocked/VBN by/IN Ac-DEVD-fmk/NN ,/, suggesting/VBG that/IN SN50-mediated/JJ apoptosis/NN is/VBZ caspase-dependent/JJ ./. 
Interestingly/RB ,/, apoptosis/NN induced/VBN by/IN NF-kappa/NN B/NN suppression/NN ,/, in/IN contrast/NN to/TO that/DT induced/VBN by/IN TPEN/NN (/( N,N,N',N'-tetrakis/JJ [2-pyridylmethyl]ethylenediamine/NN )/) or/CC soluble/JJ Fas/NN ligand/NN (/( CD95/NN )/) ,/, was/VBD observed/VBN in/IN the/DT absence/NN of/IN active/JJ death/NN effector/NN proteases/NNS caspase-1-like/JJ (/( IL-1/NN converting/NN enzyme/NN )/) ,/, caspase-3-like/JJ (/( CPP32/Yama/apopain/NN )/) ,/, and/CC caspase-6-like/JJ and/CC without/IN cleavage/NN of/IN caspase-3/NN substrates/NNS poly(ADP-ribose)/JJ polymerase/NN and/CC DNA/NN fragmentation/NN factor-45/NN ./. 
These/DT findings/NNS suggest/VBP either/CC low/JJ level/NN of/IN activation/NN is/VBZ required/VBN or/CC that/IN different/JJ caspases/NNS are/VBP involved/VBN ./. 
Preactivation/NN of/IN T/NN cells/NNS resulting/VBG in/IN NF-kappa/NN B/NN nuclear/JJ translocation/NN protected/VBD cells/NNS from/IN SN50-induced/JJ apoptosis/NN ./. 
Our/PRP$ findings/NNS demonstrate/VBP an/DT essential/JJ role/NN of/IN NF-kappa/NN B/NN in/IN survival/NN of/IN naive/JJ PBL/NN ./. 
UI/LS -/: 99305241/CD 
TI/LS -/: Signal/NN transduction/NN pathways/NNS in/IN normal/JJ human/JJ monocytes/NNS stimulated/VBN by/IN cytokines/NNS and/CC mediators/NNS :/: comparative/JJ study/NN with/IN normal/JJ human/JJ neutrophils/NNS or/CC transformed/VBN cells/NNS and/CC the/DT putative/JJ roles/NNS in/IN functionality/NN and/CC cell/NN biology/NN ./. 
AB/LS -/: Granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) and/CC interleukin/NN (/( IL/NN )/) -3/CD induced/VBD tyrosine/NN phosphorylation/NN of/IN 92-kDa/JJ protein/NN in/IN normal/JJ human/JJ monocytes/NNS ./. 
We/PRP identified/VBD this/DT 92-kDa/JJ protein/NN as/IN STAT5/NN ,/, but/CC not/RB as/IN STATs1/NN ,/, 3/CD ,/, and/CC 6/CD nor/CC c-fes/NN and/CC vav/NN protooncogene/NN products/NNS ,/, and/CC demonstrated/VBD its/PRP$ translocation/NN to/TO the/DT nucleus/NN ,/, enhancement/NN of/IN specific/JJ DNA/NN binding/NN capacity/NN ,/, and/CC potentiation/NN of/IN trancriptional/JJ activity/NN by/IN GM-CSF/NN ./. 
N-formyl-methionyl-leucyl-phenylalanine/NN (/( FMLP/NN )/) and/CC phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) induced/VBD tyrosine/NN phosphorylation/NN of/IN 42-/CD and/CC 44-kDa/JJ proteins/NNS ,/, which/WDT were/VBD identified/VBN as/IN extracellular/JJ signal-regulated/JJ kinase/NN (/( ERK/NN )/) ,/, in/IN human/JJ monocytes/NNS ./. 
In/IN marked/JJ contrast/NN to/TO neutrophils/NNS and/CC MO7e/NN cells/NNS ,/, GM-CSF/NN did/VBD not/RB induce/VB tyrosine/NN phosphorylation/NN and/CC activation/NN of/IN ERK/NN in/IN monocytes/NNS ./. 
Among/IN upstream/JJ signaling/VBG molecules/NNS of/IN ERK/NN ,/, Shc/NN was/VBD constitutively/RB associated/VBN with/IN Grb2/NN and/CC was/VBD not/RB tyrosine-phosphorylated/VBN by/IN GM-CSF/NN and/CC FMLP/NN ,/, and/CC Sos1/NN and/CC c-Raf-1/NN were/VBD not/RB phosphorylated/VBN by/IN GM-CSF/NN ,/, IL-3/NN ,/, TNF/NN ,/, and/CC FMLP/NN in/IN monocytes/NNS ,/, whereas/IN all/PDT these/DT signaling/VBG molecules/NNS were/VBD affected/VBN and/or/CC utilized/VBN by/IN GM-CSF/NN in/IN MO7e/NN cells/NNS ./. 
In/IN contrast/NN to/TO neutrophils/NNS ,/, p38/NN was/VBD constitutively/RB phosphorylated/VBN and/CC agonist-dependent/JJ phosphorylation/NN and/CC activation/NN was/VBD not/RB detected/VBN in/IN human/JJ monocytes/NNS ./. 
Superoxide/NN release/NN stimulated/VBN by/IN FMLP/NN was/VBD inhibited/VBN partially/RB by/IN PD98059/NN or/CC SB203580/NN ,/, a/DT specific/JJ inhibitor/NN of/IN ERK/NN or/CC p38/NN pathway/NN ,/, and/CC was/VBD almost/RB completely/RB inhibited/VBN by/IN the/DT combination/NN of/IN both/DT inhibitors/NNS ,/, whereas/IN PMA-induced/JJ superoxide/NN release/NN was/VBD resistant/JJ to/TO these/DT two/CD inhibitors/NNS in/IN monocytes/NNS ./. 
PD98059/NN inhibited/VBD GM-CSF-dependent/JJ proliferation/NN of/IN MO7e/NN cells/NNS ./. 
Present/JJ results/NNS indicate/VBP trancriptional/JJ roles/NNS of/IN STAT5/NN and/CC functional/JJ roles/NNS of/IN ERK/NN and/or/CC p38/NN in/IN normal/JJ human/JJ monocytes/NNS stimulated/VBN by/IN physiological/JJ receptor-mediated/JJ agonists/NNS GM-CSF/NN and/CC FMLP/NN ./. 
Possible/JJ roles/NNS of/IN ERK/NN in/IN proliferation/NN of/IN transformed/VBN cells/NNS were/VBD also/RB suggested/VBN ./. 
UI/LS -/: 99298193/CD 
TI/LS -/: Aiolos/NN transcription/NN factor/NN controls/VBZ cell/NN death/NN in/IN T/NN cells/NNS by/IN regulating/VBG Bcl-2/NN expression/NN and/CC its/PRP$ cellular/JJ localization/NN ./. 
AB/LS -/: We/PRP searched/VBD for/IN proteins/NNS that/WDT interact/VBP with/IN Ras/NN in/IN interleukin/NN (/( IL/NN )/) -2-stimulated/JJ or/CC IL-2-deprived/JJ cells/NNS ,/, and/CC found/VBD that/IN the/DT transcription/NN factor/NN Aiolos/NN interacts/VBZ with/IN Ras/NN ./. 
The/DT Ras-Aiolos/NN interaction/NN was/VBD confirmed/VBN in/FW vitro/FW and/CC in/FW vivo/FW by/IN co-immunoprecipitation/NN ./. 
Indirect/JJ immunofluorescence/NN shows/VBZ that/IN IL-2/NN controls/VBZ the/DT cellular/JJ distribution/NN of/IN Aiolos/NN and/CC induces/VBZ its/PRP$ tyrosine/NN phosphorylation/NN ,/, required/VBN for/IN dissociation/NN from/IN Ras/NN ./. 
We/PRP also/RB identified/VBD functional/JJ Aiolos-binding/JJ sites/NNS in/IN the/DT Bcl-2/NN promoter/NN ,/, which/WDT are/VBP able/JJ to/TO activate/VB the/DT luciferase/NN reporter/NN gene/NN ./. 
Mutation/NN of/IN Aiolos-binding/JJ sites/NNS within/IN the/DT Bcl-2/NN promoter/NN inhibits/VBZ transactivation/NN of/IN the/DT reporter/NN gene/NN luciferase/NN ,/, suggesting/VBG direct/JJ control/NN of/IN Bcl-2/NN expression/NN by/IN Aiolos/NN ./. 
Co-transfection/NN experiments/NNS confirm/VBP that/IN Aiolos/NN induces/VBZ Bcl-2/NN expression/NN and/CC prevents/VBZ apoptosis/NN in/IN IL-2-deprived/JJ cells/NNS ./. 
We/PRP propose/VBP a/DT model/NN for/IN the/DT regulation/NN of/IN Bcl-2/NN expression/NN via/IN Aiolos/NN ./. 
UI/LS -/: 99289427/CD 
TI/LS -/: Binding/NN of/IN YY1/NN and/CC Oct1/NN to/TO a/DT novel/JJ element/NN that/WDT downregulates/VBZ expression/NN of/IN IL-5/NN in/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: BACKGROUND/NN :/: IL-5/NN controls/VBZ development/NN of/IN eosinophilia/NN and/CC has/VBZ been/VBN shown/VBN to/TO be/VB involved/VBN in/IN the/DT pathogenesis/NN of/IN allergic/JJ diseases/NNS ./. 
In/IN both/CC atopic/JJ and/CC nonatopic/JJ asthma/NN ,/, elevated/JJ IL-5/NN has/VBZ been/VBN detected/VBN in/IN peripheral/JJ blood/NN and/CC the/DT airways/NNS ./. 
IL-5/NN is/VBZ produced/VBN mainly/RB by/IN activated/VBN T/NN cells/NNS ,/, and/CC its/PRP$ expression/NN is/VBZ regulated/VBN at/IN the/DT transcriptional/JJ level/NN ./. 
OBJECTIVE/NN :/: This/DT study/NN focuses/VBZ on/IN the/DT functional/JJ analysis/NN of/IN the/DT human/JJ IL-5/NN (/( hIL-5/NN )/) promoter/NN and/CC characterization/NN of/IN cis -regulatory/JJ elements/NNS and/CC transcription/NN factors/NNS involved/VBN in/IN the/DT suppression/NN of/IN IL-5/NN transcription/NN in/IN T/NN cells/NNS ./. 
METHODS/NNS :/: Methods/NNS used/VBN in/IN this/DT study/NN include/VBP DNase/NN I/CD footprint/NN assays/NNS ,/, electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, and/CC functional/JJ analysis/NN by/IN mammalian/JJ cell/NN transfection/NN involving/VBG deletion/NN analysis/NN and/CC site-directed/JJ mutagenesis/NN ./. 
RESULTS/NNS :/: We/PRP identified/VBD 5/CD protein/NN binding/NN regions/NNS (/( BRs/NNS )/) located/JJ within/IN the/DT proximal/JJ hIL-5/NN promoter/NN ./. 
Functional/JJ analysis/NN indicates/VBZ that/IN the/DT BRs/NNS are/VBP involved/VBN in/IN control/NN of/IN hIL-5/NN promoter/NN activity/NN ./. 
Two/CD of/IN these/DT regions/NNS ,/, BR3/NN and/CC BR4/NN located/JJ at/IN positions/NNS -102/CD to/TO -73/CD ,/, have/VBP not/RB previously/RB been/VBN described/VBN as/IN regulators/NNS of/IN IL-5/NN expression/NN in/IN T/NN cells/NNS ./. 
We/PRP show/VBP that/IN the/DT BR3/NN sequence/NN contains/VBZ a/DT novel/JJ negative/JJ regulatory/JJ element/NN located/JJ at/IN positions/NNS -90/CD to/TO -79/CD of/IN the/DT hIL-5/NN promoter/NN ,/, which/WDT binds/VBZ Oct1/NN ,/, octamer-like/JJ ,/, and/CC YY1/NN nuclear/JJ factors/NNS ./. 
Substitution/NN mutations/NNS ,/, which/WDT abolished/VBD binding/NN of/IN these/DT proteins/NNS to/TO the/DT BR3/NN sequence/NN ,/, significantly/RB increased/VBD hIL-5/NN promoter/NN activity/NN in/IN activated/VBN T/NN cells/NNS ./. 
CONCLUSION/NN :/: We/PRP suggest/VBP that/IN Oct1/NN ,/, YY1/NN ,/, and/CC octamer-like/JJ factors/NNS binding/VBG to/TO the/DT -90/-79/CD sequence/NN within/IN the/DT proximal/JJ IL-5/NN promoter/NN are/VBP involved/VBN in/IN suppression/NN of/IN IL-5/NN transcription/NN in/IN T/NN cells/NNS ./. 
UI/LS -/: 99288066/CD 
TI/LS -/: New/JJ immunosuppressive/JJ drug/NN PNU156804/NN blocks/VBZ IL-2-dependent/JJ proliferation/NN and/CC NF-kappa/NN B/NN and/CC AP-1/NN activation/NN ./. 
AB/LS -/: We/PRP had/VBD previously/RB shown/VBN that/IN the/DT drug/NN undecylprodigiosin/NN (/( UP/NN )/) blocks/VBZ human/JJ lymphocyte/NN proliferation/NN in/FW vitro/FW ./. 
We/PRP have/VBP now/RB investigated/VBN the/DT mechanism/NN of/IN action/NN of/IN a/DT new/JJ analogue/NN of/IN UP/NN ,/, PNU156804/NN ,/, which/WDT shows/VBZ a/DT more/RBR favorable/JJ activity/NN profile/NN than/IN UP/NN in/IN mice/NNS ./. 
We/PRP demonstrate/VBP here/RB that/IN the/DT biological/JJ effect/NN of/IN PNU156804/NN in/FW vitro/FW is/VBZ indistinguishable/JJ from/IN UP/NN :/: PNU156804/NN blocks/VBZ human/JJ T/NN cell/NN proliferation/NN in/IN mid-late/JJ G1/NN ,/, as/IN determined/VBN by/IN cell/NN cycle/NN analysis/NN ,/, expression/NN of/IN cyclins/NNS ,/, and/CC cyclin-dependent/JJ kinases/NNS and/CC retinoblastoma/NN phosphorylation/NN ./. 
In/IN addition/NN ,/, we/PRP show/VBP that/IN PNU156804/NN does/VBZ not/RB block/VB significantly/RB the/DT induction/NN of/IN either/DT IL-2/NN or/CC IL-2R/NN alpha-/NN and/CC gamma-chains/NNS but/CC inhibits/VBZ IL-2-dependent/JJ T/NN cell/NN proliferation/NN ./. 
We/PRP have/VBP investigated/VBN several/JJ molecular/JJ pathways/NNS that/WDT are/VBP known/VBN to/TO be/VB activated/VBN by/IN IL-2/NN in/IN T/NN cells/NNS ./. 
We/PRP show/VBP that/IN PNU156804/NN does/VBZ not/RB inhibit/VB c-myc/NN and/CC bcl-2/NN mRNA/NN induction/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, PNU156804/NN efficiently/RB inhibits/VBZ the/DT activation/NN of/IN the/DT NF-kappa/NN B/NN and/CC AP-1/NN transcription/NN factors/NNS ./. 
PNU156804/NN inhibition/NN of/IN NF-kappa/NN B/NN activation/NN is/VBZ due/JJ to/TO the/DT inhibition/NN of/IN the/DT degradation/NN of/IN I/NN kappa/NN B-alpha/NN and/CC I/NN kappa/NN B-beta/NN ./. 
PNU156804/NN action/NN is/VBZ restricted/JJ to/TO some/DT signaling/NN pathways/NNS ;/: it/PRP does/VBZ not/RB affect/VB NF-kappa/NN B/NN activation/NN by/IN PMA/NN in/IN T/NN cells/NNS but/CC blocks/VBZ that/DT induced/VBN by/IN CD40/NN cross-linking/NN in/IN B/NN lymphocytes/NNS ./. 
We/PRP conclude/VBP that/IN the/DT prodigiosin/NN family/NN of/IN immunosuppressants/NNS is/VBZ a/DT new/JJ family/NN of/IN molecules/NNS that/WDT show/VBP a/DT novel/JJ target/NN specificity/NN clearly/RB distinct/JJ from/IN that/DT of/IN other/JJ immunosuppressive/JJ drugs/NNS such/JJ as/IN cyclosporin/NN A/NN ,/, FK506/NN ,/, and/CC rapamycin/NN ./. 
UI/LS -/: 99276096/CD 
TI/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD Tax/NN protein/NN induces/VBZ the/DT expression/NN of/IN STAT1/NN and/CC STAT5/NN genes/NNS in/IN T-cells/NNS ./. 
AB/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) Tax/NN transforms/VBZ normal/JJ T-cells/NNS in/IN the/DT presence/NN of/IN interleukin/NN (/( IL/NN )/) -2/CD in/FW vitro/FW ./. 
STAT/NN is/VBZ a/DT family/NN of/IN transcription/NN factors/NNS that/WDT play/VBP a/DT pivotal/JJ role/NN in/IN cytokine-induced/JJ functions/NNS of/IN a/DT various/JJ type/NN of/IN cells/NNS ./. 
We/PRP investigated/VBD the/DT involvement/NN of/IN STATs/NNS in/IN the/DT transformation/NN of/IN T-cells/NNS by/IN HTLV-1/NN ./. 
HTLV-1-transformed/JJ T-cell/NN lines/NNS expressed/VBD higher/JJR amounts/NNS of/IN STAT1/NN ,/, STAT3/NN and/CC STAT5/NN RNA/NN and/CC proteins/NNS than/IN virus-negative/JJ T/NN cells/NNS ./. 
The/DT expression/NN of/IN STAT1/NN and/CC STAT5/NN in/IN a/DT human/JJ T-cell/NN line/NN was/VBD induced/VBN by/IN Tax/NN ./. 
IL-2/NN induced/VBD the/DT DNA/NN binding/NN activity/NN of/IN STAT3/NN and/CC STAT5/NN of/IN a/DT HTLV-1-transformed/JJ cell/NN line/NN and/CC then/RB stimulated/VBD its/PRP$ proliferation/NN ./. 
In/IN contrast/NN ,/, IL-2/NN did/VBD neither/DT in/IN a/DT cell/NN line/NN lacking/VBG STAT3/NN and/CC STAT5/NN ./. 
The/DT expression/NN of/IN STAT1/NN ,/, STAT3/NN and/CC STAT5/NN mRNAs/NNS were/VBD also/RB induced/VBN by/IN a/DT T-cell/NN mitogen/NN in/IN normal/JJ human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
Our/PRP$ results/NNS suggest/VBP that/IN the/DT induction/NN of/IN STAT1/NN and/CC STAT5/NN by/IN Tax/NN enhances/VBZ cytokine-induced/JJ functions/NNS of/IN virus-infected/JJ T-cells/NNS ,/, hence/RB the/DT induction/NN may/MD play/VB a/DT role/NN in/IN IL-2-dependent/JJ transformation/NN steps/NNS of/IN T-cells/NNS by/IN HTLV-1/NN ./. 
UI/LS -/: 99262580/CD 
TI/LS -/: Transcriptional/JJ control/NN of/IN the/DT IL-5/NN gene/NN by/IN human/JJ helper/NN T/NN cells/NNS :/: IL-5/NN synthesis/NN is/VBZ regulated/VBN independently/RB from/IN IL-2/NN or/CC IL-4/NN synthesis/NN ./. 
AB/LS -/: BACKGROUND/NN :/: IL-5/NN is/VBZ fundamentally/RB involved/VBN in/IN eosinophilic/JJ inflammation/NN ./. 
Control/NN of/IN IL-5/NN production/NN may/MD be/VB effective/JJ for/IN the/DT management/NN of/IN allergic/JJ diseases/NNS ./. 
OBJECTIVE/NN :/: We/PRP aimed/VBD to/TO find/VB the/DT transcriptional/JJ mechanisms/NNS that/WDT regulate/VBP the/DT IL-5/NN gene/NN to/TO selectively/RB control/VB IL-5/NN synthesis/NN ./. 
METHODS/NNS :/: Allergen-specific/JJ T-cell/NN clones/NNS and/CC T-cell/NN hybridomas/NNS were/VBD established/VBN from/IN the/DT peripheral/JJ blood/NN lymphocytes/NNS of/IN patients/NNS with/IN asthma/NN ,/, and/CC the/DT transcriptional/JJ regulation/NN of/IN the/DT IL-5/NN gene/NN was/VBD investigated/VBN with/IN transient/JJ transfection/NN and/CC electrophoretic/JJ mobility/NN shift/NN analysis/NN ./. 
RESULTS/NNS :/: A/DT human/JJ IL-5/NN promoter/enhancer-luciferase/NN gene/NN construct/NN ,/, pIL-5(-511)/NN Luc/NN ,/, was/VBD transcribed/VBN on/IN activation/NN of/IN IL-5-producing/JJ T-cell/NN clones/NNS ,/, but/CC not/RB IL-5-nonproducing/JJ clones/NNS ./. 
pIL-5(-511)/NN Luc/NN was/VBD transcribed/VBN by/IN T-cell/NN hybridomas/NNS derived/VBN from/IN fusion/NN between/IN IL-5-producing/JJ T-cell/NN clones/NNS and/CC an/DT IL-5/NN gene-nonexpressing/JJ T-cell/NN line/NN ,/, but/CC not/RB by/IN hybridomas/NNS derived/VBN from/IN IL-5-nonproducing/JJ T-cell/NN clones/NNS ./. 
IL-5/NN synthesis/NN was/VBD not/RB only/RB induced/VBN by/IN T-cell/NN receptor/NN stimulation/NN but/CC also/RB by/IN IL-2/NN receptor/NN stimulation/NN ./. 
Binding/NN of/IN NF-AT/NN ,/, NF-kappaB/NN ,/, and/CC AP-1/NN was/VBD induced/VBN by/IN T-cell/NN receptor/NN (/( TcR/NN )/) stimulation/NN ,/, although/IN there/EX was/VBD no/DT significant/JJ upregulation/NN of/IN binding/NN by/IN IL-2/NN stimulation/NN ./. 
CONCLUSION/NN :/: IL-5/NN synthesis/NN by/IN human/JJ helper/NN T/NN cells/NNS is/VBZ regulated/VBN at/IN the/DT transcriptional/JJ level/NN ./. 
A/DT unique/JJ transcriptional/JJ mechanism/NN distinct/JJ from/IN those/DT regulating/VBG the/DT IL-2/NN or/CC IL-4/NN genes/NNS seems/VBZ to/TO control/VB the/DT IL-5/NN gene/NN ./. 
Selective/JJ regulation/NN of/IN IL-5/NN gene/NN transcription/NN may/MD be/VB useful/JJ for/IN treating/VBG eosinophlic/JJ inflammation/NN ./. 
UI/LS -/: 99254099/CD 
TI/LS -/: Defining/VBG therapeutic/JJ targets/NNS by/IN using/VBG adenovirus/NN :/: blocking/VBG NF-kappaB/NN inhibits/VBZ both/CC inflammatory/JJ and/CC destructive/JJ mechanisms/NNS in/IN rheumatoid/JJ synovium/NN but/CC spares/VBZ anti-inflammatory/JJ mediators/NNS ./. 
AB/LS -/: The/DT role/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN in/IN the/DT pathogenesis/NN of/IN rheumatoid/JJ arthritis/NN has/VBZ long/RB been/VBN a/DT subject/NN of/IN controversy/NN ./. 
We/PRP used/VBD an/DT adenoviral/JJ technique/NN of/IN blocking/VBG NF-kappaB/NN through/IN overexpression/NN of/IN the/DT inhibitory/JJ subunit/NN IkappaBalpha/NN ,/, which/WDT has/VBZ the/DT advantage/NN that/IN it/PRP can/MD be/VB used/VBN in/IN the/DT diseased/JJ tissue/NN itself/PRP ,/, with/IN >/JJR 90/CD %/NN of/IN the/DT synovial/JJ macrophages/NNS ,/, fibroblasts/NNS ,/, and/CC T/NN cells/NNS infected/VBN ./. 
We/PRP found/VBD that/IN the/DT spontaneous/JJ production/NN of/IN tumor/NN necrosis/NN factor/NN alpha/NN and/CC other/JJ pro-inflammatory/JJ cytokines/NNS is/VBZ NF-kappaB-dependent/JJ in/IN rheumatoid/JJ synovial/JJ tissue/NN ,/, in/IN contrast/NN to/TO the/DT main/JJ anti-inflammatory/JJ mediators/NNS ,/, like/IN IL-10/NN and/CC -11/CD ,/, and/CC the/DT IL-1/NN receptor/NN antagonist/NN ./. 
Of/IN even/RB more/JJR interest/NN ,/, IkappaBalpha/NN overexpression/NN inhibited/VBD the/DT production/NN of/IN matrix/NN metalloproteinases/NNS 1/CD and/CC 3/CD while/IN not/RB affecting/VBG their/PRP$ tissue/NN inhibitor/NN ./. 
Blocking/VBG NF-kappaB/NN in/IN the/DT rheumatoid/JJ joint/NN thus/RB has/VBZ a/DT very/RB beneficial/JJ profile/NN ,/, reducing/VBG both/CC the/DT inflammatory/JJ response/NN and/CC the/DT tissue/NN destruction/NN ./. 
The/DT adenoviral/JJ technique/NN described/VBN here/RB has/VBZ widespread/JJ applicability/NN ,/, allowing/VBG rapid/JJ testing/NN of/IN the/DT effects/NNS of/IN blocking/VBG a/DT potential/JJ therapeutic/JJ target/NN in/IN either/CC cultures/NNS of/IN normal/JJ cells/NNS or/CC in/IN the/DT diseased/JJ tissue/NN itself/PRP ./. 
UI/LS -/: 99247345/CD 
TI/LS -/: Resistance/NN to/TO tumor/NN necrosis/NN factor/NN induced/JJ apoptosis/NN in/FW vitro/FW correlates/VBZ with/IN high/JJ metastatic/JJ capacity/NN of/IN cells/NNS in/FW vivo/FW ./. 
AB/LS -/: TNF/NN is/VBZ one/CD of/IN the/DT cytokines/NNS secreted/VBN by/IN the/DT cells/NNS of/IN the/DT immune/JJ system/NN ./. 
Our/PRP$ data/NNS demonstrate/VBP that/IN those/DT cell/NN lines/NNS lacking/VBG capability/NN to/TO form/VB metastatic/JJ tumors/NNS in/FW vivo/FW are/VBP susceptible/JJ to/TO TNF/NN induced/JJ apoptosis/NN in/FW vitro/FW ./. 
However/RB ,/, cell/NN lines/NNS with/IN high/JJ metastatic/JJ potential/NN are/VBP resistant/JJ to/TO TNF/NN in/FW vitro/FW ./. 
Furthermore/RB ,/, the/DT same/JJ cell/NN lines/NNS were/VBD resistant/JJ to/TO cytolytic/JJ action/NN of/IN other/JJ cytotoxic/JJ proteins/NNS secreted/VBN by/IN LAK/NN cells/NNS ./. 
Our/PRP$ data/NNS showed/VBD that/IN TNF/NN resistance/NN in/FW vitro/FW correlates/VBZ with/IN the/DT increased/VBN level/NN of/IN transcription/NN factor/NN NF-kappaB/NN ./. 
This/DT finding/NN may/MD provide/VB a/DT tool/NN to/TO improve/VB current/JJ protocols/NNS of/IN immunotherapy/NN and/CC insights/NNS to/TO how/WRB tumor/NN cells/NNS are/VBP or/CC are/VBP not/RB killed/VBN by/IN LAK/NN cells/NNS ./. 
UI/LS -/: 99335895/CD 
TI/LS -/: Clonality/NN analysis/NN of/IN granulocytes/NNS and/CC T/NN lymphocytes/NNS in/IN healthy/JJ females/NNS by/IN the/DT PCR-based/JJ HUMARA/NN method/NN ./. 
AB/LS -/: Clonality/NN analysis/NN utilizing/VBG X-chromosome/NN inactivation/NN has/VBZ been/VBN used/VBN in/IN the/DT study/NN of/IN various/JJ diseases/NNS ,/, including/VBG hematological/JJ malignancies/NNS ./. 
The/DT human/JJ androgen/NN receptor/NN gene/NN (/( HUMARA/NN )/) assay/NN is/VBZ the/DT newest/JJS of/IN such/JJ methods/NNS ,/, and/CC the/DT majority/NN of/IN the/DT female/JJ population/NN can/MD be/VB assessed/VBN by/IN this/DT relatively/RB simple/JJ procedure/NN ./. 
One/CD problem/NN in/IN using/VBG these/DT clonality/NN analysis/NN methods/NNS ,/, however/RB ,/, is/VBZ that/IN there/EX may/MD be/VB significant/JJ variation/NN in/IN Lyonization/NN in/IN blood/NN cells/NNS in/IN normal/JJ individuals/NNS ./. 
To/TO determine/VB the/DT diversity/NN in/IN X-chromosome/NN methylation/NN patterns/NNS ,/, which/WDT reflect/VBP Lyonization/NN ,/, assessed/VBN by/IN the/DT HUMARA/NN assay/NN in/IN the/DT supposedly/RB normal/JJ population/NN ,/, we/PRP analyzed/VBD granulocytes/NNS and/CC T/NN cells/NNS from/IN 97/CD relatively/RB young/JJ (/( 18-/CD to/TO 35-year-old/JJ )/) healthy/JJ female/JJ volunteers/NNS ./. 
We/PRP found/VBD that/IN the/DT methylation/NN patterns/NNS in/IN the/DT two/CD HUMARA/NN alleles/NNS were/VBD distributed/VBN even/RB more/RBR widely/RB ,/, both/CC in/IN granuloctyes/NNS and/CC in/IN T/NN cells/NNS ,/, than/IN previously/RB reported/VBN with/IN other/JJ methods/NNS ./. 
We/PRP also/RB found/VBD that/IN the/DT deviation/NN of/IN methylation/NN in/IN granulocytes/NNS and/CC T/NN cells/NNS was/VBD well/RB correlated/VBN ./. 
Thus/RB ,/, we/PRP conclude/VBP that/IN appropriate/JJ controls/NNS from/IN the/DT same/JJ individuals/NNS ,/, such/JJ as/IN T/NN cells/NNS in/IN the/DT case/NN of/IN stem/NN cell/NN disorders/NNS ,/, should/MD always/RB be/VB employed/VBN to/TO conclusively/RB determine/VB whether/IN certain/JJ cells/NNS of/IN hematopoietic/JJ origin/NN are/VBP clonal/JJ ./. 
UI/LS -/: 99315748/CD 
TI/LS -/: Functional/JJ B-cell/NN response/NN in/IN intrahepatic/JJ lymphoid/JJ follicles/NNS in/IN chronic/JJ hepatitis/NN C/NN ./. 
AB/LS -/: Intrahepatic/JJ lymphoid/JJ follicle/NN (/( ILF/NN )/) formation/NN is/VBZ one/CD of/IN the/DT most/RBS characteristic/JJ and/CC commonly/RB observed/VBN histological/JJ features/NNS in/IN patients/NNS with/IN chronic/JJ hepatitis/NN C/NN ./. 
However/RB ,/, little/JJ is/VBZ known/VBN regarding/VBG whether/IN follicles/NNS in/IN the/DT liver/NN belong/VBP to/TO functional/JJ lymphoid/JJ tissues/NNS ,/, where/WRB B/NN cells/NNS are/VBP activated/VBN ,/, differentiated/VBN ,/, and/CC proliferated/VBN ,/, or/CC if/IN the/DT lymphocytes/NNS are/VBP merely/RB infiltrated/VBN after/IN recruitment/NN from/IN the/DT secondary/JJ lymphoid/JJ organs/NNS ./. 
To/TO ascertain/VB this/DT possibility/NN ,/, we/PRP examined/VBD the/DT expression/NN of/IN markers/NNS for/IN B-cell/NN activation/NN ,/, differentiation/NN ,/, and/CC proliferation/NN in/IN ILFs/NNS in/IN patients/NNS with/IN chronic/JJ hepatitis/NN C/NN using/VBG surgically/RB resected/JJ specimens/NNS ,/, and/CC compared/VBD them/PRP with/IN specimens/NNS of/IN perihepatic/JJ lymph/NN nodes/NNS by/IN an/DT immunohistochemical/JJ technique/NN ./. 
Germinal/JJ center/NN (/( GC/NN )/) formation/NN in/IN the/DT ILFs/NNS was/VBD frequently/RB found/VBN in/IN HCV-positive/JJ cases/NNS ./. 
The/DT distribution/NN of/IN immunoglobulin/NN M/NN (/( IgM/NN )/) -/: ,/, IgD-/NN ,/, and/CC IgG-positive/JJ cells/NNS and/CC the/DT expression/NN patterns/NNS of/IN Ki-67/NN ,/, CD23/NN ,/, or/CC bcl-2/NN and/CC bcl-6/JJ gene/NN products/NNS in/IN the/DT follicles/NNS with/IN GC/NN formation/NN in/IN the/DT liver/NN of/IN patients/NNS with/IN chronic/JJ hepatitis/NN C/NN were/VBD similar/JJ to/TO those/DT of/IN lymph/NN nodes/NNS ,/, indicating/VBG that/IN B/NN cells/NNS are/VBP activated/VBN ,/, proliferated/VBN ,/, and/CC differentiated/VBN in/IN the/DT ILFs/NNS with/IN GC/NN formation/NN in/IN patients/NNS with/IN chronic/JJ hepatitis/NN C/NN ./. 
Oligoclonal/JJ expansion/NN of/IN B/NN cells/NNS in/IN the/DT livers/NNS with/IN ILFs/NNS was/VBD confirmed/VBN by/IN an/DT analysis/NN of/IN immunoglobulin/NN heavy/JJ chain/NN (/( IgH/JJ )/) gene/NN rearrangement/NN determined/VBN by/IN polymerase/NN chain/NN reaction/NN (/( PCR/NN )/) ./. 
These/DT data/NNS strongly/RB suggest/VBP that/IN ILFs/NNS with/IN GC/NN formation/NN ,/, which/WDT are/VBP frequently/RB found/VBN in/IN patients/NNS with/IN chronic/JJ hepatitis/NN C/NN ,/, may/MD functionally/RB be/VB the/DT same/JJ as/IN those/DT found/VBN in/IN lymph/NN nodes/NNS with/IN respect/NN to/TO B-cell/NN expansion/NN and/CC maturation/NN ./. 
UI/LS -/: 99305240/CD 
TI/LS -/: Downregulation/NN of/IN Wilms/NN '/POS tumor/NN gene/NN (/( WT1/NN )/) is/VBZ not/RB a/DT prerequisite/NN for/IN erythroid/JJ or/CC megakaryocytic/JJ differentiation/NN of/IN the/DT leukemic/JJ cell/NN line/NN K562/NN ./. 
AB/LS -/: The/DT Wilms/NN '/POS tumor/NN gene/NN (/( WT1/NN )/) encodes/VBZ a/DT transcription/NN factor/NN of/IN the/DT zinc/NN finger/NN type/NN ./. 
A/DT high/JJ expression/NN of/IN WT1/NN has/VBZ been/VBN detected/VBN in/IN a/DT range/NN of/IN acute/JJ leukemias/NNS ,/, and/CC WT1/NN is/VBZ downregulated/VBN during/IN induced/VBN differentiation/NN of/IN some/DT leukemic/JJ cell/NN lines/NNS ./. 
Overexpression/NN of/IN WT1/NN in/IN some/DT myeloid/JJ cell/NN lines/NNS confers/VBZ resistance/NN to/TO differentiation/NN induction/NN ./. 
These/DT observations/NNS suggest/VBP that/IN a/DT high/JJ WT1/NN expression/NN in/IN hematopoietic/JJ cells/NNS is/VBZ incompatible/JJ with/IN differentiation/NN ./. 
In/IN this/DT study/NN ,/, each/DT of/IN the/DT four/CD different/JJ isoforms/NNS of/IN WT1/NN was/VBD constitutively/RB overexpressed/VBN in/IN the/DT leukemic/JJ cell/NN line/NN K562/NN ./. 
K562/NN cells/NNS express/VBP endogenous/JJ WT1/NN ,/, which/WDT is/VBZ downregulated/VBN as/IN a/DT response/NN to/TO induced/VBN differentiation/NN along/IN the/DT erythroid/JJ and/CC megakaryocytic/JJ pathways/NNS ./. 
We/PRP now/RB demonstrate/VBP that/IN a/DT forced/JJ exogenous/JJ expression/NN of/IN the/DT four/CD different/JJ isoforms/NNS of/IN WT1/NN in/IN K562/NN does/VBZ not/RB affect/VB the/DT differentiation/NN response/NN ,/, as/IN judged/VBN by/IN accumulation/NN of/IN hemoglobin/NN in/IN response/NN to/TO hemin/NN or/CC the/DT expression/NN of/IN megakaryocytic/JJ cell/NN surface/NN markers/NNS in/IN response/NN to/TO 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) ./. 
We/PRP conclude/VBP that/IN downregulation/NN of/IN WT1/NN during/IN induced/VBN differentiation/NN of/IN K562/NN cells/NNS is/VBZ not/RB a/DT prerequisite/NN for/IN erythroid/JJ or/CC megakaryocytic/JJ differentiation/NN of/IN these/DT cells/NNS ./. 
UI/LS -/: 99296093/CD 
TI/LS -/: Association/NN of/IN the/DT interleukin-4/NN receptor/NN alpha/NN chain/NN with/IN p47phox/NN ,/, an/DT activator/NN of/IN the/DT phagocyte/NN NADPH/NN oxidase/NN in/IN B/NN cells/NNS ./. 
AB/LS -/: Interleukin/NN (/( IL/NN )/) -4/CD plays/VBZ an/DT important/JJ role/NN in/IN IgE/NN synthesis/NN in/IN B/NN cells/NNS and/CC in/IN Th2/NN differentiation/NN in/IN T/NN cells/NNS ./. 
IL-4/NN conducts/VBZ its/PRP$ biological/JJ activities/NNS through/IN binding/VBG to/TO the/DT IL-4/NN receptor/NN (/( IL-4R/NN )/) on/IN the/DT surface/NN of/IN target/NN cells/NNS ./. 
IL-4R/NN are/VBP thought/VBN to/TO be/VB composed/VBN of/IN the/DT IL-4R/NN alpha/NN chain/NN (/( IL-4R/NN alpha/NN )/) and/CC either/CC the/DT IL-2R/NN gamma/NN chain/NN or/CC the/DT IL-13R/NN alpha/NN chain/NN ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN the/DT membrane-proximal/JJ portion/NN in/IN the/DT cytoplasmic/JJ domain/NN of/IN the/DT human/JJ IL-4R/NN alpha/NN (/( hIL-4R/NN alpha/NN )/) is/VBZ critical/JJ for/IN proliferation/NN ,/, generation/NN of/IN germline/NN epsilon/NN transcript/NN ,/, and/CC activation/NN of/IN STAT6/NN ,/, based/VBN on/IN analyses/NNS of/IN truncated/VBN hIL-4R/NN alphas/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP found/VBD that/IN p47phox/NN ,/, an/DT activator/NN of/IN the/DT phagocyte/NN NADPH/NN oxidase/NN ,/, binds/VBZ to/TO this/DT portion/NN by/IN the/DT two-hybrid/JJ system/NN ./. 
Furthermore/RB ,/, we/PRP observed/VBD the/DT association/NN of/IN p47phox/NN with/IN the/DT hIL-4R/NN alpha/NN in/IN B/NN cells/NNS derived/VBN from/IN a/DT normal/JJ donor/NN ./. 
These/DT results/NNS suggest/VBP that/IN p47phox/NN is/VBZ involved/VBN in/IN the/DT signal/NN transduction/NN of/IN IL-4/NN in/IN B/NN cells/NNS ./. 
However/RB ,/, activation/NN of/IN STAT6/NN ,/, CD23/NN expression/NN ,/, and/CC IgE/NN synthesis/NN induced/VBN by/IN IL-4/NN were/VBD not/RB affected/VBN in/IN p47phox-deficient/JJ patients/NNS ,/, which/WDT raises/VBZ the/DT possibility/NN that/IN p47phox/NN may/MD be/VB important/JJ in/IN other/JJ signaling/NN activities/NNS as/RB well/RB in/IN B/NN cells/NNS ./. 
UI/LS -/: 99289426/CD 
TI/LS -/: Effects/NNS of/IN diesel/NN organic/JJ extracts/NNS on/IN chemokine/NN production/NN by/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
AB/LS -/: BACKGROUND/NN :/: Polyaromatic/NN hydrocarbons/NNS (/( PAHs/NNS )/) associated/VBN with/IN diesel/NN exhaust/NN particles/NNS (/( DEPs/NNS )/) are/VBP found/VBN in/IN the/DT atmospheric/JJ urban/JJ pollution/NN ./. 
Such/JJ compounds/NNS have/VBP been/VBN shown/VBN to/TO favor/VB IgE/NN production/NN ,/, bronchial/JJ hyperresponsiveness/NN ,/, and/CC airway/NN inflammation/NN ./. 
Chemokines/NNS are/VBP a/DT group/NN of/IN chemotactic/JJ cytokines/NNS involved/VBN in/IN the/DT recruitment/NN of/IN inflammatory/JJ cells/NNS ./. 
OBJECTIVE/NN :/: We/PRP investigated/VBD the/DT effect/NN of/IN DEP-PAHs/NNS on/IN the/DT release/NN and/CC mRNA/NN expression/NN of/IN IL-8/NN ,/, MCP-1/NN ,/, and/CC RANTES/NN by/IN PBMCs/NNS obtained/VBN from/IN healthy/JJ subjects/NNS ./. 
METHODS/NNS :/: Protein/NN production/NN in/IN supernatants/NNS was/VBD assessed/VBN by/IN ELISA/NN ,/, and/CC mRNA/NN expression/NN was/VBD evaluated/VBN by/IN semiquantitative/JJ RT-PCR/NN ./. 
RESULTS/NNS :/: Secretion/NN of/IN IL-8/NN and/CC RANTES/NN increased/VBD in/IN a/DT dose-dependent/JJ manner/NN with/IN increasing/VBG concentrations/NNS of/IN DEP-PAHs/NNS (/( range/NN ,/, 0.5/CD ng/NN to/TO 50/CD ng/mL/NN )/) ./. 
On/IN the/DT contrary/NN ,/, the/DT release/NN of/IN MCP-1/NN was/VBD significantly/RB inhibited/VBN ,/, also/RB in/IN a/DT dose-dependent/JJ manner/NN ./. 
Messenger/NN RNA/NN production/NN coding/VBG for/IN IL-8/NN ,/, RANTES/NN ,/, and/CC MCP-1/NN showed/VBD parallel/JJ variations/NNS to/TO the/DT production/NN of/IN the/DT correspondent/JJ proteins/NNS ./. 
Effects/NNS of/IN DEP-PAHs/NNS became/VBD significant/JJ at/IN 7/CD hours/NNS and/CC up/IN to/TO 48/CD hours/NNS time/NN culture/NN for/IN MCP-1/NN ,/, and/CC up/IN to/TO 24/CD hours/NNS time/NN culture/NN for/IN IL-8/NN and/CC RANTES/NN ./. 
Moreover/RB ,/, supernatants/NNS from/IN DEP-PAH-activated/JJ cells/NNS ,/, compared/VBN with/IN those/DT of/IN controls/NNS ,/, exhibited/VBD a/DT significantly/RB enhanced/VBN chemotactic/JJ activity/NN for/IN neutrophils/NNS and/CC eosinophils/NNS ,/, which/WDT was/VBD significantly/RB inhibited/VBN by/IN pretreatment/NN with/IN anti-IL-8/NN and/CC anti-RANTES/JJ neutralizing/NN antibodies/NNS ,/, respectively/RB ./. 
CONCLUSION/NN :/: These/DT findings/NNS suggest/VBP that/IN the/DT chemokine/NN pathways/NNS are/VBP modulated/VBN by/IN DEP-PAHs/NNS at/IN the/DT transcriptional/JJ level/NN ,/, reinforcing/VBG the/DT idea/NN that/IN the/DT development/NN of/IN inflammatory/JJ reactions/NNS might/MD be/VB affected/VBN by/IN diesel/NN exhaust/NN emission/NN ./. 
UI/LS -/: 99287876/CD 
TI/LS -/: 20-Epi/NN analogues/NNS of/IN 1,25-dihydroxyvitamin/NN D3/NN are/VBP highly/RB potent/JJ inducers/NNS of/IN DRIP/NN coactivator/NN complex/NN binding/NN to/TO the/DT vitamin/NN D3/NN receptor/NN ./. 
AB/LS -/: 1,25-Dihydroxyvitamin/NN D3/NN (/( 1,25(OH)2D3/NN )/) plays/VBZ a/DT major/JJ role/NN in/IN the/DT stimulation/NN of/IN bone/NN growth/NN ,/, mineralization/NN ,/, and/CC intestinal/JJ calcium/NN and/CC phosphate/NN absorption/NN ;/: it/PRP also/RB acts/VBZ as/IN a/DT general/JJ inhibitor/NN of/IN cellular/JJ proliferation/NN ./. 
Several/JJ new/JJ ,/, clinically/RB relevant/JJ compounds/NNS dissociate/VBP antiproliferative/JJ and/CC calcemic/JJ activities/NNS of/IN 1,25(OH)2D3/NN ,/, but/CC the/DT molecular/JJ basis/NN for/IN this/DT has/VBZ not/RB been/VBN clearly/RB elucidated/VBN ./. 
Here/RB ,/, we/PRP tested/VBD whether/IN the/DT potency/NN of/IN one/CD class/NN of/IN compounds/NNS ,/, 20-epi/NN analogues/NNS ,/, to/TO induce/VB myeloid/JJ cell/NN differentiation/NN ,/, is/VBZ because/IN of/IN direct/JJ molecular/JJ effects/NNS on/IN vitamin/NN D/NN receptor/NN (/( VDR/NN )/) ./. 
We/PRP report/VBP that/IN two/CD 20-epi/NN analogues/NNS ,/, MC1627/NN and/CC MC1288/NN ,/, induced/VBD differentiation/NN and/CC transcription/NN of/IN p21/NN (/( Waf1/NN ,/, Cip1/NN )/) ,/, a/DT key/JJ VDR/NN target/NN gene/NN involved/VBN in/IN growth/NN inhibition/NN ,/, at/IN a/DT concentration/NN 100-fold/RB lower/JJR than/IN that/DT of/IN 1,25(OH)2D3/NN ./. 
We/PRP compared/VBD this/DT sensitivity/NN to/TO analogue/NN effects/NNS on/IN VDR/NN interacting/NN proteins/NNS :/: RXR/NN ,/, GRIP-1/NN ,/, and/CC DRIP205/NN ,/, a/DT subunit/NN of/IN the/DT DRIP/NN coactivator/NN complex/NN ./. 
Compared/VBN with/IN the/DT interaction/NN of/IN VDR/NN with/IN RXR/NN or/CC GRIP-1/NN ,/, the/DT differentiation/NN dose-response/NN most/JJS closely/RB correlated/VBD to/TO the/DT ligand-dependent/JJ recruitment/NN of/IN the/DT DRIP/NN coactivator/NN complex/NN to/TO VDR/NN and/CC to/TO the/DT ability/NN of/IN the/DT receptor/NN to/TO activate/VB transcription/NN in/IN a/DT cell-free/JJ system/NN ./. 
These/DT results/NNS provide/VBP compelling/JJ links/NNS between/IN the/DT efficiency/NN of/IN the/DT 20-epi/NN analogue/NN in/IN inducing/VBG VDR/DRIP/NN interactions/NNS ,/, transactivation/NN in/FW vitro/FW ,/, and/CC its/PRP$ enhanced/VBN ability/NN to/TO induce/VB cellular/JJ differentiation/NN ./. 
UI/LS -/: 99278386/CD 
TI/LS -/: SLP-76/NN and/CC Vav/NN function/NN in/IN separate/JJ ,/, but/CC overlapping/VBG pathways/NNS to/TO augment/VB interleukin-2/NN promoter/NN activity/NN ./. 
AB/LS -/: SLP-76/NN and/CC Vav/NN ,/, two/CD hematopoietic/JJ cell/NN specific/JJ molecules/NNS ,/, are/VBP critical/JJ for/IN T/NN cell/NN development/NN and/CC activation/NN ./. 
Following/VBG T/NN cell/NN antigen/NN receptor/NN stimulation/NN ,/, SLP-76/NN and/CC Vav/NN both/DT undergo/VBP tyrosine/NN phosphorylation/NN and/CC associate/VBP with/IN each/DT other/JJ via/IN the/DT SH2/NN domain/NN of/IN Vav/NN and/CC phosphorylated/VBN tyrosines/NNS of/IN SLP-76/NN ./. 
Furthermore/RB ,/, SLP-76/NN and/CC Vav/NN have/VBP a/DT synergistic/JJ effect/NN on/IN interleukin/NN (/( IL/NN )/) -2/CD promoter/NN activity/NN in/IN T/NN cells/NNS ./. 
In/IN this/DT report/NN ,/, we/PRP show/VBP that/IN two/CD tyrosines/NNS ,/, Tyr-113/NN and/CC Tyr-128/NN ,/, of/IN SLP-76/NN are/VBP required/VBN for/IN its/PRP$ binding/NN to/TO Vav/NN ,/, both/CC in/FW vitro/FW and/CC in/IN intact/JJ cells/NNS ./. 
Surprisingly/RB ,/, we/PRP find/VBP also/RB that/IN the/DT interaction/NN between/IN SLP-76/NN and/CC Vav/NN is/VBZ not/RB required/VBN for/IN their/PRP$ cooperation/NN in/IN augmenting/VBG IL-2/NN promoter/NN activity/NN ,/, as/IN the/DT two/CD molecules/NNS appear/VBP to/TO function/VB in/IN different/JJ signaling/NN pathways/NNS upstream/JJ of/IN IL-2/NN gene/NN expression/NN ./. 
Overexpression/NN of/IN SLP-76/NN in/IN the/DT Jurkat/NN T/NN cell/NN line/NN potentiates/VBZ the/DT activities/NNS of/IN both/CC nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS and/CC AP-1/NN transcription/NN factors/NNS ./. 
In/IN contrast/NN ,/, overexpression/NN of/IN Vav/NN leads/VBZ to/TO enhanced/VBN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS activity/NN without/IN affecting/VBG AP-1/NN ./. 
Additionally/RB ,/, overexpression/NN of/IN Vav/NN ,/, but/CC not/RB SLP-76/NN ,/, augments/VBZ CD28-induced/JJ IL-2/NN promoter/NN activity/NN ./. 
These/DT findings/NNS suggest/VBP that/IN the/DT synergy/NN between/IN SLP-76/NN and/CC Vav/NN in/IN regulating/VBG IL-2/NN gene/NN expression/NN reflects/VBZ the/DT cooperation/NN between/IN different/JJ signaling/NN pathways/NNS ./. 
UI/LS -/: 99262417/CD 
TI/LS -/: Rel/NF-kappaB/NN can/MD trigger/VB the/DT Notch/NN signaling/NN pathway/NN by/IN inducing/VBG the/DT expression/NN of/IN Jagged1/NN ,/, a/DT ligand/NN for/IN Notch/NN receptors/NNS ./. 
AB/LS -/: Jagged1/NN belongs/VBZ to/TO the/DT DSL/NN family/NN of/IN ligands/NNS for/IN Notch/NN receptors/NNS that/WDT control/VBP the/DT proliferation/NN and/CC differentiation/NN of/IN various/JJ cell/NN lineages/NNS ./. 
However/RB ,/, little/JJ is/VBZ known/VBN about/IN the/DT transcription/NN factors/NNS that/WDT regulate/VBP its/PRP$ expression/NN ./. 
Here/RB ,/, we/PRP show/VBP that/IN Jagged1/NN is/VBZ a/DT Rel/NF-kappaB-responsive/JJ gene/NN ./. 
Both/CC c-Rel/NN and/CC RelA/NN induced/VBD jagged1/NN gene/NN expression/NN ,/, whereas/IN a/DT mutant/NN defective/JJ for/IN transactivation/NN did/VBD not/RB ./. 
Importantly/RB ,/, jagged1/NN transcripts/NNS were/VBD also/RB upregulated/VBN by/IN endogenous/JJ NF-kappaB/NN activation/NN and/CC this/DT effect/NN was/VBD inhibited/VBN by/IN a/DT dominant/JJ mutant/NN of/IN IkappaBalpha/NN ,/, a/DT physiological/JJ inhibitor/NN of/IN NF-kappaB/NN ./. 
Cell/NN surface/NN expression/NN of/IN Jagged1/NN in/IN c-Rel-expressing/JJ cell/NN monolayers/NNS led/VBD to/TO a/DT functional/JJ interaction/NN with/IN lymphocytes/NNS expressing/VBG the/DT Notch1/TAN-1/NN receptor/NN ./. 
This/DT correlated/VBD with/IN the/DT initiation/NN of/IN signaling/VBG downstream/RB of/IN Notch/NN ,/, as/IN evidenced/VBN by/IN increased/VBN levels/NNS of/IN HES-1/NN transcripts/NNS in/IN co-cultivated/JJ T/NN cells/NNS and/CC of/IN CD23/NN transcripts/NNS in/IN co-cultivated/JJ B/NN cells/NNS ./. 
Consistent/JJ with/IN its/PRP$ Rel/NF-kappaB-dependent/JJ induction/NN ,/, Jagged1/NN was/VBD found/VBN to/TO be/VB highly/RB expressed/VBN in/IN splenic/JJ B/NN cells/NNS where/WRB c-Rel/NN is/VBZ expressed/VBN constitutively/RB ./. 
These/DT results/NNS demonstrate/VBP that/IN c-Rel/NN can/MD trigger/VB the/DT Notch/NN signaling/NN pathway/NN in/IN neighboring/JJ cells/NNS by/IN inducing/VBG jagged1/NN gene/NN expression/NN ,/, and/CC suggest/VBP a/DT role/NN for/IN Jagged1/NN in/IN B-cell/NN activation/NN ,/, differentiation/NN or/CC function/NN ./. 
These/DT findings/NNS also/RB highlight/VBP the/DT potential/NN for/IN an/DT interplay/NN between/IN the/DT Notch/NN and/CC NF-kappaB/NN signaling/NN pathways/NNS in/IN the/DT immune/JJ system/NN ./. 
UI/LS -/: 99253956/CD 
TI/LS -/: Bacterial/JJ peptidoglycan/NN induces/VBZ CD14-dependent/JJ activation/NN of/IN transcription/NN factors/NNS CREB/ATF/NN and/CC AP-1/NN ./. 
AB/LS -/: Peptidoglycan/NN (/( PGN/NN )/) ,/, the/DT major/JJ cell/NN wall/NN component/NN of/IN Gram-positive/JJ bacteria/NNS ,/, induces/VBZ secretion/NN of/IN cytokines/NNS in/IN macrophages/NNS through/IN CD14/NN ,/, the/DT pattern/NN recognition/NN receptor/NN that/WDT binds/VBZ lipopolysaccharide/NN and/CC other/JJ microbial/JJ products/NNS ./. 
To/TO begin/VB to/TO elucidate/VB the/DT mechanisms/NNS that/WDT regulate/VBP the/DT transcription/NN of/IN cytokine/NN genes/NNS ,/, we/PRP wanted/VBD to/TO determine/VB which/WDT transcription/NN factors/NNS are/VBP activated/VBN by/IN PGN/NN in/IN mouse/NN RAW264.7/NN and/CC human/JJ THP-1/NN macrophage/NN cells/NNS ./. 
Our/PRP$ results/NNS demonstrated/VBD that/IN :/: (/( i/LS )/) PGN/NN induced/VBD phosphorylation/NN of/IN the/DT transcription/NN factors/NNS ATF-1/NN and/CC CREB/NN ;/: (/( ii/LS )/) ATF-1/NN and/CC CREB/NN bound/VBD DNA/NN as/IN a/DT dimer/NN and/CC induced/VBD transcriptional/JJ activation/NN of/IN a/DT CRE/NN reporter/NN plasmid/NN ,/, which/WDT was/VBD inhibited/VBN by/IN dominant/JJ negative/JJ CREB/NN and/CC ATF-1/NN ;/: (/( iii/LS )/) PGN/NN induced/VBD phosphorylation/NN of/IN c-Jun/NN ,/, protein/NN synthesis/NN of/IN JunB/NN and/CC c-Fos/NN ,/, and/CC transcriptional/JJ activation/NN of/IN the/DT AP-1/NN reporter/NN plasmid/NN ,/, which/WDT was/VBD inhibited/VBN by/IN dominant/JJ negative/JJ c-Fos/NN ;/: and/CC (/( iv/LS )/) PGN-induced/JJ activation/NN of/IN CREB/ATF/NN and/CC AP-1/NN was/VBD mediated/VBN through/IN CD14/NN ./. 
This/DT is/VBZ the/DT first/JJ study/NN to/TO demonstrate/VB activation/NN of/IN CREB/ATF/NN and/CC AP-1/NN transcription/NN factors/NNS by/IN PGN/NN or/CC by/IN any/DT other/JJ component/NN of/IN Gram-positive/JJ bacteria/NNS ./. 
UI/LS -/: 99248398/CD 
TI/LS -/: Glucocorticoid/NN receptors/NNS are/VBP down-regulated/VBN in/IN inflamed/JJ colonic/JJ mucosa/NN but/CC not/RB in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS from/IN patients/NNS with/IN inflammatory/JJ bowel/NN disease/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: BACKGROUND/NN :/: Growing/VBG evidence/NN indicates/VBZ that/IN the/DT immune/JJ system/NN and/CC the/DT hypothalamic-pituitary-adrenal/JJ system/NN are/VBP linked/VBN by/IN several/JJ mechanisms/NNS ,/, for/IN example/NN intracellular/JJ glucocorticoid/NN receptors/NNS (/( hGR/NN )/) ./. 
Glucocorticoids/NNS are/VBP the/DT standard/JJ treatment/NN of/IN acute/JJ attacks/NNS of/IN inflammatory/JJ bowel/NN disease/NN (/( IBD/NN )/) ./. 
Binding/NN of/IN glucocorticoids/NNS to/TO hGR/NN down-regulates/VBZ the/DT transcription/NN of/IN inflammatory/JJ genes/NNS that/WDT can/MD propagate/VB IBD/NN ./. 
PATIENTS/NNS AND/CC METHODS/NNS :/: IBD/NN patients/NNS were/VBD either/RB treated/VBN with/IN 5-60/CD mg/NN of/IN prednisolone/NN for/IN more/JJR than/IN 1/CD week/NN or/CC were/VBD without/IN glucocorticoid/NN treatment/NN for/IN more/JJR than/IN 4/CD weeks/NNS ./. 
hGR/NN levels/NNS were/VBD determined/VBN from/IN isolated/VBN cytosol/NN of/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMCs/NNS )/) or/CC mucosal/JJ biopsies/NNS using/VBG a/DT radioassay/NN with/IN [3H]-dexamethasone/NN ./. 
Interleukin/NN (/( IL/NN )/) 6/CD levels/NNS were/VBD determined/VBN by/IN enzyme-linked/JJ immunosorbent/JJ assay/NN (/( ELISA/NN )/) ./. 
RESULTS/NNS :/: The/DT systemic/JJ (/( PBMC/NN )/) hGR/NN levels/NNS of/IN corticosteroid-treated/JJ IBD/NN patients/NNS were/VBD significantly/RB lower/JJR than/IN those/DT of/IN control/JJ subjects/NNS (/( 59.6/CD +/-/CC 57.1/CD dpm/NN mg-1/NN cytosol/NN protein/NN vs./CC 
227.0/CD +/-/CC 90.8/CD dpm/NN mg-1/NN cytosol/NN protein/NN ,/, P/NN =/JJ 0.007/CD )/) and/CC IBD/NN patients/NNS not/RB receiving/VBG glucocorticoid/NN treatment/NN (/( 179.7/CD +/-/CC 171.3/CD dpm/NN mg-1/NN cytosol/NN protein/NN ,/, P/NN =/JJ 0.002/CD )/) ./. 
Systemic/JJ hGR/NN levels/NNS in/IN untreated/JJ IBD/NN patients/NNS did/VBD not/RB differ/VB significantly/RB from/IN those/DT in/IN control/JJ subjects/NNS ./. 
In/IN patients/NNS with/IN connective/JJ tissue/NN diseases/NNS ,/, systemic/JJ hGR/NN levels/NNS were/VBD also/RB found/VBN to/TO be/VB decreased/VBN in/IN the/DT absence/NN of/IN glucocorticoid/NN treatment/NN ./. 
Systemic/JJ hGR/NN levels/NNS in/IN patients/NNS with/IN Crohn/NN 's/POS disease/NN (/( CD/NN )/) treated/VBN with/IN steroids/NNS (/( 66.6/CD +/-/CC 61.0/CD dpm/NN mg-1/NN cytosol/NN protein/NN )/) were/VBD not/RB different/JJ from/IN those/DT in/IN patients/NNS with/IN ulcerative/JJ colitis/NN (/( UC/NN )/) (/( 56.1/CD +/-/CC 51.6/CD dpm/NN mg-1/NN cytosol/NN protein/NN )/) ./. 
In/IN contrast/NN to/TO these/DT findings/NNS ,/, mucosal/JJ hGR/NN levels/NNS were/VBD significantly/RB decreased/VBN in/IN both/DT steroid-treated/JJ (/( 18.0/CD +/-/CC 15.5/CD )/) and/CC not/RB steroid-treated/JJ (/( 37.8/CD +/-/CC 30.5/CD )/) patients/NNS compared/VBN with/IN control/JJ subjects/NNS (/( 125.6/CD +/-/CC 97.1/CD ;/: P/NN =/JJ 0.00009/CD and/CC P/NN =/JJ 0.0008/CD respectively/RB )/) ./. 
IL-6/NN levels/NNS in/IN all/DT IBD/NN groups/NNS with/IN and/CC without/IN steroids/NNS were/VBD significantly/RB different/JJ from/IN those/DT in/IN control/JJ subjects/NNS ./. 
CONCLUSION/NN :/: In/IN IBD/NN there/EX is/VBZ no/DT difference/NN in/IN systemic/JJ hGR/NN levels/NNS between/IN not/RB steroid-treated/JJ patients/NNS and/CC control/JJ subjects/NNS ,/, in/IN spite/NN of/IN inflammatory/JJ activity/NN (/( IL-6/NN )/) ./. 
Mucosal/JJ hGR/NN levels/NNS were/VBD decreased/VBN independently/RB of/IN treatment/NN ,/, probably/RB leading/VBG to/TO a/DT decreased/VBN protection/NN against/IN NF-kappaB/NN action/NN in/IN the/DT intestinal/JJ mucosa/NN ./. 
UI/LS -/: 99333679/CD 
TI/LS -/: ICSAT/NN overexpression/NN is/VBZ not/RB sufficient/JJ to/TO cause/VB adult/JJ T-cell/NN leukemia/NN or/CC multiple/JJ myeloma/NN ./. 
AB/LS -/: ICSAT/NN (/( Interferon/NN Consensus/NN Sequence/NN binding/NN protein/NN for/IN Activated/VBN T/NN cells/NNS )/) is/VBZ a/DT lymphocyte-specific/JJ member/NN of/IN the/DT interferon/NN regulatory/JJ factor/NN (/( IRF/NN )/) family/NN of/IN transcription/NN factors/NNS ,/, originally/RB identified/VBN through/IN Southwestern/NN screening/NN of/IN the/DT ATL/NN (/( Adult/NN T-cell/NN leukemia/NN )/) -16T/JJ expression/NN library/NN ./. 
In/IN this/DT study/NN ,/, we/PRP created/VBD transgenic/JJ mice/NNS overexpressing/VBG ICSAT/NN in/IN lymphocytes/NNS ./. 
Although/IN spontaneous/JJ tumorigenesis/NN was/VBD not/RB observed/VBN ,/, IL-2/NN production/NN with/IN Concanavalin/NN A/NN stimulation/NN was/VBD significantly/RB increased/VBN in/IN transgenic/JJ mice/NNS overexpressing/VBG ICSAT/NN ./. 
ICSAT/NN overexpression/NN in/IN lymphocytes/NNS seems/VBZ insufficient/JJ for/IN the/DT leukemogenesis/NN of/IN ATL/NN or/CC multiple/JJ myeloma/NN (/( MM/NN )/) ,/, however/RB ,/, it/PRP may/MD regulate/VB T/NN cell/NN activation/NN and/CC its/PRP$ overexpression/NN may/MD lead/VB to/TO leukemogenesis/NN via/IN controlling/VBG IL-2/NN production/NN ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99316341/CD 
TI/LS -/: Altered/JJ memory/NN T/NN cell/NN differentiation/NN in/IN patients/NNS with/IN early/JJ rheumatoid/JJ arthritis/NN ./. 
AB/LS -/: The/DT chronic/JJ immune/JJ response/NN in/IN rheumatoid/JJ arthritis/NN (/( RA/NN )/) might/MD be/VB driven/VBN by/IN activated/VBN Th1/NN cells/NNS without/IN sufficient/JJ Th2/NN cell/NN differentiation/NN to/TO down-modulate/VB inflammation/NN ./. 
To/TO test/VB whether/IN disordered/VBN memory/NN T/NN cell/NN differentiation/NN contributes/VBZ to/TO the/DT typical/JJ Th1-dominated/JJ chronic/JJ inflammation/NN in/IN RA/NN we/PRP investigated/VBD differentiation/NN of/IN resting/VBG CD4+/JJ memory/NN T/NN cells/NNS in/IN patients/NNS with/IN early/JJ (/( 6/CD wk/NN to/TO 12/CD mo/NN )/) untreated/JJ RA/NN and/CC in/IN age-/NN and/CC sex-matched/JJ healthy/JJ controls/NNS in/FW vitro/FW ./. 
No/DT difference/NN in/IN cytokine/NN secretion/NN profiles/NNS of/IN freshly/RB isolated/VBN memory/NN T/NN cells/NNS was/VBD detected/VBN between/IN patients/NNS and/CC controls/NNS ./. 
A/DT cell/NN culture/NN system/NN was/VBD then/RB employed/VBN that/WDT permitted/VBD the/DT differentiation/NN of/IN Th/NN effectors/NNS from/IN resting/VBG memory/NN T/NN cells/NNS by/IN short/JJ term/NN priming/NN ./. 
Marked/JJ differences/NNS were/VBD found/VBN in/IN response/NN to/TO priming/NN ./. 
Th2/NN cells/NNS could/MD be/VB induced/VBN in/IN all/DT healthy/JJ controls/NNS by/IN priming/VBG with/IN anti-CD28/NN in/IN the/DT absence/NN of/IN TCR/NN ligation/NN ./. 
By/IN contrast/NN ,/, priming/NN under/IN those/DT conditions/NNS resulted/VBD in/IN Th2/NN differentiation/NN in/IN only/RB 9/CD of/IN 24/CD RA/NN patients/NNS ./. 
Exogenous/JJ IL-4/NN could/MD overcome/VB the/DT apparent/JJ Th2/NN differentiation/NN defect/NN in/IN seven/CD patients/NNS but/CC was/VBD without/IN effect/NN in/IN the/DT remaining/VBG eight/CD patients/NNS ./. 
In/IN all/DT patients/NNS a/DT marked/JJ decrease/NN in/IN IL-2-producing/JJ cells/NNS and/CC a/DT significant/JJ increase/NN in/IN well-differentiated/JJ Th1/NN cells/NNS that/WDT produced/VBD IFN-gamma/NN but/CC not/RB IL-2/NN were/VBD evident/JJ after/IN priming/VBG with/IN anti-CD3/NN and/CC anti-CD28/NN ./. 
The/DT data/NNS suggest/VBP that/IN CD4+/JJ memory/NN T/NN cells/NNS from/IN patients/NNS with/IN early/JJ untreated/JJ RA/NN manifest/VBP an/DT intrinsic/JJ abnormality/NN in/IN their/PRP$ ability/NN to/TO differentiate/VB into/IN specific/JJ cytokine-producing/JJ effector/NN cells/NNS that/WDT might/MD contribute/VB to/TO the/DT characteristic/JJ Th1-dominated/JJ chronic/JJ (/( auto/JJ )/) immune/JJ inflammation/NN in/IN RA/NN ./. 
UI/LS -/: 99307406/CD 
TI/LS -/: The/DT intracellular/JJ parasite/NN Theileria/FW parva/FW protects/VBZ infected/JJ T/NN cells/NNS from/IN apoptosis/NN ./. 
AB/LS -/: Parasites/NNS have/VBP evolved/VBN a/DT plethora/NN of/IN strategies/NNS to/TO ensure/VB their/PRP$ survival/NN ./. 
The/DT intracellular/JJ parasite/NN Theileria/FW parva/FW secures/VBZ its/PRP$ propagation/NN and/CC spreads/VBZ through/IN the/DT infected/JJ animal/NN by/IN infecting/VBG and/CC transforming/VBG T/NN cells/NNS ,/, inducing/VBG their/PRP$ continuous/JJ proliferation/NN and/CC rendering/VBG them/PRP metastatic/JJ ./. 
In/IN previous/JJ work/NN ,/, we/PRP have/VBP shown/VBN that/IN the/DT parasite/NN induces/VBZ constitutive/JJ activation/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN ,/, by/IN inducing/VBG the/DT constitutive/JJ degradation/NN of/IN its/PRP$ cytoplasmic/JJ inhibitors/NNS ./. 
The/DT biological/JJ significance/NN of/IN NF-kappaB/NN activation/NN in/IN T./FW parva-infected/JJ cells/NNS ,/, however/RB ,/, has/VBZ not/RB yet/RB been/VBN defined/VBN ./. 
Cells/NNS that/WDT have/VBP been/VBN transformed/VBN by/IN viruses/NNS or/CC oncogenes/NNS can/MD persist/VB only/RB if/IN they/PRP manage/VBP to/TO avoid/VB destruction/NN by/IN the/DT apoptotic/JJ mechanisms/NNS that/WDT are/VBP activated/VBN on/IN transformation/NN and/CC that/WDT contribute/VBP to/TO maintain/VB cellular/JJ homeostasis/NN ./. 
We/PRP now/RB demonstrate/VBP that/IN parasite-induced/JJ NF-kappaB/NN activation/NN plays/VBZ a/DT crucial/JJ role/NN in/IN the/DT survival/NN of/IN T./FW parva-transformed/JJ T/NN cells/NNS by/IN conveying/VBG protection/NN against/IN an/DT apoptotic/JJ signal/NN that/WDT accompanies/VBZ parasite-mediated/JJ transformation/NN ./. 
Consequently/RB ,/, inhibition/NN of/IN NF-kappaB/NN nuclear/JJ translocation/NN and/CC the/DT expression/NN of/IN dominant/JJ negative/JJ mutant/JJ forms/NNS of/IN components/NNS of/IN the/DT NF-kappaB/NN activation/NN pathway/NN ,/, such/JJ as/IN IkappaBalpha/NN or/CC p65/NN ,/, prompt/VBP rapid/JJ apoptosis/NN of/IN T./FW parva-transformed/JJ T/NN cells/NNS ./. 
Our/PRP$ findings/NNS offer/VBP important/JJ insights/NNS into/IN parasite/JJ survival/NN strategies/NNS and/CC demonstrate/VBP that/IN parasite-induced/JJ constitutive/JJ NF-kappaB/NN activation/NN is/VBZ an/DT essential/JJ step/NN in/IN maintaining/VBG the/DT transformed/VBN phenotype/NN of/IN the/DT infected/JJ cells/NNS ./. 
UI/LS -/: 99295929/CD 
TI/LS -/: A/DT polymorphism/NN that/WDT affects/VBZ OCT-1/NN binding/NN to/TO the/DT TNF/NN promoter/NN region/NN is/VBZ associated/VBN with/IN severe/JJ malaria/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: Genetic/JJ variation/NN in/IN cytokine/NN promoter/NN regions/NNS is/VBZ postulated/VBN to/TO influence/VB susceptibility/NN to/TO infection/NN ,/, but/CC the/DT molecular/JJ mechanisms/NNS by/IN which/WDT such/JJ polymorphisms/NNS might/MD affect/VB gene/NN regulation/NN are/VBP unknown/JJ ./. 
Through/IN systematic/JJ DNA/NN footprinting/NN of/IN the/DT TNF/NN (/( encoding/VBG tumour/NN necrosis/NN factor/NN ,/, TNF/NN )/) promoter/NN region/NN ,/, we/PRP have/VBP identified/VBN a/DT single/JJ nucleotide/NN polymorphism/NN (/( SNP/NN )/) that/WDT causes/VBZ the/DT helix-turn-helix/JJ transcription/NN factor/NN OCT-1/NN to/TO bind/VB to/TO a/DT novel/JJ region/NN of/IN complex/JJ protein-DNA/JJ interactions/NNS and/CC alters/VBZ gene/NN expression/NN in/IN human/JJ monocytes/NNS ./. 
The/DT OCT-1-binding/JJ genotype/NN ,/, found/VBD in/IN approximately/RB 5/CD %/NN of/IN Africans/NNS ,/, is/VBZ associated/VBN with/IN fourfold/RB increased/VBN susceptibility/NN to/TO cerebral/JJ malaria/NN in/IN large/JJ case-control/JJ studies/NNS of/IN West/JJ African/JJ and/CC East/JJ African/JJ populations/NNS ,/, after/IN correction/NN for/IN other/JJ known/JJ TNF/NN polymorphisms/NNS and/CC linked/VBN HLA/NN alleles/NNS ./. 
UI/LS -/: 99286016/CD 
TI/LS -/: UV-induced/JJ CYP1A1/NN gene/NN expression/NN in/IN human/JJ cells/NNS is/VBZ mediated/VBN by/IN tryptophan/NN ./. 
AB/LS -/: Induction/NN of/IN cytochrome/NN P-4501A1/NN (/( CYP1A1/NN )/) activity/NN by/IN UV/NN has/VBZ been/VBN observed/VBN earlier/RBR in/IN animal/NN studies/NNS via/IN a/DT mechanism/NN that/WDT has/VBZ not/RB yet/RB been/VBN resolved/VBN ./. 
Our/PRP$ previous/JJ data/NNS have/VBP indicated/VBN that/IN formylated/VBN indolocarbazoles/NNS which/WDT are/VBP formed/VBN by/IN UV/NN irradiation/NN of/IN tryptophan/NN solutions/NNS are/VBP very/RB potent/JJ Ah-receptor/NN agonists/NNS ./. 
To/TO evaluate/VB the/DT effect/NN of/IN UV/NN light/NN on/IN cytochrome/NN P4501A1/NN gene/NN expression/NN ,/, we/PRP studied/VBD the/DT induction/NN of/IN CYP1A1/NN mRNA/NN by/IN UV/NN irradiation/NN of/IN cultured/VBN human/JJ keratinocytes/NNS (/( HaCaT/NN cell/NN line/NN )/) ,/, primary/JJ human/JJ blood/NN lymphocytes/NNS and/CC mouse/NN Hepa-1/NN cells/NNS ./. 
The/DT cells/NNS were/VBD exposed/VBN to/TO UV/NN light/NN delivered/VBN by/IN a/DT bank/NN of/IN 6/CD Philips/NN TL20/12RS/NN sun/NN lamps/NNS emitting/VBG primarily/RB in/IN the/DT UVB/NN range/NN in/IN the/DT absence/NN and/CC presence/NN of/IN tryptophan/NN ./. 
A/DT semiquantitative/JJ reverse/NN transcriptase-linked/JJ polymerase/NN chain/NN reaction/NN (/( RT-PCR/NN )/) was/VBD used/VBN for/IN analysis/NN of/IN gene/NN expression/NN in/IN the/DT treated/VBN cells/NNS ./. 
The/DT results/NNS show/VBP that/IN the/DT CYP1A1/NN mRNA/NN level/NN induced/VBN by/IN UV/NN in/IN the/DT presence/NN of/IN tryptophan/NN was/VBD higher/JJR than/IN that/DT induced/VBN by/IN UV/NN alone/RB in/IN both/CC HaCaT/NN cells/NNS and/CC lymphocytes/NNS after/IN 3/CD h/NN of/IN incubation/NN post-UV/JJ irradiation/NN ./. 
To/TO find/VB out/RP if/IN the/DT induction/NN by/IN UV/NN light/NN is/VBZ caused/VBN by/IN the/DT formation/NN of/IN an/DT Ah/NN receptor/NN ligand/NN ,/, Hepa-1/NN wild-type/JJ and/CC Ah/NN receptor/NN deficient/JJ c12/NN cell/NN lines/NNS were/VBD applied/VBN ./. 
Wild-type/JJ (/( wt/JJ )/) cells/NNS were/VBD inducible/JJ either/CC by/IN the/DT tryptophan/NN photoproduct/NN 6-formylindolo/JJ [/( 3/CD ,/, 2-b/JJ ]/) carbazole/NN (/( FICZ/NN )/) or/CC by/IN UV-irradiation/NN but/CC very/RB low/JJ or/CC undetectable/JJ levels/NNS were/VBD observed/VBN in/IN the/DT c12/NN cells/NNS ./. 
This/DT shows/VBZ that/IN the/DT induction/NN of/IN gene/NN expression/NN by/IN FICZ/NN and/CC UV/NN is/VBZ Ah/NN receptor/NN dependent/JJ ./. 
Together/RB ,/, these/DT results/NNS indicate/VBP that/IN UV-induced/JJ CYP1A1/NN gene/NN expression/NN in/IN mammalian/JJ cells/NNS is/VBZ mediated/VBN by/IN an/DT Ah/NN receptor/NN ligand/NN formed/VBN from/IN tryptophan/NN ./. 
Thus/RB ,/, the/DT photoproducts/NNS of/IN tryptophan/NN are/VBP suggested/VBN to/TO be/VB mediators/NNS of/IN light/NN via/IN binding/NN to/TO the/DT Ah/NN receptor/NN and/CC as/IN such/JJ also/RB could/MD have/VB a/DT role/NN in/IN light-regulated/JJ biological/JJ rhythms/NNS ./. 
UI/LS -/: 99286232/CD 
TI/LS -/: Repression/NN by/IN Ikaros/NN and/CC Aiolos/NN is/VBZ mediated/VBN through/IN histone/NN deacetylase/NN complexes/NNS ./. 
AB/LS -/: Here/RB we/PRP show/VBP that/IN the/DT lymphoid/JJ lineage-determining/JJ factors/NNS Ikaros/NN and/CC Aiolos/NN can/MD function/VB as/IN strong/JJ transcriptional/JJ repressors/NNS ./. 
This/DT function/NN is/VBZ mediated/VBN through/IN two/CD repression/NN domains/NNS and/CC is/VBZ dependent/JJ upon/IN the/DT promoter/NN context/NN and/CC cell/NN type/NN ./. 
Repression/NN by/IN Ikaros/NN proteins/NNS correlates/VBZ with/IN hypo-acetylation/NN of/IN core/NN histones/NNS at/IN promoter/NN sites/NNS and/CC is/VBZ relieved/VBN by/IN histone/NN deacetylase/NN inhibitors/NNS ./. 
Consistent/JJ with/IN these/DT findings/NNS ,/, Ikaros/NN and/CC its/PRP$ repression/NN domains/NNS can/MD interact/VB in/FW vivo/FW and/CC in/FW vitro/FW with/IN the/DT mSin3/NN family/NN of/IN co-repressors/NNS which/WDT bind/VBP to/TO histone/NN deacetylases/NNS ./. 
Based/VBN on/IN these/DT and/CC our/PRP$ recent/JJ findings/NNS of/IN associations/NNS between/IN Ikaros/NN and/CC Mi-2-HDAC/NN ,/, we/PRP propose/VBP that/IN Ikaros/NN family/NN members/NNS modulate/VBP gene/NN expression/NN during/IN lymphocyte/NN development/NN by/IN recruiting/VBG distinct/JJ histone/NN deacetylase/NN complexes/NNS to/TO specific/JJ promoters/NNS ./. 
UI/LS -/: 99272418/CD 
TI/LS -/: Protein/NN kinase/NN B/NN (/( c-Akt/NN )/) ,/, phosphatidylinositol/NN 3-kinase/NN ,/, and/CC STAT5/NN are/VBP activated/VBN by/IN erythropoietin/NN (/( EPO/NN )/) in/IN HCD57/NN erythroid/JJ cells/NNS but/CC are/VBP constitutively/RB active/JJ in/IN an/DT EPO-independent/JJ ,/, apoptosis-resistant/JJ subclone/NN (/( HCD57-SREI/NN cells/NNS )/) ./. 
AB/LS -/: We/PRP found/VBD that/IN erythropoietin/NN (/( EPO/NN )/) and/CC stem/VBP cell/NN factor/NN (/( SCF/NN )/) activated/VBD protein/NN kinase/NN B/NN (/( PKB/Akt/NN )/) in/IN EPO-dependent/JJ HCD57/NN erythroid/JJ cells/NNS ./. 
To/TO better/RBR understand/VB signals/NNS controlling/VBG proliferation/NN and/CC viability/NN ,/, erythroid/JJ cells/NNS that/WDT resist/VBP apoptosis/NN in/IN the/DT absence/NN of/IN EPO/NN were/VBD subcloned/VBN and/CC characterized/VBN (/( HCD57-SREI/NN cells/NNS )/) ./. 
Constitutive/JJ activations/NNS of/IN PKB/Akt/NN ,/, STAT5a/NN ,/, and/CC STAT5b/NN were/VBD noted/VBN in/IN these/DT EPO-independent/JJ cells/NNS ./. 
PI3-kinase/NN activity/NN was/VBD an/DT upstream/JJ activator/NN of/IN PKB/Akt/NN because/IN the/DT PI3-kinase/NN inhibitor/NN LY294002/NN blocked/VBD both/CC constitutive/JJ PKB/Akt/NN and/CC factor-dependent/JJ PKB/Akt/NN activity/NN ./. 
The/DT LY294002/NN study/NN showed/VBD that/IN proliferation/NN and/CC viability/NN of/IN both/CC HCD57-SREI/NN and/CC HCD57/NN cells/NNS correlated/VBD with/IN the/DT activity/NN of/IN PKB/Akt/NN ;/: however/RB ,/, PKB/Akt/NN activity/NN alone/RB did/VBD not/RB protect/VB these/DT cells/NNS from/IN apoptosis/NN ./. 
Treatment/NN of/IN HCD57/NN cells/NNS with/IN SCF/NN also/RB activated/VBD PKB/Akt/NN ,/, but/CC did/VBD not/RB protect/VB from/IN apoptosis/NN ./. 
This/DT result/NN suggested/VBD that/IN PKB/PI3-kinase/NN activity/NN is/VBZ necessary/JJ but/CC not/RB sufficient/JJ to/TO promote/VB viability/NN and/or/CC proliferation/NN ./. 
Constitutive/JJ STAT5/NN activity/NN ,/, activated/VBN through/IN an/DT unknown/JJ pathway/NN not/RB including/VBG JAK2/NN or/CC EPOR/NN ,/, may/MD act/VB in/IN concert/NN with/IN the/DT constitutive/JJ PI3-kinase/PKB/Akt/NN pathway/NN to/TO protect/VB the/DT EPO-independent/JJ HCD57-SREI/NN cells/NNS from/IN apoptosis/NN and/CC promote/VB limited/JJ proliferation/NN ./. 
UI/LS -/: 99262416/CD 
TI/LS -/: Disruption/NN of/IN alpha/NN beta/NN but/CC not/RB of/IN gamma/NN delta/NN T/NN cell/NN development/NN by/IN overexpression/NN of/IN the/DT helix-loop-helix/JJ protein/NN Id3/NN in/IN committed/VBN T/NN cell/NN progenitors/NNS ./. 
AB/LS -/: Enforced/VBN expression/NN of/IN Id3/NN ,/, which/WDT has/VBZ the/DT capacity/NN to/TO inhibit/VB many/JJ basic/JJ helix-loop-helix/JJ (/( bHLH/JJ )/) transcription/NN factors/NNS ,/, in/IN human/JJ CD34(+)/JJ hematopoietic/JJ progenitor/NN cells/NNS that/WDT have/VBP not/RB undergone/VBN T/NN cell/NN receptor/NN (/( TCR/NN )/) gene/NN rearrangements/NNS inhibits/VBZ development/NN of/IN the/DT transduced/VBN cells/NNS into/IN TCRalpha/NN beta/NN and/CC gamma/NN delta/NN cells/NNS in/IN a/DT fetal/JJ thymic/JJ organ/NN culture/NN (/( FTOC/NN )/) ./. 
Here/RB we/PRP document/VBP that/IN overexpression/NN of/IN Id3/NN ,/, in/IN progenitors/NNS that/WDT have/VBP initiated/VBN TCR/NN gene/NN rearrangements/NNS (/( pre-T/JJ cells/NNS )/) ,/, inhibits/VBZ development/NN into/IN TCRalpha/NN beta/NN but/CC not/RB into/IN TCRgamma/NN delta/NN T/NN cells/NNS ./. 
Furthermore/RB ,/, Id3/NN impedes/VBZ expression/NN of/IN recombination/NN activating/NN genes/NNS and/CC downregulates/VBZ pre-Talpha/JJ mRNA/NN ./. 
These/DT observations/NNS suggest/VBP possible/JJ mechanisms/NNS by/IN which/WDT Id3/NN overexpression/NN can/MD differentially/RB affect/VB development/NN of/IN pre-T/JJ cells/NNS into/IN TCRalpha/NN beta/NN and/CC gamma/NN delta/NN cells/NNS ./. 
We/PRP also/RB observed/VBD that/IN cell/NN surface/NN CD4(-)CD8(-)CD3(-)/JJ cells/NNS with/IN rearranged/VBN TCR/NN genes/NNS developed/VBD from/IN Id3-transduced/JJ but/CC not/RB from/IN control-transduced/JJ pre-T/JJ cells/NNS in/IN an/DT FTOC/NN ./. 
These/DT cells/NNS had/VBD properties/NNS of/IN both/CC natural/JJ killer/NN (/( NK/NN )/) and/CC pre-T/JJ cells/NNS ./. 
These/DT findings/NNS suggest/VBP that/IN bHLH/JJ factors/NNS are/VBP required/VBN to/TO control/VB T/NN cell/NN development/NN after/IN the/DT T/NK/NN developmental/JJ checkpoint/NN ./. 
UI/LS -/: 99249588/CD 
TI/LS -/: HIV-1/NN reactivation/NN in/IN resting/VBG peripheral/JJ blood/NN mononuclear/JJ cells/NNS of/IN infected/JJ adults/NNS upon/IN in/FW vitro/FW CD4/NN cross-linking/NN by/IN ligands/NNS of/IN the/DT CDR2-loop/NN in/IN extracellular/JJ domain/NN 1/CD ./. 
AB/LS -/: HIV-1/NN infects/VBZ resting/VBG peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMCs/NNS )/) but/CC remains/VBZ inactive/JJ state/NN until/IN subsequent/JJ cell/NN activation/NN ./. 
We/PRP have/VBP demonstrated/VBN that/IN the/DT cross-linking/NN of/IN cell/NN surface/NN CD4/NN by/IN gp120-anti-gp120/NN immune/JJ complexes/NNS or/CC heat-inactivated/JJ HIV-1/NN (/( iHIV-1/NN )/) is/VBZ sufficient/JJ to/TO trigger/VB activation/NN signals/NNS leading/VBG to/TO virus/NN reactivation/NN (/( 9/CD )/) ./. 
In/IN this/DT study/NN ,/, we/PRP demonstrate/VBP that/IN NF-kappaB/NN nuclear/JJ translocation/NN and/CC stimulation/NN of/IN virus/NN production/NN by/IN iHIV-1/NN were/VBD strictly/RB linked/VBN to/TO the/DT concentrations/NNS of/IN viral/JJ proteins/NNS used/VBN as/IN exogenous/JJ stimuli/NNS ./. 
Moreover/RB ,/, we/PRP further/RB investigated/VBD the/DT physiologic/JJ relevance/NN of/IN these/DT observations/NNS ./. 
When/WRB submitted/VBN to/TO an/DT in/FW vitro/FW CD4/NN cross-linking/NN by/IN iHIV-1/NN ,/, PBMCs/NNS from/IN HIV-1-infected/JJ patients/NNS were/VBD found/VBN to/TO produce/VB virus/NN ./. 
This/DT viral/JJ reactivation/NN was/VBD associated/VBN with/IN increased/VBN NF-kappaB/NN nuclear/JJ translocation/NN in/IN patients/NNS '/POS PBMCs/NNS ./. 
Additionally/RB ,/, virus/NN reactivation/NN in/IN resting/VBG PBMCs/NNS infected/VBN in/FW vitro/FW with/IN HIV-1/NN was/VBD found/VBN to/TO be/VB specifically/RB induced/VBN by/IN ligands/NNS of/IN the/DT CDR2-loop/JJ|NN in/IN domain/NN 1/CD (/( D1/NN )/) of/IN CD4/NN (/( virus/NN envelope/NN and/CC anti-CD4/JJ monoclonal/JJ antibodies/NNS )/) ./. 
In/IN contrast/NN ,/, virus/NN reactivation/NN was/VBD not/RB observed/VBN following/VBG CD4/NN oligomerization/NN by/IN antibodies/NNS that/WDT bind/VBP other/JJ epitopes/NNS in/IN D1/NN ,/, including/VBG the/DT D1/CDR3-loop/NN ./. 
Finally/RB ,/, soluble/JJ CD4/NN (/( sCD4/NN )/) prevented/VBD virus/NN reactivation/NN by/IN D1/CDR2-loop/NN ligands/NNS ./. 
Our/PRP$ results/NNS indicate/VBP that/IN the/DT signaling/NN events/NNS initiated/VBN in/IN PBMCs/NNS by/IN oligomerization/NN of/IN CD4/NN at/IN the/DT D1/CDR2-loop/NN can/MD trigger/VB HIV-1/NN upregulation/NN in/IN infected/JJ individuals/NNS ./. 
UI/LS -/: 99248183/CD 
TI/LS -/: Signaling/VBG through/IN the/DT lymphotoxin-beta/NN receptor/NN stimulates/VBZ HIV-1/NN replication/NN alone/RB and/CC in/IN cooperation/NN with/IN soluble/JJ or/CC membrane-bound/JJ TNF-alpha/NN ./. 
AB/LS -/: The/DT level/NN of/IN ongoing/JJ HIV-1/NN replication/NN within/IN an/DT individual/NN is/VBZ critical/JJ to/TO HIV-1/NN pathogenesis/NN ./. 
Among/IN host/NN immune/JJ factors/NNS ,/, the/DT cytokine/NN TNF-alpha/NN has/VBZ previously/RB been/VBN shown/VBN to/TO increase/VB HIV-1/NN replication/NN in/IN various/JJ monocyte/NN and/CC T/NN cell/NN model/NN systems/NNS ./. 
Here/RB ,/, we/PRP demonstrate/VBP that/IN signaling/VBG through/IN the/DT TNF/NN receptor/NN family/NN member/NN ,/, the/DT lymphotoxin-beta/NN (/( LT-beta/NN )/) receptor/NN (/( LT-betaR/NN )/) ,/, also/RB regulates/VBZ HIV-1/NN replication/NN ./. 
Furthermore/RB ,/, HIV-1/NN replication/NN is/VBZ cooperatively/RB stimulated/VBN when/WRB the/DT distinct/JJ LT-betaR/NN and/CC TNF/NN receptor/NN systems/NNS are/VBP simultaneously/RB engaged/VBN by/IN their/PRP$ specific/JJ ligands/NNS ./. 
Moreover/RB ,/, in/IN a/DT physiological/JJ coculture/NN cellular/JJ assay/NN system/NN ,/, we/PRP show/VBP that/IN membrane-bound/JJ TNF-alpha/NN and/CC LT-alpha1beta2/NN act/VBP virtually/RB identically/RB to/TO their/PRP$ soluble/JJ forms/NNS in/IN the/DT regulation/NN of/IN HIV-1/NN replication/NN ./. 
Thus/RB ,/, cosignaling/NN via/IN the/DT LT-beta/NN and/CC TNF-alpha/NN receptors/NNS is/VBZ probably/RB involved/VBN in/IN the/DT modulation/NN of/IN HIV-1/NN replication/NN and/CC the/DT subsequent/JJ determination/NN of/IN HIV-1/NN viral/JJ burden/NN in/IN monocytes/NNS ./. 
Intriguingly/RB ,/, surface/NN expression/NN of/IN LT-alpha1beta2/NN is/VBZ up-/RB regulated/VBN on/IN a/DT T/NN cell/NN line/NN acutely/RB infected/VBN with/IN HIV-1/NN ,/, suggesting/VBG a/DT positive/JJ feedback/NN loop/NN between/IN HIV-1/NN infection/NN ,/, LT-alpha1beta2/NN expression/NN ,/, and/CC HIV-1/NN replication/NN ./. 
Given/IN the/DT critical/JJ role/NN that/WDT LT-alpha1beta2/NN plays/VBZ in/IN lymphoid/JJ architecture/NN ,/, we/PRP speculate/VBP that/IN LT-alpha1beta2/NN may/MD be/VB involved/VBN in/IN HIV-associated/JJ abnormalities/NNS of/IN the/DT lymphoid/JJ organs/NNS ./. 
UI/LS -/: 99330064/CD 
TI/LS -/: Monoclonal/JJ anti-endothelial/JJ cell/NN antibodies/NNS from/IN a/DT patient/NN with/IN Takayasu/NN arteritis/NN activate/VBP endothelial/JJ cells/NNS from/IN large/JJ vessels/NNS ./. 
AB/LS -/: OBJECTIVE/NN :/: To/TO create/VB monoclonal/JJ anti-endothelial/JJ cell/NN antibodies/NNS (/( mAECA/NNS )/) from/IN a/DT patient/NN with/IN Takayasu/NN arteritis/NN to/TO evaluate/VB their/PRP$ ability/NN to/TO activate/VB human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS (/( HUVEC/NNS )/) ,/, and/CC to/TO characterize/VB the/DT mechanism/NN of/IN EC/NN activation/NN ./. 
METHODS/NNS :/: A/DT panel/NN of/IN mAECA/NNS was/VBD generated/VBN from/IN peripheral/JJ blood/NN lymphocytes/NNS of/IN a/DT patient/NN with/IN Takayasu/NN arteritis/NN ,/, using/VBG Epstein-Barr/JJ virus/NN transformation/NN ./. 
Activity/NN against/IN macrovascular/JJ EC/NN (/( HUVEC/NN )/) and/CC microvascular/JJ EC/NN (/( human/JJ bone/NN marrow/NN EC/NN immortalized/VBN by/IN SV40/NN )/) antigens/NNS was/VBD detected/VBN by/IN enzyme-linked/JJ immunosorbent/JJ assay/NN ./. 
Inhibition/NN studies/NNS were/VBD used/VBN to/TO select/VB the/DT monoclonal/JJ antibodies/NNS (/( mAECA/NNS )/) which/WDT share/VBP the/DT same/JJ EC/NN epitope/NN binding/NN specificity/NN as/IN the/DT total/JJ IgG-AECA/NN from/IN the/DT Takayasu/NN arteritis/NN patient/NN ./. 
The/DT binding/NN of/IN the/DT mAECA/NNS to/TO human/JJ aortic/JJ EC/NN was/VBD studied/VBN by/IN immunohistochemistry/NN ./. 
The/DT secretion/NN levels/NNS of/IN interleukin-6/NN (/( IL-6/NN )/) and/CC von/NN Willebrand/NN factor/NN (/( vWF/NN )/) were/VBD determined/VBN ,/, to/TO serve/VB as/IN markers/NNS for/IN EC/NN activation/NN ./. 
The/DT activated/VBN EC/NN were/VBD examined/VBN for/IN the/DT adherence/NN of/IN a/DT monocytic/JJ cell/NN line/NN (/( U937/NN )/) ,/, as/RB well/RB as/IN for/IN expression/NN of/IN vascular/JJ cell/NN adhesion/NN molecule/NN 1/CD ,/, intercellular/JJ adhesion/NN molecule/NN 1/CD ,/, and/CC E-selectin/NN ./. 
In/IN addition/NN ,/, nuclear/JJ extracts/NNS of/IN the/DT mAECA-treated/JJ EC/NN were/VBD analyzed/VBN for/IN the/DT induction/NN of/IN translocation/NN of/IN nuclear/JJ factor/NN kappaB/NN (/( NF-kappaB/NN )/) ,/, using/VBG a/DT specific/JJ NF-kappaB/NN oligoprobe/NN in/IN an/DT electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
RESULTS/NNS :/: Six/CD mAECA/NNS were/VBD selected/VBN ,/, the/DT mixture/NN of/IN which/WDT produced/VBD 100/CD %/NN inhibition/NN of/IN binding/NN of/IN the/DT original/JJ IgG/NN (/( from/IN the/DT patient/NN with/IN Takayasu/NN arteritis/NN )/) to/TO HUVEC/NNS ./. 
All/DT mAECA/NNS possessed/VBD high/JJ activity/NN against/IN macrovascular/JJ EC/NN ,/, but/CC none/NN had/VBD significant/JJ antimicrovascular/JJ EC/NN activity/NN ./. 
The/DT mAECA/NNS ,/, but/CC not/RB normal/JJ human/JJ IgG/NN ,/, had/VBD anti-human/JJ aortic/JJ EC/NN activity/NN ./. 
Four/CD of/IN the/DT 6/CD mAECA/NNS activated/VBD EC/NN ,/, manifested/VBN by/IN increased/VBN IL-6/NN and/CC vWF/NN secretion/NN ./. 
The/DT 4/CD mAECA/NNS induced/VBD EC/NN expression/NN of/IN adhesion/NN molecules/NNS and/CC increased/VBD adhesion/NN of/IN U937/NN monocytic/JJ cells/NNS to/TO EC/NN ./. 
In/IN addition/NN ,/, these/DT mAECA/NNS stimulated/VBD the/DT nuclear/JJ translocation/NN of/IN the/DT NF-kappaB/NN transcription/NN factor/NN ./. 
CONCLUSION/NN :/: Our/PRP$ findings/NNS suggest/VBP that/IN AECA/NNS may/MD directly/RB stimulate/VB EC/NN in/IN Takayasu/NN arteritis/NN through/IN elevation/NN of/IN adhesion/NN molecule/NN expression/NN associated/VBN with/IN NF-kappaB/NN activation/NN and/CC adhesion/NN of/IN monocytes/NNS ,/, and/CC may/MD therefore/RB play/VB a/DT pathogenic/JJ role/NN in/IN the/DT development/NN of/IN the/DT vasculopathy/NN in/IN Takayasu/NN arteritis/NN ./. 
UI/LS -/: 99316282/CD 
TI/LS -/: Cutting/JJ edge/NN :/: expression/NN of/IN the/DT NF/NN of/IN activated/VBN T/NN cells/NNS in/IN eosinophils/NNS :/: regulation/NN by/IN IL-4/NN and/CC IL-5/NN ./. 
AB/LS -/: We/PRP report/VBP that/IN NF-AT1/NN and/CC NF-AT4/NN are/VBP expressed/VBN cytoplasmically/RB in/IN resting/VBG eosinophils/NNS ,/, whereas/IN NF-AT2/NN and/CC NF-AT3/NN have/VBP not/RB been/VBN seen/VBN ./. 
Likewise/RB ,/, NF-AT1/NN mRNA/NN and/CC NF-AT4/NN mRNA/NN have/VBP been/VBN detected/VBN in/IN resting/VBG eosinophils/NNS ,/, and/CC their/PRP$ levels/NNS can/MD be/VB significantly/RB up-regulated/VBN by/IN the/DT Th2-associated/JJ cytokines/NNS IL-4/NN and/CC IL-5/NN ./. 
There/EX is/VBZ no/DT detectable/JJ NF-AT/NN protein/NN expression/NN in/IN the/DT nuclei/NNS of/IN resting/VBG eosinophils/NNS ./. 
However/RB NF-ATs/NNS appear/VBP in/IN the/DT nuclei/NNS of/IN IL-4-/NN ,/, IL-5-/NN ,/, or/CC ionomycin-stimulated/JJ eosinophils/NNS ./. 
Only/RB NF-AT1/NN and/CC NF-AT4/NN ,/, but/CC not/RB NF-AT2/NN and/CC NF-AT3/NN ,/, have/VBP translocated/VBN into/IN the/DT nuclei/NNS in/IN IL-4-/NN or/CC IL-5-stimulated/JJ eosinophils/NNS ./. 
These/DT findings/NNS delineate/VBP a/DT novel/JJ pathway/NN in/IN the/DT cytokine/NN network/NN in/IN which/WDT Th2/NN lymphocytes/NNS "/`` control/VBP "/'' eosinophils/NNS via/IN the/DT release/NN of/IN IL-4/NN and/CC IL-5/NN ,/, and/CC activation/NN of/IN NF-AT/NN in/IN eosinophils/NNS ./. 
The/DT findings/NNS also/RB suggest/VBP that/IN a/DT later/JJR feedback/NN "/`` talking/NN "/'' may/MD exist/VB between/IN eosinophils/NNS and/CC Th2/NN lymphocytes/NNS ./. 
UI/LS -/: 99307057/CD 
TI/LS -/: PPARalpha/NN activators/NNS inhibit/VBP cytokine-induced/JJ vascular/JJ cell/NN adhesion/NN molecule-1/NN expression/NN in/IN human/JJ endothelial/JJ cells/NNS ./. 
AB/LS -/: BACKGROUND/NN :/: Adhesion/NN molecule/NN expression/NN on/IN the/DT endothelial/JJ cell/NN (/( EC/NN )/) surface/NN is/VBZ critical/JJ for/IN leukocyte/NN recruitment/NN to/TO atherosclerotic/JJ lesions/NNS ./. 
Better/JJR understanding/NN of/IN transcriptional/JJ regulation/NN of/IN adhesion/NN molecules/NNS in/IN ECs/NNS may/MD provide/VB important/JJ insight/NN into/IN plaque/NN formation/NN ./. 
Peroxisome/NN proliferator-activated/JJ receptor-alpha/NN (/( PPARalpha/NN )/) ,/, a/DT member/NN of/IN the/DT nuclear/JJ receptor/NN family/NN ,/, regulates/VBZ gene/NN expression/NN in/IN response/NN to/TO certain/JJ fatty/JJ acids/NNS and/CC fibric/JJ acid/NN derivatives/NNS ./. 
The/DT present/JJ study/NN investigated/VBD PPARalpha/NN expression/NN in/IN human/JJ ECs/NNS and/CC their/PRP$ regulation/NN of/IN vascular/JJ cell/NN adhesion/NN molecule-1/NN (/( VCAM-1/NN )/) ./. 
METHODS/NNS AND/CC RESULTS/NNS :/: Immunohistochemistry/NN revealed/VBD that/IN human/JJ carotid/NN artery/NN ECs/NNS express/VBP PPARalpha/NN ./. 
Pretreatment/NN of/IN cultured/VBN human/JJ ECs/NNS with/IN the/DT PPARalpha/NN activators/NNS fenofibrate/NN or/CC WY14643/NN inhibited/VBD TNF-alpha-induced/JJ VCAM-1/NN in/IN a/DT time-/NN and/CC concentration-dependent/JJ manner/NN ,/, an/DT effect/NN not/RB seen/VBN with/IN PPARgamma/NN activators/NNS ./. 
Both/DT PPARalpha/NN activators/NNS decreased/VBD cytokine-induced/JJ VCAM-1/NN mRNA/NN expression/NN without/IN altering/VBG its/PRP$ mRNA/NN half-life/NN ./. 
Transient/JJ transfection/NN of/IN deletional/JJ VCAM-1/NN promoter/NN constructs/NNS and/CC electrophoretic/JJ mobility/NN shift/NN assays/NNS suggest/VBP that/IN fenofibrate/NN inhibits/VBZ VCAM-1/NN transcription/NN in/IN part/NN by/IN inhibiting/VBG NF-kappaB/NN ./. 
Finally/RB ,/, PPARalpha/NN activators/NNS significantly/RB reduced/VBD adhesion/NN of/IN U937/NN cells/NNS to/TO cultured/VBN human/JJ ECs/NNS ./. 
CONCLUSIONS/NNS :/: Human/JJ ECs/NNS express/VBP PPARalpha/NN ,/, a/DT potentially/RB important/JJ regulator/NN of/IN atherogenesis/NN through/IN its/PRP$ transcriptional/JJ control/NN of/IN VCAM-1/NN gene/NN expression/NN ./. 
Such/JJ findings/NNS also/RB have/VBP implications/NNS regarding/VBG the/DT clinical/JJ use/NN of/IN lipid-lowering/JJ agents/NNS ,/, like/IN fibric/JJ acids/NNS ,/, which/WDT can/MD activate/VB PPARalpha/NN ./. 
UI/LS -/: 99294317/CD 
TI/LS -/: CBP/p300/NN integrates/VBZ Raf/Rac-signaling/JJ pathways/NNS in/IN the/DT transcriptional/JJ induction/NN of/IN NF-ATc/NN during/IN T/NN cell/NN activation/NN ./. 
AB/LS -/: NF-ATc/NN ,/, an/DT inducibly/RB expressed/VBN transcription/NN factor/NN ,/, controls/VBZ gene/NN expression/NN in/IN T/NN lymphocytes/NNS and/CC cardiomyocytes/NNS ./. 
We/PRP show/VBP here/RB that/IN the/DT transcriptional/JJ co-activators/NNS CBP/p300/NN bind/VBP to/TO and/CC control/VBP the/DT activity/NN of/IN the/DT inducible/JJ N-terminal/JJ transactivation/NN domain/NN of/IN NF-ATc/NN ,/, TAD-A/NN ./. 
Similar/JJ to/TO the/DT N/NN terminal/JJ transactivation/NN domain/NN of/IN c-Jun/NN ,/, TAD-A/NN is/VBZ inducibly/RB phosphorylated/VBN ,/, but/CC this/DT phosphorylation/NN is/VBZ dispensable/JJ for/IN the/DT interaction/NN with/IN CBP/p300/NN ./. 
Constitutive/JJ active/JJ versions/NNS of/IN c-Raf/NN and/CC Rac/NN synergistically/RB enhance/VBP the/DT CBP/p300-mediated/JJ increase/NN of/IN TAD-A/NN activity/NN ,/, indicating/VBG the/DT important/JJ role/NN CBP/p300/NN plays/VBZ in/IN the/DT integration/NN of/IN T/NN cell/NN activation/NN signals/NNS ./. 
Since/IN a/DT mutation/NN of/IN CBP/NN abolishing/VBG HAT/NN activity/NN is/VBZ almost/RB as/RB active/JJ as/IN wild-type/JJ CBP/NN in/IN T/NN cells/NNS ,/, functions/NNS of/IN CBP/p300/NN other/JJ than/IN histone/NN acetylation/NN appear/VBP to/TO control/VB the/DT NF-AT-dependent/JJ transcription/NN in/IN T/NN cells/NNS ./. 
UI/LS -/: 99285633/CD 
TI/LS -/: Immune/JJ functions/NNS ,/, clinical/JJ parameters/NNS and/CC hormone/NN receptor/NN status/NN in/IN breast/NN cancer/NN patients/NNS ./. 
AB/LS -/: We/PRP have/VBP carried/VBN out/RP a/DT detailed/JJ analysis/NN of/IN the/DT cellular/JJ immune/JJ functions/NNS of/IN breast/NN cancer/NN patients/NNS in/IN comparison/NN with/IN healthy/JJ controls/NNS ./. 
A/DT possible/JJ correlation/NN between/IN immune/JJ and/CC clinical/JJ parameters/NNS was/VBD analysed/VBN in/IN 50/CD breast/NN cancer/NN patients/NNS ./. 
Immune/JJ parameters/NNS ,/, natural/JJ killer/NN cell/NN and/CC T/NN lymphocyte/NN functions/NNS and/CC the/DT numbers/NNS of/IN circulating/VBG T/NN lymphocytes/NNS were/VBD analysed/VBN against/IN the/DT clinical/JJ parameters/NNS comprising/VBG the/DT tumour/NN burden/NN ,/, the/DT stage/NN of/IN the/DT disease/NN and/CC the/DT expression/NN of/IN hormone/NN receptors/NNS on/IN the/DT tumour/NN ./. 
In/IN order/NN to/TO analyse/VB the/DT immune/JJ function/NN data/NNS effectively/RB ,/, low/JJ responders/NNS were/VBD identified/VBN with/IN stringent/JJ cut-off/JJ values/NNS ./. 
Considerably/RB higher/JJR proportions/NNS of/IN low/JJ responders/NNS were/VBD found/VBN among/IN the/DT patient/NN population/NN ./. 
Elevated/JJ numbers/NNS of/IN circulating/VBG T/NN lymphocytes/NNS and/CC CD3-directed/JJ cytolysis/NN correlated/VBD with/IN the/DT expression/NN of/IN oestrogen/NN receptors/NNS independently/RB of/IN the/DT clinical/histological/JJ parameters/NNS ./. 
UI/LS -/: 99286230/CD 
TI/LS -/: Latent/JJ membrane/NN protein/NN 1/CD of/IN Epstein-Barr/JJ virus/NN interacts/VBZ with/IN JAK3/NN and/CC activates/VBZ STAT/NN proteins/NNS ./. 
AB/LS -/: Latent/JJ membrane/NN protein/NN 1/CD (/( LMP1/NN )/) acts/VBZ like/IN a/DT permanently/RB activated/VBN receptor/NN of/IN the/DT tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) -receptor/NN superfamily/NN and/CC is/VBZ absolutely/RB required/VBN for/IN B/NN cell/NN immortalization/NN by/IN Epstein-Barr/JJ virus/NN ./. 
Molecular/JJ and/CC biochemical/JJ approaches/NNS demonstrated/VBD that/IN LMP1/NN usurps/VBZ cellular/JJ signaling/NN pathways/NNS resulting/VBG in/IN the/DT induction/NN of/IN NF-kappaB/NN and/CC AP-1/NN via/IN two/CD C-terminal/JJ activating/VBG regions/NNS ./. 
We/PRP demonstrate/VBP here/RB that/IN a/DT third/JJ region/NN encompassing/VBG a/DT proline/NN rich/JJ sequence/NN within/IN the/DT 33/CD bp/NN repetitive/JJ stretch/NN of/IN LMP1/NN 's/POS C-terminus/NN is/VBZ required/VBN for/IN the/DT activation/NN of/IN Janus/NN kinase/NN 3/CD (/( JAK3/NN )/) ./. 
The/DT interaction/NN of/IN LMP1/NN and/CC JAK3/NN leads/VBZ to/TO the/DT enhanced/VBN tyrosine/NN auto/transphosphorylation/NN of/IN JAK3/NN within/IN minutes/NNS after/IN crosslinking/NN of/IN a/DT conditional/JJ NGF-R:LMP1/NN chimera/NN and/CC is/VBZ a/DT prerequisite/NN for/IN the/DT activation/NN of/IN STAT/NN transcription/NN factors/NNS ./. 
These/DT results/NNS reveal/VBP a/DT novel/JJ activating/VBG region/NN in/IN the/DT LMP1/NN C-terminus/NN and/CC identify/VBP the/DT JAK/STAT/NN pathway/NN as/IN a/DT target/NN of/IN this/DT viral/JJ integral/JJ membrane/NN protein/NN in/IN B/NN cells/NNS ./. 
UI/LS -/: 99272411/CD 
TI/LS -/: Monocyte/NN arrest/NN and/CC transmigration/NN on/IN inflamed/JJ endothelium/NN in/IN shear/NN flow/NN is/VBZ inhibited/VBN by/IN adenovirus-mediated/JJ gene/NN transfer/NN of/IN IkappaB-alpha/NN ./. 
AB/LS -/: Mobilization/NN of/IN nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) activates/VBZ transcription/NN of/IN genes/NNS encoding/VBG endothelial/JJ adhesion/NN molecules/NNS and/CC chemokines/NNS that/WDT contribute/VBP to/TO monocyte/NN infiltration/NN critical/JJ in/IN atherogenesis/NN ./. 
Inhibition/NN of/IN NF-kappaB/NN has/VBZ been/VBN achieved/VBN by/IN pharmacological/JJ and/CC genetic/JJ approaches/NNS ;/: however/RB ,/, monocyte/NN interactions/NNS with/IN activated/VBN endothelium/NN in/IN shear/NN flow/NN following/VBG gene/NN transfer/NN of/IN the/DT NF-kappaB/NN inhibitor/NN IkappaB-alpha/NN have/VBP not/RB been/VBN studied/VBN ./. 
We/PRP found/VBD that/IN overexpression/NN of/IN IkappaB-alpha/NN in/IN endothelial/JJ cells/NNS using/VBG a/DT recombinant/JJ adenovirus/NN prevented/VBD tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) -induced/JJ degradation/NN of/IN IkappaB-alpha/NN and/CC suppressed/VBD the/DT upregulation/NN of/IN vascular/JJ cell/NN adhesion/NN molecule-1/NN (/( VCAM-1/NN )/) ,/, intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN )/) ,/, and/CC E-selectin/NN mRNA/NN and/CC surface/NN protein/NN expression/NN and/CC the/DT upregulation/NN of/IN transcripts/NNS for/IN the/DT chemokines/NNS monocyte/NN chemoattractant/NN protein/NN 1/CD (/( MCP-1/NN )/) and/CC growth-related/JJ activity-alpha/NN (/( GRO-alpha/NN )/) by/IN TNF-alpha/NN ./. 
This/DT was/VBD associated/VBN with/IN a/DT reduction/NN in/IN endothelial/JJ MCP-1/NN secretion/NN and/CC GRO-alpha/NN immobilization/NN ./. 
Adhesion/NN assays/NNS under/IN physiological/JJ shear/NN flow/NN conditions/NNS showed/VBD that/IN firm/JJ arrest/NN ,/, spreading/NN ,/, and/CC transmigration/NN of/IN monocytes/NNS on/IN TNF-alpha-activated/JJ endothelium/NN was/VBD markedly/RB inhibited/VBN by/IN IkappaB-alpha/NN overexpression/NN ./. 
Inhibition/NN with/IN monoclonal/JJ antibodies/NNS and/CC peptide/NN antagonists/NNS inferred/VBD that/IN this/DT was/VBD due/JJ to/TO reduced/VBN expression/NN of/IN Ig/NN integrin/NN ligand/NN as/RB well/RB as/IN of/IN chemokines/NNS specifically/RB involved/VBN in/IN these/DT events/NNS ./. 
In/IN contrast/NN ,/, rolling/NN of/IN monocytes/NNS was/VBD increased/VBN by/IN IkappaB-alpha/NN transfer/NN and/CC was/VBD partly/RB mediated/VBN by/IN P-selectin/NN ;/: however/RB ,/, it/PRP appeared/VBD to/TO be/VB unaffected/JJ by/IN the/DT inhibition/NN of/IN E-selectin/NN induction/NN ./. 
Thus/RB ,/, our/PRP$ data/NNS provide/VBP novel/JJ evidence/NN that/IN selective/JJ modulation/NN of/IN NF-kappaB/NN by/IN adenoviral/JJ transfer/NN of/IN IkappaB-alpha/NN impairs/VBZ the/DT expression/NN of/IN multiple/JJ endothelial/JJ gene/NN products/NNS required/VBN for/IN subsequent/JJ monocyte/NN arrest/NN and/CC emigration/NN in/IN shear/NN flow/NN and/CC thus/RB for/IN monocyte/NN infiltration/NN in/IN atherosclerotic/JJ plaques/NNS ./. 
UI/LS -/: 99262847/CD 
TI/LS -/: Recognition/NN of/IN NFATp/AP-1/NN composite/JJ elements/NNS within/IN genes/NNS induced/VBN upon/IN the/DT activation/NN of/IN immune/JJ cells/NNS ./. 
AB/LS -/: Composite/JJ elements/NNS are/VBP regulatory/JJ modules/NNS of/IN promoters/NNS or/CC enhancers/NNS that/WDT consist/VBP of/IN binding/VBG sites/NNS of/IN two/CD different/JJ but/CC synergizing/VBG transcription/NN factors/NNS ./. 
A/DT well-studied/JJ example/NN is/VBZ nuclear/JJ factors/NNS of/IN activated/VBN T-cell/NN (/( NFAT/NN )/) sites/NNS which/WDT are/VBP composite/JJ elements/NNS of/IN a/DT NFATp/c/NN and/CC an/DT activating/VBG protein/NN 1/CD (/( AP-1/NN )/) binding/NN site/NN ./. 
We/PRP have/VBP developed/VBN a/DT computational/JJ approach/NN to/TO identify/VB potential/JJ NFAT/NN target/NN genes/NNS which/WDT (/( a/LS )/) comprises/VBZ an/DT improved/JJ method/NN to/TO scan/VB for/IN individual/JJ NFAT/NN composite/JJ elements/NNS ;/: (/( b/LS )/) considers/VBZ positional/JJ effects/NNS relative/JJ to/TO transcription/NN start/NN sites/NNS ;/: and/CC (/( c/LS )/) involves/VBZ cluster/NN analysis/NN of/IN potential/JJ NFAT/NN composite/JJ elements/NNS ./. 
All/DT three/CD steps/NNS progressively/RB helpX?ed/VBD to/TO discriminate/VB T-cell-specific/JJ promoter/NN sequences/NNS against/IN other/JJ functional/JJ regions/NNS (/( coding/NN and/CC intronic/JJ sequences/NNS )/) of/IN the/DT same/JJ genes/NNS ,/, against/IN promoters/NNS of/IN muscle-specific/JJ genes/NNS or/CC against/IN random/JJ sequences/NNS ./. 
Using/VBG this/DT approach/NN ,/, we/PRP identified/VBD potential/JJ NFAT/NN composite/JJ elements/NNS in/IN promoters/NNS of/IN cytokine/NN genes/NNS and/CC their/PRP$ receptors/NNS as/RB well/RB as/IN in/IN promoters/NNS of/IN genes/NNS for/IN AP-1/NN family/NN members/NNS ,/, Ca2+-binding/JJ proteins/NNS and/CC some/DT other/JJ components/NNS of/IN the/DT regulatory/JJ network/NN operating/VBG in/IN activated/VBN T-cells/NNS and/CC other/JJ immune/JJ cells/NNS ./. 
The/DT method/NN developed/VBN can/MD be/VB adapted/VBN to/TO characterize/VB and/CC identify/VB other/JJ composite/JJ elements/NNS as/RB well/RB ./. 
The/DT program/NN for/IN recognition/NN NFAT/NN composite/JJ elements/NNS is/VBZ available/JJ through/IN the/DT World/NN Wide/NN Web/NN (/( http://compel.bionet.nsc.ru/FunSite/CompelScan.html/NN and/CC http://transfac.gbf.de/dbsearch/funsitep/s_comp.html/NN )/) ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99249555/CD 
TI/LS -/: The/DT oestrogen/NN receptor/NN codon/NN 10/CD polymorphism/NN detected/VBN in/IN breast/NN cancer/NN is/VBZ also/RB present/JJ in/IN non-malignant/JJ cells/NNS ./. 
AB/LS -/: The/DT effect/NN of/IN oestrogens/NNS on/IN oestrogen-receptive/JJ organs/NNS and/CC cells/NNS is/VBZ mediated/VBN via/IN intracellular/JJ receptors/NNS (/( ERalpha/NN and/CC ERbeta/NN )/) ./. 
Oestrogen/NN receptor/NN gene/NN polymorphisms/NNS in/IN the/DT region/NN encoding/VBG the/DT N-terminal/JJ portion/NN of/IN the/DT protein/NN are/VBP reportedly/RB associated/VBN with/IN pathological/JJ conditions/NNS including/VBG breast/NN cancer/NN ,/, hypertension/NN ,/, spontaneous/JJ abortion/NN and/CC coronary/JJ heart/NN disease/NN ./. 
A/DT silent/JJ mutation/NN in/IN codon/NN 10/CD of/IN exon/NN 1/CD ,/, detected/VBN in/IN ER-negative/JJ and/CC ER-positive/JJ human/JJ breast/NN cancer/NN cell/NN lines/NNS ,/, in/IN breast/NN tumors/NNS and/CC blood/NN DNA/NN from/IN breast/NN cancer/NN patients/NNS ,/, has/VBZ been/VBN recognized/VBN as/IN a/DT polymorphic/JJ site/NN ./. 
In/IN this/DT study/NN we/PRP examined/VBD ,/, by/IN denaturing/VBG gradient-gel/JJ electrophoresis/NN and/CC DNA/NN sequence/NN analysis/NN ,/, the/DT possible/JJ presence/NN of/IN a/DT codon/NN 10/CD polymorphic/JJ site/NN in/IN normal/JJ oestrogen/NN target/NN organs/NNS and/CC cells/NNS such/JJ as/IN the/DT uterus/NN (/( myometrium/NN and/CC endometrium/NN )/) ,/, in/IN the/DT placenta/NN and/CC peripheral/JJ blood/NN mononuclear/JJ cells/NNS and/CC in/IN a/DT benign/JJ uterus/NN tumour/NN (/( leiomyoma/NN )/) ./. 
We/PRP have/VBP detected/VBN ER/NN codon/NN 10/CD polymorphism/NN in/IN these/DT samples/NNS and/CC have/VBP compared/VBN them/PRP to/TO those/DT observed/VBN in/IN breast/NN cancer/NN samples/NNS ./. 
All/DT tissues/NNS and/CC cells/NNS studied/VBN were/VBD homozygous/JJ for/IN the/DT wild-type/JJ gene/NN ,/, and/CC were/VBD heterozygous/JJ as/RB well/RB as/IN homozygous/JJ for/IN the/DT codon-10-variant/JJ type/NN ./. 
These/DT results/NNS indicate/VBP that/IN the/DT presence/NN of/IN the/DT codon-10-variant/JJ type/NN is/VBZ not/RB a/DT characteristic/NN of/IN breast/NN cancer/NN ./. 
Out/IN|PRP$ current/JJ findings/NNS suggest/VBP that/IN further/JJ investigations/NNS are/VBP warranted/VBN to/TO elucidate/VB the/DT possible/JJ linkage/NN of/IN ER/NN codon/NN 10/CD polymorphism/NN to/TO physiological/JJ and/CC pathological/JJ conditions/NNS ./. 
UI/LS -/: 99248179/CD 
TI/LS -/: USF/c-Myc/NN enhances/VBZ ,/, while/IN Yin-Yang/NN 1/CD suppresses/VBZ ,/, the/DT promoter/NN activity/NN of/IN CXCR4/NN ,/, a/DT coreceptor/NN for/IN HIV-1/NN entry/NN ./. 
AB/LS -/: Transcription/NN factors/NNS USF1/NN and/CC USF2/NN up-regulate/VBP gene/NN expression/NN (/( i.e./FW ,/, HIV-1/NN long/JJ terminal/JJ repeats/NNS )/) via/IN interaction/NN with/IN an/DT E/NN box/NN on/IN their/PRP$ target/NN promoters/NNS ,/, which/WDT is/VBZ also/RB a/DT binding/VBG site/NN for/IN c-Myc/NN ./. 
The/DT c-Myc/NN oncoprotein/NN is/VBZ important/JJ in/IN control/NN of/IN cellular/JJ proliferation/NN and/CC differentiation/NN ,/, while/IN Yin-Yang/NN 1/CD (/( YY1/NN )/) has/VBZ been/VBN shown/VBN to/TO control/VB the/DT expression/NN of/IN a/DT number/NN of/IN cellular/JJ and/CC viral/JJ genes/NNS ./. 
These/DT two/CD proteins/NNS physically/RB interact/VBP with/IN each/DT other/JJ and/CC mutually/RB inhibit/VBP their/PRP$ respective/JJ biological/JJ functions/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP show/VBP that/IN USF/c-Myc/NN up-regulates/VBZ ,/, while/IN YY1/NN down-regulates/VBZ the/DT promoter/NN activity/NN of/IN CXCR4/NN ,/, a/DT coreceptor/NN for/IN T/NN cell-tropic/JJ HIV-1/NN entry/NN ./. 
We/PRP have/VBP identified/VBN an/DT E/NN box/NN around/IN -260/CD and/CC a/DT YY1/NN binding/NN site/NN around/IN -300/CD relative/JJ to/TO the/DT transcription/NN start/NN site/NN ./. 
Mutation/NN of/IN the/DT E/NN box/NN abolished/VBD USF/c-Myc-/NN mediated/JJ up-regulation/NN of/IN CXCR4/NN promoter/NN activity/NN ,/, and/CC mutation/NN of/IN the/DT YY1/NN binding/NN site/NN was/VBD associated/VBN with/IN unresponsiveness/NN to/TO YY1-mediated/JJ inhibition/NN ./. 
These/DT data/NNS suggest/VBP that/IN USF/c-Myc/NN and/CC YY1/NN may/MD play/VB an/DT important/JJ role/NN in/IN the/DT HIV-1-replicative/JJ cycle/NN ,/, by/IN modulating/VBG both/CC the/DT viral/JJ fusion/entry/NN process/NN and/CC viral/JJ expression/NN ./. 
UI/LS -/: 99328623/CD 
TI/LS -/: Suppression/NN of/IN NF-kappaB/NN activation/NN in/IN normal/JJ T/NN cells/NNS by/IN supernatant/JJ fluid/NN from/IN human/JJ renal/JJ cell/NN carcinomas/NNS ./. 
AB/LS -/: T/NN lymphocytes/NNS from/IN patients/NNS with/IN renal/JJ cell/NN carcinoma/NN (/( RCC/NN )/) show/VBP reduced/VBN immune/JJ function/NN and/CC impaired/JJ activation/NN of/IN the/DT transcription/NN factor/NN ,/, NF-kappaB/NN ./. 
We/PRP determined/VBD the/DT mechanism/NN of/IN NF-kappaB/NN suppression/NN in/IN T/NN cells/NNS of/IN RCC/NN patient/NN and/CC determined/VBD whether/IN supernatant/JJ fluid/NN from/IN RCC/NN explants/NNS (/( RCC-S/NNS )/) induced/VBD the/DT same/JJ phenotype/NN of/IN NF-kappaB/NN suppression/NN in/IN normal/JJ T/NN cells/NNS that/WDT is/VBZ observed/VBN in/RP patient/NN T/NN cells/NNS ./. 
The/DT pattern/NN of/IN kappaB-binding/JJ activity/NN in/IN T/NN cells/NNS of/IN RCC/NN patient/NN was/VBD altered/VBN as/IN compared/VBN to/TO that/DT seen/VBN in/IN T/NN cells/NNS obtained/VBN from/IN normal/JJ volunteers/NNS ./. 
In/IN some/DT patients/NNS ,/, no/DT activation/NN of/IN RelA/NFkappaB1-binding/JJ activity/NN was/VBD detectable/JJ ,/, while/IN in/IN others/NNS kappaB-binding/JJ activity/NN was/VBD modestly/RB induced/VBN but/CC the/DT duration/NN was/VBD reduced/VBN ./. 
IkappaBalpha/NN was/VBD degraded/VBN normally/RB following/VBG stimulation/NN in/IN both/CC normal/JJ controls/NNS and/CC T/NN cells/NNS from/IN RCC/NN patients/NNS ./. 
RCC-S/NNS did/VBD not/RB alter/VB the/DT cytoplasmic/JJ levels/NNS of/IN RelA/NN and/CC NF-kappaB1/NN but/CC did/VBD suppress/VB their/PRP$ nuclear/JJ localization/NN and/CC inhibited/VBD the/DT activation/NN of/IN RelA/NF-kappaB1/NN binding/NN complexes/NNS ./. 
These/DT results/NNS show/VBP that/IN RCC-S/NNS can/MD induce/VB in/IN normal/JJ T/NN cells/NNS the/DT same/JJ phenotype/NN of/IN impaired/JJ NF-kappaB/NN activation/NN that/WDT is/VBZ detected/VBN in/IN T/NN cells/NNS of/IN RCC/NN patient/NN ./. 
It/PRP also/RB appears/VBZ that/IN NF-kappaB/NN suppression/NN by/IN RCC-S/NNS may/MD contribute/VB to/TO the/DT immunosuppression/NN of/IN host/NN immunity/NN ./. 
UI/LS -/: 99315311/CD 
TI/LS -/: STAT1/NN activation/NN during/IN monocyte/NN to/TO macrophage/NN maturation/NN :/: role/NN of/IN adhesion/NN molecules/NNS ./. 
AB/LS -/: Human/JJ monocytes/NNS isolated/VBN from/IN peripheral/JJ blood/NN of/IN healthy/JJ donors/NNS show/VBP a/DT time-dependent/JJ differentiation/NN into/IN macrophages/NNS upon/IN in/FW vitro/FW cultivation/NN ,/, closely/RB mimicking/VBG their/PRP$ in/FW vivo/FW migration/NN and/CC maturation/NN into/IN extravascular/JJ tissues/NNS ./. 
The/DT mediator/NN (/( s/NNS )/) of/IN this/DT maturation/NN process/NN has/VBZ not/RB been/VBN yet/RB defined/VBN ./. 
We/PRP investigated/VBD the/DT involvement/NN of/IN signal/JJ transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STAT/NN )/) factors/NNS in/IN this/DT phenomenon/NN and/CC reported/VBD the/DT specific/JJ ,/, time-dependent/JJ ,/, activation/NN of/IN STAT1/NN protein/NN starting/VBG at/IN day/NN 0/1/CD of/IN cultivation/NN and/CC maximally/RB expressed/VBN at/IN day/NN 5/CD ./. 
STAT1/NN activity/NN was/VBD evident/JJ on/IN the/DT STAT/NN binding/NN sequences/NNS (/( SBE/NNS )/) present/JJ in/IN the/DT promoters/NNS of/IN genes/NNS which/WDT are/VBP up-regulated/VBN during/IN monocyte/NN to/TO macrophage/NN maturation/NN such/JJ as/IN FcgammaRI/NN and/CC ICAM-1/NN ,/, and/CC in/IN the/DT promoter/NN of/IN the/DT transcription/NN factor/NN IFN/NN regulatory/JJ factor-1/NN ./. 
Moreover/RB ,/, the/DT effect/NN of/IN cell/NN adhesion/NN to/TO fibronectin/NN or/CC laminin/NN was/VBD studied/VBN to/TO investigate/VB mechanisms/NNS involved/VBN in/IN STAT1/NN activation/NN ./. 
Compared/VBN with/IN monocytes/NNS adherent/JJ on/IN plastic/JJ surfaces/NNS ,/, freshly/RB isolated/VBN cells/NNS allowed/VBN to/TO adhere/VB either/CC to/TO fibronectin-/NN or/CC laminin-coated/JJ flasks/NNS exhibited/VBD an/DT increased/VBN STAT1/NN binding/NN activity/NN both/CC in/IN control/NN and/CC in/IN IFN-gamma-treated/JJ cells/NNS ./. 
The/DT molecular/JJ events/NNS leading/VBG to/TO enhanced/VBN STAT1/NN activation/NN and/CC cytokine/NN responsiveness/NN concerned/VBD both/CC Y701/NN and/CC S727/NN STAT1/NN phosphorylation/NN ./. 
Exogenous/JJ addition/NN of/IN transforming/VBG growth/NN factor-beta/NN ,/, which/WDT exerts/VBZ an/DT inhibitory/JJ effect/NN on/IN some/DT monocytic/JJ differentiation/NN markers/NNS ,/, inhibited/VBD macrophage/NN maturation/NN ,/, integrin/NN expression/NN and/CC STAT1/NN binding/NN activity/NN ./. 
Taken/VBN together/RB these/DT results/NNS indicate/VBP that/IN STAT1/NN plays/VBZ a/DT pivotal/JJ role/NN in/IN the/DT differentiation/maturation/NN process/NN of/IN monocytes/NNS as/IN an/DT early/JJ transcription/NN factor/NN initially/RB activated/VBN by/IN adherence/NN and/CC then/RB able/JJ to/TO modulate/VB the/DT expression/NN of/IN functional/JJ genes/NNS ,/, such/JJ as/IN ICAM-1/NN and/CC FcgammaRI/NN ./. 
UI/LS -/: 99303024/CD 
TI/LS -/: Expression/NN and/CC role/NN of/IN PML/NN gene/NN in/IN normal/JJ adult/JJ hematopoiesis/NN :/: functional/JJ interaction/NN between/IN PML/NN and/CC Rb/NN proteins/NNS in/IN erythropoiesis/NN ./. 
AB/LS -/: The/DT expression/NN of/IN the/DT PML/NN gene/NN was/VBD investigated/VBN in/IN purified/VBN early/JJ hematopoietic/JJ progenitor/NN cells/NNS (/( HPCs/NNS )/) induced/VBN to/TO unilineage/JJ erythroid/JJ or/CC granulocytic/JJ differentiation/NN ./. 
PML/NN mRNA/NN and/CC protein/NN ,/, while/IN barely/RB detectable/JJ in/IN quiescent/JJ HPCs/NNS ,/, are/VBP consistently/RB induced/VBN by/IN growth/NN factor/NN stimulation/NN through/IN the/DT erythroid/JJ or/CC granulocytic/JJ lineage/NN ./. 
Thereafter/RB ,/, PML/NN is/VBZ downmodulated/VBN in/IN late/JJ granulocytic/JJ maturation/NN ,/, whereas/IN it/PRP is/VBZ sustainably/RB expressed/VBN through/IN the/DT erythroid/JJ pathway/NN ./. 
In/IN functional/JJ studies/NNS ,/, PML/NN expression/NN was/VBD inhibited/VBN by/IN addition/NN of/IN antisense/JJ oligomers/NNS targeting/VBG PML/NN mRNA/NN (/( alpha-PML/NN )/) ./. 
Interestingly/RB ,/, early/JJ treatment/NN (/( day/NN 0/CD HPCs/NNS )/) with/IN alpha-PML/NN reduced/VBD the/DT number/NN of/IN both/CC erythroid/JJ and/CC granulocytic/JJ colonies/NNS ,/, whereas/IN late/JJ treatment/NN (/( day/NN 5/CD culture/NN )/) reduced/VBD erythroid/JJ ,/, but/CC not/RB granulocytic/JJ ,/, clonogenesis/NN ./. 
These/DT findings/NNS suggest/VBP that/IN PML/NN is/VBZ required/VBN for/IN early/JJ hematopoiesis/NN and/CC erythroid/JJ ,/, but/CC not/RB granulocytic/JJ maturation/NN ./. 
The/DT pattern/NN of/IN PML/NN expression/NN in/IN normal/JJ hematopoiesis/NN mimics/VBZ that/DT of/IN retinoblastoma/NN pRb/NN 105/CD ./. 
Combined/JJ treatment/NN of/IN HPCs/NNS with/IN alpha-PML/NN and/CC alpha-Rb/NN oligomers/NNS inhibited/VBD both/CC PML/NN and/CC Rb/NN protein/NN expression/NN and/CC completely/RB blocked/VBD erythroid/JJ colony/NN development/NN ./. 
Furthermore/RB ,/, PML/NN and/CC pRb/NN 105/CD were/VBD co-immunoprecipitated/VBN in/IN cellular/JJ lysates/NNS derived/VBN from/IN erythroid/JJ precursors/NNS indicating/VBG that/IN this/DT functional/JJ interaction/NN may/MD have/VB a/DT biochemical/JJ basis/NN ./. 
These/DT results/NNS suggest/VBP a/DT key/JJ functional/JJ role/NN of/IN PML/NN in/IN early/JJ hematopoiesis/NN and/CC late/JJ erythropoiesis/NN :/: the/DT latter/JJ phenomenon/NN may/MD be/VB related/JJ to/TO the/DT molecular/JJ and/CC functional/JJ interaction/NN of/IN PML/NN with/IN pRb/NN 105/CD ./. 
UI/LS -/: 99294118/CD 
TI/LS -/: Binding/NN characteristics/NNS of/IN the/DT glucocorticoid/NN receptor/NN in/IN peripheral/JJ blood/NN lymphocytes/NNS in/IN multiple/JJ sclerosis/NN ./. 
AB/LS -/: Although/IN the/DT exact/JJ etiology/NN of/IN multiple/JJ sclerosis/NN (/( MS/NN )/) remains/VBZ unresolved/JJ ,/, immune/JJ reactions/NNS are/VBP believed/VBN to/TO be/VB the/DT central/JJ pathogenic/JJ mechanisms/NNS ./. 
Endogenous/JJ and/CC therapeutic/JJ steroid/NN hormones/NNS affect/VBP the/DT immune/JJ system/NN ,/, and/CC inflammatory/JJ diseases/NNS are/VBP associated/VBN with/IN activation/NN of/IN the/DT hypothalamic-pituitary-adrenal/JJ axis/NN ,/, providing/VBG evidence/NN of/IN an/DT immune-endocrine/JJ interplay/NN ./. 
Function/NN tests/NNS in/IN MS/NN have/VBP revealed/VBN dysregulation/NN of/IN the/DT hypothalamic-pituitary-adrenal/JJ system/NN in/IN a/DT substantial/JJ proportion/NN of/IN patients/NNS ./. 
We/PRP characterized/VBD glucocorticoid/NN receptor/NN (/( GR/NN )/) binding/NN in/IN peripheral/JJ blood/NN lymphocytes/NNS from/IN 39/CD MS/NN patients/NNS and/CC 14/CD age-/NN and/CC sex-matched/JJ controls/NNS with/IN respect/NN to/TO dissociation/NN constant/NN and/CC binding/NN capacity/NN ,/, using/VBG a/DT whole-cell/JJ binding/NN assay/NN with/IN [3H]dexamethasone/NN as/IN the/DT ligand/NN ./. 
GR/NN binding/NN parameters/NNS did/VBD not/RB differ/VB significantly/RB between/IN patients/NNS (/( Kd/NN 8.98/CD +/-/CC 1.07/CD nM/NN ,/, Bmax/NN 183/CD +/-/CC 29.8/CD fmol/mg/NN )/) and/CC controls/NNS (/( Kd/NN 9.36/CD +/-/CC 1.17/CD nM/NN ,/, Bmax/NN 158/CD +/-/CC 16/CD fmol/mg/NN )/) ./. 
No/DT effect/NN of/IN age/NN ,/, sex/NN ,/, course/NN ,/, duration/NN or/CC severity/NN of/IN disease/NN ,/, or/CC prior/JJ steroid/NN treatments/NNS was/VBD detected/VBN ./. 
GR/NN binding/NN parameters/NNS were/VBD analyzed/VBN in/IN relation/NN to/TO the/DT results/NNS of/IN the/DT combined/JJ dexamethasone-CRH/JJ test/NN ,/, which/WDT reflects/VBZ corticosteroid/NN receptor/NN function/NN at/IN the/DT hypothalamus/NN ,/, in/IN 30/CD patients/NNS and/CC 9/CD controls/NNS ./. 
While/IN controls/NNS showed/VBD a/DT moderate/JJ correlation/NN between/IN binding/NN affinity/NN of/IN the/DT GR/NN in/IN lymphocytes/NNS and/CC regulatory/JJ function/NN at/IN the/DT hypothalamic/JJ level/NN ,/, the/DT patients/NNS did/VBD not/RB ./. 
These/DT data/NNS suggest/VBP that/IN the/DT physiological/JJ relationship/NN between/IN binding/NN and/CC function/NN of/IN the/DT glucocorticoid/NN receptor/NN is/VBZ disturbed/VBN in/IN MS/NN ./. 
UI/LS -/: 99285507/CD 
TI/LS -/: Phorbol/NN ester-induced/JJ mononuclear/JJ cell/NN differentiation/NN is/VBZ blocked/VBN by/IN the/DT mitogen-activated/JJ protein/NN kinase/NN kinase/NN (/( MEK/NN )/) inhibitor/NN PD98059/NN ./. 
AB/LS -/: The/DT purpose/NN of/IN this/DT study/NN was/VBD to/TO evaluate/VB whether/IN the/DT mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) signaling/NN pathway/NN contributes/VBZ to/TO 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) -induced/JJ mononuclear/JJ differentiation/NN in/IN the/DT human/JJ myeloblastic/JJ leukemia/NN ML-1/NN cells/NNS ./. 
Upon/IN TPA/NN treatment/NN ,/, the/DT activity/NN of/IN ERK1/NN and/CC ERK2/NN rapidly/RB increased/VBD ,/, with/IN maximal/JJ induction/NN between/IN 1/CD and/CC 3/CD h/NN ,/, while/IN ERK2/NN protein/NN levels/NNS remained/VBD constant/JJ ./. 
The/DT activity/NN of/IN JNK1/NN was/VBD also/RB significantly/RB induced/VBN ,/, with/IN JNK1/NN protein/NN levels/NNS increasing/VBG moderately/RB during/IN exposure/NN to/TO TPA/NN ./. 
Treatment/NN of/IN cells/NNS with/IN PD98059/NN ,/, a/DT specific/JJ inhibitor/NN of/IN mitogen-activated/JJ protein/NN kinase/NN kinase/NN (/( MEK/NN )/) ,/, inhibited/VBD TPA-induced/JJ ERK2/NN activity/NN ./. 
Furthermore/RB ,/, PD98059/NN completely/RB blocked/VBD the/DT TPA-induced/JJ differentiation/NN of/IN ML-1/NN cells/NNS ,/, as/IN assessed/VBN by/IN a/DT number/NN of/IN features/NNS associated/VBN with/IN mononuclear/JJ differentiation/NN including/VBG changes/NNS in/IN morphology/NN ,/, nonspecific/JJ esterase/NN activity/NN ,/, phagocytic/JJ ability/NN ,/, NADPH/NN oxidase/NN activity/NN ,/, mitochondrial/JJ respiration/NN ,/, and/CC c-jun/NN mRNA/NN inducibility/NN ./. 
We/PRP conclude/VBP that/IN activation/NN of/IN the/DT MEK/ERK/NN signaling/NN pathway/NN is/VBZ necessary/JJ for/IN TPA-induced/JJ mononuclear/JJ cell/NN differentiation/NN ./. 
UI/LS -/: 99285117/CD 
TI/LS -/: Glucocorticoid/NN receptors/NNS in/IN anorexia/NN nervosa/NN and/CC Cushing/NN 's/POS disease/NN ./. 
AB/LS -/: BACKGROUND/NN :/: Patients/NNS with/IN anorexia/NN nervosa/NN do/VBP not/RB display/VB cushingoid/JJ features/NNS in/IN spite/NN of/IN elevated/JJ cortisol/NN plasma/NN levels/NNS ./. 
Whether/IN a/DT cortisol/NN resistance/NN or/CC a/DT reduced/VBN availability/NN of/IN the/DT metabolic/JJ substrates/NNS necessary/JJ to/TO develop/VB the/DT effect/NN of/IN glucocorticoids/NNS is/VBZ responsible/JJ for/IN this/DT has/VBZ not/RB been/VBN established/VBN ./. 
METHODS/NNS :/: Twenty-two/CD patients/NNS with/IN severe/JJ restrictive/JJ anorexia/NN nervosa/NN ,/, 10/CD patients/NNS with/IN active/JJ Cushing/NN 's/POS disease/NN ,/, and/CC 24/CD healthy/JJ volunteers/NNS without/IN psychiatric/JJ disorders/NNS or/CC mood/NN alterations/NNS were/VBD investigated/VBN ./. 
Glucocorticoid/NN receptor/NN characteristics/NNS were/VBD examined/VBN on/IN mononuclear/JJ leukocytes/NNS by/IN measuring/VBG [3H]dexamethasone/NN binding/NN and/CC the/DT effect/NN of/IN dexamethasone/NN on/IN [3H]thymidine/NN incorporation/NN ,/, which/WDT represents/VBZ an/DT index/NN of/IN DNA/NN synthesis/NN ./. 
RESULTS/NNS :/: The/DT number/NN of/IN glucocorticoid/NN receptors/NNS on/IN mononuclear/JJ leukocytes/NNS (/( MNL/NNS )/) was/VBD comparable/JJ in/IN patients/NNS with/IN anorexia/NN nervosa/NN ,/, patients/NNS with/IN active/JJ Cushing/NN 's/POS disease/NN ,/, and/CC normal/JJ subjects/NNS (/( binding/NN capacity/NN 3.3/CD +/-/CC 0.23/CD vs./CC 3.7/CD +/-/CC 0.30/CD and/CC 3.5/CD +/-/CC 0.20/CD fmol/10(6)/NN cells/NNS )/) ./. 
Conversely/RB ,/, glucocorticoid/NN receptor/NN affinity/NN was/VBD significantly/RB decreased/VBN in/IN anorexia/NN nervosa/NN as/RB well/RB as/IN in/IN Cushing/NN 's/POS patients/NNS compared/VBN to/TO control/JJ subjects/NNS (/( dissociation/NN constant/NN 4.0/CD +/-/CC 0.31/CD and/CC 4.1/CD +/-/CC 0.34/CD vs./CC 2.9/CD +/-/CC 0.29/CD nmol/L/NN ,/, p/NN </JJR .001/CD )/) and/CC inversely/RB correlated/VBN with/IN the/DT levels/NNS of/IN urinary/JJ free/JJ cortisol/NN in/IN both/DT groups/NNS of/IN patients/NNS ./. 
Basal/JJ [3H]thymidine/NN incorporation/NN in/IN MNL/NN was/VBD significantly/RB reduced/VBN in/IN anorexia/NN nervosa/NN as/RB well/RB as/IN in/IN Cushing/NN 's/POS patients/NNS compared/VBN to/TO control/JJ subjects/NNS (/( p/NN </JJR .001/CD )/) and/CC was/VBD diminished/VBN by/IN dexamethasone/NN to/TO an/DT extent/NN similar/JJ to/TO control/JJ subjects/NNS in/IN patients/NNS with/IN anorexia/NN nervosa/NN ,/, but/CC significantly/RB (/( p/NN </JJR .001/CD )/) less/RBR in/IN those/DT with/IN Cushing/NN 's/POS disease/NN ./. 
In/IN patients/NNS with/IN anorexia/NN nervosa/NN ,/, the/DT incorporation/NN of/IN [3H]thymidine/NN into/IN the/DT MNL/NN was/VBD inversely/RB correlated/VBN with/IN urinary/JJ free/JJ cortisol/NN levels/NNS ./. 
CONCLUSIONS/NNS :/: These/DT data/NNS indicate/VBP that/IN the/DT lack/NN of/IN cushingoid/JJ features/NNS in/IN patients/NNS with/IN anorexia/NN nervosa/NN is/VBZ not/RB ascribable/JJ to/TO a/DT reduced/VBN sensitivity/NN to/TO glucocorticoids/NNS but/CC is/VBZ more/RBR likely/RB due/JJ to/TO the/DT paucity/NN of/IN metabolic/JJ substrates/NNS ./. 
UI/LS -/: 99265951/CD 
TI/LS -/: Different/JJ sequence/NN requirements/NNS for/IN expression/NN in/IN erythroid/JJ and/CC megakaryocytic/JJ cells/NNS within/IN a/DT regulatory/JJ element/NN upstream/JJ of/IN the/DT GATA-1/NN gene/NN ./. 
AB/LS -/: The/DT lineage-restricted/JJ transcription/NN factor/NN GATA-1/NN is/VBZ required/VBN for/IN differentiation/NN of/IN erythroid/JJ and/CC megakaryocytic/JJ cells/NNS ./. 
We/PRP have/VBP localized/VBN a/DT 317/CD base/NN pair/NN cis-acting/JJ regulatory/JJ element/NN ,/, HS/NN I/CD ,/, associated/VBN with/IN a/DT hematopoietic-specific/JJ DNase/NN I/CD hypersensitive/JJ site/NN ,/, which/WDT lies/VBZ approx./RB 
3.7/CD kilobases/NNS upstream/RB of/IN the/DT murine/JJ hematopoietic-specific/JJ GATA-1/NN IE/NN promoter/NN ./. 
HS/NN I/CD directs/VBZ high-level/JJ expression/NN of/IN reporter/NN GATA-1/lacZ/NN genes/NNS to/TO primitive/JJ and/CC definitive/JJ erythroid/JJ cells/NNS and/CC megakaryocytes/NNS in/IN transgenic/JJ mice/NNS ./. 
Comparative/JJ sequence/NN analysis/NN of/IN HS/NN I/CD between/IN human/JJ and/CC mouse/NN shows/VBZ approx./RB 
63/CD %/NN nucleotide/NN identity/NN with/IN a/DT more/RBR conserved/VBN core/NN of/IN 169/CD base/NN pairs/NNS (/( 86/CD %/NN identity/NN )/) ./. 
This/DT core/NN contains/VBZ a/DT GATA/NN site/NN separated/VBN by/IN 10/CD base/NN pairs/NNS from/IN an/DT E-box/NN motif/NN ./. 
The/DT composite/JJ motif/NN binds/VBZ a/DT multi-protein/JJ hematopoietic-specific/JJ transcription/NN factor/NN complex/NN which/WDT includes/VBZ GATA-1/NN ,/, SCL/tal-1/NN ,/, E2A/NN ,/, Lmo2/NN and/CC Ldb-1/NN ./. 
Point/JJ mutations/NNS of/IN the/DT GATA/NN site/NN abolishes/VBZ HS/NNS I/CD function/NN ,/, whereas/IN mutation/NN of/IN the/DT E-box/NN motif/NN still/RB allows/VBZ reporter/NN gene/NN expression/NN in/IN both/DT lineages/NNS ./. 
Strict/JJ dependence/NN of/IN HS/NN I/CD activity/NN on/IN a/DT GATA/NN site/NN implies/VBZ that/IN assembly/NN of/IN a/DT protein/NN complex/NN containing/VBG a/DT GATA-factor/NN ,/, presumably/RB GATA-1/NN or/CC GATA-2/NN ,/, is/VBZ critical/JJ to/TO activating/VBG or/CC maintaining/VBG its/PRP$ function/NN ./. 
Further/RB dissection/NN of/IN the/DT 317/CD base/NN pair/NN region/NN demonstrates/VBZ that/IN ,/, whereas/IN all/DT 317/CD base/NN pairs/NNS are/VBP required/VBN for/IN expression/NN in/IN megakaryocytes/NNS ,/, only/RB the/DT 5'/JJ 62/CD base/NN pairs/NNS are/VBP needed/VBN for/IN erythroid-specific/JJ reporter/NN expression/NN ./. 
These/DT findings/NNS demonstrate/VBP differential/JJ lineage/NN requirements/NNS for/IN expression/NN within/IN the/DT HS/NN I/CD element/NN ./. 
UI/LS -/: 99262230/CD 
TI/LS -/: Non-steroidal/JJ anti-inflammatory/JJ drugs/NNS inhibit/VBP the/DT expression/NN of/IN cytokines/NNS and/CC induce/VBP HSP70/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: Recent/JJ studies/NNS have/VBP shown/VBN that/IN the/DT non-steroidal/JJ anti-inflammatory/JJ drugs/NNS (/( NSAIDs/NNS )/) activate/VBP heat/NN shock/NN transcription/NN factor/NN (/( HSF1/NN )/) from/IN a/DT latent/JJ cytoplasmic/JJ form/NN to/TO a/DT nuclear/JJ ,/, DNA/NN binding/NN state/NN ./. 
As/IN HSF1/NN can/MD function/NN as/IN both/CC an/DT activator/NN of/IN heat/NN shock/NN genes/NNS and/CC a/DT repressor/NN of/IN non-heat/JJ shock/NN genes/NNS such/JJ as/IN IL1B/NN and/CC c- fos/NN ,/, we/PRP have/VBP examined/VBN the/DT potential/JJ role/NN of/IN HSF1/NN in/IN the/DT effects/NNS of/IN NSAIDs/NNS on/IN gene/NN expression/NN in/IN a/DT human/JJ monocytic/JJ cell/NN line/NN THP-1/NN ./. 
We/PRP found/VBD that/IN two/CD members/NNS of/IN the/DT NSAIDs/NNS ,/, sodium/NN salicylate/NN and/CC sulindac/NN repress/VBP the/DT IL1B/NN promoter/NN to/TO similar/JJ degree/NN to/TO heat/NN shock/NN or/CC HSF1/NN overexpression/NN ./. 
In/IN addition/NN ,/, sodium/NN salicylate/NN and/CC additional/JJ NSAIDs/NNS used/VBN at/IN concentrations/NNS that/WDT activate/VBP HSF1/NN also/RB inhibited/VBD the/DT expression/NN of/IN other/JJ monocytic/JJ genes/NNS (/( TNF-alpha/NN ,/, IL-1beta/NN ,/, IL-6/NN ,/, IL-8/NN ,/, IL-10/NN ,/, ICAM-1/NN )/) activated/VBN by/IN exposure/NN to/TO a/DT pro-inflammatory/JJ stimulus/NN (/( lipopolysaccharide/NN ,/, LPS/NN )/) ./. 
At/IN least/JJS in/IN the/DT case/NN of/IN the/DT IL1B/NN promoter/NN ,/, repression/NN did/VBD not/RB seem/VB to/TO involve/VB another/DT factor/NN whose/WP$ activity/NN is/VBZ affected/VBN by/IN the/DT NSAIDs/NNS ,/, NFkappaB/NN as/IN the/DT IL1B/NN promoter/NN fragment/NN used/VBN in/IN our/PRP$ studies/NNS is/VBZ not/RB NFkappaB/NN responsive/JJ and/CC binds/VBZ specifically/RB to/TO HSF1/NN ./. 
Exposure/NN to/TO NSAIDs/NNS had/VBD a/DT complex/JJ effect/NN on/IN HSP/NN gene/NN expression/NN and/CC while/IN sulindac/NN activated/VBD the/DT stress/NN responsive/JJ HSP70B/NN promoter/NN ,/, sodium/NN salicylate/NN did/VBD not/RB ./. 
In/IN addition/NN ,/, only/RB a/DT subset/NN of/IN the/DT NSAIDs/NN induced/VBD HSP70/NN mRNA/NN species/NNS ./. 
These/DT findings/NNS reflect/VBP the/DT properties/NNS of/IN HSF1/NN which/WDT can/MD be/VB activated/VBN to/TO at/IN least/JJS two/CD DNA/NN binding/NN forms/NNS only/RB one/CD of/IN which/WDT activates/VBZ heat/NN shock/NN promoters/NNS and/CC suggest/VBP that/IN individual/JJ NSAID/NN family/NN members/NNS may/MD differentially/RB induce/VB one/CD or/CC other/JJ of/IN these/DT forms/NNS ./. 
Overall/RB therefore/RB ,/, exposure/NN to/TO NSAIDs/NNS leads/VBZ to/TO a/DT profound/JJ switch/NN in/IN gene/NN expression/NN in/IN monocytic/JJ cells/NNS ,/, with/IN suppression/NN of/IN genes/NNS involved/VBN in/IN macrophage/NN activation/NN and/CC induction/NN of/IN stress/NN genes/NNS and/CC HSF1/NN appears/VBZ to/TO play/VB a/DT regulatory/JJ role/NN in/IN these/DT effects/NNS ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99252177/CD 
TI/LS -/: Immortalization/NN of/IN CD4(+)/JJ and/CC CD8(+)/JJ T/NN lymphocytes/NNS by/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD Tax/NN mutants/NNS expressed/VBN in/IN a/DT functional/JJ molecular/JJ clone/NN ./. 
AB/LS -/: The/DT human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) transcriptional/JJ trans-activator/NN Tax/NN has/VBZ been/VBN demonstrated/VBN to/TO have/VB transforming/VBG activity/NN in/IN multiple/JJ cell/NN culture/NN and/CC transgenic-mouse/JJ models/NNS ./. 
In/IN addition/NN to/TO activating/VBG transcription/NN from/IN the/DT viral/JJ long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) through/IN the/DT cyclic/JJ AMP/NN response/NN element/NN binding/NN protein/activating/VBG|NN transcription/NN factor/NN (/( CREB/ATF/NN )/) family/NN of/IN transcription/NN factors/NNS ,/, Tax/NN activates/VBZ the/DT expression/NN of/IN multiple/JJ cellular/JJ promoters/NNS through/IN the/DT NF-kappaB/NN pathway/NN of/IN transcriptional/JJ activation/NN ./. 
The/DT Tax/NN mutants/NNS M22/NN and/CC M47/NN have/VBP previously/RB been/VBN demonstrated/VBN to/TO selectively/RB abrogate/VB the/DT ability/NN of/IN Tax/NN to/TO activate/VB transcription/NN through/IN the/DT NF-kappaB/NN or/CC CREB/ATF/NN pathway/NN ,/, respectively/RB ./. 
These/DT mutations/NNS were/VBD introduced/VBN in/IN the/DT tax/NN gene/NN of/IN the/DT ACH/NN functional/JJ molecular/JJ clone/NN of/IN HTLV-1/NN ,/, and/CC virus/NN produced/VBN from/IN the/DT mutant/JJ ACH/NN clones/NNS was/VBD examined/VBN for/IN the/DT ability/NN to/TO replicate/VB and/CC immortalize/VB primary/JJ human/JJ lymphocytes/NNS ./. 
While/IN virus/NN derived/VBN from/IN the/DT clone/NN containing/VBG the/DT M47/NN mutation/NN retained/VBD the/DT ability/NN to/TO immortalize/VB T/NN lymphocytes/NNS ,/, the/DT M22/NN mutant/NN lost/VBD the/DT ability/NN to/TO immortalize/VB infected/JJ cells/NNS ./. 
These/DT results/NNS indicate/VBP that/IN activation/NN of/IN the/DT CREB/ATF/NN pathway/NN by/IN Tax/NN is/VBZ dispensable/JJ for/IN the/DT immortalization/NN of/IN T/NN cells/NNS by/IN HTLV-1/NN ,/, whereas/IN activation/NN of/IN the/DT NF-kappaB/NN pathway/NN may/MD be/VB critical/JJ ./. 
UI/LS -/: 99248162/CD 
TI/LS -/: Fibroblast/NN growth/NN factor-1/NN (/( FGF-1/NN )/) enhances/VBZ IL-2/NN production/NN and/CC nuclear/JJ translocation/NN of/IN NF-kappaB/NN in/IN FGF/NN receptor-bearing/JJ Jurkat/NN T/NN cells/NNS ./. 
AB/LS -/: Fibroblast/NN growth/NN factors/NNS (/( FGFs/NNS )/) are/VBP heparin-binding/JJ proteins/NNS crucial/JJ to/TO embryogenesis/NN ,/, angiogenesis/NN ,/, and/CC wound/NN healing/NN ./. 
FGF-1/NN is/VBZ abundantly/RB expressed/VBN in/IN the/DT synovium/NN in/IN rheumatoid/NN arthritis/NN and/CC in/IN rejecting/VBG allografts/NNS ,/, sites/NNS of/IN chronic/JJ immune-mediated/JJ inflammation/NN ./. 
The/DT frequency/NN of/IN FGF-1-responsive/JJ T/NN cells/NNS is/VBZ increased/VBN in/IN the/DT peripheral/JJ blood/NN of/IN these/DT disorders/NNS ,/, and/CC a/DT high/JJ percentage/NN of/IN infiltrating/VBG T/NN cells/NNS in/IN rheumatoid/JJ arthritis/NN synovium/NN express/VBP receptors/NNS for/IN FGF-1/NN ./. 
To/TO understand/VB the/DT action/NN of/IN FGF-1/NN in/IN T/NN cells/NNS ,/, studies/NNS were/VBD initiated/VBN in/IN Jurkat/NN T/NN cells/NNS that/WDT express/VBP the/DT signaling/JJ isoform/NN of/IN FGF/NN receptor-1/NN ./. 
These/DT experiments/NNS show/VBP that/IN FGF-1/NN stimulation/NN of/IN Jurkat/NN T/NN cells/NNS provides/VBZ a/DT second/JJ signal/NN that/WDT augments/VBZ TCR-mediated/JJ IL-2/NN production/NN ./. 
Analogous/JJ to/TO costimulation/NN via/IN CD28/NN ,/, this/DT activity/NN is/VBZ mediated/VBN through/IN activation/NN of/IN Rel/kappaB/NN ,/, a/DT family/NN of/IN transcription/NN factors/NNS known/VBN to/TO regulate/VB IL-2/NN and/CC other/JJ activation-inducible/JJ proteins/NNS ./. 
FGF-1/NN alone/RB induces/VBZ modest/JJ nuclear/JJ translocation/NN of/IN kappaB-binding/JJ proteins/NNS ,/, and/CC this/DT translocation/NN is/VBZ enhanced/VBN by/IN the/DT combination/NN of/IN anti-CD3/JJ and/CC FGF-1/NN ./. 
This/DT NF-kappaB/NN binding/NN complex/NN is/VBZ composed/VBN of/IN transcriptionally/RB active/JJ p65/NN (/( RelA/NN )/) /p50/NN heterodimers/NNS and/CC results/VBZ primarily/RB from/IN the/DT targeted/VBN degradation/NN of/IN IkappaB-alpha/NN ,/, an/DT inhibitor/NN that/WDT sequesters/VBZ Rel/kappaB/NN in/IN the/DT cytoplasm/NN ./. 
These/DT data/NNS are/VBP the/DT first/JJ to/TO show/VB a/DT connection/NN between/IN FGF-1/NN signaling/NN and/CC NF-kappaB/NN activation/NN outside/IN of/IN embryonic/JJ development/NN ./. 
The/DT signaling/NN events/NNS that/WDT link/VBP FGF/NN receptor-1/NN engagement/NN and/CC NF-kappaB/NN activation/NN in/IN Jurkat/NN are/VBP probably/RB distinct/JJ from/IN the/DT CD28/NN costimulation/NN pathway/NN ,/, since/IN FGF-1-induced/JJ Rel/kappaB/NN binding/NN proteins/NNS do/VBP not/RB contain/VB significant/JJ levels/NNS of/IN c-Rel/NN and/CC are/VBP not/RB identical/JJ with/IN the/DT CD28/NN response/NN complex/NN ./. 
UI/LS -/: 99329182/CD 
TI/LS -/: Escape/NN of/IN human/JJ cytomegalovirus/NN from/IN HLA-DR-restricted/JJ CD4(+)/JJ T-cell/NN response/NN is/VBZ mediated/VBN by/IN repression/NN of/IN gamma/NN interferon-induced/JJ class/NN II/CD transactivator/NN expression/NN ./. 
AB/LS -/: Human/JJ cytomegalovirus/NN (/( HCMV/NN )/) ,/, a/DT betaherpesvirus/NN ,/, is/VBZ a/DT pathogen/NN which/WDT escapes/VBZ immune/JJ recognition/NN through/IN various/JJ mechanisms/NNS ./. 
In/IN this/DT paper/NN ,/, we/PRP show/VBP that/IN HCMV/NN down/RB regulates/VBZ gamma/NN interferon/NN (/( IFN-gamma/NN )/) -induced/JJ HLA-DR/NN expression/NN in/IN U373/NN MG/NN astrocytoma/NN cells/NNS due/JJ to/TO a/DT defect/NN downstream/RB of/IN STAT1/NN phosphorylation/NN and/CC nuclear/JJ translocation/NN ./. 
Repression/NN of/IN class/NN II/CD transactivator/NN (/( CIITA/NN )/) mRNA/NN expression/NN is/VBZ detected/VBN within/IN the/DT first/JJ hours/NNS of/IN IFN-gamma-HCMV/NN coincubation/NN and/CC results/VBZ in/IN the/DT absence/NN of/IN HLA-DR/NN synthesis/NN ./. 
This/DT defect/NN leads/VBZ to/TO the/DT absence/NN of/IN presentation/NN of/IN the/DT major/JJ immediate-early/JJ protein/NN IE1/NN to/TO specific/JJ CD4(+)/JJ T-cell/NN clones/NNS when/WRB U373/NN MG/NN cells/NNS ,/, used/VBN as/IN antigen-presenting/JJ cells/NNS ,/, are/VBP treated/VBN with/IN IFN-gamma/NN plus/CC HCMV/NN ./. 
However/RB ,/, presentation/NN of/IN endogenously/RB synthesized/VBN IE1/NN can/MD be/VB restored/VBN when/WRB U373/NN MG/NN cells/NNS are/VBP transfected/VBN with/IN CIITA/NN prior/RB to/TO infection/NN with/IN HCMV/NN ./. 
Altogether/RB ,/, the/DT data/NNS indicate/VBP that/IN the/DT defect/NN induced/VBN by/IN HCMV/NN resides/VBZ in/IN the/DT activation/NN of/IN the/DT IFN-gamma-responsive/JJ promoter/NN of/IN CIITA/NN ./. 
This/DT is/VBZ the/DT first/JJ demonstration/NN of/IN a/DT viral/JJ inhibition/NN of/IN CIITA/NN expression/NN ./. 
UI/LS -/: 99315834/CD 
TI/LS -/: 3-deazaadenosine/NN ,/, a/DT S-adenosylhomocysteine/NN hydrolase/NN inhibitor/NN ,/, has/VBZ dual/JJ effects/NNS on/IN NF-kappaB/NN regulation/NN ./. 
Inhibition/NN of/IN NF-kappaB/NN transcriptional/JJ activity/NN and/CC promotion/NN of/IN IkappaBalpha/NN degradation/NN ./. 
AB/LS -/: Previously/RB we/PRP reported/VBD that/IN 3-deazaadenosine/NN (/( DZA/NN )/) ,/, a/DT potent/JJ inhibitor/NN and/CC substrate/NN for/IN S-adenosylhomocysteine/NN hydrolase/NN inhibits/VBZ bacterial/JJ lipopolysaccharide-induced/JJ transcription/NN of/IN tumor/NN necrosis/NN factor-alpha/NN and/CC interleukin-1beta/NN in/IN mouse/NN macrophage/NN RAW/NN 264.7/CD cells/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP demonstrate/VBP the/DT effects/NNS of/IN DZA/NN on/IN nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) regulation/NN ./. 
DZA/NN inhibits/VBZ the/DT transcriptional/JJ activity/NN of/IN NF-kappaB/NN through/IN the/DT hindrance/NN of/IN p65/NN (/( Rel-A/NN )/) phosphorylation/NN without/IN reduction/NN of/IN its/PRP$ nuclear/JJ translocation/NN and/CC DNA/NN binding/NN activity/NN ./. 
The/DT inhibitory/JJ effect/NN of/IN DZA/NN on/IN NF-kappaB/NN transcriptional/JJ activity/NN is/VBZ potentiated/VBN by/IN the/DT addition/NN of/IN homocysteine/NN ./. 
Taken/VBN together/RB ,/, DZA/NN promotes/VBZ the/DT proteolytic/JJ degradation/NN of/IN IkappaBalpha/NN ,/, but/CC not/RB IkappaBbeta/NN ,/, resulting/VBG in/IN an/DT increase/NN of/IN DNA/NN binding/NN activity/NN of/IN NF-kappaB/NN in/IN the/DT nucleus/NN in/IN the/DT absence/NN of/IN its/PRP$ transcriptional/JJ activity/NN in/IN RAW/NN 264.7/CD cells/NNS ./. 
The/DT reduction/NN of/IN IkappaBalpha/NN by/IN DZA/NN is/VBZ neither/CC involved/VBN in/IN IkappaB/NN kinase/NN complex/NN activation/NN nor/CC modulated/VBN by/IN the/DT addition/NN of/IN homocysteine/NN ./. 
This/DT study/NN strongly/RB suggests/VBZ that/IN DZA/NN may/MD be/VB a/DT potent/JJ drug/NN for/IN the/DT treatment/NN of/IN diseases/NNS in/IN which/WDT NF-kappaB/NN plays/VBZ a/DT central/JJ pathogenic/JJ role/NN ,/, as/RB well/RB as/IN a/DT useful/JJ tool/NN for/IN studying/VBG the/DT regulation/NN and/CC physiological/JJ functions/NNS of/IN NF-kappaB/NN ./. 
UI/LS -/: 99301235/CD 
TI/LS -/: The/DT role/NN of/IN gamma/delta/NN T/NN cell/NN receptor/NN positive/JJ cells/NNS in/IN pregnancy/NN ./. 
AB/LS -/: PROBLEM/NN :/: Due/JJ to/TO the/DT lack/NN of/IN classical/JJ HLA/NN antigens/NNS on/IN the/DT trophoblast/NN ,/, fetal/JJ antigens/NNS are/VBP possibly/RB presented/VBN in/IN a/DT non/JJ major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) restricted/JJ way/NN ./. 
Decidual/JJ gammadelta/NN T/NN cells/NNS ,/, which/WDT significantly/RB increase/VBP in/IN number/NN during/IN pregnancy/NN ,/, might/MD play/VB a/DT role/NN in/IN recognition/NN of/IN fetal/JJ antigens/NNS and/CC also/RB in/IN determining/VBG the/DT quality/NN of/IN the/DT response/NN to/TO these/DT antigens/NNS ./. 
Our/PRP$ study/NN was/VBD aimed/VBN at/IN investigating/VBG the/DT role/NN of/IN this/DT cell/NN population/NN in/IN progesterone-dependent/JJ immunomodulation/NN ./. 
METHOD/NN OF/IN STUDY/NN :/: Peripheral/JJ lymphocytes/NNS from/IN healthy/JJ pregnant/JJ women/NNS and/CC from/IN habitual/JJ aborters/NNS were/VBD tested/VBN by/IN immunocytochemistry/NN for/IN the/DT presence/NN of/IN gamma/delta/NN T/NN cell/NN receptor/NN (/( TCR/NN )/) and/CC progesterone/NN receptor/NN ./. 
To/TO investigate/VB the/DT effect/NN of/IN treatment/NN with/IN a/DT pan/NN anti/JJ gamma/delta/NN antibody/NN ,/, lymphocytes/NNS were/VBD incubated/VBN for/IN 3/CD hr/NN with/IN the/DT antibody/NN ,/, and/CC then/RB interleukin/NN (/( IL/NN )/) -10/CD ,/, IL-12/NN and/CC progesterone-induced/JJ blocking/VBG factor/NN (/( PIBF/NN )/) expression/NN (/( by/IN immuno-cytochemistry/NN )/) as/RB well/RB as/IN natural/JJ killer/NN (/( NK/NN )/) cell/NN activity/NN were/VBD determined/VBN ./. 
RESULTS/NNS :/: In/IN peripheral/JJ blood/NN of/IN healthy/JJ pregnant/JJ women/NNS the/DT percentage/NN of/IN gamma/delta/NN TCR+/JJ cells/NNS was/VBD significantly/RB higher/JJR (/( P/NN </JJR 0.001/CD )/) than/IN in/IN that/DT of/IN recurrent/JJ aborters/NNS or/CC of/IN non-pregnant/JJ individuals/NNS ./. 
Ninety-seven/CD percent/NN of/IN gamma/delta/NN TCR+/JJ pregnancy/NN lymphocytes/NNS expressed/VBD progesterone/NN receptor/NN ./. 
Binding/NN of/IN a/DT specific/JJ antibody/NN to/TO the/DT gamma/delta/NN TCR/NN inhibited/VBD PIBF-/NN as/RB well/RB as/IN IL-10/NN production/NN ,/, whereas/IN it/PRP increased/VBD NK/NN activity/NN and/CC IL-12/NN expression/NN ./. 
CONCLUSIONS/NNS :/: These/DT data/NNS suggest/VBP the/DT role/NN of/IN gamma/delta/NN TCR-bearing/JJ lymphocytes/NNS in/IN progesterone-dependent/JJ immunomodulation/NN ./. 
UI/LS -/: 99296619/CD 
TI/LS -/: Monocyte/NN adhesion/NN and/CC spreading/NN on/IN human/JJ endothelial/JJ cells/NNS is/VBZ dependent/JJ on/IN Rho-regulated/JJ receptor/NN clustering/NN ./. 
AB/LS -/: The/DT GTPase/NN Rho/NN is/VBZ known/VBN to/TO mediate/VB the/DT assembly/NN of/IN integrin-containing/JJ focal/JJ adhesions/NNS and/CC actin/NN stress/NN fibers/NNS ./. 
Here/RB ,/, we/PRP investigate/VBP the/DT role/NN of/IN Rho/NN in/IN regulating/VBG the/DT distribution/NN of/IN the/DT monocyte-binding/JJ receptors/NNS E-selectin/NN ,/, ICAM-1/NN ,/, and/CC VCAM-1/NN in/IN human/JJ endothelial/JJ cells/NNS ./. 
Inhibition/NN of/IN Rho/NN activity/NN with/IN C3/NN transferase/NN or/CC N19RhoA/NN ,/, a/DT dominant/JJ negative/JJ RhoA/NN mutant/NN ,/, reduced/VBD the/DT adhesion/NN of/IN monocytes/NNS to/TO activated/VBN endothelial/JJ cells/NNS and/CC inhibited/VBD their/PRP$ spreading/NN ./. 
Similar/JJ effects/NNS were/VBD observed/VBN after/IN pretreatment/NN of/IN endothelial/JJ cells/NNS with/IN cytochalasin/NN D/NN ./. 
In/IN contrast/NN ,/, dominant/JJ negative/JJ Rac/NN and/CC Cdc42/NN proteins/NNS did/VBD not/RB affect/VB monocyte/NN adhesion/NN or/CC spreading/NN ./. 
C3/NN transferase/NN and/CC cytochalasin/NN D/NN did/VBD not/RB alter/VB the/DT expression/NN levels/NNS of/IN monocyte-binding/JJ receptors/NNS on/IN endothelial/JJ cells/NNS ,/, but/CC did/VBD inhibit/VB clustering/NN of/IN E-selectin/NN ,/, ICAM-1/NN ,/, and/CC VCAM-1/NN on/IN the/DT cell/NN surface/NN induced/VBN by/IN monocyte/NN adhesion/NN or/CC cross-linking/NN antibodies/NNS ./. 
Similarly/RB ,/, N19RhoA/NN inhibited/VBD receptor/NN clustering/NN ./. 
Monocyte/NN adhesion/NN and/CC receptor/NN cross-linking/NN induced/JJ stress/NN fiber/NN assembly/NN ,/, and/CC inhibitors/NNS of/IN myosin/NN light/JJ chain/NN kinase/NN prevented/VBD this/DT response/NN but/CC did/VBD not/RB affect/VB receptor/NN clustering/NN ./. 
Finally/RB ,/, receptor/NN clusters/NNS colocalized/VBD with/IN ezrin/moesin/radixin/NN proteins/NNS ./. 
These/DT results/NNS suggest/VBP that/IN Rho/NN is/VBZ required/VBN in/IN endothelial/JJ cells/NNS for/IN the/DT assembly/NN of/IN stable/JJ adhesions/NNS with/IN monocytes/NNS via/IN the/DT clustering/NN of/IN monocyte-binding/JJ receptors/NNS and/CC their/PRP$ association/NN with/IN the/DT actin/NN cytoskeleton/NN ,/, independent/JJ of/IN stress/NN fiber/NN formation/NN ./. 
UI/LS -/: 99286827/CD 
TI/LS -/: Selection/NN of/IN the/DT T/NN cell/NN repertoire/NN ./. 
AB/LS -/: Advances/NNS in/IN gene/NN technology/NN have/VBP allowed/VBN the/DT manipulation/NN of/IN molecular/JJ interactions/NNS that/WDT shape/VBP the/DT T/NN cell/NN repertoire/NN ./. 
Although/IN recognized/VBN as/IN fundamental/JJ aspects/NNS of/IN T/NN lymphocyte/NN development/NN ,/, only/RB recently/RB have/VBP the/DT mechanisms/NNS governing/VBG positive/JJ and/CC negative/JJ selection/NN been/VBN examined/VBN at/IN a/DT molecular/JJ level/NN ./. 
Positive/JJ selection/NN refers/VBZ to/TO the/DT active/JJ process/NN of/IN rescuing/VBG MHC-restricted/JJ thymocytes/NNS from/IN programmed/VBN cell/NN death/NN ./. 
Negative/JJ selection/NN refers/VBZ to/TO the/DT deletion/NN or/CC inactivation/NN of/IN potentially/RB autoreactive/JJ thymocytes/NNS ./. 
This/DT review/NN focuses/VBZ on/IN interactions/NNS during/IN thymocyte/NN maturation/NN that/WDT define/VBP the/DT T/NN cell/NN repertoire/NN ,/, with/IN an/DT emphasis/NN placed/VBN on/IN current/JJ literature/NN within/IN this/DT field/NN ./. 
UI/LS -/: 99282947/CD 
TI/LS -/: CD28/NN costimulation/NN augments/VBZ IL-2/NN secretion/NN of/IN activated/VBN lamina/NN propria/NN T/NN cells/NNS by/IN increasing/VBG mRNA/NN stability/NN without/IN enhancing/VBG IL-2/NN gene/NN transactivation/NN ./. 
AB/LS -/: The/DT pathways/NNS leading/VBG to/TO activation/NN in/IN lamina/NN propria/NN (/( LP/NN )/) T/NN cells/NNS are/VBP different/JJ from/IN peripheral/JJ T/NN cells/NNS ./. 
LP/NN T/NN cells/NNS exhibit/VBP enhanced/VBN IL-2/NN secretion/NN when/WRB activated/VBN through/IN the/DT CD2/NN pathway/NN ./. 
Coligation/NN of/IN CD28/NN leads/VBZ to/TO synergistic/JJ enhancement/NN of/IN IL-2/NN secretion/NN ./. 
Previous/JJ studies/NNS have/VBP characterized/VBN the/DT CD28/NN augmentation/NN of/IN TCR-mediated/JJ signaling/NN in/IN peripheral/JJ blood/NN T/NN cells/NNS through/IN transcriptional/JJ activation/NN of/IN an/DT IL-2/NN promoter/NN CD28/NN response/NN element/NN (/( CD28RE/NN )/) ,/, along/IN with/IN enhanced/VBN mRNA/NN stability/NN ./. 
This/DT study/NN characterized/VBD molecular/JJ events/NNS involved/VBN in/IN CD28/NN costimulation/NN of/IN IL-2/NN production/NN in/IN LP/NN mononuclear/JJ cells/NNS (/( LPMC/NN )/) ./. 
LPMC/NN exhibited/VBD increased/VBN IL-2/NN production/NN in/IN response/NN to/TO CD28/NN costimulation/NN ,/, compared/VBN with/IN cells/NNS activated/VBN through/IN CD2/NN alone/RB ./. 
IL-2/NN secretion/NN was/VBD paralleled/VBN by/IN increased/VBN expression/NN of/IN IL-2/NN mRNA/NN ,/, resulting/VBG from/IN enhanced/VBN IL-2/NN mRNA/NN stability/NN ./. 
In/IN contrast/NN to/TO transcriptional/JJ activation/NN in/IN PBMC/NN ,/, EMSA/NN revealed/VBD that/IN CD28/NN coligation/NN of/IN CD2-activated/JJ LPMC/NN does/VBZ not/RB result/VB in/IN increased/VBN binding/NN of/IN trans-factors/NNS to/TO the/DT CD28RE/NN ,/, nor/CC did/VBD Western/NN blots/NNS detect/VB changes/NNS in/IN I-kappaBalpha/NN or/CC I-kappaBbeta/NN levels/NNS following/VBG CD28/NN coligation/NN ./. 
Furthermore/RB ,/, CD28/NN coligation/NN fails/VBZ to/TO enhance/VB IL-2/NN promoter-reporter/NN or/CC RE/AP/NN construct/NN expression/NN in/IN CD2-activated/JJ LPMC/NN ./. 
The/DT results/NNS reported/VBN herein/RB indicate/VBP that/IN the/DT molecular/JJ mechanisms/NNS involved/VBN in/IN CD28/NN cosignaling/NN and/CC regulation/NN of/IN IL-2/NN secretion/NN in/IN LP/NN T/NN cells/NNS are/VBP unique/JJ to/TO that/DT compartment/NN and/CC differ/VBP from/IN those/DT seen/VBN in/IN peripheral/JJ blood/NN T/NN cells/NNS ./. 
These/DT observations/NNS suggest/VBP a/DT biological/JJ significance/NN for/IN different/JJ mechanisms/NNS of/IN IL-2/NN activation/NN in/IN initiation/NN and/CC maintenance/NN of/IN the/DT cytokine/NN repertoire/NN found/VBN in/IN the/DT mucosa/NN ./. 
UI/LS -/: 99260407/CD 
TI/LS -/: Expression/NN of/IN Th1/NN and/CC Th2/NN type/NN cytokines/NNS responding/VBG to/TO HBsAg/NN and/CC HBxAg/NN in/IN chronic/JJ hepatitis/NN B/NN patients/NNS ./. 
AB/LS -/: The/DT cytokine/NN pattern/NN on/IN viral/JJ antigen/NN recognition/NN is/VBZ believed/VBN to/TO exert/VB a/DT profound/JJ influence/NN on/IN the/DT resolution/NN of/IN viral/JJ infections/NNS and/CC viral/JJ clearance/NN ./. 
This/DT study/NN was/VBD initiated/VBN to/TO investigate/VB whether/IN a/DT cytokine/NN imbalance/NN oriented/VBN toward/IN Th2/NN type/NN response/NN plays/VBZ a/DT role/NN in/IN chronic/JJ hepatitis/NN B/NN ./. 
Cytokine/NN profiles/NNS of/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS associated/VBN with/IN chronic/JJ hepatitis/NN B/NN were/VBD analysed/VBN by/IN RT-PCR/NN ./. 
Upon/IN HBsAg/NN stimulation/NN ,/, expression/NN of/IN IFN-gamma/NN ,/, IL-2/NN ,/, IL-4/NN ,/, and/CC IL-10/NN was/VBD detected/VBN in/IN 41/CD %/NN ,/, 8/CD %/NN ,/, 41/CD %/NN ,/, and/CC 50/CD %/NN of/IN the/DT patients/NNS ,/, respectively/RB ./. 
Among/IN these/DT cytokines/NNS ,/, the/DT expression/NN of/IN IFN-gamma/NN was/VBD associated/VBN with/IN high/JJ levels/NNS of/IN serum/NN AST/ALT/NN ./. 
However/RB ,/, we/PRP could/MD not/RB prove/VB that/IN Th2/NN type/NN cytokines/NNS had/VBD a/DT protective/JJ effect/NN on/IN hepatocytes/NNS ./. 
Upon/IN HBxAg/NN stimulation/NN ,/, there/EX was/VBD no/DT recognizable/JJ association/NN of/IN cytokine/NN patterns/NNS with/IN AST/ALT/NN levels/NNS ./. 
In/IN conclusion/NN ,/, production/NN of/IN a/DT Th1/NN cytokine/NN ,/, IFN-gamma/NN ,/, by/IN HBsAg-reactive/JJ cells/NNS was/VBD associated/VBN with/IN hepatocyte/NN damage/NN in/IN chronic/JJ hepatitis/NN B/NN ,/, while/IN no/DT counteracting/NN effect/NN of/IN Th2/NN cytokines/NNS produced/VBN by/IN those/DT cells/NNS was/VBD observed/VBN ./. 
UI/LS -/: 99258659/CD 
TI/LS -/: Apoptosis/NN and/CC growth/NN inhibition/NN in/IN malignant/JJ lymphocytes/NNS after/IN treatment/NN with/IN arsenic/JJ trioxide/NN at/IN clinically/RB achievable/JJ concentrations/NNS [/( see/VB comments/NNS ]/) 
AB/LS -/: BACKGROUND/NN :/: Arsenic/JJ trioxide/NN (/( As2O3/NN )/) can/MD induce/VB clinical/JJ remission/NN in/IN patients/NNS with/IN acute/JJ promyelocytic/JJ leukemia/NN via/IN induction/NN of/IN differentiation/NN and/CC programmed/VBN cell/NN death/NN (/( apoptosis/NN )/) ./. 
We/PRP investigated/VBD the/DT effects/NNS of/IN As2O3/NN on/IN a/DT panel/NN of/IN malignant/JJ lymphocytes/NNS to/TO determine/VB whether/IN growth-inhibitory/JJ and/CC apoptotic/JJ effects/NNS of/IN As2O3/NN can/MD be/VB observed/VBN in/IN these/DT cells/NNS at/IN clinically/RB achievable/JJ concentrations/NNS ./. 
METHODS/NNS :/: Eight/CD malignant/JJ lymphocytic/JJ cell/NN lines/NNS and/CC primary/JJ cultures/NNS of/IN lymphocytic/JJ leukemia/NN and/CC lymphoma/NN cells/NNS were/VBD treated/VBN with/IN As2O3/NN ,/, with/IN or/CC without/IN dithiothreitol/NN (/( DTT/NN )/) or/CC buthionine/NN sulfoximine/NN (/( BSO/NN )/) (/( an/DT inhibitor/NN of/IN glutathione/NN synthesis/NN )/) ./. 
Apoptosis/NN was/VBD assessed/VBN by/IN cell/NN morphology/NN ,/, flow/NN cytometry/NN ,/, annexin/NN V/NN protein/NN level/NN ,/, and/CC terminal/JJ deoxynucleotidyl/NN transferase/NN labeling/NN of/IN DNA/NN fragments/NNS ./. 
Cellular/JJ proliferation/NN was/VBD determined/VBN by/IN 5-bromo-2'-deoxyuridine/NN incorporation/NN into/IN DNA/NN and/CC flow/NN cytometry/NN and/CC by/IN use/NN of/IN a/DT mitotic/JJ arrest/NN assay/NN ./. 
Mitochondrial/JJ transmembrane/JJ potential/NN (/( delta/NN psi(m)/NN )/) was/VBD measured/VBN by/IN means/NNS of/IN rhodamine/NN 123/CD staining/NN and/CC flow/NN cytometry/NN ./. 
Protein/NN expression/NN was/VBD assessed/VBN by/IN western/NN blot/NN analysis/NN or/CC immunofluorescence/NN ./. 
RESULTS/NNS :/: Therapeutic/JJ concentrations/NNS of/IN As2O3/NN (/( 1-2/CD microM/NN )/) had/VBD dual/JJ effects/NNS on/IN malignant/JJ lymphocytes/NNS :/: 1/LS )/) inhibition/NN of/IN growth/NN through/IN adenosine/NN triphosphate/NN (/( ATP/NN )/) depletion/NN and/CC prolongation/NN of/IN cell/NN cycle/NN time/NN and/CC 2/LS )/) induction/NN of/IN apoptosis/NN ./. 
As2O3-induced/JJ apoptosis/NN was/VBD preceded/VBN by/IN delta/NN psi(m)/NN collapse/NN ./. 
DTT/NN antagonized/VBD and/CC BSO/NN enhanced/VBD As2O3-induced/JJ ATP/NN depletion/NN ,/, delta/NN psi(m)/NN collapse/NN ,/, and/CC apoptosis/NN ./. 
Caspase-3/NN activation/NN ,/, usually/RB resulting/VBG from/IN delta/NN psi(m)/NN collapse/NN ,/, was/VBD not/RB always/RB associated/VBN with/IN As2O3-induced/JJ apoptosis/NN ./. 
As2O3/NN induced/VBD PML/NN (/( promyelocytic/JJ leukemia/NN )/) protein/NN degradation/NN but/CC did/VBD not/RB modulate/VB expression/NN of/IN cell/NN cycle-related/JJ proteins/NNS ,/, including/VBG c-myc/NN ,/, retinoblastoma/NN protein/NN ,/, cyclin-dependent/JJ kinase/NN 4/CD ,/, cyclin/NN D1/NN ,/, and/CC p53/NN ,/, or/CC expression/NN of/IN differentiation-related/JJ antigens/NNS ./. 
CONCLUSIONS/NNS :/: Substantial/JJ growth/NN inhibition/NN and/CC apoptosis/NN without/IN evidence/NN of/IN differentiation/NN were/VBD induced/VBN in/IN most/JJS malignant/JJ lymphocytic/JJ cells/NNS treated/VBN with/IN 1-2/CD microM/NN As2O3/NN ./. 
As2O3/NN may/MD prove/VB useful/JJ in/IN the/DT treatment/NN of/IN malignant/JJ lymphoproliferative/JJ disorders/NNS ./. 
UI/LS -/: 99252157/CD 
TI/LS -/: Control/NN of/IN cell/NN cycle/NN entry/NN and/CC apoptosis/NN in/IN B/NN lymphocytes/NNS infected/VBN by/IN Epstein-Barr/JJ virus/NN ./. 
AB/LS -/: Infection/NN of/IN human/JJ B/NN cells/NNS with/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) results/VBZ in/IN activation/NN of/IN the/DT cell/NN cycle/NN and/CC cell/NN growth/NN ./. 
To/TO interpret/VB the/DT mechanisms/NNS by/IN which/WDT EBV/NN activates/VBZ the/DT cell/NN ,/, we/PRP have/VBP assayed/VBN many/JJ proteins/NNS involved/VBN in/IN control/NN of/IN the/DT G0/NN and/CC G1/NN phases/NNS of/IN the/DT cell/NN cycle/NN and/CC regulation/NN of/IN apoptosis/NN ./. 
In/IN EBV/NN infection/NN most/JJS of/IN the/DT changes/NNS ,/, including/VBG the/DT early/JJ induction/NN of/IN cyclin/NN D2/NN ,/, are/VBP dependent/JJ on/IN expression/NN of/IN EBV/NN genes/NNS ,/, but/CC an/DT alteration/NN in/IN the/DT E2F-4/NN profile/NN was/VBD partly/RB independent/JJ of/IN viral/JJ gene/NN expression/NN ,/, presumably/RB occurring/VBG in/IN response/NN to/TO signal/NN transduction/NN activated/VBN when/WRB the/DT virus/NN binds/VBZ to/TO its/PRP$ receptor/NN ,/, CD21/NN ./. 
By/IN comparing/VBG the/DT expression/NN of/IN genes/NNS controlling/VBG apoptosis/NN ,/, including/VBG those/DT encoding/VBG several/JJ members/NNS of/IN the/DT BCL-2/NN family/NN of/IN proteins/NNS ,/, the/DT known/JJ relative/JJ resistance/NN of/IN EBV-immortalized/JJ B-cell/NN lines/NNS to/TO apoptosis/NN induced/VBN by/IN low/JJ serum/NN was/VBD found/VBN to/TO correlate/VB with/IN expression/NN of/IN both/CC BCL-2/NN and/CC A20/NN ./. 
A20/NN can/MD be/VB regulated/VBN by/IN the/DT NF-kappaB/NN transcription/NN factor/NN ,/, which/WDT is/VBZ known/VBN to/TO be/VB activated/VBN by/IN the/DT EBV/NN LMP-1/NN protein/NN ./. 
Quantitative/JJ assays/NNS demonstrated/VBD a/DT direct/JJ temporal/JJ relationship/NN between/IN LMP-1/JJ protein/NN levels/NNS and/CC active/JJ NF-kappaB/NN during/IN the/DT time/NN course/NN of/IN infection/NN ./. 
UI/LS -/: 99248157/CD 
TI/LS -/: CTLA-4-Mediated/JJ inhibition/NN of/IN early/JJ events/NNS of/IN T/NN cell/NN proliferation/NN ./. 
AB/LS -/: CTLA-4/NN engagement/NN by/IN mAbs/NNS inhibits/VBZ ,/, while/IN CD28/NN enhances/VBZ ,/, IL-2/NN production/NN and/CC proliferation/NN upon/IN T/NN cell/NN activation/NN ./. 
Here/RB ,/, we/PRP have/VBP analyzed/VBN the/DT mechanisms/NNS involved/VBN in/IN CTLA-4-mediated/JJ inhibition/NN of/IN T/NN cell/NN activation/NN of/IN naive/JJ CD4+/JJ T/NN cells/NNS using/VBG Ab/NN cross-linking/NN ./. 
CTLA-4/NN ligation/NN inhibited/VBD CD3/CD28-induced/JJ IL-2/NN mRNA/NN accumulation/NN by/IN inhibiting/VBG IL-2/NN transcription/NN ,/, which/WDT appears/VBZ to/TO be/VB mediated/VBN in/IN part/NN through/IN decreasing/VBG NF-AT/NN accumulation/NN in/IN the/DT nuclei/NNS ./. 
However/RB ,/, CTLA-4/NN ligation/NN did/VBD not/RB appear/VB to/TO affect/VB the/DT CD28-mediated/JJ stabilization/NN of/IN IL-2/NN mRNA/NN ./. 
Further/RB ,/, CTLA-4/NN engagement/NN inhibited/VBD progression/NN through/IN the/DT cell/NN cycle/NN by/IN inhibiting/VBG the/DT production/NN of/IN cyclin/NN D3/NN ,/, cyclin-dependent/JJ kinase/NN (/( cdk/NN )/) 4/CD ,/, and/CC cdk6/NN when/WRB the/DT T/NN cells/NNS were/VBD stimulated/VBN with/IN anti-CD3/CD28/NN and/CC with/IN anti-CD3/NN alone/RB ./. 
These/DT results/NNS indicate/VBP that/IN CTLA-4/NN signaling/NN inhibits/VBZ events/NNS early/RB in/IN T/NN cell/NN activation/NN both/CC at/IN IL-2/NN transcription/NN and/CC at/IN the/DT level/NN of/IN IL-2-independent/JJ events/NNS of/IN the/DT cell/NN cycle/NN ,/, and/CC does/VBZ not/RB simply/RB oppose/VB CD28-mediated/JJ costimulation/NN ./. 
UI/LS -/: 99326307/CD 
TI/LS -/: The/DT glucocorticoid/NN receptor/NN cooperates/VBZ with/IN the/DT erythropoietin/NN receptor/NN and/CC c-Kit/NN to/TO enhance/VB and/CC sustain/VB proliferation/NN of/IN erythroid/JJ progenitors/NNS in/FW vitro/FW ./. 
AB/LS -/: Although/IN erythropoietin/NN (/( Epo/NN )/) is/VBZ essential/JJ for/IN the/DT production/NN of/IN mature/JJ red/JJ blood/NN cells/NNS ,/, the/DT cooperation/NN with/IN other/JJ factors/NNS is/VBZ required/VBN for/IN a/DT proper/JJ balance/NN between/IN progenitor/NN proliferation/NN and/CC differentiation/NN ./. 
In/IN avian/JJ erythroid/JJ progenitors/NNS ,/, steroid/NN hormones/NNS cooperate/VBP with/IN tyrosine/NN kinase/NN receptors/NNS to/TO induce/VB renewal/NN of/IN erythroid/JJ progenitors/NNS ./. 
We/PRP examined/VBD the/DT role/NN of/IN corticosteroids/NNS in/IN the/DT in/FW vitro/FW expansion/NN of/IN primary/JJ human/JJ erythroid/JJ cells/NNS in/IN liquid/JJ cultures/NNS and/CC colony/NN assays/NNS ./. 
Dexamethasone/NN (/( Dex/NN )/) ,/, a/DT synthetic/JJ glucocorticoid/NN hormone/NN ,/, cooperated/VBD with/IN Epo/NN and/CC stem/NN cell/NN factor/NN to/TO induce/VB erythroid/JJ progenitors/NNS to/TO undergo/VB 15/CD to/TO 22/CD cell/NN divisions/NNS ,/, corresponding/VBG to/TO a/DT 10(5)-/CD to/TO 10(6)-fold/JJ amplification/NN of/IN erythroid/JJ cells/NNS ./. 
Dex/NN acted/VBD directly/RB on/IN erythroid/JJ progenitors/NNS and/CC maintained/VBD the/DT colony-forming/JJ capacity/NN of/IN the/DT progenitor/NN cells/NNS expanded/VBN in/IN liquid/JJ cultures/NNS ./. 
The/DT hormone/NN delayed/VBD terminal/JJ differentiation/NN into/IN erythrocytes/NNS ,/, which/WDT was/VBD assayed/VBN by/IN morphology/NN ,/, hemoglobin/NN accumulation/NN ,/, and/CC the/DT expression/NN of/IN genes/NNS characteristic/JJ for/IN immature/JJ cells/NNS ./. 
Sustained/JJ proliferation/NN of/IN erythroid/JJ progenitors/NNS could/MD be/VB induced/VBN equally/RB well/RB from/IN purified/VBN erythroid/JJ burst-forming/JJ units/NNS (/( BFU-E/NN )/) ,/, from/IN CD34(+)/JJ blast/NN cells/NNS ,/, and/CC from/IN bone/NN marrow/NN depleted/VBN from/IN CD34(+)/JJ cells/NNS ./. 
UI/LS -/: 99310960/CD 
TI/LS -/: NF-kappaB/NN functions/VBZ as/IN both/CC a/DT proapoptotic/JJ and/CC antiapoptotic/JJ regulatory/JJ factor/NN within/IN a/DT single/JJ cell/NN type/NN ./. 
AB/LS -/: Recently/RB NF-kappaB/NN has/VBZ been/VBN shown/VBN to/TO have/VB both/CC proapoptotic/JJ and/CC antiapoptotic/JJ functions/NNS ./. 
In/IN T/NN cell/NN hybridomas/NNS ,/, both/CC T/NN cell/NN activators/NNS and/CC glucocorticoids/NNS induce/VBP apoptosis/NN ./. 
Here/RB we/PRP show/VBP that/IN blockade/NN of/IN NF-kappaB/NN activity/NN ,/, using/VBG a/DT dominant/JJ negative/JJ IkappaBalpha/NN ,/, has/VBZ opposite/JJ effects/NNS on/IN these/DT two/CD apoptotic/JJ signals/NNS ./. 
Treatment/NN with/IN PMA/NN plus/CC ionomycin/NN (/( P/I/NN )/) results/VBZ in/IN the/DT upregulation/NN of/IN Fas/NN Ligand/NN (/( FasL/NN )/) and/CC induction/NN of/IN apoptosis/NN ./. 
Inhibition/NN of/IN NF-kappaB/NN activity/NN inhibits/VBZ the/DT P/I/NN mediated/JJ induction/NN of/IN FasL/NN mRNA/NN and/CC decreases/VBZ the/DT level/NN of/IN apoptosis/NN in/IN these/DT cultures/NNS ,/, thus/RB establishing/VBG NF-kappaB/NN as/IN a/DT proapoptotic/JJ factor/NN in/IN this/DT context/NN ./. 
Conversely/RB ,/, inhibition/NN of/IN NF-kappaB/NN confers/VBZ a/DT tenfold/JJ increase/NN in/IN glucocorticoid/NN mediated/JJ apoptosis/NN ,/, establishing/VBG that/IN NF-kappaB/NN also/RB functions/VBZ as/IN an/DT antiapoptotic/JJ factor/NN ./. 
We/PRP conclude/VBP that/IN NF-kappaB/NN is/VBZ a/DT context-dependent/JJ apoptosis/NN regulator/NN ./. 
Our/PRP$ data/NN|NNS suggests/VBZ that/IN NF-kappaB/NN may/MD function/VB as/IN an/DT antiapoptotic/JJ factor/NN in/IN thymocytes/NNS while/IN functioning/VBG as/IN a/DT proapoptotic/JJ factor/NN in/IN mature/JJ peripheral/JJ T/NN cells/NNS ./. 
UI/LS -/: 99303791/CD 
TI/LS -/: SOCS-3/NN is/VBZ tyrosine/NN phosphorylated/JJ in/IN response/NN to/TO interleukin-2/NN and/CC suppresses/VBZ STAT5/NN phosphorylation/NN and/CC lymphocyte/NN proliferation/NN ./. 
AB/LS -/: Members/NNS of/IN the/DT recently/RB discovered/VBN SOCS/CIS/SSI/NN family/NN have/VBP been/VBN proposed/VBN as/IN regulators/NNS of/IN cytokine/NN signaling/NN ,/, and/CC while/IN targets/NNS and/CC mechanisms/NNS have/VBP been/VBN suggested/VBN for/IN some/DT family/NN members/NNS ,/, the/DT precise/JJ role/NN of/IN these/DT proteins/NNS remains/VBZ to/TO be/VB defined/VBN ./. 
To/TO date/VB no/DT SOCS/NN proteins/NNS have/VBP been/VBN specifically/RB implicated/VBN in/IN interleukin-2/NN (/( IL-2/NN )/) signaling/NN in/IN T/NN cells/NNS ./. 
Here/RB we/PRP report/VBP SOCS-3/NN expression/NN in/IN response/NN to/TO IL-2/NN in/IN both/CC T-cell/NN lines/NNS and/CC human/JJ peripheral/JJ blood/NN lymphocytes/NNS ./. 
SOCS-3/NN protein/NN was/VBD detectable/JJ as/RB early/RB as/IN 30/CD min/NN following/VBG IL-2/NN stimulation/NN ,/, while/IN CIS/NN was/VBD seen/VBN only/RB at/IN low/JJ levels/NNS after/IN 2/CD h/NN ./. 
Unlike/IN CIS/NN ,/, SOCS-3/NN was/VBD rapidly/RB tyrosine/NN phosphorylated/JJ in/IN response/NN to/TO IL-2/NN ./. 
Tyrosine/NN phosphorylation/NN of/IN SOCS-3/NN was/VBD observed/VBN upon/IN coexpression/NN with/IN Jak1/NN and/CC Jak2/NN but/CC only/RB weakly/RB with/IN Jak3/NN ./. 
In/IN these/DT experiments/NNS ,/, SOCS-3/NN associated/VBD with/IN Jak1/NN and/CC inhibited/VBD Jak1/NN phosphorylation/NN ,/, and/CC this/DT inhibition/NN was/VBD markedly/RB enhanced/VBN by/IN the/DT presence/NN of/IN IL-2/NN receptor/NN beta/NN chain/NN (/( IL-2Rbeta/NN )/) ./. 
Moreover/RB ,/, following/VBG IL-2/NN stimulation/NN of/IN T/NN cells/NNS ,/, SOCS-3/NN was/VBD able/JJ to/TO interact/VB with/IN the/DT IL-2/NN receptor/NN complex/NN ,/, and/CC in/IN particular/JJ tyrosine/NN phosphorylated/JJ Jak1/NN and/CC IL-2Rbeta/NN ./. 
Additionally/RB ,/, in/IN lymphocytes/NNS expressing/VBG SOCS-3/NN but/CC not/RB CIS/NN ,/, IL-2-induced/JJ tyrosine/NN phosphorylation/NN of/IN STAT5b/NN was/VBD markedly/RB reduced/VBN ,/, while/IN there/EX was/VBD only/RB a/DT weak/JJ effect/NN on/IN IL-3-mediated/JJ STAT5b/NN tyrosine/NN phosphorylation/NN ./. 
Finally/RB ,/, proliferation/NN induced/VBN by/IN both/CC IL-2-/NN and/CC IL-3/NN was/VBD significantly/RB inhibited/JJ in/IN the/DT presence/NN of/IN SOCS-3/NN ./. 
The/DT findings/NNS suggest/VBP that/IN when/WRB SOCS-3/NN is/VBZ rapidly/RB induced/VBN by/IN IL-2/NN in/IN T/NN cells/NNS ,/, it/PRP acts/VBZ to/TO inhibit/VB IL-2/NN responses/NNS in/IN a/DT classical/JJ negative/JJ feedback/NN loop/NN ./. 
UI/LS -/: 99292784/CD 
TI/LS -/: Human/JJ alveolar/JJ macrophages/NNS are/VBP markedly/RB deficient/JJ in/IN REF-1/NN and/CC AP-1/NN DNA/NN binding/NN activity/NN ./. 
AB/LS -/: Although/IN many/JJ functions/NNS of/IN human/JJ alveolar/JJ macrophages/NNS are/VBP altered/VBN compared/VBN with/IN their/PRP$ precursor/NN cell/NN ,/, the/DT blood/NN monocyte/NN (/( monocyte/NN )/) ,/, the/DT reason/NN (/( s/NNS )/) for/IN these/DT functional/JJ changes/NNS have/VBP not/RB been/VBN determined/VBN ./. 
We/PRP recently/RB reported/VBD that/IN human/JJ alveolar/JJ macrophages/NNS do/VBP not/RB express/VB AP-1/NN DNA/NN binding/NN activity/NN (/( Monick/NNP ,/, M./NNP M./NNP ,/, Carter/NN ,/, A./NNP B./NNP ,/, Gudmundsson/NN ,/, G./NNP ,/, Geist/NNP ,/, L./NNP J./NNP ,/, and/CC Hunninghake/NNP ,/, G./NNP W./NNP (/( 1998/CD )/) Am./NNP J./NNP Physiol./NNP 275/CD ,/, L389-/JJ L397/NN )/) ./. 
To/TO determine/VB why/WRB alveolar/JJ macrophages/NNS do/VBP not/RB express/VB AP-1/NN DNA/NN binding/NN activity/NN ,/, we/PRP first/RB showed/VBD that/IN there/EX was/VBD not/RB a/DT decrease/NN in/IN expression/NN of/IN the/DT FOS/NN and/CC JUN/NN proteins/NNS that/WDT make/VBP up/RP the/DT AP-1/NN complex/NN ./. 
There/EX was/VBD ,/, however/RB ,/, a/DT significant/JJ difference/NN in/IN the/DT amounts/NNS of/IN the/DT nuclear/JJ protein/NN ,/, REF-1/NN (/( which/WDT regulates/VBZ AP-1/NN DNA/NN binding/NN by/IN altering/VBG the/DT redox/NN status/NN of/IN FOS/NN and/CC JUN/NN proteins/NNS )/) ,/, in/IN alveolar/JJ macrophages/NNS compared/VBN with/IN monocytes/NNS ./. 
In/IN addition/NN ,/, in/FW vitro/FW differentiation/NN of/IN monocytes/NNS to/TO a/DT macrophage-like/JJ cell/NN resulted/VBD in/IN decreased/VBN amounts/NNS of/IN REF-1/NN ./. 
Finally/RB ,/, addition/NN of/IN REF-1/NN from/IN activated/VBN monocytes/NNS to/TO alveolar/JJ macrophage/NN nuclear/JJ proteins/NNS resulted/VBD in/IN a/DT marked/JJ increase/NN in/IN AP-1/NN DNA/NN binding/NN ./. 
These/DT studies/NNS strongly/RB suggest/VBP that/IN the/DT process/NN of/IN differentiation/NN of/IN monocytes/NNS into/IN alveolar/JJ macrophages/NNS is/VBZ associated/VBN with/IN a/DT loss/NN of/IN REF-1/NN and/CC AP-1/NN activity/NN ./. 
This/DT observation/NN may/MD explain/VB ,/, in/IN part/NN ,/, some/DT of/IN the/DT functional/JJ differences/NNS observed/VBN for/IN alveolar/JJ macrophages/NNS compared/VBN with/IN monocytes/NNS ./. 
UI/LS -/: 99286816/CD 
TI/LS -/: Development/NN and/CC maturation/NN of/IN secondary/JJ lymphoid/JJ tissues/NNS ./. 
AB/LS -/: The/DT secondary/JJ lymphoid/JJ tissues/NNS are/VBP located/JJ at/IN strategic/JJ sites/NNS where/WRB foreign/JJ antigens/NNS can/MD be/VB efficiently/RB brought/VBN together/RB with/IN immune/JJ system/NN regulatory/JJ and/CC effector/NN cells/NNS ./. 
The/DT organized/VBN structure/NN of/IN the/DT secondary/JJ lymphoid/JJ tissues/NNS is/VBZ thought/VBN to/TO enhance/VB the/DT sensitivity/NN of/IN antigen/NN recognition/NN and/CC to/TO support/VB proper/JJ regulation/NN of/IN the/DT activation/NN and/CC maturation/NN of/IN the/DT antigen-responsive/JJ lymphoid/JJ cells/NNS ./. 
Although/IN a/DT substantial/JJ amount/NN is/VBZ known/VBN about/IN the/DT cellular/JJ elements/NNS that/WDT compose/VBP the/DT lymphoid/JJ and/CC nonlymphoid/JJ components/NNS of/IN the/DT secondary/JJ lymphoid/JJ tissues/NNS ,/, information/NN concerning/VBG the/DT signals/NNS that/WDT control/VBP the/DT development/NN of/IN the/DT tissues/NNS and/CC that/WDT maintain/VBP the/DT organized/VBN tissue/NN microenvironment/NN remain/VBP undefined/JJ ./. 
Studies/NNS over/IN the/DT past/JJ few/JJ years/NNS have/VBP identified/VBN lymphotoxin/NN as/IN a/DT critical/JJ signaling/VBG molecule/NN not/RB only/RB for/IN the/DT organogenesis/NN of/IN secondary/JJ lymphoid/JJ tissues/NNS but/CC for/IN the/DT maintenance/NN of/IN aspects/NNS of/IN their/PRP$ microarchitecture/NN as/RB well/RB ./. 
Additional/JJ signaling/VBG molecules/NNS that/WDT contribute/VBP to/TO the/DT formation/NN of/IN normal/JJ lymphoid/JJ tissue/NN structure/NN are/VBP being/VBG identified/VBN at/IN an/DT accelerating/VBG pace/NN ./. 
Analyses/NNS of/IN mouse/NN strains/NNS with/IN congenital/JJ defects/NNS in/IN different/JJ aspects/NNS of/IN secondary/JJ lymphoid/JJ tissue/NN development/NN are/VBP beginning/VBG to/TO clarify/VB the/DT role/NN of/IN these/DT tissues/NNS in/IN immune/JJ responses/NNS and/CC host/NN defense/NN ./. 
This/DT review/NN focuses/VBZ on/IN studies/NNS defining/VBG recently/RB identified/VBN crucial/JJ signals/NNS for/IN the/DT biogenesis/NN of/IN secondary/JJ lymphoid/JJ organs/NNS and/CC for/IN the/DT maintenance/NN of/IN their/PRP$ proper/JJ microarchitecture/NN ./. 
It/PRP also/RB discusses/VBZ new/JJ insights/NNS into/IN how/WRB the/DT structure/NN of/IN these/DT tissues/NNS supports/VBZ effective/JJ immune/JJ responses/NNS ./. 
UI/LS -/: 99282941/CD 
TI/LS -/: Modulation/NN of/IN CD28/NN expression/NN :/: distinct/JJ regulatory/JJ pathways/NNS during/IN activation/NN and/CC replicative/JJ senescence/NN ./. 
AB/LS -/: The/DT costimulatory/JJ molecule/NN CD28/NN has/VBZ a/DT restricted/JJ tissue/NN distribution/NN and/CC is/VBZ expressed/VBN on/IN T/NN cells/NNS and/CC some/DT plasmacytoma/NN cells/NNS ./. 
Although/IN CD28/NN is/VBZ constitutively/RB expressed/VBN ,/, its/PRP$ expression/NN is/VBZ transiently/RB down-regulated/VBN following/VBG T/NN cell/NN activation/NN and/CC declines/VBZ progressively/RB with/IN in/FW vitro/FW senescence/NN ./. 
In/FW vivo/FW ,/, CD8+/JJ T/NN cells/NNS and/CC ,/, less/RBR frequently/RB ,/, CD4+/JJ T/NN cells/NNS may/MD completely/RB lose/VB CD28/NN surface/NN expression/NN during/IN chronic/JJ infections/NNS and/CC with/IN aging/NN ./. 
This/DT correlates/VBZ with/IN changes/NNS of/IN nuclear/JJ protein-binding/JJ activities/NNS to/TO two/CD motifs/NNS ,/, site/NN alpha/NN and/CC beta/NN ,/, within/IN the/DT CD28/NN minimal/JJ promoter/NN ./. 
Both/CC alpha-/NN and/CC beta-bound/JJ complexes/NNS are/VBP found/VBN only/RB in/IN lymphoid/JJ tissues/NNS ,/, in/IN CD28+/JJ T/NN cells/NNS ,/, and/CC in/IN some/DT transformed/VBN B/NN cells/NNS ./. 
These/DT complexes/NNS are/VBP coordinately/RB expressed/VBN except/IN during/IN replicative/JJ senescence/NN ,/, which/WDT is/VBZ characterized/VBN by/IN the/DT down-modulation/NN of/IN site/NN beta-/NN but/CC not/RB site/NN alpha-binding/JJ activities/NNS ./. 
In/IN contrast/NN ,/, T/NN cell/NN activation/NN induces/VBZ a/DT parallel/JJ decline/NN in/IN both/CC site/NN alpha-/NN and/CC beta-binding/JJ activities/NNS ./. 
CD4+/JJ and/CC CD8+/JJ T/NN cells/NNS differ/VBP in/IN their/PRP$ beta-binding/JJ profiles/NNS ,/, which/WDT may/MD explain/VB the/DT more/RBR pronounced/JJ down-regulation/NN of/IN CD28/NN in/IN senescent/JJ CD8+/JJ T/NN cells/NNS ./. 
In/FW vivo/FW expanded/VBN CD4+CD28null/NN and/CC CD8+CD28null/NN T/NN cells/NNS uniformly/RB lack/VBP alpha-/NN and/CC beta-bound/JJ complexes/NNS ,/, resembling/VBG the/DT pattern/NN seen/VBN in/IN chronically/RB activated/VBN cells/NNS and/CC not/RB of/IN senescent/JJ cells/NNS ./. 
UI/LS -/: 99264317/CD 
TI/LS -/: A/DT role/NN for/IN RanBP1/NN in/IN the/DT release/NN of/IN CRM1/NN from/IN the/DT nuclear/JJ pore/NN complex/NN in/IN a/DT terminal/JJ step/NN of/IN nuclear/JJ export/NN ./. 
AB/LS -/: We/PRP recently/RB developed/VBD an/DT assay/NN in/IN which/WDT nuclear/JJ export/NN of/IN the/DT shuttling/VBG transcription/NN factor/NN NFAT/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS )/) can/MD be/VB reconstituted/VBN in/IN permeabilized/JJ cells/NNS with/IN the/DT GTPase/NN Ran/NN and/CC the/DT nuclear/JJ export/NN receptor/NN CRM1/NN ./. 
We/PRP have/VBP now/RB used/VBN this/DT assay/NN to/TO identify/VB another/DT export/NN factor/NN ./. 
After/IN preincubation/NN of/IN permeabilized/JJ cells/NNS with/IN a/DT Ran/NN mutant/NN that/WDT can/MD not/RB hydrolyze/VB GTP/NN (/( RanQ69L/NN )/) ,/, cytosol/NN supports/VBZ NFAT/NN export/NN ,/, but/CC CRM1/NN and/CC Ran/NN alone/RB do/VBP not/RB ./. 
The/DT RanQ69L/NN preincubation/NN leads/VBZ to/TO accumulation/NN of/IN CRM1/NN at/IN the/DT cytoplasmic/JJ periphery/NN of/IN the/DT nuclear/JJ pore/NN complex/NN (/( NPC/NN )/) in/IN association/NN with/IN the/DT p62/NN complex/NN and/CC Can/Nup214/NN ./. 
RanGTP-dependent/JJ association/NN of/IN CRM1/NN with/IN these/DT nucleoporins/NNS was/VBD reconstituted/VBN in/FW vitro/FW ./. 
By/IN biochemical/JJ fractionation/NN and/CC reconstitution/NN ,/, we/PRP showed/VBD that/IN RanBP1/NN restores/VBZ nuclear/JJ export/NN after/IN the/DT RanQ69L/NN preincubation/NN ./. 
It/PRP also/RB stimulates/VBZ nuclear/JJ export/NN in/IN cells/NNS that/WDT have/VBP not/RB been/VBN preincubated/VBN with/IN RanQ69L/NN ./. 
RanBP1/NN as/RB well/RB as/IN Ran-binding/JJ domains/NNS of/IN the/DT cytoplasmic/JJ nucleoporin/NN RanBP2/NN promote/VBP the/DT release/NN of/IN CRM1/NN from/IN the/DT NPC/NN ./. 
Taken/VBN together/RB ,/, our/PRP$ results/NNS indicate/VBP that/IN RanGTP/NN is/VBZ important/JJ for/IN the/DT targeting/NN of/IN export/NN complexes/NNS to/TO the/DT cytoplasmic/JJ side/NN of/IN the/DT NPC/NN and/CC that/IN RanBP1/NN and/CC probably/RB RanBP2/NN are/VBP involved/VBN in/IN the/DT dissociation/NN of/IN nuclear/JJ export/NN complexes/NNS from/IN the/DT NPC/NN in/IN a/DT terminal/JJ step/NN of/IN transport/NN ./. 
UI/LS -/: 99256996/CD 
TI/LS -/: c-Myc/NN and/CC E1A/NN induced/JJ cellular/JJ sensitivity/NN to/TO activated/VBN NK/NN cells/NNS involves/VBZ cytotoxic/JJ granules/NNS as/IN death/NN effectors/NNS ./. 
AB/LS -/: The/DT contact/NN of/IN natural/JJ killer/NN (/( NK/NN )/) cells/NNS with/IN foreign/JJ cells/NNS and/CC with/IN certain/JJ virus-infected/JJ or/CC tumor/JJ cells/NNS triggers/VBZ the/DT cytolytic/JJ machinery/NN of/IN NK/NN cells/NNS ./. 
This/DT triggering/NN leads/VBZ to/TO exocytosis/NN of/IN the/DT cytotoxic/JJ NK/NN cell/NN granules/NNS ./. 
The/DT oncoproteins/NNS c-Myc/NN and/CC E1A/NN render/VBP cells/NNS vulnerable/JJ to/TO NK/NN cell/NN mediated/JJ cytolysis/NN yet/RB the/DT mechanisms/NNS of/IN sensitization/NN are/VBP not/RB well/RB understood/VBN ./. 
In/IN a/DT model/NN where/WRB foreign/JJ cells/NNS (/( rat/NN fibroblasts/NNS )/) were/VBD cocultured/VBN with/IN human/JJ IL-2/NN activated/JJ NK/NN cells/NNS ,/, we/PRP observed/VBD that/IN NK/NN cells/NNS were/VBD capable/JJ of/IN efficiently/RB killing/VBG their/PRP$ targets/NNS only/RB if/IN the/DT cells/NNS overexpressed/VBD the/DT oncogene/NN c-Myc/NN or/CC E1A/NN ./. 
Both/CC the/DT parental/JJ and/CC the/DT oncogene/NN expressing/NN fibroblasts/NNS similarly/RB triggered/VBD phosphoinositide/NN hydrolysis/NN in/IN the/DT bound/VBN NK/NN cells/NNS ,/, demonstrating/VBG that/IN NK/NN cells/NNS were/VBD cytolytically/RB activated/VBN in/IN contact/NN with/IN both/CC resistant/JJ parental/JJ and/CC oncogene/NN expressing/NN sensitive/JJ target/NN fibroblasts/NNS ./. 
The/DT cell/NN death/NN was/VBD independent/JJ of/IN wild-type/JJ p53/NN and/CC was/VBD not/RB inhibited/VBN by/IN an/DT anti-apoptotic/JJ protein/NN EIB19K/NN ./. 
These/DT results/NNS provided/VBD evidence/NN that/IN c-Myc/NN and/CC E1A/NN activated/VBD the/DT NK/NN cell/NN induced/JJ cytolysis/NN at/IN a/DT post-triggering/JJ stage/NN of/IN NK/NN cell-target/JJ cell/NN interaction/NN ./. 
In/IN consistence/NN ,/, the/DT c-Myc/NN and/CC E1A/NN overexpressing/NN fibroblasts/NNS were/VBD more/RBR sensitive/JJ to/TO the/DT cytolytic/JJ effects/NNS of/IN isolated/VBN NK/NN cell-derived/JJ granules/NNS than/IN parental/JJ cells/NNS ./. 
The/DT data/NNS indicate/VBP that/IN oncogenes/NNS activate/VBP the/DT cytotoxicity/NN of/IN NK/NN cell/NN granules/NNS ./. 
This/DT mechanism/NN can/MD have/VB a/DT role/NN in/IN directing/VBG the/DT cytolytic/JJ action/NN of/IN NK/NN cells/NNS towards/IN the/DT virus-infected/JJ and/CC cancer/NN cells/NNS ./. 
UI/LS -/: 99252090/CD 
TI/LS -/: Unicellular-unilineage/JJ erythropoietic/JJ cultures/NNS :/: molecular/JJ analysis/NN of/IN regulatory/JJ gene/NN expression/NN at/IN sibling/NN cell/NN level/NN ./. 
AB/LS -/: In/FW vitro/FW studies/NNS on/IN hematopoietic/JJ control/NN mechanisms/NNS have/VBP been/VBN hampered/VBN by/IN the/DT heterogeneity/NN of/IN the/DT analyzed/VBN cell/NN populations/NNS ,/, ie/FW ,/, lack/NN of/IN lineage/NN specificity/NN and/CC developmental/JJ stage/NN homogeneity/NN of/IN progenitor/precursor/NN cells/NNS growing/VBG in/IN culture/NN ./. 
We/PRP developed/VBD unicellular/JJ culture/NN systems/NNS for/IN unilineage/JJ differentiation/NN of/IN purified/VBN hematopoietic/JJ progenitor/NN cells/NNS followed/VBN by/IN daughter/NN cell/NN analysis/NN at/IN cellular/JJ and/CC molecular/JJ level/NN ./. 
In/IN the/DT culture/NN system/NN reported/VBN here/RB ,/, (/( 1/LS )/) the/DT growth/NN factor/NN (/( GF/NN )/) stimulus/NN induces/VBZ cord/NN blood/NN (/( CB/NN )/) progenitor/NN cells/NNS to/TO proliferate/VB and/CC differentiate/mature/VB exclusively/RB along/IN the/DT erythroid/JJ lineage/NN ;/: (/( 2/LS )/) this/DT erythropoietic/JJ wave/NN is/VBZ characterized/VBN by/IN less/JJR than/IN 4/CD %/NN apoptotic/JJ cells/NNS ;/: (/( 3/LS )/) asymmetric/JJ divisions/NNS are/VBP virtually/RB absent/JJ ,/, ie/FW ,/, nonresponsive/JJ hematopoietic/JJ progenitors/NNS with/IN no/DT erythropoietic/JJ potential/NN are/VBP forced/VBN into/IN apoptosis/NN ;/: (/( 4/LS )/) the/DT system/NN is/VBZ cell/NN division/NN controlled/JJ (/( cdc/NN )/) ,/, ie/FW ,/, the/DT number/NN of/IN divisions/NNS performed/VBN by/IN each/DT cell/NN is/VBZ monitored/VBN ./. 
Single-cell/JJ reverse/NN transcriptase-polymerase/NN chain/NN reaction/NN (/( RT-PCR/NN )/) analysis/NN was/VBD applied/VBN to/TO this/DT culture/NN system/NN to/TO investigate/VB gene/NN expression/NN of/IN diverse/JJ receptors/NNS ,/, markers/NNS of/IN differentiation/NN ,/, and/CC transcription/NN factors/NNS (/( EKLF/NN ,/, GATA-1/NN ,/, GATA-2/NN ,/, p45/NN NF-E2/NN ,/, PU.1/NN ,/, and/CC SCL/Tal1/NN )/) at/IN discrete/JJ stages/NNS of/IN erythropoietic/JJ development/NN ./. 
Freshly/RB isolated/VBN CD34(+)/JJ cells/NNS expressed/VBD CD34/NN ,/, c-kit/NN ,/, PU.1/NN ,/, and/CC GATA-2/NN but/CC did/VBD not/RB express/VB CD36/NN ,/, erythropoietin/NN receptor/NN (/( EpoR/NN )/) ,/, SCL/Tal1/NN ,/, EKLF/NN ,/, NF-E2/NN ,/, GATA-1/NN ,/, or/CC glyocophorin/NN A/NN (/( GPA/NN )/) ./. 
In/IN early/JJ to/TO intermediate/JJ stages/NNS of/IN erythroid/JJ differentiation/NN we/PRP monitored/VBD the/DT induction/NN of/IN CD36/NN ,/, Tal1/NN ,/, EKLF/NN ,/, NF-E2/NN ,/, and/CC GATA-1/NN that/WDT preceeded/VBD expression/NN of/IN EpoR/NN ./. 
In/IN late/JJ stages/NNS of/IN erythroid/JJ maturation/NN ,/, GPA/NN was/VBD upregulated/VBN ,/, whereas/IN CD34/NN ,/, c-kit/NN ,/, PU.1/NN ,/, and/CC GATA-2/NN were/VBD barely/RB or/CC not/RB detected/VBN ./. 
In/IN addition/NN ,/, competitive/JJ single-cell/JJ RT-PCR/NN was/VBD used/VBN to/TO assay/VB CD34/NN mRNA/NN transcripts/NNS in/IN sibling/NN CD34(+)/JJ CD38(-)/JJ cells/NNS differentiating/VBG in/IN unilineage/JJ erythroid/JJ cultures/NNS :/: this/DT analysis/NN allowed/VBD us/PRP to/TO semiquantitate/VB the/DT gradual/JJ downmodulation/NN of/IN CD34/NN mRNA/NN from/IN progenitor/NN cells/NNS through/IN their/PRP$ differentiating/VBG erythroid/JJ progeny/NN ./. 
It/PRP is/VBZ concluded/VBN that/IN this/DT novel/JJ culture/NN system/NN ,/, coupled/VBN with/IN single-cell/JJ RT-PCR/NN analysis/NN ,/, may/MD eliminate/VB the/DT ambiguities/NNS intrinsic/JJ to/TO molecular/JJ studies/NNS on/IN heterogeneous/JJ populations/NNS of/IN hematopoietic/JJ progenitors/precursors/NNS growing/VBG in/IN culture/NN ,/, particularly/RB in/IN the/DT initial/JJ stages/NNS of/IN development/NN ./. 
UI/LS -/: 99244330/CD 
TI/LS -/: Differences/NNS in/IN phosphorylation/NN of/IN the/DT IL-2R/NN associated/JJ JAK/STAT/NN proteins/NNS between/IN HTLV-I(+)/JJ ,/, IL-2-independent/JJ and/CC IL-2-dependent/JJ cell/NN lines/NNS and/CC uncultured/JJ leukemic/JJ cells/NNS from/IN patients/NNS with/IN adult/JJ T-cell/NN lymphoma/leukemia/NN ./. 
AB/LS -/: To/TO determine/VB activation/NN status/NN of/IN the/DT IL-2R-associated/JJ (/( Jak/STAT/NN )/) pathway/NN in/IN the/DT HTLV-I/NN infected/JJ cells/NNS ,/, we/PRP examined/VBD tyrosine/NN phosphorylation/NN of/IN Jak3/NN ,/, STAT3/NN ,/, and/CC STAT5/NN in/IN several/JJ HTLV-I(+)/JJ T-cell/NN lines/NNS and/CC in/IN uncultured/JJ leukemic/JJ T/NN cells/NNS isolated/VBN from/IN patients/NNS with/IN adult/JJ T-cell/NN lymphoma/leukemia/NN (/( ATLL/NN )/) ./. 
Constitutive/JJ basal/JJ phosphorylation/NN of/IN Jak3/NN and/CC ,/, usually/RB ,/, STAT3/NN and/CC STAT5/NN was/VBD detected/VBN in/IN all/DT four/CD IL-2-independent/JJ cell/NN lines/NNS tested/VBN ,/, but/CC in/IN none/NN of/IN the/DT three/CD IL-2-dependent/JJ cell/NN lines/NNS ./. 
Similarly/RB ,/, there/EX was/VBD no/DT detectable/JJ basal/JJ phosphorylation/NN of/IN Jak3/NN and/CC STAT5/NN in/IN the/DT leukemic/JJ cells/NNS from/IN ATLL/NN patients/NNS (/( 0/8/CD and/CC 0/3/CD ,/, respectively/RB )/) ./. 
However/RB ,/, stimulation/NN with/IN IL-2/NN resulted/VBD in/IN Jak3/NN and/CC STAT5/NN phosphorylation/NN in/IN both/CC leukemic/JJ ATLL/NN cells/NNS and/CC IL-2-dependent/JJ lines/NNS ./. 
Furthermore/RB ,/, expression/NN of/IN SHP-1/NN phosphatase/NN which/WDT is/VBZ a/DT negative/JJ regulator/NN of/IN cytokine/NN receptor/NN signaling/NN ,/, was/VBD lost/VBN in/IN most/JJS IL-2/NN independent/JJ cell/NN lines/NNS (/( 3/4/CD )/) but/CC not/RB in/IN the/DT leukemic/JJ ATLL/NN cells/NNS (/( 0/3/CD )/) ./. 
Finally/RB ,/, the/DT HTLV-I(+)/JJ T-cell/NN lines/NNS (/( 313/CD )/) but/CC not/RB the/DT control/NN ,/, HTLV-I(-)/JJ T-cell/NN lines/NNS were/VBD resistant/JJ to/TO rapamycin/NN and/CC its/PRP$ novel/JJ analog/NN RAD/NN ./. 
We/PRP conclude/VBP that/IN (/( 1/LS )/) HTLV-I/NN infection/NN per/FW se/FW does/VBZ not/RB result/VB in/IN a/DT constitutive/JJ phosphorylation/NN of/IN the/DT Jak3/NN ,/, STAT3/NN ,/, and/CC STAT5/NN proteins/NNS ;/: (/( 2/LS )/) malignant/JJ transformation/NN in/IN at/IN least/JJS some/DT cases/NNS of/IN ATLL/NN does/VBZ not/RB require/VB the/DT constitutive/JJ ,/, but/CC may/MD require/VB IL-2-induced/JJ ,/, activation/NN of/IN the/DT IL-2R/NN Jak/STAT/NN pathway/NN ;/: and/CC (/( 3/LS )/) there/EX are/VBP major/JJ differences/NNS in/IN T-cell/NN immortalization/NN mechanism/NN (/( s/NNS )/) which/WDT appear/VBP to/TO involve/VB SHP-1/NN and/CC target/NN molecules/NNS for/IN rapamycin/NN and/CC RAD/NN ./. 
UI/LS -/: 99324612/CD 
TI/LS -/: Clonality/NN analysis/NN using/VBG X-chromosome/NN inactivation/NN at/IN the/DT human/JJ androgen/NN receptor/NN gene/NN (/( Humara/NN )/) ./. 
Evaluation/NN of/IN large/JJ cohorts/NNS of/IN patients/NNS with/IN chronic/JJ myeloproliferative/JJ diseases/NNS ,/, secondary/JJ neutrophilia/NN ,/, and/CC reactive/JJ thrombocytosis/NN ./. 
AB/LS -/: Chronic/JJ myeloproliferative/JJ diseases/NNS (/( MPDs/NNS )/) are/VBP not/RB associated/VBN with/IN consistent/JJ cytogenetic/JJ or/CC molecular/JJ abnormalities/NNS ./. 
Demonstration/NN of/IN clonal/JJ cell/NN growth/NN by/IN analysis/NN of/IN X-chromosome/NN inactivation/NN (/( XCI/NN )/) patterns/NNS in/IN females/NNS provides/VBZ a/DT promising/JJ tool/NN for/IN diagnosis/NN ./. 
However/RB ,/, this/DT technique/NN can/MD be/VB complicated/VBN by/IN excessive/JJ lyonization/NN of/IN normal/JJ cells/NNS mimicking/VBG clonal/JJ cell/NN growth/NN :/: We/PRP analyzed/VBD XCI/NN patterns/NNS at/IN the/DT human/JJ androgen/NN receptor/NN (/( HUMARA/NN )/) locus/NN in/IN 146/CD healthy/JJ females/NNS ,/, 65/CD women/NNS with/IN secondary/JJ neutrophilia/NN ,/, 31/CD women/NNS with/IN reactive/JJ thrombocytosis/NN ,/, and/CC 86/CD women/NNS with/IN chronic/JJ MPDs/NNS ./. 
A/DT skewed/JJ XCI/NN pattern/NN with/IN greater/JJR than/IN 75/CD %/NN amplification/NN of/IN 1/CD allele/NN (/( allele/NN ratio/NN >/JJR 3/CD :/: 1/CD )/) was/VBD found/VBN in/IN 22/CD (/( 9.1/CD %/NN )/) of/IN 242/CD control/JJ subjects/NNS ./. 
The/DT incidence/NN of/IN skewing/NN was/VBD statistically/RB significantly/RB lower/JJR in/IN women/NNS younger/JJR than/IN 30/CD years/NNS (/( 2/73/CD )/) compared/VBN with/IN women/NNS older/JJR than/IN 60/CD years/NNS (/( 10/53/CD )/) ./. 
Of/IN 86/CD patients/NNS with/IN a/DT chronic/JJ MPD/NN ,/, 71/CD (/( 82/CD %/NN )/) exhibited/VBD an/DT allele/NN ratio/NN greater/JJR than/IN 3/CD :/: 1/CD ,/, whereas/IN only/RB 10/CD (/( 12/CD %/NN )/) of/IN 86/CD age-matched/JJ control/JJ subjects/NNS showed/VBD a/DT skewed/JJ XCI/NN pattern/NN ./. 
Although/IN statistical/JJ evaluation/NN of/IN the/DT data/NNS showed/VBD a/DT significant/JJ difference/NN between/IN patients/NNS with/IN a/DT chronic/JJ MPD/NN and/CC control/JJ subjects/NNS ,/, proof/NN of/IN clonality/NN in/IN individual/NN ,/, especially/RB elderly/JJ ,/, patients/NNS is/VBZ difficult/JJ ./. 
UI/LS -/: 99310627/CD 
TI/LS -/: GATA-1/NN and/CC erythropoietin/NN cooperate/VBP to/TO promote/VB erythroid/JJ cell/NN survival/NN by/IN regulating/VBG bcl-xL/NN expression/NN ./. 
AB/LS -/: The/DT transcription/NN factor/NN GATA-1/NN is/VBZ essential/JJ for/IN normal/JJ erythropoiesis/NN ./. 
By/IN examining/VBG in/IN vitro-differentiated/JJ embryonic/JJ stem/NN cells/NNS ,/, we/PRP showed/VBD previously/RB that/IN in/IN the/DT absence/NN of/IN GATA-1/NN ,/, committed/VBN erythroid/JJ precursors/NNS fail/VBP to/TO complete/VB maturation/NN and/CC instead/RB undergo/VBP apoptosis/NN ./. 
The/DT mechanisms/NNS by/IN which/WDT GATA-1/NN controls/VBZ cell/NN survival/NN are/VBP unknown/JJ ./. 
Here/RB we/PRP report/VBP that/IN in/IN erythroid/JJ cells/NNS ,/, GATA-1/NN strongly/RB induces/VBZ the/DT expression/NN of/IN the/DT anti-apoptotic/JJ protein/NN bcl-xL/NN ,/, but/CC not/RB the/DT related/JJ proteins/NNS bcl-2/NN and/CC mcl-1/NN ./. 
Consistent/JJ with/IN a/DT role/NN for/IN bcl-xL/NN in/IN mediating/VBG GATA-1-induced/JJ erythroid/JJ cell/NN survival/NN ,/, in/FW vitro-differentiated/JJ bcl-xL-/-/JJ embryonic/JJ stem/NN cells/NNS fail/VBP to/TO generate/VB viable/JJ mature/JJ definitive/JJ erythroid/JJ cells/NNS ,/, a/DT phenotype/NN resembling/VBG that/DT of/IN GATA-1/NN gene/NN disruption/NN ./. 
In/IN addition/NN ,/, we/PRP show/VBP that/IN erythropoietin/NN ,/, which/WDT is/VBZ also/RB required/VBN for/IN erythroid/JJ cell/NN survival/NN ,/, cooperates/VBZ with/IN GATA-1/NN to/TO stimulate/VB bcl-xL/NN gene/NN expression/NN and/CC to/TO maintain/VB erythroid/JJ cell/NN viability/NN during/IN terminal/JJ maturation/NN ./. 
Together/RB ,/, our/PRP$ data/NNS show/VBP that/IN bcl-xL/NN is/VBZ essential/JJ for/IN normal/JJ erythroid/JJ development/NN and/CC suggest/VBP a/DT regulatory/JJ hierarchy/NN in/IN which/WDT bcl-xL/NN is/VBZ a/DT critical/JJ downstream/JJ effector/NN of/IN GATA-1/NN and/CC erythropoietin-mediated/JJ signals/NNS ./. 
UI/LS -/: 99303765/CD 
TI/LS -/: p70(s6k)/NN integrates/VBZ phosphatidylinositol/NN 3-kinase/NN and/CC rapamycin-regulated/JJ signals/NNS for/IN E2F/NN regulation/NN in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: In/IN T/NN lymphocytes/NNS ,/, the/DT hematopoietic/JJ cytokine/NN interleukin-2/NN (/( IL-2/NN )/) uses/VBZ phosphatidylinositol/NN 3-kinase/NN (/( PI/NN 3-kinase/NN )/) -induced/JJ signaling/NN pathways/NNS to/TO regulate/VB E2F/NN transcriptional/JJ activity/NN ,/, a/DT critical/JJ cell/NN cycle/NN checkpoint/NN ./. 
PI/NN 3-kinase/NN also/RB regulates/VBZ the/DT activity/NN of/IN p70(s6k)/NN ,/, the/DT 40S/JJ ribosomal/JJ protein/NN S6/NN kinase/NN ,/, a/DT response/NN that/WDT is/VBZ abrogated/VBN by/IN the/DT macrolide/NN rapamycin/NN ./. 
This/DT immunosuppressive/JJ drug/NN is/VBZ known/VBN to/TO prevent/VB T-cell/NN proliferation/NN ,/, but/CC the/DT precise/JJ point/NN at/IN which/WDT rapamycin/NN regulates/VBZ T-cell/NN cycle/NN progression/NN has/VBZ yet/RB to/TO be/VB elucidated/VBN ./. 
Moreover/RB ,/, the/DT effects/NNS of/IN rapamycin/NN on/IN ,/, and/CC the/DT role/NN of/IN p70(s6k)/NN in/IN ,/, IL-2/NN and/CC PI/NN 3-kinase/NN activation/NN of/IN E2Fs/NNS have/VBP not/RB been/VBN characterized/VBN ./. 
Our/PRP$ present/JJ results/NNS show/VBP that/IN IL-2-/NN and/CC PI/NN 3-kinase-induced/JJ pathways/NNS for/IN the/DT regulation/NN of/IN E2F/NN transcriptional/JJ activity/NN include/VBP both/CC rapamycin-resistant/JJ and/CC rapamycin-sensitive/JJ components/NNS ./. 
Expression/NN of/IN a/DT rapamycin-resistant/JJ mutant/NN of/IN p70(s6k)/NN in/IN T/NN cells/NNS could/MD restore/VB rapamycin-suppressed/JJ E2F/NN responses/NNS ./. 
Thus/RB ,/, the/DT rapamycin-controlled/JJ processes/NNS involved/VBN in/IN E2F/NN regulation/NN appear/VBP to/TO be/VB mediated/VBN by/IN p70(s6k)/NN ./. 
However/RB ,/, the/DT rapamycin-resistant/JJ p70(s6k)/NN could/MD not/RB rescue/VB rapamycin/NN inhibition/NN of/IN T-cell/NN cycle/NN entry/NN ,/, consistent/JJ with/IN the/DT involvement/NN of/IN additional/JJ ,/, rapamycin-sensitive/JJ pathways/NNS in/IN the/DT control/NN of/IN T-cell/NN cycle/NN progression/NN ./. 
The/DT present/JJ results/NNS thus/RB show/VBP that/IN p70(s6k)/NN is/VBZ able/JJ to/TO regulate/VB E2F/NN transcriptional/JJ activity/NN and/CC provide/VB direct/JJ evidence/NN for/IN the/DT first/JJ time/NN for/IN a/DT link/NN between/IN IL-2/NN receptors/NNS ,/, PI/NN 3-kinase/NN ,/, and/CC p70(s6k)/NN that/WDT regulates/VBZ a/DT crucial/JJ G1/NN checkpoint/NN in/IN T/NN lymphocytes/NNS ./. 
UI/LS -/: 99292717/CD 
TI/LS -/: Oxidative/JJ stress/NN triggers/VBZ STAT3/NN tyrosine/NN phosphorylation/NN and/CC nuclear/JJ translocation/NN in/IN human/JJ lymphocytes/NNS ./. 
AB/LS -/: Oxidizing/JJ agents/NNS are/VBP powerful/JJ activators/NNS of/IN factors/NNS responsible/JJ for/IN the/DT transcriptional/JJ activation/NN of/IN cytokine-encoding/JJ genes/NNS involved/VBN in/IN tissue/NN injury/NN ./. 
In/IN this/DT study/NN we/PRP show/VBP evidence/NN that/IN STAT3/NN is/VBZ a/DT transcription/NN factor/NN whose/WP$ activity/NN is/VBZ modulated/VBN by/IN H2O2/NN in/IN human/JJ lymphocytes/NNS ,/, in/IN which/WDT endogenous/JJ catalase/NN had/VBD previously/RB been/VBN inhibited/VBN ./. 
H2O2-induced/JJ nuclear/JJ translocation/NN of/IN STAT3/NN to/TO form/VB sequence-specific/JJ DNA-bound/JJ complexes/NNS was/VBD evidenced/VBN by/IN immunoblotting/NN of/IN nuclear/JJ fractions/NNS and/CC electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, and/CC vanadate/NN was/VBD found/VBN to/TO strongly/RB synergize/VB with/IN H2O2/NN ./. 
Moreover/RB ,/, anti-STAT3/JJ antibodies/NNS specifically/RB precipitated/VBD a/DT protein/NN of/IN 92/CD kDa/NN that/WDT becomes/VBZ phosphorylated/VBN on/IN tyrosine/NN upon/IN lymphocyte/NN treatment/NN with/IN H2O2/NN ./. 
Phenylarsine/NN oxide/NN ,/, a/DT tyrosine/NN phosphatase/NN inhibitor/NN ,/, and/CC genistein/NN ,/, a/DT tyrosine/NN kinase/NN inhibitor/NN ,/, cooperated/VBD and/CC cancelled/VBD ,/, respectively/RB ,/, the/DT H2O2-promoted/JJ STAT3/NN nuclear/JJ translocation/NN ./. 
Evidence/NN is/VBZ also/RB presented/VBN ,/, using/VBG Fe2+/Cu2+/JJ ions/NNS ,/, that./IN OH/NN generated/VBN from/IN H2O2/NN through/IN Fenton/NN reactions/NNS could/MD be/VB a/DT candidate/NN oxygen/NN reactive/JJ species/NNS to/TO directly/RB activate/VB STAT3/NN ./. 
Present/JJ data/NNS suggest/VBP that/IN H2O2/NN and/CC vanadate/NN are/VBP likely/JJ to/TO inhibit/VB the/DT activity/NN of/IN intracellular/JJ tyrosine/NN phosphatase/NN (/( s/NNS )/) ,/, leading/VBG to/TO enhanced/VBN STAT3/NN tyrosine/NN phosphorylation/NN and/CC hence/RB its/PRP$ translocation/NN to/TO the/DT nucleus/NN ./. 
These/DT results/NNS demonstrate/VBP that/IN the/DT DNA/NN binding/NN activity/NN of/IN STAT3/NN can/MD be/VB modulated/VBN by/IN oxidizing/VBG agents/NNS and/CC provide/VBP a/DT framework/NN to/TO understand/VB the/DT effects/NNS of/IN oxidative/JJ stress/NN on/IN the/DT JAK-STAT/NN signaling/NN pathway/NN ./. 
UI/LS -/: 99286808/CD 
TI/LS -/: Transcriptional/JJ regulation/NN of/IN T/NN lymphocyte/NN development/NN and/CC function/NN ./. 
AB/LS -/: The/DT development/NN and/CC function/NN of/IN T/NN lymphocytes/NNS are/VBP regulated/VBN tightly/RB by/IN signal/NN transduction/NN pathways/NNS that/WDT include/VBP specific/JJ cell-surface/JJ receptors/NNS ,/, intracellular/JJ signaling/VBG molecules/NNS ,/, and/CC nuclear/JJ transcription/NN factors/NNS ./. 
Since/IN 1988/CD ,/, several/JJ families/NNS of/IN functionally/RB important/JJ T/NN cell/NN transcription/NN factors/NNS have/VBP been/VBN identified/VBN ./. 
These/DT include/VBP the/DT Ikaros/NN ,/, LKLF/NN ,/, and/CC GATA3/NN zinc-finger/JJ proteins/NNS ;/: the/DT Ets/NN ,/, CREB/ATF/NN ,/, and/CC NF-kappa/NN B/Rel/NFAT/NN transcription/NN factors/NNS ;/: the/DT Stat/NN proteins/NNS ;/: and/CC HMG/NN box/NN transcription/NN factors/NNS such/JJ as/IN LEF1/NN ,/, TCF1/NN ,/, and/CC Sox4/NN ./. 
In/IN this/DT review/NN ,/, we/PRP summarize/VBP our/PRP$ current/JJ understanding/NN of/IN the/DT transcriptional/JJ regulation/NN of/IN T/NN cell/NN development/NN and/CC function/NN with/IN particular/JJ emphasis/NN on/IN the/DT results/NNS of/IN recent/JJ gene/NN targeting/NN and/CC transgenic/JJ experiments/NNS ./. 
In/IN addition/NN to/TO increasing/VBG our/PRP$ understanding/NN of/IN the/DT molecular/JJ pathways/NNS that/WDT regulate/VBP T/NN cell/NN development/NN and/CC function/NN ,/, these/DT results/NNS have/VBP suggested/VBN novel/JJ targets/NNS for/IN genetic/JJ and/CC pharmacological/JJ manipulation/NN of/IN T/NN cell/NN immunity/NN ./. 
UI/LS -/: 99282926/CD 
TI/LS -/: In/FW vivo/FW inhibition/NN of/IN NF-kappa/NN B/NN in/IN T-lineage/JJ cells/NNS leads/VBZ to/TO a/DT dramatic/JJ decrease/NN in/IN cell/NN proliferation/NN and/CC cytokine/NN production/NN and/CC to/TO increased/VBN cell/NN apoptosis/NN in/IN response/NN to/TO mitogenic/JJ stimuli/NNS ,/, but/CC not/RB to/TO abnormal/JJ thymopoiesis/NN ./. 
AB/LS -/: To/TO understand/VB the/DT role/NN of/IN NF-kappa/NN B/NN complexes/NNS in/IN T/NN cell/NN development/NN and/CC activation/NN ,/, we/PRP have/VBP generated/VBN transgenic/JJ mice/NNS in/IN which/WDT RelA/NN and/CC c-Rel/NN complexes/NNS were/VBD selectively/RB inhibited/VBN in/IN the/DT T-lineage/JJ cells/NNS by/IN specific/JJ expression/NN of/IN a/DT trans-dominant/JJ form/NN of/IN I/NN kappa/NN B/NN alpha/NN ./. 
Transgene/NN expression/NN did/VBD not/RB affect/VB the/DT thymic/JJ development/NN ,/, but/CC led/VBD to/TO lowered/JJ numbers/NNS of/IN splenic/JJ T/NN cells/NNS and/CC to/TO a/DT dramatic/JJ decrease/NN in/IN the/DT ex/FW vivo/FW proliferative/JJ response/NN of/IN splenic/JJ T/NN lymphocytes/NNS ./. 
Analysis/NN of/IN IL-2/NN and/CC IL-2R/NN alpha/NN expression/NN demonstrated/VBD that/IN the/DT perturbation/NN of/IN the/DT proliferation/NN response/NN was/VBD not/RB attributable/JJ to/TO an/DT abnormal/JJ expression/NN of/IN these/DT genes/NNS ./. 
In/IN contrast/NN ,/, expression/NN of/IN IL-4/NN ,/, IL-10/NN ,/, and/CC IFN-gamma/NN was/VBD strongly/RB inhibited/VBN in/IN the/DT transgenic/JJ T/NN cells/NNS ./. 
The/DT proliferative/JJ deficiency/NN of/IN the/DT transgenic/JJ T/NN cells/NNS was/VBD associated/VBN with/IN an/DT increased/VBN apoptosis/NN ./. 
These/DT results/NNS point/VBP out/RP the/DT involvement/NN of/IN NF-kappa/NN B/Rel/NN family/NN proteins/NNS in/IN growth/NN signaling/NN pathways/NNS by/IN either/CC regulating/VBG proteins/NNS involved/VBN in/IN the/DT IL-2/NN signaling/NN or/CC by/IN functionally/RB interfering/VBG with/IN the/DT cell/NN cycle/NN progression/NN ./. 
UI/LS -/: 99262272/CD 
TI/LS -/: Paradoxical/JJ priming/JJ effects/NNS of/IN IL-10/NN on/IN cytokine/NN production/NN ./. 
AB/LS -/: IL-10/NN is/VBZ a/DT well-known/JJ immunosuppressive/JJ and/or/CC anti-inflammatory/JJ cytokine/NN ./. 
However/RB ,/, we/PRP report/VBP in/FW vitro/FW experimental/JJ studies/NNS in/IN which/WDT IL-10/NN primed/VBD leukocytes/NNS and/CC led/VBD to/TO an/DT enhanced/VBN production/NN of/IN tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) upon/IN further/JJ stimulation/NN by/IN lipopolysaccharide/NN (/( LPS/NN )/) ./. 
Monocytes/NNS and/CC peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NN )/) prepared/VBN from/IN whole/JJ blood/NN maintained/VBN for/IN 20/CD h/NN at/IN 37/CD degrees/NNS C/NN in/IN the/DT presence/NN of/IN recombinant/JJ human/JJ IL-10/NN had/VBD an/DT enhanced/VBN capacity/NN to/TO produce/VB TNF/NN in/IN response/NN to/TO LPS/NN ./. 
In/IN addition/NN to/TO TNF/NN ,/, LPS-induced/JJ IL-6/NN and/CC spontaneous/JJ IL-1ra/NN production/NN were/VBD also/RB enhanced/VBN ./. 
When/WRB isolated/VBN PBMC/NN were/VBD first/RB cultured/VBN for/IN 20/CD h/NN in/IN the/DT presence/NN of/IN IL-10/NN on/IN Teflon/NN to/TO prevent/VB adherence/NN ,/, washed/VBN to/TO remove/VB IL-10/NN and/CC then/RB further/RB cultured/VBN in/IN plastic/JJ dishes/NNS for/IN an/DT additional/JJ 20/CD h/NN in/IN the/DT presence/NN of/IN LPS/NN or/CC IL-1beta/NN ,/, an/DT enhanced/VBN release/NN of/IN TNF/NN was/VBD observed/VBN ./. 
This/DT was/VBD not/RB the/DT case/NN when/WRB PBMC/NN were/VBD pre-cultured/JJ in/IN plastic/JJ multidishes/NNS in/IN the/DT presence/NN of/IN IL-10/NN ./. 
TNF/NN mRNA/NN expression/NN induced/VBN by/IN LPS/NN was/VBD decreased/VBN when/WRB the/DT pre-treatment/NN of/IN PBMC/NN with/IN IL-10/NN was/VBD performed/VBN on/IN plastic/NN ,/, whereas/IN this/DT was/VBD not/RB the/DT case/NN when/WRB cells/NNS were/VBD pre-cultured/JJ with/IN IL-10/NN on/IN Teflon/NN ./. 
Furthermore/RB ,/, NFkappaB/NN translocation/NN following/VBG LPS/NN activation/NN was/VBD higher/JJR after/IN IL-10/NN pre-treatment/NN on/IN Teflon/NN than/IN on/IN plastic/NN ./. 
Interestingly/RB ,/, an/DT enhanced/VBN frequency/NN of/IN CD16/NN and/CC CD68(+)/JJ cells/NNS among/IN the/DT CD14(+)/JJ cells/NNS was/VBD observed/VBN in/IN the/DT presence/NN of/IN IL-10/NN ,/, independently/RB of/IN the/DT pre-culture/JJ conditions/NNS of/IN the/DT PBMC/NN ./. 
Altogether/RB ,/, these/DT results/NNS indicate/VBP that/IN the/DT IL-10-induced/JJ up-regulation/NN of/IN cytokine/NN production/NN depends/VBZ on/IN the/DT prevention/NN of/IN monocyte/NN adherence/NN by/IN red/JJ cells/NNS in/IN the/DT whole/JJ blood/NN assays/NNS or/CC by/IN cultures/NNS of/IN PBMC/NN on/IN Teflon/NN ./. 
In/IN contrast/NN ,/, the/DT adherence/NN parameter/NN has/VBZ no/DT effect/NN on/IN the/DT IL-10-induced/JJ modulation/NN of/IN some/DT monocyte/NN surface/NN markers/NNS ./. 
UI/LS -/: 99256982/CD 
TI/LS -/: Cell/NN growth-regulated/JJ expression/NN of/IN mammalian/JJ MCM5/NN and/CC MCM6/NN genes/NNS mediated/VBN by/IN the/DT transcription/NN factor/NN E2F/NN ./. 
AB/LS -/: Initiation/NN of/IN DNA/NN replication/NN requires/VBZ the/DT function/NN of/IN MCM/NN gene/NN products/NNS ,/, which/WDT participate/VBP in/IN ensuring/VBG that/IN DNA/NN replication/NN occurs/VBZ only/RB once/RB in/IN the/DT cell/NN cycle/NN ./. 
Expression/NN of/IN all/DT mammalian/JJ genes/NNS of/IN the/DT MCM/NN family/NN is/VBZ induced/VBN by/IN growth/NN stimulation/NN ,/, unlike/IN yeast/NN ,/, and/CC the/DT mRNA/NN levels/NNS peak/VBP at/IN G1/S/NN boundary/NN ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD the/DT transcriptional/JJ activities/NNS of/IN isolated/VBN human/JJ MCM/NN gene/NN promoters/NNS ./. 
Human/JJ MCM5/NN and/CC MCM6/NN promoters/NNS with/IN mutation/NN in/IN the/DT E2F/NN sites/NNS failed/VBD in/IN promoter/NN regulation/NN following/VBG serum/NN stimulation/NN and/CC exogenous/JJ E2F/NN expression/NN ./. 
In/IN addition/NN ,/, we/PRP identified/VBD a/DT novel/JJ E2F-like/JJ sequence/NN in/IN human/JJ MCM6/NN promoter/NN which/WDT cooperates/VBZ with/IN the/DT authentic/JJ E2F/NN sites/NNS in/IN E2F-dependent/JJ regulation/NN ./. 
Forced/JJ expression/NN of/IN E2F1/NN could/MD induce/VB expression/NN of/IN all/DT members/NNS of/IN the/DT endogenous/JJ MCM/NN genes/NNS in/IN rat/NN embryonal/JJ fibroblast/NN REF52/NN cells/NNS ./. 
Our/PRP$ results/NNS demonstrated/VBD that/IN the/DT growth-regulated/JJ expression/NN of/IN mammalian/JJ MCM5/NN and/CC MCM6/NN genes/NNS ,/, and/CC presumably/RB other/JJ MCM/NN members/NNS ,/, is/VBZ primarily/RB regulated/VBN by/IN E2F/NN through/IN binding/NN to/TO multiple/JJ E2F/NN sites/NNS in/IN the/DT promoters/NNS ./. 
UI/LS -/: 99252084/CD 
TI/LS -/: An/DT essential/JJ role/NN for/IN NF-kappaB/NN in/IN human/JJ CD34(+)/JJ bone/NN marrow/NN cell/NN survival/NN ./. 
AB/LS -/: The/DT transcription/NN factor/NN ,/, NF-kappaB/NN ,/, is/VBZ important/JJ for/IN T-cell/NN activation/NN ,/, B-cell/NN maturation/NN ,/, and/CC human/JJ immunodeficiency/NN virus/NN transcription/NN and/CC plays/VBZ a/DT role/NN in/IN alternatively/RB mediating/VBG and/CC protecting/VBG against/IN apoptosis/NN in/IN a/DT variety/NN of/IN cell/NN types/NNS ./. 
However/RB ,/, a/DT role/NN for/IN NF-kappaB/NN in/IN human/JJ CD34(+)/JJ bone/NN marrow/NN cells/NNS has/VBZ not/RB been/VBN described/VBN ./. 
We/PRP provide/VBP evidence/NN here/RB that/IN virtually/RB all/DT human/JJ CD34(+)/JJ bone/NN marrow/NN cells/NNS express/VBP NF-kappaB/NN that/WDT can/MD be/VB activated/VBN by/IN exposure/NN to/TO phorbol/NN 12-myristate/NN 13-acetate/NN and/CC a/DT variety/NN of/IN cytokines/NNS ,/, eg/FW ,/, tumor/NN necrosis/NN factor/NN alpha/NN ,/, interleukin-3/NN ,/, and/CC granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN ./. 
In/IN addition/NN ,/, we/PRP demonstrate/VBP that/IN NF-kappaB/NN may/MD be/VB required/VBN for/IN human/JJ CD34(+)/JJ bone/NN marrow/NN cell/NN clonogenic/JJ function/NN and/CC survival/NN ./. 
These/DT results/NNS offer/VBP insight/NN into/IN a/DT new/JJ role/NN for/IN NF-kappaB/NN in/IN maintaining/VBG survival/NN and/CC function/NN in/IN hematopoietic/JJ stem/NN and/CC progenitor/NN cells/NNS and/CC suggest/VBP that/IN proposed/JJ strategies/NNS involving/VBG inhibition/NN of/IN NF-kappaB/NN activation/NN as/IN an/DT adjunct/NN to/TO cancer/NN chemotherapy/NN should/MD be/VB approached/VBN with/IN caution/NN ./. 
UI/LS -/: 99244281/CD 
TI/LS -/: High/JJ molecular/JJ weight/NN dextran/NN sulfate/NN increases/VBZ the/DT activity/NN of/IN NF-kappaB-regulated/JJ promoter/NN in/IN monocyte-derived/JJ macrophages/NNS ./. 
AB/LS -/: It/PRP is/VBZ known/VBN that/IN sulfated/JJ polysaccharides/NNS can/MD mimic/VB the/DT action/NN of/IN common/JJ T-cell/NN mitogens/NNS ./. 
To/TO investigate/VB the/DT molecular/JJ basis/NN of/IN the/DT mitogenic/JJ effect/NN of/IN high/JJ molecular/JJ weight/NN dextran/NN sulfate/NN (/( HMDS/NN )/) ,/, monocyte-derived/JJ macrophages/NNS were/VBD transfected/VBN with/IN recombinant/JJ plasmid/NN containing/VBG chloramphenicol/NN acetyl/NN transferase/NN (/( CAT/NN )/) reporter/NN gene/NN under/IN the/DT control/NN of/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) promoter/NN ,/, which/WDT is/VBZ regulated/VBN by/IN transcription/NN factor/NN NF-kappaB/NN ./. 
We/PRP observed/VBD that/IN HMDS/NN ,/, similar/JJ to/TO bacterial/JJ lipopolysaccharide/NN (/( LPS/NN )/) ,/, increases/VBZ the/DT expression/NN of/IN CAT/NN reporter/NN gene/NN suggesting/VBG increased/VBN activity/NN of/IN NF-kappaB/NN ./. 
The/DT activation/NN of/IN NF-kappaB/NN correlated/VBD with/IN the/DT increased/VBN expression/NN of/IN B7.1/NN molecules/NNS ./. 
It/PRP was/VBD postulated/VBN that/IN this/DT NF-kappaB-regulated/JJ promoter/NN might/MD play/VB a/DT role/NN in/IN the/DT activation/NN of/IN the/DT accessory/NN cells/NNS as/RB well/RB as/IN the/DT rate/NN of/IN replication/NN of/IN HIV-1/NN in/IN monocyte-derived/JJ macrophages/NNS ./. 
UI/LS -/: 99240799/CD 
TI/LS -/: Transcription/NN factors/NNS Sp1/NN and/CC AP-2/NN mediate/VBP induction/NN of/IN acid/NN sphingomyelinase/NN during/IN monocytic/JJ differentiation/NN ./. 
AB/LS -/: Cells/NNS from/IN the/DT human/JJ monocytic/JJ leukemia/NN cell/NN line/NN THP-1/NN differentiate/VBP towards/IN a/DT macrophage-like/JJ phenotype/NN when/WRB stimulated/VBN with/IN phorbol/NN 12-myristate -13- acetate/NN (/( PMA/NN )/) ,/, 1,25-dihydroxy-vitamin/NN D3/NN ,/, and/CC various/JJ other/JJ agents/NNS ./. 
We/PRP demonstrate/VBP here/RB that/IN the/DT expression/NN of/IN the/DT lysosomal/JJ enzyme/NN acid/NN sphingomyelinase/NN (/( ASM/NN ;/: E.C.3.1.4.12/NN )/) is/VBZ induced/VBN during/IN this/DT process/NN and/CC is/VBZ strongly/RB elevated/JJ in/IN differentiated/VBN THP-1/NN cells/NNS ,/, as/RB well/RB as/IN in/IN differentiated/VBN human/JJ mononuclear/JJ phagocytes/NNS ./. 
Using/VBG Northern/NN blotting/NN ,/, RNase/NN protection/NN assay/NN ,/, and/CC nuclear/JJ run-on/JJ analyses/NNS ,/, we/PRP show/VBP that/IN the/DT up-regulation/NN of/IN ASM/NN expression/NN is/VBZ regulated/VBN mainly/RB at/IN the/DT level/NN of/IN transcription/NN and/CC that/IN new/JJ protein/NN synthesis/NN is/VBZ required/VBN for/IN enhanced/VBN ASM/NN activity/NN ./. 
This/DT cell-type/JJ specific/JJ induction/NN by/IN PMA/NN treatment/NN was/VBD further/RB investigated/VBN with/IN respect/NN to/TO transcriptional/JJ control/NN ./. 
A/DT series/NN of/IN 5'/JJ deletion/NN derivatives/NNS of/IN the/DT upstream/JJ regulatory/JJ region/NN were/VBD used/VBN in/IN transient/JJ transfection/NN assays/NNS to/TO identify/VB promoter/NN elements/NNS required/VBN for/IN basal/JJ and/CC inducible/JJ gene/NN expression/NN ./. 
A/DT PMA/NN responsive/JJ element/NN was/VBD localized/JJ to/TO a/DT region/NN between/IN -319/CD and/CC -219/CD bp/NN upstream/RB of/IN the/DT initiation/NN codon/NN and/CC co-transfections/NNS with/IN transcription/NN factor/NN expression/NN plasmids/NNS for/IN AP-2/NN and/CC Sp1/NN resulted/VBD in/IN augmented/JJ ASM/NN promoter/NN activity/NN ,/, which/WDT was/VBD abolished/VBN when/WRB the/DT binding/VBG sites/NNS for/IN these/DT two/CD factors/NNS were/VBD deleted/VBN ./. 
Using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS and/CC supershift/NN assays/NNS we/PRP demonstrate/VBP that/IN this/DT region/NN is/VBZ specifically/RB bound/VBN by/IN Sp1/NN and/CC AP-2/NN ./. 
These/DT factors/NNS are/VBP present/JJ in/IN nuclear/JJ extracts/NNS prepared/VBN from/IN both/CC induced/VBN and/CC uninduced/JJ THP-1/NN cells/NNS ./. 
However/RB ,/, the/DT intensity/NN of/IN the/DT complex/NN formed/VBN appeared/VBD to/TO increase/VB when/WRB nuclear/JJ extracts/NNS from/IN PMA-treated/JJ cells/NNS were/VBD used/VBN ./. 
From/IN these/DT studies/NNS ,/, we/PRP conclude/VBP that/IN a/DT concerted/JJ action/NN of/IN the/DT transcription/NN factors/NNS AP-2/NN and/CC Sp1/NN is/VBZ essential/JJ for/IN the/DT up -regulation/NN of/IN ASM/NN expression/NN during/IN the/DT process/NN of/IN macrophage/NN differentiation/NN ./. 
UI/LS -/: 99228708/CD 
TI/LS -/: LPS-Induced/JJ NF-kappaB/NN activation/NN and/CC TNF-alpha/NN release/NN in/IN human/JJ monocytes/NNS are/VBP protein/NN tyrosine/NN kinase/NN dependent/JJ and/CC protein/NN kinase/NN C/NN independent/JJ ./. 
AB/LS -/: BACKGROUND/NN :/: Tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) is/VBZ an/DT important/JJ mediator/NN of/IN septic/JJ shock/NN ./. 
Endotoxin/NN (/( LPS/NN )/) signal/NN transduction/NN in/IN human/JJ monocytes/NNS leads/VBZ to/TO activation/NN of/IN nuclear/JJ factor-kappa/NN B/NN (/( NF-kappaB/NN )/) and/CC TNF-alpha/NN release/NN ./. 
Previous/JJ studies/NNS have/VBP implicated/VBN activation/NN of/IN both/CC protein/NN kinase/NN C/NN (/( PKC/NN )/) and/CC protein/NN tyrosine/NN kinases/NNS (/( PTK/NN )/) in/IN LPS-induced/JJ NF-kappaB/NN activation/NN and/CC TNF-alpha/NN production/NN ./. 
We/PRP hypothesized/VBD that/IN inhibition/NN of/IN either/CC PKC/NN or/CC PTK/NN would/MD decrease/VB LPS-induced/JJ NF-kappaB/NN DNA/NN binding/NN and/CC TNF-alpha/NN release/NN in/IN human/JJ monocytes/NNS ./. 
MATERIALS/NNS AND/CC METHODS/NNS :/: Human/JJ monocytes/NNS were/VBD stimulated/VBN with/IN PMA/NN (/( 50/CD ng/ml/NN )/) alone/RB or/CC LPS/NN (/( 100/CD ng/ml/NN )/) with/IN and/CC without/IN a/DT nonspecific/JJ serine/threonine/NN protein/NN kinase/NN inhibitor/NN staurosporine/NN (/( Stauro/NN )/) ,/, a/DT specific/JJ pan-PKC/NN inhibitor/NN bisindolylmaleimide/NN (/( Bis/NN )/) ,/, or/CC an/DT inhibitor/NN of/IN PTK/NN genistein/NN (/( Gen/NN )/) ./. 
TNF-alpha/NN release/NN in/IN culture/NN supernatants/NNS was/VBD measured/VBN by/IN an/DT ELISA/NN ./. 
NF-kappaB/NN DNA/NN binding/NN was/VBD evaluated/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
RESULTS/NNS :/: LPS/NN increased/VBD NF-kappaB/NN DNA/NN binding/NN and/CC TNF-alpha/NN release/NN in/IN human/JJ monocytes/NNS ./. 
Nonspecific/JJ protein/NN kinase/NN inhibition/NN inhibited/VBD NF-kappaB/NN activation/NN and/CC TNF-alpha/NN release/NN ,/, while/IN specific/JJ PKC/NN inhibition/NN with/IN Bis/NN had/VBD no/DT effect/NN on/IN LPS-induced/JJ NF-kappaB/NN DNA/NN binding/NN or/CC TNF-alpha/NN release/NN ./. 
PTK/NN inhibition/NN with/IN Gen/NN attenuated/VBD both/CC LPS-induced/JJ NF-kappaB/NN DNA/NN binding/NN and/CC TNF-alpha/NN production/NN in/IN human/JJ monocytes/NNS ./. 
Direct/JJ activation/NN of/IN PKC/NN with/IN PMA/NN induced/VBD both/CC NF-kappaB/NN activation/NN and/CC TNF-alpha/NN production/NN by/IN human/JJ monocytes/NNS ./. 
CONCLUSIONS/NNS :/: These/DT results/NNS suggest/VBP that/IN LPS-induced/JJ NF-kappaB/NN activation/NN and/CC TNF-alpha/NN release/NN in/IN human/JJ monocytes/NNS are/VBP independent/JJ of/IN PKC/NN activity/NN ./. 
Furthermore/RB ,/, our/PRP$ results/NNS provide/VBP evidence/NN that/IN PTK/NN plays/VBZ a/DT role/NN in/IN LPS-induced/JJ NF-kappaB/NN activation/NN and/CC TNF-alpha/NN release/NN in/IN human/JJ monocytes/NNS and/CC thus/RB could/MD be/VB a/DT potential/JJ therapeutic/JJ target/NN in/IN inflammatory/JJ states/NNS ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99221321/CD 
TI/LS -/: Amelioration/NN of/IN rat/NN cerulein/NN pancreatitis/NN by/IN guamerin-derived/JJ peptide/NN ,/, a/DT novel/JJ elastase/NN inhibitor/NN ./. 
AB/LS -/: Increased/VBN activity/NN of/IN various/JJ proteases/NNS is/VBZ observed/VBN in/IN both/CC human/JJ and/CC experimental/JJ pancreatitis/NN ;/: however/RB ,/, the/DT information/NN on/IN the/DT effects/NNS of/IN specific/JJ protease/NN inhibitors/NNS on/IN the/DT disease/NN is/VBZ limited/JJ ./. 
In/IN this/DT study/NN we/PRP show/VBP that/IN a/DT novel/JJ elastase/NN inhibitor/NN ,/, guamerin-derived/JJ synthetic/JJ peptide/NN (/( GDSP/NN )/) ,/, improves/VBZ the/DT parameters/NNS of/IN cerulein-induced/JJ acute/JJ pancreatitis/NN in/IN the/DT rat/NN ./. 
The/DT effects/NNS of/IN GDSP/NN on/IN pancreatic/JJ weight/NN ,/, serum/NN amylase/NN and/CC lipase/NN ,/, morphologic/JJ changes/NNS in/IN the/DT pancreas/NN ,/, neutrophil/NN infiltration/NN ,/, and/CC nuclear/JJ factor/NN KB/NN (/( NF-KB/NN )/) activation/NN were/VBD measured/VBN in/IN rats/NNS infused/VBN with/IN supramaximal/JJ dose/NN of/IN cerulein/NN (/( 5/CD (/( g/kg/h/NN )/) for/IN 6/CD h/NN ./. 
The/DT effects/NNS of/IN GDSP/NN were/VBD also/RB measured/VBN on/IN superoxide/NN formation/NN by/IN activated/VBN human/JJ neutrophils/NNS ./. 
The/DT effects/NNS of/IN GDSP/NN were/VBD compared/VBN with/IN those/DT of/IN another/DT elastase/NN inhibitor/NN ,/, elastatinal/JJ ./. 
GDSP/NN significantly/RB inhibited/VBD edema/NN formation/NN ,/, neutrophil/NN infiltration/NN ,/, acinar/JJ cell/NN damage/NN ,/, and/CC plasma/NN lipase/NN and/CC amylase/NN increases/NNS caused/VBN by/IN cerulein/NN ./. 
GDSP/NN also/RB completely/RB inhibited/VBD superoxide/NN formation/NN in/IN the/DT human/JJ neutrophils/NNS stimulated/VBN by/IN N-formyl-methionine-leucine-phenyl-alanine/NN (/( fMLP/NN )/) or/CC 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) ./. 
Elastatinal/NN had/VBD some/DT of/IN the/DT same/JJ effects/NNS as/IN GDSP/NN but/CC was/VBD less/JJR potent/JJ and/CC effective/JJ ./. 
These/DT results/NNS demonstrate/VBP a/DT beneficial/JJ effect/NN of/IN GDSP/NN ,/, a/DT novel/JJ specific/JJ elastase/NN inhibitor/NN ,/, on/IN the/DT development/NN of/IN rat/NN cerulein/NN pancreatitis/NN ./. 
UI/LS -/: 99218312/CD 
TI/LS -/: A/DT novel/JJ lipopolysaccharide-induced/JJ transcription/NN factor/NN regulating/VBG tumor/NN necrosis/NN factor/NN alpha/NN gene/NN expression/NN :/: molecular/JJ cloning/NN ,/, sequencing/NN ,/, characterization/NN ,/, and/CC chromosomal/JJ assignment/NN ./. 
AB/LS -/: Lipopolysaccharide/NN (/( LPS/NN )/) is/VBZ a/DT potent/JJ stimulator/NN of/IN monocytes/NNS and/CC macrophages/NNS ,/, causing/VBG secretion/NN of/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) and/CC other/JJ inflammatory/JJ mediators/NNS ./. 
Given/IN the/DT deleterious/JJ effects/NNS to/TO the/DT host/NN of/IN TNF-alpha/NN ,/, it/PRP has/VBZ been/VBN postulated/VBN that/IN TNF-alpha/NN gene/NN expression/NN must/MD be/VB tightly/RB regulated/VBN ./. 
The/DT nature/NN of/IN the/DT nuclear/JJ factor/NN (/( s/NNS )/) that/WDT control/VBP TNF-alpha/NN gene/NN transcription/NN in/IN humans/NNS remains/VBZ obscure/JJ ,/, although/IN NF-kappaB/NN has/VBZ been/VBN suggested/VBN ./. 
Our/PRP$ previous/JJ studies/NNS pertaining/VBG to/TO macrophage/NN response/NN to/TO LPS/NN identified/VBD a/DT novel/JJ DNA-binding/JJ domain/NN located/JJ from/IN -550/CD to/TO -487/CD in/IN the/DT human/JJ TNF-alpha/NN promoter/NN that/WDT contains/VBZ transcriptional/JJ activity/NN ,/, but/CC lacks/VBZ any/DT known/JJ NF-kappaB-binding/JJ sites/NNS ./. 
We/PRP have/VBP used/VBN this/DT DNA/NN fragment/NN to/TO isolate/VB and/CC purify/VB a/DT 60-kDa/JJ protein/NN binding/VBG to/TO this/DT fragment/NN and/CC obtained/VBN its/PRP$ amino-terminal/JJ sequence/NN ,/, which/WDT was/VBD used/VBN to/TO design/VB degenerate/JJ probes/NNS to/TO screen/VB a/DT cDNA/NN library/NN from/IN THP-1/NN cells/NNS ./. 
A/DT novel/JJ cDNA/NN clone/NN (/( 1.8/CD kb/NN )/) was/VBD isolated/VBN and/CC fully/RB sequenced/VBN ./. 
Characterization/NN of/IN this/DT cDNA/NN clone/NN revealed/VBD that/IN its/PRP$ induction/NN was/VBD dependent/JJ on/IN LPS/NN activation/NN of/IN THP-1/NN cells/NNS ;/: hence/RB ,/, the/DT name/NN LPS-induced/JJ TNF-alpha/NN factor/NN (/( LITAF/NN )/) ./. 
Inhibition/NN of/IN LITAF/NN mRNA/NN expression/NN in/IN THP-1/NN cells/NNS resulted/VBD in/IN a/DT reduction/NN of/IN TNF-alpha/NN transcripts/NNS ./. 
In/IN addition/NN ,/, high/JJ level/NN of/IN expression/NN of/IN LITAF/NN mRNA/NN was/VBD observed/VBN predominantly/RB in/IN the/DT placenta/NN ,/, peripheral/JJ blood/NN leukocytes/NNS ,/, lymph/NN nodes/NNS ,/, and/CC the/DT spleen/NN ./. 
Finally/RB ,/, chromosomal/JJ localization/NN using/VBG fluorescence/NN in/FW situ/FW hybridization/NN revealed/VBD that/IN LITAF/NN mapped/VBD to/TO chromosome/NN 16p12-16p13.3/NN ./. 
Together/RB ,/, these/DT findings/NNS suggest/VBP that/IN LITAF/NN plays/VBZ an/DT important/JJ role/NN in/IN the/DT activation/NN of/IN the/DT human/JJ TNF-alpha/NN gene/NN and/CC proposes/VBZ a/DT new/JJ mechanism/NN to/TO control/VB TNF-alpha/NN gene/NN expression/NN ./. 
UI/LS -/: 99206604/CD 
TI/LS -/: A/DT human/JJ IFNGR1/NN small/JJ deletion/NN hotspot/NN associated/VBN with/IN dominant/JJ susceptibility/NN to/TO mycobacterial/JJ infection/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: The/DT immunogenetic/JJ basis/NN of/IN severe/JJ infections/NNS caused/VBN by/IN bacille/FW Calmette-Guerin/FW vaccine/NN and/CC environmental/JJ mycobacteria/NNS in/IN humans/NNS remains/VBZ largely/RB unknown/JJ ./. 
We/PRP describe/VBP 18/CD patients/NNS from/IN several/JJ generations/NNS of/IN 12/CD unrelated/JJ families/NNS who/WP were/VBD heterozygous/JJ for/IN 1/CD to/TO 5/CD overlapping/VBG IFNGR1/NN frameshift/NN small/JJ deletions/NNS and/CC a/DT wild-type/JJ IFNGR1/NN allele/NN ./. 
There/EX were/VBD 12/CD independent/JJ mutation/NN events/NNS at/IN a/DT single/JJ mutation/NN site/NN ,/, defining/VBG a/DT small/JJ deletion/NN hotspot/NN ./. 
Neighbouring/VBG sequence/NN analysis/NN favours/VBZ a/DT small/JJ deletion/NN model/NN of/IN slipped/JJ mispairing/NN events/NNS during/IN replication/NN ./. 
The/DT mutant/JJ alleles/NNS encode/VBP cell-surface/JJ IFNgamma/NN receptors/NNS that/WDT lack/VBP the/DT intra-cytoplasmic/JJ domain/NN ,/, which/WDT ,/, through/IN a/DT combination/NN of/IN impaired/JJ recycling/NN ,/, abrogated/VBD signalling/NN and/CC normal/JJ binding/NN to/TO IFNgamma/NN exert/VBP a/DT dominant-negative/JJ effect/NN ./. 
We/PRP thus/RB report/VBP a/DT hotspot/NN for/IN human/JJ IFNGR1/NN small/JJ deletions/NNS that/IN confer/VBP dominant/JJ susceptibility/NN to/TO infections/NNS caused/VBN by/IN poorly/RB virulent/JJ mycobacteria/NNS ./. 
UI/LS -/: 99196242/CD 
TI/LS -/: Characterization/NN of/IN expression/NN of/IN the/DT gene/NN for/IN human/JJ pterin/NN carbinolamine/NN dehydratase/dimerization/NN cofactor/NN of/IN HNF1/NN ./. 
AB/LS -/: Pterin/NN carbinolamine/NN dehydratase/dimerization/NN cofactor/NN of/IN HNF1/NN (/( PCD/DCoH/NN )/) is/VBZ a/DT dual-function/JJ protein/NN ./. 
In/IN the/DT cytoplasm/NN it/PRP acts/VBZ as/IN a/DT dehydratase/NN in/IN the/DT regeneration/NN of/IN tetrahydrobiopterin/NN ,/, the/DT cofactor/NN for/IN aromatic/JJ amino/NN acid/NN hydroxylases/NNS ./. 
In/IN the/DT nucleus/NN ,/, it/PRP functions/VBZ as/IN a/DT dimerization/NN cofactor/NN of/IN HNF1/NN and/CC increases/VBZ the/DT transcriptional/JJ activity/NN of/IN HNF1/NN ./. 
To/TO deepen/VB our/PRP$ understanding/NN of/IN this/DT protein/NN ,/, we/PRP characterized/VBD its/PRP$ expression/NN in/IN human/JJ tissues/NNS and/CC cells/NNS ./. 
Human/JJ PCD/DCoH/NN was/VBD present/JJ predominantly/RB in/IN liver/NN and/CC kidney/NN ,/, with/IN significant/JJ amounts/NNS in/IN testis/NN and/CC ovary/NN ,/, trace/NN amounts/NNS in/IN lung/NN ,/, and/CC undetectable/JJ levels/NNS in/IN whole/JJ brain/NN ,/, heart/NN ,/, and/CC spleen/NN ./. 
It/PRP was/VBD expressed/VBN in/IN all/DT of/IN the/DT cells/NNS that/WDT were/VBD examined/VBN ./. 
Importantly/RB ,/, it/PRP was/VBD also/RB present/JJ in/IN the/DT nucleus/NN of/IN HeLa/NN cells/NNS ,/, which/WDT lack/VBP HNF1/NN ,/, and/CC in/IN the/DT cytoplasm/NN of/IN fibroblasts/NNS that/WDT have/VBP little/JJ or/CC no/DT tetrahydrobiopterin/NN ./. 
The/DT expression/NN of/IN human/JJ PCD/DCoH/NN in/IN the/DT liver/NN and/CC nonhepatic/JJ cells/NNS was/VBD compared/VBN at/IN both/CC the/DT mRNA/NN and/CC protein/NN levels/NNS ./. 
Although/IN the/DT mRNA/NN level/NN in/IN liver/NN was/VBD only/RB fourfold/RB higher/JJR than/IN that/DT in/IN keratinocytes/NNS and/CC fibroblasts/NNS ,/, the/DT hepatic/JJ PCD/DCoH/NN protein/NN level/NN was/VBD 20-fold/RB higher/JJR than/IN that/DT in/IN normal/JJ human/JJ epidermal/JJ keratinocytes/NNS and/CC dermal/JJ fibroblasts/NNS ./. 
Cloning/NN of/IN the/DT 5'/JJ and/CC 3'/JJ untranslated/JJ region/NN (/( UTR/NN )/) of/IN human/JJ keratinocyte/NN PCD/DCoH/NN revealed/VBD that/IN it/PRP has/VBZ 53/CD bp/NN more/JJR of/IN GC-rich/JJ 5'/JJ untranslated/JJ sequence/NN than/IN the/DT published/VBN liver/NN PCD/DCoH/NN ./. 
In/FW vitro/FW transcription/NN and/CC translation/NN analysis/NN showed/VBD that/IN the/DT longer/JJR 5'/JJ UTR/NN resulted/VBD in/IN about/RB a/DT 35/CD %/NN decrease/NN in/IN translation/NN efficiency/NN ./. 
These/DT data/NNS show/VBP that/IN human/JJ PCD/DCoH/NN is/VBZ not/RB only/RB present/JJ in/IN cells/NNS where/WRB tetrahydrobiopterin/NN is/VBZ synthesized/VBN or/CC HNF1/NN is/VBZ present/JJ but/CC is/VBZ a/DT widely/RB distributed/VBN protein/NN ./. 
Its/PRP$ differential/JJ expression/NN in/IN different/JJ tissues/NNS and/CC cells/NNS is/VBZ regulated/VBN not/RB only/RB at/IN the/DT transcriptional/JJ level/NN but/CC also/RB at/IN the/DT translational/JJ level/NN ./. 
UI/LS -/: 99190512/CD 
TI/LS -/: NF-kappaB/NN regulates/VBZ Fas/APO-1/CD95-/NN and/CC TCR-mediated/JJ apoptosis/NN of/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT maintenance/NN of/IN lymphocyte/NN homeostasis/NN by/IN apoptosis/NN is/VBZ a/DT critical/JJ regulatory/JJ mechanism/NN in/IN the/DT normal/JJ immune/JJ system/NN ./. 
The/DT transcription/NN factor/NN NF-kappaB/NN has/VBZ been/VBN shown/VBN to/TO play/VB a/DT role/NN in/IN protecting/VBG cells/NNS against/IN death/NN mediated/VBN by/IN TNF/NN We/PRP show/VBP here/RB that/IN NF-kappaB/NN also/RB has/VBZ a/DT role/NN in/IN regulating/VBG Fas/APO-1/CD95-mediated/JJ death/NN ,/, a/DT major/JJ pathway/NN of/IN peripheral/JJ T/NN cell/NN death/NN ./. 
Transfection/NN of/IN Jurkat/NN cells/NNS with/IN the/DT NF-kappaB/NN subunits/NNS p50/NN and/CC p65/NN confers/VBZ resistance/NN against/IN Fas-mediated/JJ apoptosis/NN ./. 
Reciprocally/RB ,/, inhibition/NN of/IN NF-kappaB/NN activation/NN by/IN a/DT soluble/JJ peptide/NN inhibitor/NN or/CC a/DT dominant/JJ form/NN of/IN the/DT NF-kappaB/NN inhibitor/NN ,/, IkappaB/NN ,/, makes/VBZ the/DT cells/NNS more/RBR susceptible/JJ to/TO Fas-mediated/JJ apoptosis/NN ./. 
Furthermore/RB ,/, inhibition/NN of/IN NF-kappaB/NN activation/NN by/IN a/DT soluble/JJ peptide/NN inhibitor/NN rendered/VBD a/DT T/NN cell/NN hybridoma/NN more/RBR susceptible/JJ to/TO TCR-mediated/JJ apoptosis/NN ./. 
Correspondingly/RB ,/, transfection/NN of/IN p50/NN and/CC p65/NN provided/VBD considerable/JJ protection/NN from/IN TCR-mediated/JJ apoptosis/NN ./. 
These/DT observations/NNS were/VBD corroborated/VBN by/IN studies/NNS on/IN Fas-mediated/JJ death/NN in/IN primary/JJ T/NN cells/NNS ./. 
Concanavalin/NN A-activated/JJ cycling/NN T/NN cell/NN blasts/NNS from/IN mice/NNS that/WDT are/VBP transgenic/JJ for/IN the/DT dominant/JJ IkappaB/NN molecule/NN have/VBP increased/VBN sensitivity/NN to/TO Fas-mediated/JJ apoptosis/NN ,/, associated/VBN with/IN a/DT down-regulation/NN of/IN NF-kappaB/NN complexes/NNS in/IN the/DT nucleus/NN ./. 
In/IN addition/NN ,/, blocking/VBG TNF/NN ,/, itself/PRP a/DT positive/JJ regulator/NN of/IN NF-kappaB/NN ,/, with/IN neutralizing/VBG antibodies/NNS renders/VBZ the/DT cells/NNS more/RBR susceptible/JJ to/TO anti-Fas-mediated/JJ apoptosis/NN ./. 
In/IN summary/NN ,/, our/PRP$ results/NNS provide/VBP compelling/JJ evidence/NN that/IN NF-kappaB/NN protects/VBZ against/IN Fas-mediated/JJ death/NN and/CC is/VBZ likely/JJ to/TO be/VB an/DT important/JJ regulator/NN of/IN T/NN cell/NN homeostasis/NN and/CC tolerance/NN ./. 
UI/LS -/: 99187612/CD 
TI/LS -/: T/NN helper/NN differentiation/NN proceeds/VBZ through/IN Stat1-dependent/JJ ,/, Stat4-dependent/JJ and/CC Stat4-independent/JJ phases/NNS ./. 
AB/LS -/: Much/JJ of/IN our/PRP$ focus/NN in/IN understanding/VBG Th1/Th2/NN development/NN has/VBZ been/VBN on/IN the/DT signals/NNS delivered/VBN by/IN IL-12/NN and/CC IL-4/NN as/IN final/JJ determinants/NNS of/IN terminal/JJ T/NN cell/NN differentiation/NN ./. 
Because/IN extinction/NN of/IN IL-12/NN signaling/NN in/IN early/JJ Th2/NN development/NN could/MD potentially/RB be/VB important/JJ in/IN imprinting/VBG a/DT more/RBR permanent/JJ Th2/NN phenotype/NN on/IN a/DT population/NN of/IN T/NN cells/NNS ,/, we/PRP have/VBP also/RB examined/VBN various/JJ parameters/NNS regulating/VBG the/DT IL-12/NN signaling/NN pathway/NN ./. 
Whereas/IN IL-4/NN appears/VBZ to/TO repress/VB functional/JJ IL-12/NN signaling/NN through/IN inhibition/NN of/IN IL-12R/NN beta/NN 2/CD expression/NN ,/, IFN-gamma/NN in/IN the/DT mouse/NN ,/, and/CC IFN-alpha/NN in/IN the/DT human/JJ appear/VBP to/TO induce/VB IL-12R/NN beta/NN 2/CD expression/NN and/CC promote/VBP IL-12/NN responsiveness/NN ./. 
We/PRP propose/VBP that/IN Th1/NN development/NN can/MD be/VB considered/VBN in/IN two/CD stages/NNS ,/, capacitance/NN and/CC development/NN ./. 
Capacitance/NN would/MD simply/RB involve/VB expression/NN of/IN IL-12R/NN beta/NN 1/CD and/CC beta/NN 2/CD subunits/NNS ,/, regulated/VBN by/IN TCR/NN ,/, IL-4/NN and/CC IFNs/NNS ./. 
The/DT second/JJ stage/NN ,/, development/NN ,/, we/PRP propose/VBP is/VBZ the/DT true/JJ IL-12/NN induced/JJ developmental/JJ stage/NN ,/, involving/VBG expression/NN of/IN Stat4/NN inducible/JJ proteins/NNS ./. 
In/IN the/DT human/JJ ,/, this/DT may/MD also/RB occur/VB via/IN IFN-alpha/NN ,/, which/WDT is/VBZ able/JJ to/TO activate/VB Stat4/NN ./. 
It/PRP is/VBZ perhaps/RB possible/JJ that/IN all/DT of/IN Stat4/NN actions/NNS on/IN Th1/NN development/NN may/MD be/VB exert/VBN directly/RB by/IN Stat4/NN at/IN the/DT IFN-gamma/NN gene/NN ,/, however/RB we/PRP suggest/VBP that/IN ,/, more/RBR likely/JJ ,/, Stat4/NN may/MD act/VB to/TO induce/VB Th1/NN development/NN through/IN the/DT induction/NN of/IN other/JJ non-cytokine/JJ genes/NNS ,/, whose/WP$ stable/JJ expression/NN maintains/VBZ the/DT transcriptional/JJ state/NN of/IN a/DT Th1/NN cell/NN ./. 
UI/LS -/: 99178629/CD 
TI/LS -/: Lineage-specific/JJ activation/NN of/IN STAT3/NN by/IN interferon-gamma/NN in/IN human/JJ neutrophils/NNS ./. 
AB/LS -/: Binding/NN of/IN interferon-gamma/NN (/( IFN-gamma/NN )/) to/TO its/PRP$ heterodimeric/JJ receptor/NN induces/VBZ activation/NN of/IN the/DT tyrosine/NN kinases/NNS JAK1/NN and/CC JAK2/NN followed/VBN by/IN tyrosine/NN phosphorylation/NN of/IN STAT1alpha/NN ./. 
Selective/JJ activation/NN of/IN STAT1alpha/NN at/IN the/DT IFN-gamma/NN receptor/NN is/VBZ achieved/VBN by/IN specific/JJ interaction/NN between/IN a/DT cytosolic/JJ tyrosine/NN motif/NN including/VBG Y440/NN in/IN the/DT IFN-gamma/NN receptor/NN alpha-chain/NN and/CC the/DT SH2/NN domain/NN of/IN STAT1alpha/NN ./. 
We/PRP demonstrate/VBP that/IN ,/, in/IN addition/NN to/TO STAT1alpha/NN ,/, STAT3/NN is/VBZ also/RB activated/VBN by/IN IFN-gamma/NN in/IN human/JJ neutrophils/NNS ./. 
The/DT activation/NN of/IN STAT3/NN was/VBD not/RB found/VBN in/IN human/JJ eosinophils/NNS ,/, monocytes/NNS ,/, and/CC HL-60/NN cells/NNS ,/, although/IN the/DT STAT3/NN protein/NN was/VBD expressed/VBN in/IN these/DT cells/NNS ./. 
The/DT cell/NN type-specific/JJ activation/NN of/IN STAT3/NN by/IN IFN-gamma/NN was/VBD also/RB observed/VBN in/IN neutrophils/NNS that/WDT are/VBP differentiated/VBN in/FW vitro/FW from/IN human/JJ CD34+/JJ hematopoietic/JJ stem/NN cells/NNS ./. 
These/DT results/NNS indicate/VBP that/IN a/DT single/JJ cytokine/NN receptor/NN can/MD activate/VB different/JJ STAT/NN family/NN members/NNS in/IN a/DT cell-specific/JJ manner/NN ,/, which/WDT might/MD result/VB in/IN cell-specific/JJ gene/NN transcription/NN ./. 
UI/LS -/: 99170294/CD 
TI/LS -/: Alternative/JJ polyadenylation/NN events/NNS contribute/VBP to/TO the/DT induction/NN of/IN NF-ATc/NN in/IN effector/NN T/NN cells/NNS ./. 
AB/LS -/: The/DT transcription/NN factor/NN NF-ATc/NN is/VBZ synthesized/VBN in/IN three/CD prominent/JJ isoforms/NNS ./. 
These/DT differ/VBP in/IN the/DT length/NN of/IN their/PRP$ C/NN terminal/JJ peptides/NNS and/CC mode/NN of/IN synthesis/NN ./. 
Due/JJ to/TO a/DT switch/NN from/IN the/DT use/NN of/IN a/DT 3'/JJ polyA/NN site/NN to/TO a/DT more/RBR proximal/JJ polyA/NN site/NN ,/, NF-ATc/NN expression/NN switches/VBZ from/IN the/DT synthesis/NN of/IN the/DT two/CD longer/JJR isoforms/NNS in/IN naive/JJ T/NN cells/NNS to/TO that/DT of/IN short/JJ isoform/NN A/NN in/IN T/NN effector/NN cells/NNS ./. 
The/DT relative/JJ low/JJ binding/NN affinity/NN of/IN cleavage/NN stimulation/NN factor/NN CstF-64/NN to/TO the/DT proximal/JJ polyA/NN site/NN seems/VBZ to/TO contribute/VB to/TO its/PRP$ neglect/NN in/IN naive/JJ T/NN cells/NNS ./. 
These/DT alternative/JJ polyadenylation/NN events/NNS ensure/VBP the/DT rapid/JJ accumulation/NN of/IN high/JJ concentrations/NNS of/IN NF-ATc/NN necessary/JJ to/TO exceed/VB critical/JJ threshold/JJ levels/NNS of/IN NF-ATc/NN for/IN gene/NN induction/NN in/IN effector/NN T/NN cells/NNS ./. 
UI/LS -/: 99242545/CD 
TI/LS -/: Estrogen/NN and/CC progesterone/NN induction/NN of/IN survival/NN of/IN monoblastoid/JJ cells/NNS undergoing/VBG TNF-alpha-induced/JJ apoptosis/NN ./. 
AB/LS -/: Induction/NN of/IN apoptosis/NN of/IN mononucleated/JJ cells/NNS is/VBZ a/DT physiological/JJ process/NN for/IN regulating/VBG the/DT intensity/NN of/IN the/DT immune/JJ response/NN ./. 
The/DT female/JJ steroid/NN hormones/NNS estrogen/NN (/( E2/NN )/) and/CC progesterone/NN (/( Prog/NN )/) are/VBP known/VBN to/TO modulate/VB the/DT reactivity/NN of/IN the/DT immune/JJ system/NN ;/: recently/RB it/PRP has/VBZ been/VBN demonstrated/VBN that/IN they/PRP can/MD regulate/VB induction/NN of/IN apoptosis/NN of/IN endothelial/JJ cells/NNS and/CC osteoblasts/NNS ./. 
TNF-alpha-mediated/JJ induction/NN of/IN apoptosis/NN has/VBZ been/VBN well/RB characterized/VBN in/IN myeloid/JJ cells/NNS ./. 
We/PRP investigated/VBD whether/IN E2/NN and/CC Prog/NN could/MD interfere/VB with/IN TNF-alpha-induced/JJ apoptosis/NN of/IN the/DT monoblastoid/JJ U937/NN cell/NN line/NN ./. 
Treatment/NN with/IN E2/NN or/CC Prog/NN increased/VBD survival/NN and/CC prevented/VBD apoptosis/NN induced/VBN by/IN TNF-alpha/NN in/IN both/CC undifferentiated/JJ and/CC macrophage-like/JJ PMA-differentiated/JJ U937/NN cells/NNS ,/, as/IN assessed/VBN by/IN trypan/NN blue/JJ exclusion/NN cell/NN counting/NN ,/, thymidine/NN incorporation/NN ,/, AnnexinV/NN labeling/NN ,/, followed/VBN by/IN flow/NN cytometry/NN and/CC DNA/NN fragmentation/NN studies/NNS ./. 
This/DT effect/NN can/MD be/VB associated/VBN with/IN the/DT activation/NN of/IN specific/JJ hormone/NN receptors/NNS ,/, since/IN we/PRP observed/VBD the/DT expression/NN of/IN the/DT estrogen/NN receptor/NN alpha/NN (/( ER-alpha/NN )/) ,/, ER-beta/NN ,/, and/CC progesterone/NN receptor/NN (/( PR/NN )/) mRNAs/NNS ;/: the/DT ER-alpha/NN protein/NN expression/NN was/VBD confirmed/VBN by/IN immunocytochemical/JJ analysis/NN ./. 
In/IN addition/NN ,/, hormone-mediated/JJ survival/NN against/IN apoptosis/NN was/VBD concentration/NN dependent/JJ ,/, reaching/VBG the/DT half-maximal/JJ effect/NN at/IN 10/CD nM/NN and/CC blocked/VBN by/IN the/DT ER/NN antagonist/NN ICI/NN 182/CD ,/, 780/CD in/IN undifferentiated/JJ cells/NNS ,/, further/RB supporting/VBG a/DT receptor-mediated/JJ mechanism/NN of/IN cell/NN survival/NN ./. 
Other/JJ steroid/NN receptor/NN drugs/NNS such/JJ as/IN Raloxifene/NN ,/, RU486/NN ,/, or/CC the/DT ICI/NN 182/CD ,/, 780/CD in/IN PMA-differentiated/JJ cells/NNS displayed/VBD agonist/NN activity/NN by/IN preventing/VBG TNF-alpha-induced/JJ apoptosis/NN as/RB efficiently/RB as/IN the/DT hormones/NNS alone/RB ,/, providing/VBG further/JJ evidence/NN to/TO the/DT notion/NN that/IN steroid/NN receptor/NN drugs/NNS may/MD manifest/VB agonist/NN or/CC antagonist/NN activities/NNS depending/VBG on/IN the/DT cellular/JJ context/NN in/IN which/WDT they/PRP are/VBP studied/VBN ./. 
Treatment/NN with/IN E2/NN was/VBD also/RB associated/VBN with/IN a/DT time-dependent/JJ decrease/NN in/IN the/DT mRNA/NN level/NN of/IN the/DT proapoptotic/JJ Nip-2/NN protein/NN ,/, supporting/VBG the/DT hypothesis/NN that/IN hormone/NN responsiveness/NN of/IN U937/NN cells/NNS is/VBZ mediated/VBN by/IN target/NN gene/NN transcription/NN ./. 
Together/RB ,/, these/DT results/NNS demonstrate/VBP that/IN ER/NN and/CC PR/NN can/MD be/VB activated/VBN by/IN endogenous/JJ or/CC exogenous/JJ ligands/NNS to/TO induce/VB a/DT genetic/JJ response/NN that/WDT impairs/VBZ TNF-alpha-induced/JJ apoptosis/NN in/IN U937/NN cells/NNS ./. 
The/DT data/NNS presented/VBN here/RB suggest/VBP that/IN the/DT female/JJ steroid/NN receptors/NNS play/VBP a/DT role/NN in/IN regulation/NN of/IN the/DT immune/JJ response/NN by/IN preventing/VBG apoptosis/NN of/IN monoblastoid/JJ cells/NNS ;/: this/DT effect/NN might/MD have/VB important/JJ consequences/NNS in/IN the/DT clinical/JJ use/NN of/IN steroid/NN receptor/NN drugs/NNS ./. 
--/: Vegeto/NNP ,/, E./NNP ,/, Pollio/NNP ,/, G./NNP ,/, Pellicciari/NNP ,/, C./NNP ,/, Maggi/NNP ,/, A/NNP ./. 
Estrogen/NN and/CC progesterone/NN induction/NN of/IN survival/NN of/IN monoblastoid/JJ cells/NNS undergoing/VBG TNF-alpha-inuced/JJ apoptosis/NN ./. 
UI/LS -/: 99228859/CD 
TI/LS -/: Dicarba-closo-dodecaboranes/NNS as/IN a/DT pharmacophore/NN ./. 
Retinoidal/JJ antagonists/NNS and/CC potential/JJ agonists/NNS ./. 
AB/LS -/: Synthesis/NN and/CC biological/JJ evaluation/NN of/IN the/DT first/JJ dicarba-closo-dodecaborane/NN (/( carborane/NN )/) derivatives/NNS of/IN retinoids/NNS are/VBP described/VBN ./. 
Their/PRP$ retinoidal/JJ activity/NN were/VBD examined/VBN in/IN terms/NNS of/IN the/DT differentiation-inducing/JJ ability/NN toward/IN human/JJ promyelocytic/JJ leukemia/NN HL-60/NN cells/NNS ./. 
High/JJ retinoidal/JJ activity/NN (/( agonist/NN or/CC antagonist/NN for/IN retinoic/JJ acid/NN receptor/NN (/( RAR/NN )/) requires/VBZ a/DT carboxylic/JJ acid/NN moiety/NN and/CC an/DT appropriate/JJ hydrophobic/JJ group/NN located/JJ at/IN a/DT suitable/JJ position/NN on/IN the/DT molecule/NN ./. 
The/DT 4-carboranyl-substituted/JJ compounds/NNS (7, 11)/NN showed/VBD antagonistic/JJ activity/NN but/CC no/DT agonistic/JJ activity/NN even/RB in/IN the/DT presence/NN of/IN the/DT potent/JJ synergist/NN HX630/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, the/DT 3-carboranyl-substituted/JJ compounds/NNS (8, 12)/NN showed/VBD potential/JJ agonistic/JJ activity/NN ,/, but/CC no/DT antagonistic/JJ activity/NN ./. 
The/DT results/NNS indicates/VBZ that/IN carboranes/NNS are/VBP applicable/JJ as/IN the/DT hydrophobic/JJ moiety/NN of/IN biologically/RB active/JJ molecules/NNS ./. 
UI/LS -/: 99223488/CD 
TI/LS -/: Inhibition/NN of/IN T/NN cell/NN signaling/NN by/IN mitogen-activated/JJ protein/NN kinase-targeted/JJ hematopoietic/JJ tyrosine/NN phosphatase/NN (/( HePTP/NN )/) ./. 
AB/LS -/: Activation/NN of/IN T/NN lymphocytes/NNS to/TO produce/VB cytokines/NNS is/VBZ regulated/VBN by/IN the/DT counterbalance/NN of/IN protein-tyrosine/JJ kinases/NNS and/CC protein-tyrosine/JJ phosphatases/NNS ,/, many/JJ of/IN which/WDT have/VBP a/DT high/JJ degree/NN of/IN substrate/JJ specificity/NN because/IN of/IN physical/JJ association/NN with/IN their/PRP$ targets/NNS ./. 
Overexpression/NN of/IN hematopoietic/JJ protein-tyrosine/JJ phosphatase/NN (/( HePTP/NN )/) results/VBZ in/IN suppression/NN of/IN T/NN lymphocyte/NN activation/NN as/IN measured/VBN by/IN T/NN cell/NN antigen/NN receptor-induced/JJ activation/NN of/IN transcription/NN factors/NNS binding/VBG to/TO the/DT 5'/JJ promoter/NN of/IN the/DT interleukin-2/NN gene/NN ./. 
Efforts/NNS to/TO pinpoint/VB the/DT exact/JJ site/NN of/IN action/NN and/CC specificity/NN of/IN HePTP/NN in/IN the/DT signaling/NN cascade/NN revealed/VBD that/IN HePTP/NN acts/VBZ directly/RB on/IN the/DT mitogen-activated/JJ protein/NN (/( MAP/NN )/) kinases/NNS Erk1/NN and/CC 2/CD and/CC consequently/RB reduces/VBZ the/DT magnitude/NN and/CC duration/NN of/IN their/PRP$ catalytic/JJ activation/NN in/IN intact/JJ T/NN cells/NNS ./. 
In/IN contrast/NN ,/, HePTP/NN had/VBD no/DT effects/NNS on/IN N-terminal/JJ c-Jun/NN kinase/NN or/CC on/IN events/NNS upstream/RB of/IN the/DT MAP/NN kinases/NNS ./. 
The/DT specificity/NN of/IN HePTP/NN correlated/VBD with/IN its/PRP$ physical/JJ association/NN through/IN its/PRP$ noncatalytic/JJ N/NN terminus/NN with/IN Erk/NN and/CC another/DT MAP/NN kinase/NN ,/, p38/NN ,/, but/CC not/RB Jnk/NN or/CC other/JJ proteins/NNS ./. 
We/PRP propose/VBP that/IN HePTP/NN plays/VBZ a/DT negative/JJ role/NN in/IN antigen/NN receptor/NN signaling/NN by/IN specifically/RB regulating/VBG MAP/NN kinases/NNS in/IN the/DT cytosol/NN and/CC at/IN early/JJ time/NN points/NNS of/IN T/NN cell/NN activation/NN before/IN the/DT activation-induced/JJ expression/NN of/IN nuclear/JJ dual-specific/JJ MAP/NN kinase/NN phosphatases/NNS ./. 
UI/LS -/: 99218397/CD 
TI/LS -/: p38/NN mitogen-activated/JJ protein/NN kinase/NN mediates/VBZ signal/NN integration/NN of/IN TCR/CD28/NN costimulation/NN in/IN primary/JJ murine/JJ T/NN cells/NNS ./. 
AB/LS -/: Optimal/JJ T/NN cell/NN activation/NN requires/VBZ two/CD signals/NNS ,/, one/CD generated/VBN by/IN TCR/NN and/CC another/DT by/IN the/DT CD28/NN costimulatory/JJ receptor/NN ./. 
In/IN this/DT study/NN ,/, we/PRP investigated/VBD the/DT regulation/NN of/IN costimulation-induced/JJ mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) activation/NN in/IN primary/JJ mouse/NN T/NN cells/NNS ./. 
In/IN contrast/NN to/TO that/DT reported/VBN for/IN human/JJ Jurkat/NN T/NN cells/NNS ,/, we/PRP found/VBD that/IN p38/NN MAPK/NN ,/, but/CC not/RB Jun/NN NH2-terminal/JJ kinase/NN (/( JNK/NN )/) ,/, is/VBZ weakly/RB activated/VBN upon/IN stimulation/NN with/IN either/CC anti-CD3/NN or/CC anti-CD28/NN in/IN murine/JJ thymocytes/NNS and/CC splenic/JJ T/NN cells/NNS ./. 
However/RB ,/, p38/NN MAPK/NN is/VBZ activated/VBN strongly/RB and/CC synergistically/RB by/IN either/CC CD3/CD28/NN coligation/NN or/CC PMA/Ca2+/NN ionophore/NN stimulation/NN ,/, which/WDT mimics/VBZ TCR-CD3/CD28-mediated/JJ signaling/NN ./. 
Activation/NN of/IN p38/NN MAPK/NN correlates/VBZ closely/RB with/IN the/DT stimulation/NN of/IN T/NN cell/NN proliferation/NN ./. 
In/IN contrast/NN ,/, PMA-induced/NN JNK/NN activation/NN is/VBZ inhibited/VBN by/IN Ca2+/NN ionophore/NN ./. 
T/NN cell/NN proliferation/NN and/CC production/NN of/IN IL-2/NN ,/, IL-4/NN ,/, and/CC IFN-gamma/NN induced/VBN by/IN both/CC CD3/NN and/CC CD3/CD28/NN ligation/NN and/CC the/DT nuclear/JJ expression/NN of/IN the/DT c-Jun/NN and/CC ATF-2/NN proteins/NNS are/VBP each/DT blocked/VBN by/IN the/DT p38/NN MAPK/NN inhibitor/NN SB203580/NN ./. 
Our/PRP$ findings/NNS demonstrate/VBP that/IN p38/NN MAPK/NN 1/LS )/) plays/VBZ an/DT important/JJ role/NN in/IN signal/NN integration/NN during/IN costimulation/NN of/IN primary/JJ mouse/NN T/NN cells/NNS ,/, 2/LS )/) may/MD be/VB involved/VBN in/IN the/DT induction/NN of/IN c-Jun/NN activation/NN and/CC augmentation/NN of/IN AP-1/NN transcriptional/JJ activity/NN ,/, and/CC 3/LS )/) regulates/VBZ whether/IN T/NN cells/NNS enter/VBP a/DT state/NN of/IN functional/JJ unresponsiveness/NN ./. 
UI/LS -/: 99206664/CD 
TI/LS -/: Erythroid/JJ gene/NN expression/NN is/VBZ differentially/RB regulated/VBN by/IN erythropoietin/NN ,/, haemin/NN and/CC delta-aminolaevulinic/JJ acid/NN in/IN UT-7/NN cells/NNS ./. 
AB/LS -/: Erythropoietin/NN (/( Epo/NN )/) is/VBZ essential/JJ for/IN the/DT later/JJR stages/NNS of/IN erythropoiesis/NN ,/, acting/VBG to/TO promote/VB cell/NN survival/NN and/CC proliferation/NN ,/, but/CC its/PRP$ role/NN in/IN differentiation/NN remains/VBZ to/TO be/VB defined/VBN ./. 
The/DT UT-7/NN cell/NN line/NN exhibits/VBZ both/CC erythroid/JJ and/CC megakaryocytic/JJ characteristics/NNS and/CC can/MD be/VB induced/VBN to/TO differentiate/VB along/IN the/DT erythroid/JJ pathway/NN by/IN Epo/NN or/CC the/DT megakaryocytic/JJ pathway/NN by/IN phorbol/NN myristic/JJ acetate/NN ./. 
We/PRP have/VBP compared/VBN the/DT effects/NNS of/IN Epo/NN and/CC the/DT chemical/JJ inducers/NNS ,/, delta-aminolaevulinic/JJ acid/NN (/( delta-ALA/NN )/) and/CC haemin/NN on/IN the/DT differentiation/NN capacity/NN of/IN UT-7/NN cells/NNS ./. 
Epo/NN alone/RB promoted/VBD relatively/RB early/JJ events/NNS in/IN erythroid/JJ maturation/NN ,/, without/IN significant/JJ changes/NNS in/IN haemoglobin/NN production/NN or/CC morphology/NN ./. 
GATA-2/NN and/CC c-myb/NN were/VBD down-regulated/VBN by/IN Epo/NN ,/, and/CC GATA-2/NN was/VBD further/RB down-modulated/VBN by/IN the/DT inducers/NNS ./. 
Conversely/RB ,/, SCL/NN expression/NN was/VBD up-regulated/VBN by/IN Epo/NN and/CC further/RB increased/VBN by/IN haemin/NN and/CC delta-ALA/NN ./. 
Epo/NN caused/VBD an/DT increase/NN in/IN the/DT proportion/NN of/IN cells/NNS expressing/VBG cell/NN surface/NN glycophorin/NN A/NN (/( GPA/NN )/) and/CC up-regulated/VBD beta-/NN and/CC gamma-globin/NN by/IN several/JJ fold/NN ./. 
Both/CC haemin/NN and/CC delta-ALA/NN caused/VBD a/DT de/FW novo/FW increase/NN in/IN alpha-globin/NN expression/NN as/RB well/RB as/IN enhancing/VBG Epo-induced/JJ beta-globin/NN expression/NN ,/, leading/VBG to/TO a/DT marked/JJ increase/NN in/IN haemoglobin/NN production/NN ./. 
These/DT results/NNS suggest/VBP that/IN haemoglobin/NN production/NN in/IN UT-7/NN cells/NNS is/VBZ limited/VBN by/IN a/DT deficiency/NN of/IN erythroid-specific/JJ aminolaevulinic/JJ acid/NN synthase/NN (/( ALAS-E/NN )/) activity/NN or/CC globin/NN synthesis/NN as/IN a/DT consequence/NN of/IN their/PRP$ immaturity/NN as/IN a/DT multipotential/JJ cell/NN line/NN ./. 
UI/LS -/: 99201425/CD 
TI/LS -/: Essential/JJ role/NN of/IN alveolar/JJ macrophages/NNS in/IN intrapulmonary/JJ activation/NN of/IN NF-kappaB/NN ./. 
AB/LS -/: Acute/JJ inflammatory/JJ injury/NN in/IN rat/NN lung/NN induced/VBN by/IN deposition/NN of/IN immunoglobulin/NN G/NN immune/JJ complexes/NNS requires/VBZ expression/NN of/IN cytokines/NNS and/CC chemokines/NNS as/RB well/RB as/IN activation/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor/NN (/( NF/NN )/) -kappaB/NN ./. 
There/EX is/VBZ little/JJ direct/JJ evidence/NN regarding/VBG the/DT role/NN of/IN alveolar/JJ macrophages/NNS in/IN these/DT activation/NN events/NNS ./. 
In/IN the/DT present/JJ studies/NNS ,/, rat/NN lungs/NNS were/VBD depleted/VBN of/IN alveolar/JJ macrophages/NNS by/IN airway/NN instillation/NN of/IN liposome-encapsulated/JJ dichloromethylene/NN diphosphonate/NN ./. 
These/DT procedures/NNS ,/, which/WDT greatly/RB reduced/VBD the/DT number/NN of/IN retrievable/JJ alveolar/JJ macrophages/NNS ,/, suppressed/VBD activation/NN of/IN lung/NN NF-kappaB/NN in/IN the/DT inflammatory/JJ model/NN ./. 
In/IN addition/NN ,/, bronchoalveolar/JJ lavage/NN levels/NNS of/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) and/CC the/DT CXC/NN chemokine/NN ,/, macrophage/NN inflammatory/JJ protein-2/NN ,/, were/VBD substantially/RB reduced/VBN ./. 
In/IN parallel/NN ,/, upregulation/NN of/IN the/DT lung/NN vascular/JJ adhesion/NN molecule/NN ,/, intercellular/JJ adhesion/NN molecule-1/NN ,/, was/VBD greatly/RB reduced/VBN by/IN intrapulmonary/JJ instillation/NN of/IN phosphonate-containing/JJ liposomes/NNS ./. 
Neutrophil/NN accumulation/NN and/CC development/NN of/IN lung/NN injury/NN were/VBD also/RB substantially/RB diminished/VBN ./. 
Lung/NN instillation/NN of/IN TNF-alpha/NN in/IN alveolar/JJ macrophage-depleted/JJ rats/NNS restored/VBD the/DT NF-kappaB/NN activation/NN response/NN in/IN whole/JJ lung/NN ./. 
These/DT data/NNS suggest/VBP that/IN ,/, in/IN this/DT inflammatory/JJ model/NN ,/, initial/JJ activation/NN of/IN NF-kappaB/NN occurs/VBZ in/IN alveolar/JJ macrophages/NNS and/CC the/DT ensuing/VBG production/NN of/IN TNF-alpha/NN may/MD propagate/VB NF-kappaB/NN activation/NN to/TO other/JJ cell/NN types/NNS in/IN the/DT lung/NN ./. 
UI/LS -/: 99190530/CD 
TI/LS -/: Interferon-beta/NN mediates/VBZ stromal/JJ cell/NN rescue/NN of/IN T/NN cells/NNS from/IN apoptosis/NN ./. 
AB/LS -/: The/DT resolution/NN of/IN immune/JJ responses/NNS is/VBZ characterized/VBN by/IN extensive/JJ apoptosis/NN of/IN activated/VBN T/NN cells/NNS ./. 
However/RB ,/, to/TO generate/VB and/CC maintain/VB immunological/JJ memory/NN ,/, some/DT antigen-specific/JJ T/NN cells/NNS must/MD survive/VB and/CC revert/VB to/TO a/DT resting/JJ G0/G1/NN state/NN ./. 
Cytokines/NNS that/WDT bind/VBP to/TO the/DT common/JJ gamma/NN chain/NN of/IN the/DT IL-2/NN receptor/NN promote/VBP the/DT survival/NN of/IN T/NN cell/NN blasts/NNS ,/, but/CC also/RB induce/VBP proliferation/NN ./. 
In/IN contrast/NN ,/, soluble/JJ factors/NNS secreted/VBN by/IN stromal/JJ cells/NNS induce/VBP Tcell/NN survival/NN in/IN a/DT resting/JJ G0/G1/NN state/NN ./. 
We/PRP now/RB report/VBP that/IN interferon-beta/NN is/VBZ the/DT principal/JJ mediator/NN of/IN stromal/JJ cell-mediated/JJ Tcell/NN rescue/NN from/IN apoptosis/NN ./. 
Interferon-alpha/NN and/CC -beta/NN promote/VBP the/DT reversion/NN of/IN blast/NN Tcells/NNS to/TO a/DT resting/VBG G0/G1/NN configuration/NN with/IN all/PDT the/DT characteristic/JJ features/NNS of/IN stromal/JJ cell/NN rescue/NN ;/: such/JJ as/IN high/JJ Bcl-XL/NN expression/NN and/CC low/JJ Bcl-2/NN ./. 
Type/NN I/CD interferons/NNS and/CC stromal/JJ cells/NNS stimulate/VBP apparently/RB identical/JJ signaling/NN pathways/NNS ,/, leading/VBG to/TO STAT-1/NN activation/NN ./. 
We/PRP also/RB show/VBP that/IN this/DT mechanism/NN may/MD play/VB a/DT fundamental/JJ role/NN in/IN the/DT persistence/NN of/IN T/NN cells/NNS at/IN sites/NNS of/IN chronic/JJ inflammation/NN ;/: suggesting/VBG that/IN chronic/JJ inflammation/NN is/VBZ an/DT aberrant/JJ consequence/NN of/IN immunological/JJ memory/NN ./. 
UI/LS -/: 99190650/CD 
TI/LS -/: Reduction/NN of/IN tumour/NN necrosis/NN factor/NN alpha/NN expression/NN and/CC signalling/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS from/IN patients/NNS with/IN thalassaemia/NN or/CC sickle/JJ cell/NN anaemia/NN upon/IN treatment/NN with/IN desferrioxamine/NN ./. 
AB/LS -/: Recent/JJ evidence/NN indicates/VBZ that/IN the/DT rate/NN of/IN progression/NN of/IN the/DT HIV-1/NN disease/NN is/VBZ significantly/RB reduced/VBN in/IN thalassaemia/NN major/JJ patients/NNS upon/IN treatment/NN with/IN high/JJ doses/NNS of/IN desferrioxamine/NN (/( DFX/NN )/) ./. 
The/DT authors/NNS have/VBP previously/RB demonstrated/VBN that/IN in/FW vitro/FW exposure/NN of/IN mononuclear/JJ cells/NNS to/TO DFX/NN decreases/VBZ the/DT bioavailability/NN of/IN tumour/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) which/WDT has/VBZ a/DT stimulatory/JJ effect/NN on/IN HIV-1/NN replication/NN ./. 
In/IN this/DT study/NN ,/, therefore/RB ,/, TNF-alpha/NN bioavailability/NN from/IN mononuclear/JJ cells/NNS isolated/VBN from/IN 10/CD patients/NNS with/IN thalassaemia/NN or/CC sickle/JJ cell/NN anaemia/NN given/VBN DFX/NN as/IN compared/VBN to/TO 10/CD untreated/JJ subjects/NNS has/VBZ been/VBN evaluated/VBN ./. 
Evidence/NN is/VBZ presented/VBN showing/VBG that/IN DFX/NN treatment/NN reduces/VBZ TNF-alpha/NN bioavailability/NN (/( P/NN </JJR 0.05/CD )/) by/IN inhibiting/VBG its/PRP$ steady/JJ state/NN (/( P/NN </JJR 0.05/CD )/) and/CC by/IN enhancing/VBG its/PRP$ inactivation/NN through/IN binding/NN to/TO soluble/JJ TNF-alpha/NN receptor/NN type/NN II/CD (/( P/NN </JJR 0.05/CD )/) ./. 
We/PRP also/RB show/VBP that/IN DFX/NN treatment/NN limits/VBZ the/DT in/FW vivo/FW activation/NN of/IN NF-kappaB/NN ,/, a/DT transcription/NN factor/NN involved/VBN in/IN both/CC TNF-alpha/NN gene/NN transcription/NN and/CC TNF-alpha/NN signalling/NN (/( P/NN </JJR 0.005/CD )/) ./. 
We/PRP conclude/VBP that/IN TNF-alpha/NN bioavailability/NN and/CC signalling/NN are/VBP impaired/JJ in/IN patients/NNS upon/IN DFX/NN treatment/NN ./. 
This/DT mechanism/NN may/MD contribute/VB to/TO delayed/VBN progression/NN of/IN the/DT HIV-1/NN infection/NN in/FW vivo/FW ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99182542/CD 
TI/LS -/: Involvement/NN of/IN NF-kappaB/NN p50/p65/NN heterodimer/NN in/IN activation/NN of/IN the/DT human/JJ pro-interleukin-1beta/JJ gene/NN at/IN two/CD subregions/NNS of/IN the/DT upstream/JJ enhancer/NN element/NN ./. 
AB/LS -/: A/DT region/NN between/IN -3134/CD and/CC -2729/CD bp/NN upstream/RB from/IN the/DT transcription/NN site/NN of/IN the/DT human/JJ pro-interleukin/NN 1beta/NN (/( proIL-1beta/NN )/) gene/NN was/VBD identified/VBN as/IN an/DT LPS-responsive/JJ enhancer/NN element/NN ./. 
In/IN this/DT study/NN ,/, the/DT influence/NN of/IN the/DT sequences/NNS located/JJ between/IN -3134/CD and/CC -2987/CD on/IN the/DT transcriptional/JJ activity/NN of/IN the/DT proIL-1beta/NN gene/NN in/IN LPS-stimulated/JJ Raw/NN 264.7/CD cells/NNS was/VBD examined/VBN in/IN detail/NN ./. 
The/DT results/NNS obtained/VBN by/IN transient/JJ transfection/NN of/IN fos -CAT/JJ constructs/NNS that/WDT contained/VBD serial/JJ 5'-deletion/JJ mutations/NNS showed/VBD that/IN the/DT region/NN between/IN -3134/CD and/CC -3059/CD appears/VBZ to/TO be/VB required/VBN for/IN the/DT induction/NN of/IN transcription/NN by/IN LPS/NN ./. 
Gel/NN shift/NN assay/NN studies/NNS with/IN synthetic/JJ oligonucleotides/NNS corresponding/VBG to/TO partial/JJ sequences/NNS of/IN the/DT latter/JJ region/NN and/CC nuclear/JJ extracts/NNS from/IN stimulated/VBN cells/NNS revealed/VBD specific/JJ protein/NN binding/NN sites/NNS between/IN -3110/CD and/CC -3090/CD and/CC between/IN -3079/CD and/CC -3059/CD ./. 
These/DT specific/JJ bindings/NNS were/VBD time/NN and/CC LPS/NN dose/NN dependent/JJ ./. 
The/DT results/NNS of/IN supershift/NN analysis/NN using/VBG specific/JJ antibodies/NNS against/IN transcription/NN factors/NNS suggested/VBD that/IN both/DT binding/VBG complexes/NNS contained/VBD the/DT NF-kappaB/NN components/NNS p50/NN and/CC p65/NN ,/, and/CC did/VBD not/RB contain/VB other/JJ NF-kappaB/NN proteins/NNS (/( p52/NN ,/, c-Rel/NN ,/, Rel/NN B/NN )/) ,/, AP-1/NN proteins/NNS (/( c-Fos/NN ,/, C-Jun/NN )/) ,/, CREB/NN or/CC C/EBPbeta/NN (/( NF-IL6/NN )/) ./. 
Mutation/NN of/IN either/DT of/IN the/DT putative/JJ NF-kappaB-binding/JJ sites/NNS in/IN the/DT enhancer/NN element/NN decreased/VBD the/DT LPS-stimulated/JJ transcriptional/JJ activity/NN ./. 
These/DT data/NNS indicated/VBD that/IN two/CD NF-kappaB-binding/JJ sites/NNS ,/, which/WDT are/VBP located/JJ between/IN -3134/CD and/CC -3059/CD ,/, are/VBP critical/JJ for/IN the/DT activation/NN of/IN proIL-1beta/NN gene/NN transcription/NN ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99172186/CD 
TI/LS -/: N-acetyl-L-cysteine/NN inhibits/VBZ primary/JJ human/JJ T/NN cell/NN responses/NNS at/IN the/DT dendritic/JJ cell/NN level/NN :/: association/NN with/IN NF-kappaB/NN inhibition/NN ./. 
AB/LS -/: N-acetyl-L-cysteine/NN (/( NAC/NN )/) is/VBZ an/DT antioxidant/JJ molecule/NN endowed/JJ with/IN immunomodulatory/JJ properties/NNS ./. 
To/TO investigate/VB the/DT effect/NN of/IN NAC/NN on/IN the/DT induction/NN phase/NN of/IN T/NN cell/NN responses/NNS ,/, we/PRP analyzed/VBD its/PRP$ action/NN on/IN human/JJ dendritic/JJ cells/NNS (/( DC/NN )/) derived/VBN from/IN adherent/JJ PBMC/NN cultured/VBN with/IN IL-4/NN and/CC granulocyte-macrophage/JJ CSF/NN ./. 
We/PRP first/RB found/VBD that/IN NAC/NN inhibited/VBD the/DT constitutive/JJ as/RB well/RB as/IN the/DT LPS-induced/JJ activity/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN ./. 
In/IN parallel/NN ,/, NAC/NN was/VBD shown/VBN to/TO down-regulate/VB the/DT production/NN of/IN cytokines/NNS by/IN DC/NN as/RB well/RB as/IN their/PRP$ surface/NN expression/NN of/IN HLA-DR/NN ,/, CD86/NN (/( B7-2/NN )/) ,/, and/CC CD40/NN molecules/NNS both/CC at/IN the/DT basal/JJ state/NN and/CC upon/IN LPS/NN activation/NN ./. 
NAC/NN also/RB inhibited/VBD DC/NN responses/NNS induced/VBN by/IN CD40/NN engagement/NN ./. 
The/DT inhibitory/JJ effects/NNS of/IN NAC/NN were/VBD not/RB due/JJ to/TO nonspecific/JJ toxicity/NN as/IN neither/CC the/DT viability/NN of/IN DC/NN nor/CC their/PRP$ mannose/NN receptor-mediated/JJ endocytosis/NN were/VBD modified/VBN by/IN NAC/NN ./. 
Finally/RB ,/, we/PRP found/VBD that/IN the/DT addition/NN of/IN NAC/NN to/TO MLR/NN between/IN naive/JJ T/NN cells/NNS and/CC allogeneic/JJ DC/NN resulted/VBD in/IN a/DT profound/JJ inhibition/NN of/IN alloreactive/JJ responses/NNS ,/, which/WDT could/MD be/VB attributed/VBN to/TO a/DT defect/NN of/IN DC/NN as/IN APC-independent/JJ T/NN cell/NN responses/NNS were/VBD not/RB inhibited/VBN by/IN NAC/NN ./. 
Altogether/RB ,/, our/PRP$ results/NNS suggest/VBP that/IN NAC/NN might/MD impair/VB the/DT generation/NN of/IN primary/JJ immune/JJ responses/NNS in/IN humans/NNS through/IN its/PRP$ inhibitory/JJ action/NN on/IN DC/NN ./. 
UI/LS -/: 99244916/CD 
TI/LS -/: Thrombin-induced/JJ p65/NN homodimer/NN binding/NN to/TO downstream/JJ NF-kappa/NN B/NN site/NN of/IN the/DT promoter/NN mediates/VBZ endothelial/JJ ICAM-1/NN expression/NN and/CC neutrophil/NN adhesion/NN ./. 
AB/LS -/: We/PRP investigated/VBD the/DT mechanisms/NNS by/IN which/WDT proinflammatory/JJ mediator/NN ,/, thrombin/NN ,/, released/VBN during/IN intravascular/JJ coagulation/NN and/CC tissue/NN injury/NN ,/, induces/VBZ ICAM-1/NN (/( CD54/NN )/) expression/NN in/IN endothelial/JJ cells/NNS ./. 
Stimulation/NN of/IN HUVEC/NN with/IN thrombin/NN resulted/VBD in/IN dose-/NN and/CC time-dependent/JJ increases/NNS in/IN ICAM-1/NN mRNA/NN and/CC cell/NN surface/NN expression/NN and/CC in/IN ICAM-1-dependent/JJ endothelial/JJ adhesivity/NN toward/IN polymorphonuclear/JJ leukocytes/NNS ./. 
Transient/JJ transfection/NN of/IN endothelial/JJ cells/NNS with/IN ICAM-1/NN promoter/NN luciferase/NN reporter/NN gene/NN (/( ICAM-1LUC/NN )/) constructs/NNS indicated/VBD that/IN deletion/NN of/IN upstream/JJ NF-kappa/NN B/NN site/NN (/( -533/CD bases/NNS from/IN translation/NN start/NN site/NN )/) had/VBD no/DT effect/NN on/IN thrombin/NN responsiveness/NN ,/, whereas/IN mutation/deletion/NN of/IN downstream/JJ NF-kappa/NN B/NN site/NN (/( -223/CD bases/NNS from/IN the/DT translation/NN start/NN site/NN )/) prevented/VBD the/DT activation/NN of/IN ICAM-1/NN promoter/NN ,/, indicating/VBG that/IN the/DT downstream/JJ NF-kappa/NN B/NN site/NN is/VBZ critical/JJ for/IN thrombin/NN inducibility/NN ./. 
NF-kappa/NN B-directed/JJ luciferase/NN activity/NN increased/VBD approximately/RB 3-fold/RB when/WRB cells/NNS transfected/VBN with/IN the/DT plasmid/NN pNF-kappa/NN BLUC/NN containing/VBG five/CD copies/NNS of/IN consensus/NN NF-kappa/NN B/NN site/NN linked/VBN to/TO a/DT minimal/JJ adenovirus/NN E1B/NN promoter-luciferase/JJ gene/NN were/VBD exposed/VBN to/TO thrombin/NN ,/, indicating/VBG that/IN activation/NN of/IN NF-kappa/NN B/NN was/VBD essential/JJ for/IN thrombin/NN response/NN ./. 
Gel/NN supershift/NN assays/NNS demonstrated/VBD that/IN thrombin/NN induced/VBD binding/NN of/IN NF-kappa/NN Bp65/NN (/( Rel/NN A/NN )/) to/TO downstream/JJ NF-kappa/NN B/NN site/NN of/IN the/DT ICAM-1/NN promoter/NN ./. 
Thrombin/NN receptor/NN activation/NN peptide/NN ,/, a/DT 14-amino-acid/JJ peptide/NN representing/VBG the/DT new/JJ NH2/NN terminus/NN of/IN proteolytically/RB activated/VBN receptor-1/NN ,/, mimicked/VBD thrombin/NN 's/POS action/NN in/IN inducing/VBG ICAM-1/NN expression/NN ./. 
These/DT data/NNS indicate/VBP that/IN thrombin/NN activates/VBZ endothelial/JJ ICAM-1/NN expression/NN and/CC polymorphonuclear/JJ leukocyte/NN adhesion/NN by/IN NF-kappa/NN Bp65/NN binding/VBG to/TO the/DT downstream/JJ NF-kappa/NN B/NN site/NN of/IN ICAM-1/NN promoter/NN after/IN proteolytically/RB activated/VBN receptor-1/JJ activation/NN ./. 
UI/LS -/: 99240762/CD 
TI/LS -/: Differential/JJ inhibition/NN of/IN Smad6/NN and/CC Smad7/NN on/IN bone/NN morphogenetic/JJ protein-/NN and/CC activin-mediated/JJ growth/NN arrest/NN and/CC apoptosis/NN in/IN B/NN cells/NNS ./. 
AB/LS -/: Smad6/NN and/CC Smad7/NN prevent/VBP ligand-induced/JJ activation/NN of/IN signal-transducing/JJ Smad/NN proteins/NNS in/IN the/DT transforming/VBG growth/NN factor-beta/NN family/NN ./. 
Here/RB we/PRP demonstrate/VBP that/IN both/CC Smad6/NN and/CC Smad7/NN are/VBP human/JJ bone/NN morphogenetic/JJ protein-2/NN (/( hBMP-2/NN )/) -inducible/JJ antagonists/NNS of/IN hBMP-2-induced/JJ growth/NN arrest/NN and/CC apoptosis/NN in/IN mouse/NN B/NN cell/NN hybridoma/NN HS-72/NN cells/NNS ./. 
Moreover/RB ,/, we/PRP confirmed/VBD that/IN the/DT ectopic/JJ expressions/NNS of/IN Smad6/NN and/CC Smad7/NN inhibited/VBD the/DT hBMP-2-induced/JJ Smad1/Smad5/NN phosphorylation/NN ./. 
We/PRP previously/RB reported/VBD that/IN Smad7/NN is/VBZ an/DT activin/NN A-inducible/JJ antagonist/NN of/IN activin/NN A-induced/JJ growth/NN arrest/NN and/CC apoptosis/NN in/IN HS-72/NN cells/NNS ./. 
Interestingly/RB ,/, although/IN mRNA/NN expression/NN of/IN Smad6/NN was/VBD induced/VBN by/IN activin/NN A/NN in/IN HS-72/NN cells/NNS ,/, Smad6/NN showed/VBD no/DT antagonistic/JJ effect/NN on/IN activin/NN A-induced/JJ growth/NN arrest/NN and/CC apoptosis/NN ./. 
Moreover/RB ,/, we/PRP found/VBD that/IN the/DT ectopic/JJ expression/NN of/IN Smad7/NN ,/, but/CC not/RB Smad6/NN ,/, inhibited/VBD the/DT activin/NN A-induced/JJ Smad2/NN phosphorylation/NN in/IN HS-72/NN cells/NNS ./. 
Thus/RB ,/, Smad6/NN and/CC Smad7/NN exhibit/VBP differential/JJ inhibitory/JJ effects/NNS in/IN bone/NN morphogenetic/JJ protein-2-/NN and/CC activin/NN A-mediated/JJ signaling/NN in/IN B/NN lineage/NN cells/NNS ./. 
UI/LS -/: 99225047/CD 
TI/LS -/: Retinoic/JJ acid/NN induces/VBZ apoptosis/NN of/IN human/JJ CD34+/JJ hematopoietic/JJ progenitor/NN cells/NNS :/: involvement/NN of/IN retinoic/JJ acid/NN receptors/NNS and/CC retinoid/NN X/NN receptors/NNS depends/VBZ on/IN lineage/NN commitment/NN of/IN the/DT hematopoietic/JJ progenitor/NN cells/NNS ./. 
AB/LS -/: Retinoids/NNS are/VBP bifunctional/JJ regulators/NNS of/IN growth/NN and/CC differentiation/NN of/IN hematopoietic/JJ cells/NNS ./. 
In/IN this/DT study/NN we/PRP explored/VBD the/DT effects/NNS of/IN retinoic/JJ acid/NN (/( RA/NN )/) on/IN apoptosis/NN of/IN human/JJ CD34+/JJ hematopoietic/JJ progenitor/NN cells/NNS isolated/VBN from/IN normal/JJ bone/NN marrow/NN ./. 
RA/NN (/( 100/CD nM/NN )/) induced/VBD an/DT increase/NN in/IN the/DT percentage/NN of/IN dead/JJ cells/NNS from/IN 24/CD %/NN to/TO 44/CD %/NN at/IN day/NN 6/CD (/( p/NN </JJR 0.05/CD ,/, n/NN =/JJ 6/CD )/) as/IN compared/VBN to/TO control/JJ cells/NNS cultured/VBN in/IN medium/NN alone/RB ./. 
The/DT effect/NN was/VBD dose/NN dependent/JJ and/CC appeared/VBD relatively/RB late/JJ ./. 
Significant/JJ differences/NNS were/VBD observed/VBN from/IN day/NN 4/CD onward/RB ./. 
Apoptosis/NN ,/, or/CC programmed/VBN cell/NN death/NN ,/, was/VBD demonstrated/VBN as/IN the/DT mode/NN of/IN cell/NN death/NN by/IN using/VBG the/DT TUNEL/NN assay/NN ,/, which/WDT detects/VBZ single/JJ strand/NN nicks/NNS in/IN DNA/NN ,/, or/CC by/IN the/DT Nicoletti/NN technique/NN demonstrating/VBG a/DT subdiploid/JJ population/NN by/IN DNA/NN staining/NN ./. 
RA/NN previously/RB was/VBD found/VBN to/TO inhibit/VB granulocyte/NN colony-stimulating/JJ factor/NN --/: and/CC not/RB granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN --/: stimulated/VBN proliferation/NN of/IN CD34+/JJ cells/NNS ./. 
However/RB ,/, we/PRP found/VBD that/IN RA/NN opposed/VBD anti-apoptotic/JJ effects/NNS of/IN G-CSF/NN and/CC GM-CSF/NN on/IN CD34+/JJ cells/NNS (/( G-CSF/NN :/: 8/CD %/NN dead/JJ cells/NNS at/IN day/NN 6/CD ;/: G-CSF/NN +/CC RA/NN :/: 20/CD %/NN ;/: GM-CSF/NN :/: 12/CD %/NN ;/: GM-CSF/NN +/CC RA/NN :/: 27/CD %/NN )/) ./. 
Moreover/RB ,/, RA/NN induced/VBD apoptosis/NN of/IN CD34+/JJ cells/NNS and/CC CD34+CD71+/JJ cells/NNS stimulated/VBN with/IN erythropoietin/NN ./. 
To/TO explore/VB the/DT receptor/NN signaling/NN pathways/NNS involved/VBN in/IN RA-induced/JJ apoptosis/NN ,/, we/PRP used/VBD selective/JJ ligands/NNS for/IN retinoic/JJ acid/NN receptors/NNS (/( RARs/NNS ;/: RO13-7410/NN )/) and/CC retinoid/NN X/NN receptors/NNS (/( RXRs/NNS ;/: RO/NN 25-6603/CD )/) ./. 
We/PRP found/VBD that/IN RARs/NNS were/VBD involved/VBN in/IN RA-mediated/JJ apoptosis/NN of/IN myeloid/JJ progenitor/NN cells/NNS ,/, whereas/IN RARs/NNS as/RB well/RB as/IN RXRs/NNS were/VBD involved/VBN in/IN RA-mediated/JJ apoptosis/NN of/IN erythroid/JJ progenitor/NN cells/NNS ./. 
UI/LS -/: 99221887/CD 
TI/LS -/: Suppressive/JJ effects/NNS of/IN anti-inflammatory/JJ agents/NNS on/IN human/JJ endothelial/JJ cell/NN activation/NN and/CC induction/NN of/IN heat/NN shock/NN proteins/NNS ./. 
AB/LS -/: BACKGROUND/NN :/: Studies/NNS from/IN our/PRP$ laboratory/NN have/VBP shown/VBN that/IN the/DT earliest/JJS stages/NNS of/IN atherosclerosis/NN may/MD be/VB mediated/VBN by/IN an/DT autoimmune/JJ reaction/NN against/IN heat/NN shock/NN protein/NN 60/CD (/( Hsp60/NN )/) ./. 
The/DT interactions/NNS of/IN Hsp60-specific/JJ T/NN cells/NNS with/IN arterial/JJ endothelial/JJ cells/NNS (/( EC/NN )/) require/VBP expression/NN of/IN both/CC Hsp60/NN and/CC certain/JJ adhesion/NN molecules/NNS shown/VBN to/TO be/VB induced/VBN simultaneously/RB in/IN EC/NN by/IN mechanical/JJ and/CC other/JJ types/NNS of/IN stress/NN ./. 
Recently/RB ,/, it/PRP was/VBD shown/VBN that/IN suppression/NN of/IN T/NN cell-mediated/JJ immune/JJ responses/NNS by/IN cyclosporin/NN A/NN (/( CyA/NN )/) enhanced/VBD atherosclerotic/JJ lesion/NN formation/NN in/IN mice/NNS ./. 
In/IN contrast/NN ,/, aspirin/NN was/VBD found/VBN to/TO lower/VB the/DT risk/NN of/IN myocardial/JJ infarction/NN in/IN men/NNS ./. 
These/DT conflicting/VBG observations/NNS may/MD be/VB due/JJ to/TO different/JJ effects/NNS of/IN anti-inflammatory/JJ agents/NNS on/IN adhesion/NN molecule/NN and/CC Hsp/NN expression/NN in/IN EC/NN ,/, respectively/RB ./. 
MATERIAL/NN AND/CC METHODS/NNS :/: In/IN the/DT present/JJ study/NN ,/, we/PRP analyzed/VBD the/DT effects/NNS of/IN CyA/NN ,/, aspirin/NN ,/, and/CC indomethacin/NN on/IN T/NN cell/NN proliferation/NN using/VBG a/DT proliferation/NN assay/NN ./. 
To/TO explore/VB the/DT expression/NN of/IN adhesion/NN molecules/NNS ,/, monocyte/NN chemoattractant/NN protein-1/NN (/( MCP-1/NN )/) ,/, and/CC Hsp60/NN in/IN human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS (/( HUVECs/NNS )/) ,/, Northern/NN blot/NN analyses/NNS were/VBD used/VBN ./. 
To/TO examine/VB the/DT activation/NN status/NN of/IN the/DT transcription/NN factors/NNS nuclear/JJ factor/NN kappaB/NN (/( NF-kappaB/NN )/) and/CC heat/NN shock/NN factor-1/NN (/( HSF-1/NN )/) ,/, electrophoretic/JJ mobility/NN shift/NN assays/NNS were/VBD performed/VBN ./. 
RESULTS/NNS :/: With/IN the/DT exception/NN of/IN indomethacin/NN ,/, the/DT used/VBN immunosuppressive/JJ and/CC anti-inflammatory/JJ agents/NNS significantly/RB inhibited/VBD T/NN cell/NN proliferation/NN in/IN response/NN to/TO influenza/NN virus/NN antigen/NN in/IN a/DT dose-dependent/JJ manner/NN ./. 
Interestingly/RB ,/, CyA/NN and/CC indomethacin/NN did/VBD not/RB suppress/VB tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) -induced/JJ adhesion/NN molecule/NN expression/NN on/IN HUVECs/NNS ,/, whereas/IN aspirin/NN had/VBD an/DT inhibitory/JJ effect/NN ./. 
These/DT observations/NNS correlated/VBD with/IN the/DT modulation/NN of/IN NF-kappaB/NN activity/NN in/IN EC/NN ./. 
All/DT agents/NNS tested/VBN induced/VBD expression/NN of/IN Hsp60/NN 6/CD hr/NN after/IN application/NN ./. 
In/IN addition/NN ,/, aspirin/NN and/CC indomethacin/NN ,/, but/CC not/RB CyA/NN ,/, induced/VBD Hsp70/NN expression/NN in/IN HUVECs/NNS that/WDT correlated/VBD with/IN induction/NN of/IN HSF-1/NN activity/NN ./. 
CONCLUSION/NN :/: Our/PRP$ results/NNS show/VBP that/IN the/DT tested/VBN agents/NNS (/( except/IN indomethacin/NN )/) are/VBP inhibitors/NNS of/IN the/DT T/NN cell-mediated/JJ immune/JJ response/NN ,/, as/IN expected/VBN ,/, that/IN aspirin/NN is/VBZ an/DT effective/JJ suppressor/NN of/IN adhesion/NN molecule/NN expression/NN ,/, and/CC that/IN all/DT three/CD agents/NNS can/MD induce/VB Hsp60/NN in/IN HUVECs/NNS ./. 
These/DT data/NNS provide/VBP the/DT molecular/JJ basis/NN for/IN the/DT notion/NN that/IN (/( 1/LS )/) part/NN of/IN the/DT anti-atherogenic/JJ effect/NN of/IN aspirin/NN may/MD be/VB due/JJ to/TO the/DT prevention/NN of/IN the/DT adhesion/NN of/IN sensitized/VBN T/NN cells/NNS to/TO stressed/JJ EC/NN ;/: (/( 2/LS )/) that/IN part/NN of/IN the/DT atherosclerosis-promoting/JJ effect/NN of/IN CyA/NN may/MD be/VB due/JJ to/TO its/PRP$ potential/NN as/IN an/DT inducer/NN of/IN Hsp60/NN expression/NN and/CC its/PRP$ inability/NN to/TO down-regulate/VB adhesion/NN molecule/NN expression/NN on/IN EC/NN ;/: and/CC (/( 3/LS )/) that/IN down-regulation/NN of/IN MCP-1/NN expression/NN by/IN aspirin/NN may/MD result/VB in/IN decreased/VBN recruitment/NN of/IN monocytes/NNS into/IN the/DT arterial/JJ intima/NN beneath/IN stressed/JJ EC/NN ./. 
UI/LS -/: 99216457/CD 
TI/LS -/: In/FW vivo/FW modulation/NN of/IN glucocorticoid/NN receptor/NN mRNA/NN by/IN inhaled/VBN fluticasone/NN propionate/NN in/IN bronchial/JJ mucosa/NN and/CC blood/NN lymphocytes/NNS in/IN subjects/NNS with/IN mild/JJ asthma/NN ./. 
AB/LS -/: BACKGROUND/NN :/: In/FW vivo/FW regulation/NN of/IN the/DT glucocorticoid/NN receptor/NN (/( GR/NN )/) by/IN glucocorticoids/NNS provides/VBZ a/DT means/NN of/IN modulating/VBG sensitivity/NN of/IN targeted/VBN cells/NNS ./. 
OBJECTIVE/NN :/: We/PRP sought/VBD to/TO determine/VB the/DT in/FW vivo/FW modulation/NN of/IN GR/NN mRNA/NN expression/NN by/IN fluticasone/NN propionate/NN (/( FP/NN )/) in/IN subjects/NNS with/IN mild/JJ asthma/NN ./. 
METHODS/NNS :/: Ten/CD atopic/JJ asthmatic/JJ subjects/NNS were/VBD treated/VBN with/IN FP/NN 250/CD microg/NN twice/RB daily/RB for/IN 4/CD weeks/NNS ./. 
Before/IN and/CC after/IN treatment/NN ,/, the/DT patients/NNS underwent/VBD fiberoptic/JJ bronchoscopy/NN with/IN endobronchial/JJ biopsy/NN and/CC sampling/NN of/IN venous/JJ blood/NN for/IN measurements/NNS of/IN GR/NN mRNA/NN levels/NNS ./. 
A/DT solution/NN hybridization/NN assay/NN was/VBD used/VBN for/IN quantitative/JJ analysis/NN of/IN GR/NN mRNA/NN ./. 
In/IN addition/NN ,/, a/DT 24-hour/JJ urinary/JJ cortisol/NN excretion/NN and/CC an/DT adrenocorticotropic/JJ hormone/NN test/NN before/IN and/CC after/IN treatment/NN with/IN FP/NN were/VBD performed/VBN ./. 
RESULTS/NNS :/: A/DT high/JJ interindividual/JJ variation/NN in/IN GR/NN mRNA/NN expression/NN was/VBD seen/VBN ./. 
However/RB ,/, we/PRP detected/VBD a/DT significant/JJ reduction/NN of/IN the/DT GR/NN mRNA/NN levels/NNS in/IN the/DT endobronchial/JJ biopsy/NN specimens/NNS after/IN FP/NN treatment/NN (/( 36.6/CD +/-/CC 23.1/CD and/CC 25.0/CD +/-/CC 10.9/CD amol/NN GR/NN mRNA/microg/NN RNA/NN ,/, respectively/RB ;/: P/NN </JJR .01/CD )/) ./. 
In/IN the/DT peripheral/JJ blood/NN lymphocytes/NNS an/DT even/RB more/RBR striking/JJ downregulation/NN of/IN the/DT GR/NN by/IN its/PRP$ cognate/JJ ligand/NN was/VBD documented/VBN (/( 30.3/CD +/-/CC 26.5/CD and/CC 8.8/CD +/-/CC 5/CD amol/NN GR/NN mRNA/microg/NN RNA/NN ,/, respectively/RB ;/: P/NN </JJR .001/CD )/) ,/, possibly/RB reflecting/VBG differences/NNS in/IN glucocorticoid/NN sensitivity/NN between/IN tissues/NNS ./. 
A/DT small/JJ but/CC significant/JJ reduction/NN of/IN the/DT 24-hour/JJ urinary/JJ cortisol/NN excretion/NN was/VBD observed/VBN (/( 233/CD +/-/CC 109/CD and/CC 157/CD +/-/CC 66/CD nmol/L/NN ,/, respectively/RB ;/: P/NN </JJR .01/CD )/) ,/, whereas/IN the/DT feedback/NN regulation/NN of/IN glucocorticoid/NN synthesis/NN by/IN means/NNS of/IN the/DT hypothalamic-pituitary-adrenal/JJ axis/NN as/IN assessed/VBN by/IN the/DT adrenocorticotropic/JJ hormone/NN test/NN remained/VBD normal/JJ after/IN treatment/NN with/IN FP/NN ./. 
CONCLUSION/NN :/: The/DT results/NNS in/IN this/DT study/NN confirm/VBP the/DT potency/NN of/IN the/DT inhaled/VBN corticosteroid/NN FP/NN and/CC provide/VBP evidence/NN for/IN a/DT considerable/JJ tissue-specific/JJ interindividual/JJ variation/NN in/IN the/DT expression/NN of/IN the/DT GR/NN ./. 
UI/LS -/: 99207658/CD 
TI/LS -/: [/( Corticoids/NNS and/CC allergy/NN ]/) 
AB/LS -/: Inflammation/NN is/VBZ constantly/RB observed/VBN in/IN allergic/JJ reactions/NNS ./. 
Corticosteroids/NNS are/VBP most/RBS effective/JJ in/IN preventing/VBG the/DT late/JJ phase/NN of/IN allergic/JJ reaction/NN ./. 
The/DT action/NN of/IN glucocorticosteroids/NNS is/VBZ mediated/VBN through/IN glucocorticoid/NN receptors/NNS present/JJ in/IN the/DT cellular/JJ cytoplasm/NN ./. 
When/WRB activated/VBN ,/, glucocorticoid/NN receptors/NNS form/VBP a/DT dimer/NN and/CC bind/VBP to/TO DNA/NN after/IN migration/NN into/IN the/DT nucleus/NN ./. 
Interaction/NN to/TO DNA/NN induces/VBZ changes/NNS in/IN the/DT transcription/NN rate/NN ,/, leading/VBG to/TO either/CC gene/NN induction/NN or/CC gene/NN repression/NN ./. 
Glucocorticoid/NN receptors/NNS are/VBP also/RB able/JJ to/TO interact/VB with/IN transcriptional/JJ factors/NNS such/JJ as/IN AP-1/NN (/( activator/NN protein-1/NN )/) of/IN NF-kappa/NN B/NN (/( nuclear/JJ factor-kappa/NN B/NN )/) ./. 
Through/IN these/DT actions/NNS glucocorticosteroids/NNS are/VBP susceptible/JJ to/TO modify/VB functions/NNS of/IN cells/NNS involved/VBN in/IN the/DT allergic/JJ inflammatory/JJ response/NN ./. 
They/PRP are/VBP in/IN particular/JJ able/JJ to/TO inhibit/VB most/JJS of/IN the/DT pro-inflammatory/JJ functions/NNS of/IN the/DT eosinophils/NNS ./. 
UI/LS -/: 99197861/CD 
TI/LS -/: Jeg-3/NN human/JJ choriocarcinoma-induced/JJ immunosuppression/NN :/: downregulation/NN of/IN interleukin-2/NN ,/, interleukin-2/NN receptor/NN alpha-chain/NN ,/, and/CC its/PRP$ Jak/Stat/NN signaling/NN pathway/NN ./. 
AB/LS -/: PROBLEM/NN :/: The/DT mechanisms/NNS of/IN the/DT immunosuppressive/JJ and/CC immunosuppression-inducing/JJ capacities/NNS of/IN Jeg-3/NN human/JJ choriocarcinoma/NN cell/NN line/NN supernatants/NNS (/( HCSs/NNS )/) are/VBP not/RB yet/RB completely/RB understood/VBN ./. 
The/DT influence/NN on/IN interleukin/NN (/( IL/NN )/) -2/CD ,/, IL-4/NN and/CC interferon/NN (/( IFN/NN )/) -gamma/NN production/NN ;/: IL-2/NN receptor/NN (/( IL-2R/NN )/) alpha-/NN ,/, beta-/NN ,/, and/CC gamma-chain/NN ;/: and/CC the/DT signaling/NN pathway/NN molecules/NNS Janus/NN kinase/NN (/( Jak/NN )/) 1/CD ,/, Jak3/NN ,/, signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( Stat/NN )/) 1/CD ,/, Stat3/NN ,/, and/CC Stat5/NN should/MD be/VB investigated/VBN ./. 
METHOD/NN OF/IN STUDY/NN :/: For/IN assessment/NN of/IN IL/NN production/NN ,/, whole/JJ peripheral/JJ venous/JJ blood/NN from/IN healthy/JJ donors/NNS was/VBD stimulated/VBN with/IN phorbol-myristate-acetate/NN and/CC ionomycine/NN ./. 
Secretion/NN of/IN ILs/NNS was/VBD blocked/VBN with/IN monensine/NN ./. 
Intracellular/JJ ILs/NNS were/VBD analyzed/VBN by/IN flow/NN cytometry/NN ./. 
For/IN IL-2R/NN and/CC signaling/NN pathway/NN molecule/NN analysis/NN ,/, peripheral/JJ blood/NN lymphocytes/NNS were/VBD stimulated/VBN with/IN phytohemagglutinin/NN (/( PHA/NN )/) ./. 
IL-2R/NN chains/NNS were/VBD measured/VBN by/IN flow/NN cytometry/NN ,/, and/CC Jaks/Stats/NN by/IN sodium/NN dodecyl/NN sulfate/NN polyacrylamide/NN gel/NN electrophoresis/NN (/( SDS-PAGE/NN )/) and/CC Western/NN blot/NN ./. 
RESULTS/NNS :/: Phorbol-myristate-acetate/NN and/CC ionomycine/NN strongly/RB increase/VBP the/DT percent-age/NN of/IN IL-2+/JJ cells/NNS ;/: an/DT additional/JJ 50/CD %/NN HCSs/NNS significantly/RB suppresses/VBZ the/DT percentage/NN to/TO ,/, or/CC below/IN the/DT level/NN of/IN unstimulated/JJ cells/NNS ./. 
IFN-gamma/NN production/NN is/VBZ strongly/RB decreased/VBN by/IN HCSs/NNS in/IN some/DT cases/NNS ,/, but/CC not/RB in/IN others/NNS ./. 
PHA/NN stimulates/VBZ IL-2R/NN alpha-/NN ,/, beta-/NN ,/, and/CC gamma-chain/NN expression/NN and/CC their/PRP$ signaling/NN pathway/NN molecules/NNS Jak1/NN ,/, Jak3/NN ,/, Stat1/NN ,/, Stat3/NN ,/, and/CC Stat5/NN ./. 
50/CD %/NN HCS/NN downregulates/VBZ the/DT alpha-chain/NN and/CC slightly/RB upregulates/VBZ the/DT beta-chain/NN ./. 
Jak1/NN ,/, Jak3/NN ,/, Stat1/NN ,/, Stat3/NN ,/, and/CC Stat5/NN expression/NN is/VBZ suppressed/VBN approximately/RB to/TO ,/, or/CC below/IN the/DT level/NN of/IN unstimulated/JJ cells/NNS ./. 
CONCLUSIONS/NNS :/: HCS/NN forcefully/RB blocks/VBZ the/DT production/NN of/IN IL-2/NN ;/: the/DT IL-2R/NN alpha-chain/NN ;/: and/CC Jak1/NN ,/, Jak3/NN ,/, Stat1/NN ,/, Stat3/NN ,/, and/CC Stat5/NN expression/NN ./. 
The/DT observed/VBN phenomena/NNS might/MD be/VB caused/VBN by/IN downregulation/NN of/IN an/DT IL-2R/NN regulation/NN gene/NN ,/, and/CC might/MD play/VB a/DT key/JJ role/NN in/IN the/DT expansion/NN of/IN choriocarcinoma/NN ,/, and/CC possibly/RB in/IN the/DT survival/NN of/IN the/DT fetal/JJ allograft/NN ./. 
UI/LS -/: 99190497/CD 
TI/LS -/: Apoptosis-resistant/JJ T/NN cells/NNS have/VBP a/DT deficiency/NN in/IN NF-kappaB-mediated/JJ induction/NN of/IN Fas/NN ligand/NN transcription/NN ./. 
AB/LS -/: Apoptosis/NN induced/VBN through/IN the/DT TCR/NN in/IN CD4+/JJ T/NN cells/NNS is/VBZ mostly/RB mediated/VBN by/IN the/DT inducible/JJ expression/NN of/IN Fas/NN ligand/NN (/( FasL/NN )/) as/IN a/DT primary/JJ event/NN leading/VBG to/TO the/DT commitment/NN to/TO death/NN ./. 
To/TO gain/VB a/DT better/JJR understanding/NN of/IN the/DT transcriptional/JJ events/NNS that/WDT regulate/VBP this/DT expression/NN ,/, we/PRP took/VBD advantage/NN of/IN our/PRP$ previously/RB described/VBN mutant/JJ Jurkat/NN cells/NNS ./. 
These/DT cells/NNS are/VBP deficient/JJ in/IN FasL/NN expression/NN and/CC apoptosis/NN induced/VBN upon/IN TCR/NN triggering/NN ,/, although/IN their/PRP$ cytokine/NN (/( IL-2/NN and/CC IFN-gamma/NN )/) production/NN is/VBZ normal/JJ ./. 
Here/RB we/PRP show/VBP that/IN both/CC a/DT FasL-/NN and/CC a/DT consensus/NN NF-kappaB-reporter/NN construct/NN are/VBP inefficiently/RB induced/VBN in/IN these/DT cells/NNS compared/VBN to/TO wild-type/JJ cells/NNS ./. 
In/IN addition/NN ,/, we/PRP demonstrate/VBP that/IN the/DT inducible/JJ transcriptional/JJ activity/NN of/IN the/DT FasL/NN reporter/NN is/VBZ abolished/VBN by/IN specific/JJ inhibitors/NNS of/IN NF-kappaB/NN activation/NN ./. 
Thus/RB ,/, we/PRP could/MD trace/VB the/DT deficit/NN of/IN the/DT mutant/JJ cells/NNS to/TO an/DT inefficient/JJ NF-kappaB/NN activation/NN ,/, evidencing/VBG a/DT relevant/JJ role/NN for/IN NF-kappaB/NN in/IN the/DT regulation/NN of/IN FasL/NN expression/NN in/IN activated/VBN T/NN cells/NNS ./. 
Furthermore/RB ,/, our/PRP$ results/NNS suggest/VBP that/IN the/DT induction/NN of/IN FasL/NN versus/CC cytokine/NN gene/NN expression/NN is/VBZ differentially/RB sensitive/JJ to/TO NF-kappaB/NN deprivation/NN ./. 
UI/LS -/: 99189164/CD 
TI/LS -/: Decreased/VBN proteasome-mediated/JJ degradation/NN in/IN T/NN cells/NNS from/IN the/DT elderly/JJ :/: A/DT role/NN in/IN immune/JJ senescence/NN ./. 
AB/LS -/: Induction/NN of/IN NFkappaB/NN is/VBZ a/DT highly/RB regulated/VBN process/NN requiring/VBG phosphorylation/NN ,/, ubiquitination/NN ,/, and/CC proteasome-mediated/JJ degradation/NN of/IN the/DT cytosolic/JJ inhibitor/NN IkappaBalpha/NN ./. 
Analyses/NNS of/IN the/DT regulation/NN of/IN IkappaBalpha/NN in/IN TNF-alpha-treated/JJ T/NN lymphocytes/NNS from/IN young/JJ and/CC elderly/JJ donors/NNS revealed/VBD severely/RB compromised/VBN degradation/NN of/IN IkappaBalpha/NN in/IN T/NN cells/NNS from/IN the/DT elderly/JJ ./. 
Examination/NN of/IN activation-induced/JJ phosphorylation/NN and/CC ubiquitination/NN of/IN IkappaBalpha/NN did/VBD not/RB demonstrate/VB any/DT significant/JJ age-related/JJ alterations/NNS ./. 
However/RB ,/, examination/NN of/IN proteasome/NN activity/NN in/IN these/DT T/NN cells/NNS using/VBG fluorogenic/JJ peptide/NN assays/NNS revealed/VBD a/DT significant/JJ age-related/JJ decline/NN in/IN chymotryptic/JJ activity/NN ./. 
These/DT results/NNS suggest/VBP that/IN a/DT decline/NN in/IN proteasome/NN activity/NN results/VBZ in/IN a/DT failure/NN to/TO fully/RB degrade/VB IkappaBalpha/NN in/IN the/DT elderly/JJ ./. 
This/DT failure/NN to/TO degrade/VB IkappaBalpha/NN may/MD underlie/VB both/CC the/DT observed/VBN decrease/NN in/IN NFkappaB/NN induction/NN and/CC the/DT IL-2/NN receptor/NN expression/NN in/IN TNF-treated/JJ T/NN cells/NNS during/IN aging/NN ./. 
Thus/RB ,/, decreased/VBN proteasome-mediated/JJ degradation/NN may/MD be/VB central/JJ to/TO immune/JJ dysfunction/NN that/WDT accompanies/VBZ aging/NN ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99178617/CD 
TI/LS -/: Inhibition/NN of/IN IL-4-inducible/JJ gene/NN expression/NN in/IN human/JJ monocytes/NNS by/IN type/NN I/CD and/CC type/NN II/CD interferons/NNS ./. 
AB/LS -/: The/DT Th2-type/JJ cytokines/NNS ,/, interleukin-4/NN (/( IL-4/NN )/) and/CC interleukin-13/NN (/( IL-13/NN )/) ,/, induce/VBP expression/NN of/IN a/DT distinct/JJ subset/NN of/IN genes/NNS in/IN human/JJ monocytes/NNS ,/, including/VBG FcepsilonRIIb/NN (/( CD23/NN )/) ,/, 15-lipoxygenase/NN ,/, IL-1/NN receptor/NN antagonist/NN (/( IL-1ra/NN )/) ,/, and/CC type/NN I/CD and/CC type/NN II/CD IL-1/NN receptors/NNS (/( IL-1R/NN )/) ./. 
Type/NN I/CD interferons/NNS (/( IFN-alpha/NN and/CC IFN-beta/NN )/) and/CC type/NN II/CD interferon/NN (/( IFN-gamma/NN )/) inhibit/VBP induction/NN of/IN these/DT genes/NNS by/IN IL-4/NN and/CC IL-13/NN ./. 
However/RB ,/, the/DT mechanism/NN by/IN which/WDT IFNs/NNS mediate/VBP this/DT inhibition/NN has/VBZ not/RB been/VBN defined/VBN ./. 
In/IN this/DT overview/NN ,/, we/PRP discuss/VBP the/DT role/NN of/IN the/DT transcription/NN factor/NN ,/, STAT6/NN (/( signal/NN transducer/NN and/CC activator/NN of/IN transcription-6/NN )/) in/IN mediating/VBG IL-4-/NN and/CC IL-13-induced/JJ gene/NN expression/NN in/IN monocytes/NNS ./. 
We/PRP also/RB discuss/VB our/PRP$ recent/JJ findings/NNS that/IN type/NN I/CD and/CC type/NN II/CD IFNs/NNS suppress/VBP IL-4/IL-13-inducible/JJ gene/NN expression/NN by/IN inhibiting/VBG tyrosine/NN phosphorylation/NN and/CC nuclear/JJ translocation/NN of/IN STAT6/NN ./. 
The/DT ability/NN of/IN type/NN I/CD and/CC type/NN II/CD IFNs/NNS to/TO inhibit/VB IL-4/IL-13-induced/JJ STAT6/NN activity/NN is/VBZ dose-/NN and/CC time-dependent/JJ ,/, and/CC is/VBZ not/RB unique/JJ to/TO monocytes/NNS because/IN IFNs/NNS induce/VBP the/DT same/JJ effects/NNS in/IN fibroblasts/NNS ./. 
Inhibition/NN of/IN STAT6/NN activity/NN is/VBZ not/RB evident/JJ unless/IN cells/NNS are/VBP preincubated/VBN with/IN IFN/NN for/IN at/IN least/JJS 1/CD h/NN before/IN IL-4/NN stimulation/NN ./. 
Furthermore/RB ,/, inhibition/NN can/MD be/VB blocked/VBN by/IN actinomycin/NN D/NN ,/, indicating/VBG a/DT requirement/NN for/IN de/FW novo/FW transcription/NN ./. 
We/PRP propose/VBP a/DT model/NN in/IN which/WDT stimulation/NN of/IN monocytes/NNS by/IN IFN/NN activates/VBZ de/FW novo/FW synthesis/NN of/IN an/DT inhibitory/JJ factor/NN ,/, possibly/RB one/CD or/CC more/JJR members/NNS of/IN the/DT SOCS//NN SSI/CIS/NN gene/NN family/NN ,/, capable/JJ of/IN suppressing/VBG activation/NN of/IN STAT6/NN by/IN IL-4/NN and/CC IL-13/NN ./. 
Because/IN STAT6/NN activation/NN plays/VBZ an/DT essential/JJ role/NN in/IN IL-4/IL-13-induced/JJ gene/NN expression/NN ,/, the/DT ability/NN of/IN IFN-beta/NN and/CC IFN-gamma/NN to/TO inhibit/VB STAT6/NN activity/NN provides/VBZ an/DT explanation/NN for/IN how/WRB IFNs/NNS can/MD suppress/VB IL-4/IL-13-inducible/JJ gene/NN expression/NN ./. 
UI/LS -/: 99244901/CD 
TI/LS -/: HLA/NN class/NN I-mediated/JJ induction/NN of/IN cell/NN proliferation/NN involves/VBZ cyclin/NN E-mediated/JJ inactivation/NN of/IN Rb/NN function/NN and/CC induction/NN of/IN E2F/NN activity/NN ./. 
AB/LS -/: Chronic/JJ rejection/NN of/IN transplanted/VBN organs/NNS is/VBZ manifested/VBN as/IN atherosclerosis/NN of/IN the/DT blood/NN vessels/NNS of/IN the/DT allograft/NN ./. 
HLA/NN class/NN I/CD Ags/NNS have/VBP been/VBN implicated/VBN to/TO play/VB a/DT major/JJ role/NN in/IN this/DT process/NN ,/, since/IN signaling/VBG via/IN HLA/NN class/NN I/CD molecules/NNS can/MD induce/VB the/DT proliferation/NN of/IN aortic/JJ endothelial/NN as/RB well/RB as/IN smooth/JJ muscle/NN cells/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP show/VBP that/IN HLA/NN class/NN I-mediated/JJ induction/NN of/IN cell/NN proliferation/NN correlates/VBZ with/IN inactivation/NN of/IN the/DT Rb/NN protein/NN in/IN the/DT T/NN cell/NN line/NN Jurkat/NN as/RB well/RB as/IN human/JJ aortic/JJ endothelial/JJ cells/NNS ./. 
HLA/NN class/NN I-mediated/JJ inactivation/NN of/IN Rb/NN can/MD be/VB inhibited/VBN specifically/RB by/IN neutralizing/VBG Abs/NNS to/TO basic/JJ fibroblast/NN growth/NN factor/NN (/( bFGF/NN )/) ,/, suggesting/VBG a/DT role/NN for/IN FGF/NN receptors/NNS in/IN the/DT signaling/NN process/NN ./. 
Signaling/VBG through/IN HLA/NN class/NN I/CD molecules/NNS induced/VBD cyclin/NN E-associated/JJ kinase/NN activity/NN within/IN 4/CD h/NN in/IN quiescent/JJ endothelial/JJ cells/NNS ,/, and/CC appeared/VBD to/TO mediate/VB the/DT inactivation/NN of/IN Rb/NN ./. 
A/DT cdk2/NN inhibitor/NN ,/, Olomoucine/NN ,/, as/RB well/RB as/IN a/DT dominant-negative/JJ cdk2/NN construct/NN prevented/VBD HLA/NN class/NN I-mediated/JJ inactivation/NN of/IN Rb/NN ;/: in/IN contrast/NN ,/, dominant-negative/JJ cdk4/NN and/CC cdk6/NN constructs/NNS had/VBD no/DT effect/NN ./. 
Furthermore/RB ,/, there/EX was/VBD no/DT increase/NN in/IN cyclin/NN D-associated/JJ kinase/NN activity/NN upon/IN HLA/NN class/NN I/CD ligation/NN ,/, suggesting/VBG that/IN cyclin/NN E-dependent/JJ kinase/NN activity/NN mediates/VBZ Rb/NN inactivation/NN ,/, leading/VBG to/TO E2F/NN activation/NN and/CC cell/NN proliferation/NN ./. 
UI/LS -/: 99240736/CD 
TI/LS -/: Immunosuppressant/JJ PG490/NN (/( triptolide/NN )/) inhibits/VBZ T-cell/NN interleukin-2/NN expression/NN at/IN the/DT level/NN of/IN purine-box/nuclear/JJ factor/NN of/IN activated/VBN T-cells/NNS and/CC NF-kappaB/NN transcriptional/JJ activation/NN ./. 
AB/LS -/: PG490/NN (/( triptolide/NN )/) is/VBZ a/DT diterpene/JJ triepoxide/NN with/IN potent/JJ immunosuppressive/JJ and/CC antiinflammatory/JJ properties/NNS ./. 
PG490/NN inhibits/VBZ interleukin/NN (/( IL/NN )/) -2/CD expression/NN by/IN normal/JJ human/JJ peripheral/JJ blood/NN lymphocytes/NNS stimulated/VBN with/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) and/CC antibody/NN to/TO CD3/NN (/( IC50/NN of/IN 10/CD ng/ml/NN )/) ,/, and/CC with/IN PMA/NN and/CC ionomycin/NN (/( Iono/NN ,/, IC50/NN of/IN 40/CD ng/ml/NN )/) ./. 
In/IN Jurkat/NN T-cells/NNS ,/, PG490/NN inhibits/VBZ PMA/Iono-stimulated/JJ IL-2/NN transcription/NN ./. 
PG490/NN inhibits/VBZ the/DT induction/NN of/IN DNA/NN binding/NN activity/NN at/IN the/DT purine-box/antigen/NN receptor/NN response/NN element/NN (/( ARRE/NN )/) /nuclear/JJ factor/NN of/IN activated/VBN T-cells/NNS (/( NF-AT/NN )/) target/NN sequence/NN but/CC not/RB at/IN the/DT NF-kappaB/NN site/NN ./. 
PG490/NN can/MD completely/RB inhibit/VB transcriptional/JJ activation/NN at/IN the/DT purine-box/ARRE/NF-AT/NN and/CC NF-kappaB/NN target/NN DNA/NN sequences/NNS triggered/VBN by/IN all/DT stimuli/NNS examined/VBN (/( PMA/NN ,/, PMA/Iono/NN ,/, tumor/NN necrosis/NN factor-alpha/NN )/) ./. 
PG490/NN also/RB inhibits/VBZ PMA-stimulated/JJ activation/NN of/IN a/DT chimeric/JJ transcription/NN factor/NN in/IN which/WDT the/DT C-terminal/JJ TA1/NN transactivation/NN domain/NN of/IN NF-kappaB/NN p65/NN is/VBZ fused/VBN to/TO the/DT DNA/NN binding/NN domain/NN of/IN GAL4/NN ./. 
In/IN 16HBE/NN human/JJ bronchial/JJ epithelial/JJ cells/NNS ,/, IL-8/NN expression/NN is/VBZ regulated/VBN predominantly/RB by/IN NF-kappaB/NN ,/, and/CC PG490/NN but/CC not/RB cyclosporin/NN A/NN can/MD completely/RB inhibit/VB expression/NN of/IN IL-8/NN ./. 
The/DT mechanism/NN of/IN PG490/NN inhibition/NN of/IN cytokine/NN gene/NN expression/NN differs/VBZ from/IN cyclosporin/NN A/NN and/CC involves/VBZ nuclear/JJ inhibition/NN of/IN transcriptional/JJ activation/NN of/IN NF-kappaB/NN and/CC the/DT purine-box/JJ regulator/NN operating/VBG at/IN the/DT ARRE/NF-AT/NN site/NN at/IN a/DT step/NN after/IN specific/JJ DNA/NN binding/NN ./. 
UI/LS -/: 99225046/CD 
TI/LS -/: Unexpected/JJ and/CC coordinated/VBN expression/NN of/IN Spi-1/NN ,/, Fli-1/NN ,/, and/CC megakaryocytic/JJ genes/NNS in/IN four/CD Epo-dependent/JJ cell/NN lines/NNS established/VBN from/IN transgenic/JJ mice/NNS displaying/VBG erythroid-specific/JJ expression/NN of/IN a/DT thermosensitive/JJ SV40/NN T/NN antigen/NN ./. 
AB/LS -/: Most/JJS erythroleukemic/JJ cell/NN lines/NNS established/VBN in/FW vitro/FW coexpress/VBP erythrocytic/JJ and/CC megakaryocytic/JJ markers/NNS that/WDT often/RB are/VBP associated/VBN with/IN expression/NN of/IN Spi-1/NN and/or/CC Fli-1/NN transcription/NN factors/NNS known/VBN as/IN transactivators/NNS of/IN megakaryocyte-specific/JJ promoters/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP examined/VBD the/DT possibility/NN of/IN establishing/VBG new/JJ cell/NN lines/NNS keeping/VBG strictly/RB erythroid-specific/JJ properties/NNS in/FW vitro/FW through/IN the/DT targeted/VBN and/CC conditional/JJ immortalization/NN of/IN erythrocytic/JJ progenitors/NNS ./. 
For/IN that/DT purpose/NN ,/, we/PRP established/VBD several/JJ lines/NNS of/IN transgenic/JJ mice/NNS displaying/VBG erythroid-specific/JJ expression/NN of/IN a/DT thermosensitive/JJ SV40/NN T/NN antigen/NN ./. 
As/IN expected/VBN ,/, these/DT transgenic/JJ mice/NNS developed/VBD splenomegaly/NN due/JJ to/TO the/DT massive/JJ amplification/NN of/IN Ter/NN 119/CD positive/JJ erythroid/JJ nucleated/JJ cells/NNS expressing/VBG T/NN antigen/NN ./. 
Despite/IN this/DT drastic/JJ effect/NN in/FW vivo/FW ,/, the/DT in/FW vitro/FW immortalization/NN of/IN erythropoietin-dependent/JJ erythroid/JJ progenitors/NNS unexpectedly/RB occurred/VBD at/IN low/JJ frequency/NN ,/, and/CC all/DT four/CD cell/NN lines/NNS established/VBN expressed/VBD both/CC erythrocytic/JJ (/( globins/NNS )/) and/CC megakaryocytic/JJ markers/NNS (/( glycoprotein/NN IIb/NN ,/, platelet/NN factor/NN 4/CD )/) as/RB well/RB as/IN Spi-1/NN and/CC Fli-1/NN transcripts/NNS at/IN permissive/JJ temperature/NN ./. 
Switching/VBG the/DT cells/NNS to/TO the/DT nonpermissive/JJ temperature/NN led/VBD to/TO a/DT marked/JJ increase/NN in/IN globin/NN gene/NN expression/NN and/CC concomitant/JJ decrease/NN in/IN expression/NN of/IN Spi-1/NN ,/, Fli-1/NN ,/, and/CC megakaryocytic/JJ genes/NNS in/IN an/DT erythropoietin-dependent/JJ manner/NN ./. 
Interestingly/RB ,/, enhanced/VBN expression/NN of/IN Spi-1/NN and/CC Fli-1/NN genes/NNS already/RB was/VBD detected/VBN in/IN the/DT Ter/NN 119/CD positive/JJ cell/NN population/NN of/IN transgenic/JJ mice/NNS spleen/NN in/FW vivo/FW ./. 
However/RB ,/, like/IN normal/JJ Ter/NN 119/CD erythroid/JJ cells/NNS ,/, these/DT Ter/NN 119/CD positive/JJ cells/NNS from/IN transgenic/JJ mice/NNS still/RB expressed/VBD high/JJ levels/NNS of/IN beta-globin/NN and/CC very/RB low/JJ or/CC undetectable/JJ glycoprotein/NN IIb/NN and/CC platelet/NN factor/NN 4/CD megakaryocytic/JJ transcripts/NNS ./. 
Taken/VBN together/RB ,/, these/DT data/NNS indicate/VBP that/IN the/DT unexpected/JJ expression/NN of/IN megakaryocytic/JJ genes/NNS is/VBZ a/DT specific/JJ property/NN of/IN immortalized/VBN cells/NNS that/WDT can/MD not/RB be/VB explained/VBN only/RB by/IN enhanced/VBN expression/NN of/IN Spi-1/NN and/or/CC Fli-1/NN genes/NNS ./. 
UI/LS -/: 99217587/CD 
TI/LS -/: Fludarabine-induced/JJ immunosuppression/NN is/VBZ associated/VBN with/IN inhibition/NN of/IN STAT1/NN signaling/NN ./. 
AB/LS -/: Fludarabine/NN is/VBZ a/DT nucleoside/JJ analog/NN used/VBN in/IN the/DT treatment/NN of/IN hematologic/JJ malignancies/NNS that/WDT can/MD induce/VB severe/JJ and/CC prolonged/JJ immunosuppression/NN ./. 
Although/IN it/PRP can/MD be/VB incorporated/VBN into/IN the/DT DNA/NN of/IN dividing/VBG cells/NNS ,/, fludarabine/NN is/VBZ also/RB a/DT potent/JJ inhibitor/NN of/IN cells/NNS with/IN a/DT low/JJ growth/NN fraction/NN ,/, thus/RB it/PRP must/MD have/VB other/JJ mechanisms/NNS of/IN action/NN ./. 
STAT1/NN ,/, which/WDT is/VBZ activated/VBN in/IN response/NN to/TO many/JJ lymphocyte-activating/JJ cytokines/NNS including/VBG the/DT interferons/NNS ,/, is/VBZ essential/JJ for/IN cell-mediated/JJ immunity/NN ,/, as/IN the/DT absence/NN of/IN this/DT protein/NN is/VBZ associated/VBN with/IN prominent/JJ defects/NNS in/IN the/DT ability/NN to/TO control/VB viral/JJ infections/NNS ./. 
Here/RB we/PRP show/VBP that/IN fludarabine/NN ,/, but/CC not/RB the/DT immunosuppressant/JJ cyclosporine/NN A/NN ,/, inhibits/VBZ the/DT cytokine-induced/JJ activation/NN of/IN STAT1/NN and/CC STAT1-dependent/JJ gene/NN transcription/NN in/IN normal/JJ resting/VBG or/CC activated/VBN lymphocytes/NNS ./. 
Fludarabine/NN caused/VBD a/DT specific/JJ depletion/NN of/IN STAT1/NN protein/NN (/( and/CC mRNA/NN )/) but/CC not/RB of/IN other/JJ STATs/NNS ./. 
This/DT loss/NN of/IN STAT1/NN was/VBD also/RB seen/VBN in/IN cells/NNS from/IN patients/NNS treated/VBN with/IN fludarabine/NN in/FW vivo/FW ./. 
Brief/JJ exposure/NN to/TO fludarabine/NN led/VBD to/TO a/DT sustained/JJ loss/NN of/IN STAT1/NN ,/, analogous/JJ to/TO the/DT prolonged/JJ period/NN of/IN immunosuppression/NN induced/VBN by/IN exposure/NN to/TO the/DT drug/NN in/FW vivo/FW ./. 
Thus/RB ,/, STAT1/NN may/MD be/VB a/DT useful/JJ target/NN in/IN the/DT development/NN of/IN new/JJ immunosuppressive/JJ and/CC antineoplastic/JJ agents/NNS ./. 
UI/LS -/: 99211588/CD 
TI/LS -/: Studies/NNS into/IN the/DT effect/NN of/IN tyrosine/NN phosphatase/NN inhibitor/NN phenylarsine/NN oxide/NN on/IN NFkappaB/NN activation/NN in/IN T/NN lymphocytes/NNS during/IN aging/NN :/: evidence/NN for/IN altered/JJ IkappaB-alpha/NN phosphorylation/NN and/CC degradation/NN ./. 
AB/LS -/: Nuclear/JJ Factor/NN kappa/NN B/NN (/( NFkappaB/NN )/) is/VBZ a/DT critical/JJ regulator/NN of/IN several/JJ genes/NNS involved/VBN in/IN immune/JJ and/CC inflammatory/JJ responses/NNS ./. 
Treatment/NN of/IN T/NN cells/NNS with/IN a/DT variety/NN of/IN stimuli/NNS ,/, including/VBG TNF-alpha/NN ,/, leads/VBZ to/TO the/DT translocation/NN of/IN the/DT active/JJ p65-50/NN heterodimer/NN to/TO the/DT nucleus/NN ,/, albeit/IN at/IN a/DT lower/JJR level/NN in/IN T/NN cells/NNS from/IN the/DT elderly/JJ ./. 
We/PRP demonstrate/VBP here/RB that/IN pretreatment/NN with/IN PAO/NN results/VBZ in/IN the/DT inhibition/NN of/IN NFkappaB/NN induction/NN in/IN TNF-alpha/NN treated/JJ T/NN cells/NNS ,/, suggesting/VBG a/DT role/NN for/IN PAO-sensitive/JJ phosphatase/NN in/IN the/DT activation/NN of/IN the/DT NFkappaB/NN via/IN this/DT pathway/NN in/IN human/JJ T/NN cells/NNS ./. 
Furthermore/RB ,/, it/PRP demonstrates/VBZ that/IN aging/NN does/VBZ not/RB influence/VB the/DT sensitivity/NN of/IN this/DT phosphatase/NN ./. 
Treatment/NN with/IN DMP/NN prior/RB to/TO treatment/NN with/IN PAO/NN and/CC TNF/NN abolishes/VBZ the/DT inhibition/NN induced/VBN by/IN PAO/NN ,/, in/IN T/NN cells/NNS from/IN both/CC young/JJ and/CC old/JJ donors/NNS ,/, alike/RB ./. 
Finally/RB ,/, we/PRP demonstrate/VBP that/IN a/DT failure/NN to/TO degrade/VB IkappaB-alpha/NN in/IN cytosols/NNS of/IN TNF-treated/JJ T/NN cells/NNS pretreated/VBN with/IN PAO/NN is/VBZ due/JJ to/TO its/PRP$ interference/NN with/IN the/DT phosphorylation/NN of/IN IkappaB-alpha/NN and/CC not/RB due/JJ to/TO its/PRP$ inhibitory/JJ effect/NN on/IN proteasomal/JJ degradation/NN ./. 
These/DT data/NNS collectively/RB suggest/VBP that/IN PAO/NN interferes/VBZ with/IN the/DT phosphorylation/NN and/CC the/DT regulated/VBN degradation/NN of/IN IkappaB-alpha/NN ,/, induced/VBN by/IN TNF/NN ,/, without/IN affecting/VBG the/DT chymotryptic/JJ activity/NN of/IN the/DT proteasome/NN ,/, independent/JJ of/IN age/NN ./. 
UI/LS -/: 99214587/CD 
TI/LS -/: Spi-C/NN ,/, a/DT novel/JJ Ets/NN protein/NN that/WDT is/VBZ temporally/RB regulated/VBN during/IN B/NN lymphocyte/NN development/NN ./. 
AB/LS -/: A/DT novel/JJ Ets/NN protein/NN was/VBD isolated/VBN by/IN yeast/NN one-hybrid/JJ screening/NN of/IN a/DT cDNA/NN library/NN made/VBN from/IN lipopolysaccharide-stimulated/JJ mouse/NN splenic/JJ B/NN cells/NNS ,/, using/VBG the/DT SP6/NN kappa/NN promoter/NN kappaY/NN element/NN as/IN a/DT bait/NN ./. 
The/DT novel/JJ Ets/NNS protein/NN was/VBD most/RBS closely/RB related/JJ to/TO PU.1/NN and/CC Spi-B/NN within/IN the/DT DNA/NN binding/NN Ets/NN domain/NN and/CC was/VBD therefore/RB named/VBN Spi-C/NN ./. 
However/RB ,/, Spi-C/NN may/MD represent/VB a/DT novel/JJ subgroup/NN within/IN the/DT Ets/NN protein/NN family/NN ,/, as/IN it/PRP differed/VBD significantly/RB from/IN Spi-B/NN and/CC PU.1/NN within/IN helix/NN 1/CD of/IN the/DT Ets/NN domain/NN ./. 
Spi-C/NN was/VBD encoded/VBN by/IN a/DT single-copy/JJ gene/NN that/WDT was/VBD mapped/VBN to/TO chromosome/NN 10/CD ,/, region/NN C/NN ./. 
Spi-C/NN interacted/VBD with/IN DNA/NN similarly/RB to/TO PU.1/NN as/IN judged/VBN by/IN methylation/NN interference/NN ,/, band-shift/NN and/CC site/NN selection/NN analysis/NN ,/, and/CC activated/VBN transcription/NN of/IN a/DT kappaY/NN element/NN reporter/NN gene/NN upon/IN co-transfection/NN of/IN HeLa/NN cells/NNS ./. 
Spi-C/NN RNA/NN was/VBD expressed/VBN in/IN mature/JJ B/NN lymphocytes/NNS and/CC at/IN lower/JJR levels/NNS in/IN macrophages/NNS ./. 
Furthermore/RB ,/, pre-B/JJ cell/NN and/CC plasma/NN cell/NN lines/NNS were/VBD Spi-C-negative/JJ ,/, suggesting/VBG that/IN Spi-C/NN might/MD be/VB a/DT regulatory/JJ molecule/NN during/IN a/DT specific/JJ phase/NN of/IN B/NN lymphoid/JJ development/NN ./. 
UI/LS -/: 99194238/CD 
TI/LS -/: Glucocorticoid-induced/JJ cell/NN death/NN requires/VBZ autoinduction/NN of/IN glucocorticoid/NN receptor/NN expression/NN in/IN human/JJ leukemic/JJ T/NN cells/NNS ./. 
AB/LS -/: In/IN contrast/NN to/TO the/DT negative/JJ autoregulation/NN of/IN glucocorticoid/NN receptor/NN (/( GR/NN )/) expression/NN seen/VBN in/IN most/JJS cells/NNS and/CC tissues/NNS ,/, GR/NN expression/NN is/VBZ positively/RB autoregulated/VBN in/IN human/JJ leukemic/JJ T/NN cells/NNS and/CC in/IN other/JJ cells/NNS sensitive/JJ to/TO glucocorticoid-induced/JJ cell/NN death/NN ./. 
To/TO determine/VB whether/IN positive/JJ autoregulation/NN is/VBZ a/DT necessary/JJ component/NN of/IN glucocorticoid-induced/JJ cell/NN death/NN ,/, a/DT wild-type/JJ GR/NN gene/NN under/IN the/DT control/NN of/IN a/DT tetracycline-regulated/JJ promoter/NN was/VBD stably/RB transfected/VBN into/IN glucocorticoid-resistant/JJ cells/NNS lacking/VBG endogenous/JJ functional/JJ receptor/NN ./. 
Transfectants/NNS grown/VBN in/IN the/DT presence/NN of/IN tetracycline/NN contained/VBD about/RB 15,000/CD receptors/cell/NNS ,/, a/DT value/NN approximately/RB equal/JJ to/TO basal/JJ level/NN GR/NN expression/NN in/IN glucocorticoid-sensitive/JJ 6TG1.1/NN cells/NNS before/IN steroid/NN treatment/NN ./. 
Under/IN these/DT conditions/NNS ,/, dexamethasone/NN had/VBD a/DT minimal/JJ effect/NN on/IN cell/NN growth/NN ,/, elicited/VBD little/JJ internucleosomal/JJ DNA/NN fragmentation/NN ,/, and/CC induced/VBD no/DT cell/NN cycle/NN perturbation/NN ./. 
In/IN the/DT absence/NN of/IN tetracycline/NN ,/, GR/NN mRNA/NN and/CC protein/NN expression/NN increased/VBD 2-3-fold/RB ,/, and/CC cells/NNS expressed/VBD 48,000/CD receptors/NNS ,/, a/DT level/NN nearly/RB equivalent/JJ to/TO that/DT present/JJ in/IN 6TG1.1/NN cells/NNS after/IN 18/CD h/NN of/IN autoinduction/NN ./. 
Under/IN these/DT conditions/NNS ,/, dexamethasone/NN markedly/RB inhibited/VBD cell/NN growth/NN ,/, caused/VBD G1/NN arrest/NN ,/, and/CC induced/VBD significant/JJ internucleosomal/JJ DNA/NN fragmentation/NN ./. 
These/DT studies/NNS therefore/RB suggest/VBP that/IN basal/JJ level/NN GR/NN expression/NN is/VBZ inadequate/JJ to/TO mediate/VB glucocorticoid-induced/JJ apoptosis/NN in/IN glucocorticoid-sensitive/JJ T/NN cells/NNS and/CC that/IN positive/JJ autoregulation/NN is/VBZ a/DT necessary/JJ component/NN of/IN this/DT process/NN ./. 
UI/LS -/: 99192454/CD 
TI/LS -/: Constitutive/JJ activation/NN of/IN NF-kappaB/NN in/IN primary/JJ adult/JJ T-cell/NN leukemia/NN cells/NNS ./. 
AB/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) is/VBZ an/DT etiologic/JJ agent/NN of/IN adult/JJ T-cell/NN leukemia/NN (/( ATL/NN )/) ./. 
The/DT viral/JJ protein/NN Tax/NN induces/VBZ the/DT activation/NN and/CC nuclear/JJ translocalization/NN of/IN transcription/NN factor/NN NF-kappaB/NN ,/, which/WDT is/VBZ proposed/VBN to/TO play/VB a/DT crucial/JJ role/NN in/IN the/DT transformation/NN of/IN T/NN cells/NNS by/IN HTLV-I/NN ./. 
However/RB ,/, the/DT HTLV-I/NN genes/NNS including/VBG Tax/NN are/VBP not/RB expressed/VBN significantly/RB in/IN primary/JJ leukemic/JJ cells/NNS from/IN ATL/NN patients/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD the/DT basis/NN for/IN NF-kappaB/NN activation/NN in/IN freshly/RB isolated/VBN leukemic/JJ cells/NNS from/IN ATL/NN patients/NNS ./. 
We/PRP found/VBD that/IN leukemic/JJ cells/NNS from/IN ATL/NN patients/NNS ,/, like/IN HTLV-I-infected/JJ T-cell/NN lines/NNS ,/, display/VBP constitutive/JJ NF-kappaB/NN DNA/NN binding/NN activity/NN and/CC increased/VBN degradation/NN of/IN IkappaBalpha/NN (/( an/DT inhibitor/NN of/IN NF-kappaB/NN )/) ./. 
Whereas/IN the/DT NF-kappaB/NN binding/NN activity/NN in/IN Tax-expressing/JJ T-cell/NN lines/NNS consisted/VBD mostly/RB of/IN p50/c-Rel/NN ,/, fresh/JJ ATL/NN samples/NNS contained/VBD p50/p50/NN and/CC p50/p65/NN heterodimers/NNS ./. 
One/CD T-cell/NN line/NN derived/VBN from/IN ATL/NN leukemic/JJ cells/NNS ,/, TL-Om1/NN ,/, displayed/VBD constitutive/JJ NF-kappaB/NN activity/NN ,/, as/RB well/RB as/IN enhanced/VBN degradation/NN of/IN IkappaBalpha/NN ,/, despite/IN the/DT lack/NN of/IN detectable/JJ Tax/NN expression/NN ./. 
Interestingly/RB ,/, the/DT NF-kappaB/NN in/IN TL-Om1/NN consists/VBZ of/IN p50/p50/NN and/CC p50/p65/NN like/IN that/DT in/IN fresh/JJ primary/JJ leukemic/JJ cells/NNS ./. 
Our/PRP$ results/NNS suggest/VBP that/IN activation/NN of/IN NF-kappaB/NN occurs/VBZ through/IN a/DT Tax-independent/JJ mechanism/NN in/IN leukemic/JJ cells/NNS of/IN ATL/NN patients/NNS ,/, possibly/RB due/JJ to/TO differential/JJ NF-kappaB/NN subunit/NN activation/NN ./. 
UI/LS -/: 99189160/CD 
TI/LS -/: Interferon-alpha/NN induction/NN of/IN STATs1/NN ,/, -3/CD DNA/NN binding/NN and/CC growth/NN arrest/NN is/VBZ independent/JJ of/IN Lck/NN and/CC active/JJ mitogen-activated/JJ kinase/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Type/NN I/CD interferons/NNS (/( IFNs/NNS )/) are/VBP a/DT family/NN of/IN cytokines/NNS that/WDT have/VBP antiviral/JJ and/CC antiproliferative/JJ effects/NNS ./. 
Data/NNS regarding/VBG the/DT processes/NNS by/IN which/WDT these/DT cytokines/NNS transduce/VBP signals/NNS from/IN the/DT cell/NN membrane/NN to/TO the/DT nucleus/NN are/VBP becoming/VBG increasingly/RB complex/JJ ./. 
The/DT most/JJS characterized/VBN pathway/NN is/VBZ via/IN JAK-STAT/NN signaling/NN ./. 
Previous/JJ studies/NNS established/VBD a/DT potential/JJ role/NN for/IN the/DT Src-family/NN kinase/NN Lck/NN in/IN JAK-STAT/NN signaling/NN ./. 
Therefore/RB ,/, this/DT study/NN was/VBD designed/VBN to/TO analyze/VB the/DT role/NN of/IN Lck/NN in/IN IFN-alpha/NN signaling/NN by/IN using/VBG the/DT Jurkat/NN ,/, JCam/NN (/( an/DT Lck-defective/JJ cell/NN line/NN derived/VBN from/IN Jurkat/NN )/) ,/, and/CC JCam/Lck/NN (/( JCam/NN cells/NNS with/IN Lck/NN restored/VBN )/) ./. 
The/DT results/NNS show/VBP that/IN IFN-alpha/NN can/MD induce/VB MAPK/NN activity/NN ,/, but/CC only/RB in/IN cells/NNS containing/VBG Lck/NN ./. 
Furthermore/RB ,/, STATs1/NN and/CC -3/CD are/VBP effectively/RB phosphorylated/VBN and/CC activated/VBN to/TO bind/VB DNA/NN in/IN the/DT absence/NN of/IN Lck/NN expression/NN in/IN IFN-alpha-treated/JJ cells/NNS ./. 
Finally/RB ,/, the/DT results/NNS demonstrate/VBP that/IN IFN-alpha/NN exerts/VBZ an/DT antiproliferative/JJ effect/NN in/IN all/DT three/CD cell/NN lines/NNS ./. 
These/DT data/NNS indicate/VBP that/IN Lck/NN and/CC active/JJ MAPK/NN do/VBP not/RB affect/VB IFN-alpha-induced/JJ growth/NN arrest/NN or/CC induction/NN of/IN STAT1s1/NN and/CC -3/CD DNA/NN binding/NN ability/NN ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99178889/CD 
TI/LS -/: Selective/JJ activation/NN and/CC functional/JJ significance/NN of/IN p38alpha/NN mitogen-activated/JJ protein/NN kinase/NN in/IN lipopolysaccharide-stimulated/JJ neutrophils/NNS ./. 
AB/LS -/: Activation/NN of/IN leukocytes/NNS by/IN proinflammatory/JJ stimuli/NNS selectively/RB initiates/VBZ intracellular/JJ signal/NN transduction/NN via/IN sequential/JJ phosphorylation/NN of/IN kinases/NNS ./. 
Lipopolysaccharide/NN (/( LPS/NN )/) stimulation/NN of/IN human/JJ neutrophils/NNS is/VBZ known/VBN to/TO result/VB in/IN activation/NN of/IN p38/NN mitogen-activated/JJ protein/NN kinase/NN (/( MAPk/NN )/) ;/: however/RB ,/, the/DT upstream/JJ activator/NN (/( s/NNS )/) of/IN p38/NN MAPk/NN is/VBZ unknown/JJ ,/, and/CC consequences/NNS of/IN p38/NN MAPk/NN activation/NN remain/VBP largely/RB undefined/JJ ./. 
We/PRP investigated/VBD the/DT MAPk/NN kinase/NN (/( MKK/NN )/) that/WDT activates/VBZ p38/NN MAPk/NN in/IN response/NN to/TO LPS/NN ,/, the/DT p38/NN MAPk/NN isoforms/NNS that/WDT are/VBP activated/VBN as/IN part/NN of/IN this/DT pathway/NN ,/, and/CC the/DT functional/JJ responses/NNS affected/VBN by/IN p38/NN MAPk/NN activation/NN ./. 
Although/IN MKK3/NN ,/, MKK4/NN ,/, and/CC MKK6/NN all/DT activated/VBD p38/NN MAPk/NN in/IN experimental/JJ models/NNS ,/, only/RB MKK3/DT was/VBD found/VBN to/TO activate/VB recombinant/JJ p38/NN MAPk/NN in/IN LPS-treated/JJ neutrophils/NNS ./. 
Of/IN p38/NN MAPk/NN isoforms/NNS studied/VBN ,/, only/RB p38alpha/NN and/CC p38delta/NN were/VBD detected/VBN in/IN neutrophils/NNS ./. 
LPS/NN stimulation/NN selectively/RB activated/VBD p38alpha/NN ./. 
Specific/JJ inhibitors/NNS of/IN p38alpha/NN MAPk/NN blocked/VBD LPS-induced/JJ adhesion/NN ,/, nuclear/JJ factor-kappa/NN B/NN (/( NF-kappaB/NN )/) activation/NN ,/, and/CC synthesis/NN of/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) ./. 
Inhibition/NN of/IN p38alpha/NN MAPk/NN resulted/VBD in/IN a/DT transient/JJ decrease/NN in/IN TNF-alpha/NN mRNA/NN accumulation/NN but/CC persistent/JJ loss/NN of/IN TNF-alpha/NN synthesis/NN ./. 
These/DT findings/NNS support/VBP a/DT pathway/NN by/IN which/WDT LPS/NN stimulation/NN of/IN neutrophils/NNS results/VBZ in/IN activation/NN of/IN MKK3/NN ,/, which/WDT in/IN turn/NN activates/VBZ p38alpha/NN MAPk/NN ,/, ultimately/RB regulating/VBG adhesion/NN ,/, NF-kappaB/NN activation/NN ,/, enhanced/VBN gene/NN expression/NN of/IN TNF-alpha/NN ,/, and/CC regulation/NN of/IN TNF-alpha/NN synthesis/NN ./. 
UI/LS -/: 99244898/CD 
TI/LS -/: The/DT evolutionarily/RB conserved/VBN sequence/NN upstream/RB of/IN the/DT human/JJ Ig/NN heavy/JJ chain/NN S/NN gamma/NN 3/CD region/NN is/VBZ an/DT inducible/JJ promoter/NN :/: synergistic/JJ activation/NN by/IN CD40/NN ligand/NN and/CC IL-4/NN via/IN cooperative/JJ NF-kappa/NN B/NN and/CC STAT-6/NN binding/NN sites/NNS ./. 
AB/LS -/: Germline/NN C/NN gamma/NN gene/NN transcription/NN is/VBZ a/DT crucial/JJ event/NN in/IN the/DT process/NN that/WDT leads/VBZ to/TO switch/VB DNA/NN recombination/NN to/TO IgG/NN ,/, but/CC its/PRP$ regulation/NN in/IN the/DT human/JJ is/VBZ poorly/RB understood/VBN ./. 
We/PRP took/VBD advantage/NN of/IN our/PRP$ monoclonal/JJ model/NN of/IN germinal/JJ center/NN B/NN cell/NN differentiation/NN ,/, IgM+/JJ IgD+/JJ CL-01/NN cells/NNS ,/, to/TO define/VB the/DT role/NN of/IN the/DT I/NN gamma/NN 3/CD evolutionarily/RB conserved/VBN sequence/NN (/( ECS/NN )/) in/IN the/DT germline/NN transcriptional/JJ activation/NN of/IN the/DT human/JJ C/NN gamma/NN 3/CD gene/NN ./. 
The/DT I/NN gamma/NN 3/CD ECS/NN lies/VBZ upstream/RB of/IN the/DT major/JJ I/NN gamma/NN 3/CD transcription/NN initiation/NN site/NN and/CC displays/VBZ more/JJR than/IN 90/CD %/NN identity/NN with/IN the/DT corresponding/JJ human/JJ I/NN gamma/NN 1/CD ,/, I/NN gamma/NN 2/CD ,/, and/CC I/NN gamma/NN 4/CD regions/NNS ./. 
Reporter/NN luciferase/NN gene/NN vectors/NNS containing/VBG the/DT human/JJ gamma/NN 3/CD ECS/NN were/VBD used/VBN to/TO transfect/VB CL-01/NN cells/NNS ,/, which/WDT have/VBP been/VBN shown/VBN to/TO undergo/VB Smu/NN -->/TO S/NN gamma/NN 3/CD DNA/NN recombination/NN ,/, upon/IN engagement/NN of/IN CD40/NN by/IN CD40/NN ligand/NN (/( CD40L/NN )/) and/CC exposure/NN to/TO IL-4/NN ./. 
In/IN these/DT transfected/VBN CL-01/NN cells/NNS ,/, CD40:CD40L/NN engagement/NN and/CC exposure/NN to/TO IL-4/NN synergistically/RB induced/VBD gamma/NN 3/CD ECS-dependent/JJ luciferase/NN reporter/NN gene/NN activation/NN ./. 
Targeted/VBN mutational/JJ analysis/NN demonstrated/VBD that/IN a/DT tandem/JJ NF-kappa/NN B/Rel/NN binding/NN motif/NN is/VBZ critical/JJ for/IN the/DT gamma/NN 3/CD ECS/NN responsiveness/NN to/TO both/CC CD40L/NN and/CC IL-4/NN ,/, while/IN a/DT STAT-6-binding/JJ site/NN is/VBZ additionally/RB required/VBN for/IN IL-4/NN inducibility/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS showed/VBD that/IN p50/p65/c-Rel/NN and/CC STAT-6/NN are/VBP effectively/RB induced/VBN by/IN CD40L/NN and/CC IL-4/NN ,/, respectively/RB ,/, and/CC bind/VBP to/TO specific/JJ DNA/NN motifs/NNS within/IN the/DT ECS/NN ./. 
These/DT partially/RB overlapping/VBG CD40L/NN and/CC IL-4/NN responsive/JJ elements/NNS are/VBP functionally/RB cooperative/JJ as/IN the/DT disruption/NN of/IN one/CD of/IN them/PRP prevents/VBZ synergistic/JJ promoter/NN activation/NN ./. 
Thus/RB ,/, the/DT gamma/NN 3/CD ECS/NN is/VBZ an/DT inducible/JJ promoter/NN containing/VBG cis/NN elements/NNS that/WDT critically/RB mediate/VBP CD40L/NN and/CC IL-4-triggered/JJ transcriptional/JJ activation/NN of/IN the/DT human/JJ C/NN gamma/NN 3/CD gene/NN ./. 
UI/LS -/: 99236847/CD 
TI/LS -/: CIITA-induced/JJ occupation/NN of/IN MHC/NN class/NN II/CD promoters/NNS is/VBZ independent/JJ of/IN the/DT cooperative/JJ stabilization/NN of/IN the/DT promoter-bound/JJ multi-protein/JJ complexes/NNS ./. 
AB/LS -/: Precise/JJ regulation/NN of/IN MHC/NN class/NN II/CD expression/NN plays/VBZ a/DT crucial/JJ role/NN in/IN the/DT control/NN of/IN the/DT immune/JJ response/NN ./. 
The/DT transactivator/NN CIITA/NN behaves/VBZ as/IN a/DT master/JJ controller/NN of/IN constitutive/JJ and/CC inducible/JJ MHC/NN class/NN II/CD gene/NN activation/NN ,/, but/CC its/PRP$ exact/JJ mechanism/NN of/IN action/NN is/VBZ not/RB known/VBN ./. 
Activation/NN of/IN MHC/NN class/NN II/CD promoters/NNS requires/VBZ binding/NN of/IN at/IN least/JJS three/CD distinct/JJ multi-protein/JJ complexes/NNS (/( RFX/NN ,/, X2BP/NN and/CC NF-Y/NN )/) ./. 
It/PRP is/VBZ known/VBN that/IN the/DT stability/NN of/IN this/DT binding/NN results/VBZ from/IN cooperative/JJ interactions/NNS between/IN these/DT proteins/NNS ./. 
We/PRP show/VBP here/RB that/IN expression/NN of/IN CIITA/NN in/IN MHC/NN class/NN II-cells/NNS triggers/VBZ occupation/NN of/IN the/DT promoters/NNS by/IN these/DT complexes/NNS ./. 
This/DT observation/NN raised/VBD the/DT possibility/NN that/IN the/DT effect/NN of/IN CIITA/NN on/IN promoter/NN occupation/NN is/VBZ mediated/VBN by/IN an/DT effect/NN on/IN the/DT cooperative/JJ stabilization/NN of/IN the/DT DNA-bound/JJ multi-protein/JJ complexes/NNS ./. 
We/PRP show/VBP ,/, however/RB ,/, that/IN the/DT presence/NN of/IN CIITA/NN does/VBZ not/RB affect/VB the/DT stability/NN of/IN the/DT higher-order/JJ protein/NN complex/NN formed/VBN on/IN DNA/NN by/IN RFX/NN ,/, X2BP/NN and/CC NF-Y/NN ./. 
This/DT suggests/VBZ other/JJ mechanisms/NNS for/IN CIITA-induced/JJ promoter/NN occupancy/NN ,/, such/JJ as/IN an/DT effect/NN on/IN chromatin/NN structure/NN leading/VBG to/TO increased/VBN accessibility/NN of/IN MHC/NN class/NN II/CD promoters/NNS ./. 
This/DT ability/NN of/IN CIITA/NN to/TO facilitate/VB promoter/NN occupation/NN is/VBZ undissociable/JJ from/IN its/PRP$ transactivation/NN potential/NN ./. 
Finally/RB ,/, we/PRP conclude/VBP that/IN this/DT effect/NN of/IN CIITA/NN is/VBZ cell-type/JJ specific/JJ ,/, since/IN expression/NN of/IN CIITA/NN is/VBZ not/RB required/VBN for/IN normal/JJ occupation/NN of/IN MHC/NN class/NN II/CD promoters/NNS in/IN B/NN lymphocytes/NNS ./. 
UI/LS -/: 99225553/CD 
TI/LS -/: GrpL/NN ,/, a/DT Grb2-related/JJ adaptor/NN protein/NN ,/, interacts/VBZ with/IN SLP-76/NN to/TO regulate/VB nuclear/JJ factor/NN of/IN activated/VBN T/NN cell/NN activation/NN ./. 
AB/LS -/: Propagation/NN of/IN signals/NNS from/IN the/DT T/NN cell/NN antigen/NN receptor/NN (/( TCR/NN )/) involves/VBZ a/DT number/NN of/IN adaptor/NN molecules/NNS ./. 
SH2/NN domain-containing/JJ protein/NN 76/CD (/( SLP-76/NN )/) interacts/VBZ with/IN the/DT guanine/NN nucleotide/NN exchange/NN factor/NN Vav/NN to/TO activate/VB the/DT nuclear/JJ factor/NN of/IN activated/VBN cells/NNS (/( NF-AT/NN )/) ,/, and/CC its/PRP$ expression/NN is/VBZ required/VBN for/IN normal/JJ T/NN cell/NN development/NN ./. 
We/PRP report/VBP the/DT cloning/NN and/CC characterization/NN of/IN a/DT novel/JJ Grb2-like/JJ adaptor/NN molecule/NN designated/VBN as/IN Grb2-related/JJ protein/NN of/IN the/DT lymphoid/JJ system/NN (/( GrpL/NN )/) ./. 
Expression/NN of/IN GrpL/NN is/VBZ restricted/VBN to/TO hematopoietic/JJ tissues/NNS ,/, and/CC it/PRP is/VBZ distinguished/VBN from/IN Grb2/NN by/IN having/VBG a/DT proline-rich/JJ region/NN ./. 
GrpL/NN can/MD be/VB coimmunoprecipitated/VBN with/IN SLP-76/NN but/CC not/RB with/IN Sos1/NN or/CC Sos2/NN from/IN Jurkat/NN cell/NN lysates/NNS ./. 
In/IN contrast/NN ,/, Grb2/NN can/MD be/VB coimmunoprecipitated/VBN with/IN Sos1/NN and/CC Sos2/NN but/CC not/RB with/IN SLP-76/NN ./. 
Moreover/RB ,/, tyrosine-phosphorylated/JJ LAT/pp36/38/NN in/IN detergent/JJ lysates/NNS prepared/VBN from/IN anti-CD3/NN stimulated/VBD T/NN cells/NNS associated/VBN with/IN Grb2/NN but/CC not/RB GrpL/NN ./. 
These/DT data/NNS reveal/VBP the/DT presence/NN of/IN distinct/JJ complexes/NNS involving/VBG GrpL/NN and/CC Grb2/NN in/IN T/NN cells/NNS ./. 
A/DT functional/JJ role/NN of/IN the/DT GrpL-SLP-76/NN complex/NN is/VBZ suggested/VBN by/IN the/DT ability/NN of/IN GrpL/NN to/TO act/VB alone/RB or/CC in/IN concert/NN with/IN SLP-76/NN to/TO augment/VB NF-AT/NN activation/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
UI/LS -/: 99220021/CD 
TI/LS -/: Differential/JJ induction/NN of/IN interferon/NN (/( IFN/NN )/) -inducible/JJ protein/NN 10/CD following/VBG differentiation/NN of/IN a/DT monocyte/NN ,/, macrophage/NN cell/NN lineage/NN is/VBZ related/JJ to/TO the/DT changes/NNS of/IN nuclear/JJ proteins/NNS bound/VBN to/TO IFN/NN stimulus/NN response/NN element/NN and/CC kappaB/NN sites/NNS ./. 
AB/LS -/: We/PRP examined/VBD chemokine/NN gene/NN expression/NN following/VBG the/DT differentiation/NN of/IN a/DT monocyte/NN ,/, macrophage/NN cell/NN lineage/NN ./. 
The/DT human/JJ monoblastic/JJ cell/NN line/NN ,/, U937/NN was/VBD differentiated/VBN to/TO macrophages/NNS by/IN the/DT treatment/NN with/IN either/CC phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) ,/, retinoic/JJ acid/NN (/( RA/NN )/) ,/, or/CC vitamin/NN D3/NN (/( VitD3/NN )/) ./. 
The/DT gene/NN expression/NN of/IN interferon/NN (/( IFN/NN )/) -inducible/JJ protein/NN 10/CD (/( IP-10/NN )/) (/( a/DT CXC/NN chemokine/NN )/) was/VBD markedly/RB augmented/VBN by/IN the/DT IFNgamma/NN treatment/NN in/IN PMA-/NN or/CC RA-differentiated/JJ U937/NN cells/NNS ,/, but/CC only/RB marginally/RB in/IN undifferentiated/JJ or/CC VitD3-treated/JJ cells/NNS ./. 
In/IN contrast/NN ,/, another/DT inducible/JJ gene/NN expression/NN of/IN monocyte/NN chemotactic/NN protein-1/NN (/( a/DT CC/NN chemokine/NN )/) and/CC the/DT activation/NN of/IN the/DT transcriptional/JJ factor/NN (/( FcRFgamma/NN )/) bound/VBN to/TO the/DT gamma/NN response/NN region/NN were/VBD similarly/RB or/CC less/RBR abundantly/RB induced/VBN by/IN IFNgamma/NN treatment/NN in/IN PMA-/NN or/CC RA-differentiated/JJ U937/NN cells/NNS ,/, indicating/VBG that/IN increased/VBN IP-10/NN mRNA/NN induction/NN was/VBD not/RB due/JJ to/TO the/DT augmented/JJ ability/NN of/IN the/DT cells/NNS to/TO respond/VB to/TO the/DT presence/NN of/IN IFNgamma/NN ./. 
Increased/VBN expression/NN of/IN IFNgamma-induced/JJ IP-10/NN mRNA/NN following/VBG the/DT differentiation/NN of/IN U937/NN cells/NNS was/VBD mediated/VBN largely/RB by/IN augmented/JJ transcriptional/JJ activity/NN of/IN the/DT gene/NN and/CC was/VBD related/JJ to/TO differentiation-dependent/JJ changes/NNS of/IN the/DT proteins/NNS bound/VBN to/TO IFN/NN stimulus/NN response/NN element/NN (/( ISRE/NN )/) and/CC kB/NN sites/NNS ,/, suggesting/VBG that/IN these/DT nuclear/JJ proteins/NNS may/MD determine/VB the/DT IP-10/NN mRNA/NN inducibility/NN by/IN IFNgamma/NN ./. 
UI/LS -/: 99214329/CD 
TI/LS -/: Role/NN of/IN cellular/JJ tumor/NN necrosis/NN factor/IN receptor-associated/JJ factors/NNS in/IN NF-kappaB/NN activation/NN and/CC lymphocyte/NN transformation/NN by/IN herpesvirus/NN Saimiri/NN STP/NN ./. 
AB/LS -/: The/DT STP/NN oncoproteins/NNS of/IN the/DT herpesvirus/NN saimiri/NN (/( HVS/NN )/) subgroup/NN A/NN strain/NN 11/CD and/CC subgroup/NN C/NN strain/NN 488/CD are/VBP now/RB found/VBN to/TO be/VB stably/RB associated/VBN with/IN tumor/NN necrosis/NN factor/NN receptor-associated/JJ factor/NN (/( TRAF/NN )/) 1/CD ,/, 2/CD ,/, or/CC 3/CD ./. 
Mutational/JJ analyses/NNS identified/VBD residues/NNS of/IN PXQXT/S/NN in/IN STP-A11/NN as/IN critical/JJ for/IN TRAF/NN association/NN ./. 
In/IN addition/NN ,/, a/DT somewhat/RB divergent/JJ region/NN of/IN STP-C488/NN is/VBZ critical/JJ for/IN TRAF/NN association/NN ./. 
Mutational/JJ analysis/NN also/RB revealed/VBD that/IN STP-C488/NN induced/VBD NF-kappaB/NN activation/NN that/WDT was/VBD correlated/VBN with/IN its/PRP$ ability/NN to/TO associate/VB with/IN TRAFs/NNS ./. 
The/DT HVS/NN STP-C488/NN P10/NN -->/TO R/NN mutant/NN was/VBD deficient/JJ in/IN human/JJ T-lymphocyte/NN transformation/NN to/TO interleukin-2-independent/JJ growth/NN but/CC showed/VBD wild-type/JJ phenotype/NN for/IN marmoset/NN T-lymphocyte/NN transformation/NN in/FW vitro/FW and/CC in/FW vivo/FW ./. 
The/DT STP-C488/NN P10/NN -->/TO R/NN mutant/NN was/VBD also/RB defective/JJ in/IN Rat-1/NN fibroblast/NN transformation/NN ,/, and/CC fibroblast/NN cell/NN transformation/NN was/VBD blocked/VBN by/IN a/DT TRAF2/NN dominant-negative/JJ mutant/NN ./. 
These/DT data/NNS implicate/VBP TRAFs/NNS in/IN STP-C488-mediated/JJ transformation/NN of/IN human/JJ lymphocytes/NNS and/CC rodent/JJ fibroblasts/NNS ./. 
Other/JJ factors/NNS are/VBP implicated/VBN in/IN immortalization/NN of/IN common/JJ marmoset/NN T/NN lymphocytes/NNS and/CC may/MD also/RB be/VB critical/JJ in/IN the/DT transformation/NN of/IN human/JJ lymphocytes/NNS and/CC rodent/JJ fibroblasts/NNS ./. 
UI/LS -/: 99203526/CD 
TI/LS -/: Cleavage/NN of/IN transcription/NN factor/NN SP1/NN by/IN caspases/NNS during/IN anti-IgM-induced/JJ B-cell/NN apoptosis/NN ./. 
AB/LS -/: Apoptosis/NN is/VBZ instrumental/JJ in/IN the/DT processes/NNS generating/VBG the/DT diversity/NN of/IN the/DT B-cell/NN repertoire/NN ./. 
Autoreactive/JJ B-cells/NNS are/VBP eliminated/VBN by/IN anti-IgM/JJ crosslinking/NN after/IN encountering/VBG self-antigens/NNS ,/, but/CC precise/JJ mechanisms/NNS leading/VBG to/TO B-cell/NN apoptosis/NN are/VBP still/RB not/RB well/RB understood/VBN ./. 
We/PRP report/VBP here/RB the/DT cleavage/NN of/IN the/DT transcription/NN factor/NN SP1/NN in/IN the/DT human/JJ Burkitt/NN lymphoma/NN cell/NN line/NN BL60/NN during/IN anti-IgM-induced/JJ apoptosis/NN ./. 
Western/NN blot/NN analysis/NN revealed/VBD two/CD cleavage/NN products/NNS of/IN approximately/RB 68/CD kDa/NN and/CC 45/CD kDa/NN after/IN induction/NN of/IN apoptosis/NN ./. 
Cleavage/NN could/MD be/VB completely/RB inhibited/VBN by/IN zDEVD-fmk/NN ,/, an/DT inhibitor/NN specific/JJ for/IN caspase/NN 3-like/JJ proteases/NNS ./. 
In-vitro/FW cleavage/NN of/IN recombinant/JJ SP1/NN by/IN recombinant/JJ caspase/NN 3/CD (/( CPP32/NN )/) or/CC caspase/NN 7/CD (/( Mch/NN 3/CD )/) results/VBZ in/IN similar/JJ cleavage/NN products/NNS as/IN those/DT observed/VBN in/FW vivo/FW ./. 
Recombinant/JJ caspase/NN 6/CD (/( Mch/NN 2/CD )/) primarily/RB generates/VBZ a/DT 68-kDa/JJ cleavage/NN product/NN ,/, as/IN observed/VBN after/IN calcium/NN ionophore/NN (/( CaI/NN )/) induced/JJ B-cell/NN apoptosis/NN ./. 
In/IN contrast/NN ,/, caspase/NN 1/CD (/( ICE/NN )/) did/VBD not/RB cleave/VB SP1/NN in/IN vitro/FW ./. 
The/DT time/NN course/NN of/IN SP1/NN cleavage/NN during/IN anti-IgM-induced/JJ apoptosis/NN is/VBZ paralleled/VBN by/IN an/DT increase/NN of/IN caspase/NN activity/NN measured/VBN by/IN DEVD-p-nitroanilide/NN (/( DEVD-pNA/NN )/) cleavage/NN ./. 
DNA/NN band-shift/NN assays/NNS revealed/VBD a/DT decrease/NN in/IN the/DT intensity/NN of/IN the/DT full/JJ length/NN SP1/DNA/NN complex/NN and/CC an/DT increase/NN in/IN the/DT intensity/NN of/IN a/DT smaller/JJR complex/NN due/JJ to/TO the/DT binding/NN of/IN one/CD SP1/NN cleavage/NN product/NN ./. 
By/IN Edman/NN sequencing/NN we/PRP could/MD identify/VB a/DT caspase/NN 3/CD cleavage/NN site/NN after/IN Asp584/NN (/( D584AQPQAGR/NN )/) ,/, generating/VBG a/DT 22-kDa/JJ C-terminal/JJ SP1/NN protein/NN fragment/NN which/WDT still/RB contains/VBZ the/DT DNA/NN binding/NN site/NN ./. 
Our/PRP$ results/NNS show/VBP the/DT cleavage/NN of/IN the/DT human/JJ transcription/NN factor/NN SP1/NN in/FW vivo/FW and/CC in/FW vitro/FW ,/, underlining/VBG the/DT central/JJ role/NN of/IN caspase/NN 3-like/JJ proteases/NNS during/IN the/DT process/NN of/IN anti-IgM-induced/JJ apoptosis/NN ./. 
UI/LS -/: 99194225/CD 
TI/LS -/: Stimulation/NN of/IN CD40/NN on/IN immunogenic/JJ human/JJ malignant/JJ melanomas/NNS augments/VBZ their/PRP$ cytotoxic/JJ T/NN lymphocyte-mediated/JJ lysis/NN and/CC induces/VBZ apoptosis/NN ./. 
AB/LS -/: Here/RB ,/, we/PRP report/VBP the/DT functional/JJ expression/NN of/IN CD40/NN on/IN human/JJ malignant/JJ melanomas/NNS (/( MMs/NNS )/) ./. 
Comparison/NN of/IN tumor/NN specimen/NN from/IN MM/NN precursor/NN lesions/NNS ,/, primary/JJ tumors/NNS ,/, and/CC metastases/NNS revealed/VBD that/IN CD40/NN surface/NN expression/NN is/VBZ down-regulated/VBN during/IN tumor/NN progression/NN ./. 
CD40/NN expression/NN was/VBD confirmed/VBN in/IN 7/CD human/JJ MM/NN cell/NN lines/NNS established/VBN from/IN immunogenic/JJ primary/JJ tumors/NNS or/CC metastases/NNS ,/, whereas/IN 11/CD cell/NN lines/NNS established/VBN from/IN advanced/JJ stages/NNS were/VBD CD40/NN negative/JJ ./. 
CD40/NN expression/NN could/MD be/VB enhanced/VBN in/IN CD40-positive/JJ MM/NN by/IN stimulation/NN with/IN IFN-gamma/NN and/CC tumor/NN necrosis/NN factor-alpha/NN but/CC not/RB by/IN interleukin/NN (/( IL/NN )/) -1beta/NN or/CC CD40/NN triggering/NN ./. 
CD40/NN ligation/NN on/IN MM/NN by/IN CD40L-transfected/JJ murine/JJ L-cells/NNS or/CC by/IN a/DT soluble/JJ CD40L/NN fusion/NN protein/NN up-regulated/VBD their/PRP$ expression/NN of/IN intercellular/JJ adhesion/NN molecule-1/NN and/CC MHC/NN class/NN I/CD and/CC class/NN II/CD molecules/NNS and/CC their/PRP$ secretion/NN of/IN IL-6/NN ,/, IL-8/NN ,/, tumor/NN necrosis/NN factor-a/NN ,/, and/CC granulocyte/NN macrophage/NN colony-stimulating/JJ factor/NN and/CC also/RB induced/VBD a/DT rapid/JJ activation/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor/NN kappaB/NN ./. 
Furthermore/RB ,/, CD40/NN ligation/NN of/IN a/DT HLA-A2+/JJ ,/, MelanA/MART1+/JJ MM/NN cell/NN line/NN enhanced/VBD its/PRP$ susceptibility/NN to/TO specific/JJ lysis/NN by/IN a/DT HLA-A2-restricted/JJ ,/, MelanA/MART-1-specific/JJ CTL/NN clone/NN ./. 
Finally/RB ,/, CD40/NN ligation/NN induced/VBD growth/NN inhibition/NN and/CC apoptosis/NN in/IN MM/NN ./. 
These/DT results/NNS indicate/VBP that/IN CD40-CD40L/NN interactions/NNS may/MD play/VB an/DT important/JJ role/NN in/IN augmenting/VBG antitumor/NN immunity/NN and/CC inducing/VBG apoptosis/NN in/IN some/DT CD40-positive/JJ immunogenic/JJ human/JJ MMs/NNS ./. 
UI/LS -/: 99192449/CD 
TI/LS -/: Human/JJ immunodeficiency/NN virus-associated/JJ Hodgkin/NN 's/POS disease/NN derives/VBZ from/IN post-germinal/JJ center/JJ B/NN cells/NNS ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus-associated/JJ Hodgkin/NN 's/POS disease/NN (/( HIV-HD/NN )/) displays/VBZ several/JJ peculiarities/NNS when/WRB compared/VBN with/IN HD/NN of/IN the/DT general/JJ population/NN ./. 
These/DT include/VBP overrepresentation/NN of/IN clinically/RB aggressive/JJ histologic/JJ types/NNS and/CC frequent/JJ infection/NN of/IN Reed-Sternberg/NN (/( RS/NN )/) cells/NNS by/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) ./. 
Recently/RB ,/, we/PRP have/VBP reported/VBN that/IN the/DT histogenesis/NN of/IN HD/NN of/IN the/DT general/JJ population/NN may/MD be/VB assessed/VBN by/IN monitoring/VBG the/DT expression/NN pattern/NN of/IN BCL-6/NN ,/, a/DT transcription/NN factor/NN expressed/VBN in/IN germinal/JJ center/NN (/( GC/NN )/) B/NN cells/NNS ,/, and/CC of/IN CD138/syndecan-1/NN (/( syn-1/NN )/) ,/, a/DT proteoglycan/NN associated/VBN with/IN post-GC/JJ ,/, terminal/JJ B-cell/NN differentiation/NN ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP applied/VBN these/DT two/CD markers/NNS to/TO the/DT study/NN of/IN HIV-HD/NN histogenesis/NN and/CC correlated/VBN their/PRP$ expression/NN status/NN to/TO the/DT virologic/JJ features/NNS of/IN this/DT disease/NN ./. 
We/PRP have/VBP found/VBN that/IN RS/NN cells/NNS of/IN all/DT histologic/JJ categories/NNS of/IN HIV-HD/NN consistently/RB display/VBP the/DT BCL-6(-)/syn-1(+)/JJ phenotype/NN and/CC thus/RB reflect/VBP post-GC/JJ B/NN cells/NNS ./. 
Although/IN BCL-6(-)/syn-1(+)/JJ RS/NN cells/NNS of/IN HIV-HD/NN express/VBP CD40/NN ,/, they/PRP are/VBP not/RB surrounded/VBN by/IN CD40/NN ligand-positive/JJ (/( CD40L+/JJ )/) reactive/JJ T/NN lymphocytes/NNS ,/, which/WDT ,/, in/IN HD/NN of/IN the/DT general/JJ population/NN ,/, are/VBP thought/VBN to/TO regulate/VB the/DT disease/NN phenotype/NN through/IN CD40/CD40L/NN interactions/NNS ./. 
Conversely/RB ,/, RS/NN cells/NNS of/IN virtually/RB all/DT HIV-HD/NN express/VBP the/DT EBV-encoded/JJ latent/JJ membrane/NN protein/NN 1/CD (/( LMP1/NN )/) ,/, which/WDT ,/, being/VBG functionally/RB homologous/JJ to/TO CD40/NN ,/, may/MD contribute/VB ,/, at/IN least/JJS in/IN part/NN ,/, to/TO the/DT modulation/NN of/IN the/DT HIV-HD/NN phenotype/NN ./. 
UI/LS -/: 99184529/CD 
TI/LS -/: MDS1/EVI1/NN enhances/VBZ TGF-beta1/NN signaling/NN and/CC strengthens/VBZ its/PRP$ growth-inhibitory/JJ effect/NN but/CC the/DT leukemia-associated/JJ fusion/NN protein/NN AML1/MDS1/EVI1/NN ,/, product/NN of/IN the/DT t(3;21)/NN ,/, abrogates/VBZ growth-inhibition/NN in/IN response/NN to/TO TGF-beta1/NN ./. 
AB/LS -/: MDS1/EVI1/NN ,/, located/JJ on/IN chromosome/NN 3/CD band/NN q26/NN ,/, encodes/VBZ a/DT zinc-finger/JJ DNA-binding/JJ transcription/NN activator/NN not/RB detected/VBN in/IN normal/JJ hematopoietic/JJ cells/NNS but/CC expressed/VBN in/IN several/JJ normal/JJ tissues/NNS ./. 
MDS1/EVI1/NN is/VBZ inappropriately/RB activated/VBN in/IN myeloid/JJ leukemias/NNS following/VBG chromosomal/JJ rearrangements/NNS involving/VBG band/NN 3q26/NN ./. 
The/DT rearrangements/NNS lead/VBP either/RB to/TO gene/NN truncation/NN ,/, and/CC to/TO expression/NN of/IN the/DT transcription/NN repressor/NN EVI1/NN ,/, as/IN seen/VBN in/IN the/DT t(3;3)(q21;q26)/NN and/CC inv(3)(q21q26)/NN ,/, or/CC to/TO gene/NN fusion/NN ,/, as/IN seen/VBN in/IN the/DT t(3;21)(q26;q22)/NN which/WDT results/VBZ in/IN the/DT fusion/NN protein/NN AML1/MDS1/EVI1/NN ./. 
This/DT fusion/NN protein/NN contains/VBZ the/DT DNA-binding/JJ domain/NN of/IN the/DT transcription/NN factor/NN AML1/NN fused/VBN in-frame/RB to/TO the/DT entire/JJ MDS1/EVI1/NN with/IN the/DT exclusion/NN of/IN its/PRP$ first/JJ 12/CD amino/NN acids/NNS ./. 
In/IN this/DT report/NN ,/, we/PRP have/VBP analyzed/VBN the/DT response/NN of/IN the/DT hematopoietic/JJ precursor/NN cell/NN line/NN 32Dcl3/NN ,/, expressing/VBG either/CC the/DT normal/JJ protein/NN MDS1/EVI1/NN or/CC the/DT fusion/NN protein/NN AML1/MDS1/EVI1/NN ,/, to/TO factors/NNS that/WDT control/VBP cell/NN differentiation/NN or/CC cell/NN replication/NN ./. 
The/DT 32Dcl3/NN cells/NNS are/VBP IL-3-dependent/JJ for/IN growth/NN and/CC they/PRP differentiate/VBP into/IN granulocytes/NNS when/WRB exposed/VBN to/TO G-CSF/NN ./. 
They/PRP are/VBP growth-inhibited/VBN by/IN TGF-beta1/NN ./. 
We/PRP show/VBP that/IN whereas/IN the/DT expression/NN of/IN MDS1/EVI1/NN has/VBZ no/DT effect/NN on/IN granulocytic/JJ differentiation/NN induced/VBN by/IN G-CSF/NN ,/, expression/NN of/IN AML1/MDS1/EVI1/NN blocks/VBZ differentiation/NN resulting/VBG in/IN cell/NN death/NN ./. 
This/DT effect/NN is/VBZ similar/JJ to/TO that/DT previously/RB described/VBN by/IN others/NNS for/IN 32Dcl3/NN cells/NNS that/WDT express/VBP transgenic/JJ Evil/NN ./. 
Furthermore/RB ,/, we/PRP show/VBP that/IN whereas/IN the/DT expression/NN of/IN the/DT fusion/NN protein/NN AML1/MDS1/EVI1/NN completely/RB abrogates/VBZ the/DT growth-inhibitory/JJ effect/NN of/IN TGF-beta1/NN and/CC allows/VBZ 32Dcl3/NN cells/NNS to/TO proliferate/VB ,/, expression/NN of/IN the/DT normal/JJ protein/NN MDS1/EVI1/NN has/VBZ the/DT opposite/JJ effect/NN ,/, and/CC it/PRP strengthens/VBZ the/DT response/NN of/IN cells/NNS to/TO the/DT growth-inhibitory/JJ effect/NN of/IN TGF-beta1/NN ./. 
By/IN using/VBG the/DT yeast/NN two-hybrid/JJ system/NN ,/, we/PRP also/RB show/VBP that/IN EVI1/NN (/( contained/VBN in/IN its/PRP$ entirety/NN in/IN MDS1/EVI1/NN and/CC AML1/MDS1/EVI1/NN )/) physically/RB interacts/VBZ with/IN SMAD3/NN ,/, which/WDT is/VBZ an/DT intracellular/JJ mediator/NN of/IN TGF-beta1/NN signaling/NN ./. 
Finally/RB ,/, we/PRP have/VBP correlated/VBN the/DT response/NN of/IN the/DT cells/NNS to/TO G-CSF/NN or/CC TGF-beta1/NN with/IN the/DT ability/NN of/IN the/DT normal/JJ and/CC fusion/NN proteins/NNS to/TO activate/VB or/CC repress/VB promoters/NNS which/WDT they/PRP can/MD directly/RB regulate/VB by/IN binding/NN to/TO the/DT promoter/NN site/NN ./. 
We/PRP propose/VBP that/IN mutations/NNS of/IN MDS1/EVI1/NN either/CC by/IN gene/NN truncation/NN resulting/VBG in/IN the/DT transcription/NN repressor/NN EVI1/NN or/CC by/IN gene/NN fusion/NN to/TO AML1/NN lead/VBP to/TO an/DT altered/JJ cellular/JJ response/NN to/TO growth/NN and/CC differentiation/NN factors/NNS that/WDT could/MD result/VB in/IN leukemic/JJ transformation/NN ./. 
The/DT different/JJ response/NN of/IN myeloid/JJ cells/NNS ectopically/RB expressing/VBG the/DT normal/JJ or/CC the/DT fusion/NN protein/NN to/TO G-CSF/NN and/CC TGF-beta1/NN could/MD depend/VB on/IN the/DT different/JJ transactivation/NN properties/NNS of/IN these/DT proteins/NNS resulting/VBG in/IN divergent/JJ expression/NN of/IN downstream/JJ genes/NNS regulated/VBN by/IN the/DT two/CD proteins/NNS ./. 
UI/LS -/: 99176388/CD 
TI/LS -/: Abnormalities/NNS of/IN cyclic/JJ adenosine/NN monophosphate/NN signaling/NN in/IN platelets/NNS from/IN untreated/JJ patients/NNS with/IN bipolar/JJ disorder/NN ./. 
AB/LS -/: BACKGROUND/NN :/: Abnormalities/NNS in/IN the/DT cyclic/JJ adenosine/NN monophosphate/NN (/( cAMP/NN )/) -dependent/JJ phosphorylation/NN system/NN have/VBP been/VBN recently/RB reported/VBN in/IN patients/NNS with/IN bipolar/JJ disorder/NN ./. 
We/PRP evaluated/VBD the/DT immunoreactivity/NN of/IN the/DT regulatory/JJ and/CC catalytic/JJ subunits/NNS of/IN cAMP-dependent/JJ protein/NN kinase/NN (/( protein/NN kinase/NN A/NN )/) and/CC 1/CD of/IN its/PRP$ substrates/NNS ,/, Rap1/NN ,/, in/IN platelets/NNS from/IN untreated/JJ euthymic/JJ ,/, manic/JJ ,/, and/CC depressed/JJ patients/NNS with/IN bipolar/JJ disorder/NN and/CC healthy/JJ subjects/NNS ./. 
METHODS/NNS :/: Platelets/NNS were/VBD collected/VBN from/IN 112/CD drug-free/JJ patients/NNS with/IN bipolar/JJ disorder/NN (/( 52/CD euthymic/JJ ,/, 29/CD depressed/JJ ,/, and/CC 31/CD manic/JJ )/) and/CC 62/CD healthy/JJ subjects/NNS ./. 
The/DT levels/NNS of/IN cAMP-dependent/JJ protein/NN kinase/NN and/CC Rap1/NN were/VBD assessed/VBN by/IN Western/NN blot/NN analysis/NN ,/, immunostaining/NN ,/, and/CC computer-assisted/JJ imaging/NN ./. 
RESULTS/NNS :/: The/DT immunolabeling/NN of/IN the/DT catalytic/JJ subunit/NN of/IN cAMP-dependent/JJ protein/NN kinase/NN was/VBD significantly/RB different/JJ among/IN groups/NNS (/( P/NN </JJR .001/CD )/) ,/, with/IN higher/JJR values/NNS in/IN untreated/JJ depressed/JJ and/CC manic/JJ patients/NNS with/IN bipolar/JJ disorder/NN compared/VBN with/IN untreated/JJ euthymic/JJ patients/NNS with/IN bipolar/JJ disorder/NN and/CC healthy/JJ subjects/NNS ./. 
No/DT significant/JJ differences/NNS were/VBD found/VBN in/IN the/DT immunolabeling/NN of/IN the/DT regulatory/JJ subunits/NNS (/( type/NN I/CD and/CC type/NN II/CD )/) of/IN cAMP-dependent/JJ protein/NN kinase/NN ./. 
The/DT immunolabeling/NN of/IN Rap1/NN was/VBD significantly/RB higher/JJR (/( P/NN </JJR .001/CD )/) in/IN untreated/JJ euthymic/JJ ,/, depressed/JJ ,/, and/CC manic/JJ patients/NNS than/IN in/IN healthy/JJ persons/NNS ./. 
CONCLUSIONS/NNS :/: Levels/NNS of/IN Rap1/NN and/CC the/DT catalytic/JJ subunit/NN of/IN cAMP-dependent/JJ protein/NN kinase/NN are/VBP altered/VBN in/IN the/DT platelets/NNS of/IN bipolar/JJ patients/NNS ./. 
These/DT findings/NNS may/MD provide/VB clues/NNS toward/IN understanding/VBG the/DT involvement/NN of/IN cAMP/NN signaling/NN in/IN the/DT pathogenesis/NN of/IN bipolar/JJ disorder/NN ./. 
UI/LS -/: 99243471/CD 
TI/LS -/: Molecular/JJ regulation/NN of/IN cytokine/NN gene/NN expression/NN during/IN the/DT immune/JJ response/NN ./. 
AB/LS -/: Cytokine/NN expression/NN by/IN immune/JJ system/NN cells/NNS plays/VBZ an/DT important/JJ role/NN in/IN the/DT regulation/NN of/IN the/DT immune/JJ response/NN ./. 
On/IN first/JJ encounter/NN with/IN antigen/NN ,/, naive/JJ CD4+/JJ T/NN helper/NN (/( Th/NN )/) cells/NNS differentiate/VBP into/IN cytokine-producing/JJ effector/NN cells/NNS ./. 
Two/CD types/NNS of/IN effector/NN cells/NNS characterized/VBN by/IN their/PRP$ distinct/JJ expression/NN of/IN cytokine/NN profiles/NNS have/VBP been/VBN described/VBN ./. 
Th1/NN cells/NNS produce/VBP IL-2/NN and/CC IFN-gamma/NN ,/, whereas/IN Th2/NN cells/NNS produce/VBP IL-4/NN ,/, IL-5/NN ,/, IL-6/NN ,/, IL-10/NN ,/, and/CC IL-13/NN ./. 
In/IN many/JJ pathological/JJ situations/NNS ,/, the/DT balance/NN between/IN Th1/NN and/CC Th2/NN immune/JJ responses/NNS determines/VBZ the/DT outcome/NN of/IN diverse/JJ immunologically/RB mediated/VBN clinical/JJ syndromes/NNS including/VBG infectious/JJ ,/, autoimmune/JJ ,/, and/CC allergic/JJ diseases/NNS ./. 
However/RB ,/, the/DT molecular/JJ basis/NN for/IN the/DT tissue-specific/JJ expression/NN of/IN Th1/Th2-like/JJ cytokines/NNS has/VBZ remained/VBN elusive/JJ ./. 
In/IN this/DT review/NN we/PRP evaluate/VBP the/DT possible/JJ in/FW vivo/FW role/NN of/IN different/JJ transcription/NN factors/NNS and/CC transcriptional/JJ mechanisms/NNS in/IN T/NN cell/NN differentiation/NN and/CC the/DT immune/JJ response/NN ./. 
UI/LS -/: 99236832/CD 
TI/LS -/: Tcf-1-mediated/JJ transcription/NN in/IN T/NN lymphocytes/NNS :/: differential/JJ role/NN for/IN glycogen/NN synthase/NN kinase-3/NN in/IN fibroblasts/NNS and/CC T/NN cells/NNS ./. 
AB/LS -/: Beta-catenin/NN is/VBZ the/DT vertebrate/JJ homolog/NN of/IN the/DT Drosophila/NN segment/NN polarity/NN gene/NN Armadillo/NN and/CC plays/VBZ roles/NNS in/IN both/CC cell-cell/JJ adhesion/NN and/CC transduction/NN of/IN the/DT Wnt/NN signaling/NN cascade/NN ./. 
Recently/RB ,/, members/NNS of/IN the/DT Lef/Tcf/NN transcription/NN factor/NN family/NN have/VBP been/VBN identified/VBN as/IN protein/NN partners/NNS of/IN beta-catenin/NN ,/, explaining/VBG how/WRB beta-catenin/NN alters/VBZ gene/NN expression/NN ./. 
Here/RB we/PRP report/VBP that/IN in/IN T/NN cells/NNS ,/, Tcf-1/NN also/RB becomes/VBZ transcriptionally/RB active/JJ through/IN interaction/NN with/IN beta-catenin/NN ,/, suggesting/VBG that/IN the/DT Wnt/NN signal/NN transduction/NN pathway/NN is/VBZ operational/JJ in/IN T/NN lymphocytes/NNS as/RB well/RB ./. 
However/RB ,/, although/IN Wnt/NN signals/NNS are/VBP known/VBN to/TO inhibit/VB the/DT activity/NN of/IN the/DT negative/JJ regulatory/JJ protein/NN kinase/NN glycogen/NN synthase/NN kinase-3beta/NN (/( GSK-3beta/NN )/) ,/, resulting/VBG in/IN increased/VBN levels/NNS of/IN beta-catenin/NN ,/, we/PRP find/VBP no/DT evidence/NN for/IN involvement/NN of/IN GSK-3beta/NN in/IN Tcf-mediated/JJ transcription/NN in/IN T/NN cells/NNS ./. 
That/DT is/VBZ ,/, a/DT dominant/JJ negative/JJ GSK-3beta/NN does/VBZ not/RB specifically/RB activate/VB Tcf/NN transcription/NN and/CC stimuli/NNS (/( lithium/NN or/CC phytohemagglutinin/NN )/) that/WDT inhibit/VBP GSK-3beta/NN activity/NN also/RB do/VBP not/RB activate/VB Tcf/NN reporter/NN genes/NNS ./. 
Thus/RB ,/, inhibition/NN of/IN GSK-3beta/NN is/VBZ insufficient/JJ to/TO activate/VB Tcf-dependent/JJ transcription/NN in/IN T/NN lymphocytes/NNS ./. 
In/IN contrast/NN ,/, in/IN C57MG/NN fibroblast/NN cells/NNS ,/, lithium/NN inactivates/VBZ GSK-3beta/NN and/CC induces/VBZ Tcf-controlled/JJ transcription/NN ./. 
This/DT is/VBZ the/DT first/JJ demonstration/NN that/IN lithium/NN can/MD alter/VB gene/NN expression/NN of/IN Tcf-responsive/JJ genes/NNS ,/, and/CC points/VBZ to/TO a/DT difference/NN in/IN regulation/NN of/IN Wnt/NN signaling/NN between/IN fibroblasts/NNS and/CC lymphocytes/NNS ./. 
UI/LS -/: 99225548/CD 
TI/LS -/: SHP2-interacting/JJ transmembrane/JJ adaptor/NN protein/NN (/( SIT/NN )/) ,/, a/DT novel/JJ disulfide-linked/JJ dimer/NN regulating/VBG human/JJ T/NN cell/NN activation/NN ./. 
AB/LS -/: T/NN lymphocytes/NNS express/VBP several/JJ low/JJ molecular/JJ weight/NN transmembrane/JJ adaptor/NN proteins/NNS that/WDT recruit/VBP src/NN homology/NN (/( SH/NN )/) 2/CD domain-containing/JJ intracellular/JJ molecules/NNS to/TO the/DT cell/NN membrane/NN via/IN tyrosine-based/JJ signaling/JJ motifs/NNS ./. 
We/PRP describe/VBP here/RB a/DT novel/JJ molecule/NN of/IN this/DT group/NN termed/VBN SIT/NN (/( SHP2/NN interacting/NN transmembrane/JJ adaptor/NN protein/NN )/) ./. 
SIT/NN is/VBZ a/DT disulfide-linked/JJ homodimeric/JJ glycoprotein/NN that/WDT is/VBZ expressed/VBN in/IN lymphocytes/NNS ./. 
After/IN tyrosine/NN phosphorylation/NN by/IN src/NN and/CC possibly/RB syk/NN protein/NN tyrosine/NN kinases/NNS SIT/NN recruits/VBZ the/DT SH2/NN domain-containing/JJ tyrosine/NN phosphatase/NN SHP2/NN via/IN an/DT immunoreceptor/NN tyrosine-based/JJ inhibition/NN motif/NN ./. 
Overexpression/NN of/IN SIT/NN in/IN Jurkat/NN cells/NNS downmodulates/VBZ T/NN cell/NN receptor-/NN and/CC phytohemagglutinin-mediated/JJ activation/NN of/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) by/IN interfering/VBG with/IN signaling/NN processes/NNS that/WDT are/VBP probably/RB located/JJ upstream/RB of/IN activation/NN of/IN phospholipase/NN C/NN ./. 
However/RB ,/, binding/NN of/IN SHP2/NN to/TO SIT/NN is/VBZ not/RB required/VBN for/IN inhibition/NN of/IN NF-AT/NN induction/NN ,/, suggesting/VBG that/IN SIT/NN not/RB only/RB regulates/VBZ NF-AT/NN activity/NN but/CC also/RB controls/VBZ NF-AT/NN unrelated/JJ pathways/NNS of/IN T/NN cell/NN activation/NN involving/VBG SHP2/NN ./. 
UI/LS -/: 99218532/CD 
TI/LS -/: Extracellular-regulated/JJ kinase/NN 1/2/CD ,/, Jun/NN N-terminal/JJ kinase/NN ,/, and/CC c-Jun/NN are/VBP involved/VBN in/IN NF-kappa/NN B-dependent/JJ IL-6/NN expression/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: In/IN the/DT present/JJ study/NN we/PRP investigated/VBD the/DT possible/JJ involvement/NN of/IN the/DT mitogen-activated/JJ protein/NN kinase/NN family/NN members/NNS extracellular-regulated/JJ kinase/NN 1/2/CD (/( ERK1/2/NN )/) and/CC c-Jun/NN N-terminal/JJ kinase/NN (/( JNK/NN )/) in/IN mediating/VBG IL-6/NN gene/NN expression/NN in/IN human/JJ monocytes/NNS ,/, in/IN particular/JJ their/PRP$ role/NN in/IN enhancing/VBG NF-kappa/NN B/NN activity/NN ./. 
Freshly/RB isolated/VBN monocytes/NNS treated/VBN with/IN the/DT protein/NN phosphatase/NN inhibitor/NN okadaic/JJ acid/NN secreted/VBD high/JJ levels/NNS of/IN IL-6/NN protein/NN ,/, which/WDT coincided/VBD with/IN enhanced/VBN binding/NN activity/NN of/IN NF-kappa/NN B/NN as/RB well/RB as/IN with/IN phosphorylation/NN and/CC activation/NN of/IN the/DT ERK1/2/NN and/CC JNK/NN proteins/NNS ./. 
The/DT ERK/NN pathway-specific/JJ inhibitor/NN PD98059/NN inhibited/VBD IL-6/NN secretion/NN from/IN monocytes/NNS ./. 
Transient/JJ overexpression/NN of/IN inactive/JJ mutants/NNS of/IN either/CC Raf-1/NN or/CC JNK1/NN showed/VBD that/IN both/DT pathways/NNS were/VBD involved/VBN in/IN kappa/NN B-dependent/JJ IL-6/NN promoter/NN activity/NN ./. 
By/IN using/VBG PD98059/NN ,/, we/PRP demonstrated/VBD that/IN the/DT Raf1/MEK1/ERK1/2/NN pathway/NN did/VBD not/RB affect/VB the/DT DNA/NN binding/NN of/IN NF-kappa/NN B/NN but/CC ,/, rather/RB ,/, acted/VBD at/IN the/DT level/NN of/IN transcriptional/JJ activity/NN of/IN NF-kappa/NN B/NN ./. 
Interestingly/RB ,/, it/PRP was/VBD shown/VBN that/IN NF-kappa/NN B-mediated/JJ gene/NN transcription/NN ,/, both/DT in/IN the/DT context/NN of/IN the/DT IL-6/NN promoter/NN as/RB well/RB as/IN on/IN its/PRP$ own/JJ ,/, was/VBD dependent/JJ on/IN both/CC serine/JJ kinase/NN activity/NN and/CC interaction/NN with/IN c-Jun/NN protein/NN ./. 
We/PRP conclude/VBP that/IN okadaic/JJ acid-induced/JJ IL-6/NN gene/NN expression/NN is/VBZ at/IN least/JJS partly/RB mediated/VBN through/IN the/DT ERK1/2/NN and/CC JNK/NN pathway-dependent/JJ activation/NN of/IN NF-kappa/NN B/NN transcriptional/JJ capacity/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN the/DT JNK/NN pathway/NN may/MD regulate/VB NF-kappa/NN B-mediated/JJ gene/NN transcription/NN through/IN its/PRP$ phosphorylation/NN and/CC activation/NN of/IN c-Jun/NN ./. 
UI/LS -/: 99209803/CD 
TI/LS -/: The/DT Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD (/( EBNA2/NN )/) ,/, a/DT protein/NN required/VBN for/IN B/NN lymphocyte/NN immortalization/NN ,/, induces/VBZ the/DT synthesis/NN of/IN type/NN I/CD interferon/NN in/IN Burkitt/NN 's/POS lymphoma/NN cell/NN lines/NNS ./. 
AB/LS -/: Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD (/( EBNA2/NN )/) ,/, a/DT protein/NN involved/VBN in/IN cell/NN transformation/NN ,/, interferes/VBZ with/IN the/DT cellular/JJ response/NN to/TO type/NN I/CD interferons/NNS (/( IFN-alpha/beta/NN )/) ./. 
We/PRP investigated/VBD the/DT function/NN of/IN conditionally/RB expressed/VBN EBNA2/NN in/IN the/DT context/NN of/IN the/DT IFN/NN response/NN in/IN Burkitt/NN 's/POS lymphoma/NN cell/NN lines/NNS ./. 
Expression/NN of/IN EBNA2/NN led/VBD to/TO the/DT transcriptional/JJ activation/NN of/IN both/DT endogenous/JJ or/CC transfected/VBN IFN-stimulated/JJ genes/NNS (/( ISGs/NNS )/) ,/, genes/NNS which/WDT contain/VBP within/IN their/PRP$ promoters/NNS either/CC the/DT interferon-stimulated/JJ response/NN element/NN (/( ISRE/NN )/) or/CC the/DT gamma/NN interferon/NN activation/NN site/NN (/( GAS/NN )/) ./. 
In/IN search/NN of/IN a/DT molecular/JJ mechanism/NN for/IN the/DT transcriptional/JJ induction/NN of/IN ISGs/NNS ,/, we/PRP observed/VBD an/DT EBNA2-dependent/JJ synthesis/NN of/IN IFN-beta/NN mRNA/NN at/IN low/JJ levels/NNS and/CC the/DT secretion/NN of/IN low/JJ amounts/NNS of/IN IFN/NN ./. 
A/DT transfected/VBN IFN-beta/NN promoter/NN responded/VBD to/TO EBNA2/NN activation/NN ,/, and/CC a/DT sequence/NN closely/RB resembling/VBG a/DT RBP-Jkappa/NN binding/NN site/NN was/VBD pinpointed/VBN as/IN a/DT potential/JJ target/NN of/IN EBNA2/NN activity/NN ./. 
EBNA2-dependent/JJ transcriptional/JJ induction/NN of/IN the/DT IFN-beta/NN promoter/NN occurred/VBD in/IN EBV-negative/JJ Burkitt/NN 's/POS lymphoma/NN cells/NNS ,/, indicating/VBG that/IN other/JJ EBV/NN genes/NNS were/VBD not/RB required/VBN for/IN the/DT induction/NN of/IN IFN-beta/NN synthesis/NN ./. 
UI/LS -/: 99200936/CD 
TI/LS -/: PGG-glucan/NN ,/, a/DT soluble/JJ beta-(1,3)-glucan/NN ,/, enhances/VBZ the/DT oxidative/JJ burst/NN response/NN ,/, microbicidal/JJ activity/NN ,/, and/CC activates/VBZ an/DT NF-kappa/NN B-like/JJ factor/NN in/IN human/JJ PMN/NN :/: evidence/NN for/IN a/DT glycosphingolipid/NN beta-(1,3)-glucan/NN receptor/NN ./. 
AB/LS -/: PGG-Glucan/NN ,/, a/DT soluble/JJ beta-(1,6)-branched/JJ beta-(1,3)-linked/JJ glucose/NN homopolymer/NN derived/VBN from/IN the/DT cell/NN wall/NN of/IN the/DT yeast/NN Saccharomyces/FW cerevisiae/FW ,/, is/VBZ an/DT immunomodulator/NN which/WDT enhances/VBZ leukocyte/NN anti-infective/JJ activity/NN and/CC enhances/VBZ myeloid/JJ and/CC megakaryocyte/NN progenitor/NN proliferation/NN ./. 
Incubation/NN of/IN human/JJ whole/JJ blood/NN with/IN PGG-Glucan/NN significantly/RB enhanced/VBD the/DT oxidative/JJ burst/NN response/NN of/IN subsequently/RB isolated/VBN blood/NN leukocytes/NNS to/TO both/CC soluble/JJ and/CC particulate/JJ activators/NNS in/IN a/DT dose-dependent/JJ manner/NN ,/, and/CC increased/VBD leukocyte/NN microbicidal/JJ activity/NN ./. 
No/DT evidence/NN for/IN inflammatory/JJ cytokine/NN production/NN was/VBD obtained/VBN under/IN these/DT conditions/NNS ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS demonstrated/VBD that/IN PGG-Glucan/NN induced/VBD the/DT activation/NN of/IN an/DT NF-kappaB-like/JJ nuclear/JJ transcription/NN factor/NN in/IN purified/VBN human/JJ neutrophils/NNS ./. 
The/DT binding/NN of/IN 3H-PGG-Glucanto/TO human/JJ leukocyte/NN membranes/NNS was/VBD specific/JJ ,/, concentration-dependent/JJ ,/, saturable/JJ ,/, and/CC high/JJ affinity/NN (/( Kd/NN approximately/RB 6/CD nM/NN )/) ./. 
A/DT monoclonal/JJ antibody/NN specific/JJ to/TO the/DT glycosphingolipid/NN lactosylceramide/NN was/VBD able/JJ to/TO inhibit/VB activation/NN of/IN the/DT NF-kappaB-like/JJ factor/NN by/IN PGG-Glucan/NN ,/, and/CC ligand/NN binding/NN data/NNS ,/, including/VBG polysaccharide/NN specificity/NN ,/, suggested/VBD that/IN the/DT PGG-Glucan/NN binding/NN moiety/NN was/VBD lactosylceramide/NN ./. 
These/DT results/NNS indicate/VBP that/IN PGG-Glucan/NN enhances/VBZ neutrophil/NN anti-microbial/JJ functions/NNS and/CC that/IN interaction/NN between/IN this/DT beta-glucan/NN and/CC human/JJ neutrophils/NNS is/VBZ mediated/VBN by/IN the/DT glycosphingolipid/NN lactosylceramide/NN present/JJ at/IN the/DT cell/NN surface/NN ./. 
UI/LS -/: 99192785/CD 
TI/LS -/: Glucocorticoids/NNS promote/VBP nonphlogistic/JJ phagocytosis/NN of/IN apoptotic/JJ leukocytes/NNS ./. 
AB/LS -/: Phagocyte/NN recognition/NN ,/, uptake/NN ,/, and/CC nonphlogistic/JJ degradation/NN of/IN neutrophils/NNS and/CC other/JJ leukocytes/NNS undergoing/VBG apoptosis/NN promote/VBP the/DT resolution/NN of/IN inflammation/NN ./. 
This/DT study/NN assessed/VBD the/DT effects/NNS of/IN anti-inflammatory/JJ glucocorticoids/NNS on/IN this/DT leukocyte/NN clearance/NN mechanism/NN ./. 
Pretreatment/NN of/IN "/`` semimature/JJ "/'' 5-day/JJ human/JJ monocyte-derived/JJ macrophages/NNS (/( M/NN phi/NN )/) for/IN 24/CD h/NN with/IN methylprednisolone/NN ,/, dexamethasone/NN ,/, and/CC hydrocortisone/NN ,/, but/CC not/RB the/DT nonglucocorticoid/NN steroids/NNS aldosterone/NN ,/, estradiol/NN ,/, and/CC progesterone/NN ,/, potentiated/VBD phagocytosis/NN of/IN apoptotic/JJ neutrophils/NNS ./. 
These/DT effects/NNS were/VBD specific/JJ in/IN that/IN the/DT potentiated/JJ phagocytosis/NN of/IN apoptotic/JJ neutrophils/NNS was/VBD completely/RB blocked/VBN by/IN the/DT glucocorticoid/NN receptor/NN antagonist/NN RU38486/NN ,/, and/CC glucocorticoids/NNS did/VBD not/RB promote/VB 5-day/JJ M/NN phi/NN ingestion/NN of/IN opsonized/VBN erythrocytes/NNS ./. 
Similar/JJ glucocorticoid-mediated/JJ potentiation/NN was/VBD observed/VBN with/IN 5-day/JJ M/NN phi/NN uptake/NN of/IN alternative/JJ apoptotic/JJ "/`` targets/NNS "/'' (/( eosinophils/NNS and/CC Jurkat/NN T/NN cells/NNS )/) and/CC in/IN uptake/NN of/IN apoptotic/JJ neutrophils/NNS by/IN alternative/JJ phagocytes/NNS (/( human/JJ glomerular/JJ mesangial/JJ cells/NNS and/CC murine/JJ M/NN phi/NN elicited/VBN into/IN the/DT peritoneum/NN or/CC derived/VBN from/IN bone/NN marrow/NN )/) ./. 
Importantly/RB ,/, methylprednisolone-mediated/JJ enhancement/NN of/IN the/DT uptake/NN of/IN apoptotic/JJ neutrophils/NNS did/VBD not/RB trigger/VB the/DT release/NN of/IN the/DT chemokines/NNS IL-8/NN and/CC monocyte/NN chemoattractant/NN protein-1/NN ./. 
Furthermore/RB ,/, longer-term/JJ potentiation/NN by/IN methylprednisolone/NN was/VBD observed/VBN in/IN maturing/VBG human/JJ monocyte-derived/JJ M/NN phi/NN ,/, with/IN greater/JJR increases/NNS in/IN 5-day/JJ M/NN phi/NN uptake/NN of/IN apoptotic/JJ cells/NNS being/VBG observed/VBN the/DT earlier/JJR glucocorticoids/NNS were/VBD added/VBN during/IN monocyte/NN maturation/NN into/IN M/NN phi/NN ./. 
We/PRP conclude/VBP that/IN potentiation/NN of/IN nonphlogistic/JJ clearance/NN of/IN apoptotic/JJ leukocytes/NNS by/IN phagocytes/NNS is/VBZ a/DT hitherto/RB unrecognized/JJ property/NN of/IN glucocorticoids/NNS that/WDT has/VBZ potential/JJ implications/NNS for/IN therapies/NNS aimed/VBN at/IN promoting/VBG the/DT resolution/NN of/IN inflammatory/JJ diseases/NNS ./. 
UI/LS -/: 99192438/CD 
TI/LS -/: 1,25-Dihydroxyvitamin/NN D3/NN induces/VBZ differentiation/NN of/IN a/DT retinoic/JJ acid-resistant/JJ acute/JJ promyelocytic/JJ leukemia/NN cell/NN line/NN (/( UF-1/NN )/) associated/VBN with/IN expression/NN of/IN p21/NN (/( WAF1/CIP1/NN )/) and/CC p27/NN (/( KIP1/NN )/) ./. 
AB/LS -/: Retinoic/JJ acid/NN (/( RA/NN )/) resistance/NN is/VBZ a/DT serious/JJ problem/NN for/IN patients/NNS with/IN acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) who/WP are/VBP receiving/VBG all-trans/JJ RA/NN ./. 
However/RB ,/, the/DT mechanisms/NNS and/CC strategies/NNS to/TO overcome/VB RA/NN resistance/NN by/IN APL/NN cells/NNS are/VBP still/RB unclear/JJ ./. 
The/DT biologic/JJ effects/NNS of/IN RA/NN are/VBP mediated/VBN by/IN two/CD distinct/JJ families/NNS of/IN transcriptional/JJ factors/NNS :/: RA/NN receptors/NNS (/( RARs/NNS )/) and/CC retinoid/NN X/NN receptors/NNS (/( RXRs/NNS )/) ./. 
RXRs/NNS heterodimerize/VBP with/IN 1, 25-dihydroxyvitamin/NN D3/NN [/( 1,25(OH)2D3/NN ]/) receptor/NN (/( VDR/NN )/) ,/, enabling/VBG their/PRP$ efficient/JJ transcriptional/JJ activation/NN ./. 
The/DT cyclin-dependent/JJ kinase/NN (/( cdk/NN )/) inhibitor/NN p21/NN (/( WAF1/CIP1/NN )/) has/VBZ a/DT vitamin/NN D3-responsive/JJ element/NN (/( VDRE/NN )/) in/IN its/PRP$ promoter/NN ,/, and/CC 1,25(OH)2D3/NN enhances/VBZ the/DT expression/NN of/IN p21/NN (/( WAF1/CIP1/NN )/) and/CC induces/VBZ differentiation/NN of/IN selected/VBN myeloid/JJ leukemic/JJ cell/NN lines/NNS ./. 
We/PRP have/VBP recently/RB established/VBN a/DT novel/JJ APL/NN cell/NN line/NN (/( UF-1/NN )/) with/IN features/NNS of/IN RA/NN resistance/NN ./. 
1,25(OH)2D3/NN can/MD induce/VB growth/NN inhibition/NN and/CC G1/NN arrest/NN of/IN UF-1/NN cells/NNS ,/, resulting/VBG in/IN differentiation/NN of/IN these/DT cells/NNS toward/IN granulocytes/NNS ./. 
This/DT 1, 25(OH)2D3-induced/JJ G1/NN arrest/NN is/VBZ enhanced/VBN by/IN all-trans/JJ RA/NN ./. 
Also/RB ,/, 1, 25(OH)2D3/NN (/( 10(-10)/CD to/TO 10(-7)/CD mol/L/NN )/) in/IN combination/NN with/IN RA/NN markedly/RB inhibits/VBZ cellular/JJ proliferation/NN in/IN a/DT dose-/NN and/CC time-dependent/JJ manner/NN ./. 
Associated/VBN with/IN these/DT findings/NNS ,/, the/DT levels/NNS of/IN p21/NN (/( WAF1/CIP1/NN )/) and/CC p27/NN (/( KIP1/NN )/) mRNA/NN and/CC protein/NN increased/VBD in/IN these/DT cells/NNS ./. 
Northern/NN blot/NN analysis/NN showed/VBD that/IN p21/NN (/( WAF1/CIP1/NN )/) and/CC p27/NN (/( KIP1/NN )/) mRNA/NN and/CC protein/NN increased/VBD in/IN these/DT cells/NNS ./. 
Northern/NN blot/NN analysis/NN showed/VBD that/IN p21/NN (/( WAF1/CIP1/NN )/) and/CC p27/NN (/( KIP1/NN )/) transcripts/NNS were/VBD induced/VBN after/IN 6/CD hours/NNS '/POS exposure/NN to/TO 1,25(OH)2D3/NN and/CC then/RB decreased/VBD to/TO basal/JJ levels/NNS over/IN 48/CD hours/NNS ./. 
Western/NN blot/NN experiments/NNS showed/VBD that/IN p21/NN (/( WAF1/CIP1/NN )/) protein/NN levels/NNS increased/VBD and/CC became/VBD detectable/JJ after/IN 12/CD hours/NNS of/IN 1,25(OH)2D3/NN treatment/NN and/CC induction/NN of/IN p27/NN (/( KIP1/NN )/) protein/NN was/VBD much/RB more/RBR gradual/JJ and/CC sustained/JJ in/IN UF-1/NN cells/NNS ./. 
Interestingly/RB ,/, the/DT combination/NN of/IN 1, 25(OH)2D3/NN and/CC RA/NN markedly/RB enhanced/VBD the/DT levels/NNS of/IN p27/NN (/( KIP1/NN )/) transcript/NN and/CC protein/NN as/IN compared/VBN with/IN levels/NNS induced/VBN by/IN 1, 25(OH)2D3/NN alone/RB ./. 
In/IN addition/NN ,/, exogenous/JJ p27/NN (/( KIP1/NN )/) expression/NN can/MD enhance/VB the/DT level/NN of/IN CD11b/NN antigen/NN in/IN myeloid/JJ leukemic/JJ cells/NNS ./. 
In/IN contrast/NN ,/, RA/NN alone/RB can/MD induce/VB G1/NN arrest/NN of/IN UF-1/NN cells/NNS ;/: however/RB ,/, it/PRP did/VBD not/RB result/VB in/IN an/DT increase/NN of/IN p21/NN (/( WAF1/CIP1/NN )/) and/CC p27/NN (/( KIP1/NN )/) transcript/NN and/CC protein/NN expression/NN in/IN RA-resistant/JJ cells/NNS ./. 
Taken/VBN together/RB ,/, we/PRP conclude/VBP that/IN 1,25(OH)2D3/NN induces/VBZ increased/VBN expression/NN of/IN cdk/NN inhibitors/NNS ,/, which/WDT mediates/VBZ a/DT G1/NN arrest/NN ,/, and/CC this/DT may/MD be/VB associated/VBN with/IN differentiation/NN of/IN RA-resistant/JJ UF-1/NN cells/NNS toward/IN mature/JJ granulocytes/NNS ./. 
UI/LS -/: 99182374/CD 
TI/LS -/: Molecular/JJ mechanisms/NNS of/IN neutrophil-endothelial/JJ cell/NN adhesion/NN induced/VBN by/IN redox/NN imbalance/NN ./. 
AB/LS -/: Previous/JJ studies/NNS have/VBP implicated/VBN a/DT role/NN for/IN intracellular/JJ thiols/NNS in/IN the/DT activation/NN of/IN nuclear/JJ factor-kappaB/NN and/CC transcriptional/JJ regulation/NN of/IN endothelial/JJ cell/NN adhesion/NN molecules/NNS ./. 
This/DT study/NN was/VBD designed/VBN to/TO determine/VB whether/IN changes/NNS in/IN endothelial/JJ cell/NN glutathione/NN (/( GSH/NN )/) or/CC oxidized/VBN glutathione/NN (/( GSSG/NN )/) can/MD alter/VB neutrophil/NN adhesivity/NN and/CC to/TO define/VB the/DT molecular/JJ mechanism/NN that/WDT underlies/VBZ this/DT GSSG/GSH-induced/JJ adhesion/NN response/NN ./. 
Treatment/NN of/IN human/JJ umbilical/JJ vein/NN endothelial/JJ cell/NN (/( HUVEC/NN )/) monolayers/NNS for/IN 6/CD hours/NNS with/IN 0.2/CD mmol/L/NN diamide/NN and/CC 1/CD mmol/L/NN buthionine/NN sulfoximine/NN (/( BSO/NN )/) decreased/VBD GSH/NN levels/NNS and/CC increased/VBD the/DT ratio/NN of/IN GSSG/NN to/TO GSH/NN without/IN cell/NN toxicity/NN ./. 
These/DT redox/NN changes/NNS are/VBP similar/JJ to/TO those/DT observed/VBN with/IN anoxia/reoxygenation/NN ./. 
Diamide/NN plus/CC BSO-induced/JJ thiol/disulfide/NN imbalance/NN was/VBD associated/VBN with/IN a/DT biphasic/JJ increase/NN in/IN neutrophil/NN adhesion/NN to/TO HUVECs/NNS with/IN peak/JJ responses/NNS observed/VBN at/IN 15/CD minutes/NNS (/( phase/NN 1/CD )/) and/CC 240/CD minutes/NNS (/( phase/NN 2/CD )/) ./. 
N-Acetylcysteine/NN treatment/NN attenuated/VBD neutrophil/NN adhesion/NN in/IN both/DT phases/NNS ,/, which/WDT indicated/VBD a/DT role/NN for/IN GSH/NN in/IN the/DT adhesion/NN responses/NNS ./. 
Interestingly/RB ,/, phase/NN 1/CD adhesion/NN was/VBD inversely/RB correlated/VBN with/IN GSH/NN levels/NNS but/CC not/RB with/IN the/DT GSSG/GSH/NN ratio/NN ,/, whereas/IN phase/NN 2/CD neutrophil/NN adhesion/NN was/VBD positively/RB correlated/VBN with/IN GSSG/GSH/NN ratio/NN but/CC not/RB with/IN GSH/NN levels/NNS ./. 
Intercellular/JJ adhesion/NN molecule-1/NN and/CC P-selectin-specific/JJ monoclonal/JJ antibodies/NNS attenuated/VBD the/DT increased/VBN neutrophil/NN adhesion/NN during/IN both/DT phases/NNS ,/, whereas/IN an/DT anti-E-selectin/JJ monoclonal/JJ antibody/NN also/RB attenuated/VBD the/DT phase/NN 2/CD response/NN ./. 
Pretreatment/NN with/IN actinomycin/NN D/NN and/CC cycloheximide/NN or/CC with/IN competing/VBG ds-oligonucleotides/NNS that/WDT contained/VBD nuclear/JJ factor-kappaB/NN or/CC activator/NN protein-1/NN cognate/NN DNA/NN sequences/NNS significantly/RB attenuated/VBD the/DT phase/NN 2/CD response/NN ,/, which/WDT implicated/VBD a/DT role/NN for/IN de/FW novo/FW protein/NN synthesis/NN ./. 
Surface/NN expression/NN of/IN intercellular/JJ adhesion/NN molecule-1/NN ,/, P-/JJ selectin/NN ,/, and/CC E-selectin/NN on/IN HUVECs/NNS correlated/VBD with/IN the/DT phase/NN 1/CD and/CC 2/CD neutrophil/NN adhesion/NN responses/NNS ./. 
This/DT study/NN demonstrates/VBZ that/IN changes/NNS in/IN endothelial/JJ cell/NN GSSG/GSH/NN cause/VBP transcription-independent/JJ and/CC transcription-dependent/JJ surface/NN expression/NN of/IN different/JJ endothelial/JJ cell/NN adhesion/NN molecules/NNS ,/, which/WDT leads/VBZ to/TO a/DT 2-phase/JJ neutrophil-endothelial/JJ adhesion/NN response/NN ./. 
UI/LS -/: 99174774/CD 
TI/LS -/: Glucocorticoid/NN hormone/NN suppression/NN of/IN human/JJ neutrophil-mediated/JJ tumor/NN cell/NN cytostasis/NN ./. 
AB/LS -/: In/IN the/DT present/JJ study/NN ,/, we/PRP have/VBP investigated/VBN the/DT effect/NN of/IN glucocorticoid/NN hormones/NNS on/IN neutrophil-mediated/JJ tumor/NN cell/NN cytostasis/NN and/CC found/VBN that/IN hydrocortisone/NN and/CC a/DT synthetic/JJ hormone/NN ,/, dexamethasone/NN (/( Dex/NN )/) ,/, inhibited/VBD cytostasis/NN in/IN the/DT presence/NN or/CC absence/NN of/IN tumor/NN necrosis/NN factor-alpha/NN ./. 
The/DT effect/NN of/IN Dex/NN was/VBD completely/RB reversed/VBN by/IN a/DT glucocorticoid/NN receptor/NN antagonist/NN ,/, RU38486/NN ./. 
To/TO clarify/VB the/DT underlying/JJ mechanisms/NNS ,/, we/PRP examined/VBD effects/NNS of/IN Dex/NN on/IN the/DT binding/NN avidity/NN of/IN beta2/NN integrin/NN on/IN the/DT neutrophil/NN surface/NN and/CC how/WRB these/DT might/MD in/IN turn/NN affect/VB neutrophil-to-tumor/JJ cell/NN binding/NN ./. 
Dex/NN was/VBD found/VBN to/TO inhibit/VB these/DT neutrophil/NN properties/NNS ,/, and/CC RU38486/NN completely/RB suppressed/VBD both/DT forms/NNS of/IN Dex/NN inhibition/NN ./. 
Taken/VBN together/RB ,/, our/PRP$ findings/NNS suggest/VBP that/IN glucocorticoid/NN hormone/NN inhibition/NN of/IN neutrophil-mediated/JJ tumor/NN cell/NN cytostasis/NN is/VBZ at/IN least/JJS partially/RB due/JJ to/TO a/DT lowering/NN of/IN the/DT ligand/NN binding/NN avidity/NN of/IN beta2/NN integrin/NN on/IN the/DT neutrophil/NN surface/NN ./. 
UI/LS -/: 99242633/CD 
TI/LS -/: Constitutive/JJ activation/NN of/IN an/DT epithelial/JJ signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) pathway/NN in/IN asthma/NN ./. 
AB/LS -/: Cytokine/NN effects/NNS on/IN immunity/NN and/CC inflammation/NN often/RB depend/VBP on/IN the/DT transcription/NN factors/NNS termed/VBN signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STATs/NNS )/) ,/, so/RB STAT/NN signaling/NN pathways/NNS are/VBP candidates/NNS for/IN influencing/VBG inflammatory/JJ disease/NN ./. 
We/PRP reasoned/VBD that/IN selective/JJ IFN/NN responsiveness/NN of/IN the/DT first/JJ STAT/NN family/NN member/NN (/( Stat1/NN )/) and/CC Stat1-dependent/JJ immune-response/JJ genes/NNS such/JJ as/IN intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN )/) ,/, IFN/NN regulatory/JJ factor-1/NN (/( IRF-1/NN )/) ,/, and/CC Stat1/NN itself/PRP in/IN airway/NN epithelial/JJ cells/NNS provides/VBZ a/DT basis/NN for/IN detecting/VBG cytokine/NN signaling/NN abnormalities/NNS in/IN inflammatory/JJ airway/NN disease/NN ./. 
On/IN the/DT basis/NN of/IN nuclear/JJ localization/NN and/CC phosphorylation/NN ,/, we/PRP found/VBD that/IN epithelial/JJ Stat1/NN (/( but/CC not/RB other/JJ control/NN transcription/NN factors/NNS )/) was/VBD invariably/RB activated/VBN in/IN asthmatic/JJ compared/VBN with/IN normal/JJ control/JJ or/CC chronic/JJ bronchitis/NN subjects/NNS ./. 
Furthermore/RB ,/, epithelial/JJ levels/NNS of/IN activated/VBN Stat1/NN correlated/VBD with/IN levels/NNS of/IN expression/NN for/IN epithelial/JJ ICAM-1/NN ,/, IRF-1/NN ,/, and/CC Stat1/NN ,/, and/CC in/IN turn/NN ,/, ICAM-1/NN levels/NNS correlated/VBD with/IN T-cell/NN accumulation/NN in/IN tissue/NN ./. 
However/RB ,/, only/RB low/JJ levels/NNS of/IN IFN-gamma/NN or/CC IFN-gamma-producing/JJ cells/NNS were/VBD detected/VBN in/IN airway/NN tissue/NN in/IN all/DT subjects/NNS ./. 
The/DT results/NNS therefore/RB provide/VBP initial/JJ evidence/NN linking/VBG abnormal/JJ behavior/NN of/IN STAT/NN pathways/NNS for/IN cytokine/NN signaling/NN to/TO the/DT development/NN of/IN an/DT inflammatory/JJ disease/NN ./. 
In/IN that/DT context/NN ,/, the/DT results/NNS also/RB change/VBP the/DT current/JJ scheme/NN for/IN asthma/NN pathogenesis/NN to/TO one/CD that/WDT must/MD include/VB a/DT localized/JJ gain/NN in/IN transcriptional/JJ signal/NN ordinarily/RB used/VBN for/IN a/DT T/NN helper/NN 1-type/JJ cytokine/NN (/( IFN-gamma/NN )/) in/IN combination/NN with/IN allergy-driven/JJ overproduction/NN of/IN T/NN helper/NN 2-type/JJ cytokines/NNS ./. 
UI/LS -/: 99237607/CD 
TI/LS -/: Leukocyte/NN populations/NNS ,/, hormone/NN receptors/NNS and/CC apoptosis/NN in/IN eutopic/JJ and/CC ectopic/JJ first/JJ trimester/NN human/JJ pregnancies/NNS ./. 
AB/LS -/: The/DT implantation/NN of/IN trophoblast/NN cells/NNS at/IN extrauterine/JJ sites/NNS still/RB results/VBZ in/IN decidualization/NN ./. 
The/DT objective/NN of/IN the/DT present/JJ study/NN was/VBD to/TO compare/VB decidualization/NN at/IN eutopic/JJ and/CC ectopic/JJ implantation/NN sites/NNS ./. 
Tissues/NNS from/IN women/NNS undergoing/VBG elective/JJ termination/NN of/IN uterine/JJ pregnancy/NN and/CC from/IN women/NNS with/IN ectopic/JJ pregnancy/NN were/VBD used/VBN to/TO detect/VB the/DT presence/NN of/IN cells/NNS important/JJ for/IN the/DT maintenance/NN of/IN pregnancy/NN ,/, such/JJ as/IN BCL-2+/JJ ,/, CD56+/JJ ,/, CD3+/JJ ,/, CD8+/JJ and/CC CD68+/JJ cells/NNS ,/, and/CC the/DT presence/NN of/IN oestrogen/NN (/( ER/NN )/) and/CC progesterone/NN receptors/NNS (/( PR/NN )/) by/IN immunohistochemistry/NN ./. 
In-situ/FW detection/NN of/IN fragmented/JJ DNA/NN was/VBD performed/VBN to/TO identify/VB apoptotic/JJ cells/NNS ./. 
The/DT percentage/NN of/IN CD3+/JJ cells/NNS among/IN all/DT immunocompetent/JJ cells/NNS in/IN the/DT tubal/JJ epithelium/NN was/VBD 46.6/CD %/NN (/( 39.9/CD %/NN of/IN CD3+/JJ were/VBD also/RB CD8+/JJ )/) ;/: the/DT other/JJ 53.4/CD %/NN were/VBD CD68+/JJ cells/NNS ./. 
CD56+/JJ cells/NNS were/VBD undetectable/JJ in/IN ectopic/JJ decidua/NN at/IN the/DT feto-maternal/JJ interface/NN in/IN ectopic/JJ tissue/NN ./. 
In/IN uterine/JJ decidua/NN ,/, we/PRP found/VBD 29.9/CD %/NN CD3+/JJ cells/NNS (/( 2.2/CD %/NN of/IN CD3+/JJ were/VBD CD8+/JJ )/) ,/, 51.6/CD %/NN CD56+/JJ cells/NNS and/CC 18.5/CD %/NN CD68+/JJ cells/NNS ./. 
The/DT ratio/NN of/IN BCL2+/JJ to/TO CD3+/JJ cells/NNS in/IN ectopic/JJ pregnancy/NN was/VBD 0.41/CD ./. 
In/IN uterine/JJ pregnancy/NN ,/, the/DT ratio/NN of/IN BCL-2/NN to/TO CD3/NN was/VBD 0.44/CD and/CC 0.39/CD for/IN CD56/NN ./. 
Tissues/NNS from/IN both/CC ectopic/JJ and/CC uterine/JJ pregnancies/NNS were/VBD positive/JJ for/IN PR/NN ./. 
Fewer/JJR apoptotic/JJ cell/NN bodies/NNS were/VBD present/JJ in/IN ectopic/JJ pregnancy/NN ./. 
The/DT use/NN of/IN tissue/NN obtained/VBN from/IN ectopic/JJ pregnancy/NN may/MD become/VB an/DT excellent/JJ model/NN to/TO identify/VB the/DT mechanism/NN of/IN trophoblast/NN invasion/NN in/IN eutopic/JJ pregnancies/NNS ./. 
UI/LS -/: 99225313/CD 
TI/LS -/: Angiotensin/NN II/CD activates/VBZ the/DT proinflammatory/JJ transcription/NN factor/NN nuclear/JJ factor-kappaB/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: The/DT renin-angiotensin/JJ system/NN may/MD contribute/VB to/TO the/DT pathogenesis/NN of/IN atherosclerosis/NN ./. 
A/DT common/JJ feature/NN of/IN all/DT stages/NNS of/IN atherosclerosis/NN is/VBZ inflammation/NN of/IN the/DT vessel/NN wall/NN ./. 
The/DT transcription/NN factor/NN nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) participates/VBZ in/IN most/JJS signaling/NN pathways/NNS involved/VBN in/IN inflammation/NN ./. 
This/DT study/NN therefore/RB examined/VBD the/DT effect/NN of/IN angiotensin/NN (/( ANG/NN )/) II/CD on/IN NF-kappaB/NN activation/NN in/IN monocytic/JJ cells/NNS ,/, a/DT major/JJ cellular/JJ component/NN of/IN human/JJ atheroma/NN ,/, by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
ANG/NN II/CD ,/, like/IN TNFalpha/NN ,/, caused/VBD rapid/JJ activation/NN of/IN NF-kappaB/NN in/IN human/JJ mononuclear/JJ cells/NNS isolated/VBN from/IN peripheral/JJ blood/NN by/IN Ficoll/NN density/NN gradient/NN ./. 
This/DT ANG/NN II/CD effect/NN was/VBD blocked/VBN by/IN the/DT angiotensin/NN AT1/NN receptor/NN antagonist/NN losartan/NN ./. 
Specificity/NN of/IN ANG/NN II-induced/JJ NF-kappaB/NN activation/NN was/VBD ascertained/VBN by/IN supershift/NN and/CC competition/NN experiments/NNS ./. 
Moreover/RB ,/, ANG/NN II/CD stimulated/VBD NF-kappaB/NN activation/NN in/IN human/JJ monocytes/NNS ,/, but/CC not/RB in/IN lymphocytes/NNS from/IN the/DT same/JJ preparation/NN ./. 
Together/RB ,/, the/DT data/NNS demonstrate/VBP the/DT ability/NN of/IN the/DT vasoactive/JJ peptide/NN ANG/NN II/CD to/TO activate/VB inflammatory/JJ pathways/NNS in/IN human/JJ monocytes/NNS ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99218525/CD 
TI/LS -/: Signal/NN transduction/NN pathways/NNS activated/VBN in/IN endothelial/JJ cells/NNS following/VBG infection/NN with/IN Chlamydia/NN pneumoniae/FW ./. 
AB/LS -/: Chlamydia/NN pneumoniae/FW is/VBZ an/DT important/JJ respiratory/JJ pathogen/NN ./. 
Recently/RB ,/, its/PRP$ presence/NN has/VBZ been/VBN demonstrated/VBN in/IN atherosclerotic/JJ lesions/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP characterized/VBD C./FW pneumoniae-mediated/JJ activation/NN of/IN endothelial/JJ cells/NNS and/CC demonstrated/VBD an/DT enhanced/VBN expression/NN of/IN endothelial/JJ adhesion/NN molecules/NNS followed/VBN by/IN subsequent/JJ rolling/NN ,/, adhesion/NN ,/, and/CC transmigration/NN of/IN leukocytes/NNS (/( monocytes/NNS ,/, granulocytes/NNS )/) ./. 
These/DT effects/NNS were/VBD blocked/VBN by/IN mAbs/NNS against/IN endothelial/JJ and/or/CC leukocyte/NN adhesion/NN molecules/NNS (/( beta1/NN and/CC beta2/NN integrins/NNS )/) ./. 
Additionally/RB ,/, activation/NN of/IN different/JJ signal/NN transduction/NN pathways/NNS in/IN C./FW pneumoniae-infected/JJ endothelial/JJ cells/NNS was/VBD shown/VBN :/: protein/NN tyrosine/NN phosphorylation/NN ,/, up-regulation/NN of/IN phosphorylated/VBN p42/p44/NN mitogen-activated/JJ protein/NN kinase/NN ,/, and/CC NF-kappaB/NN activation/translocation/NN occurred/VBD within/IN 10-15/CD min/NN ./. 
Increased/VBN mRNA/NN and/CC surface/NN expression/NN of/IN E-selectin/NN ,/, ICAM-1/NN ,/, and/CC VCAM-1/NN were/VBD noted/VBN within/IN hours/NNS ./. 
Thus/RB ,/, C./FW pneumoniae/FW triggers/VBZ a/DT cascade/NN of/IN events/NNS that/WDT could/MD lead/VB to/TO endothelial/JJ activation/NN ,/, inflammation/NN ,/, and/CC thrombosis/NN ,/, which/WDT in/IN turn/NN may/MD result/VB in/IN or/CC may/MD promote/VB atherosclerosis/NN ./. 
UI/LS -/: 99209754/CD 
TI/LS -/: Transient/JJ pseudo-hypoaldosteronism/NN following/VBG resection/NN of/IN the/DT ileum/NN :/: normal/JJ level/NN of/IN lymphocytic/JJ aldosterone/NN receptors/NNS outside/IN the/DT acute/JJ phase/NN ./. 
AB/LS -/: Pseudo-hypoaldosteronism/NN (/( PHA/NN )/) is/VBZ due/JJ to/TO mineralocorticoid/NN resistance/NN and/CC manifests/VBZ as/IN hyponatremia/NN and/CC hyperkalemia/NN with/IN increased/VBN plasma/NN aldosterone/NN levels/NNS ./. 
It/PRP may/MD be/VB familial/JJ or/CC secondary/JJ to/TO abnormal/JJ renal/JJ sodium/NN handling/NN ./. 
We/PRP report/VBP the/DT case/NN of/IN a/DT 54-year-old/JJ woman/NN with/IN multifocal/JJ cancer/NN of/IN the/DT colon/NN ,/, who/WP developed/VBD PHA/NN after/IN subtotal/JJ colectomy/NN ,/, ileal/JJ resection/NN and/CC jejunostomy/NN ./. 
She/PRP was/VBD treated/VBN with/IN 6/CD g/NN of/IN salt/NN daily/RB to/TO prevent/VB dehydration/NN ,/, which/WDT she/PRP stopped/VBD herself/PRP because/IN of/IN reduced/VBN fecal/JJ losses/NNS ./. 
One/CD month/NN later/RB she/PRP was/VBD admitted/VBN with/IN signs/NNS of/IN acute/JJ adrenal/JJ failure/NN ,/, i.e./FW fatigue/NN ,/, severe/JJ nausea/NN ,/, blood/NN pressure/NN of/IN 80/60/CD mmHg/NN ,/, extracellular/JJ dehydration/NN ,/, hyponatremia/NN (/( 118/CD mmol/l/NN )/) ;/: hyperkalemia/NN (/( 7.6/CD mmol/l/NN )/) ,/, increased/VBN blood/NN urea/NN nitrogen/NN (/( BUN/NN )/) (/( 200/CD mg/dl/NN )/) and/CC creatininemia/NN (/( 2.5/CD mg/dl/NN )/) ,/, and/CC decreased/VBN plasma/NN bicarbonates/NNS level/NN (/( HCO3-/JJ :/: 16/CD mmol/l/NN ;/: N/NN :/: 27-30/CD )/) ./. 
However/RB ,/, the/DT plasma/NN cortisol/NN was/VBD high/JJ (/( 66/CD microg/100/NN ml/NN at/IN 10:00/CD h/NN ;/: N/NN :/: 8-15/CD )/) and/CC the/DT ACTH/NN was/VBD normal/JJ (/( 13/CD pg/ml/NN ,/, N/NN :/: 10-60/CD )/) ;/: there/EX was/VBD a/DT marked/JJ increase/NN in/IN plasma/NN renin/NN activity/NN (/( >/JJR 37/CD ng/ml/h/NN ;/: N/NN supine/NN </JJR 3/CD )/) ,/, active/JJ renin/NN (/( 869/CD pg/ml/NN ;/: N/NN supine/NN :/: 1.120/CD )/) ,/, aldosterone/NN (/( >/JJR 2000/CD pg/ml/NN ;/: N/NN supine/NN </JJR 150/CD )/) and/CC plasma/NN AVP/NN (/( 20/CD pmol/l/NN ;/: N/NN :/: 0.5-2.5/CD )/) ./. 
The/DT plasma/NN ANH/NN level/NN was/VBD 38/CD pmol/l/NN (/( N/NN supine/NN :/: 5-25/CD )/) ./. 
A/DT urinary/JJ steroidogram/NN resulted/VBD in/IN highly/RB elevated/JJ tetrahydrocortisol/NN (/( THF/NN :/: 13.3/CD mg/24h/NN ;/: N/NN :/: 1.4+/-0.8/CD )/) with/IN no/DT increase/NN in/IN tetrahydrocortisone/NN (/( THE/DT :/: 3.16/CD mg/24h/NN ;/: N/NN :/: 2.7+/-2.0/CD )/) excretion/NN ,/, and/CC with/IN low/JJ THE/THF/NN (/( 0.24/CD ;/: N/NN :/: 1.87+/-0.36/CD )/) and/CC alpha/NN THF/THF/NN (/( 0.35/CD ;/: N/NN :/: 0.92+/-0.42/CD )/) ratios/NNS ./. 
The/DT number/NN of/IN mineralocorticoid/NN receptors/NNS in/IN mononuclear/JJ leukocytes/NNS was/VBD in/IN the/DT lower/JJR normal/JJ range/NN for/IN age/NN ,/, while/IN the/DT number/NN of/IN glucocorticoid/NN receptors/NNS was/VBD reduced/VBN ./. 
Small-bowel/JJ resection/NN in/IN ileostomized/JJ patients/NNS causes/VBZ excessive/JJ fecal/JJ sodium/NN losses/NNS and/CC results/VBZ in/IN chronic/JJ sodium/NN depletion/NN with/IN contraction/NN of/IN the/DT plasma/NN volume/NN and/CC severe/JJ secondary/JJ hyperaldosteronism/NN ./. 
Nevertheless/RB ,/, this/DT hyperaldosteronism/NN may/MD be/VB associated/VBN with/IN hyponatremia/NN and/CC hyperkalemia/NN suggesting/VBG PHA/NN related/JJ to/TO the/DT major/JJ importance/NN of/IN the/DT colon/NN for/IN the/DT absorption/NN of/IN sodium/NN ./. 
In/IN conclusion/NN ,/, this/DT case/NN report/NN emphasizes/VBZ 1/LS )/) the/DT possibility/NN of/IN a/DT syndrome/NN of/IN acquired/VBN PHA/NN with/IN severe/JJ hyperkalemia/NN after/IN resection/NN of/IN the/DT ileum/NN and/CC colon/NN responding/VBG to/TO oral/JJ salt/NN supplementation/NN ;/: 2/LS )/) the/DT major/JJ increase/NN in/IN AVP/NN and/CC the/DT small/JJ increase/NN in/IN ANH/NN ;/: 3/LS )/) the/DT strong/JJ increase/NN in/IN urinary/JJ THF/NN with/IN low/JJ THE/THF/NN and/CC alpha/NN THF/THF/NN ratios/NNS ;/: 4/LS )/) the/DT normal/JJ number/NN of/IN lymphocytic/JJ mineralocorticoid/NN receptors/NNS outside/IN the/DT acute/JJ episode/NN ./. 
UI/LS -/: 99200786/CD 
TI/LS -/: Modulation/NN of/IN the/DT immune/JJ response/NN by/IN progesterone-induced/JJ lymphocyte/NN factors/NNS ./. 
AB/LS -/: Rat/NN spleen/NN and/CC peripheral/JJ blood/NN lymphocytes/NNS express/VBP progesterone/NN receptors/NNS whose/WP$ concentration/NN is/VBZ increased/VBN greatly/RB during/IN the/DT early/JJ phase/NN of/IN pregnancy/NN ./. 
After/IN stimulation/NN of/IN progesterone/NN the/DT expression/NN of/IN receptors/NNS was/VBD augmented/JJ 2-3/CD times/NNS ./. 
When/WRB cells/NNS were/VBD cultured/VBN in/IN the/DT presence/NN of/IN progesterone/NN they/PRP released/VBD a/DT soluble/JJ factor/NN that/WDT inhibited/VBD cellular/JJ immunoreactions/NNS (/( MLR/NN ,/, CRC/NN )/) and/CC cellular/JJ proliferation/NN as/IN measured/VBN by/IN thymidine/NN incorporation/NN by/IN spleen-cell/JJ culture/NN ./. 
This/DT factor/NN also/RB inhibited/VBD the/DT synthesis/NN of/IN anti-DNP/JJ antibodies/NNS by/IN a/DT mouse/NN hybridoma/NN and/CC diminished/VBD the/DT proportion/NN of/IN cells/NNS in/IN phase/NN S/NN ./. 
However/RB ,/, the/DT percentage/NN of/IN asymmetric/JJ molecules/NNS produced/VBN by/IN the/DT hybridoma/NN remained/VBD unaltered/JJ ./. 
These/DT results/NNS support/VBP the/DT hypothesis/NN that/IN soluble/JJ factors/NNS released/VBN by/IN rat/NN lymphocytes/NNS modulate/VBP the/DT immune/JJ response/NN of/IN the/DT mother/NN and/CC participate/VBP in/IN the/DT mechanism/NN that/WDT protects/VBZ the/DT fetus/NN against/IN antipaternal/JJ antibodies/NNS ./. 
UI/LS -/: 99192765/CD 
TI/LS -/: Differential/JJ regulation/NN of/IN 4E-BP1/NN and/CC 4E-BP2/NN ,/, two/CD repressors/NNS of/IN translation/NN initiation/NN ,/, during/IN human/JJ myeloid/JJ cell/NN differentiation/NN ./. 
AB/LS -/: Human/JJ myeloid/JJ differentiation/NN is/VBZ accompanied/VBN by/IN a/DT decrease/NN in/IN cell/NN proliferation/NN ./. 
Because/IN the/DT translation/NN rate/NN is/VBZ an/DT important/JJ determinant/NN of/IN cell/NN proliferation/NN ,/, we/PRP have/VBP investigated/VBN translation/NN initiation/NN during/IN human/JJ myeloid/JJ cell/NN differentiation/NN using/VBG the/DT HL-60/NN promyelocytic/JJ leukemia/NN cell/NN line/NN and/CC the/DT U-937/NN monoblastic/JJ cell/NN line/NN ./. 
A/DT decrease/NN in/IN the/DT translation/NN rate/NN is/VBZ observed/VBN when/WRB the/DT cells/NNS are/VBP induced/VBN to/TO differentiate/VB along/IN the/DT monocytic/macrophage/NN pathway/NN or/CC along/IN the/DT granulocytic/JJ pathway/NN ./. 
The/DT inhibition/NN in/IN protein/NN synthesis/NN correlates/VBZ with/IN specific/JJ regulation/NN of/IN two/CD repressors/NNS of/IN translation/NN initiation/NN ,/, 4E-BP1/NN and/CC 4E-BP2/NN ./. 
Induction/NN of/IN HL-60/NN and/CC U-937/NN cell/NN differentiation/NN into/IN monocytes/macrophages/NNS by/IN IFN-gamma/NN or/CC PMA/NN results/VBZ in/IN a/DT dephosphorylation/NN and/CC consequent/JJ activation/NN of/IN 4E-BP1/NN ./. 
Dephosphorylation/NN of/IN 4E-BP1/NN was/VBD also/RB observed/VBN when/WRB U-937/NN cells/NNS were/VBD induced/VBN to/TO differentiate/VB into/IN monocytes/macrophages/NNS following/VBG treatment/NN with/IN retinoic/JJ acid/NN or/CC DMSO/NN ./. 
In/IN contrast/NN ,/, treatment/NN of/IN HL-60/NN cells/NNS with/IN retinoic/JJ acid/NN or/CC DMSO/NN ,/, which/WDT results/VBZ in/IN a/DT granulocytic/JJ differentiation/NN of/IN these/DT cells/NNS ,/, decreases/VBZ 4E-BP1/NN amount/NN without/IN affecting/VBG its/PRP$ phosphorylation/NN and/CC strongly/RB increases/VBZ 4E-BP2/NN amount/NN ./. 
Taken/VBN together/RB ,/, these/DT data/NNS provide/VBP evidence/NN for/IN differential/JJ regulation/NN of/IN the/DT translational/JJ machinery/NN during/IN human/JJ myeloid/JJ differentiation/NN ,/, specific/JJ to/TO the/DT monocytic/macrophage/NN pathway/NN or/CC to/TO the/DT granulocytic/JJ pathway/NN ./. 
UI/LS -/: 99192430/CD 
TI/LS -/: Nonimmunoglobulin/JJ gene/NN hypermutation/NN in/IN germinal/JJ center/NN B/NN cells/NNS ./. 
AB/LS -/: Somatic/JJ hypermutation/NN is/VBZ the/DT most/RBS critical/JJ mechanism/NN underlying/VBG the/DT diversification/NN of/IN Ig/NN genes/NNS ./. 
Although/IN mutation/NN occurs/VBZ specifically/RB in/IN B/NN cells/NNS during/IN the/DT germinal/JJ center/NN reaction/NN ,/, it/PRP remains/VBZ a/DT matter/NN of/IN debate/NN whether/IN the/DT mutation/NN machinery/NN also/RB targets/VBZ non-Ig/JJ genes/NNS ./. 
We/PRP have/VBP studied/VBN mutations/NNS in/IN the/DT 5'/JJ noncoding/JJ region/NN of/IN the/DT Bcl6/NN gene/NN in/IN different/JJ subtypes/NNS of/IN lymphomas/NNS ./. 
We/PRP found/VBD frequent/JJ hypermutation/NN in/IN follicular/JJ lymphoma/NN (/( 25/CD of/IN 59/CD =/JJ 42/CD %/NN )/) (/( germinal/JJ center/NN cell/NN origin/NN )/) and/CC mucosa-associated/JJ lymphoid/JJ tissue/NN (/( MALT/NN )/) lymphoma/NN (/( 19/CD of/IN 45/CD =/JJ 42/CD %/NN )/) (/( postgerminal/JJ center/NN )/) ,/, but/CC only/RB occasionally/RB in/IN mantle/NN cell/NN lymphoma/NN (/( 1/CD of/IN 21/CD =/JJ 4.8/CD %/NN )/) (/( pregerminal/JJ center/NN )/) ./. 
Most/JJS mutations/NNS were/VBD outside/IN the/DT motifs/NNS potentially/RB important/JJ for/IN transcription/NN ,/, suggesting/VBG they/PRP were/VBD not/RB important/JJ in/IN lymphomagenesis/NN but/CC may/MD ,/, like/IN Ig/NN mutation/NN ,/, represent/VB an/DT inherent/JJ feature/NN of/IN the/DT lymphoma/NN precursor/NN cells/NNS ./. 
Therefore/RB ,/, we/PRP investigated/VBD their/PRP$ normal/JJ cell/NN counterparts/NNS microdissected/VBN from/IN a/DT reactive/JJ tonsil/NN ./. 
Bcl6/NN mutation/NN was/VBD found/VBN in/IN 13/CD of/IN 24/CD (/( 54/CD %/NN )/) clones/NNS from/IN the/DT germinal/JJ centre/NN but/CC only/RB in/IN 1/CD of/IN 24/CD (/( 4/CD %/NN )/) clones/NNS from/IN the/DT naive/JJ B/NN cells/NNS of/IN the/DT mantle/NN zone/NN ./. 
The/DT frequency/NN ,/, distribution/NN ,/, and/CC nature/NN of/IN these/DT mutations/NNS were/VBD similar/JJ to/TO those/DT resulting/VBG from/IN the/DT Ig/NN hypermutation/NN process/NN ./. 
The/DT results/NNS show/VBP unequivocal/JJ evidence/NN of/IN non-Ig/JJ gene/NN hypermutation/NN in/IN germinal/JJ center/NN B/NN cells/NNS and/CC provide/VBP fresh/JJ insights/NNS into/IN the/DT process/NN of/IN hypermutation/NN and/CC lymphomagenesis/NN ./. 
UI/LS -/: 99180473/CD 
TI/LS -/: Impaired/JJ binding/NN of/IN a/DT DQ2/NN and/CC DQ8-binding/JJ HSV/NN VP16/NN peptide/NN to/TO a/DT DQA1*0501/DQB1*0302/NN trans/JJ class/NN II/CD heterodimer/NN ./. 
AB/LS -/: DQalpha/NN and/CC DQbeta/NN trans/JJ heterodimeric/JJ HLA-DQ/NN molecules/NNS form/VBP in/IN individuals/NNS heterozygous/JJ for/IN the/DT DQ2/NN and/CC DQ8/NN specificities/NNS ./. 
Unique/JJ functions/NNS and/CC disease/NN associations/NNS have/VBP been/VBN postulated/VBN for/IN such/JJ trans-dimers/NNS ,/, which/WDT may/MD be/VB different/JJ from/IN cis-encoded/JJ DQ/NN molecules/NNS encoded/VBN by/IN the/DT corresponding/JJ haplotypes/NNS ./. 
We/PRP analyzed/VBD the/DT ability/NN of/IN the/DT trans-dimer/NN encoded/VBN by/IN HLA-DQA1*0501/DQB1*0302/NN to/TO bind/VB a/DT peptide/NN antigen/NN which/WDT interacts/VBZ with/IN DQ/NN molecules/NNS encoded/VBN by/IN both/DT parental/JJ haplotypes/NNS ./. 
Markedly/RB impaired/JJ binding/NN was/VBD observed/VBN ,/, consistent/JJ with/IN both/CC the/DT use/NN of/IN different/JJ anchor/NN residues/NNS and/CC with/IN changes/NNS in/IN levels/NNS of/IN DQ/NN cis-dimer/JJ availability/NN for/IN peptide/NN binding/NN interactions/NNS ./. 
UI/LS -/: 99177408/CD 
TI/LS -/: Detection/NN of/IN intracellular/JJ phosphorylated/VBN STAT-1/NN by/IN flow/NN cytometry/NN ./. 
AB/LS -/: We/PRP have/VBP applied/VBN flow/NN cytometry/NN to/TO the/DT investigation/NN of/IN interferon-gamma/NN activation/NN of/IN human/JJ monocytes/NNS ./. 
This/DT approach/NN uses/VBZ monoclonal/JJ antibodies/NNS that/WDT distinguish/VBP between/IN the/DT native/JJ and/CC phosphorylated/JJ forms/NNS of/IN STAT-1/NN ./. 
It/PRP enables/VBZ rapid/JJ and/CC quantitative/JJ assessment/NN of/IN STAT-1/NN phosphorylation/NN on/IN a/DT discrete/JJ cell/NN basis/NN and/CC is/VBZ both/CC more/RBR sensitive/JJ and/CC less/JJR time/NN consuming/JJ than/IN immunoblotting/NN ./. 
Furthermore/RB ,/, it/PRP allows/VBZ for/IN discrimination/NN between/IN a/DT mixture/NN of/IN cells/NNS that/WDT differ/VBP in/IN their/PRP$ response/NN to/TO interferon-gamma/NN ./. 
This/DT approach/NN should/MD allow/VB for/IN the/DT evaluation/NN of/IN different/JJ intracellular/JJ signaling/NN pathways/NNS using/VBG a/DT combination/NN of/IN monoclonal/JJ reagents/NNS that/WDT are/VBP specific/JJ for/IN native/JJ and/CC activation/NN modified/JJ proteins/NNS ./. 
Application/NN of/IN this/DT form/NN of/IN testing/NN should/MD prove/VB valuable/JJ in/IN screening/VBG for/IN signaling/VBG defects/NNS in/IN selected/VBN patients/NNS with/IN recurrent/JJ infections/NNS ./. 
In/IN addition/NN ,/, this/DT technique/NN should/MD permit/VB dissection/NN of/IN a/DT full/JJ range/NN of/IN cellular/JJ signaling/NN pathways/NNS at/IN the/DT protein/NN level/NN ./. 
UI/LS -/: 99239883/CD 
TI/LS -/: Activation/NN of/IN nuclear/JJ factor-kappaB/NN by/IN lipopolysaccharide/NN in/IN mononuclear/JJ leukocytes/NNS is/VBZ prevented/VBN by/IN inhibitors/NNS of/IN cytosolic/JJ phospholipase/NN A2/NN ./. 
AB/LS -/: In/IN monocytes/NNS ,/, lipopolysaccharide/NN induces/VBZ synthesis/NN and/CC activity/NN of/IN the/DT 85-kDa/JJ cytosolic/JJ phospholipase/NN A2/NN ./. 
This/DT enzyme/NN releases/VBZ arachidonic/JJ acid/NN and/CC lyso-phospholipids/NNS from/IN membranes/NNS which/WDT are/VBP metabolized/VBN to/TO eicosanoids/NNS and/CC platelet-activating-factor/NN ./. 
These/DT lipid/NN mediators/NNS increase/VBP activity/NN of/IN transcription/NN factors/NNS and/CC expression/NN of/IN cytokine/NN genes/NNS indicating/VBG a/DT function/NN for/IN cytosolic/JJ phospholipase/NN A2/NN in/IN signal/NN transduction/NN and/CC inflammation/NN ./. 
We/PRP have/VBP shown/VBN previously/RB that/IN trifluoromethylketone/NN inhibitors/NNS of/IN cytosolic/JJ phospholipase/NN A2/NN suppressed/VBD interleukin-1beta/NN protein/NN and/CC steady-state/JJ mRNA/NN levels/NNS in/IN human/JJ lipopolysaccharide-stimulated/JJ peripheral/JJ blood/NN mononuclear/JJ leukocytes/NNS ./. 
In/IN this/DT study/NN ,/, the/DT subcellular/JJ mechanisms/NNS were/VBD analyzed/VBN by/IN which/WDT trifluoromethylketones/NNS interfere/VBP with/IN gene/NN expression/NN ./. 
We/PRP found/VBD that/IN they/PRP reduced/VBD the/DT initial/JJ interleukin-1beta/NN mRNA/NN transcription/NN rate/NN through/IN prevention/NN of/IN degradation/NN of/IN inhibitor-kappaB/NN alpha/NN ./. 
Consequently/RB ,/, cytosolic/JJ activation/NN ,/, nuclear/JJ translocation/NN and/CC DNA-binding/NN of/IN nuclear/JJ factor-kappaB/NN were/VBD decreased/VBN ./. 
Trifluoromethylketones/NNS ameliorate/VBP chronic/JJ inflammation/NN in/IN vivo/FW ./. 
Thus/RB ,/, this/DT therapeutic/JJ potency/NN may/MD reside/VB in/IN retention/NN of/IN inactive/JJ nuclear/JJ factor-kappaB/NN in/IN the/DT cytosol/NN thereby/RB abrogating/VBG interleukin-1beta/NN gene/NN transcription/NN ./. 
UI/LS -/: 99231886/CD 
TI/LS -/: Cellular/JJ disposition/NN of/IN sulphamethoxazole/NN and/CC its/PRP$ metabolites/NNS :/: implications/NNS for/IN hypersensitivity/NN ./. 
AB/LS -/: 1./LS Bioactivation/NN of/IN sulphamethoxazole/NN (/( SMX/NN )/) to/TO chemically-reactive/JJ metabolites/NNS and/CC subsequent/JJ protein/NN conjugation/NN is/VBZ thought/VBN to/TO be/VB involved/VBN in/IN SMX/NN hypersensitivity/NN ./. 
We/PRP have/VBP therefore/RB examined/VBN the/DT cellular/JJ metabolism/NN ,/, disposition/NN and/CC conjugation/NN of/IN SMX/NN and/CC its/PRP$ metabolites/NNS in/FW vitro/FW ./. 
2./FW Flow/NN cytometry/NN revealed/VBD binding/NN of/IN N-hydroxy/NN (/( SMX-NHOH/NN )/) and/CC nitroso/NN (/( SMX-NO/NN )/) metabolites/NNS of/IN SMX/NN ,/, but/CC not/RB of/IN SMX/NN itself/PRP ,/, to/TO the/DT surface/NN of/IN viable/JJ white/JJ blood/NN cells/NNS ./. 
Cellular/JJ haptenation/NN by/IN SMX-NO/NN was/VBD reduced/VBN by/IN exogenous/JJ glutathione/NN (/( GSH/NN )/) ./. 
3./LS SMX-NHOH/NN and/CC SMX-NO/NN were/VBD rapidly/RB reduced/VBN back/RB to/TO the/DT parent/JJ compound/NN by/IN cysteine/NN (/( CYS/NN )/) ,/, GSH/NN ,/, human/JJ peripheral/JJ blood/NN cells/NNS and/CC plasma/NN ,/, suggesting/VBG that/IN this/DT is/VBZ an/DT important/JJ and/CC ubiquitous/JJ bioinactivation/NN mechanism/NN ./. 
4./LS Fluorescence/NN HPLC/NN showed/VBD that/IN SMX-NHOH/NN and/CC SMX-NO/NN depleted/VBD CYS/NN and/CC GSH/NN in/IN buffer/NN ,/, and/CC to/TO a/DT lesser/JJR extent/NN ,/, in/IN cells/NNS and/CC plasma/NN ./. 
5./LS Neutrophil/NN apoptosis/NN and/CC inhibition/NN of/IN neutrophil/NN function/NN were/VBD induced/VBN at/IN lower/JJR concentrations/NNS of/IN SMX-NHOH/NN and/CC SMX-NO/NN than/IN those/DT inducing/VBG loss/NN of/IN membrane/NN viability/NN ,/, with/IN SMX/NN having/VBG no/DT effect/NN ./. 
Lymphocytes/NNS were/VBD significantly/RB (/( P/NN </JJR 0.05/CD )/) more/RBR sensitive/JJ to/TO the/DT direct/JJ cytotoxic/JJ effects/NNS of/IN SMX-NO/NN than/IN neutrophils/NNS ./. 
6./LS Partitioning/NN of/IN SMX-NHOH/NN into/IN red/JJ blood/NN cells/NNS was/VBD significantly/RB (/( P/NN </JJR 0.05/CD )/) lower/JJR than/IN with/IN the/DT hydroxylamine/NN of/IN dapsone/NN ./. 
7./LS Our/PRP$ results/NNS suggest/VBP that/IN the/DT balance/NN between/IN oxidation/NN of/IN SMX/NN to/TO its/PRP$ toxic/JJ metabolites/NNS and/CC their/PRP$ reduction/NN is/VBZ an/DT important/JJ protective/JJ cellular/JJ mechanism/NN ./. 
If/IN an/DT imbalance/NN exists/VBZ ,/, haptenation/NN of/IN the/DT toxic/JJ metabolites/NNS to/TO bodily/JJ proteins/NNS including/VBG the/DT surface/NN of/IN viable/JJ cells/NNS can/MD occur/VB ,/, and/CC may/MD result/VB in/IN drug/NN hypersensitivity/NN ./. 
UI/LS -/: 99223160/CD 
TI/LS -/: Bcl-6/NN expression/NN in/IN reactive/JJ follicular/JJ hyperplasia/NN ,/, follicular/JJ lymphoma/NN ,/, and/CC angioimmunoblastic/JJ T-cell/NN lymphoma/NN with/IN hyperplastic/JJ germinal/JJ centers/NNS :/: heterogeneity/NN of/IN intrafollicular/JJ T-cells/NNS and/CC their/PRP$ altered/JJ distribution/NN in/IN the/DT pathogenesis/NN of/IN angioimmunoblastic/JJ T-cell/NN lymphoma/NN ./. 
AB/LS -/: BACKGROUND/NN :/: The/DT Bcl-6/NN gene/NN product/NN ,/, a/DT nuclear/JJ phosphoprotein/NN ,/, is/VBZ expressed/VBN independently/RB of/IN Bcl-6/NN gene/NN rearrangement/NN ./. 
In/IN lymph/NN nodes/NNS ,/, expression/NN of/IN Bcl-6/NN protein/NN is/VBZ restricted/JJ to/TO germinal/JJ center/NN (/( GC/NN )/) B-cells/NNS and/CC 10/CD %/NN to/TO 15/CD %/NN of/IN CD3/CD4+/JJ intrafollicular/JJ T/NN cells/NNS ./. 
Interfollicular/JJ cells/NNS are/VBP negative/JJ for/IN Bcl-6/NN protein/NN ,/, except/IN for/IN rare/JJ CD3+/CD4+/JJ T/NN cells/NNS ./. 
Recently/RB ,/, we/PRP reported/VBD cases/NNS of/IN angioimmunoblastic/JJ T-cell/NN lymphoma/NN (/( AITL/NN )/) with/IN hyperplastic/JJ GCs/NNS (/( AITL/GC/NN )/) ,/, and/CC observed/VBD that/IN borders/NNS of/IN enlarged/JJ GCs/NNS were/VBD ill/RB defined/VBN ,/, with/IN features/NNS suggestive/JJ of/IN an/DT outward/JJ migration/NN of/IN GC/NN cells/NNS to/TO surrounding/JJ interfollicular/JJ zones/NNS ./. 
This/DT prompted/VBD a/DT study/NN of/IN follicular/JJ borders/NNS with/IN Bcl-6/NN staining/NN in/IN reactive/JJ follicular/JJ hyperplasias/NN and/CC follicular/JJ lymphomas/NNS to/TO compare/VB with/IN AITL/GC/NN ./. 
MATERIALS/NNS AND/CC METHODS/NNS :/: Formalin-fixed/JJ paraffin/NN sections/NNS were/VBD used/VBN for/IN immunostaining/NN of/IN Bcl-6/NN ./. 
Six/CD cases/NNS of/IN AITL/GC/NN ,/, 12/CD nonspecific/JJ reactive/JJ follicular/JJ hyperplasia/NN (/( FH/NN )/) ,/, 7/CD HIV/NN adenopathy/NN ,/, 10/CD follicular/JJ lymphoma/NN (/( FL/NN )/) ,/, and/CC 8/CD typical/JJ AITL/NN (/( ie/FW ,/, AITL/NN without/IN GC/NN )/) were/VBD studied/VBN ./. 
Double/JJ staining/NN for/IN Bcl-6/CD20/NN ,/, Bcl-6/CD3/NN ,/, and/CC Bcl-6/CD57/NN was/VBD performed/VBN in/IN selected/VBN cases/NNS ./. 
RESULTS/NNS :/: In/IN FH/NN and/CC HIV/NN adenopathy/NN ,/, staining/NN for/IN Bcl-6/NN revealed/VBD densely/RB populated/JJ GCs/NNS with/IN well-defined/JJ and/CC regular/JJ GC/NN borders/NNS ,/, whereas/IN Bcl-6+/JJ cells/NNS were/VBD rare/JJ in/IN the/DT interfollicular/JJ areas/NNS ./. 
An/DT occasional/JJ GC/NN with/IN an/DT ill-defined/JJ border/NN was/VBD invariably/RB surrounded/VBN by/IN a/DT broad/JJ mantle/NN zone/NN ;/: those/DT with/IN indistinct/JJ mantle/NN zones/NNS had/VBD well-defined/JJ ,/, regular/JJ borders/NNS ./. 
In/IN FL/NN ,/, follicles/NNS were/VBD densely/RB populated/JJ ,/, and/CC their/PRP$ borders/NNS were/VBD irregular/JJ ,/, with/IN some/DT Bcl-6+/JJ cells/NNS in/IN the/DT interfollicular/JJ zones/NNS ./. 
In/IN AITL/GC/NN ,/, GCs/NNS were/VBD less/RBR dense/JJ ,/, GC/NN borders/NNS were/VBD ill/RB defined/VBN and/CC irregular/JJ ,/, and/CC the/DT number/NN of/IN interfollicular/JJ Bcl-6+/JJ cells/NNS was/VBD markedly/RB increased/VBN ./. 
Double/JJ staining/NN revealed/VBD that/IN these/DT interfollicular/JJ Bcl-6+/JJ cells/NNS in/IN AITL/GC/NN were/VBD Bcl6+/CD3+/CD20-/CD57-/JJ T/NN cells/NNS ./. 
Moreover/RB ,/, CD3+/JJ intrafollicular/JJ T/NN cells/NNS were/VBD depleted/VBN in/IN AITL/GC/NN ,/, whereas/IN they/PRP were/VBD abundant/JJ in/IN FH/NN ./. 
Intrafollicular/JJ CD57+/JJ cells/NNS did/VBD not/RB stain/VB for/IN Bcl-6/NN ,/, and/CC were/VBD also/RB depleted/VBN in/IN AITL/GC/NN ./. 
In/IN typical/JJ AITL/NN ,/, some/DT neoplastic/JJ cells/NNS were/VBD positive/JJ for/IN Bcl-6/NN ,/, showing/VBG variable/JJ degrees/NNS of/IN staining/NN ./. 
CONCLUSIONS/NNS :/: (/( 1/LS )/) GCs/NNS of/IN AITL/GC/NN differed/VBD from/IN those/DT of/IN other/JJ reactive/JJ follicular/JJ hyperplasias/NN and/CC follicular/JJ lymphomas/NNS ,/, and/CC staining/VBG for/IN Bcl-6/NN was/VBD useful/JJ to/TO discern/VB them/PRP ./. 
(/( 2/LS )/) Intrafollicular/JJ CD3+/JJ T/NN cells/NNS ,/, many/JJ of/IN which/WDT were/VBD also/RB positive/JJ for/IN Bcl-6/NN ,/, were/VBD markedly/RB depleted/VBN in/IN AITL/GC/NN ,/, with/IN increased/VBN interfollicular/JJ Bcl-6+/CD3+/JJ cells/NNS ,/, suggesting/VBG an/DT outward/JJ migration/NN of/IN intrafollicular/JJ T/NN cells/NNS in/IN this/DT condition/NN ./. 
(/( 3/LS )/) Interfollicular/JJ Bcl-6+/CD3+/JJ cells/NNS in/IN AITL/GC/NN were/VBD too/RB numerous/JJ to/TO be/VB accounted/VBN for/IN by/IN migration/NN alone/RB ,/, suggesting/VBG local/JJ proliferation/NN ./. 
(/( 4/LS )/) Intrafollicular/JJ CD57+/JJ cells/NNS were/VBD negative/JJ for/IN Bcl-6/NN ,/, indicating/VBG heterogeneity/NN of/IN the/DT intrafollicular/JJ T-cell/NN population/NN ./. 
(/( 5/LS )/) Some/DT neoplastic/JJ cells/NNS in/IN AITL/NN stained/VBD for/IN Bcl-6/NN ,/, suggesting/VBG up-regulation/NN of/IN Bcl-6/NN expression/NN in/IN this/DT tumor/NN ./. 
UI/LS -/: 99218522/CD 
TI/LS -/: Human/JJ cytomegalovirus/NN binding/VBG to/TO human/JJ monocytes/NNS induces/VBZ immunoregulatory/JJ gene/NN expression/NN ./. 
AB/LS -/: To/TO continue/VB our/PRP$ investigation/NN of/IN the/DT cellular/JJ events/NNS that/WDT occur/VBP following/VBG human/JJ CMV/NN (/( HCMV/NN )/) infection/NN ,/, we/PRP focused/VBD on/IN the/DT regulation/NN of/IN cellular/JJ activation/NN following/VBG viral/JJ binding/NN to/TO human/JJ monocytes/NNS ./. 
First/RB ,/, we/PRP showed/VBD that/IN viral/JJ binding/NN induced/VBD a/DT number/NN of/IN immunoregulatory/JJ genes/NNS (/( IL-1beta/NN ,/, A20/NN ,/, NF-kappaB-p105/p50/NN ,/, and/CC IkappaBalpha/NN )/) in/IN unactivated/JJ monocytes/NNS and/CC that/IN neutralizing/VBG Abs/NNS to/TO the/DT major/JJ HCMV/NN glycoproteins/NNS ,/, gB/NN (/( UL55/NN )/) and/CC gH/NN (/( UL75/NN )/) ,/, inhibited/VBD the/DT induction/NN of/IN these/DT genes/NNS ./. 
Next/RB ,/, we/PRP demonstrated/VBD that/IN these/DT viral/JJ ligands/NNS directly/RB up-regulated/VBD monocyte/NN gene/NN expression/NN upon/IN their/PRP$ binding/NN to/TO their/PRP$ appropriate/JJ cellular/JJ receptors/NNS ./. 
We/PRP then/RB investigated/VBD if/IN HCMV/NN binding/NN also/RB resulted/VBD in/IN the/DT translation/NN and/CC secretion/NN of/IN cytokines/NNS ./. 
Our/PRP$ results/NNS showed/VBD that/IN HCMV/NN binding/NN to/TO monocytes/NNS resulted/VBD in/IN the/DT production/NN and/CC release/NN of/IN IL-1beta/NN protein/NN ./. 
Because/IN these/DT induced/VBN gene/NN products/NNS have/VBP NF-kappaB/NN sites/NNS in/IN their/PRP$ promoter/NN regions/NNS ,/, we/PRP next/RB examined/VBD whether/IN there/EX was/VBD an/DT up-regulation/NN of/IN nuclear/JJ NF-kappaB/NN levels/NNS ./. 
These/DT experiments/NNS showed/VBD that/IN ,/, in/IN fact/NN ,/, NF-kappaB/NN was/VBD translocated/VBN to/TO the/DT nucleus/NN following/VBG viral/JJ binding/NN or/CC purified/VBN viral/JJ ligand/NN binding/NN ./. 
Changes/NNS in/IN IkappaBalpha/NN levels/NNS correlated/VBD with/IN the/DT changes/NNS in/IN NF-kappaB/NN translocation/NN ./. 
Lastly/RB ,/, we/PRP demonstrated/VBD that/IN p38/NN kinase/NN activity/NN played/VBD a/DT central/JJ role/NN in/IN IL-1beta/NN production/NN and/CC that/IN it/PRP was/VBD rapidly/RB up-regulated/VBN following/VBG infection/NN ./. 
These/DT results/NNS support/VBP our/PRP$ hypothesis/NN that/IN HCMV/NN initiates/VBZ a/DT signal/NN transduction/NN pathway/NN that/WDT leads/VBZ to/TO monocyte/NN activation/NN and/CC pinpoints/VBZ a/DT potential/JJ mechanism/NN whereby/RB HCMV/NN infection/NN of/IN monocytes/NNS can/MD result/VB in/IN profound/JJ pathogenesis/NN ,/, especially/RB in/IN chronic/JJ inflammatory-type/JJ conditions/NNS ./. 
UI/LS -/: 99211949/CD 
TI/LS -/: Regulation/NN of/IN the/DT megakaryocytic/JJ glycoprotein/NN IX/CD promoter/NN by/IN the/DT oncogenic/JJ Ets/NN transcription/NN factor/NN Fli-1/NN ./. 
AB/LS -/: Glycoprotein/NN (/( GP/NN )/) IX/CD is/VBZ a/DT subunit/NN of/IN the/DT von/NN Willebrand/NN receptor/NN ,/, GPIb-/JJ V-IX/NN ,/, which/WDT mediates/VBZ adhesion/NN of/IN platelets/NNS to/TO the/DT subendothelium/NN of/IN damaged/VBN blood/NN vessels/NNS ./. 
Previous/JJ characterization/NN of/IN the/DT GPIX/NN promoter/NN identified/VBD a/DT functional/JJ Ets/NN site/NN that/WDT ,/, when/WRB disrupted/VBN ,/, reduced/VBD promoter/NN activity/NN ./. 
However/RB ,/, the/DT Ets/NN protein/NN (/( s/NNS )/) that/WDT regulated/VBD GPIX/NN promoter/NN expression/NN was/VBD unknown/JJ ./. 
In/IN this/DT study/NN ,/, transient/JJ cotransfection/NN of/IN several/JJ GPIX/NN promoter/reporter/NN constructs/NNS into/IN 293T/NN kidney/NN fibroblasts/NNS with/IN a/DT Fli-1/NN expression/NN vector/NN shows/VBZ that/IN the/DT oncogenic/JJ protein/NN Fli-1/NN can/MD transactivate/VB the/DT GPIX/NN promoter/NN when/WRB an/DT intact/JJ GPIX/NN Ets/NN site/NN is/VBZ present/JJ ./. 
In/IN addition/NN ,/, Fli-1/NN binding/NN of/IN the/DT GPIX/NN Ets/NN site/NN was/VBD identified/VBN in/IN antibody/NN supershift/NN experiments/NNS in/IN nuclear/JJ extracts/NNS derived/VBN from/IN hematopoietic/JJ human/JJ erythroleukemia/NN cells/NNS ./. 
Comparative/JJ studies/NNS showed/VBD that/IN Fli-1/NN was/VBD also/RB able/JJ to/TO transactivate/VB the/DT GPIbalpha/NN and/CC ,/, to/TO a/DT lesser/JJR extent/NN ,/, the/DT GPIIb/NN promoter/NN ./. 
Immunoblot/NN analysis/NN identified/VBD Fli-1/NN protein/NN in/IN lysates/NNS derived/VBN from/IN platelets/NNS ./. 
In/IN addition/NN ,/, expression/NN of/IN Fli-1/NN was/VBD identified/VBN immunohistochemically/RB in/IN megakaryocytes/NNS derived/VBN from/IN CD34(+)/JJ cells/NNS treated/VBN with/IN the/DT megakaryocyte/NN differentiation/NN and/CC proliferation/NN factor/NN ,/, thrombopoietin/NN ./. 
These/DT results/NNS suggest/VBP that/IN Fli-1/NN is/VBZ likely/JJ to/TO regulate/VB lineage-specific/JJ genes/NNS during/IN megakaryocytopoiesis/NN ./. 
UI/LS -/: 99200773/CD 
TI/LS -/: Expression/NN of/IN IkappaBalpha/NN in/IN the/DT nucleus/NN of/IN human/JJ peripheral/JJ blood/NN T/NN lymphocytes/NNS ./. 
AB/LS -/: According/VBG to/TO current/JJ models/NNS the/DT inhibitory/JJ capacity/NN of/IN I/NN (/( kappa/NN )/) B/NN (/( alpha/NN )/) would/MD be/VB mediated/VBN through/IN the/DT retention/NN of/IN Rel/NF-kappaB/NN proteins/NNS in/IN the/DT cytosol/NN ./. 
However/RB ,/, I/NN (/( kappa/NN )/) B/NN (/( alpha/NN )/) has/VBZ also/RB been/VBN detected/VBN in/IN the/DT nucleus/NN of/IN cell/NN lines/NNS and/CC when/WRB overexpressed/VBN by/IN transient/JJ transfection/NN ./. 
To/TO gain/VB better/JJR insight/NN into/IN the/DT potential/JJ role/NN of/IN nuclear/JJ I/NN (/( kappa/NN )/) B/NN (/( alpha/NN )/) in/IN a/DT physiological/JJ context/NN we/PRP have/VBP analysed/VBN its/PRP$ presence/NN in/IN the/DT nucleus/NN of/IN human/JJ peripheral/JJ blood/NN T/NN lymphocytes/NNS (/( PBL/NN )/) ./. 
We/PRP demonstrate/VBP the/DT nuclear/JJ localization/NN of/IN I/NN (/( kappa/NN )/) B/NN (/( alpha/NN )/) in/IN PBL/NN by/IN different/JJ techniques/NNS :/: Western/NN blot/NN ,/, indirect/JJ immunofluorescence/NN and/CC electron/NN microscopy/NN ./. 
Low/JJ levels/NNS of/IN nuclear/JJ I/NN (/( kappa/NN )/) B/NN (/( alpha/NN )/) were/VBD detected/VBN in/IN resting/VBG cells/NNS whereas/IN a/DT superinduction/NN was/VBD obtained/VBN after/IN PMA/NN activation/NN ./. 
The/DT nuclear/JJ pool/NN of/IN I/NN (/( kappa/NN )/) B/NN (/( alpha/NN )/) showed/VBD a/DT higher/JJR stability/NN than/IN cytosolic/JJ I/NN (/( kappa/NN )/) B/NN (/( alpha/NN )/) and/CC was/VBD partially/RB independent/JJ of/IN the/DT resynthesis/NN of/IN the/DT protein/NN ./. 
Unexpectedly/RB ,/, the/DT presence/NN of/IN nuclear/JJ I/NN (/( kappa/NN )/) B/NN (/( alpha/NN )/) did/VBD not/RB inhibit/VB NF-kappaB/NN binding/NN to/TO DNA/NN and/CC this/DT phenomenon/NN was/VBD not/RB due/JJ to/TO the/DT presence/NN of/IN IkappaBbeta/NN at/IN the/DT nuclear/JJ level/NN ./. 
Immunoprecipitation/NN experiments/NNS failed/VBD to/TO demonstrate/VB an/DT association/NN between/IN nuclear/JJ I/NN (/( kappa/NN )/) B/NN (/( alpha/NN )/) and/CC NF-kappaB/NN proteins/NNS ./. 
Our/PRP$ results/NNS demonstrate/VBP that/IN in/IN resting/VBG and/CC PMA-activated/JJ human/JJ PBL/NN ,/, I/NN (/( kappa/NN )/) B/NN (/( alpha/NN )/) is/VBZ present/JJ in/IN the/DT nucleus/NN in/IN an/DT apparently/RB inactive/JJ form/NN unable/JJ to/TO disrupt/VB NF-kappaB/NN binding/NN from/IN DNA/NN ./. 
UI/LS -/: 99192761/CD 
TI/LS -/: Impaired/JJ fetal/JJ thymocyte/NN development/NN after/IN efficient/JJ adenovirus-mediated/JJ inhibition/NN of/IN NF-kappa/NN B/NN activation/NN ./. 
AB/LS -/: We/PRP introduce/VBP a/DT new/JJ experimental/JJ system/NN combining/VBG adenovirus-mediated/JJ gene/NN transfer/NN and/CC fetal/JJ thymic/JJ organ/NN culture/NN (/( FTOC/NN )/) ./. 
This/DT system/NN allowed/VBD us/PRP to/TO efficiently/RB express/VB in/IN developing/VBG thymocytes/NNS a/DT mutant/JJ form/NN of/IN the/DT NF-kappa/NN B/NN inhibitor/NN I/NN kappa/NN B/NN alpha/NN (/( mut-I/NN kappa/NN B/NN )/) and/CC to/TO study/VB the/DT maturation/NN defects/NNS occurring/VBG when/WRB NF-kappa/NN B/NN activation/NN is/VBZ inhibited/VBN during/IN fetal/JJ development/NN ./. 
Fetal/JJ thymocytes/NNS infected/VBN with/IN adenovirus/NN containing/VBG mut-I/NN kappa/NN B/NN were/VBD found/VBN to/TO develop/VB normally/RB until/IN the/DT CD44-CD25+/JJ ,/, CD4-CD8-/JJ double-negative/JJ stage/NN ,/, while/IN production/NN of/IN more/RBR mature/JJ double-positive/JJ and/CC single-positive/JJ populations/NNS was/VBD strongly/RB decreased/VBN ./. 
Proliferation/NN ,/, as/IN measured/VBN by/IN the/DT percentage/NN of/IN cells/NNS in/IN cycle/NN appeared/VBD normal/JJ ,/, as/IN did/VBD rearrangement/NN and/CC expression/NN of/IN the/DT TCR/NN beta-chain/NN ./. 
However/RB ,/, apoptosis/NN was/VBD much/RB higher/JJR in/IN FTOC/NN infected/VBN with/IN adenovirus/NN containing/VBG mut-I/NN kappa/NN B/NN than/IN in/IN FTOC/NN infected/VBN with/IN a/DT control/JJ virus/NN ./. 
Taken/VBN together/RB ,/, these/DT results/NNS suggest/VBP that/IN NF-kappa/NN B/NN plays/VBZ a/DT crucial/JJ role/NN in/IN ensuring/VBG the/DT differentiation/NN and/CC survival/NN of/IN thymocytes/NNS in/IN the/DT early/JJ stages/NNS of/IN their/PRP$ development/NN ./. 
UI/LS -/: 99188724/CD 
TI/LS -/: The/DT relationship/NN between/IN Ca2+-ATPase/NN and/CC freely/RB exchangeable/JJ Ca2+/NN in/IN the/DT dense/JJ tubules/NNS :/: a/DT study/NN in/IN platelets/NNS from/IN women/NNS ./. 
AB/LS -/: The/DT main/JJ aims/NNS of/IN this/DT work/NN were/VBD to/TO examine/VB in/IN women/NNS :/: the/DT relationship/NN between/IN the/DT freely/RB exchangeable/JJ Ca2+/NN (/( FECa2+/NN )/) in/IN the/DT dense/JJ tubules/NNS and/CC the/DT activity/NN of/IN the/DT sarco/NN (/( endo/NN )/) plasmic/JJ reticulum/NN (/( SER/NN )/) Ca2+-ATPase/NN (/( SERCA/NN )/) in/IN platelets/NNS ,/, and/CC the/DT relationship/NN of/IN these/DT parameters/NNS with/IN blood/NN pressure/NN and/CC serum/NN lipoproteins/NNS ./. 
Platelets/NNS from/IN 14/CD white/JJ and/CC 13/CD black/JJ women/NNS in/IN good/JJ health/NN were/VBD studied/VBN ./. 
The/DT FECa2+/NN was/VBD measured/VBN as/IN the/DT ionomycin-evoked/JJ Ca2+/NN release/NN (/( in/IN the/DT presence/NN of/IN thapsigargin/NN )/) in/IN Ca2+-/JJ free/JJ medium/NN ./. 
SERCA/NN activity/NN was/VBD measured/VBN as/IN the/DT thapsigargin/NN sensitive/JJ ,/, Ca2+/NN dependent/JJ and/CC ouabain/NN resistant/JJ ,/, ATP/NN hydrolyses/NNS in/IN platelet/NN membranes/NNS ./. 
Relative/JJ expressions/NNS of/IN SERCA/NN 2/CD and/CC 3/CD isoforms/NNS and/CC Ras-related/JJ protein/NN (/( Rap/NN )/) 1/CD in/IN platelet/NN membranes/NNS were/VBD determined/VBN by/IN Western/NN immunoblots/NNS ./. 
Highly/RB significant/JJ correlations/NNS were/VBD observed/VBN for/IN FECa2+/NN in/IN the/DT dense/JJ tubules/NNS with/IN :/: 1/LS )/) the/DT maximal/JJ reaction/NN velocity/NN (/( Vmax/NN )/) of/IN the/DT SERCA/NN (/( r/NN =/JJ 0.592/CD ,/, P/NN =/JJ .0014/CD )/) ,/, and/CC 2/LS )/) Rapl/NN (/( r/NN =/JJ 0.551/CD ,/, P/NN =/JJ .0035/CD )/) ./. 
In/IN addition/NN ,/, negative/JJ correlations/NNS were/VBD observed/VBN between/IN FECa2+/NN in/IN the/DT dense/JJ tubules/NNS and/CC age/NN ./. 
No/DT correlations/NNS were/VBD observed/VBN for/IN these/DT variables/NNS with/IN blood/NN pressure/NN or/CC serum/NN lipoproteins/NNS ./. 
We/PRP conclude/VBP the/DT FECa2+/NN and/CC the/DT Vmax/NN of/IN the/DT SERCA/NN are/VBP reliable/JJ indicators/NNS of/IN Ca2+/NN load/NN in/IN platelets/NNS from/IN women/NNS ./. 
However/RB ,/, in/IN women/NNS ,/, unlike/IN previous/JJ observations/NNS in/IN men/NNS ,/, these/DT platelet/NN parameters/NNS are/VBP not/RB correlated/VBN with/IN blood/NN pressure/NN and/CC serum/NN lipoproteins/NNS ./. 
UI/LS -/: 99180171/CD 
TI/LS -/: Cobalt/NN chloride-induced/JJ signaling/NN in/IN endothelium/NN leading/VBG to/TO the/DT augmented/JJ adherence/NN of/IN sickle/JJ red/JJ blood/NN cells/NNS and/CC transendothelial/JJ migration/NN of/IN monocyte-like/JJ HL-60/NN cells/NNS is/VBZ blocked/VBN by/IN PAF-receptor/NN antagonist/NN ./. 
AB/LS -/: In/IN response/NN to/TO hypoxia/NN ,/, sickle/JJ red/JJ blood/NN cells/NNS (/( SS/NN RBC/NN )/) and/CC leukocytes/NNS exhibit/VBP increased/VBN adherence/NN to/TO the/DT vascular/JJ endothelium/NN ,/, while/IN diapedesis/NN of/IN leukocytes/NNS through/IN the/DT blood/NN vessel/NN increases/VBZ ./. 
However/RB ,/, the/DT cellular/JJ signaling/NN pathway/NN (/( s/NNS )/) caused/VBN by/IN hypoxia/NN is/VBZ poorly/RB understood/VBN ./. 
We/PRP utilized/VBD CoCl2/NN as/IN a/DT mimetic/JJ molecule/NN for/IN hypoxia/NN to/TO study/VB cellular/JJ signaling/NN pathways/NNS ./. 
We/PRP found/VBD that/IN in/IN human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS (/( HUVEC/NN )/) ,/, CoCl2/NN at/IN 2/CD mM/NN concentration/NN induced/VBD the/DT surface/NN expression/NN of/IN a/DT subset/NN of/IN CAMs/NNS (/( VCAM-1/NN )/) and/CC activation/NN of/IN transcription/NN factor/NN NF-kappaB/NN in/IN the/DT nuclear/JJ extracts/NNS of/IN HUVEC/NN ./. 
Furthermore/RB ,/, CoCl2/NN also/RB caused/VBD time-dependent/JJ tyrosine/NN phosphorylation/NN of/IN mitogen-activated/JJ protein/NN (/( MAP/NN )/) kinase/NN isoform/NN ERK2/NN without/IN significantly/RB affecting/VBG ERK1/NN ,/, indicating/VBG ERK2/NN is/VBZ the/DT preferred/JJ substrate/NN for/IN upstream/JJ kinase/NN of/IN the/DT MAPK/NN pathway/NN ./. 
Inhibitors/NNS of/IN MAP/NN kinase/NN (/( PD98059/NN )/) or/CC platelet-activating/JJ factor/NN (/( PAF/NN )/) - receptor/NN antagonist/NN (/( CV3988/NN )/) inhibited/VBD the/DT CoCl2-induced/JJ NF-kappaB/NN activation/NN and/CC VCAM-1/NN expression/NN ./. 
Augmented/JJ expression/NN of/IN VCAM-1/NN led/VBD to/TO increased/VBN SS/NN RBC/NN adhesion/NN ,/, inhibitable/JJ by/IN a/DT VCAM-1/NN antibody/NN ./. 
Additionally/RB ,/, CoCl2/NN caused/VBD a/DT two-/CD to/TO threefold/JJ increase/NN in/IN the/DT rate/NN of/IN transendothelial/JJ migration/NN of/IN monocyte-like/JJ HL-60/NN cells/NNS and/CC a/DT twentyfold/JJ increase/NN in/IN phosphorylation/NN of/IN platelet/NN endothelial/JJ cell/NN adhesion/NN molecules/NNS (/( PECAM-1/NN )/) ./. 
The/DT transendothelial/JJ migration/NN of/IN monocytes/NNS was/VBD inhibited/VBN by/IN an/DT antibody/NN to/TO PECAM-1/NN ./. 
Both/CC phosphorylation/NN of/IN PECAM-1/NN and/CC transendothelial/JJ migration/NN of/IN monocytes/NNS in/IN response/NN to/TO CoCl2/NN were/VBD inhibited/VBN by/IN protein/NN kinase/NN inhibitor/NN (/( GF109203X/NN )/) and/CC augmented/VBN by/IN protein/NN phosphatase/NN inhibitor/NN (/( Calyculin/NN A/NN )/) ./. 
Our/PRP$ data/NNS suggests/VBZ that/IN CoCl2-induced/JJ cellular/JJ signals/NNS directing/VBG increased/VBN expression/NN of/IN VCAM-1/NN in/IN HUVEC/NN involve/VBP downstream/JJ activation/NN of/IN MAP/NN kinase/NN and/CC NF-kappaB/NN ,/, while/IN the/DT phosphorylation/NN of/IN PECAM-1/NN occurs/VBZ as/IN a/DT result/NN of/IN activation/NN of/IN PKC/NN ./. 
We/PRP conclude/VBP that/IN PAF-receptor/NN antagonist/NN inhibits/VBZ the/DT CoCl2-/NN or/CC hypoxia-induced/JJ increase/NN in/IN the/DT adhesion/NN of/IN SS/NN RBC/NN ,/, PECAM-1/NN phosphorylation/NN ,/, and/CC the/DT concomitant/JJ transendothelial/JJ migration/NN of/IN monocytes/NNS ./. 
UI/LS -/: 99175125/CD 
TI/LS -/: Bacterial/JJ lipopolysaccharide/NN activates/VBZ nuclear/JJ factor-kappaB/NN through/IN interleukin-1/NN signaling/NN mediators/NNS in/IN cultured/VBN human/JJ dermal/JJ endothelial/JJ cells/NNS and/CC mononuclear/JJ phagocytes/NNS ./. 
AB/LS -/: Bacterial/JJ lipopolysaccharide/NN (/( LPS/NN )/) -mediated/JJ immune/JJ responses/NNS ,/, including/VBG activation/NN of/IN monocytes/NNS ,/, macrophages/NNS ,/, and/CC endothelial/JJ cells/NNS ,/, play/VBP an/DT important/JJ role/NN in/IN the/DT pathogenesis/NN of/IN Gram-negative/JJ bacteria-induced/JJ sepsis/NN syndrome/NN ./. 
Activation/NN of/IN NF-kappaB/NN is/VBZ thought/VBN to/TO be/VB required/VBN for/IN cytokine/NN release/NN from/IN LPS-responsive/JJ cells/NNS ,/, a/DT critical/JJ step/NN for/IN endotoxic/JJ effects/NNS ./. 
Here/RB we/PRP investigated/VBD the/DT role/NN and/CC involvement/NN of/IN interleukin-1/NN (/( IL-1/NN )/) and/CC tumor/NN necrosis/NN factor/NN (/( TNF-alpha/NN )/) signal/NN transducer/NN molecules/NNS in/IN LPS/NN signaling/NN in/IN human/JJ dermal/JJ microvessel/NN endothelial/JJ cells/NNS (/( HDMEC/NN )/) and/CC THP-1/NN monocytic/JJ cells/NNS ./. 
LPS/NN stimulation/NN of/IN HDMEC/NN and/CC THP-1/NN cells/NNS initiated/VBD an/DT IL-1/NN receptor-like/JJ NF-kappaB/NN signaling/NN cascade/NN ./. 
In/IN transient/JJ cotransfection/NN experiments/NNS ,/, dominant/JJ negative/JJ mutants/NNS of/IN the/DT IL-1/NN signaling/NN pathway/NN ,/, including/VBG MyD88/NN ,/, IRAK/NN ,/, IRAK2/NN ,/, and/CC TRAF6/NN inhibited/VBD both/CC IL-1-/NN and/CC LPS-induced/JJ NF-kappaB-luciferase/NN activity/NN ./. 
LPS-induced/JJ NF-kappaB/NN activation/NN was/VBD not/RB inhibited/VBN by/IN a/DT dominant/JJ negative/JJ mutant/NN of/IN TRAF2/NN that/WDT is/VBZ involved/VBN in/IN TNF/NN signaling/NN ./. 
LPS-induced/JJ activation/NN of/IN NF-kappaB-responsive/JJ reporter/NN gene/NN was/VBD not/RB inhibited/VBN by/IN IL-1/NN receptor/NN antagonist/NN ./. 
TLR2/NN and/CC TLR4/NN were/VBD expressed/VBN on/IN the/DT cell/NN surface/NN of/IN HDMEC/NN and/CC THP-1/NN cells/NNS ./. 
These/DT findings/NNS suggest/VBP that/IN a/DT signal/NN transduction/NN molecule/NN in/IN the/DT LPS/NN receptor/NN complex/NN may/MD belong/VB to/TO the/DT IL-1/NN receptor/toll-like/JJ receptor/NN (/( TLR/NN )/) super/JJ family/NN ,/, and/CC the/DT LPS/NN signaling/NN cascade/NN uses/VBZ an/DT analogous/JJ molecular/JJ framework/NN for/IN signaling/NN as/IN IL-1/NN in/IN mononuclear/JJ phagocytes/NNS and/CC endothelial/JJ cells/NNS ./. 
UI/LS -/: 99242525/CD 
TI/LS -/: Signal/NN transduction/NN through/IN interferon-gamma/NN receptor/NN on/IN human/JJ eosinophils/NNS ./. 
AB/LS -/: BACKGROUND/NN :/: We/PRP reported/VBD on/IN the/DT constitutive/JJ interferon-gamma/NN receptor/NN (/( IFN-gammaR/NN )/) expression/NN on/IN eosinophils/NNS ./. 
But/CC signal/NN transduction/NN through/IN IFN-gammaR/NN on/IN eosinophils/NNS remains/VBZ to/TO be/VB elucidated/VBN ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD the/DT involvement/NN of/IN the/DT Jak/Stat/NN pathway/NN in/IN the/DT signaling/NN of/IN eosinophils/NNS after/IN IFN-gammaR/NN conjugation/NN by/IN the/DT ligand/NN binding/NN ./. 
METHODS/NNS :/: Purified/VBN peripheral/JJ eosinophils/NNS were/VBD stimulated/VBN with/IN IFN-gamma/NN at/IN 37/CD degrees/NNS C/NN for/IN 1-60/CD min/NN ./. 
Tyrosine/NN phosphorylation/NN of/IN IFN-gammaR/NN ,/, Jak1/NN ,/, Jak2/NN ,/, and/CC Stat1alpha/NN was/VBD examined/VBN by/IN immunoblotting/NN ./. 
Gel-shift/JJ assay/NN was/VBD also/RB examined/VBN to/TO show/VB the/DT formation/NN of/IN Stat1alpha-DNA/NN complexes/NNS ./. 
RESULTS/NNS :/: We/PRP show/VBP that/IN binding/NN of/IN IFN-gamma/NN to/TO human/JJ eosinophils/NNS initiated/VBD a/DT series/NN of/IN events/NNS that/WDT resulted/VBD in/IN the/DT rapid/JJ tyrosine/NN phosphorylation/NN of/IN not/RB only/RB the/DT IFN-gammaRalpha/NN chain/NN but/CC also/RB Jak1/NN ,/, Jak2/NN ,/, and/CC Stat1alpha/NN ./. 
In/IN addition/NN ,/, IFN-gamma/NN enhanced/VBD the/DT DNA-binding/JJ activity/NN of/IN Stat1alpha/NN ./. 
CONCLUSION/NN :/: These/DT data/NNS indicate/VBP that/IN IFN-gamma/NN affects/VBZ eosinophils/NNS through/IN its/PRP$ specific/JJ receptor/NN and/CC utilizes/VBZ the/DT Jak/Stat/NN pathway/NN as/IN its/PRP$ mode/NN of/IN signaling/NN ./. 
UI/LS -/: 99233638/CD 
TI/LS -/: Expression/NN of/IN E2A-HLF/NN chimeric/JJ protein/NN induced/VBD T-cell/NN apoptosis/NN ,/, B-cell/NN maturation/NN arrest/NN ,/, and/CC development/NN of/IN acute/JJ lymphoblastic/JJ leukemia/NN ./. 
AB/LS -/: The/DT E2A-HLF/NN fusion/NN gene/NN ,/, generated/VBN by/IN t(17;19)(q22;p13)/NN in/IN acute/JJ lymphoblastic/JJ leukemia/NN (/( ALL/NN )/) ,/, encodes/VBZ a/DT chimeric/JJ transcription/NN factor/NN in/IN which/WDT the/DT trans-activating/JJ domains/NNS of/IN E2A/NN are/VBP fused/VBN to/TO the/DT DNA-binding/JJ and/CC dimerization/NN domains/NNS of/IN hepatic/JJ leukemic/JJ factor/NN (/( HLF/NN )/) ./. 
To/TO investigate/VB its/PRP$ biological/JJ role/NN ,/, we/PRP generated/VBD transgenic/JJ mice/NNS expressing/VBG E2A-HLF/NN using/VBG Ig/NN enhancer/NN and/CC promoter/NN ,/, which/WDT direct/VBP transgene/NN expression/NN in/IN cells/NNS committed/VBN to/TO the/DT lymphoid/JJ lineage/NN ./. 
The/DT transgenic/JJ mice/NNS exhibited/VBD abnormal/JJ development/NN in/IN the/DT thymus/NN and/CC spleen/NN and/CC were/VBD susceptible/JJ to/TO infection/NN ./. 
The/DT thymus/NN contained/VBD small/JJ numbers/NNS of/IN thymocytes/NNS ,/, and/CC TUNEL/NN staining/NN showed/VBD that/IN higher/JJR population/NN of/IN thymocytes/NNS were/VBD undergoing/VBG apoptosis/NN ./. 
The/DT spleen/NN exhibited/VBD a/DT marked/JJ reduction/NN in/IN splenic/JJ lymphocytes/NNS and/CC the/DT flow/NN cytometric/JJ analyses/NNS and/CC the/DT in/FW vitro/FW colony/NN formation/NN assays/NNS showed/VBD that/IN the/DT B-cell/NN maturation/NN was/VBD blocked/VBN at/IN a/DT very/RB early/JJ developmental/JJ stage/NN ./. 
These/DT findings/NNS indicated/VBD that/IN the/DT expression/NN of/IN E2A-HLF/NN induced/VBD T-cell/NN apoptosis/NN and/CC B-cell/NN maturation/NN arrest/NN in/FW vivo/FW and/CC that/IN the/DT susceptibility/NN of/IN the/DT transgenic/JJ mice/NNS to/TO infection/NN was/VBD due/JJ to/TO immunodeficiency/NN ./. 
Moreover/RB ,/, several/JJ transgenic/JJ mice/NNS developed/VBD acute/JJ leukemia/NN ,/, classified/VBN as/IN T-ALL/NN based/VBN on/IN the/DT surface/NN marker/NN analysis/NN and/CC DNA/NN rearrangements/NNS ,/, suggesting/VBG that/IN an/DT additional/JJ event/NN is/VBZ required/VBN for/IN malignant/JJ transformation/NN of/IN lymphoid/JJ cells/NNS expressing/VBG E2A-HLF/NN ./. 
Our/PRP$ findings/NNS provide/VBP insight/NN into/IN the/DT biological/JJ function/NN of/IN E2A-HLF/NN in/IN lymphoid/JJ development/NN and/CC also/RB its/PRP$ role/NN in/IN leukemogenesis/NN ./. 
UI/LS -/: 99223566/CD 
TI/LS -/: Retinoid/NN X/NN receptor/NN (/( RXR/NN )/) agonist-induced/JJ activation/NN of/IN dominant-negative/JJ RXR-retinoic/JJ acid/NN receptor/NN alpha403/NN heterodimers/NNS is/VBZ developmentally/RB regulated/VBN during/IN myeloid/JJ differentiation/NN ./. 
AB/LS -/: The/DT multiple/JJ biologic/JJ activities/NNS of/IN retinoic/JJ acid/NN (/( RA/NN )/) are/VBP mediated/VBN through/IN RAR/NN and/CC retinoid/NN X/NN receptor/NN (/( RXR/NN )/) nuclear/JJ receptors/NNS that/WDT interact/VBP with/IN specific/JJ DNA/NN target/NN sequences/VBZ as/IN heterodimers/NNS (/( RXR-RAR/NN )/) or/CC homodimers/NNS (/( RXR-RXR/NN )/) ./. 
RA/NN receptor/NN activation/NN appears/VBZ critical/JJ to/TO regulating/VBG important/JJ aspects/NNS of/IN hematopoiesis/NN ,/, since/IN transducing/VBG a/DT COOH-terminally/RB truncated/VBN RARalpha/NN exhibiting/VBG dominant-negative/JJ activity/NN (/( RARalpha403/NN )/) into/IN normal/JJ mouse/NN bone/NN marrow/NN generates/VBZ hematopoietic/JJ growth/NN factor-dependent/JJ cell/NN lines/NNS frozen/VBN at/IN the/DT multipotent/JJ progenitor/NN (/( EML/NN )/) or/CC committed/VBN promyelocyte/JJ (/( MPRO/NN )/) stages/NNS ./. 
Nevertheless/RB ,/, relatively/RB high/JJ ,/, pharmacological/JJ concentrations/NNS of/IN RA/NN (/( 1/CD to/TO 10/CD &/CC mgr/NN ;/: M/NN )/) overcome/VBP these/DT differentiation/NN blocks/NNS and/CC induce/VBP terminal/JJ granulocytic/JJ differentiation/NN of/IN the/DT MPRO/NN promyelocytes/NNS while/IN potentiating/VBG interleukin-3/NN (/( IL-3/NN )/) -induced/JJ commitment/NN of/IN EML/NN cells/NNS to/TO the/DT granulocyte/monocyte/NN lineage/NN ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP utilized/VBD RXR-/NN and/CC RAR-specific/JJ agonists/NNS and/CC antagonists/NNS to/TO determine/VB how/WRB RA/NN overcomes/VBZ the/DT dominant-negative/JJ activity/NN of/IN the/DT truncated/VBN RARalpha/NN in/IN these/DT different/JJ myeloid/JJ developmental/JJ stages/NNS ./. 
Unexpectedly/RB ,/, we/PRP observed/VBD that/IN an/DT RXR-specific/JJ ,/, rather/RB than/IN an/DT RAR-specific/JJ ,/, agonist/NN induces/VBZ terminal/JJ granulocytic/JJ differentiation/NN of/IN MPRO/NN promyelocytes/NNS ,/, and/CC this/DT differentiation/NN is/VBZ associated/VBN with/IN activation/NN of/IN DNA/NN response/NN elements/NNS corresponding/VBG to/TO RAR-RXR/NN heterodimers/NNS rather/RB than/IN RXR-RXR/NN homodimers/NNS ./. 
This/DT RXR/NN agonist/NN activity/NN is/VBZ blocked/VBN by/IN RAR-specific/JJ antagonists/NNS ,/, suggesting/VBG extensive/JJ cross-talk/NN between/IN the/DT partners/NNS of/IN the/DT RXR-RARalpha403/NN heterodimer/NN ./. 
In/IN contrast/NN ,/, in/IN the/DT more/RBR immature/JJ ,/, multipotent/JJ EML/NN cells/NNS we/PRP observed/VBD that/IN this/DT RXR-specific/JJ agonist/NN is/VBZ inactive/JJ either/CC in/IN potentiating/VBG IL-3-mediated/JJ commitment/NN of/IN EML/NN cells/NNS to/TO the/DT granulocyte/NN lineage/NN or/CC in/IN transactivating/VBG RAR-RXR/NN response/NN elements/NNS ./. 
RA-triggered/JJ GALdbd-RARalpha/NN hybrid/NN activity/NN in/IN these/DT cells/NNS indicates/VBZ that/IN the/DT multipotent/JJ EML/NN cells/NNS harbor/VBP substantial/JJ nuclear/JJ hormone/NN receptor/NN coactivator/NN activity/NN ./. 
However/RB ,/, the/DT histone/NN deacetylase/NN (/( HDAC/NN )/) inhibitor/NN trichostatin/NN A/NN readily/RB activates/VBZ an/DT RXR-RAR/NN reporter/NN construct/NN in/IN the/DT multipotent/JJ EML/NN cells/NNS but/CC not/RB in/IN the/DT committed/VBN MPRO/NN promyelocytes/NNS ,/, indicating/VBG that/IN differences/NNS in/IN HDAC-containing/JJ repressor/NN complexes/NNS in/IN these/DT two/CD closely/RB related/JJ but/CC distinct/JJ hematopoietic/JJ lineages/NNS might/MD account/VB for/IN the/DT differential/JJ activation/NN of/IN the/DT RXR-RARalpha403/NN heterodimers/NNS that/WDT we/PRP observed/VBD at/IN these/DT different/JJ stages/NNS of/IN myeloid/JJ development/NN ./. 
UI/LS -/: 99218482/CD 
TI/LS -/: The/DT functional/JJ synergy/NN between/IN IL-12/NN and/CC IL-2/NN involves/VBZ p38/NN mitogen-activated/JJ protein/NN kinase/NN and/CC is/VBZ associated/VBN with/IN the/DT augmentation/NN of/IN STAT/NN serine/NN phosphorylation/NN ./. 
AB/LS -/: IL-12/NN and/CC IL-2/NN can/MD stimulate/VB mitogen-/NN or/CC CD3-activated/JJ T/NN cells/NNS to/TO proliferate/VB ,/, produce/VB IFN-gamma/NN ,/, and/CC kill/VB tumor/NN cells/NNS ./. 
The/DT magnitude/NN of/IN these/DT functional/JJ responses/NNS is/VBZ greatly/RB augmented/JJ when/WRB T/NN cells/NNS are/VBP activated/VBN by/IN the/DT combination/NN of/IN IL-12/NN and/CC IL-2/NN ./. 
Although/IN peripheral/JJ blood/NN T/NN cells/NNS are/VBP largely/RB unresponsive/JJ to/TO these/DT cytokines/NNS without/IN prior/JJ activation/NN ,/, a/DT small/JJ subset/NN of/IN CD8+/JJ T/NN cells/NNS (/( CD8+CD18bright/NN )/) is/VBZ strongly/RB activated/VBN by/IN the/DT combination/NN of/IN IL-12/NN and/CC IL-2/NN ./. 
In/IN this/DT report/NN we/PRP show/VBP that/IN the/DT functional/JJ synergy/NN between/IN IL-12/NN and/CC IL-2/NN in/IN CD8+CD18bright/NN T/NN cells/NNS correlates/VBZ with/IN the/DT activation/NN of/IN the/DT stress/NN kinases/NNS ,/, p38/NN mitogen-activated/JJ protein/NN (/( MAP/NN )/) kinase/NN and/CC stress-activated/JJ protein/NN kinase/NN (/( SAPK/NN )/) /Jun/NN N-terminal/JJ kinase/NN ,/, but/CC not/RB with/IN the/DT activation/NN of/IN the/DT extracellular/JJ signal-regulated/JJ kinases/NNS ./. 
The/DT functional/JJ synergy/NN between/IN IL-2/NN and/CC IL-12/NN is/VBZ also/RB associated/VBN with/IN a/DT prominent/JJ increase/NN in/IN STAT1/NN and/CC STAT3/NN serine/NN phosphorylation/NN over/IN that/DT observed/VBN with/IN IL-12/NN or/CC IL-2/NN alone/RB ./. 
By/IN contrast/NN ,/, STAT/NN tyrosine/NN phosphorylation/NN is/VBZ not/RB augmented/JJ over/IN that/DT seen/VBN with/IN either/DT cytokine/NN alone/RB ./. 
A/DT specific/JJ inhibitor/NN of/IN p38/NN MAP/NN kinase/NN completely/RB inhibits/VBZ the/DT serine/JJ phosphorylation/NN of/IN STAT1/NN and/CC STAT3/NN induced/VBN by/IN IL-12/NN and/CC IL-2/NN and/CC abrogates/VBZ the/DT functional/JJ synergy/NN between/IN IL-12/NN and/CC IL-2/NN without/IN affecting/VBG STAT/NN tyrosine/NN phosphorylation/NN ./. 
This/DT suggests/VBZ that/IN p38/NN MAP/NN kinase/NN may/MD play/VB an/DT important/JJ role/NN in/IN regulating/VBG STAT/NN serine/NN phosphorylation/NN in/IN response/NN to/TO the/DT combination/NN of/IN IL-12/NN and/CC IL-2/NN ./. 
Furthermore/RB ,/, these/DT findings/NNS indicate/VBP that/IN the/DT optimal/JJ activation/NN of/IN T/NN cells/NNS by/IN IL-12/NN and/CC IL-2/NN may/MD depend/VB on/IN an/DT interaction/NN between/IN the/DT p38/NN MAP/NN kinase/NN and/CC Janus/NN kinase/STAT/NN signaling/NN pathways/NNS ./. 
UI/LS -/: 99210381/CD 
TI/LS -/: Activation/NN of/IN NF-kappaB/NN in/IN Mycobacterium/NN tuberculosis-induced/JJ interleukin-2/NN receptor/NN expression/NN in/IN mononuclear/JJ phagocytes/NNS ./. 
AB/LS -/: Soluble/JJ interleukin-2/NN receptor-alpha/NN (/( IL-2Ralpha/NN )/) has/VBZ been/VBN reported/VBN to/TO be/VB increased/VBN in/IN the/DT sera/NNS of/IN patients/NNS with/IN advanced/JJ tuberculosis/NN ,/, and/CC levels/NNS decline/VBP after/IN therapy/NN in/IN accordance/NN with/IN improvement/NN of/IN radiologic/JJ findings/NNS ./. 
We/PRP investigated/VBD expression/NN of/IN the/DT IL-2Ralpha/NN in/IN bronchoalveolar/JJ lavage/NN (/( BAL/NN )/) cells/NNS in/IN active/JJ pulmonary/JJ tuberculosis/NN ,/, and/CC evaluated/VBD the/DT mechanism/NN Mycobacterium/NN tuberculosis/NN induces/VBZ in/IN the/DT IL-2Ralpha/NN using/VBG the/DT THP-1/NN mononuclear/JJ phagocyte/NN cell/NN line/NN ./. 
We/PRP found/VBD IL-2Ralpha/NN expression/NN to/TO be/VB increased/VBN in/IN BAL/NN cells/NNS from/IN involved/VBN sites/NNS of/IN active/JJ pulmonary/JJ tuberculosis/NN ./. 
Expression/NN of/IN the/DT alpha-chain/NN of/IN IL-2Ralpha/NN on/IN peripheral/JJ blood/NN monocytes/NNS (/( PBM/NN )/) was/VBD induced/VBN by/IN M./NN tuberculosis/NN by/IN flow/NN cytometry/NN evaluation/NN ./. 
Northern/NN analysis/NN demonstrated/VBD increased/VBN IL-2Ralpha/NN gene/NN expression/NN after/IN stimulation/NN with/IN M./NN tuberculosis/NN which/WDT was/VBD further/RBR induced/VBN by/IN interferon-gamma/NN (/( IFN-gamma/NN )/) ./. 
The/DT IL-2Ralpha/NN promoter/NN containing/VBG the/DT nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappaB/NN )/) site/NN was/VBD transcriptionally/RB induced/VBN by/IN M./NN tuberculosis/NN and/CC this/DT NF-kappaB/NN site/NN could/MD confer/VB inducibility/NN to/TO a/DT heterologous/JJ herpes/NN thymidine/NN kinase/NN (/( TK/NN )/) promoter/NN by/IN M./NN tuberculosis/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS (/( EMSAs/NNS )/) revealed/VBD specific/JJ binding/NN of/IN nuclear/JJ protein/NN to/TO the/DT NF-kappaB/NN site/NN upon/IN induction/NN with/IN M./NN tuberculosis/NN ./. 
Using/VBG antibodies/NNS against/IN the/DT p50/NN and/CC p65/NN subunits/NNS of/IN NF-kappaB/NN in/IN EMSAs/NNS ,/, the/DT involvement/NN of/IN both/CC p50/NN and/CC p65/NN proteins/NNS was/VBD further/RBR demonstrated/VBN ./. 
Functional/JJ expression/NN of/IN the/DT IL-2Ralpha/NN on/IN mononuclear/JJ phagocytes/NNS in/IN M./NN tuberculosis/NN infection/NN may/MD play/VB an/DT important/JJ immunomodulatory/JJ role/NN in/IN the/DT host/NN response/NN ./. 
UI/LS -/: 99203164/CD 
TI/LS -/: Vitamin/NN D/NN receptor/NN 3'-untranslated/JJ region/NN polymorphisms/NNS :/: lack/NN of/IN effect/NN on/IN mRNA/NN stability/NN ./. 
AB/LS -/: Allelic/JJ variation/NN at/IN the/DT 3'-end/NN of/IN the/DT vitamin/NN D/NN receptor/NN (/( VDR/NN )/) gene/NN has/VBZ been/VBN associated/VBN with/IN a/DT 3-5-fold/RB increased/VBN risk/NN of/IN developing/VBG prostate/NN cancer/NN and/CC with/IN differences/NNS in/IN bone/NN mineralization/NN ./. 
This/DT genetic/JJ diversity/NN does/VBZ not/RB alter/VB the/DT VDR/NN protein/NN structurally/RB ,/, but/CC instead/RB may/MD be/VB a/DT marker/NN (/( s/NNS )/) of/IN other/JJ ,/, nearby/JJ polymorphisms/NNS that/WDT influence/VBP message/NN stability/NN or/CC translation/NN ./. 
The/DT work/NN reported/VBN here/RB was/VBD instigated/VBN to/TO identify/VB additional/JJ VDR/NN 3'-UTR/NN polymorphisms/NNS that/WDT may/MD have/VB functional/JJ significance/NN and/CC to/TO then/RB test/VB whether/IN these/DT genetic/JJ variants/NNS alter/VBP message/NN stability/NN ./. 
Initially/RB ,/, four/CD novel/JJ ,/, frequently/RB occurring/VBG sequence/NN variants/NNS were/VBD identified/VBN that/WDT associated/VBD with/IN two/CD common/JJ haplotypes/NNS that/WDT were/VBD described/VBN previously/RB ./. 
These/DT common/JJ sequence/NN variants/NNS were/VBD not/RB found/VBN within/IN three/CD message-destabilizing/JJ elements/NNS that/WDT we/PRP mapped/VBD within/IN the/DT 3'-UTR/NN of/IN the/DT vitamin/NN D/NN receptor/NN mRNA/NN ./. 
Furthermore/RB ,/, the/DT two/CD VDR/NN 3'-UTR/NN haplotypes/NNS conferred/VBD an/DT identical/JJ half-life/NN on/IN a/DT heterologous/JJ beta-globin/NN reporter/NN gene/NN ,/, in/IN an/DT in/FW vitro/FW assay/NN ./. 
We/PRP therefore/RB conclude/VBP that/IN common/JJ polymorphisms/NNS within/IN the/DT VDR/NN 3'-UTR/NN do/VBP not/RB influence/VB message/NN stability/NN ./. 
UI/LS -/: 99192743/CD 
TI/LS -/: IL-2-mediated/JJ cell/NN cycle/NN progression/NN and/CC inhibition/NN of/IN apoptosis/NN does/VBZ not/RB require/VB NF-kappa/NN B/NN or/CC activating/VBG protein-1/NN activation/NN in/IN primary/JJ human/JJ T/NN cells/NNS ./. 
AB/LS -/: The/DT IL-2/NN growth/NN hormone/NN is/VBZ the/DT major/JJ growth/NN factor/NN of/IN activated/VBN T/NN lymphocytes/NNS during/IN a/DT developing/VBG immune/JJ response/NN ./. 
IL-2/NN is/VBZ required/VBN not/RB only/RB for/IN cell/NN cycle/NN progression/NN but/CC also/RB to/TO protect/VB Ag-activated/JJ T/NN cells/NNS from/IN programmed/VBN cell/NN death/NN ./. 
In/IN several/JJ cell/NN types/NNS ,/, activation/NN of/IN NF-kappa/NN B/NN and/or/CC activating/VBG protein-1/NN (/( AP-1/NN )/) has/VBZ been/VBN demonstrated/VBN to/TO be/VB extremely/RB important/JJ in/IN blocking/VBG apoptosis/NN ./. 
To/TO determine/VB whether/IN either/DT or/CC both/DT of/IN these/DT transcription/NN factors/NNS are/VBP involved/VBN in/IN cell/NN survival/NN or/CC cell/NN cycle/NN progression/NN in/IN response/NN to/TO IL-2/NN ,/, primary/JJ human/JJ T/NN cells/NNS responsive/JJ to/TO the/DT growth/NN factor/NN were/VBD analyzed/VBN for/IN NF-kappa/NN B/NN and/CC AP-1/NN activation/NN ./. 
The/DT current/JJ study/NN clearly/RB demonstrates/VBZ that/IN IL-2/NN does/VBZ not/RB induce/VB I/NN kappa/NN B/NN alpha/NN degradation/NN or/CC NF-kappa/NN B/NN activation/NN in/IN primary/JJ human/JJ T/NN cells/NNS that/WDT respond/VBP to/TO IL-2/NN by/IN entering/VBG the/DT cell/NN cycle/NN and/CC avoiding/VBG apoptosis/NN ./. 
Similarly/RB ,/, IL-2/NN neither/CC activates/VBZ JNK/NN nor/CC increases/VBZ AP-1/NN binding/NN activity/NN to/TO a/DT consensus/NN o-tetradecanoylphorbol/NN 13-acetate/NN (/( TPA/NN )/) response/NN element/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, the/DT growth/NN factor/NN does/VBZ induce/VB the/DT activation/NN of/IN STAT3/NN and/CC STAT5/NN in/IN these/DT cells/NNS ,/, as/IN has/VBZ been/VBN previously/RB demonstrated/VBN ./. 
These/DT data/NNS show/VBP that/IN neither/CC NF-kappa/NN B/NN nor/CC AP-1/NN activation/NN is/VBZ required/VBN for/IN IL-2-mediated/JJ survival/NN or/CC cell/NN cycle/NN progression/NN in/IN activated/VBN primary/JJ human/JJ T/NN cells/NNS ./. 
UI/LS -/: 99189777/CD 
TI/LS -/: Estrone/NN potentiates/VBZ myeloid/JJ cell/NN differentiation/NN :/: a/DT role/NN for/IN 17/CD beta-hydroxysteroid/NN dehydrogenase/NN in/IN modulating/VBG hemopoiesis/NN ./. 
AB/LS -/: Hormones/NNS such/JJ as/IN 1/CD alpha, 25-dihydroxy/NN vitamin/NN D3/NN (/( D3/NN )/) ,/, all-trans/JJ retinoic/JJ acid/NN ,/, and/CC 9-cis/JJ retinoic/JJ acid/NN stimulate/VBP differentiation/NN of/IN myeloid/JJ progenitor/NN cells/NNS via/IN their/PRP$ interaction/NN with/IN specific/JJ hormone/NN receptors/NNS ./. 
However/RB ,/, the/DT sensitivity/NN of/IN cells/NNS to/TO these/DT agents/NNS is/VBZ not/RB merely/RB governed/VBN by/IN the/DT expression/NN of/IN their/PRP$ receptors/NNS and/CC the/DT availability/NN of/IN ligand/NN to/TO bind/VB them/PRP ./. 
Recent/JJ studies/NNS from/IN our/PRP$ group/NN suggested/VBD that/IN the/DT actions/NNS of/IN D3/NN and/CC retinoids/NNS on/IN myelopoiesis/NN also/RB are/VBP influenced/VBN by/IN endogenous/JJ mechanisms/NNS involving/VBG other/JJ steroid/NN hormones/NNS ./. 
In/IN this/DT study/NN we/PRP examined/VBD the/DT influence/NN of/IN local/JJ estrogen/NN metabolism/NN on/IN the/DT differentiation/NN of/IN HL60/NN cells/NNS and/CC normal/JJ primitive/JJ myeloid/JJ progenitor/NN cells/NNS ./. 
Quantitative/JJ thin-layer/JJ chromatography/NN (/( TLC/NN )/) analyses/NNS showed/VBD that/IN HL60/NN and/CC normal/JJ cells/NNS are/VBP able/JJ to/TO generate/VB estrone/NN (/( E1/NN )/) from/IN estradiol/NN (/( E2/NN )/) ./. 
Neither/DT cell/NN population/NN generated/VBD significant/JJ amounts/NNS of/IN E2/NN from/IN E1/NN ./. 
Reverse/NN transcriptase/NN polymerase/NN chain/NN reaction/NN and/CC Northern/NN analyses/NNS confirmed/VBD that/IN normal/JJ and/CC leukemic/JJ myeloid/JJ progenitor/NN cells/NNS expressed/VBD mRNA/NN for/IN the/DT type/NN I/CD and/CC IV/CD isoforms/NNS of/IN 17/CD beta-hydroxysteroid/NN dehydrogenase/NN ./. 
Conversion/NN of/IN E2/NN to/TO E1/NN was/VBD upregulated/VBN within/IN 24/CD hours/NNS when/WRB HL60/NN cells/NNS were/VBD treated/VBN with/IN either/CC all-trans/JJ retinoic/JJ acid/NN or/CC D3/NN at/IN doses/NNS that/WDT induce/VBP their/PRP$ differentiation/NN toward/IN neutrophils/NNS or/CC monocytes/NNS ,/, respectively/RB ./. 
Similarly/RB ,/, D3-induced/JJ monocyte/NN differentiation/NN of/IN normal/JJ myeloid/JJ progenitor/NN cells/NNS was/VBD associated/VBN with/IN increased/VBN capacity/NN to/TO generate/VB E1/NN from/IN E2/NN ./. 
When/WRB HL60/NN cells/NNS or/CC normal/JJ myeloid/JJ progenitor/NN cells/NNS were/VBD exposed/VBN to/TO exogenous/JJ E1/NN they/PRP became/VBD more/RBR sensitive/JJ to/TO the/DT differentiation-inducing/JJ effects/NNS of/IN D3/NN ./. 
Data/NNS presented/VBN provide/VBP further/JJ evidence/NN for/IN the/DT local/JJ modulation/NN of/IN myelopoiesis/NN by/IN intracrine/JJ mechanisms/NNS ./. 
In/IN particular/JJ ,/, our/PRP$ findings/NNS suggest/VBP that/IN local/JJ metabolism/NN of/IN steroids/NNS by/IN normal/JJ as/RB well/RB as/IN leukemic/JJ myeloid/JJ cells/NNS influences/VBZ their/PRP$ responsiveness/NN to/TO D3/NN and/CC retinoids/NNS ./. 
UI/LS -/: 99182340/CD 
TI/LS -/: Phosphorylation/NN of/IN TRAF2/NN inhibits/VBZ binding/NN to/TO the/DT CD40/NN cytoplasmic/JJ domain/NN ./. 
AB/LS -/: TRAF2/NN is/VBZ a/DT signal/NN transducing/NN adaptor/NN molecule/NN which/WDT binds/VBZ to/TO the/DT CD40/NN cytoplasmic/JJ domain/NN ./. 
We/PRP have/VBP found/VBN that/IN it/PRP is/VBZ phosphorylated/JJ ,/, predominantly/RB on/IN serine/NN residues/NNS ,/, when/WRB transiently/RB overexpressed/VBN in/IN 293/CD cells/NNS ./. 
The/DT phosphorylation/NN appears/VBZ to/TO be/VB related/JJ to/TO the/DT signaling/NN events/NNS that/WDT are/VBP activated/VBN by/IN TRAF2/NN under/IN these/DT circumstances/NNS ,/, since/IN two/CD nonfunctional/JJ mutants/NNS were/VBD found/VBN to/TO be/VB phosphorylated/VBN significantly/RB less/RBR than/IN the/DT wild-type/JJ protein/NN ./. 
Furthermore/RB ,/, the/DT phosphorylation/NN status/NN of/IN TRAF2/NN had/VBD significant/JJ effects/NNS on/IN the/DT ability/NN of/IN the/DT protein/NN to/TO bind/VB to/TO CD40/NN ,/, as/IN evidenced/VBN by/IN our/PRP$ observations/NNS that/IN the/DT CD40/NN cytoplasmic/JJ domain/JJ interacted/VBD preferentially/RB with/IN underphosphorylated/VBN TRAF2/NN and/CC that/IN phosphatase/NN treatment/NN significantly/RB enhanced/VBD the/DT binding/NN of/IN TRAF2/NN to/TO CD40/NN ./. 
We/PRP conclude/VBP from/IN these/DT studies/NNS that/IN the/DT phosphorylation/NN of/IN TRAF2/NN is/VBZ likely/JJ to/TO play/VB an/DT important/JJ role/NN in/IN regulating/VBG signaling/NN by/IN virtue/NN of/IN its/PRP$ ability/NN to/TO influence/VB the/DT CD40-TRAF2/JJ interaction/NN ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99175479/CD 
TI/LS -/: A/DT direct/JJ interaction/NN between/IN the/DT adaptor/NN protein/NN Cbl-b/NN and/CC the/DT kinase/NN zap-70/NN induces/VBZ a/DT positive/JJ signal/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Engagement/NN of/IN the/DT T-cell/NN receptor/NN (/( TCR/NN )/) -CD3/JJ complex/NN induces/VBZ a/DT rapid/JJ increase/NN in/IN the/DT activities/NNS of/IN Src-family/NN and/CC Syk/Zap-70-family/NN kinases/NNS [/( 1/CD ]/) [/( 2/CD ]/) ./. 
These/DT activated/VBN kinases/NNS then/RB induce/VBP the/DT tyrosine/NN phosphorylation/NN of/IN multiple/JJ intracellular/JJ proteins/NNS ,/, eventually/RB leading/VBG to/TO T-cell/NN activation/NN ./. 
One/CD of/IN the/DT prominent/JJ substrates/NNS for/IN these/DT kinases/NNS is/VBZ the/DT adaptor/NN protein/NN Cbl/NN [/( 3/CD ]/) and/CC recent/JJ studies/NNS suggest/VBP that/IN Cbl/NN negatively/RB regulates/VBZ upstream/JJ kinases/NNS such/JJ as/IN Syk/NN and/CC Zap-70/NN [/( 4/CD ]/) [/( 5/CD ]/) ./. 
Cbl-b/NN ,/, a/DT homologue/NN of/IN Cbl/NN ,/, is/VBZ widely/RB expressed/VBN in/IN many/JJ tissues/NNS and/CC cells/NNS including/VBG hematopoietic/JJ cells/NNS [/( 6/CD ]/) [/( 7/CD ]/) ./. 
Cbl-b/NN undergoes/VBZ rapid/JJ tyrosine/NN phosphorylation/NN upon/IN stimulation/NN of/IN the/DT TCR/NN and/CC cytokine/NN receptors/NNS [/( 8/CD ]/) [/( 9/CD ]/) ./. 
The/DT role/NN of/IN Cbl-b/NN is/VBZ unclear/JJ ,/, however/RB ./. 
Here/RB ,/, we/PRP show/VBP that/IN overexpression/NN of/IN Cbl-b/NN in/IN T/NN cells/NNS induced/VBD the/DT constitutive/JJ activation/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) ./. 
A/DT loss-of-function/JJ mutation/NN in/IN Cbl-b/NN disrupted/VBD the/DT interaction/NN between/IN Cbl-b/NN and/CC Zap-70/NN and/CC nearly/RB completely/RB abrogated/VBD the/DT Cbl-b-mediated/JJ activation/NN of/IN NFAT/NN ./. 
Unlike/IN the/DT proposed/JJ role/NN of/IN Cbl/NN as/IN a/DT negative/JJ regulator/NN ,/, our/PRP$ results/NNS suggest/VBP that/IN the/DT Cbl/NN homologue/NN Cbl-b/NN has/VBZ a/DT positive/JJ role/NN in/IN T-cell/NN signaling/NN ,/, most/RBS likely/RB via/IN a/DT direct/JJ interaction/NN with/IN the/DT upstream/JJ kinase/NN Zap-70/NN ./. 
UI/LS -/: 99242637/CD 
TI/LS -/: Grf40/NN ,/, A/DT novel/JJ Grb2/NN family/NN member/NN ,/, is/VBZ involved/VBN in/IN T/NN cell/NN signaling/NN through/IN interaction/NN with/IN SLP-76/NN and/CC LAT/NN ./. 
AB/LS -/: We/PRP molecularly/RB cloned/VBD a/DT new/JJ Grb2/NN family/NN member/NN ,/, named/VBN Grf40/NN ,/, containing/VBG the/DT common/JJ SH3-SH2-SH3/NN motif/NN ./. 
Expression/NN of/IN Grf40/NN is/VBZ predominant/JJ in/IN hematopoietic/JJ cells/NNS ,/, particularly/RB T/NN cells/NNS ./. 
Grf40/NN binds/VBZ to/TO the/DT SH2/NN domain-containing/JJ leukocyte/NN protein/NN of/IN 76/CD kD/NN (/( SLP-76/NN )/) via/IN its/PRP$ SH3/NN domain/NN more/RBR tightly/RB than/IN Grb2/NN ./. 
Incidentally/RB ,/, Grf40/NN binds/VBZ to/TO linker/NN for/IN activation/NN of/IN T/NN cells/NNS (/( LAT/NN )/) possibly/RB via/IN its/PRP$ SH2/NN domain/NN ./. 
Overexpression/NN of/IN wild-type/JJ Grf40/NN in/IN Jurkat/NN cells/NNS induced/VBD a/DT significant/JJ increase/NN of/IN SLP-76-dependent/JJ interleukin/NN (/( IL/NN )/) -2/CD promoter/NN and/CC nuclear/JJ factor/NN of/IN activated/VBN T/NN cell/NN (/( NF-AT/NN )/) activation/NN upon/IN T/NN cell/NN receptor/NN (/( TCR/NN )/) stimulation/NN ,/, whereas/IN the/DT COOH-terminal/JJ SH3-deleted/JJ Grf40/NN mutant/NN lacked/VBD any/DT recognizable/JJ increase/NN in/IN IL-2/NN promoter/NN activity/NN ./. 
Furthermore/RB ,/, the/DT SH2-deleted/JJ Grf40/NN mutant/JJ led/VBD to/TO a/DT marked/JJ inhibition/NN of/IN these/DT regulatory/JJ activities/NNS ,/, the/DT effect/NN of/IN which/WDT is/VBZ apparently/RB stronger/JJR than/IN that/DT of/IN the/DT SH2-deleted/JJ Grb2/NN mutant/NN ./. 
Our/PRP$ data/NNS suggest/VBP that/IN Grf40/NN is/VBZ an/DT adaptor/NN molecule/NN involved/VBN in/IN TCR-mediated/JJ signaling/NN through/IN a/DT more/RBR efficient/JJ interaction/NN than/IN Grb2/NN with/IN SLP-76/NN and/CC LAT/NN ./. 
UI/LS -/: 99229667/CD 
TI/LS -/: Modulation/NN of/IN the/DT immune/JJ response/NN and/CC tumor/NN growth/NN by/IN activated/VBN Ras/NN ./. 
AB/LS -/: As/IN a/DT result/NN of/IN its/PRP$ transforming/VBG abilities/NNS ,/, activated/VBN Ras/NN is/VBZ expressed/VBN in/IN a/DT great/JJ number/NN of/IN cancers/NNS ./. 
The/DT ras/NN mutation/NN frequency/NN varies/VBZ between/IN 95/CD %/NN in/IN pancreatic/JJ cancer/NN and/CC 5/CD %/NN in/IN breast/NN cancer/NN ./. 
In/IN leukemia/NN ,/, the/DT highest/JJS frequency/NN (/( 30/CD %/NN )/) is/VBZ found/VBN in/IN acute/JJ myeloid/JJ leukemia/NN ./. 
The/DT presence/NN of/IN ras/NN mutations/NNS has/VBZ been/VBN correlated/VBN with/IN a/DT poor/JJ prognosis/NN and/CC negative/JJ clinical/JJ outcome/NN ./. 
This/DT suggests/VBZ that/IN mutated/VBN Ras/NN activates/VBZ mechanisms/NNS ,/, which/WDT favor/VBP tumor/NN growth/NN ,/, enhance/VBP the/DT metastatic/JJ capacity/NN of/IN tumors/NNS or/CC modulate/VBP tumor-specific/JJ immune/JJ responses/NNS ./. 
Several/JJ new/JJ functions/NNS of/IN Ras/NN ,/, such/JJ as/IN downregulation/NN of/IN major/JJ histocompatibility/NN complex/NN molecules/NNS ,/, upregulation/NN of/IN certain/JJ cytokines/NNS ,/, growth/NN factors/NNS and/CC degradative/JJ enzymes/NNS have/VBP been/VBN uncovered/JJ in/IN the/DT last/JJ decade/NN ./. 
Additionally/RB ,/, mutated/VBN Ras/NN can/MD also/RB serve/VB as/IN a/DT primary/JJ target/NN for/IN the/DT development/NN of/IN immunotherapy/NN or/CC drug/NN therapy/NN ./. 
This/DT review/NN will/MD discuss/VB the/DT mechanisms/NNS by/IN which/WDT Ras/NN expressing/NN tumors/NNS are/VBP able/JJ to/TO evade/VB destruction/NN by/IN the/DT immune/JJ system/NN and/CC enhance/VBP their/PRP$ growth/NN and/CC metastatic/JJ potential/NN ./. 
It/PRP will/MD further/RB elaborate/VB on/IN the/DT attempts/NNS to/TO develop/VB successful/JJ immunotherapy/NN and/CC drug/NN therapy/NN targeting/VBG Ras/NN expressing/NN tumors/NNS ./. 
UI/LS -/: 99223528/CD 
TI/LS -/: Modulation/NN of/IN E2F/NN complexes/NNS during/IN G0/NN to/TO S/NN phase/NN transition/NN in/IN human/JJ primary/JJ B-lymphocytes/NNS ./. 
AB/LS -/: The/DT pocket/NN protein-E2F/JJ complexes/NNS are/VBP convergence/NN points/NNS for/IN cell/NN cycle/NN signaling/NN ./. 
In/IN the/DT present/JJ report/NN ,/, we/PRP identified/VBD and/CC monitored/VBD the/DT pocket/NN protein-E2F/JJ complexes/NNS in/IN human/JJ primary/JJ B-lymphocytes/NNS after/IN activation/NN by/IN phorbol/NN 12-myristate/NN 13-acetate/NN ./. 
Consistent/JJ with/IN previous/JJ data/NNS from/IN human/JJ and/CC mouse/NN fibroblasts/NNS and/CC T-lymphocytes/NNS ,/, E2F4/NN and/CC DP1/NN form/VBP the/DT predominant/JJ E2F/NN heterodimers/NNS both/CC in/IN G0/NN and/CC G1/NN phases/NNS of/IN the/DT human/JJ B-lymphocyte/NN cell/NN cycle/NN ,/, whereas/IN E2F1/NN and/CC -3/CD are/VBP first/RB detected/VBN in/IN late/JJ G1/NN ,/, and/CC their/PRP$ expression/NN levels/NNS increase/VBP towards/IN S/NN phase/NN ./. 
Intriguingly/RB ,/, the/DT major/JJ E2F/NN complex/NN that/WDT we/PRP detected/VBD in/IN quiescent/JJ human/JJ B-lymphocytes/NNS is/VBZ consisted/VBN of/IN pRB/NN ,/, E2F4/NN ,/, and/CC DP1/NN ./. 
Though/IN the/DT levels/NNS of/IN DP1/NN and/CC -2/CD increase/VBP when/WRB cells/NNS progress/VBP from/IN G0/NN to/TO S/NN ,/, the/DT proportion/NN of/IN DP1/NN to/TO DP2/NN remains/VBZ relatively/RB constant/JJ during/IN the/DT cell/NN cycle/NN ./. 
We/PRP also/RB observed/VBD an/DT increase/NN in/IN electrophoretic/JJ mobility/NN of/IN the/DT predominant/JJ E2F/NN components/NNS ,/, DP1/NN and/CC E2F4/NN ,/, as/IN B-lymphocytes/NNS progressed/VBD from/IN G0/NN into/IN early/JJ G1/NN ./. 
This/DT increase/NN in/IN mobility/NN was/VBD attributable/JJ to/TO dephosphorylation/NN ,/, as/IN lambda/NN phosphatase/NN treatment/NN could/MD convert/VB the/DT slower/JJR migrating/JJ forms/NNS into/IN the/DT corresponding/JJ faster/JJR mobility/NN forms/NNS ./. 
We/PRP further/RB demonstrated/VBD that/IN this/DT change/NN in/IN phosphorylation/NN status/NN correlates/VBZ with/IN a/DT decrease/NN in/IN DNA/NN binding/NN activity/NN ./. 
This/DT modulation/NN of/IN DNA/NN binding/NN activity/NN mediated/VBN through/IN the/DT dephosphorylation/NN of/IN DP1/NN and/CC E2F4/NN could/MD help/VB to/TO explain/VB the/DT lack/NN of/IN in/FW vivo/FW DNA/NN footprinting/NN in/IN late/JJ G1/NN and/CC S/NN phases/NNS of/IN gene/NN promoters/NNS negatively/RB regulated/VBN through/IN E2F/NN sites/NNS and/CC suggests/VBZ a/DT novel/JJ mechanism/NN for/IN controlling/VBG E2F/NN transcriptional/JJ activity/NN during/IN the/DT transition/NN from/IN quiescence/NN to/TO proliferation/NN ./. 
UI/LS -/: 99218427/CD 
TI/LS -/: Engagement/NN of/IN natural/JJ cytotoxicity/NN programs/NNS regulates/VBZ AP-1/NN expression/NN in/IN the/DT NKL/NN human/JJ NK/NN cell/NN line/NN ./. 
AB/LS -/: NK/NN cell/NN cytotoxicity/NN is/VBZ a/DT fast/JJ and/CC efficient/JJ mechanism/NN of/IN target/NN cell/NN lysis/NN ./. 
Using/VBG transcription/NN analysis/NN ,/, such/JJ as/IN multiplex/JJ messenger/NN assays/NNS ,/, we/PRP show/VBP here/RB that/IN natural/JJ cytotoxicity/NN exerted/VBN by/IN the/DT human/JJ NKL/NN cell/NN line/NN correlates/VBZ with/IN mRNA/NN accumulation/NN of/IN very/RB early/JJ activator/NN protein/NN (/( AP/NN )/) -1/CD transcription/NN factor/NN genes/NNS such/JJ as/IN JunB/NN ,/, FosB/NN and/CC c-Fos/NN ./. 
In/IN addition/NN ,/, DNA-binding/JJ activities/NNS of/IN Jun-Fos/NN heterodimers/NNS were/VBD observed/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS during/IN the/DT course/NN of/IN natural/JJ cytotoxicity/NN ./. 
Interaction/NN between/IN immunoglobulin-like/JJ transcript-2/leukocyte/NN Ig-like/JJ receptor/NN 1/CD on/IN NKL/NN cells/NNS and/CC HLA-B27/NN on/IN target/NN cells/NNS leads/VBZ to/TO an/DT impairment/NN of/IN NKL/NN natural/JJ cytotoxicity/NN ,/, which/WDT correlates/VBZ with/IN an/DT absence/NN of/IN JunB/NN ,/, FosB/NN ,/, and/CC c-Fos/NN transcription/NN ,/, as/RB well/RB as/IN an/DT absence/NN of/IN their/PRP$ DNA-binding/JJ activity/NN ./. 
Our/PRP$ studies/NNS thus/RB indicate/VBP that/IN ,/, despite/IN the/DT rapidity/NN of/IN NK/NN cell-mediated/JJ lysis/NN ,/, AP-1/NN transcription/NN factor/NN is/VBZ activated/VBN during/IN the/DT early/JJ stage/NN of/IN NK/NN cell/NN cytolytic/JJ programs/NNS and/CC that/IN engagement/NN of/IN NK/NN cell/NN inhibitory/JJ receptors/NNS for/IN MHC/NN class/NN I/CD molecules/NNS impairs/VBZ the/DT very/RB early/JJ activation/NN of/IN AP-1/NN ./. 
UI/LS -/: 99208363/CD 
TI/LS -/: Evidence/NN for/IN a/DT polyclonal/JJ etiology/NN of/IN palmar/JJ fibromatosis/NNS ./. 
AB/LS -/: X/NN chromosome/NN inactivation/NN patterns/NNS at/IN the/DT androgen/NN receptor/NN locus/NN were/VBD evaluated/VBN to/TO determine/VB clonality/NN in/IN microdissected/JJ lesional/JJ tissue/NN and/CC in/IN leukocytes/NNS from/IN 2/CD women/NNS with/IN Dupuytren/NN 's/POS disease/NN ./. 
The/DT tissue/NN from/IN both/DT patients/NNS generated/VBD a/DT polyclonal/JJ pattern/NN of/IN X/NN chromosome/NN inactivation/NN of/IN the/DT human/JJ androgen/NN receptor/NN gene/NN ./. 
This/DT finding/NN supports/VBZ a/DT polyclonal/JJ reactive/JJ process/NN as/IN the/DT underlying/JJ etiology/NN for/IN palmar/JJ fibromatosis/NNS ./. 
UI/LS -/: 99201482/CD 
TI/LS -/: Inhibition/NN of/IN cyclooxygenase-2/NN expression/NN by/IN 4-trifluoromethyl/NN derivatives/NNS of/IN salicylate/NN ,/, triflusal/NN ,/, and/CC its/PRP$ deacetylated/VBN metabolite/NN ,/, 2-hydroxy-4-trifluoromethylbenzoic/JJ acid/NN ./. 
AB/LS -/: The/DT therapeutic/JJ potential/NN of/IN drugs/NNS that/WDT block/VBP the/DT induction/NN of/IN cyclooxygenase-2/NN has/VBZ been/VBN emphasized/VBN ./. 
When/WRB two/CD 4-trifluoromethyl/NN salicylate/NN derivatives/NNS [/( 2-acetoxy-4-trifluoromethyl-benzoic/JJ acid/NN (/( triflusal/NN )/) and/CC its/PRP$ deacetylated/VBN metabolite/NN 2-hydroxy-4-trifluoromethylbenzoic/JJ acid/NN (/( HTB/NN )/) ]/) were/VBD compared/VBN with/IN aspirin/NN and/CC sodium/NN salicylate/NN as/IN cyclooxygenase-2/NN (/( COX-2/NN )/) inhibitors/NNS ,/, we/PRP observed/VBD that/IN in/IN bacterial/JJ lipopolysaccharide-activated/JJ human/JJ blood/NN ,/, triflusal/NN ,/, aspirin/NN ,/, and/CC HTB/NN ,/, but/CC not/RB sodium/NN salicylate/NN ,/, inhibited/VBD COX-2-mediated/JJ prostaglandin/NN E2/NN (/( PGE2/NN )/) production/NN (/( IC50/NN =/JJ 0.16/CD ,/, 0.18/CD ,/, 0.39/CD ,/, and/CC >/JJR 10/CD mM/NN ,/, respectively/RB )/) ./. 
However/RB ,/, only/RB triflusal/NN and/CC aspirin/NN inhibited/VBD purified/VBN COX-2/NN enzyme/NN ./. 
To/TO test/VB this/DT apparent/JJ discrepancy/NN ,/, we/PRP realized/VBD that/IN HTB/NN and/CC triflusal/NN (/( but/CC neither/CC aspirin/NN nor/CC salicylate/NN )/) produced/VBD a/DT concentration-dependent/JJ inhibition/NN of/IN COX-2/NN protein/NN expression/NN in/IN peripheral/JJ human/JJ mononuclear/JJ cells/NNS ./. 
This/DT observation/NN was/VBD further/RB confirmed/VBN in/IN a/DT rat/NN air/NN pouch/NN model/NN in/FW vivo/FW ,/, in/IN which/WDT both/CC aspirin/NN and/CC triflusal/NN inhibited/VBD PGE2/NN production/NN (/( ID50/NN =/JJ 18.9/CD and/CC 11.4/CD mg/kg/NN p.o./NN ,/, respectively/RB )/) but/CC only/RB triflusal-treated/JJ animals/NNS showed/VBD a/DT decrease/NN in/IN COX-2/NN expression/NN ./. 
This/DT different/JJ behavior/NN may/MD be/VB ,/, at/IN least/JJS in/IN part/NN ,/, due/JJ to/TO the/DT ability/NN of/IN HTB/NN and/CC triflusal/NN to/TO block/VB the/DT activation/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor-kappaB/NN to/TO a/DT higher/JJR extent/NN than/IN aspirin/NN and/CC sodium/NN salicylate/NN ./. 
Thus/RB ,/, in/IN addition/NN to/TO inhibiting/VBG the/DT COX-2/NN activity/NN at/IN therapeutic/JJ concentrations/NNS ,/, triflusal/NN is/VBZ able/JJ to/TO block/VB through/IN its/PRP$ metabolite/NN HTB/NN the/DT expression/NN of/IN new/JJ enzyme/NN ,/, and/CC hence/RB the/DT resumption/NN of/IN PGE2/NN synthesis/NN ./. 
Triflusal/NN and/CC HTB/NN may/MD exert/VB beneficial/JJ effects/NNS in/IN processes/NNS in/IN which/WDT de/FW novo/FW COX-2/NN expression/NN is/VBZ involved/VBN and/CC ,/, in/IN a/DT broader/JJR sense/NN ,/, in/IN pathological/JJ situations/NNS in/IN which/WDT genes/NNS under/IN nuclear/JJ factor-kappaB/NN control/NN are/VBP up-regulated/VBN ./. 
UI/LS -/: 99192735/CD 
TI/LS -/: Evidence/NN for/IN distinct/JJ intracellular/JJ signaling/NN pathways/NNS in/IN CD34+/JJ progenitor/NN to/TO dendritic/JJ cell/NN differentiation/NN from/IN a/DT human/JJ cell/NN line/NN model/NN ./. 
AB/LS -/: Intracellular/JJ signals/NNS that/WDT mediate/VBP differentiation/NN of/IN pluripotent/JJ hemopoietic/JJ progenitors/NNS to/TO dendritic/JJ cells/NNS (/( DC/NN )/) are/VBP largely/RB undefined/JJ ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) activation/NN (/( with/IN phorbol/NN ester/NN (/( PMA/NN )/) alone/RB )/) specifically/RB induces/VBZ differentiation/NN of/IN primary/JJ human/JJ CD34+/JJ hemopoietic/JJ progenitor/NN cells/NNS (/( HPC/NN )/) to/TO mature/JJ DC/NN ./. 
We/PRP now/RB find/VBP that/IN cytokine-driven/JJ (/( granulocyte-macrophage/JJ CSF/NN and/CC TNF-alpha/NN )/) CD34+/JJ HPC/NN -->/TO DC/NN differentiation/NN is/VBZ preferentially/RB blocked/VBN by/IN inhibitors/NNS of/IN PKC/NN activation/NN ./. 
To/TO further/RB identify/VB intracellular/JJ signals/NNS and/CC downstream/JJ events/NNS important/JJ in/IN CD34+/JJ HPC/NN -->/TO DC/NN differentiation/NN we/PRP have/VBP characterized/VBN a/DT human/JJ leukemic/JJ cell/NN line/NN model/NN of/IN this/DT process/NN ./. 
The/DT CD34+/JJ myelomonocytic/JJ cell/NN line/NN KG1/NN differentiates/VBZ into/IN dendritic-like/JJ cells/NNS in/IN response/NN to/TO granulocyte-macrophage/JJ CSF/NN plus/CC TNF-alpha/NN ,/, or/CC PMA/NN (/( with/IN or/CC without/IN the/DT calcium/NN ionophore/NN ionomycin/NN ,/, or/CC TNF-alpha/NN )/) ,/, with/IN different/JJ stimuli/NNS mediating/VBG different/JJ aspects/NNS of/IN the/DT process/NN ./. 
Phenotypic/JJ DC/NN characteristics/NNS of/IN KG1/NN dendritic-like/JJ cells/NNS include/VBP morphology/NN (/( loosely/RB adherent/JJ cells/NNS with/IN long/JJ neurite/NN processes/NNS )/) ,/, MHC/NN I+/MHC/JJ|NN IIbright/CD83+/CD86+/CD14-/JJ|NN surface/NN Ag/NN expression/NN ,/, and/CC RelB/NN and/CC DC-CK1/NN gene/NN expression/NN ./. 
Functional/JJ DC/NN characteristics/NNS include/VBP fluid/NN phase/NN macromolecule/NN uptake/NN (/( FITC-dextran/NN )/) and/CC activation/NN of/IN resting/VBG T/NN cells/NNS ./. 
Comparison/NN of/IN KG1/NN to/TO the/DT PMA-unresponsive/JJ subline/NN KG1a/NN reveals/VBZ differences/NNS in/IN expression/NN of/IN TNF/NN receptors/NNS 1/CD and/CC 2/CD ;/: PKC/NN isoforms/NNS alpha/NN ,/, beta/NN I/CD ,/, beta/NN II/CD ,/, and/CC mu/NN ;/: and/CC RelB/NN ,/, suggesting/VBG that/IN these/DT components/pathways/NNS are/VBP important/JJ for/IN DC/NN differentiation/NN ./. 
Together/RB ,/, these/DT findings/NNS demonstrate/VBP that/IN cytokine/NN or/CC phorbol/NN ester/NN stimulation/NN of/IN KG1/NN is/VBZ a/DT model/NN of/IN human/JJ CD34+/JJ HPC/NN to/TO DC/NN differentiation/NN and/CC suggest/VBP that/IN specific/JJ intracellular/JJ signaling/NN pathways/NNS mediate/VBP specific/JJ events/NNS in/IN DC/NN lineage/NN commitment/NN ./. 
UI/LS -/: 99190753/CD 
TI/LS -/: Involvement/NN of/IN adenylate/JJ cyclase/NN and/CC p70(S6)-kinase/NN activation/NN in/IN IL-10/NN up-regulation/NN in/IN human/JJ monocytes/NNS by/IN gp41/NN envelope/NN protein/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD ./. 
AB/LS -/: Our/PRP$ previous/JJ results/NNS show/VBP that/IN recombinant/JJ gp41/NN (/( aa565-647/NN )/) ,/, the/DT extracellular/JJ domain/NN of/IN HIV-1/NN transmembrane/JJ glycoprotein/NN ,/, stimulates/VBZ interleukin-10/NN (/( IL-10/NN )/) production/NN in/IN human/JJ monocytes/NNS ./. 
The/DT signal/NN cascade/NN transducing/VBG this/DT effect/NN is/VBZ not/RB yet/RB clear/JJ ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD whether/IN gp41-induced/JJ IL-10/NN up-regulation/NN is/VBZ mediated/VBN by/IN the/DT previously/RB described/VBN synergistic/JJ activation/NN of/IN cAMP/NN and/CC NF-kappaB/NN pathways/NNS ./. 
gp41/NN induced/VBD cAMP/NN accumulation/NN in/IN monocytes/NNS in/IN a/DT time-/NN and/CC concentration-dependent/JJ manner/NN and/CC the/DT adenylate/JJ cyclase/NN inhibitor/NN SQ/NN 22536/CD suppressed/VBD gp41-induced/JJ IL-10/NN production/NN in/IN monocytes/NNS ./. 
In/IN contrast/NN ,/, gp41/NN failed/VBD to/TO stimulate/VB NF-kappaB/NN binding/NN activity/NN in/IN as/RB much/JJ as/IN no/DT NF-kappaB/NN bound/VBD to/TO the/DT main/JJ NF-kappaB-binding/JJ site/NN 2/CD of/IN the/DT IL-10/NN promoter/NN after/IN addition/NN of/IN gp41/NN ./. 
We/PRP also/RB examined/VBD the/DT involvement/NN of/IN other/JJ signal/NN transduction/NN pathways/NNS ./. 
Specific/JJ inhibitors/NNS of/IN p70(S6)-kinase/NN (/( rapamycin/NN )/) ,/, and/CC Gi/NN protein/NN (/( pertussis/NN toxin/NN )/) ,/, prevented/VBD induction/NN of/IN IL-10/NN production/NN by/IN gp41/NN in/IN monocytes/NNS ,/, while/IN inhibitors/NNS of/IN the/DT phosphatidylinositol/NN 3-kinase/NN (/( PI/NN 3-kinase/NN )/) (/( wortmannin/NN )/) and/CC mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) pathway/NN (/( PD/NN 98059/CD )/) did/VBD not/RB ./. 
Thus/RB HIV-1/NN gp41-induced/JJ IL-10/NN up-regulation/NN in/IN monocytes/NNS may/MD not/RB involve/VB NF-kappaB/NN ,/, MAPK/NN ,/, or/CC PI/NN 3-kinase/NN activation/NN ,/, but/CC rather/RB may/MD operate/VB through/IN activation/NN of/IN adenylate/JJ cyclase/NN and/CC pertussis-toxin-sensitive/JJ Gi/Go/NN protein/NN to/TO effect/VB p70(S6)-kinase/NN activation/NN ./. 
UI/LS -/: 99182530/CD 
TI/LS -/: Analysis/NN of/IN the/DT modulation/NN of/IN transcriptional/JJ activity/NN in/IN myelopoiesis/NN and/CC leukemogenesis/NN ./. 
AB/LS -/: Acute/JJ myeloid/JJ leukemia/NN (/( AML/NN )/) is/VBZ still/RB associated/VBN with/IN a/DT mortality/NN of/IN 60/CD to/TO 80/CD %/NN ./. 
AML/NN is/VBZ characterized/VBN by/IN a/DT block/NN in/IN myeloid/JJ differentiation/NN ./. 
The/DT transcription/NN factors/NNS PU.1/NN and/CC C/EBPalpha/NN are/VBP responsible/JJ for/IN normal/JJ myeloid/JJ differentiation/NN from/IN stem/NN cells/NNS to/TO monocytes/NNS or/CC granulocytes/NNS ./. 
In/IN particular/JJ ,/, PU.1/NN induces/VBZ expression/NN of/IN the/DT macrophage/NN colony-stimulating/JJ factor/NN (/( M-CSF/NN )/) receptor/NN and/CC the/DT development/NN of/IN monocytes/NNS ,/, whereas/IN C/EBPalpha/NN increases/VBZ the/DT expression/NN of/IN the/DT granulocyte/NN colony-stimulating/JJ factor/NN (/( G-CSF/NN )/) receptor/NN and/CC leads/VBZ to/TO mature/JJ granulocytes/NNS ./. 
In/IN AML/NN ,/, chromosomal/JJ aberrations/NNS result/VBP in/IN oncoproteins/NNS such/JJ as/IN AML1/ETO/NN ,/, PML/RARalpha/NN ,/, or/CC activated/VBN Ras/NN ,/, which/WDT can/MD deregulate/VB genes/NNS important/JJ for/IN normal/JJ myelopoiesis/NN ./. 
Thus/RB ,/, AML1/ETO/NN can/MD bind/VB to/TO the/DT transcription/NN factor/NN C/EBPalpha/NN ,/, inhibit/VB C/EBPalpha-dependent/JJ transcription/NN ,/, and/CC block/VB granulocytic/JJ differentiation/NN ./. 
However/RB ,/, AML1/ETO/NN can/MD also/RB synergize/VB with/IN the/DT transcription/NN factor/NN AML1/NN to/TO enhance/VB the/DT activity/NN of/IN the/DT M-CSF/NN receptor/NN promoter/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, the/DT PML/RARalpha/NN fusion/NN protein/NN causes/VBZ transcriptional/JJ repression/NN by/IN recruiting/VBG the/DT nuclear/JJ corepressor/NN (/( N-CoR/NN )/) histone/NN deacetylase/NN complex/NN to/TO the/DT DNA/NN ,/, which/WDT results/VBZ in/IN decreased/VBN histone/NN acetylation/NN and/CC a/DT repressive/JJ chromatin/NN organization/NN ./. 
Here/RB we/PRP describe/VBP methods/NNS to/TO investigate/VB whether/IN and/CC how/WRB signaling/JJ agonists/NNS induce/VBP myeloid/JJ differentiation/NN and/CC how/WRB oncoproteins/NNS might/MD cause/VB AML/NN by/IN modulating/VBG the/DT activity/NN of/IN transcription/NN factors/NNS that/WDT are/VBP pivotal/JJ for/IN normal/JJ myeloid/JJ development/NN ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99172218/CD 
TI/LS -/: NF-ATc/NN isoforms/NNS are/VBP differentially/RB expressed/VBN and/CC regulated/VBN in/IN murine/JJ T/NN and/CC mast/NN cells/NNS ./. 
AB/LS -/: NF/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) denotes/VBZ a/DT family/NN of/IN transcription/NN factors/NNS that/WDT regulate/VBP the/DT activation-dependent/JJ expression/NN of/IN many/JJ immunologically/RB important/JJ proteins/NNS ./. 
At/IN least/JJS four/CD distinct/JJ genes/NNS encode/VBP the/DT various/JJ family/NN members/NNS ,/, and/CC several/JJ isoforms/NNS of/IN these/DT have/VBP been/VBN identified/VBN as/RB well/RB ./. 
The/DT overlapping/VBG expression/NN patterns/NNS and/CC similar/JJ in/FW vitro/FW binding/NN and/CC trans-activation/JJ activities/NNS on/IN various/JJ promoter/NN elements/NNS of/IN NF-AT-regulated/JJ genes/NNS suggest/VBP some/DT redundancy/NN in/IN the/DT function/NN of/IN these/DT proteins/NNS ./. 
However/RB ,/, the/DT phenotypic/JJ analysis/NN of/IN NF-AT-deficient/JJ mice/NNS supports/VBZ the/DT idea/NN that/IN there/EX are/VBP tissue-/NN and/CC gene-specific/JJ functions/NNS as/RB well/RB ./. 
In/IN this/DT study/NN we/PRP have/VBP characterized/VBN the/DT expression/NN of/IN NF-AT/NN cDNAs/NNS in/IN murine/JJ mast/NN cells/NNS ./. 
The/DT majority/NN of/IN clones/NNS identified/VBN correspond/VBP to/TO two/CD NF-ATc/NN isoforms/NNS that/WDT differ/VBP only/RB in/IN their/PRP$ amino-terminal/JJ sequence/NN ./. 
Despite/IN minimal/JJ discrepancies/NNS in/IN the/DT coding/VBG region/NN ,/, there/EX are/VBP striking/JJ tissue-/NN and/CC cell/NN type-specific/JJ differences/NNS in/IN isoform/NN expression/NN patterns/NNS ./. 
Detection/NN of/IN NF-ATc.alpha/NN mRNA/NN is/VBZ strictly/RB dependent/JJ on/IN cell/NN activation/NN signals/NNS in/IN both/CC T/NN and/CC mast/NN cell/NN lines/NNS ./. 
In/IN contrast/NN ,/, the/DT beta/NN isoform/NN is/VBZ expressed/VBN at/IN very/RB low/JJ constitutive/JJ levels/NNS in/IN both/DT cell/NN types/NNS but/CC is/VBZ only/RB up-regulated/VBN in/IN response/NN to/TO mast/NN cell/NN activation/NN signals/NNS delivered/VBN through/IN the/DT FcepsilonRI/NN or/CC via/IN calcium/NN ionophores/NNS ./. 
These/DT results/NNS demonstrate/VBP another/DT level/NN of/IN regulation/NN within/IN the/DT NF-AT/NN family/NN that/WDT can/MD contribute/VB to/TO cell/NN type-specific/JJ gene/NN expression/NN ./. 
UI/LS -/: 99162595/CD 
TI/LS -/: Crossreactive/JJ recognition/NN of/IN viral/JJ ,/, self/NN ,/, and/CC bacterial/JJ peptide/NN ligands/NNS by/IN human/JJ class/NN I-restricted/JJ cytotoxic/JJ T/NN lymphocyte/NN clonotypes/NNS :/: implications/NNS for/IN molecular/JJ mimicry/NN in/IN autoimmune/JJ disease/NN ./. 
AB/LS -/: The/DT immunodominant/JJ ,/, CD8(+)/JJ cytotoxic/JJ T/NN lymphocyte/NN (/( CTL/NN )/) response/NN to/TO the/DT HLA-B8-restricted/JJ peptide/NN ,/, RAKFKQLL/NN ,/, located/JJ in/IN the/DT Epstein-Barr/JJ virus/NN immediate-early/JJ antigen/NN ,/, BZLF1/NN ,/, is/VBZ characterized/VBN by/IN a/DT diverse/JJ T/NN cell/NN receptor/NN (/( TCR/NN )/) repertoire/NN ./. 
Here/RB ,/, we/PRP show/VBP that/IN this/DT diversity/NN can/MD be/VB partitioned/VBN on/IN the/DT basis/NN of/IN crossreactive/JJ cytotoxicity/NN patterns/NNS involving/VBG the/DT recognition/NN of/IN a/DT self/NN peptide/NN -/: RSKFRQIV/NN -/: located/JJ in/IN a/DT serine/threonine/NN kinase/NN and/CC a/DT bacterial/JJ peptide/NN -/: RRKYKQII/NN -/: located/JJ in/IN Staphylococcus/FW aureus/FW replication/NN initiation/NN protein/NN ./. 
Thus/RB CTL/NN clones/NNS that/WDT recognized/VBD the/DT viral/JJ ,/, self/NN ,/, and/CC bacterial/JJ peptides/NNS expressed/VBD a/DT highly/RB restricted/JJ alphabeta/NN TCR/NN phenotype/NN ./. 
The/DT CTL/NN clones/NNS that/WDT recognized/VBD viral/JJ and/CC self/NN peptides/NNS were/VBD more/RBR oligoclonal/JJ ,/, whereas/IN clones/NNS that/WDT strictly/RB recognized/VBD the/DT viral/JJ peptide/NN displayed/VBD a/DT diverse/JJ TCR/NN profile/NN ./. 
Interestingly/RB ,/, the/DT self/NN and/CC bacterial/JJ peptides/NNS equally/RB were/VBD substantially/RB less/RBR effective/JJ than/IN the/DT cognate/JJ viral/JJ peptide/NN in/IN sensitizing/VBG target/NN cell/NN lysis/NN ,/, and/CC also/RB resulted/VBD only/RB in/IN a/DT weak/JJ reactivation/NN of/IN memory/NN CTLs/NNS in/IN limiting/VBG dilution/NN assays/NNS ,/, whereas/IN the/DT cognate/JJ peptide/NN was/VBD highly/RB immunogenic/JJ ./. 
The/DT described/VBN crossreactions/NNS show/VBP that/IN human/JJ antiviral/JJ ,/, CD8(+)/JJ CTL/NN responses/NNS can/MD be/VB shaped/VBN by/IN peptide/NN ligands/NNS derived/VBN from/IN autoantigens/NNS and/CC environmental/JJ bacterial/JJ antigens/NNS ,/, thereby/RB providing/VBG a/DT firm/JJ structural/JJ basis/NN for/IN molecular/JJ mimicry/NN involving/VBG class/NN I-restricted/JJ CTLs/NNS in/IN the/DT pathogenesis/NN of/IN autoimmune/JJ disease/NN ./. 
UI/LS -/: 99146379/CD 
TI/LS -/: RFLAT-1/NN :/: a/DT new/JJ zinc/NN finger/NN transcription/NN factor/NN that/WDT activates/VBZ RANTES/NN gene/NN expression/NN in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: RANTES/NN (/( Regulated/VBN upon/IN Activation/NN ,/, Normal/JJ T/NN cell/NN Expressed/VBN and/CC Secreted/VBN )/) is/VBZ a/DT chemoattractant/NN cytokine/NN (/( chemokine/NN )/) important/JJ in/IN the/DT generation/NN of/IN inflammatory/JJ infiltrate/NN and/CC human/JJ immunodeficiency/NN virus/NN entry/NN into/IN immune/JJ cells/NNS ./. 
RANTES/NN is/VBZ expressed/VBN late/RB (/( 3-5/CD days/NNS )/) after/IN activation/NN in/IN T/NN lymphocytes/NNS ./. 
Using/VBG expression/NN cloning/NN ,/, we/PRP identified/VBD the/DT first/JJ "/`` late/JJ "/'' T/NN lymphocyte/NN associated/JJ transcription/NN factor/NN and/CC named/VBD it/PRP "/`` RANTES/NN Factor/NN of/IN Late/JJ Activated/VBN T/NN Lymphocytes-1/NNS "/'' (/( RFLAT-1/NN )/) ./. 
RFLAT-1/NN is/VBZ a/DT novel/JJ ,/, phosphorylated/VBN ,/, zinc/NN finger/NN transcription/NN factor/NN that/WDT is/VBZ expressed/VBN in/IN T/NN cells/NNS 3/CD days/NNS after/IN activation/NN ,/, coincident/JJ with/IN RANTES/NN expression/NN ./. 
While/IN Rel/NN proteins/NNS play/VBP the/DT dominant/JJ role/NN in/IN RANTES/NN gene/NN expression/NN in/IN fibroblasts/NNS ,/, RFLAT-1/NN is/VBZ a/DT strong/JJ transactivator/NN for/IN RANTES/NN in/IN T/NN cells/NNS ./. 
UI/LS -/: 99138892/CD 
TI/LS -/: Fas/NN ligand/NN induction/NN in/IN human/JJ NK/NN cells/NNS is/VBZ regulated/VBN by/IN redox/NN through/IN a/DT calcineurin-nuclear/JJ factors/NNS of/IN activated/VBN T/NN cell-dependent/JJ pathway/NN ./. 
AB/LS -/: Fas/NN ligand/NN (/( FasL/NN )/) on/IN cytotoxic/JJ lymphocytes/NNS is/VBZ important/JJ for/IN mediating/VBG apoptosis/NN of/IN activated/VBN lymphocytes/NNS and/CC other/JJ target/NN cells/NNS ./. 
We/PRP have/VBP reported/VBN that/IN NK/NN cell/NN functions/NNS ,/, such/JJ as/IN proliferation/NN ,/, cell/NN death/NN ,/, and/CC killing/NN activity/NN ,/, are/VBP subject/JJ to/TO regulation/NN by/IN cellular/JJ redox/NN status/NN ./. 
Here/RB ,/, we/PRP report/VBP that/IN expression/NN of/IN FasL/NN protein/NN and/CC mRNA/NN in/IN activated/VBN NK/NN cells/NNS is/VBZ also/RB regulated/VBN by/IN redox/NN ./. 
Ligation/NN of/IN CD16/NN on/IN IL-2-preactivated/JJ NK/NN cells/NNS resulted/VBD in/IN reduction/NN of/IN intracellular/JJ peroxide/NN level/NN as/RB well/RB as/IN induction/NN of/IN FasL/NN expression/NN ./. 
This/DT CD16-induced/JJ FasL/NN expression/NN was/VBD suppressed/VBN by/IN oxidative/JJ stress/NN ,/, including/VBG thiol/NN deprivation/NN or/CC treatment/NN with/IN hydrogen/NN peroxide/NN (/( H2O2/NN )/) ./. 
Addition/NN of/IN thiol-reducing/JJ compounds/NNS ,/, such/JJ as/IN L-cystine/NN ,/, 2-ME/NN ,/, or/CC N-acetyl/JJ cysteine/NN ,/, restored/VBD FasL/NN expression/NN ./. 
These/DT data/NNS suggest/VBP that/IN CD16/NN stimulation/NN requires/VBZ cellular/JJ reducing/VBG status/NN for/IN FasL/NN induction/NN in/IN NK/NN cells/NNS ./. 
Because/IN FasL/NN gene/NN activation/NN following/VBG CD16/NN cross-linking/NN is/VBZ regulated/VBN by/IN the/DT NF/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) ,/, we/PRP examined/VBD the/DT effect/NN of/IN oxidative/JJ stresses/NNS on/IN NFAT/NN activation/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS revealed/VBD that/IN both/CC thiol/NN insufficiency/NN and/CC H2O2/NN treatment/NN suppressed/VBD DNA-binding/NN activity/NN of/IN NFAT/NN and/CC that/IN addition/NN of/IN thiol-reducing/JJ compounds/NNS reversed/VBD or/CC even/RB enhanced/VBD it/PRP ./. 
Furthermore/RB ,/, these/DT oxidative/JJ stresses/NNS inhibited/VBD activity/NN of/IN calcineurin/NN ,/, a/DT serine/threonine/NN phosphatase/NN that/WDT regulates/VBZ NFAT/NN activation/NN ./. 
These/DT results/NNS suggest/VBP that/IN suppression/NN of/IN calcineurin/NN and/CC NFAT/NN activation/NN is/VBZ a/DT mechanism/NN by/IN which/WDT oxidative/JJ stress/NN inhibits/VBZ FasL/NN induction/NN in/IN activated/VBN NK/NN cells/NNS and/CC further/RB support/VBP the/DT hypothesis/NN that/IN thiol-reducing/JJ compounds/NNS might/MD be/VB required/VBN for/IN maintenance/NN of/IN optimal/JJ NK/NN functions/NNS under/IN physiologic/JJ oxidative/JJ conditions/NNS ./. 
UI/LS -/: 99126191/CD 
TI/LS -/: Heterogeneity/NN of/IN clonal/JJ development/NN in/IN chronic/JJ myeloproliferative/JJ disorders/NNS ./. 
AB/LS -/: Recent/JJ reports/NNS have/VBP suggested/VBN a/DT previously/RB unexpected/JJ variability/NN in/IN the/DT expression/NN of/IN the/DT dominant/JJ neoplastic/JJ clone/NN in/IN myeloproliferative/JJ disorders/NNS (/( MPD/NN )/) ./. 
We/PRP evaluated/VBD 49/CD female/JJ patients/NNS with/IN MPD/NN and/CC informative/JJ at/IN the/DT X-linked/JJ androgen/NN receptor/NN (/( AR/NNS )/) locus/NN to/TO establish/VB the/DT X/NN chromosome/NN inactivation/NN pattern/NN of/IN hemopoietic/JJ cells/NNS ./. 
Whereas/IN in/IN chronic/JJ myelogenous/JJ leukemia/NN (/( CML/NN )/) the/DT granulocytes/NNS (/( PMN/NN )/) were/VBD uniformly/RB of/IN monoclonal/JJ origin/NN ,/, a/DT striking/JJ heterogeneity/NN of/IN clonal/JJ development/NN was/VBD found/VBN in/IN PMN/NN from/IN patients/NNS with/IN other/JJ MPD/NN ,/, with/IN up/IN to/TO 50/CD %/NN of/IN them/PRP expressing/VBG a/DT polyclonal/JJ pattern/NN of/IN X/NN inactivation/NN ./. 
UI/LS -/: 99115659/CD 
TI/LS -/: CD80/NN and/CC CD86/NN are/VBP not/RB equivalent/JJ in/IN their/PRP$ ability/NN to/TO induce/VB the/DT tyrosine/NN phosphorylation/NN of/IN CD28/NN ./. 
AB/LS -/: Ligation/NN of/IN either/CC CD80/NN (/( B7-1/NN )/) or/CC CD86/NN (/( B7-2/NN )/) ,/, two/CD principal/JJ ligands/NNS for/IN CD28/NN ,/, is/VBZ thought/VBN to/TO skew/VB the/DT immune/JJ response/NN toward/IN Th1/NN or/CC Th2/NN differentiation/NN ./. 
We/PRP have/VBP examined/VBN early/JJ signal/NN transduction/NN pathways/NNS recruited/VBN following/VBG T/NN cell/NN stimulation/NN with/IN either/CC CD80/NN or/CC CD86/NN ./. 
Purified/VBN human/JJ peripheral/JJ T/NN cells/NNS or/CC Jurkat/NN T/NN cells/NNS were/VBD stimulated/VBN with/IN Chinese/JJ hamster/NN ovary/NN (/( CHO/NN )/) cells/NNS expressing/VBG either/CC human/JJ CD80/NN (/( CHO-CD80/NN )/) or/CC human/JJ CD86/NN (/( CHO-CD86/NN )/) or/CC with/IN anti-CD28/JJ monoclonal/JJ antibody/NN (/( mAb/NN )/) ./. 
In/IN the/DT presence/NN of/IN phorbol/NN 12-myristate/NN 13-acetate/NN ,/, both/CC CHO-CD80/NN and/CC CHO-CD86/NN ,/, like/IN anti-CD28/JJ mAb/NN ,/, were/VBD capable/JJ of/IN stimulating/VBG cytokine/NN production/NN from/IN both/CC human/JJ peripheral/JJ T/NN cells/NNS and/CC Jurkat/NN T/NN cells/NNS ./. 
Both/CC CHO-CD80/NN and/CC CHO-CD86/NN ,/, in/IN the/DT presence/NN of/IN anti-CD3/JJ mAb/NN ,/, costimulated/VBD NFAT-dependent/JJ transcriptional/JJ activation/NN ./. 
Several/JJ intracellular/JJ signaling/VBG proteins/NNS ,/, such/JJ as/IN CBL/NN and/CC VAV/NN ,/, were/VBD phosphorylated/VBN on/IN tyrosine/NN in/IN response/NN to/TO CD80/NN ,/, CD86/NN ,/, and/CC anti-CD28/JJ mAb/NN ./. 
Surprisingly/RB ,/, although/IN stimulation/NN of/IN Jurkat/NN T/NN cells/NNS with/IN either/CC CHO-CD80/NN or/CC anti-CD28/JJ mAb/NN resulted/VBD in/IN robust/JJ tyrosine/NN phosphorylation/NN of/IN CD28/NN itself/PRP ,/, ligation/NN with/IN CHO-CD86/NN was/VBD unable/JJ to/TO induce/VB detectable/JJ CD28/NN tyrosyl/NN phosphorylation/NN over/IN a/DT range/NN of/IN stimulation/NN conditions/NNS ./. 
In/IN addition/NN ,/, the/DT association/NN of/IN phosphoinositide/NN 3-kinase/NN with/IN CD28/NN and/CC enhanced/VBN tyrosine/NN phosphorylation/NN of/IN phospholipase/NN Cgamma/NN were/VBD seen/VBN after/IN anti-CD28/JJ mAb/NN and/CC CHO-CD80/NN stimulation/NN but/CC to/TO a/DT much/RB lesser/JJR extent/NN after/IN CHO-CD86/NN stimulation/NN ./. 
Thus/RB ,/, ligation/NN of/IN CD28/NN with/IN either/CC CD80/NN or/CC CD86/NN leads/VBZ to/TO shared/JJ early/JJ signal/NN transduction/NN events/NNS such/JJ as/IN the/DT tyrosine/NN phosphorylation/NN of/IN CBL/NN and/CC VAV/NN ,/, to/TO NFAT-mediated/JJ transcriptional/JJ activation/NN ,/, and/CC to/TO the/DT costimulation/NN of/IN interleukin-2/NN and/CC granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN production/NN ./. 
However/RB ,/, CD80/NN and/CC CD86/NN also/RB induce/VBP distinct/JJ signal/NN transduction/NN pathways/NNS including/VBG the/DT tyrosine/NN phosphorylation/NN of/IN CD28/NN and/CC phospholipase/NN Cgamma1/NN and/CC the/DT SH2-dependent/JJ association/NN of/IN phosphoinositide/NN 3-kinase/NN with/IN CD28/NN ./. 
These/DT quantitative/JJ ,/, if/IN not/RB qualitative/JJ ,/, differences/NNS between/IN signaling/NN initiated/VBN by/IN these/DT two/CD ligands/NNS for/IN CD28/NN may/MD contribute/VB to/TO functional/JJ differences/NNS (/( e.g./FW Th1/NN or/CC Th2/NN differentiation/NN )/) in/IN T/NN cell/NN responses/NNS ./. 
UI/LS -/: 99098272/CD 
TI/LS -/: Binding/NN of/IN HMG-I/NN (/( Y/NN )/) elicits/VBZ structural/JJ changes/NNS in/IN a/DT silencer/NN of/IN the/DT human/JJ beta-globin/NN gene/NN ./. 
AB/LS -/: Proteins/NNS involved/VBN in/IN repression/NN of/IN the/DT human/JJ beta-globin/NN gene/NN may/MD be/VB useful/JJ in/IN the/DT treatment/NN of/IN sickle/JJ cell/NN anemia/NN ,/, in/IN conjunction/NN with/IN therapy/NN to/TO reactivate/VB fetal/JJ globin/NN genes/NNS ./. 
If/IN there/EX is/VBZ a/DT reciprocal/JJ elevation/NN of/IN gamma-globin/NN expression/NN upon/IN repression/NN ,/, this/DT approach/NN could/MD be/VB useful/JJ in/IN additional/JJ hemoglobinopathies/NNS ./. 
We/PRP previously/RB showed/VBD that/IN repression/NN of/IN the/DT beta-globin/NN gene/NN appears/VBZ to/TO be/VB mediated/VBN through/IN two/CD DNA/NN sequences/NNS ,/, silencers/NNS I/CD and/CC II/CD ,/, and/CC identified/VBD a/DT protein/NN termed/VBN BP1/NN which/WDT binds/VBZ to/TO both/DT silencer/JJ sequences/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP cloned/VBD two/CD cDNAs/NNS encoding/NN proteins/NNS which/WDT bind/VBP to/TO an/DT oligonucleotide/NN in/IN silencer/NN I/CD containing/VBG a/DT BP1/NN binding/NN site/NN ./. 
These/DT cDNAs/NNS correspond/VBP to/TO HMG-I/NN and/CC HMG-Y/NN ,/, isoforms/NNS regarded/VBN as/IN architectural/JJ proteins/NNS ./. 
We/PRP demonstrate/VBP that/IN binding/NN of/IN HMG-I(Y)/NN to/TO this/DT oligonucleotide/NN causes/VBZ bending/flexure/NN of/IN the/DT DNA/NN ./. 
HMG-I(Y)/NN also/RB binds/VBZ to/TO a/DT second/JJ oligonucleotide/NN containing/VBG a/DT BP1/NN binding/NN site/NN located/JJ in/IN a/DT negative/JJ control/NN region/NN upstream/JJ of/IN the/DT delta-globin/NN gene/NN ,/, suggesting/VBG a/DT role/NN for/IN HMG-I(Y)/NN in/IN repression/NN of/IN adult/JJ globin/NN genes/NNS ./. 
Expression/NN studies/NNS revealed/VBD that/IN HMG-I(Y)/NN is/VBZ ubiquitously/RB expressed/VBN in/IN human/JJ tissues/NNS that/WDT do/VBP not/RB express/VB beta-globin/NN ,/, being/VBG present/JJ in/IN 48/CD of/IN 50/CD tissues/NNS and/CC six/CD hematopoietic/JJ cell/NN lines/NNS examined/VBN ./. 
Furthermore/RB ,/, HMG-I(Y)/NN expression/NN is/VBZ down-regulated/VBN during/IN differentiation/NN of/IN primary/JJ erythroid/JJ cells/NNS ./. 
We/PRP present/VBP a/DT model/NN in/IN which/WDT HMG-I(Y)/NN alters/VBZ DNA/NN conformation/NN to/TO allow/VB binding/NN of/IN repressor/NN proteins/NNS ,/, and/CC in/IN which/WDT the/DT relative/JJ amount/NN of/IN HMG-I(Y)/NN helps/VBZ to/TO determine/VB the/DT repressive/JJ state/NN of/IN the/DT beta-globin/NN gene/NN ./. 
UI/LS -/: 99078032/CD 
TI/LS -/: Interactions/NNS between/IN the/DT class/NN II/CD transactivator/NN and/CC CREB/NN binding/NN protein/NN increase/VBP transcription/NN of/IN major/JJ histocompatibility/NN complex/NN class/NN II/CD genes/NNS ./. 
AB/LS -/: Class/NN II/CD major/JJ histocompatibility/NN (/( class/NN II/CD )/) genes/NNS are/VBP regulated/VBN in/IN a/DT B-cell-specific/JJ and/CC gamma/NN interferon-inducible/JJ fashion/NN ./. 
The/DT master/JJ switch/NN for/IN the/DT expression/NN of/IN these/DT genes/NNS is/VBZ the/DT class/NN II/CD transactivator/NN (/( CIITA/NN )/) ./. 
In/IN this/DT report/NN ,/, we/PRP demonstrate/VBP that/IN one/CD of/IN the/DT functions/NNS of/IN CIITA/NN is/VBZ to/TO recruit/VB the/DT CREB/NN binding/NN protein/NN (/( CBP/NN )/) to/TO class/NN II/CD promoters/NNS ./. 
Not/RB only/RB functional/JJ but/CC also/RB specific/JJ binding/NN interactions/NNS between/IN CIITA/NN and/CC CBP/NN were/VBD demonstrated/VBN ./. 
Moreover/RB ,/, a/DT dominant/JJ negative/JJ form/NN of/IN CBP/NN decreased/VBD the/DT activity/NN of/IN class/NN II/CD promoters/NNS and/CC levels/NNS of/IN class/NN II/CD determinants/NNS on/IN the/DT surface/NN of/IN cells/NNS ./. 
Finally/RB ,/, the/DT inhibition/NN of/IN class/NN II/CD gene/NN expression/NN by/IN the/DT glucocorticoid/NN hormone/NN could/MD be/VB attributed/VBN to/TO the/DT squelching/NN of/IN CBP/NN by/IN the/DT glucocorticoid/NN receptor/NN ./. 
We/PRP conclude/VBP that/IN CBP/NN ,/, a/DT histone/NN acetyltransferase/NN ,/, plays/VBZ an/DT important/JJ role/NN in/IN the/DT transcription/NN of/IN class/NN II/CD genes/NNS ./. 
UI/LS -/: 98208264/CD 
TI/LS -/: Role/NN of/IN cyclic/JJ AMP/NN response/NN element-binding/JJ protein/NN in/IN cyclic/JJ AMP/NN inhibition/NN of/IN NF-kappaB-mediated/JJ transcription/NN ./. 
AB/LS -/: The/DT NF-kappaB/NN family/NN of/IN transcription/NN factors/NNS regulates/VBZ the/DT inducible/JJ expression/NN of/IN a/DT variety/NN of/IN genes/NNS ./. 
Recently/RB ,/, we/PRP showed/VBD that/IN elevation/NN of/IN intracellular/JJ cyclic/JJ AMP/NN inhibits/VBZ NF-kappaB-mediated/JJ transcription/NN in/IN human/JJ monocytes/NNS and/CC endothelial/JJ cells/NNS without/IN preventing/VBG nuclear/JJ translocation/NN of/IN NF-kappaB/NN complexes/NNS ./. 
The/DT present/JJ study/NN examined/VBD the/DT molecular/JJ mechanism/NN of/IN this/DT inhibition/NN ./. 
We/PRP hypothesized/VBD that/IN activation/NN of/IN the/DT protein/NN kinase/NN A/NN signaling/NN pathway/NN may/MD inhibit/VB NF-kappaB-mediated/JJ transcription/NN by/IN phosphorylating/VBG proteins/NNS ,/, such/JJ as/IN cAMP/NN response/NN element-binding/JJ protein/NN (/( CREB/NN )/) ,/, which/WDT compete/VBP for/IN limiting/VBG amounts/NNS of/IN the/DT coactivator/NN CBP/NN ./. 
Here/RB ,/, we/PRP show/VBP that/IN the/DT amino-terminal/JJ region/NN (/( amino/NN acids/NNS 1-450/CD )/) of/IN CBP/NN specifically/RB interacts/VBZ with/IN the/DT carboxyl-terminal/JJ region/NN (/( amino/NN acids/NNS 286-551/CD )/) of/IN NF-kappaB/NN p65/NN (/( RelA/NN )/) both/CC in/FW vitro/FW and/CC in/FW vivo/FW ./. 
Functional/JJ studies/NNS using/VBG human/JJ endothelial/JJ cells/NNS demonstrated/VBD that/IN overexpression/NN of/IN CBP/NN rescued/VBD cAMP/NN inhibition/NN of/IN NF-kappaB-mediated/JJ transcription/NN and/CC transcription/NN mediated/VBN by/IN a/DT chimeric/JJ protein/NN ,/, GAL4-p65/NN (/( 286-551/CD )/) ,/, which/WDT contained/VBD the/DT GAL4/NN DNA/NN binding/NN domain/NN fused/VBN to/TO the/DT carboxyl-terminal/JJ region/NN of/IN p65/NN (/( amino/NN acids/NNS 286-551/CD )/) ./. 
In/IN contrast/NN ,/, overexpression/NN of/IN CREB/NN inhibited/VBD GAL4-p65(286-551)-mediated/JJ transcription/NN ./. 
These/DT results/NNS suggest/VBP that/IN activation/NN of/IN the/DT protein/NN kinase/NN A/NN pathway/NN inhibits/VBZ NF-kappaB/NN transcription/NN by/IN phosphorylating/VBG CREB/NN ,/, which/WDT competes/VBZ with/IN p65/NN for/IN limiting/VBG amounts/NNS of/IN CBP/NN ./. 
UI/LS -/: 98133462/CD 
TI/LS -/: Glucocorticoid/NN receptors/NNS in/IN cord/NN blood/NN lymphocytes/NNS of/IN healthy/JJ neonates/NNS and/CC of/IN preterms/NNS suffering/VBG from/IN respiratory/JJ distress/NN syndrome/NN ./. 
AB/LS -/: We/PRP measured/VBD the/DT number/NN of/IN glucocorticoid/NN receptors/NNS (/( GR/NN )/) in/IN cord/NN blood/NN lymphocytes/NNS and/CC the/DT binding/NN affinity/NN (/( Kd/NN )/) in/IN 15/CD term/NN and/CC in/IN 20/CD preterm/JJ babies/NNS ./. 
Thirteen/CD preterms/NNS of/IN the/DT latter/JJ group/NN received/VBD prenatal/JJ steroid/NN treatment/NN ./. 
Seven/CD preterms/NNS developed/VBD neonatal/JJ respiratory/JJ distress/NN syndrome/NN (/( NRDS/NN )/) ./. 
The/DT number/NN of/IN GR/NN and/CC the/DT Kd/NN were/VBD similar/JJ in/IN the/DT term/NN and/CC preterm/JJ (/( with/IN and/CC without/IN NRDS/NN )/) babies/NNS ./. 
The/DT maximum/NN (3H)-thymidine/NN incorporation/NN into/IN DNA/NN of/IN cord/NN blood/NN lymphocytes/NNS from/IN all/DT preterms/NNS ,/, with/IN or/CC without/IN NRDS/NN was/VBD suppressed/VBN when/WRB compared/VBN to/TO that/DT from/IN term/NN babies/NNS or/CC adults/NNS ./. 
This/DT could/MD partly/RB be/VB explained/VBN by/IN the/DT antenatal/JJ steroid/NN treatment/NN ./. 
Sensitivity/NN (/( ID50/NN )/) of/IN the/DT lymphocytes/NNS for/IN the/DT inhibitory/JJ effect/NN of/IN dexamethasone/NN was/VBD the/DT same/JJ in/IN all/DT groups/NNS ./. 
In/IN this/DT study/NN on/IN the/DT number/NN and/CC function/NN of/IN GR/NN in/IN lymphocytes/NNS ,/, we/PRP were/VBD unable/JJ to/TO find/VB a/DT relation/NN between/IN the/DT functionality/NN of/IN the/DT GR/NN and/CC the/DT development/NN of/IN NRDS/NN ./. 
UI/LS -/: 98104470/CD 
TI/LS -/: Inefficient/JJ termination/NN of/IN antigen/NN responses/NNS in/IN NF-ATp-deficient/JJ mice/NNS ./. 
AB/LS -/: In/IN order/NN to/TO elucidate/VB the/DT role/NN of/IN NF-ATp/NN ,/, one/CD of/IN the/DT most/RBS prominent/JJ members/NNS of/IN family/NN of/IN NF-AT/NN transcription/NN factors/NNS in/IN peripheral/JJ T/NN lymphocytes/NNS ,/, in/IN T/NN cell/NN activation/NN and/CC differentiation/NN we/PRP created/VBD NF-ATp-deficient/JJ mice/NNS by/IN gene/NN targeting/VBG ./. 
Such/JJ NF-ATp-/-/JJ mice/NNS are/VBP born/JJ and/CC appear/VBP to/TO develop/VB a/DT normal/JJ immune/JJ system/NN ./. 
Apart/RB from/IN clear-cut/JJ defects/NNS in/IN the/DT synthesis/NN of/IN mRNAs/NNS for/IN Th2-type/JJ lymphokines/NNS ,/, such/JJ as/IN IL-4/NN ,/, IL-5/NN ,/, IL-10/NN and/CC IL-13/NN ,/, in/IN primary/JJ and/CC secondary/JJ stimulations/NNS of/IN spleen/NN cells/NNS in/FW vitro/FW ,/, of/IN a/DT distinct/JJ impaired/JJ deletion/NN of/IN V/NN beta/NN 11+/CD4+/JJ T/NN lymphocytes/NNS from/IN these/DT mice/NNS was/VBD detected/VBN after/IN superantigen/NN injection/NN ./. 
Moreover/RB ,/, NF-ATp-/-/JJ mice/NNS older/JJR than/IN 6/CD weeks/NNS show/VBP an/DT 2-5/CD fold/JJ increase/NN in/IN number/NN of/IN lymphocytes/NNS ./. 
This/DT is/VBZ correlated/VBN with/IN an/DT increased/VBN expression/NN of/IN activation/NN markers/NNS CD44/NN and/CC CD69/NN and/CC decreased/VBN expression/NN of/IN CD62/NN ./. 
UI/LS -/: 99161827/CD 
TI/LS -/: AML/NN and/CC Ets/NN proteins/NNS regulate/VBP the/DT I/NN alpha1/NN germ-line/NN promoter/NN ./. 
AB/LS -/: The/DT immunoglobulin/NN heavy/JJ chain/NN (/( IgH/JJ )/) class/NN switch/NN recombination/NN of/IN B/NN lymphocytes/NNS preferentially/RB targets/VBZ unrearranged/JJ IgH/JJ genes/NNS that/WDT have/VBP already/RB been/VBN rendered/VBN transcriptionally/RB active/JJ ./. 
Transcription/NN of/IN the/DT germ-line/NN IgH/JJ genes/NNS is/VBZ controlled/VBN by/IN intervening/VBG (/( I/CD )/) regions/NNS upstream/RB of/IN their/PRP$ switch/NN regions/NNS ./. 
The/DT I/NN alpha1/NN promoter/NN activates/VBZ transcription/NN of/IN the/DT human/JJ germ-line/NN C/NN alpha1/NN gene/NN for/IN IgA1/NN and/CC mediates/VBZ the/DT transforming/VBG growth/NN factor/NN (/( TGF/NN )/) -beta1/NN responsiveness/NN of/IN this/DT locus/NN ./. 
Here/RB we/PRP show/VBP that/IN the/DT I/NN alpha1/NN promoter/NN contains/VBZ several/JJ binding/VBG sites/NNS for/IN the/DT AML/PEBP2/CBF/NN family/NN of/IN transcription/NN factors/NNS and/CC that/IN AML/NN and/CC Ets/NN proteins/NNS are/VBP major/JJ regulators/NNS of/IN the/DT basal/JJ and/CC TGF-beta-inducible/JJ promoter/NN activity/NN ./. 
Our/PRP$ data/NNS constitute/VBP a/DT starting/VBG point/NN for/IN studies/NNS to/TO elucidate/VB the/DT molecular/JJ mechanism/NN by/IN which/WDT TGF-beta/NN regulates/VBZ IgA/NN production/NN ./. 
UI/LS -/: 99150505/CD 
TI/LS -/: Daidzein/NN and/CC genistein/NN glucuronides/NNS in/FW vitro/FW are/VBP weakly/RB estrogenic/JJ and/CC activate/VBP human/JJ natural/JJ killer/NN cells/NNS at/IN nutritionally/RB relevant/JJ concentrations/NNS ./. 
AB/LS -/: Daidzein/NN and/CC genistein/NN glucuronides/NNS (/( DG/NNS and/CC GG/NNS )/) ,/, major/JJ isoflavone/NN metabolites/NNS ,/, may/MD be/VB partly/RB responsible/JJ for/IN biological/JJ effects/NNS of/IN isoflavones/NNS ,/, such/JJ as/IN estrogen/NN receptor/NN binding/NN and/CC natural/JJ killer/NN cell/NN (/( NK/NN )/) activation/NN or/CC inhibition/NN ./. 
DG/NNS and/CC GG/NNS were/VBD synthesized/VBN using/VBG 3-methylcholanthrene-induced/JJ rat/NN liver/NN microsomes/NNS ./. 
The/DT Km/NN and/CC Vmax/NN for/IN daidzein/NN and/CC genistein/NN were/VBD 9.0/CD and/CC 7.7/CD micromol/L/NN ,/, and/CC 0.7/CD and/CC 1.6/CD micromol//NN (/( mg/NN protein./NN min/NN )/) ,/, respectively/RB ./. 
The/DT absence/NN of/IN ultraviolet/JJ absorbance/NN maxima/NNS shifts/NNS in/IN the/DT presence/NN of/IN sodium/NN acetate/NN confirmed/VBD that/IN the/DT synthesized/VBN products/NNS were/VBD 7-O-glucuronides/NNS ./. 
DG/NNS and/CC GG/NNS were/VBD further/RB purified/VBN by/IN a/DT Sephadex/NN LH-20/NN column/NN ./. 
DG/NNS and/CC GG/NNS competed/VBD with/IN the/DT binding/NN of/IN 17beta-(3H) estradiol/NN to/TO estrogen/NN receptors/NNS of/IN B6D2F1/NN mouse/NN uterine/NN cytosol/NN ./. 
The/DT concentrations/NNS required/VBN for/IN 50/CD %/NN displacement/NN of/IN 17beta-(3H) estradiol/NN (/( CB50/NN )/) were/VBD :/: 17beta-estradiol/NN ,/, 1.34/CD nmol/L/NN ;/: diethylstilbestrol/NN ,/, 1.46/CD nmol/L/NN ;/: daidzein/NN ,/, 1.6/CD micromol/L/NN ;/: DG/NNS ,/, 14.7/CD micromol/L/NN ;/: genistein/NN ,/, 0.154/CD micromol/L/NN ;/: GG/NNS ,/, 7.27/CD micromol/L/NN ./. 
In/IN human/JJ peripheral/JJ blood/NN NK/NN cells/NNS ,/, genistein/NN at/IN </JJR 0.5/CD micromol/L/NN and/CC DG/NNS and/CC GG/NNS at/IN 0.1-10/CD micromol/L/NN enhanced/VBD NK/NN cell-mediated/JJ K562/NN cancer/NN cell/NN killing/NN significantly/RB (/( P/NN </JJR 0.05/CD )/) ./. 
At/IN >/JJR 0.5/CD micromol/L/NN ,/, genistein/NN inhibited/VBD NK/NN cytotoxicity/NN significantly/RB (/( P/NN </JJR 0.05/CD )/) ./. 
The/DT glucuronides/NNS only/RB inhibited/VBD NK/NN cytotoxicity/NN at/IN 50/CD micromol/L/NN ./. 
Isoflavones/NNS ,/, and/CC especially/RB the/DT isoflavone/NN glucuronides/NNS ,/, enhanced/VBD activation/NN of/IN NK/NN cells/NNS by/IN interleukin-2/NN (/( IL-2/NN )/) ,/, additively/RB ./. 
At/IN physiological/JJ concentrations/NNS ,/, DG/NNS and/CC GG/NNS were/VBD weakly/RB estrogenic/JJ ,/, and/CC they/PRP activated/VBD human/JJ NK/NN cells/NNS in/IN nutritionally/RB relevant/JJ concentrations/NNS in/FW vitro/FW ,/, probably/RB at/IN a/DT site/NN different/JJ from/IN IL-2/NN action/NN ./. 
UI/LS -/: 99138943/CD 
TI/LS -/: Cross-linking/NN of/IN CD44/NN on/IN rheumatoid/JJ synovial/JJ cells/NNS up-regulates/VBZ VCAM-1/NN ./. 
AB/LS -/: CD44/NN is/VBZ a/DT ubiquitous/JJ molecule/NN also/RB known/VBN as/IN hyaluronic/JJ acid/NN or/CC homing/JJ receptor/NN ./. 
However/RB ,/, the/DT cellular/JJ functions/NNS and/CC its/PRP$ role/NN in/IN inflammation/NN ,/, for/IN example/NN ,/, rheumatoid/JJ synovitis/NN ,/, are/VBP currently/RB unknown/JJ ./. 
In/IN this/DT study/NN ,/, we/PRP propose/VBP a/DT novel/JJ function/NN for/IN CD44/NN ./. 
Using/VBG synovial/JJ cells/NNS from/IN rheumatoid/JJ arthritis/NN (/( RA/NN )/) patients/NNS ,/, we/PRP demonstrated/VBD that/IN CD44/NN cross-linking/NN and/CC binding/VBG to/TO hyaluronan/NN augmented/VBD VCAM-1/NN expression/NN and/CC subsequently/RB VCAM-1-mediated/JJ cell/NN adhesion/NN ./. 
Briefly/RB ,/, we/PRP found/VBD that/IN 1/LS )/) rheumatoid/JJ synovial/JJ cells/NNS highly/RB expressed/VBD CD44/NN ;/: 2/LS )/) cross-linking/NN of/IN CD44/NN markedly/RB but/CC transiently/RB augmented/VBD VCAM-1/NN expression/NN and/CC its/PRP$ mRNA/NN transcription/NN much/RB more/JJR than/IN did/VBD IL-1beta/NN and/CC TNF-alpha/NN ;/: 3/LS )/) hyaluronan/NN ,/, especially/RB when/WRB fragmented/JJ ,/, also/RB up-regulated/VBD VCAM-1/NN ;/: 4/LS )/) CD44/NN activated/VBD the/DT transcription/NN factor/NN AP-1/NN ;/: and/CC 5/LS )/) the/DT integrin-dependent/JJ adhesive/JJ function/NN of/IN RA/NN synovial/JJ cells/NNS to/TO T/NN cells/NNS was/VBD also/RB amplified/VBD by/IN CD44/NN cross-linking/NN ./. 
These/DT results/NNS indicate/VBP that/IN the/DT adhesion/NN of/IN RA/NN synovial/JJ cells/NNS to/TO matrices/NNS such/JJ as/IN hyaluronic/JJ acid/NN through/IN CD44/NN could/MD up-regulate/VB VCAM-1/NN expression/NN and/CC VCAM-1-mediated/JJ adhesion/NN to/TO T/NN cells/NNS ,/, which/WDT might/MD in/IN turn/NN cause/VB activation/NN of/IN T/NN cells/NNS and/CC synovial/JJ cells/NNS in/IN RA/NN synovitis/NN ./. 
We/PRP therefore/RB propose/VBP that/IN such/JJ cross-talking/NN among/IN distinct/JJ adhesion/NN molecules/NNS may/MD be/VB involved/VBN in/IN the/DT pathogenesis/NN of/IN inflammation/NN ,/, including/VBG RA/NN synovitis/NN ./. 
UI/LS -/: 99134363/CD 
TI/LS -/: NF-kappaB/NN activation/NN is/VBZ a/DT critical/JJ regulator/NN of/IN human/JJ granulocyte/NN apoptosis/NN in/FW vitro/FW ./. 
AB/LS -/: During/IN beneficial/JJ inflammation/NN ,/, potentially/RB tissue-damaging/JJ granulocytes/NNS undergo/VBP apoptosis/NN before/IN being/VBG cleared/VBN by/IN phagocytes/NNS in/IN a/DT non-phlogistic/JJ manner/NN ./. 
Here/RB we/PRP show/VBP that/IN the/DT rate/NN of/IN constitutive/JJ apoptosis/NN in/IN human/JJ neutrophils/NNS and/CC eosinophils/NNS is/VBZ greatly/RB accelerated/VBN in/IN both/CC a/DT rapid/JJ and/CC concentration-dependent/JJ manner/NN by/IN the/DT fungal/JJ metabolite/NN gliotoxin/NN ,/, but/CC not/RB by/IN its/PRP$ inactive/JJ analog/NN methylthiogliotoxin/NN ./. 
This/DT induction/NN of/IN apoptosis/NN was/VBD abolished/VBN by/IN the/DT caspase/NN inhibitor/NN zVAD-fmk/NN ,/, correlated/VBN with/IN the/DT inhibition/NN of/IN nuclear/JJ factor-kappa/NN B/NN (/( NF-kappaB/NN )/) ,/, and/CC was/VBD mimicked/VBN by/IN a/DT cell/NN permeable/JJ inhibitory/JJ peptide/NN of/IN NF-kappaB/NN ,/, SN-50/NN ;/: other/JJ NF-kappaB/NN inhibitors/NNS ,/, curcumin/NN and/CC pyrrolidine/NN dithiocarbamate/NN ;/: and/CC the/DT proteasome/NN inhibitor/NN ,/, MG-132/NN ./. 
Gliotoxin/NN also/RB augmented/VBD dramatically/RB the/DT early/JJ (/( 2-6/CD h/NN )/) pro-apoptotic/JJ effects/NNS of/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) in/IN neutrophils/NNS and/CC unmasked/VBD the/DT ability/NN of/IN TNF-alpha/NN to/TO induce/VB eosinophil/NN apoptosis/NN ./. 
In/IN neutrophils/NNS ,/, TNF-alpha/NN caused/VBD a/DT gliotoxin-inhibitable/JJ activation/NN of/IN an/DT inducible/JJ form/NN of/IN NF-kappaB/NN ,/, a/DT response/NN that/WDT may/MD underlie/VB the/DT ability/NN of/IN TNF-alpha/NN to/TO delay/VB apoptosis/NN at/IN later/JJ times/NNS (/( 12-24/CD h/NN )/) and/CC limit/VB its/PRP$ early/JJ killing/NN effect/NN ./. 
Furthermore/RB ,/, cycloheximide/NN displayed/VBD a/DT similar/JJ capacity/NN to/TO enhance/VB TNF-alpha/NN induced/VBN neutrophil/NN apoptosis/NN even/RB at/IN time/NN points/NNS when/WRB cycloheximide/NN alone/RB had/VBD no/DT pro-apoptotic/JJ effect/NN ,/, suggesting/VBG that/IN NF-kappaB/NN may/MD regulate/VB the/DT production/NN of/IN protein/NN (/( s/NNS )/) which/WDT protect/VBP neutrophils/NNS from/IN the/DT cytotoxic/JJ effects/NNS of/IN TNF-alpha/NN ./. 
These/DT data/NNS shed/VBD light/NN on/IN the/DT biochemical/JJ and/CC molecular/JJ mechanisms/NNS regulating/VBG human/JJ granulocyte/NN apoptosis/NN and/CC ,/, in/IN particular/JJ ,/, indicate/VBP that/IN the/DT transcription/NN factor/NN NF-kappaB/NN plays/VBZ a/DT crucial/JJ role/NN in/IN regulating/VBG the/DT physiological/JJ cell/NN death/NN pathway/NN in/IN granulocytes/NNS ./. 
UI/LS -/: 99115672/CD 
TI/LS -/: Role/NN of/IN Egr-2/NN in/IN up-regulation/NN of/IN Fas/NN ligand/NN in/IN normal/JJ T/NN cells/NNS and/CC aberrant/JJ double-negative/JJ lpr/NN and/CC gld/NN T/NN cells/NNS ./. 
AB/LS -/: We/PRP previously/RB identified/VBD a/DT Fas/NN ligand/NN regulatory/JJ element/NN (/( FLRE/NN )/) in/IN the/DT Fas/NN ligand/NN (/( fasL/NN )/) promoter/NN that/IN binds/VBZ Egr/NN family/NN proteins/NNS and/CC demonstrated/VBD that/IN Egr-3/NN (/( PILOT/NN )/) but/CC not/RB Egr-1/NN (/( NGFI-A/NN ,/, Krox-24/NN ,/, Tis-8/NN ,/, and/CC Zif-268/NN )/) induces/VBZ transcription/NN of/IN fasL/NN ./. 
The/DT aberrant/JJ CD4(-)/JJ CD8(-)/JJ T/NN cells/NNS from/IN lpr/lpr/NN and/CC gld/gld/NN mice/NNS ,/, which/WDT have/VBP mutations/NNS in/IN the/DT genes/NNS encoding/VBG Fas/NN and/CC FasL/NN ,/, respectively/RB ,/, have/VBP an/DT activated/VBN phenotype/NN and/CC constitutively/RB express/VBP high/JJ levels/NNS of/IN fasL/NN mRNA/NN ,/, prompting/VBG us/PRP to/TO ask/VB what/WP role/NN if/IN any/DT the/DT FLRE/NN and/CC Egr/NN family/NN proteins/NNS have/VBP in/IN this/DT aberrant/JJ expression/NN of/IN fasL/NN ./. 
Unstimulated/JJ MRL-lpr/lpr/NN and/CC C3H-gld/gld/JJ CD4(-)/JJ CD8(-)/JJ T/NN cells/NNS constitutively/RB contained/VBD high/JJ levels/NNS of/IN two/CD proteins/NNS that/WDT bound/VBD to/TO the/DT FLRE/NN ./. 
Supershift/NN analysis/NN revealed/VBD these/DT proteins/NNS to/TO be/VB Egr-1/NN and/CC Egr-2/NN (/( Krox-20/NN )/) ;/: Egr-3/NN was/VBD not/RB detected/VBN ./. 
Activation/NN of/IN normal/JJ lymph/NN node/NN cells/NNS resulted/VBD in/IN increased/VBN expression/NN of/IN Egr-1/NN ,/, -2/CD ,/, and/CC -3/CD ./. 
As/IN with/IN egr-3/NN ,/, expression/NN of/IN egr-2/NN was/VBD blocked/VBN by/IN cyclosporin/NN A/NN ./. 
Although/IN overexpressed/VBN Egr-1/NN was/VBD ineffective/JJ ,/, overexpressed/VBN Egr-2/NN was/VBD as/RB potent/JJ as/IN Egr-3/NN in/IN inducing/VBG fasL/NN promoter-dependent/JJ reporter/NN constructs/NNS in/IN T/NN cell/NN hybridomas/NNS and/CC HeLa/NN cells/NNS ,/, and/CC both/DT up-regulated/VBN endogenous/JJ fasL/NN mRNA/NN in/IN HeLa/NN cells/NNS ./. 
FasL-dependent/JJ reporter/NN constructs/NNS in/IN MRL-lpr/lpr/NN and/CC C3H-gld/gld/JJ CD4(-)/JJ CD8(-)/JJ T/NN cells/NNS were/VBD constitutively/RB active/JJ ,/, and/CC this/DT activity/NN was/VBD largely/RB prevented/VBN by/IN mutation/NN of/IN the/DT critical/JJ Egr/NN family/NN binding/NN element/NN ./. 
Thus/RB ,/, Egr-2/NN ,/, in/IN addition/NN to/TO Egr-3/NN ,/, regulates/VBZ FasL/NN expression/NN in/IN activated/VBN normal/JJ T/NN cells/NNS ,/, and/CC Egr-2/NN is/VBZ likely/JJ to/TO play/VB a/DT direct/JJ role/NN in/IN aberrant/NN fasL/NN up-regulation/NN in/IN lpr/lpr/NN and/CC gld/gld/NN CD4(-)/JJ CD8(-)/JJ T/NN cells/NNS ./. 
UI/LS -/: 99102381/CD 
TI/LS -/: The/DT activity/NN of/IN the/DT CCAAT-box/NN binding/NN factor/NN NF-Y/NN is/VBZ modulated/VBN through/IN the/DT regulated/VBN expression/NN of/IN its/PRP$ A/NN subunit/NN during/IN monocyte/NN to/TO macrophage/NN differentiation/NN :/: regulation/NN of/IN tissue-specific/JJ genes/NNS through/IN a/DT ubiquitous/JJ transcription/NN factor/NN ./. 
AB/LS -/: In/IN this/DT study/NN ,/, we/PRP analyzed/VBD the/DT regulation/NN of/IN NF-Y/NN expression/NN during/IN human/JJ monocyte/NN to/TO macrophage/NN maturation/NN ./. 
NF-Y/NN is/VBZ a/DT ubiquitous/JJ and/CC evolutionarily/RB conserved/VBN transcription/NN factor/NN that/WDT binds/VBZ specifically/RB to/TO the/DT CCAAT/NN motif/NN present/JJ in/IN the/DT 5'/JJ promoter/NN region/NN of/IN a/DT wide/JJ variety/NN of/IN genes/NNS ./. 
We/PRP show/VBP here/RB that/IN in/IN circulating/VBG monocytes/NNS ,/, NF-Y/NN binding/NN activity/NN is/VBZ not/RB detected/VBN on/IN the/DT CCAAT/NN motif/NN present/JJ in/IN the/DT promoters/NNS of/IN genes/NNS such/JJ as/IN major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II/CD ,/, gp91-phox/NN ,/, mig/NN ,/, and/CC fibronectin/NN ,/, whereas/IN during/IN macrophage/NN differentiation/NN ,/, a/DT progressive/JJ increase/NN in/IN NF-Y/NN binding/NN activity/NN is/VBZ observed/VBN on/IN these/DT promoters/NNS ./. 
Analysis/NN of/IN NF-Y/NN subunit/NN expression/NN indicates/VBZ that/IN the/DT absence/NN of/IN NF-Y/NN activity/NN in/IN circulating/VBG monocytes/NNS is/VBZ caused/VBN by/IN a/DT lack/NN of/IN the/DT A/NN subunit/NN ./. 
Furthermore/RB ,/, addition/NN of/IN the/DT recombinant/JJ NF-YA/NN subunit/NN restores/VBZ NF-Y/NN binding/NN ./. 
We/PRP show/VBP that/IN the/DT lack/NN of/IN NF-YA/NN protein/NN is/VBZ due/JJ to/TO posttranscriptional/JJ regulation/NN and/CC not/RB to/TO a/DT specific/JJ proteolytic/JJ activity/NN ./. 
In/IN fact/NN ,/, NF-YA/NN mRNA/NN is/VBZ present/JJ at/IN the/DT same/JJ level/NN at/IN all/DT days/NNS of/IN monocyte/NN cultivation/NN ,/, whereas/IN the/DT protein/NN is/VBZ absent/JJ in/IN freshly/RB isolated/VBN monocytes/NNS but/CC is/VBZ progressively/RB synthesized/VBN during/IN the/DT maturation/NN process/NN ./. 
We/PRP thus/RB conclude/VBP that/IN the/DT NF-YA/NN subunit/NN plays/VBZ a/DT relevant/JJ role/NN in/IN activating/VBG transcription/NN of/IN genes/NNS highly/RB expressed/VBN in/IN mature/JJ monocytes/NNS ./. 
In/IN line/NN with/IN this/DT conclusion/NN ,/, we/PRP show/VBP that/IN the/DT cut/CDP/NN protein/NN ,/, a/DT transcriptional/JJ repressor/NN that/WDT inhibits/VBZ gpc91-phox/JJ gene/NN expression/NN by/IN preventing/VBG NF-Y/NN binding/NN to/TO the/DT CAAT/NN box/NN ,/, is/VBZ absent/JJ in/IN monocytes/NNS ./. 
UI/LS -/: 99078033/CD 
TI/LS -/: Interdomain/NN B/NN in/IN ZAP-70/NN regulates/VBZ but/CC is/VBZ not/RB required/VBN for/IN ZAP-70/NN signaling/NN function/NN in/IN lymphocytes/NNS ./. 
AB/LS -/: The/DT protein/NN tyrosine/NN kinase/NN ZAP-70/NN plays/VBZ an/DT important/JJ role/NN in/IN T-cell/NN activation/NN and/CC development/NN ./. 
After/IN T-cell/NN receptor/NN stimulation/NN ,/, ZAP-70/NN associates/VBZ with/IN the/DT receptor/NN and/CC is/VBZ phosphorylated/VBN on/IN many/JJ tyrosines/NNS ,/, including/VBG Y292/NN ,/, Y315/NN ,/, and/CC Y319/NN within/IN interdomain/NN B/NN ./. 
Previously/RB ,/, we/PRP demonstrated/VBD that/IN Y292/NN negatively/RB regulates/VBZ ZAP-70/NN function/NN and/CC that/IN Y315/NN positively/RB regulates/VBZ ZAP-70/NN function/NN by/IN interacting/VBG with/IN Vav/NN ./. 
Recent/JJ studies/NNS have/VBP suggested/VBN that/IN Y319/NN also/RB positively/RB regulate/VBP ZAP-70/NN function/NN ./. 
Paradoxically/RB ,/, removal/NN of/IN interdomain/NN B/NN (/( to/TO create/VB the/DT construct/NN designated/VBN Delta/NN )/) ,/, containing/VBG the/DT Y292/NN ,/, Y315/NN ,/, and/CC Y319/NN sites/NNS ,/, did/VBD not/RB eliminate/VB the/DT ability/NN of/IN ZAP-70/NN to/TO induce/VB multiple/JJ gene/NN reporters/NNS in/IN Syk-deficient/JJ DT-40/NN B/NN cells/NNS and/CC ZAP-70/Syk-deficient/JJ Jurkat/NN cells/NNS ./. 
Here/RB we/PRP show/VBP that/IN Delta/NN still/RB utilizes/VBZ the/DT same/JJ pathways/NNS as/IN wild-type/JJ ZAP-70/NN to/TO mediate/VB NF-AT/NN induction/NN ./. 
This/DT is/VBZ manifested/VBN by/IN the/DT ability/NN of/IN Delta/NN to/TO restore/VB induction/NN of/IN calcium/NN fluxes/NNS and/CC mitogen-activated/JJ protein/NN kinase/NN activation/NN and/CC by/IN the/DT ability/NN of/IN dominant/JJ negative/JJ Ras/NNS and/CC FK506/NN to/TO block/VB the/DT induction/NN of/IN NF-AT/NN activity/NN mediated/VBN by/IN Delta/NN ./. 
Biochemically/RB we/PRP show/VBP that/IN the/DT stimulated/VBN tyrosine/NN phosphorylation/NN of/IN Vav/NN ,/, Shc/NN ,/, and/CC ZAP-70/NN itself/PRP is/VBZ diminished/VBN ,/, whereas/IN that/DT of/IN Slp-76/NN is/VBZ increased/VBN in/IN cells/NNS reconstituted/VBN with/IN Delta/NN ./. 
Deletion/NN of/IN interdomain/NN B/NN did/VBD not/RB affect/VB the/DT ability/NN of/IN ZAP-70/NN to/TO bind/VB to/TO the/DT receptor/NN ./. 
The/DT in/FW vitro/FW kinase/NN activity/NN of/IN ZAP-70/NN lacking/VBG interdomain/NN B/NN was/VBD markedly/RB reduced/VBN ,/, but/CC the/DT kinase/NN activity/NN was/VBD still/RB required/VBN for/IN the/DT protein/NN 's/POS in/FW vivo/FW activity/NN ./. 
Based/VBN on/IN these/DT data/NNS ,/, we/PRP concluded/VBD that/IN interdomain/NN B/NN regulates/VBZ but/CC is/VBZ not/RB required/VBN for/IN ZAP-70/NN signaling/NN function/NN leading/VBG to/TO cellular/JJ responses/NNS ./. 
UI/LS -/: 98208270/CD 
TI/LS -/: Differential/JJ induction/NN of/IN DNA-binding/NN activities/NNS following/VBG CD19/NN cross-linking/NN in/IN human/JJ B/NN lineage/NN cells/NNS ./. 
AB/LS -/: The/DT B/NN cell-specific/JJ cell/NN surface/NN molecule/NN CD19/NN is/VBZ expressed/VBN at/IN all/DT stages/NNS of/IN B/NN cell/NN development/NN ,/, including/VBG normal/JJ plasma/NN cells/NNS ,/, and/CC mediates/VBZ signal/NN transduction/NN via/IN interaction/NN with/IN cytoplasmic/JJ effector/NN proteins/NNS ./. 
Cross-linking/VBG CD19/NN on/IN early/JJ human/JJ B/NN lineage/NN cells/NNS induces/VBZ the/DT formation/NN of/IN a/DT CD19/Vav/phosphatidylinositol-3/NN kinase/NN complex/NN ,/, tyrosine/NN phosphorylation/NN of/IN CD19/NN and/CC Vav/NN ,/, and/CC activation/NN of/IN the/DT Ras/NN pathway/NN ./. 
To/TO further/RB explore/VB the/DT ramifications/NNS of/IN CD19/NN signaling/NN ,/, the/DT current/JJ study/NN examined/VBD whether/IN phosphorylation/NN of/IN Elk-1/NN ,/, activation/NN of/IN activator/NN protein-1/NN (/( AP-1/NN )/) ,/, or/CC activation/NN of/IN nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) transcription/NN factors/NNS occurred/VBD following/VBG CD19/NN cross-linking/NN ./. 
The/DT cells/NNS used/VBN were/VBD the/DT BLIN-1/NN pre-B/JJ cell/NN line/NN expressing/VBG low/JJ levels/NNS of/IN cell/NN surface/NN mu/NN heavy/JJ chain/NN associated/VBN with/IN surrogate/NN light/NN chain/NN and/CC the/DT 1E8/NN immature/JJ B/NN cell/NN line/NN expressing/VBG cell/NN surface/NN mu/kappa/NN ./. 
Lysates/NNS from/IN CD19/NN cross-linked/JJ 1E8/NN cells/NNS induced/VBD robust/JJ phosphorylation/NN of/IN an/DT Elk-1/NN fusion/NN protein/NN in/FW vitro/FW ,/, whereas/IN no/DT phosphorylation/NN of/IN Elk-1/NN fusion/NN protein/NN occurred/VBD using/VBG lysates/NNS from/IN CD19/NN cross-linked/JJ BLIN-1/NN cells/NNS ./. 
An/DT electrophoretic/JJ mobility/NN shift/NN assay/NN employing/VBG AP-1/NN and/CC NF-kappaB/NN consensus/NN oligonucleotides/NNS was/VBD used/VBN to/TO demonstrate/VB that/IN AP-1-binding/JJ activity/NN increased/VBD ,/, while/IN constitutive/JJ NF-kappaB-binding/JJ activity/NN was/VBD not/RB enhanced/VBN ,/, following/VBG 2/CD h/NN of/IN CD19/NN cross-linking/NN in/IN 1E8/NN cells/NNS ./. Supershift/NN experiments/NNS revealed/VBD that/IN JunD/NN and/CC c-Fos/NN proteins/NNS mediated/VBD anti-CD19/NN induced/JJ AP-1-binding/JJ activity/NN in/IN 1E8/NN cells/NNS ./. 
In/IN contrast/NN ,/, CD19/NN cross-linking/NN in/IN BLIN-1/NN cells/NNS resulted/VBD in/IN the/DT induction/NN of/IN NF-kappaB/NN ,/, but/CC had/VBD no/RB apparent/JJ effect/NN on/IN AP-1-binding/JJ activity/NN ./. 
These/DT data/NNS suggest/VBP that/IN CD19-mediated/JJ signal/NN transduction/NN activates/VBZ different/JJ transcription/NN factors/NN at/IN juxtaposed/VBN stages/NNS of/IN B/NN cell/NN development/NN that/IN may/MD culminate/VB in/IN the/DT activation/NN or/CC suppression/NN of/IN distinct/JJ sets/NNS of/IN genes/NNS ./. 
UI/LS -/: 98140255/CD 
TI/LS -/: Oxidants/NNS ,/, transcription/NN factors/NNS ,/, and/CC intestinal/JJ inflammation/NN ./. 
AB/LS -/: It/PRP is/VBZ now/RB well/RB appreciated/VBN that/IN chronic/JJ gut/NN inflammation/NN is/VBZ characterized/VBN by/IN enhanced/VBN production/NN of/IN reactive/JJ metabolites/NNS of/IN oxygen/NN and/CC nitrogen/NN ./. 
Some/DT of/IN these/DT oxidants/NNS are/VBP known/VBN to/TO modulate/VB the/DT expression/NN of/IN a/DT variety/NN of/IN genes/NNS that/WDT are/VBP involved/VBN in/IN the/DT immune/JJ and/CC inflammatory/JJ responses/NNS ./. 
For/IN example/NN ,/, certain/JJ oxidants/NNS are/VBP known/VBN to/TO activate/VB the/DT nuclear/JJ transcription/NN factor/NN kappa/NN B/NN ,/, which/WDT regulates/VBZ the/DT expression/NN of/IN a/DT variety/NN of/IN different/JJ adhesion/NN molecules/NNS ,/, cytokines/NNS ,/, and/CC enzymes/NNS ./. 
Oxidants/NNS are/VBP also/RB known/VBN to/TO activate/VB another/DT transcription/NN factor/NN ,/, activator/NN protein-1/NN ./. 
This/DT transcription/NN factor/NN is/VBZ composed/VBN of/IN products/NNS from/IN the/DT fos/NN and/CC jun/NN proto-oncogene/NN family/NN and/CC is/VBZ believed/VBN to/TO be/VB important/JJ in/IN regulating/VBG cell/NN growth/NN and/CC proliferation/NN ./. 
Finally/RB ,/, oxidants/NNS are/VBP believed/VBN to/TO promote/VB intestinal/JJ epithelial/JJ cell/NN apoptosis/NN ,/, and/CC the/DT B-cell/NN lymphoma/leukemia-2/NN gene/NN product/NN is/VBZ believed/VBN to/TO inhibit/VB this/DT phenomenon/NN in/IN an/DT antioxidant-dependent/JJ manner/NN ./. 
Taken/VBN together/RB ,/, these/DT observations/NNS suggest/VBP that/IN nontoxic/JJ concentrations/NNS of/IN reactive/JJ metabolites/NNS of/IN oxygen/NN and/CC nitrogen/NN play/VBP an/DT important/JJ role/NN in/IN regulating/VBG the/DT expression/NN of/IN genes/NNS involved/VBN in/IN the/DT inflammatory/JJ response/NN and/CC in/IN modulating/VBG apoptosis/NN ./. 
UI/LS -/: 98104475/CD 
TI/LS -/: Identification/NN of/IN target/NN genes/NNS of/IN the/DT lymphoid-specific/JJ transcription/NN factor/NN Oct2/NN ./. 
AB/LS -/: The/DT Oct2/NN transcription/NN factor/NN is/VBZ expressed/VBN predominantly/RB in/IN B/NN lymphocytes/NNS and/CC plays/VBZ an/DT essential/JJ role/NN during/IN the/DT terminal/JJ phase/NN of/IN B/NN cell/NN differentiation/NN ./. 
The/DT regulatory/JJ regions/NNS of/IN several/JJ genes/NNS specifically/RB expressed/VBN in/IN B/NN cells/NNS contain/VBP functional/JJ binding/VBG sites/NNS for/IN Oct2/NN ./. 
Nevertheless/RB ,/, none/NN of/IN the/DT genes/NNS originally/RB thought/VBN to/TO be/VB regulated/VBN by/IN Oct2/NN were/VBD affected/VBN in/IN their/PRP$ expression/NN in/IN Oct2-deficient/JJ B/NN cells/NNS ./. 
In/IN an/DT attempt/NN to/TO find/VB such/JJ elusive/JJ Oct2/NN target/NN genes/NNS and/CC to/TO understand/VB the/DT molecular/JJ function/NN of/IN Oct2/NN in/IN B/NN cell/NN development/NN ,/, we/PRP isolated/VBD cDNAs/NNS for/IN Oct2/NN target/NN genes/NNS ./. 
So/RB far/RB ,/, we/PRP have/VBP identified/VBN five/CD potential/JJ targets/NNS for/IN Oct2/NN :/: the/DT membrane/NN glycoprotein/NN CD36/NN ,/, the/DT cysteine-rich/JJ secreted/VBN protein/NN 3/CD (/( CRISP-3/NN )/) ,/, a/DT mouse/NN homolog/NN of/IN the/DT human/JJ monocyte/neutrophil/NN elastase/NN inhibitor/NN (/( mEI/NN )/) and/CC two/CD unknown/JJ cDNA/NN sequences/NNS Nov1/NN and/CC Nov2/NN ./. 
These/DT target/NN genes/NNS show/VBP quite/RB distinct/JJ expression/NN patterns/NNS demonstrating/VBG that/IN transcription/NN factors/NNS in/IN addition/NN to/TO Oct2/NN are/VBP involved/VBN in/IN their/PRP$ regulation/NN ./. 
Whereas/IN CD36/NN and/CC mEI/NN were/VBD expressed/VBN in/IN all/DT hematopoetic/JJ cell/NN lines/NNS containing/VBG Oct2/NN ,/, ./. 
CRISP-3/NN is/VBZ pre-B/JJ cell-specific/JJ ,/, Nov1/NN is/VBZ plasma/NN B/NN cell-specific/JJ and/CC Nov2/NN is/VBZ B/NN cell-specifically/RB expressed/VBN ./. 
UI/LS -/: 99170284/CD 
TI/LS -/: RFX-B/NN is/VBZ the/DT gene/NN responsible/JJ for/IN the/DT most/RBS common/JJ cause/NN of/IN the/DT bare/JJ lymphocyte/NN syndrome/NN ,/, an/DT MHC/NN class/NN II/CD immunodeficiency/NN [/( published/VBN erratum/NN appears/VBZ in/IN Immunity/NN 1999/CD Mar/NNP ;/: 10/CD (/( 3/CD )/) :/: 399/CD ]/) 
AB/LS -/: The/DT bare/JJ lymphocyte/NN syndrome/NN (/( BLS/NN )/) is/VBZ characterized/VBN by/IN the/DT absence/NN of/IN MHC/NN class/NN II/CD transcription/NN and/CC humoral-/JJ and/CC cellular-mediated/JJ immune/JJ responses/NNS to/TO foreign/JJ antigens/NNS ./. 
Three/CD of/IN the/DT four/CD BLS/NN genetic/JJ complementation/NN groups/NNS have/VBP defects/NNS in/IN the/DT activity/NN of/IN the/DT MHC/NN class/NN II/CD transcription/NN factor/NN RFX/NN ./. 
We/PRP have/VBP purified/VBN the/DT RFX/NN complex/NN and/CC sequenced/VBN its/PRP$ three/CD subunits/NNS ./. 
The/DT sequence/NN of/IN the/DT smallest/JJS subunit/NN describes/VBZ a/DT novel/JJ gene/NN ,/, termed/VBN RFX-B/NN ./. 
RFX-B/NN complements/VBZ the/DT predominant/JJ BLS/NN complementation/NN group/NN (/( group/NN B/NN )/) and/CC was/VBD found/VBN to/TO be/VB mutant/JJ in/IN cell/NN lines/NNS from/IN this/DT BLS/NN group/NN ./. 
The/DT protein/NN has/VBZ no/DT known/JJ DNA-binding/JJ domain/NN but/CC does/VBZ contain/VB three/CD ankyrin/NN repeats/NNS that/WDT are/VBP likely/JJ to/TO be/VB important/JJ in/IN protein-protein/JJ interactions/NNS ./. 
UI/LS -/: 99158164/CD 
TI/LS -/: Binding/NN of/IN c-Rel/NN to/TO STAT5/NN target/NN sequences/NNS in/IN HTLV-I-transformed/JJ T/NN cells/NNS ./. 
AB/LS -/: The/DT type/NN I/CD human/JJ T-cell/NN leukemia/NN virus/NN (/( HTLV-I/NN )/) induces/VBZ abnormal/JJ growth/NN and/CC subsequent/JJ transformation/NN of/IN T/NN cells/NNS ,/, which/WDT is/VBZ associated/VBN with/IN the/DT development/NN of/IN an/DT acute/JJ T-cell/NN malignancy/NN termed/VBD adult/JJ T-cell/NN leukemia/NN ./. 
A/DT characteristic/NN of/IN HTLV-I-transformed/JJ T/NN cells/NNS is/VBZ the/DT constitutive/JJ nuclear/JJ expression/NN of/IN NF-kappaB/Rel/NN family/NN of/IN transcription/NN factors/NNS ,/, which/WDT appears/VBZ to/TO be/VB essential/JJ for/IN the/DT growth/NN of/IN these/DT transformed/VBN cells/NNS ./. 
Although/IN NF-kappaB/Rel/NN factors/NNS are/VBP known/VBN to/TO induce/VB the/DT expression/NN of/IN T-cell/NN growth/NN factor/NN interleukin/NN (/( IL/NN )/) -2/CD ,/, it/PRP is/VBZ unclear/JJ how/WRB they/PRP participate/VBP in/IN the/DT IL-2-independent/JJ growth/NN of/IN HTLV-I-transformed/JJ cells/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP show/VBP that/IN certain/JJ NF-kappaB/Rel/NN members/NNS ,/, predominantly/RB c-Rel/NN ,/, interact/VBP with/IN enhancer/NN sequences/NNS for/IN STAT5/NN ,/, a/DT key/JJ transcription/NN factor/NN mediating/VBG IL-2-induced/JJ T-cell/NN proliferation/NN ./. 
Reporter/NN gene/NN assays/NNS reveal/VBP that/IN the/DT binding/NN of/IN c-Rel/NN to/TO the/DT STAT5/NN site/NN present/JJ in/IN the/DT Fc/NN gammaR1/NN gene/NN leads/VBZ to/TO potent/JJ transactivation/NN of/IN this/DT enhancer/NN ./. 
Binding/NN of/IN c-Rel/NN to/TO the/DT Fc/NN gammaR1/NN STAT/NN site/NN also/RB occurs/VBZ in/IN human/JJ peripheral/JJ blood/NN T/NN cells/NNS immortalized/VBN with/IN HTLV-I/NN in/FW vitro/FW and/CC is/VBZ correlated/VBN with/IN enhanced/VBN levels/NNS of/IN proliferation/NN of/IN these/DT cells/NNS ./. 
These/DT results/NNS raise/VBP the/DT possibility/NN that/IN NF-kappaB/Rel/NN may/MD participate/VB in/IN the/DT growth/NN control/NN of/IN HTLV-I-transformed/JJ T/NN cells/NNS by/IN regulating/VBG genes/NNS driven/VBN by/IN both/CC kappaB/NN and/CC certain/JJ STAT/NN enhancers/NNS ./. 
UI/LS -/: 99147045/CD 
TI/LS -/: Activation-dependent/JJ transcriptional/JJ regulation/NN of/IN the/DT human/JJ Fas/NN promoter/NN requires/VBZ NF-kappaB/NN p50-p65/NN recruitment/NN ./. 
AB/LS -/: Fas/NN (/( CD95/NN )/) and/CC Fas/NN ligand/NN (/( CD95L/NN )/) are/VBP an/DT interacting/VBG receptor-ligand/JJ pair/NN required/VBN for/IN immune/JJ homeostasis/NN ./. 
Lymphocyte/NN activation/NN results/VBZ in/IN the/DT upregulation/NN of/IN Fas/NN expression/NN and/CC the/DT acquisition/NN of/IN sensitivity/NN to/TO FasL-mediated/JJ apoptosis/NN ./. 
Although/IN Fas/NN upregulation/NN is/VBZ central/JJ to/TO the/DT preservation/NN of/IN immunologic/JJ tolerance/NN ,/, little/JJ is/VBZ known/VBN about/IN the/DT molecular/JJ machinery/NN underlying/VBG this/DT process/NN ./. 
To/TO investigate/VB the/DT events/NNS involved/VBN in/IN activation-induced/JJ Fas/NN upregulation/NN ,/, we/PRP have/VBP examined/VBN mRNA/NN accumulation/NN ,/, fas/NN promoter/NN activity/NN ,/, and/CC protein/NN expression/NN in/IN the/DT Jurkat/NN T-cell/NN line/NN treated/VBN with/IN phorbol/NN myristate/NN acetate/NN and/CC ionomycin/NN (/( P/I/NN )/) ,/, pharmacological/JJ mimics/NNS of/IN T-cell/NN receptor/NN activation/NN ./. 
Although/IN resting/VBG Jurkat/NN cells/NNS express/VBP Fas/NN ,/, Fas/NN mRNA/NN was/VBD induced/VBN approximately/RB 10-fold/RB in/IN 2/CD h/NN upon/IN P/I/NN stimulation/NN ./. 
Using/VBG sequential/JJ deletion/NN mutants/NNS of/IN the/DT human/JJ fas/NN promoter/NN in/IN transient/JJ transfection/NN assays/NNS ,/, we/PRP identified/VBD a/DT 47-bp/JJ sequence/NN (/( positions/NNS -306/CD to/TO -260/CD relative/JJ to/TO the/DT ATG/NN )/) required/VBN for/IN activation-driven/JJ fas/NN upregulation/NN ./. 
Sequence/NN analysis/NN revealed/VBD the/DT presence/NN of/IN a/DT previously/RB unrecognized/JJ composite/JJ binding/NN site/NN for/IN both/CC the/DT Sp1/NN and/CC NF-kappaB/NN transcription/NN factors/NNS at/IN positions/NNS -295/CD to/TO -286/CD ./. 
Electrophoretic/JJ mobility/NN shift/NN assay/NN (/( EMSA/NN )/) and/CC supershift/NN analyses/NNS of/IN this/DT region/NN documented/VBD constitutive/JJ binding/NN of/IN Sp1/NN in/IN unactivated/JJ nuclear/JJ extracts/NNS and/CC inducible/JJ binding/NN of/IN p50-p65/NN NF-kappaB/NN heterodimers/NNS after/IN P/I/NN activation/NN ./. 
Sp1/NN and/CC NF-kappaB/NN transcription/NN factor/NN binding/NN was/VBD shown/VBN to/TO be/VB mutually/RB exclusive/JJ by/IN EMSA/NN displacement/NN studies/NNS with/IN purified/VBN recombinant/JJ Sp1/NN and/CC recombinant/JJ p50/NN ./. 
The/DT functional/JJ contribution/NN of/IN the/DT kappaB-Sp1/NN composite/JJ site/NN in/IN P/I-inducible/JJ fas/NN promoter/NN activation/NN was/VBD verified/VBN by/IN using/VBG kappaB-Sp1/NN concatamers/NNS (/( -295/CD to/TO -286/CD )/) in/IN a/DT thymidine/NN kinase/NN promoter-driven/JJ reporter/NN construct/NN and/CC native/JJ promoter/NN constructs/NNS in/IN Jurkat/NN cells/NNS overexpressing/VBG IkappaB-alpha/NN ./. 
Site-directed/JJ mutagenesis/NN of/IN the/DT critical/JJ guanine/NN nucleotides/NNS in/IN the/DT kappaB-Sp1/NN element/NN documented/VBD the/DT essential/JJ role/NN of/IN this/DT site/NN in/IN activation-dependent/JJ fas/NN promoter/NN induction/NN ./. 
UI/LS -/: 99138825/CD 
TI/LS -/: Evidence/NN for/IN repression/NN of/IN IL-2/NN gene/NN activation/NN in/IN anergic/JJ T/NN cells/NNS ./. 
AB/LS -/: The/DT induction/NN of/IN clonal/JJ anergy/NN in/IN a/DT T/NN cell/NN inhibits/VBZ IL-2/NN secretion/NN because/IN of/IN the/DT development/NN of/IN a/DT proximal/JJ signal/NN transduction/NN defect/NN ./. 
Fusion/NN of/IN anergic/JJ murine/JJ T/NN cells/NNS to/TO human/JJ Jurkat/NN T/NN leukemia/NN cells/NNS and/CC formation/NN of/IN heterokaryons/NNS failed/VBD to/TO result/VB in/IN a/DT complementation/NN of/IN this/DT signaling/NN defect/NN and/CC restoration/NN of/IN murine/JJ IL-2/NN mRNA/NN inducibility/NN ./. 
Instead/RB ,/, signal/NN transduction/NN to/TO the/DT human/JJ IL-2/NN gene/NN became/VBD disrupted/VBN ./. 
Heterokaryons/NNS formed/VBN by/IN the/DT fusion/NN of/IN anergic/JJ murine/JJ T/NN cells/NNS to/TO normal/JJ murine/JJ T/NN cells/NNS also/RB failed/VBD to/TO accumulate/VB intracellular/JJ IL-2/NN protein/NN in/IN response/NN to/TO stimulation/NN either/CC with/IN the/DT combination/NN of/IN CD3/NN and/CC CD28/NN mAbs/NNS or/CC with/IN ionomycin/NN plus/CC a/DT protein/NN kinase/NN C-activating/JJ phorbol/NN ester/NN ./. 
The/DT results/NNS argue/VBP against/IN a/DT loss-of-function/JJ signaling/NN defect/NN as/IN the/DT sole/JJ basis/NN for/IN clonal/JJ anergy/NN induction/NN and/CC document/VBP the/DT presence/NN of/IN a/DT dominant-acting/JJ repressor/NN molecule/NN that/WDT inhibits/VBZ signal/NN transduction/NN to/TO the/DT IL-2/NN gene/NN within/IN viable/JJ anergic/JJ T/NN cells/NNS ./. 
UI/LS -/: 99125803/CD 
TI/LS -/: Comparison/NN of/IN HTLV-I/NN basal/JJ transcription/NN and/CC expression/NN of/IN CREB/ATF-1/CREM/NN family/NN members/NNS in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS and/CC Jurkat/NN T/NN cells/NNS ./. 
AB/LS -/: HTLV-I/NN is/VBZ the/DT etiologic/JJ agent/NN of/IN adult/JJ T-cell/NN leukemia/lymphoma/NN and/CC is/VBZ associated/VBN with/IN tropical/JJ spastic/JJ paraparesis/HTLV-I-associated/JJ myelopathy/NN ./. 
Following/VBG integration/NN into/IN the/DT host/NN cell/NN genome/NN ,/, HTLV-I/NN replication/NN is/VBZ regulated/VBN by/IN both/CC host/NN and/CC viral/JJ mechanisms/NNS that/WDT control/VBP transcription/NN ./. 
Low/JJ levels/NNS of/IN viral/JJ transcription/NN (/( basal/JJ transcription/NN )/) occur/VBP before/IN expression/NN of/IN the/DT virally/RB encoded/VBN Tax/NN protein/NN (/( Tax-mediated/JJ transcription/NN )/) ./. 
Members/NNS of/IN the/DT cyclic/JJ adenosine/NN monophosphate/NN (/( cAMP/NN )/) response/VBP element/NN binding/NN (/( CREB/NN )/) /activating/VBG transcription/NN factor/NN 1/CD (/( ATF-1/NN )/) family/NN of/IN transcription/NN factors/NNS bind/VBP three/CD 21-bp/JJ repeats/NNS (/( Tax-responsive/JJ element-1/NN ,/, or/CC TRE-1/NN )/) within/IN the/DT viral/JJ promoter/NN and/CC are/VBP important/JJ for/IN basal/JJ and/CC Tax-mediated/JJ transcription/NN ./. 
Using/VBG mitogen/NN stimulated/JJ and/CC quiescent/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NN )/) and/CC Jurkat/NN cells/NNS ,/, we/PRP compared/VBD differences/NNS in/IN basal/JJ transcription/NN and/CC amounts/NNS and/CC binding/NN of/IN transcription/NN factors/NNS with/IN TRE-1/NN ./. 
We/PRP demonstrate/VBP that/IN amounts/NNS of/IN transcriptionally/RB active/JJ phosphorylated/VBN CREB/NN protein/NN (/( P-CREB/NN )/) differ/VBP between/IN activated/VBN PBMC/NN and/CC Jurkat/NN cells/NNS ./. 
Following/VBG stimulation/NN ,/, P-CREB/JJ levels/NNS remain/VBP elevated/JJ in/IN PBMC/NN for/IN up/RB to/TO 24/CD hours/NNS whereas/IN CREB/NN is/VBZ dephosphorylated/VBN in/IN Jurkat/NN cells/NNS within/IN 4/CD hours/NNS following/VBG stimulation/NN ./. 
The/DT differences/NNS in/IN P-CREB/NN levels/NNS between/IN PBMC/NN and/CC Jurkat/NN cells/NNS were/VBD directly/RB correlated/VBN with/IN basal/JJ transcription/NN of/IN HTLV-I/NN in/IN the/DT two/CD cell/NN types/NNS ./. 
Using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, we/PRP determined/VBD that/IN the/DT pattern/NN of/IN band/NN migration/NN differed/VBD between/IN the/DT two/CD cell/NN types/NNS ./. 
These/DT data/NNS demonstrate/VBP that/IN PBMC/NN differentially/RB regulate/VBP basal/JJ HTLV-I/NN transcription/NN compared/VBN with/IN Jurkat/NN T/NN cells/NNS ,/, and/CC this/DT differential/JJ regulation/NN is/VBZ due/JJ ,/, in/IN part/NN to/TO differential/JJ phosphorylation/NN and/CC binding/NN of/IN CREB/ATF-1/NN to/TO TRE-1/NN in/IN the/DT HTLV-I/NN promoter/NN ./. 
We/PRP demonstrate/VBP the/DT utility/NN of/IN using/VBG primary/JJ lymphocyte/NN models/NNS to/TO study/VB HTLV-I/NN transcription/NN in/IN the/DT context/NN of/IN cell/NN signaling/NN and/CC suggest/VBP that/IN activated/VBN PBMC/NN maintain/VBP elevated/JJ levels/NNS of/IN P-CREB/NN ,/, which/WDT promote/VBP basal/JJ HTLV-I/NN transcription/NN and/CC enhance/VBP viral/JJ persistence/NN in/FW vivo/FW ./. 
UI/LS -/: 99115412/CD 
TI/LS -/: Anoxia/reoxygenation-induced/JJ tolerance/NN with/IN respect/NN to/TO polymorphonuclear/JJ leukocyte/NN adhesion/NN to/TO cultured/VBN endothelial/JJ cells/NNS ./. 
A/DT nuclear/JJ factor-kappaB-mediated/JJ phenomenon/NN ./. 
AB/LS -/: Exposing/VBG human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS (/( HUVECs/NNS )/) to/TO anoxia/reoxygenation/NN (/( A/R/NN )/) results/VBZ in/IN an/DT increase/NN in/IN polymorphonuclear/JJ leukocyte/NN (/( PMN/NN )/) adhesion/NN to/TO HUVECs/NNS ./. 
This/DT A/R-induced/JJ hyperadhesion/NN is/VBZ completely/RB prevented/VBN by/IN a/DT previous/JJ (/( 24/CD hours/NNS earlier/RBR )/) exposure/NN of/IN HUVECs/NNS to/TO A/R/NN ./. 
This/DT phenomenon/NN has/VBZ been/VBN termed/VBN "/`` A/R/NN tolerance/NN ./. "/'' 
Exposing/VBG HUVECs/NNS to/TO A/R/NN induces/VBZ an/DT increase/NN in/IN nuclear/JJ factor/NN kappaB/NN (/( NF-kappaB/NN )/) in/IN HUVEC/NN nuclei/NNS within/IN 4/CD hours/NNS ./. 
Interfering/VBG with/IN either/CC NF-kappaB/NN activation/NN (/( proteasome/NN inhibitor/NN )/) or/CC translocation/NN (/( double-stranded/JJ oligonucleotides/NNS containing/VBG NF-kappaB/NN binding/NN sequence/NN )/) prevents/VBZ the/DT development/NN of/IN A/R/NN tolerance/NN (/( ie/FW ,/, the/DT increase/NN in/IN A/R-induced/JJ PMN/NN adhesion/NN to/TO HUVECs/NNS is/VBZ the/DT same/JJ after/IN the/DT first/JJ and/CC second/JJ A/R/NN challenges/NNS )/) ./. 
NO/NN production/NN by/IN HUVECs/NNS is/VBZ increased/VBN after/IN the/DT second/JJ A/R/NN challenge/NN ,/, but/CC not/RB after/IN the/DT first/JJ A/R/NN challenge/NN ./. 
Inhibition/NN of/IN NO/DT synthase/NN (/( NOS/NN )/) during/IN the/DT second/JJ A/R/NN challenge/NN prevents/VBZ the/DT development/NN of/IN A/R/NN tolerance/NN with/IN respect/NN to/TO PMN/NN adhesion/NN ./. 
However/RB ,/, while/IN HUVECs/NNS contained/VBD endothelial/JJ NOS/NN protein/NN ,/, no/DT inducible/JJ NOS/NN was/VBD detected/VBN in/IN either/CC tolerant/JJ or/CC nontolerant/JJ cells/NNS ./. 
Further/JJ studies/NNS indicated/VBD that/IN inhibition/NN of/IN GTP-cyclohydrolase/NN I/CD (/( an/DT enzyme/NN involved/VBN in/IN de/FW novo/FW synthesis/NN of/IN an/DT important/JJ cofactor/NN for/IN NOS/NN activity/NN ,/, tetrahydrobiopterin/NN )/) prevented/VBD the/DT generation/NN of/IN NO/NN in/IN A/R-tolerant/JJ cells/NNS ./. 
Extracellular/JJ generation/NN of/IN NO/NN (/( NO/NN donor/NN )/) did/VBD not/RB effect/VB the/DT hyperadhesion/NN response/NN induced/VBN by/IN the/DT initial/JJ A/R/NN challenge/NN ./. 
A/R/NN also/RB induced/VBD an/DT oxidant/JJ stress/NN in/IN naive/JJ HUVECs/NNS ,/, but/CC not/RB in/IN A/R-tolerant/JJ HUVECs/NNS ./. 
Inhibition/NN of/IN NOS/NN during/IN the/DT second/JJ A/R/NN insult/NN results/VBZ in/IN the/DT generation/NN of/IN an/DT oxidant/JJ stress/NN similar/JJ to/TO that/DT observed/VBN after/IN the/DT first/JJ A/R/NN challenge/NN ./. 
Taken/VBN together/RB ,/, the/DT findings/NNS of/IN the/DT present/JJ study/NN are/VBP consistent/JJ with/IN a/DT role/NN for/IN NF-kappaB/NN in/IN the/DT development/NN of/IN A/R/NN tolerance/NN (/( with/IN respect/NN to/TO PMN/NN adhesion/NN )/) ,/, perhaps/RB by/IN transcriptional/JJ regulation/NN of/IN GTP-cyclohydrolase/NN ./. 
The/DT increased/VBN NO/NN production/NN during/IN the/DT second/JJ A/R/NN insult/NN reduces/VBZ PMN/NN adhesion/NN most/RBS likely/RB by/IN reducing/VBG the/DT intracellular/JJ oxidant/JJ stress/NN induced/VBN by/IN A/R/NN ./. 
UI/LS -/: 99102085/CD 
TI/LS -/: Mildly/RB oxidized/VBN low-density/JJ lipoproteins/NNS decrease/VBP early/JJ production/NN of/IN interleukin/NN 2/CD and/CC nuclear/JJ factor/NN kappaB/NN binding/VBG to/TO DNA/NN in/IN activated/VBN T-/NN lymphocytes/NNS ./. 
AB/LS -/: Activated/VBN T-lymphocytes/NNS are/VBP found/VBN early/RB in/IN atherosclerosis/NN lesions/NNS ,/, but/CC little/JJ is/VBZ known/VBN about/IN their/PRP$ role/NN ./. 
Oxidized/VBN low-density/JJ lipoproteins/NNS (/( oxLDLs/NNS )/) are/VBP considered/VBN to/TO be/VB involved/VBN in/IN the/DT pathogenesis/NN of/IN the/DT lesions/NNS ,/, and/CC we/PRP have/VBP previously/RB demonstrated/VBN that/IN oxLDLs/NNS inhibit/VBP not/RB only/RB interleukin/NN (/( IL/NN )/) -2-receptor/NN expression/NN on/IN the/DT surface/NN of/IN in/FW vitro-activated/JJ T-lymphocytes/NNS but/CC also/RB their/PRP$ proliferation/NN ./. 
We/PRP have/VBP now/RB investigated/VBN the/DT effect/NN of/IN oxLDLs/NNS on/IN blast/NN differentiation/NN ,/, on/IN IL-2/NN synthesis/NN and/CC on/IN the/DT activation/NN of/IN the/DT nuclear/JJ factor/NN kappaB/NN (/( NF-kappaB/NN )/) system/NN in/IN activated/VBN lymphocytes/NNS ./. 
Mildly/RB oxLDLs/NNS (/( 50/CD and/CC 100/CD microgram/ml/NN )/) decreased/VBD the/DT number/NN of/IN lymphoblasts/NNS and/CC the/DT level/NN of/IN IL-2/NN concentration/NN in/IN the/DT culture/NN supernatants/NNS after/IN activation/NN of/IN lymphocytes/NNS by/IN phytohaemagglutinin/NN and/CC PMA+ionomycin/NN ./. 
The/DT inhibition/NN of/IN IL-2/NN production/NN was/VBD observed/VBN in/IN the/DT CD3(+)/JJ T-lymphocyte/NN cytoplasm/NN as/RB early/RB as/IN 4/CD h/NN after/IN activation/NN by/IN PMA+ionomycin/NN ./. 
The/DT study/NN of/IN NF-kappaB/NN showed/VBD that/IN oxLDLs/NNS led/VBD to/TO a/DT decrease/NN of/IN activation-induced/JJ p65/p50/NN NF-kappaB/NN heterodimer/NN binding/NN to/TO DNA/NN ,/, whereas/IN the/DT presence/NN of/IN the/DT constitutive/JJ nuclear/JJ form/NN of/IN p50/NN dimer/NN was/VBD unchanged/JJ ./. 
This/DT was/VBD correlated/VBN with/IN an/DT unchanged/JJ level/NN of/IN the/DT active/JJ form/NN of/IN the/DT cytosolic/JJ inhibitor/NN protein/NN IkappaB-alpha/NN ./. 
Taken/VBN together/RB ,/, these/DT observations/NNS suggest/VB that/IN the/DT immunosuppressive/JJ effect/NN of/IN oxLDLs/NNS might/MD operate/VB via/IN a/DT dysregulation/NN of/IN the/DT T-lymphocyte/NN activation/NN mechanisms/NNS ./. 
UI/LS -/: 99077977/CD 
TI/LS -/: The/DT B29/NN (/( immunoglobulin/NN beta-chain/NN )/) gene/NN is/VBZ a/DT genetic/JJ target/NN for/IN early/JJ B-cell/NN factor/NN ./. 
AB/LS -/: Early/JJ B-cell/NN factor/NN (/( EBF/NN )/) is/VBZ a/DT transcription/NN factor/NN suggested/VBN as/IN essential/JJ for/IN early/JJ B-lymphocyte/NN development/NN by/IN findings/NNS in/IN mice/NNS where/WRB the/DT coding/VBG gene/NN has/VBZ been/VBN inactivated/VBN by/IN homologous/JJ disruption/NN ./. 
This/DT makes/VBZ the/DT identification/NN of/IN genetic/JJ targets/NNS for/IN this/DT transcription/NN factor/NN pertinent/JJ for/IN the/DT understanding/NN of/IN early/JJ B-cell/NN development/NN ./. 
The/DT lack/NN of/IN B29/NN transcripts/NNS ,/, coding/VBG for/IN the/DT beta/NN subunit/NN of/IN the/DT B-cell/NN receptor/NN complex/NN ,/, in/IN pro-B/JJ cells/NNS from/IN EBF-deficient/JJ mice/NNS suggested/VBD that/IN B29/NN might/MD be/VB a/DT genetic/JJ target/NN for/IN EBF/NN ./. 
We/PRP here/RB present/VBP data/NNS suggesting/VBG that/IN EBF/NN interacts/VBZ with/IN three/CD independent/JJ sites/NNS within/IN the/DT mouse/NN B29/NN promoter/NN ./. 
Furthermore/RB ,/, ectopic/JJ expression/NN of/IN EBF/NN in/IN HeLa/NN cells/NNS activated/VBD a/DT B29/NN promoter-controlled/JJ reporter/NN construct/NN 13-fold/RB and/CC induced/VBD a/DT low/JJ level/NN of/IN expression/NN from/IN the/DT endogenous/JJ B29/NN gene/NN ./. 
Finally/RB ,/, mutations/NNS in/IN the/DT EBF/NN binding/NN sites/NNS diminished/VBD B29/NN promoter/NN activity/NN in/IN pre-B/JJ cells/NNS while/IN the/DT same/JJ mutations/NNS did/VBD not/RB have/VB as/IN striking/JJ an/DT effect/NN on/IN the/DT promoter/NN function/NN in/IN B-cell/NN lines/NNS of/IN later/JJ differentiation/NN stages/NNS ./. 
These/DT data/NNS suggest/VBP that/IN the/DT B29/NN gene/NN is/VBZ a/DT genetic/JJ target/NN for/IN EBF/NN in/IN early/JJ B-cell/NN development/NN ./. 
UI/LS -/: 98208262/CD 
TI/LS -/: Delta-opioid/JJ receptors/NNS expressed/VBN by/IN Jurkat/NN T/NN cells/NNS enhance/VBP IL-2/NN secretion/NN by/IN increasing/VBG AP-1/NN complexes/NNS and/CC activity/NN of/IN the/DT NF-AT/AP-1-binding/JJ promoter/NN element/NN ./. 
AB/LS -/: Recent/JJ molecular/JJ evidence/NN points/VBZ to/TO transient/JJ and/or/CC stage-specific/JJ expression/NN of/IN delta-/NN and/CC kappa-opioid/JJ receptors/NNS by/IN thymic/JJ and/CC peripheral/JJ T/NN lymphocytes/NNS ./. 
Since/IN medical/JJ treatments/NNS or/CC stress/NN commonly/RB increase/VBP opioid/JJ levels/NNS ,/, it/PRP is/VBZ important/JJ to/TO understand/VB the/DT mechanisms/NNS by/IN which/WDT opioids/NNS affect/VBP T/NN lymphocyte/NN functions/NNS ./. 
We/PRP therefore/RB created/VBD and/CC studied/VBD a/DT T/NN cell/NN line/NN expressing/VBG the/DT cloned/VBN delta-opioid/JJ receptor/NN (/( DOR1/NN )/) ./. 
DOR1/NN ligation/NN by/IN a/DT specific/JJ DOR1/NN agonist/NN ,/, deltorphin/NN ,/, augmented/VBD IL-2/NN secretion/NN by/IN synergizing/VBG with/IN signals/NNS from/IN TCR-CD3/NN and/CC CD28/NN ./. 
Reporter/NN gene/NN constructs/NNS were/VBD used/VBN to/TO map/VB this/DT effect/NN of/IN deltorphin/NN to/TO the/DT AP-1-/NN and/CC NF-AT/AP-1-binding/JJ sites/NNS of/IN the/DT IL-2/NN promoter/NN ./. 
Although/IN DOR1/NN signaling/NN increased/VBD [Ca2+]i/NN ,/, deltorphin/NN enhanced/VBD transcriptional/JJ activity/NN of/IN the/DT NF-AT/AP-1-binding/JJ site/NN via/IN a/DT mechanism/NN independent/JJ of/IN calcineurin/NN and/CC distinct/JJ from/IN the/DT effects/NNS of/IN elevated/JJ [Ca2+]i/NN ./. 
Deltorphin/NN also/RB increased/VBD accumulation/NN of/IN AP-1/NN transcription/NN factor/NN complexes/NNS ,/, suggesting/VBG that/IN DOR1/NN augments/VBZ IL-2/NN secretion/NN by/IN increasing/VBG the/DT AP-1/NN component/NN of/IN the/DT NF-AT/AP-1/NN transcription/NN factor/NN ./. 
These/DT results/NNS advance/VBP the/DT molecular/JJ understanding/NN of/IN opioid/JJ effects/NNS on/IN lymphocytes/NNS ,/, and/CC in/IN addition/NN ,/, demonstrate/VBP regulation/NN of/IN IL-2/NN synthesis/NN and/CC secretion/NN by/IN the/DT novel/JJ mechanism/NN of/IN receptor-mediated/JJ AP-1/NN induction/NN ./. 
UI/LS -/: 98124483/CD 
TI/LS -/: Induction/NN of/IN interleukin-12/NN p40/NN transcript/NN by/IN CD40/NN ligation/NN via/IN activation/NN of/IN nuclear/JJ factor-kappaB/NN ./. 
AB/LS -/: Interleukin-12/NN is/VBZ produced/VBN in/IN response/NN to/TO infection/NN with/IN bacteria/NNS or/CC parasites/NNS or/CC to/TO bacterial/JJ constituents/NNS such/JJ as/IN LPS/NN in/IN monocytes/macrophages/NNS and/CC dendritic/JJ cells/NNS ,/, and/CC also/RB generated/VBN by/IN the/DT interaction/NN between/IN activated/VBN T/NN cells/NNS and/CC antigen-presenting/JJ cells/NNS via/IN CD40-CD40/NN ligand/NN (/( CD40L/NN )/) ./. 
So/RB far/RB ,/, transcriptional/JJ analyses/NNS of/IN p40/NN have/VBP been/VBN carried/VBN out/RP only/RB using/VBG bacterial/JJ constituents/NNS such/JJ as/IN LPS/NN as/IN stimuli/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP have/VBP characterized/VBN the/DT transcriptional/JJ induction/NN of/IN p40/NN by/IN CD40/NN ligation/NN in/IN a/DT human/JJ B/NN lymphoblastoid/JJ cell/NN line/NN ,/, Daudi/NN ,/, and/CC a/DT human/JJ acute/JJ monocytic/JJ leukemia/NN cell/NN line/NN ,/, THP-1/NN ./. 
These/DT cells/NNS ,/, stimulated/VBN by/IN an/DT agonistic/JJ monoclonal/JJ antibody/NN against/IN CD40/NN or/CC by/IN transfection/NN with/IN a/DT CD40L/NN expression/NN vector/NN ,/, secreted/VBD p40/NN and/CC showed/VBD enhanced/VBN p40/NN mRNA/NN expression/NN ./. 
Sequence/NN analysis/NN of/IN the/DT p40/NN promoter/NN region/NN identified/VBD two/CD potential/JJ nuclear/JJ factor/NN (/( NF/NN )/) -kappaB/NN binding/NN sites/NNS conserved/VBN between/IN mouse/NN and/CC human/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assay/NN revealed/VBD that/IN the/DT potential/JJ NF-kappaB/NN binding/NN sequence/NN which/WDT is/VBZ located/JJ around/IN 120/CD bp/NN upstream/RB of/IN the/DT transcription/NN initiation/NN site/NN in/IN murine/JJ and/CC human/JJ p40/NN genes/NNS formed/VBD an/DT NF-kappaB/NN complex/NN with/IN nuclear/JJ extract/NN from/IN Daudi/NN cells/NNS stimulated/VBN by/IN CD40/NN ligation/NN ./. 
Moreover/RB ,/, transfection/NN of/IN Daudi/NN cells/NNS with/IN the/DT polymerized/JJ NF-kappaB/NN binding/NN sequence/NN ligated/VBN to/TO a/DT thymidine/NN kinase/chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) reporter/NN plasmid/NN greatly/RB induced/VBD CAT/NN activity/NN ,/, but/CC transfection/NN with/IN the/DT polymerized/JJ mutated/VBN NF-kappaB/NN binding/NN sequence/NN did/VBD not/RB ./. 
These/DT results/NNS suggest/VBP that/IN the/DT NF-kappaB/NN binding/NN site/NN located/JJ around/IN 120/CD bp/NN upstream/RB of/IN the/DT transcription/NN initiation/NN site/NN in/IN murine/JJ and/CC human/JJ p40/NN promoter/NN regions/NNS could/MD be/VB important/JJ for/IN the/DT p40/NN induction/NN by/IN CD40/NN ligation/NN via/IN activation/NN of/IN NF-kappaB/NN ./. 
UI/LS -/: 99168501/CD 
TI/LS -/: High/JJ frequency/NN of/IN germ-line/NN BRCA2/NN mutations/NNS among/IN Hungarian/JJ male/JJ breast/NN cancer/NN patients/NNS without/IN family/NN history/NN ./. 
AB/LS -/: To/TO determine/VB the/DT contribution/NN of/IN BRCA1/NN and/CC BRCA2/NN mutations/NNS to/TO the/DT pathogenesis/NN of/IN male/JJ breast/NN cancer/NN in/IN Hungary/NNP ,/, the/DT country/NN with/IN the/DT highest/JJS male/JJ breast/NN cancer/NN mortality/NN rates/NNS in/IN continental/JJ Europe/NN ,/, a/DT series/NN of/IN 18/CD male/JJ breast/NN cancer/NN patients/NNS and/CC three/CD patients/NNS with/IN gynecomastia/NN was/VBD analyzed/VBN for/IN germ-line/NN mutations/NNS in/IN both/CC BRCA1/NN and/CC BRCA2/NN ./. 
Although/IN no/DT germ-line/NN BRCA1/NN mutation/NN was/VBD observed/VBN ,/, 6/CD of/IN the/DT 18/CD male/JJ breast/NN cancer/NN cases/NNS (/( 33/CD %/NN )/) carried/VBD truncating/JJ mutations/NNS in/IN the/DT BRCA2/NN gene/NN ./. 
Unexpectedly/RB ,/, none/NN of/IN them/PRP reported/VBD a/DT family/NN history/NN for/IN breast/ovarian/JJ cancer/NN ./. 
Four/CD of/IN six/CD truncating/JJ mutations/NNS were/VBD novel/JJ ,/, and/CC two/CD mutations/NNS were/VBD recurrent/JJ ./. 
Four/CD patients/NNS (/( 22/CD %/NN )/) had/VBD a/DT family/NN history/NN of/IN breast/ovarian/JJ cancer/NN in/IN at/IN least/JJS one/CD first-/JJ or/CC second-degree/JJ relative/JJ ;/: however/RB ,/, no/DT BRCA2/NN mutation/NN was/VBD identified/VBN among/IN them/PRP ./. 
No/DT mutation/NN was/VBD identified/VBN in/IN either/DT of/IN the/DT genes/NNS in/IN the/DT gynecomastias/NNS ./. 
These/DT results/NNS provide/VBP evidence/NN for/IN a/DT strong/JJ genetic/JJ component/NN of/IN male/JJ breast/NN cancer/NN in/IN Hungary/NNP ./. 
UI/LS -/: 99156941/CD 
TI/LS -/: T-cell/NN expression/NN of/IN the/DT human/JJ GATA-3/NN gene/NN is/VBZ regulated/VBN by/IN a/DT non-lineage-specific/JJ silencer/NN ./. 
AB/LS -/: The/DT GATA-3/NN transcription/NN factor/NN is/VBZ required/VBN for/IN development/NN of/IN the/DT T-cell/NN lineage/NN and/CC Th2/NN cytokine/NN gene/NN expression/NN in/IN CD4/NN T-cells/NNS ./. 
We/PRP have/VBP mapped/VBN the/DT DNase-I-hypersensitive/JJ (/( HS/JJ )/) regions/NNS of/IN the/DT human/JJ GATA-3/NN gene/NN in/IN T-cells/NNS and/CC non-T-cells/NNS and/CC studied/VBD their/PRP$ transcriptional/JJ activities/NNS ./. 
HS/NN I-III/CD ,/, located/JJ 5'/RB from/IN the/DT transcriptional/JJ initiation/NN site/NN ,/, were/VBD found/VBN in/IN hematopoietic/JJ and/CC non-hematopoietic/JJ cells/NNS ,/, whereas/IN HS/NN IV-VII/CD ,/, located/JJ 3'/RB from/IN the/DT transcriptional/JJ start/NN site/NN ,/, were/VBD exclusively/RB observed/VBN in/IN T-cells/NNS ./. 
Among/IN these/DT hypersensitive/JJ sites/NNS ,/, two/CD transcriptional/JJ control/NN elements/NNS were/VBD found/VBN ,/, one/CD in/IN the/DT first/JJ intron/NN of/IN the/DT GATA-3/NN gene/NN and/CC the/DT other/JJ between/IN 8.3/CD and/CC 5.9/CD kilobases/NNS 5'/JJ from/IN the/DT GATA-3/NN transcriptional/JJ initiation/NN site/NN ./. 
The/DT first/JJ intron/NN acted/VBD as/IN a/DT strong/JJ transcriptional/JJ activator/NN in/IN a/DT position-dependent/JJ manner/NN and/CC with/IN no/DT cell-type/JJ specificity/NN ./. 
The/DT upstream/JJ regulatory/JJ element/NN could/MD confer/VB T-cell/NN specificity/NN to/TO the/DT GATA-3/NN promoter/NN activity/NN ,/, and/CC analysis/NN of/IN this/DT region/NN revealed/VBD a/DT 707-base/JJ pair/NN silencer/NN that/WDT drastically/RB inhibited/VBD GATA-3/NN promoter/NN activity/NN in/IN non-T-cells/NNS ./. 
Two/CD CAGGTG/NN E-boxes/NNS ,/, located/JJ at/IN the/DT 5'-/JJ and/CC 3'-ends/NNS of/IN the/DT silencer/NN ,/, were/VBD necessary/JJ for/IN this/DT silencer/NN activity/NN ./. 
The/DT 3'-CAGGTG/NN E-box/NN could/MD bind/VB USF/NN proteins/NNS ,/, the/DT ubiquitous/JJ repressor/NN ZEB/NN ,/, or/CC the/DT basic/JJ helix-loop-helix/JJ proteins/NNS E2A/NN and/CC HEB/NN ,/, and/CC we/PRP showed/VBD that/IN a/DT competition/NN between/IN ZEB/NN and/CC E2A/HEB/NN proteins/NNS is/VBZ involved/VBN in/IN the/DT silencer/NN activity/NN ./. 
UI/LS -/: 99147030/CD 
TI/LS -/: Reactive/JJ oxygen/NN intermediate-dependent/JJ NF-kappaB/NN activation/NN by/IN interleukin-1beta/NN requires/VBZ 5-lipoxygenase/NN or/CC NADPH/NN oxidase/NN activity/NN ./. 
AB/LS -/: We/PRP previously/RB reported/VBD that/IN the/DT role/NN of/IN reactive/JJ oxygen/NN intermediates/NNS (/( ROIs/NNS )/) in/IN NF-kappaB/NN activation/NN by/IN proinflammatory/JJ cytokines/NNS was/VBD cell/NN specific/JJ ./. 
However/RB ,/, the/DT sources/NNS for/IN ROIs/NNS in/IN various/JJ cell/NN types/NNS are/VBP yet/RB to/TO be/VB determined/VBN and/CC might/MD include/VB 5-lipoxygenase/NN (/( 5-LOX/NN )/) and/CC NADPH/NN oxidase/NN ./. 
5-LOX/NN and/CC 5-LOX/NN activating/NN protein/NN (/( FLAP/NN )/) are/VBP coexpressed/VBN in/IN lymphoid/JJ cells/NNS but/CC not/RB in/IN monocytic/JJ or/CC epithelial/JJ cells/NNS ./. 
Stimulation/NN of/IN lymphoid/JJ cells/NNS with/IN interleukin-1beta/NN (/( IL-1beta/NN )/) led/VBD to/TO ROI/NN production/NN and/CC NF-kappaB/NN activation/NN ,/, which/WDT could/MD both/DT be/VB blocked/VBN by/IN antioxidants/NNS or/CC FLAP/NN inhibitors/NNS ,/, confirming/VBG that/IN 5-LOX/NN was/VBD the/DT source/NN of/IN ROIs/NNS and/CC was/VBD required/VBN for/IN NF-kappaB/NN activation/NN in/IN these/DT cells/NNS ./. 
IL-1beta/NN stimulation/NN of/IN epithelial/JJ cells/NNS did/VBD not/RB generate/VB any/DT ROIs/NNS and/CC NF-kappaB/NN induction/NN was/VBD not/RB influenced/VBN by/IN 5-LOX/NN inhibitors/NNS ./. 
However/RB ,/, reintroduction/NN of/IN a/DT functional/JJ 5-LOX/NN system/NN in/IN these/DT cells/NNS allowed/VBD ROI/NN production/NN and/CC 5-LOX-dependent/JJ NF-kappaB/NN activation/NN ./. 
In/IN monocytic/JJ cells/NNS ,/, IL-1beta/NN treatment/NN led/VBD to/TO a/DT production/NN of/IN ROIs/NNS which/WDT is/VBZ independent/JJ of/IN the/DT 5-LOX/NN enzyme/NN but/CC requires/VBZ the/DT NADPH/NN oxidase/NN activity/NN ./. 
This/DT pathway/NN involves/VBZ the/DT Rac1/NN and/CC Cdc42/NN GTPases/NN ,/, two/CD enzymes/NNS which/WDT are/VBP not/RB required/VBN for/IN NF-kappaB/NN activation/NN by/IN IL-1beta/NN in/IN epithelial/JJ cells/NNS ./. 
In/IN conclusion/NN ,/, three/CD different/JJ cell-specific/JJ pathways/NNS lead/VBP to/TO NF-kappaB/NN activation/NN by/IN IL-1beta/NN :/: a/DT pathway/NN dependent/JJ on/IN ROI/NN production/NN by/IN 5-LOX/NN in/IN lymphoid/JJ cells/NNS ,/, an/DT ROI-/NN and/CC 5-LOX-independent/JJ pathway/NN in/IN epithelial/JJ cells/NNS ,/, and/CC a/DT pathway/NN requiring/VBG ROI/NN production/NN by/IN NADPH/NN oxidase/NN in/IN monocytic/JJ cells/NNS ./. 
UI/LS -/: 99138796/CD 
TI/LS -/: Cutting/JJ edge/NN :/: dominant/JJ effect/NN of/IN Ile50Val/NN variant/NN of/IN the/DT human/JJ IL-4/NN receptor/NN alpha-chain/NN in/IN IgE/NN synthesis/NN ./. 
AB/LS -/: Two/CD variants/NNS of/IN the/DT IL-4R/NN alpha-chain/NN (/( IL-4Ralpha/NN )/) gene/NN have/VBP been/VBN recently/RB identified/VBN in/IN association/NN with/IN different/JJ atopic/JJ disorders/NNS ./. 
To/TO clarify/VB the/DT etiological/JJ relationship/NN between/IN the/DT two/CD variants/NNS ,/, we/PRP analyzed/VBD responsiveness/NN to/TO IL-4/NN of/IN transfectants/NNS with/IN four/CD kinds/NNS of/IN IL-4Ralpha/NN carrying/VBG either/CC Val/NN or/CC Ile/NN at/IN 50/CD and/CC either/CC Gln/NN or/CC Arg/NN at/IN 551/CD ./. 
The/DT substitution/NN of/IN Ile/NN for/IN Val/NN augmented/VBD STAT6/NN activation/NN ,/, proliferation/NN ,/, and/CC transcription/NN activity/NN of/IN the/DT Iepsilon/NN promoter/NN by/IN IL-4/NN ,/, whereas/IN that/DT of/IN Arg/NN for/IN Gln/NN did/VBD not/RB change/VB these/DT IL-4/NN signals/NNS ./. 
Arg551/NN was/VBD not/RB associated/VBN with/IN atopic/JJ asthma/NN in/IN the/DT Japanese/JJ population/NN ./. 
CD23/NN expression/NN and/CC IgE/NN synthesis/NN by/IN IL-4/NN were/VBD augmented/JJ in/IN Ile50-bearing/JJ PBMC/NN ,/, compared/VBN with/IN those/DT bearing/VBG Val50/NN ./. 
Taken/VBN together/RB ,/, substitution/NN of/IN Arg551/NN does/VBZ not/RB enhance/VB the/DT IL-4/NN signal/NN for/IN generation/NN of/IN germline/NN epsilon/NN transcript/NN ,/, whereas/IN the/DT substitution/NN of/IN Ile50/NN contributes/VBZ to/TO enhancement/NN of/IN IgE/NN synthesis/NN ./. 
UI/LS -/: 99120322/CD 
TI/LS -/: A/DT novel/JJ growth-factor-dependent/JJ myeloid/JJ cell/NN line/NN derived/VBN from/IN mouse/NN bone/NN marrow/NN cells/NNS contains/VBZ progenitors/NNS endowed/JJ with/IN high/JJ proliferative/JJ potential/NN ./. 
AB/LS -/: Constitutive/JJ expression/NN of/IN human/JJ colony-stimulating/JJ factor-1/NN receptor/NN (/( CSF-1R/NN )/) confers/VBZ long-lasting/JJ CSF-1-dependent/JJ proliferation/NN to/TO mouse/NN myeloid/JJ cell/NN lines/NNS ./. 
We/PRP developed/VBD mice/NNS transgenic/JJ for/IN human/JJ CSF-1R/NN because/IN mouse/NN CSF-1/NN can/MD not/RB activate/VB human/JJ CSF-1R/NN ./. 
Then/RB bone/NN marrow/NN cells/NNS from/IN transgenic/JJ mice/NNS were/VBD plated/VBN onto/IN MS-5/NN stromal/JJ cells/NNS expressing/VBG the/DT membrane/NN form/NN of/IN human/JJ CSF-1/NN (/( 2M-1/NN cells/NNS )/) in/IN order/NN to/TO combine/VB the/DT hematopoietic/JJ supporting/NN properties/NNS of/IN stromal/JJ cells/NNS and/CC the/DT proliferative/JJ effects/NNS of/IN CSF-1/NN ./. 
Thus/RB ,/, we/PRP were/VBD able/JJ to/TO derive/VB a/DT hematopoietic/JJ cell/NN line/NN ,/, called/VBN 47.10/CD ,/, that/WDT grew/VBD indefinitely/RB under/IN these/DT conditions/NNS ,/, whereas/IN no/DT cell/NN line/NN could/MD be/VB developed/VBN from/IN nontransgenic/JJ mice/NNS ./. 
Proliferation/NN of/IN 47.10/CD cells/NNS is/VBZ severely/RB affected/VBN by/IN neutralizing/VBG anti-CSF-1R/JJ monoclonal/JJ antibodies/NNS ./. 
Morphologic/JJ and/CC cytofluorometry/NN analysis/NN established/VBD that/IN most/JJS 47.10/CD cells/NNS are/VBP immature/JJ myelomonocytic/JJ cells/NNS ./. 
Consistent/JJ with/IN this/DT phenotype/NN ,/, the/DT myeloid/JJ transcription/NN factor/NN PU.1/NN ,/, but/CC not/RB the/DT erythroid/JJ transcription/NN factor/NN GATA-1/NN ,/, is/VBZ expressed/VBN in/IN 47.10/CD cells/NNS ./. 
A/DT few/JJ 47.10/CD cells/NNS (/( 3-5/CD %/NN )/) do/VBP not/RB express/VB lineage/NN specific/JJ markers/NNS ;/: they/PRP differentiate/VBP spontaneously/RB to/TO lineage-positive/JJ cells/NNS after/IN replating/VBG on/IN 2M-1/NN cells/NNS ./. 
In/IN agar/NN cultures/NNS ,/, 47.10/CD cells/NNS form/VBP 7-/CD and/CC 14-day/JJ colonies/NNS in/IN response/NN to/TO a/DT cocktail/NN of/IN granulocyte/macrophage/NN colony-stimulating/JJ factor/NN (/( 2.5/CD ng/mL/NN )/) ,/, interleukin-3/NN (/( 1/CD ng/mL/NN )/) ,/, and/CC mouse/NN CSF-1/NN (/( 10/CD ng/mL/NN )/) ./. 
Under/IN these/DT conditions/NNS ,/, about/RB 0.5/CD %/NN of/IN 47.10/CD cells/NNS formed/VBD large/JJ 14-day/JJ colonies/NNS (/( >/JJR 1/CD mm/NN )/) composed/VBN of/IN mature/JJ monocytes/NNS and/CC granulocytes/NNS ,/, reflecting/VBG the/DT presence/NN of/IN progenitors/NNS endowed/JJ with/IN high/JJ proliferative/JJ potential/NN (/( HPP-47.10/CD cells/NNS )/) ./. 
In/IN conclusion/NN ,/, we/PRP have/VBP characterized/VBN a/DT novel/JJ continuous/JJ myeloid/JJ cell/NN line/NN presenting/VBG a/DT hierarchical/JJ structure/NN similar/JJ to/TO that/DT of/IN the/DT bone/NN marrow/NN progenitor/NN cell/NN compartment/NN ./. 
UI/LS -/: 99107758/CD 
TI/LS -/: Regulation/NN of/IN IL-4/NN expression/NN by/IN the/DT transcription/NN factor/NN JunB/NN during/IN T/NN helper/NN cell/NN differentiation/NN ./. 
AB/LS -/: The/DT molecular/JJ basis/NN for/IN restricted/JJ cytokine/NN expression/NN by/IN T/NN helper/NN 1/CD (/( Th1/NN )/) and/CC T/NN helper/NN 2/CD (/( Th2/NN )/) cells/NNS is/VBZ unclear/JJ ./. 
Previous/JJ studies/NNS found/VBD that/IN P1/NN ,/, an/DT element/NN of/IN the/DT interleukin/NN 4/CD (/( IL-4/NN )/) promoter/NN that/WDT binds/VBZ AP-1/NN ,/, is/VBZ important/JJ for/IN Th2-restricted/JJ IL-4/NN expression/NN ./. 
Here/RB we/PRP show/VBP that/IN JunB/NN ,/, but/CC not/RB the/DT other/JJ Jun/NN family/NN members/NNS ,/, was/VBD selectively/RB induced/VBN in/IN Th2/NN cells/NNS and/CC not/RB in/IN Th1/NN cells/NNS during/IN differentiation/NN ./. 
JunB/NN has/VBZ previously/RB been/VBN considered/VBN to/TO be/VB a/DT negative/JJ regulator/NN of/IN transcription/NN ./. 
However/RB ,/, we/PRP show/VBP that/IN JunB/NN binds/VBZ directly/RB to/TO the/DT P1/NN site/NN and/CC synergizes/VBZ with/IN c-Maf/NN to/TO activate/VB an/DT IL-4/NN luciferase/NN reporter/NN gene/NN ./. 
JunB-control/NN of/IN IL-4/NN expression/NN is/VBZ mediated/VBN by/IN the/DT phosphorylation/NN of/IN JunB/NN at/IN Thr102/NN and/CC -104/CD by/IN JNK/NN MAP/NN kinase/NN ./. 
The/DT synergy/NN between/IN c-Maf/NN and/CC JunB/NN can/MD be/VB attributed/VBN to/TO cooperative/JJ DNA/NN binding/NN ,/, which/WDT is/VBZ facilitated/VBN by/IN JunB/NN phosphorylation/NN ./. 
In/IN transgenic/JJ mice/NNS ,/, elevated/JJ JunB/NN levels/NNS caused/VBD increased/VBN expression/NN of/IN several/JJ Th2/NN cytokines/NNS in/IN developing/VBG Th1/NN cells/NNS ./. 
JunB/NN also/RB upregulated/VBD IL-4/NN expression/NN in/IN response/NN to/TO immunization/NN ./. 
Thus/RB ,/, the/DT early/JJ increase/NN of/IN JunB/NN protein/NN in/IN Th2/NN cells/NNS can/MD provide/VB the/DT specificity/NN for/IN c-Maf/NN in/IN IL-4/NN expression/NN during/IN T/NN cell/NN development/NN and/CC directs/VBZ thereby/RB Th2/NN differentiation/NN ./. 
UI/LS -/: 99099017/CD 
TI/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD tax/NN protein/NN abrogates/VBZ interleukin-2/NN dependence/NN in/IN a/DT mouse/NN T-cell/NN line/NN ./. 
AB/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) is/VBZ the/DT etiologic/JJ agent/NN of/IN adult/JJ T-cell/NN leukemia/NN ./. 
Tax/NN ,/, the/DT viral/JJ protein/NN ,/, is/VBZ thought/VBN to/TO be/VB crucial/JJ in/IN the/DT development/NN of/IN the/DT disease/NN ,/, since/IN it/PRP transforms/VBZ healthy/JJ T/NN cells/NNS in/FW vitro/FW and/CC induces/VBZ tumors/NNS in/IN transgenic/JJ animals/NNS ./. 
We/PRP examined/VBD the/DT effect/NN of/IN Tax/NN activity/NN on/IN the/DT growth/NN of/IN the/DT interleukin-2/NN (/( IL-2/NN )/) -dependent/JJ T-cell/NN line/NN CTLL-2/NN ./. 
Stable/JJ expression/NN of/IN Tax/NN in/IN CTLL-2/NN transformed/VBD cell/NN growth/NN from/IN being/VBG IL-2/NN dependent/JJ to/TO IL-2/NN independent/JJ ./. 
Tax/NN stimulated/VBD transcription/NN through/IN NF-kappaB/NN and/CC the/DT cyclic/JJ AMP-responsive/JJ element-like/JJ sequence/NN in/IN the/DT HTLV-1/NN promoter/NN ./. 
The/DT finding/NN of/IN Tax/NN mutants/NNS segregating/VBG these/DT two/CD pathways/NNS suggested/VBD that/IN the/DT NF-kappaB/NN pathway/NN was/VBD essential/JJ for/IN IL-2-independent/JJ growth/NN of/IN CTLL-2/NN cells/NNS while/IN the/DT CRE/NN pathway/NN was/VBD unnecessary/JJ ./. 
However/RB ,/, both/DT pathways/NNS were/VBD necessary/JJ for/IN another/DT transformation-related/JJ activity/NN (/( colony/NN formation/NN in/IN soft/JJ agar/NN )/) of/IN CTLL-2/Tax/NN ./. 
Our/PRP$ results/NNS show/VBP that/IN Tax/NN has/VBZ at/IN least/JJS two/CD distinct/JJ activities/NNS on/IN T/NN cells/NNS ,/, and/CC suggest/VBP that/IN Tax/NN plays/VBZ a/DT crucial/JJ role/NN in/IN IL-2-independent/JJ T-cell/NN transformation/NN induced/VBN by/IN HTLV-1/NN ,/, in/IN addition/NN to/TO its/PRP$ well-known/JJ IL-2-dependent/JJ cell/NN transformation/NN ./. 
UI/LS -/: 99102590/CD 
TI/LS -/: Accessing/VBG Epstein-Barr/JJ virus-specific/JJ T-cell/NN memory/NN with/IN peptide-loaded/JJ dendritic/JJ cells/NNS ./. 
AB/LS -/: The/DT conventional/JJ means/NNS of/IN studying/VBG Epstein-Barr/JJ virus/NN (/( EBV/NN )/) -induced/JJ cytotoxic/JJ T-lymphocyte/NN (/( CTL/NN )/) memory/NN ,/, by/IN in/FW vitro/FW stimulation/NN with/IN the/DT latently/RB infected/JJ autologous/JJ lymphoblastoid/JJ cell/NN line/NN (/( LCL/NN )/) ,/, has/VBZ important/JJ limitations/NNS ./. 
First/RB ,/, it/PRP gives/VBZ no/DT information/NN on/IN memory/NN to/TO lytic/JJ cycle/NN antigens/NNS ;/: second/RB ,/, it/PRP preferentially/RB amplifies/VBZ the/DT dominant/JJ components/NNS of/IN latent/JJ antigen-specific/JJ memory/NN at/IN the/DT expense/NN of/IN key/JJ subdominant/JJ reactivities/NNS ./. 
Here/RB we/PRP describe/VBP an/DT alternative/JJ approach/NN ,/, based/VBN on/IN in/FW vitro/FW stimulation/NN with/IN epitope/NN peptide-loaded/JJ dendritic/JJ cells/NNS (/( DCs/NNS )/) ,/, which/WDT allows/VBZ one/PRP to/TO probe/VB the/DT CTL/NN repertoire/NN for/IN any/DT individual/JJ reactivity/NN of/IN choice/NN ;/: this/DT method/NN proved/VBD significantly/RB more/RBR efficient/JJ than/IN stimulation/NN with/IN peptide/NN alone/RB ./. 
Using/VBG this/DT approach/NN we/PRP first/RB show/VBP that/IN reactivities/NNS to/TO the/DT immunodominant/JJ and/CC subdominant/JJ lytic/JJ cycle/NN epitopes/NNS identified/VBN by/IN T/NN cells/NNS during/IN primary/JJ EBV/NN infection/NN are/VBP regularly/RB detectable/JJ in/IN the/DT CTL/NN memory/NN of/IN virus/NN carriers/NNS ;/: this/DT implies/VBZ that/IN in/IN such/JJ carriers/NNS chronic/JJ virus/NN replication/NN remains/VBZ under/IN direct/JJ T-cell/NN control/NN ./. 
We/PRP further/RB show/VBP that/IN subdominant/JJ latent/JJ cycle/NN reactivities/NNS to/TO epitopes/NNS in/IN the/DT latent/JJ membrane/NN protein/NN LMP2/NN ,/, though/IN rarely/RB undetectable/JJ in/IN LCL-stimulated/JJ populations/NNS ,/, can/MD be/VB reactivated/VBN by/IN DC/NN stimulation/NN and/CC selectively/RB expanded/VBN as/IN polyclonal/JJ CTL/NN lines/NNS ;/: the/DT adoptive/JJ transfer/NN of/IN such/JJ preparations/NNS may/MD be/VB of/IN value/NN in/IN targeting/VBG certain/JJ EBV-positive/JJ malignancies/NNS ./. 
UI/LS -/: 98168883/CD 
TI/LS -/: Regulation/NN of/IN the/DT human/JJ interleukin-2/NN gene/NN by/IN the/DT alpha/NN and/CC beta/NN isoforms/NNS of/IN the/DT glucocorticoid/NN receptor/NN ./. 
AB/LS -/: The/DT immunosuppressive/JJ effects/NNS of/IN glucocorticoids/NNS are/VBP largely/RB due/JJ to/TO transcriptional/JJ inhibition/NN of/IN immunologically/RB relevant/JJ genes/NNS ,/, such/JJ as/IN the/DT interleukin-2/NN (/( IL-2/NN )/) gene/NN ./. 
These/DT effects/NNS are/VBP mediated/VBN by/IN the/DT intracellular/JJ glucocorticoid/NN receptor/NN (/( GR/NN )/) ./. 
In/IN humans/NNS ,/, alternative/JJ splicing/NN of/IN the/DT GR/NN precursor/NN mRNA/NN gives/VBZ rise/NN to/TO two/CD receptor/NN isoforms/NNS ,/, termed/VBN GRalpha/NN and/CC GRbeta/NN ./. 
We/PRP previously/RB demonstrated/VBD that/IN GRbeta/NN could/MD antagonize/VB GRalpha-mediated/JJ transactivation/NN of/IN a/DT glucocorticoid-/NN responsive/JJ element/NN (/( GRE/NN )/) -driven/JJ reporter/NN gene/NN in/IN COS-7/NN cells/NNS ./. 
The/DT present/JJ study/NN was/VBD designed/VBN to/TO analyze/VB the/DT roles/NNS of/IN the/DT two/CD GR/NN isoforms/NNS on/IN glucocorticoid-mediated/JJ transrepression/NN of/IN the/DT IL-2/NN gene/NN ./. 
Using/VBG a/DT recently/RB developed/VBN transfection/NN technique/NN ,/, we/PRP demonstrate/VBP that/IN in/IN primary/JJ human/JJ lymphocytes/NNS ,/, stimulation/NN of/IN a/DT 548/CD bp/NN IL-2/NN promoter-luciferase/JJ reporter/NN construct/NN by/IN phorbol/NN ester/NN and/CC calcium/NN ionophore/NN is/VBZ reversed/VBN by/IN dexamethasone/NN to/TO a/DT similar/JJ extent/NN as/IN in/IN Jurkat/NN T/NN lymphoma/NN cells/NNS transfected/VBN with/IN a/DT GRalpha/NN expression/NN vector/NN ./. 
Transfection/NN of/IN a/DT GRbeta/NN expression/NN vector/NN alone/RB did/VBD not/RB result/VB in/IN IL-2/NN promoter/NN repression/NN in/IN response/NN to/TO glucocorticoids/NNS ./. 
Furthermore/RB ,/, GRbeta/NN did/VBD not/RB antagonize/VB the/DT repressive/JJ effects/NNS of/IN GRalpha/NN on/IN IL-2/NN promoter/NN activity/NN ./. 
Surprisingly/RB ,/, overexpression/NN of/IN GRbeta/NN in/IN Jurkat/NN cells/NNS did/VBD not/RB cause/VB significant/JJ inhibition/NN of/IN GRalpha-induced/JJ transactivation/NN of/IN a/DT GRE-dependent/JJ luciferase/NN reporter/NN gene/NN either/RB ./. 
We/PRP conclude/VBP that/IN the/DT transrepressive/JJ effect/NN of/IN glucocorticoids/NNS on/IN IL-2/NN gene/NN transcription/NN is/VBZ exclusively/RB mediated/VBN by/IN GRalpha/NN ./. 
GRbeta/NN can/MD neither/CC antagonize/VB GRalpha-mediated/JJ transactivation/NN nor/CC transrepression/NN in/IN Jurkat/NN cells/NNS ,/, indicating/VBG a/DT cell/NN type-specific/JJ pattern/NN of/IN GRbeta-mediated/JJ antiglucocorticoid/NN activity/NN ./. 
UI/LS -/: 98039716/CD 
TI/LS -/: Extinction/NN of/IN immunoglobulin/NN gene/NN expression/NN in/IN B/NN cells/NNS upon/IN fusion/NN with/IN HeLa/NN cells/NNS is/VBZ preceded/VBN by/IN rapid/JJ nuclear/JJ depletion/NN of/IN essential/JJ transcription/NN factors/NNS and/CC is/VBZ accompanied/VBN by/IN widespread/JJ inactivation/NN of/IN genes/NNS expressed/VBN in/IN a/DT B/NN cell-specific/JJ manner/NN ./. 
AB/LS -/: When/WRB immunoglobulin/NN (/( Ig/NN )/) expressing/NN B/NN cells/NNS are/VBP fused/VBN with/IN non-B/JJ cells/NNS ,/, Ig/NN expression/NN is/VBZ rapidly/RB suppressed/VBN at/IN the/DT level/NN of/IN transcription/NN ,/, a/DT phenomenon/NN termed/VBN extinction/NN ./. 
Here/RB we/PRP demonstrate/VBP that/IN fusion/NN of/IN HeLa/NN cells/NNS with/IN either/CC diploid/JJ or/CC tetraploid/JJ B/NN cells/NNS (/( Daudi/NN )/) results/VBZ in/IN widespread/JJ extinction/NN of/IN several/JJ other/JJ B/NN cell-encoded/JJ genes/NNS that/WDT are/VBP expressed/VBN in/IN a/DT B/NN cell-specific/JJ manner/NN ./. 
In/IN contrast/NN ,/, expression/NN of/IN B/NN cell-expressed/JJ genes/NNS that/WDT are/VBP not/RB dependent/JJ on/IN cell-specific/JJ controls/NNS is/VBZ unaffected/JJ ./. 
We/PRP show/VBP that/IN the/DT molecular/JJ mechanism/NN (/( s/NNS )/) underlying/VBG Ig/NN gene/NN extinction/NN can/MD be/VB explained/VBN ,/, at/IN least/JJS in/IN part/NN ,/, by/IN a/DT lack/NN of/IN transcription/NN factors/NNS that/WDT are/VBP essential/JJ for/IN Ig/NN gene/NN transcription/NN ./. 
These/DT transcription/NN factors/NNS are/VBP either/CC not/RB produced/VBN due/JJ to/TO block/NN of/IN transcription/NN of/IN their/PRP$ respective/JJ genes/NNS (/( Oct-2/NN ,/, OBF-1/NN ,/, PU.1/NN )/) ,/, or/CC are/VBP rendered/VBN inactive/JJ posttranslationally/RB (/( NF-kappa/NN B/NN ,/, E47/NN )/) ./. 
By/IN isolating/VBG Daudi/JJ x/NN HeLa/NN heterokaryons/NNS a/DT few/JJ hours/NNS after/IN fusion/NN ,/, we/PRP have/VBP studied/VBN the/DT initial/JJ fate/NN of/IN two/CD B/NN cell-specific/JJ transcription/NN factors/NNS involved/VBN in/IN Ig/NN gene/NN transcription/NN ,/, Oct-2/NN and/CC NF-kappa/NN B/NN ./. 
This/DT report/NN provides/VBZ the/DT first/JJ demonstration/NN that/IN upon/IN fusion/NN with/IN HeLa/NN cells/NNS ,/, the/DT nuclear/JJ contents/NNS of/IN B/NN cell-expressed/JJ transcription/NN factors/NNS are/VBP depleted/VBN within/IN a/DT few/JJ hours/NNS with/IN kinetics/NNS that/WDT are/VBP as/IN fast/JJ or/CC faster/JJR than/IN that/DT of/IN Ig/NN gene/NN extinction/NN ./. 
Thus/RB ,/, the/DT extinguishing/NN mechanism/NN is/VBZ effective/JJ very/RB early/RB after/IN fusion/NN ./. 
We/PRP suggest/VBP that/IN extinction/NN of/IN Ig/NN genes/NNS is/VBZ part/NN of/IN a/DT global/JJ mechanism/NN that/WDT suppresses/VBZ the/DT differentiation/NN program/NN foreign/JJ to/TO the/DT HeLa/NN phenotype/NN ./. 
UI/LS -/: 99166958/CD 
TI/LS -/: Evidence/NN for/IN suppressed/VBN activity/NN of/IN the/DT transcription/NN factor/NN NFAT1/NN at/IN its/PRP$ proximal/JJ binding/NN element/NN P0/NN in/IN the/DT IL-4/NN promoter/NN associated/VBN with/IN enhanced/VBN IL-4/NN gene/NN transcription/NN in/IN T/NN cells/NNS of/IN atopic/JJ patients/NNS ./. 
AB/LS -/: Allergen-specific/JJ T/NN cells/NNS in/IN atopic/JJ patients/NNS are/VBP polarized/VBN IL-4-producing/JJ Th2/NN cells/NNS ,/, promoting/VBG IgE/NN synthesis/NN by/IN B/NN cells/NNS ./. 
The/DT molecular/JJ basis/NN for/IN increased/VBN IL-4/NN gene/NN expression/NN in/IN atopy/NN is/VBZ not/RB fully/RB understood/VBN ./. 
IL-4/NN gene/NN regulation/NN in/IN general/JJ involves/VBZ the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) family/NN of/IN transcription/NN factors/NNS ,/, of/IN which/WDT NFAT1/NN and/CC NFAT2/NN are/VBP most/RBS prominent/JJ in/IN peripheral/JJ T/NN cells/NNS ./. 
Recently/RB ,/, a/DT unique/JJ inhibitory/JJ role/NN of/IN NFAT1/NN in/IN IL-4/NN gene/NN control/NN was/VBD shown/VBN in/IN the/DT mouse/NN ./. 
In/IN a/DT series/NN of/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS with/IN protein/NN extracts/NNS of/IN highly/RB polarized/VBN Th2/NN clones/NNS from/IN atopics/NNS and/CC Th1/NN clones/NNS from/IN controls/NNS we/PRP compared/VBD DNA-binding/NN activities/NNS at/IN the/DT two/CD NFAT-binding/JJ elements/NNS P0/NN and/CC P1/NN of/IN the/DT crucial/JJ proximal/JJ human/JJ IL-4/NN promoter/NN ./. 
At/IN the/DT most/RBS proximal/JJ P0/NN site/NN ,/, NFAT-containing/JJ complexes/NNS devoid/JJ of/IN NFAT2/NN were/VBD readily/RB inducible/JJ in/IN the/DT Th1/NN clones/NNS ,/, but/CC hardly/RB or/CC not/RB in/IN the/DT Th2/NN clones/NNS ./. 
In/IN contrast/NN ,/, both/CC in/IN Th1/NN and/CC Th2/NN clones/NNS NFAT-containing/JJ complexes/NNS were/VBD strongly/RB inducible/JJ at/IN the/DT P1/NN site/NN ,/, consisting/VBG of/IN NFAT2/NN and/CC a/DT P0-compatible/JJ NFAT/NN activity/NN ,/, without/IN apparent/JJ differences/NNS between/IN Th1/NN and/CC Th2/NN clones/NNS ./. 
Like/IN in/IN Th2/NN clones/NNS ,/, suppressed/VBN NFAT-P0/NN complex/NN formation/NN was/VBD observed/VBN also/RB at/IN the/DT polyclonal/JJ level/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NN )/) of/IN three/CD of/IN five/CD severe/JJ atopic/JJ dermatitis/NN patients/NNS with/IN strongly/RB elevated/JJ serum/NN IgE/NN levels/NNS ,/, but/CC not/RB in/IN control/JJ PBMC/NN ./. 
These/DT findings/NNS suggest/VBP that/IN high-level/JJ IL-4/NN production/NN in/IN atopic/JJ Th2/NN cells/NNS is/VBZ associated/VBN with/IN selective/JJ reduction/NN of/IN suppressive/JJ NFAT1/NN activity/NN at/IN the/DT IL-4/NN P0/NN element/NN and/CC that/IN some/DT patients/NNS with/IN this/DT multifactorial/JJ disease/NN may/MD have/VB a/DT putative/JJ systemic/JJ disorder/NN at/IN this/DT level/NN ./. 
UI/LS -/: 99154742/CD 
TI/LS -/: Differential/JJ expression/NN and/CC phosphorylation/NN of/IN CTCF/NN ,/, a/DT c-myc/NN transcriptional/JJ regulator/NN ,/, during/IN differentiation/NN of/IN human/JJ myeloid/JJ cells/NNS ./. 
AB/LS -/: CTCF/NN is/VBZ a/DT transcriptional/JJ repressor/NN of/IN the/DT c-myc/NN gene/NN ./. 
Although/IN CTCF/NN has/VBZ been/VBN characterized/VBN in/IN some/DT detail/NN ,/, there/EX is/VBZ very/RB little/JJ information/NN about/IN the/DT regulation/NN of/IN CTCF/NN activity/NN ./. 
Therefore/RB we/PRP investigated/VBD CTCF/NN expression/NN and/CC phosphorylation/NN during/IN induced/VBN differentiation/NN of/IN human/JJ myeloid/JJ leukemia/NN cells/NNS ./. 
We/PRP found/VBD that/IN :/: (/( i/LS )/) both/CC CTCF/NN mRNA/NN and/CC protein/NN are/VBP down-regulated/VBN during/IN terminal/JJ differentiation/NN in/IN most/JJS cell/NN lines/NNS tested/VBN ;/: (/( ii/LS )/) CTCF/NN down-regulation/NN is/VBZ retarded/VBN and/CC less/RBR pronounced/JJ than/IN that/DT of/IN c-myc/NN ;/: (/( iii/LS )/) CTCF/NN protein/NN is/VBZ differentially/RB phosphorylated/VBN and/CC the/DT phosphorylation/NN profiles/NNS depend/VBP on/IN the/DT differentiation/NN pathway/NN ./. 
We/PRP concluded/VBD that/IN CTCF/NN expression/NN and/CC activity/NN is/VBZ controlled/VBN at/IN transcriptional/JJ and/CC post-transcriptional/JJ levels/NNS ./. 
UI/LS -/: 99145033/CD 
TI/LS -/: Glucocorticoid/NN resistance/NN in/IN the/DT squirrel/NN monkey/NN is/VBZ associated/VBN with/IN overexpression/NN of/IN the/DT immunophilin/NN FKBP51/NN ./. 
AB/LS -/: Squirrel/NN monkeys/NNS are/VBP neotropical/JJ primates/NNS that/WDT have/VBP high/JJ circulating/VBG cortisol/NN to/TO compensate/VB for/IN expression/NN of/IN glucocorticoid/NN receptors/NNS (/( GRs/NNS )/) with/IN reduced/VBN affinity/NN ./. 
The/DT low/JJ binding/NN affinity/NN of/IN squirrel/NN monkey/NN GR/NN does/VBZ not/RB result/VB from/IN substitutions/NNS in/IN the/DT receptor/NN ,/, because/IN squirrel/NN monkey/NN GR/NN expressed/VBN in/FW vitro/FW exhibits/VBZ high/JJ affinity/NN ./. 
Rather/RB ,/, squirrel/NN monkeys/NNS express/VBP a/DT soluble/JJ factor/NN that/WDT ,/, in/IN mixing/JJ studies/NNS of/IN cytosol/NN from/IN squirrel/NN monkey/NN lymphocytes/NNS (/( SML/NNS )/) and/CC mouse/NN L929/NN cells/NNS ,/, reduced/VBD GR/NN binding/NN affinity/NN by/IN 11-fold/JJ ./. 
In/IN an/DT effort/NN to/TO identify/VB this/DT factor/NN ,/, the/DT cellular/JJ levels/NNS of/IN components/NNS of/IN the/DT GR/NN heterocomplex/NN in/IN SML/NNS and/CC human/JJ lymphocytes/NNS (/( HL/NNS )/) were/VBD compared/VBN ./. 
The/DT immunophilin/NN FKBP51/NN was/VBD 13-fold/RB higher/JJR in/IN SML/NNS than/IN in/IN HL/NNS cytosol/NN ;/: FKBP52/NN in/IN SML/NNS was/VBD 42/CD %/NN of/IN that/DT in/IN HL/NNS cytosol/NN ./. 
A/DT role/NN for/IN changes/NNS in/IN immunophilins/NNS ,/, causing/VBG glucocorticoid/NN resistance/NN in/IN neotropical/JJ primates/NNS ,/, is/VBZ supported/VBN by/IN the/DT following/NN :/: the/DT changes/NNS in/IN FKBP51/NN and/CC FKBP52/NN were/VBD observed/VBN in/IN cells/NNS from/IN other/JJ neotropical/JJ primates/NNS with/IN glucocorticoid/NN resistance/NN ;/: the/DT elevated/JJ level/NN of/IN FKBP51/NN was/VBD reflected/VBN in/IN an/DT abundance/NN of/IN FKBP51/NN in/IN heat/NN shock/NN protein/NN 90/CD complexes/NNS in/IN SML/NNS ;/: when/WRB cytosols/NNS of/IN SML/NNS and/CC L929/NN cells/NNS were/VBD mixed/VBN ,/, the/DT decrease/NN in/IN GR/NN binding/NN was/VBD associated/VBN with/IN incorporation/NN of/IN FKBP51/NN into/IN GR/NN heterocomplexes/NNS ;/: the/DT effect/NN of/IN SML/NNS cytosol/NN on/IN GR/NN binding/NN was/VBD reproduced/VBN with/IN cytosol/NN from/IN COS/NN cells/NNS expressing/VBG squirrel/NN monkey/NN FKBP51/NN ;/: and/CC both/CC the/DT effect/NN of/IN SML/NNS cytosol/NN on/IN GR/NN binding/NN and/CC the/DT incorporation/NN of/IN FKBP51/NN into/IN GR/NN heterocomplexes/NNS were/VBD blocked/VBN by/IN FK506/NN ./. 
Regulation/NN of/IN GR/NN binding/NN by/IN FKBP51/NN represents/VBZ a/DT previously/RB unrecognized/JJ mechanism/NN for/IN regulating/VBG glucocorticoid/NN sensitivity/NN ./. 
UI/LS -/: 99138988/CD 
TI/LS -/: High-level/JJ replication/NN of/IN human/JJ immunodeficiency/NN virus/NN in/IN thymocytes/NNS requires/VBZ NF-kappaB/NN activation/NN through/IN interaction/NN with/IN thymic/JJ epithelial/JJ cells/NNS ./. 
AB/LS -/: We/PRP have/VBP previously/RB demonstrated/VBN that/IN interaction/NN of/IN infected/JJ thymocytes/NNS with/IN autologous/JJ thymic/JJ epithelial/JJ cells/NNS (/( TEC/NNS )/) is/VBZ a/DT prerequisite/NN for/IN a/DT high/JJ level/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) replication/NN in/IN thymocytes/NNS (/( M.Rothe/NNP ,/, L.Chene/NNP ,/, M.Nugeyre/NNP ,/, F.Barre-Sinoussi/NNP ,/, and/CC N.Israel/NNP ,/, J.Virol.72/NNP :/: 5852-5861/CD ,/, 1998/CD )/) ./. 
We/PRP report/VBP here/RB that/IN this/DT activation/NN of/IN HIV/NN replication/NN takes/VBZ place/NN at/IN the/DT transcriptional/JJ level/NN through/IN activation/NN of/IN the/DT Rel/NF-kappaB/NN transcription/NN factors/NNS ./. 
We/PRP first/RB demonstrate/VBP that/IN an/DT HIV-1/NN provirus/NN (/( SF-2/NN strain/NN )/) very/RB effectively/RB replicates/VBZ in/IN thymocytes/NNS cocultured/VBN with/IN TEC/NNS whereas/IN this/DT provirus/NN ,/, with/IN kappaB/NN sites/NNS deleted/VBN ,/, fails/VBZ to/TO replicate/VB ./. 
We/PRP provide/VBP evidence/NN that/IN several/JJ NF-kappaB/NN complexes/NNS are/VBP constitutively/RB found/VBN in/IN the/DT nuclei/NNS of/IN thymocytes/NNS either/CC freshly/RB isolated/VBN from/IN the/DT thymus/NN or/CC maintained/VBN in/IN coculture/NN with/IN autologous/JJ or/CC heterologous/JJ TEC/NNS ./. 
The/DT prevalent/JJ complex/NN is/VBZ the/DT heterodimer/NN p50-p65/NN ./. 
NF-kappaB/NN activity/NN is/VBZ tightly/RB correlated/VBN with/IN the/DT transcriptional/JJ activity/NN of/IN a/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) of/IN HIV-1/NN transfected/VBN in/IN thymocytes/NNS ./. 
The/DT cotransfection/NN of/IN this/DT LTR/NN with/IN a/DT mutated/VBN IkappaBalpha/NN molecule/NN formally/RB demonstrates/VBZ that/IN LTR/NN transactivation/NN is/VBZ regulated/VBN by/IN members/NNS of/IN the/DT Rel/NF-kappaB/NN family/NN in/IN thymocytes/NNS ./. 
We/PRP also/RB showed/VBD that/IN tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) and/CC to/TO a/DT lesser/JJR extent/NN interleukin-1/NN (/( IL-1/NN )/) ,/, secreted/VBN within/IN the/DT coculture/NN ,/, induce/VBP NF-kappaB/NN activity/NN and/CC a/DT correlative/JJ LTR/NN transactivation/NN ./. 
However/RB IL-7/NN ,/, a/DT crucial/JJ factor/NN for/IN thymopoiesis/NN that/WDT is/VBZ secreted/VBN mainly/RB by/IN TEC/NNS ,/, is/VBZ a/DT necessary/JJ cofactor/NN for/IN NF-kappaB/NN activation/NN elicited/VBN by/IN TNF/NN or/CC IL-1/NN ./. 
Together/RB ,/, these/DT data/NNS indicate/VBP that/IN NF-kappaB/NN activation/NN ,/, required/VBN for/IN a/DT high/JJ level/NN of/IN HIV/NN replication/NN in/IN thymocytes/NNS ,/, is/VBZ regulated/VBN in/IN a/DT specific/JJ manner/NN in/IN the/DT thymic/JJ microenvironment/NN which/WDT provides/VBZ the/DT necessary/JJ cytokines/NNS :/: TNF/NN ,/, IL-1/NN ,/, and/CC IL-7/NN ./. 
UI/LS -/: 99120900/CD 
TI/LS -/: Imbalanced/JJ expression/NN of/IN the/DT glucocorticoid/NN receptor/NN isoforms/NNS in/IN cultured/VBN lymphocytes/NNS from/IN a/DT patient/NN with/IN systemic/JJ glucocorticoid/NN resistance/NN and/CC chronic/JJ lymphocytic/JJ leukemia/NN ./. 
AB/LS -/: The/DT human/JJ glucocorticoid/NN receptor/NN (/( GR/NN )/) is/VBZ expressed/VBN as/IN two/CD alternatively/RB spliced/VBN isoforms/NNS ,/, GRalpha/NN and/CC GRbeta/NN ./. 
Whereas/IN GRalpha/NN is/VBZ a/DT hormone-activated/JJ transcription/NN factor/NN ,/, GRbeta/NN does/VBZ not/RB bind/VB glucocorticoids/NNS (/( GCs/NNS )/) ,/, is/VBZ transcriptionally/RB inactive/JJ ,/, and/CC is/VBZ a/DT potential/JJ inhibitor/NN of/IN activated/VBN GRalpha/NN ./. 
Differential/JJ expression/NN of/IN GR/NN isoforms/NNS may/MD play/VB a/DT role/NN in/IN generalized/VBN or/CC tissue-specific/JJ GC/NN resistance/NN ./. 
GCs/NNS induce/VBP apoptosis/NN in/IN neoplastic/JJ lymphoid/JJ cells/NNS ;/: and/CC ,/, defective/JJ apoptosis/NN is/VBZ implicated/VBN in/IN the/DT genesis/NN of/IN chronic/JJ lymphocytic/JJ leukemia/NN (/( CLL/NN )/) ./. 
We/PRP studied/VBD a/DT patient/NN with/IN generalized/VBN GC/NN resistance/NN and/CC CLL/NN ./. 
GR/NN number/NN in/IN the/DT patient/NN 's/POS transformed/VBN lymphocytes/NNS was/VBD approximately/RB one/CD half/NN that/DT of/IN control/JJ cells/NNS with/IN a/DT approximately/RB 10-fold/JJ reduction/NN in/IN binding/NN affinity/NN for/IN dexamethasone/NN ./. 
In/FW vitro/FW apoptosis/NN induction/NN in/IN CLL/NN cells/NNS was/VBD delayed/VBN in/IN response/NN to/TO GCs/NNS ,/, but/CC not/RB to/TO other/JJ apoptosis/NN inducers/NNS ./. 
Sequencing/NN of/IN the/DT GR/NN cDNA/NN and/CC gene/NN including/VBG the/DT 2.3-kb/JJ coding/NN region/NN ,/, the/DT intron/exon/NN junctions/NNS ,/, the/DT known/JJ 5'-regulatory/JJ region/NN ,/, and/CC approximately/RB 300/CD bp/NN of/IN the/DT 3'-region/NN revealed/VBD no/DT alterations/NNS ./. 
Western/NN blot/NN with/IN an/DT N-terminal/JJ antibody/NN showed/VBD normal/JJ levels/NNS of/IN immunoreactive/JJ GR/NN ,/, but/CC quantitative/JJ analysis/NN with/IN isoform-specific/JJ C-terminal/JJ antibodies/NNS revealed/VBD a/DT markedly/RB reduced/VBN GRalpha/NN expression/NN ,/, and/CC high/JJ GRbeta/NN expression/NN ./. 
These/DT findings/NNS indicate/VBP that/IN imbalanced/JJ expression/NN of/IN the/DT GR/NN isoforms/NNS may/MD be/VB a/DT mechanism/NN of/IN GC/NN resistance/NN ,/, and/CC may/MD have/VB implications/NNS for/IN tumorigenesis/NN by/IN enhancing/VBG cell/NN survival/NN ./. 
Copyright/NN 1999/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99107757/CD 
TI/LS -/: Intranuclear/JJ targeted/VBN delivery/NN of/IN functional/JJ NF-kappaB/NN by/IN 70/CD kDa/NN heat/NN shock/NN protein/NN ./. 
AB/LS -/: The/DT 70/CD kDa/NN heat/NN shock/NN protein/NN (/( Hsp70/NN )/) is/VBZ a/DT highly/RB conserved/VBN ,/, ubiquitous/JJ protein/NN involved/VBN in/IN chaperoning/VBG proteins/NNS to/TO various/JJ cellular/JJ organelles/NNS ./. 
Here/RB we/PRP show/VBP that/IN when/WRB added/VBN exogenously/RB to/TO cells/NNS ,/, Hsp70/NN is/VBZ readily/RB imported/VBN into/IN both/CC cytoplasmic/JJ and/CC nuclear/JJ compartments/NNS in/IN a/DT cell-type-specific/JJ fashion/NN ./. 
We/PRP exploited/VBD this/DT ability/NN of/IN Hsp70/NN to/TO deliver/VB NF-kappaB/NN ,/, a/DT key/JJ transcriptional/JJ regulator/NN of/IN inflammatory/JJ responses/NNS ./. 
We/PRP demonstrate/VBP that/IN a/DT fusion/NN protein/NN composed/VBN of/IN a/DT C-terminal/JJ Hsp70/NN peptide/NN and/CC the/DT p50/NN subunit/NN of/IN NF-kappaB/NN was/VBD directed/VBN into/IN the/DT nucleus/NN of/IN cells/NNS ,/, could/MD bind/VB DNA/NN specifically/RB ,/, and/CC activated/VBD Igkappa/NN expression/NN and/CC TNFalpha/NN production/NN ./. 
We/PRP therefore/RB propose/VBP that/IN Hsp70/NN can/MD be/VB used/VBN as/IN a/DT vehicle/NN for/IN intracytoplasmic/JJ and/CC intranuclear/JJ delivery/NN of/IN proteins/NNS or/CC DNA/NN to/TO modulate/VB gene/NN expression/NN and/CC thereby/RB control/VB immune/JJ responses/NNS ./. 
UI/LS -/: 99098921/CD 
TI/LS -/: Characterization/NN of/IN the/DT human/JJ elk-1/NN promoter/NN ./. 
Potential/JJ role/NN of/IN a/DT downstream/JJ intronic/JJ sequence/NN for/IN elk-1/NN gene/NN expression/NN in/IN monocytes/NNS ./. 
AB/LS -/: To/TO characterize/VB the/DT human/JJ elk-1/NN promoter/NN ,/, we/PRP mapped/VBD the/DT transcriptional/JJ start/NN site/NN and/CC isolated/VBD elk-1-specific/JJ genomic/JJ phage/NN clones/NNS that/WDT contained/VBD extensive/JJ upstream/JJ and/CC downstream/JJ sequences/NNS ./. 
A/DT TATA-like/JJ motif/NN was/VBD identified/VBN immediately/RB upstream/RB of/IN the/DT transcriptional/JJ start/NN site/NN ./. 
Functional/JJ analyses/NNS of/IN DNA/NN fragments/NNS containing/VBG the/DT TATA/NN element/NN and/CC the/DT identification/NN of/IN a/DT DNase/NN I-hypersensitive/JJ chromatin/NN site/NN (/( HS/NN 1/CD )/) in/IN close/JJ proximity/NN to/TO the/DT TATA/NN box/NN suggest/VBP that/IN the/DT identified/VBN TATA/NN motif/NN is/VBZ important/JJ for/IN elk-1/NN transcription/NN in/FW vivo/FW ./. 
Sequences/NNS upstream/JJ and/CC downstream/JJ from/IN the/DT TATA/NN box/NN were/VBD found/VBN to/TO contribute/VB to/TO elk-1/NN promoter/NN activity/NN ./. 
A/DT second/JJ hypersensitive/JJ site/NN (/( HS/NN 2/CD )/) was/VBD identified/VBN within/IN the/DT first/JJ intron/NN in/IN pre-monocytic/JJ cells/NNS ,/, which/WDT express/VBP Elk-1/NN only/RB when/WRB differentiating/VBG to/TO monocytes/NNS ./. 
In/IN a/DT variety/NN of/IN other/JJ cell/NN types/NNS ,/, which/WDT display/VBP a/DT constitutive/JJ Elk-1/NN expression/NN ,/, HS/NN 2/CD did/VBD not/RB exist/VB ,/, suggesting/VBG that/IN inducibility/NN of/IN elk-1/NN expression/NN is/VBZ associated/VBN with/IN the/DT presence/NN of/IN HS/NN 2/CD ./. 
Egr-1/NN and/CC the/DT serum/NN response/NN factor/NN were/VBD found/VBN to/TO interact/VB specifically/RB with/IN the/DT intronic/JJ sequence/NN at/IN +265/CD and/CC +448/CD ,/, respectively/RB ./. 
Because/IN Egr-1/NN mRNA/NN and/CC protein/NN levels/NNS were/VBD observed/VBN to/TO increase/VB significantly/RB before/IN induction/NN of/IN elk-1/NN expression/NN ,/, we/PRP propose/VBP that/IN Egr-1/NN is/VBZ important/JJ for/IN the/DT regulation/NN of/IN elk-1/NN transcription/NN in/IN differentiating/VBG monocytes/NNS ./. 
UI/LS -/: 99111186/CD 
TI/LS -/: Immunohistochemical/JJ study/NN of/IN c-fos-positive/JJ lymphocytes/NNS infiltrated/VBN into/IN human/JJ squamous/JJ cell/NN carcinomas/NNS of/IN the/DT head/NN and/CC neck/NN during/IN radiation/NN therapy/NN and/CC its/PRP$ clinical/JJ significance/NN ./. 
AB/LS -/: C-fos/NN has/VBZ been/VBN reported/VBN to/TO be/VB one/CD of/IN the/DT immediate/JJ early/JJ genes/NNS in/IN signal/NN transduction/NN systems/NNS after/IN many/JJ kinds/NNS of/IN stresses/NNS ,/, including/VBG ionizing/VBG radiation/NN ./. 
Changes/NNS in/IN c-fos/NN expression/NN induced/VBN by/IN radiation/NN therapy/NN in/IN tumor/NN tissues/NNS have/VBP not/RB yet/RB been/VBN reported/VBN ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP attempted/VBN to/TO determine/VB whether/IN c-fos/NN expression/NN is/VBZ induced/VBN by/IN radiotherapy/NN in/IN human/JJ squamous/JJ cell/NN carcinomas/NNS of/IN the/DT head/NN and/CC neck/NN and/CC to/TO establish/VB a/DT possible/JJ correlation/NN between/IN c-fos/NN expression/NN and/CC the/DT therapeutic/JJ effects/NNS of/IN radiation/NN therapy/NN ./. 
Twenty-seven/CD patients/NNS with/IN tumors/NNS of/IN the/DT oral/JJ cavity/NN ,/, oropharynx/NN ,/, and/CC maxillary/JJ sinus/NN were/VBD examined/VBN ,/, all/DT of/IN which/WDT were/VBD confirmed/VBN as/IN squamous/JJ cell/NN carcinomas/NNS ./. 
After/IN obtaining/VBG the/DT patients/NNS '/POS informed/VBN consent/NN ,/, biopsies/NNS were/VBD performed/VBN before/IN treatment/NN and/CC at/IN doses/NNS of/IN 4/CD ,/, 10/CD ,/, and/CC 20/CD Gy/NN of/IN radiotherapy/NN ,/, and/CC the/DT specimens/NNS were/VBD preserved/VBN in/IN liquid/JJ nitrogen/NN for/IN further/JJ examination/NN ./. 
Serial/JJ sectioning/NN of/IN 6/CD micrometer/NN was/VBD performed/VBN using/VBG a/DT cryostat/NN ,/, and/CC samples/NNS were/VBD immunohistochemically/RB stained/VBN using/VBG the/DT streptoavidin-biotin/JJ peroxidase/NN method/NN and/CC a/DT monoclonal/JJ antibody/NN against/IN c-fos/NN ./. 
Three/CD of/IN the/DT 27/CD patients/NNS with/IN squamous/JJ cell/NN carcinoma/NN showed/VBD slight/JJ expression/NN of/IN c-fos/NN in/IN their/PRP$ tumor/NN cells/NNS before/IN and/or/CC at/IN 4/CD or/CC 10/CD Gy/NN of/IN radiotherapy/NN ./. 
The/DT tumors/NNS showed/VBD high/JJ radiosensitivity/NN ./. 
Concerning/VBG tumor-infiltrating/JJ lymphocytes/NNS ,/, the/DT rate/NN of/IN moderate/JJ or/CC remarkable/JJ grades/NNS of/IN c-fos-positive/JJ lymphocytes/NNS before/IN radiotherapy/NN and/CC at/IN radiation/NN doses/NNS of/IN 4/CD ,/, 10/CD ,/, and/CC 20/CD Gy/NN was/VBD 8.0/CD ,/, 29.2/CD ,/, 4.8/CD ,/, and/CC 0/CD %/NN ,/, respectively/RB ./. 
The/DT relationship/NN between/IN the/DT immunohistochemical/JJ findings/NNS and/CC the/DT antitumor/NN effect/NN at/IN a/DT radiation/NN dose/NN of/IN 20/CD Gy/NN was/VBD examined/VBN on/IN the/DT corresponding/JJ H/NN &/CC E-stained/JJ sections/NNS ./. 
In/IN patients/NNS whose/WP$ infiltration/NN of/IN c-fos-positive/JJ lymphocytes/NNS into/IN tumor/NN tissues/NNS were/VBD moderate/JJ or/CC remarkable/JJ at/IN 4/CD Gy/NN of/IN radiotherapy/NN ,/, the/DT tumors/NNS responded/VBD significantly/RB well/RB to/TO radiation/NN therapy/NN (/( P/NN </JJR 0.025/CD ,/, chi2/NN test/NN )/) ,/, and/CC the/DT patients/NNS took/VBD a/DT significantly/RB favorable/JJ clinical/JJ course/NN (/( P/NN </JJR 0.05/CD ,/, chi2/NN test/NN )/) ./. 
In/IN a/DT sample/NN from/IN one/CD of/IN the/DT patients/NNS ,/, c-fos-positive/JJ lymphocytes/NNS were/VBD identified/VBN as/IN CD4/NN positive/JJ and/CC CD8/NN negative/JJ ./. 
Therefore/RB ,/, the/DT high/JJ radiosensitivity/NN of/IN squamous/JJ cell/NN carcinomas/NNS in/IN our/PRP$ samples/NNS could/MD be/VB explained/VBN by/IN an/DT overexpression/NN of/IN c-fos/NN in/IN the/DT tumor-infiltrating/JJ lymphocytes/NNS induced/VBN by/IN small/JJ doses/NNS of/IN radiation/NN therapy/NN ,/, and/CC these/DT activated/VBN lymphocytes/NNS exerted/VBD a/DT cytotoxic/JJ effect/NN against/IN the/DT cancer/NN cells/NNS ./. 
UI/LS -/: 98030536/CD 
TI/LS -/: Paternal/JJ expression/NN of/IN WT1/NN in/IN human/JJ fibroblasts/NNS and/CC lymphocytes/NNS ./. 
AB/LS -/: The/DT Wilms/NN '/POS tumor/NN suppressor/NN gene/NN (/( WT1/NN )/) was/VBD previously/RB identified/VBN as/IN being/VBG imprinted/VBN ,/, with/IN frequent/JJ maternal/JJ expression/NN in/IN human/JJ placentae/NN and/CC fetal/JJ brains/NNS ./. 
We/PRP examined/VBD the/DT allele-specific/JJ expression/NN of/IN WT1/NN in/IN cultured/VBN human/JJ fibroblasts/NNS from/IN 15/CD individuals/NNS ./. 
Seven/CD of/IN 15/CD fibroblast/NN lines/NNS were/VBD heterozygous/JJ for/IN polymorphic/JJ alleles/NNS ,/, and/CC the/DT expression/NN patterns/NNS were/VBD variable/JJ ,/, i.e./FW ,/, equal/JJ ,/, unequal/JJ or/CC monoallelic/JJ paternal/JJ expression/NN in/IN three/CD ,/, two/CD and/CC two/CD cases/NNS ,/, respectively/RB ./. 
Exclusive/JJ paternal/JJ expression/NN of/IN WT1/NN was/VBD also/RB shown/VBN in/IN non-cultured/JJ peripheral/JJ lymphocytes/NNS from/IN the/DT latter/JJ two/CD individuals/NNS ./. 
The/DT allele-specific/JJ expression/NN profiles/NNS of/IN other/JJ imprinted/JJ genes/NNS ,/, IGF2/NN and/CC H19/NN ,/, on/IN human/JJ chromosome/NN 11/CD were/VBD constant/JJ and/CC consistent/JJ with/IN those/DT in/IN other/JJ tissues/NNS ./. 
Our/PRP$ unexpected/JJ observations/NNS of/IN paternal/JJ or/CC biallelic/JJ expression/NN of/IN WT1/NN in/IN fibroblasts/NNS and/CC lymphocytes/NNS ,/, together/RB with/IN the/DT previous/JJ findings/NNS of/IN maternal/JJ or/CC biallelic/JJ expression/NN in/IN placentae/NN and/CC brains/NNS ,/, suggest/VBP that/IN the/DT allele-specific/JJ regulatory/JJ system/NN of/IN WT1/NN is/VBZ unique/JJ and/CC may/MD be/VB controlled/VBN by/IN a/DT putative/JJ tissue-/NN and/CC individual-specific/JJ modifier/NN ./. 
UI/LS -/: 98076121/CD 
TI/LS -/: T/NN cell/NN reactivity/NN to/TO Sjogren/NN 's/POS syndrome/NN related/JJ antigen/NN La/NN (/( SSB/NN )/) ./. 
AB/LS -/: OBJECTIVE/NN ./. 
Many/JJ patients/NNS with/IN primary/JJ Sjogren/NN 's/POS syndrome/NN (/( SS/NN )/) make/VBP high/JJ titer/NN IgG/NN autoantibodies/NNS to/TO the/DT La/NN (/( SSB/NN )/) antigen/NN ,/, suggesting/VBG antigen/NN specific/JJ T/NN cell-B/NN cell/NN interactions/NNS ./. 
T/NN cell/NN responses/NNS to/TO some/DT nuclear/JJ antigens/NNS ,/, particularly/RB U1RNP/NN ,/, have/VBP been/VBN detected/VBN in/IN patients/NNS with/IN systemic/JJ lupus/NN erythematosus/NN (/( SLE/NN )/) and/CC in/IN healthy/JJ subjects/NNS ./. 
We/PRP investigated/VBD T/NN cell/NN reactivity/NN to/TO the/DT autoantigen/NN SSB/NN in/IN patients/NNS with/IN SS/NN and/CC healthy/JJ controls/NNS ./. 
METHODS/NNS ./. 
Using/VBG the/DT [3H]thymidine/NN proliferation/NN assay/NN ,/, we/PRP determined/VBD reactivity/NN to/TO purified/VBN recombinant/JJ SSB/NN (/( rSSB/NN )/) in/IN 20/CD patients/NNS with/IN SS/NN and/CC 19/CD controls/NNS ./. 
Specificity/NN was/VBD determined/VBN using/VBG tetanus/NN toxoid/NN ,/, endotoxin/NN ,/, and/CC 3/CD other/JJ autoantigens/NNS (/( PBC.M2/NN ,/, Sc170/NN ,/, and/CC GAD/NN )/) ./. 
Precursor/NN frequency/NN was/VBD calculated/VBN by/IN limiting/VBG dilution/NN analysis/NN ./. 
HLA/NN Class/NN II/CD dependency/NN was/VBD investigated/VBN using/VBG anti-Class/JJ II/CD monoclonal/JJ antibodies/NNS ./. 
HLA-DR/NN typing/NN was/VBD by/IN polymerase/NN chain/NN reaction/NN and/CC sequence/NN specific/JJ oligonucleotide/NN typing/NN ./. 
RESULTS/NNS ./. 
Six/CD of/IN 20/CD patients/NNS with/IN SS/NN and/CC 10/19/CD controls/NNS proliferated/VBD to/TO La/NN (/( rSSB/NN )/) ./. 
Precursor/NN frequency/NN of/IN anti-SSB/JJ T/NN cells/NNS was/VBD 1:77,040/CD and/CC 1:115,000/CD in/IN 2/CD healthy/JJ subjects/NNS and/CC 1:230,250/CD and/CC 1:103,034/CD in/IN two/CD patients/NNS with/IN SS/NN ./. 
Anti-HLA-DR/NN abrogated/VBD proliferation/NN to/TO SSB/NN and/CC tetanus/NN toxoid/NN ./. 
Thirteen/CD of/IN 15/CD patients/NNS with/IN SS/NN and/CC 4/17/CD controls/NNS were/VBD HLA-DR3/NN positive/JJ ,/, with/IN no/DT apparent/JJ association/NN of/IN HLA-DR3/NN with/IN SSB/NN reactivity/NN in/IN controls/NNS ./. 
CONCLUSION/NN ./. 
Anti-La(SSB)/NN specific/JJ T/NN cells/NNS occur/VBP in/IN a/DT significant/JJ proportion/NN of/IN controls/NNS and/CC in/IN some/DT patients/NNS with/IN SS/NN ./. 
The/DT function/NN of/IN SSB/NN T/NN cells/NNS in/IN controls/NNS remains/VBZ to/TO be/VB defined/VBN ./. 
They/PRP may/MD represent/VB immunoregulatory/JJ cells/NNS ,/, and/CC further/JJ analysis/NN of/IN these/DT cells/NNS ,/, and/CC a/DT comparison/NN to/TO those/DT found/VBN in/IN patients/NNS with/IN SS/NN ,/, may/MD elucidate/VB normal/JJ immunoregulation/NN and/CC the/DT derangements/NNS that/WDT lead/VBP to/TO Sjogren/NN 's/POS syndrome/NN ./. 
UI/LS -/: 99166942/CD 
TI/LS -/: Anti-rheumatic/JJ compound/NN aurothioglucose/NN inhibits/VBZ tumor/NN necrosis/NN factor-alpha-induced/JJ HIV-1/NN replication/NN in/IN latently/RB infected/JJ OM10.1/NN and/CC Ach2/NN cells/NNS ./. 
AB/LS -/: NF-kappaB/NN is/VBZ a/DT potent/JJ cellular/JJ activator/NN of/IN HIV-1/NN gene/NN expression/NN ./. 
Down-regulation/NN of/IN NF-kappaB/NN activation/NN is/VBZ known/VBN to/TO inhibit/VB HIV/NN replication/NN from/IN the/DT latently/RB infected/JJ cells/NNS ./. 
Gold/NN compounds/NNS have/VBP been/VBN effectively/RB used/VBN for/IN many/JJ decades/NNS in/IN the/DT treatment/NN of/IN rheumatoid/JJ arthritis/NN ./. 
We/PRP previously/RB reported/VBD that/IN gold/NN compounds/NNS ,/, especially/RB aurothioglucose/NN (/( AuTG/NN )/) containing/VBG monovalent/JJ gold/NN ion/NN ,/, inhibited/VBD the/DT DNA-binding/NN of/IN NF-kappaB/NN in/FW vitro/FW ./. 
In/IN this/DT report/NN we/PRP have/VBP examined/VBN the/DT efficacy/NN of/IN the/DT gold/NN compound/NN AuTG/NN as/IN an/DT inhibitor/NN of/IN HIV/NN replication/NN in/IN latently/RB infected/JJ OM10.1/NN and/CC Ach2/NN cells/NNS ./. 
Tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) -alpha-induced/JJ HIV-1/NN replication/NN in/IN OM10.1/NN or/CC Ach2/NN cells/NNS was/VBD significantly/RB inhibited/VBN by/IN non-cytotoxic/JJ doses/NNS of/IN AuTG/NN (/( >/JJR 10/CD microM/NN in/IN OM10.1/NN cells/NNS and/CC >/JJR 25/CD F.M/NN in/IN Ach2/NN cells/NNS )/) ,/, while/IN 25/CD microM/NN of/IN the/DT counter-anion/JJ thioglucose/NN (/( TG/NN )/) or/CC gold/NN compound/NN containing/VBG divalent/JJ gold/NN ion/NN ,/, HAuCl3/NN ,/, had/VBD no/DT effect/NN ./. 
The/DT effect/NN of/IN AuTG/NN on/IN NF-kappaB-dependent/JJ gene/NN expression/NN was/VBD confirmed/VBN by/IN a/DT transient/JJ CAT/NN assay/NN ./. 
Specific/JJ staining/NN as/RB well/RB as/IN electron/NN microscopic/JJ examinations/NNS revealed/VBD the/DT accumulation/NN of/IN metal/NN gold/NN in/IN the/DT cells/NNS ,/, supporting/VBG our/PRP$ previous/JJ hypothesis/NN that/IN gold/NN ions/NNS could/MD block/VB NF-kappaB-DNA/JJ binding/NN by/IN a/DT redox/NN mechanism/NN ./. 
These/DT observations/NNS indicate/VBP that/IN the/DT monovalent/JJ gold/NN compound/NN AuTG/NN is/VBZ a/DT potentially/RB useful/JJ drug/NN for/IN the/DT treatment/NN of/IN patients/NNS infected/VBN with/IN HIV/NN ./. 
UI/LS -/: 99155344/CD 
TI/LS -/: Clonality/NN of/IN isolated/VBN eosinophils/NNS in/IN the/DT hypereosinophilic/JJ syndrome/NN ./. 
AB/LS -/: The/DT idiopathic/JJ hypereosinophilic/JJ syndrome/NN (/( IHES/NN )/) is/VBZ a/DT rare/JJ disorder/NN characterized/VBN by/IN unexplained/JJ ,/, persistent/JJ eosinophilia/NN associated/VBN with/IN multiple/JJ organ/NN dysfunction/NN due/JJ to/TO eosinophilic/JJ tissue/NN infiltration/NN ./. 
In/IN the/DT absence/NN of/IN karyotypic/JJ abnormalities/NNS ,/, there/EX is/VBZ no/DT specific/JJ test/NN to/TO detect/VB clonal/JJ eosinophilia/NN in/IN IHES/NN ./. 
Analysis/NN of/IN X-chromosome/NN inactivation/NN patterns/NNS can/MD be/VB used/VBN to/TO determine/VB whether/IN proliferative/JJ disorders/NNS are/VBP clonal/JJ in/IN origin/NN ./. 
Methylation/NN of/IN HpaII/NN and/CC Hha/NN I/CD sites/NNS near/IN the/DT polymorphic/JJ trinucleotide/NN repeat/NN of/IN the/DT human/JJ androgen/NN receptor/NN gene/NN (/( HUMARA/NN )/) has/VBZ been/VBN shown/VBN to/TO correlate/VB with/IN X-inactivation/NN ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP used/VBN the/DT polymerase/NN chain/NN reaction/NN (/( PCR/NN )/) with/IN nested/JJ primers/NNS to/TO analyze/VB X-inactivation/JJ patterns/NNS of/IN the/DT HUMARA/NN loci/NNS in/IN purified/VBN eosinophils/NNS from/IN female/JJ patients/NNS with/IN eosinophilia/NN ./. 
Peripheral/JJ blood/NN eosinophils/NNS were/VBD isolated/VBN by/IN their/PRP$ autofluoresence/NN using/VBG flow/NN cytometric/JJ sorting/NN ./. 
Eosinophils/NNS purified/VBN from/IN a/DT female/JJ patient/NN presenting/VBG with/IN IHES/NN were/VBD found/VBN to/TO show/VB a/DT clonal/JJ pattern/NN of/IN X-inactivation/NN ./. 
Eosinophil-depleted/JJ leukocytes/NNS from/IN this/DT patient/NN were/VBD polyclonal/JJ by/IN HUMARA/NN analysis/NN ,/, thus/RB excluding/VBG skewedness/NN of/IN random/JJ X-/JJ inactivation/NN ./. 
After/IN corticosteroid/NN suppression/NN of/IN her/PRP$ blood/NN eosinophilia/NN ,/, a/DT clonal/JJ population/NN of/IN eosinophils/NNS could/MD no/RB longer/RB be/VB detected/VBN in/IN purified/JJ eosinophils/NNS ./. 
In/IN contrast/NN ,/, eosinophils/NNS purified/VBN from/IN a/DT patient/NN with/IN Churg-Strauss/JJ syndrome/NN and/CC from/IN six/CD patients/NNS with/IN reactive/JJ eosinophilias/NNS attributed/VBN to/TO allergy/NN ,/, parasitic/JJ infection/NN ,/, or/CC drug/NN reaction/NN showed/VBD a/DT polyclonal/JJ pattern/NN of/IN X-inactivation/NN by/IN HUMARA/NN analysis/NN ./. 
The/DT finding/NN of/IN clonal/JJ eosinophilia/NN in/IN a/DT patient/NN presenting/VBG with/IN IHES/NN indicates/VBZ that/IN such/JJ patients/NNS may/MD have/VB ,/, in/IN reality/NN ,/, a/DT low-grade/JJ clonal/JJ disorder/NN that/WDT can/MD be/VB distinguished/VBN from/IN reactive/JJ eosinophilias/NNS by/IN HUMARA/NN analysis/NN ./. 
Further/RB ,/, the/DT method/NN described/VBN can/MD be/VB used/VBN to/TO monitor/VB disease/NN progression/NN ./. 
UI/LS -/: 99145586/CD 
TI/LS -/: GA-binding/JJ protein/NN factors/NNS ,/, in/IN concert/NN with/IN the/DT coactivator/NN CREB/NN binding/NN protein/p300/NN ,/, control/VBP the/DT induction/NN of/IN the/DT interleukin/NN 16/CD promoter/NN in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: Interleukin/NN 16/CD (/( IL-16/NN )/) is/VBZ a/DT chemotactic/JJ cytokine/NN that/WDT binds/VBZ to/TO the/DT CD4/NN receptor/NN and/CC affects/VBZ the/DT activation/NN of/IN T/NN cells/NNS and/CC replication/NN of/IN HIV/NN ./. 
It/PRP is/VBZ expressed/VBN as/IN a/DT large/JJ 67-kDa/JJ precursor/NN protein/NN (/( pro-IL-16/NN )/) in/IN lymphocytes/NNS ,/, macrophages/NNS ,/, and/CC mast/NN cells/NNS ,/, as/RB well/RB as/IN in/IN airway/NN epithelial/JJ cells/NNS from/IN asthmatics/NNS after/IN challenge/NN with/IN allergen/NN ./. 
This/DT pro-IL-16/NN is/VBZ subsequently/RB processed/VBN to/TO the/DT mature/JJ cytokine/NN of/IN 13/CD kDa/NN ./. 
To/TO study/VB the/DT expression/NN of/IN IL-16/NN at/IN the/DT transcriptional/JJ level/NN ,/, we/PRP cloned/VBD the/DT human/JJ chromosomal/JJ IL-16/NN gene/NN and/CC analyzed/VBD its/PRP$ promoter/NN ./. 
The/DT human/JJ IL-16/NN gene/NN consists/VBZ of/IN seven/CD exons/NNS and/CC six/CD introns/NNS ./. 
The/DT 5'/JJ sequences/NNS up/RP to/TO nucleotide/NN -120/CD of/IN the/DT human/JJ and/CC murine/JJ IL-16/NN genes/NNS share/VBP >/JJR 84/CD %/NN sequence/NN homology/NN and/CC harbor/VBP promoter/NN elements/NNS for/IN constitutive/JJ and/CC inducible/JJ transcription/NN in/IN T/NN cells/NNS ./. 
Although/IN both/DT promoters/NNS lack/VBP any/DT TATA/NN box/NN ,/, they/PRP contain/VBP two/CD CAAT/NN box-like/JJ motifs/NNS and/CC three/CD binding/VBG sites/NNS of/IN GA-binding/JJ protein/NN (/( GABP/NN )/) transcription/NN factors/NNS ./. 
Two/CD of/IN these/DT motifs/NNS are/VBP part/NN of/IN a/DT highly/RB conserved/VBN and/CC inducible/JJ dyad/NN symmetry/NN element/NN shown/VBN previously/RB to/TO control/VB a/DT remote/JJ IL-2/NN enhancer/NN and/CC the/DT CD18/NN promoter/NN ./. 
In/IN concert/NN with/IN the/DT coactivator/NN CREB/NN binding/NN protein/p300/NN ,/, which/WDT interacts/VBZ with/IN GABPalpha/NN ,/, the/DT binding/NN of/IN GABPalpha/NN and/CC -beta/NN to/TO the/DT dyad/NN symmetry/NN element/NN controls/VBZ the/DT induction/NN of/IN IL-16/NN promoter/NN in/IN T/NN cells/NNS ./. 
Supplementing/VBG the/DT data/NNS on/IN the/DT processing/NN of/IN pro-IL-16/NN ,/, our/PRP$ results/NNS indicate/VBP the/DT complexity/NN of/IN IL-16/NN expression/NN ,/, which/WDT is/VBZ tightly/RB controlled/VBN at/IN the/DT transcriptional/JJ and/CC posttranslational/JJ levels/NNS in/IN T/NN lymphocytes/NNS ./. 
UI/LS -/: 99137815/CD 
TI/LS -/: Tuberculosis/NN and/CC chronic/JJ hepatitis/NN B/NN virus/NN infection/NN in/IN Africans/NNS and/CC variation/NN in/IN the/DT vitamin/NN D/NN receptor/NN gene/NN ./. 
AB/LS -/: The/DT active/JJ metabolite/NN of/IN vitamin/NN D/NN ,/, 1,25/CD dihydroxyvitamin/NN D3/NN ,/, is/VBZ an/DT important/JJ immunoregulatory/JJ hormone/NN [/( 1/CD ]/) ./. 
Its/PRP$ effects/NNS are/VBP exerted/VBN by/IN interaction/NN with/IN the/DT vitamin/NN D/NN receptor/NN ,/, which/WDT is/VBZ present/JJ on/IN human/JJ monocytes/NNS and/CC activated/VBN T/NN and/CC B/NN lymphocytes/NNS ./. 
Variation/NN in/IN the/DT vitamin/NN D/NN receptor/NN gene/NN was/VBD typed/VBN in/IN 2015/CD subjects/NNS from/IN large/JJ case-control/JJ studies/NNS of/IN three/CD major/JJ infectious/JJ diseases/NNS :/: tuberculosis/NN ,/, malaria/NN ,/, and/CC hepatitis/NN B/NN virus/NN ./. 
Homozygotes/NNS for/IN a/DT polymorphism/NN at/IN codon/NN 352/CD (/( genotype/NN tt/NN )/) were/VBD significantly/RB underrepresented/JJ among/IN those/DT with/IN tuberculosis/NN (/( chi2/NN =/JJ 6.22/CD ,/, 1/CD df/NN ,/, P/NN =/JJ .01/CD )/) and/CC persistent/JJ hepatitis/NN B/NN infection/NN (/( chi2/NN =/JJ 6.25/CD ,/, 1/CD df/NN ,/, P/NN =/JJ .01/CD )/) but/CC not/RB in/IN subjects/NNS with/IN clinical/JJ malaria/NN compared/VBN with/IN the/DT other/JJ genotypes/NNS ./. 
Therefore/RB ,/, this/DT genetic/JJ variant/NN ,/, which/WDT predisposes/VBZ to/TO low/JJ bone/NN mineral/JJ density/NN in/IN many/JJ populations/NNS ,/, may/MD confer/VB resistance/NN to/TO certain/JJ infectious/JJ diseases/NNS ./. 
UI/LS -/: 99118181/CD 
TI/LS -/: Inhibition/NN of/IN NF-kappa/NN B/NN activation/NN in/FW vitro/FW and/CC in/FW vivo/FW :/: role/NN of/IN 26S/NN proteasome/NN ./. 
AB/LS -/: It/PRP is/VBZ becoming/VBG increasingly/RB apparent/JJ that/IN NF-kappa/NN B/NN plays/VBZ a/DT critical/JJ role/NN in/IN regulating/VBG the/DT inflammatory/JJ response/NN ./. 
Data/NNS obtained/VBN from/IN studies/NNS in/IN our/PRP$ laboratories/NNS demonstrate/VBP that/IN the/DT proteasome/NN plays/VBZ an/DT important/JJ role/NN in/IN the/DT inflammatory/JJ cascade/NN by/IN regulating/VBG the/DT activation/NN of/IN NF-kappa/NN B/NN ./. 
Indeed/RB ,/, the/DT availability/NN of/IN selective/JJ and/CC orally/RB active/JJ proteasome/NN inhibitors/NNS should/MD prove/VB useful/JJ in/IN delineating/VBG the/DT roles/NNS of/IN the/DT proteasome/NN and/CC NF-kappa/NN B/NN in/IN other/JJ pathophysiological/JJ conditions/NNS such/JJ as/IN cancer/NN and/CC heart/NN disease/NN ./. 
UI/LS -/: 99106021/CD 
TI/LS -/: Tissue/NN factor/NN expression/NN of/IN human/JJ monocytes/NNS is/VBZ suppressed/VBN by/IN lysophosphatidylcholine/NN ./. 
AB/LS -/: The/DT expression/NN of/IN tissue/NN factor/NN (/( TF/NN )/) ,/, the/DT principal/JJ initiator/NN of/IN coagulation/NN ,/, is/VBZ increased/VBN during/IN inflammation/NN and/CC atherosclerosis/NN ./. 
Both/DT conditions/NNS are/VBP promoted/VBN by/IN lysophosphatidylcholine/NN (/( lysoPC/NN )/) ./. 
We/PRP observed/VBD in/IN the/DT present/JJ study/NN that/IN lysoPC/NN (/( 1/CD to/TO 10/CD micromol/L/NN )/) dose-dependently/RB reduced/VBD TF/NN activity/NN in/IN human/JJ monocytes/NNS ,/, as/IN elicited/VBN by/IN lipopolysaccharide/NN (/( LPS/NN )/) ./. 
Lysophosphatidylethanolamine/NN (/( lysoPE/NN )/) and/CC other/JJ lysophospholipids/NNS did/VBD not/RB affect/VB LPS-induced/JJ TF/NN activity/NN of/IN human/JJ monocytes/NNS ./. 
TF/NN antigen/NN expression/NN as/IN elicited/VBN by/IN LPS/NN was/VBD also/RB lowered/VBN by/IN lysoPC/NN ./. 
Phospholipid/NN analyses/NNS indicated/VBD a/DT selective/JJ increase/NN in/IN the/DT lysoPC/NN content/NN of/IN the/DT monocytes/NNS after/IN preincubation/NN with/IN the/DT lysophospholipid/NN ./. 
LysoPC/NN inhibited/VBD the/DT TF/NN activity/NN of/IN Mono/NN Mac-6/NN cells/NNS to/TO a/DT similar/JJ extent/NN as/IN in/IN the/DT monocytes/NNS ./. 
LPS/NN binding/NN to/TO plasma/NN membrane/NN receptors/NNS and/CC internalization/NN of/IN LPS/NN into/IN monocytes/NNS were/VBD not/RB affected/VBN by/IN lysoPC/NN ./. 
In/IN contrast/NN ,/, LPS-mediated/JJ nuclear/JJ binding/NN of/IN nuclear/JJ factor-kappaB/Rel/NN to/TO a/DT TF-specific/JJ kappaB/NN site/NN was/VBD inhibited/VBN by/IN lysoPC/NN ./. 
Induction/NN of/IN TF/NN mRNA/NN expression/NN by/IN LPS/NN tended/VBD to/TO be/VB partially/RB reduced/VBN by/IN the/DT lysophospholipid/NN ./. 
Preincubation/NN with/IN lysoPC/NN increased/VBD monocytic/JJ cAMP/NN levels/NNS ./. 
Inhibition/NN of/IN adenylyl/JJ cyclase/NN by/IN pretreatment/NN with/IN 2'-deoxy-3'-adenosine/JJ monophosphate/NN partially/RB reversed/VBD the/DT inhibition/NN of/IN TF/NN activity/NN promoted/VBN by/IN lysoPC/NN ./. 
In/IN conclusion/NN ,/, lysoPC/NN markedly/RB decreases/VBZ LPS-mediated/JJ TF/NN expression/NN of/IN human/JJ monocytes/NNS ,/, the/DT effect/NN probably/RB being/VBG mediated/VBN by/IN both/CC transcriptional/JJ and/CC posttranscriptional/JJ mechanisms/NNS ./. 
LysoPC/NN may/MD thus/RB attenuate/VB activation/NN of/IN coagulation/NN during/IN inflammation/NN and/CC atherosclerosis/NN ./. 
UI/LS -/: 99091640/CD 
TI/LS -/: Regulation/NN of/IN fas-ligand/NN expression/NN during/IN activation-induced/JJ cell/NN death/NN in/IN T/NN lymphocytes/NNS via/IN nuclear/JJ factor/NN kappaB/NN ./. 
AB/LS -/: T/NN cell/NN receptor/NN engagement/NN activates/VBZ transcription/NN factors/NNS important/JJ for/IN cytokine/NN gene/NN regulation/NN ./. 
Additionally/RB ,/, this/DT signaling/NN pathway/NN also/RB leads/VBZ to/TO activation-induced/JJ apoptosis/NN in/IN T/NN lymphocytes/NNS that/WDT is/VBZ dependent/JJ on/IN FasL/NN transcription/NN and/CC expression/NN ./. 
Here/RB we/PRP demonstrate/VBP that/IN nuclear/JJ factor/NN kappaB/NN (/( NF-kappaB/NN )/) ,/, which/WDT is/VBZ involved/VBN in/IN the/DT transcriptional/JJ regulation/NN of/IN many/JJ cytokine/NN genes/NNS expressed/VBN in/IN activated/VBN lymphocytes/NNS ,/, also/RB plays/VBZ a/DT role/NN in/IN T/NN cell/NN activation-induced/JJ FasL/NN expression/NN ./. 
Inhibition/NN of/IN NF-kappaB/NN activity/NN in/IN a/DT T/NN cell/NN hybridoma/NN leads/VBZ to/TO decreased/VBN FasL/NN expression/NN and/CC apoptosis/NN upon/IN T/NN cell/NN receptor/NN stimulation/NN ./. 
We/PRP identified/VBD the/DT NF-kappaB/NN site/NN in/IN the/DT FasL/NN promoter/NN that/WDT contributes/VBZ to/TO such/JJ regulation/NN ./. 
Co-expression/NN of/IN p65/NN (/( Rel/NN A/NN )/) with/IN the/DT FasL/NN promoter/NN enhanced/VBD its/PRP$ activity/NN ,/, and/CC co-expression/NN of/IN IkappaB/NN dramatically/RB inhibited/VBD the/DT inducible/JJ promoter/NN activity/NN ./. 
In/IN contrast/NN ,/, the/DT transcription/NN factor/NN AP-1/NN is/VBZ not/RB required/VBN for/IN activation-induced/JJ FasL/NN promoter/NN activity/NN ./. 
These/DT results/NNS define/VBP a/DT role/NN for/IN NF-kappaB/NN in/IN mediating/VBG FasL/NN expression/NN during/IN T/NN cell/NN activation/NN ./. 
UI/LS -/: 99030293/CD 
TI/LS -/: Promoter/NN sequence/NN ,/, exon/NN :/: intron/NN structure/NN ,/, and/CC synteny/NN of/IN genetic/JJ location/NN show/VBP that/IN a/DT chicken/NN cytokine/NN with/IN T-cell/NN proliferative/JJ activity/NN is/VBZ IL2/NN and/CC not/RB IL15/NN ./. 
AB/LS -/: The/DT gene/NN encoding/VBG a/DT chicken/NN cytokine/NN with/IN T-cell/NN proliferative/JJ activity/NN was/VBD cloned/VBN ,/, sequenced/VBN ,/, and/CC mapped/VBN ./. 
The/DT results/NNS show/VBP that/IN this/DT cytokine/NN is/VBZ chicken/NN IL2/NN and/CC not/RB IL15/NN ./. 
The/DT exon:intron/NN structure/NN of/IN chicken/NN IL2/NN corresponds/VBZ almost/RB exactly/RB to/TO those/DT of/IN mammalian/JJ IL2s/NNS with/IN the/DT exceptions/NNS of/IN exon/NN 2/CD and/CC introns/NNS 2/CD and/CC 3/CD which/WDT are/VBP shorter/JJR ./. 
Chicken/NN IL2/NN contains/VBZ five/CD repeats/NNS of/IN the/DT "/`` instability/NN "/'' motif/NN ATTTA/NN in/IN the/DT 3'untranslated/JJ region/NN in/IN exon/NN 4/CD ./. 
It/PRP is/VBZ a/DT single-copy/JJ gene/NN ,/, with/IN neither/CC structural/JJ (/( amino/NN acid/NN )/) nor/CC promoter/NN sequence/NN polymorphisms/NNS identified/VBN ./. 
Analysis/NN of/IN the/DT predicted/VBN amino/NN acid/NN sequence/NN suggests/VBZ that/IN overall/JJ protein/NN structure/NN is/VBZ conserved/VBN ,/, but/CC the/DT receptor/NN binding/NN sites/NNS are/VBP not/RB ./. 
A/DT number/NN of/IN potential/JJ regulatory/JJ sequences/NNS similar/JJ to/TO those/DT found/VBN in/IN mammals/NNS have/VBP been/VBN identified/VBN in/IN the/DT promoter/NN ./. 
These/DT include/VBP (/( 5'-3'/JJ )/) a/DT composite/JJ NF-AT//JJ "/`` AP-1/NN "/'' element/NN ,/, a/DT CD28/NN response/NN element/NN ,/, an/DT AP-1/NN element/NN ,/, an/DT NF-AT/NN element/NN ,/, and/CC the/DT AP-1/NN part/NN of/IN an/DT AP-1/octamer/NN composite/JJ element/NN ./. 
The/DT mammalian/JJ NF-kappaB/NN and/CC octamer/NN binding/NN sites/NNS seem/VBP to/TO be/VB absent/JJ ,/, although/IN there/EX are/VBP alternative/JJ potential/JJ NF-kappaB/NN and/CC octamer-binding/JJ elements/NNS in/IN the/DT chicken/NN IL2/NN promoter/NN ,/, in/IN close/JJ proximity/NN to/TO their/PRP$ mammalian/JJ homologues/NNS ./. 
Sequence/NN comparisons/NNS also/RB predict/VBP other/JJ potential/JJ transcription/NN factor/NN binding/NN sites/NNS as/IN yet/RB undescribed/JJ in/IN mammalian/JJ IL2/NN promoters/NNS ./. 
A/DT Taq/NN I/CD polymorphism/NN was/VBD identified/VBN which/WDT enabled/VBD chicken/NN IL2/NN to/TO be/VB mapped/VBN to/TO chromosome/NN 4/CD ,/, linked/VBN to/TO ANX5/NN ,/, with/IN synteny/NN with/IN mouse/NN chromosome/NN 3/CD and/CC human/JJ chromosome/NN 4/CD ./. 
This/DT is/VBZ the/DT first/JJ non-mammalian/JJ cytokine/NN gene/NN to/TO be/VB mapped/VBN ./. 
UI/LS -/: 98158921/CD 
TI/LS -/: Endothelial/JJ production/NN of/IN MCP-1/NN :/: modulation/NN by/IN heparin/NN and/CC consequences/NNS for/IN mononuclear/JJ cell/NN activation/NN ./. 
AB/LS -/: Heparin/NN is/VBZ a/DT polyanionic/JJ glycosaminoglycan/NN (/( GAG/NN )/) that/WDT can/MD bind/VB with/IN high/JJ affinity/NN to/TO a/DT range/NN of/IN cytokines/NNS including/VBG interferon-gamma/NN (/( IFN-gamma/NN )/) and/CC members/NNS of/IN the/DT chemokine/NN superfamily/NN ./. 
This/DT GAG/NN also/RB possesses/VBZ immunomodulatory/JJ activity/NN in/FW vivo/FW and/CC can/MD antagonize/VB the/DT capacity/NN of/IN IFN-gamma/NN to/TO induce/VB class/NN II/CD MHC/NN antigen/NN expression/NN ,/, and/CC to/TO up-regulate/VBP intercellular/JJ adhesion/NN molecule-1/NN ,/, by/IN cultured/VBN endothelial/JJ cells/NNS ./. 
Previous/JJ studies/NNS have/VBP shown/VBN that/IN binding/NN to/TO cell-surface/JJ heparan/NN sulphate/NN is/VBZ essential/JJ for/IN optimal/JJ activity/NN of/IN IFN-gamma/NN and/CC that/IN free/JJ heparin/NN competitively/RB inhibits/VBZ this/DT sequestration/NN process/NN ./. 
The/DT present/JJ study/NN was/VBD performed/VBN to/TO increase/VB our/PRP$ understanding/NN of/IN the/DT immunosuppressive/JJ activity/NN of/IN heparin/NN by/IN investigation/NN of/IN potential/JJ antagonism/NN of/IN the/DT production/NN and/CC function/NN of/IN monocyte/NN chemotactic/JJ peptide-1/NN (/( MCP-1/NN )/) ,/, a/DT chemokine/NN important/JJ for/IN mononuclear/JJ leucocyte/NN recruitment/NN across/IN vascular/JJ endothelium/NN ./. 
It/PRP was/VBD found/VBN that/IN mixture/NN of/IN heparin/NN with/IN IFN-gamma/NN inhibited/VBD up-regulation/NN of/IN the/DT signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN protein/NN ,/, STAT-1/NN produced/VBN normally/RB by/IN treatment/NN of/IN endothelial/JJ cells/NNS with/IN IFN-gamma/NN ./. 
An/DT inhibition/NN of/IN MCP-1/NN production/NN was/VBD observed/VBN that/WDT was/VBD specifically/RB caused/VBN by/IN mixture/NN of/IN IFN-gamma/NN with/IN heparin-like/JJ ,/, and/CC therefore/RB cytokine-binding/JJ ,/, GAGs/NNS ./. 
It/PRP was/VBD also/RB shown/VBN that/IN mixture/NN of/IN heparin-like/JJ GAGs/NNS with/IN MCP-1/NN inhibited/VBD the/DT rapid/JJ tyrosine/NN phosphorylation/NN of/IN phosphatidylinositol/NN 3-kinase/NN which/WDT is/VBZ normally/RB produced/VBN by/IN treatment/NN of/IN mononuclear/JJ leucocytes/NNS with/IN this/DT chemokine/NN ./. 
Blockade/NN of/IN this/DT intracellular/JJ signalling/NN event/NN was/VBD associated/VBN with/IN a/DT reduction/NN in/IN the/DT normal/JJ transendothelial/JJ migration/NN response/NN towards/IN MCP-1/NN ./. 
Results/NNS from/IN this/DT study/NN indicate/VBP that/IN soluble/JJ ,/, heparin-like/JJ GAGs/NNS can/MD block/VB IFN-gamma-dependent/JJ up-regulation/NN of/IN MCP-1/NN production/NN by/IN cultured/VBN endothelial/JJ cells/NNS ,/, and/CC can/MD also/RB antagonize/VB the/DT leucocyte-activating/JJ and/CC migration-promoting/JJ properties/NNS of/IN pre-existing/JJ MCP-1/NN ./. 
These/DT activities/NNS may/MD contribute/VB to/TO the/DT immunomodulatory/JJ properties/NNS of/IN heparin/NN ./. 
UI/LS -/: 98073333/CD 
TI/LS -/: [/( Molecular-biologic/JJ aspects/NNS of/IN interaction/NN between/IN nervous/JJ and/CC immune/JJ systems/NNS ]/) 
AB/LS -/: The/DT problem/NN of/IN the/DT neuro-immuno/JJ interactions/NNS on/IN the/DT level/NN of/IN the/DT protein/NN trans-factors/NNS ,/, stimulating/VBG interleukin-2/NN (/( IL-2/NN )/) gene/NN expression/NN was/VBD discussed/VBN ./. 
The/DT physico-chemical/JJ and/CC functional/JJ parameters/NNS of/IN the/DT low/JJ molecular/JJ nuclear/JJ proteins/NNS (/( SP/NN and/CC BP-14/NN ,/, 18/CD ,/, 19/CD kDs/NNS )/) isolated/VBN from/IN splenic/JJ and/CC brain/NN cells/NNS of/IN immunized/JJ rats/NNS were/VBD studied/VBN ./. 
The/DT binding/NN of/IN these/DT proteins/NNS to/TO the/DT regulatory/JJ region/NN of/IN IL-2/NN gene/NN in/FW vitro/FW and/CC stimulation/NN of/IN the/DT IL-2mRNA/NN synthesis/NN in/IN splenic/JJ T-/NN lymphocytes/NNS culture/NN in/IN normal/JJ conditions/NNS were/VBD shown/VBN ./. 
The/DT protective/JJ effect/NN of/IN SP/NN and/CC BP/NN on/IN the/DT IL-2mRNA/NN synthesis/NN in/IN stressful/JJ conditions/NNS and/CC by/IN the/DT T-cells/NNS treatment/NN with/IN the/DT CsA/NN was/VBD demonstrated/VBN ./. 
UI/LS -/: 99168986/CD 
TI/LS -/: Interferon-alpha/NN activates/VBZ multiple/JJ STAT/NN proteins/NNS and/CC upregulates/VBZ proliferation-associated/JJ IL-2Ralpha/NN ,/, c-myc/NN ,/, and/CC pim-1/NN genes/NNS in/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: Interferon-alpha/NN (/( IFN-alpha/NN )/) is/VBZ a/DT pleiotropic/JJ cytokine/NN that/WDT has/VBZ antiviral/JJ ,/, antiproliferative/JJ ,/, and/CC immunoregulatory/JJ functions/NNS ./. 
There/EX is/VBZ increasing/VBG evidence/NN that/IN IFN-alpha/NN has/VBZ an/DT important/JJ role/NN in/IN T-cell/NN biology/NN ./. 
We/PRP have/VBP analyzed/VBN the/DT expression/NN of/IN IL-2Ralpha/NN ,/, c-myc/NN ,/, and/CC pim-1/NN genes/NNS in/IN anti-CD3-activated/JJ human/JJ T/NN lymphocytes/NNS ./. 
The/DT induction/NN of/IN these/DT genes/NNS is/VBZ associated/VBN with/IN interleukin-2/NN (/( IL-2/NN )/) -induced/JJ T-cell/NN proliferation/NN ./. 
Treatment/NN of/IN T/NN lymphocytes/NNS with/IN IFN-alpha/NN ,/, IL-2/NN ,/, IL-12/NN ,/, and/CC IL-15/NN upregulated/VBD IL-2Ralpha/NN ,/, c-myc/NN ,/, and/CC pim-1/NN gene/NN expression/NN ./. 
IFN-alpha/NN also/RB sensitized/VBD T/NN cells/NNS to/TO IL-2-induced/JJ proliferation/NN ,/, further/RBR suggesting/VBG that/IN IFN-alpha/NN may/MD be/VB involved/VBN in/IN the/DT regulation/NN of/IN T-cell/NN mitogenesis/NN ./. 
When/WRB we/PRP analyzed/VBD the/DT nature/NN of/IN STAT/NN proteins/NNS capable/JJ of/IN binding/VBG to/TO IL-2Ralpha/NN ,/, pim-1/NN ,/, and/CC IRF-1/NN GAS/NN elements/NNS after/IN cytokine/NN stimulation/NN ,/, we/PRP observed/VBD IFN-alpha-induced/JJ binding/NN of/IN STAT1/NN ,/, STAT3/NN ,/, and/CC STAT4/NN ,/, but/CC not/RB STAT5/NN to/TO all/DT of/IN these/DT elements/NNS ./. 
Yet/RB ,/, IFN-alpha/NN was/VBD able/JJ to/TO activate/VB binding/NN of/IN STAT5/NN to/TO the/DT high-affinity/JJ IFP53/NN GAS/NN site/NN ./. 
IFN-alpha/NN enhanced/VBD tyrosine/NN phosphorylation/NN of/IN STAT1/NN ,/, STAT3/NN ,/, STAT4/NN ,/, STAT5a/NN ,/, and/CC STAT5b/NN ./. 
IL-12/NN induced/VBD STAT4/NN and/CC IL-2/NN and/CC IL-15/NN induced/VBD STAT5/NN binding/NN to/TO the/DT GAS/NN elements/NNS ./. 
Taken/VBN together/RB ,/, our/PRP$ results/NNS suggest/VBP that/IN IFN-alpha/NN ,/, IL-2/NN ,/, IL-12/NN ,/, and/CC IL-15/NN have/VBP overlapping/VBG activities/NNS on/IN human/JJ T/NN cells/NNS ./. 
These/DT findings/NNS thus/RB emphasize/VBP the/DT importance/NN of/IN IFN-alpha/NN as/IN a/DT T-cell/NN regulatory/JJ cytokine/NN ./. 
UI/LS -/: 99155339/CD 
TI/LS -/: The/DT Megakaryocyte/Platelet-specific/JJ enhancer/NN of/IN the/DT alpha2beta1/NN integrin/NN gene/NN :/: two/CD tandem/JJ AP1/NN sites/NNS and/CC the/DT mitogen-activated/JJ protein/NN kinase/NN signaling/NN cascade/NN ./. 
AB/LS -/: The/DT alpha2beta1/NN integrin/NN ,/, a/DT collagen/NN receptor/NN on/IN platelets/NNS and/CC megakaryocytes/NNS ,/, is/VBZ required/VBN for/IN normal/JJ platelet/NN function/NN ./. 
Transcriptional/JJ regulation/NN of/IN the/DT alpha2/NN integrin/NN gene/NN in/IN cells/NNS undergoing/VBG megakaryocytic/JJ differentiation/NN requires/VBZ a/DT core/NN promoter/NN between/IN bp/NN -30/CD and/CC -92/CD ,/, a/DT silencer/NN between/IN bp/NN -92/CD and/CC -351/CD ,/, and/CC megakaryocytic/JJ enhancers/NNS in/IN the/DT distal/JJ 5'/JJ flank/NN ./. 
We/PRP have/VBP now/RB identified/VBN a/DT 229-bp/JJ region/NN of/IN the/DT distal/JJ 5/CD '/POS flank/NN of/IN the/DT alpha2/CD integrin/NN gene/NN required/VBN for/IN high-level/JJ enhancer/NN activity/NN in/IN cells/NNS with/IN megakaryocytic/JJ features/NNS ./. 
Two/CD tandem/JJ AP1/NN binding/NN sites/NNS with/IN dyad/NN symmetry/NN are/VBP required/VBN for/IN enhancer/NN activity/NN and/CC for/IN DNA-protein/JJ complex/NN formation/NN with/IN members/NNS of/IN the/DT c-fos/c-jun/NN family/NN ./. 
The/DT requirement/NN for/IN AP1/NN activation/NN suggested/VBD a/DT role/NN for/IN the/DT mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) signaling/NN pathway/NN in/IN regulating/VBG alpha2/NN integrin/NN gene/NN expression/NN ./. 
Inhibition/NN of/IN the/DT MAP/NN kinase/NN cascade/NN with/IN PD98059/NN ,/, a/DT specific/JJ inhibitor/NN of/IN MAPK/NN kinase/NN 1/CD ,/, prevented/VBD the/DT expression/NN of/IN the/DT alpha2/NN integrin/NN subunit/NN in/IN cells/NNS induced/VBN to/TO become/VB megakaryocytic/JJ ./. 
We/PRP provide/VBP a/DT model/NN of/IN megakaryocytic/JJ differentiation/NN in/IN which/WDT expression/NN of/IN the/DT alpha2/NN integrin/NN gene/NN requires/VBZ signaling/VBG via/IN the/DT MAP/NN kinase/NN pathway/NN to/TO activate/VB two/CD tandem/JJ AP1/NN binding/NN sites/NNS in/IN the/DT alpha2/NN integrin/NN enhancer/NN ./. 
UI/LS -/: 99142609/CD 
TI/LS -/: Functional/JJ association/NN of/IN Nmi/NN with/IN Stat5/NN and/CC Stat1/NN in/IN IL-2-/NN and/CC IFNgamma-mediated/JJ signaling/NN ./. 
AB/LS -/: Using/VBG the/DT coiled-coil/JJ region/NN of/IN Stat5b/NN as/IN the/DT bait/NN in/IN a/DT yeast/NN two-hybrid/JJ screen/NN ,/, we/PRP identified/VBD the/DT association/NN of/IN Nmi/NN ,/, a/DT protein/NN of/IN unknown/JJ function/NN previously/RB reported/VBN as/IN an/DT N-Myc/NN interactor/NN ./. 
We/PRP further/RB show/VBP that/IN Nmi/NN interacts/VBZ with/IN all/DT STATs/NNS except/IN Stat2/NN ./. 
We/PRP evaluated/VBD two/CD cytokine/NN systems/NNS ,/, IL-2/NN and/CC IFNgamma/NN ,/, and/CC demonstrate/VBP that/IN Nmi/NN augments/VBZ STAT-mediated/JJ transcription/NN in/IN response/NN to/TO these/DT cytokines/NNS ./. 
Interestingly/RB ,/, Nmi/NN lacks/VBZ an/DT intrinsic/JJ transcriptional/JJ activation/NN domain/NN ;/: instead/RB ,/, Nmi/NN enhances/VBZ the/DT association/NN of/IN CBP/p300/NN coactivator/NN proteins/NNS with/IN Stat1/NN and/CC Stat5/NN ,/, and/CC together/RB with/IN CBP/p300/NN can/MD augment/VB IL-2-/NN and/CC IFNgamma-dependent/JJ transcription/NN ./. 
Therefore/RB ,/, our/PRP$ data/NNS not/RB only/RB reveal/VBP that/IN Nmi/NN can/MD potentiate/VB STAT-dependent/JJ transcription/NN ,/, but/CC also/RB suggest/VBP that/IN it/PRP can/MD augment/VB coactivator/NN protein/NN recruitment/NN to/TO at/IN least/JJS some/DT members/NNS of/IN a/DT group/NN of/IN sequence-specific/JJ transcription/NN factors/NNS ./. 
UI/LS -/: 99137801/CD 
TI/LS -/: Lactobacilli/NN and/CC vaginal/JJ host/NN defense/NN :/: activation/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD long/JJ terminal/JJ repeat/NN ,/, cytokine/NN production/NN ,/, and/CC NF-kappaB/NN ./. 
AB/LS -/: Lactobacilli/NN ,/, a/DT component/NN of/IN the/DT normal/JJ vaginal/JJ flora/NN ,/, can/MD activate/VB the/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) -1/CD long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) in/IN the/DT Jurkat/NN T/NN lymphocyte/NN and/CC THP-1/NN macrophage/NN cell/NN lines/NNS ./. 
Activation/NN of/IN the/DT LTR/NN in/IN Jurkat/NN cells/NNS was/VBD strongly/RB enhanced/VBN by/IN vanadate/NN and/CC inhibited/VBN by/IN catalase/NN ,/, implicating/VBG H2O2/NN ./. 
In/IN contrast/NN ,/, activation/NN in/IN THP-1/NN cells/NNS occurred/VBD in/IN the/DT absence/NN of/IN vanadate/NN and/CC was/VBD unaffected/VBN by/IN catalase/NN ./. 
The/DT active/JJ material/NN partitioned/VBD into/IN the/DT phenol/NN layer/NN on/IN hot/JJ aqueous/JJ phenol/NN extraction/NN ./. 
Lactobacilli/NN also/RB increased/VBD tumor/NN necrosis/NN factor-alpha/NN and/CC interleukin-1beta/NN production/NN and/CC activated/VBD NF-kappaB/NN in/IN THP-1/NN cells/NNS and/CC increased/VBD tumor/NN necrosis/NN factor-alpha/NN production/NN by/IN human/JJ monocytes/NNS ./. 
Human/JJ vaginal/JJ fluid/NN specimens/NNS had/VBD comparable/JJ properties/NNS ,/, which/WDT correlated/VBD with/IN their/PRP$ bacterial/JJ content/NN ./. 
These/DT findings/NNS suggest/VBP the/DT presence/NN in/IN vaginal/JJ fluid/NN of/IN agent/NN (/( s/NNS )/) derived/VBN from/IN indigenous/JJ bacteria/NNS that/WDT can/MD activate/VB the/DT HIV-1/NN LTR/NN ,/, cytokine/NN production/NN ,/, and/CC NF-kappaB/NN in/IN cells/NNS of/IN macrophage/NN lineage/NN ,/, with/IN possible/JJ influence/NN on/IN vaginal/JJ physiology/NN and/CC host/NN defense/NN ./. 
UI/LS -/: 99113747/CD 
TI/LS -/: T/NN cell/NN priming/NN enhances/VBZ IL-4/NN gene/NN expression/NN by/IN increasing/VBG nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS ./. 
AB/LS -/: The/DT repetitive/JJ activation/NN of/IN T/NN cells/NNS (/( priming/NN )/) enhances/VBZ the/DT expression/NN of/IN many/JJ cytokines/NNS ,/, such/JJ as/IN IL-4/NN ,/, but/CC not/RB others/NNS ,/, such/JJ as/IN IL-2/NN ./. 
Molecular/JJ mechanisms/NNS underlying/VBG selective/JJ expression/NN of/IN cytokines/NNS by/IN T/NN cells/NNS remain/VBP poorly/RB understood/VBN ./. 
Here/RB we/PRP show/VBP that/IN priming/NN of/IN CD4/NN T/NN cells/NNS selectively/RB enhances/VBZ IL-4/NN expression/NN relative/JJ to/TO IL-2/NN expression/NN by/IN a/DT transcriptional/JJ mechanism/NN involving/VBG nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) proteins/NNS ./. 
As/IN detected/VBN by/IN in/FW vivo/FW footprinting/NN ,/, priming/NN markedly/RB increases/VBZ the/DT activation-dependent/JJ engagement/NN of/IN the/DT P0/NN and/CC P1/NN NFAT-binding/JJ elements/NNS of/IN the/DT IL-4/NN promoter/NN ./. 
Moreover/RB ,/, each/DT proximal/JJ P/NN element/NN is/VBZ essential/JJ for/IN optimal/JJ IL-4/NN promoter/NN activity/NN ./. 
Activated/VBN primed/VBN CD4/NN T/NN cells/NNS contain/VBP more/JJR NFAT1/NN and/CC support/VBP greater/JJR NFAT-directed/JJ transcription/NN than/IN unprimed/JJ CD4/NN T/NN cells/NNS ,/, while/IN activator/NN protein/NN 1/CD binding/NN and/CC activator/NN protein/NN 1-mediated/JJ transcription/NN by/IN both/DT cell/NN types/NNS is/VBZ similar/JJ ./. 
Increased/VBN expression/NN of/IN wild-type/JJ NFAT1/NN substantially/RB increases/VBZ IL-4/NN promoter/NN activity/NN in/IN unprimed/JJ CD4/NN T/NN cells/NNS ,/, suggesting/VBG NFAT1/NN may/MD be/VB limiting/VBG for/IN IL-4/NN gene/NN expression/NN in/IN this/DT cell/NN type/NN ./. 
Furthermore/RB ,/, a/DT truncated/JJ form/NN of/IN NFAT1/NN acts/VBZ as/IN a/DT dominant-negative/JJ ,/, reducing/VBG IL-4/NN promoter/NN activity/NN in/IN primed/VBN CD4/NN T/NN cells/NNS and/CC confirming/VBG the/DT importance/NN of/IN endogenous/JJ NFAT/NN to/TO increased/VBN IL-4/NN gene/NN expression/NN by/IN effector/NN T/NN cells/NNS ./. 
NFAT1/NN appears/VBZ to/TO be/VB the/DT major/JJ NFAT/NN family/NN member/NN responsible/JJ for/IN the/DT initial/JJ increased/VBN expression/NN of/IN IL-4/NN by/IN primed/VBN CD4/NN T/NN cells/NNS ./. 
UI/LS -/: 99103960/CD 
TI/LS -/: Differential/JJ monocyte/NN adhesion/NN and/CC adhesion/NN molecule/NN expression/NN in/IN venous/JJ and/CC arterial/JJ endothelial/JJ cells/NNS ./. 
AB/LS -/: We/PRP compared/VBD U-937/NN cell/NN adhesion/NN and/CC adhesion/NN molecule/NN expression/NN in/IN human/JJ umbilical/JJ venous/JJ (/( HUVECs/NNS )/) and/CC arterial/JJ (/( HUAECs/NNS )/) endothelial/JJ cells/NNS exposed/VBN to/TO tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) ,/, interleukin-1/NN ,/, and/CC lipopolysaccharide/NN (/( LPS/NN )/) ./. 
TNF/NN and/CC LPS/NN stimulated/VBD vascular/JJ cell/NN adhesion/NN molecule/NN (/( VCAM/NN )/) -1/CD surface/NN expression/NN and/CC adhesion/NN of/IN U-937/NN monocyte-like/JJ cells/NNS to/TO HUVECs/NNS but/CC not/RB to/TO HUAECs/NNS ./. 
Antibody/NN studies/NNS demonstrated/VBD that/IN in/IN HUVECs/NNS at/IN least/JJS 75/CD %/NN of/IN the/DT adhesion/NN response/NN is/VBZ VCAM-1/NN mediated/VBN ./. 
Interleukin-1/NN stimulated/VBD U-937/NN cell/NN adhesion/NN to/TO and/CC VCAM-1/NN surface/NN expression/NN in/IN both/CC HUVECs/NNS and/CC HUAECs/NNS ./. 
Pyrrolidinedithiocarbamate/NN and/CC the/DT proteasome/NN inhibitor/NN MG-132/NN blocked/VBD TNF-/NN and/CC LPS-stimulated/JJ U-937/NN cell/NN adhesion/NN to/TO HUVECs/NNS ./. 
These/DT agents/NNS also/RB significantly/RB decreased/VBD TNF-/NN and/CC LPS-stimulated/JJ increases/NNS in/IN HUVEC/NN surface/NN VCAM-1/NN ./. 
TNF/NN increased/VBD VCAM-1/NN protein/NN and/CC mRNA/NN in/IN HUVECs/NNS that/WDT was/VBD blocked/VBN by/IN pyrrolidinedithiocarbamate/NN ./. 
However/RB ,/, neither/CC TNF/NN or/CC LPS/NN stimulated/VBD VCAM-1/NN expression/NN in/IN HUAECs/NNS ./. 
TNF/NN stimulated/VBD expression/NN of/IN both/CC intercellular/JJ adhesion/NN molecule-1/NN and/CC E-selectin/NN in/IN HUVECs/NNS ,/, but/CC in/IN HUAECs/NNS ,/, only/RB intercellular/JJ adhesion/NN molecule-1/NN was/VBD increased/VBN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS demonstrated/VBD no/DT difference/NN in/IN the/DT pattern/NN of/IN TNF-stimulated/JJ nuclear/JJ factor-kappaB/NN activation/NN between/IN HUVECs/NNS and/CC HUAECs/NNS ./. 
These/DT studies/NNS demonstrate/VBP a/DT novel/JJ and/CC striking/JJ insensitivity/NN of/IN arterial/JJ endothelium/NN to/TO the/DT effects/NNS of/IN TNF/NN and/CC LPS/NN and/CC indicate/VBP a/DT dissociation/NN between/IN the/DT ability/NN of/IN HUAECs/NNS to/TO upregulate/VB nuclear/JJ factor-kappaB/NN and/CC VCAM-1/NN ./. 
UI/LS -/: 99091536/CD 
TI/LS -/: Functional/JJ testosterone/NN receptors/NNS in/IN plasma/NN membranes/NNS of/IN T/NN cells/NNS ./. 
AB/LS -/: T/NN cells/NNS are/VBP considered/VBN to/TO be/VB unresponsive/JJ to/TO testosterone/NN due/JJ to/TO the/DT absence/NN of/IN androgen/NN receptors/NNS (/( AR/NNS )/) ./. 
Here/RB ,/, we/PRP demonstrate/VBP the/DT testosterone/NN responsiveness/NN of/IN murine/JJ splenic/JJ T/NN cells/NNS in/FW vitro/FW as/RB well/RB as/IN the/DT presence/NN of/IN unconventional/JJ cell/NN surface/NN receptors/NNS for/IN testosterone/NN and/CC classical/JJ intracellular/JJ AR/NNS ./. 
Binding/VBG sites/NNS for/IN testosterone/NN on/IN the/DT surface/NN of/IN both/CC CD4(+)/JJ and/CC CD8(+)/JJ subsets/NNS of/IN T/NN cells/NNS are/VBP directly/RB revealed/VBN with/IN the/DT impeded/JJ ligand/NN testosterone-BSA-FITC/NN by/IN confocal/JJ laser/NN scanning/NN microscopy/NN (/( CLSM/NN )/) and/CC flow/NN cytometry/NN ,/, respectively/RB ./. 
Binding/NN of/IN the/DT plasma/NN membrane/NN impermeable/JJ testosterone-BSA/NN conjugate/NN induces/VBZ a/DT rapid/JJ rise/NN (/( </JJR 5/CD s/NN )/) in/IN [Ca2+]i/NN of/IN Fura-2-loaded/JJ T/NN cells/NNS ./. 
This/DT rise/NN reflects/VBZ influx/NN of/IN extracellular/JJ Ca2+/NN through/IN non-voltage-gated/JJ and/CC Ni2+-blockable/JJ Ca2+/NN channels/NNS of/IN the/DT plasma/NN membrane/NN ./. 
The/DT testosterone-BSA-induced/JJ Ca2+/NN import/NN is/VBZ not/RB affected/VBN by/IN cyproterone/NN ,/, a/DT blocker/NN of/IN the/DT AR/NNS ./. 
In/IN addition/NN ,/, AR/NNS are/VBP not/RB detectable/JJ on/IN the/DT surface/NN of/IN intact/JJ T/NN cells/NNS when/WRB using/VBG anti-AR/JJ antibodies/NNS directed/VBN against/IN the/DT amino/NN and/CC carboxy/NN terminus/NN of/IN the/DT AR/NNS ,/, although/IN T/NN cells/NNS contain/VBP AR/NNS ,/, as/IN revealed/VBN by/IN reverse/JJ transcription-polymerase/JJ chain/NN reactions/NNS and/CC Western/NN blotting/NN ./. 
AR/NN can/MD be/VB visualized/VBN with/IN the/DT anti-AR/JJ antibodies/NNS in/IN the/DT cytoplasm/NN of/IN permeabilized/JJ T/NN cells/NNS by/IN using/VBG CLSM/NN ,/, though/IN AR/NNS are/VBP not/RB detectable/JJ in/IN cytosol/NN fractions/NNS when/WRB using/VBG the/DT charcoal/NN binding/NN assay/NN with/IN 3H-R1881/NN as/IN ligand/NN ./. 
Cytoplasmic/JJ AR/NNS do/VBP not/RB translocate/VB to/TO the/DT nucleus/NN of/IN T/NN cells/NNS in/IN the/DT presence/NN of/IN testosterone/NN ,/, in/IN contrast/NN to/TO cytoplasmic/JJ AR/NNS in/IN human/JJ cancer/NN LNCaP/NN cells/NNS ./. 
These/DT findings/NNS suggest/VBP that/IN the/DT classical/JJ AR/NNS present/JJ in/IN splenic/JJ T/NN cells/NNS are/VBP not/RB active/JJ in/IN the/DT genomic/JJ pathway/NN ./. 
By/IN contrast/NN ,/, the/DT cell/NN surface/NN receptors/NNS for/IN testosterone/NN are/VBP in/IN a/DT functionally/RB active/JJ state/NN ,/, enabling/VBG T/NN cells/NNS a/DT nongenomic/JJ response/NN to/TO testosterone/NN ./. 
UI/LS -/: 98295583/CD 
TI/LS -/: Limited/JJ proteolysis/NN for/IN assaying/VBG ligand/NN binding/NN affinities/NNS of/IN nuclear/JJ receptors/NNS ./. 
AB/LS -/: The/DT binding/NN of/IN natural/JJ or/CC synthetic/JJ ligands/NNS to/TO nuclear/JJ receptors/NNS is/VBZ the/DT triggering/VBG event/NN leading/VBG to/TO gene/NN transcription/NN activation/NN or/CC repression/NN ./. 
Ligand/NN binding/VBG to/TO the/DT ligand/NN binding/NN domain/NN of/IN these/DT receptors/NNS induces/VBZ conformational/JJ changes/NNS that/WDT are/VBP evidenced/VBN by/IN an/DT increased/VBN resistance/NN of/IN this/DT domain/NN to/TO proteases/NNS ./. 
In/FW vitro/FW labeled/VBN receptors/NNS were/VBD incubated/VBN with/IN various/JJ synthetic/JJ or/CC natural/JJ agonists/NNS or/CC antagonists/NNS and/CC submitted/VBN to/TO trypsin/NN digestion/NN ./. 
Proteolysis/NN products/NNS were/VBD separated/VBN by/IN SDS-PAGE/NN and/CC quantified/VBN ./. 
The/DT amount/NN of/IN trypsin-resistant/JJ fragments/NNS was/VBD proportional/JJ to/TO receptor/NN occupancy/NN by/IN the/DT ligand/NN ,/, and/CC allowed/VBD the/DT determination/NN of/IN dissociation/NN constants/NNS (/( kDa/NN )/) ./. 
Using/VBG the/DT wild-type/JJ or/CC mutated/VBN human/JJ retinoic/JJ acid/NN receptor/NN alpha/NN as/IN a/DT model/NN ,/, kDa/NN values/NNS determined/VBN by/IN classical/JJ competition/NN binding/NN assays/NNS using/VBG tritiated/JJ ligands/NNS are/VBP in/IN agreement/NN with/IN those/DT measured/VBN by/IN the/DT proteolytic/JJ assay/NN ./. 
This/DT method/NN was/VBD successfully/RB extended/VBN to/TO human/JJ retinoic/JJ X/NN receptor/NN alpha/NN ,/, glucocorticoid/NN receptor/NN ,/, and/CC progesterone/NN receptor/NN ,/, thus/RB providing/VBG a/DT basis/NN for/IN a/DT new/JJ ,/, faster/JJR assay/NN to/TO determine/VB simultaneously/RB the/DT affinity/NN and/CC conformation/NN of/IN receptors/NNS when/WRB bound/VBN to/TO a/DT given/JJ ligand/NN ./. 
UI/LS -/: 98153997/CD 
TI/LS -/: Genes/NNS that/WDT regulate/VBP interleukin-4/NN expression/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Interleukin-4/NN is/VBZ an/DT immunomodulatory/JJ cytokine/NN which/WDT plays/VBZ a/DT central/JJ role/NN in/IN the/DT regulation/NN of/IN allergic/JJ and/CC atopic/JJ immune/JJ responses/NNS ./. 
Significant/JJ progress/NN has/VBZ been/VBN made/VBN in/IN gaining/VBG a/DT detailed/JJ understanding/NN of/IN the/DT transcriptional/JJ regulation/NN of/IN the/DT interleukin-4/NN gene/NN ./. 
The/DT recent/JJ identification/NN and/CC characterization/NN of/IN several/JJ key/JJ transcription/NN factors/NNS has/VBZ helped/VBN to/TO elucidate/VB the/DT molecular/JJ mechanisms/NNS of/IN T/NN helper/NN cell/NN cytokine/NN gene/NN expression/NN ./. 
UI/LS -/: 98064072/CD 
TI/LS -/: B/NN lymphocytes/NNS from/IN patients/NNS with/IN chronic/JJ lymphocytic/JJ leukemia/NN contain/VBP signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) 1/CD and/CC STAT3/NN constitutively/RB phosphorylated/VBN on/IN serine/NN residues/NNS ./. 
AB/LS -/: To/TO explore/VB the/DT pathogenesis/NN of/IN chronic/JJ lymphocytic/JJ leukemia/NN (/( CLL/NN )/) ,/, we/PRP examined/VBD whether/IN phosphorylation/NN of/IN one/CD or/CC more/JJR signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) factors/NNS was/VBD abnormal/JJ in/IN cells/NNS from/IN CLL/NN patients/NNS ./. 
No/DT constitutive/JJ tyrosine/NN phosphorylation/NN was/VBD detected/VBN on/IN any/DT STAT/NN in/IN CLL/NN cells/NNS ./. 
To/TO assess/VB the/DT phosphorylation/NN of/IN serine/NN residues/NNS of/IN STAT1/NN and/CC STAT3/NN in/IN CLL/NN cells/NNS ,/, we/PRP raised/VBD antibodies/NNS that/WDT specifically/RB recognize/VBP the/DT form/NN of/IN STAT1/NN phosphorylated/VBN on/IN ser-727/NN and/CC the/DT form/NN of/IN STAT3/NN phosphorylated/VBN on/IN ser-727/NN ./. 
We/PRP found/VBD that/IN in/IN 100/CD %/NN of/IN patients/NNS with/IN CLL/NN (/( n/NN =/JJ 32/CD )/) ,/, STAT1/NN and/CC STAT3/NN were/VBD constitutively/RB phosphorylated/VBN on/IN serine/NN ./. 
This/DT was/VBD in/IN contrast/NN to/TO normal/JJ peripheral/JJ blood/NN B/NN lymphocytes/NNS or/CC CD5+)/JJ B/NN cells/NNS isolated/VBN from/IN tonsils/NNS ,/, in/IN which/WDT this/DT phosphorylation/NN was/VBD absent/JJ ./. 
Serine/NN phosphorylation/NN of/IN STAT1/NN and/CC STAT3/NN was/VBD seen/VBN occasionally/RB in/IN other/JJ leukemias/NNS ,/, but/CC it/PRP was/VBD a/DT universal/JJ finding/NN only/RB in/IN CLL/NN ./. 
The/DT serine/NN phosphorylation/NN of/IN these/DT STATs/NNS was/VBD a/DT continuous/JJ process/NN ,/, as/IN incubation/NN of/IN CLL/NN cells/NNS with/IN the/DT kinase/NN inhibitor/NN H7/NN led/VBD to/TO the/DT dephosphorylation/NN of/IN these/DT serine/NN residues/NNS ./. 
The/DT STAT/NN serine/NN kinase/NN in/IN CLL/NN cells/NNS has/VBZ not/RB been/VBN identified/VBN ,/, and/CC appears/VBZ to/TO be/VB neither/DT mitogen-activated/JJ protein/NN kinase/NN nor/CC pp70(s6k)/NN ./. 
In/IN summary/NN ,/, the/DT constitutive/JJ serine/NN phosphorylation/NN of/IN STAT1/NN and/CC STAT3/NN is/VBZ present/JJ in/IN all/DT CLL/NN samples/NNS tested/VBN to/TO date/NN ,/, although/IN the/DT physiologic/JJ significance/NN of/IN this/DT modification/NN remains/VBZ to/TO be/VB determined/VBN ./. 
UI/LS -/: 99169183/CD 
TI/LS -/: Activation/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD expression/NN by/IN Gardnerella/FW vaginalis/FW ./. 
AB/LS -/: Bacterial/JJ vaginosis/NN (/( BV/NN )/) is/VBZ associated/VBN with/IN an/DT increased/VBN rate/NN of/IN sexual/JJ transmission/NN of/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) type/NN 1/CD ,/, and/CC Gardnerella/FW vaginalis/FW is/VBZ frequently/RB isolated/VBN from/IN the/DT genital/JJ tracts/NNS of/IN women/NNS with/IN BV/NN ./. 
G./FW vaginalis/FW lysates/NNS were/VBD found/VBN to/TO significantly/RB stimulate/VB HIV/NN expression/NN in/IN monocytoid/JJ cells/NNS ./. 
Stimulation/NN was/VBD significantly/RB higher/JJR when/WRB lysates/NNS were/VBD heated/VBN at/IN 100/CD degrees/NNS C/NN for/IN 5/CD min/NN but/CC was/VBD reduced/VBN by/IN treatment/NN with/IN lysozyme/NN or/CC protease/NN ./. 
G./FW vaginalis/FW lysates/NNS also/RB activated/VBD HIV/NN expression/NN in/IN certain/JJ T/NN cell/NN lines/NNS ./. 
G./FW vaginalis/FW lysates/NNS activated/VBD HIV/NN long-terminal/JJ repeat/NN transcription/NN in/IN HIV-infected/JJ cells/NNS and/CC increased/VBD NF-kappaB/NN binding/NN activity/NN ,/, indicating/VBG an/DT effect/NN by/IN G./FW vaginalis/FW on/IN HIV/NN transcription/NN ./. 
The/DT activation/NN of/IN HIV/NN production/NN by/IN G./FW vaginalis/FW suggests/VBZ that/IN genital/JJ tract/NN infection/NN with/IN G./FW vaginalis/FW increases/VBZ the/DT risk/NN of/IN HIV/NN transmission/NN by/IN increasing/VBG HIV/NN expression/NN in/IN the/DT genital/JJ tract/NN ./. 
This/DT may/MD explain/VB ,/, at/IN least/JJS in/IN part/NN ,/, the/DT increased/VBN rate/NN of/IN HIV/NN transmission/NN in/IN women/NNS with/IN BV/NN ./. 
UI/LS -/: 99155321/CD 
TI/LS -/: Interleukin-10/NN inhibits/VBZ expression/NN of/IN both/CC interferon/NN alpha-/NN and/CC interferon/NN gamma-induced/JJ genes/NNS by/IN suppressing/VBG tyrosine/NN phosphorylation/NN of/IN STAT1/NN ./. 
AB/LS -/: Interleukin-10/NN (/( IL-10/NN )/) helps/VBZ maintain/VB polarized/VBN T-helper/NN cells/NNS in/IN a/DT T-helper/NN lymphocyte/NN 2/CD (/( Th2/NN )/) phenotype/NN ./. 
Part/NN of/IN this/DT process/NN involves/VBZ the/DT prevention/NN of/IN the/DT development/NN of/IN Th1/NN cells/NNS ,/, which/WDT are/VBP a/DT primary/JJ source/NN of/IN interferon/NN gamma/NN (/( IFNgamma/NN )/) ,/, a/DT potent/JJ activator/NN of/IN monocytes/NNS and/CC an/DT inhibitor/NN of/IN Th2/NN proliferation/NN ./. 
Because/IN monocytes/NNS and/CC macrophages/NNS are/VBP important/JJ mediators/NNS of/IN Th1-type/JJ responses/NNS ,/, such/JJ as/IN delayed-type/JJ hypersensitivity/NN ,/, we/PRP sought/VBD to/TO determine/VB if/IN IL-10/NN could/MD directly/RB mediate/VB inhibition/NN of/IN IFNgamma-/NN and/CC IFNalpha-induced/JJ gene/NN expression/NN in/IN these/DT cells/NNS ./. 
Highly/RB purified/VBN monocytes/NNS were/VBD incubated/VBN with/IN IL-10/NN for/IN 60/CD to/TO 90/CD minutes/NNS before/IN the/DT addition/NN of/IN IFNgamma/NN or/CC IFNalpha/NN ./. 
IL-10/NN preincubation/NN resulted/VBD in/IN the/DT inhibition/NN of/IN gene/NN expression/NN for/IN several/JJ IFN-induced/JJ genes/NNS ,/, such/JJ as/IN IP-10/NN ,/, ISG54/NN ,/, and/CC intercellular/JJ adhesion/NN molecule-1/NN ./. 
The/DT reduction/NN in/IN gene/NN expression/NN resulted/VBD from/IN the/DT ability/NN of/IN IL-10/NN to/TO suppress/VB IFN-induced/JJ assembly/NN of/IN signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) factors/NNS to/TO specific/JJ promoter/NN motifs/NNS on/IN IFNalpha-/NN and/CC IFNgamma-inducible/JJ genes/NNS ./. 
This/DT was/VBD accomplished/VBN by/IN preventing/VBG the/DT IFN-induced/JJ tyrosine/NN phosphorylation/NN of/IN STAT1/NN ,/, a/DT component/NN of/IN both/CC IFNalpha-/NN and/CC IFNgamma-induced/JJ DNA/NN binding/NN complexes/NNS ./. 
Therefore/RB ,/, IL-10/NN can/MD directly/RB inhibit/VB STAT-dependent/JJ early/JJ response/NN gene/NN expression/NN induced/VBN by/IN both/CC IFNalpha/NN and/CC IFNgamma/NN in/IN monocytes/NNS by/IN suppressing/VBG the/DT tyrosine/NN phosphorylation/NN of/IN STAT1/NN ./. 
This/DT may/MD occur/VB through/IN the/DT ability/NN of/IN IL-10/NN to/TO induce/VB expression/NN of/IN the/DT gene/NN ,/, suppressor/NN of/IN cytokine/NN signaling/NN 3/CD (/( SOCS3/NN )/) ./. 
UI/LS -/: 99139903/CD 
TI/LS -/: Clonality/NN analysis/NN of/IN refractory/JJ anemia/NN with/IN ring/NN sideroblasts/NNS :/: simultaneous/JJ study/NN of/IN clonality/NN and/CC cytochemistry/NN of/IN bone/NN marrow/NN progenitors/NNS ./. 
AB/LS -/: X/NN chromosome/NN inactivation/NN and/CC polymorphism/NN of/IN the/DT human/JJ androgen/NN receptor/NN (/( HUMARA/NN )/) gene/NN has/VBZ been/VBN applied/VBN for/IN analyzing/VBG the/DT clonality/NN of/IN blood/NN cells/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, the/DT clonal/JJ relationship/NN was/VBD investigated/VBN between/IN peripheral/JJ blood/NN polymorphonuclear/JJ cells/NNS (/( PMNCs/NNS )/) and/CC marrow/JJ progenitor/NN cells/NNS and/CC the/DT origin/NN of/IN ringed/JJ sideroblasts/NNS in/IN patients/NNS with/IN refractory/JJ anemia/NN with/IN ring/NN sideroblasts/NNS (/( RARS/NN )/) by/IN polymerase/NN chain/NN reaction/NN (/( PCR/NN )/) of/IN HUMARA/NN gene/NN ./. 
The/DT X-inactivation/NN patterns/NNS of/IN circulating/VBG PMNCs/NNS and/CC T/NN lymphocytes/NNS as/RB well/RB as/IN individual/JJ granulocyte/NN colonies/NNS grown/VBN in/FW vitro/FW from/IN bone/NN marrow/NN cells/NNS were/VBD analyzed/VBN ./. 
The/DT development/NN of/IN ringed/JJ sideroblasts/NNS in/IN erythroid/JJ colonies/NNS by/IN iron/NN staining/NN and/CC their/PRP$ X-inactivation/NN pattern/NN were/VBD also/RB examined/VBN ./. 
All/DT three/CD RARS/NNS patients/NNS showed/VBD monoclonal/JJ PMNCs/NNS ./. 
In/IN granulocyte/NN colonies/NNS ,/, however/RB ,/, two/CD different/JJ X-inactivation/NN patterns/NNS were/VBD observed/VBN in/IN all/DT patients/NNS ,/, indicating/VBG that/IN non-clonal/JJ progenitor/NN cells/NNS remained/VBD in/IN the/DT bone/NN marrow/NN ./. 
All/DT erythroid/JJ colonies/NNS consisted/VBN of/IN ringed/JJ sideroblasts/NNS exclusively/RB showed/VBD one/CD pattern/NN dominant/JJ in/IN those/DT of/IN PMNCs/NNS ./. 
Our/PRP$ findings/NNS suggest/VBP that/IN non-clonal/JJ progenitor/NN cells/NNS persist/VBP in/IN some/DT RARS/NN cases/NNS ,/, that/IN erythroid/JJ progenitors/NNS show/VBP mosaicism/NN ,/, and/CC that/IN ringed/JJ sideroblasts/NNS may/MD be/VB derived/VBN from/IN an/DT abnormal/JJ clone/NN involved/VBN in/IN the/DT pathogenesis/NN of/IN this/DT disease/NN ./. 
UI/LS -/: 99135975/CD 
TI/LS -/: Granulosa/NN cell/NN tumor/NN of/IN the/DT ovary/NN ./. 
Immunohistochemical/JJ evidence/NN of/IN low/JJ proliferative/JJ activity/NN and/CC virtual/JJ absence/NN of/IN mutation/NN of/IN the/DT p53/NN tumor-suppressor/NN gene/NN ./. 
AB/LS -/: BACKGROUND/NN AND/CC METHODS/NNS :/: Because/IN the/DT use/NN of/IN immunohistochemistry/NN in/IN the/DT diagnosis/NN of/IN granulosa/NN cell/NN tumor/NN (/( GCT/NN )/) has/VBZ not/RB been/VBN fully/RB explored/VBN ,/, routinely/RB processed/VBN (/( formalin-fixed/JJ ,/, paraffin-embedded/JJ )/) tissue/NN from/IN 11/CD GCT/NN ,/, adult/JJ type/NN ,/, was/VBD investigated/VBN immunohistochemically/RB (/( ABC/NN method/NN )/) with/IN a/DT broad/JJ spectrum/NN of/IN antibodies/NNS against/IN various/JJ markers/NNS ,/, including/VBG p53/NN and/CC Ki-67/NN ./. 
All/DT of/IN the/DT tumors/NNS exhibited/VBD typical/JJ morphology/NN ,/, were/VBD limited/VBN to/TO the/DT ovary/NN (/( stage/NN I/CD )/) ,/, and/CC 7/CD cases/NNS followed/VBD a/DT benign/JJ clinical/JJ course/NN ./. 
RESULTS/NNS :/: All/PDT the/DT tumors/NNS exhibited/VBD strong/JJ expression/NN of/IN vimentin/NN ,/, but/CC most/JJS other/JJ antigens/NNS (/( including/VBG smooth/JJ muscle/NN actin/NN )/) were/VBD expressed/VBN infrequently/RB by/IN a/DT minority/NN of/IN tumor/NN cells/NNS or/CC not/RB at/IN all/DT ./. 
Tumor/NN cells/NNS in/IN 9/CD GCT/NN expressed/VBD inhibin/NN A/NN ./. 
All/PDT the/DT tumors/NNS exhibited/VBD very/RB low/JJ proliferative/JJ activity/NN ,/, fewer/JJR than/IN 10/CD %/NN of/IN the/DT tumor/NN cell/NN nuclei/NNS being/VBG stained/VBN by/IN the/DT antibody/NN MIB-1/NN (/( Ki-67/NN antigen/NN )/) ./. 
The/DT antibody/NN D07/RB revealed/VBD marked/JJ overexpression/NN of/IN p53/NN protein/NN in/IN only/RB one/CD tumor/NN ./. 
Clinical/JJ outcome/NN was/VBD not/RB found/VBN to/TO be/VB related/JJ to/TO immunophenotypic/JJ differences/NNS ./. 
CONCLUSIONS/NNS :/: The/DT diagnosis/NN of/IN GCT/NN should/MD be/VB based/VBN primarily/RB on/IN the/DT typical/JJ morphology/NN revealed/VBN by/IN conventional/JJ stains/NNS ,/, but/CC additional/JJ immunohistochemical/JJ staining/NN with/IN a/DT small/JJ panel/NN of/IN selected/VBN antibodies/NNS (/( for/IN example/NN ,/, against/IN keratin/NN ,/, vimentin/NN ,/, and/CC inhibin/NN A/NN )/) may/MD be/VB helpful/JJ in/IN a/DT few/JJ cases/NNS ./. 
The/DT very/RB low/JJ proliferative/JJ activity/NN and/CC the/DT lack/NN of/IN overexpression/NN of/IN p53/NN protein/NN are/VBP consistent/JJ with/IN the/DT benign/JJ clinical/JJ behavior/NN of/IN the/DT majority/NN of/IN GCT/NN ./. 
UI/LS -/: 99113717/CD 
TI/LS -/: Protective/JJ effects/NNS of/IN notch-1/NN on/IN TCR-induced/JJ apoptosis/NN ./. 
AB/LS -/: The/DT Notch/NN receptor/NN protein/NN was/VBD originally/RB identified/VBN in/IN Drosophila/NN and/CC is/VBZ known/VBN to/TO mediate/VB cell/NN to/TO cell/NN communication/NN and/CC influence/VB cell/NN fate/NN decisions/NNS ./. 
Members/NNS of/IN this/DT family/NN have/VBP been/VBN isolated/VBN from/IN invertebrates/NNS as/RB well/RB as/IN vertebrates/NNS ./. 
We/PRP isolated/VBD mouse/NN Notch-1/NN in/IN a/DT yeast/NN two-hybrid/JJ screen/NN with/IN Nur77/NN ,/, which/WDT is/VBZ a/DT protein/NN that/WDT has/VBZ been/VBN shown/VBN previously/RB to/TO be/VB required/VBN for/IN apoptosis/NN in/IN T/NN cell/NN lines/NNS ./. 
The/DT data/NNS presented/VBN below/IN indicate/VBP that/IN Notch-1/NN expression/NN provides/VBZ significant/JJ protection/NN to/TO T/NN cell/NN lines/NNS from/IN TCR-mediated/JJ apoptosis/NN ./. 
These/DT data/NNS demonstrate/VBP a/DT new/JJ antiapoptotic/JJ role/NN for/IN Notch-1/NN ,/, providing/VBG evidence/NN that/IN ,/, in/IN addition/NN to/TO regulating/VBG cell/NN fate/NN decisions/NNS ,/, Notch-1/NN can/MD play/VB a/DT critical/JJ role/NN in/IN controlling/VBG levels/NNS of/IN cell/NN death/NN in/IN T/NN cells/NNS ./. 
UI/LS -/: 99101524/CD 
TI/LS -/: Comparison/NN of/IN primary/JJ sensitization/NN of/IN naive/JJ human/JJ T/NN cells/NNS to/TO varicella-zoster/NN virus/NN peptides/NNS by/IN dendritic/JJ cells/NNS in/FW vitro/FW with/IN responses/NNS elicited/VBN in/FW vivo/FW by/IN varicella/NN vaccination/NN ./. 
AB/LS -/: Dendritic/JJ cells/NNS (/( DC/NNS )/) are/VBP potent/JJ APC/NN during/IN primary/JJ and/CC secondary/JJ immune/JJ responses/NNS ./. 
The/DT first/JJ objective/NN of/IN this/DT study/NN was/VBD to/TO determine/VB whether/IN human/JJ DC/NNS mediate/VBP in/FW vitro/FW sensitization/NN of/IN naive/JJ CD4+/JJ T/NN cells/NNS to/TO epitopes/NNS of/IN the/DT immediate/JJ early/JJ 62/CD (/( IE62/NN )/) protein/NN of/IN varicella/NN zoster/NN virus/NN (/( VZV/NN )/) ./. 
The/DT induction/NN of/IN CD4+/JJ T/NN cell/NN proliferative/JJ responses/NNS to/TO eight/CD synthetic/JJ peptides/NNS representing/VBG amino/NN acid/NN sequences/NNS of/IN the/DT VZV/NN IE62/NN protein/NN was/VBD assessed/VBN using/VBG T/NN cells/NNS and/CC DC/NNS from/IN VZV-susceptible/JJ donors/NNS ./. 
The/DT second/JJ objective/NN was/VBD to/TO compare/VB in/FW vitro/FW responses/NNS of/IN naive/JJ T/NN cells/NNS with/IN responses/NNS to/TO VZV/NN peptides/NNS induced/VBN in/FW vivo/FW after/IN immunization/NN with/IN varicella/NN vaccine/NN ./. 
T/NN cell/NN proliferation/NN was/VBD induced/VBN by/IN three/CD peptides/NNS ,/, P1/NN ,/, P4/NN ,/, and/CC P7/NN ,/, in/IN 71-100/CD %/NN of/IN the/DT donors/NNS tested/VBN before/IN and/CC after/IN vaccination/NN using/VBG DC/NNS as/IN APC/NN ./. 
Monocytes/NNS were/VBD effective/JJ APC/NN for/IN VZV/NN peptides/NNS only/RB after/IN immunization/NN ./. 
Two/CD peptides/NNS ,/, P2/NN and/CC P8/NN ,/, induced/VBD naive/JJ T/NN cell/NN proliferation/NN less/RBR effectively/RB and/CC were/VBD also/RB less/RBR immunogenic/JJ for/IN T/NN cells/NNS from/IN vaccinated/VBN or/CC naturally/RB immune/JJ donors/NNS ./. 
T/NN cell/NN recognition/NN of/IN specific/JJ peptides/NNS was/VBD concordant/JJ between/IN naive/JJ ,/, DC-mediated/JJ responses/NNS ,/, and/CC postvaccine/JJ responses/NNS using/VBG monocytes/NNS as/IN APC/NN in/IN 69/CD %/NN of/IN comparisons/NNS (/( p/NN =/JJ 0.05/CD ;/: chi2/NN )/) ;/: the/DT predictive/JJ value/NN of/IN a/DT positive/JJ response/NN to/TO an/DT IE62/NN peptide/NN before/IN immunization/NN for/IN T/NN cell/NN sensitization/NN in/FW vivo/FW was/VBD 82/CD %/NN ./. 
These/DT observations/NNS indicate/VBP that/IN primary/JJ T/NN cell/NN responses/NNS detected/VBN in/FW vitro/FW using/VBG DC/NNS as/IN APC/NN may/MD be/VB useful/JJ to/TO characterize/VB the/DT potential/JJ immunogenicity/NN of/IN viral/JJ protein/NN epitopes/NNS in/FW vivo/FW ./. 
UI/LS -/: 99081619/CD 
TI/LS -/: Mechanism/NN of/IN interleukin-10/NN inhibition/NN of/IN T-helper/NN cell/NN activation/NN by/IN superantigen/NN at/IN the/DT level/NN of/IN the/DT cell/NN cycle/NN ./. 
AB/LS -/: We/PRP have/VBP analyzed/VBN the/DT effects/NNS of/IN interleukin-10/NN (/( IL-10/NN )/) on/IN the/DT entry/NN of/IN quiescent/JJ CD4(+)/JJ T/NN cells/NNS into/IN the/DT cell/NN cycle/NN upon/IN stimulation/NN with/IN the/DT superantigen/NN staphylococcal/JJ enterotoxin/NN B/NN (/( SEB/NN )/) ./. 
IL-10/NN arrested/VBD cells/NNS at/IN G0/G1/NN ./. 
IL-10/NN treatment/NN prevented/VBD the/DT downregulation/NN of/IN p27/NN (/( Kip1/NN )/) ,/, an/DT inhibitory/JJ protein/NN that/WDT controls/VBZ progression/NN out/IN of/IN the/DT G0/NN phase/NN of/IN the/DT cell/NN cycle/NN ./. 
IL-10/NN also/RB prevented/VBD the/DT upregulation/NN of/IN the/DT G1/NN cyclins/NNS D2/NN and/CC D3/NN ,/, proteins/NNS necessary/JJ for/IN entry/NN and/CC progression/NN through/IN the/DT G1/NN phase/NN of/IN the/DT cell/NN cycle/NN ./. 
Associated/VBN with/IN the/DT inhibition/NN of/IN the/DT cell/NN cycle/NN ,/, IL-10/NN suppressed/VBD SEB/NN induction/NN of/IN interleukin-2/NN (/( IL-2/NN )/) ./. 
Addition/NN of/IN exogenous/JJ IL-2/NN to/TO IL-10-treated/JJ cells/NNS significantly/RB reversed/VBD the/DT antiproliferative/JJ effects/NNS of/IN IL-10/NN ./. 
Moreover/RB ,/, IL-10/NN effects/NNS on/IN the/DT early/JJ G1/NN proteins/NNS p27/NN (/( Kip1/NN )/) and/CC cyclin/NN D2/NN were/VBD similarly/RB reversed/VBN by/IN exogenous/JJ IL-2/NN ./. 
Although/IN this/DT reversal/NN by/IN IL-2/NN was/VBD pronounced/JJ ,/, it/PRP was/VBD not/RB complete/JJ ,/, suggesting/VBG that/IN IL-10/NN may/MD have/VB some/DT effects/NNS not/RB directly/RB related/VBN to/TO the/DT suppression/NN of/IN IL-2/NN production/NN ./. 
Cell/NN separation/NN experiments/NNS suggest/VBP that/IN IL-10/NN can/MD effect/VB purified/VBN CD4(+)/JJ T/NN cells/NNS directly/RB ,/, providing/VBG functional/JJ evidence/NN for/IN the/DT presence/NN of/IN IL-10/NN receptors/NNS on/IN CD4(+)/JJ T/NN cells/NNS ./. 
IL-10/NN also/RB inhibited/VBD expression/NN of/IN IL-2/NN transcriptional/JJ regulators/NNS c-fos/NN and/CC c-jun/NN ,/, which/WDT also/RB inhibit/VBP other/JJ cell/NN functions/NNS ./. 
Our/PRP$ studies/NNS show/VBP that/IN the/DT mechanism/NN of/IN IL-10/NN regulation/NN of/IN quiescent/JJ CD4(+)/JJ T-cell/NN activation/NN is/VBZ mainly/RB by/IN blocking/VBG induction/NN of/IN IL-2/NN that/WDT is/VBZ critical/JJ to/TO downregulation/NN of/IN p27/NN (/( Kip1/NN )/) and/CC upregulation/NN of/IN D/NN cyclins/NNS in/IN T-cell/NN activation/NN and/CC entry/NN into/IN the/DT cell/NN cycle/NN ./. 
UI/LS -/: 98209796/CD 
TI/LS -/: IFN-gamma/NN and/CC IL-10/NN inhibit/VBP induction/NN of/IN IL-1/NN receptor/NN type/NN I/CD and/CC type/NN II/CD gene/NN expression/NN by/IN IL-4/NN and/CC IL-13/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: The/DT Th2-type/JJ cytokines/NNS IL-4/NN and/CC IL-13/NN induce/VBP expression/NN of/IN a/DT distinct/JJ subset/NN of/IN genes/NNS in/IN human/JJ monocytes/NNS ./. 
These/DT include/VBP Fc/NN epsilonRII/NN (/( CD23/NN )/) ,/, 15-lipoxygenase/NN ,/, IL-1/NN receptor/NN antagonist/NN (/( IL-1ra/NN )/) ,/, and/CC type/NN I/CD and/CC type/NN II/CD IL-1/NN receptors/NNS (/( IL-1R/NN )/) ./. 
IFN-gamma/NN has/VBZ been/VBN shown/VBN to/TO inhibit/VB induction/NN of/IN CD23/NN and/CC 15-lipoxygenase/NN in/IN monocytes/NNS ;/: however/RB ,/, the/DT effects/NNS of/IN IFN-gamma/NN on/IN type/NN I/CD and/CC type/NN II/CD IL-1R/NN gene/NN expression/NN have/VBP not/RB been/VBN defined/VBN ./. 
We/PRP examined/VBD the/DT effects/NNS of/IN IFN-gamma/NN on/IN both/CC basal/JJ and/CC IL-4/IL-13-induced/JJ IL-1R/NN gene/NN expression/NN in/IN primary/JJ monocytes/NNS ./. 
IL-4/NN and/CC IL-13/NN induced/VBD dose-/NN and/CC time-dependent/JJ increases/NNS in/IN IL-1RI/NN and/CC IL-1RII/NN mRNA/NN levels/NNS ./. 
IFN-gamma/NN decreased/VBD basal/JJ expression/NN as/RB well/RB as/IN the/DT induction/NN of/IN these/DT genes/NNS by/IN IL-4/NN and/CC IL-13/NN ./. 
Inhibition/NN of/IN IL-1RI/JJ and/CC IL-1RII/NN mRNA/NN levels/NNS by/IN IFN-gamma/NN was/VBD transcriptionally/RB mediated/VBN ,/, and/CC correlated/VBN directly/RB with/IN decreased/VBN production/NN of/IN soluble/JJ IL-1RII/NN ./. 
Furthermore/RB ,/, the/DT ability/NN to/TO suppress/VB IL-1RI/NN and/CC IL-1RII/NN mRNA/NN levels/NNS was/VBD not/RB unique/JJ to/TO IFN-gamma/NN because/IN IL-10/NN also/RB inhibited/VBD expression/NN of/IN these/DT genes/NNS in/IN IL-4/IL-13-stimulated/JJ monocytes/NNS ./. 
Inhibition/NN of/IN IL-1R/NN gene/NN expression/NN by/IN IFN-gamma/NN and/CC IL-10/NN was/VBD not/RB due/JJ to/TO down-regulation/NN of/IN surface/NN IL-4R/NN because/IN pretreatment/NN with/IN these/DT cytokines/NNS did/VBD not/RB decrease/VB the/DT number/NN of/IN IL-4/NN binding/NN sites/NNS per/IN cell/NN ./. 
However/RB ,/, suppression/NN of/IN IL-1R/NN gene/NN expression/NN by/IN IFN-gamma/NN and/CC IL-10/NN was/VBD associated/VBN with/IN decreased/VBN tyrosine/NN phosphorylation/NN and/CC nuclear/JJ translocation/NN of/IN the/DT IL-4/IL-13-inducible/JJ transcription/NN factor/NN ,/, Stat6/NN ,/, suggesting/VBG a/DT potential/JJ mechanism/NN by/IN which/WDT IFN-gamma/NN and/CC IL-10/NN may/MD mediate/VB their/PRP$ suppressive/JJ effects/NNS ./. 
These/DT findings/NNS demonstrate/VBP that/IN certain/JJ cytokines/NNS ,/, including/VBG IFN-gamma/NN and/CC IL-10/NN ,/, antagonize/VBP the/DT ability/NN of/IN IL-4/NN and/CC IL-13/NN to/TO induce/VB increased/VBN expression/NN of/IN the/DT IL-1RI/NN and/CC IL-1RII/NN genes/NNS in/IN monocytes/NNS ./. 
UI/LS -/: 98147373/CD 
TI/LS -/: Cytokine/NN rescue/NN from/IN glucocorticoid/NN induced/JJ apoptosis/NN in/IN T/NN cells/NNS is/VBZ mediated/VBN through/IN inhibition/NN of/IN IkappaBalpha/NN ./. 
AB/LS -/: We/PRP previously/RB reported/VBD that/IN dexamethasone/NN (/( DEX/NN )/) ,/, a/DT synthetic/JJ glucocorticoid/NN ,/, causes/VBZ apoptosis/NN in/IN mature/JJ Th/NN cell/NN lines/NNS ,/, and/CC that/IN this/DT induction/NN of/IN cell/NN death/NN is/VBZ prevented/VBN by/IN specific/JJ cytokines/NNS ,/, namely/RB ,/, by/IN IL-2/NN in/IN Th1/NN cells/NNS and/CC by/IN IL-4/NN in/IN Th2/NN cells/NNS ./. 
We/PRP now/RB show/VBP that/IN this/DT differential/JJ rescue/NN by/IN specific/JJ cytokines/NNS in/IN Th/NN cells/NNS correlates/VBZ with/IN the/DT level/NN of/IN IkappaBalpha/NN that/WDT is/VBZ regulated/VBN by/IN DEX/NN and/CC cytokines/NNS ./. 
In/IN both/DT cell/NN types/NNS the/DT cellular/JJ levels/NNS of/IN IkappaBalpha/NN mRNA/NN and/CC protein/NN were/VBD evaluated/VBN by/IN DEX/NN treatment/NN ./. 
Interestingly/RB ,/, the/DT DEX-mediated/JJ IkappaBalpha/NN induction/NN was/VBD completely/RB inhibited/VBN by/IN IL-2/NN ,/, but/CC not/RB IL-4/NN ,/, in/IN Th1/NN cells/NNS ,/, while/IN the/DT reverse/NN profile/NN was/VBD seen/VBN in/IN Th2/NN cells/NNS ./. 
In/IN both/DT cell/NN types/NNS ,/, the/DT cytokine/NN that/WDT inhibits/VBZ the/DT induction/NN of/IN IkappaBalpha/NN by/IN DEX/NN ,/, also/RB rescues/VBZ these/DT cells/NNS from/IN DEX-induced/JJ apoptosis/NN ,/, although/IN the/DT rescue/NN cytokine/NN is/VBZ different/JJ in/IN Th1/NN and/CC Th2/NN cells/NNS ./. 
Our/PRP$ results/NNS imply/VBP that/IN T/NN cells/NNS need/VBP to/TO maintain/VB a/DT certain/JJ level/NN of/IN NF-kappaB/NN transcriptional/JJ activity/NN in/IN order/NN to/TO survive/VB ;/: up-/JJ or/CC down-regulation/NN of/IN nuclear/JJ NF/NN kappaB/NN through/IN modulation/NN of/IN IkappaBalpha/NN expression/NN by/IN cytokines/NNS or/CC DEX/NN may/MD lead/VB to/TO cell/NN survival/NN or/CC cell/NN death/NN ,/, respectively/RB ./. 
UI/LS -/: 98104482/CD 
TI/LS -/: Expression/NN of/IN transcription/NN factor/NN genes/NNS after/IN influenza/NN A/NN virus/NN infection/NN ./. 
AB/LS -/: Infection/NN of/IN human/JJ monocytes/NNS with/IN influenza/NN A/NN virus/NN induces/VBZ a/DT broad/JJ range/NN of/IN proinflammatory/JJ cytokines/NNS and/CC mononuclear/JJ cell/NN attracting/NN chemokines/NNS before/IN the/DT infected/JJ cells/NNS undergo/VBP apoptosis/NN ./. 
The/DT underlying/VBG mechanisms/NNS by/IN which/WDT the/DT corresponding/JJ genes/NNS are/VBP transcriptionally/RB initiated/VBN after/IN virus/NN infection/NN are/VBP still/RB poorly/RB understood/VBN ./. 
Activation/NN of/IN NF-kappa/NN B/NN seems/VBZ to/TO play/VB an/DT important/JJ role/NN in/IN the/DT regulation/NN of/IN many/JJ proinflammatory/JJ cytokine/NN genes/NNS ,/, but/CC can/MD not/RB be/VB the/DT only/JJ mechanism/NN ,/, since/IN several/JJ cytokine/NN genes/NNS lack/VBP respective/JJ binding/VBG sites/NNS in/IN their/PRP$ promoter/NN regions/NNS ./. 
Therefore/RB ,/, we/PRP additionally/RB investigated/VBD other/JJ transcription/NN factors/NNS of/IN possible/JJ importance/NN such/JJ as/IN CREB/NN ,/, CTF/NN ,/, OTF-1/NN ,/, and/CC OTF-2/NN ./. 
To/TO explore/VB long-term/JJ regulatory/JJ mechanisms/NNS ,/, we/PRP investigated/VBD the/DT induction/NN of/IN transcription/NN factors/NNS on/IN the/DT gene/NN expression/NN level/NN which/WDT may/MD be/VB important/JJ to/TO substitute/VB for/IN metabolized/VBN transcription/NN factor/NN proteins/NNS after/IN their/PRP$ activation/NN ./. 
We/PRP identified/VBD a/DT cell-type-specific/JJ differential/JJ response/NN :/: CREB/NN ,/, CTF/NN ,/, OTF-1/NN ,/, OFT-2/NN ,/, and/CC NF-kappa/NN B/NN genes/NNS were/VBD strongly/RB induced/VBN 1/CD to/TO 4/CD hours/NNS after/IN influenza/NN A/NN virus/NN infection/NN in/IN the/DT monocytic/JJ cell/NN line/NN Mono/NN Mac/NN 6/CD ,/, while/IN in/IN freshly/RB prepared/VBN human/JJ monocytes/NNS no/DT significant/JJ changes/NNS were/VBD detected/VBN ./. 
In/IN infected/JJ monocytes/NNS ,/, which/WDT die/VBP by/IN apoptosis/NN ,/, the/DT expression/NN of/IN CREB/NN ,/, CTF/NN ,/, and/CC OTF-2/NN was/VBD rather/RB suppressed/VBN 8/CD hours/NNS after/IN infection/NN ./. 
In/IN conclusion/NN ,/, the/DT long-term/JJ regulation/NN of/IN transcription/NN factor/NN gene/NN expression/NN in/IN non-proliferating/JJ cells/NNS seems/VBZ to/TO be/VB of/IN minor/JJ importance/NN after/IN influenza/NN infection/NN since/IN in/IN apoptosisprone/JJ cells/NNS an/DT immediate/JJ availability/NN of/IN transcription/NN factor/NN proteins/NNS is/VBZ required/VBN ./. 
UI/LS -/: 99161866/CD 
TI/LS -/: Peripheral/JJ blood/NN mononuclear/JJ cells/NNS isolated/VBN from/IN patients/NNS with/IN diabetic/JJ nephropathy/NN show/VBP increased/VBN activation/NN of/IN the/DT oxidative-stress/NN sensitive/JJ transcription/NN factor/NN NF-kappaB/NN ./. 
AB/LS -/: Increased/VBN oxidative/JJ stress/NN and/CC subsequent/JJ activation/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN has/VBZ been/VBN linked/VBN to/TO the/DT development/NN of/IN late/JJ diabetic/JJ complications/NNS ./. 
To/TO determine/VB whether/IN oxidative/JJ stress/NN dependent/JJ NF-kappaB/NN activation/NN is/VBZ evident/JJ in/IN patients/NNS with/IN diabetic/JJ nephropathy/NN we/PRP used/VBD an/DT Electrophoretic/JJ Mobility/NN Shift/NN Assay/NN based/JJ semiquantitative/JJ detection/NN system/NN which/WDT enabled/VBD us/PRP to/TO determine/VB NF-kappaB/NN activation/NN in/IN ex/FW vivo/FW isolated/VBN peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
We/PRP examined/VBD 33/CD patients/NNS with/IN diabetes/NN mellitus/NN (/( Type/NN I/CD and/CC Type/NN II/CD )/) ./. 
Patients/NNS with/IN diabetic/JJ nephropathy/NN showed/VBD higher/JJR NF-kappaB/NN binding/NN activity/NN in/IN Electrophoretic/JJ Mobility/NN Shift/NN Assays/NNS and/CC stronger/JJR immunohistological/JJ staining/NN for/IN activated/VBN NF-kappaBp65/NN than/IN patients/NNS without/IN renal/JJ complications/NNS ./. 
NF-kappaB/NN binding/NN activity/NN correlated/VBD with/IN the/DT degree/NN of/IN albuminuria/NN (/( r/NN =/JJ 0.316/CD )/) and/CC with/IN thrombomodulin/NN plasma/NN concentrations/NNS (/( r/NN =/JJ 0.33/CD )/) ,/, indicative/JJ for/IN albuminuria/NN associated/JJ endothelial/JJ dysfunction/NN ./. 
In/IN a/DT 3/CD day/NN intervention/NN study/NN in/IN which/WDT 600/CD mg/NN of/IN the/DT antioxidant/JJ thioctic/JJ acid/NN (/( alpha-lipoic/JJ acid/NN )/) per/IN day/NN were/VBD given/VBN to/TO nine/CD patients/NNS with/IN diabetic/JJ nephropathy/NN oxidative/JJ stress/NN in/IN plasma/NN samples/NNS was/VBD decreased/VBN by/IN 48/CD %/NN and/CC NF-kappaB/NN binding/NN activity/NN in/IN ex/FW vivo/FW isolated/VBN peripheral/JJ blood/NN mononuclear/JJ cells/NNS by/IN 38/CD %/NN ./. 
In/IN conclusion/NN ,/, activation/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN in/IN ex/FW vivo/FW isolated/VBN peripheral/JJ blood/NN mononuclear/JJ cells/NNS of/IN patients/NNS with/IN diabetes/NN mellitus/NN correlates/VBZ with/IN the/DT degree/NN of/IN diabetic/JJ nephropathy/NN ./. 
NF-kappaB/NN activation/NN is/VBZ at/IN least/JJS in/IN part/NN dependent/JJ on/IN oxidative/JJ stress/NN since/IN thioctic/JJ acid/NN (/( alpha-lipoic/JJ acid/NN )/) reduced/VBD NF-kappaB/NN binding/NN activity/NN ./. 
UI/LS -/: 99148535/CD 
TI/LS -/: Osteoclast/NN markers/NNS accumulate/VBP on/IN cells/NNS developing/VBG from/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ precursors/NNS ./. 
AB/LS -/: Recent/JJ studies/NNS show/VBP that/IN human/JJ osteoclasts/NNS develop/VBP in/FW vitro/FW from/IN hematopoietic/JJ cells/NNS ;/: however/RB ,/, special/JJ cultures/NNS conditions/NNS and/or/CC cytokine/NN mobilized/VBN peripheral/JJ blood/NN are/VBP apparently/RB required/VBN ./. 
Here/RB ,/, we/PRP report/VBP that/IN cells/NNS expressing/VBG osteoclast/NN markers/NNS differentiate/VBP from/IN precursors/NNS present/JJ in/IN nonmobilized/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NN )/) ,/, without/IN the/DT addition/NN of/IN stromal/JJ cells/NNS ,/, growth/NN factors/NNS ,/, cytokines/NNS or/CC steroids/NNS ;/: and/CC characterize/VBP their/PRP$ phenotype/NN ./. 
Three/CD days/NNS after/IN establishing/VBG high-density/JJ PBMC/NN cultures/NNS (/( 1.5/CD x/CC 10(6)/CD cells/cm2/NNS )/) ,/, in/IN serum-containing/JJ medium/JJ ,/, small/JJ adherent/JJ colonies/NNS of/IN tartrate/JJ resistant/JJ acid/NN phosphatase/NN positive/JJ (/( TRAP+/JJ )/) cells/NNS emerge/VBP ,/, amidst/IN massive/JJ monocyte/NN cell/NN death/NN ./. 
These/DT adherent/JJ cells/NNS have/VBP an/DT eccentrically/RB placed/JJ ,/, round/JJ nucleus/NN ,/, and/CC express/VB low/JJ levels/NNS of/IN TRAP/NN and/CC sodium/NN fluoride-resistant- alpha-naphthyl-acetate-esterase/NN (/( NaF-R-NSE/NN )/) ./. 
Over/IN the/DT next/JJ week/NN ,/, this/DT cell/NN population/NN accumulates/VBZ phenotypic/JJ markers/NNS of/IN osteoclasts/NNS (/( vitronectin/NN receptor/NN [/( VR/NN ]/) ,/, calcitonin/NN receptor/NN ,/, TRAP/NN ,/, cathepsin/NN K/NN protein/NN ,/, and/CC mRNA/NN )/) with/IN increased/VBN nuclearity/NN ,/, covering/VBG the/DT entire/JJ surface/NN by/IN 15/CD days/NNS ./. 
When/WRB cultured/VBN on/IN bone/NN ,/, VR+/JJ ,/, TRAP+/JJ cells/NNS of/IN low/JJ multinuclearity/NN appear/VBP and/CC cover/VBP up/RB to/TO 50/CD %/NN of/IN the/DT surface/NN ./. 
Resorption/NN lacunae/NNS can/MD be/VB observed/VBN by/IN day/NN 22/CD ./. 
Although/IN these/DT pits/NNS are/VBP not/RB nearly/RB as/IN numerous/JJ as/IN the/DT cells/NNS of/IN preosteoclast/JJ phenotype/NN ,/, they/PRP do/VBP represent/VB the/DT activity/NN of/IN a/DT subset/NN of/IN osteoclast-like/JJ cells/NNS that/WDT has/VBZ achieved/VBN osteoclastic/JJ maturity/NN under/IN these/DT culture/NN conditions/NNS ./. 
Transcripts/NNS for/IN osteoprotegerin/NN ligand/NN (/( OPGL/NN )/) ,/, an/DT osteoclast/JJ differentiation/NN factor/NN (/( also/RB known/VBN as/IN RANKL/NN and/CC TRANCE/NN )/) are/VBP expressed/VBN ,/, likely/RB by/IN adherent/JJ cells/NNS ./. 
Thus/RB ,/, an/DT adherent/JJ population/NN of/IN cells/NNS ,/, with/IN preosteoclast/osteoclast/JJ phenotypic/JJ properties/NNS ,/, arises/VBZ selectively/RB under/IN simple/JJ culture/NN conditions/NNS from/IN normal/JJ PBMC/NN ./. 
Further/JJ characterization/NN of/IN these/DT cells/NNS should/MD identify/VB factors/NNS involved/VBN in/IN the/DT growth/NN ,/, terminal/JJ differentiation/NN and/CC activation/NN of/IN osteoclasts/NNS ./. 
UI/LS -/: 99141282/CD 
TI/LS -/: Oleic/JJ acid/NN inhibits/VBZ endothelial/JJ activation/NN :/: A/DT direct/JJ vascular/JJ antiatherogenic/JJ mechanism/NN of/IN a/DT nutritional/JJ component/NN in/IN the/DT mediterranean/JJ diet/NN ./. 
AB/LS -/: Because/IN oleic/JJ acid/NN is/VBZ implicated/VBN in/IN the/DT antiatherogenic/JJ effects/NNS attributed/VBN to/TO the/DT Mediterranean/JJ diet/NN ,/, we/PRP investigated/VBD whether/IN this/DT fatty/JJ acid/NN can/MD modulate/VB endothelial/JJ activation/NN ,/, ie/FW ,/, the/DT concerted/JJ expression/NN of/IN gene/NN products/NNS involved/VBN in/IN leukocyte/NN recruitment/NN and/CC early/JJ atherogenesis/NN ./. 
We/PRP incubated/VBD sodium/NN oleate/NN with/IN human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS for/IN 0/CD to/TO 72/CD hours/NNS ,/, followed/VBN by/IN coincubation/NN of/IN oleate/NN with/IN human/JJ recombinant/JJ tumor/NN necrosis/NN factor/NN ,/, interleukin/NN (/( IL/NN )/) -1alpha/NN ,/, IL-1beta/NN ,/, IL-4/NN ,/, Escherichia/FW coli/FW lipopolysaccharide/NN (/( LPS/NN )/) ,/, or/CC phorbol/NN 12-myristate/NN 13-acetate/NN for/IN a/DT further/JJ 6/CD to/TO 24/CD hours/NNS ./. 
The/DT endothelial/JJ expression/NN of/IN vascular/JJ cell/NN adhesion/NN molecule-1/NN (/( VCAM-1/NN )/) ,/, E-selectin/NN ,/, and/CC intercellular/JJ adhesion/NN molecule-1/NN was/VBD monitored/VBN by/IN cell/NN surface/NN enzyme/NN immunoassays/NNS or/CC flow/NN cytometry/NN ,/, and/CC steady-state/JJ levels/NNS of/IN VCAM-1/NN mRNA/NN were/VBD assessed/VBN by/IN Northern/NN blot/NN analysis/NN ./. 
At/IN 10/CD to/TO 100/CD micromol/L/NN for/IN >/JJR 24/CD hours/NNS ,/, oleate/NN inhibited/VBD the/DT expression/NN of/IN all/DT adhesion/NN molecules/NNS tested/VBN ./. 
After/IN a/DT 72-hour/JJ incubation/NN with/IN oleate/NN and/CC a/DT further/JJ 16-hour/JJ incubation/NN with/IN oleate/NN plus/CC 1/CD microg/mL/NN LPS/NN ,/, VCAM-1/NN expression/NN was/VBD reduced/VBN by/IN >/JJR 40/CD %/NN compared/VBN with/IN control/NN ./. 
Adhesion/NN of/IN monocytoid/JJ U937/NN cells/NNS to/TO LPS-treated/JJ endothelial/JJ cells/NNS was/VBD reduced/VBN concomitantly/RB ./. 
Oleate/NN also/RB produced/VBD a/DT quantitatively/RB similar/JJ reduction/NN of/IN VCAM-1/NN mRNA/NN levels/NNS on/IN Northern/NN blot/NN analysis/NN and/CC inhibited/VBD nuclear/JJ factor-kappaB/NN activation/NN on/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ./. 
Incubation/NN of/IN endothelial/JJ cells/NNS with/IN oleate/NN for/IN 72/CD hours/NNS decreased/VBD the/DT relative/JJ proportions/NNS of/IN saturated/JJ (/( palmitic/JJ and/CC stearic/JJ )/) acids/NNS in/IN total/JJ cell/NN lipids/NNS and/CC increased/VBD the/DT proportions/NNS of/IN oleate/NN in/IN total/JJ cell/NN lipids/NNS without/IN significantly/RB changing/VBG the/DT relative/JJ proportions/NNS of/IN polyunsaturated/JJ fatty/JJ acids/NNS ./. 
Although/IN less/JJR potent/JJ than/IN polyunsaturated/JJ fatty/JJ acids/NNS in/IN inhibiting/VBG endothelial/JJ activation/NN ,/, oleic/JJ acid/NN may/MD contribute/VB to/TO the/DT prevention/NN of/IN atherogenesis/NN through/IN selective/JJ displacement/NN of/IN saturated/JJ fatty/JJ acids/NNS in/IN cell/NN membrane/NN phospholipids/NNS and/CC a/DT consequent/JJ modulation/NN of/IN gene/NN expression/NN for/IN molecules/NNS involved/VBN in/IN monocyte/JJ recruitment/NN ./. 
UI/LS -/: 99135866/CD 
TI/LS -/: Both/CC Stat3-activation/JJ and/CC Stat3-independent/JJ BCL2/NN downregulation/NN are/VBP important/JJ for/IN interleukin-6-induced/JJ apoptosis/NN of/IN 1A9-M/NN cells/NNS ./. 
AB/LS -/: A/DT unique/JJ subclone/NN of/IN a/DT bone/NN marrow-derived/JJ stromal/JJ cell/NN line/NN ,/, BMS2.4/NN ,/, produces/VBZ soluble/JJ factors/NNS that/WDT inhibit/VBP proliferation/NN of/IN several/JJ types/NNS of/IN hematopoietic/JJ cell/NN lines/NNS ./. 
An/DT understanding/NN of/IN these/DT molecules/NNS may/MD be/VB informative/JJ about/IN negative/JJ regulatory/JJ circuits/NNS that/WDT can/MD potentially/RB limit/VB blood/NN cell/NN formation/NN ./. 
We/PRP used/VBD expression/NN cloning/VBG to/TO identify/VB interleukin-6/NN (/( IL-6/NN )/) as/IN one/CD factor/NN that/WDT suppressed/VBD growth/NN of/IN a/DT pre-B-cell/NN variant/JJ line/NN ,/, 1A9-M/NN ./. 
Moreover/RB ,/, IL-6/NN induced/VBD macrophage-differentiation/NN and/CC apoptosis/NN of/IN 1A9-M/NN cells/NNS ./. 
During/IN this/DT process/NN ,/, IL-6/NN downregulated/VBD expression/NN of/IN BCL2/NN in/IN 1A9-M/NN cells/NNS and/CC stimulated/VBD BCL-XL/NN expression/NN ,/, but/CC had/VBD no/DT effect/NN on/IN p53/NN ,/, Bax/NN ,/, or/CC Bak/NN gene/NN expression/NN ./. 
Mechanisms/NNS for/IN transduction/NN of/IN IL-6-induced/JJ signals/NNS were/VBD then/RB evaluated/VBN in/IN IL-6-stimulated/JJ 1A9-M/NN cells/NNS ./. 
Whereas/IN the/DT signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN 3/CD (/( Stat3/NN )/) was/VBD phosphorylated/VBN and/CC activated/VBN ,/, there/EX was/VBD no/DT effect/NN on/IN either/CC Stat1/NN or/CC Stat5/NN ./. 
The/DT importance/NN of/IN BCL2/NN and/CC Stat3/NN on/IN IL-6-induced/JJ macrophage-differentiation/NN and/CC apoptosis/NN was/VBD studied/VBN with/IN 1A9-M/NN cells/NNS expressing/VBG human/JJ BCL2/NN or/CC a/DT dominant-negative/JJ form/NN of/IN Stat3/NN ,/, respectively/RB ./. 
IL-6-induced/JJ apoptosis/NN ,/, but/CC not/RB macrophage-differentiation/NN ,/, was/VBD blocked/VBN by/IN continuously/RB expressed/VBN BCL2/NN ./. 
A/DT dominant-negative/JJ form/NN of/IN Stat3/NN inhibited/VBD both/CC macrophage-differentiation/NN and/CC apoptosis/NN induced/VBN by/IN IL-6/NN ./. 
However/RB ,/, diminished/VBN Stat3/NN activity/NN did/VBD not/RB prevent/VB IL-6-induced/JJ downregulation/NN of/IN the/DT BCL2/NN gene/NN ./. 
Therefore/RB ,/, activation/NN of/IN Stat3/NN is/VBZ essential/JJ for/IN IL-6-induced/JJ macrophage-differentiation/NN and/CC programmed/VBN cell/NN death/NN in/IN this/DT model/NN ./. 
Whereas/IN overexpression/NN of/IN BCL2/NN abrogates/VBZ the/DT apoptotic/JJ response/NN ,/, Stat3-independent/JJ signals/NNS appear/VBP to/TO downregulate/VB expression/NN of/IN the/DT BCL2/NN gene/NN ./. 
UI/LS -/: 99115544/CD 
TI/LS -/: Involvement/NN of/IN mitogen-activated/JJ protein/NN kinase/NN pathways/NNS in/IN interleukin-8/NN production/NN by/IN human/JJ monocytes/NNS and/CC polymorphonuclear/JJ cells/NNS stimulated/VBN with/IN lipopolysaccharide/NN or/CC Mycoplasma/NN fermentans/NNS membrane/NN lipoproteins/NNS ./. 
AB/LS -/: Interleukin-8/NN (/( IL-8/NN )/) is/VBZ a/DT chemokine/NN that/WDT belongs/VBZ to/TO the/DT alpha-chemokine/NN or/CC CXC/NN subfamily/NN and/CC is/VBZ produced/VBN by/IN a/DT wide/JJ variety/NN of/IN human/JJ cells/NNS ,/, including/VBG monocytes/NNS and/CC polymorphonuclear/JJ cells/NNS (/( PMN/NN )/) ./. 
IL-8/NN is/VBZ secreted/VBN in/IN response/NN to/TO inflammatory/JJ stimuli/NNS ,/, notably/RB bacterial/JJ products/NNS such/JJ as/IN lipopolysaccharide/NN (/( LPS/NN )/) ,/, but/CC little/JJ is/VBZ known/VBN about/IN the/DT mechanisms/NNS by/IN which/WDT these/DT agents/NNS mediate/VBP IL-8/NN induction/NN ./. 
In/IN this/DT report/NN ,/, we/PRP show/VBP that/IN Mycoplasma/NN fermentans/NNS lipid-associated/JJ membrane/NN proteins/NNS (/( LAMPf/NN )/) induce/VBP the/DT production/NN of/IN high/JJ levels/NNS of/IN IL-8/NN by/IN THP-1/NN (/( human/JJ monocyte/NN )/) cells/NNS and/CC PMN/NN at/IN the/DT same/JJ extent/NN as/IN LPS/NN ./. 
It/PRP was/VBD previously/RB demonstrated/VBN that/IN stimulation/NN of/IN monocytic/JJ cells/NNS with/IN either/CC LPS/NN or/CC LAMPf/NN led/VBD to/TO a/DT series/NN of/IN common/JJ downstream/JJ signaling/NN events/NNS ,/, including/VBG the/DT activation/NN of/IN protein/NN tyrosine/NN kinase/NN and/CC of/IN mitogen-activated/JJ protein/NN kinase/NN cascades/NNS ./. 
By/IN using/VBG PD-98059/NN and/CC SB203580/NN ,/, two/CD potent/JJ and/CC selective/JJ inhibitors/NNS of/IN MEK1/NN (/( a/DT kinase/NN upstream/RB of/IN ERK1/2/NN )/) and/CC p38/NN ,/, respectively/RB ,/, we/PRP have/VBP demonstrated/VBN that/IN both/CC ERK1/2/NN and/CC p38/NN cascades/NNS play/VBP a/DT key/JJ role/NN in/IN the/DT production/NN of/IN IL-8/NN by/IN monocytes/NNS and/CC PMN/NN stimulated/VBN with/IN bacterial/JJ fractions/NNS ./. 
UI/LS -/: 99101510/CD 
TI/LS -/: Regulation/NN of/IN IL-6/NN synthesis/NN in/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS by/IN C3a/NN and/CC C3a/NN (/( desArg/NN )/) ./. 
AB/LS -/: The/DT anaphylatoxin/NN C3a/NN has/VBZ been/VBN reported/VBN to/TO have/VB immunomodulatory/JJ effects/NNS on/IN a/DT number/NN of/IN different/JJ cell/NN types/NNS ./. 
In/IN this/DT study/NN we/PRP investigated/VBD the/DT effects/NNS of/IN C3a/NN and/CC C3a/NN (/( desArg/NN )/) on/IN gene/NN expression/NN and/CC protein/NN secretion/NN of/IN IL-6/NN in/IN human/JJ PBMCs/NNS ,/, either/CC alone/RB or/CC in/IN combination/NN with/IN LPS/NN or/CC IL-1beta/NN ./. 
C3a/NN or/CC C3a/NN (/( desArg/NN )/) alone/RB exhibited/VBD no/DT effect/NN on/IN the/DT expression/NN or/CC secretion/NN of/IN IL-6/NN ./. 
However/RB ,/, when/WRB PBMC/NN were/VBD stimulated/VBN with/IN LPS/NN or/CC IL-1beta/NN ,/, both/CC C3a/NN and/CC C3a/NN (/( desArg/NN )/) were/VBD found/VBN to/TO enhance/VB IL-6/NN release/NN by/IN PBMC/NN in/IN a/DT dose-dependent/JJ manner/NN ./. 
Since/IN C3a/NN has/VBZ been/VBN shown/VBN to/TO induce/VB PGE2/NN production/NN by/IN monocytes/NNS ,/, and/CC PGE2/NN has/VBZ been/VBN shown/VBN to/TO influence/VB cytokine/NN production/NN ,/, we/PRP investigated/VBD the/DT potential/JJ role/NN of/IN PGE2/NN in/IN C3a-mediated/JJ enhancement/NN of/IN LPS-/NN and/CC IL-1beta-induced/JJ IL-6/NN production/NN ./. 
Indomethacin/NN blocked/VBD PGE2/NN release/NN ,/, but/CC had/VBD no/DT influence/NN on/IN the/DT observed/VBN effects/NNS of/IN C3a/NN ,/, suggesting/VBG that/IN the/DT effects/NNS of/IN C3a/NN on/IN IL-6/NN production/NN are/VBP independent/JJ of/IN PGE2/NN formation/NN by/IN monocytes/NNS ./. 
Northern/NN blot/NN analysis/NN showed/VBD that/DT C3a/NN as/RB well/RB as/IN C3a/NN (/( desArg/NN )/) enhanced/VBD LPS-induced/JJ mRNA/NN levels/NNS for/IN IL-6/NN ./. 
Pretreatment/NN of/IN PBMCs/NNS with/IN pertussis/NN toxin/NN blocked/VBD the/DT functions/NNS of/IN C3a/NN and/CC C3a/NN (/( desArg/NN )/) ,/, indicating/VBG that/IN the/DT actions/NNS of/IN these/DT two/CD molecules/NNS are/VBP mediated/VBN by/IN a/DT G/NN protein-coupled/JJ pathway/NN ./. 
Furthermore/RB ,/, we/PRP investigated/VBD the/DT effects/NNS of/IN C3a/NN and/CC C3a/NN (/( desArg/NN )/) on/IN induction/NN of/IN NF-kappaB/NN and/CC activating/VBG protein-1/NN binding/NN ./. 
Both/DT molecules/NNS enhanced/VBD LPS-induced/JJ NF-kappaB/NN and/CC activating/NN protein-1/NN binding/NN activity/NN ./. 
These/DT results/NNS demonstrate/VBP the/DT capacity/NN of/IN intact/JJ C3a/NN and/CC its/PRP$ circulating/VBG des-Arg/JJ form/NN to/TO exert/VB immunmodulatory/JJ effects/NNS in/FW vitro/FW ./. 
UI/LS -/: 99080869/CD 
TI/LS -/: Phenylarsine/NN oxide/NN inhibits/VBZ ex/FW vivo/FW HIV-1/NN expression/NN ./. 
AB/LS -/: Phenylarsine/NN oxide/NN (/( PAO/NN )/) ,/, which/WDT is/VBZ described/VBN as/IN an/DT inhibitor/NN of/IN tyrosine/NN phosphatase/NN activity/NN ,/, inhibits/VBZ H2O2/NN release/NN from/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMCs/NNS )/) as/IN measured/VBN by/IN electrochemistry/NN ./. 
Since/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) replication/NN is/VBZ known/VBN to/TO be/VB favored/VBN under/IN oxidative/JJ stress/NN conditions/NNS ,/, ex/FW vivo/FW experiments/NNS using/VBG uninfected/JJ PBMCs/NNS ,/, primary/JJ monocytes/NNS or/CC a/DT latently/RB infected/JJ promonocytic/JJ U1/NN cell/NN line/NN show/VBP that/IN HIV-1/NN replication/NN and/CC reactivation/NN ,/, monitored/VBN by/IN p24/NN antigen/NN measurement/NN ,/, are/VBP inhibited/VBN by/IN PAO/NN in/IN a/DT time-/NN and/CC concentration-dependent/JJ manner/NN ./. 
These/DT observations/NNS can/MD be/VB linked/VBN with/IN the/DT inhibition/NN of/IN NF-kappa/NN B/NN activation/NN when/WRB uninfected/JJ monocytes/NNS are/VBP induced/VBN by/IN either/CC tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) or/CC lipopolysaccharide/NN (/( LPS/NN )/) ./. 
UI/LS -/: 98209755/CD 
TI/LS -/: Pharmacological/JJ control/NN of/IN antigen/NN responsiveness/NN in/IN genetically/RB modified/VBN T/NN lymphocytes/NNS ./. 
AB/LS -/: A/DT chimeric/JJ TCR/NN gene/NN ,/, comprising/VBG an/DT anti-hapten/JJ single-chain/JJ Ab/NN variable/JJ fragment/NN fused/VBN to/TO the/DT transmembrane/JJ and/CC cytoplasmic/JJ regions/NNS of/IN the/DT human/JJ TCR/NN zeta-chain/NN ,/, was/VBD used/VBN to/TO determine/VB whether/IN the/DT tetracycline-regulatable/JJ system/NN could/MD be/VB used/VBN to/TO regulate/VB gene/NN expression/NN in/IN T/NN cells/NNS ./. 
Jurkat/NN T/NN cells/NNS were/VBD stably/RB transfected/VBN with/IN a/DT single/JJ vector/NN encoding/VBG the/DT tetracycline/NN trans-activator/JJ protein/NN ,/, controlled/VBN by/IN a/DT constitutive/JJ promoter/NN ,/, and/CC the/DT chimeric/JJ TCR/NN ,/, under/IN the/DT control/NN of/IN a/DT trans-activator/JJ protein-responsive/JJ promoter/NN ./. 
In/IN the/DT absence/NN of/IN tetracyclines/NNS ,/, the/DT transfected/VBN T/NN cells/NNS were/VBD shown/VBN to/TO express/VB the/DT chimeric/JJ receptor/NN on/IN the/DT cell/NN surface/NN and/CC could/MD be/VB activated/VBN by/IN its/PRP$ cognate/JJ Ag/NN ,/, leading/VBG to/TO the/DT secretion/NN of/IN IL-2/NN ./. 
When/WRB the/DT cells/NNS were/VBD exposed/VBN to/TO increasing/VBG concentrations/NNS of/IN tetracyclines/NNS ,/, surface/NN expression/NN of/IN the/DT chimeric/JJ receptor/NN was/VBD suppressed/VBN in/IN a/DT dose-dependent/JJ manner/NN ,/, and/CC this/DT suppression/NN was/VBD sufficient/JJ to/TO result/VB in/IN complete/JJ loss/NN of/IN responsiveness/NN to/TO the/DT targeted/VBN Ag/NN ./. 
Prolonged/JJ suppression/NN of/IN trans-gene/JJ expression/NN for/IN up/RB to/TO 7/CD days/NNS was/VBD observed/VBN after/IN doxycycline/NN was/VBD removed/VBN from/IN the/DT cultures/NNS ,/, but/CC eventual/JJ recovery/NN of/IN surface/NN expression/NN was/VBD complete/JJ ,/, and/CC the/DT absolute/JJ time/NN to/TO recovery/NN was/VBD directly/RB proportional/JJ to/TO the/DT initial/JJ concentration/NN of/IN the/DT drug/NN ./. 
Pharmacologic/JJ control/NN of/IN trans-gene/JJ expression/NN in/IN gene-modified/JJ T/NN cells/NNS will/MD not/RB only/RB facilitate/VB new/JJ approaches/NNS to/TO the/DT study/NN of/IN different/JJ aspects/NNS of/IN T/NN cell/NN biology/NN ,/, but/CC will/MD also/RB provide/VB the/DT basis/NN for/IN new/JJ gene/NN therapy/NN strategies/NNS ./. 
UI/LS -/: 98144699/CD 
TI/LS -/: Glucocorticoid/NN receptors/NNS ,/, fibromyalgia/NN and/CC low/JJ back/JJ pain/NN ./. 
AB/LS -/: Recently/RB ,/, fibromyalgia/NN (/( FMS/NN )/) was/VBD shown/VBN to/TO be/VB a/DT disorder/NN associated/VBN with/IN an/DT altered/JJ functioning/NN of/IN the/DT stress/NN response/NN system/NN ./. 
FMS/NN patients/NNS display/VBP a/DT hyperreactive/JJ pituitary/JJ adrenocorticotropic/JJ hormone/NN (/( ACTH/NN )/) release/NN in/IN response/NN to/TO corticotropin-releasing/JJ hormone/NN (/( CRH/NN )/) and/CC to/TO insulin-induced/JJ hypoglycemia/NN ./. 
We/PRP suggested/VBD that/IN negative/JJ feedback/NN of/IN cortisol/NN could/MD be/VB deranged/VBN ./. 
Therefore/RB we/PRP investigated/VBD the/DT properties/NNS and/CC function/NN of/IN the/DT glucocorticoid/NN receptors/NNS (/( GR/NN )/) in/IN FMS/NN patients/NNS and/CC compared/VBD the/DT results/NNS with/IN those/DT of/IN healthy/JJ persons/NNS and/CC patients/NNS with/IN chronic/JJ low/JJ back/JJ pain/NN (/( LBP/NN a/DT localized/JJ pain/NN condition/NN )/) ./. 
Forty/CD primary/JJ FMS/NN patients/NNS (/( F/NN :/: M/NN =/JJ 36/CD :/: 4/CD )/) ,/, 28/CD LBP/NN patients/NNS (/( 25/CD :/: 3/CD )/) and/CC 14/CD (/( 12/CD :/: 2/CD )/) healthy/JJ ,/, sedentary/JJ control/JJ persons/NNS were/VBD recruited/VBN for/IN the/DT study/NN ./. 
Urinary/JJ free/JJ cortisol/NN excretion/NN in/IN FMS/NN and/CC LBP/NN patients/NNS was/VBD lower/JJR compared/VBN to/TO controls/NNS ./. 
Only/RB FMS/NN patients/NNS displayed/VBD lower/JJR CBG/NN and/CC basal/JJ serum/NN cortisol/NN concentrations/NNS when/WRB compared/VBN to/TO controls/NNS ./. 
However/RB ,/, plasma/NN free/JJ cortisol/NN concentrations/NNS were/VBD similar/JJ in/IN the/DT three/CD groups/NNS ./. 
There/EX was/VBD no/DT difference/NN in/IN the/DT number/NN of/IN GR/NN per/IN cell/NN among/IN the/DT three/CD groups/NNS (/( FMS/NN :/: 6498/CD +/-/CC 252/CD ,/, LBP/NN :/: 6625/CD +/-/CC 284/CD ,/, controls/NNS :/: 6576/CD +/-/CC 304/CD )/) ,/, but/CC the/DT dissociation/NN constant/NN (/( Kd/NN )/) of/IN the/DT FMS/NN (/( 14.5/CD +/-/CC 0.9/CD nmol/l/NN )/) and/CC LBP/NN (/( 14.7/CD +/-/CC 1.3/CD nmol/l/NN )/) subjects/NNS was/VBD significantly/RB higher/JJR than/IN that/DT of/IN the/DT controls/NNS (/( 10.9/CD +/-/CC 0.8/CD nmol/l/NN )/) (/( p/NN </JJR .05/CD )/) ./. 
The/DT maximal/JJ stimulation/NN of/IN the/DT lymphocytes/NNS ,/, as/IN measured/VBN by/IN the/DT maximal/JJ thymidine/NN incorporation/NN (/( in/IN the/DT absence/NN of/IN cortisol/NN )/) in/IN the/DT FMS/NN group/NN was/VBD approximately/RB 1.5/CD times/NNS higher/JJR (/( p/NN </JJR .05/CD )/) than/IN in/IN the/DT control/JJ or/CC LBP/NN group/NN ./. 
The/DT ED50/NN (/( the/DT cortisol/NN concentration/NN giving/VBG 50/CD %/NN inhibition/NN of/IN the/DT thymidine/JJ incorporation/NN )/) ,/, however/RB ,/, was/VBD identical/JJ in/IN all/DT three/CD groups/NNS ./. 
We/PRP conclude/VBP that/IN FMS/NN patients/NNS have/VBP a/DT mild/JJ hypocortisolemia/NN ,/, increased/VBN cortisol/NN feedback/NN resistance/NN in/IN combination/NN probably/RB with/IN a/DT reduced/VBN CRH/NN synthesis/NN or/CC release/NN in/IN the/DT hypothalamus/NN ./. 
The/DT role/NN of/IN the/DT GR/NN and/CC mineralocorticoid/NN receptor/NN (/( MR/NN )/) in/IN the/DT CRH/NN regulation/NN in/IN the/DT FMS/NN patients/NNS remains/VBZ to/TO be/VB solved/VBN ./. 
UI/LS -/: 98104477/CD 
TI/LS -/: Temporal/JJ control/NN of/IN IgH/JJ gene/NN expression/NN in/IN developing/VBG B/NN cells/NNS by/IN the/DT 3'/JJ locus/NN control/NN region/NN ./. 
AB/LS -/: The/DT suggested/VBN roles/NNS of/IN the/DT downstream/JJ 3'/JJ regions/NNS acting/VBG as/IN a/DT Locus/NN Control/NN Region/NN (/( LCR/NN )/) ,/, have/VBP allowed/VBN comparisons/NNS to/TO be/VB made/VBN between/IN the/DT regulation/NN of/IN the/DT IgH/JJ locus/NN with/IN other/JJ model/NN systems/NNS whose/WP$ gene/NN expression/NN is/VBZ governed/VBN by/IN LCR/NN activity/NN ./. 
Here/RB we/PRP summarize/VBP the/DT importance/NN of/IN the/DT IgH/JJ 3'LCR/NN and/CC its/PRP$ putative/JJ functional/JJ role/NN in/IN IgH/JJ gene/NN expression/NN and/CC compare/VBP it/PRP with/IN the/DT 5'LCR/NN regulatory/JJ region/NN of/IN the/DT human/JJ beta-globin/NN locus/NN ./. 
UI/LS -/: 98090595/CD 
TI/LS -/: HLA/NN binding/NN characteristics/NNS and/CC generation/NN of/IN cytotoxic/JJ lymphocytes/NNS against/IN peptides/NNS derived/VBN from/IN oncogenic/JJ proteins/NNS ./. 
AB/LS -/: AIMS/NNS AND/CC BACKGROUND/NN :/: Structurally/RB altered/VBN proteins/NNS (/( derived/VBN from/IN chromosomal/JJ translocations/NNS or/CC gene/NN mutations/NNS )/) can/MD be/VB considered/VBN tumor/NN specific/JJ antigens/NNS and/CC represent/VB an/DT attractive/JJ target/NN for/IN a/DT T-cell/NN mediated/JJ response/NN ./. 
T/NN lymphocytes/NNS recognize/VBP antigens/NNS in/IN the/DT form/NN of/IN peptides/NNS bound/VBN to/TO HLA-molecules/NNS ./. 
MATERIALS/NNS AND/CC METHODS/NNS :/: Peptides/NNS derived/VBN from/IN oncogenic/JJ proteins/NNS were/VBD screened/VBN for/IN the/DT presence/NN of/IN HLA/NN binding/NN motifs/NNS ;/: actual/JJ binding/NN were/VBD evaluated/VBN by/IN HLA/NN stabilization/NN experiments/NNS using/VBG transfectants/NNS and/CC specific/JJ anti-HLA/JJ antibodies/NNS ./. 
Specific/JJ lymphocytes/NNS were/VBD induced/VBN by/IN in/FW vitro/FW peptide/NN sensitization/NN and/CC screened/VBN by/IN thymidine/NN uptake/NN or/CC cellular/JJ cytotoxic/JJ assays/NNS ./. 
RESULTS/NNS :/: We/PRP identified/VBD peptides/NNS derived/VBN from/IN EWS/FLI-1/NN fusion/NN protein/NN and/CC from/IN mutated/VBN K-RAS/NN protein/NN (/( encompassing/VBG respectively/RB the/DT fusion/NN point/NN and/CC the/DT mutation/NN at/IN position/NN 12/CD )/) that/WDT showed/VBD binding/VBG motif/NN for/IN HLA-Cw*0702/NN and/CC HLA-A3/NN respectively/RB ./. 
The/DT actual/JJ binding/NN of/IN these/DT peptides/NNS was/VBD analysed/VBN in/IN a/DT stabilization/NN assay/NN ./. 
We/PRP detected/VBD binding/NN for/IN the/DT EWS/FLI-1/NN peptide/NN and/CC for/IN 5/CD RAS/NN peptides/NNS (/( 1/CD wild/JJ type/NN and/CC 4/CD mutated/VBN )/) ./. 
The/DT effect/NN of/IN temperature/NN ,/, beta/NN 2-microglobulin/NN (/( beta/NN 2-m/NN )/) and/CC fetal/JJ calf/NN serum/NN (/( FCS/NN )/) on/IN the/DT binding/NN and/CC the/DT stability/NN of/IN the/DT HLA/peptide/NN complex/NN was/VBD studied/VBN ./. 
A/DT low/JJ temperature/NN (/( 26/CD degrees/NNS C/NN )/) increased/VBD the/DT binding/NN both/CC in/IN HLA-A3/NN and/CC HLA-Cw*0702/NN ,/, while/IN FCS/NN reduced/VBD it/PRP ./. 
beta/NN 2-m/NN increased/VBD the/DT binding/NN to/TO the/DT HLA-A3/NN molecule/NN but/CC did/VBD not/RB influence/VB the/DT binding/NN to/TO the/DT HLA-Cw*0702/NN ./. 
The/DT stability/NN of/IN already/RB formed/VBN complexed/VBN was/VBD somewhat/RB different/JJ in/IN the/DT HLA-A3/NN and/CC HLA-Cw*0702/NN system/NN :/: both/DT were/VBD more/RBR stable/JJ at/IN 26/CD degrees/NNS C/NN than/IN at/IN 37/CD degrees/NNS C/NN but/CC while/IN the/DT beta/NN 2-m/NN and/CC FCS/NN did/VBD not/RB influence/VB the/DT stability/NN of/IN the/DT HLA-A3/peptide/NN complex/NN ,/, they/PRP seemed/VBD to/TO cause/VB opposite/JJ effects/NNS in/IN the/DT HLA-Cw*0702/NN system/NN (/( beta/NN 2-m/NN stabilized/VBD and/CC FCS/NN destabilized/VBD the/DT complex/NN )/) ./. 
Finally/RB ,/, we/PRP were/VBD able/JJ to/TO generate/VB a/DT specific/JJ CD8+/JJ CTL/NN line/NN against/IN a/DT K-RAS/NN mutated/JJ peptide/NN ./. 
CONCLUSIONS/NNS :/: Although/IN binding/VBG motifs/NNS and/CC actual/JJ HLA/NN binding/NN can/MD be/VB detected/VBN in/IN several/JJ cases/NNS ,/, the/DT generation/NN of/IN a/DT cellular/JJ response/NN is/VBZ infrequent/JJ ,/, confirming/VBG that/IN HLA/NN binding/NN is/VBZ necessary/JJ but/CC not/RB sufficient/JJ to/TO obtain/VB an/DT in/FW vitro/FW response/NN ./. 
Further/RB optimization/NN of/IN culture/NN conditions/NNS ,/, type/NN of/IN Antigen/NN Presenting/NN Cells/NNS (/( APC/NNS )/) ,/, peptides/NNS ,/, use/NN of/IN stabilizers/NNS like/IN beta/NN 2-m/NN are/VBP still/RB needed/VBN ./. 
UI/LS -/: 98038798/CD 
TI/LS -/: OCA-B/NN is/VBZ a/DT functional/JJ analog/NN of/IN VP16/NN but/CC targets/VBZ a/DT separate/JJ surface/NN of/IN the/DT Oct-1/NN POU/NN domain/NN [/( published/VBN erratum/NN appears/VBZ in/IN Mol/NNP Cell/NNP Biol/NNP 1998/CD Apr/NNP ;/: 18/CD (/( 4/CD )/) :/: 2430/CD ]/) 
AB/LS -/: OCA-B/NN is/VBZ a/DT B-cell-specific/JJ coregulator/NN of/IN the/DT broadly/RB expressed/VBN POU/NN domain/NN transcription/NN factor/NN Oct-1/NN ./. 
OCA-B/NN associates/VBZ with/IN the/DT Oct-1/NN POU/NN domain/NN ,/, a/DT bipartite/JJ DNA-binding/JJ structure/NN containing/VBG a/DT POU-specific/JJ (/( POU[S]/JJ )/) domain/NN joined/VBN by/IN a/DT flexible/JJ linker/NN to/TO a/DT POU/NN homeodomain/NN (/( POU[H]/NN )/) ./. 
Here/RB ,/, we/PRP show/VBP that/IN OCA-B/NN alters/VBZ the/DT activity/NN of/IN Oct-1/NN in/IN two/CD ways/NNS ./. 
It/PRP provides/VBZ a/DT transcriptional/JJ activation/NN domain/NN which/WDT ,/, unlike/IN Oct-1/NN ,/, activates/VBZ an/DT mRNA-type/JJ promoter/NN effectively/RB ,/, and/CC it/PRP stabilizes/VBZ Oct-1/NN on/IN the/DT Oct-1-responsive/JJ octamer/NN sequence/NN ATGCAAAT/NN ./. 
These/DT properties/NNS of/IN OCA-B/NN parallel/VBP those/DT displayed/VBN by/IN the/DT herpes/NN simplex/JJ virus/NN Oct-1/NN coregulator/NN VP16/NN ./. 
OCA-B/NN ,/, however/RB ,/, interacts/VBZ with/IN a/DT different/JJ surface/NN of/IN the/DT DNA-bound/JJ Oct-1/NN POU/NN domain/NN ,/, interacting/VBG with/IN both/CC the/DT POU(S)/JJ and/CC POU(H)/NN domains/NNS and/CC the/DT center/NN of/IN the/DT ATGCAAAT/NN octamer/NN sequence/NN ./. 
The/DT OCA-B/NN and/CC VP16/NN interactions/NNS with/IN the/DT Oct-1/NN POU/NN domain/NN are/VBP sufficiently/RB different/JJ to/TO permit/VB OCA-B/NN and/CC VP16/NN to/TO bind/VB the/DT Oct-1/NN POU/NN domain/NN simultaneously/RB ./. 
These/DT results/NNS emphasize/VBP the/DT structural/JJ versatility/NN of/IN the/DT Oct-1/NN POU/NN domain/NN in/IN its/PRP$ interaction/NN with/IN coregulators/NNS ./. 
UI/LS -/: 98051057/CD 
TI/LS -/: Phosphatidylinositol/NN 3-kinase/NN couples/VBZ the/DT interleukin-2/NN receptor/NN to/TO the/DT cell/NN cycle/NN regulator/NN E2F/NN ./. 
AB/LS -/: Cell/NN cycle/NN progression/NN initiated/VBN by/IN interleukin-2/NN (/( IL-2/NN )/) in/IN T/NN cells/NNS is/VBZ critical/JJ for/IN lymphoproliferation/NN and/CC an/DT immune/JJ response/NN ./. 
Phosphatidyl/NN inositol/NN 3-kinase/NN (/( PI3K/NN )/) is/VBZ activated/VBN by/IN IL-2/NN ./. 
However/RB ,/, nuclear/JJ targets/NNS for/IN PI3K/NN are/VBP not/RB known/VBN ./. 
Here/RB we/PRP identify/VBP the/DT cell/NN cycle/NN regulator/NN E2F/NN as/IN an/DT IL-2/NN target/NN in/IN T/NN lymphocytes/NNS and/CC PI3K/NN as/IN the/DT critical/JJ signaling/NN pathway/NN ./. 
We/PRP eliminate/VBP both/CC Stat5/NN and/CC Raf/MEK/NN pathways/NNS from/IN E2F/NN regulation/NN ./. 
Protein/NN kinase/NN B/NN (/( PKB/NN )/) is/VBZ activated/VBN by/IN IL-2/NN via/IN PI3K/NN ./. 
The/DT expression/NN of/IN an/DT active/JJ PKB/NN is/VBZ sufficient/JJ to/TO induce/VB E2F/NN activity/NN ./. 
Inhibition/NN of/IN PI3K/NN inhibits/VBZ phosphorylation/NN of/IN Rb/NN ,/, induction/NN of/IN cyclin/NN D3/NN ,/, and/CC degradation/NN of/IN p27kip1/NN ./. 
These/DT results/NNS establish/VBP a/DT crucial/JJ PI3K/PKB-mediated/JJ link/NN between/IN the/DT IL-2/NN teceptor/NN and/CC the/DT cell/NN cycle/NN machinery/NN ./. 
UI/LS -/: 98024176/CD 
TI/LS -/: The/DT Epstein-Barr/JJ virus/NN oncogene/NN product/NN latent/JJ membrane/NN protein/NN 1/CD engages/VBZ the/DT tumor/NN necrosis/NN factor/NN receptor-associated/JJ death/NN domain/NN protein/NN to/TO mediate/VB B/NN lymphocyte/NN growth/NN transformation/NN and/CC activate/VB NF-kappaB/NN ./. 
AB/LS -/: The/DT Epstein-Barr/JJ virus/NN latent/JJ membrane/NN protein/NN 1/CD (/( LMP1/NN )/) is/VBZ essential/JJ for/IN the/DT transformation/NN of/IN B/NN lymphocytes/NNS into/IN lymphoblastoid/JJ cell/NN lines/NNS ./. 
Previous/JJ data/NNS are/VBP consistent/JJ with/IN a/DT model/NN that/IN LMP1/NN is/VBZ a/DT constitutively/RB activated/VBN receptor/NN that/WDT transduces/VBZ signals/NNS for/IN transformation/NN through/IN its/PRP$ carboxyl-terminal/JJ cytoplasmic/JJ tail/NN ./. 
One/CD transformation/NN effector/NN site/NN (/( TES1/NN )/) ,/, located/JJ within/IN the/DT membrane/NN proximal/JJ 45/CD residues/NNS of/IN the/DT cytoplasmic/JJ tail/NN ,/, constitutively/RB engages/VBZ tumor/NN necrosis/NN factor/NN receptor-associated/JJ factors/NNS ./. 
Signals/NNS from/IN TES1/NN are/VBP sufficient/JJ to/TO drive/VB initial/JJ proliferation/NN of/IN infected/JJ resting/VBG B/NN lymphocytes/NNS ,/, but/CC most/JJS lymphoblastoid/JJ cells/NNS infected/VBN with/IN a/DT virus/NN that/WDT does/VBZ not/RB express/VB the/DT 155/CD residues/NNS beyond/IN TES1/NN fail/VBP to/TO grow/VB as/IN long-term/JJ cell/NN lines/NNS ./. 
We/PRP now/RB find/VBP that/IN mutating/VBG two/CD tyrosines/NNS to/TO an/DT isoleucine/NN at/IN the/DT carboxyl/NN end/NN of/IN the/DT cytoplasmic/JJ tail/NN cripples/VBZ the/DT ability/NN of/IN EBV/NN to/TO cause/VB lymphoblastoid/JJ cell/NN outgrowth/NN ,/, thereby/RB marking/VBG a/DT second/JJ transformation/NN effector/NN site/NN ,/, TES2/NN ./. 
A/DT yeast/NN two-hybrid/JJ screen/NN identified/VBD TES2/NN interacting/NN proteins/NNS ,/, including/VBG the/DT tumor/NN necrosis/NN factor/NN receptor-associated/JJ death/NN domain/NN protein/NN (/( TRADD/NN )/) ./. 
TRADD/NN was/VBD the/DT only/JJ protein/NN that/WDT interacted/VBD with/IN wild-type/JJ TES2/NN and/CC not/RB with/IN isoleucine-mutated/JJ TES2/NN ./. 
TRADD/NN associated/VBD with/IN wild-type/JJ LMP1/NN but/CC not/RB with/IN isoleucine-mutated/JJ LMP1/NN in/IN mammalian/JJ cells/NNS ,/, and/CC TRADD/NN constitutively/RB associated/VBD with/IN LMP1/NN in/IN EBV-transformed/JJ cells/NNS ./. 
In/IN transfection/NN assays/NNS ,/, TRADD/NN and/CC TES2/NN synergistically/RB mediated/VBD high-level/JJ NF-kappaB/NN activation/NN ./. 
These/DT results/NNS indicate/VBP that/IN LMP1/NN appropriates/VBZ TRADD/NN to/TO enable/VB efficient/JJ long-term/JJ lymphoblastoid/JJ cell/NN outgrowth/NN ./. 
High-level/JJ NF-kappaB/NN activation/NN also/RB appears/VBZ to/TO be/VB a/DT critical/JJ component/NN of/IN long-term/JJ outgrowth/NN ./. 
UI/LS -/: 98012234/CD 
TI/LS -/: Inhibition/NN of/IN T/NN cell/NN and/CC promotion/NN of/IN natural/JJ killer/NN cell/NN development/NN by/IN the/DT dominant/JJ negative/JJ helix/NN loop/NN helix/NN factor/NN Id3/NN ./. 
AB/LS -/: Bipotential/JJ T/natural/JJ killer/NN (/( NK/NN )/) progenitor/NN cells/NNS are/VBP present/JJ in/IN the/DT human/JJ thymus/NN ./. 
Despite/IN their/PRP$ bipotential/JJ capacity/NN ,/, these/DT progenitors/NNS develop/VBP predominantly/RB to/TO T/NN cells/NNS in/IN the/DT thymus/NN ./. 
The/DT mechanisms/NNS controlling/VBG this/DT developmental/JJ choice/NN are/VBP unknown/JJ ./. 
Here/RB we/PRP present/VBP evidence/NN that/IN a/DT member/NN (/( s/NNS )/) of/IN the/DT family/NN of/IN basic/JJ helix/NN loop/NN helix/NN (/( bHLH/JJ )/) transcription/NN factors/NNS determines/VBZ lineage/NN specification/NN of/IN NK/T/NN cell/NN progenitors/NNS ./. 
The/DT natural/JJ dominant/JJ negative/JJ HLH/JJ factor/NN Id3/NN ,/, which/WDT blocks/VBZ transcriptional/JJ activity/NN of/IN a/DT number/NN of/IN known/JJ bHLH/JJ factors/NNS ,/, was/VBD expressed/VBN in/IN CD34+/JJ progenitor/NN cells/NNS by/IN retrovirus-mediated/JJ gene/NN transfer/NN ./. 
Constitutive/JJ expression/NN of/IN Id3/NN completely/RB blocks/VBZ development/NN of/IN CD34+/JJ cells/NNS into/IN T/NN cells/NNS in/IN a/DT fetal/JJ thymic/JJ organ/NN culture/NN (/( FTOC/NN )/) ./. 
In/IN contrast/NN ,/, development/NN into/IN NK/NN cells/NNS in/IN an/DT FTOC/NN is/VBZ enhanced/VBN ./. 
Thus/RB ,/, the/DT activity/NN of/IN a/DT bHLH/JJ transcription/NN factor/NN is/VBZ necessary/JJ for/IN T/NN lineage/NN differentiation/NN of/IN bipotential/JJ precursors/NNS ,/, in/IN the/DT absence/NN of/IN which/WDT a/DT default/NN pathway/NN leading/VBG to/TO NK/NN cell/NN development/NN is/VBZ chosen/VBN ./. 
Our/PRP$ results/NNS identify/VBP a/DT molecular/JJ switch/NN for/IN lineage/NN specification/NN in/IN early/JJ lymphoid/JJ precursors/NNS of/IN humans/NNS ./. 
UI/LS -/: 98001396/CD 
TI/LS -/: Late/JJ gene/NN expression/NN from/IN the/DT Epstein-Barr/JJ virus/NN BcLF1/NN and/CC BFRF3/NN promoters/NNS does/VBZ not/RB require/VB DNA/NN replication/NN in/IN cis/NN ./. 
AB/LS -/: Late/JJ gene/NN expression/NN follows/VBZ and/CC is/VBZ dependent/JJ upon/IN lytic/JJ replication/NN of/IN the/DT viral/JJ genome/NN ./. 
Although/IN experimental/JJ evidence/NN is/VBZ lacking/JJ ,/, lytic/JJ viral/JJ DNA/NN replication/NN is/VBZ believed/VBN to/TO remove/VB modifications/NNS or/CC binding/VBG factors/NNS from/IN the/DT genome/NN which/WDT serve/VBP to/TO repress/VB late/JJ gene/NN expression/NN during/IN latency/NN or/CC the/DT early/JJ lytic/JJ cycle/NN ./. 
We/PRP have/VBP developed/VBN a/DT reporter/NN assay/NN to/TO begin/VB characterizing/VBG the/DT mechanisms/NNS that/WDT regulate/VBP late/JJ gene/NN expression/NN in/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) ./. 
In/IN this/DT model/NN system/NN ,/, the/DT activities/NNS of/IN late/JJ promoter-reporter/JJ fusions/NNS are/VBP measured/VBN following/VBG transient/JJ transfection/NN into/IN tissue/NN culture/NN cells/NNS expressing/VBG EBV/NN during/IN different/JJ stages/NNS of/IN the/DT lytic/JJ cycle/NN ./. 
This/DT system/NN faithfully/RB recapitulates/VBZ late/JJ expression/NN patterns/NNS from/IN the/DT endogenous/JJ virus/NN ,/, implicating/VBG specific/JJ cis-active/JJ sequences/NNS in/IN the/DT control/NN of/IN late/JJ gene/NN expression/NN ./. 
In/IN addition/NN ,/, these/DT promoters/NNS respond/VBP only/RB indirectly/RB to/TO the/DT viral/JJ immediate-early/JJ transactivator/NN ,/, ZEBRA/NN ./. 
This/DT indirect/JJ response/NN is/VBZ mediated/VBN by/IN other/JJ viral/JJ or/CC virally/RB induced/VBN activities/NNS downstream/JJ of/IN ZEBRA/NN in/IN the/DT lytic/JJ cascade/NN ./. 
In/IN this/DT system/NN ,/, late/JJ gene/NN expression/NN is/VBZ sensitive/JJ to/TO inhibitors/NNS of/IN the/DT viral/JJ DNA/NN polymerase/NN such/JJ as/IN phosphonoacetic/JJ acid/NN ,/, although/IN the/DT reporters/NNS lack/VBP a/DT eukaryotic/JJ origin/NN of/IN replication/NN and/CC are/VBP not/RB replicated/VBN under/IN the/DT assay/NN conditions/NNS ./. 
Thus/RB ,/, replication/NN of/IN the/DT transcriptional/JJ template/NN is/VBZ not/RB a/DT prerequisite/NN for/IN expression/NN with/IN late/JJ kinetics/NNS ,/, a/DT finding/NN inconsistent/JJ with/IN the/DT current/JJ models/NNS which/WDT posit/VBP a/DT cis-active/JJ relationship/NN between/IN lytic/JJ EBV/NN DNA/NN replication/NN and/CC late/JJ gene/NN expression/NN ./. 
Rather/RB ,/, analysis/NN of/IN this/DT system/NN has/VBZ revealed/VBN a/DT trans/JJ relationship/NN between/IN late/JJ gene/NN expression/NN and/CC viral/JJ DNA/NN replication/NN and/CC highlights/VBZ the/DT indirect/JJ and/CC complex/JJ link/NN between/IN these/DT two/CD events/NNS ./. 
UI/LS -/: 98025882/CD 
TI/LS -/: Modulation/NN of/IN mRNA/NN expression/NN of/IN a/DT novel/JJ human/JJ myeloid-selective/JJ CCAAT/enhancer/NN binding/NN protein/NN gene/NN (/( C/EBP/NN epsilon/NN )/) ./. 
AB/LS -/: Human/JJ C/EBP/NN epsilon/NN is/VBZ a/DT newly/RB cloned/VBN gene/NN coding/VBG for/IN a/DT CCAAT/enhancer/NN binding/NN protein/NN that/WDT may/MD be/VB involved/VBN in/IN the/DT regulation/NN of/IN myeloid/JJ differentiation/NN ./. 
Our/PRP$ studies/NNS showed/VBD that/IN levels/NNS of/IN C/EBP/NN epsilon/NN mRNA/NN were/VBD markedly/RB increased/VBN in/IN NB4/NN cells/NNS (/( promyelocytic/JJ leukemia/NN line/NN )/) ,/, because/IN they/PRP were/VBD induced/VBN by/IN 9-cis/JJ retinoic/JJ acid/NN (/( 9-cis/JJ RA/NN )/) to/TO differentiate/VB towards/IN granulocytes/NNS ./. 
Accumulation/NN of/IN C/EBP/NN epsilon/NN mRNA/NN occurred/VBD as/RB early/RB as/IN 1/CD hour/NN after/IN exposure/NN of/IN NB4/NN cells/NNS to/TO 9-cis/JJ RA/NN (/( 5/CD x/CC 10(-7)/CD mol/L/NN )/) ;/: and/CC at/IN 48/CD hours/NNS ,/, levels/NNS were/VBD increased/VBN by/IN 5.1-fold/RB ./. 
Dose-response/JJ studies/NNS showed/VBD that/IN 10(-7)/CD to/TO 10(-6)/CD mol/L/NN 9-cis/JJ RA/NN (/( 12/CD hours/NNS )/) resulted/VBD in/IN peak/NN levels/NNS of/IN C/EBP/NN epsilon/NN mRNA/NN ;/: but/CC even/RB 10(-10)/CD mol/L/NN 9-cis/JJ RA/NN increased/VBD levels/NNS of/IN these/DT transcripts/NNS ./. 
NB4/NN cells/NNS pulse-exposed/JJ (/( 30/CD minutes/NNS )/) to/TO all-trans/JJ retinoic/JJ acid/NN (/( ATRA/NN )/) ,/, washed/VBN ,/, and/CC cultured/VBN (/( 3/CD days/NNS )/) with/IN either/CC dimethylsulfoxide/NN (/( DMSO/NN )/) or/CC hexamethylene/NN bisacetamide/NN (/( HMBA/NN )/) had/VBD a/DT prominent/JJ increase/NN in/IN levels/NNS of/IN C/EBP/NN epsilon/NN mRNA/NN and/CC an/DT increase/NN in/IN granulocytic/JJ differentiation/NN ,/, but/CC exposure/NN to/TO either/CC DMSO/NN or/CC HMBA/NN alone/RB had/VBD no/DT effect/NN on/IN base/NN levels/NNS of/IN C/EBP/NN epsilon/NN and/CC did/VBD not/RB induce/VB differentiation/NN ./. 
Macrophage-differentiation/NN of/IN NB4/NN reduced/VBD levels/NNS of/IN C/EBP/NN epsilon/NN mRNA/NN ./. 
Nuclear/JJ run-off/JJ assays/NNS and/CC half-life/JJ studies/NNS showed/VBD that/IN accumulation/NN of/IN C/EBP/NN epsilon/NN mRNA/NN by/IN 9-cis/JJ RA/NN was/VBD due/JJ to/TO enhanced/VBN transcription/NN ./. 
Furthermore/RB ,/, this/DT C/EBP/NN epsilon/NN mRNA/NN accumulation/NN did/VBD not/RB require/VB synthesis/NN of/IN new/JJ protein/NN factors/NNS because/IN 9-cis/JJ RA/NN induced/VBD C/EBP/NN epsilon/NN mRNA/NN accumulation/NN in/IN the/DT absence/NN of/IN new/JJ protein/NN synthesis/NN ./. 
ATRA/NN also/RB induced/VBD expression/NN of/IN C/EBP/NN epsilon/NN protein/NN in/IN NB4/NN cells/NNS ,/, as/IN shown/VBN by/IN Western/NN blotting/NN ./. 
In/IN contrast/NN to/TO the/DT increase/NN of/IN C/EBP/NN epsilon/NN in/IN 9-cis/JJ RA-mediated/JJ granulocytic/JJ differentiation/NN ,/, the/DT DMSO-induced/JJ differentiation/NN of/IN HL-60/NN cells/NNS down/IN the/DT granulocytic/JJ pathway/NN was/VBD associated/VBN with/IN an/DT initial/JJ reduction/NN of/IN C/EBP/NN epsilon/NN mRNA/NN levels/NNS ./. 
In/IN summary/NN ,/, we/PRP have/VBP discovered/VBN that/IN expression/NN of/IN C/EBP/NN epsilon/NN mRNA/NN is/VBZ markedly/RB enhanced/VBN as/IN the/DT NB4/NN promyelocytes/NNS are/VBP induced/VBN by/IN retinoids/NNS to/TO differentiate/VB towards/IN granulocytes/NNS ./. 
This/DT induction/NN of/IN C/EBP/NN epsilon/NN mRNA/NN expression/NN is/VBZ transcriptionally/RB mediated/VBN and/CC occurs/VBZ in/IN the/DT absence/NN of/IN synthesis/NN of/IN additional/JJ protein/NN factors/NNS ./. 
We/PRP suspect/VBP that/IN the/DT C/EBP/NN epsilon/NN promoter/enhancer/NN contains/VBZ a/DT retinoic/JJ acid-response/JJ element/NN that/WDT is/VBZ directly/RB stimulated/VBN by/IN retinoids/NNS ./. 
UI/LS -/: 97461470/CD 
TI/LS -/: Dual/JJ effects/NNS of/IN LPS/NN antibodies/NNS on/IN cellular/JJ uptake/NN of/IN LPS/NN and/CC LPS-induced/JJ proinflammatory/JJ functions/NNS ./. 
AB/LS -/: Human/JJ phagocytes/NNS recognize/VBP bacterial/JJ LPS/NN (/( endotoxin/NN )/) through/IN membrane/NN CD14/NN (/( mCD14/NN )/) ,/, a/DT proinflammatory/JJ LPS/NN receptor/NN ./. 
This/DT study/NN tested/VBD the/DT hypothesis/NN that/IN anti-LPS/JJ Abs/NNS neutralize/VBP endotoxin/NN by/IN blocking/VBG cellular/JJ uptake/NN through/IN mCD14/NN ./. 
Ab-associated/JJ changes/NNS in/IN the/DT uptake/NN and/CC cellular/JJ distribution/NN of/IN FITC-LPS/NN were/VBD assessed/VBN by/IN flow/NN cytometry/NN and/CC laser/NN scanning/NN confocal/JJ microscopy/NN in/IN human/JJ CD14-transfected/JJ Chinese/JJ hamster/NN ovary/JJ fibroblasts/NNS (/( CHO-CD14/NN cells/NNS )/) and/CC human/JJ peripheral/JJ blood/NN monocytes/NNS ./. 
LPS/NN core-/NN and/CC O-side/JJ chain-specific/JJ mAbs/NNS inhibited/VBD mCD14-mediated/JJ LPS/NN uptake/NN by/IN both/DT cell/NN types/NNS in/IN the/DT presence/NN of/IN serum/NN ./. 
O-side/JJ chain-specific/JJ mAb/NN concurrently/RB enhanced/VBD complement-dependent/JJ LPS/NN uptake/NN by/IN monocytes/NNS through/IN complement/NN receptor-1/NN (/( CR1/NN )/) and/CC uptake/NN by/IN CHO-CD14/NN cells/NNS involving/VBG another/DT heat-labile/JJ serum/NN factor/NN (/( s/NNS )/) and/CC cell-associated/JJ recognition/NN molecule/NN (/( s/NNS )/) ./. 
Core-specific/JJ mAb/NN inhibited/VBD mCD14-mediated/JJ uptake/NN of/IN homologous/JJ and/CC heterologous/JJ LPS/NN ,/, while/IN producing/VBG less/RBR concurrent/JJ enhancement/NN of/IN non-mCD14-mediated/JJ LPS/NN uptake/NN ./. 
The/DT modulation/NN by/IN anti-LPS/JJ mAbs/NNS of/IN mCD14-mediated/JJ LPS/NN uptake/NN was/VBD associated/VBN with/IN inhibition/NN of/IN LPS-induced/JJ nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) translocation/NN and/CC TNF-alpha/NN secretion/NN in/IN CHO-CD14/NN cells/NNS and/CC monocytes/NNS ,/, respectively/RB ,/, while/IN mAb/NN enhancement/NN of/IN non-mCD14-mediated/JJ LPS/NN uptake/NN stimulated/VBD these/DT activities/NNS ./. 
LPS-specific/JJ Abs/NNS thus/RB mediate/VBP anti-inflammatory/JJ and/CC proinflammatory/JJ functions/NNS ,/, respectively/RB ,/, by/IN preventing/VBG target/NN cell/NN uptake/NN of/IN LPS/NN through/IN mCD14/NN and/CC augmenting/VBG uptake/NN through/IN CR1/NN or/CC other/JJ cell/NN receptors/NNS ./. 
UI/LS -/: 97456880/CD 
TI/LS -/: Four/CD P-like/JJ elements/NNS are/VBP required/VBN for/IN optimal/JJ transcription/NN of/IN the/DT mouse/NN IL-4/NN gene/NN :/: involvement/NN of/IN a/DT distinct/JJ set/NN of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS and/CC activator/NN protein-1/NN family/NN proteins/NNS ./. 
AB/LS -/: We/PRP previously/RB identified/VBD the/DT P/NN sequence/NN as/IN a/DT critical/JJ regulatory/JJ element/NN of/IN the/DT human/JJ IL-4/NN promoter/NN ./. 
In/IN the/DT mouse/NN IL-4/NN promoter/NN ,/, there/EX are/VBP five/CD elements/NNS homologous/JJ to/TO the/DT human/JJ P/NN sequence/NN designated/VBN conserved/JJ lymphokine/NN element/NN 0/CD (/( CLE0/NN )/) ,/, P/NN ,/, P2/NN ,/, P3/NN and/CC P4/NN ./. 
To/TO characterize/VB the/DT role/NN of/IN these/DT P-like/JJ elements/NNS and/CC their/PRP$ binding/NN factors/NNS in/IN the/DT native/JJ promoter/NN ,/, we/PRP did/VBD transient/JJ transfection/NN and/CC electrophoretic/JJ mobility/NN shift/NN assays/NNS (/( EMSA/NN )/) ./. 
Transfection/NN of/IN EL-4/NN cells/NNS with/IN the/DT IL-4/NN promoter-reporter/NN constructs/NNS carrying/VBG mutated/VBN P-like/JJ elements/NNS showed/VBD that/IN four/CD P-like/JJ elements/NNS ,/, CLE0/NN ,/, P/NN ,/, P2/NN and/CC P4/NN ,/, but/CC not/RB P3/NN ,/, were/VBD required/VBN for/IN optimal/JJ activation/NN of/IN the/DT IL-4/NN promoter/NN ./. 
EMSA/NN showed/VBD that/IN both/CC constitutive/JJ and/CC inducible/JJ complexes/NNS bound/VBD to/TO CLE0/NN ,/, P/NN ,/, P2/NN and/CC P4/NN ,/, whereas/IN only/RB a/DT constitutive/JJ complex/NN bound/VBD to/TO P3/NN ./. 
In/IN competition/NN and/CC antibody/NN supershift/NN assays/NNS in/IN EMSA/NN ,/, complexes/NNS formed/VBN with/IN P/NN or/CC P2/NN proved/VBD to/TO contain/VB nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) family/NN proteins/NNS as/IN major/JJ components/NNS ./. 
Activator/NN protein/NN (/( AP/NN )/) -1/CD family/NN proteins/NNS interacted/VBD with/IN CLE0/NN ,/, P/NN ,/, P2/NN and/CC P4/NN ./. 
NFAT/AP-1/NN complex/NN formed/VBD only/RB with/IN P/NN and/CC P2/NN ./. 
Cross-competition/NN assays/NNS among/IN the/DT P-like/JJ elements/NNS revealed/VBD element-specific/JJ and/CC common/JJ complexes/NNS ./. 
Six/CD tandem/JJ repeats/NNS of/IN the/DT P/NN element/NN linked/VBN to/TO the/DT SV40/NN promoter/NN responded/VBD to/TO phorbol/NN 12-myristate/NN 13-acetate/NN ,/, while/IN that/DT of/IN other/JJ elements/NNS did/VBD not/RB ./. It/PRP would/MD thus/RB appear/VB that/IN components/NNS of/IN each/DT P-like/JJ element-binding/JJ complexes/NNS are/VBP not/RB identical/JJ and/CC may/MD coordinately/RB contribute/VB to/TO transcriptional/JJ activity/NN ./. 
UI/LS -/: 98090689/CD 
TI/LS -/: Constitutive/JJ expression/NN c-fos/NN ,/, c-jun/NN ,/, and/CC NF/NN kappa/NN B/NN mRNA/NN is/VBZ in/IN nucleated/JJ fetal/JJ blood/NN cells/NNS and/CC up-regulation/NN of/IN c-fos/NN and/CC c-jun/NN with/IN anti-CD3/JJ stimulation/NN ./. 
AB/LS -/: Fetal/JJ and/CC neonatal/JJ lymphocytes/NNS are/VBP relatively/RB resistant/JJ to/TO activation/NN and/CC cytokine/NN production/NN when/WRB stimulated/VBN either/CC via/IN their/PRP$ T-cell/NN antigen/NN receptors/NNS or/CC lectins/NNS ./. 
The/DT molecular/JJ mechanism/NN (/( s/NNS )/) responsible/JJ for/IN this/DT phenomenon/NN have/VBP not/RB been/VBN clearly/RB elucidated/VBN ./. 
We/PRP have/VBP hypothesized/VBN that/IN such/JJ defects/NNS in/IN fetal/neonatal/JJ T-cell/NN activation/NN may/MD be/VB due/JJ to/TO lack/NN of/IN expression/NN of/IN the/DT transcriptional/JJ regulatory/JJ elements/NNS required/VBN for/IN T-cell/NN activation/NN ./. 
We/PRP used/VBD reverse/JJ transcriptase-polymerase/JJ chain/NN reaction/NN to/TO examine/VB both/CC fetal/JJ and/CC term/JJ neonatal/JJ cord/NN bloods/NNS for/IN mRNA/NN expression/NN of/IN three/CD transcription/NN factors/NNS implicated/VBN in/IN T-cell/NN activation/NN :/: c-jun/NN ,/, c-fos/NN ,/, and/CC NF/NN kappa/NN B/NN (/( p50/NN subunit/NN )/) ./. 
We/PRP demonstrate/VBP that/IN mRNAs/NNS for/IN all/DT three/CD of/IN these/DT regulatory/JJ factors/NNS are/VBP expressed/VBN in/IN fetal/JJ blood/NN cells/NNS by/IN the/DT 27th/JJ week/NN of/IN gestation/NN and/CC in/IN term/NN cord/NN bloods/NNS ./. 
Activation/NN of/IN term/NN infant/NN cord/NN blood/NN mononuclear/JJ cells/NNS with/IN anti-CD3/JJ monoclonal/JJ antibodies/NNS resulted/VBD in/IN up-regulation/NN of/IN both/CC c-jun/NN and/CC c-fos/NN mRNAs/NNS within/IN 15/CD min/NN of/IN stimulation/NN ./. 
However/RB ,/, secretion/NN of/IN IL-2/NN by/IN anti-CD3-stimulated/JJ cord/NN blood/NN mononuclear/JJ cells/NNS was/VBD still/RB blunted/VBN compared/VBN with/IN control/JJ cells/NNS from/IN adults/NNS ./. 
We/PRP conclude/VBP that/IN fetal/JJ nucleated/JJ blood/NN cells/NNS constitutively/RB express/VBP important/JJ genes/NNS for/IN cytokine/NN regulation/NN and/CC are/VBP able/JJ to/TO increase/VB intracellular/JJ accumulation/NN of/IN the/DT mRNAs/NNS for/IN these/DT factors/NNS in/IN response/NN to/TO anti-CD3/JJ stimulation/NN ./. 
Thus/RB ,/, qualitative/JJ differences/NNS in/IN the/DT capacity/NN to/TO regulate/VB these/DT factors/NNS could/MD not/RB be/VB shown/VBN in/IN fetal/JJ blood/NN cells/NNS ./. 
Quantitative/JJ experiments/NNS comparing/VBG binding/NN of/IN these/DT transcription/NN factors/NNS to/TO the/DT IL-2/NN promoter/NN are/VBP currently/RB under/IN investigation/NN ./. 
UI/LS -/: 98043822/CD 
TI/LS -/: Nuclear/JJ accumulation/NN of/IN NFAT4/NN opposed/VBN by/IN the/DT JNK/NN signal/NN transduction/NN pathway/NN ./. 
AB/LS -/: The/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) group/NN of/IN transcription/NN factors/NNS is/VBZ retained/VBN in/IN the/DT cytoplasm/NN of/IN quiescent/JJ cells/NNS ./. 
NFAT/NN activation/NN is/VBZ mediated/VBN in/IN part/NN by/IN induced/VBN nuclear/JJ import/NN ./. 
This/DT process/NN requires/VBZ calcium-dependent/JJ dephosphorylation/NN of/IN NFAT/NN caused/VBN by/IN the/DT phosphatase/NN calcineurin/NN ./. 
The/DT c-Jun/NN amino-terminal/JJ kinase/NN (/( JNK/NN )/) phosphorylates/VBZ NFAT4/NN on/IN two/CD sites/NNS ./. 
Mutational/JJ removal/NN of/IN the/DT JNK/NN phosphorylation/NN sites/NNS caused/VBD constitutive/JJ nuclear/JJ localization/NN of/IN NFAT4/NN ./. 
In/IN contrast/NN ,/, JNK/NN activation/NN in/IN calcineurin-stimulated/JJ cells/NNS caused/VBD nuclear/JJ exclusion/NN of/IN NFAT4/NN ./. 
These/DT findings/NNS show/VBP that/IN the/DT nuclear/JJ accumulation/NN of/IN NFAT4/NN promoted/VBN by/IN calcineurin/NN is/VBZ opposed/VBN by/IN the/DT JNK/NN signal/NN transduction/NN pathway/NN ./. 
UI/LS -/: 98056814/CD 
TI/LS -/: Thiol/NN modulation/NN inhibits/VBZ the/DT interleukin/NN (/( IL/NN )/) -1-mediated/JJ activation/NN of/IN an/DT IL-1/NN receptor-associated/JJ protein/NN kinase/NN and/CC NF-kappa/NN B/NN ./. 
AB/LS -/: The/DT interleukin-1/NN receptor/NN type/NN I/CD (/( IL-1RI/NN )/) is/VBZ associated/VBN with/IN other/JJ proteins/NNS thus/RB forming/VBG a/DT complex/JJ system/NN by/IN which/WDT IL-1/NN exerts/VBZ its/PRP$ various/JJ signals/NNS ./. 
The/DT initiating/VBG event/NN is/VBZ still/RB uncertain/JJ ,/, but/CC activation/NN of/IN a/DT recently/RB described/VBN receptor-associated/JJ protein/NN kinase/NN is/VBZ one/CD of/IN the/DT earliest/JJS events/NNS detectable/JJ (/( Martin/NNP et/FW al./FW ,/, Eur.J.Immunol.1994.24/NN :/: 1566/CD )/) ./. 
IL-1/NN signaling/NN is/VBZ commonly/RB accompanied/VBN by/IN oxidative/JJ processes/NNS and/CC is/VBZ thought/VBN to/TO be/VB subject/JJ to/TO redox/NN regulation/NN ./. 
We/PRP therefore/RB investigated/VBD whether/IN the/DT activation/NN of/IN the/DT IL-1RI-associated/JJ protein/NN kinase/NN could/MD be/VB a/DT target/NN for/IN redox/NN regulation/NN and/CC whether/IN an/DT altered/JJ activity/NN of/IN the/DT kinase/NN could/MD influence/VB IL-1-mediated/JJ NF-kappa/NN B/NN activation/NN ./. 
A/DT murine/JJ T/NN cell/NN line/NN ,/, EL4/NN ,/, was/VBD stimulated/VBN with/IN IL-1/NN with/IN and/CC without/IN pretreatment/NN with/IN different/JJ compounds/NNS known/VBN to/TO influence/VB the/DT cellular/JJ redox/NN status/NN ./. 
Thiol/NN modifying/NN agents/NNS like/IN diamide/NN ,/, menadione/NN ,/, pyrrolidine/NN dithiocarbamate/NN (/( PDTC/NN )/) ,/, diethyl/NN dithiocarbamate/NN or/CC phenylarsine/NN oxide/NN inhibited/VBD the/DT IL-1-induced/JJ activation/NN of/IN the/DT IL-1RI-associated/JJ protein/NN kinase/NN ./. 
N-Acetylcysteine/NN ,/, alpha,alpha'-dipyridyl/NN ,/, aminotriazole/NN or/CC nitrofurantoin/NN did/VBD not/RB show/VB any/DT effect/NN ./. 
The/DT inhibition/NN by/IN PDTC/NN was/VBD reversible/JJ unless/IN glutathione/NN synthesis/NN was/VBD blocked/VBN by/IN buthionine/NN sulfoximine/NN ./. 
The/DT described/VBN conditions/NNS which/WDT inhibited/VBD or/CC prevented/VBD the/DT activation/NN of/IN the/DT IL-1RI-associated/JJ kinase/NN similarly/RB impaired/VBD the/DT activation/NN of/IN NF-kappa/NN B/NN in/IN EL4/NN cells/NNS ./. 
From/IN these/DT observations/NNS we/PRP conclude/VBP that/IN free/JJ thiols/NNS in/IN the/DT IL-1RI/NN complex/NN are/VBP essential/JJ for/IN the/DT activation/NN of/IN the/DT IL-1RI-associated/JJ protein/NN kinase/NN and/CC that/IN this/DT process/NN is/VBZ mandatory/JJ for/IN IL-1/NN signaling/NN leading/VBG to/TO NF-kappa/NN B/NN activation/NN ./. 
UI/LS -/: 98019986/CD 
TI/LS -/: Switching/VBG gears/NNS during/IN T-cell/NN maturation/NN :/: RANTES/NN and/CC late/JJ transcription/NN ./. 
AB/LS -/: Although/IN much/JJ is/VBZ understood/VBN about/IN the/DT induction/NN of/IN genes/NNS expressed/VBN early/RB (/( within/IN 24/CD h/NN )/) after/IN T-cell/NN activation/NN ,/, little/JJ is/VBZ known/VBN about/IN the/DT regulation/NN of/IN expression/NN of/IN genes/NNS expressed/VBN '/`` late/JJ '/'' (/( three/CD or/CC more/JJR days/NNS )/) post-stimulation/NN ./. 
A/DT better/JJR understanding/NN of/IN transcriptional/JJ regulation/NN at/IN this/DT important/JJ stage/NN of/IN T-cell/NN maturation/NN may/MD yield/VB new/JJ insights/NNS into/IN T-cell/NN development/NN and/CC new/JJ immunotherapeutic/JJ targets/NNS ./. 
UI/LS -/: 98011518/CD 
TI/LS -/: Involvement/NN of/IN different/JJ transduction/NN pathways/NNS in/IN NF-kappa/NN B/NN activation/NN by/IN several/JJ inducers/NNS ./. 
AB/LS -/: Double-stimulation/NN was/VBD used/VBN to/TO demonstrate/VB that/IN ,/, in/IN a/DT T/NN lymphocytic/JJ cell/NN line/NN (/( CEM/NN )/) ,/, phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) rapidly/RB induced/VBD NF-kappa/NN B/NN through/IN a/DT signaling/NN pathway/NN which/WDT did/VBD not/RB involve/VB reactive/JJ oxygen/NN species/NNS (/( ROS/NNS )/) and/CC was/VBD different/JJ from/IN the/DT activation/NN triggered/VBN by/IN either/CC H2O2/NN or/CC tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) ./. 
Since/IN these/DT latter/JJ compounds/NNS were/VBD known/VBN to/TO activate/VB NF-kappa/NN B/NN translocation/NN in/IN a/DT redox-sensitive/JJ way/NN ,/, we/PRP have/VBP demonstrated/VBN that/IN NF-kappa/NN B/NN activation/NN by/IN PMA/NN was/VBD resistant/JJ to/TO antioxidant/JJ N-acetyl-L-cysteine/NN (/( NAC/NN )/) and/CC sensitive/JJ to/TO kinase/NN inhibitors/NNS staurosporine/NN and/CC H7/NN while/IN activation/NN by/IN H2O2/NN or/CC TNF-alpha/NN were/VBD not/RB ./. 
UI/LS -/: 98001571/CD 
TI/LS -/: Blockade/NN of/IN T-cell/NN activation/NN by/IN dithiocarbamates/NNS involves/VBZ novel/JJ mechanisms/NNS of/IN inhibition/NN of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS ./. 
AB/LS -/: Dithiocarbamates/NNS (/( DTCs/NNS )/) have/VBP recently/RB been/VBN reported/VBN as/IN powerful/JJ inhibitors/NNS of/IN NF-kappaB/NN activation/NN in/IN a/DT number/NN of/IN cell/NN types/NNS ./. 
Given/IN the/DT role/NN of/IN this/DT transcription/NN factor/NN in/IN the/DT regulation/NN of/IN gene/NN expression/NN in/IN the/DT inflammatory/JJ response/NN ,/, NF-kappaB/NN inhibitors/NNS have/VBP been/VBN suggested/VBN as/IN potential/JJ therapeutic/JJ drugs/NNS for/IN inflammatory/JJ diseases/NNS ./. 
We/PRP show/VBP here/RB that/IN DTCs/NNS inhibited/VBD both/CC interleukin/NN 2/CD (/( IL-2/NN )/) synthesis/NN and/CC membrane/NN expression/NN of/IN antigens/NNS which/WDT are/VBP induced/VBN during/IN T-cell/NN activation/NN ./. 
This/DT inhibition/NN ,/, which/WDT occurred/VBD with/IN a/DT parallel/JJ activation/NN of/IN c-Jun/NN transactivating/NN functions/NNS and/CC expression/NN ,/, was/VBD reflected/VBN by/IN transfection/NN experiments/NNS at/IN the/DT IL-2/NN promoter/NN level/NN ,/, and/CC involved/VBD not/RB only/RB the/DT inhibition/NN of/IN NF-kappaB-driven/JJ reporter/NN activation/NN but/CC also/RB that/DT of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) ./. 
Accordingly/RB ,/, electrophoretic/JJ mobility/NN shift/NN assays/NNS (/( EMSAs/NNS )/) indicated/VBD that/IN pyrrolidine/NN DTC/NN (/( PDTC/NN )/) prevented/VBD NF-kappaB/NN ,/, and/CC NFAT/NN DNA-binding/NN activity/NN in/IN T/NN cells/NNS stimulated/VBN with/IN either/CC phorbol/NN myristate/NN acetate/NN plus/CC ionophore/NN or/CC antibodies/NNS against/IN the/DT CD3-T-cell/NN receptor/NN complex/NN and/CC simultaneously/RB activated/VBD the/DT binding/NN of/IN AP-1/NN ./. 
Furthermore/RB ,/, PDTC/NN differentially/RB targeted/VBD both/CC NFATp/NN and/CC NFATc/NN family/NN members/NNS ,/, inhibiting/VBG the/DT transactivation/NN functions/NNS of/IN NFATp/NN and/CC mRNA/NN induction/NN of/IN NFATc/NN ./. 
Strikingly/RB ,/, Western/NN blotting/NN and/CC immunocytochemical/JJ experiments/NNS indicated/VBD that/IN PDTC/NN promoted/VBD a/DT transient/JJ and/CC rapid/JJ shuttling/NN of/IN NFATp/NN and/CC NFATc/NN ,/, leading/VBG to/TO their/PRP$ accelerated/VBN export/NN from/IN the/DT nucleus/NN of/IN activated/VBN T/NN cells/NNS ./. 
We/PRP propose/VBP that/IN the/DT activation/NN of/IN an/DT NFAT/NN kinase/NN by/IN PDTC/NN could/MD be/VB responsible/JJ for/IN the/DT rapid/JJ shuttling/NN of/IN the/DT NFAT/NN ,/, therefore/RB transiently/RB converting/VBG the/DT sustained/JJ transactivation/NN of/IN this/DT transcription/NN factor/NN that/WDT occurs/VBZ during/IN lymphocyte/NN activation/NN ,/, and/CC show/VBP that/IN c-Jun/NN NH2-terminal/JJ kinase/NN (/( JNK/NN )/) can/MD act/VB by/IN directly/RB phosphorylating/VBG NFATp/NN ./. 
In/IN addition/NN ,/, the/DT combined/JJ inhibitory/JJ effects/NNS on/IN NFAT/NN and/CC NF-KB/NN support/VBP a/DT potential/JJ use/NN of/IN DTCs/NNS as/IN immunosuppressants/NNS ./. 
UI/LS -/: 97450830/CD 
TI/LS -/: Activation/NN of/IN a/DT novel/JJ gene/NN in/IN 3q21/NN and/CC identification/NN of/IN intergenic/JJ fusion/NN transcripts/NNS with/IN ecotropic/JJ viral/JJ insertion/NN site/NN I/CD in/IN leukemia/NN ./. 
AB/LS -/: We/PRP have/VBP identified/VBN a/DT novel/JJ gene/NN ,/, GR6/NN ,/, located/JJ within/IN the/DT leukemia/NN breakpoint/NN region/NN of/IN 3q21/NN ,/, that/WDT is/VBZ normally/RB expressed/VBN in/IN early/JJ fetal/JJ development/NN but/CC not/RB in/IN adult/JJ peripheral/JJ blood/NN ./. 
GR6/NN is/VBZ activated/VBN in/IN the/DT UCSD-AML1/NN cell/NN line/NN and/CC in/IN a/DT leukemic/JJ sample/NN ,/, both/DT of/IN which/WDT carry/VBP a/DT t(3;3)(q21;q26)/NN ./. 
In/IN UCSD-AML1/NN ,/, we/PRP have/VBP also/RB identified/VBN fusion/NN transcripts/NNS between/IN the/DT ecotropic/JJ viral/JJ insertion/NN site/NN I/CD (/( EVI1/NN )/) gene/NN in/IN 3q26/NN and/CC GR6/NN and/CC between/IN EVI1/NN and/CC Ribophorin/NN I/NN that/WDT maps/VBZ 30/CD kb/NN telomeric/NN to/TO GR6/NN in/IN 3q21/NN ./. 
All/DT fusions/NNS splice/VBP the/DT 5'/JJ ends/NNS of/IN the/DT 3q21/NN genes/NNS into/IN exon/NN 2/CD of/IN the/DT EVI1/NN gene/NN ,/, an/DT event/NN that/WDT is/VBZ similar/JJ to/TO the/DT normal/JJ intergenic/JJ splicing/NN of/IN MDS1-EVI1/NN and/CC to/TO those/DT previously/RB documented/VBN in/IN leukemias/NNS with/IN t(3;21)/NN and/CC t(3;12)/NN ,/, in/IN which/WDT acute/JJ myelogenous/JJ leukemia/NN 1-EVI1/NN fusions/NNS and/CC ETV6-EVI1/JJ fusions/NNS ,/, respectively/RB ,/, occur/VBP ./. 
The/DT Ribophorin/NN I-EVI1/NN fusion/NN in/IN particular/JJ may/MD be/VB a/DT common/JJ occurrence/NN in/IN t(3;3)/NN ./. 
UI/LS -/: 97462662/CD 
TI/LS -/: The/DT A-myb/NN transcription/NN factor/NN in/IN neoplastic/JJ and/CC normal/JJ B/NN cells/NNS ./. 
AB/LS -/: The/DT myb/NN family/NN of/IN transcription/NN factors/NNS has/VBZ been/VBN strongly/RB implicated/VBN in/IN the/DT regulation/NN of/IN cell/NN growth/NN and/CC differentiation/NN in/IN the/DT haematopoietic/JJ system/NN ./. 
The/DT v-myb/NN oncogene/NN ,/, carried/VBN by/IN avian/JJ defective/JJ retroviruses/NNS ,/, causes/VBZ leukaemias/NNS in/IN the/DT chicken/NN and/CC transforms/VBZ haematopoietic/JJ cells/NNS in/FW vitro/FW ./. 
Its/PRP$ normal/JJ cellular/JJ equivalent/JJ c-myb/NN ,/, has/VBZ been/VBN shown/VBN to/TO promote/VB the/DT proliferation/NN and/CC block/VB the/DT differentiation/NN of/IN haematopoietic/JJ cells/NNS in/IN several/JJ experimental/JJ models/NNS and/CC is/VBZ required/VBN for/IN fetal/JJ haematopoiesis/NN ./. 
Two/CD other/JJ members/NNS of/IN the/DT family/NN have/VBP been/VBN cloned/VBN more/RBR recently/RB ,/, A-myb/NN and/CC B-myb/NN ,/, which/WDT show/VBP sequence/NN homology/NN with/IN c-myb/NN in/IN several/JJ domains/NNS ,/, of/IN which/WDT the/DT DNA/NN binding/NN domain/NN as/RB well/RB as/IN other/JJ regulatory/JJ domains/NNS ./. 
Both/DT have/VBP been/VBN shown/VBN to/TO be/VB transcription/NN factors/NNS ./. 
B-myb/NN is/VBZ also/RB involved/VBN in/IN the/DT control/NN of/IN proliferation/NN and/CC differentiation/NN ,/, but/CC ,/, unlike/IN c-myb/NN ,/, it/PRP is/VBZ expressed/VBN in/IN many/JJ cell/NN types/NNS ./. 
The/DT third/JJ member/NN of/IN the/DT family/NN ,/, A-myb/NN ,/, shows/VBZ the/DT most/RBS restricted/JJ pattern/NN of/IN expression/NN ,/, suggesting/VBG a/DT very/RB specific/JJ role/NN for/IN this/DT transcription/NN factor/NN ./. 
A-myb/NN is/VBZ expressed/VBN in/IN a/DT subpopulation/NN of/IN normal/JJ B/NN lymphocytes/NNS activated/VBN in/FW vivo/FW and/CC localised/JJ in/IN the/DT germinal/JJ center/NN of/IN peripheral/JJ lymphoid/JJ organs/NNS and/CC is/VBZ not/RB detected/VBN at/IN significant/JJ levels/NNS in/IN all/DT other/JJ mature/JJ or/CC immature/JJ haematopoietic/JJ populations/NNS studied/VBN ,/, including/VBG bone/NN marrow/JJ cells/NNS ,/, T/NN lymphocytes/NNS ,/, granulocytes/NNS ,/, monocytes/NNS ,/, either/CC at/IN rest/NN or/CC after/RB in/FW vitro/FW activation/NN ./. 
These/DT studies/NNS indicate/VBP that/IN A-myb/NN plays/VBZ a/DT role/NN during/IN a/DT narrow/JJ window/NN of/IN normal/JJ B/NN cell/NN differentiation/NN ./. 
A-myb/NN expression/NN has/VBZ also/RB been/VBN studied/VBN in/IN a/DT wide/JJ range/NN of/IN neoplastic/JJ B/NN cells/NNS ,/, representing/VBG the/DT whole/JJ spectrum/NN of/IN B/NN cell/NN differentiation/NN ./. 
A-myb/NN is/VBZ strongly/RB expressed/VBN in/IN Burkitt/NN 's/POS lymphomas/NNS (/( BL/NNS )/) and/CC slg+/JJ B-acute/JJ lymphoblastic/JJ leukaemias/NNS (/( B-ALL/NNS )/) and/CC not/RB in/IN all/DT other/JJ leukaemias/lymphomas/NNS tested/VBN ,/, with/IN the/DT exception/NN of/IN a/DT subset/NN of/IN CLL/NN (/( about/RB 25/CD %/NN of/IN cases/NNS )/) ./. 
It/PRP is/VBZ intriguing/JJ that/IN the/DT A-myb/NN genome/NN has/VBZ been/VBN localised/JJ relatively/RB close/RB to/TO the/DT c-myc/NN gene/NN on/IN chromosome/NN 8/CD ,/, suggesting/VBG that/IN the/DT c-myc/NN translocation/NN in/IN BL/NNS and/CC B-ALL/NNS may/MD affect/VB A-myb/NN transcription/NN ./. 
Studies/NNS are/VBP in/IN progress/NN to/TO investigate/VB the/DT functional/JJ relationship/NN between/IN A-myb/NN and/CC c-myc/NN ,/, particularly/RB in/IN the/DT context/NN of/IN BL/NNS cells/NNS and/CC to/TO determine/VB whether/IN A-myb/NN is/VBZ deregulated/VBN in/IN these/DT cells/NNS ./. 
UI/LS -/: 97457067/CD 
TI/LS -/: Expression/NN of/IN bcl-6/NN protein/NN in/IN normal/JJ skin/NN and/CC epidermal/JJ neoplasms/NNS ./. 
AB/LS -/: Bcl-6/NN protein/NN is/VBZ a/DT recently/RB identified/VBN novel/JJ transcription/NN factor/NN whose/WP$ deregulated/VBN expression/NN is/VBZ associated/VBN with/IN diffuse/JJ large/JJ B/NN cell/NN lymphomas/NNS ./. 
It/PRP was/VBD recently/RB shown/VBN by/IN us/PRP that/IN the/DT protein/NN is/VBZ located/JJ in/IN germinal/JJ center/NN B/NN cells/NNS and/CC their/PRP$ neoplastic/JJ counterparts/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, the/DT expression/NN of/IN bcl-6/NN protein/NN on/IN normal/JJ epidermis/NN ,/, benign/JJ ,/, and/CC malignant/JJ tumors/NNS originating/VBG from/IN epidermal/JJ cells/NNS ,/, and/CC squamous/JJ cell/NN carcinoma/NN (/( SCC/NN )/) cell/NN lines/NNS are/VBP investigated/VBN ./. 
With/IN the/DT use/NN of/IN immunohistochemistry/NN ,/, bcl-6/NN protein/NN was/VBD shown/VBN to/TO stain/VB intensely/RB on/IN normal/JJ prickle/NN cells/NNS ,/, but/CC none/NN to/TO only/RB slightly/RB on/IN epidermal/JJ basal/JJ cells/NNS ./. 
Papillomas/NNS and/CC keratoacanthomas/NNS copied/VBD their/PRP$ normal/JJ counterparts/NNS in/IN the/DT mode/NN of/IN expression/NN ./. 
Various/JJ levels/NNS of/IN expression/NN were/VBD found/VBN on/IN seborrheic/JJ keratoses/NNS ,/, while/IN the/DT expression/NN level/NN on/IN basal/JJ cell/NN epitheliomas/NNS was/VBD low/JJ ./. 
Peculiarly/RB ,/, eccrine/JJ poromas/NNS and/CC undifferentiated/JJ spindle-shaped/JJ basal/JJ cell/NN epitheliomas/NNS were/VBD totally/RB unstained/JJ ./. 
Squamous/JJ cell/NN carcinomas/NNS showed/VBD a/DT variety/NN of/IN expression/NN levels/NNS ,/, while/IN two/CD undifferentiated/JJ spindle-shaped/JJ carcinomas/NNS and/CC one/CD undifferentiated/JJ SCC/NN cell/NN line/NN remained/VBD unstained/JJ ./. 
These/DT results/NNS suggest/VBP that/IN the/DT expression/NN of/IN bcl-6/NN protein/NN may/MD be/VB associated/VBN with/IN morphological/JJ differentiation/NN in/IN normal/JJ and/CC neoplastic/JJ epidermal/JJ cells/NNS ./. 
UI/LS -/: 97442480/CD 
TI/LS -/: Sp3/NN mediates/VBZ transcriptional/JJ activation/NN of/IN the/DT leukocyte/NN integrin/NN genes/NNS CD11C/NN and/CC CD11B/NN and/CC cooperates/VBZ with/IN c-Jun/NN to/TO activate/VB CD11C/NN ./. 
AB/LS -/: The/DT leukocyte/NN integrin/NN genes/NNS CD11c/NN and/CC CD11b/NN are/VBP expressed/VBN predominately/RB in/IN myelomonocytic/JJ cells/NNS ./. 
In/IN previous/JJ experiments/NNS ,/, the/DT -70/CD to/TO -65/CD and/CC -121/CD to/TO -103/CD regions/NNS of/IN the/DT CD11c/NN promoter/NN and/CC the/DT -66/CD to/TO -59/CD region/NN of/IN the/DT CD11b/NN promoter/NN were/VBD shown/VBN to/TO be/VB essential/JJ for/IN Sp1-mediated/JJ activation/NN of/IN these/DT genes/NNS ./. 
In/FW vivo/FW genomic/JJ footprinting/NN had/VBD also/RB revealed/VBN cell-specific/JJ binding/NN of/IN protein/NN ,/, presumably/RB Sp1/NN ,/, to/TO these/DT regions/NNS ./. 
In/IN this/DT study/NN ,/, electrophoretic/JJ mobility/NN shift/NN analysis/NN showed/VBD that/IN the/DT Sp1-related/JJ factor/NN ,/, Sp3/NN ,/, also/RB binds/VBZ at/IN or/CC near/IN these/DT same/JJ regions/NNS ./. 
Cotransfection/NN of/IN Sp3/NN along/IN with/IN CD11c/NN promoter-luciferase/NN constructs/NNS into/IN Sp-deficient/JJ Drosophila/NN Schneider/NN 2/CD cells/NNS showed/VBD that/IN Sp3/NN could/MD activate/VB the/DT CD11c/NN promoter/NN ./. 
Deletion/NN of/IN both/CC the/DT -70/CD to/TO -65/CD and/CC -121/CD to/TO -103/CD regions/NNS of/IN the/DT CD11c/NN promoter/NN resulted/VBD in/IN the/DT loss/NN of/IN activation/NN by/IN Sp3/NN ./. 
Both/DT sites/NNS showed/VBD activation/NN by/IN Sp3/NN ;/: however/RB ,/, the/DT -70/CD to/TO -65/CD region/NN was/VBD more/JJR responsive/JJ to/TO Sp3/NN than/IN to/TO Sp1/NN ./. 
Similar/JJ transfection/NN analysis/NN of/IN the/DT -66/CD to/TO -59/CD region/NN of/IN the/DT CD11b/NN promoter/NN showed/VBD Sp3-dependent/JJ expression/NN ./. 
Further/RB ,/, cotransfection/NN analysis/NN in/IN Drosophila/NN cells/NNS showed/VBD that/IN Sp3/NN ,/, as/IN was/VBD previously/RB shown/VBN for/IN Sp1/NN ,/, also/RB synergizes/VBZ with/IN c-Jun/NN to/TO activate/VB CD11c/NN ./. 
Antisense/JJ experiments/NNS that/WDT knocked/VBD out/RP endogenous/JJ Sp3/NN expression/NN in/IN the/DT myelomocytic/JJ cell/NN line/NN ,/, HL60/NN ,/, revealed/VBD that/IN Sp3/NN participates/VBZ in/IN activation/NN of/IN the/DT CD11c/NN and/CC CD11b/NN promoters/NNS in/FW vivo/FW ./. 
UI/LS -/: 98104469/CD 
TI/LS -/: The/DT winged-helix/JJ transcription/NN factor/NN Trident/NN is/VBZ expressed/VBN in/IN actively/RB dividing/VBG lymphocytes/NNS ./. 
AB/LS -/: We/PRP recently/RB identified/VBD the/DT winged-helix/JJ transcription/NN factor/NN Trident/NN and/CC described/VBD its/PRP$ expression/NN pattern/NN in/IN synchronized/VBN fibroblasts/NNS ./. 
We/PRP have/VBP now/RB studied/VBN Trident/NN expression/NN in/IN cell/NN lines/NNS ,/, differentiating/VBG thymocytes/NNS and/CC in/IN lymphocytes/NNS derived/VBN from/IN peripheral/JJ blood/NN ./. 
During/IN T/NN cell/NN differentiation/NN ,/, expression/NN peaked/VBD in/IN the/DT actively/RB dividing/VBG immature/JJ single/JJ positive/JJ cells/NNS ./. 
In/IN peripheral/JJ blood/NN lymphocytes/NNS ,/, expression/NN of/IN Trident/NN mRNA/NN was/VBD absent/JJ ,/, but/CC could/MD be/VB induced/VBN upon/IN stimulation/NN with/IN mitogens/NNS in/FW vitro/FW ./. 
These/DT observations/NNS imply/VBP a/DT function/NN for/IN Trident/NN in/IN dividing/VBG lymphocytes/NNS ./. 
UI/LS -/: 98089072/CD 
TI/LS -/: Estrogen/NN receptor/NN diminishes/VBZ DNA-binding/JJ activities/NNS of/IN chicken/NN GATA-1/NN and/CC CACCC-binding/JJ proteins/NNS ./. 
AB/LS -/: The/DT estrogen/NN receptor/NN (/( ER/NN )/) repressed/VBD erythroid/JJ differentiation/NN and/CC erythroid-specific/JJ gene/NN expression/NN ./. 
In/IN this/DT study/NN ,/, we/PRP investigated/VBD the/DT effect/NN of/IN ER/NN alpha/NN (/( referred/VBN to/TO throughout/RB as/IN ER/NN )/) on/IN DNA-binding/JJ activities/NNS of/IN transcription/NN factors/NNS involved/VBN in/IN regulating/VBG the/DT expression/NN of/IN erythroid-specific/JJ genes/NNS ,/, and/CC ,/, in/IN particular/JJ ,/, the/DT histone/NN H5/NN gene/NN ./. 
Using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, we/PRP found/VBD that/IN in/IN the/DT presence/NN of/IN rabbit/NN reticulocyte/NN lysate/NN ,/, human/JJ ER/NN reduced/VBD the/DT binding/NN activities/NNS of/IN chicken/NN immature/JJ erythrocyte/NN nuclear/JJ extracted/JJ proteins/NNS to/TO GATA/NN and/CC CACCC/NN sites/NNS in/IN the/DT H5/NN promoter/NN and/CC enhancer/NN ./. 
In/IN contrast/NN ,/, the/DT binding/NN activities/NNS of/IN NF1/NN and/CC Sp1/NN were/VBD not/RB affected/VBN by/IN ER/NN ./. 
Binding/NN of/IN ER/NN to/TO an/DT estrogen/NN response/NN element/NN was/VBD enhanced/VBN by/IN addition/NN of/IN rabbit/NN reticulocyte/NN lysate/NN ./. 
This/DT lysate/NN was/VBD also/RB necessary/JJ for/IN ER/NN to/TO diminish/VB the/DT DNA-binding/JJ activity/NN of/IN GATA-1/NN ./. 
These/DT results/NNS suggest/VBP that/IN additional/JJ factor/NN (/( s/NNS )/) are/VBP necessary/JJ for/IN full/JJ ER/NN function/NN ./. 
Both/CC GATA-1/NN and/CC CACCC-binding/JJ proteins/NNS are/VBP critical/JJ for/IN the/DT developmentally/RB regulated/VBN expression/NN of/IN erythroid-specific/JJ genes/NNS ./. 
We/PRP hypothesize/VBP that/IN interference/NN in/IN DNA-binding/JJ activities/NNS of/IN GATA-1/NN and/CC CACCC-binding/JJ proteins/NNS is/VBZ the/DT mechanism/NN by/IN which/WDT the/DT ER/NN inhibits/VBZ regulation/NN of/IN these/DT genes/NNS ./. 
UI/LS -/: 98038749/CD 
TI/LS -/: Regulation/NN of/IN Id3/NN cell/NN cycle/NN function/NN by/IN Cdk-2-dependent/JJ phosphorylation/NN ./. 
AB/LS -/: The/DT functions/NNS of/IN basic/JJ helix-loop-helix/JJ (/( bHLH/JJ )/) transcription/NN factors/NNS in/IN activating/VBG differentiation-linked/JJ gene/NN expression/NN and/CC in/IN inducing/VBG G1/NN cell/NN cycle/NN arrest/NN are/VBP negatively/RB regulated/VBN by/IN members/NNS of/IN the/DT Id/NN family/NN of/IN HLH/JJ proteins/NNS ./. 
These/DT bHLH/JJ antagonists/NNS are/VBP induced/VBN during/IN a/DT mitogenic/JJ signalling/NN response/NN ,/, and/CC they/PRP function/VBP by/IN sequestering/VBG their/PRP$ bHLH/JJ targets/NNS in/IN inactive/JJ heterodimers/NNS that/WDT are/VBP unable/JJ to/TO bind/VB to/TO specific/JJ gene/NN regulatory/JJ (/( E/NN box/NN )/) sequences/NNS ./. 
Recently/RB ,/, cyclin/NN E-Cdk2-/NN and/CC cyclin/NN A-Cdk2-dependent/JJ phosphorylation/NN of/IN a/DT single/JJ conserved/VBN serine/NN residue/NN (/( Ser5/NN )/) in/IN Id2/NN has/VBZ been/VBN shown/VBN to/TO occur/VB during/IN late/JJ G1-to-S/JJ phase/NN transition/NN of/IN the/DT cell/NN cycle/NN ,/, and/CC this/DT neutralizes/VBZ the/DT function/NN of/IN Id2/NN in/IN abrogating/VBG E-box-dependent/JJ bHLH/JJ homo-/JJ or/CC heterodimer/NN complex/NN formation/NN in/FW vitro/FW (/( E.Hara/NN ,/, M.Hall/NN ,/, and/CC G.Peters/NN ,/, EMBO/NNP J.16/NNP :/: 332-342/CD ,/, 1997/CD )/) ./. 
We/PRP now/RB show/VBP that/IN an/DT analogous/JJ cell-cycle-regulated/JJ phosphorylation/NN of/IN Id3/NN alters/VBZ the/DT specificity/NN of/IN Id3/NN for/IN abrogating/VBG both/CC E-box-dependent/JJ bHLH/JJ homo-/NN or/CC heterodimer/NN complex/NN formation/NN in/FW vitro/FW and/CC E-box-dependent/JJ reporter/NN gene/NN function/NN in/FW vivo/FW ./. 
Furthermore/RB ,/, compared/VBN with/IN wild-type/JJ Id3/NN ,/, an/DT Id3/NN Asp5/NN mutant/NN (/( mimicking/VBG phosphorylation/NN )/) is/VBZ unable/JJ to/TO promote/VB cell/NN cycle/NN S/NN phase/NN entry/NN in/IN transfected/VBN fibroblasts/NNS ,/, whereas/IN an/DT Id3/NN Ala5/NN mutant/NN (/( ablating/VBG phosphorylation/NN )/) displays/VBZ an/DT activity/NN significantly/RB greater/JJR than/IN that/DT of/IN wild-type/JJ Id3/NN protein/NN ./. 
Cdk2-dependent/JJ phosphorylation/NN therefore/RB provides/VBZ a/DT switch/NN during/IN late/JJ G1-to-S/JJ phase/NN that/WDT both/CC nullifies/VBZ an/DT early/JJ G1/NN cell/NN cycle/NN regulatory/JJ function/NN of/IN Id3/NN and/CC modulates/VBZ its/PRP$ target/NN bHLH/JJ specificity/NN ./. 
These/DT data/NNS also/RB demonstrate/VBP that/IN the/DT ability/NN of/IN Id3/NN to/TO promote/VB cell/NN cycle/NN S/NN phase/NN entry/NN is/VBZ not/RB simply/RB a/DT function/NN of/IN its/PRP$ ability/NN to/TO modulate/VB bHLH/JJ heterodimer-dependent/JJ gene/NN expression/NN and/CC establish/VB a/DT biologically/RB important/JJ mechanism/NN through/IN which/WDT Cdk2/NN and/CC Id-bHLH/JJ functions/NNS are/VBP integrated/VBN in/IN the/DT coordination/NN of/IN cell/NN proliferation/NN and/CC differentiation/NN ./. 
UI/LS -/: 98049829/CD 
TI/LS -/: Molecular/JJ cloning/NN and/CC functional/JJ characterization/NN of/IN murine/JJ cDNA/NN encoding/NN transcription/NN factor/NN NFATc/NN ./. 
AB/LS -/: Transcription/NN factors/NNS of/IN the/DT NFAT/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS )/) family/NN play/VBP important/JJ roles/NNS in/IN immune/JJ and/CC inflammatory/JJ responses/NNS by/IN regulating/VBG the/DT expression/NN of/IN genes/NNS encoding/VBG cytokines/NNS and/CC immunoregulatory/JJ proteins/NNS ./. 
Here/RB we/PRP describe/VBP cloning/NN and/CC characterization/NN of/IN full-length/JJ cDNA/NN encoding/NN murine/JJ (/( m/JJ )/) NFATc/NN which/WDT predicts/VBZ that/IN the/DT protein/NN has/VBZ all/PDT the/DT conserved/VBN structural/JJ motifs/NNS of/IN NFAT/NN family/NN members/NNS ,/, including/VBG the/DT rel/NN homology/NN domain/NN ,/, the/DT NFAT/NN homology/NN domain/NN and/CC the/DT nuclear/JJ translocation/NN signals/NNS ./. 
mNFATc/NN complexed/VBN with/IN AP-1/NN bound/VBD specifically/RB to/TO the/DT murine/JJ IL-2/NN NFAT/NN recognition/NN sequence/NN and/CC activated/VBD transcription/NN from/IN the/DT co-transfected/JJ IL-2/NN promoter/NN in/IN COS-7/NN cells/NNS ./. 
Northern/NN blot/NN analysis/NN showed/VBD that/IN the/DT cDNA/NN probe/NN hybridized/VBD with/IN a/DT 4.5/CD kb/NN transcript/NN which/WDT is/VBZ highly/RB inducible/JJ in/IN murine/JJ T/NN cells/NNS ./. 
By/IN Northern/NN and/CC in/FW situ/FW hybridization/NN ,/, mNFATc/NN transcript/NN was/VBD detected/VBN from/IN the/DT early/JJ stage/NN of/IN development/NN ./. 
In/IN the/DT mouse/NN embryo/NN ,/, mNFATc/NN transcript/NN was/VBD strongly/RB expressed/VBN in/IN thymus/NN ,/, lung/NN and/CC submandibular/JJ gland/NN and/CC weakly/RB in/IN skeletal/JJ muscle/NN and/CC heart/NN suggesting/VBG that/IN mNFATc/NN may/MD have/VB a/DT role/NN both/CC in/IN embryogenesis/NN and/CC in/IN mature/JJ T/NN cells/NNS ./. 
UI/LS -/: 98022968/CD 
TI/LS -/: TNFalpha/NN cooperates/VBZ with/IN the/DT protein/NN kinase/NN A/NN pathway/NN to/TO synergistically/RB increase/VB HIV-1/NN LTR/NN transcription/NN via/IN downstream/JJ TRE-like/JJ cAMP/NN response/NN elements/NNS ./. 
AB/LS -/: Activating/VBG protein-1/NN (/( AP-1/NN )/) binding/NN TPA/NN responsive/JJ elements/NNS (/( TRE/NN )/) are/VBP located/JJ downstream/RB of/IN the/DT transcription/NN initiation/NN site/NN in/IN the/DT U5/NN region/NN of/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ./. 
These/DT downstream/JJ sequence/NN elements/NNS ,/, termed/VBN DSE/NN ,/, can/MD bind/VB both/CC AP-1/NN and/CC CREB/ATF/NN transcription/NN factors/NNS ./. 
Recently/RB ,/, we/PRP demonstrated/VBD that/IN the/DT DSE/NN are/VBP also/RB cAMP-responsive/JJ elements/NNS (/( CRE/NN )/) ,/, since/IN they/PRP mediated/VBD activation/NN signals/NNS elicited/VBN by/IN cholera/NN toxin/NN (/( Ctx/NN )/) ,/, a/DT potent/JJ activator/NN of/IN the/DT cAMP-dependent/JJ protein/NN kinase/NN A/NN (/( PKA/NN )/) signal/NN transduction/NN pathway/NN ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP demonstrate/VBP that/IN the/DT HIV-1/NN DSE/NN can/MD mediate/VB the/DT transcriptional/JJ synergy/NN elicited/VBN by/IN the/DT combination/NN of/IN Ctx/NN and/CC TNFalpha/NN ./. 
Ctx/NN combined/VBD with/IN TNFalpha/NN or/CC IL-1beta/NN to/TO produce/VB a/DT synergistic/JJ increase/NN in/IN p24/NN antigen/NN production/NN in/IN U1/NN promonocytic/JJ cells/NNS ./. 
Transfection/NN studies/NNS of/IN LTR/NN reporter/NN constructs/NNS indicated/VBD that/IN mutation/NN of/IN the/DT DSE/NN sites/NNS abrogated/VBD the/DT LTR-mediated/JJ synergy/NN induced/VBN by/IN Ctx/NN and/CC TNFalpha/NN ,/, whereas/IN the/DT synergy/NN induced/VBN by/IN Ctx/NN and/CC IL-1beta/NN was/VBD unaffected/JJ ,/, suggesting/VBG TNFalpha/NN and/CC IL-1beta/NN cooperate/VBP differently/RB with/IN the/DT cAMP/PKA/NN activation/NN pathway/NN to/TO induce/VB HIV-1/NN expression/NN in/IN U1/NN cells/NNS ./. 
Because/IN the/DT DSE/NN are/VBP also/RB TRE/NN sites/NNS ,/, we/PRP assessed/VBD the/DT effect/NN of/IN the/DT agonist/NN combinations/NNS on/IN AP-1-dependent/JJ transcription/NN ./. 
TNFalpha/NN as/RB well/RB as/IN IL-1beta/NN cooperated/VBD with/IN Ctx/NN to/TO produce/VB a/DT synergistic/JJ activation/NN of/IN AP-1-mediated/JJ transcription/NN ./. 
These/DT data/NNS indicate/VBP that/IN the/DT TRE-like/JJ cAMP-responsive/JJ DSE/NN sites/NNS within/IN the/DT 5'-untranslated/JJ leader/NN can/MD mediate/VB the/DT transcriptional/JJ cooperativity/NN between/IN TNFalpha/NN and/CC the/DT cAMP/PKA/NN pathway/NN ./. 
Since/IN the/DT DSE/NN and/CC TRE/NN sites/NNS can/MD not/RB bind/VB CREB/ATF/NN homodimers/NNS ,/, we/PRP propose/VBP a/DT mechanism/NN in/IN which/WDT the/DT HIV-1/NN DSE/NN bind/VBP heterodimers/NNS composed/VBN of/IN both/CC AP-1/NN and/CC CREB/ATF/NN proteins/NNS ./. 
Copyright/NN 1997/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 98012230/CD 
TI/LS -/: Association/NN of/IN glucocorticoid/NN insensitivity/NN with/IN increased/VBN expression/NN of/IN glucocorticoid/NN receptor/NN beta/NN ./. 
AB/LS -/: In/IN many/JJ chronic/JJ inflammatory/JJ disorders/NNS ,/, glucocorticoid/NN (/( GC/NN )/) insensitivity/NN is/VBZ a/DT challenging/JJ clinical/JJ problem/NN associated/VBN with/IN life-threatening/JJ disease/NN progression/NN ./. 
The/DT molecular/JJ basis/NN of/IN GC/NN insensitivity/NN ,/, however/RB ,/, is/VBZ unknown/JJ ./. 
Alternative/JJ splicing/NN of/IN the/DT GC/NN receptor/NN (/( R/NN )/) pre-messenger/NN RNA/NN generates/VBZ a/DT second/JJ GCR/NN ,/, termed/VBN GCR-beta/NN ,/, which/WDT does/VBZ not/RB bind/VB GCs/NNS but/CC antagonizes/VBZ the/DT transactivating/NN activity/NN of/IN the/DT classic/JJ GCR/NN ,/, termed/VBN GCR-alpha/NN ./. 
In/IN the/DT current/JJ study/NN ,/, we/PRP demonstrate/VBP that/IN GC-insensitive/JJ asthma/NN is/VBZ associated/VBN with/IN a/DT significantly/RB higher/JJR number/NN of/IN GCR-beta-immunoreactive/JJ cells/NNS in/IN peripheral/JJ blood/NN than/IN GC-sensitive/JJ asthmatics/NNS or/CC normal/JJ controls/NNS ./. 
Furthermore/RB ,/, we/PRP show/VBP that/IN patients/NNS with/IN GC-insensitive/JJ asthma/NN have/VBP cytokine-induced/JJ abnormalities/NNS in/IN the/DT DNA/NN binding/NN capability/NN of/IN the/DT GCR/NN ./. 
These/DT abnormalities/NNS can/MD be/VB reproduced/VBN by/IN transfection/NN of/IN cell/NN lines/NNS with/IN the/DT GCR-beta/NN gene/NN resulting/VBG in/IN significant/JJ reduction/NN of/IN their/PRP$ GCR-alpha/NN DNA/NN binding/NN capacity/NN ./. 
We/PRP conclude/VBP that/IN increased/VBN expression/NN of/IN GCR-beta/NN is/VBZ cytokine/NN inducible/JJ and/CC may/MD account/VB for/IN GC/NN insensitivity/NN in/IN this/DT common/JJ inflammatory/JJ condition/NN ./. 
UI/LS -/: 98001378/CD 
TI/LS -/: Epstein-Barr/JJ virus/NN EBNA3C/NN represses/VBZ Cp/NN ,/, the/DT major/JJ promoter/NN for/IN EBNA/NN expression/NN ,/, but/CC has/VBZ no/DT effect/NN on/IN the/DT promoter/NN of/IN the/DT cell/NN gene/NN CD21/NN ./. 
AB/LS -/: EBNA3C/NN is/VBZ a/DT potent/JJ repressor/NN of/IN transcription/NN when/WRB bound/VBN to/TO DNA/NN as/IN a/DT fusion/NN with/IN the/DT DNA/NN binding/NN domain/NN (/( DBD/NN )/) of/IN GALA/NN ./. 
A/DT survey/NN of/IN promoters/NNS has/VBZ revealed/VBN that/IN the/DT wild-type/JJ ,/, unfused/JJ EBNA3C/NN can/MD specifically/RB repress/VB expression/NN from/IN reporter/NN plasmids/NNS containing/VBG the/DT Epstein-Barr/JJ virus/NN Cp/NN latency-associated/JJ promoter/NN ./. 
Repression/NN of/IN Cp/NN activity/NN required/VBD amino/NN acids/NNS 207/CD to/TO 368/CD ,/, which/WDT encompasses/VBZ a/DT region/NN resembling/VBG a/DT basic/JJ DBD/NN adjacent/JJ to/TO a/DT leucine/NN zipper/NN DNA/NN binding/NN motif/NN and/CC a/DT site/NN which/WDT binds/VBZ to/TO the/DT cellular/JJ factor/NN CBF1/RBP-Jkappa/NN ./. 
However/RB ,/, amino/NN acids/NNS 207/CD to/TO 368/CD are/VBP dispensable/JJ when/WRB the/DT protein/NN is/VBZ bound/VBN to/TO DNA/NN as/IN a/DT fusion/NN with/IN the/DT GAL4/NN DBD/NN ,/, thus/RB implicating/VBG this/DT region/NN in/IN DNA/NN binding/NN ./. 
Mutation/NN of/IN the/DT CBF1/RBP-Jkappa/NN binding/NN site/NN in/IN EBNA3C/NN abrogated/VBD repression/NN ,/, strongly/RB suggesting/VBG that/IN CBF1/RBP-Jkappa/NN is/VBZ necessary/JJ for/IN targeting/VBG the/DT viral/JJ protein/NN to/TO Cp/NN ./. 
Consistent/JJ with/IN this/DT result/NN ,/, mutation/NN of/IN the/DT EBNA2/NN response/NN element/NN (/( a/DT CBF1/RBP-Jkappa/NN binding/NN site/NN )/) in/IN Cp/NN also/RB prevented/VBD significant/JJ repression/NN ./. 
In/IN addition/NN ,/, amino/NN acids/NNS 346/CD to/TO 543/CD ,/, which/WDT were/VBD previously/RB defined/VBN as/IN important/JJ for/IN the/DT repressor/NN activity/NN of/IN the/DT GAL4-EBNA3C/NN fusion/NN proteins/NNS ,/, also/RB appear/VBP to/TO be/VB necessary/JJ for/IN the/DT repression/NN of/IN Cp/NN ./. 
Since/IN repression/NN by/IN these/DT fusions/NNS was/VBD not/RB observed/VBN in/IN all/DT cell/NN types/NNS ,/, it/PRP seems/VBZ likely/RB that/IN EBNA3C/NN either/CC depends/VBZ on/IN a/DT corepressor/NN which/WDT may/MD interact/VB with/IN amino/NN acids/NNS 346/CD to/TO 543/CD or/CC is/VBZ modified/VBN in/IN a/DT cell-specific/JJ manner/NN in/IN order/NN to/TO repress/VB ./. 
These/DT data/NNS are/VBP consistent/JJ with/IN EBNA3C/NN contributing/VBG to/TO the/DT regulation/NN of/IN EBNA/NN expression/NN in/IN latently/RB infected/JJ B/NN cells/NNS through/IN CBF1/RBP-Jkappa/NN and/CC another/DT factor/NN ,/, but/CC this/DT need/VBP not/RB directly/RB involve/VB EBNA2/NN ./. 
Finally/RB ,/, although/IN it/PRP has/VBZ been/VBN reported/VBN that/IN EBNA3C/NN can/MD upregulate/VB CD21/NN in/IN some/DT B/NN cells/NNS ,/, we/PRP were/VBD unable/JJ to/TO demonstrate/VB any/DT effect/NN of/IN EBNA3C/NN on/IN reporter/NN plasmids/NNS which/WDT contain/VBP the/DT CD21/NN promoter/NN ./. 
UI/LS -/: 98018399/CD 
TI/LS -/: Relationship/NN between/IN glucocorticoid/NN receptor/NN and/CC response/NN to/TO glucocorticoid/NN therapy/NN in/IN ulcerative/JJ colitis/NN ./. 
AB/LS -/: PURPOSE/NN :/: To/TO clarify/VB the/DT relationship/NN between/IN the/DT glucocorticoid/NN receptor/NN and/CC the/DT effectiveness/NN of/IN glucocorticoid/NN therapy/NN in/IN patients/NNS with/IN ulcerative/JJ colitis/NN ,/, we/PRP investigated/VBD the/DT number/NN and/CC apparent/JJ dissociation/NN constant/NN of/IN glucocorticoid/NN receptor/NN in/IN peripheral/JJ blood/NN mononuclear/JJ leukocytes/NNS of/IN patients/NNS with/IN ulcerative/JJ colitis/NN ./. 
MATERIALS/NNS AND/CC METHODS/NNS :/: Eleven/CD patients/NNS with/IN ulcerative/JJ colitis/NN (/( 5/CD who/WP responded/VBD to/TO intravenous/JJ glucocorticoids/NNS and/CC 6/CD who/WP did/VBD not/RB )/) and/CC ten/CD control/JJ subjects/NNS were/VBD studied/VBN ./. 
The/DT number/NN and/CC apparent/JJ dissociation/NN constant/NN of/IN glucocorticoid/NN receptor/NN were/VBD measured/VBN using/VBG a/DT whole-cell/JJ binding/NN assay/NN ./. 
Results/NNS were/VBD expressed/VBN as/IN a/DT median/NN (/( interquartile/JJ range/NN )/) ./. 
RESULTS/NNS :/: The/DT number/NN of/IN glucocorticoid/NN receptors/NNS from/IN the/DT six/CD nonresponders/NNS ,/, five/CD responders/NNS ,/, and/CC ten/CD healthy/JJ controls/NNS were/VBD 4922/CD (/( range/NN ,/, 4484-5643/CD )/) ,/, 3413/CD (/( range/NN ,/, 3183-4450/CD )/) ,/, and/CC 3610/CD (/( range/NN ,/, 2594-3979/CD )/) binding/VBG sites/cell/NNS ,/, respectively/RB ./. 
The/DT apparent/JJ dissociation/NN constant/NN of/IN the/DT glucocorticoid/NN receptors/NNS from/IN the/DT nonresponders/NNS ,/, responders/NNS ,/, and/CC healthy/JJ controls/NNS were/VBD 7.03/CD (/( range/NN ,/, 5.66-10/CD )/) ,/, 4.27/CD (/( range/NN ,/, 4-5.13/CD )/) ,/, and/CC 6.18/CD (/( range/NN ,/, 5.86-6.74/CD )/) nM/NN ,/, respectively/RB ./. 
Nonresponders/NNS had/VBD a/DT significant/JJ increase/NN both/CC in/IN the/DT number/NN of/IN binding/VBG sites/NNS and/CC in/IN the/DT apparent/JJ dissociation/NN constant/NN compared/VBN with/IN responders/NNS (/( P/NN =/JJ 0.045/CD ;/: P/NN =/JJ 0.029/CD )/) ./. 
CONCLUSIONS/NNS :/: The/DT increased/VBN number/NN and/CC apparent/JJ dissociation/NN constant/NN of/IN glucocorticoid/NN receptor/NN are/VBP closely/RB associated/VBN with/IN the/DT effectiveness/NN of/IN glucocorticoid/NN therapy/NN ./. 
The/DT measurement/NN of/IN the/DT number/NN and/CC apparent/JJ dissociation/NN constant/NN of/IN glucocorticoid/NN receptor/NN may/MD be/VB useful/JJ in/IN predicting/VBG response/NN to/TO glucocorticoids/NNS ./. 
UI/LS -/: 97461450/CD 
TI/LS -/: Cooperation/NN of/IN binding/VBG sites/NNS for/IN STAT6/NN and/CC NF/NN kappa/NN B/rel/NN in/IN the/DT IL-4-induced/JJ up-regulation/NN of/IN the/DT human/JJ IgE/NN germline/NN promoter/NN ./. 
AB/LS -/: Ig/NN heavy/JJ chain/NN class/NN switching/NN is/VBZ directed/VBN by/IN cytokines/NNS inducing/VBG transcription/NN from/IN unrearranged/JJ CH/NN genes/NNS ./. 
Subsequently/RB ,/, such/JJ primed/VBN cells/NNS can/MD undergo/VB switch/NN recombination/NN to/TO express/VB the/DT selected/VBN new/JJ isotype/NN ./. 
In/IN the/DT case/NN of/IN IgE/NN class/NN switching/NN ,/, IL-4/NN activates/VBZ the/DT IgE/NN germline/NN promoter/NN by/IN inducing/VBG the/DT interaction/NN of/IN the/DT transcription/NN factor/NN STAT6/NN (/( IL-4STAT/NN )/) with/IN a/DT responsive/JJ DNA/NN element/NN in/IN the/DT proximal/JJ region/NN of/IN the/DT promoter/NN ./. 
This/DT study/NN describes/VBZ the/DT characterization/NN of/IN two/CD additional/JJ cis-acting/JJ elements/NNS that/WDT interact/VBP with/IN members/NNS of/IN the/DT NF/NN kappa/NN B/rel/NN transcription/NN factor/NN family/NN in/IN an/DT IL-4-independent/JJ fashion/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS show/VBP that/IN the/DT nucleoprotein/NN complex/NN formed/VBN on/IN the/DT upstream/JJ site/NN (/( NF/NN kappa/NN B1/NN )/) contains/VBZ the/DT classical/JJ p50/p65/NN heterodimer/NN ./. 
The/DT complex/NN on/IN the/DT proximal/JJ site/NN (/( NF/NN kappa/NN B2/NN )/) appears/VBZ to/TO be/VB composed/VBN of/IN p50/NN and/CC relB/NN ./. 
IgE/NN germline/NN promoter/NN reporter/NN gene/NN constructs/NNS carrying/VBG point/NN mutations/NNS in/IN the/DT NF/NN kappa/NN B2/NN site/NN were/VBD largely/RB unresponsive/JJ to/TO IL-4/NN stimulation/NN in/IN transient/JJ transfection/NN experiments/NNS ,/, while/IN plasmids/NNS with/IN similar/JJ mutations/NNS in/IN the/DT NF/NN kappa/NN B1/NN site/NN responded/VBD to/TO cytokine/NN stimulation/NN better/RBR than/IN the/DT wild-type/JJ promoter/NN ./. 
The/DT NF/NN kappa/NN B2/NN effect/NN was/VBD dependent/JJ on/IN the/DT presence/NN of/IN the/DT STAT6/NN binding/NN site/NN ,/, demonstrating/VBG that/IN the/DT NF/NN kappa/NN B2/NN motif/NN is/VBZ necessary/JJ but/CC not/RB sufficient/JJ for/IN mediating/VBG cytokine/NN up-regulation/NN ./. 
In/IN addition/NN ,/, the/DT combination/NN of/IN a/DT NF/NN kappa/NN B/rel/NN binding/NN site/NN and/CC the/DT STAT6/NN response/NN element/NN conferred/VBD IL-4/NN inducibility/NN to/TO a/DT heterologous/JJ minimal/JJ promoter/NN ,/, while/IN the/DT individual/JJ sites/NNS had/VBD no/DT effect/NN ./. 
The/DT available/JJ data/NNS suggest/VBP that/IN the/DT NF/NN kappa/NN B2/NN nucleoprotein/NN complex/NN may/MD cooperate/VB with/IN DNA-bound/JJ STAT6/NN to/TO achieve/VB IL-4-dependent/JJ activation/NN of/IN the/DT human/JJ IgE/NN germline/NN gene/NN ./. 
UI/LS -/: 97454876/CD 
TI/LS -/: Alcohol-induced/JJ regulation/NN of/IN nuclear/JJ regulatory/JJ factor-kappa/NN beta/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: Acute/JJ ethanol/NN exposure/NN has/VBZ the/DT capacity/NN to/TO modulate/VB immune/JJ functions/NNS ,/, particularly/RB ,/, to/TO down/RP regulate/VB monocyte/NN production/NN of/IN inflammatory/JJ cytokines/NNS ./. 
However/RB ,/, the/DT intracellular/JJ mechanisms/NNS for/IN these/DT effects/NNS of/IN ethanol/NN are/VBP yet/RB to/TO be/VB understood/VBN ./. 
Considering/VBG that/IN nuclear/JJ regulatory/JJ factor-kappa/NN beta/NN (/( NF-kappa/NN B/NN )/) /Rel/NN is/VBZ a/DT common/JJ regulatory/JJ element/NN of/IN the/DT promoter/NN region/NN of/IN the/DT inflammatory/JJ cytokine/NN genes/NNS ,/, herein/RB ,/, we/PRP tested/VBD the/DT hypothesis/NN that/IN acute/JJ ethanol/NN affects/VBZ NF-kappa/NN B/NN activation/NN in/IN human/JJ monocytes/NNS ./. 
Adherence-isolated/JJ monocytes/NNS showed/VBD constitutive/JJ DNA/NN binding/NN activity/NN of/IN NF-kappa/NN B/NN ./. 
A/DT clinically/RB relevant/JJ dose/NN (/( 25/CD mM/NN )/) of/IN acute/JJ ethanol/NN treatment/NN in/FW vitro/FW increased/VBD NF-kappa/NN B/NN binding/NN activity/NN in/IN monocytes/NNS with/IN a/DT preferential/JJ induction/NN of/IN the/DT inhibitory/JJ ,/, p50/p50/NN ,/, NF-kappa/NN B/Rel/NN homodimer/NN ,/, and/CC resulted/VBD in/IN no/DT induction/NN of/IN the/DT p65/p50/NN heterodimer/NN ./. 
In/IN contrast/NN ,/, lipopolysaccharide/NN stimulation/NN primarily/RB induced/VBD the/DT p65/p50/NN heterodimer/NN that/WDT has/VBZ been/VBN shown/VBN to/TO result/VB in/IN gene/NN activation/NN ./. 
Thus/RB ,/, such/JJ unique/JJ activation/NN of/IN the/DT inhibitory/JJ p50/p50/NN homodimer/NN by/IN acute/JJ ethanol/NN treatment/NN may/MD result/VB in/IN inhibition/NN rather/RB than/IN activation/NN of/IN NF-kappa/NN B-regulated/JJ inflammatory/JJ cytokine/NN genes/NNS ./. 
Consequently/RB ,/, these/DT results/NNS suggest/VBP that/IN physiologically/RB relevant/JJ concentrations/NNS of/IN ethanol/NN may/MD affect/VB production/NN of/IN inflammatory/JJ cytokines/NNS ,/, such/JJ as/IN tumor/NN necrosis/NN factor-alpha/NN ,/, interleukin-1/NN beta/NN ,/, and/CC interleukin-6/NN by/IN disrupting/VBG NF-kappa/NN B/NN signaling/NN in/IN monocytes/NNS ./. 
UI/LS -/: 98104462/CD 
TI/LS -/: LPS/NN tolerance/NN in/IN monocytes/macrophages/NNS :/: three/CD 3'/JJ cytosins/NNS are/VBP required/VBN in/IN the/DT DNA/NN binding/NN motif/NN for/IN detection/NN of/IN upregulated/VBN NF-kappa/NN B/NN p50/NN homodimers/NNS ./. 
AB/LS -/: When/WRB monocytes/NNS are/VBP stimulated/VBN with/IN LPS/NN (/( lipopolysaccharide/NN )/) repeatedly/RB then/RB the/DT initially/RB high/JJ expression/NN of/IN the/DT TNF/NN (/( tumor/NN necrosis/NN factor/NN )/) gene/NN is/VBZ only/RB very/RB low/JJ ,/, i.e./FW the/DT cells/NNS are/VBP tolerant/JJ to/TO LPS/NN ./. 
Tolerant/JJ cells/NNS still/RB express/VBP the/DT CD14/NN receptor/NN and/CC they/PRP can/MD still/RB be/VB activated/VBN to/TO mobilize/VB NF-kappa/NN B/NN into/IN nucleus/NN ./. 
Analysis/NN of/IN the/DT binding/VBG proteins/NNS employing/VBG the/DT -605/CD motif/NN of/IN the/DT human/JJ TNF/NN promoter/NN (/( GGGGCTGTCCC/NN )/) revealed/VBD that/IN in/IN tolerant/JJ cells/NNS of/IN the/DT human/JJ monocytic/JJ cell/NN line/NN Mono/NN Mac/NN 6/CD there/EX is/VBZ a/DT predominance/NN of/IN p50p50/NN of/IN NF-kappa/NN B/NN ./. 
We/PRP now/RB show/VBP that/IN a/DT mutant/JJ motif/NN that/WDT exchanges/VBZ the/DT terminal/JJ 3'/JJ C/NN for/IN a/DT G/NN fails/VBZ to/TO bind/VB the/DT p50/NN homodimer/NN that/WDT is/VBZ upregulated/VBN in/IN LPS/NN toler/NN ant/JJ human/JJ Mono/NN Mac/NN 6/CD cells/NNS ./. 
The/DT same/JJ is/VBZ true/JJ for/IN nuclear/JJ extracts/NNS taken/VBN from/IN the/DT murine/JJ P388D1/NN macrophage/NN cell/NN line/NN when/WRB tested/VBN with/IN the/DT -516/CD motif/NN of/IN the/DT murine/JJ TNF/NN promoter/NN (/( GGGGGCTTTCCC/NN )/) ./. 
Here/RB the/DT wild/JJ type/NN motif/NN gives/VBZ efficient/JJ binding/NN of/IN p50p50/NN that/WDT again/RB is/VBZ upregulated/VBN in/IN tolerant/JJ cells/NNS whereas/IN a/DT mutant/NN with/IN a/DT 3'/JJ G/NN shows/VBZ hardly/RB any/DT binding/NN of/IN p50p50/NN ./. 
Conversely/RB ,/, the/DT murine/JJ kappa/NN light/JJ chain/NN enhancer/NN motif/NN (/( GGGGACTTTCCG/NN )/) does/VBZ not/RB efficiently/RB bind/VB the/DT nuclear/JJ p50p50/NN from/IN tolerant/JJ murine/JJ P388/NN macrophages/NNS ./. 
Binding/NN is/VBZ ,/, however/RB ,/, readily/RB detected/VBN when/WRB the/DT 3'/JJ G/NN is/VBZ replaced/VBN by/IN a/DT C/NN ./. 
These/DT data/NNS show/VBP that/IN the/DT detection/NN of/IN upregulated/VBN p50/NN homodimers/NNS in/IN LPS/NN tolerant/JJ cells/NNS is/VBZ dependent/JJ on/IN subtle/JJ differences/NNS in/IN the/DT sequence/NN of/IN the/DT DNA/NN binding/NN motif/NN ./. 
UI/LS -/: 98089069/CD 
TI/LS -/: Cyclosporin/NN A/NN inhibits/VBZ early/JJ mRNA/NN expression/NN of/IN G0/G1/NN switch/NN gene/NN 2/CD (/( G0S2/NN )/) in/IN cultured/VBN human/JJ blood/NN mononuclear/JJ cells/NNS ./. 
AB/LS -/: Cyclosporin/NN A/NN (/( CsA/NN )/) may/MD achieve/VB its/PRP$ immunosuppressive/JJ effects/NNS by/IN inhibiting/VBG the/DT calcium-/NN and/CC calmodulin-dependent/JJ phosphatase/NN calcineurin/NN which/WDT is/VBZ required/VBN for/IN activation/NN of/IN target/NN genes/NNS by/IN members/NNS of/IN the/DT NFAT/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS )/) transcription/NN factor/NN family/NN ./. 
Among/IN these/DT target/NN genes/NNS is/VBZ the/DT gene/NN encoding/VBG interleukin-2/NN (/( IL2/NN )/) ,/, a/DT cytokine/NN facilitating/VBG progression/NN through/IN the/DT G1/NN phase/NN of/IN the/DT cell/NN cycle/NN ./. 
However/RB ,/, IL2/NN does/VBZ not/RB reverse/VB CsA/NN inhibition/NN ,/, suggesting/VBG that/IN at/IN least/JJS one/CD other/JJ NFAT-sensitive/JJ gene/NN may/MD be/VB involved/VBN ./. 
The/DT human/JJ G0/G1/NN switch/NN gene/NN ,/, G0S2/NN ,/, has/VBZ potential/JJ NFAT-binding/JJ sites/NNS in/IN the/DT 5'/JJ flank/NN and/CC encodes/VBZ a/DT small/JJ basic/JJ potential/JJ phosphoprotein/NN of/IN unknown/JJ function/NN ./. 
Using/VBG a/DT sensitive/JJ ,/, reverse/JJ transcription-polymerase/NN chain/NN reaction/NN (/( RT-PCR/NN )/) assay/NN ,/, G0S2/NN mRNA/NN levels/NNS were/VBD assayed/VBN in/IN cultured/VBN blood/NN mononuclear/JJ cells/NNS ./. 
Freshly/RB isolated/VBN cells/NNS contain/VBP high/JJ levels/NNS of/IN G0S2/NN mRNA/NN which/WDT rapidly/RB decline/VBP ./. 
This/DT "/`` spontaneous/JJ stimulation/NN "/'' is/VBZ also/RB noted/VBN with/IN some/DT other/JJ G0S/NN genes/NNS and/CC has/VBZ been/VBN attributed/VBN to/TO some/DT aspect/NN of/IN the/DT isolation/NN procedure/NN ./. 
In/IN cells/NNS that/WDT have/VBP been/VBN preincubated/VBN to/TO lower/VB mRNA/NN levels/NNS ,/, there/EX is/VBZ a/DT transient/JJ increase/NN in/IN G0S2/NN mRNA/NN ,/, peaking/VBG between/IN 1-2/CD h/NN ,/, in/IN response/NN to/TO Concanavalin-A/NN (/( ConA/NN )/) ,/, or/CC to/TO the/DT combination/NN of/IN phorbol/NN ester/NN (/( TPA/NN )/) ,/, and/CC the/DT calcium/NN ionophore/NN ,/, ionomycin/NN ./. 
Both/PDT these/DT responses/NNS are/VBP inhibited/VBN by/IN CsA/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN G0S2/NN expression/NN is/VBZ required/VBN to/TO commit/VB cells/NNS to/TO enter/VB the/DT G1/NN phase/NN of/IN the/DT cell/NN cycle/NN ,/, and/CC that/IN ,/, while/IN not/RB excluding/VBG other/DT possible/JJ targets/NNS ,/, early/JJ inhibition/NN of/IN G0S2/NN expression/NN by/IN CsA/NN may/MD be/VB important/JJ in/IN achieving/VBG immunosuppression/NN ./. 
G0S2/NN may/MD be/VB of/IN value/NN as/IN a/DT reporter/NN gene/NN for/IN analyzing/VBG the/DT mechanism/NN of/IN action/NN of/IN CsA/NN and/CC its/PRP$ influence/NN on/IN the/DT positive/JJ and/CC negative/JJ selection/NN of/IN lymphocytes/NNS in/IN response/NN to/TO self/NN and/CC not-self/JJ antigens/NNS ./. 
UI/LS -/: 98074940/CD 
TI/LS -/: c-Rel/NN and/CC p65/NN subunits/NNS bind/VBP to/TO an/DT upstream/JJ NF-kappaB/NN site/NN in/IN human/JJ granulocyte/NN macrophage-colony/NN stimulating/NN factor/NN promoter/NN involved/VBN in/IN phorbol/NN ester/NN response/NN in/IN 5637/CD cells/NNS ./. 
AB/LS -/: To/TO further/RB clarify/VB the/DT complex/JJ transcriptional/JJ regulation/NN of/IN the/DT human/JJ GM-CSF/NN gene/NN ,/, which/WDT was/VBD extensively/RB investigated/VBN in/IN activated/VBN T/NN cells/NNS ,/, we/PRP have/VBP studied/VBN the/DT role/NN of/IN an/DT upstream/JJ NF-kappaB/NN like/JJ site/NN in/IN the/DT 5637/CD non-lymphoid/JJ cell/NN line/NN ,/, which/WDT derives/VBZ from/IN a/DT bladder/NN carcinoma/NN and/CC constitutively/RB produces/VBZ GM-CSF/NN ./. 
This/DT sequence/NN ,/, named/VBN the/DT A/NN element/NN ,/, has/VBZ an/DT active/JJ role/NN on/IN GM-CSF/NN transcription/NN and/CC is/VBZ responsive/JJ to/TO the/DT tumor/NN promoter/NN PMA/NN in/IN transient/JJ transfection/NN experiments/NNS ./. 
We/PRP describe/VBP here/RB a/DT heterodimeric/JJ binding/NN complex/NN of/IN NF-kappaB/NN subunits/NNS (/( c-Rel/NN and/CC p65/NN )/) which/WDT is/VBZ identical/JJ to/TO the/DT one/CD obtained/VBN using/VBG the/DT HIV-LTR-kappaB/NN site/NN as/IN recognition/NN sequence/NN and/CC different/JJ from/IN the/DT one/CD (/( c-Rel/NN and/CC p50/NN )/) observed/VBN with/IN nuclear/JJ extracts/NNS from/IN Mo/NN T-lymphoid/NN HTLV-II/NN infected/JJ cells/NNS ./. 
UI/LS -/: 98037648/CD 
TI/LS -/: Repression/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD through/IN the/DT novel/JJ cooperation/NN of/IN human/JJ factors/NNS YY1/NN and/CC LSF/NN [/( published/VBN erratum/NN appears/VBZ in/IN J/NNP Virol/NNP 1998/CD Feb/NNP ;/: 72/CD (/( 2/CD )/) :/: 1709/CD ]/) 
AB/LS -/: A/DT subpopulation/NN of/IN stably/RB infected/JJ CD4+/JJ cells/NNS capable/JJ of/IN producing/VBG virus/NN upon/IN stimulation/NN has/VBZ been/VBN identified/VBN in/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) -positive/JJ individuals/NNS (/( T.-W.Chun/NNP ,/, D.Finzi/NNP ,/, J.Margolick/NNP ,/, K.Chadwick/NNP ,/, D.Schwartz/NNP ,/, and/CC R.F.Siliciano/NNP ,/, Nat.Med.1/NNP :/: 1284-1290/CD ,/, 1995/CD )/) ./. 
Few/JJ host/NN factors/NNS that/WDT directly/RB limit/VBP HIV-1/NN transcription/NN and/CC could/MD support/VB this/DT state/NN of/IN nonproductive/JJ HIV-1/NN infection/NN have/VBP been/VBN described/VBN ./. 
YY1/NN ,/, a/DT widely/RB distributed/VBN human/JJ transcription/NN factor/NN ,/, is/VBZ known/VBN to/TO inhibit/VB HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) transcription/NN and/CC virus/NN production/NN ./. 
LSF/NN (/( also/RB known/VBN as/IN LBP-1/NN ,/, UBP/NN ,/, and/CC CP-2/NN )/) has/VBZ been/VBN shown/VBN to/TO repress/VB LTR/NN transcription/NN in/FW vitro/FW ,/, but/CC transient/JJ expression/NN of/IN LSF/NN has/VBZ no/DT effect/NN on/IN LTR/NN activity/NN in/FW vivo/FW ./. 
We/PRP report/VBP that/IN both/CC YY1/NN and/CC LSF/NN participate/VBP in/IN the/DT formation/NN of/IN a/DT complex/NN that/WDT recognizes/VBZ the/DT initiation/NN region/NN of/IN the/DT HIV-1/NN LTR/NN ./. 
Further/RB ,/, we/PRP have/VBP found/VBN that/IN these/DT factors/NNS cooperate/VBP in/IN the/DT repression/NN of/IN LTR/NN expression/NN and/CC viral/JJ replication/NN ./. 
This/DT cooperative/JJ function/NN may/MD account/VB for/IN the/DT divergent/JJ effects/NNS of/IN LSF/NN previously/RB observed/VBN in/FW vitro/FW and/CC in/FW vivo/FW ./. 
Thus/RB ,/, the/DT cooperation/NN of/IN two/CD general/JJ cellular/JJ transcription/NN factors/NNS may/MD allow/VB for/IN the/DT selective/JJ downregulation/NN of/IN HIV/NN transcription/NN ./. 
Through/IN this/DT mechanism/NN of/IN gene/NN regulation/NN ,/, YY1/NN and/CC LSF/NN could/MD contribute/VB to/TO the/DT establishment/NN and/CC maintenance/NN of/IN a/DT population/NN of/IN cells/NNS stably/RB but/CC nonproductively/RB infected/VBN with/IN HIV-1/NN ./. 
UI/LS -/: 98022722/CD 
TI/LS -/: Analysis/NN of/IN interactions/NNS between/IN huGATA-3/NN transcription/NN factor/NN and/CC three/CD GATA/NN regulatory/JJ elements/NNS of/IN HIV-1/NN long/JJ terminal/JJ repeat/NN ,/, by/IN surface/NN plasmon/NN resonance/NN ./. 
AB/LS -/: Relative/JJ affinities/NNS of/IN transcriptional/JJ regulatory/JJ elements/NNS for/IN their/PRP$ respective/JJ factor/NN have/VBP been/VBN essentially/RB studied/VBN by/IN bandshift/NN analysis/NN ./. 
Here/RB we/PRP report/VBP a/DT real-time/JJ study/NN of/IN factor/DNA/NN interactions/NNS using/VBG a/DT surface/NN plasmon/NN resonance/NN approach/NN and/CC further/JJ characterization/NN of/IN recovered/VBN proteins/NNS involved/VBN in/IN this/DT interaction/NN ./. 
For/IN this/DT purpose/NN ,/, human/JJ GATA-3/NN ,/, either/CC recombinant/JJ or/CC in/IN nuclear/JJ extracts/NNS ,/, and/CC three/CD natural/JJ GATA/NN elements/NNS of/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN (/( sites/NNS 1/CD ,/, 2/CD ,/, and/CC 3/CD )/) were/VBD chosen/VBN ,/, in/IN which/WDT only/JJ site/NN 2/CD is/VBZ a/DT noncanonical/JJ GATA/NN site/NN ./. 
Direct/JJ analysis/NN of/IN sensorgrams/NNS ,/, with/IN recombinant/JJ huGATA-3/NN ,/, allowed/VBD the/DT comparison/NN of/IN association/NN and/CC dissociation/NN profiles/NNS of/IN the/DT three/CD DNA/NN regions/NNS and/CC their/PRP$ ranking/NN according/VBG to/TO their/PRP$ relative/JJ affinities/NNS ./. 
This/DT result/NN ,/, confirmed/VBN by/IN competitions/NNS with/IN each/DT GATA/NN site/NN ,/, demonstrated/VBD the/DT higher/JJR relative/JJ affinity/NN (/( at/IN least/JJS sevenfold/JJ )/) of/IN site/NN 3/CD ./. 
Interactions/NNS between/IN the/DT canonical/JJ and/CC unique/JJ GATA/NN site/NN 3/CD and/CC nuclear/JJ extracts/NNS were/VBD also/RB studied/VBN in/IN real/JJ time/NN and/CC provided/VBD information/NN on/IN its/PRP$ association/NN and/CC dissociation/NN rates/NNS for/IN native/JJ huGATA-3/NN ./. 
Finally/RB ,/, recovered/VBN protein/NN was/VBD identified/VBN as/IN genuine/JJ huGATA-3/NN by/IN SDS-PAGE/NN ,/, Western/NN blotting/NN ,/, and/CC bandshift/NN assays/NNS ./. 
Copyright/NN 1997/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 98005040/CD 
TI/LS -/: Stable/JJ transfection/NN of/IN U937/NN cells/NNS with/IN sense/NN or/CC antisense/JJ RXR-alpha/NN cDNA/NN suggests/VBZ a/DT role/NN for/IN RXR-alpha/NN in/IN the/DT control/NN of/IN monoblastic/JJ differentiation/NN induced/VBN by/IN retinoic/JJ acid/NN and/CC vitamin/NN D/NN ./. 
AB/LS -/: Although/IN retinoic/JJ acid/NN (/( RA/NN )/) has/VBZ been/VBN known/VBN for/IN many/JJ years/NNS to/TO be/VB a/DT modulating/VBG agent/NN that/WDT plays/VBZ a/DT role/NN in/IN generating/VBG both/CC granulocytes/NNS and/CC monocytes/NNS ,/, the/DT molecular/JJ mechanism/NN underlying/VBG this/DT role/NN has/VBZ not/RB been/VBN defined/VBN in/IN the/DT monoblast/NN lineage/NN ./. 
In/IN particular/JJ ,/, the/DT part/NN played/VBN by/IN the/DT retinoid/JJ X/NN receptors/NNS (/( RXRs/NNS )/) ,/, which/WDT are/VBP members/NNS of/IN the/DT steroid/thyroid/NN hormone/NN nuclear/JJ receptor/NN family/NN ,/, has/VBZ not/RB been/VBN explored/VBN ./. 
In/IN this/DT study/NN ,/, therefore/RB ,/, the/DT human/JJ monoblastic/JJ leukemia/NN cell/NN line/NN U937/NN has/VBZ been/VBN used/VBN as/IN a/DT model/NN system/NN to/TO investigate/VB the/DT role/NN of/IN one/CD of/IN the/DT RXRs/NNS ,/, RXR-alpha/NN ,/, in/IN monoblast/NN differentiation/NN ./. 
RXR-alpha/NN mRNA/NN was/VBD present/JJ in/IN untreated/JJ U937/NN cells/NNS ,/, and/CC levels/NNS increased/VBD after/IN induction/NN of/IN differentiation/NN with/IN phorbol/NN ester/NN ./. 
The/DT same/JJ was/VBD found/VBN for/IN RXR-beta/NN mRNA/NN ./. 
Using/VBG plasmids/NNS containing/VBG sense/NN or/CC antisense/JJ RXR-alpha/NN sequences/NNS under/IN the/DT control/NN of/IN an/DT inducible/JJ promoter/NN ,/, we/PRP generated/VBD stably/RB transfected/VBN cell/NN lines/NNS which/WDT expressed/VBD either/CC increased/VBN or/CC decreased/VBN levels/NNS of/IN RXR-alpha/NN ,/, respectively/RB ./. 
The/DT sense/NN cell/NN lines/NNS (/( U/NN alpha/NN S/NN and/CC its/PRP$ clonal/JJ derivative/JJ alpha/NN G2S/NN )/) showed/VBD increased/VBN sensitivity/NN to/TO RA/NN ,/, while/IN the/DT antisense/JJ cell/NN lines/NNS (/( U/NN alpha/NN A/NN and/CC its/PRP$ clonal/JJ derivative/JJ alpha/NN B5A/NN )/) showed/VBD decreased/VBN sensitivity/NN to/TO RA/NN ,/, as/IN demonstrated/VBN by/IN growth/NN inhibition/NN and/CC by/IN regulation/NN of/IN an/DT RA-responsive/JJ reporter/NN gene/NN ./. 
Both/CC U/NN alpha/NN A/NN and/CC alpha/NN B5A/NN also/RB failed/VBD to/TO respond/VB to/TO another/DT modulating/VBG agent/NN ,/, 1/CD alpha,25-dihydroxycholecalciferol/NN (/( DHCC/NN )/) ,/, but/CC only/RB U/NN alpha/NN S/NN and/CC not/RB alpha/NN G2S/NN showed/VBD an/DT enhanced/VBN response/NN to/TO DHCC/NN ./. 
The/DT combination/NN of/IN RA/NN and/CC DHCC/NN together/RB inhibited/VBD growth/NN of/IN both/CC sense/NN and/CC antisense/JJ cell/NN lines/NNS ./. 
In/IN addition/NN ,/, alpha/NN G2S/NN exhibited/VBD increased/VBN expression/NN of/IN CD11b/NN and/CC CD54/NN ,/, while/IN alpha/NN B5A/NN cells/NNS showed/VBD increased/VBN expression/NN of/IN CD102/NN ,/, suggesting/VBG that/IN RXR-alpha/NN has/VBZ a/DT role/NN in/IN regulating/VBG expression/NN of/IN cell/NN adhesion/NN molecules/NNS in/IN U937/NN cells/NNS ./. 
These/DT results/NNS demonstrate/VBP that/IN RXR-alpha/NN has/VBZ a/DT role/NN in/IN mediating/VBG growth/NN inhibition/NN and/CC cell/NN adhesion/NN during/IN myelomonocytic/JJ differentiation/NN ,/, and/CC suggest/VBP that/IN different/JJ species/NNS of/IN heterodimers/NNS involving/VBG RXR-alpha/NN may/MD control/VB the/DT acquisition/NN of/IN different/JJ features/NNS of/IN mature/JJ monocyte/macrophage/NN function/NN ./. 
UI/LS -/: 98001375/CD 
TI/LS -/: Transcriptional/JJ activation/NN of/IN the/DT vascular/JJ cell/NN adhesion/NN molecule-1/NN gene/NN in/IN T/NN lymphocytes/NNS expressing/VBG human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD Tax/NN protein/NN ./. 
AB/LS -/: Recruitment/NN and/CC extravasation/NN of/IN T/NN cells/NNS through/IN the/DT blood-brain/JJ barrier/NN are/VBP favored/VBN by/IN adhesion/NN molecule-mediated/JJ interactions/NNS of/IN circulating/VBG T/NN cells/NNS with/IN endothelial/JJ cells/NNS ./. 
Since/IN a/DT common/JJ pathological/JJ finding/NN in/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) -associated/JJ diseases/NNS is/VBZ the/DT infiltration/NN of/IN HTLV-1-infected/JJ T/NN lymphocytes/NNS into/IN various/JJ organs/NNS ,/, we/PRP have/VBP looked/VBN for/IN the/DT profile/NN of/IN adhesion/NN molecules/NNS expressed/VBN by/IN HTLV-1-transformed/JJ T/NN cells/NNS ./. 
Flow/NN cytometry/NN analysis/NN indicated/VBD that/IN these/DT cells/NNS were/VBD expressing/VBG high/JJ levels/NNS of/IN vascular/JJ cell/NN adhesion/NN molecule/NN 1/CD (/( VCAM-1/NN [/( CD106/NN ]/) )/) ,/, a/DT 110-kDa/JJ member/NN of/IN the/DT immunoglobulin/NN gene/NN superfamily/NN ,/, first/RB identified/VBN on/IN endothelial/JJ cells/NNS stimulated/VBN with/IN inflammatory/JJ cytokines/NNS ./. 
This/DT adhesion/NN molecule/NN was/VBD also/RB expressed/VBN by/IN T/NN cells/NNS obtained/VBN from/IN one/CD patient/NN with/IN HTLV-1-associated/JJ myelopathy/tropical/JJ spastic/JJ paraparesis/NN but/CC not/RB by/IN activated/VBN T/NN cells/NNS isolated/VBN from/IN one/CD normal/JJ blood/NN donor/NN ./. 
The/DT role/NN of/IN the/DT viral/JJ trans-activator/NN Tax/NN protein/NN in/IN the/DT induction/NN of/IN VCAM-1/NN was/VBD first/RB indicated/VBN by/IN the/DT detection/NN of/IN this/DT adhesion/NN molecule/NN on/IN Jurkat/NN T-cell/NN clones/NNS stably/RB expressing/VBG the/DT tax/NN gene/NN ./. 
The/DT effect/NN of/IN Tax/NN on/IN VCAM-1/NN gene/NN transcription/NN was/VBD next/RB confirmed/VBN in/IN JPX-9/NN cells/NNS ,/, a/DT subclone/NN of/IN Jurkat/NN cells/NNS ,/, carrying/VBG the/DT tax/NN sequences/NNS under/IN the/DT control/NN of/IN an/DT inducible/JJ promoter/NN ./. 
Furthermore/RB ,/, deletion/NN and/CC mutation/NN analyses/NNS of/IN the/DT VCAM-1/NN promoter/NN performed/VBN with/IN chloramphenicol/NN acetyltransferase/NN constructs/NNS revealed/VBD that/IN Tax/NN was/VBD trans/JJ activating/VBG the/DT VCAM-1/NN promoter/NN via/IN two/CD NF-kappaB/NN sites/NNS present/JJ at/IN bp/NN -72/CD and/CC -57/CD in/IN the/DT VCAM-1/NN gene/NN promoter/NN ,/, with/IN both/DT of/IN them/PRP being/VBG required/VBN for/IN the/DT Tax-induced/JJ expression/NN of/IN this/DT adhesion/NN molecule/NN ./. 
Finally/RB ,/, gel/NN mobility/NN shift/NN assays/NNS demonstrated/VBD the/DT nuclear/JJ translocation/NN of/IN proteins/NNS specifically/RB bound/VBN to/TO these/DT two/CD NF-kappaB/NN motifs/NNS ,/, confirming/VBG that/IN VCAM-1/NN was/VBD induced/VBN on/IN Tax-expressing/JJ cells/NNS in/IN a/DT kappaB-dependent/JJ manner/NN ./. 
Collectively/RB ,/, these/DT results/NNS therefore/RB suggest/VBP that/IN the/DT exclusive/JJ Tax-induced/JJ expression/NN of/IN VCAM-1/NN on/IN T/NN cells/NNS may/MD represent/VB a/DT pivotal/JJ event/NN in/IN the/DT progression/NN of/IN HTLV-1-associated/JJ diseases/NNS ./. 
UI/LS -/: 97475199/CD 
TI/LS -/: HIV-1/NN Vpr/NN suppresses/VBZ immune/JJ activation/NN and/CC apoptosis/NN through/IN regulation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: The/DT HIV-1/NN accessory/NN gene/NN product/NN Vpr/NN can/MD influence/VB viral/JJ pathogenesis/NN by/IN affecting/VBG viral/JJ replication/NN as/RB well/RB as/IN host/NN cell/NN transcription/NN and/CC proliferation/NN ./. 
We/PRP have/VBP investigated/VBN the/DT effects/NNS of/IN Vpr/NN on/IN host/NN cell/NN activation/NN and/CC confirm/VBP that/IN it/PRP influences/VBZ cellular/JJ proliferation/NN ./. 
However/RB ,/, we/PRP have/VBP also/RB found/VBN that/IN Vpr/NN modulates/VBZ T-cell/NN receptor/NN (/( TCR/NN )/) -triggered/JJ apoptosis/NN in/IN a/DT manner/NN similar/JJ to/TO that/DT of/IN glucocorticoids/NNS ./. 
In/IN the/DT absence/NN of/IN TCR-mediated/JJ activation/NN ,/, Vpr/NN induces/VBZ apoptosis/NN whereas/IN in/IN its/PRP$ presence/NN ,/, Vpr/NN interrupts/VBZ the/DT expected/VBN induction/NN of/IN apoptosis/NN ./. 
This/DT regulation/NN of/IN apoptosis/NN is/VBZ linked/VBN to/TO Vpr/NN suppression/NN of/IN NF-kappa/NN B/NN activity/NN via/IN the/DT induction/NN of/IN I/NN kappa/NN B/NN ,/, an/DT inhibitor/NN of/IN NF-kappa/NN B/NN ./. 
Further/RB ,/, Vpr/NN suppresses/VBZ expression/NN of/IN IL-2/NN ,/, IL-10/NN ,/, IL-12/NN ,/, TNF/NN alpha/NN and/CC IL-4/NN ,/, all/DT of/IN which/WDT are/VBP NF-kappa/NN B-dependent/JJ ./. 
The/DT effects/NNS of/IN Vpr/NN could/MD be/VB reversed/VBN by/IN RU486/NN ./. 
Our/PRP$ finding/NN that/IN Vpr/NN can/MD regulate/VB NF-kappa/NN B/NN supports/VBZ the/DT hypothesis/NN that/IN some/DT aspects/NNS of/IN viral/JJ pathogenesis/NN are/VBP the/DT consequence/NN of/IN cell/NN dysregulation/NN by/IN Vpr/NN ./. 
UI/LS -/: 97459703/CD 
TI/LS -/: Tissue/NN transglutaminase-dependent/JJ posttranslational/JJ modification/NN of/IN the/DT retinoblastoma/NN gene/NN product/NN in/IN promonocytic/JJ cells/NNS undergoing/VBG apoptosis/NN ./. 
AB/LS -/: The/DT retinoblastoma/NN gene/NN product/NN (/( pRB/NN )/) plays/VBZ an/DT important/JJ role/NN in/IN controlling/VBG both/CC cell/NN release/NN from/IN the/DT G1/NN phase/NN and/CC apoptosis/NN ./. 
We/PRP show/VBP here/RB that/IN in/IN the/DT early/JJ phases/NNS of/IN apoptosis/NN ,/, pRB/NN is/VBZ posttranslationally/RB modified/VBN by/IN a/DT tissue/NN transglutaminase/NN (/( tTG/NN )/) -catalyzed/JJ reaction/NN ./. 
In/IN fact/NN ,/, by/IN employing/VBG a/DT novel/JJ haptenized/VBN lysis/NN synthetic/JJ substrate/NN which/WDT allows/VBZ the/DT isolation/NN of/IN glutaminyl-tTG/JJ substrates/NNS in/FW vivo/FW ,/, we/PRP identified/VBD pRB/NN as/IN a/DT potential/JJ tTG/NN substrate/NN in/IN U937/NN cells/NNS undergoing/VBG apoptosis/NN ./. 
In/IN keeping/VBG with/IN this/DT finding/NN ,/, we/PRP showed/VBD that/IN apoptosis/NN of/IN U937/NN cells/NNS is/VBZ characterized/VBN by/IN the/DT rapid/JJ disappearance/NN of/IN the/DT 105,000-/CD to/TO 110,000-molecular-weight/JJ pRB/NN forms/NNS concomitantly/RB with/IN the/DT appearance/NN of/IN a/DT smear/NN of/IN immunoreactive/JJ products/NNS with/IN a/DT molecular/JJ weight/NN of/IN greater/JJR than/IN 250,000/CD ./. 
The/DT shift/NN in/IN pRB/NN molecular/JJ weight/NN was/VBD reproduced/VBN by/IN adding/VBG exogenous/JJ purified/VBN tTG/NN to/TO extracts/NNS obtained/VBN from/IN viable/JJ U937/NN cells/NNS and/CC was/VBD prevented/VBN by/IN dansylcadaverine/NN ,/, a/DT potent/JJ enzyme/NN inhibitor/NN ./. 
The/DT effect/NN of/IN the/DT pRB/NN posttranslational/JJ modification/NN during/IN apoptosis/NN was/VBD investigated/VBN by/IN determining/VBG the/DT E2F-1/NN levels/NNS and/CC by/IN isolating/VBG and/CC characterizing/VBG pRB-null/JJ clones/NNS from/IN U937/NN cells/NNS ./. 
Notably/RB ,/, the/DT lack/NN of/IN pRB/NN in/IN these/DT U937-derived/JJ clones/NNS renders/VBZ these/DT p53-null/JJ cells/NNS highly/RB resistant/JJ to/TO apoptosis/NN induced/VBN by/IN serum/NN withdrawal/NN ,/, calphostin/NN C/NN ,/, and/CC ceramide/NN ./. 
Taken/VBN together/RB ,/, these/DT data/NNS suggest/VBP that/IN tTG/NN ,/, acting/VBG on/IN the/DT pRB/NN protein/NN ,/, might/MD play/VB an/DT important/JJ role/NN in/IN the/DT cell/NN progression/NN through/IN the/DT death/NN program/NN ./. 
UI/LS -/: 97450986/CD 
TI/LS -/: STAT3/NN is/VBZ a/DT serine/NN kinase/NN target/NN in/IN T/NN lymphocytes/NNS ./. 
Interleukin/NN 2/CD and/CC T/NN cell/NN antigen/NN receptor/NN signals/NNS converge/VBP upon/IN serine/NN 727/CD ./. 
AB/LS -/: Interleukin/NN 2/CD (/( IL-2/NN )/) induces/VBZ tyrosine/NN phosphorylation/NN of/IN STATs/NNS 3/CD and/CC 5/CD (/( signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN )/) ./. 
We/PRP now/RB show/VBP that/IN IL-2/NN regulation/NN of/IN STAT3/NN proteins/NNS in/IN T/NN cells/NNS is/VBZ a/DT complex/JJ response/NN involving/VBG activation/NN of/IN two/CD forms/NNS of/IN STAT3/NN :/: 90-kDa/JJ STAT3alpha/NN and/CC an/DT 83-kDa/JJ carboxyl-terminal/JJ truncated/VBN STAT3beta/NN ./. 
The/DT phosphorylation/NN of/IN STAT/NN proteins/NNS on/IN serine/NN residues/NNS is/VBZ also/RB required/VBN for/IN competent/JJ STAT/NN transcription/NN ./. 
A/DT critical/JJ serine/NN phosphorylation/NN site/NN in/IN STAT3alpha/NN is/VBZ at/IN position/NN 727/CD ./. 
In/IN this/DT study/NN we/PRP have/VBP produced/VBN an/DT antisera/NN specific/JJ for/IN STAT3alpha/NN proteins/NNS phosphorylated/VBN on/IN serine/NN 727/CD and/CC used/VBN this/DT to/TO monitor/VB the/DT phosphorylation/NN of/IN this/DT residue/NN during/IN T/NN lymphocyte/NN activation/NN ./. 
Our/PRP$ results/NNS show/VBP that/IN phosphorylation/NN of/IN STAT3alpha/NN on/IN serine/NN 727/CD is/VBZ not/RB constitutive/JJ in/IN quiescent/JJ T/NN cells/NNS but/CC can/MD be/VB induced/VBN by/IN the/DT cytokine/NN IL-2/NN ./. 
Interestingly/RB ,/, triggering/NN of/IN the/DT T/NN cell/NN antigen/NN receptor/NN complex/NN or/CC activation/NN of/IN protein/NN kinase/NN C/NN with/IN phorbol/NN esters/NNS also/RB induces/VBZ phosphorylation/NN of/IN serine/NN 727/CD but/CC without/IN simultaneously/RB inducing/VBG STAT3/NN tyrosine/NN phosphorylation/NN or/CC DNA/NN binding/NN ./. 
Hence/RB ,/, the/DT present/JJ results/NNS show/VBP that/IN STAT3/NN serine/NN phosphorylation/NN can/MD be/VB regulated/VBN independently/RB of/IN the/DT tyrosine/NN phosphorylation/NN of/IN this/DT molecule/NN ./. 
IL-2/NN and/CC T/NN cell/NN antigen/NN receptor/NN complex/NN induction/NN of/IN STAT3alpha/NN serine/NN 727/CD phosphorylation/NN is/VBZ dependent/JJ on/IN the/DT activity/NN of/IN the/DT MEK/ERK/NN pathway/NN ./. 
Previous/JJ studies/NNS have/VBP identified/VBN H-7-sensitive/JJ kinase/NN pathways/NNS that/WDT regulate/VBP STAT3/NN DNA/NN binding/NN ./. 
We/PRP show/VBP that/IN H-7-sensitive/JJ pathways/NNS regulate/VBP STAT3/NN DNA/NN binding/NN in/IN T/NN cells/NNS ./. 
Nevertheless/RB ,/, we/PRP show/VBP that/IN H-7-sensitive/JJ kinases/NNS do/VBP not/RB regulate/VB STAT3/NN tyrosine/NN phosphorylation/NN or/CC phosphorylation/NN of/IN serine/NN 727/CD ./. 
These/DT results/NNS thus/RB show/VBP that/IN STAT3/NN proteins/NNS are/VBP targets/NNS for/IN multiple/JJ kinase/NN pathways/NNS in/IN T/NN cells/NNS and/CC can/MD integrate/VB signals/NNS from/IN both/CC cytokine/NN receptors/NNS and/CC antigen/NN receptors/NNS ./. 
UI/LS -/: 98104459/CD 
TI/LS -/: NF-kappa/NN B/Rel/NN family/NN members/NNS regulating/VBG the/DT ICAM-1/NN promoter/NN in/IN monocytic/JJ THP-1/NN cells/NNS ./. 
AB/LS -/: A/DT kappa/NN B-site/NN was/VBD identified/VBN in/IN the/DT promoter/NN of/IN the/DT intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN )/) gene/NN ,/, which/WDT is/VBZ involved/VBN in/IN regulation/NN of/IN ICAM-1/NN expression/NN by/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) and/CC glucocorticoids/NNS ./. 
We/PRP now/RB report/VBP on/IN the/DT transcription/NN factors/NNS which/WDT bind/VBP and/CC transactivate/VBP this/DT enhancer/NN sequence/NN ./. 
In/FW vitro/FW ,/, the/DT ICAM-1/NN kappa/NN B/NN site/NN appeared/VBD to/TO bind/VB RelA/NN and/CC c-Rel/NN homodimers/NNS as/RB well/RB as/IN heterodimers/NNS with/IN NF-kappa/NN B1/NN ,/, but/CC weakly/RB NF-kappa/NN B1/NN homodimers/NNS ./. 
In/IN addition/NN ,/, both/CC RelA/NN and/CC c-Rel/NN ,/, but/CC not/RB NF-kappa/NN B1/NN ,/, were/VBD shown/VBN to/TO transactivate/VB an/DT ICAM-1/NN kappa/NN B-reporter/JJ construct/NN ./. 
In/IN monocytic/JJ THP-1/NN cells/NNS TNF-alpha/NN induced/VBD two/CD nuclear/JJ complexes/NNS which/WDT in/FW vitro/FW bound/VBD to/TO the/DT ICAM-1/NN kappa/NN B/NN site/NN ./. 
Using/VBG antibodies/NNS in/IN an/DT electrophoretic/JJ mobility/NN supershift/NN assay/NN ,/, one/CD of/IN these/DT complexes/NNS was/VBD shown/VBN to/TO contain/VB NF-kappa/NN B1/NN and/CC RelA/NN ,/, and/CC to/TO bind/VB with/IN higher/JJR affinity/NN to/TO the/DT consensus/NN kappa/NN B/NN site/NN in/IN the/DT HIV/NN long/JJ terminal/JJ repeat/NN ./. 
The/DT second/JJ complex/NN contained/VBD RelA/NN ,/, and/CC exhibited/VBD higher/JJR affinity/NN towards/IN the/DT ICAM-1/NN kappa/NN B/NN than/IN to/TO the/DT HIV/NN kappa/NN B/NN site/NN ./. 
The/DT glucocorticoid/NN receptor/NN was/VBD shown/VBN to/TO repress/VB activity/NN of/IN both/CC the/DT RelA/NN homodimer/NN and/CC the/DT NF-kappa/NN B1/RelA/NN heterodimer/NN ./. 
We/PRP argue/VBP that/IN in/FW vivo/FW RelA/NN homodimers/NNS are/VBP likely/JJ to/TO play/VB a/DT dominant/JJ role/NN in/IN TNF-alpha-induced/JJ ICAM-1/NN transcription/NN in/IN monocytic/JJ cells/NNS ./. 
UI/LS -/: 98087405/CD 
TI/LS -/: Competent/JJ transcription/NN initiation/NN by/IN RNA/NN polymerase/NN II/CD in/IN cell-free/JJ extracts/NNS from/IN xeroderma/NN pigmentosum/NN groups/NNS B/NN and/CC D/NN in/IN an/DT optimized/VBN RNA/NN transcription/NN assay/NN ./. 
AB/LS -/: The/DT human/JJ autosomal/JJ recessive/JJ disease/NN ,/, xeroderma/NN pigmentosum/NN (/( XP/NN )/) ,/, can/MD result/VB from/IN mutations/NNS in/IN any/DT one/CD of/IN seven/CD genes/NNS ,/, designated/VBN XPA/NN through/IN XPG/NN ./. 
Of/IN these/DT ,/, the/DT XPB/NN and/CC XPD/NN genes/NNS encode/VBP proteins/NNS that/WDT are/VBP subunits/NNS of/IN a/DT general/JJ transcription/NN factor/NN ,/, TFIIH/NN ,/, involved/VBN in/IN both/CC nucleotide/NN excision/NN repair/NN (/( NER/NN )/) and/CC initiation/NN of/IN mRNA/NN transcription/NN by/IN RNA/NN polymerase/NN II/CD ./. 
In/IN humans/NNS ,/, mutation/NN of/IN the/DT XPB/NN or/CC XPD/NN gene/NN impairs/VBZ NER/NN ,/, resulting/VBG in/IN hyper-sensitivity/NN to/TO sunlight/NN and/CC greatly/RB increased/VBN skin/NN tumor/NN formation/NN ./. 
However/RB ,/, no/DT transcription/NN deficiency/NN has/VBZ been/VBN demonstrated/VBN in/IN either/CC XP-B/NN or/CC XP-D/NN ./. 
We/PRP have/VBP employed/VBN an/DT optimized/VBN cell-free/JJ RNA/NN transcription/NN assay/NN to/TO analyze/VB transcription/NN activity/NN of/IN XP-B/NN and/CC XP-D/NN ./. 
Although/IN the/DT growth/NN rate/NN was/VBD normal/JJ ,/, the/DT XP-B/NN and/CC XP-D/NN cells/NNS contained/VBD reduced/VBN amounts/NNS of/IN TFIIH/NN ./. 
Extracts/NNS prepared/VBN from/IN XP-B/NN and/CC XP-D/NN lymphoblastoid/JJ cells/NNS exhibited/VBD similar/JJ transcription/NN activity/NN from/IN the/DT adenovirus/NN major/JJ late/JJ promoter/NN when/WRB compared/VBN to/TO that/DT in/IN extracts/NNS from/IN normal/JJ cells/NNS ./. 
Thus/RB ,/, we/PRP conclude/VBP that/IN the/DT XP-B/NN and/CC XP-D/NN lymphoblastoid/JJ cells/NNS do/VBP not/RB have/VB impaired/JJ RNA/NN transcription/NN activity/NN ./. 
We/PRP consider/VBP the/DT possible/JJ consequences/NNS of/IN the/DT reduced/VBN cellular/JJ content/NN of/IN TFIIH/NN for/IN the/DT clinical/JJ symptoms/NNS in/IN XP-B/NN or/CC XP-D/NN patients/NNS ,/, and/CC discuss/VBP a/DT '/`` conditional/JJ phenotype/NN '/'' that/WDT may/MD involve/VB an/DT impairment/NN of/IN cellular/JJ function/NN only/RB under/IN certain/JJ growth/NN conditions/NNS ./. 
UI/LS -/: 98074810/CD 
TI/LS -/: A/DT novel/JJ form/NN of/IN the/DT myeloid-specific/JJ zinc/NN finger/NN protein/NN (/( MZF-2/NN )/) ./. 
AB/LS -/: BACKGROUND/NN :/: Myeloid/JJ cell/NN development/NN is/VBZ controlled/VBN by/IN tissue-specific/JJ transcription/NN factors/NNS ./. 
Human/JJ myeloid/JJ zinc/NN finger/NN protein/NN (/( MZF-1/NN )/) is/VBZ a/DT putative/JJ transcription/NN factor/NN containing/VBG 13/CD zinc/NN fingers/NNS ,/, and/CC has/VBZ been/VBN suggested/VBN that/IN it/PRP regulates/VBZ the/DT development/NN of/IN neutrophilic/JJ granulocytes/NNS ./. 
RESULTS/NNS :/: Here/RB ,/, we/PRP have/VBP isolated/VBN the/DT murine/JJ and/CC human/JJ cDNAs/NNS which/WDT encode/VBP a/DT novel/JJ form/NN of/IN MZF/NN protein/NN (/( MZF-2/NN )/) ./. 
Murine/JJ and/CC human/JJ MZF-2/NN proteins/NNS consisted/VBD of/IN 814/CD and/CC 775/CD amino/NN acids/NNS ,/, respectively/RB ,/, and/CC have/VBP identity/NN of/IN 75.3/CD %/NN between/IN them/PRP ./. 
The/DT C-terminal/JJ half/NN of/IN human/JJ MZF-2/NN ,/, carrying/VBG the/DT zinc/NN finger/NN domains/NNS ,/, was/VBD completely/RB identical/JJ with/IN that/DT of/IN human/JJ MZF-1/NN ,/, whereas/IN the/DT N-terminal/JJ half/NN of/IN MZF-2/NN was/VBD different/JJ from/IN the/DT corresponding/JJ region/NN of/IN human/JJ MZF-1/NN ,/, and/CC was/VBD coded/VBN by/IN distinct/JJ exons/NNS ./. 
MZF-2/NN mRNA/NN was/VBD expressed/VBN in/IN myeloid/JJ cells/NNS ,/, particularly/RB in/IN the/DT cells/NNS committed/VBN to/TO the/DT neutrophilic/JJ lineage/NN ,/, and/CC down-regulated/VBN by/IN G-CSF/NN ./. 
CONCLUSIONS/NNS :/: MZF-1/NN and/CC MZF-2/NN mRNAs/NNS seem/VBP to/TO be/VB produced/VBN by/IN the/DT alternative/JJ use/NN of/IN two/CD different/JJ transcription/NN initiation/NN sites/NNS ./. 
The/DT distinct/JJ N-terminal/JJ half/NN of/IN MZF-2/NN carries/VBZ two/CD characteristic/JJ domains/NNS ,/, a/DT leucine-rich/JJ domain/NN called/VBN LeR/NN and/CC an/DT acidic/JJ domain/NN ,/, which/WDT suggests/VBZ a/DT unique/JJ function/NN of/IN MZF-2/NN in/IN neutrophil/NN development/NN ./. 
UI/LS -/: 98034220/CD 
TI/LS -/: Impaired/JJ cortisol/NN binding/NN to/TO glucocorticoid/NN receptors/NNS in/IN hypertensive/JJ patients/NNS ./. 
AB/LS -/: We/PRP compared/VBD glucocorticoid/NN receptor/NN binding/NN characteristics/NNS and/CC glucocorticoid/NN responsiveness/NN of/IN human/JJ mononuclear/JJ leukocytes/NNS (/( HML/NN )/) from/IN hypertensive/JJ patients/NNS and/CC matched/VBD normotensive/JJ volunteers/NNS ./. 
We/PRP also/RB considered/VBD associations/NNS of/IN these/DT variables/NNS with/IN plasma/NN renin/NN activity/NN ,/, aldosterone/NN ,/, cortisol/NN ,/, corticotropin/NN ,/, and/CC electrolyte/NN concentrations/NNS ./. 
We/PRP calculated/VBD binding/NN affinity/NN (/( Kd/NN ;/: nmol/L/NN )/) and/CC capacity/NN (/( Bmax/NN ;/: sites/cell/NNS )/) for/IN dexamethasone/NN and/CC cortisol/NN from/IN homologous/JJ and/CC heterologous/JJ competition/NN curves/NNS for/IN specific/JJ [3H]dexamethasone/NN binding/NN sites/NNS on/IN HML/NN isolated/VBN from/IN the/DT blood/NN of/IN normotensive/JJ volunteers/NNS and/CC subjects/NNS with/IN essential/JJ hypertension/NN ./. 
Glucocorticoid/NN responsiveness/NN of/IN HML/NN was/VBD evaluated/VBN as/IN IC50/NN values/NNS (/( nmol/L/NN )/) for/IN dexamethasone/NN and/CC cortisol/NN for/IN the/DT inhibition/NN of/IN lysozyme/NN release/NN ./. 
We/PRP measured/VBD plasma/NN hormones/NNS by/IN radioimmunoassay/NN ./. 
Kd/NN values/NNS (/( mean+/-SE/NN )/) for/IN cortisol/NN in/IN HML/NN of/IN hypertensive/JJ patients/NNS were/VBD higher/JJR than/IN in/IN control/NN subjects/NNS (/( 24.6+/-2.4/CD versus/CC 17.5+/-1.7/CD nmol/L/NN ,/, P/NN </JJR .04/CD )/) ./. 
Binding/NN capacity/NN (/( 4978+/-391/CD versus/CC 4131+/-321/CD sites/cell/NNS )/) ,/, Kd/NN values/NNS for/IN dexamethasone/NN (/( 6.7+/-0.5/CD versus/CC 5.7+/-0.3/CD nmol/L/NN )/) ,/, and/CC IC50/NN values/NNS for/IN dexamethasone/NN (/( 3.4+/-0.3/CD versus/CC 3.1+/-0.2/CD nmol/L/NN )/) and/CC cortisol/NN (/( 12.2+/-1.6/CD versus/CC 9.5+/-0.3/CD nmol/L/NN )/) were/VBD not/RB significantly/RB different/JJ ./. 
Patients/NNS with/IN renin/NN values/NNS less/JJR than/IN 0.13/CD ng/NN angiotensin/NN I/L/NN per/IN second/NN were/VBD markedly/RB less/RBR sensitive/JJ to/TO cortisol/NN than/IN those/DT with/IN higher/JJR values/NNS ./. 
Both/CC Kd/NN (/( 30.3+/-2.5/CD versus/CC 19.2+/-2.4/CD nmol/L/NN )/) and/CC IC50/NN values/NNS (/( 15.5+/-1.8/CD versus/CC 8.9+/-1.2/CD nmol/L/NN )/) for/IN cortisol/NN were/VBD significantly/RB higher/JJR in/IN patients/NNS with/IN lower/JJR renin/NN values/NNS (/( P/NN </JJR .03/CD )/) ./. 
Other/JJ variables/NNS ,/, including/VBG plasma/NN hormone/NN and/CC electrolyte/NN values/NNS and/CC binding/NN characteristics/NNS for/IN dexamethasone/NN ,/, were/VBD not/RB different/JJ ./. 
These/DT data/NNS suggest/VBP that/IN cortisol/NN binding/NN to/TO glucocorticoid/NN receptor/NN is/VBZ slightly/RB impaired/JJ in/IN patients/NNS with/IN essential/JJ hypertension/NN ./. 
In/FW vivo/FW ,/, this/DT could/MD lead/VB to/TO inappropriate/JJ binding/NN of/IN cortisol/NN to/TO mineralocorticoid/NN receptors/NNS ./. 
Hence/RB ,/, decreased/VBN sensitivity/NN to/TO cortisol/NN is/VBZ associated/VBN with/IN renin/NN suppression/NN ./. 
This/DT hypothesis/NN is/VBZ supported/VBN by/IN evidence/NN of/IN hypertension/NN and/CC low/JJ renin/NN activity/NN ,/, which/WDT others/NNS have/VBP described/VBN in/IN patients/NNS with/IN primary/JJ glucocorticoid/NN resistance/NN due/JJ to/TO mutations/NNS of/IN the/DT glucocorticoid/NN receptor/NN ./. 
UI/LS -/: 98022792/CD 
TI/LS -/: PU.1/Pip/NN and/CC basic/JJ helix/NN loop/NN helix/NN zipper/NN transcription/NN factors/NNS interact/VBP with/IN binding/VBG sites/NNS in/IN the/DT CD20/NN promoter/NN to/TO help/VB confer/VB lineage-/NN and/CC stage-specific/JJ expression/NN of/IN CD20/NN in/IN B/NN lymphocytes/NNS ./. 
AB/LS -/: CD20/NN is/VBZ a/DT B-lineage-specific/JJ gene/NN expressed/VBN at/IN the/DT pre-B-cell/JJ stage/NN of/IN B-cell/NN development/NN that/WDT disappears/VBZ on/IN differentiation/NN to/TO plasma/NN cells/NNS ./. 
As/IN such/JJ ,/, it/PRP serves/VBZ as/IN an/DT excellent/JJ paradigm/NN for/IN the/DT study/NN of/IN lineage/NN and/CC developmental/JJ stage-specific/JJ gene/NN expression/NN ./. 
Using/VBG in/FW vivo/FW footprinting/NN we/PRP identified/VBD two/CD sites/NNS in/IN the/DT promoter/NN at/IN -45/CD and/CC -160/CD that/WDT were/VBD occupied/VBN only/RB in/IN CD20+/JJ B/NN cells/NNS ./. 
The/DT -45/CD site/NN is/VBZ an/DT E/NN box/NN that/WDT binds/VBZ basic/JJ helix-loop-helix-zipper/JJ proteins/NNS whereas/IN the/DT -160/CD site/NN is/VBZ a/DT composite/JJ PU.1/NN and/CC Pip/NN binding/NN site/NN ./. 
Transfection/NN studies/NNS with/IN reporter/NN constructs/NNS and/CC various/JJ expression/NN vectors/NNS verified/VBD the/DT importance/NN of/IN these/DT sites/NNS ./. 
The/DT composite/JJ PU.1/NN and/CC Pip/NN site/NN likely/RB accounts/VBZ for/IN both/CC lineage/NN and/CC stage-specific/JJ expression/NN of/IN CD20/NN whereas/IN the/DT CD20/NN E/NN box/NN binding/NN proteins/NNS enhance/VBP overall/JJ promoter/NN activity/NN and/CC may/MD link/VB the/DT promoter/NN to/TO a/DT distant/JJ enhancer/NN ./. 
UI/LS -/: 97469932/CD 
TI/LS -/: Glucocorticoids/NNS and/CC the/DT immune/JJ function/NN in/IN the/DT human/JJ immunodeficiency/NN virus/NN infection/NN :/: a/DT study/NN in/IN hypercortisolemic/JJ and/CC cortisol-resistant/JJ patients/NNS ./. 
AB/LS -/: Immunological/JJ studies/NNS in/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) -positive/JJ patients/NNS suggest/VBP that/IN the/DT disease/NN progression/NN is/VBZ accompanied/VBN by/IN a/DT defective/JJ production/NN of/IN type/NN 1/CD cytokines/NNS (/( interleukin-2/NN (/( IL-2/NN )/) and/CC IL-12/NN ]/) ,/, an/DT increased/VBN production/NN of/IN type/NN 2/CD cytokines/NNS (/( IL-4/NN ,/, IL-6/NN ,/, and/CC IL-10/NN )/) ,/, and/CC an/DT increased/VBN production/NN of/IN IgE/NN ./. 
HIV/NN infection/NN is/VBZ also/RB associated/VBN with/IN activation/NN of/IN the/DT hypothalamo-pituitary-adrenal/JJ axis/NN function/NN and/CC increased/VBD plasma/NN and/CC urinary/JJ cortisol/NN concentrations/NNS ./. 
As/IN cortisol/NN is/VBZ involved/VBN in/IN the/DT physiological/JJ regulation/NN of/IN cytokines/NNS ,/, a/DT study/NN was/VBD conducted/VBN to/TO examine/VB cytokine/NN patterns/NNS in/IN two/CD groups/NNS of/IN hypercortisolemic/JJ patients/NNS ,/, one/CD with/IN normal/JJ sensitivity/NN to/TO glucocorticoids/NNS and/CC the/DT other/JJ with/IN glucocorticoid/NN resistance/NN ./. 
Ten/CD HIV-infected/JJ patients/NNS with/IN normal/JJ receptor/NN affinity/NN to/TO glucocorticoids/NNS (/( AIDS-C/NN )/) ,/, 10/CD HIV-infected/JJ patients/NNS with/IN low/JJ receptor/NN affinity/NN to/TO glucocorticoids/NNS (/( AIDS-GR/NN )/) ,/, and/CC 20/CD healthy/JJ subjects/NNS were/VBD studied/VBN ./. 
Receptor/NN characteristics/NNS of/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS were/VBD evaluated/VBN by/IN [3H]dexamethasone/NN binding/NN ./. 
Serum/NN cortisol/NN and/CC urinary/JJ free/JJ cortisol/NN were/VBD measured/VBN by/IN RIA/NN ./. 
Serum/NN ACTH/NN and/CC IgE/NN were/VBD measured/VBN by/IN immunoradiometric/JJ assay/NN ,/, and/CC IL-2/NN ,/, IL-4/NN ,/, and/CC IL-10/NN cytokines/NNS and/CC interferon-gamma/NN were/VBD measured/VBN by/IN enzyme-linked/JJ immunosorbent/JJ assay/NN ./. 
AIDS-C/NN patients/NNS showed/VBD low/JJ IL-2/NN and/CC high/JJ IL-4/NN ,/, IL-10/NN ,/, and/CC IgE/NN concentratios/NNS ;/: conversely/RB ,/, AIDS-GR/NN patients/NNS showed/VBD high/JJ IL-2/NN and/CC low/JJ IL-4/NN and/CC IgE/NN concentrations/NNS ./. 
Thus/RB ,/, in/IN HIV/NN infection/NN ,/, elevated/JJ cortisol/NN levels/NNS suppress/VBP cell-mediated/JJ immunity/NN and/CC stimulate/VBP humoral/JJ immunity/NN ,/, whereas/IN this/DT response/NN is/VBZ not/RB detected/VBN in/IN cortisol-resistant/JJ patients/NNS ./. 
These/DT findings/NNS indicate/VBP that/IN cortisol/NN and/CC its/PRP$ receptors/NNS are/VBP critically/RB involved/VBN in/IN the/DT regulation/NN of/IN immune/JJ function/NN in/IN HIV/NN infection/NN ./. 
UI/LS -/: 98000233/CD 
TI/LS -/: Monocytic/JJ differentiation/NN of/IN HL-60/NN promyelocytic/JJ leukemia/NN cells/NNS correlates/VBZ with/IN the/DT induction/NN of/IN Bcl-xL/NN ./. 
AB/LS -/: Treatment/NN of/IN human/JJ promyelocytic/JJ leukemia/NN HL-60/NN cells/NNS with/IN phorbol/NN esters/NNS ultimately/RB induces/VBZ the/DT differentiation/NN of/IN these/DT cells/NNS along/IN the/DT monocyte/macrophage/NN lineage/NN ,/, whereas/IN treatment/NN with/IN retinoic/JJ acid/NN or/CC DMSO/NN induces/VBZ granulocytic/neutrophillic/JJ differentiation/NN ./. 
In/IN this/DT study/NN ,/, we/PRP demonstrate/VBP the/DT disparate/JJ fates/NNS of/IN HL-60/NN cells/NNS treated/VBN with/IN the/DT phorbol/NN ester/NN 12,13-phorbol/NN dibutyric/JJ acid/NN (/( PDBu/NN )/) or/CC DMSO/NN ./. 
After/IN DMSO/NN treatment/NN ,/, HL-60/NN cells/NNS eventually/RB died/VBD via/IN apoptosis/NN ,/, whereas/IN the/DT viability/NN of/IN PDBu-treated/JJ cells/NNS was/VBD not/RB affected/VBN during/IN the/DT same/JJ interval/NN ./. 
The/DT levels/NNS of/IN the/DT apoptosis/NN effector/NN proteins/NNS Bak/NN and/CC Bad/NN were/VBD enhanced/VBN ,/, whereas/IN there/EX was/VBD a/DT slight/JJ down-regulation/NN of/IN the/DT apoptosis/NN suppressor/NN protein/NN Bcl-2/NN after/IN treatment/NN of/IN the/DT cells/NNS with/IN PDBu/NN and/CC DMSO/NN ./. 
Treatment/NN with/IN DMSO/NN resulted/VBD in/IN the/DT elevation/NN of/IN the/DT apoptosis/NN effector/NN Bax/NN ,/, whereas/IN treatment/NN with/IN PDBu/NN did/VBD not/RB significantly/RB alter/VB the/DT levels/NNS of/IN this/DT protein/NN ./. 
However/RB ,/, treatment/NN of/IN HL-60/NN cells/NNS with/IN PDBu/NN induced/VBD the/DT rapid/JJ expression/NN of/IN the/DT apoptosis/NN suppressor/NN protein/NN Bcl-xL/NN ,/, whereas/IN the/DT expression/NN of/IN this/DT protein/NN remained/VBD unaltered/JJ in/IN DMSO-treated/JJ cells/NNS ./. 
The/DT generality/NN of/IN this/DT finding/NN was/VBD confirmed/VBN by/IN the/DT induction/NN of/IN Bcl-xL/NN in/IN human/JJ myeloid/JJ U-937/NN cells/NNS ,/, human/JJ peripheral/JJ blood/NN monocytes/NNS exposed/VBN to/TO phorbol/NN ester/NN ,/, and/CC mouse/NN thioglycollate-activated/JJ and/CC resident/JJ peritoneal/JJ macrophages/NNS ./. 
PDBu-treated/JJ HL-60/NN cells/NNS remained/VBD viable/JJ for/IN 7/CD days/NNS and/CC thereafter/RB began/VBD to/TO die/VB via/IN apoptosis/NN ,/, with/IN a/DT concomitant/JJ down-regulation/NN of/IN Bcl-xL/NN ./. 
In/IN conclusion/NN ,/, we/PRP propose/VBP that/IN Bcl-xL/NN expression/NN is/VBZ associated/VBN with/IN differentiation/NN and/CC survival/NN of/IN hematopoietic/JJ cells/NNS along/IN the/DT monocyte/macrophage/NN lineage/NN ./. 
UI/LS -/: 97476217/CD 
TI/LS -/: Monochloramine/NN inhibits/VBZ phorbol/NN ester-inducible/JJ neutrophil/NN respiratory/NN burst/NN activation/NN and/CC T/NN cell/NN interleukin-2/NN receptor/NN expression/NN by/IN inhibiting/VBG inducible/JJ protein/NN kinase/NN C/NN activity/NN ./. 
AB/LS -/: Monochloramine/NN derivatives/NNS are/VBP long/RB lived/VBN physiological/JJ oxidants/NNS produced/VBN by/IN neutrophils/NNS during/IN the/DT respiratory/JJ burst/NN ./. 
The/DT effects/NNS of/IN chemically/RB prepared/VBN monochloramine/NN (/( NH2Cl/NN )/) on/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) and/CC PKC-mediated/JJ cellular/JJ responses/NNS were/VBD studied/VBN in/IN elicited/JJ rat/NN peritoneal/NN neutrophils/NNS and/CC human/JJ Jurkat/NN T/NN cells/NNS ./. 
Neutrophils/NNS pretreated/VBN with/IN NH2Cl/NN (/( 30-50/CD microM/NN )/) showed/VBD a/DT marked/JJ decrease/NN in/IN the/DT respiratory/JJ burst/NN activity/NN induced/VBN by/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) ,/, which/WDT is/VBZ a/DT potent/JJ PKC/NN activator/NN ./. 
These/DT cells/NNS ,/, however/RB ,/, were/VBD viable/JJ and/CC showed/VBD a/DT complete/JJ respiratory/JJ burst/NN upon/IN arachidonic/JJ acid/NN stimulation/NN ,/, which/WDT induces/VBZ the/DT respiratory/JJ burst/NN by/IN a/DT PKC-independent/JJ mechanism/NN ./. 
The/DT NH2Cl-treated/JJ neutrophils/NNS showed/VBD a/DT decrease/NN in/IN both/CC PKC/NN activity/NN and/CC PMA-induced/JJ phosphorylation/NN of/IN a/DT 47-kDa/JJ protein/NN ,/, which/WDT corresponds/VBZ to/TO the/DT cytosolic/JJ factor/NN of/IN NADPH/NN oxidase/NN ,/, p47/NN (/( phox/NN )/) ./. 
Jurkat/NN T/NN cells/NNS pretreated/VBN with/IN NH2Cl/NN (/( 20-70/CD microM/NN )/) showed/VBD a/DT decrease/NN in/IN the/DT expression/NN of/IN the/DT interleukin-2/NN receptor/NN alpha/NN chain/NN following/VBG PMA/NN stimulation/NN ./. 
This/DT was/VBD also/RB accompanied/VBN by/IN a/DT decrease/NN in/IN both/CC PKC/NN activity/NN and/CC nuclear/JJ transcription/NN factor-kappaB/NN activation/NN ,/, also/RB without/IN loss/NN of/IN cell/NN viability/NN ./. 
These/DT results/NNS show/VBP that/IN NH2Cl/NN inhibits/VBZ PKC-mediated/JJ cellular/JJ responses/NNS through/IN inhibition/NN of/IN the/DT inducible/JJ PKC/NN activity/NN ./. 
UI/LS -/: 97460018/CD 
TI/LS -/: Evidence/NN that/IN calcineurin/NN is/VBZ rate-limiting/JJ for/IN primary/JJ human/JJ lymphocyte/NN activation/NN ./. 
AB/LS -/: Cyclosporine/NN (/( CsA/NN )/) is/VBZ both/CC a/DT clinical/JJ immunosuppressive/JJ drug/NN and/CC a/DT probe/NN to/TO dissect/VB intracellular/JJ signaling/NN pathways/NNS ./. 
In/FW vitro/FW ,/, CsA/NN inhibits/VBZ lymphocyte/NN gene/NN activation/NN by/IN inhibiting/VBG the/DT phosphatase/NN activity/NN of/IN calcineurin/NN (/( CN/NN )/) ./. 
In/IN clinical/JJ use/NN ,/, CsA/NN treatment/NN inhibits/VBZ 50-75/CD %/NN of/IN CN/NN activity/NN in/IN circulating/VBG leukocytes/NNS ./. 
We/PRP modeled/VBD this/DT degree/NN of/IN CN/NN inhibition/NN in/IN primary/JJ human/JJ leukocytes/NNS in/FW vitro/FW in/IN order/NN to/TO study/VB the/DT effect/NN of/IN partial/JJ CN/NN inhibition/NN on/IN the/DT downstream/JJ signaling/NN events/NNS that/WDT lead/VBP to/TO gene/NN activation/NN ./. 
In/IN CsA-treated/JJ leukocytes/NNS stimulated/VBN by/IN calcium/NN ionophore/NN ,/, the/DT degree/NN of/IN reduction/NN in/IN CN/NN activity/NN was/VBD accompanied/VBN by/IN a/DT similar/JJ degree/NN of/IN inhibition/NN of/IN each/DT event/NN tested/VBN :/: dephosphorylation/NN of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cell/NN proteins/NNS ,/, nuclear/JJ DNA/NN binding/NN ,/, activation/NN of/IN a/DT transfected/VBN reporter/NN gene/NN construct/NN ,/, IFN-gamma/NN and/CC IL-2/NN mRNA/NN accumulation/NN ,/, and/CC IFN-gamma/NN production/NN ./. 
Furthermore/RB ,/, the/DT degree/NN of/IN CN/NN inhibition/NN was/VBD reflected/VBN by/IN a/DT similar/JJ degree/NN of/IN reduction/NN in/IN lymphocyte/NN proliferation/NN and/CC IFN-gamma/NN production/NN in/IN the/DT allogeneic/JJ mixed/JJ lymphocyte/NN cultures/NNS ./. 
These/DT data/NNS support/VBP the/DT conclusion/NN that/IN CN/NN activity/NN is/VBZ rate-limiting/JJ for/IN the/DT activation/NN of/IN primary/JJ human/JJ T/NN lymphocytes/NNS ./. 
Thus/RB ,/, the/DT reduction/NN of/IN CN/NN activity/NN observed/VBN in/IN CsA-treated/JJ patients/NNS is/VBZ accompanied/VBN by/IN a/DT similar/JJ degree/NN of/IN reduction/NN in/IN lymphocyte/NN gene/NN activation/NN ,/, and/CC accounts/VBZ for/IN the/DT immunosuppression/NN observed/VBN ./. 
UI/LS -/: 97449280/CD 
TI/LS -/: Selection/NN of/IN down-regulated/VBN sequences/NNS along/IN the/DT monocytic/JJ differentiation/NN of/IN leukemic/JJ HL60/NN cells/NNS ./. 
AB/LS -/: In/IN order/NN to/TO dissect/VB the/DT molecular/JJ mechanisms/NNS of/IN monocytic/JJ differentiation/NN we/PRP have/VBP developed/VBN a/DT subtractive/JJ hybridisation/NN method/NN based/VBN on/IN a/DT simplified/JJ '/`` representational/JJ difference/NN analysis/NN '/'' ./. 
We/PRP have/VBP selected/VBN 16/CD sequences/NNS and/CC confirmed/VBN their/PRP$ down-regulation/NN along/IN the/DT TPA-induced/JJ monocytic/JJ differentiation/NN of/IN HL60/NN cells/NNS ./. 
Among/IN these/DT sequences/NNS we/PRP have/VBP identified/VBN the/DT alpha-tubulin/NN ,/, the/DT TaxREB/NN protein/NN and/CC two/CD ribosomal/JJ protein/NN sequences/NNS which/WDT had/VBD not/RB been/VBN previously/RB described/VBN as/IN differentially/RB expressed/VBN ./. 
These/DT results/NNS add/VBP to/TO our/PRP$ knowledge/NN about/IN the/DT molecules/NNS implicated/VBN along/IN the/DT monocytic/JJ differentiation/NN and/CC growth/NN arrest/NN of/IN leukemic/JJ cells/NNS and/CC provide/VBP a/DT first/JJ step/NN in/IN the/DT study/NN of/IN their/PRP$ respective/JJ roles/NNS ./. 
UI/LS -/: 98104456/CD 
TI/LS -/: Control/NN of/IN NF-kappa/NN B/NN activity/NN by/IN the/DT I/NN kappa/NN B/NN beta/NN inhibitor/NN ./. 
AB/LS -/: The/DT transcription/NN factor/NN NF-kappa/NN B/NN is/VBZ maintained/JJ in/IN an/DT inactive/JJ cytoplasmic/JJ state/NN by/IN I/NN kappa/NN B/NN inhibitors/NNS ./. 
In/IN mammalian/JJ cells/NNS ,/, I/NN kappa/NN B/NN alpha/NN and/CC I/NN kappa/NN B/NN beta/NN proteins/NNS have/VBP been/VBN purified/VBN and/CC shown/VBN to/TO be/VB the/DT inhibitors/NNS of/IN NF-kappa/NN B/NN through/IN their/PRP$ association/NN with/IN the/DT p65/NN or/CC c-Rel/NN subunits/NNS ./. 
In/IN addition/NN ,/, we/PRP have/VBP isolated/VBN a/DT third/JJ NF-kappa/NN B/NN inhibitor/NN ,/, I/NN kappa/NN B/NN epsilon/NN (/( 1/CD )/) ./. 
Upon/IN treatment/NN with/IN a/DT large/JJ variety/NN of/IN inducers/NNS ,/, I/NN kappa/NN B/NN alpha/NN ,/, I/NN kappa/NN B/NN beta/NN are/VBP proteolytically/RB degraded/VBN ,/, resulting/VBG in/IN NF-kappa/NN B/NN translocation/NN into/IN the/DT nucleus/NN ./. 
Here/RB we/PRP show/VBP that/IN in/IN E29.1/NN T/NN cell/NN hybridoma/NN I/NN kappa/NN B/NN alpha/NN and/CC I/NN kappa/NN B/NN beta/NN are/VBP equally/RB associated/VBN with/IN p65/NN and/CC that/IN I/NN kappa/NN B/NN beta/NN is/VBZ degraded/VBN in/IN response/NN to/TO TNF/NN alpha/NN in/IN contrast/NN to/TO what/WP has/VBZ been/VBN originally/RB published/VBN ./. 
Our/PRP$ data/NNS also/RB suggest/VBP that/IN ,/, unlike/IN I/NN kappa/NN B/NN alpha/NN ,/, I/NN kappa/NN B/NN beta/NN is/VBZ constitutively/RB phosphorylated/VBN and/CC resynthesized/VBN as/IN a/DT hypophosphorylated/VBN form/NN ./. 
The/DT absence/NN of/IN slow/JJ migrating/JJ forms/NNS of/IN I/NN kappa/NN B/NN beta/NN following/VBG stimulation/NN suggests/VBZ that/IN the/DT phosphorylation/NN does/VBZ not/RB necessarily/RB constitute/VB the/DT signal-induced/JJ event/NN which/WDT targets/VBZ the/DT molecule/NN for/IN proteolysis/NN ./. 
UI/LS -/: 98080700/CD 
TI/LS -/: Agonistic/JJ activity/NN of/IN a/DT CD40-specific/JJ single-chain/JJ Fv/NN constructed/VBN from/IN the/DT variable/JJ regions/NNS of/IN mAb/NN G28-5/NN ./. 
AB/LS -/: A/DT single-chain/JJ Fv/NN (/( sFv/NN )/) was/VBD expressed/VBN from/IN the/DT variable/JJ regions/NNS of/IN the/DT CD40-specific/JJ mAb/NN G28-5/NN ./. 
The/DT molecule/NN bound/VBD CD40/NN with/IN a/DT high/JJ affinity/NN (/( 2.2/CD nM/NN )/) and/CC was/VBD a/DT monomer/NN in/IN solution/NN ./. 
Surprisingly/RB ,/, G28-5/NN sFv/NN was/VBD a/DT potent/JJ CD40/NN agonist/NN that/WDT rapidly/RB crosslinked/VBD CD40/NN on/IN the/DT cell/NN surface/NN but/CC did/VBD not/RB crosslink/VB CD40-Ig/NN in/IN solution/NN ./. 
G28-5/NN sFv/NN was/VBD a/DT more/RBR potent/JJ agonist/NN than/IN G28-5/NN IgG/NN and/CC was/VBD able/JJ to/TO stimulate/VB CD40/NN responses/NNS by/IN B/NN cells/NNS and/CC monocytes/NNS ./. 
G28-5/NN IgG/NN partially/RB blocked/VBD ,/, whereas/IN G28-5/NN sFv/NN augmented/VBD CD40/NN responses/NNS during/IN stimulation/NN with/IN natural/JJ ligand/NN (/( gp39-CD8/JJ fusion/NN protein/NN )/) ./. 
These/DT results/NNS indicate/VBP that/IN the/DT functional/JJ activity/NN of/IN ligands/NNS built/VBN from/IN the/DT binding/VBG site/NN of/IN G28-5/NN is/VBZ highly/RB dependent/JJ upon/IN the/DT size/NN and/CC physical/JJ properties/NNS of/IN the/DT molecule/NN both/CC in/IN solution/NN and/CC on/IN the/DT cell/NN surfaces/NNS ./. 
UI/LS -/: 98068683/CD 
TI/LS -/: C/EBP/NN activates/VBZ the/DT human/JJ corticotropin-releasing/JJ hormone/NN gene/NN promoter/NN ./. 
AB/LS -/: The/DT purpose/NN of/IN these/DT studies/NNS was/VBD to/TO identify/VB whether/IN transcription/NN factors/NNS ,/, associated/VBN with/IN cytokine/NN signalling/NN ,/, affected/VBD promoter/NN activity/NN of/IN the/DT corticotropin/NN releasing/NN hormone/NN (/( CRH/NN )/) gene/NN ./. 
Fragments/NNS of/IN a/DT 3.6/CD kb/NN sequence/NN of/IN the/DT human/JJ CRH/NN gene/NN promoter/NN were/VBD amplified/VBN by/IN PCR/NN and/CC ligated/VBN upstream/RB of/IN a/DT CAT/NN reporter/NN ./. 
These/DT constructs/NNS were/VBD transfected/VBN into/IN a/DT variety/NN of/IN cell/NN lines/NNS ,/, either/CC alone/RB or/CC together/RB ,/, with/IN transcription/NN factor/NN expression/NN vectors/NNS ./. 
Basal/JJ activity/NN of/IN a/DT 3070/CD bp/NN CRH/NN promoter/NN fragment/NN was/VBD only/RB seen/VBN in/IN neuronal/JJ and/CC lymphoblastoid/JJ cell/NN lines/NNS ./. 
Promoter/NN activity/NN was/VBD increased/VBN by/IN the/DT transcription/NN factors/NNS C/EBPbeta/NN (/( NF-IL6/NN )/) and/CC more/RBR strongly/RB ,/, by/IN C/EBPdelta/NN (/( NF-IL6beta/NN )/) ./. 
Increased/VBN CRH/NN promoter/NN activity/NN following/VBG phorbol/NN ester/NN treatment/NN was/VBD inhibited/VBN by/IN a/DT dominant/JJ negative/JJ NF-IL6/NN mutant/NN ,/, showing/VBG that/IN the/DT effects/NNS of/IN phorbol/NN ester/NN were/VBD principally/RB mediated/VBN by/IN C/EBP/NN ./. 
Moreover/RB ,/, the/DT inverse/JJ changes/NNS in/IN the/DT expression/NN of/IN CRH/NN in/IN the/DT hypothalamus/NN and/CC spleens/NNS of/IN arthritic/JJ rats/NNS were/VBD paralleled/VBN by/IN similar/JJ inverse/NN changes/NNS in/IN NF-IL6beta/NN expression/NN in/IN these/DT organs/NNS ./. 
These/DT data/NNS show/VBP that/IN some/DT transcription/NN factors/NNS associated/VBN with/IN cytokine/NN signalling/NN can/MD also/RB activate/VB the/DT CRH/NN promoter/NN ./. 
UI/LS -/: 98031856/CD 
TI/LS -/: Aberrant/JJ splicing/NN of/IN the/DT TSG101/NN and/CC FHIT/NN genes/NNS occurs/VBZ frequently/RB in/IN multiple/JJ malignancies/NNS and/CC in/IN normal/JJ tissues/NNS and/CC mimics/VBZ alterations/NNS previously/RB described/VBN in/IN tumours/NNS ./. 
AB/LS -/: Intragenic/JJ deletions/NNS of/IN TSG101/NN ,/, the/DT human/JJ homolog/NN of/IN a/DT mouse/NN gene/NN (/( tsg101/NN )/) that/WDT acts/VBZ to/TO suppress/VB malignant/JJ cell/NN growth/NN ,/, were/VBD reported/VBN in/IN human/JJ breast/NN tumours/NNS ./. 
We/PRP screened/VBD TSG101/NN for/IN somatic/JJ mutations/NNS in/IN DNA/NN and/CC RNA/NN samples/NNS isolated/VBN from/IN a/DT variety/NN of/IN common/JJ human/JJ malignancies/NNS ,/, EBV-immortalised/JJ B-cells/NNS ,/, and/CC normal/JJ lung/NN parenchyma/NN ./. 
Intragenic/JJ TSG101/NN deletions/NNS in/IN RNA/NN transcripts/NNS were/VBD frequently/RB found/VBN in/IN all/DT types/NNS of/IN samples/NNS ./. 
Analysis/NN of/IN DNA/NN failed/VBD to/TO show/VB genomic/JJ rearrangements/NNS corresponding/VBG to/TO transcripts/NNS containing/VBG deletions/NNS in/IN the/DT same/JJ samples/NNS ./. 
The/DT breakpoints/NNS of/IN most/JJS transcript/NN deletions/NNS coincide/VBP with/IN genuine/JJ or/CC cryptic/JJ splice/NN site/NN sequences/NNS ,/, suggesting/VBG that/IN they/PRP result/VBP from/IN alternative/JJ or/CC aberrant/JJ splicing/NN ./. 
A/DT similar/JJ spectrum/NN of/IN transcript/NN deletions/NNS has/VBZ previously/RB been/VBN described/VBN in/IN the/DT putative/JJ tumour/NN suppressor/NN gene/NN FHIT/NN ./. 
We/PRP analysed/VBD FHIT/NN in/IN the/DT same/JJ series/NN of/IN RNA/NN samples/NNS and/CC detected/VBD truncated/VBN FHIT/NN transcripts/NNS frequently/RB in/IN both/CC tumour/NN and/CC normal/JJ tissues/NNS ./. 
In/IN addition/NN ,/, transcripts/NNS from/IN TSG101/NN ,/, FHIT/NN and/CC seven/CD other/JJ genes/NNS were/VBD analysed/VBN in/IN RNA/NN isolated/VBN from/IN normal/JJ peripheral/JJ blood/NN lymphocytes/NNS ./. 
Large/JJ TSG101/NN and/CC FHIT/NN intragenic/JJ transcript/NN deletions/NNS were/VBD detected/VBN and/CC these/DT appeared/VBD to/TO be/VB the/DT predominant/JJ transcript/NN in/IN '/`` aged/JJ '/'' lymphocytes/NNS ./. 
Similar/JJ alterations/NNS were/VBD not/RB detected/VBN in/IN transcripts/NNS of/IN the/DT other/JJ genes/NNS which/WDT were/VBD analysed/VBN ./. 
Our/PRP$ findings/NNS demonstrate/VBP that/IN truncated/VBN TSG101/NN and/CC FHIT/NN transcripts/NNS are/VBP commonly/RB detected/VBN in/IN both/CC normal/JJ and/CC malignant/JJ tissues/NNS and/CC that/IN a/DT significant/JJ fraction/NN of/IN these/DT are/VBP likely/JJ to/TO be/VB the/DT result/NN of/IN aberrant/JJ splicing/NN ./. 
While/IN we/PRP can/MD not/RB exclude/VB that/IN alterations/NNS in/IN TSG101/NN and/CC FHIT/NN occur/VBP during/IN cancer/NN development/NN ,/, our/PRP$ data/NNS indicate/VBP that/IN in/IN this/DT context/NN the/DT commonly/RB observed/VBN transcript/NN abnormalities/NNS are/VBP misleading/JJ ./. 
UI/LS -/: 98014713/CD 
TI/LS -/: Inhibition/NN of/IN proliferation/NN and/CC apoptosis/NN of/IN human/JJ and/CC rat/NN T/NN lymphocytes/NNS by/IN curcumin/NN ,/, a/DT curry/NN pigment/NN ./. 
AB/LS -/: Curcumin/NN (/( diferuoylmethane/NN )/) ,/, the/DT yellow/JJ pigment/NN in/IN the/DT rhizome/NN of/IN tumeric/JJ (/( Curcuma/FW longa/FW )/) ,/, an/DT ingredient/NN of/IN curry/NN spice/NN ,/, is/VBZ known/VBN to/TO exhibit/VB a/DT variety/NN of/IN pharmacological/JJ effects/NNS including/VBG antitumor/JJ ,/, antiinflammatory/JJ ,/, and/CC antiinfectious/JJ activities/NNS ./. 
Although/IN its/PRP$ precise/JJ mode/NN of/IN action/NN remains/VBZ elusive/JJ ,/, curcumin/NN has/VBZ been/VBN shown/VBN to/TO suppress/VB the/DT activity/NN of/IN the/DT AP-1/NN transcription/NN factor/NN in/IN cells/NNS stimulated/VBN to/TO proliferate/VB ./. 
In/IN this/DT study/NN ,/, we/PRP observed/VBD that/IN curcumin/NN (/( 50/CD microM/NN )/) inhibited/VBD proliferation/NN of/IN rat/NN thymocytes/NNS stimulated/VBN with/IN concanavalin/NN A/NN (/( Con/NN A/NN )/) as/RB well/RB as/IN that/DT of/IN human/JJ Jurkat/NN lymphoblastoid/JJ cells/NNS in/IN the/DT logarithmic/JJ growth/NN phase/NN ./. 
The/DT pigment/NN also/RB inhibited/VBD apoptosis/NN in/IN dexamethasone-treated/JJ rat/NN thymocytes/NNS and/CC in/IN UV-irradiated/JJ Jurkat/NN cells/NNS as/IN judged/VBN by/IN DNA/NN ladder/NN formation/NN ,/, cellular/JJ morphological/JJ changes/NNS ,/, and/CC flow/NN cytometry/NN analysis/NN ./. 
The/DT inhibition/NN of/IN apoptosis/NN by/IN curcumin/NN in/IN rat/NN thymocytes/NNS was/VBD accompanied/VBN by/IN partial/JJ suppression/NN of/IN AP-1/NN activity/NN ./. 
Complete/JJ suppression/NN of/IN AP-1/NN activity/NN was/VBD observed/VBN in/IN Con/NN A-treated/NN ,/, proliferating/VBG thymocytes/NNS ./. 
The/DT capacity/NN of/IN curcumin/NN to/TO inhibit/VB both/CC cell/NN growth/NN and/CC death/NN strongly/RB implies/VBZ that/IN these/DT two/CD biological/JJ processes/NNS share/VBP a/DT common/JJ pathway/NN at/IN some/DT point/NN and/CC that/IN curcumin/NN affects/VBZ a/DT common/JJ step/NN ,/, presumably/RB involving/VBG a/DT modulation/NN of/IN the/DT AP-1/NN transcription/NN factor/NN ./. 
UI/LS -/: 97465516/CD 
TI/LS -/: Interleukin-7/NN upregulates/VBZ the/DT interleukin-2-gene/JJ expression/NN in/IN activated/VBN human/JJ T/NN lymphocytes/NNS at/IN the/DT transcriptional/JJ level/NN by/IN enhancing/VBG the/DT DNA/NN binding/NN activities/NNS of/IN both/CC nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS and/CC activator/NN protein-1/NN ./. 
AB/LS -/: In/IN the/DT present/JJ report/NN ,/, we/PRP studied/VBD the/DT role/NN of/IN the/DT stromal-derived/JJ cytokine/NN interleukin-7/NN (/( IL-7/NN )/) in/IN the/DT IL-2-gene/JJ regulation/NN in/IN activated/VBN T/NN lymphocytes/NNS ./. 
Production/NN of/IN IL-2/NN requires/VBZ the/DT formation/NN of/IN transcription/NN factors/NNS involved/VBN in/IN the/DT IL-2-gene/JJ regulation/NN ./. 
T-cell/NN receptor/NN (/( TCR/NN )/) /CD3/NN engagement/NN results/VBZ in/IN the/DT activation/NN of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) ,/, activator/NN protein-1/NN (/( AP-1/NN )/) ,/, and/CC nuclear/JJ factor/NN kappaB/NN (/( NFkappaB/NN )/) ,/, whereas/IN the/DT CD28/NN responsive/JJ complex/NN (/( CD28RC/NN )/) is/VBZ activated/VBN in/IN response/NN to/TO the/DT CD28/NN signal/NN ./. 
Costimulation/NN of/IN phytohemagglutinin/anti-CD28/JJ activated/VBN T/NN lymphocytes/NNS with/IN IL-7/NN induces/VBZ a/DT fivefold/RB enhanced/VBN IL-2-mRNA/NN accumulation/NN and/CC a/DT 2.5-fold/RB enhanced/VBN protein/NN secretion/NN ./. 
The/DT IL-2-gene/JJ transcription/NN rate/NN is/VBZ increased/VBN 3.4-fold/RB ,/, indicating/VBG that/IN the/DT effect/NN of/IN IL-7/NN is/VBZ in/IN part/NN mediated/VBN at/IN the/DT transcriptional/JJ level/NN ./. 
The/DT molecular/JJ mechanisms/NNS underlying/VBG the/DT IL-7/NN effect/NN involve/VBP the/DT upregulation/NN of/IN the/DT DNA/NN binding/NN activity/NN of/IN NFAT/NN (/( 60/CD %/NN )/) and/CC AP-1/NN (/( 120/CD %/NN )/) ,/, without/IN affecting/VBG the/DT activities/NNS of/IN NFkappaB/NN and/CC CD28RC/NN ,/, which/WDT was/VBD confirmed/VBN by/IN transfection/NN assays/NNS ./. 
We/PRP also/RB show/VBP that/IN the/DT IL-7-induced/JJ enhancement/NN of/IN the/DT AP-1-DNA/JJ binding/NN activity/NN is/VBZ not/RB cyclosporin/NN A-sensitive/JJ ./. 
Since/IN AP-1/NN is/VBZ part/NN of/IN the/DT NFAT/NN complex/NN ,/, we/PRP conclude/VBP that/IN the/DT IL-7-signaling/JJ pathway/NN is/VBZ involved/VBN in/IN the/DT activation/NN of/IN the/DT fos/NN and/CC jun/NN proteins/NNS of/IN which/WDT AP-1/NN consists/VBZ ./. 
UI/LS -/: 98001085/CD 
TI/LS -/: The/DT spatial/JJ distribution/NN of/IN human/JJ immunoglobulin/NN genes/NNS within/IN the/DT nucleus/NN :/: evidence/NN for/IN gene/NN topography/NN independent/JJ of/IN cell/NN type/NN and/CC transcriptional/JJ activity/NN ./. 
AB/LS -/: The/DT three-dimensional/JJ positioning/NN of/IN immunoglobulin/NN (/( Ig/NN )/) genes/NNS within/IN the/DT nucleus/NN of/IN human/JJ cells/NNS was/VBD investigated/VBN using/VBG in/FW situ/FW hybridization/NN and/CC confocal/JJ microscopy/NN ./. 
The/DT visualization/NN of/IN heavy/JJ and/CC light/JJ chain/NN genes/NNS in/IN B-lymphoid/JJ cells/NNS showed/VBD that/IN the/DT three/CD Ig/NN genes/NNS are/VBP differentially/RB and/CC nonrandomly/RB distributed/VBN in/IN different/JJ nuclear/JJ subvolumes/NNS :/: the/DT kappa/NN genes/NNS were/VBD found/VBN to/TO be/VB preferentially/RB confined/VBN to/TO an/DT outer/JJ nuclear/JJ volume/NN ,/, whereas/IN the/DT gamma/NN and/CC lambda/NN genes/NNS consistently/RB occupied/VBD more/RBR central/JJ positions/NNS within/IN the/DT nucleus/NN ,/, the/DT lambda/NN genes/NNS being/VBG more/RBR interior/JJ when/WRB compared/VBN with/IN the/DT gamma/NN genes/NNS ./. 
The/DT data/NNS further/RB show/VBP that/IN these/DT overall/JJ topographical/JJ distributions/NNS are/VBP independent/JJ of/IN gene/NN transcriptional/JJ activity/NN and/CC are/VBP conserved/VBN in/IN different/JJ cell/NN types/NNS ./. 
Although/IN subtle/JJ gene/NN movements/NNS within/IN those/DT defined/VBN topographical/JJ regions/NNS can/MD not/RB be/VB excluded/VBN by/IN this/DT study/NN ,/, the/DT results/NNS indicate/VBP that/IN tissue/NN specificity/NN of/IN gene/NN expression/NN is/VBZ not/RB accompanied/VBN by/IN drastic/JJ changes/NNS in/IN gene/NN nuclear/JJ topography/NN ,/, rather/RB suggesting/VBG that/IN gene/NN organization/NN within/IN the/DT nucleus/NN may/MD be/VB primarily/RB dependent/JJ on/IN structural/JJ constraints/NNS imposed/VBN on/IN the/DT respective/JJ chromosomes/NNS ./. 
UI/LS -/: 97472344/CD 
TI/LS -/: Dominant/JJ cytotoxic/JJ T/NN lymphocyte/NN response/NN to/TO the/DT immediate-early/JJ trans-activator/JJ protein/NN ,/, BZLF1/NN ,/, in/IN persistent/JJ type/NN A/NN or/CC B/NN Epstein-Barr/JJ virus/NN infection/NN ./. 
AB/LS -/: Five/CD healthy/JJ human/JJ leukocyte/NN antigen-B8/NN (/( HLA-B8/NN )/) -positive/JJ virus/NN carriers/NNS were/VBD studied/VBN to/TO investigate/VB the/DT CD8+/JJ cytotoxic/JJ T/NN lymphocyte/NN (/( CTL/NN )/) response/NN to/TO an/DT HLA-B8-restricted/JJ peptide/NN ,/, RAKFKQLLQ/NN ,/, located/JJ in/IN the/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) immediate-early/JJ trans-activator/NN protein/NN ,/, BZLF1/NN ./. 
Of/IN the/DT 5/CD virus/NN carriers/NNS ,/, 4/CD were/VBD infected/VBN with/IN type/NN A/NN and/CC 1/CD with/IN type/NN B/NN EBV/NN ./. 
Using/VBG limiting-dilution/JJ analysis/NN of/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS ,/, a/DT high/JJ RAKFKQLLQ-specific/JJ CTL/NN precursor/NN frequency/NN was/VBD demonstrated/VBN after/IN specific/JJ peptide/NN or/CC autologous/JJ lymphoblastoid/JJ cell/NN line/NN stimulation/NN in/IN both/CC type/NN A/NN and/CC type/NN B/NN EBV/NN carriers/NNS ./. 
The/DT RAKFKQLLQ-specific/JJ CTL/NN precursor/NN frequencies/NNS in/IN all/DT 5/CD persons/NNS were/VBD at/IN least/JJS as/RB dominant/JJ as/IN those/DT observed/VBN with/IN two/CD other/JJ EBV-associated/JJ ,/, HLA-B8-restricted/JJ latent/JJ epitopes/NNS ,/, FLRGRAYGL/NN and/CC QAKWRLQTL/NN ./. 
These/DT findings/NNS show/VBP that/IN healthy/JJ virus/NN carriers/NNS maintain/VBP a/DT high/JJ frequency/NN of/IN BZLF1-specific/JJ memory/NN T/NN cells/NNS ,/, potentially/RB to/TO control/VB virus/NN spread/VBN from/IN lytically/RB infected/JJ cells/NNS ./. 
UI/LS -/: 97460074/CD 
TI/LS -/: The/DT DNA/NN binding/NN domain/NN of/IN the/DT A-MYB/NN transcription/NN factor/NN is/VBZ responsible/JJ for/IN its/PRP$ B/NN cell-specific/JJ activity/NN and/CC binds/VBZ to/TO a/DT B/NN cell/NN 110-kDa/JJ nuclear/JJ protein/NN ./. 
AB/LS -/: Expression/NN studies/NNS as/RB well/RB as/IN the/DT use/NN of/IN transgenic/JJ animals/NNS have/VBP demonstrated/VBN that/IN the/DT A-MYB/NN transcription/NN factor/NN plays/VBZ central/JJ and/CC specific/JJ role/NN in/IN the/DT regulation/NN of/IN mature/JJ B/NN cell/NN proliferation/NN and/or/CC differentiation/NN ./. 
Furthermore/RB ,/, it/PRP is/VBZ highly/RB expressed/VBN in/IN Burkitt/NN 's/POS lymphoma/NN cells/NNS and/CC may/MD participate/VB in/IN the/DT pathogenesis/NN of/IN this/DT disease/NN ./. 
We/PRP have/VBP therefore/RB investigated/VBN the/DT transcriptional/JJ activity/NN of/IN A-MYB/NN and/CC its/PRP$ regulation/NN in/IN several/JJ human/JJ lymphoid/JJ cell/NN lines/NNS using/VBG co-transfection/NN assays/NNS and/CC show/VBP that/IN A-MYB/NN is/VBZ transcriptionally/RB active/JJ in/IN all/PDT the/DT B/NN cell/NN lines/NNS studied/VBN ,/, but/CC not/RB in/IN T/NN cells/NNS ./. 
In/IN particular/JJ the/DT best/JJS responder/NN cell/NN line/NN was/VBD the/DT Burkitt/NN 's/POS cell/NN line/NN Namalwa/NN ./. 
The/DT activity/NN of/IN A-MYB/NN in/IN B/NN and/CC not/RB T/NN cells/NNS was/VBD observed/VBN when/WRB either/CC an/DT artificial/JJ construct/NN or/CC the/DT c-MYC/NN promoter/NN was/VBD used/VBN as/IN a/DT reporter/NN ./. 
Furthermore/RB ,/, the/DT functional/JJ domains/NNS responsible/JJ for/IN DNA/NN binding/NN ,/, transactivation/NN ,/, and/CC negative/JJ regulation/NN ,/, previously/RB characterized/VBN in/IN a/DT fibroblast/NN context/NN ,/, were/VBD found/VBN to/TO have/VB similar/JJ activity/NN in/IN B/NN cells/NNS ./. 
The/DT region/NN of/IN A-MYB/NN responsible/JJ for/IN the/DT B/NN cell/NN specific/JJ activity/NN was/VBD defined/VBN to/TO be/VB the/DT N-terminal/JJ 218/CD amino/NN acids/NNS containing/VBG the/DT DNA/NN binding/NN domain/NN ./. 
Finally/RB ,/, a/DT 110-kDa/JJ protein/NN has/VBZ been/VBN identified/VBN in/IN the/DT nuclei/NNS of/IN all/PDT the/DT B/NN ,/, but/CC not/RB T/NN ,/, cell/NN lines/NNS that/WDT specifically/RB binds/VBZ to/TO this/DT A-MYB/NN N-terminal/JJ domain/NN ./. 
We/PRP hypothesize/VBP that/IN this/DT 110-kDa/JJ protein/NN may/MD be/VB a/DT functionally/RB important/JJ B/NN cell-specific/JJ co-activator/NN of/IN A-MYB/NN ./. 
UI/LS -/: 97444155/CD 
TI/LS -/: Transcription/NN factor/NN Egr-1/NN activity/NN down-regulates/VBZ Fas/NN and/CC CD23/NN expression/NN in/IN B/NN cells/NNS ./. 
AB/LS -/: Activation/NN of/IN mature/JJ B/NN cells/NNS via/IN Ag/NN receptor/NN cross-linking/NN induces/VBZ transient/JJ expression/NN of/IN the/DT transcription/NN factor/NN Egr-1/NN ./. 
Although/IN the/DT activating/VBG signals/NNS leading/VBG to/TO Egr-1/NN induction/NN have/VBP been/VBN studied/VBN extensively/RB ,/, little/JJ is/VBZ known/VBN about/IN the/DT genes/NNS that/WDT are/VBP placed/VBN further/RBR downstream/RB within/IN this/DT activation/NN cascade/NN and/CC that/WDT are/VBP transcriptionally/RB regulated/VBN by/IN Egr-1/NN ./. 
To/TO identify/VB such/JJ target/NN genes/NNS ,/, we/PRP established/VBD Egr-1-overexpressing/JJ transfectants/NNS from/IN the/DT murine/JJ B/NN cell/NN line/NN K46/NN and/CC from/IN human/JJ Ramos/NN B/NN cells/NNS ./. 
All/DT clones/NNS derived/VBN from/IN K46/NN B/NN cells/NNS showed/VBD increased/VBN expression/NN of/IN CD44/NN ./. 
Most/RBS interestingly/RB ,/, expression/NN of/IN CD95/NN (/( Fas/Apo-1/NN )/) and/CC of/IN CD23/NN was/VBD down-regulated/VBN in/IN all/DT K46/NN transfectants/NNS ./. 
As/IN a/DT consequence/NN ,/, they/PRP became/VBD resistant/JJ to/TO apoptosis/NN induced/VBN by/IN anti-CD95/JJ Ab/NN treatment/NN ./. 
Similarly/RB ,/, the/DT Egr-1-expressing/JJ Ramos/NN cells/NNS showed/VBD reduced/VBN levels/NNS of/IN CD95/NN expression/NN ./. 
Thus/RB ,/, Egr-1/NN seems/VBZ to/TO control/VB the/DT expression/NN of/IN downstream/JJ target/NN genes/NNS not/RB only/RB as/IN a/DT transcriptional/JJ activator/NN ,/, but/CC also/RB as/IN a/DT repressor/NN molecule/NN ./. 
In/IN B/NN cells/NNS ,/, Egr-1/NN therefore/RB plays/VBZ a/DT critical/JJ role/NN in/IN integrating/VBG the/DT short-lived/JJ signal/NN delivered/VBN by/IN triggering/NN of/IN the/DT Ag/NN receptor/NN into/IN phenotypic/JJ changes/NNS ,/, including/VBG repression/NN of/IN CD95/NN and/CC CD23/NN transcription/NN ./. 
UI/LS -/: 98104455/CD 
TI/LS -/: Regulation/NN of/IN NF-kappa/NN B/NN activity/NN by/IN I/NN kappa/NN B/NN alpha/NN and/CC I/NN kappa/NN B/NN beta/NN stability/NN ./. 
AB/LS -/: Transcription/NN factor/NN NF-kappa/NN B/NN must/MD be/VB released/VBN from/IN cytoplasmic/JJ inhibitory/JJ molecules/NNS (/( I/NN kappa/NN Bs/NNS )/) in/IN order/NN to/TO move/VB to/TO the/DT nucleus/NN and/CC to/TO activate/VB its/PRP$ target/NN genes/NNS ./. 
Little/JJ is/VBZ known/VBN about/IN the/DT mechanisms/NNS regulating/VBG the/DT maintenance/NN of/IN constitutive/JJ nuclear/JJ NF-kappa/NN B/NN in/IN some/DT cell-types/NNS and/CC of/IN sustained/JJ nuclear/JJ NF-kappa/NN B/NN activity/NN after/IN stimulation/NN ./. 
Increased/VBN turnover/NN has/VBZ been/VBN implicated/VBN in/IN the/DT regulation/NN of/IN constitutive/JJ NF-kappa/NN B/NN activity/NN in/IN mature/JJ B/NN cells/NNS ./. 
We/PRP therefore/RB compared/VBD the/DT turnover/NN of/IN I/NN kappa/NN B/NN alpha/NN and/CC I/NN kappa/NN B/NN beta/NN in/IN mature/JJ B/NN cells/NNS and/CC HeLa/NN cells/NNS ./. 
Both/DT proteins/NNS display/VBP a/DT high/JJ turnover/NN in/IN B/NN cells/NNS although/IN I/NN kappa/NN B/NN beta/NN is/VBZ considerably/RB more/RBR stable/JJ than/IN I/NN kappa/NN B/NN alpha/NN ./. 
The/DT half-life/NN of/IN both/DT inhibitors/NNS is/VBZ increased/VBN in/IN HeLa/NN cells/NNS ./. 
In/IN contrast/NN ,/, all/DT other/JJ NF-kappa/NN B/I/NN kappa/NN B/NN molecules/NNS tested/VBN are/VBP relatively/RB stable/JJ in/IN both/DT cell-types/NNS ./. 
The/DT elevated/JJ turnover/NN of/IN endogenous/JJ I/NN kappa/NN B/NN alpha/NN in/IN Namalwa/NN cells/NNS is/VBZ inhibited/VBN by/IN a/DT proteasome/NN inhibitor/NN and/CC thus/RB seems/VBZ to/TO be/VB driven/VBN by/IN the/DT same/JJ degradation/NN machinery/NN as/IN the/DT slower/JJR turnover/NN in/IN non-B/JJ cells/NNS ./. 
Furthermore/RB ,/, we/PRP investigated/VBD the/DT processes/NNS involved/VBN in/IN persistent/JJ activation/NN of/IN NF-kappa/NN B/NN ./. 
TNF-alpha/NN signaling/NN leads/VBZ to/TO a/DT rapid/JJ depletion/NN of/IN cellular/JJ I/NN kappa/NN B/NN beta/NN pools/NNS ./. 
I/NN kappa/NN B/NN alpha/NN is/VBZ efficiently/RB resynthesized/VBN whereas/IN I/NN kappa/NN B/NN beta/NN levels/NNS stay/VBP low/JJ for/IN a/DT prolonged/JJ time/NN ./. 
NF-kappa/NN B/NN binding/NN activity/NN can/MD be/VB detected/VBN for/IN several/JJ hours/NNS after/IN stimulation/NN ./. 
We/PRP found/VBD that/IN removal/NN of/IN the/DT TNF-alpha/NN containing/NN medium/NN causes/VBZ a/DT rapid/JJ decrease/NN in/IN nuclear/JJ NF-kappa/NN B/NN ./. 
A/DT phosphoform/NN of/IN newly/RB synthesized/VBN I/NN kappa/NN B/NN alpha/NN is/VBZ visible/JJ when/WRB degradation/NN by/IN the/DT proteasome/NN is/VBZ inhibited/VBN and/CC new/JJ I/NN kappa/NN B/NN alpha/NN displays/VBZ the/DT same/JJ properties/NNS regarding/VBG phosphorylation/NN and/CC degradation/NN in/IN response/NN to/TO a/DT second/JJ inducer/NN ./. 
There/EX is/VBZ no/DT significant/JJ difference/NN in/IN the/DT turnover/NN of/IN pre-/JJ and/CC post-inductive/JJ I/NN kappa/NN B/NN alpha/NN ./. 
These/DT observations/NNS suggest/VBP that/IN resynthesis/NN of/IN I/NN kappa/NN B/NN alpha/NN and/CC removal/NN of/IN the/DT stimulus/NN are/VBP obligatory/JJ steps/NNS for/IN the/DT inactivation/NN of/IN nuclear/JJ NF/NN kappa/NN B/NN ./. 
UI/LS -/: 98079330/CD 
TI/LS -/: Selection/NN of/IN a/DT diverse/JJ TCR/NN repertoire/NN in/IN response/NN to/TO an/DT Epstein-Barr/JJ virus-encoded/JJ transactivator/NN protein/NN BZLF1/NN by/IN CD8+/JJ cytotoxic/JJ T/NN lymphocytes/NNS during/IN primary/JJ and/CC persistent/JJ infection/NN ./. 
AB/LS -/: We/PRP investigated/VBD the/DT CD8+/JJ cytotoxic/JJ T/NN lymphocyte/NN (/( CTL/NN )/) repertoire/NN to/TO an/DT HLA/NN B8-restricted/JJ peptide/NN ,/, RAKFKQLLQ/NN ,/, located/JJ in/IN the/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) immediate-early/JJ protein/NN ,/, BZLF1/NN ./. 
Repertoire/JJ selection/NN was/VBD monitored/VBN by/IN determining/VBG the/DT TCR/NN beta/NN chain/NN sequences/NNS of/IN RAKFKQLLQ-specific/JJ CTL/NN established/VBN from/IN primary/JJ infected/JJ and/CC healthy/JJ virus/NN carriers/NNS ./. 
PCR/NN analysis/NN of/IN spontaneous/JJ EBV-transformed/JJ lymphoblastoid/JJ cell/NN lines/NNS (/( LCL/NNS )/) from/IN three/CD individuals/NNS with/IN primary/JJ infection/NN showed/VBD that/IN two/CD were/VBD infected/VBN with/IN type/NN A/NN and/CC one/CD with/IN type/NN B/NN EBV/NN ./. 
Polyclonal/JJ and/CC clonal/JJ CTL/NN that/WDT were/VBD generated/VBN by/IN stimulating/VBG peripheral/JJ blood/NN mononuclear/JJ cells/NNS with/IN an/DT HLA/NN B8+/JJ homozygous/JJ LCL/NNS lysed/JJ T/NN cell/NN blasts/NNS pulsed/JJ with/IN the/DT peptide/NN ,/, RAKFKQLLQ/NN ;/: lysis/NN of/IN certain/JJ HLA/NN B8+/JJ LCL/NNS targets/NNS was/VBD associated/VBN with/IN the/DT abundance/NN of/IN BZLF1/NN transcripts/NNS ./. 
TCR/NN beta/NN analysis/NN showed/VBD that/IN while/IN there/EX was/VBD loop/NN length/NN restriction/NN in/IN the/DT putative/JJ peptide/NN contact/NN site/NN of/IN all/DT responding/VBG beta/NN chains/NNS ,/, diverse/JJ and/CC unique/JJ (/( non-recurrent/JJ )/) TCR/NN beta/NN clonotypes/NNS were/VBD selected/VBN in/IN individuals/NNS during/IN primary/JJ infection/NN and/CC continued/VBD to/TO emerge/VB after/IN long-term/JJ virus/NN exposure/NN ./. 
TCR-contact/JJ site/NN heterogeneity/NN was/VBD excluded/VBN as/IN the/DT selective/JJ force/NN in/IN diversity/NN generation/NN since/IN the/DT epitope-encoded/JJ sequences/NNS were/VBD found/VBN to/TO be/VB identical/JJ within/IN endogenous/JJ virus/NN isolates/NNS ./. 
In/IN this/DT first/JJ study/NN of/IN TCR/NN repertoire/NN selection/NN for/IN an/DT EBV/NN lytic/JJ antigen/NN ,/, a/DT BZLF1-reactive/JJ component/NN of/IN diverse/JJ clonotypes/NNS was/VBD identified/VBN in/IN primary/JJ type/NN A/NN or/CC type/NN B/NN EBV/NN infection/NN which/WDT was/VBD sustained/JJ in/IN the/DT EBV-specific/JJ memory/NN response/NN throughout/IN life-long/JJ infection/NN ./. 
This/DT diversity/NN selection/NN is/VBZ likely/JJ to/TO play/VB a/DT critical/JJ role/NN in/IN maintaining/VBG a/DT balanced/JJ viral/JJ load/NN throughout/IN EBV/NN persistence/NN ./. 
UI/LS -/: 98062932/CD 
TI/LS -/: Molecular/JJ mechanisms/NNS of/IN anoxia/reoxygenation-induced/JJ neutrophil/NN adherence/NN to/TO cultured/VBN endothelial/JJ cells/NNS ./. 
AB/LS -/: The/DT objectives/NNS of/IN this/DT study/NN were/VBD to/TO (/( 1/LS )/) determine/VB the/DT time/NN course/NN of/IN neutrophil/NN adhesion/NN to/TO monolayers/NNS of/IN human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS (/( HUVECs/NNS )/) that/WDT were/VBD exposed/VBN to/TO 60/CD minutes/NNS of/IN anoxia/NN followed/VBN by/IN 30/CD to/TO 600/CD minutes/NNS of/IN reoxygenation/NN and/CC (/( 2/LS )/) define/VB the/DT mechanisms/NNS responsible/JJ for/IN both/CC the/DT early/JJ (/( minutes/NNS )/) and/CC late/JJ (/( hours/NNS )/) hyperadhesivity/NN of/IN postanoxic/JJ HUVECs/NNS to/TO human/JJ neutrophils/NNS ./. 
The/DT results/NNS clearly/RB demonstrate/VBP that/IN anoxia/reoxygenation/NN (/( A/R/NN )/) leads/VBZ to/TO a/DT biphasic/JJ increase/NN in/IN neutrophil/NN adhesion/NN to/TO HUVECs/NNS ,/, with/IN peak/NN responses/NNS occurring/VBG at/IN 30/CD minutes/NNS (/( phase/NN 1/CD )/) and/CC 240/CD minutes/NNS (/( phase/NN 2/CD )/) after/IN reoxygenation/NN ./. 
Oxypurinol/NN and/CC catalase/NN inhibited/VBD phase-1/JJ adhesion/NN ,/, suggesting/VBG a/DT role/NN for/IN xanthine/NN oxidase/NN and/CC H2O2/NN ./. 
In/IN comparison/NN ,/, platelet/NN activating/NN factor/NN (/( PAF/NN )/) contributed/VBD to/TO both/CC phases/NNS of/IN neutrophil/NN adhesion/NN ./. 
Anti-intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN )/) and/CC anti-P-selectin/JJ antibodies/NNS (/( monoclonal/JJ antibodies/NNS [/( mAbs/NNS ]/) )/) attenuated/VBD phase-1/JJ neutrophil/NN adhesion/NN ,/, consistent/JJ with/IN roles/NNS for/IN constitutively/RB expressed/VBN ICAM-1/NN and/CC enhanced/VBN surface/NN expression/NN of/IN preformed/JJ P-selectin/NN ./. 
Phase-2/NN neutrophil/NN adhesion/NN was/VBD attenuated/VBN by/IN an/DT anti-E-selectin/JJ mAb/NN ,/, indicating/VBG a/DT dominant/JJ role/NN of/IN this/DT adhesion/NN molecule/NN in/IN the/DT late/JJ phase/NN response/NN ./. 
Pretreatment/NN with/IN actinomycin/NN D/NN and/CC cycloheximide/NN or/CC with/IN competing/VBG ds-oligonucleotides/NNS containing/VBG the/DT nuclear/JJ factor-kappa/NN B/NN or/CC activator/NN protein-1/NN cognate/NN DNA/NN sequences/NNS significantly/RB attenuated/VBD phase-2/NN response/NN ,/, suggesting/VBG a/DT role/NN for/IN de/FW novo/FW macromolecule/NN synthesis/NN ./. 
Surface/NN expression/NN of/IN ICAM-1/NN ,/, P-selectin/NN ,/, and/CC E-selectin/NN on/IN HUVECs/NNS correlated/VBD with/IN the/DT phase-1/JJ and/CC -2/CD neutrophil/NN adhesion/NN responses/NNS ./. 
Collectively/RB ,/, these/DT findings/NNS indicate/VBP that/IN A/R/NN elicits/VBZ a/DT two-phase/JJ neutrophil-endothelial/JJ cell/NN adhesion/NN response/NN that/WDT involves/VBZ transcription-independent/JJ and/CC transcription-dependent/JJ surface/NN expression/NN of/IN different/JJ endothelial/JJ cell/NN adhesion/NN molecules/NNS ./. 
UI/LS -/: 98031743/CD 
TI/LS -/: Characterization/NN of/IN CD40/NN signaling/NN determinants/NNS regulating/VBG nuclear/JJ factor-kappa/NN B/NN activation/NN in/IN B/NN lymphocytes/NNS ./. 
AB/LS -/: CD40/NN signaling/NN to/TO B/NN cells/NNS is/VBZ important/JJ for/IN generating/VBG an/DT effective/JJ humoral/JJ immune/JJ response/NN ./. 
CD40/NN ligation/NN leads/VBZ to/TO B/NN cell/NN activation/NN events/NNS such/JJ as/IN proliferation/NN ,/, Ig/NN secretion/NN ,/, isotype/NN switching/NN ,/, and/CC up-regulation/NN of/IN cell/NN surface/NN molecules/NNS ,/, as/RB well/RB as/IN the/DT generation/NN of/IN memory/NN B/NN cells/NNS ./. 
Many/JJ of/IN these/DT events/NNS are/VBP dependent/JJ upon/IN the/DT ability/NN of/IN CD40/NN to/TO activate/VB the/DT transcription/NN factor/NN NF-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ./. 
To/TO define/VB the/DT CD40/NN signaling/NN components/NNS upstream/JJ of/IN NF-kappa/NN B/NN activation/NN and/CC the/DT functional/JJ consequences/NNS downstream/JJ of/IN NF-kappa/NN B/NN activation/NN ,/, we/PRP examined/VBD mouse/NN B/NN cell/NN transfectants/NNS expressing/VBG wild-type/JJ or/CC mutant/JJ human/JJ CD40/NN ./. 
Analysis/NN of/IN CD40/NN cytoplasmic/JJ domain/NN truncation/NN and/CC point/NN mutants/NNS defined/VBD a/DT 10-amino/JJ acid/NN CD40/NN cytoplasmic/JJ signaling/NN determinant/NN required/VBN for/IN NF-kappa/NN B/NN activation/NN ./. 
A/DT threonine/NN residue/NN at/IN position/NN 234/CD ,/, previously/RB shown/VBN to/TO be/VB important/JJ for/IN CD40/NN association/NN with/IN TNF/NN receptor-associated/JJ factor/NN 2/CD (/( TRAF2/NN )/) ,/, TRAF3/NN ,/, and/CC TRAF5/NN ,/, was/VBD not/RB required/VBN for/IN NF-kappa/NN B/NN activation/NN ./. 
This/DT suggests/VBZ that/IN in/IN B/NN cells/NNS ,/, CD40-induced/JJ NF-kappa/NN B/NN activation/NN can/MD occur/VB independently/RB of/IN TRAF2/NN and/CC TRAF5/NN association/NN ./. 
NF-kappa/NN B/NN activation/NN was/VBD independent/JJ of/IN the/DT transmembrane/JJ domain/NN of/IN CD40/NN ,/, suggesting/VBG that/IN it/PRP is/VBZ independent/JJ of/IN p23/NN ,/, a/DT molecule/NN that/WDT associates/VBZ with/IN CD40/NN in/IN a/DT region/NN other/JJ than/IN the/DT cytoplasmic/JJ domain/NN ./. 
Proteasome-dependent/JJ inhibitory/JJ kappa/NN B/NN alpha/NN (/( I/NN kappa/NN B/NN alpha/NN )/) and/CC I/NN kappa/NN B/NN beta/NN degradation/NN occurred/VBD downstream/JJ of/IN CD40/NN ligation/NN and/CC preceded/VBD CD40-mediated/JJ NF-kappa/NN B/NN nuclear/JJ translocation/NN ./. 
CD40-/NN or/CC pervanadate-mediated/JJ I/NN kappa/NN B/NN tyrosine/NN phosphorylation/NN was/VBD not/RB detected/VBN ./. 
NF-kappa/NN B/NN activation/NN correlated/VBD with/IN the/DT ability/NN of/IN CD40/NN to/TO induce/VB Ab/NN secretion/NN and/CC the/DT up-regulation/NN of/IN ICAM-1/NN and/CC LFA-1/NN ./. 
However/RB ,/, NF-kappa/NN B/NN activation/NN was/VBD insufficient/JJ for/IN CD40-mediated/JJ up-regulation/NN of/IN B7-1/NN ,/, Fas/NN ,/, and/CC CD23/NN ./. 
UI/LS -/: 98019162/CD 
TI/LS -/: CD30-dependent/JJ degradation/NN of/IN TRAF2/NN :/: implications/NNS for/IN negative/JJ regulation/NN of/IN TRAF/NN signaling/NN and/CC the/DT control/NN of/IN cell/NN survival/NN ./. 
AB/LS -/: CD30/NN is/VBZ a/DT cell-surface/NN receptor/NN that/WDT can/MD augment/VB lymphocyte/NN activation/NN and/CC survival/NN through/IN its/PRP$ ability/NN to/TO induce/VB the/DT transcription/NN factor/NN NF-kappaB/NN ./. 
CD30/NN ,/, however/RB ,/, has/VBZ also/RB been/VBN implicated/VBN in/IN the/DT induction/NN of/IN apoptotic/JJ cell/NN death/NN of/IN lymphocytes/NNS ./. 
Here/RB we/PRP show/VBP that/IN one/CD of/IN the/DT effects/NNS of/IN CD30/NN signal/NN transduction/NN is/VBZ to/TO render/VB cells/NNS sensitive/JJ to/TO apoptosis/NN induced/VBN by/IN the/DT type/NN 1/CD tumor/NN necrosis/NN factor/NN receptor/NN (/( TNFR1/NN )/) ./. 
This/DT sensitization/NN is/VBZ dependent/JJ on/IN the/DT TRAF-binding/NN sites/NNS within/IN the/DT CD30/NN cytoplasmic/JJ domain/NN ./. 
One/CD of/IN the/DT proteins/NNS that/WDT binds/VBZ to/TO these/DT sites/NNS is/VBZ TRAF2/NN ,/, a/DT signal/NN transduction/NN molecule/NN that/WDT is/VBZ also/RB utilized/VBN by/IN TNFR1/NN to/TO mediate/VB the/DT activation/NN of/IN several/JJ downstream/JJ kinases/NNS and/CC transcription/NN factors/NNS ./. 
During/IN CD30/NN signal/NN transduction/NN ,/, we/PRP found/VBD that/IN binding/NN of/IN TRAF2/NN to/TO the/DT cytoplasmic/JJ domain/NN of/IN CD30/NN results/VBZ in/IN the/DT rapid/JJ depletion/NN of/IN TRAF2/NN and/CC the/DT associated/VBN protein/NN TRAF1/NN by/IN proteolysis/NN ./. 
These/DT data/NNS suggest/VBP a/DT model/NN in/IN which/WDT CD30/NN limits/VBZ its/PRP$ own/JJ ability/NN to/TO transduce/VB cell/NN survival/NN signals/NNS through/IN signal-coupled/JJ depletion/NN of/IN TRAF2/NN ./. 
Depletion/NN of/IN intracellular/JJ TRAF2/NN and/CC its/PRP$ coassociated/JJ proteins/NNS also/RB increased/VBD the/DT sensitivity/NN of/IN the/DT cell/NN to/TO undergoing/VBG apoptosis/NN during/IN activation/NN of/IN death-inducing/JJ receptors/NNS such/JJ as/IN TNFR1/NN ./. 
Consistent/JJ with/IN this/DT hypothesis/NN ,/, expression/NN of/IN a/DT dominant-negative/JJ form/NN of/IN TRAF2/NN was/VBD found/VBN to/TO potentiate/VB TNFR1-mediated/JJ death/NN ./. 
These/DT studies/NNS provide/VBP a/DT potential/JJ mechanism/NN through/IN which/WDT CD30/NN ,/, as/RB well/RB as/IN other/JJ TRAF-binding/JJ members/NNS of/IN the/DT TNFR/NN superfamily/NN ,/, can/MD negatively/RB regulate/VB cell/NN survival/NN ./. 
UI/LS -/: 97467112/CD 
TI/LS -/: Analysis/NN of/IN myeloid-associated/JJ genes/NNS in/IN human/JJ hematopoietic/JJ progenitor/NN cells/NNS ./. 
AB/LS -/: The/DT distribution/NN of/IN myeloid/JJ lineage-associated/JJ cytokine/NN receptors/NNS and/CC lysosomal/JJ proteins/NNS was/VBD analyzed/VBN in/IN human/JJ CD34+/JJ cord/NN blood/NN cell/NN (/( CB/NN )/) subsets/NNS at/IN different/JJ stages/NNS of/IN myeloid/JJ commitment/NN by/IN reverse-transcriptase/NN polymerase/NN chain/NN reaction/NN (/( RT-PCR/NN )/) ./. 
The/DT highly/RB specific/JJ granulomonocyte-associated/JJ lysosomal/JJ proteins/NNS myeloperoxidase/NN (/( MPO/NN )/) and/CC lysozyme/NN (/( LZ/NN )/) ,/, as/RB well/RB as/IN the/DT transcription/NN factor/NN PU.1/NN ,/, were/VBD already/RB detectable/JJ in/IN the/DT most/RBS immature/JJ CD34+Thy-1+/JJ subset/NN ./. 
Messenger/NN RNA/NN (/( mRNA/NN )/) levels/NNS for/IN the/DT granulocyte-colony/NN stimulating/NN factor/NN (/( G-CSF/NN )/) receptor/NN ,/, granulocyte-macrophage/JJ (/( GM/NN )/) -CSF/NN receptor/NN alpha/NN subunit/NN and/CC tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) receptors/NNS I/CD (/( p55/NN )/) and/CC II/CD (/( p75/NN )/) were/VBD also/RB detected/VBN in/IN this/DT subset/NN in/IN addition/NN to/TO c-kit/NN and/CC flt-3/NN ,/, receptors/NNS known/VBN to/TO be/VB expressed/VBN on/IN progenitor/NN cells/NNS ./. 
By/IN contrast/NN ,/, the/DT monocyte-macrophage/JJ colony/NN stimulating/NN factor/NN (/( M-CSF/NN )/) receptor/NN was/VBD largely/RB absent/JJ at/IN this/DT stage/NN and/CC in/IN the/DT CD34+Thy-1-CD45RA-/JJ subsets/NNS ./. 
The/DT M-CSF/NN receptor/NN was/VBD first/RB detectable/JJ in/IN the/DT myeloid-committed/JJ CD34+Thy-l-CD45RA+/JJ subset/NN ./. 
All/DT other/JJ molecules/NNS studied/VBN were/VBD found/VBN to/TO be/VB expressed/VBN at/IN this/DT stage/NN of/IN differentiation/NN ./. 
Different/JJ cocktails/NNS of/IN the/DT identified/VBN ligands/NNS were/VBD added/VBN to/TO sorted/VBN CD34+Thy-1+/JJ single/JJ cells/NNS ./. 
Low/JJ proliferative/JJ capacity/NN was/VBD observed/VBN after/IN 1/CD week/NN in/IN culture/NN in/IN the/DT presence/NN of/IN stem/NN cell/NN factor/NN (/( SCF/NN )/) +/JJ Flt-3/NN ligand/NN (/( FL/NN )/) +/JJ G-CSF/NN ./. 
Addition/NN of/IN GM-CSF/NN to/TO this/DT basic/JJ cocktail/NN consistently/RB increased/VBD the/DT clonogenic/JJ capacity/NN of/IN single/JJ CD34+Thy-1+/JJ cells/NNS ,/, and/CC this/DT effect/NN was/VBD further/RB enhanced/VBN (/( up/RB to/TO 72.3/CD +/-/CC 4.3/CD %/NN on/IN day/NN 7/CD )/) by/IN the/DT inclusion/NN of/IN TNF-alpha/NN ./. 
In/IN conclusion/NN ,/, the/DT presence/NN of/IN myeloid-associated/JJ growth/NN factor/NN receptor/NN transcripts/NNS in/IN CD34+/JJ CB/NN subsets/NNS does/VBZ not/RB discriminate/VB the/DT various/JJ stages/NNS of/IN differentiation/NN ,/, with/IN the/DT exception/NN of/IN the/DT M-CSF/NN receptor/NN ./. 
In/IN addition/NN ,/, we/PRP show/VBP that/IN TNF-alpha/NN is/VBZ a/DT potent/JJ costimulatory/JJ factor/NN of/IN the/DT very/RB immature/JJ CD34+Thy-1+/JJ CB/NN subset/NN ./. 
UI/LS -/: 98000963/CD 
TI/LS -/: Induction/NN of/IN endothelial/JJ cell/NN surface/NN adhesion/NN molecules/NNS by/IN tumor/NN necrosis/NN factor/NN is/VBZ blocked/VBN by/IN protein/NN tyrosine/NN phosphatase/NN inhibitors/NNS :/: role/NN of/IN the/DT nuclear/JJ transcription/NN factor/NN NF-kappa/NN B/NN ./. 
AB/LS -/: Recent/JJ studies/NNS from/IN our/PRP$ laboratory/NN have/VBP indicated/VBN that/IN protein/NN tyrosine/NN phosphatase/NN (/( PTPase/NN )/) inhibitors/NNS can/MD down-modulate/VB the/DT tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) -mediated/JJ activation/NN of/IN the/DT nuclear/JJ transcription/NN factor/NN NF-kappa/NN B/NN in/IN ML-1a/NN ,/, a/DT monocytic/JJ cell/NN line/NN (/( Singh/NNP and/CC Aggarwal/NNP ,/, J./NNP Biol./NNP Chem./NNP 1995/CD :/: 270/CD :/: 10631/CD )/) ./. 
Since/IN TNF/NN is/VBZ one/CD of/IN the/DT major/JJ inducers/NNS of/IN various/JJ adhesion/NN molecules/NNS in/IN human/JJ endothelial/JJ cells/NNS and/CC their/PRP$ expression/NN is/VBZ known/VBN to/TO require/VB the/DT activation/NN of/IN NF-kappa/NN B/NN ,/, we/PRP examined/VBD the/DT effect/NN of/IN PTPase/NN inhibitors/NNS on/IN the/DT TNF-mediated/JJ induction/NN of/IN intracellular/JJ adhesion/NN molecule/NN (/( ICAM/NN )/) -1/CD ,/, vascular/JJ cell/NN adhesion/NN molecule/NN (/( VCAM/NN )/) -1/CD and/CC endothelial/JJ leukocyte/NN adhesion/NN molecule/NN (/( ELAM/NN )/) -1/CD ./. 
Like/IN ML-1a/NN ,/, human/JJ dermal/JJ microvessel/NN endothelial/JJ cells/NNS (/( MVEC/NNS )/) treated/VBN with/IN TNF/NN rapidly/RB activated/VBD (/( within/IN 30/CD min/NN )/) NF-kappa/NN B/NN ;/: this/DT effect/NN was/VBD completely/RB abolished/VBN by/IN co-treatment/NN with/IN phenylarsine/NN oxide/NN (/( PAO/NN )/) ,/, a/DT specific/JJ inhibitor/NN of/IN PTPase/NN ./. 
The/DT induction/NN of/IN ICAM-1/NN ,/, VCAM-1/NN ,/, and/CC ELAM-1/NN by/IN TNF/NN in/IN MVEC/NNS occurred/VBD within/IN 6/CD h/NN and/CC was/VBD also/RB completely/RB down-regulated/VBN by/IN PAO/NN in/IN a/DT dose-dependent/JJ manner/NN ./. 
PAO/NN was/VBD found/VBN to/TO be/VB effective/JJ even/RB when/WRB added/VBN 3/CD h/NN after/IN TNF/NN ,/, suggesting/VBG a/DT rapid/JJ mode/NN of/IN action/NN of/IN this/DT inhibitor/NN ./. 
Besides/IN PAO/NN ,/, other/JJ inhibitors/NNS of/IN PTPase/NN ,/, including/VBG pervanadate/NN and/CC diamide/NN ,/, also/RB blocked/VBD TNF-dependent/JJ NF-kappa/NN B/NN activation/NN and/CC induction/NN of/IN all/PDT the/DT three/CD adhesion/NN proteins/NNS ./. 
Consistent/JJ with/IN these/DT results/NNS ,/, the/DT attachment/NN of/IN monocytes/NNS to/TO MVEC/NNS was/VBD also/RB blocked/VBN by/IN the/DT PTPase/NN inhibitors/NNS ./. 
Thus/RB ,/, overall/RB ,/, our/PRP$ results/NNS demonstrate/VBP that/IN a/DT PTPase/NN is/VBZ involved/VBN either/CC directly/RB or/CC indirectly/RB in/IN the/DT pathway/NN leading/VBG to/TO the/DT induction/NN of/IN endothelial/JJ cell/NN adhesion/NN molecules/NNS by/IN TNF/NN ./. 
Because/IN of/IN their/PRP$ role/NN in/IN cell/NN adhesion/NN ,/, PTPase/NN may/MD provide/VB a/DT novel/JJ target/NN of/IN drug/NN development/NN for/IN treatment/NN of/IN inflammation/NN ,/, atherogenesis/NN ,/, and/CC tumor/NN metastasis/NN ./. 
UI/LS -/: 98018275/CD 
TI/LS -/: Regulation/NN of/IN nuclear/JJ factor-kappa/NN B/NN and/CC its/PRP$ inhibitor/NN I/NN kappa/NN B-alpha/MAD-3/NN in/IN monocytes/NNS by/IN Mycobacterium/NN tuberculosis/NN and/CC during/IN human/JJ tuberculosis/NN ./. 
AB/LS -/: Blood/NN monocytes/NNS from/IN patients/NNS with/IN active/JJ tuberculosis/NN are/VBP activated/VBN in/FW vivo/FW ,/, as/IN evidenced/VBN by/IN an/DT increase/NN in/IN the/DT stimulated/VBN release/NN of/IN proinflammatory/JJ cytokines/NNS ,/, such/JJ as/IN TNF-alpha/NN ,/, and/CC the/DT spontaneous/JJ expression/NN of/IN IL-2R/NN ./. 
Further/RB ,/, monocytes/NNS from/IN patients/NNS demonstrate/VBP an/DT augmented/JJ susceptibility/NN to/TO a/DT productive/JJ infection/NN with/IN HIV-1/NN in/FW vitro/FW ./. 
Mycobacterium/NN tuberculosis/NN and/CC its/PRP$ components/NNS are/VBP strong/JJ signals/NNS to/TO activate/VB monocytes/NNS to/TO production/NN of/IN cytokines/NNS ./. 
In/IN this/DT study/NN we/PRP examined/VBD the/DT basis/NN of/IN activation/NN of/IN monocytes/NNS during/IN active/JJ tuberculosis/NN and/CC by/IN M./NN tuberculosis/NN ./. 
We/PRP found/VBD a/DT constitutive/JJ degradation/NN of/IN I/NN kappa/NN B-alpha/NN ,/, the/DT major/JJ cytoplasmic/JJ inhibitor/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ,/, in/IN freshly/RB isolated/VBN PBMC/NN and/CC monocytes/NNS from/IN patients/NNS with/IN tuberculosis/NN ./. 
In/IN contrast/NN ,/, I/NN kappa/NN B-alpha/NN levels/NNS in/IN PBMC/NN and/CC monocytes/NNS from/IN healthy/JJ subjects/NNS or/CC from/IN patients/NNS with/IN nontuberculous/JJ pulmonary/JJ conditions/NNS were/VBD intact/JJ ./. 
Further/RB ,/, by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN ,/, NF-kappa/NN B/NN was/VBD activated/VBN in/IN monocytes/NNS from/IN tuberculous/JJ patients/NNS ./. 
The/DT expression/NN of/IN I/NN kappa/NN B-alpha/NN gene/NN ,/, which/WDT is/VBZ responsive/JJ to/TO activation/NN by/IN NF-kappa/NN B/NN ,/, was/VBD up-regulated/VBN in/IN PBMC/NN and/CC monocytes/NNS from/IN patients/NNS ,/, but/CC not/RB in/IN mononuclear/JJ cells/NNS from/IN healthy/JJ subjects/NNS or/CC those/DT with/IN nontuberculous/JJ lung/NN diseases/NNS ./. 
By/IN contrast/NN ,/, the/DT expression/NN of/IN other/JJ adherence-associated/JJ early/JJ genes/NNS ,/, such/JJ as/IN IL-8/NN and/CC IL-1/NN beta/NN ,/, was/VBD not/RB up-regulated/VBN in/IN PBMC/NN of/IN tuberculous/JJ patients/NNS ./. 
Further/RB ,/, M./NN tuberculosis/NN and/CC its/PRP$ tuberculin/NN ,/, purified/VBN protein/NN derivative/NN ,/, induced/VBD the/DT degradation/NN of/IN I/NN kappa/NN B-alpha/NN and/CC the/DT expression/NN of/IN I/NN kappa/NN B-alpha/NN mRNA/NN ,/, and/CC purified/VBN protein/NN derivative/NN induced/VBD the/DT activation/NN of/IN NF-kappa/NN B/NN in/IN monocytes/NNS ./. 
UI/LS -/: 97459950/CD 
TI/LS -/: Cooperation/NN of/IN Spi-1/PU.1/NN with/IN an/DT activated/VBN erythropoietin/NN receptor/NN inhibits/VBZ apoptosis/NN and/CC Epo-dependent/JJ differentiation/NN in/IN primary/JJ erythroblasts/NNS and/CC induces/VBZ their/PRP$ Kit/NN ligand-dependent/JJ proliferation/NN ./. 
AB/LS -/: Spi-1/PU.1/NN is/VBZ a/DT myeloid-/JJ and/CC B-cell/NN specific/JJ transcription/NN factor/NN which/WDT is/VBZ also/RB involved/VBN in/IN Friend/NN virus-induced/JJ murine/JJ erythroleukemia/NN ./. 
The/DT pre-leukemic/JJ phase/NN of/IN Friend/NN erythroleukemia/NN results/VBZ from/IN activation/NN of/IN the/DT erythropoietin/NN receptor/NN (/( EpoR/NN )/) by/IN the/DT spleen/NN focus/NN forming/VBG virus/NN (/( SFFV/NN )/) envelope/NN glycoprotein/NN ,/, followed/VBN by/IN the/DT emergence/NN of/IN leukemic/JJ clones/NNS characterized/VBN by/IN overexpression/NN of/IN Spi-1/NN and/CC mutation/NN of/IN the/DT p53/NN tumor/NN suppressor/NN gene/NN ./. 
We/PRP developed/VBD a/DT heterologous/JJ system/NN to/TO analyze/VB the/DT contribution/NN of/IN these/DT alterations/NNS to/TO the/DT induction/NN of/IN primary/JJ erythroblast/NN transformation/NN ./. 
Avian/JJ erythroblasts/NNS expressing/VBG the/DT activated/VBN mouse/NN EpoR/NN (/( R129C/NN )/) differentiated/VBD into/IN erythrocytes/NNS in/IN response/NN to/TO hEpo/NN ./. 
Expression/NN of/IN Spi-1/NN in/IN these/DT cells/NNS inhibited/VBD this/DT ability/NN to/TO differentiate/VB and/CC rescued/VBD the/DT cells/NNS from/IN the/DT apoptotic/JJ cell/NN death/NN program/NN normally/RB induced/VBN upon/IN hEpo/NN withdrawal/NN ./. 
Although/IN devoid/JJ of/IN any/DT effect/NN by/IN itself/PRP ,/, a/DT mutant/JJ p53/NN cooperated/VBD with/IN Spi-1/NN and/CC EpoR/NN (/( R129C/NN )/) to/TO reinforce/VB both/DT phenotypes/NNS ./. 
Analysis/NN of/IN erythroblasts/NNS co-expressing/VBG Spi-1/NN and/CC the/DT wild-type/JJ mouse/NN EpoR/NN showed/VBD that/IN differentiation/NN arrest/NN and/CC inhibition/NN of/IN apoptosis/NN depended/VBD on/IN specific/JJ cooperation/NN between/IN Spi-1/NN and/CC EpoR/NN (/( R129C/NN )/) ./. 
This/DT cooperation/NN was/VBD also/RB required/VBN to/TO induce/VB the/DT sustained/JJ proliferation/NN of/IN differentiation-blocked/JJ erythroblasts/NNS in/IN response/NN to/TO ligand/NN activation/NN of/IN the/DT endogenous/JJ tyrosine/NN kinase/NN receptor/NN c-Kit/NN ./. 
These/DT results/NNS show/VBP that/IN Spi-1/PU.1/NN requires/VBZ signals/NNS emanating/VBG from/IN specific/JJ cytokine/NN and/CC growth/NN factor/NN receptors/NNS to/TO affect/VB the/DT survival/NN ,/, proliferation/NN and/CC differentiation/NN control/NN of/IN primary/JJ erythroblasts/NNS ./. 
They/PRP also/RB suggest/VBP that/IN the/DT function/NN of/IN Spi-1/PU.1/NN in/IN the/DT late/JJ phase/NN of/IN Friend/NN leukemia/NN requires/VBZ specific/JJ signaling/NN from/IN the/DT gp55-modified/JJ EpoR/NN generated/VBN during/IN the/DT early/JJ phase/NN of/IN the/DT disease/NN ./. 
UI/LS -/: 97445684/CD 
TI/LS -/: The/DT role/NN of/IN Rel/NF-kappa/NN B/NN proteins/NNS in/IN viral/JJ oncogenesis/NN and/CC the/DT regulation/NN of/IN viral/JJ transcription/NN ./. 
AB/LS -/: Rel/NF-kappa/NN B/NN is/VBZ a/DT ubiquitous/JJ transcription/NN factor/NN that/WDT consists/VBZ of/IN multiple/JJ polypeptide/NN subunits/NNS ,/, and/CC is/VBZ subject/JJ to/TO complex/JJ regulatory/JJ mechanisms/NNS that/WDT involve/VBP protein-protein/JJ interactions/NNS ,/, phosphorylation/NN ,/, ubiquitination/NN ,/, proteolytic/JJ degradation/NN ,/, and/CC nucleocytoplasmic/JJ translocation/NN ./. 
The/DT sophisticated/JJ control/NN of/IN Rel/NF-kappa/NN B/NN activity/NN is/VBZ not/RB surprising/JJ since/IN this/DT transcription/NN factor/NN is/VBZ involved/VBN in/IN a/DT wide/JJ array/NN of/IN cellular/JJ responses/NNS to/TO extracellular/JJ cues/NNS ,/, associated/VBN with/IN growth/NN ,/, development/NN ,/, apoptosis/NN ,/, and/CC pathogen/NN invasion/NN ./. 
Thus/RB ,/, it/PRP is/VBZ not/RB unexpected/JJ that/IN this/DT versatile/JJ cellular/JJ homeostatic/JJ switch/NN would/MD be/VB affected/VBN by/IN a/DT variety/NN of/IN viral/JJ pathogens/NNS ,/, which/WDT have/VBP evolved/VBN mechanisms/NNS to/TO utilize/VB various/JJ aspects/NNS of/IN Rel/NF-kappa/NN B/NN activity/NN to/TO facilitate/VB their/PRP$ replication/NN ,/, cell/NN survival/NN and/CC possibly/RB evasion/NN of/IN immune/JJ responses/NNS ./. 
This/DT review/NN will/MD cover/VB the/DT molecular/JJ mechanisms/NNS that/WDT are/VBP utilized/VBN by/IN mammalian/JJ oncogenic/JJ viruses/NNS to/TO affect/VB the/DT activity/NN of/IN Rel/NF-kappa/NN B/NN transcription/NN factors/NNS and/CC the/DT role/NN of/IN Rel/NF-kappa/NN B/NN in/IN the/DT regulation/NN of/IN viral/JJ gene/NN expression/NN and/CC replication/NN ./. 
UI/LS -/: 98101496/CD 
TI/LS -/: Cellular/JJ and/CC molecular/JJ mechanisms/NNS of/IN IL-5/NN synthesis/NN in/IN atopic/JJ diseases/NNS :/: a/DT study/NN with/IN allergen-specific/JJ human/JJ helper/NN T/NN cells/NNS ./. 
AB/LS -/: BACKGROUND/NN :/: Cytokines/NNS produced/VBN by/IN helper/NN T/NN cells/NNS are/VBP intimately/RB involved/VBN in/IN chronic/JJ allergic/JJ diseases/NNS associated/VBN with/IN eosinophilic/JJ inflammation/NN ./. 
OBJECTIVE/NN :/: We/PRP investigated/VBD the/DT production/NN of/IN IL-5/NN ,/, a/DT potent/JJ growth/NN factor/NN and/CC chemotactic/JJ factor/NN for/IN eosinophils/NNS ,/, by/IN CD4+/JJ T/NN lymphocytes/NNS in/IN patients/NNS with/IN asthma/NN ./. 
METHODS/NNS :/: Allergen-specific/JJ T/NN cell/NN clones/NNS and/CC T/NN cell/NN hybridomas/NNS were/VBD established/VBN from/IN the/DT peripheral/JJ blood/NN lymphocytes/NNS of/IN patients/NNS with/IN asthma/NN ,/, and/CC the/DT responses/NNS to/TO various/JJ stimuli/NNS were/VBD determined/VBN ./. 
RESULTS/NNS :/: After/IN nonspecific/JJ stimulation/NN ,/, IL-5/NN production/NN by/IN CD4+/JJ T/NN cells/NNS from/IN both/CC atopic/JJ and/CC nonatopic/JJ subjects/NNS with/IN asthma/NN was/VBD significantly/RB enhanced/VBN compared/VBN with/IN that/DT by/IN cells/NNS from/IN healthy/JJ controls/NNS ./. 
Peripheral/JJ blood/NN mononuclear/JJ cells/NNS from/IN atopic/JJ asthma/NN patients/NNS both/CC proliferated/VBD and/CC produced/VBD IL-5/NN after/IN incubation/NN with/IN mite/JJ allergen/NN ,/, suggesting/VBG that/IN mite-specific/JJ helper/NN T/NN cells/NNS were/VBD involved/VBN in/IN the/DT eosinophilic/JJ inflammation/NN of/IN atopic/JJ asthma/NN ./. 
A/DT human/JJ IL-5/NN promoter/enhancer/NN luciferase/NN gene/NN construct/NN transfected/VBN into/IN IL-5-producing/JJ T/NN cell/NN clones/NNS was/VBD clearly/RB transcribed/VBN after/IN stimulation/NN ,/, indicating/VBG that/IN the/DT 515/CD base/NN pair/NN IL-5/NN gene/NN segment/NN upstream/JJ of/IN the/DT coding/VBG region/NN was/VBD sufficient/JJ to/TO respond/VB to/TO activating/VBG signals/NNS in/IN human/JJ helper/NN T/NN cells/NNS ./. 
The/DT same/JJ gene/NN segment/NN was/VBD not/RB transcribed/VBN in/IN IL-5-nonproducing/JJ T/NN cell/NN clones/NNS ,/, suggesting/VBG that/IN human/JJ T/NN cell/NN IL-5/NN synthesis/NN is/VBZ regulated/VBN at/IN the/DT transcriptional/JJ level/NN ./. 
Experiments/NNS with/IN T/NN cell/NN hybridomas/NNS confirmed/VBD these/DT findings/NNS and/CC suggested/VBD that/IN a/DT unique/JJ transcription/NN factor/NN may/MD be/VB essential/JJ for/IN human/JJ IL-5/NN gene/NN transcription/NN ./. 
CONCLUSION/NN :/: Enhanced/VBN IL-5/NN production/NN by/IN helper/NN T/NN cells/NNS seems/VBZ to/TO cause/VB the/DT eosinophilic/JJ inflammation/NN of/IN both/CC atopic/JJ and/CC nonatopic/JJ asthma/NN ./. 
Elucidation/NN of/IN IL-5-specific/JJ regulatory/JJ mechanisms/NNS may/MD facilitate/VB the/DT development/NN of/IN novel/JJ treatments/NNS for/IN allergic/JJ diseases/NNS associated/VBN with/IN eosinophilic/JJ inflammation/NN ./. 
UI/LS -/: 98077369/CD 
TI/LS -/: Cyclosporin/NN A/NN inhibits/VBZ monocyte/NN tissue/NN factor/NN activation/NN in/IN cardiac/JJ transplant/NN recipients/NNS ./. 
AB/LS -/: BACKGROUND/NN :/: Fibrin/NN deposition/NN and/CC thrombosis/NN have/VBP been/VBN implicated/VBN in/IN both/CC allograft/NN rejection/NN and/CC vasculopathy/NN after/IN cardiac/JJ transplantation/NN ./. 
Because/IN monocytes/NNS play/VBP a/DT pivotal/JJ role/NN in/IN the/DT pathophysiology/NN of/IN intravascular/JJ coagulation/NN activation/NN through/IN their/PRP$ ability/NN to/TO synthesize/VB tissue/NN factor/NN (/( TF/NN )/) ,/, we/PRP asked/VBD (/( 1/LS )/) whether/IN monocyte/NN TF/NN activation/NN occurs/VBZ in/IN cardiac/JJ transplant/NN recipients/NNS and/CC (/( 2/LS )/) whether/IN monocyte/NN TF/NN expression/NN is/VBZ affected/VBN by/IN treatment/NN with/IN cyclosporin/NN A/NN (/( CsA/NN )/) ./. 
METHODS/NNS AND/CC RESULTS/NNS :/: We/PRP measured/VBD levels/NNS of/IN TF/NN activity/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS and/CC highly/RB purified/VBN monocytes/macrophages/NNS from/IN 10/CD consecutive/JJ cardiac/JJ transplant/NN recipients/NNS and/CC 10/CD healthy/JJ control/JJ subjects/NNS ./. 
TF/NN activity/NN generated/VBN by/IN both/CC unstimulated/JJ and/CC endotoxin-stimulated/JJ cells/NNS was/VBD significantly/RB higher/JJR in/IN transplant/NN recipients/NNS than/IN in/IN control/JJ subjects/NNS (/( P/NN </JJR .05/CD )/) ./. 
Increased/VBN monocyte/NN TF/NN expression/NN in/IN transplant/NN recipients/NNS was/VBD shown/VBN to/TO be/VB adversely/RB affected/VBN by/IN treatment/NN with/IN CsA/NN :/: TF/NN induction/NN was/VBD markedly/RB reduced/VBN by/IN CsA/NN serum/NN concentrations/NNS reaching/VBG peak/JJ CsA/NN drug/NN levels/NNS ./. 
Inhibition/NN of/IN TF/NN induction/NN in/IN the/DT presence/NN of/IN high/JJ CsA/NN blood/NN concentrations/NNS was/VBD also/RB observed/VBN when/WRB stimulation/NN of/IN cells/NNS was/VBD performed/VBN with/IN interferon-gamma/NN or/CC interleukin-1beta/NN ./. 
As/IN shown/VBN by/IN reverse/JJ transcription-polymerase/NN chain/NN reaction/NN and/CC electrophoretic/JJ mobility/NN shift/NN assay/NN ,/, respectively/RB ,/, treatment/NN with/IN CsA/NN leads/VBZ to/TO decreased/VBN TF/NN mRNA/NN expression/NN and/CC reduced/VBN activation/NN of/IN the/DT NF-kappaB/NN transcription/NN factor/NN ,/, which/WDT is/VBZ known/VBN to/TO contribute/VB to/TO the/DT induction/NN of/IN the/DT TF/NN promotor/NN in/IN human/JJ monocytes/NNS ./. 
CONCLUSIONS/NNS :/: This/DT study/NN demonstrates/VBZ that/IN TF/NN activation/NN ,/, occurring/VBG in/IN mononuclear/JJ cells/NNS of/IN cardiac/JJ transplant/NN recipients/NNS ,/, is/VBZ inhibited/VBN by/IN treatment/NN with/IN CsA/NN ./. 
Inhibition/NN of/IN monocyte/NN TF/NN induction/NN by/IN CsA/NN may/MD contribute/VB to/TO its/PRP$ successful/JJ use/NN in/IN cardiac/JJ transplant/NN medicine/NN and/CC might/MD be/VB useful/JJ in/IN managing/VBG further/JJ settings/NNS of/IN vascular/JJ pathology/NN also/RB known/VBN to/TO involve/VB TF/NN expression/NN and/CC NF-kappaB/NN activation/NN ./. 
UI/LS -/: 98063340/CD 
TI/LS -/: IL-2/NN and/CC IL-7/NN induce/VBP heterodimerization/NN of/IN STAT5/NN isoforms/NNS in/IN human/JJ peripheral/JJ blood/NN T/NN lymphoblasts/NNS ./. 
AB/LS -/: Despite/IN differences/NNS in/IN T/NN cell/NN responses/NNS induced/VBN by/IN interleukin/NN (/( IL/NN )/) -2/CD and/CC IL-7/NN ,/, both/DT cytokines/NNS modulate/VBP T/NN cell/NN functions/NNS by/IN activation/NN of/IN signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STAT/NN )/) proteins/NNS ./. 
We/PRP examined/VBD the/DT contribution/NN of/IN the/DT two/CD isoforms/NNS of/IN STAT5/NN ,/, STAT5A/NN and/CC STAT5B/NN ,/, to/TO IL-2-/NN and/CC IL-7-induced/JJ activation/NN of/IN human/JJ peripheral/JJ blood/NN T/NN lymphoblasts/NNS ./. 
Both/DT cytokines/NNS induced/VBD assembly/NN of/IN STAT5A/NN and/CC STAT5B/NN containing/VBG complexes/NNS capable/JJ of/IN binding/VBG to/TO the/DT interferon-gamma/NN activation/NN sequence/NN (/( GAS/NN )/) ,/, and/CC these/DT complexes/NNS rapidly/RB translocated/VBD (/( within/IN 1/CD min/NN )/) into/IN the/DT nucleus/NN of/IN IL-2-/NN or/CC IL-7-treated/JJ cells/NNS ./. 
The/DT kinetics/NNS of/IN this/DT translocation/NN were/VBD delayed/VBN in/IN IL-7-treated/JJ as/IN compared/VBN to/TO IL-2-treated/JJ cells/NNS ./. 
IL-2/NN and/CC IL-7/NN were/VBD equivalent/JJ in/IN their/PRP$ ability/NN to/TO induce/VB tyrosine/NN phosphorylation/NN of/IN STAT5A/NN and/CC STAT5B/NN and/CC to/TO facilitate/VB binding/NN of/IN these/DT STATs/NNS to/TO an/DT immobilized/VBN GAS/NN element/NN ./. 
Both/CC IL-2/NN and/CC IL-7/NN induced/VBD substantial/JJ amounts/NNS of/IN STAT5A/STAT5B/NN heterodimerization/NN ./. 
Moreover/RB ,/, we/PRP observed/VBD constitutive/JJ association/NN of/IN STAT3/NN with/IN each/DT STAT5/NN isomer/NN ./. 
These/DT data/NNS suggest/VBP that/IN IL-2/NN and/CC IL-7/NN induce/VBP assembly/NN of/IN STAT/NN heterodimers/NNS in/IN a/DT similar/JJ manner/NN and/CC that/IN subsequent/JJ cellular/JJ responses/NNS may/MD be/VB driven/VBN by/IN induction/NN of/IN similar/JJ sets/NNS of/IN genes/NNS ./. 
UI/LS -/: 98030550/CD 
TI/LS -/: Transcription/NN factor/NN NF-kappaB/NN regulates/VBZ inducible/JJ Oct-2/NN gene/NN expression/NN in/IN precursor/NN B/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT POU/NN transcription/NN factors/NNS Oct-1/NN and/CC Oct-2/NN regulate/VBP the/DT activity/NN of/IN octamer-dependent/JJ promoters/NNS ,/, including/VBG those/DT that/WDT direct/VBP transcription/NN from/IN rearranged/VBN immunoglobulin/NN genes/NNS ./. 
Unlike/IN Oct-1/NN ,/, which/WDT is/VBZ constitutively/RB expressed/VBN in/IN many/JJ cell/NN types/NNS ,/, Oct-2/NN expression/NN is/VBZ restricted/JJ primarily/RB to/TO B/NN lymphocytes/NNS and/CC can/MD be/VB induced/VBN in/IN precursor/NN B/NN cells/NNS by/IN stimulation/NN with/IN bacterial/JJ lipopolysaccharide/NN (/( LPS/NN )/) ./. 
However/RB ,/, the/DT precise/JJ factors/NNS that/WDT mediate/VBP this/DT induction/NN mechanism/NN remain/VBP unknown/JJ ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP monitored/VBD Oct-2/NN expression/NN in/IN cells/NNS arrested/VBN for/IN the/DT activation/NN of/IN NF-kappaB/NN ,/, an/DT LPS-responsive/JJ member/NN of/IN the/DT Rel/NN transcription/NN factor/NN family/NN ./. 
Despite/IN stimulation/NN with/IN LPS/NN ,/, disruption/NN of/IN the/DT NF-kappaB/NN signaling/NN pathway/NN in/IN precursor/NN B/NN cells/NNS led/VBD to/TO the/DT loss/NN of/IN inducible/JJ Oct-2/NN DNA/NN binding/NN activity/NN in/FW vitro/FW and/CC the/DT suppression/NN of/IN Oct-2-directed/JJ transcription/NN in/FW vivo/FW ./. 
This/DT biochemical/JJ defect/NN correlated/VBD with/IN a/DT specific/JJ block/NN to/TO Oct-2/NN gene/NN expression/NN at/IN the/DT level/NN of/IN transcription/NN ,/, whereas/IN the/DT expression/NN of/IN Oct-1/NN was/VBD unaffected/JJ ./. 
The/DT finding/NN that/IN Oct-2/NN is/VBZ under/IN NF-kappaB/NN control/NN highlights/VBZ an/DT important/JJ cross-talk/NN mechanism/NN involving/VBG two/CD distinct/JJ transcription/NN factor/NN families/NNS that/WDT regulate/VBP B/NN lymphocyte/NN function/NN ./. 
UI/LS -/: 98013637/CD 
TI/LS -/: Suppression/NN of/IN MHC/NN class/NN II/CD expression/NN by/IN human/JJ class/NN II/CD trans-activator/NN constructs/NNS lacking/VBG the/DT N-terminal/JJ domain/NN ./. 
AB/LS -/: The/DT class/NN II/CD trans-activator/NN (/( CIITA/NN )/) is/VBZ a/DT bi-/RB or/CC multi-functional/JJ domain/NN protein/NN which/WDT plays/VBZ a/DT critical/JJ role/NN in/IN the/DT expression/NN of/IN MHC/NN class/NN II/CD genes/NNS ./. 
We/PRP report/VBP that/DT removal/NN of/IN the/DT N-terminal/JJ 151/CD amino/NN acids/NNS ,/, encompassing/VBG all/DT of/IN the/DT acidic/JJ domain/NN but/CC leaving/VBG intact/JJ the/DT proline/serine/threonine-rich/JJ domain/NN ,/, results/VBZ in/IN a/DT mutant/JJ protein/NN with/IN potent/JJ suppressive/JJ properties/NNS for/IN MHC/NN class/NN II/CD expression/NN ./. 
HeLa/NN cells/NNS stably/RB or/CC transiently/RB transfected/VBN with/IN mutant/JJ CIITA/NN constructs/NNS showed/VBD up/RB to/TO 99/CD %/NN suppression/NN of/IN MHC/NN class/NN II/CD antigen/NN induction/NN by/IN IFN-gamma/NN and/CC marked/JJ suppression/NN of/IN HLA-DRA/NN mRNA/NN expression/NN ./. 
Transient/JJ transfection/NN of/IN a/DT B/NN lymphoma/NN line/NN resulted/VBD in/IN up/RB to/TO 89/CD %/NN reduction/NN of/IN constitutive/JJ MHC/NN class/NN II/CD expression/NN within/IN 5/CD days/NNS and/CC suppression/NN of/IN HLA-DRA/NN mRNA/NN synthesis/NN ./. 
UI/LS -/: 98006327/CD 
TI/LS -/: Helenalin/NN ,/, an/DT anti-inflammatory/JJ sesquiterpene/NN lactone/NN from/IN Arnica/FW ,/, selectively/RB inhibits/VBZ transcription/NN factor/NN NF-kappaB/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: Alcoholic/JJ extracts/NNS prepared/VBN form/IN Arnicae/FW flos/FW ,/, the/DT collective/JJ name/NN for/IN flowerheads/NNS from/IN Arnica/FW montana/FW and/CC A./FW chamissonis/FW ssp./FW foliosa/FW ,/, are/VBP used/VBN therapeutically/RB as/IN anti-inflammatory/JJ remedies/NNS ./. 
The/DT active/JJ ingredients/NNS mediating/VBG the/DT pharmacological/JJ effect/NN are/VBP mainly/RB sesquiterpene/NN lactones/NNS ,/, such/JJ as/IN helenalin/NN ,/, 11alpha,13-dihydrohelenalin/NN ,/, chamissonolid/NN and/CC their/PRP$ ester/NN derivatives/NNS ./. 
While/IN these/DT compounds/NNS affect/VBP various/JJ cellular/JJ processes/NNS ,/, current/JJ data/NNS do/VBP not/RB fully/RB explain/VB how/WRB sesquiterpene/NN lactones/NNS exert/VBP their/PRP$ anti-inflammatory/JJ effect/NN ./. 
We/PRP show/VBP here/RB that/IN helenalin/NN ,/, and/CC ,/, to/TO a/DT much/RB lesser/JJR degree/NN ,/, 11alpha,13-dihydrohelenalin/NN and/CC chamissonolid/NN ,/, inhibit/VBP activation/NN of/IN transcription/NN factor/NN NF-kappaB/NN ./. 
This/DT difference/NN in/IN efficacy/NN ,/, which/WDT correlates/VBZ with/IN the/DT compounds/NNS '/POS anti-inflammatory/JJ potency/NN in/FW vivo/FW ,/, may/MD be/VB explained/VBN by/IN differences/NNS in/IN structure/NN and/CC conformation/NN ./. 
NF-kappaB/NN ,/, which/WDT resides/VBZ in/IN an/DT inactive/JJ ,/, cytoplasmic/JJ complex/NN in/IN unstimulated/JJ cells/NNS ,/, is/VBZ activated/VBN by/IN phosphorylation/NN and/CC degradation/NN of/IN its/PRP$ inhibitory/JJ subunit/NN ,/, IkappaB/NN ./. 
Helenalin/NN inhibits/VBZ NF-kappaB/NN activation/NN in/IN response/NN to/TO four/CD different/JJ stimuli/NNS in/IN T-cells/NNS ,/, B-cells/NNS and/CC epithelial/JJ cells/NNS and/CC abrogates/VBZ kappaB-driven/JJ gene/NN expression/NN ./. 
This/DT inhibition/NN is/VBZ selective/JJ ,/, as/IN the/DT activity/NN of/IN four/CD other/JJ transcription/NN factors/NNS ,/, Oct-1/NN ,/, TBP/NN ,/, Sp1/NN and/CC STAT/NN 5/CD was/VBD not/RB affected/VBN ./. 
We/PRP show/VBP that/IN inhibition/NN is/VBZ not/RB due/JJ to/TO a/DT direct/JJ modification/NN of/IN the/DT active/JJ NF-kappaB/NN heterodimer/NN ./. 
Rather/RB ,/, helenalin/NN modifies/VBZ the/DT NF-kappaB/IkappaB/NN complex/NN ,/, preventing/VBG the/DT release/NN of/IN IkappaB/NN ./. 
These/DT data/NNS suggest/VBP a/DT molecular/JJ mechanism/NN for/IN the/DT anti-inflammatory/JJ effect/NN of/IN sesquiterpene/NN lactones/NNS ,/, which/WDT differs/VBZ from/IN that/DT of/IN other/JJ nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS (/( NSAIDs/NNS )/) ,/, indomethacin/NN and/CC acetyl/NN salicylic/JJ acid/NN ./. 
UI/LS -/: 98001728/CD 
TI/LS -/: The/DT tax/NN protein/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD mediates/VBZ the/DT transactivation/NN of/IN the/DT c-sis/platelet-derived/JJ growth/NN factor-B/NN promoter/NN through/IN interactions/NNS with/IN the/DT zinc/NN finger/NN transcription/NN factors/NNS Sp1/NN and/CC NGFI-A/Egr-1/NN ./. 
AB/LS -/: Transcriptional/JJ up-regulation/NN of/IN the/DT c-sis/platelet-derived/JJ growth/NN factor-B/NN (/( PDGF-B/NN )/) proto-oncogene/NN by/IN the/DT Tax/NN protein/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD has/VBZ been/VBN implicated/VBN as/IN one/CD possible/JJ mechanism/NN of/IN cellular/JJ transformation/NN by/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD ./. 
In/IN previous/JJ work/NN ,/, we/PRP identified/VBD an/DT essential/JJ site/NN in/IN the/DT c-sis/PDGF-B/NN promoter/NN ,/, Tax-responsive/JJ element/NN 1/CD (/( TRE1/NN )/) ,/, necessary/JJ for/IN transactivation/NN by/IN Tax/NN ./. 
We/PRP also/RB identified/VBD Sp1/NN ,/, Sp3/NN ,/, and/CC NGFI-A/Egr-1/NN as/IN the/DT primary/JJ nuclear/JJ transcription/NN factors/NNS binding/VBG to/TO TRE1/NN which/WDT mediate/VBP Tax/NN responsiveness/NN ./. 
In/IN the/DT present/JJ work/NN ,/, we/PRP have/VBP investigated/VBN the/DT mechanism/NN (/( s/NNS )/) whereby/WRB Tax/NN transactivates/VBZ the/DT c-sis/PDGF-B/NN proto-oncogene/NN ./. 
In/FW vitro/FW transcription/NN assays/NNS showed/VBD that/IN Tax/NN was/VBD able/JJ to/TO significantly/RB increase/VB the/DT transcriptional/JJ activity/NN of/IN a/DT template/NN containing/VBG the/DT -257/CD to/TO +74/CD region/NN of/IN the/DT c-sis/PDGF-B/NN promoter/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assay/NN analysis/NN showed/VBD that/DT Tax/NN increased/VBD the/DT DNA/NN binding/NN activity/NN of/IN both/CC Sp1/NN and/CC NGFI-A/Egr-1/NN using/VBG a/DT TRE1/NN probe/NN ./. 
Analysis/NN of/IN Tax/NN mutants/NNS showed/VBD that/IN two/CD mutants/NNS ,/, IEXC29S/NN and/CC IEXL320G/NN ,/, were/VBD unable/JJ to/TO significantly/RB transactivate/VB the/DT c-sis/PDGF-B/NN promoter/NN ./. 
Finally/RB ,/, co-immunoprecipitation/NN analysis/NN revealed/VBD that/IN Tax/NN is/VBZ able/JJ to/TO stably/RB bind/VB to/TO both/CC Sp1/NN and/CC NGFI-A/Egr-1/NN ./. 
Interestingly/RB ,/, co-immunoprecipitation/NN analysis/NN also/RB revealed/VBD that/IN Tax/NN mutant/NN IEXC29S/NN is/VBZ unable/JJ to/TO interact/VB with/IN NGFI-A/Egr-1/NN ,/, whereas/IN Tax/NN mutant/NN IEXL320G/NN is/VBZ able/JJ to/TO interact/VB with/IN NGFI-A/Egr-1/NN ./. 
UI/LS -/: 98018226/CD 
TI/LS -/: Nuclear/JJ localization/NN of/IN RelB/NN is/VBZ associated/VBN with/IN effective/JJ antigen-presenting/JJ cell/NN function/NN ./. 
AB/LS -/: Dendritic/JJ cells/NNS (/( DC/NNS )/) are/VBP potent/JJ APCs/NNS that/WDT enter/VBP resting/VBG tissues/NNS as/IN precursors/NNS and/CC ,/, after/IN Ag/NN exposure/NN ,/, differentiate/VBP and/CC migrate/VBP to/TO draining/VBG lymph/NN nodes/NNS ./. 
The/DT phenotype/NN of/IN RelB/NN knockout/NN mice/NNS implicates/VBZ this/DT member/NN of/IN the/DT NF/NN kappa/NN B/Rel/NN family/NN in/IN DC/NNS differentiation/NN ./. 
To/TO further/RB elucidate/VB the/DT role/NN of/IN RelB/NN in/IN DC/NNS differentiation/NN ,/, mRNA/NN ,/, intracellular/JJ protein/NN expression/NN ,/, and/CC DNA/NN binding/NN activity/NN of/IN RelB/NN were/VBD examined/VBN in/IN immature/JJ and/CC differentiated/VBN human/JJ DC/NNS ,/, as/RB well/RB as/IN other/JJ PB/NN mononuclear/JJ cell/NN populations/NNS ./. 
RelB/NN protein/NN and/CC mRNA/NN were/VBD detected/VBN constitutively/RB in/IN lymphocytes/NNS and/CC in/IN activated/VBN monocytes/NNS ,/, differentiated/VBN DC/NNS ,/, and/CC monocyte-derived/JJ DC/NNS ./. 
Immunohistochemical/JJ staining/NN demonstrated/VBD RelB/NN within/IN the/DT differentiated/VBN lymph/NN node/NN interdigitating/NN DC/NNS and/CC follicular/JJ DC/NNS ,/, but/CC not/RB undifferentiated/JJ DC/NNS in/IN normal/JJ skin/NN ./. 
Active/JJ nuclear/JJ RelB/NN was/VBD detected/VBN by/IN supershift/NN assay/NN only/RB in/IN differentiated/JJ DC/NNS derived/VBN from/IN either/CC PB/NN precursors/NNS or/CC monocytes/NNS and/CC in/IN activated/VBN B/NN cells/NNS ./. 
These/DT RelB+/JJ APC/NN were/VBD potent/JJ stimulators/NNS of/IN the/DT MLR/NN ./. 
The/DT data/NNS indicate/VBP that/IN RelB/NN expression/NN is/VBZ regulated/VBN both/CC transcriptionally/RB and/CC post-translationally/RB in/IN myeloid/JJ cells/NNS ./. 
Within/IN the/DT nucleus/NN ,/, RelB/NN may/NN specifically/RB transactivate/VB genes/NNS that/WDT are/VBP critical/JJ for/IN APC/NN function/NN ./. 
UI/LS -/: 97458245/CD 
TI/LS -/: NF-AT/NN activation/NN induced/VBN by/IN a/DT CAML-interacting/JJ member/NN of/IN the/DT tumor/NN necrosis/NN factor/NN receptor/NN superfamily/NN ./. 
AB/LS -/: Activation/NN of/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS transcription/NN factor/NN (/( NF-AT/NN )/) is/VBZ a/DT key/JJ event/NN underlying/VBG lymphocyte/NN action/NN ./. 
The/DT CAML/NN (/( calcium-modulator/NN and/CC cyclophilin/NN ligand/NN )/) protein/NN is/VBZ a/DT coinducer/NN of/IN NF-AT/NN activation/NN when/WRB overexpressed/VBN in/IN Jurkat/NN T/NN cells/NNS ./. 
A/DT member/NN of/IN the/DT tumor/NN necrosis/NN factor/NN receptor/NN superfamily/NN was/VBD isolated/VBN by/IN virtue/NN of/IN its/PRP$ affinity/NN for/IN CAML/NN ./. 
Cross-linking/NN of/IN this/DT lymphocyte-specific/JJ protein/NN ,/, designated/VBN TACI/NN (/( transmembrane/JJ activator/NN and/CC CAML-interactor/NN )/) ,/, on/IN the/DT surface/NN of/IN transfected/VBN Jurkat/NN cells/NNS with/IN TACI-specific/JJ antibodies/NNS led/VBD to/TO activation/NN of/IN the/DT transcription/NN factors/NNS NF-AT/NN ,/, AP-1/NN ,/, and/CC NFkappaB/NN ./. 
TACI-induced/JJ activation/NN of/IN NF-AT/NN was/VBD specifically/RB blocked/VBN by/IN a/DT dominant-negative/JJ CAML/NN mutant/NN ,/, thus/RB implicating/VBG CAML/NN as/IN a/DT signaling/VBG intermediate/NN ./. 
UI/LS -/: 97445683/CD 
TI/LS -/: Rel/NF-kappa/NN B/NN transcription/NN factors/NNS and/CC the/DT control/NN of/IN apoptosis/NN ./. 
AB/LS -/: The/DT process/NN of/IN apoptosis/NN is/VBZ used/VBN to/TO eliminate/VB unwanted/JJ cells/NNS from/IN a/DT wide/JJ variety/NN of/IN organisms/NNS ./. 
Various/JJ extracellular/JJ signals/NNS ,/, often/RB converging/VBG in/IN common/JJ intracellular/JJ pathways/NNS ,/, can/MD induce/VB apoptosis/NN in/IN a/DT cell-type-specific/JJ fashion/NN ./. 
Recent/JJ work/NN from/IN several/JJ laboratories/NNS has/VBZ demonstrated/VBN that/IN Rel/NF-kappa/NN B/NN transcription/NN factors/NNS regulate/VBP apoptosis/NN in/IN many/JJ cell/NN types/NNS ./. 
In/IN most/JJS cells/NNS ,/, Rel/NF-kappa/NN B/NN transcription/NN factors/NNS appear/VBP to/TO mediate/VB survival/JJ signals/NNS that/WDT protect/VBP cells/NNS from/IN apoptosis/NN ;/: however/RB ,/, under/IN some/DT circumstances/NNS ,/, activation/NN of/IN these/DT factors/NNS may/MD also/RB promote/VB apoptosis/NN ./. 
UI/LS -/: 98101492/CD 
TI/LS -/: A/DT thiol/NN antioxidant/NN regulates/VBZ IgE/NN isotype/NN switching/NN by/IN inhibiting/VBG activation/NN of/IN nuclear/JJ factor-kappaB/NN ./. 
AB/LS -/: The/DT binding/VBG site/NN for/IN nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) is/VBZ present/JJ at/IN the/DT promoter/NN region/NN of/IN the/DT germline/NN Cepsilon/NN gene/NN ,/, but/CC there/EX is/VBZ little/JJ information/NN on/IN whether/IN this/DT factor/NN is/VBZ involved/VBN in/IN regulating/VBG IgE/NN synthesis/NN by/IN human/JJ B/NN cells/NNS ./. 
Accordingly/RB ,/, we/PRP studied/VBD the/DT role/NN of/IN NF-kappaB/NN in/IN germline/NN Cepsilon/NN transcription/NN by/IN using/VBG two/CD human/JJ Burkitt/NN 's/POS lymphoma/NN B/NN cell/NN lines/NNS ,/, DND39/NN and/CC DG75/NN ./. 
In/IN both/DT cell/NN lines/NNS ,/, n-acetyl-L-cysteine/NN (/( NAC/NN )/) ,/, a/DT potent/JJ thiol/NN antioxidant/NN ,/, inhibited/VBD the/DT triggering/NN of/IN the/DT nuclear/JJ expression/NN of/IN NF-kappaB/NN by/IN IL-4/NN and/CC by/IN anti-CD40/JJ monoclonal/JJ antibody/NN ./. 
Although/IN IL-4/NN activated/VBD signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STAT/NNS )/) 6/CD in/IN addition/NN to/TO NF-kappaB/NN ,/, NAC/NN treatment/NN or/CC the/DT transfection/NN of/IN decoy/NN oligodeoxynucleotides/NNS for/IN NF-kappaB/NN or/CC STAT6/NN only/RB partly/RB blocked/VBD IL-4-induced/JJ germline/NN Cepsilon/NN transcription/NN ./. 
However/RB ,/, these/DT two/CD decoy/NN oligodeoxynucleotides/NNS together/RB almost/RB completely/RB abrogated/VBD IL-4-induced/JJ germline/NN Cepsilon/NN transcription/NN ./. 
Of/IN note/NN ,/, CD40-mediated/JJ enhancement/NN of/IN IL-4-driven/JJ germline/NN Cepsilon/NN transcription/NN was/VBD markedly/RB decreased/VBN by/IN NAC/NN or/CC by/IN a/DT decoy/NN oligodeoxynucleotide/NN for/IN NF-kappaB/NN ./. 
The/DT effect/NN of/IN NAC/NN was/VBD also/RB examined/VBN on/IN deletional/JJ switch/NN recombination/NN underlying/VBG the/DT isotype/NN switch/NN to/TO IgE/NN ./. 
NAC/NN inhibited/VBD the/DT generation/NN of/IN Smu/Sepsilon/NN switch/NN fragments/NNS in/IN normal/JJ human/JJ B/NN cells/NNS costimulated/VBN with/IN IL-4/NN and/CC anti-CD40/JJ monoclonal/JJ antibody/NN ./. 
It/PRP also/RB abolished/VBD IL-4-induced/JJ upregulation/NN of/IN CD40/NN but/CC promoted/VBD upregulation/NN of/IN CD23/NN ./. 
These/DT results/NNS suggest/VBP that/IN coordination/NN of/IN NF-kappaB/NN and/CC STAT6/NN may/MD be/VB required/VBN for/IN induction/NN of/IN germline/NN Cepsilon/NN transcription/NN by/IN IL-4/NN ,/, and/CC that/IN CD40-mediated/JJ NF-kappaB/NN activation/NN may/MD be/VB important/JJ in/IN regulating/VBG both/CC enhancement/NN of/IN germline/NN Cepsilon/NN transcription/NN and/CC class/NN switching/NN to/TO IgE/NN ./. 
UI/LS -/: 98045094/CD 
TI/LS -/: Pathogenesis/NN ./. 
AB/LS -/: There/EX are/VBP many/JJ hypotheses/NNS concerning/VBG the/DT pathogenesis/NN of/IN endometriosis/NN ,/, though/IN no/DT single/JJ theory/NN can/MD explain/VB all/DT cases/NNS ./. 
It/PRP is/VBZ likely/JJ that/IN several/JJ mechanisms/NNS are/VBP involved/VBN ./. 
Early/JJ studies/NNS concentrated/VBD on/IN the/DT histogenesis/NN of/IN the/DT endometriotic/JJ lesion/NN ./. 
Recent/JJ evidence/NN has/VBZ implicated/VBN components/NNS of/IN the/DT immune/JJ system/NN in/IN the/DT pathogenesis/NN of/IN endometriosis/NN ./. 
This/DT review/NN considers/VBZ the/DT evidence/NN for/IN different/JJ theories/NNS of/IN the/DT histogenesis/NN of/IN endometriosis/NN and/CC discusses/VBZ possible/JJ immune/JJ factors/NNS that/WDT may/MD be/VB involved/VBN in/IN the/DT pathophysiology/NN of/IN the/DT disease/NN ./. 
UI/LS -/: 98062912/CD 
TI/LS -/: ATF1/NN and/CC CREB/NN trans-activate/VBP a/DT cell/NN cycle/NN regulated/JJ histone/NN H4/NN gene/NN at/IN a/DT distal/JJ nuclear/JJ matrix/NN associated/JJ promoter/NN element/NN ./. 
AB/LS -/: Proteins/NNS of/IN the/DT ATF/CREB/NN class/NN of/IN transcription/NN factors/NNS stimulate/VBP gene/NN expression/NN of/IN several/JJ cell/NN growth-related/JJ genes/NNS through/IN protein/NN kinase/NN A-related/JJ cAMP/NN response/NN elements/NNS ./. 
The/DT promoter/NN activity/NN of/IN cell/NN cycle/NN regulated/JJ histone/NN H4/NN genes/NNS is/VBZ regulated/VBN by/IN at/IN least/JJS four/CD principal/JJ cis-acting/VBG elements/NNS which/WDT mediate/VBP G1/S/NN phase/NN control/NN and/or/CC enhancement/NN of/IN transcription/NN during/IN the/DT cell/NN cycle/NN ./. 
Using/VBG protein-DNA/JJ interaction/NN assays/NNS we/PRP show/VBP that/IN the/DT H4/NN promoter/NN contains/VBZ two/CD ATF/CREB/NN recognition/NN motifs/NNS which/WDT interact/VBP with/IN CREB/NN ,/, ATF1/NN ,/, and/CC ATF2/NN but/CC not/RB with/IN ATF4/CREB2/NN ./. 
One/CD ATF/CRE/NN motif/NN is/VBZ located/JJ in/IN the/DT distal/JJ promoter/NN at/IN the/DT nuclear/JJ matrix-associated/JJ Site/NN IV/CD ,/, and/CC the/DT second/JJ motif/NN is/VBZ present/JJ in/IN the/DT proximal/JJ promoter/NN at/IN Site/NN I/CD ./. 
Both/DT ATF/CRE/NN motifs/NNS overlap/VBP binding/VBG sequences/NNS for/IN the/DT multifunctional/JJ YY1/NN transcription/NN factor/NN ,/, which/WDT has/VBZ previously/RB been/VBN shown/VBN to/TO be/VB nuclear/JJ matrix/NN associated/JJ ./. 
Subnuclear/JJ fractionation/NN reveals/VBZ that/IN there/EX are/VBP two/CD ATF1/NN isoforms/NNS which/WDT appear/VBP to/TO differ/VB with/IN respect/NN to/TO DNA/NN binding/NN activity/NN and/CC partition/NN selectively/RB between/IN nuclear/JJ matrix/NN and/CC nonmatrix/JJ compartments/NNS ,/, consistent/JJ with/IN the/DT role/NN of/IN the/DT nuclear/JJ matrix/NN in/IN regulating/VBG gene/NN expression/NN ./. 
Site-directed/JJ mutational/JJ studies/NNS demonstrate/VBP that/IN Site/NN I/CD and/CC Site/NN IV/CD together/RB support/VBP ATF1-/NN and/CC CREB-induced/JJ trans-activation/NN of/IN the/DT H4/NN promoter/NN ./. 
Thus/RB ,/, our/PRP$ data/NNS establish/VBP that/IN ATF/CREB/NN factors/NNS functionally/RB modulate/VBP histone/NN H4/NN gene/NN transcription/NN at/IN distal/JJ and/CC proximal/JJ promoter/NN elements/NNS ./. 
UI/LS -/: 98030794/CD 
TI/LS -/: Is/VBZ celiac/JJ disease/NN due/JJ to/TO molecular/JJ mimicry/NN between/IN gliadin/NN peptide-HLA/NN class/NN II/CD molecule-T/NN cell/NN interactions/NNS and/CC those/DT of/IN some/DT unidentified/JJ superantigen/NN ?/. 
AB/LS -/: This/DT paper/NN presents/VBZ a/DT new/JJ hypothesis/NN for/IN the/DT etiology/NN and/CC pathogenesis/NN of/IN celiac/JJ disease/NN (/( CD/NN )/) ./. 
It/PRP is/VBZ our/PRP$ contention/NN that/IN CD/NN is/VBZ triggered/VBN by/IN the/DT binding/NN of/IN one/CD or/CC more/JJR gliadin/NN peptides/NNS to/TO CD-associated/JJ HLA/NN class/NN II/CD molecules/NNS ./. 
Furthermore/RB ,/, we/PRP propose/VBP that/IN these/DT putative/JJ CD/NN peptides/NNS bind/VBP to/TO oligosaccharide/NN residues/NNS on/IN HLA/NN class/NN II/CD molecules/NNS distal/JJ to/TO the/DT peptide-binding/JJ groove/NN invoking/VBG recognition/NN and/CC binding/NN by/IN specialized/VBN subsets/NNS of/IN gamma/NN delta/NN T/NN cell/NN receptor-bearing/JJ lymphocytes/NNS ./. 
The/DT binding/NN of/IN these/DT gamma/NN delta/NN T/NN cells/NNS serves/VBZ as/IN a/DT signal/NN for/IN abrogation/NN of/IN oral/JJ tolerance/NN to/TO ingested/VBN proteins/NNS setting/VBG in/RP motion/NN a/DT series/NN of/IN immune/JJ responses/NNS directed/VBN against/IN the/DT small/JJ intestinal/JJ epithelium/NN of/IN CD/NN patients/NNS ./. 
CD/NN patients/NNS are/VBP victimized/VBN by/IN this/DT self-distructed/JJ immune/JJ response/NN because/IN of/IN inheritance/NN of/IN certain/JJ combinations/NNS of/IN HLA-DQ/NN and/CC DR/NN haplotypes/NNS ./. 
Dimers/NNS encoded/VBN by/IN HLA-DR/NN haplotypes/NNS may/MD be/VB the/DT primary/JJ restriction/NN elements/NNS for/IN lectin-like/JJ ,/, gliadin/NN peptides/NNS while/IN the/DT degree/NN of/IN immune/JJ suppression/NN (/( or/CC lack/NN thereof/RB )/) to/TO ingested/VBN gliadins/NNS is/VBZ governed/VBN by/IN inherited/VBN HLA-DQ/NN haplotypes/NNS ./. 
Finally/RB ,/, we/PRP speculate/VBP that/IN molecular/JJ mimicry/NN between/IN one/CD or/CC more/JJR gliadin/NN peptides/NNS and/CC some/DT ,/, as/IN yet/RB unidentified/JJ ,/, bacterial/JJ or/CC viral/JJ superantigen/NN plays/VBZ a/DT role/NN in/IN disease/NN pathogenesis/NN ./. 
UI/LS -/: 98062995/CD 
TI/LS -/: Epstein-Barr/JJ virus/NN latent/JJ membrane/NN protein-1/NN triggers/VBZ AP-1/NN activity/NN via/IN the/DT c-Jun/NN N-terminal/JJ kinase/NN cascade/NN ./. 
AB/LS -/: The/DT Epstein-Barr/JJ virus/NN latent/JJ membrane/NN protein-1/NN (/( LMP-1/NN )/) is/VBZ an/DT integral/JJ membrane/NN protein/NN which/WDT transforms/VBZ fibroblasts/NNS and/CC is/VBZ essential/JJ for/IN EBV-mediated/JJ B-cell/NN immortalization/NN ./. 
LMP-1/NN has/VBZ been/VBN shown/VBN to/TO trigger/VB cellular/JJ NF-kappa/NN B/NN activity/NN which/WDT ,/, however/RB ,/, can/MD not/RB fully/RB explain/VB the/DT oncogenic/JJ potential/NN of/IN LMP-1/NN ./. 
Here/RB we/PRP show/VBP that/IN LMP-1/NN induces/VBZ the/DT activity/NN of/IN the/DT AP-1/NN transcription/NN factor/NN ,/, a/DT dimer/NN of/IN Jun/Jun/NN or/CC Jun/Fos/NN proteins/NNS ./. 
LMP-1/NN effects/NNS on/IN AP-1/NN are/VBP mediated/VBN through/IN activation/NN of/IN the/DT c-Jun/NN N-terminal/JJ kinase/NN (/( JNK/NN )/) cascade/NN ,/, but/CC not/RB the/DT extracellular/JJ signal-regulated/JJ kinase/NN (/( Erk/NN )/) pathway/NN ./. 
Consequently/RB ,/, LMP-1/NN triggers/VBZ the/DT activity/NN of/IN the/DT c-Jun/NN N-terminal/JJ transactivation/NN domain/NN which/WDT is/VBZ known/VBN to/TO be/VB activated/VBN upon/IN JNK-mediated/JJ phosphorylation/NN ./. 
Deletion/NN analysis/NN indicates/VBZ that/IN the/DT 55/CD C-terminal/JJ amino/NN acids/NNS of/IN the/DT LMP-1/NN molecule/NN ,/, but/CC not/RB its/PRP$ TRAF/NN interaction/NN domain/NN ,/, are/VBP essential/JJ for/IN AP-1/NN activation/NN ./. 
JNK-mediated/JJ transcriptional/JJ activation/NN of/IN AP-1/NN is/VBZ the/DT direct/JJ output/NN of/IN LMP-1-triggered/JJ signaling/NN ,/, as/IN shown/VBN by/IN an/DT inducible/JJ LMP-1/NN mutant/NN ./. 
Using/VBG a/DT tetracycline-regulated/JJ LMP-1/NN allele/NN ,/, we/PRP demonstrate/VBP that/IN JNK/NN is/VBZ also/RB an/DT effector/NN of/IN non-cytotoxic/JJ LMP-1/NN signaling/NN in/IN B/NN cells/NNS ,/, the/DT physiological/JJ target/NN cells/NNS of/IN EBV/NN ./. 
In/IN summary/NN ,/, our/PRP$ data/NNS reveal/VBP a/DT novel/JJ effector/NN of/IN LMP-1/NN ,/, the/DT SEK/JNK/c-Jun/AP-1/NN pathway/NN ,/, which/WDT contributes/VBZ to/TO our/PRP$ understanding/NN of/IN the/DT immortalizing/JJ and/CC transforming/JJ potential/NN of/IN LMP-1/NN ./. 
UI/LS -/: 97451158/CD 
TI/LS -/: Abnormal/JJ apoptosis/NN and/CC cell/NN cycle/NN progression/NN in/IN humans/NNS exposed/VBN to/TO methyl/NN tertiary-butyl/NN ether/NN and/CC benzene/NN contaminating/NN water/NN ./. 
AB/LS -/: 1/CD ./. In/IN this/DT study/NN we/PRP hypothesized/VBD that/IN in/IN individuals/NNS with/IN certain/JJ genetic/JJ makeup/NN ,/, MTBE/NN ,/, benzene/NN or/CC their/PRP$ metabolites/NNS act/VBP as/IN adducts/NNS and/CC may/MD induce/VB programmed/VBN cell/NN death/NN ./. 
2/CD ./. Our/PRP$ study/NN involved/VBD a/DT group/NN of/IN 60/CD male/NN and/CC female/JJ subjects/NNS who/WP were/VBD exposed/VBN to/TO MTBE/NN and/CC benzene-contaminated/JJ water/NN concentrations/NNS up/IN to/TO 76/CD PPB/NN for/IN MTBE/NN and/CC 14/CD PPB/NN for/IN benzene/NN ,/, for/IN a/DT period/NN of/IN 5/CD to/TO 8/CD years/NNS ./. 
For/IN comparison/NN ,/, we/PRP recruited/VBD a/DT control/NN group/NN consisting/VBG of/IN 32/CD healthy/JJ males/NNS and/CC females/NNS with/IN similar/JJ age/NN distribution/NN and/CC without/IN a/DT history/NN of/IN exposure/NN to/TO MTBE/NN or/CC benzene/NN ./. 
3/CD ./. Peripheral/JJ blood/NN lymphocytes/NNS (/( PBL/NNS )/) of/IN both/CC groups/NNS were/VBD tested/VBN for/IN the/DT percentage/NN of/IN apoptotic/JJ cells/NNS and/CC cell/NN cycle/NN progression/NN using/VBG flow/NN cytometry/NN ./. 
4/CD ./. When/WRB apoptotic/JJ lymphocytes/NNS from/IN exposed/VBN individuals/NNS were/VBD compared/VBN to/TO apoptotic/JJ lymphocytes/NNS from/IN the/DT control/JJ group/NN ,/, statistically-significant/JJ differences/NNS between/IN each/DT mean/NN group/NN were/VBD detected/VBN (/( 26.4/CD +/-/CC 1.8/CD and/CC 12.1/CD +/-/CC 1.3/CD ,/, respectively/RB )/) ,/, indicating/VBG an/DT increased/VBN rate/NN of/IN apoptosis/NN in/IN 80.5/CD %/NN of/IN exposed/VBN individuals/NNS (/( P/NN </JJR 0.0001/CD ,/, Mann-Whitney/JJ U-Test/NN )/) ./. 
MTBE/NN and/CC benzene-induced/JJ apoptosis/NN is/VBZ attributed/VBN to/TO a/DT discrete/JJ block/NN within/IN the/DT cell/NN cycle/NN progression/NN ./. 
Because/IN cell/NN cycle/NN analysis/NN showed/VBD that/IN in/IN PBL/NNS from/IN chemically-exposed/JJ individuals/NNS ,/, between/IN 20-50/CD %/NN of/IN cells/NNS were/VBD accumulated/VBN at/IN the/DT S-G2/M/JJ boundaries/NNS ./. 
5/CD ./. One/CD of/IN the/DT signaling/VBG molecules/NNS which/WDT mediates/VBZ programmed/VBN cell/NN death/NN is/VBZ nuclear/JJ factor/NN Kappa-B/NN (/( NF-kappa/NN B/NN )/) ./. 
NF-kappa/NN B/NN was/VBD examined/VBN as/IN one/CD of/IN the/DT many/JJ molecular/JJ mechanisms/NNS for/IN mediating/VBG cell/NN death/NN by/IN MTBE/NN and/CC benzene/NN ./. 
Indeed/RB ,/, addition/NN of/IN inhibitors/NNS of/IN NF-kappa/NN B/NN activation/NN pyrrolidine/NN dithiocarbamate/NN (/( PDTC/NN )/) ,/, to/TO the/DT lymphocytes/NNS of/IN the/DT chemically-exposed/JJ group/NN was/VBD capable/JJ of/IN inhibiting/VBG programmed/VBN cell/NN death/NN by/IN 40/CD %/NN ./. 
This/DT reversal/NN of/IN apoptosis/NN almost/RB to/TO the/DT control/NN level/NN by/IN inhibitor/NN of/IN NF-kappa/NN B/NN activation/NN may/MD indicate/VB involvement/NN of/IN this/DT signaling/VBG molecule/NN in/IN MTBE/NN and/CC benzene/NN induction/NN of/IN programmed/VBN cell/NN death/NN ./. 
UI/LS -/: 98001686/CD 
TI/LS -/: Purification/NN and/CC characterization/NN of/IN the/DT human/JJ SR/NN 31747A-binding/JJ protein/NN ./. 
A/DT nuclear/JJ membrane/NN protein/NN related/JJ to/TO yeast/NN sterol/NN isomerase/NN ./. 
AB/LS -/: SR/NN 31747A/NN ,/, defined/VBN as/IN a/DT sigma/NN ligand/NN ,/, is/VBZ a/DT novel/JJ immunosuppressive/JJ agent/NN that/WDT blocks/VBZ proliferation/NN of/IN human/JJ and/CC mouse/NN lymphocytes/NNS ./. 
Using/VBG a/DT radiolabeled/JJ chemical/JJ probe/NN ,/, we/PRP here/RB purified/VBD a/DT target/NN of/IN SR/NN 31747A/NN and/CC called/VBD it/PRP SR/NN 31747A-binding/JJ protein/NN (/( SR-BP/NN )/) ./. 
Purified/VBN SR-BP/NN retained/VBD its/PRP$ binding/NN properties/NNS and/CC migrated/VBD on/IN SDS-polyacrylamide/JJ gel/NN as/IN a/DT Mr/NN 28,000/CD protein/NN ./. 
Cloning/NN of/IN the/DT cDNA/NN encoding/VBG human/JJ SR-BP/NN shows/VBZ an/DT open/JJ reading/NN frame/NN for/IN a/DT 223-amino/NN acid/NN protein/NN ,/, which/WDT is/VBZ homologous/JJ to/TO the/DT recently/RB cloned/VBN sigma/NN 1/CD receptor/NN ./. 
Interestingly/RB ,/, the/DT deduced/VBN amino/NN acid/NN sequence/NN was/VBD found/VBN to/TO be/VB related/JJ to/TO fungal/JJ C8-C7/NN sterol/NN isomerase/NN ,/, encoded/VBN by/IN the/DT ERG2/NN gene/NN ./. 
The/DT ERG2/NN gene/NN product/NN has/VBZ been/VBN identified/VBN recently/RB as/IN the/DT molecular/JJ target/NN of/IN SR/NN 31747A/NN that/WDT mediates/VBZ antiproliferative/JJ effects/NNS of/IN the/DT drug/NN in/IN yeast/NN ./. 
Northern/NN blot/NN analysis/NN of/IN SR-BP/NN gene/NN expression/NN revealed/VBD a/DT single/JJ transcript/NN of/IN 2/CD kilobases/NNS which/WDT was/VBD widely/RB expressed/VBN among/IN organs/NNS ,/, with/IN the/DT highest/JJS abundance/NN in/IN liver/NN and/CC the/DT lowest/JJS abundance/NN in/IN brain/NN ./. 
Subcellular/JJ localization/NN analysis/NN in/IN various/JJ cells/NNS ,/, using/VBG a/DT specific/JJ monoclonal/JJ antibody/NN raised/VBN against/IN SR-BP/NN ,/, demonstrated/VBD that/IN this/DT protein/NN was/VBD associated/VBN with/IN the/DT nuclear/JJ envelope/NN ./. 
When/WRB studying/VBG the/DT binding/NN of/IN SR/NN 31747A/NN on/IN membranes/NNS from/IN yeast/NN expressing/VBG SR-BP/NN ,/, we/PRP found/VBD a/DT pharmacological/JJ profile/NN of/IN sigma/NN 1/CD receptors/NNS ;/: binding/NN was/VBD displaced/VBN by/IN (+)-pentazocine/NN ,/, haloperidol/NN ,/, and/CC (+)-SKF/NN 10,047/CD ,/, with/IN (+)-SKF/NN 10, 047/CD being/VBG a/DT more/RBR potent/JJ competitor/NN than/IN (-)-SKF/NN 10,047/CD ./. 
Scatchard/NN plot/NN analysis/NN revealed/VBD Kd/NN values/NNS of/IN 7.1/CD nM/NN and/CC 0.15/CD nM/NN for/IN (+)-pentazocine/NN and/CC SR/NN 31747A/NN ,/, respectively/RB ,/, indicating/VBG an/DT affinity/NN of/IN SR-BP/NN 50-fold/RB higher/JJR for/IN SR/NN 31747A/NN than/IN for/IN pentazocine/NN ./. 
Additionally/RB ,/, we/PRP showed/VBD that/IN pentazocine/NN ,/, a/DT competitive/JJ inhibitor/NN of/IN SR/NN 31747A/NN binding/NN ,/, also/RB prevents/VBZ the/DT immunosuppressive/JJ effect/NN of/IN SR/NN 31747A/NN ./. 
Taken/VBN together/RB ,/, these/DT findings/NNS strongly/RB suggest/VBP that/IN SR-BP/NN represents/VBZ the/DT molecular/JJ target/NN for/IN SR/NN 31747A/NN in/IN mammalian/JJ tissues/NNS ,/, which/WDT could/MD be/VB critical/JJ for/IN T/NN cell/NN proliferation/NN ./. 
UI/LS -/: 97468093/CD 
TI/LS -/: Phospholipase/NN C/NN gamma/NN 1/CD overexpression/NN and/CC activation/NN induced/VBN by/IN interferon/NN beta/NN in/IN human/JJ T/NN lymphocytes/NNS :/: an/DT ISGF3-independent/JJ response/NN ./. 
AB/LS -/: Interferons/NNS exert/VBP their/PRP$ antiviral/JJ ,/, antiproliferative/JJ and/CC immunoregulatory/JJ activities/NNS by/IN stimulating/VBG the/DT expression/NN of/IN several/JJ genes/NNS ./. 
Such/JJ genes/NNS disclose/VBP a/DT common/JJ element/NN within/IN their/PRP$ promoters/NNS ,/, defined/VBN Interferon/NN Stimulated/NN Response/NN Element/NN (/( ISRE/NN )/) ,/, which/WDT binds/VBZ a/DT nuclear/JJ factor/NN (/( s/NNS )/) translocated/VBN from/IN the/DT cytoplasm/NN to/TO the/DT nucleus/NN (/( ISGF3/NN )/) after/IN the/DT binding/NN of/IN interferon/NN (/( IFN/NN )/) to/TO the/DT specific/JJ receptor/NN ./. 
Here/RB we/PRP report/VBP the/DT induction/NN of/IN the/DT synthesis/NN and/CC of/IN the/DT hydrolytic/JJ activity/NN of/IN phospholipase/NN C/NN gamma/NN 1/CD (/( PLC/NN gamma/NN 1/CD )/) in/IN human/JJ T/NN lymphocytes/NNS by/IN IFN-beta/NN ./. 
The/DT increased/VBN level/NN of/IN PLC/NN gamma/NN 1/CD becomes/VBZ evident/JJ after/IN 90/CD min/NN of/IN IFN-beta/NN treatment/NN and/CC is/VBZ still/RB detectable/JJ after/IN 24/CD h/NN ./. 
Neither/CC the/DT PLC/NN gamma/NN 1/CD overexpression/NN induced/VBN by/IN IFN/NN nor/CC the/DT increased/VBN hydrolytic/JJ activity/NN of/IN the/DT enzyme/NN appear/VBP to/TO be/VB affected/VBN by/IN pretreatment/NN of/IN the/DT cells/NNS with/IN the/DT protein/NN tyrosine/NN kinase/NN inhibitor/NN genistein/NN ,/, which/WDT is/VBZ known/VBN to/TO prevent/VB the/DT association/NN of/IN ISGF3/NN components/NNS ./. 
These/DT results/NNS suggest/VBP that/IN in/IN human/JJ T/NN lymphocytes/NNS IFN-beta/NN can/MD activate/VB other/JJ transcription/NN factor/NN (/( s/NNS )/) distinct/JJ from/IN ISGF3/NN to/TO regulate/VB PLC/NN gamma/NN 1/CD expression/NN ./. 
In/IN addition/NN ,/, the/DT ability/NN of/IN this/DT enzyme/NN to/TO hydrolyse/VB PIP2/NN ,/, also/RB in/IN the/DT presence/NN of/IN genistein/NN ,/, implies/VBZ the/DT possibility/NN that/IN this/DT enzyme/NN can/MD exert/VB its/PRP$ hydrolytic/JJ activity/NN independently/RB of/IN protein/NN tyrosine/NN kinase/NN activation/NN ./. 
UI/LS -/: 97458236/CD 
TI/LS -/: Negative/JJ regulation/NN by/IN HLA-DO/NN of/IN MHC/NN class/NN II-restricted/JJ antigen/NN processing/NN ./. 
AB/LS -/: HLA-DM/NN is/VBZ a/DT major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II-like/JJ molecule/NN that/WDT facilitates/VBZ antigen/NN processing/NN by/IN catalyzing/VBG the/DT exchange/NN of/IN invariant/JJ chain-derived/JJ peptides/NNS (/( CLIP/NNS )/) from/IN class/NN II/CD molecules/NNS for/IN antigenic/JJ peptides/NNS ./. 
HLA-DO/NN is/VBZ a/DT second/JJ class/NN II-like/JJ molecule/NN that/WDT physically/RB associates/VBZ with/IN HLA-DM/NN in/NN B/NN cells/NNS ./. 
HLA-DO/NN was/VBD shown/VBN to/TO block/VB HLA-DM/NN function/NN ./. 
Purified/VBN HLA-DM-DO/NN complexes/NNS could/MD not/RB promote/VB peptide/NN exchange/NN in/FW vitro/FW ./. 
Expression/NN of/IN HLA-DO/NN in/IN a/DT class/NN II+/JJ and/CC DM+/JJ ,/, DO-/JJ human/JJ T/NN cell/NN line/NN caused/VBD the/DT accumulation/NN of/IN class/NN II-CLIP/NN complexes/NNS ,/, indicating/VBG that/IN HLA-DO/NN blocked/VBD DM/NN function/NN in/FW vivo/FW and/CC suggesting/VBG that/IN HLA-DO/NN is/VBZ an/DT important/JJ modulator/NN of/IN class/NN II-restricted/JJ antigen/NN processing/NN ./. 
UI/LS -/: 97445128/CD 
TI/LS -/: Vitamin/NN D/NN receptor/NN :/: no/DT evidence/NN for/IN allele-specific/JJ mRNA/NN stability/NN in/IN cells/NNS which/WDT are/VBP heterozygous/JJ for/IN the/DT Taq/NN I/NN restriction/NN enzyme/NN polymorphism/NN ./. 
AB/LS -/: Allelic/JJ variations/NNS of/IN the/DT vitamin/NN D/NN receptor/NN (/( VDR/NN )/) gene/NN have/VBP been/VBN associated/VBN with/IN the/DT risk/NN of/IN developing/VBG prostate/NN cancer/NN in/IN men/NNS and/CC osteoporosis/NN in/IN postmenopausal/JJ women/NNS ./. 
Three/CD RFLPs/NNS (/( TaqI/NN ,/, ApaI/NN ,/, BsmI/NN )/) define/VBP two/CD common/JJ haplotypes/NNS :/: BAt/NN and/CC baT/NN ./. 
None/NN of/IN these/DT polymorphisms/NNS change/VBP the/DT translated/VBN protein/NN ./. 
Since/IN sequence/NN variations/NNS in/IN the/DT 3'/JJ UTR/NN of/IN VDR/NN have/VBP been/VBN linked/VBN to/TO the/DT different/JJ haplotypes/NNS ,/, investigators/NNS have/VBP proposed/VBN that/IN the/DT stability/NN of/IN VDR/NN mRNA/NN is/VBZ influenced/VBN by/IN allelic/JJ variations/NNS ./. 
Indirect/JJ evidence/NN suggested/VBD that/IN allele/NN T/NN is/VBZ less/RBR stable/JJ than/IN allele/NN t/NN ./. 
In/IN this/DT study/NN ,/, we/PRP used/VBD a/DT RT-PCR/NN based/JJ approach/NN to/TO compare/VB the/DT stability/NN of/IN the/DT big/JJ T/NN and/CC small/JJ t/NN allele/NN in/IN normal/JJ heterozygous/JJ lymphocytes/NNS and/CC the/DT heterozygous/JJ cell/NN lines/NNS NB4/NN (/( myeloid/JJ leukemia/NN )/) and/CC PC-3/NN and/CC DU/NN 145/CD (/( prostate/NN cancers/NNS )/) ./. 
In/IN all/DT three/CD cases/NNS ,/, we/PRP did/VBD not/RB find/VB a/DT significant/JJ difference/NN in/IN stability/NN ./. 
Interestingly/RB ,/, we/PRP consistently/RB observed/VBD 30/CD %/NN less/JJR RT-PCR/NN product/NN derived/VBN from/IN the/DT small/JJ t/NN allele/NN mRNA/NN in/IN steady/JJ state/NN ,/, a/DT finding/NN which/WDT also/RB speaks/VBZ against/IN a/DT higher/JJR stability/NN of/IN the/DT small/JJ t/NN allele/NN mRNA/NN ./. 
These/DT results/NNS indicate/VBP a/DT variation/NN in/IN transcriptional/JJ regulation/NN rather/RB than/IN mRNA/NN stability/NN between/IN the/DT alleles/NNS ./. 
We/PRP hypothesize/VBP that/IN an/DT unknown/JJ gene/NN or/CC genes/NNS in/IN linkage/NN with/IN the/DT polymorphisms/NNS is/VBZ (/( are/VBP )/) responsible/JJ for/IN the/DT relationship/NN between/IN risk/NN of/IN prostate/NN cancer/NN and/CC VDR/NN polymorphisms/NNS ./. 
UI/LS -/: 98099332/CD 
TI/LS -/: Replication/NN of/IN human/JJ immunodeficiency/NN virus-1/NN in/IN primary/JJ human/JJ T/NN cells/NNS is/VBZ dependent/JJ on/IN the/DT autocrine/JJ secretion/NN of/IN tumor/NN necrosis/NN factor/NN through/IN the/DT control/NN of/IN nuclear/JJ factor-kappa/NN B/NN activation/NN ./. 
AB/LS -/: Tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) -alpha/NN controls/VBZ T-cell/NN activation/NN and/CC is/VBZ a/DT major/JJ inducer/NN of/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) -1/CD replication/NN in/IN chronically/RB infected/JJ cells/NNS ./. 
Therefore/RB ,/, we/PRP have/VBP investigated/VBN its/PRP$ role/NN in/IN primary/JJ cultures/NNS of/IN HIV-infected/JJ human/JJ T/NN lymphocytes/NNS by/IN using/VBG neutralizing/VBG anti-TNF-alpha/JJ antibodies/NNS or/CC TNF-alpha/NN ./. 
Primary/JJ resting/VBG T/NN lymphocytes/NNS produced/VBD TNF-alpha/NN and/CC supported/VBD HIV/NN replication/NN after/IN T-cell/NN receptor/NN activation/NN ./. 
Addition/NN of/IN neutralizing/VBG anti-TNF-alpha/JJ antibodies/NNS drastically/RB reduced/VBD p24/NN antigen/NN release/NN and/CC prevented/VBD CD4+/JJ cell/NN depletion/NN associated/VBN with/IN infection/NN ./. 
Anti-TNF-alpha/NN also/RB prevented/VBD nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) activation/NN ,/, and/CC a/DT good/JJ correlation/NN between/IN this/DT inhibition/NN and/CC inhibition/NN of/IN HIV/NN replication/NN was/VBD observed/VBN ./. 
Moreover/RB ,/, supplementing/VBG the/DT cultures/NNS with/IN high/JJ doses/NNS of/IN IL-2/NN reverted/VBD anti-TNF-alpha/JJ inhibition/NN of/IN cell/NN proliferation/NN but/CC did/VBD not/RB affect/VB the/DT inhibition/NN of/IN HIV/NN p24/NN antigen/NN release/NN or/CC NF-kappa/NN B/NN activation/NN in/IN the/DT same/JJ cultures/NNS ./. 
Moreover/RB ,/, anti-TNF-alpha/NN inhibited/VBD HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) -driven/JJ transcription/NN of/IN a/DT reporter/NN gene/NN in/IN primary/JJ T/NN cells/NNS in/IN response/NN to/TO activation/NN ,/, either/CC in/IN the/DT presence/NN or/CC the/DT absence/NN of/IN HIV-1/NN Tat/NN ./. 
Our/PRP$ results/NNS support/VBP an/DT important/JJ role/NN for/IN autocrine/JJ TNF-alpha/NN secretion/NN in/IN controlling/VBG HIV/NN replication/NN in/IN primary/JJ T/NN cells/NNS because/IN of/IN its/PRP$ ability/NN to/TO maintain/VB NF-kappa/NN B/NN elevated/JJ in/IN the/DT nucleus/NN of/IN T/NN cells/NNS ./. 
UI/LS -/: 98042055/CD 
TI/LS -/: Hypoxia/NN enhances/VBZ induction/NN of/IN endothelial/JJ ICAM-1/NN :/: role/NN for/IN metabolic/JJ acidosis/NN and/CC proteasomes/NNS ./. 
AB/LS -/: Intercellular/JJ adhesion/NN molecule/NN 1/CD (/( ICAM-1/NN )/) is/VBZ an/DT important/JJ molecule/NN in/IN promotion/NN of/IN polymorphonuclear/JJ neutrophil/NN transendothelial/JJ migration/NN during/IN inflammation/NN ./. 
Coincident/JJ with/IN many/JJ inflammatory/JJ diseases/NNS is/VBZ tissue/NN hypoxia/NN ./. 
Thus/RB we/PRP hypothesized/VBD that/IN combinations/NNS of/IN hypoxia/NN and/CC inflammatory/JJ stimuli/NNS may/MD differentially/RB regulate/VB expression/NN of/IN endothelial/JJ ICAM-1/NN ./. 
Human/JJ endothelial/JJ cells/NNS were/VBD exposed/VBN to/TO hypoxia/NN in/IN the/DT presence/NN or/CC absence/NN of/IN added/VBN lipopolysaccharide/NN (/( LPS/NN )/) and/CC examined/VBN for/IN expression/NN of/IN functional/JJ ICAM-1/NN ./. 
Although/IN hypoxia/NN alone/RB did/VBD not/RB induce/VB ICAM-1/NN ,/, the/DT combination/NN of/IN LPS/NN and/CC hypoxia/NN enhanced/VBD (/( 3/CD +/-/CC 0.4-fold/JJ over/IN normoxia/NN )/) ICAM-1/NN expression/NN ./. 
Combinations/NNS of/IN hypoxia/NN and/CC LPS/NN significantly/RB increased/VBD lymphocyte/NN binding/NN ,/, and/CC such/JJ increases/NNS were/VBD inhibited/VBN by/IN addition/NN of/IN anti-ICAM-1/JJ antibodies/NNS or/CC antisense/JJ oligonucleotides/NNS ./. 
Hypoxic/JJ endothelia/NN showed/VBD a/DT >/JJR 10-fold/JJ increase/NN in/IN sensitivity/NN to/TO inhibitors/NNS of/IN proteasome/NN activation/NN ,/, and/CC combinations/NNS of/IN hypoxia/NN and/CC LPS/NN enhanced/VBD proteasome-dependent/JJ cytoplasmic-to-nuclear/JJ localization/NN of/IN the/DT nuclear/JJ transcription/NN factor-kappa/NN B/NN p65/NN (/( Rel/NN A/NN )/) subunit/NN ./. 
Such/JJ proteasome/NN activation/NN correlated/VBD with/IN hypoxia-evoked/JJ decreases/NNS in/IN both/CC extracellular/JJ and/CC intracellular/JJ pH/NN ./. 
We/PRP conclude/VBP from/IN these/DT studies/NNS that/IN endothelial/JJ hypoxia/NN provides/VBZ a/DT novel/JJ ,/, proteasome-dependent/JJ stimulus/NN for/IN ICAM-1/NN induction/NN ./. 
UI/LS -/: 98058835/CD 
TI/LS -/: Differanisole/NN A/NN ,/, a/DT novel/JJ antitumor/JJ antibiotic/NN ,/, enhances/VBZ growth/NN inhibition/NN and/CC differentiation/NN of/IN human/JJ myeloid/JJ leukemia/NN cells/NNS induced/VBN by/IN 9-cis/JJ retinoic/JJ acid/NN ./. 
AB/LS -/: Differanisole/NN A/NN ,/, 3,5-dichloro-2-hydroxy-4-methoxy-6-n-propylbenzoic/JJ acid/NN ,/, inhibited/VBD growth/NN of/IN human/JJ myeloid/JJ leukemia/NN cells/NNS ./. 
The/DT compound/NN induced/VBD G1/NN arrest/NN and/CC granulocytic/JJ differentiation/NN of/IN HL-60/NN cells/NNS ,/, although/IN the/DT differentiation-inducing/JJ effect/NN was/VBD modest/JJ ./. 
Differanisole/NN A/DT and/CC 9-cis/JJ retinoic/JJ acid/NN (/( 9cisRA/NN )/) synergistically/RB inhibited/VBD the/DT growth/NN and/CC induced/VBD functional/JJ and/CC morphologic/JJ differentiation/NN of/IN HL-60/NN and/CC NB4/NN cells/NNS ,/, whereas/IN the/DT combined/JJ treatment/NN with/IN differanisole/NN A/NN and/CC all-trans/JJ retinoic/JJ acid/NN or/CC 1alpha,25-dihydroxyvitamin/NN D3/NN was/VBD less/RBR effective/JJ ./. 
Similar/JJ results/NNS were/VBD obtained/VBN in/IN primary/JJ culture/NN of/IN leukemia/NN cells/NNS from/IN a/DT patient/NN with/IN acute/JJ promyelocytic/JJ leukemia/NN ./. 
The/DT synergistic/JJ effect/NN on/IN growth/NN inhibition/NN and/CC induction/NN of/IN differentiation/NN required/VBD simultaneous/JJ treatment/NN with/IN differanisole/NN A/NN and/CC 9cisRA/NN ./. 
Differanisole/NN A/NN and/CC an/DT RXR-specific/JJ ligand/NN (/( Ro47-5944/NN )/) cooperatively/RB inhibited/VBD the/DT cell/NN growth/NN ,/, while/IN the/DT combined/JJ effect/NN of/IN differanisole/NN A/NN and/CC an/DT RAR-specific/JJ ligand/NN Am80/NN was/VBD just/RB additive/JJ ./. 
Differanisole/NN A/NN in/IN combination/NN with/IN 9cisRA/NN may/MD have/VB implications/NNS for/IN therapy/NN of/IN acute/JJ promyelocytic/JJ leukemia/NN patients/NNS ./. 
UI/LS -/: 98028550/CD 
TI/LS -/: The/DT activation/NN of/IN the/DT JAK2/STAT5/NN pathway/NN is/VBZ commonly/RB involved/VBN in/IN signaling/NN through/IN the/DT human/JJ IL-5/NN receptor/NN ./. 
AB/LS -/: The/DT JAK/NN (/( Janus/NN kinase/NN )/) family/NN of/IN protein/NN tyrosine/NN kinases/NNS and/CC the/DT STATs/NNS (/( signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN )/) have/VBP been/VBN shown/VBN to/TO be/VB activated/VBN in/IN response/NN to/TO a/DT number/NN of/IN cytokines/NNS and/CC growth/NN factors/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP evaluated/VBD the/DT activation/NN of/IN JAK/STAT/NN pathway/NN upon/IN human/JJ interleukin-5/NN (/( hIL-5/NN )/) stimulation/NN of/IN two/CD different/JJ hIL-5-responsive/JJ cell/NN lines/NNS ,/, hIL-5/NN receptor/NN alpha-subunit/NN (/( hIL-5R/NN alpha/NN )/) cDNA-transfected/JJ TF-1/NN (/( TF-h5R/NN alpha/NN )/) and/CC butyric-acid-treated/JJ YY-1/NN (/( YY-Bu/NN )/) ,/, and/CC peripheral/JJ eosinophils/NNS ./. 
Immunoprecipitation/NN and/CC electrophoretic/JJ mobility/NN shift/NN analysis/NN revealed/VBD that/IN tyrosine/NN phosphorylation/NN of/IN JAK2/NN and/CC activation/NN of/IN STAT5/NN were/VBD induced/VBN upon/IN stimulation/NN with/IN hIL-5/NN in/IN all/DT three/CD cell/NN types/NNS ,/, while/IN STAT1/NN activation/NN was/VBD only/RB observed/VBN in/IN eosinophils/NNS ./. 
These/DT results/NNS indicate/VBP that/IN JAK2/STAT5/NN activation/NN is/VBZ a/DT common/JJ JAK/STAT/NN pathway/NN for/IN hIL-5-mediated/JJ signal/NN in/IN these/DT cells/NNS ./. 
UI/LS -/: 98012705/CD 
TI/LS -/: Dysregulation/NN of/IN monocytic/JJ nuclear/JJ factor-kappa/NN B/NN by/IN oxidized/VBN low-density/JJ lipoprotein/NN ./. 
AB/LS -/: Nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) /Rel/NN transcription/NN factors/NNS may/MD be/VB involved/VBN in/IN atherosclerosis/NN ,/, as/IN is/VBZ suggested/VBN by/IN the/DT presence/NN of/IN activated/VBN NF-kappa/NN B/NN in/IN human/JJ atherosclerotic/JJ lesions/NNS ./. 
The/DT aim/NN of/IN the/DT present/JJ study/NN was/VBD to/TO investigate/VB the/DT effects/NNS of/IN oxidized/VBN LDL/NN (/( oxLDL/NN )/) on/IN the/DT NF-kappa/NN B/NN system/NN in/IN human/JJ THP-1/NN monocytic/JJ cells/NNS as/RB well/RB as/IN adherent/JJ monocytes/NNS ./. 
Our/PRP$ results/NNS demonstrate/VBP that/IN short-term/JJ incubation/NN of/IN these/DT cells/NNS with/IN oxLDL/NN activated/VBD p50/p65/NN containing/VBG NF-kappa/NN B/NN dimers/NNS and/CC induced/VBD the/DT expression/NN of/IN the/DT target/NN gene/NN IL-8/NN ./. 
This/DT activation/NN of/IN NF-kappa/NN B/NN was/VBD inhibited/VBN by/IN the/DT antioxidant/JJ and/CC H2O2/NN scavenger/NN pyrrolidine/NN dithiocarbamate/NN and/CC the/DT proteasome/NN inhibitor/NN PSI/NN ./. 
The/DT oxLDL-induced/JJ NF-kappa/NN B/NN activation/NN was/VBD accompanied/VBN by/IN an/DT initial/JJ depletion/NN of/IN I/NN kappa/NN B-alpha/NN followed/VBN by/IN a/DT slight/JJ transient/JJ increase/NN in/IN the/DT level/NN of/IN this/DT inhibitor/NN protein/NN ./. 
In/IN contrast/NN ,/, long-term/JJ treatment/NN with/IN oxLDL/NN prevented/VBD the/DT lipopolysaccharide-induced/JJ depletion/NN of/IN I/NN kappa/NN B-alpha/NN ,/, accompanied/VBN by/IN an/DT inhibition/NN of/IN both/CC NF-kappa/NN B/NN activation/NN and/CC the/DT expression/NN of/IN tumor/NN necrosis/NN factor-alpha/NN and/CC interleukin-1/NN beta/NN genes/NNS ./. 
These/DT observations/NNS provide/VBP additional/JJ evidence/NN that/IN oxLDL/NN is/VBZ a/DT potent/JJ modulator/NN of/IN gene/NN expression/NN and/CC suggest/VBP that/IN (/( dys/JJ )/) regulation/NN of/IN NF-kappa/NN B/Rel/NN is/VBZ likely/JJ to/TO play/VB an/DT important/JJ role/NN in/IN atherogenesis/NN ./. 
UI/LS -/: 98003050/CD 
TI/LS -/: Suppression/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN and/CC CD18-mediated/JJ leukocyte/NN adhesion/NN to/TO the/DT corneal/NN endothelium/NN by/IN dexamethasone/NN ./. 
AB/LS -/: PURPOSE/NN :/: To/TO demonstrate/VB that/IN leukocyte/NN adhesion/NN to/TO cultured/VBN corneal/NN endothelial/JJ cells/NNS is/VBZ mediated/VBN by/IN the/DT CD18/NN antigen/NN ,/, and/CC to/TO determine/VB whether/IN dexamethasone/NN directly/RB suppresses/VBZ adhesion/NN by/IN inhibiting/VBG activation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NFkappaB/NN )/) ./. 
METHODS/NNS :/: Cultured/VBN bovine/JJ corneal/NN endothelium/NN was/VBD stimulated/VBN for/IN 6/CD hours/NNS by/IN 40/CD micron/ml/NN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNFalpha/NN )/) ./. 
Dexamethasone/NN was/VBD added/VBN 1/CD hour/NN before/IN TNFalpha/NN stimulation/NN in/IN the/DT dexamethasone/NN group/NN ./. 
After/IN stimulation/NN ,/, neutrophils/NNS separated/VBN from/IN a/DT healthy/JJ human/JJ volunteer/NN were/VBD added/VBN with/IN or/CC without/IN anti-CD18/JJ antibody/NN ./. 
The/DT culture/NN plate/NN was/VBD settled/VBN for/IN 15/CD minutes/NNS at/IN 37/CD degrees/NNS C/NN ,/, and/CC then/RB neutrophils/NNS were/VBD activated/VBN by/IN N-formyl-methionyl-leucyl-phenylalanine/NN for/IN 5/CD minutes/NNS ./. 
Nonadherent/JJ neutrophils/NNS were/VBD removed/VBN by/IN sealing/VBG and/CC inverting/VBG the/DT culture/NN well/RB ./. 
The/DT intracellular/JJ localization/NN of/IN NFkappaB/NN after/IN TNFalpha/NN simulation/NN was/VBD determined/VBN by/IN confocal/JJ immunocytochemistry/NN using/VBG an/DT anti-p65/JJ antibody/NN ./. 
RESULTS/NNS :/: Neutrophil/NN adhesion/NN to/TO cultured/VBN corneal/NN endothelial/JJ cells/NNS increased/VBD significantly/RB on/IN exposure/NN to/TO TNFalpha/NN (/( 451.4+/-45.4/CD cells/mm2/NNS ,/, n/NN =/JJ 16/CD )/) compared/VBN to/TO control/NN (/( 156.7+/-27.3/CD cells/mm2/NNS ,/, n/NN =/JJ 16/CD ,/, P/NN </JJR 0.01/CD )/) ./. 
This/DT increased/VBN adhesion/NN was/VBD suppressed/VBN by/IN the/DT addition/NN of/IN anti-CD18/JJ antibody/NN (/( 157.6+/-25.1/CD cells/mm2/NNS ,/, n/NN =/JJ 8/CD ,/, P/NN </JJR 0.01/CD )/) and/CC by/IN pretreatment/NN with/IN 10(-7)/CD M/NN dexamethasone/NN (/( 207.9+/-31.5/CD cells/mm2/NNS ,/, n/NN =/JJ 10/CD ,/, P/NN </JJR 0.01/CD )/) ./. 
Immunocytochemistry/NN 60/CD minutes/NNS after/IN stimulation/NN revealed/VBD that/IN NFkappaB/NN was/VBD located/JJ in/IN the/DT cytoplasm/NN in/IN unstimulated/JJ cells/NNS ;/: however/RB ,/, the/DT addition/NN of/IN TNFalpha/NN caused/VBD NFkappaB/NN to/TO translocate/VB into/IN the/DT nucleus/NN ./. 
Pretreatment/NN with/IN dexamethasone/NN tapered/VBD NFkappaB/NN translocation/NN into/IN the/DT nucleus/NN ./. 
CONCLUSIONS/NNS :/: Leukocyte/NN adhesion/NN to/TO the/DT corneal/NN endothelium/NN was/VBD shown/VBN to/TO be/VB mediated/VBN by/IN CD18/NN expressed/VBN on/IN activated/VBN leukocytes/NNS ./. 
Pretreatment/NN of/IN the/DT endothelium/NN with/IN dexamethasone/NN inhibited/VBD leukocyte/NN adhesion/NN ;/: this/DT may/MD be/VB due/JJ in/IN part/NN to/TO the/DT suppression/NN of/IN NFkappaB/NN entry/NN into/IN the/DT nucleus/NN ./. 
UI/LS -/: 97480711/CD 
TI/LS -/: Molecular/JJ characterization/NN and/CC pattern/NN of/IN tissue/NN expression/NN of/IN the/DT gene/NN for/IN neutrophil/NN gelatinase-associated/JJ lipocalin/NN from/IN humans/NNS ./. 
AB/LS -/: Neutrophil/NN gelatinase-associated/JJ lipocalin/NN (/( NGAL/NN )/) is/VBZ a/DT 25-kDa/JJ lipocalin/NN first/RB identified/VBN as/IN a/DT protein/NN stored/VBN in/IN specific/JJ granules/NNS of/IN the/DT human/JJ neutrophil/NN ./. 
The/DT protein/NN is/VBZ believed/VBN to/TO bind/VB small/JJ lipophilic/JJ substances/NNS such/JJ as/IN bacterial/JJ derived/VBN formylpeptides/NNS and/CC lipopolysaccharides/NNS (/( LPS/NNS )/) and/CC might/MD function/NN as/IN a/DT modulator/NN of/IN inflammation/NN ./. 
To/TO characterize/VB the/DT regulation/NN of/IN NGAL/NN further/RB ,/, we/PRP have/VBP cloned/VBN and/CC sequenced/VBN a/DT 5869-bp/JJ region/NN of/IN the/DT NGAL/NN gene/NN including/VBG 1695/CD bp/NN of/IN the/DT 5'/JJ nontranscribed/JJ region/NN and/CC a/DT 3696-bp/JJ coding/VBG region/NN encompassing/VBG seven/CD exons/NNS and/CC six/CD introns/NNS ./. 
The/DT transcriptional/JJ start/NN sites/NNS were/VBD identified/VBN by/IN an/DT RNase/NN protection/NN assay/NN ./. 
The/DT NGAL/NN gene/NN is/VBZ highly/RB homologous/JJ to/TO the/DT mouse/NN gene/NN 24p3/NN ./. 
NGAL/NN was/VBD expressed/VBN in/IN bone/NN marrow/NN and/CC in/IN tissues/NNS that/WDT are/VBP prone/JJ to/TO exposure/NN to/TO microorganisms/NNS ./. 
Potential/JJ cis-acting/JJ elements/NNS were/VBD identified/VBN in/IN the/DT promoter/NN region/NN of/IN the/DT NGAL/NN gene/NN by/IN computer/NN analysis/NN and/CC include/VBP binding/VBG sites/NNS for/IN CTF/CBP/NN ,/, the/DT hematopoietic/JJ transcription/NN factors/NNS GATA-1/NN and/CC PU.1/NN ,/, and/CC the/DT LPS-inducible/JJ factor/NN NF-kappa/NN B/NN ./. 
UI/LS -/: 97462740/CD 
TI/LS -/: Human/JJ neutrophils/NNS express/VBP GH-N/NN gene/NN transcripts/NNS and/CC the/DT pituitary/JJ transcription/NN factor/NN Pit-1b/NN ./. 
AB/LS -/: Since/IN GH/NN stimulates/VBZ the/DT development/NN and/CC function/NN of/IN granulocytes/NNS ,/, we/PRP investigated/VBD the/DT expression/NN of/IN GH/NN in/IN granulocyte/JJ subsets/NNS ./. 
By/IN immunocytochemistry/NN ,/, 25/CD +/-/CC 7/CD %/NN of/IN the/DT human/JJ neutrophils/NNS were/VBD shown/VBN to/TO express/VB immunoreactive/JJ GH/NN ,/, whereas/IN eosinophils/NNS were/VBD negative/JJ ./. 
Reversed/VBN transcription/NN (/( RT/NN )/) -PCR/JJ analysis/NN demonstrated/VBD GH/NN mRNA/NN in/IN neutrophils/NNS ./. 
Restriction/NN analysis/NN revealed/VBD that/IN neutrophils/NNS express/VBP the/DT GH-N/NN gene/NN but/CC not/RB the/DT GH-V/NN gene/NN ./. 
Furthermore/RB ,/, we/PRP demonstrated/VBD by/IN western/NN blot/NN analysis/NN that/IN neutrophils/NNS express/VBP an/DT alternatively/RB spliced/VBN variant/NN of/IN the/DT pituitary/JJ transcription/NN factor/NN Pit-1/NN ,/, designated/VBN Pit-1b/NN ./. 
UI/LS -/: 97456516/CD 
TI/LS -/: The/DT ability/NN of/IN BHRF1/NN to/TO inhibit/VB apoptosis/NN is/VBZ dependent/JJ on/IN stimulus/NN and/CC cell/NN type/NN ./. 
AB/LS -/: The/DT development/NN of/IN resistance/NN to/TO host/NN defense/NN mechanisms/NNS such/JJ as/IN tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) -/: and/CC Fas-mediated/JJ apoptosis/NN of/IN transformed/VBN or/CC virus-infected/JJ cells/NNS may/MD be/VB a/DT critical/JJ component/NN in/IN the/DT development/NN of/IN disease/NN ./. 
To/TO find/VB genes/NNS that/WDT protect/VBP cells/NNS from/IN apoptosis/NN ,/, we/PRP used/VBD an/DT expression/NN cloning/NN strategy/NN and/CC identified/VBD BHRF1/NN ,/, an/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) early-lytic-cycle/JJ protein/NN with/IN distant/JJ homology/NN to/TO Bcl-2/NN ,/, as/IN an/DT anti-apoptosis/JJ protein/NN ./. 
Expression/NN of/IN BHRF1/NN in/IN MCF-Fas/NN cells/NNS conferred/VBD nearly/RB complete/JJ resistance/NN against/IN both/CC anti-Fas/JJ antibody/NN and/CC TNF-mediated/JJ apoptosis/NN ./. 
In/IN addition/NN ,/, BHRF1/NN protected/VBD these/DT cells/NNS from/IN monocyte-mediated/JJ killing/NN but/CC failed/VBD to/TO protect/VB them/PRP from/IN killing/NN mediated/VBN by/IN lymphokine-activated/JJ killer/NN cells/NNS ./. 
The/DT ability/NN of/IN BHRF1/NN to/TO protect/VB MCF-Fas/NN cells/NNS from/IN apoptosis/NN induced/VBN by/IN various/JJ stimuli/NNS was/VBD identical/JJ to/TO that/DT of/IN Bcl-2/NN and/CC Bcl-xL/NN ./. 
Moreover/RB ,/, the/DT mechanism/NN of/IN action/NN of/IN BHRF1/NN resembled/VBD that/DT of/IN Bcl-2/NN and/CC Bcl-xL/NN as/IN it/PRP inhibited/VBD TNF-/NN and/CC anti-Fas-induced/JJ activation/NN of/IN two/CD enzymes/NNS participating/VBG in/IN the/DT apoptosis/NN pathway/NN ,/, cytosolic/JJ phospholipase/NN A2/NN and/CC caspase-3/CPP32/NN ,/, but/CC did/VBD not/RB interfere/VB with/IN the/DT activation/NN of/IN NF-kappaB-like/JJ transcription/NN factors/NNS ./. 
A/DT putative/JJ function/NN of/IN BHRF1/NN in/IN EBV-infected/JJ epithelial/JJ cells/NNS may/MD be/VB to/TO protect/VB virus-infected/JJ cells/NNS from/IN TNF-/NN and/or/CC anti-Fas-induced/JJ cell/NN death/NN in/IN order/NN to/TO maximize/VB virus/NN production/NN ./. 
Surprisingly/RB ,/, expression/NN of/IN neither/CC BHRF1/NN nor/CC Bcl-2/NN in/IN a/DT B-cell/NN line/NN ,/, BJAB/NN ,/, protected/VBD the/DT cells/NNS from/IN anti-Fas-mediated/JJ apoptosis/NN even/RB though/IN they/PRP increased/VBD the/DT survival/NN of/IN serum-starved/JJ cells/NNS ./. 
Thus/RB ,/, the/DT protective/JJ role/NN of/IN BHRF1/NN against/IN apoptosis/NN resembles/VBZ that/DT of/IN Bcl-2/NN in/IN being/VBG cell/NN type/NN specific/JJ and/CC dependent/JJ on/IN the/DT apoptotic/JJ stimulus/NN ./. 
UI/LS -/: 97445071/CD 
TI/LS -/: Genomic/JJ organization/NN ,/, sequence/NN ,/, and/CC transcriptional/JJ regulation/NN of/IN the/DT human/JJ eotaxin/NN gene/NN ./. 
AB/LS -/: Eotaxin/NN is/VBZ an/DT eosinophil/NN specific/JJ beta-chemokine/NN assumed/VBN to/TO be/VB involved/VBN in/IN eosinophilic/JJ inflammatory/JJ diseases/NNS such/JJ as/IN atopic/JJ dermatitis/NN ,/, allergic/JJ rhinitis/NN ,/, asthma/NN and/CC parasitic/JJ infections/NNS ./. 
Its/PRP$ expression/NN is/VBZ stimulus-/NN and/CC cell-specific/JJ ./. 
We/PRP here/RB describe/VBP the/DT genomic/JJ organisation/NN (/( 3/CD exons/NNS of/IN 132/CD ,/, 112/CD and/CC 542/CD bp/NN and/CC 2/CD introns/NNS of/IN 1211/CD and/CC 378/CD bp/NN )/) and/CC sequence/NN including/VBG 3/CD kb/NN of/IN DNA/NN from/IN the/DT immediate/JJ 5'/JJ upstream/JJ region/NN of/IN the/DT human/JJ eotaxin/NN gene/NN ./. 
Among/IN the/DT regulatory/JJ promoter/NN elements/NNS potentially/RB regulating/VBG eotaxin/NN gene/NN expression/NN and/or/CC mediating/VBG the/DT effects/NNS of/IN anti-inflammatory/JJ drugs/NNS we/PRP identified/VBD consensus/NN sequences/NNS known/VBN to/TO interact/VB with/IN nuclear/JJ factors/NNS like/IN NF-IL6/NN ,/, AP-1/NN ,/, a/DT NF-kappa-B/NN like/JJ consensus/NN sequence/NN and/CC gamma-interferon-/NN as/RB well/RB as/IN glucocorticoid/NN response/NN elements/NNS ./. 
UI/LS -/: 97400349/CD 
TI/LS -/: Differential/JJ interaction/NN of/IN nuclear/JJ factors/NNS with/IN the/DT leukocyte-specific/JJ pp52/NN promoter/NN in/IN B/NN and/CC T/NN cells/NNS ./. 
AB/LS -/: The/DT leukocyte-specific/JJ ,/, cytoskeleton-binding/JJ pp52/NN (/( LSP-1/NN ,/, WP-34/NN )/) protein/NN is/VBZ widely/RB expressed/VBN in/IN multiple/JJ leukocyte/NN lineages/NNS ,/, including/VBG B/NN and/CC T/NN lymphocytes/NNS ,/, granulocytes/NNS ,/, and/CC macrophages/NNS ./. 
We/PRP previously/RB detected/VBD a/DT tissue-specific/JJ promoter/NN preceding/VBG the/DT exon/NN encoding/VBG the/DT N/NN terminus/NN of/IN the/DT pp52/NN leukocyte/NN protein/NN ./. 
Here/RB we/PRP describe/VBP the/DT functional/JJ characterization/NN of/IN this/DT promoter/NN and/CC identification/NN of/IN the/DT factors/NNS in/IN B/NN and/CC T/NN cells/NNS that/WDT regulate/VBP its/PRP$ activity/NN ./. 
The/DT pp52/NN promoter/NN contains/VBZ an/DT initiator/NN specifying/VBG the/DT unique/JJ 5'/JJ terminus/NN of/IN pp52/NN mRNA/NN ,/, tandem/JJ pairs/NNS of/IN Ets/NN and/CC SP1/NN motifs/NNS ,/, and/CC a/DT lone/JJ C/EBP/NN motif/NN ./. 
All/PDT these/DT motifs/NNS are/VBP essential/JJ and/CC collectively/RB control/VBP transcriptional/JJ activity/NN ./. 
DNA/NN binding/NN studies/NNS and/CC Ab/NN supershift/NN assays/NNS revealed/VBD that/IN different/JJ combinations/NNS of/IN factors/NNS interact/VBP with/IN these/DT motifs/NNS in/IN B/NN cells/NNS vs/CC T/NN cells/NNS ./. 
The/DT Ets/NN motifs/NNS are/VBP preferentially/RB bound/VBN by/IN PU-1/NN in/IN B/NN cell/NN extracts/NNS from/IN all/DT stages/NNS of/IN development/NN ,/, whereas/IN a/DT different/JJ Ets/NN family/NN member/NN reacts/VBZ with/IN these/DT motifs/NNS in/IN T/NN cell/NN extracts/NNS ./. 
The/DT C/EBP/NN motif/NN is/VBZ bound/VBN by/IN Ig/EBP-1/NN in/IN pre-B/JJ cell/NN and/CC T/NN cell/NN extracts/NNS ,/, but/CC is/VBZ replaced/VBN by/IN nuclear/JJ factor-IL-6beta/NN or/CC a/DT nuclear/JJ factor-IL-6beta-Ig/EBP-1/NN heterodimer/NN in/IN plasmacytoma/NN cell/NN extracts/NNS ./. 
Despite/IN its/PRP$ reported/VBN role/NN as/IN a/DT negative/JJ regulator/NN of/IN transcription/NN ,/, Ig/EBP-1/NN appears/VBZ to/TO exert/VB a/DT stimulatory/JJ effect/NN on/IN this/DT promoter/NN ./. 
These/DT findings/NNS reveal/VBP the/DT features/NNS controlling/VBG the/DT pp52/NN promoter/NN in/IN B/NN and/CC T/NN cells/NNS and/CC provide/VBP the/DT foundation/NN for/IN determining/VBG the/DT regulation/NN of/IN this/DT promoter/NN in/IN other/JJ leukocyte/NN lineages/NNS ./. 
UI/LS -/: 97383366/CD 
TI/LS -/: Regulation/NN of/IN B-cell/NN commitment/NN to/TO plasma/NN cells/NNS or/CC to/TO memory/NN B/NN cells/NNS ./. 
AB/LS -/: During/IN humoral/JJ immune/JJ responses/NNS ,/, B-lymphocyte/NN activation/NN is/VBZ followed/VBN by/IN differentiation/NN along/IN either/CC the/DT plasma/NN cell/NN pathway/NN or/CC the/DT memory/NN B-cell/NN pathway/NN ./. 
Recent/JJ studies/NNS suggest/VBP that/IN CD40-CD40/JJ ligand/NN ,/, OX-OX40/JJ ligand/NN ,/, a/DT group/NN of/IN cytokines/NNS and/CC intracellular/JJ transcriptional/JJ factors/NNS may/MD all/DT contribute/VB to/TO B-lymphocyte/NN differentiation/NN control/NN ./. 
UI/LS -/: 97366676/CD 
TI/LS -/: Transcription/NN factor/NN binding/NN sites/NNS downstream/JJ of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD transcription/NN start/NN site/NN are/VBP important/JJ for/IN virus/NN infectivity/NN ./. 
AB/LS -/: When/WRB transcriptionally/RB active/JJ ,/, the/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) promoter/NN contains/VBZ a/DT nucleosome-free/JJ region/NN encompassing/VBG both/CC the/DT promoter/enhancer/NN region/NN and/CC a/DT large/JJ region/NN (/( 255/CD nucleotides/NNS [/( nt/NN ]/) )/) downstream/JJ of/IN the/DT transcription/NN start/NN site/NN ./. 
We/PRP have/VBP previously/RB identified/VBN new/JJ binding/VBG sites/NNS for/IN transcription/NN factors/NNS downstream/RB of/IN the/DT transcription/NN start/NN site/NN (/( nt/NN 465/CD to/TO 720/CD )/) :/: three/CD AP-1/NN sites/NNS (/( I/CD ,/, II/CD ,/, and/CC III/CD )/) ,/, an/DT AP3-like/JJ motif/NN (/( AP3-L/NN )/) ,/, a/DT downstream/JJ binding/NN factor/NN (/( DBF/NN )/) site/NN ,/, and/CC juxtaposed/VBN Sp1/NN sites/NNS ./. 
Here/RB ,/, we/PRP show/VBP that/IN the/DT DBF/NN site/NN is/VBZ an/DT interferon-responsive/JJ factor/NN (/( IRF/NN )/) binding/NN site/NN and/CC that/IN the/DT AP3-L/NN motif/NN binds/VBZ the/DT T-cell-specific/JJ factor/NN NF-AT/NN ./. 
Mutations/NNS that/WDT abolish/VBP the/DT binding/NN of/IN each/DT factor/NN to/TO its/PRP$ cognate/JJ site/NN are/VBP introduced/VBN in/IN an/DT infectious/JJ HIV-1/NN molecular/JJ clone/NN to/TO study/VB their/PRP$ effect/NN on/IN HIV-1/NN transcription/NN and/CC replication/NN ./. 
Individual/JJ mutation/NN of/IN the/DT DBF/NN or/CC AP3-L/NN site/NN as/RB well/RB as/IN the/DT double/JJ mutation/NN AP-1(III)/AP3-L/NN did/VBD not/RB affect/VB HIV-1/NN replication/NN compared/VBN to/TO that/DT of/IN the/DT wild-type/JJ virus/NN ./. 
In/IN contrast/NN ,/, proviruses/NNS carrying/VBG mutations/NNS in/IN the/DT Sp1/NN sites/NNS were/VBD totally/RB defective/JJ in/IN terms/NNS of/IN replication/NN ./. 
Virus/NN production/NN occurred/VBD with/IN slightly/RB delayed/VBN kinetics/NNS for/IN viruses/NNS containing/VBG combined/JJ mutations/NNS in/IN the/DT AP-1(III)/NN ,/, AP3-L/NN ,/, and/CC DBF/NN sites/NNS and/CC in/IN the/DT AP3-L/NN and/CC DBF-sites/NNS ,/, whereas/IN viruses/NNS mutated/VBN in/IN the/DT AP-1(I,II,III)/NN and/CC AP3-L/NN sites/NNS and/CC in/IN the/DT AP-1(I,II,III)/NN ,/, AP3-L/NN ,/, and/CC DBF/NN sites/NNS exhibited/VBD a/DT severely/RB defective/JJ replicative/JJ phenotype/NN ./. 
No/DT RNA-packaging/JJ defect/NN could/MD be/VB measured/VBN for/IN any/DT of/IN the/DT mutant/JJ viruses/NNS as/IN determined/VBN by/IN quantification/NN of/IN their/PRP$ HIV/NN genomic/JJ RNA/NN ./. 
Measurement/NN of/IN the/DT transcriptional/JJ activity/NN of/IN the/DT HIV-1/NN promoter/NN after/IN transient/JJ transfection/NN of/IN the/DT HIV-1/NN provirus/NN DNA/NN or/CC of/IN long/JJ terminal/JJ repeat-luciferase/JJ constructs/NNS showed/VBD a/DT positive/JJ correlation/NN between/IN the/DT transcriptional/JJ and/CC the/DT replication/NN defects/NNS for/IN most/JJS mutants/NNS ./. 
UI/LS -/: 97379649/CD 
TI/LS -/: Glucocorticoid/NN receptor/NN regulates/VBZ expression/NN of/IN L-selectin/NN and/CC CD11/CD18/NN on/IN human/JJ neutrophils/NNS [/( see/VB comments/NNS ]/) 
AB/LS -/: BACKGROUND/NN :/: Recent/JJ studies/NNS have/VBP raised/VBN the/DT hypothesis/NN that/IN glucocorticoids/NNS could/MD diminish/VB the/DT ability/NN of/IN endothelial/JJ cells/NNS to/TO direct/VB leukocyte/NN traffic/JJ into/IN inflamed/JJ tissues/NNS by/IN inhibiting/VBG expression/NN of/IN the/DT adhesion/NN molecules/NNS endothelial-leukocyte/JJ adhesion/NN molecule-1/NN and/CC intercellular/JJ adhesion/NN molecule-1/NN ./. 
The/DT aim/NN of/IN the/DT present/JJ study/NN was/VBD to/TO investigate/VB whether/IN glucocorticoids/NNS also/RB regulate/VBP the/DT expression/NN of/IN L-selectin/NN and/CC CD11/CD18/NN integrins/NNS on/IN human/JJ neutrophil/NN granulocytes/NNS ./. 
METHODS/NNS AND/CC RESULTS/NNS :/: Incubation/NN of/IN human/JJ whole/JJ blood/NN with/IN platelet-activating/JJ factor/NN (/( PAF/NN ,/, 1/CD mumol/L/NN )/) evoked/VBD downregulation/NN of/IN L-selectin/NN and/CC upregulation/NN of/IN CD11/CD18/NN adhesion/NN receptors/NNS on/IN neutrophils/NNS as/IN measured/VBN by/IN flow/NN cytometry/NN ./. 
While/IN dexamethasone/NN (/( 0.1/CD nmol/L/NN to/TO 100/CD mumol/L/NN )/) did/VBD not/RB affect/VB expression/NN of/IN adhesion/NN molecules/NNS on/IN resting/VBG neutrophils/NNS ,/, it/PRP attenuated/VBD the/DT PAF-induced/JJ changes/NNS in/IN L-selectin/NN and/CC CD18/NN expression/NN in/IN a/DT time-/NN and/CC concentration-dependent/JJ fashion/NN with/IN IC50/NN values/NNS of/IN 31/CD and/CC 13/CD nmol/L/NN ,/, respectively/RB ./. 
These/DT effects/NNS of/IN dexamethasone/NN were/VBD completely/RB aborted/VBN by/IN RU-486/NN (/( 10/CD mumol/L/NN )/) ,/, which/WDT blocks/VBZ transcriptional/JJ activation/NN of/IN the/DT glucocorticoid/NN receptor/NN ,/, and/CC by/IN the/DT protein/NN synthesis/NN inhibitor/NN cycloheximide/NN (/( 35.5/CD mumol/L/NN )/) ./. 
Dexamethasone/NN ,/, up/RB to/TO a/DT concentration/NN of/IN 1/CD mumol/L/NN ,/, neither/CC affected/VBD significantly/RB the/DT release/NN of/IN granule/NN enzymes/NNS nor/CC interfered/VBD with/IN PAF/NN binding/VBG to/TO its/PRP$ membrane/NN receptors/NNS ./. 
CONCLUSIONS/NNS :/: Our/PRP$ results/NNS show/VBP that/IN glucocorticoids/NNS at/IN clinically/RB relevant/JJ concentrations/NNS exert/VBP specific/JJ actions/NNS on/IN expression/NN of/IN adhesion/NN molecules/NNS on/IN activated/VBN neutrophils/NNS ,/, which/WDT are/VBP mediated/VBN through/IN ligation/NN of/IN glucocorticoid/NN receptors/NNS and/CC induction/NN of/IN protein/NN synthesis/NN ,/, and/CC suggest/VBP a/DT novel/JJ mechanism/NN by/IN which/WDT anti-inflammatory/JJ corticosteroids/NNS may/MD inhibit/VB leukocyte/NN accumulation/NN ./. 
UI/LS -/: 97342608/CD 
TI/LS -/: The/DT immediate-early/JJ gene/NN product/NN Egr-1/NN regulates/VBZ the/DT human/JJ interleukin-2/NN receptor/NN beta-chain/NN promoter/NN through/IN noncanonical/JJ Egr/NN and/CC Sp1/NN binding/NN sites/NNS ./. 
AB/LS -/: The/DT interleukin-2/NN IL-2/NN receptor/NN beta-chain/NN (/( IL-2Rbeta/NN )/) is/VBZ an/DT essential/JJ component/NN of/IN the/DT receptors/NNS for/IN IL-2/NN and/CC IL-15/NN ./. 
Although/IN IL-2Rbeta/NN is/VBZ constitutively/RB expressed/VBN by/IN lymphocytes/NNS ,/, its/PRP$ expression/NN can/MD be/VB further/RB induced/VBN by/IN a/DT number/NN of/IN stimuli/NNS ,/, including/VBG phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) ./. 
We/PRP have/VBP now/RB characterized/VBN factors/NNS that/WDT bind/VBP to/TO an/DT enhancer/NN region/NN located/JJ between/IN nucleotides/NNS -170/CD and/CC -139/CD of/IN the/DT human/JJ IL-2Rbeta/NN promoter/NN ./. 
Both/CC Sp1/NN and/CC Sp3/NN bound/VBD to/TO the/DT 5'/JJ portion/NN of/IN this/DT region/NN ,/, whereas/IN a/DT PMA-inducible/JJ factor/NN (/( PIF/NN )/) mainly/RB bound/VBD to/TO its/PRP$ 3'/JJ portion/NN and/CC bound/VBD to/TO the/DT Sp/NN binding/NN motifs/NNS as/RB well/RB ./. 
In/IN Jurkat/NN T/NN cells/NNS ,/, induction/NN of/IN PIF/NN DNA/NN binding/NN activity/NN was/VBD rapidly/RB induced/VBN ,/, required/VBD de/FW novo/FW protein/NN synthesis/NN ,/, and/CC was/VBD sustained/JJ at/IN a/DT high/JJ level/NN for/IN at/IN least/JJS 23/CD h/NN ./. 
Interestingly/RB ,/, PIF/NN was/VBD constitutively/RB activated/VBN in/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1-transformed/JJ MT-2/NN cells/NNS ./. 
In/IN this/DT paper/NN ,/, we/PRP demonstrate/VBP that/IN PIF/NN is/VBZ Egr-1/NN based/VBN on/IN its/PRP$ recognition/NN by/IN anti-Egr-1/JJ antisera/NNS in/IN gel/NN mobility/NN shift/NN assays/NNS ,/, even/RB though/IN the/DT IL-2Rbeta/NN DNA/NN binding/NN motif/NN differed/VBD substantially/RB from/IN the/DT canonical/JJ Egr-1/NN binding/NN site/NN ./. 
In/IN addition/NN ,/, Egr-1/NN bound/VBD to/TO the/DT Sp/NN binding/NN site/NN ./. 
In/IN Jurkat/NN cells/NNS ,/, both/DT sites/NNS were/VBD required/VBN for/IN maximal/JJ IL-2Rbeta/NN promoter/NN activity/NN ,/, and/CC in/IN HeLaS3/NN cells/NNS ,/, transfection/NN of/IN Egr-1/NN could/MD drive/VB activity/NN of/IN a/DT reporter/NN construct/NN containing/VBG both/DT sites/NNS ./. 
Moreover/RB ,/, Sp1/NN and/CC Egr-1/NN could/MD form/VB a/DT complex/NN with/IN kinetics/NNS that/WDT correlated/VBD with/IN the/DT production/NN of/IN Egr-1/NN in/IN Jurkat/NN cells/NNS upon/IN PMA/NN stimulation/NN ./. 
Thus/RB ,/, Sp1/NN and/CC Egr-1/NN physically/RB and/CC functionally/RB cooperate/VBP to/TO mediate/VB maximal/JJ IL-2Rbeta/NN promoter/NN activity/NN ./. 
UI/LS -/: 97326105/CD 
TI/LS -/: Overexpression/NN of/IN HSF2-beta/NN inhibits/VBZ hemin-induced/JJ heat/NN shock/NN gene/NN expression/NN and/CC erythroid/JJ differentiation/NN in/IN K562/NN cells/NNS ./. 
AB/LS -/: Acquisition/NN of/IN heat/NN shock/NN factor/NN 2/CD (/( HSF2/NN )/) DNA/NN binding/NN activity/NN is/VBZ accompanied/VBN by/IN induced/VBN transcription/NN of/IN heat/NN shock/NN genes/NNS in/IN hemin-treated/JJ K562/NN cells/NNS undergoing/VBG erythroid/JJ differentiation/NN ./. 
Previous/JJ studies/NNS revealed/VBD that/IN HSF2/NN consists/VBZ of/IN two/CD alternatively/RB spliced/VBN isoforms/NNS ,/, HSF2-alpha/NN and/CC HSF2-beta/NN ,/, whose/WP$ relative/JJ abundance/NN is/VBZ developmentally/RB regulated/VBN and/CC varies/VBZ between/IN different/JJ tissues/NNS ./. 
To/TO investigate/VB whether/IN the/DT molar/JJ ratio/NN of/IN HSF2-alpha/NN and/CC HSF2-beta/NN isoforms/NNS is/VBZ crucial/JJ for/IN the/DT activation/NN of/IN HSF2/NN and/CC whether/IN the/DT HSF2/NN isoforms/NNS play/VBP functionally/RB distinct/JJ roles/NNS during/IN the/DT hemin-mediated/JJ erythroid/JJ differentiation/NN ,/, we/PRP generated/VBD cell/NN clones/NNS expressing/VBG different/JJ levels/NNS of/IN HSF2-alpha/NN and/CC HSF2-beta/NN ./. 
We/PRP show/VBP that/IN in/IN parental/JJ K562/NN cells/NNS ,/, the/DT HSF2-alpha/NN isoform/NN is/VBZ predominantly/RB expressed/VBN and/CC HSF2/NN can/MD be/VB activated/VBN upon/IN hemin/NN treatment/NN ./. 
In/IN contrast/NN ,/, when/WRB HSF2-beta/NN is/VBZ expressed/VBN at/IN levels/NNS exceeding/VBG those/DT of/IN endogenous/JJ HSF2-alpha/NN ,/, the/DT hemin-induced/JJ DNA/NN binding/NN activity/NN and/CC transcription/NN of/IN heat/NN shock/NN genes/NNS are/VBP repressed/VBN ,/, whereas/IN overexpression/NN of/IN HSF2-alpha/NN results/VBZ in/IN an/DT enhanced/VBN hemin/NN response/NN ./. 
Furthermore/RB ,/, the/DT hemin-induced/JJ accumulation/NN of/IN globin/NN ,/, known/VBN as/IN a/DT marker/NN of/IN erythroid/JJ differentiation/NN ,/, is/VBZ decreased/VBN in/IN cells/NNS overexpressing/VBG HSF2-beta/NN ./. 
We/PRP suggest/VBP that/IN HSF2-beta/NN acts/VBZ as/IN a/DT negative/JJ regulator/NN of/IN HSF2/NN activity/NN during/IN hemin-mediated/JJ erythroid/JJ differentiation/NN of/IN K562/NN cells/NNS ./. 
UI/LS -/: 97307606/CD 
TI/LS -/: Sequential/JJ development/NN of/IN structural/JJ and/CC functional/JJ alterations/NNS in/IN T/NN cells/NNS from/IN tumor-bearing/NN mice/NNS ./. 
AB/LS -/: The/DT TCR/NN alpha/NN beta/NN or/CC -gamma/NN delta/NN chains/NNS bind/VBP the/DT peptide/NN ligand/NN ,/, whereas/IN the/DT associated/VBN CD3/NN delta/NN epsilon/NN gamma/NN and/CC TCR/NN zeta/NN subunits/NNS couple/VBP the/DT TCR/NN to/TO intracellular/JJ signal/NN transduction/NN components/NNS ./. 
Recently/RB ,/, several/JJ groups/NNS have/VBP described/VBN marked/JJ alterations/NNS in/IN signal/NN transduction/NN elements/NNS in/IN T/NN cells/NNS from/IN cancer/NN patients/NNS or/CC in/IN mice/NNS bearing/VBG tumor/NN for/IN a/DT few/JJ weeks/NNS (/( >/JJR 26/CD days/NNS )/) ./. 
The/DT sequence/NN in/IN which/WDT these/DT alterations/NNS develop/VBP is/VBZ unknown/JJ ./. 
The/DT aim/NN of/IN this/DT study/NN was/VBD to/TO explore/VB the/DT kinetics/NNS of/IN the/DT development/NN of/IN alterations/NNS in/IN signal/NN transduction/NN molecules/NNS (/( TCR/NN zeta/NN chain/NN ,/, NF/NN kappaB/NN family/NN proteins/NNS ,/, and/CC tyrosine/NN kinase/NN p56/NN (/( lck/NN )/) )/) in/IN mice/NNS bearing/VBG MC38/NN colon/NN adenocarcinoma/NN ./. 
The/DT results/NNS demonstrate/VBP that/IN alterations/NNS in/IN NF/NN kappaB/NN family/NN proteins/NNS ,/, specifically/RB the/DT failure/NN of/IN p65/NN translocation/NN to/TO the/DT nucleus/NN ,/, occur/VBP earlier/RBR and/CC more/RBR frequently/RB than/IN the/DT decrease/NN in/IN zeta-chain/NN ./. 
These/DT defects/NNS are/VBP paralleled/VBN by/IN an/DT impaired/JJ ability/NN to/TO produce/VB Th1/NN cytokines/NNS (/( IL-2/NN and/CC IFN-gamma/NN )/) ./. 
These/DT initial/JJ changes/NNS are/VBP followed/VBN by/IN the/DT eventual/JJ loss/NN of/IN TCR/NN zeta/NN chain/NN and/CC p56/NN (/( lck/NN )/) and/CC a/DT marked/JJ decrease/NN in/IN cytotoxic/JJ function/NN ./. 
An/DT increased/VBN rate/NN of/IN lysosomal/JJ degradation/NN is/VBZ one/CD of/IN the/DT mechanisms/NNS responsible/JJ for/IN the/DT loss/NN of/IN zeta-chain/NN ./. 
UI/LS -/: 97289591/CD 
TI/LS -/: HLA-DMA/NN and/CC HLA-DMB/NN gene/NN expression/NN functions/VBZ through/IN the/DT conserved/VBN S-X-Y/NN region/NN ./. 
AB/LS -/: The/DT MHC/NN class/NN II/CD homologous/JJ proteins/NNS HLA-DMA/NN and/CC HLA-DMB/NN function/VBP in/IN the/DT loading/NN of/IN peptides/NNS onto/IN class/NN II/CD molecules/NNS ./. 
Like/IN the/DT class/NN II/CD genes/NNS ,/, the/DT HLA-DM/NN genes/NNS contain/VBP upstream/JJ regulatory/JJ sequences/NNS similar/JJ to/TO the/DT S-X-Y/NN regulatory/JJ region/NN as/RB well/RB as/IN additional/JJ putative/JJ regulatory/JJ sites/NNS ./. 
To/TO determine/VB whether/IN the/DT DM/NN genes/NNS are/VBP regulated/VBN in/IN a/DT similar/JJ manner/NN as/IN class/NN II/CD genes/NNS ,/, a/DT series/NN of/IN in/FW vivo/FW and/CC in/FW vitro/FW analyses/NNS was/VBD performed/VBN ./. 
Deletion/NN analysis/NN showed/VBD that/IN expression/NN from/IN the/DT DM/NN promoters/NNS is/VBZ dependent/JJ on/IN the/DT conserved/VBN S-X-Y/NN region/NN ./. 
The/DT class/NN II-specific/JJ transcription/NN factors/NNS RFX/NN and/CC CIITA/NN are/VBP also/RB required/VBN for/IN expression/NN ,/, as/IN cell/NN lines/NNS deficient/JJ in/IN these/DT factors/NNS failed/VBD to/TO allow/VB transcription/NN from/IN the/DT DM/NN promoters/NNS ./. 
In/IN addition/NN ,/, in/FW vivo/FW footprint/NN analysis/NN showed/VBD the/DT putative/JJ X/NN and/CC Y/NN boxes/NNS to/TO be/VB occupied/VBN by/IN transcription/NN factors/NNS in/IN wild-type/JJ B/NN cells/NNS ,/, but/CC not/RB in/IN RFX-deficient/JJ B/NN cells/NNS ./. 
In/IN astrocytes/NNS ,/, IFN-gamma/NN treatment/NN induced/VBD increased/VBN occupancy/NN of/IN these/DT sites/NNS ./. 
None/NN of/IN the/DT other/JJ putative/JJ regulatory/JJ sites/NNS was/VBD occupied/VBN in/FW vivo/FW ,/, indicating/VBG that/IN they/PRP may/MD not/RB be/VB functional/JJ ./. 
Finally/RB ,/, gel/NN shift/NN analysis/NN showed/VBD synergistic/JJ complex/JJ formation/NN between/IN proteins/NNS that/WDT bind/VBP to/TO the/DT putative/JJ X/NN boxes/NNS of/IN the/DT DM/NN genes/NNS ,/, as/IN is/VBZ found/VBN for/IN the/DT DRA/NN gene/NN ./. 
Therefore/RB ,/, the/DT DM/NN genes/NNS share/VBP a/DT common/JJ mechanism/NN of/IN regulation/NN with/IN the/DT class/NN II/CD genes/NNS ./. 
UI/LS -/: 97344875/CD 
TI/LS -/: Effect/NN of/IN adenovirus/NN 2/CD on/IN cellular/JJ gene/NN activation/NN in/IN blood-derived/JJ monocytes/NNS and/CC macrophages/NNS ./. 
AB/LS -/: We/PRP have/VBP investigated/VBN the/DT effect/NN of/IN adenovirus/NN 2/CD (/( Ad2/NN )/) infection/NN on/IN human/JJ monocytes/NNS and/CC monocyte-derived/JJ macrophages/NNS with/IN regard/NN to/TO expression/NN of/IN TNF-alpha/NN and/CC IL-1/NN beta/NN ./. 
In/IN monocytes/NNS ,/, the/DT virus/NN was/VBD bound/VBN to/TO the/DT surface/NN without/IN being/VBG internalized/VBN ./. 
On/IN the/DT other/JJ hand/NN ,/, Ad2/NN was/VBD internalized/VBN by/IN macrophages/NNS ./. 
No/DT virus/NN replication/NN and/CC no/DT transcription/NN of/IN the/DT Ad2/NN early/JJ genes/NNS was/VBD observed/VBN in/IN either/DT of/IN the/DT cells/NNS ./. 
Ad2/NN infection/NN induced/VBD transient/JJ increase/NN in/IN the/DT mRNA/NN levels/NNS for/IN TNF-alpha/NN and/CC IL-1/NN beta/NN in/IN both/CC monocytes/NNS and/CC in/IN macrophages/NNS ,/, although/IN the/DT kinetics/NNS of/IN the/DT transcription/NN was/VBD slightly/RB different/JJ ./. 
The/DT production/NN of/IN both/DT cytokines/NNS ,/, measured/VBN by/IN ELISA/NN tests/NNS ,/, was/VBD enhanced/VBN in/IN monocytes/NNS ./. 
In/IN macrophages/NNS ,/, a/DT slight/JJ enhancement/NN of/IN TNF-alpha/NN production/NN was/VBD seen/VBN ,/, whereas/IN IL-1/NN beta/NN was/VBD not/RB detected/VBN ./. 
The/DT data/NNS indicate/VBP that/IN cellular/JJ genes/NNS might/MD be/VB activated/VBN by/IN Ad2/NN virus/NN infection/NN in/IN nonpermissive/JJ cells/NNS where/WRB no/DT viral/JJ gene/NN products/NNS could/MD be/VB detected/VBN ./. 
UI/LS -/: 97281772/CD 
TI/LS -/: Structure/NN and/CC function/NN analysis/NN of/IN the/DT human/JJ myeloid/JJ cell/NN nuclear/JJ differentiation/NN antigen/NN promoter/NN :/: evidence/NN for/IN the/DT role/NN of/IN Sp1/NN and/CC not/RB of/IN c-Myb/NN or/CC PU.1/NN in/IN myelomonocytic/JJ lineage-specific/JJ expression/NN ./. 
AB/LS -/: The/DT human/JJ myeloid/JJ nuclear/JJ differentiation/NN antigen/NN (/( MNDA/NN )/) is/VBZ expressed/VBN specifically/RB in/IN maturing/VBG cells/NNS of/IN the/DT myelomonocytic/JJ lineage/NN and/CC in/IN monocytes/NNS and/CC granulocytes/NNS ./. 
Epitope/NN enhancement/NN was/VBD used/VBN to/TO confirm/VB the/DT strict/JJ lineage-/NN and/CC stage-specific/JJ expression/NN of/IN MNDA/NN in/IN bone/NN marrow/NN as/RB well/RB as/IN in/IN other/JJ paraffin-embedded/JJ fixed/JJ tissues/NNS ./. 
A/DT 1-kb/JJ region/NN of/IN the/DT gene/NN that/WDT includes/VBZ 5'/JJ flanking/JJ sequence/NN was/VBD reported/VBN earlier/RBR to/TO contain/VB functional/JJ promoter/NN activity/NN and/CC was/VBD specifically/RB demethylated/VBN in/IN expressing/VBG cells/NNS in/IN contrast/NN to/TO null/NN cells/NNS ./. 
Further/JJ analysis/NN has/VBZ revealed/VBN that/IN this/DT 1-kb/JJ fragment/NN promotes/VBZ higher/JJR reporter/NN gene/NN activity/NN in/IN MNDA-expressing/JJ cells/NNS than/IN non-expressing/JJ cells/NNS ,/, indicating/VBG cell-specific/JJ differences/NNS in/IN transactivation/NN ./. 
This/DT sequence/NN contains/VBZ consensus/NN elements/NNS consistent/JJ with/IN myeloid-specific/JJ gene/NN expression/NN ,/, including/VBG a/DT PU.1/NN consensus/NN site/NN near/IN the/DT major/JJ transcription/NN start/NN site/NN and/CC a/DT cluster/NN of/IN c-Myb/NN sites/NNS located/JJ several/JJ hundred/CD bases/NNS upstream/RB of/IN this/DT region/NN ./. 
However/RB ,/, analysis/NN of/IN deletion/NN mutants/NNS localized/VBD nearly/RB all/DT of/IN the/DT promoter/NN activity/NN to/TO a/DT short/JJ region/NN (/( -73/CD to/TO -16/CD )/) that/WDT did/VBD not/RB include/VB the/DT cluster/NN of/IN c-Myb/NN sites/NNS ./. 
A/DT 4-bp/JJ mutation/NN of/IN the/DT core/NN Sp1/NN consensus/NN element/NN (/( GC/NN box/NN )/) (/( -20/CD )/) reduced/VBD overall/JJ promoter/NN activity/NN of/IN the/DT 1-kb/JJ fragment/NN ./. 
Mutation/NN of/IN the/DT PU.1/NN site/NN did/VBD not/RB significantly/RB affect/VB promoter/NN activity/NN ./. 
Only/RB a/DT small/JJ region/NN (/( -35/CD to/TO +22/CD )/) including/VBG the/DT Sp1/NN element/NN and/CC transcription/NN start/NN site/NN ,/, but/CC not/RB the/DT PU.1/NN site/NN was/VBD footprinted/VBN ./. 
The/DT 4-bp/JJ mutation/NN of/IN the/DT core/NN Sp1/NN consensus/NN element/NN abolished/VBD footprinting/NN at/IN the/DT site/NN and/CC an/DT antibody/JJ super-shift/JJ reaction/NN showed/VBD that/IN Sp1/NN is/VBZ one/CD of/IN the/DT factors/NNS binding/VBG the/DT consensus/NN site/NN ./. 
The/DT Sp1/NN site/NN also/RB co-localizes/VBZ with/IN a/DT DNase/NN I/CD hypersensitive/JJ site/NN ./. 
The/DT results/NNS indicate/VBP that/IN DNA/NN methylation/NN ,/, chromatin/NN structure/NN ,/, and/CC transactivation/NN at/IN an/DT Sp1/NN site/NN contribute/VBP to/TO the/DT highly/RB restricted/JJ expression/NN of/IN this/DT myelomonocytic/JJ lineage/NN specific/JJ gene/NN ./. 
UI/LS -/: 97407922/CD 
TI/LS -/: Critical/JJ cytoplasmic/JJ domains/NNS of/IN human/JJ interleukin-9/NN receptor/NN alpha/NN chain/NN in/IN interleukin-9-mediated/JJ cell/NN proliferation/NN and/CC signal/NN transduction/NN ./. 
AB/LS -/: Interleukin-9/NN receptor/NN (/( IL-9R/NN )/) complex/NN consists/VBZ of/IN a/DT ligand-specific/JJ alpha/NN chain/NN and/CC IL-2R/NN gamma/NN chain/NN ./. 
In/IN this/DT study/NN ,/, two/CD regions/NNS in/IN the/DT cytoplasmic/JJ domain/NN of/IN human/JJ IL-9Ralpha/NN were/VBD found/VBN to/TO be/VB important/JJ for/IN IL-9-mediated/JJ cell/NN growth/NN ./. 
A/DT membrane-proximal/JJ region/NN that/WDT contains/VBZ the/DT BOX1/NN consensus/NN sequence/NN is/VBZ required/VBN for/IN IL-9-induced/JJ cell/NN proliferation/NN and/CC tyrosine/NN phosphorylation/NN of/IN Janus/NN kinases/NNS (/( JAKs/NNS )/) ./. 
Deletion/NN of/IN this/DT region/NN or/CC internal/JJ deletion/NN of/IN the/DT BOX1/NN motif/NN abrogated/VBD IL-9-induced/JJ cell/NN proliferation/NN and/CC signal/NN transduction/NN ./. 
However/RB ,/, substitution/NN of/IN the/DT Pro-X-Pro/NN in/IN the/DT BOX1/NN motif/NN with/IN Ala-X-Ala/NN failed/VBD to/TO abolish/VB IL-9-induced/JJ cell/NN proliferation/NN but/CC decreased/VBD IL-9-mediated/JJ tyrosine/NN phosphorylation/NN of/IN JAK/NN kinases/NNS ,/, insulin/NN receptor/NN substrate-2/NN ,/, and/CC signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN 3/CD (/( STAT3/NN )/) and/CC expression/NN of/IN c-myc/NN and/CC junB/NN ./. 
Another/DT important/JJ region/NN is/VBZ downstream/JJ of/IN the/DT BOX1/NN motif/NN and/CC contains/VBZ a/DT STAT3/NN binding/NN motif/NN YLPQ/NN ./. 
Deletion/NN of/IN this/DT region/NN significantly/RB impaired/VBD IL-9-induced/JJ cell/NN growth/NN ,/, activation/NN of/IN JAK/NN kinases/NNS ,/, insulin/NN receptor/NN substrate-2/NN ,/, and/CC STAT3/NN and/CC expression/NN of/IN early/JJ response/NN genes/NNS ./. 
A/DT point/NN mutation/NN changing/VBG YLPQ/NN into/IN YLPA/NN greatly/RB reduced/VBD IL-9-induced/JJ activation/NN of/IN STAT3/NN and/CC expression/NN of/IN c-myc/NN but/CC did/VBD not/RB affect/VB cell/NN proliferation/NN ./. 
These/DT results/NNS suggest/VBP that/IN cooperation/NN or/CC cross-talk/NN of/IN signaling/VBG molecules/NNS associated/VBN with/IN different/JJ domains/NNS of/IN IL-9Ralpha/NN other/JJ than/IN STAT3/NN is/VBZ essential/JJ for/IN IL-9-mediated/JJ cell/NN growth/NN ./. 
UI/LS -/: 97384936/CD 
TI/LS -/: Bcl-2/NN protein/NN inhibits/VBZ bufalin-induced/JJ apoptosis/NN through/IN inhibition/NN of/IN mitogen-activated/JJ protein/NN kinase/NN activation/NN in/IN human/JJ leukemia/NN U937/NN cells/NNS ./. 
AB/LS -/: In/IN a/DT previous/JJ study/NN ,/, we/PRP demonstrated/VBD that/IN bufalin/NN ,/, which/WDT is/VBZ an/DT active/JJ principle/NN of/IN Chinese/NN medicine/NN ,/, chan'su/NN ,/, caused/VBD apoptosis/NN in/IN human/JJ leukemia/NN U937/NN cells/NNS by/IN anomalous/JJ activation/NN of/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) via/IN the/DT signaling/NN pathway/NN of/IN Ras/NN ,/, Raf-1/NN ,/, and/CC MAPK/NN kinase-1/NN ./. 
Here/RB ,/, we/PRP report/VBP the/DT effect/NN of/IN overexpression/NN of/IN bcl-2/NN in/IN U937/NN cells/NNS on/IN the/DT signaling/NN pathway/NN of/IN apoptosis/NN that/WDT is/VBZ induced/VBN by/IN bufalin/NN ./. 
The/DT results/NNS indicated/VBD that/IN the/DT apoptosis/NN induced/VBN by/IN bufalin/NN in/IN U937/NN cells/NNS was/VBD significantly/RB inhibited/VBN by/IN overexpression/NN of/IN the/DT Bcl-2/NN protein/NN ./. 
No/DT significant/JJ difference/NN was/VBD detected/VBN in/IN the/DT activation/NN of/IN MAPK/NN kinase-1/NN that/WDT is/VBZ induced/VBN by/IN bufalin/NN in/IN wild-type/JJ or/CC Bcl-2-overexpressed/JJ U937/NN cells/NNS ;/: however/RB ,/, the/DT activation/NN of/IN MAPK/NN by/IN bufalin/NN was/VBD significantly/RB attenuated/VBN in/IN the/DT cells/NNS overexpressing/VBG Bcl-2/NN ./. 
Bufalin/NN treatment/NN activated/VBD activator/NN protein-1/NN transcriptional/JJ activity/NN ;/: however/RB ,/, this/DT activation/NN was/VBD decreased/VBN to/TO 40/CD %/NN in/IN bcl-2-overexpressed/JJ U937/NN cells/NNS ./. 
These/DT results/NNS indicate/VBP that/IN Bcl-2/NN acts/VBZ downstream/RB of/IN MAPK/NN kinase-1/NN but/CC upstream/RB of/IN MAPK/NN and/CC suggest/VBP that/IN ,/, in/IN the/DT signaling/NN pathway/NN of/IN the/DT apoptotic/JJ process/NN induced/VBN by/IN bufalin/NN ,/, the/DT transcriptional/JJ activity/NN of/IN activator/NN protein-1/NN may/MD be/VB down-regulated/VBN through/IN the/DT inhibition/NN of/IN MAPK/NN activity/NN by/IN Bcl-2/NN ./. 
UI/LS -/: 97375347/CD 
TI/LS -/: Pancreatic/JJ islet/NN expression/NN studies/NNS and/CC polymorphic/JJ DNA/NN markers/NNS in/IN the/DT genes/NNS encoding/VBG hepatocyte/NN nuclear/JJ factor-3alpha/NN ,/, -3beta/NN ,/, -3gamma/NN ,/, -4gamma/NN ,/, and/CC -6/CD ./. 
AB/LS -/: The/DT genes/NNS encoding/VBG the/DT functionally/RB related/JJ hepatocyte/NN nuclear/JJ factors/NNS HNF-1alpha/NN and/CC HNF-4alpha/NN play/VBP a/DT critical/JJ role/NN in/IN normal/JJ pancreatic/JJ beta-cell/NN function/NN ./. 
Mutations/NNS in/IN these/DT liver-enriched/JJ transcription/NN factors/NNS result/VBP in/IN two/CD forms/NNS of/IN early-onset/JJ type/NN 2/CD diabetes/NNS (/( maturity-onset/JJ diabetes/NNS of/IN the/DT young/JJ [/( MODY/NN ]/) )/) ,/, MODY3/NN and/CC MODY1/NN ,/, which/WDT are/VBP characterized/VBN by/IN impaired/JJ glucose-stimulated/JJ insulin/NN secretion/NN ,/, early/RB disease/NN onset/NN ,/, and/CC autosomal/JJ dominant/JJ inheritance/NN ./. 
The/DT transcriptional/JJ hierarchy/NN of/IN HNFs/NNS suggests/VBZ that/IN other/JJ proteins/NNS of/IN the/DT regulatory/JJ cascade/NN might/MD be/VB responsible/JJ for/IN other/JJ forms/NNS of/IN MODY/NN and/or/CC late-onset/JJ type/NN 2/CD diabetes/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP show/VBP that/IN HNF-3alpha/NN ,/, -3beta/NN ,/, -3gamma/NN ,/, -4gamma/NN ,/, and/CC -6/CD are/VBP expressed/VBN in/IN pancreatic/JJ beta-cells/NNS ./. 
We/PRP report/VBP the/DT identification/NN and/CC characterization/NN of/IN simple/JJ tandem/JJ repeat/NN DNA/NN polymorphisms/NNS in/IN the/DT genes/NNS encoding/VBG HNF-3alpha/NN ,/, -3beta/NN ,/, -3gamma/NN ,/, -4gamma/NN ,/, and/CC -6/CD and/CC the/DT mapping/NN of/IN HNF-6/NN to/TO chromosome/NN bands/NNS 15q21.1-21.2/NN by/IN fluorescence/NN in/FW situ/FW hybridization/NN ./. 
These/DT markers/NNS will/MD be/VB useful/JJ to/TO study/VB the/DT role/NN of/IN genetic/JJ variation/NN in/IN these/DT genes/NNS in/IN the/DT pathogenesis/NN of/IN type/NN 2/CD diabetes/NNS ./. 
UI/LS -/: 97387731/CD 
TI/LS -/: Induction/NN of/IN nuclear/JJ factor/NN kappa/NN B/Rel/NN nuclear/JJ activity/NN in/IN human/JJ peripheral/JJ blood/NN T/NN lymphocytes/NNS by/IN anti-HLA/JJ class/NN I/CD monoclonal/JJ antibodies/NNS ./. 
AB/LS -/: Monoclonal/JJ antibodies/NNS against/IN either/CC monomorphic/JJ or/CC polymorphic/JJ determinants/NNS of/IN class/NN I/CD antigen/NN induced/VBD in/IN PBMC/NN and/CC highly/RB purified/VBN T/NN lymphocytes/NNS the/DT nuclear/JJ activity/NN of/IN NF-kappa/NN B/Rel/NN complexes/NNS ./. 
These/DT included/VBD both/CC p50/p50/NN and/CC p50/p65/NN dimers/NNS ,/, recognized/VBN by/IN specific/JJ antibodies/NNS in/IN EMSA/NN ./. 
The/DT induced/VBN complexes/NNS were/VBD detectable/JJ in/IN extracts/NNS of/IN cells/NNS incubated/VBN with/IN anti-class/JJ I/CD monoclonal/JJ antibody/NN (/( mAb/NN )/) for/IN 1.5/CD h/NN ;/: the/DT induction/NN was/VBD maximal/JJ at/IN 5/CD h/NN ,/, persistent/JJ at/IN 16/CD h/NN and/CC no/DT longer/JJR observed/VBN at/IN 40/CD h/NN ./. 
The/DT mAb/NN failed/VBD to/TO induce/VB NF-kappa/NN B/Rel/NN nuclear/JJ activity/NN in/IN cells/NNS incubated/VBN in/IN the/DT presence/NN of/IN 3,4-dichloroisocoumarin/NN ,/, an/DT inhibitor/NN of/IN I/NN kappa/NN B-alpha/NN degradation/NN ./. 
Together/RB ,/, these/DT results/NNS suggest/VBP that/IN class/NN I/CD triggering/NN can/MD induce/VB the/DT activity/NN of/IN NF-kappa/NN B/Rel/NN nuclear/JJ activity/NN in/IN peripheral/JJ blood/NN T/NN lymphocytes/NNS ,/, thereby/RB modulating/VBG the/DT expression/NN of/IN genes/NNS regulated/VBN by/IN these/DT transcription/NN factors/NNS ./. 
UI/LS -/: 97342767/CD 
TI/LS -/: Anti-Ehrlichia/FW chaffeensis/FW antibody/NN complexed/VBN with/IN E./FW chaffeensis/FW induces/VBZ potent/JJ proinflammatory/JJ cytokine/NN mRNA/NN expression/NN in/IN human/JJ monocytes/NNS through/IN sustained/JJ reduction/NN of/IN IkappaB-alpha/NN and/CC activation/NN of/IN NF-kappaB/NN ./. 
AB/LS -/: Ehrlichia/FW chaffeensis/FW is/VBZ an/DT obligatory/JJ intracellular/JJ bacterium/NN that/WDT infects/VBZ monocytes/NNS and/CC macrophages/NNS and/CC is/VBZ the/DT etiologic/JJ agent/NN of/IN human/JJ ehrlichiosis/NN in/IN the/DT United/NNP States/NNPS ./. 
Our/PRP$ previous/JJ studies/NNS showed/VBD that/IN the/DT exposure/NN of/IN human/JJ monocytes/NNS to/TO E./FW chaffeensis/FW induces/VBZ the/DT expression/NN of/IN interleukin-1beta/NN (/( IL-1beta/NN )/) ,/, IL-8/NN ,/, and/CC IL-10/NN genes/NNS in/FW vitro/FW but/CC not/RB the/DT expression/NN of/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) and/CC IL-6/NN mRNAs/NNS ./. 
In/IN this/DT study/NN ,/, the/DT effect/NN of/IN anti-E./FW chaffeensis/FW antibody/NN complexed/VBN with/IN E./FW chaffeensis/FW on/IN the/DT expression/NN of/IN major/JJ proinflammatory/JJ cytokines/NNS in/IN human/JJ monocytes/NNS was/VBD examined/VBN ./. 
Human/JJ monocytic/JJ cell/NN line/NN THP-1/NN was/VBD treated/VBN with/IN E./FW chaffeensis/FW which/WDT had/VBD been/VBN preincubated/JJ with/IN human/JJ anti-E./FW chaffeensis/FW serum/NN for/IN 2/CD h/NN ,/, and/CC the/DT levels/NNS of/IN cytokine/NN mRNAs/NNS were/VBD evaluated/VBN by/IN competitive/JJ reverse/JJ transcription-PCR/NN ./. 
Anti-E./FW chaffeensis/FW antibody/NN complexed/VBN with/IN E./FW chaffeensis/FW significantly/RB enhanced/VBD mRNA/NN expression/NN of/IN IL-1beta/NN in/IN THP-1/NN cells/NNS ./. 
The/DT expression/NN of/IN TNF-alpha/NN and/CC IL-6/NN mRNAs/NNS was/VBD also/RB induced/VBN ./. 
The/DT levels/NNS of/IN secreted/VBN IL-1beta/NN ,/, TNF-alpha/NN ,/, and/CC IL-6/NN during/IN 24/CD h/NN of/IN stimulation/NN were/VBD comparable/JJ to/TO those/DT induced/VBN by/IN Escherichia/FW coli/FW lipopolysaccharide/NN at/IN 1/CD microg/ml/NN ./. 
Fab/NN fragment/NN of/IN anti-E./FW chaffeensis/FW immunoglobulin/NN G/NN complexed/VBN with/IN E./FW chaffeensis/FW did/VBD not/RB induce/VB any/DT of/IN these/DT three/CD cytokines/NNS ,/, indicating/VBG that/IN ehrlichial/JJ binding/NN is/VBZ required/VBN for/IN IL-1beta/NN mRNA/NN expression/NN and/CC that/IN binding/NN of/IN the/DT immune/JJ complex/NN to/TO the/DT Fc/NN gamma/NN receptor/NN is/VBZ required/VBN for/IN TNF-alpha/NN and/CC IL-6/NN mRNA/NN expression/NN and/CC enhanced/VBD IL-1beta/NN mRNA/NN expression/NN ./. 
Furthermore/RB ,/, prolonged/JJ degradation/NN of/IN IkappaB-alpha/NN and/CC activation/NN of/IN NF-kappaB/NN were/VBD demonstrated/VBN in/IN THP-1/NN cells/NNS exposed/VBN to/TO anti-E./FW chaffeensis/FW serum/NN and/CC E./FW chaffeensis/FW ./. 
This/DT result/NN implies/VBZ that/IN development/NN of/IN anti-E./FW chaffeensis/FW antibody/NN in/IN patients/NNS can/MD result/VB in/IN the/DT production/NN of/IN major/JJ proinflammatory/JJ cytokines/NNS ,/, which/WDT may/MD play/VB an/DT important/JJ role/NN in/IN the/DT pathophysiology/NN of/IN ehrlichiosis/NN and/CC immune/JJ responses/NNS to/TO it/PRP ./. 
UI/LS -/: 97315348/CD 
TI/LS -/: The/DT class/NN II/CD trans-activator/NN CIITA/NN interacts/VBZ with/IN the/DT TBP-associated/JJ factor/NN TAFII32/NN ./. 
AB/LS -/: The/DT class/NN II/CD trans- activator/NN (/( CIITA/NN )/) is/VBZ the/DT main/JJ transcriptional/JJ co-activator/NN for/IN the/DT expression/NN of/IN MHC/NN class/NN II/CD proteins/NNS ./. 
Its/PRP$ N-terminal/JJ 125/CD amino/NN acids/NNS function/VBP as/IN an/DT independent/JJ transcriptional/JJ activation/NN domain/NN ./. 
Analyses/NNS of/IN the/DT primary/JJ amino/NN acid/NN sequence/NN of/IN the/DT activation/NN domain/NN predict/VBP the/DT presence/NN of/IN three/CD alpha-helices/NNS ,/, each/DT with/IN a/DT high/JJ proportion/NN of/IN acidic/JJ residues/NNS ./. 
Using/VBG site-directed/JJ mutagenesis/NN ,/, we/PRP found/VBD that/IN two/CD of/IN these/DT predicted/VBN alpha-helices/NNS are/VBP required/VBN for/IN full/JJ transcriptional/JJ activation/NN by/IN CIITA/NN ./. 
Moreover/RB ,/, a/DT CIITA/NN protein/NN in/IN which/WDT both/DT functional/JJ alpha-helices/NNS have/VBP been/VBN deleted/VBN displays/VBZ a/DT dominant/JJ negative/JJ phenotype/NN ./. 
This/DT activation/NN domain/NN of/IN CIITA/NN interacts/VBZ with/IN the/DT 32/CD kDa/NN subunit/NN of/IN the/DT general/JJ transcription/NN complex/NN TFIID/NN ,/, TAFII32/NN ./. 
Decreased/VBN transcriptional/JJ activation/NN by/IN N-terminal/JJ deletions/NNS of/IN CIITA/NN is/VBZ correlated/VBN directly/RB with/IN their/PRP$ reduced/VBN binding/NN to/TO TAFII32/NN ./. 
We/PRP conclude/VBP that/IN interactions/NNS between/IN TAFII32/NN and/CC CIITA/NN are/VBP responsible/JJ for/IN activation/NN of/IN class/NN II/CD genes/NNS ./. 
UI/LS -/: 97309442/CD 
TI/LS -/: Characterization/NN of/IN interleukin-10/NN receptor/NN expression/NN on/IN B-cell/NN chronic/JJ lymphocytic/JJ leukemia/NN cells/NNS ./. 
AB/LS -/: B-cell/NN chronic/JJ lymphocytic/JJ leukemia/NN (/( B-CLL/NN )/) cells/NNS accumulate/VBP in/FW vivo/FW in/IN the/DT G0/G1/NN phase/NN of/IN the/DT cell/NN cycle/NN ,/, suggesting/VBG that/IN their/PRP$ malignant/JJ expansion/NN is/VBZ due/JJ ,/, at/IN least/JJS in/IN part/NN ,/, to/TO a/DT delay/NN in/IN cell/NN death/NN ./. 
However/RB ,/, the/DT cellular/JJ or/CC molecular/JJ factors/NNS responsible/JJ for/IN a/DT delay/NN in/IN B-CLL/NN cell/NN death/NN are/VBP unknown/JJ ./. 
B-CLL/NN cells/NNS do/VBP express/VB receptors/NNS for/IN interferon-alpha/NN (/( IFN-alpha/NN )/) and/CC IFN-gamma/NN ,/, and/CC activation/NN of/IN both/DT has/VBZ been/VBN shown/VBN to/TO promote/VB B-CLL/NN survival/NN in/FW vitro/FW by/IN preventing/VBG apoptosis/NN ./. 
The/DT interleukin-10/NN (/( IL-10/NN )/) receptor/NN is/VBZ another/DT member/NN of/IN the/DT IFN/NN receptor/NN family/NN ,/, but/CC its/PRP$ ligand/NN ,/, IL-10/NN ,/, has/VBZ been/VBN reported/VBN to/TO induce/VB apoptosis/NN in/IN B-CLL/NN cells/NNS ./. 
In/IN the/DT current/JJ study/NN ,/, we/PRP undertook/VBD a/DT biochemical/JJ analysis/NN of/IN IL-10/NN receptor/NN expression/NN on/IN freshly/RB isolated/VBN B-CLL/NN cells/NNS and/CC characterized/VBD the/DT functional/JJ responsiveness/NN of/IN IL-10/NN binding/NN to/TO its/PRP$ constitutively/RB expressed/VBN receptor/NN ./. 
We/PRP show/VBP that/IN B-CLL/NN cells/NNS bind/VBP IL-10/NN with/IN significant/JJ specificity/NN and/CC express/VBP between/IN 47/CD and/CC 127/CD IL-10/NN receptor/NN sites/NNS per/IN cell/NN ,/, with/IN a/DT dissociation/NN constant/NN in/IN the/DT range/NN of/IN 168/CD to/TO 426/CD x/CC 10(-12)/CD mol/L/NN ./. 
Ligand/NN binding/NN and/CC activation/NN of/IN the/DT IL-10/NN receptor/NN expressed/VBN on/IN B-CLL/NN cells/NNS results/VBZ in/IN the/DT phosphorylation/NN of/IN signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN 1/CD (/( STAT1/NN )/) and/CC STAT3/NN proteins/NNS ./. 
This/DT pattern/NN of/IN STAT/NN protein/NN phosphorylation/NN is/VBZ identical/JJ to/TO IL-10/NN receptor/NN activation/NN on/IN normal/JJ cells/NNS and/CC similar/JJ to/TO IFN-alpha/NN (/( STAT1/NN and/CC STAT3/NN )/) and/CC IFN-gamma/NN (/( STAT1/NN )/) receptor/NN activation/NN in/IN CLL/NN ./. 
Further/RB ,/, in/IN consecutive/JJ samples/NNS of/IN fresh/JJ blood/NN obtained/VBN from/IN patients/NNS with/IN B-CLL/NN cells/NNS ,/, the/DT addition/NN of/IN IL-10/NN inhibited/VBD B-CLL/NN proliferation/NN ,/, enhanced/VBD B-CLL/NN differentiation/NN ,/, but/CC did/VBD not/RB induce/VB apoptosis/NN ./. 
Indeed/RB ,/, IL-10/NN ,/, like/IN IFN-gamma/NN ,/, was/VBD able/JJ to/TO significantly/RB reduce/VB the/DT amount/NN of/IN B-CLL/NN cell/NN death/NN caused/VBN by/IN hydrocortisone-induced/JJ apoptosis/NN ./. 
We/PRP conclude/VBP that/IN cytokines/NNS ,/, which/WDT signal/VBP through/IN the/DT interferon/NN family/NN of/IN receptors/NNS ,/, have/VBP comparable/JJ functional/JJ effects/NNS on/IN B-CLL/NN cells/NNS ./. 
UI/LS -/: 97293200/CD 
TI/LS -/: Involvement/NN of/IN the/DT N-terminal/JJ region/NN of/IN the/DT human/JJ mineralocorticoid/NN receptor/NN hormone-binding/JJ domain/NN in/IN agonist/NN and/CC antagonist/NN binding/NN as/IN revealed/VBN by/IN a/DT new/JJ monoclonal/JJ antibody/NN ./. 
AB/LS -/: To/TO gain/VB a/DT better/JJR understanding/NN of/IN the/DT mechanism/NN of/IN binding/VBG to/TO the/DT human/JJ mineralocorticoid/NN receptor/NN (/( hMR/NN )/) ,/, we/PRP developed/VBD a/DT new/JJ monoclonal/JJ antibody/NN (/( mAb/NN )/) raised/VBN against/IN the/DT hormone-binding/JJ domain/NN (/( HBD/NN )/) ./. 
For/IN this/DT purpose/NN ,/, mice/NNS were/VBD immunized/VBN with/IN a/DT fusion/NN protein/NN including/VBG the/DT sequence/NN Thr729-Lys984/NN of/IN hMR/NN ./. 
After/IN ELISA/NN screening/NN ,/, mAb/NN 18C7/NN was/VBD selected/VBN for/IN its/PRP$ specificity/NN towards/IN the/DT HBD/NN ./. 
This/DT antibody/NN recognized/VBD both/CC the/DT denatured/VBN and/CC native/JJ MR/NN forms/NNS ,/, as/RB well/RB as/IN the/DT hetero-oligomeric/JJ MR/NN form/NN and/CC the/DT transformed/JJ MR/NN state/NN ./. 
By/IN using/VBG several/JJ HBD/NN subfragments/NNS ,/, the/DT mAb/NN 18C7/NN epitope/NN was/VBD located/JJ in/IN the/DT N-terminal/JJ region/NN of/IN the/DT HBD/NN from/IN Thr729/NN to/TO Leu765/NN ./. 
We/PRP then/RB studied/VBD the/DT effect/NN of/IN the/DT antibody/NN on/IN aldosterone/NN and/CC progesterone/NN binding/NN to/TO the/DT hMR/NN ./. 
When/WRB 18C7/NN was/VBD incubated/VBN with/IN liganded/JJ MR/NN ,/, it/PRP was/VBD able/JJ to/TO partly/RB displace/VB (/( 20/CD %/NN )/) the/DT hormone/NN from/IN its/PRP$ binding/VBG site/NN ./. 
When/WRB 18C7/NN was/VBD incubated/VBN with/IN MR/NN before/IN aldosterone/NN or/CC progesterone/NN ,/, the/DT antibody/NN inhibited/VBD 75-80/CD %/NN of/IN the/DT binding/NN ./. 
The/DT effect/NN of/IN 18C7/NN on/IN the/DT binding/NN was/VBD similar/JJ with/IN both/DT hormones/NNS ./. 
A/DT sucrose/NN gradient/JJ analysis/NN indicated/VBD the/DT simultaneous/JJ presence/NN of/IN two/CD kinds/NNS of/IN receptor/NN complexes/NNS :/: the/DT steroid-MR/JJ complex/NN and/CC the/DT antibody-MR/JJ complex/NN ./. 
After/IN its/PRP$ associated/VBN proteins/NNS ,/, especially/RB the/DT heat-shock/JJ protein/NN hsp90/NN ,/, had/VBD been/VBN cross-linked/JJ with/IN the/DT hMR/NN by/IN dimethylpimelimidate/NN ,/, 18C7/NN was/VBD still/RB able/JJ to/TO react/VB with/IN the/DT receptor/NN ./. 
Our/PRP$ results/NNS indicated/VBD that/IN the/DT epitope/NN recognized/VBN by/IN 18C7/NN was/VBD directly/RB implicated/VBN in/IN hormone/NN binding/NN ./. 
The/DT lack/NN of/IN steroid/NN binding/NN of/IN HBD/NN mutants/NNS with/IN the/DT Thr729-Leu765/JJ sequence/NN deleted/VBN [/( Jalaguier/NNP ,/, Mesnier/NNP ,/, Leger/NNP and/CC Auzou/NNP (/( 1996/CD )/) J.Steroid/NNP Biochem.Mol.Biol.57/NNP ,/, 43-50/CD ]/) supports/VBZ this/DT hypothesis/NN ./. 
Because/IN of/IN the/DT similar/JJ behaviours/NNS of/IN aldosterone/NN and/CC progesterone/NN ,/, we/PRP conclude/VBP that/IN the/DT N-terminal/JJ Thr729-Leu765/JJ region/NN of/IN the/DT HBD/NN is/VBZ similarly/RB involved/VBN in/IN the/DT binding/NN of/IN both/DT hormones/NNS ./. 
UI/LS -/: 97277292/CD 
TI/LS -/: Molecular/JJ cloning/NN of/IN SLAP-130/NN ,/, an/DT SLP-76-associated/JJ substrate/NN of/IN the/DT T/NN cell/NN antigen/NN receptor-stimulated/JJ protein/NN tyrosine/NN kinases/NNS ./. 
AB/LS -/: Previous/JJ work/NN has/VBZ demonstrated/VBN that/IN SLP-76/NN ,/, a/DT Grb2-associated/JJ tyrosine-phosphorylated/JJ protein/NN ,/, augments/VBZ Interleukin-2/NN promoter/NN activity/NN when/WRB overexpressed/VBN in/IN the/DT Jurkat/NN T/NN cell/NN line/NN ./. 
This/DT activity/NN requires/VBZ regions/NNS of/IN SLP-76/NN that/WDT mediate/VBP protein-protein/JJ interactions/NNS with/IN other/JJ molecules/NNS in/IN T/NN cells/NNS ,/, suggesting/VBG that/IN SLP-76-associated/JJ proteins/NNS also/RB function/VBP to/TO regulate/VB signal/NN transduction/NN ./. 
Here/RB we/PRP describe/VBP the/DT molecular/JJ cloning/NN of/IN SLAP-130/NN ,/, a/DT SLP-76-associated/JJ phosphoprotein/NN of/IN 130/CD kDa/NN ./. 
We/PRP demonstrate/VBP that/IN SLAP-130/NN is/VBZ hematopoietic/JJ cell-specific/JJ and/CC associates/VBZ with/IN the/DT SH2/NN domain/NN of/IN SLP-76/NN ./. 
Additionally/RB ,/, we/PRP show/VBP that/IN SLAP-130/NN is/VBZ a/DT substrate/NN of/IN the/DT T/NN cell/NN antigen/NN receptor-induced/JJ protein/NN tyrosine/NN kinases/NNS ./. 
Interestingly/RB ,/, we/PRP find/VBP that/IN in/IN contrast/NN to/TO SLP-76/NN ,/, overexpression/NN of/IN SLAP-130/NN diminishes/VBZ T/NN cell/NN antigen/NN receptor-induced/JJ activation/NN of/IN the/DT interleukin-2/NN promoter/NN in/IN Jurkat/NN T/NN cells/NNS and/CC interferes/VBZ with/IN the/DT augmentation/NN of/IN interleukin-2/NN promoter/NN activity/NN seen/VBN when/WRB SLP-76/NN is/VBZ overexpressed/VBN in/IN these/DT cells/NNS ./. 
These/DT data/NNS suggest/VBP that/IN SLP-76/NN recruits/VBZ a/DT negative/JJ regulator/NN ,/, SLAP-130/NN ,/, as/RB well/RB as/IN positive/JJ regulators/NNS of/IN signal/NN transduction/NN in/IN T/NN cells/NNS ./. 
UI/LS -/: 97287044/CD 
TI/LS -/: Molecular/JJ actions/NNS of/IN prolactin/NN in/IN the/DT immune/JJ system/NN ./. 
AB/LS -/: The/DT immunoregulatory/JJ properties/NNS of/IN prolactin/NN ,/, a/DT pituitary/JJ peptide/NN hormone/NN ,/, have/VBP received/VBN renewed/JJ attention/NN ./. 
The/DT prolactin/NN receptor/NN ,/, a/DT member/NN of/IN the/DT hematopoietin/cytokine/NN receptor/NN superfamily/NN ,/, is/VBZ ubiquitously/RB expressed/VBN by/IN cells/NNS in/IN the/DT immune/JJ system/NN ./. 
Certain/JJ subpopulations/NNS of/IN lymphocytes/NNS synthesize/VBP and/CC secrete/VBP biologically/RB active/JJ prolactin/NN ,/, which/WDT suggests/VBZ that/IN prolactin/NN can/MD act/VB as/IN an/DT autocrine/NN and/or/CC paracrine/NN factor/NN to/TO modulate/VB the/DT activities/NNS of/IN cells/NNS of/IN the/DT immune/JJ system/NN ./. 
This/DT review/NN focuses/VBZ on/IN the/DT molecular/JJ actions/NNS of/IN prolactin/NN in/IN the/DT immune/JJ system/NN ./. 
Emphasis/NN is/VBZ given/VBN to/TO recent/JJ information/NN about/IN the/DT molecular/JJ mechanisms/NNS of/IN prolactin/NN receptor/NN signal/NN transduction/NN ,/, and/CC the/DT signaling/VBG molecules/NNS and/CC prolactin-inducible/JJ target/NN genes/NNS that/WDT participate/VBP in/IN these/DT responses/NNS ./. 
In/IN particular/JJ ,/, the/DT prolactin-inducible/JJ interferon/NN regulatory/JJ factor-1/NN gene/NN and/CC its/PRP$ roles/NNS in/IN mediating/VBG diverse/JJ immune/JJ responses/NNS ./. 
UI/LS -/: 97436422/CD 
TI/LS -/: Transcriptional/JJ regulation/NN during/IN myelopoiesis/NN ./. 
AB/LS -/: The/DT coordinated/VBN production/NN of/IN all/DT blood/NN cells/NNS from/IN a/DT common/JJ stem/NN cell/NN is/VBZ a/DT highly/RB regulated/VBN process/NN involving/VBG successive/JJ stages/NNS of/IN commitment/NN and/CC differentiation/NN ./. 
From/IN analyses/NNS of/IN mice/NNS deficient/JJ in/IN transcription/NN factor/NN genes/NNS and/CC from/IN the/DT characterizations/NNS of/IN chromosome/NN breakpoints/NNS in/IN human/JJ leukemias/NNS ,/, it/PRP has/VBZ become/VBN evident/JJ that/IN transcription/NN factors/NNS are/VBP important/JJ regulators/NNS of/IN hematopoiesis/NN ./. 
During/IN myelopoiesis/NN ,/, which/WDT includes/VBZ the/DT development/NN of/IN granulocytic/JJ and/CC monocytic/JJ lineages/NNS ,/, transcription/NN factors/NNS from/IN several/JJ families/NNS are/VBP active/JJ ,/, including/VBG AML1/CBF/NN beta/NN ,/, C/EBP/NN ,/, Ets/NN ,/, c-Myb/NN ,/, HOX/NN ,/, and/CC MZF-1/NN ./. 
Few/JJ of/IN these/DT factors/NNS are/VBP expressed/VBN exclusively/RB in/IN myeloid/JJ cells/NNS ;/: instead/RB it/PRP appears/VBZ that/IN they/PRP cooperatively/RB regulate/VBP transcription/NN of/IN myeloid-specific/JJ genes/NNS ./. 
Here/RB we/PRP discuss/VBP recent/JJ advances/NNS in/IN transcriptional/JJ regulation/NN during/IN myelopoiesis/NN ./. 
UI/LS -/: 97420486/CD 
TI/LS -/: Activation/NN of/IN transcription/NN factor/NN NF-kappa/NN B/NN by/IN phagocytic/JJ stimuli/NNS in/IN human/JJ neutrophils/NNS ./. 
AB/LS -/: Phagocytosis/NN represents/VBZ an/DT important/JJ physiological/JJ trigger/NN for/IN the/DT inducible/JJ expression/NN of/IN several/JJ genes/NNS in/IN human/JJ neutrophils/NNS ./. 
Here/RB ,/, we/PRP report/VBP that/IN a/DT DNA-binding/JJ activity/NN primarily/RB consisting/VBG of/IN the/DT classical/JJ NF-kappa/NN B/NN heterodimer/NN ,/, p50/RelA/NN ,/, is/VBZ induced/VBN in/IN phagocytosing/VBG neutrophils/NNS ./. 
Under/IN these/DT conditions/NNS ,/, NF-kappa/NN B/NN activation/NN was/VBD found/VBN to/TO be/VB a/DT rapid/JJ and/CC transient/JJ response/NN ,/, reaching/VBG a/DT maximum/NN by/IN 10-15/CD min/NN ,/, and/CC returning/VBG to/TO near-basal/JJ levels/NNS by/IN 30/CD min/NN ./. 
In/IN neutrophils/NNS undergoing/VBG the/DT phagocytosis/NN of/IN opsonized/JJ yeasts/NNS ,/, the/DT onset/NN of/IN NF-kappa/NN B/NN activation/NN was/VBD paralleled/VBN by/IN a/DT decline/NN in/IN immunoreactive/JJ I/NN kappa/NN B-alpha/NN protein/NN levels/NNS ,/, and/CC the/DT cellular/JJ I/NN kappa/NN B-alpha/NN pool/NN was/VBD replenished/VBN by/IN 30/CD min/NN ,/, in/IN agreement/NN with/IN our/PRP$ gel/NN shift/NN data/NNS ./. 
We/PRP conclude/VBP that/IN NF-kappa/NN B/NN activation/NN could/MD constitute/VB one/CD of/IN the/DT mechanisms/NNS whereby/IN the/DT expression/NN of/IN kappa/NN B-responsive/JJ genes/NNS is/VBZ enhanced/VBN in/IN phagocytosing/VBG neutrophils/NNS ./. 
To/TO our/PRP$ knowledge/NN ,/, this/DT represents/VBZ the/DT first/JJ demonstration/NN that/IN phagocytic/JJ stimuli/NNS can/MD induce/VB NF-kappa/NN B/NN activation/NN in/IN human/JJ neutrophils/NNS ./. 
UI/LS -/: 97379394/CD 
TI/LS -/: Induction/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD expression/NN in/IN monocytic/JJ cells/NNS by/IN Cryptococcus/FW neoformans/FW and/CC Candida/FW albicans/FW ./. 
AB/LS -/: Because/IN candidiasis/NN and/CC cryptococcosis/NN are/VBP common/JJ in/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) -infected/JJ persons/NNS ,/, the/DT effect/NN of/IN Cryptococcus/FW neoformans/FW and/CC Candida/FW albicans/FW on/IN HIV/NN expression/NN in/IN monocytic/JJ cells/NNS was/VBD examined/VBN ./. 
Stimulation/NN of/IN the/DT latently/RB HIV-infected/JJ myelomonocytic/JJ cell/NN line/NN OM-10.1/NN with/IN C./FW neoformans/FW and/CC C./FW albicans/FW in/IN the/DT presence/NN of/IN pooled/JJ human/JJ serum/NN caused/VBD a/DT ratio-dependent/JJ increase/NN in/IN HIV/NN production/NN ./. 
Induction/NN of/IN HIV/NN by/IN C./FW neoformans/FW was/VBD enhanced/VBN by/IN anti-capsular/JJ antibody/NN ,/, while/IN induction/NN by/IN both/DT organisms/NNS was/VBD inhibited/VBN by/IN anti-TNF-alpha/JJ antibody/NN ./. 
In/IN THP-1/NN cells/NNS transfected/VBN with/IN HIV/NN plasmid/NN constructs/NNS ,/, both/DT organisms/NNS induced/VBD transcription/NN from/IN the/DT HIV/NN long/JJ terminal/JJ repeat/NN that/WDT was/VBD dependent/JJ on/IN intact/JJ NF-kappaB/NN binding/NN sequences/NNS ./. 
Thus/RB ,/, C./FW neoformans/FW and/CC C./FW albicans/FW enhance/VBP HIV/NN expression/NN in/IN monocytic/JJ cells/NNS through/IN a/DT TNF-alpha-/NN and/CC NF-kappaB-dependent/JJ mechanism/NN ./. 
In/IN HIV-infected/JJ patients/NNS ,/, such/JJ enhancement/NN may/MD further/RB impair/VB host/NN immunity/NN and/CC could/MD accelerate/VB the/DT course/NN of/IN HIV/NN disease/NN ./. 
UI/LS -/: 97398336/CD 
TI/LS -/: Nuclear/JJ levels/NNS of/IN NF-kappaB/NN correlate/VBP with/IN syncytium-forming/JJ capacity/NN of/IN 8e51/NN cells/NNS ,/, expressing/VBG a/DT defective/JJ HIV/NN virus/NN ./. 
AB/LS -/: The/DT double/JJ NF-kappaB/NN site/NN identified/VBN in/IN the/DT LTR/NN of/IN the/DT human/JJ immunodeficiency/NN virus-1/NN (/( HIV-1/NN )/) has/VBZ been/VBN demonstrated/VBN to/TO be/VB necessary/JJ for/IN efficient/JJ viral/JJ transcription/NN ./. 
In/IN this/DT report/NN we/PRP present/VBP the/DT characterisation/NN of/IN NF-kappaB/NN subunits/NNS engaged/VBN in/IN complexes/NNS binding/VBG to/TO the/DT HIV-1/NN NF-kappaB/NN site/NN in/IN human/JJ 8e51/NN T-cells/NNS ,/, that/WDT harbour/VBP a/DT defective/JJ HIV-1/NN ./. 
At/IN least/JJS four/CD different/JJ specific/JJ NF-kappaB/NN complexes/NNS are/VBP present/JJ in/IN the/DT nucleus/NN of/IN these/DT cells/NNS ./. 
With/IN the/DT use/NN of/IN specific/JJ antibodies/NNS we/PRP have/VBP determined/VBN the/DT composition/NN of/IN each/DT complex/NN using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS ./. 
The/DT results/NNS show/VBP the/DT presence/NN of/IN several/JJ NF-kappaB/NN family/NN members/NNS ,/, with/IN the/DT transactivating/VBG RelA/NN being/VBG engaged/VBN in/IN multiple/JJ complexes/NNS ./. 
The/DT importance/NN of/IN NF-kappaB/NN complexes/NNS in/IN viral/JJ functions/NNS has/VBZ been/VBN established/VBN comparing/VBG the/DT level/NN of/IN NF-kappaB/NN DNA-binding/JJ complexes/NNS with/IN syncytia-forming/JJ activity/NN of/IN 8e51/NN cells/NNS ./. 
In/IN fact/NN ,/, 8e51/NN cells/NNS that/WDT had/VBD almost/RB lost/VBN their/PRP$ syncytia-forming/JJ capacity/NN were/VBD found/VBN to/TO contain/VB at/IN least/JJS 10/CD times/NNS less/RBR active/JJ NF-kappaB/NN DNA-binding/JJ complex/NN than/IN the/DT actively/RB fusing/VBG cells/NNS ./. 
The/DT correlation/NN is/VBZ specific/JJ as/IN the/DT level/NN of/IN at/IN least/JJS three/CD other/JJ transcription/NN factors/NNS did/VBD not/RB change/VB ./. 
UI/LS -/: 97377031/CD 
TI/LS -/: c-Myb/NN and/CC Ets/NN proteins/NNS synergize/VBP to/TO overcome/VB transcriptional/JJ repression/NN by/IN ZEB/NN ./. 
AB/LS -/: The/DT Zfh/NN family/NN of/IN zinc/NN finger/homeodomain/NN proteins/NNS was/VBD first/RB identified/VBN in/IN Drosophila/FW where/WRB it/PRP is/VBZ required/VBN for/IN differentiation/NN of/IN tissues/NNS such/JJ as/IN the/DT central/JJ nervous/JJ system/NN and/CC muscle/NN ./. 
ZEB/NN ,/, a/DT vertebrate/JJ homolog/NN of/IN Zfh-1/NN ,/, binds/VBZ a/DT subset/NN of/IN E/NN boxes/NNS and/CC blocks/VBZ myogenesis/NN through/IN transcriptional/JJ repression/NN of/IN muscle/NN genes/NNS ./. 
We/PRP present/VBP evidence/NN here/RB that/IN ZEB/NN also/RB has/VBZ an/DT important/JJ role/NN in/IN controlling/VBG hematopoietic/JJ gene/NN transcription/NN ./. 
Two/CD families/NNS of/IN transcription/NN factors/NNS that/WDT are/VBP required/VBN for/IN normal/JJ hematopoiesis/NN are/VBP c-Myb/NN and/CC Ets/NN ./. 
These/DT factors/NNS act/VBP synergistically/RB to/TO activate/VB transcription/NN ,/, and/CC this/DT synergy/NN is/VBZ required/VBN for/IN transcription/NN of/IN at/IN least/JJS several/JJ important/JJ hematopoietic/JJ genes/NNS ./. 
ZEB/NN blocks/VBZ the/DT activity/NN of/IN c-Myb/NN and/CC Ets/NN individually/RB ,/, but/CC together/RB the/DT factors/NNS synergize/VBP to/TO resist/VB this/DT repression/NN ./. 
Such/JJ repression/NN imposes/VBZ a/DT requirement/NN for/IN both/CC c-Myb/NN and/CC Ets/NN for/IN transcriptional/JJ activity/NN ,/, providing/VBG one/CD explanation/NN for/IN why/WRB synergy/NN between/IN these/DT factors/NNS is/VBZ important/JJ ./. 
The/DT balance/NN between/IN repression/NN by/IN ZEB/NN and/CC transcriptional/JJ activation/NN by/IN c-Myb/Ets/NN provides/VBZ a/DT flexible/JJ regulatory/JJ mechanism/NN for/IN controlling/VBG gene/NN expression/NN in/IN hematopoietic/JJ cells/NNS ./. 
We/PRP demonstrate/VBP that/IN one/CD target/NN of/IN this/DT positive/negative/JJ regulation/NN in/FW vivo/FW is/VBZ the/DT alpha4/NN integrin/NN ,/, which/WDT play/VBP a/DT key/JJ role/NN in/IN normal/JJ hematopoiesis/NN and/CC function/NN of/IN mature/JJ leukocytes/NNS ./. 
UI/LS -/: 97342603/CD 
TI/LS -/: Comparison/NN of/IN the/DT transactivation/NN domains/NNS of/IN Stat5/NN and/CC Stat6/NN in/IN lymphoid/JJ cells/NNS and/CC mammary/JJ epithelial/JJ cells/NNS ./. 
AB/LS -/: Stat/NN (/( signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN )/) and/CC Jak/NN (/( Janus/NN kinases/NNS )/) proteins/NNS are/VBP central/JJ components/NNS in/IN the/DT signal/NN transduction/NN events/NNS in/IN hematopoietic/JJ and/CC epithelial/JJ cells/NNS ./. 
They/PRP are/VBP rapidly/RB activated/VBN by/IN various/JJ cytokines/NNS ,/, hormones/NNS ,/, and/CC growth/NN factors/NNS ./. 
Upon/IN ligand/NN binding/NN and/CC cytokine/NN receptor/NN dimerization/NN ,/, Stat/NN proteins/NNS are/VBP phosphorylated/VBN on/IN tyrosine/NN residues/NNS by/IN Jak/NN kinases/NNS ./. 
Activated/VBN Stat/NN proteins/NNS form/VBP homo-/JJ or/CC heterodimers/NNS ,/, translocate/VBP to/TO the/DT nucleus/NN ,/, and/CC induce/VBP transcription/NN from/IN responsive/JJ genes/NNS ./. 
Stat5/NN and/CC Stat6/NN are/VBP transcription/NN factors/NNS active/JJ in/IN mammary/JJ epithelial/JJ cells/NNS and/CC immune/JJ cells/NNS ./. 
Prolactin/NN activates/VBZ Stat5/NN ,/, and/CC interleukin-4/NN (/( IL-4/NN )/) activates/VBZ Stat6/NN ./. 
Both/DT cytokines/NNS are/VBP able/JJ to/TO stimulate/VB cell/NN proliferation/NN ,/, differentiation/NN ,/, and/CC survival/NN ./. 
We/PRP investigated/VBD the/DT transactivation/NN potential/NN of/IN Stat6/NN and/CC found/VBD that/IN it/PRP is/VBZ not/RB restricted/JJ to/TO lymphocytes/NNS ./. 
IL-4-dependent/JJ activation/NN of/IN Stat6/NN was/VBD also/RB observed/VBN in/IN HC11/NN mammary/JJ epithelial/JJ cells/NNS ./. 
In/IN these/DT cells/NNS ,/, Stat6/NN activation/NN led/VBD to/TO the/DT induction/NN of/IN the/DT beta-casein/NN gene/NN promoter/NN ./. 
The/DT induction/NN of/IN this/DT promoter/NN was/VBD confirmed/VBN in/IN COS7/NN cells/NNS ./. 
The/DT glucocorticoid/NN receptor/NN was/VBD able/JJ to/TO further/RB enhance/VB IL-4-induced/JJ gene/NN transcription/NN through/IN the/DT action/NN of/IN Stat6/NN ./. 
Deletion/NN analysis/NN of/IN the/DT carboxyl-terminal/JJ region/NN of/IN Stat6/NN and/CC recombination/NN of/IN this/DT region/NN with/IN a/DT heterologous/JJ DNA/NN binding/NN domain/NN allowed/VBD the/DT delimitation/NN and/CC characterization/NN of/IN the/DT transactivation/NN domain/NN of/IN Stat6/NN ./. 
The/DT potencies/NNS of/IN the/DT transactivation/NN domains/NNS of/IN Stat5/NN ,/, Stat6/NN ,/, and/CC viral/JJ protein/NN VP16/NN were/VBD compared/VBN ./. 
Stat6/NN had/VBD a/DT transactivation/NN domain/NN which/WDT was/VBD about/RB 10-fold/RB stronger/JJR than/IN that/DT of/IN Stat5/NN ./. 
In/IN pre-B/JJ cells/NNS (/( Ba/F3/NN )/) ,/, the/DT transactivation/NN domain/NN of/IN Stat6/NN was/VBD IL-4/NN regulated/JJ ,/, independently/RB from/IN its/PRP$ DNA/NN binding/NN function/NN ./. 
UI/LS -/: 97334204/CD 
TI/LS -/: ETS1/NN ,/, NFkappaB/NN and/CC AP1/NN synergistically/RB transactivate/VBP the/DT human/JJ GM-CSF/NN promoter/NN ./. 
AB/LS -/: Activation/NN of/IN helper/NN T/NN cells/NNS results/VBZ in/IN coordinate/JJ expression/NN of/IN a/DT number/NN of/IN cytokines/NNS involved/VBN in/IN differentiation/NN ,/, proliferation/NN and/CC activation/NN of/IN the/DT haematopoietic/JJ system/NN ./. 
Granulocyte-macrophage/JJ colony/NN stimulating/NN factor/NN (/( GM-CSF/NN )/) is/VBZ one/CD such/JJ cytokine/NN ,/, whose/WP$ increased/VBN expression/NN results/VBZ mostly/RB from/IN increases/NNS in/IN transcription/NN ./. 
Cis-acting/JJ elements/NNS with/IN NFkappaB/NN ,/, AP1/NN and/CC ETS-like/JJ binding/VBG motifs/NNS have/VBP been/VBN identified/VBN in/IN the/DT promoter/NN region/NN of/IN the/DT GM-CSF/NN gene/NN ,/, and/CC are/VBP important/JJ or/CC essential/JJ for/IN transcriptional/JJ activity/NN following/VBG T/NN cell/NN activation/NN ./. 
ETS1/NN is/VBZ a/DT transcription/NN factor/NN of/IN the/DT ETS/NN family/NN that/WDT is/VBZ expressed/VBN in/IN T/NN cells/NNS ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN ETS1/NN can/MD transactivate/VB GM-CSF/NN in/IN Jurkat/NN T/NN cells/NNS ,/, but/CC only/RB after/IN the/DT cells/NNS have/VBP been/VBN stimulated/VBN by/IN treatment/NN with/IN PMA/NN and/CC ionomycin/NN ,/, agents/NNS that/WDT mimic/VBP T/NN cell/NN activation/NN ./. 
Thus/RB we/PRP proposed/VBD that/IN ETS1/NN ,/, which/WDT is/VBZ expressed/VBN constitutively/RB in/IN Jurkat/NN cells/NNS ,/, may/MD act/VB in/IN concert/NN with/IN PMA/ionomycin/NN inducible/JJ factors/NNS ./. 
Here/RB we/PRP show/VBP that/IN ETS1/NN can/MD transactivate/VB a/DT GM-CSF/NN reporter/NN construct/NN in/IN unstimulated/JJ Jurkat/NN cells/NNS ,/, providing/VBG that/IN either/CC NFkappaB/NN or/CC AP1/NN transcription/NN factors/NNS are/VBP supplied/VBN by/IN co-transfection/NN ./. 
We/PRP confirm/VBP that/IN binding/NN of/IN endogenous/JJ NFkappaB/NN and/CC AP1/NN is/VBZ induced/VBN following/VBG PMA/ionomycin/NN treatment/NN of/IN T/NN cells/NNS ./. 
Transactivation/NN by/IN ETS1/NN ,/, NFkappaB/NN and/CC AP1/NN is/VBZ synergistic/JJ ,/, and/CC mutation/NN of/IN the/DT individual/JJ binding/VBG sites/NNS reveals/VBZ that/IN the/DT transcriptional/JJ activities/NNS of/IN these/DT factors/NNS are/VBP interdependent/JJ ./. 
Our/PRP$ results/NNS suggest/VBP that/IN constitutive/JJ ETS1/NN ,/, and/CC inducible/JJ NFkappaB/NN and/CC AP1/NN ,/, cooperate/VBP as/IN part/NN of/IN a/DT higher/JJR order/NN transcriptional/JJ complex/NN in/IN activated/VBN T/NN cells/NNS ./. 
UI/LS -/: 97307577/CD 
TI/LS -/: Abnormal/JJ T/NN lymphocyte/NN development/NN induced/VBN by/IN targeted/VBN overexpression/NN of/IN IkappaB/NN alpha/NN ./. 
AB/LS -/: A/DT role/NN in/IN thymic/JJ maturation/NN for/IN factors/NNS of/IN the/DT NF-kappaB/NN family/NN has/VBZ long/RB been/VBN suspected/VBN ,/, but/CC not/RB yet/RB proven/VBN ./. 
Transgenic/JJ mice/NNS with/IN a/DT lymphocyte-specific/JJ defect/NN in/IN NF-kappaB/NN activation/NN were/VBD produced/VBN by/IN targeted/VBN expression/NN of/IN human/JJ IkappaB/NN alpha/NN ./. 
The/DT thymic/JJ cellularity/NN of/IN these/DT mice/NNS was/VBD significantly/RB decreased/VBN ./. 
The/DT proportion/NN of/IN mature/JJ ,/, TCRhigh/JJ thymocytes/NNS of/IN the/DT alphabeta/NN lineage/NN was/VBD reduced/VBN ,/, and/CC the/DT remaining/VBG TCRhigh/JJ population/NN contained/VBD an/DT unusually/RB high/JJ proportion/NN of/IN double-positive/JJ cells/NNS ./. 
This/DT defect/NN in/IN maturation/NN resulted/VBD in/IN a/DT transgene/NN dose-dependent/JJ reduction/NN in/IN peripheral/JJ T/NN lymphocytes/NNS ,/, with/IN the/DT CD8/NN lineage/NN being/VBG more/RBR severely/RB affected/VBN ./. 
These/DT data/NNS provide/VBP direct/JJ evidence/NN for/IN the/DT involvement/NN of/IN NF-kappaB/Rel/NN family/NN proteins/NNS in/IN late/JJ stages/NNS of/IN T/NN lymphocyte/NN development/NN ,/, coincident/JJ with/IN positive/JJ and/CC negative/JJ selection/NN ./. 
UI/LS -/: 97289574/CD 
TI/LS -/: CD40/NN is/VBZ a/DT functional/JJ activation/NN antigen/NN and/CC B7-independent/JJ T/NN cell/NN costimulatory/JJ molecule/NN on/IN normal/JJ human/JJ lung/NN fibroblasts/NNS ./. 
AB/LS -/: CD40/NN is/VBZ an/DT important/JJ signaling/NN and/CC activation/NN Ag/NN found/VBN on/IN certain/JJ bone/NN marrow-derived/JJ cells/NNS ./. 
Recently/RB ,/, CD40/NN also/RB has/VBZ been/VBN shown/VBN to/TO be/VB expressed/VBN by/IN mesenchymal/JJ cells/NNS ,/, including/VBG human/JJ fibroblasts/NNS ./. 
Little/JJ is/VBZ known/VBN about/IN the/DT role/NN of/IN CD40/NN in/IN fibroblasts/NNS ./. 
The/DT current/JJ study/NN investigates/VBZ the/DT hypothesis/NN that/IN CD40/NN expressed/VBN on/IN lung/NN fibroblasts/NNS is/VBZ an/DT activation/NN structure/NN and/CC mechanism/NN for/IN interaction/NN with/IN hemopoietic/JJ cells/NNS ./. 
Communication/NN between/IN resident/JJ tissue/NN fibroblasts/NNS and/CC T/NN cells/NNS is/VBZ necessary/JJ for/IN normal/JJ wound/NN healing/NN ,/, and/CC can/MD be/VB pathologic/JJ ,/, resulting/VBG in/IN tissue/NN fibrosis/NN ./. 
Signaling/NN through/IN CD40/NN with/IN soluble/JJ CD40/NN ligand/NN stimulated/VBD fibroblast/NN activation/NN ,/, as/IN evidenced/VBN by/IN mobilization/NN of/IN nuclear/JJ factor-kappaB/NN and/CC by/IN induction/NN of/IN the/DT proinflammatory/JJ and/CC chemoattractant/JJ cytokines/NNS IL-6/NN and/CC IL-8/NN ./. 
IFN-gamma-primed/JJ lung/NN fibroblasts/NNS costimulate/VBP T/NN lymphocyte/NN proliferation/NN utilizing/VBG CD40/NN ,/, but/CC not/RB the/DT well-studied/JJ costimulatory/JJ molecules/NNS B7-1/NN and/CC B7-2/NN ./. 
Data/NNS reported/VBN herein/RB support/VBP the/DT hypothesis/NN that/IN cognate/JJ interactions/NNS between/IN tissue/NN fibroblasts/NNS and/CC infiltrating/VBG T/NN lymphocytes/NNS ,/, via/IN the/DT CD40/CD40L/NN pathway/NN ,/, augment/VBP inflammation/NN and/CC may/MD promote/VB fibrogenesis/NN by/IN activating/VBG both/DT cell/NN types/NNS ./. 
UI/LS -/: 97338567/CD 
TI/LS -/: Biphasic/JJ control/NN of/IN NF-kappa/NN B/NN activation/NN induced/VBN by/IN the/DT triggering/NN of/IN HLA-DR/NN antigens/NNS expressed/VBN on/IN B/NN cells/NNS ./. 
AB/LS -/: The/DT regulation/NN of/IN NF-kappa/NN B/NN activation/NN following/VBG the/DT triggering/NN of/IN HLA-DR/NN antigens/NNS by/IN mAb/NN L243/NN has/VBZ been/VBN studied/VBN at/IN various/JJ times/NNS in/IN Raji/NN cells/NNS ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS demonstrated/VBD a/DT strong/JJ increase/NN of/IN NF-kappa/NN B/NN DNA/NN binding/NN after/IN triggering/NN of/IN HLA-DR/NN antigens/NNS ./. 
Using/VBG TNF-alpha-activity/NN neutralizing/NN antibodies/NNS ,/, the/DT authors/NNS demonstrated/VBD that/IN the/DT upregulation/NN of/IN NF-kappa/NN B/NN was/VBD found/VBN to/TO depend/VB ,/, at/IN later/JJR time/NN point/NN ,/, on/IN an/DT autocrine/JJ effect/NN of/IN TNF-alpha/NN secreted/VBN following/VBG triggering/NN of/IN HLA-DR/NN antigens/NNS ./. 
In/IN contrast/NN ,/, it/PRP was/VBD found/VBN to/TO be/VB TNF-alpha/NN independent/JJ in/IN the/DT early/JJ time/NN point/NN ./. 
Moreover/RB ,/, the/DT upregulation/NN of/IN NF-kappa/NN B/NN binding/NN activity/NN is/VBZ regulated/VBN by/IN the/DT triggering/NN of/IN selected/VBN epitopes/NNS of/IN HLA-DR/NN antigens/NNS ./. 
In/IN fact/NN ,/, mAb/NN L243/NN but/CC not/RB the/DT staphylococcal/JJ superantigens/NNS ,/, staphylococcal/JJ exotoxin/NN toxic/JJ shock/NN syndrome/NN toxin-I/NN or/CC staphylococcal/JJ enterotoxin/NN B/NN ,/, regulate/VBP the/DT NF-kappa/NN B/NN binding/NN activity/NN ./. 
UI/LS -/: 97426442/CD 
TI/LS -/: Regulation/NN of/IN inosine-5'-monophosphate/NN dehydrogenase/NN type/NN II/CD gene/NN expression/NN in/IN human/JJ T/NN cells/NNS ./. 
Role/NN for/IN a/DT novel/JJ 5'/JJ palindromic/JJ octamer/NN sequence/NN ./. 
AB/LS -/: Expression/NN of/IN the/DT gene/NN encoding/VBG human/JJ inosine- 5'-monophosphate/NN dehydrogenase/NN (/( IMPDH/NN )/) type/NN II/CD ,/, an/DT enzyme/NN catalyzing/VBG the/DT rate-limiting/JJ step/NN in/IN the/DT generation/NN of/IN guanine/NN nucleotides/NNS ,/, is/VBZ increased/VBN more/JJR than/IN 10-fold/RB in/IN activated/VBN peripheral/JJ blood/NN T/NN lymphocytes/NNS and/CC is/VBZ required/VBN for/IN T/NN cell/NN activation/NN ./. 
We/PRP have/VBP examined/VBN the/DT 5'-regulatory/JJ sequences/NNS that/WDT are/VBP important/JJ for/IN the/DT transcriptional/JJ regulation/NN of/IN this/DT gene/NN in/IN T/NN cells/NNS ./. 
DNase/NN I/CD mapping/NN of/IN genomic/JJ DNA/NN identified/VBD a/DT hypersensitive/JJ element/NN near/IN the/DT transcription/NN initiation/NN site/NN ./. 
Fine/JJ mapping/NN by/IN in/FW vivo/FW footprinting/NN demonstrated/VBD five/CD transcription/NN factor/NN binding/NN sites/NNS that/WDT are/VBP occupied/VBN in/IN both/CC resting/VBG and/CC activated/VBN peripheral/JJ blood/NN T/NN lymphocytes/NNS ;/: these/DT are/VBP tandem/JJ CRE/NN motifs/NNS ,/, a/DT Sp1/NN site/NN ,/, an/DT overlapping/JJ Egr-1/Sp1/NN site/NN ,/, and/CC a/DT novel/JJ palindromic/JJ octamer/NN sequence/NN (/( POS/NN )/) ./. 
The/DT tandem/JJ CRE/NN and/CC POS/NN sites/NNS are/VBP of/IN major/JJ functional/JJ importance/NN as/IN judged/VBN by/IN mutational/JJ and/CC electrophoretic/JJ mobility/NN shift/NN analyses/NNS ./. 
These/DT data/NNS provide/VBP evidence/NN that/IN expression/NN of/IN the/DT human/JJ IMPDH/NN type/NN II/CD gene/NN is/VBZ predominantly/RB regulated/VBN by/IN the/DT nuclear/JJ factors/NNS ATF-2/NN and/CC an/DT as/RB yet/RB unidentified/JJ POS-binding/JJ protein/NN ./. 
Additional/JJ major/JJ protein-DNA/JJ interactions/NNS do/VBP not/RB occur/VB within/IN the/DT promoter/NN region/NN after/IN T/NN lymphocyte/NN activation/NN ,/, indicating/VBG a/DT requirement/NN for/IN additional/JJ protein-protein/JJ interactions/NNS and/or/CC post-translational/JJ modifications/NNS of/IN pre-bound/JJ transcription/NN factors/NNS to/TO account/VB for/IN the/DT observed/VBN increase/NN in/IN IMPDH/NN type/NN II/CD gene/NN expression/NN ./. 
UI/LS -/: 97423557/CD 
TI/LS -/: Distinct/JJ mechanisms/NNS for/IN N-acetylcysteine/NN inhibition/NN of/IN cytokine-induced/JJ E-selectin/NN and/CC VCAM-1/NN expression/NN ./. 
AB/LS -/: We/PRP have/VBP examined/VBN the/DT effects/NNS of/IN N-acetyl-L-cysteine/NN (/( NAC/NN )/) ,/, a/DT well-characterized/JJ ,/, thiol-containing/JJ antioxidant/NN ,/, on/IN agonist-induced/JJ monocytic/JJ cell/NN adhesion/NN to/TO endothelial/JJ cells/NNS (/( EC/NNS )/) ./. 
NAC/NN inhibited/VBD interleukin-1/NN (/( IL-1/NN beta/NN )/) -induced/JJ ,/, but/CC not/RB basal/JJ ,/, adhesion/NN with/IN 50/CD %/NN inhibition/NN at/IN approximately/RB 20/CD mM/NN ./. 
Monocytic/JJ cell/NN adhesion/NN to/TO EC/NNS in/IN response/NN to/TO tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) ,/, lipopolysaccharide/NN (/( LPS/NN )/) ,/, alpha-thrombin/NN ,/, or/CC phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) was/VBD similarly/RB inhibited/VBN by/IN NAC/NN ./. 
Unlike/IN published/VBN studies/NNS with/IN pyrrolidinedithiocarbamate/NN ,/, which/WDT specifically/RB inhibited/VBD vascular/JJ cell/NN adhesion/NN molecule/NN 1/CD (/( VCAM-1/NN )/) ,/, NAC/NN inhibited/VBD IL-1/NN beta-induced/JJ mRNA/NN and/CC cell/NN surface/NN expression/NN of/IN both/CC E-selectin/NN and/CC VCAM-1/NN ./. 
NAC/NN had/VBD no/DT effect/NN on/IN the/DT half-life/NN of/IN E-selectin/NN or/CC VCAM-1/NN mRNA/NN ./. 
Although/IN NAC/NN reduced/VBD nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) activation/NN in/IN EC/NNS as/IN measured/VBN by/IN gel-shift/JJ assays/NNS using/VBG an/DT oligonucleotide/NN probe/NN corresponding/VBG to/TO the/DT consensus/NN NF-kappa/NN B/NN binding/NN sites/NNS of/IN the/DT VCAM-1/NN gene/NN (/( VCAM-NF-kappa/NN B/NN )/) ,/, the/DT antioxidant/NN had/VBD no/DT appreciable/JJ effect/NN when/WRB an/DT oligomer/NN corresponding/VBG to/TO the/DT consensus/NN NF-kappa/NN B/NN binding/NN site/NN of/IN the/DT E-selectin/NN gene/NN (/( E-selectin-NF-kappa/NN B/NN )/) was/VBD used/VBN ./. 
Because/IN NF-kappa/NN B/NN has/VBZ been/VBN reported/VBN to/TO be/VB redox/NN sensitive/JJ ,/, we/PRP studied/VBD the/DT effects/NNS of/IN NAC/NN on/IN the/DT EC/NNS redox/NN environment/NN ./. 
NAC/NN caused/VBD an/DT expected/VBN dramatic/JJ increase/NN in/IN the/DT reduced/VBN glutathione/NN (/( GSH/NN )/) levels/NNS in/IN EC/NNS ./. 
In/FW vitro/FW studies/NNS demonstrated/VBD that/IN whereas/IN the/DT binding/NN affinity/NN of/IN NF-kappa/NN B/NN to/TO the/DT VCAM-NF-kappa/JJ B/NN oligomer/NN peaked/VBD at/IN a/DT GSH-to-oxidized/JJ glutathione/NN (/( GSSG/NN )/) ratio/NN of/IN approximately/RB 200/CD and/CC decreased/VBD at/IN higher/JJR ratios/NNS ,/, the/DT binding/NN to/TO the/DT E-selectin-NF-kappa/NN B/NN oligomer/NN appeared/VBD relatively/RB unaffected/JJ even/RB at/IN ratios/NNS >/JJR 400/CD ,/, i.e./FW ,/, those/DT achieved/VBN in/IN EC/NNS treated/VBN with/IN 40/CD mM/NN NAC/NN ./. 
These/DT results/NNS suggest/VBP that/IN NF-kappa/NN B/NN binding/NN to/TO its/PRP$ consensus/NN sequences/NNS in/IN the/DT VCAM-1/NN and/CC E-selectin/NN gene/NN exhibits/VBZ marked/JJ differences/NNS in/IN redox/NN sensitivity/NN ,/, allowing/VBG for/IN differential/JJ gene/NN expression/NN regulated/VBN by/IN the/DT same/JJ transcription/NN factor/NN ./. 
Our/PRP$ data/NNS also/RB demonstrate/VBP that/IN NAC/NN increases/VBZ the/DT GSH-to-GSSG/JJ ratio/NN within/IN the/DT EC/NNS suggesting/VBG one/CD possible/JJ mechanism/NN through/IN which/WDT this/DT antioxidant/NN inhibits/VBZ agonist-induced/JJ monocyte/NN adhesion/NN to/TO EC/NNS ./. 
UI/LS -/: 97378061/CD 
TI/LS -/: Opposite/JJ effects/NNS of/IN the/DT acute/JJ promyelocytic/JJ leukemia/NN PML-retinoic/JJ acid/NN receptor/NN alpha/NN (/( RAR/NN alpha/NN )/) and/CC PLZF-RAR/NN alpha/NN fusion/NN proteins/NNS on/IN retinoic/JJ acid/NN signalling/NN ./. 
AB/LS -/: Fusion/NN proteins/NNS involving/VBG the/DT retinoic/JJ acid/NN receptor/NN alpha/NN (/( RAR/NN alpha/NN )/) and/CC the/DT PML/NN or/CC PLZF/NN nuclear/JJ protein/NN are/VBP the/DT genetic/JJ markers/NNS of/IN acute/JJ promyelocytic/JJ leukemias/NNS (/( APLs/NNS )/) ./. 
APLs/NNS with/IN the/DT PML-RAR/NN alpha/NN or/CC the/DT PLZF-RAR/NN alpha/NN fusion/NN protein/NN are/VBP phenotypically/RB indistinguishable/JJ except/IN that/IN they/PRP differ/VBP in/IN their/PRP$ sensitivity/NN to/TO retinoic/JJ acid/NN (/( RA/NN )/) -induced/JJ differentiation/NN :/: PML-RAR/NN alpha/NN blasts/NNS are/VBP sensitive/JJ to/TO RA/NN and/CC patients/NNS enter/VBP disease/NN remission/NN after/IN RA/NN treatment/NN ,/, while/IN patients/NNS with/IN PLZF-RAR/NN alpha/NN do/VBP not/RB ./. 
We/PRP here/RB report/VBP that/IN (/( i/LS )/) like/IN PML-RAR/NN alpha/NN expression/NN ,/, PLZF-RAR/NN alpha/NN expression/NN blocks/VBZ terminal/JJ differentiation/NN of/IN hematopoietic/JJ precursor/NN cell/NN lines/NNS (/( U937/NN and/CC HL-60/NN )/) in/IN response/NN to/TO different/JJ stimuli/NNS (/( vitamin/NN D3/NN ,/, transforming/VBG growth/NN factor/NN beta1/NN ,/, and/CC dimethyl/NN sulfoxide/NN )/) ;/: (/( ii/LS )/) PML-RAR/NN alpha/NN ,/, but/CC not/RB PLZF-RAR/NN alpha/NN ,/, increases/VBZ RA/NN sensitivity/NN of/IN hematopoietic/JJ precursor/NN cells/NNS and/CC restores/VBZ RA/NN sensitivity/NN of/IN RA-resistant/JJ hematopoietic/JJ cells/NNS ;/: (/( iii/LS )/) PML-RAR/NN alpha/NN and/CC PLZF-RAR/NN alpha/NN have/VBP similar/JJ RA/NN binding/NN affinities/NNS ;/: and/CC (/( iv/LS )/) PML-RAR/NN alpha/NN enhances/VBZ the/DT RA/NN response/NN of/IN RA/NN target/NN genes/NNS (/( those/DT for/IN RAR/NN beta/NN ,/, RAR/NN gamma/NN ,/, and/CC transglutaminase/NN type/NN II/CD [/( TGase/NN ]/) )/) in/FW vivo/FW ,/, while/IN PLZF-RAR/NN alpha/NN expression/NN has/VBZ either/CC no/DT effect/NN (/( RAR/NN beta/NN )/) or/CC an/DT inhibitory/JJ activity/NN (/( RAR/NN gamma/NN and/CC type/NN II/CD TGase/NN )/) ./. 
These/DT data/NNS demonstrate/VBP that/IN PML-RAR/NN alpha/NN and/CC PLZF-RAR/NN alpha/NN have/VBP similar/JJ (/( inhibitory/JJ )/) effects/NNS on/IN RA-independent/JJ differentiation/NN and/CC opposite/JJ (/( stimulatory/JJ or/CC inhibitory/JJ )/) effects/NNS on/IN RA-dependent/JJ differentiation/NN and/CC that/IN they/PRP behave/VBP in/FW vivo/FW as/IN RA-dependent/JJ enhancers/NNS or/CC inhibitors/NNS of/IN RA-responsive/JJ genes/NNS ,/, respectively/RB ./. 
Their/PRP$ different/JJ activities/NNS on/IN the/DT RA/NN signalling/NN pathway/NN might/MD underlie/VB the/DT different/JJ responses/NNS of/IN PML-RAR/NN alpha/NN and/CC PLZF-RAR/NN alpha/NN APLs/NNS to/TO RA/NN treatment/NN ./. 
The/DT PLZF-RAR/NN alpha/NN fusion/NN protein/NN contains/VBZ an/DT approximately/RB 120-amino-acid/JJ N-terminal/JJ motif/NN (/( called/VBN the/DT POZ/NN domain/NN )/) ,/, which/WDT is/VBZ also/RB found/VBN in/IN a/DT variety/NN of/IN zinc/NN finger/NN proteins/NNS and/CC a/DT group/NN of/IN poxvirus/NN proteins/NNS and/CC which/WDT mediates/VBZ protein-protein/JJ interactions/NNS ./. 
Deletion/NN of/IN the/DT PLZF/NN POZ/NN domain/NN partially/RB abrogated/VBD the/DT inhibitory/JJ effect/NN of/IN PLZF-RAR/NN alpha/NN on/IN RA-induced/JJ differentiation/NN and/CC on/IN RA-mediated/JJ type/NN II/CD TGase/NN up-regulation/NN ,/, suggesting/VBG that/IN POZ-mediated/JJ protein/NN interactions/NNS might/MD be/VB responsible/JJ for/IN the/DT inhibitory/JJ transcriptional/JJ activities/NNS of/IN PLZF-RAR/NN alpha/NN ./. 
UI/LS -/: 97379437/CD 
TI/LS -/: A/DT human/JJ homologue/NN of/IN the/DT Drosophila/FW Toll/NN protein/NN signals/VBZ activation/NN of/IN adaptive/JJ immunity/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: Induction/NN of/IN the/DT adaptive/JJ immune/JJ response/NN depends/VBZ on/IN the/DT expression/NN of/IN co-stimulatory/JJ molecules/NNS and/CC cytokines/NNS by/IN antigen-presenting/JJ cells/NNS ./. 
The/DT mechanisms/NNS that/WDT control/VBP the/DT initial/JJ induction/NN of/IN these/DT signals/NNS upon/IN infection/NN are/VBP poorly/RB understood/VBN ./. 
It/PRP has/VBZ been/VBN proposed/VBN that/IN their/PRP$ expression/NN is/VBZ controlled/VBN by/IN the/DT non-clonal/JJ ,/, or/CC innate/JJ ,/, component/NN of/IN immunity/NN that/WDT preceded/VBD in/IN evolution/NN the/DT development/NN of/IN an/DT adaptive/JJ immune/JJ system/NN in/IN vertebrates/NNS ./. 
We/PRP report/VBP here/RB the/DT cloning/NN and/CC characterization/NN of/IN a/DT human/JJ homologue/NN of/IN the/DT Drosophila/FW toll/NN protein/NN (/( Toll/NN )/) which/WDT has/VBZ been/VBN shown/VBN to/TO induce/VB the/DT innate/JJ immune/JJ response/NN in/IN adult/JJ Drosophila/FW ./. 
Like/IN Drosophila/FW Toll/NN ,/, human/JJ Toll/NN is/VBZ a/DT type/NN I/CD transmembrane/JJ protein/NN with/IN an/DT extracellular/JJ domain/NN consisting/VBG of/IN a/DT leucine-rich/JJ repeat/NN (/( LRR/NN )/) domain/NN ,/, and/CC a/DT cytoplasmic/JJ domain/NN homologous/JJ to/TO the/DT cytoplasmic/JJ domain/NN of/IN the/DT human/JJ interleukin/NN (/( IL/NN )/) -1/CD receptor/NN ./. 
Both/CC Drosophila/FW Toll/NN and/CC the/DT IL-1/NN receptor/NN are/VBP known/VBN to/TO signal/VB through/IN the/DT NF-kappaB/NN pathway/NN ./. 
We/PRP show/VBP that/IN a/DT constitutively/RB active/JJ mutant/NN of/IN human/JJ Toll/NN transfected/VBN into/IN human/JJ cell/NN lines/NNS can/MD induce/VB the/DT activation/NN of/IN NF-kappaB/NN and/CC the/DT expression/NN of/IN NF-kappaB-controlled/JJ genes/NNS for/IN the/DT inflammatory/JJ cytokines/NNS IL-1/NN ,/, IL-6/NN and/CC IL-8/NN ,/, as/RB well/RB as/IN the/DT expression/NN of/IN the/DT co-stimulatory/JJ molecule/NN B7.1/NN ,/, which/WDT is/VBZ required/VBN for/IN the/DT activation/NN of/IN naive/JJ T/NN cells/NNS ./. 
UI/LS -/: 97344237/CD 
TI/LS -/: Role/NN of/IN ascorbate/NN in/IN the/DT activation/NN of/IN NF-kappaB/NN by/IN tumour/NN necrosis/NN factor-alpha/NN in/IN T-cells/NNS ./. 
AB/LS -/: The/DT first/JJ product/NN of/IN ascorbate/NN oxidation/NN ,/, the/DT ascorbate/NN free/JJ radical/NN (/( AFR/NN )/) ,/, acts/VBZ in/IN biological/JJ systems/NNS mainly/RB as/IN an/DT oxidant/NN ,/, and/CC through/IN its/PRP$ role/NN in/IN the/DT plasma/NN membrane/NN redox/NN system/NN exerts/VBZ different/JJ effects/NNS on/IN the/DT cell/NN ./. 
We/PRP have/VBP investigated/VBN the/DT role/NN of/IN ascorbate/NN ,/, AFR/NN and/CC dehydroascorbate/NN (/( DHA/NN )/) in/IN the/DT activation/NN of/IN the/DT NF-kappaB/NN transcription/NN factor/NN in/IN Jurkat/NN T-cells/NNS stimulated/VBN by/IN tumour/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) ./. 
Here/RB we/PRP show/VBP ,/, by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, that/IN ascorbate/NN increases/VBZ the/DT binding/NN of/IN NF-kappaB/NN to/TO DNA/NN in/IN TNF-alpha-stimulated/JJ Jurkat/NN cells/NNS ./. 
The/DT ability/NN of/IN ascorbate/NN to/TO enhance/VB cytoplasmic/JJ inhibitory/JJ IkBalpha/NN protein/NN degradation/NN correlates/VBZ completely/RB with/IN its/PRP$ capacity/NN to/TO induce/VB NF-kappaB/NN binding/NN to/TO DNA/NN and/CC to/TO potentiate/VB NF-kappaB-mediated/JJ transactivation/NN of/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN promoter/NN in/IN TNF-alpha-stimulated/JJ Jurkat/NN cells/NNS but/CC not/RB in/IN cells/NNS stimulated/VBN with/IN PMA/NN plus/CC ionomycin/NN ./. 
AFR/NN behaves/VBZ like/IN ascorbate/NN ,/, while/IN DHA/NN and/CC ascorbate/NN phosphate/NN do/VBP not/RB affect/VB TNF-alpha-mediated/JJ NF-kappaB/NN activation/NN ./. 
These/DT results/NNS provide/VBP new/JJ evidence/NN for/IN a/DT possible/JJ relationship/NN between/IN the/DT activation/NN of/IN the/DT electron-transport/JJ system/NN at/IN the/DT plasma/NN membrane/NN by/IN ascorbate/NN or/CC its/PRP$ free/JJ radical/NN and/CC redox-dependent/JJ gene/NN transcription/NN in/IN T-cells/NNS ./. 
UI/LS -/: 97332417/CD 
TI/LS -/: Human/JJ cytomegalovirus/NN induces/VBZ interleukin-8/NN production/NN by/IN a/DT human/JJ monocytic/JJ cell/NN line/NN ,/, THP-1/NN ,/, through/IN acting/VBG concurrently/RB on/IN AP-1-/NN and/CC NF-kappaB-binding/JJ sites/NNS of/IN the/DT interleukin-8/NN gene/NN ./. 
AB/LS -/: Cytomegalovirus/NN (/( CMV/NN )/) infection/NN induced/VBD interleukin-8/NN (/( IL-8/NN )/) gene/NN transcription/NN in/IN a/DT human/JJ monocytic/JJ cell/NN line/NN ,/, THP-1/NN cells/NNS ,/, leading/VBG to/TO IL-8/NN secretion/NN ./. 
The/DT functional/JJ analysis/NN of/IN the/DT IL-8/NN gene/NN revealed/VBD that/IN both/CC AP-1-/NN and/CC NF-kappaB/NN factor-binding/JJ elements/NNS were/VBD involved/VBN in/IN conferring/VBG the/DT responsiveness/NN to/TO CMV/NN ./. 
Moreover/RB ,/, electrophoretic/JJ mobility/NN shift/NN assays/NNS demonstrated/VBD that/IN CMV/NN induced/VBD the/DT formation/NN of/IN NF-kappaB/NN and/CC AP-1/NN complexes/NNS ./. 
These/DT results/NNS suggest/VBP that/IN CMV/NN activates/VBZ these/DT transcriptional/JJ factors/NNS ,/, resulting/VBG in/IN IL-8/NN gene/NN expression/NN ./. 
UI/LS -/: 97333610/CD 
TI/LS -/: Construction/NN and/CC biological/JJ characterization/NN of/IN an/DT interleukin-12/NN fusion/NN protein/NN (/( Flexi-12/NN )/) :/: delivery/NN to/TO acute/JJ myeloid/JJ leukemic/JJ blasts/NNS using/VBG adeno-associated/JJ virus/NN ./. 
AB/LS -/: Interleukin-12/NN (/( IL-12/NN )/) is/VBZ a/DT cytokine/NN that/WDT exhibits/VBZ pleiotropic/JJ effects/NNS on/IN lymphocytes/NNS and/CC natural/JJ killer/NN cells/NNS and/CC has/VBZ been/VBN shown/VBN to/TO have/VB promise/NN for/IN the/DT immunotherapy/NN of/IN cancer/NN ./. 
The/DT combination/NN of/IN the/DT immune/JJ costimulatory/JJ molecule/NN B7.1/NN and/CC IL-12/NN has/VBZ been/VBN shown/VBN to/TO be/VB synergistic/JJ for/IN T/NN cell/NN activation/NN ./. 
By/IN transfecting/VBG tumor/NN cells/NNS with/IN both/CC IL-12/NN and/CC B7.1/NN cDNAs/NNS ,/, it/PRP may/MD be/VB possible/JJ to/TO use/VB these/DT modified/VBN targets/NNS as/IN vaccines/NNS ./. 
A/DT major/JJ obstacle/NN in/IN designing/VBG a/DT vector/NN to/TO deliver/VB these/DT genes/NNS results/VBZ from/IN the/DT structure/NN of/IN IL-12/NN ./. 
Functional/JJ IL-12/NN is/VBZ a/DT heterodimer/NN composed/VBN of/IN two/CD distinct/JJ subunits/NNS that/WDT are/VBP encoded/VBN by/IN separate/JJ genes/NNS on/IN different/JJ chromosomes/NNS ./. 
Production/NN of/IN functional/JJ IL-12/NN requires/VBZ the/DT coordinated/VBN expression/NN of/IN both/DT genes/NNS ./. 
This/DT presents/VBZ several/JJ problems/NNS in/IN vectors/NNS ,/, particularly/RB those/DT in/IN which/WDT additional/JJ genes/NNS ,/, either/CC a/DT co-stimulatory/JJ gene/NN or/CC a/DT selectable/JJ marker/NN ,/, are/VBP inserted/VBN ./. 
Therefore/RB ,/, we/PRP have/VBP constructed/VBN a/DT single/JJ cDNA/NN that/WDT encodes/VBZ a/DT single-chain/JJ protein/NN ,/, called/VBN Flexi-12/NN ,/, which/WDT retains/VBZ all/DT of/IN the/DT biological/JJ characteristics/NNS of/IN recombinant/JJ IL-12/NN (/( rIL-12/NN )/) ./. 
The/DT monomeric/JJ polypeptide/NN Flexi-12/NN is/VBZ able/JJ to/TO induce/VB the/DT proliferation/NN of/IN phytohemagglutinin/NN (/( PHA/NN )/) blasts/NNS ,/, induce/VB PHA/NN blasts/NNS to/TO secrete/VB interferon-gamma/NN (/( IFN-gamma/NN )/) and/CC additionally/RB ,/, by/IN preincubation/NN ,/, enhance/VB the/DT killing/NN of/IN K562/NN targets/NNS by/IN PBLs/NNS ./. 
These/DT phenomena/NNS are/VBP in/IN a/DT dose-dependent/JJ manner/NN comparable/JJ to/TO that/DT seen/VBN with/IN rIL-12/NN ./. 
We/PRP have/VBP also/RB shown/VBN that/IN tyrosine/NN phosphorylation/NN of/IN the/DT STAT/NN 4/CD transcription/NN factor/NN ,/, which/WDT has/VBZ been/VBN shown/VBN to/TO be/VB unique/JJ to/TO the/DT IL-12/NN signaling/NN pathway/NN ,/, occurs/VBZ with/IN Flexi-12/NN at/IN levels/NNS similar/JJ to/TO those/DT seen/VBN with/IN rIL-12/NN ./. 
We/PRP have/VBP packaged/VBN Flexi-12/NN into/IN a/DT recombinant/JJ adeno-associated/JJ virus/NN (/( AAV/NN )/) and/CC used/VBN this/DT vector/NN to/TO infect/VB acute/JJ myeloid/JJ leukemic/JJ (/( AML/NN )/) blasts/NNS ./. 
Infected/JJ AML/NN blasts/NNS produced/VBD between/IN 2/CD and/CC 6/CD ng/NN of/IN IL-12/10/NN (/( 6/CD )/) cells/NNS per/IN ml/NN per/IN 48/CD hr/NN ./. 
These/DT studies/NNS also/RB confirm/VBP that/IN AAV/NN is/VBZ an/DT efficient/JJ delivery/NN vehicle/NN for/IN cytokines/NNS to/TO leukemic/JJ cells/NNS ./. 
Direct/JJ analysis/NN of/IN these/DT modified/VBN cells/NNS acting/VBG as/IN tumor/NN vaccines/NNS is/VBZ underway/JJ ./. 
UI/LS -/: 97292307/CD 
TI/LS -/: Plasma/NN sialyltransferase/NN levels/NNS in/IN psychiatric/JJ disorders/NNS as/IN a/DT possible/JJ indicator/NN of/IN HPA/JJ axis/NN function/NN ./. 
AB/LS -/: A/DT dysfunction/NN in/IN the/DT regulation/NN of/IN the/DT hypothalamic-pituitary-adrenal/JJ (/( HPA/JJ )/) axis/NN ,/, possibly/RB attributed/VBN to/TO a/DT change/NN in/IN glucocorticoid/NN receptor/NN (/( GR/NN )/) functionality/NN ,/, has/VBZ been/VBN implicated/VBN in/IN depression/NN ./. 
We/PRP have/VBP measured/VBN both/CC lymphocyte/NN GR/NN receptor/NN binding/NN parameters/NNS and/CC plasma/NN sialyltransferase/NN activity/NN ,/, as/IN a/DT biochemical/JJ marker/NN of/IN GR/NN function/NN ,/, in/IN two/CD groups/NNS of/IN patients/NNS suffering/VBG from/IN depression/NN or/CC schizophrenia/NN and/CC in/IN a/DT group/NN of/IN age-/NN and/CC sex-matched/JJ controls/NNS ./. 
While/IN there/EX was/VBD a/DT significant/JJ increase/NN in/IN plasma/NN cortisol/NN levels/NNS in/IN the/DT depressed/JJ group/NN ,/, there/EX were/VBD no/DT changes/NNS in/IN the/DT lymphocyte/NN GR/NN binding/NN parameters/NNS (/( K/NN (/( m/NN )/) and/CC Bmax/NN )/) ./. 
There/EX was/VBD ,/, however/RB ,/, a/DT significant/JJ decrease/NN in/IN the/DT plasma/NN sialyltransferase/NN :/: cortisol/NN ratio/NN in/IN the/DT depressed/JJ group/NN suggesting/VBG an/DT inability/NN of/IN the/DT raised/VBN cortisol/NN levels/NNS to/TO induce/VB enzyme/NN expression/NN and/CC this/DT ratio/NN may/MD provide/VB a/DT useful/JJ biochemical/JJ marker/NN of/IN cortisol/NN receptor/NN function/NN ./. 
Although/IN there/EX was/VBD an/DT increase/NN in/IN the/DT plasma/NN activity/NN of/IN the/DT alpha/NN 2,6/CD sialyltransferase/NN isozyme/NN in/IN the/DT schizophrenic/JJ group/NN ,/, no/DT other/JJ changes/NNS were/VBD determined/VBN ./. 
Therefore/RB ,/, while/IN the/DT total/JJ plasma/NN sialyltransferase/NN :/: cortisol/NN ratio/NN reflects/VBZ HPA/JJ axis/NN function/NN ,/, alterations/NNS in/IN specific/JJ isozyme/NN activity/NN may/MD also/RB be/VB associated/VBN with/IN other/JJ CNS/NN disease/NN states/NNS ./. 
UI/LS -/: 97289567/CD 
TI/LS -/: Regulation/NN of/IN CD95/NN (/( Fas/NN )/) ligand/NN expression/NN by/IN TCR-mediated/JJ signaling/NN events/NNS ./. 
AB/LS -/: Stimulation/NN of/IN mature/JJ peripheral/JJ T/NN cells/NNS by/IN TCR/NN engagement/NN results/VBZ in/IN activation/NN of/IN signals/NNS that/WDT drive/VBP induction/NN of/IN cytokine/NN gene/NN expression/NN and/CC clonal/JJ expansion/NN ./. 
However/RB ,/, under/IN some/DT conditions/NNS ,/, engagement/NN of/IN the/DT TCR/NN leads/VBZ instead/RB to/TO apoptosis/NN ./. 
Recent/JJ studies/NNS demonstrate/VBP that/IN TCR-stimulated/JJ apoptosis/NN requires/VBZ expression/NN of/IN CD95/NN ligand/NN on/IN activated/VBN T/NN cells/NNS followed/VBN by/IN an/DT interaction/NN between/IN CD95/NN ligand/NN and/CC the/DT CD95/NN receptor/NN also/RB expressed/VBN on/IN this/DT population/NN ./. 
The/DT experiments/NNS reported/VBN in/IN this/DT study/NN were/VBD designed/VBN to/TO address/VB the/DT signaling/NN events/NNS triggered/VBN by/IN TCR/NN engagement/NN that/WDT are/VBP important/JJ for/IN regulating/VBG CD95/NN ligand/NN gene/NN expression/NN ./. 
To/TO approach/VB this/DT ,/, we/PRP generated/VBD a/DT luciferase/NN reporter/NN construct/NN containing/VBG elements/NNS of/IN the/DT CD95/NN ligand/NN promoter/NN ./. 
Using/VBG a/DT previously/RB described/VBN mutant/NN of/IN the/DT Jurkat/NN T/NN cell/NN line/NN ,/, we/PRP show/VBP that/IN proximal/JJ signaling/NN events/NNS dependent/JJ on/IN the/DT presence/NN of/IN the/DT CD45/NN tyrosine/NN phosphatase/NN are/VBP required/VBN for/IN TCR-stimulated/JJ CD95/NN ligand/NN expression/NN ./. 
Transient/JJ transfection/NN studies/NNS demonstrate/VBP further/RB that/IN TCR-stimulated/JJ activation/NN of/IN the/DT Ras/NN signaling/NN pathway/NN is/VBZ required/VBN for/IN optimal/JJ activation/NN of/IN CD95/NN ligand/NN ./. 
Next/RB ,/, in/IN an/DT effort/NN to/TO determine/VB critical/JJ transcription/NN factors/NNS that/WDT regulate/VBP CD95/NN ligand/NN expression/NN ,/, we/PRP demonstrate/VBP a/DT cyclosporin/NN A-sensitive/JJ nuclear/JJ factor-AT/NN response/NN element/NN in/IN the/DT promoter/NN region/NN of/IN this/DT gene/NN that/WDT is/VBZ critical/JJ for/IN optimal/JJ CD95/NN ligand/NN reporter/NN activity/NN in/IN stimulated/VBN T/NN cells/NNS ./. 
Together/RB ,/, these/DT studies/NNS begin/VBP a/DT dissection/NN of/IN the/DT biochemical/JJ events/NNS that/WDT lead/VBP to/TO expression/NN of/IN CD95/NN ligand/NN ,/, a/DT required/JJ step/NN for/IN TCR-induced/JJ apoptosis/NN ./. 
UI/LS -/: 97321386/CD 
TI/LS -/: Reactive/JJ oxygen/NN species/NNS and/CC antioxidants/NNS in/IN inflammatory/JJ diseases/NNS ./. 
AB/LS -/: This/DT paper/NN aims/VBZ to/TO review/VB the/DT role/NN of/IN free/JJ radical-induced/JJ tissue/NN damage/NN and/CC antioxidant/JJ defence/NN mechanisms/NNS in/IN inflammatory/JJ diseases/NNS that/WDT involve/VBP pathogenic/JJ processes/NNS similar/JJ to/TO the/DT periodontal/JJ diseases/NNS ./. 
There/EX is/VBZ a/DT clearly/RB defined/VBN and/CC substantial/JJ role/NN for/IN free/JJ radicals/NNS or/CC reactive/JJ oxygen/NN species/NNS (/( ROS/NNS )/) in/IN periodontitis/NN ,/, but/CC little/JJ research/NN has/VBZ been/VBN performed/VBN in/IN this/DT area/NN ./. 
This/DT paper/NN reviews/VBZ the/DT considerable/JJ data/NNS available/JJ relating/VBG ROS/NNS activity/NN and/CC antioxidant/JJ defence/NN to/TO inflammatory/JJ diseases/NNS and/CC attempts/VBZ to/TO draw/VB parallels/NNS with/IN periodontitis/NN ,/, in/IN an/DT effort/NN to/TO stimulate/VB more/RBR periodontal/JJ research/NN in/IN this/DT important/JJ area/NN ./. 
The/DT recent/JJ discovery/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) is/VBZ reviewed/VBN and/CC several/JJ potential/JJ pathways/NNS for/IN cytokine-induced/JJ periodontal/JJ tissue/NN damage/NN ,/, mediated/VBN by/IN NF-kappa/NN B1/NN are/VBP discussed/VBN ./. 
Emphasis/NN is/VBZ placed/VBN on/IN cytokines/NNS that/WDT have/VBP been/VBN studied/VBN in/IN periodontitis/NN ,/, principally/RB TNF-alpha/NN ,/, IL-1/NN ,/, IL-6/NN ,/, IL-8/NN and/CC beta-interferon/NN ./. 
The/DT link/NN between/IN cellular/JJ production/NN of/IN such/JJ important/JJ mediators/NNS of/IN inflammation/NN and/CC the/DT antioxidant/JJ (/( AO/JJ )/) thiols/NNS ,/, cysteine/NN and/CC reduced/VBN glutathione/NN (/( GSH/NN )/) ,/, is/VBZ discussed/VBN and/CC it/PRP is/VBZ hypothesised/VBN that/IN NF-kappa/NN B/NN antagonists/NNS may/MD offer/VB important/JJ therapeutic/JJ benefits/NNS ./. 
UI/LS -/: 97449161/CD 
TI/LS -/: Mutations/NNS in/IN the/DT TSC2/NN gene/NN :/: analysis/NN of/IN the/DT complete/JJ coding/VBG sequence/NN using/VBG the/DT protein/NN truncation/NN test/NN (/( PTT/NN )/) ./. 
AB/LS -/: Mutations/NNS in/IN the/DT TSC2/NN gene/NN on/IN chromosome/NN 16p13.3/NN are/VBP responsible/JJ for/IN approximately/RB 50/CD %/NN of/IN familial/JJ tuberous/JJ sclerosis/NN (/( TSC/NN )/) ./. 
The/DT gene/NN has/VBZ 41/CD small/JJ exons/NNS spanning/VBG 45/CD kb/NN of/IN genomic/JJ DNA/NN and/CC encoding/VBG a/DT 5.5/CD kb/NN mRNA/NN ./. 
Large/JJ germline/NN deletions/NNS of/IN TSC2/NN occur/VBP in/IN </JJR 5/CD %/NN of/IN cases/NNS ,/, and/CC a/DT number/NN of/IN small/JJ intragenic/JJ mutations/NNS have/VBP been/VBN described/VBN ./. 
We/PRP analysed/VBD mRNA/NN from/IN 18/CD unrelated/JJ cases/NNS of/IN TSC/NN for/IN TSC2/NN mutations/NNS using/VBG the/DT protein/NN truncation/NN test/NN (/( PTT/NN )/) ./. 
Three/CD cases/NNS were/VBD predicted/VBN to/TO be/VB TSC2/NN mutations/NNS on/IN the/DT basis/NN of/IN linkage/NN analysis/NN or/CC because/IN a/DT hamartoma/NN from/IN the/DT patient/NN showed/VBD loss/NN of/IN heterozygosity/NN for/IN 16p13.3/NN markers/NNS ./. 
Three/CD overlapping/VBG PCR/NN products/NNS ,/, covering/VBG the/DT complete/JJ coding/VBG sequence/NN of/IN mRNA/NN ,/, were/VBD generated/VBN from/IN lymphoblastoid/JJ cell/NN lines/NNS ,/, translated/VBN into/IN 35S-methionine/NN labelled/JJ protein/NN ,/, and/CC analysed/VBN by/IN SDS-PAGE/NN ./. 
PCR/NN products/NNS showing/VBG PTT/NN shifts/NNS were/VBD directly/RB sequenced/VBN ,/, and/CC mutations/NNS confirmed/VBN by/IN restriction/NN enzyme/NN digestion/NN where/WRB possible/JJ ./. 
Six/CD PTT/NN shifts/NNS were/VBD identified/VBN ./. 
Five/CD of/IN these/DT were/VBD caused/VBN by/IN mutations/NNS predicted/VBN to/TO produce/VB a/DT truncated/VBN protein/NN :/: (/( i/LS )/) a/DT sporadic/JJ case/NN showed/VBD a/DT 32/CD bp/NN deletion/NN in/IN exon/NN 11/CD ,/, and/CC a/DT mutant/JJ mRNA/NN without/IN exon/NN 11/CD was/VBD produced/VBN ;/: the/DT normal/JJ exon/NN 10/CD was/VBD also/RB spliced/VBN out/RP ;/: (/( ii/LS )/) a/DT sporadic/JJ case/NN had/VBD a/DT 1/CD bp/NN deletion/NN in/IN exon/NN 12/CD (/( 1634delT/NN )/) ;/: (/( iii/LS )/) a/DT TSC2-linked/JJ mother/NN and/CC daughter/NN pair/NN had/VBD a/DT G/NN -->/TO T/NN transversion/NN in/IN exon/NN 23/CD (/( G2715T/NN )/) introducing/VBG a/DT cryptic/JJ splice/NN site/NN causing/VBG a/DT 29/CD bp/NN truncation/NN of/IN mRNA/NN from/IN exon/NN 23/CD ;/: (/( iv/LS )/) a/DT sporadic/JJ case/NN showed/VBD a/DT 2/CD bp/NN deletion/NN in/IN exon/NN 36/CD ;/: (/( v/LS )/) a/DT sporadic/JJ case/NN showed/VBD a/DT 1/CD bp/NN insertion/NN disrupting/VBG the/DT donor/NN splice/NN site/NN of/IN exon/NN 37/CD (/( 5007+2insA/NN )/) ,/, resulting/VBG in/IN the/DT use/NN of/IN an/DT upstream/JJ exonic/JJ cryptic/JJ splice/NN site/NN to/TO cause/VB a/DT 29/CD bp/NN truncation/NN of/IN mRNA/NN from/IN exon/NN 37/CD ./. 
In/IN one/CD case/NN ,/, the/DT PTT/NN shift/NN was/VBD explained/VBN by/IN in-frame/JJ splicing/NN out/RP of/IN exon/NN 10/CD ,/, in/IN the/DT presence/NN of/IN a/DT normal/JJ exon/NN 10/CD genomic/JJ sequence/NN ./. 
Alternative/JJ splicing/NN of/IN exon/NN 10/CD of/IN the/DT TSC2/NN gene/NN may/MD be/VB a/DT normal/JJ variant/NN ./. 
Three/CD 3rd/JJ base/NN substitution/NN polymorphisms/NNS were/VBD also/RB detected/VBN during/IN direct/JJ sequencing/NN of/IN PCR/NN products/NNS ./. 
Confirmed/VBN mutations/NNS were/VBD identified/VBN in/IN 28/CD %/NN of/IN the/DT families/NNS studied/VBN and/CC on/IN the/DT assumption/NN that/IN half/NN of/IN the/DT sporadic/JJ cases/NNS should/MD have/VB TSC2/NN mutations/NNS ,/, a/DT crude/JJ estimate/NN of/IN the/DT detection/NN rate/NN would/MD be/VB 60/CD %/NN ./. 
This/DT compares/VBZ favourably/RB with/IN other/JJ screening/NN methods/NNS used/VBN for/IN TSC2/NN ,/, notably/RB SSCP/NN ,/, and/CC since/IN PTT/NN involves/VBZ much/RB less/JJR work/NN it/PRP may/MD be/VB the/DT method/NN of/IN choice/NN ./. 
UI/LS -/: 97423536/CD 
TI/LS -/: alpha-Tocopheryl/NN succinate/NN inhibits/VBZ monocytic/JJ cell/NN adhesion/NN to/TO endothelial/JJ cells/NNS by/IN suppressing/VBG NF-kappa/NN B/NN mobilization/NN ./. 
AB/LS -/: The/DT adherence/NN of/IN monocytes/NNS to/TO activated/VBN endothelium/NN is/VBZ an/DT early/JJ event/NN in/IN atherogenesis/NN ./. 
Because/IN antioxidants/NNS have/VBP been/VBN considered/VBN to/TO be/VB of/IN antiatherosclerotic/JJ potential/NN ,/, we/PRP investigated/VBD the/DT effects/NNS of/IN alpha-tocopherol/NN (/( TCP/NN )/) and/CC its/PRP$ acetate/NN and/CC succinate/NN esters/NNS on/IN monocyte/NN adhesion/NN to/TO cytokine-stimulated/JJ human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS (/( HUVEC/NNS )/) ./. 
Endothelial/JJ cells/NNS were/VBD treated/VBN with/IN TCP/NN ,/, alpha-tocopherol/NN acetate/NN (/( TCP/NN acetate/NN )/) ,/, or/CC alpha-tocopheryl/NN succinate/NN (/( TCP/NN succinate/NN )/) before/IN stimulation/NN with/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN ;/: 10/CD U/ml/NN ,/, 6/CD h/NN )/) or/CC interleukin-1/NN beta/NN (/( IL-1/NN beta/NN ;/: 10/CD U/ml/NN ,/, 6/CD h/NN )/) ./. 
Cytokine-stimulated/JJ cell/NN surface/NN expression/NN of/IN vascular/JJ cell/NN adhesion/NN molecule-1/NN (/( VCAM-1/NN ,/, CD106/NN )/) and/CC E-selectin/NN (/( ELAM-1/NN ,/, CD62E/NN )/) ,/, but/CC not/RB of/IN intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN ,/, CD54/NN )/) ,/, was/VBD time-/NN and/CC dose-/NN dependently/RB inhibited/VBN by/IN TCP/NN succinate/NN but/CC not/RB by/IN TCP/NN or/CC TCP/NN acetate/NN ./. 
TCP/NN succinate/JJ (/( 200/CD microM/NN ,/, 24/CD h/NN )/) reduced/VBD TNF-induced/JJ VCAM-1/NN and/CC E-selectin/NN expression/NN from/IN a/DT specific/JJ mean/NN fluorescence/NN intensity/NN of/IN 151/CD +/-/CC 28/CD to/TO 12/CD +/-/CC 4/CD channels/NNS and/CC from/IN 225/CD +/-/CC 38/CD to/TO 79/CD +/-/CC 21/CD channels/NNS ,/, respectively/RB ./. 
Succinate/NN alone/RB had/VBD no/DT effect/NN ./. 
Decreased/VBN adhesion/NN molecule/NN expression/NN was/VBD associated/VBN with/IN a/DT reduction/NN of/IN monocytic/JJ cell/NN adhesion/NN ./. 
TCP/NN succinate/NN (/( 20/CD microM/NN ,/, 72/CD h/NN )/) ,/, but/CC not/RB TCP/NN (/( 200/CD microM/NN ,/, 72/CD h/NN )/) ,/, reduced/VBD U-937/NN cell/NN adhesion/NN to/TO TNF-alpha-stimulated/JJ (/( 10/CD U/ml/NN ,/, 6/CD h/NN )/) HUVEC/NNS by/IN 30/CD %/NN (/( P/NN </JJR 0.025/CD )/) and/CC to/TO IL-1/NN beta-stimulated/JJ HUVEC/NNS by/IN 56/CD %/NN (/( P/NN </JJR 0.010/CD )/) ./. 
Electrophoretic/JJ mobility-shift/JJ assays/NNS of/IN HUVEC/NNS nuclear/JJ proteins/NNS revealed/VBD a/DT decrease/NN in/IN TNF-alpha-stimulated/JJ nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) activation/NN after/IN pretreatment/NN of/IN HUVEC/NNS with/IN TCP/NN succinate/NN but/CC not/RB with/IN TCP/NN ,/, TCP/NN acetate/NN ,/, or/CC succinate/NN alone/RB ./. 
In/IN conclusion/NN ,/, we/PRP demonstrate/VBP that/IN the/DT vitamin/NN E/NN derivative/NN TCP/NN succinate/NN prevents/VBZ monocytic/JJ cell/NN adhesion/NN to/TO cytokine-stimulated/JJ endothelial/JJ cells/NNS by/IN inhibiting/VBG the/DT activation/NN of/IN NF-kappa/NN B/NN ,/, further/RB emphasizing/VBG the/DT antiatherosclerotic/JJ potential/NN of/IN lipid/NN soluble/JJ antioxidants/NNS ./. 
UI/LS -/: 97378046/CD 
TI/LS -/: The/DT product/NN of/IN the/DT murine/JJ homolog/NN of/IN the/DT Drosophila/FW extra/JJ sex/NN combs/NNS gene/NN displays/VBZ transcriptional/JJ repressor/NN activity/NN ./. 
AB/LS -/: The/DT heterogeneous/JJ nuclear/JJ ribonucleoprotein/NN K/NN protein/NN represents/VBZ a/DT novel/JJ class/NN of/IN proteins/NNS that/WDT may/MD act/VB as/IN docking/NN platforms/NNS that/WDT orchestrate/VBP cross-talk/NN among/IN molecules/NNS involved/VBN in/IN signal/NN transduction/NN and/CC gene/NN expression/NN ./. 
Using/VBG a/DT fragment/NN of/IN K/NN protein/NN as/IN bait/NN in/IN the/DT yeast/NN two-hybrid/JJ screen/NN ,/, we/PRP isolated/VBD a/DT cDNA/NN that/WDT encodes/VBZ a/DT protein/NN whose/WP$ primary/JJ structure/NN has/VBZ extensive/JJ similarity/NN to/TO the/DT Drosophila/FW melanogaster/FW extra/FW sex/NN combs/NNS (/( esc/NNS )/) gene/NN product/NN ,/, Esc/NN ,/, a/DT putative/JJ silencer/NN of/IN homeotic/JJ genes/NNS ./. 
The/DT cDNA/NN that/WDT we/PRP isolated/VBD is/VBZ identical/JJ to/TO the/DT cDNA/NN of/IN the/DT recently/RB positionally/RB cloned/VBN mouse/NN embryonic/JJ ectoderm/NN development/NN gene/NN ,/, eed/NN ./. 
Like/IN Esc/NN ,/, Eed/NN contains/VBZ six/CD WD-40/NN repeats/NNS in/IN the/DT C-terminal/JJ half/NN of/IN the/DT protein/NN and/CC is/VBZ thought/VBN to/TO repress/VB homeotic/JJ gene/NN expression/NN during/IN mouse/NN embryogenesis/NN ./. 
Eed/NN binds/VBZ to/TO K/NN protein/NN through/IN a/DT domain/NN in/IN its/PRP$ N/NN terminus/NN ,/, but/CC interestingly/RB ,/, this/DT domain/NN is/VBZ not/RB found/VBN in/IN the/DT Drosophila/FW Esc/NN ./. 
Gal4-Eed/JJ fusion/NN protein/NN represses/VBZ transcription/NN of/IN a/DT reporter/NN gene/NN driven/VBN by/IN a/DT promoter/NN that/WDT contains/VBZ Gal4-binding/JJ DNA/NN elements/NNS ./. 
Eed/NN also/RB represses/VBZ transcription/NN when/WRB recruited/VBN to/TO a/DT target/NN promoter/NN by/IN Gal4-K/NN protein/NN ./. 
Point/NN mutations/NNS within/IN the/DT eed/NN gene/NN that/WDT are/VBP responsible/JJ for/IN severe/JJ embryonic/JJ development/NN abnormalities/NNS abolished/VBD the/DT transcriptional/JJ repressor/NN activity/NN of/IN Eed/NN ./. 
Results/NNS of/IN this/DT study/NN suggest/VBP that/IN Eed-restricted/JJ homeotic/JJ gene/NN expression/NN during/IN embryogenesis/NN reflects/VBZ the/DT action/NN of/IN Eed/NN as/IN a/DT transcriptional/JJ repressor/NN ./. 
The/DT Eed-mediated/JJ transcriptional/JJ effects/NNS are/VBP likely/JJ to/TO reflect/VB the/DT interaction/NN of/IN Eed/NN with/IN multiple/JJ molecular/JJ partners/NNS ,/, including/VBG K/NN protein/NN ./. 
UI/LS -/: 97361636/CD 
TI/LS -/: Interferons/NNS up-regulate/VBP STAT1/NN ,/, STAT2/NN ,/, and/CC IRF/NN family/NN transcription/NN factor/NN gene/NN expression/NN in/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS and/CC macrophages/NNS ./. 
AB/LS -/: IFN/NN signaling/NN is/VBZ mediated/VBN by/IN binding/NN of/IN IFNs/NNS to/TO their/PRP$ receptors/NNS and/CC subsequent/JJ activation/NN of/IN Janus/NN tyrosine/NN kinase/NN (/( JAK/NN )/) -STAT/JJ signaling/NN pathway/NN ./. 
Stimulation/NN of/IN cells/NNS with/IN IFN-alpha/NN leads/VBZ to/TO the/DT assembly/NN of/IN IFN-stimulated/JJ gene/NN factor/NN 3/CD transcription/NN factor/NN complex/NN formed/VBN by/IN STAT1/NN ,/, STAT2/NN ,/, and/CC p48/NN protein/NN ./. 
IFN-gamma/NN signaling/NN is/VBZ mediated/VBN by/IN homodimeric/JJ STAT1/NN protein/NN ./. 
Although/IN these/DT signaling/VBG molecules/NNS are/VBP expressed/VBN constitutively/RB ,/, there/EX is/VBZ also/RB evidence/NN of/IN transcriptional/JJ regulation/NN by/IN IFNs/NNS ./. 
We/PRP have/VBP characterized/VBN the/DT expression/NN of/IN STAT/NN and/CC IFN/NN regulatory/JJ factor/NN (/( IRF/NN )/) family/NN transcription/NN factors/NNS in/IN primary/JJ human/JJ blood/NN mononuclear/JJ cells/NNS and/CC macrophages/NNS in/IN response/NN to/TO IFN-alpha/NN and/CC IFN-gamma/NN stimulation/NN ./. 
We/PRP show/VBP that/IN IFN-alpha/NN and/CC IFN-gamma/NN rapidly/RB and/CC efficiently/RB enhanced/VBD STAT1/NN ,/, STAT2/NN ,/, p48/NN ,/, and/CC IRF-1/NN gene/NN expression/NN ./. 
IFN-gamma/NN induced/VBD IRF-1/NN gene/NN expression/NN more/RBR strongly/RB than/IN IFN-alpha/NN ./. 
Stimulation/NN experiments/NNS in/IN the/DT presence/NN of/IN protein/NN synthesis/NN inhibitor/NN ,/, cycloheximide/NN ,/, suggested/VBD that/IN these/DT genes/NNS were/VBD activated/VBN directly/RB by/IN IFNs/NNS ./. 
IRF-2/NN gene/NN was/VBD apparently/RB only/RB weakly/RB responsive/JJ to/TO IFNs/NNS in/IN these/DT cells/NNS ./. 
When/WRB macrophages/NNS were/VBD pretreated/JJ with/IN low/JJ doses/NNS of/IN IFN-gamma/NN and/CC then/RB stimulated/VBN with/IN IFN-alpha/NN ,/, clearly/RB enhanced/VBN formation/NN of/IN specific/JJ transcription/NN factor/NN complexes/NNS was/VBD detected/VBN ./. 
This/DT suggests/VBZ that/IN higher/JJR intracellular/JJ levels/NNS of/IN STAT1/NN ,/, STAT2/NN ,/, and/CC p48/NN protein/NN may/MD result/VB in/IN enhanced/VBN signal/NN transduction/NN for/IN cytokines/NNS utilizing/VBG these/DT transcription/NN factors/NNS ./. 
UI/LS -/: 97367500/CD 
TI/LS -/: The/DT role/NN of/IN nuclear/JJ factor-kappa/NN B/NN in/IN cytokine/NN gene/NN regulation/NN ./. 
AB/LS -/: Transcription/NN factors/NNS are/VBP DNA-binding/JJ proteins/NNS that/WDT regulate/VBP gene/NN expression/NN ./. 
Nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) is/VBZ a/DT critical/JJ transcription/NN factor/NN for/IN maximal/JJ expression/NN of/IN many/JJ cytokines/NNS that/WDT are/VBP involved/VBN in/IN the/DT pathogenesis/NN of/IN inflammatory/JJ diseases/NNS ,/, such/JJ as/IN adult/JJ respiratory/JJ distress/NN syndrome/NN (/( ARDS/NN )/) and/CC sepsis/NN syndrome/NN ./. 
Activation/NN and/CC regulation/NN of/IN NF-kappa/NN B/NN are/VBP tightly/RB controlled/VBN by/IN a/DT group/NN of/IN inhibitory/JJ proteins/NNS (/( I/NN kappa/NN B/NN )/) that/WDT sequester/VBP NF-kappa/NN B/NN in/IN the/DT cytoplasm/NN of/IN immune/inflammatory/JJ effector/NN cells/NNS ./. 
NF-kappa/NN B/NN activation/NN involves/VBZ signaled/VBN phosphorylation/NN ,/, ubiquitination/NN ,/, and/CC proteolysis/NN of/IN I/NN kappa/NN B/NN ./. 
Liberated/VBN NF-kappa/NN B/NN migrates/VBZ to/TO the/DT nucleus/NN ,/, where/WRB it/PRP binds/VBZ to/TO specific/JJ promoter/NN sites/NNS and/CC activates/VBZ gene/NN transcription/NN ./. 
The/DT activation/NN of/IN NF-kappa/NN B/NN initiates/VBZ both/CC extracellular/JJ and/CC intracellular/JJ regulatory/JJ events/NNS that/WDT result/VBP in/IN autoregulation/NN of/IN the/DT inflammatory/JJ cascade/NN through/IN modulation/NN of/IN NF-kappa/NN B/NN activation/NN ./. 
Recently/RB ,/, activation/NN of/IN NF-kappa/NN B/NN has/VBZ been/VBN linked/VBN to/TO ARDS/NN and/CC has/VBZ been/VBN shown/VBN to/TO be/VB a/DT critical/JJ proximal/JJ step/NN in/IN the/DT initiation/NN of/IN neutrophilic/JJ inflammation/NN in/IN animal/NN models/NNS ./. 
Activation/NN of/IN NF-kappa/NN B/NN can/MD be/VB inhibited/VBN in/FW vivo/FW by/IN treatment/NN with/IN antioxidants/NNS ,/, corticosteroids/NNS ,/, and/CC the/DT induction/NN of/IN endotoxin/NN tolerance/NN ./. 
Identification/NN of/IN more/RBR specific/JJ and/CC efficacious/JJ inhibitors/NNS of/IN NF-kappa/NN B/NN activation/NN might/MD prove/VB beneficial/JJ for/IN the/DT treatment/NN of/IN cytokine-mediated/JJ inflammatory/JJ diseases/NNS ./. 
UI/LS -/: 97349094/CD 
TI/LS -/: Chimeric/JJ oncoprotein/NN E2a-Pbx1/NN induces/VBZ apoptosis/NN of/IN hematopoietic/JJ cells/NNS by/IN a/DT p53-independent/JJ mechanism/NN that/WDT is/VBZ suppressed/VBN by/IN Bcl-2/NN ./. 
AB/LS -/: The/DT chimeric/JJ oncoprotein/NN E2a-Pbx1/NN results/VBZ from/IN fusion/NN of/IN the/DT E2A/NN and/CC PBX1/NN genes/NNS following/VBG t(1;19)/NN chromosomal/JJ translocations/NNS in/IN B/NN cell/NN precursor/NN acute/JJ leukemias/NNS ./. 
Experimentally/RB B/NN cell/NN progenitors/NNS do/VBP not/RB tolerate/VB constitutive/JJ expression/NN of/IN E2a-Pbx1/NN which/WDT contrasts/VBZ with/IN transformation/NN of/IN several/JJ other/JJ cell/NN types/NNS following/VBG its/PRP$ stable/JJ expression/NN both/CC in/FW vitro/FW and/CC in/FW vivo/FW ./. 
To/TO further/RB investigate/VB the/DT effects/NNS of/IN E2a-Pbx1/NN on/IN the/DT B/NN cell/NN progenitors/NNS ,/, we/PRP conditionally/RB expressed/VBD E2a-Pbx1/NN under/IN control/NN of/IN a/DT metal/JJ response/NN element/NN in/IN hematopoietic/JJ precursor/NN cell/NN lines/NNS in/FW vitro/FW ./. 
Inducible/JJ expression/NN of/IN E2a-Pbx1/NN resulted/VBD in/IN cell/NN death/NN with/IN the/DT morphologic/JJ and/CC molecular/JJ features/NNS of/IN apoptosis/NN ./. 
A/DT structure-function/JJ analysis/NN demonstrated/VBD that/IN induction/NN of/IN apoptosis/NN was/VBD not/RB a/DT dominant-negative/JJ effect/NN of/IN the/DT E2a/NN moiety/NN but/CC ,/, rather/RB ,/, required/VBD the/DT DNA-binding/JJ homeodomain/NN of/IN Pbx1/NN ./. 
E2a-Pbx1-induced/JJ apoptosis/NN proceeded/VBD through/IN a/DT BCL2-responsive/JJ checkpoint/NN eventuating/NN in/IN PARP/NN inactivation/NN but/CC did/VBD require/VB p53/NN ./. 
Constitutive/JJ expression/NN of/IN E2a-Pbx1/NN did/VBD not/RB induce/VB apoptosis/NN or/CC continued/JJ cycling/NN of/IN Rat-1/NN fibroblasts/NNS in/IN low/JJ serum/NN conditions/NNS ./. 
These/DT studies/NNS demonstrate/VBP that/IN E2a-Pbx1/NN initiates/VBZ programmed/VBN cell/NN death/NN of/IN hematopoietic/JJ precursers/NNS by/IN a/DT mechanism/NN that/WDT requires/VBZ its/PRP$ chimeric/JJ transcriptional/JJ properties/NNS ,/, but/CC ,/, unlike/IN other/JJ nuclear/JJ oncoproteins/NNS ,/, is/VBZ independent/JJ of/IN p53/NN ./. 
UI/LS -/: 97322395/CD 
TI/LS -/: CCAAT/enhancer/NN binding/NN protein/NN epsilon/NN is/VBZ preferentially/RB up-regulated/VBN during/IN granulocytic/JJ differentiation/NN and/CC its/PRP$ functional/JJ versatility/NN is/VBZ determined/VBN by/IN alternative/JJ use/NN of/IN promoters/NNS and/CC differential/JJ splicing/NN ./. 
AB/LS -/: CCAAT/enhancer/NN binding/NN protein/NN (/( C/EBP/NN )/) epsilon/NN is/VBZ a/DT recently/RB cloned/VBN member/NN of/IN the/DT C/EBP/NN family/NN of/IN transcription/NN factors/NNS and/CC is/VBZ expressed/VBN exclusively/RB in/IN cells/NNS of/IN hematopoietic/JJ origin/NN ./. 
The/DT human/JJ C/EBPepsilon/NN gene/NN is/VBZ transcribed/VBN by/IN two/CD alternative/JJ promoters/NNS ,/, Palpha/NN and/CC Pbeta/NN ./. 
A/DT combination/NN of/IN differential/JJ splicing/NN and/CC alternative/JJ use/NN of/IN promoters/NNS generates/VBZ four/CD mRNA/NN isoforms/NNS ,/, of/IN 2.6/CD kb/NN and/CC 1.3-1.5/CD kb/NN in/IN size/NN ./. 
These/DT transcripts/NNS can/MD encode/VB three/CD proteins/NNS of/IN calculated/VBN molecular/JJ mass/NN 32.2/CD kDa/NN ,/, 27.8/CD kDa/NN ,/, and/CC 14.3/CD kDa/NN ./. 
Accordingly/RB ,/, Western/NN blots/NNS with/IN antibodies/NNS specific/JJ for/IN the/DT DNA-binding/JJ domain/NN ,/, that/WDT is/VBZ common/JJ to/TO all/DT forms/NNS ,/, identify/VBP multiple/JJ proteins/NNS ./. 
C/EBPepsilon/NN mRNA/NN was/VBD greatly/RB induced/VBN during/IN in/FW vitro/FW granulocytic/JJ differentiation/NN of/IN human/JJ primary/JJ CD34(+)/JJ cells/NNS ./. 
Retinoic/JJ acid/NN treatment/NN of/IN HL60/NN promyelocytic/JJ leukemia/NN cells/NNS for/IN 24/CD hr/NN induced/VBD C/EBPepsilon/NN mRNA/NN levels/NNS by/IN 4-fold/RB ,/, while/IN prolonged/JJ treatment/NN gradually/RB reduced/VBD mRNA/NN expression/NN to/TO pretreatment/JJ levels/NNS ./. 
Transient/JJ transfection/NN experiments/NNS with/IN expression/NN vectors/NNS for/IN two/CD of/IN the/DT isoforms/NNS demonstrated/VBD that/IN the/DT 32.2-kDa/JJ protein/NN is/VBZ an/DT activator/NN of/IN transcription/NN of/IN granulocyte/NN colony-stimulating/JJ factor/NN receptor/NN promoter/NN ,/, while/IN the/DT 14.3-kDa/JJ protein/NN is/VBZ not/RB ./. 
Thus/RB ,/, C/EBPepsilon/NN is/VBZ regulated/VBN in/IN a/DT complex/JJ fashion/NN and/CC may/MD play/VB a/DT role/NN in/IN the/DT regulation/NN of/IN genes/NNS involved/VBN in/IN myeloid/JJ differentiation/NN ./. 
UI/LS -/: 97284012/CD 
TI/LS -/: Effects/NNS of/IN TPA/NN ,/, bryostatin/NN 1/CD ,/, and/CC retinoic/JJ acid/NN on/IN PO-B/NN ,/, AP-1/NN ,/, and/CC AP-2/NN DNA/NN binding/NN during/IN HL-60/NN differentiation/NN ./. 
AB/LS -/: PO-B/NN was/VBD originally/RB characterized/VBN as/IN a/DT transcriptional/JJ regulatory/JJ factor/NN of/IN the/DT pro-opiomelanocortin/JJ (/( POMC/JJ )/) gene/NN ;/: however/RB ,/, it/PRP has/VBZ become/VBN increasingly/RB clear/JJ that/IN this/DT protein/NN may/MD be/VB active/JJ in/IN tissues/NNS outside/IN the/DT pituitary/NN ,/, since/IN it/PRP is/VBZ present/JJ in/IN diverse/JJ cell/NN types/NNS ,/, including/VBG differentiated/VBN HL-60/NN promyelocytic/JJ leukemia/NN cells/NNS ./. 
We/PRP previously/RB showed/VBD that/IN PO-B/NN DNA-binding/NN is/VBZ progressively/RB induced/VBN during/IN differentiation/NN of/IN promyelomonocytic/JJ leukemic/JJ HL-60/NN cells/NNS to/TO the/DT macrophage-like/JJ lineage/NN (/( with/IN phorbol/NN esters/NNS )/) ./. 
We/PRP now/RB report/VBP that/IN PO-B/NN DNA-binding/NN in/IN HL-60/NN cells/NNS is/VBZ similarly/RB induced/VBN during/IN differentiation/NN to/TO the/DT granulocytic/JJ lineage/NN (/( with/IN either/CC retinoic/JJ acid/NN or/CC dimethylsulfoxide/NN )/) ./. 
Either/CC a/DT genetic/JJ or/CC pharmacologic/JJ blockade/NN of/IN HL-60/NN differentiation/NN prohibited/VBD these/DT inductive/JJ effects/NNS ./. 
These/DT studies/NNS have/VBP prompted/VBN our/PRP$ interest/NN in/IN the/DT dynamics/NNS of/IN other/JJ transcription/NN factor/NN changes/NNS during/IN HL-60/NN differentiation/NN ./. 
Of/IN these/DT ,/, we/PRP observed/VBD that/IN another/DT transcription/NN factor/NN (/( AP-1/NN )/) is/VBZ also/RB robustly/RB induced/VBN at/IN the/DT DNA-binding/JJ level/NN during/IN macrophage-like/JJ HL-60/NN differentiation/NN ,/, but/CC not/RB during/IN granulocytic/JJ differentiation/NN ./. 
Conversely/RB ,/, the/DT DNA-binding/NN of/IN the/DT transcription/NN factor/NN AP-2/NN was/VBD slightly/RB reduced/VBN by/IN TPA-induced/JJ HL-60/NN differentiation/NN but/CC unchanged/JJ during/IN granulocyte/NN differentiation/NN ./. 
From/IN these/DT data/NNS ,/, we/PRP conclude/VBP that/IN the/DT induction/NN of/IN PO-B/NN DNA/NN binding/NN is/VBZ a/DT general/JJ marker/NN of/IN HL-60/NN myelomonocytic/JJ differentiation/NN ,/, but/CC that/IN qualitative/JJ aspects/NNS of/IN the/DT induction/NN of/IN additional/JJ distinct/JJ transcription/NN factors/NNS ,/, such/JJ as/IN AP-1/NN ,/, may/MD contribute/VB to/TO lineage-specific/JJ determinants/NNS of/IN cell/NN fate/NN ./. 
UI/LS -/: 97277179/CD 
TI/LS -/: A/DT novel/JJ genetic/JJ system/NN to/TO isolate/VB a/DT dominant/JJ negative/JJ effector/NN on/IN DNA-binding/JJ activity/NN of/IN Oct-2/NN ./. 
AB/LS -/: Recent/JJ studies/NNS have/VBP revealed/VBN that/IN interactions/NNS between/IN transcription/NN factors/NNS play/VBP an/DT important/JJ role/NN in/IN regulation/NN of/IN gene/NN expression/NN in/IN eukaryotic/JJ cells/NNS ./. 
To/TO isolate/VB cDNA/NN clones/NNS that/WDT dominantly/RB inhibit/VBP the/DT DNA-binding/JJ activity/NN of/IN Oct-2/NN ,/, chosen/VBN as/IN a/DT representative/JJ factor/NN ,/, we/PRP have/VBP developed/VBN a/DT novel/JJ screening/JJ system/NN ./. 
This/DT employs/VBZ an/DT Escherichia/FW coli/FW tester/NN strain/NN carrying/VBG a/DT modified/VBN lac/NN operon/NN as/IN a/DT reporter/NN gene/NN ,/, with/IN the/DT lac/NN operator/NN sequence/NN replaced/VBN by/IN an/DT octamer/NN sequence/NN ./. 
Oct-2/NN expressed/VBN in/IN this/DT tester/NN strain/NN represses/VBZ the/DT expression/NN of/IN the/DT reporter/NN gene/NN and/CC changes/VBZ the/DT phenotype/NN of/IN the/DT cell/NN from/IN Lac+/JJ to/TO Lac-/JJ ./. 
Introduction/NN of/IN a/DT cDNA/NN expression/NN library/NN prepared/VBN from/IN a/DT human/JJ T-cell/NN line/NN into/IN the/DT Oct-2-harboring/JJ tester/NN strain/NN allowed/VBD selection/NN of/IN three/CD Lac+/JJ clones/NNS out/RP of/IN 1/CD x/CC 10(5)/CD transformants/NNS ./. 
One/CD of/IN them/PRP ,/, hT86/NN ,/, encoding/VBG a/DT putative/JJ zinc/NN finger/NN protein/NN was/VBD found/VBN to/TO derepress/VB beta-galactosidase/NN activity/NN in/IN the/DT Oct-2-harboring/JJ tester/NN strain/NN at/IN the/DT transcriptional/JJ level/NN ./. 
In/IN gel/NN mobility/NN shift/NN assays/NNS ,/, hT86/NN attenuated/VBD the/DT intensity/NN of/IN the/DT retarded/VBN band/NN composed/VBN of/IN the/DT octamer/NN probe/NN and/CC Oct-2/NN ,/, suggesting/VBG a/DT dominant/JJ negative/JJ effect/NN on/IN the/DT DNA-binding/JJ activity/NN of/IN Oct-2/NN ./. 
The/DT strategy/NN described/VBN here/RB provides/VBZ a/DT new/JJ approach/NN for/IN studying/VBG protein-protein/JJ interactions/NNS that/WDT govern/VBP the/DT complex/JJ regulation/NN of/IN gene/NN expression/NN ./. 
UI/LS -/: 97318898/CD 
TI/LS -/: Tap/NN :/: a/DT novel/JJ cellular/JJ protein/NN that/WDT interacts/VBZ with/IN tip/NN of/IN herpesvirus/NN saimiri/NN and/CC induces/VBZ lymphocyte/NN aggregation/NN ./. 
AB/LS -/: Tip/NN of/IN herpesvirus/NN saimiri/NN associates/VBZ with/IN Lck/NN and/CC down-regulates/VBZ Lck-mediated/JJ activation/NN ./. 
We/PRP identified/VBD a/DT novel/JJ cellular/JJ Tip-associated/JJ protein/NN (/( Tap/NN )/) by/IN a/DT yeast/NN two-hybrid/JJ screen/NN ./. 
Tap/NN associated/VBD with/IN Tip/NN following/VBG transient/JJ expression/NN in/IN COS-1/NN cells/NNS and/CC stable/JJ expression/NN in/IN human/JJ Jurkat-T/NN cells/NNS ./. 
Expression/NN of/IN Tip/NN and/CC Tap/NN in/IN Jurkat-T/NN cells/NNS induced/VBD dramatic/JJ cell/NN aggregation/NN ./. 
Aggregation/NN was/VBD likely/RB caused/VBN by/IN the/DT up-regulated/VBN surface/NN expression/NN of/IN adhesion/NN molecules/NNS including/VBG integrin/NN alpha/NN ,/, L-selectin/NN ,/, ICAM-3/NN ,/, and/CC H-CAM/NN ./. 
Furthermore/RB ,/, NF-kappaB/NN transcriptional/JJ factor/NN of/IN aggregated/JJ cells/NNS had/VBD approximately/RB 40-fold/RB higher/JJR activity/NN than/IN that/DT of/IN parental/JJ cells/NNS ./. 
Thus/RB ,/, Tap/NN is/VBZ likely/JJ to/TO be/VB an/DT important/JJ cellular/JJ mediator/NN of/IN Tip/NN function/NN in/IN T/NN cell/NN transformation/NN by/IN herpesvirus/NN saimiri/NN ./. 
UI/LS -/: 97422566/CD 
TI/LS -/: Human/JJ monocyte/NN binding/VBG to/TO fibronectin/NN enhances/VBZ IFN-gamma-induced/JJ early/JJ signaling/NN events/NNS ./. 
AB/LS -/: Leukocyte/NN integrins/NNS are/VBP fundamentally/RB important/JJ in/IN modulating/VBG adhesion/NN to/TO extracellular/JJ matrix/NN components/NNS and/CC to/TO other/JJ cells/NNS ./. 
This/DT integrin-mediated/JJ adhesion/NN controls/VBZ leukocyte/NN arrest/NN and/CC extravasation/NN during/IN the/DT onset/NN of/IN inflammatory/JJ responses/NNS ./. 
Moreover/RB ,/, integrin-ligand/JJ interactions/NNS trigger/VBP signaling/NN pathways/NNS that/WDT may/MD influence/VB leukocyte/NN phenotype/NN and/CC function/VB at/IN sites/NNS of/IN inflammation/NN ./. 
In/IN the/DT current/JJ studies/NNS ,/, we/PRP evaluated/VBD the/DT combinatorial/JJ effects/NNS of/IN monocyte/NN adhesion/NN and/CC IFN-gamma/NN on/IN intracellular/JJ signaling/NN pathways/NNS ./. 
IFN-gamma/NN triggers/VBZ a/DT well-defined/JJ signal/NN transduction/NN pathway/NN ,/, which/WDT although/IN not/RB directly/RB stimulated/VBN by/IN monocyte/NN adherence/NN to/TO fibronectin/NN or/CC arginine-glycine-aspartate/NN (/( RGD/NN )/) -coated/JJ substrata/NNS ,/, was/VBD enhanced/VBN significantly/RB in/IN these/DT matrix-adherent/JJ cells/NNS ./. 
Compared/VBN with/IN monocytes/NNS in/IN suspension/NN or/CC adherent/JJ on/IN plastic/JJ surfaces/NNS ,/, monocytes/NNS adherent/JJ to/TO fibronectin/NN or/CC RGD/NN exhibited/VBD a/DT greater/JJR than/IN threefold/JJ increase/NN in/IN steady/JJ state/NN levels/NNS of/IN IFN-gamma-induced/JJ mRNA/NN for/IN the/DT high/JJ affinity/NN Fc/NN gammaRI/NN receptor/NN ./. 
By/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, this/DT increase/NN in/IN mRNA/NN was/VBD associated/VBN with/IN a/DT 5-/CD to/TO 10-fold/JJ increase/NN in/IN the/DT STAT1-containing/JJ DNA-binding/JJ complex/NN that/WDT binds/VBZ to/TO Fc/NN gammaRI/NN promoter/NN elements/NNS ./. 
Furthermore/RB ,/, the/DT tyrosine/NN phosphorylation/NN of/IN STAT1/NN and/CC the/DT tyrosine/NN kinases/NNS JAK1/NN and/CC JAK2/NN was/VBD enhanced/VBN significantly/RB in/IN RGD-adherent/JJ monocytes/NNS compared/VBN with/IN control/JJ cells/NNS ./. 
These/DT results/NNS suggest/VBP a/DT novel/JJ mechanism/NN by/IN which/WDT integrin-mediated/JJ cell/NN adhesion/NN can/MD modulate/VB the/DT magnitude/NN of/IN cytokine-induced/JJ signal/NN transduction/NN pathways/NNS ,/, thereby/RB amplifying/VBG cellular/JJ events/NNS leading/VBG to/TO monocyte/NN activation/NN and/CC inflammation/NN ./. 
UI/LS -/: 97423508/CD 
TI/LS -/: Surfactant/JJ protein/NN A/NN activates/VBZ NF-kappa/NN B/NN in/IN the/DT THP-1/NN monocytic/JJ cell/NN line/NN ./. 
AB/LS -/: The/DT expression/NN of/IN many/JJ genes/NNS for/IN which/WDT products/NNS are/VBP involved/VBN in/IN inflammation/NN is/VBZ controlled/VBN by/IN the/DT transcriptional/JJ regulator/NN nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN ./. 
Because/IN surfactant/JJ protein/NN (/( SP/NN )/) A/NN is/VBZ involved/VBN in/IN local/JJ host/NN defense/NN in/IN the/DT lung/NN and/CC alters/VBZ immune/JJ cell/NN function/NN by/IN modulating/VBG the/DT expression/NN of/IN proinflammatory/JJ cytokines/NNS as/RB well/RB as/IN surface/NN proteins/NNS involved/VBN in/IN inflammation/NN ,/, we/PRP hypothesized/VBD that/IN SP-A/NN exerts/VBZ its/PRP$ action/NN ,/, at/IN least/JJS in/IN part/NN ,/, via/IN activation/NN of/IN NF-kappa/NN B/NN ./. 
We/PRP used/VBD gel/NN shift/NN assays/NNS to/TO determine/VB whether/IN SP-A/NN activated/VBD NF-kappa/NN B/NN in/IN the/DT THP-1/NN cell/NN line/NN ,/, a/DT human/JJ monocytic/JJ cell/NN line/NN ./. 
Activation/NN of/IN NF-kappa/NN B/NN in/IN THP-1/NN cells/NNS by/IN SP-A/NN doses/NNS as/RB low/JJ as/IN 1/CD microgram/ml/NN occurred/VBD within/IN 30/CD min/NN of/IN SP-A/NN treatment/NN ,/, peaked/VBD at/IN 60/CD min/NN ,/, and/CC then/RB declined/VBD ./. 
This/DT activation/NN is/VBZ inhibited/VBN by/IN known/JJ inhibitors/NNS of/IN NF-kappa/NN B/NN or/CC by/IN simultaneous/JJ treatment/NN of/IN the/DT cells/NNS with/IN surfactant/JJ lipids/NNS ./. 
Moreover/RB ,/, the/DT NF-kappa/NN B/NN inhibitors/NNS blocked/VBD SP-A-dependent/JJ increases/NNS in/IN tumor/NN necrosis/NN factor-alpha/NN mRNA/NN levels/NNS ./. 
These/DT observations/NNS suggest/VBP a/DT mechanism/NN by/IN which/WDT SP-A/NN plays/VBZ a/DT role/NN in/IN the/DT pathogenesis/NN of/IN some/DT lung/NN conditions/NNS and/CC point/VBP to/TO potential/JJ therapeutic/JJ measures/NNS that/WDT could/MD be/VB used/VBN to/TO prevent/VB SP-A/NN induced/JJ inflammation/NN in/IN the/DT lung/NN ./. 
UI/LS -/: 97378015/CD 
TI/LS -/: GABP/NN factors/NNS bind/VBP to/TO a/DT distal/JJ interleukin/NN 2/CD (/( IL-2/NN )/) enhancer/NN and/CC contribute/VBP to/TO c-Raf-mediated/JJ increase/NN in/IN IL-2/NN induction/NN ./. 
AB/LS -/: Triggering/NN of/IN the/DT T-cell/NN receptor-CD3/JJ complex/NN activates/VBZ two/CD major/JJ signal/NN cascades/NNS in/IN T/NN lymphocytes/NNS ,/, (/( i/LS )/) Ca2+-dependent/JJ signal/NN cascades/NNS and/CC (/( ii/LS )/) protein/NN kinase/NN cascades/NNS ./. 
Both/DT signal/NN cascades/NNS contribute/VBP to/TO the/DT induction/NN of/IN the/DT interleukin/NN 2/CD (/( IL-2/NN )/) gene/NN during/IN T-cell/NN activation/NN ./. 
Prominent/JJ protein/NN kinase/NN cascades/NNS are/VBP those/DT that/WDT activate/VBP mitogen-activated/JJ protein/NN (/( MAP/NN )/) kinases/NNS ./. 
We/PRP show/VBP here/RB that/IN c-Raf/NN ,/, which/WDT is/VBZ at/IN the/DT helm/NN of/IN the/DT classic/JJ MAP-Erk/JJ cascade/NN ,/, contributes/VBZ to/TO IL-2/NN induction/NN through/IN a/DT distal/JJ enhancer/NN element/NN spanning/VBG the/DT nucleotides/NNS from/IN positions/NNS -502/CD to/TO -413/CD in/IN front/NN of/IN the/DT transcriptional/JJ start/NN site/NN of/IN the/DT IL-2/NN gene/NN ./. 
Induction/NN of/IN this/DT distal/JJ IL-2/NN enhancer/NN differs/VBZ from/IN induction/NN of/IN the/DT proximal/JJ IL-2/NN promoter-enhancer/NN ,/, since/IN it/PRP is/VBZ induced/VBN by/IN phorbol/NN esters/NNS alone/RB and/CC independent/JJ from/IN Ca2+/NN signals/NNS ./. 
In/IN DNA-protein/JJ binding/NN studies/NNS ,/, we/PRP detected/VBD the/DT binding/NN of/IN transcription/NN factors/NNS GABP/NN alpha/NN and/CC -beta/NN to/TO a/DT dyad/JJ symmetry/NN element/NN (/( DSE/NN )/) of/IN the/DT distal/JJ enhancer/NN ,/, which/WDT is/VBZ formed/VBN by/IN palindromic/JJ binding/VBG sites/NNS of/IN Ets-like/JJ factors/NNS ./. 
Introduction/NN of/IN point/NN mutations/NNS suppressing/VBG GABP/NN binding/NN to/TO the/DT DSE/NN interfered/VBD with/IN the/DT induction/NN of/IN the/DT distal/JJ enhancer/NN and/CC the/DT entire/JJ IL-2/NN promoter-enhancer/NN ,/, while/IN overexpression/NN of/IN both/DT GABP/NN factors/NNS enhanced/VBD the/DT IL-2/NN promoter-enhancer/JJ induction/NN ./. 
Overexpression/NN of/IN BXB/NN ,/, a/DT constitutive/JJ active/JJ version/NN of/IN c-Raf/NN ,/, and/CC of/IN further/JJ members/NNS of/IN the/DT Ras-Raf-Erksignal/NN cascade/NN exerted/VBD an/DT increase/NN of/IN GABP-mediated/JJ promoter-enhancer/JJ induction/NN ./. 
In/IN conjunction/NN with/IN previously/RB published/VBN data/NNS on/IN c-Raf-induced/JJ phosphorylation/NN of/IN GABP/NN factors/NNS (/( E.Flory/NNP ,/, A./NNP Hoffmeyer/NNP ,/, U.Smola/NNP ,/, U.R.Rapp/NNP ,/, and/CC J.T.Bruder/NNP ,/, J.Virol.70/NNP :/: 2260- 2268/CD ,/, 1996/CD )/) ,/, these/DT results/NNS indicate/VBP a/DT contribution/NN of/IN GABP/NN factors/NNS to/TO the/DT Raf-mediated/JJ enhancement/NN of/IN IL-2/NN induction/NN during/IN T-cell/NN activation/NN ./. 
UI/LS -/: 97362276/CD 
TI/LS -/: Lipopolysaccharide/NN induction/NN of/IN the/DT tumor/NN necrosis/NN factor-alpha/NN promoter/NN in/IN human/JJ monocytic/JJ cells/NNS ./. 
Regulation/NN by/IN Egr-1/NN ,/, c-Jun/NN ,/, and/CC NF-kappaB/NN transcription/NN factors/NNS ./. 
AB/LS -/: Biosynthesis/NN of/IN tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) is/VBZ predominantly/RB by/IN cells/NNS of/IN the/DT monocytic/JJ lineage/NN ./. 
This/DT study/NN examined/VBD the/DT role/NN of/IN various/JJ cis-acting/JJ regulatory/JJ elements/NNS in/IN the/DT lipopolysaccharide/NN (/( LPS/NN )/) induction/NN of/IN the/DT human/JJ TNF-alpha/NN promoter/NN in/IN cells/NNS of/IN monocytic/JJ lineage/NN ./. 
Functional/JJ analysis/NN of/IN monocytic/JJ THP-1/NN cells/NNS transfected/VBN with/IN plasmids/NNS containing/VBG various/JJ lengths/NNS of/IN TNF-alpha/NN promoter/NN localized/VBD enhancer/NN elements/NNS in/IN a/DT region/NN (/( -182/CD to/TO -37/CD base/NN pairs/NNS (/( bp/NN )/) )/) that/WDT were/VBD required/VBN for/IN optimal/JJ transcription/NN of/IN the/DT TNF-alpha/NN gene/NN in/IN response/NN to/TO LPS/NN ./. 
Two/CD regions/NNS were/VBD identified/VBN :/: region/NN I/CD (/( -182/CD to/TO -162/CD bp/NN )/) contained/VBD an/DT overlapping/VBG Sp1/Egr-1/NN site/NN ,/, and/CC region/NN II/CD (/( -119/CD to/TO -88/CD )/) contained/VBD CRE/NN and/CC NF-kappaB/NN (/( designated/VBN kappaB3/NN )/) sites/NNS ./. 
In/IN unstimulated/JJ THP-1/NN ,/, CRE-binding/JJ protein/NN and/CC ,/, to/TO a/DT lesser/JJR extent/NN ,/, c-Jun/NN complexes/NNS were/VBD found/VBN to/TO bind/VB to/TO the/DT CRE/NN site/NN ./. 
LPS/NN stimulation/NN increased/VBD the/DT binding/NN of/IN c-Jun-containing/JJ complexes/NNS ./. 
In/IN addition/NN ,/, LPS/NN stimulation/NN induced/VBD the/DT binding/NN of/IN cognate/JJ nuclear/JJ factors/NNS to/TO the/DT Egr-1/NN and/CC kappaB3/NN sites/NNS ,/, which/WDT were/VBD identified/VBN as/IN Egr-1/NN and/CC p50/p65/NN ,/, respectively/RB ./. 
The/DT CRE/NN and/CC kappaB3/NN sites/NNS in/IN region/NN II/CD together/RB conferred/VBD strong/JJ LPS/NN responsiveness/NN to/TO a/DT heterologous/JJ promoter/NN ,/, whereas/IN individually/RB they/PRP failed/VBD to/TO provide/VB transcriptional/JJ activation/NN ./. 
Furthermore/RB ,/, increasing/VBG the/DT spacing/NN between/IN the/DT CRE/NN and/CC the/DT kappaB3/NN sites/NNS completely/RB abolished/VBD LPS/NN induction/NN ,/, suggesting/VBG a/DT cooperative/JJ interaction/NN between/IN c-Jun/NN complexes/NNS and/CC p50/p65/NN ./. 
These/DT studies/NNS indicate/VBP that/IN maximal/JJ LPS/NN induction/NN of/IN the/DT TNF-alpha/NN promoter/NN is/VBZ mediated/VBN by/IN concerted/VBN participation/NN of/IN at/IN least/JJS two/CD separate/JJ cis-acting/JJ regulatory/JJ elements/NNS ./. 
UI/LS -/: 97361882/CD 
TI/LS -/: Rescue/NN by/IN cytokines/NNS of/IN apoptotic/JJ cell/NN death/NN induced/VBN by/IN IL-2/NN deprivation/NN of/IN human/JJ antigen-specific/JJ T/NN cell/NN clones/NNS ./. 
AB/LS -/: The/DT control/NN of/IN cell/NN survival/NN and/CC cell/NN death/NN is/VBZ of/IN central/JJ importance/NN in/IN tissues/NNS with/IN high/JJ cell/NN turnover/NN such/JJ as/IN the/DT lymphoid/JJ system/NN ./. 
We/PRP have/VBP examined/VBN the/DT effect/NN of/IN cytokines/NNS on/IN IL-2/NN deprivation-induced/JJ apoptosis/NN of/IN human/JJ antigen-specific/JJ T/NN helper/NN clones/NNS with/IN different/JJ cytokine/NN production/NN profiles/NNS ./. 
We/PRP found/VBD that/IN IL-2/NN ,/, interferon-alpha/NN (/( IFN-alpha/NN )/) ,/, and/CC IFN-beta/NN inhibited/VBD IL-2/NN deprivation/NN apoptosis/NN in/IN Th0/NN ,/, Th1/NN ,/, and/CC Th2/NN clones/NNS ./. 
We/PRP also/RB found/VBD that/IN IL-2/NN protects/VBZ T/NN cell/NN clones/NNS from/IN IL-2/NN deprivation/NN apoptosis/NN accompanying/VBG active/JJ proliferation/NN and/CC enhanced/VBN expression/NN of/IN P53/NN ,/, Rb/NN and/CC Bcl-xL/NN proteins/NNS ./. 
In/IN contrast/NN ,/, IFN-alpha/beta/NN rescued/VBD T/NN cell/NN clones/NNS from/IN apoptosis/NN without/IN active/JJ proliferation/NN ,/, and/CC expression/NN of/IN apoptosis-associated/JJ proteins/NNS tested/VBN so/RB far/JJ was/VBD unaffected/JJ ./. 
This/DT may/MD be/VB due/JJ to/TO the/DT fact/NN that/IN T/NN cells/NNS treated/VBN with/IN IL-2/NN contained/VBD those/DT located/JJ in/IN S/NN +/CC G2/M/NN phases/NNS of/IN the/DT cell/NN cycle/NN ,/, whereas/IN the/DT vast/JJ majority/NN of/IN T/NN cells/NNS treated/VBN with/IN IFN-alpha/beta/NN were/VBD located/JJ in/IN G0/G1/NN phase/NN ./. 
IFN-alpha/beta/NN specifically/RB induced/VBD tyrosine/NN phosphorylation/NN and/CC translocation/NN into/IN nucleus/NN of/IN signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STAT/NN )/) 2/CD protein/NN in/IN the/DT T/NN cell/NN clones/NNS ./. 
In/IN addition/NN ,/, over-expression/NN of/IN STAT2/NN by/IN transfection/NN of/IN the/DT cDNA/NN prevented/VBD apoptosis/NN of/IN the/DT T/NN cell/NN clones/NNS ./. 
Our/PRP$ present/JJ study/NN shows/VBZ that/IN IFN-alpha/NN and/CC -beta/NN mediate/VBP anti-apoptotic/JJ effect/NN through/IN other/JJ pathways/NNS than/IN that/DT of/IN IL-2/NN in/IN growth/NN factor/NN deprivation/NN apoptosis/NN ./. 
UI/LS -/: 97335975/CD 
TI/LS -/: Interleukin-10/NN inhibits/VBZ interferon-gamma-induced/JJ intercellular/JJ adhesion/NN molecule-1/NN gene/NN transcription/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: Interleukin-10/NN (/( IL-10/NN )/) is/VBZ a/DT potent/JJ monocyte/NN regulatory/JJ cytokine/NN that/WDT inhibits/VBZ gene/NN expression/NN of/IN proinflammatory/JJ mediators/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP investigated/VBD the/DT mechanism/NN by/IN which/WDT IL-10/NN downregulates/VBZ expression/NN of/IN intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN )/) on/IN the/DT cell/NN surface/NN of/IN normal/JJ human/JJ monocytes/NNS activated/VBN with/IN interferon-gamma/NN (/( IFN-gamma/NN )/) ./. 
IL-10/NN inhibition/NN of/IN IFN-gamma-induced/JJ ICAM-1/NN expression/NN was/VBD apparent/JJ as/RB early/RB as/IN 3/CD hours/NNS and/CC was/VBD blocked/VBN by/IN an/DT anti-IL-10/JJ antibody/NN but/CC not/RB by/IN an/DT isotype-matched/JJ control/JJ antibody/NN ./. 
Northern/NN blot/NN analysis/NN showed/VBD that/IN IL-10/NN reduced/VBD the/DT accumulation/NN of/IN ICAM-1/NN mRNA/NN in/IN IFN-gamma-stimulated/JJ monocytes/NNS ./. 
IL-10/NN inhibition/NN of/IN ICAM-1/NN steady-state/JJ mRNA/NN was/VBD detected/VBN at/IN 3/CD hours/NNS and/CC remained/VBD at/IN 24/CD hours/NNS ./. 
Nuclear/JJ run-on/JJ transcription/NN assays/NNS showed/VBD that/IN IL-10/NN inhibited/VBD the/DT rate/NN of/IN IFN-gamma-induced/JJ transcription/NN of/IN the/DT ICAM-1/NN gene/NN ,/, and/CC mRNA/NN stability/NN studies/NNS showed/VBD that/IN IL-10/NN did/VBD not/RB alter/VB the/DT half-life/NN of/IN IFN-gamma-induced/JJ ICAM-1/NN message/NN ./. 
Thus/RB ,/, IL-10/NN inhibits/VBZ IFN-gamma-induced/JJ ICAM-1/NN expression/NN in/IN monocytes/NNS primarily/RB at/IN the/DT level/NN of/IN gene/NN transcription/NN ./. 
Activation/NN of/IN IFN-gamma-responsive/JJ genes/NNS requires/VBZ tyrosine/NN phosphorylation/NN of/IN the/DT transcriptional/JJ factor/NN STAT-1alpha/NN (/( signal/NN transducer/NN and/CC activator/NN of/IN transcription-1alpha/NN )/) ./. 
However/RB ,/, IL-10/NN did/VBD not/RB affect/VB IFN-gamma-induced/JJ tyrosine/NN phosphorylation/NN of/IN STAT-1alpha/NN or/CC alter/VB STAT-1alpha/NN binding/NN to/TO the/DT IFN-gamma/NN response/NN element/NN (/( IRE/NN )/) in/IN the/DT ICAM-1/NN promoter/NN ./. 
Instead/RB ,/, IL-10/NN prevented/VBD IFN-gamma-induced/JJ binding/NN activity/NN at/IN the/DT NF-kappaB/NN site/NN of/IN the/DT tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) -responsive/JJ NF-kappaB/C-EBP/NN composite/NN element/NN in/IN the/DT ICAM-1/NN promoter/NN ./. 
These/DT data/NNS indicate/VBP that/IN IL-10/NN inhibits/VBZ IFN-gamma-induced/JJ transcription/NN of/IN the/DT ICAM-1/NN gene/NN by/IN a/DT regulatory/JJ mechanism/NN that/WDT may/MD involve/VB NF-kappaB/NN ./. 
UI/LS -/: 97322372/CD 
TI/LS -/: Specific/JJ complex/NN formation/NN between/IN the/DT type/NN II/CD bare/JJ lymphocyte/NN syndrome-associated/JJ transactivators/NNS CIITA/NN and/CC RFX5/NN ./. 
AB/LS -/: Two/CD of/IN the/DT genes/NNS defective/JJ in/IN the/DT five/CD complementation/NN groups/NNS identified/VBN in/IN the/DT class/NN II-negative/JJ bare/JJ lymphocyte/NN syndrome/NN or/CC corresponding/JJ laboratory/JJ mutants/NNS have/VBP been/VBN cloned/VBN ./. 
One/CD gene/NN encodes/VBZ a/DT protein/NN ,/, RFX5/NN ,/, that/WDT is/VBZ a/DT member/NN of/IN the/DT RFX/NN family/NN of/IN DNA/NN binding/NN proteins/NNS ./. 
The/DT other/JJ ,/, CIITA/NN ,/, encodes/VBZ a/DT large/JJ protein/NN with/IN a/DT defined/VBN acidic/JJ transcriptional/JJ activation/NN domain/NN ;/: this/DT protein/NN does/VBZ not/RB interact/VB with/IN DNA/NN ./. 
Expression/NN plasmids/NNS encoding/VBG regions/NNS of/IN RFX5/NN fused/VBN to/TO the/DT GAL4/NN DNA/NN binding/NN domain/NN activated/VBD transcription/NN from/IN a/DT reporter/NN construct/NN containing/VBG GAL4/NN sites/NNS in/IN a/DT cotransfection/NN assay/NN in/IN the/DT Raji/NN human/JJ B/NN cell/NN line/NN ./. 
However/RB ,/, these/DT plasmids/NNS produced/VBD transcriptional/JJ activity/NN in/IN HeLa/NN cells/NNS only/RB in/IN conjunction/NN with/IN interferon/NN gamma/NN stimulation/NN ,/, a/DT condition/NN in/IN which/WDT expression/NN of/IN both/CC CIITA/NN and/CC class/NN II/CD major/JJ histocompatibility/NN complex/NN surface/NN proteins/NNS are/VBP induced./VBN 
Furthermore/RB ,/, these/DT plasmids/NNS were/VBD not/RB active/JJ in/IN RJ2.2.5/NN ,/, an/DT in/FW vitro/FW mutagenized/VBN derivative/NN of/IN Raji/NN in/IN which/WDT both/DT copies/NNS of/IN CIITA/NN are/VBP defective/JJ ./. 
Transcriptional/JJ activation/NN by/IN the/DT RFX5/NN fusion/NN protein/NN could/MD be/VB restored/VBN in/IN RJ2.2.5/NN by/IN cotransfection/NN with/IN a/DT CIITA/NN expression/NN plasmid/NN ./. 
Finally/RB ,/, a/DT direct/JJ interaction/NN between/IN RFX5/NN and/CC CIITA/NN was/VBD detected/VBN with/IN the/DT yeast/NN two-hybrid/JJ and/CC far-Western/JJ blot/NN assays/NNS ./. 
Thus/RB ,/, RFX5/NN can/MD activate/VB transcription/NN only/RB in/IN cooperation/NN with/IN CIITA/NN ./. 
RFX5/NN and/CC CIITA/NN associate/VBP to/TO form/VB a/DT complex/NN capable/JJ of/IN activating/VBG transcription/NN from/IN class/NN II/CD major/JJ histocompatibility/NN complex/NN promoters/NNS ./. 
In/IN this/DT complex/NN ,/, promoter/NN specificity/NN is/VBZ determined/VBN by/IN the/DT DNA/NN binding/NN domain/NN of/IN RFX5/NN and/CC the/DT general/JJ transcription/NN apparatus/NN is/VBZ recruited/VBN by/IN the/DT acidic/JJ activation/NN domain/NN of/IN CIITA/NN ./. 
UI/LS -/: 97306366/CD 
TI/LS -/: Involvement/NN of/IN phosphatidylinositol/NN 3-kinase/NN in/IN NFAT/NN activation/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Phosphatidylinositol/NN 3-kinase/NN (/( PI3-K/NN )/) has/VBZ been/VBN implicated/VBN in/IN the/DT regulation/NN of/IN cell/NN proliferation/NN in/IN many/JJ cell/NN types/NNS ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN in/IN T/NN cells/NNS the/DT PI3-K/NN inhibitor/NN ,/, wortmannin/NN ,/, interferes/VBZ with/IN activation/NN of/IN the/DT mitogen-activated/JJ kinase/NN ,/, Erk2/NN ,/, after/IN T/NN cell/NN receptor/NN (/( TcR/NN )/) stimulation/NN ./. 
To/TO further/RB explore/VB the/DT involvement/NN of/IN PI3-K/NN in/IN T/NN cell/NN activation/NN ,/, we/PRP created/VBD a/DT set/NN of/IN potentially/RB dominant/JJ negative/JJ PI3-K/NN constructs/NNS comprising/VBG individual/JJ or/CC tandem/JJ domains/NNS of/IN the/DT regulatory/JJ p85/NN subunit/NN and/CC tested/VBD their/PRP$ effect/NN on/IN downstream/JJ signaling/NN events/NNS like/IN Erk2/NN activation/NN and/CC transcription/NN from/IN an/DT NFAT/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS )/) element/NN taken/VBN from/IN the/DT interleukin-2/NN promoter/NN ./. 
Following/VBG TcR/NN stimulation/NN ,/, activation/NN of/IN Erk2/NN was/VBD only/RB inhibited/VBN by/IN a/DT previously/RB described/VBN truncated/JJ form/NN of/IN p85/NN that/WDT can/MD not/RB bind/VB the/DT catalytic/JJ subunit/NN ,/, but/CC not/RB by/IN other/JJ constructs/NNS of/IN p85/NN ./. 
In/IN contrast/NN ,/, several/JJ mutant/JJ p85/NN alleles/NNS had/VBD dramatic/JJ effects/NNS on/IN NFAT/NN activation/NN ./. 
Most/RBS interestingly/RB ,/, the/DT N-terminal/JJ SH2/NN domain/NN had/VBD an/DT inhibitory/JJ effect/NN ,/, whereas/IN a/DT mutant/JJ p85/NN containing/VBG only/RB the/DT two/CD SH2/NN domains/NNS enhanced/VBD basal/JJ NFAT/NN activity/NN in/IN a/DT Ras-dependent/JJ manner/NN ./. 
Ionomycin/NN induced/VBD synergistic/JJ activation/NN of/IN NFAT/NN in/IN cells/NNS expressing/VBG p85/NN mutants/NNS that/WDT contained/VBD the/DT C-terminal/JJ SH2/NN domain/NN ./. 
Analysis/NN of/IN phosphotyrosine-containing/JJ proteins/NNS bound/VBN to/TO truncated/VBN p85/NN constructs/NNS revealed/VBD cooperative/JJ binding/NN of/IN the/DT two/CD SH2/NN domains/NNS but/CC no/DT apparent/JJ differences/NNS between/IN the/DT N-/NN and/CC C-terminal/JJ SH2/NN domains/NNS ./. 
Wortmannin/NN did/VBD not/RB interfere/VB with/IN NFAT/NN activation/NN ,/, although/IN it/PRP inhibited/VBD PI3-K/NN and/CC Erk2/NN activation/NN in/IN the/DT same/JJ experiment/NN ./. 
These/DT results/NNS suggest/VBP that/IN PI3-K/NN is/VBZ involved/VBN in/IN NFAT/NN activation/NN through/IN a/DT complex/JJ adaptor/NN function/NN of/IN its/PRP$ regulatory/JJ subunit/NN and/CC that/IN its/PRP$ lipid/NN kinase/NN activity/NN is/VBZ dispensable/JJ for/IN this/DT effect/NN ./. 
UI/LS -/: 97289761/CD 
TI/LS -/: Acute/JJ leukemia/NN with/IN promyelocytic/JJ features/NNS in/IN PML/RARalpha/NN transgenic/JJ mice/NNS ./. 
AB/LS -/: Acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) is/VBZ associated/VBN with/IN reciprocal/JJ chromosomal/JJ translocations/NNS involving/VBG the/DT retinoic/JJ acid/NN receptor/NN alpha/NN (/( RARalpha/NN )/) locus/NN on/IN chromosome/NN 17/CD ./. 
In/IN the/DT majority/NN of/IN cases/NNS ,/, RARalpha/NN translocates/VBZ and/CC fuses/VBZ with/IN the/DT promyelocytic/JJ leukemia/NN (/( PML/NN )/) gene/NN located/JJ on/IN chromosome/NN 15/CD ./. 
The/DT resulting/VBG fusion/NN genes/NNS encode/VBP the/DT two/CD structurally/RB unique/JJ PML/RARalpha/NN and/CC RARalpha/PML/NN fusion/NN proteins/NNS as/RB well/RB as/IN aberrant/JJ PML/NN gene/NN products/NNS ,/, the/DT respective/JJ pathogenetic/JJ roles/NNS of/IN which/WDT have/VBP not/RB been/VBN elucidated/VBN ./. 
We/PRP have/VBP generated/VBN transgenic/JJ mice/NNS in/IN which/WDT the/DT PML/RARalpha/NN fusion/NN protein/NN is/VBZ specifically/RB expressed/VBN in/IN the/DT myeloid-promyelocytic/JJ lineage/NN ./. 
During/IN their/PRP$ first/JJ year/NN of/IN life/NN ,/, all/PDT the/DT PML/RARalpha/NN transgenic/JJ mice/NNS have/VBP an/DT abnormal/JJ hematopoiesis/NN that/WDT can/MD best/RB be/VB described/VBN as/IN a/DT myeloproliferative/JJ disorder/NN ./. 
Between/IN 12/CD and/CC 14/CD months/NNS of/IN age/NN ,/, 10/CD %/NN of/IN them/PRP develop/VBP a/DT form/NN of/IN acute/JJ leukemia/NN with/IN a/DT differentiation/NN block/NN at/IN the/DT promyelocytic/JJ stage/NN that/WDT closely/RB mimics/VBZ human/JJ APL/NN even/RB in/IN its/PRP$ response/NN to/TO retinoic/JJ acid/NN ./. 
Our/PRP$ results/NNS are/VBP conclusive/JJ in/FW vivo/FW evidence/NN that/IN PML/RARalpha/NN plays/VBZ a/DT crucial/JJ role/NN in/IN the/DT pathogenesis/NN of/IN APL/NN ./. 
UI/LS -/: 97317585/CD 
TI/LS -/: Constitutive/JJ and/CC inducible/JJ protein/DNA/NN interactions/NNS of/IN the/DT interferon-gamma/NN promoter/NN in/FW vivo/FW in/NN [/( corrected/VBN ]/) CD45RA/NN and/CC CD45R0/NN T/NN helper/NN subsets/NNS [/( published/VBN erratum/NN appears/VBZ in/IN Eur/NNP J/NNP Immunol/NNP 1997/CD Jul/NNP ;/: 27/CD (/( 7/CD )/) :/: 1830/CD ]/) 
AB/LS -/: Interferon-gamma/NN (/( IFN-gamma/NN )/) is/VBZ a/DT key/JJ cytokine/NN of/IN T/NN lymphocytes/NNS with/IN major/JJ regulatory/JJ functions/NNS in/IN the/DT immune/JJ system/NN ./. 
To/TO determine/VB and/CC compare/VB protein/DNA/NN interactions/NNS at/IN the/DT native/JJ IFN-gamma/NN locus/NN in/IN T/NN cells/NNS ,/, we/PRP analyzed/VBD the/DT human/JJ IFN-gamma/NN promoter/NN by/IN ligation-mediated/JJ polymerase/NN chain/NN reaction/NN (/( LM-PCR/NN )/) techniques/NNS ./. 
Accordingly/RB ,/, Jurkat/NN T/NN cells/NNS and/CC primary/JJ CD45RA/NN and/CC CD45R0/NN CD4+/JJ T/NN cell/NN subsets/NNS isolated/VBN from/IN peripheral/JJ blood/NN using/VBG immunomagnetic/JJ beads/NNS were/VBD cultured/VBN and/CC analyzed/VBN by/IN LM-PCR/NN ./. 
Constitutive/JJ and/CC inducible/JJ protein/DNA/NN interactions/NNS of/IN the/DT IFN-gamma/NN promoter/NN in/FW vivo/FW were/VBD detected/VBN in/IN all/DT T/NN cells/NNS tested/VBN ./. 
Interestingly/RB ,/, an/DT inducible/JJ footprint/NN between/IN -183/CD and/CC -196/CD was/VBD consistently/RB observed/VBN in/IN Jurkat/NN T/NN cells/NNS and/CC CD45RA/NN and/CC CD45R0/NN T/NN helper/NN subsets/NNS upon/IN stimulation/NN with/IN phorbol/NN 12-myristate/NN 13-acetate+phytohemagglutinin/NN (/( PMA+PHA/NN )/) that/WDT was/VBD highly/RB sensitive/JJ to/TO treatment/NN with/IN corticosteroids/NNS ./. 
This/DT novel/JJ target/NN site/NN ,/, denoted/VBN the/DT C-site/NN ,/, was/VBD shown/VBN by/IN several/JJ criteria/NNS ,/, including/VBG cell/NN distribution/NN studies/NNS ,/, stimulation/NN experiments/NNS ,/, supershift/NN assays/NNS ,/, and/CC cross-competition/JJ electrophoretic/JJ mobility/NN shift/NN assays/NNS to/TO bind/VB the/DT transcription/NN factor/NN AP-1/NN ./. 
Mutation/NN of/IN the/DT C-site/NN that/WDT prevented/VBD AP-1/NN binding/NN to/TO this/DT site/NN was/VBD sufficient/JJ strikingly/RB to/TO reduce/VB inducible/JJ promoter/NN activity/NN in/IN primary/JJ CD45R0/NN T/NN cells/NNS ./. 
In/IN summary/NN ,/, the/DT data/NNS demonstrate/VBP that/IN IFN-gamma/NN gene/NN transcription/NN in/IN primary/JJ T/NN cells/NNS is/VBZ regulated/VBN in/FW vivo/FW at/IN the/DT level/NN of/IN constitutive/JJ and/CC inducible/JJ protein/DNA/NN interactions/NNS ./. 
We/PRP propose/VBP a/DT model/NN where/WRB basal/JJ transcription/NN is/VBZ maintained/VBN by/IN binding/NN of/IN various/JJ transcription/NN factors/NNS to/TO the/DT IFN-gamma/NN promoter/NN ,/, whereas/IN PMA+PHA-inducible/JJ IFN-gamma/NN transcription/NN in/IN CD45R0/NN T/NN cells/NNS is/VBZ associated/VBN with/IN binding/NN of/IN AP-1/NN to/TO the/DT C-site/NN ./. 
UI/LS -/: 97404663/CD 
TI/LS -/: Activation/NN domain/NN requirements/NNS for/IN disruption/NN of/IN Epstein-Barr/JJ virus/NN latency/NN by/IN ZEBRA/NN ./. 
AB/LS -/: Latent/JJ infection/NN of/IN B/NN lymphocytes/NNS by/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) can/MD be/VB disrupted/VBN by/IN expression/NN of/IN the/DT EBV/NN ZEBRA/NN protein/NN ./. 
ZEBRA/NN ,/, a/DT transcriptional/JJ activator/NN ,/, initiates/VBZ the/DT EBV/NN lytic/JJ cascade/NN by/IN activating/VBG viral/JJ gene/NN expression/NN ./. 
ZEBRA/NN is/VBZ also/RB indispensable/JJ for/IN viral/JJ replication/NN and/CC binds/VBZ directly/RB to/TO the/DT EBV/NN lytic/JJ origin/NN of/IN replication/NN ./. 
The/DT studies/NNS described/VBN herein/RB demonstrate/VBP that/IN the/DT activation/NN domain/NN ./. 
ZEBRA/NN activation/NN can/MD be/VB replaced/VBN by/IN a/DT heterologous/JJ acidic/JJ ,/, proline-rich/JJ ,/, or/CC glutamine-rich/JJ activation/NN domain/NN ./. 
ZEBRA/NN activation/NN domain/NN swap/NN constructs/NNS retain/VBP ZEBRA/NN 's/POS native/JJ abilities/NNS to/TO activate/VB specific/JJ EBV/NN promoters/NNS ,/, to/TO disrupt/VB EBV/NN latency/NN ,/, and/CC to/TO stimulate/VB replication/NN at/IN the/DT EBV/NN lytic/JJ origin/NN ./. 
Additional/JJ work/NN ,/, employing/VBG sequential/JJ and/CC internal/JJ deletions/NNS of/IN ZEBRA/NN 's/POS N-terminal/JJ activation/NN domain/NN ,/, indicates/VBZ that/IN its/PRP$ separate/JJ activities/NNS are/VBP not/RB attributable/JJ to/TO specific/JJ subdomains/NNS but/CC are/VBP spread/VBN throughout/IN its/PRP$ N/NN terminus/NN and/CC therefore/RB can/MD not/RB be/VB inactivated/VBN by/IN deleting/VBG localized/JJ regions/NNS ./. 
UI/LS -/: 97415553/CD 
TI/LS -/: CholecystokininB/NN receptor/NN from/IN human/JJ Jurkat/NN lymphoblastic/JJ T/NN cells/NNS is/VBZ involved/VBN in/IN activator/NN protein-1-responsive/JJ gene/NN activation/NN ./. 
AB/LS -/: The/DT aim/NN of/IN this/DT study/NN was/VBD to/TO analyze/VB the/DT role/NN of/IN cholecystokinin/NN (/( CCK(B)/NN )/) receptor/NN in/IN human/JJ lymphoblastic/JJ Jurkat/NN T/NN cells/NNS ./. 
We/PRP investigated/VBD the/DT trophic/JJ effect/NN resulting/VBG from/IN activation/NN of/IN such/JJ a/DT receptor/NN by/IN using/VBG the/DT reporter/NN gene/NN strategy/NN ./. 
For/IN this/DT purpose/NN ,/, we/PRP transiently/RB transfected/VBN Jurkat/NN T/NN cells/NNS with/IN the/DT reporter/NN plasmid/NN p/NN [(TRE)3-tk-Luc]/NN and/CC found/VBD that/IN CCK-8/NN was/VBD able/JJ to/TO dose-dependently/RB induce/VB luciferase/NN expression/NN related/JJ to/TO activator/NN protein-1/NN (/( AP-1/NN )/) activation/NN with/IN a/DT maximal/JJ response/NN identical/JJ to/TO that/DT obtained/VBN with/IN compounds/NNS known/VBN to/TO activate/VB AP-1/NN complex/NN (/( quantitatively/RB ,/, the/DT same/JJ level/NN of/IN induction/NN was/VBD obtained/VBN with/IN 1/CD nM/NN 12-O-tetradecanoylphorbol-13-acetate/NN ,/, 100/CD microM/NN diacylglycerol/NN ,/, or/CC 4/CD nM/NN epidermal/JJ growth/NN factor/NN )/) ./. 
The/DT involvement/NN of/IN the/DT CCK(B)/NN receptor/NN in/IN such/JJ a/DT stimulation/NN was/VBD demonstrated/VBN by/IN the/DT inhibiting/NN effect/NN of/IN the/DT selective/JJ CCK(B)/NN receptor/NN antagonist/NN PD-135,158/NN ./. 
This/DT effect/NN was/VBD confirmed/VBN in/IN COS-7/NN cells/NNS transfected/VBN with/IN the/DT cDNA/NN of/IN CCK(B)/NN receptor/NN cloned/VBN from/IN Jurkat/NN T/NN cells/NNS ./. 
To/TO better/RBR understand/VB the/DT AP-1-dependent/JJ luciferase/NN expression/NN in/IN Jurkat/NN T/NN cells/NNS ,/, we/PRP tested/VBD two/CD specific/JJ inhibitors/NNS of/IN serine/threonine/NN phosphatases-1/NN and/CC -2A/NN :/: okadaic/JJ acid/NN and/CC calyculin/NN A/NN ./. 
These/DT compounds/NNS strongly/RB increased/VBD the/DT phorbol-12-myristate-13-acetate/NN response/NN ,/, whereas/IN we/PRP have/VBP not/RB observed/VBN a/DT contribution/NN of/IN phosphatase/NN inhibitors/NNS on/IN a/DT CCK-8-induced/JJ luciferase/NN activity/NN ./. 
To/TO confirm/VB that/IN CCK(B)/NN receptors/NNS are/VBP involved/VBN in/IN AP-1/NN response/NN ,/, we/PRP investigated/VBD the/DT CCK-8/NN effect/NN on/IN interleukin-2/NN expression/NN ,/, a/DT natural/JJ endogenous/JJ gene/NN regulated/VBN by/IN several/JJ factors/NNS ,/, including/VBG AP-1/NN ./. 
In/IN Jurkat/NN T/NN cells/NNS activated/VBN by/IN phorbol-12-myristate-13-acetate/NN and/CC phytohemagglutinin/NN ,/, CCK-8/NN induced/VBD IL-2/NN expression/NN ./. 
This/DT induction/NN was/VBD abolished/VBN by/IN PD-135,158/NN ./. 
Our/PRP$ results/NNS indicate/VBP that/IN CCK-8/NN exerts/VBZ a/DT trophic/JJ effect/NN in/IN Jurkat/NN T/NN cells/NNS through/IN stimulation/NN of/IN CCK(B)/NN receptors/NNS by/IN modulation/NN of/IN expression/NN of/IN AP-1-regulated/JJ genes/NNS ./. 
UI/LS -/: 97377998/CD 
TI/LS -/: A/DT conserved/VBN tissue-specific/JJ structure/NN at/IN a/DT human/JJ T-cell/NN receptor/NN beta-chain/NN core/NN promoter/NN ./. 
AB/LS -/: The/DT T-cell/NN receptor/NN (/( TCR/NN )/) beta-chain/NN promoters/NNS have/VBP been/VBN characterized/VBN as/IN nonstructured/JJ basal/JJ promoters/NNS that/WDT carry/VBP a/DT single/JJ conserved/VBN ubiquitous/JJ cyclic/JJ AMP-responsive/JJ element/NN ./. 
Our/PRP$ investigation/NN of/IN the/DT human/JJ TCR/NN beta/NN gene/NN uncovers/VBZ a/DT surprisingly/RB complex/JJ and/CC tissue-specific/JJ structure/NN at/IN the/DT TCR/NN Vbeta/NN 8.1/NN promoter/NN ./. 
The/DT core/NN of/IN the/DT promoter/NN (/( positions/NNS -42/CD to/TO +11/CD )/) is/VBZ recognized/VBN by/IN the/DT lymphoid/JJ cell-specific/JJ transcription/NN factors/NNS Ets-1/NN ,/, LEF1/NN ,/, and/CC AML1/NN as/RB well/RB as/IN by/IN CREB/ATF-1/NN ,/, as/IN is/VBZ demonstrated/VBN in/IN gel/NN shift/NN and/CC footprinting/NN experiments/NNS ./. 
With/IN the/DT exception/NN of/IN LEF1/NN ,/, these/DT factors/NNS activate/VBP transcription/NN in/IN T/NN cells/NNS ./. 
Binding/VBG sites/NNS at/IN the/DT core/NN region/NN show/VBP little/JJ conservation/NN with/IN consensus/NN sites/NNS ./. 
Nonetheless/RB ,/, CREB/NN ,/, Ets-1/NN ,/, and/CC AML1/NN bind/VBP and/CC activate/VBP cooperatively/RB and/CC very/RB efficiently/RB through/IN the/DT nonconsensus/JJ binding/VBG sites/NNS at/IN the/DT core/NN promoter/NN region/NN ./. 
Moderate/JJ ubiquitous/JJ activation/NN is/VBZ further/RB induced/VBN by/IN CREB/ATF/NN and/CC Sp1/NN factors/NNS through/IN proximal/JJ upstream/JJ elements/NNS ./. 
The/DT tissue-specific/JJ core/NN promoter/NN structure/NN is/VBZ apparently/RB conserved/VBN in/IN other/JJ T-cell-specifically/RB expressed/VBN genes/NNS such/JJ as/IN the/DT CD4/NN gene/NN ./. 
Our/PRP$ observations/NNS suggest/VBP that/IN both/CC the/DT enhancer/NN and/CC the/DT promoter/NN have/VBP a/DT complex/JJ tissue-specific/JJ structure/NN whose/WP$ functional/JJ interplay/NN potentiates/VBZ T-cell-specific/JJ transcription/NN ./. 
UI/LS -/: 97362232/CD 
TI/LS -/: The/DT cytoplasmic/JJ domain/NN of/IN granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) receptor/NN alpha/NN subunit/NN is/VBZ essential/JJ for/IN both/CC GM-CSF-mediated/JJ growth/NN and/CC differentiation/NN ./. 
AB/LS -/: Granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) regulates/VBZ differentiation/NN ,/, survival/NN ,/, and/CC proliferation/NN of/IN colony-forming/JJ unit-granulocyte-macrophage/JJ progenitor/NN cells/NNS ./. 
The/DT biologic/JJ actions/NNS of/IN GM-CSF/NN are/VBP mediated/VBN by/IN binding/VBG to/TO a/DT specific/JJ receptor/NN consisting/VBG of/IN two/CD chains/NNS designated/VBN as/IN alpha/NN and/CC beta/NN subunits/NNS ./. 
We/PRP have/VBP demonstrated/VBN that/IN the/DT murine/JJ FDC-P1-derived/JJ cell/NN line/NN WT-19/NN transfected/VBN with/IN the/DT human/JJ GM-CSF/NN receptor/NN alpha/NN and/CC beta/NN subunits/NNS (/( GM-CSFRalpha/NN and/CC beta/NN )/) can/MD be/VB induced/VBN to/TO differentiate/VB by/IN the/DT addition/NN of/IN human/JJ GM-CSF/NN (/( hGM-CSF/NN )/) ./. 
By/IN expressing/VBG a/DT series/NN of/IN GM-CSFRalpha/NN mutants/NNS in/IN WT19/NN cells/NNS ,/, we/PRP have/VBP determined/VBN the/DT amino/NN acid/NN domains/NNS of/IN the/DT GM-CSFRalpha/NN cytoplasmic/JJ domain/NN that/WDT regulate/VBP cell/NN differentiation/NN ,/, proliferation/NN ,/, and/CC survival/NN ./. 
We/PRP found/VBD that/IN the/DT membrane/NN proximal/JJ proline-rich/JJ domain/NN and/CC adjacent/JJ 16/CD residues/NNS are/VBP essential/JJ for/IN both/CC hGM-CSF-dependent/JJ cell/NN proliferation/NN and/CC differentiation/NN ./. 
In/IN contrast/NN ,/, the/DT C-terminal/JJ region/NN of/IN the/DT GM-CSFRalpha/NN cytoplasmic/JJ domain/NN was/VBD not/RB necessary/JJ for/IN cell/NN differentiation/NN mediated/VBN by/IN hGM-CSF/NN ,/, but/CC the/DT removal/NN of/IN this/DT region/NN severely/RB impaired/VBD the/DT ability/NN of/IN hGM-CSF/NN to/TO support/VB cell/NN survival/NN ./. 
While/IN the/DT activation/NN of/IN JAK2/NN ,/, Shc/NN ,/, Erk/NN ,/, and/CC STAT5/NN proteins/NNS correlated/VBD with/IN hGM-CSF-mediated/JJ cell/NN growth/NN ,/, cellular/JJ differentiation/NN occurred/VBD in/IN the/DT absence/NN of/IN activation/NN of/IN these/DT signal/NN transduction/NN pathways/NNS ./. 
UI/LS -/: 97358178/CD 
TI/LS -/: gamma-Interferon-induced/JJ resistance/NN to/TO 1,25-(OH)2/NN D3/NN in/IN human/JJ monocytes/NNS and/CC macrophages/NNS :/: a/DT mechanism/NN for/IN the/DT hypercalcemia/NN of/IN various/JJ granulomatoses/NNS ./. 
AB/LS -/: The/DT hypercalcemia/NN of/IN various/JJ granulomatoses/NNS is/VBZ caused/VBN by/IN endogenous/JJ 1,25-dihydroxyvitamin/NN D/NN [/( 1,25-(OH)2D3/NN ]/) overproduction/NN by/IN disease-activated/JJ macrophages/NNS ./. 
The/DT inability/NN of/IN 1,25(OH)2D3/NN to/TO suppress/VB its/PRP$ synthesis/NN in/IN macrophages/NNS contrasts/VBZ with/IN the/DT tight/JJ control/NN of/IN its/PRP$ production/NN in/IN macrophage/NN precursors/NNS ,/, peripheral/JJ blood/NN monocytes/NNS (/( PBM/NNS )/) ./. 
We/PRP examined/VBD whether/IN 1,25(OH)2D3/NN resistance/NN develops/VBZ as/IN PBM/NNS differentiate/VBP to/TO macrophages/NNS or/CC with/IN macrophage/NN activation/NN ./. 
Normal/JJ human/JJ pulmonary/JJ alveolar/JJ macrophages/NNS (/( PAM/NNS )/) are/VBP less/RBR sensitive/JJ to/TO 1,25(OH)2D3/NN than/IN PBM/NNS ,/, despite/IN similar/JJ vitamin/NN D/NN receptor/NN content/NN ;/: however/RB ,/, both/CC PBM/NNS and/CC PAM/NNS respond/VBP to/TO exogenous/JJ 1,25-(OH)2D3/NN by/IN inhibiting/VBG 1,25(OH)2D3/NN synthesis/NN and/CC inducing/VBG 1,25(OH)2D3/NN degradation/NN through/IN enhancement/NN of/IN 24-hydroxylase/NN mRNA/NN levels/NNS and/CC activity/NN ./. 
The/DT human/JJ monocytic/JJ cell/NN line/NN THP-1/NN mimics/VBZ PAM/NNS in/IN 1,25(OH)2D3/NN synthesis/NN and/CC sensitivity/NN to/TO exogenous/JJ 1,25(OH)2D3/NN ./. 
We/PRP utilized/VBD THP-1/NN cells/NNS to/TO examine/VB the/DT response/NN to/TO 1,25(OH)2D3/NN with/IN macrophage/NN activation/NN ./. 
Activation/NN of/IN THP-1/NN cells/NNS with/IN gamma-interferon/NN (/( gamma-IFN/NN )/) enhances/VBZ 1,25(OH)2D3/NN synthesis/NN 30-fold/RB ,/, blocks/VBZ 1,25-(OH)2D3/NN suppression/NN of/IN its/PRP$ synthesis/NN ,/, and/CC reduces/VBZ by/IN 42.2/CD %/NN 1,25-(OH)2D3/NN induction/NN of/IN its/PRP$ degradation/NN ./. 
The/DT antagonistic/JJ effects/NNS of/IN gamma-IFN/NN are/VBP not/RB merely/RB restricted/JJ to/TO enzymatic/JJ activities/NNS ./. 
In/IN THP-1/NN cells/NNS and/CC in/IN normal/JJ PBM/NNS ,/, gamma-IFN/NN inhibits/VBZ 1,25-(OH)2D3/NN induction/NN of/IN 24-hydroxylase/NN mRNA/NN levels/NNS without/IN reducing/VBG mRNA/NN stability/NN ,/, suggesting/VBG gamma-IFN/NN inhibition/NN of/IN 1,25(OH)2D3/NN transactivating/NN function/NN ./. 
These/DT results/NNS explain/VBP 1,25(OH)2D3/NN overproduction/NN in/IN granulomatoses/NNS and/CC demonstrate/VBP potent/JJ inhibition/NN by/IN gamma-IFN/NN of/IN 1,25(OH)2D3/NN action/NN in/IN immune/JJ cells/NNS ./. 
UI/LS -/: 97335974/CD 
TI/LS -/: Molecular/JJ cloning/NN and/CC characterization/NN of/IN a/DT cDNA/NN ,/, CHEMR1/NN ,/, encoding/VBG a/DT chemokine/NN receptor/NN with/IN a/DT homology/NN to/TO the/DT human/JJ C-C/NN chemokine/NN receptor/NN ,/, CCR-4/NN ./. 
AB/LS -/: Chemokines/NNS refer/VBP to/TO a/DT rapidly/RB expanding/VBG family/NN of/IN small/JJ cytokines/NNS whose/WP$ primary/JJ function/NN is/VBZ recruitment/NN of/IN leukocytes/NNS to/TO inflammatory/JJ sites/NNS ./. 
These/DT are/VBP known/VBN to/TO bind/VB to/TO seven-transmembrane-domain/NN containing/VBG receptors/NNS ./. 
A/DT cDNA/NN clone/NN ,/, CHEMR1/NN ,/, resembling/VBG the/DT typical/JJ G/NN protein-coupled/JJ receptor/NN ,/, was/VBD isolated/VBN from/IN a/DT mouse/NN cytotoxic/JJ T-lymphocyte/NN (/( CTL/NN )/) library/NN ./. 
Northern/NN blot/NN analysis/NN in/IN mouse/NN cell/NN lines/NNS suggests/VBZ that/IN its/PRP$ expression/NN is/VBZ found/VBN in/IN a/DT variety/NN of/IN cells/NNS ,/, including/VBG T/NN cells/NNS ,/, B/NN cells/NNS ,/, and/CC macrophages/NNS ./. 
The/DT CHEMR1/NN gene/NN Scya3r2/NN is/VBZ a/DT single-copy/JJ gene/NN whose/WP$ open/JJ reading/NN frame/NN may/MD be/VB in/IN a/DT single/JJ exon/NN and/CC maps/VBZ to/TO the/DT distal/JJ region/NN of/IN mouse/NN Chr/NN 9/CD where/WRB the/DT mouse/NN macrophage/NN inflammatory/JJ protein-1alpha/NN (/( MIP-1alpha/NN )/) receptor/NN gene/NN Scya3r/NN and/CC two/CD related/JJ C-C/NN chemokine/NN receptor-like/JJ genes/NNS reside/VBP ./. 
Amino/NN acid/NN sequence/NN comparison/NN shows/VBZ that/IN CHEMR1/NN is/VBZ 84/CD %/NN identical/JJ to/TO human/JJ CCR-4/NN ,/, indicating/VBG that/IN CHEMR1/NN is/VBZ likely/JJ to/TO be/VB a/DT mouse/NN CCR-4/NN ./. 
Binding/NN assays/NNS using/VBG 125I-labeled/JJ C-C/NN chemokines/NNS in/IN mammalian/JJ cells/NNS indicated/VBD that/IN CHEMR1/NN did/VBD not/RB bind/VB MIP-1alpha/NN ,/, RANTES/NN ,/, or/CC MIP-1beta/NN ,/, whereas/IN CCR-1/NN binds/VBZ MIP-1alpha/NN and/CC RANTES/NN ./. 
Our/PRP$ result/NN is/VBZ different/JJ from/IN the/DT reported/VBN properties/NNS of/IN human/JJ CCR-4/NN ./. 
This/DT suggests/VBZ that/IN CHEMR1/NN may/MD be/VB a/DT receptor/NN for/IN unidentified/JJ C-C/NN chemokine/NN or/CC a/DT low-affinity/JJ receptor/NN for/IN MIP-1alpha/NN ./. 
UI/LS -/: 97322371/CD 
TI/LS -/: Transactivation/NN by/IN CIITA/NN ,/, the/DT type/NN II/CD bare/JJ lymphocyte/NN syndrome-associated/JJ factor/NN ,/, requires/VBZ participation/NN of/IN multiple/JJ regions/NNS of/IN the/DT TATA/NN box/NN binding/NN protein/NN ./. 
AB/LS -/: CIITA/NN is/VBZ a/DT positive/JJ regulator/NN of/IN class/NN II/CD major/JJ histocompatibility/NN complex/NN gene/NN transcription/NN that/WDT has/VBZ been/VBN found/VBN to/TO be/VB defective/JJ in/IN one/CD of/IN the/DT five/CD complementation/NN groups/NNS of/IN class/NN II/CD major/JJ histocompatibility/NN complex-negative/JJ cell/NN lines/NNS ./. 
Its/PRP$ N-terminal/JJ region/NN is/VBZ capable/JJ of/IN activating/VBG transcription/NN from/IN a/DT reporter/NN gene/NN when/WRB fused/VBN to/TO a/DT DNA/NN binding/NN domain/NN ./. 
We/PRP have/VBP investigated/VBN the/DT mechanism/NN of/IN transactivation/NN mediated/VBN by/IN the/DT CIITA/NN activation/NN domain/NN by/IN studying/VBG its/PRP$ role/NN in/IN the/DT process/NN of/IN transcription/NN initiation/NN and/CC elongation/NN ./. 
Specifically/RB the/DT altered/JJ specificity/NN TBP/NN (/( TATA/NN box/NN binding/NN protein/NN )/) assay/NN has/VBZ been/VBN used/VBN to/TO analyze/VB the/DT response/NN of/IN the/DT CIITA/NN activation/NN domain/NN to/TO mutations/NNS in/IN TBP/NN known/VBN to/TO disrupt/VB its/PRP$ interaction/NN with/IN its/PRP$ associated/VBN general/JJ factors/NNS ./. 
Transactivation/NN by/IN CIITA/NN was/VBD extremely/RB sensitive/JJ to/TO a/DT mutation/NN in/IN TBP/NN that/WDT in/IN yeast/NN is/VBZ known/VBN to/TO abolish/VB VP16-mediated/JJ transcription/NN but/CC leaves/VBZ basal/JJ transcription/NN unaffected/JJ ./. 
A/DT TBP/NN mutant/NN defective/JJ in/IN interaction/NN with/IN TBP-associated/JJ factor/NN TAFII250/NN also/RB failed/VBD to/TO mediate/VB transactivation/NN through/IN the/DT CIITA/NN activation/NN domain/NN ./. 
Certain/JJ interactions/NNS between/IN TBP/NN and/CC general/JJ factors/NNS that/WDT are/VBP specifically/RB required/VBN for/IN acidic/JJ activation/NN domains/NNS were/VBD also/RB required/VBN for/IN CIITA-mediated/JJ transactivation/NN to/TO reach/VB its/PRP$ full/JJ potential/NN ./. 
Finally/RB ,/, like/IN VP16/NN ,/, CIITA/NN was/VBD able/JJ to/TO stimulate/VB elongation/NN of/IN transcription/NN ./. 
Overall/RB the/DT mechanism/NN of/IN transactivation/NN by/IN the/DT human/JJ B-cell-specific/JJ CIITA/NN is/VBZ very/RB similar/JJ to/TO that/DT mediated/VBN by/IN the/DT herpes/NN virus/NN transactivator/NN VP16/NN in/IN the/DT ways/NNS that/WDT have/VBP been/VBN tested/VBN ./. 
UI/LS -/: 97334360/CD 
TI/LS -/: Relief/NN of/IN cyclin/NN A/NN gene/NN transcriptional/JJ inhibition/NN during/IN activation/NN of/IN human/JJ primary/JJ T/NN lymphocytes/NNS via/IN CD2/NN and/CC CD28/NN adhesion/NN molecules/NNS ./. 
AB/LS -/: Cyclin/NN A/NN transcription/NN is/VBZ cell/NN cycle/NN regulated/JJ and/CC induced/VBN by/IN cell/NN proliferative/JJ signals/NNS ./. 
To/TO understand/VB the/DT mechanisms/NNS underlined/VBN in/IN this/DT regulation/NN in/IN normal/JJ human/JJ cells/NNS ,/, we/PRP have/VBP analysed/VBN in/FW vivo/FW protein-DNA/JJ interactions/NNS at/IN the/DT Cyclin/NN A/NN locus/NN in/IN primary/JJ T/NN lymphocytes/NNS ./. 
Stimulation/NN of/IN purified/VBN T/NN lymphocytes/NNS by/IN a/DT combination/NN of/IN monoclonal/JJ antibodies/NNS directed/VBN at/IN CD2/NN and/CC CD28/NN adhesion/NN molecules/NNS gives/VBZ rise/NN to/TO a/DT long/JJ lasting/JJ proliferation/NN in/IN the/DT absence/NN of/IN accessory/NN cells/NNS ./. 
Cyclin/NN A/NN was/VBD observed/VBN after/IN 4/CD days/NNS of/IN costimulation/NN with/IN anti/JJ CD2/NN +/CC CD28/NN whereas/IN stimulation/NN by/IN anti/JJ CD2/NN or/CC anti/JJ CD28/NN alone/RB was/VBD not/RB effective/JJ ./. 
In/FW vivo/FW genomic/JJ DMS/NN footprinting/NN revealed/VBD upstream/RB of/IN the/DT major/JJ transcription/NN initiation/NN sites/NNS ,/, the/DT presence/NN of/IN at/IN least/JJS three/CD protein/NN binding/NN sites/NNS ,/, two/CD of/IN which/WDT were/VBD constitutively/RB occupied/VBN ./. 
They/PRP bind/VBP in/FW vitro/FW respectively/RB ATF-1/NN and/CC NF-Y/NN proteins/NNS ./. 
The/DT third/JJ site/NN was/VBD occupied/VBN in/IN quiescent/JJ cells/NNS or/CC in/IN cells/NNS stimulated/VBN by/IN anti/JJ CD2/NN or/CC anti/JJ CD28/NN alone/RB ./. 
The/DT mitogenic/JJ combination/NN of/IN anti/JJ CD2/NN +/CC anti/JJ CD28/NN released/VBD the/DT footprint/NN as/IN cells/NNS were/VBD committed/VBN to/TO proliferation/NN ./. 
Consistent/JJ with/IN theses/DT results/NNS ,/, nuclear/JJ extracts/NNS prepared/VBN from/IN quiescent/JJ cells/NNS formed/VBD a/DT specific/JJ complex/NN with/IN this/DT element/NN ,/, whereas/IN extracts/NNS prepared/VBN from/IN cells/NNS treated/VBN with/IN anti/JJ CD2/NN +/CC anti/JJ CD28/NN failed/VBD to/TO do/VB so/RB after/IN cells/NNS entered/VBD a/DT proliferative/JJ state/NN ./. 
UI/LS -/: 97289747/CD 
TI/LS -/: An/DT enhancer-blocking/JJ element/NN between/IN alpha/NN and/CC delta/NN gene/NN segments/NNS within/IN the/DT human/JJ T/NN cell/NN receptor/NN alpha/delta/NN locus/NN ./. 
AB/LS -/: T/NN cell/NN receptor/NN (/( TCR/NN )/) alpha/NN and/CC delta/NN gene/NN segments/NNS are/VBP organized/VBN within/IN a/DT single/JJ genetic/JJ locus/NN but/CC are/VBP differentially/RB regulated/VBN during/IN T/NN cell/NN development/NN ./. 
An/DT enhancer-blocking/JJ element/NN (/( BEAD-1/NN ,/, for/IN blocking/VBG element/NN alpha/delta/NN 1/CD )/) was/VBD localized/JJ to/TO a/DT 2.0-kb/JJ region/NN 3'/RB of/IN TCR/NN delta/NN gene/NN segments/NNS and/CC 5'/RB of/IN TCR/NN alpha/NN joining/NN gene/NN segments/NNS within/IN this/DT locus/NN ./. 
BEAD-1/NN blocked/VBD the/DT ability/NN of/IN the/DT TCR/NN delta/NN enhancer/NN (/( Edelta/NN )/) to/TO activate/VB a/DT promoter/NN when/WRB located/JJ between/IN the/DT two/CD in/IN a/DT chromatin-integrated/JJ construct/NN ./. 
We/PRP propose/VBP that/IN BEAD-1/NN functions/VBZ as/IN a/DT boundary/NN that/WDT separates/VBZ the/DT TCR/NN alpha/delta/NN locus/NN into/IN distinct/JJ regulatory/JJ domains/NNS controlled/VBN by/IN Edelta/NN and/CC the/DT TCR/NN alpha/NN enhancer/NN ,/, and/CC that/IN it/PRP prevents/VBZ Edelta/NN from/IN opening/VBG the/DT chromatin/NN of/IN the/DT TCR/NN alpha/NN joining/NN gene/NN segments/NNS for/IN VDJ/NN recombination/NN at/IN an/DT early/JJ stage/NN of/IN T/NN cell/NN development/NN ./. 
UI/LS -/: 97312374/CD 
TI/LS -/: Uncoupling/NN of/IN cell/NN cycle/NN arrest/NN from/IN the/DT expression/NN of/IN monocytic/JJ differentiation/NN markers/NNS in/IN HL60/NN cell/NN variants/NNS ./. 
AB/LS -/: Differentiation/NN generally/RB leads/VBZ to/TO cell/NN cycle/NN arrest/NN ./. 
Human/JJ leukemia/NN HL60/NN cells/NNS respond/VBP to/TO the/DT presence/NN of/IN 1,25-dihydroxyvitamin/NN D3/NN (/( 1,25D3/NN )/) by/IN expressing/VBG a/DT number/NN of/IN markers/NNS of/IN the/DT monocyte/macrophage/NN phenotype/NN and/CC become/VBP arrested/VBN predominantly/RB in/IN the/DT G1/NN phase/NN of/IN the/DT cell/NN cycle/NN ./. 
We/PRP have/VBP recently/RB reported/VBN a/DT series/NN (/( A/NN )/) of/IN 1,25D3-resistant/JJ variants/NNS of/IN HL60/NN cells/NNS which/WDT proliferate/VBP in/IN the/DT presence/NN of/IN 1,25D3/NN and/CC do/VBP not/RB express/VB differentiation/NN markers/NNS (/( Exp./NNP Cell/NNP Res./NNP 224/CD ,/, 312/CD ,/, 1996/CD )/) ./. 
We/PRP now/RB describe/VBP another/DT series/NN (/( B/NN )/) of/IN such/JJ variants/NNS ,/, which/WDT differ/VBP from/IN A/NN series/NN cells/NNS grown/VBN in/IN similar/JJ concentrations/NNS of/IN 1,25D3/NN in/IN that/IN they/PRP express/VBP the/DT CD14/NN antigen/NN and/CC nonspecific/JJ esterase/NN ,/, characteristic/JJ of/IN the/DT monocyte/NN ,/, while/IN continuing/VBG to/TO proliferate/NN and/CC they/PRP develop/VBP hypotetraploid/JJ DNA/NN (/( 4C/NN )/) content/NN at/IN higher/JJR concentrations/NNS of/IN ambient/JJ 1,25D3/NN than/IN the/DT A/NN series/NN cells/NNS ./. 
Cells/NNS in/IN the/DT B/NN series/NN with/IN 4C/NN DNA/NN content/NN (/( 100B/NN and/CC 200B/NN )/) also/RB differed/VBD from/IN the/DT A/NN series/NN 4C/NN cells/NNS by/IN the/DT absence/NN of/IN DNA/NN binding/NN by/IN the/DT full-length/JJ Sp1/NN transcription/NN factor/NN ./. 
However/RB ,/, B/NN series/NN cells/NNS resembled/VBD the/DT A/NN series/NN cells/NNS in/IN exhibiting/VBG faster/JJR growth/NN rates/NNS than/IN the/DT parental/JJ HL60/NN cells/NNS and/CC showed/VBD high/JJ levels/NNS of/IN vitamin/NN D/NN receptor/NN and/CC retinoid/NN receptor/NN X/NN proteins/NNS ./. 
These/DT results/NNS show/VBP that/IN the/DT initial/JJ steps/NNS in/IN the/DT 1,25D3/NN signaling/NN pathway/NN are/VBP intact/JJ in/IN B/NN series/NNS resistant/JJ cells/NNS and/CC lead/VBP to/TO the/DT appearance/NN of/IN early/JJ markers/NNS of/IN monocytic/JJ differentiation/NN ./. 
However/RB ,/, the/DT progression/NN to/TO subsequent/JJ events/NNS which/WDT comprise/VBP terminal/JJ differentiation/NN and/CC cell/NN cycle/NN arrest/NN is/VBZ halted/VBN during/IN the/DT adaptation/NN to/TO the/DT presence/NN of/IN 1,25D3/NN in/IN these/DT cells/NNS ./. 
Thus/RB ,/, the/DT availability/NN of/IN these/DT variant/JJ cells/NNS should/MD provide/VB a/DT system/NN for/IN studying/VBG the/DT link/NN between/IN differentiation/NN and/CC cell/NN cycle/NN arrest/NN ./. 
UI/LS -/: 97404655/CD 
TI/LS -/: Inhibition/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD replication/NN in/FW vitro/FW by/IN a/DT novel/JJ combination/NN of/IN anti-Tat/JJ single-chain/JJ intrabodies/NNS and/CC NF-kappa/NN B/NN antagonists/NNS ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) Tat/NN ,/, an/DT early/JJ regulatory/JJ protein/NN that/WDT is/VBZ critical/JJ for/IN viral/JJ gene/NN expression/NN and/CC replication/NN ,/, transactivates/VBZ the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) via/IN its/PRP$ binding/NN to/TO the/DT transactivation/NN response/NN element/NN (/( TAR/NN )/) and/CC ,/, along/IN with/IN other/JJ cellular/JJ factors/NNS ,/, increases/VBZ viral/JJ transcription/NN initiation/NN and/CC elongation/NN ./. 
Tat/NN also/RB superactivates/VBZ the/DT HIV-1/NN promoter/NN through/IN a/DT TAR-independent/JJ mechanism/NN ,/, including/VBG tumor/NN necrosis/NN factor/NN alpha-induced/JJ and/CC protein/NN kinase/NN C/NN (/( PKC/NN )/) -dependent/JJ activation/NN of/IN NF-kappa/NN B/NN ,/, and/CC inhibitors/NNS of/IN Tat/NN and/CC NF-kappa/NN B/NN cooperatively/RB down-regulate/VBP this/DT Tat-mediated/JJ LTR/NN superactivation/NN ./. 
In/IN this/DT study/NN ,/, a/DT combined/JJ pharmacologic/JJ and/CC genetic/JJ strategy/NN using/VBG two/CD PKC/NN (/( NF-kappa/NN B/NN )/) inhibitors/NNS ,/, pentoxifylline/NN (/( PTX/NN )/) and/CC Go-6976/NN ,/, and/CC a/DT stably/RB expressed/VBN anti-Tat/JJ single-chain/JJ intracellular/JJ antibody/NN (/( sFv/NN intrabody/NN )/) was/VBD employed/VBN to/TO obtain/VB cooperative/JJ inhibition/NN of/IN both/CC HIV-1/NN LTR-driven/JJ gene/NN expression/NN and/CC HIV-1/NN replication/NN ./. 
Treatment/NN of/IN cells/NNS with/IN PTX/NN and/CC Go-6976/NN resulted/VBD in/IN cooperative/JJ inhibition/NN of/IN both/CC HIV-1/NN LTR-driven/JJ gene/NN expression/NN and/CC HIV-1/NN replication/NN ./. 
In/IN addition/NN ,/, the/DT combined/JJ use/NN of/IN anti-Tat/JJ sFv/NN intrabodies/NNS and/CC the/DT two/CD NF-kappa/NN B/NN inhibitors/NNS retained/VBD the/DT virus/NN in/IN the/DT latent/JJ state/NN for/IN as/RB long/JJ as/IN 45/CD days/NNS ./. 
The/DT combined/JJ treatment/NN resulted/VBD in/IN more/RBR durable/JJ inhibition/NN of/IN HIV-1/NN replication/NN than/IN was/VBD seen/VBN with/IN the/DT NF-kappa/NN B/NN inhibitors/NNS alone/RB or/CC the/DT anti-Tat/NN sFv/NN intrabodies/NNS alone/RB ./. 
Together/RB ,/, these/DT results/NNS suggest/VBP that/IN in/IN future/JJ clinical/JJ gene/NN therapy/NN trials/NNS ,/, a/DT combined/JJ pharmacologic/JJ and/CC genetic/JJ strategy/NN like/IN the/DT one/CD reported/VBN here/RB may/MD improve/VB the/DT survival/NN of/IN transduced/VBN cells/NNS and/CC prolong/VB clinical/JJ benefit/NN ./. 
UI/LS -/: 97410435/CD 
TI/LS -/: Transcription/NN factors/NNS in/IN immune-mediated/JJ disease/NN ./. 
AB/LS -/: A/DT large/JJ amount/NN of/IN detailed/JJ information/NN about/IN the/DT intracellular/JJ proteins/NNS regulating/VBG NF-kappa/NN B/NN activation/NN and/CC the/DT cellular/JJ response/NN to/TO NF-kappa/NN B/NN activation/NN has/VBZ emerged/VBN recently/RB ./. 
Several/JJ small/JJ molecules/NNS ,/, an/DT antisense/JJ oligonucleotide/NN ,/, and/CC gene/NN therapeutic/JJ agents/NNS that/WDT inhibit/VBP NF-kappa/NN b/NN activation/NN have/VBP been/VBN described/VBN ./. 
Despite/IN this/DT ,/, there/EX are/VBP still/RB significant/JJ gaps/NNS in/IN our/PRP$ understanding/NN of/IN this/DT process/NN and/CC its/PRP$ consequences/NNS ./. 
In/IN contrast/NN ,/, the/DT characterization/NN of/IN transcription/NN factors/NNS selectively/RB regulating/VBG cytokine/NN production/NN by/IN CD4+/JJ T/NN cell/NN subsets/NNS is/VBZ at/IN a/DT very/RB early/JJ stage/NN ./. 
Three/CD interacting/VBG proteins/NNS have/VBP recently/RB been/VBN shown/VBN to/TO contribute/VB to/TO subset-restricted/JJ expression/NN of/IN the/DT IL-4/NN gene/NN ./. 
There/EX are/VBP other/JJ elements/NNS regulating/VBG IL-4/NN gene/NN expression/NN ,/, however/RB ,/, and/CC the/DT relative/JJ importance/NN of/IN these/DT recently/RB identified/VBN proteins/NNS has/VBZ yet/RB to/TO be/VB determined/VBN ./. 
UI/LS -/: 97376857/CD 
TI/LS -/: Involvement/NN of/IN Rel/NN ,/, Fos/NN ,/, and/CC Jun/NN proteins/NNS in/IN binding/NN activity/NN to/TO the/DT IL-2/NN promoter/NN CD28/NN response/NN element/AP-1/NN sequence/NN in/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: CD28/NN is/VBZ an/DT important/JJ costimulatory/JJ molecule/NN in/IN the/DT activation/NN of/IN human/JJ T/NN cells/NNS ./. 
Costimulation/NN of/IN T/NN cells/NNS through/IN both/CC the/DT Ag/NN receptor/NN and/CC CD28/NN leads/VBZ to/TO high/JJ level/NN IL-2/NN production/NN ,/, which/WDT is/VBZ vital/JJ to/TO the/DT development/NN of/IN an/DT immune/JJ response/NN in/FW vivo/FW ./. 
Previous/JJ reports/NNS have/VBP suggested/VBN the/DT CD28/NN stimulation/NN contributes/VBZ to/TO the/DT activation/NN of/IN the/DT IL-2/NN promoter/NN by/IN up-regulating/VBG the/DT activity/NN of/IN several/JJ transcription/NN factors/NNS ,/, including/VBG AP-1/NN and/CC nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) /Rel/NN family/NN members/NNS as/RB well/RB as/IN an/DT uncharacterized/JJ transcription/NN factor/NN called/VBN CD28/NN response/NN complex/NN ./. 
While/IN several/JJ lines/NNS of/IN investigation/NN have/VBP suggested/VBN that/IN NF-kappaB/Rel/NN family/NN members/NNS make/VBP up/RB the/DT CD28/NN response/NN complex/NN transcription/NN factor/NN ,/, other/JJ work/NN has/VBZ not/RB supported/VBN this/DT conclusion/NN ./. 
Recent/JJ studies/NNS suggest/VBP that/IN the/DT CD28/NN response/NN element/NN (/( CD28RE/NN )/) does/VBZ not/RB function/VB independently/RB but/CC works/VBZ instead/RB in/IN conjunction/NN with/IN the/DT adjacent/JJ promoter/NN proximal/JJ AP-1-binding/JJ site/NN and/CC this/DT hypothesis/NN is/VBZ confirmed/VBN here/RB ./. 
Also/RB in/IN the/DT current/JJ study/NN ,/, binding/NN activity/NN to/TO the/DT CD28RE/AP-1/NN sequence/NN of/IN the/DT IL-2/NN promoter/NN is/VBZ evaluated/VBN ./. 
Although/IN four/CD specific/JJ complexes/NNS can/MD be/VB detected/VBN binding/VBG to/TO this/DT sequence/NN ,/, only/RB one/CD of/IN these/DT complexes/NNS is/VBZ specific/JJ for/IN both/CC the/DT CD28RE/NN and/CC the/DT adjacent/JJ AP-1/NN site/NN ./. 
Of/IN the/DT NF-kappaB/Rel/NN family/NN members/NNS tested/VBN ,/, this/DT CD28RE/AP-1-specific/JJ complex/NN contains/VBZ predominantly/RB c-Rel/NN ,/, despite/IN the/DT fact/NN that/IN both/CC p50/NN and/CC RelA/NN can/MD efficiently/RB bind/VB to/TO the/DT CD28RE/NN ./. 
c-Fos/NN and/CC c-Jun/NN are/VBP also/RB found/VBN in/IN this/DT CD28RE/AP-1-specific/JJ complex/NN ./. 
These/DT data/NNS indicate/VBP that/IN functional/JJ complexes/NNS encompassing/VBG both/CC the/DT CD28RE/NN and/CC the/DT AP-1-binding/JJ sites/NNS influence/VBP IL-2/NN promoter/NN activity/NN in/IN CD28-costimulated/JJ T/NN cells/NNS ./. 
UI/LS -/: 97362321/CD 
TI/LS -/: Inducible/JJ expression/NN and/CC phosphorylation/NN of/IN coactivator/NN BOB.1/OBF.1/NN in/IN T/NN cells/NNS [/( see/VB comments/NNS ]/) 
AB/LS -/: BOB.1/OBF.1/NN is/VBZ a/DT transcriptional/JJ coactivator/NN that/WDT is/VBZ constitutively/RB expressed/VBN in/IN B/NN cells/NNS and/CC interacts/VBZ with/IN the/DT Oct1/NN and/CC Oct2/NN transcription/NN factors/NNS ./. 
Upon/IN activation/NN of/IN Jurkat/NN T/NN cells/NNS and/CC primary/JJ murine/JJ thymocytes/NNS with/IN phorbol/NN esters/NNS and/CC ionomycin/NN ,/, BOB.1/OBF.1/NN expression/NN and/CC transactivation/NN function/NN were/VBD induced/VBN ./. 
BOB.1/OBF.1/NN was/VBD phosphorylated/VBN at/IN Ser184/NN both/CC in/FW vivo/FW and/CC in/FW vitro/FW ,/, and/CC this/DT modification/NN was/VBD required/VBN for/IN inducible/JJ activation/NN ./. 
Mutation/NN of/IN Ser184/NN also/RB diminished/VBD transactivation/NN function/NN in/IN B/NN cells/NNS ,/, suggesting/VBG that/IN the/DT activating/VBG phosphorylation/NN that/WDT is/VBZ inducible/JJ in/IN T/NN cells/NNS is/VBZ constitutively/RB present/JJ in/IN B/NN cells/NNS ./. 
Thus/RB ,/, BOB.1/OBF.1/NN is/VBZ a/DT transcriptional/JJ coactivator/NN that/WDT is/VBZ critically/RB regulated/VBN by/IN posttranslational/JJ modifications/NNS to/TO mediate/VB cell/NN type-specific/JJ gene/NN expression/NN ./. 
UI/LS -/: 97355572/CD 
TI/LS -/: Increased/VBN expression/NN of/IN Gs(alpha)/NN enhances/VBZ activation/NN of/IN the/DT adenylyl/NN cyclase/NN signal/NN transduction/NN cascade/NN ./. 
AB/LS -/: Expression/NN of/IN the/DT stimulatory/JJ G/NN protein/NN ,/, G(S)alpha/NN ,/, can/MD vary/VB over/IN a/DT 3-fold/JJ range/NN in/IN human/JJ tissues/NNS and/CC in/IN rodent/JJ central/JJ nervous/JJ system/NN ./. 
In/IN fact/NN ,/, the/DT offspring/NN of/IN alcoholics/NNS have/VBP higher/JJR levels/NNS of/IN G(S)alpha/NN expression/NN in/IN certain/JJ tissues/NNS compared/VBN with/IN the/DT offspring/NN of/IN nonalcoholics/NNS ./. 
The/DT aim/NN of/IN this/DT research/NN was/VBD to/TO test/VB the/DT hypothesis/NN that/IN a/DT causal/JJ relationship/NN exists/VBZ between/IN the/DT level/NN of/IN expression/NN of/IN G(S)alpha/NN and/CC induction/NN of/IN the/DT adenylyl/NN cyclase/NN (/( AC/NN )/) cascade/NN ./. 
The/DT methodology/NN employed/VBD transient/JJ transfection/NN of/IN HEK/NN 293/CD cells/NNS with/IN a/DT cDNA/NN for/IN the/DT 52-kDa/JJ form/NN of/IN G(S)alpha/NN under/IN regulation/NN by/IN inducible/JJ metallothionein/NN promoters/NNS ./. 
Transfectants/NNS were/VBD exposed/VBN to/TO varying/VBG concentrations/NNS (/( 0-125/CD microM/NN )/) of/IN zinc/NN sulfate/NN that/WDT produced/VBD a/DT 3-fold/JJ range/NN of/IN membrane/NN G(S)alpha/NN expression/NN ./. 
The/DT range/NN of/IN G(S)alpha/NN expression/NN produced/VBN was/VBD found/VBN to/TO mimic/VB a/DT physiologically/RB relevant/JJ spectrum/NN of/IN G(S)alpha/NN expression/NN in/IN membranes/NNS derived/VBN from/IN human/JJ tissues/NNS and/CC rat/NN brain/NN ./. 
It/PRP was/VBD observed/VBN that/IN induction/NN of/IN G(S)alpha/NN expression/NN increased/VBD constitutive/JJ as/RB well/RB as/IN stimulated/VBN cAMP/NN accumulation/NN ./. 
Moreover/RB ,/, induction/NN of/IN G(S)alpha/NN expression/NN increased/VBD events/NNS distal/JJ to/TO the/DT accumulation/NN of/IN cAMP/NN including/VBG the/DT phosphorylation/NN of/IN the/DT transcription/NN factor/NN ,/, cAMP/NN response/NN element/NN binding/NN protein/NN and/CC transcriptional/JJ activation/NN of/IN cAMP-dependent/JJ reporter/NN genes/NNS ./. 
In/IN summary/NN ,/, these/DT studies/NNS show/VBP that/IN the/DT amount/NN of/IN G(S)alpha/NN expression/NN has/VBZ a/DT marked/JJ impact/NN on/IN the/DT level/NN of/IN activity/NN of/IN the/DT AC/NN cascade/NN from/IN the/DT membrane/NN through/IN to/TO the/DT nucleus/NN ./. 
It/PRP is/VBZ hypothesized/VBN that/IN individuals/NNS who/WP differ/VBP in/IN G(S)alpha/NN expression/NN may/MD also/RB differ/VB in/IN the/DT expression/NN of/IN certain/JJ cAMP-dependent/JJ genes/NNS ./. 
UI/LS -/: 97335966/CD 
TI/LS -/: Thrombin/NN generation/NN by/IN apoptotic/JJ vascular/JJ smooth/NN muscle/NN cells/NNS ./. 
AB/LS -/: Thrombin/NN activation/NN requires/VBZ assembly/NN of/IN a/DT prothrombinase/NN complex/NN of/IN activated/VBN coagulation/NN factors/NNS on/IN an/DT anionic/JJ phospholipid/NN surface/NN ,/, classically/RB provided/VBN by/IN activated/VBN platelets/NNS ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN anionic/JJ phosphatidylserine/NN is/VBZ exposed/VBN by/IN rat/NN vascular/JJ smooth/NN muscle/NN cells/NNS (/( VSMCs/NNS )/) undergoing/VBG apoptosis/NN after/IN serum/NN withdrawal/NN ./. 
In/IN this/DT study/NN ,/, using/VBG a/DT chromogenic/JJ assay/NN ,/, we/PRP have/VBP shown/VBN thrombin/NN generation/NN by/IN apoptotic/JJ VSMCs/NNS expressing/VBG c-myc/NN (/( VSMC-myc/NN )/) with/IN an/DT area/NN under/IN the/DT thrombin-generation/NN curve/NN (/( AUC/NN )/) of/IN 305/CD +/-/CC 17/CD nmol/NN x/CC min/L/NN and/CC a/DT peak/NN thrombin/NN (/( PT/NN )/) of/IN 154/CD +/-/CC 9/CD nmol/L/NN ./. 
The/DT thrombin-generating/JJ potential/NN of/IN the/DT apoptotic/JJ VSMC-myc/NN cells/NNS was/VBD greater/JJR than/IN that/DT of/IN unactivated/JJ platelets/NNS (/( P/NN =/JJ .003/CD for/IN AUC/NN ;/: P/NN =/JJ .0002/NN for/IN PT/NN )/) and/CC similar/JJ to/TO calcium-ionophore/JJ activated/VBN platelets/NNS (/( AUC/NN of/IN 332/CD +/-/CC 15/CD nmol/NN x/NN min/L/NN ,/, P/NN =/JJ .3/NN ;/: PT/NN of/IN 172/CD +/-/CC 8/CD nmol/L/NN ,/, P/NN =/JJ .2/NN )/) ./. 
Thrombin/NN activation/NN was/VBD also/RB seen/VBN with/IN apoptotic/JJ human/JJ VSMCs/NNS (/( AUC/NN of/IN 211/CD +/-/CC 8/CD nmol/NN x/NN min/L/NN ;/: PT/NN of/IN 103/CD +/-/CC 4/CD nmol/L/NN )/) and/CC was/VBD inhibited/VBN by/IN annexin/NN V/NN (/( P/NN </JJR .0001/CD for/IN AUC/NN and/CC PT/NN )/) ./. 
VSMC-myc/JJ cells/NNS maintained/VBN in/IN serum/NN generated/VBD less/RBR thrombin/NN than/IN after/IN serum/NN withdrawal/NN (/( P/NN =/JJ .0002/NN for/IN AUC/NN and/CC PT/NN )/) ./. 
VSMCs/NNS derived/VBN from/IN human/JJ coronary/JJ atherosclerotic/JJ plaques/NNS that/WDT apoptose/VBP even/RB in/IN serum/NN also/RB generated/VBN thrombin/NN (/( AUC/NN of/IN 260/CD +/-/CC 2/CD nmol/NN x/NN min/L/NN ;/: PT/NN of/IN 128/CD +/-/CC 4/CD nmol/L/NN )/) ./. 
We/PRP conclude/VBP that/IN apoptotic/JJ VSMCs/NNS possess/VBP a/DT significant/JJ thrombin-generating/NN capacity/NN secondary/JJ to/TO phosphatidylserine/NN exposure/NN ./. 
Apoptotic/JJ cells/NNS within/IN atherosclerotic/JJ plaques/NNS may/MD allow/VB local/JJ thrombin/NN activation/NN ,/, thereby/RB contributing/VBG to/TO disease/NN progression/NN ./. 
UI/LS -/: 97311087/CD 
TI/LS -/: An/DT isotype-specific/JJ activator/NN of/IN major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II/CD genes/NNS that/WDT is/VBZ independent/JJ of/IN class/NN II/CD transactivator/NN ./. 
AB/LS -/: Patients/NNS with/IN one/CD type/NN of/IN major/JJ histocompatibility/NN complex/NN class/NN II/CD combined/JJ immunodeficiency/NN have/VBP mutations/NNS in/IN a/DT gene/NN termed/VBN class/NN II/CD transactivator/NN (/( CIITA/NN )/) ,/, which/WDT coordinately/RB controls/VBZ the/DT transcription/NN of/IN the/DT three/CD major/JJ human/JJ class/NN II/CD genes/NNS ,/, HLA-DR/NN ,/, -DQ/NN ,/, and/CC -DP/NN ./. 
However/RB ,/, the/DT experimentally/RB derived/VBN B-lymphoblastoid/JJ cell/NN line/NN ,/, clone/NN 13/CD ,/, expresses/VBZ high/JJ levels/NNS of/IN HLADQ/NN in/IN the/DT absence/NN of/IN HLA-DR/NN and/CC HLA-DP/NN ,/, despite/IN its/PRP$ mapping/NN by/IN complementation/NN analysis/NN to/TO this/DT group/NN ./. 
It/PRP was/VBD possible/JJ that/IN one/CD of/IN the/DT clone/NN 13/CD CIITA/NN alleles/NNS bore/VBP a/DT mutation/NN that/WDT allowed/VBD HLA-DQ/NN ,/, but/CC not/RB HLA-DR/NN or/CC -DP/NN transcription/NN ./. 
Alternatively/RB ,/, another/DT factor/NN ,/, distinct/JJ from/IN CIITA/NN ,/, might/MD control/VB HLA-DQ/NN expression/NN ./. 
We/PRP report/VBP here/RB that/IN ectopic/JJ expression/NN of/IN CIITA/NN cDNAs/NNS derived/VBN by/IN reverse/JJ transcriptase/NN polymerase/NN chain/NN reaction/NN from/IN clone/NN 13/CD do/VBP not/RB restore/VB expression/NN of/IN HLA-DQ/NN in/IN another/DT CIITA-deficient/JJ cell/NN line/NN ,/, RJ2.2.5/NN ./. 
In/IN addition/NN ,/, no/DT CIITA/NN protein/NN is/VBZ detectable/JJ in/IN clone/NN 13/CD nuclear/JJ extracts/NNS ./. 
In/IN contrast/NN ,/, somatic/JJ cell/NN fusion/NN between/IN clone/NN 13/CD and/CC RJ2.2.5/NN restored/VBD expression/NN of/IN the/DT HLA-DQ/NN haplotype/NN encoded/VBN by/IN the/DT RJ2.2.5/NN DQB/NN gene/NN ./. 
Taken/VBN together/RB ,/, these/DT data/NNS demonstrate/VBP the/DT existence/NN of/IN an/DT HLA-DQ/NN isotype-specific/JJ trans-acting/JJ factor/NN ,/, which/WDT functions/VBZ independently/RB of/IN CIITA/NN ./. 
UI/LS -/: 97303223/CD 
TI/LS -/: Homodimerization/NN of/IN the/DT human/JJ interleukin/NN 4/CD receptor/NN alpha/NN chain/NN induces/VBZ Cepsilon/NN germline/NN transcripts/NNS in/IN B/NN cells/NNS in/IN the/DT absence/NN of/IN the/DT interleukin/NN 2/CD receptor/NN gamma/NN chain/NN ./. 
AB/LS -/: The/DT cytokines/NNS interleukin/NN (/( IL/NN )/) -4/CD and/CC IL-13/NN play/VBP a/DT critical/JJ role/NN in/IN inducing/VBG Cepsilon/NN germline/NN transcripts/NNS and/CC IgE/NN isotype/NN switching/NN in/IN human/JJ B/NN cells/NNS ./. 
The/DT IL-4/NN receptor/NN (/( IL-4R/NN )/) in/IN B/NN cells/NNS is/VBZ composed/VBN of/IN two/CD chains/NNS ,/, the/DT IL-4-binding/JJ IL-4Ralpha/NN chain/NN ,/, which/WDT is/VBZ shared/VBN with/IN the/DT IL-13R/NN ,/, and/CC the/DT IL-2Rgamma/NN (/( gammac/NN )/) chain/NN ,/, which/WDT is/VBZ shared/VBN with/IN IL-7R/NN ,/, IL-9R/NN ,/, and/CC IL-15R/NN ./. 
IL-4/NN induces/VBZ Cepsilon/NN germline/NN transcripts/NNS and/CC IgE/NN isotype/NN switching/NN in/IN B/NN cells/NNS from/IN patients/NNS with/IN gammac/NN chain/NN deficiency/NN ./. 
Induction/NN of/IN Cepsilon/NN germline/NN transcripts/NNS by/IN IL-4/NN in/IN B/NN cells/NNS that/WDT lack/VBP the/DT gammac/NN chain/NN may/MD involve/VB signaling/NN via/IN the/DT IL-13R/NN ./. 
Alternatively/RB ,/, the/DT IL-4Ralpha/NN chain/NN may/MD transduce/VB intracellular/JJ signals/NNS that/WDT lead/VBP to/TO Cepsilon/NN gene/NN transcription/NN independently/RB of/IN its/PRP$ association/NN with/IN other/JJ chains/NNS ./. 
We/PRP show/VBP that/IN ligand-induced/JJ homodimerization/NN of/IN chimeric/JJ surface/NN receptors/NNS consisting/VBG of/IN the/DT extracellular/JJ and/CC transmembrane/JJ domains/NNS of/IN the/DT erythropoietin/NN receptor/NN and/CC of/IN the/DT intracellular/JJ domain/NN of/IN IL-4Ralpha/NN induces/VBZ Janus/NN kinase/NN 1/CD (/( Jak1/NN )/) activation/NN ,/, STAT6/NN activation/NN ,/, and/CC Cepsilon/NN germline/NN transcripts/NNS in/IN human/JJ B/NN cell/NN line/NN BJAB/NN ./. 
Disruption/NN of/IN the/DT Jak1-binding/JJ proline-rich/JJ Box1/NN region/NN of/IN IL-4Ralpha/NN abolished/VBD signaling/NN by/IN this/DT chimeric/JJ receptor/NN ./. 
Furthermore/RB ,/, B/NN cells/NNS transfected/VBN with/IN a/DT chimeric/JJ CD8alpha/IL-4Ralpha/NN receptor/NN ,/, which/WDT is/VBZ expressed/VBN on/IN the/DT cell/NN surface/NN as/IN a/DT homodimer/NN ,/, constitutively/RB expressed/VBD Cepsilon/NN germline/NN transcripts/NNS ./. 
These/DT results/NNS suggest/VBP that/IN homodimerization/NN of/IN the/DT IL-4Ralpha/NN chain/NN is/VBZ sufficient/JJ to/TO transduce/VB Jak1-dependent/JJ intracellular/JJ signals/NNS that/WDT lead/VBP to/TO IgE/NN isotype/NN switching/NN ./. 
UI/LS -/: 97324097/CD 
TI/LS -/: Transcriptional/JJ activity/NN and/CC constitutive/JJ nuclear/JJ localization/NN of/IN the/DT ETS/NN protein/NN Elf-1/NN ./. 
AB/LS -/: Elf-1/NN is/VBZ a/DT lymphoid-specific/JJ transcription/NN factor/NN that/WDT belongs/VBZ to/TO the/DT ETS/NN protein/NN family/NN ./. 
It/PRP can/MD bind/VB to/TO DNA/NN target/NN sequences/NNS within/IN a/DT variety/NN of/IN cytokine/NN genes/NNS ./. 
We/PRP demonstrate/VBP that/IN Elf-1/NN is/VBZ constitutively/RB localized/JJ in/IN the/DT nucleus/NN which/WDT is/VBZ dependent/JJ on/IN the/DT presence/NN of/IN amino/NN acids/NNS 86-265/CD ./. 
Analysis/NN of/IN Gal4-Elf-1/NN fusion/NN proteins/NNS revealed/VBD that/IN the/DT N-terminal/JJ 86/CD amino/NN acids/NNS of/IN Elf-1/NN contain/VBP a/DT transcriptional/JJ activation/NN domain/NN ,/, the/DT activity/NN of/IN which/WDT is/VBZ attenuated/VBN by/IN an/DT internal/JJ repression/NN domain/NN ./. 
Furthermore/RB ,/, Elf-1/NN interacts/VBZ specifically/RB with/IN the/DT E74/NN target/NN sequence/NN and/CC can/MD stimulate/VB transcription/NN driven/VBN by/IN the/DT E74/NN site/NN independent/JJ of/IN mitogenic/JJ signaling/NN ./. 
Thus/RB ,/, Elf-1/NN is/VBZ able/JJ to/TO stimulate/VB gene/NN transcription/NN which/WDT may/MD be/VB required/VBN for/IN the/DT development/NN and/CC activity/NN of/IN lymphocytes/NNS ./. 
UI/LS -/: 97304524/CD 
TI/LS -/: Characterization/NN of/IN peripheral/JJ blood/NN T-lymphocytes/NNS transduced/VBN with/IN HTLV-I/NN Tax/NN mutants/NNS with/IN different/JJ trans-activating/JJ phenotypes/NNS ./. 
AB/LS -/: Tax1/NN ,/, a/DT transcriptional/JJ trans-activator/NN of/IN the/DT Human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) ,/, induces/VBZ the/DT expression/NN of/IN many/JJ cellular/JJ genes/NNS through/IN interaction/NN with/IN at/IN least/JJS three/CD distinct/JJ cellular/JJ transcription/NN factors/NNS ;/: CREB/ATF/NN ,/, NF-kappaB/NN ,/, and/CC SRF/NN ./. 
This/DT Tax1-induced/JJ activation/NN of/IN cellular/JJ genes/NNS is/VBZ considered/VBN to/TO be/VB a/DT critical/JJ event/NN in/IN T-cell/NN transformation/NN by/IN HTLV-I/NN ./. 
To/TO elucidate/VB the/DT role/NN of/IN each/DT Tax1-inducible/JJ transcriptional/JJ pathway/NN in/IN T-cell/NN transformation/NN ,/, we/PRP introduced/VBD Tax1/NN mutants/NNS with/IN different/JJ trans-activating/JJ phenotypes/NNS into/IN peripheral/JJ blood/NN lymphocytes/NNS (/( PBL/NNS )/) by/IN retroviral/JJ vectors/NNS ./. 
Analysis/NN of/IN these/DT PBLs/NNS revealed/VBD that/IN activation/NN of/IN the/DT NF-kappaB/NN pathway/NN is/VBZ sufficient/JJ to/TO promote/VB the/DT growth/NN response/NN to/TO IL-2/NN ./. 
However/RB ,/, for/IN the/DT clonal/JJ expansion/NN of/IN CD4+/JJ T-cells/NNS ,/, which/WDT is/VBZ a/DT characteristic/JJ result/NN of/IN HTLV-I/NN infection/NN ,/, activation/NN of/IN the/DT CREB/ATF/NN and/CC SRF/NN pathways/NNS is/VBZ also/RB required/VBN ./. 
UI/LS -/: 97419190/CD 
TI/LS -/: Epstein-Barr/JJ virus/NN binding/VBG to/TO CD21/NN activates/VBZ the/DT initial/JJ viral/JJ promoter/NN via/IN NF-kappaB/NN induction/NN ./. 
AB/LS -/: Epstein-Barr/JJ virus/NN (/( EBV/NN )/) ,/, an/DT oncogenic/JJ human/JJ herpesvirus/NN ,/, binds/VBZ to/TO and/CC infects/VBZ normal/JJ human/JJ B/NN lymphocytes/NNS via/IN CD21/NN ,/, the/DT CR2/NN complement/NN receptor/NN ./. 
Studies/NNS of/IN the/DT mechanisms/NNS that/WDT enable/VBP EBV/NN to/TO infect/VB nonactivated/JJ ,/, noncycling/JJ B/NN cells/NNS provide/VBP compelling/JJ evidence/NN for/IN a/DT sequence/NN of/IN events/NNS in/IN which/WDT EBV/NN binding/VBG to/TO CD21/NN on/IN purified/VBN resting/VBG human/JJ B/NN cells/NNS rapidly/RB activates/VBZ the/DT NF-kappaB/NN transcription/NN factor/NN ,/, which/WDT ,/, in/IN turn/NN ,/, binds/VBZ to/TO and/CC mediates/VBZ transcriptional/JJ activation/NN of/IN Wp/NN ,/, the/DT initial/JJ viral/JJ latent/JJ gene/NN promoter/NN ./. 
Thus/RB ,/, EBV/NN binding/VBG to/TO its/PRP$ cellular/JJ receptor/NN on/IN resting/VBG B/NN cells/NNS triggers/VBZ an/DT NF-kappaB-dependent/JJ intracellular/JJ signaling/NN pathway/NN which/WDT is/VBZ required/VBN for/IN infection/NN ./. 
UI/LS -/: 97402252/CD 
TI/LS -/: Synthetic/JJ glucocorticoids/NNS that/WDT dissociate/VBP transactivation/NN and/CC AP-1/NN transrepression/NN exhibit/VBP antiinflammatory/JJ activity/NN in/FW vivo/FW ./. 
AB/LS -/: Some/DT of/IN the/DT most/RBS potent/JJ antiinflammatory/JJ and/CC immunosuppressive/JJ agents/NNS are/VBP synthetic/JJ glucocorticoids/NNS ./. 
However/RB ,/, major/JJ side/NN effects/NNS severely/RB limit/VBP their/PRP$ therapeutic/JJ use/NN ./. 
The/DT development/NN of/IN improved/JJ glucocorticoid-based/JJ drugs/NNS will/MD require/VB the/DT separation/NN of/IN beneficial/JJ from/IN deleterious/JJ effects/NNS ./. 
One/CD possibility/NN toward/IN this/DT goal/NN is/VBZ to/TO try/VB to/TO dissociate/VB two/CD main/JJ activities/NNS of/IN glucocorticoids/NNS ,/, i.e./FW transactivation/NN and/CC transrepression/NN ./. 
Screening/NN of/IN a/DT library/NN of/IN compounds/NNS using/VBG transactivation/NN and/CC AP-1/NN transrepression/NN models/NNS in/IN transiently/RB transfected/VBN cells/NNS identified/VBD dissociated/VBN glucocorticoids/NNS ,/, which/WDT exert/VBP strong/JJ AP-1/NN inhibition/NN but/CC little/JJ or/CC no/DT transactivation/NN ./. 
Importantly/RB ,/, despite/IN high/JJ ligand/NN binding/NN affinity/NN ,/, the/DT prototypic/JJ dissociated/VBN compound/NN ,/, RU24858/NN ,/, acted/VBD as/IN a/DT weak/JJ agonist/NN and/CC did/VBD not/RB efficiently/RB antagonize/VB dexamethasone-induced/JJ transcription/NN in/IN transfected/VBN cells/NNS ./. 
Similar/JJ results/NNS were/VBD obtained/VBN in/IN hepatic/JJ HTC/NN cells/NNS for/IN the/DT transactivation/NN of/IN the/DT endogenous/JJ tyrosine/NN amino/NN transferase/NN gene/NN (/( TAT/NN )/) ,/, which/WDT encodes/VBZ one/CD of/IN the/DT enzymes/NNS involved/VBN in/IN the/DT glucocorticoid-dependent/JJ stimulation/NN of/IN neoglucogenesis/NN ./. 
To/TO investigate/VB whether/IN dissociated/VBN glucocorticoids/NNS retained/VBD the/DT antiinflammatory/JJ and/CC immunosuppressive/JJ potential/NN of/IN classic/JJ glucocorticoids/NNS ,/, several/JJ in/FW vitro/FW and/CC in/FW vivo/FW models/NNS were/VBD used/VBN ./. 
Indeed/RB ,/, secretion/NN of/IN the/DT proinflammatory/JJ lymphokine/NN interleukin-1beta/NN was/VBD severely/RB inhibited/VBN by/IN dissociated/VBN glucocorticoids/NNS in/IN human/JJ monocytic/JJ THP/NN 1/CD cells/NNS ./. 
Moreover/RB ,/, in/IN two/CD in/FW vivo/FW models/NNS ,/, these/DT compounds/NNS exerted/VBD an/DT antiinflammatory/JJ and/CC immunosuppressive/JJ activity/NN as/IN potent/JJ as/IN that/DT of/IN the/DT classic/JJ glucocorticoid/NN prednisolone/NN ./. 
These/DT results/NNS may/MD lead/VB to/TO an/DT improvement/NN of/IN antiinflammatory/JJ and/CC immunosuppressive/JJ therapies/NNS and/CC provide/VB a/DT novel/JJ concept/NN for/IN drug/NN discovery/NN ./. 
UI/LS -/: 97376853/CD 
TI/LS -/: In/FW vivo/FW footprinting/NN and/CC mutational/JJ analysis/NN of/IN the/DT proximal/JJ CD19/NN promoter/NN reveal/VBP important/JJ roles/NNS for/IN an/DT SP1/Egr-1/NN binding/NN site/NN and/CC a/DT novel/JJ site/NN termed/VBN the/DT PyG/NN box/NN ./. 
AB/LS -/: CD19/NN expression/NN begins/VBZ at/IN the/DT pro-B/JJ cell/NN stage/NN of/IN B/NN cell/NN development/NN ./. 
As/IN such/JJ it/PRP serves/VBZ as/IN a/DT good/JJ prototype/NN for/IN B/NN cell-specific/JJ genes/NNS whose/WP$ expression/NN begins/VBZ shortly/RB after/IN lineage/NN commitment/NN ./. 
To/TO understand/VB the/DT molecular/JJ mechanisms/NNS controlling/VBG CD19/NN gene/NN expression/NN ,/, we/PRP isolated/VBD and/CC functionally/RB characterized/VBD the/DT CD19/NN promoter/NN using/VBG in/FW vivo/FW footprinting/NN ,/, gel/NN shift/NN assays/NNS ,/, and/CC transfection/NN studies/NNS ./. 
Reporter/NN constructs/NNS spanning/VBG portions/NNS of/IN the/DT promoter/NN identified/VBD a/DT region/NN between/IN -85/CD and/CC -200/CD that/WDT produced/VBD high/JJ levels/NNS of/IN reporter/NN gene/NN activity/NN in/IN lymphoid/JJ cells/NNS ./. 
In/FW vivo/FW footprinting/NN identified/VBD protected/JJ regions/NNS over/IN the/DT known/JJ high/JJ affinity/NN B/NN cell/NN lineage-specific/JJ activator/NN protein/NN (/( BSAP/NN )/) site/NN ,/, the/DT low/JJ affinity/NN BSAP/NN site/NN ,/, a/DT SP1/Egr-1/NN site/NN termed/VBN the/DT CD19/NN GC/NN box/NN ,/, and/CC two/CD novel/JJ sites/NNS named/VBN the/DT AT/NN box/NN and/CC PyG/NN box/NN ./. 
Phorbol/NN ester/NN treatment/NN of/IN a/DT pre-B/JJ cell/NN line/NN up-regulated/VBD CD19/NN expression/NN ,/, induced/VBD Egr-1/NN ,/, and/CC enhanced/VBD the/DT footprint/NN over/IN the/DT GC/NN box/NN ./. 
Gel/NN shift/NN assays/NNS demonstrated/VBD SP1/NN and/CC Egr-1/NN binding/VBG to/TO the/DT CD19/NN GC/NN box/NN ,/, while/IN unknown/JJ nuclear/JJ proteins/NNS bound/VBD the/DT PyG/NN and/CC AT/NN boxes/NNS ./. 
Mutations/NNS in/IN the/DT AT/NN box/NN or/CC in/IN the/DT BSAP/NN sites/NNS did/VBD not/RB affect/VB CD19/NN reporter/NN construct/NN activity/NN ,/, while/IN a/DT mutation/NN of/IN the/DT GC/NN box/NN reduced/VBD it/PRP modestly/RB ,/, and/CC a/DT PyG/NN box/NN mutation/NN reduced/VBD it/PRP dramatically/RB ./. 
BSAP/NN failed/VBD to/TO trans-activate/VB CD19/NN promoter/NN constructs/NNS in/IN B/NN cells/NNS or/CC non-B/JJ cells/NNS ,/, suggesting/VBG that/IN cis/JJ elements/NNS such/JJ as/IN the/DT PyG/NN and/CC GC/NN boxes/NNS are/VBP also/RB necessary/JJ for/IN high/JJ level/NN CD19/NN promoter/NN expression/NN ./. 
UI/LS -/: 97394399/CD 
TI/LS -/: EBF/NN and/CC E47/NN collaborate/VBP to/TO induce/VB expression/NN of/IN the/DT endogenous/JJ immunoglobulin/NN surrogate/JJ light/JJ chain/NN genes/NNS ./. 
AB/LS -/: Early/JJ B/NN cell/NN factor/NN (/( EBF/NN )/) and/CC E47/NN participate/VBP in/IN the/DT transcriptional/JJ control/NN of/IN early/JJ B/NN lymphocyte/NN differentiation/NN ./. 
With/IN the/DT aim/NN of/IN identifying/VBG genetic/JJ targets/NNS for/IN these/DT transcription/NN factors/NNS ,/, we/PRP stably/RB transfected/VBD cDNAs/NNS encoding/VBG EBF/NN or/CC a/DT covalent/JJ homodimer/NN of/IN E47/NN ,/, individually/RB or/CC together/RB ,/, into/IN immature/JJ hematopoietic/JJ Ba/F3/NN cells/NNS ,/, which/WDT lack/VBP both/DT factors/NNS ./. 
In/IN combination/NN ,/, EBF/NN and/CC E47/NN induce/VBP efficient/JJ expression/NN of/IN the/DT endogenous/JJ immunoglobulin/NN surrogate/JJ light/JJ chain/NN genes/NNS ,/, lambda5/NN and/CC VpreB/NN ,/, whereas/IN other/JJ pre-B/JJ cell-specific/JJ genes/NNS remain/VBP silent/JJ ./. 
Multiple/JJ functionally/RB important/JJ EBF/NN and/CC E47/NN binding/NN sites/NNS were/VBD identified/VBN in/IN the/DT lambda5/NN promoter/enhancer/NN region/NN ,/, indicating/VBG that/IN lambda5/NN is/VBZ a/DT direct/JJ genetic/JJ target/NN for/IN these/DT transcription/NN factors/NNS ./. 
Taken/VBN together/RB ,/, these/DT data/NNS suggest/VBP that/IN EBF/NN and/CC E47/NN synergize/VBP to/TO activate/VB expression/NN of/IN a/DT subset/NN of/IN genes/NNS that/WDT define/VBP an/DT early/JJ stage/NN of/IN the/DT B/NN cell/NN lineage/NN ./. 
UI/LS -/: 97362375/CD 
TI/LS -/: Cytokines/NNS :/: shared/JJ receptors/NNS ,/, distinct/JJ functions/NNS ./. 
AB/LS -/: That/IN the/DT signal/NN transduction/NN pathways/NNS used/VBN by/IN the/DT cytokines/NNS IL-2/NN and/CC IL-15/NN are/VBP identical/JJ would/MD suggest/VBP that/IN these/DT cytokines/NNS have/VBP redundant/JJ roles/NNS in/IN lymphoid/JJ development/NN ;/: instead/RB ,/, IL-2/NN is/VBZ the/DT guardian/NN of/IN thymus-derived/JJ T-cell/NN homeostasis/NN ,/, while/IN interleukin-15/NN promotes/VBZ extrathymic/JJ development/NN of/IN T/NN and/CC NK/NN cells/NNS ./. 
UI/LS -/: 97334241/CD 
TI/LS -/: The/DT IL-4/NN receptor/NN alpha-chain/NN cytoplasmic/JJ domain/NN is/VBZ sufficient/JJ for/IN activation/NN of/IN JAK-1/NN and/CC STAT6/NN and/CC the/DT induction/NN of/IN IL-4-specific/JJ gene/NN expression/NN ./. 
AB/LS -/: The/DT common/JJ gamma-chain/NN (/( gamma(c)/NN )/) is/VBZ a/DT functional/JJ component/NN of/IN the/DT IL-4R/NN ,/, yet/RB cells/NNS lacking/VBG gamma(c)/NN are/VBP able/JJ to/TO respond/VB to/TO IL-4/NN ./. 
This/DT has/VBZ led/VBN to/TO the/DT suggestion/NN that/IN a/DT surrogate/JJ gamma'-chain/NN ,/, which/WDT can/MD interact/VB with/IN the/DT IL-4R/NN alpha/NN chain/NN to/TO mediate/VB signaling/NN ,/, is/VBZ expressed/VBN on/IN cells/NNS lacking/VBG gamma(c)/NN ./. 
An/DT alternative/JJ possibility/NN is/VBZ that/IN in/IN the/DT absence/NN of/IN gamma(c)/NN ,/, the/DT IL-4R/NN alpha/NN chain/NN is/VBZ able/JJ to/TO transduce/VB signals/NNS by/IN homodimerization/NN ./. 
To/TO test/VB this/DT latter/JJ possibility/NN ,/, a/DT chimeric/JJ receptor/NN containing/VBG the/DT extracellular/JJ domain/NN of/IN c-kit/NN (/( the/DT stem/NN cell/NN factor/NN (/( SCF/NN )/) receptor/NN )/) and/CC the/DT cytoplasmic/JJ and/CC transmembrane/JJ domains/NNS of/IN the/DT IL-4R/NN alpha/NN chain/NN was/VBD generated/VBN ./. 
Treatment/NN of/IN cells/NNS expressing/VBG the/DT chimeric/JJ receptor/NN kit/IL-4R/NN alpha/NN with/IN SCF/NN induces/VBZ activation/NN of/IN the/DT IL-4R/NN alpha-associated/JJ kinase/NN JAK-1/NN and/CC the/DT transcription/NN factor/NN STAT6/NN ./. 
However/RB ,/, tyrosine/NN phosphorylation/NN of/IN JAK-3/NN ,/, which/WDT associates/VBZ with/IN gamma(c)/NN ,/, is/VBZ not/RB induced/VBN by/IN SCF/NN in/IN these/DT cells/NNS ./. 
SCF-mediated/JJ ligation/NN of/IN kit/IL-4R/NN alpha/NN is/VBZ sufficient/JJ to/TO elicit/VB IL-4-specific/JJ gene/NN expression/NN ,/, including/VBG up-regulation/NN of/IN CD23/NN and/CC synthesis/NN of/IN germ-line/NN epsilon/NN transcripts/NNS ./. 
In/IN the/DT T/NN cell/NN line/NN CTLL2/NN ,/, ligation/NN of/IN kit/IL-4R/NN alpha/NN induces/VBZ cellular/JJ proliferation/NN ./. 
Finally/RB ,/, in/IN JAK-1-deficient/JJ HeLa/NN cells/NNS ,/, STAT6/NN activation/NN by/IN IL-4/NN is/VBZ completely/RB abolished/VBN ./. 
Together/RB ,/, these/DT data/NNS demonstrate/VBP that/IN the/DT IL-4R/NN alpha/NN cytoplasmic/JJ domain/NN is/VBZ sufficient/JJ to/TO activate/VB JAK-1/NN and/CC STAT6/NN and/CC to/TO induce/VB expression/NN of/IN IL-4/NN target/NN genes/NNS ,/, thus/RB identifying/VBG a/DT mechanism/NN by/IN which/WDT IL-4/NN signaling/NN can/MD proceed/VB in/IN the/DT absence/NN of/IN JAK-3/NN and/CC gamma(c)/NN ./. 
UI/LS -/: 97330829/CD 
TI/LS -/: Histamine/NN modulates/VBZ the/DT expression/NN of/IN c-fos/NN through/IN cyclic/JJ AMP/NN production/NN via/IN the/DT H2/NN receptor/NN in/IN the/DT human/JJ promonocytic/JJ cell/NN line/NN U937/NN ./. 
AB/LS -/: We/PRP examined/VBD the/DT effects/NNS of/IN histamine/NN and/CC its/PRP$ agonists/NNS on/IN the/DT expression/NN of/IN the/DT c-fos/NN and/CC c-myc/NN proto-oncogenes/NNS at/IN the/DT transcriptional/JJ and/CC translational/JJ levels/NNS in/IN the/DT human/JJ promonocytic/JJ U937/NN cell/NN line/NN ./. 
Histamine/NN transiently/RB increased/VBD cAMP/NN and/CC c-fos/NN expression/NN through/IN H2/NN receptors/NNS ./. 
Dibutyryl/NN cAMP/NN also/RB increased/VBD c-fos/NN mRNA/NN and/CC protein/NN ,/, and/CC levels/NNS remained/VBD elevated/JJ even/RB after/IN 12/CD hr/NN of/IN treatment/NN ./. 
Dose-dependence/JJ studies/NNS using/VBG histamine/NN and/CC dimaprit/NN showed/VBD that/IN the/DT EC50/NN values/NNS for/IN cAMP/NN production/NN and/CC c-fos/NN increase/NN were/VBD similar/JJ ,/, suggesting/VBG that/IN cAMP/NN might/MD be/VB involved/VBN in/IN c-fos/NN induction/NN via/IN H2/NN receptors/NNS ./. 
Furthermore/RB ,/, studies/NNS carried/VBD out/IN using/VBG H7/NN ,/, a/DT protein/NN kinase/NN A/protein/NN kinase/NN C/NN inhibitor/NN ,/, blocked/VBD c-fos/NN induction/NN ,/, whereas/IN no/DT effect/NN was/VBD observed/VBN with/IN bisindolylmaleimide/NN ,/, a/DT specific/JJ protein/NN kinase/NN C/NN inhibitor/NN ./. 
No/DT modification/NN of/IN c-myc/NN expression/NN could/MD be/VB detected/VBN on/IN treatment/NN with/IN histamine/NN or/CC its/PRP$ analogues/NNS ./. 
Nevertheless/RB ,/, dibutyryl/JJ cAMP/NN induced/VBD a/DT down-regulation/NN of/IN the/DT levels/NNS of/IN this/DT proto-oncogene/NN ./. 
In/IN addition/NN ,/, dibutyryl/JJ cAMP/NN inhibited/VBD cell/NN growth/NN in/IN a/DT dose-dependent/JJ manner/NN ,/, whereas/IN histamine/NN failed/VBD to/TO affect/VB proliferation/NN and/CC differentiation/NN of/IN U937/NN cells/NNS ./. 
Cells/NNS pretreated/JJ with/IN dimaprit/NN showed/VBD a/DT decrease/NN in/IN the/DT cAMP/NN response/NN to/TO subsequent/JJ addition/NN of/IN H2/NN agonists/NNS ,/, whereas/IN the/DT cAMP/NN response/NN to/TO prostaglandin/NN E2/NN remained/VBD unaltered/JJ ./. 
This/DT homologous/JJ mechanism/NN of/IN H2/NN receptor/NN desensitization/NN was/VBD time/NN dependent/JJ ./. 
These/DT results/NNS indicate/VBP that/IN histamine/NN activates/VBZ several/JJ mechanisms/NNS involved/VBN in/IN the/DT induction/NN of/IN differentiation/NN ,/, such/JJ as/IN cAMP/NN and/CC c-fos/NN production/NN ,/, but/CC fails/VBZ to/TO promote/VB differentiation/NN of/IN U937/NN cells/NNS ,/, apparently/RB due/JJ to/TO the/DT rapid/JJ desensitization/NN of/IN H2/NN receptors/NNS ./. 
UI/LS -/: 97314059/CD 
TI/LS -/: Induction/NN of/IN cytokine/NN expression/NN in/IN leukocytes/NNS by/IN binding/NN of/IN thrombin-stimulated/JJ platelets/NNS ./. 
AB/LS -/: BACKGROUND/NN :/: Activated/VBN platelets/NNS tether/VBP and/CC activate/VBP myeloid/JJ leukocytes/NNS ./. 
To/TO investigate/VB the/DT potential/JJ relevance/NN of/IN this/DT mechanism/NN in/IN acute/JJ myocardial/JJ infarction/NN (/( AMI/NN )/) ,/, we/PRP examined/VBD cytokine/NN induction/NN by/IN leukocyte-platelet/JJ adhesion/NN and/CC the/DT occurrence/NN of/IN leukocyte-platelet/JJ conjugates/NNS in/IN patients/NNS with/IN AMI/NN ./. 
METHODS/NNS AND/CC RESULTS/NNS :/: We/PRP obtained/VBD peripheral/JJ venous/JJ blood/NN samples/NNS in/IN 20/CD patients/NNS with/IN AMI/NN before/IN and/CC daily/RB for/IN 5/CD days/NNS after/IN direct/JJ percutaneous/JJ transluminal/JJ coronary/JJ angioplasty/NN (/( PTCA/NN )/) and/CC in/IN 20/CD patients/NNS undergoing/VBG elective/JJ PTCA/NN ./. 
Throughout/IN the/DT study/NN period/NN ,/, CD41/NN immunofluorescence/NN of/IN leukocytes/NNS (/( flow/NN cytometry/NN )/) revealed/VBD increased/VBN leukocyte-platelet/JJ adhesion/NN in/IN patients/NNS with/IN AMI/NN compared/VBN with/IN control/JJ patients/NNS (/( mean/NN +/-/CC SE/NN of/IN fluorescence/NN [/( channels/NNS ]/) before/IN PTCA/NN :/: 77/CD +/-/CC 16/CD versus/CC 35/CD +/-/CC 9/CD ;/: P/NN =/JJ .003/CD )/) ./. 
In/FW vitro/FW ,/, thrombin-stimulated/JJ fixed/JJ platelets/NNS bound/VBD to/TO neutrophils/NNS and/CC monocytes/NNS ./. 
Within/IN 2/CD hours/NNS ,/, this/DT resulted/VBD in/IN increased/VBN mRNA/NN for/IN interleukin/NN (/( IL/NN )/) ,/, 1/CD beta/NN ,/, IL-8/NN ,/, and/CC monocyte/NN chemoattractant/NN protein/NN (/( MCP/NN )/) -1/CD in/IN unfractionated/JJ leukocytes/NNS ./. 
After/IN 4/CD hours/NNS ,/, IL-1/NN beta/NN and/CC IL-8/NN concentration/NN of/IN the/DT cell-free/JJ supernatant/NN had/VBD increased/VBN by/IN 268/CD +/-/CC 36/CD %/NN and/CC 210/CD +/-/CC 7/CD %/NN ,/, respectively/RB ,/, and/CC cellular/JJ MCP-1/NN content/NN had/VBD increased/VBN by/IN 170/CD +/-/CC 8/CD %/NN ./. 
Addition/NN of/IN activated/VBN platelets/NNS to/TO adherent/JJ monocytes/NNS had/VBD a/DT similar/JJ effect/NN and/CC was/VBD associated/VBN with/IN nuclear/JJ factor-kappa/NN B/NN activation/NN ./. 
Inhibition/NN of/IN binding/NN by/IN anti-P/JJ selectin/NN antibodies/NNS reduced/VBD the/DT effect/NN of/IN activated/VBN platelets/NNS on/IN cytokine/NN production/NN ./. 
CONCLUSIONS/NNS :/: In/IN patients/NNS with/IN AMI/NN ,/, leukocyte-platelet/JJ adhesion/NN is/VBZ increased/VBN ./. 
Binding/NN of/IN activated/VBN platelets/NNS induces/VBZ IL-1/NN beta/NN ,/, IL-8/NN ,/, and/CC MCP-1/NN in/IN leukocytes/NNS ./. 
Our/PRP$ findings/NNS suggest/VBP that/IN leukocyte-platelet/JJ adhesion/NN contributes/VBZ to/TO the/DT regulation/NN of/IN inflammatory/JJ responses/NNS in/IN AMI/NN ./. 
UI/LS -/: 97296314/CD 
TI/LS -/: Immediate/JJ early/JJ and/CC early/JJ lytic/JJ cycle/NN proteins/NNS are/VBP frequent/JJ targets/NNS of/IN the/DT Epstein-Barr/JJ virus-induced/JJ cytotoxic/JJ T/NN cell/NN response/NN ./. 
AB/LS -/: Epstein-Barr/JJ virus/NN (/( EBV/NN )/) ,/, a/DT human/JJ gamma-herpesvirus/NN ,/, can/MD establish/VB both/CC nonproductive/JJ (/( latent/JJ )/) and/CC productive/JJ (/( lytic/JJ )/) infections/NNS ./. 
Although/IN the/DT CD8+/JJ cytotoxic/JJ T/NN lymphocyte/NN (/( CTL/NN )/) response/NN to/TO latently/RB infected/JJ cells/NNS is/VBZ well/RB characterized/VBN ,/, very/RB little/JJ is/VBZ known/VBN about/IN T/NN cell/NN controls/NNS over/IN lytic/JJ infection/NN ;/: this/DT imbalance/NN in/IN our/PRP$ understanding/NN belies/VBZ the/DT importance/NN of/IN virus-replicative/JJ lesions/NNS in/IN several/JJ aspects/NNS of/IN EBV/NN disease/NN pathogenesis/NN ./. 
The/DT present/JJ work/NN shows/VBZ that/IN the/DT primary/JJ CD8+/JJ CTL/NN response/NN to/TO EBV/NN in/IN infectious/JJ mononucleosis/NN patients/NNS contains/VBZ multiple/JJ lytic/JJ antigen-specific/JJ reactivities/NNS at/IN levels/NNS at/IN least/JJS as/RB high/JJ as/IN those/DT seen/VBN against/IN latent/JJ antigens/NNS ;/: similar/JJ reactivities/NNS are/VBP also/RB detectable/JJ in/IN CTL/NN memory/NN ./. 
Clonal/JJ analysis/NN revealed/VBD individual/JJ responses/NNS to/TO the/DT two/CD immediate/JJ early/JJ proteins/NNS BZLF1/NN and/CC BRLF1/NN ,/, and/CC to/TO three/CD (/( BMLF1/NN ,/, BMRF1/NN ,/, and/CC BALF2/NN )/) of/IN the/DT six/CD early/JJ proteins/NNS tested/VBN ./. 
In/IN several/JJ cases/NNS ,/, the/DT peptide/NN epitope/NN and/CC HLA-restricting/JJ determinant/NN recognized/VBN by/IN these/DT CTLs/NNS has/VBZ been/VBN defined/VBN ,/, one/CD unusual/JJ feature/NN being/VBG the/DT number/NN of/IN responses/NNS restricted/JJ through/IN HLA-C/NN alleles/NNS ./. 
The/DT work/NN strongly/RB suggests/VBZ that/IN EBV-replicative/JJ lesions/NNS are/VBP subject/JJ to/TO direct/JJ CTL/NN control/NN in/FW vivo/FW and/CC that/IN immediate/JJ early/JJ and/CC early/JJ proteins/NNS are/VBP frequently/RB the/DT immunodominant/JJ targets/NNS ./. 
This/DT contrasts/VBZ with/IN findings/NNS in/IN alpha-/NN and/CC beta-herpesvirus/NN systems/NNS (/( herpes/NN simplex/NN ,/, cytomegalovirus/NN )/) where/WRB viral/JJ interference/NN with/IN the/DT antigen-processing/JJ pathway/NN during/IN lytic/JJ infection/NN renders/VBZ immediate/JJ early/JJ and/CC early/JJ proteins/NNS much/RB less/RBR immunogenic/JJ ./. 
The/DT unique/JJ capacity/NN of/IN gamma-herpesvirus/NN to/TO amplify/VB the/DT viral/JJ load/NN in/FW vivo/FW through/IN a/DT latent/JJ growth-transforming/JJ infection/NN may/MD have/VB rendered/VBN these/DT agents/NNS less/RBR dependent/JJ upon/IN viral/JJ replication/NN as/IN a/DT means/NN of/IN successfully/RB colonizing/VBG their/PRP$ hosts/NNS ./. 
UI/LS -/: 97294025/CD 
TI/LS -/: Triggering/NN of/IN HLA-DR/NN antigens/NNS differentially/RB modulates/VBZ tumor/NN necrosis/NN factor/NN alpha/NN release/NN by/IN B/NN cells/NNS at/IN distinct/JJ stage/NN of/IN maturation/NN ./. 
AB/LS -/: Triggering/NN of/IN HLA/NN class/NN II/CD antigens/NNS by/IN the/DT anti-HLA-DR/JJ monoclonal/JJ antibody/NN (/( mAb/NN )/) L243/NN significantly/RB (/( P/NN </JJR 0.05/CD )/) and/CC differentially/RB enhanced/VBD the/DT release/NN of/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) by/IN the/DT non-Hodgkin/JJ 's/POS lymphoma/NN cells/NNS Ri-I/NN ,/, Ci-I/NN ,/, and/CC Sc-I/NN ,/, which/WDT are/VBP at/IN a/DT distinct/JJ stage/NN of/IN B-cell/NN differentiation/NN ,/, and/CC by/IN the/DT more/RBR mature/JJ Burkitt/NN lymphoma/NN cell/NN Raji/NN ;/: in/IN contrast/NN ,/, it/PRP did/VBD not/RB induce/VB TNF-alpha/NN release/NN by/IN the/DT pre-B/JJ leukemia/NN cells/NNS Nalm-6/NN and/CC BV173/NN ./. 
TNF-alpha/NN release/NN peaked/VBD at/IN 24/CD h/NN and/CC decreased/VBD thereafter/RB ,/, and/CC it/PRP was/VBD dose/NN dependent/JJ and/CC preceded/VBN by/IN an/DT increase/NN of/IN TNF-alpha/NN mRNA/NN detectable/JJ after/IN 3/CD h/NN of/IN stimulation/NN with/IN mAb/NN L243/NN ./. 
Secreted/VBN TNF-alpha/NN mediated/VBD the/DT enhancement/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) and/CC activator/NN protein-1/NN (/( AP-1/NN )/) binding/NN activity/NN ;/: in/IN fact/NN ,/, the/DT triggering/NN of/IN HLA-DR/NN antigens/NNS in/IN the/DT presence/NN of/IN antihuman/JJ TNF-alpha-neutralizing/JJ antibodies/NNS did/VBD not/RB upregulate/VB NF-kappa/NN B/NN and/CC AP-1/NN ./. 
In/IN contrast/NN ,/, released/VBN TNF-alpha/NN was/VBD not/RB responsible/JJ for/IN the/DT homotypic/JJ aggregation/NN of/IN Ri-I/NN ,/, Ci-I/NN ,/, Sc-I/NN ,/, and/CC Raji/NN cells/NNS induced/VBN by/IN mAb/NN L243/NN ,/, and/CC it/PRP did/VBD not/RB affect/VB the/DT proliferation/NN of/IN B/NN cells/NNS investigated/VBN ./. 
Altogether/RB ,/, our/PRP$ data/NNS demonstrate/VBP that/IN :/: (/( a/LS )/) the/DT ability/NN of/IN B/NN cells/NNS to/TO release/VB TNF-alpha/NN after/IN triggering/NN of/IN HLA-DR/NN antigens/NNS depends/VBZ on/IN their/PRP$ stage/NN of/IN differentiation/NN ;/: (/( b/LS )/) levels/NNS of/IN released/VBN TNF-alpha/NN seem/VBP to/TO correlate/VB with/IN the/DT stage/NN of/IN B-cell/NN maturation/NN but/CC do/VBP not/RB correlate/VB with/IN the/DT amounts/NNS of/IN cell/NN surface/NN HLA-DR/NN antigens/NNS ;/: (/( c/LS )/) secreted/VBN TNF-alpha/NN regulates/VBZ the/DT levels/NNS of/IN expression/NN of/IN NF-kappa/NN B/NN and/CC AP-1/NN by/IN an/DT autocrine/JJ loop/NN ;/: and/CC (/( d/LS )/) intracellular/JJ signals/NNS mediating/VBG TNF-alpha/NN release/NN by/IN B/NN cells/NNS are/VBP distinct/JJ from/IN those/DT regulating/VBG homotypic/JJ aggregation/NN and/CC proliferation/NN ./. 
UI/LS -/: 97407957/CD 
TI/LS -/: Transcription/NN factor/NN GATA-3/NN is/VBZ differentially/RB expressed/VBN in/IN murine/JJ Th1/NN and/CC Th2/NN cells/NNS and/CC controls/VBZ Th2-specific/JJ expression/NN of/IN the/DT interleukin-5/NN gene/NN ./. 
AB/LS -/: Interleukin-5/NN (/( IL-5/NN )/) ,/, which/WDT is/VBZ produced/VBN by/IN CD4(+)/JJ T/NN helper/NN 2/CD (/( Th2/NN )/) cells/NNS ,/, but/CC not/RB by/IN Th1/NN cells/NNS ,/, plays/VBZ a/DT key/JJ role/NN in/IN the/DT development/NN of/IN eosinophilia/NN in/IN asthma/NN ./. 
Despite/IN increasing/VBG evidence/NN that/IN the/DT outcome/NN of/IN many/JJ diseases/NNS is/VBZ determined/VBN by/IN the/DT ratio/NN of/IN the/DT two/CD subsets/NNS of/IN CD4(+)/JJ T/NN helper/NN cells/NNS ,/, Th1/NN and/CC Th2/NN ,/, the/DT molecular/JJ basis/NN for/IN Th1-/NN and/CC Th2-specific/JJ gene/NN expression/NN remains/VBZ to/TO be/VB elucidated/VBN ./. 
We/PRP previously/RB established/VBD a/DT critical/JJ role/NN for/IN the/DT transcription/NN factor/NN GATA-3/NN in/IN IL-5/NN promoter/NN activation/NN in/IN EL-4/NN cells/NNS ,/, which/WDT express/VBP both/CC Th1-/NN and/CC Th2-type/JJ cytokines/NNS ./. 
Our/PRP$ studies/NNS reported/VBN here/RB demonstrate/VBP that/IN GATA-3/NN is/VBZ critical/JJ for/IN expression/NN of/IN the/DT IL-5/NN gene/NN in/IN bona/FW fide/FW Th2/NN cells/NNS ./. 
Whereas/IN mutations/NNS in/IN the/DT GATA-3/NN site/NN abolished/VBD antigen-/JJ or/CC cAMP-stimulated/JJ IL-5/NN promoter/NN activation/NN in/IN Th2/NN cells/NNS ,/, ectopic/JJ expression/NN of/IN GATA-3/NN in/IN Th1/NN cells/NNS or/CC in/IN a/DT non-lymphoid/JJ ,/, non-IL-5-producing/JJ cell/NN line/NN activated/VBD the/DT IL-5/NN promoter/NN ./. 
During/IN the/DT differentiation/NN of/IN naive/JJ CD4(+)/JJ T/NN cells/NNS isolated/VBN from/IN T/NN cell/NN receptor/NN transgenic/JJ mice/NNS ,/, GATA-3/NN gene/NN expression/NN was/VBD up-regulated/VBN in/IN developing/VBG Th2/NN cells/NNS ,/, but/CC was/VBD down-regulated/VBN in/IN Th1/NN cells/NNS ,/, and/CC antigen-/NN or/CC cAMP-activated/JJ Th2/NN cells/NNS (/( but/CC not/RB Th1/NN cells/NNS )/) expressed/VBD the/DT GATA-3/NN protein/NN ./. 
Thus/RB ,/, GATA-3/NN may/MD play/VB an/DT important/JJ role/NN in/IN the/DT balance/NN between/IN Th1/NN and/CC Th2/NN subsets/NNS in/IN immune/JJ responses/NNS ./. 
Inhibition/NN of/IN GATA-3/NN activity/NN has/VBZ therapeutic/JJ potential/NN in/IN the/DT treatment/NN of/IN asthma/NN and/CC other/JJ hypereosinophilic/JJ diseases/NNS ./. 
UI/LS -/: 97385069/CD 
TI/LS -/: A/DT shortened/VBN life/NN span/NN of/IN EKLF-/-/JJ adult/JJ erythrocytes/NNS ,/, due/JJ to/TO a/DT deficiency/NN of/IN beta-globin/NN chains/NNS ,/, is/VBZ ameliorated/VBN by/IN human/JJ gamma-globin/NN chains/NNS ./. 
AB/LS -/: Using/VBG homologous/JJ recombination/NN ,/, both/DT EKLF/NN alleles/NNS in/IN murine/JJ embryonic/JJ stem/NN (/( ES/NN )/) cells/NNS were/VBD inactivated/VBN ./. 
These/DT EKLF-/-/JJ ES/NN cells/NNS were/VBD capable/JJ of/IN undergoing/VBG in/FW vitro/FW differentiation/NN to/TO form/VB definitive/JJ erythroid/JJ colonies/NNS that/WDT were/VBD similar/JJ in/IN size/NN and/CC number/NN to/TO those/DT formed/VBN by/IN wild-type/JJ ES/NN cells/NNS ./. 
However/RB ,/, the/DT EKLF-/-/JJ colonies/NNS were/VBD poorly/RB hemoglobinized/VBN and/CC enucleated/VBN erythrocytes/NNS in/IN these/DT colonies/NNS contained/VBD numerous/JJ Heinz/NN bodies/NNS ./. 
Reverse/JJ transcriptase-polymerase/NN chain/NN reaction/NN (/( RT-PCR/NN )/) analyses/NNS revealed/VBD that/IN adult/JJ and/CC embryonic/JJ globin/NN genes/NNS were/VBD appropriately/RB regulated/VBN ,/, with/IN the/DT exception/NN of/IN beta/NN h1-globin/NN ,/, which/WDT continued/VBD to/TO be/VB expressed/VBN at/IN a/DT very/RB low/JJ level/NN ./. 
The/DT ratio/NN of/IN adult/JJ beta-globin/alpha-globin/NN mRNA/NN in/IN the/DT mutant/JJ ES/NN cells/NNS was/VBD 1/15/CD of/IN that/DT in/IN wild-type/JJ ES/NN cells/NNS ./. 
When/WRB the/DT EKLF-/-/JJ cells/NNS were/VBD injected/VBN into/IN blastocysts/NNS ,/, they/PRP did/VBD not/RB contribute/VB at/IN a/DT detectable/JJ level/NN to/TO the/DT mature/JJ erythrocyte/NN compartment/NN of/IN the/DT chimeric/JJ animals/NNS ,/, based/VBN on/IN analysis/NN of/IN glucose/NN phosphate/NN isomerase-1/NN (/( GPI-1/NN )/) isozymes/NNS and/CC hemoglobins/NNS that/WDT distinguish/VBP ES/NN cell-derived/JJ erythrocytes/NNS from/IN host/NN blastocyst-derived/JJ erythrocytes/NNS ./. 
In/IN contrast/NN ,/, semiquantitative/JJ RT-PCR/NN analysis/NN of/IN RNA/NN from/IN reticulocytes/NNS of/IN the/DT same/JJ chimeric/JJ animals/NNS suggested/VBD that/IN the/DT ES/NN cell-derived/JJ reticulocytes/NNS were/VBD present/JJ at/IN a/DT level/NN of/IN 6/CD %/NN to/TO 8/CD %/NN ./. 
This/DT indicated/VBD that/IN the/DT EKLF-/-/JJ erythrocytes/NNS in/IN adult/JJ animals/NNS must/MD be/VB short-lived/JJ ,/, apparently/RB due/JJ to/TO the/DT imbalance/NN of/IN beta-/NN versus/CC alpha-globin/NN chains/NNS ,/, leading/VBG to/TO the/DT precipitation/NN of/IN excess/JJ alpha-globin/NN chains/NNS to/TO form/VB Heinz/NN bodies/NNS ./. 
Consistent/JJ with/IN this/DT hypothesis/NN ,/, the/DT short/JJ life/NN span/NN was/VBD ameliorated/VBN by/IN introduction/NN into/IN the/DT EKLF-/-/JJ ES/NN cells/NNS of/IN a/DT human/JJ LCR/gamma-globin/NN gene/NN ,/, as/IN evidenced/VBN by/IN the/DT presence/NN of/IN ES/NN cell-derived/JJ reticulocytes/NNS as/RB well/RB as/IN mature/JJ erythrocytes/NNS in/IN the/DT blood/NN of/IN the/DT chimeric/JJ animals/NNS ./. 
UI/LS -/: 97376852/CD 
TI/LS -/: RP1/NN ,/, a/DT new/JJ member/NN of/IN the/DT adenomatous/JJ polyposis/NN coli-binding/JJ EB1-like/JJ gene/NN family/NN ,/, is/VBZ differentially/RB expressed/VBN in/IN activated/VBN T/NN cells/NNS ./. 
AB/LS -/: Cross-linking/NN of/IN the/DT CD3/NN and/CC CD28/NN molecules/NNS on/IN T/NN lymphocytes/NNS represents/VBZ one/CD of/IN the/DT most/RBS effective/JJ signals/NNS for/IN T/NN lymphocyte/NN activation/NN and/CC triggering/NN of/IN their/PRP$ cytotoxic/JJ effector/NN function/NN ./. 
To/TO identify/VB genes/NNS that/WDT are/VBP expressed/VBN in/IN T/NN cells/NNS after/IN stimulation/NN ,/, mRNA/NN from/IN T/NN lymphocytes/NNS that/WDT had/VBD been/VBN activated/VBN by/IN the/DT simultaneous/JJ stimulation/NN of/IN the/DT CD3/NN and/CC CD28/NN trigger/NN molecules/NNS was/VBD transcribed/VBN for/IN a/DT differential/JJ mRNA/NN display/NN analysis/NN into/IN cDNA/NN and/CC was/VBD compared/VBN with/IN cDNA/NN from/IN CD28-/NN or/CC CD3-activated/JJ or/CC resting/VBG lymphocytes/NNS ./. 
Differential/JJ expression/NN was/VBD confirmed/VBN subsequently/RB by/IN Northern/NN blot/NN analysis/NN ./. 
One/CD of/IN the/DT cDNA/NN fragments/NNS expressed/VBN specifically/RB in/IN CD3-/NN and/CC CD28-activated/JJ T/NN cells/NNS was/VBD designated/VBN RP1/NN ./. 
The/DT predictive/JJ protein-coding/JJ region/NN of/IN RP1/NN had/VBD a/DT significant/JJ homology/NN to/TO members/NNS of/IN the/DT recently/RB found/VBN adenomatous/JJ polyposis/NN coli/NN (/( APC/NN )/) protein-binding/JJ EB1/NN gene/NN family/NN ,/, which/WDT codes/VBZ for/IN yet/RB unknown/JJ protein/NN (/( s/NNS )/) ./. 
Bacterially/RB expressed/VBN RP1/NN protein/NN revealed/VBD specific/JJ binding/NN to/TO wild-type/JJ but/CC not/RB to/TO mutated/VBN APC/NN protein/NN ./. 
The/DT rapid/JJ up-regulation/NN of/IN RP1/NN mRNA/NN in/IN properly/RB activated/VBN T/NN cells/NNS suggests/VBZ that/IN this/DT gene/NN might/MD belong/VB to/TO the/DT immediate/early/JJ gene/NN family/NN ,/, which/WDT controls/VBZ the/DT signal/NN transduction/NN cascade/NN downstream/RB of/IN the/DT TCR/NN ./. 
As/IN the/DT expression/NN level/NN of/IN the/DT RP1/NN gene/NN in/IN activated/VBN T/NN cells/NNS and/CC a/DT spectrum/NN of/IN tumor-derived/JJ cell/NN lines/NNS correlates/VBZ with/IN the/DT proliferative/JJ status/NN of/IN the/DT cells/NNS ,/, members/NNS of/IN the/DT EB1-like/JJ gene/NN family/NN may/MD not/RB only/RB be/VB involved/VBN in/IN the/DT tumorigenesis/NN of/IN colorectal/JJ cancers/NNS but/CC may/MD also/RB play/VB a/DT role/NN in/IN the/DT proliferative/JJ control/NN of/IN normal/JJ cells/NNS ./. 
UI/LS -/: 97390710/CD 
TI/LS -/: Cyclosporin/NN A/NN interferes/VBZ with/IN the/DT inducible/JJ degradation/NN of/IN NF-kappa/NN B/NN inhibitors/NNS ,/, but/CC not/RB with/IN the/DT processing/NN of/IN p105/NF-kappa/NN B1/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: The/DT transcription/NN factor/NN NF-kappa/NN B/NN controls/VBZ the/DT induction/NN of/IN numerous/JJ cytokine/NN promoters/NNS during/IN the/DT activation/NN of/IN T/NN lymphocytes/NNS ./. 
Inhibition/NN of/IN T/NN cell/NN activation/NN by/IN the/DT immunosuppressants/NNS cyclosporin/NN A/NN (/( CsA/NN )/) and/CC FK506/NN exerts/VBZ a/DT suppressive/JJ effect/NN on/IN the/DT induction/NN of/IN these/DT NF-kappa/NN B-controlled/JJ cytokine/NN promoters/NNS ./. 
We/PRP show/VBP for/IN human/JJ Jurkat/NN T/NN leukemia/NN cells/NNS ,/, as/RB well/RB as/IN human/JJ and/CC mouse/NN primary/JJ T/NN lymphocytes/NNS ,/, that/IN this/DT inhibitory/JJ effect/NN is/VBZ accompanied/VBN by/IN an/DT impaired/JJ nuclear/JJ translocation/NN of/IN the/DT Rel/NN proteins/NNS c-Rel/NN ,/, RelA/p65/NN and/CC NF-kappa/NN B1/p50/NN ,/, whereas/IN the/DT nuclear/JJ appearance/NN of/IN RelB/NN remains/VBZ unaffected/JJ ./. 
CsA/NN does/VBZ not/RB interfere/VB with/IN the/DT synthesis/NN of/IN Rel/NN proteins/NNS ,/, but/CC prevents/VBZ the/DT inducible/JJ degradation/NN of/IN cytosolic/JJ NF-kappa/NN B/NN inhibitors/NNS I/NN kappa/NN B/NN alpha/NN and/CC I/NN kappa/NN B/NN beta/NN upon/IN T/NN cell/NN activation/NN ./. 
CsA/NN neither/CC inhibits/VBZ the/DT processing/NN of/IN the/DT NF-kappa/NN B1/NN precursor/NN p105/NN to/TO p50/NN ,/, nor/CC does/VBZ it/PRP "/`` stabilize/VB "/'' the/DT C-terminal/JJ portion/NN of/IN p105/NN ,/, I/NN kappa/NN B/NN gamma/NN ,/, which/WDT is/VBZ degraded/VBN during/IN p105/NN processing/NN to/TO mature/JJ p50/NN ./. 
These/DT results/NNS indicate/VBP that/IN CsA/NN interferes/VBZ with/IN a/DT specific/JJ event/NN in/IN the/DT signal-induced/JJ degradation/NN of/IN I/NN kappa/NN B/NN alpha/NN and/CC I/NN kappa/NN B/NN beta/NN ,/, but/CC does/VBZ not/RB affect/VB the/DT processing/NN of/IN NF-kappa/NN B1/p105/NN to/TO p50/NN ./. 
UI/LS -/: 97353010/CD 
TI/LS -/: Activation/NN of/IN nuclear/JJ factor-kappa/NN B/NN by/IN beta-amyloid/NN peptides/NNS and/CC interferon-gamma/NN in/IN murine/JJ microglia/NNS ./. 
AB/LS -/: An/DT increasing/VBG body/NN of/IN evidence/NN suggests/VBZ that/IN amyloid-beta/NN (/( A/NN beta/NN )/) peptides/NNS and/CC microglia/NNS are/VBP crucially/RB involved/VBN in/IN the/DT pathogenesis/NN of/IN Alzheimer/NN 's/POS disease/NN ./. 
In/IN an/DT effort/NN to/TO further/RB elucidate/VB the/DT biological/JJ effects/NNS of/IN A/NN beta/NN towards/IN microglia/NNS ,/, we/PRP investigated/VBD the/DT ability/NN of/IN A/NN beta/NN peptides/NNS to/TO activate/VB nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN in/IN the/DT N9/NN murine/JJ microglial/JJ cell/NN line/NN ./. 
Co-stimulation/NN of/IN microglia/NNS with/IN suboptimal/JJ concentrations/NNS of/IN A/NN beta/NN (/( 25-35/CD )/) and/CC 100/CD U/ml/NN IFN/NN gamma/NN resulted/VBD in/IN the/DT detection/NN of/IN a/DT specific/JJ NF-kappa/NN B/NN DNA-binding/JJ activity/NN in/IN nuclear/JJ extracts/NNS ,/, as/IN determined/VBN in/IN gel/NN mobility/NN shift/NN assays/NNS ./. 
This/DT response/NN required/VBD at/IN least/JJS 120/CD min/NN to/TO be/VB evident/JJ and/CC supershift/NN experiments/NNS revealed/VBD that/IN the/DT NF-kappa/NN B/NN complex/NN contains/VBZ both/CC RelA/NN and/CC p50/NN ./. 
Accordingly/RB ,/, immunoblot/NN experiments/NNS showed/VBD that/IN amongst/IN NF-kappa/NN B/Rel/NN proteins/NNS ,/, RelA/NN and/CC p50/NN are/VBP mobilized/VBN to/TO the/DT nucleus/NN following/VBG microglial/JJ cell/NN stimulation/NN with/IN A/NN beta/NN (/( 25-35/CD )/) plus/CC IFN/NN gamma/NN ./. 
Higher/JJR concentrations/NNS of/IN A/NN beta/NN (/( 25-35/CD )/) were/VBD effective/JJ by/IN themselves/PRP in/IN inducing/VBG NF-kappa/NN B/NN activation/NN ,/, both/CC in/IN the/DT N9/NN microglial/JJ cell/NN line/NN and/CC in/IN rat/NN primary/JJ microglia/NNS ,/, as/RB well/RB as/IN in/IN human/JJ monocytes/NNS ./. 
For/IN purposes/NNS of/IN comparison/NN ,/, microglia/NNS were/VBD also/RB stimulated/VBN with/IN bacterial/JJ LPS/NN ,/, a/DT known/JJ NF-kappa/NN B/NN inducer/NN ./. 
As/IN expected/VBN ,/, LPS/NN strongly/RB induced/VBD the/DT formation/NN of/IN two/CD NF-kappa/NN B/NN DNA-binding/NN activities/NNS ,/, one/CD of/IN which/WDT was/VBD identified/VBN as/IN RelA/p50/NN ./. 
The/DT LPS/NN response/NN was/VBD also/RB more/RBR rapid/JJ ,/, as/IN it/PRP was/VBD already/RB evident/JJ by/IN 40/CD min/NN and/CC remained/VBD sustained/JJ for/IN up/CD to/TO 3/CD h/NN ./. 
Collectively/RB ,/, these/DT findings/NNS indicate/VBP that/IN NF-kappa/NN B/NN activation/NN might/MD constitute/VB one/CD of/IN the/DT mechanisms/NNS underlying/VBG the/DT inducible/JJ expression/NN of/IN kappa/NN B-dependent/JJ genes/NNS in/IN microglia/NNS stimulated/VBN by/IN A/NN beta/NN peptides/NNS and/CC IFN/NN gamma/NN ,/, or/CC by/IN LPS/NN ./. 
UI/LS -/: 97330981/CD 
TI/LS -/: Glucocorticoid-mediated/JJ repression/NN of/IN cytokine/NN gene/NN transcription/NN in/IN human/JJ arteritis-SCID/NN chimeras/NNS ./. 
AB/LS -/: Giant/JJ cell/NN arteritis/NN (/( GCA/NN )/) is/VBZ a/DT vasculitic/JJ syndrome/NN that/WDT preferentially/RB affects/VBZ medium/NN and/CC large-sized/JJ arteries/NNS ./. 
Glucocorticoid/NN therapy/NN resolves/VBZ clinical/JJ symptoms/NNS within/IN hours/NNS to/TO days/NNS ,/, but/CC therapy/NN has/VBZ to/TO be/VB continued/VBN over/IN several/JJ years/NNS to/TO prevent/VB disease/NN relapses/NNS ./. 
It/PRP is/VBZ not/RB known/VBN whether/IN and/CC how/WRB glucocorticoids/NNS affect/VBP the/DT function/NN of/IN the/DT inflammatory/JJ infiltrate/NN or/CC why/IN the/DT disease/NN persists/VBZ subclinically/RB despite/IN chronic/JJ treatment/NN ./. 
GCA/NN is/VBZ self-sustained/JJ in/IN temporal/JJ arteries/NNS engrafted/VBN into/IN SCID/NN mice/NNS ,/, providing/VBG a/DT model/NN in/IN which/WDT the/DT mechanisms/NNS of/IN action/NN and/CC limitations/NNS of/IN glucocorticoid/NN therapy/NN can/MD be/VB examined/VBN in/FW vivo/FW ./. 
Administration/NN of/IN dexamethasone/NN to/TO temporal/JJ artery-SCID/NN chimeras/NNS for/IN 1/CD wk/NN induced/VBD a/DT partial/JJ suppression/NN of/IN T/NN cell/NN and/CC macrophage/NN function/NN as/IN indicated/VBN by/IN the/DT reduced/VBN tissue/NN concentrations/NNS of/IN IL-2/NN ,/, IL-1beta/NN ,/, and/CC IL-6/NN mRNA/NN ,/, and/CC by/IN the/DT diminished/VBN expression/NN of/IN inducible/JJ NO/NN synthase/NN ./. 
In/IN contrast/NN ,/, synthesis/NN of/IN IFN-gamma/NN mRNA/NN was/VBD only/RB slightly/RB decreased/VBN ,/, and/CC expression/NN of/IN TGF-beta1/NN was/VBD unaffected/JJ ./. 
These/DT findings/NNS correlated/VBD with/IN activation/NN of/IN the/DT IkappaBalpha/NN gene/NN and/CC blockade/NN of/IN the/DT nuclear/JJ translocation/NN of/IN NFkappaB/NN in/IN the/DT xenotransplanted/VBN tissue/NN ./. 
Dose-response/JJ experiments/NNS suggested/VBD that/IN steroid/NN doses/NNS currently/RB used/VBN in/IN clinical/JJ medicine/NN are/VBP suboptimal/JJ in/IN repressing/VBG NFkappaB-mediated/JJ cytokine/NN production/NN in/IN the/DT inflammatory/JJ lesions/NNS ./. 
Chronic/JJ steroid/NN therapy/NN was/VBD able/JJ to/TO deplete/VB the/DT T/NN cell/NN products/NNS IL-2/NN and/CC IFN-gamma/NN ,/, whereas/IN the/DT activation/NN of/IN tissue-infiltrating/JJ macrophages/NNS was/VBD only/RB partially/RB affected/VBN ./. 
IL-1beta/NN transcription/NN was/VBD abrogated/VBN ;/: in/IN contrast/NN ,/, TGF-beta1/NN mRNA/NN synthesis/NN was/VBD steroid/NN resistant/JJ ./. 
The/DT persistence/NN of/IN TGF-beta1-transcribing/JJ macrophages/NNS ,/, despite/IN paralysis/NN of/IN T/NN cell/NN function/NN ,/, may/MD provide/VB an/DT explanation/NN for/IN the/DT chronicity/NN of/IN the/DT disease/NN ,/, and/CC may/MD identify/VB a/DT novel/JJ therapeutic/JJ target/NN in/IN this/DT inflammatory/JJ vasculopathy/NN ./. 
UI/LS -/: 97315062/CD 
TI/LS -/: Defective/JJ survival/NN and/CC activation/NN of/IN thymocytes/NNS in/IN transgenic/JJ mice/NNS expressing/VBG a/DT catalytically/RB inactive/JJ form/NN of/IN Ca2+/calmodulin-dependent/JJ protein/NN kinase/NN IV/CD ./. 
AB/LS -/: We/PRP have/VBP generated/VBN transgenic/JJ mice/NNS that/WDT express/VBP a/DT catalytically/RB inactive/JJ form/NN of/IN Ca2+/calmodulin-dependent/JJ protein/NN kinase/NN IV/CD (/( CaMKIV/NN )/) specifically/RB in/IN thymic/JJ T/NN cells/NNS ./. 
The/DT presence/NN of/IN this/DT protein/NN results/VBZ in/IN a/DT markedly/RB reduced/VBN thymic/JJ cellularity/NN ,/, although/IN the/DT distribution/NN of/IN the/DT remaining/VBG cells/NNS is/VBZ normal/JJ based/VBN on/IN evaluation/NN of/IN the/DT CD4/NN and/CC CD8/NN cell/NN surface/NN antigens/NNS that/WDT are/VBP used/VBN to/TO gauge/VB T/NN cell/NN development/NN ./. 
Isolated/VBN thymic/JJ T/NN cells/NNS from/IN the/DT transgenic/JJ mice/NNS also/RB show/VBP a/DT dramatically/RB decreased/VBN survival/NN rate/NN when/WRB evaluated/VBN in/IN culture/NN under/IN conditions/NNS that/WDT do/VBP not/RB favor/VB activation/NN ./. 
When/WRB challenged/VBN with/IN an/DT activating/VBG stimulus/NN such/JJ as/IN alpha-CD3/NN or/CC a/DT combination/NN of/IN phorbol/NN ester/NN plus/CC ionophore/NN ,/, the/DT cells/NNS are/VBP severely/RB compromised/VBN in/IN their/PRP$ ability/NN to/TO produce/VB the/DT cytokine/NN interleukin-2/NN (/( IL-2/NN )/) ./. 
Reduction/NN of/IN IL-2/NN production/NN is/VBZ secondary/JJ to/TO the/DT inability/NN to/TO phosphorylate/VB the/DT cAMP/NN response/NN element/NN binding/NN protein/NN ,/, CREB/NN ,/, and/CC induce/VBP expression/NN of/IN the/DT immediate/JJ early/JJ genes/NNS such/JJ as/IN Fos/NN B/NN that/WDT are/VBP required/VBN to/TO transactivate/VB the/DT IL-2/NN promoter/NN ./. 
Because/IN transgene/NN expression/NN was/VBD regulated/VBN by/IN the/DT proximal/JJ promoter/NN of/IN the/DT murine/JJ lck/NN gene/NN and/CC this/DT promoter/NN is/VBZ inactivated/VBN in/IN T/NN cells/NNS that/WDT exit/VBP the/DT thymus/NN ,/, the/DT mutant/JJ hCaMKIV/NN is/VBZ not/RB present/JJ in/IN peripheral/JJ T/NN cells/NNS ./. 
Consequently/RB ,/, T/NN lymphocytes/NNS present/JJ in/IN the/DT spleen/NN can/MD be/VB activated/VBN normally/RB in/IN response/NN to/TO either/DT stimulus/NN mentioned/VBN above/RB ,/, demonstrating/VBG that/IN the/DT effects/NNS of/IN the/DT inactive/JJ CaMKIV/NN on/IN activation/NN are/VBP reversible/JJ ./. 
Our/PRP$ results/NNS suggest/VBP that/IN CaMKIV/NN may/MD represent/VB a/DT physiologically/RB relevant/JJ CREB/NN kinase/NN in/IN T/NN cells/NNS and/CC that/IN the/DT enzyme/NN is/VBZ also/RB required/VBN to/TO ensure/VB normal/JJ expansion/NN of/IN T/NN cells/NNS in/IN the/DT thymus/NN ./. 
Whereas/IN the/DT pathway/NN responsible/JJ for/IN this/DT latter/JJ role/NN is/VBZ yet/RB to/TO be/VB elucidated/VBN ,/, it/PRP is/VBZ unlikely/JJ to/TO include/VB CREB/NN phosphorylation/NN ./. 
UI/LS -/: 97296513/CD 
TI/LS -/: A/DT new/JJ mouse/NN gene/NN ,/, SRG3/NN ,/, related/JJ to/TO the/DT SWI3/NN of/IN Saccharomyces/FW cerevisiae/FW ,/, is/VBZ required/VBN for/IN apoptosis/NN induced/VBN by/IN glucocorticoids/NNS in/IN a/DT thymoma/NN cell/NN line/NN ./. 
AB/LS -/: We/PRP isolated/VBD a/DT new/JJ mouse/NN gene/NN that/WDT is/VBZ highly/RB expressed/VBN in/IN thymocytes/NNS ,/, testis/NN ,/, and/CC brain/NN ./. 
This/DT gene/NN ,/, SRG3/NN ,/, showed/VBD a/DT significant/JJ sequence/NN homology/NN to/TO SWI3/NN ,/, a/DT yeast/NN transcriptional/JJ activator/NN ,/, and/CC its/PRP$ human/JJ homolog/NN BAF155/NN ./. 
SRG3/NN encodes/VBZ 1,100/CD amino/NN acids/NNS and/CC has/VBZ 33-47/CD %/NN identity/NN with/IN SWI3/NN protein/NN over/IN three/CD regions/NNS ./. 
The/DT SRG3/NN protein/NN contains/VBZ an/DT acidic/JJ NH2/NN terminus/NN ,/, a/DT myb-like/JJ DNA/NN binding/NN domain/NN ,/, a/DT leucine-zipper/JJ motif/NN ,/, and/CC a/DT proline-/NN and/CC glutamine-rich/JJ region/NN at/IN its/PRP$ COOH/NN terminus/NN ./. 
Rabbit/NN antiserum/NN raised/VBN against/IN a/DT COOH-terminal/JJ polypeptide/NN of/IN the/DT SRG3/NN recognized/VBD a/DT protein/NN with/IN an/DT apparent/JJ molecular/JJ mass/NN of/IN 155/CD kD/NN ./. 
The/DT serum/NN also/RB detected/VBD a/DT 170-kD/JJ protein/NN that/WDT seems/VBZ to/TO be/VB a/DT mouse/NN homologue/NN of/IN human/JJ BAF170/NN ./. 
Immunoprecipitation/NN of/IN cell/NN extract/NN with/IN the/DT antiserum/NN against/IN the/DT mouse/NN SRG3/NN also/RB brought/VBD down/RP a/DT 195-kD/JJ protein/NN that/WDT could/MD be/VB recognized/VBN by/IN an/DT antiserum/NN raised/VBN against/IN human/JJ SWI2/NN protein/NN ./. 
The/DT results/NNS suggest/VBP that/IN the/DT SRG3/NN protein/NN associates/VBZ with/IN a/DT mouse/NN SWI2/NN ./. 
The/DT SRG3/NN protein/NN is/VBZ expressed/VBN about/RB three/CD times/NNS higher/JJR in/IN thymocytes/NNS than/IN in/IN peripheral/JJ lymphocytes/NNS ./. 
The/DT expression/NN of/IN anti-sense/JJ RNA/NN to/TO SRG3/NN mRNA/NN in/IN a/DT thymoma/NN cell/NN line/NN ,/, S49.1/NN ,/, reduced/VBD the/DT expression/NN level/NN of/IN the/DT SRG3/NN protein/NN ,/, and/CC decreased/VBD the/DT apoptotic/JJ cell/NN death/NN induced/VBN by/IN glucocorticoids/NNS ./. 
These/DT results/NNS suggest/VBP that/IN the/DT SRG3/NN protein/NN is/VBZ involved/VBN in/IN the/DT glucocorticoid-induced/JJ apoptosis/NN in/IN the/DT thymoma/NN cell/NN line/NN ./. 
This/DT implicates/VBZ that/IN the/DT SRG3/NN may/MD play/VB an/DT important/JJ regulatory/JJ role/NN during/IN T/NN cell/NN development/NN in/IN thymus/NN ./. 
UI/LS -/: 97277320/CD 
TI/LS -/: Transcriptional/JJ induction/NN of/IN collagenase-1/NN in/IN differentiated/VBN monocyte-like/JJ (/( U937/NN )/) cells/NNS is/VBZ regulated/VBN by/IN AP-1/NN and/CC an/DT upstream/JJ C/EBP-beta/NN site/NN ./. 
AB/LS -/: In/IN this/DT report/NN ,/, we/PRP demonstrate/VBP that/IN the/DT AP-1/NN site/NN and/CC a/DT distal/JJ promoter/NN element/NN regulate/VBP transcriptional/JJ induction/NN of/IN collagenase-1/NN during/IN monocytic/JJ differentiation/NN ./. 
Chloramphenicol/NN acetyltransferase/NN expression/NN constructs/NNS containing/VBG regions/NNS of/IN the/DT human/JJ collagenase-1/NN promoter/NN were/VBD stably/RB or/CC transiently/RB transfected/VBN into/IN U937/NN cells/NNS ,/, and/CC reporter/NN activity/NN was/VBD assessed/VBN at/IN various/JJ times/NNS after/IN the/DT onset/NN of/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) -mediated/JJ differentiation/NN ./. 
Rapid/JJ and/CC strong/JJ induction/NN of/IN promoter/NN activity/NN was/VBD lost/VBN in/IN constructs/NNS with/IN a/DT mutant/JJ AP-1/NN element/NN ;/: however/RB ,/, at/IN 16-96/CD h/NN post-PMA/NN ,/, the/DT mutant/JJ collagenase-1/NN promoter/NN displayed/VBD AP-1/NN independent/JJ PMA-mediated/JJ transactivation/NN ./. 
The/DT AP-1/NN mutant/JJ constructs/NNS also/RB showed/VBD delayed/VBN transcriptional/JJ activation/NN in/IN PMA-treated/JJ fibroblasts/NNS ./. 
Western/NN and/CC supershift/NN analyses/NNS indicated/VBD that/IN functional/JJ Jun/NN and/CC Fos/NN proteins/NNS were/VBD present/JJ in/IN nuclear/JJ extracts/NNS of/IN PMA-differentiated/JJ U937/NN cells/NNS ./. 
Promoter/NN deletion/NN constructs/NNS demonstrated/VBD the/DT potential/JJ role/NN of/IN distal/JJ promoter/NN sequences/NNS in/IN regulating/VBG collagenase-1/NN transcription/NN ./. 
In/IN particular/JJ ,/, Western/NN ,/, supershift/NN ,/, and/CC promoter/NN deletion/NN analyses/NNS suggested/VBD a/DT role/NN for/IN CCAAT/enhancer-binding/JJ protein-beta/NN (/( C/EBP-beta/NN )/) binding/NN site/NN between/IN -2010/CD and/CC -1954/CD in/IN regulating/VBG transcription/NN of/IN collagenase-1/NN in/IN monocytic/JJ cells/NNS ./. 
Our/PRP$ findings/NNS suggest/VBP that/IN distinct/JJ regulatory/JJ elements/NNS ,/, acting/VBG somewhat/RB independently/RB of/IN each/DT other/JJ ,/, control/VBP expression/NN of/IN collagenase-1/NN ./. 
In/IN addition/NN ,/, our/PRP$ data/NNS suggests/VBZ that/IN the/DT rapid/JJ PMA-mediated/JJ induction/NN of/IN collagenase-1/NN transcription/NN is/VBZ controlled/VBN by/IN a/DT mechanism/NN distinct/JJ from/IN that/DT regulating/VBG the/DT sustained/JJ expression/NN of/IN this/DT proteinase/NN in/IN activated/VBN macrophages/NNS ./. 
UI/LS -/: 97289433/CD 
TI/LS -/: Quantification/NN of/IN vitamin/NN D/NN receptor/NN mRNA/NN by/IN competitive/JJ polymerase/NN chain/NN reaction/NN in/IN PBMC/NN :/: lack/NN of/IN correspondence/NN with/IN common/JJ allelic/JJ variants/NNS ./. 
AB/LS -/: It/PRP has/VBZ been/VBN recently/RB claimed/VBN that/IN polymorphism/NN for/IN the/DT vitamin/NN D/NN receptor/NN (/( VDR/NN )/) influences/VBZ several/JJ aspects/NNS of/IN calcium/NN and/CC bone/NN metabolism/NN ./. 
To/TO evaluate/VB the/DT physiologic/JJ plausibility/NN of/IN these/DT claims/NNS ,/, we/PRP compared/VBD the/DT abundance/NN of/IN the/DT VDR/NN mRNA/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMCs/NNS )/) between/IN different/JJ VDR/NN genotypes/NNS using/VBG a/DT quantitative/JJ reverse/JJ transcribed/VBN polymerase/NN chain/NN reaction-based/JJ method/NN ./. 
The/DT method/NN is/VBZ based/VBN on/IN the/DT coamplification/NN of/IN VDR/NN cDNA/NN and/CC an/DT internal/JJ standard/NN consisting/VBG of/IN known/JJ concentrations/NNS of/IN a/DT human/JJ VDR/NN CDNA/NN mutated/VBN at/IN a/DT BglII/NN restriction/NN site/NN ;/: the/DT interassay/JJ coefficient/NN of/IN variation/NN is/VBZ 11/CD %/NN ./. 
To/TO validate/VB the/DT method/NN ,/, we/PRP made/VBD use/NN of/IN earlier/JJR receptor/NN binding/NN studies/NNS indicating/VBG that/IN normal/JJ human/JJ monocytes/NNS and/CC activated/VBN ,/, but/CC not/RB resting/VBG ,/, lymphocytes/NNS expressed/VBD the/DT VDR/NN ./. 
The/DT concentration/NN of/IN the/DT VDR/NN mRNA/NN was/VBD 10(-8)/CD to/TO 10(-7)/CD g/g/NN of/IN total/JJ RNA/NN in/IN cell-sorted/JJ monocytes/NNS and/CC in/IN in/FW vitro/FW activated/VBN lymphocytes/NNS ,/, but/CC only/RB 10(-12)/CD g/g/NN of/IN total/JJ mRNA/NN in/IN resting/VBG lymphocytes/NNS ,/, establishing/VBG that/IN the/DT VDR/NN mRNA/NN determined/VBN by/IN our/PRP$ method/NN in/IN PBMCs/NNS is/VBZ due/JJ to/TO constitutive/JJ expression/NN in/IN monocytes/NNS ./. 
Following/VBG an/DT initial/JJ genotype/NN screening/NN of/IN 85/CD normal/JJ volunteers/NNS by/IN polymerase/NN chain/NN reaction/NN or/CC restriction/NN fragment/NN length/NN polymorphism/NN analysis/NN ,/, 14/CD individuals/NNS with/IN the/DT Bb/NN genotype/NN ,/, 12/CD with/IN the/DT bb/NN genotype/NN ,/, and/CC 12/CD with/IN the/DT BB/NN genotype/NN were/VBD selected/VBN ./. 
The/DT concentration/NN of/IN the/DT VDR/NN mRNA/NN ,/, corrected/VBN for/IN the/DT number/NN of/IN monocytes/NNS ,/, was/VBD similar/JJ among/IN the/DT three/CD genotype/NN groups/NNS ,/, as/IN were/VBD the/DT other/JJ variables/NNS examined/VBN :/: serum/NN calcitriol/NN ,/, serum/NN osteocalcin/NN ,/, and/CC vertebral/NN and/CC hip/NN bone/NN density/NN ./. 
We/PRP conclude/VBP that/IN VDR/NN polymorphism/NN does/VBZ not/RB affect/VB the/DT abundance/NN of/IN the/DT VDR/NN mRNA/NN ./. 
UI/LS -/: 97269040/CD 
TI/LS -/: Oncogenic/JJ forms/NNS of/IN NOTCH1/NN lacking/VBG either/CC the/DT primary/JJ binding/VBG site/NN for/IN RBP-Jkappa/NN or/CC nuclear/JJ localization/NN sequences/NNS retain/VBP the/DT ability/NN to/TO associate/VB with/IN RBP-Jkappa/NN and/CC activate/VB transcription/NN ./. 
AB/LS -/: Truncated/JJ forms/NNS of/IN the/DT NOTCH1/NN transmembrane/JJ receptor/NN engineered/VBN to/TO resemble/VB mutant/JJ forms/NNS of/IN NOTCH1/NN found/VBN in/IN certain/JJ cases/NNS of/IN human/JJ T/NN cell/NN leukemia/lymphoma/NN (/( T-ALL/NN )/) efficiently/RB induce/VBP T-ALL/NN when/WRB expressed/VBN in/IN the/DT bone/NN marrow/NN of/IN mice/NNS ./. 
Unlike/IN full-sized/JJ NOTCH1/NN ,/, two/CD such/JJ truncated/JJ forms/NNS of/IN the/DT protein/NN either/CC lacking/VBG a/DT major/JJ portion/NN of/IN the/DT extracellular/JJ domain/NN (/( DeltaE/NN )/) or/CC consisting/VBG only/RB of/IN the/DT intracellular/JJ domain/NN (/( ICN/NN )/) were/VBD found/VBN to/TO activate/VB transcription/NN in/IN cultured/VBN cells/NNS ,/, presumably/RB through/IN RBP-Jkappa/NN response/NN elements/NNS within/IN DNA/NN ./. 
Both/CC truncated/JJ forms/NNS also/RB bound/VBD to/TO the/DT transcription/NN factor/NN RBP-Jkappa/NN in/IN extracts/NNS prepared/VBN from/IN human/JJ and/CC murine/JJ T-ALL/NN cell/NN lines/NNS ./. 
Transcriptional/JJ activation/NN required/VBD the/DT presence/NN of/IN a/DT weak/JJ RBP-Jkappa-binding/JJ site/NN within/IN the/DT NOTCH1/NN ankyrin/NN repeat/NN region/NN of/IN the/DT intracellular/JJ domain/NN ./. 
Unexpectedly/RB ,/, a/DT second/JJ ,/, stronger/JJR RBP-Jkappa-binding/JJ site/NN ,/, which/WDT lies/VBZ within/IN the/DT intracellular/JJ domain/NN close/JJ to/TO the/DT transmembrane/JJ region/NN and/CC significantly/RB augments/VBZ association/NN with/IN RBP-Jkappa/NN ,/, was/VBD not/RB needed/VBN for/IN oncogenesis/NN or/CC for/IN transcriptional/JJ activation/NN ./. 
While/IN ICN/NN appeared/VBD primarily/RB in/IN the/DT nucleus/NN ,/, DeltaE/NN localized/VBD to/TO cytoplasmic/JJ and/CC nuclear/JJ membranes/NNS ,/, suggesting/VBG that/IN intranuclear/JJ localization/NN is/VBZ not/RB essential/JJ for/IN oncogenesis/NN or/CC transcriptional/JJ activation/NN ./. 
In/IN support/NN of/IN this/DT interpretation/NN ,/, mutation/NN of/IN putative/JJ nuclear/JJ localization/NN sequences/NNS decreased/VBD nuclear/JJ localization/NN and/CC increased/VBD transcriptional/JJ activation/NN by/IN membrane-bound/JJ DeltaE/NN ./. 
Transcriptional/JJ activation/NN by/IN this/DT mutant/JJ form/NN of/IN membrane-bound/JJ DeltaE/NN was/VBD approximately/RB equivalent/JJ to/TO that/DT produced/VBN by/IN intranuclear/JJ ICN/NN ./. 
These/DT data/NNS are/VBP most/RBS consistent/JJ with/IN NOTCH1/NN oncogenesis/NN and/CC transcriptional/JJ activation/NN being/VBG independent/JJ of/IN association/NN with/IN RBP-Jkappa/NN at/IN promoter/NN sites/NNS ./. 
UI/LS -/: 97353023/CD 
TI/LS -/: Sp/NN family/NN members/NNS preferentially/RB interact/VBP with/IN the/DT promoter/NN proximal/JJ repeat/NN within/IN the/DT HTLV-I/NN enhancer/NN ./. 
AB/LS -/: Human/JJ T/NN cell/NN lymphotropic/JJ virus/NN type/NN I/CD (/( HTLV-I/NN )/) encodes/VBZ the/DT transactivator/NN protein/NN ,/, Tax/NN ,/, which/WDT facilitates/VBZ viral/JJ transcription/NN from/IN three/CD 21/CD bp/NN repeated/JJ elements/NNS within/IN the/DT U3/NN region/NN of/IN the/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ./. 
Examination/NN of/IN the/DT basal/JJ factors/NNS interacting/VBG with/IN the/DT 21/CD bp/NN repeat/NN elements/NNS through/IN electrophoretic/JJ mobility/NN shift/NN (/( EMS/NN )/) analyses/NNS has/VBZ demonstrated/VBN the/DT formation/NN of/IN DNA-protein/JJ complexes/NNS common/JJ to/TO each/DT of/IN the/DT 21/CD bp/NN repeats/NNS (/( C1-C3/NN )/) as/RB well/RB as/IN three/CD DNA-protein/JJ complexes/NNS specific/JJ to/TO the/DT promoter/NN proximal/JJ (/( pp/NN )/) repeat/NN (/( U1/NN (/( U1A/U1B/NN )/) and/CC U2/NN ;/: 1-4/CD )/) ./. 
These/DT studies/NNS have/VBP indicated/VBN that/IN the/DT individual/JJ repeats/NNS are/VBP not/RB identical/JJ with/IN respect/NN to/TO the/DT cellular/JJ factors/NNS with/IN which/WDT they/PRP interact/VBP ./. 
EMS/NN analyses/NNS utilizing/VBG a/DT series/NN of/IN mutated/VBN pp/NN repeat/NN elements/NNS demonstrate/VBP that/IN the/DT nucleotide/NN sequence/NN requirements/NNS for/IN U1/NN (/( U1A/U1B/NN )/) and/CC U2/NN formation/NN are/VBP separable/JJ from/IN those/DT required/VBN for/IN C1-C3/NN formation/NN ./. 
Competition/NN EMS/NN analyses/NNS utilizing/VBG Sp1/NN and/CC CREB/NN binding/NN site/NN oligonucleotides/NNS demonstrate/VBP that/IN Sp/NN family/NN members/NNS are/VBP critical/JJ components/NNS of/IN U1/NN (/( U1A/U1B/NN )/) and/CC U2/NN and/CC that/IN ATF/CREB/NN family/NN members/NNS are/VBP critical/JJ components/NNS of/IN C1-C3/NN ./. 
EMS/NN supershift/NN analyses/NNS have/VBP demonstrated/VBN that/IN Sp1/NN is/VBZ involved/VBN in/IN U1A/NN formation/NN while/IN Sp3/NN is/VBZ involved/VBN in/IN U1B/NN and/CC U2/NN formation/NN ./. 
EMS/NN analyses/NNS performed/VBN with/IN nuclear/JJ extracts/NNS from/IN Tax-expressing/JJ Jurkat/NN cells/NNS and/CC HTLV-I-transformed/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS demonstrate/VBP that/IN Tax/NN prevents/VBZ the/DT formation/NN of/IN U1/NN (/( U1A/U1B/NN )/) and/CC U2/NN DNA-protein/JJ complexes/NNS ./. 
Therefore/RB ,/, Tax/NN appears/VBZ to/TO inhibit/VB the/DT interaction/NN of/IN Sp/NN family/NN members/NNS with/IN the/DT pp/NN repeat/NN ./. 
Based/VBN on/IN these/DT observations/NNS ,/, it/PRP is/VBZ possible/JJ that/IN the/DT interaction/NN of/IN Sp/NN and/CC ATF/CREB/NN family/NN members/NNS with/IN the/DT pp/NN repeat/NN during/IN basal/JJ and/CC Tax-mediated/JJ transcription/NN may/MD play/VB a/DT critical/JJ role/NN in/IN viral/JJ gene/NN expression/NN during/IN the/DT initial/JJ stages/NNS of/IN virus/NN infection/NN or/CC during/IN activation/NN of/IN a/DT latent/JJ infection/NN ./. 
UI/LS -/: 97234679/CD 
TI/LS -/: Lineage-/NN and/CC stage-specific/JJ expression/NN of/IN runt/NN box/NN polypeptides/NNS in/IN primitive/JJ and/CC definitive/JJ hematopoiesis/NN ./. 
AB/LS -/: Translocations/NNS involving/VBG the/DT human/JJ CBFA2/NN locus/NN have/VBP been/VBN associated/VBN with/IN leukemia/NN ./. 
This/DT gene/NN ,/, originally/RB named/VBN AML1/NN ,/, is/VBZ a/DT human/JJ homologue/NN of/IN the/DT Drosophila/FW gene/NN runt/NN that/WDT controls/VBZ early/JJ events/NNS in/IN fly/NN embryogenesis/NN ./. 
To/TO clarify/VB the/DT role/NN of/IN mammalian/JJ runt/NN products/NNS in/IN normal/JJ and/CC leukemic/JJ hematopoiesis/NN ,/, we/PRP have/VBP studied/VBN their/PRP$ pattern/NN of/IN expression/NN in/IN mouse/NN hematopoietic/JJ tissues/NNS in/IN the/DT adult/JJ and/CC during/IN ontogeny/NN using/VBG an/DT anti-runt/JJ box/NN antiserum/NN ./. 
In/IN the/DT adult/JJ bone/NN marrow/NN ,/, we/PRP found/VBD expression/NN of/IN runt/NN polypeptides/NNS in/IN differentiating/VBG myeloid/JJ cells/NNS and/CC in/IN B/NN lymphocytes/NNS ./. 
Within/IN the/DT erythroid/JJ lineage/NN ,/, runt/NN expression/NN is/VBZ biphasic/JJ ,/, clearly/RB present/JJ in/IN the/DT erythroblasts/NNS of/IN early/JJ blood/NN islands/NNS and/CC of/IN the/DT fetal/JJ liver/NN ,/, but/CC absent/JJ in/IN the/DT adult/NN ./. 
Biochemical/JJ analysis/NN by/IN Western/NN blotting/NN of/IN fetal/JJ and/CC adult/JJ hematopoietic/JJ populations/NNS shows/VBZ several/JJ runt/JJ isoforms/NNS ./. 
At/IN least/JJS one/CD of/IN them/PRP appears/VBZ to/TO be/VB myeloid/JJ specific/JJ ./. 
UI/LS -/: 97228139/CD 
TI/LS -/: Signal/NN transducer/NN and/CC activator/NN of/IN transcription-3/NN (/( STAT3/NN )/) is/VBZ constitutively/RB activated/VBN in/IN normal/JJ ,/, self-renewing/JJ B-1/NN cells/NNS but/CC only/RB inducibly/RB expressed/VBN in/IN conventional/JJ B/NN lymphocytes/NNS [/( see/VB comments/NNS ]/) 
AB/LS -/: Cytokine/NN and/CC growth/NN factor/NN receptor/NN engagement/NN leads/VBZ to/TO the/DT rapid/JJ phosphorylation/NN and/CC activation/NN of/IN latent/JJ ,/, cytosolic/JJ signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STAT/NN )/) proteins/NNS ,/, which/WDT then/RB translocate/VBP to/TO the/DT nucleus/NN where/WRB they/PRP regulate/VBP transcriptional/JJ events/NNS from/IN specific/JJ promoter/NN sequences/NNS ./. 
STAT3/NN expression/NN in/IN particular/JJ has/VBZ been/VBN associated/VBN with/IN Abl/NN ,/, Src/NN ,/, and/CC HTLV-1/NN transformation/NN of/IN normal/JJ cells/NNS ./. 
B-1/NN lymphocytes/NNS are/VBP self-renewing/JJ ,/, CD5+/JJ B/NN cells/NNS that/WDT display/VBP a/DT propensity/NN for/IN malignant/JJ transformation/NN and/CC are/VBP the/DT normal/JJ counterpart/NN to/TO human/JJ chronic/JJ lymphocytic/JJ leukemias/NNS ./. 
Further/RB ,/, B-1/NN cells/NNS are/VBP characterized/VBN by/IN aberrant/JJ intracellular/JJ signaling/NN ,/, including/VBG hyperresponsiveness/NN to/TO phorbol/NN ester/NN PKC/NN agonists/NNS ./. 
Here/RB we/PRP demonstrate/VBP that/IN B-1/NN lymphocytes/NNS constitutively/RB express/VBP nuclear/JJ activated/VBN STAT3/NN ,/, which/WDT is/VBZ not/RB expressed/VBN by/IN unmanipulated/JJ conventional/JJ (/( B-2/NN )/) lymphocytes/NNS ./. 
In/IN contrast/NN ,/, STAT3/NN activation/NN is/VBZ induced/VBN in/IN B-2/NN cells/NNS after/IN antigen/NN receptor/NN engagement/NN in/IN a/DT delayed/JJ fashion/NN (/( after/IN 3/CD h/NN )/) ./. 
Induction/NN of/IN STAT3/NN is/VBZ inhibited/VBN by/IN both/CC the/DT serine/threonine/NN protein/NN kinase/NN inhibitor/NN H-7/NN and/CC the/DT immunosuppressive/JJ drug/NN rapamycin/NN and/CC requires/VBZ de/FW novo/FW protein/NN synthesis/NN ,/, demonstrating/VBG novel/JJ coupling/NN between/IN sIg/NN and/CC STAT/NN proteins/NNS that/WDT differs/VBZ from/IN the/DT classical/JJ paradigm/NN for/IN STAT/NN induction/NN by/IN cytokine/NN receptors/NNS ./. 
The/DT inability/NN of/IN prolonged/JJ stimulation/NN of/IN conventional/JJ B-2/NN cells/NNS with/IN anti-Ig/NN ,/, a/DT treatment/NN sufficient/JJ to/TO induce/VB CD5/NN expression/NN ,/, to/TO result/VB in/IN sustained/JJ STAT3/NN activation/NN suggests/VBZ that/IN STAT3/NN is/VBZ a/DT specific/JJ nuclear/JJ marker/NN for/IN B-1/NN cells/NNS ./. 
Thus/RB ,/, STAT3/NN may/MD play/VB a/DT role/NN in/IN B/NN cell/NN antigen-specific/JJ signaling/NN responses/NNS ,/, and/CC its/PRP$ constitutive/JJ activation/NN is/VBZ associated/VBN with/IN a/DT normal/JJ cell/NN population/NN exhibiting/VBG intrinsic/JJ proliferative/JJ behavior/NN ./. 
UI/LS -/: 97276922/CD 
TI/LS -/: Significance/NN of/IN quantitative/JJ analysis/NN of/IN AML1/ETO/NN transcripts/NNS in/IN peripheral/JJ blood/NN stem/NN cells/NNS from/IN t(8;21)/NN acute/JJ myelogenous/JJ leukemia/NN ./. 
AB/LS -/: Autologous/JJ peripheral/JJ blood/NN stem/NN cell/NN transplantation/NN (/( PBSCT/NN )/) is/VBZ replacing/VBG autologous/JJ bone/NN marrow/NN transplantation/NN (/( BMT/NN )/) in/IN the/DT treatment/NN of/IN leukemia/NN ./. 
One/CD of/IN the/DT potential/JJ advantages/NNS of/IN autologous/JJ PBSCT/NN is/VBZ the/DT possibility/NN that/IN peripheral/JJ blood/NN stem/NN cells/NNS (/( PBSC/NNS )/) are/VBP less/RBR likely/JJ to/TO be/VB contaminated/VBN by/IN leukemic/JJ cells/NNS than/IN bone/NN marrow/NN grafts/NNS ./. 
However/RB ,/, the/DT major/JJ problem/NN still/RB remains/VBZ the/DT high/JJ incidence/NN of/IN leukemic/JJ relapse/NN following/VBG autologous/JJ PBSCT/NN ,/, which/WDT may/MD be/VB caused/VBN by/IN the/DT reinfusion/NN of/IN PBSC/NNS contaminated/VBN by/IN leukemic/JJ cells/NNS ./. 
Recently/RB ,/, we/PRP have/VBP developed/VBN a/DT quantitative/JJ assay/NN using/VBG competitive/JJ reverse/JJ transcriptase/NN polymerase/NN chain/NN reaction/NN that/WDT estimates/VBZ the/DT number/NN of/IN AML1/ETO/NN transcripts/NNS in/IN t(8;21)/NN acute/JJ myelogenous/JJ leukemia/NN (/( AML/NN )/) ,/, in/IN order/NN to/TO determine/VB the/DT degree/NN of/IN leukemic/JJ cell/NN contamination/NN in/IN PBSC/NNS harvests/NNS ,/, and/CC to/TO monitor/VB minimal/JJ residual/JJ disease/NN (/( MRD/NN )/) quantitatively/RB in/IN patients/NNS with/IN t(8;21)/NN AML/NN ./. 
Our/PRP$ data/NNS indicate/VBP that/IN although/IN PBSC/NNS harvests/NNS collected/VBN after/IN consolidation/NN chemotherapy/NN are/VBP contaminated/VBN by/IN leukemic/JJ cells/NNS ,/, the/DT degree/NN of/IN leukemic/JJ cell/NN contamination/NN decreases/VBZ with/IN repeated/JJ cycles/NNS of/IN chemotherapy/NN ./. 
Furthermore/RB ,/, the/DT MRD/NN in/IN PBSC/NNS harvests/NNS is/VBZ less/JJR than/IN in/IN the/DT corresponding/JJ bone/NN marrow/NN obtained/VBN on/IN the/DT day/NN of/IN the/DT PBSC/NNS collection/NN ./. 
There/EX appears/VBZ to/TO be/VB no/DT relationship/NN between/IN the/DT number/NN of/IN AML1/ETO/NN transcripts/NNS found/VBN in/IN the/DT infused/VBN PBSC/NNS harvests/NNS and/CC the/DT incidence/NN of/IN leukemic/JJ relapse/NN following/VBG autologous/JJ PBSCT/NNS in/IN our/PRP$ study/NN ./. 
However/RB ,/, a/DT substantial/JJ decrease/NN of/IN AML1/ETO/NN transcripts/NNS was/VBD seen/VBN following/VBG autologous/JJ PBSCT/NNS ./. 
Thus/RB ,/, the/DT quantitative/JJ analysis/NN of/IN AML1/ETO/NN transcripts/NNS may/MD be/VB clinically/RB useful/JJ in/IN patients/NNS with/IN t(8;21)/NN AML/NN ./. 
UI/LS -/: 97210575/CD 
TI/LS -/: Upregulation/NN of/IN c-Fos/NN in/IN activated/VBN T/NN lymphoid/JJ and/CC monocytic/JJ cells/NNS by/IN human/JJ immunodeficiency/NN virus-1/NN Tat/NN protein/NN ./. 
AB/LS -/: The/DT regulatory/JJ Tat/NN protein/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type-1/NN (/( HIV-1/NN )/) is/VBZ essential/JJ for/IN viral/JJ replication/NN and/CC also/RB shows/VBZ pleiotropic/JJ activities/NNS on/IN various/JJ cell/NN functions/NNS ./. 
To/TO get/VB further/JJ insights/NNS into/IN the/DT molecular/JJ mechanisms/NNS underlying/VBG the/DT biological/JJ activity/NN of/IN Tat/NN ,/, we/PRP investigated/VBD the/DT effect/NN of/IN endogenous/JJ and/CC exogenous/JJ Tat/NN protein/NN on/IN c-fos/NN gene/NN expression/NN in/IN T/NN lymphoblastoid/NN (/( Jurkat/NN )/) and/CC monocytic/JJ (/( U937/NN )/) cell/NN lines/NNS ,/, as/RB well/RB as/IN in/IN primary/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NNS )/) ./. 
Transient/JJ cotransfection/NN of/IN tat/NN cDNA/NN in/IN sense/JJ orientation/NN (/( tat/S/NN )/) ,/, together/RB with/IN a/DT plasmid/NN containing/VBG the/DT c-fos/NN promoter/NN (/( FC3/NN ,/, from/IN -711/CD to/TO +42/CD )/) in/IN front/NN of/IN the/DT bacterial/JJ chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) gene/NN significantly/RB enhanced/VBD CAT/NN activity/NN in/IN Jurkat/NN cells/NNS activated/VBN by/IN the/DT addition/NN of/IN 15/CD %/NN fetal/JJ calf/NN serum/NN (/( FCS/NN )/) or/CC 5/CD micrograms/mL/NNS phytohemagglutinin/NN plus/CC 10(-7)/CD mol/L/NN phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) and/CC U937/NN cells/NNS activated/VBN by/IN 15/CD %/NN FCS/NN or/CC 10(-7)/CD mol/L/NN PMA/NN ./. 
This/DT effect/NN was/VBD specifically/RB due/JJ to/TO Tat/NN ,/, since/IN Jurkat/NN and/CC U937/NN cells/NNS cotransfected/VBN either/CC with/IN tat/NN cDNA/NN in/IN antisense/JJ orientation/NN (/( tat/AS/NN )/) ,/, tat/NN carrying/VBG a/DT mutation/NN in/IN the/DT aminoacid/JJ cys22-gly22/NN (/( tat/NN 22/S/NN )/) or/CC with/IN the/DT backbone/NN vector/NN alone/RB (/( pRPneo-SL3/NN )/) did/VBD not/RB show/VB any/DT significant/JJ difference/NN in/IN c-fos/NN promoter/NN activity/NN as/IN compared/VBN to/TO cells/NNS transfected/VBN with/IN FC3/NN plasmid/NN alone/RB ./. 
By/IN using/VBG deletion/NN mutants/NNS of/IN the/DT c-fos/NN promoter/NN ,/, we/PRP found/VBD that/IN the/DT minimal/JJ DNA/NN sequence/NN required/VBN for/IN Tat/NN activity/NN was/VBD located/JJ between/IN nucleotides/NNS -404/-220/CD and/CC that/IN the/DT serum/NN responsive/JJ element/NN (/( SRE/NN ,/, -317/-288/CD )/) ,/, present/JJ within/IN this/DT region/NN ,/, was/VBD still/RB responsive/JJ to/TO Tat/NN ./. 
A/DT single/JJ point/NN mutation/NN in/IN the/DT SRE/NN completely/RB abrogated/VBD the/DT responsiveness/NN to/TO tat/S/NN ./. 
Exogenous/JJ recombinant/JJ Tat/NN protein/NN was/VBD also/RB able/JJ to/TO upregulate/VB c-fos/NN promoter/NN activity/NN in/IN serum-activated/JJ Jurkat/NN and/CC U937/NN cells/NNS ,/, as/RB well/RB as/IN endogenous/JJ c-fos/NN mRNA/NN expression/NN and/CC c-Fos/NN protein/NN synthesis/NN in/IN both/CC serum-activated/JJ cell/NN lines/NNS and/CC primary/JJ PBMC/NN ./. 
c-Fos/NN protein/NN was/VBD shown/VBN essential/JJ for/IN an/DT optimal/JJ transactivation/NN of/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) by/IN Tat/NN :/: incubation/NN of/IN Jurkat/NN cells/NNS with/IN antisense/JJ ,/, but/CC not/RB sense/NN ,/, c-fos/NN oligonucleotides/NNS significantly/RB reduced/VBD either/CC the/DT Tat-enhanced/JJ expression/NN of/IN an/DT LTR-CAT/NN reporter/NN construct/NN or/CC the/DT levels/NNS of/IN gag/NN p24/NN in/IN the/DT culture/NN supernatants/NNS of/IN Jurkat/NN cells/NNS and/CC PBMC/NN acutely/RB infected/VBN with/IN HIV-1/NN ./. 
Our/PRP$ data/NNS suggest/VBP that/IN the/DT c-fos/NN upregulation/NN mediated/VBN by/IN Tat/NN might/MD play/VB a/DT significant/JJ role/NN in/IN the/DT control/NN of/IN viral/JJ gene/NN transactivation/NN ./. 
UI/LS -/: 97239596/CD 
TI/LS -/: Cytokine/NN signal/NN networks/NNS and/CC a/DT new/JJ era/NN in/IN biomedical/JJ research/NN ./. 
AB/LS -/: Elucidation/NN of/IN the/DT biochemical/JJ nature/NN of/IN the/DT signal/NN transduction/NN pathway/NN that/WDT regulate/VBP transcription/NN and/CC replication/NN is/VBZ the/DT focus/NN of/IN attention/NN in/IN molecular/JJ biology/NN ./. 
This/DT research/NN may/MD make/VB feasible/JJ manipulation/NN of/IN growth/NN and/CC differentiation/NN of/IN mammalian/JJ cells/NNS ,/, which/WDT in/IN turn/NN would/MD have/VB profound/JJ implication/NN in/IN biomedical/JJ research/NN on/IN cell/NN and/CC gene/NN therapy/NN ,/, and/CC development/NN of/IN pharmaceutical/JJ products/NNS ./. 
Cytokines/NNS control/VBP growth/NN ,/, differentiation/NN ,/, death/NN ,/, and/CC function/NN of/IN cells/NNS of/IN lymphocytic/JJ ,/, hemopoietic/JJ systems/NNS ,/, and/CC together/RB with/IN nerve/JJ cells/NNS provide/VBP a/DT pertinent/JJ model/NN to/TO study/VB intercellular/JJ communications/NNS and/CC intercellular/JJ signal/NN networks/NNS ./. 
This/DT review/NN outlines/VBZ general/JJ features/NNS of/IN signal/NN transduction/NN and/CC several/JJ aspects/NNS of/IN cytokine/NN networks/NNS are/VBP discussed/VBN with/IN emphasis/NN on/IN :/: transcriptional/JJ regulation/NN of/IN Th1/NN and/CC Th2-specific/JJ cytokine/NN genes/NNS in/IN T/NN cells/NNS ,/, the/DT roles/NNS of/IN cytokines/NNS and/CC their/PRP$ receptors/NNS in/IN growth/NN and/CC differentiation/NN of/IN hemopoietic/JJ cells/NNS ,/, and/CC the/DT manipulation/NN of/IN cytokine/NN networks/NNS ./. 
UI/LS -/: 97205502/CD 
TI/LS -/: Regulation/NN of/IN the/DT tissue/NN factor/NN gene/NN in/IN human/JJ monocytic/JJ cells/NNS ./. 
Role/NN of/IN AP-1/NN ,/, NF-kappa/NN B/Rel/NN ,/, and/CC Sp1/NN proteins/NNS in/IN uninduced/JJ and/CC lipopolysaccharide-induced/JJ expression/NN ./. 
AB/LS -/: Tissue/NN factor/NN (/( TF/NN )/) expression/NN by/IN peripheral/JJ blood/NN monocytes/NNS during/IN sepsis/NN initiates/VBZ intravascular/JJ thrombosis/NN ./. 
Bacterial/JJ lipopolysaccharide/NN (/( LPS/NN )/) rapidly/RB induces/VBZ TF/NN gene/NN transcription/NN in/IN monocytes/NNS ./. 
The/DT human/JJ TF/NN promoter/NN contains/VBZ binding/VBG sites/NNS for/IN the/DT transcription/NN factors/NNS AP-1/NN ,/, c-Rel/p65/NN ,/, Egr-1/NN ,/, and/CC Sp1/NN ./. 
NF-kappa/NN B/Rel/NN proteins/NNS have/VBP been/VBN shown/VBN to/TO physically/RB interact/VB with/IN both/CC AP-1/NN and/CC Sp1/NN proteins/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP investigated/VBD the/DT role/NN of/IN these/DT transcription/NN factors/NNS in/IN uninduced/JJ and/CC LPS-induced/JJ TF/NN gene/NN expression/NN in/IN human/JJ monocytic/JJ THP-1/NN cells/NNS ./. 
Deletional/JJ analysis/NN indicated/VBD that/IN five/CD Sp1/NN sites/NNS mediated/VBD basal/JJ expression/NN in/IN uninduced/JJ cells/NNS ./. 
The/DT two/CD AP-1/NN sites/NNS bound/VBD c-Fos/c-Jun/NN heterodimers/NNS in/IN both/CC unstimulated/JJ and/CC LPS-stimulated/JJ cells/NNS ./. 
Maximal/JJ LPS/NN induction/NN of/IN the/DT TF/NN promoter/NN required/VBD the/DT two/CD AP-1/NN sites/NNS and/CC the/DT kappa/NN B/NN site/NN within/IN the/DT LPS/NN response/NN element/NN ./. 
Disruption/NN of/IN the/DT conserved/VBN spacing/NN between/IN the/DT proximal/JJ AP-1/NN site/NN and/CC the/DT kappa/NN B/NN site/NN abolished/VBD LPS/NN induction/NN ./. 
Replacement/NN of/IN the/DT two/CD AP-1/NN sites/NNS with/IN intrinsically/RB bent/JJ DNA/NN partially/RB restored/VBD LPS/NN induction/NN ,/, suggesting/VBG an/DT additional/JJ structural/JJ role/NN for/IN the/DT AP-1/NN sites/NNS ./. 
Synergistic/JJ transactivation/NN of/IN the/DT LPS/NN response/NN element/NN in/IN Drosophila/FW Schneider/NN cells/NNS by/IN coexpression/NN of/IN c-Fos/NN ,/, c-Jun/NN ,/, c-Rel/NN ,/, and/CC p65/NN or/CC c-Jun/NN and/CC p65/NN required/VBD the/DT transactivation/NN domains/NNS of/IN c-Jun/NN and/CC p65/NN ./. 
These/DT data/NNS indicated/VBD that/IN c-Fos/c-Jun/NN ,/, c-Rel/p65/NN ,/, and/CC Sp1/NN regulate/VBP TF/NN gene/NN expression/NN in/IN human/JJ monocytic/JJ cells/NNS ./. 
UI/LS -/: 97166081/CD 
TI/LS -/: Inhibitory/JJ effect/NN of/IN growth/NN hormone/NN on/IN TNF-alpha/NN secretion/NN and/CC nuclear/JJ factor-kappaB/NN translocation/NN in/IN lipopolysaccharide-stimulated/JJ human/JJ monocytes/NNS ./. 
AB/LS -/: Several/JJ studies/NNS have/VBP pointed/VBN to/TO a/DT link/NN between/IN immune/JJ and/CC endocrine/JJ systems/NNS ,/, including/VBG a/DT regulatory/JJ function/NN of/IN GH/NN on/IN monocyte/NN activation/NN ./. 
The/DT present/JJ study/NN demonstrates/VBZ that/IN human/JJ THP-1/NN promonocytic/JJ cells/NNS ,/, engineered/VBN by/IN gene/NN transfer/NN to/TO constitutively/RB produce/VB human/JJ growth/NN hormone/NN (/( hGH/NN )/) ,/, secreted/VBD depressed/VBN amounts/NNS of/IN TNF-alpha/NN in/IN response/NN to/TO challenge/NN by/IN LPS/NN ./. 
The/DT effect/NN of/IN GH/NN appears/VBZ to/TO occur/VB in/IN an/DT autocrine/JJ fashion/NN ,/, since/IN the/DT inhibitory/JJ effect/NN on/IN TNF-alpha/NN secretion/NN by/IN constitutive/JJ GH/NN production/NN could/MD be/VB abolished/VBN in/IN the/DT presence/NN of/IN anti-hGH/JJ mAb/NN ./. 
The/DT GH-induced/JJ inhibitory/JJ effect/NN was/VBD also/RB observed/VBN using/VBG normal/JJ human/JJ monocytes/NNS and/CC monocyte-derived/JJ macrophages/NNS ./. 
Inhibition/NN of/IN TNF-alpha/NN production/NN by/IN THP-1-hGH-transfected/JJ cells/NNS cultured/VBN in/IN the/DT presence/NN of/IN LPS/NN is/VBZ dependent/JJ on/IN a/DT selective/JJ pathway/NN ,/, since/IN no/DT inhibition/NN of/IN TNF-alpha/NN production/NN was/VBD observed/VBN when/WRB cells/NNS were/VBD cultured/VBN in/IN the/DT presence/NN of/IN PMA/NN ./. 
Inhibition/NN of/IN TNF-alpha/NN secretion/NN by/IN LPS-stimulated/JJ THP-1-hGH/NN cells/NNS was/VBD associated/VBN with/IN a/DT decrease/NN in/IN nuclear/JJ translocation/NN of/IN nuclear/JJ factor-kappaB/NN ./. 
The/DT capacity/NN of/IN GH/NN to/TO inhibit/VB LPS-induced/JJ TNF-alpha/NN production/NN by/IN monocytes/NNS without/IN altering/VBG other/JJ pathways/NNS leading/VBG to/TO TNF-alpha/NN production/NN may/MD be/VB of/IN potential/JJ relevance/NN in/IN septic/JJ shock/NN ,/, since/IN GH/NN is/VBZ available/JJ for/IN clinical/JJ use/NN ./. 
UI/LS -/: 97162234/CD 
TI/LS -/: Nuclear/JJ factor-kappaB/NN activation/NN in/IN human/JJ monocytes/NNS stimulated/VBN with/IN lipopolysaccharide/NN is/VBZ inhibited/VBN by/IN fibroblast/NN conditioned/JJ medium/NN and/CC exogenous/JJ PGE2/NN ./. 
AB/LS -/: The/DT nuclear/JJ factor/NN kappaB/NN (/( NF-kappaB/NN )/) is/VBZ thought/VBN to/TO be/VB crucially/RB involved/VBN in/IN the/DT gene/NN activation/NN of/IN several/JJ cytokines/NNS ,/, including/VBG tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF/NN )/) ./. 
Previously/RB ,/, we/PRP showed/VBD that/IN fibroblast/NN conditioned/JJ medium/NN (/( FCM/NN )/) is/VBZ able/JJ to/TO inhibit/VB both/CC TNF/NN mRNA/NN accumulation/NN and/CC protein/NN release/NN in/IN peripheral/JJ blood-derived/JJ human/JJ monocytes/NNS (/( PBM/NNS )/) stimulated/VBN with/IN lipopolysaccharide/NN (/( LPS/NN )/) ./. 
In/IN this/DT study/NN we/PRP have/VBP investigated/VBN the/DT effect/NN of/IN FCM/NN on/IN the/DT LPS-induced/JJ DNA-binding/NN activity/NN of/IN NF-kappaB/NN ,/, by/IN means/NNS of/IN electrophoretic/JJ shift/NN assay/NN (/( EMSA/NN )/) ./. 
We/PRP provide/VBP evidence/NN that/IN FCM/NN strongly/RB inhibits/VBZ the/DT LPS-induced/JJ NF-kappaB/NN activation/NN in/IN PBM/NNS ./. 
Furthermore/RB ,/, we/PRP show/VBP that/IN exogenous/JJ PGE2/NN mimics/VBZ the/DT NF-kappaB/NN inhibitory/JJ effect/NN of/IN FCM/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, FCM/NN produced/VBN in/IN the/DT presence/NN of/IN indomethacin/NN does/VBZ not/RB inhibit/VB NF-kappaB/NN activation/NN by/IN LPS/NN ./. 
Our/PRP$ results/NNS lend/VBP further/JJ support/NN to/TO the/DT hypothesis/NN that/IN inflammatory/JJ and/CC immune/JJ responses/NNS of/IN monocytes/macrophages/NNS may/MD be/VB modulated/VBN at/IN the/DT molecular/JJ level/NN by/IN signals/NNS originating/VBG from/IN tissue/NN structural/JJ cells/NNS such/JJ as/IN fibroblasts/NNS ./. 
UI/LS -/: 97269081/CD 
TI/LS -/: Human/JJ neutrophil/NN elastase/NN proteolytically/RB activates/VBZ the/DT platelet/NN integrin/NN alphaIIbbeta3/NN through/IN cleavage/NN of/IN the/DT carboxyl/NN terminus/NN of/IN the/DT alphaIIb/NN subunit/NN heavy/JJ chain/NN ./. 
Involvement/NN in/IN the/DT potentiation/NN of/IN platelet/NN aggregation/NN ./. 
AB/LS -/: Neutrophil/NN elastase/NN (/( NE/NN )/) and/CC cathepsin/NN G/NN are/VBP two/CD serine/NN proteinases/NNS released/VBN concomitantly/RB by/IN stimulated/VBN polymorphonuclear/JJ neutrophils/NNS ./. 
We/PRP previously/RB demonstrated/VBD that/IN while/IN NE/NN by/IN itself/PRP does/VBZ not/RB activate/VB human/JJ platelets/NNS ,/, it/PRP strongly/RB enhances/VBZ the/DT weak/JJ aggregation/NN induced/VBN by/IN a/DT threshold/NN concentration/NN of/IN cathepsin/NN G/NN (/( threshold/NN of/IN cathepsin/NN G/NN )/) (/( Renesto/NNP ,/, P./NNP ,/, and/CC Chignard/NNP ,/, M./NNP (/( 1993/CD )/) Blood/NNP 82/CD ,/, 139-144/CD )/) ./. 
The/DT aim/NN of/IN this/DT study/NN was/VBD to/TO delineate/VB the/DT molecular/JJ mechanisms/NNS involved/VBN in/IN this/DT potentiation/NN process/NN ./. 
Two/CD main/JJ pieces/NNS of/IN data/NNS prompted/VBD us/PRP to/TO focus/VB on/IN the/DT activation/NN of/IN the/DT platelet/NN fibrinogen/NN receptor/NN ,/, the/DT alphaIIbbeta3/NN integrin/NN ./. 
First/RB ,/, previous/JJ studies/NNS have/VBP shown/VBN this/DT integrin/NN to/TO be/VB particularly/RB prone/JJ to/TO proteolytic/JJ regulation/NN of/IN its/PRP$ function/NN ./. 
Second/RB ,/, we/PRP found/VBD that/IN the/DT potentiating/NN activity/NN of/IN NE/NN on/IN the/DT threshold/NN of/IN cathepsin/NN G-induced/JJ platelet/NN aggregation/NN was/VBD strictly/RB dependent/JJ on/IN the/DT presence/NN of/IN exogenous/JJ fibrinogen/NN ./. 
Using/VBG flow/NN cytometry/NN analysis/NN ,/, NE/NN was/VBD shown/VBN to/TO trigger/VB a/DT time-dependent/JJ binding/NN of/IN PAC-1/NN and/CC AP-5/NN ,/, two/CD monoclonal/JJ antibodies/NNS specific/JJ for/IN the/DT activated/VBN and/CC ligand-occupied/JJ conformers/NNS of/IN alphaIIbbeta3/NN ./. 
Furthermore/RB ,/, the/DT potentiated/JJ aggregation/NN was/VBD shown/VBN to/TO result/VB from/IN an/DT increased/VBN capacity/NN of/IN platelets/NNS to/TO bind/VB fibrinogen/NN ./. 
Indeed/RB ,/, the/DT combination/NN of/IN NE/NN and/CC threshold/NN of/IN cathepsin/NN G/NN increased/VBD the/DT binding/NN of/IN PAC-1/NN approximately/RB 5.5-fold/RB over/IN basal/JJ values/NNS measured/VBN on/IN nontreated/JJ platelets/NNS ,/, whereas/IN this/DT binding/NN raised/VBD only/RB by/IN approximately/RB 3-fold/RB in/IN threshold/NN of/IN cathepsin/NN G-stimulated/JJ platelets/NNS (/( p/NN </JJR 0.05/CD )/) ./. 
By/IN contrast/NN ,/, phosphatidic/JJ acid/NN accumulation/NN ,/, pleckstrin/NN phosphorylation/NN ,/, and/CC calcium/NN mobilization/NN produced/VBN by/IN the/DT combination/NN of/IN NE/NN and/CC threshold/NN of/IN cathepsin/NN G/NN were/VBD not/RB significantly/RB different/JJ from/IN those/DT measured/VBN with/IN threshold/NN of/IN cathepsin/NN G/NN alone/RB (/( p/NN >/JJR 0.05/CD )/) ,/, indicating/VBG that/IN the/DT phospholipase/NN C/protein/NN kinase/NN C/NN pathway/NN is/VBZ not/RB involved/VBN in/IN the/DT potentiation/NN of/IN aggregation/NN ./. 
The/DT foregoing/JJ data/NNS ,/, as/RB well/RB as/IN the/DT requirement/NN of/IN catalytically/RB active/JJ NE/NN to/TO trigger/VB alphaIIbbeta3/NN activation/NN and/CC potentiate/VB threshold/NN of/IN cathepsin/NN G-initiated/JJ platelet/NN aggregation/NN ,/, led/VBD us/PRP to/TO examine/VB whether/IN the/DT structure/NN of/IN this/DT integrin/NN was/VBD affected/VBN by/IN NE/NN ./. 
Immunoblot/NN and/CC flow/NN cytometry/NN analysis/NN revealed/VBD a/DT limited/JJ proteolysis/NN of/IN the/DT carboxyl/NN terminus/NN of/IN the/DT alphaIIb/NN subunit/NN heavy/JJ chain/NN (/( alphaIIbH/NN )/) ,/, as/IN judged/VBN by/IN the/DT disappearance/NN of/IN the/DT epitope/NN for/IN the/DT monoclonal/JJ antibody/JJ PMI-1/NN ./. 
Mass/JJ spectrometry/NN studies/NNS performed/VBN on/IN a/DT synthetic/JJ peptide/NN mapping/VBG over/IN the/DT cleavage/NN domain/NN of/IN alphaIIbH/NN predicted/VBD the/DT site/NN of/IN proteolysis/NN as/IN located/JJ between/IN Val837/NN and/CC Asp838/NN ./. 
Treatment/NN by/IN NE/NN of/IN ATP-depleted/JJ platelets/NNS or/CC Chinese/JJ hamster/NN ovary/NN cells/NNS expressing/VBG human/JJ recombinant/NN alphaIIbbeta3/NN clearly/RB established/VBD that/IN activation/NN of/IN the/DT integrin/NN was/VBD independent/JJ of/IN signal/NN transduction/NN events/NNS and/CC was/VBD concomitant/JJ with/IN the/DT proteolysis/NN of/IN alphaIIbH/NN ./. 
UI/LS -/: 97353026/CD 
TI/LS -/: AP-1/NN derived/VBN from/IN mature/JJ monocytes/NNS and/CC astrocytes/NNS preferentially/RB interacts/VBZ with/IN the/DT HTLV-I/NN promoter/NN central/JJ 21/CD bp/NN repeat/NN ./. 
AB/LS -/: Characterization/NN of/IN the/DT cellular/JJ transcription/NN factors/NNS interacting/VBG with/IN the/DT human/JJ T/NN cell/NN lymphotropic/JJ virus/NN type/NN I/CD (/( HTLV-I/NN )/) long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) is/VBZ essential/JJ to/TO dissecting/VBG the/DT mechanisms/NNS involved/VBN in/IN viral/JJ transcription/NN that/WDT may/MD be/VB pertinent/JJ to/TO the/DT oncogenic/JJ and/CC neuropathogenic/JJ processes/NNS associated/VBN with/IN HTLV-I/NN infection/NN in/IN both/CC the/DT immune/JJ and/CC nervous/JJ systems/NNS ./. 
Electrophoretic/JJ mobility/NN shift/NN (/( EMS/NN )/) analyses/NNS utilizing/VBG oligonucleotides/NNS homologous/JJ to/TO each/DT of/IN the/DT 21/CD bp/NN repeat/NN elements/NNS reacted/VBN with/IN nuclear/JJ extracts/NNS derived/VBN from/IN cell/NN lines/NNS of/IN lymphocytic/JJ ,/, monocytic/JJ ,/, neuronal/JJ ,/, and/CC glial/JJ cell/NN origin/NN have/VBP demonstrated/VBN differential/JJ binding/NN of/IN cellular/JJ factors/NNS to/TO the/DT three/CD 21/CD bp/NN repeats/NNS (/( 1-4/CD )/) ./. 
ATF/CREB/NN and/CC Sp/NN family/NN members/NNS interacted/VBD with/IN the/DT 21/CD bp/NN repeats/NNS to/TO form/VB DNA-protein/JJ complexes/NNS common/JJ to/TO all/DT cell/NN types/NNS examined/VBN ./. 
However/RB ,/, a/DT unique/JJ DNA-protein/JJ complex/NN was/VBD detected/VBN when/WRB the/DT promoter/NN central/JJ 21/CD bp/NN repeat/NN was/VBD reacted/VBN with/IN nuclear/JJ extracts/NNS derived/VBN from/IN either/CC the/DT U-373/NN MG/NN glioblastoma/NN cell/NN line/NN or/CC the/DT THP-1/NN mature/JJ monocytic/JJ cell/NN line/NN ./. 
Based/VBN on/IN nucleotide/NN sequence/NN requirements/NNS and/CC immunoreactivity/NN ,/, we/PRP demonstrate/VBP that/IN this/DT DNA-protein/JJ complex/NN is/VBZ comprised/VBN of/IN the/DT AP-1/NN components/NNS ,/, Fos/NN and/CC Jun/NN ./. 
UI/LS -/: 97248268/CD 
TI/LS -/: HIV/NN does/VBZ not/RB replicate/VB in/IN naive/JJ CD4/NN T/NN cells/NNS stimulated/VBN with/IN CD3/CD28/NN ./. 
AB/LS -/: In/IN this/DT report/NN ,/, we/PRP demonstrate/VBP that/IN the/DT T/NN cell/NN tropic/JJ strain/NN of/IN HIV/NN ,/, LAI/NN ,/, does/VBZ not/RB replicate/VB in/IN naive/JJ CD4/NN T/NN cells/NNS stimulated/VBN by/IN cross-linking/JJ CD3/NN and/CC CD28/NN ./. 
In/IN contrast/NN ,/, LAI/NN replicates/VBZ well/RB in/IN memory/NN CD4/NN T/NN cells/NNS stimulated/VBN in/IN the/DT same/JJ way/NN ./. 
Unlike/IN this/DT physiologically/RB relevant/JJ stimulation/NN ,/, PHA/NN stimulates/VBZ productive/JJ LAI/NN replication/NN in/IN both/CC naive/JJ and/CC memory/NN T/NN cells/NNS ./. 
These/DT studies/NNS were/VBD conducted/VBN with/IN highly/RB purified/VBN (/( FACS-isolated/JJ )/) subsets/NNS of/IN CD4/NN T/NN cells/NNS identified/VBN by/IN expression/NN of/IN both/CC CD45RA/NN and/CC CD62L/NN ./. 
Remixing/NN of/IN purified/VBN T/NN cells/NNS showed/VBD that/IN naive/JJ T/NN cells/NNS do/VBP not/RB suppress/VB LAI/NN replication/NN in/IN memory/NN T/NN cells/NNS and/CC that/IN memory/NN T/NN cells/NNS do/VBP not/RB restore/VB LAI/NN expression/NN in/IN naive/JJ T/NN cells/NNS ./. 
The/DT suppression/NN of/IN productive/JJ LAI/NN replication/NN in/IN naive/JJ T/NN cells/NNS is/VBZ not/RB due/JJ to/TO differential/JJ expression/NN of/IN viral/JJ coreceptors/NNS ,/, nor/CC is/VBZ it/PRP due/JJ to/TO inhibition/NN of/IN activation/NN of/IN the/DT important/JJ HIV/NN transcription/NN factors/NNS ,/, nuclear/JJ factor-kappaB/NN and/CC activator/NN protein-1/NN ./. 
The/DT inherent/JJ resistance/NN of/IN naive/JJ T/NN cells/NNS to/TO productive/JJ HIV/NN infection/NN ,/, coupled/VBN with/IN their/PRP$ proliferative/JJ advantage/NN as/IN demonstrated/VBN here/RB ,/, provides/VBZ a/DT sound/JJ basis/NN for/IN proposed/JJ clinical/JJ therapies/NNS using/VBG ex/FW vivo/FW expansion/NN and/CC reinfusion/NN of/IN CD4/NN T/NN cells/NNS from/IN HIV-infected/JJ adults/NNS ./. 
UI/LS -/: 97225991/CD 
TI/LS -/: A/DT PMLRARalpha/NN transgene/NN initiates/VBZ murine/JJ acute/JJ promyelocytic/JJ leukemia/NN ./. 
AB/LS -/: The/DT malignant/JJ cells/NNS of/IN acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) contain/VBP a/DT reciprocal/JJ chromosomal/JJ translocation/NN that/WDT fuses/VBZ the/DT promyelocytic/JJ leukemia/NN gene/NN (/( PML/NN )/) with/IN the/DT retinoic/JJ acid/NN receptor/NN alpha/NN gene/NN (/( RAR/NN alpha/NN )/) ./. 
To/TO test/VB the/DT hypothesis/NN that/IN the/DT chimera/NN PMLRAR/NN alpha/NN plays/VBZ a/DT role/NN in/IN leukemogenesis/NN ,/, we/PRP expressed/VBD a/DT PMLRAR/NN alpha/NN cDNA/NN in/IN myeloid/JJ cells/NNS of/IN transgenic/JJ mice/NNS ./. 
PMLRAR/NN alpha/NN transgenic/JJ mice/NNS exhibited/VBD impaired/JJ neutrophil/NN maturation/NN early/RB in/IN life/NN ,/, which/WDT progressed/VBD at/IN a/DT low/JJ frequency/NN over/IN the/DT course/NN of/IN several/JJ months/NNS to/TO overt/JJ APL/NN ./. 
Both/CC the/DT preleukemic/JJ state/NN and/CC the/DT leukemia/NN could/MD be/VB transplanted/VBN to/TO nontransgenic/JJ mice/NNS ,/, and/CC the/DT transplanted/VBN preleukemia/NN could/MD progress/VB to/TO APL/NN ./. 
The/DT APL/NN recapitulated/VBD features/NNS of/IN the/DT human/JJ disease/NN ,/, including/VBG a/DT response/NN to/TO retinoic/JJ acid/NN ./. 
Retinoic/JJ acid/NN caused/VBD the/DT leukemic/JJ cells/NNS to/TO differentiate/VB in/FW vitro/FW and/CC in/FW vivo/FW ,/, eliciting/VBG remissions/NNS of/IN both/CC the/DT preleukemic/JJ state/NN and/CC APL/NN in/IN mice/NNS ./. 
Our/PRP$ results/NNS demonstrate/VBP that/IN PMLRAR/NN alpha/NN impairs/VBZ neutrophil/NN differentiation/NN and/CC initiates/VBZ the/DT development/NN of/IN APL/NN ./. 
The/DT transgenic/JJ mice/NNS described/VBN here/RB provide/VBP an/DT apparently/RB accurate/JJ model/NN for/IN human/JJ APL/NN that/WDT includes/VBZ clear/JJ evidence/NN of/IN tumor/NN progression/NN ./. 
The/DT model/NN should/MD be/VB useful/JJ for/IN exploring/VBG the/DT molecular/JJ pathogenesis/NN of/IN APL/NN and/CC the/DT mechanisms/NNS of/IN the/DT therapeutic/JJ response/NN to/TO retinoic/JJ acid/NN ,/, as/RB well/RB as/IN for/IN preclinical/JJ studies/NNS of/IN therapeutic/JJ regimens/NNS ./. 
UI/LS -/: 97276992/CD 
TI/LS -/: DNA/NN methylation/NN changes/NNS in/IN hematologic/JJ malignancies/NNS :/: biologic/JJ and/CC clinical/JJ implications/NNS ./. 
AB/LS -/: DNA/NN methylation/NN changes/NNS are/VBP among/IN the/DT most/RBS common/JJ detectable/JJ abnormalities/NNS in/IN human/JJ neoplasia/NN ./. 
Hypermethylation/NN within/IN the/DT promoters/NNS of/IN selected/VBN genes/NNS appears/VBZ to/TO be/VB especially/RB common/JJ in/IN all/DT types/NNS of/IN human/JJ hematopoietic/JJ neoplasms/NNS ,/, and/CC is/VBZ usually/RB associated/VBN with/IN inactivation/NN of/IN the/DT involved/VBN gene/NN (/( s/NNS )/) ./. 
Such/JJ hypermethylation-associated/JJ silencing/NN of/IN gene/NN expression/NN has/VBZ been/VBN shown/VBN for/IN several/JJ genes/NNS regulating/VBG the/DT growth/NN and/CC differentiation/NN of/IN hematopoietic/JJ cells/NNS ,/, including/VBG the/DT estrogen/NN receptor/NN (/( ER/NN )/) gene/NN ,/, P15/NN ,/, P16/NN and/CC others/NNS ./. 
Hypermethylation/NN within/IN the/DT promoters/NNS of/IN some/DT genes/NNS appear/VBP to/TO be/VB an/DT early/JJ event/NN in/IN the/DT pathogenesis/NN of/IN neoplasia/NN (/( ER/NN ,/, P15/NN )/) ,/, while/IN other/JJ genes/NNS seem/VBP to/TO become/VB methylated/VBN during/IN the/DT progression/NN of/IN leukemias/NNS (/( HIC1/NN ,/, c-abl/NN )/) ./. 
The/DT high/JJ prevalence/NN of/IN promoter/NN methylation/NN suggests/VBZ that/IN this/DT molecular/JJ abnormality/NN can/MD be/VB used/VBN to/TO monitor/VB disease/NN activity/NN during/IN therapy/NN ./. 
In/IN addition/NN ,/, new/JJ technology/NN allows/VBZ the/DT sensitive/JJ identification/NN of/IN gene/NN hypermethylation/NN in/IN a/DT background/NN of/IN normal/JJ cells/NNS ,/, suggesting/VBG possible/JJ new/JJ strategies/NNS for/IN the/DT detection/NN of/IN minimal/JJ residual/JJ disease/NN ./. 
Finally/RB ,/, reactivation/NN of/IN tumor-suppressor/JJ gene/NN expression/NN through/IN pharmacologic/JJ inhibition/NN of/IN DNA/NN methyltransferase/NN and/CC resultant/JJ DNA/NN demethylation/NN appears/VBZ to/TO be/VB a/DT promising/JJ new/JJ avenue/NN of/IN therapy/NN in/IN acute/JJ leukemia/NN ./. 
UI/LS -/: 97214626/CD 
TI/LS -/: Redox/NN regulation/NN of/IN the/DT mitogen-activated/JJ protein/NN kinase/NN pathway/NN during/IN lymphocyte/NN activation/NN ./. 
AB/LS -/: We/PRP have/VBP previously/RB demonstrated/VBN an/DT obligatory/JJ requirement/NN for/IN intracellular/JJ reactive/JJ oxygen/NN species/NNS generation/NN during/IN T/NN lymphocyte/NN activation/NN ,/, and/CC have/VBP proposed/VBN that/IN intracellular/JJ reactive/JJ oxygen/NN species/NNS may/MD act/VB as/IN signalling/NN agents/NNS in/IN the/DT regulation/NN of/IN certain/JJ cellular/JJ processes/NNS ,/, for/IN example/NN ,/, during/IN cell/NN cycle/NN entry/NN ./. 
To/TO test/VB this/DT hypothesis/NN ,/, we/PRP have/VBP been/VBN interested/VBN to/TO determine/VB which/WP ,/, if/IN any/DT ,/, cell/NN cycle/NN entry/NN events/NNS are/VBP affected/VBN by/IN oxidative/JJ signalling/NN ./. 
In/IN earlier/JJR studies/NNS ,/, we/PRP have/VBP identified/VBN the/DT transcription/NN factors/NNS NF-kappa/NN B/NN and/CC AP-1/NN as/IN molecular/JJ targets/NNS for/IN oxidative/JJ signalling/NN processes/NNS during/IN cell/NN cycle/NN entry/NN ,/, and/CC have/VBP shown/VBN that/IN oxidative/JJ signalling/NN is/VBZ involved/VBN in/IN the/DT regulation/NN of/IN early/JJ changes/NNS in/IN gene/NN expression/NN during/IN the/DT G0/NN to/TO G1/NN phase/NN transition/NN ./. 
To/TO extend/VB these/DT initial/JJ observations/NNS ,/, we/PRP have/VBP examined/VBN the/DT effect/NN of/IN antioxidant/JJ treatment/NN on/IN the/DT activity/NN of/IN the/DT mitogen-activated/JJ protein/NN kinases/NNS erk1/NN and/CC erk2/NN ,/, as/IN members/NNS of/IN a/DT signal/NN transduction/NN pathway/NN known/VBN to/TO directly/RB regulate/VB transcription/NN factor/NN function/NN ./. 
Using/VBG as/IN a/DT probe/NN cysteamine/NN ,/, an/DT aminothiol/NN compound/NN with/IN both/CC antioxidant/JJ and/CC antiproliferative/JJ activity/NN ,/, we/PRP have/VBP identified/VBN erk2/NN ,/, a/DT key/JJ element/NN of/IN the/DT MAP/NN kinase/NN pathway/NN ,/, as/IN being/VBG responsive/JJ to/TO oxidative/JJ signalling/NN during/IN lymphocyte/NN activation/NN ./. 
These/DT observations/NNS provide/VBP further/JJ evidence/NN to/TO suggest/VB a/DT role/NN for/IN intracellular/JJ oxidant/JJ generation/NN as/IN a/DT regulatory/JJ mechanism/NN during/IN cell/NN cycle/NN entry/NN ,/, and/CC establish/VBP a/DT link/NN between/IN oxidative/JJ signalling/NN and/CC other/JJ aspects/NNS of/IN the/DT intracellular/JJ signalling/NN network/NN that/WDT is/VBZ activated/VBN in/IN response/NN to/TO mitogenic/JJ stimulation/NN ./. 
UI/LS -/: 97184448/CD 
TI/LS -/: Physical/JJ and/CC functional/JJ interaction/NN between/IN the/DT human/JJ T-cell/NN lymphotropic/JJ virus/NN type/NN 1/CD Tax1/NN protein/NN and/CC the/DT CCAAT/NN binding/NN protein/NN NF-Y/NN ./. 
AB/LS -/: Tax1/NN ,/, a/DT potent/JJ activator/NN of/IN human/JJ T-cell/NN lymphotropic/JJ virus/NN type/NN 1/CD (/( HTLV-1/NN )/) transcription/NN ,/, has/VBZ been/VBN shown/VBN to/TO modulate/VB expression/NN of/IN many/JJ cellular/JJ genes/NNS ./. 
Tax1/NN does/VBZ not/RB bind/VB DNA/NN directly/RB but/CC regulates/VBZ transcription/NN through/IN protein-protein/JJ interactions/NNS with/IN sequence-specific/JJ transcription/NN factors/NNS ./. 
Using/VBG the/DT yeast/NN two-hybrid/JJ system/NN to/TO screen/VB for/IN proteins/NNS which/WDT interact/VBP with/IN Tax1/NN ,/, we/PRP isolated/VBD the/DT B/NN subunit/NN of/IN the/DT CCAAT/NN binding/NN protein/NN NF-Y/NN from/IN a/DT HeLa/NN cDNA/NN library/NN ./. 
The/DT interaction/NN of/IN Tax1/NN with/IN NF-YB/NN was/VBD specific/JJ in/IN that/IN NF-YB/NN did/VBD not/RB interact/VB with/IN a/DT variety/NN of/IN other/JJ transcription/NN factors/NNS ,/, including/VBG human/JJ immunodeficiency/NN virus/NN Tat/NN ,/, human/JJ papillomavirus/NN E6/NN ,/, and/CC Bicoid/NN ,/, or/CC with/IN the/DT M7/NN (/( amino/NN acids/NNS 29CP-AS/NN )/) Tax1/NN mutant/NN ./. 
However/RB ,/, NF-YB/NN did/VBD interact/VBP with/IN the/DT C-terminal/JJ Tax1/NN mutants/NNS M22/NN (/( 130TL-AS/NN )/) and/CC M47/NN (/( 319LL-RS/NN )/) ./. 
We/PRP also/RB show/VBP that/IN in/FW vitro-translated/JJ NF-YB/NN specifically/RB bound/VBD to/TO a/DT glutathione/NN S-transferase-Tax1/NN fusion/NN protein/NN ./. 
Further/RB ,/, Tax1/NN coimmunoprecipitated/VBD with/IN NF-Y/NN from/IN nuclear/JJ extracts/NNS of/IN HTLV-1-transformed/JJ cells/NNS ,/, providing/VBG evidence/NN for/IN in/FW vivo/FW interaction/NN of/IN Tax1/NN and/CC NF-YB/NN ./. 
We/PRP further/RB demonstrate/VBP that/IN Tax1/NN specifically/RB activated/VBD the/DT NF-Y-responsive/JJ DQbeta/NN promoter/NN ,/, as/RB well/RB as/IN a/DT minimal/JJ promoter/NN which/WDT contains/VBZ only/RB the/DT Y-box/NN element/NN ./. 
In/IN addition/NN ,/, mutation/NN of/IN the/DT Y-box/NN element/NN alone/RB abrogated/VBD Tax1-mediated/JJ activation/NN ./. 
Taken/VBN together/RB ,/, these/DT data/NNS indicate/VBP that/IN Tax1/NN interacts/VBZ with/IN NF-Y/NN through/IN the/DT B/NN subunit/NN and/CC that/IN this/DT interaction/NN results/VBZ in/IN activation/NN of/IN the/DT major/JJ histocompatibility/NN complex/NN class/NN II/CD promoter/NN ./. 
Through/IN activation/NN of/IN this/DT and/CC other/JJ NF-Y/NN driven/JJ promoters/NNS ,/, the/DT Tax1-NF-Y/NN interaction/NN may/MD play/VB a/DT critical/JJ role/NN in/IN causing/VBG cellular/JJ transformation/NN and/CC HTLV-1/NN pathogenesis/NN ./. 
UI/LS -/: 97265687/CD 
TI/LS -/: High/JJ levels/NNS of/IN the/DT DNA-binding/NN activity/NN of/IN E2F/NN in/IN adult/JJ T-cell/NN leukemia/NN and/CC human/JJ T-cell/NN leukemia/NN virus/NN type/NN I-infected/JJ cells/NNS :/: possible/JJ enhancement/NN of/IN DNA-binding/NN of/IN E2F/NN by/IN the/DT human/JJ T-cell/NN leukemia/NN virus/NN I/CD transactivating/NN protein/NN ,/, Tax/NN ./. 
AB/LS -/: Transcription/NN factor/NN E2F/NN binds/VBZ to/TO cellular/JJ promoters/NNS of/IN certain/JJ growth-/NN and/CC cell/NN cycle-controlling/JJ genes/NNS and/CC forms/VBZ distinct/JJ heteromeric/JJ complexes/NNS with/IN other/JJ nuclear/JJ proteins/NNS ./. 
It/PRP has/VBZ therefore/RB been/VBN proposed/VBN that/IN E2F/NN is/VBZ involved/VBN in/IN cellular/JJ proliferation/NN control/NN ./. 
Human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) is/VBZ an/DT etiological/JJ agent/NN of/IN adult/JJ T-cell/NN leukemia/NN (/( ATL/NN )/) ./. 
We/PRP show/VBP here/RB by/IN mobility-shift/NN assay/NN that/IN E2F-containing/JJ DNA-binding/JJ complexes/NNS were/VBD detected/VBN in/IN HTLV-I-infected/JJ T-cell/NN lines/NNS and/CC leukemic/JJ cells/NNS obtained/VBN from/IN ATL/NN patients/NNS but/CC not/RB in/IN an/DT uninfected/JJ T-cell/NN line/NN ,/, Jurkat/NN ,/, and/CC normal/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
The/DT Tax/NN protein/NN ,/, encoded/VBN by/IN HTLV-I/NN ,/, is/VBZ a/DT potent/JJ transcription/NN activator/NN of/IN viral/JJ and/CC several/JJ cellular/JJ genes/NNS ./. 
We/PRP demonstrate/VBP that/IN expression/NN of/IN Tax/NN can/MD induce/VB the/DT E2F-containing/JJ DNA-binding/JJ complexes/NNS in/IN Jurkat/NN T/NN cells/NNS ./. 
Thus/RB ,/, Tax/NN ,/, through/IN enhancement/NN of/IN the/DT DNA-binding/NN activity/NN of/IN E2F/NN ,/, may/MD be/VB capable/JJ of/IN regulating/VBG cellular/JJ gene/NN expression/NN implicated/VBN in/IN the/DT proliferation/NN and/CC transformation/NN of/IN T/NN cells/NNS in/IN ATL/NN ./. 
This/DT activity/NN may/MD be/VB relevant/JJ to/TO the/DT mechanisms/NNS whereby/WRB HTLV-I/NN which/WDT does/VBZ not/RB contain/VB oncogenes/NNS induces/VBZ neoplasia/NN ./. 
UI/LS -/: 97167598/CD 
TI/LS -/: Dissociation/NN of/IN the/DT Jak/NN kinase/NN pathway/NN from/IN G-CSF/NN receptor/NN signaling/NN in/IN neutrophils/NNS ./. 
AB/LS -/: Activation/NN of/IN the/DT granulocyte/NN colony-stimulating/JJ factor/NN receptor/NN (/( G-CSFR/NN )/) induces/VBZ rapid/JJ tyrosine/NN phosphorylation/NN of/IN multiple/JJ intracellular/JJ substrates/NNS in/IN proliferating/VBG cells/NNS and/CC nonproliferating/JJ ,/, terminally/RB differentiated/VBN neutrophils/NNS ./. 
The/DT kinases/NNS that/WDT couple/VBP ligand/NN binding/VBG to/TO tyrosine/NN phosphorylation/NN of/IN cellular/JJ substrates/NNS by/IN the/DT G-CSFR/NN with/IN activation/NN of/IN specific/JJ functional/JJ programs/NNS are/VBP largely/RB unknown/JJ ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD early/JJ signaling/NN events/NNS in/IN proliferating/VBG and/CC terminally/RB differentiated/VBN cells/NNS following/VBG G-CSF/NN stimulation/NN to/TO determine/VB whether/IN identical/JJ signaling/NN cascades/NNS are/VBP activated/VBN ./. 
In/IN murine/JJ Ba/F3/NN cells/NNS transfected/VBN with/IN the/DT human/JJ G-CSFR/NN and/CC NFS-60/NN cells/NNS constitutively/RB expressing/VBG the/DT murine/JJ G-CSFR/NN ,/, G-CSF/NN induced/VBD tyrosine/NN phosphorylation/NN and/CC activation/NN of/IN Jak1/NN ,/, Jak2/NN ,/, and/CC Tyk2/NN ./. 
Tyrosine/NN phosphorylation/NN of/IN Stat3/NN and/CC ,/, to/TO a/DT lesser/JJR extent/NN ,/, Stat1/NN was/VBD also/RB detected/VBN following/VBG G-CSF/NN stimulation/NN ./. 
Using/VBG a/DT mitogenically/RB incompetent/JJ human/JJ G-CSFR/NN mutant/NN in/IN which/WDT Pro639/NN and/CC Pro641/NN were/VBD substituted/VBN by/IN alanine/NN ,/, the/DT box/NN 1/CD PDP/NN motif/NN was/VBD found/VBN to/TO be/VB required/VBN for/IN activation/NN of/IN Jak/NN kinases/NNS ,/, tyrosine/NN phosphorylation/NN of/IN the/DT G-CSFR/NN ,/, and/CC recruitment/NN of/IN Stat/NN proteins/NNS ./. 
Notably/RB ,/, no/DT activation/NN of/IN Jak1/NN ,/, Jak2/NN ,/, Tyk2/NN ,/, Stat1/NN ,/, or/CC Stat3/NN was/VBD observed/VBN in/IN neutrophils/NNS following/VBG G-CSF/NN stimulation/NN ./. 
In/IN addition/NN ,/, there/EX was/VBD no/DT detectable/JJ activation/NN in/IN neutrophils/NNS of/IN the/DT recently/RB cloned/VBN Jak3/NN kinase/NN ,/, which/WDT has/VBZ been/VBN reported/VBN to/TO be/VB expressed/VBN at/IN high/JJ levels/NNS as/IN myeloid/JJ cells/NNS undergo/VBP terminal/JJ neutrophilic/JJ maturation/NN ./. 
These/DT results/NNS indicate/VBP a/DT lack/NN of/IN involvement/NN of/IN Jak/NN kinases/NNS in/IN signaling/NN by/IN the/DT G-CSFR/NN in/IN neutrophils/NNS ,/, and/CC suggest/VBP utilization/NN of/IN alternative/JJ signal/NN transduction/NN pathways/NNS distinct/JJ from/IN those/DT in/IN proliferating/VBG cells/NNS ./. 
Activation/NN of/IN the/DT Jak-Stat/JJ pathway/NN correlates/VBZ with/IN proliferative/JJ signaling/NN by/IN the/DT G-CSFR/NN and/CC requires/VBZ the/DT membrane-proximal/JJ box/NN 1/CD PXP/NN motif/NN ,/, which/WDT is/VBZ conserved/VBN in/IN members/NNS of/IN the/DT cytokine/NN receptor/NN superfamily/NN ./. 
UI/LS -/: 97167569/CD 
TI/LS -/: Impaired/JJ induction/NN of/IN c-fos/c-jun/NN genes/NNS and/CC of/IN transcriptional/JJ regulatory/JJ proteins/NNS binding/VBG distinct/JJ c-fos/c-jun/NN promoter/NN elements/NNS in/IN activated/VBN human/JJ T/NN cells/NNS during/IN aging/NN ./. 
AB/LS -/: The/DT activation/NN of/IN transcriptional/JJ factor/NN c-Fos/c-Jun/NN AP-1/NN is/VBZ essential/JJ for/IN normal/JJ T/NN cell/NN responsiveness/NN and/CC is/VBZ often/RB impaired/JJ in/IN T/NN cells/NNS during/IN aging/NN ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP investigated/VBD whether/IN aberrancies/NNS in/IN the/DT regulation/NN of/IN c-fos/c-jun/NN at/IN the/DT mRNA/NN or/CC protein/NN level/NN might/MD underlie/VB the/DT age-associated/JJ impairments/NNS of/IN AP-1/NN in/IN human/JJ T/NN cells/NNS ./. 
Whereas/IN T/NN cells/NNS from/IN young/JJ subjects/NNS stimulated/VBN with/IN cross-linked/JJ anti-CD3epsilon/JJ mAb/NN OKT3/NN plus/CC PMA/NN or/CC with/IN the/DT lectin/NN PHA/NN plus/CC PMA/NN demonstrated/VBD considerable/JJ increases/NNS in/IN c-Fos/NN protein/NN expression/NN ,/, the/DT expression/NN of/IN c-Fos/NN but/CC not/RB c-Jun/NN was/VBD markedly/RB reduced/VBN in/IN stimulated/VBN T/NN cells/NNS from/IN certain/JJ elderly/JJ subjects/NNS ./. 
In/IN addition/NN ,/, RNase/NN protection/NN assays/NNS revealed/VBD that/IN anti-CD3/PMA-stimulated/JJ T/NN cells/NNS from/IN a/DT substantial/JJ proportion/NN of/IN elderly/JJ subjects/NNS exhibited/VBD decreased/JJ levels/NNS of/IN c-fos/NN and/or/CC c-jun/NN mRNA/NN compared/VBN to/TO T/NN cells/NNS from/IN young/JJ subjects/NNS ./. 
Using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, the/DT levels/NNS of/IN nuclear/JJ regulatory/JJ proteins/NNS recognizing/VBG the/DT AP-1/NN consensus/NN TRE/NN motif/NN ,/, the/DT proximal/JJ c-jun/NN TRE-like/JJ promoter/NN element/NN ,/, and/CC the/DT c-fos/NN serum/NN response/NN element/NN (/( SRE/NN )/) were/VBD determined/VBN in/IN resting/VBG and/CC stimulated/VBN T/NN cells/NNS ./. 
Although/IN the/DT stimulation/NN of/IN T/NN cells/NNS from/IN young/JJ subjects/NNS resulted/VBD in/IN coordinated/VBN increases/NNS of/IN nuclear/JJ protein/NN complexes/NNS binding/VBG the/DT AP-1/NN TRE/NN ,/, c-jun/NN TRE/NN ,/, and/CC c-fos/NN SRE/NN DNA/NN sequence/NN motifs/NNS ,/, age-related/JJ reductions/NNS in/IN the/DT activation/NN of/IN AP-1/NN were/VBD accompanied/VBN by/IN decreased/VBN levels/NNS of/IN c-jun/NN TRE/NN and/CC c-fos/NN SRE/NN binding/NN complexes/NNS ./. 
Furthermore/RB ,/, the/DT nuclear/JJ protein/NN complexes/NNS binding/VBG the/DT SRE/NN motif/NN induced/VBN in/IN activated/VBN T/NN cells/NNS of/IN young/JJ and/CC elderly/JJ subjects/NNS contained/VBD serum/NN response/NN factor/NN and/CC Elk-1/NN pointing/VBG toward/IN age-related/JJ defects/NNS in/IN the/DT activation/NN of/IN transcriptional/JJ regulatory/JJ proteins/NNS distinct/JJ from/IN c-jun/AP-1/NN ./. 
These/DT results/NNS suggest/VBP that/IN underlying/VBG aberrancies/NNS in/IN the/DT induction/NN of/IN c-fos/c-jun/NN as/RB well/RB as/IN their/PRP$ nuclear/JJ regulatory/JJ proteins/NNS may/MD contribute/VB to/TO the/DT age-related/JJ impairments/NNS of/IN AP-1/NN activation/NN in/IN human/JJ T/NN cells/NNS ./. 
UI/LS -/: 97276819/CD 
TI/LS -/: Retinoic/JJ acid-induced/JJ modulation/NN of/IN IL-2/NN mRNA/NN production/NN and/CC IL-2/NN receptor/NN expression/NN on/IN T/NN cells/NNS ./. 
AB/LS -/: BACKGROUND/NN :/: Retinoic/JJ acid/NN (/( RA/NN )/) has/VBZ important/JJ immune-modulating/JJ effects/NNS on/IN both/CC T/NN and/CC B/NN cell/NN function/NN ./. 
Our/PRP$ laboratory/NN has/VBZ shown/VBN that/IN RA/NN can/MD enhance/VB in/FW vitro/FW polyclonal/JJ B/NN cell/NN immunoglobulin/NN (/( Ig/NN )/) response/NN ./. 
Investigating/VBG cytokines/NNS known/VBN to/TO affect/VB B/NN cell/NN differentiation/NN ,/, we/PRP have/VBP recently/RB shown/VBN that/IN IL-6/NN production/NN is/VBZ augmented/VBN by/IN RA/NN ./. 
In/IN the/DT present/JJ study/NN we/PRP have/VBP examined/VBN the/DT immune/JJ modulating/JJ effects/NNS of/IN RA/NN on/IN IL-2/NN mRNA/NN ,/, another/DT important/JJ cytokine/NN for/IN B/NN cell/NN immunoglobulin/NN production/NN ,/, the/DT expression/NN of/IN IL-2/NN receptors/NNS on/IN T/NN cells/NNS ,/, and/CC the/DT RA/NN nuclear/JJ receptors/NNS ./. 
METHODS/NNS :/: Purified/VBN T/NN cells/NNS were/VBD obtained/VBN from/IN adenoidal/JJ tissues/NNS ,/, and/CC incubated/VBN with/IN RA/NN (/( 10(-7)/CD M/NN )/) or/CC DMSO/NN solvent/media/NN control/NN for/IN 0/CD ,/, 6-8/CD ,/, and/CC 24/CD h/NN ./. 
Total/JJ mRNA/NN was/VBD extracted/VBN from/IN T/NN cells/NNS ,/, and/CC using/VBG RT-PCR/NN ,/, changes/NNS in/IN the/DT production/NN of/IN IL-2/NN and/CC RA/NN receptors/NNS (/( RAR/NNS )/) -alpha/NN ,/, beta/NN ,/, gamma/NN mRNA/NN were/VBD determined/VBN ./. 
The/DT effects/NNS of/IN RA/NN on/IN IL-2-alpha/NN receptor/NN expression/NN was/VBD determined/VBN by/IN flow/NN cytometry/NN on/IN T/NN cells/NNS ./. 
CONCLUSION/NN :/: These/DT studies/NNS suggest/VBP that/IN RA/NN can/MD augment/VB IL-2/NN mRNA/NN production/NN by/IN T/NN cells/NNS with/IN a/DT possible/JJ paracrine/NN effect/NN on/IN IL-2R-alpha/NN expression/NN ./. 
These/DT changes/NNS appear/VBP to/TO be/VB mediated/VBN by/IN RAR-alpha/NN ./. 
Thus/RB ,/, IL-2/NN may/MD be/VB another/DT important/JJ cytokine/NN modulated/VBN by/IN RA/NN in/IN the/DT immune/JJ response/NN ./. 
UI/LS -/: 97263762/CD 
TI/LS -/: Involvement/NN of/IN an/DT SAF-like/JJ transcription/NN factor/NN in/IN the/DT activation/NN of/IN serum/NN amyloid/NN A/NN gene/NN in/IN monocyte/macrophage/NN cells/NNS by/IN lipopolysaccharide/NN ./. 
AB/LS -/: Serum/NN amyloid/NN A/NN (/( SAA/NN )/) has/VBZ been/VBN linked/VBN to/TO atherosclerosis/NN because/IN of/IN its/PRP$ ability/NN to/TO remodel/VB high-density/JJ lipoprotein/NN by/IN the/DT depletion/NN of/IN apolipoprotein/NN A1/NN ,/, its/PRP$ ability/NN to/TO bind/VB cholesterol/NN ,/, and/CC its/PRP$ presence/NN in/IN the/DT atherosclerotic/JJ plaques/NNS of/IN coronary/JJ and/CC carotid/JJ arteries/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP investigated/VBD the/DT induction/NN mechanism/NN of/IN SAA/NN gene/NN in/IN THP-1/NN monocyte/macrophage/NN cells/NNS which/WDT play/VBP a/DT critical/JJ role/NN in/IN the/DT development/NN of/IN atherosclerotic/JJ fatty/JJ streak/NN and/CC plaque/NN formation/NN ./. 
We/PRP and/CC others/NNS have/VBP shown/VBN that/IN SAA/NN gene/NN is/VBZ induced/VBN in/IN monocyte/macrophage/NN cells/NNS by/IN lipopolysaccharide/NN (/( LPS/NN )/) ./. 
By/IN promoter/NN function/NN analysis/NN ,/, we/PRP show/VBP that/IN the/DT SAA/NN promoter/NN sequence/NN between/IN -280/CD and/CC -226/CD can/MD confer/VB LPS/NN responsiveness/NN ./. 
Gel/NN electrophoretic/JJ mobility/NN shift/NN assay/NN detected/VBD an/DT induced/VBN DNA-binding/NN activity/NN in/IN these/DT cells/NNS in/IN response/NN to/TO LPS/NN ./. 
Characterization/NN of/IN the/DT DNA-binding/JJ protein/NN by/IN UV/NN cross-linking/NN ,/, Southwestern/NN blot/NN ,/, and/CC antibody/JJ ablation/supershift/NN assays/NNS revealed/VBD that/IN it/PRP is/VBZ similar/JJ to/TO a/DT recently/RB reported/VBN nuclear/JJ factor/NN designated/VBN SAF/NN ./. 
These/DT results/NNS demonstrated/VBD that/IN LPS-mediated/JJ SAA/NN gene/NN induction/NN in/IN monocyte/macrophage/NN cells/NNS is/VBZ primarily/RB due/JJ to/TO the/DT induction/NN of/IN SAF/NN activity/NN ./. 
UI/LS -/: 97298895/CD 
TI/LS -/: Cytomegalovirus/NN immediate/JJ early/JJ genes/NNS upregulate/VBP interleukin-6/NN gene/NN expression/NN ./. 
AB/LS -/: BACKGROUND/NN :/: The/DT immediate/JJ early/JJ genes/NNS (/( IE/NN )/) of/IN human/JJ cytomegalovirus/NN (/( CMV/NN )/) can/MD be/VB expressed/VBN in/IN monocytic/JJ cells/NNS and/CC are/VBP known/VBN to/TO regulate/VB viral/JJ and/CC cellular/JJ genes/NNS ./. 
Interleukin-6/NN (/( IL-6/NN )/) plays/VBZ a/DT central/JJ role/NN in/IN numerous/JJ inflammatory/JJ and/CC immune/JJ processes/NNS ./. 
Interleukin-6/NN levels/NNS are/VBP increased/VBN in/IN lung/NN transplant/NN patients/NNS clinically/RB diagnosed/VBN with/IN CMV/NN pneumonitis/NN ./. 
The/DT regulation/NN of/IN IL-6/NN is/VBZ dependent/JJ on/IN various/JJ stimuli/NNS that/WDT include/VBP lipopolysaccharide/NN (/( LPS/NN )/) ,/, viruses/NNS ,/, and/CC other/JJ cytokines/NNS ./. 
These/DT studies/NNS examined/VBD the/DT ability/NN of/IN CMV/NN IE/NN gene/NN products/NNS to/TO modulate/VB IL-6/NN production/NN ./. 
METHODS/NNS :/: THP-1/NN cells/NNS ,/, a/DT monocytic/JJ cell/NN line/NN ,/, were/VBD transfected/VBN with/IN the/DT CMV/NN IE/NN genes/NNS ./. 
Interleukin-6/NN protein/NN and/CC IL-6/NN mRNA/NN were/VBD measured/VBN in/IN control/JJ and/CC CMV/NN immediate/JJ early/JJ transfected/VBN cells/NNS ./. 
Cotransfection/NN of/IN CMV/NN IE/NN genes/NNS and/CC IL-6/NN chloramphenicol/NN acetyl/NN transferase/NN (/( CAT/NN )/) or/CC IL-6/NN luciferase/NN constructs/NNS were/VBD used/VBN to/TO study/VB IL-6/NN promoter/NN activity/NN ./. 
RESULTS/NNS :/: Interleukin-6/NN protein/NN and/CC mRNA/NN production/NN were/VBD significantly/RB increased/VBN in/IN cells/NNS transfected/VBN with/IN the/DT CMV/NN IE/NN genes/NNS and/CC stimulated/VBN with/IN LPS/NN compared/VBN to/TO LPS-stimulated/JJ control/JJ cells/NNS ./. 
Cytomegalovirus/NN IE/NN gene/NN products/NNS significantly/RB enhanced/VBD LPS/NN stimulation/NN of/IN IL-6/NN promoter/NN activity/NN in/IN both/CC IL-6/NN CAT/NN and/CC IL-6/NN luciferase/NN assays/NNS ./. 
A/DT deletion/NN construct/NN that/WDT contains/VBZ a/DT NF-kappa/NN B/NN site/NN but/CC is/VBZ missing/VBG the/DT multiple/JJ response/NN region/NN demonstrated/VBD a/DT continued/JJ increase/NN in/IN IL-6/NN luciferase/NN activity/NN in/IN LPS-stimulated/JJ CMV/NN transfected/JJ cells/NNS ./. 
CONCLUSION/NN :/: Cytomegalovirus/NN immediate/JJ early/JJ gene/NN products/NNS significantly/RB enhanced/VBD expression/NN of/IN IL-6/NN in/IN LPS-stimulated/JJ cells/NNS ./. 
The/DT increase/NN in/IN IL-6/NN luciferase/NN activity/NN occurs/VBZ in/IN the/DT absence/NN of/IN the/DT multiple/JJ response/NN region/NN ,/, the/DT area/NN of/IN the/DT IL-6/NN promoter/NN responsive/JJ to/TO IL-1/NN ,/, TNF/NN alpha/NN ,/, cyclic/JJ amp/NN ,/, and/CC phorbol/NN 12-myristate/NN 13-acetate/NN ./. 
The/DT ability/NN of/IN CMV/NN IE/NN gene/NN products/NNS to/TO enhance/VB IL-6/NN production/NN may/MD play/VB an/DT important/JJ role/NN in/IN immune/JJ inflammatory/JJ states/NNS associated/VBN with/IN CMV/NN infection/NN ./. 
UI/LS -/: 97255754/CD 
TI/LS -/: Induction/NN of/IN relA/NN (/( p65/NN )/) and/CC I/NN kappa/NN B/NN alpha/NN subunit/NN expression/NN during/IN differentiation/NN of/IN human/JJ peripheral/JJ blood/NN monocytes/NNS to/TO macrophages/NNS ./. 
AB/LS -/: We/PRP evaluated/VBD the/DT expression/NN and/CC DNA/NN binding/NN activity/NN of/IN nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN subunits/NNS in/IN human/JJ peripheral/JJ blood/NN monocytes/NNS and/CC in/IN monocyte-derived/JJ macrophages/NNS (/( MDMs/NNS )/) ./. 
Constitutive/JJ DNA/NN binding/NN activity/NN consisting/VBG of/IN p50/NN homodimers/NNS was/VBD detected/VBN in/IN nuclear/JJ extracts/NNS from/IN both/DT cell/NN types/NNS ./. 
An/DT additional/JJ complex/NN composed/VBN of/IN p50/RelA/NN (/( p65/NN )/) heterodimers/NNS appeared/VBD only/RB in/IN nuclear/JJ extracts/NNS from/IN 7-day/JJ MDMs/NNS ./. 
Immunoblot/NN analysis/NN showed/VBD that/IN the/DT p50/NN subunit/NN was/VBD constitutively/RB expressed/VBN in/IN monocytes/NNS and/CC MDMs/NNS ./. 
In/IN contrast/NN ,/, the/DT RelA/NN (/( p65/NN )/) subunit/NN was/VBD barely/RB detectable/JJ in/IN monocytes/NNS ,/, but/CC its/PRP$ level/NN increased/VBD markedly/RB in/IN MDMs/NNS ./. 
Analysis/NN of/IN RelA/NN (/( p65/NN )/) mRNA/NN revealed/VBD that/IN the/DT stability/NN of/IN RelA/NN (/( p65/NN )/) mRNA/NN was/VBD significantly/RB higher/JJR in/IN MDMs/NNS ,/, compared/VBN with/IN monocytes/NNS ./. 
In/IN MDMs/NNS ,/, an/DT upregulation/NN of/IN I/NN kappa/NN B/NN alpha/NN synthesis/NN as/RB well/RB as/IN the/DT appearance/NN of/IN a/DT novel/JJ M(r)/NN 40,000/CD form/NN of/IN I/NN kappa/NN B/NN alpha/NN were/VBD also/RB observed/VBN ./. 
These/DT results/NNS suggest/VBP that/IN macrophage/NN differentiation/NN results/VBZ in/IN the/DT expression/NN of/IN active/JJ p50/RelA/NN (/( p65/NN )/) heterodimers/NNS with/IN the/DT capacity/NN to/TO activate/VB target/NN gene/NN expression/NN ./. 
The/DT parallel/JJ induction/NN of/IN I/NN kappa/NN B/NN alpha/NN synthesis/NN may/MD allow/VB for/IN the/DT continuous/JJ presence/NN of/IN a/DT cytoplasmic/JJ reservoir/NN of/IN p50/RelA/NN (/( p65/NN )/) complexes/NNS that/WDT are/VBP readily/RB available/JJ for/IN inducer-mediated/JJ stimulation/NN ./. 
UI/LS -/: 97211823/CD 
TI/LS -/: Nuclear/JJ Rel-A/NN and/CC c-Rel/NN protein/NN complexes/NNS are/VBP differentially/RB distributed/VBN within/IN human/JJ thymocytes/NNS ./. 
AB/LS -/: Nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) /Rel/NN proteins/NNS are/VBP inducible/JJ transcriptional/JJ regulators/NNS of/IN numerous/JJ cellular/JJ genes/NNS ./. 
They/PRP are/VBP particularly/RB abundant/JJ in/IN lymphoid/JJ tissues/NNS and/CC are/VBP thought/VBN to/TO be/VB critical/JJ for/IN the/DT transcription/NN of/IN genes/NNS involved/VBN in/IN immune/JJ and/CC inflammatory/JJ responses/NNS ./. 
We/PRP have/VBP reported/VBN previously/RB that/IN a/DT nuclear/JJ NF-kappa/NN B/NN activity/NN was/VBD present/JJ in/IN freshly/RB extracted/VBN human/JJ thymocytes/NNS in/IN the/DT absence/NN of/IN in/FW vitro/FW treatment/NN of/IN these/DT cells/NNS ./. 
In/IN the/DT present/JJ report/NN ,/, we/PRP identified/VBD NF-kappa/NN B/NN proteins/NNS extracted/VBN from/IN human/JJ thymocyte/NN nuclei/NNS as/IN being/VBG p50/p65/NN and/CC p50/c-Rel/NN complexes/NNS ./. 
Immunochemical/JJ and/CC immunofluorescent/JJ staining/NN of/IN thymus/NN sections/NNS using/VBG specific/JJ Abs/NNS allowed/VBD visualization/NN of/IN nuclear/JJ NF-kappa/NN B/NN proteins/NNS in/IN both/CC thymocytes/NNS and/CC nonthymocyte/JJ cells/NNS ./. 
This/DT detection/NN suggested/VBD a/DT preferential/JJ activation/NN of/IN p50/c-Rel/NN in/IN medullary/JJ thymocytes/NNS ,/, whereas/IN p50/p65/NN was/VBD present/JJ in/IN both/CC cortical/JJ and/CC medullary/JJ regions/NNS of/IN human/JJ thymus/NN lobules/NNS ./. 
However/RB ,/, the/DT intensity/NN of/IN p65/NN labeling/NN was/VBD much/RB higher/JJR in/IN several/JJ thymocytes/NNS from/IN the/DT medulla/NN ./. 
p65/NN ,/, p50/NN ,/, and/CC c-Rel/NN activities/NNS were/VBD found/VBN in/IN both/CC CD4-/NN and/CC CD8-positive/JJ thymocytes/NNS ./. 
These/DT observations/NNS suggest/VBP that/IN p65/NN and/CC c-Rel/NN complexes/NNS play/VBP distinct/JJ roles/NNS in/IN gene/NN expression/NN and/CC that/IN both/DT forms/NNS of/IN NF-kappa/NN B/NN play/VBP critical/JJ roles/NNS during/IN late/JJ stages/NNS of/IN the/DT intrathymic/JJ maturation/NN of/IN T/NN cells/NNS ./. 
UI/LS -/: 97230366/CD 
TI/LS -/: ALY/NN ,/, a/DT context-dependent/JJ coactivator/NN of/IN LEF-1/NN and/CC AML-1/NN ,/, is/VBZ required/VBN for/IN TCRalpha/NN enhancer/NN function/NN ./. 
AB/LS -/: LEF-1/NN is/VBZ a/DT transcription/NN factor/NN that/WDT participates/VBZ in/IN the/DT regulation/NN of/IN the/DT T-cell/NN receptor/NN alpha/NN (/( TCR/NN alpha/NN )/) enhancer/NN by/IN facilitating/VBG the/DT assembly/NN of/IN multiple/JJ proteins/NNS into/IN a/DT higher/JJR order/NN nucleoprotein/NN complex/NN ./. 
The/DT function/NN of/IN LEF-1/NN is/VBZ dependent/JJ ,/, in/IN part/NN ,/, on/IN the/DT HMG/NN domain/NN that/WDT induces/VBZ a/DT sharp/JJ bend/NN in/IN the/DT DNA/NN helix/NN ,/, and/CC on/IN an/DT activation/NN domain/NN that/WDT stimulates/VBZ transcription/NN only/RB in/IN a/DT specific/JJ context/NN of/IN other/JJ enhancer-binding/JJ proteins/NNS ./. 
With/IN the/DT aim/NN of/IN gaining/VBG insight/NN into/IN the/DT function/NN of/IN context-dependent/JJ activation/NN domains/NNS ,/, we/PRP cloned/VBD ALY/NN ,/, a/DT novel/JJ LEF-1-interacting/JJ protein/NN ./. 
ALY/NN is/VBZ a/DT ubiquitously/RB expressed/VBN ,/, nuclear/JJ protein/NN that/WDT specifically/RB associates/VBZ with/IN the/DT activation/NN domains/NNS of/IN LEF-1/NN and/CC AML-1/NN (/( CBF/NN alpha2/NN ,/, PEBP2/NN alpha/NN (/( B/NN )/) ,/, which/WDT is/VBZ another/DT protein/NN component/NN of/IN the/DT TCR/NN alpha/NN enhancer/NN complex/NN ./. 
In/IN addition/NN ,/, ALY/NN can/MD increase/VB DNA/NN binding/NN by/IN both/CC LEF-1/NN and/CC AML/NN proteins/NNS ./. 
Overexpression/NN of/IN ALY/NN stimulates/VBZ the/DT activity/NN of/IN the/DT TCR/NN alpha/NN enhancer/NN complex/NN reconstituted/VBN in/IN transfected/VBN nonlymphoid/JJ HeLa/NN cells/NNS ,/, whereas/IN down-regulation/NN of/IN ALY/NN by/IN anti-sense/JJ oligonucleotides/NNS virtually/RB eliminates/VBZ TCR/NN alpha/NN enhancer/NN activity/NN in/IN T/NN cells/NNS ./. 
Similar/JJ to/TO LEF-1/NN ,/, ALY/NN can/MD stimulate/VB transcription/NN in/IN the/DT context/NN of/IN the/DT TCR/NN alpha/NN enhancer/NN but/CC apparently/RB not/RB when/WRB tethered/VBN to/TO DNA/NN through/IN an/DT heterologous/JJ DNA-binding/JJ domain/NN ./. 
We/PRP propose/VBP that/IN ALY/NN mediates/VBZ context-dependent/JJ transcriptional/JJ activation/NN by/IN facilitating/VBG the/DT functional/JJ collaboration/NN of/IN multiple/JJ proteins/NNS in/IN the/DT TCR/NN alpha/NN enhancer/NN complex/NN ./. 
UI/LS -/: 97209374/CD 
TI/LS -/: AML1a/NN but/CC not/RB AML1b/NN inhibits/VBZ erythroid/JJ differentiation/NN induced/VBN by/IN sodium/NN butyrate/NN and/CC enhances/VBZ the/DT megakaryocytic/JJ differentiation/NN of/IN K562/NN leukemia/NN cells/NNS ./. 
AB/LS -/: AML1/NN may/MD play/VB a/DT role/NN in/IN growth/NN and/CC differentiation/NN of/IN cells/NNS along/IN erythroid/JJ and/or/CC megakaryocytic/JJ lineages/NNS ,/, because/IN a/DT significant/JJ level/NN of/IN the/DT AML1/NN gene/NN is/VBZ expressed/VBN in/IN these/DT cells/NNS ./. 
We/PRP overexpressed/VBD AML1a/NN (/( without/IN the/DT transcription-activating/JJ domain/NN )/) and/CC AML1b/NN (/( with/IN the/DT domain/NN )/) proteins/NNS in/IN K562/NN leukemia/NN cells/NNS ,/, which/WDT can/MD be/VB induced/VBN to/TO differentiate/VB into/IN hemoglobin-producing/JJ cells/NNS and/CC megakaryocytes/NNS ./. 
The/DT AML1a-transfected/JJ K562/NN cells/NNS had/VBD a/DT reduced/VBN capacity/NN to/TO differentiate/VB in/IN the/DT presence/NN of/IN sodium/NN n-butyrate/NN but/CC not/RB in/IN the/DT presence/NN of/IN other/JJ inducers/NNS ,/, such/JJ as/IN hemin/NN ,/, 1-beta-D-arabinofuranosylcytosine/NN ,/, and/CC herbimycin/NN A/NN ./. 
The/DT AML1/NN antisense/JJ oligodeoxynucleotide/NN but/CC not/RB the/DT sense/NN oligomer/NN recovered/VBD its/PRP$ differentiation-inducing/JJ capacity/NN in/IN the/DT presence/NN of/IN butyrate/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, AML1b/NN conferred/VBD a/DT similar/JJ differentiation-inducing/JJ capacity/NN upon/IN K562/NN cells/NNS transfected/VBN with/IN vector/NN alone/RB ./. 
AML1a/NN expression/NN was/VBD associated/VBN with/IN enhanced/VBN sensitivity/NN to/TO megakaryocytic/JJ differentiation/NN induced/VBN by/IN phorbol/NN ester/NN ./. 
These/DT results/NNS provide/VBP evidence/NN that/IN AML1/NN proteins/NNS play/VBP a/DT role/NN in/IN erythroid/JJ and/CC megakaryocytic/JJ differentiation/NN ./. 
UI/LS -/: 97218151/CD 
TI/LS -/: Identification/NN of/IN sequence/NN alterations/NNS in/IN the/DT upstream/JJ regulatory/JJ region/NN of/IN the/DT estrogen/NN receptor/NN gene/NN in/IN an/DT ER-negative/JJ breast/NN cancer/NN cell/NN line/NN ./. 
AB/LS -/: Given/IN the/DT important/JJ role/NN of/IN the/DT estrogen/NN receptor/NN (/( ER/NN )/) in/IN the/DT development/NN and/CC physiology/NN of/IN the/DT breast/NN ,/, it/PRP is/VBZ essential/JJ to/TO delineate/VB the/DT mechanisms/NNS responsible/JJ for/IN its/PRP$ failed/JJ expression/NN in/IN some/DT breast/NN tumors/NNS ./. 
We/PRP have/VBP cloned/VBN and/CC sequenced/VBN a/DT portion/NN of/IN the/DT ER/NN upstream/JJ regulatory/JJ region/NN from/IN the/DT ER-positive/JJ MCF-7/NN and/CC the/DT ER-negative/JJ MDA-MB-231/NN breast/NN cancer/NN cell/NN lines/NNS to/TO determine/VB if/IN sequence/NN alterations/NNS in/IN this/DT region/NN account/VBP for/IN the/DT ER-negative/JJ phenotype/NN of/IN some/DT tumors/NNS ./. 
From/IN this/DT ,/, we/PRP identified/VBD a/DT number/NN of/IN variations/NNS between/IN the/DT sequences/NNS ,/, two/CD of/IN which/WDT were/VBD determined/VBN to/TO be/VB associated/VBN with/IN a/DT 50/CD %/NN decrease/NN in/IN CAT/NN activity/NN ./. 
UI/LS -/: 97228922/CD 
TI/LS -/: Suppression/NN by/IN azelastine/NN hydrochloride/NN of/IN NF-kappa/NN B/NN activation/NN involved/VBN in/IN generation/NN of/IN cytokines/NNS and/CC nitric/JJ oxide/NN ./. 
AB/LS -/: The/DT influence/NN of/IN the/DT anti-allergy/JJ agent/NN azelastine/NN hydrochloride/NN (/( Azeptin/NN )/) on/IN NF-kappa/NN B/NN activation/NN associated/VBN with/IN the/DT generation/NN of/IN cytokines/NNS and/CC nitric/JJ oxide/NN (/( NO/NN )/) was/VBD investigated/VBN in/IN various/JJ kinds/NNS of/IN human/JJ and/CC mouse/NN cells/NNS ./. 
Azeptin/NN dose-dependently/RB suppressed/VBD both/CC DNA/NN and/CC protein/NN synthesis/NN in/IN human/JJ gingival/JJ fibroblasts/NNS (/( HF/NNS )/) and/CC also/RB suppressed/VBD blastogenesis/NN of/IN human/JJ peripheral/JJ blood/NN lymphocytes/NNS (/( PBL/NNS )/) ./. Generation/NN of/IN tumor/NN necrosis/NN factor-alpha/NN ,/, interleukin/NN 1-beta/NN ,/, granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN and/CC interleukin-6/NN from/IN 10(-5)/CD M/NN Azeptin-treated/JJ PBL/NNS and/CC human/JJ monocytes/NNS (/( HM/NNS )/) was/VBD decreased/VBN to/TO approximately/RB 1/3/CD to/TO 2/3/CD of/IN the/DT control/NN levels/NNS ./. 
In/IN parallel/NN with/IN the/DT decreased/VBN cytokine/NN generation/NN ,/, each/DT cytokine/NN mRNA/NN was/VBD less/RBR expressed/VBN in/IN the/DT presence/NN of/IN 10(-5)/CD M/NN Azeptin/NN ./. 
In/IN addition/NN ,/, both/CC inducible/JJ nitric/JJ oxide/NN synthase-mRNA/NN level/NN and/CC NO/NN generation/NN in/IN mouse/NN peritoneal/JJ macrophages/NNS were/VBD suppressed/VBN by/IN 10(-5)/CD M/NN Azeptin/NN ./. 
Being/VBG compatible/JJ with/IN those/DT results/NNS ,/, Azeptin/NN (/( 10(-5)/CD M/NN )/) suppressed/VBD activation/NN of/IN NF-kappa/NN B/NN in/IN PBL/NNS ,/, HM/NNS and/CC HF/NNS ./. 
These/DT results/NNS appear/VBP to/TO indicate/VB that/IN suppression/NN of/IN cytokine/NN and/CC NO/NN generation/NN by/IN Azeptin/NN results/VBZ at/IN least/JJS partially/RB from/IN the/DT inhibition/NN of/IN NF-kappa/NN B/NN activation/NN ./. 
UI/LS -/: 97166066/CD 
TI/LS -/: Differential/JJ interaction/NN of/IN nuclear/JJ factors/NNS with/IN the/DT PRE-I/NN enhancer/NN element/NN of/IN the/DT human/JJ IL-4/NN promoter/NN in/IN different/JJ T/NN cell/NN subsets/NNS ./. 
AB/LS -/: The/DT immunomodulatory/JJ cytokine/NN IL-4/NN affects/VBZ cells/NNS of/IN most/JJS hemopoietic/JJ lineages/NNS ./. 
IL-4/NN is/VBZ secreted/VBN by/IN activated/VBN Th2/NN but/CC not/RB Th1/NN cells/NNS and/CC plays/VBZ a/DT major/JJ role/NN in/IN the/DT immune/JJ response/NN by/IN modulating/VBG the/DT differentiation/NN of/IN naive/JJ Th/NN cells/NNS toward/IN the/DT Th2/NN phenotype/NN ./. 
We/PRP have/VBP previously/RB identified/VBN an/DT enhancer/NN element/NN ,/, PRE-I/NN ,/, that/WDT is/VBZ essential/JJ for/IN the/DT function/NN of/IN the/DT human/JJ IL-4/NN promoter/NN ./. 
To/TO investigate/VB the/DT mechanisms/NNS responsible/JJ for/IN tissue-specific/JJ expression/NN of/IN the/DT IL-4/NN gene/NN ,/, we/PRP analyzed/VBD nuclear/JJ factors/NNS binding/VBG to/TO the/DT PRE-I/NN site/NN and/CC compared/VBD the/DT binding/NN activities/NNS of/IN these/DT factors/NNS to/TO the/DT IL-4/NN promoter/NN of/IN Th1/NN and/CC Th2/NN cells/NNS ./. 
We/PRP show/VBP that/IN PRE-I/NN interacts/VBZ with/IN PMA-/NN and/CC PMA/ionomycin-inducible/JJ ,/, cyclosporin/NN A-sensitive/JJ nuclear/JJ factors/NNS ./. 
Using/VBG anti-C/EBPbeta/JJ (/( NF-IL6/NN )/) ,/, anti-C/EBPdelta/JJ (/( NF-IL6beta/NN )/) ,/, anti-NF-ATc/JJ ,/, anti-NF-ATp/JJ ,/, anti-Fos/JJ ,/, and/CC anti-Jun/JJ Abs/NNS we/PRP demonstrate/VBP that/IN the/DT previously/RB identified/VBN PRE-I/NN binding/NN factor/NN POS-1/NN is/VBZ composed/VBN of/IN different/JJ transcription/NN factors/NNS in/IN different/JJ Th/NN cell/NN subsets/NNS ./. 
In/IN the/DT IL-4-producing/JJ Th0-like/JJ human/JJ Jurkat/NN and/CC mouse/NN EL-4/NN cells/NNS ,/, POS-1/NN (/( designated/VBN POS-1a/NN )/) contains/VBZ NF-IL6beta/NN and/CC Jun/NN ./. 
In/IN the/DT mouse/NN Th2/NN D10/NN cells/NNS and/CC in/IN the/DT human/JJ Th2/NN clones/NNS ,/, POS-1/NN (/( designated/VBN POS-1b/NN )/) contains/VBZ NF-IL6beta/NN ,/, Jun/NN ,/, and/CC NF-ATc/p/NN ./. 
In/IN contrast/NN ,/, POS-1/NN was/VBD not/RB found/VBN in/IN nuclear/JJ extracts/NNS of/IN human/JJ Th1/NN clones/NNS ./. 
These/DT findings/NNS suggest/VBP that/IN PRE-I/NN may/MD play/VB a/DT role/NN in/IN the/DT differential/JJ regulation/NN of/IN IL-4/NN gene/NN expression/NN levels/NNS ./. 
UI/LS -/: 97276784/CD 
TI/LS -/: Regulation/NN of/IN human/JJ epsilon/NN germline/NN transcription/NN :/: role/NN of/IN B-cell-specific/JJ activator/NN protein/NN ./. 
AB/LS -/: Germline/NN transcripts/NNS initiate/VBP from/IN promoters/NNS upstream/RB of/IN the/DT immunoglobulin/NN switch/NN region/NN ,/, and/CC are/VBP necessary/JJ to/TO target/VB the/DT appropriate/JJ switch/NN region/NN for/IN recombination/NN and/CC switching/NN ./. 
Different/JJ cytokines/NNS activate/VBP transcription/NN at/IN the/DT appropriate/JJ germline/NN promoter/NN ./. 
Because/IN binding/VBG sites/NNS for/IN B-cell-specific/JJ activator/NN protein/NN (/( BSAP/NN )/) are/VBP located/JJ upstream/RB of/IN several/JJ switch/NN regions/NNS in/IN the/DT immunoglobulin/NN heavy/JJ chain/NN gene/NN cluster/NN ,/, BSAP/NN might/MD play/VB a/DT role/NN in/IN the/DT regulation/NN of/IN germline/NN transcription/NN and/CC isotype/NN switching/NN ./. 
We/PRP investigated/VBD whether/IN BSAP/NN plays/VBZ a/DT role/NN in/IN the/DT transcriptional/JJ regulation/NN of/IN the/DT epsilon/NN germline/NN promoter/NN in/IN human/JJ B/NN cells/NNS ./. 
Our/PRP$ results/NNS showed/VBD that/IN BSAP/NN plays/VBZ a/DT role/NN in/IN both/CC IL-4-dependent/JJ induction/NN and/CC CD40-mediated/JJ upregulation/NN of/IN human/JJ epsilon/NN germline/NN transcription/NN ./. 
BSAP/NN is/VBZ unique/JJ among/IN the/DT transcription/NN factors/NNS that/WDT regulate/VBP epsilon/NN germline/NN expression/NN ,/, because/IN it/PRP is/VBZ B/NN cell/NN specific/JJ ,/, and/CC is/VBZ at/IN the/DT merging/JJ point/NN of/IN two/CD signalling/NN pathways/NNS that/WDT are/VBP critical/JJ for/IN IgE/NN switching/NN ./. 
UI/LS -/: 97263535/CD 
TI/LS -/: Experimental/JJ expression/NN in/IN mice/NNS and/CC spontaneous/JJ expression/NN in/IN human/JJ SLE/NN of/IN polyomavirus/NN T-antigen/NN ./. 
A/DT molecular/JJ basis/NN for/IN induction/NN of/IN antibodies/NNS to/TO DNA/NN and/CC eukaryotic/JJ transcription/NN factors/NNS ./. 
AB/LS -/: We/PRP have/VBP previously/RB demonstrated/VBN that/IN experimental/JJ expression/NN of/IN the/DT polyomavirus/NN transcription/NN factor/NN T-antigen/NN has/VBZ the/DT potential/NN to/TO induce/VB anti-DNA/JJ antibodies/NNS in/IN mice/NNS ./. 
Two/CD sets/NNS of/IN independent/JJ evidences/NNS are/VBP presented/VBN here/RB that/WDT demonstrate/VBP a/DT biological/JJ relevance/NN for/IN this/DT model/NN ./. 
First/RB ,/, we/PRP describe/VBP results/NNS demonstrating/VBG that/IN mice/NNS inoculated/VBN with/IN T-antigen-expressing/JJ plasmids/NNS produced/VBD antibodies/NNS ,/, not/RB only/RB to/TO T-antigen/NN and/CC DNA/NN ,/, but/CC also/RB to/TO the/DT DNA-binding/JJ eukaryotic/JJ transcription/NN factors/NNS TATA-binding/JJ protein/NN (/( TBP/NN )/) ,/, and/CC to/TO the/DT cAMP-response-element-binding/JJ protein/NN (/( CREB/NN )/) ./. 
Secondly/RB ,/, we/PRP investigated/VBD whether/IN polyomavirus/NN reactivation/NN occurs/VBZ in/IN SLE/NN patients/NNS ,/, and/CC whether/IN antibodies/NNS to/TO T-antigen/NN ,/, DNA/NN ,/, and/CC to/TO TBP/NN and/CC CREB/NN are/VBP linked/VBN to/TO such/JJ events/NNS ./. 
Both/CC within/IN and/CC among/IN these/DT SLE/NN patients/NNS ,/, frequent/JJ polyomavirus/NN reactivations/NNS were/VBD observed/VBN that/WDT could/MD not/RB be/VB explained/VBN by/IN certain/JJ rearrangements/NNS of/IN the/DT noncoding/JJ control/NN regions/NNS ,/, nor/CC by/IN corticosteroid/NN treatment/NN ./. 
Linked/VBN to/TO these/DT events/NNS ,/, antibodies/NNS to/TO T-antigen/NN ,/, DNA/NN ,/, TBP/NN ,/, and/CC CREB/NN were/VBD detected/VBN ,/, identical/JJ to/TO what/WP we/PRP observed/VBD in/IN mice/NNS ./. 
Antibodies/NNS recognizing/VBG double-stranded/JJ DNA/NN were/VBD confined/VBN to/TO patients/NNS with/IN frequent/JJ polyomavirus/NN reactivations/NNS ./. 
The/DT results/NNS described/VBN here/RB indicate/VBP that/IN cognate/JJ interaction/NN of/IN B/NN cells/NNS recognizing/VBG DNA/NN or/CC DNA-associated/JJ proteins/NNS and/CC T/NN cells/NNS recognizing/VBG T/NN antigen/NN had/VBD taken/VBN place/NN as/IN a/DT consequence/NN of/IN complex/JJ formation/NN between/IN T/NN ag/NN and/CC DNA/NN in/FW vivo/FW in/IN the/DT context/NN of/IN polyomavirus/NN reactivations/NNS ./. 
UI/LS -/: 97278840/CD 
TI/LS -/: Jak3/NN is/VBZ associated/VBN with/IN CD40/NN and/CC is/VBZ critical/JJ for/IN CD40/NN induction/NN of/IN gene/NN expression/NN in/IN B/NN cells/NNS ./. 
AB/LS -/: CD40/NN is/VBZ a/DT receptor/NN that/WDT is/VBZ critical/JJ for/IN the/DT survival/NN ,/, growth/NN ,/, differentiation/NN ,/, and/CC isotype/NN switching/NN of/IN B/NN lymphocytes/NNS ./. 
Although/IN CD40/NN lacks/VBZ intrinsic/JJ tyrosine/NN kinase/NN activity/NN ,/, its/PRP$ ligation/NN induces/VBZ protein/NN tyrosine/NN phosphorylation/NN ,/, which/WDT is/VBZ necessary/JJ for/IN several/JJ CD40-mediated/JJ events/NNS ./. 
We/PRP show/VBP that/IN engagement/NN of/IN CD40/NN induces/VBZ tyrosine/NN phosphorylation/NN and/CC activation/NN of/IN Jak3/NN as/RB well/RB as/IN of/IN STAT3/NN ./. 
Jak3/NN is/VBZ constitutively/RB associated/VBN with/IN CD40/NN ,/, and/CC this/DT interaction/NN requires/VBZ a/DT proline-rich/JJ sequence/NN in/IN the/DT membrane-proximal/JJ region/NN of/IN CD40/NN ./. 
Deletion/NN of/IN this/DT sequence/NN abolishes/VBZ the/DT capacity/NN of/IN CD40/NN to/TO induce/VB expression/NN of/IN CD23/NN ,/, ICAM-1/NN ,/, and/CC lymphotoxin-alpha/NN genes/NNS in/IN B/NN cells/NNS ./. 
These/DT results/NNS indicate/VBP that/IN signaling/NN through/IN Jak3/NN is/VBZ activated/VBN by/IN CD40/NN and/CC plays/VBZ an/DT important/JJ role/NN in/IN CD40-mediated/JJ functions/NNS ./. 
UI/LS -/: 98145608/CD 
TI/LS -/: Transcription/NN factors/NNS required/VBN for/IN lymphoid/JJ lineage/NN commitment/NN ./. 
AB/LS -/: Intimate/JJ interactions/NNS between/IN multipotential/JJ hemopoietic/JJ stem/NN cells/NNS and/CC their/PRP$ microenvironment/NN work/VBP towards/IN redefining/VBG the/DT identity/NN and/CC the/DT differentiative/JJ fate/NN of/IN these/DT primitive/JJ cells/NNS ./. 
Molecular/JJ cues/NNS delivered/VBN by/IN the/DT microenvironment/NN frequently/RB act/VBP in/IN an/DT instructive/JJ fashion/NN by/IN initiating/VBG intracellular/JJ signaling/NN pathways/NNS that/WDT ultimately/RB target/VBP a/DT select/JJ group/NN of/IN transcription/NN factors/NNS ./. 
These/DT transcriptional/JJ regulators/NNS in/IN turn/NN trigger/VBP a/DT cascade/NN of/IN genetic/JJ changes/NNS that/WDT ultimately/RB determine/VBP the/DT course/NN of/IN the/DT cells/NNS during/IN differentiation/NN ./. 
Gene/NN inactivation/NN studies/NNS on/IN the/DT PU.1/NN ,/, Ikaros/NN and/CC GATA-3/NN genes/NNS have/VBP revealed/VBN that/IN their/PRP$ encoded/VBN factors/NNS are/VBP essential/JJ for/IN the/DT earliest/JJS commitment/NN step/NN into/IN the/DT B/NN and/CC T/NN lymphoid/JJ lineages/NNS ./. 
UI/LS -/: 97207294/CD 
TI/LS -/: Interleukin-4/NN signaling/NN in/IN B/NN lymphocytes/NNS from/IN patients/NNS with/IN X-linked/JJ severe/JJ combined/JJ immunodeficiency/NN ./. 
AB/LS -/: Interleukin-4/NN (/( IL-4/NN )/) is/VBZ an/DT important/JJ cytokine/NN for/IN B/NN and/CC T/NN lymphocyte/NN function/NN and/CC mediates/VBZ its/PRP$ effects/NNS via/IN a/DT receptor/NN that/WDT contains/VBZ gammac/NN ./. 
B/NN cells/NNS derived/VBN from/IN patients/NNS with/IN X-linked/JJ severe/JJ combined/JJ immunodeficiency/NN (/( X-SCID/NN )/) are/VBP deficient/JJ in/IN gammac/NN and/CC provide/VBP a/DT useful/JJ model/NN in/IN which/WDT to/TO dissect/VB the/DT role/NN of/IN this/DT subunit/NN in/IN IL-4-mediated/JJ signaling/NN ./. 
We/PRP found/VBD that/IN although/IN IL-4/NN stimulation/NN of/IN X-SCID/NN B/NN cells/NNS did/VBD not/RB result/VB in/IN Janus/NN tyrosine/NN kinase-3/NN (/( JAK3/NN )/) phosphorylation/NN ,/, other/JJ IL-4/NN substrates/NNS including/VBG JAK1/NN and/CC IRS-1/NN were/VBD phosphorylated/VBN ./. 
Additionally/RB ,/, we/PRP detected/VBD signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN 6/CD (/( STAT6/NN )/) tyrosine/NN phosphorylation/NN and/CC DNA/NN binding/NN activity/NN in/IN X-SCID/NN B/NN cells/NNS with/IN a/DT wide/JJ range/NN of/IN gammac/NN mutations/NNS ./. 
However/RB ,/, reconstitution/NN of/IN these/DT X-SCID/NN B/NN cells/NNS with/IN gammac/NN enhanced/VBD IL-4-mediated/JJ responses/NNS including/VBG STAT6/NN phosphorylation/NN and/CC DNA/NN binding/NN activity/NN and/CC resulted/VBD in/IN increased/VBN CD23/NN expression/NN ./. 
Thus/RB ,/, gammac/NN is/VBZ not/RB necessary/JJ to/TO trigger/VB IL-4-mediated/JJ responses/NNS in/IN B/NN cells/NNS ,/, but/CC its/PRP$ presence/NN is/VBZ important/JJ for/IN optimal/JJ IL-4-signaling/NN ./. 
These/DT results/NNS suggest/VBP that/IN two/CD distinct/JJ IL-4/NN signaling/NN pathways/NNS exist/VBP ./. 
UI/LS -/: 97234588/CD 
TI/LS -/: Cell-to-cell/JJ contact/NN activates/VBZ the/DT long/JJ terminal/JJ repeat/NN of/IN human/JJ immunodeficiency/NN virus/NN 1/CD through/IN its/PRP$ kappaB/NN motif/NN ./. 
AB/LS -/: Cell-to-cell/JJ contact/NN between/IN peripheral/JJ blood/NN lymphocytes/NNS and/CC transfected/VBN human/JJ colonic/JJ carcinoma/NN cell/NN line/NN HT29/NN activates/VBZ transcription/NN of/IN the/DT long/JJ terminal/JJ repeats/NNS (/( LTR/NNS )/) of/IN human/JJ immunodeficiency/NN virus/NN ./. 
HIV-1/NN LTR/NNS transcription/NN is/VBZ controlled/VBN by/IN a/DT complex/JJ array/NN of/IN virus-encoded/JJ and/CC cellular/JJ proteins/NNS ./. 
Using/VBG various/JJ constructs/NNS expressing/VBG a/DT lacZ/NN reporter/NN gene/NN under/IN the/DT control/NN of/IN the/DT intact/JJ or/CC three/CD deleted/JJ forms/NNS of/IN HIV-1/NN LTR/NNS ,/, we/PRP obtained/VBD evidence/NN that/IN the/DT kappaB/NN regulatory/JJ elements/NNS located/JJ in/IN the/DT U3/NN region/NN are/VBP involved/VBN in/IN cell-to-cell/JJ activation/NN of/IN HIV-1/NN LTR/NNS ./. 
Cell-to-cell/JJ contact/NN activates/VBZ in/FW vitro/FW binding/NN of/IN the/DT nuclear/JJ factor/NN kappaB/NN (/( NF-kappaB/NN )/) p50/p65/NN heterodimer/NN to/TO an/DT HIV-1/NN kappaB/NN oligonucleotide/NN ./. 
Cell-to-cell/JJ contact/NN activation/NN of/IN NF-kappaB/NN was/VBD only/RB partially/RB inhibited/VBN by/IN 100/CD microM/NN pyrrolidine/NN dithiocarbamate/NN and/CC was/VBD not/RB correlated/VBN with/IN a/DT significant/JJ decrease/NN of/IN cellular/JJ inhibitor/NN kappaB/NN alpha/NN ./. 
NF-kappaB/NN nuclear/JJ activation/NN was/VBD not/RB detectable/JJ before/IN 1/CD h/NN after/IN cell/NN contact/NN and/CC was/VBD dependent/JJ on/IN protein/NN synthesis/NN ./. 
UI/LS -/: 97184601/CD 
TI/LS -/: Identification/NN of/IN nucleotide/NN sequences/NNS that/WDT regulate/VBP transcription/NN of/IN the/DT MCF13/NN murine/JJ leukemia/NN virus/NN long/JJ terminal/JJ repeat/NN in/IN activated/VBN T/NN cells/NNS ./. 
AB/LS -/: The/DT region/NN downstream/JJ of/IN the/DT enhancer/NN (/( DEN/NN )/) of/IN the/DT long/JJ terminal/JJ repeat/NN of/IN the/DT mink/NN cell/NN focus-forming/JJ murine/JJ leukemia/NN virus/NN is/VBZ important/JJ for/IN viral/JJ pathogenicity/NN ./. 
Another/DT important/JJ activity/NN of/IN DEN/NN is/VBZ its/PRP$ control/NN of/IN transcription/NN in/IN activated/VBN T/NN cells/NNS ,/, and/CC we/PRP have/VBP determined/VBN that/IN an/DT NF-kappaB/NN site/NN is/VBZ critical/JJ for/IN this/DT activity/NN ./. 
UI/LS -/: 97223498/CD 
TI/LS -/: Possible/JJ role/NN of/IN nuclear/JJ factor-kappa/NN B/NN activity/NN in/IN germline/NN C/NN epsilon/NN transcription/NN in/IN a/DT human/JJ Burkitt/NN lymphoma/NN B/NN cell/NN line/NN ./. 
AB/LS -/: Nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) plays/VBZ a/DT broad/JJ role/NN in/IN gene/NN regulation/NN ,/, but/CC it/PRP is/VBZ not/RB evident/JJ whether/IN NF-kappa/NN B/NN acts/VBZ as/IN a/DT messenger/NN system/NN for/IN germline/NN C/NN epsilon/NN transcription/NN ./. 
We/PRP report/VBP here/RB that/IN the/DT signaling/NN cascade/NN triggered/VBN by/IN interleukin-4/NN (/( IL-4/NN )/) or/CC anti-CD40/JJ monoclonal/JJ antibody/NN (/( mAb/NN )/) participates/VBZ in/IN NF-kappa/NN B/NN activation/NN responsible/JJ for/IN germline/NN C/NN epsilon/NN transcription/NN in/IN a/DT human/JJ Burkitt/NN lymphoma/NN B/NN cell/NN line/NN ,/, DND39/NN ./. 
Both/CC IL-4/NN and/CC anti-CD40/JJ mAb/NN induced/VBD activation/NN of/IN phosphatidylinositol/NN 3-kinase/NN (/( PI3-kinase/NN )/) ,/, translocation/NN of/IN a/DT zeta/NN isoform/NN of/IN protein/NN kinase/NN C/NN ,/, and/CC nuclear/JJ expression/NN of/IN NF-kappa/NN B/NN ./. 
All/DT such/JJ events/NNS were/VBD abrogated/VBN by/IN treatment/NN with/IN LY294002/NN ,/, a/DT specific/JJ inhibitor/NN of/IN PI3-kinase/NN ./. 
In/IN addition/NN ,/, N-acetyl-L-cysteine/NN (/( NAC/NN )/) ,/, a/DT potent/JJ antioxidant/NN ,/, decreased/VBD NF-kappa/NN B/NN activation/NN caused/VBN by/IN IL-4/NN ,/, anti-CD40/JJ mAb/NN ,/, or/CC their/PRP$ combination/NN ./. 
NAC/NN was/VBD also/RB effective/JJ in/IN diminishing/VBG germline/NN C/NN epsilon/NN transcription/NN ,/, and/CC its/PRP$ potency/NN was/VBD higher/JJR in/IN cultures/NNS costimulated/VBN with/IN IL-4/NN and/CC anti-CD40/JJ mAb/NN than/IN in/IN those/DT stimulated/VBN with/IN IL-4/NN alone/RB ./. 
These/DT results/NNS indicate/VBP that/IN IL-4/NN and/CC ligation/NN of/IN CD40/NN induce/VBP NF-kappa/NN B/NN expression/NN via/IN at/IN least/JJS a/DT mechanism/NN dependent/JJ on/IN the/DT PI3-kinase/NN pathway/NN and/CC suggest/VBP that/IN NF-kappa/NN B/NN sensitive/JJ to/TO NAC/NN may/MD play/VB a/DT role/NN in/IN regulating/VBG germline/NN C/NN epsilon/NN transcription/NN ./. 
UI/LS -/: 97209911/CD 
TI/LS -/: Differentiation/NN of/IN U-937/NN promonocytic/JJ cells/NNS by/IN etoposide/NN and/CC ICRF-193/NN ,/, two/CD antitumour/JJ DNA/NN topoisomerase/NN II/CD inhibitors/NNS with/IN different/JJ mechanisms/NNS of/IN action/NN ./. 
AB/LS -/: We/PRP have/VBP compared/VBN the/DT action/NN on/IN U-937/NN human/JJ promonocytic/JJ leukemia/NN cells/NNS of/IN two/CD DNA/NN topoisomerase/NN II/CD inhibitors/NNS ,/, namely/RB the/DT epipodophyllotoxin/NN etoposide/NN and/CC the/DT bisdioxopiperazine/NN ICRF-193/NN ./. 
One/CD hour/NN pulse-treatment/NN with/IN 3/CD microM/NN etoposide/NN caused/VBD topoisomerase/NN associated/JJ ,/, primary/JJ DNA/NN breakage/NN ,/, which/WDT was/VBD rapidly/RB followed/VBN by/IN apoptosis/NN ./. 
By/IN contrast/NN ,/, these/DT effects/NNS were/VBD not/RB observed/VBN upon/IN pulse-treatment/NN with/IN 6/CD microM/NN ICRF-193/NN ./. 
However/RB ,/, continuous/JJ treatments/NNS with/IN subcytotoxic/JJ concentrations/NNS of/IN etoposide/NN (/( 0.15/CD microM/NN )/) and/CC ICRF-193/NN (/( 0.3/CD microM/NN )/) produced/VBD several/JJ similar/JJ effects/NNS ,/, namely/RB decreased/VBN cell/NN proliferation/NN ,/, accumulation/NN of/IN cells/NNS at/IN G2/NN ,/, increase/NN in/IN cell/NN mass/NN ,/, and/CC induction/NN of/IN differentiation/NN ./. 
Under/IN these/DT conditions/NNS ,/, etoposide/NN produced/VBD a/DT biphasic/JJ activation/NN of/IN protein/NN kinase/NN C/NN ,/, which/WDT consisted/VBD in/IN an/DT early/JJ transient/JJ activation/NN (/( from/IN hours/NNS 1/CD to/TO 6/CD )/) of/IN the/DT membrane-bound/JJ enzyme/NN followed/VBN by/IN a/DT later/JJ activation/NN (/( hour/NN 48/CD )/) of/IN the/DT total/JJ ,/, membrane-bound/JJ and/CC cytosolic/JJ enzyme/NN ./. 
By/IN contrast/NN ,/, ICRF-193/NN only/RB provoked/VBD a/DT late/JJ activation/NN (/( from/IN hours/NNS 72/CD to/TO 96/CD )/) of/IN the/DT total/JJ enzyme/NN ./. 
When/WRB used/VBN at/IN differentiation-inducing/JJ concentrations/NNS ,/, both/DT topoisomerase/NN inhibitors/NNS caused/VBD a/DT great/JJ stimulation/NN of/IN AP-1/NN binding/NN activity/NN ,/, with/IN maximum/JJ value/NN at/IN hour/NN 12/CD in/IN etoposide-treated/JJ cells/NNS and/CC at/IN hour/NN 48/CD in/IN ICRF-193-treated/JJ cells/NNS ./. 
By/IN contrast/NN ,/, the/DT binding/NN activity/NN of/IN the/DT NF-kappa/NN (/( B/NN )/) and/CC EGR-1/NN transcription/NN factors/NNS was/VBD little/RB affected/VBN ./. 
It/PRP is/VBZ concluded/VBN that/IN topoisomerase/NN II/CD inhibitors/NNS may/MD induce/VB the/DT differentiation/NN of/IN promonocytic/JJ cells/NNS ,/, independently/RB of/IN their/PRP$ capacity/NN to/TO cause/VB DNA/NN strand/NN breaks/NN ./. 
However/RB ,/, there/EX are/VBP other/JJ effects/NNS ,/, such/JJ as/IN the/DT early/JJ activation/NN of/IN protein/NN kinase/NN C/NN ,/, which/WDT are/VBP probably/RB derived/VBN from/IN the/DT production/NN of/IN primary/JJ DNA/NN breakage/NN by/IN some/DT anti-topoisomerase/JJ drugs/NNS ./. 
UI/LS -/: 97153026/CD 
TI/LS -/: GATA-1/NN DNA/NN binding/NN activity/NN is/VBZ down-regulated/VBN in/IN late/JJ S/NN phase/NN in/IN erythroid/JJ cells/NNS ./. 
AB/LS -/: We/PRP have/VBP set/VBN out/RP to/TO test/VB a/DT model/NN for/IN tissue-specific/JJ gene/NN expression/NN that/WDT relies/VBZ on/IN the/DT early/JJ replication/NN of/IN expressed/VBN genes/NNS to/TO sequester/VB limiting/VBG activating/VBG transcription/NN factors/NNS ./. 
Using/VBG an/DT erythroid/JJ cell/NN line/NN ,/, we/PRP have/VBP tested/VBN the/DT changes/NNS in/IN the/DT DNA/NN binding/NN activity/NN of/IN the/DT lineage-restricted/JJ transcription/NN factor/NN GATA-1/NN through/IN the/DT cell/NN cycle/NN ./. 
We/PRP find/VBP that/IN GATA-1/NN activity/NN is/VBZ low/JJ in/IN G1/NN ,/, peaks/VBZ in/IN mid-S/NN phase/NN ,/, and/CC then/RB decreases/VBZ in/IN G2/M/NN ./. 
In/IN contrast/NN ,/, the/DT binding/NN activities/NNS of/IN two/CD ubiquitous/JJ transcription/NN factors/NNS ,/, Oct1/NN and/CC Sp1/NN ,/, remain/VBP high/JJ in/IN G2/M/NN ./. 
GATA-1/NN protein/NN and/CC mRNA/NN vary/VBP in/IN a/DT similar/JJ manner/NN through/IN the/DT cell/NN cycle/NN ,/, suggesting/VBG that/IN the/DT expression/NN of/IN the/DT gene/NN or/CC the/DT stability/NN of/IN its/PRP$ message/NN is/VBZ regulated/VBN ./. 
Although/IN a/DT number/NN of/IN transcription/NN factors/NNS involved/VBN in/IN the/DT control/NN of/IN the/DT cell/NN cycle/NN or/CC DNA/NN replication/NN have/VBP been/VBN shown/VBN to/TO peak/VB in/IN S/NN phase/NN ,/, this/DT is/VBZ the/DT first/JJ example/NN of/IN a/DT lineage-restricted/JJ transcription/NN factor/NN displaying/VBG S/NN phase-specific/JJ DNA/NN binding/NN activity/NN ./. 
One/CD interpretation/NN of/IN these/DT data/NNS leads/VBZ to/TO a/DT model/NN in/IN which/WDT the/DT peak/NN in/IN GATA-1/NN DNA/NN binding/NN amplifies/VBZ the/DT effect/NN of/IN early/JJ replication/NN on/IN the/DT activation/NN of/IN erythroid-specific/JJ genes/NNS at/IN the/DT same/JJ time/NN as/IN preventing/VBG activation/NN of/IN non-erythroid/JJ genes/NNS containing/VBG GATA-responsive/JJ elements/NNS ./. 
These/DT results/NNS may/MD also/RB relate/VB to/TO recent/JJ data/NNS implicating/VBG GATA-1/NN function/NN in/IN apoptosis/NN and/CC cell/NN cycle/NN progression/NN 
UI/LS -/: 97275156/CD 
TI/LS -/: Activation/NN of/IN the/DT NF-kappaB/NN pathway/NN by/IN inflammatory/JJ stimuli/NNS in/IN human/JJ neutrophils/NNS ./. 
AB/LS -/: Activated/VBN neutrophils/NNS have/VBP the/DT ability/NN to/TO upregulate/VB the/DT expression/NN of/IN many/JJ genes/NNS ,/, in/IN particular/JJ those/DT encoding/VBG cytokines/NNS and/CC chemokines/NNS ,/, and/CC to/TO subsequently/RB release/VB the/DT corresponding/JJ proteins/NNS ./. 
Although/IN little/JJ is/VBZ known/VBN to/TO date/NN concerning/VBG the/DT regulation/NN of/IN gene/NN transcription/NN in/IN neutrophils/NNS ,/, it/PRP is/VBZ noteworthy/JJ that/IN many/JJ of/IN these/DT genes/NNS depend/VBP on/IN the/DT activation/NN of/IN transcription/NN factors/NNS ,/, such/JJ as/IN NF-kappaB/NN ,/, for/IN inducible/JJ expression/NN ./. 
We/PRP therefore/RB investigated/VBD whether/IN NF-kappaB/Rel/NN proteins/NNS are/VBP expressed/VBN in/IN human/JJ neutrophils/NNS ,/, as/RB well/RB as/IN their/PRP$ fate/NN on/IN cell/NN activation/NN ./. 
We/PRP now/RB report/VBP that/IN dimers/NNS consisting/VBG of/IN p50/NN NFkappaB1/NN ,/, p65/NN RelA/NN ,/, and/or/CC c-Rel/NN are/VBP present/JJ in/IN neutrophils/NNS and/CC that/IN the/DT greater/JJR part/NN of/IN these/DT protein/NN complexes/NNS is/VBZ physically/RB associated/VBN with/IN cytoplasmic/JJ IkappaB-alpha/NN in/IN resting/VBG cells/NNS ./. 
Following/VBG neutrophil/NN stimulation/NN with/IN proinflammatory/JJ agonists/NNS (/( such/JJ as/IN lipopolysaccharide/NN [/( LPS/NN ]/) ,/, tumor/NN necrosis/NN factor-alpha/NN [/( TNF-alpha/NN ]/) ,/, and/CC fMet-Leu-Phe/NN )/) that/WDT induce/VBP the/DT production/NN of/IN cytokines/NNS and/CC chemokines/NNS in/IN these/DT cells/NNS ,/, NF-kappaB/Rel/NN proteins/NNS translocated/VBD to/TO nuclear/JJ fractions/NNS ,/, resulting/VBG in/IN a/DT transient/JJ induction/NN of/IN NF-kappaB/NN DNA/NN binding/NN activity/NN ,/, as/IN determined/VBN in/IN gel/NN mobility/NN shift/NN assays/NNS ./. 
The/DT onset/NN of/IN both/DT processes/NNS was/VBD found/VBN to/TO be/VB closely/RB paralleled/VBN by/IN ,/, and/CC dependent/JJ on/IN ,/, IkappaB-alpha/NN degradation/NN ./. 
Proinflammatory/JJ neutrophil/NN stimuli/NNS also/RB promoted/VBD the/DT accumulation/NN of/IN IkappaB-alpha/NN mRNA/NN transcripts/NNS ,/, resulting/VBG in/IN the/DT reexpression/NN of/IN the/DT IkappaB-alpha/NN protein/NN ./. 
To/TO our/PRP$ knowledge/NN ,/, this/DT constitutes/VBZ the/DT first/JJ indication/NN that/IN NF-kappaB/NN activation/NN may/MD underlie/VB the/DT action/NN of/IN proinflammatory/JJ stimuli/NNS towards/IN human/JJ neutrophil/NN gene/NN expression/NN and/CC ,/, as/IN such/JJ ,/, adds/VBZ a/DT new/JJ facet/NN to/TO our/PRP$ understanding/NN of/IN neutrophil/NN biology/NN ./. 
UI/LS -/: 97261995/CD 
TI/LS -/: Two/CD distinct/JJ pathways/NNS of/IN interleukin-5/NN synthesis/NN in/IN allergen-specific/JJ human/JJ T-cell/NN clones/NNS are/VBP suppressed/VBN by/IN glucocorticoids/NNS ./. 
AB/LS -/: Glucocorticoids/NNS (/( GC/NNS )/) have/VBP long/RB been/VBN used/VBN as/IN the/DT most/RBS effective/JJ agents/NNS for/IN the/DT treatment/NN of/IN allergic/JJ diseases/NNS accompanied/VBN by/IN eosinophilia/NN such/JJ as/IN chronic/JJ asthma/NN and/CC atopic/JJ dermatitis/NN ./. 
The/DT development/NN of/IN chronic/JJ eosinophilic/JJ inflammation/NN is/VBZ dependent/JJ on/IN interleukin-5/NN (/( IL-5/NN )/) ,/, a/DT selective/JJ eosinophil-activating/JJ factor/NN ,/, produced/VBN by/IN helper/NN T/NN cells/NNS ./. 
To/TO delineate/VB the/DT regulatory/JJ mechanisms/NNS of/IN human/JJ IL-5/NN synthesis/NN ,/, we/PRP established/VBD allergen-specific/JJ CD4+/JJ T-cell/NN clones/NNS from/IN asthmatic/JJ patients/NNS ./. 
GC/NNS efficiently/RB suppressed/VBD IL-5/NN synthesis/NN of/IN T-cell/NN clones/NNS activated/VBN via/IN either/CC T-cell/NN receptor/NN (/( TCR/NN )/) or/CC IL-2/NN receptor/NN (/( IL-2R/NN )/) ./. 
Induction/NN of/IN IL-5/NN mRNA/NN upon/IN TCR/NN and/CC IL-2R/NN stimulation/NN was/VBD totally/RB inhibited/VBN by/IN dexamethasone/NN ./. 
Human/JJ IL-5/NN promoter/enhancer-luciferase/NN gene/NN construct/NN transfected/VBN to/TO T-cell/NN clones/NNS was/VBD transcribed/VBN on/IN either/CC TCR/NN or/CC IL-2R/NN stimulation/NN and/CC was/VBD clearly/RB downregulated/VBN by/IN dexamethasone/NN ,/, indicating/VBG that/IN the/DT approximately/RB 500-bp/JJ human/JJ IL-5/NN gene/NN segment/NN located/JJ 5'/RB upstream/RB of/IN the/DT coding/VBG region/NN contains/VBZ activation-inducible/JJ enhancer/NN elements/NNS responsible/JJ for/IN the/DT regulation/NN by/IN GC/NNS ./. 
Electrophoretic/JJ mobility/NN shift/NN assay/NN analysis/NN suggested/VBD that/IN AP-1/NN and/CC NF-kappaB/NN are/VBP among/IN the/DT possible/JJ targets/NNS of/IN GC/NNS actions/NNS on/IN TCR-stimulated/JJ T/NN cells/NNS ./. 
NF-AT/NN and/CC NF-kappaB/NN were/VBD not/RB significantly/RB induced/VBN by/IN IL-2/NN stimulation/NN ./. 
Our/PRP$ results/NNS showing/VBG that/IN GC/NNS suppressed/VBD IL-5/NN production/NN by/IN human/JJ CD4+/JJ T/NN cells/NNS activated/VBN by/IN two/CD distinct/JJ stimuli/NNS ,/, TCR/NN and/CC IL-2R/NN stimulation/NN ,/, underscore/VBP the/DT efficacy/NN of/IN GC/NNS in/IN the/DT treatment/NN of/IN allergic/JJ diseases/NNS via/IN suppression/NN of/IN T-cell/NN IL-5/NN synthesis/NN ./. 
UI/LS -/: 97276939/CD 
TI/LS -/: Itk/NN ,/, a/DT T/NN cell-specific/JJ tyrosine/NN kinase/NN ,/, is/VBZ required/VBN for/IN CD2-mediated/JJ interleukin-2/NN promoter/NN activation/NN in/IN the/DT human/JJ T/NN cell/NN line/NN Jurkat/NN ./. 
AB/LS -/: We/PRP investigated/VBD the/DT functional/JJ role/NN of/IN Itk/NN ,/, a/DT member/NN of/IN the/DT cytoplasmic/JJ tyrosine/NN kinase/NN Tec/NN family/NN ,/, in/IN T/NN cell/NN activation/NN ./. 
Stimulation/NN of/IN either/CC CD2/NN or/CC T/NN cell/NN receptor/NN (/( TCR/NN )/) /CD3/NN on/IN Tcells/NNS by/IN monoclonal/JJ antibody-mediated/JJ cross-linking/NN induced/VBD tyrosine/NN phosphorylation/NN of/IN Itk/NN ,/, which/WDT was/VBD maximal/JJ as/RB early/RB as/IN 1/CD min/NN after/IN stimulation/NN ./. 
The/DT tyrosine/NN kinase/NN activity/NN in/IN the/DT anti-Itk/JJ immunoprecipitate/NN was/VBD significantly/RB activated/VBN upon/IN these/DT stimulations/NNS ./. 
Interleukin-2/NN (/( IL-2/NN )/) promoter/NN activity/NN stimulated/VBN by/IN cross-linking/NN of/IN CD2/NN ,/, TCR/CD3/NN ,/, and/CC CD28/NN with/IN antibodies/NNS was/VBD significantly/RB reduced/VBN by/IN transient/JJ expression/NN of/IN an/DT Itk/NN mutant/NN lacking/VBG the/DT kinase/NN activity/NN ./. 
The/DT reduction/NN paralleled/VBD a/DT decrease/NN in/IN tyrosine/NN phosphorylation/NN of/IN endogenous/JJ wild-type/JJ Itk/NN ./. 
Stimulation/NN of/IN CD2/NN or/CC TCR/CD3/NN induced/VBD activation/NN of/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) ,/, the/DT binding/VBG site/NN of/IN which/WDT is/VBZ included/VBN in/IN the/DT IL-2/NN gene/NN promoter/NN ./. 
The/DT activation/NN of/IN NFAT/NN was/VBD also/RB impaired/VBN by/IN expression/NN of/IN the/DT Itk/NN mutant/NN ./. 
These/DT results/NNS demonstrate/VBP that/IN Itk/NN plays/VBZ a/DT role/NN in/IN IL-2/NN production/NN ,/, indicating/VBG a/DT critical/JJ involvement/NN of/IN Itk/NN in/IN the/DT initial/JJ stage/NN of/IN T/NN cell/NN activation/NN by/IN mediating/VBG signals/NNS from/IN the/DT TCR/CD3/NN complex/NN ,/, CD2/NN ,/, and/CC CD28/NN ./. 
UI/LS -/: 97251018/CD 
TI/LS -/: Expression/NN of/IN LAZ3/BCL6/NN in/IN follicular/JJ center/NN (/( FC/NN )/) B/NN cells/NNS of/IN reactive/JJ lymph/NN nodes/NNS and/CC FC-derived/JJ non-Hodgkin/JJ lymphomas/NNS ./. 
AB/LS -/: Chromosomal/JJ translocation/NN resulting/VBG in/IN abnormal/JJ expression/NN of/IN the/DT LAZ3/BCL6/NN gene/NN in/IN B/NN cells/NNS has/VBZ been/VBN implicated/VBN in/IN the/DT tumorigenesis/NN of/IN non-Hodgkin/JJ lymphoma/NN (/( NHL/NN )/) ./. 
Therefore/RB we/PRP studied/VBD the/DT expression/NN pattern/NN of/IN LAZ3/BCL6/NN by/IN in/FW situ/FW hybridization/NN with/IN synthetic/JJ oligonucleotide/NN probes/NNS in/IN frozen/VBN tissue/NN sections/NNS from/IN five/CD reactive/JJ lymph/NN nodes/NNS and/CC 38/CD B/NN cell/NN and/CC non-B/JJ NHL/NN ./. 
In/IN addition/NN ,/, we/PRP investigated/VBD the/DT expression/NN of/IN LAZ3/BCL6/NN by/IN Northern/NN blot/NN analysis/NN on/IN multiple/JJ human/JJ tissues/NNS ./. 
The/DT LAZ3/BCL6/NN transcript/NN was/VBD found/VBN in/IN a/DT variety/NN of/IN tissues/NNS ,/, including/VBG skeletal/JJ muscle/NN ,/, peripheral/JJ blood/NN leukocytes/NNS ,/, and/CC weakly/RB in/IN normal/JJ lymph/NN nodes/NNS ./. 
In/IN the/DT tumor/NN samples/NNS ,/, expression/NN of/IN LAZ3/BCL6/NN was/VBD observed/VBN in/IN 68/CD %/NN of/IN all/DT B/NN cell/NN NHL/NN and/CC none/NN of/IN the/DT non-B/JJ lymphomas/NNS ./. 
All/DT cases/NNS of/IN follicular/JJ ,/, mixed/JJ small/JJ and/CC large/JJ cell/NN lymphomas/NNS showed/VBD LAZ3/BCL6/NN expression/NN confined/VBN to/TO the/DT neoplastic/JJ follicles/NNS ./. 
A/DT follicular/JJ expression/NN pattern/NN was/VBD also/RB found/VBN in/IN all/DT non-malignant/JJ reactive/JJ lymph/NN nodes/NNS ./. 
Hence/RB ,/, the/DT expression/NN of/IN LAZ3/BCL6/NN does/VBZ not/RB correlate/VB to/TO malignancy/NN ,/, but/CC reflects/VBZ the/DT origin/NN of/IN B/NN cells/NNS from/IN the/DT germinal/JJ centers/NNS ./. 
UI/LS -/: 97197832/CD 
TI/LS -/: Jak1/NN expression/NN is/VBZ required/VBN for/IN mediating/VBG interleukin-4-induced/JJ tyrosine/NN phosphorylation/NN of/IN insulin/NN receptor/NN substrate/NN and/CC Stat6/NN signaling/NN molecules/NNS ./. 
AB/LS -/: The/DT Jak1/NN ,/, Jak2/NN ,/, Jak3/NN ,/, and/CC Fes/NN tyrosine/NN kinases/NNS have/VBP been/VBN demonstrated/VBN to/TO undergo/VB tyrosine/NN phosphorylation/NN in/IN response/NN to/TO interleukin/NN (/( IL/NN )/) -4/CD stimulation/NN in/IN different/JJ cell/NN systems/NNS ./. 
However/RB ,/, it/PRP is/VBZ not/RB clear/JJ which/WDT ,/, if/IN any/DT ,/, of/IN these/DT kinases/NNS are/VBP responsible/JJ for/IN initiating/VBG IL-4-induced/JJ tyrosine/NN phosphorylation/NN of/IN intracellular/JJ substrates/NNS in/FW vivo/FW ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP have/VBP utilized/VBN a/DT mutant/JJ Jak1-deficient/JJ HeLa/NN cell/NN line/NN ,/, E1C3/NN ,/, and/CC its/PRP$ parental/JJ Jak1-expressing/JJ counterpart/NN ,/, 1D4/NN ,/, to/TO analyze/VB the/DT role/NN of/IN Jak1/NN in/IN mediating/VBG IL-4-induced/JJ tyrosine/NN phosphorylation/NN events/NNS ./. 
IL-4/NN treatment/NN rapidly/RB induced/VBD tyrosine/NN phosphorylation/NN of/IN insulin/NN receptor/NN substrate/NN (/( IRS/NN )/) -1/CD and/CC IRS-2/NN in/IN 1D4/NN but/CC not/RB in/IN E1C3/NN cells/NNS ./. 
IL-4-mediated/JJ tyrosine/NN phosphorylation/NN of/IN Stat6/NN was/VBD pronounced/VBN in/IN 1D4/NN cells/NNS ,/, while/IN no/DT IL-4-induced/JJ Stat6/NN phosphorylation/NN was/VBD detected/VBN in/IN E1C3/NN cells/NNS ./. 
IL-4/NN also/RB induced/VBD Stat6/NN DNA/NN binding/NN activity/NN from/IN lysates/NNS of/IN 1D4/NN but/CC not/RB E1C3/NN cells/NNS utilizing/VBG a/DT radiolabeled/VBN immunoglobulin/NN heavy/JJ chain/NN germline/NN epsilon/NN promotor/NN sequence/NN (/( Iepsilon/NN )/) in/IN an/DT electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
Reconstitution/NN of/IN Jak1/NN expression/NN in/IN E1C3/NN cells/NNS restored/VBD the/DT ability/NN of/IN IL-4/NN to/TO induce/VB IRS/NN and/CC Stat6/NN tyrosine/NN phosphorylation/NN ./. 
These/DT results/NNS provide/VBP evidence/NN that/IN Jak1/NN expression/NN is/VBZ required/VBN for/IN mediating/VBG tyrosine/NN phosphorylation/NN and/CC activation/NN of/IN crucial/JJ molecules/NNS involved/VBN in/IN IL-4/NN signal/NN transduction/NN ./. 
UI/LS -/: 97249714/CD 
TI/LS -/: Oxidant-regulation/NN of/IN gene/NN expression/NN in/IN the/DT chronically/RB inflamed/JJ intestine/NN ./. 
AB/LS -/: It/PRP is/VBZ becoming/VBG increasingly/RB apparent/JJ that/IN the/DT chronic/JJ gut/NN inflammation/NN observed/VBN in/IN the/DT idiopathic/JJ inflammatory/JJ bowel/NN diseases/NNS (/( e.g./FW ulcerative/JJ colitis/NN ,/, Crohn/NN 's/POS disease/NN )/) is/VBZ associated/VBN with/IN enhanced/VBN production/NN of/IN leukocyte-derived/JJ oxidants/NNS ./. 
Oxidants/NNS such/JJ as/IN hydrogen/NN peroxide/NN are/VBP known/VBN to/TO activate/VB certain/JJ transcription/NN factors/NNS such/JJ as/IN nuclear/JJ transcription/NN factor/NN kappa/NN beta/NN ./. 
Nuclear/JJ transcription/NN factor/NN kB/NN (/( NF-kappa/NN B/NN )/) is/VBZ a/DT ubiquitous/JJ transcription/NN factor/NN and/CC pleiotropic/JJ regulator/NN of/IN numerous/JJ genes/NNS involved/VBN in/IN the/DT immune/JJ and/CC inflammatory/JJ responses/NNS ./. 
This/DT transcription/NN factor/NN is/VBZ activated/VBN via/IN the/DT selective/JJ phosphorylation/NN ,/, ubiquination/NN and/CC degradation/NN of/IN its/PRP$ inhibitor/NN protein/NN I-kB/NN thereby/RB allowing/VBG translocation/NN of/IN NF-kappa/NN B/NN into/IN the/DT nucleus/NN where/WRB it/PRP upregulates/VBZ the/DT transcription/NN of/IN a/DT variety/NN of/IN adhesion/NN molecules/NNS (/( e.g./FW ICAM-1/NN ,/, VCAM-1/NN )/) ,/, cytokines/NNS (/( TNF/NN ,/, IL-1/NN ,/, IL-6/NN )/) and/CC enzymes/NNS (/( iNOS/NN )/) ./. 
The/DT proteolytic/JJ degradation/NN of/IN the/DT post-translationally/RB modified/VBN I-kappa/NN B/NN is/VBZ known/VBN to/TO be/VB mediated/VBN by/IN the/DT 26S/NN proteasome/NN complex/NN ./. 
Based/VBN upon/IN work/NN from/IN our/PRP$ laboratory/NN ,/, we/PRP propose/VBP that/IN inhibition/NN of/IN NF-kappa/NN B/NN activation/NN produces/VBZ significant/JJ anti/JJ inflammatory/JJ activity/NN which/WDT may/MD be/VB mediated/VBN by/IN the/DT inhibition/NN of/IN transcription/NN of/IN certain/JJ pro-inflammatory/JJ mediators/NNS and/CC adhesion/NN molecules/NNS ./. 
UI/LS -/: 97184561/CD 
TI/LS -/: Generation/NN of/IN cytotoxic/JJ T/NN lymphocytes/NNS against/IN immunorecessive/JJ epitopes/NNS after/IN multiple/JJ immunizations/NNS with/IN adenovirus/NN vectors/NNS is/VBZ dependent/JJ on/IN haplotype/NN ./. 
AB/LS -/: Currently/RB ,/, adenovirus/NN (/( Ad/NN )/) is/VBZ being/VBG considered/VBN as/IN a/DT vector/NN for/IN the/DT treatment/NN of/IN cystic/JJ fibrosis/NN as/RB well/RB as/IN other/JJ diseases/NNS ./. 
However/RB ,/, the/DT cytotoxic/JJ T/NN lymphocyte/NN (/( CTL/NN )/) response/NN to/TO Ad/NN could/MD limit/VB the/DT effectiveness/NN of/IN such/JJ approaches/NNS ./. 
Since/IN the/DT CTL/NN response/NN to/TO virus/NN infection/NN is/VBZ often/RB focused/VBN on/IN one/CD or/CC a/DT few/JJ immunodominant/JJ epitopes/NNS ,/, one/CD approach/NN to/TO circumvent/VB this/DT response/NN is/VBZ to/TO create/VB vectors/NNS that/WDT lack/VBP these/DT immunodominant/JJ epitopes/NNS ./. 
The/DT effectiveness/NN of/IN this/DT approach/NN was/VBD tested/VBN by/IN immunizing/VBG mice/NNS with/IN human/JJ group/NN C/NN adenoviruses/NNS ./. 
Three/CD mouse/NN strains/NNS (/( C57BL/10SnJ/NN [/( H-2b/NN ]/) ,/, C3HeB/FeJ/NN [/( H-2k/NN ]/) ,/, and/CC BALB/cByJ/NN [/( H-2d/NN ]/) )/) were/VBD immunized/VBN with/IN wild-type/JJ Ad/NN or/CC Ad/NN vectors/NNS lacking/VBG the/DT immunodominant/JJ antigen/NN (/( s/NNS )/) ,/, and/CC the/DT CTL/NN responses/NNS were/VBD measured/VBN ./. 
In/IN C57BL/10/NN (/( B10/NN )/) mice/NNS ,/, a/DT single/JJ inoculation/NN intraperitoneally/RB (/( i.p./RB )/) led/VBD to/TO the/DT recognition/NN of/IN an/DT immunodominant/JJ antigen/NN in/IN E1A/NN ./. 
When/WRB B10/NN mice/NNS were/VBD inoculated/VBN multiple/JJ times/NNS either/CC i.p./RB 
or/CC intranasally/RB with/IN wild-type/JJ Ad/NN or/CC an/DT Ad/NN vector/NN lacking/VBG most/JJS of/IN the/DT E1/NN region/NN ,/, subdominant/JJ epitopes/NNS outside/IN this/DT region/NN were/VBD recognized/VBN ./. 
In/IN contrast/NN ,/, C3H/NN mice/NNS inoculated/VBN with/IN wild-type/JJ Ad/NN recognized/VBD an/DT epitope/NN mapping/VBG within/IN E1B/NN ./. When/WRB inoculated/VBN twice/RB with/IN Ad/NN vectors/NNS lacking/VBG both/CC E1A/NN and/CC E1B/NN ,/, no/DT immunorecessive/JJ epitopes/NNS were/VBD recognized/VBN ./. 
The/DT immune/JJ response/NN to/TO Ad/NN in/IN BALB/c/NN mice/NNS was/VBD more/RBR complex/JJ ./. 
CTLs/NNS from/IN BALB/c/NN mice/NNS inoculated/VBN i.p./RB with/IN wild-type/JJ Ad/NN recognized/VBD E1B/NN in/IN the/DT context/NN of/IN the/DT major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN I/CD Dd/NN allele/NN and/CC a/DT region/NN outside/IN E1/NN associated/VBD with/IN the/DT Kd/NN allele/NN ./. 
When/WRB BALB/c/NN mice/NNS were/VBD inoculated/VBN with/IN E1-deleted/JJ Ad/NN vectors/NNS ,/, only/RB the/DT immunodominant/JJ Kd-restricted/JJ epitope/NN was/VBD recognized/VBN ,/, and/CC Dd-restricted/JJ CTLs/NNS did/VBD not/RB develop/VB ./. 
This/DT report/NN indicates/VBZ that/IN the/DT emergence/NN of/IN CTLs/NNS against/IN immunorecessive/JJ epitopes/NNS following/VBG multiple/JJ administrations/NNS of/IN Ad/NN vectors/NNS lacking/VBG immunodominant/JJ antigens/NNS is/VBZ dependent/JJ on/IN haplotype/NN and/CC could/MD present/VB an/DT obstacle/NN to/TO gene/NN therapy/NN in/IN an/DT MHC-diverse/JJ human/JJ population/NN ./. 
UI/LS -/: 97180731/CD 
TI/LS -/: Characterization/NN of/IN the/DT human/JJ platelet/endothelial/JJ cell/NN adhesion/NN molecule-1/NN promoter/NN :/: identification/NN of/IN a/DT GATA-2/NN binding/NN element/NN required/VBN for/IN optimal/JJ transcriptional/JJ activity/NN ./. 
AB/LS -/: Platelet/endothelial/JJ cell/NN adhesion/NN molecule-1/NN (/( PECAM-1/NN )/) is/VBZ a/DT 130-kD/JJ member/NN of/IN the/DT Ig/NN gene/NN superfamily/NN that/WDT is/VBZ expressed/VBN on/IN platelets/NNS ,/, endothelial/JJ cells/NNS ,/, and/CC certain/JJ leukocyte/NN subsets/NNS ./. 
To/TO examine/VB the/DT factors/NNS controlling/VBG vascular-specific/JJ expression/NN of/IN PECAM-1/NN ,/, we/PRP cloned/VBD the/DT 5'-flanking/JJ region/NN of/IN the/DT PECAM-1/NN gene/NN and/CC analyzed/VBD its/PRP$ transcriptional/JJ activity/NN ./. 
5'-Rapid/JJ amplification/NN of/IN cDNA/NN ends/NNS (/( 5'-RACE/NNS )/) analysis/NN showed/VBD that/IN transcription/NN initiation/NN occurred/VBD at/IN several/JJ closely/RB spaced/JJ nearby/NN sites/NNS originating/VBG approximately/RB 204/CD bp/NN upstream/RB from/IN the/DT translation/NN start/NN site/NN ./. 
Analysis/NN of/IN the/DT sequence/NN immediately/RB upstream/JJ from/IN the/DT transcription/NN initiation/NN site/NN (/( TIS/NN )/) showed/VBD no/DT canonical/JJ TATA/NN or/CC CAAT/NN elements/NNS ,/, however/RB an/DT initiator/NN element/NN commonly/RB found/VBN in/IN TATA-less/JJ promoters/NNS encompassed/VBD the/DT TIS/NN ./. 
5'-serially/RB truncated/VBN PECAM-1/NN promoter/NN segments/NNS cloned/VBN in/IN front/NN of/IN a/DT luciferase/NN reporter/NN drove/VBD transcription/NN in/IN both/CC a/DT lineage-/NN and/CC orientation-specific/JJ manner/NN ./. 
Putative/JJ cis-acting/JJ control/NN elements/NNS present/JJ within/IN a/DT 300-bp/JJ core/NN promoter/NN included/VBD two/CD ets/NN sites/NNS ,/, an/DT Sp1/NN site/NN ,/, tandem/JJ E-box/NN domains/NNS ,/, two/CD GATA-associated/JJ sites/NNS (/( CACCC/NN )/) ,/, an/DT AP-2/NN binding/NN site/NN ,/, and/CC a/DT GATA/NN element/NN at/IN -24/CD ./. 
Mutational/JJ analysis/NN showed/VBD that/IN optimal/JJ transcriptional/JJ activity/NN required/VBD the/DT GATA/NN sequence/NN at/IN position/NN -24/CD ,/, and/CC gel-shift/JJ assays/NNS further/RB showed/VBD that/IN the/DT GATA-2/NN transcription/NN factor/NN ,/, but/CC not/RB GATA-1/NN ,/, bound/VBD to/TO this/DT region/NN of/IN the/DT PECAM-1/NN promoter/NN ./. 
Understanding/VBG the/DT cis-/JJ and/CC transacting/VBG factors/NNS that/WDT regulate/VBP the/DT tissue-specific/JJ expression/NN of/IN PECAM-1/NN should/MD increase/VB our/PRP$ understanding/NN of/IN the/DT mechanisms/NNS by/IN which/WDT vascular-specific/JJ gene/NN expression/NN is/VBZ achieved/VBN ./. 
UI/LS -/: 97205231/CD 
TI/LS -/: A/DT negative/JJ regulatory/JJ region/NN containing/VBG a/DT glucocorticosteroid/NN response/NN element/NN (/( nGRE/NN )/) in/IN the/DT human/JJ interleukin-1beta/NN gene/NN ./. 
AB/LS -/: Interleukin-1/NN beta/NN (/( IL-1beta/NN )/) is/VBZ one/CD of/IN the/DT most/RBS important/JJ inflammatory/JJ mediators/NNS in/IN human/JJ inflammatory/JJ and/CC immunological/JJ diseases/NNS ./. 
The/DT regulation/NN of/IN human/JJ IL-1beta/NN gene/NN expression/NN has/VBZ been/VBN studied/VBN for/IN several/JJ years/NNS ,/, and/CC a/DT few/JJ regulatory/JJ elements/NNS have/VBP been/VBN discovered/VBN in/IN the/DT promoter/NN region/NN ./. 
However/RB ,/, little/JJ is/VBZ known/VBN about/IN negative/JJ regulation/NN of/IN IL-1beta/NN expression/NN at/IN the/DT transcriptional/JJ level/NN ,/, which/WDT may/MD play/VB an/DT important/JJ role/NN in/IN anti-inflammatory/JJ and/CC immunosuppressive/JJ effects/NNS ./. 
We/PRP have/VBP identified/VBN a/DT negative/JJ regulatory/JJ element/NN located/JJ in/IN the/DT region/NN between/IN -685/CD and/CC -395/CD ./. 
Within/IN this/DT region/NN ,/, a/DT 19-bp/JJ nuclear/JJ factor/NN binding/NN site/NN (/( -570/CD to/TO -552/CD )/) was/VBD characterized/VBN by/IN DNase/NN I/NN footprinting/NN and/CC electromobility/NN shift/NN assay/NN ./. 
A/NN consensus/NN sequence/NN for/IN a/DT negative/JJ glucocorticoid/NN response/NN element/NN (/( nGRE/NN )/) and/CC a/DT transcription/NN activator/NN protein-2/NN binding/NN site/NN were/VBD noted/VBN within/IN this/DT footprint/NN ./. 
Functional/JJ studies/NNS showed/VBD a/DT 2.5-fold/JJ increase/NN in/IN promoter/NN activity/NN when/WRB this/DT 19-bp/JJ binding/VBG site/NN was/VBD deleted/VBN in/IN the/DT reporter/NN constructs/NNS IL-1beta/CAT/NN and/CC IL-1beta/SV40/NN promoter/CAT/NN ./. 
Dexamethasone/NN (/( 10(-8)/CD M/NN )/) repressed/VBD chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) production/NN by/IN 75/CD %/NN in/IN the/DT wild-type/JJ fragment/NN but/CC not/RB in/IN a/DT deletion/NN mutant/NN lacking/VBG the/DT 19-bp/JJ site/NN ./. 
A/DT protein/NN of/IN about/RB 150/CD kD/NN that/WDT bound/VBD to/TO this/DT negative/JJ regulatory/JJ sequence/NN was/VBD identified/VBN by/IN UV/NN cross-linking/NN ./. 
This/DT is/VBZ the/DT first/JJ description/NN of/IN a/DT negative/JJ regulatory/JJ region/NN responsive/JJ to/TO glucocorticoids/NNS in/IN a/DT cytokine/NN gene/NN ./. 
UI/LS -/: 97170874/CD 
TI/LS -/: Interaction/NN of/IN transcription/NN factors/NNS RFX1/NN and/CC MIBP1/NN with/IN the/DT gamma/NN motif/NN of/IN the/DT negative/JJ regulatory/JJ element/NN of/IN the/DT hepatitis/NN B/NN virus/NN core/NN promoter/NN ./. 
AB/LS -/: The/DT negative/JJ regulatory/JJ element/NN (/( NRE/NN )/) of/IN the/DT hepatitis/NN B/NN virus/NN (/( HBV/NN )/) core/NN promoter/NN contains/VBZ three/CD subregions/NNS which/WDT act/VBP synergistically/RB to/TO suppress/VB core/NN promoter/NN activity/NN ./. 
One/CD of/IN these/DT subregions/NNS ,/, NRE/NN gamma/NN ,/, is/VBZ active/JJ in/IN both/CC HeLa/NN cervical/JJ carcinoma/NN cells/NNS and/CC Huh7/NN hepatoma/NN cells/NNS and/CC was/VBD found/VBN to/TO be/VB bound/VBN by/IN a/DT protein/NN factor/NN present/JJ in/IN both/DT cell/NN types/NNS ./. 
Here/RB we/PRP show/VBP that/IN the/DT transcription/NN factor/NN RFX1/NN can/MD bind/VB to/TO NRE/NN gamma/NN and/CC transactivate/VB the/DT core/NN promoter/NN through/IN this/DT site/NN ./. 
Mutations/NNS which/WDT abrogated/VBD the/DT gene-suppressive/JJ activity/NN of/IN NRE/NN gamma/NN prevented/VBD RFX1/NN from/IN binding/NN to/TO NRE/NN gamma/NN ./. 
In/IN addition/NN ,/, RFX1/NN can/MD bind/VB simultaneously/RB ,/, most/RBS likely/JJ as/IN a/DT heterodimer/NN ,/, with/IN the/DT transcription/NN factor/NN MIBP1/NN to/TO NRE/NN gamma/NN ./. 
In/IN the/DT absence/NN of/IN a/DT cloned/VBN MIBP1/NN gene/NN for/IN further/JJ studies/NNS ,/, we/PRP hypothesize/VBP that/IN RFX1/NN acts/VBZ with/IN MIBP1/NN to/TO negatively/RB regulate/VB the/DT core/NN promoter/NN activity/NN through/IN the/DT NRE/NN gamma/NN site/NN ./. 
The/DT ability/NN of/IN RFX1/NN to/TO transactivate/VB the/DT core/NN promoter/NN raises/VBZ the/DT possibility/NN that/IN RFX1/NN may/MD play/VB a/DT dual/JJ role/NN in/IN regulating/VBG HBV/NN gene/NN expression/NN 
UI/LS -/: 97275148/CD 
TI/LS -/: Use/NN of/IN arsenic/JJ trioxide/NN (/( As2O3/NN )/) in/IN the/DT treatment/NN of/IN acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) :/: II/CD ./. 
Clinical/JJ efficacy/NN and/CC pharmacokinetics/NNS in/IN relapsed/JJ patients/NNS ./. 
AB/LS -/: The/DT therapeutic/JJ effect/NN of/IN arsenic/JJ trioxide/NN (/( As2O3/NN )/) in/IN the/DT treatment/NN of/IN acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) was/VBD evaluated/VBN among/IN 15/CD APL/NN patients/NNS at/IN relapse/NN after/IN all-trans/JJ retinoic/JJ acid/NN (/( ATRA/NN )/) induced/VBD and/CC chemotherapy/NN maintained/VBD complete/JJ remission/NN (/( CR/NN )/) ./. 
As2O3/NN was/VBD administered/VBN intravenously/RB at/IN the/DT dose/NN of/IN 10/CD mg/d/NN ./. 
Clinical/JJ CR/NN was/VBD achieved/VBN in/IN nine/CD of/IN 10/CD (/( 90/CD %/NN )/) patients/NNS treated/VBN with/IN As2O3/NN alone/RB and/CC in/IN the/DT remaining/VBG five/CD patients/NNS treated/VBN by/IN the/DT combination/NN of/IN As2O3/NN and/CC low-dose/JJ chemotherapeutic/JJ drugs/NNS or/CC ATRA/NN ./. 
During/IN the/DT treatment/NN with/IN As2O3/NN ,/, there/EX was/VBD no/DT bone/NN marrow/NN depression/NN and/CC only/RB limited/JJ side/JJ effects/NNS were/VBD encountered/VBN ./. 
Pharmacokinetic/JJ studies/NNS ,/, which/WDT were/VBD performed/VBN in/IN eight/CD patients/NNS ,/, showed/VBD that/IN after/IN a/DT peak/JJ level/NN of/IN 5.54/CD micromol/L/NN to/TO 7.30/CD micromol/L/NN ,/, plasma/NN arsenic/NN was/VBD rapidly/RB eliminated/VBN ,/, and/CC the/DT continuous/JJ administration/NN of/IN As2O3/NN did/VBD not/RB alter/VB its/PRP$ pharmacokinetic/JJ behaviors/NNS ./. 
In/IN addition/NN ,/, increased/VBN amounts/NNS of/IN arsenic/NN appeared/VBD in/IN the/DT urine/NN ,/, with/IN a/DT daily/JJ excretion/NN accounting/VBG for/IN approximately/RB 1/CD %/NN to/TO 8/CD %/NN of/IN the/DT total/JJ daily/RB dose/NN administered/VBN ./. 
Arsenic/JJ contents/NNS in/IN hair/NN and/CC nail/NN were/VBD increased/VBN ,/, and/CC the/DT peak/JJ content/NN of/IN arsenic/JJ could/MD reach/VB 2.5/CD to/TO 2.7/CD microg/g/NN tissue/NN at/IN CR/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, a/DT decline/NN of/IN the/DT arsenic/JJ content/NN in/IN hair/NN and/CC nail/NN was/VBD observed/VBN after/IN withdrawal/NN of/IN the/DT drug/NN ./. 
We/PRP conclude/VBP that/IN As2O3/NN treatment/NN is/VBZ an/DT effective/JJ and/CC relatively/RB safe/JJ drug/NN in/IN APL/NN patients/NNS refractory/JJ to/TO ATRA/NN and/CC conventional/JJ chemotherapy/NN ./. 
UI/LS -/: 97268616/CD 
TI/LS -/: Nucleolin/NN is/VBZ one/CD component/NN of/IN the/DT B/NN cell-specific/JJ transcription/NN factor/NN and/CC switch/NN region/NN binding/NN protein/NN ,/, LR1/NN ./. 
AB/LS -/: LR1/NN is/VBZ a/DT B/NN cell-specific/JJ ,/, sequence-specific/JJ DNA/NN binding/NN activity/NN that/WDT regulates/VBZ transcription/NN in/IN activated/VBN B/NN cells/NNS ./. 
LR1/NN also/RB binds/VBZ Ig/NN heavy/JJ chain/NN switch/NN region/NN sequences/NNS and/CC may/MD function/VB in/IN class/NN switch/NN recombination/NN ./. 
LR1/NN contains/VBZ two/CD polypeptides/NNS ,/, of/IN 106/CD kDa/NN and/CC 45/CD kDa/NN ,/, and/CC here/RB we/PRP report/VBP that/IN the/DT 106-kDa/JJ component/NN of/IN LR1/NN is/VBZ nucleolin/NN ./. 
This/DT identification/NN ,/, initially/RB made/VBN by/IN microsequence/NN analysis/NN ,/, was/VBD verified/VBN by/IN showing/VBG that/IN (/( i/LS )/) LR1-DNA/NN binding/NN activity/NN increased/VBD in/IN B/NN cells/NNS transfected/VBN with/IN a/DT nucleolin/NN cDNA/NN expression/NN construct/NN ;/: (/( ii/LS )/) LR1-DNA/NN binding/NN activity/NN was/VBD recognized/VBN by/IN antibodies/NNS raised/VBN against/IN recombinant/JJ human/JJ nucleolin/NN ;/: and/CC (/( iii/LS )/) in/IN B/NN cells/NNS transfected/VBN with/IN epitope-tagged/JJ nucleolin/NN expression/NN constructs/NNS ,/, the/DT LR1-DNA/JJ complex/NN was/VBD recognized/VBN by/IN the/DT anti-tag/JJ antibody/NN ./. 
Nucleolin/NN is/VBZ an/DT abundant/JJ nucleolar/JJ protein/NN which/WDT is/VBZ believed/VBN to/TO play/VB a/DT role/NN in/IN rDNA/NN transcription/NN or/CC organization/NN ,/, or/CC rRNA/NN processing/NN ./. 
Homology/NN between/IN nucleolin/NN and/CC histone/NN H1/NN suggests/VBZ that/IN nucleolin/NN may/MD alter/VB DNA/NN organization/NN in/IN response/NN to/TO cell/NN cycle/NN controls/NNS ,/, and/CC the/DT nucleolin/NN component/NN of/IN LR1/NN may/MD therefore/RB function/VB to/TO organize/VB switch/NN regions/NNS before/IN ,/, during/IN ,/, or/CC after/IN switch/NN recombination/NN ./. 
The/DT demonstration/NN that/IN nucleolin/NN is/VBZ a/DT component/NN of/IN a/DT B/NN cell-specific/JJ complex/NN that/WDT binds/VBZ switch/NN region/NN sequences/NNS suggests/VBZ that/IN the/DT G-rich/JJ switch/NN regions/NNS may/MD have/VB evolved/VBN from/IN rDNA/NN ./. 
UI/LS -/: 97276244/CD 
TI/LS -/: Glucocorticoid-resistance/NN in/IN peripheral-blood/JJ lymphocytes/NNS does/VBZ not/RB correlate/VB with/IN number/NN of/IN affinity/NN of/IN glucocorticoid-receptors/NNS in/IN chronic/JJ renal/JJ failure/NN patients/NNS ./. 
AB/LS -/: Glucocorticoid/NN (/( GC/NN )/) resistance/NN in/IN patients/NNS with/IN chronic/JJ renal/JJ failure/NN (/( CRF/NN )/) seriously/RB impairs/VBZ successive/JJ GC/NN therapy/NN after/IN renal/JJ transplantation/NN ./. 
We/PRP examined/VBD the/DT relationship/NN between/IN GC-receptor/NN (/( GC-R/NN )/) parameters/NNS in/IN peripheral-blood/JJ mononuclear/JJ cells/NNS (/( PBMC/NN )/) and/CC PBMC/NN resistance/NN to/TO GC/NN in/IN 21/CD CRF/NN patients/NNS and/CC 18/CD healthy/JJ subjects/NNS ./. 
Each/DT subject/NN group/NN was/VBD divided/VBN into/IN two/CD subgroups/NNS according/VBG to/TO PBMC/NN sensitivity/NN to/TO prednisolone/NN in/IN a/DT mitogen/NN assay/NN procedure/NN ;/: i.e./FW ,/, sensitive/JJ (/( IC50/NN </JJR 381/CD ng/mL/NN )/) and/CC resistant/JJ (/( IC50/NN >/JJR 381/CD ng/mL/NN )/) groups/NNS ./. 
In/IN healthy/JJ subjects/NNS ,/, the/DT mean/NN GC-R/NN Bmax/NN and/CC Kd/NN in/IN quiescent/JJ PBMC/NN of/IN the/DT GC-sensitive/JJ group/NN were/VBD 2.89/CD +/-/CC 1.23/CD fmol/10(6)/NN cells/NNS and/CC 4.00/CD +/-/CC 2.24/CD nM/NN ,/, respectively/RB ./. 
The/DT Bmax/NN in/IN these/DT subjects/NNS significantly/RB increased/VBD to/TO 6.61/CD +/-/CC 2.02/CD (/( 257.7/CD +/-/CC 107.8/CD %/NN )/) after/IN 24/CD h/NN stimulation/NN with/IN concanavalin/NN A/NN (/( p/NN </JJR 0.01/CD )/) ,/, while/IN the/DT Kd/NN change/NN was/VBD not/RB significant/JJ ./. 
The/DT GC-R/NN Bmax/NN and/CC Kd/NN in/IN quiescent/JJ PBMC/NN of/IN the/DT GC-resistant/JJ group/NN were/VBD 5.33/CD +/-/CC 1.37/CD fmol/10(6)/NN cells/NNS and/CC 3.20/CD +/-/CC 1.39/CD nM/NN ,/, respectively/RB ./. 
Both/DT of/IN these/DT parameters/NNS ,/, however/RB ,/, did/VBD not/RB change/VB significantly/RB after/IN mitogen/NN stimulation/NN ./. 
There/EX was/VBD a/DT significant/JJ negative/JJ correlation/NN between/IN IC50S/NN of/IN prednisolone/NN and/CC increase-ratios/NN (/( post/pre/JJ ratio/NN )/) of/IN Bmax/NN after/IN mitogen/NN stimulation/NN (/( p/NN </JJR 0.05/CD )/) ./. 
In/IN CRF/NN patients/NNS ,/, Bmax/NN and/CC Kd/NN in/IN quiescent/JJ PBMC/NN of/IN the/DT GC-sensitive/JJ group/NN were/VBD 6.04/CD +/-/CC 2.35/CD fmol/10(6)/NN cells/NNS and/CC 3.49/CD +/-/CC 1.72/CD nM/NN ,/, respectively/RB ,/, while/IN those/DT in/IN PBMC/NN of/IN the/DT GC-resistant/JJ group/NN were/VBD 5.13/CD +/-/CC 2.31/CD fmol/10(6)/NN cells/NNS and/CC 4.04/CD +/-/CC 1.62/CD nM/NN ,/, respectively/RB ./. 
The/DT Bmax/NN and/CC Kd/NN were/VBD not/RB significantly/RB changed/VBN after/IN mitogen/NN stimulation/NN in/IN both/DT subgroups/NNS of/IN CRF/NN ./. 
Moreover/RB ,/, in/IN contrast/NN to/TO healthy/JJ subjects/NNS ,/, there/EX was/VBD no/DT correlation/NN between/IN IC50/NN and/CC GC-R/NN parameters/NNS in/IN CRF/NN ./. 
We/PRP concluded/VBD that/IN ,/, in/IN healthy/JJ subjects/NNS ,/, decreased/VBN PBMC/NN capacity/NN to/TO amplify/VB GC-R/NN numbers/NNS in/IN response/NN to/TO mitogen/NN is/VBZ correlated/VBN with/IN GC/NN resistance/NN ,/, whereas/IN in/IN CRF/NN patients/NNS the/DT resistant/JJ mechanism/NN is/VBZ not/RB correlated/VBN with/IN GC-R/NN parameters/NNS ./. 
An/DT unknown/JJ event/NN might/MD be/VB involved/VBN in/IN GC-resistance/NN of/IN CRF/NN ./. 
UI/LS -/: 97213977/CD 
TI/LS -/: Alteration/NN of/IN a/DT single/JJ serine/NN in/IN the/DT basic/JJ domain/NN of/IN the/DT Epstein-Barr/JJ virus/NN ZEBRA/NN protein/NN separates/VBZ its/PRP$ functions/NNS of/IN transcriptional/JJ activation/NN and/CC disruption/NN of/IN latency/NN ./. 
AB/LS -/: The/DT ZEBRA/NN protein/NN from/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) activates/VBZ a/DT switch/NN from/IN the/DT latent/JJ to/TO the/DT lytic/JJ expression/NN program/NN of/IN the/DT virus/NN ./. 
ZEBRA/NN ,/, a/DT member/NN of/IN the/DT bZIP/NN family/NN of/IN DNA-binding/JJ proteins/NNS ,/, is/VBZ a/DT transcriptional/JJ activator/NN capable/JJ of/IN inducing/VBG expression/NN from/IN viral/JJ lytic/JJ cycle/NN promoters/NNS ./. 
It/PRP had/VBD previously/RB been/VBN thought/VBN that/IN ZEBRA/NN 's/POS capacity/NN to/TO disrupt/VB EBV/NN latency/NN resided/VBD primarily/RB in/IN its/PRP$ ability/NN to/TO activate/VB transcription/NN of/IN genes/NNS that/WDT encode/VBP products/NNS required/VBN for/IN lytic/JJ replication/NN ./. 
We/PRP generated/VBD a/DT point/NN mutant/NN of/IN ZEBRA/NN ,/, Z/NN (/( S186A/NN )/) ,/, that/WDT was/VBD not/RB impaired/JJ in/IN its/PRP$ ability/NN to/TO activate/VB transcription/NN ;/: however/RB ,/, this/DT mutation/NN abolished/VBD its/PRP$ ability/NN to/TO initiate/VB the/DT viral/JJ lytic/JJ cascade/NN ./. 
The/DT mutant/NN ,/, containing/VBG a/DT serine-to-alanine/JJ substitution/NN in/IN the/DT DNA-binding/JJ domain/NN of/IN the/DT protein/NN ,/, bound/VBD to/TO several/JJ known/JJ ZEBRA-binding/JJ sites/NNS and/CC activated/VBD transcription/NN from/IN reporters/NNS bearing/VBG known/JJ ZEBRA-responsive/JJ promoters/NNS but/CC did/VBD not/RB disrupt/VB latency/NN in/IN EBV-infected/JJ cell/NN lines/NNS ./. 
Therefore/RB ,/, initiation/NN of/IN the/DT EBV/NN lytic/JJ cycle/NN by/IN the/DT ZEBRA/NN protein/NN requires/VBZ a/DT function/NN in/IN addition/NN to/TO transcriptional/JJ activation/NN ;/: a/DT change/NN of/IN serine/NN 186/CD to/TO alanine/NN in/IN the/DT DNA-binding/JJ domain/NN of/IN ZEBRA/NN abolished/VBD this/DT additional/JJ function/NN and/CC uncovered/VBD a/DT new/JJ role/NN for/IN the/DT ZEBRA/NN protein/NN in/IN disruption/NN of/IN EBV/NN latency/NN ./. 
The/DT additional/JJ function/NN that/WDT is/VBZ required/VBN for/IN initiation/NN of/IN the/DT lytic/JJ viral/JJ life/NN cycle/NN is/VBZ likely/JJ to/TO require/VB phosphorylation/NN of/IN serine/NN 186/CD of/IN the/DT ZEBRA/NN protein/NN ,/, which/WDT may/MD influence/VB either/CC DNA/NN recognition/NN or/CC transcriptional/JJ activation/NN of/IN lytic/JJ viral/JJ promoters/NNS in/IN a/DT chromatinized/VBN viral/JJ episome/NN ./. 
UI/LS -/: 97197910/CD 
TI/LS -/: Immune/JJ hyperactivation/NN of/IN HIV-1-infected/JJ T/NN cells/NNS mediated/VBN by/IN Tat/NN and/CC the/DT CD28/NN pathway/NN ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus-type/NN 1/CD (/( HIV-1/NN )/) infection/NN is/VBZ characterized/VBN by/IN a/DT chronic/JJ state/NN of/IN immune/JJ hyperactivation/NN in/IN patients/NNS ./. 
Infection/NN of/IN human/JJ peripheral/JJ blood/NN lymphocytes/NNS with/IN HIV-1/NN in/FW vitro/FW resulted/VBD in/IN increased/VBN interleukin-2/NN (/( IL-2/NN )/) secretion/NN in/IN response/NN to/TO T/NN cell/NN activation/NN via/IN the/DT CD3/NN and/CC CD28/NN receptors/NNS ./. 
Expression/NN of/IN the/DT HIV-1/NN transactivator/NN Tat/NN recapitulated/VBD this/DT phenotype/NN and/CC was/VBD associated/VBN with/IN increased/VBN IL-2/NN secretion/NN in/IN response/NN to/TO costimulation/NN with/IN CD3/NN plus/CC CD28/NN ./. 
IL-2/NN superinduction/NN by/IN Tat/NN occurred/VBD at/IN the/DT transcriptional/JJ level/NN ,/, was/VBD mediated/VBN by/IN the/DT CD28-responsive/JJ element/NN in/IN the/DT IL-2/NN promoter/NN ,/, and/CC was/VBD exclusively/RB dependent/JJ on/IN the/DT 29/CD amino/NN acids/NNS encoded/VBN by/IN the/DT second/JJ exon/NN of/IN Tat/NN ./. 
UI/LS -/: 97242104/CD 
TI/LS -/: Response/NN to/TO intranasal/JJ fluticasone/NN propionate/NN in/IN perennial/JJ allergic/JJ rhinitis/NN not/RB associated/VBN with/IN glucocorticoid/NN receptor/NN characteristics/NNS ./. 
AB/LS -/: BACKGROUND/NN :/: The/DT reduction/NN of/IN symptoms/NNS due/JJ to/TO treatment/NN with/IN corticosteroids/NNS varies/VBZ among/IN patients/NNS with/IN perennial/JJ rhinitis/NN ./. 
Most/JJS patients/NNS will/MD respond/VB but/CC a/DT few/JJ patients/NNS respond/VBP less/RBR to/TO these/DT drugs/NNS ./. 
OBJECTIVE/NN :/: To/TO investigate/VB the/DT association/NN in/IN reduction/NN of/IN symptoms/NNS due/JJ to/TO glucocorticoids/NNS and/CC glucocorticoid/NN receptor/NN characteristics/NNS in/IN patients/NNS with/IN perennial/JJ allergic/JJ rhinitis/NN ,/, in/FW vitro/FW glucocorticoid/NN receptor/NN binding/NN studies/NNS were/VBD performed/VBN with/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS using/VBG dexamethasone/NN and/CC in/FW vitro/FW production/NN of/IN mediators/NNS were/VBD measured/VBN ./. 
METHODS/NNS :/: During/IN a/DT double-blind/JJ placebo-controlled/JJ crossover/JJ study/NN ,/, 200/CD micrograms/NNS fluticasone/NN propionate/JJ aqueous/JJ nasal/JJ spray/NN (/( in/IN the/DT active/JJ treatment/NN period/NN )/) and/CC placebo/NN (/( in/IN the/DT placebo/NN treatment/NN period/NN )/) were/VBD administered/VBN twice/RB daily/RB for/IN 2/CD weeks/NNS to/TO 22/CD patients/NNS allergic/JJ to/TO house/NN dust/NN mite/NN ./. 
At/IN the/DT end/NN of/IN both/DT treatment/NN periods/NNS symptoms/NNS were/VBD scored/VBN after/IN allergen/NN provocation/NN (/( 100/CD ,/, 1000/CD ,/, 10000/CD BU/mL/NN )/) and/CC during/IN the/DT 9.5/CD hours/NNS after/IN this/DT challenge/NN ./. 
Receptor/NN binding/NN studies/NNS with/IN dexamethasone/NN were/VBD performed/VBN with/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
Leukotriene/NN B4/NN produced/VBN by/IN monocytes/NNS in/FW vitro/FW and/CC soluble/JJ interleukin-2/NN receptor/NN released/VBN by/IN lymphocytes/NNS in/FW vitro/FW and/CC cortisol/NN levels/NNS in/IN plasma/NN were/VBD determined/VBN ./. 
RESULTS/NNS :/: No/DT significant/JJ partial/JJ correlations/NNS of/IN the/DT number/NN of/IN the/DT peripheral/JJ blood/NN mononuclear/JJ cell/NN glucocorticoid/NN receptors/NNS (/( 6821/CD +/-/CC 5669/CD binding/VBG sites/NNS per/IN cell/NN )/) and/CC the/DT affinity/NN (/( Kd/NN :/: 16.5/CD +/-/CC 13.51/CD nmol/L/NN )/) for/IN the/DT glucocorticoid/NN receptors/NNS with/IN the/DT symptom/NN score/NN (/( placebo/NN :/: 4.3/CD +/-/CC 2.45/CD pts/NNS ;/: fluticasone/NN :/: 2.4/CD +/-/CC 1.55/CD pts/NNS )/) after/IN active/JJ treatment/NN were/VBD found/VBN ./. 
Also/RB no/DT significant/JJ partial/JJ correlations/NNS of/IN the/DT levels/NNS of/IN leukotriene/NN B4/NN (/( 45.6/CD +/-/CC 105.3/CD ng/10(6)/CD cells/NNS )/) produced/VBN by/IN monocytes/NNS in/FW vitro/FW ,/, soluble/JJ interleukin-2/NN receptor/NN (/( 734/CD +/-/CC 237/CD ng/10(6)/CD cells/NNS )/) released/VBN by/IN lymphocytes/NNS in/FW vitro/FW and/CC cortisol/NN levels/NNS (/( 571/CD +/-/CC 236/CD ng/mL/NN )/) in/IN plasma/NN with/IN the/DT symptom/NN score/NN after/IN active/JJ treatment/NN were/VBD found/VBN ./. 
CONCLUSIONS/NNS :/: The/DT reduction/NN of/IN symptoms/NNS due/JJ to/TO topical/JJ fluticasone/NN propionate/NN in/IN patients/NNS with/IN rhinitis/NN and/CC allergy/NN to/TO house/NN dust/NN mite/NN is/VBZ not/RB correlated/VBN with/IN the/DT characteristics/NNS of/IN the/DT glucocorticoid/NN receptor/NN ./. 
UI/LS -/: 97184542/CD 
TI/LS -/: Constitutive/JJ expression/NN of/IN p50/NN homodimer/NN in/IN freshly/RB isolated/VBN human/JJ monocytes/NNS decreases/VBZ with/IN in/FW vitro/FW and/CC in/FW vivo/FW differentiation/NN :/: a/DT possible/JJ mechanism/NN influencing/VBG human/JJ immunodeficiency/NN virus/NN replication/NN in/IN monocytes/NNS and/CC mature/JJ macrophages/NNS ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) replicates/VBZ more/RBR efficiently/RB in/FW vitro/FW in/IN differentiated/VBN macrophages/NNS than/IN in/IN freshly/RB isolated/VBN monocytes/NNS ./. 
We/PRP investigated/VBD whether/IN this/DT may/MD be/VB partly/RB explained/VBN by/IN changes/NNS in/IN expression/NN of/IN NF-kappaB/NN with/IN monocyte/NN differentiation/NN ./. 
We/PRP demonstrated/VBD that/IN constitutive/JJ expression/NN of/IN NF-kappaB/NN in/IN primary/JJ human/JJ monocytes/NNS changed/VBD significantly/RB with/IN differentiation/NN in/FW vitro/FW to/TO monocyte-derived/JJ macrophages/NNS (/( MDMs/NNS )/) and/CC differentiation/NN in/FW vivo/FW to/TO alveolar/JJ macrophages/NNS (/( AMs/NNS )/) ./. 
Freshly/RB isolated/VBN monocytes/NNS constitutively/RB expressed/VBD high/JJ levels/NNS of/IN transcriptionally/RB inactive/JJ p50/NN homodimer/NN which/WDT decreased/VBD with/IN time/NN in/IN culture/NN in/IN favor/NN of/IN the/DT transcriptionally/RB active/JJ p50/p65/NN and/CC p50/RelB/NN heterodimers/NNS ./. 
As/IN in/IN MDMs/NNS ,/, AMs/NNS constitutively/RB expressed/VBD p50/p65/NN and/CC p50/RelB/NN although/IN at/IN lower/JJR levels/NNS ./. 
HIV/NN infection/NN of/IN fresh/JJ monocytes/NNS failed/VBD to/TO induce/VB p50/p65/NN as/IN seen/VBN in/IN MDMs/NNS ./. 
The/DT replacement/NN of/IN p50/NN homodimers/NNS with/IN transcriptionally/RB active/JJ heterodimers/NNS following/VBG time/NN in/IN culture/NN may/MD partially/RB explain/VB the/DT progressive/JJ increase/NN in/IN susceptibility/NN of/IN monocytes/NNS to/TO HIV/NN infection/NN during/IN in/FW vitro/FW culture/NN ./. 
The/DT change/NN in/IN NF-kappaB/NN components/NNS with/IN monocyte/NN differentiation/NN in/FW vivo/FW may/MD also/RB explain/VB the/DT different/JJ transcriptional/JJ activities/NNS of/IN these/DT cell/NN populations/NNS in/IN HIV-infected/JJ individuals/NNS ./. 
UI/LS -/: 97186415/CD 
TI/LS -/: NF-kappa/NN B-independent/JJ suppression/NN of/IN HIV/NN expression/NN by/IN ascorbic/JJ acid/NN ./. 
AB/LS -/: Ascorbic/JJ acid/NN (/( ascorbate/NN or/CC vitamin/NN C/NN )/) has/VBZ been/VBN shown/VBN to/TO suppress/VB the/DT induction/NN of/IN HIV/NN in/IN latently/RB infected/JJ T/NN lymphocytic/JJ cells/NNS following/VBG stimulation/NN with/IN a/DT tumor/NN promoter/NN (/( PMA/NN )/) and/CC inflammatory/JJ cytokine/NN (/( TNF-alpha/NN )/) ./. 
To/TO assess/VB whether/IN this/DT inhibition/NN was/VBD mediated/VBN via/IN modulation/NN of/IN the/DT cellular/JJ transcription/NN factor/NN ,/, NF-kappa/NN B/NN ,/, we/PRP carried/VBD out/RP gel/NN shift/NN analysis/NN on/IN nuclear/JJ extracts/NNS prepared/VBN under/IN different/JJ conditions/NNS of/IN cell/NN stimulation/NN in/IN the/DT presence/NN or/CC absence/NN of/IN ascorbate/NN ,/, N-acetylcysteine/NN (/( NAC/NN )/) ,/, or/CC zidovudine/NN (/( AZT/NN )/) ./. 
Pretreatment/NN of/IN ACH-2/NN T/NN cells/NNS by/IN NAC/NN followed/VBN by/IN stimulation/NN with/IN PMA/NN ,/, TNF-alpha/NN ,/, or/CC hydrogen/NN peroxide/NN (/( H2O2/NN )/) resulted/VBD in/IN strong/JJ suppression/NN of/IN NF-kappa/NN B/NN activation/NN ./. 
In/IN contrast/NN ,/, neither/CC ascorbate/NN nor/CC AZT/NN affected/VBD NF-kappa/NN B/NN activity/NN under/IN all/DT three/CD induction/NN conditions/NNS in/IN the/DT ACH-2/NN cell/NN line/NN ./. 
Ascorbate/NN and/CC AZT/NN also/RB had/VBD no/DT effect/NN on/IN NF-kappa/NN B/NN activation/NN following/VBG TNF-alpha-/NN or/CC PMA-induced/JJ stimulation/NN of/IN U1/NN promonocytic/JJ cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN the/DT molecular/JJ mechanism/NN of/IN HIV/NN inhibition/NN by/IN ascorbate/NN is/VBZ not/RB mediated/VBN via/IN NF-kappa/NN B/NN inhibition/NN ,/, unlike/IN that/DT seen/VBN with/IN other/JJ antioxidants/NNS ./. 
UI/LS -/: 97199263/CD 
TI/LS -/: A/DT T/NN cell-specific/JJ enhancer/NN in/IN the/DT interleukin-3/NN locus/NN is/VBZ activated/VBN cooperatively/RB by/IN Oct/NN and/CC NFAT/NN elements/NNS within/IN a/DT DNase/NN I-hypersensitive/JJ site/NN ./. 
AB/LS -/: Interleukin-3/NN (/( IL-3/NN )/) is/VBZ a/DT cytokine/NN that/WDT is/VBZ expressed/VBN primarily/RB in/IN activated/VBN T/NN cells/NNS ./. 
Here/RB we/PRP identified/VBD an/DT inducible/JJ T/NN cell-specific/JJ enhancer/NN 14/CD kb/NN upstream/RB of/IN the/DT IL-3/NN gene/NN that/WDT responded/VBD to/TO activation/NN of/IN T/NN cell/NN receptor/NN signaling/NN pathways/NNS ./. 
The/DT IL-3/NN enhancer/NN spanned/VBD an/DT inducible/JJ cyclosporin/NN A-sensitive/JJ DNase/NN I-hypersensitive/JJ site/NN found/VBN only/RB in/IN T/NN cells/NNS ./. 
Four/CD NFAT-like/JJ elements/NNS exist/VBP within/IN the/DT enhancer/NN ./. 
The/DT two/CD most/RBS active/JJ NFAT-like/JJ elements/NNS were/VBD located/JJ at/IN the/DT center/NN of/IN the/DT DNase/NN I-hypersensitive/JJ site/NN ./. 
One/CD of/IN these/DT NFAT-like/JJ elements/NNS encompassed/VBD overlapping/VBG Oct-/NN and/CC NFATp/c-binding/JJ sites/NNS ,/, which/WDT functioned/VBD in/IN a/DT highly/RB synergistic/JJ manner/NN ./. 
We/PRP suggest/VBP that/IN the/DT T/NN cell-/NN specific/JJ expression/NN of/IN the/DT IL-3/NN gene/NN is/VBZ partly/RB controlled/VBN through/IN the/DT enhancer/NN by/IN cooperation/NN between/IN Oct/NN and/CC NFAT/NN family/NN proteins/NNS ./. 
UI/LS -/: 97170849/CD 
TI/LS -/: Adenovirus/NN E1B/NN 19K/NN protein/NN is/VBZ required/VBN for/IN efficient/JJ DNA/NN replication/NN in/IN U937/NN cells/NNS ./. 
AB/LS -/: The/DT adenovirus/NN E1B/NN 19K/NN gene/NN plays/VBZ an/DT essential/JJ role/NN in/IN transformation/NN of/IN primary/JJ rodent/JJ cells/NNS in/IN cooperation/NN with/IN E1A/NN and/CC in/IN the/DT inhibition/NN of/IN apoptosis/NN during/IN lytic/JJ infection/NN ./. 
It/PRP has/VBZ been/VBN shown/VBN that/IN this/DT E1B/NN 19K/NN protein/NN is/VBZ not/RB necessary/JJ for/IN viral/JJ DNA/NN replication/NN in/IN human/JJ cell/NN lines/NNS ,/, such/JJ as/IN HeLa/NN and/CC KB/NN ./. 
We/PRP reported/VBD here/RB that/IN the/DT E1B/NN 19K/NN mutant/JJ viruses/NNS were/VBD unable/JJ to/TO replicate/VB efficiently/RB in/IN a/DT monocyte/NN cell/NN line/NN ,/, U937/NN ./. 
Viral/JJ DNA/NN synthesis/NN and/CC late/JJ gene/NN expression/NN were/VBD found/VBN to/TO be/VB defective/JJ in/IN U937/NN cells/NNS infected/VBN with/IN E1B/NN 19K/NN mutants/NNS compared/VBN with/IN wild-type/JJ virus/NN ./. 
Early/RB viral/JJ RNA/NN splicing/NN patterns/NNS also/RB differ/VBP between/IN wild-type/JJ and/CC dl337-infected/JJ cells/NNS ./. 
Furthermore/RB ,/, the/DT defect/NN in/IN viral/JJ replication/NN could/MD be/VB complemented/VBN by/IN dl312/NN virus/NN defective/JJ in/IN E1A/NN expression/NN 4/CD days/NNS after/IN infection/NN with/IN E1B/NN mutants/NNS ,/, suggesting/VBG persistence/NN of/IN the/DT E1B/NN mutant/JJ genome/NN in/IN the/DT infected/JJ cells/NNS despite/IN defective/JJ onset/NN of/IN the/DT late/JJ phase/NN of/IN replication/NN ./. 
These/DT results/NNS imply/VBP that/IN E1B/NN 19K/NN is/VBZ required/VBN for/IN efficient/JJ viral/JJ DNA/NN replication/NN in/IN U937/NN cells/NNS ./. 
Inefficient/JJ DNA/NN replication/NN is/VBZ also/RB found/VBN in/IN another/DT monocyte/NN cell/NN line/NN ,/, THP-1/NN 
UI/LS -/: 97272160/CD 
TI/LS -/: Activation/NN of/IN Ras/NN and/CC mitogen-activated/JJ protein/NN kinase/NN pathway/NN by/IN terminal/JJ complement/NN complexes/NNS is/VBZ G/NN protein/NN dependent/JJ ./. 
AB/LS -/: Assembly/NN of/IN terminal/JJ complement/NN complexes/NNS (/( TCC/NN )/) C5b-7/NN ,/, C5b-8/NN ,/, and/CC C5b-9/NN on/IN target/NN cells/NNS during/IN acute/JJ and/CC chronic/JJ inflammation/NN induces/VBZ hydrolysis/NN of/IN plasma/NN membrane/NN phospholipids/NNS and/CC heterotrimeric/JJ G/NN protein/NN activation/NN ./. 
TCC/NN also/RB stimulate/VBP a/DT variety/NN of/IN cellular/JJ activities/NNS ,/, which/WDT include/VBP cytokine/NN synthesis/NN ,/, proto-oncogene/JJ activation/NN ,/, and/CC mitotic/JJ signaling/NN ./. 
Now/RB we/PRP report/VBP that/IN sublytic/JJ TCC/NN induced/VBD Ras/NN ,/, Raf-1/NN ,/, and/CC extracellular/JJ signal-regulated/JJ kinase/NN (/( ERK/NN )/) 1/CD activation/NN in/IN JY25/NN B/NN cell/NN line/NN ./. 
When/WRB cells/NNS were/VBD exposed/VBN to/TO C5b-9/NN ,/, GTP-bound/JJ Ras/NN in/IN anti-C5b-9/JJ immunoprecipitates/NNS was/VBD increased/VBN 3.2-fold/RB at/IN 2/CD min/NN ,/, while/IN GTP-bound/JJ Ras/NN in/IN anti-Ras/JJ immunoprecipitates/NNS was/VBD increased/VBN 2-fold/RB at/IN 10/CD min/NN ./. 
Both/CC C5b-9/NN and/CC C5b-7/NN ,/, but/CC not/RB C5b6/NN ,/, increased/VBD Raf-1/NN kinase/NN activity/NN maximum/NN 3.3-fold/RB at/IN 2/CD min/NN and/CC 2.8-fold/RB at/IN 5/CD min/NN ,/, respectively/RB ./. 
ERK1/NN activity/NN was/VBD 2-fold/RB increased/VBN by/IN C5b-9/NN at/IN 2/CD min/NN and/CC by/IN C5b-7/NN at/IN 10/CD min/NN ,/, over/IN the/DT C5b6/NN level/NN ./. 
The/DT role/NN of/IN mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) pathway/NN on/IN TCC-inducible/JJ mitotic/JJ signaling/NN was/VBD evaluated/VBN by/IN assessing/VBG DNA/NN synthesis/NN and/CC activator/NN protein/NN 1/CD (/( AP-1/NN )/) DNA-binding/NN activity/NN ./. 
The/DT MAPK/ERK-specific/JJ inhibitor/NN PD/NN 098,059/CD abolished/VBD the/DT C5b-9-induced/JJ DNA/NN synthesis/NN ./. 
Involvement/NN of/IN G/NN protein/NN in/IN the/DT activation/NN of/IN MAPK/NN pathway/NN by/IN TCC/NN was/VBD indicated/VBN by/IN inhibition/NN of/IN Raf-1/NN and/CC ERK1/NN kinase/NN activity/NN ,/, as/RB well/RB as/IN the/DT DNA/NN synthesis/NN by/IN pretreatment/NN of/IN cells/NNS with/IN pertussis/NN toxin/NN ./. 
Overexpression/NN of/IN beta-adrenergic/JJ receptor/NN kinase/NN 1/CD carboxyl-terminal/JJ peptide/NN in/IN JY25/NN cells/NNS also/RB inhibited/VBD Raf-1/NN and/CC ERK1/NN activity/NN ,/, indicating/VBG a/DT direct/JJ involvement/NN of/IN G/NN betagamma/NN subunits/NNS in/IN the/DT signal/NN transduction/NN generated/VBN through/IN activation/NN of/IN MAPK/NN pathway/NN by/IN TCC/NN assembly/NN in/IN the/DT plasma/NN membrane/NN ./. 
UI/LS -/: 97288306/CD 
TI/LS -/: Spontaneous/JJ occurrence/NN of/IN early/JJ region/NN 1A/NN reiteration/NN mutants/NNS of/IN type/NN 5/CD adenovirus/NN in/IN persistently/RB infected/JJ human/JJ T-lymphocytes/NNS ./. 
AB/LS -/: Mutants/NNS of/IN type/NN 5/CD adenovirus/NN (/( Ad5/NN )/) with/IN reiterated/VBN DNA/NN sequences/NNS in/IN the/DT E1a/NN region/NN appeared/VBD in/IN a/DT human/JJ T-lymphocyte/NN cell/NN line/NN ,/, Molt-4/NN ,/, persistently/RB infected/VBN with/IN H5sub304/NN ,/, a/DT deletion/substitution/NN mutant/NN that/WDT has/VBZ a/DT wild-type/JJ phenotype/NN in/IN viral/JJ replication/NN ./. 
Endonuclease/NN analyses/NNS and/CC DNA/NN sequencing/NN revealed/VBD DNA/NN reiteration/NN in/IN each/DT mutant/NN ./. 
In/IN the/DT four/CD representative/JJ mutants/NNS investigated/VBN ,/, the/DT DNA/NN reiterations/NNS all/DT started/VBD within/IN a/DT six-base-pair/JJ consensus/NN sequence/NN ,/, G/NN (/( or/CC C/NN )/) CTGTG/NN ,/, located/JJ in/IN the/DT second/JJ exon/NN of/IN the/DT E1a/NN region/NN (/( at/IN nt/NN 1333/CD ,/, 1367/CD ,/, or/CC 1419/CD )/) ./. 
There/EX was/VBD not/RB any/DT DNA/NN homology/NN between/IN the/DT breakpoints/NNS in/IN the/DT second/JJ exon/NN and/CC the/DT inserting/JJ sequences/NNS (/( starting/VBG at/IN nt/NN 532/CD ,/, 710/CD ,/, or/CC 792/CD )/) ./. 
Northern/NN analyses/NNS suggested/VBD that/IN the/DT reiterated/VBN splicing/NN sites/NNS of/IN the/DT representative/JJ mutants/NNS were/VBD all/DT used/VBN in/IN RNA/NN splicing/NN ,/, and/CC the/DT closest/JJS donor/NN and/CC recipient/NN joints/NNS were/VBD used/VBN most/RBS frequently/RB ./. 
These/DT observations/NNS imply/VBP that/IN during/IN persistent/JJ infection/NN Ad5/NN underwent/VBD spontaneous/JJ mutations/NNS by/IN sequence-specific/JJ breakage/NN and/CC nonhomologous/JJ end-end/JJ joining/NN recombination/NN events/NNS ./. 
These/DT E1a/NN reiteration/NN mutants/NNS could/MD be/VB propagated/VBN in/IN HeLa/NN ,/, A549/NN ,/, and/CC KB/NN cells/NNS ;/: they/PRP were/VBD genetically/RB stable/JJ ;/: and/CC they/PRP killed/VBD CREF/NN cells/NNS at/IN a/DT strikingly/RB high/JJ frequency/NN ./. 
Preliminary/JJ observations/NNS tend/VBP to/TO correlate/VB this/DT CREF/NN cell/NN killing/NN with/IN the/DT accumulation/NN of/IN the/DT early/JJ viral/JJ proteins/NNS and/or/CC viral/JJ DNA/NN in/IN the/DT infected/JJ cells/NNS ./. 
This/DT degree/NN of/IN cell/NN damage/NN was/VBD not/RB observed/VBN in/IN Ad5wt/NN or/CC H5sub304/NN infection/NN of/IN CREF/NN cells/NNS ./. 
The/DT observed/VBN E1a/NN reiterations/NNS provide/VBP a/DT model/NN to/TO gain/VB insight/NN into/IN understanding/VBG the/DT evolutionary/JJ events/NNS of/IN some/DT ,/, if/IN not/RB all/DT ,/, adenovirus/NN types/NNS during/IN many/JJ years/NNS of/IN symbiotic/JJ ,/, persistent/JJ relationship/NN in/IN human/JJ tonsils/NNS and/CC adenoids/NNS and/CC possibly/RB other/JJ lymphoid/JJ organs/NNS ./. 
UI/LS -/: 97276226/CD 
TI/LS -/: Preferential/JJ presentation/NN of/IN herpes/NN simplex/NN virus/NN T-cell/NN antigen/NN by/IN HLA/NN DQA1*0501/DQB1*0201/NN in/IN comparison/NN to/TO HLA/NN DQA1*0201/DQB1*0201/NN ./. 
AB/LS -/: The/DT HLA/NN DQA1/NN locus/NN is/VBZ polymorphic/JJ ./. 
Haplotypes/NNS containing/VBG HLA/NN DQA1*0501/NN ,/, but/CC not/RB HLA/NN DQA1*0201/NN ,/, together/RB with/IN HLA/NN DQB1*0201/NN are/VBP associated/VBN with/IN Grave/NN 's/POS disease/NN and/CC celiac/JJ sprue/NN ./. 
In/IN this/DT report/NN ,/, we/PRP demonstrate/VBP a/DT functional/JJ correlate/NN of/IN DQA1/NN polymorphism/NN ./. 
T/NN cells/NNS infiltrating/VBG a/DT herpes/NN simplex/NN virus/NN (/( HSV/NN )/) lesion/NN from/IN a/DT HLA/NN DQ/NN 2,7/CD individual/NN yielded/VBD a/DT virus-specific/JJ CD4+/JJ clone/NN restricted/VBN by/IN DQ2/NN ./. 
Presentation/NN of/IN viral/JJ peptide/NN and/CC protein/NN segregated/VBD with/IN DQA1/NN allele/NN ,/, because/IN cell/NN lines/NNS bearing/VBG DQA1*0501/DQB1*0201/NN heterodimers/NNS presented/VBD antigen/NN in/IN proliferation/NN and/CC cytotoxicity/NN assays/NNS much/RB more/RBR efficiently/RB than/IN cell/NN lines/NNS bearing/VBG DQA1*0201/DQB1*0201/NN ./. 
Binding/NN of/IN viral/JJ peptide/NN to/TO cell/NN lines/NNS bearing/VBG DQA1*0201/NN ,/, in/IN comparison/NN to/TO DQA1*0501/NN ,/, was/VBD only/RB moderately/RB reduced/VBN and/CC may/MD not/RB explain/VB this/DT effect/NN ./. 
Truncation/NN and/CC substitution/NN analyses/NNS of/IN peptide/NN binding/NN and/CC T-cell/NN activation/NN were/VBD performed/VBN to/TO determine/VB which/WDT viral/JJ peptide/NN residues/NNS contacting/VBG TCR/NN might/MD therefore/RB be/VB presented/VBN in/IN an/DT altered/JJ conformation/NN by/IN DQA1*0201/DQB1*0201/NN ./. 
Residues/NNS 432/CD ,/, 435/CD ,/, 437/CD ,/, 438/CD ,/, and/CC 440/CD (/( position/NN P1/NN ,/, P4/NN ,/, P6/NN ,/, P7/NN ,/, and/CC P9/NN )/) contributed/VBD to/TO DQ2/NN binding/NN ,/, whereas/IN residues/NNS 431/CD ,/, 433/CD ,/, 434/CD ,/, and/CC 436/CD (/( positions/NNS P/NN 1/CD ,/, P2/NN ,/, P3/NN ,/, and/CC P5/NN )/) contributed/VBD to/TO TCR/NN contact/NN ./. 
Differential/JJ presentation/NN of/IN peptide/NN by/IN HLA/NN DQ2/NN heterodimers/NNS varying/VBG at/IN the/DT DQA1/NN locus/NN may/MD have/VB relevance/NN to/TO host/NN defense/NN and/CC the/DT pathogenesis/NN of/IN HLA/NN DQ2-associated/JJ autoimmune/JJ diseases/NNS ./. 
UI/LS -/: 97282709/CD 
TI/LS -/: Inhibitor/NN (/( IK/NN )/) of/IN IFN-gamma/NN induced/JJ HLA/NN class/NN II/CD antigens/NNS expression/NN also/RB inhibits/VBZ HLA/NN class/NN II/CD constitutive/JJ expression/NN in/IN the/DT human/JJ Raji/NN B/NN cell/NN line/NN ./. 
AB/LS -/: The/DT expression/NN of/IN major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II/CD antigens/NNS is/VBZ constitutive/JJ in/IN professional/JJ antigen/NN presenting/NN cells/NNS (/( APCs/NNS )/) but/CC can/MD also/RB be/VB induced/VBN by/IN interferon-gamma/NN (/( IFN-gamma/NN )/) on/IN the/DT majority/NN of/IN the/DT non/JJ professional/JJ APCs/NNS (/( e.g./FW fibroblasts/NNS )/) ./. 
We/PRP have/VBP recently/RB characterised/VBN a/DT new/JJ factor/NN called/VBN IK/NN which/WDT is/VBZ an/DT efficient/JJ inhibitor/NN of/IN IFN-gamma/NN induction/NN of/IN MHC/NN class/NN II/CD antigens/NNS expression/NN ./. 
Here/RB ,/, we/PRP demonstrate/VBP a/DT novel/JJ role/NN for/IN IK/NN in/IN MHC/NN class/NN II/CD expression/NN since/IN over-expression/NN of/IN this/DT protein/NN by/IN stable/JJ transfection/NN into/IN human/JJ B/NN cells/NNS led/VBD to/TO a/DT total/JJ disappearance/NN of/IN constitutive/JJ MHC/NN class/NN II/CD mRNA/NN expression/NN ./. 
The/DT class/NN II/CD transactivator/NN (/( CIITA/NN )/) is/VBZ necessary/JJ for/IN both/CC constitutive/JJ and/CC IFN-gamma/NN induced/JJ MHC/NN class/NN II/CD expressions/NNS ./. 
Examination/NN of/IN CIITA/NN mRNA/NN in/IN IK/NN stably/RB transfected/VBN clones/NNS revealed/VBD a/DT marked/JJ reduction/NN of/IN CIITA/NN mRNA/NN transcription/NN ./. 
Taken/VBN together/RB these/DT results/NNS demonstrate/VBP that/IN the/DT IK/NN protein/NN plays/VBZ a/DT key/JJ role/NN in/IN the/DT constitutive/JJ expression/NN of/IN MHC/NN class/NN II/CD antigens/NNS and/CC that/IN inhibition/NN induced/VBN by/IN IK/NN is/VBZ upstream/JJ of/IN CIITA/NN in/IN this/DT regulatory/JJ pathway/NN ./. 
UI/LS -/: 97217364/CD 
TI/LS -/: Selective/JJ expression/NN of/IN an/DT interleukin-12/NN receptor/NN component/NN by/IN human/JJ T/NN helper/NN 1/CD cells/NNS ./. 
AB/LS -/: Interleukin-12/NN (/( IL-12/NN )/) ,/, a/DT heterodimeric/JJ cytokine/NN produced/VBN by/IN activated/VBN monocytes/NNS and/CC dendritic/JJ cells/NNS ,/, plays/VBZ a/DT crucial/JJ role/NN in/IN regulating/VBG interferon/NN (/( IFN/NN )/) -gamma/NN production/NN and/CC in/IN the/DT generation/NN of/IN IFN-gamma-producing/JJ T/NN helper/NN 1/CD (/( Th1/NN )/) cells/NNS ./. 
Here/RB we/PRP show/VBP that/IN the/DT IL-12/NN receptor/NN (/( IL-12R/NN )/) beta/NN 2/CD subunit/NN ,/, a/DT recently/RB cloned/VBN binding/NN and/CC signal/NN transducing/NN component/NN of/IN the/DT IL-12R/NN ,/, is/VBZ expressed/VBN on/IN human/JJ Th1/NN but/CC not/RB Th2/NN clones/NNS and/CC is/VBZ induced/VBN during/IN differentiation/NN of/IN human/JJ naive/JJ cells/NNS along/IN the/DT Th1/NN but/CC not/RB the/DT Th2/NN pathway/NN ./. 
IL-12/NN and/CC type/NN I/CD but/CC not/RB type/NN II/CD interferons/NNS induce/VBP expression/NN of/IN the/DT IL-12R/NN beta/NN 2/CD chain/NN during/IN in/FW vitro/FW T/NN cell/NN differentiation/NN after/IN antigen/NN receptor/NN triggering/NN ./. 
The/DT selective/JJ expression/NN and/CC regulation/NN of/IN the/DT IL-12R/NN beta/NN 2/CD subunit/NN may/MD help/VB to/TO understand/VB the/DT basis/NN of/IN Th1/Th2/NN differentiation/NN and/CC may/MD provide/VB therapeutic/JJ options/NNS for/IN altering/VBG the/DT Th1/Th2/NN balance/NN in/IN several/JJ immuno-pathological/JJ conditions/NNS such/JJ as/IN autoimmune/JJ diseases/NNS and/CC allergies/NNS ./. 
UI/LS -/: 97230346/CD 
TI/LS -/: The/DT T/NN cell/NN activation/NN factor/NN NF-ATc/NN positively/RB regulates/VBZ HIV-1/NN replication/NN and/CC gene/NN expression/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Clinical/JJ deterioration/NN in/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) infection/NN is/VBZ associated/VBN with/IN increased/VBN levels/NNS of/IN viral/JJ replication/NN and/CC burden/NN in/IN the/DT peripheral/JJ blood/NN and/CC lymphoid/JJ organs/NNS ./. 
T/NN cell/NN activation/NN and/CC ensuing/JJ cellular/JJ gene/NN activation/NN can/MD be/VB critical/JJ for/IN HIV-1/NN replication/NN ./. 
The/DT hypothesis/NN that/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) may/MD influence/VB HIV-1/NN replication/NN is/VBZ therefore/RB compelling/JJ given/VBN the/DT tight/JJ correlation/NN of/IN HIV-1/NN transcriptional/JJ induction/NN to/TO T/NN cell/NN activation/NN ./. 
We/PRP report/VBP that/IN certain/JJ NF-AT/NN (/( Rel/NN )/) family/NN members/NNS productively/RB bind/VBP the/DT kappaB/NN regulatory/JJ elements/NNS ,/, synergize/VBP with/IN NF-kappaB/NN and/CC Tat/NN in/IN transcriptional/JJ activation/NN of/IN HIV-1/NN ,/, and/CC enhance/VBP HIV-1/NN replication/NN in/IN T/NN cells/NNS ./. 
These/DT results/NNS link/VBP regulatory/JJ factors/NNS critical/JJ to/TO T/NN cell/NN commitment/NN directly/RB to/TO HIV-1/NN replication/NN ./. 
UI/LS -/: 97184478/CD 
TI/LS -/: Transcription/NN mediated/VBN by/IN NFAT/NN is/VBZ highly/RB inducible/JJ in/IN effector/NN CD4+/JJ T/NN helper/NN 2/CD (/( Th2/NN )/) cells/NNS but/CC not/RB in/IN Th1/NN cells/NNS ./. 
AB/LS -/: Transcriptional/JJ factors/NNS of/IN the/DT NFAT/NN family/NN play/VBP an/DT important/JJ role/NN in/IN regulating/VBG the/DT expression/NN of/IN several/JJ cytokine/NN genes/NNS during/IN the/DT immune/JJ response/NN ,/, such/JJ as/IN the/DT genes/NNS for/IN interleukin/NN 2/CD (/( IL-2/NN )/) and/CC IL-4/NN ,/, among/IN others/NNS ./. 
Upon/IN antigen/NN stimulation/NN ,/, precursor/NN CD4+/JJ T/NN helper/NN (/( pTh/NN )/) cells/NNS proliferate/VBP and/CC differentiate/VBP into/IN two/CD populations/NNS of/IN effector/NN cells/NNS (/( eTh1/NN and/CC eTh2/NN )/) ,/, each/DT one/NN expressing/VBG a/DT specific/JJ pattern/NN of/IN cytokines/NNS that/WDT distinguishes/VBZ them/PRP from/IN their/PRP$ precursors/NNS ./. 
eTh2/NN cells/NNS are/VBP the/DT major/JJ source/NN of/IN IL-4/NN ,/, while/IN gamma/NN interferon/NN is/VBZ produced/VBN by/IN eTh1/NN cells/NNS ./. 
Here/RB we/PRP have/VBP used/VBN reporter/NN transgenic/JJ mice/NNS to/TO show/VB that/IN DNA/NN binding/NN and/CC transcriptional/JJ activities/NNS of/IN NFAT/NN are/VBP transiently/RB induced/VBN during/IN the/DT differentiation/NN of/IN pTh/NN cells/NNS into/IN either/CC eTh1/NN or/CC eTh2/NN cells/NNS to/TO mediate/VB the/DT expression/NN of/IN IL-2/NN as/IN a/DT common/JJ growth/NN factor/NN in/IN both/CC pathways/NNS ./. 
However/RB ,/, although/IN NFAT/NN DNA/NN binding/NN is/VBZ similarly/RB induced/VBN in/IN both/CC eTh1/NN and/CC eTh2/NN cells/NNS upon/IN antigen/NN stimulation/NN ,/, only/RB the/DT NFAT/NN complexes/NNS present/JJ in/IN eTh2/NN cells/NNS are/VBP able/JJ to/TO mediate/VB high-level/JJ transcription/NN ,/, and/CC relatively/RB little/JJ NFAT/NN transcriptional/JJ activity/NN was/VBD induced/VBN in/IN eTh1/NN cells/NNS ./. 
In/IN contrast/NN to/TO activated/VBN pTh/NN cells/NNS ,/, neither/CC eTh1/NN nor/CC eTh2/NN cells/NNS produced/VBD significant/JJ IL-2/NN upon/IN stimulation/NN ,/, but/CC the/DT high/JJ levels/NNS of/IN NFAT/NN transcriptional/JJ activities/NNS directly/RB correlate/VBP with/IN the/DT IL-4/NN production/NN induced/VBN in/IN response/NN to/TO antigen/NN stimulation/NN in/IN eTh2/NN cells/NNS ./. 
These/DT data/NNS suggest/VBP that/IN activated/VBN NFAT/NN is/VBZ involved/VBN in/IN the/DT effector/NN function/NN of/IN eTh2/NN cells/NNS and/CC that/IN the/DT failure/NN of/IN eTh1/NN cells/NNS to/TO produce/VB IL-4/NN in/IN response/NN to/TO an/DT antigen/NN is/VBZ due/JJ ,/, at/IN least/JJS partially/RB ,/, to/TO a/DT failure/NN to/TO induce/VB high-level/JJ transcription/NN of/IN the/DT IL-4/NN gene/NN by/IN NFAT/NN ./. 
Regulation/NN of/IN NFAT/NN could/MD be/VB therefore/RB a/DT critical/JJ element/NN in/IN the/DT polarization/NN to/TO eTh1/NN or/CC eTh2/NN ./. 
UI/LS -/: 97218076/CD 
TI/LS -/: Activation/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN in/IN lipopolysaccharide-stimulated/JJ U937/NN cells/NNS ./. 
AB/LS -/: During/IN the/DT course/NN of/IN serious/JJ bacterial/JJ infections/NNS ,/, lipopolysaccharide/NN (/( LPS/NN )/) interacts/VBZ with/IN monocyte/macrophage/NN receptors/NNS ,/, resulting/VBG in/IN the/DT generation/NN of/IN inflammatory/JJ cytokines/NNS ./. 
Transcription/NN factor/NN NF-kappaB/NN is/VBZ crucial/JJ in/IN activating/VBG the/DT transcription/NN of/IN genes/NNS encoding/VBG proinflammatory/JJ cytokines/NNS ./. 
In/IN this/DT paper/NN ,/, we/PRP demonstrate/VBP that/IN the/DT activation/NN of/IN NF-kappaB/NN by/IN LPS/NN in/IN a/DT promonocytic/JJ cell/NN line/NN (/( U937/NN )/) followed/VBD a/DT rather/RB slow/JJ kinetics/NN ,/, depending/VBG on/IN the/DT rate/NN of/IN IkappaB-alpha/NN inhibitor/NN hydrolysis/NN ./. 
No/DT degradation/NN of/IN p105/NN and/CC p100/NN inhibitors/NNS was/VBD observed/VBN under/IN these/DT conditions/NNS ./. 
The/DT transduction/NN pathway/NN leading/VBG to/TO NF-kappaB/NN activation/NN in/IN U937/NN cells/NNS involved/VBD the/DT intracellular/JJ generation/NN of/IN reactive/JJ oxygen/NN species/NNS (/( ROS/NNS )/) ,/, as/IN demonstrated/VBN by/IN the/DT concomitant/JJ inhibitory/JJ effects/NNS of/IN antioxidants/NNS on/IN NF-kappaB/NN activation/NN and/CC the/DT emission/NN of/IN a/DT fluorescent/JJ probe/NN reacting/VBG intracellularly/RB with/IN hydrogen/NN peroxide/NN ./. 
This/DT ROS/NNS pathway/NN was/VBD also/RB characterized/VBN by/IN the/DT use/NN of/IN other/JJ inhibitors/NNS ./. 
This/DT finding/NN indicates/VBZ that/IN phospholipase/NN A2/NN and/CC 5-lipoxygenase/NN are/VBP also/RB involved/VBN ./. 
However/RB ,/, the/DT NF-kappaB/NN activation/NN pathway/NN involving/VBG the/DT acidic/JJ sphingomyelinase/NN of/IN the/DT endolysosomial/JJ membrane/NN did/VBD not/RB seem/VB to/TO participate/VB in/IN the/DT LPS-induced/JJ NF-kappaB/NN activation/NN in/IN U937/NN cells/NNS ./. 
UI/LS -/: 97199262/CD 
TI/LS -/: c-Rel/NN is/VBZ a/DT target/NN of/IN pentoxifylline-mediated/JJ inhibition/NN of/IN T/NN lymphocyte/NN activation/NN ./. 
AB/LS -/: The/DT possible/JJ clinical/JJ use/NN of/IN the/DT methyl/NN xanthine/NN derivative/JJ ,/, pentoxifylline/NN (/( PF/NN )/) ,/, for/IN the/DT treatment/NN of/IN T/NN cell-dependent/JJ diseases/NNS is/VBZ being/VBG noted/VBN with/IN increasing/VBG interest/NN ./. 
In/IN this/DT paper/NN ,/, we/PRP studied/VBD the/DT molecular/JJ consequences/NNS of/IN PF/NN treatment/NN during/IN lymphocyte/NN activation/NN ./. 
We/PRP found/VBD that/IN in/IN T/NN cells/NNS ,/, anti-CD3-induced/JJ c-Rel/NN expression/NN was/VBD blocked/VBN by/IN PF/NN ,/, whereas/IN the/DT induction/NN of/IN other/JJ NF-kappaB/NN family/NN members/NNS was/VBD not/RB significantly/RB affected/VBN ./. 
However/RB ,/, induction/NN of/IN NF-AT/NN ,/, which/WDT has/VBZ the/DT same/JJ signaling/NN requirements/NNS as/IN c-Rel/NN induction/NN ,/, was/VBD not/RB inhibited/VBN by/IN PF/NN ./. 
Among/IN genes/NNS that/WDT respond/VBP to/TO these/DT transcription/NN factors/NNS ,/, IL-2/NN mRNA/NN induction/NN was/VBD suppressed/VBN by/IN PF/NN ,/, whereas/IN IL-2R/NN (/( alpha/NN )/) chain/NN mRNA/NN induction/NN was/VBD not/RB affected/VBN ./. 
These/DT observations/NNS implicated/VBD c-Rel/NN as/IN an/DT IL-2/NN promoter/NN factor/IN ,/, for/IN which/WDT experimental/JJ support/NN was/VBD obtained/VBN from/IN transient/JJ transfection/NN experiments/NNS ./. 
In/IN contrast/NN with/IN the/DT observation/NN in/IN T/NN cells/NNS ,/, c-Rel/NN induction/NN was/VBD not/RB blocked/VBN by/IN PF/NN in/IN B/NN cells/NNS ./. 
The/DT greater/JJR selectivity/NN of/IN PF/NN ,/, compared/VBN with/IN FK506/NN ,/, at/IN both/CC the/DT molecular/JJ and/CC cellular/JJ levels/NNS may/MD prove/VB advantageous/JJ in/IN manipulating/VBG T/NN cell/NN responses/NNS in/FW vivo/FW ./. 
UI/LS -/: 97159684/CD 
TI/LS -/: V3/NN loop/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD suppresses/VBZ interleukin/NN 2-induced/JJ T/NN cell/NN growth/NN [/( published/VBN erratum/NN appears/VBZ in/IN AIDS/NNP Res/NNP Hum/NNP Retroviruses/NNPS 1997/CD May/NN 1/CD ;/: 13/CD (/( 7/CD )/) :/: 633/CD ]/) 
AB/LS -/: We/PRP tested/VBD the/DT effect/NN of/IN three/CD linear/JJ or/CC two/CD loop/NN peptides/NNS derived/VBN from/IN the/DT V3/NN region/NN of/IN the/DT HTLV-III/NN BH10/NN clone/NN or/CC the/DT SF2/NN strain/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD on/IN IL-2-driven/JJ T/NN cell/NN proliferation/NN ./. 
V3-BH10/NN ,/, which/WDT consists/VBZ of/IN 42/CD amino/NN acids/NNS and/CC has/VBZ a/DT loop/NN structure/NN ,/, suppressed/VBD IL-2-driven/JJ proliferation/NN of/IN all/DT IL-2-dependent/JJ cells/NNS [/( Kit225/NN ,/, ED-40515(+)/NN ,/, KT-3/NN ,/, 7-day/JJ PHA-blasts/NNS ,/, and/CC fresh/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS ]/) tested/VBN ,/, whereas/IN it/PRP did/VBD not/RB suppress/VB the/DT cell/NN growth/NN of/IN IL-2-independent/JJ cell/NN lines/NNS (/( Hut102/NN ,/, Molt-4/NN ,/, and/CC Jurkat/NN )/) ./. 
This/DT suppressive/JJ effect/NN was/VBD also/RB seen/VBN in/IN IL-2-driven/JJ cell/NN growth/NN of/IN CD8-positive/JJ lymphocytes/NNS purified/VBN from/IN 7-day/JJ PHA-blasts/NNS ,/, indicating/VBG that/IN CD4/NN molecules/NNS were/VBD not/RB required/VBN for/IN the/DT suppression/NN ./. 
The/DT treatment/NN with/IN anti-V3/JJ loop/NN monoclonal/JJ antibody/NN (/( 902/CD antibody/NN )/) completely/RB abolished/VBD the/DT suppressive/JJ effect/NN of/IN V3-BH10/NN ./. 
In/IN addition/NN ,/, V3-BH10/NN generated/VBD the/DT arrest/NN of/IN Kit225/NN cells/NNS and/CC also/RB purified/VBD CD8-positive/JJ lymphocytes/NNS in/IN G1/NN phase/NN in/IN the/DT presence/NN of/IN IL-2/NN ./. 
Neither/CC chromatin/NN condensation/NN nor/CC DNA/NN fragmentation/NN was/VBD detected/VBN in/IN Kit225/NN cells/NNS cultured/VBN with/IN V3-BH10/NN and/CC IL-2/NN ./. 
V3-BH10/NN neither/CC blocked/VBD radiolabeled/VBN IL-2/NN binding/NN to/TO IL-2/NN receptors/NNS nor/CC affected/VBD tyrosyl/NN phosphorylation/NN of/IN several/JJ cellular/JJ proteins/NNS (/( p120/NN ,/, p98/NN ,/, p96/NN ,/, p54/NN ,/, and/CC p38/NN )/) ,/, which/WDT is/VBZ immediately/RB induced/VBN by/IN IL-2/NN stimulation/NN ./. 
However/RB ,/, V3-BH10/NN enhanced/VBD IL-2-induced/JJ mRNA/NN expression/NN of/IN c-fos/NN but/CC not/RB c-myc/NN or/CC junB/NN ./. 
Thus/RB ,/, the/DT binding/NN of/IN V3/NN loop/NN of/IN gp120/NN to/TO the/DT cell/NN surface/NN molecule/NN (/( s/NNS )/) appears/VBZ to/TO affect/VB intracellular/JJ IL-2/NN signaling/NN ,/, which/WDT leads/VBZ to/TO the/DT suppression/NN of/IN IL-2-induced/JJ T/NN cell/NN growth/NN 
UI/LS -/: 97277252/CD 
TI/LS -/: A/DT negative/JJ role/NN for/IN phosphoinositide/NN 3-kinase/NN in/IN T-cell/NN antigen/NN receptor/NN function/NN ./. 
AB/LS -/: BACKGROUND/NN :/: A/DT delicate/JJ balance/NN between/IN positive/JJ and/CC negative/JJ regulatory/JJ mechanisms/NNS during/IN T-cell/NN activation/NN determines/VBZ the/DT specificity/NN and/CC magnitude/NN of/IN an/DT immune/JJ response/NN ./. 
Phosphoinositide/NN 3-kinase/NN (/( PI/NN 3-kinase/NN )/) is/VBZ activated/VBN by/IN a/DT diverse/JJ set/NN of/IN receptors/NNS that/WDT determine/VBP T-cell/NN function/NN ,/, including/VBG the/DT T-cell/NN antigen/NN receptor/NN (/( TCR/NN )/) ,/, the/DT costimulatory/JJ receptor/NN CD28/NN ,/, and/CC negative/JJ regulators/NNS of/IN T-cell/NN activation/NN such/JJ as/IN CTLA-4/NN ./. 
PI/NN 3-kinase/NN is/VBZ also/RB regulated/VBN by/IN the/DT haematopoietic/JJ cytokines/NNS that/WDT determine/VBP T-cell/NN differentiation/NN and/CC lymphocyte/NN proliferation/NN ./. 
PI/NN 3-kinase/NN can/MD thus/RB dynamically/RB influence/VB the/DT outcome/NN of/IN the/DT immune/JJ reactions/NNS at/IN various/JJ stages/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP investigated/VBD the/DT importance/NN of/IN PI/NN 3-kinase/NN in/IN TCR-directed/JJ T-cell/NN activation/NN using/VBG activated/VBN or/CC inhibitory/JJ versions/NNS of/IN PI/NN 3-kinase/NN ./. 
RESULTS/NNS :/: Certain/JJ aspects/NNS of/IN TCR/NN responses/NNS such/JJ as/IN the/DT induction/NN of/IN transcriptional/JJ activity/NN of/IN AP1/NN and/CC serum/NN response/NN factor/NN were/VBD not/RB affected/VBN by/IN expression/NN of/IN the/DT mutant/JJ forms/NNS of/IN PI/NN 3-kinase/NN ./. 
We/PRP found/VBD ,/, however/RB ,/, that/IN PI/NN 3-kinase/NN profoundly/RB influenced/VBD the/DT transactivation/NN capacity/NN of/IN '/`` nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS '/'' (/( NF-AT/NN )/) elicited/VBN by/IN the/DT TCR/NN :/: expression/NN of/IN an/DT activated/JJ form/NN of/IN PI/NN 3-kinase/NN inhibited/VBD TCR-mediated/JJ NF-AT/NN responses/NNS ,/, whereas/IN expression/NN of/IN a/DT dominant/JJ negative/JJ mutant/NN of/IN PI/NN 3-kinase/NN potently/RB enhanced/VBD TCR-controlled/JJ NF-AT/NN induction/NN ./. 
These/DT effects/NNS of/IN PI/NN 3-kinase/NN were/VBD not/RB mediated/VBN by/IN previously/RB identified/VBN PI/NN 3-kinase/NN effectors/NNS ,/, such/JJ as/IN protein/NN kinase/NN B/NN ,/, a/DT positive/JJ regulator/NN of/IN PI/NN 3-kinase/NN ,/, or/CC the/DT GTPase/NN Rac/NN ,/, and/CC are/VBP therefore/RB likely/JJ to/TO involve/VB a/DT novel/JJ ,/, as/IN yet/RB unknown/JJ ,/, effector/NN molecule/NN ./. 
CONCLUSIONS/NNS :/: Our/PRP$ results/NNS establish/VBP that/IN PI/NN 3-kinase/NN can/MD both/CC positively/RB and/CC negatively/RB regulate/VB T-cell/NN function/NN ,/, and/CC uncover/VBP a/DT previously/RB unrecognized/JJ function/NN for/IN PI/NN 3-kinase/NN in/IN T/NN cells/NNS as/IN a/DT selective/JJ negative/JJ regulator/NN of/IN TCR-signalling/JJ events/NNS and/CC therefore/RB as/IN a/DT determinant/NN of/IN T-cell/NN homeostasis/NN ./. 
UI/LS -/: 97248576/CD 
TI/LS -/: The/DT Pax-5/NN gene/NN is/VBZ alternatively/RB spliced/VBN during/IN B-cell/NN development/NN ./. 
AB/LS -/: The/DT transcription/NN factor/NN Pax-5/NN is/VBZ expressed/VBN during/IN the/DT early/JJ stages/NNS of/IN B-cell/NN differentiation/NN and/CC influences/VBZ the/DT expression/NN of/IN several/JJ B-cell-specific/JJ genes/NNS ./. 
In/IN addition/NN to/TO the/DT existing/VBG isoform/NN (/( Pax-5/NN ,/, which/WDT we/PRP have/VBP named/VBN Pax-5a/NN )/) ,/, we/PRP have/VBP isolated/VBN three/CD new/JJ isoforms/NNS ,/, Pax-5b/NN ,/, Pax-5d/NN ,/, and/CC Pax-5e/NN ,/, from/IN murine/JJ spleen/NN and/CC B-lymphoid/JJ cell/NN lines/NNS using/VBG library/NN screenings/NNS and/CC polymerase/NN chain/NN reaction/NN amplification/NN ./. 
Isoforms/NNS Pax-5b/NN and/CC Pax-5e/NN have/VBP spliced/VBN out/RP their/PRP$ second/JJ exon/NN ,/, resulting/VBG in/IN proteins/NNS with/IN only/RB a/DT partial/JJ DNA-binding/JJ domain/NN ./. 
Isoforms/NNS Pax-5d/NN and/CC Pax-5e/NN have/VBP deleted/VBN the/DT 3'-region/NN ,/, which/WDT encodes/VBZ the/DT transactivating/VBG domain/NN ,/, and/CC replaced/VBN it/PRP with/IN a/DT novel/JJ sequence/NN ./. 
The/DT existence/NN of/IN alternative/JJ Pax-5/NN transcripts/NNS was/VBD confirmed/VBN using/VBG RNase/NN protection/NN assays/NNS ./. 
Furthermore/RB ,/, Pax-5a/NN and/CC Pax-5b/NN proteins/NNS were/VBD detected/VBN using/VBG Western/NN blot/NN analysis/NN ./. 
Pax-5a/NN was/VBD detectable/JJ in/IN pro-/JJ ,/, pre-/JJ ,/, and/CC mature/JJ B-cell/NN lines/NNS ,/, but/CC not/RB in/IN two/CD plasmacytomas/NNS ;/: Pax-5b/NN was/VBD shown/VBN to/TO be/VB present/JJ at/IN low/JJ levels/NNS in/IN mature/JJ B-cell/NN lines/NNS and/CC ,/, unexpectedly/RB ,/, in/IN one/CD plasma/NN cell/NN line/NN ,/, but/CC not/RB in/IN pro-B-cell/JJ or/CC T-cell/NN lines/NNS ./. 
Mobility/NN shift/NN assays/NNS showed/VBD that/IN in/FW vitro/FW translated/VBN Pax-5a/NN and/CC Pax-5d/NN ,/, but/CC not/RB Pax-5b/NN or/CC Pax-5e/NN ,/, could/MD interact/VB with/IN a/DT B-cell-specific/JJ activator/NN protein-binding/JJ site/NN on/IN the/DT blk/NN promoter/NN ./. 
Using/VBG this/DT assay/NN ,/, we/PRP also/RB showed/VBD that/IN Pax-5d/NN was/VBD present/JJ in/IN nuclear/JJ extracts/NNS of/IN some/DT (/( but/CC not/RB all/DT )/) B-lymphoid/JJ lines/NNS and/CC interacts/VBZ with/IN the/DT B-cell-specific/JJ activator/NN protein-binding/JJ site/NN ./. 
The/DT pattern/NN of/IN differential/JJ expression/NN of/IN alternatively/RB spliced/VBN Pax-5/NN isoforms/NNS suggests/VBZ that/IN they/PRP may/MD be/VB important/JJ regulators/NNS of/IN transcription/NN during/IN B-cell/NN maturation/NN ./. 
UI/LS -/: 97274642/CD 
TI/LS -/: Reconstitution/NN of/IN T/NN cell/NN antigen/NN receptor-induced/JJ Erk2/NN kinase/NN activation/NN in/IN Lck-negative/JJ JCaM1/NN cells/NNS by/IN Syk/NN ./. 
AB/LS -/: The/DT two/CD related/JJ protein-tyrosine/JJ kinases/NNS Syk/NN and/CC Zap/NN are/VBP rapidly/RB phosphorylated/VBN on/IN tyrosine/NN residues/NNS and/CC enzymatically/RB activated/VBN upon/IN crosslinking/NN of/IN the/DT T/NN cell/NN antigen/NN receptor/NN ./. 
We/PRP have/VBP previously/RB reported/VBN that/IN the/DT activation/NN of/IN Syk/NN is/VBZ less/RBR dependent/JJ on/IN the/DT Src/NN family/NN kinase/NN Lck/NN than/IN the/DT activation/NN of/IN Zap/NN ./. 
Here/RB we/PRP report/VBP that/IN overexpression/NN of/IN Syk/NN in/IN the/DT Lck-negative/JJ JCaM1/NN cells/NNS enabled/VBD the/DT T/NN cell/NN antigen/NN receptor/CD3/NN complex/NN to/TO induce/VB a/DT normal/JJ activation/NN of/IN the/DT mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) pathway/NN and/CC expression/NN of/IN a/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS reporter/NN construct/NN ./. 
In/IN contrast/NN ,/, Zap/NN and/CC other/JJ protein-tyrosine/JJ kinases/NNS were/VBD unable/JJ to/TO reconstitute/VB these/DT signaling/NN pathways/NNS when/WRB expressed/VBN at/IN the/DT same/JJ levels/NNS ./. 
In/IN parallel/NN ,/, Syk/NN was/VBD phosphorylated/VBN on/IN tyrosine/NN ,/, while/IN Zap/NN was/VBD not/RB ./. 
The/DT Syk-mediated/JJ T/NN cell/NN antigen/NN receptor-induced/JJ MAPK/NN activation/NN was/VBD detectable/JJ within/IN 1/CD min/NN of/IN receptor/NN stimulation/NN and/CC peaked/VBD at/IN 3-5/CD min/NN ./. 
The/DT capacity/NN of/IN Syk/NN to/TO reconstitute/VB the/DT MAPK/NN response/NN required/VBD the/DT catalytic/JJ activity/NN of/IN Syk/NN ,/, an/DT intact/JJ autophosphorylation/NN site/NN (/( Y518/NN and/CC Y519/NN )/) ,/, both/DT Src/NN homology/NN 2/CD domains/NNS and/CC it/PRP was/VBD blocked/VBN by/IN the/DT inhibitory/JJ N17-mutated/JJ dominant-negative/JJ Ras/NN construct/NN ./. 
A/DT Y341/NN -->/TO F/NN mutant/NN of/IN Syk/NN ,/, which/WDT is/VBZ deficient/JJ in/IN its/PRP$ interaction/NN with/IN phospholipase/NN Cy1/NN and/CC Vav/NN ,/, was/VBD less/RBR efficient/JJ than/IN wild-type/JJ Syk/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN Syk/NN ,/, in/IN contrast/NN to/TO Zap/NN ,/, can/MD transduce/VB signals/NNS from/IN the/DT T/NN cell/NN antigen/NN receptor/NN independently/RB of/IN Lck/NN ./. 
UI/LS -/: 97222140/CD 
TI/LS -/: Activation/NN of/IN the/DT transcription/NN factor/NN MEF2C/NN by/IN the/DT MAP/NN kinase/NN p38/NN in/IN inflammation/NN ./. 
AB/LS -/: For/IN cells/NNS of/IN the/DT innate/JJ immune/JJ system/NN to/TO mount/VB a/DT host/NN defence/NN response/NN to/TO infection/NN ,/, they/PRP must/MD recognize/VB products/NNS of/IN microbial/JJ pathogens/NNS such/JJ as/IN lipopolysaccharide/NN (/( LPS/NN )/) ,/, the/DT endotoxin/NN secreted/VBN by/IN Gram-negative/JJ bacteria/NNS ./. 
These/DT cellular/JJ responses/NNS require/VBP intracellular/JJ signalling/NN pathways/NNS ,/, such/JJ as/IN the/DT four/CD MAP/NN kinase/NN (/( MAPK/NN )/) pathways/NNS ./. 
In/IN mammalian/JJ cells/NNS the/DT MAPK/NN p38/NN is/VBZ thought/VBN to/TO play/VB an/DT important/JJ role/NN in/IN the/DT regulation/NN of/IN cellular/JJ responses/NNS during/IN infection/NN through/IN its/PRP$ effects/NNS on/IN the/DT expression/NN of/IN proinflammatory/JJ molecules/NNS ./. 
One/CD means/NN of/IN understanding/VBG the/DT role/NN of/IN p38/NN in/IN these/DT responses/NNS is/VBZ to/TO identify/VB proteins/NNS with/IN functions/NNS regulated/VBN by/IN p38-catalysed/JJ phosphorylation/NN ./. 
Here/RB we/PRP demonstrate/VBP a/DT link/NN between/IN the/DT p38/NN pathway/NN and/CC a/DT member/NN of/IN the/DT myocyte-enhancer/NN factor/NN 2/CD (/( MEF2/NN )/) group/NN of/IN transcription/NN factors/NNS ./. 
We/PRP found/VBD that/IN in/IN monocytic/JJ cells/NNS ,/, LPS/NN increases/VBZ the/DT transactivation/NN activity/NN of/IN MEF2C/NN through/IN p38-catalysed/JJ phosphorylation/NN ./. 
One/CD consequence/NN of/IN MEF2C/NN activation/NN is/VBZ increased/VBN c-jun/NN gene/NN transcription/NN ./. 
Our/PRP$ results/NNS show/VBP that/IN p38/NN may/MD influence/VB host/NN defence/NN and/CC inflammation/NN by/IN maintaining/VBG the/DT balance/NN of/IN c-Jun/NN protein/NN consumed/VBN during/IN infection/NN ./. 
UI/LS -/: 97300635/CD 
TI/LS -/: Cellular/JJ redox/NN status/NN influences/VBZ both/CC cytotoxic/JJ and/CC NF-kappa/NN B/NN activation/NN in/IN natural/JJ killer/NN cells/NNS ./. 
AB/LS -/: The/DT role/NN of/IN cellular/JJ redox/NN status/NN in/IN both/CC cytotoxic/JJ activity/NN and/CC NF-kappa/NN B/NN activation/NN in/IN natural/JJ killer/NN (/( NK/NN )/) cells/NNS was/VBD investigated/VBN ./. 
The/DT results/NNS indicate/VBP that/IN stimulation/NN of/IN NK/NN cells/NNS ,/, either/CC freshly/RB isolated/VBN from/IN peripheral/JJ blood/NN lymphocytes/NNS (/( PBL/NNS )/) or/CC long-term/JJ cultured/VBN NK/NN clones/NNS ,/, with/IN specific/JJ cell/NN targets/NNS results/VBZ in/IN an/DT increased/VBN binding/NN activity/NN of/IN NF-kappa/NN B/NN and/CC AP-1/NN transcription/NN factors/NNS measured/VBN by/IN gel/NN retardation/NN ./. 
Pretreatment/NN of/IN NK/NN cells/NNS with/IN the/DT antioxidant/JJ pyrrolidine/NN dithiocarbarmate/NN (/( PDTC/NN )/) leads/VBZ to/TO the/DT inhibition/NN of/IN NF-kappa/NN B/NN activation/NN but/CC the/DT AP-1/NN binding/NN to/TO DNA/NN was/VBD superinduced/VBN ./. 
The/DT inhibition/NN of/IN NF-kappa/NN B/NN by/IN PDTC/NN paralleled/VBD with/IN an/DT inhibition/NN of/IN spontaneous/JJ cytotoxicity/NN mediated/VBN by/IN NK/NN cells/NNS ./. 
Moreover/RB ,/, the/DT inhibitors/NNS of/IN serine/NN proteases/NNS ,/, N-alpha-tosyl-L-lysine/NN chloromethyl/NN ketone/NN and/CC N-alpha-tosyl-L-phenylalanine/NN chloromethyl/NN ketone/NN ,/, also/RB blocked/VBD the/DT cytolytic/JJ activity/NN of/IN NK/NN cells/NNS against/IN the/DT sensitive/JJ target/NN K562/NN ./. 
In/IN contrast/NN ,/, NK/NN activity/NN was/VBD not/RB affected/VBN by/IN pretreatment/NN of/IN the/DT effector/NN cells/NNS with/IN the/DT proteasome/NN inhibitor/NN N-acetyl-leu-leu-norleucinal/NN which/WDT selectively/RB inhibits/VBZ NF-kappa/NN B/NN activation/NN ./. 
Altogether/RB ,/, these/DT results/NNS support/VBP the/DT hypothesis/NN that/IN the/DT activation/NN of/IN NK/NN cells/NNS involved/VBD transcriptional/JJ and/CC post-transcriptional/JJ events/NNS ,/, and/CC that/IN reactive/JJ intermediates/NNS may/MD play/VB an/DT important/JJ role/NN in/IN the/DT molecular/JJ processes/NNS related/JJ with/IN the/DT generation/NN of/IN a/DT cytotoxic/JJ response/NN by/IN NK/NN cells/NNS ./. 
UI/LS -/: 97228330/CD 
TI/LS -/: The/DT predominant/JJ E2F/NN complex/NN in/IN human/JJ primary/JJ haemopoietic/JJ cells/NNS and/CC in/IN AML/NN blasts/NNS contains/VBZ E2F-4/NN ,/, DP-1/NN and/CC p130/NN ./. 
AB/LS -/: The/DT E2F/NN family/NN of/IN transcription/NN factors/NNS are/VBP thought/VBN to/TO play/VB an/DT important/JJ role/NN in/IN the/DT control/NN of/IN cell/NN cycle/NN progression/NN ./. 
There/EX is/VBZ now/RB also/RB increasing/VBG evidence/NN that/IN some/DT family/NN members/NNS may/MD act/VB as/IN oncogenes/NNS or/CC tumour/NN suppressor/NN genes/NNS ./. 
The/DT characterization/NN of/IN these/DT proteins/NNS in/IN human/JJ primary/JJ haemopoietic/JJ cells/NNS and/CC acute/JJ myeloid/JJ leukaemia/NN (/( AML/NN )/) blasts/NNS may/MD thus/RB give/VB an/DT insight/NN to/TO the/DT molecular/JJ mechanisms/NNS governing/VBG proliferation/NN and/CC leukaemogenesis/NN in/IN these/DT cells/NNS ./. 
Therefore/RB we/PRP analysed/VBD the/DT expression/NN of/IN E2F-DNA/NN binding/NN activity/NN and/CC the/DT constituent/JJ proteins/NNS found/VBN in/IN the/DT complexes/NNS in/IN human/JJ primary/JJ haemopoietic/JJ cells/NNS of/IN various/JJ lineages/NNS ./. 
We/PRP also/RB studied/VBD blasts/NNS from/IN 18/CD patients/NNS with/IN acute/JJ myeloid/JJ leukaemia/NN (/( AML/NN )/) ./. 
On/IN electromobility/NN shift/NN assays/NNS (/( EMSA/NNS )/) a/DT single/JJ E2F-DNA/NN binding/NN complex/NN was/VBD detected/VBN in/IN T/NN cells/NNS ,/, B/NN cells/NNS and/CC monocytes/NNS which/WDT was/VBD shown/VBN to/TO contain/VB E2F-4/NN ,/, DP-1/NN and/CC p130/NN ,/, indicating/VBG that/IN all/DT quiescent/JJ haemopoietic/JJ cells/NNS have/VBP the/DT same/JJ complex/NN ./. 
Examination/NN of/IN 18/CD AML/NN samples/NNS by/IN EMSA/NNS revealed/VBD the/DT presence/NN of/IN E2F/NN binding/NN and/CC no/DT gross/JJ abnormalities/NNS were/VBD detected/VBN ./. 
An/DT E2F-4/p130/NN complex/NN was/VBD detected/VBN in/IN representative/JJ samples/NNS of/IN all/DT FAB/NN types/NNS analysed/VBN ./. 
Thus/RB abnormalities/NNS of/IN E2F/NN function/NN are/VBP unlikely/JJ to/TO play/VB a/DT primary/JJ pathogenic/JJ role/NN in/IN AML/NN ./. 
UI/LS -/: 97184469/CD 
TI/LS -/: Characterization/NN of/IN a/DT mutant/JJ cell/NN line/NN that/WDT does/VBZ not/RB activate/VB NF-kappaB/NN in/IN response/NN to/TO multiple/JJ stimuli/NNS ./. 
AB/LS -/: Numerous/JJ genes/NNS required/VBN during/IN the/DT immune/JJ or/CC inflammation/NN response/NN as/RB well/RB as/IN the/DT adhesion/NN process/NN are/VBP regulated/VBN by/IN nuclear/JJ factor/NN kappaB/NN (/( NF-kappaB/NN )/) ./. 
Associated/VBN with/IN its/PRP$ inhibitor/NN ,/, I/NN kappaB/NN ,/, NF-kappaB/NN resides/VBZ as/IN an/DT inactive/JJ form/NN in/IN the/DT cytoplasm/NN ./. 
Upon/IN stimulation/NN by/IN various/JJ agents/NNS ,/, I/NN kappaB/NN is/VBZ proteolyzed/VBN and/CC NF-kappaB/NN translocates/VBZ to/TO the/DT nucleus/NN ,/, where/WRB it/PRP activates/VBZ its/PRP$ target/NN genes/NNS ./. 
The/DT transduction/NN pathways/NNS that/WDT lead/VBP to/TO I/NN kappaB/NN inactivation/NN remain/VBP poorly/RB understood/VBN ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP characterized/VBN a/DT cellular/JJ mutant/NN ,/, the/DT 70/Z3-derived/JJ 1.3E2/NN murine/JJ pre-B/JJ cell/NN line/NN ,/, that/WDT does/VBZ not/RB activate/VB NF-kappaB/NN in/IN response/NN to/TO several/JJ stimuli/NNS ./. 
We/PRP demonstrate/VBP that/IN upon/IN stimulation/NN by/IN lipopolysaccharide/NN ,/, Taxol/NN ,/, phorbol/NN myristate/NN acetate/NN ,/, interleukin-1/NN ,/, or/CC double-stranded/JJ RNA/NN ,/, I/NN kappaB/NN alpha/NN is/VBZ not/RB degraded/VBN ,/, as/IN a/DT result/NN of/IN an/DT absence/NN of/IN induced/VBN phosphorylation/NN on/IN serines/NNS 32/CD and/CC 36/CD ./. 
Neither/CC a/DT mutation/NN in/IN I/NN kappaB/NN alpha/NN nor/CC a/DT mutation/NN in/IN p50/NN or/CC relA/NN ,/, the/DT two/CD major/JJ subunits/NNS of/IN NF-kappaB/NN in/IN this/DT cell/NN line/NN ,/, accounts/VBZ for/IN this/DT phosphorylation/NN defect/NN ./. 
As/RB well/RB as/IN culminating/VBG in/IN the/DT inducible/JJ phosphorylation/NN of/IN I/NN kappaB/NN alpha/NN on/IN serines/NNS 32/CD and/CC 36/CD ,/, all/PDT the/DT stimuli/NNS that/WDT are/VBP inactive/JJ on/IN 1.3E2/NN cells/NNS exhibit/VBP a/DT sensitivity/NN to/TO the/DT antioxidant/JJ pyrrolidine/NN dithiocarbamate/NN (/( PDTC/NN )/) ./. 
In/IN contrast/NN ,/, stimuli/NNS such/JJ as/IN hyperosmotic/JJ shock/NN or/CC phosphatase/NN inhibitors/NNS ,/, which/WDT use/VBP PDTC-insensitive/JJ pathways/NNS ,/, induce/VBP I/NN kappaB/NN alpha/NN degradation/NN in/IN 1.3E2/NN ./. 
Analysis/NN of/IN the/DT redox/JJ status/NN of/IN 1.3E2/NN does/VBZ not/RB reveal/VB any/DT difference/NN from/IN wild-type/JJ 70Z/3/NN ./. 
We/PRP also/RB report/VBP that/IN the/DT human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) -derived/JJ Tax/NN trans-activator/NN induces/VBZ NF-kappaB/NN activity/NN in/IN 1.3E2/NN ,/, suggesting/VBG that/IN this/DT viral/JJ protein/NN does/VBZ not/RB operate/VB via/IN the/DT defective/JJ pathway/NN ./. 
Finally/RB ,/, we/PRP show/VBP that/IN two/CD other/JJ I/NN kappaB/NN molecules/NNS ,/, I/NN kappaB/NN beta/NN and/CC the/DT recently/RB identified/VBN I/NN kappaB/NN epsilon/NN ,/, are/VBP not/RB degraded/VBN in/IN the/DT 1.3E2/NN cell/NN line/NN following/VBG stimulation/NN ./. 
Our/PRP$ results/NNS demonstrate/VBP that/IN 1.3E2/NN is/VBZ a/DT cellular/JJ transduction/NN mutant/NN exhibiting/VBG a/DT defect/NN in/IN a/DT step/NN that/WDT is/VBZ required/VBN by/IN several/JJ different/JJ stimuli/NNS to/TO activate/VB NF-kappaB/NN ./. 
In/IN addition/NN ,/, this/DT analysis/NN suggests/VBZ a/DT common/JJ step/NN in/IN the/DT signaling/NN pathways/NNS that/WDT trigger/VBP I/NN kappaB/NN alpha/NN ,/, I/NN kappaB/NN beta/NN ,/, and/CC I/NN kappaB/NN epsilon/NN degradation/NN ./. 
UI/LS -/: 97188782/CD 
TI/LS -/: Involvement/NN of/IN Egr-1/RelA/NN synergy/NN in/IN distinguishing/VBG T/NN cell/NN activation/NN from/IN tumor/NN necrosis/NN factor-alpha-induced/JJ NF-kappa/NN B1/NN transcription/NN ./. 
AB/LS -/: NF-kappa/NN B/NN is/VBZ an/DT important/JJ transcription/NN factor/NN required/VBN for/IN T/NN cell/NN proliferation/NN and/CC other/JJ immunological/JJ functions/NNS ./. 
The/DT NF-kappa/NN B1/NN gene/NN encodes/VBZ a/DT 105-kD/JJ protein/NN that/WDT is/VBZ the/DT precursor/NN of/IN the/DT p50/NN component/NN of/IN NF-kappa/NN B/NN ./. 
Previously/RB ,/, we/PRP and/CC others/NNS have/VBP demonstrated/VBN that/IN NF-kappa/NN B/NN regulates/VBZ the/DT NF-kappa/NN B1/NN gene/NN ./. 
In/IN this/DT manuscript/NN we/PRP have/VBP investigated/VBN the/DT molecular/JJ mechanisms/NNS by/IN which/WDT T/NN cell/NN lines/NNS stimulated/VBN with/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) and/CC phytohemagglutin/NN (/( PHA/NN )/) display/VBP significantly/RB higher/JJR levels/NNS of/IN NF-kappa/NN B1/NN encoding/NN transcripts/NNS than/IN cells/NNS stimulated/VBN with/IN tumor/NN necrosis/NN factor-alpha/NN ,/, despite/IN the/DT fact/NN that/IN both/DT stimuli/NNS activate/VBP NF-kappa/NN B/NN ./. 
Characterization/NN of/IN the/DT NF-kappa/NN B1/NN promoter/NN identified/VBD an/DT Egr-1/NN site/NN which/WDT was/VBD found/VBN to/TO be/VB essential/JJ for/IN both/CC the/DT PMA/PHA-mediated/JJ induction/NN as/RB well/RB as/IN the/DT synergistic/JJ activation/NN observed/VBN after/IN the/DT expression/NN of/IN the/DT RelA/NN subunit/NN of/IN NF-kappa/NN B/NN and/CC Egr-1/NN ./. 
Furthermore/RB ,/, Egr-1/NN induction/NN was/VBD required/VBN for/IN endogenous/JJ NF-kappa/NN B1/NN gene/NN expression/NN ,/, since/IN PMA/PHA-stimulated/JJ T/NN cell/NN lines/NNS expressing/VBG antisense/JJ Egr-1/NN RNA/NN were/VBD inhibited/VBN in/IN their/PRP$ ability/NN to/TO upregulate/VB NF-kappa/NN B1/NN transcription/NN ./. 
Our/PRP$ studies/NNS indicate/VBP that/IN transcriptional/JJ synergy/NN mediated/VBN by/IN activation/NN of/IN both/CC Egr-1/NN and/CC NF-kappa/NN B/NN may/MD have/VBP important/JJ ramifications/NNS in/IN T/NN cell/NN development/NN by/IN upregulating/VBG NF-kappa/NN B1/NN gene/NN expression/NN ./. 
UI/LS -/: 97189104/CD 
TI/LS -/: The/DT synthesis/NN and/CC immunogenicity/NN of/IN varicella-zoster/NN virus/NN glycoprotein/NN E/NN and/CC immediate-early/JJ protein/NN (/( IE62/NN )/) expressed/VBN in/IN recombinant/JJ herpes/NN simplex/NN virus-1/NN ./. 
AB/LS -/: In/IN order/NN to/TO evaluate/VB the/DT conditions/NNS for/IN optimal/JJ expression/NN and/CC immunogenicity/NN of/IN varicella-zoster/JJ virus/NN (/( VZV/NN )/) proteins/NNS in/IN a/DT herpes/NN simplex/NN virus-1/NN (/( HSV-1/NN )/) vector/NN ,/, we/PRP selected/VBD the/DT VZV/NN glycoprotein/NN E/NN (/( gE/NN )/) ,/, encoded/VBN by/IN ORF/NN 68/CD and/CC the/DT VZV/NN product/NN of/IN ORF/NN 62/CD ,/, an/DT immediate-early/JJ major/JJ tegument/NN protein/NN (/( IE62/NN )/) ./. 
Three/CD HSV/VZV/NN recombinants/NNS were/VBD generated/VBN :/: (/( 1/LS )/) VZV/NN gE/NN protein/NN coding/NN sequences/NNS along/IN with/IN the/DT promoter/NN region/NN were/VBD inserted/VBN into/IN the/DT thymidine/NN kinase/NN (/( TK/NN )/) gene/NN of/IN HSV-1/NN strain/NN KOS/NN ;/: (/( 2/LS )/) VZV/NN gE/NN expressed/VBN from/IN the/DT HSV-1/NN ICP4/NN promoter/NN was/VBD inserted/VBN into/IN the/DT glycoprotein/NN C/NN (/( gC/NN )/) gene/NN of/IN HSV-1/NN strain/NN F/NN ;/: and/CC (/( 3/LS )/) VZV/NN IE62/NN protein/NN coding/NN sequences/NNS under/IN the/DT control/NN of/IN the/DT HSV-1/NN ICP4/NN promoter/NN were/VBD inserted/VBN into/IN the/DT gC/NN gene/NN of/IN HSV-1/NN strain/NN F/NN ./. 
Immunoblot/NN analysis/NN and/CC immunoperoxidase/NN staining/NN of/IN infected/JJ cell/NN monolayers/NNS demonstrated/VBD vector/NN expression/NN of/IN VZV/NN proteins/NNS ./. 
Following/VBG intracranial/JJ inoculation/NN in/IN mice/NNS ,/, both/CC VZV/NN gE-HSV/NN (/( TK/NN )/) and/CC VZV/NN IE62-HSV/NN (/( gC/NN )/) induced/VBD an/DT IgG/NN response/NN against/IN VZV/NN gE/NN or/CC VZV/NN IE62/NN ./. 
When/WRB tested/VBN in/IN cytotoxicity/NN assays/NNS using/VBG T-lymphocytes/NNS from/IN VZV/NN immune/JJ human/JJ donors/NNS ,/, the/DT range/NN of/IN precursor/NN frequencies/NNS for/IN T-lymphocytes/NNS that/WDT recognized/VBD VZV/NN gE/NN or/CC VZV/NN IE62/NN was/VBD similar/JJ whether/IN these/DT proteins/NNS were/VBD expressed/VBN by/IN HSV-1/NN or/CC a/DT vaccinia/NN vector/NN ./. 
These/DT experiments/NNS demonstrate/VBP that/IN HSV-1/NN is/VBZ a/DT competent/JJ vector/NN for/IN expression/NN of/IN these/DT VZV/NN proteins/NNS and/CC support/VBP the/DT feasibility/NN of/IN engineering/VBG a/DT combined/JJ vaccine/NN for/IN these/DT closely/RB related/JJ alpha-herpesviruses/NNS ./. 
UI/LS -/: 97153085/CD 
TI/LS -/: Constitutive/JJ dephosphorylation/NN and/CC activation/NN of/IN a/DT member/NN of/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS ,/, NF-AT1/NN ,/, in/IN Tax-expressing/JJ and/CC type/NN I/CD human/JJ T-cell/NN leukemia/NN virus-infected/JJ human/JJ T/NN cells/NNS ./. 
AB/LS -/: The/DT tax/NN gene/NN product/NN of/IN the/DT type/NN I/CD human/JJ T-cell/NN leukemia/NN virus/NN (/( HTLV-I/NN )/) transactivates/VBZ interleukin-2/NN (/( IL-2/NN )/) gene/NN through/IN activation/NN of/IN an/DT enhancer/NN termed/VBN CD28/NN responsive/JJ element/NN (/( CD28RE/NN )/) ./. 
Tax/NN activation/NN of/IN the/DT CD28RE/NN is/VBZ partially/RB mediated/VBN by/IN a/DT member/NN of/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS ,/, NF-AT1/NN ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN NF-AT1/NN is/VBZ constitutively/RB active/JJ in/IN Jurkat/NN T/NN cells/NNS stably/RB transfected/VBN with/IN the/DT Tax/NN cDNA/NN ,/, although/IN the/DT underlying/VBG molecular/JJ mechanism/NN and/CC physiological/JJ relevance/NN of/IN this/DT finding/NN remain/VBP unclear/JJ ./. 
In/IN this/DT report/NN ,/, we/PRP demonstrate/VBP that/IN the/DT active/JJ form/NN of/IN NF-AT1/NN is/VBZ also/RB present/JJ in/IN the/DT nuclei/NNS of/IN HTLV-I-transformed/JJ T/NN cells/NNS that/WDT express/VBP the/DT Tax/NN protein/NN ./. 
Interestingly/RB ,/, the/DT constitutive/JJ activation/NN of/IN NF-AT1/NN in/IN these/DT T/NN cells/NNS is/VBZ associated/VBN with/IN its/PRP$ dephosphorylation/NN ./. 
Furthermore/RB ,/, the/DT dephosphorylated/VBN NF-AT1/NN can/MD be/VB rapidly/RB rephosphorylated/VBN when/WRB the/DT cells/NNS are/VBP incubated/VBN with/IN cyclosporin/NN A/NN ,/, an/DT immunosuppressant/NN inhibiting/VBG the/DT serine/threonine/NN phosphatase/NN calcineurin/NN ./. 
These/DT results/NNS suggest/VBP that/IN activation/NN of/IN NF-AT1/NN in/IN Tax-expressing/JJ and/CC HTLV-I-transformed/JJ T/NN cells/NNS results/VBZ from/IN its/PRP$ dephosphorylation/NN ,/, which/WDT in/IN turn/NN may/MD be/VB due/JJ to/TO deregulation/NN of/IN calcineurin/NN 
UI/LS -/: 97265379/CD 
TI/LS -/: Expression/NN of/IN NFAT-family/NN proteins/NNS in/IN normal/JJ human/JJ T/NN cells/NNS ./. 
AB/LS -/: NFAT/NN proteins/NNS constitute/VBP a/DT family/NN of/IN transcription/NN factors/NNS involved/VBN in/IN mediating/VBG signal/NN transduction/NN ./. 
Using/VBG a/DT panel/NN of/IN specific/JJ antisera/NNS in/IN immunoprecipitation/NN assays/NNS ,/, we/PRP found/VBD that/IN NFATp/NN (/( 135/CD kDa/NN )/) is/VBZ constitutively/RB expressed/VBN in/IN normal/JJ human/JJ T/NN cells/NNS ,/, while/IN synthesis/NN of/IN NFATc/NN (/( predominant/JJ form/NN of/IN 86/CD kDa/NN )/) is/VBZ induced/VBN by/IN ionomycin/NN treatment/NN ./. 
NFAT4/x/NN was/VBD very/RB weakly/RB expressed/VBN in/IN unstimulated/JJ cells/NNS ,/, and/CC its/PRP$ level/NN did/VBD not/RB increase/VB upon/IN treatment/NN with/IN activating/VBG agents/NNS ./. 
NFAT3/NN protein/NN was/VBD not/RB observed/VBN under/IN any/DT conditions/NNS ./. 
Higher-molecular-weight/JJ species/NNS of/IN NFATc/NN (/( of/IN 110/CD and/CC 140/CD kDa/NN )/) were/VBD also/RB detected/VBN ./. 
In/IN addition/NN ,/, translation/NN of/IN NFATc/NN mRNA/NN apparently/RB initiates/VBZ at/IN two/CD different/JJ AUG/NN codons/NNS ,/, giving/VBG rise/NN to/TO proteins/NNS that/WDT differ/VBP in/IN size/NN by/IN 36/CD amino/NN acids/NNS ./. 
Additional/JJ size/NN heterogeneity/NN of/IN both/CC NFATc/NN and/CC NFATp/NN results/VBZ from/IN phosphorylation/NN ./. 
In/IN contrast/NN to/TO ionomycin/NN treatment/NN ,/, exposure/NN of/IN cells/NNS to/TO phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) plus/CC anti-CD28/NN did/VBD not/RB induce/VB NFATc/NN ,/, indicating/VBG that/IN under/IN these/DT conditions/NNS ,/, interleukin-2/NN synthesis/NN by/IN these/DT cells/NNS is/VBZ apparently/RB independent/JJ of/IN NFATc/NN ./. 
In/IN DNA/NN binding/NN assays/NNS ,/, both/CC PMA/NN plus/CC anti-CD28/NN and/CC PMA/NN plus/CC ionomycin/NN resulted/VBD in/IN nuclear/JJ NFAT/NN ./. 
Surprisingly/RB ,/, the/DT PMA-ionomycin-induced/JJ synthesis/NN of/IN NFATc/NN that/WDT was/VBD detected/VBN by/IN immunoprecipitation/NN was/VBD not/RB mirrored/VBN in/IN the/DT DNA/NN binding/NN assays/NNS :/: nearly/RB all/DT of/IN the/DT activity/NN was/VBD due/JJ to/TO NFATp/NN ./. 
This/DT is/VBZ the/DT first/JJ study/NN of/IN expression/NN of/IN all/DT family/NN members/NNS at/IN the/DT protein/NN level/NN in/IN normal/JJ human/JJ T/NN cells/NNS ./. 
UI/LS -/: 97353180/CD 
TI/LS -/: Of/IN the/DT GATA-binding/JJ proteins/NNS ,/, only/RB GATA-4/NN selectively/RB regulates/VBZ the/DT human/JJ IL-5/NN gene/NN promoter/NN in/IN IL-5/NN producing/NN cells/NNS which/WDT express/VBP multiple/JJ GATA-binding/JJ proteins/NNS ./. 
AB/LS -/: Interleukin-5/NN (/( IL-5/NN )/) is/VBZ produced/VBN by/IN T/NN lymphocytes/NNS and/CC known/VBN to/TO support/VB B/NN cell/NN growth/NN and/CC eosinophilic/JJ differentiation/NN of/IN the/DT progenitor/NN cells/NNS ./. 
Using/VBG ATL-16T/NN cells/NNS which/WDT express/VBP IL-5/NN mRNA/NN ,/, we/PRP have/VBP identified/VBN a/DT region/NN ,/, within/IN the/DT human/JJ IL-5/NN gene/NN promoter/NN ,/, that/WDT regulates/VBZ IL-5/NN gene/NN transcription/NN ./. 
This/DT cis-acting/JJ sequence/NN contains/VBZ the/DT core/NN binding/NN motif/NN ,/, (A/T)GATA(A/G)/NN ,/, for/IN GATA-binding/NN family/NN proteins/NNS and/CC thus/RB suggests/VBZ the/DT involvement/NN of/IN these/DT family/NN members/NNS ./. 
In/IN this/DT report/NN ,/, we/PRP describe/VBP the/DT cloning/NN of/IN human/JJ GATA-4/NN (/( hGATA-4/NN )/) and/CC show/VBP that/IN hGATA-4/NN selectively/RB interacts/VBZ with/IN the/DT -70/CD GATA/NN site/NN within/IN the/DT IL-5/NN proximal/JJ promoter/NN region/NN ./. 
By/IN promoter/NN deletion/NN and/CC mutation/NN analyses/NNS ,/, we/PRP established/VBD this/DT region/NN as/IN a/DT positive/JJ regulatory/JJ element/NN ./. 
Cotransfection/NN experiments/NNS revealed/VBD that/IN both/CC hGATA-4/NN and/CC PMA/A23187/NN stimulation/NN are/VBP necessary/JJ for/IN the/DT IL-5/NN promoter/NN activation/NN ./. 
The/DT requirement/NN of/IN another/DT regulatory/JJ element/NN called/VBN CLE0/NN ,/, which/WDT lies/VBZ downstream/RB of/IN the/DT -70/CD GATA/NN site/NN ,/, was/VBD also/RB demonstrated/VBN ./. 
ATL-16T/NN cells/NNS express/VBP mRNA/NN of/IN three/CD GATA-binding/JJ proteins/NNS ,/, hGATA-2/NN ,/, hGATA-3/NN and/CC hGATA-4/NN ,/, and/CC each/DT of/IN them/PRP has/VBZ a/DT potential/NN to/TO bind/VB to/TO the/DT consensus/NN (A/T)GATA(G/ A)/NN motif/NN ./. 
However/RB ,/, using/VBG ATL-16T/NN nuclear/JJ extract/NN ,/, we/PRP demonstrated/VBD that/IN GATA-4/NN is/VBZ the/DT only/RB GATA-binding/JJ protein/NN that/WDT forms/VBZ specific/JJ DNA-protein/JJ complex/NN with/IN the/DT -70/CD GATA/NN site/NN ./. 
The/DT electrophoretic/JJ mobility/NN shift/NN assay/NN with/IN extracts/NNS of/IN COS/NN cells/NNS expressing/VBG GATA-binding/JJ proteins/NNS showed/VBD that/IN GATA-4/NN has/VBZ the/DT highest/JJS binding/NN affinity/NN to/TO the/DT -70/CD GATA/NN site/NN among/IN the/DT three/CD GATA-binding/JJ proteins/NNS ./. 
When/WRB the/DT transactivation/NN ability/NN was/VBD compared/VBN among/IN the/DT three/CD ,/, GATA-4/NN showed/VBD the/DT highest/JJS activity/NN ./. 
These/DT results/NNS demonstrate/VBP the/DT selective/JJ role/NN of/IN GATA-4/NN in/IN the/DT transcriptional/JJ regulation/NN of/IN the/DT IL-5/NN gene/NN in/IN a/DT circumstance/NN where/WRB multiple/JJ members/NNS of/IN the/DT GATA-binding/JJ proteins/NNS are/VBP expressed/VBN ./. 
UI/LS -/: 97219997/CD 
TI/LS -/: Control/NN of/IN NFATx1/NN nuclear/JJ translocation/NN by/IN a/DT calcineurin-regulated/JJ inhibitory/JJ domain/NN ./. 
AB/LS -/: The/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) regulates/VBZ cytokine/NN gene/NN expression/NN in/IN T/NN cells/NNS through/IN cis-acting/JJ elements/NNS located/JJ in/IN the/DT promoters/NNS of/IN several/JJ cytokine/NN genes/NNS ./. 
NFATx1/NN ,/, which/WDT is/VBZ preferentially/RB expressed/VBN in/IN the/DT thymus/NN and/CC peripheral/JJ blood/NN leukocytes/NNS ,/, is/VBZ one/CD of/IN four/CD members/NNS of/IN the/DT NFAT/NN family/NN of/IN transcription/NN factors/NNS ./. 
We/PRP have/VBP performed/VBN domain/NN analysis/NN of/IN NFATx1/NN by/IN examining/VBG the/DT effects/NNS of/IN deletion/NN mutations/NNS ./. 
We/PRP found/VBD that/IN NFATx1/NN DNA/NN binding/NN activity/NN and/CC interaction/NN with/IN AP-1/NN polypeptides/NNS were/VBD dependent/JJ on/IN its/PRP$ central/JJ Rel/NN similarity/NN region/NN and/CC that/IN transcriptional/JJ activation/NN was/VBD reduced/VBN by/IN deletions/NNS of/IN either/CC its/PRP$ N-terminal/JJ domain/NN or/CC its/PRP$ C-terminal/JJ domain/NN ,/, suggesting/VBG the/DT presence/NN of/IN intrinsic/JJ transcriptional/JJ activation/NN motifs/NNS in/IN both/DT regions/NNS ./. 
We/PRP also/RB identified/VBD a/DT potent/JJ inhibitory/JJ sequence/NN within/IN its/PRP$ N-terminal/JJ domain/NN ./. 
We/PRP show/VBP that/IN the/DT inactivation/NN of/IN the/DT inhibition/NN was/VBD dependent/JJ on/IN the/DT activity/NN of/IN calcineurin/NN ,/, a/DT calcium-calmodulin-dependent/JJ phosphatase/NN ./. 
We/PRP also/RB show/VBP that/IN calcineurin/NN associated/VBD with/IN the/DT N-terminal/JJ domain/NN of/IN NFATx1/NN at/IN multiple/JJ docking/NN sites/NNS and/CC caused/VBD a/DT reduction/NN of/IN size/NN ,/, indicative/JJ of/IN dephosphorylation/NN ,/, in/IN NFATx1/NN ./. 
We/PRP have/VBP mapped/VBN the/DT inhibitory/JJ activity/NN to/TO less/JJR than/IN 60/CD residues/NNS ,/, containing/VBG motifs/NNS that/WDT are/VBP conserved/VBN in/IN all/DT NFAT/NN proteins/NNS ./. 
Finally/RB ,/, we/PRP demonstrate/VBP that/IN deletion/NN in/IN NFATx1/NN of/IN the/DT mapped/VBN 60/CD residues/NNS leads/VBZ to/TO its/PRP$ nuclear/JJ translocation/NN independent/JJ of/IN calcium/NN signaling/NN ./. 
Our/PRP$ results/NNS support/VBP the/DT model/NN proposing/VBG that/IN the/DT N-terminal/JJ domain/NN confers/VBZ calcium-signaling/JJ dependence/NN on/IN NFATx1/NN transactivation/NN activity/NN by/IN regulating/VBG its/PRP$ intracellular/JJ localization/NN through/IN a/DT protein/NN module/NN that/WDT associates/VBZ with/IN calcineurin/NN and/CC is/VBZ a/DT target/NN of/IN its/PRP$ phosphatase/NN activity/NN ./. 
UI/LS -/: 97226013/CD 
TI/LS -/: Neuronal/JJ (/( type/NN I/CD )/) nitric/JJ oxide/NN synthase/NN regulates/VBZ nuclear/JJ factor/NN kappaB/NN activity/NN and/CC immunologic/JJ (/( type/NN II/CD )/) nitric/JJ oxide/NN synthase/NN expression/NN ./. 
AB/LS -/: Nitric/JJ oxide/NN subserves/VBZ diverse/JJ physiologic/JJ roles/NNS in/IN the/DT nervous/JJ system/NN ./. 
NO/NN is/VBZ produced/VBN from/IN at/IN least/JJS three/CD different/JJ NO/NN synthase/NN (/( NOS/NN )/) isoforms/NNS :/: neuronal/JJ NOS/NN (/( nNOS/NN )/) ,/, endothelial/JJ NOS/NNS ,/, and/CC immunologic/JJ NOS/NN (/( iNOS/NN )/) ./. 
We/PRP show/VBP that/IN nNOS/NN is/VBZ the/DT predominant/JJ isoform/NN constitutively/RB expressed/VBN in/IN glia/NN ./. 
NO/NN derived/VBN from/IN nNOS/NN in/IN glia/NN inhibits/VBZ the/DT transcription/NN factor/NN nuclear/JJ factor/NN kappaB/NN (/( NF/NN kappaB/NN )/) as/IN NOS/NN inhibitors/NNS enhance/VBP basal/JJ NF/NN kappaB/NN activation/NN ./. 
Pyrrolidine/NN dithiocarbamate/NN (/( PDTC/NN )/) is/VBZ an/DT inhibitor/NN of/IN NF/NN kappaB/NN in/IN most/JJS cells/NNS ;/: however/RB ,/, we/PRP show/VBP that/IN PDTC/NN is/VBZ also/RB a/DT potent/JJ scavenger/NN of/IN NO/NN through/IN formation/NN of/IN mononitrosyl/NN iron/NN complexes/NNS with/IN PDTC/NN ./. 
In/IN Jurkat/NN cells/NNS ,/, a/DT human/JJ T-cell/NN lymphoma/NN cell/NN line/NN ,/, tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) induces/VBZ NF/NN kappaB/NN activation/NN that/WDT is/VBZ inhibited/VBN by/IN PDTC/NN ./. 
Contrary/JJ to/TO the/DT results/NNS in/IN Jurkat/NN cells/NNS ,/, PDTC/NN did/VBD not/RB inhibit/VB tumor/NN necrosis/NN factor-alpha-induced/JJ NF/NN kappaB/NN activation/NN in/IN astrocytes/NNS ;/: instead/RB PDTC/NN itself/PRP induces/VBZ NF/JJ kappaB/NN activation/NN in/IN astrocytes/NNS ,/, and/CC this/DT may/MD be/VB related/JJ to/TO scavenging/NN of/IN endogenously/RB produced/VBD NO/NN by/IN the/DT PDTC/NN iron/NN complex/NN ./. 
In/IN astrocytes/NNS PDTC/NN also/RB dramatically/RB induces/VBZ the/DT NF/NN kappaB-/NN dependent/JJ enzyme/NN ,/, iNOS/NN ,/, supporting/VBG the/DT physiologic/JJ relevance/NN of/IN endogenous/JJ NO/NN regulation/NN of/IN NF/NN kappaB/NN ./. 
NF/NN kappaB/NN activation/NN in/IN glia/NN from/IN mice/NNS lacking/VBG nNOS/NN responds/VBZ more/RBR rapidly/RB to/TO PDTC/NN compared/VBN with/IN astrocytes/NNS from/IN wild-type/JJ mice/NNS ./. 
Our/PRP$ data/NNS suggest/VBP that/IN nNOS/NN in/IN astrocytes/NNS regulates/VBZ NF/NN kappaB/NN activity/NN and/CC iNOS/NN expression/NN ,/, and/CC indicate/VBP a/DT novel/JJ regulatory/JJ role/NN for/IN nNOS/NN in/IN tonically/RB suppressing/VBG central/JJ nervous/JJ system/NN ,/, NF/NN kappaB-regulated/JJ genes/NNS ./. 
UI/LS -/: 97300620/CD 
TI/LS -/: Involvement/NN of/IN Stat3/NN in/IN interleukin-6-induced/JJ IgM/NN production/NN in/IN a/DT human/JJ B-cell/NN line/NN ./. 
AB/LS -/: Interleukin-6/NN (/( IL-6/NN )/) is/VBZ an/DT important/JJ B-cell/NN growth/NN and/CC differentiation/NN factor/NN ./. 
IL-6/NN treatment/NN of/IN the/DT human/JJ lymphoblastoid/JJ cell/NN line/NN ,/, SKW6.4/NN ,/, leads/VBZ to/TO increased/VBN IgM/NN production/NN ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN IL-6/NN induces/VBZ activation/NN of/IN JAK1/NN and/CC JAK2/NN in/IN human/JJ B/NN cell/NN lines/NNS ./. 
A/DT chimeric/JJ IL-6/NN receptor/NN ,/, comprised/VBD of/IN the/DT intracellular/JJ tail/NN of/IN the/DT IL-6/NN receptor/NN subunit/NN gp130/NN fused/VBN to/TO the/DT extracellular/JJ domain/NN of/IN the/DT epidermal/JJ growth/NN factor/NN (/( EGF/NN )/) receptor/NN ,/, was/VBD stably/RB transfected/VBN into/IN SKW6.4/NN cells/NNS ./. 
EGF/NN treatment/NN induced/VBD IgM/NN production/NN in/IN cells/NNS transfected/VBN with/IN an/DT intact/JJ gp130/NN cytoplasmic/JJ tail/NN ,/, but/CC not/RB in/IN untransfected/JJ cells/NNS or/CC cells/NNS transfected/VBN with/IN a/DT cytoplasmic/JJ tail/NN lacking/VBG all/DT four/CD signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( Stat/NN )/) binding/NN sites/NNS ./. 
Moreover/RB ,/, EGF/NN treatment/NN induced/VBD Stat3/NN phosphorylation/NN in/IN cells/NNS transfected/VBN with/IN the/DT intact/JJ chimeric/JJ EGF-gp130/NN receptor/NN along/IN with/IN induction/NN of/IN DNA-mobility/JJ shift/NN of/IN a/DT classical/JJ interferon-gamma-activated/JJ site/NN ./. 
To/TO define/VB further/RB the/DT relation/NN between/IN Stat3/NN activation/NN and/CC enhanced/VBN IgM/NN production/NN ,/, we/PRP determined/VBD the/DT effect/NN of/IN chimeric/JJ gp130/NN on/IN the/DT transcriptional/JJ activation/NN of/IN a/DT genetic/JJ element/NN linked/VBN to/TO immunoglobulin/NN production/NN ,/, namely/RB the/DT immunoglobulin/NN heavy/JJ chain/NN enhancer/NN (/( IgH-enhancer/NN )/) ./. 
Parental/JJ as/RB well/RB as/IN transfected/VBN SKW6.4/NN cells/NNS were/VBD transiently/RB transfected/VBN with/IN an/DT IgH-enhancer-luciferase/JJ construct/NN ./. 
The/DT transcriptional/JJ activity/NN of/IN the/DT IgH-luciferase/JJ construct/NN was/VBD induced/VBN upon/IN ligation/NN of/IN the/DT full-length/JJ chimeric/JJ receptor/NN but/CC not/RB by/IN truncated/VBN gp130/NN receptors/NNS ./. 
Moreover/RB ,/, the/DT gp130-induced/JJ activity/NN of/IN this/DT reporter/NN gene/NN was/VBD abrogated/VBN by/IN Stat3EE/NN ,/, a/DT mutant/JJ Stat3/NN incapable/JJ of/IN binding/VBG DNA/NN ./. 
These/DT results/NNS indicate/VBP that/IN IL-6-induced/JJ B-cell/NN differentiation/NN ,/, as/IN measured/VBN by/IN IgM/NN production/NN ,/, may/MD be/VB controlled/VBN by/IN Stat3/NN proteins/NNS ./. 
UI/LS -/: 97236919/CD 
TI/LS -/: T-lymphocytes/NNS from/IN individuals/NNS with/IN filarial/JJ inflammatory/JJ disease/NN have/VBP increased/VBN transendothelial/JJ migration/NN in/FW vitro/FW ./. 
AB/LS -/: The/DT in/FW vitro/FW transendothelial/JJ migration/NN of/IN circulating/VBG filarial/JJ antigen-specific/JJ T-cells/NNS was/VBD examined/VBN in/IN Wuchereria/FW banerofti/FW infection/NN ./. 
Circulating/VBG T-cells/NNS from/IN individuals/NNS with/IN filaria-induced/JJ lymphatic/JJ pathology/NN (/( LP/NN )/) had/VBD significantly/RB greater/JJR migration/NN through/IN unstimulated/JJ HUVEC/NN monolayers/NNS than/IN did/VBD T-cells/NNS from/IN asymptomatic/JJ infected/JJ (/( MF/NN )/) individuals/NNS (/( P/NN =/JJ 0.04/CD )/) ./. 
In/IN contrast/NN to/TO the/DT MF/NN individuals/NNS where/WRB no/DT effect/NN was/VBD seen/VBN ,/, transendothelial/JJ migration/NN of/IN 48-hr/JJ filarial/JJ antigen/NN stimulated/JJ T-cells/NNS from/IN LP/NN individuals/NNS was/VBD significantly/RB (/( P/NN =/JJ 0.01/CD )/) greater/JJR than/IN migration/NN of/IN 48-hr/JJ media-stimulated/JJ T-cells/NNS ./. 
In/IN six/CD of/IN seven/CD patients/NNS examined/VBN ,/, inhibition/NN of/IN the/DT VLA-4/VCAM-1/NN pathway/NN resulted/VBD in/IN greater/JJR than/IN 50/CD %/NN inhibition/NN of/IN transendothelial/JJ migration/NN of/IN T-cells/NNS ./. 
UI/LS -/: 97184463/CD 
TI/LS -/: Transcriptional/JJ regulation/NN of/IN the/DT ferritin/NN heavy-chain/JJ gene/NN :/: the/DT activity/NN of/IN the/DT CCAAT/NN binding/NN factor/NN NF-Y/NN is/VBZ modulated/VBN in/IN heme-treated/JJ Friend/NN leukemia/NN cells/NNS and/CC during/IN monocyte-to-macrophage/JJ differentiation/NN ./. 
AB/LS -/: The/DT ferritin/NN H-chain/JJ gene/NN promoter/NN regulation/NN was/VBD analyzed/VBN in/IN heme-treated/JJ Friend/NN leukemia/NN cells/NNS (/( FLCs/NNS )/) and/CC during/IN monocyte-to-macrophage/JJ differentiation/NN ./. 
In/IN the/DT majority/NN of/IN cell/NN lines/NNS studied/VBN ,/, the/DT regulation/NN of/IN ferritin/NN expression/NN was/VBD exerted/VBN mostly/RB at/IN the/DT translational/JJ level/NN ./. 
However/RB ,/, in/IN differentiating/VBG erythroid/JJ cells/NNS ,/, which/WDT must/MD incorporate/VB high/JJ levels/NNS of/IN iron/NN to/TO sustain/VB hemoglobin/NN synthesis/NN ,/, and/CC in/IN macrophages/NNS ,/, which/WDT are/VBP involved/VBN in/IN iron/NN storage/NN ,/, transcriptional/JJ regulation/NN seemed/VBD to/TO be/VB a/DT relevant/JJ mechanism/NN ./. 
We/PRP show/VBP here/RB that/IN the/DT minimum/JJ region/NN of/IN the/DT ferritin/NN H-gene/NN promoter/NN that/WDT is/VBZ able/JJ to/TO confer/VB transcriptional/JJ regulation/NN by/IN heme/NN in/IN FLCs/NNS to/TO a/DT reporter/NN gene/NN is/VBZ 77/CD nucleotides/NNS upstream/JJ of/IN the/DT TATA/NN box/NN ./. 
This/DT cis/JJ element/NN binds/VBZ a/DT protein/NN complex/NN referred/VBN to/TO as/IN HRF/NN (/( heme-responsive/JJ factor/NN )/) ,/, which/WDT is/VBZ greatly/RB enhanced/VBN both/CC in/IN heme-treated/JJ FLCs/NNS and/CC during/IN monocyte-to-macrophage/JJ differentiation/NN ./. 
The/DT CCAAT/NN element/NN present/JJ in/IN reverse/JJ orientation/NN in/IN this/DT promoter/NN region/NN of/IN the/DT ferritin/NN H-chain/JJ gene/NN is/VBZ necessary/JJ for/IN binding/NN and/CC for/IN gene/NN activity/NN ,/, since/IN a/DT single/JJ point/NN mutation/NN is/VBZ able/JJ to/TO abolish/VB the/DT binding/NN of/IN HRF/NN and/CC the/DT transcriptional/JJ activity/NN in/IN transfected/VBN cells/NNS ./. 
By/IN competition/NN experiments/NNS and/CC supershift/NN assays/NNS ,/, we/PRP identified/VBD the/DT induced/VBN HRF/NN as/IN containing/VBG at/IN least/JJS the/DT ubiquitous/JJ transcription/NN factor/NN NF-Y/NN ./. 
NF-Y/NN is/VBZ formed/VBN by/IN three/CD subunits/NNS ,/, A/DT ,/, B/NN ,/, and/CC C/NN ,/, all/DT of/IN which/WDT are/VBP necessary/JJ for/IN DNA/NN binding/NN ./. 
Cotransfection/NN with/IN a/DT transdominant/JJ negative/JJ mutant/NN of/IN the/DT NF-YA/NN subunit/NN abolishes/VBZ the/DT transcriptional/JJ activation/NN by/IN heme/NN ,/, indicating/VBG that/IN NF-Y/NN plays/VBZ an/DT essential/JJ role/NN in/IN this/DT activation/NN ./. 
We/PRP have/VBP also/RB observed/VBN a/DT differential/JJ expression/NN of/IN the/DT NF-YA/NN subunit/NN in/IN heme-treated/JJ and/CC control/JJ FLCs/NNS and/CC during/IN monocyte-to-macrophage/JJ differentiation/NN ./. 
UI/LS -/: 97332608/CD 
TI/LS -/: Concomitant/JJ downregulation/NN of/IN IgH/NN 3'/JJ enhancer/NN activity/NN and/CC c-myc/NN expression/NN in/IN a/DT plasmacytoma/NN x/NN fibroblast/NN environment/NN :/: implications/NNS for/IN dysregulation/NN of/IN translocated/VBN c-myc/NN ./. 
AB/LS -/: Regulation/NN of/IN immunoglobulin/NN heavy/JJ chain/NN (/( IgH/NN )/) gene/NN expression/NN is/VBZ controlled/VBN by/IN a/DT B/NN cell-specific/JJ promoter/NN ,/, intronic/JJ enhancer/NN and/CC additional/JJ B/NN cell-specific/JJ enhancer/NN elements/NNS identified/VBN recently/RB in/IN the/DT 3'/JJ end/NN of/IN the/DT IgH/NN locus/NN ./. 
One/CD of/IN the/DT latter/JJ elements/NNS ,/, the/DT IgH/NN 3'/JJ enhancer/NN ,/, is/VBZ of/IN particular/JJ interest/NN :/: (/( 1/LS )/) it/PRP is/VBZ B/NN cell-specific/JJ and/CC active/JJ only/RB in/IN late/JJ B/NN cell/NN development/NN ;/: (/( 2/LS )/) in/IN rodent/JJ plasmacytomas/NNS and/CC in/IN some/DT human/JJ Burkitt/NN 's/POS lymphomas/NNS it/PRP is/VBZ part/NN of/IN a/DT locus/NN control/NN region/NN (/( LCR/NN )/) that/WDT is/VBZ involved/VBN in/IN deregulation/NN of/IN the/DT c-myc/NN oncogene/NN as/IN a/DT result/NN of/IN translocation/NN into/IN the/DT IgH/NN locus/NN ;/: and/CC (/( 3/LS )/) it/PRP has/VBZ been/VBN implicated/VBN in/IN the/DT mechanisms/NNS that/WDT control/VBP Ig/NN gene/NN class/NN switch/NN recombination/NN ./. 
We/PRP have/VBP used/VBN a/DT somatic/JJ cell/NN hybridization/NN approach/NN to/TO genetically/RB analyse/VB regulation/NN of/IN the/DT activity/NN of/IN the/DT IgH/NN 3'/JJ enhancer/NN ./. 
When/WRB mouse/NN MPC11/NN plasmacytoma/NN cells/NNS ,/, in/IN which/WDT the/DT IgH/NN 3'/JJ enhancer/NN is/VBZ active/JJ ,/, are/VBP fused/VBN with/IN fibroblasts/NNS ,/, Ig/NN expression/NN is/VBZ extinguished/VBN at/IN the/DT level/NN of/IN transcription/NN ./. 
Here/RB we/PRP show/VBP that/IN in/IN a/DT MPC11/NN plasmacytoma/NN x/NN fibroblast/NN environment/NN ,/, the/DT IgH/NN 3'/JJ enhancer/NN is/VBZ transcriptionally/RB inactive/JJ ./. 
Furthermore/RB ,/, we/PRP demonstrate/VBP that/IN binding/NN of/IN several/JJ B/NN cell-specific/JJ transcription/NN factors/NNS ,/, essential/JJ for/IN IgH/NN 3'/JJ enhancer/NN activity/NN ,/, is/VBZ lacking/VBG ,/, which/WDT may/MD explain/VB 3'/JJ enhancer/NN inactivity/NN ,/, although/IN the/DT binding/NN of/IN repressors/NNS can/MD not/RB be/VB excluded/VBN ./. 
Moreover/RB ,/, the/DT high/JJ expression/NN level/NN of/IN c-myc/NN ,/, characteristic/JJ of/IN the/DT parental/JJ MPC11/NN cells/NNS carrying/VBG the/DT t(12;15)/NN translocation/NN ,/, is/VBZ down-regulated/VBN in/IN the/DT hybrids/NNS to/TO that/DT in/IN unfused/JJ fibroblasts/NNS ./. 
Therefore/RB ,/, inactivation/NN of/IN the/DT IgH/NN 3'/JJ enhancer/NN is/VBZ a/DT multifactorial/JJ process/NN affecting/VBG several/JJ transcription/NN factors/NNS that/WDT control/VBP the/DT cell-specific/JJ and/CC developmental/JJ activity/NN of/IN the/DT enhancer/NN ./. 
UI/LS -/: 97184665/CD 
TI/LS -/: Activation/NN of/IN the/DT NF-kappaB/NN transcription/NN factor/NN in/IN a/DT T-lymphocytic/JJ cell/NN line/NN by/IN hypochlorous/JJ acid/NN ./. 
AB/LS -/: Reactive/JJ oxygen/NN species/NNS (/( ROS/NNS )/) such/JJ as/IN hydrogen/NN peroxide/NN serve/VBP as/IN second/JJ messengers/NNS in/IN the/DT induction/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN ,/, and/CC hence/RB in/IN the/DT activation/NN and/CC replication/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) in/IN human/JJ cells/NNS ./. 
During/IN inflammatory/JJ reactions/NNS ,/, many/JJ oxidative/JJ species/NNS are/VBP produced/VBN ,/, one/CD of/IN which/WDT is/VBZ hypochlorous/JJ acid/NN (/( HOCl/NN )/) ,/, which/WDT is/VBZ responsible/JJ for/IN the/DT microbicidal/JJ effects/NNS of/IN activated/VBN human/JJ polymorphonuclear/JJ leukocytes/NNS ./. 
Treatment/NN of/IN a/DT T-lymphocytic/JJ cell/NN line/NN with/IN micromolar/JJ concentrations/NNS of/IN HOCl/NN promoted/VBD the/DT appearance/NN of/IN transcription/NN factor/NN NF-kappaB/NN (/( the/DT heterodimer/NN p50/p65/NN )/) in/IN the/DT nucleus/NN of/IN the/DT cells/NNS ,/, even/RB in/IN the/DT absence/NN of/IN de/FW novo/FW protein/NN synthesis/NN ./. 
Western/NN blot/NN analysis/NN of/IN the/DT NF-kappaB/NN inhibitory/JJ subunits/NNS (/( IkappaB/NN )/) demonstrated/VBD that/IN both/CC IkappaB-alpha/NN proteolysis/NN and/CC p105/NN processing/NN were/VBD induced/VBN by/IN the/DT treatment/NN ./. 
NF-kappaB/NN activation/NN was/VBD very/RB effective/JJ when/WRB cells/NNS were/VBD subjected/VBN to/TO hyperthermia/NN before/IN being/VBG treated/VBN with/IN HOCl/NN ./. 
Various/JJ antioxidants/NNS ,/, such/JJ as/IN pyrrolidine/NN dithiocarbamate/NN ,/, p-bromophenacyl-bromide/NN and/CC nordihydroguaiaretic/JJ acid/NN could/MD strongly/RB reduce/VB NF-kappaB/NN translocation/NN ,/, demonstrating/VBG the/DT importance/NN of/IN oxidative/JJ species/NNS in/IN the/DT transduction/NN mechanism/NN ./. 
Moreover/RB ,/, ACH-2/NN cells/NNS treated/VBN with/IN HOCl/NN or/CC H2O2/NN released/VBD tumour/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) in/IN the/DT supernatants/NNS ./. 
The/DT importance/NN of/IN TNF-alpha/NN release/NN in/IN NF-kappaB/NN induction/NN by/IN HOCl/NN or/CC H2O2/NN was/VBD demonstrated/VBN by/IN the/DT fact/NN that/IN :/: (/( 1/LS )/) the/DT nuclear/JJ appearance/NN of/IN NF-kappaB/NN was/VBD promoted/VBN in/IN untreated/JJ cells/NNS ;/: and/CC (/( 2/LS )/) synergism/NN between/IN TNF-alpha/NN and/CC HOCl/NN was/VBD detected/VBN ./. 
Collectively/RB ,/, these/DT results/NNS suggest/VBP that/IN HOCl/NN should/MD be/VB considered/VBN as/IN an/DT oxidative/JJ species/NNS capable/JJ of/IN inducing/VBG NF-kappaB/NN in/IN a/DT T-lymphocytic/JJ cell/NN line/NN through/IN a/DT transduction/NN mechanism/NN involving/VBG ROS/NNS ,/, and/CC having/VBG a/DT long-distance/JJ effect/NN through/IN subsequent/JJ TNF-alpha/NN release/NN ./. 
UI/LS -/: 97180928/CD 
TI/LS -/: Rapid/JJ Ca2+-mediated/JJ activation/NN of/IN Rap1/NN in/IN human/JJ platelets/NNS ./. 
AB/LS -/: Rap1/NN is/VBZ a/DT small/JJ ,/, Ras-like/JJ GTPase/NN whose/WP$ function/NN and/CC regulation/NN are/VBP still/RB largely/RB unknown/JJ ./. 
We/PRP have/VBP developed/VBN a/DT novel/JJ assay/NN to/TO monitor/VB the/DT active/JJ ,/, GTP-bound/JJ form/NN of/IN Rap1/NN based/VBN on/IN the/DT differential/JJ affinity/NN of/IN Rap1GTP/NN and/CC Rap1GDP/NN for/IN the/DT Rap/NN binding/NN domain/NN of/IN RalGDS/NN (/( RBD/NN )/) ./. 
Stimulation/NN of/IN blood/NN platelets/NNS with/IN alpha-thrombin/NN or/CC other/JJ platelet/NN activators/NNS caused/VBD a/DT rapid/JJ and/CC strong/JJ induction/NN of/IN Rap1/NN that/WDT associated/VBD with/IN RBD/NN in/FW vitro/FW ./. 
Binding/NN to/TO RBD/NN increased/VBD from/IN undetectable/JJ levels/NNS in/IN resting/VBG platelets/NNS to/TO >/JJR 50/CD %/NN of/IN total/JJ Rap1/NN within/IN 30/CD s/NN after/IN stimulation/NN ./. 
An/DT increase/NN in/IN the/DT intracellular/JJ Ca2+/NN concentration/NN is/VBZ both/CC necessary/JJ and/CC sufficient/JJ for/IN Rap1/NN activation/NN since/IN it/PRP was/VBD induced/VBN by/IN agents/NNS that/WDT increase/VBP intracellular/JJ Ca2+/NN and/CC inhibited/VBN by/IN a/DT Ca2+-chelating/JJ agent/NN ./. 
Neither/CC inhibition/NN of/IN translocation/NN of/IN Rap1/NN to/TO the/DT cytoskeleton/NN nor/CC inhibition/NN of/IN platelet/NN aggregation/NN affected/VBD thrombin-induced/JJ activation/NN of/IN Rap1/NN ./. 
In/IN contrast/NN ,/, prostaglandin/NN I2/NN (/( PGI2/NN )/) ,/, a/DT strong/JJ negative/JJ regulator/NN of/IN platelet/NN function/NN ,/, inhibited/VBD agonist-induced/JJ as/RB well/RB as/IN Ca2+-induced/JJ activation/NN of/IN Rap1/NN ./. 
From/IN our/PRP$ results/NNS ,/, we/PRP conclude/VBP that/IN Rap1/NN activation/NN in/IN platelets/NNS is/VBZ an/DT important/JJ common/JJ event/NN in/IN early/JJ agonist-induced/JJ signalling/NN ,/, and/CC that/IN this/DT activation/NN is/VBZ mediated/VBN by/IN an/DT increased/VBN intracellular/JJ Ca2+/NN concentration/NN 
UI/LS -/: 97248400/CD 
TI/LS -/: Physical/JJ interactions/NNS between/IN Ets/NN and/CC NF-kappaB/NFAT/NN proteins/NNS play/VBP an/DT important/JJ role/NN in/IN their/PRP$ cooperative/JJ activation/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN enhancer/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: The/DT transcriptional/JJ regulatory/JJ elements/NNS of/IN many/JJ inducible/JJ T-cell/NN genes/NNS contain/VBP adjacent/JJ or/CC overlapping/VBG binding/VBG sites/NNS for/IN the/DT Ets/NN and/CC NF-kappaB/NFAT/NN families/NNS of/IN transcription/NN factors/NNS ./. 
Similar/JJ arrays/NNS of/IN functionally/RB important/JJ NF-kappaB/NFAT/NN and/CC Ets/NN binding/NN sites/NNS are/VBP present/JJ in/IN the/DT transcriptional/JJ enhancers/NNS of/IN human/JJ immunodeficiency/NN viruses/NNS types/NNS 1/CD and/CC 2/CD (/( HIV-1/NN and/CC HIV-2/NN )/) ,/, suggesting/VBG that/IN this/DT pattern/NN of/IN nuclear/JJ protein/NN binding/NN sites/NNS reflects/VBZ an/DT evolutionarily/RB conserved/VBN mechanism/NN for/IN regulating/VBG inducible/JJ T-cell/NN gene/NN expression/NN that/WDT has/VBZ been/VBN co-opted/VBN during/IN HIV/NN evolution/NN ./. 
Despite/IN these/DT findings/NNS ,/, the/DT molecular/JJ mechanisms/NNS by/IN which/WDT Ets/NN and/CC NF-kappaB/NFAT/NN proteins/NNS cooperatively/RB regulate/VBP inducible/JJ T-cell/NN gene/NN expression/NN remained/VBD unknown/JJ ./. 
In/IN the/DT studies/NNS described/VBN in/IN this/DT report/NN ,/, we/PRP demonstrated/VBD a/DT physical/JJ interaction/NN between/IN multiple/JJ Ets/NN and/CC NF-kappaB/NFAT/NN proteins/NNS both/CC in/FW vitro/FW and/CC in/IN activated/VBN normal/JJ human/JJ T/NN cells/NNS ./. 
This/DT interaction/NN is/VBZ mediated/VBN by/IN the/DT Ets/NN domain/NN of/IN Ets/NN proteins/NNS and/CC the/DT C-terminal/JJ region/NN of/IN the/DT Rel/NN homology/NN domains/NNS of/IN NF-kappaB/NFAT/NN proteins/NNS ./. 
In/IN addition/NN ,/, the/DT Ets-NF-kappaB/NFAT/NN interaction/NN requires/VBZ the/DT presence/NN of/IN DNA/NN binding/NN sites/NNS for/IN both/DT proteins/NNS ,/, as/IN it/PRP is/VBZ abolished/VBN by/IN the/DT DNA/NN intercalating/NN agents/NNS propidium/NN iodide/NN and/CC ethidium/NN bromide/NN and/CC enhanced/VBN by/IN the/DT presence/NN of/IN synthetic/JJ oligonucleotides/NNS containing/VBG binding/VBG sites/NNS for/IN Ets/NN and/CC NF-kappaB/NN proteins/NNS ./. 
A/DT dominant-negative/JJ mutant/NN of/IN NF-kappaB/NN p50/NN that/WDT binds/VBZ DNA/NN but/CC fails/VBZ to/TO interact/VB with/IN Ets/NN proteins/NNS inhibits/VBZ the/DT synergistic/JJ activation/NN of/IN the/DT HIV-1/NN and/CC HIV-2/NN enhancers/NNS by/IN NF-kappaB/NN (/( p50/NN +/CC p65/NN )/) and/CC Ets-1/NN ,/, suggesting/VBG that/IN physical/JJ interaction/NN between/IN Ets/NN and/CC NF-kappaB/NN proteins/NNS is/VBZ required/VBN for/IN the/DT transcriptional/JJ activity/NN of/IN the/DT HIV-1/NN and/CC HIV-2/NN enhancers/NNS ./. 
Taken/VBN together/RB ,/, these/DT findings/NNS suggest/VBP that/IN evolutionarily/RB conserved/VBN physical/JJ interactions/NNS between/IN Ets/NN and/CC NF-kappaB/NFAT/NN proteins/NNS are/VBP important/JJ in/IN regulating/VBG the/DT inducible/JJ expression/NN of/IN T-cell/NN genes/NNS and/CC viruses/NNS ./. 
These/DT interactions/NNS represent/VBP a/DT potential/JJ target/NN for/IN the/DT development/NN of/IN novel/JJ immunosuppressive/JJ and/CC antiviral/JJ therapies/NNS ./. 
UI/LS -/: 97353114/CD 
TI/LS -/: An/DT acute/JJ myeloid/JJ leukemia/NN gene/NN ,/, AML1/NN ,/, regulates/VBZ transcriptional/JJ activation/NN and/CC hemopoietic/JJ myeloid/JJ cell/NN differentiation/NN antagonistically/RB by/IN two/CD alternative/JJ spliced/JJ forms/NNS ./. 
AB/LS -/: The/DT AML1/NN gene/NN on/IN chromosome/NN 21/CD is/VBZ disrupted/VBN in/IN the/DT (8;21)(q22;q22)/NN and/CC (3;21)(q26;q22)/NN translocations/NNS associated/VBN with/IN myelogenous/JJ leukemias/NNS and/CC encodes/VBZ a/DT DNA-binding/JJ protein/NN ./. 
From/IN AML1/NN gene/NN ,/, two/CD representative/JJ forms/NNS of/IN proteins/NNS ,/, AML1a/NN and/CC AML1b/NN ,/, are/VBP produced/VBN by/IN an/DT alternative/JJ splicing/NN ./. 
Both/DT forms/NNS have/VBP DNA-binding/JJ domain/NN ,/, but/CC AML1a/NN lacks/VBZ a/DT putative/JJ transcriptional/JJ activation/NN domain/NN which/WDT AML1b/NN has/VBZ ./. 
Here/RB we/PRP demonstrate/VBP that/IN AML1a/NN ,/, which/WDT solely/RB has/VBZ no/DT effects/NNS as/IN a/DT transcriptional/JJ regulator/NN ,/, dominantly/RB suppresses/VBZ transcriptional/JJ activation/NN by/IN AML1b/NN ,/, and/CC that/IN AML1a/NN exhibits/VBZ the/DT higher/JJR affinity/NN for/IN DNA-binding/JJ than/IN AML1b/NN ./. 
Furthermore/RB a/DT dominant/JJ negative/JJ form/NN of/IN AML1/NN ,/, AML1a/NN ,/, totally/RB suppressed/VBD granulocytic/JJ differentiation/NN otherwise/RB induced/VBN by/IN granulocyte/NN colony-stimulating/JJ factor/NN when/WRB AML1a/NN was/VBD overexpressed/VBN in/IN 32Dc13/NN murine/JJ myeloid/JJ cells/NNS ./. 
Such/JJ differentiation/NN block/NN by/IN AML1a/NN was/VBD canceled/VBN by/IN the/DT concomitant/JJ overexpression/NN of/IN AML1b/NN ./. 
These/DT data/NNS strongly/RB suggest/VBP that/IN a/DT transcriptionally/RB active/JJ form/NN of/IN AML1/NN is/VBZ essential/JJ for/IN the/DT myeloid/JJ cell/NN differentiation/NN ./. 
In/IN addition/NN ,/, we/PRP observed/VBD an/DT altered/JJ expression/NN level/NN of/IN AML1/NN along/IN with/IN the/DT myeloid/JJ differentiation/NN in/IN several/JJ hemopoietic/JJ cell/NN lines/NNS ./. 
In/IN these/DT cases/NNS ,/, at/IN least/JJS ,/, the/DT AML1/NN expression/NN level/NN is/VBZ a/DT potential/JJ regulator/NN for/IN myeloid/JJ cell/NN differentiation/NN ./. 
UI/LS -/: 97240797/CD 
TI/LS -/: Nuclear/JJ factor-kappa/NN B/NN potently/RB up-regulates/VBZ the/DT promoter/NN activity/NN of/IN RANTES/NN ,/, a/DT chemokine/NN that/WDT blocks/VBZ HIV/NN infection/NN ./. 
AB/LS -/: The/DT complex/JJ network/NN of/IN cytokines/NNS that/WDT are/VBP involved/VBN in/IN inflammatory/JJ and/CC immunoregulatory/JJ responses/NNS plays/VBZ a/DT critical/JJ role/NN in/IN the/DT pathogenesis/NN of/IN HIV/NN infection/NN ./. 
RANTES/NN (/( regulated/VBN upon/IN activation/NN ,/, normal/JJ T/NN cell/NN expressed/VBN and/CC secreted/VBN )/) is/VBZ a/DT cytokine/NN that/WDT belongs/VBZ to/TO the/DT beta-chemokine/NN family/NN ;/: it/PRP is/VBZ chemoattractant/JJ for/IN CD4+/CD45RO/JJ T/NN cells/NNS ,/, it/PRP is/VBZ produced/VBN by/IN various/JJ cell/NN types/NNS including/VBG CD8+/JJ and/CC CD4+/JJ T/NN cells/NNS as/RB well/RB as/IN monocytes/macrophages/NNS ,/, and/CC has/VBZ recently/RB been/VBN shown/VBN to/TO suppress/VB replication/NN of/IN macrophage-tropic/JJ strains/NNS of/IN HIV/NN in/IN CD4+/JJ T/NN cells/NNS ./. 
To/TO investigate/VB the/DT molecular/JJ mechanisms/NNS of/IN RANTES/NN expression/NN ,/, the/DT RANTES/NN promoter/NN region/NN was/VBD analyzed/VBN by/IN transient/JJ expression/NN and/CC gel-mobility/JJ shift/NN assays/NNS ./. 
We/PRP demonstrate/VBP that/IN :/: 1/LS )/) RANTES/NN promoter/NN activity/NN is/VBZ up-regulated/VBN by/IN PMA/NN plus/CC ionomycin/NN ,/, coexpression/NN of/IN the/DT p65/NN subunit/NN of/IN nuclear/JJ factor/NN (/( NF/NN )/) -kappa/NN B/NN ,/, the/DT proinflammatory/JJ cytokines/NNS TNF-alpha/NN and/CC IL-1/NN beta/NN ,/, and/CC the/DT CD28/NN costimulatory/JJ pathway/NN ;/: 2/LS )/) the/DT RANTES/NN promoter/NN region/NN contains/VBZ four/CD NF-kappa/NN B/NN binding/NN sites/NNS at/IN positions/NNS -30/CD ,/, -44/CD ,/, -213/CD ,/, and/CC -579/CD relative/JJ to/TO the/DT transcription/NN start/NN site/NN ;/: 3/LS )/) one/CD site/NN (/( -213/CD )/) is/VBZ an/DT NF-AT/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS )/) binding/NN site/NN that/WDT also/RB has/VBZ weak/JJ affinity/NN to/TO NF-kappa/NN B/NN ,/, and/CC the/DT most/RBS distal/JJ site/NN (/( -579/CD )/) also/RB serves/VBZ as/IN a/DT CD28-responsive/JJ element/NN ;/: and/CC 4/LS )/) mutation/NN on/IN any/DT of/IN those/DT NF-kappa/NN B/NN sites/NNS or/CC coexpression/NN of/IN I/NN kappa/NN B/NN alpha/NN (/( cytoplasmic/JJ inhibitor/NN of/IN NF-kappa/NN B/NN )/) markedly/RB reduced/VBD the/DT promoter/NN activity/NN ./. 
Thus/RB ,/, NF-kappa/NN B/NN ,/, a/DT potent/JJ transcriptional/JJ activator/NN of/IN HIV/NN expression/NN ,/, is/VBZ also/RB involved/VBN in/IN the/DT expression/NN of/IN RANTES/NN ,/, a/DT chemokine/NN that/WDT blocks/VBZ infection/NN by/IN macrophage-tropic/JJ strains/NNS of/IN HIV/NN ./. 
UI/LS -/: 97226001/CD 
TI/LS -/: Pivotal/JJ role/NN for/IN the/DT NFIL3/E4BP4/NN transcription/NN factor/NN in/IN interleukin/NN 3-mediated/JJ survival/NN of/IN pro-B/JJ lymphocytes/NNS ./. 
AB/LS -/: The/DT E2A-HLF/NN (/( hepatic/JJ leukemia/NN factor/NN )/) oncoprotein/NN ,/, generated/VBN in/IN pro-B/JJ lymphocytes/NNS by/IN fusion/NN of/IN the/DT trans-activation/NN domain/NN of/IN E2A/NN to/TO the/DT basic/JJ region/leucine/NN zipper/NN (/( bZIP/NN )/) domain/NN of/IN HLF/NN ,/, functions/VBZ as/IN an/DT anti-apoptotic/JJ transcription/NN factor/NN in/IN leukemic/JJ cell/NN transformation/NN ./. 
When/WRB introduced/VBN into/IN interleukin/NN 3/CD (/( IL-3/NN )/) -dependent/JJ mouse/NN pro-B/JJ lymphocytes/NNS ,/, E2A-HLF/NN prevents/VBZ apoptosis/NN induced/VBN by/IN growth/NN factor/NN deprivation/NN ,/, suggesting/VBG that/IN IL-3/NN mediates/VBZ cell/NN survival/NN through/IN activation/NN of/IN a/DT transcription/NN factor/NN whose/WP$ activity/NN can/MD be/VB constitutively/RB replaced/VBN by/IN the/DT chimeric/JJ oncoprotein/NN ./. 
We/PRP considered/VBD four/CD bZIP/NN transcription/NN factors/NNS as/IN candidates/NNS for/IN this/DT putative/JJ IL-3-regulated/JJ factor/NN ,/, each/DT of/IN which/WDT binds/VBZ avidly/RB to/TO the/DT DNA/NN consensus/NN sequence/NN recognized/VBN by/IN E2A-HLF/NN and/CC is/VBZ related/JJ to/TO the/DT Caenorhabditis/NN elegans/NN CES-2/NN (/( cell/NN death/NN specification/NN protein/NN )/) neuron-specific/JJ mediator/NN of/IN cell/NN death/NN ./. 
The/DT expression/NN and/CC binding/NN activity/NN of/IN the/DT Nfil3/NN protein/NN (/( also/RB called/VBN E4bp4/NN )/) ,/, but/CC not/RB of/IN Hlf/NN ,/, Dbp/NN ,/, or/CC Tef/NN ,/, was/VBD found/VBN to/TO be/VB regulated/VBN by/IN IL-3/NN in/IN mouse/NN pro-B/JJ cell/NN lines/NNS (/( Baf-3/NN and/CC FL5.12/NN )/) ./. 
Northern/NN blot/NN analysis/NN showed/VBD that/IN Nfil3/E4bp4/NN is/VBZ regulated/VBN as/IN a/DT "/`` delayed-early/JJ "/'' IL-3-responsive/JJ gene/NN ,/, requiring/VBG de/FW novo/FW protein/NN synthesis/NN ./. 
In/IN the/DT absence/NN of/IN IL-3/NN ,/, enforced/JJ expression/NN of/IN the/DT human/JJ NFIL3/E4BP4/NN cDNA/NN promoted/VBD the/DT survival/NN but/CC not/RB the/DT growth/NN of/IN IL-3-dependent/JJ pro-B/JJ cells/NNS ./. 
Our/PRP$ results/NNS implicate/VBP NFIL3/E4BP4/NN (/( nuclear/JJ factor/NN regulated/VBN by/IN IL-3/adenovirus/NN E4/NN promoter/NN binding/NN protein/NN )/) in/IN a/DT distinct/JJ growth/NN factor-regulated/JJ signaling/NN pathway/NN that/WDT is/VBZ responsible/JJ for/IN the/DT survival/NN of/IN early/JJ B-cell/NN progenitors/NNS ,/, and/CC whose/WP$ alteration/NN by/IN E2A-HLF/NN leads/VBZ to/TO childhood/NN B/NN lineage/NN leukemia/NN ./. 
UI/LS -/: 97218353/CD 
TI/LS -/: Detection/NN of/IN adenovirus/NN DNA/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS by/IN polymerase/NN chain/NN reaction/NN assay/NN ./. 
AB/LS -/: Adenovirus/NN can/MD establish/VB persistent/JJ infections/NNS which/WDT may/MD reactivate/VB and/CC cause/VB disease/NN in/IN immunocompromised/JJ hosts/NNS ./. 
Lymphocytes/NNS have/VBP been/VBN postulated/VBN to/TO serve/VB as/IN a/DT site/NN of/IN adenoviral/JJ persistence/NN based/VBN upon/IN the/DT ability/NN to/TO isolate/VB adenovirus/NN from/IN tonsils/NNS and/CC to/TO detect/VB adenovirus/NN DNA/NN by/IN Southern/NN blot/NN hybridization/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NN )/) ./. 
To/TO test/VB this/DT hypothesis/NN ,/, a/DT more/RBR sensitive/JJ and/CC specific/JJ polymerase/NN chain/NN reaction/NN (/( PCR/NN )/) assay/NN was/VBD developed/VBN to/TO detect/VB adenovirus/NN DNA/NN ./. 
Two/CD sets/NNS of/IN nested/VBD primers/NNS were/VBD designed/VBN to/TO conserved/VBN sequences/NNS in/IN the/DT adenovirus/NN E1A/NN and/CC hexon/NN genes/NNS ./. 
The/DT E1A/NN and/CC hexon/NN primers/NNS amplified/VBD DNA/NN from/IN representative/JJ adenoviral/JJ serotypes/NNS in/IN all/DT six/CD adenoviral/JJ groups/NNS (/( A-F/NNS )/) ./. 
Both/DT primers/NNS detected/VBD a/DT single/JJ copy/NN of/IN the/DT adenovirus/NN type/NN 2/CD genome/NN but/CC were/VBD less/RBR sensitive/JJ for/IN the/DT group/NN B/NN type/NN 35/CD ./. 
None/NN of/IN 33/CD PBMC/NN specimens/NNS from/IN healthy/JJ adults/NNS and/CC only/RB one/CD of/IN 40/CD pediatric/JJ samples/NNS was/VBD positive/JJ (/( at/IN a/DT low/JJ level/NN )/) for/IN adenovirus/NN DNA/NN by/IN nested/JJ PCR/NN assay/NN ./. 
In/IN comparison/NN ,/, PBMC/NN from/IN two/CD children/NNS with/IN fatal/JJ adenoviral/JJ infection/NN were/VBD both/RB strongly/RB positive/JJ for/IN adenovirus/NN DNA/NN ./. 
It/PRP is/VBZ concluded/VBN that/IN ,/, in/IN contrast/NN to/TO a/DT previous/JJ study/NN ,/, PBMC/NN are/VBP not/RB a/DT common/JJ site/NN of/IN persistent/JJ group/NN C/NN adenoviral/JJ infection/NN ./. 
In/IN addition/NN ,/, assay/NN of/IN PBMC/NN by/IN the/DT adenovirus-specific/JJ PCR/NN may/MD help/VB detect/VB early/JJ invasive/JJ disease/NN and/CC warrants/VBZ further/JJ evaluation/NN ./. 
UI/LS -/: 97216066/CD 
TI/LS -/: Common/JJ and/CC distinct/JJ intracellular/JJ signaling/NN pathways/NNS in/IN human/JJ neutrophils/NNS utilized/VBN by/IN platelet/NN activating/NN factor/NN and/CC FMLP/NN ./. 
AB/LS -/: Stimulation/NN of/IN human/JJ neutrophils/NNS with/IN chemoattractants/NNS FMLP/NN or/CC platelet/NN activating/NN factor/NN (/( PAF/NN )/) results/VBZ in/IN different/JJ but/CC overlapping/VBG functional/JJ responses/NNS ./. 
We/PRP questioned/VBD whether/IN these/DT differences/NNS might/MD reflect/VB patterns/NNS of/IN intracellular/JJ signal/NN transduction/NN ./. 
Stimulation/NN with/IN either/CC PAF/NN or/CC FMLP/NN resulted/VBD in/IN equivalent/JJ phosphorylation/NN and/CC activation/NN of/IN the/DT mitogen-activated/JJ protein/NN kinase/NN (/( MAPk/NN )/) homologue/NN 38-kD/JJ murine/JJ MAP/NN kinase/NN homologous/JJ to/TO HOG-1/NN (/( p38/NN )/) MAPk/NN ./. 
Neither/CC FMLP/NN nor/CC PAF/NN activated/VBD c-jun/NN NH2-terminal/JJ MAPk/NN (/( JNKs/NNS )/) ./. 
Under/IN identical/JJ conditions/NNS ,/, FMLP/NN but/CC not/RB PAF/NN ,/, resulted/VBD in/IN significant/JJ p42/44/NN (/( ERK/NN )/) MAPk/NN activation/NN ./. 
Both/CC FMLP/NN and/CC PAF/NN activated/VBD MAP/NN kinase/NN kinase-3/NN (/( MKK3/NN )/) ,/, a/DT known/JJ activator/NN of/IN p38/NN MAPk/NN ./. 
Both/CC MAP/NN ERK/NN kinase/NN kinase-1/NN (/( MEKK1/NN )/) and/CC Raf/NN are/VBP activated/VBN strongly/RB by/IN FMLP/NN ,/, but/CC minimally/RB by/IN PAF/NN ./. 
Pertussis/NN toxin/NN blocked/VBD FMLP-induced/JJ activation/NN of/IN the/DT p42/44/NN (/( ERK/NN )/) MAPk/NN cascade/NN ,/, but/CC not/RB that/DT of/IN p38/NN MAPk/NN ./. 
A/DT specific/JJ p38/NN MAPk/NN inhibitor/NN (/( SK&F/NN 86002/CD )/) blocked/VBD superoxide/NN anion/NN production/NN in/IN response/NN to/TO FMLP/NN and/CC reduced/VBD adhesion/NN and/CC chemotaxis/NN in/IN response/NN to/TO PAF/NN or/CC FMLP/NN ./. 
These/DT results/NNS demonstrate/VBP distinct/JJ patterns/NNS of/IN intracellular/JJ signaling/NN for/IN two/CD chemoattractants/NNS and/CC suggest/VBP that/IN selective/JJ activation/NN of/IN intracellular/JJ signaling/NN cascades/NNS may/MD underlie/VB different/JJ patterns/NNS of/IN functional/JJ responses/NNS ./. 
UI/LS -/: 97184462/CD 
TI/LS -/: Cloning/NN of/IN the/DT novel/JJ human/JJ myeloid-cell-specific/JJ C/EBP-epsilon/NN transcription/NN factor/NN ./. 
AB/LS -/: Chicken/NN NF-M/NN transcription/NN factor/NN ,/, in/IN cooperation/NN with/IN either/CC c-Myb/NN or/CC v-Myb/NN ,/, is/VBZ active/JJ in/IN the/DT combinatorial/JJ activation/NN of/IN myeloid-cell-specific/JJ genes/NNS in/IN heterologous/JJ cell/NN types/NNS ,/, such/JJ as/IN embryonic/JJ fibroblasts/NNS ./. 
In/IN humans/NNS ,/, similar/JJ effects/NNS were/VBD observed/VBN with/IN homologous/JJ members/NNS of/IN the/DT CCAAT/enhancer-binding/JJ protein/NN (/( C/EBP/NN )/) family/NN of/IN transcriptional/JJ regulators/NNS ,/, especially/RB the/DT human/JJ homolog/NN of/IN chicken/NN NF-M/NN ,/, C/EBP-beta/NN (/( NF-IL6/NN )/) ./. 
However/RB ,/, the/DT NF-IL6/NN gene/NN is/VBZ expressed/VBN in/IN a/DT variety/NN of/IN nonmyeloid/JJ cell/NN types/NNS and/CC is/VBZ strongly/RB inducible/JJ in/IN response/NN to/TO inflammatory/JJ stimuli/NNS ,/, making/VBG it/PRP an/DT unlikely/JJ candidate/NN to/TO have/VB an/DT exclusive/JJ role/NN as/IN a/DT combinatorial/JJ differentiation/NN switch/NN during/IN myelopoiesis/NN in/IN human/JJ cells/NNS ./. 
By/IN using/VBG a/DT reverse/JJ transcription-PCR-based/JJ approach/NN and/CC a/DT set/NN of/IN primers/NNS specific/JJ for/IN the/DT DNA-binding/JJ domains/NNS of/IN highly/RB homologous/JJ members/NNS of/IN the/DT C/EBP/NN family/NN of/IN transcriptional/JJ regulators/NNS ,/, we/PRP have/VBP cloned/VBN a/DT novel/JJ human/JJ gene/NN encoding/VBG a/DT member/NN of/IN the/DT C/EBP/NN gene/NN family/NN ,/, identified/VBN as/IN the/DT human/JJ homolog/NN of/IN CRP1/NN ,/, C/EBP-epsilon/NN ./. 
A/DT 1.2-kb/JJ cDNA/NN encoding/VBG full-length/JJ human/JJ C/EBP-epsilon/NN was/VBD cloned/VBN from/IN a/DT promyelocyte-late/JJ myeloblast-derived/JJ lambda/NN gt11/NN library/NN ./. 
Molecular/JJ analysis/NN of/IN the/DT cDNA/NN and/CC genomic/JJ clones/NNS indicated/VBD the/DT presence/NN of/IN two/CD exons/NNS encoding/VBG a/DT protein/NN with/IN an/DT apparent/JJ molecular/JJ mass/NN of/IN 32/CD kDa/NN and/CC a/DT pI/NN of/IN 9.5/CD ./. 
Primer/NN extension/NN analysis/NN of/IN C/EBP-epsilon/NN mRNA/NN detected/VBD a/DT single/JJ major/JJ transcription/NN start/NN site/NN approximately/RB 200/CD bp/NN upstream/RB of/IN the/DT start/NN codon/NN ./. 
The/DT putative/JJ promoter/NN area/NN is/VBZ similar/JJ to/TO those/DT of/IN several/JJ other/JJ myeloid-cell-specific/JJ genes/NNS in/IN that/IN it/PRP contains/VBZ no/DT TATAAA/NN box/NN but/CC has/VBZ a/DT number/NN of/IN purine-rich/JJ stretches/NNS with/IN multiple/JJ sites/NNS for/IN the/DT factors/NNS of/IN the/DT Ets/NN family/NN of/IN transcriptional/JJ regulators/NNS ./. 
Northern/NN blot/NN analyses/NNS indicated/VBD a/DT highly/RB restricted/JJ mRNA/NN expression/NN pattern/NN ,/, with/IN the/DT strongest/JJS expression/NN occurring/VBG in/IN promyelocyte/NN and/CC late-myeloblast-like/JJ cell/NN lines/NNS ./. 
Western/NN blot/NN and/CC immunoprecipitation/NN studies/NNS using/VBG rabbit/NN anti-C/EBP-epsilon/JJ antibodies/NNS raised/VBN against/IN the/DT N-terminal/JJ portion/NN of/IN C/EBP-epsilon/NN (/( amino/NN acids/NNS 1/CD to/TO 115/CD )/) showed/VBD that/IN C/EBP-epsilon/NN is/VBZ a/DT 32-kDa/JJ nuclear/JJ phosphoprotein/NN ./. 
The/DT human/JJ C/EBP-epsilon/NN protein/NN exhibited/VBD strong/JJ and/CC specific/JJ binding/NN to/TO double-stranded/JJ DNA/NN containing/VBG consensus/NN C/EBP/NN sites/NNS ./. 
Cotransfection/NN of/IN the/DT C/EBP-epsilon/NN sense/NN and/CC antisense/JJ expression/NN constructs/NNS together/RB with/IN chloramphenicol/NN acetyltransferase/NN reporter/NN vectors/NNS containing/VBG myeloid-cell-specific/JJ c-mim/NN and/CC human/JJ myeloperoxidase/JJ promoters/NNS suggested/VBD a/DT role/NN for/IN C/EBP-epsilon/NN transcription/NN factor/NN in/IN the/DT regulation/NN of/IN a/DT subset/NN of/IN myeloid-cell-specific/JJ genes/NNS ./. 
Transient/JJ tranfection/NN of/IN a/DT promyelocyte/NN cell/NN line/NN (/( NB4/NN )/) with/IN a/DT C/EBP-epsilon/NN expression/NN plasmid/NN increased/VBD cell/NN growth/NN by/IN sevenfold/RB ,/, while/IN antisense/JJ C/EBP-epsilon/NN caused/VBD a/DT fivefold/JJ decrease/NN in/IN clonal/JJ growth/NN of/IN these/DT cells/NNS ./. 
UI/LS -/: 97281244/CD 
TI/LS -/: The/DT tumour/NN associated/JJ cell/NN surface/NN antigen/NN A6H/NN is/VBZ costimulatory/JJ for/IN human/JJ CD4+/JJ but/CC not/RB CD8+/JJ T/NN cells/NNS ./. 
AB/LS -/: The/DT A6H/NN monoclonal/JJ antibody/NN (/( mAb/NN )/) recognizes/VBZ a/DT 120,000-140,000/CD MW/NN antigen/NN that/WDT is/VBZ expressed/VBN at/IN similar/JJ densities/NNS on/IN 85-90/CD %/NN of/IN human/JJ CD4+/JJ and/CC CD8+/JJ T/NN cells/NNS and/CC on/IN renal/JJ cell/NN carcinomas/NNS ./. 
The/DT binding/NN of/IN the/DT A6H/NN mAb/NN induced/VBD a/DT costimulatory/JJ signal/NN in/IN anti-CD3/JJ activated/VBN T/NN cells/NNS ./. 
In/IN the/DT present/JJ report/NN ,/, we/PRP show/VBP that/IN A6H/NN costimulated/VBD cell/NN proliferation/NN and/CC cytokine/NN production/NN in/IN purified/VBN CD4+/JJ T/NN cells/NNS ./. 
Unexpectedly/RB ,/, the/DT CD8+/JJ T-cell/NN subpopulation/NN failed/VBD to/TO respond/VB ./. 
CD4+/JJ T/NN cells/NNS costimulated/VBN with/IN the/DT A6H/NN mAb/NN upregulated/VBD CD80/NN ,/, CD86/NN ,/, CD71/NN ,/, interleukin-2/NN (/( IL-2/NN )/) R/NN alpha/NN ,/, IL-2R/NN beta/NN and/CC IL-2R/NN gamma/NN ,/, while/IN no/DT corresponding/JJ up-regulation/NN of/IN these/DT cell/NN surface/NN molecules/NNS was/VBD seen/VBN in/IN CD8+/JJ T/NN cells/NNS ./. 
In/IN order/NN to/TO investigate/VB the/DT nature/NN of/IN the/DT A6H/NN mAb/NN costimulus/NN at/IN the/DT transcriptional/JJ level/NN we/PRP have/VBP examined/VBN induction/NN of/IN the/DT transcription/NN factors/NNS OCT-1/NN ,/, AP-1/NN and/CC NF-kappa/NN B/NN which/WDT are/VBP known/VBN to/TO be/VB transcriptional/JJ regulators/NNS of/IN several/JJ cytokine/NN and/CC cytokine/NN receptor/NN genes/NNS ,/, including/VBG the/DT IL-2/NN and/CC IL-2R/NN genes/NNS ./. 
Co-ligation/NN of/IN the/DT A6H/NN antigen/NN and/CC the/DT CD3/NN complex/NN induced/VBD expression/NN of/IN the/DT transcription/NN factor/NN AP-1/NN in/IN CD4+/JJ T/NN cells/NNS ,/, whereas/IN no/DT increase/NN in/IN NF-kappa/NN B/NN and/CC octamer-binding/JJ (/( Oct/NN )/) proteins/NNS was/VBD seen/VBN compared/VBN to/TO T/NN cells/NNS stimulated/VBN with/IN anti-CD3/NN alone/RB ./. 
Furthermore/RB ,/, no/DT induction/NN of/IN AP-1/NN was/VBD seen/VBN in/IN A6H/NN costimulated/JJ CD8+/JJ T/NN cells/NNS ./. 
These/DT results/NNS suggests/VBZ that/IN both/CC proximal/JJ steps/NNS in/IN CD8+/JJ T-cell/NN activation/NN as/RB well/RB as/IN the/DT later/JJ phases/NNS are/VBP unresponsive/JJ to/TO A6H/NN ligation/NN ./. 
Molecular/JJ differences/NNS of/IN the/DT A6H/NN molecule/NN or/CC distinct/JJ regulation/NN of/IN the/DT A6H/NN transduced/JJ AP-1/NN activation/NN pathway/NN may/MD exist/VB in/IN CD4+/JJ and/CC CD8+/JJ T/NN cell/NN subpopulations/NNS ./. 
UI/LS -/: 97176699/CD 
TI/LS -/: Cloning/NN and/CC expression/NN of/IN the/DT glucocorticoid/NN receptor/NN from/IN the/DT squirrel/NN monkey/NN (/( Saimiri/FW boliviensis/FW boliviensis/FW )/) ,/, a/DT glucocorticoid-resistant/JJ primate/NN ./. 
AB/LS -/: New/JJ World/NN primates/NNS such/JJ as/IN the/DT squirrel/NN monkey/NN have/VBP elevated/VBN cortisol/NN levels/NNS and/CC glucocorticoid/NN resistance/NN ./. 
We/PRP have/VBP shown/VBN that/IN the/DT apparent/JJ binding/NN affinity/NN of/IN the/DT glucocorticoid/NN receptor/NN in/IN squirrel/NN monkey/NN lymphocytes/NNS is/VBZ 5-fold/RB lower/JJR than/IN that/DT in/IN human/JJ lymphocytes/NNS (/( apparent/JJ Kd/NN ,/, 20.9/CD +/-/CC 1.8/CD and/CC 4.3/CD +/-/CC 0.2/CD nmol/L/NN ,/, respectively/RB ;/: n/NN =/JJ 3/CD )/) ,/, consistent/JJ with/IN previous/JJ studies/NNS in/IN mononuclear/JJ leukocytes/NNS isolated/VBN from/IN the/DT two/CD species/NNS ./. 
As/IN a/DT first/JJ step/NN in/IN understanding/VBG the/DT mechanism/NN of/IN decreased/VBN binding/NN affinity/NN in/IN New/JJ World/NN primates/NNS ,/, we/PRP used/VBD reverse/JJ transcription-PCR/NN to/TO clone/VB the/DT glucocorticoid/NN receptor/NN from/IN squirrel/NN monkey/NN liver/NN and/CC have/VBP compared/VBN the/DT sequence/NN to/TO receptor/NN sequences/NNS obtained/VBN from/IN owl/NN monkey/NN liver/NN ,/, cotton-top/JJ tamarin/NN B95-8/NN cells/NNS ,/, and/CC human/JJ lymphocytes/NNS ./. 
The/DT squirrel/NN monkey/NN glucocorticoid/NN receptor/NN is/VBZ approximately/RB 97/CD %/NN identical/JJ in/IN nucleotide/NN and/CC amino/NN acid/NN sequence/NN to/TO the/DT human/JJ receptor/NN ./. 
The/DT ligand-binding/JJ domain/NN (/( amino/NN acids/NNS 528-777/CD )/) of/IN the/DT squirrel/NN monkey/NN glucocorticoid/NN receptor/NN contains/VBZ four/CD amino/NN acid/NN differences/NNS (/( Ser551/NN to/TO Thr/NN ,/, Ser616/NN to/TO Ala/NN ,/, Ala618/NN to/TO Ser/NN ,/, and/CC Ile761/NN to/TO Leu/NN )/) ,/, all/DT of/IN which/WDT are/VBP present/JJ in/IN owl/NN monkey/NN and/CC cotton-top/JJ tamarin/NN receptors/NNS ./. 
The/DT DNA-binding/JJ domain/NN (/( amino/NN acids/NNS 421-486/CD )/) is/VBZ completely/RB conserved/VBN among/IN human/JJ ,/, squirrel/NN monkey/NN ,/, owl/NN monkey/NN ,/, and/CC cotton-top/JJ tamarin/NN receptors/NNS ./. 
Twenty-two/CD differences/NNS from/IN the/DT human/JJ sequence/NN were/VBD found/VBN in/IN the/DT N-terminal/JJ region/NN (/( amino/NN acids/NNS 1-421/CD )/) of/IN the/DT squirrel/NN monkey/NN receptor/NN ./. 
None/NN of/IN the/DT substitutions/NNS in/IN the/DT ligand-binding/JJ domain/NN matched/VBD mutations/NNS known/VBN to/TO influence/VB binding/NN affinity/NN in/IN other/JJ species/NNS ./. 
To/TO determine/VB whether/IN the/DT substitutions/NNS per/FW se/FW were/VBD responsible/JJ for/IN decreased/VBN affinity/NN ,/, squirrel/NN monkey/NN and/CC human/JJ glucocorticoid/NN receptors/NNS were/VBD expressed/VBN in/IN the/DT TNT/NN Coupled/JJ Reticulocyte/NN Lysate/NN System/NN ./. 
Expressions/NNS of/IN human/JJ and/CC squirrel/NN monkey/NN glucocorticoid/NN receptors/NNS and/CC a/DT squirrel/NN monkey/NN receptor/NN in/IN which/WDT Phe774/NN was/VBD mutated/VBN to/TO Leu/NN (/( F774L/NN )/) were/VBD similar/JJ ./. 
When/WRB expressed/VBN in/IN the/DT TNT/NN System/NN ,/, squirrel/NN monkey/NN and/CC human/JJ glucocorticoid/NN receptors/NNS had/VBD similar/JJ ,/, high/JJ affinity/NN binding/NN for/IN dexamethasone/NN (/( apparent/JJ Kd/NN ,/, 5.9/CD +/-/CC 1.2/CD and/CC 4.3/CD +/-/CC 0.5/CD nmol/L/NN ,/, respectively/RB ;/: n/NN =/JJ 3/CD )/) ,/, whereas/IN the/DT squirrel/NN monkey/NN F774L/NN receptor/NN had/VBD lower/JJR affinity/NN binding/NN (/( apparent/JJ Kd/NN ,/, 20.4/CD +/-/CC 2.0/CD nmol/L/NN ;/: n/NN =/JJ 3/CD )/) ./. 
Thus/RB ,/, substitutions/NNS within/IN the/DT ligand-binding/JJ domain/NN of/IN the/DT squirrel/NN monkey/NN glucocorticoid/NN receptor/NN can/MD not/RB account/VB for/IN the/DT decreased/VBN binding/NN affinity/NN of/IN these/DT receptors/NNS in/IN squirrel/NN monkey/NN cells/NNS ./. 
Rather/RB ,/, the/DT binding/NN affinity/NN is/VBZ probably/RB influenced/VBN by/IN the/DT expression/NN of/IN cytosolic/JJ factors/NNS that/WDT affect/VBP glucocorticoid/NN receptor/NN function/NN ./. 
UI/LS -/: 97158624/CD 
TI/LS -/: Shared/JJ gamma(c)/NN subunit/NN within/IN the/DT human/JJ interleukin-7/NN receptor/NN complex/NN ./. 
A/DT molecular/JJ basis/NN for/IN the/DT pathogenesis/NN of/IN X-linked/JJ severe/JJ combined/JJ immunodeficiency/NN ./. 
AB/LS -/: Genetic/JJ evidence/NN suggests/VBZ that/IN mutations/NNS in/IN the/DT gamma(c)/NN receptor/NN subunit/NN cause/VBP X-linked/JJ severe/JJ combined/JJ immunodeficiency/NN (/( X-SCID/NN )/) ./. 
The/DT gamma(c)/NN subunit/NN can/MD be/VB employed/VBN in/IN receptor/NN complexes/NNS for/IN IL-2/NN ,/, -4/CD ,/, -7/CD ,/, -9/CD ,/, and/CC -15/CD ,/, and/CC the/DT multiple/JJ signaling/NN defects/NNS that/WDT would/MD result/VB from/IN a/DT defective/JJ gamma(c)/NN chain/NN in/IN these/DT receptors/NNS are/VBP proposed/VBN to/TO cause/VB the/DT severe/JJ phenotype/NN of/IN X-SCID/NN patients/NNS ./. 
Interestingly/RB ,/, gene/NN disruption/NN of/IN either/CC IL-7/NN or/CC the/DT IL-7/NN receptor/NN (/( IL-7R/NN )/) alpha/NN subunit/NN in/IN mice/NNS leads/VBZ to/TO immunological/JJ defects/NNS that/WDT are/VBP similar/JJ to/TO human/JJ X-SCID/NN ./. 
These/DT observations/NNS suggest/VBP the/DT functional/JJ importance/NN of/IN gamma(c)/NN in/IN the/DT IL-7R/NN complex/NN ./. 
In/IN the/DT present/JJ study/NN ,/, structure/function/NN analyses/NNS of/IN the/DT IL-7R/NN complex/NN using/VBG a/DT chimeric/JJ receptor/NN system/NN demonstrated/VBD that/IN gamma(c)/NN is/VBZ indeed/RB critical/JJ for/IN IL-7R/NN function/NN ./. 
Nonetheless/RB ,/, only/RB a/DT limited/JJ portion/NN of/IN the/DT cytoplasmic/JJ domain/NN of/IN gamma(c)/NN is/VBZ necessary/JJ for/IN IL-7R/NN signal/NN transduction/NN ./. 
Furthermore/RB ,/, replacement/NN of/IN the/DT gamma(c)/NN cytoplasmic/JJ domain/NN by/IN a/DT severely/RB truncated/VBN erythropoeitin/NN receptor/NN does/VBZ not/RB affect/VB measured/VBN IL-7R/NN signaling/NN events/NNS ./. 
These/DT findings/NNS support/VBP a/DT model/NN in/IN which/WDT gamma(c)/NN serves/VBZ primarily/RB to/TO activate/VB signal/NN transduction/NN by/IN the/DT IL-7R/NN complex/NN ,/, while/IN IL-7R/NN alpha/NN determines/VBZ specific/JJ signaling/NN events/NNS through/IN its/PRP$ association/NN with/IN cytoplasmic/JJ signaling/NN molecules/NNS ./. 
Finally/RB ,/, these/DT studies/NNS are/VBP consistent/JJ with/IN the/DT hypothesis/NN that/IN the/DT molecular/JJ pathogenesis/NN of/IN X-SCID/NN is/VBZ due/JJ primarily/RB to/TO gamma(c)-mediated/JJ defects/NNS in/IN the/DT IL-7/IL-7R/NN system/NN 
UI/LS -/: 97343293/CD 
TI/LS -/: S-allyl/JJ cysteine/NN inhibits/VBZ activation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN in/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: Reactive/JJ oxygen/NN species/NNS are/VBP involved/VBN in/IN signal/NN transduction/NN pathways/NNS leading/VBG to/TO nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) activation/NN which/WDT has/VBZ been/VBN implicated/VBN in/IN the/DT regulation/NN of/IN gene/NN transcription/NN ./. 
We/PRP recently/RB reported/VBD that/IN a/DT garlic/JJ compound/NN ,/, S-allyl/JJ cysteine/NN (/( SAC/NN )/) ,/, protects/VBZ bovine/JJ pulmonary/JJ artery/NN endothelial/JJ cells/NNS from/IN oxidant/JJ injury/NN induced/VBN by/IN hydrogen/NN peroxide/NN (/( H2O2/NN )/) ./. 
In/IN this/DT study/NN we/PRP determined/VBD the/DT effects/NNS of/IN SAC/NN on/IN NF-kappa/NN B/NN activation/NN in/IN human/JJ T/NN lymphocytes/NNS (/( Jurkat/NN cells/NNS )/) induced/VBN by/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF- alpha/NN )/) and/CC H2O2/NN ./. 
Activated/VBN NF-kappa/NN B/NN in/IN nuclear/JJ extracts/NNS was/VBD measured/VBN by/IN an/DT electrophoretic/JJ mobility/NN shift/NN assay/NN using/VBG 32P-labeled/JJ probe/NN ./. 
SAC/NN consistently/RB exhibited/VBD a/DT dose-dependent/JJ inhibition/NN of/IN NF-kappa/NN B/NN activation/NN induced/VBN by/IN both/CC TNF-alpha/NN and/CC H2O2/NN ./. 
Supershift/NN with/IN specific/JJ antibodies/NNS to/TO NF-kappa/NN B/NN subunits/NNS confirmed/VBD that/IN the/DT inducible/JJ retarded/VBN bands/NNS observed/VBN in/IN the/DT EMSA/NN and/CC p65-p50/NN heterodimer/NN of/IN the/DT NF-kappa/NN B/Rel/NN protein/NN ./. 
Our/PRP$ data/NNS suggest/VBP that/IN SAC/NN may/MD act/VB via/IN antioxidant/JJ mechanisms/NNS to/TO block/VB NF-kappa/NN B/NN activation/NN in/IN Jurkat/NN cells/NNS ./. 
UI/LS -/: 97154704/CD 
TI/LS -/: Elf-2/NN ,/, a/DT rhombotin-2/NN binding/NN ets/NN transcription/NN factor/NN :/: discovery/NN and/CC potential/JJ role/NN in/IN T/NN cell/NN leukemia/NN ./. 
AB/LS -/: Rhombotin-2/NN (/( RBTN-2/NN )/) is/VBZ a/DT proto-oncogene/NN only/RB in/IN the/DT context/NN of/IN T/NN lymphocytes/NNS ./. 
We/PRP postulated/VBD that/IN the/DT oncogenic/JJ effect/NN of/IN RBTN-2/NN in/IN T/NN cells/NNS is/VBZ likely/RB mediated/VBN by/IN binding/VBG protein/NN (/( s/NNS )/) with/IN T/NN cell-specific/JJ expression/NN ./. 
By/IN screening/VBG a/DT T/NN cell/NN cDNA/NN library/NN ,/, we/PRP identified/VBD a/DT novel/JJ ets/NN transcription/NN factor/NN that/WDT binds/VBZ RBTN-2/NN ./. 
This/DT protein/NN was/VBD named/VBN elf-2/NN because/IN its/PRP$ DNA-binding/JJ domain/NN is/VBZ virtually/RB identical/JJ to/TO that/DT of/IN ets/NN family/NN member/NN elf-1/NN ./. 
Northern/NN analyses/NNS showed/VBD similar/JJ levels/NNS of/IN two/CD elf-2/NN transcripts/NNS (/( 3.5/CD kb/NN and/CC 3.8/CD kb/NN )/) in/IN all/DT tissues/NNS except/IN thymus/NN ./. 
Thymocytes/NNS expressed/VBD four-/CD to/TO 10-fold/RB greater/JJR amounts/NNS of/IN the/DT 3.5/CD kb/NN transcript/NN than/IN other/JJ tissues/NNS ./. 
Sequence/NN analyses/NNS of/IN cDNA/NN clones/NNS indicated/VBD that/IN these/DT transcripts/NNS encode/VBP proteins/NNS differing/VBG only/RB at/IN their/PRP$ amino/NN termini/NNS ,/, and/CC likely/RB represent/VBP alternatively/RB spliced/VBN isoforms/NNS ./. 
These/DT isoforms/NNS (/( elf-2a/NN and/CC elf-2b/NN )/) contain/VBP identical/JJ RBTN-2/NN binding/NN regions/NNS and/CC DNA-binding/JJ domains/NNS ./. 
Elf-2b/NN lacks/VBZ a/DT putative/JJ transactivation/NN domain/NN ./. 
The/DT expression/NN patterns/NNS suggest/VBP that/IN RBTN-2/NN normally/RB interacts/VBZ equally/RB with/IN elf-2a/NN and/CC elf-2b/NN ./. 
In/IN contrast/NN ,/, when/WRB RBTN-2/NN is/VBZ inappropriately/RB expressed/VBN in/IN T/NN cells/NNS ,/, RBTN-2/NN would/MD interact/VB predominantly/RB with/IN elf-2b/NN ;/: this/DT interaction/NN may/MD lead/VB to/TO T/NN cell/NN proliferation/NN ./. 
UI/LS -/: 99126331/CD 
TI/LS -/: Transcription/NN factor/NN effects/NNS on/IN chromosome/NN constitution/NN of/IN cell/NN hybrids/NNS ./. 
AB/LS -/: When/WRB immunoglobulin/NN (/( Ig/NN )/) -secreting/JJ plasmacytomas/NNS are/VBP fused/VBN to/TO a/DT T-cell/NN lymphoma/NN ,/, Ig/NN gene/NN expression/NN ceases/VBZ in/IN greater/JJR than/IN 95/CD %/NN of/IN the/DT resulting/VBG hybrids/NNS ./. 
In/IN the/DT rare/JJ hybrids/NNS that/WDT continue/VBP to/TO express/VB Ig/NN ,/, all/DT other/JJ tested/VBN B/NN lymphocyte-specific/JJ genes/NNS also/RB remain/VBP active/JJ ./. 
The/DT low/JJ frequency/NN with/IN which/WDT these/DT Ig-expressing/JJ hybrids/NNS are/VBP recovered/VBN ,/, along/IN with/IN the/DT fact/NN that/IN cell/NN fusions/NNS can/MD lead/VB to/TO chromosome/NN loss/NN ,/, led/VBD us/PRP to/TO propose/VB that/IN this/DT rare/JJ phenotype/NN was/VBD due/JJ to/TO loss/NN of/IN a/DT T-cell-derived/JJ chromosome/NN encoding/VBG a/DT factor/NN or/CC factors/NNS with/IN gene/NN silencing/NN activity/NN ./. 
To/TO identify/VB the/DT relevant/JJ chromosome/NN ,/, we/PRP have/VBP used/VBN a/DT polymerase/NN chain/NN reaction/NN (/( PCR/NN )/) -assisted/JJ method/NN of/IN chromosome/NN mapping/NN to/TO analyze/VB both/CC Ig-silenced/JJ (/( common/JJ )/) and/CC Ig-expressing/JJ (/( rare/JJ )/) hybrids/NNS ./. 
Although/IN no/DT single/JJ chromosome/NN was/VBD found/VBN to/TO correlate/VB with/IN Ig/NN gene/NN silencing/NN ,/, we/PRP discovered/VBD that/IN the/DT two/CD types/NNS of/IN hybrids/NNS had/VBD undergone/VBN distinct/JJ patterns/NNS of/IN chromosome/NN loss/NN ./. 
Moreover/RB ,/, we/PRP found/VBD that/IN ectopic/JJ expression/NN of/IN a/DT B-cell-specific/JJ transcription/NN factor/NN (/( Oct-2/NN )/) dramatically/RB altered/VBD both/CC the/DT phenotype/NN and/CC chromosome/NN constitution/NN of/IN hybrids/NNS arising/VBG in/IN these/DT cell/NN fusions/NNS ./. 
UI/LS -/: 99097434/CD 
TI/LS -/: Reactivation/NN of/IN Kaposi/NN 's/POS sarcoma-associated/JJ herpesvirus/NN infection/NN from/IN latency/NN by/IN expression/NN of/IN the/DT ORF/NN 50/CD transactivator/NN ,/, a/DT homolog/NN of/IN the/DT EBV/NN R/NN protein/NN ./. 
AB/LS -/: Kaposi/NN 's/POS sarcoma/NN (/( KS/NN )/) -associated/JJ herpesvirus/NN (/( KSHV/NN )/) ,/, or/CC human/JJ herpesvirus/NN 8/CD ,/, is/VBZ a/DT lymphotropic/JJ virus/NN strongly/RB linked/VBN to/TO several/JJ AIDS-related/JJ neoplasms/NNS ./. 
The/DT primary/JJ reservoir/NN of/IN infection/NN consists/VBZ of/IN latently/RB infected/JJ B/NN lymphocytes/NNS and/CC possibly/RB other/JJ mononuclear/JJ cells/NNS ./. 
Viral/JJ reactivation/NN from/IN latency/NN and/CC spread/NN from/IN this/DT lymphoid/JJ reservoir/NN is/VBZ presumably/RB required/VBN for/IN development/NN of/IN nonlymphoid/JJ tumors/NNS like/IN KS/NN ./. 
Here/RB we/PRP show/VBP that/IN deregulated/VBN expression/NN of/IN a/DT single/JJ viral/JJ gene/NN ,/, ORF/NN 50/CD ,/, which/WDT encodes/VBZ a/DT transactivator/NN able/JJ to/TO selectively/RB upregulate/VB delayed-early/JJ viral/JJ genes/NNS ,/, suffices/VBZ to/TO disrupt/VB latency/NN and/CC induce/VB the/DT lytic/JJ gene/NN cascade/NN in/IN latently/RB infected/JJ B/NN cells/NNS ./. 
The/DT identification/NN of/IN this/DT gene/NN opens/VBZ the/DT way/NN to/TO studies/NNS of/IN the/DT physiologic/JJ mechanisms/NNS controlling/VBG reactvation/NN of/IN KSHV/NN from/IN latency/NN ./. 
Copyright/NN 1998/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99077502/CD 
TI/LS -/: Nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS and/CC AP-1/NN are/VBP insufficient/JJ for/IN IL-2/NN promoter/NN activation/NN :/: requirement/NN for/IN CD28/NN up-regulation/NN of/IN RE/AP/NN ./. 
AB/LS -/: IL-2/NN gene/NN transcription/NN in/IN T/NN cells/NNS requires/VBZ both/CC TCR/NN and/CC costimulatory/JJ signals/NNS ./. 
IL-2/NN promoter/NN activation/NN in/IN Jurkat/NN T/NN cells/NNS stimulated/VBN with/IN superantigen/NN presented/VBN by/IN Raji/NN B/NN cells/NNS requires/VBZ CD28/NN activation/NN ./. 
The/DT addition/NN of/IN rCTLA4Ig/NN ,/, which/WDT blocks/VBZ CD28/NN binding/NN to/TO its/PRP$ ligand/NN ,/, to/TO the/DT cultures/NNS decreased/VBD IL-2/NN promoter/NN activation/NN by/IN >/JJR 80/CD %/NN ./. 
Interestingly/RB ,/, CTLA4Ig/NN did/VBD not/RB significantly/RB inhibit/VB the/DT activation/NN of/IN either/CC NF/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) or/CC AP-1/NN reporters/NNS ./. 
Therefore/RB ,/, activation/NN of/IN NFAT/NN and/CC AP-1/NN is/VBZ insufficient/JJ for/IN IL-2/NN promoter/NN activation/NN ./. 
In/IN contrast/NN ,/, an/DT RE/AP/NN reporter/NN was/VBD blocked/VBN by/IN CTLA4Ig/NN by/IN >/JJR 90/CD %/NN ./. 
Thus/RB ,/, the/DT requirement/NN for/IN CD28/NN in/IN IL-2/NN promoter/NN activation/NN appears/VBZ to/TO be/VB due/JJ to/TO RE/AP/NN and/CC not/RB the/DT NFAT/NN or/CC AP-1/NN sites/NNS ./. 
In/IN addition/NN ,/, these/DT data/NNS suggest/VBP that/IN transcriptional/JJ activation/NN of/IN RE/AP/NN is/VBZ not/RB mediated/VBN by/IN NFAT/NN ,/, because/IN activation/NN of/IN a/DT NFAT/NN reporter/NN is/VBZ not/RB affected/VBN by/IN the/DT addition/NN of/IN CTLA4Ig/NN ./. 
UI/LS -/: 99074403/CD 
TI/LS -/: The/DT control/NN of/IN lytic/JJ replication/NN of/IN Epstein-Barr/JJ virus/NN in/IN B/NN lymphocytes/NNS (/( Review/NN )/) ./. 
AB/LS -/: Uncontrolled/JJ replication/NN of/IN a/DT virus/NN ,/, which/WDT is/VBZ harmful/JJ to/TO the/DT host/NN is/VBZ also/RB disadvantageous/JJ to/TO the/DT virus/NN ./. 
Most/JJS viruses/NNS can/MD not/RB compete/VB with/IN the/DT various/JJ immune/JJ mechanisms/NNS and/CC become/VBP eliminated/VBN in/IN the/DT course/NN of/IN infection/NN ./. 
Therefore/RB ,/, only/RB the/DT time/NN between/IN infection/NN and/CC eradication/NN remains/VBZ for/IN these/DT viruses/NNS to/TO proliferate/VB ./. 
A/DT few/JJ viruses/NNS ,/, like/IN the/DT Herpesviruses/NNS or/CC the/DT papillomaviruses/NNS ,/, however/RB ,/, have/VBP developed/VBN a/DT sophisticated/JJ strategy/NN for/IN persisting/VBG lifelong/RB ,/, usually/RB asymptomatically/RB in/IN the/DT host/NN ,/, hiding/VBG from/IN the/DT immune/JJ system/NN and/CC producing/VBG infectious/JJ progeny/NN at/IN the/DT same/JJ time/NN ./. 
This/DT strategy/NN depends/VBZ on/IN a/DT separation/NN of/IN latency/NN and/CC the/DT lytic/JJ replication/NN ,/, either/CC by/IN time/NN due/JJ to/TO differentiation-dependent/JJ mechanisms/NNS or/CC by/IN spatial/JJ separation/NN as/IN the/DT result/NN of/IN different/JJ host/NN cell/NN types/NNS ./. 
Both/DT are/VBP true/JJ for/IN the/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) ./. 
B/NN cells/NNS and/CC epithelial/JJ cells/NNS have/VBP a/DT pivotal/JJ role/NN in/IN the/DT life/NN cycle/NN of/IN the/DT virus/NN ./. 
The/DT former/JJ can/MD become/VB latently/RB infected/JJ and/CC are/VBP thought/VBN to/TO be/VB the/DT virus/NN reservoir/NN in/FW vivo/FW ,/, whereas/IN the/DT latter/JJ were/VBD shown/VBN to/TO be/VB permissive/JJ for/IN lytic/JJ replication/NN ./. 
However/RB ,/, replication/NN of/IN EBV/NN in/FW vivo/FW is/VBZ controlled/VBN primarily/RB by/IN host/NN immune/JJ mechanisms/NNS selecting/VBG for/IN cells/NNS that/WDT are/VBP not/RB permissive/JJ for/IN viral/JJ replication/NN as/IN the/DT result/NN of/IN a/DT particular/JJ set/NN of/IN transcription/NN factors/NNS ./. 
These/DT factors/NNS control/VBP the/DT activity/NN of/IN the/DT regulatory/JJ immediate-early/JJ genes/NNS and/CC ,/, in/IN addition/NN ,/, lytic/JJ and/CC latent/JJ cycle/NN regulatory/JJ genes/NNS negatively/RB interfere/VBP with/IN each/DT other/JJ and/CC thus/RB link/VBP cellular/JJ and/CC viral/JJ gene/NN regulatory/JJ mechanisms/NNS ./. 
Disturbance/NN of/IN both/CC the/DT immune/JJ surveillance/NN as/RB well/RB as/IN viral/JJ gene/NN regulation/NN may/MD result/VB in/IN EBV-associated/JJ disease/NN ./. 
UI/LS -/: 99060915/CD 
TI/LS -/: Adaptor/NN function/NN for/IN the/DT Syk/NN kinases-interacting/JJ protein/NN 3BP2/NN in/IN IL-2/NN gene/NN activation/NN ./. 
AB/LS -/: Syk-family/JJ tyrosine/NN kinases/NNS are/VBP essential/JJ for/IN lymphocyte/NN development/NN and/CC activation/NN ./. 
Using/VBG a/DT yeast/NN two-hybrid/JJ screen/NN to/TO identify/VB Syk/NN kinases-interacting/JJ proteins/NNS (/( SKIPs/NNS )/) ,/, we/PRP isolated/VBD 3BP2/NN ,/, an/DT Abl/NN SH3-interacting/JJ protein/NN of/IN unknown/JJ function/NN ./. 
3BP2/NN was/VBD selectively/RB expressed/VBN in/IN hematopoietic/lymphoid/JJ tissues/NNS and/CC bound/VBD via/IN its/PRP$ SH2/NN domain/NN activated/VBN Syk-family/JJ kinases/NNS in/IN mammalian/JJ cells/NNS ,/, including/VBG in/IN antigen/NN receptor-stimulated/JJ T/NN cells/NNS ./. 
In/IN addition/NN to/TO Zap-70/NN ,/, the/DT 3BP2/NN SH2/NN domain/NN associated/VBD in/FW vitro/FW with/IN LAT/NN ,/, Grb2/NN ,/, PLCgamma1/NN ,/, and/CC Cbl/NN from/IN activated/VBN T/NN cell/NN lysates/NNS ./. 
Transient/JJ 3BP2/NN overexpression/NN induced/VBD transcriptional/JJ activation/NN of/IN the/DT IL-2/NN promoter/NN and/CC its/PRP$ NFAT/NN or/CC AP-1/NN elements/NNS ./. 
This/DT activity/NN was/VBD dependent/JJ on/IN the/DT SH2/NN and/CC pleckstrin-homology/JJ domains/NNS of/IN 3BP2/NN ,/, and/CC required/VBD functional/JJ Syk/NN kinases/NNS ,/, Ras/NN ,/, and/CC calcineurin/NN ./. 
Thus/RB ,/, 3BP2/NN is/VBZ an/DT important/JJ adaptor/NN that/WDT may/MD couple/VB activated/VBN Zap-70/Syk/NN to/TO a/DT LAT-containing/JJ signaling/VBG complex/NN involved/VBN in/IN TCR-mediated/JJ gene/NN transcription/NN ./. 
UI/LS -/: 99054996/CD 
TI/LS -/: In/FW vitro/FW suppression/NN of/IN programmed/VBN cell/NN death/NN of/IN B/NN cells/NNS by/IN tissue/NN inhibitor/NN of/IN metalloproteinases-1/NN ./. 
AB/LS -/: Cellular/JJ pathways/NNS for/IN induction/NN of/IN programmed/VBN cell/NN death/NN (/( PCD/NN )/) have/VBP been/VBN identified/VBN ,/, but/CC little/JJ is/VBZ known/VBN about/IN specific/JJ extracellular/JJ matrix/NN processes/NNS that/WDT may/MD affect/VB apoptosis/NN along/IN those/DT pathways/NNS ./. 
In/IN this/DT study/NN ,/, a/DT series/NN of/IN Burkitt/NN 's/POS lymphoma/NN (/( BL/NN )/) cell/NN lines/NNS were/VBD assayed/VBN for/IN their/PRP$ expression/NN of/IN tissue/NN inhibitor/NN of/IN metalloproteinases/NNS (/( TIMP/NNS )/) -1/CD ./. 
Results/NNS indicate/VBP that/IN TIMP-1-positive/JJ BL/NN lines/NNS show/VBP resistance/NN to/TO cold-shock-induced/JJ apoptosis/NN ./. 
Furthermore/RB ,/, recombinant/JJ TIMP-1/NN ,/, but/CC not/RB TIMP-2/NN or/CC a/DT synthetic/JJ metalloproteinase/NN inhibitor/NN (/( BB-94/NN )/) ,/, confers/VBZ resistance/NN to/TO apoptosis/NN induced/VBN by/IN both/CC CD95-dependent/JJ and/CC -independent/JJ (/( cold/JJ shock/NN ,/, serum/NN deprivation/NN ,/, and/CC gamma-radiation/NN )/) pathways/NNS in/IN TIMP-1-negative/JJ BL/NN lines/NNS ./. 
TIMP-1/NN suppression/NN of/IN PCD/NN is/VBZ not/RB due/JJ to/TO metalloproteinase/NN inhibition/NN ,/, as/IN reduction/NN and/CC alkylation/NN of/IN the/DT TIMP-1/NN did/VBD not/RB abolish/VB this/DT activity/NN ./. 
Retroviral/JJ induction/NN of/IN TIMP-1/NN not/RB only/RB resulted/VBD in/IN cell/NN survival/NN but/CC also/RB in/IN continued/JJ DNA/NN synthesis/NN for/IN up/RB to/TO 5/CD d/NN in/IN the/DT absence/NN of/IN serum/NN ,/, while/IN controls/NNS underwent/VBD apoptosis/NN ./. 
This/DT resistance/NN to/TO apoptosis/NN is/VBZ reversed/VBN by/IN anti-TIMP-1/JJ antibodies/NNS ,/, demonstrating/VBG that/IN secreted/VBN TIMP-1/NN is/VBZ active/JJ in/IN blocking/VBG apoptosis/NN ./. 
Furthermore/RB ,/, TIMP-1/NN upregulation/NN induced/VBD expression/NN of/IN Bcl-XL/NN but/CC not/RB Bcl-2/NN as/RB well/RB as/IN decreased/VBN NF-kappaB/NN activity/NN as/IN compared/VBN with/IN controls/NNS ./. 
These/DT results/NNS demonstrate/VBP that/IN TIMP-1/NN suppresses/VBZ apoptosis/NN in/IN B/NN cells/NNS and/CC suggests/VBZ a/DT novel/JJ activity/NN for/IN TIMP-1/NN in/IN tissue/NN homeostasis/NN ./. 
UI/LS -/: 99045415/CD 
TI/LS -/: Spi-1/PU.1/NN proto-oncogene/NN induces/VBZ opposite/JJ effects/NNS on/IN monocytic/JJ and/CC erythroid/JJ differentiation/NN of/IN K562/NN cells/NNS ./. 
AB/LS -/: Spi-1/PU.1/NN is/VBZ a/DT hematopoietic/JJ transcription/NN factor/NN of/IN the/DT Ets/NN family/NN ./. 
To/TO analyze/VB the/DT effects/NNS of/IN ectopic/JJ expression/NN of/IN spi-1/NN on/IN the/DT proliferation/differentiation/NN of/IN human/JJ myeloid/JJ leukemia/NN cells/NNS ,/, K562/NN cells/NNS were/VBD stably/RB transfected/VBN with/IN a/DT spi-1/NN expression/NN vector/NN ./. 
The/DT transfected/VBN cell/NN lines/NNS expressed/VBD elevated/JJ levels/NNS of/IN spi-1/NN mRNA/NN and/CC protein/NN and/CC high/JJ Spi-1-DNA/JJ binding/NN activity/NN ./. 
The/DT spi-1/NN transfected/JJ cells/NNS showed/VBD reduced/VBN growth/NN rates/NNS and/CC reduced/VBN clonogenic/JJ cell/NN growth/NN ./. 
When/WRB the/DT erythroid/JJ and/CC monocytic/JJ differentiation/NN markers/NNS were/VBD analyzed/VBN ,/, spi-1/NN overexpression/NN resulted/VBD in/IN opposite/JJ effects/NNS :/: erythroid/JJ differentiation/NN was/VBD significantly/RB inhibited/VBN in/IN spi-1/NN transfectants/NNS ,/, while/IN spi-1/NN overexpression/NN increased/VBD the/DT monocytic/JJ differentiation/NN of/IN cells/NNS ./. 
These/DT results/NNS indicate/VBP a/DT differential/JJ role/NN of/IN Spi-1/NN on/IN the/DT differentiation/NN of/IN human/JJ myeloid/JJ leukemia/NN cells/NNS ./. 
Copyright/NN 1998/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99034605/CD 
TI/LS -/: In/FW vivo/FW function/NN of/IN an/DT interleukin/NN 2/CD receptor/NN beta/NN chain/NN (/( IL-2Rbeta/NN )/) //: IL-4Ralpha/NN cytokine/NN receptor/NN chimera/NN potentiates/VBZ allergic/JJ airway/NN disease/NN ./. 
AB/LS -/: Strength/NN of/IN T/NN cell/NN receptor/NN (/( TCR/NN )/) signaling/NN ,/, coreceptors/NNS ,/, costimulation/NN ,/, antigen-presenting/JJ cell/NN type/NN ,/, and/CC cytokines/NNS all/DT play/VBP crucial/JJ roles/NNS in/IN determining/VBG the/DT efficiency/NN with/IN which/WDT type/NN 2/CD T/NN lymphocytes/NNS (/( Th2/NN ,/, Tc2/NN )/) develop/VBP from/IN uncommitted/JJ precursors/NNS ./. 
To/TO investigate/VB in/FW vivo/FW regulatory/JJ mechanisms/NNS that/WDT control/VBP the/DT population/NN of/IN type/NN 2/CD T/NN cells/NNS and/CC disease/NN susceptibility/NN ,/, we/PRP have/VBP created/VBN lines/NNS of/IN transgenic/JJ mice/NNS in/IN which/WDT expression/NN of/IN a/DT chimeric/JJ cytokine/NN receptor/NN (/( the/DT mouse/NN interleukin/NN 2/CD receptor/NN beta/NN chain/NN [/( IL-2Rbeta/NN ]/) extracellular/JJ domain/NN fused/VBN to/TO the/DT cytoplasmic/JJ tail/NN of/IN IL-4Ralpha/NN )/) is/VBZ targeted/VBN to/TO the/DT T/NN lymphoid/JJ lineage/NN using/VBG the/DT proximal/JJ lck/NN promoter/NN ./. 
This/DT chimera/NN transduced/VBD IL-4-specific/JJ signals/NNS in/IN response/NN to/TO IL-2/NN binding/NN and/CC dramatically/RB enhanced/VBD type/NN 2/CD responses/NNS (/( IL-4/NN ,/, IL-5/NN ,/, and/CC immunoglobulin/NN E/NN production/NN )/) upon/IN in/FW vitro/FW TCR/NN stimulation/NN or/CC in/FW vivo/FW antigen/NN challenge/NN ./. 
Thus/RB ,/, type/NN 2/CD effector/NN function/NN was/VBD augmented/VBN by/IN IL-4/NN signals/NNS transduced/VBN through/IN a/DT chimeric/JJ receptor/NN expressed/VBN in/IN a/DT T/NN cell-specific/JJ manner/NN ./. 
This/DT influence/NN was/VBD sufficient/JJ for/IN establishment/NN of/IN antigen-induced/JJ allergic/JJ airway/NN hyperresponsiveness/NN on/IN a/DT disease-resistant/JJ background/NN 
UI/LS -/: 97148606/CD 
TI/LS -/: Differentiation-dependent/JJ expression/NN of/IN a/DT human/JJ carboxylesterase/NN in/IN monocytic/JJ cells/NNS and/CC transcription/NN factor/NN binding/VBG to/TO the/DT promoter/NN ./. 
AB/LS -/: Carboxylesterases/NNS play/VBP an/DT important/JJ role/NN in/IN defense/NN and/CC clearance/NN mechanisms/NNS of/IN the/DT monocyte/macrophage/NN system/NN ./. 
During/IN the/DT differentiation/NN process/NN of/IN cells/NNS from/IN the/DT monocytic/JJ cell/NN line/NN THP-1/NN we/PRP observed/VBD a/DT transient/JJ transcriptional/JJ upregulation/NN of/IN a/DT human/JJ carboxylesterase/NN analyzed/VBN by/IN means/NN of/IN Northern/NN blots/NNS ./. 
In/IN PMA-treated/JJ THP-1/NN cells/NNS we/PRP could/MD detect/VB three/CD major/JJ transcription/NN initiation/NN sites/NNS as/IN revealed/VBN by/IN Nuclease/NN Protection/NN Assay/NN carried/VBN out/IN with/IN two/CD overlapping/VBG antisense/JJ RNA/NN probes/NNS ./. 
We/PRP have/VBP recently/RB cloned/VBN the/DT carboxylesterase/NN upstream/JJ sequence/NN and/CC showed/VBN its/PRP$ basal/JJ promoter/NN activity/NN in/IN CHO/NN cells/NNS ./. 
Using/VBG electrophoretic/JJ mobility/NN shift/NN analysis/NN we/PRP demonstrated/VBD that/IN the/DT promoter/NN region/NN spanning/VBG base/NN pairs/NNS -1/CD to/TO -275/CD ,/, which/WDT contains/VBZ several/JJ putative/JJ binding/VBG sites/NNS for/IN transcription/NN factors/NNS ,/, is/VBZ bound/VBN by/IN nuclear/JJ factors/NNS Sp1/NN and/CC IRBP/NN but/CC not/RB by/IN C/EBPs/NNS ./. 
Taken/VBN together/RB these/DT data/NNS indicate/VBP that/IN carboxylesterase/NN gene/NN transcription/NN in/IN THP-1/NN cells/NNS starts/VBZ at/IN multiple/JJ initiation/NN sites/NNS and/CC that/IN Sp1/NN and/CC IRBP/NN may/MD be/VB critical/JJ factors/NNS for/IN modulating/VBG the/DT differentiation-dependent/JJ transcription/NN of/IN this/DT human/JJ carboxylesterase/NN gene/NN ./. 
UI/LS -/: 97288734/CD 
TI/LS -/: The/DT role/NN of/IN the/DT Ikaros/NN gene/NN in/IN lymphocyte/NN development/NN and/CC homeostasis/NN ./. 
AB/LS -/: The/DT Ikaros/NN gene/NN ,/, which/WDT encodes/VBZ a/DT family/NN of/IN hemopoietic-specific/JJ zinc/NN finger/NN proteins/NNS ,/, is/VBZ described/VBN as/IN a/DT central/JJ regulator/NN of/IN lymphocyte/NN differentiation/NN ./. 
During/IN fetal/JJ development/NN ,/, it/PRP is/VBZ required/VBN at/IN the/DT earliest/JJS stage/NN of/IN T/NN cell/NN and/CC B/NN cell/NN specification/NN ./. 
In/IN the/DT adult/NN ,/, however/RB ,/, lymphoid/JJ lineages/NNS rely/VBP on/IN Ikaros/NN at/IN distinct/JJ phases/NNS of/IN their/PRP$ development/NN ./. 
Its/PRP$ activity/NN is/VBZ essential/JJ for/IN the/DT generation/NN of/IN B/NN cell/NN but/CC not/RB of/IN T/NN cell/NN precursors/NNS ,/, although/IN the/DT differentiation/NN of/IN the/DT latter/JJ is/VBZ not/RB normal/JJ ./. 
A/DT significant/JJ increase/NN in/IN CD4/NN thymocytes/NNS and/CC their/PRP$ immediate/JJ precursors/NNS is/VBZ detected/VBN ,/, and/CC because/IN these/DT cells/NNS lack/VBP markers/NNS that/WDT correlate/VBP with/IN positive/JJ selection/NN ,/, a/DT deregulation/NN in/IN their/PRP$ maturation/NN process/NN is/VBZ suggested/VBN ./. 
Furthermore/RB ,/, Ikaros-null/JJ thymocytes/NNS hyperproliferate/VBP in/IN response/NN to/TO T/NN cell/NN receptor/NN (/( TCR/NN )/) signaling/NN ;/: within/IN days/NNS after/IN their/PRP$ appearance/NN in/IN the/DT thymus/NN ,/, clonally/RB expanding/VBG populations/NNS are/VBP detected/VBN ./. 
Deregulated/JJ TCR-mediated/JJ responses/NNS and/CC the/DT fast/JJ kinetics/NNS of/IN tumor/NN development/NN in/IN these/DT mutant/JJ thymocytes/NNS implicate/VBP Ikaros/NN as/IN a/DT central/JJ tumor/NN suppressor/NN gene/NN for/IN the/DT T/NN cell/NN lineage/NN ./. 
In/IN addition/NN ,/, lack/NN of/IN natural/JJ killer/NN cells/NNS and/CC selective/JJ defects/NNS in/IN gamma/NN delta/NN T/NN cells/NNS and/CC dendritic/JJ antigen-presenting/JJ cells/NNS point/VBP to/TO Ikaros/NN as/IN an/DT essential/JJ factor/NN for/IN the/DT establishment/NN of/IN early/JJ branchpoints/NNS of/IN the/DT T/NN cell/NN pathway/NN ./. 
The/DT dominant/JJ interference/NN activity/NN of/IN Ikaros/NN isoforms/NNS unable/JJ to/TO bind/VB DNA/NN and/CC their/PRP$ effects/NNS in/IN lymphocyte/NN development/NN suggest/VBP that/IN Ikaros/NN works/VBZ in/IN concert/NN with/IN other/JJ factors/NNS ./. 
The/DT role/NN of/IN Aiolos/NN ,/, a/DT lymphoid-restricted/JJ and/CC structurally/RB related/JJ gene/NN ,/, in/IN lymphoid/JJ differentiation/NN is/VBZ discussed/VBN ./. 
A/DT model/NN is/VBZ proposed/VBN that/WDT defines/VBZ Ikaros/NN as/IN the/DT backbone/NN of/IN a/DT complex/JJ regulatory/JJ protein/NN network/NN that/WDT controls/VBZ cell/NN fate/NN decisions/NNS and/CC regulates/VBZ homeostasis/NN in/IN the/DT hemo-lymphoid/JJ system/NN ./. 
Changes/NNS in/IN this/DT regulatory/JJ network/NN may/MD reflect/VB differentiation/NN and/CC proliferation/NN adjustments/NNS made/VBN in/IN hemo-lymphoid/JJ progenitors/NNS and/CC precursors/NNS as/IN they/PRP give/VBP rise/NN to/TO the/DT cells/NNS of/IN our/PRP$ immune/JJ system/NN ./. 
UI/LS -/: 97138389/CD 
TI/LS -/: STAT1/NN pathway/NN is/VBZ involved/VBN in/IN activation/NN of/IN caprine/JJ arthritis-encephalitis/JJ virus/NN long/JJ terminal/JJ repeat/NN in/IN monocytes/NNS ./. 
AB/LS -/: The/DT caprine/JJ arthritis-encephalitis/JJ virus/NN (/( CAEV/NN )/) long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) is/VBZ activated/VBN by/IN gamma/NN interferon/NN (/( IFN-gamma/NN )/) in/IN promonocytic/JJ cells/NNS ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN a/DT 70-bp/JJ element/NN is/VBZ necessary/JJ and/CC sufficient/JJ for/IN the/DT response/NN of/IN the/DT CAEV/NN LTR/NN to/TO this/DT cytokine/NN ./. 
At/IN the/DT 5'/JJ end/NN ,/, this/DT 70-bp/JJ IFN-gamma/NN response/NN element/NN contains/VBZ sequence/NN similarity/NN to/TO the/DT gamma/NN activated/JJ site/NN (/( GAS/NN )/) ./. 
Here/RB we/PRP demonstrate/VBP that/IN the/DT putative/JJ GAS/NN element/NN in/IN the/DT CAEV/NN LTR/NN binds/VBZ specifically/RB to/TO a/DT cellular/JJ factor/NN induced/VBN by/IN IFN-gamma/NN in/IN promonocytic/JJ cells/NNS ./. 
Substitution/NN mutations/NNS in/IN this/DT consensus/NN sequence/NN eliminate/VBP binding/NN of/IN the/DT inducible/JJ factor/NN ./. 
The/DT GAS/NN element/NN from/IN the/DT 70-bp/JJ motif/NN is/VBZ sufficient/JJ to/TO confer/VB responsiveness/NN to/TO IFN-gamma/NN using/VBG a/DT heterologous/JJ minimal/JJ promoter/NN ./. 
Consistent/JJ with/IN the/DT binding/NN data/NNS ,/, the/DT same/JJ mutations/NNS in/IN the/DT GAS/NN element/NN eliminate/VBP responsiveness/NN to/TO IFN-gamma/NN in/IN the/DT context/NN of/IN both/CC a/DT functional/JJ CAEV/NN LTR/NN and/CC a/DT heterologous/JJ promoter/NN ./. 
The/DT cellular/JJ factor/NN that/WDT binds/VBZ to/TO the/DT GAS/NN element/NN is/VBZ present/JJ from/IN 5/CD min/NN to/TO 14/CD h/NN after/IN stimulation/NN with/IN IFN-gamma/NN ./. 
Binding/NN of/IN the/DT nuclear/JJ factor/NN to/TO the/DT GAS/NN element/NN in/IN the/DT CAEV/NN LTR/NN is/VBZ inhibited/VBN by/IN antibody/NN directed/VBN against/IN STAT1/NN (/( p91/84/NN )/) ./. 
Thus/RB ,/, the/DT GAS/NN sequence/NN in/IN the/DT CAEV/NN LTR/NN is/VBZ essential/JJ for/IN the/DT response/NN to/TO IFN-gamma/NN and/CC a/DT STAT1-like/JJ factor/NN binds/VBZ to/TO this/DT site/NN ./. 
The/DT STAT-1/NN signaling/NN pathway/NN provides/VBZ at/IN least/JJS one/CD mechanism/NN for/IN activation/NN of/IN the/DT CAEV/NN LTR/NN by/IN IFN-gamma/NN in/IN monocytes/NNS ./. 
These/DT data/NNS are/VBP the/DT first/JJ demonstration/NN of/IN a/DT role/NN for/IN a/DT STAT/NN family/NN member/NN in/IN the/DT regulation/NN of/IN a/DT viral/JJ promoter/NN ./. 
UI/LS -/: 99121740/CD 
TI/LS -/: 1,25-Dihydroxyvitamin/NN D3/NN receptors/NNS in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS from/IN patients/NNS with/IN renal/JJ insufficiency/NN ./. 
AB/LS -/: A/DT reduced/VBN expression/NN of/IN the/DT vitamin/NN D/NN receptor/NN (/( VDR/NN )/) in/IN parathyroid/JJ glands/NNS of/IN uremic/JJ animals/NNS and/CC humans/NNS has/VBZ been/VBN observed/VBN ./. 
Similar/JJ results/NNS have/VBP been/VBN obtained/VBN by/IN our/PRP$ own/JJ group/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NNS )/) from/IN patients/NNS with/IN secondary/JJ hyperparathyroidism/NN to/TO chronic/JJ renal/JJ failure/NN ./. 
However/RB ,/, the/DT reasons/NNS for/IN these/DT changes/NNS are/VBP not/RB clear/JJ ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP have/VBP investigated/VBN the/DT specific/JJ uptake/NN of/IN [3H]1,25(OH)2D3/NN by/IN PBMC/NNS of/IN 11/CD women/NNS with/IN advanced/JJ chronic/JJ renal/JJ failure/NN (/( A-CRF/NN )/) ,/, 6/CD women/NNS with/IN mild-moderate/JJ renal/JJ insufficiency/NN (/( M-CRF/NN )/) ,/, and/CC 23/CD healthy/JJ women/NNS ./. 
The/DT mean/JJ dissociation/NN constant/NN (/( KD/NN )/) was/VBD similar/JJ in/IN both/CC groups/NNS of/IN patients/NNS and/CC in/IN healthy/JJ women/NNS (/( A-CRF/NN :/: 0.7/CD +/-/CC 0.5/CD x/CC 10(-10)/CD M/NN ;/: M-CRF/NN :/: 1.1/CD +/-/CC 0.9/CD x/CC 10(-10)/CD M/NN ;/: controls/NNS :/: 1.0/CD +/-/CC 0.6/CD x/CC 10(-10)/CD M/NN )/) ./. 
However/RB ,/, VDR/NN concentration/NN was/VBD significantly/RB decreased/VBN in/IN A-CRF/NN (/( 0.8/CD +/-/CC 0.5/CD fmol/10(7)/NN cells/NNS vs./CC 2.3/CD +/-/CC 0.9/CD fmol/10(7)/NN cells/NNS in/IN controls/NNS ,/, p/NN </JJR 0.001/CD )/) ,/, whereas/IN no/DT changes/NNS were/VBD seen/VBN in/IN M-CRF/NN (/( 1.7/CD +/-/CC 0.7/CD fmol/10(7)/NN cells/NNS vs./CC 2.3/CD +/-/CC 0.9/CD fmol/10(7)/NN cells/NNS in/IN controls/NNS )/) ./. 
No/DT correlation/NN was/VBD seen/VBN between/IN VDR/NN and/CC serum/NN calcitriol/NN or/CC PTH/NN levels/NNS ,/, when/WRB considering/VBG both/DT groups/NNS of/IN patients/NNS together/RB or/CC separately/RB ./. 
Conversely/RB ,/, a/DT significant/JJ negative/JJ correlation/NN was/VBD found/VBN between/IN VDR/NN and/CC serum/NN creatinine/NN values/NNS when/WRB A-CRF/NN and/CC M-CRF/NN were/VBD considered/VBN altogether/RB (/( r/NN =/JJ -0.63/CD ;/: p/NN </JJR 0.01/CD )/) ./. 
Treatment/NN with/IN two/CD different/JJ schedules/NNS of/IN oral/JJ calcitriol/NN (/( five/CD patients/NNS with/IN 0.5/CD microgram/day/NNS for/IN 1/CD month/NN and/CC four/CD patients/NNS with/IN 2/CD micrograms/day/NN for/IN 7/CD days/NNS )/) did/VBD not/RB change/VB VDR/NN concentrations/NNS ./. 
We/PRP conclude/VBP that/IN the/DT low/JJ levels/NNS of/IN serum/NN 1,25(OH)2D3/NN of/IN uremia/NN are/VBP not/RB responsible/JJ for/IN the/DT decrease/NN in/IN VDR/NN concentration/NN found/VBN in/IN these/DT patients/NNS ./. 
UI/LS -/: 99090715/CD 
TI/LS -/: Transcription/NN factor/NN binding/VBG to/TO the/DT core/NN promoter/NN of/IN the/DT human/JJ monoamine/NN oxidase/NN B/NN gene/NN in/IN the/DT cerebral/JJ cortex/NN and/CC in/IN blood/NN cells/NNS ./. 
AB/LS -/: Many/JJ studies/NNS show/VBP that/IN monoamine/NN oxidase/NN B/NN in/IN blood/NN cells/NNS is/VBZ a/DT biological/JJ marker/NN for/IN personality/NN characteristics/NNS such/JJ as/IN sensation/NN seeking/NN ./. 
The/DT mechanism/NN underlying/VBG this/DT association/NN is/VBZ so/RB far/RB not/RB explored/VBN ./. 
In/IN the/DT present/JJ study/NN we/PRP have/VBP performed/VBN electrophoretic/JJ mobility-shift/JJ assays/NNS to/TO investigate/VB the/DT pattern/NN of/IN protein/NN binding/NN to/TO a/DT 150/CD bp/NN fragment/NN of/IN the/DT proximal/JJ 5'-flanking/JJ region/NN of/IN the/DT human/JJ monoamine/NN oxidase/NN B/NN gene/NN ./. 
We/PRP compared/VBD the/DT pattern/NN using/VBG nuclear/JJ extracts/NNS from/IN human/JJ brain/NN and/CC lymphocytes/NNS ./. 
Interestingly/RB ,/, a/DT correlation/NN was/VBD observed/VBN between/IN monoamine/NN oxidase/NN B/NN enzyme/NN activity/NN in/IN blood/NN cells/NNS (/( platelets/NNS )/) and/CC the/DT binding/NN pattern/NN of/IN two/CD uncharacterized/JJ transcription/NN factors/NNS ./. 
These/DT data/NNS are/VBP well/RB in/IN line/NN with/IN the/DT long-standing/JJ notion/NN that/IN interindividual/JJ differences/NNS in/IN platelet/NN monoamine/NN oxidase/NN may/MD represent/VB differences/NNS in/IN expression/NN of/IN the/DT enzyme/NN rather/RB than/IN genotypic/JJ variation/NN ./. 
UI/LS -/: 99075480/CD 
TI/LS -/: Enhanced/VBN differentiation/NN of/IN HL-60/NN leukemia/NN cells/NNS to/TO macrophages/NNS induced/VBN by/IN ciprofibrate/NN ./. 
AB/LS -/: Ciprofibrate/NN ,/, an/DT hypolipidaemic/JJ peroxisome/NN proliferator/NN ,/, induced/VBD differentiation/NN of/IN HL-60/NN cells/NNS ./. 
The/DT effect/NN was/VBD greatly/RB potentiated/VBN by/IN phorbol/NN 12-myristate/NN 13-acetate/NN at/IN a/DT concentration/NN where/WRB neither/CC phorbol/NN ester/NN nor/CC ciprofibrate/NN alone/RB had/VBD any/DT effect/NN on/IN these/DT cells/NNS ./. 
As/IN occurs/VBZ for/IN HL-60/NN cell/NN differentiation/NN induced/VBN by/IN high/JJ phorbol/NN ester/NN concentration/NN ,/, the/DT ciprofibrate-induced/JJ phorbol/NN ester-dependent/JJ differentiation/NN of/IN HL-60/NN cells/NNS proceeded/VBD through/IN the/DT monocytic/macrophage/JJ pathway/NN and/CC induced/VBD the/DT phosphorylation/NN of/IN proteins/NNS with/IN similar/JJ molecular/JJ weights/NNS suggesting/VBG that/IN increased/VBN protein/NN kinase/NN C/NN activity/NN may/MD be/VB involved/VBN in/IN the/DT effect/NN ./. 
The/DT peroxisome/NN proliferator-activated/JJ receptor/NN (/( PPARalpha/NN )/) transcription/NN factor/NN is/VBZ expressed/VBN in/IN HL-60/NN cells/NNS ,/, but/CC no/DT changes/NNS were/VBD observed/VBN in/IN its/PRP$ expression/NN upon/IN HL-60/NN cell/NN differentiation/NN ./. 
UI/LS -/: 99069401/CD 
TI/LS -/: The/DT involvement/NN of/IN multiple/JJ tumor/NN necrosis/NN factor/NN receptor/NN (/( TNFR/NN )/) -associated/JJ factors/NNS in/IN the/DT signaling/NN mechanisms/NNS of/IN receptor/NN activator/NN of/IN NF-kappaB/NN ,/, a/DT member/NN of/IN the/DT TNFR/NN superfamily/NN ./. 
AB/LS -/: Receptor/NN activator/NN of/IN NF-kappaB/NN (/( RANK/NN )/) is/VBZ a/DT recently/RB identified/VBN member/NN of/IN the/DT tumor/NN necrosis/NN factor/NN receptor/NN superfamily/NN and/CC is/VBZ expressed/VBN on/IN activated/VBN T/NN cells/NNS and/CC dendritic/JJ cells/NNS ./. 
Its/PRP$ cognate/JJ ligand/NN (/( RANKL/NN )/) plays/VBZ significant/JJ roles/NNS in/IN the/DT activation/NN of/IN dendritic/JJ cell/NN function/NN and/CC osteoclast/NN differentiation/NN ./. 
We/PRP demonstrate/VBP here/RB the/DT interaction/NN of/IN RANK/NN with/IN tumor/NN necrosis/NN factor/NN receptor-associated/JJ factors/NNS (/( TRAFs/NNS )/) 1/CD ,/, 2/CD ,/, 3/CD ,/, 5/CD ,/, and/CC 6/CD both/CC in/FW vitro/FW and/CC in/IN cells/NNS ./. 
Mapping/NN of/IN the/DT structural/JJ requirements/NNS for/IN TRAF/RANK/NN interaction/NN revealed/VBD multiple/JJ TRAF/NN binding/NN sites/NNS clustered/VBN in/IN two/CD distinct/JJ domains/NNS in/IN the/DT RANK/NN cytoplasmic/JJ tail/NN ./. 
These/DT TRAF/NN binding/NN domains/NNS were/VBD shown/VBN to/TO be/VB functionally/RB important/JJ for/IN the/DT RANK-dependent/JJ induction/NN of/IN NF-kappaB/NN and/CC c-Jun/NN NH2-terminal/JJ kinase/NN activities/NNS ./. 
Site-directed/JJ mutagenesis/NN demonstrated/VBD that/IN these/DT TRAF/NN binding/NN sites/NNS exhibited/VBD selective/JJ binding/NN for/IN different/JJ TRAF/NN proteins/NNS ./. 
In/IN particular/JJ ,/, TRAF6/NN interacted/VBD with/IN membrane-proximal/JJ determinants/NNS distinct/JJ from/IN those/DT binding/VBG TRAFs/NNS 1/CD ,/, 2/CD ,/, 3/CD ,/, and/CC 5/CD ./. 
When/WRB this/DT membrane-proximal/JJ TRAF6/NN interaction/NN domain/NN was/VBD deleted/VBN ,/, RANK-mediated/JJ NF-kappaB/NN signaling/NN was/VBD completely/RB inhibited/VBN while/IN c-Jun/NN NH2-terminal/JJ kinase/NN activation/NN was/VBD partially/RB inhibited/VBN ./. 
An/DT NH2-terminal/JJ truncation/NN mutant/NN of/IN TRAF6/NN inhibited/VBD RANKL-mediated/JJ NF-kappaB/NN activation/NN ,/, but/CC failed/VBD to/TO affect/VB constitutive/JJ signaling/NN induced/VBN by/IN receptor/NN overexpression/NN ,/, revealing/VBG a/DT selective/JJ role/NN for/IN TRAF6/NN in/IN ligand-induced/JJ activation/NN events/NNS ./. 
UI/LS -/: 99061768/CD 
TI/LS -/: Stat6/NN inhibits/VBZ human/JJ interleukin-4/NN promoter/NN activity/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: The/DT differentiation/NN of/IN naive/JJ T-helper/NN (/( Th/NN )/) cells/NNS into/IN cytokine-secreting/JJ effector/NN Th/NN cells/NNS requires/VBZ exposure/NN to/TO multiple/JJ signals/NNS ,/, including/VBG exogenous/JJ cytokines/NNS ./. 
Interleukin-4/NN (/( IL-4/NN )/) plays/VBZ a/DT major/JJ role/NN in/IN this/DT process/NN by/IN promoting/VBG the/DT differentiation/NN of/IN IL-4-secreting/JJ Th2/NN cells/NNS ./. 
In/IN Th2/NN cells/NNS ,/, IL-4/NN gene/NN expression/NN is/VBZ tightly/RB controlled/VBN at/IN the/DT level/NN of/IN transcription/NN by/IN the/DT coordinated/VBN binding/NN of/IN multiple/JJ transcription/NN factors/NNS to/TO regulatory/JJ elements/NNS in/IN the/DT proximal/JJ promoter/NN region/NN ./. 
Nuclear/JJ factor/NN of/IN activated/VBN T/NN cell/NN (/( NFAT/NN )/) family/NN members/NNS play/VBP a/DT critical/JJ role/NN in/IN regulating/VBG IL-4/NN transcription/NN and/CC interact/VBP with/IN up/RB to/TO five/CD sequences/NNS (/( termed/VBN P0/NN through/IN P4/NN )/) in/IN the/DT IL-4/NN promoter/NN ./. 
The/DT molecular/JJ mechanisms/NNS by/IN which/WDT IL-4/NN induces/VBZ expression/NN of/IN the/DT IL-4/NN gene/NN are/VBP not/RB known/VBN ,/, although/IN the/DT IL-4-activated/JJ transcription/NN factor/NN signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN 6/CD (/( Stat6/NN )/) is/VBZ required/VBN for/IN this/DT effect/NN ./. 
We/PRP report/VBP here/RB that/IN Stat6/NN interacts/VBZ with/IN three/CD binding/VBG sites/NNS in/IN the/DT human/JJ IL-4/NN promoter/NN by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ./. 
These/DT sites/NNS overlap/VBP the/DT P1/NN ,/, P2/NN ,/, and/CC P4/NN NFAT/NN elements/NNS ./. 
To/TO investigate/VB the/DT role/NN of/IN Stat6/NN in/IN regulating/VBG IL-4/NN transcription/NN ,/, we/PRP used/VBD Stat6-deficient/JJ Jurkat/NN T/NN cells/NNS with/IN different/JJ intact/JJ IL-4/NN promoter/NN constructs/NNS in/IN cotransfection/NN assays/NNS ./. 
We/PRP show/VBP that/IN ,/, whereas/IN a/DT multimerized/JJ response/NN element/NN from/IN the/DT germline/NN IgE/NN promoter/NN was/VBD highly/RB induced/VBN by/IN IL-4/NN in/IN Stat6-expressing/JJ Jurkat/NN cells/NNS ,/, the/DT intact/JJ human/JJ IL-4/NN promoter/NN was/VBD repressed/VBN under/IN similar/JJ conditions/NNS ./. 
We/PRP conclude/VBP that/IN the/DT function/NN of/IN Stat6/NN is/VBZ highly/RB dependent/JJ on/IN promoter/NN context/NN and/CC that/IN this/DT factor/NN promotes/VBZ IL-4/NN gene/NN expression/NN in/IN an/DT indirect/JJ manner/NN ./. 
UI/LS -/: 99055586/CD 
TI/LS -/: Epithelial/JJ cell-initiated/JJ inflammation/NN plays/VBZ a/DT crucial/JJ role/NN in/IN early/JJ tissue/NN damage/NN in/IN amebic/JJ infection/NN of/IN human/JJ intestine/NN ./. 
AB/LS -/: BACKGROUND/NN &/CC AIMS/NNS :/: Entamoeba/FW histolytica/NN infection/NN of/IN the/DT intestine/NN can/MD induce/VB severe/JJ gut/NN inflammation/NN ./. 
The/DT aims/NNS of/IN this/DT study/NN were/VBD to/TO assess/VB the/DT role/NN of/IN the/DT host/NN inflammatory/JJ response/NN in/IN the/DT tissue/NN damage/NN observed/VBN with/IN amebiasis/NN and/CC the/DT role/NN of/IN the/DT intestinal/JJ epithelial/JJ cell/NN in/IN initiating/VBG that/DT response/NN ./. 
METHODS/NNS :/: E./FW histolytica/NN infection/NN was/VBD established/VBN in/IN human/JJ intestinal/JJ xenografts/NNS in/IN severe/JJ combined/JJ immunodeficient/JJ (/( SCID-HU-INT/JJ )/) mice/NNS ./. 
Human/JJ intestinal/JJ epithelial/JJ cell/NN inflammatory/JJ responses/NNS to/TO amebic/JJ infection/NN were/VBD inhibited/VBN by/IN the/DT intraluminal/JJ administration/NN of/IN an/DT antisense/JJ oligonucleotide/NN to/TO the/DT human/JJ p65/NN subunit/NN of/IN nuclear/JJ factor/NN kappaB/NN ,/, and/CC the/DT role/NN of/IN neutrophils/NNS in/IN tissue/NN damage/NN observed/VBN with/IN amebiasis/NN was/VBD studied/VBN by/IN depleting/VBG neutrophils/NNS from/IN SCID-HU-INT/JJ mice/NNS ./. 
RESULTS/NNS :/: Administration/NN of/IN the/DT antisense/JJ oligonucleotide/NN blocked/VBD the/DT production/NN of/IN human/JJ interleukin/NN 1beta/NN and/CC interleukin/NN 8/CD by/IN intestinal/JJ epithelial/JJ cells/NNS and/CC inhibited/VBD neutrophil/NN influx/NN into/IN the/DT E./FW histolytica-infected/JJ intestinal/JJ xenografts/NNS ./. 
Inhibition/NN of/IN the/DT gut/NN inflammatory/JJ response/NN by/IN the/DT antisense/JJ oligonucleotide/NN or/CC the/DT depletion/NN of/IN neutrophils/NNS from/IN SCID-HU- INT/JJ mice/NNS blocked/VBD the/DT increase/NN in/IN intestinal/JJ permeability/NN observed/VBN with/IN amebic/JJ infection/NN ./. 
CONCLUSIONS/NNS :/: Intestinal/JJ epithelial/JJ cells/NNS initiate/VBP an/DT inflammatory/JJ response/NN with/IN resulting/VBG neutrophil-mediated/JJ tissue/NN damage/NN in/IN response/NN to/TO E./FW histolytica/NN infection/NN ;/: this/DT inflammatory/JJ cascade/NN can/MD be/VB blocked/VBN by/IN inhibiting/VBG the/DT transcription/NN of/IN genes/NNS regulated/VBN by/IN nuclear/JJ factor/NN kappaB/NN ./. 
UI/LS -/: 99041401/CD 
TI/LS -/: Triptolide/NN induces/VBZ apoptotic/JJ death/NN of/IN T/NN lymphocyte/NN ./. 
AB/LS -/: Extract/NN of/IN Tripterygium/FW wilfordii/FW Hook./FW f/FW (/( TWHf/FW )/) has/VBZ immunosuppressive/JJ activity/NN and/CC has/VBZ been/VBN used/VBN as/IN anti-inflammatory/JJ agent/NN in/IN traditional/JJ Chinese/JJ medicine/NN for/IN centuries/NNS ./. 
Recent/JJ studies/NNS have/VBP demonstrated/VBN that/IN triptolide/NN is/VBZ the/DT major/JJ active/JJ component/NN in/IN the/DT extract/NN that/WDT inhibits/VBZ antigen/NN or/CC mitogen-induced/JJ T/NN cell/NN proliferation/NN ./. 
In/IN attempting/VBG to/TO investigate/VB its/PRP$ effect/NN on/IN activation/NN of/IN T/NN lymphocytes/NNS ,/, we/PRP found/VBD triptolide/NN induces/VBZ apoptotic/JJ death/NN of/IN T/NN cell/NN hybridomas/NNS and/CC peripheral/JJ T/NN cells/NNS but/CC not/RB that/DT of/IN thymocytes/NNS ./. 
The/DT triptolide-induced/JJ apoptosis/NN is/VBZ accompanied/VBN by/IN increase/NN of/IN DEVD-cleavable/JJ caspases/NNS activity/NN and/CC degradation/NN of/IN caspase/NN substrate/NN poly/NN (/( ADP-ribose/NN )/) polymerase/NN (/( PARP/NN )/) ./. 
A/DT specific/JJ inhibitor/NN of/IN caspases/NNS ,/, zVAD-FMK/NN ,/, prevents/VBZ triptolide-induced/JJ PARP/NN degradation/NN and/CC DNA/NN fragmentation/NN but/CC not/RB growth/NN arrest/NN ./. 
Furthermore/RB ,/, enforced/VBN expression/NN of/IN Bcl-2/NN inhibited/VBD triptolide-induced/JJ degradation/NN of/IN PARP/NN and/CC apoptosis/NN ./. 
These/DT results/NNS indicate/VBP that/IN triptolide/NN induces/VBZ T/NN cell/NN apoptosis/NN through/IN activating/VBG caspases/NNS ,/, and/CC suggest/VBP the/DT growth/NN arrest/NN and/CC apoptotic/JJ effect/NN of/IN triptolide/NN may/MD contribute/VB to/TO the/DT immunosuppressive/JJ activity/NN of/IN TWHf/FW extract/NN 
UI/LS -/: 97150708/CD 
TI/LS -/: A/DT novel/JJ transcription/NN factor/NN regulates/VBZ expression/NN of/IN the/DT vacuolar/JJ H+-ATPase/NN B2/NN subunit/NN through/IN AP-2/NN sites/NNS during/IN monocytic/JJ differentiation/NN ./. 
AB/LS -/: During/IN monocyte-to-macrophage/JJ differentiation/NN ,/, the/DT cellular/JJ content/NN of/IN vacuolar/JJ H+-ATPase/NN (/( V-ATPase/NN )/) increases/VBZ more/RBR than/IN 4-fold/RB ./. 
We/PRP have/VBP shown/VBN previously/RB that/IN amplified/VBN expression/NN of/IN the/DT B2/NN subunit/NN of/IN the/DT V-ATPase/NN occurs/VBZ solely/RB by/IN increased/VBN transcription/NN ,/, and/CC that/IN the/DT 5'-untranslated/JJ region/NN of/IN the/DT B2/NN gene/NN ,/, containing/VBG multiple/JJ consensus/NN binding/NN sites/NNS for/IN the/DT transcription/NN factors/NNS AP-2/NN and/CC Sp1/NN ,/, is/VBZ required/VBN for/IN this/DT expression/NN ./. 
The/DT present/JJ study/NN demonstrates/VBZ that/IN AP-2/NN binding/NN sequences/NNS are/VBP essential/JJ for/IN increased/VBN transcription/NN from/IN the/DT B2/NN promoter/NN during/IN monocyte-macrophage/JJ differentiation/NN and/CC that/IN AP-2/NN ,/, expressed/VBN exogenously/RB in/IN THP-1/NN and/CC other/JJ cells/NNS ,/, activates/VBZ transcription/NN from/IN the/DT B2/NN promoter/NN ./. 
In/IN mobility/NN shift/NN assays/NNS ,/, a/DT nuclear/JJ factor/NN from/IN THP-1/NN and/CC U-937/NN cells/NNS was/VBD identified/VBN that/WDT binds/VBZ to/TO several/JJ AP-2/NN response/NN elements/NNS within/IN the/DT B2/NN promoter/NN ,/, but/CC does/VBZ not/RB react/VB with/IN AP-2/NN antibodies/NNS ,/, and/CC has/VBZ a/DT DNA/NN sequence/NN binding/NN affinity/NN profile/NN that/WDT differs/VBZ from/IN AP-2/NN ./. 
These/DT findings/NNS suggest/VBP that/IN a/DT novel/JJ AP-2-like/JJ transcription/NN factor/NN is/VBZ responsible/JJ for/IN V-ATPase/NN B/NN subunit/NN amplification/NN during/IN monocyte/NN differentiation/NN ./. 
UI/LS -/: 97261053/CD 
TI/LS -/: c-Jun/NN and/CC GST-pi/NN expression/NN in/IN human/JJ plasma/NN cells/NNS ./. 
AB/LS -/: Bone/NN marrow/NN samples/NNS from/IN 33/CD patients/NNS affected/VBN by/IN MM/NN and/CC MGUS/NN ,/, and/CC 8/CD patients/NNS not/RB affected/VBN by/IN lymphoproliferative/JJ diseases/NNS were/VBD studied/VBN for/IN expression/NN of/IN c-Jun/NN (/( a/DT component/NN of/IN the/DT transcription/NN factor/NN AP-1/NN )/) and/CC glutathione-S-transferase/NN pi/NN (/( GST-pi/NN )/) using/VBG immunocytochemical/JJ methods/NNS ./. 
A/DT high/JJ and/CC frequent/JJ expression/NN of/IN these/DT two/CD proteins/NNS was/VBD found/VBN both/CC in/IN MM/NN and/CC MGUS/NN patients/NNS (/( 31/33/CD patients/NNS positive/JJ for/IN c-Jun/NN and/CC 29/33/CD patients/NNS positive/JJ for/IN GST-pi/NN )/) and/CC in/IN controls/NNS not/RB affected/VBN by/IN monoclonal/JJ gammopathy/NN (/( 7/8/CD patients/NNS positive/JJ for/IN both/CC c-Jun/NN and/CC GST-pi/NN )/) ./. 
No/DT statistically/RB significant/JJ correlation/NN was/VBD found/VBN between/IN c-Jun-/NN and/CC GST-pi-positive/JJ plasma/NN cells/NNS ./. 
The/DT expression/NN of/IN these/DT two/CD proteins/NNS was/VBD not/RB related/JJ to/TO clinical/JJ or/CC laboratory/NN data/NNS ./. 
Our/PRP$ results/NNS seem/VBP to/TO confirm/VB a/DT possible/JJ role/NN of/IN the/DT transcriptional/JJ complex/NN AP-1/NN in/IN activating/VBG GST-pi/NN promoter/NN in/IN human/JJ plasma/NN cells/NNS ./. 
UI/LS -/: 97134898/CD 
TI/LS -/: Activation/NN of/IN signaling/NN pathways/NNS and/CC prevention/NN of/IN apoptosis/NN by/IN cytokines/NNS in/IN eosinophils/NNS ./. 
AB/LS -/: Inhibition/NN of/IN apoptosis/NN in/IN eosinophils/NNS by/IN cytokines/NNS such/JJ as/IN IL-5/NN and/CC GM-CSF/NN may/MD play/VB an/DT important/JJ role/NN in/IN the/DT pathogenesis/NN of/IN allergic/JJ and/CC parasitic/JJ disorders/NNS ./. 
Recently/RB ,/, there/EX has/VBZ been/VBN some/DT progress/NN in/IN the/DT understanding/NN of/IN the/DT signal/NN transduction/NN pathways/NNS activated/VBN by/IN these/DT cytokines/NNS in/IN eosinophils/NNS ./. 
The/DT IL-3/NN ,/, IL-5/NN and/CC GM-CSF/NN receptors/NNS share/VBP a/DT common/JJ signal/NN transducer/NN that/WDT possesses/VBZ no/DT intrinsic/JJ kinase/NN domain/NN ./. 
It/PRP has/VBZ been/VBN shown/VBN that/IN eosinophil/NN stimulation/NN by/IN these/DT cytokines/NNS is/VBZ associated/VBN with/IN increases/NNS in/IN tyrosine/NN phosphorylation/NN of/IN several/JJ cellular/JJ substrates/NNS ./. 
In/IN the/DT past/JJ few/JJ years/NNS ,/, there/EX has/VBZ been/VBN some/DT progress/NN in/IN defining/VBG the/DT tyrosine/NN kinases/NNS that/WDT are/VBP activated/VBN by/IN the/DT IL-3/IL-5/GM-CSF/NN receptor/NN beta-subunit/NN in/IN eosinophils/NNS ./. 
This/DT review/NN will/MD concentrate/VB on/IN this/DT topic/JJ and/CC on/IN its/PRP$ role/NN for/IN the/DT regulation/NN of/IN eosinophil/NN apoptosis/NN ./. 
UI/LS -/: 99119105/CD 
TI/LS -/: Requirement/NN of/IN GATA-1/NN and/CC p45/NN NF-E2/NN expression/NN in/IN butyric/JJ acid-induced/JJ erythroid/JJ differentiation/NN ./. 
AB/LS -/: Butyric/JJ acid/NN (/( BA/NN )/) is/VBZ known/VBN to/TO induce/VB overexpression/NN of/IN fetal/JJ hemoglobin/NN and/CC then/RB erythroid/JJ differentiation/NN ./. 
Therefore/RB ,/, BA/NN is/VBZ currently/RB under/IN clinical/JJ investigation/NN as/IN a/DT potential/JJ therapy/NN for/IN the/DT treatment/NN of/IN sickle/JJ cell/NN disease/NN and/CC cancer/NN ./. 
Nevertheless/RB ,/, the/DT molecular/JJ mechanisms/NNS involved/VBN in/IN BA-induced/JJ differentiation/NN remain/VBP largely/RB unknown/JJ ./. 
Previous/JJ reports/NNS have/VBP shown/VBN that/IN BA-induced/JJ overexpression/NN of/IN erythroid/JJ genes/NNS occurred/VBD at/IN the/DT transcriptional/JJ level/NN ,/, suggesting/VBG the/DT involvement/NN of/IN erythroid/JJ transcription/NN factors/NNS ./. 
Here/RB ,/, we/PRP intend/VBP to/TO demonstrate/VB the/DT requirement/NN of/IN GATA-1/NN and/CC NF-E2/NN transcription/NN factors/NNS in/IN the/DT BA-induced/JJ erythroid/JJ differentiation/NN of/IN human/JJ leukemic/JJ K562/NN cells/NNS ./. 
Time-course/JJ experiments/NNS showed/VBD that/IN nuclear/JJ levels/NNS of/IN GATA-1/NN and/CC p45/NN NF-E2/NN proteins/NNS increased/VBD during/IN BA/NN treatment/NN ./. 
Moreover/RB ,/, antisense/JJ oligodeoxynucleotides/NNS targeting/VBG either/CC GATA-1/NN or/CC p45/NN NF-E2/NN proteins/NNS inhibited/VBD both/CC protein/NN expression/NN and/CC BA-induced/JJ differentiation/NN ./. 
In/IN contrast/NN ,/, BA-induced/JJ cell/NN growth/NN inhibition/NN was/VBD not/RB affected/VBN ./. 
These/DT results/NNS provide/VBP the/DT first/JJ direct/JJ evidence/NN for/IN the/DT requirement/NN of/IN GATA-1/NN and/CC NF-E2/NN in/IN BA-induced/JJ differentiation/NN process/NN ./. 
UI/LS -/: 99092484/CD 
TI/LS -/: Characterisation/NN of/IN regulatory/JJ sequences/NNS at/IN the/DT Epstein-Barr/JJ virus/NN BamHI/NN W/NN promoter/NN ./. 
AB/LS -/: Epstein-Barr/JJ virus/NN ,/, a/DT human/JJ gammaherpesvirus/NN ,/, possesses/VBZ a/DT unique/JJ set/NN of/IN latent/JJ genes/NNS whose/WP$ constitutive/JJ expression/NN in/IN B/NN cells/NNS leads/VBZ to/TO cell/NN growth/NN transformation/NN ./. 
The/DT initiation/NN of/IN this/DT growth/NN transforming/NN infection/NN depends/VBZ on/IN a/DT viral/JJ promoter/NN in/IN BamHI/NN W/NN (/( Wp/NN )/) whose/WP$ regulation/NN is/VBZ poorly/RB understood/VBN ./. 
Using/VBG Wp/NN reporter/NN constructs/NNS in/IN in/FW vitro/FW transfection/NN assays/NNS ,/, we/PRP found/VBD that/IN Wp/NN was/VBD 11-/CD to/TO 190-fold/RB more/RBR active/JJ in/IN B/NN cell/NN than/IN in/IN non-B/JJ cell/NN lines/NNS and/CC that/IN three/CD regions/NNS of/IN the/DT promoter/NN (/( termed/VBN UAS1/NN ,/, UAS2/NN ,/, and/CC UAS3/NN )/) contributed/VBD to/TO transcriptional/JJ activation/NN ./. 
The/DT upstream/JJ regions/NNS UAS3/NN (/( -1168/CD to/TO -440/CD )/) and/CC UAS2/NN (/( -352/CD to/TO -264/CD )/) both/DT functioned/VBD in/IN a/DT cell/NN lineage-independent/JJ manner/NN and/CC were/VBD together/RB responsible/JJ for/IN the/DT bulk/NN of/IN Wp/NN activity/NN in/IN non-B/JJ cells/NNS ;/: mutational/JJ analysis/NN indicated/VBD the/DT importance/NN of/IN a/DT YY1/NN binding/NN site/NN in/IN UAS2/NN in/IN that/DT context/NN ./. 
By/IN contrast/NN ,/, UAS1/NN (/( -140/CD to/TO -87/CD )/) was/VBD B/NN cell/NN specific/JJ and/CC was/VBD the/DT key/JJ determinant/NN of/IN the/DT promoter/NN 's/POS increased/VBN activity/NN in/IN B/NN cell/NN lines/NNS ./. 
Mutational/JJ analysis/NN of/IN UAS1/NN sequences/NNS combined/VBN with/IN in/FW vitro/FW bandshift/NN assays/NNS revealed/VBD the/DT presence/NN of/IN three/CD binding/VBG sites/NNS for/IN cellular/JJ factors/NNS in/IN this/DT region/NN ./. 
When/WRB mutations/NNS that/WDT abolished/VBD factor/NN binding/NN in/IN bandshift/NN assays/NNS were/VBD introduced/VBN into/IN a/DT Wp/NN reporter/NN construct/NN ,/, the/DT loss/NN of/IN any/DT one/CD of/IN the/DT three/CD UAS1/NN binding/NN sites/NNS was/VBD sufficient/JJ to/TO reduce/VB promoter/NN activity/NN by/IN 10-/CD to/TO 30-fold/RB in/IN B/NN cells/NNS ./. 
From/IN sequence/NN analysis/NN ,/, two/CD of/IN these/DT appear/VBP to/TO be/VB novel/JJ transcription/NN factor/NN binding/NN sites/NNS ,/, whereas/IN the/DT third/JJ was/VBD identified/VBN as/IN a/DT cyclic/JJ AMP/NN response/NN element/NN (/( CRE/NN )/) ./. 
Our/PRP$ data/NNS indicate/VBP that/IN this/DT CRE/NN interacts/VBZ with/IN CREB/NN and/CC ATF1/NN proteins/NNS present/JJ in/IN B/NN cell/NN nuclear/JJ extracts/NNS and/CC that/IN this/DT interaction/NN is/VBZ important/JJ for/IN Wp/NN activity/NN ./. 
UI/LS -/: 99075977/CD 
TI/LS -/: In/FW situ/FW RT-PCR/NN detection/NN of/IN Epstein-Barr/JJ virus/NN immediate-early/JJ transcripts/NNS in/IN CD4+/JJ and/CC CD8+/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: AIDS-related/JJ Epstein-Barr/JJ virus/NN (/( EBV/NN )/) -associated/JJ T/NN cell/NN lymphomas/NNS are/VBP emerging/VBG as/IN a/DT new/JJ ,/, distinct/JJ histopathological/JJ entity/NN ./. 
The/DT pathway/NN whereby/WRB EBV/NN infects/VBZ T/NN cells/NNS as/RB well/RB as/IN the/DT initial/JJ EBV/NN transcriptional/JJ program/NN in/IN T/NN cells/NNS has/VBZ not/RB been/VBN established/VBN ./. 
In/IN order/NN to/TO shed/VB light/NN on/IN the/DT early/JJ events/NNS of/IN the/DT EBV/NN infection/NN of/IN T/NN cells/NNS ,/, we/PRP have/VBP used/VBN in/FW situ/FW reverse/JJ transcription/NN based/JJ polymerase/NN chain/NN reaction/NN (/( RT-PCR/NN )/) to/TO study/VB the/DT initial/JJ EBV/NN transcriptional/JJ program/NN in/IN homogeneous/JJ CD4+/JJ and/CC CD8+/JJ lymphocytes/NNS ./. 
Following/VBG EBV/NN infection/NN ,/, Epstein-Barr/JJ nuclear/JJ antigen/NN (/( EBNA/NN )/) expression/NN could/MD be/VB detected/VBN in/IN T/NN rosetting/NN CD4+/JJ and/CC CD8+/JJ T/NN lymphocytes/NNS ./. 
Only/RB a/DT few/JJ cells/NNS showed/VBD viral/JJ capsid/NN antigen/NN (/( VCA/NN )/) ./. 
EBV/NN immediate-early/JJ gene/NN transcripts/NNS (/( BZLF1/NN ,/, BRLF1/NN ,/, and/CC BMLF1/NN )/) encoded/VBN in/IN the/DT BamHI/NN Z/NN ,/, R/NN ,/, and/CC M/NN fragments/NNS could/MD be/VB detected/VBN by/IN in/FW situ/FW RT-PCR/NN in/IN the/DT EBV/NN producer/NN cell/NN line/NN B95.8/NN ./. 
Both/CC BZLF1/NN and/CC BRLF1/NN immediate-early/JJ transcripts/NNS ,/, but/CC not/RB BMLF1/NN transcript/NN ,/, could/MD be/VB detected/VBN in/IN individual/JJ CD4+/JJ and/CC CD8+/JJ T/NN cells/NNS infected/VBN with/IN EBV/NN ./. 
Demonstration/NN of/IN EBV/NN mRNA/NN transcripts/NNS encoding/VBG immediate-early/JJ transcriptional/JJ transactivators/NNS in/IN EBV-infected/JJ T/NN cells/NNS provides/VBZ the/DT first/JJ evidence/NN for/IN a/DT possible/JJ mechanism/NN whereby/IN EBV/NN could/MD contribute/VB to/TO T/NN cell/NN proliferation/NN and/CC EBV-associated/JJ T/NN cell/NN malignancies/NNS ./. 
UI/LS -/: 99067836/CD 
TI/LS -/: The/DT linkage/NN between/IN T-cell/NN and/CC dendritic/JJ cell/NN development/NN in/IN the/DT mouse/NN thymus/NN ./. 
AB/LS -/: Thymic/JJ dendritic/JJ cells/NNS (/( DC/NNS )/) mediate/VBP negative/JJ selection/NN at/IN a/DT relatively/RB late/JJ stage/NN of/IN the/DT T-cell/NN developmental/JJ pathway/NN ./. 
We/PRP present/VBP evidence/NN that/IN the/DT development/NN of/IN thymic/JJ DC/NNS and/CC of/IN T-lineage/NN cells/NNS is/VBZ linked/VBN via/IN a/DT common/JJ precursor/NN at/IN an/DT early/JJ stage/NN of/IN thymocyte/NN development/NN ./. 
T-lineage/NN precursor/NN populations/NNS from/IN the/DT adult/JJ mouse/NN thymus/NN ,/, prior/JJ to/TO T-cell/NN receptor/NN gene/NN rearrangement/NN ,/, display/VBP a/DT capacity/NN to/TO produce/VB DC/NNS as/RB well/RB as/IN T/NN cells/NNS in/IN the/DT thymus/NN ,/, and/CC are/VBP very/RB efficient/JJ precursors/NNS of/IN DC/NNS in/IN culture/NN ./. 
These/DT lymphoid/DC/JJ precursors/NNS have/VBP little/JJ capacity/NN to/TO form/VB myeloid/JJ cells/NNS ,/, indicating/VBG that/IN thymic/JJ DC/NNS are/VBP a/DT lymphoid-related/JJ rather/RB than/IN myeloid-related/JJ lineage/NN ./. 
In/IN contrast/NN to/TO myeloid-related/JJ DC/NNS ,/, granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN is/VBZ not/RB required/VBN for/IN the/DT development/NN of/IN these/DT lymphoid-related/JJ DC/NNS in/FW vivo/FW or/CC in/FW vitro/FW ./. 
DC/NNS can/MD develop/VB in/IN mutant/JJ mice/NNS lacking/VBG mature/JJ T/NN cells/NNS ,/, provided/VBN the/DT common/JJ precursors/NNS are/VBP present/JJ ./. 
However/RB ,/, in/IN mutant/JJ mice/NNS lacking/VBG functional/JJ Ikaros/NN transcription/NN factors/NNS ,/, there/EX are/VBP deficiencies/NNS in/IN lymphoid/JJ precursor/NN cells/NNS ,/, in/IN mature/JJ lymphoid/JJ cells/NNS and/CC in/IN DC/NNS ./. 
UI/LS -/: 99059495/CD 
TI/LS -/: Host/NN control/NN of/IN HIV-1/NN parasitism/NN in/IN T/NN cells/NNS by/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS ./. 
AB/LS -/: Post/IN HIV-1/NN entry/NN ,/, productive/JJ HIV-1/NN infection/NN of/IN primary/JJ T/NN cells/NNS requires/VBZ overcoming/VBG several/JJ cellular/JJ blocks/NNS to/TO provirus/NN establishment/NN and/CC replication/NN ./. 
Activation/NN of/IN unknown/JJ host/NN intracellular/JJ events/NNS overcomes/VBZ such/JJ inhibitory/JJ steps/NNS and/CC is/VBZ concomitant/JJ with/IN HIV-1/NN replication/NN ./. 
We/PRP show/VBP that/IN the/DT transcription/NN factor/NN NFATc/NN was/VBD sufficient/JJ as/IN a/DT cellular/JJ factor/NN to/TO induce/VB a/DT highly/RB permissive/JJ state/NN for/IN HIV-1/NN replication/NN in/IN primary/JJ CD4+/JJ T/NN cells/NNS ./. 
NFATc/NN overcame/VBD a/DT blockade/NN at/IN reverse/JJ transcription/NN and/CC permitted/VBD active/JJ HIV-1/NN replication/NN ./. 
Pharmacologic/JJ blockade/NN of/IN endogenous/JJ NFAT/NN activity/NN by/IN FK506/NN or/CC CsA/NN inhibited/VBD synthesis/NN of/IN reverse/JJ transcription/NN and/CC also/RB potently/RB blocked/VBD HIV-1/NN replication/NN ./. 
T/NN cells/NNS therefore/RB can/MD become/VB competent/JJ for/IN HIV-1/NN replication/NN by/IN control/NN of/IN regulated/VBN host/NN factors/NNS such/JJ as/IN the/DT NFATc/NN transcription/NN factor/NN ./. 
The/DT host/NN mechanisms/NNS regulated/VBN by/IN such/JJ permissivity/NN factors/NNS are/VBP potential/JJ targets/NNS for/IN anti-HIV-1/JJ therapy/NN ./. 
UI/LS -/: 99049838/CD 
TI/LS -/: Regulation/NN of/IN NF-kappa/NN B/NN ,/, AP-1/NN ,/, NFAT/NN ,/, and/CC STAT1/NN nuclear/JJ import/NN in/IN T/NN lymphocytes/NNS by/IN noninvasive/JJ delivery/NN of/IN peptide/NN carrying/VBG the/DT nuclear/JJ localization/NN sequence/NN of/IN NF-kappa/NN B/NN p50/NN ./. 
AB/LS -/: Activation/NN of/IN T/NN lymphocytes/NNS by/IN Ags/NNS or/CC cytokines/NNS results/VBZ in/IN translocation/NN of/IN the/DT transcription/NN factors/NNS NF-kappa/NN B/NN ,/, AP-1/NN ,/, NFAT/NN ,/, and/CC STAT/NN from/IN the/DT cytoplasm/NN into/IN the/DT nucleus/NN ./. 
The/DT first/JJ step/NN in/IN the/DT nuclear/JJ import/NN process/NN is/VBZ recognition/NN of/IN a/DT nuclear/JJ localization/NN sequence/NN (/( NLS/NN )/) within/IN the/DT karyophilic/JJ protein/NN by/IN a/DT cytoplasmic/JJ receptor/NN such/JJ as/IN the/DT importin/NN (/( karyopherin/NN )/) -alpha/NN subunit/NN ./. 
The/DT NLSs/NNS of/IN NF-kappa/NN B/NN ,/, AP-1/NN ,/, and/CC NFAT/NN differ/VBP and/CC the/DT NLS/NN of/IN STAT1/NN has/VBZ not/RB yet/RB been/VBN identified/VBN ./. 
Herein/RB we/PRP demonstrate/VBP that/IN the/DT inducible/JJ nuclear/JJ import/NN of/IN NF-kappa/NN B/NN ,/, AP-1/NN ,/, NFAT/NN ,/, and/CC STAT1/NN in/IN Jurkat/NN T/NN lymphocytes/NNS is/VBZ significantly/RB inhibited/VBN by/IN a/DT cell-permeable/JJ peptide/NN carrying/VBG the/DT NLS/NN of/IN the/DT NF-kappa/NN B/NN p50/NN subunit/NN ./. 
NLS/NN peptide-mediated/JJ disruption/NN of/IN the/DT nuclear/JJ import/NN of/IN these/DT transcription/NN factors/NNS results/VBZ in/IN inhibition/NN of/IN I/NN kappa/NN B/NN alpha/NN and/CC IL-2/NN gene/NN expression/NN ,/, processes/NNS dependent/JJ on/IN NF-kappa/NN B/NN or/CC the/DT combination/NN of/IN NF-kappa/NN B/NN ,/, AP-1/NN ,/, and/CC NFAT/NN ./. 
Further/RB ,/, we/PRP show/VBP that/IN inhibitory/JJ NLS/NN peptide/NN interacts/VBZ in/FW vitro/FW with/IN a/DT cytoplasmic/JJ NLS/NN receptor/NN complex/NN comprised/VBN of/IN the/DT Rch1/importin/NN (/( karyopherin/NN )/) -beta/NN heterodimer/NN expressed/VBN in/IN Jurkat/NN T/NN cells/NNS ./. 
Taken/VBN together/RB ,/, these/DT data/NNS indicate/VBP that/IN the/DT inducible/JJ nuclear/JJ import/NN of/IN NF-kappa/NN B/NN ,/, AP-1/NN ,/, NFAT/NN ,/, and/CC STAT1/NN in/IN Jurkat/NN T/NN cells/NNS can/MD be/VB regulated/VBN by/IN NLS/NN peptide/NN delivered/VBN noninvasively/RB to/TO the/DT cytoplasm/NN of/IN Jurkat/NN T/NN cells/NNS to/TO target/NN members/NNS of/IN the/DT importin/NN (/( karyopherin/NN )/) -alpha/NN beta/NN NLS/NN receptor/NN complex/NN ./. 
UI/LS -/: 99041167/CD 
TI/LS -/: Membrane-associated/JJ lymphotoxin/NN on/IN natural/JJ killer/NN cells/NNS activates/VBZ endothelial/JJ cells/NNS via/IN an/DT NF-kappaB-dependent/JJ pathway/NN ./. 
AB/LS -/: BACKGROUND/NN :/: Inhibition/NN of/IN complement/NN in/IN small/JJ animal/NN models/NNS of/IN xenotransplantation/NN has/VBZ demonstrated/VBN graft/NN infiltration/NN with/IN natural/JJ killer/NN (/( NK/NN )/) cells/NNS and/CC monocytes/NNS associated/VBN with/IN endothelial/JJ cell/NN (/( EC/NN )/) activation/NN ./. 
We/PRP have/VBP previously/RB demonstrated/VBN that/IN human/JJ NK/NN cells/NNS activate/VBP porcine/NN EC/NN in/FW vitro/FW ,/, which/WDT results/VBZ in/IN adhesion/NN molecule/NN expression/NN and/CC cytokine/NN secretion/NN ./. 
In/IN this/DT study/NN ,/, we/PRP used/VBD the/DT NK/NN cell/NN line/NN NK92/NN to/TO define/VB the/DT molecular/JJ and/CC cellular/JJ basis/NN of/IN NK/NN cell-mediated/JJ EC/NN activation/NN ./. 
METHODS/NNS :/: EC/NNS were/VBD transfected/VBN with/IN either/CC reporter/NN constructs/NNS containing/VBG the/DT luciferase/NN gene/NN driven/VBN either/CC by/IN E-selectin/NN or/CC interleukin/NN (/( IL/NN )/) -8/CD promoters/NNS or/CC a/DT synthetic/JJ NF-kappaB-dependent/JJ promoter/NN ./. 
In/IN addition/NN ,/, a/DT dominant-negative/JJ mutant/JJ tumor/NN necrosis/NN factor/NN receptor/NN I/CD (/( TNFRI/NN )/) expression/NN vector/NN was/VBD co-transfected/VBN in/IN inhibition/NN studies/NNS ./. 
Forty-eight/CD hours/NNS after/IN transfection/NN ,/, EC/NNS were/VBD stimulated/VBN with/IN NK/NN cells/NNS or/CC NK/NN cell/NN membrane/NN extracts/NNS for/IN 7/CD hr/NN and/CC activation/NN was/VBD measured/VBN by/IN a/DT luciferase/NN assay/NN ./. 
RESULTS/NNS :/: Co-culture/NN of/IN NK/NN cells/NNS with/IN transfected/VBN EC/NN enhanced/VBD E-selectin/NN ,/, IL-8/NN ,/, and/CC NF-kappaB-dependent/JJ promoter/NN activity/NN ./. 
NK/NN cell/NN membrane/NN extracts/NNS retained/VBD the/DT capacity/NN to/TO activate/VB EC/NN and/CC induced/VBD nuclear/JJ translocation/NN of/IN NF-kappaB/NN (/( p50/NN and/CC p65/NN )/) ./. 
Western/NN blotting/NN of/IN NK/NN cell/NN and/CC membrane/NN extracts/NNS detected/VBD the/DT presence/NN of/IN Lymphotoxin-alpha/NN (/( LTalpha/NN )/) but/CC not/RB tumor/NN necrosis/NN factor-alpha/NN ./. 
Furthermore/RB ,/, LTalpha/NN was/VBD secreted/VBN in/IN NK:EC/NN co-cultures/NNS ./. 
Co-transfection/NN with/IN dominant-negative/JJ mutant/JJ TNFRI/NN inhibited/VBD EC/NN activation/NN by/IN NK/NN cell/NN membrane/NN extracts/NNS and/CC by/IN NK/NN cells/NNS by/IN 80/CD %/NN and/CC 47/CD %/NN ,/, respectively/RB ./. 
The/DT same/JJ pattern/NN of/IN inhibition/NN was/VBD observed/VBN using/VBG anti-human/JJ LT/NN sera/NNS ./. 
CONCLUSIONS/NNS :/: Human/JJ NK/NN cell/NN membrane-bound/JJ LT/NN signals/VBZ across/IN species/NNS via/IN TNFRI/NN ,/, leading/VBG to/TO NF-kappaB/NN nuclear/JJ translocation/NN and/CC transcription/NN of/IN E-selectin/NN and/CC IL-8/NN ,/, which/WDT results/VBZ in/IN EC/NN activation/NN ./. 
The/DT discrepancy/NN in/IN the/DT degree/NN of/IN inhibition/NN by/IN membrane/NN extracts/NNS and/CC NK/NN cells/NNS with/IN mutant/JJ TNFRI/NN suggests/VBZ that/IN additional/JJ pathways/NNS are/VBP utilized/VBN by/IN NK/NN cells/NNS to/TO activate/VB EC/NN 
UI/LS -/: 97150707/CD 
TI/LS -/: Ras-dependent/JJ ,/, Ca2+-stimulated/JJ activation/NN of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS by/IN a/DT constitutively/RB active/JJ Cbl/NN mutant/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: T/NN cell/NN receptor/NN (/( TCR/NN )/) stimulation/NN induces/VBZ rapid/JJ tyrosine/NN phosphorylation/NN of/IN cellular/JJ proteins/NNS ,/, including/VBG Cbl/NN ,/, a/DT protooncogene/NN product/NN whose/WP$ function/NN remains/VBZ unclear/JJ ./. 
As/IN a/DT first/JJ step/NN toward/IN elucidating/VBG the/DT function/NN of/IN Cbl/NN in/IN TCR-initiated/JJ signaling/NN ,/, we/PRP evaluated/VBD the/DT ability/NN of/IN wild-type/JJ Cbl/NN or/CC a/DT transforming/VBG Cbl/NN mutant/NN (/( 70Z/3/NN )/) to/TO induce/VB transcriptional/JJ activation/NN of/IN a/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) element/NN derived/VBN from/IN the/DT interleukin/NN 2/CD (/( IL2/NN )/) promoter/NN in/IN transiently/RB cotransfected/VBN Jurkat-TAg/NN T/NN cells/NNS ./. 
70Z/3/NN ,/, but/CC not/RB Cbl/NN ,/, caused/VBD NFAT/NN activation/NN which/WDT was/VBD significantly/RB enhanced/VBN by/IN stimulation/NN with/IN calcium/NN ionophore/NN ,/, and/CC was/VBD drastically/RB reduced/VBN by/IN cyclosporin/NN A/NN pretreatment/NN ./. 
A/DT point/NN mutation/NN of/IN a/DT potential/JJ phosphatidylinositol/NN 3-kinase/NN (/( PI3-K/NN )/) binding/NN site/NN (/( Y731EAM/NN to/TO Y731EAC/NN )/) in/IN 70Z/3/NN disrupted/VBD the/DT association/NN of/IN PI3-K/NN with/IN 70Z/3/NN ,/, but/CC did/VBD not/RB reduce/VB the/DT induction/NN of/IN NFAT/NN activity/NN ,/, suggesting/VBG that/IN the/DT interaction/NN between/IN Cbl/NN and/CC PI3-K/NN is/VBZ not/RB required/VBN in/IN the/DT 70Z/3-mediated/JJ induction/NN of/IN NFAT/NN ./. 
Additional/JJ mapping/NN studies/NNS indicated/VBD that/IN defined/VBN deletions/NNS of/IN C-terminal/JJ 70Z/3/NN sequences/NNS affected/VBD to/TO a/DT variable/JJ degree/NN its/PRP$ ability/NN to/TO stimulate/VB NFAT/NN activity/NN ./. 
Strikingly/RB ,/, deletion/NN of/IN 346/CD C-terminal/JJ residues/NNS augmented/VBD this/DT activity/NN ,/, whereas/IN removal/NN of/IN 20/CD additional/JJ residues/NNS abolished/VBD it/PRP ./. 
Coexpression/NN of/IN dominant/JJ negative/JJ Ras/NN abrogated/VBD the/DT basal/JJ or/CC ionomycin-stimulated/JJ ,/, 70Z/3-mediated/JJ NFAT/NN activation/NN ,/, suggesting/VBG a/DT functional/JJ Ras/NN is/VBZ required/VBN for/IN this/DT activation/NN ./. 
These/DT results/NNS implicate/VBP Cbl/NN in/IN Ras-dependent/JJ signaling/NN pathways/NNS which/WDT lead/VBP to/TO NFAT/NN activation/NN ./. 
UI/LS -/: 97259535/CD 
TI/LS -/: Requirement/NN of/IN prestimulated/JJ THP-1/NN monocytic/JJ cells/NNS for/IN endothelial/JJ cell/NN activation/NN ./. 
Involvement/NN of/IN TNF/NN alpha/NN ./. 
AB/LS -/: Blood/NN monocytes/NNS spontaneously/RB activate/VBP endothelial/JJ cells/NNS in/IN culture/NN ,/, leading/VBG to/TO adhesion/NN of/IN monocytic/JJ cells/NNS onto/IN the/DT endothelial/JJ surface/NN and/CC overproduction/NN of/IN endothelial/JJ proteins/NNS such/JJ as/IN von/NN Willebrand/NN factor/NN (/( vWf/NN )/) and/CC plasminogen/NN activator/NN inhibitor/NN type/NN 1/CD (/( PAI-1/NN )/) ./. 
To/TO overcome/VB the/DT difficulty/NN in/IN obtaining/VBG quiescent/JJ monocytes/NNS ,/, we/PRP studied/VBD the/DT ability/NN of/IN promonocytic/JJ THP-1/NN cells/NNS to/TO activate/VB endothelial/JJ cells/NNS ./. 
Lipopolysaccharide/NN (/( LPS/NN )/) -prestimulated/JJ and/CC untreated/JJ THP-1/NN cells/NNS were/VBD cocultured/VBN with/IN resting/VBG human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS (/( HUVEC/NNS )/) for/IN 3/CD and/CC 24/CD h/NN in/IN the/DT presence/NN of/IN colimycin/NN to/TO neutralize/VB LPS/NN traces/NNS ./. 
Addition/NN of/IN untreated/JJ THP-1/NN cells/NNS had/VBD little/JJ effect/NN on/IN HUVEC/NNS adhesiveness/NN ./. 
Addition/NN of/IN prestimulated/JJ THP-1/NN cells/NNS was/VBD followed/VBN by/IN a/DT noticeable/JJ adhesion/NN after/IN 3/CD h/NN which/WDT reversed/VBD to/TO basal/JJ values/NNS within/IN 24/CD h/NN ./. 
Under/IN these/DT conditions/NNS HUVEC/NNS adhesion/NN molecules/NNS ,/, E-selectin/NN ,/, VCAM-1/NN and/CC ICAM-1/NN ,/, were/VBD increased/VBN at/IN 3/CD h/NN with/IN only/RB ICAM-1/NN remaining/VBG overexpressed/VBN at/IN 24/CD h/NN ./. 
Diffusible/JJ endothelial/JJ proteins/NNS such/JJ as/IN soluble/JJ E-selectin/NN ,/, PAI-1/NN and/CC vWf/NN to/TO a/DT minimal/JJ extent/NN ,/, increased/VBD in/IN supernatants/NNS from/IN HUVEC/NNS cocultured/VBN for/IN 24/CD h/NN with/IN prestimulated/JJ THP-1/NN cells/NNS ./. 
In/IN those/DT cocultures/NNS ,/, TNF/NN alpha/NN concentrations/NNS peaked/VBD at/IN 3/CD h/NN whereas/IN IL-1/NN beta/NN levels/NNS progressively/RB rose/VBD until/IN 24/CD h/NN ./. 
Addition/NN of/IN an/DT anti-TNF/JJ alpha/NN antibody/NN decreased/VBD by/IN 40/CD %/NN E-selectin/NN and/CC ICAM-1/NN induction/NN and/CC suppressed/VBD PAI-1/NN overproduction/NN with/IN a/DT weak/JJ effect/NN on/IN vWf/NN ./. 
An/DT anti-IL-1/JJ beta/NN antibody/NN had/VBD negligible/JJ effects/NNS on/IN HUVEC/NNS adhesion/NN molecules/NNS ,/, PAI-1/NN or/CC vWf/NN production/NN ./. 
These/DT results/NNS provide/VBP evidence/NN that/IN promonocytic/JJ THP-1/NN cells/NNS require/VBP prestimulation/NN in/IN order/NN to/TO activate/VB HUVEC/NNS and/CC that/IN TNF/NN alpha/NN contributes/VBZ to/TO this/DT phenomenon/NN ./. 
UI/LS -/: 97132947/CD 
TI/LS -/: Engagement/NN of/IN the/DT Lewis/NN X/NN antigen/NN (/( CD15/NN )/) results/VBZ in/IN monocyte/NN activation/NN ./. 
AB/LS -/: We/PRP previously/RB reported/VBD that/IN monocyte/NN adhesion/NN to/TO tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) -treated/JJ endothelial/JJ cells/NNS increased/VBD expression/NN of/IN tissue/NN factor/NN and/CC CD36/NN on/IN monocytes/NNS ./. 
Using/VBG immunological/JJ cross-linking/NN to/TO mimic/VB receptor/NN engagement/NN by/IN natural/JJ ligands/NNS ,/, we/PRP now/RB show/VBP that/IN CD15/NN (/( Lewis/NN X/NN )/) ,/, a/DT monocyte/NN counter-receptor/NN for/IN endothelial/JJ selectins/NNS may/MD participate/VB in/IN this/DT response/NN ./. 
We/PRP used/VBD cytokine/NN production/NN as/IN a/DT readout/NN for/IN monocyte/NN activation/NN and/CC found/VBD that/IN CD15/NN cross-linking/NN induced/VBD TNF-alpha/NN release/NN from/IN peripheral/JJ blood/NN monocytes/NNS and/CC cells/NNS from/IN the/DT monocytic/JJ cell/NN line/NN MM6/NN ./. 
Quantitative/JJ reverse/JJ transcriptase-polymerase/JJ chain/NN reaction/NN (/( RT-PCR/NN )/) showed/VBD an/DT increase/NN in/IN steady-state/JJ TNF-alpha/NN mRNA/NN after/IN 3/CD to/TO 4/CD hours/NNS of/IN cross-linking/NN ./. 
CD15/NN cross-linking/NN also/RB concomitantly/RB increased/VBD interleukin-1/NN beta/NN (/( IL-1/NN beta/NN )/) mRNA/NN ,/, while/IN no/DT apparent/JJ change/NN was/VBD observed/VBN in/IN the/DT levels/NNS of/IN beta-actin/NN mRNA/NN ,/, indicating/VBG specificity/NN ./. 
To/TO examine/VB transcriptional/JJ regulation/NN of/IN cytokine/NN genes/NNS by/IN CD15/NN engagement/NN ,/, a/DT CAT/NN plasmid/NN reporter/NN construct/NN containing/VBG IL-1/NN beta/NN promoter/enhancer/NN sequences/NNS was/VBD introduced/VBN into/IN MM6/NN ./. 
Subsequent/JJ cross-linking/NN of/IN CD15/NN increased/VBD CAT/NN activity/NN ./. 
CD15/NN engagement/NN by/IN monoclonal/JJ antibody/NN also/RB attenuated/VBD IL-1/NN beta/NN transcript/NN degradation/NN ,/, demonstrating/VBG that/IN signaling/NN via/IN CD15/NN also/RB had/VBD posttranscriptional/JJ effects/NNS ./. 
Nuclear/JJ extracts/NNS of/IN anti-CD15/JJ cross-linked/JJ cells/NNS demonstrated/VBD enhanced/VBN levels/NNS of/IN the/DT transcriptional/JJ factor/NN activator/NN protein-1/NN ,/, minimally/RB changed/VBD nuclear/JJ factor-kappa/NN B/NN ,/, and/CC did/VBD not/RB affect/VB SV40/NN promoter/NN specific/JJ protein-1/NN ./. 
We/PRP conclude/VBP that/IN engagement/NN of/IN CD15/NN on/IN monocytes/NNS results/VBZ in/IN monocyte/NN activation/NN ./. 
In/IN addition/NN to/TO its/PRP$ well-recognized/JJ adhesive/JJ role/NN ,/, CD15/NN may/MD function/VB as/IN an/DT important/JJ signaling/VBG molecule/NN capable/JJ of/IN initiating/VBG proinflammatory/JJ events/NNS in/IN monocytes/NNS that/WDT come/VBP into/IN contact/NN with/IN activated/VBN endothelium/NN ./. 
UI/LS -/: 99111421/CD 
TI/LS -/: CD2/NN signalling/NN induces/VBZ phosphorylation/NN of/IN CREB/NN in/IN primary/JJ lymphocytes/NNS ./. 
AB/LS -/: Promoter/NN sequences/NNS responsive/JJ to/TO cyclic/JJ AMP/NN (/( cAMP/NN )/) are/VBP found/VBN in/IN a/DT number/NN of/IN cellular/JJ genes/NNS ,/, and/CC bind/VBP transcription/NN factors/NNS of/IN the/DT cAMP/NN response/NN element/NN binding/NN protein/NN (/( CREB/NN )/) //: activating/JJ transcription/NN factor-1/NN (/( ATF-1/NN )/) family/NN ./. 
We/PRP have/VBP used/VBN a/DT human/JJ T-lymphotropic/JJ virus/NN type/NN 1/CD (/( HTLV-1/NN )/) model/NN of/IN cAMP/NN response/NN element/NN (/( CRE/NN )/) transcription/NN to/TO investigate/VB the/DT influence/NN of/IN lymphocyte/NN activation/NN on/IN transcription/NN from/IN homologous/JJ regions/NNS in/IN the/DT viral/JJ promoter/NN ./. 
We/PRP previously/RB demonstrated/VBD increased/VBN HTLV-1/NN transcription/NN following/VBG CD2/NN but/CC not/RB CD3/NN receptor/NN cross-linking/NN ./. 
We/PRP hypothesized/VBD that/IN this/DT increased/VBN viral/JJ transcription/NN was/VBD mediated/VBN ,/, in/IN part/NN ,/, through/IN the/DT phosphorylation/NN of/IN CREB/NN ./. 
Therefore/RB ,/, we/PRP investigated/VBD CD2/NN and/CC CD3/NN receptor-mediated/JJ signalling/NN in/IN primary/JJ human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NNS )/) ./. 
CD2/NN ,/, but/CC not/RB CD3/NN ,/, cross-linking/NN increased/VBD cAMP/NN detected/VBN by/IN competitive/JJ enzyme-linked/JJ immunosorbent/JJ assay/NN (/( ELISA/NN )/) approximately/RB fourfold/RB ./. 
CD2/NN cross-linking/NN concurrently/RB increased/VBD phosphorylation/NN of/IN CREB/NN detected/VBN by/IN immunoblot/NN assay/NN eightfold/RB ./. 
Consistent/JJ with/IN post-translational/JJ regulation/NN ,/, no/DT change/NN in/IN total/JJ level/NN of/IN CREB/NN protein/NN was/VBD observed/VBN ./. 
Phosphorylation/NN of/IN CREB/NN occurred/VBD through/IN a/DT herbimycin/NN A/NN and/CC Rp-cAMP-sensitive/JJ pathway/NN ,/, suggesting/VBG phosphorylation/NN required/VBD antecedent/JJ activation/NN of/IN both/CC protein/NN tyrosine/NN kinases/NNS (/( PTK/NNS )/) and/CC protein/NN kinase/NN A/NN (/( PKA/NN )/) ./. 
Both/CC CD2/NN and/CC CD3/NN cross-linking/NN increased/VBD binding/NN of/IN nuclear/JJ proteins/NNS to/TO a/DT radiolabelled/JJ CRE/NN oligonucleotide/NN probe/NN in/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS suggesting/VBG that/IN lymphocyte/NN activation/NN enhances/VBZ binding/NN independently/RB of/IN phosphorylation/NN of/IN CREB/NN at/IN serine/NN 133/CD ./. 
These/DT data/NNS indicate/VBP specific/JJ modulation/NN of/IN the/DT CREB/ATF-1/NN family/NN of/IN transcription/NN factors/NNS by/IN the/DT CD2/NN signalling/NN pathway/NN and/CC suggest/VBP CD2/NN receptor/NN modulation/NN of/IN CRE-mediated/JJ transcription/NN following/VBG ligand/NN engagement/NN (/( e.g./FW cell-to-cell/JJ contact/NN )/) ./. 
UI/LS -/: 99089911/CD 
TI/LS -/: X-rays-induced/JJ secretion/NN of/IN cellular/JJ factor/NN (/( s/NNS )/) that/WDT enhance/VBP (/( s/VBZ )/) HIV-1/NN promoter/NN transcription/NN in/IN various/JJ non-irradiated/JJ transfected/VBN cell/NN lines/NNS ./. 
AB/LS -/: Various/JJ cellular/JJ stress/NN agents/NNS like/IN ionizing/VBG radiation/NN exposure/NN could/MD activate/VB human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV- 1/NN )/) replication/NN or/CC reporter/NN gene/NN expression/NN ./. 
In/IN addition/NN ,/, extracellular/JJ factor/NN (/( s/NNS )/) released/VBN by/IN X-ray-treated/JJ human/JJ colonic/JJ carcinoma/NN cell/NN line/NN (/( HT29/NN )/) might/MD activate/VB the/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) of/IN HIV-1/NN in/IN non-irradiated/JJ HT29/NN cells/NNS ./. 
In/IN the/DT present/JJ report/NN we/PRP show/VBP that/IN in/IN various/JJ transiently/RB or/CC stably/RB transfected/VBN cell/NN lines/NNS ,/, X-ray/NN irradiation/NN up-regulates/VBZ HIV-1/NN LTR/NN transcription/NN through/IN the/DT kappaB/NN regulatory/JJ elements/NNS ./. 
A/DT factor/NN (/( s/NNS )/) ,/, which/WDT is/VBZ processed/VBN by/IN and/CC acts/VBZ upon/IN a/DT variety/NN of/IN cell/NN types/NNS ,/, was/VBD detected/VBN by/IN addition/NN to/TO non-irradiated/JJ cells/NNS of/IN either/CC X-ray-treated/JJ cells/NNS or/CC a/DT conditioned/JJ medium/NN taken/VBN from/IN irradiated/JJ cultures/NNS ./. 
The/DT magnitude/NN of/IN responsiveness/NN is/VBZ cell/NN type/NN dependent/JJ ./. 
In/IN addition/NN ,/, X-ray/NN activation/NN of/IN HIV-1/NN LTR/NN in/IN transiently/RB or/CC stably/RB transfected/VBN cell/NN lines/NNS is/VBZ inhibited/VBN by/IN a/DT potent/JJ antioxidant/JJ drug/NN ,/, pyrrolidine/NN dithiocarbamate/NN and/CC by/IN another/DT drug/NN ,/, known/VBN for/IN its/PRP$ role/NN in/IN the/DT trapping/NN of/IN growth/NN factors/NNS ,/, suramin/NN ./. 
The/DT importance/NN of/IN these/DT observations/NNS in/IN the/DT pathophysiology/NN of/IN patients/NNS with/IN AIDS-related/JJ cancers/NNS treated/VBN by/IN radiotherapy/NN remains/VBZ to/TO be/VB established/VBN ./. 
UI/LS -/: 99073952/CD 
TI/LS -/: Activation/NN of/IN the/DT human/JJ delta-globin/NN gene/NN promoter/NN in/IN primary/JJ adult/JJ erythroid/JJ cells/NNS ./. 
AB/LS -/: Restoration/NN of/IN the/DT CCAAT/NN box/NN or/CC insertion/NN of/IN an/DT erythroid/JJ Kruppel-like/JJ factor/NN (/( EKLF/NN )/) binding/NN site/NN in/IN the/DT delta/NN promoter/NN activates/VBZ its/PRP$ expression/NN in/IN several/JJ erythroid/JJ cell/NN lines/NNS ./. 
We/PRP extended/VBD these/DT studies/NNS using/VBG a/DT novel/JJ primary/JJ human/JJ adult/JJ erythroid/JJ cell/NN (/( hAEC/NN )/) system/NN to/TO investigate/VB these/DT effects/NNS at/IN the/DT late/JJ erythroblast/NN stage/NN ./. 
Restoration/NN of/IN the/DT CCAAT/NN box/NN at/IN -70/CD bp/NN ,/, or/CC insertion/NN of/IN an/DT EKLF/NN binding/NN site/NN at/IN -85/CD bp/NN or/CC -95/CD bp/NN in/IN the/DT promoter/NN significantly/RB increased/VBD delta/NN globin/NN gene/NN expression/NN in/IN hAEC/NN ./. 
Our/PRP$ results/NNS demonstrate/VBP that/IN the/DT altered/JJ CCAAT/NN box/NN (/( CCAAC/NN )/) and/CC the/DT lack/NN of/IN an/DT EKLF/NN binding/NN site/NN in/IN delta-globin/NN contribute/VBP to/TO its/PRP$ low/JJ level/NN of/IN expression/NN in/IN the/DT hAEC/NN model/NN as/RB well/RB ./. 
UI/LS -/: 99065132/CD 
TI/LS -/: Constitutive/JJ association/NN of/IN JAK1/NN and/CC STAT5/NN in/IN pro-B/JJ cells/NNS is/VBZ dissolved/VBN by/IN interleukin-4-induced/JJ tyrosine/NN phosphorylation/NN of/IN both/DT proteins/NNS ./. 
AB/LS -/: The/DT bipartite/JJ human/JJ interleukin-4/NN (/( IL-4/NN )/) receptor/NN was/VBD functionally/RB expressed/VBN in/IN murine/JJ pro-B/JJ cells/NNS and/CC activated/VBN by/IN human/JJ IL-4/NN to/TO evoke/VB intracellular/JJ signaling/NN ./. 
Mutual/JJ association/NN of/IN signal/NN transducing/NN proteins/NNS within/IN the/DT receptor/NN complex/NN was/VBD then/RB studied/VBN in/IN dependence/NN of/IN ligand/NN stimulation/NN ./. 
Besides/IN ligand-induced/JJ receptor/NN heterodimerization/NN and/CC contacts/NNS of/IN the/DT two/CD IL-4/NN receptor/NN subunits/NNS alpha/NN and/CC gamma/NN with/IN Janus/NN kinases/NNS JAK1/NN and/CC JAK3/NN a/DT prominent/JJ constitutive/JJ binding/NN between/IN JAK1/NN and/CC signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN STAT5/NN was/VBD detected/VBN ./. 
Since/IN both/DT these/DT proteins/NNS become/VBP phosphorylated/VBN in/IN response/NN to/TO IL-4/NN receptor/NN stimulation/NN ,/, the/DT influence/NN of/IN tyrosine/NN phosphorylation/NN on/IN their/PRP$ mutual/JJ contact/NN was/VBD analyzed/VBN ./. 
Association/NN of/IN JAK1/NN and/CC STAT5/NN was/VBD found/VBN to/TO occur/VB exclusively/RB between/IN unphosphorylated/JJ proteins/NNS ./. 
UI/LS -/: 99061637/CD 
TI/LS -/: Activation/NN of/IN human/JJ macrophages/NNS by/IN mechanical/JJ ventilation/NN in/FW vitro/FW ./. 
AB/LS -/: Positive-pressure/JJ mechanical/JJ ventilation/NN supports/VBZ gas/NN exchange/NN in/IN patients/NNS with/IN respiratory/JJ failure/NN but/CC is/VBZ also/RB responsible/JJ for/IN significant/JJ lung/NN injury/NN ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP developed/VBN an/DT in/FW vitro/FW model/NN in/IN which/WDT isolated/VBN lung/NN cells/NNS can/MD be/VB submitted/VBN to/TO a/DT prolonged/JJ cyclic/JJ pressure-stretching/JJ strain/NN resembling/VBG that/DT of/IN conventional/JJ mechanical/JJ ventilation/NN ./. 
In/IN this/DT model/NN ,/, cells/NNS cultured/VBN on/IN a/DT Silastic/JJ membrane/NN were/VBD elongated/VBN up/RB to/TO 7/CD %/NN of/IN their/PRP$ initial/JJ diameter/NN ,/, corresponding/VBG to/TO a/DT 12/CD %/NN increase/NN in/IN cell/NN surface/NN ./. 
The/DT lung/NN macrophage/NN was/VBD identified/VBN as/IN the/DT main/JJ cellular/JJ source/NN for/IN critical/JJ inflammatory/JJ mediators/NNS such/JJ as/IN tumor/NN necrosis/NN factor-alpha/NN ,/, the/DT chemokines/NNS interleukin/NN (/( IL/NN )/) -8/CD and/CC -6/CD ,/, and/CC matrix/NN metalloproteinase-9/NN in/IN this/DT model/JJ system/NN of/IN mechanical/JJ ventilation/NN ./. 
These/DT mediators/NNS were/VBD measured/VBN in/IN supernatants/NNS from/IN ventilated/VBN alveolar/JJ macrophages/NNS ,/, monocyte-derived/JJ macrophages/NNS ,/, and/CC promonocytic/JJ THP-1/NN cells/NNS ./. 
Nuclear/JJ factor-kappaB/NN was/VBD found/VBN to/TO be/VB activated/VBN in/IN ventilated/VBN macrophages/NNS ./. 
Synergistic/JJ proinflammatory/JJ effects/NNS of/IN mechanical/JJ stress/NN and/CC molecules/NNS such/JJ as/IN bacterial/JJ endotoxin/NN were/VBD observed/VBN ,/, suggesting/VBG that/IN mechanical/JJ ventilation/NN might/MD be/VB particularly/RB deleterious/JJ in/IN preinjured/JJ or/CC infected/JJ lungs/NNS ./. 
Dexamethasone/NN prevented/VBD IL-8/NN and/CC tumor/NN necrosis/NN factor-alpha/NN secretion/NN in/IN ventilated/VBN macrophages/NNS ./. 
Mechanical/JJ ventilation/NN induced/VBD low/JJ levels/NNS of/IN IL-8/NN secretion/NN by/IN alveolar/JJ type/NN II-like/JJ cells/NNS ./. 
Other/JJ lung/NN cell/NN types/NNS such/JJ as/IN endothelial/JJ cells/NNS ,/, bronchial/JJ cells/NNS ,/, and/CC fibroblasts/NNS failed/VBD to/TO produce/VB IL-8/NN in/IN response/NN to/TO a/DT prolonged/JJ cyclic/JJ pressure-stretching/JJ load/NN ./. 
This/DT model/NN is/VBZ of/IN particular/JJ value/NN for/IN exploring/VBG physical/JJ stress-induced/JJ signaling/NN pathways/NNS ,/, as/RB well/RB as/IN for/IN testing/VBG the/DT effects/NNS of/IN novel/JJ ventilatory/JJ strategies/NNS or/CC adjunctive/JJ substances/NNS aimed/VBN at/IN modulating/VBG cell/NN activation/NN induced/VBN by/IN mechanical/JJ ventilation/NN ./. 
UI/LS -/: 99049827/CD 
TI/LS -/: Signaling/NN pathways/NNS mediated/VBN by/IN the/DT TNF-/NN and/CC cytokine-receptor/JJ families/NNS target/VBP a/DT common/JJ cis-element/NN of/IN the/DT IFN/NN regulatory/JJ factor/NN 1/CD promoter/NN ./. 
AB/LS -/: CD40/NN activation/NN of/IN B/NN cells/NNS is/VBZ strongly/RB influenced/VBN by/IN the/DT presence/NN of/IN cytokines/NNS ./. 
However/RB ,/, the/DT molecular/JJ basis/NN for/IN the/DT interplay/NN between/IN these/DT distinct/JJ stimuli/NNS is/VBZ not/RB clearly/RB delineated/VBN ./. 
IFN/NN regulatory/JJ factor/NN 1/CD (/( IRF-1/NN )/) is/VBZ a/DT transcription/NN factor/NN activated/VBN by/IN either/CC CD40/NN or/CC cytokines/NNS ./. 
We/PRP have/VBP found/VBN that/IN these/DT different/JJ sets/NNS of/IN signals/NNS target/VBP a/DT common/JJ cis-acting/JJ element/NN in/IN the/DT promoter/NN of/IN this/DT gene/NN ,/, the/DT IRF-1/NN gamma-activated/JJ site/NN (/( GAS/NN )/) ./. 
Targeting/NN of/IN the/DT IRF-1/NN GAS/NN is/VBZ not/RB confined/VBN to/TO activation/NN via/IN CD40/NN but/CC extends/VBZ to/TO other/JJ stimuli/NNS that/WDT mimic/VBP the/DT CD40/NN signaling/NN cascade/NN ,/, like/IN TNF-alpha/NN and/CC EBV/NN ./. 
In/IN contrast/NN to/TO induction/NN of/IN STATs/NNS by/IN cytokines/NNS ,/, the/DT IRF-1/NN GAS-binding/JJ complex/NN activated/VBN by/IN CD40/NN ,/, TNF-alpha/NN ,/, or/CC EBV/NN contains/VBZ Rel/NN proteins/NNS ,/, specifically/RB p50/NN and/CC p65/NN ./. 
In/IN this/DT system/NN ,/, simultaneous/JJ exposure/NN to/TO CD40L/NN together/RB with/IN either/CC IL-4/NN or/CC IFN-gamma/NN does/VBZ not/RB lead/VB to/TO the/DT activation/NN of/IN novel/JJ Rel/STAT/NN complexes/NNS ./. 
Given/VBN the/DT importance/NN of/IN IRF-1/NN in/IN a/DT variety/NN of/IN biologic/JJ functions/NNS from/IN proliferation/NN to/TO apoptosis/NN ,/, our/PRP$ findings/NNS support/VBP the/DT notion/NN that/IN modulation/NN of/IN IRF-1/NN levels/NNS may/MD be/VB a/DT critical/JJ control/NN point/NN in/IN B/NN cell/NN activation/NN ./. 
UI/LS -/: 99069282/CD 
TI/LS -/: Differential/JJ effects/NNS of/IN protein/NN kinase/NN C/NN inhibitors/NNS on/IN fibronectin-induced/JJ interleukin-beta/NN gene/NN transcription/NN ,/, protein/NN synthesis/NN and/CC secretion/NN in/IN human/JJ monocytic/JJ cells/NNS ./. 
AB/LS -/: Human/JJ monocytic/JJ cells/NNS express/VBP interleukin-1beta/NN (/( IL-1beta/NN )/) when/WRB stimulated/VBN with/IN the/DT extracellular/JJ matrix/NN glycoprotein/NN ,/, fibronectin/NN (/( FN/NN )/) ./. 
Protein/NN kinase/NN C/NN (/( PKC/NN )/) activation/NN is/VBZ considered/VBN important/JJ for/IN this/DT process/NN ;/: however/RB ,/, the/DT metabolic/JJ steps/NNS at/IN which/WDT PKC/NN acts/VBZ upon/IN to/TO mediate/VB the/DT FN-induced/JJ IL-1beta/NN response/NN remain/VBP unclear/JJ ./. 
We/PRP performed/VBD an/DT analysis/NN of/IN the/DT mechanisms/NNS by/IN which/WDT two/CD PKC/NN inhibitors/NNS ,/, Calphostin/NN C/NN and/CC Staurosporine/NN ,/, prevent/VBP the/DT FN-induced/JJ IL-1beta/NN response/NN ./. 
Both/DT inhibitors/NNS blocked/VBD the/DT secretion/NN of/IN IL-1beta/NN protein/NN into/IN the/DT media/NNS of/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS exposed/VBN to/TO FN/NN ./. 
Immunoprecipitation/NN analysis/NN revealed/VBD that/IN unde3r/IN these/DT circumstances/NNS ,/, Calphostin/NN C/NN inhibited/VBD the/DT production/NN of/IN IL-1beta/NN protein/NN ,/, whereas/IN Staurosporine/NN allowed/VBD protein/NN production/NN ,/, but/CC inhibited/VBD its/PRP$ secretion/NN ./. 
To/TO determine/VB the/DT mechanisms/NNS responsible/JJ for/IN these/DT differences/NNS ,/, we/PRP turned/VBD to/TO human/JJ U937/NN promonocytic/JJ cells/NNS ./. 
U937/NN cells/NNS transfected/VBN with/IN the/DT human/JJ full-length/JJ IL-1beta/NN promoter/NN connected/VBN to/TO a/DT luciferase/NN reporter/NN gene/NN were/VBD submitted/VBN to/TO transcription/NN assays/NNS ,/, Northern/NN blotting/NN ,/, and/CC DNA/NN electrophoresis/NN mobility/NN gel/NN shift/NN assays/NNS ./. 
These/DT studies/NNS revealed/VBD that/IN Calphostin/NN C/NN inhibited/VBD the/DT nuclear/JJ translocation/NN of/IN the/DT transcription/NN factor/NN activator/NN protein-1/NN (/( AP-1/NN )/) which/WDT is/VBZ considered/VBN necessary/JJ for/IN FN/NN induction/NN of/IN IL-1beta/NN gene/NN transcription/NN ,/, and/CC prevented/VBD the/DT transcription/NN of/IN the/DT IL-1beta/NN gene/NN ./. 
In/IN contrast/NN ,/, Staurosporine/NN alone/RB induced/VBD AP-1/NN translocation/NN and/CC stimulation/NN of/IN the/DT gene/NN ./. 
Overall/RB ,/, our/PRP$ data/NNS indicate/VBP that/IN Calphostin/NN C/NN prevents/VBZ the/DT transcription/NN of/IN the/DT IL-1beta/NN gene/NN thereby/RB inhibiting/VBG protein/NN synthesis/NN ./. 
Based/VBN on/IN the/DT high/JJ specificity/NN of/IN this/DT compound/NN for/IN PKC/NN ,/, we/PRP conclude/VBP that/IN PKC/NN is/VBZ necessary/JJ for/IN FN-induced/JJ IL-1beta/NN protein/NN production/NN ./. 
In/IN contrast/NN ,/, Staurosporine/NN prevented/VBD secretion/NN of/IN IL-1beta/NN by/IN unknown/JJ mechanisms/NNS 
UI/LS -/: 97429889/CD 
TI/LS -/: The/DT carboxyl-terminal/JJ cytoplasmic/JJ domain/NN of/IN CD36/NN is/VBZ required/VBN for/IN oxidized/VBN low-density/JJ lipoprotein/NN modulation/NN of/IN NF-kappaB/NN activity/NN by/IN tumor/NN necrosis/NN factor-alpha/NN ./. 
AB/LS -/: The/DT binding/NN of/IN oxidized/VBN low-density/JJ lipoprotein/NN (/( Ox/NN LDL/NN )/) by/IN monocyte-macrophages/NNS causes/VBZ pleiotropic/JJ effects/NNS ,/, including/VBG changes/NNS in/IN gene/NN expression/NN ,/, and/CC is/VBZ thought/VBN to/TO represent/VB an/DT early/JJ event/NN in/IN atherogenesis/NN ./. 
The/DT integral/JJ membrane/NN glycoprotein/NN CD36/NN appears/VBZ to/TO play/VB a/DT physiological/JJ role/NN in/IN binding/NN and/CC uptake/NN of/IN Ox/NN LDL/NN by/IN monocyte-macrophages/NNS ,/, although/IN the/DT molecular/JJ events/NNS associated/VBN with/IN CD36-Ox/NN LDL/NN interaction/NN are/VBP unknown/JJ ./. 
To/TO approach/VB this/DT issue/NN ,/, we/PRP used/VBD CD36/NN transfected/JJ Chinese/JJ hampster/NN ovary/NN (/( CHO/NN )/) cells/NNS ,/, exposed/VBD them/PRP to/TO Ox/NN LDL/NN ,/, and/CC determined/VBD changes/NNS in/IN the/DT activity/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN ./. 
We/PRP report/VBP here/RB that/IN Ox/NN LDL/NN enhanced/VBD DNA/NN binding/NN activity/NN of/IN nuclear/JJ extracts/NNS to/TO an/DT NF-kappaB/NN sequence/NN following/VBG activation/NN of/IN CD36-producing/JJ CHO/NN cells/NNS with/IN the/DT proinflammatory/JJ cytokine/NN tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) ./. 
This/DT enhanced/VBN DNA/NN binding/NN activity/NN was/VBD inhibited/VBN by/IN coincubation/NN of/IN CD36/NN transfected/VBN cells/NNS with/IN the/DT human/JJ CD36-specific/JJ antibody/NN OKM5/NN ./. 
We/PRP also/RB determined/VBD that/IN activation/NN of/IN NF-kappaB/NN DNA/NN binding/NN activity/NN required/VBD an/DT intact/JJ carboxyl-terminal/JJ cytoplasmic/JJ segment/NN on/IN CD36/NN ./. 
Our/PRP$ results/NNS support/VBP the/DT idea/NN that/IN human/JJ CD36/NN mediates/VBZ signal/NN transduction/NN events/NNS in/IN response/NN to/TO Ox/NN LDL/NN ./. 
UI/LS -/: 97205335/CD 
TI/LS -/: TRAMP/NN ,/, a/DT novel/JJ apoptosis-mediating/JJ receptor/NN with/IN sequence/NN homology/NN to/TO tumor/NN necrosis/NN factor/NN receptor/NN 1/CD and/CC Fas/NN (/( Apo-1/CD95/NN )/) ./. 
AB/LS -/: A/DT novel/JJ member/NN of/IN the/DT tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) receptor/NN family/NN ,/, designated/VBN TRAMP/NN ,/, has/VBZ been/VBN identified/VBN ./. 
The/DT structural/JJ organization/NN of/IN the/DT 393/CD amino/NN acid/NN long/JJ human/JJ TRAMP/NN is/VBZ most/RBS homologous/JJ to/TO TNF/NN receptor/NN 1/CD ./. 
TRAMP/NN is/VBZ abundantly/RB expressed/VBN on/IN thymocytes/NNS and/CC lymphocytes/NNS ./. 
Its/PRP$ extracellular/JJ domain/NN is/VBZ composed/VBN of/IN four/CD cysteine-rich/JJ domains/NNS ,/, and/CC the/DT cytoplasmic/JJ region/NN contains/VBZ a/DT death/NN domain/NN known/VBN to/TO signal/NN apoptosis/NN ./. 
Overexpression/NN of/IN TRAMP/NN leads/VBZ to/TO two/CD major/JJ responses/NNS ,/, NF-kappaB/NN activation/NN and/CC apoptosis/NN ./. 
TRAMP-induced/JJ cell/NN death/NN is/VBZ inhibited/VBN by/IN an/DT inhibitor/NN of/IN ICE-like/JJ proteases/NNS ,/, but/CC not/RB by/IN Bcl-2/NN ./. 
In/IN addition/NN ,/, TRAMP/NN does/VBZ not/RB appear/VB to/TO interact/VB with/IN any/DT of/IN the/DT known/JJ apoptosis-inducing/JJ ligands/NNS of/IN the/DT TNF/NN family/NN ./. 
UI/LS -/: 97131727/CD 
TI/LS -/: The/DT state/NN of/IN maturation/NN of/IN monocytes/NNS into/IN macrophages/NNS determines/VBZ the/DT effects/NNS of/IN IL-4/NN and/CC IL-13/NN on/IN HIV/NN replication/NN ./. 
AB/LS -/: The/DT molecular/JJ mechanisms/NNS of/IN the/DT effects/NNS of/IN IL-4/NN and/CC IL-13/NN on/IN HIV/NN infection/NN in/IN human/JJ monocytes/NNS as/IN they/PRP matured/VBD into/IN monocyte-derived/JJ macrophages/NNS over/IN 7/CD days/NNS were/VBD investigated/VBN using/VBG HIV-1/NN (/( BaL/NN )/) ,/, and/CC low/JJ passage/NN clinical/JJ strains/NNS ./. 
IL-4/NN and/CC IL-13/NN up-regulated/VBD the/DT expression/NN of/IN both/CC genomic/JJ and/CC spliced/VBN HIV/NN mRNA/NN in/IN monocytes/NNS cultured/VBN on/IN Teflon/NN ,/, as/IN determined/VBN by/IN Northern/NN analysis/NN and/CC p24/NN Ag/NN assay/NN ./. 
Using/VBG a/DT nuclear/JJ run-on/JJ assay/NN ,/, IL-4/NN stimulation/NN was/VBD shown/VBN to/TO enhance/VB transcription/NN by/IN two-/CD to/TO threefold/RB ./. 
IL-4/NN stimulated/VBD nuclear/JJ factor-kappaB/NN nuclear/JJ translocation/NN and/CC binding/NN before/IN enhancement/NN of/IN HIV/NN RNA/NN expression/NN ./. 
Conversely/RB ,/, IL-4/NN and/CC IL-13/NN markedly/RB and/CC significantly/RB inhibited/VBD HIV/NN replication/NN at/IN the/DT transcriptional/JJ level/NN in/IN monocyte-derived/JJ macrophages/NNS ,/, and/CC this/DT occurred/VBD whether/IN these/DT cytokines/NNS were/VBD added/VBN before/IN or/CC after/IN HIV/NN infection/NN ./. 
The/DT reversal/NN from/IN stimulation/NN to/TO inhibition/NN occurred/VBD after/IN 3/CD to/TO 5/CD days/NNS of/IN adherence/NN to/TO plastic/NN ./. 
IL-4/NN had/VBD no/DT significant/JJ effect/NN on/IN HIV/NN reverse/JJ transcription/NN ./. 
The/DT effect/NN of/IN both/DT cytokines/NNS on/IN the/DT monocyte/NN maturation/differentiation/NN (/( CD11b/NN ,/, CD13/NN ,/, and/CC CD26/NN )/) and/CC other/JJ macrophage/NN markers/NNS (/( CD14/NN and/CC CD68/NN )/) was/VBD examined/VBN ./. 
IL-4/NN enhanced/VBD CD11b/NN ,/, but/CC inhibited/VBD CD26/NN expression/NN and/CC delayed/VBD CD13/NN loss/NN ./. 
IL-13/NN had/VBD similar/JJ effects/NNS on/IN CD11b/NN and/CC CD13/NN ,/, but/CC no/DT effect/NN on/IN CD26/NN ./. 
Hence/RB ,/, these/DT cytokines/NNS do/VBP not/RB simply/RB enhance/VB monocyte/NN differentiation/NN ,/, but/CC have/VBP complex/JJ and/CC slightly/RB divergent/JJ effects/NNS that/WDT impact/VBP on/IN HIV/NN replication/NN probably/RB through/IN cell/NN signaling/NN pathways/NNS and/CC nuclear/JJ factor-kappaB/NN translocation/NN ./. 
UI/LS -/: 99101008/CD 
TI/LS -/: Mice/NNS lacking/VBG the/DT transcription/NN factor/NN CIITA/NN --/: a/DT second/JJ look/NN ./. 
AB/LS -/: We/PRP have/VBP generated/VBN a/DT second/JJ line/NN of/IN mice/NNS lacking/VBG a/DT transcription/NN factor/NN thought/VBN to/TO be/VB a/DT critical/JJ regulator/NN of/IN MHC/NN class/NN II/CD gene/NN expression/NN ,/, CIITA/NN (/( for/IN class/NN II/CD transactivator/NN )/) ./. 
Our/PRP$ and/CC the/DT previously/RB published/VBN lines/NNS differ/VBP in/IN the/DT deletion/NN that/WDT was/VBD engineered/VBN and/CC by/IN the/DT fact/NN that/IN we/PRP removed/VBD the/DT neomycin-resistance/JJ promoter/NN and/CC structural/JJ gene/NN via/IN the/DT cre-loxP/JJ recombination/NN system/NN ./. 
Characterization/NN of/IN our/PRP$ line/NN led/VBD to/TO two/CD new/JJ findings/NNS ./. 
First/RB ,/, a/DT substantial/JJ number/NN of/IN cells/NNS can/MD express/VB class/NN II/CD molecules/NNS in/IN the/DT absence/NN of/IN CIITA/NN ,/, albeit/IN at/IN 5-fold/RB reduced/VBN levels/NNS ,/, most/RBS notably/RB dendritic/JJ cells/NNS in/IN s.c./NN lymph/NN nodes/NNS ;/: therefore/RB ,/, the/DT CIITA/NN gene/NN can/MD not/RB be/VB an/DT absolute/JJ '/`` master/NN gene/NN '/'' controlling/VBG the/DT expression/NN of/IN class/NN II/CD molecules/NNS ,/, as/IN had/VBD been/VBN thought/VBN ./. 
Second/RB ,/, in/IN contrast/NN to/TO recent/JJ results/NNS on/IN human/JJ cell/NN lines/NNS ,/, CIITA/NN is/VBZ not/RB critically/RB involved/VBN in/IN the/DT IFN-gamma-induced/JJ up-regulation/NN of/IN MHC/NN class/NN I/CD genes/NNS ./. 
UI/LS -/: 99087711/CD 
TI/LS -/: Interleukin-10/NN stabilizes/VBZ inhibitory/JJ kappaB-alpha/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: Interleukin-10/NN (/( IL-10/NN )/) protects/VBZ animals/NNS from/IN lethal/JJ endotoxemia/NN ./. 
This/DT beneficial/JJ effect/NN is/VBZ mediated/VBN ,/, in/IN part/NN ,/, by/IN inhibition/NN of/IN inflammatory/JJ cytokine/NN production/NN ,/, including/VBG tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) ./. 
Evidence/NN suggests/VBZ that/IN IL-10/NN may/MD inhibit/VB activation/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) through/IN an/DT unknown/JJ mechanism/NN ./. 
NF-kappaB/NN activation/NN in/IN response/NN to/TO inflammatory/JJ signals/NNS is/VBZ dependent/JJ upon/IN degradation/NN of/IN its/PRP$ associated/VBN inhibitory/JJ peptide/NN ,/, inhibitory/JJ kappaB-alpha/NN (/( IkappaB-alpha/NN )/) ./. 
We/PRP hypothesized/VBD that/IN IL-10/NN prevents/VBZ human/JJ monocyte/NN NF-kappaB/NN activation/NN and/CC resultant/JJ TNF-alpha/NN production/NN by/IN stabilization/NN of/IN IkappaB-alpha/NN ./. 
The/DT purpose/NN of/IN this/DT study/NN was/VBD to/TO determine/VB the/DT effect/NN of/IN IL-10/NN on/IN lipopolysaccharide/NN (/( LPS/NN )/) -induced/JJ human/JJ monocyte/NN TNF-alpha/NN production/NN ,/, NF-kappaB/NN activation/NN ,/, and/CC IkappaB-alpha/NN degradation/NN ./. 
Monocytes/NNS were/VBD isolated/VBN from/IN human/JJ donors/NNS ./. 
Cells/NNS were/VBD stimulated/VBN with/IN endotoxin/NN (/( LPS/NN ,/, 100/CD ng/mL/NN )/) with/IN and/CC without/IN human/JJ IL-10/NN (/( 10/CD ng/mL/NN )/) ./. 
Following/VBG stimulation/NN ,/, TNF-alpha/NN was/VBD measured/VBN in/IN cell/NN supernatants/NNS by/IN ELISA/NN ,/, NF-kappaB/NN activity/NN by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN ,/, and/CC IkappaB-alpha/NN levels/NNS by/IN Western/NN blot/NN ./. 
We/PRP observed/VBD that/IN after/IN LPS/NN stimulation/NN of/IN human/JJ monocytes/NNS ,/, TNF-alpha/NN increased/VBD to/TO 798+/-67/CD pg/mL/NN (/( p/NN </JJR .001/CD versus/CC control/NN )/) ./. 
IL-10/NN attenuated/VBD LPS-stimulated/JJ TNF-alpha/NN production/NN (/( 297+/-54/CD ;/: p/NN </JJR .001/CD versus/CC LPS/NN alone/RB )/) ./. 
After/IN LPS/NN stimulation/NN in/IN human/JJ monocytes/NNS ,/, IkappaB-alpha/NN protein/NN levels/NNS decreased/VBD ,/, and/CC NF-kappaB/NN DNA/NN binding/NN increased/VBD ./. 
IL-10/NN pretreatment/NN prevented/VBD LPS-induced/JJ decreases/NNS in/IN IkappaB-alpha/NN protein/NN levels/NNS and/CC attenuated/VBD NF-kappaB/NN DNA/NN binding/NN ./. 
IL-10/NN appears/VBZ to/TO prevent/VB activation/NN of/IN NF-kappaB/NN by/IN preserving/VBG IkappaB-alpha/NN protein/NN levels/NNS ,/, leading/VBG to/TO a/DT reduction/NN in/IN TNF-alpha/NN release/NN ./. 
UI/LS -/: 99074319/CD 
TI/LS -/: Down-regulation/NN of/IN human/JJ granzyme/NN B/NN expression/NN by/IN glucocorticoids/NNS ./. 
Dexamethasone/NN inhibits/VBZ binding/VBG to/TO the/DT Ikaros/NN and/CC AP-1/NN regulatory/JJ elements/NNS of/IN the/DT granzyme/NN B/NN promoter/NN ./. 
AB/LS -/: The/DT serine/NN protease/NN granzyme/NN B/NN is/VBZ an/DT essential/JJ component/NN of/IN the/DT granule/NN exocytosis/NN pathway/NN ,/, a/DT major/JJ apoptotic/JJ mechanism/NN used/VBN by/IN cytotoxic/JJ T/NN lymphocytes/NNS and/CC natural/JJ killer/NN cells/NNS to/TO induce/VB target/NN cell/NN apoptosis/NN ./. 
Granzyme/NN B/NN gene/NN transcription/NN is/VBZ induced/VBN in/IN activated/VBN lymphocytes/NNS upon/IN antigenic/JJ stimulation/NN ,/, and/CC several/JJ regulatory/JJ regions/NNS including/VBG CBF/NN ,/, AP-1/NN ,/, and/CC Ikaros/NN binding/NN sites/NNS have/VBP been/VBN shown/VBN to/TO be/VB essential/JJ in/IN the/DT control/NN of/IN granzyme/NN B/NN promoter/NN activation/NN ./. 
Dexamethasone/NN ,/, a/DT glucocorticoid/NN that/WDT is/VBZ widely/RB used/VBN as/IN an/DT immunomodulatory/JJ and/CC anti-inflammatory/JJ agent/NN ,/, inhibits/VBZ granzyme/NN B/NN mRNA/NN transcript/NN in/IN phytohemagglutinin-activated/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
Transfection/NN of/IN a/DT reporter/NN construct/NN containing/VBG the/DT -148/CD to/TO +60/CD region/NN of/IN the/DT human/JJ granzyme/NN B/NN promoter/NN demonstrated/VBD that/IN this/DT region/NN was/VBD the/DT target/NN for/IN dexamethasone/NN repression/NN ./. 
Mutation/NN of/IN Ikaros/NN or/CC AP-1/NN binding/NN sites/NNS in/IN the/DT context/NN of/IN the/DT granzyme/NN B/NN promoter/NN demonstrated/VBD that/IN both/DT sites/NNS participate/VBP in/IN dexamethasone-mediated/JJ inhibition/NN of/IN the/DT granzyme/NN B/NN promoter/NN activity/NN ./. 
Electromobility/NN shift/NN assay/NN revealed/VBD that/IN dexamethasone/NN abolished/VBD the/DT binding/NN of/IN nuclear/JJ transcription/NN factors/NNS to/TO the/DT Ikaros/NN binding/NN site/NN and/CC reduced/VBD AP-1/NN binding/NN activity/NN ./. 
These/DT results/NNS indicate/VBP that/IN dexamethasone/NN is/VBZ able/JJ to/TO abrogate/VB the/DT transcriptional/JJ activity/NN of/IN the/DT human/JJ granzyme/NN B/NN gene/NN promoter/NN by/IN inhibiting/VBG the/DT binding/NN of/IN nuclear/JJ factors/NNS at/IN the/DT AP-1/NN and/CC Ikaros/NN sites/NNS ./. 
UI/LS -/: 99064961/CD 
TI/LS -/: Glucocorticoid/NN receptors/NNS on/IN mononuclear/JJ leukocytes/NNS in/IN polycystic/JJ ovary/JJ syndrome/NN ./. 
AB/LS -/: OBJECTIVE/NN :/: Many/JJ studies/NNS have/VBP suggested/VBN that/IN there/EX is/VBZ a/DT possible/JJ hormonal/JJ dysregulation/NN of/IN hypothalamic-pituitary-adrenal/JJ (/( HPA/JJ )/) axis/NN and/CC an/DT increased/VBN cortisol/NN clearance/NN in/IN patients/NNS with/IN polycystic/JJ ovary/JJ syndrome/NN (/( PCOS/NN )/) ./. 
Therefore/RB in/IN this/DT study/NN ,/, we/PRP have/VBP examined/VBN the/DT role/NN of/IN glucocorticoid/NN receptor/s/NN|NNS (/( GR/NN|NNS )/) characteristics/NNS in/IN the/DT developing/NN of/IN these/DT abnormalities/NNS in/IN patients/NNS with/IN PCOS/NN ./. 
METHOD/NN :/: For/IN this/DT purpose/NN ,/, the/DT number/NN and/CC affinity/NN of/IN GR/NN|NNS in/IN peripheral/JJ mononuclear/JJ leukocytes/NNS (/( MNL/NNS )/) of/IN 10/CD patients/NNS with/IN PCOS/NN and/CC 10/CD healthy/JJ women/NNS (/( controls/NNS )/) were/VBD determined/VBN ./. 
RESULTS/NNS :/: There/EX were/VBD no/DT significant/JJ differences/NNS in/IN the/DT number/NN (/( 6500+/-1001/CD sites/cell/NNS and/CC 6352+/-1697/CD sites/cell/NNS ,/, respectively/RB ;/: P/NN >/JJR 0.05/CD )/) and/CC affinity/NN (/( 3.93+/-0.89/CD nM/NN and/CC 4.49+/-0.71/CD nM/NN ,/, respectively/RB ;/: P/NN >/JJR 0.05/CD )/) of/IN GR/NN|NNS between/IN the/DT PCOS/NN patients/NNS and/CC the/DT controls/NNS ./. 
CONCLUSIONS/NNS :/: These/DT results/NNS suggest/VBP that/IN the/DT alterations/NNS in/IN the/DT HPA/JJ axis/NN and/CC in/IN the/DT cortisol/NN metabolism/NN observed/VBN in/IN PCOS/NN are/VBP not/RB related/JJ to/TO GR/NN|NNS deficiency/NN ./. 
UI/LS -/: 99057097/CD 
TI/LS -/: Heterogeneous/JJ expression/NN of/IN the/DT lipocalin/NN NGAL/NN in/IN primary/JJ breast/NN cancers/NNS ./. 
AB/LS -/: We/PRP have/VBP previously/RB shown/VBN that/IN neu/NN oncogene-initiated/JJ rat/NN mammary/JJ carcinomas/NNS uniquely/RB over-express/VBP neu-related/JJ lipocalin/NN (/( NRL/NN )/) ,/, a/DT member/NN of/IN the/DT calycin/NN protein/NN superfamily/NN ./. 
Here/RB ,/, we/PRP characterize/VBP the/DT putative/JJ human/JJ homolog/NN of/IN NRL/NN ,/, neutrophil/NN gelatinase-associated/JJ lipocalin/NN (/( NGAL/NN )/) ./. 
ngal/JJ gene/NN expression/NN was/VBD found/VBN at/IN moderate/JJ levels/NNS in/IN only/RB 2/CD of/IN 17/CD human/JJ tissues/NNS examined/VBN ,/, breast/NN and/CC lung/NN ./. 
When/WRB breast/NN cancers/NNS were/VBD examined/VBN for/IN NGAL/NN mRNA/NN and/CC protein/NN levels/NNS ,/, they/PRP were/VBD found/VBN to/TO exhibit/VB heterogeneous/JJ expression/NN ./. 
NGAL/NN levels/NNS varied/VBD in/IN these/DT tumors/NNS from/IN undetectable/JJ to/TO exceeding/VBG those/DT in/IN normal/JJ breast/NN parenchyma/NN ./. 
Immuno-histochemical/JJ analysis/NN confirmed/VBD the/DT presence/NN of/IN NGAL/NN within/IN breast/NN carcinoma/NN cells/NNS but/CC detected/VBD only/RB low/JJ levels/NNS of/IN this/DT protein/NN in/IN normal/JJ ductal/JJ epithelium/NN ./. 
In/IN contrast/NN ,/, large/JJ amounts/NNS of/IN the/DT protein/NN were/VBD localized/JJ to/TO the/DT lumen/NN of/IN normal/JJ breast/NN ducts/NNS in/IN the/DT vicinity/NN of/IN NGAL-expressing/JJ tumors/NNS ./. 
Interestingly/RB ,/, unlike/IN NRL/NN in/IN rat/NN mammary/JJ carcinomas/NNS ,/, no/DT significant/JJ association/NN between/IN NGAL/NN expression/NN and/CC HER-2/neu/NN activation/NN was/VBD found/VBN in/IN human/JJ breast/NN tumors/NNS ./. 
In/IN contrast/NN ,/, a/DT significant/JJ correlation/NN between/IN NGAL/NN expression/NN in/IN breast/NN cancer/NN was/VBD found/VBN with/IN several/JJ other/JJ markers/NNS of/IN poor/JJ prognosis/NN ,/, including/VBG estrogen/NN and/CC progesterone/NN receptor-negative/JJ status/NN and/CC high/JJ proliferation/NN (/( S-phase/NN fraction/NN )/) ./. 
NGAL/NN levels/NNS were/VBD stratified/VBN as/IN high/JJ or/CC low/JJ in/IN breast/NN cancers/NNS from/IN a/DT cohort/NN of/IN node-positive/JJ patients/NNS with/IN known/JJ outcome/NN ./. 
No/DT significant/JJ association/NN between/IN NGAL/NN expression/NN and/CC disease-free/JJ or/CC overall/JJ survival/NN was/VBD observed/VBN ./. 
UI/LS -/: 99049801/CD 
TI/LS -/: BASH/NN ,/, a/DT novel/JJ signaling/VBG molecule/NN preferentially/RB expressed/VBN in/IN B/NN cells/NNS of/IN the/DT bursa/NN of/IN Fabricius/NN ./. 
AB/LS -/: The/DT bursa/NN of/IN Fabricius/NN is/VBZ a/DT gut-associated/JJ lymphoid/JJ organ/NN that/WDT is/VBZ essential/JJ for/IN the/DT generation/NN of/IN a/DT diversified/JJ B/NN cell/NN repertoire/NN in/IN the/DT chicken/NN ./. 
We/PRP describe/VBP here/RB a/DT novel/JJ gene/NN preferentially/RB expressed/VBN in/IN bursal/JJ B/NN cells/NNS ./. 
The/DT gene/NN encodes/VBZ an/DT 85-kDa/JJ protein/NN ,/, designated/VBN BASH/NN (/( B/NN cell/NN adaptor/NN containing/VBG SH2/NN domain/NN )/) ,/, that/WDT contains/VBZ N-terminal/JJ acidic/JJ domains/NNS with/IN SH2/NN domain-binding/JJ phosphotyrosine-based/JJ motifs/NNS ,/, a/DT proline-rich/JJ domain/NN ,/, and/CC a/DT C-terminal/JJ SH2/NN domain/NN ./. 
BASH/NN shows/VBZ a/DT substantial/JJ sequence/NN similarity/NN to/TO SLP-76/NN ,/, an/DT adaptor/NN protein/NN functioning/VBG in/IN TCR-signal/JJ transduction/NN ./. 
BASH/NN becomes/VBZ tyrosine-phosphorylated/JJ with/IN the/DT B/NN cell/NN Ag/NN receptor/NN (/( BCR/NN )/) cross-link/NN or/CC by/IN coexpression/NN with/IN Syk/NN and/CC Lyn/NN and/CC associates/VBZ with/IN signaling/VBG molecules/NNS including/VBG Syk/NN and/CC a/DT putative/JJ chicken/NN Shc/NN homologue/NN ./. 
Overexpression/NN of/IN BASH/NN results/VBZ in/IN suppression/NN of/IN the/DT NF-AT/NN activation/NN induced/VBN by/IN BCR-cross-linking/NN ./. 
These/DT findings/NNS suggest/VBP that/IN BASH/NN is/VBZ involved/VBN in/IN BCR-mediated/JJ signal/NN transduction/NN and/CC could/MD play/VB a/DT critical/JJ role/NN in/IN B/NN cell/NN development/NN in/IN the/DT bursa/NN ./. 
UI/LS -/: 99039380/CD 
TI/LS -/: Granulocyte/NN colony-stimulating/JJ factor/NN activates/VBZ a/DT 72-kDa/JJ isoform/NN of/IN STAT3/NN in/IN human/JJ neutrophils/NNS ./. 
AB/LS -/: Granulocyte/NN colony-stimulating/JJ factor/NN (/( G-CSF/NN )/) signaling/NN involves/VBZ activation/NN of/IN STATs/NNS ,/, proteins/NNS that/WDT serve/VBP the/DT dual/JJ function/NN of/IN signal/NN transduction/NN and/CC activation/NN of/IN transcription/NN ./. 
We/PRP previously/RB demonstrated/VBD that/IN G-CSF/NN activated/VBD a/DT distinct/JJ Stat3-like/JJ protein/NN in/IN immature/JJ and/CC mature/JJ normal/JJ myeloid/JJ cells/NNS ,/, StatG/NN ./. 
StatG/NN in/IN normal/JJ immature/JJ human/JJ myeloid/JJ cells/NNS ,/, i.e./FW adult/JJ CD34+/JJ bone/NN marrow/NN cells/NNS ,/, was/VBD composed/VBN of/IN Stat3beta/NN ./. 
This/DT investigation/NN was/VBD undertaken/VBN to/TO determine/VB the/DT composition/NN of/IN StatG/NN in/IN mature/JJ normal/JJ human/JJ myeloid/JJ cells/NNS ,/, i.e./FW polymorphonuclear/JJ neutrophilic/JJ granulocytes/NNS (/( PMN/NNS )/) ./. 
These/DT studies/NNS revealed/VBD that/IN the/DT major/JJ protein/NN in/IN extracts/NNS of/IN PMN/NN activated/VBN by/IN G-CSF/NN to/TO bind/VB the/DT high-affinity/JJ serum-inducible/JJ element/NN (/( hSIE/NN )/) is/VBZ a/DT 72-kDa/JJ protein/NN that/WDT cross-reacts/VBZ with/IN Stat3/NN monoclonal/JJ antibody/NN ,/, which/WDT we/PRP have/VBP designated/VBN Stat3gamma/NN ./. 
Stat3gamma/NN is/VBZ derived/VBN from/IN Stat3alpha/NN by/IN limited/JJ proteolysis/NN and/CC lacks/VBZ the/DT carboxyl-terminal/JJ portion/NN of/IN Stat3alpha/NN ./. 
Because/IN this/DT region/NN of/IN Stat3alpha/NN is/VBZ involved/VBN in/IN transcriptional/JJ activation/NN ,/, our/PRP$ findings/NNS suggest/VBP the/DT possibility/NN that/IN Stat3gamma/NN may/MD be/VB transcriptionally/RB inactive/JJ and/CC may/MD compete/VB with/IN Stat3alpha/NN for/IN Stat3/NN binding/NN sites/NNS in/IN these/DT terminally/RB differentiated/VBN myeloid/JJ cells/NNS 
UI/LS -/: 97362594/CD 
TI/LS -/: Association/NN between/IN expression/NN of/IN intercellular/JJ adhesion/NN molecule-1/NN and/CC integration/NN of/IN human/JJ T-cell-leukemia/JJ virus/NN type/NN 1/CD in/IN adult/JJ T-cell/NN leukemia/NN cells/NNS ./. 
AB/LS -/: It/PRP is/VBZ known/VBN that/IN the/DT expression/NN levels/NNS of/IN intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN )/) in/IN adult/JJ T/NN cell/NN leukemia/NN (/( ATL/NN )/) cells/NNS are/VBP high/JJ ,/, whereas/IN those/DT in/IN T-lymphoid/NN cells/NNS are/VBP not/RB ./. 
In/IN order/NN to/TO investigate/VB the/DT factors/NNS that/WDT influence/VBP the/DT induction/NN of/IN ICAM-1/NN molecules/NNS ,/, Northern/NN blot/NN analysis/NN to/TO measure/VB the/DT expression/NN level/NN of/IN ICAM-1/NN mRNAs/NNS and/CC Southern/NN blot/NN hybridization/NN to/TO analyze/VB the/DT integration/NN of/IN human/JJ T-cell-leukemia/JJ virus/NN type/NN 1/CD (/( HTLV-1/NN )/) provirus/NN were/VBD done/VBN ./. 
The/DT levels/NNS of/IN ICAM-1/NN mRNA/NN expression/NN of/IN ATL/NN cells/NNS were/VBD generally/RB higher/JJR than/IN those/DT of/IN T-lymphoid/NN cells/NNS ./. 
However/RB ,/, ILT-mat/NN cells/NNS and/CC ATL16T(-)/JJ cells/NNS ,/, although/IN they/PRP were/VBD ATL/NN cells/NNS ,/, showed/VBD rather/RB low/JJ surface/NN ICAM-1/NN expression/NN and/CC ICAM-1/NN mRNA/NN expression/NN ./. 
Southern/NN blot/NN hybridization/NN showed/VBD that/IN only/RB two/CD and/CC four/CD bands/NNS were/VBD found/VBN in/IN ILT-mat/NN and/CC ATL16T(-)/JJ cells/NNS ,/, respectively/RB ,/, whereas/IN >/JJR 10/CD bands/NNS were/VBD detected/VBN in/IN other/JJ ATL/NN cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN monoclonal/JJ integration/NN of/IN HTLV-1/NN provirus/NN to/TO the/DT genome/NN of/IN T/NN cell/NN ,/, especially/RB the/DT number/NN of/IN integration/NN sites/NNS ,/, is/VBZ one/CD of/IN the/DT factors/NNS for/IN induction/NN of/IN ICAM-1/NN molecules/NNS ./. 
UI/LS -/: 97196961/CD 
TI/LS -/: Heat-shock/NN and/CC cadmium/NN chloride/NN increase/VBP the/DT vimentin/NN mRNA/NN and/CC protein/NN levels/NNS in/IN U-937/NN human/JJ promonocytic/JJ cells/NNS ./. 
AB/LS -/: Heat-shock/NN for/IN 2/CD hours/NNS at/IN 42/CD degrees/NNS C/NN ,/, or/CC the/DT administration/NN for/IN 3/CD hours/NNS of/IN 100/CD or/CC 150/CD microM/NN cadmium/NN chloride/NN ,/, inhibited/VBD the/DT subsequent/JJ proliferation/NN activity/NN ,/, induced/VBD the/DT expression/NN of/IN functional/JJ differentiation/NN markers/NNS ,/, and/CC caused/VBD an/DT increase/NN in/IN the/DT amount/NN of/IN the/DT stress-responsive/JJ HSP70/NN protein/NN in/IN U-937/NN human/JJ promonocytic/JJ cells/NNS ./. 
In/IN addition/NN ,/, both/CC heat/NN and/CC cadmium/NN produced/VBD an/DT increase/NN in/IN the/DT amount/NN of/IN the/DT intermediate/JJ filament/NN protein/NN vimentin/NN ,/, as/IN determined/VBN by/IN immunoblot/NN and/CC immunofluorescence/NN assays/NNS ./. 
By/IN contrast/NN ,/, the/DT amounts/NNS of/IN actin/NN and/CC beta-tubulin/NN were/VBD not/RB significantly/RB altered/VBN ./. 
The/DT amount/NN of/IN vimentin/NN mRNA/NN was/VBD also/RB increased/VBN during/IN recovery/NN from/IN stress/NN ,/, indicating/VBG that/IN vimentin/NN expression/NN was/VBD not/RB exclusively/RB regulated/VBN at/IN the/DT protein/NN level/NN ./. 
Although/IN cadmium/NN caused/VBD an/DT early/JJ ,/, transient/JJ stimulation/NN of/IN c-jun/NN and/CC c-fos/NN expression/NN and/CC AP-1/NN binding/NN activity/NN ,/, heat-shock/NN failed/VBD to/TO alter/VB both/CC protooncogene/NN expression/NN and/CC transcription/NN factor/NN binding/NN ,/, indicating/VBG that/IN the/DT stress-induced/JJ vimentin/NN increase/NN was/VBD not/RB the/DT result/NN of/IN AP-1-mediated/JJ transcriptional/JJ activation/NN ./. 
Finally/RB ,/, it/PRP was/VBD observed/VBN that/IN the/DT rate/NN of/IN decay/NN of/IN vimentin/NN mRNA/NN upon/IN actinomycin/NN D/NN administration/NN was/VBD decreased/VBN in/IN heat-/NN and/CC cadmium-pretreated/JJ cells/NNS in/IN comparison/NN to/TO untreated/JJ cells/NNS ./. 
These/DT results/NNS indicate/VBP that/IN stress/NN treatments/NNS cause/VBP an/DT increase/NN in/IN vimentin/NN levels/NNS in/IN promonocytic/JJ cells/NNS ,/, which/WDT may/MD be/VB explained/VBN at/IN least/JJS in/IN part/NN by/IN transcript/NN stabilization/NN ./. 
UI/LS -/: 99321124/CD 
TI/LS -/: Ovarian/JJ and/CC breast/NN cytotoxic/JJ T/NN lymphocytes/NNS can/MD recognize/VB peptides/NNS from/IN the/DT amino/NN enhancer/NN of/IN split/JJ protein/NN of/IN the/DT Notch/NN complex/NN ./. 
AB/LS -/: In/IN this/DT study/NN we/PRP investigated/VBD recognition/NN by/IN ovarian/JJ tumor/NN associated/JJ lymphocyte/NN (/( OVTAL/NN )/) ,/, and/CC breast/NN tumor/NN associated/JJ lymphocytes/NNS (/( BRTAL/NNS )/) ,/, of/IN peptides/NNS corresponding/VBG to/TO the/DT sequence/NN 125-135/CD of/IN the/DT Aminoenhancer/NN of/IN split/JJ (/( AES/NN )/) protein/NN ./. 
Three/CD of/IN these/DT peptides/NNS designated/VBN as/IN G75:AES1/2/NN (/( 128-135/CD )/) ,/, G60: AES1/2/NN (/( 127-137/CD )/) and/CC G61: AES1/2/NN (/( 125-133/CD )/) correspond/VBP to/TO the/DT wildtype/JJ AES/NN sequence/NN ,/, while/IN the/DT fourth/JJ G76:GPLTPLPV/NN ,/, AES1/2/NN (/( 128-135/CD )/) corresponds/VBZ to/TO a/DT variant/JJ sequence/NN of/IN the/DT peptide/NN G75/NN with/IN the/DT N-terminal/JJ Leu/NN substituted/VBN to/TO glycine/NN ./. 
These/DT sequences/NNS were/VBD chosen/VBN for/IN study/NN because/IN mass-spectrometric/JJ analysis/NN (/( MS/NN )/) of/IN a/DT CTL/NN active/JJ HPLC/NN peptide/NN fraction/NN eluted/VBN from/IN immunoaffinity/NN precipitated/JJ HLA-A2/NN molecule/NN ,/, revealed/VBD :/: (/( a/LS )/) the/DT presence/NN of/IN an/DT ion/NN with/IN a/DT mass-to-charge/JJ ratio/NN (/( m/z/NN )/) of/IN 793/CD which/WDT was/VBD more/RBR abundant/JJ than/IN other/JJ ions/NNS of/IN similar/JJ masses/NNS ;/: (/( b/LS )/) the/DT tentatively/RB reconstituted/VBN sequence/NN of/IN the/DT ion/NN 793/CD matched/VBD the/DT sequence/NN of/IN peptide/NN G76/NN ./. 
We/PRP found/VBD that/IN AES/NN peptides/NNS G75/NN (/( 128-135/CD )/) and/CC G76/NN (/( 128-135/CD )/) (/( L128G/NN )/) reconstituted/VBD CTL/NN recognition/NN at/IN concentrations/NNS ranging/VBG between/IN 200-500/CD nM/NN ./. 
These/DT concentrations/NNS are/VBP lower/JJR than/IN concentrations/NNS reported/VBN to/TO activate/VB effector/NN function/NN of/IN CTL/NN recognizing/VBG other/JJ epithelial/JJ tumor/NN Ag/NN ./. 
Furthermore/RB ,/, analysis/NN with/IN cloned/VBN CD8+/JJ T/NN cells/NNS indicated/VBD that/IN G75/NN and/CC G76/NN were/VBD not/RB cross-reactive/JJ specificities/NNS ,/, suggesting/VBG a/DT key/JJ role/NN for/IN the/DT N-terminal/JJ residues/NNS of/IN the/DT variant/JJ peptide/NN in/IN dictating/VBG specificities/NNS ./. 
Since/IN the/DT AES/NN proteins/NNS are/VBP part/NN of/IN a/DT set/NN of/IN transcriptional/JJ repressors/NNS encoded/VBN by/IN the/DT Enhancer/NN of/IN split/JJ [/( E(spl)/NN ]/) genes/NNS ,/, and/CC since/IN these/DT repressors/NNS are/VBP activated/VBN to/TO suppress/VB cell/NN differentiation/NN in/IN response/NN to/TO Notch/NN receptors/NNS signalling/NN ,/, the/DT AES/NN peptides/NNS may/MD represent/VB a/DT novel/JJ class/NN of/IN self-antigens/NNS that/WDT deserve/VBP further/JJ consideration/NN as/IN tumor/NN Ag/NN in/IN epithelial/JJ cancers/NNS ./. 
UI/LS -/: 99098435/CD 
TI/LS -/: Induction/NN of/IN the/DT pro-myelocytic/JJ leukaemia/NN gene/NN by/IN type/NN I/CD and/CC type/NN II/CD interferons/NNS ./. 
AB/LS -/: The/DT physiological/JJ role/NN of/IN the/DT pro-myelocytic/JJ leukaemia/NN (/( PML/NN )/) gene/NN product/NN is/VBZ poorly/RB defined/VBN ./. 
Among/IN other/JJ functions/NNS ,/, PML/NN is/VBZ involved/VBN in/IN haematopoietic/JJ differentiation/NN and/CC in/IN control/NN of/IN cell/NN growth/NN and/CC tumorigenesis/NN ./. 
We/PRP investigated/VBD the/DT regulation/NN of/IN human/JJ PML/NN expression/NN by/IN interferons/NNS (/( IFNs/NNS )/) and/CC IL-1/NN in/IN various/JJ human/JJ haematopoietic/JJ lines/NNS (/( U937/NN ,/, THP1/NN ,/, HL60/NN ,/, NB4/NN )/) ,/, in/IN human/JJ diploid/JJ fibroblasts/NNS and/CC in/IN human/JJ peripheral/JJ blood/NN leukocytes/NNS ./. 
Cytokine-induced/JJ modulation/NN of/IN PML/NN expression/NN was/VBD assessed/VBN by/IN Northern/NN blot/NN analyses/NNS ,/, flow/NN cytometry/NN studies/NNS and/CC in/FW situ/FW immunolabelling/NN ./. 
Our/PRP$ data/NNS show/VBP that/IN IFNs/NNS and/CC IL-1/NN upregulate/VBP PML/NN transcript/NN and/CC protein/NN expression/NN in/IN a/DT time/NN and/CC dose-dependent/JJ manner/NN ./. 
In/FW situ/FW immunolabelling/NN revealed/VBD that/IN upregulation/NN of/IN protein/NN expression/NN by/IN IFN-alpha/NN is/VBZ a/DT consequence/NN of/IN a/DT marked/JJ increase/NN in/IN both/CC the/DT number/NN and/CC the/DT intensity/NN of/IN the/DT staining/NN of/IN so-called/JJ PML/NN nuclear/JJ bodies/NNS ./. 
Our/PRP$ data/NNS suggest/VBP that/IN stimulation/NN of/IN PML/NN expression/NN by/IN interferons/NNS and/CC IL-1/NN may/MD account/VB for/IN upregulation/NN of/IN PML/NN proteins/NNS observed/VBN in/IN inflammatory/JJ tissues/NNS and/CC in/IN proliferative/JJ states/NNS ./. 
UI/LS -/: 99086128/CD 
TI/LS -/: The/DT position/NN of/IN the/DT ZEBRA/NN activation/NN domain/NN does/VBZ not/RB influence/VB its/PRP$ biological/JJ activity/NN ./. 
AB/LS -/: Epstein-Barr/JJ virus/NN (/( EBV/NN )/) is/VBZ a/DT human/JJ herpesvirus/NN which/WDT latently/RB infects/VBZ B/NN lymphocytes/NNS ./. 
EBV/NN encodes/VBZ a/DT unique/JJ transcriptional/JJ activator/NN ,/, known/VBN as/IN ZEBRA/NN ,/, which/WDT can/MD disrupt/VB viral/JJ latency/NN in/IN B/NN cells/NNS and/CC induce/VB lytic/JJ viral/JJ replication/NN ./. 
Furthermore/RB ,/, ZEBRA/NN has/VBZ been/VBN shown/VBN to/TO bind/VB at/IN the/DT EBV/NN origin/NN of/IN lytic/JJ replication/NN ,/, and/CC is/VBZ necessary/JJ for/IN viral/JJ DNA/NN replication/NN to/TO occur/VB ./. 
Previously/RB we/PRP demonstrated/VBD that/IN heterologous/JJ activation/NN domains/NNS can/MD fully/RB substitute/VB for/IN the/DT ZEBRA/NN activation/NN domain/NN ./. 
Here/RB we/PRP extend/VBP those/DT results/NNS by/IN showing/VBG that/IN the/DT position/NN of/IN the/DT ZEBRA/NN activation/NN domain/NN or/CC a/DT heterologous/JJ replacement/NN domain/NN does/VBZ not/RB influence/VB its/PRP$ ability/NN to/TO function/VB in/IN the/DT disruption/NN of/IN EBV/NN latency/NN ./. 
In/IN this/DT study/NN three/CD novel/JJ clones/NNS were/VBD constructed/VBN in/IN which/WDT the/DT ZEBRA/NN activation/NN region/NN was/VBD repositioned/VBN to/TO the/DT carboxy/NN terminus/NN of/IN the/DT protein/NN ./. 
These/DT mutants/NNS were/VBD used/VBN to/TO demonstrate/VB that/IN the/DT ability/NN of/IN ZEBRA/NN 's/POS wild/JJ type/NN domain/NN to/TO function/VB in/IN the/DT complex/JJ biological/JJ process/NN of/IN virus/NN activation/NN is/VBZ not/RB compromised/VBN by/IN altering/VBG its/PRP$ position/NN within/IN the/DT protein/NN ./. 
UI/LS -/: 99071844/CD 
TI/LS -/: The/DT modulation/NN of/IN glucocorticoid/NN receptor/NN content/NN by/IN 3-O-methyl-D-glucose/NN transport/NN in/IN human/JJ mononuclear/JJ leukocyte/NN in/IN obesity/NN ./. 
AB/LS -/: Glucocorticoid/NN receptors/NNS (/( GR/NNS )/) and/CC 3-O-methyl-D/JJ glucose/NN (/( 3-O-MG/NN )/) transport/NN were/VBD determined/VBN in/IN mononuclear/JJ leukocytes/NNS (/( MNL/NNS )/) from/IN 11/CD abdominal/JJ obese/JJ subjects/NNS ,/, 10/CD pituitary-dependent/JJ Cushing/NN 's/POS syndrome/NN (/( Cushing/NN 's/POS disease/NN )/) and/CC 10/CD healthy/JJ controls/NNS ./. 
Using/VBG a/DT whole-cell/JJ competitive/JJ binding/NN assay/NN and/CC 3H-dexamethasone/NN as/IN tracer/NN ,/, MNL/NNS of/IN abdominal/JJ obese/JJ subjects/NNS were/VBD found/VBN to/TO have/VB 4855/CD +/-/CC 1389/CD sites/cell/NNS which/WDT was/VBD significantly/RB lower/JJR (/( p/NN </JJR 0.05/CD )/) than/IN controls/NNS (/( 6234/CD +/-/CC 1568/CD sites/cell/NNS )/) ,/, although/IN no/DT significant/JJ difference/NN was/VBD found/VBN in/IN the/DT mean/JJ serum/NN cortisol/NN level/NN ./. 
Their/PRP$ mean/JJ Kd/NN (/( affinity/NN )/) was/VBD also/RB significantly/RB lower/JJR than/IN that/DT found/VBN in/IN the/DT healthy/JJ controls/NNS (/( obese/JJ Kd/NN :/: 2.92/CD +/-/CC 0.84/CD nmol/l/NN ,/, control/JJ Kd/NN :/: 4.55/CD +/-/CC 0.67/CD nM/NN ,/, p/NN </JJR 0.05/CD )/) ./. 
On/IN the/DT other/JJ hand/NN ,/, the/DT receptor/NN characteristics/NNS in/IN Cushing/NN 's/POS disease/NN patients/NNS were/VBD within/IN the/DT normal/JJ range/NN ./. 
At/IN the/DT same/JJ time/NN ,/, 3-O-MG/NN transport/NN was/VBD determined/VBN in/IN the/DT same/JJ subjects/NNS ./. 
In/IN Cushing/NN 's/POS disease/NN ,/, 3-O-MG/NN transport/NN was/VBD within/IN the/DT normal/JJ range/NN ,/, whereas/IN in/IN abdominal/JJ obesity/NN this/DT value/NN was/VBD significantly/RB lower/JJR than/IN the/DT healthy/JJ controls/NNS (/( abdominal/JJ obese/JJ :/: 31.90/CD +/-/CC 8.20/CD ;/: control/NN :/: 46.26/CD +/-/CC 12.91/CD fmol/10(6)/NN cell/NN ,/, min/NN ,/, p/NN </JJR 0.05/CD )/) ./. 
We/PRP also/RB found/VBD a/DT positive/JJ correlation/NN between/IN 3-O-MG/JJ transport/NN and/CC GR/NNS binding/NN capacity/NN in/IN abdominal/JJ subjects/NNS (/( r/NN =/JJ 0.89/CD ,/, p/NN </JJR 0.001/CD )/) ,/, however/RB we/PRP did/VBD not/RB find/VB such/JJ a/DT correlation/NN in/IN Cushing/NN 's/POS disease/NN (/( r/NN =/JJ 0.60/CD ,/, p/NN >/JJR 0.05/CD )/) ./. 
These/DT results/NNS indicated/VBD that/IN ,/, in/IN abdominal/JJ obesity/NN ,/, the/DT GR/NNS binding/NN capacity/NN in/IN MNL/NNS is/VBZ influenced/VBN by/IN the/DT changes/NNS in/IN glucose/NN transport/NN ./. 
UI/LS -/: 99065678/CD 
TI/LS -/: Interleukin-10/NN and/CC transforming/VBG growth/NN factor-beta/NN promoter/NN polymorphisms/NNS in/IN allergies/NNS and/CC asthma/NN ./. 
AB/LS -/: Interleukin-10/NN (/( IL-10/NN )/) and/CC transforming/VBG growth/NN factor/NN beta/NN (/( TGF-beta/NN )/) are/VBP inhibitory/JJ for/IN B/NN and/CC T/NN cells/NNS ,/, IgE/NN production/NN ,/, and/CC mast/NN cell/NN proliferation/NN ,/, and/CC they/PRP induce/VBP apoptosis/NN in/IN eosinophils/NNS ./. 
These/DT cytokines/NNS are/VBP therefore/RB candidate/NN genes/NNS which/WDT could/MD contribute/VB to/TO the/DT development/NN of/IN asthma/NN or/CC allergies/NNS ./. 
We/PRP investigated/VBD the/DT hypothesis/NN that/IN polymorphic/JJ nucleotides/NNS within/IN the/DT IL-10/NN and/CC TGF-beta/NN gene/NN promoters/NNS would/MD link/VB to/TO the/DT expression/NN of/IN allergies/NNS and/CC asthma/NN ./. 
DNA/NN taken/VBN from/IN families/NNS with/IN an/DT asthmatic/JJ proband/NN was/VBD examined/VBN for/IN base/NN exchanges/NNS by/IN single-stranded/JJ conformational/JJ polymorphism/NN (/( SSCP/NN )/) ./. 
We/PRP demonstrated/VBD the/DT presence/NN of/IN a/DT polymorphism/NN in/IN the/DT promoter/NN region/NN of/IN the/DT IL-10/NN gene/NN and/CC four/CD in/IN the/DT TGF-beta/NN gene/NN promoters/NNS (/( 3/CD in/IN TGF-beta1/NN and/CC 1/CD in/IN TGF-beta2/NN )/) ./. 
The/DT IL-10/NN gene/NN polymorphism/NN was/VBD a/DT C-to-A/JJ exchange/NN 571/CD base/NN pairs/NNS upstream/JJ from/IN the/DT translation/NN start/NN site/NN and/CC was/VBD present/JJ between/IN consensus/NN binding/NN sequences/NNS for/IN Sp1/NN and/CC elevated/JJ total/JJ serum/NN ./. 
This/DT polymorphism/NN was/VBD associated/VBN with/IN elevated/JJ total/JJ serum/NN IgE/NN in/IN subjects/NNS heterozygotic/JJ or/CC homozygotic/JJ for/IN this/DT base/NN exchange/NN (/( p/NN </JJR 0.009/CD )/) ./. 
The/DT base/NN exchange/NN at/IN -509/CD (/( from/IN the/DT transcription/NN initiation/NN site/NN )/) in/IN the/DT TGF-beta/NN promoter/NN also/RB linked/VBD to/TO elevated/JJ total/JJ IgE/NN (/( p/NN </JJR 0.01/CD )/) ./. 
This/DT polymorphism/NN represented/VBD a/DT C-to-T/JJ base/NN exchange/NN which/WDT induced/VBD a/DT YY1/NN consensus/NN sequence/NN and/CC is/VBZ present/JJ in/IN a/DT region/NN of/IN the/DT promoter/NN associated/VBN with/IN negative/JJ transcription/NN regulation/NN ./. 
UI/LS -/: 99054659/CD 
TI/LS -/: Tpl-2/NN induces/VBZ IL-2/NN expression/NN in/IN T-cell/NN lines/NNS by/IN triggering/VBG multiple/JJ signaling/NN pathways/NNS that/WDT activate/VBP NFAT/NN and/CC NF-kappaB/NN ./. 
AB/LS -/: The/DT Tpl-2/NN kinase/NN activates/VBZ the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) and/CC induces/VBZ IL-2/NN expression/NN in/IN T-cell/NN lines/NNS ./. 
Here/RB we/PRP show/VBP that/IN the/DT activation/NN of/IN the/DT IL-2/NN promoter/NN by/IN Tpl-2/NN is/VBZ inhibited/VBN by/IN mutant/JJ signaling/VBG molecules/NNS that/WDT inhibit/VBP the/DT mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) or/CC the/DT calcineurin/NFAT/NN pathways/NNS and/CC is/VBZ promoted/VBN by/IN combinations/NNS of/IN signaling/VBG molecules/NNS that/WDT activate/VBP these/DT pathways/NNS ./. 
We/PRP ,/, therefore/RB ,/, conclude/VBP that/IN signals/NNS generated/VBN by/IN the/DT convergence/NN of/IN the/DT MAPK/NN and/CC the/DT calcineurin/NFAT/NN pathway/NN are/VBP necessary/JJ and/CC sufficient/JJ for/IN the/DT activation/NN of/IN the/DT IL-2/NN promoter/NN by/IN Tpl-2/NN ./. 
The/DT activation/NN of/IN both/CC the/DT IL-2/NN promoter/NN and/CC an/DT NFAT-driven/JJ minimal/JJ promoter/NN were/VBD shown/VBN to/TO depend/VB on/IN signals/NNS transduced/VBN by/IN Raf1/NN ./. 
However/RB ,/, it/PRP was/VBD only/RB the/DT IL-2/NN promoter/NN whose/WP$ activation/NN by/IN Tpl-2/NN was/VBD fully/RB blocked/VBN by/IN the/DT dominant/JJ negative/JJ mutant/JJ MEK1S218/222A/NN and/CC the/DT MEK1/MEK2/NN inhibitor/NN PD098059/NN ./. 
Since/IN the/DT activation/NN of/IN NFAT/NN is/VBZ MAPK-dependent/JJ these/DT findings/NNS suggested/VBD that/IN the/DT activation/NN of/IN MAPK/NN by/IN Tpl-2/NN is/VBZ either/CC independent/JJ or/CC only/RB partially/RB dependent/JJ on/IN MEK1/NN and/CC MEK2/NN ./. 
In/IN addition/NN ,/, they/PRP suggested/VBD that/IN the/DT activation/NN of/IN the/DT IL-2/NN promoter/NN is/VBZ under/IN the/DT control/NN of/IN not/RB only/RB NFAT/NN but/CC also/RB a/DT second/JJ factor/NN whose/WP$ activation/NN is/VBZ MEK-dependent/JJ ./. 
Experiments/NNS in/IN COS-1/NN and/CC EL-4/NN cells/NNS confirmed/VBD both/DT hypotheses/NNS and/CC revealed/VBD that/IN the/DT second/JJ factor/NN activated/VBN by/IN Tpl-2/NN is/VBZ NF-kappaB/NN ./. 
While/IN the/DT activation/NN of/IN the/DT IL-2/NN promoter/NN and/CC an/DT NFAT-driven/JJ minimal/JJ promoter/NN by/IN Tpl-2/NN was/VBD fully/RB blocked/VBN by/IN the/DT dominant/JJ negative/JJ mutant/JJ NFAT/NN delta418/NN ,/, it/PRP was/VBD only/RB partially/RB blocked/VBN by/IN the/DT calcineurin/NN inhibitor/NN cyclosporin/NN A/NN suggesting/VBG that/IN the/DT Tpl-2-mediated/JJ NFAT/NN activation/NN is/VBZ under/IN the/DT control/NN of/IN a/DT combination/NN of/IN calcineurin-dependent/JJ and/CC independent/JJ pathways/NNS ./. 
Both/DT pathways/NNS were/VBD fully/RB blocked/VBN by/IN Bcl-2/NN or/CC Bcl-X(L)/NN ./. 
UI/LS -/: 99048705/CD 
TI/LS -/: Differential/JJ activation/NN of/IN functionally/RB distinct/JJ STAT5/NN proteins/NNS by/IN IL-5/NN and/CC GM-CSF/NN during/IN eosinophil/NN and/CC neutrophil/NN differentiation/NN from/IN human/JJ CD34+/JJ hematopoietic/JJ stem/NN cells/NNS ./. 
AB/LS -/: Interleukin-5/NN (/( IL-5/NN )/) and/CC granulocyte/NN macrophage-colony/NN stimulating/NN factor/NN (/( GM-CSF/NN )/) are/VBP important/JJ cytokines/NNS for/IN the/DT proliferation/NN ,/, differentiation/NN ,/, and/CC activation/NN of/IN myeloid/JJ lineages/NNS ./. 
The/DT JAK/STAT/NN pathway/NN is/VBZ one/CD of/IN the/DT signaling/NN pathways/NNS implicated/VBN in/IN mediating/VBG biological/JJ responses/NNS induced/VBN by/IN these/DT cytokines/NNS ./. 
Previous/JJ studies/NNS have/VBP demonstrated/VBN that/IN these/DT cytokines/NNS predominantly/RB activate/VBP an/DT 80/CD kDa/NN STAT5/NN isoform/NN in/IN mature/JJ granulocytes/NNS ./. 
To/TO better/RBR understand/VB the/DT role/NN of/IN STAT/NN proteins/NNS during/IN growth/NN and/CC differentiation/NN of/IN granulocytes/NNS ,/, we/PRP evaluated/VBD differentiation/NN of/IN human/JJ CD34+/JJ hematopoietic/JJ stem/NN cells/NNS ex/FW vivo/FW toward/IN eosinophils/NNS and/CC neutrophils/NNS ./. 
Bandshift/NN experiments/NNS showed/VBD that/IN in/IN an/DT early/JJ stage/NN of/IN both/DT differentiation/NN pathways/NNS (/( 14/CD days/NNS )/) ,/, the/DT 94/CD kDa/NN STAT5B/NN protein/NN was/VBD activated/VBN by/IN both/CC IL-5/NN (/( eosinophil/NN lineage/NN )/) and/CC GM-CSF/NN (/( neutrophil/NN lineage/NN )/) ./. 
However/RB ,/, during/IN maturation/NN of/IN both/DT lineages/NNS (/( days/NNS 21/CD and/CC 28/CD )/) ,/, increased/VBN expression/NN of/IN a/DT functionally/RB distinct/JJ 80/CD kDa/NN STAT5/NN isoform/NN was/VBD observed/VBN ,/, resulting/VBG in/IN heterodimer/NN DNA-binding/JJ complexes/NNS containing/VBG both/CC the/DT 94/CD and/CC 80/CD kDa/NN STAT5/NN proteins/NNS ./. 
The/DT finding/NN that/IN functionally/RB distinct/JJ isoforms/NNS of/IN STAT5/NN are/VBP activated/VBN during/IN the/DT early/JJ and/CC late/JJ differentiation/NN stages/NNS of/IN granulocytes/NNS suggests/VBZ that/IN they/PRP might/MD be/VB involved/VBN in/IN regulating/VBG different/JJ biological/JJ functions/NNS in/IN these/DT cells/NNS ./. 
UI/LS -/: 99038208/CD 
TI/LS -/: The/DT T-cell/NN oncogenic/JJ protein/NN HOX11/NN activates/VBZ Aldh1/NN expression/NN in/IN NIH/NN 3T3/NN cells/NNS but/CC represses/VBZ its/PRP$ expression/NN in/IN mouse/NN spleen/NN development/NN ./. 
AB/LS -/: Hox11/NN is/VBZ a/DT homeobox/NN gene/NN essential/JJ for/IN spleen/NN formation/NN in/IN mice/NNS ,/, since/IN atrophy/NN of/IN the/DT anlage/NN of/IN a/DT developing/VBG spleen/NN occurs/VBZ in/IN early/JJ embryonic/JJ development/NN in/IN Hox11/NN null/JJ mice/NNS ./. 
HOX11/NN is/VBZ also/RB expressed/VBN in/IN a/DT subset/NN of/IN T-cell/NN acute/JJ leukemias/NNS after/IN specific/JJ chromosomal/JJ translocations/NNS ./. 
Since/IN the/DT protein/NN has/VBZ a/DT homeodomain/NN and/CC can/MD activate/VB transcription/NN ,/, it/PRP probably/RB exerts/VBZ at/IN least/JJS some/DT of/IN its/PRP$ effects/NNS in/FW vivo/FW by/IN regulation/NN of/IN target/NN genes/NNS ./. 
Representational/JJ difference/NN analysis/NN has/VBZ been/VBN used/VBN to/TO isolate/VB cDNA/NN clones/NNS corresponding/VBG to/TO mRNA/NN species/NNS activated/VBN following/VBG stable/JJ expression/NN of/IN HOX11/NN in/IN NIH/NN 3T3/NN cells/NNS ./. 
The/DT gene/NN encoding/VBG the/DT retinoic/JJ acid-synthesizing/JJ enzyme/NN aldehyde/NN dehydrogenase/NN 1/CD (/( Aldh1/NN )/) ,/, initially/RB called/VBN Hdg-1/NN ,/, was/VBD found/VBN to/TO be/VB ectopically/RB activated/VBN by/IN HOX11/NN in/IN this/DT system/NN ./. 
Study/NN of/IN Aldh1/NN gene/NN expression/NN during/IN spleen/NN development/NN showed/VBD that/IN the/DT presence/NN of/IN Aldh1/NN mRNA/NN inversely/RB correlated/VBD with/IN Hox11/NN ./. 
Hox11/NN null/JJ mouse/NN embryos/NNS have/VBP elevated/JJ Aldh1/NN mRNA/NN in/IN spleen/NN primordia/NN prior/JJ to/TO atrophy/NN ,/, while/IN Aldh1/NN seems/VBZ to/TO be/VB repressed/VBN by/IN Hox11/NN during/IN organogenesis/NN of/IN the/DT spleens/NNS of/IN wild-type/JJ mice/NNS ./. 
This/DT result/NN suggests/VBZ that/IN expression/NN of/IN Aldh1/NN protein/NN is/VBZ negatively/RB regulated/VBN by/IN Hox11/NN and/CC that/IN abnormal/JJ expression/NN of/IN Aldh1/NN in/IN Hox11/NN null/JJ mice/NNS may/MD cause/VB loss/NN of/IN splenic/JJ precursor/NN cells/NNS by/IN aberrant/JJ retinoic/JJ acid/NN metabolism/NN 
UI/LS -/: 97364688/CD 
TI/LS -/: Role/NN of/IN the/DT X2/NN box/NN in/IN activated/VBN transcription/NN from/IN the/DT DRA/NN promoter/NN in/IN B/NN cells/NNS ./. 
AB/LS -/: We/PRP investigated/VBD the/DT function/NN of/IN the/DT evolutionary/JJ conserved/VBN X2/NN box/NN in/IN the/DT promoter/NN of/IN the/DT HLA-DRA/NN gene/NN from/IN the/DT human/JJ major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) in/IN resting/VBG and/CC activated/VBN B/NN cells/NNS ./. 
NF-X2/NN ,/, which/WDT contains/VBZ members/NNS of/IN the/DT AP-1/ATF/CREB/NN families/NNS of/IN transcription/NN factors/NNS ,/, interacts/VBZ with/IN the/DT X2/NN box/NN (/( 5'-TGCGTCA-3'/NN )/) from/IN positions/NNS -97/CD to/TO -91/CD in/IN the/DT DRA/NN promoter/NN ./. 
In/IN resting/VBG Raji/NN cells/NNS ,/, little/JJ to/TO no/DT binding/NN to/TO the/DT X2/NN box/NN was/VBD observed/VBN ./. 
In/IN sharp/JJ contrast/NN ,/, in/IN B/NN cells/NNS treated/VBN with/IN the/DT phorbol/NN ester/NN 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) ,/, strong/JJ interactions/NNS between/IN the/DT X2/NN box/NN and/CC NF-X2/NN containing/VBG c-Fos/NN were/VBD observed/VBN ./. 
As/IN determined/VBN by/IN transient/JJ expression/NN and/CC RNA/NN analyses/NNS ,/, the/DT activation/NN of/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) also/RB increased/VBD rates/NNS of/IN transcription/NN from/IN the/DT wild-type/JJ DRA/NN promoter/NN but/CC not/RB from/IN a/DT DRA/NN promoter/NN bearing/VBG clustered/JJ point/NN mutations/NNS in/IN the/DT X2/NN box/NN ./. 
Since/IN the/DT co-expression/NN with/IN a/DT dominant/JJ negative/JJ c-Fos/NN abolished/VBD the/DT responsiveness/NN to/TO TPA/NN ,/, we/PRP conclude/VBP that/IN activated/VBN transcription/NN of/IN the/DT DRA/NN gene/NN depends/VBZ on/IN interactions/NNS between/IN the/DT X2/NN box/NN and/CC NF-X2/NN ,/, which/WDT contains/VBZ c-Fos/NN ./. 
UI/LS -/: 97196870/CD 
TI/LS -/: Thymocytes/NNS control/VBP the/DT CD4/NN gene/NN differently/RB from/IN mature/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: We/PRP analyzed/VBD the/DT activity/NN of/IN the/DT enhancer/NN ,/, the/DT promoter/NN and/CC the/DT silencer/NN of/IN the/DT human/JJ CD4/NN gene/NN during/IN T/NN cell/NN development/NN using/VBG transgenic/JJ mice/NNS ./. 
Immunofluorescence/NN studies/NNS on/IN thymic/JJ populations/NNS of/IN mice/NNS carrying/VBG transgenes/NNS in/IN various/JJ combinations/NNS of/IN these/DT regulatory/JJ DNA/NN elements/NNS revealed/VBD that/IN thymocytes/NNS control/VBP the/DT CD4/NN gene/NN in/IN a/DT different/JJ manner/NN than/IN mature/JJ peripheral/JJ T/NN lymphocytes/NNS ./. 
The/DT 5'-positive/JJ regulatory/JJ unit/NN ,/, consisting/VBG of/IN the/DT promoter/NN and/CC the/DT 5'/JJ enhancer/NN ,/, is/VBZ already/RB active/JJ at/IN the/DT CD4-CD8-double-negative/JJ (/( DN/JJ )/) stage/NN of/IN development/NN ./. 
However/RB ,/, its/PRP$ activity/NN becomes/VBZ lower/JJR in/IN the/DT double-positive/JJ and/CC a/DT fraction/NN of/IN the/DT CD4+/JJ CD8int/-/JJ cell/NN population/NN ,/, indicating/VBG that/IN an/DT additional/JJ enhancer/NN ,/, located/JJ in/IN either/CC the/DT first/JJ or/CC the/DT third/JJ intron/NN of/IN the/DT CD4/NN gene/NN ,/, is/VBZ required/VBN for/IN CD4/NN gene/NN expression/NN in/IN this/DT population/NN ./. 
The/DT other/JJ studied/VBN regulatory/JJ element/NN is/VBZ the/DT minimal/JJ CD4/NN silencer/NN which/WDT inhibits/VBZ CD4/NN gene/NN expression/NN in/IN peripheral/JJ CD8/NN T/NN lymphocytes/NNS ./. 
This/DT silencer/NN is/VBZ inactive/JJ in/IN the/DT most/RBS immature/JJ DN/JJ thymocytes/NNS ,/, which/WDT probably/RB use/VBP a/DT distinct/JJ silencer/NN mechanism/NN to/TO down-regulate/VB CD4/NN gene/NN expression/NN ./. 
Unexpectedly/RB ,/, the/DT CD4/NN silencer/NN is/VBZ also/RB active/JJ in/IN CD4+/JJ CD8int/-/JJ cells/NNS of/IN the/DT thymus/NN ,/, implying/VBG that/IN an/DT anti-silencer/NN may/MD be/VB required/VBN to/TO resume/VB CD4/NN expression/NN in/IN this/DT cell/NN population/NN ./. 
Altogether/RB ,/, the/DT CD4/NN gene/NN is/VBZ regulated/VBN by/IN several/JJ positive/JJ and/CC negative/JJ regulatory/JJ mechanisms/NNS which/WDT come/VBP into/IN play/NN in/IN a/DT developmentally/RB coordinated/VBN manner/NN ./. 
UI/LS -/: 99201818/CD 
TI/LS -/: [/( Induction/NN of/IN apoptosis/NN in/IN lymphocytes/NNS by/IN glucocorticoids/NNS :/: between/IN physiology/NN and/CC pharmacology/NN ]/) 
AB/LS -/: Glucocorticoids/NNS are/VBP physiological/JJ molecules/NNS that/WDT are/VBP also/RB extensively/RB used/VBN in/IN clinics/NNS as/IN anti-inflammatory/JJ ,/, immunosuppressive/JJ or/CC anti-tumoral/JJ agents/NNS ./. 
Glucocorticoids/NNS can/MD induce/VB apoptosis/NN on/IN normal/JJ lymphoid/JJ cells/NNS and/CC play/VB a/DT key/JJ role/NN in/IN the/DT physiology/NN of/IN thymic/JJ selection/NN ./. 
In/IN clinics/NNS these/DT molecules/NNS are/VBP also/RB used/VBN for/IN their/PRP$ potencies/NNS in/IN inducing/VBG apoptosis/NN of/IN malignant/JJ lymphoid/JJ cells/NNS ./. 
Glucocorticoids/NNS are/VBP mediating/VBG their/PRP$ effects/NNS after/IN binding/VBG to/TO an/DT intracellular/JJ receptor/NN belonging/VBG to/TO the/DT steroid/NN receptor/NN superfamily/NN :/: the/DT glucocorticoid/NN receptor/NN (/( GR/NN )/) ./. 
Once/IN activated/VBN ,/, the/DT GR/NN ,/, can/MD mediate/VB his/PRP$ effects/NNS through/IN direct/JJ binding/NN on/IN the/DT DNA/NN or/CC via/IN protein/protein/NN interactions/NNS with/IN transcription/NN factors/NNS ./. 
Depending/VBG on/IN the/DT type/NN of/IN lymphocytes/NNS ,/, the/DT mechanism/NN of/IN apoptosis/NN induced/VBN by/IN glucocorticoids/NNS fall/VBP roughly/RB in/IN two/CD categories/NNS :/: induction/NN of/IN "/`` death/NN genes/NNS "/'' by/IN the/DT activated/VBN GR/NN (/( I/NN kappa/NN B/NN ,/, c-jun/NN )/) or/CC repression/NN of/IN survival/NN factors/NNS (/( AP-1/NN ,/, c-Myc/NN )/) ./. 
In/IN the/DT case/NN of/IN thymic/JJ selection/NN the/DT mechanism/NN is/VBZ more/RBR subtle/JJ depending/VBG on/IN the/DT mutual/JJ repression/NN of/IN Nur77/NN and/CC GR/NN ./. 
UI/LS -/: 99096304/CD 
TI/LS -/: Direct/JJ suppression/NN of/IN Stat1/NN function/NN during/IN adenoviral/JJ infection/NN ./. 
AB/LS -/: The/DT action/NN of/IN adenoviral/JJ E1A/NN oncoprotein/NN on/IN host/NN immune-response/JJ genes/NNS has/VBZ been/VBN attributed/VBN to/TO interaction/NN with/IN p300/CBP-type/JJ transcriptional/JJ coactivators/NNS in/IN competition/NN with/IN endogenous/JJ transcription/NN factors/NNS such/JJ as/IN signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) proteins/NNS ./. 
However/RB ,/, we/PRP show/VBP that/IN mutant/JJ forms/NNS of/IN E1A/NN that/WDT no/RB longer/RBR bind/VBP p300/CBP/NN can/MD still/RB interact/VB directly/RB with/IN Stat1/NN (/( via/IN E1A/NN N-terminal/JJ and/CC Stat1/NN C-terminal/JJ residues/NNS )/) and/CC block/VB IFNgamma-driven/JJ ,/, Stat1-dependent/JJ gene/NN activation/NN and/CC consequent/JJ function/NN during/IN early-phase/JJ infection/NN in/IN the/DT natural/JJ host/NN cell/NN ./. 
The/DT results/NNS provide/VBP a/DT distinct/JJ and/CC more/RBR specific/JJ mechanism/NN for/IN E1A-mediated/JJ immune/JJ suppression/NN and/CC an/DT alternative/JJ model/NN of/IN IFNgamma-driven/JJ enhanceosome/NN formation/NN that/WDT may/MD allow/VB for/IN other/JJ adaptors/NNS (/( in/IN addition/NN to/TO p300/CBP/NN )/) to/TO link/VB Stat1/NN to/TO the/DT basal/JJ transcription/NN complex/NN ./. 
UI/LS -/: 99083144/CD 
TI/LS -/: Effect/NN of/IN environmental/JJ estrogens/NNS on/IN IL-1beta/NN promoter/NN activity/NN in/IN a/DT macrophage/NN cell/NN line/NN ./. 
AB/LS -/: Environmental/JJ estrogens/NNS or/CC estrogen/NN disrupters/NNS have/VBP recently/RB received/VBN a/DT great/JJ deal/NN of/IN attention/NN because/IN of/IN their/PRP$ potential/JJ health/NN impact/NN on/IN reproductive/JJ tissues/NNS ./. 
Few/JJ ,/, if/IN any/DT ,/, studies/NNS have/VBP been/VBN made/VBN on/IN the/DT impact/NN of/IN these/DT compounds/NNS on/IN the/DT immune/JJ system/NN ./. 
We/PRP sought/VBD to/TO determine/VB the/DT activities/NNS of/IN various/JJ environmental/JJ estrogens/NNS on/IN the/DT modulation/NN of/IN the/DT interleukin-1beta/NN (/( IL-1beta/NN )/) gene/NN in/IN a/DT model/NN monocytic/JJ cell/NN line/NN ,/, hER+IL-1beta-CAT+/NN ./. 
This/DT cell/NN line/NN stably/RB transfected/VBN with/IN the/DT human/JJ estrogen/NN receptor/NN ,/, and/CC an/DT IL-1beta/NN promoter/NN construct/NN fused/VBN to/TO the/DT CAT/NN reporter/NN gene/NN allows/VBZ us/PRP to/TO monitor/VB the/DT effect/NN of/IN estrogenic/JJ compounds/NNS on/IN IL-1beta/NN promoter/NN activity/NN ./. 
17beta-estradiol/NN (/( E2/NN )/) markedly/RB enhanced/VBD lipopolysaccharide-/NN (/( LPS/NN )/) induced/JJ IL-1beta/NN promoter-driven/JJ CAT/NN activity/NN in/IN a/DT dose-dependent/JJ manner/NN ./. 
The/DT mycotoxins/NNS alpha-zearalenol/NN and/CC zearalenone/NN both/DT exhibited/VBD full/JJ agonist/NN activity/NN ,/, but/CC at/IN lower/JJR potencies/NNS ,/, with/IN EC50/NN values/NNS of/IN 1.8/CD and/CC 54/CD nM/NN ,/, respectively/RB ,/, compared/VBN with/IN E2/NN at/IN 0.5/CD nM/NN ./. 
In/IN addition/NN ,/, genistein/NN was/VBD a/DT very/RB low-potency/JJ agonist/NN ,/, having/VBG an/DT EC50/NN of/IN 1.5/CD microM/NN ./. 
Similar/JJ to/TO the/DT E2/NN response/NN ,/, the/DT slope/NN factors/NNS for/IN alpha-zearalenol/NN ,/, zearalenone/NN ,/, and/CC genistein/NN were/VBD close/JJ to/TO 3.0/CD ,/, suggesting/VBG positive/JJ cooperativity/NN in/IN the/DT estrogenic/JJ response/NN ./. 
The/DT activity/NN of/IN the/DT mycotoxins/NNS appeared/VBD to/TO be/VB mediated/VBN through/IN the/DT estrogen/NN receptor/NN ,/, since/IN both/CC the/DT antiestrogens/NNS H1285/NN and/CC ICI/NN 182/CD ,/, 780/CD effectively/RB inhibited/VBD their/PRP$ agonist/NN activity/NN in/IN a/DT dose-dependent/JJ manner/NN ./. 
Representative/JJ environmental/JJ estrogenic/JJ compounds/NNS both/CC from/IN plant/NN and/CC industrial/JJ sources/NNS were/VBD also/RB tested/VBN ./. 
Unlike/IN the/DT mycoestrogens/NNS ,/, none/NN of/IN the/DT compounds/NNS ,/, with/IN the/DT exception/NN of/IN genistein/NN ,/, synergized/VBD with/IN LPS/NN to/TO enhance/VB IL-1beta/NN promoter/NN activity/NN ./. 
When/WRB tested/VBN for/IN antiestrogenic/JJ activity/NN ,/, the/DT industrial/JJ compound/NN 4-octylphenol/NN was/VBD able/JJ to/TO antagonize/VB the/DT response/NN to/TO E2/NN ;/: however/RB ,/, the/DT response/NN was/VBD three/CD orders/NNS of/IN magnitude/NN less/RBR potent/JJ than/IN H/NN 1285/CD ./. 
Naringenin/NN ,/, a/DT plant/NN flavonoid/NN ,/, showed/VBD little/JJ or/CC no/DT ability/NN to/TO antagonize/VB the/DT response/NN to/TO E2/NN ./. 
Overall/RB ,/, the/DT results/NNS show/VBP that/IN some/DT environmental/JJ estrogens/NNS that/WDT display/VBP agonist/NN activity/NN in/IN reproductive/JJ tissue/NN also/RB have/VBP an/DT effect/NN on/IN IL-1/NN gene/NN expression/NN in/IN hemopoietic-derived/JJ tissue/NN ./. 
UI/LS -/: 99070073/CD 
TI/LS -/: Isolation/NN and/CC utilization/NN of/IN human/JJ dendritic/JJ cells/NNS from/IN peripheral/JJ blood/NN to/TO assay/VB an/DT in/FW vitro/FW primary/JJ immune/JJ response/NN to/TO varicella-zoster/NN virus/NN peptides/NNS ./. 
AB/LS -/: A/DT human/JJ dendritic/JJ cell-based/JJ assay/NN used/VBN to/TO monitor/VB a/DT T/NN cell/NN proliferation/NN response/NN to/TO viral/JJ peptides/NNS in/FW vitro/FW is/VBZ described/VBN ./. 
Dendritic/JJ cells/NNS and/CC autologous/JJ CD4+/JJ T/NN cells/NNS were/VBD isolated/VBN from/IN peripheral/JJ blood/NN by/IN a/DT series/NN of/IN density-gradient/JJ centrifugations/NNS or/CC magnetic/JJ bead/NN separations/NNS (/( or/CC both/DT )/) ./. 
Peptides/NNS corresponding/VBG to/TO residues/NNS of/IN the/DT immediate/JJ early/JJ protein/NN ,/, IE62/NN ,/, of/IN varicella-zoster/NN virus/NN (/( VZV/NN )/) were/VBD used/VBN as/IN stimulating/VBG antigens/NNS ,/, and/CC persons/NNS with/IN no/DT history/NN of/IN varicella/NN and/CC no/DT humoral/JJ or/CC cellular/JJ immunity/NN to/TO VZV/NN served/VBD as/IN naive/JJ donors/NNS for/IN the/DT assays/NNS ./. 
Three/CD VZV-susceptible/JJ donors/NNS were/VBD tested/VBN ,/, and/CC all/DT demonstrated/VBD an/DT in/FW vitro/FW response/NN to/TO multiple/JJ VZV/NN peptides/NNS ./. 
This/DT assay/NN has/VBZ potential/NN as/IN a/DT screen/NN to/TO establish/VB the/DT immunogenicity/NN of/IN viral/JJ antigens/NNS in/FW vitro/FW using/VBG T/NN cells/NNS from/IN naive/JJ donors/NNS ./. 
UI/LS -/: 98168578/CD 
TI/LS -/: Xenogeneic/JJ human/JJ serum/NN promotes/VBZ leukocyte/NN adhesion/NN to/TO porcine/NN endothelium/NN under/IN flow/NN conditions/NNS ,/, possibly/RB through/IN the/DT activation/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN ./. 
AB/LS -/: Endothelial/JJ cell/NN activation/NN and/CC leukocyte/NN infiltration/NN are/VBP a/DT consistent/JJ feature/NN of/IN discordant/JJ xenograft/NN rejection/NN ./. 
Here/RB we/PRP evaluated/VBD whether/IN xenogeneic/JJ serum/NN ,/, as/IN a/DT source/NN of/IN xenoreactive/JJ natural/JJ antibodies/NNS and/CC complement/NN ,/, induced/VBD endothelial/JJ cell/NN activation/NN with/IN consequent/JJ leukocyte/NN adhesion/NN under/IN flow/NN conditions/NNS ./. 
Porcine/JJ aortic/JJ endothelial/JJ cells/NNS (/( PAEC/NNS )/) were/VBD incubated/VBN for/IN 1/CD hr/NN 30/CD min/NN or/CC 5/CD hr/NN with/IN 10/CD %/NN homologous/JJ porcine/JJ serum/NN (/( control/NN )/) or/CC 10/CD %/NN xenogeneic/JJ human/JJ serum/NN and/CC then/RB perfused/VBN with/IN total/JJ human/JJ leukocytes/NNS in/IN a/DT parallel/NN plate/NN flow/NN chamber/NN under/IN laminar/JJ flow/NN (/( 1.5/CD dynes/cm2/NNS )/) ./. 
Adherent/JJ cells/NNS were/VBD counted/VBN by/IN digital/JJ image/NN analysis/NN ./. 
Xenogeneic/JJ human/JJ serum/NN significantly/RB (/( P/NN </JJR 0.01/CD )/) increased/VBD the/DT number/NN of/IN adherent/JJ leukocytes/NNS as/IN compared/VBN with/IN porcine/JJ serum/NN ./. 
A/DT similar/JJ adhesive/JJ response/NN was/VBD elicited/VBN by/IN TNF/NN alpha/NN (/( 100/CD U/ml/NN )/) ,/, one/CD of/IN the/DT most/RBS potent/JJ inducers/NNS of/IN endothelial/JJ cell/NN adhesive/JJ properties/NNS ,/, here/RB used/VBN as/IN positive/JJ control/NN ./. 
In/IN order/NN to/TO elucidate/VB possible/JJ mechanisms/NNS underlying/VBG endothelial/JJ cell/NN activation/NN by/IN xenogeneic/JJ serum/NN ,/, we/PRP focussed/VBD on/IN transcription/NN factor/NN NF-kappa/NN B/NN ,/, a/DT central/JJ regulator/NN for/IN the/DT induction/NN of/IN different/JJ genes/NNS ,/, including/VBG adhesive/JJ molecules/NNS and/CC chemoattractants/NNS ./. 
By/IN confocal/JJ fluorescence/NN microscopy/NN ,/, we/PRP observed/VBD a/DT positive/JJ staining/NN for/IN NF-kappa/NN B/NN (/( p65/NN subunit/NN )/) in/IN the/DT nuclei/NNS of/IN PAEC/NNS exposed/VBN for/IN 1/CD hr/NN 30/CD min/NN to/TO human/JJ serum/NN ,/, which/WDT indicated/VBD NF-kappa/NN B/NN activation/NN in/IN this/DT setting/NN ./. 
At/IN variance/NN ,/, in/IN PAEC/NNS incubated/VBN with/IN the/DT homologous/JJ serum/NN ,/, NF-kappa/NN B/NN was/VBD strictly/RB localized/JJ in/IN the/DT cell/NN cytoplasm/NN ./. 
Treatment/NN of/IN PAEC/NNS exposed/VBN to/TO xenogeneic/JJ serum/NN with/IN the/DT NF-kappa/NN B/NN inhibitors/NNS pyrrolidinedithiocarbamate/NN (/( PDTC/NN ,/, 25/CD microM/NN )/) and/CC tosyl-phechloromethylketone/NN (/( TPCK/NN ,/, 25/CD microM/NN )/) significantly/RB (/( P/NN </JJR 0.01/CD )/) reduced/VBD leukocyte/NN adhesion/NN in/IN respect/NN to/TO PAEC/NNS treated/VBN with/IN human/JJ serum/NN alone/RB ./. 
Findings/NNS that/IN xenogeneic/JJ serum/NN promotes/VBZ leukocyte-endothelium/JJ interaction/NN possibly/RB through/IN NF-kappa/NN B/NN activation/NN might/MD be/VB relevant/JJ for/IN designing/VBG future/JJ therapeutic/JJ strategies/NNS aimed/VBN at/IN prolonging/VBG xenograft/NN survival/NN ./. 
UI/LS -/: 99057586/CD 
TI/LS -/: Anaphylatoxins/NNS C5a/NN and/CC C3a/NN induce/VBP nuclear/JJ factor/NN kappaB/NN activation/NN in/IN human/JJ peripheral/JJ blood/NN monocytes/NNS ./. 
AB/LS -/: The/DT anaphylatoxins/NNS C5a/NN and/CC C3a/NN are/VBP involved/VBN in/IN the/DT regulation/NN of/IN cytokine/NN production/NN ./. 
In/IN this/DT study/NN the/DT capability/NN of/IN C5a/NN and/CC C3a/NN to/TO induce/VB transcription/NN factor/NN activation/NN was/VBD examined/VBN ./. 
C5a/NN and/CC C3a/NN stimulation/NN of/IN human/JJ peripheral/JJ blood/NN monocytes/NNS resulted/VBD in/IN nuclear/JJ expression/NN of/IN a/DT DNA/NN binding/NN activity/NN with/IN specificity/NN to/TO the/DT kappaB/NN sequence/NN ./. 
The/DT p50/NN and/CC p65/NN proteins/NNS ,/, constituents/NNS of/IN the/DT prototypic/JJ nuclear/JJ factor/NN kappaB/NN ,/, were/VBD identified/VBN as/IN components/NNS of/IN the/DT DNA-protein/JJ complexes/NNS by/IN anti-peptide/JJ antibodies/NNS in/IN gel/NN supershift/NN assays/NNS ./. 
C5a/NN induced/JJ kappaB/NN binding/NN activity/NN was/VBD detected/VBN 15/CD min/NN after/IN agonist/NN stimulation/NN ,/, peaked/VBD at/IN 30-40/CD min/NN ,/, and/CC remained/VBD detectable/JJ at/IN 2/CD h/NN ./. 
Binding/NN to/TO kappaB/NN sequence/NN was/VBD accompanied/VBN by/IN an/DT initial/JJ decrease/NN and/CC subsequent/JJ increase/NN in/IN the/DT cytoplasmic/JJ IkappaBalpha/NN levels/NNS ,/, as/IN detected/VBN by/IN Western/NN blotting/NN using/VBG an/DT anti-IkappaBalpha/JJ antibody/NN ./. 
Pertussis/NN toxin/NN treatment/NN markedly/RB decreased/VBD kappaB/NN binding/NN activities/NNS induced/VBN by/IN both/CC C5a/NN and/CC C3a/NN ,/, whereas/IN cholera/NN toxin/NN displayed/VBD no/DT inhibitory/JJ effect/NN ./. 
Neither/DT of/IN the/DT two/CD toxins/NNS affected/VBD kappaB/NN binding/NN activity/NN induced/VBN by/IN TNFalpha/NN in/IN the/DT same/JJ cells/NNS ./. 
These/DT results/NNS imply/VBP a/DT potential/JJ role/NN of/IN the/DT anaphylatoxins/NNS C5a/NN and/CC C3a/NN in/IN regulating/VBG leukocytes/NNS gene/NN expression/NN through/IN G/NN protein-coupled/JJ transcription/NN factor/NN activation/NN ./. 
UI/LS -/: 99047055/CD 
TI/LS -/: Thrombopoietin/NN and/CC its/PRP$ receptor/NN ./. 
AB/LS -/: Thrombopoietin/NN (/( TPO/NN )/) ,/, the/DT primary/JJ physiological/JJ regulator/NN of/IN platelet/NN production/NN ,/, was/VBD initially/RB thought/VBN to/TO be/VB a/DT lineage-specific/JJ factor/NN acting/VBG predominantly/RB on/IN megakaryocytopoiesis/NN ./. 
Detailed/JJ studies/NNS establish/VBP that/IN this/DT cytokine/NN mediates/VBZ biological/JJ effects/NNS on/IN a/DT broad/JJ spectrum/NN of/IN hematopoietic/JJ progenitor/NN cells/NNS ,/, including/VBG stem/NN cells/NNS ./. 
TPO/NN is/VBZ a/DT hormone/NN constitutively/RB produced/VBN mainly/RB by/IN the/DT liver/NN and/CC kidney/NN ./. 
Plasma/NN TPO/NN levels/NNS are/VBP regulated/VBN by/IN the/DT platelet/NN and/CC megakaryocyte/NN mass/NN through/IN Mpl/NN receptor/NN binding/NN ,/, internalization/NN and/CC degradation/NN ./. 
The/DT Mpl/NN receptor/NN is/VBZ a/DT member/NN of/IN the/DT hematopoietin/NN receptor/NN superfamily/NN lacking/VBG intrinsic/JJ kinase/NN activity/NN ./. 
Upon/IN ligand-induced/JJ Mpl/NN homodimerization/NN ,/, the/DT major/JJ signaling/NN events/NNS for/IN proliferation/NN are/VBP mediated/VBN through/IN the/DT JAK2/STAT5/NN pathway/NN ,/, while/IN differentiation/NN might/MD occur/VB through/IN a/DT prolonged/JJ activation/NN of/IN the/DT MAPK/NN pathway/NN ./. 
Preclinical/JJ and/CC clinical/JJ studies/NNS demonstrate/VBP the/DT potential/JJ use/NN of/IN TPO/NN in/IN a/DT variety/NN of/IN contexts/NNS ,/, but/CC it/PRP is/VBZ too/RB early/JJ to/TO evaluate/VB its/PRP$ benefit/NN in/IN reducing/VBG platelet/NN transfusion/NN ./. 
UI/LS -/: 99038200/CD 
TI/LS -/: TAL1/NN and/CC LIM-only/JJ proteins/NNS synergistically/RB induce/VBP retinaldehyde/NN dehydrogenase/NN 2/CD expression/NN in/IN T-cell/NN acute/JJ lymphoblastic/JJ leukemia/NN by/IN acting/VBG as/IN cofactors/NNS for/IN GATA3/NN ./. 
AB/LS -/: Previously/RB ,/, we/PRP have/VBP shown/VBN that/IN TAL1/NN and/CC the/DT LIM-only/JJ protein/NN gene/NN (/( LMO/NN )/) are/VBP regularly/RB coactivated/VBN in/IN T-cell/NN acute/JJ lymphoblastic/JJ leukemia/NN (/( T-ALL/NN )/) ./. 
This/DT observation/NN is/VBZ likely/JJ to/TO relate/VB to/TO the/DT findings/NNS that/IN TAL1/NN and/CC LMO/NN are/VBP highly/RB synergistic/JJ in/IN T-cell/NN tumorigenesis/NN in/IN double-transgenic/JJ mice/NNS ./. 
To/TO understand/VB the/DT molecular/JJ mechanisms/NNS of/IN functional/JJ synergy/NN between/IN TAL1/NN and/CC LMO/NN in/IN tumorigenesis/NN and/CC transcriptional/JJ regulation/NN ,/, we/PRP tried/VBD to/TO identify/VB downstream/JJ target/NN genes/NNS regulated/VBN by/IN TAL1/NN and/CC LMO/NN by/IN a/DT subtractive/JJ PCR/NN method/NN ./. 
One/CD of/IN the/DT isolated/VBN genes/NNS ,/, that/DT for/IN retinaldehyde/NN dehydrogenase/NN 2/CD (/( RALDH2/NN )/) ,/, was/VBD regularly/RB expressed/VBN in/IN most/JJS of/IN the/DT T-ALL/NN cell/NN lines/NNS that/WDT coexpressed/VBD TAL1/NN and/CC LMO/NN ./. 
Exogenously/RB transfected/VBN TAL1/NN and/CC LMO/NN ,/, but/CC not/RB either/DT alone/RB ,/, induced/VBD RALDH2/NN expression/NN in/IN a/DT T-ALL/NN cell/NN line/NN ,/, HPB-ALL/NN ,/, not/RB expressing/VBG endogeneous/JJ TAL1/NN or/CC LMO/NN ./. 
The/DT RALDH2/NN transcripts/NNS in/IN T-ALL/NN were/VBD ,/, however/RB ,/, mostly/RB initiated/VBN within/IN the/DT second/JJ intron/NN ./. 
Promoter/NN analysis/NN revealed/VBD that/IN a/DT GATA/NN site/NN in/IN a/DT cryptic/JJ promoter/NN in/IN the/DT second/JJ intron/NN was/VBD essential/JJ and/CC sufficient/JJ for/IN the/DT TAL1-/NN and/CC LMO-dependent/JJ transcriptional/JJ activation/NN ,/, and/CC GATA3/NN binds/VBZ to/TO this/DT site/NN ./. 
In/IN addition/NN ,/, forced/VBN expression/NN of/IN GATA3/NN potentiated/VBD the/DT induction/NN of/IN RALDH2/NN by/IN TAL1/NN and/CC LMO/NN ,/, and/CC these/DT three/CD factors/NNS formed/VBD a/DT complex/NN in/FW vivo/FW ./. 
Furthermore/RB ,/, a/DT TAL1/NN mutant/NN not/RB binding/VBG to/TO DNA/NN also/RB activated/VBD the/DT transcription/NN of/IN RALDH2/NN in/IN the/DT presence/NN of/IN LMO/NN and/CC GATA3/NN ./. 
Collectively/RB ,/, we/PRP have/VBP identified/VBN the/DT RALDH2/NN gene/NN as/IN a/DT first/JJ example/NN of/IN direct/JJ transcriptional/JJ target/NN genes/NNS regulated/VBN by/IN TAL1/NN and/CC LMO/NN in/IN T-ALL/NN ./. 
In/IN this/DT case/NN ,/, TAL1/NN and/CC LMO/NN act/VBP as/IN cofactors/NNS for/IN GATA3/NN to/TO activate/VB the/DT transcription/NN of/IN RALDH2/NN 
UI/LS -/: 97360262/CD 
TI/LS -/: Glucocorticoid/NN receptors/NNS in/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS in/IN relation/NN to/TO age/NN and/CC to/TO sport/NN activity/NN ./. 
AB/LS -/: Glucocorticoid/NN receptors/NNS (/( GR/NNS )/) are/VBP ubiquitous/JJ molecules/NNS and/CC are/VBP present/JJ also/RB in/IN the/DT hippocampus/NN and/CC in/IN several/JJ other/JJ nervous/JJ and/CC immune/JJ tissues/NNS ./. 
Peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMCs/NNS )/) are/VBP a/DT good/JJ model/NN for/IN studies/NNS of/IN GR/NNS in/IN humans/NNS ./. 
Glucocorticoids/NNS are/VBP important/JJ for/IN maintaining/VBG cellular/JJ and/CC humoral/JJ homeostasis/NN and/CC are/VBP key/JJ mediators/NNS of/IN neuroendocrine-immune/JJ regulatory/JJ interactions/NNS ./. 
The/DT increase/NN of/IN cortisol/NN is/VBZ immunosuppressive/JJ and/CC reduces/VBZ GR/NNS concentration/NN both/CC in/IN nervous/JJ and/CC immune/JJ systems/NNS ./. 
Variation/NN of/IN glucocorticoids/NNS in/IN healthy/JJ aged/JJ subjects/NNS and/CC athletes/NNS has/VBZ been/VBN shown/VBN ./. 
Prompted/VBN by/IN these/DT results/NNS ,/, we/PRP have/VBP investigated/VBN in/IN man/NN a/DT possible/JJ relationship/NN between/IN GR/NNS binding/NN capacity/NN in/IN the/DT PBMCs/NNS and/CC age/NN ,/, in/IN relation/NN also/RB to/TO plasma/NN testosterone/NN and/CC cortisol/NN ./. 
The/DT same/JJ parameters/NNS have/VBP been/VBN examined/VBN in/IN a/DT group/NN of/IN soccer/NN players/NNS for/IN comparison/NN with/IN the/DT sedentary/JJ group/NN ./. 
GR/NNS binding/NN capacity/NN was/VBD higher/JJR in/IN younger/JJR subjects/NNS than/IN in/IN older/JJR ones/NNS ,/, and/CC lower/JJR in/IN the/DT group/NN of/IN athletes/NNS than/IN in/IN the/DT younger/JJR and/CC older/JJR sedentary/JJ subjects/NNS ./. 
In/IN the/DT sedentary/JJ group/NN a/DT negative/JJ correlation/NN was/VBD present/JJ between/IN GR/NNS binding/NN capacity/NN and/CC age/NN ./. 
Plasma/NN cortisol/NN was/VBD higher/JJR and/CC testosterone/NN lower/JJR in/IN the/DT athletes/NNS ;/: they/PRP were/VBD negatively/RB correlated/VBN in/IN athletes/NNS and/CC positively/RB correlated/VBN in/IN the/DT sedentary/JJ subjects/NNS ./. 
The/DT results/NNS for/IN athletes/NNS agree/VBP with/IN their/PRP$ lower/JJR anabolic/catabolic/JJ balance/NN ./. 
The/DT mechanism/NN of/IN reduced/VBN GR/NNS levels/NNS in/IN relation/NN to/TO age/NN and/CC sport/NN activity/NN could/MD involve/VB a/DT loss/NN or/CC an/DT involution/NN of/IN receptor/NN synthesis/NN ./. 
However/RB other/JJ possibilities/NNS ,/, such/JJ as/IN altered/JJ distribution/NN of/IN lymphocyte/NN subpopulations/NNS with/IN different/JJ receptor/NN concentrations/NNS and/CC with/IN different/JJ cytokine/NN production/NN ,/, can/MD not/RB be/VB excluded/VBN ./. 
Several/JJ neuroendocrine-immune/JJ interactions/NNS could/MD be/VB responsible/JJ for/IN reduced/VBN GR/NNS levels/NNS with/IN age/NN and/CC sport/NN activity/NN in/IN man/NN ./. 
UI/LS -/: 97148782/CD 
TI/LS -/: Glycation-dependent/JJ ,/, reactive/JJ oxygen/NN species-mediated/JJ suppression/NN of/IN the/DT insulin/NN gene/NN promoter/NN activity/NN in/IN HIT/NN cells/NNS ./. 
AB/LS -/: Prolonged/JJ poor/JJ glycemic/JJ control/NN in/IN non-insulin-dependent/JJ diabetes/NN mellitus/NN patients/NNS often/RB leads/VBZ to/TO a/DT decline/NN in/IN insulin/NN secretion/NN from/IN pancreatic/JJ beta/NN cells/NNS ,/, accompanied/VBN by/IN a/DT decrease/NN in/IN the/DT insulin/NN content/NN of/IN the/DT cells/NNS ./. 
As/IN a/DT step/NN toward/IN elucidating/VBG the/DT pathophysiological/JJ background/NN of/IN the/DT so-called/JJ glucose/NN toxicity/NN to/TO pancreatic/JJ beta/NN cells/NNS ,/, we/PRP induced/VBD glycation/NN in/IN HIT-T15/NN cells/NNS using/VBG a/DT sugar/NN with/IN strong/JJ deoxidizing/NN activity/NN ,/, D-ribose/NN ,/, and/CC examined/VBD the/DT effects/NNS on/IN insulin/NN gene/NN transcription/NN ./. 
The/DT results/NNS of/IN reporter/NN gene/NN analyses/NNS revealed/VBD that/IN the/DT insulin/NN gene/NN promoter/NN is/VBZ more/RBR sensitive/JJ to/TO glycation/NN than/IN the/DT control/JJ beta-actin/NN gene/NN promoter/NN ;/: approximately/RB 50/CD and/CC 80/CD %/NN of/IN the/DT insulin/NN gene/NN promoter/NN activity/NN was/VBD lost/VBN when/WRB the/DT cells/NNS were/VBD kept/VBN for/IN 3/CD d/NN in/IN the/DT presence/NN of/IN 40/CD and/CC 60/CD mM/NN D-ribose/NN ,/, respectively/RB ./. 
In/IN agreement/NN with/IN this/DT ,/, decrease/NN in/IN the/DT insulin/NN mRNA/NN and/CC insulin/NN content/NN was/VBD observed/VBN in/IN the/DT glycation-induced/JJ cells/NNS ./. 
Also/RB ,/, gel/NN mobility/NN shift/NN analyses/NNS using/VBG specific/JJ antiserum/NN revealed/VBD decrease/NN in/IN the/DT DNA-binding/NN activity/NN of/IN an/DT insulin/NN gene/NN transcription/NN factor/NN ,/, PDX-1/IPF1/STF-1/NN ./. 
These/DT effects/NNS of/IN D-ribose/NN seemed/VBD almost/RB irreversible/JJ but/CC could/MD be/VB prevented/VBN by/IN addition/NN of/IN 1/CD mM/NN aminoguanidine/NN or/CC 10/CD mM/NN N-acetylcysteine/NN ,/, thus/RB suggesting/VBG that/IN glycation/NN and/CC reactive/JJ oxygen/NN species/NNS ,/, generated/VBN through/IN the/DT glycation/NN reaction/NN ,/, serve/VBP as/IN mediators/NNS of/IN the/DT phenomena/NNS ./. 
These/DT observations/NNS suggest/VBP that/IN protein/NN glycation/NN in/IN pancreatic/JJ beta/NN cells/NNS ,/, which/WDT occurs/VBZ in/FW vivo/FW under/IN chronic/JJ hyperglycemia/NN ,/, suppresses/VBZ insulin/NN gene/NN transcription/NN and/CC thus/RB can/MD explain/VB part/NN of/IN the/DT beta/NN cell/NN glucose/NN toxicity/NN ./. 
UI/LS -/: 99169427/CD 
TI/LS -/: Nuclear/JJ factor-kappa/NN B/NN activity/NN in/IN T/NN cells/NNS from/IN patients/NNS with/IN rheumatic/JJ diseases/NNS :/: a/DT preliminary/JJ report/NN ./. 
AB/LS -/: OBJECTIVE/NN :/: The/DT NF-kappa/NN B/Rel/NN family/NN of/IN transcription/NN factors/NNS regulates/VBZ the/DT expression/NN of/IN many/JJ genes/NNS involved/VBN in/IN the/DT immune/JJ or/CC inflammatory/JJ response/NN at/IN the/DT transcriptional/JJ level/NN ./. 
The/DT aim/NN of/IN this/DT study/NN was/VBD to/TO determine/VB whether/IN distinctive/JJ patterns/NNS of/IN NF-kappa/NN B/NN activation/NN are/VBP seen/VBN in/IN different/JJ forms/NNS of/IN joint/NN disease/NN ./. 
METHODS/NNS :/: The/DT DNA/NN binding/NN activity/NN of/IN these/DT nucleoproteins/NNS was/VBD examined/VBN in/IN purified/VBN synovial/JJ and/CC peripheral/JJ T/NN cells/NNS from/IN patients/NNS with/IN various/JJ chronic/JJ rheumatic/JJ diseases/NNS (/( 12/CD :/: four/CD with/IN rheumatoid/JJ arthritis/NN ;/: five/CD with/IN spondyloarthropathies/NNS ;/: and/CC three/CD with/IN osteoarthritis/NN )/) ./. 
RESULTS/NNS :/: Electrophoretic/JJ mobility/NN shift/NN assays/NNS disclosed/VBD two/CD specific/JJ complexes/NNS bound/VBN to/TO a/DT NF-kappa/NN B/NN specific/JJ 32P-labelled/JJ oligonucleotide/NN in/IN nucleoproteins/NNS extracted/VBN from/IN purified/VBN T/NN cells/NNS isolated/VBN from/IN synovial/JJ fluid/NN and/CC peripheral/JJ blood/NN of/IN patients/NNS with/IN rheumatoid/JJ arthritis/NN ./. 
The/DT complexes/NNS consisted/VBD of/IN p50/p50/NN homodimers/NNS and/CC p50/p65/NN heterodimers/NNS ./. 
Increased/VBN NF-kappa/NN B/NN binding/NN to/TO DNA/NN in/IN synovial/JJ T/NN cells/NNS was/VBD observed/VBN relative/JJ to/TO peripheral/JJ T/NN cells/NNS ./. 
In/IN non-rheumatoid/JJ arthritis/NN ,/, binding/NN of/IN NF-kappa/NN B/NN in/IN synovial/JJ T/NN cells/NNS was/VBD exclusively/RB mediated/VBN by/IN p50/p50/NN homodimers/NNS ./. 
CONCLUSION/NN :/: Overall/RB ,/, the/DT results/NNS suggest/VBP that/IN NF-kappa/NN B/NN may/MD play/VB a/DT central/JJ part/NN in/IN the/DT activation/NN of/IN infiltrating/VBG T/NN cells/NNS in/IN chronic/JJ rheumatoid/JJ arthritis/NN ./. 
The/DT activation/NN of/IN this/DT nuclear/JJ factor/NN is/VBZ qualitatively/RB different/JJ in/IN rheumatoid/JJ synovial/JJ T/NN cells/NNS to/TO that/DT in/IN other/JJ forms/NNS of/IN non-rheumatoid/JJ arthritis/NN (/( for/IN example/NN ,/, osteoarthritis/NN ,/, spondyloarthropathies/NNS )/) ./. 
UI/LS -/: 99097163/CD 
TI/LS -/: X/NN chromosome/NN inactivation/NN patterns/NNS in/IN normal/JJ females/NNS ./. 
AB/LS -/: Since/IN one/CD of/IN the/DT two/CD X/NN chromosomes/NNS is/VBZ randomly/RB inactivated/VBN at/IN an/DT early/JJ stage/NN of/IN female/NN embryonic/JJ development/NN ,/, X-linked/JJ markers/NNS have/VBP been/VBN used/VBN to/TO study/VB the/DT origin/NN and/CC development/NN of/IN various/JJ neoplastic/JJ disorders/NNS in/IN affected/VBN heterozygous/JJ women/NNS ;/: clonality/NN assays/NNS have/VBP provided/VBN a/DT useful/JJ tool/NN to/TO the/DT understanding/NN of/IN the/DT mechanisms/NNS underlying/VBG the/DT development/NN of/IN neoplasia/NN ./. 
Recently/RB ,/, a/DT technique/NN of/IN clonal/JJ analysis/NN has/VBZ been/VBN devised/VBN that/WDT takes/VBZ advantage/NN of/IN a/DT highly/RB polymorphic/JJ short/JJ tandem/JJ repeat/NN within/IN the/DT X-linked/JJ human/JJ androgen/NN receptor/NN (/( AR/NN )/) gene/NN ,/, resulting/VBG in/IN a/DT heterozygosity/NN rate/NN approaching/VBG 90/CD %/NN ./. 
The/DT rapid/JJ expansion/NN of/IN the/DT number/NN of/IN women/NNS now/RB suitable/JJ for/IN X/NN inactivation/NN analysis/NN has/VBZ however/RB given/VBN rise/NN to/TO new/JJ controversies/NNS ,/, one/CD of/IN the/DT more/RBR troublesome/JJ being/VBG the/DT possibility/NN of/IN a/DT modification/NN of/IN the/DT pattern/NN of/IN X- chromosome/NN inactivation/NN pattern/NN in/IN blood/NN cells/NNS of/IN elderly/JJ women/NNS ./. 
In/IN the/DT present/JJ study/NN we/PRP analyze/VBP with/IN the/DT AR/NN assay/NN a/DT group/NN of/IN 166/CD healthy/JJ females/NNS aged/JJ between/IN 8/CD and/CC 94/CD years/NNS ,/, with/IN no/DT history/NN of/IN genetic/JJ or/CC neoplastic/JJ familial/JJ disorders/NNS ./. 
We/PRP failed/VBD to/TO find/VB any/DT correlation/NN between/IN age/NN and/CC X- chromosome/NN inactivation/NN pattern/NN (/( r/NN =/JJ 0.17/CD )/) ,/, even/RB subdividing/VBG the/DT subjects/NNS in/IN different/JJ age/NN groups/NNS according/VBG to/TO the/DT criteria/NNS used/VBN by/IN other/JJ researchers/NNS ,/, and/CC therefore/RB reaffirm/VBP that/IN ,/, when/WRB tested/VBN for/IN with/IN well-standardized/JJ and/CC accurate/JJ criteria/NNS ,/, extremely/RB unbalanced/JJ inactivation/NN of/IN the/DT X/NN chromosome/NN is/VBZ a/DT truly/RB uncommon/JJ phenomenon/NN in/IN normal/JJ women/NNS ./. 
Copyright/NN 1998/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99077519/CD 
TI/LS -/: The/DT role/NN of/IN Stat4/NN in/IN species-specific/JJ regulation/NN of/IN Th/NN cell/NN development/NN by/IN type/NN I/CD IFNs/NNS ./. 
AB/LS -/: Type/NN I/CD IFNs/NNS (/( IFN-alpha/beta/NN )/) ,/, in/IN addition/NN to/TO IL-12/NN ,/, have/VBP been/VBN shown/VBN to/TO play/VB an/DT important/JJ role/NN in/IN the/DT differentiation/NN of/IN human/JJ ,/, but/CC not/RB mouse/NN ,/, Th/NN cells/NNS ./. 
We/PRP show/VBP here/RB that/IN IFN-alpha/beta/NN act/VBP directly/RB on/IN human/JJ T/NN cells/NNS to/TO drive/VB Th1/NN development/NN ,/, bypassing/VBG the/DT need/NN for/IN IL-12-induced/JJ signaling/NN ,/, whereas/IN IFN-alpha/NN can/MD not/RB substitute/VB IL-12/NN for/IN mouse/NN Th1/NN development/NN ./. 
The/DT molecular/JJ basis/NN for/IN this/DT species/NNS specificity/NN is/VBZ that/IN IFN-alpha/beta/NN activate/VBP Stat4/NN in/IN differentiating/VBG human/JJ ,/, but/CC not/RB mouse/NN ,/, Th/NN cells/NNS ./. 
Unlike/IN IL-12/NN ,/, which/WDT acts/VBZ only/RB on/IN Th1/NN cells/NNS ,/, IFN-alpha/beta/NN can/MD activate/VB Stat4/NN not/RB only/RB in/IN human/JJ Th1/NN ,/, but/CC also/RB in/IN Th2/NN cells/NNS ./. 
However/RB ,/, restimulation/NN of/IN human/JJ Th2/NN lines/NNS and/CC clones/NNS in/IN the/DT presence/NN of/IN IFN-alpha/NN does/VBZ not/RB induce/VB the/DT production/NN of/IN IFN-gamma/NN ./. 
These/DT results/NNS suggest/VBP that/IN activation/NN of/IN Stat4/NN ,/, which/WDT is/VBZ necessary/JJ for/IN the/DT differentiation/NN of/IN naive/JJ T/NN cells/NNS into/IN polarized/VBN Th1/NN cells/NNS ,/, is/VBZ not/RB sufficient/JJ to/TO induce/VB phenotype/NN reversal/NN of/IN human/JJ Th2/NN cells/NNS ./. 
UI/LS -/: 99070060/CD 
TI/LS -/: Molecular/JJ cloning/NN of/IN FKHRL1P2/NN ,/, a/DT member/NN of/IN the/DT developmentally/RB regulated/VBN fork/NN head/NN domain/NN transcription/NN factor/NN family/NN ./. 
AB/LS -/: Here/RB we/PRP report/VBP the/DT expression/NN of/IN a/DT fork/NN head/NN domain/NN protein/NN in/IN human/JJ T/NN helper/NN cells/NNS ./. 
We/PRP cloned/VBD and/CC characterized/VBD a/DT fork/NN head/NN cDNA/NN from/IN human/JJ T/NN helper/NN cell/NN mRNA/NN using/VBG differential/JJ display/NN RT-PCR/NN ./. 
The/DT cDNA/NN contains/VBZ a/DT 546-nucleotide/JJ (/( nt/NN )/) open/JJ reading/NN frame/NN (/( ORF/NN )/) that/WDT codes/VBZ for/IN the/DT carboxyl-terminal/JJ 180/CD amino/NN acids/NNS (/( aa/NNS )/) of/IN the/DT recently/RB identified/VBN fkhrl1/NN gene/NN ./. 
This/DT ORF/NN does/VBZ not/RB contain/VB the/DT characteristic/JJ DNA-binding/JJ domain/NN found/VBN in/IN members/NNS of/IN the/DT forkhead/NN protein/NN family/NN ./. 
In-vitro/FW transcription/translation/NN of/IN this/DT cDNA/NN expressed/VBD a/DT protein/NN of/IN approximately/RB 20/CD kDa/NN ./. 
We/PRP have/VBP generated/VBN antibodies/NNS that/WDT specifically/RB immunoprecipitated/VBD the/DT in-vitro-translated/JJ 20-kDa/JJ protein/NN ./. 
This/DT antibody/NN also/RB recognizes/VBZ in/IN human/JJ T/NN lymphocytes/NNS a/DT 70-kDa/JJ protein/NN corresponding/VBG in/IN size/NN to/TO that/DT predicted/VBN for/IN the/DT fkhrl1/NN gene/NN product/NN ./. 
The/DT mRNA/NN levels/NNS for/IN fkhrl1/NN is/VBZ elevated/JJ in/IN T/NN helper-induced/JJ lymphocytes/NNS in/IN comparison/NN to/TO PHA-stimulated/JJ T/NN lymphocytes/NNS ./. 
Further/JJ characterization/NN of/IN FKHRL1/NN and/CC its/PRP$ related/JJ family/NN members/NNS should/MD shed/VB light/NN on/IN the/DT transcriptional/JJ mechanisms/NNS of/IN this/DT fork/NN head/NN gene/NN subfamily/NN and/CC their/PRP$ role/NN in/IN T/NN helper/NN cell/NN differentiation/NN and/CC regulation/NN of/IN cell/NN growth/NN ./. 
UI/LS -/: 99060929/CD 
TI/LS -/: Inhibition/NN of/IN Th1/NN development/NN mediated/VBN by/IN GATA-3/NN through/IN an/DT IL-4-independent/JJ mechanism/NN ./. 
AB/LS -/: Recently/RB ,/, the/DT transcription/NN factor/NN GATA-3/NN was/VBD shown/VBN to/TO be/VB selectively/RB expressed/VBN in/IN Th2/NN but/CC not/RB Th1/NN cells/NNS and/CC to/TO augment/VB Th2-specific/JJ cytokines/NNS ./. 
Here/RB ,/, we/PRP show/VBP that/IN loss/NN of/IN GATA-3/NN expression/NN by/IN developing/VBG Th1/NN cells/NNS requires/VBZ IL-12/NN signaling/NN through/IN Stat4/NN and/CC does/VBZ not/RB simply/RB result/VB from/IN an/DT absence/NN of/IN IL-4/NN ./. 
Moreover/RB ,/, we/PRP demonstrate/VBP a/DT novel/JJ role/NN for/IN GATA-3/NN in/IN directly/RB repressing/VBG Th1/NN development/NN distinct/JJ from/IN its/PRP$ positive/JJ actions/NNS on/IN Th2-specific/JJ cytokines/NNS ./. 
GATA-3/NN inhibits/VBZ Th1/NN cytokines/NNS by/IN a/DT cell-intrinsic/JJ mechanism/NN that/WDT is/VBZ not/RB dependent/JJ on/IN IL-4/NN and/CC that/WDT may/MD involve/VB repression/NN of/IN IL-12/NN signaling/NN ./. 
Thus/RB ,/, GATA-3/NN expression/NN and/CC IL-12/NN signaling/NN are/VBP mutually/RB antagonistic/JJ ,/, which/WDT facilitates/VBZ rapid/JJ dominance/NN of/IN one/CD pathway/NN during/IN early/JJ Th/NN development/NN ,/, producing/VBG a/DT stable/JJ divergence/NN in/IN cytokine/NN profiles/NNS ./. 
UI/LS -/: 99058080/CD 
TI/LS -/: Conserved/VBN elements/NNS containing/VBG NF-E2/NN and/CC tandem/JJ GATA/NN binding/NN sites/NNS are/VBP required/VBN for/IN erythroid-specific/JJ chromatin/NN structure/NN reorganization/NN within/IN the/DT human/JJ beta-globin/NN locus/NN control/NN region/NN ./. 
AB/LS -/: Proper/JJ expression/NN of/IN the/DT genes/NNS of/IN the/DT human/JJ beta-globin/NN gene/NN locus/NN requires/VBZ the/DT associated/VBN locus/NN control/NN region/NN (/( LCR/NN )/) ./. 
Structurally/RB ,/, the/DT LCR/NN is/VBZ defined/VBN by/IN the/DT presence/NN of/IN four/CD domains/NNS of/IN erythroid-specific/JJ chromatin/NN structure/NN ./. 
These/DT domains/NNS ,/, which/WDT have/VBP been/VBN characterized/VBN as/IN DNase/NN I/CD hypersensitive/JJ sites/NNS (/( HSs/NNS )/) ,/, comprise/VBP the/DT active/JJ elements/NNS of/IN the/DT LCR/NN ./. 
The/DT major/JJ focus/NN of/IN this/DT research/NN is/VBZ to/TO define/VB the/DT cis -acting/JJ elements/NNS which/WDT are/VBP required/VBN for/IN the/DT formation/NN of/IN these/DT domains/NNS of/IN unique/JJ chromatin/NN structure/NN ./. 
Our/PRP$ previous/JJ investigations/NNS on/IN the/DT formation/NN of/IN LCR/NN HS4/NN demonstrated/VBD that/IN NF-E2/NN and/CC tandem/JJ ,/, inverted/JJ GATA/NN binding/NN sites/NNS are/VBP required/VBN for/IN the/DT formation/NN of/IN the/DT native/JJ HS/NN ./. 
Similarly/RB arranged/VBN NF-E2/NN and/CC tandem/JJ GATA/NN sites/NNS are/VBP present/JJ within/IN the/DT core/NN regions/NNS of/IN the/DT other/JJ human/JJ LCR/NN HSs/NNS and/CC are/VBP evolutionarily/RB conserved/VBN ./. 
Using/VBG site-directed/JJ mutagenesis/NN of/IN human/JJ HSs/NNS 2/CD and/CC 3/CD we/PRP have/VBP tested/VBN the/DT hypothesis/NN that/IN these/DT NF-E2/NN and/CC GATA/NN sites/NNS are/VBP common/JJ requirements/NNS for/IN the/DT formation/NN of/IN all/DT LCR/NN HSs/NNS ./. 
We/PRP find/VBP that/IN mutation/NN of/IN these/DT elements/NNS ,/, and/CC particularly/RB the/DT GATA/NN elements/NNS ,/, results/VBZ in/IN a/DT decrease/NN or/CC complete/JJ loss/NN of/IN DNase/NN I/CD hypersensitivity/NN ./. 
These/DT data/NNS imply/VBP the/DT presence/NN of/IN common/JJ structural/JJ elements/NNS within/IN the/DT core/NN of/IN each/DT LCR/NN HS/NN which/WDT are/VBP required/VBN for/IN erythroid-specific/JJ chromatin/NN structure/NN reorganization/NN ./. 
UI/LS -/: 99047534/CD 
TI/LS -/: Cloning/NN of/IN ARE-containing/JJ genes/NNS by/IN AU-motif-directed/JJ display/NN ./. 
AB/LS -/: A/DT procedure/NN suitable/JJ for/IN cloning/VBG labile/JJ mRNAs/NNS that/WDT contain/VBP AU/NN motifs/NNS is/VBZ presented/VBN (/( AU-DD/NN )/) ./. 
These/DT motifs/NNS are/VBP regulatory/JJ sequences/NNS within/IN the/DT so-called/JJ AU-rich/JJ elements/NNS (/( AREs/NNS )/) often/RB found/VBN in/IN 3'/JJ untranslated/JJ regions/NNS of/IN genes/NNS such/JJ as/IN cytokines/NNS ,/, proto-oncogenes/NNS ,/, and/CC transcription/NN factors/NNS ./. 
AU-DD/NN is/VBZ an/DT AU-motif-directed/JJ differential/JJ display/NN that/WDT permits/VBZ the/DT identification/NN of/IN ARE-containing/JJ genes/NNS differentially/RB expressed/VBN after/IN cell/NN activation/NN ./. 
It/PRP has/VBZ been/VBN applied/VBN to/TO peripheral/JJ blood/NN monocytes/NNS and/CC a/DT T/NN cell/NN clone/NN to/TO isolate/VB 59/CD cDNA/NN fragments/NNS associated/VBN to/TO activation/NN ./. 
Fourteen/CD percent/NN of/IN isolated/VBN fragments/NNS belong/VBP to/TO already/RB known/JJ genes/NNS that/WDT certainly/RB are/VBP cytokines/NNS and/CC transduction/transcription/NN factors/NNS ./. 
The/DT remaining/VBG 86/CD %/NN correspond/VBP to/TO unknown/JJ genes/NNS of/IN which/WDT 92/CD %/NN have/VBP been/VBN confirmed/VBN to/TO be/VB differentially/RB expressed/VBN ./. 
These/DT data/NNS demonstrate/VBP the/DT efficiency/NN of/IN the/DT system/NN and/CC support/VBP the/DT notion/NN that/IN numerous/JJ genes/NNS falling/VBG into/IN those/DT categories/NNS remain/VBP unidentified/JJ and/CC that/IN they/PRP can/MD be/VB cloned/VBN by/IN this/DT method/NN ./. 
Copyright/NN 1998/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99034460/CD 
TI/LS -/: Transcription/NN factor/NN NF-kappaB/NN regulation/NN of/IN renal/JJ fibrosis/NN during/IN ureteral/JJ obstruction/NN ./. 
AB/LS -/: Irrespective/RB of/IN the/DT etiology/NN ,/, many/JJ kidney/NN diseases/NNS result/VBP in/IN inflammation/NN and/CC fibrosis/NN of/IN the/DT tubulointerstitium/NN ,/, with/IN the/DT subsequent/JJ loss/NN of/IN renal/JJ function/NN ./. 
To/TO initiate/VB any/DT disease/NN process/NN or/CC for/IN any/DT disease/NN process/NN to/TO progress/VB ,/, there/EX must/MD be/VB changes/NNS in/IN the/DT transcription/NN of/IN genes/NNS within/IN the/DT affected/VBN tissue/NN ./. 
The/DT nuclear/JJ factor-kappa/NN B/NN (/( NF-kappaB/NN )/) family/NN of/IN transcription/NN factors/NNS regulates/VBZ genes/NNS involved/VBN in/IN inflammation/NN ,/, cell/NN proliferation/NN ,/, and/CC cell/NN differentiation/NN ./. 
This/DT review/NN discusses/VBZ the/DT NF-kappaB/NN transcription/NN factor/NN family/NN in/IN general/JJ and/CC the/DT association/NN of/IN NF-kappaB/NN activation/NN with/IN cellular/molecular/JJ events/NNS of/IN renal/JJ inflammation/NN and/CC fibrosis/NN 
UI/LS -/: 97358652/CD 
TI/LS -/: Expression/NN of/IN transcription/NN factors/NNS during/IN sodium/NN phenylacetate/NN induced/VBD erythroid/JJ differentiation/NN in/IN K562/NN cells/NNS ./. 
AB/LS -/: During/IN 15/CD days/NNS of/IN treatment/NN of/IN K562/NN cells/NNS with/IN sodium/NN phenylacetate/NN ,/, we/PRP observed/VBD an/DT increase/NN in/IN the/DT cellular/JJ hemoglobin/NN concentration/NN with/IN a/DT similar/JJ increase/NN in/IN the/DT expression/NN of/IN gamma-globin/NN mRNA/NN ./. 
Morphological/JJ studies/NNS demonstrated/VBD characteristic/JJ features/NNS of/IN erythroid/JJ differentiation/NN and/CC maturation/NN ./. 
At/IN the/DT same/JJ time/NN there/EX was/VBD no/DT change/NN in/IN the/DT level/NN of/IN expression/NN of/IN the/DT cell/NN surface/NN antigenes/NNS CD33/NN ,/, CD34/NN ,/, CD45/NN ,/, CD71/NN and/CC glycophorin/NN A/NN ./. 
Likewise/RB ,/, the/DT level/NN of/IN expression/NN of/IN the/DT erythroid/JJ transcription/NN factors/NNS GATA-1/NN ,/, GATA-2/NN ,/, NF-E2/NN ,/, SCL/NN and/CC RBTN2/NN ,/, all/DT expressed/VBN in/IN untreated/JJ K562/NN cells/NNS ,/, did/VBD not/RB increase/VB during/IN sodium/NN phenylacetate/NN induced/JJ erythroid/JJ differentiation/NN ./. 
The/DT expression/NN of/IN the/DT nuclear/JJ factors/NNS Evi-1/NN and/CC c-myb/NN ,/, known/VBN to/TO inhibit/VB erythroid/JJ differentiation/NN ,/, did/VBD not/RB decrease/VB ./. 
We/PRP conclude/VBP that/IN sodium/NN phenylacetate/NN treatment/NN of/IN K562/NN cells/NNS increases/VBZ gamma-globin/NN mRNA/NN and/CC induces/VBZ cell/NN maturation/NN as/IN judged/VBN by/IN morphology/NN without/IN affecting/VBG the/DT expression/NN of/IN the/DT erythroid/JJ transcription/NN factors/NNS ,/, some/DT of/IN which/WDT are/VBP known/VBN to/TO be/VB involved/VBN in/IN the/DT regulation/NN of/IN beta-like/JJ globin/NN genes/NNS ./. 
UI/LS -/: 97155934/CD 
TI/LS -/: Isolation/NN of/IN a/DT B-cell-specific/JJ promoter/NN for/IN the/DT human/JJ class/NN II/CD transactivator/NN ./. 
AB/LS -/: The/DT class/NN II/CD transactivator/NN (/( CIITA/NN )/) is/VBZ essential/JJ for/IN the/DT expression/NN of/IN major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II/CD antigens/NNS ./. 
The/DT tissular/JJ patterns/NNS of/IN CIITA/NN and/CC MHC/NN class/NN II/CD gene/NN expression/NN are/VBP tightly/RB correlated/VBN :/: CIITA/NN mRNA/NN is/VBZ highly/RB expressed/VBN in/IN B/NN cells/NNS ,/, and/CC is/VBZ induced/VBN by/IN interferon/NN gamma/NN (/( IFN-gamma/NN )/) in/IN macrophage/NN and/CC epithelial/JJ cell/NN lines/NNS ./. 
We/PRP first/RB isolated/VBD two/CD overlapping/VBG cosmids/NNS encoding/VBG human/JJ CIITA/NN which/WDT ,/, when/WRB co-transfected/VBN ,/, are/VBP able/JJ to/TO restore/VB MHC/NN class/NN II/CD expression/NN in/IN a/DT B-lymphoblastoid/JJ cell/NN line/NN (/( B-LCL/NN )/) defective/JJ for/IN CIITA/NN ./. 
Subsequently/RB ,/, a/DT 1.8/CD kilobase/NN (/( kb/NN )/) fragment/NN of/IN the/DT CIITA/NN promoter/NN was/VBD isolated/VBN and/CC sequenced/VBN ./. 
A/DT motif/NN presenting/VBG a/DT strong/JJ similarity/NN to/TO an/DT initiator/NN was/VBD detected/VBN ,/, as/RB well/RB as/IN putative/JJ binding/VBG sites/NNS for/IN Sp1/NN ,/, GATA-2/NN ,/, LyF-1/NN ,/, ets-1/NN ,/, AP1/NN ,/, and/CC MZF1/NN transcription/NN factors/NNS ,/, and/CC two/CD GAS/NN motifs/NNS ./. 
When/WRB introduced/VBN in/IN front/NN of/IN a/DT luciferase/NN reporter/NN gene/NN ,/, this/DT promoter/NN is/VBZ able/JJ to/TO direct/VB a/DT high/JJ luciferase/NN activity/NN in/IN a/DT human/JJ B-LCL/NN ./. 
In/IN contrast/NN ,/, luciferase/NN expression/NN was/VBD not/RB stimulated/VBN after/IN IFN-gamma/NN treatment/NN when/WRB the/DT construct/NN was/VBD transfected/VBN in/IN macrophage/NN or/CC in/IN epithelial/JJ cell/NN lines/NNS ./. 
However/RB ,/, an/DT induction/NN of/IN the/DT human/JJ CIITA/NN gene/NN was/VBD observed/VBN in/IN mouse/NN macrophage/NN and/CC fibrosarcoma/NN cell/NN lines/NNS ,/, when/WRB the/DT cells/NNS were/VBD transfected/VBN with/IN a/DT cosmid/NN containing/VBG the/DT human/JJ CIITA/NN gene/NN ,/, but/CC lacking/VBG the/DT 1.8/CD kb/NN promoter/NN described/VBN above/RB ./. 
Taken/VBN together/RB ,/, these/DT data/NNS suggest/VBP the/DT existence/NN of/IN an/DT intragenic/JJ promoter/NN driving/VBG an/DT IFN-gamma-inducible/JJ expression/NN of/IN CIITA/NN ./. 
UI/LS -/: 99149869/CD 
TI/LS -/: Phenotypic/JJ and/CC functional/JJ studies/NNS of/IN leukocytes/NNS in/IN human/JJ endometrium/NN and/CC endometriosis/NN ./. 
AB/LS -/: The/DT aetiology/NN of/IN endometriosis/NN ,/, a/DT common/JJ and/CC disabling/VBG disorder/NN ,/, is/VBZ presently/RB unknown/JJ ,/, although/IN immune/JJ dysfunction/NN could/MD allow/VB ectopic/JJ endometrial/JJ fragments/NNS to/TO survive/VB outside/IN the/DT uterine/JJ cavity/NN ./. 
These/DT studies/NNS investigate/VBP the/DT relationship/NN between/IN leukocyte/NN populations/NNS ,/, steroid/NN hormone/NN receptor/NN expression/NN ,/, proliferative/JJ activity/NN ,/, bcl-2/NN expression/NN and/CC apoptosis/NN in/IN eutopic/JJ and/CC ectopic/JJ endometrium/NN from/IN women/NNS with/IN endometriosis/NN or/CC adenomyosis/NN at/IN different/JJ phases/NNS of/IN the/DT menstrual/JJ cycle/NN ./. 
Significantly/RB increased/VBN oestrogen/NN receptor/NN expression/NN ,/, bcl-2/NN expression/NN and/CC numbers/NNS of/IN CD8+/JJ leukocytes/NNS were/VBD found/VBN in/IN ectopic/JJ compared/VBN with/IN eutopic/JJ endometrium/NN in/IN endometriosis/NN ,/, and/CC CD56+/JJ endometrial/JJ granulated/JJ lymphocytes/NNS (/( eGLs/NNS )/) were/VBD significantly/RB reduced/VBN in/IN ectopic/JJ endometrium/NN ./. 
Apoptotic/JJ cells/NNS were/VBD rarely/RB found/VBN in/IN control/JJ and/CC subject/NN endometria/NN ./. 
In/IN contrast/NN with/IN endometriosis/NN ,/, adenomyotic/JJ lesions/NNS showed/VBD identical/JJ steroid/NN hormone/NN receptor/NN expression/NN ,/, proliferative/JJ activity/NN ,/, bcl-2/NN expression/NN and/CC leukocyte/NN subpopulations/NNS to/TO eutopic/JJ endometrium/NN ,/, indicating/VBG different/JJ aetiologies/NNS for/IN these/DT disorders/NNS ./. 
The/DT unusual/JJ CD56+/JJ CD16-/JJ eGLs/NNS present/JJ in/IN large/JJ numbers/NNS in/IN late/JJ secretory/JJ phase/NN eutopic/JJ endometrium/NN were/VBD highly/RB purified/VBN (/( >/JJR 98/CD %/NN )/) by/IN immunomagnetic/JJ separation/NN ./. 
Except/IN for/IN a/DT negligible/JJ cytotoxic/JJ activity/NN of/IN eGLs/NNS from/IN early/JJ proliferative/JJ samples/NNS ,/, cytotoxic/JJ activity/NN of/IN eGLs/NNS from/IN non-pregnant/JJ endometrium/NN during/IN the/DT menstrual/JJ cycle/NN was/VBD comparable/JJ with/IN those/DT in/IN peripheral/JJ blood/NN ,/, predominantly/RB CD56+/JJ CD16+/JJ natural/JJ killer/NN cells/NNS ./. 
eGLs/NNS from/IN non-pregnant/JJ endometrium/NN and/CC early/JJ pregnancy/NN showed/VBD a/DT variable/JJ proliferative/JJ response/NN to/TO 5/CD and/CC 100/CD U/ml/NN interleukin-2/NN over/IN 48-h/JJ and/CC 120-h/JJ time/NN courses/NNS ./. 
eGLs/NNS are/VBP evidently/RB functionally/RB important/JJ in/IN the/DT eutopic/JJ endometrium/NN ./. 
Their/PRP$ absence/NN in/IN endometriotic/JJ lesions/NNS together/RB with/IN increased/VBN CD+8/JJ T-cell/NN numbers/NNS and/CC increased/VBN oestrogen/NN receptor/NN and/CC bcl-2/NN expression/NN may/MD have/VB significant/JJ effects/NNS on/IN the/DT development/NN and/CC progression/NN of/IN endometriosis/NN ./. 
UI/LS -/: 99097447/CD 
TI/LS -/: Regulation/NN of/IN interleukin-1beta/NN transcription/NN by/IN Epstein-Barr/JJ virus/NN involves/VBZ a/DT number/NN of/IN latent/JJ proteins/NNS via/IN their/PRP$ interaction/NN with/IN RBP/NN ./. 
AB/LS -/: Epstein-Barr/JJ virus/NN (/( EBV/NN )/) infects/VBZ B/NN cells/NNS ,/, resulting/VBG in/IN the/DT outgrowth/NN of/IN immortalised/JJ lymphoblastoid/JJ cell/NN lines/NNS (/( LCLs/NNS )/) ./. 
Here/RB ,/, we/PRP demonstrate/VBP through/IN the/DT use/NN of/IN intracellular/JJ staining/NN that/IN interleukin-1beta/NN (/( IL-1beta/NN )/) is/VBZ expressed/VBN in/IN LCLs/NNS and/CC investigate/VBP the/DT influence/NN of/IN the/DT individual/JJ latent/JJ proteins/NNS on/IN the/DT expression/NN of/IN IL-1beta/NN ./. 
Using/VBG RT-PCR/NN ,/, IL-1beta/NN was/VBD shown/VBN to/TO be/VB up-regulated/VBN in/IN EBV-transformed/JJ LCLs/NNS as/RB well/RB as/IN in/IN group/NN III/CD Burkitt/NN 's/POS lymphoma/NN (/( BL/NN )/) cell/NN lines/NNS ,/, compared/VBN with/IN group/NN I/CD BL/NN cell/NN lines/NNS ./. 
The/DT up-regulation/NN of/IN IL-1beta/NN message/NN could/MD be/VB mediated/VBN by/IN the/DT latent/JJ membrane/NN protein-1/NN ,/, EBV/NN nuclear/JJ proteins/NNS 2/CD ,/, 3/CD ,/, 4/CD ,/, and/CC 6/CD genes/NNS ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS (/( EMSAs/NNS )/) demonstrated/VBD that/IN the/DT -300/CD region/NN of/IN the/DT IL-1beta/NN promoter/NN ,/, which/WDT contains/VBZ a/DT nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) binding/NN site/NN ,/, contained/VBD a/DT functional/JJ RBP/NN binding/NN site/NN ./. 
Binding/NN of/IN RBP/NN to/TO this/DT site/NN could/MD be/VB inhibited/VBN by/IN addition/NN of/IN EBV/NN nuclear/JJ proteins/NNS 3/CD and/CC 6/CD ,/, suggesting/VBG that/IN these/DT proteins/NNS displace/VBP RBP/NN from/IN its/PRP$ recognition/NN sequence/NN ,/, removing/VBG transcriptional/JJ repression/NN and/CC allowing/VBG gene/NN transcription/NN to/TO occur/VB ./. 
In/IN group/NN I/CD BL/NN cells/NNS ,/, containing/VBG low/JJ levels/NNS of/IN NF-kappaB/NN ,/, only/RB RBP/NN binding/NN was/VBD observed/VBN in/IN EMSAs/NNS ,/, whereas/IN NF-kappaB/NN binding/NN could/MD be/VB demonstrated/VBN in/IN EBV-transformed/JJ B/NN cell/NN lines/NNS containing/VBG high/JJ levels/NNS of/IN activated/VBN NF-kappaB/NN ./. 
In/IN addition/NN ,/, the/DT expression/NN of/IN latent/JJ membrane/NN protein-1/NN led/VBD to/TO activation/NN of/IN NF-kappaB/NN that/WDT was/VBD capable/JJ of/IN binding/VBG the/DT IL-1beta/NN promoter/NN ./. 
The/DT study/NN demonstrates/VBZ that/IN EBV/NN can/MD up-regulate/VB IL-1beta/NN expression/NN ,/, possibly/RB by/IN using/VBG RBP/NN ,/, NF-kappaB/NN ,/, or/CC both/DT ./. 
Copyright/NN 1998/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99077509/CD 
TI/LS -/: CD27/CD70/NN interaction/NN augments/VBZ IgE/NN secretion/NN by/IN promoting/VBG the/DT differentiation/NN of/IN memory/NN B/NN cells/NNS into/IN plasma/NN cells/NNS ./. 
AB/LS -/: The/DT induction/NN of/IN IgE/NN switching/NN in/IN B/NN cells/NNS requires/VBZ several/JJ signals/NNS given/VBN by/IN cytokines/NNS and/CC cell/NN contact-delivered/JJ signals/NNS ./. 
Here/RB ,/, we/PRP investigated/VBD the/DT role/NN of/IN CD27/CD70/NN interaction/NN in/IN B/NN cell/NN IgE/NN synthesis/NN ./. 
The/DT addition/NN of/IN CD27/NN ligand/NN (/( CD70/NN )/) transfectants/NNS to/TO B/NN cell/NN cultures/NNS increased/VBD the/DT IgE/NN synthesis/NN synergistically/RB in/IN the/DT presence/NN of/IN IL-4/NN plus/CC anti-CD40/JJ mAb/NN (/( anti-CD40/NN )/) ./. 
The/DT effect/NN of/IN CD70/NN transfectants/NNS was/VBD dose/NN dependent/JJ and/CC was/VBD completely/RB blocked/VBN by/IN anti-CD70/JJ mAb/NN ./. 
CD27+/JJ B/NN cells/NNS had/VBD the/DT ability/NN to/TO produce/VB IgE/NN ,/, which/WDT was/VBD increased/VBN by/IN contact/NN with/IN CD70/NN transfectants/NNS ,/, whereas/IN CD27- B/NN cells/NNS did/VBD not/RB produce/VB IgE/NN ./. 
CD27/CD70/NN interaction/NN enhanced/VBD B/NN cell/NN proliferation/NN in/IN the/DT presence/NN of/IN IL-4/NN or/CC IL-4/NN plus/CC anti-CD40/NN ./. 
The/DT augmentation/NN of/IN B/NN cell/NN proliferation/NN by/IN CD70/NN transfectants/NNS was/VBD apparent/JJ in/IN CD27+/JJ B/NN cells/NNS ,/, but/CC was/VBD mild/JJ in/IN CD27- B/NN cells/NNS ./. 
The/DT helper/NN activity/NN for/IN IgE/NN synthesis/NN by/IN the/DT CD27/CD70/NN interaction/NN did/VBD not/RB contribute/VB to/TO the/DT enhancement/NN of/IN germline/NN epsilon/NN transcripts/NNS ./. 
Flow/NN cytometric/JJ and/CC morphological/JJ analyses/NNS demonstrated/VBD that/IN the/DT addition/NN of/IN CD70/NN transfectants/NNS to/TO B/NN cell/NN cultures/NNS remarkably/RB promoted/VBD differentiation/NN into/IN plasma/NN cells/NNS in/IN the/DT presence/NN of/IN IL-4/NN and/CC CD40/NN signaling/NN ./. 
Finally/RB ,/, CD27/NN cross-linking/NN resulted/VBD in/IN the/DT up-regulation/NN of/IN positive/JJ regulatory/JJ domain/NN I-binding/JJ factor-1/NN ./. 
Taken/VBN together/RB ,/, our/PRP$ findings/NNS indicate/VBP that/IN signaling/NN via/IN CD27/NN on/IN B/NN cells/NNS induces/VBZ IgE/NN synthesis/NN ,/, in/IN cooperation/NN with/IN IL-4/NN and/CC CD40/NN signaling/NN ,/, by/IN promoting/VBG the/DT generation/NN of/IN plasma/NN cells/NNS through/IN up-regulation/NN of/IN positive/JJ regulatory/JJ domain/NN I-binding/JJ factor-1/NN ./. 
UI/LS -/: 99074502/CD 
TI/LS -/: Human/JJ immunodeficiency/NN virus/NN type-1/NN transcription/NN :/: role/NN of/IN the/DT 5'-untranslated/JJ leader/NN region/NN (/( review/NN )/) ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus/NN type-1/NN (/( HIV-1/NN )/) transcription/NN is/VBZ dependent/JJ on/IN the/DT interaction/NN of/IN host-cell/JJ transcription/NN factors/NNS with/IN cis-regulatory/JJ DNA/NN elements/NNS within/IN the/DT viral/JJ long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ./. 
Much/JJ attention/NN has/VBZ focused/VBN on/IN the/DT series/NN of/IN sequence/NN elements/NNS upstream/JJ of/IN the/DT transcriptional/JJ initiation/NN site/NN in/IN the/DT U3/NN region/NN of/IN the/DT LTR/NN including/VBG the/DT Sp1/NN and/CC NF-kappaB/NN binding/NN sites/NNS ./. 
Recent/JJ studies/NNS ,/, however/RB ,/, demonstrate/VBP that/IN the/DT transcribed/VBN 5'-untranslated/JJ leader/NN region/NN (/( 5'-UTR/NN )/) also/RB contains/VBZ important/JJ transcriptional/JJ elements/NNS ./. 
These/DT regulatory/JJ elements/NNS situated/JJ downstream/JJ of/IN transcription/NN interact/VBP with/IN constitutive/JJ and/CC inducible/JJ transcription/NN factors/NNS ,/, mediate/VBP transmission/NN of/IN cellular/JJ activation/NN signals/NNS ,/, and/CC are/VBP important/JJ for/IN efficient/JJ HIV-1/NN transcription/NN and/CC replication/NN ./. 
The/DT 5'-UTR/NN contains/VBZ binding/VBG sites/NNS for/IN the/DT transcription/NN factors/NNS AP-1/NN ,/, NF-kappaB/NN ,/, NF-AT/NN ,/, IRF/NN ,/, and/CC Sp1/NN ./. 
Mutations/NNS in/IN these/DT binding/VBG sites/NNS can/MD interfere/VB with/IN the/DT viral/JJ response/NN to/TO cell/NN activation/NN signals/NNS ,/, decrease/VB LTR/NN transcription/NN ,/, and/CC inhibit/VB viral/JJ replication/NN ./. 
The/DT 5'-UTR/NN also/RB interacts/VBZ with/IN a/DT specific/JJ nucleosome/NN that/WDT is/VBZ rapidly/RB displaced/VBN during/IN transcriptional/JJ activation/NN of/IN the/DT latent/JJ provirus/NN ./. 
We/PRP propose/VBP that/IN the/DT inducible/JJ transcription/NN factor/NN binding/NN sites/NNS in/IN the/DT 5'-UTR/NN comprise/VBP a/DT downstream/JJ enhancer/NN domain/NN that/WDT can/MD function/VB independent/JJ of/IN ,/, or/CC in/IN concert/NN with/IN ,/, the/DT LTR/NN promoter/NN to/TO rapidly/RB increase/VB latent/JJ proviral/JJ transcription/NN in/IN response/NN to/TO cell/NN activation/NN signals/NNS ./. 
In/IN this/DT review/NN ,/, we/PRP describe/VBP the/DT host-cell/JJ transcription/NN factors/NNS that/WDT interact/VBP with/IN the/DT 5'-UTR/NN and/CC discuss/VBP their/PRP$ role/NN in/IN the/DT transcriptional/JJ regulation/NN of/IN HIV-1/NN gene/NN expression/NN ./. 
UI/LS -/: 99060916/CD 
TI/LS -/: Regulation/NN of/IN PAK/NN activation/NN and/CC the/DT T/NN cell/NN cytoskeleton/NN by/IN the/DT linker/NN protein/NN SLP-76/NN ./. 
AB/LS -/: Tyrosine/NN phosphorylation/NN of/IN linker/NN proteins/NNS enables/VBZ the/DT T/NN cell/NN antigen/NN receptor/NN (/( TCR/NN )/) -associated/JJ protein/NN tyrosine/NN kinases/NNS to/TO phosphorylate/VB and/CC regulate/VB effector/NN molecules/NNS that/WDT generate/VBP second/JJ messengers/NNS ./. 
We/PRP demonstrate/VBP here/RB that/IN the/DT SLP-76/NN linker/NN protein/NN interacts/VBZ with/IN both/CC nck/NN ,/, an/DT adaptor/NN protein/NN ,/, and/CC Vav/NN ,/, a/DT guanine/JJ nucleotide/NN exchange/NN factor/NN for/IN Rho-family/JJ GTPases/NNS ./. 
The/DT assembly/NN of/IN this/DT tri-molecular/JJ complex/NN permits/VBZ the/DT activated/VBN Rho-family/JJ GTPases/NNS to/TO regulate/VB target/NN effectors/NNS that/WDT interact/VBP through/IN nck/NN ./. 
In/IN turn/NN ,/, assembly/NN of/IN this/DT complex/NN mediates/VBZ the/DT enzymatic/JJ activation/NN of/IN the/DT p21-activated/JJ protein/NN kinase/NN 1/CD and/CC facilitates/VBZ actin/NN polymerization/NN ./. 
Hence/RB ,/, phosphorylation/NN of/IN linker/NN proteins/NNS not/RB only/RB bridges/VBZ the/DT TCR-associated/JJ PTK/NN ,/, ZAP-70/NN ,/, with/IN downstream/JJ effector/NN proteins/NNS ,/, but/CC also/RB provides/VBZ a/DT scaffold/NN to/TO integrate/VB distinct/JJ signaling/VBG complexes/NNS to/TO regulate/VB T/NN cell/NN function/NN ./. 
UI/LS -/: 99057540/CD 
TI/LS -/: Interleukin-12/NN expression/NN in/IN B/NN cells/NNS by/IN transformation/NN with/IN Epstein-Barr/JJ virus/NN ./. 
AB/LS -/: Although/IN interleukin/NN (/( IL/NN )/) -12/CD was/VBD originally/RB purified/VBN from/IN an/DT Epstein-Barr/JJ (/( EBV/NN )/) -transformed/JJ B/NN cell/NN line/NN and/CC the/DT high/JJ correlation/NN of/IN EBV/NN infection/NN and/CC IL-12/NN expression/NN has/VBZ been/VBN suggested/VBN ,/, no/DT study/NN has/VBZ reported/VBN whether/IN EBV/NN infection/NN is/VBZ directly/RB linked/VBN to/TO IL-12/NN expression/NN ./. 
To/TO address/VB this/DT issue/NN ,/, we/PRP have/VBP investigated/VBN IL-12/NN expression/NN in/IN B/NN cells/NNS during/IN in/FW vitro/FW transformation/NN with/IN EBV/NN ./. 
Human/JJ peripheral/JJ B/NN cells/NNS became/VBD capable/JJ of/IN constitutively/RB producing/VBG p40/NN by/IN in/FW vitro/FW transformation/NN with/IN EBV/NN ,/, coincident/JJ with/IN the/DT expression/NN of/IN latent/JJ membrane/NN protein/NN 1/CD (/( LMP1/NN )/) of/IN EBV/NN ./. 
These/DT B/NN cells/NNS expressed/VBD p40/NN and/CC p35/NN mRNA/NN ,/, and/CC phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) stimulation/NN strongly/RB enhanced/VBD p40/NN and/CC p70/NN production/NN ./. 
Furthermore/RB ,/, transfection/NN with/IN LMP1/NN expression/NN vector/NN into/IN a/DT human/JJ B/NN lymphoma/NN cell/NN line/NN ,/, Daudi/NN ,/, led/VBD to/TO p40/NN production/NN with/IN nuclear/JJ factor/NN (/( NF/NN )/) -kappaB/NN activation/NN ./. 
These/DT results/NNS suggest/VBP that/IN transformation/NN of/IN primary/JJ B/NN cells/NNS with/IN EBV/NN induces/VBZ IL-12/NN expression/NN potentially/RB through/IN LMP1/NN expression/NN ./. 
Copyright/NN 1998/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99047525/CD 
TI/LS -/: The/DT human/JJ gene/NN encoding/VBG the/DT lectin-type/JJ oxidized/VBN LDL/NN receptor/NN (/( OLR1/NN )/) is/VBZ a/DT novel/JJ member/NN of/IN the/DT natural/JJ killer/NN gene/NN complex/NN with/IN a/DT unique/JJ expression/NN profile/NN ./. 
AB/LS -/: LOX-1/NN is/VBZ an/DT endothelial/JJ receptor/NN for/IN oxidized/VBN low-density/JJ lipoprotein/NN that/WDT plays/VBZ essential/JJ roles/NNS in/IN atherogenesis/NN ./. 
LOX-1/NN has/VBZ the/DT highest/JJS homology/NN with/IN C-type/JJ lectin/NN receptors/NNS expressed/VBN on/IN natural/JJ killer/NN cells/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP cloned/VBD and/CC characterized/VBD the/DT human/JJ LOX-1/NN gene/NN (/( HGMW-approved/JJ symbol/NN OLR1/NN )/) ./. 
The/DT gene/NN structure/NN of/IN LOX-1/NN resembles/VBZ that/DT of/IN the/DT natural/JJ killer/NN cell/NN receptors/NNS ./. 
Fluorescence/NN in/FW situ/FW hybridization/NN and/CC analyses/NNS of/IN a/DT yeast/NN artificial/JJ chromosome/NN contig/NN revealed/VBD that/IN the/DT human/JJ LOX-1/NN gene/NN is/VBZ located/JJ in/IN the/DT natural/JJ killer/NN gene/NN complex/NN on/IN chromosome/NN 12p12-p13/NN ,/, where/WRB the/DT genes/NNS of/IN the/DT natural/JJ killer/NN cell/NN receptors/NNS cluster/VBP ./. 
In/IN contrast/NN ,/, the/DT expression/NN pattern/NN of/IN LOX-1/NN is/VBZ different/JJ from/IN that/DT of/IN the/DT natural/JJ killer/NN cell/NN receptors/NNS ;/: LOX-1/NN is/VBZ expressed/VBN in/IN vascular-rich/JJ organs/NNS ,/, but/CC not/RB in/IN lymphocytes/NNS ./. 
A/DT 1753-bp/JJ fragment/NN of/IN the/DT 5'/JJ flanking/JJ region/NN of/IN the/DT LOX-1/NN gene/NN had/VBD a/DT functional/JJ promoter/NN activity/NN ./. 
This/DT region/NN contains/VBZ binding/VBG sites/NNS for/IN several/JJ transcription/NN factors/NNS ,/, including/VBG the/DT STAT/NN family/NN and/CC NF-IL6/NN ,/, and/CC the/DT expression/NN of/IN LOX-1/NN was/VBD upregulated/VBN by/IN several/JJ cytokines/NNS ./. 
These/DT results/NNS demonstrate/VBP that/IN the/DT human/JJ LOX-1/NN gene/NN is/VBZ a/DT new/JJ member/NN of/IN the/DT natural/JJ killer/NN gene/NN complex/NN with/IN a/DT unique/JJ expression/NN profile/NN ./. 
Copyright/NN 1998/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99032541/CD 
TI/LS -/: Transcriptional/JJ regulation/NN of/IN the/DT beta-casein/NN gene/NN by/IN cytokines/NNS :/: cross-talk/NN between/IN STAT5/NN and/CC other/JJ signaling/VBG molecules/NNS ./. 
AB/LS -/: The/DT beta-casein/NN promoter/NN has/VBZ been/VBN widely/RB used/VBN to/TO monitor/VB the/DT activation/NN of/IN STAT/NN (/( signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN )/) 5/CD since/IN STAT5/NN was/VBD originally/RB found/VBN as/IN a/DT mediator/NN of/IN PRL-inducible/JJ beta-casein/NN expression/NN ./. 
However/RB ,/, not/RB only/RB is/VBZ expression/NN of/IN the/DT beta-casein/NN gene/NN regulated/VBN by/IN STAT5/NN but/CC it/PRP is/VBZ also/RB affected/VBN by/IN other/JJ molecules/NNS such/JJ as/IN glucocorticoid/NN and/CC Ras/NN ./. 
In/IN this/DT report/NN ,/, we/PRP describe/VBP the/DT transcriptional/JJ regulation/NN of/IN the/DT beta-casein/NN gene/NN by/IN cytokines/NNS in/IN T/NN cells/NNS ./. 
We/PRP have/VBP found/VBN that/IN the/DT beta-casein/NN gene/NN is/VBZ expressed/VBN in/IN a/DT cytotoxic/JJ T/NN cell/NN line/NN ,/, CTLL-2/NN ,/, in/IN response/NN to/TO interleukin-2/NN (/( IL-2/NN )/) ,/, which/WDT activates/VBZ STAT5/NN ./. 
While/IN IL-4/NN does/VBZ not/RB activate/VB STAT5/NN ,/, it/PRP induces/VBZ expression/NN of/IN STAT5-regulated/JJ genes/NNS in/IN CTLL-2/NN ,/, i.e./FW beta-casein/NN ,/, a/DT cytokine-inducible/JJ SH2-containing/JJ protein/NN (/( CIS/NN )/) ,/, and/CC oncostatin/NN M/NN (/( OSM/NN )/) ,/, suggesting/VBG that/IN STAT6/NN activated/VBN by/IN IL-4/NN substitutes/VBZ for/IN the/DT function/NN of/IN STAT5/NN in/IN T/NN cells/NNS ./. 
IL-2-induced/JJ beta-casein/NN expression/NN was/VBD enhanced/VBN by/IN dexamethasone/NN ,/, and/CC this/DT synergistic/JJ effect/NN of/IN Dexamethasone/NN requires/VBZ the/DT sequence/NN between/IN -155/CD and/CC -193/CD in/IN the/DT beta-casein/NN promoter/NN ./. 
Coincidentally/RB ,/, a/DT deletion/NN of/IN this/DT region/NN enhanced/VBD the/DT IL-2-induced/JJ expression/NN of/IN beta-casein/NN ./. 
Expression/NN of/IN an/DT active/JJ form/NN of/IN Ras/NN ,/, Ras(G12V)/NN ,/, suppressed/VBD the/DT IL-2-induced/JJ beta-casein/NN and/CC OSM/NN gene/NN expression/NN ,/, and/CC the/DT negative/JJ effect/NN of/IN Ras/NN is/VBZ mediated/VBN by/IN the/DT region/NN between/IN -105/CD and/CC -193/CD in/IN the/DT beta-casein/NN promoter/NN ./. 
In/IN apparent/JJ contradiction/NN ,/, expression/NN of/IN a/DT dominant/JJ negative/JJ form/NN of/IN Ras/NN ,/, RasN17/NN ,/, also/RB inhibited/VBD IL-2-induced/JJ activation/NN of/IN the/DT promoter/NN containing/VBG the/DT minimal/JJ beta-casein/NN STAT5/NN element/NN as/RB well/RB as/IN the/DT promoters/NNS of/IN CIS/NN and/CC OSM/NN ./. 
In/IN addition/NN ,/, Ras(G12V)/NN complemented/VBD signaling/NN by/IN an/DT erythropoietin/NN receptor/NN mutant/NN defective/JJ in/IN Ras/NN activation/NN and/CC augmented/VBD the/DT activation/NN of/IN the/DT beta-casein/NN promoter/NN by/IN the/DT mutant/JJ erythropoietin/NN receptor/NN signaling/NN ,/, suggesting/VBG a/DT possible/JJ role/NN of/IN Ras/NN in/IN Stat5-mediated/JJ gene/NN expression/NN ./. 
These/DT results/NNS collectively/RB reveal/VBP a/DT complex/JJ interaction/NN of/IN STAT5/NN with/IN other/JJ signaling/NN pathways/NNS and/CC illustrate/VBP that/IN regulation/NN of/IN gene/NN expression/NN requires/VBZ integration/NN of/IN opposing/JJ signals/NNS 
UI/LS -/: 99015774/CD 
TI/LS -/: GATA-3/NN represses/VBZ gp91phox/NN gene/NN expression/NN in/IN eosinophil-committed/JJ HL-60-C15/NN cells/NNS ./. 
AB/LS -/: To/TO study/VB the/DT regulatory/JJ mechanism/NN of/IN gp91phox/NN gene/NN expression/NN in/IN eosinophils/NNS ,/, we/PRP transiently/RB transfected/VBD eosinophil-committed/JJ HL-60-C15/NN cells/NNS with/IN gp91phox/NN promoter/NN constructs/NNS ,/, and/CC identified/VBD a/DT negative/JJ element/NN from/IN bp/NN -267/CD to/TO -246/CD of/IN the/DT gp91phox/NN gene/NN ,/, the/DT deletion/NN of/IN which/WDT caused/VBD an/DT 83/CD %/NN increase/NN in/IN promoter/NN activity/NN ./. 
Electrophoresis/NN mobility/NN shift/NN assays/NNS demonstrated/VBD GATA-3/NN binds/VBZ to/TO the/DT GATA/NN consensus/NN site/NN from/IN bp/NN -256/CD to/TO -250/CD ./. 
An/DT 81/CD %/NN increment/NN in/IN promoter/NN activity/NN was/VBD obtained/VBN when/WRB a/DT mutation/NN was/VBD introduced/VBN in/IN the/DT GATA-3/NN binding/NN site/NN of/IN the/DT bp/NN -267/CD to/TO +12/CD construct/NN ,/, which/WDT is/VBZ comparable/JJ to/TO that/DT of/IN the/DT bp/NN -245/CD to/TO +12/CD construct/NN ./. 
We/PRP therefore/RB conclude/VBP that/IN GATA-3/NN specifically/RB binding/VBG to/TO the/DT GATA/NN site/NN negatively/RB regulates/VBZ the/DT expression/NN of/IN the/DT gene/NN in/IN HL-60-C15/NN cells/NNS ./. 
UI/LS -/: 99008506/CD 
TI/LS -/: Uncoupling/VBG activation-dependent/JJ HS1/NN phosphorylation/NN from/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS transcriptional/JJ activation/NN in/IN Jurkat/NN T/NN cells/NNS :/: differential/JJ signaling/NN through/IN CD3/NN and/CC the/DT costimulatory/JJ receptors/NNS CD2/NN and/CC CD28/NN ./. 
AB/LS -/: CD3/NN ,/, CD2/NN ,/, and/CC CD28/NN are/VBP functionally/RB distinct/JJ receptors/NNS on/IN T/NN lymphocytes/NNS ./. 
Engagement/NN of/IN any/DT of/IN these/DT receptors/NNS induces/VBZ the/DT rapid/JJ tyrosine/NN phosphorylation/NN of/IN a/DT shared/JJ group/NN of/IN intracellular/JJ signaling/NN proteins/NNS ,/, including/VBG Vav/NN ,/, Cbl/NN ,/, p85/NN phosphoinositide/NN 3-kinase/NN ,/, and/CC the/DT Src/NN family/NN kinases/NNS Lck/NN and/CC Fyn/NN ./. 
Ligation/NN of/IN CD3/NN also/RB induces/VBZ the/DT tyrosine/NN phosphorylation/NN of/IN HS1/NN ,/, a/DT 75-kDa/JJ hematopoietic/JJ cell-specific/JJ intracellular/JJ signaling/NN protein/NN of/IN unknown/JJ function/NN ./. 
We/PRP have/VBP examined/VBN changes/NNS in/IN HS1/NN phosphorylation/NN after/IN differential/JJ stimulation/NN of/IN CD3/NN ,/, CD2/NN ,/, and/CC CD28/NN to/TO elucidate/VB its/PRP$ role/NN in/IN T/NN cells/NNS and/CC to/TO further/RB delineate/VB the/DT signaling/NN pathways/NNS recruited/VBN by/IN these/DT receptors/NNS ./. 
Unlike/IN ligation/NN of/IN CD3/NN ,/, stimulation/NN with/IN anti-CD28/JJ mAb/NN or/CC CHO/NN cells/NNS expressing/VBG the/DT CD28/NN ligands/NNS CD80/NN or/CC CD86/NN did/VBD not/RB lead/VB to/TO tyrosine/NN phosphorylation/NN of/IN HS1/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
Additionally/RB ,/, no/DT tyrosine/NN phosphorylation/NN of/IN HS1/NN was/VBD induced/VBN by/IN mitogenic/JJ pairs/NNS of/IN anti-CD2/JJ mAbs/NNS capable/JJ of/IN activating/VBG the/DT transcription/NN factor/NN NFAT/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS )/) ./. 
Costimulation/NN through/IN CD28/NN and/or/CC CD2/NN did/VBD not/RB modulate/VB the/DT CD3-dependent/JJ phosphorylation/NN of/IN HS1/NN ./. 
In/FW vivo/FW studies/NNS indicated/VBD that/IN CD3-induced/JJ HSI/NN phosphorylation/NN was/VBD dependent/JJ upon/IN both/CC the/DT Src/NN family/NN tyrosine/NN kinase/NN Lck/NN and/CC the/DT tyrosine/NN phosphatase/NN CD45/NN ,/, did/VBD not/RB require/VB MEK1/NN kinase/NN activity/NN ,/, and/CC was/VBD regulated/VBN by/IN protein/NN kinase/NN C/NN activation/NN ./. 
Thus/RB ,/, although/IN CD3/NN ,/, CD28/NN ,/, and/CC CD2/NN activate/VBP many/JJ of/IN the/DT same/JJ signaling/NN molecules/NNS ,/, they/PRP differed/VBD in/IN their/PRP$ capacity/NN to/TO induce/VB the/DT tyrosine/NN phosphorylation/NN of/IN HSI/NN ./. 
Furthermore/RB ,/, activation-dependent/JJ tyrosine/NN phosphorylation/NN of/IN HS1/NN was/VBD not/RB required/VBN for/IN NFAT/NN transcriptional/JJ activation/NN ./. 
UI/LS -/: 99003459/CD 
TI/LS -/: c-fos/NN and/CC c-jun/NN mRNA/NN expression/NN in/IN activated/VBN cord/NN and/CC adult/JJ lymphocytes/NNS :/: an/DT analysis/NN by/IN Northern/NN hybridization/NN ./. 
AB/LS -/: BACKGROUND/NN AND/CC OBJECTIVES/NNS :/: To/TO further/RB analyze/VB the/DT neonatal/JJ immune/JJ response/NN to/TO an/DT antigenic/JJ challenge/NN such/JJ as/IN blood/NN transfusion/NN ,/, c-fos/NN and/CC c-jun/NN mRNA/NN expression/NN were/VBD analyzed/VBN in/IN twelve/CD in-vitro-stimulated/JJ normal/JJ cord/NN blood/NN and/CC ten/CD in-vitro-stimulated/JJ normal/JJ adult/JJ peripheral/JJ blood/NN lymphocyte/NN samples/NNS ./. 
MATERIALS/NNS AND/CC METHODS/NNS :/: Lymphocyte/NN samples/NNS were/VBD stimulated/VBN by/IN either/CC the/DT mitogen/NN phytohemagglutinin/NN (/( PHA/NN )/) or/CC the/DT monoclonal/JJ antibody/NN alphaCD3/NN ./. 
Proliferation/NN rate/NN and/CC Northern/NN blot/NN hybridization/NN were/VBD employed/VBN ./. 
RESULTS/NNS :/: Cord/NN lymphocytes/NNS revealed/VBD a/DT greater/JJR proliferation/NN rate/NN with/IN PHA/NN and/CC alphaCD3/NN than/IN adult/JJ lymphocytes/NNS (/( p/NN =/JJ 0.0081/CD and/CC 0.0023/CD ,/, respectively/RB )/) ./. 
In/IN addition/NN ,/, Northern/NN blot/NN analysis/NN of/IN cord/NN and/CC adult/JJ samples/NNS revealed/VBD similar/JJ maximal/JJ increases/NNS in/IN c-fos/NN (/( 99+/-15/CD and/CC 126+/-11/CD %/NN ,/, p/NN =/JJ 0.0126/CD )/) and/CC c-jun/NN (/( 123+/-9/CD and/CC 185+/-38/CD %/NN ,/, p/NN =/JJ 0.0291/CD )/) mRNA/NN expression/NN ,/, respectively/RB ,/, as/RB early/RB as/IN 15/CD min/NN post-alphaCD3/JJ stimulation/NN ./. 
Adult/JJ lymphocytes/NNS showed/VBD an/DT equivalent/JJ increase/NN in/IN mRNA/NN expression/NN of/IN c-fos/NN and/CC c-jun/NN (/( 140+/-25/CD and/CC 155+/-31/CD %/NN )/) at/IN 30/CD min/NN post-PHA/JJ stimulation/NN ,/, while/IN cord/NN lymphocyte/NN maximum/NN c-fos/NN and/CC c-jun/NN expression/NN (/( 82+/-6/CD and/CC 142+/-12/CD %/NN )/) occurred/VBD at/IN 15/CD min/NN post-PHA/JJ stimulation/NN (/( c-fos/NN ,/, p/NN =/JJ 0.0354/CD ;/: c-jun/NN ,/, p/NN =/JJ 0.0112/CD )/) ./. 
CONCLUSION/NN :/: Although/IN cord/JJ lymphocyte/NN proliferation/NN rates/NNS were/VBD significantly/RB greater/JJR than/IN those/DT of/IN adult/JJ lymphocytes/NNS following/VBG stimulation/NN ,/, lymphocyte/NN activation/NN ,/, as/IN analyzed/VBN by/IN c-fos/NN and/CC c-jun/NN mRNA/NN expression/NN ,/, appears/VBZ similar/JJ in/IN both/CC cord/NN and/CC adult/JJ samples/NNS ./. 
We/PRP conclude/VBP that/IN cord/NN lymphocyte/NN activation/NN exhibits/VBZ an/DT adult-type/JJ profile/NN ./. 
UI/LS -/: 98438540/CD 
TI/LS -/: Fcgamma/NN receptor-mediated/JJ mitogen-activated/JJ protein/NN kinase/NN activation/NN in/IN monocytes/NNS is/VBZ independent/JJ of/IN Ras/NN ./. 
AB/LS -/: Receptors/NNS for/IN the/DT Fc/NN portion/NN of/IN immunoglobulin/NN molecules/NNS (/( FcR/NNS )/) present/JJ on/IN leukocyte/NN cell/NN membranes/NNS mediate/VBP a/DT large/JJ number/NN of/IN cellular/JJ responses/NNS that/WDT are/VBP very/RB important/JJ in/IN host/NN defense/NN ,/, including/VBG phagocytosis/NN ,/, cell/NN cytotoxicity/NN ,/, production/NN and/CC secretion/NN of/IN inflammatory/JJ mediators/NNS ,/, and/CC modulation/NN of/IN the/DT immune/JJ response/NN ./. 
Cross-linking/NN of/IN FcR/NNS with/IN immune/JJ complexes/NNS leads/VBZ ,/, first/RB to/TO activation/NN of/IN protein-tyrosine/JJ kinases/NNS ./. 
The/DT molecular/JJ events/NNS that/WDT follow/VBP and/CC that/WDT transduce/VBP signals/NNS from/IN these/DT receptors/NNS to/TO the/DT nucleus/NN are/VBP still/RB poorly/RB defined/VBN ./. 
We/PRP have/VBP investigated/VBN the/DT signal/NN transduction/NN pathway/NN from/IN Fc/NN receptors/NNS that/WDT leads/VBZ to/TO gene/NN activation/NN and/CC production/NN of/IN cytokines/NNS in/IN monocytes/NNS ./. 
Cross-linking/NN of/IN FcR/NNS ,/, on/IN the/DT THP-1/NN monocytic/JJ cell/NN line/NN ,/, by/IN immune/JJ complexes/NNS resulted/VBD in/IN both/CC activation/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN and/CC interleukin/NN 1/CD production/NN ./. 
These/DT responses/NNS were/VBD completely/RB blocked/VBN by/IN tyrosine/NN kinase/NN inhibitors/NNS ./. 
In/IN contrast/NN ,/, expression/NN of/IN dominant/JJ negative/JJ mutants/NNS of/IN Ras/NN and/CC Raf-1/NN ,/, in/IN these/DT cells/NNS ,/, did/VBD not/RB have/VB any/DT effect/NN on/IN FcR-mediated/JJ nuclear/JJ factor/NN activation/NN ,/, suggesting/VBG that/IN the/DT mitogen-activated/JJ protein/NN kinase/NN (/( MAPK/NN )/) signaling/NN pathway/NN was/VBD not/RB used/VBN by/IN these/DT receptors/NNS ./. 
However/RB ,/, MAPK/NN activation/NN was/VBD easily/RB detected/VBN by/IN in/FW vitro/FW kinase/NN assays/NNS ,/, after/IN FcR/NNS cross-linking/NN with/IN immune/JJ complexes/NNS ./. 
Using/VBG the/DT specific/JJ MAPK/extracellular/JJ signal-regulated/JJ kinase/NN kinase/NN (/( MAPK/NN kinase/NN )/) inhibitor/NN PD98059/NN ,/, we/PRP found/VBD that/IN MAPK/NN activation/NN is/VBZ necessary/JJ for/IN FcR-dependent/JJ activation/NN of/IN the/DT nuclear/JJ factor/NN NF-kappaB/NN ./. 
These/DT results/NNS strongly/RB suggest/VBP that/IN the/DT signaling/NN pathway/NN from/IN Fc/NN receptors/NNS leading/VBG to/TO expression/NN of/IN different/JJ genes/NNS important/JJ to/TO leukocyte/NN biology/NN ,/, initiates/VBZ with/IN tyrosine/NN kinases/NNS and/CC requires/VBZ MAPK/NN activation/NN ;/: but/CC in/IN contrast/NN to/TO other/JJ tyrosine/NN kinase/NN receptors/NNS ,/, FcR-mediated/JJ MAPK/NN activation/NN does/VBZ not/RB involve/VB Ras/NN and/CC Raf/NN ./. 
UI/LS -/: 98426236/CD 
TI/LS -/: BCL-6/NN mutations/NNS in/IN normal/JJ germinal/JJ center/NN B/NN cells/NNS :/: evidence/NN of/IN somatic/JJ hypermutation/NN acting/VBG outside/IN Ig/NN loci/NNS ./. 
AB/LS -/: The/DT molecular/JJ mechanism/NN involved/VBN in/IN the/DT process/NN of/IN antigen-driven/JJ somatic/JJ hypermutation/NN of/IN Ig/NN genes/NNS is/VBZ unknown/JJ ,/, but/CC it/PRP is/VBZ commonly/RB believed/VBN that/IN this/DT mechanism/NN is/VBZ restricted/JJ to/TO the/DT Ig/NN loci/NNS ./. 
B/NN cell/NN lymphomas/NNS commonly/RB display/VBP multiple/JJ somatic/JJ mutations/NNS clustering/VBG in/IN the/DT 5'-regulatory/JJ region/NN of/IN BCL-6/NN ,/, a/DT proto-oncogene/NN encoding/VBG for/IN a/DT POZ/Zinc/NN finger/NN transcriptional/JJ repressor/NN expressed/VBN in/IN germinal/JJ center/NN (/( GC/NN )/) B/NN cells/NNS and/CC required/VBN for/IN GC/NN formation/NN ./. 
To/TO determine/VB whether/IN BCL-6/NN mutations/NNS represent/VBP a/DT tumor-associated/JJ phenomenon/NN or/CC reflect/VBP a/DT physiologic/JJ mechanism/NN ,/, we/PRP screened/VBD single/JJ human/JJ tonsillar/JJ GC/NN B/NN cells/NNS for/IN mutations/NNS occurring/VBG in/IN the/DT BCL-6/NN 5'-noncoding/JJ region/NN and/CC in/IN the/DT Ig/NN variable/JJ heavy/JJ chain/NN sequences/NNS ./. 
Thirty/CD percent/NN of/IN GC/NN B/NN cells/NNS ,/, but/CC not/RB naive/JJ B/NN cells/NNS ,/, displayed/VBD mutations/NNS in/IN the/DT 742/CD bp/NN region/NN analyzed/VBN within/IN the/DT first/JJ intron/NN of/IN BCL-6/NN (/( overall/JJ frequency/NN :/: 5/CD x/CC 10(-4)/bp/NN )/) ./. 
Accordingly/RB ,/, an/DT expanded/VBN survey/NN in/IN lymphoid/JJ malignancies/NNS showed/VBD that/IN BCL-6/NN mutations/NNS are/VBP restricted/JJ to/TO B/NN cell/NN tumors/NNS displaying/VBG GC/NN or/CC post-GC/JJ phenotype/NN and/CC carrying/VBG mutated/VBN Ig/NN variable/JJ heavy/JJ chain/NN sequences/NNS ./. 
These/DT results/NNS indicate/VBP that/IN the/DT somatic/JJ hypermutation/NN mechanism/NN active/JJ in/IN GC/NN B/NN cells/NNS physiologically/RB targets/VBZ non-Ig/JJ sequences/NNS ./. 
UI/LS -/: 98414619/CD 
TI/LS -/: The/DT AD1/NN and/CC AD2/NN transactivation/NN domains/NNS of/IN E2A/NN are/VBP essential/JJ for/IN the/DT antiapoptotic/JJ activity/NN of/IN the/DT chimeric/JJ oncoprotein/NN E2A-HLF/NN ./. 
AB/LS -/: The/DT chimeric/JJ oncoprotein/NN E2A-HLF/NN ,/, generated/VBN by/IN the/DT t(17;19)/NN chromosomal/JJ translocation/NN in/IN pro-B-cell/JJ acute/JJ lymphoblastic/JJ leukemia/NN ,/, incorporates/VBZ the/DT transactivation/NN domains/NNS of/IN E2A/NN and/CC the/DT basic/JJ leucine/NN zipper/NN (/( bZIP/NN )/) DNA-binding/NN and/CC protein/NN dimerization/NN domain/NN of/IN HLF/NN (/( hepatic/JJ leukemic/JJ factor/NN )/) ./. 
The/DT ability/NN of/IN E2A-HLF/NN to/TO prolong/VB the/DT survival/NN of/IN interleukin-3/NN (/( IL-3/NN )/) -dependent/JJ murine/JJ pro-B/JJ cells/NNS after/IN IL-3/NN withdrawal/NN suggests/VBZ that/IN it/PRP disrupts/VBZ signaling/NN pathways/NNS normally/RB responsible/JJ for/IN cell/NN suicide/NN ,/, allowing/VBG the/DT cells/NNS to/TO accumulate/VB as/IN transformed/VBN lymphoblasts/NNS ./. 
To/TO determine/VB the/DT structural/JJ motifs/NNS that/WDT contribute/VBP to/TO this/DT antiapoptotic/JJ effect/NN ,/, we/PRP constructed/VBD a/DT panel/NN of/IN E2A-HLF/NN mutants/NNS and/CC programmed/VBD their/PRP$ expression/NN in/IN IL-3-dependent/JJ murine/JJ pro-B/JJ cells/NNS (/( FL5.12/NN line/NN )/) ,/, using/VBG a/DT zinc-inducible/JJ vector/NN ./. 
Neither/RB the/DT E12/NN nor/CC the/DT E47/NN product/NN of/IN the/DT E2A/NN gene/NN nor/CC the/DT wild-type/JJ HLF/NN protein/NN was/VBD able/JJ to/TO protect/VB the/DT cells/NNS from/IN apoptosis/NN induced/VBN by/IN IL-3/NN deprivation/NN ./. 
Surprisingly/RB ,/, different/JJ combinations/NNS of/IN disabling/VBG mutations/NNS within/IN the/DT HLF/NN bZIP/NN domain/NN had/VBD little/JJ effect/NN on/IN the/DT antiapoptotic/JJ property/NN of/IN the/DT chimeric/JJ protein/NN ,/, so/RB long/RB as/IN the/DT amino-terminal/JJ portion/NN of/IN E2A/NN remained/VBD intact/JJ ./. 
In/IN the/DT context/NN of/IN a/DT bZIP/NN domain/NN defective/JJ in/IN DNA/NN binding/NN ,/, mutants/NNS retaining/VBG either/DT of/IN the/DT two/CD transactivation/NN domains/NNS of/IN E2A/NN were/VBD able/JJ to/TO extend/VB cell/NN survival/NN after/IN growth/NN factor/NN deprivation/NN ./. 
Thus/RB ,/, the/DT block/NN of/IN apoptosis/NN imposed/VBN by/IN E2A-HLF/NN in/IN pro-B/JJ lymphocytes/NNS depends/VBZ critically/RB on/IN the/DT transactivating/JJ regions/NNS of/IN E2A/NN ./. 
Since/IN neither/CC DNA/NN binding/NN nor/CC protein/NN dimerization/NN through/IN the/DT bZIP/NN domain/NN of/IN HLF/NN is/VBZ required/VBN for/IN this/DT effect/NN ,/, we/PRP propose/VBP mechanisms/NNS whereby/IN protein-protein/JJ interactions/NNS with/IN the/DT amino-terminal/JJ region/NN of/IN E2A/NN allow/VBP the/DT chimera/NN to/TO act/VB as/IN a/DT transcriptional/JJ cofactor/NN to/TO alter/VB the/DT expression/NN of/IN genes/NNS regulating/VBG the/DT apoptotic/JJ machinery/NN in/IN pro-B/JJ cells/NNS ./. 
UI/LS -/: 98400847/CD 
TI/LS -/: Induction/NN of/IN Mn/NN SOD/NN in/IN human/JJ monocytes/NNS without/IN inflammatory/JJ cytokine/NN production/NN by/IN a/DT mutant/JJ endotoxin/NN ./. 
AB/LS -/: Endotoxin/NN selectively/RB induces/VBZ monocyte/NN Mn/NN superoxide/NN dismutase/NN (/( SOD/NN )/) without/IN affecting/VBG levels/NNS of/IN Cu/NN ,/, Zn/NN SOD/NN ,/, catalase/NN ,/, or/CC glutathione/NN peroxidase/NN ./. 
However/RB ,/, little/JJ is/VBZ known/VBN about/IN the/DT structure-activity/JJ relationship/NN and/CC the/DT mechanism/NN by/IN which/WDT endotoxin/NN induces/VBZ Mn/JJ SOD/NN ./. 
In/IN this/DT study/NN we/PRP demonstrated/VBD that/IN a/DT mutant/JJ Escherichia/FW coli/FW endotoxin/NN lacking/VBG myristoyl/NN fatty/NN acid/NN at/IN the/DT 3'/JJ R-3-hydroxymyristate/NN position/NN of/IN the/DT lipid/NN A/NN moiety/NN retained/VBD its/PRP$ full/JJ capacity/NN to/TO coagulate/VB Limulus/JJ amoebocyte/NN lysate/NN compared/VBN with/IN the/DT wild-type/JJ E./FW coli/FW endotoxin/NN and/CC markedly/RB stimulated/VBD the/DT activation/NN of/IN human/JJ monocyte/NN nuclear/JJ factor-kappaB/NN and/CC the/DT induction/NN of/IN Mn/NN SOD/NN mRNA/NN and/CC enzyme/NN activity/NN ./. 
However/RB ,/, in/IN contrast/NN to/TO the/DT wild-type/JJ endotoxin/NN ,/, it/PRP failed/VBD to/TO induce/VB significant/JJ production/NN of/IN tumor/NN necrosis/NN factor-alpha/NN and/CC macrophage/NN inflammatory/JJ protein-1alpha/NN by/IN monocytes/NNS and/CC did/VBD not/RB induce/VB the/DT phosphorylation/NN and/CC nuclear/JJ translocation/NN of/IN mitogen-activated/JJ protein/NN kinase/NN ./. 
These/DT results/NNS suggest/VBP that/IN 1/LS )/) lipid/NN A/NN myristoyl/NN fatty/NN acid/NN ,/, although/IN it/PRP is/VBZ important/JJ for/IN the/DT induction/NN of/IN inflammatory/JJ cytokine/NN production/NN by/IN human/JJ monocytes/NNS ,/, is/VBZ not/RB necessary/JJ for/IN the/DT induction/NN of/IN Mn/NN SOD/NN ,/, 2/CD )/) endotoxin-mediated/JJ induction/NN of/IN Mn/NN SOD/NN and/CC inflammatory/JJ cytokines/NNS are/VBP regulated/VBN ,/, at/IN least/JJS in/IN part/NN ,/, through/IN different/JJ signal/NN transduction/NN pathways/NNS ,/, and/CC 3/CD )/) failure/NN of/IN the/DT mutant/JJ endotoxin/NN to/TO induce/VB tumor/NN necrosis/NN factor-alpha/NN production/NN is/VBZ ,/, at/IN least/JJS in/IN part/NN ,/, due/JJ to/TO its/PRP$ inability/NN to/TO activate/VB mitogen-activated/JJ protein/NN kinase/NN ./. 
UI/LS -/: 98389282/CD 
TI/LS -/: Regulation/NN of/IN the/DT vitellogenin/NN gene/NN B1/NN promoter/NN after/IN transfer/NN into/IN hepatocytes/NNS in/IN primary/JJ cultures/NNS ./. 
AB/LS -/: The/DT estrogen-dependent/JJ and/CC tissue-specific/JJ regulation/NN of/IN the/DT Xenopus/NN laevis/NN vitellogenin/NN gene/NN B1/NN promoter/NN has/VBZ been/VBN studied/VBN by/IN lipid-mediated/JJ DNA/NN transfer/NN into/IN Xenopus/NN hepatocytes/NNS in/IN primary/JJ culture/NN ./. 
Hepatocytes/NNS achieve/VBP an/DT efficient/JJ hormonal/JJ control/NN of/IN this/DT promoter/NN through/IN a/DT functional/JJ interaction/NN between/IN the/DT estrogen/NN responsive/JJ elements/NNS and/CC a/DT promoter/NN proximal/JJ region/NN upstream/JJ of/IN the/DT TATA/NN box/NN ,/, which/WDT is/VBZ characterized/VBN by/IN a/DT high/JJ density/NN of/IN binding/VBG sites/NNS for/IN the/DT transcription/NN factors/NNS CTF/NF-1/NN ,/, C/EBP/NN and/CC HNF3/NN ./. 
DNA/NN accessibility/NN to/TO restriction/NN enzymes/NNS within/IN the/DT chromosomal/JJ copy/NN of/IN the/DT vitellogenin/NN gene/NN B1/NN promoter/NN shows/VBZ that/IN the/DT estrogen/NN responsive/JJ unit/NN and/CC the/DT promoter/NN proximal/JJ region/NN are/VBP sensitive/JJ to/TO digestion/NN in/IN uninduced/JJ and/CC estrogen-induced/JJ hepatocytes/NNS but/CC not/RB in/IN erythrocyte/NN nuclei/NNS ./. 
Together/RB ,/, these/DT findings/NNS support/VBP the/DT notion/NN that/IN chromatin/NN configuration/NN as/RB well/RB as/IN the/DT interplay/NN of/IN promoter/NN elements/NNS mediate/VBP proper/JJ hormone-dependent/JJ and/CC tissue-specific/JJ expression/NN of/IN the/DT B1/NN vitellogenin/NN gene/NN ./. 
UI/LS -/: 98380997/CD 
TI/LS -/: Characterization/NN of/IN cytokine/NN differential/JJ induction/NN of/IN STAT/NN complexes/NNS in/IN primary/JJ human/JJ T/NN and/CC NK/NN cells/NNS ./. 
AB/LS -/: Cytokines/NNS ,/, IL-2/NN ,/, IL-4/NN ,/, IL-6/NN ,/, IL-7/NN ,/, IL-12/NN ,/, and/CC IL-15/NN are/VBP key/JJ regulators/NNS of/IN human/JJ peripheral/JJ blood/NN T/NN and/CC NK/NN cell/NN activation/NN and/CC differentiation/NN but/CC the/DT precise/JJ mechanisms/NNS that/WDT give/VBP rise/VBP to/TO their/PRP$ differential/JJ activities/NNS within/IN these/DT cells/NNS are/VBP not/RB clear/JJ ./. 
Recent/JJ studies/NNS reveal/VBP that/IN a/DT family/NN of/IN transcription/NN factors/NNS ,/, signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STATs/NNS )/) directly/RB mediate/VB many/JJ cytokine/NN signals/NNS ./. 
We/PRP analyzed/VBD the/DT activation/NN of/IN STATs/NNS in/IN primary/JJ human/JJ T/NN and/CC NK/NN cells/NNS by/IN a/DT variety/NN of/IN specific/JJ cytokines/NNS ./. 
We/PRP demonstrate/VBP that/IN IL-12/NN induces/VBZ STAT4/NN only/RB in/IN freshly/RB isolated/VBN primary/JJ NK/NN cells/NNS ,/, but/CC not/RB in/IN primary/JJ T/NN cells/NNS ,/, consistent/JJ with/IN the/DT lack/NN of/IN the/DT IL-12/NN receptor/NN in/IN resting/VBG T/NN cells/NNS ./. 
In/IN contrast/NN ,/, IL-4/NN induces/VBZ different/JJ C/NN epsilon/NN GAS/NN DNA-protein/JJ binding/NN complexes/NNS in/IN both/CC T/NN and/CC NK/NN cells/NNS ./. 
Moreover/RB ,/, IL-4/NN costimulation/NN with/IN IL-2/NN or/CC IL-12/NN does/VBZ not/RB alter/VB their/PRP$ own/JJ preferential/JJ GAS-like/JJ DNA/NN binding/NN patterns/NNS when/WRB C/NN epsilon-/NN ,/, Fc/NN gamma/NN RI-/NN ,/, and/CC SIE/NN GAS/NN motif/NN containing/VBG oligonucleotide/NN probes/NNS are/VBP compared/VBN ,/, suggesting/VBG that/IN induction/NN of/IN GAS-like/JJ DNA-protein/JJ binding/NN complexes/NNS by/IN IL-2/NN ,/, IL-4/NN ,/, and/CC IL-12/NN is/VBZ highly/RB selective/JJ and/CC represents/VBZ one/CD important/JJ factor/NN in/IN determining/VBG specific/JJ gene/NN activation/NN ./. 
In/IN addition/NN ,/, IL-6/NN and/CC IL-2/NN synergistically/RB induce/VBP homo-/JJ and/CC heterodimerized/JJ STAT1/NN alpha/NN and/CC STAT3/NN in/IN both/CC NK/NN and/CC T/NN cells/NNS ,/, consistent/JJ with/IN their/PRP$ reported/VBN synergism/NN in/IN modulating/VBG perforin/NN gene/NN expression/NN ./. 
We/PRP further/RB demonstrated/VBD that/IN IL-2/NN ,/, -7/CD ,/, and/CC -15/CD induce/VBP multiple/JJ STAT/NN proteins/NNS ,/, including/VBG STAT5a/NN ,/, STAT5b/NN ,/, STAT1/NN alpha/NN ,/, STAT3/NN ,/, and/CC another/DT unidentified/JJ Fc/NN gamma/NN RI/NN GAS/NN DNA-binding/NN protein/NN ./. 
Finally/RB ,/, we/PRP observed/VBD that/IN activated/VBN STAT5a/NN and/CC STAT5b/NN proteins/NNS form/VBP distinct/JJ Fc/NN gamma/NN RI/NN GAS/NN binding/NN patterns/NNS in/IN T/NN and/CC NK/NN cells/NNS ,/, suggesting/VBG that/IN they/PRP might/MD have/VB different/JJ roles/NNS in/IN gene/NN regulation/NN ./. 
Our/PRP$ data/NNS provide/VBP evidence/NN that/IN the/DT differential/JJ responses/NNS in/IN gene/NN expression/NN and/CC cell/NN activation/NN seen/VBN in/IN primary/JJ NK/NN and/CC T/NN cells/NNS on/IN direct/JJ stimulation/NN with/IN different/JJ cytokines/NNS may/MD be/VB a/DT direct/JJ result/NN of/IN distinct/JJ activation/NN of/IN STAT/NN transcription/NN factors/NNS ./. 
UI/LS -/: 98373989/CD 
TI/LS -/: A/DT regulatory/JJ element/NN in/IN the/DT CD95/NN (/( APO-1/Fas/NN )/) ligand/NN promoter/NN is/VBZ essential/JJ for/IN responsiveness/NN to/TO TCR-mediated/JJ activation/NN ./. 
AB/LS -/: Expression/NN of/IN the/DT CD95/NN (/( APO-1/Fas/NN )/) ligand/NN (/( CD95L/NN )/) in/IN activated/VBN T/NN cells/NNS is/VBZ a/DT major/JJ cause/NN of/IN T/NN cell/NN activation-induced/JJ apoptosis/NN ./. 
To/TO study/VB the/DT molecular/JJ mechanisms/NNS of/IN transcriptional/JJ control/NN of/IN CD95L/NN expression/NN in/IN T/NN cells/NNS ,/, we/PRP investigated/VBD the/DT human/JJ CD95L/NN promoter/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
Deletion/NN studies/NNS revealed/VBD that/IN the/DT CD95L/NN proximal/JJ promoter/NN sequence/NN from/IN -220/CD to/TO the/DT transcription/NN start/NN site/NN is/VBZ essential/JJ for/IN T/NN cell/NN stimulation-induced/JJ expression/NN of/IN CD95L/NN ./. 
In/IN this/DT study/NN ,/, we/PRP discovered/VBD a/DT novel/JJ regulatory/JJ element/NN located/JJ at/IN -120/CD of/IN the/DT CD95L/NN promoter/NN which/WDT contains/VBZ DNA/NN binding/NN sites/NNS for/IN SP-1/NN and/CC a/DT yet/RB unknown/JJ inducible/JJ factor/NN ./. 
Mutation/NN analysis/NN demonstrated/VBD that/IN binding/NN of/IN the/DT inducible/JJ factor/NN to/TO the/DT -120/CD region/NN is/VBZ crucial/JJ for/IN the/DT biological/JJ function/NN of/IN the/DT CD95L/NN promoter/NN upon/IN T/NN cell/NN stimulation/NN ./. 
The/DT DNA/NN sequence/NN at/IN -120/CD also/RB contains/VBZ two/CD DNA/NN motifs/NNS homologous/JJ to/TO the/DT binding/VBG site/NN for/IN NF-AT/NN ./. 
NF-AT/NN does/VBZ not/RB directly/RB bind/VB to/TO this/DT element/NN ./. 
However/RB ,/, cotransfection/NN studies/NNS with/IN an/DT NF-AT/NN expression/NN vector/NN showed/VBD that/IN NF-AT/NN may/MD confer/VB a/DT strong/JJ inducible/JJ activity/NN to/TO the/DT CD95L/NN promoter/NN at/IN this/DT regulatory/JJ region/NN ./. 
Our/PRP$ data/NNS also/RB show/VBP that/IN the/DT immunosuppressive/JJ agent/NN cyclosporin/NN A/NN down-regulates/VBZ CD95L/NN transcription/NN by/IN inhibiting/VBG the/DT function/NN of/IN this/DT positive/JJ regulatory/JJ element/NN 
UI/LS -/: 99021680/CD 
TI/LS -/: A/DT nongenomic/JJ mechanism/NN for/IN progesterone-mediated/JJ immunosuppression/NN :/: inhibition/NN of/IN K+/NN channels/NNS ,/, Ca2+/NN signaling/NN ,/, and/CC gene/NN expression/NN in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT mechanism/NN by/IN which/WDT progesterone/NN causes/VBZ localized/JJ suppression/NN of/IN the/DT immune/JJ response/NN during/IN pregnancy/NN has/VBZ remained/VBN elusive/JJ ./. 
Using/VBG human/JJ T/NN lymphocytes/NNS and/CC T/NN cell/NN lines/NNS ,/, we/PRP show/VBP that/IN progesterone/NN ,/, at/IN concentrations/NNS found/VBN in/IN the/DT placenta/NN ,/, rapidly/RB and/CC reversibly/RB blocks/VBZ voltage-gated/JJ and/CC calcium-activated/JJ K+/NN channels/NNS (/( KV/NN and/CC KCa/NN ,/, respectively/RB )/) ,/, resulting/VBG in/IN depolarization/NN of/IN the/DT membrane/NN potential/NN ./. 
As/IN a/DT result/NN ,/, Ca2+/NN signaling/NN and/CC nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) -driven/JJ gene/NN expression/NN are/VBP inhibited/VBN ./. 
Progesterone/NN acts/VBZ distally/RB to/TO the/DT initial/JJ steps/NNS of/IN T/NN cell/NN receptor/NN (/( TCR/NN )/) -mediated/JJ signal/NN transduction/NN ,/, since/IN it/PRP blocks/VBZ sustained/JJ Ca2+/NN signals/NNS after/IN thapsigargin/NN stimulation/NN ,/, as/RB well/RB as/IN oscillatory/JJ Ca2+/NN signals/NNS ,/, but/CC not/RB the/DT Ca2+/NN transient/JJ after/IN TCR/NN stimulation/NN ./. 
K+/NN channel/NN blockade/NN by/IN progesterone/NN is/VBZ specific/JJ ;/: other/JJ steroid/NN hormones/NNS had/VBD little/JJ or/CC no/DT effect/NN ,/, although/IN the/DT progesterone/NN antagonist/NN RU/NN 486/CD also/RB blocked/VBD KV/NN and/CC KCa/NN channels/NNS ./. 
Progesterone/NN effectively/RB blocked/VBD a/DT broad/JJ spectrum/NN of/IN K+/NN channels/NNS ,/, reducing/VBG both/CC Kv1.3/NN and/CC charybdotoxin-resistant/JJ components/NNS of/IN KV/NN current/NN and/CC KCa/NN current/NN in/IN T/NN cells/NNS ,/, as/RB well/RB as/IN blocking/VBG several/JJ cloned/VBN KV/NN channels/NNS expressed/VBN in/IN cell/NN lines/NNS ./. 
Progesterone/NN had/VBD little/JJ or/CC no/DT effect/NN on/IN a/DT cloned/VBN voltage-gated/JJ Na+/NN channel/NN ,/, an/DT inward/JJ rectifier/NN K+/NN channel/NN ,/, or/CC on/IN lymphocyte/NN Ca2+/NN and/CC Cl-/NN channels/NNS ./. 
We/PRP propose/VBP that/IN direct/JJ inhibition/NN of/IN K+/NN channels/NNS in/IN T/NN cells/NNS by/IN progesterone/NN contributes/VBZ to/TO progesterone-induced/JJ immunosuppression/NN ./. 
UI/LS -/: 99008517/CD 
TI/LS -/: A/DT mouse/NN carrying/VBG genetic/JJ defect/NN in/IN the/DT choice/NN between/IN T/NN and/CC B/NN lymphocytes/NNS ./. 
AB/LS -/: Transgenic/JJ mice/NNS with/IN human/JJ CD3epsilon/NN gene/NN have/VBP been/VBN shown/VBN to/TO exhibit/VB early/JJ arrest/NN of/IN T/NN cell/NN development/NN in/IN the/DT thymus/NN ./. 
The/DT present/JJ study/NN shows/VBZ that/IN ,/, instead/RB of/IN T/NN cells/NNS ,/, B/NN cells/NNS are/VBP generated/VBN in/IN the/DT thymus/NN of/IN a/DT line/NN ,/, tg/NN epsilon26/NN ,/, of/IN the/DT human/JJ CD3epsilon/NN transgenic/JJ mice/NNS ./. 
The/DT accumulation/NN of/IN mature/JJ B/NN cells/NNS in/IN the/DT thymus/NN was/VBD found/VBN only/RB in/IN tg/NN epsilon26/NN mice/NNS ,/, not/RB in/IN other/JJ human/JJ CD3epsilon/NN transgenic/JJ mouse/NN lines/NNS or/CC other/JJ T/NN cell-deficient/JJ mice/NNS ,/, including/VBG CD3-epsilon/NN knockout/JJ mice/NNS and/CC TCR-beta/TCR-delta/NN double/JJ knockout/JJ mice/NNS ./. 
Hanging/VBG drop-mediated/JJ transfer/NN into/IN 2-deoxyguanosine-treated/JJ thymus/NN lobes/NNS showed/VBD that/IN lymphoid/JJ progenitor/NN cells/NNS rather/RB than/IN thymus/NN stromal/JJ cells/NNS were/VBD responsible/JJ for/IN abnormal/JJ B/NN cell/NN development/NN in/IN tg/NN epsilon26/NN thymus/NN ,/, and/CC that/IN tg/NN epsilon26/NN fetal/JJ liver/NN cells/NNS were/VBD destined/VBN to/TO become/VB B/NN cells/NNS in/IN normal/JJ thymus/NN even/RB in/IN the/DT presence/NN of/IN normal/JJ progenitor/NN cells/NNS undergoing/VBG T/NN cell/NN development/NN ./. 
These/DT results/NNS indicate/VBP that/IN lymphoid/JJ progenitor/NN cells/NNS in/IN tg/NN epsilon26/NN mice/NNS are/VBP genetically/RB defective/JJ in/IN thymic/JJ choice/NN between/IN T/NN cells/NNS and/CC B/NN cells/NNS ,/, generating/VBG B/NN cells/NNS even/RB in/IN normal/JJ thymus/NN environment/NN ./. 
Interestingly/RB ,/, tg/NN epsilon26/NN thymocytes/NNS expressed/VBD GATA-3/NN and/CC TCF-1/NN ,/, but/CC not/RB LEF-1/NN and/CC PEBP-2alpha/NN ,/, among/IN T/NN cell-specific/JJ transcription/NN factors/NNS that/WDT are/VBP involved/VBN in/IN early/JJ T/NN cell/NN development/NN ,/, indicating/VBG that/IN GATA-3/NN and/CC TCF-1/NN expressed/VBN during/IN thymocyte/NN development/NN do/VBP not/RB necessarily/RB determine/VB the/DT cell/NN fate/NN into/IN T/NN cell/NN lineage/NN ./. 
Thus/RB ,/, tg/NN epsilon26/NN mice/NNS provide/VBP a/DT novel/JJ mouse/NN model/NN in/IN that/IN lineage/NN choice/NN between/IN T/NN and/CC B/NN lymphocytes/NNS is/VBZ genetically/RB defective/JJ ./. 
UI/LS -/: 99003230/CD 
TI/LS -/: Downstream/JJ activation/NN of/IN a/DT TATA-less/JJ promoter/NN by/IN Oct-2/NN ,/, Bob1/NN ,/, and/CC NF-kappaB/NN directs/VBZ expression/NN of/IN the/DT homing/JJ receptor/NN BLR1/NN to/TO mature/JJ B/NN cells/NNS ./. 
AB/LS -/: The/DT chemokine/NN receptor/NN ,/, BLR1/NN ,/, is/VBZ a/DT major/JJ regulator/NN of/IN the/DT microenvironmental/JJ homing/NN of/IN B/NN cells/NNS in/IN lymphoid/JJ organs/NNS ./. 
In/FW vitro/FW studies/NNS identify/VBP three/CD essential/JJ elements/NNS of/IN the/DT TATA-less/JJ blr1/NN core/NN promoter/NN that/WDT confer/VBP cell/NN type-/NN and/CC differentiation-specific/JJ expression/NN in/IN the/DT B/NN cells/NNS of/IN both/CC humans/NNS and/CC mice/NNS ,/, a/DT functional/JJ promoter/NN region/NN (/( -36/CD with/IN respect/NN to/TO the/DT transcription/NN start/NN site/NN )/) ,/, a/DT NF-kappaB/NN motif/NN (/( +44/CD )/) ,/, and/CC a/DT noncanonical/JJ octamer/NN motif/NN (/( +157/CD )/) ./. 
The/DT importance/NN of/IN these/DT sites/NNS was/VBD confirmed/VBN by/IN in/FW vivo/FW studies/NNS in/IN gene-targeted/JJ mice/NNS deficient/JJ of/IN either/CC Oct-2/NN ,/, Bob1/NN ,/, or/CC both/CC NF-kappaB/NN subunits/NNS p50/NN and/CC p52/NN ./. 
In/IN all/DT of/IN these/DT animals/NNS ,/, the/DT expression/NN of/IN BLR1/NN was/VBD reduced/VBN or/CC absent/JJ ./. 
In/IN mice/NNS deficient/JJ only/RB of/IN p52/NF-kappaB/NN ,/, BLR1/NN expression/NN was/VBD unaffected/JJ ./. 
Thus/RB our/PRP$ data/NNS demonstrate/VBP that/IN BLR1/NN is/VBZ a/DT target/NN gene/NN for/IN Oct-2/NN ,/, Bob1/NN ,/, and/CC members/NNS of/IN the/DT NF-kappaB/Rel/NN family/NN and/CC provides/VBZ a/DT link/NN to/TO the/DT impaired/JJ B/NN cell/NN functions/NNS in/IN mice/NNS deficient/JJ for/IN these/DT factors/NNS ./. 
UI/LS -/: 98440543/CD 
TI/LS -/: CD4/NN promoter/NN transactivation/NN by/IN human/JJ herpesvirus/NN 6/CD ./. 
AB/LS -/: The/DT observation/NN that/IN human/JJ herpesvirus/NN 6/CD (/( HHV-6/NN )/) can/MD induce/VB CD4/NN gene/NN transcription/NN and/CC expression/NN in/IN CD4(-)/JJ cells/NNS was/VBD reported/VBN several/JJ years/NNS ago/RB (/( P.Lusso/NNP ,/, A.De/NNP Maria/NNP ,/, M.Malnati/NNP ,/, F.Lori/NNP ,/, S.E.DeRocco/NNP ,/, M./NNP Baseler/NNP ,/, and/CC R.C.Gallo/NNP ,/, Nature/NNP 349/CD :/: 533-535/CD ,/, 1991/CD )/) and/CC subsequently/RB confirmed/VBN (/( P.Lusso/NNP ,/, M.S.Malnati/NNP ,/, A.Garzino-Demo/NNP ,/, R.W.Crowley/NNP ,/, E./NNP O.Long/NNP ,/, and/CC R.C.Gallo/NNP ,/, Nature/NNP 362/CD :/: 458-462/CD ,/, 1993/CD ;/: G.Furlini/NNP ,/, M./NNP Vignoli/NNP ,/, E.Ramazzotti/NNP ,/, M.C.Re/NNP ,/, G.Visani/NNP ,/, and/CC M.LaPlaca/NNP ,/, Blood/NNP 87/CD :/: 4737-4745/CD ,/, 1996/CD )/) ./. 
Our/PRP$ objective/JJ was/VBD to/TO identify/VB the/DT mechanisms/NNS underlying/VBG such/JJ phenomena/NNS ./. 
Using/VBG reporter/NN gene/NN constructs/NNS driven/VBN by/IN the/DT CD4/NN promoter/NN ,/, we/PRP report/VBP that/IN HHV-6/NN can/MD efficiently/RB transactivate/VB such/JJ genetic/JJ elements/NNS ./. 
Activation/NN of/IN the/DT CD4/NN promoter/NN occurs/VBZ in/IN the/DT presence/NN of/IN the/DT viral/JJ DNA/NN polymerase/NN inhibitor/NN phosphonoformic/JJ acid/NN ,/, which/WDT limits/VBZ expression/NN to/TO the/DT immediate-early/JJ and/CC early/JJ classes/NNS of/IN viral/JJ genes/NNS ./. 
Using/VBG deletion/NN mutants/NNS and/CC specific/JJ CD4/NN promoter/NN mutants/NNS ,/, we/PRP identified/VBD an/DT ATF/CRE/NN binding/NN site/NN located/JJ at/IN nucleotides/NNS -67/CD to/TO -60/CD upstream/JJ of/IN the/DT CD4/NN gene/NN transcription/NN start/NN site/NN that/WDT is/VBZ important/JJ for/IN HHV-6/NN transactivation/NN ./. 
The/DT ATF/CRE/NN site/NN is/VBZ also/RB essential/JJ for/IN CD4/NN promoter/NN activation/NN by/IN forskolin/NN ,/, an/DT activator/NN of/IN adenylate/NN cyclase/NN ./. 
Using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS and/CC specific/JJ antibodies/NNS ,/, we/PRP showed/VBD that/IN CREB-1/NN binds/VBZ specifically/RB to/TO the/DT -79/CD to/TO -52/CD region/NN of/IN the/DT CD4/NN promoter/NN ./. 
Last/RB ,/, we/PRP have/VBP identified/VBN two/CD open/JJ reading/NN frames/NNS (/( ORFs/NNS )/) of/IN HHV-6/NN ,/, U86/NN and/CC U89/NN from/IN the/DT immediate-early/JJ locus/NN A/NN ,/, that/WDT can/MD transactivate/VB the/DT CD4/NN promoter/NN in/IN HeLa/NN cells/NNS ./. 
However/RB ,/, transactivation/NN of/IN the/DT CD4/NN promoter/NN by/IN ORFs/NNS U86/NN and/CC U89/NN is/VBZ independent/JJ of/IN the/DT CRE/NN element/NN ,/, suggesting/VBG that/IN additional/JJ HHV-6/NN ORFs/NNS are/VBP likely/JJ to/TO contribute/VB to/TO CD4/NN gene/NN activation/NN ./. 
Taken/VBN together/RB ,/, our/PRP$ results/NNS will/MD help/VB to/TO understand/VB the/DT complex/JJ interactions/NNS occurring/VBG between/IN HHV-6/NN and/CC the/DT CD4/NN promoter/NN and/CC provide/VB additional/JJ information/NN regarding/VBG the/DT class/NN of/IN transcription/NN factors/NNS involved/VBN in/IN the/DT control/NN of/IN CD4/NN gene/NN expression/NN ./. 
UI/LS -/: 98426244/CD 
TI/LS -/: The/DT PEBP2betaMYH11/NN fusion/NN created/VBN by/IN Inv(16)(p13;q22)/NN in/IN myeloid/JJ leukemia/NN impairs/VBZ neutrophil/NN maturation/NN and/CC contributes/VBZ to/TO granulocytic/JJ dysplasia/NN ./. 
AB/LS -/: Chromosomal/JJ translocations/NNS involving/VBG the/DT genes/NNS encoding/VBG the/DT alpha/NN and/CC beta/NN subunits/NNS of/IN the/DT Pebp2/Cbf/NN transcription/NN factor/NN have/VBP been/VBN associated/VBN with/IN human/JJ acute/JJ myeloid/JJ leukemia/NN and/CC the/DT preleukemic/JJ condition/NN ,/, myelodysplasia/NN ./. 
Inv(16)(p13;q22)/NN fuses/VBZ the/DT gene/NN encoding/VBG the/DT beta/NN subunit/NN of/IN Pebp2/NN to/TO the/DT MYH11/NN gene/NN encoding/VBG a/DT smooth/JJ muscle/NN myosin/NN heavy/NN chain/NN (/( Smmhc/NN )/) ./. 
To/TO examine/VB the/DT effect/NN of/IN the/DT inv(16)(p13;q22)/NN on/IN myelopoiesis/NN ,/, we/PRP used/VBD the/DT hMRP8/NN promoter/NN element/NN to/TO generate/VB transgenic/JJ mice/NNS expressing/VBG the/DT Pebp2betaSmmhc/NN chimeric/JJ fusion/NN protein/NN in/IN myeloid/JJ cells/NNS ./. 
Neutrophil/NN maturation/NN was/VBD impaired/JJ in/IN PEBP2betaMYH11/NN transgenic/JJ mice/NNS ./. 
Although/IN the/DT transgenic/JJ mice/NNS had/VBD normal/JJ numbers/NNS of/IN circulating/VBG neutrophils/NNS ,/, their/PRP$ bone/NN marrow/NN contained/VBD increased/VBN numbers/NNS of/IN immature/JJ neutrophilic/JJ cells/NNS ,/, which/WDT exhibited/VBD abnormal/JJ characteristics/NNS ./. 
In/IN addition/NN ,/, PEBP2betaMYH11/NN inhibited/VBD neutrophilic/JJ differentiation/NN in/IN colonies/NNS derived/VBN from/IN hematopoietic/JJ progenitors/NNS ./. 
Coexpression/NN of/IN both/CC PEBP2betaMYH11/NN and/CC activated/VBN NRAS/NNS induced/VBD a/DT more/RBR severe/JJ phenotype/NN characterized/VBN by/IN abnormal/JJ nuclear/JJ morphology/NN indicative/JJ of/IN granulocytic/JJ dysplasia/NN ./. 
These/DT results/NNS show/VBP that/IN PEBP2betaMYH11/NN can/MD impair/VB neutrophil/NN development/NN and/CC provide/VBP evidence/NN that/IN alterations/NNS of/IN Pebp2/NN can/MD contribute/VB to/TO the/DT genesis/NN of/IN myelodysplasia/NN ./. 
UI/LS -/: 98414302/CD 
TI/LS -/: Human/JJ T/NN cell/NN leukemia/NN virus-I/NN (/( HTLV-I/NN )/) Tax-mediated/JJ apoptosis/NN in/IN activated/VBN T/NN cells/NNS requires/VBZ an/DT enhanced/VBN intracellular/JJ prooxidant/JJ state/NN ./. 
AB/LS -/: We/PRP have/VBP shown/VBN that/IN an/DT estradiol-dependent/JJ activation/NN of/IN human/JJ T/NN cell/NN leukemia/NN virus-I/NN Tax/NN leads/VBZ to/TO the/DT inhibition/NN of/IN cell/NN proliferation/NN and/CC to/TO the/DT induction/NN of/IN apoptosis/NN ./. 
The/DT present/JJ study/NN demonstrates/VBZ that/IN a/DT hormone-dependent/JJ activation/NN of/IN Tax/NN promotes/VBZ an/DT enhanced/VBN prooxidant/JJ state/NN in/IN stably/RB transfected/VBN Jurkat/NN cells/NNS as/IN measured/VBN by/IN changes/NNS in/IN the/DT intracellular/JJ levels/NNS of/IN glutathione/NN and/CC H2O2/NN ;/: these/DT changes/NNS are/VBP followed/VBN by/IN apoptotic/JJ cell/NN death/NN ./. 
Additional/JJ stimulation/NN of/IN the/DT CD3/TCR/NN pathway/NN enhances/VBZ the/DT oxidative/JJ and/CC apoptotic/JJ effects/NNS ./. 
Both/CC Tax-mediated/JJ apoptosis/NN and/CC oxidative/JJ stress/NN can/MD be/VB potently/RB suppressed/VBN by/IN antioxidants/NNS ,/, as/IN is/VBZ seen/VBN with/IN the/DT administration/NN of/IN recombinant/JJ thioredoxin/NN (/( adult/JJ T/NN cell/NN leukemia-derived/JJ factor/NN )/) or/CC pyrrolidine/NN dithiocarbamate/NN ./. 
Hormone-induced/JJ Tax/NN activation/NN induces/VBZ a/DT long-lasting/JJ activation/NN of/IN NF-kappaB/NN ,/, which/WDT is/VBZ a/DT major/JJ target/NN of/IN reactive/JJ oxygen/NN intermediates/NNS ./. 
The/DT long-term/JJ exposure/NN of/IN Jurkat/NN cells/NNS to/TO hormone/NN eventually/RB results/VBZ in/IN a/DT selection/NN of/IN cell/NN clones/NNS that/WDT have/VBP lost/VBN Tax/NN activity/NN ./. 
A/DT subsequent/JJ transfection/NN of/IN these/DT apparently/RB "/`` nonresponsive/JJ "/'' clones/NNS allows/VBZ the/DT recovery/NN of/IN Tax/NN responses/NNS in/IN these/DT cells/NNS ./. 
Our/PRP$ observations/NNS indicate/VBP that/IN changes/NNS in/IN the/DT intracellular/JJ redox/NN status/NN may/MD be/VB a/DT determining/VBG factor/NN in/IN Tax-mediated/JJ DNA/NN damage/NN ,/, apoptosis/NN ,/, and/CC selection/NN against/IN the/DT long-term/JJ expression/NN of/IN Tax/NN function/NN ./. 
UI/LS -/: 98401161/CD 
TI/LS -/: An/DT allosteric/JJ drug/NN ,/, o,o'-bismyristoyl/NN thiamine/NN disulfide/NN ,/, suppresses/VBZ HIV-1/NN replication/NN through/IN prevention/NN of/IN nuclear/JJ translocation/NN of/IN both/CC HIV-1/NN Tat/NN and/CC NF-kappa/NN B/NN ./. 
AB/LS -/: The/DT efficacy/NN of/IN o/NN ,/, o'-bismyristoyl/NN thiamine/NN disulfide/NN (/( BMT/NN )/) was/VBD examined/VBN in/IN detail/NN against/IN HIV-1/NN laboratory/JJ isolates/NNS (/( HTLV-IIIB/NN ,/, JRFL/NNP ,/, and/CC MN/NN )/) ,/, primary/JJ isolates/NNS (/( KMT/NN and/CC KMO/NN )/) ,/, and/CC simian/JJ immunodeficiency/NN virus/NN (/( SIVmac251/NN )/) in/FW vitro/FW ./. 
BMT/NN inhibited/VBD the/DT replication/NN of/IN HIV-1/NN in/IN both/CC laboratory/JJ and/CC primary/JJ isolates/NNS in/FW vitro/FW ./. 
In/IN addition/NN ,/, BMT/NN exhibited/VBD antiviral/JJ activity/NN against/IN SIVmac251/NN ./. 
Minimizing/VBG energy/NN studies/NNS of/IN BMT/NN structure/NN reveal/VBP that/IN a/DT trans-disulfide/NN of/IN thiamine/NN (/( holo/NN drug/NN )/) disulfide/NN (/( TDS/NN ,/, protodrug/NN )/) is/VBZ allosterically/RB transited/VBN to/TO the/DT reactive/JJ twisted/JJ disulfide/NN of/IN BMT/NN (/( allo/NN drug/NN )/) by/IN o/NN ,/, o'-bismyristoyl/JJ esterification/NN of/IN TDS/NN ./. 
BMT/NN inhibits/VBZ nuclear/JJ translocation/NN of/IN both/CC HIV-1/NN transactivator/NN (/( TAT/NN )/) and/CC the/DT cellular/JJ transcriptional/JJ nuclear/JJ factor-KB/NN (/( NF-kappa/NN B/NN )/) ,/, resulting/VBG in/IN the/DT suppression/NN of/IN HIV-1/NN replication/NN ./. 
UI/LS -/: 98389427/CD 
TI/LS -/: Glucocorticoid-induced/JJ apoptosis/NN and/CC regulation/NN of/IN NF-kappaB/NN activity/NN in/IN human/JJ leukemic/JJ T/NN cells/NNS ./. 
AB/LS -/: Glucocorticoid-induced/JJ apoptosis/NN was/VBD investigated/VBN in/IN glucocorticoid-sensitive/JJ 6TG1.1/NN and/CC resistant/JJ ICR27TK.3/NN human/JJ leukemic/JJ T/NN cells/NNS ./. 
Following/VBG glucocorticoid/NN treatment/NN of/IN 6TG1.1/NN cells/NNS ,/, chromatin/NN fragmentation/NN was/VBD observed/VBN after/IN a/DT delay/NN of/IN 24/CD h/NN ./. 
Fragmentation/NN was/VBD not/RB observed/VBN in/IN ICR27TK.3/NN cells/NNS containing/VBG mutant/JJ glucocorticoid/NN receptors/NNS (/( L753F/NN )/) that/WDT are/VBP activation-deficient/JJ but/CC retain/VBP the/DT ability/NN to/TO repress/VB AP-1/NN activity/NN ./. 
Nor/CC was/VBD fragmentation/NN observed/VBN after/IN treatment/NN with/IN RU38486/NN ,/, indicating/VBG that/IN repression/NN of/IN AP-1/NN activity/NN is/VBZ not/RB involved/VBN ./. 
As/IN described/VBN in/IN other/JJ systems/NNS ,/, fragmentation/NN required/VBD ongoing/JJ protein/NN synthesis/NN ./. 
However/RB ,/, inhibition/NN of/IN protein/NN synthesis/NN with/IN cycloheximide/NN anytime/RB during/IN the/DT first/JJ 18/CD h/NN of/IN steroid/NN treatment/NN was/VBD as/IN effective/JJ in/IN blocking/VBG chromatin/NN fragmentation/NN as/IN inhibition/NN for/IN the/DT entire/JJ period/NN ,/, suggesting/VBG that/IN synthesis/NN of/IN a/DT component/NN with/IN a/DT rapid/JJ turnover/NN rate/NN is/VBZ required/VBN ./. 
Dexamethasone/NN treatment/NN completely/RB blocked/VBD 12-O-tetradecanoylphorbol/NN 13-acetate/NN induction/NN of/IN nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) activity/NN and/CC elicited/VBD an/DT increase/NN in/IN the/DT amount/NN of/IN immunoreactive/JJ IkappaB/NN alpha/NN in/IN sensitive/JJ 6TG1.1/NN cells/NNS but/CC not/RB in/IN resistant/JJ ICR27TK.3/NN cells/NNS ./. 
In/IN addition/NN ,/, mild/JJ detergent/NN treatment/NN of/IN cell/NN extracts/NNS indicated/VBD that/IN a/DT substantial/JJ amount/NN of/IN cytoplasmic/JJ NF-kappaB/NN is/VBZ complexed/VBN with/IN IkappaB/NN alpha/NN or/CC some/DT other/JJ inhibitory/JJ factor/NN ./. These/DT results/NNS suggest/VBP that/IN induction/NN of/IN a/DT labile/JJ inhibitory/JJ factor/NN such/JJ as/IN IkappaB/NN alpha/NN may/MD contribute/VB to/TO glucocorticoid-induced/JJ apoptosis/NN ./. 
UI/LS -/: 98379695/CD 
TI/LS -/: Inhibition/NN of/IN HIV-1/NN replication/NN by/IN combination/NN of/IN a/DT novel/JJ inhibitor/NN of/IN TNF-alpha/NN with/IN AZT/NN ./. 
AB/LS -/: The/DT small/JJ molecule/NN S9a/NN was/VBD derived/VBN from/IN an/DT established/JJ tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) inhibitor/NN (/( Canventol/NN )/) by/IN replacement/NN of/IN the/DT isopropylidine/NN group/NN with/IN a/DT phenyl/NN ring/NN ./. 
S9a/NN at/IN 10/CD to/TO 100/CD nM/NN inhibited/VBD HIV/NN production/NN as/RB potently/RB as/IN 3'-azido-3'-deoxythymidine/NN (/( AZT/NN )/) ,/, an/DT inhibitor/NN of/IN viral/JJ reverse/JJ transcriptase/NN ./. 
Furthermore/RB ,/, S9a/NN and/CC AZT/NN in/IN combination/NN ,/, at/IN noncytoxic/JJ concentrations/NNS strongly/RB inhibited/VBD HIV-1/NN replication/NN that/WDT was/VBD more/RBR than/IN additive/JJ and/CC substantially/RB prolonged/VBD the/DT appearance/NN of/IN virus/NN both/CC in/IN acutely/RB infected/JJ CD4+/JJ lymphocytes/NNS (/( SupT/NN )/) in/IN culture/NN and/CC in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMCs/NNS )/) infected/VBN with/IN a/DT primary/JJ HIV-1/NN isolate/NN ./. 
S9a/NN inhibited/VBD TNF-alpha/NN promoter-driven/JJ reporter/NN gene/NN activity/NN ./. 
It/PRP was/VBD proposed/VBN that/IN the/DT mechanism/NN of/IN antiviral/JJ action/NN of/IN S9a/NN was/VBD on/IN the/DT host/NN cell/NN ,/, by/IN blocking/VBG TNF-alpha/NN transcription/NN via/IN a/DT Tat-induced/JJ tar-independent/JJ loop/NN ,/, which/WDT decreases/VBZ downstream/JJ NF-kappaB/NN activation/NN of/IN HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ./. 
S9a/NN was/VBD superior/JJ to/TO the/DT first/JJ generation/NN compound/JJ Canventol/NN ,/, which/WDT was/VBD superior/JJ to/TO the/DT natural/JJ compound/NN sarcophytol/NN A/NN ,/, demonstrating/VBG that/IN further/JJ structure-based/JJ enhancement/NN of/IN potency/NN of/IN these/DT compounds/NNS is/VBZ feasible/JJ ./. 
This/DT study/NN suggests/VBZ a/DT therapeutic/JJ approach/NN against/IN AIDS/NN by/IN application/NN of/IN two/CD drugs/NNS ,/, one/CD against/IN a/DT cellular/JJ and/CC the/DT other/JJ a/DT viral/JJ target/NN ,/, which/WDT may/MD provide/VB an/DT approach/NN to/TO the/DT problem/NN of/IN frequent/JJ emergence/NN of/IN resistant/JJ variants/NNS to/TO combinations/NNS of/IN drugs/NNS that/WDT target/VBP only/RB HIV/NN genes/NNS ./. 
UI/LS -/: 98376488/CD 
TI/LS -/: Highly/RB polarized/VBN HLA/NN class/NN II/CD antigen/NN processing/NN and/CC presentation/NN by/IN human/JJ intestinal/JJ epithelial/JJ cells/NNS ./. 
AB/LS -/: The/DT high/JJ concentration/NN of/IN foreign/JJ antigen/NN in/IN the/DT lumen/NN of/IN the/DT gastrointestinal/JJ tract/NN is/VBZ separated/VBN from/IN the/DT underlying/VBG lymphocytes/NNS by/IN a/DT single/JJ cell/NN layer/NN of/IN polarized/VBN epithelium/NN ./. 
Intestinal/JJ epithelial/JJ cells/NNS can/MD express/VB HLA/NN class/NN II/CD antigens/NNS and/CC may/MD function/VB as/IN antigen-presenting/JJ cells/NNS to/TO CD4(+)/JJ T/NN cells/NNS within/IN the/DT intestinal/JJ mucosa/NN ./. 
Using/VBG tetanus/NN toxoid/NN specific/JJ and/CC HLA-DR-restricted/JJ T/NN lymphocytes/NNS ,/, we/PRP show/VBP that/IN polarized/VBN intestinal/JJ epithelial/JJ cells/NNS directed/VBN to/TO express/VB HLA-DR/NN molecules/NNS are/VBP able/JJ to/TO initiate/VB class/NN II/CD processing/NN only/RB after/IN internalization/NN of/IN antigen/NN from/IN their/PRP$ apical/JJ surface/NN ./. 
Coexpression/NN of/IN the/DT class/NN II/CD transactivator/NN CIITA/NN in/IN these/DT cells/NNS ,/, which/WDT stimulates/VBZ highly/RB efficient/JJ class/NN II/CD processing/NN without/IN the/DT characteristic/JJ decline/NN in/IN barrier/NN function/NN seen/VBN in/IN polarized/VBN monolayers/NNS treated/VBN with/IN the/DT proinflammatory/JJ cytokine/NN gamma-IFN/NN ,/, facilitates/VBZ antigen/NN processing/NN from/IN the/DT basolateral/JJ surface/NN ./. 
In/IN both/DT cases/NNS ,/, peptide/NN presentation/NN to/TO T/NN cells/NNS via/IN class/NN II/CD molecules/NNS was/VBD restricted/JJ to/TO the/DT basolateral/JJ surface/NN ./. 
These/DT data/NNS indicate/VBP a/DT highly/RB polarized/VBN functional/JJ architecture/NN for/IN antigen/NN processing/NN and/CC presentation/NN by/IN intestinal/JJ epithelial/JJ cells/NNS ,/, and/CC suggest/VBP that/IN the/DT functional/JJ outcome/NN of/IN antigen/NN processing/NN by/IN the/DT intestinal/JJ epithelium/NN is/VBZ both/CC dependent/JJ on/IN the/DT cellular/JJ surface/NN at/IN which/WDT the/DT foreign/JJ antigen/NN is/VBZ internalized/VBN and/CC by/IN the/DT underlying/JJ degree/NN of/IN mucosal/JJ inflammation/NN 
UI/LS -/: 99032837/CD 
TI/LS -/: Tobacco/NN smoke/NN induces/VBZ coordinate/JJ activation/NN of/IN HSF/NN and/CC inhibition/NN of/IN NFkappaB/NN in/IN human/JJ monocytes/NNS :/: effects/NNS on/IN TNFalpha/NN release/NN ./. 
AB/LS -/: Tobacco/NN smoke/NN (/( TS/NN )/) exposure/NN is/VBZ a/DT major/JJ risk/NN factor/NN for/IN human/JJ disease/NN ,/, and/CC macrophages/NNS of/IN healthy/JJ smokers/NNS have/VBP a/DT depressed/VBN capacity/NN to/TO release/VB cytokines/NNS ,/, including/VBG tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) alpha/NN ./. 
TS/NN induces/VBZ the/DT synthesis/NN of/IN heat/NN shock/NN (/( HS/NN )/) /stress/NN proteins/NNS (/( HSP/NN )/) ,/, and/CC ,/, in/IN particular/JJ ,/, of/IN Hsp70/NN ./. 
We/PRP determined/VBD whether/IN Hsp70/NN induction/NN by/IN TS/NN was/VBD mediated/VBN by/IN the/DT activation/NN of/IN the/DT HS/NN transcription/NN factor/NN ,/, HSF/NN ./. 
HSF/NN activation/NN has/VBZ been/VBN shown/VBN to/TO inhibit/VB NFkappaB/NN ./. 
Thus/RB ,/, we/PRP also/RB determined/VBD the/DT effects/NNS of/IN TS/NN on/IN NFkappaB/NN ./. 
U937/NN cells/NNS and/CC human/JJ peripheral/JJ blood/NN monocytes/NNS were/VBD exposed/VBN to/TO TS/NN ,/, binding/NN activities/NNS of/IN the/DT respective/JJ transcription/NN factors/NNS were/VBD analyzed/VBN ,/, and/CC Hsp70/NN expression/NN and/CC TNFalpha/NN release/NN were/VBD determined/VBN in/IN parallel/NN ./. 
TS/NN activated/VBD HSF/NN ,/, which/WDT was/VBD associated/VBN with/IN Hsp70/NN overexpression/NN and/CC inhibition/NN of/IN NFkappaB/NN binding/NN activity/NN and/CC TNFalpha/NN release/NN ./. 
The/DT altered/JJ cytokine/NN profile/NN observed/VBN in/IN smokers/NNS may/MD relate/VB to/TO an/DT HSF/Hsp70-mediated/JJ inhibition/NN of/IN NFkappaB/NN activity/NN ./. 
Copyright/NN 1998/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99016857/CD 
TI/LS -/: [/( Molecular/JJ mechanism/NN of/IN cytokine/NN gene/NN expression/NN in/IN Th1/NN and/CC Th2/NN ]/) 
AB/LS -/: Upon/IN activation/NN by/IN antigens/NNS ,/, helper/NN T/NN cells/NNS differentiate/VBP into/IN one/CD of/IN several/JJ subsets/NNS ,/, characterized/VBN by/IN their/PRP$ distinct/JJ cytokine-production/NN patterns/NNS ./. 
Among/IN these/DT subsets/NNS ,/, Th1/NN cells/NNS are/VBP known/VBN to/TO activate/VB cellular/JJ immunity/NN resulting/VBG in/IN inflammatory/JJ response/NN ,/, whereas/IN Th2/NN cells/NNS induce/VBP humoral/JJ and/CC allergic/JJ responses/NNS and/CC suppress/VBP inflammation/NN ./. 
Th1/NN and/CC Th2/NN effector/NN functions/NNS and/CC their/PRP$ development/NN are/VBP attributable/JJ to/TO their/PRP$ distinct/JJ cytokine/NN expression/NN patterns/NNS ./. 
Recent/JJ reports/NNS have/VBP demonstrated/VBN that/IN differential/JJ expression/NN of/IN cell/NN surface/NN molecules/NNS ,/, such/JJ as/IN adhesion/NN molecule/NN and/CC chemokine/NN receptor/NN ,/, is/VBZ involved/VBN in/IN their/PRP$ recruitment/NN into/IN target/NN tissues/NNS ./. 
It/PRP is/VBZ ,/, therefore/RB ,/, suggested/VBN that/IN clarification/NN of/IN the/DT mechanisms/NNS of/IN differential/JJ gene/NN expression/NN in/IN Th1/Th2/NN should/MD lead/VB to/TO rational/JJ strategies/NNS for/IN manipulating/VBG pathological/JJ immune/JJ responses/NNS ./. 
Activation/NN of/IN helper/NN T/NN cells/NNS mediated/VBN by/IN the/DT T/NN cell/NN receptor/NN induces/VBZ a/DT series/NN of/IN biochemical/JJ events/NNS ./. 
Among/IN them/PRP ,/, both/CC the/DT activation/NN of/IN PKC/Ras-/NN and/CC CaM/CN-mediated/JJ pathways/NNS play/VBP a/DT central/JJ role/NN in/IN the/DT signal/NN transduction/NN of/IN cytokine/NN gene/NN expression/NN ./. 
Closer/JJR examination/NN using/VBG non-transformed/JJ murine/JJ Th1/NN and/CC Th2/NN clones/NNS suggested/VBD that/IN a/DT balance/NN between/IN the/DT activities/NNS of/IN the/DT two/CD signaling/NN pathways/NNS contributes/VBZ to/TO cytokine/NN gene/NN expression/NN ./. 
We/PRP propose/VBP that/IN one/CD of/IN the/DT targets/NNS of/IN PGE2/NN ,/, whose/WP$ effect/NN distinguishes/VBZ Th1/NN from/IN Th2/NN ,/, resides/VBZ in/IN the/DT downstream/JJ PKC/Ras-mediated/JJ pathway/NN ./. 
UI/LS -/: 99008372/CD 
TI/LS -/: Signalling/NN into/IN the/DT T-cell/NN nucleus/NN :/: NFAT/NN regulation/NN ./. 
AB/LS -/: The/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) plays/VBZ an/DT important/JJ role/NN in/IN T-cell/NN biology/NN ./. 
Activation/NN of/IN T/NN cells/NNS results/VBZ in/IN the/DT rapid/JJ calcineurin-dependent/JJ translocation/NN of/IN NFAT/NN transcription/NN factors/NNS from/IN the/DT cytoplasm/NN to/TO the/DT nucleus/NN ./. 
This/DT translocation/NN process/NN coupled/VBN to/TO the/DT subsequent/JJ active/JJ maintenance/NN of/IN NFAT/NN in/IN the/DT nucleus/NN compartment/NN is/VBZ critical/JJ for/IN the/DT induction/NN of/IN expression/NN of/IN several/JJ genes/NNS encoding/VBG cytokines/NNS and/CC membrane/NN proteins/NNS that/WDT modulate/VBP immune/JJ responses/NNS ./. 
The/DT molecular/JJ cloning/NN of/IN the/DT NFAT/NN family/NN of/IN transcription/NN factors/NNS has/VBZ facilitated/VBN rapid/JJ progress/NN in/IN the/DT understanding/NN of/IN the/DT signalling/NN mechanisms/NNS that/WDT control/VBP the/DT activity/NN of/IN NFAT/NN ./. 
UI/LS -/: 98455230/CD 
TI/LS -/: Differential/JJ RNA/NN display/NN identifies/VBZ novel/JJ genes/NNS associated/VBN with/IN decreased/VBN vitamin/NN D/NN receptor/NN expression/NN ./. 
AB/LS -/: To/TO characterize/VB further/RB the/DT function/NN of/IN the/DT intracellular/JJ vitamin/NN D/NN receptor/NN (/( VDR/NN )/) ,/, we/PRP have/VBP developed/VBN stable/JJ transfectant/JJ variants/NNS of/IN a/DT vitamin/NN D-responsive/JJ cell/NN line/NN (/( U937/NN )/) which/WDT express/VBP either/CC decreased/VBN or/CC increased/VBN numbers/NNS of/IN VDR/NN ./. 
In/IN this/DT study/NN we/PRP have/VBP analyzed/VBN changes/NNS in/IN gene/NN expression/NN associated/VBN with/IN this/DT variable/JJ VDR/NN expression/NN ./. 
Initial/JJ experiments/NNS indicated/VBD that/IN a/DT 50/CD %/NN decrease/NN in/IN VDR/NN levels/NNS was/VBD associated/VBN with/IN a/DT 2-fold/JJ increase/NN in/IN cell/NN proliferation/NN and/CC a/DT similar/JJ rise/NN in/IN c-myc/NN mRNA/NN expression/NN ./. 
Further/JJ studies/NNS were/VBD carried/VBN out/RP using/VBG differential/JJ RNA/NN display/NN (/( DD/NN )/) ./. 
Sequence/NN analysis/NN of/IN DD/NN products/NNS revealed/VBD two/CD cDNAs/NNS with/IN identity/NN to/TO known/VBN gene/NN products/NNS :/: the/DT catalytic/JJ sub-unit/NN of/IN DNA-protein/JJ kinase/NN (/( DNA-PK(CS)/NN )/) ,/, and/CC the/DT peroxisomal/JJ enzyme/NN 17beta-hydroxysteroid/NN dehydrogenase/NN type/NN IV/CD (/( 17beta-HSD/NN IV/CD )/) ./. 
Northern/NN analysis/NN confirmed/VBD that/IN expression/NN of/IN both/DT mRNAs/NNS was/VBD reduced/VBN in/IN cells/NNS with/IN decreased/VBN numbers/NNS of/IN VDR/NN ./. 
Down-regulation/NN of/IN 17beta-HSD/NN IV/CD mRNA/NN expression/NN was/VBD associated/VBN with/IN enhanced/VBN estradiol/NN inactivation/NN by/IN U937/NN cells/NNS ,/, suggesting/VBG a/DT link/NN between/IN estrogenic/JJ pathways/NNS and/CC cell/NN proliferation/NN ./. 
Further/JJ Northern/NN analyses/NNS indicated/VBD that/IN there/EX was/VBD no/DT significant/JJ change/NN in/IN 17beta-HSD/NN IV/CD or/CC DNA-PK(CS)/NN mRNA/NN levels/NNS following/VBG treatment/NN with/IN 1,25(OH)2D3/NN ,/, although/IN expression/NN of/IN both/DT genes/NNS varied/VBD with/IN changes/NNS in/IN cell/NN proliferation/NN ./. 
These/DT data/NNS suggest/VBP that/IN ,/, in/IN addition/NN to/TO its/PRP$ established/JJ role/NN as/IN a/DT hormone-dependent/JJ trans-activator/NN ,/, VDR/NN may/MD influence/VB gene/NN expression/NN by/IN ligand-independent/JJ mechanisms/NNS ./. 
UI/LS -/: 98438501/CD 
TI/LS -/: Prostaglandin/NN E2/NN Up-regulates/VBZ HIV-1/NN long/JJ terminal/JJ repeat-driven/JJ gene/NN activity/NN in/IN T/NN cells/NNS via/IN NF-kappaB-dependent/JJ and/CC -independent/JJ signaling/NN pathways/NNS ./. 
AB/LS -/: Replication/NN of/IN human/JJ immunodeficiency/NN virus/NN type-1/NN (/( HIV-1/NN )/) is/VBZ highly/RB dependent/JJ on/IN the/DT state/NN of/IN activation/NN of/IN the/DT infected/JJ cells/NNS and/CC is/VBZ modulated/VBN by/IN interactions/NNS between/IN viral/JJ and/CC host/NN cellular/JJ factors/NNS ./. 
Prostaglandin/NN E2/NN (/( PGE2/NN )/) ,/, a/DT pleiotropic/JJ immunomodulatory/JJ molecule/NN ,/, is/VBZ observed/VBN at/IN elevated/JJ levels/NNS during/IN HIV-1/NN infection/NN as/RB well/RB as/IN during/IN the/DT course/NN of/IN other/JJ pathogenic/JJ infections/NNS ./. 
In/IN 1G5/NN ,/, a/DT Jurkat-derived/JJ T/NN cell/NN line/NN stably/RB transfected/VBN with/IN a/DT luciferase/NN gene/NN driven/VBN by/IN HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ,/, we/PRP found/VBD that/IN PGE2/NN markedly/RB enhanced/VBD HIV-1/NN LTR-mediated/JJ reporter/NN gene/NN activity/NN ./. 
Experiments/NNS have/VBP been/VBN conducted/VBN to/TO identify/VB second/JJ messengers/NNS involved/VBN in/IN this/DT PGE2-dependent/JJ up-regulating/VBG effect/NN on/IN the/DT regulatory/JJ element/NN of/IN HIV-1/NN ./. 
In/IN this/DT study/NN ,/, we/PRP present/VBP evidence/NN indicating/VBG that/IN signal/NN transduction/NN pathways/NNS induced/VBN by/IN PGE2/NN necessitate/VBP the/DT participation/NN of/IN cyclic/JJ AMP/NN ,/, protein/NN kinase/NN A/NN ,/, and/CC Ca2+/NN ./. 
Experiments/NNS conducted/VBN with/IN different/JJ HIV-1/NN LTR-based/NN vectors/NNS suggested/VBD that/IN PGE2-mediated/JJ activation/NN effect/NN on/IN HIV-1/NN transcription/NN was/VBD transduced/VBN via/IN both/CC NF-kappaB-dependent/JJ and/CC -independent/JJ signaling/NN pathways/NNS ./. 
The/DT involvement/NN of/IN NF-kappaB/NN in/IN the/DT PGE2-dependent/JJ activating/VBG effect/NN on/IN HIV-1/NN transcription/NN was/VBD further/RB confirmed/VBN using/VBG a/DT kappaB-regulated/JJ luciferase/NN encoding/NN vector/NN and/CC by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ./. 
Results/NNS from/IN Northern/NN blot/NN and/CC flow/NN cytometric/JJ analyses/NNS ,/, as/RB well/RB as/IN the/DT use/NN of/IN a/DT selective/JJ antagonist/NN indicated/VBD that/IN PGE2/NN modulation/NN of/IN HIV-1/NN LTR-driven/JJ reporter/NN gene/NN activity/NN in/IN studied/VBN T/NN lymphoid/JJ cells/NNS is/VBZ transduced/VBN via/IN the/DT EP4/NN receptor/NN subtype/NN ./. 
These/DT results/NNS suggest/VBP that/IN secretion/NN of/IN PGE2/NN by/IN macrophages/NNS in/IN response/NN to/TO infection/NN or/CC inflammatory/JJ activators/NNS could/MD induce/VB signaling/NN events/NNS resulting/VBG in/IN activation/NN of/IN proviral/JJ DNA/NN present/JJ into/IN T/NN cells/NNS latently/RB infected/VBN with/IN HIV-1/NN ./. 
UI/LS -/: 98422270/CD 
TI/LS -/: Activation/NN of/IN distinct/JJ transcription/NN factors/NNS in/IN neutrophils/NNS by/IN bacterial/JJ LPS/NN ,/, interferon-gamma/NN ,/, and/CC GM-CSF/NN and/CC the/DT necessity/NN to/TO overcome/VB the/DT action/NN of/IN endogenous/JJ proteases/NNS ./. 
AB/LS -/: Human/JJ neutrophils/NNS can/MD be/VB induced/VBN to/TO actively/RB transcribe/VB a/DT number/NN of/IN early-response/JJ genes/NNS ,/, in/IN particular/JJ those/DT encoding/VBG cytokines/NNS ,/, chemokines/NNS ,/, and/CC the/DT high-affinity/JJ surface/NN receptor/NN for/IN IgG/NN ,/, FcgammaRI/NN ./. 
Although/IN little/JJ is/VBZ known/VBN to/TO date/NN about/IN the/DT regulation/NN of/IN gene/NN transcription/NN in/IN neutrophils/NNS ,/, several/JJ indications/NNS point/VBP to/TO a/DT role/NN for/IN distinct/JJ transcription/NN factors/NNS ,/, such/JJ as/IN members/NNS of/IN the/DT NF-kappaB/NN and/CC STAT/NN families/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP investigated/VBD whether/IN these/DT transcription/NN factors/NNS become/VBP activated/VBN under/IN stimulatory/JJ conditions/NNS which/WDT are/VBP known/VBN to/TO induce/VB gene/NN transcription/NN in/IN neutrophils/NNS ./. 
Unexpectedly/RB ,/, we/PRP found/VBD that/IN conventional/JJ procedures/NNS employed/VBN to/TO prepare/VB cellular/JJ extracts/NNS cause/VBP the/DT release/NN of/IN proteolytic/JJ activities/NNS that/WDT are/VBP normally/RB stored/VBN in/IN intracellular/JJ granules/NNS ,/, resulting/VBG in/IN the/DT degradation/NN of/IN various/JJ NF-kappaB/Rel/NN and/CC STAT/NN proteins/NNS ./. 
To/TO circumvent/VB this/DT problem/NN ,/, we/PRP developed/VBD an/DT alternative/JJ procedure/NN which/WDT allowed/VBD us/PRP to/TO show/VB that/IN in/IN neutrophils/NNS ,/, LPS/NN and/CC TNFalpha/NN induce/VBP a/DT NF-kappaB/NN DNA-binding/JJ activity/NN which/WDT essentially/RB consists/VBZ of/IN p50/RelA/NN dimers/NNS ,/, and/CC that/IN IFNgamma/NN promotes/VBZ the/DT binding/NN of/IN STAT1/NN homodimers/NNS to/TO the/DT IFNgamma/NN response/NN region/NN of/IN the/DT FcgammaRI/NN promoter/NN ./. 
Moreover/RB ,/, we/PRP report/VBP that/IN neutrophil/NN stimulation/NN with/IN GM-CSF/NN results/VBZ in/IN the/DT formation/NN of/IN a/DT STAT5-containing/JJ DNA-binding/JJ activity/NN ./. 
Collectively/RB ,/, the/DT current/JJ findings/NNS open/VBP new/JJ perspectives/NNS about/IN mechanisms/NNS that/WDT are/VBP likely/JJ to/TO regulate/VB gene/NN transcription/NN in/IN neutrophils/NNS ./. 
In/IN addition/NN ,/, the/DT procedure/NN described/VBN herein/RB could/MD prove/VB useful/JJ in/IN other/JJ cell/NN types/NNS that/WDT express/VBP high/JJ levels/NNS of/IN endogenous/JJ proteases/NNS ./. 
UI/LS -/: 98413772/CD 
TI/LS -/: Low/JJ CD3+CD28-induced/JJ interleukin-2/NN production/NN correlates/VBZ with/IN decreased/VBN reactive/JJ oxygen/NN intermediate/JJ formation/NN in/IN neonatal/JJ T/NN cells/NNS ./. 
AB/LS -/: The/DT capacity/NN of/IN neonatal/JJ T/NN cells/NNS to/TO secrete/VB interleukin-2/NN (/( IL-2/NN )/) has/VBZ been/VBN reported/VBN to/TO be/VB variable/JJ ./. 
We/PRP analysed/VBD IL-2/NN production/NN in/IN purified/VBN neonatal/JJ and/CC adult/JJ T/NN cells/NNS using/VBG polyclonal/JJ activator/NN phorbol/NN ester/NN +/CC calcium/NN ionophore/NN (/( PDBu/NN +/CC iono/NN )/) or/CC receptor-mediated/JJ anti-CD3/anti-CD3+/JJ anti-CD28/JJ stimulation/NN ./. 
PDBu/NN +/CC iono/NN induced/VBD equally/RB high/JJ IL-2/NN levels/NNS in/IN both/DT groups/NNS and/CC ,/, when/WRB stimulated/VBN with/IN plate-bound/JJ anti-CD3/JJ monoclonal/JJ antibody/NN (/( mAb/NN )/) ,/, the/DT IL-2/NN secretion/NN by/IN neonatal/JJ cells/NNS was/VBD undetectable/JJ and/CC adult/JJ cells/NNS produced/VBD low/JJ amounts/NNS of/IN IL-2/NN (/( mean/NN 331/CD +/-/CC 86/CD pg/ml/NN )/) ./. 
The/DT addition/NN of/IN anti-CD28/JJ mAb/NN to/TO anti-CD3-stimulated/JJ cells/NNS markedly/RB increased/VBD IL-2/NN production/NN in/IN both/DT cell/NN types/NNS ,/, but/CC levels/NNS of/IN IL-2/NN in/IN neonatal/JJ T/NN cells/NNS remained/VBD clearly/RB lower/JJR than/IN those/DT of/IN adult/JJ T/NN cells/NNS (/( respective/JJ mean/JJ values/NNS :/: 385/CD +/-/CC 109/CD pg/ml/NN and/CC 4494/CD +/-/CC 1199/CD pg/ml/NN )/) ./. 
As/IN NF-kappa/NN B/NN is/VBZ a/DT critical/JJ transcription/NN factor/NN in/IN the/DT control/NN of/IN IL-2/NN expression/NN ,/, we/PRP next/RB analysed/VBD its/PRP$ nuclear/JJ translocation/NN in/IN neonatal/JJ and/CC adult/JJ T/NN cells/NNS using/VBG the/DT electrophoretic/JJ mobility/NN shift/NN assay/NN and/CC ,/, because/IN induction/NN of/IN reactive/JJ oxygen/NN intermediates/NNS (/( ROI/NNS )/) is/VBZ required/VBN for/IN the/DT activation/NN of/IN NF-kappa/NN B/NN ,/, we/PRP also/RB analysed/VBD levels/NNS of/IN intracellular/JJ ROI/NNS in/IN these/DT cells/NNS using/VBG the/DT ROI-reactive/JJ fluorochrome/NN DCFH-DA/NN and/CC flow/NN cytometry/NN ./. 
In/IN neonatal/JJ T/NN cells/NNS NF-kappa/NN B/NN activation/NN and/CC ROI/NNS formation/NN after/IN anti-CD3/JJ stimulation/NN were/VBD low/JJ compared/VBN with/IN adult/JJ T/NN cells/NNS and/CC ,/, although/IN addition/NN of/IN anti-CD28/JJ mAb/NN increased/VBD induction/NN of/IN NF-kappa/NN B/NN and/CC ROI/NNS formation/NN ,/, levels/NNS similar/JJ to/TO those/DT of/IN adults/NNS were/VBD not/RB achieved/VBN ./. 
After/IN PDBu/NN +/CC iono/NN stimulation/NN ,/, the/DT cells/NNS showed/VBD similar/JJ ROI/NNS formation/NN and/CC IL-2/NN secretion/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN reduced/VBN IL-2/NN production/NN by/IN neonatal/JJ T/NN cells/NNS is/VBZ specific/JJ for/IN anti-CD3/JJ and/CC anti-CD3+/JJ anti-CD28-mediated/JJ stimulation/NN and/CC that/IN these/DT activators/NNS can/MD not/RB effectively/RB activate/VB the/DT ROI-NF-kappa/NN B/NN signalling/NN pathway/NN in/IN neonatal/JJ T/NN cells/NNS ./. 
UI/LS -/: 98397262/CD 
TI/LS -/: CD30/NN is/VBZ a/DT CD40-inducible/JJ molecule/NN that/WDT negatively/RB regulates/VBZ CD40-mediated/JJ immunoglobulin/NN class/NN switching/NN in/IN non-antigen-selected/JJ human/JJ B/NN cells/NNS ./. 
AB/LS -/: We/PRP used/VBD our/PRP$ monoclonal/JJ model/NN of/IN germinal/JJ center/NN maturation/NN ,/, CL-01/NN B/NN cells/NNS ,/, to/TO investigate/VB the/DT role/NN of/IN CD30/NN in/IN human/JJ B/NN cell/NN differentiation/NN ./. 
CL-01/NN cells/NNS are/VBP IgM+/JJ IgD+/JJ CD30+/JJ and/CC switch/VBP to/TO IgG/NN ,/, IgA/NN ,/, and/CC IgE/NN when/WRB exposed/VBN to/TO CD40L/NN and/CC IL-4/NN ./. 
Switching/NN is/VBZ hampered/VBN by/IN CD30/NN coengagement/NN ,/, possibly/RB through/IN interference/NN with/IN the/DT CD40-mediated/JJ NF-kappaB-dependent/JJ transcriptional/JJ activation/NN of/IN downstream/JJ C(H)/NN genes/NNS ./. 
The/DT physiological/JJ relevance/NN of/IN this/DT phenomenon/NN is/VBZ emphasized/VBN by/IN similar/JJ CD30-mediated/JJ effects/NNS in/IN naive/JJ B/NN cells/NNS ./. 
Expression/NN of/IN CD30/NN by/IN these/DT cells/NNS is/VBZ induced/VBN by/IN CD40L/NN but/CC is/VBZ inhibited/VBN by/IN B/NN cell/NN receptor/NN coengagement/NN and/or/CC exposure/NN to/TO IL-6/NN and/CC IL-12/NN ./. 
Our/PRP$ data/NNS suggest/VBP that/IN CD30/NN critically/RB regulates/VBZ the/DT CD40-mediated/JJ differentiation/NN of/IN non-antigen-selected/JJ human/JJ B/NN cells/NNS ./. 
UI/LS -/: 98390872/CD 
TI/LS -/: Calcineurin/NN and/CC the/DT biological/JJ effect/NN of/IN cyclosporine/NN and/CC tacrolimus/NN ./. 
AB/LS -/: The/DT mechanism/NN of/IN the/DT immunosuppressive/JJ effect/NN of/IN CyA/NN and/CC FK/NN 506/CD can/MD be/VB monitored/VBN in/FW vivo/FW in/IN humans/NNS ./. 
The/DT picture/NN emerging/VBG is/VBZ of/IN a/DT close/JJ relationship/NN between/IN drug/NN concentrations/NNS and/CC CN/NN inhibition/NN ./. 
But/CC many/JJ puzzles/NNS of/IN the/DT drugs/NNS remain/VBP ./. 
What/WP is/VBZ the/DT role/NN of/IN CyA/NN in/IN the/DT activation/NN of/IN transforming/VBG growth/NN factor-beta/NN (/( TGF-beta/NN )/) ,/, particularly/RB in/IN relationship/NN to/TO nephrotoxicity/NN and/CC fibrogenesis/NN ?/. 
How/WRB important/JJ are/VBP the/DT anti-inflammatory/JJ (/( non/JJ T/NN )/) effects/NNS of/IN CyA/NN ,/, and/CC which/WDT cells/NNS do/VBP they/PRP operate/VB in/IN ?/. 
Are/VBP there/EX effects/NNS of/IN CyA/NN and/CC FK/NN 506/CD all/DT attributable/JJ to/TO CN/NN inhibition/NN ,/, and/CC how/WRB much/JJ of/IN them/PRP are/VBP mediated/VBN through/IN the/DT NFATC/NN family/NN of/IN transcription/NN factors/NNS ?/. 
Finally/RB ,/, it/PRP would/MD be/VB useful/JJ to/TO know/VB what/WP the/DT inhibitory/JJ effects/NNS of/IN CyA/NN are/VBP on/IN tolerance/NN and/CC negative/JJ regulatory/JJ events/NNS ./. 
UI/LS -/: 98380286/CD 
TI/LS -/: Stimulation/NN of/IN B/NN and/CC T/NN cells/NNS activates/VBZ expression/NN of/IN transcription/NN and/CC differentiation/NN factors/NNS ./. 
AB/LS -/: During/IN B/NN and/CC T/NN cell/NN differentiation/NN and/CC proliferation/NN many/JJ genes/NNS are/VBP induced/VBN or/CC repressed/VBN while/IN certain/JJ genes/NNS are/VBP constitutively/RB expressed/VBN ./. 
To/TO investigate/VB processes/NNS related/JJ to/TO B/NN and/CC T/NN cell/NN activation/NN ,/, the/DT gene/NN expression/NN of/IN stimulated/VBN and/CC nonstimulated/JJ Ramos/NN and/CC Jurkat/NN cells/NNS was/VBD studied/VBN using/VBG cDNA/NN microarray/NN technology/NN ./. 
Simultaneous/JJ analysis/NN of/IN close/JJ to/TO 600/CD genes/NNS indicated/VBD highest/JJS increase/NN in/IN the/DT expression/NN of/IN certain/JJ transcription/NN ,/, differentiation/NN and/CC proliferation/NN factors/NNS ./. 
Many/JJ of/IN these/DT genes/NNS have/VBP not/RB previously/RB been/VBN shown/VBN to/TO funcion/VB in/IN the/DT stimulated/VBN lymphocytes/NNS ./. 
Also/RB genes/NNS encoding/VBG proteins/NNS involved/VBN in/IN DNA/NN replication/NN ,/, binding/NN ,/, transcription/NN and/CC translation/NN were/VBD induced/VBN ./. 
Large/JJ part/NN of/IN the/DT activated/VBN genes/NNS were/VBD under/IN very/RB stringent/JJ regulation/NN being/VBG expressed/VBN only/RB after/IN stimulation/NN ./. 
The/DT mechanism/NN and/CC function/NN of/IN the/DT expressed/VBN genes/NNS during/IN lymphocyte/NN differentiation/NN and/CC in/IN disorders/NNS is/VBZ discussed/VBN ./. 
UI/LS -/: 99030136/CD 
TI/LS -/: Interleukin/NN 2/CD and/CC 15/CD activate/VBP Stat3alpha/NN in/IN human/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: Signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN 3/CD (/( Stat3/NN )/) has/VBZ recently/RB been/VBN shown/VBN to/TO exist/VB in/IN two/CD alternatively/RB spliced/VBN isoforms/NNS ,/, a/DT short/JJ form/NN ,/, Stat3beta/NN ,/, and/CC a/DT longer/JJR form/NN ,/, Stat3alpha/NN ,/, displaying/VBG differences/NNS in/IN transcriptional/JJ activity/NN ./. 
It/PRP is/VBZ unknown/JJ which/WDT Stat3/NN isoform/NN (/( s/NNS )/) is/VBZ activated/VBN in/IN response/NN to/TO interleukin/NN (/( IL/NN )/) -2/CD and/CC IL-15/NN ./. 
Here/RB ,/, cytokine-induced/JJ activation/NN of/IN Stat3/NN in/IN previously/RB activated/VBN CD4(+)/JJ human/JJ T/NN cells/NNS was/VBD examined/VBN using/VBG Stat3/NN antibodies/NNS directed/VBN against/IN different/JJ regions/NNS of/IN Stat3/NN ./. 
As/IN determined/VBN by/IN tyrosine/NN phosphorylation/NN ,/, nuclear/JJ translocation/NN and/CC binding/VBG to/TO an/DT hSIE-oligonucleotide/NN probe/NN ,/, IL-2/NN and/CC IL-15/NN activated/VBD the/DT slowly/RB migrating/VBG isoform/NN ,/, Stat3alpha/NN ./. 
In/IN contrast/NN ,/, minimal/JJ or/CC no/DT activation/NN of/IN Stat3beta/NN was/VBD observed/VBN ,/, suggesting/VBG that/IN IL-2/NN and/CC IL-15/NN predominantly/RB activate/VBP Stat3alpha/NN in/IN human/JJ CD4(+)/JJ T/NN cells/NNS ./. 
In/IN this/DT way/NN ,/, diversity/NN in/IN the/DT expression/NN and/CC activation/NN of/IN Stat3/NN proteins/NNS may/MD provide/VB additional/JJ means/NNS of/IN regulating/VBG cytokine-induced/JJ T/NN cell/NN responses/NNS ./. 
Copyright/NN 1998/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 99018025/CD 
TI/LS -/: Transcriptional/JJ regulation/NN of/IN lysosomal/JJ acid/NN lipase/NN in/IN differentiating/VBG monocytes/NNS is/VBZ mediated/VBN by/IN transcription/NN factors/NNS Sp1/NN and/CC AP-2/NN ./. 
AB/LS -/: Human/JJ lysosomal/JJ acid/NN lipase/NN (/( LAL/NN )/) is/VBZ a/DT hydrolase/NN required/VBN for/IN the/DT cleavage/NN of/IN cholesteryl/NN esters/NNS and/CC triglycerides/NNS derived/VBN from/IN plasma/NN lipoproteins/NNS ./. 
It/PRP is/VBZ shown/VBN here/RB that/IN during/IN monocyte/NN to/TO macrophage/NN differentiation/NN ,/, the/DT expression/NN of/IN LAL-mRNA/NN is/VBZ induced/VBN ./. 
This/DT induction/NN is/VBZ dependent/JJ on/IN protein/NN kinase/NN C/NN activity/NN and/CC protein/NN synthesis/NN ./. 
The/DT cell/NN type-specific/JJ increase/NN in/IN LAL/NN expression/NN is/VBZ further/RB investigated/VBN in/IN the/DT THP-1/NN cell/NN line/NN with/IN respect/NN to/TO transcriptional/JJ regulation/NN ./. 
The/DT human/JJ monocytic/JJ leukemia/NN cell/NN line/NN THP-1/NN differentiates/VBZ into/IN macrophage-like/JJ cells/NNS when/WRB treated/VBN with/IN phorbol/NN esters/NNS ./. 
In/IN order/NN to/TO determine/VB the/DT cis-acting/JJ elements/NNS necessary/JJ for/IN both/CC basal/JJ and/CC phorbol/NN 12-myristate-13/JJ acetate/NN (/( PMA/NN )/) -enhanced/JJ promoter/NN activity/NN ,/, we/PRP performed/VBD deletion/NN analysis/NN and/CC reporter/NN gene/NN assays/NNS ./. 
A/DT PMA/NN responsive/JJ element/NN has/VBZ been/VBN identified/VBN between/IN -182/CD bp/NN and/CC -107/CD bp/NN upstream/RB of/IN the/DT major/JJ transcription/NN start/NN site/NN ./. 
Gel/NN mobility/NN shift/NN assays/NNS demonstrated/VBD that/IN binding/NN of/IN Sp1/NN and/CC AP-2/NN to/TO the/DT LAL/NN promoter/NN is/VBZ increased/VBN by/IN PMA/NN in/IN THP-1/NN cells/NNS ./. 
Co-transfections/NNS with/IN expression/NN plasmids/NNS for/IN Sp1/NN and/CC AP-2/NN further/RB emphasized/VBD the/DT important/JJ role/NN of/IN these/DT transcription/NN factors/NNS in/IN both/CC basal/JJ and/CC PMA-enhanced/JJ LAL/NN expression/NN ./. 
Our/PRP$ data/NNS suggest/VBP that/IN differentiation/NN dependent/JJ increase/NN of/IN lysosomal/JJ acid/NN lipase/NN (/( LAL/NN )/) expression/NN in/IN THP-1/NN cells/NNS is/VBZ mediated/VBN by/IN a/DT concerted/JJ action/NN of/IN Sp1/NN and/CC AP-2/NN ./. 
UI/LS -/: 99008340/CD 
TI/LS -/: Relationship/NN between/IN IkappaBalpha/NN constitutive/JJ expression/NN ,/, TNFalpha/NN synthesis/NN ,/, and/CC apoptosis/NN in/IN EBV-infected/JJ lymphoblastoid/JJ cells/NNS ./. 
AB/LS -/: In/IN order/NN to/TO understand/VB the/DT role/NN of/IN NF-kappaB/NN in/IN EBV/NN transformation/NN we/PRP have/VBP established/VBN stably/RB transfected/VBN IkappaBalpha/NN into/IN lymphoblastoid/JJ cells/NNS ./. 
Two/CD clones/NNS were/VBD obtained/VBN in/IN which/WDT the/DT loss/NN of/IN NF-kappaB/NN binding/NN activity/NN correlated/VBD with/IN the/DT constitutive/JJ expression/NN of/IN the/DT transgenic/JJ IkappaBalpha/NN ./. 
Protein/NN latency/NN expression/NN was/VBD determined/VBN by/IN immunocytochemistry/NN ./. 
Expression/NN of/IN surface/NN markers/NNS ,/, intracytoplasmic/JJ content/NN of/IN cytokines/NNS cell/NN cycle/NN analysis/NN after/IN BrdU/NN incorporation/NN and/CC DNA/NN staining/NN with/IN propidium/NN iodide/NN were/VBD studied/VBN by/IN flow/NN cytometry/NN ./. 
Percentage/NN of/IN apoptotic/JJ cells/NNS was/VBD determined/VBN by/IN in-situ/FW labelling/NN of/IN DNA/NN strand/NN breaks/NNS ./. 
No/DT significative/JJ changes/NNS in/IN EBV/NN latency/NN nor/CC in/IN cell/NN surface/NN marker/NN expression/NN was/VBD found/VBN ./. 
In/IN contrast/NN ,/, intracytoplasmic/JJ TNFalpha/NN levels/NNS were/VBD strongly/RB reduced/VBN in/IN transfected/VBN clones/NNS ./. 
Furthermore/RB ,/, 30/CD %/NN of/IN IkappaBalpha/NN transfected/JJ cells/NNS were/VBD apoptotic/JJ after/IN 8/CD h/NN of/IN TNFalpha/NN treatment/NN ./. 
This/DT correlated/VBD with/IN a/DT strong/JJ reduction/NN of/IN BrdU/NN incorporation/NN after/IN 24/CD h/NN of/IN TNFalpha/NN treatment/NN ./. 
No/DT effect/NN was/VBD seen/VBN with/IN non/JJ transfected/JJ cells/NNS or/CC with/IN cells/NNS transfected/VBN with/IN a/DT control/JJ plasmid/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN the/DT TNFalpha/NN gene/NN could/MD be/VB one/CD of/IN the/DT targets/NNS of/IN NF-kappaB/NN in/IN EBV/NN infected/JJ cells/NNS and/CC that/IN NF-kappaB/NN protects/VBZ EBV-infected/JJ cells/NNS from/IN apoptosis/NN induced/VBN by/IN TNFalpha/NN ,/, which/WDT may/MD favour/VB the/DT proliferative/JJ effect/NN of/IN this/DT cytokine/NN ./. 
UI/LS -/: 98455033/CD 
TI/LS -/: Seminoma/NN in/IN a/DT postmenopausal/JJ woman/NN with/IN a/DT Y;15/NN translocation/NN in/IN peripheral/JJ blood/NN lymphocytes/NNS and/CC a/DT t(Y;15)/45,X/NN Turner/NN mosaic/JJ pattern/NN in/IN skin/NN fibroblasts/NNS ./. 
AB/LS -/: We/PRP report/VBP an/DT unusual/JJ case/NN of/IN a/DT 55/CD year/NN old/JJ Japanese/NN woman/NN with/IN a/DT seminoma/NN but/CC relatively/RB normal/JJ menses/NNS ./. 
The/DT patient/NN was/VBD a/DT phenotypic/JJ female/NN with/IN late/JJ onset/NN menarche/NN (/( 18/CD years/NNS of/IN age/NN )/) ,/, who/WP was/VBD amenorrhoeic/JJ for/IN the/DT first/JJ year/NN ,/, followed/VBN by/IN menses/NNS of/IN one/CD to/TO three/CD days/NNS '/POS slight/JJ flow/NN with/IN dysmenorrhoea/NN ,/, but/CC an/DT otherwise/RB normal/JJ menstrual/JJ history/NN ./. 
A/DT typical/JJ seminoma/NN was/VBD removed/VBN from/IN the/DT left/JJ adnexal/JJ region/NN and/CC an/DT immature/JJ testis/NN was/VBD identified/VBN separately/RB as/IN an/DT associated/VBN right/JJ adnexal/JJ mass/NN ./. 
Repeated/JJ karyotypic/JJ studies/NNS on/IN peripheral/JJ blood/NN lymphocyte/NN cultures/NNS showed/VBD only/RB 46,X,-Y,t(Y;15)(q12;p13)/NN ./. 
Cytogenetic/JJ examination/NN of/IN the/DT patient/NN 's/POS younger/JJR brother/NN ,/, who/WP had/VBD fathered/VBN three/CD healthy/JJ children/NNS ,/, showed/VBD an/DT identical/JJ karyotype/NN ./. 
Mosaicism/NN of/IN 46,X,-Y,t(Y;15)(q12;p13)/45,X/NN cell/NN lines/NNS was/VBD found/VBN in/IN skin/NN samples/NNS from/IN the/DT patient/NN 's/POS elbow/NN and/CC genital/JJ regions/NNS ,/, although/IN there/EX were/VBD no/DT clinical/JJ stigmata/NN of/IN Turner/NN syndrome/NN ./. 
An/DT androgen/NN receptor/NN binding/NN assay/NN of/IN cultured/VBN genital/JJ skin/NN fibroblasts/NNS was/VBD negative/JJ ./. 
Molecular/JJ analysis/NN using/VBG Southern/NN blot/NN hybridisation/NN ,/, PCR/NN ,/, and/CC direct/JJ DNA/NN sequencing/NN showed/VBD that/IN neither/CC the/DT patient/NN nor/CC her/PRP$ brother/NN had/VBD a/DT detectable/JJ deletion/NN or/CC other/JJ abnormalities/NNS of/IN Y/NN chromosome/NN sequences/NNS ,/, including/VBG the/DT SRY/NN (/( sex/NN determining/NN region/NN of/IN the/DT Y/NN chromosome/NN )/) gene/NN sequence/NN ./. 
These/DT findings/NNS suggest/VBP that/IN Turner/NN mosaicism/NN of/IN the/DT 45,X/NN cell/NN line/NN may/MD have/VB contributed/VBN to/TO this/DT atypical/JJ presentation/NN in/IN an/DT XY/NN female/NN ,/, although/IN we/PRP can/MD not/RB exclude/VB abnormalities/NNS of/IN other/JJ genes/NNS related/JJ to/TO sex/NN differentiation/NN ./. 
UI/LS -/: 98435936/CD 
TI/LS -/: Potent/JJ inhibition/NN of/IN HIV/NN type/NN 1/CD replication/NN by/IN an/DT antiinflammatory/JJ alkaloid/NN ,/, cepharanthine/NN ,/, in/IN chronically/RB infected/JJ monocytic/JJ cells/NNS ./. 
AB/LS -/: Cepharanthine/NN is/VBZ a/DT biscoclaurine/JJ alkaloid/NN isolated/VBN from/IN Stephania/FW cepharantha/FW Hayata/FW and/CC has/VBZ been/VBN shown/VBN to/TO have/VB antiinflammatory/JJ ,/, antiallergic/JJ ,/, and/CC immunomodulatory/JJ activities/NNS in/FW vivo/FW ./. 
As/IN several/JJ inflammatory/JJ cytokines/NNS and/CC oxidative/JJ stresses/NNS are/VBP involved/VBN in/IN the/DT pathogenesis/NN of/IN HIV-1/NN infection/NN ,/, we/PRP investigated/VBD the/DT inhibitory/JJ effects/NNS of/IN cepharanthine/NN on/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) -/CC and/CC phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) -induced/JJ HIV-1/NN replication/NN in/IN chronically/RB infected/JJ cell/NN lines/NNS ./. 
Two/CD chronically/RB HIV-1-infected/JJ cell/NN lines/NNS ,/, U1/NN (/( monocytic/JJ )/) and/CC ACH-2/NN (/( T/NN lymphocytic/JJ )/) ,/, were/VBD stimulated/VBN with/IN TNF-alpha/NN or/CC PMA/NN and/CC cultured/VBN in/IN the/DT presence/NN of/IN various/JJ concentrations/NNS of/IN the/DT compound/NN ./. 
HIV-1/NN replication/NN was/VBD determined/VBN by/IN p24/NN antigen/NN level/NN ./. 
The/DT inhibitory/JJ effects/NNS of/IN cepharanthine/NN on/IN HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) -driven/JJ gene/NN expression/NN and/CC nuclear/JJ factor/NN kappaB/NN (/( NF-kappaB/NN )/) activation/NN were/VBD also/RB examined/VBN ./. 
Cepharanthine/NN dose/NN dependently/RB inhibited/VBD HIV-1/NN replication/NN in/IN TNF-alpha-/NN and/CC PMA-stimulated/JJ U1/NN cells/NNS but/CC not/RB in/IN ACH-2/NN cells/NNS ./. 
Its/PRP$ 50/CD %/NN effective/JJ and/CC cytotoxic/JJ concentrations/NNS were/VBD 0.016/CD and/CC 2.2/CD microg/ml/NN in/IN PMA-stimulated/JJ U1/NN cells/NNS ,/, respectively/RB ./. 
Cepharanthine/NN was/VBD found/VBN to/TO suppress/VB HIV-1/NN LTR-driven/JJ gene/NN expression/NN through/IN the/DT inhibition/NN of/IN NF-kappaB/NN activation/NN ./. 
These/DT results/NNS indicate/VBP that/IN cepharanthine/NN is/VBZ a/DT highly/RB potent/JJ inhibitor/NN of/IN HIV-1/NN replication/NN in/IN a/DT chronically/RB infected/JJ monocytic/JJ cell/NN line/NN ./. 
Since/IN biscoclaurine/NN alkaloids/NNS ,/, containing/VBG cepharanthine/NN as/IN a/DT major/JJ component/NN ,/, are/VBP widely/RB used/VBN for/IN the/DT treatment/NN of/IN patients/NNS with/IN various/JJ inflammatory/JJ diseases/NNS in/IN Japan/NNP ,/, cepharanthine/NN should/MD be/VB further/RB pursued/VBN for/IN its/PRP$ chemotherapeutic/JJ potential/NN in/IN HIV-1-infected/JJ patients/NNS ./. 
UI/LS -/: 98418492/CD 
TI/LS -/: NF-kappaB/NN only/RB partially/RB mediates/VBZ Epstein-Barr/JJ virus/NN latent/JJ membrane/NN protein/NN 1/CD activation/NN of/IN B/NN cells/NNS ./. 
AB/LS -/: The/DT latent/JJ membrane/NN protein/NN 1/CD (/( LMP1/NN )/) of/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) is/VBZ required/VBN for/IN EBV-induced/JJ immortalization/NN of/IN human/JJ B/NN cells/NNS and/CC causes/VBZ tumorigenic/JJ transformation/NN of/IN cell/NN lines/NNS ./. 
LMP1/NN expression/NN induces/VBZ phenotypic/JJ changes/NNS resembling/VBG B/NN cell/NN activation/NN ,/, such/JJ as/IN cell/NN size/NN increase/NN and/CC up-regulation/NN of/IN cell/NN surface/NN activation/NN markers/NNS ./. 
LMP1/NN contains/VBZ two/CD domains/NNS that/WDT activate/VBP the/DT transcription/NN factor/NN NF-kappaB/NN ,/, one/CD through/IN interactions/NNS with/IN TRAF/NN proteins/NNS and/CC the/DT other/JJ with/IN the/DT TRADD/NN protein/NN ./. 
The/DT purpose/NN of/IN the/DT present/JJ study/NN was/VBD to/TO investigate/VB the/DT importance/NN of/IN NF-kappaB/NN induction/NN in/IN the/DT up-regulation/NN of/IN the/DT B/NN cell/NN activation/NN markers/NNS ICAM-1/NN and/CC CD71/NN by/IN LMP1/NN ./. 
This/DT study/NN shows/VBZ that/IN expression/NN of/IN LMP1/NN activates/VBZ transcription/NN from/IN p50/p65-/NN and/CC c-Rel-responsive/JJ promoters/NNS ,/, and/CC that/IN this/DT activity/NN can/MD be/VB completely/RB inhibited/VBN by/IN expression/NN of/IN a/DT dominant/JJ inhibitory/JJ IkappaB/NN mutant/NN ./. 
ICAM-1/NN and/CC CD71/NN are/VBP nevertheless/RB up-regulated/VBN by/IN LMP1/NN in/IN primary/JJ B/NN cells/NNS and/CC cell/NN lines/NNS expressing/VBG the/DT dominant/JJ IkappaB/NN ./. 
Furthermore/RB ,/, LMP1-induced/JJ cell/NN size/NN increase/NN of/IN primary/JJ B/NN cells/NNS was/VBD unaffected/VBN by/IN IkappaB/NN expression/NN ./. 
It/PRP was/VBD concluded/VBN that/IN even/RB when/WRB LMP1/NN is/VBZ unable/JJ to/TO activate/VB NF-kappaB/NN ,/, it/PRP is/VBZ still/RB capable/JJ of/IN inducing/VBG certain/JJ characteristics/NNS of/IN activated/VBN B/NN cells/NNS ,/, strongly/RB suggesting/VBG that/IN LMP1/NN can/MD also/RB activate/VB cells/NNS independently/RB of/IN NF-kappaB/NN ./. 
UI/LS -/: 98407711/CD 
TI/LS -/: Models/NNS of/IN lineage/NN switching/NN in/IN hematopoietic/JJ development/NN :/: a/DT new/JJ myeloid-committed/JJ eosinophil/NN cell/NN line/NN (/( YJ/NN )/) demonstrates/VBZ trilineage/NN potential/NN ./. 
AB/LS -/: A/DT new/JJ human/JJ leukemia/NN cell/NN line/NN with/IN an/DT eosinophilic/JJ phenotype/NN ,/, designated/VBN YJ/NN ,/, was/VBD established/VBN from/IN the/DT peripheral/JJ blood/NN cells/NNS of/IN a/DT patient/NN with/IN chronic/JJ myelomonocytic/JJ leukemia/NN (/( CMMoL/NN )/) with/IN eosinophilia/NN ./. 
When/WRB cultured/VBN in/IN RPMI/NN 1640/CD medium/NN containing/VBG 10/CD %/NN fetal/JJ bovine/JJ serum/NN ,/, most/JJS YJ/NN cells/NNS were/VBD myeloblastoid/JJ with/IN a/DT small/JJ number/NN of/IN the/DT cells/NNS having/VBG eosinophilic/JJ granules/NNS ./. 
Cell/NN surface/NN markers/NNS in/IN the/DT YJ/NN cells/NNS were/VBD positive/JJ for/IN CD33/NN and/CC were/VBD negative/JJ for/IN CD34/NN ,/, CD16/NN and/CC CD23/NN ./. 
The/DT eosinophilic/JJ characteristics/NNS of/IN YJ/NN cells/NNS were/VBD confirmed/VBN by/IN histochemical/JJ staining/NN with/IN Fast-Green/Neutral-Red/NN and/CC by/IN the/DT expression/NN of/IN mRNAs/NNS for/IN eosinophil-associated/JJ granule/NN proteins/NNS ,/, eosinophil/NN cationic/JJ protein/NN (/( ECP/NN )/) ,/, eosinophil-derived/JJ neurotoxin/NN (/( EDN/NN )/) ,/, eosinophil/NN peroxidase/NN (/( EPO/NN )/) ,/, and/CC major/JJ basic/JJ protein/NN (/( MBP/NN )/) ,/, and/CC for/IN the/DT Charcot-Leyden/NN crystal/NN (/( CLC/NN )/) protein/NN ./. 
The/DT YJ/NN cells/NNS could/MD be/VB induced/VBN towards/IN monocytic/JJ differentiation/NN by/IN stimulation/NN with/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) ./. 
The/DT monocytic/JJ characteristics/NNS of/IN YJ/NN cells/NNS treated/VBN with/IN PMA/NN were/VBD confirmed/VBN by/IN morphological/JJ analysis/NN with/IN alpha-naphthyl/NN butyrate/NN esterase/NN staining/NN ,/, by/IN CD14/NN expression/NN ,/, and/CC by/IN increased/VBN expression/NN of/IN Egr-1/NN mRNA/NN ./. 
Furthermore/RB ,/, YJ/NN cells/NNS could/MD be/VB differentiated/VBN towards/IN the/DT neutrophil/NN lineage/NN by/IN stimulation/NN with/IN all-trans/JJ retinoic/JJ acid/NN (/( RA/NN )/) ./. 
YJ/NN cells/NNS treated/VBN in/FW vitro/FW with/IN 2/CD microM/NN RA/NN differentiated/VBD into/IN metamyelocytes/NNS and/CC band/NN neutrophils/NNS ,/, and/CC increased/VBD the/DT number/NN of/IN nitroblue/JJ tetrazolium/NN (/( NBT/NN )/) -positive/JJ cells/NNS and/CC increased/VBD gp91phox/NN mRNA/NN expression/NN ./. 
Thus/RB ,/, the/DT YJ/NN cell/NN line/NN exhibited/VBD eosinophilic/JJ characteristics/NNS ,/, but/CC was/VBD able/JJ to/TO differentiate/VB to/TO the/DT monocytic/JJ or/CC neutrophilic/JJ lineages/NNS in/IN response/NN to/TO PMA/NN or/CC RA/NN ,/, respectively/RB ./. 
The/DT expression/NN of/IN genes/NNS for/IN transcription/NN factors/NNS involved/VBN in/IN myeloid/JJ differentiation/NN was/VBD evaluated/VBN by/IN Northern/NN blot/NN analysis/NN ./. 
Increased/VBN expression/NN of/IN Egr-1/NN was/VBD observed/VBN with/IN macrophage/NN differentiation/NN ./. 
In/IN contrast/NN ,/, increased/VBN expressions/NNS of/IN C/EBPbeta/NN and/CC MZF-1/NN mRNA/NN occurred/VBD with/IN neutrophilic/JJ differentiation/NN ./. 
The/DT YJ/NN cell/NN line/NN should/MD be/VB useful/JJ for/IN elucidating/VBG the/DT molecular/JJ mechanisms/NNS governing/VBG lineage/NN switching/NN from/IN the/DT eosinophil/NN to/TO monocytic/JJ or/CC neutrophil/NN lineages/NNS ./. 
UI/LS -/: 98400938/CD 
TI/LS -/: Interleukin-6/NN production/NN in/IN hemorrhagic/JJ shock/NN is/VBZ accompanied/VBN by/IN neutrophil/NN recruitment/NN and/CC lung/NN injury/NN ./. 
AB/LS -/: Hemorrhagic/JJ shock/NN (/( HS/NN )/) initiates/VBZ an/DT inflammatory/JJ cascade/NN that/WDT includes/VBZ the/DT production/NN of/IN cytokines/NNS and/CC recruitment/NN of/IN neutrophils/NNS (/( PMN/NN )/) and/CC may/MD progress/VB to/TO organ/JJ failure/NN ,/, inducing/VBG acute/JJ respiratory/JJ distress/NN syndrome/NN (/( ARDS/NN )/) ./. 
To/TO examine/VB the/DT hypothesis/NN that/IN interleukin-6/NN (/( IL-6/NN )/) contributes/VBZ to/TO PMN/NN infiltration/NN and/CC lung/NN damage/NN in/IN HS/NN ,/, we/PRP examined/VBD the/DT lungs/NNS of/IN rats/NNS subjected/VBN to/TO unresuscitated/JJ and/CC resuscitated/VBN HS/NN for/IN the/DT production/NN of/IN IL-6/NN and/CC activation/NN of/IN Stat3/NN ./. 
Using/VBG semiquantitative/JJ RT-PCR/NN ,/, we/PRP found/VBD a/DT striking/JJ increase/NN in/IN IL-6/NN mRNA/NN levels/NNS only/RB in/IN resuscitated/JJ HS/NN ,/, with/IN peak/NN levels/NNS observed/VBN 1/CD h/NN after/IN initiation/NN of/IN resuscitation/NN ./. 
Increased/VBN IL-6/NN protein/NN expression/NN was/VBD localized/JJ to/TO bronchial/JJ and/CC alveolar/JJ cells/NNS ./. 
Electrophoretic/JJ mobility/NN shift/NN assay/NN of/IN protein/NN extracts/NNS from/IN shock/NN lungs/NNS exhibited/VBD an/DT increase/NN in/IN Stat3/NN activation/NN with/IN kinetics/NN similar/JJ to/TO IL-6/NN mRNA/NN ./. 
In/FW situ/FW DNA/NN binding/NN assay/NN determined/VBD Stat3/NN activation/NN predominantly/RB within/IN alveoli/NNS ./. 
Intratracheal/JJ instillation/NN of/IN IL-6/NN alone/RB into/IN normal/JJ rats/NNS resulted/VBD in/IN PMN/NN infiltration/NN into/IN lung/NN interstitium/NN and/CC alveoli/NNS ,/, marked/JJ elevation/NN of/IN bronchoalveolar/JJ lavage/NN cellularity/NN ,/, and/CC increased/VBN wet-to-dry/JJ ratio/NN ./. 
These/DT findings/NNS indicate/VBP that/IN IL-6/NN production/NN and/CC Stat3/NN activation/NN occur/VBP early/RB in/IN HS/NN and/CC may/MD contribute/VB to/TO PMN-mediated/JJ lung/NN injury/NN ,/, including/VBG ARDS/NN after/IN HS/NN ./. 
UI/LS -/: 98391735/CD 
TI/LS -/: The/DT MHC/NN class/NN II/CD transactivator/NN (/( CIITA/NN )/) requires/VBZ conserved/VBN leucine/NN charged/JJ domains/NNS for/IN interactions/NNS with/IN the/DT conserved/VBN W/NN box/NN promoter/NN element/NN ./. 
AB/LS -/: The/DT class/NN II/CD transactivator/NN CIITA/NN is/VBZ required/VBN for/IN transcriptional/JJ activation/NN of/IN the/DT major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II/CD genes/NNS ./. 
Aside/IN from/IN an/DT N-terminal/JJ acidic/JJ transcriptional/JJ activation/NN domain/NN ,/, little/JJ is/VBZ known/VBN about/IN how/WRB this/DT factor/NN functions/VBZ ./. 
Extensive/JJ mutagenesis/NN of/IN CIITA/NN was/VBD undertaken/VBN to/TO identify/VB structural/JJ motifs/NNS required/VBN for/IN function/NN ./. 
The/DT ability/NN of/IN mutants/NNS to/TO activate/VB a/DT reporter/NN gene/NN under/IN the/DT control/NN of/IN MHC/NN class/NN II/CD conserved/JJ W-X-Y/NN or/CC X-Y/NN regulatory/JJ elements/NNS was/VBD determined/VBN ./. 
Two/CD mutants/NNS displayed/VBD differential/JJ activity/NN between/IN the/DT two/CD promoters/NNS ,/, activating/VBG transcription/NN with/IN the/DT W-X-Y/NN but/CC not/RB the/DT X-Y/NN elements/NNS ./. 
All/DT mutants/NNS were/VBD tested/VBN for/IN their/PRP$ ability/NN to/TO interfere/VB with/IN wild-type/JJ CIITA/NN activity/NN ./. 
Five/CD CIITA/NN mutant/JJ constructions/NNS were/VBD able/JJ to/TO down-regulate/VB wild-type/JJ CIITA/NN activity/NN ./. 
Three/CD of/IN these/DT mutants/NNS contained/VBD targeted/VBN disruptions/NNS of/IN potential/JJ functional/JJ motifs/NNS :/: the/DT acidic/JJ activation/NN domain/NN ,/, a/DT putative/JJ GTP-binding/JJ motif/NN and/CC two/CD leucine/NN charged/JJ domains/NNS (/( LCD/NNS motifs/NNS )/) ./. 
The/DT other/JJ two/CD contained/VBD mutations/NNS in/IN regions/NNS that/WDT do/VBP not/RB have/VB homology/NN to/TO described/VBN proteins/NNS ./. 
The/DT characterization/NN of/IN CIITA/NN mutants/NNS that/WDT are/VBP able/JJ to/TO discriminate/VB between/IN promoters/NNS with/IN or/CC without/IN the/DT W/NN box/NN strongly/RB suggests/VBZ that/IN CIITA/NN requires/VBZ such/JJ interactions/NNS for/IN function/NN ./. 
The/DT identification/NN of/IN LCD/NNS motifs/NNS required/VBN for/IN CIITA/NN function/NN brings/VBZ to/TO light/NN a/DT previously/RB undefined/VBN role/NN of/IN these/DT motifs/NNS in/IN CIITA/NN function/NN ./. 
UI/LS -/: 98380268/CD 
TI/LS -/: The/DT peroxisome/NN proliferator-activated/JJ receptor/NN alpha/NN (/( PPARalpha/NN )/) ligand/NN WY/NN 14,643/CD does/VBZ not/RB interfere/VB with/IN leukotriene/NN B4/NN induced/JJ adhesion/NN of/IN neutrophils/NNS to/TO endothelial/JJ cells/NNS ./. 
AB/LS -/: Peroxisome/NN proliferator-activated/JJ receptors/NNS (/( PPAR/NNS )/) control/VBP discrete/JJ genes/NNS involved/VBN in/IN fatty/JJ acid/NN and/CC lipid/NN metabolism/NN ./. 
Recently/RB ,/, it/PRP was/VBD suggested/VBN that/IN activation/NN of/IN the/DT alpha/NN isoform/NN of/IN PPAR/NNS by/IN the/DT potent/JJ proinflammatory/JJ mediator/NN leukotriene/NN B4/NN (/( LTB4/NN )/) enhanced/VBD degradation/NN of/IN this/DT eicosanoid/NN ,/, offersuggesting/VBG a/DT new/JJ aspect/NN of/IN down-regulation/NN of/IN inflammation/NN ./. 
Here/RB ,/, we/PRP studied/VBD whether/IN PPARalpha/NN activation/NN (/( by/IN means/NNS of/IN the/DT selective/JJ agonist/NN WY/NN 14,643/CD )/) of/IN endothelial/JJ cells/NNS ,/, pivotal/JJ in/IN the/DT regulation/NN of/IN inflammatory/JJ responses/NNS ,/, interfered/VBN with/IN LTB4/NN induced/VBD adhesion/NN of/IN PMN/NN neutrophil/NN granulocytes/NNS in/FW vitro/FW ./. 
When/WRB endothelial/JJ cells/NNS were/VBD treated/VBN with/IN WY/NN 14,643/CD prior/RB to/TO activation/NN with/IN LTB4/NN (/( or/CC fMLP/NN ,/, IL-1beta/NN or/CC TNFalpha/NN ,/, as/IN controls/NNS )/) we/PRP could/MD not/RB document/VB any/DT effect/NN on/IN the/DT number/NN of/IN adhering/JJ PMN/NN or/CC duration/NN of/IN the/DT response/NN ./. 
Thus/RB ,/, this/DT study/NN provides/VBZ no/DT evidence/NN indicating/VBG a/DT regulatory/JJ function/NN of/IN PPARalpha/NN in/IN LTB4/NN induced/JJ adhesive/JJ interactions/NNS between/IN endothelial/JJ cells/NNS and/CC neutrophils/NNS 
UI/LS -/: 99025966/CD 
TI/LS -/: Interaction/NN of/IN sickle/NN erythrocytes/NNS with/IN endothelial/JJ cells/NNS in/IN the/DT presence/NN of/IN endothelial/JJ cell/NN conditioned/JJ medium/NN induces/VBZ oxidant/JJ stress/NN leading/VBG to/TO transendothelial/JJ migration/NN of/IN monocytes/NNS ./. 
AB/LS -/: The/DT abnormal/JJ adherence/NN of/IN sickle/NN red/JJ blood/NN cells/NNS (/( SS/NN RBC/NNS )/) to/TO endothelial/JJ cells/NNS has/VBZ been/VBN thought/VBN to/TO contribute/VB to/TO vascular/JJ occlusion/NN ,/, a/DT major/JJ cause/NN of/IN morbidity/NN in/IN sickle/NN cell/NN disease/NN (/( SCD/NN )/) ./. 
We/PRP determined/VBD whether/IN the/DT interaction/NN of/IN SS/NN RBC/NNS with/IN cultured/VBN endothelial/JJ cells/NNS induced/VBD cellular/JJ oxidant/JJ stress/NN that/WDT would/MD culminate/VB in/IN expression/NN of/IN cell/NN adhesion/NN molecules/NNS (/( CAMs/NNS )/) involved/VBN in/IN the/DT adhesion/NN and/CC diapedesis/NN of/IN monocytes/NNS and/CC the/DT adherence/NN of/IN SS/NN reticulocytes/NNS ./. 
We/PRP showed/VBD that/IN the/DT interaction/NN of/IN SS/NN RBC/NNS at/IN 2/CD %/NN concentration/NN in/IN the/DT presence/NN of/IN multimers/NNS of/IN von/NN Willebrand/NN factor/NN (/( vWf/NN )/) ,/, derived/VBN from/IN endothelial/JJ cell-derived/JJ conditioned/VBN medium/NN (/( E-CM/NN )/) with/IN cultured/VBN human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS (/( HUVEC/NN )/) ,/, resulted/VBD in/IN a/DT fivefold/RB increased/VBN formation/NN of/IN thiobarbituric/JJ acid-reactive/JJ substances/NNS (/( TBARS/NNS )/) and/CC activation/NN of/IN the/DT transcription/NN factor/NN NF-kB/NN ,/, both/DT indicators/NNS of/IN cellular/JJ oxidant/JJ stress/NN ./. 
Normal/JJ RBC/NNS show/VBP none/DT of/IN these/DT phenomena/NNS ./. 
The/DT oxidant/JJ stress-induced/JJ signaling/NN resulted/VBD in/IN an/DT increased/VBN surface/NN expression/NN of/IN a/DT subset/NN of/IN CAMs/NNS ,/, ICAM-1/NN ,/, E-selectin/NN ,/, and/CC VCAM-1/NN in/IN HUVEC/NN ./. 
The/DT addition/NN of/IN oxygen/NN radical/JJ scavenger/NN enzymes/NNS (/( catalase/NN ,/, superoxide/NN dismutase/NN )/) and/CC antioxidant/NN (/( probucol/NN )/) inhibited/VBD these/DT events/NNS ./. 
Additionally/RB ,/, preincubation/NN of/IN HUVEC/NN with/IN a/DT synthetic/JJ peptide/NN Arg-Gly-Asp/NN (/( RGD/NN )/) that/WDT prevents/VBZ vWf-mediated/JJ adhesion/NN of/IN SS/NN RBC/NNS reduced/VBD the/DT surface/NN expression/NN of/IN VCAM-1/NN and/CC NF-kB/NN activation/NN ./. 
Furthermore/RB ,/, SS/NN RBC-induced/JJ oxidant/JJ stress/NN resulted/VBD in/IN a/DT twofold/JJ increase/NN in/IN the/DT transendothelial/JJ migration/NN of/IN both/CC monocyte-like/JJ HL-60/NN cells/NNS and/CC human/JJ peripheral/JJ blood/NN monocytes/NNS ,/, and/CC approximately/RB a/DT sixfold/JJ increase/NN in/IN platelet-endothelial/JJ cell/NN adhesion/NN molecule-1/NN (/( PECAM-1/NN )/) phosphorylation/NN ,/, each/DT of/IN which/WDT was/VBD blocked/VBN by/IN protein/NN kinase/NN C/NN inhibitor/NN and/CC antioxidants/NNS ./. 
These/DT results/NNS suggest/VBP that/IN the/DT adherence/contact/NN of/IN SS/NN RBC/NNS to/TO endothelial/JJ cells/NNS in/IN large/JJ vessel/NN can/MD generate/VB enhanced/VBN oxidant/JJ stress/NN leading/VBG to/TO increased/VBN adhesion/NN and/CC diapedesis/NN of/IN monocytes/NNS ,/, as/RB well/RB as/IN heightened/VBN adherence/NN of/IN SS/NN reticulocytes/NNS ,/, indicating/VBG that/IN injury/activation/NN of/IN endothelium/NN can/MD contribute/VB to/TO vaso-occlusion/NN in/IN SCD/NN ./. 
UI/LS -/: 99010987/CD 
TI/LS -/: Signal/NN transduction/NN abnormalities/NNS in/IN T/NN lymphocytes/NNS from/IN patients/NNS with/IN advanced/JJ renal/JJ carcinoma/NN :/: clinical/JJ relevance/NN and/CC effects/NNS of/IN cytokine/NN therapy/NN ./. 
AB/LS -/: Studies/NNS have/VBP demonstrated/VBN abnormalities/NNS of/IN the/DT CD3/T-cell/NN antigen/NN receptor/NN (/( TCR/NN )/) and/CC pathways/NNS of/IN signal/NN transduction/NN in/IN T/NN lymphocytes/NNS from/IN animals/NNS and/CC patients/NNS with/IN advanced/JJ malignancy/NN ./. 
Diminished/VBN expression/NN of/IN TCRzeta/NN and/CC p56(lck)/NN that/WDT are/VBP associated/VBN with/IN the/DT TCR/NN and/CC reduced/VBN nuclear/JJ localization/NN of/IN RelA/NN containing/VBG nuclear/JJ factor/NN kappaB/NN (/( NFkappaB/NN )/) complexes/NNS have/VBP been/VBN noted/VBN ./. 
These/DT defects/NNS have/VBP been/VBN described/VBN in/IN T/NN cells/NNS from/IN patients/NNS with/IN malignant/JJ melanoma/NN ,/, renal/JJ cell/NN carcinoma/NN (/( RCC/NN )/) ,/, ovarian/JJ cancer/NN ,/, and/CC colorectal/JJ cancer/NN ./. 
Preliminary/JJ observations/NNS also/RB indicate/VBP possible/JJ correlation/NN with/IN clinical/JJ variables/NNS such/JJ as/IN stage/NN in/IN selected/VBN instances/NNS ./. 
To/TO further/RB characterize/VB altered/JJ expression/NN of/IN TCRzeta/NN ,/, p56(lck)/NN ,/, and/CC impaired/JJ activation/NN of/IN NFkappaB/NN ,/, T/NN lymphocytes/NNS were/VBD obtained/VBN from/IN 65/CD patients/NNS with/IN RCC/NN ,/, the/DT majority/NN of/IN whom/WP were/VBD receiving/VBG combination/NN cytokine/NN therapy/NN [/( interleukin/NN (/( IL/NN )/) -2/CD ,/, IFN/NN alpha-containing/JJ regimens/NNS ]/) and/CC 37/CD control/JJ individuals/NNS ./. 
In/IN 29/CD of/IN these/DT patients/NNS ,/, levels/NNS of/IN TCRzeta/NN and/CC p56(lck)/NN were/VBD determined/VBN by/IN Western/NN blots/NNS of/IN T-cell/NN lysates/NNS and/CC semiquantitated/VBN using/VBG densitometry/NN ./. 
Relative/JJ levels/NNS were/VBD then/RB correlated/VBN with/IN a/DT series/NN of/IN clinical/JJ variables/NNS including/VBG response/NN to/TO therapy/NN ,/, performance/NN status/NN ,/, survival/NN ,/, disease/NN sites/NNS ,/, age/NN ,/, and/CC others/NNS ./. 
In/IN another/DT group/NN of/IN 28/CD patients/NNS (/( three/CD individuals/NNS from/IN the/DT first/JJ group/NN )/) ,/, the/DT frequency/NN of/IN abnormal/JJ NFkappaB/NN activation/NN was/VBD studied/VBN using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS after/IN activation/NN of/IN T/NN cells/NNS with/IN phorbol/NN myristate/NN acetate/ionomycin/NN or/CC anti-CD3/JJ monoclonal/JJ antibody/NN ./. 
Changes/NNS in/IN these/DT signaling/VBG molecules/NNS during/IN cytokine/NN treatment/NN were/VBD also/RB investigated/VBN ./. 
TCRzeta/NN and/CC p56(lck)/NN were/VBD detected/VBN in/IN the/DT peripheral/JJ blood/NN T/NN cells/NNS in/IN 27/CD of/IN 29/CD patients/NNS ,/, and/CC overall/RB ,/, reduced/VBN levels/NNS were/VBD noted/VBN visually/RB in/IN 12/CD of/IN 29/CD (/( 41/CD %/NN )/) and/CC 13/CD of/IN 29/CD (/( 45/CD %/NN )/) individuals/NNS ,/, respectively/RB ./. 
When/WRB levels/NNS were/VBD semiquantitated/VBN using/VBG densitometry/NN ,/, significant/JJ decreases/NNS of/IN TCRzeta/NN (/( P/NN =/JJ 0.029/CD )/) and/CC p56(lck)/NN (/( P/NN =/JJ 0.029/CD )/) but/CC not/RB CD3epsilon/NN (/( P/NN =/JJ 0.131/CD )/) ,/, compared/VBN with/IN control/NN levels/NNS ,/, were/VBD found/VBN ./. 
In/IN patients/NNS treated/VBN with/IN IL-2/IFN/NN alpha-based/JJ therapy/NN ,/, relative/JJ levels/NNS of/IN TCRzeta/NN increased/VBD significantly/RB (/( P/NN =/JJ 0.002/CD )/) on/IN day/NN 15/CD of/IN cycle/NN one/CD compared/VBN with/IN the/DT baseline/NN ./. 
Correlations/NNS of/IN TCRzeta/NN or/CC p56(lck)/NN levels/NNS with/IN response/NN or/CC disease/NN variables/NNS ,/, except/IN for/IN lower/JJR TCRzeta/NN levels/NNS (/( P/NN </JJR 0.001/CD )/) in/IN the/DT presence/NN of/IN bone/NN metastases/NNS ,/, were/VBD not/RB found/VBN ./. 
Abnormal/JJ NFkappaB/NN activation/NN after/IN stimulation/NN with/IN phorbol/NN myristate/NN acetate/ionomycin/NN and/or/CC anti-CD3/JJ monoclonal/JJ antibody/NN was/VBD found/VBN in/IN 59/CD %/NN of/IN patients/NNS (/( 17/CD of/IN 28/CD )/) and/CC was/VBD not/RB accounted/VBN for/IN by/IN the/DT advanced/JJ age/NN of/IN the/DT study/NN cohort/NN ./. 
Activation/NN of/IN NFkappaB/NN in/IN peripheral/JJ blood/NN T/NN cells/NNS was/VBD inducible/JJ during/IN cytokine/NN therapy/NN in/IN four/CD of/IN six/CD individuals/NNS who/WP displayed/VBD impaired/JJ NFkappaB/NN activity/NN prior/RB to/TO therapy/NN ./. 
Moreover/RB ,/, impaired/JJ activation/NN of/IN NFkappaB/NN does/VBZ not/RB appear/VB linked/VBN to/TO a/DT reduction/NN of/IN TCRzeta/NN expression/NN ,/, because/IN in/IN five/CD patients/NNS ,/, normal/JJ TCRzeta/NN levels/NNS were/VBD present/JJ although/IN kappaB/NN binding/NN was/VBD not/RB inducible/JJ ./. 
In/IN the/DT majority/NN of/IN patients/NNS with/IN advanced/JJ RCC/NN ,/, peripheral/JJ blood/NN T/NN cells/NNS express/VBP TCRzeta/NN and/CC p56(lck)/NN ,/, and/CC in/IN a/DT subset/NN ,/, reduced/VBN levels/NNS of/IN these/DT TCRzeta/NN associated/JJ molecules/NNS are/VBP seen/VBN that/WDT may/MD increase/VB during/IN cytokine-based/JJ therapy/NN ./. 
Abnormal/JJ activation/NN of/IN NFkappaB/NN is/VBZ also/RB present/JJ in/IN >/JJR 50/CD %/NN of/IN patients/NNS and/CC may/MD also/RB revert/VB to/TO normal/JJ during/IN IL-2/IFN/NN alpha-based/JJ treatment/NN ./. 
This/DT alteration/NN in/IN NFkappaB/NN activation/NN occurred/VBD in/IN the/DT presence/NN of/IN normal/JJ expression/NN of/IN TCRzeta-associated/JJ signaling/NN elements/NNS ./. 
The/DT clinical/JJ significance/NN of/IN these/DT findings/NNS remains/VBZ unclear/JJ ./. 
UI/LS -/: 99006780/CD 
TI/LS -/: Identification/NN of/IN transcription/NN factors/NNS expressed/VBN during/IN ATRA-induced/JJ neutrophil/NN differentiation/NN of/IN HL60/NN cells/NNS ./. 
AB/LS -/: A/DT recent/JJ clinical/JJ therapeutic/JJ initiative/NN has/VBZ been/VBN the/DT use/NN of/IN chemical/JJ agents/NNS which/WDT induce/VBP the/DT leukaemic/JJ cells/NNS to/TO overcome/VB their/PRP$ block/NN in/IN differentiation/NN ./. 
In/IN order/NN to/TO understand/VB this/DT block/NN the/DT cascade/NN of/IN molecular/JJ events/NNS needs/VBZ to/TO be/VB characterized/VBN ./. 
Haemopoietic/JJ differentiation/NN is/VBZ ultimately/RB controlled/VBN at/IN the/DT level/NN of/IN gene/NN transcription/NN which/WDT is/VBZ mediated/VBN by/IN an/DT array/NN of/IN transcription/NN factors/NNS ./. 
Many/JJ transcription/NN factors/NNS contain/VBP similar/JJ structural/JJ protein/NN sequences/NNS ,/, and/CC we/PRP have/VBP used/VBN an/DT RT-PCR-based/JJ approach/NN to/TO isolate/VB sequences/NNS ,/, from/IN transcription/NN factor/NN gene/NN families/NNS which/WDT share/VBP similar/JJ domains/NNS ./. 
Degenerate/NN primers/NNS corresponding/VBG to/TO the/DT TFIIIA/NN zinc-finger/JJ consensus/NN amino/NN acid/NN sequences/NNS and/CC to/TO the/DT POU-homeodomain/NN and/CC POU-specific/JJ domain/NN were/VBD used/VBN to/TO amplify/VB genes/NNS on/IN the/DT basis/NN that/IN they/PRP contained/VBD similarities/NNS in/IN structural/JJ motifs/NNS shared/VBN within/IN these/DT families/NNS of/IN transcription/NN factors/NNS ./. 
A/DT serum-independent/JJ HL60/NN cell/NN line/NN was/VBD induced/VBN towards/IN the/DT neutrophil/NN lineage/NN by/IN treatment/NN with/IN all-trans/JJ retinoic/JJ acid/NN (/( ATRA/NN )/) for/IN 24/CD h/NN ./. 
CD38+/JJ cells/NNS committed/VBN towards/IN this/DT lineage/NN were/VBD enriched/JJ and/CC a/DT population/NN of/IN these/DT cells/NNS treated/VBN with/IN dihydroxyvitamin/NN D3/NN to/TO induce/VB neutrophil/NN maturation/NN ./. 
RNA/NN extracted/VBN from/IN uninduced/JJ ,/, ATRA-induced/JJ CD38+/JJ cells/NNS ,/, and/CC vitamin/NN D3/NN treated/JJ maturing/JJ cell/NN cultures/NNS were/VBD amplified/VBN using/VBG the/DT degenerate/NN primers/NNS ./. 
PCR/NN fragments/NNS were/VBD cloned/VBN ,/, sequenced/VBN ,/, clustered/VBN into/IN homologous/JJ groups/NNS ,/, and/CC the/DT group/NN sequences/NNS searched/VBN on/IN the/DT GenBank/NN database/NN ./. 
The/DT Oct/NN 1/CD transcription/NN factor/NN ,/, and/CC a/DT very/RB close/JJ homologue/NN ,/, KIAA0144/NN ,/, was/VBD identified/VBN using/VBG the/DT POU/NN family/NN primers/NNS ./. 
The/DT zinc-finger/JJ primers/NNS identified/VBD three/CD zinc-finger/JJ genes/NNS ./. 
The/DT pattern/NN of/IN gene/NN expression/NN was/VBD suggested/VBN from/IN the/DT number/NN of/IN clones/NNS in/IN each/DT group/NN at/IN neutrophil/NN commitment/NN and/CC maturation/NN ./. 
The/DT differential/JJ expression/NN of/IN the/DT genes/NNS in/IN the/DT zinc/NN finger/NN and/CC POU/NN families/NNS will/MD lead/VB to/TO a/DT better/JJR understanding/NN of/IN the/DT cascade/NN of/IN gene/NN expression/NN which/WDT occurs/VBZ following/VBG ATRA-induced/JJ differentiation/NN ./. 
UI/LS -/: 98451426/CD 
TI/LS -/: GATA-3-dependent/JJ enhancer/NN activity/NN in/IN IL-4/NN gene/NN regulation/NN ./. 
AB/LS -/: Previously/RB ,/, we/PRP analyzed/VBD the/DT proximal/JJ IL-4/NN promoter/NN in/IN directing/VBG Th2-specific/JJ activity/NN ./. 
An/DT 800-base/JJ pair/NN proximal/JJ promoter/NN conferred/VBD some/DT Th2-selective/JJ expression/NN in/IN transgenic/JJ mice/NNS ./. 
However/RB ,/, this/DT region/NN directed/VBD extremely/RB low/JJ reporter/NN mRNA/NN levels/NNS relative/JJ to/TO endogenous/JJ IL-4/NN mRNA/NN ,/, suggesting/VBG that/IN full/JJ gene/NN activity/NN requires/VBZ additional/JJ enhancer/NN elements/NNS ./. 
Here/RB ,/, we/PRP analyzed/VBD large/JJ genomic/JJ IL-4/NN regions/NNS for/IN enhancer/NN activity/NN and/CC interaction/NN with/IN transcription/NN factors/NNS ./. 
The/DT proximal/JJ IL-4/NN promoter/NN is/VBZ only/RB moderately/RB augmented/VBN by/IN GATA-3/NN ,/, but/CC certain/JJ genomic/JJ regions/NNS significantly/RB enhanced/VBD GATA-3/NN promoter/NN transactivation/NN ./. 
Some/DT enhancing/VBG regions/NNS contained/VBD consensus/NN ,/, GATA/NN sites/NNS that/WDT bound/VBD Th2-specific/JJ complexes/NNS ./. 
However/RB ,/, retroviral/JJ transduction/NN of/IN GATA-3/NN into/IN developing/VBG T/NN cells/NNS induced/VBD IL-5/NN to/TO full/JJ Th2/NN levels/NNS ,/, but/CC only/RB partially/RB restored/VBD IL-4/NN production/NN ./. 
Thus/RB ,/, we/PRP propose/VBP that/IN GATA-3/NN is/VBZ permissive/JJ ,/, but/CC not/RB sufficient/JJ ,/, for/IN full/JJ IL-4/NN enhancement/NN and/CC may/MD act/VB through/IN GATA/NN elements/NNS surrounding/VBG the/DT IL-13/IL-4/NN gene/NN locus/NN ./. 
UI/LS -/: 98438422/CD 
TI/LS -/: Position/NN effect/NN of/IN translocations/NNS involving/VBG the/DT inactive/JJ X/NN chromosome/NN :/: physical/JJ linkage/NN to/TO XIC/XIST/NN does/VBZ not/RB lead/VB to/TO long-range/JJ de/FW novo/FW inactivation/NN in/IN human/JJ differentiated/VBN cells/NNS ./. 
AB/LS -/: Given/VBN the/DT reported/VBN long-range/JJ cis-inactivating/JJ effect/NN of/IN the/DT XIST/NN gene/NN in/IN early/JJ embryonic/JJ development/NN and/CC the/DT lack/NN of/IN requirement/NN of/IN X-/NN chromosome-specific/JJ elements/NNS for/IN propagating/VBG the/DT inactive/JJ state/NN ,/, there/EX exists/VBZ the/DT possibility/NN of/IN cis/JJ inactivation/NN of/IN autosomal/JJ material/JJ after/IN de/FW novo/FW translocation/NN to/TO an/DT inactive/JJ X/NN chromosome/NN (/( Xi/NN )/) in/IN differentiated/VBN cells/NNS ./. 
We/PRP have/VBP analyzed/VBN de/FW novo/FW radiation-induced/JJ translocations/NNS between/IN the/DT Xi/NN and/CC autosomes/NNS to/TO study/VB the/DT maintenance/NN and/CC spreading/NN of/IN X-chromosome/NN inactivation/NN (/( X/NN inactivation/NN )/) in/IN relation/NN to/TO the/DT position/NN of/IN the/DT X-inactivation/NN center/NN (/( XIC/NN )/) /XIST/NN in/IN differentiated/VBN cells/NNS ./. 
Autosome/Xi/NN translocations/NNS were/VBD detected/VBN by/IN fluorescence/NN in/FW situ/FW hybridization/NN (/( FISH/NN )/) ./. 
The/DT activation/NN status/NN of/IN the/DT chromosomes/NNS involved/VBN in/IN the/DT translocation/NN was/VBD determined/VBN by/IN simultaneous/JJ immunocytogenetic/JJ studies/NNS using/VBG antibodies/NNS against/IN either/CC BrdU/NN incorporated/VBN at/IN late/JJ S/NN phase/NN or/CC acetylated/VBN histone/NN H4/NN ./. 
The/DT position/NN of/IN XIC/XIST/NN in/IN the/DT reciprocal/JJ products/NNS of/IN the/DT translocation/NN was/VBD determined/VBN by/IN XIST-specific/JJ FISH/NN and/CC computer/NN enhancement/NN ./. 
In/IN other/JJ experiments/NNS ,/, the/DT Xq13/NN region/NN carrying/VBG XIC/XIST/NN was/VBD localized/VBN by/IN computer/NN enhancement/NN of/IN the/DT DAPI/NN banding/NN pattern/NN ./. 
Our/PRP$ study/NN in/IN differentiated/VBN cells/NNS provides/VBZ a/DT visual/JJ demonstration/NN that/IN physical/JJ separation/NN from/IN XIC/XIST/NN does/VBZ not/RB result/VB in/IN reactivation/NN of/IN inactive/JJ X-chromosome/NN material/NN and/CC that/IN X/NN inactivation/NN is/VBZ not/RB spread/VBN to/TO the/DT translocated/VBN autosomes/NNS irrespective/RB of/IN the/DT position/NN of/IN XIC/XIST/NN ./. 
This/DT observation/NN suggests/VBZ that/IN physical/JJ linkage/NN to/TO XIC/XIST/NN does/VBZ not/RB lead/VB to/TO de/FW novo/FW inactivation/NN of/IN autosomal/JJ material/JJ ./. 
UI/LS -/: 98421396/CD 
TI/LS -/: Interleukin-4/NN and/CC -13/CD induce/VBP upregulation/NN of/IN the/DT murine/JJ macrophage/NN 12/15-lipoxygenase/NN activity/NN :/: evidence/NN for/IN the/DT involvement/NN of/IN transcription/NN factor/NN STAT6/NN ./. 
AB/LS -/: When/WRB human/JJ monocytes/NNS or/CC alveolar/JJ macrophages/NNS are/VBP cultured/VBN in/IN the/DT presence/NN of/IN interleukin/NN (/( IL/NN )/) -4/CD or/CC IL-13/NN ,/, the/DT expression/NN of/IN the/DT reticulocyte-type/JJ 15-lipoxygenase/NN is/VBZ induced/VBN ./. 
In/IN mice/NNS a/DT 15-lipoxygenase/NN is/VBZ not/RB expressed/VBN ,/, but/CC a/DT leukocyte-type/NN 12-lipoxygenase/NN is/VBZ present/JJ in/IN peritoneal/JJ macrophages/NNS ./. 
To/TO investigate/VB whether/IN both/CC lipoxygenase/NN isoforms/NNS exhibit/VBP a/DT similar/JJ regulatory/JJ response/NN toward/IN cytokine/NN stimulation/NN ,/, we/PRP studied/VBD the/DT regulation/NN of/IN the/DT leukocyte-type/NN 12-lipoxygenase/NN of/IN murine/JJ peritoneal/JJ macrophages/NNS by/IN interleukins/NNS and/CC found/VBD that/IN the/DT activity/NN of/IN this/DT enzyme/NN is/VBZ upregulated/VBN in/IN a/DT dose-dependent/JJ manner/NN when/WRB the/DT cells/NNS were/VBD cultured/VBN in/IN the/DT presence/NN of/IN the/DT IL-4/NN or/CC IL-13/NN but/CC not/RB by/IN IL-10/NN ./. 
When/WRB peripheral/JJ murine/JJ monocytes/NNS that/WDT do/VBP not/RB express/VB the/DT lipoxygenase/NN were/VBD treated/VBN with/IN IL-4/NN expression/NN of/IN 12/15-lipoxygenase/NN mRNA/NN was/VBD induced/VBN ,/, suggesting/VBG pretranslational/JJ control/NN mechanisms/NNS ./. 
In/IN contrast/NN ,/, no/DT upregulation/NN of/IN the/DT lipoxygenase/NN activity/NN was/VBD observed/VBN when/WRB the/DT macrophages/NNS were/VBD prepared/VBN from/IN homozygous/JJ STAT6-deficient/JJ mice/NNS ./. 
Peritoneal/JJ macrophages/NNS of/IN transgenic/JJ mice/NNS that/WDT systemically/RB overexpress/VBP IL-4/NN exhibited/VBD a/DT threefold/RB to/TO fourfold/RB higher/JJR 12-lipoxygenase/NN activity/NN than/IN cells/NNS prepared/VBN from/IN control/JJ animals/NNS ./. 
A/DT similar/JJ upregulation/NN of/IN 12-lipoxygenase/NN activity/NN was/VBD detected/VBN in/IN heart/NN ,/, spleen/NN ,/, and/CC lung/NN of/IN the/DT transgenic/JJ animals/NNS ./. 
Moreover/RB ,/, a/DT strong/JJ induction/NN of/IN the/DT enzyme/NN was/VBD observed/VBN in/IN red/JJ cells/NNS during/IN experimental/JJ anemia/NN in/IN mice/NNS ./. 
The/DT data/NNS presented/VBN here/RB indicate/VBP that/IN (/( 1/LS )/) the/DT 12-lipoxygenase/NN activity/NN of/IN murine/JJ macrophages/NNS is/VBZ upregulated/VBN in/FW vitro/FW and/CC in/FW vivo/FW by/IN IL-4/NN and/or/CC IL-13/NN ,/, (/( 2/LS )/) this/DT upregulation/NN requires/VBZ expression/NN of/IN the/DT transcription/NN factor/NN STAT6/NN ,/, and/CC (/( 3/LS )/) the/DT constitutive/JJ expression/NN of/IN the/DT enzyme/NN appears/VBZ to/TO be/VB STAT6/NN independent/JJ ./. 
The/DT cytokine-dependent/JJ upregulation/NN of/IN the/DT murine/JJ macrophage/NN 12-lipoxygenase/NN and/CC its/PRP$ induction/NN during/IN experimental/JJ anemia/NN suggests/VBZ its/PRP$ close/JJ relatedness/NN with/IN the/DT human/JJ reticulocyte-type/NN 15-lipoxygenase/NN despite/IN their/PRP$ differences/NNS in/IN the/DT positional/JJ specificity/NN of/IN arachidonic/JJ acid/NN oxygenation/NN ./. 
UI/LS -/: 98405747/CD 
TI/LS -/: Interferon-gamma-induced/JJ factor/NN binding/VBG to/TO the/DT interleukin-4-responsive/JJ element/NN of/IN CD23b/NN promoter/NN in/IN human/JJ tonsillar/JJ mononuclear/JJ cells/NNS :/: role/NN in/IN transient/JJ up-regulation/NN of/IN the/DT interleukin-4-induced/JJ CD23b/NN mRNA/NN ./. 
AB/LS -/: Stimulation/NN of/IN human/JJ tonsillar/JJ mononuclear/JJ cells/NNS with/IN interleukin-4/NN (/( IL-4/NN )/) and/CC interferon-gamma/NN (/( IFN-gamma/NN )/) rapidly/RB induced/VBD the/DT activation/NN of/IN distinct/JJ nuclear/JJ factors/NNS with/IN different/JJ mobilities/NNS ,/, both/DT of/IN which/WDT bind/VBP the/DT IL-4/NN response/NN element/NN (/( IL-4RE/NN )/) of/IN CD23b/NN promoter/NN as/IN examined/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS (/( EMSA/NNS )/) ./. 
Co-treatment/NN of/IN IL-4/NN and/CC IFN-gamma/NN induced/VBD ,/, in/IN addition/NN to/TO the/DT two/CD distinct/JJ complexes/NNS ,/, a/DT new/JJ complex/NN with/IN an/DT intermediate/JJ mobility/NN ./. 
The/DT IL-4-induced/JJ complex/NN reacted/VBD with/IN anti-STAT/NN (/( signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN )/) 6/CD ,/, resulting/VBG in/IN a/DT supershift/NN whereas/IN the/DT formation/NN of/IN the/DT IFN-gamma-induced/JJ complex/NN was/VBD inhibited/VBN by/IN anti-STAT/NN 1/CD ./. 
The/DT intermediate/JJ complex/NN appeared/VBD to/TO react/VB with/IN both/CC anti-STAT/NN 6/CD and/CC anti-STAT/NN 1/CD ./. 
Although/IN IFN-gamma/NN alone/RB did/VBD not/RB induce/VB CD23/NN mRNA/NN transcription/NN ,/, Northern/NN blot/NN analysis/NN revealed/VBD a/DT transient/JJ up-regulation/NN of/IN the/DT IL-4-induced/JJ CD23/NN mRNA/NN by/IN IFN-gamma/NN within/IN 2/CD h/NN of/IN IFN-gamma/NN treatment/NN in/IN these/DT tonsillar/JJ cells/NNS ./. 
The/DT results/NNS suggest/VBP that/IN the/DT IL-4RE/NN of/IN the/DT IL-4-inducible/JJ gene/NN can/MD accommodate/VB both/CC IL-4-/NN and/CC IFN-gamma-activated/JJ factors/NNS ,/, such/JJ as/IN STAT/NNS 6/CD and/CC STAT/NN 1/CD ,/, either/CC in/IN homodimeric/JJ or/CC heterodimeric/JJ forms/NNS and/CC the/DT binding/NN of/IN these/DT different/JJ proteins/NNS to/TO the/DT respective/JJ promoter/NN may/MD play/VB a/DT potential/JJ regulatory/JJ role/NN in/IN the/DT IL-4-/NN inducible/NN gene/NN expression/NN ./. 
UI/LS -/: 98395152/CD 
TI/LS -/: A/DT p56lck-independent/JJ pathway/NN of/IN CD2/NN signaling/NN involves/VBZ Jun/NN kinase/NN ./. 
AB/LS -/: The/DT p56/NN Src/NN family/NN non-receptor/JJ tyrosine/NN kinase/NN has/VBZ been/VBN shown/VBN to/TO be/VB critical/JJ for/IN T/NN lymphocyte/NN differentiation/NN and/CC activation/NN ./. 
Hence/RB in/IN the/DT absence/NN of/IN p56/NN ,/, T/NN cell/NN receptor/NN triggered/JJ activation/NN does/VBZ not/RB occur/VB ./. 
We/PRP now/RB provide/VBP evidence/NN for/IN a/DT CD2-based/JJ signaling/NN pathway/NN which/WDT ,/, in/IN contrast/NN to/TO that/DT of/IN the/DT T/NN cell/NN receptor/NN ,/, is/VBZ independent/JJ of/IN p56/NN ./. 
CD2-mediated/JJ interleukin-2/NN production/NN occurs/VBZ via/IN activation/NN of/IN Jun/NN kinase/NN in/IN cell/NN lines/NNS lacking/VBG p56/NN ./. 
Jun/NN kinase/NN then/RB facilitates/VBZ the/DT binding/NN of/IN c-Jun/c-Fos/NN heterodimers/NNS to/TO the/DT AP-1/NN consensus/NN site/NN and/CC the/DT subsequent/JJ transcriptional/JJ activity/NN of/IN the/DT interleukin-2/NN promoter/NN ./. 
These/DT data/NNS elucidate/VBP differences/NNS between/IN TCR/NN and/CC CD2/NN signaling/NN pathways/NNS in/IN the/DT same/JJ T/NN cells/NNS ./. 
UI/LS -/: 98389801/CD 
TI/LS -/: Activation/NN of/IN E2F-mediated/JJ transcription/NN by/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD Tax/NN protein/NN in/IN a/DT p16/NN (/( INK4A/NN )/) -negative/JJ T-cell/NN line/NN ./. 
AB/LS -/: The/DT human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) is/VBZ a/DT causative/JJ agent/NN of/IN adult/JJ T-cell/NN leukemia/NN ./. 
Although/IN the/DT exact/NN mechanism/NN by/IN which/WDT HTLV-I/NN contributes/VBZ to/TO leukemogenesis/NN is/VBZ still/RB unclear/JJ ,/, the/DT Tax/NN protein/NN is/VBZ thought/VBN to/TO play/VB a/DT major/JJ role/NN in/IN this/DT process/NN ./. 
This/DT 40-kDa/JJ polypeptide/NN is/VBZ able/JJ to/TO interact/VB with/IN the/DT tumor/NN suppressor/NN p16/NN (/( INK4A/NN )/) ./. 
Consequently/RB ,/, Tax/NN can/MD activate/VB the/DT signaling/NN pathway/NN that/WDT lead/VBP to/TO the/DT release/NN of/IN E2F/NN that/WDT in/IN turn/NN induces/VBZ expression/NN of/IN factors/NNS required/VBN for/IN cell/NN cycle/NN progression/NN ./. 
In/IN this/DT paper/NN ,/, we/PRP demonstrate/VBP that/IN Tax/NN can/MD also/RB activate/VB E2F-mediated/JJ transcription/NN independently/RB of/IN p16/NN (/( INK4A/NN )/) ./. 
Indeed/RB ,/, when/WRB Tax/NN is/VBZ coexpressed/VBN with/IN the/DT E2F-1/NN transcription/NN factor/NN in/IN CEM/NN T-cells/NNS ,/, which/WDT lack/VBP expression/NN of/IN p16/NN (/( INK4A/NN )/) ,/, it/PRP strongly/RB potentiates/VBZ the/DT E2F-dependent/JJ activation/NN of/IN a/DT reporter/NN construct/NN driven/VBN by/IN a/DT promoter/NN containing/VBG E2F/NN binding/NN sites/NNS ./. 
This/DT stimulation/NN is/VBZ abrogated/VBN by/IN mutations/NNS affecting/VBG the/DT E2F-binding/JJ sites/NNS ./. 
In/IN addition/NN ,/, Tax/NN also/RB stimulates/VBZ the/DT transcription/NN of/IN the/DT E2F-1/NN gene/NN itself/PRP ./. 
Using/VBG Tax/NN mutants/NNS that/WDT fail/VBP to/TO activate/VB either/CC ATF-/NN or/CC NF-kappaB-dependent/JJ promoters/NNS and/CC different/JJ 5'/JJ truncation/NN mutants/NNS of/IN the/DT E2F-1/NN promoter/NN ,/, we/PRP show/VBP that/IN the/DT Tax-dependent/JJ transcriptional/JJ control/NN of/IN the/DT E2F1/NN gene/NN involves/VBZ ,/, at/IN least/JJS in/IN part/NN ,/, the/DT ATF/NN binding/NN site/NN located/JJ in/IN the/DT E2F-1/NN promoter/NN ./. 
UI/LS -/: 98375886/CD 
TI/LS -/: Inducible/JJ nitric/JJ oxide/NN :/: an/DT autoregulatory/JJ feedback/NN inhibitor/NN of/IN vascular/JJ inflammation/NN ./. 
AB/LS -/: Inducible/JJ nitric/JJ oxide/NN (/( iNO/NN )/) is/VBZ produced/VBN at/IN sites/NNS of/IN vascular/JJ inflammation/NN by/IN resident/JJ and/CC nonresident/JJ vascular/JJ wall/NN cells/NNS ,/, but/CC its/PRP$ role/NN in/IN the/DT inflammatory/JJ process/NN is/VBZ not/RB known/VBN ./. 
In/IN this/DT study/NN ,/, we/PRP show/VBP that/IN a/DT novel/JJ function/NN of/IN iNO/NN is/VBZ to/TO terminate/VB inflammatory/JJ processes/NNS ./. 
We/PRP find/VBP that/IN iNO/NN produced/VBN by/IN murine/JJ macrophage-like/JJ cells/NNS ,/, RAW264.7/NN ,/, can/MD inhibit/VB cytokine-induced/JJ endothelial/JJ cell/NN activation/NN in/IN a/DT separated/JJ and/CC mixed/JJ endothelial-RAW264.7/NN coculture/NN system/NN ./. 
Both/CC iNO/NN production/NN and/CC endothelial/JJ VCAM-1/NN expression/NN were/VBD induced/VBN simultaneously/RB with/IN bacterial/JJ LPS/NN and/CC murine-specific/JJ IFN-gamma/NN ./. 
Inhibition/NN of/IN iNO/NN synthase/NN (/( iNOS/NN )/) activity/NN with/IN N/NN omega-monomethyl-L-arginine/NN in/IN endothelial-RAW264.7/NN cocultures/NNS ,/, stimulated/VBN with/IN murine-specific/JJ IFN-gamma/NN and/CC LPS/NN ,/, decreased/VBD iNO/NN production/NN by/IN 86/CD %/NN ,/, augmented/VBD VCAM-1/NN and/CC iNOS/NN expression/NN in/IN endothelial/JJ and/CC RAW264.7/NN cells/NNS ,/, respectively/RB ,/, and/CC increased/VBD monocyte/NN adhesion/NN to/TO the/DT endothelial/JJ cell/NN surface/NN ./. 
Transient/JJ transfection/NN studies/NNS using/VBG various/JJ VCAM-1/NN promoter/NN constructs/NNS demonstrated/VBD that/IN inhibitory/JJ effects/NNS of/IN iNO/NN on/IN VCAM-1/NN gene/NN transcription/NN were/VBD mediated/VBN ,/, in/IN part/NN ,/, by/IN inhibitory/JJ effects/NNS of/IN iNO/NN on/IN kappa/NN B/NN cis-acting/JJ elements/NNS ./. 
Immunofluorescence/NN studies/NNS using/VBG an/DT Ab/NN to/TO the/DT RelA/NN (/( p65/NN )/) subunit/NN of/IN nuclear/JJ factor-kappa/NN B/NN revealed/VBD that/IN iNO/NN inhibited/VBD the/DT activation/NN of/IN nuclear/JJ factor-kappa/NN B/NN ./. 
These/DT studies/NNS indicate/VBP that/IN iNO/NN attenuates/VBZ iNOS/NN expression/NN in/IN macrophages/NNS and/CC inhibits/VBZ monocyte/NN adhesion/NN to/TO endothelial/JJ cells/NNS ,/, and/CC suggest/VBP that/IN endogenously/RB derived/VBN iNO/NN may/MD be/VB an/DT important/JJ autoregulatory/JJ inhibitor/NN of/IN vascular/JJ inflammation/NN 
UI/LS -/: 99023607/CD 
TI/LS -/: Detection/NN of/IN oestrogen/NN receptor/NN variants/NNS in/IN endometrium/NN ,/, myometrium/NN ,/, leiomyoma/NN and/CC peripheral/JJ blood/NN mononuclear/JJ cells/NNS :/: comparison/NN to/TO variants/NNS present/JJ in/IN breast/NN cancer/NN ./. 
AB/LS -/: Oestradiol/NN has/VBZ mitogenic/JJ and/CC regulatory/JJ effects/NNS on/IN various/JJ organs/NNS and/CC cells/NNS ,/, mediated/VBN mainly/RB by/IN its/PRP$ nuclear/JJ receptor/NN (/( ER/NN )/) ./. 
The/DT presence/NN of/IN aberrant/JJ ER/NN forms/NNS in/IN Oestrogen-dependent/JJ tumours/NNS has/VBZ been/VBN discussed/VBN in/IN correlation/NN with/IN tumour/NN progression/NN ./. 
ER/NN variants/NNS ,/, generated/VBN by/IN alternative/JJ splicing/NN ,/, have/VBP been/VBN detected/VBN in/IN human/JJ breast/NN cancer/NN ,/, but/CC also/RB in/IN normal/JJ mammary/JJ glands/NNS ,/, therefore/RB their/PRP$ role/NN in/IN tumorigenesis/NN has/VBZ been/VBN questioned/VBN ./. 
We/PRP have/VBP investigated/VBN ,/, by/IN the/DT use/NN of/IN the/DT reverse/JJ transcription/NN polymerase/NN chain/NN reaction/NN amplification/NN technique/NN ,/, the/DT possible/JJ existence/NN of/IN ER/NN variants/NNS in/IN other/JJ normal/JJ oestrogen/NN target/NN organs/NNS and/CC cells/NNS ,/, such/JJ as/IN uterus/NN (/( myometrium/NN and/CC endometrium/NN )/) ,/, in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS and/CC in/IN a/DT benign/JJ uterus/NN tumour/NN (/( leiomyoma/NN )/) ./. 
We/PRP have/VBP detected/VBN variant/JJ ER/NN in/IN these/DT samples/NNS and/CC have/VBP compared/VBN the/DT variant/JJ profile/NN to/TO that/DT observed/VBN in/IN breast/NN cancer/NN ./. 
All/DT tissues/NNS and/CC cells/NNS studied/VBN expressed/VBD both/CC wild-type/JJ ER/NN and/CC variant/JJ species/NNS ./. 
Variant/JJ forms/NNS encompassed/VBD ER/NN with/IN deletions/NNS of/IN exons/NNS 2/CD ,/, 5/CD and/CC 7/CD ./. 
Variants/NNS with/IN exon/NN 5/CD deleted/VBN were/VBD detected/VBN only/RB in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS and/CC in/IN breast/NN cancer/NN ./. 
Variants/NNS with/IN exons/NNS 2/CD and/CC 7/CD deleted/VBN were/VBD present/JJ in/IN all/DT specimens/NNS tested/VBN ./. 
These/DT results/NNS corroborate/VBP previous/JJ findings/NNS that/IN the/DT presence/NN of/IN ER/NN variants/NNS is/VBZ not/RB a/DT characteristic/NN of/IN breast/NN cancer/NN ./. 
The/DT physiological/JJ significance/NN and/CC possible/JJ clinical/JJ relevance/NN of/IN the/DT variant/JJ ER/NN forms/NNS remain/VBP to/TO be/VB elucidated/VBN ./. 
UI/LS -/: 99010726/CD 
TI/LS -/: p21ras/NN initiates/VBZ Rac-1/NN but/CC not/RB phosphatidyl/NN inositol/NN 3/CD kinase/PKB/NN ,/, mediated/VBN signaling/NN pathways/NNS in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: p21ras/NN is/VBZ activated/VBN by/IN the/DT T/NN cell/NN antigen/NN receptor/NN (/( TCR/NN )/) and/CC then/RB co-ordinates/VBZ important/JJ signaling/NN pathways/NNS for/IN T/NN lymphocyte/NN activation/NN ./. 
Effector/NN pathways/NNS for/IN this/DT guanine/NN nucleotide/NN binding/NN protein/NN in/IN T/NN cells/NNS are/VBP mediated/VBN by/IN the/DT serine/threonine/NN kinase/NN Raf-1/NN and/CC the/DT Ras-related/JJ GTPase/NN Rac-1/NN ./. 
In/IN fibroblasts/NNS ,/, an/DT important/JJ effector/NN for/IN the/DT Ras/NN oncogene/NN is/VBZ Phosphatidylinositol/NN 3-kinase/NN (/( PtdIns/NN 3-kinase/NN )/) ./. 
Activation/NN of/IN this/DT lipid/NN kinase/NN is/VBZ able/JJ to/TO induce/VB critical/JJ Rac-1/NN signaling/NN pathways/NNS and/CC can/MD couple/VB p21ras/NN to/TO cell/NN survival/NN mechanisms/NNS via/IN the/DT serine/threonine/NN kinase/NN Akt/PKB/NN ./. 
The/DT role/NN of/IN PtdIns/NN 3-kinase/NN in/IN Ras/NN signaling/NN in/IN T/NN cells/NNS has/VBZ not/RB been/VBN explored/VBN ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP examined/VBD the/DT ability/NN of/IN PtdIns/NN 3-kinase/NN to/TO initiate/VB the/DT Rac-1/NN signaling/NN pathways/NNS important/JJ for/IN T/NN cell/NN activation/NN ./. 
We/PRP also/RB examined/VBD the/DT possibility/NN that/IN Akt/PKB/NN is/VBZ regulated/VBN by/IN Ras/NN signaling/NN pathways/NNS in/IN T/NN lymphocytes/NNS ./. 
The/DT results/NNS show/VBP that/IN Ras/NN can/MD initiate/VB a/DT Rac-1/NN mediated/JJ pathway/NN that/WDT regulates/VBZ the/DT transcriptional/JJ function/NN of/IN AP-1/NN complexes/NNS ./. 
PtdIns/NN 3-kinase/NN signals/NNS can/MD not/RB mimic/VB p21ras/NN and/CC induce/VB the/DT Rac/NN mediated/JJ responses/NNS of/IN AP-1/NN transcriptional/JJ activation/NN ./. 
Moreover/RB ,/, neither/CC TCR/NN or/CC Ras/NN activation/NN of/IN AP-1/NN is/VBZ dependent/JJ on/IN PtdIns/NN 3-kinase/NN ./. 
PKB/NN is/VBZ activated/VBN in/IN response/NN to/TO triggering/NN of/IN the/DT T/NN cell/NN antigen/NN receptor/NN ;/: PtdIns/NN 3-kinase/NN activity/NN is/VBZ both/CC required/VBN and/CC sufficient/JJ for/IN this/DT TCR/NN response/NN ./. 
In/IN contrast/NN ,/, p21ras/NN signals/NNS are/VBP unable/JJ to/TO induce/VB Akt/PKB/NN activity/NN in/IN T/NN cell/NN nor/CC is/VBZ Ras/NN function/NN required/VBN for/IN Akt/PKB/NN activation/NN in/IN response/NN to/TO the/DT TCR/NN ./. 
The/DT present/JJ data/NNS thus/RB highlight/VBP that/IN PtdIns/NN 3-kinase/NN and/CC Akt/PKB/NN are/VBP not/RB universal/JJ Ras/NN effector/NN molecules/NNS ./. 
Ras/NN can/MD initiate/VB Rac-1/NN regulated/JJ signaling/NN pathways/NNS in/IN the/DT context/NN of/IN T/NN cell/NN antigen/NN receptor/NN function/NN independently/RB of/IN PtdIns/NN 3-kinase/NN activity/NN ./. 
UI/LS -/: 99006628/CD 
TI/LS -/: Interleukin/NN 1beta/NN mediates/VBZ the/DT modulatory/JJ effects/NNS of/IN monocytes/NNS on/IN LNCaP/NN human/JJ prostate/NN cancer/NN cells/NNS ./. 
AB/LS -/: Proliferative/JJ and/CC secretory/JJ responses/NNS in/IN androgen-sensitive/JJ prostate/NN cancer/NN LNCaP/NN cells/NNS are/VBP regulated/VBN by/IN steroid/NN and/CC peptide/NN hormones/NNS and/CC by/IN differentiation-promoting/JJ substances/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP evaluated/VBD whether/IN peripheral/JJ blood/NN monocytes/NNS that/WDT exhibit/VBP anti-tumour/JJ activity/NN in/IN haematopoietic/JJ and/CC solid/JJ tumours/NNS influence/VBP growth/NN and/CC secretion/NN in/IN the/DT LNCaP/NN cell/NN line/NN ./. 
For/IN this/DT purpose/NN ,/, LNCaP/NN cells/NNS were/VBD incubated/VBN with/IN monocyte-conditioned/JJ medium/NN (/( MCM/NN )/) ,/, and/CC proliferation/NN as/RB well/RB as/IN expression/NN of/IN androgen/NN receptor/NN (/( AR/NN )/) and/CC secretion/NN of/IN prostate-specific/JJ antigen/NN (/( PSA/NN )/) were/VBD assessed/VBN ./. 
Conditioned/JJ medium/NN from/IN monocytes/NNS reduced/VBD proliferation/NN in/IN a/DT dose-dependent/JJ manner/NN ./. 
Incubation/NN with/IN 40/CD %/NN MCM/NN caused/VBD a/DT 50/CD %/NN reduction/NN in/IN cell/NN proliferation/NN ./. 
AR/NN protein/NN decreased/VBD by/IN 70/CD %/NN and/CC PSA/NN levels/NNS in/IN supernatants/NNS from/IN LNCaP/NN cells/NNS were/VBD reduced/VBN by/IN approximately/RB 80/CD %/NN following/VBG treatment/NN with/IN MCM/NN ./. 
We/PRP focused/VBD on/IN the/DT contribution/NN of/IN two/CD major/JJ products/NNS of/IN activated/VBN monocytes/NNS ,/, prostaglandin/NN E2/NN and/CC interleukin/NN 1beta/NN (/( IL-1beta/NN )/) ,/, to/TO the/DT MCM/NN modulatory/JJ action/NN ./. 
LNCaP/NN cells/NNS treated/VBN with/IN prostaglandin/NN E2/NN showed/VBD neither/CC a/DT reduction/NN in/IN proliferation/NN nor/CC a/DT down-regulation/NN of/IN AR/NN and/CC PSA/NN levels/NNS ./. 
The/DT effects/NNS of/IN MCM/NN on/IN cellular/JJ proliferation/NN ,/, AR/NN protein/NN and/CC PSA/NN secretion/NN were/VBD abolished/VBN by/IN pretreatment/NN of/IN MCM/NN with/IN a/DT neutralizing/VBG anti-IL-1beta/NN antibody/NN ./. 
In/IN addition/NN ,/, recombinant/JJ IL-1beta/NN was/VBD able/JJ to/TO replace/VB MCM/NN for/IN the/DT inhibition/NN of/IN proliferation/NN and/CC down-regulation/NN of/IN AR/NN and/CC PSA/NN proteins/NNS ./. 
LNCaP/NN cells/NNS were/VBD shown/VBN to/TO express/VB the/DT IL-1beta/NN receptor/NN type/NN 1/CD ,/, which/WDT transduces/VBZ IL-1beta/NN signal/NN ./. 
Our/PRP$ findings/NNS reveal/VBP that/IN monocyte-derived/JJ IL-1beta/NN inhibits/VBZ the/DT proliferation/NN of/IN androgen-responsive/JJ prostate/NN tumour/NN cells/NNS and/CC reduces/VBZ AR/NN and/CC PSA/NN levels/NNS ./. 
UI/LS -/: 98451425/CD 
TI/LS -/: Differential/JJ responsiveness/NN of/IN the/DT IL-5/NN and/CC IL-4/NN genes/NNS to/TO transcription/NN factor/NN GATA-3/NN ./. 
AB/LS -/: The/DT cytokines/NNS IL-4/NN and/CC IL-5/NN are/VBP often/RB coordinately/RB produced/VBN by/IN Th2/NN cells/NNS as/IN in/IN asthma/NN ./. 
However/RB ,/, it/PRP is/VBZ unclear/JJ whether/IN similar/JJ molecular/JJ mechanisms/NNS underlie/VBP transcription/NN of/IN the/DT two/CD genes/NNS ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN the/DT transcription/NN factor/NN GATA-3/NN is/VBZ expressed/VBN in/IN Th2/NN but/CC not/RB Th1/NN cells/NNS and/CC is/VBZ crucial/JJ for/IN activation/NN of/IN the/DT IL-5/NN promoter/NN by/IN different/JJ stimuli/NNS ./. 
In/IN a/DT different/JJ study/NN ,/, GATA-3/NN was/VBD shown/VBN to/TO be/VB sufficient/JJ for/IN the/DT expression/NN of/IN IL-4/NN and/CC other/JJ Th2/NN cytokine/NN genes/NNS ./. 
Here/RB ,/, we/PRP show/VBP that/IN ectopic/JJ expression/NN of/IN GATA-3/NN is/VBZ sufficient/JJ to/TO drive/VB IL-5/NN but/CC not/RB IL-4/NN gene/NN expression/NN ./. 
Also/RB ,/, in/IN Th2/NN cells/NNS ,/, antisense/JJ GATA-3/NN RNA/NN inhibits/VBZ IL-5/NN but/CC not/RB IL-4/NN promoter/NN activation/NN ./. 
The/DT induction/NN of/IN IL-5/NN gene/NN expression/NN by/IN GATA-3/NN involves/VBZ high/JJ affinity/NN binding/NN of/IN GATA-3/NN to/TO an/DT inverted/JJ GATA/NN repeat/NN in/IN the/DT IL-5/NN promoter/NN ./. 
UI/LS -/: 98438586/CD 
TI/LS -/: The/DT interleukin/NN 2/CD receptor/NN alpha/NN chain/CD25/NN promoter/NN is/VBZ a/DT target/NN for/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS ./. 
AB/LS -/: The/DT expression/NN of/IN the/DT murine/JJ interleukin/NN (/( IL/NN )/) -2/CD receptor/NN alpha/NN chain/CD25/NN is/VBZ strongly/RB induced/VBN at/IN the/DT transcriptional/JJ level/NN after/IN T/NN cell/NN activation/NN ./. 
We/PRP show/VBP here/RB that/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cell/NN (/( NF-AT/NN )/) factors/NNS are/VBP involved/VBN in/IN the/DT control/NN of/IN CD25/NN promoter/NN induction/NN in/IN T/NN cells/NNS ./. 
NF-ATp/NN and/CC NF-ATc/NN bind/VBP to/TO two/CD sites/NNS around/IN positions/NNS -585/CD and/CC -650/CD located/JJ upstream/JJ of/IN the/DT proximal/JJ CD25/NN promoter/NN ./. 
Immediately/RB 3'/JJ from/IN these/DT NF-AT/NN motifs/NNS ,/, nonconsensus/JJ sites/NNS are/VBP located/JJ for/IN the/DT binding/NN of/IN AP-1-like/JJ factors/NNS ./. 
Mutations/NNS of/IN sites/NNS that/WDT suppress/VBP NF-AT/NN binding/NN impair/VBP the/DT induction/NN and/CC strong/JJ NF-ATp-mediated/JJ transactivation/NN of/IN the/DT CD25/NN promoter/NN in/IN T/NN cells/NNS ./. 
In/IN T/NN lymphocytes/NNS from/IN NF-ATp-deficient/JJ mice/NNS ,/, the/DT expression/NN of/IN CD25/NN is/VBZ severely/RB impaired/JJ ,/, leading/VBG to/TO a/DT delayed/VBN IL-2/NN receptor/NN expression/NN after/IN T/NN cell/NN receptor/NN (/( TCR/NN )/) /CD3/NN stimulation/NN ./. 
Our/PRP$ data/NNS indicate/VBP an/DT important/JJ role/NN for/IN NF-AT/NN in/IN the/DT faithful/JJ expression/NN of/IN high/JJ affinity/NN IL-2/NN receptors/NNS and/CC a/DT close/JJ link/NN between/IN the/DT TCR-mediated/JJ induction/NN of/IN IL-2/NN and/CC IL-2/NN receptor/NN alpha/NN chain/NN promoters/NNS ,/, both/DT of/IN which/WDT are/VBP regulated/VBN by/IN NF-AT/NN factors/NNS ./. 
UI/LS -/: 98421365/CD 
TI/LS -/: A/DT novel/JJ mutation/NN in/IN the/DT coding/VBG sequence/NN of/IN the/DT FY*B/NN allele/NN of/IN the/DT Duffy/NN chemokine/NN receptor/NN gene/NN is/VBZ associated/VBN with/IN an/DT altered/JJ erythrocyte/NN phenotype/NN ./. 
AB/LS -/: The/DT Duffy/NN blood/NN group/NN system/NN is/VBZ of/IN clinical/JJ and/CC biological/JJ significance/NN ./. 
Antibodies/NNS to/TO Duffy/NN antigens/NNS are/VBP responsible/JJ for/IN some/DT cases/NNS of/IN transfusion/NN incompatibility/NN and/CC newborn/JJ hemolytic/JJ disease/NN ./. 
The/DT Duffy/NN protein/NN is/VBZ a/DT receptor/NN for/IN the/DT Plasmodium/NN vivax/NN erythrocyte-binding/JJ protein/NN and/CC is/VBZ also/RB a/DT receptor/NN for/IN various/JJ chemokines/NNS (/( thus/RB renamed/VBN Duffy/NN Antigen/NN Receptor/NN for/IN Chemokines/NNS [/( DARC/NN ]/) )/) ./. 
The/DT two/CD Duffy/NN polymorphic/JJ antigens/NNS ,/, Fya/NN and/CC Fyb/NN (/( coded/VBN by/IN the/DT FY*A/NN and/CC FY*B/NN alleles/NNS )/) ,/, are/VBP present/JJ on/IN erythrocyte/NN membranes/NNS ./. 
The/DT Fy(a-b-)/NN phenotype/NN is/VBZ the/DT predominant/JJ one/CD in/IN populations/NNS of/IN black/JJ people/NN and/CC also/RB occurs/VBZ in/IN other/JJ populations/NNS ,/, including/VBG some/DT non-Ashkenazi/JJ Jewish/JJ|NN groups/NNS ./. 
The/DT Fy(a-b-)/NN phenotype/NN has/VBZ been/VBN associated/VBN with/IN a/DT mutation/NN in/IN the/DT FY*B/NN promoter/NN at/IN the/DT GATA/NN box/NN that/WDT abolishes/VBZ the/DT expression/NN of/IN erythrocyte/NN Duffy/NN protein/NN ./. 
We/PRP describe/VBP here/RB a/DT novel/JJ mutation/NN ,/, present/JJ in/IN the/DT FY*B/NN coding/VBG sequence/NN (/( 271C/NN -->/TO T/NN )/) ,/, that/WDT is/VBZ associated/VBN with/IN some/DT Fy(b-)/NN phenotypes/NNS among/IN non-Ashkenazi/JJ Jews/NNS and/CC among/IN Brazilian/JJ blacks/NNS ./. 
The/DT mutation/NN is/VBZ present/JJ in/IN Fy(b-)/NN individuals/NNS ,/, who/WP have/VBP wild-type/JJ FY*B/NN GATA/NN and/CC carry/VBP the/DT previously/RB described/VBN 304G/NN -->/TO A/NN substitution/NN ./. 
The/DT 271C/NN -->/TO T/NN and/CC 304G/NN -->/TO A/NN can/MD be/VB identified/VBN by/IN restriction/NN enzyme-generated/JJ restriction/NN fragment/NN length/NN polymorphisms/NNS ./. 
The/DT 271C/NN -->/TO T/NN substitution/NN represents/VBZ a/DT considerable/JJ change/NN in/IN chemical/JJ nature/NN (/( Arg91/NN -->/TO Cys/NN )/) ,/, one/CD which/WDT may/MD affect/VB the/DT antigenic/JJ determinants/NNS of/IN DARC/NN ,/, and/CC thus/RB be/VB of/IN clinical/JJ significance/NN ./. 
The/DT mutation/NN may/MD have/VB implications/NNS for/IN some/DT physiological/JJ roles/NNS of/IN DARC/NN and/CC be/VB of/IN interest/NN in/IN malaria/NN research/NN and/CC in/IN studies/NNS of/IN population/NN genetics/NNS ./. 
UI/LS -/: 98403730/CD 
TI/LS -/: Establishment/NN and/CC characterization/NN of/IN EBV-positive/JJ and/CC EBV-negative/JJ primary/JJ effusion/NN lymphoma/NN cell/NN lines/NNS harbouring/VBG human/JJ herpesvirus/NN type-8/NN ./. 
AB/LS -/: In/IN this/DT study/NN we/PRP report/VBP on/IN the/DT establishment/NN and/CC characterization/NN of/IN two/CD novel/JJ lymphoma/NN cell/NN lines/NNS (/( CRO-AP/3/NN and/CC CRO-AP/5/NN )/) which/WDT carry/VBP infection/NN by/IN human/JJ herpesvirus/NN type-8/NN (/( HHV-8/NN )/) and/CC have/VBP derived/VBN from/IN AIDS-related/JJ primary/JJ effusion/NN lymphoma/NN (/( PEL/NN )/) ./. 
These/DT two/CD cell/NN lines/NNS are/VBP representative/JJ of/IN different/JJ virologic/JJ subtypes/NNS of/IN PEL/NN ,/, i.e./FW HHV-8+/EBV-/JJ PEL/NN in/IN the/DT case/NN of/IN CRO-AP/3/NN and/CC HHV-8+/EBV+/JJ PEL/NN in/IN the/DT case/NN of/IN CRO-AP/5/NN ./. 
Consistent/JJ with/IN the/DT diagnosis/NN of/IN PEL/NN ,/, both/CC CRO-AP/3/NN and/CC CRO-AP/5/NN expressed/VBD indeterminate/JJ (/( i.e./FW non-B/JJ ,/, non-T/JJ )/) phenotypes/NNS although/IN immunogenotypic/JJ studies/NNS documented/VBD their/PRP$ B-cell/NN origin/NN ./. 
Both/DT cell/NN lines/NNS are/VBP devoid/JJ of/IN genetic/JJ lesions/NNS of/IN c-MYC/NN ,/, BCL-2/NN and/CC p53/NN as/RB well/RB as/IN gross/JJ rearrangements/NNS of/IN BCL-6/NN ./. 
Detailed/JJ histogenetic/JJ characterization/NN of/IN these/DT novel/JJ PEL/NN cell/NN lines/NNS suggests/VBZ that/IN PEL/NN may/MD derive/VB from/IN a/DT post-germinal/JJ centre/NN B/NN cell/NN which/WDT has/VBZ undergone/VBN pre-terminal/JJ differentiation/NN ./. 
The/DT CRO-AP/3/NN and/CC CRO-AP/5/NN cell/NN lines/NNS may/MD provide/VB a/DT valuable/JJ model/NN for/IN clarifying/VBG the/DT pathogenesis/NN of/IN PEL/NN ./. 
In/IN particular/JJ ,/, these/DT cell/NN lines/NNS may/MD help/VB understand/VB the/DT relative/JJ contribution/NN of/IN HHV-8/NN and/CC EBV/NN to/TO PEL/NN growth/NN and/CC development/NN and/CC may/MD facilitate/VB the/DT identification/NN of/IN recurrent/JJ cytogenetic/JJ abnormalities/NNS highlighting/VBG putative/JJ novel/JJ cancer/NN related/JJ loci/NNS relevant/JJ to/TO PEL/NN ./. 
UI/LS -/: 98395103/CD 
TI/LS -/: Two-site/JJ interaction/NN of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS with/IN activated/VBN calcineurin/NN ./. 
AB/LS -/: Transcription/NN factors/NNS belonging/VBG to/TO the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) family/NN regulate/VBP the/DT expression/NN of/IN cytokine/NN genes/NNS and/CC other/JJ inducible/JJ genes/NNS during/IN the/DT immune/JJ response/NN ./. 
The/DT functions/NNS of/IN NFAT/NN proteins/NNS are/VBP directly/RB controlled/VBN by/IN the/DT calcium-/NN and/CC calmodulin-dependent/JJ phosphatase/NN calcineurin/NN ./. 
Here/RB we/PRP show/VBP that/IN the/DT binding/NN of/IN calcineurin/NN to/TO NFAT/NN is/VBZ substantially/RB increased/VBN when/WRB calcineurin/NN is/VBZ activated/VBN with/IN calmodulin/NN and/CC calcium/NN ./. 
FK506.FKBP12/NN drug-immunophilin/NN complexes/NNS inhibited/VBD the/DT interaction/NN of/IN NFAT/NN with/IN activated/VBN calcineurin/NN much/RB more/RBR effectively/RB than/IN they/PRP inhibited/VBD the/DT interaction/NN with/IN inactive/JJ calcineurin/NN ,/, suggesting/VBG that/IN part/NN of/IN the/DT interaction/NN with/IN activated/VBN calcineurin/NN involved/VBD the/DT enzyme/NN active/JJ site/NN ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN NFAT/NN is/VBZ targeted/VBN to/TO inactive/JJ calcineurin/NN at/IN a/DT region/NN distinct/JJ from/IN the/DT calcineurin/NN active/JJ site/NN (/( Aramburu/NNP ,/, J./NNP ,/, Garcia-Cozar/NNP ,/, F./NNP J./NNP ,/, Raghavan/NNP ,/, A./NNP ,/, Okamura/NNP ,/, H./NNP ,/, Rao/NNP ,/, A./NNP ,/, and/CC Hogan/NNP ,/, P./NNP G./NNP (/( 1998/CD )/) Mol./NNP Cell/NNP 1/CD ,/, 627-637/CD )/) ;/: this/DT region/NN is/VBZ also/RB involved/VBN in/IN NFAT/NN binding/NN to/TO activated/VBN calcineurin/NN ,/, since/IN binding/NN is/VBZ inhibited/VBN by/IN an/DT NFAT/NN peptide/NN spanning/VBG the/DT calcineurin/NN docking/NN site/NN on/IN NFAT/NN ./. 
The/DT interacting/VBG surfaces/NNS are/VBP located/JJ on/IN the/DT catalytic/JJ domain/NN of/IN the/DT calcineurin/NN A/NN chain/NN and/CC on/IN an/DT 86-amino/NN acid/NN fragment/NN of/IN the/DT NFAT/NN regulatory/JJ domain/NN ./. 
NFAT/NN binding/NN to/TO the/DT calcineurin/NN catalytic/JJ domain/NN was/VBD inhibited/VBN by/IN the/DT calcineurin/NN autoinhibitory/JJ domain/NN and/CC the/DT RII/NN substrate/NN peptide/NN ,/, which/WDT bind/VBP in/IN the/DT calcineurin/NN active/JJ site/NN ,/, as/RB well/RB as/IN by/IN the/DT NFAT/NN docking/NN site/NN peptide/NN ,/, which/WDT binds/VBZ to/TO a/DT region/NN of/IN calcineurin/NN distinct/JJ from/IN the/DT active/JJ site/NN ./. 
We/PRP propose/VBP that/IN ,/, in/IN resting/VBG cells/NNS ,/, NFAT/NN is/VBZ targeted/VBN to/TO a/DT region/NN of/IN the/DT calcineurin/NN catalytic/JJ domain/NN that/WDT does/VBZ not/RB overlap/VB the/DT calcineurin/NN active/JJ site/NN ./. 
Upon/IN cell/NN activation/NN ,/, displacement/NN of/IN the/DT autoinhibitory/JJ domain/NN by/IN calmodulin/NN binding/NN allows/VBZ NFAT/NN to/TO bind/VB additionally/RB to/TO the/DT calcineurin/NN active/JJ site/NN ,/, thus/RB positioning/VBG NFAT/NN for/IN immediate/JJ dephosphorylation/NN at/IN functional/JJ phosphoserine/NN residues/NNS ./. 
UI/LS -/: 98385602/CD 
TI/LS -/: Nuclear/JJ factor-kappaB/NN induction/NN in/IN CD45RO+/JJ and/CC CD45RA+/JJ T/NN cell/NN subsets/NNS during/IN aging/NN ./. 
AB/LS -/: An/DT increase/NN in/IN the/DT ratio/NN of/IN memory/NN to/TO naive/JJ T/NN cells/NNS has/VBZ been/VBN postulated/VBN to/TO underlie/VB immune/JJ hyporesponsiveness/NN accompanying/VBG aging/NN ./. 
Our/PRP$ analyses/NNS of/IN the/DT induction/NN of/IN nuclear/JJ factor-kappaB/NN (/( NFkappaB/NN )/) in/IN activated/VBN memory/NN (/( CD45RO+/JJ )/) and/CC naive/JJ (/( CD45RA+/JJ )/) T/NN cell/NN subsets/NNS from/IN young/JJ and/CC elderly/JJ donors/NNS has/VBZ demonstrated/VBN that/IN ,/, regardless/RB of/IN donor/NN age/NN ,/, memory/NN T/NN cells/NNS are/VBP not/RB significantly/RB altered/VBN in/IN their/PRP$ responsiveness/NN to/TO TNF-alpha-mediated/JJ induction/NN of/IN NFkappaB/NN ./. 
Although/IN treatment/NN with/IN TNF-alpha/NN induced/VBD nuclear/JJ localization/NN of/IN NFkappaB/NN in/IN both/CC memory/NN and/CC naive/JJ T/NN cell/NN subsets/NNS ,/, irrespective/RB of/IN the/DT age/NN of/IN the/DT donor/NN ,/, the/DT levels/NNS of/IN induced/VBN NFkappaB/NN were/VBD significantly/RB lower/JJR in/IN both/DT subsets/NNS of/IN T/NN cells/NNS obtained/VBN from/IN the/DT elderly/JJ ,/, when/WRB compared/VBN to/TO those/DT in/IN young/JJ ./. 
Examination/NN of/IN IkappaB/NN alpha/NN regulation/NN revealed/VBD that/IN TNF-alpha-mediated/JJ degradation/NN of/IN IkappaB/NN alpha/NN in/IN both/CC memory/NN and/CC naive/JJ T/NN cells/NNS from/IN the/DT elderly/JJ was/VBD severely/RB impaired/JJ ,/, thus/RB contributing/VBG to/TO the/DT lowered/JJ induction/NN of/IN the/DT observed/VBN NFkappaB/NN ./. 
In/IN addition/NN ,/, this/DT age-related/JJ decrease/NN in/IN induction/NN of/IN nuclear/JJ NFkappaB/NN correlated/VBD with/IN decrease/NN in/IN intracellular/JJ IL-2/NN receptor/NN expression/NN and/CC anti-CD3-induced/JJ proliferation/NN of/IN both/CC memory/NN and/CC naive/JJ T/NN cells/NNS subsets/NNS ./. 
Taken/VBN together/RB ,/, our/PRP$ results/NNS suggest/VBP that/IN the/DT age-related/JJ hyporesponsiveness/NN can/MD not/RB be/VB attributed/VBN to/TO a/DT skewing/NN of/IN the/DT T/NN cell/NN population/NN towards/IN a/DT memory/NN phenotype/NN in/IN the/DT elderly/JJ ./. 
UI/LS -/: 98375865/CD 
TI/LS -/: Cyclosporin/NN A-resistant/JJ transactivation/NN of/IN the/DT IL-2/NN promoter/NN requires/VBZ activity/NN of/IN okadaic/JJ acid-sensitive/JJ serine/threonine/NN phosphatases/NNS ./. 
AB/LS -/: Expression/NN of/IN the/DT IL-2/NN gene/NN requires/VBZ activation/NN of/IN T/NN cells/NNS through/IN stimulation/NN of/IN the/DT TCR/NN and/CC costimulation/NN through/IN accessory/NN receptors/NNS ./. 
We/PRP have/VBP found/VBN recently/RB that/IN okadaic/JJ acid-sensitive/JJ Ser/Thr/NN phosphatases/NNS are/VBP involved/VBN in/IN a/DT cyclosporin/NN A-insensitive/JJ pathway/NN that/WDT selectively/RB transmits/VBZ costimulatory/JJ signals/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP analyzed/VBD whether/IN activities/NNS of/IN these/DT phosphatases/NNS are/VBP necessary/JJ for/IN the/DT expression/NN of/IN the/DT IL-2/NN gene/NN ./. 
In/IN both/CC activated/VBN peripheral/JJ blood/NN T/NN lymphocytes/NNS and/CC activated/VBN tumorigenic/JJ T/NN cell/NN lines/NNS ,/, IL-2/NN gene/NN expression/NN was/VBD blocked/VBN at/IN the/DT transcriptional/JJ level/NN by/IN okadaic/JJ acid/NN ./. 
The/DT transcription/NN factors/NNS active/JJ at/IN the/DT IL-2/NN promoter/NN were/VBD differentially/RB influenced/VBN :/: upon/IN down-modulation/NN of/IN okadaic/JJ acid-sensitive/JJ phosphatases/NNS ,/, transactivation/NN by/IN octamer/NN ,/, NF-kappa/NN B/NN ,/, and/CC NF/NN of/IN activated/VBN T/NN cells/NNS proteins/NNS was/VBD abrogated/VBN ,/, while/IN transactivation/NN by/IN AP-1/NN proteins/NNS was/VBD even/RB enhanced/VBN ./. 
UI/LS -/: 99023506/CD 
TI/LS -/: YM268/NN increases/VBZ the/DT glucose/NN uptake/NN ,/, cell/NN differentiation/NN ,/, and/CC mRNA/NN expression/NN of/IN glucose/NN transporter/NN in/IN 3T3-L1/NN adipocytes/NNS ./. 
AB/LS -/: The/DT purpose/NN of/IN this/DT study/NN was/VBD to/TO examine/VB the/DT effects/NNS of/IN bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]/NN methane/NN (/( YM-268/NN )/) ,/, a/DT thiazolidinedione/JJ derivative/NN ,/, on/IN glucose/NN uptake/NN ,/, adipocyte/NN differentiation/NN through/IN peroxisome/NN proliferator-activated/JJ receptor/NN gamma/NN (/( PPARgamma/NN )/) ,/, and/CC phosphatidylinositol/NN 3-kinase/NN (/( PI/NN 3-kinase/NN )/) activity/NN in/IN cultured/VBN cells/NNS ./. 
YM268/NN and/CC pioglitazone/NN dose-dependently/RB increased/VBD the/DT 2-deoxyglucose/NN uptake/NN in/IN 3T3-L1/NN cells/NNS ./. 
YM268/NN facilitated/VBD the/DT insulin-stimulated/JJ triglyceride/NN accumulation/NN in/IN 3T3-L1/NN adipocytes/NNS and/CC increased/VBD the/DT mRNA/NN expression/NN of/IN fatty/JJ acid-binding/JJ protein/NN ./. 
YM268/NN ,/, with/IN and/CC without/IN insulin/NN ,/, increased/VBD the/DT mRNA/NN expression/NN of/IN glucose/NN transporter/NN isoforms/NNS such/JJ as/IN GLUT1/NN and/CC GLUT4/NN ,/, indicating/VBG enhancement/NN of/IN adipocyte/NN differentiation/NN ./. 
Additionally/RB ,/, YM268/NN and/CC pioglitazone/NN showed/VBD activity/NN of/IN the/DT PPARgamma/NN ligand/NN ,/, a/DT member/NN of/IN the/DT nuclear/JJ receptor/NN superfamily/NN responsible/JJ for/IN adipogenesis/NN ./. 
To/TO examine/VB the/DT possible/JJ involvement/NN of/IN the/DT increased/VBN activity/NN of/IN PI/NN 3-kinase/NN in/IN YM268-stimulated/JJ glucose/NN uptake/NN ,/, the/DT enzyme/NN activity/NN was/VBD estimated/VBN by/IN measuring/VBG the/DT phosphatidylinositol-3,4,5-trisphosphate/NN (/( PI-3,4,5-P3/NN )/) concentration/NN in/IN human/JJ monocytic/JJ cells/NNS ./. 
Insulin/NN dose-dependently/RB increased/VBD the/DT PI-3,4,5-P3/NN production/NN but/CC YM268/NN had/VBD no/DT significant/JJ effect/NN on/IN the/DT insulin-dependent/JJ and/CC -independent/JJ PI/NN 3-kinase/NN activation/NN ./. 
These/DT results/NNS indicate/VBP that/IN the/DT mechanism/NN by/IN which/WDT YM268/NN increased/VBD glucose/NN uptake/NN ,/, may/MD be/VB accounted/VBN for/IN in/IN part/NN by/IN the/DT enhancement/NN of/IN GLUT1/NN and/CC GLUT4/NN expression/NN through/IN PPARgamma/NN activation/NN ./. 
UI/LS -/: 99014176/CD 
TI/LS -/: The/DT nuclear/JJ receptor/NN PPARgamma/NN -/: bigger/JJR than/IN fat/NN ./. 
AB/LS -/: Work/NN reported/VBD over/IN the/DT past/JJ year/NN has/VBZ provided/VBN insights/NNS into/IN the/DT mechanisms/NNS whereby/WRB ligand/NN activation/NN of/IN the/DT nuclear/JJ receptor/NN peroxisome/NN proliferator-activated/JJ receptor/NN gamma/NN (/( PPARgamma/NN )/) regulates/VBZ systemic/JJ glucose/NN and/CC lipid/NN homeostasis/NN ./. 
PPARgamma/NN has/VBZ also/RB been/VBN implicated/VBN recently/RB in/IN the/DT biology/NN of/IN monocytes/NNS and/CC in/IN cell-cycle/JJ regulation/NN and/CC cancer/NN ./. 
Polyunsaturated/JJ fatty/JJ acids/NNS and/CC eicosanoids/NNS bind/VBP and/CC activate/VBP PPARgamma/NN ,/, suggesting/VBG that/IN these/DT lipids/NNS may/MD serve/VB as/IN hormonal/JJ regulators/NNS of/IN a/DT variety/NN of/IN biological/JJ processes/NNS ./. 
UI/LS -/: 99007753/CD 
TI/LS -/: The/DT role/NN of/IN caspases/NNS in/IN T/NN cell/NN development/NN and/CC the/DT control/NN of/IN immune/JJ responses/NNS ./. 
AB/LS -/: Apoptosis/NN is/VBZ responsible/JJ for/IN the/DT removal/NN of/IN potentially/RB autoreactive/JJ or/CC useless/JJ T/NN cells/NNS during/IN thymic/JJ selection/NN and/CC activated/VBN T/NN cells/NNS in/IN the/DT periphery/NN ./. 
Specific/JJ families/NNS of/IN receptors/NNS ,/, kinases/NNS ,/, transcription/NN factors/NNS ,/, and/CC cysteine/NN proteases/NNS ,/, termed/VBN caspases/NNS ,/, are/VBP involved/VBN in/IN the/DT apoptotic/JJ cascade/NN leading/VBG to/TO proteolysis/NN of/IN specific/JJ substrates/NNS and/CC to/TO morphological/JJ changes/NNS associated/VBN with/IN programmed/VBN cell/NN death/NN ./. 
Although/IN common/JJ members/NNS of/IN the/DT apoptotic/JJ cascade/NN are/VBP shared/VBN between/IN different/JJ cell/NN types/NNS ,/, it/PRP appears/VBZ that/IN cell-specific/JJ factors/NNS can/MD influence/VB the/DT response/NN to/TO a/DT given/JJ apoptotic/JJ stimuli/NNS ./. 
Characterization/NN and/CC understanding/NN of/IN the/DT basic/JJ mechanisms/NNS involved/VBN in/IN the/DT different/JJ pathways/NNS protecting/VBG or/CC leading/VBG to/TO cell/NN death/NN may/MD provide/VB novel/JJ ways/NNS to/TO control/VB inappropriate/JJ apoptosis/NN involved/VBN in/IN several/JJ diseases/NNS ./. 
UI/LS -/: 98451423/CD 
TI/LS -/: Cross-priming/NN of/IN CTL/NN responses/NNS in/FW vivo/FW does/VBZ not/RB require/VB antigenic/JJ peptides/NNS in/IN the/DT endoplasmic/JJ reticulum/NN of/IN immunizing/JJ cells/NNS ./. 
AB/LS -/: It/PRP has/VBZ been/VBN proposed/VBN that/IN the/DT cross-priming/NN of/IN CTL/NN responses/NNS in/FW vivo/FW involves/VBZ the/DT transfer/NN to/TO host/NN APCs/NNS of/IN heat/NN shock/NN protein/NN glycoprotein/NN 96-chaperoned/JJ antigenic/JJ peptides/NNS released/VBN from/IN the/DT endoplasmic/JJ reticulum/NN (/( ER/NN )/) of/IN dying/VBG or/CC infected/JJ cells/NNS ./. 
We/PRP have/VBP tested/VBN this/DT possibility/NN directly/RB using/VBG TAP-deficient/JJ cell/NN lines/NNS lacking/VBG antigenic/JJ ER/NN peptides/NNS derived/VBN from/IN two/CD model/NN Ags/NNS ,/, the/DT human/JJ adenovirus/NN type/NN 5/CD early/JJ regions/NNS E1A/NN and/CC E1B/NN ./. 
Although/IN both/DT proteins/NNS were/VBD well/RB expressed/VBN ,/, the/DT cells/NNS were/VBD not/RB recognized/VBN by/IN E1A-/NN or/CC E1B-specific/JJ CTLs/NNS unless/IN the/DT relevant/JJ epitope/NN was/VBD either/CC provided/VBN exogenously/RB as/IN a/DT synthetic/JJ peptide/NN or/CC targeted/VBN to/TO the/DT ER/NN in/IN a/DT TAP-independent/JJ fashion/NN ./. 
Despite/IN the/DT absence/NN of/IN these/DT ER/NN peptides/NNS ,/, the/DT TAP1-/-/JJ cells/NNS were/VBD able/JJ to/TO efficiently/RB cross-prime/VB E1A-/NN and/CC E1B-specific/JJ CTLs/NNS following/VBG immunization/NN of/IN syngeneic/JJ mice/NNS ./. 
These/DT results/NNS indicate/VBP that/IN ,/, although/IN purified/VBN peptide/glycoprotein/NN 96/CD complexes/NNS are/VBP potent/JJ immunogens/NNS ,/, the/DT mechanism/NN of/IN CTL/NN cross-priming/NN in/FW vivo/FW does/VBZ not/RB depend/VB upon/IN antigenic/JJ peptides/NNS in/IN the/DT ER/NN of/IN immunizing/JJ cells/NNS ./. 
UI/LS -/: 98438583/CD 
TI/LS -/: A/DT critical/JJ role/NN of/IN the/DT p75/NN tumor/NN necrosis/NN factor/NN receptor/NN (/( p75TNF-R/NN )/) in/IN organ/NN inflammation/NN independent/JJ of/IN TNF/NN ,/, lymphotoxin/NN alpha/NN ,/, or/CC the/DT p55TNF-R/NN ./. 
AB/LS -/: Despite/IN overwhelming/JJ evidence/NN that/IN enhanced/VBN production/NN of/IN the/DT p75/NN tumor/NN necrosis/NN factor/NN receptor/NN (/( p75TNF-R/NN )/) accompanies/VBZ development/NN of/IN specific/JJ human/JJ inflammatory/JJ pathologies/NNS such/JJ as/IN multi-organ/JJ failure/NN during/IN sepsis/NN ,/, inflammatory/JJ liver/NN disease/NN ,/, pancreatitis/NN ,/, respiratory/JJ distress/NN syndrome/NN ,/, or/CC AIDS/NN ,/, the/DT function/NN of/IN this/DT receptor/NN remains/VBZ poorly/RB defined/VBN in/FW vivo/FW ./. 
We/PRP show/VBP here/RB that/IN at/IN levels/NNS relevant/JJ to/TO human/JJ disease/NN ,/, production/NN of/IN the/DT human/JJ p75TNF-R/NN in/IN transgenic/JJ mice/NNS results/VBZ in/IN a/DT severe/JJ inflammatory/JJ syndrome/NN involving/VBG mainly/RB the/DT pancreas/NN ,/, liver/NN ,/, kidney/NN ,/, and/CC lung/NN ,/, and/CC characterized/VBN by/IN constitutively/RB increased/VBN NF-kappaB/NN activity/NN in/IN the/DT peripheral/JJ blood/NN mononuclear/JJ cell/NN compartment/NN ./. 
This/DT process/NN is/VBZ shown/VBN to/TO evolve/VB independently/RB of/IN the/DT presence/NN of/IN TNF/NN ,/, lymphotoxin/NN alpha/NN ,/, or/CC the/DT p55TNF-R/NN ,/, although/IN coexpression/NN of/IN a/DT human/JJ TNF/NN transgene/NN accelerated/VBD pathology/NN ./. 
These/DT results/NNS establish/VBP an/DT independent/JJ role/NN for/IN enhanced/VBN p75TNF-R/NN production/NN in/IN the/DT pathogenesis/NN of/IN inflammatory/JJ disease/NN and/CC implicate/VBP the/DT direct/JJ involvement/NN of/IN this/DT receptor/NN in/IN a/DT wide/JJ range/NN of/IN human/JJ inflammatory/JJ pathologies/NNS ./. 
UI/LS -/: 98421363/CD 
TI/LS -/: Expression/NN status/NN of/IN BCL-6/NN and/CC syndecan-1/NN identifies/VBZ distinct/JJ histogenetic/JJ subtypes/NNS of/IN Hodgkin/NN 's/POS disease/NN ./. 
AB/LS -/: The/DT tumor/NN cells/NNS in/IN most/JJS cases/NNS of/IN Hodgkin/NN 's/POS disease/NN (/( HD/NN )/) have/VBP been/VBN recently/RB recognized/VBN to/TO originate/VB from/IN the/DT B-cell/NN lineage/NN ,/, but/CC their/PRP$ precise/JJ differentiation/NN stage/NN is/VBZ not/RB fully/RB clarified/VBN ./. 
Recently/RB ,/, we/PRP have/VBP reported/VBN that/IN the/DT histogenesis/NN of/IN B-cell/NN lymphomas/NNS may/MD be/VB assessed/VBN by/IN monitoring/VBG the/DT expression/NN pattern/NN of/IN BCL-6/NN ,/, a/DT transcription/NN factor/NN expressed/VBN in/IN germinal/JJ center/NN (/( GC/NN )/) B/NN cells/NNS ,/, and/CC CD138/syndecan-1/NN (/( syn-1/NN )/) ,/, a/DT proteoglycan/NN associated/VBN with/IN post-GC/JJ ,/, terminal/JJ B-cell/NN differentiation/NN ./. 
In/IN this/DT study/NN ,/, we/PRP have/VBP applied/VBN these/DT two/CD markers/NNS to/TO the/DT study/NN of/IN HD/NN histogenesis/NN ./. 
We/PRP have/VBP found/VBN that/IN in/IN nodular/JJ lymphocyte/NN predominance/NN HD/NN (/( NLPHD/NN )/) tumor/NN cells/NNS consistently/RB display/VBP the/DT BCL-6(+)/syn-1(-)/JJ phenotype/NN ,/, indicating/VBG their/PRP$ derivation/NN from/IN GC/NN B/NN cells/NNS ./. 
Conversely/RB ,/, classic/JJ HD/NN (/( CHD/NN )/) is/VBZ heterogeneous/JJ because/IN the/DT tumor/NN cells/NNS of/IN a/DT fraction/NN of/IN CHD/NN display/VBP the/DT BCL-6(-)/syn-1(+)/JJ phenotype/NN of/IN post-GC/JJ B-cells/NNS ,/, whereas/IN another/DT fraction/NN of/IN CHD/NN is/VBZ constituted/VBN by/IN a/DT mixture/NN of/IN tumor/NN cells/NNS reflecting/VBG the/DT GC/NN (/( BCL-6(+)/syn-1(-)/JJ )/) or/CC post-GC/JJ (/( BCL-6(-)/syn-1(+)/JJ )/) phenotypes/NNS ./. 
BCL-6(-)/syn-1(+)/JJ tumor/NN cells/NNS of/IN CHD/NN are/VBP mostly/RB found/VBN surrounded/VBN by/IN T/NN cells/NNS expressing/VBG CD40L/NN ,/, consistent/JJ with/IN the/DT observation/NN that/IN CD40/NN signaling/NN downregulates/VBZ BCL-6/NN expression/NN ./. 
These/DT data/NNS indicate/VBP that/IN tumor/NN cells/NNS of/IN NLPHD/NN uniformly/RB display/VBP a/DT GC/NN B-cell/NN phenotype/NN ,/, whereas/IN the/DT phenotype/NN of/IN tumor/NN cells/NNS of/IN CHD/NN appears/VBZ to/TO be/VB modulated/VBN by/IN the/DT surrounding/JJ cellular/JJ background/NN ,/, particularly/RB CD40L+/JJ reactive/JJ T/NN cells/NNS ./. 
UI/LS -/: 98406210/CD 
TI/LS -/: Molecular/JJ and/CC cellular/JJ analysis/NN of/IN human/JJ immunodeficiency/NN virus-induced/JJ apoptosis/NN in/IN lymphoblastoid/JJ T-cell-line-expressing/JJ wild-type/JJ and/CC mutated/VBN CD4/NN receptors/NNS ./. 
AB/LS -/: We/PRP have/VBP previously/RB shown/VBN that/IN the/DT presence/NN of/IN the/DT CD4/NN cytoplasmic/JJ tail/NN is/VBZ critical/JJ for/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) -induced/JJ apoptosis/NN (/( J.Corbeil/NNP ,/, M.Tremblay/NNP ,/, and/CC D.D.Richman/NNP ,/, J.Exp.Med.183/NNP :/: 39-48/CD ,/, 1996/CD )/) ./. 
We/PRP have/VBP pursued/VBN our/PRP$ investigation/NN of/IN the/DT role/NN of/IN the/DT CD4/NN transduction/NN pathway/NN in/IN HIV-induced/JJ apoptosis/NN ./. 
To/TO do/VBP this/DT ,/, wild-type/JJ and/CC mutant/JJ forms/NNS of/IN the/DT CD4/NN cytoplasmic/JJ tail/NN were/VBD stably/RB expressed/VBN in/IN the/DT lymphoblastoid/JJ T-cell/NN line/NN A2.01/NN ./. 
Apoptosis/NN was/VBD prevented/VBN when/WRB CD4/NN truncated/VBN at/IN residue/NN 402/CD was/VBD expressed/VBN ;/: however/RB ,/, cells/NNS expressing/VBG mutated/VBN receptors/NNS that/WDT do/VBP not/RB associate/VB with/IN p56(lck)/NN (/( mutated/VBN at/IN the/DT dicysteine/NN motif/NN and/CC truncated/VBN at/IN residue/NN 418/CD )/) but/CC which/WDT conserved/VBD proximal/JJ domains/NNS of/IN the/DT cytoplasmic/JJ tail/NN underwent/VBD apoptosis/NN like/IN wild- type/JJ CD4/NN ./. 
The/DT differences/NNS between/IN wild-type/JJ and/CC mutated/VBN receptors/NNS in/IN the/DT induction/NN of/IN apoptosis/NN were/VBD not/RB related/JJ to/TO levels/NNS of/IN p56(lck)/NN or/CC NF- kappaB/NN activation/NN ./. 
Initial/JJ signaling/NN through/IN the/DT CD4/NN receptor/NN played/VBD a/DT major/JJ role/NN in/IN the/DT sensitization/NN of/IN HIV-infected/JJ T/NN cells/NNS to/TO undergo/VB apoptosis/NN ./. 
Incubation/NN of/IN HIV-infected/JJ cells/NNS with/IN monoclonal/JJ antibody/NN (/( MAb/NN )/) 13B8-2/NN ,/, which/WDT binds/VBZ to/TO CD4/NN in/IN a/DT region/NN critical/JJ for/IN dimerization/NN of/IN the/DT receptor/NN ,/, prevented/VBD apoptosis/NN without/IN inhibiting/VBG HIV/NN replication/NN ./. 
Moreover/RB ,/, the/DT apoptotic/JJ process/NN was/VBD not/RB related/JJ to/TO Fas-Fas/JJ ligand/NN interaction/NN ;/: however/RB ,/, an/DT antagonistic/JJ anti-Fas/JJ MAb/NN (/( ZB-4/NN )/) enhanced/VBD apoptosis/NN in/IN HIV-infected/JJ cells/NNS without/IN inducing/VBG apoptosis/NN in/IN uninfected/JJ cells/NNS ./. 
These/DT observations/NNS demonstrate/VBP that/IN CD4/NN signaling/NN mediates/VBZ HIV-induced/JJ apoptosis/NN by/IN a/DT mechanism/NN independent/JJ of/IN Fas-Fas/JJ ligand/NN interaction/NN ,/, does/VBZ not/RB require/VB p56(lck)/NN signaling/NN ,/, and/CC may/MD involve/VB a/DT critical/JJ region/NN for/IN CD4/NN dimerization/NN ./. 
UI/LS -/: 98395073/CD 
TI/LS -/: p130/NN ,/, p107/NN ,/, and/CC pRb/NN are/VBP differentially/RB regulated/VBN in/IN proliferating/VBG cells/NNS and/CC during/IN cell/NN cycle/NN arrest/NN by/IN alpha-interferon/NN ./. 
AB/LS -/: We/PRP have/VBP determined/VBN how/WRB the/DT phosphorylation/NN of/IN the/DT retinoblastoma/NN family/NN (/( pRb/NN ,/, p107/NN ,/, and/CC p130/NN )/) is/VBZ governed/VBN in/IN individual/JJ cell/NN cycle/NN phases/NNS of/IN Daudi/NN B-cells/NNS during/IN cell/NN cycle/NN exit/NN triggered/VBN by/IN alpha-interferon/NN (/( alpha-IFN/NN )/) ./. 
alpha-IFN/NN causes/VBZ dephosphorylation/NN of/IN pRb/NN and/CC loss/NN of/IN p130/NN phosphorylated/JJ Form/NN 3/CD ./. 
However/RB ,/, the/DT change/NN in/IN p130/NN phosphorylation/NN in/IN response/NN to/TO alpha-IFN/NN occurs/VBZ before/IN dephosphorylation/NN of/IN pRb/NN is/VBZ complete/JJ because/IN loss/NN of/IN p130/NN Form/NN 3/CD occurs/VBZ throughout/IN the/DT cell/NN cycle/NN prior/JJ to/TO complete/JJ arrest/NN in/IN G1/NN ,/, whereas/IN pRb/NN is/VBZ dephosphorylated/VBN only/RB in/IN G1/NN ./. 
In/IN contrast/NN ,/, p107/NN is/VBZ dephosphorylated/VBN and/CC is/VBZ then/RB depleted/VBN from/IN cells/NNS as/IN they/PRP exit/VBP the/DT cell/NN cycle/NN ./. 
p130/NN ,/, predominantly/RB in/IN Form/NN 1/CD ,/, and/CC hypophosphorylated/VBN pRb/NN bind/VBP an/DT E2F/NN DNA/NN binding/NN site/NN ;/: p130/NN complexes/NNS E2F-4/NN ,/, whereas/IN pRb/NN binds/VBZ both/CC E2F-4/NN and/CC E2F-1/NN ./. 
The/DT phosphorylated/JJ forms/NNS of/IN E2F-4/NN that/WDT bind/VBP to/TO the/DT E2F/NN DNA/NN site/NN are/VBP different/JJ from/IN hyperphosphorylated/VBN E2F-4/NN ,/, which/WDT predominates/VBZ in/IN primary/JJ hemopoietic/JJ cells/NNS in/IN G0/NN ./. 
We/PRP conclude/VBP that/IN although/IN cell/NN cycle/NN arrest/NN induced/VBN by/IN alpha-IFN/NN may/MD be/VB mediated/VBN in/IN part/NN by/IN formation/NN of/IN a/DT complex/NN containing/VBG p130/NN and/CC E2F-4/NN ,/, alpha-IFN/NN does/VBZ not/RB induce/VB hyperphosphorylation/NN of/IN E2F-4/NN ,/, which/WDT characterizes/VBZ primary/JJ hemopoietic/JJ cells/NNS in/IN G0/NN ./. 
UI/LS -/: 98383419/CD 
TI/LS -/: The/DT transcription/NN factors/NNS c-myb/NN and/CC C/EBP/NN alpha/NN regulate/VBP the/DT monocytic/myeloic/JJ gene/NN MRP14/NN ./. 
AB/LS -/: The/DT entry/NN of/IN microorganisms/NNS into/IN the/DT body/NN induces/VBZ inflammatory/JJ processes/NNS ./. 
During/IN this/DT process/NN a/DT sequence/NN of/IN cellular/JJ ,/, humoral/JJ ,/, non-specific/JJ and/CC specific/JJ actions/NNS are/VBP evoked/VBN to/TO combat/VB the/DT infection/NN ./. 
Macrophages/NNS and/CC granulocytes/NNS ,/, which/WDT are/VBP developed/VBN from/IN a/DT common/JJ progenitor/NN cell/NN ,/, are/VBP the/DT cellular/JJ components/NNS of/IN the/DT specific/JJ and/CC non-specific/JJ immunoreaction/NN ./. 
MRP14/NN (/( Macrophage/NN migration/NN inhibitory/JJ related/JJ protein/NN )/) and/CC MRP8/NN ,/, two/CD S-100/NN proteins/NNS contained/VBN in/IN high/JJ concentrations/NNS in/IN these/DT cells/NNS are/VBP obviously/RB essential/JJ for/IN adhesion/NN and/CC migration/NN of/IN monocytes/NNS and/CC granulocytes/NNS ./. 
To/TO investigate/VB the/DT transcriptional/JJ regulation/NN of/IN these/DT genes/NNS we/PRP cotransfected/VBD constructs/NNS expressing/VBG CAT/NN under/IN control/NN of/IN the/DT MRP14/NN promoter/NN and/CC expression/NN constructs/NNS of/IN C/EBP/NN alpha/NN and/CC v-myb/NN ,/, two/CD transcription/NN factors/NNS involved/VBN in/IN myeloid/monocytic/JJ differentiation/NN ./. 
Transfection/NN with/IN C/EBP/NN alpha/NN revealed/VBD a/DT massive/JJ enhancement/NN of/IN the/DT MRP14/NN promoter/NN in/IN both/CC ,/, HL/NN 60/CD cells/NNS (/( granulocytic/JJ differentiated/VBN )/) and/CC L132/NN fibroblasts/NNS ./. 
In/IN contrast/NN ,/, v-myb/NN reduces/VBZ MRP14/NN promoter/NN activity/NN ./. 
Northern/NN blot/NN analysis/NN of/IN L132/NN cells/NNS transfected/VBN with/IN the/DT C/EBP/NN alpha/NN expression/NN vector/NN demonstrate/VBP that/IN C/EBP/NN alpha/NN is/VBZ sufficient/JJ to/TO enhance/VB MRP14/NN expression/NN in/IN the/DT context/NN of/IN the/DT whole/JJ genome/NN ./. 
UI/LS -/: 98375844/CD 
TI/LS -/: A/DT CD28-associated/JJ signaling/NN pathway/NN leading/VBG to/TO cytokine/NN gene/NN transcription/NN and/CC T/NN cell/NN proliferation/NN without/IN TCR/NN engagement/NN ./. 
AB/LS -/: Stimulation/NN of/IN resting/VBG human/JJ T/NN cells/NNS with/IN the/DT CD28-specific/JJ mAb/NN BW/NN 828/CD induces/VBZ proliferation/NN and/CC cytokine/NN synthesis/NN without/IN further/JJ requirement/NN for/IN TCR/NN coengagement/NN ./. 
This/DT observation/NN prompted/VBD us/PRP to/TO postulate/VB that/IN signal/NN 2/CD (/( costimulatory/JJ signal/NN )/) alone/RB without/IN signal/NN 1/CD (/( TCR/NN signal/NN )/) can/MD activate/VB T/NN cells/NNS ./. 
To/TO test/VB whether/IN this/DT putative/JJ function/NN of/IN CD28/NN is/VBZ mediated/VBN via/IN a/DT particular/JJ signaling/NN pathway/NN ,/, we/PRP compared/VBD early/JJ signaling/NN events/NNS initiated/VBN in/IN resting/VBG T/NN cells/NNS by/IN the/DT stimulatory/JJ mAb/NN BW/NN 828/CD with/IN signals/NNS triggered/VBN by/IN the/DT nonstimulating/JJ CD28/NN mAb/NN 9.3/CD ./. 
Stimulation/NN of/IN T/NN cells/NNS with/IN BW/NN 828/CD induced/VBD an/DT increase/NN in/IN intracellular/JJ Ca2+/NN ,/, but/CC did/VBD not/RB lead/VB to/TO detectable/JJ activation/NN of/IN the/DT protein/NN kinases/NNS p56(lck)/NN and/CC c-Raf-1/NN ./. 
This/DT pathway/NN resulted/VBD in/IN the/DT induction/NN of/IN the/DT transcription/NN factors/NNS NF-kappa/NN B/NN ,/, NF-AT/NN ,/, and/CC proteins/NNS binding/VBG to/TO the/DT CD28/NN response/NN element/NN of/IN the/DT IL-2/NN promoter/NN ./. 
On/IN the/DT other/JJ hand/NN ,/, stimulation/NN of/IN T/NN cells/NNS with/IN mAb/NN 9.3/CD increased/VBD the/DT level/NN of/IN intracellular/JJ Ca2+/NN and/CC triggered/VBD the/DT activation/NN of/IN p56(lck)/NN and/CC c-Raf-1/NN ,/, but/CC was/VBD unable/JJ to/TO induce/VB the/DT binding/NN of/IN transcription/NN factors/NNS to/TO the/DT IL-2/NN promoter/NN ./. 
In/IN contrast/NN to/TO the/DT differential/JJ signaling/NN of/IN BW/NN 828/CD and/CC 9.3/CD in/IN resting/VBG T/NN cells/NNS ,/, the/DT two/CD mAbs/NNS exhibited/VBD a/DT similar/JJ pattern/NN of/IN early/JJ signaling/NN events/NNS in/IN activated/VBN T/NN cells/NNS and/CC Jurkat/NN cells/NNS (/( p56(lck)/NN activation/NN ,/, association/NN of/IN phosphatidylinositol/NN 3-kinase/NN with/IN CD28/NN )/) ,/, indicating/VBG that/IN the/DT signaling/NN capacity/NN of/IN CD28/NN changes/VBZ with/IN activation/NN ./. 
These/DT data/NNS support/VBP the/DT view/NN that/IN stimulation/NN through/IN CD28/NN can/MD induce/VB some/DT effector/NN functions/NNS in/IN T/NN cells/NNS and/CC suggest/VBP that/IN this/DT capacity/NN is/VBZ associated/VBN with/IN a/DT particular/JJ pattern/NN of/IN early/JJ signaling/NN events/NNS 
UI/LS -/: 99023375/CD 
TI/LS -/: Decreased/VBN IL-12/NN production/NN and/CC Th1/NN cell/NN development/NN by/IN acetyl/NN salicylic/JJ acid-mediated/JJ inhibition/NN of/IN NF-kappaB/NN ./. 
AB/LS -/: IL-12/NN is/VBZ a/DT 75-kDa/JJ heterodimeric/JJ cytokine/NN composed/VBN of/IN two/CD covalently/RB linked/VBN p35/NN and/CC p40/NN chains/NNS ./. 
This/DT pro-inflammatory/JJ cytokine/NN plays/VBZ a/DT prominent/JJ role/NN in/IN the/DT development/NN of/IN Th1/NN cell-mediated/JJ immune/JJ responses/NNS ./. 
Th1/NN cell-mediated/JJ immune/JJ responses/NNS have/VBP been/VBN implicated/VBN in/IN the/DT pathogenesis/NN of/IN chronic/JJ inflammatory/JJ autoimmune/JJ diseases/NNS ./. 
Thus/RB ,/, IL-12/NN appears/VBZ to/TO be/VB a/DT critical/JJ factor/NN in/IN the/DT generation/NN and/CC maintenance/NN of/IN chronic/JJ inflammatory/JJ conditions/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP investigated/VBD the/DT effects/NNS of/IN a/DT commonly/RB prescribed/VBN anti-inflammatory/JJ drug/NN ,/, acetyl/NN salicylic/JJ acid/NN (/( ASA/NN )/) ,/, on/IN IL-12/NN production/NN and/CC Th1/NN cell/NN development/NN ./. 
ASA/NN was/VBD found/VBN to/TO inhibit/VB secretion/NN of/IN the/DT IL-12/NN heterodimer/NN as/RB well/RB as/IN p40/NN monomer/NN by/IN human/JJ monocytic/JJ cells/NNS ./. 
This/DT was/VBD associated/VBN with/IN the/DT down-regulation/NN of/IN IL-12p40/NN mRNA/NN expression/NN ./. 
Analysis/NN of/IN the/DT regulation/NN of/IN the/DT p40/NN gene/NN promoter/NN revealed/VBD that/IN ASA/NN inhibited/VBD NF-kappaB/NN activation/NN and/CC binding/NN to/TO the/DT p40-kappaB/NN site/NN in/IN the/DT p40/NN promoter/NN ,/, leading/VBG to/TO transcriptional/JJ repression/NN of/IN the/DT p40/NN gene/NN ./. 
Addition/NN of/IN ASA/NN to/TO an/DT in/FW vitro/FW T/NN helper/NN cell/NN differentiation/NN system/NN ,/, at/IN concentrations/NNS compatible/JJ with/IN plasma/NN levels/NNS reached/VBN during/IN anti-inflammatory/JJ therapy/NN ,/, resulted/VBD in/IN reduced/VBN development/NN of/IN Th1/NN cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN the/DT inhibition/NN of/IN NF-kappaB/NN activation/NN by/IN ASA/NN leads/VBZ to/TO down-regulation/NN of/IN IL-12/NN production/NN and/CC inhibition/NN of/IN Th1/NN cell/NN development/NN ./. 
UI/LS -/: 99008553/CD 
TI/LS -/: Attenuation/NN of/IN HLA-DR/NN expression/NN by/IN mononuclear/JJ phagocytes/NNS infected/VBN with/IN Mycobacterium/NN tuberculosis/NN is/VBZ related/JJ to/TO intracellular/JJ sequestration/NN of/IN immature/JJ class/NN II/CD heterodimers/NNS ./. 
AB/LS -/: MHC/NN class/NN II/CD expression/NN was/VBD examined/VBN in/IN macrophages/NNS infected/VBN with/IN Mycobacterium/NN tuberculosis/NN ./. 
IFN-gamma/NN increased/VBD the/DT surface/NN expression/NN of/IN class/NN II/CD molecules/NNS in/IN THP-1/NN cells/NNS and/CC this/DT was/VBD markedly/RB reduced/VBN in/IN cells/NNS infected/VBN with/IN M./NN tuberculosis/NN ./. 
Despite/IN this/DT effect/NN ,/, steady/JJ state/NN levels/NNS of/IN HLA-DRalpha/NN ,/, HLA-DRbeta/NN ,/, and/CC invariant/JJ (/( Ii/NN )/) chains/NNS were/VBD equivalent/JJ in/IN control/JJ and/CC infected/JJ cells/NNS ./. 
Metabolic/JJ labeling/NN combined/VBN with/IN pulse-chase/JJ experiments/NNS and/CC biochemical/JJ analysis/NN showed/VBD that/IN the/DT majority/NN of/IN class/NN II/CD molecules/NNS in/IN infected/JJ cells/NNS became/VBD resistant/JJ to/TO endoglycosidase/NN H/NN ,/, consistent/JJ with/IN normal/JJ Golgi/NN processing/NN ./. 
However/RB ,/, results/NNS of/IN intracellular/JJ staining/NN and/CC dual/JJ color/NN confocal/JJ microscopy/NN revealed/VBD a/DT significant/JJ defect/NN in/IN transport/NN of/IN newly/RB synthesized/VBN class/NN II/CD molecules/NNS through/IN the/DT endocytic/JJ compartment/NN ./. 
Thus/RB ,/, compared/VBN with/IN findings/NNS in/IN control/JJ cells/NNS ,/, class/NN II/CD molecules/NNS in/IN infected/JJ cells/NNS colocalized/VBD to/TO a/DT minimal/JJ extent/NN with/IN a/DT lysosomal-associated/JJ membrane/NN protein-1+/JJ endosomal/JJ compartment/NN ./. 
In/IN addition/NN ,/, in/IN contrast/NN to/TO control/JJ cells/NNS ,/, class/NN II/CD molecules/NNS in/IN infected/JJ cells/NNS failed/VBD to/TO colocalize/VB with/IN endocytosed/VBN BSA/NN under/IN conditions/NNS where/WRB this/DT marker/NN is/VBZ known/VBN to/TO label/VB late/JJ endosomes/NNS ,/, lysosomes/NNS ,/, and/CC the/DT MHC/NN class/NN II/CD compartment/NN ./. 
Consistent/JJ with/IN defective/JJ transport/NN along/IN the/DT endocytic/JJ pathway/NN ,/, the/DT maturation/NN of/IN SDS-stable/JJ class/NN II/CD alphabeta/NN dimers/NNS --/: dependent/JJ upon/IN removal/NN of/IN Ii/NN chain/NN and/CC peptide/NN loading/NN of/IN class/NN II/CD dimers/NNS in/IN the/DT MHC/NN class/NN II/CD compartment/NN --/: was/VBD markedly/RB impaired/JJ in/IN M./NN tuberculosis-infected/JJ cells/NNS ./. 
These/DT findings/NNS indicate/VBP that/IN defective/JJ transport/NN and/CC processing/NN of/IN class/NN II/CD molecules/NNS through/IN the/DT endosomal/lysosomal/JJ system/NN is/VBZ responsible/JJ for/IN diminished/VBN cell/NN surface/NN expression/NN of/IN MHC/NN class/NN II/CD molecules/NNS in/IN cells/NNS infected/VBN with/IN M./NN tuberculosis/NN ./. 
UI/LS -/: 99187985/CD 
TI/LS -/: Identification/NN of/IN upstream/JJ regulatory/JJ elements/NNS that/WDT repress/VBP expression/NN of/IN adult/JJ beta-like/JJ globin/NN genes/NNS in/IN a/DT primitive/JJ erythroid/JJ environment/NN ./. 
AB/LS -/: Our/PRP$ investigations/NNS have/VBP focused/VBN on/IN localizing/VBG cis-elements/NNS responsible/JJ for/IN the/DT down/JJ regulation/NN of/IN the/DT adult/JJ beta-like/JJ globin/NN genes/NNS (/( delta/NN and/CC beta/NN )/) in/IN immature/JJ ,/, or/CC primitive/JJ erythroid/JJ tissues/NNS ./. 
We/PRP studied/VBD their/PRP$ activity/NN after/IN transfection/NN into/IN K562/NN cells/NNS ,/, an/DT erythroleukemia/NN cell/NN line/NN with/IN an/DT embryonic-fetal/JJ phenotype/NN ./. 
Analyzed/VBN DNA/NN sequences/NNS included/VBD delta/NN and/CC beta/NN 5'/JJ flanking/NN regions/NNS extending/VBG from/IN approximately/RB -500/CD to/TO +50bp/NN (/( promoter/NN regions/NNS )/) ,/, truncated/JJ delta/NN and/CC beta/NN 5'/JJ flanking/NN regions/NNS extending/VBG from/IN approximately/RB -250/CD to/TO +50/CD bp/NN ,/, and/CC chimeric/JJ promoter/NN constructions/NNS ,/, which/WDT consisted/VBD of/IN a/DT distal/JJ delta/NN or/CC beta/NN fragment/NN fused/VBN to/TO a/DT proximal/JJ beta/NN or/CC delta/NN sequence/NN ./. 
In/IN CAT/NN reporter/NN constructions/NNS no/DT appreciable/JJ level/NN of/IN CAT/NN activity/NN was/VBD supported/VBN by/IN the/DT beta/NN globin/NN promoter/NN ,/, and/CC only/RB low/JJ level/NN activity/NN by/IN the/DT delta/NN promoter/NN ./. 
Truncation/NN of/IN the/DT beta/NN globin/NN promoter/NN led/VBD to/TO a/DT 2-3/CD fold/JJ increase/NN in/IN promoter/NN activity/NN ./. 
In/IN contrast/NN ,/, deletion/NN of/IN the/DT upstream/JJ portion/NN of/IN the/DT delta/NN promoter/NN led/VBD to/TO a/DT 10/CD fold/JJ decrease/NN in/IN expression/NN ./. 
Coupling/NN of/IN the/DT upstream/JJ beta/NN globin/NN sequence/NN from/IN approximately/RB -500/CD to/TO -250/CD bp/NN to/TO the/DT truncated/VBN delta/NN promoter/NN fragment/NN led/VBD to/TO complete/JJ extinction/NN of/IN transcription/NN activity/NN ,/, consistent/JJ with/IN a/DT negative/JJ regulatory/JJ effect/NN of/IN the/DT beta/NN globin/NN gene/NN upstream/JJ element/NN (/( s/NNS )/) ./. 
Fusion/NN of/IN the/DT upstream/JJ portion/NN of/IN the/DT delta/NN promoter/NN to/TO the/DT truncated/VBN beta/NN globin/NN promoter/NN yielded/VBD a/DT modest/JJ increase/NN in/IN promoter/NN strength/NN relative/JJ to/TO the/DT truncated/VBN beta/NN gene/NN promoter/NN ,/, indicating/VBG the/DT presence/NN of/IN a/DT positive/JJ transcriptional/JJ element/NN (/( s/NNS )/) in/IN the/DT upstream/JJ delta/NN globin/NN regulatory/JJ region/NN ./. 
Site-directed/JJ mutagenesis/NN of/IN binding/VBG sites/NNS for/IN the/DT repressor/NN proteins/NNS BP1/NN and/CC BP2/NN in/IN the/DT upstream/JJ portion/NN of/IN the/DT beta/NN globin/NN gene/NN flanking/NN region/NN led/VBD to/TO a/DT 4-6/CD fold/JJ increase/NN in/IN promoter/NN activity/NN ./. 
DNase/NN I/CD footprinting/NN of/IN the/DT upstream/JJ delta-globin/JJ region/NN revealed/VBD protected/JJ sequences/NNS corresponding/VBG to/TO consensus/NN binding/NN sites/NNS for/IN GATA-1/NN and/CC BP2/NN ./. 
These/DT results/NNS confirm/VBP that/IN sequences/NNS in/IN the/DT upstream/JJ promoter/NN region/NN of/IN the/DT adult/JJ beta/NN globin/NN gene/NN contribute/VBP to/TO its/PRP$ factor-mediated/JJ suppression/NN early/JJ in/IN development/NN and/CC then/RB may/MD modulate/VB its/PRP$ expression/NN at/IN a/DT later/JJ stage/NN ./. 
UI/LS -/: 98439530/CD 
TI/LS -/: Analysis/NN of/IN cytokine/NN signaling/NN in/IN patients/NNS with/IN extrinsic/JJ asthma/NN and/CC hyperimmunoglobulin/NN E/NN ./. 
AB/LS -/: BACKGROUND/NN :/: Recent/JJ data/NNS suggest/VBP that/IN the/DT regulation/NN of/IN class/NN switching/NN to/TO IgE/NN by/IN cytokines/NNS is/VBZ mediated/VBN by/IN STAT/NN transcription/NN factors/NNS ./. 
The/DT induction/NN of/IN IgE/NN by/IN IL-4/NN and/CC IL-13/NN occurs/VBZ through/IN the/DT activation/NN of/IN the/DT intracellular/JJ signal-transducing/JJ protein/NN Stat6/NN ,/, whereas/IN the/DT inhibition/NN of/IN IgE/NN class/NN switching/NN by/IN interferon-y/NN (/( IFN-gamma/NN )/) occurs/VBZ through/IN the/DT activation/NN of/IN Statl/NN ./. 
OBJECTIVE/NN :/: We/PRP hypothesized/VBD that/IN in/IN extrinsic/JJ asthma/NN or/CC in/IN cases/NNS of/IN markedly/RB elevated/JJ IgE/NN (/( ie/NN ,/, hyperimmunoglobulin/NN E/NN [/( HIE/NN ]/) )/) increased/VBN levels/NNS of/IN IgE/NN may/MD be/VB associated/VBN with/IN alterations/NNS in/IN the/DT cytokine/NN levels/NNS or/CC the/DT activation/NN of/IN Stat6/NN ./. 
METHODS/NNS :/: PBMCs/NNS and/CC sera/NNS from/IN 8/CD patients/NNS with/IN extrinsic/JJ asthma/NN (/( mean/JJ IgE/NN ,/, 285+/-100/CD IU/mL/NN )/) ,/, 3/CD patients/NNS with/IN HIE/NN (/( mean/JJ IgE/NN ,/, 7050+/-1122/CD IU/mL/NN )/) ,/, and/CC 14/CD nonatopic/JJ control/JJ subjects/NNS (/( mean/JJ IgE/NN ,/, 112+/-28/CD IU/mL/NN )/) were/VBD analyzed/VBN ./. 
RESULTS/NNS :/: The/DT mean/JJ IL-4/NN level/NN detected/VBN by/IN ELISA/NN was/VBD much/RB greater/JJR in/IN patients/NNS with/IN HIE/NN than/IN control/JJ subjects/NNS (/( 88.6+/-11.5/CD pg/mL/NN vs/CC 11.5+/-7.1/CD pg/mL/NN ,/, P/NN =/JJ .005/NN )/) ,/, and/CC increased/VBN IL-4/NN levels/NNS among/IN patients/NNS with/IN both/CC asthma/NN and/CC HIE/NN correlated/VBD with/IN the/DT increased/VBN IgE/NN levels/NNS ./. 
In/IN contrast/NN ,/, IL-13/NN levels/NNS were/VBD not/RB elevated/JJ ./. 
Levels/NNS of/IN Stat6/NN protein/NN present/JJ in/IN PBMCs/NNS did/VBD not/RB differ/VB in/IN the/DT patients/NNS and/CC control/JJ subjects/NNS ./. 
Examination/NN of/IN Stat6/NN DNA-binding/NN activity/NN demonstrated/VBD no/DT activation/NN of/IN IL-4/NN signaling/NN in/IN patients/NNS with/IN either/CC HIE/NN or/CC acute/JJ asthma/NN ./. 
Interestingly/RB ,/, evidence/NN for/IN the/DT presence/NN of/IN B/NN cells/NNS that/WDT have/VBP already/RB switched/VBN to/TO IgE/NN was/VBD seen/VBN in/IN PBMCs/NNS of/IN several/JJ patients/NNS with/IN asthma/NN or/CC HIE/NN ./. 
CONCLUSION/NN :/: These/DT results/NNS indicate/VBP that/IN (/( 1/LS )/) IgE/NN production/NN in/IN asthma/NN and/CC HIE/NN usually/RB is/VBZ associated/VBN with/IN elevated/JJ levels/NNS of/IN IL-4/NN ,/, but/CC not/RB IL-13/NN ,/, in/IN the/DT peripheral/JJ blood/NN ;/: (/( 2/LS )/) the/DT increased/VBN sera/NNS IL-4/NN levels/NNS in/IN asthma/NN and/CC HIE/NN are/VBP not/RB sufficient/JJ to/TO induce/VB Stat6/NN activation/NN in/IN PBMCs/NNS ;/: and/CC (/( 3/LS )/) evidence/NN of/IN switch/NN recombination/NN to/TO epsilon/NN may/MD be/VB detected/VBN in/IN isolated/VBN cases/NNS of/IN elevated/JJ IgE/NN ./. 
This/DT implies/VBZ that/IN high/JJ levels/NNS of/IN IgE/NN in/IN these/DT patients/NNS either/CC results/VBZ from/IN B/NN cells/NNS that/WDT have/VBP already/RB undergone/VBN class/NN switching/NN ,/, from/IN Ig/NN class/NN switching/NN that/WDT is/VBZ localized/JJ to/TO target/NN tissues/NNS ,/, or/CC both/DT ./. 
UI/LS -/: 98430664/CD 
TI/LS -/: Carboxyl-terminal/JJ 15-amino/JJ acid/NN sequence/NN of/IN NFATx1/NN is/VBZ possibly/RB created/VBN by/IN tissue-specific/JJ splicing/NN and/CC is/VBZ essential/JJ for/IN transactivation/NN activity/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: NFAT/NN regulates/VBZ transcription/NN of/IN a/DT number/NN of/IN cytokine/NN and/CC other/JJ immunoregulatory/JJ genes/NNS ./. 
We/PRP have/VBP isolated/VBN NFATx/NN ,/, which/WDT is/VBZ one/CD of/IN four/CD members/NNS of/IN the/DT NFAT/NN family/NN of/IN transcription/NN factors/NNS and/CC is/VBZ preferentially/RB expressed/VBN in/IN the/DT thymus/NN and/CC peripheral/JJ blood/NN leukocytes/NNS ,/, and/CC an/DT isoform/NN of/IN NFATx/NN ,/, NFATx1/NN ./. 
Here/RB we/PRP provide/VBP evidence/NN showing/VBG that/IN 15/CD amino/NN acids/NNS in/IN the/DT carboxyl-terminal/JJ end/NN of/IN NFATx1/NN are/VBP required/VBN for/IN its/PRP$ maximum/JJ transactivation/NN activity/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
A/DT fusion/NN between/IN these/DT 15/CD amino/NN acids/NNS and/CC the/DT GAL4/NN DNA/NN binding/NN domain/NN was/VBD capable/JJ of/IN transactivating/VBG reporters/NNS driven/VBN by/IN the/DT GAL4/NN DNA/NN binding/NN site/NN ./. 
Interestingly/RB ,/, this/DT 15-amino/JJ acid/NN transactivation/NN sequence/NN is/VBZ well/RB conserved/VBN in/IN NFAT/NN family/NN proteins/NNS ,/, although/IN the/DT sequences/NNS contiguous/JJ to/TO the/DT carboxyl-terminal/JJ regions/NNS of/IN the/DT NFAT/NN family/NN are/VBP much/JJ less/RBR conserved/VBN ./. 
We/PRP also/RB report/VBP three/CD additional/JJ isoforms/NNS of/IN NFATx/NN ,/, designated/VBN NFATx2/NN ,/, NFATx3/NN ,/, and/CC NFATx4/NN ./. 
This/DT transactivation/NN sequence/NN is/VBZ altered/VBN by/IN tissue-specific/JJ alternative/JJ splicing/NN in/IN newly/RB isolated/VBN NFATx/NN isoforms/NNS ,/, resulting/VBG in/IN lower/JJR transactivation/NN activity/NN in/IN Jurkat/NN T/NN cells/NNS ./. 
NFATx1/NN is/VBZ expressed/VBN predominantly/RB in/IN the/DT thymus/NN and/CC peripheral/JJ blood/NN leukocyte/NN ,/, while/IN the/DT skeletal/JJ muscle/NN expressed/VBD primarily/RB NFATx2/NN ./. 
In/IN Jurkat/NN cells/NNS ,/, transcription/NN from/IN the/DT NFAT/NN site/NN of/IN the/DT IL-2/NN promoter/NN is/VBZ activated/VBN strongly/RB by/IN NFATx1/NN but/CC only/RB weakly/RB by/IN NFATx2/NN ./. 
These/DT data/NNS demonstrate/VBP that/IN the/DT 15-amino/JJ acid/NN sequence/NN of/IN NFATx1/NN is/VBZ a/DT major/JJ transactivation/NN sequence/NN required/VBN for/IN induction/NN of/IN genes/NNS by/IN NFATx1/NN in/IN T/NN cells/NNS and/CC possibly/RB regulates/VBZ NFAT/NN activity/NN through/IN tissue-specific/JJ alternative/JJ splicing/NN ./. 
UI/LS -/: 98417611/CD 
TI/LS -/: Altered/JJ DNA-binding/JJ specificity/NN mutants/NNS of/IN EKLF/NN and/CC Sp1/NN show/VBP that/IN EKLF/NN is/VBZ an/DT activator/NN of/IN the/DT beta-globin/NN locus/NN control/NN region/NN in/FW vivo/FW ./. 
AB/LS -/: The/DT locus/NN control/NN region/NN of/IN the/DT beta-globin/NN cluster/NN contains/VBZ five/CD DNase/NN I/CD hypersensitive/JJ sites/NNS (/( 5'HS1-5/NN )/) required/VBN for/IN locus/NN activation/NN ./. 
5'HS3/NN contains/VBZ six/CD G-rich/JJ motifs/NNS that/WDT are/VBP essential/JJ for/IN its/PRP$ activity/NN ./. 
Members/NNS of/IN a/DT protein/NN family/NN ,/, characterized/VBN by/IN three/CD zinc/NN fingers/NNS highly/RB homologous/JJ to/TO those/DT found/VBN in/IN transcription/NN factor/NN Sp1/NN ,/, interact/VBP with/IN these/DT motifs/NNS ./. 
Because/IN point/NN mutagenesis/NN can/MD not/RB distinguish/VB between/IN family/NN members/NNS ,/, it/PRP is/VBZ not/RB known/VBN which/WDT protein/NN activates/VBZ 5'HS3/NN ./. 
We/PRP show/VBP that/IN the/DT function/NN of/IN such/JJ closely/RB related/JJ proteins/NNS can/MD be/VB distinguished/VBN in/FW vivo/FW by/IN matching/VBG point/NN mutations/NNS in/IN 5'HS3/NN with/IN amino/NN acid/NN changes/NNS in/IN the/DT zinc/NN fingers/NNS of/IN Sp1/NN and/CC EKLF/NN ./. 
Testing/VBG their/PRP$ activity/NN in/IN transgenic/JJ mice/NNS shows/VBZ that/IN EKLF/NN is/VBZ a/DT direct/JJ activator/NN of/IN 5'HS3/NN ./. 
UI/LS -/: 98406200/CD 
TI/LS -/: The/DT Epstein-Barr/JJ virus/NN Rta/NN protein/NN activates/VBZ lytic/JJ cycle/NN genes/NNS and/CC can/MD disrupt/VB latency/NN in/IN B/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT transition/NN of/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) from/IN latency/NN into/IN the/DT lytic/JJ cycle/NN is/VBZ associated/VBN with/IN the/DT expression/NN of/IN two/CD immediate-early/JJ viral/JJ genes/NNS ,/, BZLF1/NN and/CC BRLF1/NN ./. 
Overexpression/NN of/IN ZEBRA/NN ,/, the/DT product/NN of/IN BZLF1/NN ,/, is/VBZ sufficient/JJ to/TO disrupt/VB latency/NN in/IN B/NN lymphocytes/NNS and/CC epithelial/JJ cells/NNS by/IN stimulating/VBG expression/NN of/IN lytic/JJ cycle/NN genes/NNS ,/, including/VBG BRLF1/NN ./. 
The/DT BRLF1/NN product/NN Rta/NN functions/VBZ as/IN a/DT transcriptional/JJ activator/NN in/IN both/CC B/NN lymphocytes/NNS and/CC epithelial/JJ cells/NNS ./. 
However/RB ,/, Rta/NN has/VBZ recently/RB been/VBN reported/VBN to/TO disrupt/VB latency/NN in/IN an/DT epithelial/JJ specific/JJ manner/NN (/( S./NNP Zalani/NNP ,/, E./NNP Holley-Guthrie/NNP ,/, and/CC S./NNP Kenney/NNP ,/, Proc./NNP Natl./NNP Acad./NNP Sci./NNP USA/NNP 93/CD :/: 9194-9199/CD ,/, 1996/CD )/) ./. 
Here/RB we/PRP demonstrate/VBP that/IN expression/NN of/IN Rta/NN is/VBZ also/RB sufficient/JJ for/IN disruption/NN of/IN latency/NN in/IN a/DT permissive/JJ B-cell/NN line/NN ./. 
In/IN HH514-16/NN cells/NNS ,/, transfection/NN of/IN Rta/NN leads/VBZ to/TO synthesis/NN of/IN ZEBRA/NN ,/, viral/JJ DNA/NN replication/NN ,/, and/CC late/JJ gene/NN expression/NN ./. 
However/RB ,/, Rta/NN by/IN itself/PRP is/VBZ less/RBR potent/JJ than/IN ZEBRA/NN in/IN the/DT ability/NN to/TO activate/VB most/RBS early/JJ and/CC late/JJ lytic/JJ cycle/NN genes/NNS ./. 
In/IN light/NN of/IN previous/JJ work/NN implicating/VBG ZEBRA/NN in/IN the/DT activation/NN of/IN Rta/NN ,/, we/PRP suggest/VBP a/DT cooperative/JJ model/NN for/IN EBV/NN entry/NN into/IN the/DT lytic/JJ cycle/NN ./. 
Expression/NN of/IN either/CC BZLF1/NN or/CC BRLF1/NN triggers/VBZ expression/NN of/IN the/DT other/JJ immediate-early/JJ factor/NN ,/, and/CC together/RB these/DT activators/NNS act/VBP individually/RB or/CC in/IN synergy/NN on/IN downstream/JJ targets/NNS to/TO activate/VB the/DT viral/JJ lytic/JJ cycle/NN ./. 
UI/LS -/: 98391036/CD 
TI/LS -/: Transcription/NN of/IN a/DT minimal/JJ promoter/NN from/IN the/DT NF-IL6/NN gene/NN is/VBZ regulated/VBN by/IN CREB/ATF/NN and/CC SP1/NN proteins/NNS in/IN U937/NN promonocytic/JJ cells/NNS ./. 
AB/LS -/: NF-IL6/NN is/VBZ an/DT important/JJ transcriptional/JJ regulator/NN of/IN genes/NNS induced/VBN in/IN activated/VBN monocytes/macrophages/NNS ,/, and/CC NF-IL6/NN is/VBZ the/DT only/RB CCAAT/enhancer-binding/JJ protein/NN (/( C/EBP/NN )/) family/NN member/NN whose/WP$ steady-state/JJ mRNA/NN levels/NNS increase/VBP upon/IN activation/NN of/IN monocytes/NNS (/( 1/CD )/) ./. 
We/PRP show/VBP that/IN increased/VBN transcription/NN of/IN the/DT NF-IL6/NN gene/NN is/VBZ responsible/JJ ,/, at/IN least/JJS in/IN part/NN ,/, for/IN induction/NN of/IN NF-IL6/NN mRNA/NN following/VBG activation/NN of/IN U937/NN promonocytic/JJ cells/NNS ./. 
We/PRP have/VBP identified/VBN a/DT 104-bp/JJ minimal/JJ promoter/NN region/NN of/IN the/DT NF-IL6/NN gene/NN that/WDT is/VBZ sufficient/JJ for/IN basal/JJ and/CC activation-dependent/JJ induction/NN of/IN transcription/NN in/IN U937/NN cells/NNS ./. 
This/DT region/NN contains/VBZ binding/VBG sites/NNS for/IN the/DT cAMP/NN response/NN element-binding/JJ protein/activation/NN transcription/NN factor/NN (/( CREB/ATF/NN )/) and/CC Sp1/NN families/NNS of/IN transcription/NN factors/NNS ./. 
Each/JJ site/NN is/VBZ functionally/RB important/JJ and/CC contributes/VBZ independently/RB to/TO transcription/NN of/IN the/DT NF-IL6/NN gene/NN in/IN U937/NN cells/NNS ./. 
UI/LS -/: 98384373/CD 
TI/LS -/: CIITA/NN B-cell-specific/JJ promoter/NN suppression/NN in/IN MHC/NN class/NN II-silenced/JJ cell/NN hybrids/NNS ./. 
AB/LS -/: In/IN this/DT study/NN ,/, various/JJ sets/NNS of/IN somatic/JJ cell/NN hybrids/NNS ,/, generated/VBN by/IN the/DT fusion/NN of/IN epithelial/JJ cell/NN lines/NNS with/IN B-lymphoblastoid/JJ cell/NN lines/NNS ,/, were/VBD analyzed/VBN for/IN the/DT expression/NN of/IN major/JJ histocompatibility/NN complex/NN (/( MHC/NN )/) class/NN II/CD antigens/NNS ./. 
We/PRP first/RB demonstrate/VBP ,/, in/IN human/JJ and/CC mouse/NN intraspecies/NNS hybrids/NNS ,/, the/DT coordinate/JJ suppression/NN of/IN MHC/NN class/NN II/CD ,/, Ii/NN (/( invariant/JJ chain/NN )/) and/CC HLA-DM/NN gene/NN transcription/NN ,/, and/CC the/DT release/NN of/IN the/DT silencing/NN by/IN the/DT addition/NN of/IN interferon/NN gamma/NN ./. 
Using/VBG interspecies/NNS hybrids/NNS ,/, the/DT segregation/NN of/IN human/JJ chromosomes/NNS allowed/VBD us/PRP to/TO establish/VB that/IN MHC/NN class/NN II/CD extinction/NN is/VBZ linked/VBN to/TO the/DT presence/NN in/IN the/DT hybrids/NNS of/IN the/DT chromosomes/NNS from/IN the/DT epithelial/JJ fusion/NN partner/NN ./. 
Moreover/RB ,/, our/PRP$ data/NNS provide/VBP evidence/NN that/IN the/DT expression/NN pattern/NN of/IN MHC/NN class/NN II/CD mRNA/NN is/VBZ correlated/VBN with/IN that/DT of/IN the/DT class/NN II/CD transactivator/NN (/( CIITA/NN )/) ,/, suggesting/VBG that/IN CIITA/NN is/VBZ the/DT actual/JJ target/NN of/IN the/DT silencing/NN ./. 
To/TO gain/VB further/JJ insight/NN into/IN the/DT suppression/NN phenomenon/NN we/PRP performed/VBD luciferase/NN assays/NNS which/WDT show/VBP that/IN silencing/NN affects/VBZ the/DT activity/NN of/IN the/DT B-cell-specific/JJ promoter/NN of/IN CIITA/NN ./. 
These/DT results/NNS therefore/RB demonstrate/VBP that/IN the/DT MHC/NN class/NN II/CD gene/NN silencing/NN in/IN somatic/JJ cell/NN hybrids/NNS is/VBZ due/JJ to/TO an/DT active/JJ suppression/NN of/IN one/CD of/IN the/DT promoters/NNS of/IN the/DT CIITA/NN gene/NN ,/, mediated/VBN by/IN the/DT epithelial/JJ cell/NN fusion/NN partner/NN ./. 
UI/LS -/: 98375837/CD 
TI/LS -/: Class/NN II/CD transactivator-independent/JJ endothelial/JJ cell/NN MHC/NN class/NN II/CD gene/NN activation/NN induced/VBN by/IN lymphocyte/NN adhesion/NN ./. 
AB/LS -/: NK/NN cells/NNS induce/VBP MHC/NN class/NN II/CD molecules/NNS on/IN the/DT surface/NN of/IN allogeneic/JJ endothelial/JJ cells/NNS in/IN an/DT adhesion-dependent/JJ ,/, IFN-gamma-independent/JJ manner/NN ./. 
Here/RB ,/, we/PRP demonstrate/VBP that/IN NK/NN cells/NNS induce/VBP HLA-DR/NN on/IN the/DT surface/NN of/IN a/DT mutant/JJ cell/NN line/NN that/WDT is/VBZ defective/JJ in/IN IFN-gamma-induced/JJ MHC/NN class/NN II/CD expression/NN ./. 
RNA/NN analysis/NN in/IN these/DT cells/NNS and/CC in/IN a/DT cell/NN line/NN that/WDT is/VBZ defective/JJ in/IN class/NN II/CD transactivator/NN (/( CIITA/NN )/) demonstrates/VBZ that/IN NK/NN cell-induced/JJ HLA-DR/NN alpha/NN mRNA/NN expression/NN is/VBZ also/RB CIITA-independent/JJ ./. 
The/DT Janus/NN kinase-1-deficient/JJ cell/NN line/NN U4A/NN expresses/VBZ HLA-DR/NN alpha/NN mRNA/NN in/IN response/NN to/TO NK/NN cell/NN activation/NN ,/, and/CC HLA-DR/NN alpha/NN promoter/NN constructs/NNS transfected/VBN into/IN these/DT cells/NNS are/VBP induced/VBN by/IN NK/NN cells/NNS but/CC not/RB IFN-gamma/NN ./. 
These/DT data/NNS indicate/VBP that/IN the/DT IFN-gamma-independent/JJ component/NN of/IN the/DT target/NN cell/NN HLA-DR/NN expression/NN induced/VBN by/IN lymphocyte/NN adhesion/NN uses/VBZ a/DT signaling/NN pathway/NN that/WDT is/VBZ distinct/JJ from/IN the/DT IFN-gamma-dependent/JJ mechanism/NN and/CC also/RB suggest/VBP that/IN CIITA/NN is/VBD not/RB required/VBN ./. 
UI/LS -/: 99023364/CD 
TI/LS -/: Effects/NNS of/IN overexpression/NN of/IN IL-1/NN receptor-associated/JJ kinase/NN on/IN NFkappaB/NN activation/NN ,/, IL-2/NN production/NN and/CC stress-activated/JJ protein/NN kinases/NNS in/IN the/DT murine/JJ T/NN cell/NN line/NN EL4/NN ./. 
AB/LS -/: The/DT association/NN and/CC activation/NN of/IN the/DT IL-1/NN receptor-associated/JJ protein/NN kinase/NN (/( IRAK/NN )/) to/TO the/DT IL-1/NN receptor/NN complex/NN is/VBZ one/CD of/IN the/DT earliest/JJS events/NNS detectable/JJ in/IN IL-1/NN signal/NN transduction/NN ./. 
We/PRP generated/VBD permanent/JJ clones/NNS of/IN the/DT murine/JJ T/NN cell/NN line/NN EL4/NN 6.1/CD overexpressing/VBG human/JJ (/( h/NN )/) IRAK/NN to/TO evaluate/VB the/DT role/NN of/IN this/DT kinase/NN in/IN IL-1/NN signaling/NN ./. 
Overexpression/NN of/IN hIRAK/NN enhanced/VBD IL-1-stimulated/JJ activation/NN of/IN the/DT transcription/NN factor/NN NFkappaB/NN ,/, whereas/IN a/DT truncated/VBN form/NN (/( N-IRAK/NN )/) specifically/RB inhibited/VBD IL-1-dependent/JJ NFkappaB/NN activity/NN ./. 
In/IN clones/NNS stably/RB overexpressing/VBG hIRAK/NN a/DT weak/JJ constitutive/JJ activation/NN of/IN NFkappaB/NN correlated/VBD with/IN a/DT low/JJ basal/JJ IL-2/NN production/NN which/WDT was/VBD enhanced/VBN in/IN an/DT IL-1-dependent/JJ manner/NN ./. 
Compared/VBN to/TO the/DT parental/JJ cell/NN line/NN the/DT dose-response/JJ curve/NN of/IN IL-1-induced/JJ IL-2/NN production/NN was/VBD shifted/VBN in/IN both/CC potency/NN and/CC efficacy/NN ./. 
These/DT results/NNS demonstrate/VBP that/IN IRAK/NN directly/RB triggers/VBZ NFkappaB-mediated/JJ gene/NN expression/NN in/IN EL4/NN cells/NNS ./. 
Qualitatively/RB different/JJ effects/NNS were/VBD observed/VBN for/IN the/DT IL-1-induced/JJ activation/NN of/IN stress-activated/JJ protein/NN (/( SAP/NN )/) kinases/NNS :/: permanent/JJ overexpression/NN of/IN IRAK/NN did/VBD not/RB affect/VB the/DT dose/NN dependence/NN but/CC prolonged/VBD the/DT kinetics/NN of/IN IL-1-induced/JJ activation/NN of/IN SAP/NN kinases/NNS ,/, suggesting/VBG that/IN this/DT signaling/VBG branch/NN may/MD be/VB regulated/VBN by/IN distinct/JJ mechanisms/NNS ./. 
UI/LS -/: 99008545/CD 
TI/LS -/: The/DT role/NN of/IN protein/NN kinase/NN C/NN signaling/NN in/IN activated/VBN DRA/NN transcription/NN ./. 
AB/LS -/: Expression/NN of/IN human/JJ MHC/NN HLA-DRA/NN class/NN II/CD gene/NN can/MD be/VB up-regulated/VBN in/IN B/NN cells/NNS by/IN Ig/NN cross-linking/NN as/RB well/RB as/IN by/IN phorbol/NN esters/NNS such/JJ as/IN 12-O-tetradecanoyl/NN phorbol/NN 13-acetate/NN (/( TPA/NN )/) ./. 
Induced/VBN DRA/NN expression/NN involves/VBZ activation/NN of/IN restricted/JJ protein/NN kinase/NN C/NN (/( PKC/NN )/) isoforms/NNS ,/, resulting/VBG in/IN activated/VBN activator/NN protein-1-dependent/JJ transcription/NN ./. 
In/IN this/DT report/NN expression/NN profiles/NNS and/CC activation/NN of/IN PKC/NN were/VBD analyzed/VBN in/IN human/JJ Raji/NN B/NN lymphoblastoid/JJ cells/NNS ./. 
Transient/JJ transfection/NN analysis/NN with/IN target/NN plasmids/NNS containing/VBG either/CC DRA/NN promoter/NN (/( wild-type/JJ or/CC mutated/VBN )/) or/CC TPA/NN response/NN elements/NNS demonstrated/VBD that/IN pretreatment/NN with/IN the/DT selective/JJ PKC/NN inhibitor/NN GF/NN 109203X/NN repressed/VBD TPA-mediated/JJ activation/NN ./. 
Western/NN analysis/NN performed/VBN on/IN cellular/JJ fractions/NNS of/IN resting/VBG cells/NNS and/CC of/IN TPA-activated/JJ cells/NNS revealed/VBD abundant/JJ expression/NN of/IN classical/JJ PKC-alpha/NN (/( cPKC-alpha/NN )/) ,/, cPKC-betaII/NN ,/, and/CC atypical/JJ PKC-zeta/NN isoforms/NNS and/CC identified/VBD a/DT sustained/JJ translocation/NN of/IN cPKC-alpha/NN and/CC cPKC-betaII/NN from/IN the/DT cytosolic/JJ compartment/NN to/TO membranes/NNS ./. 
As/IN expected/VBN ,/, the/DT distribution/NN of/IN atypical/JJ PKC-zeta/NN was/VBD unaffected/JJ by/IN TPA/NN treatment/NN and/CC displayed/VBD an/DT even/JJ distribution/NN between/IN cytosol/NN and/CC membranes/NNS ./. 
This/DT finding/NN was/VBD confirmed/VBN by/IN immunofluorescence/NN microscopy/NN ./. 
The/DT TPA-mediated/JJ translocation/NN of/IN cPKC-alpha/NN and/CC cPKC-betaII/NN was/VBD not/RB influenced/VBN by/IN pretreatment/NN with/IN GF/NN 109203X/NN ./. 
Finally/RB ,/, functional/JJ activation/NN and/CC translocation/NN of/IN PKC/NN were/VBD investigated/VBN with/IN a/DT selective/JJ in/FW vitro/FW kinase/NN assay/NN ./. 
Together/RB ,/, these/DT results/NNS show/VBP that/IN activated/VBN HLA-DRA/NN expression/NN in/IN response/NN to/TO TPA/NN treatment/NN is/VBZ strictly/RB dependent/JJ on/IN PKC/NN activation/NN acting/VBG on/IN the/DT X2/NN box/NN of/IN the/DT DRA/NN promoter/NN and/CC that/IN selective/JJ inhibition/NN of/IN PKC/NN enzymatic/JJ activity/NN does/VBZ not/RB influence/VB subcellular/JJ localization/NN of/IN expressed/VBN PKC/NN isoenzymes/NNS ./. 
Thus/RB ,/, the/DT translocation/NN event/NN per/FW se/FW occurs/VBZ independently/RB of/IN PKC/NN activation/NN in/IN these/DT cells/NNS ./. 
UI/LS -/: 99007236/CD 
TI/LS -/: Inhibition/NN of/IN RNA/NN polymerase/NN II/CD transcription/NN in/IN human/JJ cells/NNS by/IN synthetic/JJ DNA-binding/JJ ligands/NNS [/( see/VB comments/NNS ]/) 
AB/LS -/: Sequence-specific/JJ DNA-binding/JJ small/JJ molecules/NNS that/WDT can/MD permeate/VB human/JJ cells/NNS potentially/RB could/MD regulate/VB transcription/NN of/IN specific/JJ genes/NNS ./. 
Multiple/JJ cellular/JJ DNA-binding/JJ transcription/NN factors/NNS are/VBP required/VBN by/IN HIV/NN type/NN 1/CD for/IN RNA/NN synthesis/NN ./. 
Two/CD pyrrole-imidazole/JJ polyamides/NNS were/VBD designed/VBN to/TO bind/VB DNA/NN sequences/NNS immediately/RB adjacent/JJ to/TO binding/VBG sites/NNS for/IN the/DT transcription/NN factors/NNS Ets-1/NN ,/, lymphoid-enhancer/JJ binding/NN factor/NN 1/CD ,/, and/CC TATA-box/NN binding/NN protein/NN ./. 
These/DT synthetic/JJ ligands/NNS specifically/RB inhibit/VBP DNA-binding/NN of/IN each/DT transcription/NN factor/NN and/CC HIV/NN type/NN 1/CD transcription/NN in/IN cell-free/JJ assays/NNS ./. 
When/WRB used/VBN in/IN combination/NN ,/, the/DT polyamides/NNS inhibit/VBP virus/NN replication/NN by/IN >/JJR 99/CD %/NN in/IN isolated/VBN human/JJ peripheral/JJ blood/NN lymphocytes/NNS ,/, with/IN no/DT detectable/JJ cell/NN toxicity/NN ./. 
The/DT ability/NN of/IN small/JJ molecules/NNS to/TO target/VB predetermined/JJ DNA/NN sequences/NNS located/JJ within/IN RNA/NN polymerase/NN II/CD promoters/NNS suggests/VBZ a/DT general/JJ approach/NN for/IN regulation/NN of/IN gene/NN expression/NN ,/, as/RB well/RB as/IN a/DT mechanism/NN for/IN the/DT inhibition/NN of/IN viral/JJ replication/NN ./. 
UI/LS -/: 98440284/CD 
TI/LS -/: musculin/NN :/: a/DT murine/JJ basic/JJ helix-loop-helix/JJ transcription/NN factor/NN gene/NN expressed/VBN in/IN embryonic/JJ skeletal/JJ muscle/NN ./. 
AB/LS -/: We/PRP describe/VBP the/DT embryonic/JJ expression/NN of/IN musculin/NN ,/, a/DT new/JJ murine/JJ member/NN of/IN the/DT bHLH/JJ family/NN of/IN transcription/NN factors/NNS ./. 
Musculin/NN protein/NN is/VBZ closely/RB related/JJ to/TO human/JJ ABF-1/NN ,/, which/WDT is/VBZ expressed/VBN in/IN activated/VBN B/NN cells/NNS ,/, and/CC to/TO epicardin/capsulin/Pod-1/NN ,/, which/WDT is/VBZ expressed/VBN in/IN branchial/JJ myoblasts/NNS ,/, visceral/JJ and/CC urogenital/JJ mesoderm/NN and/CC epicardium/NN ./. 
In/FW situ/FW hybridisation/NN revealed/VBD musculin/NN expression/NN in/IN embryos/NNS was/VBD largely/RB restricted/JJ to/TO the/DT embryonic/JJ skeletal/JJ muscle/NN lineage/NN ./. 
While/IN all/DT skeletal/JJ muscles/NNS expressed/VBD the/DT gene/NN ,/, only/RB a/DT subset/NN of/IN myocytes/NNS within/IN each/DT muscle/NN were/VBD positive/JJ ,/, indicating/VBG molecular/JJ heterogeneity/NN within/IN fetal/JJ muscle/NN ./. 
Copyright/NN 1998/CD Elsevier/NNP Science/NNP Ireland/NNP Ltd/NNP ./. 
All/DT Rights/NNS Reserved/VBN ./. 
UI/LS -/: 98437269/CD 
TI/LS -/: Induction/NN of/IN T/NN cell/NN anergy/NN by/IN high/JJ concentrations/NNS of/IN immunodominant/JJ native/JJ peptide/NN is/VBZ accompanied/VBN by/IN IL-10/NN production/NN and/CC a/DT block/NN in/IN JNK/NN activity/NN ./. 
AB/LS -/: The/DT ability/NN to/TO induce/VB anergy/NN in/IN antigen-specific/JJ T/NN cells/NNS has/VBZ potential/JJ therapeutic/JJ value/NN for/IN altering/VBG pathologic/JJ immune/JJ responses/NNS ./. 
This/DT study/NN was/VBD undertaken/VBN to/TO further/RB analyze/VB changes/NNS in/IN cytokine/NN production/NN and/CC intracellular/JJ signaling/NN during/IN anergy/NN induction/NN using/VBG high/JJ concentrations/NNS of/IN native/JJ peptide/NN ligand/NN of/IN tetanus/NN toxoid/NN (/( TT/NN )/) -/: and/CC myelin/JJ basic/JJ protein/NN (/( MBP/NN )/) -specific/JJ human/JJ T/NN cell/NN lines/NNS ./. 
The/DT TT-selected/JJ T/NN cell/NN line/NN could/MD be/VB rendered/VBN unresponsive/JJ to/TO its/PRP$ dominant/JJ epitope/NN in/IN a/DT dose-dependent/JJ manner/NN (/( IC50/NN =/JJ 0.03/CD microg/ml/NN )/) ./. 
The/DT TT-selected/JJ line/NN ,/, as/RB well/RB as/IN three/CD T/NN cell/NN clones/NNS established/VBN from/IN this/DT line/NN ,/, continued/VBD to/TO produce/VB IFN-gamma/NN and/CC significantly/RB increased/VBD IL-4/NN and/CC IL-10/NN production/NN when/WRB anergy/NN was/VBD induced/VBN with/IN high/JJ concentrations/NNS of/IN the/DT immunodominant/JJ epitope/NN ./. 
JNK/NN enzymatic/JJ activity/NN was/VBD blocked/VBN in/IN anergized/VBN T/NN cells/NNS ./. 
The/DT MBP-selected/JJ line/NN could/MD likewise/RB be/VB rendered/VBN unresponsive/JJ by/IN incubation/NN with/IN supraoptimal/JJ concentrations/NNS of/IN immunodominant/JJ peptide/NN and/CC anergy/NN induction/NN was/VBD accompanied/VBN by/IN IL-10/NN release/NN ./. 
Both/DT T/NN cell/NN lines/NNS could/MD be/VB anergized/VBN by/IN the/DT autopresentation/NN of/IN native/JJ peptide/NN since/IN anergy/NN was/VBD induced/VBN in/IN cultures/NNS lacking/VBG fresh/JJ antigen-presenting/JJ cells/NNS ./. 
This/DT study/NN shows/VBZ that/IN the/DT mitogen-activated/JJ protein/NN kinase/NN cascade/NN is/VBZ blocked/VBN when/WRB anergy/NN is/VBZ induced/VBN to/TO high/JJ concentrations/NNS of/IN soluble/JJ peptide/NN ./. 
Copyright/NN 1998/CD Academic/NNP Press/NNP ./. 
UI/LS -/: 98416180/CD 
TI/LS -/: Upregulation/NN of/IN interleukin/NN 6/CD and/CC granulocyte/NN colony-stimulating/JJ factor/NN receptors/NNS by/IN transcription/NN factor/NN CCAAT/NN enhancer/NN binding/NN protein/NN alpha/NN (/( C/EBP/NN alpha/NN )/) is/VBZ critical/JJ for/IN granulopoiesis/NN ./. 
AB/LS -/: Cytokines/NNS stimulate/VBP granulopoiesis/NN through/IN signaling/NN via/IN receptors/NNS whose/WP$ expression/NN is/VBZ controlled/VBN by/IN lineage-specific/JJ transcription/NN factors/NNS ./. 
Previously/RB ,/, we/PRP demonstrated/VBD that/IN granulocyte/NN colony-stimulating/JJ factor/NN (/( G-CSF/NN )/) receptor/NN mRNA/NN was/VBD undetectable/JJ and/CC granulocyte/NN maturation/NN blocked/VBN in/IN CCAAT/NN enhancer/NN binding/NN protein/NN alpha/NN (/( C/EBPalpha/NN )/) -deficient/JJ mice/NNS ./. 
This/DT phenotype/NN is/VBZ distinct/JJ from/IN that/DT of/IN G-CSF/NN receptor-/-/JJ mice/NNS ,/, suggesting/VBG that/IN other/JJ genes/NNS are/VBP likely/JJ to/TO be/VB adversely/RB affected/VBN by/IN loss/NN of/IN C/EBPalpha/NN ./. 
Here/RB we/PRP demonstrate/VBP loss/NN of/IN interleukin/NN 6/CD (/( IL-6/NN )/) receptor/NN and/CC IL-6-responsive/JJ colony-forming/JJ units/NNS (/( CFU-IL6/NNS )/) in/IN C/EBPalpha-/-/JJ mice/NNS ./. 
The/DT observed/VBN failure/NN of/IN granulopoiesis/NN could/MD be/VB rescued/VBN by/IN the/DT addition/NN of/IN soluble/JJ IL-6/NN receptor/NN and/CC IL-6/NN or/CC by/IN retroviral/JJ transduction/NN of/IN G-CSF/NN receptors/NNS ,/, demonstrating/VBG that/IN loss/NN of/IN both/DT of/IN these/DT receptors/NNS contributes/VBZ to/TO the/DT absolute/JJ block/NN in/IN granulocyte/NN maturation/NN observed/VBN in/IN C/EBPalpha-deficient/JJ hematopoietic/JJ cells/NNS ./. 
The/DT results/NNS of/IN these/DT and/CC other/JJ studies/NNS suggest/VBP that/IN additional/JJ C/EBPalpha/NN target/NN genes/NNS ,/, possibly/RB other/JJ cytokine/NN receptors/NNS ,/, are/VBP also/RB important/JJ for/IN the/DT block/NN in/IN granulocyte/NN differentiation/NN observed/VBN in/FW vivo/FW in/IN C/EBPalpha-deficient/JJ mice/NNS ./. 
UI/LS -/: 98406066/CD 
TI/LS -/: Phosphatidylinositides/NNS bind/VBP to/TO plasma/NN membrane/NN CD14/NN and/CC can/MD prevent/VB monocyte/NN activation/NN by/IN bacterial/JJ lipopolysaccharide/NN ./. 
AB/LS -/: Although/IN bacterial/JJ lipopolysaccharides/NNS (/( LPS/NNS )/) and/CC several/JJ other/JJ microbial/JJ agonists/NNS can/MD bind/VB to/TO mCD14/NN (/( membrane/NN CD14/NN )/) ,/, a/DT cell-surface/JJ receptor/NN found/VBN principally/RB on/IN monocytes/NNS and/CC neutrophils/NNS ,/, host-derived/JJ mCD14/NN ligands/NNS are/VBP poorly/RB defined/VBN ./. 
We/PRP report/VBP here/RB that/IN phosphatidylinositol/NN (/( PtdIns/NN )/) ,/, phosphatidylinositol-4-phosphate/NN ,/, and/CC other/JJ phosphatidylinositides/NNS can/MD bind/VB to/TO mCD14/NN ./. 
Phosphatidylserine/NN (/( PS/NN )/) ,/, another/DT anionic/JJ glycerophospholipid/NN ,/, binds/VBZ to/TO mCD14/NN with/IN lower/JJR apparent/JJ affinity/NN than/IN does/VBZ PtdIns/NN ./. 
LPS-binding/JJ protein/NN ,/, a/DT lipid/NN transfer/NN protein/NN found/VBN in/IN serum/NN ,/, facilitates/VBZ both/CC PS-/NN and/CC PtdIns-mCD14/NN binding/NN ./. 
PtdIns/NN binding/VBG to/TO mCD14/NN can/MD be/VB blocked/VBN by/IN anti-CD14/JJ monoclonal/JJ antibodies/NNS that/WDT inhibit/VBP LPS-mCD14/NN binding/NN ,/, and/CC PtdIns/NN can/MD inhibit/VB both/CC LPS-mCD14/NN binding/NN and/CC LPS-induced/JJ responses/NNS in/IN monocytes/NNS ./. 
Serum-equilibrated/JJ PtdIns/NN also/RB binds/VBZ to/TO mCD14-expressing/JJ cells/NNS ,/, raising/VBG the/DT possibility/NN that/IN endogenous/JJ PtdIns/NN may/MD modulate/VB cellular/JJ responses/NNS to/TO LPS/NNS and/CC other/JJ mCD14/NN ligands/NNS in/FW vivo/FW ./. 
UI/LS -/: 98391028/CD 
TI/LS -/: Protein/NN kinase/NN C/NN regulates/VBZ Fas/NN (/( CD95/APO-1/NN )/) expression/NN ./. 
AB/LS -/: Fas/NN (/( CD95/APO-1/NN )/) is/VBZ a/DT transmembrane/JJ protein/NN of/IN the/DT TNF/neuron/NN growth/NN factor/NN receptor/NN family/NN ./. 
Ligation/NN of/IN Fas/NN by/IN specific/JJ Abs/NNS or/CC Fas/NN ligand/NN (/( FasL/CD95/NN ligand/NN )/) induces/VBZ rapid/JJ apoptotic/JJ cell/NN death/NN in/IN a/DT variety/NN of/IN cell/NN types/NNS ./. 
Despite/IN progress/NN in/IN understanding/VBG the/DT death/NN signals/NNS transduced/VBN from/IN Fas/NN ,/, very/RB little/JJ is/VBZ known/VBN with/IN regard/NN to/TO the/DT mechanisms/NNS by/IN which/WDT Fas/NN expression/NN is/VBZ regulated/VBN ./. 
Using/VBG our/PRP$ previously/RB established/JJ murine/JJ T/NN cell/NN hybridoma/NN model/NN A1.1/NN ,/, we/PRP show/VBP that/IN specific/JJ protein/NN kinase/NN C/NN (/( PKC/NN )/) inhibitors/NNS could/MD block/VB activation-induced/JJ Fas/NN expression/NN and/CC apoptosis/NN ./. 
The/DT activation/NN of/IN PKC/NN with/IN PMA/NN or/CC 1-oleoyl-2-acetyl-sn-glycerol/NN could/MD mimic/VB the/DT TCR/NN signal/NN by/IN inducing/VBG the/DT expression/NN of/IN Fas/NN but/CC not/RB FasL/NN ./. 
PKC-dependent/JJ Fas/NN expression/NN was/VBD also/RB observed/VBN in/IN several/JJ murine/JJ and/CC human/JJ tumor/NN cell/NN lines/NNS ./. 
Since/IN the/DT inhibition/NN of/IN Ca2+/NN redistribution/NN by/IN an/DT inhibitor/NN of/IN intracellular/JJ Ca2+/NN mobilization/NN ,/, 8-(diethylamino)-octyl-3,4,5-trimethoxybenzoate/NN hydrochloride/NN ,/, inhibited/VBD TCR-induced/JJ FasL/NN but/CC not/RB Fas/NN ,/, the/DT expression/NN of/IN Fas/NN appears/VBZ to/TO be/VB independent/JJ of/IN Ca2+/NN mobilization/NN ./. 
Significantly/RB ,/, expression/NN of/IN the/DT newly/RB identified/VBN Fas-regulatory/JJ gene/NN ,/, TDAG51/NN ,/, was/VBD found/VBN to/TO be/VB dependent/JJ upon/IN the/DT activity/NN of/IN PKC/NN ./. 
PKC/NN activation/NN only/RB induced/VBD Fas/NN expression/NN in/IN cells/NNS expressing/VBG wild-type/JJ TDAG51/NN ./. 
Thus/RB ,/, Fas/NN expression/NN is/VBZ likely/RB mediated/VBN by/IN PKC/NN through/IN TDAG51/NN ./. 
UI/LS -/: 98384235/CD 
TI/LS -/: Retinoic/JJ acid/NN inhibits/VBZ CD40/NN +/CC interleukin-4-mediated/JJ IgE/NN production/NN in/FW vitro/FW ./. 
AB/LS -/: To/TO elucidate/VB the/DT role/NN of/IN retinoic/JJ acid/NN (/( RA/NN )/) in/IN anti-CD40/NN +/CC interleukin-4/NN (/( IL-4/NN )/) -mediated/JJ B-cell/NN activation/NN ,/, the/DT effect/NN of/IN 10(-12)/CD to/TO 10(-6)/CD mol/L/NN RA/NN was/VBD studied/VBN in/IN anti-CD40/NN (/( 1/CD microgram/mL/NN )/) +/CC IL-4/NN (/( 5/CD ng/mL/NN )/) -mediated/JJ proliferation/NN and/CC Ig/NN synthesis/NN by/IN human/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NNS )/) and/CC B/NN cells/NNS in/IN healthy/JJ donors/NNS ./. 
Anti-CD40/NN +/CC IL-4-mediated/JJ proliferation/NN of/IN PBMC/NNS and/CC B/NN cells/NNS was/VBD inhibited/VBN by/IN RA/NN in/IN a/DT dose-dependent/JJ manner/NN ,/, with/IN maximal/JJ inhibition/NN of/IN 62/CD %/NN +/-/CC 5/CD %/NN in/IN PBMC/NNS and/CC 55/CD %/NN +/-/CC 4.4/CD %/NN in/IN B/NN cells/NNS by/IN all-trans/JJ RA/NN ,/, and/CC 58/CD %/NN +/-/CC 6.7/CD %/NN and/CC 51/CD %/NN +/-/CC 4.7/CD %/NN ,/, respectively/RB by/IN 13-cis/JJ RA/NN ./. 
IgE/NN synthesis/NN was/VBD even/RB more/RBR markedly/RB inhibited/VBN by/IN RA/NN starting/VBG at/IN concentrations/NNS of/IN >/JJR 10(-14)/CD mol/L/NN for/IN B/NN cells/NNS and/CC >/JJR 10(-10)/CD mol/L/NN for/IN PBMC/NNS ./. 
Maximal/JJ inhibition/NN of/IN IgE/NN production/NN for/IN B/NN cells/NNS was/VBD at/IN 10(-8)/CD mol/L/NN for/IN all-trans/JJ RA/NN (/( 94/CD %/NN +/-/CC 1.8/CD %/NN )/) and/CC 96/CD %/NN +/-/CC 3.2/CD %/NN for/IN 13-cis/JJ RA/NN ./. 
Low/JJ concentrations/NNS of/IN RA/NN inhibiting/VBG IgE/NN synthesis/NN (/( 10(-10)/CD mol/L/NN )/) affected/VBD neither/CC B-cell/NN proliferation/NN nor/CC the/DT production/NN of/IN IgA/NN ,/, IgG/NN ,/, and/CC IgM/NN ./. 
Elucidation/NN of/IN the/DT mechanism/NN involved/VBN in/IN this/DT inhibition/NN of/IN IgE/NN production/NN shows/VBZ that/IN epsilon/NN germline/NN transcription/NN is/VBZ decreased/VBN by/IN RA/NN ,/, whereas/IN production/NN of/IN interferon-gamma/NN (/( IFN-gamma/NN )/) was/VBD not/RB enhanced/VBN in/IN the/DT presence/NN of/IN RA/NN ./. 
To/TO differentiate/VB whether/IN the/DT RA/NN effect/NN was/VBD mediated/VBN by/IN RA/NN receptors/NNS alpha/NN ,/, beta/NN ,/, and/CC gamma/NN ,/, the/DT expression/NN of/IN the/DT retinoic/JJ acid/NN receptors/NNS (/( RAR/NNS )/) was/VBD examined/VBN by/IN reverse/JJ transcriptase-polymerase/JJ chain/NN reaction/NN (/( RT-PCR/NN )/) ./. 
The/DT data/NNS show/VBP that/IN unstimulated/JJ human/JJ peripheral/JJ B/NN cells/NNS express/VBP mRNA/NN of/IN the/DT RA/NN receptor/NN alpha/NN ,/, beta/NN ,/, and/CC gamma/NN ./. 
Using/VBG retinoids/NNS with/IN different/JJ receptor/NN binding/NN specificity/NN (/( CD336/NN ,/, CD437/NN ,/, CD2019/NN ,/, CD367/NN )/) ,/, dose-dependent/JJ inhibition/NN of/IN IgE/NN synthesis/NN was/VBD shown/VBN by/IN all/DT four/CD derivates/NNS ,/, but/CC was/VBD most/RBS marked/VBN by/IN an/DT RA/NN binding/VBG the/DT alpha/NN receptor/NN with/IN high/JJ specificity/NN ./. 
Taken/VBN together/RB ,/, this/DT study/NN shows/VBZ that/IN RA/NN inhibits/VBZ IgE/NN production/NN of/IN anti-CD40/NN +/CC IL-4-stimulated/JJ B/NN cells/NNS in/FW vitro/FW ./. 
Copyright/NN 1998/CD by/IN The/NNP American/NNP Society/NNP of/IN Hematology/NNP ./. 
UI/LS -/: 98378528/CD 
TI/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD Tax/NN induction/NN of/IN NF-kappaB/NN involves/VBZ activation/NN of/IN the/DT IkappaB/NN kinase/NN alpha/NN (/( IKKalpha/NN )/) and/CC IKKbeta/NN cellular/JJ kinases/NNS ./. 
AB/LS -/: Tax/NN corresponds/VBZ to/TO a/DT 40-kDa/JJ transforming/VBG protein/NN from/IN the/DT pathogenic/JJ retrovirus/NN human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) that/WDT activates/VBZ nuclear/JJ expression/NN of/IN the/DT NF-kappaB/Rel/NN family/NN of/IN transcription/NN factors/NNS by/IN an/DT unknown/JJ mechanism/NN ./. 
Tax/NN expression/NN promotes/VBZ N-terminal/JJ phosphorylation/NN and/CC degradation/NN of/IN IkappaB/NN alpha/NN ,/, a/DT principal/JJ cytoplasmic/JJ inhibitor/NN of/IN NF-kappaB/NN ./. 
Our/PRP$ studies/NNS now/RB demonstrate/VBP that/IN HTLV-1/NN Tax/NN activates/VBZ the/DT recently/RB identified/VBN cellular/JJ kinases/NNS IkappaB/NN kinase/NN alpha/NN (/( IKKalpha/NN )/) and/CC IKKbeta/NN ,/, which/WDT normally/RB phosphorylate/VBP IkappaB/NN alpha/NN on/IN both/DT of/IN its/PRP$ N-terminal/JJ regulatory/JJ serines/NNS in/IN response/NN to/TO tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) and/CC interleukin-1/NN (/( IL-1/NN )/) stimulation/NN ./. 
In/IN contrast/NN ,/, a/DT mutant/NN of/IN Tax/NN termed/VBN M22/NN ,/, which/WDT does/VBZ not/RB induce/VB NF-kappaB/NN ,/, fails/VBZ to/TO activate/VB either/CC IKKalpha/NN or/CC IKKbeta/NN ./. 
Furthermore/RB ,/, endogenous/JJ IKK/NN enzymatic/JJ activity/NN was/VBD significantly/RB elevated/JJ in/IN HTLV-1-infected/JJ and/CC Tax-expressing/JJ T-cell/NN lines/NNS ./. 
Transfection/NN of/IN kinase-deficient/JJ mutants/NNS of/IN IKKalpha/NN and/CC IKKbeta/NN into/IN either/CC human/JJ Jurkat/NN T/NN or/CC 293/CD cells/NNS also/RB inhibits/VBZ NF-kappaB-dependent/JJ reporter/NN gene/NN expression/NN induced/VBN by/IN Tax/NN ./. 
Similarly/RB ,/, a/DT kinase-deficient/JJ mutant/NN of/IN NIK/NN (/( NF-kappaB-inducing/NN kinase/NN )/) ,/, which/WDT represents/VBZ an/DT upstream/JJ kinase/NN in/IN the/DT TNF-alpha/NN and/CC IL-1/NN signaling/NN pathways/NNS leading/VBG to/TO IKKalpha/NN and/CC IKKbeta/NN activation/NN ,/, blocks/VBZ Tax/NN induction/NN of/IN NF-kappaB/NN ./. 
However/RB ,/, plasma/NN membrane-proximal/JJ elements/NNS in/IN these/DT proinflammatory/JJ cytokine/NN pathways/NNS are/VBP apparently/RB not/RB involved/VBN since/IN dominant/JJ negative/JJ mutants/NNS of/IN the/DT TRAF2/NN and/CC TRAF6/NN adaptors/NNS ,/, which/WDT effectively/RB block/VBP signaling/NN through/IN the/DT cytoplasmic/JJ tails/NNS of/IN the/DT TNF-alpha/NN and/CC IL-1/NN receptors/NNS ,/, respectively/RB ,/, do/VBP not/RB inhibit/VB Tax/NN induction/NN of/IN NF-kappaB/NN ./. 
Together/RB ,/, these/DT studies/NNS demonstrate/VBP that/IN HTLV-1/NN Tax/NN exploits/VBZ a/DT distal/JJ part/NN of/IN the/DT proinflammatory/JJ cytokine/NN signaling/NN cascade/NN leading/VBG to/TO induction/NN of/IN NF-kappaB/NN ./. 
The/DT pathological/JJ alteration/NN of/IN this/DT cytokine/NN pathway/NN leading/VBG to/TO NF-kappaB/NN activation/NN by/IN Tax/NN may/MD play/VB a/DT central/JJ role/NN in/IN HTLV-1-mediated/JJ transformation/NN of/IN human/JJ T/NN cells/NNS ,/, clinically/RB manifested/VBN as/IN the/DT adult/JJ T-cell/NN leukemia/NN 
UI/LS -/: 99023967/CD 
TI/LS -/: Role/NN of/IN IKK1/NN and/CC IKK2/NN in/IN lipopolysaccharide/NN signaling/NN in/IN human/JJ monocytic/JJ cells/NNS ./. 
AB/LS -/: Mononuclear/JJ phagocytes/NNS play/VBP a/DT major/JJ role/NN in/IN immune/JJ and/CC inflammatory/JJ responses/NNS ./. 
Bacterial/JJ lipopolysaccharide/NN (/( LPS/NN )/) induces/VBZ monocytes/NNS to/TO express/VB a/DT variety/NN of/IN genes/NNS by/IN activating/VBG the/DT NF-kappaB/Rel/NN transcription/NN factor/NN family/NN ./. 
Recently/RB ,/, we/PRP have/VBP reported/VBN that/IN the/DT tumor/NN necrosis/NN factor/NN and/CC interleukin/NN 1/CD signaling/NN pathways/NNS activate/VBP two/CD kinases/NNS ,/, IKK1/NN and/CC IKK2/NN ./. 
Phosphorylation/NN of/IN the/DT IkappaB/NN cytoplasmic/JJ inhibitors/NNS ,/, IkappaBalpha/NN ,/, IkappaBbeta/NN ,/, and/CC IkappaBepsilon/NN ,/, by/IN these/DT kinases/NNS triggers/VBZ proteolytic/JJ degradation/NN and/CC the/DT release/NN of/IN NF-kappaB/Rel/NN proteins/NNS into/IN the/DT nucleus/NN ./. 
At/IN present/NN ,/, the/DT role/NN of/IN the/DT IKKs/NNS in/IN LPS/NN signaling/NN has/VBZ not/RB been/VBN investigated/VBN ./. 
Here/RB ,/, we/PRP report/VBP that/IN LPS/NN induces/VBZ IKK/NN activity/NN in/IN human/JJ monocytes/NNS and/CC THP-1/NN monocytic/JJ cells/NNS ./. 
The/DT kinetics/NN of/IN activation/NN of/IN kinase/NN activity/NN in/IN monocytic/JJ cells/NNS are/VBP relatively/RB slow/JJ with/IN maximal/JJ activity/NN observed/VBN at/IN 60/CD min/NN ,/, which/WDT coincides/VBZ with/IN the/DT degradation/NN of/IN IkappaBs/NNS and/CC the/DT nuclear/JJ translocation/NN of/IN NF-kappaB/NN ./. 
In/IN transfection/NN experiments/NNS ,/, overexpression/NN of/IN wild/JJ type/NN IKK1/NN ,/, a/DT dominant/JJ negative/JJ mutant/JJ IKK1/NN (/( K44M/NN )/) ,/, or/CC wild/JJ type/NN IKK2/NN did/VBD not/RB affect/VB LPS-induced/JJ kappaB-dependent/JJ transcription/NN in/IN monocytic/JJ cells/NNS ./. 
In/IN contrast/NN ,/, a/DT dominant/JJ negative/JJ mutant/NN of/IN IKK2/NN inhibited/VBD LPS/NN induction/NN of/IN kappaB-dependent/JJ transcription/NN in/IN a/DT dose-dependent/JJ manner/NN ./. 
These/DT results/NNS indicate/VBP that/IN LPS/NN induction/NN of/IN kappaB-dependent/JJ gene/NN expression/NN in/IN human/JJ monocytic/JJ cells/NNS requires/VBZ activation/NN of/IN IKK2/NN ./. 
UI/LS -/: 99008520/CD 
TI/LS -/: IL-7/NN reconstitutes/VBZ multiple/JJ aspects/NNS of/IN v-Abl-mediated/JJ signaling/NN ./. 
AB/LS -/: The/DT mechanism/NN by/IN which/WDT early/JJ lymphoid/JJ cells/NNS are/VBP selectively/RB transformed/VBN by/IN v-Abl/NN is/VBZ currently/RB unknown/JJ ./. 
Previous/JJ studies/NNS have/VBP shown/VBN constitutive/JJ activation/NN of/IN IL-4/NN and/CC IL-7/NN signaling/NN pathways/NNS ,/, as/IN measured/VBN by/IN activation/NN of/IN Janus/NN protein/NN kinase/NN (/( JAK/NN )/) 1/CD ,/, JAK3/NN ,/, STAT5/NN ,/, and/CC STAT6/NN ,/, in/IN pre-B/JJ cells/NNS transformed/VBN by/IN v-Abl/NN ./. 
To/TO determine/VB whether/IN activation/NN of/IN these/DT cytokine/NN signaling/NN pathways/NNS by/IN v-Abl/NN is/VBZ important/JJ in/IN the/DT cellular/JJ events/NNS induced/VBN by/IN the/DT Abelson/NN murine/JJ leukemia/NN virus/NN ,/, the/DT effects/NNS of/IN IL-4/NN and/CC IL-7/NN on/IN pre-B/JJ cells/NNS transformed/VBN with/IN a/DT temperature-sensitive/JJ v-Abl/NN mutant/NN were/VBD examined/VBN ./. 
Whereas/IN IL-4/NN had/VBD little/JJ or/CC no/DT effect/NN ,/, IL-7/NN delayed/VBD both/CC the/DT apoptosis/NN and/CC cell/NN cycle/NN arrest/NN that/WDT occur/VBP upon/IN v-Abl/NN kinase/NN inactivation/NN ./. 
IL-7/NN also/RB delayed/VBD the/DT decreases/NNS in/IN the/DT levels/NNS of/IN c-Myc/NN ,/, Bcl-2/NN ,/, and/CC Bcl-xL/NN that/WDT occur/VBP upon/IN loss/NN of/IN v-Abl/NN kinase/NN activity/NN ./. 
IL-7/NN did/VBD not/RB maintain/VB v-Abl-mediated/JJ differentiation/NN arrest/NN of/IN the/DT pre-B/JJ cells/NNS ,/, as/IN activation/NN of/IN NF-kappaB/NN and/CC RAG/NN gene/NN transcription/NN was/VBD unaffected/JJ by/IN IL-7/NN ./. 
These/DT results/NNS identify/VBP a/DT potential/JJ role/NN for/IN IL-7/NN signaling/NN pathways/NNS in/IN transformation/NN by/IN v-Abl/NN while/IN demonstrating/VBG that/IN a/DT combination/NN of/IN IL-4/NN and/CC IL-7/NN signaling/NN can/MD not/RB substitute/VB for/IN an/DT active/JJ v-Abl/NN kinase/NN in/IN transformed/VBN pre-B/JJ cells/NNS ./. 
UI/LS -/: 99005376/CD 
TI/LS -/: Differential/JJ regulation/NN of/IN coproporphyrinogen/NN oxidase/NN gene/NN between/IN erythroid/JJ and/CC nonerythroid/JJ cells/NNS ./. 
AB/LS -/: Coproporphyrinogen/NN oxidase/NN (/( CPO/NN )/) catalyzes/VBZ the/DT sixth/JJ step/NN of/IN the/DT heme/NN biosynthetic/JJ pathway/NN ./. 
To/TO assess/VB the/DT tissue-specific/JJ regulation/NN of/IN the/DT CPO/NN gene/NN promoter/NN ,/, mouse/NN genomic/JJ DNA/NN clones/NNS for/IN CPO/NN were/VBD isolated/VBN ./. 
Structural/JJ analysis/NN demonstrated/VBD that/IN the/DT mouse/NN CPO/NN gene/NN spans/VBZ approximately/RB 11/CD kb/NN and/CC consists/VBZ of/IN seven/CD exons/NNS ,/, just/RB like/IN its/PRP$ human/JJ counterpart/NN ./. 
Functional/JJ analysis/NN of/IN the/DT promoter/NN by/IN transient/JJ transfection/NN assays/NNS indicated/VBD that/IN synergistic/JJ action/NN between/IN an/DT SP-1-like/JJ element/NN at/IN -21/-12/CD ,/, a/DT GATA/NN site/NN at/IN -59/-54/CD ,/, and/CC a/DT novel/JJ regulatory/JJ element/NN ,/, CPRE/NN (/( -GGACTACAG-/NN )/) at/IN -49/-41/CD ,/, is/VBZ essential/JJ for/IN the/DT promoter/NN activity/NN in/IN murine/JJ erythroleukemia/NN (/( MEL/NN )/) cells/NNS ./. 
In/IN nonerythroid/JJ NIH3T3/NN cells/NNS ,/, however/RB ,/, the/DT GATA/NN site/NN is/VBZ not/RB required/VBN ./. 
Gel/NN mobility/NN shift/NN assays/NNS demonstrated/VBD that/IN specific/JJ DNA-protein/JJ complexes/NNS can/MD be/VB formed/VBN with/IN each/DT element/NN ,/, and/CC that/IN there/EX are/VBP cell-specific/JJ differences/NNS in/IN factors/NNS ,/, which/WDT bind/VBP to/TO the/DT SP-1-like/JJ element/NN between/IN MEL/NN and/CC NIH3T3/NN cells/NNS ./. 
These/DT results/NNS provide/VBP evidence/NN for/IN differential/JJ regulation/NN of/IN the/DT promoter/NN function/NN of/IN CPO/NN gene/NN between/IN erythroid/JJ and/CC nonerythroid/JJ cells/NNS ./. 
Copyright/NN 1998/CD by/IN The/NNP American/NNP Society/NNP of/IN Hematology/NNP 
UI/LS -/: 98438043/CD 
TI/LS -/: Tumor/NN suppressor/NN proteins/NNS as/IN regulators/NNS of/IN cell/NN differentiation/NN ./. 
AB/LS -/: The/DT products/NNS of/IN the/DT tumor/NN suppressor/NN genes/NNS are/VBP considered/VBN to/TO function/VB as/IN specific/JJ inhibitors/NNS of/IN tumor/NN cell/NN growth/NN ./. 
In/IN this/DT communication/NN ,/, we/PRP present/VBP evidence/NN to/TO show/VB that/IN these/DT proteins/NNS inhibit/VBP tumor/NN cell/NN proliferation/NN by/IN participating/VBG in/IN the/DT activation/NN of/IN tumor/NN cell/NN differentiation/NN ./. 
The/DT ML-1/NN human/JJ myeloblastic/JJ leukemia/NN cells/NNS used/VBN in/IN this/DT study/NN proliferate/VBP when/WRB treated/VBN with/IN insulin-like/JJ growth/NN factor/NN I/CD and/CC transferrin/NN but/CC differentiate/VBP to/TO monocytes/NNS when/WRB exposed/VBN to/TO tumor/NN necrosis/NN factor/NN alpha/NN or/CC transforming/VBG growth/NN factor/NN beta1/NN ,/, or/CC to/TO macrophage-like/JJ cells/NNS when/WRB treated/VBN with/IN both/DT these/DT cytokines/NNS ./. 
Initiation/NN of/IN proliferation/NN but/CC not/RB of/IN differentiation/NN was/VBD followed/VBN by/IN a/DT 20-/CD to/TO 25-fold/JJ increase/NN in/IN the/DT nuclear/JJ level/NN of/IN the/DT DNA/NN polymerase-associated/JJ processivity/NN factor/NN PCNA/NN and/CC of/IN the/DT proliferation-specific/JJ transcription/NN factor/NN E2F1/NN ./. 
In/IN contrast/NN ,/, induction/NN of/IN differentiation/NN but/CC not/RB of/IN proliferation/NN was/VBD followed/VBN by/IN a/DT 25-/CD to/TO 30-fold/JJ increase/NN in/IN the/DT nuclear/JJ level/NN of/IN the/DT tumor/NN suppressor/NN proteins/NNS p53/NN (/( wild/JJ type/NN )/) ,/, pRb/NN ,/, and/CC p130/Rb2/NN and/CC of/IN the/DT p53-dependent/JJ cyclin/NN kinase/NN inhibitor/NN p21/Cip1/NN ./. 
p53/NN and/CC p21/Cip1/NN ,/, respectively/RB ,/, inhibit/VBP the/DT expression/NN and/CC activation/NN of/IN PCNA/NN ,/, whereas/IN p130/NN and/CC pRb/NN ,/, respectively/RB ,/, inhibit/VBP the/DT expression/NN and/CC activation/NN of/IN E2F1/NN ./. 
As/IN a/DT result/NN ,/, G1-S-associated/JJ DNA/NN and/CC mRNA/NN synthesis/NN is/VBZ inhibited/VBN ,/, growth/NN uncoupled/VBD from/IN differentiation/NN ,/, and/CC maturation/NN enabled/VBD to/TO proceed/VB ./. 
Where/WRB this/DT function/NN of/IN the/DT tumor/NN suppressor/NN proteins/NNS is/VBZ impaired/JJ ,/, the/DT capacity/NN for/IN differentiation/NN is/VBZ lost/VBN ,/, which/WDT leads/VBZ to/TO the/DT sustained/JJ proliferation/NN that/WDT is/VBZ characteristic/JJ of/IN the/DT cancer/NN cell/NN ./. 
UI/LS -/: 98427848/CD 
TI/LS -/: Transcription/NN factor/NN activation/NN in/IN lymphokine/NN activated/JJ killer/NN cells/NNS and/CC lymphocytes/NNS from/IN patients/NNS receiving/VBG IL-2/NN immunotherapy/NN ./. 
AB/LS -/: Administration/NN of/IN the/DT cytokine/NN interleukin-2/NN (/( IL-2/NN )/) can/MD result/VB in/IN therapeutic/JJ benefits/NNS for/IN individuals/NNS with/IN renal/JJ cell/NN carcinoma/NN and/CC melanoma/NN ./. 
Here/RB we/PRP report/VBP an/DT analysis/NN of/IN the/DT transcription/NN factor/NN families/NNS AP-1/NN ,/, Sp1/NN ,/, NF-kappaB/NN ,/, and/CC signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( STAT/NN )/) in/IN cancer/NN patients/NNS '/POS lymphocytes/NNS before/IN and/CC after/IN IL-2/NN immunotherapy/NN ,/, as/IN assessed/VBN by/IN a/DT gel-shift/JJ assay/NN ./. 
An/DT in/FW vitro/FW surrogate/NN of/IN IL-2/NN immunotherapy/NN is/VBZ the/DT incubation/NN of/IN fresh/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NNS )/) from/IN healthy/JJ individuals/NNS in/IN IL-2/NN for/IN several/JJ days/NNS ,/, resulting/VBG in/IN the/DT production/NN of/IN lymphokine-activated/JJ killer/NN (/( LAK/NN )/) activity/NN in/IN these/DT cultures/NNS ./. 
One/CD purpose/NN of/IN this/DT study/NN was/VBD to/TO describe/VB the/DT profile/NN of/IN transcription/NN factor/NN activation/NN in/IN these/DT different/JJ populations/NNS ,/, and/CC assess/VB whether/IN the/DT patterns/NNS observed/VBN correlated/VBD with/IN functional/JJ differences/NNS in/IN these/DT cells/NNS ./. 
Prior/JJ to/TO in/FW vivo/FW IL-2/NN administration/NN ,/, the/DT typical/JJ binding/NN pattern/NN of/IN transcription/NN factors/NNS in/IN PBMC/NNS from/IN patients/NNS resembled/VBD that/DT seen/VBN in/IN fresh/JJ PBMC/NNS from/IN healthy/JJ individuals/NNS ./. 
Over/IN a/DT 3-week/JJ course/NN of/IN IL-2/NN therapy/NN ,/, in/IN most/JJS patients/NNS the/DT binding/NN patterns/NNS of/IN AP-1/NN ,/, Sp1/NN ,/, and/CC NF-kappaB/NN proteins/NNS changed/VBD to/TO resemble/VB those/DT seen/VBN in/IN PBMC/NNS activated/VBN by/IN IL-2/NN in/FW vitro/FW ./. 
However/RB ,/, the/DT cells/NNS obtained/VBN from/IN IL-2-treated/JJ patients/NNS did/VBD not/RB have/VB low-level/JJ constitutive/JJ expression/NN of/IN STAT/NN binding/NN factors/NNS as/IN did/VBD LAK/NN cells/NNS ./. 
When/WRB these/DT patient/NN cells/NNS were/VBD further/RB stimulated/VBN by/IN IL-2/NN in/FW vitro/FW ,/, additional/JJ differences/NNS in/IN STAT/NN induction/NN patterns/NNS were/VBD noted/VBN ./. 
These/DT data/NNS provide/VBP further/JJ information/NN on/IN the/DT molecular/JJ events/NNS occurring/VBG in/IN immune/JJ cells/NNS generated/VBN through/IN in/FW vivo/FW and/CC in/FW vitro/FW administration/NN of/IN IL-2/NN ,/, and/CC further/RB document/VBP that/IN there/EX is/VBZ not/RB a/DT precise/JJ congruence/NN between/IN PBMC/NNS activated/VBN in/FW vivo/FW and/CC in/FW vitro/FW by/IN IL-2/NN ./. 
UI/LS -/: 98416141/CD 
TI/LS -/: Activated/VBN platelets/NNS induce/VBP monocyte/NN chemotactic/JJ protein-1/NN secretion/NN and/CC surface/NN expression/NN of/IN intercellular/JJ adhesion/NN molecule-1/NN on/IN endothelial/JJ cells/NNS [/( see/VB comments/NNS ]/) 
AB/LS -/: BACKGROUND/NN :/: Platelet/endothelium/NN interaction/NN plays/VBZ an/DT important/JJ role/NN in/IN the/DT pathophysiology/NN of/IN inflammation/NN and/CC atherosclerosis/NN ./. 
The/DT role/NN of/IN platelets/NNS for/IN monocyte/NN chemotactic/JJ protein-1/NN (/( MCP-1/NN )/) secretion/NN and/CC surface/NN expression/NN of/IN intercellular/JJ adhesion/NN molecule-1/NN (/( ICAM-1/NN )/) on/IN endothelial/JJ cells/NNS has/VBZ been/VBN assessed/VBN ./. 
METHODS/NNS AND/CC RESULTS/NNS :/: Monolayers/NNS of/IN human/JJ umbilical/JJ vein/NN endothelial/JJ cells/NNS were/VBD incubated/VBN with/IN nonstimulated/JJ or/CC ADP-activated/JJ platelets/NNS for/IN 6/CD hours/NNS ,/, and/CC secretion/NN of/IN MCP-1/NN and/CC surface/NN expression/NN of/IN ICAM-1/NN were/VBD determined/VBN by/IN ELISA/NN and/CC flow/NN cytometry/NN ,/, respectively/RB ./. 
In/IN the/DT presence/NN of/IN ADP-activated/JJ platelets/NNS ,/, both/CC MCP-1/NN secretion/NN and/CC ICAM-1/NN surface/NN expression/NN were/VBD significantly/RB increased/VBN compared/VBN with/IN nonstimulated/JJ platelets/NNS (/( P/NN </JJR 0.02/CD )/) ./. 
Activation/NN of/IN the/DT transcription/NN factor/NN nuclear/JJ factor-kappaB/NN (/( NF-kappaB/NN )/) determined/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN and/CC kappaB-dependent/JJ transcriptional/JJ activity/NN was/VBD enhanced/VBN in/IN the/DT presence/NN of/IN activated/VBN platelets/NNS ./. 
In/IN addition/NN ,/, ADP-activated/JJ platelets/NNS induced/VBD MCP-1/NN and/CC ICAM-1/NN promoter-dependent/JJ transcription/NN ./. 
Liposomal/JJ transfection/NN of/IN a/DT double-stranded/JJ kappaB/NN phosphorothioate/NN oligonucleotide/NN ,/, but/CC not/RB of/IN the/DT mutated/JJ form/NN ,/, inhibited/VBD MCP-1/NN secretion/NN and/CC surface/NN expression/NN of/IN ICAM-1/NN on/IN activated/VBN endothelium/NN (/( P/NN </JJR 0.05/CD )/) ./. 
CONCLUSIONS/NNS :/: The/DT present/JJ study/NN indicates/VBZ that/IN activated/VBN platelets/NNS modulate/VBP chemotactic/JJ (/( MCP-1/NN )/) and/CC adhesive/JJ (/( ICAM-1/NN )/) properties/NNS of/IN endothelial/JJ cells/NNS via/IN an/DT NF-kappaB-dependent/JJ mechanism/NN ./. 
Platelet-induced/JJ activation/NN of/IN the/DT NF-kappaB/NN system/NN might/MD contribute/VB to/TO early/JJ inflammatory/JJ events/NNS in/IN atherogenesis/NN ./. 
UI/LS -/: 98400423/CD 
TI/LS -/: Retinoid/NN X/NN receptor/NN and/CC c-cerbA/thyroid/NN hormone/NN receptor/NN regulate/VBP erythroid/JJ cell/NN growth/NN and/CC differentiation/NN ./. 
AB/LS -/: Nuclear/JJ receptors/NNS are/VBP important/JJ regulators/NNS of/IN erythroid/JJ cell/NN development/NN ./. 
Here/RB we/PRP investigated/VBD the/DT impact/NN of/IN retinoid/NN X/NN receptor/NN (/( RXR/NN )/) ,/, retinoic/JJ acid/NN receptor/NN (/( RAR/NN )/) ,/, and/CC of/IN the/DT c-erbA/thyroid/NN hormone/NN (/( T3/NN )/) receptor/NN (/( c-erbA/TR/NN )/) on/IN growth/NN and/CC differentiation/NN of/IN erythroid/JJ cells/NNS using/VBG an/DT in/FW vitro/FW culture/NN system/NN of/IN stem/NN cell/NN factor-dependent/JJ erythroid/JJ progenitors/NNS ./. 
RXR/NN ,/, RAR/NN ,/, and/CC c-erbA/TR-specific/JJ ligands/NNS were/VBD found/VBN to/TO induce/VB erythroid-specific/JJ gene/NN expression/NN and/CC to/TO accelerate/VB erythroid/JJ differentiation/NN in/IN culture/NN ,/, with/IN T3/NN being/VBG most/RBS effective/JJ ./. 
Furthermore/RB ,/, while/IN ligand-activated/JJ c-erbA/TR/NN accelerated/VBD differentiation/NN ,/, unliganded/JJ c-erbA/TR/NN effectively/RB blocked/VBD differentiation/NN and/CC supported/VBD sustained/JJ progenitor/NN growth/NN in/IN culture/NN ./. 
Thus/RB ,/, c-erbA/TR/NN appears/VBZ to/TO act/VB as/IN a/DT binary/JJ switch/NN affecting/VBG erythroid/JJ cell/NN fate/NN :/: unliganded/JJ c-erbA/TR/NN supports/VBZ growth/NN while/IN ligand-activated/JJ c-erbA/TR/NN induces/VBZ differentiation/NN ./. 
Additionally/RB ,/, to/TO determine/VB the/DT impact/NN of/IN RXR/NN for/IN erythroid/JJ cell/NN development/NN ,/, dominant/JJ interfering/VBG mutant/JJ RXRs/NNS ,/, lacking/VBG the/DT transcriptional/JJ activator/NN functions/NNS AF-1/NN and/CC AF-2/NN ,/, or/CC AF-2/NN only/RB ,/, or/CC the/DT entire/JJ DNA-binding/JJ domain/NN ,/, were/VBD introduced/VBN into/IN erythroid/JJ progenitor/NN cells/NNS via/IN recombinant/JJ retrovirus/NN vectors/NNS and/CC analyzed/VBN for/IN RXR-specific/JJ effects/NNS ./. 
It/PRP was/VBD found/VBN that/IN expression/NN of/IN wild-type/JJ RXR/NN and/CC of/IN the/DT RXR/NN mutants/NNS devoid/JJ of/IN AF-1/NN and/or/CC AF-2/NN supported/VBD a/DT transient/JJ outgrowth/NN of/IN erythroid/JJ cells/NNS ./. 
In/IN marked/JJ contrast/NN ,/, expression/NN of/IN the/DT dominant/JJ interfering/VBG deltaDNA-binding/JJ domain/NN RXR/NN ,/, containing/VBG a/DT deletion/NN of/IN the/DT entire/JJ DNA-binding/JJ domain/NN ,/, was/VBD incompatible/JJ with/IN erythroid/JJ cell/NN growth/NN in/FW vitro/FW ,/, suggesting/VBG a/DT pivotal/JJ role/NN of/IN RXR/NN for/IN erythroid/JJ cell/NN development/NN ./. 
UI/LS -/: 98389481/CD 
TI/LS -/: Peripheral/JJ T/NN lymphocytes/NNS from/IN women/NNS with/IN breast/NN cancer/NN exhibit/VBP abnormal/JJ protein/NN expression/NN of/IN several/JJ signaling/VBG molecules/NNS ./. 
AB/LS -/: We/PRP examined/VBD signaling/VBG molecules/NNS of/IN peripheral/JJ blood/NN T/NN lymphocytes/NNS obtained/VBN from/IN women/NNS with/IN breast/NN cancer/NN ./. 
In/IN 6/CD of/IN 14/CD patients/NNS ,/, T/NN lymphocytes/NNS displayed/VBD an/DT impaired/JJ ability/NN to/TO translocate/VB NFeB/NN p65/NN (/( Rel-A/NN )/) following/VBG activation/NN by/IN anti-CD3/NN and/CC IL-2/NN ./. 
This/DT observation/NN was/VBD made/VBN despite/IN normal/JJ cytoplasmic/JJ levels/NNS of/IN the/DT Rel-A/NN protein/NN ./. 
We/PRP also/RB detected/VBD abnormally/RB low/JJ levels/NNS of/IN the/DT signaling/VBG molecules/NNS T-cell/NN receptor/NN (/( TCR/NN )/) -zeta/NN ,/, ZAP-70/NN and/CC p56lck/NN in/IN 4/CD of/IN 14/CD breast/NN cancer/NN patients/NNS ,/, i.e./FW ,/, defects/NNS in/IN T-cell/NN signaling/VBG molecules/NNS ./. 
T/NN lymphocytes/NNS from/IN 6/CD of/IN the/DT 14/CD patients/NNS also/RB exhibited/VBD an/DT increased/VBN expression/NN of/IN the/DT dual/JJ specificity/NN phosphatase/NN ,/, map/NN kinase/NN phosphatase-1/NN (/( MKP-1/NN )/) ./. 
MKP-1/NN inactivates/VBZ MAP/NN kinase/NN and/CC therefore/RB may/MD interfere/VB with/IN the/DT activation/NN of/IN c-jun/NN and/CC c-fos/NN ./. 
Abnormalities/NNS of/IN I/CD or/CC more/RBR signaling/VBG molecules/NNS were/VBD found/VBN in/IN 9/CD of/IN 14/CD patients/NNS ;/: however/RB ,/, only/RB 3/CD patients/NNS had/VBD T/NN cells/NNS that/WDT exhibited/VBD all/DT 5/CD defects/NNS ./. 
Our/PRP$ data/NNS have/VBP implications/NNS for/IN the/DT detection/NN of/IN potentially/RB dysfunctional/JJ T/NN cells/NNS in/IN patients/NNS with/IN cancer/NN ./. 
For/IN example/NN ,/, the/DT analysis/NN of/IN only/RB 1/CD signaling/VBG molecule/NN may/MD allow/VB patients/NNS with/IN significant/JJ defects/NNS in/IN T-cell/NN signaling/NN to/TO go/VB unnoticed/JJ ./. 
Finally/RB ,/, despite/IN impaired/JJ Rel-A/NN translocation/NN ,/, T/NN cells/NNS were/VBD capable/JJ of/IN transcribing/VBG IL-2/NN ./. 
Impairments/NNS in/IN the/DT translocation/NN of/IN Rel-B/NN and/CC c-Rel/NN further/RB suggest/VBP that/IN the/DT NFKB/NN family/NN members/NNS Rel-A/NN ,/, Rel-B/NN and/CC c-Rel/NN are/VBP not/RB required/VBN for/IN the/DT transcription/NN of/IN IL-2/NN in/IN the/DT peripheral/JJ T/NN lymphocytes/NNS of/IN patients/NNS with/IN breast/NN cancer/NN ./. 
UI/LS -/: 98379823/CD 
TI/LS -/: Specific/JJ glucocorticoid/NN binding/NN at/IN different/JJ levels/NNS of/IN human/JJ motor/NN activity/NN ./. 
AB/LS -/: We/PRP studied/VBD the/DT number/NN of/IN glucocorticoid/NN receptors/NNS and/CC dissociation/NN constant/NN in/IN isolated/VBN human/JJ lymphocytes/NNS as/RB well/RB as/IN blood/NN concentrations/NNS of/IN hormones/NNS produced/VBN by/IN the/DT hypothalamic-hypophyseal-adrenocortical/JJ system/NN in/IN three/CD experimental/JJ series/NNS :/: at/IN normal/JJ (/( 17/CD subjects/NNS )/) ,/, decreased/VBN (/( 10/CD subjects/NNS ,/, a/DT 360-d/JJ head-down/JJ bed/NN rest/NN )/) and/CC increased/VBN (/( 8/CD subjects/NNS ,/, physical/JJ exercise/NN on/IN bicycle/NN ergometer/NN )/) levels/NNS of/IN motor/NN activity/NN ./. 
In/IN the/DT first/JJ series/NN we/PRP found/VBD that/IN the/DT number/NN of/IN glucocorticoid/NN receptors/NNS and/CC dissociation/NN constant/NN did/VBD not/RB depend/VB on/IN the/DT season/NN ,/, on/IN the/DT age/NN of/IN subjects/NNS nor/CC on/IN cortisol/NN concentrations/NNS in/IN blood/NN ./. 
In/IN the/DT second/JJ series/NN we/PRP observed/VBD the/DT following/NN :/: at/IN the/DT end/NN of/IN the/DT first/JJ month/NN of/IN bed/NN rest/NN the/DT number/NN of/IN glucocorticoid/NN receptors/NNS and/CC receptor/NN affinity/NN significantly/RB increased/VBD ;/: at/IN the/DT beginning/NN of/IN the/DT third/JJ month/NN of/IN bed/NN rest/NN specific/JJ glucocorticoid/NN binding/NN significantly/RB decreased/VBD and/CC circadian/JJ rhythms/NNS of/IN adrenocorticotropin/NN and/CC cortisol/NN in/IN blood/NN varied/VBD markedly/RB ;/: at/IN the/DT end/NN of/IN the/DT sixth/JJ month/NN of/IN bed/NN rest/NN the/DT number/NN of/IN glucocorticoid/NN receptors/NNS returned/VBD to/TO prebed/JJ rest/NN levels/NNS and/CC dissociation/NN constant/NN decreased/VBD ./. 
In/IN the/DT third/JJ series/NN physical/JJ exercises/NNS that/WDT induced/VBD an/DT activation/NN of/IN the/DT hypothalamic-hypophyseal-adrenocortical/JJ system/NN (/( maximal/JJ physical/JJ exercises/NNS and/CC prolonged/JJ submaximal/JJ exercises/NNS at/IN 70/CD %/NN of/IN maximal/JJ oxygen/NN uptake/NN )/) led/VBD to/TO a/DT significant/JJ increase/NN in/IN the/DT number/NN of/IN glucocorticoid/NN receptors/NNS without/IN changes/NNS of/IN dissociation/NN constant/NN ./. 
These/DT results/NNS indicate/VBP that/IN both/CC a/DT decrease/NN and/CC an/DT increase/NN of/IN human/JJ motor/NN activity/NN resulted/VBD in/IN significant/JJ changes/NNS of/IN specific/JJ glucocorticoid/NN binding/NN which/WDT were/VBD not/RB influenced/VBN by/IN changes/NNS of/IN circulating/VBG hormone/NN concentrations/NNS in/IN blood/NN but/CC by/IN some/DT other/JJ factors/NNS affected/VBN by/IN physical/JJ activity/NN ./. 
UI/LS -/: 98378510/CD 
TI/LS -/: The/DT small/JJ GTP-binding/JJ protein/NN Rho/NN potentiates/VBZ AP-1/NN transcription/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: The/DT Rho/NN family/NN of/IN small/JJ GTP-binding/JJ proteins/NNS is/VBZ involved/VBN in/IN the/DT regulation/NN of/IN cytoskeletal/JJ structure/NN ,/, gene/NN transcription/NN ,/, specific/JJ cell/NN fate/NN development/NN ,/, and/CC transformation/NN ./. 
We/PRP demonstrate/VBP in/IN this/DT report/NN that/IN overexpression/NN of/IN an/DT activated/JJ form/NN of/IN Rho/NN enhances/VBZ AP-1/NN activity/NN in/IN Jurkat/NN T/NN cells/NNS in/IN the/DT presence/NN of/IN phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) ,/, but/CC activated/VBN Rho/NN (/( V14Rho/NN )/) has/VBZ little/JJ or/CC no/DT effect/NN on/IN NFAT/NN ,/, Oct-1/NN ,/, and/CC NF-kappaB/NN enhancer/NN element/NN activities/NNS under/IN similar/JJ conditions/NNS ./. 
Overexpression/NN of/IN a/DT V14Rho/NN construct/NN incapable/JJ of/IN membrane/NN localization/NN (/( CAAX/NN deleted/VBN )/) abolishes/VBZ PMA-induced/JJ AP-1/NN transcriptional/JJ activation/NN ./. 
The/DT effect/NN of/IN Rho/NN on/IN AP-1/NN is/VBZ independent/JJ of/IN the/DT mitogen-activated/JJ protein/NN kinase/NN pathway/NN ,/, as/IN a/DT dominant-negative/JJ MEK/NN and/CC a/DT MEK/NN inhibitor/NN (/( PD98059/NN )/) did/VBD not/RB affect/VB Rho-induced/JJ AP-1/NN activity/NN ./. 
V14Rho/NN binds/VBZ strongly/RB to/TO protein/NN kinase/NN Calpha/NN (/( PKCalpha/NN )/) in/FW vivo/FW ;/: however/RB ,/, deletion/NN of/IN the/DT CAAX/NN site/NN on/IN V14Rho/NN severely/RB diminished/VBD this/DT association/NN ./. 
Evidence/NN for/IN a/DT role/NN for/IN PKCalpha/NN as/IN an/DT effector/NN of/IN Rho/NN was/VBD obtained/VBN by/IN the/DT observation/NN that/IN coexpression/NN of/IN the/DT N-terminal/JJ domain/NN of/IN PKCalpha/NN blocked/VBD the/DT effects/NNS of/IN activated/VBN Rho/NN plus/CC PMA/NN on/IN AP-1/NN transcriptional/JJ activity/NN ./. 
These/DT data/NNS suggest/VBP that/IN Rho/NN potentiates/VBZ AP-1/NN transcription/NN during/IN T-cell/NN activation/NN 
UI/LS -/: 98365377/CD 
TI/LS -/: Changes/NNS in/IN PKC/NN isoforms/NNS in/IN human/JJ alveolar/JJ macrophages/NNS compared/VBN with/IN blood/NN monocytes/NNS ./. 
AB/LS -/: Alveolar/JJ macrophages/NNS play/VBP an/DT important/JJ role/NN in/IN host/NN defense/NN and/CC in/IN other/JJ types/NNS of/IN inflammatory/JJ processes/NNS in/IN the/DT lung/NN ./. 
These/DT cells/NNS exhibit/VBP many/JJ alterations/NNS in/IN function/NN compared/VBN with/IN their/PRP$ precursor/NN cells/NNS ,/, blood/NN monocytes/NNS ./. 
To/TO evaluate/VB a/DT potential/JJ mechanism/NN for/IN these/DT differences/NNS in/IN function/NN ,/, we/PRP evaluated/VBD expression/NN of/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) isoforms/NNS ./. 
We/PRP found/VBD an/DT increase/NN in/IN Ca2+-dependent/JJ PKC/NN isoforms/NNS in/IN monocytes/NNS compared/VBN with/IN alveolar/JJ macrophages/NNS ./. 
We/PRP also/RB found/VBD differential/JJ expression/NN of/IN the/DT Ca2+-independent/JJ isoforms/NNS in/IN alveolar/JJ macrophages/NNS compared/VBN with/IN monocytes/NNS ./. 
One/CD consequence/NN of/IN the/DT activation/NN of/IN PKC/NN can/MD be/VB increased/VBN expression/NN of/IN mitogen-activated/JJ protein/NN (/( MAP/NN )/) kinase/NN pathways/NNS ./. 
Therefore/RB ,/, we/PRP also/RB evaluated/VBD activation/NN of/IN the/DT MAP/NN kinase/NN extracellular/JJ signal-regulated/JJ kinase/NN (/( ERK/NN )/) 2/CD by/IN the/DT phorbol/NN ester/NN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) ./. 
PMA/NN activated/JJ ERK2/NN kinase/NN in/IN both/CC alveolar/JJ macrophages/NNS and/CC monocytes/NNS ;/: however/RB ,/, monocytes/NNS consistently/RB showed/VBD a/DT significantly/RB greater/JJR activation/NN of/IN ERK2/NN kinase/NN by/IN PMA/NN compared/VBN with/IN alveolar/JJ macrophages/NNS ./. 
Another/DT known/JJ consequence/NN of/IN the/DT activation/NN of/IN PKC/NN and/CC subsequent/JJ activation/NN of/IN ERK/NN kinase/NN is/VBZ activation/NN of/IN the/DT transcription/NN factor/NN activator/NN protein-1/NN (/( AP-1/NN )/) ./. 
We/PRP evaluated/VBD the/DT activation/NN of/IN AP-1/NN by/IN PMA/NN in/IN both/CC monocytes/NNS and/CC macrophages/NNS ./. 
We/PRP found/VBD very/RB little/JJ detectable/JJ activation/NN of/IN AP-1/NN ,/, as/IN assessed/VBN in/IN a/DT gel/NN shift/NN assay/NN ,/, in/IN alveolar/JJ macrophages/NNS ,/, whereas/IN monocytes/NNS showed/VBD a/DT substantial/JJ activation/NN of/IN AP-1/NN by/IN PMA/NN ./. 
These/DT studies/NNS show/VBP that/IN the/DT differential/JJ expression/NN of/IN PKC/NN isoforms/NNS in/IN alveolar/JJ macrophages/NNS and/CC blood/NN monocytes/NNS is/VBZ associated/VBN with/IN important/JJ functional/JJ alterations/NNS in/IN the/DT cells/NNS ./. 
UI/LS -/: 98353227/CD 
TI/LS -/: Expression/NN of/IN gamma-IFN/NN responsive/JJ genes/NNS in/IN scavenger/NN receptor/NN over-expressing/NN monocytes/NNS is/VBZ associated/VBN with/IN xanthomatosis/NN ./. 
AB/LS -/: We/PRP have/VBP recently/RB described/VBN an/DT inherited/VBN over-expression/NN of/IN the/DT macrophage/NN scavenger/NN receptor/NN (/( SR/NN )/) in/IN blood/NN monocytes/NNS from/IN members/NNS of/IN a/DT kindred/NN ,/, only/RB two/CD of/IN whom/WP displayed/VBD extensive/JJ xanthomatosis/NN ./. 
Using/VBG mRNA/NN differential/JJ display/NN we/PRP demonstrated/VBD abnormally/RB high/JJ expression/NN of/IN the/DT signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT1alpha/NN )/) in/IN monocytes/NNS from/IN the/DT proband/NN II-2/NN|CD ./. 
Expression/NN of/IN gamma-interferon/NN inducible/JJ protein/NN 10/CD (/( IP-10/NN )/) ,/, a/DT STAT1alpha-responsive/JJ gene/NN and/CC mediator/NN of/IN inflammatory/JJ response/NN ,/, was/VBD also/RB abnormally/RB expressed/VBN in/IN the/DT monocytes/NNS from/IN II-2/NN|CD ./. 
Over-expression/NN of/IN both/DT genes/NNS was/VBD restricted/JJ to/TO monocytes/NNS from/IN II-2/NN|CD and/CC was/VBD not/RB observed/VBN in/IN monocytes/NNS from/IN the/DT clinically/RB unaffected/JJ family/NN members/NNS ,/, unlike/IN that/DT of/IN SR/NN ./. 
Gel/NN retardation/NN assays/NNS with/IN THP-1/NN cell/NN extracts/NNS identified/VBD gamma-IFN/NN inducible/JJ DNA/NN binding/NN activity/NN to/TO three/CD potential/JJ STATI/NN DNA/NN binding/NN elements/NNS in/IN the/DT human/JJ IP-10/NN promoter/NN region/NN from/IN nucleotides/NNS - 245/CD to/TO - 188/CD ./. 
Taken/VBN together/RB these/DT results/NNS suggest/VBP that/IN gamma-interferon/NN mediated/VBD cell/NN activation/NN is/VBZ responsible/JJ for/IN STAT1alpha-induced/JJ transcription/NN of/IN the/DT IP-10/NN gene/NN in/IN THP-1/NN macrophages/NNS as/RB well/RB as/IN in/IN monocytes/NNS from/IN II-2/NN|CD ./. 
Analysis/NN of/IN monocytes/NNS from/IN familial/JJ hypercholesterolemic/JJ (/( FH/NN )/) subjects/NNS ,/, who/WP frequently/RB develop/VBP xanthomatosis/NN ,/, revealed/VBD a/DT significant/JJ number/NN of/IN subjects/NNS with/IN elevated/JJ STAT1alpha/NN and/CC IP-10/NN expression/NN ./. 
Our/PRP$ data/NNS suggest/VBP that/IN the/DT inflammatory/JJ effects/NNS of/IN gamma-IFN/NN signaling/NN could/MD play/VB a/DT role/NN in/IN foam/NN cell/NN formation/NN and/CC xanthomatosis/NN ./. 
UI/LS -/: 98343775/CD 
TI/LS -/: Redox/NN signals/NNS and/CC NF-kappaB/NN activation/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Accumulating/JJ data/NNS from/IN a/DT number/NN of/IN laboratories/NNS have/VBP recently/RB indicated/VBN that/IN the/DT response/NN of/IN transcription/NN factor/NN NF-kappaB/NN to/TO alterations/NNS in/IN the/DT redox/NN homeostasis/NN of/IN cells/NNS may/MD play/VB an/DT important/JJ role/NN in/IN modulating/VBG immune/JJ function/NN ./. 
The/DT activation/NN of/IN NF-kappaB/NN has/VBZ been/VBN recognized/VBN to/TO regulate/VB a/DT number/NN of/IN genes/NNS necessary/JJ for/IN normal/JJ T/NN cell/NN responses/NNS including/VBG IL-2/NN ,/, IL-6/NN ,/, IL-8/NN ,/, and/CC several/JJ T/NN cell/NN surface/NN receptors/NNS ./. 
Diminished/JJ NF-kappaB/NN activity/NN has/VBZ been/VBN shown/VBN to/TO occur/VB in/IN T/NN cells/NNS with/IN aging/NN ,/, suggesting/VBG that/IN impaired/JJ activation/NN of/IN NF-kappaB/NN might/MD occur/VB during/IN cellular/JJ senescence/NN ./. 
In/IN addition/NN ,/, aberrancies/NNS in/IN NF-kappaB/NN activity/NN have/VBP been/VBN implicated/VBN in/IN the/DT immunopathogenesis/NN of/IN diseases/NNS involving/VBG immune/JJ or/CC inflammatory/JJ processes/NNS such/JJ as/IN atherosclerosis/NN and/CC HIV-1/NN infection/NN ./. 
The/DT role/NN of/IN H2O2/NN and/CC other/JJ reactive/JJ oxygen/NN species/NNS (/( ROS/NN )/) as/IN an/DT integratory/JJ secondary/JJ messenger/NN for/IN divergent/JJ T/NN cell/NN signals/NNS has/VBZ been/VBN complicated/VBN by/IN the/DT fact/NN that/IN various/JJ T/NN cell/NN lines/NNS and/CC peripheral/JJ blood/NN T/NN cells/NNS differ/VBP markedly/RB in/IN the/DT levels/NNS of/IN NF-kappaB/NN activation/NN induced/VBN by/IN oxidant/JJ stress/NN ./. 
Additionally/RB ,/, proposed/JJ pathways/NNS of/IN NF-kappaB/NN activation/NN have/VBP been/VBN based/VBN on/IN indirect/JJ evidence/NN provided/VBN by/IN experiments/NNS which/WDT used/VBD antioxidants/NNS to/TO inhibit/VB active/JJ NF-kappaB/NN formation/NN ./. 
Further/RB ,/, complete/JJ activation/NN of/IN T/NN cells/NNS requires/VBZ at/IN least/JJS two/CD signals/NNS ,/, one/CD that/IN stimulates/VBZ an/DT increase/NN in/IN intracellular/JJ calcium/NN and/CC one/CD that/WDT stimulates/VBZ enzymatic/JJ processes/NNS including/VBG kinases/NNS ./. 
Similarly/RB ,/, substantial/JJ evidence/NN indicates/VBZ that/IN full/JJ activation/NN of/IN NF-kappaB/NN requires/VBZ dual/JJ signals/NNS ./. 
The/DT ability/NN of/IN H2O2/NN or/CC other/JJ ROS/NN to/TO induce/VB T/NN cell/NN signals/NNS and/CC functional/JJ responses/NNS by/IN these/DT two/CD mechanisms/NNS is/VBZ reviewed/VBN and/CC the/DT specific/JJ response/NN of/IN NF-kappaB/NN to/TO redox/NN changes/NNS in/IN T/NN cells/NNS is/VBZ examined/VBN ./. 
Data/NNS are/VBP also/RB presented/VBN to/TO suggest/VB that/IN the/DT redox/NN regulation/NN in/IN NF-kappaB/NN activation/NN may/MD be/VB relevant/JJ to/TO immune-related/JJ diseases/NNS and/CC to/TO aging/NN ./. 
UI/LS -/: 98332778/CD 
TI/LS -/: Uncoupling/NN of/IN nonreceptor/JJ tyrosine/NN kinases/NNS from/IN PLC-gamma1/NN in/IN an/DT SLP-76-deficient/JJ T/NN cell/NN ./. 
AB/LS -/: Activation/NN of/IN nonreceptor/JJ protein/NN tyrosine/NN kinases/NNS (/( PTKs/NN )/) is/VBZ essential/JJ for/IN T/NN cell/NN receptor/NN (/( TCR/NN )/) responsiveness/NN ;/: however/RB ,/, the/DT function/NN of/IN individual/JJ PTK/NN substrates/NNS is/VBZ often/RB uncertain/JJ ./. 
A/DT mutant/JJ T/NN cell/NN line/NN was/VBD isolated/VBN that/WDT lacked/VBD expression/NN of/IN SLP-76/NN (/( SH2/NN domain-containing/JJ leukocyte/NN protein/NN of/IN 76/CD kilodaltons/NNS )/) ,/, a/DT hematopoietically/RB expressed/VBN adaptor/NN protein/NN and/CC PTK/NN substrate/NN ./. 
SLP-76/NN was/VBD not/RB required/VBN for/IN TCR-induced/JJ tyrosine/NN phosphorylation/NN of/IN most/JJS proteins/NNS ,/, but/CC was/VBD required/VBN for/IN optimal/JJ tyrosine/NN phosphorylation/NN and/CC activation/NN of/IN phospholipase/NN C-gamma1/NN (/( PLC-gamma1/NN )/) ,/, as/RB well/RB as/IN Ras/NN pathway/NN activation/NN ./. 
TCR-inducible/JJ gene/NN expression/NN was/VBD dependent/JJ on/IN SLP-76/NN ./. 
Thus/RB ,/, coupling/NN of/IN TCR-regulated/JJ PTKs/NN to/TO downstream/JJ signaling/NN pathways/NNS requires/VBZ SLP-76/NN ./. 
UI/LS -/: 98322151/CD 
TI/LS -/: A/DT novel/JJ function/NN of/IN Stat1/NN and/CC Stat3/NN proteins/NNS in/IN erythropoietin-induced/JJ erythroid/JJ differentiation/NN of/IN a/DT human/JJ leukemia/NN cell/NN line/NN ./. 
AB/LS -/: We/PRP recently/RB determined/VBD that/IN erythropoietin/NN (/( EPO/NN )/) activates/VBZ 3/CD members/NNS of/IN the/DT signal/NN transducer/NN and/CC activator/NN of/IN transcription/NN (/( STAT/NN )/) family/NN ,/, Stat1alpha/NN ,/, Stat3/NN ,/, and/CC Stat5/NN ,/, in/IN the/DT human/JJ EPO-dependent/JJ cell/NN lines/NNS ,/, UT-7/NN and/CC UT-7/EPO/NN (/( Kirito/NNP et/FW al/FW ,/, J/NNP Biol/NNP Chem/NNP 272/CD :/: 16507/CD ,/, 1997/CD )/) ./. 
In/IN addition/NN ,/, we/PRP have/VBP shown/VBN that/IN Stat1alpha/NN ,/, but/CC not/RB Stat3/NN ,/, is/VBZ involved/VBN in/IN EPO-induced/JJ cellular/JJ proliferation/NN ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD the/DT roles/NNS of/IN Stat1alpha/NN and/CC Stat3/NN in/IN EPO-induced/JJ erythroid/JJ differentiation/NN ./. 
UT-7/GM/NN was/VBD used/VBN as/IN a/DT model/NN system/NN ,/, because/IN this/DT cell/NN line/NN can/MD differentiate/VB into/IN erythroid-lineage/JJ cells/NNS with/IN EPO/NN treatment/NN (/( Komatsu/NN et/FW al/FW ,/, Blood/NNP 89/CD :/: 4021/CD ,/, 1997/CD )/) ./. 
We/PRP found/VBD that/IN EPO/NN did/VBD not/RB activate/VB Stat1alpha/NN or/CC Stat3/NN in/IN UT-7/GM/NN cells/NNS ./. 
Transfection/NN experiments/NNS showed/VBD that/IN both/CC Stat1alpha/NN and/CC Stat3/NN inhibited/VBD the/DT induction/NN by/IN EPO/NN of/IN gamma-globin/NN and/CC erythroid-specific/JJ 5-aminolevulinate/JJ synthetase/NN transcripts/NNS ,/, resulting/VBG in/IN a/DT reduction/NN of/IN the/DT percentage/NN of/IN hemoglobin-positive/JJ cells/NNS ./. 
Dominant/JJ negative/JJ forms/NNS of/IN Stat1alpha/NN or/CC Stat3/NN promoted/VBD the/DT EPO-induced/JJ erythroid/JJ differentiation/NN of/IN UT-7/GM/NN cells/NNS ,/, even/RB in/IN the/DT presence/NN of/IN granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN ,/, although/IN this/DT cytokine/NN never/RB induced/VBD erythroid/JJ differentiation/NN of/IN the/DT parent/JJ UT-7/GM/NN cells/NNS with/IN or/CC without/IN EPO/NN ./. 
A/DT cell/NN cycle/NN analysis/NN showed/VBD that/IN the/DT constitutive/JJ activation/NN of/IN Stat1alpha/NN ,/, but/CC not/RB Stat3/NN ,/, shortened/VBD the/DT period/NN of/IN G0/G1/NN prolongation/NN caused/VBN by/IN EPO/NN stimulation/NN ./. 
Taken/VBN together/RB ,/, our/PRP$ data/NNS suggest/VBP that/IN Stat1alpha/NN and/CC Stat3/NN act/VBP as/IN negative/JJ regulators/NNS in/IN EPO-induced/JJ erythroid/JJ differentiation/NN ./. 
Specifically/RB ,/, Stat1alpha/NN may/MD activate/VB a/DT cell/NN cycle-associated/JJ gene/NN (/( s/NNS )/) ,/, leading/VBG to/TO the/DT entry/NN of/IN cells/NNS into/IN the/DT cell/NN cycle/NN ./. 
UI/LS -/: 98313295/CD 
TI/LS -/: Ro/NN 09-2210/CD exhibits/VBZ potent/JJ anti-proliferative/JJ effects/NNS on/IN activated/VBN T/NN cells/NNS by/IN selectively/RB blocking/VBG MKK/NN activity/NN ./. 
AB/LS -/: By/IN using/VBG high/JJ throughput/NN screening/NN of/IN microbial/JJ broths/NNS ,/, we/PRP have/VBP identified/VBN a/DT compound/NN ,/, designated/VBN Ro/NN 09-2210/CD ,/, which/WDT is/VBZ able/JJ to/TO block/VB anti-CD3/JJ induced/JJ peripheral/JJ blood/NN T/NN cell/NN activation/NN with/IN an/DT IC50/NN =/JJ 40/CD nM/NN ./. 
Ro/NN 09-2210/CD was/VBD also/RB able/JJ to/TO block/VB antigen-induced/JJ IL-2/NN secretion/NN with/IN an/DT IC50/NN =/JJ 30/CD nM/NN ,/, but/CC was/VBD considerably/RB less/RBR potent/JJ at/IN blocking/VBG Ca2+/NN flux/NN stimulated/VBN by/IN anti-CD3/JJ treatment/NN ./. 
To/TO determine/VB the/DT mechanism/NN of/IN action/NN of/IN Ro/NN 09-2210/CD ,/, we/PRP set/VBD up/IN a/DT transient/JJ expression/NN system/NN in/IN Jurkat/NN T/NN cells/NNS using/VBG a/DT variety/NN of/IN reporter/NN gene/NN constructs/NNS and/CC showed/VBD effective/JJ inhibition/NN of/IN phorbol/NN ester/ionomycin-induced/JJ NF-AT/NN activation/NN and/CC anti-CD3/NN induced/VBD NF-AT/NN with/IN IC50/NN =/JJ 7.7/CD and/CC 10/CD nM/NN ,/, respectively/RB ./. 
Ro/NN 09-2210/CD was/VBD also/RB able/JJ to/TO inhibit/VB phorbol/NN ester/ionomycin-induced/JJ activation/NN of/IN AP1/NN with/IN IC50/NN =/JJ </JJR 10/CD nM/NN ./. 
We/PRP further/RB showed/VBD that/IN Ro/NN 09-2210/CD was/VBD unable/JJ to/TO inhibit/VB c-jun/NN induced/JJ expression/NN of/IN AP1-dependent/JJ reporter/NN constructs/NNS (/( IC50/NN >/JJR 500/CD nM/NN )/) ,/, but/CC was/VBD able/JJ to/TO potently/RB inhibit/VB ras-induced/JJ AP1/NN activation/NN (/( IC50/NN =/JJ 20/CD nM/NN )/) ./. 
This/DT suggested/VBD that/IN Ro/NN 09-2210/CD was/VBD inhibiting/VBG an/DT activator/NN of/IN AP-1/NN which/WDT was/VBD upstream/JJ of/IN c-jun/NN and/CC downstream/RB of/IN ras/NN signaling/NN ./. 
To/TO investigate/VB further/RB ,/, we/PRP then/RB purified/VBN a/DT number/NN of/IN different/JJ kinases/NNS ,/, including/VBG PKC/NN ,/, PhK/NN ,/, ZAP-70/NN ,/, ERK/NN ,/, and/CC MEK/NN 1/CD (/( a/NN|DT MKK/NN )/) ,/, and/CC showed/VBD that/IN Ro/NN 09-2210/CD was/VBD a/DT selective/JJ inhibitor/NN of/IN MEK1/NN in/FW vitro/FW (/( IC50/NN =/JJ 59/CD nM/NN )/) ./. 
UI/LS -/: 98298224/CD 
TI/LS -/: Coactivation/NN by/IN OCA-B/NN :/: definition/NN of/IN critical/JJ regions/NNS and/CC synergism/NN with/IN general/JJ cofactors/NNS ./. 
AB/LS -/: Molecular/JJ dissection/NN of/IN the/DT B-cell-specific/JJ transcription/NN coactivator/NN OCA-B/NN has/VBZ revealed/VBN distinct/JJ regions/NNS important/JJ ,/, respectively/RB ,/, for/IN recruitment/NN to/TO immunoglobulin/NN promoters/NNS through/IN interaction/NN with/IN octamer-bound/JJ Oct-1/NN and/CC for/IN subsequent/JJ coactivator/NN function/NN ./. 
Further/JJ analysis/NN of/IN general/JJ coactivator/NN requirements/NNS showed/VBD that/IN selective/JJ removal/NN of/IN PC4/NN from/IN the/DT essential/JJ USA/NN fraction/NN severely/RB impairs/VBZ Oct-1/NN and/CC OCA-B/NN function/NN in/IN a/DT cell-free/JJ system/NN reconstituted/VBN with/IN partially/RB purified/VBN factors/NNS ./. 
Full/JJ activity/NN can/MD be/VB restored/VBN by/IN the/DT combined/JJ action/NN of/IN recombinant/JJ PC4/NN and/CC the/DT PC4-depleted/JJ USA/NN fraction/NN ,/, thus/RB suggesting/VBG a/DT joint/NN requirement/NN for/IN PC4/NN and/CC another/DT ,/, USA-derived/JJ component/NN (/( s/NNS )/) for/IN optimal/JJ function/NN of/IN Oct-1/OCA-B/NN in/IN the/DT reconstituted/JJ system/NN ./. 
Indeed/RB ,/, USA-derived/JJ PC2/NN was/VBD found/VBN to/TO act/VB synergistically/RB with/IN PC4/NN in/IN reproducing/VBG the/DT function/NN of/IN intact/JJ USA/NN in/IN the/DT assay/NN system/NN ./. 
Consistent/JJ with/IN the/DT requirement/NN for/IN PC4/NN in/IN the/DT reconstituted/JJ system/NN ,/, OCA-B/NN was/VBD found/VBN to/TO interact/VB directly/RB with/IN PC4/NN ./. 
Surprisingly/RB ,/, however/RB ,/, removal/NN of/IN PC4/NN from/IN the/DT unfractionated/JJ nuclear/JJ extract/NN has/VBZ no/DT detrimental/JJ effect/NN on/IN OCA-B/Oct-1-dependent/JJ transcription/NN ./. 
These/DT results/NNS lead/VBP to/TO a/DT general/JJ model/NN for/IN the/DT synergistic/JJ function/NN of/IN activation/NN domains/NNS in/IN Oct-1/NN and/CC OCA-B/NN (/( mediated/VBN by/IN the/DT combined/JJ action/NN of/IN the/DT multiple/JJ USA/NN components/NNS )/) and/CC ,/, further/RB ,/, suggest/VBP a/DT functional/JJ redundancy/NN in/IN general/JJ coactivators/NNS ./. 
UI/LS -/: 98241397/CD 
TI/LS -/: Activation/NN of/IN Stat-3/NN is/VBZ involved/VBN in/IN the/DT induction/NN of/IN apoptosis/NN after/IN ligation/NN of/IN major/JJ histocompatibility/NN complex/NN class/NN I/NN molecules/NNS on/IN human/JJ Jurkat/NN T/NN cells/NNS ./. 
AB/LS -/: Activation/NN of/IN Janus/NN tyrosine/NN kinases/NNS (/( Jak/NN )/) and/CC Signal/NN transducers/NNS and/CC activators/NNS of/IN transcription/NN (/( Stat/NNS )/) after/IN ligation/NN of/IN major/JJ histocompatibility/NN complex/NN class/NN I/CD (/( MHC-I/NN )/) was/VBD explored/VBN in/IN Jurkat/NN T/NN cells/NNS ./. 
Cross-linking/NN of/IN MHC-I/NN mediated/VBD tyrosine/NN phosphorylation/NN of/IN Tyk2/NN ,/, but/CC not/RB Jak1/NN ,/, Jak2/NNP ,/, and/CC Jak3/NN ./. 
In/IN addition/NN ,/, the/DT transcription/NN factor/NN Stat-3/NN was/VBD tyrosine/NN phosphorylated/VBN in/IN the/DT cytoplasm/NN and/CC subsequently/RB translocated/VBN to/TO the/DT cell/NN nucleus/NN ./. 
Data/NN obtained/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN suggested/VBD that/IN the/DT activated/VBN Stat-3/NN protein/NN associates/VBZ with/IN the/DT human/JJ serum-inducible/JJ element/NN (/( hSIE/NN )/) DNA-probe/NN derived/VBN from/IN the/DT interferon-gamma/NN activated/JJ site/NN (/( GAS/NN )/) in/IN the/DT c-fos/NN promoter/NN ,/, a/DT common/JJ DNA/NN sequence/NN for/IN Stat/NNS protein/NN binding/NN ./. 
An/DT association/NN between/IN hSIE/NN and/CC Stat-3/NN after/IN MHC-I/NN ligation/NN was/VBD directly/RB demonstrated/VBN by/IN precipitating/VBG Stat-3/NN from/IN nuclear/JJ extracts/NNS with/IN biotinylated/VBN hSIE/NN probe/NN and/CC avidin-coupled/JJ agarose/NN ./. 
To/TO investigate/VB the/DT function/NN of/IN the/DT activated/VBN Stat-3/NN ,/, Jurkat/NN T/NN cells/NNS were/VBD transiently/RB transfected/VBN with/IN a/DT Stat-3/NN isoform/NN lacking/VBG the/DT transactivating/VBG domain/NN ./. 
This/DT dominant-negative/JJ acting/VBG Stat-3/NN isoform/NN significantly/RB inhibited/VBD apoptosis/NN induced/VBN by/IN ligation/NN of/IN MHC-I/NN ./. 
In/IN conclusion/NN ,/, our/PRP$ data/NNS suggest/VBP the/DT involvement/NN of/IN the/DT Jak/Stat/NN signal/NN pathway/NN in/IN MHC-I-induced/JJ signal/NN transduction/NN in/IN T/NN cells/NNS ./. 
UI/LS -/: 98281217/CD 
TI/LS -/: IL-2-induced/JJ growth/NN of/IN CD8+/JJ T/NN cell/NN prolymphocytic/JJ leukemia/NN cells/NNS mediated/VBN by/IN NF-kappaB/NN induction/NN and/CC IL-2/NN receptor/NN alpha/NN expression/NN ./. 
AB/LS -/: The/DT binding/NN of/IN interleukin-2/NN (/( IL-2/NN )/) to/TO its/PRP$ receptor/NN on/IN normal/JJ T/NN cells/NNS induces/VBZ nuclear/JJ expression/NN of/IN nuclear/JJ factor/NN kappaB/NN (/( NF-kappaB/NN )/) ,/, activation/NN of/IN the/DT IL-2/NN receptor/NN (/( IL-2R/NN )/) alpha/NN chain/NN gene/NN ,/, and/CC cell/NN proliferation/NN ./. 
In/IN the/DT present/JJ study/NN ,/, the/DT role/NN of/IN IL-2R/NN signaling/NN in/IN the/DT growth/NN of/IN CD8+/JJ T/NN cell/NN prolymphocytic/JJ leukemia/NN (/( T-PLL/NN )/) cells/NNS has/VBZ been/VBN investigated/VBN ./. 
Flow/NN cytometry/NN revealed/VBD that/IN primary/JJ leukemia/NN cells/NNS from/IN a/DT patient/NN with/IN CD8+/JJ T-PLL/NN expressed/VBD IL-2Ralpha/NN and/CC beta/NN chains/NNS ,/, and/CC the/DT cells/NNS showed/VBD a/DT proliferative/JJ response/NN and/CC an/DT increase/NN in/IN IL-2Ralpha/NN expression/NN on/IN culture/NN with/IN exogeneous/JJ IL-2/NN ./. 
Northern/NN blot/NN analysis/NN failed/VBD to/TO detect/VB IL-2/NN mRNA/NN ,/, suggesting/VBG that/IN IL-2/NN may/MD act/VB in/IN a/DT paracrine/JJ manner/NN in/FW vivo/FW ./. 
Electrophoretic/JJ mobility-shift/NN assays/NNS revealed/VBD that/IN recombinant/JJ IL-2/NN increased/VBD NF-kappaB/NN binding/NN activity/NN in/IN nuclear/JJ extracts/NNS of/IN the/DT leukemia/NN cells/NNS ,/, and/CC Northern/NN blot/NN analysis/NN showed/VBD that/IN IL-2/NN increased/VBD the/DT abundance/NN of/IN mRNAs/NNS encoding/VBG the/DT NF-kappaB/NN components/NNS c-Rel/NN and/CC KBF1/NN in/IN these/DT cells/NNS ./. 
IL-2/NN binding/NN analysis/NN demonstrated/VBD that/IN IL-2/NN markedly/RB increased/VBD the/DT number/NN of/IN low/JJ affinity/NN IL-2Rs/NNS on/IN the/DT leukemia/NN cells/NNS ,/, without/IN an/DT effect/NN on/IN the/DT number/NN of/IN high-affinity/JJ IL-2Rs/NNS ./. 
These/DT results/NNS show/VBP that/IN IL-2/NN is/VBZ capable/JJ of/IN inducing/VBG the/DT nuclear/JJ expression/NN of/IN NF-kappaB/NN in/IN primary/JJ CD8+/JJ T-PLL/NN cells/NNS ,/, and/CC that/IN this/DT effect/NN is/VBZ mediated/VBN ,/, at/IN least/JJS in/IN part/NN ,/, at/IN a/DT pretranslational/JJ level/NN 
UI/LS -/: 98373923/CD 
TI/LS -/: Dimethyldithiocarbamate/NN inhibits/VBZ in/FW vitro/FW activation/NN of/IN primary/JJ human/JJ CD4+/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: Dithiocarbamates/NNS (/( DTC/NN )/) ,/, a/DT diverse/JJ group/NN of/IN industrial/JJ and/CC therapeutic/JJ chemicals/NNS ,/, have/VBP been/VBN reported/VBN to/TO inhibit/VB ,/, enhance/VBP or/CC have/VBP no/DT effect/NN on/IN the/DT immune/JJ system/NN ./. 
These/DT apparent/JJ inconsistencies/NNS reflect/VBP the/DT complexity/NN of/IN the/DT DTCs/NNS biological/JJ activities/NNS and/CC are/VBP probably/RB due/JJ in/IN part/NN to/TO differences/NNS in/IN dose/NN ,/, route/NN of/IN exposure/NN ,/, animal/JJ species/NNS used/VBN and/or/CC specific/JJ compound/NN tested/VBN ./. 
The/DT studies/NNS described/VBN herein/RB were/VBD undertaken/VBN to/TO investigate/VB the/DT immunotoxicity/NN of/IN one/CD member/NN of/IN this/DT family/NN ,/, dimethyldithiocarbamate/NN (/( DMDTC/NN )/) ./. 
We/PRP demonstrate/VBP that/IN 0.1-0.5/CD microM/NN DMDTC/NN inhibits/VBZ TNF-alpha-induced/JJ activation/NN of/IN NF-kappaB/NN in/IN primary/JJ human/JJ CD4+/JJ T/NN cells/NNS ./. 
This/DT inhibition/NN is/VBZ not/RB accompanied/VBN by/IN a/DT loss/NN in/IN viability/NN ,/, and/CC DMDTC-treated/JJ T/NN cells/NNS retain/VBP other/JJ active/JJ signaling/NN pathways/NNS throughout/IN the/DT exposure/NN duration/NN ./. 
The/DT inhibition/NN of/IN NF-kappaB/NN is/VBZ apparently/RB permanent/JJ as/IN DMDTC-treated/JJ T/NN cells/NNS did/VBD not/RB regain/VB normal/JJ TNF-alpha/NN activation/NN ,/, even/RB after/IN 72/CD h/NN in/IN culture/NN ./. 
DMDTC/NN does/VBZ not/RB appear/VB to/TO alter/VB NF-kappaB/NN directly/RB as/IN pre-incubation/NN of/IN nuclear/JJ extracts/NNS with/IN DMDTC/NN does/VBZ not/RB diminish/VB binding/NN activity/NN of/IN this/DT protein/NN ./. 
We/PRP further/RB demonstrate/VBP that/IN 0.1-0.5/CD microM/NN DMDTC/NN inhibits/VBZ intracellular/JJ IL-2/NN production/NN and/CC decreases/VBZ surface/NN expression/NN of/IN CD25/NN (/( the/DT alpha/NN subunit/NN of/IN the/DT IL-2/NN receptor/NN )/) in/IN T/NN cells/NNS stimulated/VBN with/IN phorbol/NN ester/NN ./. 
These/DT data/NNS demonstrate/VBP that/IN DMDTC/NN is/VBZ a/DT potent/JJ immunosuppressive/JJ compound/NN in/FW vitro/FW ./. 
UI/LS -/: 98363633/CD 
TI/LS -/: Human/JJ 15-lipoxygenase/NN gene/NN promoter/NN :/: analysis/NN and/CC identification/NN of/IN DNA/NN binding/NN sites/NNS for/IN IL-13-induced/JJ regulatory/JJ factors/NNS in/IN monocytes/NNS ./. 
AB/LS -/: In/IN order/NN to/TO study/VB the/DT transcriptional/JJ control/NN of/IN 15-LO/NN expression/NN ,/, we/PRP have/VBP cloned/VBN and/CC sequenced/VBD the/DT human/JJ 15-LO/NN promoter/NN region/NN ./. 
The/DT 15-LO/NN promoter/NN is/VBZ associated/VBN with/IN a/DT CpG/NN island/NN at/IN the/DT 5'-end/NN of/IN the/DT gene/NN ,/, and/CC sequence/NN analysis/NN reveals/VBZ putative/JJ Sp1/NN and/CC Ap2/NN binding/NN site/s/NNS and/CC absence/NN of/IN TATA/NN or/CC CAAT/NN motifs/NNS ./. 
Transcription/NN is/VBZ initiated/VBN at/IN one/CD major/JJ site/NN ./. 
Using/VBG deletion/NN constructs/NNS ,/, we/PRP have/VBP defined/VBN an/DT active/JJ promoter/NN region/NN of/IN 1056/CD bp/NN ./. 
Gel-shift/NN assays/NNS revealed/VBD that/IN transcriptional/JJ factor/NN (/( s/NNS )/) induced/VBN only/RB in/IN response/NN to/TO IL-13/NN treatment/NN of/IN human/JJ peripheral/JJ blood/NN monocytes/NNS bind/VBP to/TO the/DT 15-LO/NN promoter/NN DNA/NN ./. 
Two/CD regions/NNS ,/, DP1/NN (/( -140/CD to/TO -92/CD bp/NN )/) and/CC DP2/NN (/( -353/CD to/TO -304/CD bp/NN )/) of/IN the/DT promoter/NN were/VBD essential/JJ for/IN transcription/NN in/IN HeLa/NN cells/NNS and/CC human/JJ peripheral/JJ monocytes/NNS ./. 
Hela/NN nuclear/JJ extracts/NNS contained/VBD a/DT specific/JJ nuclear/JJ factor/NN (/( s/NNS )/) binding/VBG to/TO 15-LO/NN promoter/NN DNA/NN which/WDT are/VBP distinct/JJ from/IN those/DT derived/VBN from/IN IL-13-treated/JJ human/JJ peripheral/JJ monocyte/NN nuclear/JJ extracts/NNS ./. 
In/IN addition/NN ,/, fluorescent/JJ in/FW situ/FW hybridization/NN (/( FISH/NN )/) results/VBZ refined/VBD the/DT previous/JJ localization/NN of/IN 15-LO/NN to/TO human/JJ chromosome/NN 17p13.3/NN ./. 
UI/LS -/: 98352765/CD 
TI/LS -/: Ex/FW vivo/FW activation/NN of/IN tumor-draining/JJ lymph/NN node/NN T/NN cells/NNS reverses/VBZ defects/VBZ in/IN signal/NN transduction/NN molecules/NNS ./. 
AB/LS -/: The/DT adoptive/JJ transfer/NN of/IN tumor-draining/JJ lymph/NN node/NN (/( LN/NN )/) T/NN cells/NNS activated/VBD ex/FW vivo/FW with/IN anti-CD3/NN and/CC interleukin/NN 2/CD (/( IL-2/NN )/) mediates/VBZ the/DT regression/NN of/IN the/DT poorly/RB immunogenic/JJ murine/JJ melanoma/NN D5/NN ./. 
The/DT efficacy/NN of/IN the/DT activated/VBN LN/NN cells/NNS is/VBZ augmented/VBN when/WRB the/DT sensitizing/VBG tumor/NN is/VBZ a/DT genetically/RB modified/VBN variant/NN (/( designated/VBN D5G6/NN )/) that/WDT secretes/VBZ granulocyte/macrophage-colony-stimulating/JJ factor/NN ./. 
In/IN contrast/NN to/TO anti-CD3/IL-2-activated/JJ LN/NN cells/NNS ,/, adoptive/JJ transfer/NN of/IN freshly/RB isolated/VBN tumor-draining/JJ LN/NN T/NN cells/NNS has/VBZ no/DT therapeutic/JJ activity/NN ./. 
To/TO determine/VB whether/IN the/DT acquisition/NN of/IN antitumor/JJ function/NN during/IN ex/FW vivo/FW activation/NN is/VBZ associated/VBN with/IN modifications/NNS in/IN signal/NN transduction/NN capacity/NN ,/, the/DT protein/NN tyrosine/NN kinases/NNS p56lck/NN and/CC p59fyn/NN and/CC proteins/NNS of/IN the/DT NF-kappaB/NN family/NN were/VBD analyzed/VBN in/IN tumor-draining/JJ LN/NN T/NN cells/NNS ./. 
The/DT levels/NNS of/IN p56lck/NN and/CC p59fyn/NN were/VBD lower/JJR in/IN tumor-draining/JJ than/IN in/IN normal/JJ LN/NN T/NN cells/NNS and/CC production/NN of/IN tyrosine-phosphorylated/JJ substrates/NNS was/VBD markedly/RB depressed/VBN following/VBG anti-CD3/JJ stimulation/NN ./. 
After/IN 5-day/JJ anti-CD3/IL-2/JJ activation/NN ,/, levels/NNS of/IN p56lck/NN and/CC p59fyn/NN and/CC protein/NN tyrosine/NN kinase/NN activity/NN increased/VBN ./. 
Interestingly/RB ,/, the/DT levels/NNS of/IN p56lck/NN ,/, p59fyn/NN ,/, and/CC tyrosine/NN kinase/NN activity/NN were/VBD higher/JJR in/IN activated/VBN T/NN cells/NNS derived/VBN from/IN LN/NN that/IN drained/VBD D5G6/NN than/IN they/PRP were/VBD in/IN those/DT from/IN D5/NN tumors/NNS ./. 
In/IN contrast/NN ,/, the/DT cytoplasmic/JJ levels/NNS of/IN c-Rel/NN and/CC Rel/NN A/NN were/VBD normal/JJ in/IN freshly/RB isolated/VBN tumor-draining/JJ LN/NN ,/, as/IN was/VBD nuclear/JJ kappaB/NN DNA-binding/JJ activity/NN induced/VBN by/IN anti-CD3/JJ mAb/NN or/CC phorbol/NN myristate/NN acetate/NN ./. 
Stimulation/NN of/IN activated/VBN LN/NN cells/NNS with/IN D5/NN tumor/NN cells/NNS induced/VBD the/DT nuclear/JJ translocation/NN of/IN NF-kappaB/NN ./. 
These/DT findings/NNS indicate/VBP that/IN the/DT recovery/NN of/IN proteins/NNS mediating/VBG signal/NN transduction/NN through/IN the/DT T/NN cell/NN receptor/CD3/NN complex/NN in/IN LN/NN T/NN cells/NNS activated/VBD ex/FW vivo/FW was/VBD associated/VBN with/IN the/DT acquisition/NN of/IN antitumor/JJ function/NN ./. 
UI/LS -/: 98343423/CD 
TI/LS -/: Suppression/NN of/IN human/JJ anti-porcine/JJ T-cell/NN immune/JJ responses/NNS by/IN major/JJ histocompatibility/NN complex/NN class/NN II/CD transactivator/NN constructs/NNS lacking/VBG the/DT amino/NN terminal/JJ domain/NN ./. 
AB/LS -/: BACKGROUND/NN :/: The/DT class/NN II/CD transactivator/NN (/( CIITA/NN )/) is/VBZ a/DT bi-/JJ or/CC multifunctional/JJ domain/NN protein/NN that/WDT acts/VBZ as/IN a/DT transcriptional/JJ activator/NN and/CC plays/VBZ a/DT critical/JJ role/NN in/IN the/DT expression/NN of/IN MHC/NN class/NN II/CD genes/NNS ./. 
We/PRP have/VBP previously/RB demonstrated/VBN that/IN a/DT mutated/VBN form/NN of/IN the/DT human/JJ CIITA/NN gene/NN ,/, coding/VBG for/IN a/DT protein/NN lacking/VBG the/DT amino/NN terminal/JJ 151/CD amino/NN acids/NNS ,/, acts/VBZ as/IN a/DT potent/JJ dominant-negative/JJ suppressor/NN of/IN HLA/NN class/NN II/CD expression/NN ./. 
Porcine/NN MHC/NN class/NN II/CD antigens/NNS are/VBP potent/JJ stimulators/NNS of/IN direct/JJ T-cell/NN recognition/NN by/IN human/JJ CD4+/JJ T/NN cells/NNS and/CC are/VBP ,/, therefore/RB ,/, likely/JJ to/TO play/VB an/DT important/JJ role/NN in/IN the/DT rejection/NN responses/NNS to/TO transgenic/JJ pig/NN donors/NNS in/IN clinical/JJ xenotransplantation/NN ./. 
We/PRP were/VBD ,/, therefore/RB ,/, interested/VBD in/IN examining/VBG mutated/VBN CIITA/NN constructs/NNS for/IN their/PRP$ effect/NN on/IN porcine/NN MHC/NN class/NN II/CD expression/NN ./. 
METHODS/NNS :/: Stable/JJ transfectants/NNS of/IN the/DT porcine/NN vascular/JJ endothelial/JJ cell/NN line/NN PIEC/NN with/IN mutated/VBN CIITA/NN constructs/NNS were/VBD tested/VBN for/IN SLA-DR/NN and/CC SLA-DQ/NN induction/NN by/IN recombinant/JJ porcine/NN interferon-gamma/NN ./. 
Transient/JJ transfectants/NNS of/IN the/DT porcine/NN B-cell/NN line/NN L23/NN with/IN the/DT mutated/VBN CIITA/NN constructs/NNS were/VBD tested/VBN for/IN the/DT suppression/NN of/IN constitutive/JJ SLA-DR/NN and/CC SLA-DQ/NN expression/NN ./. 
T-cell/NN proliferation/NN studies/NNS were/VBD performed/VBN using/VBG highly/RB purified/VBN human/JJ CD4+/JJ T/NN cells/NNS ./. 
RESULTS/NNS :/: In/FW preliminary/JJ studies/NNS ,/, we/PRP demonstrated/VBD that/IN transfection/NN of/IN the/DT PIEC/NN line/NN with/IN full-length/JJ human/JJ CIITA/NN constructs/NNS resulted/VBD in/IN strong/JJ expression/NN of/IN SLA-DR/NN and/CC SLA-DQ/NN antigens/NNS ,/, thus/RB establishing/VBG the/DT cross-species/JJ effectiveness/NN of/IN human/JJ CIITA/NN in/IN the/DT pig/NN ./. 
The/DT mutated/VBN human/JJ CIITA/NN constructs/NNS were/VBD ,/, therefore/RB ,/, tested/VBN in/IN the/DT pig/NN ./. 
PIEC/NN clones/NNS stably/RB transfected/VBN with/IN one/CD of/IN these/DT constructs/NNS showed/VBD up/RB to/TO 99/CD %/NN suppression/NN of/IN SLA-DR/NN and/CC SLA-DQ/NN antigen/NN induction/NN and/CC marked/JJ suppression/NN of/IN SLA-DRA/NN mRNA/NN induction/NN ./. 
Moreover/RB ,/, transient/JJ transfection/NN of/IN the/DT porcine/NN B-cell/NN line/NN L23/NN showed/VBD up/RB to/TO 90/CD %/NN suppression/NN of/IN constitutive/JJ SLA-DR/NN and/CC SLA-DQ/NN antigen/NN expression/NN in/IN 5-8/CD days/NNS ./. 
In/IN functional/JJ studies/NNS ,/, interferon-gamma-stimulated/JJ PIEC/NN clones/NNS transfected/VBN with/IN this/DT mutated/VBN CIITA/NN construct/NN failed/VBD to/TO stimulate/VB purified/VBN human/JJ CD4+/JJ T/NN lymphocytes/NNS ./. 
CONCLUSION/NN :/: Mutated/JJ human/JJ CIITA/NN constructs/NNS are/VBP potent/JJ suppressors/NNS of/IN porcine/NN MHC/NN class/NN II/CD expression/NN ./. 
UI/LS -/: 98328397/CD 
TI/LS -/: Macrophages/NNS in/IN human/JJ atheroma/NN contain/VBP PPARgamma/NN :/: differentiation-dependent/JJ peroxisomal/JJ proliferator-activated/JJ receptor/NN gamma/NN (/( PPARgamma/NN )/) expression/NN and/CC reduction/NN of/IN MMP-9/NN activity/NN through/IN PPARgamma/NN activation/NN in/IN mononuclear/JJ phagocytes/NNS in/FW vitro/FW ./. 
AB/LS -/: Mononuclear/JJ phagocytes/NNS play/VBP an/DT important/JJ role/NN in/IN atherosclerosis/NN and/CC its/PRP$ sequela/NN plaque/NN rupture/NN in/IN part/NN by/IN their/PRP$ secretion/NN of/IN matrix/NN metalloproteinases/NNS (/( MMPs/NNS )/) ,/, including/VBG MMP-9/NN ./. 
Peroxisomal/JJ proliferator-activated/JJ receptor/NN gamma/NN (/( PPARgamma/NN )/) ,/, a/DT transcription/NN factor/NN in/IN the/DT nuclear/JJ receptor/NN superfamily/NN ,/, regulates/VBZ gene/NN expression/NN in/IN response/NN to/TO various/JJ activators/NNS ,/, including/VBG 15-deoxy-delta12,14-prostaglandin/NN J2/NN and/CC the/DT antidiabetic/JJ agent/NN troglitazone/NN ./. 
The/DT role/NN of/IN PPARgamma/NN in/IN human/JJ atherosclerosis/NN is/VBZ unexplored/JJ ./. 
We/PRP report/VBP here/RB that/IN monocytes/macrophages/NNS in/IN human/JJ atherosclerotic/JJ lesions/NNS (/( n/NN =/JJ 12/CD )/) express/VBP immunostainable/JJ PPARgamma/NN ./. 
Normal/JJ artery/NN specimens/NNS (/( n/NN =/JJ 6/CD )/) reveal/VBP minimal/JJ immunoreactive/JJ PPARgamma/NN ./. 
Human/JJ monocytes/NNS and/CC monocyte-derived/JJ macrophages/NNS cultured/VBN for/IN 6/CD days/NNS in/IN 5/CD %/NN human/JJ serum/NN expressed/VBD PPARgamma/NN mRNA/NN and/CC protein/NN by/IN reverse/JJ transcription-polymerase/NN chain/NN reaction/NN and/CC Western/NN blotting/NN ,/, respectively/RB ./. 
In/IN addition/NN ,/, PPARgamma/NN mRNA/NN expression/NN in/IN U937/NN cells/NNS increased/VBN during/IN phorbol/NN 12-myristate/NN 13/CD acetate-induced/JJ differentiation/NN ./. 
Stimulation/NN of/IN PPARgamma/NN with/IN troglitazone/NN or/CC 15-deoxy-delta12,14-prostaglandin/NN J2/NN in/IN human/JJ monocyte-derived/JJ macrophages/NNS inhibited/VBD MMP-9/NN gelatinolytic/JJ activity/NN in/IN a/DT concentration-dependent/JJ fashion/NN as/IN revealed/VBN by/IN zymography/NN ./. 
This/DT inhibition/NN correlates/VBZ with/IN decreased/VBN MMP-9/NN secretion/NN as/IN determined/VBN by/IN Western/NN blotting/NN ./. 
Thus/RB ,/, PPARgamma/NN is/VBZ present/JJ in/IN macrophages/NNS in/IN human/JJ atherosclerotic/JJ lesions/NNS and/CC may/MD regulate/VB expression/NN and/CC activity/NN of/IN MMP-9/NN ,/, an/DT enzyme/NN implicated/VBN in/IN plaque/NN rupture/NN ./. 
PPARgamma/NN is/VBZ likely/JJ to/TO be/VB an/DT important/JJ regulator/NN of/IN monocyte/macrophage/NN function/NN with/IN relevance/NN for/IN human/JJ atherosclerotic/JJ disease/NN ./. 
UI/LS -/: 98322149/CD 
TI/LS -/: Erythropoietin/NN induces/VBZ tyrosine/NN phosphorylation/NN of/IN Jak2/NN ,/, STAT5A/NN ,/, and/CC STAT5B/NN in/IN primary/JJ cultured/VBN human/JJ erythroid/JJ precursors/NNS ./. 
AB/LS -/: We/PRP examined/VBD signaling/NN by/IN erythropoietin/NN in/IN highly/RB purified/VBN human/JJ colony/NN forming/NN unit-erythroid/JJ cells/NNS ,/, generated/VBN in/FW vitro/FW from/IN CD34(+)/JJ cells/NNS ./. 
We/PRP found/VBD that/IN erythropoietin/NN induces/VBZ tyrosine/NN phosphorylation/NN of/IN Jak2/NN ,/, STAT5A/NN ,/, and/CC STAT5B/NN ./. 
Tyrosine/NN phosphorylation/NN of/IN Jak2/NN reaches/VBZ a/DT peak/NN around/IN 10/CD minutes/NNS after/IN stimulation/NN and/CC is/VBZ maximum/JJ at/IN 5/CD U/mL/NN of/IN erythropoietin/NN ./. 
Tyrosine/NN phosphorylation/NN of/IN STAT5/NN is/VBZ accompanied/VBN by/IN the/DT translocation/NN of/IN activated/VBN STAT5/NN to/TO the/DT nucleus/NN as/IN shown/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN (/( EMSA/NN )/) using/VBG 32Pi-labeled/JJ STAT5/NN binding/NN site/NN in/IN the/DT beta-casein/NN promoter/NN ./. 
Tyrosine/NN phosphorylation/NN STAT1/NN or/CC STAT3/NN was/VBD not/RB detected/VBN in/IN human/JJ erythroid/JJ precursors/NNS after/IN stimulation/NN with/IN erythropoietin/NN ./. 
Crkl/NN ,/, an/DT SH2/SH3/NN adapter/NN protein/NN ,/, becomes/VBZ coimmunoprecipitated/VBN specifically/RB with/IN STAT5/NN from/IN erythropoietin-stimulated/JJ erythroid/JJ cells/NNS ;/: although/IN it/PRP was/VBD shown/VBN to/TO become/VB associated/VBN with/IN c-Cbl/NN in/IN the/DT studies/NNS using/VBG cell/NN lines/NNS ./. 
Thus/RB ,/, human/JJ erythroid/JJ precursors/NNS can/MD be/VB expanded/VBN in/FW vitro/FW in/IN sufficient/JJ numbers/NNS and/CC purity/NN to/TO allow/VB its/PRP$ usage/NN in/IN signal/NN transduction/NN studies/NNS ./. 
This/DT report/NN sets/VBZ a/DT basis/NN for/IN further/JJ studies/NNS on/IN signaling/NN in/IN primary/JJ cultured/VBN human/JJ erythroid/JJ precursors/NNS ,/, which/WDT in/IN turn/NN contribute/VBP to/TO our/PRP$ better/JJR understanding/NN in/IN the/DT differentiation/NN processes/NNS of/IN erythrocytes/NNS and/CC their/PRP$ precursors/NNS ./. 
UI/LS -/: 98311520/CD 
TI/LS -/: Oxidative/JJ stress/NN suppresses/VBZ transcription/NN factor/NN activities/NNS in/IN stimulated/VBN lymphocytes/NNS ./. 
AB/LS -/: Effects/NNS of/IN oxidative/JJ stress/NN on/IN stimulation-dependent/JJ signal/NN transduction/NN ,/, leading/VBG to/TO IL-2/NN expression/NN ,/, were/VBD studied/VBN ./. 
Purified/VBN quiescent/JJ human/JJ blood/NN T/NN lymphocytes/NNS were/VBD subjected/VBN to/TO :/: (/( i/LS )/) acute/JJ exposure/NN to/TO hydrogen/NN peroxide/NN ;/: (/( ii/LS )/) chronic/JJ exposure/NN to/TO hydrogen/NN peroxide/NN ;/: and/CC (/( iii/LS )/) acute/JJ exposure/NN to/TO ionizing/VBG radiation/NN ./. 
The/DT cells/NNS were/VBD then/RB stimulated/VBN for/IN 6/CD h/NN ./. 
DNA-binding/JJ activities/NNS (/( determined/VBN by/IN the/DT electrophoretic/JJ mobility/NN shift/NN assay/NN )/) of/IN three/CD transcription/NN factors/NNS :/: NFkappaB/NN ,/, AP-1/NN and/CC NFAT/NN ,/, were/VBD abolished/VBN in/IN the/DT lymphocytes/NNS by/IN all/DT three/CD modes/NNS of/IN oxidative/JJ stress/NN ./. 
The/DT lymphocytes/NNS exhibited/VBD lipid/NN peroxidation/NN only/RB upon/IN exposure/NN to/TO the/DT lowest/JJS level/NN of/IN hydrogen/NN peroxide/NN used/VBN (/( 20/CD microM/NN )/) ./. 
All/DT three/CD modes/NNS of/IN oxidative/JJ stress/NN induced/VBD catalase/NN activity/NN in/IN the/DT lymphocytes/NNS ./. 
The/DT only/RB exception/NN was/VBD hydrogen/NN peroxide/NN at/IN 20/CD microM/NN ,/, which/WDT did/VBD not/RB induce/VB catalase/NN activity/NN ./. 
We/PRP conclude/VBP that/IN :/: (/( i/LS )/) suppression/NN of/IN specific/JJ transcription/NN factor/NN functions/NNS can/MD potentially/RB serve/VB as/IN a/DT marker/NN of/IN exposure/NN to/TO oxidative/JJ stress/NN and/CC its/PRP$ effects/NNS on/IN human/JJ lymphocytes/NNS ;/: (/( ii/LS )/) lipid/NN peroxidation/NN is/VBZ only/RB detectable/JJ in/IN human/JJ lymphocytes/NNS upon/IN exposure/NN to/TO weak/JJ oxidative/JJ stress/NN which/WDT does/VBZ not/RB induce/VB catalase/NN activity/NN ;/: (/( iii/LS )/) therefore/RB ,/, transcription/NN factor/NN DNA-binding/JJ activities/NNS are/VBP more/RBR sensitive/JJ to/TO oxidative/JJ stress/NN than/IN lipid/NN peroxidation/NN ./. 
UI/LS -/: 98299642/CD 
TI/LS -/: IL-4-dependent/JJ regulation/NN of/IN TGF-alpha/NN and/CC TGF-beta1/NN expression/NN in/IN human/JJ eosinophils/NNS ./. 
AB/LS -/: TGFs/NNS play/VBP important/JJ roles/NNS in/IN wound/NN healing/NN and/CC carcinogenesis/NN ./. 
We/PRP have/VBP previously/RB demonstrated/VBN that/IN eosinophils/NNS infiltrating/VBG into/IN different/JJ pathologic/JJ processes/NNS elaborate/VBP TGF-alpha/NN and/CC TGF-beta1/NN ./. 
Eosinophils/NNS infiltrating/VBG hamster/NN cutaneous/JJ wounds/NNS were/VBD found/VBN to/TO express/VB TGFs/NNS sequentially/RB ./. 
In/IN this/DT study/NN ,/, we/PRP examined/VBD the/DT biologic/JJ mediators/NNS that/WDT may/MD regulate/VB the/DT expression/NN of/IN TGF-alpha/NN and/CC -beta1/NN by/IN eosinophils/NNS ./. 
Eosinophils/NNS were/VBD isolated/VBN from/IN the/DT peripheral/JJ blood/NN of/IN healthy/JJ donors/NNS and/CC cultured/VBN in/IN the/DT absence/NN or/CC presence/NN of/IN IL-3/NN ,/, IL-4/NN ,/, and/CC IL-5/NN ./. 
Cells/NNS were/VBD analyzed/VBN by/IN in/FW situ/FW hybridization/NN and/CC immunohistochemistry/NN ./. 
Supernatants/NNS from/IN these/DT cultures/NNS were/VBD assayed/VBN for/IN secreted/VBN TGF-alpha/NN and/CC TGF-beta1/NN using/VBG TGF-specific/JJ ELISAs/NNS ./. 
IL-3/NN ,/, IL-4/NN ,/, and/CC IL-5/NN independently/RB up-regulated/VBD TGF-beta1/NN mRNA/NN and/CC product/NN expression/NN by/IN eosinophils/NNS in/IN all/DT donors/NNS ./. 
Interestingly/RB ,/, TGF-alpha/NN production/NN by/IN eosinophils/NNS was/VBD up-regulated/VBN by/IN IL-3/NN and/CC IL-5/NN but/CC was/VBD down-regulated/VBN by/IN IL-4/NN ./. 
Consistent/JJ with/IN the/DT ability/NN of/IN IL-4/NN to/TO regulate/VB eosinophil/NN responses/NNS ,/, IL-4/NN signaling/NN molecules/NNS are/VBP present/JJ in/IN human/JJ eosinophils/NNS ./. 
The/DT observation/NN that/IN IL-4/NN can/MD differentially/RB regulate/VB the/DT expression/NN of/IN TGF-alpha/NN and/CC TGF-beta1/NN suggests/VBZ that/IN IL-4/NN may/MD serve/VB as/IN a/DT physiologic/JJ molecular/JJ switch/NN of/IN TGF/NN expression/NN by/IN the/DT infiltrating/VBG eosinophils/NNS in/IN wound/NN healing/NN and/CC carcinogenesis/NN ./. 
UI/LS -/: 98282210/CD 
TI/LS -/: MLL/NN and/CC CALM/NN are/VBP fused/VBN to/TO AF10/NN in/IN morphologically/RB distinct/JJ subsets/NNS of/IN acute/JJ leukemia/NN with/IN translocation/NN t(10;11)/NN :/: both/DT rearrangements/NNS are/VBP associated/VBN with/IN a/DT poor/JJ prognosis/NN ./. 
AB/LS -/: The/DT translocation/NN t(10;11)(p13;q14)/NN has/VBZ been/VBN observed/VBN in/IN acute/JJ lymphoblastic/JJ leukemia/NN (/( ALL/NN )/) as/RB well/RB as/IN acute/JJ myeloid/JJ leukemia/NN (/( AML/NN )/) ./. 
A/DT recent/JJ study/NN showed/VBD a/DT MLL/AF10/NN fusion/NN in/IN all/DT cases/NNS of/IN AML/NN with/IN t(10;11)/NN and/CC various/JJ breakpoints/NNS on/IN chromosome/NN 11/CD ranging/VBG from/IN q13/NN to/TO q23/NN ./. 
We/PRP recently/RB cloned/VBN CALM/NN (/( Clathrin/NN Assembly/NN Lymphoid/JJ Myeloid/JJ leukemia/NN gene/NN )/) ,/, the/DT fusion/NN partner/NN of/IN AF10/NN at/IN 11q14/NN in/IN the/DT monocytic/JJ cell/NN line/NN U937/NN ./. 
To/TO further/RB define/VB the/DT role/NN of/IN these/DT genes/NNS in/IN acute/JJ leukemias/NNS ,/, 10/CD cases/NNS (/( 9/CD AML/NN and/CC 1/CD ALL/NN )/) with/IN cytogenetically/RB proven/JJ t(10;11)(p12-14;q13-21)/NN and/CC well-characterized/VBD morphology/NN ,/, immunophenotype/NN ,/, and/CC clinical/JJ course/NN were/VBD analyzed/VBN ./. 
Interphase/NN fluorescence/NN in/FW situ/FW hybridization/NN (/( FISH/NN )/) was/VBD performed/VBN with/IN 2/CD YACs/NNS flanking/VBG the/DT CALM/NN region/NN ,/, a/DT YAC/NN contig/NN of/IN the/DT MLL/NN region/NN ,/, and/CC a/DT YAC/NN spanning/VBG the/DT AF10/NN breakpoint/NN ./. 
Rearrangement/NN of/IN at/IN least/JJS one/CD of/IN these/DT genes/NNS was/VBD detected/VBN in/IN all/DT cases/NNS with/IN balanced/JJ t(10;11)/NN ./. 
In/IN 4/CD cases/NNS ,/, including/VBG 3/CD AML/NN with/IN immature/JJ morphology/NN (/( 1/CD AML-M0/NN and/CC 2/CD AML-M1/NN )/) and/CC 1/CD ALL/NN ,/, the/DT signals/NNS of/IN the/DT CALM/NN YACS/NNS were/VBD separated/VBN in/IN interphase/NN cells/NNS ,/, indicating/VBG a/DT translocation/NN breakpoint/NN within/IN the/DT CALM/NN region/NN ./. 
MLL/NN was/VBD rearranged/VBN in/IN 3/CD AML/NN with/IN myelomonocytic/JJ differentiation/NN (/( 2/CD AML-M2/NN and/CC 1/CD AML-M5/NN )/) ,/, including/VBG 1/CD secondary/JJ AML/NN ./. 
In/IN all/DT 3/CD cases/NNS ,/, a/DT characteristic/JJ immunophenotype/NN was/VBD identified/VBN (/( CD4+/JJ ,/, CD13-/NN ,/, CD33+/JJ ,/, CD65s+/JJ )/) ./. 
AF-10/NN was/VBD involved/VBN in/IN 5/CD of/IN 6/CD evaluable/JJ cases/NNS ,/, including/VBG 1/CD case/NN without/IN detectable/JJ CALM/NN or/CC MLL/NN rearrangement/NN ./. 
In/IN 2/CD complex/NN translocations/NNS ,/, none/NN of/IN the/DT three/CD genes/NNS was/VBD rearranged/VBN ./. 
All/DT cases/NNS had/VBD a/DT remarkably/RB poor/JJ prognosis/NN ,/, with/IN a/DT mean/NN survival/NN of/IN 9.6/CD +/-/CC 6.6/CD months/NNS ./. 
For/IN the/DT 7/CD AML/NN cases/NNS that/WDT were/VBD uniformly/RB treated/VBN according/VBG to/TO the/DT AMLCG86/92/NN protocols/NNS ,/, disease-free/JJ and/CC overall/JJ survival/NN was/VBD significantly/RB worse/JJ than/IN for/IN the/DT overall/JJ study/NN group/NN (/( P/NN =/JJ .03/CD and/CC P/NN =/JJ .01/CD ,/, respectively/RB )/) ./. 
We/PRP conclude/VBP that/IN the/DT t(10;11)(p13;q14)/NN indicates/VBZ CALM/NN and/CC MLL/NN rearrangements/NNS in/IN morphologically/RB distinct/JJ subsets/NNS of/IN acute/JJ leukemia/NN and/CC may/MD be/VB associated/VBN with/IN a/DT poor/JJ prognosis/NN ./. 
UI/LS -/: 98282482/CD 
TI/LS -/: The/DT role/NN of/IN E-proteins/NNS in/IN B-/NN and/CC T-lymphocyte/NN development/NN ./. 
AB/LS -/: Department/NN of/IN lymphocytes/NNS from/IN hematopoietic/JJ stem/NN cells/NNS is/VBZ controlled/VBN ,/, in/IN part/NN ,/, by/IN the/DT activity/NN of/IN transcriptional/JJ regulatory/JJ proteins/NNS ./. 
In/IN particular/JJ ,/, one/CD class/NN of/IN helix-loop-helix/JJ proteins/NNS ,/, termed/VBN E-proteins/NNS ,/, have/VBP been/VBN implicated/VBN in/IN the/DT regulation/NN of/IN gene/NN expression/NN during/IN B-cell/NN development/NN ./. 
Recent/JJ analysis/NN of/IN gene-targeted/JJ mice/NNS has/VBZ allowed/VBN a/DT direct/JJ assessment/NN of/IN the/DT functional/JJ roles/NNS of/IN several/JJ E-protein/NN family/NN members/NNS in/IN hematopoiesis/NN ./. 
In/IN this/DT review/NN we/PRP describe/VBP the/DT defects/NNS in/IN B-/NN and/CC T-lymphocyte/NN development/NN in/IN mice/NNS carrying/VBG targeted/VBN mutations/NNS in/IN the/DT E-protein/NN genes/NNS and/CC discuss/VBP our/PRP$ current/JJ understanding/NN of/IN the/DT role/NN of/IN these/DT proteins/NNS in/IN lymphoid/JJ development/NN 
UI/LS -/: 98374313/CD 
TI/LS -/: Epstein-Barr/JJ virus-transforming/JJ protein/NN latent/JJ infection/NN membrane/NN protein/NN 1/CD activates/VBZ transcription/NN factor/NN NF-kappaB/NN through/IN a/DT pathway/NN that/WDT includes/VBZ the/DT NF-kappaB-inducing/NN kinase/NN and/CC the/DT IkappaB/NN kinases/NNS IKKalpha/NN and/CC IKKbeta/NN ./. 
AB/LS -/: The/DT Epstein-Barr/JJ virus/NN oncoprotein/NN latent/JJ infection/NN membrane/NN protein/NN 1/CD (/( LMP1/NN )/) is/VBZ a/DT constitutively/RB aggregated/VBN pseudo-tumor/NN necrosis/NN factor/NN receptor/NN (/( TNFR/NN )/) that/WDT activates/VBZ transcription/NN factor/NN NF-kappaB/NN through/IN two/CD sites/NNS in/IN its/PRP$ C-terminal/JJ cytoplasmic/JJ domain/NN ./. 
One/CD site/NN is/VBZ similar/JJ to/TO activated/VBN TNFRII/NN in/IN associating/VBG with/IN TNFR-associated/JJ factors/NNS TRAF1/NN and/CC TRAF2/NN ,/, and/CC the/DT second/JJ site/NN is/VBZ similar/JJ to/TO TNFRI/NN in/IN associating/VBG with/IN the/DT TNFRI/NN death/NN domain/NN interacting/VBG protein/NN TRADD/NN ./. 
TNFRI/NN has/VBZ been/VBN recently/RB shown/VBN to/TO activate/VB NF-kappaB/NN through/IN association/NN with/IN TRADD/NN ,/, RIP/NN ,/, and/CC TRAF2/NN ;/: activation/NN of/IN the/DT NF-kappaB-inducing/NN kinase/NN (/( NIK/NN )/) ;/: activation/NN of/IN the/DT IkappaB/NN alpha/NN kinases/NNS (/( IKKalpha/NN and/CC IKKbeta/NN )/) ;/: and/CC phosphorylation/NN of/IN IkappaB/NN alpha/NN ./. 
IkappaB/NN alpha/NN phosphorylation/NN on/IN Ser-32/NN and/CC Ser-36/NN is/VBZ followed/VBN by/IN its/PRP$ degradation/NN and/CC NF-kappaB/NN activation/NN ./. 
In/IN this/DT report/NN ,/, we/PRP show/VBP that/IN NF-kappaB/NN activation/NN by/IN LMP1/NN or/CC by/IN each/DT of/IN its/PRP$ effector/NN sites/NNS is/VBZ mediated/VBN by/IN a/DT pathway/NN that/WDT includes/VBZ NIK/NN ,/, IKKalpha/NN ,/, and/CC IKKbeta/NN ./. 
Dominant/JJ negative/JJ mutants/NNS of/IN NIK/NN ,/, IKKalpha/NN ,/, or/CC IKKbeta/NN substantially/RB inhibited/VBD NF-kappaB/NN activation/NN by/IN LMP1/NN or/CC by/IN each/DT of/IN its/PRP$ effector/NN sites/NNS ./. 
UI/LS -/: 98361309/CD 
TI/LS -/: Targeted/JJ disruption/NN of/IN the/DT MyD88/NN gene/NN results/VBZ in/IN loss/NN of/IN IL-1-/NN and/CC IL-18-mediated/JJ function/NN ./. 
AB/LS -/: MyD88/NN ,/, originally/RB isolated/VBN as/IN a/DT myeloid/JJ differentiation/NN primary/JJ response/NN gene/NN ,/, is/VBZ shown/VBN to/TO act/VB as/IN an/DT adaptor/NN in/IN interleukin-1/NN (/( IL-1/NN )/) signaling/NN by/IN interacting/VBG with/IN both/CC the/DT IL-1/NN receptor/NN complex/NN and/CC IL-1/NN receptor-associated/JJ kinase/NN (/( IRAK/NN )/) ./. 
Mice/NNS generated/VBN by/IN gene/NN targeting/NN to/TO lack/VB MyD88/NN have/VBP defects/VBZ in/IN T/NN cell/NN proliferation/NN as/RB well/RB as/IN induction/NN of/IN acute/JJ phase/NN proteins/NNS and/CC cytokines/NNS in/IN response/NN to/TO IL-1/NN ./. 
Increases/NNS in/IN interferon-gamma/NN production/NN and/CC natural/JJ killer/NN cell/NN activity/NN in/IN response/NN to/TO IL-18/NN are/VBP abrogated/VBN ./. 
In/FW vivo/FW Th1/NN response/NN is/VBZ also/RB impaired/JJ ./. 
Furthermore/RB ,/, IL-18-induced/JJ activation/NN of/IN NF-kappaB/NN and/CC c-Jun/NN N-terminal/JJ kinase/NN (/( JNK/NN )/) is/VBZ blocked/VBN in/IN MyD88-/-/JJ Th1-developing/NN cells/NNS ./. 
Taken/VBN together/RB ,/, these/DT results/NNS demonstrate/VBP that/IN MyD88/NN is/VBZ a/DT critical/JJ component/NN in/IN the/DT signaling/NN cascade/NN that/WDT is/VBZ mediated/VBN by/IN IL-1/NN receptor/NN as/RB well/RB as/IN IL-18/NN receptor/NN ./. 
UI/LS -/: 98353313/CD 
TI/LS -/: Ciprofloxacin/NN induces/VBZ an/DT immunomodulatory/JJ stress/NN response/NN in/IN human/JJ T/NN lymphocytes/NNS ./. 
AB/LS -/: Exposure/NN of/IN cells/NNS to/TO adverse/JJ environmental/JJ conditions/NNS invokes/VBZ a/DT genetically/RB programmed/VBN series/NNS of/IN events/NNS resulting/VBG in/IN the/DT induction/NN of/IN specific/JJ genes/NNS ./. 
The/DT fluoroquinolone/NN antibiotic/JJ ciprofloxacin/NN has/VBZ recently/RB been/VBN reported/VBN to/TO upregulate/VB interleukin-2/NN (/( IL-2/NN )/) gene/NN induction/NN ./. 
In/IN the/DT present/JJ investigation/NN ,/, the/DT effect/NN of/IN ciprofloxacin/NN at/IN supratherapeutic/JJ concentrations/NNS on/IN immediate-early/JJ (/( </JJR 2/CD h/NN )/) gene/NN expression/NN in/IN primary/JJ human/JJ peripheral/JJ blood/NN lymphocytes/NNS was/VBD studied/VBN with/IN Northern/NN blots/NNS ./. 
In/IN addition/NN ,/, transcriptional/JJ activity/NN of/IN IL-2/NN and/CC metallothionein/NN enhancer/NN and/CC promoter/NN regions/NNS and/CC transcription/NN factors/NNS AP-1/NN ,/, NF-kappaB/NN ,/, and/CC NF-AT/NN were/VBD analyzed/VBN by/IN chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) and/CC electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, respectively/RB ./. 
The/DT concentration/NN of/IN c-fos/NN ,/, c-jun/NN ,/, c-myc/NN ,/, junB/NN ,/, and/CC fra-1/NN mRNAs/NNS was/VBD increased/VBN in/IN activated/VBN peripheral/JJ blood/NN lymphocytes/NNS incubated/VBN with/IN ciprofloxacin/NN compared/VBN to/TO that/DT in/IN untreated/JJ controls/NNS ./. 
Ciprofloxacin/NN increased/VBD CAT/NN activity/NN in/IN stimulated/VBN lymphocytes/NNS transfected/VBN with/IN plasmids/NNS containing/VBG either/CC the/DT IL-2/NN or/CC metallothionein/NN enhancer/NN ./. 
Furthermore/RB ,/, among/IN the/DT transcription/NN factors/NNS tested/VBN ,/, AP-1/NN activity/NN was/VBD increased/VBN in/IN stimulated/VBN purified/VBN T/NN helper/NN lymphocytes/NNS incubated/VBN with/IN ciprofloxacin/NN compared/VBN to/TO drug-free/JJ controls/NNS ./. 
Taken/VBN together/RB ,/, ciprofloxacin/NN increased/VBD the/DT levels/NNS of/IN immediate-early/JJ transcripts/NNS ,/, enhanced/VBD IL-2/NN and/CC metallothionein/NN promoter/NN induction/NN ,/, and/CC upregulated/VBD AP-1/NN concentrations/NNS in/IN primary/JJ lymphocytes/NNS ,/, reflecting/VBG a/DT program/NN commonly/RB observed/VBN in/IN mammalian/JJ stress/NN responses/NNS ./. 
UI/LS -/: 98341858/CD 
TI/LS -/: A/DT novel/JJ retinoic/JJ acid/NN receptor/NN (/( RAR/NN )/) -selective/JJ antagonist/NN inhibits/VBZ differentiation/NN and/CC apoptosis/NN of/IN HL-60/NN cells/NNS :/: implications/NNS of/IN RARalpha-mediated/JJ signals/NNS in/IN myeloid/JJ leukemic/JJ cells/NNS ./. 
AB/LS -/: Retinoic/JJ acid/NN (/( RA/NN )/) induces/VBZ HL-60/NN cells/NNS to/TO differentiate/VB terminally/RB into/IN mature/JJ granulocytes/NNS ,/, which/WDT subsequently/RB die/VBP by/IN apoptosis/NN ./. 
The/DT biological/JJ effects/NNS of/IN RA/NN are/VBP mediated/VBN by/IN two/CD distinct/JJ families/NNS of/IN transcription/NN factors/NNS :/: retinoic/JJ acid/NN receptors/NNS (/( RARs/NNS )/) and/CC retinoid/NN X/NN receptors/NNS (/( RXRs/NNS )/) ./. 
RARs/NNS and/CC RXRs/NNS form/NN heterodimers/NNS and/CC regulate/VBP retinoid-mediated/JJ gene/NN expression/NN ./. 
We/PRP have/VBP recently/RB developed/VBN a/DT novel/JJ RAR-selective/JJ antagonist/NN (/( ER27191/NN )/) which/WDT prevents/VBZ RAR/NN activation/NN by/IN retinoids/NNS ./. 
Using/VBG this/DT RAR-selective/JJ antagonist/NN ,/, and/CC RXR/NN and/CC RAR/NN agonist/NN ,/, we/PRP demonstrate/VBP the/DT RAR-mediated/JJ signaling/NN pathway/NN is/VBZ important/JJ for/IN differentiation/NN and/CC apoptosis/NN of/IN myeloid/JJ leukemic/JJ cells/NNS ./. 
Simple/JJ activation/NN of/IN RXRs/NNS is/VBZ not/RB sufficient/JJ to/TO induce/VB apoptosis/NN of/IN the/DT cells/NNS ./. 
Interestingly/RB ,/, the/DT combination/NN of/IN the/DT RAR-selective/JJ antagonist/NN and/CC 9-cis/JJ RA/NN resulted/VBD in/IN partial/JJ differentiation/NN and/CC apoptosis/NN of/IN HL-60/NN and/CC NB4/NN cells/NNS ,/, whereas/IN the/DT RAR/NN antagonist/NN completely/RB blocked/VBD all-trans/JJ RA-induced/JJ differentiation/NN and/CC apoptosis/NN of/IN the/DT cells/NNS ./. 
Additional/JJ experiments/NNS showed/VBD that/IN levels/NNS of/IN BCL-2/NN protein/NN decreased/VBD during/IN differentiation/NN of/IN myeloid/JJ leukemic/JJ cells/NNS ./. 
Furthermore/RB ,/, HL-60/NN cells/NNS transduced/VBN with/IN a/DT bcl-2/NN expression/NN vector/NN showed/VBD the/DT same/JJ differentiation/NN response/NN to/TO retinoids/NNS as/IN did/VBD parental/JJ HL-60/NN cells/NNS even/RB though/IN apoptosis/NN was/VBD inhibited/VBN in/IN these/DT bcl-2-transduced/JJ cells/NNS ,/, suggesting/VBG that/IN differentiation/NN and/CC apoptosis/NN are/VBP regulated/VBN independently/RB in/IN myeloid/JJ leukemic/JJ cells/NNS ./. 
UI/LS -/: 98326600/CD 
TI/LS -/: Thrombopoietin/NN supports/VBZ in/FW vitro/FW erythroid/JJ differentiation/NN via/IN its/PRP$ specific/JJ receptor/NN c-Mpl/NN in/IN a/DT human/JJ leukemia/NN cell/NN line/NN ./. 
AB/LS -/: Thrombopoietin/NN (/( TPO/NN )/) acts/VBZ on/IN megakaryopoiesis/NN and/CC erythropoiesis/NN in/FW vitro/FW and/CC in/FW vivo/FW ./. 
We/PRP isolated/VBD a/DT novel/JJ subline/NN ,/, UT-7/GMT/NN ,/, from/IN the/DT human/JJ leukemia/NN cell/NN line/NN UT-7/GM/NN (/( N./NN Komatsu/NN ,/, et/FW al./FW ,/, Blood/NN ,/, 89/CD :/: 4021-4033/CD ,/, 1997/CD )/) ./. 
A/DT small/JJ population/NN of/IN UT-7/GM/NN cells/NNS positively/RB stained/VBN for/IN hemoglobin/NN (/( Hb/NN )/) after/IN a/DT 7-day/JJ exposure/NN to/TO TPO/NN ./. 
More/JJR than/IN 50/CD %/NN of/IN TPO-treated/JJ UT-7/GMT/NN cells/NNS positively/RB stained/VBN for/IN Hb/NN ./. 
Using/VBG UT-7/GMT/NN cells/NNS ,/, we/PRP examined/VBD how/WRB TPO/NN promotes/VBZ hemoglobinization/NN ./. 
TPO/NN induced/VBD tyrosine/NN phosphorylation/NN of/IN the/DT TPO/NN receptor/NN but/CC not/RB the/DT erythropoietin/NN (/( EPO/NN )/) receptor/NN ./. 
There/EX was/VBD no/DT competition/NN between/IN TPO/NN and/CC EPO/NN for/IN binding/NN to/TO EPO/NN receptor/NN ./. 
These/DT findings/NNS suggest/VBP that/IN TPO/NN has/VBZ a/DT direct/JJ effect/NN on/IN hemoglobinization/NN via/IN a/DT specific/JJ receptor/NN on/IN UT-7/GMT/NN cells/NNS ./. 
Isoelectric/JJ focusing/NN demonstrated/VBD that/IN TPO/NN induced/VBD fetal/JJ and/CC adult/JJ Hb/NN synthesis/NN ,/, whereas/IN EPO/NN induced/VBD embryonic/JJ ,/, fetal/JJ ,/, and/CC adult/JJ Hb/NN synthesis/NN ./. 
Thus/RB ,/, our/PRP$ data/NNS suggest/VBP that/IN TPO/NN has/VBZ a/DT distinct/JJ action/NN on/IN erythropoiesis/NN ./. 
UI/LS -/: 98322148/CD 
TI/LS -/: Role/NN of/IN GATA-1/NN in/IN proliferation/NN and/CC differentiation/NN of/IN definitive/JJ erythroid/JJ and/CC megakaryocytic/JJ cells/NNS in/FW vivo/FW ./. 
AB/LS -/: To/TO elucidate/VB the/DT contributions/NNS of/IN GATA-1/NN to/TO definitive/JJ hematopoiesis/NN in/FW vivo/FW ,/, we/PRP have/VBP examined/VBN adult/JJ mice/NNS that/WDT were/VBD rendered/VBN genetically/RB defective/JJ in/IN GATA-1/NN synthesis/NN (/( Takahashi/NNP et/FW al/FW ,/, J/NNP Biol/NNP Chem/NNP 272/CD :/: 12611/CD ,/, 1997/CD )/) ./. 
Because/IN the/DT GATA-1/NN gene/NN is/VBZ located/JJ on/IN the/DT X/NN chromosome/NN ,/, which/WDT is/VBZ randomly/RB inactivated/VBN in/IN every/JJ cell/NN ,/, heterozygous/JJ females/NNS can/MD bear/VB either/CC an/DT active/JJ wild-type/JJ or/CC mutant/JJ (/( referred/VBN to/TO as/IN GATA-1.05/NN )/) GATA-1/NN allele/NN ,/, consequently/RB leading/VBG to/TO variable/JJ anemic/JJ severity/NN ./. 
These/DT heterozygous/JJ mutant/JJ mice/NNS usually/RB developed/VBN normally/RB ,/, but/CC they/PRP began/VBD to/TO die/VB after/IN 5/CD months/NNS ./. 
These/DT affected/VBN animals/NNS displayed/VBD marked/JJ splenomegaly/NN ,/, anemia/NN ,/, and/CC thrombocytopenia/NN ./. 
Proerythroblasts/NNS and/CC megakaryocytes/NNS massively/RB accumulated/VBN in/IN the/DT spleens/NNS of/IN the/DT heterozygotes/NNS ,/, and/CC we/PRP showed/VBD that/IN the/DT neomycin/NN resistance/NN gene/NN (/( which/WDT is/VBZ the/DT positive/JJ selection/NN marker/NN in/IN ES/NN cells/NNS )/) was/VBD expressed/VBN profusely/RB in/IN the/DT abnormally/RB abundant/JJ cells/NNS generated/VBN in/IN the/DT GATA-1.05/NN mutant/JJ females/NNS ./. 
We/PRP also/RB observed/VBD hematopoiesis/NN outside/NN of/IN the/DT bone/NN marrow/NN in/IN the/DT affected/VBN mutant/JJ mice/NNS ./. 
These/DT data/NNS suggest/VBP that/IN a/DT small/JJ number/NN of/IN GATA-1.05/NN mutant/JJ hematopoietic/JJ progenitor/NN cells/NNS begin/VBP to/TO proliferate/VB vigorously/RB during/IN early/JJ adulthood/NN ,/, but/CC because/IN the/DT cells/NNS are/VBP unable/JJ to/TO terminally/RB differentiate/VB ,/, this/DT leads/VBZ to/TO progenitor/NN proliferation/NN in/IN the/DT spleen/NN and/CC consequently/RB death/NN ./. 
Thus/RB ,/, GATA-1/NN plays/VBZ important/JJ in/FW vivo/FW roles/NNS for/IN directing/VBG definitive/JJ hematopoietic/JJ progenitors/NNS to/TO differentiate/VB along/IN both/CC the/DT erythroid/JJ and/CC megakaryocytic/JJ pathways/NNS ./. 
The/DT GATA-1/NN heterozygous/JJ mutant/JJ mouse/NN shows/VBZ a/DT phenotype/NN that/WDT is/VBZ analogous/JJ to/TO human/JJ myelodysplastic/JJ syndrome/NN and/CC thus/RB may/MD serve/VB as/IN a/DT useful/JJ model/NN for/IN this/DT disorder/NN ./. 
UI/LS -/: 98309442/CD 
TI/LS -/: Differential/JJ regulation/NN of/IN the/DT Janus/NN kinase-STAT/NN pathway/NN and/CC biologic/JJ function/NN of/IN IL-13/NN in/IN primary/JJ human/JJ NK/NN and/CC T/NN cells/NNS :/: a/DT comparative/JJ study/NN with/IN IL-4/NN ./. 
AB/LS -/: IL-13/NN ,/, a/DT cytokine/NN similar/JJ to/TO IL-4/NN ,/, is/VBZ a/DT regulator/NN of/IN human/JJ B/NN cell/NN and/CC monocyte/NN functions/NNS ./. 
Biologic/JJ effects/NNS of/IN IL-13/NN on/IN primary/JJ human/JJ NK/NN and/CC T/NN cells/NNS have/VBP not/RB been/VBN well/RB defined/VBN ./. 
We/PRP demonstrate/VBP that/IN ,/, in/IN primary/JJ NK/NN cells/NNS ,/, IL-13/NN ,/, but/CC not/RB IL-4/NN ,/, may/MD induce/VB low/JJ levels/NNS of/IN IFN-gamma/NN secretion/NN ./. 
When/WRB NK/NN cells/NNS were/VBD costimulated/VBN with/IN IL-13/NN and/CC IL-2/NN ,/, IL-13/NN generally/RB resulted/VBD in/IN two/CD types/NNS of/IN reactivity/NN :/: IL-13/NN synergized/VBD with/IN IL-2/NN to/TO stimulate/VB IFN-gamma/NN production/NN or/CC it/PRP modestly/RB inhibited/VBD IL-2-/NN mediated/JJ IFN-gamma/NN production/NN ./. 
In/IN both/DT types/NNS of/IN donors/NNS ,/, the/DT effect/NN of/IN IL-13/NN on/IN IL-2-induced/JJ IFN-gamma/NN production/NN was/VBD in/IN marked/JJ contrast/NN to/TO the/DT strong/JJ inhibition/NN seen/VBN with/IN IL-4/NN in/IN NK/NN cells/NNS ./. 
Additionally/RB ,/, IL-13/NN suppresses/VBZ IL-2-induced/JJ NK/NN cytolytic/JJ and/CC proliferative/JJ activities/NNS although/IN less/JJR efficiently/RB than/IN IL-4/NN ./. 
In/IN T/NN cells/NNS ,/, IL-13/NN inhibits/VBZ anti-CD3/JJ mAb/IL-2-/NN or/CC PHA-mediated/JJ IFN-gamma/NN production/NN and/CC enhances/VBZ cytolytic/JJ potential/NN ./. 
Furthermore/RB ,/, we/PRP demonstrate/VBP that/IN IL-13/NN ,/, like/IN IL-4/NN ,/, induces/VBZ distinct/JJ STAT6-DNA/NN binding/NN complexes/NNS and/CC tyrosine/NN phosphorylation/NN of/IN STAT6/NN and/CC Janus/NN kinase/NN 3/CD (/( JAK3/NN )/) in/IN NK/NN and/CC T/NN cells/NNS ./. 
We/PRP observed/VBD that/IN Abs/NNS directed/VBN against/IN unique/JJ domains/NNS of/IN STAT6/NN have/VBP differential/JJ effects/NNS on/IN complexes/NNS in/IN T/NN cells/NNS but/CC not/RB in/IN NK/NN cells/NNS ,/, suggesting/VBG different/JJ STAT6/NN isoforms/NNS ./. 
These/DT findings/NNS show/VBP that/IN IL-13/NN and/CC IL-4/NN have/VBP the/DT ability/NN to/TO regulate/VB NK/NN and/CC T/NN cell/NN activation/NN and/CC that/IN IL-/NN 13/CD is/VBZ a/DT potent/JJ regulator/NN of/IN STAT6/NN and/CC JAK3/NN in/IN these/DT cell/NN types/NNS ./. 
UI/LS -/: 98290745/CD 
TI/LS -/: The/DT human/JJ toll/NN signaling/NN pathway/NN :/: divergence/NN of/IN nuclear/JJ factor/NN kappaB/NN and/CC JNK/SAPK/NN activation/NN upstream/RB of/IN tumor/NN necrosis/NN factor/NN receptor-associated/JJ factor/NN 6/CD (/( TRAF6/NN )/) ./. 
AB/LS -/: The/DT human/JJ homologue/NN of/IN Drosophila/FW Toll/NN (/( hToll/NN )/) is/VBZ a/DT recently/RB cloned/VBN receptor/NN of/IN the/DT interleukin/NN 1/CD receptor/NN (/( IL-1R/NN )/) superfamily/NN ,/, and/CC has/VBZ been/VBN implicated/VBN in/IN the/DT activation/NN of/IN adaptive/JJ immunity/NN ./. 
Signaling/NN by/IN hToll/NN is/VBZ shown/VBN to/TO occur/VB through/IN sequential/JJ recruitment/NN of/IN the/DT adapter/NN molecule/NN MyD88/NN and/CC the/DT IL-1R-associated/JJ kinase/NN ./. 
Tumor/NN necrosis/NN factor/NN receptor-activated/JJ factor/NN 6/CD (/( TRAF6/NN )/) and/CC the/DT nuclear/JJ factor/NN kappaB/NN (/( NF-kappaB/NN )/) -inducing/JJ kinase/NN (/( NIK/NN )/) are/VBP both/CC involved/VBN in/IN subsequent/JJ steps/NNS of/IN NF-kappaB/NN activation/NN ./. 
Conversely/RB ,/, a/DT dominant/JJ negative/JJ version/NN of/IN TRAF6/NN failed/VBD to/TO block/VB hToll-induced/JJ activation/NN of/IN stress-activated/JJ protein/NN kinase/c-Jun/NN NH2-terminal/JJ kinases/NNS ,/, thus/RB suggesting/VBG an/DT early/JJ divergence/NN of/IN the/DT two/CD pathways/NNS ./. 
UI/LS -/: 98282206/CD 
TI/LS -/: Inhibition/NN of/IN nuclear/JJ factor/NN kappaB/NN activation/NN attenuates/VBZ apoptosis/NN resistance/NN in/IN lymphoid/JJ cells/NNS ./. 
AB/LS -/: Death-inducing/NN ligands/NNS (/( DILs/NNS )/) such/JJ as/IN tumor/NN necrosis/NN factor/NN alpha/NN (/( TNFalpha/NN )/) or/CC the/DT cytotoxic/JJ drug/NN doxorubicin/NN have/VBP been/VBN shown/VBN to/TO activate/VB a/DT nuclear/JJ factor/NN kappaB/NN (/( NFkappaB/NN )/) -dependent/JJ program/NN that/WDT may/MD rescue/VB cells/NNS from/IN apoptosis/NN induction/NN ./. 
We/PRP demonstrate/VBP here/RB that/IN TRAIL/NN (/( TNF-related/JJ apoptosis-inducing/NN ligand/NN )/) ,/, a/DT recently/RB identified/VBN DIL/NN ,/, also/RB activates/VBZ NFkappaB/NN in/IN lymphoid/JJ cell/NN lines/NNS in/IN a/DT kinetic/JJ similar/JJ to/TO TNFalpha/NN ./. 
NFkappaB/NN activity/NN is/VBZ independent/JJ from/IN FADD/NN ,/, caspases/NNS ,/, and/CC apoptosis/NN induction/NN ./. 
To/TO study/VB the/DT influence/NN of/IN NFkappaB/NN activity/NN on/IN apoptosis/NN mediated/VBN by/IN TRAIL/NN ,/, CD95/NN ,/, TNFalpha/NN ,/, or/CC doxorubicin/NN ,/, NFkappaB/NN activation/NN was/VBD inhibited/VBN using/VBG the/DT proteasome/NN inhibitor/NN N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal/NN or/CC transient/JJ overexpression/NN of/IN mutant/JJ IkappaBalpha/NN ./. 
Sensitivity/NN for/IN induction/NN of/IN apoptosis/NN was/VBD markedly/RB increased/VBN by/IN these/DT treatments/NNS in/IN apoptosis/NN sensitive/JJ cell/NN lines/NNS ./. 
Moreover/RB ,/, both/CC in/IN cell/NN lines/NNS and/CC in/IN primary/JJ leukemia/NN cells/NNS that/WDT are/VBP resistant/JJ towards/IN induction/NN of/IN apoptosis/NN by/IN DILs/NN and/CC doxorubicin/NN ,/, antagonization/NN of/IN NFkappaB/NN activity/NN partially/RB restored/VBD apoptosis/NN sensitivity/NN ./. 
These/DT data/NNS suggest/VBP that/IN inhibition/NN of/IN NFkappaB/NN activation/NN may/MD provide/VB a/DT molecular/JJ approach/NN to/TO increase/VB apoptosis/NN sensitivity/NN in/IN anticancer/JJ treatment/NN ./. 
UI/LS -/: 98282481/CD 
TI/LS -/: Loss-/NN and/CC gain-of-function/NN mutations/NNS reveal/VBP an/DT important/JJ role/NN of/IN BSAP/NN (/( Pax-5/NN )/) at/IN the/DT start/NN and/CC end/NN of/IN B/NN cell/NN differentiation/NN ./. 
AB/LS -/: Pax-5/NN codes/VBZ for/IN the/DT transcription/NN factor/NN BSAP/NN which/WDT is/VBZ expressed/VBN throughout/IN B/NN cell/NN development/NN except/NN in/IN terminally/RB differentiated/VBN plasma/NN cells/NNS ./. 
Gene/NN targeting/NN experiments/NNS in/IN the/DT mouse/NN revealed/VBD a/DT differential/JJ dependency/NN of/IN fetal/JJ and/CC adult/JJ B-lymphopoiesis/NN on/IN this/DT transcription/NN factor/NN ./. 
BSAP/NN is/VBZ required/VBN for/IN B-lineage/NN commitment/NN in/IN the/DT fetal/JJ liver/NN and/CC for/IN progression/NN beyond/IN an/DT early/JJ pro-B/NN cell/NN stage/NN in/IN adult/JJ bone/NN marrow/NN ./. 
The/DT characterization/NN of/IN Pax-5-deficient/JJ pro-B/NN cells/NNS demonstrated/VBD an/DT important/JJ role/NN of/IN BSAP/NN in/IN the/DT regulation/NN of/IN the/DT CD19/NN ,/, mb-1/NN (/( Ig/NN alpha/NN )/) and/CC N-myc/NN genes/NNS as/RB well/RB as/IN in/IN the/DT developmental/JJ pathway/NN controlling/VBG VH-to-DHJH/JJ recombination/NN at/IN the/DT immunoglobulin/NN heavy-chain/JJ (/( IgH/NN )/) locus/NN ./. 
The/DT human/JJ PAX-5/NN gene/NN was/VBD recently/RB shown/VBN to/TO participate/VB together/RB with/IN the/DT IgH/NN locus/NN in/IN the/DT chromosomal/JJ translocation/NN t(9;14)(p13;q32)/NN ./. 
This/DT translocation/NN is/VBZ characteristic/JJ of/IN a/DT small/JJ subset/NN of/IN non-Hodgkin/JJ lymphomas/NNS exhibiting/VBG plasmacytoid/JJ differentiation/NN ./. 
The/DT translocated/JJ PAX-5/NN gene/NN is/VBZ deregulated/VBN by/IN the/DT insertion/NN of/IN IgH/NN regulatory/JJ elements/NNS into/IN its/PRP$ 5'/JJ region/NN ,/, which/WDT may/MD contribute/VB to/TO tumorigenesis/NN by/IN interfering/VBG with/IN the/DT shut-down/NN of/IN PAX-5/NN transcription/NN and/CC thus/RB with/IN the/DT completion/NN of/IN plasma/NN cell/NN differentiation/NN 
UI/LS -/: 98374270/CD 
TI/LS -/: Acetylation/NN and/CC modulation/NN of/IN erythroid/JJ Kruppel-like/JJ factor/NN (/( EKLF/NN )/) activity/NN by/IN interaction/NN with/IN histone/NN acetyltransferases/NNS ./. 
AB/LS -/: Erythroid/JJ Kruppel-like/JJ factor/NN (/( EKLF/NN )/) is/VBZ a/DT red/JJ cell-specific/JJ transcriptional/JJ activator/NN that/WDT is/VBZ crucial/JJ for/IN consolidating/VBG the/DT switch/NN to/TO high/JJ levels/NNS of/IN adult/JJ beta-globin/NN expression/NN during/IN erythroid/JJ ontogeny/NN ./. 
EKLF/NN is/VBZ required/VBN for/IN integrity/NN of/IN the/DT chromatin/NN structure/NN at/IN the/DT beta-like/JJ globin/NN locus/NN ,/, and/CC it/PRP interacts/VBZ with/IN a/DT positive-acting/JJ factor/NN in/FW vivo/FW ./. 
We/PRP find/VBP that/IN EKLF/NN is/VBZ an/DT acetylated/VBN transcription/NN factor/NN ,/, and/CC that/IN it/PRP interacts/VBZ in/FW vivo/FW with/IN CBP/NN ,/, p300/NN ,/, and/CC P/CAF/NN ./. 
However/RB ,/, its/PRP$ interactions/NNS with/IN these/DT histone/NN acetyltransferases/NNS are/VBP not/RB equivalent/JJ ,/, as/IN CBP/NN and/CC p300/NN ,/, but/CC not/RB P/CAF/NN ,/, utilize/VBP EKLF/NN as/IN a/DT substrate/NN for/IN in/FW vitro/FW acetylation/NN within/IN its/PRP$ trans-activation/NN region/NN ./. 
The/DT functional/JJ effects/NNS of/IN these/DT interactions/NNS are/VBP that/IN CBP/NN and/CC p300/NN ,/, but/CC not/RB P/CAF/NN ,/, enhance/VBP EKLF/NN 's/POS transcriptional/JJ activation/NN of/IN the/DT beta-globin/NN promoter/NN in/IN erythroid/JJ cells/NNS ./. 
These/DT results/NNS establish/VBP EKLF/NN as/IN a/DT tissue-specific/JJ transcription/NN factor/NN that/WDT undergoes/VBZ post-translational/JJ acetylation/NN and/CC suggest/VBP a/DT mechanism/NN by/IN which/WDT EKLF/NN is/VBZ able/JJ to/TO alter/VB chromatin/NN structure/NN and/CC induce/VB beta-globin/NN expression/NN within/IN the/DT beta-like/JJ globin/NN cluster/NN ./. 
UI/LS -/: 98362153/CD 
TI/LS -/: Recognition/NN of/IN herpes/NN simplex/NN virus/NN type/NN 2/CD tegument/NN proteins/NNS by/IN CD4/NN T/NN cells/NNS infiltrating/VBG human/JJ genital/JJ herpes/NN lesions/NNS ./. 
AB/LS -/: The/DT local/JJ cellular/JJ immune/JJ response/NN to/TO herpes/NN simplex/NN virus/NN (/( HSV/NN )/) is/VBZ important/JJ in/IN the/DT control/NN of/IN recurrent/JJ HSV/NN infection/NN ./. 
The/DT antiviral/JJ functions/NNS of/IN infiltrating/VBG CD4-bearing/JJ T/NN cells/NNS may/MD include/VBP cytotoxicity/NN ,/, inhibition/NN of/IN viral/JJ growth/NN ,/, lymphokine/NN secretion/NN ,/, and/CC support/NN of/IN humoral/JJ and/CC CD8/NN responses/NNS ./. 
The/DT antigens/NNS recognized/VBN by/IN many/JJ HSV-specific/JJ CD4/NN T/NN cells/NNS localizing/VBG to/TO genital/JJ HSV-2/NN lesions/NNS are/VBP unknown/JJ ./. 
T/NN cells/NNS recognizing/VBG antigens/NNS encoded/VBN within/IN map/NN units/NNS 0/CD ./. 67/CD to/TO 0.73/CD of/IN HSV/NN DNA/NN are/VBP frequently/RB recovered/VBN from/IN herpetic/JJ lesions/NNS ./. 
Expression/NN cloning/NN with/IN this/DT region/NN of/IN DNA/NN now/RB shows/VBZ that/IN tegument/NN protein/NN VP22/NN and/CC the/DT viral/JJ dUTPase/NN ,/, encoded/VBN by/IN genes/NNS UL49/NN and/CC UL50/NN ,/, respectively/RB ,/, are/VBP T-cell/NN antigens/NNS ./. 
Separate/JJ epitopes/NNS in/IN VP22/NN were/VBD defined/VBN for/IN T-cell/NN clones/NNS from/IN each/DT of/IN three/CD patients/NNS ./. 
Reactivity/NN with/IN the/DT tegument/JJ protein/NN encoded/VBN by/IN UL21/NN was/VBD identified/VBN for/IN an/DT additional/JJ patient/NN ./. 
Three/CD new/JJ epitopes/NNS were/VBD identified/VBN in/IN VP16/NN ,/, a/DT tegument/JJ protein/NN associated/VBN with/IN VP22/NN ./. 
Some/DT tegument-specific/JJ CD4/NN T-cell/NN clones/NNS exhibited/VBD cytotoxic/JJ activity/NN against/IN HSV-infected/JJ cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN herpes/NN simplex/NN tegument/NN proteins/NNS are/VBP processed/VBN for/IN antigen/NN presentation/NN in/FW vivo/FW and/CC are/VBP possible/JJ candidate/NN compounds/NNS for/IN herpes/NN simplex/NN vaccines/NNS ./. 
UI/LS -/: 98349401/CD 
TI/LS -/: Fibrinogen/NN activates/VBZ NF-kappa/NN B/NN transcription/NN factors/NNS in/IN mononuclear/JJ phagocytes/NNS ./. 
AB/LS -/: Adhesion/NN to/TO extracellular/JJ matrices/NNS is/VBZ known/VBN to/TO modulate/VB leukocyte/NN activation/NN ,/, although/IN the/DT mechanisms/NNS are/VBP not/RB fully/RB understood/VBN ./. 
Mononuclear/JJ phagocytes/NNS are/VBP exposed/VBN to/TO fibrinous/JJ provisional/JJ matrix/NN throughout/IN migration/NN into/IN inflammatory/JJ foci/NNS ,/, so/RB this/DT study/NN was/VBD undertaken/VBN to/TO determine/VB whether/IN fibrinogen/NN triggers/VBZ activation/NN of/IN NF-kappa/NN B/NN transcription/NN factors/NNS ./. 
U937/NN cells/NNS differentiated/VBN with/IN PMA/NN in/IN nonadherent/JJ culture/NN were/VBD shown/VBN to/TO express/VB two/CD fibrinogen-binding/JJ integrins/NNS ,/, predominately/RB CD11b/CD18/NN ,/, and/CC to/TO a/DT lesser/JJR extent/NN ,/, CD11c/CD18/NN ./. 
Cells/NNS stimulated/VBN with/IN fibrinogen/NN (/( 10-100/CD microg/ml/NN )/) /Mn2+/JJ (/( 50/CD microM/NN )/) for/IN 2/CD h/NN were/VBD examined/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
NF-kappa/NN B/NN activation/NN ,/, minimal/JJ in/IN unstimulated/JJ cells/NNS ,/, was/VBD substantially/RB up-regulated/VBN by/IN fibrinogen/NN ./. 
Fibrinogen/NN also/RB caused/VBD activation/NN of/IN AP-1/NN ,/, but/CC not/RB SP1/NN or/CC cAMP/NN response/NN element-binding/JJ protein/NN (/( CREB/NN )/) factors/NNS ./. 
Blocking/NN mAbs/NNS against/IN CD18/NN and/CC CD11b/NN abrogated/VBD fibrinogen-induced/JJ NF-kappa/NN B/NN activation/NN ./. 
To/TO determine/VB the/DT effects/NNS on/IN transcriptional/JJ regulation/NN ,/, U937/NN cells/NNS were/VBD transfected/VBN with/IN a/DT plasmid/NN containing/VBG the/DT HIV-1/NN enhancer/NN (/( bearing/VBG two/CD NF-kappa/NN B/NN sites/NNS )/) coupled/VBN to/TO a/DT chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) reporter/NN ./. 
Cells/NNS were/VBD subsequently/RB stimulated/VBN with/IN 1/LS )/) PMA/NN for/IN 24/CD h/NN ,/, inducing/VBG CAT/NN activity/NN by/IN 2.6-fold/JJ ,/, 2/LS )/) fibrinogen/Mn2+/NN for/IN 2/CD h/NN ,/, inducing/VBG CAT/NN activity/NN by/IN 3.2-fold/JJ ,/, or/CC 3/LS )/) costimulation/NN with/IN fibrinogen/NN and/CC PMA/NN ,/, inducing/VBG 5.7-fold/JJ the/DT CAT/NN activity/NN induced/VBN by/IN PMA/NN alone/RB ./. 
We/PRP conclude/VBP that/IN contact/NN with/IN fibrinogen-derived/JJ proteins/NNS may/MD contribute/VB to/TO mononuclear/JJ phagocyte/NN activation/NN by/IN signaling/NN through/IN CD11b/CD18/NN ,/, resulting/VBG in/IN selective/JJ activation/NN of/IN transcriptional/JJ regulatory/JJ factors/NNS ,/, including/VBG NF-kappa/NN B/NN ./. 
UI/LS -/: 98339383/CD 
TI/LS -/: Peripheral/JJ blood/NN T/NN cells/NNS and/CC monocytes/NNS and/CC B/NN cell/NN lines/NNS derived/VBN from/IN patients/NNS with/IN lupus/NN express/VBP estrogen/NN receptor/NN transcripts/NNS similar/JJ to/TO those/DT of/IN normal/JJ cells/NNS ./. 
AB/LS -/: OBJECTIVE/NN :/: To/TO identify/VB and/CC characterize/VB estrogen/NN receptor/NN (/( ER/NN )/) transcripts/NNS expressed/VBN in/IN immune/JJ cells/NNS of/IN patients/NNS with/IN systemic/JJ lupus/NN erythematosus/NN (/( SLE/NN )/) and/CC healthy/JJ donors/NNS ./. 
METHODS/NNS :/: Peripheral/JJ blood/NN monocytes/NNS and/CC T/NN cells/NNS were/VBD prepared/VBN from/IN patients/NNS with/IN SLE/NN (/( n/NN =/JJ 6/CD )/) and/CC healthy/JJ donors/NNS (/( n/NN =/JJ 8/CD )/) ./. 
T/NN cells/NNS were/VBD separated/VBN into/IN CD4/NN and/CC CD8/NN ./. 
Some/DT monocytes/NNS and/CC T/NN cells/NNS were/VBD stimulated/VBN with/IN estradiol/NN ,/, PMA/NN ,/, and/CC ionomycin/NN ./. 
Epstein-Barr/JJ virus-transformed/JJ B/NN cell/NN lines/NNS (/( n/NN =/JJ 7/CD )/) and/CC B/NN cell/NN hybridomas/NNS (/( n/NN =/JJ 2/LS )/) established/VBN from/IN patients/NNS with/IN SLE/NN and/CC a/DT healthy/JJ individual/JJ were/VBD used/VBN as/IN a/DT B/NN cell/NN source/RB ./. 
These/DT cells/NNS were/VBD examined/VBN for/IN ER/NN mRNA/NN by/IN reverse/JJ transcription/NN nested/JJ polymerase/NN chain/NN reaction/NN ./. 
Amplified/JJ cDNA/NN were/VBD sequenced/VBN by/IN standard/JJ methods/NNS ./. 
RESULTS/NNS :/: In/IN all/DT cells/NNS tested/VBN ,/, ER/NN mRNA/NN was/VBD expressed/VBN without/IN prior/JJ in/FW vitro/FW stimulation/NN ./. 
Partial/JJ sequences/NNS from/IN exons/NNS 1-8/CD were/VBD nearly/RB identical/JJ to/TO the/DT published/VBN sequence/NN of/IN the/DT human/JJ ER/NN mRNA/NN ./. 
There/EX were/VBD no/DT notable/JJ differences/NNS in/IN the/DT ER/NN transcripts/NNS between/IN patients/NNS and/CC healthy/JJ controls/NNS ./. 
Variant/JJ receptor/NN transcripts/NNS lacking/VBG exon/NN 5/CD or/CC exon/NN 7/CD ,/, which/WDT encodes/VBZ the/DT hormone/NN binding/NN domain/NN ,/, were/VBD identified/VBN in/IN the/DT majority/NN of/IN the/DT cells/NNS ./. 
Precise/JJ deletion/NN of/IN the/DT exons/NNS suggests/VBZ that/IN they/PRP are/VBP alternatively/RB spliced/VBN transcripts/NNS ./. 
Whether/IN the/DT detected/JJ transcripts/NNS are/VBP translated/VBN into/IN functional/JJ receptor/NN proteins/NNS remains/VBZ to/TO be/VB determined/VBN ./. 
In/FW vitro/FW stimulation/NN did/VBD not/RB affect/VB ER/NN mRNA/NN expression/NN ./. 
The/DT presence/NN of/IN variants/NNS did/VBD not/RB correlate/VB with/IN disease/NN activity/NN or/CC medication/NN ./. 
CONCLUSION/NN :/: Monocytes/NNS ,/, T/NN cells/NNS ,/, and/CC B/NN cells/NNS in/IN patients/NNS express/VBP transcripts/NNS of/IN the/DT normal/JJ wild/JJ type/NN ER/NN and/CC the/DT hormone/NN binding/NN domain/NN variants/NNS in/FW vivo/FW ./. 
UI/LS -/: 98325368/CD 
TI/LS -/: DNA/NN damaging/NN agents/NNS induce/VBP expression/NN of/IN Fas/NN ligand/NN and/CC subsequent/JJ apoptosis/NN in/IN T/NN lymphocytes/NNS via/IN the/DT activation/NN of/IN NF-kappa/NN B/NN and/CC AP-1/NN ./. 
AB/LS -/: Apoptosis/NN induced/VBN by/IN DNA/NN damage/NN and/CC other/JJ stresses/NNS can/MD proceed/VB via/IN expression/NN of/IN Fas/NN ligand/NN (/( FasL/NN )/) and/CC ligation/NN of/IN its/PRP$ receptor/NN ,/, Fas/NN (/( CD95/NN )/) ./. 
We/PRP report/VBP that/IN activation/NN of/IN the/DT two/CD transcription/NN factors/NNS NF-kappa/NN B/NN and/CC AP-1/NN is/VBZ crucially/RB involved/VBN in/IN FasL/NN expression/NN induced/VBN by/IN etoposide/NN ,/, teniposide/NN ,/, and/CC UV/NN irradiation/NN ./. 
A/DT nondegradable/JJ mutant/NN of/IN I/NN kappa/NN B/NN blocked/VBD both/CC FasL/NN expression/NN and/CC apoptosis/NN induced/VBN by/IN DNA/NN damage/NN but/CC not/RB Fas/NN ligation/NN ./. 
These/DT stimuli/NNS also/RB induced/VBD the/DT stress-activated/JJ kinase/NN pathway/NN (/( SAPK/JNK/NN )/) ,/, which/WDT was/VBD required/VBN for/IN the/DT maximal/JJ induction/NN of/IN apoptosis/NN ./. 
A/DT 1.2/CD kb/NN FasL/NN promoter/NN responded/VBD to/TO DNA/NN damage/NN ,/, as/RB well/RB as/IN coexpression/NN with/IN p65/NN Rel/NN or/CC Fos/Jun/NN ./. 
Mutations/NNS in/IN the/DT relevant/JJ NF-kappa/NN B/NN and/CC AP-1/NN binding/NN sites/NNS eliminated/VBD these/DT responses/NNS ./. 
Thus/RB ,/, activation/NN of/IN NF-kappa/NN B/NN and/CC AP-1/NN contributes/VBZ to/TO stress-induced/JJ apoptosis/NN via/IN the/DT expression/NN of/IN FasL/NN ./. 
UI/LS -/: 98322350/CD 
TI/LS -/: A/DT small/JJ ,/, nonpeptidyl/JJ mimic/NN of/IN granulocyte-colony-stimulating/JJ factor/NN [/( see/VB commetns/NNS ]/) 
AB/LS -/: A/DT nonpeptidyl/JJ small/JJ molecule/NN SB/NN 247464/CD ,/, capable/JJ of/IN activating/VBG granulocyte-colony-stimulating/JJ factor/NN (/( G-CSF/NN )/) signal/NN transduction/NN pathways/NNS ,/, was/VBD identified/VBN in/IN a/DT high-throughput/JJ assay/NN in/IN cultured/VBN cells/NNS ./. 
Like/IN G-CSF/NN ,/, SB/NN 247464/CD induced/VBD tyrosine/NN phosphorylation/NN of/IN multiple/JJ signaling/NN proteins/NNS and/CC stimulated/VBN primary/JJ murine/JJ bone/NN marrow/NN cells/NNS to/TO form/VB granulocytic/JJ colonies/NNS in/FW vitro/FW ./. 
It/PRP also/RB elevated/JJ peripheral/JJ blood/NN neutrophil/NN counts/NNS in/IN mice/NNS ./. 
The/DT extracellular/JJ domain/NN of/IN the/DT murine/JJ G-CSF/NN receptor/NN was/VBD required/VBN for/IN the/DT activity/NN of/IN SB/NN 247464/CD ,/, suggesting/VBG that/IN the/DT compound/NN acts/VBZ by/IN oligomerizing/VBG receptor/NN chains/NNS ./. 
The/DT results/NNS indicate/VBP that/IN a/DT small/JJ molecule/NN can/MD activate/VB a/DT receptor/NN that/WDT normally/RB binds/VBZ a/DT relatively/RB large/JJ protein/NN ligand/NN ./. 
UI/LS -/: 98305722/CD 
TI/LS -/: Minimal/JJ residual/JJ disease/NN in/IN acute/JJ myelogenous/JJ leukemia/NN with/IN PML/RAR/NN alpha/NN or/CC AML1/ETO/NN mRNA/NN and/CC phenotypic/JJ analysis/NN of/IN possible/JJ T/NN and/CC natural/JJ killer/NN cells/NNS in/IN bone/NN marrow/NN ./. 
AB/LS -/: Here/RB we/PRP studied/VBN minimal/JJ residual/JJ disease/NN (/( MRD/NN )/) of/IN patients/NNS with/IN acute/JJ myeloid/JJ leukemia/NN (/( AML/NN )/) who/WP have/VBP PML/RAR/NN alpha/NN or/CC AML1/ETO/NN as/RB well/RB as/IN the/DT phenotypic/JJ analysis/NN of/IN lymphocyte/NN subsets/NNS involved/VBN in/IN antitumor/NN immunity/NN ./. 
Eight/CD patients/NNS in/IN long-term/JJ (/( LT/JJ ;/: 3/CD to/TO 15/CD years/NNS )/) and/CC 15/CD patients/NNS in/IN short-term/JJ (/( ST/JJ ;/: up/RB to/TO 3/CD years/NN )/) remission/NN were/VBD studied/VBN ./. 
Using/VBG the/DT reverse/JJ transcription-polymerase/NN chain/NN reaction/NN (/( RT/NN )/) assay/NN ,/, the/DT limit/NN of/IN detection/NN was/VBD 10(-5)/CD to/TO 10(-6)/CD for/IN PML/RAR/NN alpha/NN transcript/NN and/CC 10(-4)/CD to/TO 10(-5)/CD for/IN the/DT AML1/ETO/NN transcript/NN ./. 
Simultaneously/RB ,/, T/NN lymphocyte/NN subsets/NNS and/CC NK/NN cells/NNS from/IN the/DT peripheral/JJ blood/NN (/( PB/NN )/) and/CC bone/NN marrow/NN (/( BM/NN )/) were/VBD investigated/VBN by/IN flow/NN cytometric/JJ analysis/NN ./. 
Four/CD of/IN the/DT eight/CD patients/NNS in/IN LT/JJ and/CC 7/CD of/IN the/DT 15/CD patients/NNS in/IN ST/JJ remission/NN were/VBD MRD-positive/JJ ./. 
Although/IN all/DT MRD-positive/JJ patients/NNS in/IN LT/JJ remission/NN are/VBP still/RB until/IN now/RB event-free/RB ,/, 3/CD of/IN the/DT 7/CD MRD-positive/JJ (/( MRD+/JJ )/) patients/NNS in/IN ST/JJ remission/NN soon/IN relapsed/NN ./. 
The/DT total/JJ populations/NNS of/IN CD4+/JJ ,/, CD8+/JJ and/CC CD56+/JJ [/( possible/JJ T-cell/NN and/CC natural/JJ killer/NN (/( T/NK/NN )/) populations/NNS ]/) in/IN the/DT BM/NN of/IN ST/JJ patients/NNS and/CC MRD+/LT/JJ patients/NNS were/VBD significantly/RB (/( p/NN </JJR .01/CD )/) low/JJ ./. 
The/DT CD8+/JJ CD28+/JJ population/NN showed/VBD the/DT same/JJ tendency/NN (/( p/NN </JJR .01-.02/CD )/) ./. 
The/DT T/NK/NN subsets/NNS in/IN the/DT BM/NN of/IN MRD-negative/JJ (/( MRD-/JJ )/) LT/JJ (/( MRD-/LT/JJ )/) patients/NNS showed/VBD similar/JJ numbers/NNS of/IN cells/NNS as/IN normal/JJ volunteers/NNS ./. 
Basically/RB ,/, the/DT total/JJ percentage/NN of/IN the/DT CD4+/JJ ,/, CD8+/JJ and/CC CD56+/JJ cell/NN populations/NNS in/IN the/DT BM/NN was/VBD increased/VBN and/CC in/IN the/DT following/VBG order/NN :/: MRD-/LT/JJ patients/NNS ,/, normal/JJ volunteers/NNS ,/, MRD+/LT/JJ patients/NNS and/CC MRD+/JJ or/CC -/ST/JJ patients/NNS ./. 
The/DT percentages/NNS of/IN the/DT T/NK-cell/NN subsets/NNS in/IN the/DT PB/NN were/VBD not/RB significantly/RB different/JJ among/IN these/DT groups/NNS ./. 
Thus/RB ,/, the/DT difference/NN of/IN the/DT possible/JJ T/NK-cell/JJ phenotype/NN in/IN the/DT BM/NN may/MD strongly/RB influence/VB clinical/JJ and/CC molecular/JJ remission/NN ./. 
These/DT results/NNS still/RB remain/VBP to/TO be/VB confirmed/VBN by/IN further/JJ studies/NNS of/IN the/DT functional/JJ anti-tumor/JJ immunity/NN of/IN T/NK/NN cells/NNS of/IN AML/NN in/IN remission/NN ./. 
UI/LS -/: 98295832/CD 
TI/LS -/: Mycobacterium/FW tuberculosis/FW mannose-capped/JJ lipoarabinomannan/NN can/MD induce/VB NF-kappaB-dependent/JJ activation/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD long/JJ terminal/JJ repeat/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Tuberculosis/NN has/VBZ emerged/VBN as/IN an/DT epidemic/JJ ,/, extended/VBN by/IN the/DT large/JJ number/NN of/IN individuals/NNS infected/VBN with/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) ./. 
The/DT major/JJ goal/NN of/IN this/DT study/NN was/VBD to/TO determine/VB whether/IN the/DT mycobacterial/JJ cell/NN wall/NN component/NN mannose-capped/JJ lipoarabinomannan/NN (/( ManLAM/NN )/) of/IN Mycobacterium/FW tuberculosis/FW (/( M./FW tuberculosis/FW )/) could/MD activate/VB transcription/NN of/IN HIV-1/NN in/IN T/NN cells/NNS with/IN the/DT use/NN of/IN an/DT in/FW vitro/FW cell/NN culture/NN system/NN ./. 
These/DT experiments/NNS are/VBP of/IN prime/JJ importance/NN considering/VBG that/IN CD4-expressing/JJ T/NN lymphocytes/NNS represent/VBP the/DT major/JJ virus/NN reservoir/NN in/IN the/DT peripheral/JJ blood/NN of/IN infected/JJ individuals/NNS ./. 
Using/VBG the/DT 1G5/NN cell/NN line/NN harbouring/VBG the/DT luciferase/NN reporter/NN gene/NN under/IN the/DT control/NN of/IN the/DT HIV-1/NN LTR/NN ,/, it/PRP was/VBD first/RB found/VBN that/IN culture/NN protein/NN filtrates/NNS (/( CFP/NNS )/) from/IN M./FW tuberculosis/FW or/CC purified/VBN ManLAM/NN could/MD activate/VB HIV-1/NN LTR-dependent/JJ gene/NN expression/NN unlike/IN similarly/RB prepared/VBN CFP/NN extracts/NNS devoid/JJ of/IN ManLAM/NN ./. 
The/DT implication/NN of/IN protein/NN tyrosine/NN kinase/NN (/( s/NNS )/) ,/, protein/NN kinase/NN A/NN and/or/CC protein/NN kinase/NN C/NN was/VBD highlighted/VBN by/IN the/DT abrogation/NN of/IN the/DT ManLAM-mediated/JJ activation/NN of/IN HIV-1/NN LTR-driven/JJ gene/NN expression/NN using/VBG herbimycin/NN A/NN and/CC H7/NN ./. 
It/PRP was/VBD also/RB determined/VBN ,/, using/VBG electrophoresis/NN mobility/NN shift/NN assays/NNS ,/, that/IN M./FW tuberculosis/FW ManLAM/NN led/VBD to/TO the/DT nuclear/JJ translocation/NN of/IN the/DT transcription/NN factor/NN NF-kappaB/NN ./. 
M./FW tuberculosis/FW ManLAM/NN resulted/VBD in/IN clear/JJ induction/NN of/IN the/DT luciferase/NN gene/NN placed/VBN under/IN the/DT control/NN of/IN the/DT wild-type/JJ ,/, but/CC not/RB the/DT kappaB-mutated/JJ ,/, HIV-1/NN LTR/NN region/NN ./. 
Finally/RB ,/, the/DT ManLAM-mediated/JJ activation/NN of/IN HIV-1/NN LTR/NN transcription/NN was/VBD found/VBN to/TO be/VB independent/JJ of/IN the/DT autocrine/JJ or/CC paracrine/JJ action/NN of/IN endogenous/JJ TNF-alpha/NN ./. 
The/DT results/NNS suggest/VBP that/IN M./FW tuberculosis/FW can/MD upregulate/VB HIV-1/NN expression/NN in/IN T/NN cells/NNS and/CC could/MD thus/RB have/VB the/DT potential/NN to/TO influence/VB the/DT pathogenesis/NN of/IN HIV-1/NN infection/NN ./. 
UI/LS -/: 98230439/CD 
TI/LS -/: Human/JJ immunodeficiency/NN virus/NN type/NN 1/CD long/JJ terminal/JJ repeat/NN quasispecies/NNS differ/VBP in/IN basal/JJ transcription/NN and/CC nuclear/JJ factor/NN recruitment/NN in/IN human/JJ glial/JJ cells/NNS and/CC lymphocytes/NNS ./. 
AB/LS -/: The/DT generation/NN of/IN genomic/JJ diversity/NN during/IN the/DT course/NN of/IN infection/NN has/VBZ the/DT potential/NN to/TO affect/VB all/DT aspects/NNS of/IN HIV-1/NN replication/NN ,/, including/VBG expression/NN of/IN the/DT proviral/JJ genome/NN ./. 
To/TO gain/VB a/DT better/JJR understanding/NN of/IN the/DT impact/NN of/IN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) sequence/NN diversity/NN on/IN LTR-directed/JJ gene/NN expression/NN in/IN cells/NNS of/IN the/DT central/JJ nervous/JJ system/NN (/( CNS/NN )/) and/CC immune/JJ system/NN ,/, we/PRP amplified/VBD and/CC cloned/VBN LTRs/NNS from/IN proviral/JJ DNA/NN in/IN HIV-1-infected/JJ peripheral/JJ blood/NN ./. 
Sequence/NN analysis/NN of/IN nineteen/CD LTRs/NNS cloned/VBN from/IN 2/CD adult/JJ and/CC 3/CD pediatric/JJ patients/NNS revealed/VBD an/DT average/NN of/IN 33/CD nucleotide/NN changes/NNS (/( with/IN respect/NN to/TO the/DT sequence/NN of/IN the/DT LAI/NN LTR/NN )/) within/IN the/DT 455-bp/JJ U3/NN region/NN ./. 
Transient/JJ expression/NN analyses/NNS in/IN cells/NNS of/IN neuroglial/JJ and/CC lymphocytic/JJ origin/NN demonstrated/VBD that/IN some/DT of/IN these/DT LTRs/NNS had/VBD activities/NNS which/WDT varied/VBD significantly/RB from/IN the/DT LAI/NN LTR/NN in/IN U-373/NN MG/NN cells/NNS (/( an/DT astrocytoma/NN cell/NN line/NN )/) as/RB well/RB as/IN in/IN Jurkat/NN cells/NNS (/( a/DT CD4-/JJ positive/JJ lymphocyte/NN cell/NN line/NN )/) ./. 
While/IN LTRs/NNS which/WDT demonstrated/VBD the/DT highest/JJS activities/NNS in/IN U-373/NN MG/NN cells/NNS also/RB yielded/VBD high/JJ activities/NNS in/IN Jurkat/NN cells/NNS ,/, the/DT LTRs/NNS were/VBD generally/RB more/RBR active/JJ in/IN Jurkat/NN cells/NNS when/WRB compared/VBN to/TO the/DT LAI/NN LTR/NN ./. 
Differences/NNS in/IN LTR/NN sequence/NN also/RB resulted/VBD in/IN differences/NNS in/IN transcription/NN factor/NN recruitment/NN to/TO cis-acting/JJ sites/NNS within/IN the/DT U3/NN region/NN of/IN the/DT LTR/NN ,/, as/IN demonstrated/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ./. 
In/IN particular/JJ ,/, naturally/RB occurring/VBG sequence/NN variation/NN impacted/JJ transcription/NN factor/NN binding/VBG to/TO an/DT activating/VBG transcription/NN factor/cAMP/NN response/NN element/NN binding/NN (/( ATF/CREB/NN )/) binding/NN site/NN (/( located/JJ between/IN the/DT LEF-1/NN and/CC distal/JJ NF-kappaB/NN transcription/NN factor/NN binding/NN sites/NNS )/) that/WDT we/PRP identified/VBN in/IN previous/JJ studies/NNS of/IN the/DT HIV-1/NN LTR/NN ./. 
These/DT findings/NNS suggest/VBP that/IN LTR/NN sequence/NN changes/NNS can/MD significantly/RB affect/VB basal/JJ LTR/NN function/NN and/CC transcription/NN factor/NN recruitment/NN ,/, which/WDT may/MD ,/, in/IN turn/NN ,/, alter/VB the/DT course/NN of/IN viral/JJ replication/NN in/IN cells/NNS of/IN CNS/NN and/CC immune/JJ system/NN origin/NN ./. 
UI/LS -/: 98282480/CD 
TI/LS -/: HMG/NN box/NN containing/VBG transcription/NN factors/NNS in/IN lymphocyte/NN differentiation/NN ./. 
AB/LS -/: The/DT identification/NN of/IN the/DT mammalian/JJ sex-determining/JJ gene/NN Sry/NN has/VBZ led/VBN to/TO the/DT discovery/NN of/IN a/DT large/JJ family/NN of/IN related/JJ (/( '/`` HMG/NN box/NN '/'' )/) transcription/NN factors/NNS that/WDT control/VBP developmental/JJ events/NNS in/IN yeast/NN ,/, C./FW elegans/FW ,/, Drosophila/FW and/CC vertebrates/NNS ./. 
In/IN lymphocyte/NN differentiation/NN ,/, several/JJ HMG/NN box/NN proteins/NNS play/VBP a/DT decisive/JJ role/NN ./. 
Sox-4/NN is/VBZ important/JJ for/IN very/RB early/JJ B-cell/NN differentiation/NN ,/, while/IN TCF-1/LEF-1/NN play/VBP a/DT crucial/JJ role/NN in/IN early/JJ thymocyte/NN development/NN ./. 
TCF/LEF/NN proteins/NNS have/VBP recently/RB been/VBN found/VBN to/TO constitute/VB a/DT downstream/JJ component/NN of/IN the/DT Wingless/Wnt/NN signal/NN transduction/NN pathway/NN ./. 
In/IN flies/NNS ,/, this/DT pathway/NN controls/VBZ segment/NN polarity/NN ;/: in/IN Xenopus/FW it/PRP controls/VBZ the/DT definition/NN of/IN the/DT body/NN axis/NN ./. 
Deregulation/NN of/IN the/DT pathway/NN occurs/VBZ in/IN several/JJ human/JJ tumors/NNS ./. 
These/DT insights/VBZ in/IN the/DT molecular/JJ events/NNS that/WDT are/VBP involved/VBN in/IN TCF/LEF/NN function/NN in/IN these/DT organisms/NNS may/MD eventually/RB lead/VB to/TO the/DT understanding/NN of/IN the/DT function/NN of/IN these/DT HMG/NN box/NN proteins/NNS in/IN lymphoid/JJ development/NN 
UI/LS -/: 93315600/CD 
TI/LS -/: Single/JJ strand/NN conformation/NN polymorphism/NN analysis/NN of/IN androgen/NN receptor/NN gene/NN mutations/NNS in/IN patients/NNS with/IN androgen/NN insensitivity/NN syndromes/NNS :/: application/NN for/IN diagnosis/NN ,/, genetic/JJ counseling/NN ,/, and/CC therapy/NN ./. 
AB/LS -/: Recent/JJ studies/NNS indicate/VBP that/IN mutations/NNS in/IN the/DT androgen/NN receptor/NN gene/NN are/VBP associated/VBN with/IN androgen/NN insensitivity/NN syndromes/NNS ,/, a/DT heterogeneous/JJ group/NN of/IN related/JJ disorders/NNS involving/VBG defective/JJ sexual/JJ differentiation/NN in/IN karyotypic/JJ males/NNS ./. 
In/IN this/DT report/NN ,/, we/PRP address/VBP the/DT possibility/NN of/IN rapid/JJ mutational/JJ analysis/NN of/IN the/DT androgen/NN receptor/NN gene/NN for/IN initial/JJ diagnosis/NN ,/, genetic/JJ counseling/NN ,/, and/CC molecular/JJ subclassification/NN of/IN affected/VBN patients/NNS and/CC their/PRP$ families/NNS ./. 
DNA/NN from/IN peripheral/JJ blood/NN leukocytes/NNS of/IN six/CD patients/NNS from/IN five/CD families/NNS with/IN various/JJ degrees/NNS of/IN androgen/NN insensitivity/NN was/VBD studied/VBN ./. 
Exons/NNS 2/CD to/TO 8/CD of/IN the/DT androgen/NN receptor/NN gene/NN were/VBD analyzed/VBN using/VBG a/DT combination/NN of/IN single/JJ strand/NN conformation/NN polymorphism/NN analysis/NN and/CC direct/JJ DNA/NN sequencing/NN ./. 
Female/JJ family/NN members/NNS were/VBD also/RB studied/VBN to/TO identify/VB heterozygote/NN carriers/NNS ./. 
Point/NN mutations/NNS in/IN the/DT AR/NN gene/NN were/VBD identified/VBN in/IN all/DT six/CD patients/NNS ,/, and/CC all/DT mutations/NNS caused/VBD amino/NN acid/NN substitutions/NNS ./. 
One/CD patient/NN with/IN incomplete/JJ androgen/NN insensitivity/NN was/VBD a/DT mosaic/NN for/IN the/DT mutation/NN ./. 
Four/CD of/IN the/DT five/CD mothers/NNS ,/, as/RB well/RB as/IN a/DT young/JJ sister/NN of/IN one/CD patient/NN ,/, were/VBD carriers/NNS of/IN the/DT mutation/NN present/JJ in/IN the/DT affected/VBN child/NN ./. 
Our/PRP$ data/NNS show/VBP that/IN new/JJ mutations/NNS may/MD occur/VB in/IN the/DT androgen/NN receptor/NN gene/NN leading/VBG to/TO sporadic/JJ androgen/NN insensitivity/NN syndrome/NN ./. 
Molecular/JJ genetic/JJ characterization/NN of/IN the/DT variant/JJ allele/NN can/MD serve/VB as/IN a/DT primary/JJ tool/NN for/IN diagnosis/NN and/CC subsequent/JJ therapy/NN ,/, and/CC can/MD provide/VB a/DT basis/NN for/IN distinguishing/VBG heterozygous/JJ carriers/NNS in/IN familial/JJ androgen/NN resistance/NN ./. 
The/DT identification/NN of/IN carriers/NNS is/VBZ of/IN substantial/JJ clinical/JJ importance/NN for/IN genetic/JJ counseling/NN ./. 
UI/LS -/: 93284506/CD 
TI/LS -/: Proliferation/NN index/NN as/IN a/DT prognostic/JJ marker/NN in/IN breast/NN cancer/NN ./. 
AB/LS -/: BACKGROUND/NN ./. 
The/DT proliferative/JJ activity/NN of/IN tumors/NNS has/VBZ been/VBN extensively/RB investigated/VBN with/IN different/JJ approaches/NNS ,/, among/IN which/WDT the/DT use/NN of/IN the/DT monoclonal/JJ antibody/NN Ki-67/NN represents/VBZ an/DT easy/JJ and/CC reliable/JJ means/NN of/IN assessing/VBG cell/NN proliferation/NN ./. 
In/IN this/DT study/NN ,/, the/DT proliferative/JJ activity/NN of/IN 129/CD primary/JJ breast/NN cancers/NNS was/VBD investigated/VBN ,/, and/CC the/DT results/NNS were/VBD related/JJ to/TO prognosis/NN ./. 
METHODS/NNS ./. 
Tumor/NN samples/NNS ,/, obtained/VBN from/IN 129/CD patients/NNS who/WP underwent/VBD surgery/NN between/IN January/NNP 1987/CD and/CC December/NNP 1988/CD ,/, were/VBD processed/VBN for/IN staining/VBG by/IN an/DT immunohistochemical/JJ procedure/NN (/( avidin-biotin/NN complex/NN )/) ./. 
The/DT median/JJ time/NN of/IN observation/NN was/VBD 42/CD months/NNS (/( range/NN ,/, 31-55/CD months/NNS )/) ./. 
Life-table/JJ analysis/NN (/( Mantel-Cox/NN )/) was/VBD used/VBN to/TO assess/VB the/DT probability/NN of/IN disease-free/JJ survival/NN (/( DFS/NN )/) and/CC overall/JJ survival/NN (/( OS/NN )/) ./. 
RESULTS/NNS ./. 
Tumors/NNS with/IN high/JJ Ki-67/NN proliferation/NN indices/NNS (/( >/JJR 20/CD %/NN )/) were/VBD associated/VBN with/IN a/DT higher/JJR 4-year/JJ probability/NN of/IN relapse/NN of/IN disease/NN (/( 55.3/CD %/NN versus/CC 79.1/CD %/NN ;/: P/NN =/JJ 0.003/CD )/) and/CC death/NN (/( 71/CD %/NN versus/CC 95.6/CD %/NN ;/: P/NN =/JJ 0.00005/CD )/) when/WRB compared/VBN with/IN tumors/NNS with/IN low/JJ Ki-67/NN values/NNS ./. 
In/IN addition/NN ,/, this/DT proliferative/JJ parameter/NN maintained/VBD its/PRP$ prognostic/JJ significance/NN when/WRB the/DT patients/NNS were/VBD stratified/VBN according/VBG to/TO lymph/NN node/NN involvement/NN ,/, menopausal/JJ status/NN ,/, and/CC nuclear/JJ estrogen/NN receptor/NN content/NN ./. 
CONCLUSIONS/NNS ./. 
Tumor/NN proliferative/JJ activity/NN as/IN evaluated/VBN by/IN the/DT monoclonal/JJ antibody/NN Ki-67/NN seems/VBZ to/TO be/VB an/DT effective/JJ indicator/NN of/IN prognosis/NN in/IN breast/NN cancer/NN for/IN DFS/NN and/CC OS/NN ./. 
UI/LS -/: 93262492/CD 
TI/LS -/: Regulation/NN of/IN the/DT Ets-related/JJ transcription/NN factor/NN Elf-1/NN by/IN binding/VBG to/TO the/DT retinoblastoma/NN protein/NN ./. 
AB/LS -/: The/DT retinoblastoma/NN gene/NN product/NN (/( Rb/NN )/) is/VBZ a/DT nuclear/JJ phosphoprotein/NN that/WDT regulates/VBZ cell/NN cycle/NN progression/NN ./. 
Elf-1/NN is/VBZ a/DT lymphoid-specific/JJ Ets/NN transcription/NN factor/NN that/WDT regulates/VBZ inducible/JJ gene/NN expression/NN during/IN T/NN cell/NN activation/NN ./. 
In/IN this/DT report/NN ,/, it/PRP is/VBZ demonstrated/VBN that/IN Elf-1/NN contains/VBZ a/DT sequence/NN motif/NN that/WDT is/VBZ highly/RB related/JJ to/TO the/DT Rb/NN binding/NN sites/NNS of/IN several/JJ viral/JJ oncoproteins/NNS and/CC binds/VBZ to/TO the/DT pocket/NN region/NN of/IN Rb/NN both/CC in/FW vitro/FW and/CC in/FW vivo/FW ./. 
Elf-1/NN binds/VBZ exclusively/RB to/TO the/DT underphosphorylated/JJ form/NN of/IN Rb/NN and/CC fails/VBZ to/TO bind/VB to/TO Rb/NN mutants/NNS derived/VBN from/IN patients/NNS with/IN retinoblastoma/NN ./. 
Co-immunoprecipitation/NN experiments/NNS demonstrated/VBD an/DT association/NN between/IN Elf-1/NN and/CC Rb/NN in/IN resting/VBG normal/JJ human/JJ T/NN cells/NNS ./. 
After/IN T/NN cell/NN activation/NN ,/, the/DT phosphorylation/NN of/IN Rb/NN results/VBZ in/IN the/DT release/NN of/IN Elf-1/NN ,/, which/WDT is/VBZ correlated/VBN temporally/RB with/IN the/DT activation/NN of/IN Elf-1-mediated/JJ transcription/NN ./. 
Overexpression/NN of/IN a/DT phosphorylation-defective/JJ form/NN of/IN Rb/NN inhibited/VBD Elf-1-dependent/JJ transcription/NN during/IN T/NN cell/NN activation/NN ./. 
These/DT results/NNS demonstrate/VBP that/IN Rb/NN interacts/VBZ specifically/RB with/IN a/DT lineage-restricted/JJ Ets/NN transcription/NN factor/NN ./. 
This/DT regulated/JJ interaction/NN may/MD be/VB important/JJ for/IN the/DT coordination/NN of/IN lineage-specific/JJ effector/NN functions/NNS such/JJ as/IN lymphokine/NN production/NN with/IN cell/NN cycle/NN progression/NN in/IN activated/VBN T/NN cells/NNS ./. 
UI/LS -/: 93238864/CD 
TI/LS -/: Human/JJ CD3-CD16+/JJ natural/JJ killer/NN cells/NNS express/VBP the/DT hGATA-3/NN T/NN cell/NN transcription/NN factor/NN and/CC an/DT unrearranged/JJ 2.3-kb/JJ TcR/NN delta/NN transcript/NN ./. 
AB/LS -/: In/IN this/DT study/NN we/PRP analyzed/VBD the/DT T/NN cell/NN receptor/NN (/( TcR/NN )/) delta/NN transcripts/NNS expressed/VBN by/IN CD3-CD16+/JJ cells/NNS and/CC we/PRP investigated/VBD whether/IN these/DT cells/NNS expressed/VBD the/DT hGATA-3/NN T/NN cell/NN transcription/NN factor/NN and/CC the/DT recombination-activating/JJ gene/NN (/( RAG/NN )/) -1/CD ./. 
Multiple/JJ TcR/NN delta/NN transcripts/NNS deriving/VBG from/IN an/DT unrearranged/JJ TcR/NN delta/NN gene/NN were/VBD detected/VBN in/IN both/CC polyclonal/JJ and/CC clonal/JJ CD3-CD16+/JJ natural/JJ killer/NN (/( NK/NN )/) cell/NN lines/NNS ./. 
Two/CD unrearranged/JJ TcR/NN delta/NN transcripts/NNS had/VBD a/DT size/NN similar/JJ to/TO that/DT of/IN the/DT functional/JJ TcR/NN delta/NN mRNA/NN (/( 2.3/CD and/CC 1.3/CD kb/NN )/) found/VBN in/IN TcR/NN gamma/delta+/JJ T/NN lymphocytes/NNS ./. 
Sequence/NN analysis/NN of/IN nine/CD different/JJ 2.3-kb/JJ cDNA/NN clones/NNS obtained/VBN from/IN NK-derived/JJ polyA+/JJ RNA/NN confirmed/VBD that/IN they/PRP corresponded/VBD to/TO an/DT unrearranged/JJ TcR/NN delta/NN gene/NN ./. 
These/DT cDNA/NN were/VBD 2343/CD bp/NN long/JJ and/CC their/PRP$ transcription/NN initiation/NN site/NN was/VBD located/JJ 814/CD bp/NN upstream/RB from/IN the/DT J/NN delta/NN 1/CD segment/NN ./. 
The/DT sequence/NN located/JJ upstream/RB of/IN the/DT J/NN delta/NN 1/CD segment/NN corresponded/VBD to/TO the/DT previously/RB reported/VBN germ-line/JJ sequence/NN ./. 
The/DT J/NN delta/NN 1/CD segment/NN was/VBD correctly/RB spliced/VBN to/TO C/NN delta/NN ;/: in/IN addition/NN the/DT four/CD C/NN delta/NN exons/NNS were/VBD found/VBN to/TO be/VB already/RB assembled/VBN ./. 
Two/CD polyadenylation/NN sites/NNS were/VBD present/JJ in/IN the/DT fourth/JJ C/NN delta/NN exon/NN ./. 
However/RB ,/, only/JJ that/WDT located/JJ at/IN the/DT 3'/JJ end/NN appeared/VBD to/TO be/VB utilized/VBN in/IN the/DT 2.3-kb/JJ cDNA/NN ./. 
The/DT expression/NN of/IN hGATA-3/NN ,/, a/DT T/NN cell-specific/JJ factor/NN known/VBN to/TO be/VB involved/VBN in/IN the/DT regulation/NN of/IN the/DT transcription/NN of/IN TcR/NN delta/NN locus/NN ,/, was/VBD analyzed/VBN by/IN Northern/NN blot/NN ,/, in/IN cultured/VBN NK/NN cell/NN population/NN and/CC clones/NNS (/( but/CC not/RB in/IN freshly/RB derived/VBN cell/NN populations/NNS )/) ./. 
All/DT NK/NN clones/NNS and/CC cell/NN lines/NNS studied/VBN were/VBD found/VBN to/TO express/VB hGATA-3-specific/JJ mRNA/NN ,/, suggesting/VBG that/IN hGATA-3/NN may/MD be/VB involved/VBN in/IN the/DT regulation/NN of/IN the/DT unrearranged/JJ TcR/NN delta/NN gene/NN expression/NN in/IN NK/NN cells/NNS ./. 
Finally/RB ,/, no/DT transcription/NN of/IN the/DT RAG-1/NN gene/NN could/MD be/VB detected/VBN in/IN all/DT NK/NN cell/NN lines/NNS or/CC clones/NNS analyzed/VBN ./. 
UI/LS -/: 93232271/CD 
TI/LS -/: Negative/JJ transcriptional/JJ regulation/NN of/IN human/JJ interleukin/NN 2/CD (/( IL-2/NN )/) gene/NN by/IN glucocorticoids/NNS through/IN interference/NN with/IN nuclear/JJ transcription/NN factors/NNS AP-1/NN and/CC NF-AT/NN ./. 
AB/LS -/: IL-2/NN gene/NN transcription/NN is/VBZ affected/VBN by/IN several/JJ nuclear/JJ proteins/NNS ./. 
We/PRP asked/VBD whether/IN dexamethasone/NN (/( Dex/NN )/) and/CC cyclosporin/NN A/NN (/( CsA/NN )/) inhibit/VBP IL-2/NN gene/NN transcription/NN by/IN interfering/VBG with/IN the/DT activity/NN of/IN nuclear/JJ proteins/NNS that/WDT bind/VBP to/TO the/DT IL-2/NN promoter/NN ./. 
Nuclear/JJ extracts/NNS from/IN primary/JJ human/JJ T/NN lymphocytes/NNS were/VBD analyzed/VBN by/IN electrophoretic/JJ DNA/NN mobility/NN shift/NN assays/NNS ./. 
Both/CC Dex/NN and/CC CsA/NN inhibited/VBD the/DT binding/NN of/IN transcription/NN factors/NNS AP-1/NN and/CC NF-AT/NN ,/, but/CC not/RB of/IN NF-kB/NN and/CC OCT-1/OAF/NN ,/, to/TO their/PRP$ corresponding/JJ sites/NNS on/IN the/DT IL-2/NN gene/NN promoter/NN ./. 
To/TO correlate/VB changes/NNS in/IN nuclear/JJ factor/NN binding/NN in/FW vitro/FW with/IN transcriptional/JJ activity/NN in/FW vivo/FW and/CC define/VB the/DT structural/JJ requirements/NNS for/IN IL-2/NN promoter/NN repression/NN ,/, we/PRP used/VBD transient/JJ DNA/NN transfections/NNS ./. 
Jurkat/NN cells/NNS were/VBD transfected/VBN with/IN plasmids/NNS containing/VBG either/CC the/DT intact/JJ IL-2/NN promoter/NN or/CC its/PRP$ AP-1/NN ,/, NF-AT/NN ,/, and/CC NF-kB/NN motifs/NNS ./. 
Dex/NN inhibited/VBD the/DT IL-2/NN promoter/NN and/CC the/DT AP-1/NN ,/, but/CC not/RB the/DT NF-AT/NN and/CC NF-kB/NN plasmids/NNS ./. 
In/IN contrast/NN ,/, CsA/NN inhibited/VBD the/DT IL-2/NN promoter/NN and/CC the/DT NF-AT/NN ,/, but/CC not/RB the/DT AP-1/NN and/CC NF-kB/NN plasmids/NNS ./. 
These/DT results/NNS suggest/VBP that/IN in/IN human/JJ T/NN lymphocytes/NNS both/CC Dex/NN and/CC CsA/NN inhibited/VBD IL-2/NN gene/NN transcription/NN through/IN interference/NN with/IN transcription/NN factors/NNS AP-1/NN and/CC NF-AT/NN ./. 
We/PRP propose/VBP that/IN ,/, while/IN maximum/NN inhibition/NN may/MD involve/VB interaction/NN with/IN both/DT transcription/NN factors/NNS ,/, AP-1/NN is/VBZ the/DT primary/JJ target/NN of/IN Dex/NN ./. 
UI/LS -/: 93322080/CD 
TI/LS -/: Nuclear/JJ factor/NN kappa/NN B/NN ,/, a/DT mediator/NN of/IN lipopolysaccharide/NN effects/NNS ./. 
AB/LS -/: Exposure/NN of/IN certain/JJ cell/NN types/NNS to/TO bacterial/JJ lipopolysaccharide/NN (/( LPS/NN )/) leads/VBZ to/TO activation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ,/, an/DT inducible/JJ transcription/NN factor/NN ./. 
One/CD of/IN NF-kappa/NN B/NN 's/POS unique/JJ properties/NNS is/VBZ its/PRP$ posttranslational/JJ activation/NN via/IN release/NN of/IN an/DT inhibitory/JJ subunit/NN ,/, called/VBN inhibitor/NN of/IN NF-kappa/NN B/NN (/( I/NN kappa/NN B/NN )/) ,/, from/IN a/DT sequestered/JJ cytoplasmic/JJ form/NN ./. 
This/DT event/NN is/VBZ also/RB triggered/VBN under/IN various/JJ other/JJ conditions/NNS of/IN biomedical/JJ importance/NN ./. 
Other/JJ bacterial/JJ toxins/NNS ,/, tumor/NN necrosis/NN factor-alpha/NN (/( TNF/NN )/) ,/, interleukin-1/NN (/( IL-1/NN )/) ,/, T/NN cell/NN mitogens/NNS ,/, UV/NN light/NN ,/, gamma/NN rays/NNS and/CC oxidative/JJ stress/NN were/VBD reported/VBN to/TO induce/VB NF-kappa/NN B/NN ./. 
The/DT activated/JJ form/NN of/IN NF-kappa/NN B/NN ,/, which/WDT is/VBZ rapidly/RB taken/VBN up/RP into/IN nuclei/NNS ,/, initiates/VBZ transcription/NN from/IN immediate/JJ early/JJ genes/NNS in/IN a/DT wide/JJ variety/NN of/IN cell/NN types/NNS ./. 
Most/JJS of/IN the/DT target/NN genes/NNS for/IN NF-kappa/NN B/NN are/VBP of/IN relevance/NN for/IN the/DT immune/JJ response/NN and/CC can/MD be/VB grouped/VBN into/IN those/DT encoding/JJ cytokines/NNS ,/, cell/NN surface/NN receptors/NNS ,/, acute/JJ phase/NN proteins/NNS and/CC viral/JJ genomes/NNS ,/, such/JJ as/IN that/DT of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) ./. 
We/PRP will/MD discuss/VB recent/JJ experimental/JJ evidences/NNS suggesting/VBG that/IN LPS/NN might/MD share/VB a/DT pathway/NN of/IN NF-kappa/NN B/NN activation/NN with/IN other/JJ inducers/NNS of/IN the/DT factor/NN ./. 
This/DT common/JJ pathway/NN may/MD involve/VB reactive/JJ oxygen/NN intermediates/NNS (/( ROI/NN )/) as/IN messenger/NN molecules/NNS ./. 
UI/LS -/: 93260875/CD 
TI/LS -/: [/( The/DT trend/NN of/IN molecular/JJ biology/NN study/NN on/IN eosinophils/NNS ]/) 
AB/LS -/: Recently/RB ,/, many/JJ investigators/NNS have/VBP been/VBN interested/JJ in/IN the/DT study/NN on/IN eosinophil/NN biology/NN since/IN genes/NNS association/NN with/IN eosinophils/NNS such/JJ as/IN interleukin-5/NN or/CC eosinophil/NN granule/NN proteins/NNS (/( EPO/NN ,/, ECP/NN ,/, EDN/NN ,/, MBP/NN ,/, and/CC CLC/NN )/) ,/, were/VBD isolated/VBN ./. 
However/RB ,/, the/DT molecular/JJ basis/NN for/IN the/DT commitment/NN of/IN progenitors/NNS to/TO the/DT eosinophil/NN lineage/NN has/VBZ not/RB been/VBN determined/VBN ./. 
The/DT mechanism/NN by/IN which/WDT eosinophil-specific/JJ genes/NNS encoding/VBG primary/JJ and/CC secondary/JJ granule/NN proteins/NNS (/( e.g./FW ECP/NN ,/, EDN/NN ,/, EPO/NN ,/, MBP/NN ,/, and/CC CLC/NN )/) are/VBP expressed/VBN and/CC regulated/VBN during/IN eosinophilopoiesis/NN is/VBZ also/RB unknown/JJ ./. 
In/IN this/DT paper/NN ,/, I/PRP described/VBD the/DT characterization/NN of/IN genes/NNS encoding/VBG eosinophil/NN granule/NN proteins/NNS and/CC the/DT mRNA/NN expression/NN of/IN GATA-1/NN binding/NN transcription/NN factor/NN during/IN eosinophil/NN differentiation/NN ./. 
UI/LS -/: 93155114/CD 
TI/LS -/: Characterization/NN of/IN the/DT nuclear/JJ and/CC cytoplasmic/JJ components/NNS of/IN the/DT lymphoid-specific/JJ nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) complex/NN ./. 
AB/LS -/: The/DT lymphoid-specific/JJ transcription/NN complex/NN ,/, NF-AT/NN ,/, is/VBZ involved/VBN in/IN early/JJ gene/NN activation/NN in/IN T/NN cells/NNS and/CC is/VBZ assembled/VBN from/IN a/DT pre-existing/JJ ,/, T/NN cell/NN restricted/JJ cytoplasmic/JJ factor/NN and/CC an/DT inducible/JJ ubiquitous/JJ nuclear/JJ component/NN within/IN 30/CD min/NN after/IN activation/NN through/IN the/DT antigen/NN receptor/NN ./. 
Recent/JJ studies/NNS have/VBP implicated/VBN the/DT family/NN of/IN AP1/NN factors/NNS as/IN components/NNS of/IN the/DT murine/JJ NF-AT/NN complex/NN ./. 
Evidence/NN is/VBZ provided/VBN here/RB that/IN the/DT nuclear/JJ component/NN of/IN human/JJ NF-AT/NN contains/VBZ the/DT phorbol/NN ester-inducible/JJ transcription/NN factor/NN AP1/NN (/( Jun/Fos/NN )/) ./. 
We/PRP further/RB characterize/VBP which/WDT AP1/NN family/NN members/NNS can/MD assume/VB this/DT role/NN ./. 
Antisera/NN to/TO Fos/NN inhibits/VBZ NF-AT/NN DNA/NN binding/NN as/IN does/VBZ an/DT oligonucleotide/NN containing/VBG a/DT binding/VBG site/NN for/IN AP1/NN ./. 
Constitutive/JJ expression/NN in/FW vivo/FW of/IN Fos/NN ,/, and/CC to/TO a/DT lesser/JJR extent/NN Fra-1/NN ,/, eliminates/VBZ the/DT requirement/NN for/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) stimulation/NN ,/, leaving/VBG NF-AT-directed/JJ transcription/NN responsive/JJ to/TO calcium/NN ionophore/NN alone/RB ./. 
Overexpression/NN of/IN cJun/NN or/CC JunD/NN ,/, but/CC not/RB JunB/NN ,/, also/RB eliminates/VBZ the/DT requirement/NN for/IN PMA/NN ,/, indicating/VBG that/IN many/JJ but/CC not/RB all/DT Jun-/NN and/CC Fos-related/JJ proteins/NNS functionally/RB activate/VBP NF-AT-dependent/JJ transcription/NN in/IN the/DT presence/NN of/IN the/DT cytoplasmic/JJ component/NN ./. 
NF-AT/NN DNA/NN binding/NN can/MD be/VB reconstituted/VBN in/FW vitro/FW using/VBG semi-purified/JJ AP1/NN proteins/NNS mixed/VBN with/IN cytosol/NN from/IN T/NN lymphocytes/NNS ./. 
Fos/NN proteins/NNS are/VBP not/RB needed/VBN for/IN this/DT reconstitution/NN ,/, and/CC although/IN JunB/NN is/VBZ not/RB functional/JJ ,/, it/PRP can/MD participate/VB in/IN the/DT NF-AT/NN DNA/NN binding/NN complex/NN ./. 
Finally/RB ,/, we/PRP have/VBP partially/RB purified/VBN the/DT cytoplasmic/JJ component/NN of/IN NF-AT/NN and/CC show/VBP by/IN elution/NN and/CC renaturation/NN from/IN SDS-polyacrylamide/NN gel/NN electrophoresis/NN gels/NNS that/IN it/PRP has/VBZ a/DT molecular/JJ mass/NN between/IN 94/CD and/CC 116/CD kDa/NN and/CC may/MD have/VB multiple/JJ differentially/RB modified/JJ forms/NNS ./. 
UI/LS -/: 93289270/CD 
TI/LS -/: Glucocorticoid/NN receptors/NNS in/IN mononuclear/JJ cells/NNS of/IN patients/NNS with/IN sepsis/NN ./. 
AB/LS -/: Glucocorticoid/NN receptor/NN (/( GR/NN )/) hormone-binding/NN activity/NN was/VBD studied/VBN by/IN a/DT whole-cell/JJ method/NN in/IN mononuclear/JJ cells/NNS (/( MNC/NN )/) from/IN peripheral/JJ blood/NN of/IN 7/CD patients/NNS during/IN the/DT hemodynamic/JJ compensatory/JJ phase/NN of/IN sepsis/NN ./. 
4/CD patients/NNS were/VBD receiving/VBG dopamine/NN ,/, which/WDT did/VBD not/RB affect/VB the/DT GR/NN count/NN ./. 
The/DT patients/NNS '/POS plasma/NN cortisol/NN concentrations/NNS were/VBD normal/JJ or/CC slightly/RB elevated/JJ ./. 
Despite/IN a/DT wide/JJ range/NN ,/, the/DT mean/NN GR/NN count/NN and/CC affinity/NN in/IN MNC/NN from/IN septic/JJ patients/NNS did/VBD not/RB differ/VB from/IN those/DT in/IN normal/JJ controls/NNS ,/, suggesting/VBG that/IN glucocorticoids/NNS could/MD still/RB be/VB effective/JJ in/IN the/DT hemodynamic/JJ compensatory/JJ phase/NN of/IN sepsis/NN ./. 
UI/LS -/: 94026053/CD 
TI/LS -/: The/DT impaired/JJ transcription/NN factor/NN AP-1/NN DNA/NN binding/NN activity/NN in/IN lymphocytes/NNS derived/VBN from/IN subjects/NNS with/IN some/DT symptoms/NNS of/IN premature/JJ aging/NN ./. 
AB/LS -/: The/DT study/NN of/IN human/JJ disorders/NNS known/VBN as/IN premature/JJ aging/NN syndromes/NNS may/MD provide/VB insight/NN into/IN the/DT mechanisms/NNS of/IN cellular/JJ senescence/NN ./. 
The/DT main/JJ feature/NN of/IN cellular/JJ senescence/NN in/FW vitro/FW is/VBZ cessation/NN of/IN cell/NN proliferation/NN ./. 
Down/NN syndrome/NN (/( DS/NN )/) and/CC neuronal/JJ ceroid-lypofuscinosis/NN (/( NCL/NN )/) are/VBP clinically/RB characterized/VBN by/IN the/DT premature/JJ onset/NN of/IN numerous/JJ features/NNS normally/RB associated/VBN with/IN human/JJ aging/NN ./. 
Phytohemagglutinin/NN stimulated/JJ lymphocytes/NNS derived/VBN from/IN DS/NN subjects/NNS showed/VBD a/DT statistically/RB significant/JJ diminished/VBN proliferation/NN capacity/NN in/IN comparison/NN with/IN lymphocytes/NNS derived/VBN from/IN NCL/NN and/CC healthy/JJ individuals/NNS ./. 
We/PRP demonstrated/VBD ,/, by/IN applying/VBG the/DT electrophoretic/JJ mobility/NN shift/NN assay/NN ,/, slightly/RB impaired/JJ AP-1/NN DNA/NN binding/NN activity/NN in/IN NCL/NN lymphocytes/NNS and/CC strong/JJ in/IN DS/NN ones/NNS ./. 
Our/PRP$ results/NNS showed/VBD that/IN the/DT same/JJ molecular/JJ mechanisms/NNS of/IN proliferation/NN cessation/NN could/MD exist/VB in/IN fibroblasts/NNS characterized/VBN by/IN replicative/JJ senescence/NN and/CC in/IN lymphocytes/NNS derived/VBN from/IN individuals/NNS with/IN premature/JJ aging/NN syndromes/NNS (/( Down/NN 
UI/LS -/: 93287269/CD 
TI/LS -/: Differential/JJ contribution/NN of/IN herpes/NN simplex/NN virus/NN type/NN 1/CD gene/NN products/NNS and/CC cellular/JJ factors/NNS to/TO the/DT activation/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD provirus/NN ./. 
AB/LS -/: We/PRP have/VBP previously/RB reported/VBN that/IN infection/NN with/IN herpes/NN simplex/NN virus/NN type/NN 1/CD (/( HSV-1/NN )/) activates/VBZ expression/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) provirus/NN in/IN T/NN cells/NNS ./. 
Activation/NN of/IN the/DT HIV-1/NN provirus/NN correlated/VBD with/IN the/DT activation/NN of/IN binding/NN of/IN 55-/CD and/CC 85-kDa/JJ proteins/NNS to/TO the/DT kappa/NN B/NN enhancer/NN and/CC binding/NN of/IN the/DT 50-kDa/JJ HLP-1/NN protein/NN to/TO the/DT LBP-1/NN sequences/NNS of/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN ./. 
Further/RB examination/NN of/IN this/DT system/NN has/VBZ shown/VBN that/IN the/DT inhibition/NN of/IN HSV-1/NN replication/NN by/IN the/DT antiviral/JJ drug/NN acyclovir/NN does/VBZ not/RB inhibit/VB HSV-1-mediated/JJ induction/NN of/IN HIV-1/NN provirus/NN ./. 
Surprisingly/RB ,/, the/DT NF-kappa/NN B/NN and/CC HLP-1/NN binding/NN activities/NNS were/VBD substantially/RB inhibited/VBN in/IN acyclovir-treated/JJ cells/NNS ./. 
In/IN the/DT transient-transfection/JJ assay/NN ,/, ICP0/NN ,/, but/CC not/RB ICP4/NN ,/, activated/VBD the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN promoter/NN region/NN and/CC the/DT effect/NN of/IN ICP0/NN was/VBD greatly/RB enhanced/VBN in/IN the/DT presence/NN of/IN the/DT NF-kappa/NN B/NN binding/NN proteins/NNS ,/, suggesting/VBG that/IN induction/NN of/IN the/DT HIV-1/NN provirus/NN involves/VBZ cooperation/NN between/IN the/DT HSV-1-activated/JJ cellular/JJ factor/NN ,/, NF-kappa/NN B/NN ,/, and/CC the/DT virus-encoded/JJ transactivator/NN ,/, ICP0/NN ./. 
UI/LS -/: 93294310/CD 
TI/LS -/: Transcriptional/JJ activation/NN of/IN the/DT macrophage/NN colony-stimulating/JJ factor/NN gene/NN by/IN IL-2/NN is/VBZ associated/VBN with/IN secretion/NN of/IN bioactive/JJ macrophage/NN colony-stimulating/JJ factor/NN protein/NN by/IN monocytes/NNS and/CC involves/VBZ activation/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN ./. 
AB/LS -/: Human/JJ peripheral/JJ blood/NN monocytes/NNS (/( Mo/NN )/) constitutively/RB display/VBP the/DT beta-chain/NN of/IN the/DT receptor/NN for/IN IL-2/NN ,/, whereas/IN expression/NN of/IN the/DT IL-2R/NN alpha-chain/NN is/VBZ not/RB constitutive/JJ but/CC inducible/JJ with/IN IL-2/NN ./. 
Here/RB we/PRP report/VBP that/IN binding/NN of/IN human/JJ IL-2/NN to/TO its/PRP$ binding/VBG site/NN leads/VBZ to/TO transcriptional/JJ activation/NN of/IN the/DT macrophage/NN CSF/NN (/( M-CSF/NN )/) gene/NN in/IN Mo/NN resulting/VBG in/IN accumulation/NN of/IN M-CSF/NN mRNA/NN and/CC subsequent/JJ release/NN of/IN bioactive/JJ M-CSF/NN protein/NN as/IN demonstrated/VBN by/IN ELISA/NN and/CC inhibition/NN of/IN IL-2/NN induced/JJ release/NN of/IN an/DT activity-stimulating/JJ growth/NN of/IN monocyte-type/JJ colonies/NNS by/IN a/DT neutralizing/VBG anti-M-CSF/JJ antibody/NN ./. 
Transcriptional/JJ activation/NN of/IN the/DT M-CSF/NN gene/NN by/IN IL-2/NN is/VBZ preceded/VBN by/IN enhanced/VBN binding/NN activity/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN to/TO its/PRP$ recognition/NN sequence/NN in/IN the/DT 5'/JJ regulatory/JJ enhancer/NN region/NN of/IN the/DT M-CSF/NN gene/NN ./. 
Moreover/RB ,/, using/VBG a/DT heterologous/JJ promoter/NN (/( herpes/NN thymidine/NN kinase/NN )/) construct/NN containing/VBG the/DT NF-kappa/NN B/NN consensus/NN sequence/NN ,/, it/PRP is/VBZ shown/VBN that/IN NF-kappa/NN B/NN binding/NN by/IN an/DT IL-2-induced/JJ monocyte-derived/JJ nuclear/JJ protein/NN confers/VBZ reporter/NN gene/NN (/( human/JJ growth/NN hormone/NN )/) activity/NN ./. 
Taken/VBN together/RB ,/, our/PRP$ findings/NNS indicate/VBP that/IN IL-2/NN induces/VBZ gene/NN expression/NN of/IN M-CSF/NN in/IN human/JJ blood-derived/JJ Mo/NN and/CC provide/VBP evidence/NN for/IN involvement/NN of/IN NF-kappa/NN B/NN in/IN transcriptional/JJ regulation/NN of/IN this/DT gene/NN ./. 
UI/LS -/: 93268332/CD 
TI/LS -/: Regulation/NN of/IN the/DT interleukin-1/NN beta/NN (/( IL-1/NN beta/NN )/) gene/NN by/IN mycobacterial/JJ components/NNS and/CC lipopolysaccharide/NN is/VBZ mediated/VBN by/IN two/CD nuclear/JJ factor-IL6/JJ motifs/NNS ./. 
AB/LS -/: The/DT cytokines/NNS interleukin-1/NN beta/NN (/( IL-1/NN beta/NN )/) and/CC tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) are/VBP released/VBN by/IN mononuclear/JJ phagocytes/NNS in/FW vitro/FW after/IN stimulation/NN with/IN mycobacteria/NNS and/CC are/VBP considered/VBN to/TO mediate/VB pathophysiologic/JJ events/NNS ,/, including/VBG granuloma/NN formation/NN and/CC systemic/JJ symptoms/NNS ./. 
We/PRP demonstrated/VBD that/IN the/DT Mycobacterium/NN tuberculosis/NN cell/NN wall/NN component/NN lipoarabinomannan/NN (/( LAM/NN )/) is/VBZ a/DT very/RB potent/JJ inducer/NN of/IN IL-1/NN beta/NN gene/NN expression/NN in/IN human/JJ monocytes/NNS and/CC investigated/VBD the/DT mechanism/NN of/IN this/DT effect/NN ./. 
We/PRP localized/VBD the/DT LAM-/NN ,/, lipopolysaccharide/NN (/( LPS/NN )/) -/: ,/, and/CC TNF-alpha-inducible/JJ promoter/NN activity/NN to/TO a/DT -131/+15/CD (/( positions/NNS -131/CD to/TO +15/CD )/) DNA/NN fragment/NN of/IN the/DT IL-1/NN beta/NN gene/NN by/IN deletion/NN analysis/NN and/CC chloramphenicol/NN acetyltransferase/NN assay/NN ./. 
Within/IN this/DT DNA/NN fragment/NN ,/, there/EX were/VBD two/CD novel/JJ 9-bp/JJ motifs/NNS (/( -90/-82/CD and/CC -40/-32/CD )/) with/IN high/JJ homology/NN to/TO the/DT nuclear/JJ factor-IL6/NN (/( NF-IL6/NN )/) binding/NN site/NN ./. 
Site-directed/JJ mutagenesis/NN demonstrated/VBD that/IN the/DT two/CD NF-IL-6/NN motifs/NNS could/MD be/VB independently/RB activated/VBN by/IN LAM/NN ,/, LPS/NN ,/, or/CC TNF-alpha/NN and/CC that/IN they/PRP acted/VBD in/IN an/DT orientation-independent/JJ manner/NN ./. 
DNA/NN mobility/NN shift/NN assay/NN revealed/VBD specific/JJ binding/NN of/IN nuclear/JJ protein/NN (/( s/NNS )/) from/IN LAM-/NN ,/, LPS-/NN ,/, or/CC TNF-alpha-stimulated/JJ THP-1/NN cells/NNS to/TO the/DT NF-IL6/NN motifs/NNS ./. 
We/PRP conclude/VBP that/IN the/DT two/CD NF-IL6/NN sites/NNS mediate/VBP induction/NN of/IN IL-1/NN beta/NN in/IN response/NN to/TO the/DT stimuli/NNS LAM/NN ,/, LPS/NN ,/, and/CC TNF-alpha/NN ./. 
UI/LS -/: 93242763/CD 
TI/LS -/: HIV-1/NN Nef/NN protein/NN inhibits/VBZ the/DT recruitment/NN of/IN AP-1/NN DNA-binding/JJ activity/NN in/IN human/JJ T-cells/NNS ./. 
AB/LS -/: The/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD long/JJ terminal/JJ repeat/NN ,/, HIV-1-LTR/NN ,/, contains/VBZ binding/VBG sites/NNS for/IN several/JJ cellular/JJ transcription/NN factors/NNS which/WDT contribute/VBP to/TO HIV-1/NN gene/NN expression/NN ./. 
Our/PRP$ previous/JJ studies/NNS on/IN the/DT function/NN of/IN the/DT HIV-1-encoded/JJ Nef/NN protein/NN suggested/VBD that/IN Nef/NN may/MD be/VB an/DT inhibitor/NN HIV-1/NN transcription/NN ./. 
To/TO determine/VB whether/IN Nef/NN affects/VBZ the/DT binding/NN of/IN cellular/JJ factors/NNS implicated/VBN in/IN HIV-1/NN regulation/NN ,/, 32P-labeled/JJ oligonucleotides/NNS corresponding/VBG to/TO the/DT binding/VBG sites/NNS were/VBD incubated/VBN with/IN nuclear/JJ extracts/NNS prepared/VBN from/IN Nef-expressing/JJ T-cell/NN lines/NNS that/WDT were/VBD not/RB stimulated/VBN or/CC were/VBD stimulated/VBN with/IN T-cell/NN mitogens/NNS ./. 
We/PRP found/VBD that/IN Nef/NN inhibited/VBD the/DT recruitment/NN of/IN AP-1/NN DNA-binding/JJ activity/NN in/IN mitogen-stimulated/JJ human/JJ T-cells/NNS ./. 
Additionally/RB ,/, Nef/NN expressing/NN cells/NNS were/VBD transiently/RB transfected/VBN with/IN a/DT plasmid/NN in/IN which/WDT HIV-1/NN AP-1/NN DNA/NN recognition/NN sequences/NNS were/VBD cloned/VBN downstream/RB of/IN the/DT chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) gene/NN ./. 
Mitogen-mediated/JJ transcriptional/JJ activation/NN of/IN the/DT CAT/NN gene/NN in/IN this/DT construct/NN was/VBD inhibited/VBN in/IN Nef-expressing/JJ cells/NNS but/CC not/RB in/IN control/NN cells/NNS ./. 
These/DT studies/NNS suggest/VBP that/IN ,/, by/IN inhibiting/VBG AP-1/NN activation/NN ,/, Nef/NN may/MD play/VB a/DT role/NN in/IN regulating/VBG HIV-1/NN gene/NN expression/NN in/IN infected/JJ T-cells/NNS ./. 
UI/LS -/: 93278095/CD 
TI/LS -/: Regulation/NN of/IN the/DT beta-globin/NN locus/NN ./. 
AB/LS -/: Transcription/NN of/IN the/DT human/JJ beta-globin/NN gene/NN cluster/NN depends/VBZ upon/IN upstream/JJ regulatory/JJ sequences/NNS ,/, which/WDT are/VBP collectively/RB termed/VBN the/DT locus/NN control/NN region/NN ./. 
Recent/JJ studies/NNS have/VBP provided/VBN new/JJ insights/NNS into/IN how/WRB the/DT individual/JJ genes/NNS of/IN the/DT cluster/NN are/VBP regulated/VBN through/IN development/NN ./. 
The/DT crux/NN of/IN transcriptional/JJ activation/NN is/VBZ how/WRB the/DT locus/NN control/NN region/NN communicates/VBZ with/IN the/DT gene-proximal/JJ regulatory/JJ elements/NNS ./. 
UI/LS -/: 93346062/CD 
TI/LS -/: Enhancing/NN effect/NN of/IN 17/CD beta-estradiol/NN on/IN human/JJ NK/NN cell/NN activity/NN ./. 
AB/LS -/: The/DT in/FW vitro/FW effect/NN of/IN 17/CD beta-estradiol/NN on/IN NK/NN activity/NN was/VBD studied/VBN ./. 
The/DT proliferation/NN and/CC NK/NN activity/NN of/IN YT-N17/NN (/( a/DT human/JJ NK-like/JJ cell/NN line/NN )/) were/VBD enhanced/VBN by/IN 17/CD beta-estradiol/NN (/( E2/NN )/) ,/, and/CC the/DT enhancement/NN was/VBD blocked/VBN by/IN tamoxifen/NN (/( Tx/NN )/) ,/, an/DT antagonist/NN of/IN E2/NN ./. 
On/IN the/DT contrary/NN ,/, other/JJ steroid/NN hormones/NNS such/JJ as/IN Tx/NN ,/, progesterone/NN ,/, and/CC testosterone/NN had/VBD no/DT effect/NN ./. 
YT-N17/NN contained/VBD 11.8/CD fmol/mg/NN protein/NN of/IN estrogen/NN receptor/NN (/( mean/NN of/IN two/CD independent/JJ assays/NNS )/) ,/, a/DT value/NN which/WDT was/VBD 5-10-fold/RB higher/JJR than/IN that/DT of/IN other/JJ hematopoietic/JJ cell/NN lines/NNS ./. 
An/DT enhancement/NN of/IN NK/NN activity/NN by/IN E2/NN was/VBD also/RB seen/VBN in/IN large/JJ granular/JJ lymphocytes/NNS obtained/VBN from/IN normal/JJ subjects/NNS ,/, and/CC it/PRP was/VBD again/RB suppressed/VBN by/IN Tx/NN ./. 
These/DT data/NNS suggest/VBP that/IN E2/NN is/VBZ one/CD of/IN the/DT activating/VBG factors/NNS for/IN NK/LGL/NN cells/NNS ./. 
UI/LS -/: 93186809/CD 
TI/LS -/: A/DT serum/NN response/NN element/NN and/CC a/DT binding/VBG site/NN for/IN NF-Y/NN mediate/VB the/DT serum/NN response/NN of/IN the/DT human/JJ thrombospondin/NN 1/CD gene/NN ./. 
AB/LS -/: The/DT expression/NN of/IN thrombospondin/NN 1/CD (/( TSP/NN 1/CD )/) ,/, a/DT member/NN of/IN the/DT TSP/NN gene/NN family/NN ,/, is/VBZ rapidly/RB induced/VBN by/IN growth/NN factors/NNS ./. 
We/PRP tested/VBD the/DT ability/NN of/IN human/JJ TSP/NN 1-chloramphenicol/JJ acetyltransferase/NN constructs/NNS to/TO respond/VB to/TO serum/NN in/IN stably/RB transfected/VBN NIH-3T3/NN cells/NNS ./. 
Two/CD transcriptional/JJ elements/NNS in/IN the/DT TSP/NN 1/CD promoter/NN ,/, a/DT distal/JJ element/NN at/IN -1280/CD and/CC a/DT proximal/JJ element/NN at/IN -65/CD ,/, were/VBD required/VBN for/IN the/DT response/NN of/IN the/DT human/JJ TSP/NN 1/CD gene/NN to/TO serum/NN ./. 
The/DT distal/JJ element/NN contains/VBZ the/DT 5'-CC(A + T)6GG-3'/NN consensus/NN sequence/NN characteristic/JJ of/IN a/DT serum-response/JJ element/NN (/( SRE/NN )/) ./. 
Deletions/NNS or/CC mutations/NNS in/IN this/DT element/NN reduced/VBD the/DT serum/NN response/NN of/IN the/DT TSP/NN 1/CD gene/NN by/IN 80-90/CD %/NN ./. 
In/IN gel-shift/JJ assays/NNS ,/, the/DT -1280/CD element/NN and/CC the/DT c-fos/NN SRE/NN cross-competed/VBD ,/, whereas/IN their/PRP$ functional/JJ and/CC binding/VBG mutants/NNS did/VBD not/RB ./. 
The/DT proximal/JJ element/NN contains/VBZ the/DT sequence/NN 5'-GGCCAATGGG-3'/NN ,/, which/WDT closely/RB resembles/VBZ the/DT consensus/NN binding/NN motif/NN for/IN the/DT CCAAT-binding/JJ factor/NN NF-Y/NN (/( CBF/NN ,/, CP1/NN ,/, alpha/NN CP1/NN )/) ./. 
Deletions/NNS or/CC mutations/NNS in/IN this/DT element/NN also/RB reduced/VBD the/DT serum/NN response/NN by/IN 80-90/CD %/NN ./. 
Methylation/NN interference/NN analysis/NN of/IN the/DT -65/CD region/NN identified/VBD a/DT pattern/NN of/IN contacts/NNS with/IN nuclear/JJ factors/NNS resembling/VBG that/DT for/IN NF-Y/NN ,/, and/CC an/DT NF-Y-binding/JJ site/NN and/CC the/DT proximal/JJ TSP/NN 1/CD element/NN cross-competed/VBD in/IN gel-shift/JJ assays/NNS ,/, whereas/IN their/PRP$ binding/VBG mutants/NNS did/VBD not/RB ./. 
Finally/RB ,/, an/DT abbreviated/VBN TSP/NN 1/CD promoter/5'-flank/NN ,/, containing/VBG the/DT SRE-/NN and/CC NF-Y-binding/JJ sites/NNS ,/, mediated/VBD a/DT serum/NN response/NN that/WDT was/VBD close/JJ in/IN magnitude/NN to/TO that/DT of/IN the/DT parent/NN promoter/NN ./. 
We/PRP conclude/VBP that/IN the/DT serum/NN response/NN of/IN the/DT human/JJ TSP/NN 1/CD gene/NN requires/VBZ the/DT coordinated/VBN function/NN of/IN an/DT SRE-/NN and/CC NF-Y-binding/JJ site/NN ./. 
UI/LS -/: 93152870/CD 
TI/LS -/: Cell-type-specific/JJ transactivation/NN of/IN the/DT parathyroid/JJ hormone-related/JJ protein/NN gene/NN promoter/NN by/IN the/DT human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) tax/NN and/CC HTLV-II/NN tax/NN proteins/NNS ./. 
AB/LS -/: The/DT human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) and/CC HTLV-II/NN Tax/NN proteins/NNS are/VBP potent/JJ transactivators/NNS of/IN viral/JJ and/CC cellular/JJ gene/NN expression/NN ./. 
Using/VBG deletion/NN mutants/NNS ,/, the/DT downstream/JJ parathyroid/JJ hormone-related/JJ protein/NN (/( PTHrP/NN )/) promoter/NN is/VBZ shown/VBN to/TO be/VB responsive/JJ to/TO both/CC HTLV-I/NN and/CC HTLV-II/NN Tax/NN as/RB well/RB as/IN the/DT AP1/c-jun/NN proto-oncogene/NN ./. 
Transactivation/NN of/IN PTHrP/NN by/IN Tax/NN was/VBD seen/VBN in/IN T/NN cells/NNS but/CC not/RB in/IN B-cell/NN lines/NNS or/CC fibroblasts/NNS ./. 
A/DT carboxy/NN terminal/JJ Tax/NN deletion/NN mutant/NN was/VBD deficient/JJ in/IN transactivation/NN of/IN both/CC the/DT PTHrP/NN and/CC IL2R/NN alpha/NN promoters/NNS but/CC not/RB the/DT HTLV-I/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ./. 
Exogenous/JJ provision/NN of/IN NFkB/NN rescued/VBD IL2R/NN alpha/NN expression/NN but/CC not/RB the/DT PTHrP/NN promoter/NN ./. 
Thus/RB ,/, HTLV-I/NN Tax/NN ,/, HTLV-II/NN Tax/NN ,/, and/CC c-jun/NN transactivate/VBP PTHrP/NN and/CC may/MD contribute/VB to/TO the/DT pathogenesis/NN of/IN hypercalcemia/NN in/IN adult/JJ T-cell/NN leukemia/NN ./. 
UI/LS -/: 93123257/CD 
TI/LS -/: Involvement/NN of/IN Alu/NN sequences/NNS in/IN the/DT cell-specific/JJ regulation/NN of/IN transcription/NN of/IN the/DT gamma/NN chain/NN of/IN Fc/NN and/CC T/NN cell/NN receptors/NNS ./. 
AB/LS -/: The/DT Fc/NN epsilon/NN RI-gamma/NN chains/NNS are/VBP expressed/VBN in/IN a/DT variety/NN of/IN hematopoietic/JJ cells/NNS where/WRB they/PRP play/VBP a/DT critical/JJ role/NN in/IN signal/NN transduction/NN ./. 
They/PRP are/VBP part/NN of/IN the/DT high/JJ affinity/NN IgE/NN receptor/NN in/IN mast/NN cells/NNS ,/, basophils/NNS ,/, Langerhans/NN cells/NNS ,/, and/CC possibly/RB other/JJ cells/NNS ;/: a/DT component/NN of/IN the/DT low/JJ affinity/NN receptor/NN for/IN IgG/NN (/( Fc/NN gamma/NN RIIIA/NN or/CC CD16/NN )/) in/IN natural/JJ killer/NN cells/NNS and/CC macrophages/NNS ;/: and/CC part/NN of/IN the/DT T/NN cell/NN antigen/NN receptor/NN in/IN subsets/NNS of/IN T/NN cells/NNS ./. 
Here/RB we/PRP have/VBP investigated/VBN the/DT transcriptional/JJ regulation/NN of/IN the/DT gamma/NN chain/NN gene/NN by/IN analyzing/VBG the/DT 2.5-kilobase/JJ sequence/NN upstream/JJ of/IN the/DT transcription/NN start/NN site/NN ./. 
This/DT sequence/NN contains/VBZ a/DT promoter/NN specific/JJ to/TO cells/NNS of/IN hematopoietic/JJ lineage/NN ./. 
However/RB ,/, the/DT tissue/NN specificity/NN of/IN this/DT promoter/NN is/VBZ only/RB partial/JJ because/IN it/PRP is/VBZ active/JJ in/IN all/DT of/IN the/DT hematopoietic/JJ cells/NNS tested/VBN here/RB ,/, regardless/RB of/IN whether/IN they/PRP constitutively/RB express/VBP Fc/NN epsilon/NN RI-gamma/NN chain/NN transcripts/NNS ./. 
We/PRP have/VBP identified/VBN two/CD adjacent/JJ cis-acting/JJ regulatory/JJ elements/NNS ,/, both/DT of/IN which/WDT are/VBP part/NN of/IN an/DT Alu/NN repeat/NN ./. 
The/DT first/JJ (/( -445/-366/CD )/) is/VBZ a/DT positive/JJ element/NN active/JJ in/IN both/CC basophils/NNS and/CC T/NN cells/NNS ./. 
The/DT second/JJ (/( -365/-264/CD )/) binds/VBZ to/TO nuclear/JJ factors/NNS ,/, which/WDT appear/VBP to/TO be/VB different/JJ in/IN basophils/NNS and/CC T/NN cells/NNS ,/, and/CC acts/VBZ as/IN a/DT negative/JJ element/NN in/IN basophils/NNS and/CC as/IN a/DT positive/JJ one/NN in/IN T/NN cells/NNS ./. 
Thus/RB ,/, this/DT Alu/NN repeat/NN (/( 90/CD %/NN identical/JJ to/TO Alu/NN consensus/NN sequences/NNS )/) has/VBZ evolved/VBN to/TO become/VB both/CC a/DT positive/JJ and/CC negative/JJ regulator/NN ./. 
UI/LS -/: 94077003/CD 
TI/LS -/: Chlorinated/VBN dibenzo-p-dioxins/NNS and/CC dibenzofurans/NNS and/CC the/DT human/JJ immune/JJ system/NN ./. 
1/LS ./. Blood/NN cell/NN receptors/NNS in/IN volunteers/NNS with/IN moderately/RB increased/VBN body/NN burdens/NNS ./. 
AB/LS -/: Using/VBG monoclonal/JJ antibodies/NNS (/( mAbs/NNS )/) and/CC flow/NN cytometry/NN ,/, we/PRP studied/VBD a/DT variety/NN of/IN surface/NN receptors/NNS on/IN lymphocyte/NN subpopulations/NNS of/IN workers/NNS with/IN moderately/RB increased/VBN body/NN burdens/NNS of/IN 2,3,7,8-tetrachlorodibenzo-p-dioxin/NN (/( TCDD/NN )/) and/CC of/IN other/JJ polychlorinated/VBN dibenzo-p-dioxins/NNS and/CC dibenzofurans/NNS (/( PCDD/PCDF/NN )/) ,/, expressed/VBN here/RB as/IN International-Toxicity/NN Equivalencies/NN (/( I-TE/NN )/) ./. 
The/DT hypothesis/NN to/TO be/VB tested/VBN was/VBD whether/IN or/CC not/RB humans/NNS exhibit/VBP a/DT similar/JJ susceptibility/NN to/TO PCDDs/PCDFs/NNS with/IN respect/NN to/TO the/DT surface/NN receptors/NNS found/VBN previously/RB to/TO respond/VB to/TO small/JJ doses/NNS of/IN 2,3,7,8-tetrachlorodibenzo-p-dioxin/NN (/( TCDD/NN )/) in/IN Callithrix/FW jacchus/FW ./. 
These/DT are/VBP :/: helper-inducer/JJ (/( memory/NN )/) T/NN cells/NNS (/( CD4+CD45R0+CD45RA-CD29highCD11a+/JJ )/) ,/, CD20+/JJ B/NN cells/NNS ,/, and/CC cytotoxic/JJ T/NN cells/NNS (/( CD8+CD56+/CD57+/JJ )/) ./. 
Furthermore/RB ,/, 68/CD triple-labellings/NNS with/IN mAbs/NNS were/VBD performed/VBN on/IN the/DT cells/NNS of/IN each/DT volunteer/NN to/TO possibly/RB generate/VB further/JJ hypotheses/NNS ./. 
It/PRP was/VBD evaluated/VBN whether/IN any/DT of/IN the/DT variables/NNS might/MD be/VB used/VBN as/IN a/DT biomarker/NN of/IN effects/NNS for/IN this/DT class/NN of/IN compounds/NNS ./. 
There/EX were/VBD two/CD main/JJ goals/NNS :/: (/( 1/LS )/) to/TO evaluate/VB whether/IN workers/NNS with/IN a/DT moderately/RB increased/VBN PCDD/PCDF-body/NN burden/NN [/( 25-140/CD ppt/NN TCDD/NN or/CC 104-522/CD ppt/NN I-TE/NN in/IN blood/NN fat/NN ]/) exhibit/VBP changes/NNS in/IN the/DT surface/NN receptors/NNS of/IN white/JJ blood/NN cells/NNS ,/, as/IN observed/VBN in/IN previous/JJ studies/NNS in/IN non-human/JJ primates/NNS ,/, and/CC (/( 2/LS )/) to/TO clarify/VB whether/IN persons/NNS at/IN the/DT upper/JJ range/NN [/( 10-23/CD ppt/NN TCDD/NN or/CC 30-90/CD ppt/NN I-TE/NN in/IN blood/NN fat/NN ]/) of/IN the/DT body/NN burden/NN reference/NN values/NNS of/IN a/DT not/RB particularly/RB exposed/VBN population/NN show/VBP detectable/JJ deviations/NNS in/IN these/DT immunological/JJ variables/NNS ,/, when/WRB compared/VBN with/IN persons/NNS at/IN the/DT lower/JJR and/CC medium/NN range/NN [/( 1-3/CD ppt/NN TCDD/NN or/CC 9-29/CD ppt/NN I-TE/NN ]/) of/IN these/DT body/NN burden/NN reference/NN values/NNS ./. 
Regression/NN analysis/NN of/IN our/PRP$ data/NNS revealed/VBD slight/JJ trends/NNS for/IN some/DT of/IN the/DT biomarkers/NNS (/( e.g./FW CD45R0+/JJ )/) ./. 
With/IN one/CD exception/NN ,/, these/DT were/VBD all/DT increases/NNS ./. 
None/NN of/IN the/DT alterations/NNS observed/VBN are/VBP of/IN medical/JJ relevance/NN ./. 
The/DT slight/JJ increase/NN in/IN the/DT percentage/NN of/IN CD4+CD45R0+/JJ cells/NNS remained/VBD significant/JJ even/RB after/IN covariant/JJ analysis/NN taking/VBG age-related/JJ changes/NNS into/IN account/NN ./. 
Altogether/RB ,/, the/DT data/NNS do/VBP not/RB provide/VB any/DT evidence/NN to/TO support/VB an/DT assumption/NN that/IN moderately/RB increased/VBN body/NN burdens/NNS of/IN PCDDs/PCDFs/NNS in/IN adults/NNS induce/VBP decreases/NNS in/IN the/DT cellular/JJ components/NNS of/IN the/DT human/JJ immune/JJ system/NN ./. 
Adult/JJ humans/NNS certainly/RB are/VBP less/RBR susceptible/JJ to/TO this/DT action/NN of/IN PCDDs/PCDFs/NNS than/IN adolescent/JJ Callithrix/FW jacchus/FW 
UI/LS -/: 94031267/CD 
TI/LS -/: Inhibition/NN of/IN HIV-1/NN latency/NN reactivation/NN by/IN dehydroepiandrosterone/NN (/( DHEA/NN )/) and/CC an/DT analog/NN of/IN DHEA/NN ./. 
AB/LS -/: The/DT initial/JJ infection/NN with/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) in/IN most/JJS individuals/NNS usually/RB results/VBZ in/IN the/DT establishment/NN of/IN a/DT latent/JJ or/CC chronic/JJ infection/NN before/IN eventual/JJ progression/NN toward/IN acquired/VBN immunodeficiency/NN syndrome/NN ./. 
HIV-1/NN can/MD also/RB establish/VB a/DT latent/JJ or/CC persistent/JJ infection/NN in/IN some/DT T/NN cell/NN lines/NNS that/WDT show/VBP minimal/JJ constitutive/JJ virus/NN expression/NN ./. 
However/RB ,/, activation/NN of/IN the/DT T/NN cell/NN lines/NNS leading/VBG to/TO enhanced/VBN HIV-1/NN replication/NN can/MD be/VB induced/VBN by/IN antigens/NNS ,/, mitogens/NNS ,/, and/CC cytokines/NNS (/( tumor/NN necrosis/NN factor/NN alpha/NN [/( TNF-alpha/NN ]/) ,/, interleukin/NN 1/CD ,/, and/CC interleukin-2/NN )/) ./. 
Various/JJ gene/NN products/NNS from/IN other/JJ viruses/NNS (/( HTLV-1/NN ,/, HSV/NN ,/, EBV/NN ,/, CMV/NN ,/, HBV/NN ,/, and/CC HHV-6/NN )/) can/MD also/RB enhance/VB HIV-1/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) -driven/JJ reporter/NN gene/NN activity/NN ./. 
On/IN the/DT basis/NN of/IN these/DT observations/NNS ,/, it/PRP has/VBZ been/VBN proposed/VBN that/IN reactivation/NN of/IN latent/JJ HIV-1/NN harbored/VBN in/IN chronically/RB infected/JJ T/NN lymphocytes/NNS ,/, monocytes/NNS ,/, or/CC macrophages/NNS plays/VBZ an/DT important/JJ role/NN in/IN the/DT pathogenesis/NN of/IN AIDS/NN ./. 
So/RB far/RB ,/, there/EX are/VBP no/DT drugs/NNS or/CC therapy/NN available/JJ that/WDT can/MD provide/VB protection/NN against/IN HIV-1/NN latency/NN reactivation/NN ./. 
ACH-2/NN ,/, derived/VBN from/IN a/DT human/JJ T/NN cell/NN line/NN (/( CEM/NN )/) ,/, is/VBZ chronically/RB infected/VBN with/IN HIV-1/NN ,/, with/IN low/JJ levels/NNS of/IN constitutive/JJ virus/NN expression/NN ./. 
ACH-2/NN can/MD be/VB converted/VBN to/TO productive/JJ infection/NN by/IN stimulation/NN of/IN the/DT cells/NNS with/IN 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) ,/, mitogen/NN or/CC cytokines/NNS (/( TNF-alpha/NN )/) ,/, or/CC infection/NN with/IN HSV/NN ./. 
Therefore/RB the/DT ACH-2/NN cell/NN line/NN is/VBZ a/DT good/JJ candidate/NN for/IN studying/VBG the/DT effects/NNS of/IN drugs/NNS on/IN HIV-1/NN activation/NN ./. 
Previously/RB ,/, we/PRP have/VBP reported/VBN that/IN DHEA/NN and/CC synthetic/JJ analogs/NNS of/IN DHEA/NN can/MD be/VB modest/JJ inhibitors/NNS of/IN HIV-1/NN IIIB/NN replication/NN in/IN phytohemagglutinin-stimulated/JJ peripheral/JJ blood/NN lymphocyte/NN cultures/NNS ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 93314685/CD 
TI/LS -/: Occurrence/NN of/IN a/DT silencer/NN of/IN the/DT interleukin-2/NN gene/NN in/IN naive/JJ but/CC not/RB in/IN memory/NN resting/VBG T/NN helper/NN lymphocytes/NNS ./. 
AB/LS -/: In/IN the/DT immune/JJ system/NN the/DT first/JJ activation/NN of/IN a/DT naive/JJ T/NN cell/NN by/IN antigen/NN is/VBZ a/DT key/JJ step/NN in/IN the/DT shaping/NN of/IN the/DT peripheral/JJ T/NN cell/NN specificity/NN repertoire/NN and/CC maintenance/NN of/IN self-tolerance/NN ./. 
In/IN the/DT present/JJ study/NN ,/, analysis/NN of/IN the/DT interleukin-2/NN (/( IL-2/NN )/) gene/NN activation/NN shows/VBZ that/IN naive/JJ human/JJ helper/NN T/NN cells/NNS (/( cord/NN blood/NN CD4+/JJ T/NN cells/NNS ,/, adult/JJ CD4+CD45RO-/JJ T/NN cells/NNS )/) regulate/VBP IL-2/NN transcription/NN by/IN a/DT mechanism/NN involving/VBG both/CC a/DT silencer/NN and/CC an/DT activator/NN acting/VBG on/IN the/DT purine-rich/JJ IL-2/NN promoter/NN elements/NNS (/( NF-AT/NN binding/NN sites/NNS )/) ./. 
By/IN contrast/NN ,/, memory/NN cells/NNS ,/, either/CC in/FW vitro/FW activated/VBN helper/NN T/NN cells/NNS reverting/VBG to/TO a/DT resting/JJ state/NN ,/, or/CC CD4+/JJ T/NN (/( memory/NN )/) clones/NNS ,/, or/CC CD4+CD45RO+/JJ T/NN cells/NNS isolated/VBN ex/FW vivo/FW ,/, no/RB longer/RB have/VBP a/DT silencer/NN ./. 
Their/PRP$ IL-2/NN transcription/NN seems/VBZ to/TO be/VB controlled/VBN solely/RB by/IN the/DT transition/NN from/IN inactive/JJ to/TO active/JJ functional/JJ state/NN of/IN a/DT positive/JJ transcription/NN factor/NN binding/VBG to/TO these/DT promoter/NN elements/NNS as/RB well/RB as/IN its/PRP$ cytoplasmic/JJ or/CC nuclear/JJ location/NN :/: in/IN resting/VBG memory/NN T/NN cells/NNS the/DT activator/NN is/VBZ located/JJ in/IN the/DT cytoplasm/NN and/CC is/VBZ inactive/JJ ,/, whereas/IN in/IN stimulated/VBN cells/NNS it/PRP is/VBZ functional/JJ in/IN promoting/VBG transcription/NN and/CC now/RB resides/VBZ in/IN the/DT nucleus/NN ./. 
Thus/RB ,/, the/DT regulation/NN of/IN the/DT gene/NN coding/VBG for/IN the/DT main/JJ T/NN cell/NN growth/NN factor/NN changes/VBZ irreversibly/RB after/IN the/DT first/JJ encounter/NN of/IN T/NN cells/NNS with/IN antigen/NN ./. 
It/PRP is/VBZ most/RBS likely/JJ that/IN the/DT presence/NN of/IN a/DT silencer/NN contributes/VBZ to/TO the/DT more/RBR stringent/JJ activation/NN requirements/NNS of/IN naive/JJ CD4+/JJ T/NN cells/NNS ./. 
UI/LS -/: 93283670/CD 
TI/LS -/: Expression/NN of/IN mRNA/NN for/IN the/DT GATA-binding/JJ proteins/NNS in/IN human/JJ eosinophils/NNS and/CC basophils/NNS :/: potential/JJ role/NN in/IN gene/NN transcription/NN ./. 
AB/LS -/: The/DT expression/NN of/IN the/DT hematopoietic/JJ transcription/NN factors/NNS GATA-1/NN ,/, GATA-2/NN ,/, and/CC GATA-3/NN was/VBD studied/VBN in/IN eosinophils/NNS and/CC basophils/NNS ./. 
Eosinophils/NNS express/VBP mRNA/NN for/IN GATA-1/NN ,/, GATA-2/NN ,/, and/CC GATA-3/NN ./. 
Basophils/NNS express/VBP GATA-2/NN and/CC GATA-3/NN ./. 
Treatment/NN of/IN HL-60/NN eosinophilic/JJ sublines/NNS with/IN either/CC interleukin-5/NN or/CC butyric/JJ acid/NN increased/VBD the/DT expression/NN of/IN GATA-1/NN mRNA/NN concomitant/JJ with/IN the/DT expression/NN of/IN eosinophil-specific/JJ genes/NNS ,/, whereas/IN levels/NNS of/IN GATA-2/NN mRNA/NN remained/VBD relatively/RB constant/JJ ./. 
The/DT presence/NN of/IN mRNA/NN for/IN these/DT proteins/NNS in/IN eosinophils/NNS and/CC basophils/NNS suggests/VBZ that/IN gene/NN transcription/NN in/IN these/DT lineages/NNS may/MD be/VB regulated/VBN by/IN GATA-binding/JJ proteins/NNS ./. 
UI/LS -/: 93266597/CD 
TI/LS -/: Oxidoreductive/JJ regulation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN ./. 
Involvement/NN of/IN a/DT cellular/JJ reducing/NN catalyst/NN thioredoxin/NN ./. 
AB/LS -/: We/PRP have/VBP investigated/VBN an/DT oxidoreductive/JJ regulatory/JJ pathway/NN for/IN the/DT DNA/NN binding/NN activity/NN of/IN a/DT pleiotropic/JJ cellular/JJ transcription/NN factor/NN ,/, nuclear/JJ factor/NN kappa/NN B/NN (/( NF/NN kappa/NN B/NN )/) ,/, has/VBZ been/VBN investigated/VBN by/IN using/VBG NF/NN kappa/NN B/NN prepared/VBN from/IN the/DT nucleus/NN and/CC the/DT cytosol/NN of/IN the/DT primary/JJ human/JJ T/NN lymphocytes/NNS ./. 
We/PRP show/VBP that/IN a/DT cellular/JJ reducing/NN catalyst/NN thioredoxin/NN (/( Trx/NN )/) plays/VBZ a/DT major/JJ role/NN in/IN activation/NN of/IN the/DT DNA/NN binding/NN of/IN NF/NN kappa/NN B/NN in/FW vitro/FW and/CC stimulation/NN of/IN transcription/NN from/IN the/DT NF/NN kappa/NN B-dependent/JJ gene/NN expression/NN ./. 
We/PRP demonstrate/VBP evidence/NN suggesting/VBG that/IN redox/NN regulation/NN of/IN NF/NN kappa/NN B/NN by/IN Trx/NN might/MD be/VB exerted/VBN at/IN a/DT step/NN after/IN dissociation/NN of/IN the/DT inhibitory/JJ molecule/NN I/NN kappa/NN B/NN ,/, a/DT cytosolic-anchoring/JJ protein/NN for/IN NF/NN kappa/NN B/NN ./. 
To/TO examine/VB the/DT effect/NN of/IN Trx/NN in/IN intact/JJ cells/NNS ,/, we/PRP performed/VBD transient/JJ assay/NN with/IN a/DT chloramphenicol/NN acetyltransferase-expressing/JJ plasmid/NN under/IN the/DT control/NN of/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) long/JJ terminal/JJ repeat/NN and/CC an/DT effector/NN plasmid/NN expressing/VBG human/JJ Trx/NN ./. 
The/DT promoter/NN activity/NN from/IN HIV/NN long/JJ terminal/JJ repeat/NN was/VBD greatly/RB augmented/VBN by/IN co-transfecting/VBG the/DT Trx-expressing/NN plasmid/NN ,/, whose/WP$ effect/NN was/VBD dependent/JJ on/IN the/DT NF/NN kappa/NN B-binding/NN sites/NNS ./. 
These/DT findings/NNS have/VBP suggested/VBN that/IN cysteine/NN residue/NN (/( s/NNS )/) of/IN NF/NN kappa/NN B/NN might/MD be/VB involved/VBN in/IN the/DT DNA-recognition/NN by/IN NF/NN kappa/NN B/NN and/CC that/IN the/DT redox/NN control/NN mechanism/NN mediated/VBN by/IN Trx/NN might/MD have/VB a/DT regulatory/JJ role/NN in/IN the/DT NF/NN kappa/NN B-mediated/JJ gene/NN expression/NN ./. 
These/DT results/NNS may/MD also/RB provide/VB a/DT clue/NN to/TO understanding/NN of/IN the/DT molecular/JJ process/NN of/IN AIDS/NN pathogenesis/NN and/CC its/PRP$ possible/JJ biochemical/JJ intervention/NN ./. 
UI/LS -/: 93269273/CD 
TI/LS -/: Synergism/NN between/IN the/DT CD3/NN antigen-/NN and/CC CD2/NN antigen-derived/JJ signals/NNS ./. 
Exploration/NN at/IN the/DT level/NN of/IN induction/NN of/IN DNA-binding/JJ proteins/NNS and/CC characterization/NN of/IN the/DT inhibitory/JJ activity/NN of/IN cyclosporine/NN ./. 
AB/LS -/: We/PRP have/VBP demonstrated/VBN earlier/RBR that/IN the/DT crosslinkage/NN of/IN the/DT CD3/TCR/NN complex/NN with/IN the/DT CD2/NN antigen/NN results/VBZ in/IN the/DT proliferation/NN of/IN normal/JJ human/JJ T/NN cells/NNS ./. 
The/DT effect/NN of/IN this/DT synergism/NN was/VBD perceptible/JJ at/IN the/DT level/NN of/IN induction/NN of/IN the/DT IL-2/NN gene/NN ,/, a/DT process/NN critical/JJ for/IN T/NN cell/NN growth/NN ./. 
To/TO further/RB understand/VB the/DT molecular/JJ and/CC nuclear/JJ basis/NN for/IN this/DT synergism/NN ,/, we/PRP have/VBP explored/VBN the/DT induction/NN of/IN DNA-binding/JJ proteins/NNS in/IN highly/RB purified/VBN normal/JJ human/JJ T/NN cells/NNS signaled/VBN via/IN the/DT CD3/NN and/or/CC CD2/NN proteins/NNS ./. 
The/DT effect/NN of/IN transmembrane/NN signaling/NN of/IN T/NN cells/NNS with/IN ionomycin/NN ,/, and/or/CC sn-1/NN ,/, 2/CD dioctanoyl/NN glycerol/NN ,/, was/VBD also/RB determined/VBN ./. 
The/DT emergence/NN of/IN nuclear/JJ binding/NN proteins/NNS was/VBD investigated/VBN using/VBG interleukin-2/NN sequence/NN specific/JJ oligonucleotide/NN probes/NNS in/IN the/DT electrophoretic/JJ mobility/NN shift/NN assay/NN ./. 
Our/PRP$ studies/NNS demonstrate/VBP for/IN the/DT first/JJ time/NN that/IN CD3/NN antigen-derived/JJ signals/NNS and/CC CD2/NN antigen-derived/JJ signals/NNS are/VBP synergistic/JJ in/IN inducing/VBG the/DT emergence/NN of/IN transcription/NN factors/NNS that/WDT bind/VBP to/TO the/DT NF-AT1/NN ,/, AP-1/NN ,/, and/CC NF-kB/NN sites/NNS located/JJ in/IN the/DT promoter/enhancer/NN region/NN of/IN the/DT IL-2/NN gene/NN ./. 
Moreover/RB ,/, cyclosporine/NN ,/, at/IN concentrations/NNS readily/RB accomplished/VBN in/IN clinical/JJ practice/NN ,/, was/VBD found/VBN to/TO inhibit/VB the/DT emergence/NN of/IN these/DT DNA-binding/JJ proteins/NNS in/IN normal/JJ human/JJ T/NN cells/NNS signaled/VBN via/IN cell/NN surface/NN proteins/NNS implicated/VBN in/IN antigen-dependent/JJ T/NN cell/NN activation/NN and/CC in/IN T/NN cells/NNS stimulated/VBN by/IN mobilization/NN of/IN cellular/JJ calcium/NN and/CC activation/NN of/IN protein/NN kinase/NN C/NN ./. 
UI/LS -/: 93215800/CD 
TI/LS -/: Induced/VBN myeloid/JJ differentiation/NN of/IN K562/NN cells/NNS with/IN downregulation/NN of/IN erythroid/JJ and/CC megakaryocytic/JJ transcription/NN factors/NNS :/: a/DT novel/JJ experimental/JJ model/NN for/IN hemopoietic/JJ lineage/NN restriction/NN ./. 
AB/LS -/: The/DT human/JJ erythroleukemia/NN cell/NN line/NN K562/NN can/MD be/VB induced/VBN to/TO differentiate/VB along/IN the/DT erythroid/JJ and/CC megakaryocytic/JJ lineages/NNS ./. 
Here/RB we/PRP demonstrate/VBP that/IN hexamethylene/NN bisacetamide/NN (/( HMBA/NN )/) induced/VBD K562/NN cells/NNS to/TO differentiate/VB along/IN a/DT third/JJ pathway/NN ./. 
This/DT was/VBD accompanied/VBN by/IN downregulation/NN of/IN two/CD transcription/NN factors/NNS normally/RB expressed/VBN in/IN erythroid/JJ ,/, mast/NN and/CC megakaryocyte/NN lineages/NNS ./. 
Northern/NN analysis/NN demonstrated/VBD coordinate/JJ downregulation/NN of/IN alpha/NN globin/NN and/CC gamma/NN globin/NN in/IN addition/NN to/TO the/DT two/CD lineage-restricted/JJ transcription/NN factors/NNS ,/, SCL/NN and/CC GATA-1/NN ./. 
Proliferation/NN of/IN the/DT K562/NN cells/NNS was/VBD also/RB suppressed/VBN ./. 
Clonal/JJ assay/NN showed/VBD that/IN the/DT suppression/NN was/VBD irreversible/JJ and/CC appeared/VBD analogous/JJ to/TO the/DT commitment/NN of/IN murine/JJ erythroleukemia/NN (/( MEL/NN )/) cells/NNS to/TO terminal/JJ differentiation/NN ./. 
In/IN contrast/NN to/TO MEL/NN cells/NNS ,/, however/RB ,/, K562/NN cells/NNS acquired/VBD a/DT macrophage-like/JJ morphology/NN and/CC exhibited/VBD a/DT complete/JJ failure/NN to/TO generate/VB benzidine-positive/JJ cells/NNS ./. 
Electron/NN microscopy/NN revealed/VBD a/DT marked/JJ increase/NN in/IN granules/NNS resembling/VBG those/DT specific/JJ for/IN eosinophils/NNS ./. 
Surface/NN marker/NN analysis/NN showed/VBD that/IN HMBA-induced/JJ cells/NNS expressed/VBD reduced/VBN levels/NNS of/IN glycophorin/NN A/NN ,/, CD5/NN ,/, CD7/NN and/CC CD11b/NN ./. 
No/DT upregulation/NN of/IN megakaryocyte/NN or/CC lymphoid/JJ markers/NNS occurred/VBD ./. 
Thus/RB the/DT response/NN of/IN K562/NN cells/NNS to/TO HMBA/NN may/MD provide/VB a/DT useful/JJ experimental/JJ system/NN for/IN studying/VBG the/DT molecular/JJ mechanisms/NNS responsible/JJ for/IN downmodulation/NN of/IN lineage-restricted/JJ transcription/NN factors/NNS during/IN hemopoietic/JJ lineage/NN commitment/NN ./. 
UI/LS -/: 93264305/CD 
TI/LS -/: Activation/NN of/IN primary/JJ human/JJ T-lymphocytes/NNS through/IN CD2/NN plus/CC CD28/NN adhesion/NN molecules/NNS induces/VBZ long-term/JJ nuclear/JJ expression/NN of/IN NF-kappa/NN B/NN ./. 
AB/LS -/: Stimulation/NN of/IN highly/RB purified/VBN human/JJ T-cells/NNS via/IN CD2/NN and/CC CD28/NN adhesion/NN molecules/NNS induces/VBZ and/CC maintains/VBZ proliferation/NN for/IN more/JJR than/IN 3/CD weeks/NNS ./. 
This/DT potent/JJ interleukin/NN 2/CD (/( IL-2/NN )/) -dependent/JJ activation/NN does/VBZ not/RB require/VB monocytes/NNS or/CC accessory/JJ cells/NNS ./. 
Long-lasting/JJ IL-2/NN receptivity/NN is/VBZ associated/VBN with/IN high-level/JJ expression/NN of/IN the/DT inducible/JJ IL-2/NN receptor/NN alpha/NN chain/NN (/( IL-2R/NN alpha/NN )/) gene/NN that/WDT is/VBZ regulated/VBN at/IN both/CC transcriptional/JJ and/CC posttranscriptional/JJ levels/NNS ./. 
Increase/NN of/IN IL-2R/NN alpha/NN gene/NN transcription/NN involves/VBZ the/DT enhanced/VBN binding/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN to/TO its/PRP$ consensus/NN sequence/NN in/IN the/DT 5'-regulatory/JJ region/NN of/IN the/DT IL-2R/NN alpha/NN gene/NN ./. 
To/TO dissect/VB the/DT molecular/JJ basis/NN for/IN the/DT unusually/RB persistent/JJ transcription/NN of/IN the/DT IL-2R/NN alpha/NN gene/NN ,/, we/PRP analyzed/VBD nuclear/JJ NF-kappa/NN B/NN binding/VBG to/TO a/DT radiolabeled/VBN IL-2R/NN alpha/NN kappa/NN B-specific/JJ oligonucleotide/NN probe/NN during/IN the/DT time/NN course/NN of/IN CD2/NN +/CC CD28/NN activation/NN ./. 
Resting/VBG T-cell/NN nuclear/JJ extracts/NNS contained/VBD KBF1/p50/NN homodimer/NN ./. 
After/IN stimulation/NN ,/, two/CD new/JJ kappa/NN B-specific/JJ complexes/NNS were/VBD identified/VBN as/IN NF-kappa/NN B/NN p50-p65/NN heterodimer/NN and/CC putative/JJ c-Rel/NN homodimer/NN or/CC c-Rel-p65/NN heterodimer/NN ./. 
Both/DT inducible/JJ complexes/NNS persisted/VBD for/IN at/IN least/JJS 3/CD weeks/NNS ./. 
Their/PRP$ relative/JJ levels/NNS were/VBD very/RB similar/JJ for/IN the/DT duration/NN of/IN proliferation/NN ./. 
In/IN parallel/NN ,/, CD2/NN +/CC CD28/NN activation/NN triggered/VBD a/DT significant/JJ intracellular/JJ thiol/NN decrease/NN ,/, suggesting/VBG that/IN oxygen/NN radicals/NNS are/VBP involved/VBN in/IN the/DT signaling/NN pathway/NN of/IN adhesion/NN molecules/NNS ./. 
Finally/RB ,/, micromolar/JJ amounts/NNS of/IN pyrrolidine/NN dithiocarbamate/NN ,/, an/DT oxygen/NN radical/NN scavenger/NN that/WDT efficiently/RB blocked/VBD the/DT nuclear/JJ appearance/NN of/IN NF-kappa/NN B/NN in/IN T-lymphocytes/NNS ,/, also/RB inhibited/VBD IL-2/NN secretion/NN ,/, IL-2R/NN alpha/NN cell/NN surface/NN expression/NN ,/, and/CC T-cell/NN proliferation/NN ./. 
Together/RB ,/, these/DT results/NNS suggest/VBP that/IN NF-kappa/NN B/NN plays/VBZ an/DT important/JJ role/NN in/IN long-term/JJ activation/NN of/IN human/JJ primary/JJ T-lymphocytes/NNS via/IN CD2/NN +/CC CD28/NN ./. 
UI/LS -/: 93228833/CD 
TI/LS -/: Immobilization/NN and/CC recovery/NN of/IN fusion/NN proteins/NNS and/CC B-lymphocyte/NN cells/NNS using/VBG magnetic/JJ separation/NN ./. 
AB/LS -/: A/DT new/JJ approach/NN to/TO facilitate/VB immobilization/NN and/CC affinity/NN purification/NN of/IN recombinant/JJ proteins/NNS and/CC selected/VBN human/JJ B/NN lymphocytes/NNS has/VBZ been/VBN developed/VBN ./. 
Using/VBG magnetic/JJ beads/NNS with/IN attached/VBN DNA/NN containing/VBG the/DT Escherichia/FW coli/FW lac/NN operator/NN ,/, fusion/NN proteins/NNS comprising/VBG the/DT DNA-binding/JJ lac/NN repressor/NN could/MD be/VB affinity-purified/JJ and/CC recovered/VBN by/IN gentle/JJ elution/NN conditions/NNS ,/, such/JJ as/IN with/IN a/DT lactose/NN analogue/NN or/CC by/IN enzymatic/JJ means/NNS using/VBG either/CC deoxyribonuclease/NN (/( DNase/NN )/) or/CC restriction/NN endonucleases/NNS ./. 
The/DT results/NNS show/VBP for/IN the/DT first/JJ time/NN that/IN a/DT DNA-binding/JJ protein/NN can/MD be/VB used/VBN for/IN affinity/NN purification/NN of/IN fusion/NN proteins/NNS as/IN exemplified/VBN by/IN the/DT specific/JJ and/CC gentle/JJ recovery/NN of/IN beta-galactosidase/NN and/CC alkaline/NN phosphatase/NN from/IN bacterial/JJ lysates/NNS using/VBG immunomagnetic/JJ separation/NN ./. 
The/DT approach/NN was/VBD further/RB extended/VBN to/TO cell/NN separation/NN by/IN the/DT efficient/JJ recovery/NN and/CC elution/NN of/IN human/JJ CD37/NN B/NN lymphocytes/NNS from/IN peripheral/JJ blood/NN ./. 
UI/LS -/: 93155082/CD 
TI/LS -/: ras/NN protein/NN activity/NN is/VBZ essential/JJ for/IN T-cell/NN antigen/NN receptor/NN signal/NN transduction/NN ./. 
AB/LS -/: In/IN a/DT Jurkat/NN cell/NN model/NN of/IN T-cell/NN activation/NN an/DT interleukin-2/NN promoter/reporter/NN gene/NN construct/NN was/VBD activated/VBN by/IN antigen/NN receptor/NN agonism/NN in/IN combination/NN with/IN the/DT lymphokine/NN interleukin-1/NN ./. 
Antigen/NN receptor/NN signals/NNS could/MD be/VB mimicked/VBN by/IN suboptimal/JJ activation/NN of/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) with/IN phorbol/NN esters/NNS in/IN combination/NN with/IN calcium/NN mobilization/NN by/IN an/DT ionophore/NN ./. 
In/IN cotransfection/NN experiments/NNS ,/, oncogenic/JJ rats/NNS obviated/VBD the/DT need/NN for/IN PKC/NN stimulation/NN but/CC did/VBD not/RB replace/VB either/CC the/DT calcium/NN signal/NN or/CC interleukin-1/NN ./. 
Activated/VBN ras/NN expression/NN also/RB replaced/VBD the/DT requirement/NN for/IN PKC/NN stimulation/NN in/IN activation/NN of/IN the/DT T-cell/NN transcription/NN factor/NN NF-AT/NN ./. 
A/DT dominant/JJ inhibitory/JJ ras/NN mutant/NN specifically/RB blocked/VBD antigen/NN receptor/NN agonism/NN ,/, indicating/VBG that/IN ras/NN activity/NN is/VBZ required/VBN for/IN antigen/NN receptor/NN signaling/NN ./. 
In/IN addition/NN ,/, an/DT inhibitor/NN of/IN PKC/NN blocked/VBD both/CC activated/VBD ras/NN and/CC phorbol/NN ester/NN stimulation/NN ,/, suggesting/VBG a/DT role/NN for/IN ras/NN upstream/JJ of/IN PKC/NN ./. 
UI/LS -/: 93189882/CD 
TI/LS -/: Expression/NN of/IN the/DT Tat/NN protein/NN of/IN HIV1/NN in/IN human/JJ promonocytic/JJ U937/NN cells/NNS ./. 
AB/LS -/: Numerous/JJ studies/NNS have/VBP shown/VBN that/IN ,/, upon/IN HIV1/NN infection/NN ,/, human/JJ promonocytic/JJ U937/NN cells/NNS were/VBD induced/VBN to/TO differentiate/VB ,/, as/IN indicated/VBN ,/, for/IN example/NN ,/, by/IN increased/VBN expression/NN of/IN adhesion/NN molecules/NNS ./. 
One/CD of/IN the/DT viral/JJ proteins/NNS involved/VBN in/IN this/DT process/NN might/MD be/VB the/DT Tat/NN protein/NN ./. 
Indeed/RB ,/, this/DT viral/JJ protein/NN ,/, which/WDT is/VBZ essential/JJ for/IN productive/JJ infection/NN ,/, has/VBZ also/RB been/VBN shown/VBN to/TO display/VB growth-stimulating/JJ properties/NNS and/CC immunomodulatory/JJ activities/NNS ./. 
In/IN order/NN to/TO apprehend/VB the/DT role/NN of/IN the/DT HIV1/NN tat/NN gene/NN in/IN inducing/VBG the/DT differentiation/NN of/IN HIV1-infected/JJ U937/NN cells/NNS ,/, we/PRP have/VBP successfully/RB introduced/VBN this/DT gene/NN into/IN U937/NN cells/NNS by/IN infecting/VBG them/PRP with/IN retroviral/JJ particles/NNS transducing/VBG tat/NN ./. 
The/DT effect/NN of/IN the/DT Tat/NN protein/NN constitutively/RB expressed/VBN by/IN these/DT cells/NNS upon/IN their/PRP$ differentiation/NN was/VBD then/RB evaluated/VBN by/IN looking/VBG for/IN the/DT expression/NN of/IN the/DT c-fos/NN and/CC of/IN the/DT c-fms/NN proto-oncogenes/NNS which/WDT are/VBP linked/VBN to/TO the/DT differentiation/NN of/IN myelomonoblastic/JJ cells/NNS ./. 
Northern/NN blot/NN analysis/NN revealed/VBD in/IN these/DT cells/NNS ,/, an/DT increase/NN in/IN the/DT transcription/NN of/IN these/DT two/CD proto-oncogenes/NNS ,/, and/CC this/DT increase/NN was/VBD amplified/VBN after/IN treatment/NN with/IN phorbol/NN myristate/NN acetate/NN ./. 
No/DT such/JJ increase/NN was/VBD observed/VBN in/IN control/NN U937/NN cells/NNS ./. 
These/DT results/NNS indicate/VBP that/IN ,/, among/IN HIV1/NN gene/NN products/NNS ,/, the/DT Tat/NN protein/NN appears/VBZ to/TO trigger/VB monocytic/JJ differentiation/NN ,/, and/CC suggests/VBZ that/IN this/DT viral/JJ protein/NN directs/VBZ progenitors/NNS of/IN the/DT monocyte/macrophage/NN lineage/NN towards/IN a/DT differentiation/NN stage/NN in/IN which/WDT production/NN of/IN viral/JJ antigens/NNS and/CC virions/NNS might/MD be/VB more/RBR efficient/JJ ./. 
UI/LS -/: 93329079/CD 
TI/LS -/: Analysis/NN of/IN the/DT preexisting/JJ and/CC nuclear/JJ forms/NNS of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS ./. 
AB/LS -/: The/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) 3/CD is/VBZ an/DT inducible/JJ DNA-binding/JJ protein/NN that/WDT is/VBZ essential/JJ for/IN transcriptional/JJ induction/NN of/IN the/DT IL-2/NN gene/NN during/IN T/NN cell/NN activation/NN ./. 
NF-AT/NN is/VBZ thought/VBN to/TO consist/VB of/IN two/CD components/NNS :/: a/DT ubiquitous/JJ ,/, inducible/JJ nuclear/JJ component/NN that/WDT we/PRP have/VBP identified/VBN as/IN Fos/NN and/CC Jun/NN proteins/NNS ,/, and/CC a/DT preexisting/VBG ,/, T/NN cell-specific/JJ component/NN (/( NF-ATp/NN )/) which/WDT is/VBZ the/DT target/NN for/IN the/DT immunosuppressive/JJ agents/NNS cyclosporin/NN A/NN (/( CsA/NN )/) and/CC FK506/NN ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN nuclear/JJ extracts/NNS from/IN activated/VBN T/NN cells/NNS form/VBP two/CD inducible/JJ NF-AT/NN complexes/NNS with/IN an/DT oligonucleotide/NN corresponding/VBG to/TO the/DT distal/JJ NF-AT/NN site/NN of/IN the/DT murine/JJ IL-2/NN promoter/NN ,/, although/IN hypotonic/JJ extracts/NNS of/IN unstimulated/JJ T/NN cells/NNS form/VBP a/DT single/JJ complex/NN containing/VBG NF-ATp/NN ./. 
We/PRP show/VBP that/IN the/DT ability/NN to/TO detect/VB NF-ATp/NN in/IN a/DT gel/NN shift/NN assay/NN ,/, which/WDT is/VBZ essential/JJ for/IN purification/NN and/CC biochemical/JJ studies/NNS of/IN this/DT protein/NN ,/, is/VBZ strikingly/RB dependent/JJ on/IN the/DT precise/JJ sequence/NN of/IN the/DT NF-AT/NN oligonucleotide/NN used/VBN as/IN the/DT labeled/JJ probe/NN ./. 
Moreover/RB we/PRP present/VBP evidence/NN that/IN the/DT component/NN that/WDT forms/VBZ the/DT faster-migrating/JJ (/( "/`` lower/JJR "/'' )/) nuclear/JJ NF-AT/NN complex/NN is/VBZ derived/VBN by/IN a/DT calcium-dependent/JJ ,/, cyclosporin-sensitive/JJ ,/, posttranslational/JJ modification/NN of/IN NF-ATp/NN ,/, and/CC that/IN Fos/NN and/CC Jun/NN proteins/NNS stabilize/VBP its/PRP$ interaction/NN with/IN DNA/NN ./. 
The/DT results/NNS are/VBP discussed/VBN in/IN the/DT context/NN of/IN a/DT model/NN relating/VBG the/DT two/CD nuclear/JJ NF-AT/NN complexes/NNS to/TO NF-ATp/NN ./. 
UI/LS -/: 93309430/CD 
TI/LS -/: Cell/NN cycle/NN analysis/NN of/IN E2F/NN in/IN primary/JJ human/JJ T/NN cells/NNS reveals/VBZ novel/JJ E2F/NN complexes/NNS and/CC biochemically/RB distinct/JJ forms/NNS of/IN free/JJ E2F/NN ./. 
AB/LS -/: The/DT transcription/NN factor/NN E2F/NN activates/VBZ the/DT expression/NN of/IN multiple/JJ genes/NNS involved/VBN in/IN cell/NN proliferation/NN ,/, such/JJ as/IN c-myc/NN and/CC the/DT dihydrofolate/JJ reductase/NN gene/NN ./. 
Regulation/NN of/IN E2F/NN involves/VBZ its/PRP$ interactions/NNS with/IN other/JJ cellular/JJ proteins/NNS ,/, including/VBG the/DT retinoblastoma/NN protein/NN (/( Rb/NN )/) ,/, the/DT Rb-related/JJ protein/NN p107/NN ,/, cyclin/NN A/NN ,/, and/CC cdk2/NN ./. 
We/PRP undertook/VBD a/DT detailed/JJ analysis/NN of/IN E2F/NN DNA-binding/JJ activities/NNS and/CC their/PRP$ cell/NN cycle/NN behavior/NN in/IN primary/JJ human/JJ T/NN cells/NNS ./. 
Three/CD E2F/NN DNA-binding/JJ activities/NNS were/VBD identified/VBN in/IN resting/VBG (/( G0/NN )/) T/NN cells/NNS with/IN mobilities/NNS in/IN gel/NN shift/NN assays/NNS distinct/JJ from/IN those/DT of/IN previously/RB defined/VBN E2F/NN complexes/NNS ./. 
One/CD of/IN these/DT activities/NNS was/VBD found/VBN to/TO be/VB a/DT novel/JJ ,/, less/RBR abundant/JJ ,/, Rb-E2F/NN complex/NN ./. 
The/DT most/RBS prominent/JJ E2F/NN activity/NN in/IN resting/VBG T/NN cells/NNS (/( termed/VBN complex/JJ X/NN )/) was/VBD abundant/JJ in/IN both/CC G0/NN and/CC G1/NN but/CC disappeared/VBD as/IN cells/NNS entered/VBD S/NN phase/NN ,/, suggesting/VBG a/DT possible/JJ role/NN in/IN negatively/RB regulating/VBG E2F/NN function/NN ./. 
Complex/NN X/NN could/MD be/VB dissociated/VBN by/IN adenovirus/NN E1A/NN with/IN a/DT requirement/NN for/IN an/DT intact/JJ E1A/NN conserved/VBN region/NN 2/CD ./. 
However/RB ,/, X/NN failed/VBD to/TO react/VB with/IN a/DT variety/NN of/IN antibodies/NNS against/IN Rb/NN or/CC p107/NN ,/, implicating/VBG the/DT involvement/NN of/IN an/DT E1A-binding/JJ protein/NN other/JJ than/IN Rb/NN or/CC p107/NN ./. 
In/IN addition/NN to/TO these/DT novel/JJ E2F/NN complexes/NNS ,/, three/CD distinct/JJ forms/NNS of/IN unbound/JJ (/( free/JJ )/) E2F/NN were/VBD resolved/VBN in/IN gel/NN shift/NN experiments/NNS ./. 
These/DT species/NNS showed/VBD different/JJ cell/NN cycle/NN kinetics/NNS ./. 
UV/NN cross-linking/JJ experiments/NNS suggested/VBD that/IN a/DT distinct/JJ E2F/NN DNA-binding/JJ protein/NN is/VBZ uniquely/RB associated/VBN with/IN the/DT S-phase/NN p107/NN complex/NN and/CC is/VBZ not/RB associated/VBN with/IN Rb/NN ./. 
Together/RB ,/, these/DT results/NNS suggest/VBP that/IN E2F/NN consists/VBZ of/IN multiple/JJ ,/, biochemically/RB distinct/JJ DNA-binding/JJ proteins/NNS which/WDT function/VBP at/IN different/JJ points/NNS in/IN the/DT cell/NN cycle/NN ./. 
UI/LS -/: 93286051/CD 
TI/LS -/: Defective/JJ translocation/NN of/IN protein/NN kinase/NN C/NN in/IN multidrug-resistant/JJ HL-60/NN cells/NNS confers/VBZ a/DT reversible/JJ loss/NN of/IN phorbol/NN ester-induced/JJ monocytic/JJ differentiation/NN ./. 
AB/LS -/: Previous/JJ studies/NNS have/VBP demonstrated/VBN that/IN human/JJ HL-60/NN myeloid/JJ leukemia/NN cells/NNS differentiate/VBP in/IN response/NN to/TO phorbol/NN esters/NNS ./. 
This/DT event/NN is/VBZ associated/VBN with/IN induction/NN of/IN the/DT c-jun/NN early/JJ response/NN gene/NN and/CC appearance/NN of/IN a/DT monocytic/JJ phenotype/NN ./. 
The/DT present/JJ studies/NNS have/VBP examined/VBN the/DT effects/NNS of/IN vincristine-selected/JJ ,/, multidrug/JJ resistance/NN on/IN 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) -induced/JJ HL-60/NN cell/NN differentiation/NN ./. 
The/DT results/NNS demonstrate/VBP that/IN multidrug-resistant/JJ HL-60/NN cells/NNS ,/, designated/VBN HL-60/vinc/NN ,/, fail/VBP to/TO respond/VB to/TO TPA/NN with/IN an/DT increase/NN in/IN c-jun/NN transcripts/NNS or/CC other/JJ phenotypic/JJ characteristics/NNS of/IN monocytic/JJ differentiation/NN ./. 
By/IN contrast/NN ,/, treatment/NN of/IN HL-60/vinc/NN cells/NNS with/IN okadaic/JJ acid/NN ,/, an/DT inhibitor/NN of/IN serine/threonine/NN protein/NN phosphatases/NNS ,/, induces/VBZ c-jun/NN transcription/NN ,/, growth/NN arrest/NN ,/, and/CC expression/NN of/IN the/DT c-fms/NN gene/NN ./. 
Studies/NNS were/VBD also/RB performed/VBN with/IN an/DT HL-60/vinc/NN revertant/NN (/( HL-60/vinc/R/NN )/) line/NN that/WDT has/VBZ regained/VBN partial/JJ sensitivity/NN to/TO vincristine/NN ./. 
The/DT finding/NN that/IN HL-60/vinc/R/NN cells/NNS respond/VBP to/TO TPA/NN with/IN induction/NN of/IN a/DT monocytic/JJ phenotype/NN ,/, but/CC not/RB c-jun/NN expression/NN ,/, suggests/VBZ that/IN c-jun/NN induction/NN is/VBZ not/RB obligatory/JJ for/IN monocytic/JJ differentiation/NN ./. 
Other/JJ studies/NNS further/RB demonstrate/VBP that/IN the/DT jun-B/NN and/CC fra-1/NN genes/NNS are/VBP induced/VBN by/IN TPA/NN in/IN both/CC HL-60/vinc/NN and/CC HL-60/vinc/R/NN cells/NNS ,/, whereas/IN c-fos/NN expression/NN is/VBZ attenuated/VBN in/IN the/DT HL-60/vinc/NN line/NN ./. 
Since/IN TPA/NN activates/VBZ protein/NN kinase/NN C/NN (/( PKC/NN )/) ,/, we/PRP examined/VBD translocation/NN of/IN PKC/NN from/IN the/DT cytosol/NN to/TO the/DT membrane/NN fraction/NN ./. 
Although/IN HL-60/NN and/CC HL-60/vinc/R/NN cells/NNS demonstrated/VBD translocation/NN of/IN PKC/NN activity/NN ,/, this/DT subcellular/JJ redistribution/NN was/VBD undetectable/JJ in/IN HL-60/vinc/NN cells/NNS ./. 
Activity/NN of/IN the/DT mitogen-activated/JJ protein/NN kinase/NN family/NN with/IN associated/JJ phosphorylation/NN of/IN c-Jun/NN Y-peptide/NN was/VBD markedly/RB diminished/VBN in/IN TPA-treated/JJ HL-60/vinc/NN cells/NNS ,/, but/CC not/RB in/IN response/NN to/TO okadaic/JJ acid/NN ./. 
Taken/VBN together/RB ,/, these/DT findings/NNS suggest/VBP that/IN vincristine/NN resistance/NN confers/VBZ insensitivity/NN to/TO TPA-induced/JJ differentiation/NN and/CC can/MD include/VB defects/NNS in/IN PKC-mediated/JJ signaling/NN events/NNS and/CC induction/NN of/IN jun/fos/NN early/JJ response/NN gene/NN expression/NN ./. 
UI/LS -/: 93281652/CD 
TI/LS -/: Molecular/JJ basis/NN of/IN a/DT multiple/JJ lymphokine/NN deficiency/NN in/IN a/DT patient/NN with/IN severe/JJ combined/JJ immunodeficiency/NN ./. 
AB/LS -/: We/PRP have/VBP previously/RB reported/VBN that/IN the/DT T/NN lymphocytes/NNS of/IN a/DT child/NN with/IN severe/JJ combined/JJ immunodeficiency/NN are/VBP defective/JJ in/IN the/DT transcription/NN of/IN several/JJ lymphokine/NN genes/NNS that/WDT include/VBP IL2/NN ,/, IL3/NN ,/, IL4/NN ,/, and/CC IL5/NN ,/, which/WDT encode/VBP interleukins/NNS 2/CD ,/, 3/CD ,/, 4/CD ,/, and/CC 5/CD (/( IL-2/NN ,/, -3/CD ,/, -4/CD ,/, and/CC -5/CD )/) ./. 
To/TO determine/VB whether/IN the/DT defect/NN in/IN the/DT patient/NN 's/POS T/NN lymphocytes/NNS involved/VBD a/DT trans-acting/JJ factor/NN common/JJ to/TO the/DT affected/VBN lymphokine/NN genes/NNS ,/, we/PRP examined/VBD the/DT ability/NN of/IN nuclear/JJ factors/NNS from/IN the/DT patient/NN 's/POS T/NN lymphocytes/NNS to/TO bind/VB response/NN elements/NNS present/JJ in/IN the/DT regulatory/JJ region/NN of/IN IL2/NN ./. 
Nuclear/JJ factor/NN NF-kB/NN ,/, activation/NN protein/NN 1/CD (/( AP-1/NN )/) ,/, OCT-1/NN ,/, and/CC NF-IL-2B/NN binding/NN activity/NN were/VBD normal/JJ ./. 
In/IN contrast/NN ,/, the/DT binding/NN of/IN the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) to/TO its/PRP$ response/NN element/NN in/IN the/DT IL2/NN enhancer/NN and/CC to/TO an/DT NF-AT-like/JJ response/NN element/NN present/JJ in/IN the/DT IL4/NN enhancer/NN was/VBD abnormal/JJ ./. 
To/TO ascertain/VB whether/IN the/DT abnormal/JJ NF-AT/NN binding/NN activity/NN was/VBD related/JJ to/TO an/DT impaired/JJ function/NN ,/, we/PRP transfected/VBD patient/NN and/CC control/NN T/NN lymphocytes/NNS with/IN constructs/NNS containing/VBG the/DT reporter/NN gene/NN encoding/JJ chloramphenicol/NN acetyl/NN transferase/NN (/( CAT/NN )/) under/IN the/DT control/NN of/IN the/DT entire/JJ IL2/NN regulatory/JJ region/NN or/CC of/IN multimers/NNS of/IN individual/JJ enhancer/NN sequences/NNS ./. 
CAT/NN expression/NN directed/VBN by/IN the/DT IL2/NN regulatory/JJ region/NN or/CC by/IN a/DT multimer/NN of/IN the/DT NF-AT-binding/JJ site/NN was/VBD markedly/RB lower/JJR in/IN the/DT patient/NN relative/JJ to/TO controls/NNS ./. 
In/IN contrast/NN ,/, CAT/NN gene/NN expression/NN directed/VBN by/IN a/DT multimer/NN of/IN the/DT OCT-1/NN proximal/NN (/( OCT-1p/NN )/) -binding/JJ site/NN was/VBD equivalent/JJ in/IN patient/NN and/CC controls/NNS ./. 
These/DT results/NNS indicate/VBP that/IN an/DT abnormality/NN of/or/IN|CC influencing/JJ NF-AT/NN may/MD underlie/VB the/DT multiple/JJ lymphokine/NN deficiency/NN in/IN this/DT patient/NN ./. 
UI/LS -/: 94025289/CD 
TI/LS -/: FK506/NN and/CC ciclosporin/NN :/: molecular/JJ probes/NNS for/IN studying/VBG intracellular/JJ signal/NN transduction/NN ./. 
AB/LS -/: The/DT immunosuppressants/NNS ciclosporin/NN and/CC FK506/NN block/VBP the/DT Ca(2+)-dependent/JJ signal-transduction/NN pathway/NN emanating/VBG from/IN the/DT T-cell/NN receptor/NN ,/, thereby/RB inhibiting/VBG the/DT activation/NN of/IN helper/NN T/NN cells/NNS ./. 
Using/VBG these/DT drugs/NNS as/IN probes/NNS ,/, chemists/NNS and/CC biologists/NNS have/VBP uncovered/VBN several/JJ intracellular/JJ signalling/NN molecules/NNS bridging/VBG the/DT generation/NN of/IN second-messenger/NN Ca2+/NN ions/NNS and/CC the/DT transcriptional/JJ activation/NN of/IN IL-2/NN ,/, among/IN which/WDT are/VBP calmodulin/NN ,/, calcineurin/NN and/CC the/DT nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) ./. 
Hence/RB ,/, Ca2+/NN binds/VBZ to/TO calmodulin/NN ,/, leading/VBG to/TO the/DT binding/NN of/IN calmodulin/NN to/TO calcineurin/NN ;/: the/DT activated/VBN calcineurin/NN ,/, in/IN turn/NN ,/, may/MD dephosphorylate/VB the/DT cytoplasmic/JJ subunit/NN of/IN NF-AT/NN ,/, resulting/VBG in/IN its/PRP$ translocation/NN from/IN the/DT cytoplasm/NN into/IN the/DT nucleus/NN to/TO form/VB a/DT competent/JJ transcriptional/JJ activator/NN ./. 
As/IN described/VBN by/IN Jun/NNP Liu/NNP ,/, these/DT drugs/NNS manifest/VBP their/PRP$ effects/NNS in/IN an/DT unprecedented/JJ fashion/NN ./. 
They/PRP do/VBP not/RB directly/RB intercept/VB intracellular/JJ signalling/NN molecules/NNS ./. 
Instead/RB ,/, they/PRP form/VBP tight/JJ complexes/NNS with/IN two/CD different/JJ classes/NNS of/IN abundant/JJ cytosolic/JJ receptors/NNS called/VBN immunophilins/NNS upon/IN entering/VBG the/DT cell/NN ,/, and/CC consequently/RB inhibit/VBP their/PRP$ peptidyl/JJ prolyl/JJ cis-trans/JJ isomerase/NN activities/NNS ./. 
The/DT two/CD structurally/RB distinct/JJ immunophilin-drug/JJ complexes/NNS bind/VBP to/TO ,/, and/CC inhibit/VBP ,/, the/DT phosphatase/JJ activity/NN of/IN calcineurin/NN ./. 
UI/LS -/: 93209552/CD 
TI/LS -/: p105/NN and/CC p98/NN precursor/NN proteins/NNS play/VBP an/DT active/JJ role/NN in/IN NF-kappa/NN B-mediated/JJ signal/NN transduction/NN ./. 
AB/LS -/: The/DT Rel/NF-kappa/NN B/NN family/NN of/IN transcription/NN factors/NNS is/VBZ composed/VBN of/IN two/CD distinct/JJ subgroups/NNS ,/, proteins/NNS that/WDT undergo/VBP proteolytic/JJ processing/NN and/CC contain/VBP SWI6/ankyrin/NN repeats/NNS in/IN their/PRP$ carboxyl/NN termini/NNS (/( p105/NN ,/, p98/NN )/) ,/, and/CC those/DT without/IN such/JJ repeats/NNS that/WDT do/VBP not/RB require/VB processing/NN (/( p65/NN ,/, c-Rel/NN ,/, RelB/NN ,/, and/CC Dorsal/NN )/) ./. 
We/PRP demonstrate/VBP that/IN the/DT p105/NN and/CC p98/NN precursors/NNS share/VBP functional/JJ properties/NNS with/IN the/DT I/NN kappa/NN B/NN proteins/NNS ,/, which/WDT also/RB contain/VBP SWI6/ankyrin/NN repeats/NNS ./. 
Both/CC p105/NN and/CC p98/NN were/VBD found/VBN to/TO form/VB stable/JJ complexes/NNS with/IN other/JJ Rel/NF-kappa/NN B/NN family/NN members/NNS ,/, including/VBG p65/NN and/CC c-Rel/NN ./. 
Association/NN with/IN the/DT precursors/NNS is/VBZ sufficient/JJ for/IN cytoplasmic/JJ retention/NN of/IN either/CC p65/NN or/CC c-Rel/NN ,/, both/DT of/IN which/WDT are/VBP otherwise/RB nuclear/JJ ./. 
These/DT complexes/NNS undergo/VBP stimulus-responsive/JJ processing/NN to/TO produce/VB active/JJ p50/c-Rel/NN and/CC p55/c-Rel/NN complexes/NNS ./. 
These/DT observations/NNS suggest/VBP a/DT second/JJ pathway/NN leading/VBG to/TO NF-kappa/NN B/NN induction/NN ,/, in/IN which/WDT processing/NN of/IN the/DT precursors/NNS rather/RB than/IN phosphorylation/NN of/IN I/NN kappa/NN B/NN plays/VBZ a/DT major/JJ role/NN ./. 
UI/LS -/: 93206138/CD 
TI/LS -/: NF-kappa/NN B/NN controls/VBZ expression/NN of/IN inhibitor/NN I/NN kappa/NN B/NN alpha/NN :/: evidence/NN for/IN an/DT inducible/JJ autoregulatory/JJ pathway/NN ./. 
AB/LS -/: The/DT eukaryotic/JJ transcription/NN factor/NN nuclear/JJ factor-kappa/NN B/NN (/( NF-kappa/NN B/NN )/) participates/VBZ in/IN many/JJ parts/NNS of/IN the/DT genetic/JJ program/NN mediating/VBG T/NN lymphocyte/NN activation/NN and/CC growth/NN ./. 
Nuclear/JJ expression/NN of/IN NF-kappa/NN B/NN occurs/VBZ after/IN its/PRP$ induced/VBN dissociation/NN from/IN its/PRP$ cytoplasmic/JJ inhibitor/NN I/NN kappa/NN B/NN alpha/NN ./. 
Phorbol/NN ester/NN and/CC tumor/NN necrosis/NN factor-alpha/NN induction/NN of/IN nuclear/JJ NF-kappa/NN B/NN is/VBZ associated/VBN with/IN both/CC the/DT degradation/NN of/IN performed/VBN I/NN kappa/NN B/NN alpha/NN and/CC the/DT activation/NN of/IN I/NN kappa/NN B/NN alpha/NN gene/NN expression/NN ./. 
Transfection/NN studies/NNS indicate/VBP that/IN the/DT I/NN kappa/NN B/NN alpha/NN gene/NN is/VBZ specifically/RB induced/VBN by/IN the/DT 65-kilodalton/JJ transactivating/VBG subunit/NN of/IN NF-kappa/NN B/NN ./. 
Association/NN of/IN the/DT newly/RB synthesized/VBN I/NN kappa/NN B/NN alpha/NN with/IN p65/NN restores/VBZ intracellular/JJ inhibition/NN of/IN NF-kappa/NN B/NN DNA/NN binding/NN activity/NN and/CC prolongs/VBZ the/DT survival/NN of/IN this/DT labile/JJ inhibitor/NN ./. 
Together/RB ,/, these/DT results/NNS show/VBP that/IN NF-kappa/NN B/NN controls/VBZ the/DT expression/NN of/IN I/NN kappa/NN B/NN alpha/NN by/IN means/NNS of/IN an/DT inducible/JJ autoregulatory/JJ pathway/NN ./. 
UI/LS -/: 93180777/CD 
TI/LS -/: The/DT human/JJ prointerleukin/NN 1/CD beta/NN gene/NN requires/VBZ DNA/NN sequences/NNS both/CC proximal/JJ and/CC distal/JJ to/TO the/DT transcription/NN start/NN site/NN for/IN tissue-specific/JJ induction/NN ./. 
AB/LS -/: In/IN these/DT studies/NNS ,/, we/PRP have/VBP identified/VBN DNA/NN sequences/NNS and/CC specific/JJ protein/NN interactions/NNS necessary/JJ for/IN transcriptional/JJ regulation/NN of/IN the/DT human/JJ prointerleukin/NN 1/CD beta/NN (/( proIL-1/NN beta/NN )/) gene/NN ./. 
A/DT cell-type-independent/JJ lipopolysaccharide/NN (/( LPS/NN )/) -responsive/JJ enhancer/NN element/NN located/JJ between/IN -3757/CD and/CC -2729/CD bp/NN upstream/RB from/IN the/DT transcription/NN start/NN site/NN (/( cap/NN site/NN )/) consisted/VBD of/IN at/IN least/JJS six/CD discrete/JJ subregions/NNS which/WDT were/VBD essential/JJ to/TO the/DT maximal/JJ induction/NN by/IN LPS/NN in/IN transfected/VBN monocytes/NNS ./. 
The/DT enhancer/NN also/RB appeared/VBD to/TO mediate/VB phorbol/NN myristate/NN acetate/NN induction/NN in/IN monocytes/NNS and/CC IL-1/NN responsiveness/NN in/IN fibroblasts/NNS ./. 
Deletion/NN and/CC base/NN substitution/NN mutations/NNS along/IN with/IN DNA/NN binding/NN studies/NNS demonstrated/VBD that/IN the/DT enhancer/NN contained/VBD a/DT minimum/NN of/IN three/CD functional/JJ protein/NN binding/NN sequences/NNS ,/, two/CD of/IN which/WDT appeared/VBD to/TO be/VB important/JJ for/IN gene/NN induction/NN ./. 
One/CD of/IN the/DT essential/JJ proteins/NNS which/WDT bound/VBD to/TO the/DT enhancer/NN was/VBD similar/JJ or/CC identical/JJ to/TO members/NNS of/IN the/DT C/EBP/NN family/NN of/IN transcription/NN factors/NNS required/VBN for/IN both/CC IL-1-/NN and/CC LPS-specific/JJ induction/NN of/IN the/DT IL-6/NN gene/NN (/( i.e./FW ,/, the/DT NF-IL6/NN proteins/NNS )/) ./. 
When/WRB ligated/VBN to/TO the/DT proIL-1/NN beta/NN cap/NN site-proximal/JJ region/NN (/( located/JJ between/IN -131/CD to/TO +12/CD )/) ,/, both/CC the/DT proIL-1/NN beta/NN and/CC the/DT simian/JJ virus/NN 40/CD enhancer/NN elements/NNS functioned/VBD more/RBR efficiently/RB in/IN monocytes/NNS than/IN in/IN HeLa/NN cells/NNS ,/, which/WDT are/VBP not/RB normally/RB competent/JJ for/IN IL-1/NN beta/NN expression/NN ./. 
When/WRB ligated/VBN to/TO the/DT murine/JJ c-fos/NN promoter/NN ,/, however/RB ,/, the/DT proIL-1/NN beta/NN enhancer/NN was/VBD inducible/JJ in/IN phorbol/NN myristate/NN acetate-stimulated/JJ HeLa/NN cells/NNS ,/, suggesting/VBG the/DT existence/NN of/IN a/DT proIL-1/NN beta/NN promoter-proximal/JJ requirement/NN for/IN tissue/NN specificity/NN ./. 
UI/LS -/: 93233083/CD 
TI/LS -/: Lymphocytes/NNS from/IN the/DT site/NN of/IN disease/NN suggest/VBP adenovirus/NN is/VBZ one/CD cause/NN of/IN persistent/JJ or/CC recurrent/JJ inflammatory/JJ arthritis/NN ./. 
AB/LS -/: The/DT assessment/NN of/IN synovial/JJ lymphocyte/NN reactivity/NN to/TO adenovirus/NN antigen/NN stimulation/NN was/VBD undertaken/VBN in/IN patients/NNS with/IN persistent/JJ or/CC recurrent/JJ inflammatory/JJ arthritis/NN ./. 
The/DT 3H-thymidine/JJ uptake/NN procedure/NN was/VBD employed/VBN ,/, incorporating/VBG multiple/JJ microbiological/JJ antigens/NNS ./. 
Five/CD patients/NNS were/VBD found/VBN with/IN repeated/VBN maximal/JJ responses/NNS to/TO adenovirus/NN antigen/NN ;/: in/IN one/CD of/IN these/DT adenovirus/NN nucleotide/NN sequences/NNS were/VBD present/JJ in/IN a/DT synovial/JJ biopsy/NN specimen/NN ./. 
It/PRP is/VBZ concluded/VBN that/IN adenovirus/NN may/MD be/VB one/CD cause/NN of/IN persistent/JJ or/CC recurrent/JJ inflammatory/JJ arthritis/NN ./. 
UI/LS -/: 93183827/CD 
TI/LS -/: Expression/NN of/IN PILOT/NN ,/, a/DT putative/JJ transcription/NN factor/NN ,/, requires/VBZ two/CD signals/NNS and/CC is/VBZ cyclosporin/NN A/NN sensitive/JJ in/IN T/NN cells/NNS ./. 
AB/LS -/: Few/JJ known/JJ genes/NNS (/( IL-2/NN ,/, members/NNS of/IN the/DT IL-8/NN family/NN ,/, interferon-gamma/NN )/) are/VBP induced/VBN in/IN T/NN cells/NNS only/RB through/IN the/DT combined/JJ effect/NN of/IN phorbol/NN myristic/JJ acetate/NN (/( PMA/NN )/) and/CC a/DT Ca(2+)-ionophore/NN ,/, and/CC expression/NN of/IN only/RB these/DT genes/NNS can/MD be/VB fully/RB suppressed/VBN by/IN Cyclosporin/NN A/NN (/( CyA/NN )/) ./. 
We/PRP have/VBP identified/VBN a/DT putative/JJ transcription/NN factor/NN ,/, designated/VBN PILOT/NN ,/, with/IN an/DT identical/JJ dual/JJ signal/NN requirement/NN for/IN expression/NN ./. 
Induction/NN of/IN the/DT PILOT/NN gene/NN is/VBZ detectable/JJ in/IN human/JJ T/NN cells/NNS 20/CD min/NN following/VBG activation/NN in/IN the/DT presence/NN of/IN cycloheximide/NN and/CC is/VBZ fully/RB suppressed/VBN by/IN CyA/NN ./. 
The/DT PILOT/NN protein/NN has/VBZ a/DT calculated/VBN M(r)/NN of/IN 42.6/CD kDa/NN and/CC contains/VBZ three/CD zinc/NN fingers/NNS of/IN the/DT C2H2-type/NN at/IN the/DT carboxyl-terminus/NN which/WDT are/VBP highly/RB homologous/JJ to/TO the/DT zinc/NN finger/NN regions/NNS of/IN the/DT transcription/NN factors/NNS EGR1/NNS ,/, EGR2/NNS ,/, and/CC pAT/NN 133/CD ./. 
In/IN contrast/NN to/TO T/NN cells/NNS ,/, in/IN fibroblasts/NNS PILOT/NN gene/NN expression/NN requires/VBZ only/RB one/CD signal/NN (/( PMA/NN )/) and/CC is/VBZ not/RB affected/VBN by/IN CyA/NN ./. 
This/DT observation/NN directly/RB demonstrates/VBZ the/DT existence/NN of/IN a/DT Ca2+/NN signal-dependent/JJ regulatory/JJ element/NN obligatory/JJ for/IN expression/NN of/IN some/DT genes/NNS in/IN T/NN cells/NNS but/CC not/RB in/IN fibroblasts/NNS ./. 
This/DT differential/JJ expression/NN model/NN will/MD be/VB valuable/JJ in/IN the/DT dissection/NN of/IN the/DT dual/JJ signal/NN pathway/NN in/IN T/NN cells/NNS and/CC the/DT effects/NNS of/IN CyA/NN upon/IN it/PRP ./. 
UI/LS -/: 93320446/CD 
TI/LS -/: Antisense/JJ oligonucleotides/NNS to/TO the/DT p65/NN subunit/NN of/IN NF-kappa/NN B/NN block/VBP CD11b/NN expression/NN and/CC alter/VBP adhesion/NN properties/NNS of/IN differentiated/VBN HL-60/NN granulocytes/NNS ./. 
AB/LS -/: NF-kappa/NN B/NN is/VBZ a/DT pleiotropic/JJ regulator/NN of/IN a/DT variety/NN of/IN genes/NNS implicated/VBN in/IN the/DT cellular/JJ response/NN to/TO injury/NN ./. 
This/DT function/NN has/VBZ been/VBN attributed/VBN to/TO the/DT coordinated/VBN binding/NN of/IN subunits/NNS of/IN NF-kappa/NN B/NN to/TO distinct/JJ regions/NNS of/IN the/DT promoter/JJ elements/NNS of/IN numerous/JJ genes/NNS ,/, including/VBG cytokines/NNS ,/, growth/NN factor/NN receptors/NNS ,/, and/CC adhesion/NN molecules/NNS ./. 
Antisense/JJ phosphorothioate/JJ oligonucleotides/NNS to/TO the/DT p50/NN and/CC p65/NN subunits/NNS of/IN the/DT NF-kappa/NN B/NN complex/NN were/VBD used/VBN to/TO define/VB the/DT physiologic/JJ role/NN of/IN this/DT transcription/NN factor/NN in/IN resting/VBG and/CC stimulated/VBN granulocytes/NNS ./. 
A/DT reduction/NN in/IN the/DT expression/NN of/IN p65/NN was/VBD produced/VBN by/IN treatment/NN with/IN the/DT phosphorothioate/JJ antisense/JJ oligodeoxynucleotide/NN ./. 
This/DT reduction/NN was/VBD accompanied/VBN by/IN rapid/JJ changes/NNS in/IN the/DT cellular/JJ adhesion/NN of/IN dimethyl/JJ sulfoxide-differentiated/JJ HL-60/NN leukemia/NN cells/NNS stimulated/VBN by/IN 12-O-tetradecanoylphorbol/NN 13-acetate/NN (/( TPA/NN )/) ./. 
These/DT effects/NNS were/VBD characterized/VBN by/IN a/DT marked/JJ reduction/NN in/IN CD11b/NN integrin/JJ expression/NN on/IN the/DT surface/NN of/IN treated/VBN cells/NNS ./. 
Furthermore/RB ,/, the/DT p65/NN antisense/JJ oligomer/NN effectively/RB abolished/VBD an/DT upregulation/NN of/IN CD11b/NN that/WDT was/VBD produced/VBN by/IN formyl-met-leu-phe/NN and/CC TPA/NN ./. 
However/RB ,/, the/DT p65/NN antisense/JJ phosphorothioate/JJ oligodeoxynucleotide/NN had/VBD no/DT significant/JJ effect/NN on/IN the/DT production/NN of/IN reactive/JJ oxygen/NN intermediates/NNS or/CC on/IN phagocytosis/NNS by/IN these/DT cells/NNS ./. 
These/DT findings/NNS indicate/VBP that/IN antisense/JJ oligomers/NNS to/TO p65/NN can/MD be/VB used/VBN to/TO define/VB the/DT role/NN of/IN NF-kappa/NN B/NN in/IN the/DT activation/NN pathways/NNS of/IN neutrophils/NNS ./. 
UI/LS -/: 93307660/CD 
TI/LS -/: The/DT p65/NN subunit/NN of/IN NF-kappa/NN B/NN regulates/VBZ I/NN kappa/NN B/NN by/IN two/CD distinct/JJ mechanisms/NNS ./. 
AB/LS -/: Transcription/NN factor/NN NF-kappa/NN B/NN (/( p50/p65/NN )/) is/VBZ generally/RB localized/JJ to/TO the/DT cytoplasm/NN by/IN its/PRP$ inhibitor/NN I/NN kappa/NN B/NN ./. 
Overproduced/JJ I/NN kappa/NN B/NN ,/, free/JJ from/IN NF-kappa/NN B/NN ,/, is/VBZ rapidly/RB degraded/VBN ./. 
Overexpression/NN of/IN p65/NN increases/VBZ endogenous/JJ I/NN kappa/NN B/NN protein/NN in/IN both/CC carcinoma/NN and/CC lymphoid/JJ cells/NNS by/IN two/CD mechanisms/NNS :/: protein/NN stabilization/NN and/CC increased/VBN transcription/NN of/IN I/NN kappa/NN B/NN mRNA/NN ./. 
In/IN contrast/NN ,/, p65/NN delta/NN ,/, a/DT naturally/RB occurring/VBG splice/NN variant/NN ,/, fails/VBZ to/TO markedly/RB augment/VB I/NN kappa/NN B/NN protein/NN levels/NNS ./. 
Both/CC overexpressed/JJ p65/NN and/CC coexpressed/JJ p50/NN are/VBP cytoplasmic/JJ ,/, whereas/IN p65/NN delta/NN is/VBZ partly/RB nuclear/JJ ,/, indicating/VBG that/IN the/DT I/NN kappa/NN B/NN induced/VBN by/IN p65/NN can/MD maintain/VB NF-kappa/NN B/NN in/IN the/DT cytoplasm/NN ./. 
Thus/RB ,/, p65/NN and/CC I/NN kappa/NN B/NN are/VBP linked/VBN in/IN an/DT autoregulatory/JJ loop/NN ,/, ensuring/VBG that/IN NF-kappa/NN B/NN is/VBZ held/VBN in/IN the/DT cytoplasm/NN until/IN cells/NNS are/VBP specifically/RB induced/VBN to/TO translocate/VB it/PRP to/TO the/DT nucleus/NN ./. 
UI/LS -/: 93280143/CD 
TI/LS -/: Lipopolysaccharide/NN induces/VBZ phosphorylation/NN of/IN MAD3/NN and/CC activation/NN of/IN c-Rel/NN and/CC related/JJ NF-kappa/NN B/NN proteins/NNS in/IN human/JJ monocytic/JJ THP-1/NN cells/NNS ./. 
AB/LS -/: Many/JJ effects/NNS of/IN lipopolysaccharide/NN (/( LPS/NN )/) on/IN gene/NN expression/NN ,/, including/VBG that/DT of/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) ,/, in/IN monocytic/JJ cells/NNS are/VBP mediated/VBN by/IN activation/NN of/IN kappa/NN B/NN DNA-binding/JJ proteins/NNS ./. 
However/RB ,/, the/DT specific/JJ members/NNS of/IN the/DT NF-kappa/NN B/Rel/NN transcription/NN factor/NN family/NN involved/VBN in/IN the/DT LPS/NN response/NN ,/, and/CC the/DT mechanisms/NNS through/IN which/WDT LPS-generated/JJ signals/NNS are/VBP transduced/VBN remain/VBP unclear/JJ ./. 
Here/RB we/PRP show/VBP that/IN LPS/NN induces/VBZ nuclear/JJ expression/NN of/IN c-Rel/p50/NN heterodimers/NNS as/RB well/RB as/IN p50/p65/NN (/( NF-kappa/NN B/NN )/) kappa/NN B/NN DNA-binding/JJ complexes/NNS in/IN human/JJ monocytic/JJ THP-1/NN cells/NNS ./. 
Nuclear/JJ localization/NN of/IN these/DT proteins/NNS occurred/VBD concomitantly/RB with/IN a/DT rapid/JJ decrease/NN in/IN their/PRP$ cytosolic/JJ levels/NNS and/CC was/VBD independent/JJ of/IN phorbol/NN ester-sensitive/JJ protein/NN kinase/NN C/NN ./. 
Within/IN 24/CD h/NN following/VBG LPS/NN stimulation/NN there/EX was/VBD a/DT striking/JJ increase/NN in/IN the/DT levels/NNS of/IN c-Rel/NN ,/, p105/NN ,/, and/CC p50/NN in/IN the/DT cytosol/NN ./. 
The/DT increased/VBN levels/NNS of/IN these/DT proteins/NNS correlated/VBD with/IN increases/NNS in/IN the/DT amounts/NNS of/IN their/PRP$ mRNAs/NNS during/IN LPS/NN activation/NN of/IN THP-1/NN cells/NNS ./. 
LPS/NN activation/NN of/IN THP-1/NN cells/NNS resulted/VBD in/IN phosphorylation/NN of/IN MAD3/NN (/( an/DT I/NN kappa/NN B-like/JJ protein/NN )/) ,/, a/DT rapid/JJ increase/NN in/IN MAD3/NN mRNA/NN ,/, and/CC an/DT increase/NN in/IN MAD3/NN protein/NN by/IN 2/CD h/NN ./. 
Thus/RB ,/, LPS/NN activation/NN of/IN human/JJ monocytic/JJ cells/NNS results/VBZ in/IN nuclear/JJ expression/NN of/IN c-Rel/p50/NN and/CC p50/p65/NN (/( NF-kappa/NN B/NN )/) and/CC induces/VBZ phosphorylation/NN of/IN MAD3/NN ./. 
UI/LS -/: 93252936/CD 
TI/LS -/: A/DT chimeric/JJ type/NN II/CD //: type/NN I/CD interleukin-1/NN receptor/NN can/MD mediate/VB interleukin-1/NN induction/NN of/IN gene/NN expression/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: The/DT type/NN I/CD interleukin-1/NN receptor/NN (/( IL-1R/NN )/) is/VBZ capable/JJ of/IN transducing/VBG a/DT signal/NN resulting/VBG in/IN promoter/NN activation/NN in/IN T/NN cells/NNS ./. 
This/DT signal/NN transduction/NN is/VBZ dependent/JJ on/IN the/DT cytoplasmic/JJ domain/NN ,/, which/WDT consists/VBZ of/IN 213/CD amino/NN acids/NNS ./. 
In/IN contrast/NN to/TO the/DT type/NN I/CD receptor/NN ,/, the/DT type/NN II/CD IL-1R/NN has/VBZ a/DT small/JJ cytoplasmic/JJ tail/NN ,/, and/CC it/PRP is/VBZ not/RB clear/JJ whether/IN this/DT receptor/NN is/VBZ a/DT signal-transducing/JJ or/CC a/DT regulatory/JJ molecule/NN ./. 
Here/RB we/PRP report/VBP that/IN the/DT type/NN II/CD IL-1R/NN does/VBZ not/RB mediate/VB gene/NN activation/NN in/IN Jurkat/NN cells/NNS ./. 
However/RB ,/, a/DT hybrid/NN receptor/NN composed/VBN of/IN the/DT extracellular/JJ and/CC transmembrane/NN regions/NNS of/IN the/DT human/JJ type/NN II/CD interleukin-1/NN fused/VBN to/TO the/DT cytoplasmic/JJ domain/NN of/IN the/DT human/JJ type/NN I/CD IL-1R/NN was/VBD capable/JJ of/IN transducing/VBG a/DT signal/NN across/IN the/DT membrane/NN resulting/VBG in/IN a/DT pattern/NN of/IN gene/NN activation/NN identical/JJ to/TO that/DT mediated/VBN by/IN the/DT type/NN I/CD IL-1R/NN ./. 
Our/PRP$ results/NNS indicated/VBD that/IN the/DT extracellular/JJ domain/NN of/IN the/DT type/NN II/CD IL-1R/NN was/VBD capable/JJ of/IN functionally/RB interacting/VBG with/IN interleukin-1/NN and/CC transmitting/VBG the/DT resulting/VBG signal/NN to/TO a/DT heterologous/JJ cytoplasmic/JJ domain/NN ./. 
UI/LS -/: 93253031/CD 
TI/LS -/: A/DT mutation/NN of/IN the/DT glucocorticoid/NN receptor/NN in/IN primary/JJ cortisol/NN resistance/NN ./. 
AB/LS -/: The/DT precise/JJ molecular/JJ abnormalities/NNS that/WDT cause/VBP primary/JJ cortisol/NN resistance/NN have/VBP not/RB been/VBN completely/RB described/VBN ./. 
In/IN a/DT subject/NN with/IN primary/JJ cortisol/NN resistance/NN we/PRP have/VBP observed/VBN glucocorticoid/NN receptors/NNS (/( hGR/NN )/) with/IN a/DT decreased/VBN affinity/NN for/IN dexamethasone/NN ./. 
We/PRP hypothesize/VBP that/IN a/DT mutation/NN of/IN the/DT hGR/NN glucocorticoid-binding/JJ domain/NN is/VBZ the/DT cause/NN of/IN cortisol/NN resistance/NN ./. 
Total/JJ RNA/NN isolated/VBN from/IN the/DT index/NN subject/NN 's/POS mononuclear/JJ leukocytes/NNS was/VBD used/VBN to/TO produce/VB first/JJ strand/NN hGR/NN cDNAs/NNS ,/, and/CC the/DT entire/JJ hGR/NN cDNA/NN was/VBD amplified/VBN in/IN segments/NNS and/CC sequenced/VBN ./. 
At/IN nucleotide/NN 2/CD ,/, 317/CD we/PRP identified/VBD a/DT homozygous/JJ A/NN for/IN G/NN point/NN mutation/NN that/WDT predicts/VBZ an/DT isoleucine/NN (/( ATT/NN )/) for/IN valine/NN (/( GTT/NN )/) substitution/NN at/IN amino/NN acid/NN 729/CD ./. 
When/WRB the/DT wild-type/JJ hGR/NN and/CC hGR-Ile/NN 729/CD were/VBD expressed/VBN in/IN COS-1/NN cells/NNS and/CC assayed/VBN for/IN [3H]-Dexamethasone/NN binding/NN ,/, the/DT dissociation/NN constants/NNS were/VBD 0.799/CD +/-/CC 0.068/CD and/CC 1.54/CD +/-/CC 0.06/CD nM/NN (/( mean/NN +/-/CC SEM/NN )/) (/( P/NN </JJR 0.01/CD )/) ,/, respectively/RB ./. 
When/WRB the/DT wild-type/JJ hGR/NN and/CC hGR-Ile/NN 729/CD were/VBD expressed/VBN in/IN CV-1/NN cells/NNS that/WDT were/VBD cotransfected/VBN with/IN the/DT mouse/NN mammary/JJ tumor/NN virus/NN long/JJ terminal/JJ repeat/NN fused/VBN to/TO the/DT chloramphenicol/NN acetyl/NN transferase/NN (/( CAT/NN )/) gene/NN ,/, the/DT hGR-Ile/NN 729/CD conferred/VBD a/DT fourfold/JJ decrease/NN in/IN apparent/JJ potency/NN on/IN dexamethasone/NN stimulation/NN of/IN CAT/NN activity/NN ./. 
The/DT isoleucine/NN for/IN valine/NN substitution/NN at/IN amino/NN acid/NN 729/CD impairs/VBZ the/DT function/NN of/IN the/DT hGR/NN and/CC is/VBZ the/DT likely/JJ cause/NN of/IN primary/JJ cortisol/NN resistance/NN in/IN this/DT subject/NN ./. 
UI/LS -/: 93205400/CD 
TI/LS -/: The/DT transcriptionally/RB active/JJ factors/NNS mediating/VBG the/DT effect/NN of/IN the/DT HTLV-I/NN Tax/NN transactivator/NN on/IN the/DT IL-2R/NN alpha/NN kappa/NN B/NN enhancer/NN include/VBP the/DT product/NN of/IN the/DT c-rel/NN proto-oncogene/NN ./. 
AB/LS -/: The/DT transactivator/NN HTLV-I/NN Tax/NN activates/VBZ the/DT promoter/NN of/IN the/DT gene/NN coding/VBG for/IN the/DT interleukin/NN 2/CD alpha-chain/JJ receptor/NN (/( IL-2R/NN alpha/NN )/) via/IN a/DT kappa/NN B/NN site/NN that/WDT can/MD bind/VB several/JJ protein/NN species/NNS of/IN the/DT rel/NN family/NN ./. 
Tax1/NN strongly/RB activates/VBZ the/DT enhancer/NN activity/NN of/IN this/DT motif/NN ,/, in/IN both/CC epithelial/JJ HeLa/NN and/CC lymphoid/JJ Jurkat/NN cells/NNS ./. 
This/DT activation/NN was/VBD not/RB observed/VBN in/IN undifferentiated/JJ embryocarcinoma/NN F9/NN cells/NNS ./. 
Overexpression/NN of/IN the/DT p50/NN ,/, p65/NN and/CC Rel/NN proteins/NNS in/IN these/DT cells/NNS showed/VBD that/IN significant/JJ activation/NN of/IN the/DT IL-2R/NN alpha/NN kappa/NN B/NN site/NN was/VBD observed/VBN only/RB with/IN Rel/NN and/CC Rel/NN plus/CC p65/NN ./. 
Moreover/RB ,/, whereas/IN both/CC Tax/NN and/CC phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) are/VBP able/JJ to/TO efficiently/RB induce/VB the/DT binding/NN of/IN NF-kappa/NN B/NN to/TO the/DT IL-2R/NN alpha/NN kappa/NN B/NN site/NN ,/, PMA/NN is/VBZ functionally/RB inactive/JJ ./. 
Using/VBG the/DT DNA/NN affinity/NN precipitation/NN assay/NN ,/, we/PRP observed/VBD that/IN Tax1/NN is/VBZ able/JJ to/TO efficiently/RB induce/VB the/DT binding/NN of/IN Rel/NN ,/, whereas/IN PMA/NN is/VBZ not/RB ./. 
This/DT established/VBD a/DT clear/JJ difference/NN between/IN both/DT stimuli/NNS ,/, indicating/VBG that/IN Rel/NN is/VBZ the/DT functionally/RB active/JJ factor/NN ./. 
We/PRP conclude/VBP from/IN these/DT results/NNS that/IN the/DT functional/JJ activity/NN of/IN members/NNS of/IN the/DT rel/NN family/NN is/VBZ regulated/VBN by/IN their/PRP$ interaction/NN with/IN DNA/NN and/CC that/IN Rel/NN can/MD be/VB a/DT potent/JJ transcriptional/JJ activator/NN on/IN specific/JJ kappa/NN B/NN sites/NNS ./. 
UI/LS -/: 93203219/CD 
TI/LS -/: Transcriptional/JJ regulation/NN of/IN interleukin/NN 3/CD (/( IL3/NN )/) in/IN primary/JJ human/JJ T/NN lymphocytes/NNS ./. 
Role/NN of/IN AP-1-/NN and/CC octamer-binding/JJ proteins/NNS in/IN control/NN of/IN IL3/NN gene/NN expression/NN ./. 
AB/LS -/: We/PRP have/VBP investigated/VBN the/DT molecular/JJ and/CC biochemical/JJ basis/NN for/IN activation/NN of/IN interleukin/NN 3/CD (/( IL3/NN )/) gene/NN expression/NN in/IN primary/JJ human/JJ T/NN lymphocytes/NNS following/VBG CD3/NN and/CC CD2/NN receptor/NN stimulation/NN or/CC activation/NN by/IN phytohemagglutinin/NN plus/CC phorbol/NN 12-myristate/NN 13-acetate/NN ./. 
Using/VBG transfection/NN and/CC reporter/NN gene/NN assays/NNS specifically/RB designed/VBN for/IN primary/JJ T/NN lymphocytes/NNS in/IN conjunction/NN with/IN gel/NN retardation/NN assays/NNS ,/, Western/NN blot/NN analyses/NNS and/CC UV/NN cross-linking/JJ studies/NNS ,/, we/PRP found/VBD that/IN c-Jun/NN ,/, c-Fos/NN ,/, and/CC octamer-binding/NN proteins/NNS play/VBP a/DT major/JJ role/NN in/IN transcriptional/JJ activation/NN of/IN the/DT IL3/NN gene/NN via/IN their/PRP$ interaction/NN with/IN two/CD specific/JJ regions/NNS contained/VBN within/IN the/DT IL3/NN 5'-flanking/JJ sequence/NN ./. 
Additionally/RB ,/, the/DT region/NN between/IN bases/NNS -107/CD and/CC -59/CD of/IN the/DT IL3/NN promoter/NN containing/VBG putative/JJ AP-2/NN and/CC Sp1/NN binding/NN motifs/NNS appears/VBZ necessary/JJ for/IN basal/JJ level/NN expression/NN of/IN the/DT IL3/NN gene/NN ./. 
The/DT data/NNS also/RB indicate/VBP that/IN CD2/NN receptor/NN activation/NN and/CC phytohemagglutinin/NN plus/CC phorbol/NN 12-myristate/NN 13-acetate/NN stimulation/NN augment/VBP T/NN cell/NN IL3/NN gene/NN expression/NN through/IN the/DT same/JJ cis-/JJ and/CC trans-activating/JJ signals/NNS ./. 
These/DT results/NNS should/MD contribute/VB to/TO a/DT better/JJR understanding/NN of/IN the/DT regulation/NN of/IN IL3/NN gene/NN expression/NN in/IN human/JJ T/NN lymphocytes/NNS ./. 
UI/LS -/: 93180775/CD 
TI/LS -/: Dimerization/NN of/IN NF-KB2/NN with/IN RelA/NN (/( p65/NN )/) regulates/VBZ DNA/NN binding/NN ,/, transcriptional/JJ activation/NN ,/, and/CC inhibition/NN by/IN an/DT I/NN kappa/NN B-alpha/NN (/( MAD-3/NN )/) ./. 
AB/LS -/: Inducible/JJ expression/NN of/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) is/VBZ regulated/VBN by/IN a/DT cellular/JJ transcription/NN factor/NN ,/, nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ./. 
NF-kappa/NN B/NN is/VBZ composed/VBN of/IN distinct/JJ subunits/NNS ;/: five/CD independent/JJ genes/NNS ,/, NFKB1/NN (/( p105/NN )/) ,/, NFKB2/NN (/( p100/NN )/) ,/, RelA/NN (/( p65/NN )/) ,/, c-rel/NN and/CC relB/NN ,/, that/WDT encode/VBP related/JJ proteins/NNS that/WDT bind/VBP to/TO kappa/NN B/NN DNA/NN elements/NNS have/VBP been/VBN isolated/VBN ./. 
We/PRP have/VBP previously/RB found/VBN that/IN NFKB2/NN (/( p49/p52/NN )/) acts/VBZ in/IN concert/NN with/IN RelA/NN (/( p65/NN )/) to/TO stimulate/VB the/DT HIV/NN enhancer/NN in/IN Jurkat/NN T-leukemia/NN cells/NNS ./. 
Here/RB we/PRP examine/VBP the/DT biochemical/JJ basis/NN for/IN the/DT transcriptional/JJ regulation/NN of/IN HIV/NN by/IN NFKB2/NN ./. 
Using/VBG Scatchard/NN analysis/NN ,/, we/PRP have/VBP determined/VBN the/DT dissociation/NN constants/NNS of/IN homodimeric/JJ p49/NN and/CC heterodimeric/JJ p49/p65/NN for/IN binding/NN to/TO the/DT HIV/NN kappa/NN B/NN site/NN ./. 
p49/NN has/VBZ a/DT approximately/RB 18-fold-lower/JJ affinity/NN for/IN the/DT HIV/NN kappa/NN B/NN site/NN (/( KD/NN =/JJ 69.1/CD pM/NN )/) than/IN does/VBZ the/DT approximately/RB 50-kDa/JJ protein/NN NFKB1/NN (/( p50/NN )/) derived/VBN from/IN p105/NN (/( KD/NN =/JJ 3.9/CD pM/NN )/) ./. 
In/IN contrast/NN ,/, the/DT affinity/NN of/IN heterodimeric/JJ NFKB2/NN (/( p49/NN )/) /RelA/NN (/( p65/NN )/) for/IN this/DT site/NN is/VBZ approximately/RB 6-fold/RB higher/JJR (/( KD/NN =/JJ 11.8/CD pM/NN )/) than/IN that/DT of/IN p49/NN alone/RB ./. 
Consistent/JJ with/IN these/DT findings/NNS ,/, in/FW vitro/FW transcription/NN was/VBD stimulated/VBN 18-fold/RB by/IN the/DT addition/NN of/IN preformed/JJ ,/, heterodimeric/JJ NFKB2/NN (/( p49/NN )/) /RelA/NN (/( p65/NN )/) protein/NN ./. 
Transcriptional/JJ activation/NN of/IN the/DT HIV/NN enhancer/NN was/VBD also/RB subject/JJ to/TO regulation/NN by/IN recently/RB cloned/VBN I/NN kappa/NN B-alpha/NN (/( MAD-3/NN )/) ./. 
Recombinant/JJ I/NN kappa/NN B-alpha/NN (/( MAD-3/NN )/) inhibited/VBD the/DT DNA/NN binding/NN activity/NN of/IN p65/NN ,/, p49/p65/NN ,/, and/CC p50/p65/NN but/CC stimulated/VBD the/DT binding/NN of/IN NFKB2/NN (/( p49/NN )/) or/CC NFKB1/NN (/( p50/NN )/) ./. 
Functional/JJ activation/NN of/IN an/DT HIV/NN reporter/NN plasmid/NN by/IN p49/p65/NN in/IN transiently/RB transfected/VBN Jurkat/NN T-leukemia/JJ cells/NNS was/VBD also/RB inhibited/VBN by/IN coexpression/NN of/IN MAD-3/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 93157335/CD 
TI/LS -/: The/DT c-rel/NN protooncogene/NN product/NN represses/VBZ NF-kappa/NN B/NN p65-mediated/JJ transcriptional/JJ activation/NN of/IN the/DT long/JJ terminal/JJ repeat/NN of/IN type/NN 1/CD human/JJ immunodeficiency/NN virus/NN ./. 
AB/LS -/: The/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) of/IN the/DT type/NN 1/CD human/JJ immunodeficiency/NN virus/NN (/( HIV-1/NN )/) and/CC the/DT 5'/JJ regulatory/JJ region/NN of/IN the/DT gene/NN encoding/VBG the/DT interleukin/NN 2/CD receptor/NN alpha/NN subunit/NN (/( IL-2R/NN alpha/NN )/) share/NN functional/JJ kappa/NN B/NN enhancer/NN elements/NNS involved/VBN in/IN the/DT regulation/NN of/IN these/DT inducible/JJ transcription/NN units/NNS during/IN T-cell/NN activation/NN ./. 
These/DT kappa/NN B/NN enhancer/NN elements/NNS are/VBP recognized/VBN by/IN a/DT structurally/RB related/JJ family/NN of/IN interactive/JJ proteins/NNS that/WDT includes/VBZ p50/NN ,/, p65/NN ,/, and/CC the/DT product/NN of/IN the/DT c-rel/NN protooncogene/NN (/( c-Rel/NN )/) ./. 
Recent/JJ biochemical/JJ studies/NNS have/VBP shown/VBN that/IN p65/NN and/CC p50/NN form/VBP the/DT prototypical/JJ NF-kappa/NN B/NN complex/NN ,/, which/WDT is/VBZ rapidly/RB translocated/VBN from/IN the/DT cytoplasm/NN to/TO the/DT nucleus/NN during/IN T-cell/NN activation/NN ./. 
This/DT intracellular/JJ signaling/NN complex/NN potently/RB stimulates/VBZ kappa/NN B-directed/JJ transcription/NN from/IN either/CC the/DT HIV-1/NN LTR/NN or/CC the/DT IL-2R/NN alpha/NN promoter/NN via/IN the/DT strong/JJ transactivation/NN domain/NN present/JJ in/IN p65/NN ./. 
We/PRP now/RB demonstrate/VBP that/IN nuclear/JJ expression/NN of/IN human/JJ c-Rel/NN ,/, which/WDT is/VBZ induced/VBN by/IN either/DT phorbol/NN ester/NN or/CC tumor/NN necrosis/NN factor/NN alpha/NN with/IN delayed/VBN kinetics/NNS relative/JJ to/TO p65/NN ,/, markedly/RB represses/VBZ p65-mediated/JJ activation/NN of/IN these/DT transcription/NN units/NNS ./. 
These/DT inhibitory/JJ effects/NNS of/IN c-Rel/NN correlate/VBP with/IN its/PRP$ DNA-binding/JJ activity/NN but/CC not/RB with/IN its/PRP$ ability/NN to/TO heterodimerize/VB with/IN p50/NN ,/, suggesting/VBG that/IN c-Rel/NN inhibition/NN involves/VBZ competition/NN with/IN p50/p65/NN for/IN occupancy/NN of/IN the/DT kappa/NN B/NN enhancer/NN element/NN ./. 
Together/RB ,/, these/DT findings/NNS suggest/VBP that/IN one/CD function/NN of/IN c-Rel/NN is/VBZ as/IN a/DT physiologic/JJ repressor/NN of/IN the/DT HIV-1/NN LTR/NN and/CC IL-2R/NN alpha/NN promoters/NNS ,/, serving/VBG to/TO efficiently/RB counter/VB the/DT strong/JJ transcriptional/JJ activating/JJ effects/NNS of/IN p65/NN ./. 
UI/LS -/: 93141262/CD 
TI/LS -/: Ras/NN oncogene/NN transformation/NN of/IN human/JJ B/NN lymphoblasts/NNS is/VBZ associated/VBN with/IN lymphocyte/NN activation/NN and/CC with/IN a/DT block/NN of/IN differentiation/NN ./. 
AB/LS -/: The/DT p21ras/NN small/JJ GTP/NN binding/NN proteins/NNS participate/VBP in/IN signal/JJ transduction/NN from/IN cell/NN surface/NN receptors/NNS and/CC affect/VB neoplastic/JJ transformation/NN and/CC development/NN in/IN many/JJ different/JJ cell/NN types/NNS ./. 
In/IN the/DT present/JJ study/NN ,/, we/PRP examined/VBD the/DT relationship/NN between/IN ras/NN transformation/NN and/CC differentiation/NN of/IN human/JJ B/NN lymphocytes/NNS ./. 
We/PRP show/VBP that/IN the/DT constitutive/JJ expression/NN of/IN the/DT T24/NN Ha-ras/NN oncogene/NN in/IN EBV-immortalized/JJ B/NN lymphoblasts/NNS was/VBD associated/VBN with/IN the/DT induction/NN of/IN the/DT interleukin/NN 2/CD receptor/NN alpha/NN subunit/NN ,/, with/IN an/DT impaired/JJ immunoglobulin/NN gene/NN expression/NN ,/, altered/JJ adhesion/NN properties/NNS and/CC increased/VBN survival/NN in/IN serum-free/JJ medium/NN ./. 
Since/IN induction/NN of/IN the/DT IL-2/NN receptor/NN alpha/NN subunit/NN is/VBZ a/DT hallmark/NN of/IN lymphocyte/NN activation/NN ,/, we/PRP suggest/VBP that/IN p21ras/NN naturally/RB triggers/VBZ B/NN cell/NN activation/NN ./. 
The/DT ras-transformed/JJ lymphocytes/NNS displayed/VBD a/DT fully/RB functional/JJ IL-2r/NN ,/, as/IN assessed/VBN by/IN c-fos/NN induction/NN following/VBG treatment/NN with/IN IL-2/NN ;/: nevertheless/RB ,/, they/PRP were/VBD not/RB growth/NN stimulated/VBN by/IN this/DT lymphokine/NN ./. 
The/DT decreased/VBN expression/NN of/IN immunoglobulin/NN genes/NNS indicates/VBZ that/IN the/DT ras/NN oncogene/NN blocks/VBZ terminal/JJ differentiation/NN to/TO plasma/NN cells/NNS ,/, possibly/RB by/IN inhibiting/VBG the/DT activity/NN of/IN lymphocyte-specific/JJ transcription/NN factors/NNS ./. 
Somewhat/RB unexpectedly/RB ,/, the/DT constitutive/JJ p21ras/NN activity/NN did/VBD not/RB cause/VB an/DT increased/VBN DNA/NN binding/NN of/IN transcription/NN factors/NNS PEA1/NN (/( AP1/NN )/) ,/, PEA3/NN ,/, Oct-2/NN or/CC NF-kB/NN 
UI/LS -/: 93300824/CD 
TI/LS -/: Comparative/JJ analysis/NN of/IN NFAT/NN (/( nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS )/) complex/JJ in/IN human/JJ T/NN and/CC B/NN lymphocytes/NNS ./. 
AB/LS -/: Nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NFAT/NN )/) is/VBZ a/DT transcriptional/JJ activator/NN that/WDT binds/VBZ to/TO sequences/NNS in/IN the/DT interleukin-2/NN (/( IL-2/NN )/) promoter/NN and/CC is/VBZ thought/VBN to/TO be/VB largely/RB responsible/JJ for/IN the/DT T/NN cell-specific/JJ inducibility/NN of/IN IL-2/NN expression/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS (/( EMSA/NN )/) showed/VBD that/IN specific/JJ NFAT/NN binding/NN activity/NN could/MD also/RB be/VB induced/VBN in/IN human/JJ B/NN cells/NNS ./. 
The/DT B/NN cell/NN NFAT/NN complex/NN ,/, however/RB ,/, was/VBD not/RB functional/JJ ,/, since/IN it/PRP failed/VBD to/TO activate/VB transcription/NN from/IN an/DT NFAT-driven/JJ chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) construct/NN ./. 
Competition/NN with/IN an/DT AP-1/NN motif/NN or/CC with/IN anti-Jun/JJ and/CC anti-Fos/JJ antibodies/NNS abolished/VBD binding/NN to/TO the/DT NFAT/NN motif/NN in/IN both/CC T/NN and/CC B/NN cells/NNS ,/, indicating/VBG that/IN Jun/NN and/CC Fos/NN are/VBP critical/JJ for/IN NFAT/NN complex/NN formation/NN in/IN both/DT cell/NN types/NNS ./. 
Purified/VBN recombinant/JJ Jun/NN and/CC Fos/NN proteins/NNS failed/VBD to/TO bind/VB directly/RB to/TO the/DT NFAT/NN motif/NN ./. 
However/RB ,/, when/WRB combined/VBN with/IN unstimulated/JJ B/NN or/CC T/NN cell/NN extracts/NNS ,/, full-length/JJ ,/, but/CC not/RB truncated/VBN ,/, Jun/Fos/NN heterodimers/NNS were/VBD able/JJ to/TO form/VB an/DT NFAT/NN complex/NN ,/, indicating/VBG the/DT presence/NN of/IN a/DT constitutively/RB expressed/VBN nuclear/JJ factor/NN (/( s/NNS )/) in/IN B/NN and/CC T/NN cells/NNS necessary/JJ for/IN the/DT formation/NN of/IN the/DT NFAT/NN complex/NN in/IN both/DT cell/NN types/NNS ./. 
An/DT NFAT/NN oligonucleotide/NN carrying/VBG mutations/NNS in/IN the/DT 5'/JJ purine-rich/JJ part/NN of/IN the/DT NFAT/NN sequence/NN failed/VBD to/TO form/VB a/DT complex/NN and/CC to/TO compete/VB with/IN the/DT wild/JJ type/NN motif/NN for/IN NFAT/NN complex/NN formation/NN in/IN both/CC T/NN and/CC B/NN cells/NNS ./. 
We/PRP therefore/RB propose/VBP a/DT model/NN whereby/WRB a/DT core/NN NFAT/NN complex/NN consisting/VBG of/IN Jun/NN ,/, Fos/NN ,/, and/CC a/DT constitutive/JJ nuclear/JJ factor/NN is/VBZ formed/VBN in/IN both/DT T/NN and/CC B/NN cells/NNS ,/, but/CC an/DT additional/JJ factor/NN and/or/CC post-translational/JJ modification/NN of/IN a/DT factor/NN ,/, missing/VBG in/IN B/NN cells/NNS ,/, might/MD be/VB required/VBN for/IN transactivation/NN by/IN NFAT/NN ./. 
UI/LS -/: 93307152/CD 
TI/LS -/: Differential/JJ autoregulation/NN of/IN glucocorticoid/NN receptor/NN expression/NN in/IN human/JJ T-/NN and/CC B-cell/NN lines/NNS ./. 
AB/LS -/: Regulation/NN of/IN glucocorticoid/NN receptor/NN (/( GR/NN )/) expression/NN by/IN its/PRP$ cognate/JJ ligand/NN was/VBD examined/VBN in/IN the/DT glucocorticoid-sensitive/JJ human/JJ leukemic/JJ T-cell/NN line/NN 6TG1.1/NN and/CC in/IN the/DT human/JJ B-cell/NN line/NN IM-9/NN ./. 
In/IN contrast/NN to/TO the/DT decrease/NN in/IN GR/NN mRNA/NN seen/VBN in/IN IM-9/NN cells/NNS after/IN treatment/NN with/IN 1/CD microM/NN dexamethasone/NN for/IN 16-18/CD h/NN ,/, treatment/NN of/IN 6TG1.1/NN cells/NNS resulted/VBD in/IN an/DT 8-fold/JJ increase/NN in/IN GR/NN mRNA/NN ,/, as/IN determined/VBN by/IN Northern/NN blot/NN and/CC RNase/NN protection/NN analysis/NN ,/, with/IN a/DT corresponding/JJ 3-/CD to/TO 4-fold/JJ increase/NN in/IN GR/NN protein/NN ./. 
Half-maximal/JJ induction/NN of/IN GR/NN mRNA/NN and/CC protein/NN in/IN 6TG1.1/NN cells/NNS was/VBD observed/VBN between/IN 10-100/CD nM/NN dexamethasone/NN ,/, and/CC inclusion/NN of/IN 1/CD microM/NN RU/NN 38486/CD completely/RB blocked/VBD the/DT effects/NNS of/IN 100/CD nM/NN dexamethasone/NN ,/, demonstrating/VBG that/IN positive/JJ autoregulation/NN of/IN GR/NN expression/NN in/IN 6TG1.1/NN cells/NNS is/VBZ a/DT receptor-mediated/JJ response/NN ./. 
Positive/JJ autoregulation/NN of/IN GR/NN expression/NN was/VBD also/RB observed/VBN in/IN glucocorticoid-resistant/JJ CEM-C1/NN cells/NNS ,/, which/WDT contain/VBP functional/JJ GR/NN ,/, but/CC whose/WP$ growth/NN is/VBZ unaffected/VBN by/IN glucocorticoids/NNS ./. 
Thus/RB ,/, positive/JJ autoregulation/NN is/VBZ neither/CC a/DT consequence/NN nor/CC the/DT sole/JJ cause/NN of/IN growth/NN arrest/NN ./. 
The/DT degree/NN of/IN negative/JJ autoregulation/NN in/IN IM-9/NN cells/NNS and/CC positive/JJ autoregulation/NN in/IN 6TG1.1/NN cells/NNS was/VBD unaffected/VBN by/IN inhibition/NN of/IN protein/NN synthesis/NN with/IN cycloheximide/NN ./. 
Measurement/NN of/IN GR/NN mRNA/NN turnover/NN in/IN 6TG1.1/NN cells/NNS treated/VBN with/IN actinomycin-D/NN revealed/VBD a/DT half-life/NN of/IN 2.5/CD h/NN ,/, which/WDT was/VBD unaffected/JJ by/IN dexamethasone/NN treatment/NN ./. 
A/DT similar/JJ half-life/NN was/VBD determined/VBN in/IN IM-9/NN cells/NNS and/CC was/VBD also/RB unaffected/JJ by/IN steroid/NN treatment/NN ./. 
These/DT results/NNS are/VBP consistent/JJ with/IN the/DT interpretation/NN that/IN glucocorticoid-mediated/JJ autoregulation/NN of/IN GR/NN expression/NN is/VBZ a/DT tissue-specific/JJ primary/JJ transcriptional/JJ response/NN ./. 
UI/LS -/: 93280865/CD 
TI/LS -/: Induction/NN of/IN CD8/NN antigen/NN and/CC suppressor/NN activity/NN by/IN glucocorticoids/NNS in/IN a/DT CEM/NN human/JJ leukemic/JJ cell/NN clone/NN ./. 
AB/LS -/: The/DT relationship/NN between/IN glucocorticoid/NN effect/NN and/CC regulation/NN of/IN cell/NN surface/NN antigens/NNS was/VBD investigated/VBN in/IN two/CD models/NNS of/IN leukemic/JJ cell/NN lines/NNS ,/, CEM/NN C7/NN denoted/VBN (/( r+/JJ ,/, ly+/JJ )/) and/CC CEM/NN C1/NN (/( r+/JJ ,/, ly-/JJ )/) ./. 
The/DT reactivity/NN of/IN murine/JJ monoclonal/JJ antibodies/NNS ,/, anti-CD4-FITC/NN ,/, anti-CD8-FITC/NN ,/, anti-CD2-FITC/NN and/CC anti-calla-FITC/NN ,/, were/VBD analyzed/VBN using/VBG flow/NN cytometry/NN ./. 
The/DT suppressor/NN function/NN was/VBD determined/VBN using/VBG [3H]thymidine/NN incorporation/NN into/IN phytohemagglutinin-activated/JJ peripheral/JJ blood/NN lymphocytes/NNS ./. 
Dexamethasone/NN treatment/NN of/IN a/DT human/JJ leukemic/JJ cell/NN clone/NN CEM/NN C7/NN caused/VBD an/DT increase/NN in/IN a/DT subset/NN of/IN cells/NNS expressing/VBG the/DT surface/NN antigen/NN CD8/NN ,/, which/WDT is/VBZ present/JJ on/IN suppressor/NN and/CC cytotoxic/JJ T-lymphocytes/NNS ./. 
By/IN comparison/NN ,/, there/EX was/VBD no/DT modification/NN of/IN the/DT expression/NN of/IN CD4/NN antigen/NN ,/, which/WDT is/VBZ expressed/VBN at/IN high/JJ levels/NNS in/IN these/DT cells/NNS ./. 
After/IN two/CD days/NNS of/IN treatment/NN with/IN 5/CD x/NN 10/CD (/( -8/CD )/) M/NN dexamethasone/NN ,/, CEM/NN C7/NN cells/NNS showed/VBD a/DT two-fold/JJ increase/NN in/IN suppressor/NN activity/NN compared/VBN to/TO untreated/JJ cells/NNS ./. 
In/IN contrast/NN ,/, there/EX was/VBD no/DT regulation/NN by/IN glucocorticoids/NNS of/IN either/CC the/DT CD8/NN or/CC CD4/NN antigens/NNS in/IN the/DT leukemic/JJ clone/NN CEM/NN C1/NN ./. 
Furthermore/RB ,/, no/DT modification/NN of/IN the/DT suppressor/NN function/NN in/IN CEM/NN C1/NN cells/NNS by/IN dexamethasone/NN was/VBD observed/VBN ./. 
In/IN the/DT human/JJ leukemic/JJ cells/NNS studied/VBN here/RB ,/, the/DT ability/NN to/TO induce/VB CD8/NN antigen/NN expression/NN in/IN a/DT CD4+/JJ cells/NNS correlates/VBZ with/IN the/DT ability/NN to/TO induce/VB cell/NN lysis/NN in/IN a/DT glucocorticoid/NN receptor/NN positive/JJ cell/NN population/NN ./. 
UI/LS -/: 93246644/CD 
TI/LS -/: Adenovirus/NN E1A/NN inhibits/VBZ IFN-induced/JJ resistance/NN to/TO cytolysis/NN by/IN natural/JJ killer/NN cells/NNS ./. 
AB/LS -/: Infection/NN of/IN target/NN cells/NNS with/IN cytopathic/JJ viruses/NNS inhibits/VBZ IFN/NN induction/NN of/IN cytolytic/JJ resistance/NN to/TO NK/NN cell-mediated/JJ cytolysis/NN [/( IFN-mediated/JJ cytoprotection/NN (/( IFN-MCP/NN )/) ]/) ./. 
It/PRP has/VBZ been/VBN thought/VBN that/IN the/DT virally/RB induced/VBN inhibition/NN of/IN IFN-MCP/NN is/VBZ secondary/JJ to/TO the/DT shutdown/NN of/IN cellular/JJ macromolecular/JJ synthesis/NN that/WDT accompanies/VBZ cytopathic/JJ virus/NN infections/NNS ./. 
Group/NN C/NN ,/, adenovirus/NN serotype/NN 5/CD (/( Ad5/NN )/) infection/NN inhibits/VBZ both/CC IFN-MCP/NN and/CC cellular/JJ protein/NN synthesis/NN ./. 
This/DT study/NN determined/VBD if/IN the/DT Ad5-induced/JJ inhibition/NN of/IN IFN-MCP/NN was/VBD independent/JJ of/IN adenovirus/NN (/( Ad/NN )/) infection/NN and/CC secondary/JJ only/RB to/TO the/DT expression/NN of/IN the/DT Ad/NN early/JJ region/NN 1A/NN gene/NN (/( E1A/NN )/) ./. 
To/TO test/VB this/DT hypothesis/NN ,/, 4-h/JJ NK/NN cytolysis/NN assays/NNS were/VBD performed/VBN on/IN IFN-gamma-treated/JJ human/JJ cells/NNS infected/VBN with/IN an/DT Ad5/NN E1A/NN deletion/NN mutant/NN ,/, dl343/NN ,/, or/CC transfected/VBN with/IN the/DT Ad5/NN E1A/NN gene/NN ./. 
IFN-MCP/NN was/VBD not/RB inhibited/VBN by/IN infection/NN with/IN dl343/NN ,/, despite/IN the/DT production/NN of/IN large/JJ amounts/NNS of/IN both/CC early/JJ (/( E1B/NN ,/, p55/NN )/) and/CC late/JJ (/( hexon/NN )/) Ad/NN proteins/NNS ./. 
In/IN contrast/NN to/TO E1A-negative/JJ ,/, parental/JJ cell/NN lines/NNS ,/, IFN-MCP/NN was/VBD blocked/VBN in/IN Ad5/NN E1A-transfected/JJ epithelial/JJ and/CC fibroblastic/JJ cell/NN lines/NNS ./. 
Genetic/JJ mapping/NN studies/NNS within/IN the/DT E1A/NN gene/NN demonstrated/VBD that/IN expression/NN of/IN only/RB the/DT first/JJ exon/NN of/IN E1A/NN was/VBD sufficient/JJ to/TO inhibit/VB IFN-MCP/NN ./. 
DNA/NN sequence/NN homology/NN of/IN E1A/NN genes/NNS between/IN different/JJ Ad/NN groups/NNS (/( group/NN A/NN ,/, Ad12/NN ;/: group/NN C/NN ,/, Ad5/NN )/) is/VBZ limited/VBN almost/RB entirely/RB to/TO three/CD conserved/VBN regions/NNS located/JJ within/IN the/DT first/JJ exon/NN of/IN E1A/NN ./. 
Because/IN IFN-MCP/NN was/VBD also/RB blocked/VBN in/IN Ad12/NN E1A-transfected/JJ cell/NN lines/NNS ,/, expression/NN of/IN one/CD or/CC more/JJR of/IN the/DT E1A-conserved/JJ regions/NNS may/MD be/VB necessary/JJ to/TO inhibit/VB IFN-MCP/NN ./. 
In/IN summary/NN ,/, the/DT expression/NN of/IN E1A/NN gene/NN products/NNS inhibited/VBD IFN-MCP/NN independently/RB of/IN virus/NN infection/NN ./. 
E1A/NN 's/POS inhibition/NN of/IN IFN-MCP/NN has/VBZ the/DT net/JJ effect/NN of/IN promoting/VBG the/DT selective/JJ NK/NN cell-mediated/JJ clearance/NN of/IN Ad-infected/JJ or/CC Ad-transformed/JJ human/JJ cells/NNS ./. 
UI/LS -/: 93224733/CD 
TI/LS -/: A/DT protein/NN of/IN the/DT AP-1/NN family/NN is/VBZ a/DT component/NN of/IN nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS ./. 
AB/LS -/: Nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS (/( NF-AT/NN )/) is/VBZ a/DT transcriptional/JJ activator/NN involved/VBN in/IN the/DT induction/NN of/IN IL-2/NN gene/NN expression/NN ./. 
The/DT response/NN element/NN for/IN NF-AT/NN is/VBZ a/DT sequence/NN localized/JJ between/IN -285/-254/CD in/IN the/DT IL-2/NN regulatory/JJ region/NN ./. 
The/DT composition/NN of/IN NF-AT/NN protein/NN is/VBZ still/RB not/RB fully/RB elucidated/VBN ./. 
We/PRP demonstrate/VBP that/IN ,/, in/IN normal/JJ human/JJ T/NN cells/NNS ,/, an/DT AP-1/NN protein/NN is/VBZ a/DT component/NN of/IN the/DT NF-AT/NN protein/NN complex/NN ./. 
This/DT was/VBD evidenced/VBN by/IN the/DT ability/NN of/IN the/DT AP-1/NN site/NN to/TO compete/VB with/IN the/DT NF-AT/NN site/NN for/IN binding/NN to/TO NF-AT/NN and/CC by/IN the/DT capacity/NN of/IN immobilized/VBN anti-Jun/JJ and/CC anti-Fos/JJ antibodies/NNS to/TO deplete/VB NF-AT-binding/NN activity/NN from/IN nuclear/JJ extracts/NNS of/IN activated/VBN T/NN cells/NNS ./. 
There/EX was/VBD no/DT detectable/JJ binding/NN of/IN in/FW vitro/FW translated/VBN Jun/Fos/NN heterodimer/NN (/( AP-1/NN )/) to/TO the/DT NF-AT/NN sequence/NN ,/, and/CC the/DT NF-AT/NN sequence/NN was/VBD unable/JJ to/TO inhibit/VB the/DT binding/NN of/IN Jun/Fos/NN to/TO the/DT AP-1/NN sequence/NN ./. 
The/DT presence/NN of/IN an/DT AP-1/NN protein/NN in/IN the/DT NF-AT/NN protein/NN complex/NN may/MD regulate/VB NF-AT-binding/JJ activity/NN through/IN protein-protein/JJ interaction/NN ./. 
UI/LS -/: 93204999/CD 
TI/LS -/: Interaction/NN between/IN NF-kappa/NN B-/NN and/CC serum/NN response/NN factor-binding/JJ elements/NNS activates/VBZ an/DT interleukin-2/NN receptor/NN alpha-chain/JJ enhancer/NN specifically/RB in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: We/PRP find/VBP that/IN a/DT short/JJ enhancer/NN element/NN containing/VBG the/DT NF-kappa/NN B/NN binding/NN site/NN from/IN the/DT interleukin-2/NN receptor/NN alpha-chain/JJ gene/NN (/( IL-2R/NN alpha/NN )/) is/VBZ preferentially/RB activated/VBN in/IN T/NN cells/NNS ./. 
The/DT IL-2R/NN alpha/NN enhancer/NN binds/VBZ NF-kappa/NN B/NN poorly/RB and/CC is/VBZ only/RB weakly/RB activated/VBN by/IN the/DT NF-kappa/NN B/NN site/NN alone/RB ./. 
Serum/NN response/NN factor/NN (/( SRF/NN )/) binds/VBZ to/TO a/DT site/NN adjacent/JJ to/TO the/DT NF-kappa/NN B/NN site/NN in/IN the/DT IL-2R/NN enhancer/NN ,/, and/CC both/DT sites/NNS together/RB have/VBP strong/JJ transcriptional/JJ activity/NN specifically/RB in/IN T/NN cells/NNS ./. 
Surprisingly/RB ,/, the/DT levels/NNS of/IN SRF/NN constitutively/RB expressed/VBN in/IN T/NN cells/NNS are/VBP consistently/RB higher/JJR than/IN in/IN other/JJ cell/NN types/NNS ./. 
Overexpression/NN of/IN SRF/NN in/IN B/NN cells/NNS causes/VBZ the/DT IL-2R/NN enhancer/NN to/TO function/VB as/RB well/RB as/IN it/PRP does/VBZ in/IN T/NN cells/NNS ,/, suggesting/VBG that/IN the/DT high/JJ level/NN of/IN SRF/NN binding/NN in/IN T/NN cells/NNS is/VBZ functionally/RB important/JJ ./. 
UI/LS -/: 93211996/CD 
TI/LS -/: Mutual/JJ regulation/NN of/IN the/DT transcriptional/JJ activator/NN NF-kappa/NN B/NN and/CC its/PRP$ inhibitor/NN ,/, I/NN kappa/NN B-alpha/NN ./. 
AB/LS -/: The/DT NK-kappa/NN B/NN transcription/NN factor/NN complex/NN is/VBZ sequestered/VBN in/IN the/DT cytoplasm/NN by/IN the/DT inhibitory/JJ protein/NN I/NN kappa/NN B-alpha/NN (/( MAD-3/NN )/) ./. 
Various/JJ cellular/JJ stimuli/NNS relieve/VBP this/DT inhibition/NN by/IN mechanisms/NNS largely/RB unknown/JJ ,/, leading/VBG to/TO NF-kappa/NN B/NN nuclear/JJ localization/NN and/CC transactivation/NN of/IN its/PRP$ target/NN genes/NNS ./. 
It/PRP is/VBZ demonstrated/VBN here/RB with/IN human/JJ T/NN lymphocytes/NNS and/CC monocytes/NNS that/IN different/JJ stimuli/NNS ,/, including/VBG tumor/NN necrosis/NN factor/NN alpha/NN and/CC phorbol/NN 12-myristate/NN 13-acetate/NN ,/, cause/VB rapid/JJ degradation/NN of/IN I/NN kappa/NN B-alpha/NN ,/, with/IN concomitant/JJ activation/NN of/IN NF-kappa/NN B/NN ,/, followed/VBN by/IN a/DT dramatic/JJ increase/NN in/IN I/NN kappa/NN B-alpha/NN mRNA/NN and/CC protein/NN synthesis/NN ./. 
Transfection/NN studies/NNS reveal/VBP that/IN the/DT I/NN kappa/NN B-alpha/NN mRNA/NN and/CC the/DT encoded/VBN protein/NN are/VBP potently/RB induced/VBN by/IN NF-kappa/NN B/NN and/CC by/IN homodimers/NNS of/IN p65/NN and/CC of/IN c-Rel/NN ./. 
We/PRP propose/VBP a/DT model/NN in/IN which/WDT NF-kappa/NN B/NN and/CC I/NN kappa/NN B-alpha/NN mutually/RB regulate/VBP each/DT other/JJ in/IN a/DT cycle/NN :/: saturating/JJ amounts/NNS of/IN the/DT inhibitory/JJ I/NN kappa/NN B-alpha/NN protein/NN are/VBP destroyed/VBN upon/IN stimulation/NN ,/, allowing/VBG rapid/JJ activation/NN of/IN NF-kappa/NN B/NN ./. 
Subsequently/RB ,/, I/NN kappa/NN B-alpha/NN mRNA/NN and/CC protein/NN levels/NNS are/VBP quickly/RB induced/VBN by/IN the/DT activated/VBN NF-kappa/NN B/NN ./. 
This/DT resurgence/NN of/IN I/NN kappa/NN B-alpha/NN protein/NN acts/VBZ to/TO restore/VB an/DT equilibrium/NN in/IN which/WDT NF-kappa/NN B/NN is/VBZ again/RB inhibited/VBN ./. 
UI/LS -/: 93172387/CD 
TI/LS -/: Replication/NN of/IN type/NN 1/CD human/JJ immunodeficiency/NN viruses/NNS containing/VBG linker/NN substitution/NN mutations/NNS in/IN the/DT -201/CD to/TO -130/CD region/NN of/IN the/DT long/JJ terminal/JJ repeat/NN ./. 
AB/LS -/: In/IN previous/JJ transfection/NN analyses/NNS using/VBG the/DT chloramphenicol/JJ acetyltransferase/NN reporter/NN gene/NN system/NN ,/, we/PRP determined/VBD that/IN linker/NN substitution/NN (/( LS/NN )/) mutations/NNS between/IN -201/CD and/CC -130/CD (/( relative/JJ to/TO the/DT transcription/NN start/NN site/NN )/) of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) caused/VBD moderate/JJ decreases/NNS in/IN LTR/NN transcriptional/JJ activity/NN in/IN a/DT T-cell/NN line/NN (/( S.L.Zeichner/NNP ,/, J.Y.H./NNP Kim/NNP ,/, and/CC J.C.Alwine/NNP ,/, J.Virol.65/NNP :/: 2436-2444/CD ,/, 1991/CD )/) ./. 
In/IN order/NN to/TO confirm/VB the/DT significance/NN of/IN this/DT region/NN in/IN the/DT context/NN of/IN viral/JJ replication/NN ,/, we/PRP constructed/VBD several/JJ of/IN these/DT LS/NN mutations/NNS (/( -201/CD to/TO - 184/CD ,/, -183/CD to/TO -166/CD ,/, -165/CD to/TO -148/CD ,/, and/CC -148/CD to/TO -130/CD )/) in/IN proviruses/NNS and/CC prepared/VBD viral/JJ stocks/NNS by/IN cocultivation/NN of/IN transfected/VBN RD/NN cells/NNS with/IN CEMx174/NN cells/NNS ./. 
In/IN addition/NN ,/, two/CD mutations/NNS between/IN -93/CD and/CC -76/CD and/CC between/IN -75/CD and/CC -58/CD were/VBD utilized/VBN ,/, since/IN they/PRP affect/VBP the/DT nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) -/: and/CC Sp1-binding/JJ sites/NNS and/CC were/VBD expected/VBN to/TO diminish/VB viral/JJ replication/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN while/IN transfection/NN analyses/NNS offer/VBP an/DT adequate/JJ approximation/NN of/IN the/DT effects/NNS of/IN the/DT LS/NN mutations/NNS ,/, the/DT analysis/NN of/IN viral/JJ replication/NN using/VBG a/DT mutant/JJ viral/JJ stock/NN presents/VBZ a/DT more/RBR accurate/JJ picture/NN ,/, which/WDT is/VBZ sometimes/RB at/IN variance/NN with/IN the/DT transfection/NN results/NNS ./. 
Three/CD mutants/NNS (/( -201/-184/CD NXS/NN|NNS ,/, -165/-148/CD NXS/NN|NNS ,/, and/CC -147/-130/CD NXS/NN|NNS )/) had/VBD effects/NNS on/IN viral/JJ replication/NN that/WDT were/VBD much/RB more/RBR severe/JJ than/IN the/DT effects/NNS predicted/VBN from/IN their/PRP$ performance/NN in/IN transfection/NN analyses/NNS ,/, and/CC the/DT effects/NNS of/IN two/CD LS/NN mutations/NNS (/( -201/-184/CD NXS/NN and/CC -183/-166/CD NXS/NN )/) were/VBD not/RB predicted/VBN by/IN their/PRP$ effects/NNS in/IN transfection/NN ./. 
In/IN addition/NN ,/, we/PRP observed/VBD cell/NN type-specific/JJ permissiveness/NN to/TO replication/NN of/IN some/DT mutant/JJ viruses/NNS ./. 
In/IN the/DT cell/NN types/NNS tested/VBN ,/, the/DT LS/NN mutations/NNS indicated/VBD an/DT apparent/JJ requirement/NN not/RB only/RB for/IN the/DT intact/JJ NF-kappa/NN B/NN and/CC SP1-binding/JJ sites/NNS but/CC also/RB for/IN several/JJ regions/NNS between/IN -201/CD and/CC -130/CD not/RB previously/RB associated/VBN with/IN viral/JJ infectivity/NN ./. 
UI/LS -/: 93141620/CD 
TI/LS -/: Transcription/NN factor/NN GATA-1/NN and/CC erythroid/JJ development/NN ./. 
AB/LS -/: In/IN summary/NN ,/, we/PRP derived/VBD an/DT experimental/JJ system/NN that/WDT allows/VBZ us/PRP to/TO dissect/VB the/DT function/NN of/IN GATA-1/NN in/IN red/JJ cell/NN development/NN at/IN a/DT genetic/JJ level/NN ./. 
We/PRP have/VBP established/VBN the/DT essential/JJ nature/NN of/IN GATA-1/NN during/IN both/CC primitive/JJ and/CC definitive/JJ erythropoiesis/NN ./. 
By/IN ablating/VBG the/DT expression/NN of/IN the/DT endogenous/JJ GATA-1/NN gene/NN ,/, we/PRP are/VBP in/IN a/DT position/NN to/TO introduce/VB a/DT variety/NN of/IN constructs/NNS that/WDT harbor/VBP subtle/JJ modifications/NNS in/IN flanking/JJ or/CC protein-coding/JJ sequences/NNS ./. 
We/PRP can/MD now/RB study/VB regulatory/JJ regions/NNS and/CC functional/JJ domains/NNS of/IN the/DT protein/NN in/IN the/DT context/NN of/IN a/DT true/JJ erythroid/JJ environment/NN ,/, experiments/NNS that/WDT have/VBP not/RB been/VBN possible/JJ heretofore/RB ./. 
Although/IN the/DT assay/NN involves/VBZ the/DT dramatic/JJ loss/NN of/IN red/JJ cell/NN production/NN ,/, it/PRP should/MD be/VB possible/JJ to/TO define/VB important/JJ regulatory/JJ domains/NNS that/WDT can/MD then/RB be/VB assayed/VBN using/VBG less/RBR stringent/JJ systems/NNS ,/, such/JJ as/IN cell-free/JJ extracts/NNS for/IN in/FW vitro/FW transcription/NN ./. 
The/DT ideal/JJ situation/NN would/MD be/VB analyses/NNS conducted/VBN in/IN GATA-1-erythroid/JJ cells/NNS ./. 
However/RB ,/, these/DT cells/NNS have/VBP been/VBN impossible/JJ to/TO generate/VB given/VBN the/DT requirement/NN of/IN GATA-1/NN for/IN Epo/NN receptor/NN expression/NN and/CC red/JJ cell/NN viability/NN (/( C./NNP Simon/NNP and/CC S./NNP Orkin/NNP ,/, unpublished/JJ observations/NNS )/) ./. 
It/PRP may/MD be/VB possible/JJ to/TO produce/VB such/JJ cells/NNS by/IN first/RB expressing/VBG the/DT Epo/NN receptor/NN under/IN the/DT influence/NN of/IN a/DT constitutive/JJ promoter/NN and/CC then/RB targeting/VBG the/DT GATA-1/NN gene/NN ./. 
If/IN GATA-1-red/JJ cells/NNS were/VBD available/JJ ,/, the/DT analyses/NNS would/MD involve/VB the/DT actual/JJ transcription/NN of/IN or/CC chromatin/NN structure/NN surrounding/VBG the/DT globin/NN genes/NNS ./. 
Structure-function/JJ studies/NNS of/IN the/DT GATA-1/NN protein/NN could/MD be/VB greatly/RB simplified/VBN and/CC a/DT larger/JJR number/NN of/IN mutants/NNS studied/VBN ./. 
However/RB ,/, the/DT ES/NN cell/NN system/NN can/MD be/VB used/VBN as/IN an/DT alternative/NN until/IN targeted/VBN erythroleukemia/NN cells/NNS become/VBP available/JJ ./. 
Other/JJ applications/NNS involve/VBP the/DT introduction/NN of/IN other/JJ GATA-binding/JJ protein/NN family/NN members/NNS to/TO determine/VB whether/IN they/PRP rescue/VBP the/DT mutation/NN ./. 
If/IN they/PRP can/MD not/RB ,/, chimeric/JJ proteins/NNS can/MD be/VB tested/VBN to/TO identify/VB which/WDT amino/NN acids/NNS distinguish/VBP the/DT different/JJ family/NN members/NNS ./. 
We/PRP feel/VBP that/IN these/DT experiments/NNS are/VBP vital/JJ to/TO understanding/VBG the/DT function/NN of/IN GATA-1/NN during/IN erythroid/JJ ontogeny/NN ./. 
How/WRB does/VBZ GATA-1/NN regulate/VB red/JJ cell/NN genes/NNS like/IN globin/NN or/CC the/DT Epo/NN receptor/NN ?/. Once/IN we/PRP identify/VB the/DT functional/JJ domains/NNS of/IN the/DT GATA-binding/JJ proteins/NNS ,/, we/PRP hope/VBP to/TO learn/VB what/WP proteins/NNS GATA-1/NN binds/VBZ to/TO in/IN the/DT basic/JJ transcription/NN machinery/NN or/CC in/IN chromatin/NN ./. 
Is/VBZ GATA-1/NN necessary/JJ for/IN globin/NN gene/NN switching/NN ?/. GATA-1/NN may/MD be/VB modified/VBN differently/RB during/IN development/NN so/IN that/IN the/DT locus/NN control/NN region/NN can/MD interact/VB with/IN different/JJ globin/NN promoters/NNS ./. 
We/PRP may/MD find/VB that/IN one/CD region/NN of/IN the/DT protein/NN is/VBZ required/VBN for/IN embryonic/JJ expression/NN and/CC another/DT for/IN adult/JJ globin/NN gene/NN expression/NN ./. 
UI/LS -/: 93135830/CD 
TI/LS -/: A/DT human/JJ putative/JJ lymphocyte/NN G0/G1/NN switch/VBP gene/NN homologous/JJ to/TO a/DT rodent/JJ gene/NN encoding/VBG a/DT zinc-binding/JJ potential/JJ transcription/NN factor/NN ./. 
AB/LS -/: G0S24/NN is/VBZ a/DT member/NN of/IN a/DT set/NN of/IN genes/NNS (/( putative/JJ G0/G1/NN switch/NN regulatory/JJ genes/NNS )/) that/WDT are/VBP expressed/VBN transiently/RB within/IN 1-2/CD hr/NN of/IN the/DT addition/NN of/IN lectin/NN or/CC cycloheximide/NN to/TO human/JJ blood/NN mononuclear/JJ cells/NNS ./. 
Comparison/NN of/IN a/DT full-length/JJ cDNA/NN sequence/NN with/IN the/DT corresponding/JJ genomic/JJ sequence/NN reveals/VBZ an/DT open/JJ reading/NN frame/NN of/IN 326/CD amino/NN acids/NNS ,/, distributed/VBN across/IN two/CD exons/NNS ./. 
Potential/JJ phosphorylation/NN sites/NNS include/VBP the/DT sequence/NN PSPTSPT/NN ,/, which/WDT resembles/VBZ an/DT RNA/NN polymerase/NN II/CD repeat/NN reported/VBN to/TO be/VB a/DT target/NN of/IN the/DT cell/NN cycle/NN control/NN kinase/NN cdc2/NN ./. 
Comparison/NN of/IN the/DT derived/VBN protein/NN sequence/NN with/IN those/DT of/IN rodent/JJ homologs/NNS allows/VBZ classification/NN into/IN three/CD groups/NNS ./. 
Group/NN 1/CD contains/VBZ G0S24/NN and/CC the/DT rat/NN and/CC mouse/NN TIS11/NN genes/NNS (/( also/RB known/VBN as/IN TTP/NN ,/, Nup475/NN ,/, and/CC Zfp36/NN )/) ./. 
Members/NNS of/IN this/DT group/NN have/VBP three/CD tetraproline/JJ repeats/NNS ./. 
Groups/NNS 1/CD and/CC 2/CD have/VBP a/DT serine-rich/JJ region/NN and/CC an/DT "/`` arginine/NN element/NN "/'' (/( RRLPIF/NN )/) at/IN the/DT carboxyl/NN terminus/NN ./. 
All/DT groups/NNS contain/VBP cysteine-/NN and/CC histidine-rich/JJ putative/JJ zinc/NN finger/NN domains/NNS and/CC a/DT serine-phenylalanine/JJ "/`` SFS/NNS "/'' domain/NN similar/JJ to/TO part/NN of/IN the/DT large/JJ subunit/NN of/IN eukaryotic/JJ RNA/NN polymerase/NN II/CD ./. 
Comparison/NN of/IN group/NN 1/CD human/JJ and/CC mouse/NN genomic/JJ sequences/NNS shows/VBZ high/JJ conservation/NN in/IN the/DT 5'/JJ flank/NN and/CC exons/NNS ./. 
A/DT CpG/NN island/NN suggests/VBZ expression/NN in/IN the/DT germ/NN line/NN ./. 
G0S24/NN has/VBZ potential/JJ sites/NNS for/IN transcription/NN factors/NNS in/IN the/DT 5'/JJ flank/NN and/CC intron/NN ;/: these/DT include/VBP a/DT serum/NN response/NN element/NN ./. 
Protein/NN and/CC genomic/JJ sequences/NNS show/VBP similarities/NNS with/IN those/DT of/IN a/DT variety/NN of/IN proteins/NNS involved/VBN in/IN transcription/NN ,/, suggesting/VBG that/IN the/DT G0S24/NN product/NN has/VBZ a/DT similar/JJ role/NN ./. 
UI/LS -/: 93303626/CD 
TI/LS -/: Regulation/NN of/IN lymphoid-specific/JJ immunoglobulin/NN mu/NN heavy/NN chain/NN gene/NN enhancer/NN by/IN ETS-domain/JJ proteins/NNS ./. 
AB/LS -/: The/DT enhancer/NN for/IN the/DT immunoglobulin/NN mu/NN heavy/NN chain/NN gene/NN (/( IgH/NN )/) activates/VBZ a/DT heterologous/JJ gene/NN at/IN the/DT pre-B/JJ cell/NN stage/NN of/IN B/NN lymphocyte/NN differentiation/NN ./. 
A/DT lymphoid-specific/JJ element/NN ,/, microB/NN ,/, is/VBZ necessary/JJ for/IN enhancer/NN function/NN in/IN pre-B/JJ cells/NNS ./. 
A/DT microB/NN binding/NN protein/NN is/VBZ encoded/VBN by/IN the/DT PU.1/Spi-1/NN proto-oncogene/NN ./. 
Another/DT sequence/NN element/NN ,/, microA/NN ,/, was/VBD identified/VBN in/IN the/DT mu/NN enhancer/NN that/WDT binds/VBZ the/DT product/NN of/IN the/DT ets-1/NN proto-oncogene/NN ./. 
The/DT microA/NN motif/NN was/VBD required/VBN for/IN microB-dependent/JJ enhancer/NN activity/NN ,/, which/WDT suggests/VBZ that/IN a/DT minimal/JJ B/NN cell-specific/JJ enhancer/NN is/VBZ composed/VBN of/IN both/CC the/DT PU.1/NN and/CC Ets-1/NN binding/NN sites/NNS ./. 
Co-expression/NN of/IN both/CC PU.1/NN and/CC Ets-1/NN in/IN nonlymphoid/JJ cells/NNS trans-activated/JJ reporter/NN plasmids/NNS that/WDT contained/VBD the/DT minimal/JJ mu/NN enhancer/NN ./. 
These/DT results/NNS implicate/VBP two/CD members/NNS of/IN the/DT Ets/NN family/NN in/IN the/DT activation/NN of/IN IgH/NN gene/NN expression/NN ./. 
UI/LS -/: 93300929/CD 
TI/LS -/: 1,25-Dihydroxy/NN vitamin/NN D3/NN and/CC 12-O-tetradecanoyl/NN phorbol-13-acetate/NN synergistically/RB induce/VBP monocytic/JJ cell/NN differentiation/NN :/: FOS/NN and/CC RB/NN expression/NN ./. 
AB/LS -/: 1,25-dihydroxy/NN vitamin/NN D3/NN and/CC 12-O-tetradecanoyl/NN phorbol-13-acetate/NN (/( TPA/NN )/) interact/VBP synergistically/RB to/TO induce/VB monocytic/JJ differentiation/NN of/IN U937/NN histiocytic/JJ lymphoma/NN cells/NNS ./. 
Addition/NN of/IN TPA/NN causes/VBZ an/DT otherwise/JJ ineffective/JJ dose/NN of/IN 1,25-dihydroxy/NN vitamin/NN D3/NN to/TO induce/VB differentiation/NN ./. 
The/DT induced/VBD differentiation/NN depends/VBZ on/IN the/DT simultaneous/JJ (/( vs./CC sequential/JJ )/) presence/NN of/IN both/DT agents/NNS ./. 
The/DT kinetics/NNS of/IN induced/JJ differentiation/NN are/VBP consistent/JJ with/IN a/DT G1/NN specific/JJ cellular/JJ response/NN to/TO initiate/VB the/DT metabolic/JJ cascade/NN culminating/VBG in/IN cell/NN differentiation/NN ./. 
The/DT induced/VBD differentiation/NN occurs/VBZ with/IN down-regulation/NN of/IN c-fos/NN protein/NN and/CC an/DT accompanying/VBG up-regulation/NN of/IN RB/NN protein/NN expression/NN ,/, consistent/JJ with/IN a/DT possible/JJ need/NN for/IN up-regulated/JJ RB/NN expression/NN to/TO maintain/VB a/DT given/JJ differentiated/VBN phenotype/NN and/CC suppress/VB transcriptional/JJ activators/NNS that/WDT might/MD typically/RB be/VB associated/VBN with/IN proliferation/NN ./. 
UI/LS -/: 93279468/CD 
TI/LS -/: Ectopic/JJ expression/NN of/IN a/DT conditional/JJ GATA-2/estrogen/NN receptor/NN chimera/NN arrests/VBZ erythroid/JJ differentiation/NN in/IN a/DT hormone-dependent/JJ manner/NN ./. 
AB/LS -/: The/DT GATA/NN factors/NNS are/VBP a/DT family/NN of/IN transcriptional/JJ regulatory/JJ proteins/NNS in/IN eukaryotes/NNS that/WDT share/VBP extensive/JJ homology/NN in/IN their/PRP$ DNA-binding/JJ domains/NNS ./. 
One/CD enigmatic/JJ aspect/NN of/IN GATA/NN factor/NN expression/NN is/VBZ that/IN several/JJ GATA/NN proteins/NNS ,/, which/WDT ostensibly/RB share/VBP the/DT same/JJ DNA-binding/JJ site/NN specificity/NN ,/, are/VBP coexpressed/VBN in/IN erythroid/JJ cells/NNS ./. 
To/TO elucidate/VB the/DT roles/NNS of/IN individual/JJ GATA/NN factors/NNS in/IN erythropoiesis/NN ,/, conditional/JJ alleles/NNS of/IN GATA-1/NN ,/, GATA-2/NN ,/, and/CC GATA-3/NN were/VBD prepared/VBN by/IN fusing/VBG each/DT of/IN the/DT factors/NNS to/TO the/DT hormone-binding/JJ domain/NN of/IN the/DT human/JJ estrogen/NN receptor/NN (/( ER/NN )/) ./. 
These/DT GATA/ER/NN chimeric/JJ factors/NNS were/VBD shown/VBN to/TO be/VB hormone-inducible/JJ trans-activating/JJ proteins/NNS in/IN transient/JJ transfection/NN assays/NNS ./. 
When/WRB stably/RB introduced/VBN into/IN primary/JJ erythroblasts/NNS or/CC conditionally/RB transformed/VBN erythroid/JJ progenitors/NNS cells/NNS ,/, exogenous/JJ GATA-2/ER/NN promoted/VBD proliferation/NN and/CC inhibited/VBD terminal/JJ differentiation/NN in/IN an/DT estrogen-dependent/JJ manner/NN ./. 
These/DT phenotypic/JJ effects/NNS are/VBP specifically/RB attributable/JJ to/TO the/DT action/NN of/IN ectopically/RB expressed/VBN GATA-2/ER/NN because/IN erythroblasts/NNS expressing/VBG exogenous/JJ GATA-2/NN are/VBP constitutively/RB arrested/VBN in/IN differentiation/NN and/CC because/IN erythroid/JJ progenitors/NNS expressing/VBG either/CC Gal/ER/NN or/CC GATA-3/ER/NN do/VBP not/RB display/VB a/DT hormone-responsive/JJ block/NN in/IN differentiation/NN ./. 
Thus/RB ,/, the/DT GATA-2/NN transcription/NN factor/NN appears/VBZ to/TO play/VB a/DT role/NN in/IN regulating/VBG the/DT self-renewal/JJ capacity/NN of/IN early/JJ erythroid/JJ progenitor/NN cells/NNS ./. 
UI/LS -/: 93258811/CD 
TI/LS -/: Mice/NNS deficient/NN for/IN the/DT 55/CD kd/JJ tumor/NN necrosis/NN factor/NN receptor/NN are/VBP resistant/JJ to/TO endotoxic/JJ shock/NN ,/, yet/RB succumb/VBP to/TO L./FW monocytogenes/NNS infection/NN ./. 
AB/LS -/: The/DT multiple/JJ biological/JJ activities/NNS of/IN tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) are/VBP mediated/VBN by/IN two/CD distinct/JJ cell/NN surface/NN receptors/NNS of/IN 55/CD kd/NNS (/( TNFRp55/NN )/) and/CC 75/CD kd/NN (/( TNFRp75/NN )/) ./. 
Using/VBG gene/NN targeting/NN ,/, we/PRP generated/VBD a/DT TNFRp55-deficient/JJ mouse/NN strain/NN ./. 
Cells/NNS from/IN TNFRp55-/-mutant/JJ mice/NNS lack/VBP expression/NN of/IN TNFRp55/NN but/CC display/VBP normal/JJ numbers/NNS of/IN high/JJ affinity/NN TNFRp75/NN molecules/NNS ./. 
Thymocyte/NN development/NN and/CC lymphocyte/NN populations/NNS are/VBP unaltered/JJ ,/, and/CC clonal/JJ deletion/NN of/IN potentially/RB self-reactive/JJ T/NN cells/NNS is/VBZ not/RB impaired/JJ ./. 
However/RB ,/, TNF/NN signaling/NN is/VBZ largely/RB abolished/VBN ,/, as/IN judged/VBN by/IN the/DT failure/NN of/IN TNF/NN to/TO induce/VB NF-kappa/NN B/NN in/IN T/NN lymphocytes/NNS from/IN TNFRp55-deficient/JJ mice/NNS ./. 
The/DT loss/NN of/IN TNFRp55/NN function/NN renders/VBZ mice/NNS resistant/JJ to/TO lethal/JJ dosages/NNS of/IN either/CC lipopolysaccharides/NNS or/CC S./FW aureus/FW enterotoxin/NN B/NN ./. 
In/IN contrast/NN ,/, TNFRp55-deficient/JJ mice/NNS are/VBP severely/RB impaired/JJ to/TO clear/VB L./FW monocytogenes/FW and/CC readily/RB succumb/VBP to/TO infection/NN ./. 
Thus/RB ,/, the/DT 55/CD kd/NN TNFR/NN plays/VBZ a/DT decisive/JJ role/NN in/IN the/DT host/NN 's/POS defense/NN against/IN microorganisms/NNS and/CC their/PRP$ pathogenic/JJ factors/NNS ./. 
UI/LS -/: 93224719/CD 
TI/LS -/: Costimulation/NN of/IN peripheral/JJ blood/NN T/NN cell/NN activation/NN by/IN human/JJ endothelial/JJ cells/NNS ./. 
Enhanced/VBD IL-2/NN transcription/NN correlates/VBZ with/IN increased/VBN c-fos/NN synthesis/NN and/CC increased/VBN Fos/NN content/NN of/IN AP-1/NN ./. 
AB/LS -/: Endothelial/JJ cells/NNS (/( EC/NN )/) act/VBP as/IN APC/NN for/IN resting/VBG PBL/NN in/FW vitro/FW ,/, and/CC may/MD have/VB important/JJ roles/NNS in/FW vivo/FW in/IN the/DT pathogenesis/NN of/IN allograft/NN rejection/NN and/CC delayed/VBN hypersensitivity/NN ./. 
We/PRP previously/RB reported/VBD that/IN human/JJ umbilical/JJ vein/NN EC/NN provide/VBP costimulatory/JJ signals/NNS to/TO PHA-stimulated/JJ PBL/NN via/IN CD2/NN :/: lymphocyte/NN function-associated/JJ Ag-3/NN and/CC an/DT unidentified/JJ ligand/NN pair/NN ,/, resulting/VBG in/IN a/DT three-/CD to/TO eight-fold/JJ enhancement/NN of/IN IL-2/NN production/NN ./. 
The/DT physiologic/JJ relevance/NN of/IN this/DT increase/NN was/VBD demonstrated/VBN by/IN the/DT proliferative/JJ advantage/NN provided/VBN by/IN EC/NN to/TO PBL/NN suboptimally/RB stimulated/VBN with/IN mAb/NN OKT3/NN ./. 
We/PRP now/RB report/VBP that/IN EC/NN costimulation/NN causes/VBZ increased/VBN levels/NNS of/IN IL-2/NN mRNA/NN as/IN a/DT result/NN of/IN increased/VBN IL-2/NN transcription/NN in/IN PBL/NN ./. 
We/PRP therefore/RB examined/VBD the/DT effects/NNS of/IN EC/NN on/IN T/NN cell/NN nuclear/JJ factors/NNS known/VBN to/TO regulate/VB IL-2/NN transcription/NN ,/, including/VBG c-jun/NN and/CC c-fos-two/NN components/NNS of/IN the/DT transcription/NN factor/NN AP-1/NN ,/, NFAT/NN ,/, and/CC others/NNS ./. 
PBL/NN constitutively/RB express/VBP c-jun/NN transcripts/NNS ,/, and/CC the/DT level/NN of/IN c-jun/NN mRNA/NN is/VBZ not/RB altered/VBN by/IN PHA/NN activation/NN in/IN the/DT absence/NN or/CC presence/NN of/IN EC/NN ./. 
In/IN contrast/NN ,/, c-fos/NN mRNA/NN is/VBZ absent/JJ from/IN resting/VBG T/NN cells/NNS and/CC is/VBZ induced/VBN on/IN PHA/NN activation/NN ./. 
EC/NN alone/RB do/VBP not/RB induce/VB c-fos/NN mRNA/NN but/CC augment/VBP the/DT level/NN of/IN c-fos/NN mRNA/NN in/IN PHA-activated/JJ T/NN cells/NNS by/IN 3-/CD to/TO 10-fold/RB ./. 
This/DT effect/NN is/VBZ largely/RB independent/JJ of/IN the/DT CD2/NN :/: lymphocyte/NN function-/NN associated/VBN Ag-3/NN pathway/NN ./. 
Gel-shift/NN analysis/NN reveals/VBZ the/DT constitutive/JJ presence/NN of/IN nuclear/JJ factors/NNS in/IN resting/VBG PBL/NN that/WDT bind/VBP to/TO the/DT proximal/JJ AP-1/NN site/NN of/IN the/DT IL-2/NN promoter/NN and/CC that/IN contain/VBP immunoreactive/JJ c-Jun/NN but/CC not/RB c-Fos/NN protein/NN ./. 
In/IN contrast/NN ,/, AP-1/NN from/IN PHA-activated/JJ cells/NNS contains/VBZ c-Jun/NN and/CC low/JJ levels/NNS of/IN c-Fos/NN ./. 
Strikingly/RB ,/, costimulation/NN with/IN EC/NN results/VBZ in/IN a/DT dramatic/JJ increase/NN (/( up/NN to/TO 15-fold/JJ )/) in/IN the/DT c-Fos/NN content/NN of/IN AP-1/NN ./. 
Levels/NNS of/IN other/JJ nuclear/JJ factors/NNS involved/VBN in/IN IL-2/NN regulation/NN were/VBD not/RB altered/VBN by/IN EC/NN ,/, although/IN NFAT-DNA/NN complexes/NNS migrated/VBD at/IN a/DT slightly/RB different/JJ mobility/NN ./. 
In/IN summary/NN ,/, our/PRP$ data/NNS suggest/VBP that/IN changes/NNS in/IN the/DT composition/NN of/IN transcription/NN factor/NN AP-1/NN is/VBZ a/DT key/JJ molecular/JJ mechanism/NN for/IN increasing/VBG IL-2/NN transcription/NN and/CC may/MD underlie/VB the/DT phenomenon/NN of/IN costimulation/NN by/IN EC/NN ./. 
UI/LS -/: 93204975/CD 
TI/LS -/: Transcriptional/JJ activation/NN of/IN human/JJ zeta/NN 2/CD globin/NN promoter/NN by/IN the/DT alpha/NN globin/NN regulatory/JJ element/NN (/( HS-40/NN )/) :/: functional/JJ role/NN of/IN specific/JJ nuclear/JJ factor-DNA/JJ complexes/NNS ./. 
AB/LS -/: We/PRP studied/VBD the/DT functional/JJ interaction/NN between/IN human/JJ embryonic/JJ zeta/NN 2/CD globin/NN promoter/NN and/CC the/DT alpha/NN globin/NN regulatory/JJ element/NN (/( HS-40/NN )/) located/JJ 40/CD kb/NN upstream/RB of/IN the/DT zeta/NN 2/CD globin/NN gene/NN ./. 
It/PRP was/VBD shown/VBN by/IN transient/JJ expression/NN assay/NN that/IN HS-40/NN behaved/VBD as/IN an/DT authentic/JJ enhancer/NN for/IN high-level/JJ zeta/NN 2/CD globin/NN promoter/NN activity/NN in/IN K562/NN cells/NNS ,/, an/DT erythroid/JJ cell/NN line/NN of/IN embryonic/JJ and/or/CC fetal/JJ origin/NN ./. 
Although/IN sequences/NNS located/JJ between/IN -559/CD and/CC -88/CD of/IN the/DT zeta/NN 2/CD globin/NN gene/NN were/VBD dispensable/JJ for/IN its/PRP$ expression/NN on/IN enhancerless/NN plasmids/NNS ,/, they/PRP were/VBD required/VBN for/IN the/DT HS-40/NN enhancer-mediated/JJ activity/NN of/IN the/DT zeta/NN 2/CD globin/NN promoter/NN ./. 
Site-directed/JJ mutagenesis/NN demonstrated/VBD that/IN this/DT HS-40/NN enhancer-zeta/NN 2/CD globin/NN promoter/NN interaction/NN is/VBZ mediated/VBN by/IN the/DT two/CD GATA-1/NN factor/NN binding/NN motifs/NNS located/JJ at/IN -230/CD and/CC -104/CD ,/, respectively/RB ./. 
The/DT functional/JJ domains/NNS of/IN HS-40/NN were/VBD also/RB mapped/VBN ./. 
Bal/NN 31/CD deletion/NN mapping/VBG data/NNS suggested/VBD that/IN one/CD GATA-1/NN motif/NN ,/, one/CD GT/NN motif/NN ,/, and/CC two/CD NF-E2/AP1/NN motifs/NNS together/RB formed/VBD the/DT functional/JJ core/NN of/IN HS-40/NN in/IN the/DT erythroid-specific/JJ activation/NN of/IN the/DT zeta/NN 2/CD globin/NN promoter/NN ./. 
Site-directed/JJ mutagenesis/NN further/RBR demonstrated/VBD that/IN the/DT enhancer/NN function/NN of/IN one/CD of/IN the/DT two/CD NF-E2/AP1/NN motifs/NNS of/IN HS-40/NN is/VBZ mediated/VBN through/IN its/PRP$ binding/NN to/TO NF-E2/NN but/CC not/RB AP1/NN transcription/NN factor/NN ./. 
Finally/RB ,/, we/PRP did/VBD genomic/JJ footprinting/NN of/IN the/DT HS-40/NN enhancer/NN region/NN in/IN K562/NN cells/NNS ,/, adult/JJ nucleated/JJ erythroblasts/NNS ,/, and/CC different/JJ nonerythroid/JJ cells/NNS ./. 
All/DT sequence/NN motifs/NNS within/IN the/DT functional/JJ core/NN of/IN HS-40/NN ,/, as/IN mapped/VBN by/IN transient/JJ expression/NN analysis/NN ,/, appeared/VBD to/TO bind/VB a/DT nuclear/JJ factor/NN (/( s/NNS )/) in/IN living/VBG K562/NN cells/NNS but/CC not/RB in/IN nonerythroid/JJ cells/NNS ./. 
On/IN the/DT other/JJ hand/NN ,/, only/RB one/CD of/IN the/DT apparently/RB nonfunctional/JJ sequence/NN motifs/NNS was/VBD bound/VBN with/IN factors/NNS in/FW vivo/FW ./. 
In/IN comparison/NN to/TO K562/NN ,/, nucleated/JJ erythroblasts/NNS from/IN adult/JJ human/JJ bone/NN marrow/NN exhibited/VBD a/DT similar/JJ but/CC nonidentical/JJ pattern/NN of/IN nuclear/JJ factor/NN binding/NN in/FW vivo/FW at/IN the/DT HS-40/NN region/NN ./. 
These/DT data/NNS suggest/VBP that/IN transcriptional/JJ activation/NN of/IN human/JJ embryonic/JJ zeta/NN 2/CD globin/NN gene/NN and/CC the/DT fetal/adult/JJ alpha/NN globin/NN genes/NNS is/VBZ mediated/VBN by/IN erythroid/JJ cell-specific/JJ and/CC developmental/JJ stage-specific/JJ nuclear/JJ factor-DNA/NN complexes/NNS which/WDT form/VBP at/IN the/DT enhancer/NN (/( HS-40/NN )/) and/CC the/DT globin/NN promoters/NNS ./. 
UI/LS -/: 93194832/CD 
TI/LS -/: Transcriptional/JJ regulation/NN of/IN the/DT pyruvate/NN kinase/NN erythroid-specific/JJ promoter/NN ./. 
AB/LS -/: Mammal/JJ pyruvate/NN kinases/NNS are/VBP encoded/VBN by/IN two/CD genes/NNS ./. 
The/DT L/NN gene/NN produces/VBZ the/DT erythroid/JJ (/( R-PK/NN )/) or/CC the/DT hepatic/JJ (/( L-PK/JJ )/) isozymes/NNS by/IN the/DT alternative/JJ use/NN of/IN two/CD promoters/NNS ./. 
We/PRP report/VBP the/DT characterization/NN of/IN the/DT cis-/JJ and/CC trans-acting/JJ elements/NNS involved/VBN in/IN the/DT tissue-specific/JJ activity/NN of/IN the/DT L/NN gene/NN erythroid/JJ promoter/NN ./. 
A/DT R-PK/NN DNA/NN fragment/NN extending/VBG from/IN -870/CD to/TO +54/CD relative/JJ to/TO the/DT cap/NN site/NN confers/VBZ erythroid/JJ specificity/NN to/TO a/DT reporter/NN gene/NN ./. 
Within/IN this/DT region/NN ,/, we/PRP define/VBP a/DT minimal/JJ promoter/NN (/( -62/CD to/TO +54/CD )/) that/WDT displays/VBZ erythroid-specific/JJ activity/NN and/CC contains/VBZ two/CD DNA/NN binding/NN sites/NNS ./. 
One/CD ,/, located/JJ at/IN -50/CD ,/, binds/VBZ members/NNS of/IN the/DT CCACC/Sp1/NN family/NN and/CC the/DT other/JJ ,/, located/JJ at/IN -20/CD ,/, binds/VBZ the/DT erythroid/JJ factor/NN GATA-1/NN ./. 
Although/IN the/DT -20/CD GATA/NN binding/NN site/NN (/( AGATAA/NN )/) is/VBZ also/RB a/DT potential/JJ TFIID/NN binding/NN site/NN ,/, it/PRP does/VBZ not/RB bind/VB TFIID/NN ./. 
Furthermore/RB ,/, the/DT substitution/NN of/IN this/DT GATA/NN binding/NN site/NN by/IN a/DT canonical/JJ TFIID/NN binding/NN site/NN suppresses/VBZ the/DT promoter/NN activity/NN ./. 
Mutations/NNS and/CC deletions/NNS of/IN both/DT sites/NNS indicate/VBP that/IN only/RB the/DT association/NN of/IN CCACC/Sp1/NN and/CC GATA/NN binding/NN sites/NNS can/MD drive/VB efficient/JJ and/CC tissue-specific/JJ expression/NN of/IN this/DT R-PK/NN minimal/JJ promoter/NN ./. 
Finally/RB ,/, by/IN co-transfection/NN experiments/NNS ,/, we/PRP study/VBD the/DT elements/NNS involved/VBN in/IN the/DT hGATA-1/NN transactivation/NN of/IN the/DT R-PK/NN promoter/NN in/IN HeLa/NN cells/NNS ./. 
UI/LS -/: 93171603/CD 
TI/LS -/: Protease/NN treatment/NN of/IN nuclear/JJ extracts/NNS distinguishes/VBZ between/IN class/NN II/CD MHC/NN X1/NN box/NN DNA-binding/JJ proteins/NNS in/IN wild-type/JJ and/CC class/NN II-deficient/JJ B/NN cells/NNS ./. 
AB/LS -/: The/DT X/NN box/NN region/NN is/VBZ critical/JJ for/IN directing/VBG the/DT expression/NN of/IN class/NN II/CD major/JJ histocompatibility/NN complex/NN genes/NNS in/IN B/NN lymphocytes/NNS ./. 
Although/IN several/JJ class/NN II/CD promoter-specific/JJ DNA/NN binding/NN factors/NNS have/VBP been/VBN described/VBN ,/, only/RB the/DT X/NN box/NN region/NN factor/NN ,/, RFX/NN ,/, shows/VBZ a/DT genetic/JJ correlation/NN with/IN class/NN II/CD expression/NN ,/, being/VBG deficient/JJ in/IN some/DT B/NN cell/NN lines/NNS derived/VBN from/IN patients/NNS with/IN class/NN II-deficient/JJ congenital/JJ immunodeficiency/NN ./. 
To/TO further/RB evaluate/VB the/DT role/NN of/IN X/NN box/NN DNA-binding/JJ proteins/NNS in/IN class/NN II/CD gene/NN expression/NN ,/, the/DT role/NN of/IN the/DT X/NN box/NN region/NN was/VBD examined/VBN in/IN both/DT class/NN II-positive/JJ and/CC -negative/JJ lymphoid/JJ cells/NNS ./. 
In/IN addition/NN to/TO the/DT wild-type/JJ B/NN cell/NN line/NN Raji/NN ,/, two/CD class/NN II/CD transcriptional/JJ mutant/JJ cell/NN lines/NNS ,/, SJO/NN and/CC RJ2.2.5/NN ,/, and/CC Jurkat/NN ,/, a/DT class/NN II/CD negative/JJ T/NN cell/NN line/NN ,/, were/VBD examined/VBN ./. 
In/IN contrast/NN to/TO wild-type/JJ B/NN cells/NNS ,/, neither/DT of/IN the/DT class/NN II/CD mutant/JJ cell/NN lines/NNS could/MD use/VB the/DT X/NN box/NN region/NN to/TO direct/VB the/DT expression/NN of/IN a/DT transiently/RB transfected/VBN reporter/NN gene/NN ,/, indicating/VBG that/IN the/DT X/NN box-dependent/JJ transcriptional/JJ pathway/NN is/VBZ defective/JJ in/IN these/DT cells/NNS ./. 
The/DT binding/NN activity/NN of/IN the/DT X1/NN box/NN DNA-binding/JJ protein/NN RFX/NN was/VBD examined/VBN and/CC found/VBN to/TO be/VB present/JJ in/IN wild-type/JJ B/NN cells/NNS and/CC the/DT mutant/JJ RJ2.2.5/NN but/CC was/VBD absent/JJ in/IN SJO/NN and/CC Jurkat/NN ./. 
However/RB ,/, other/JJ X1/NN box-specific/JJ activities/NNS were/VBD detected/VBN in/IN all/DT these/DT cell/NN lines/NNS ./. 
To/TO determine/VB whether/IN these/DT different/JJ X1/NN box/NN activities/NNS represented/VBD distinct/JJ DNA/NN binding/NN proteins/NNS or/CC multimeric/JJ forms/NNS of/IN the/DT same/JJ factor/NN (/( s/NNS )/) ,/, protease/NN treatment/NN of/IN the/DT crude/JJ nuclear/JJ extracts/NNS followed/VBN by/IN DNA-binding/JJ assays/NNS were/VBD carried/VBN out/RP and/CC demonstrated/VBD that/IN B/NN cell/NN extracts/NNS contain/VBP at/IN least/JJS two/CD X1-specific/JJ factors/NNS ./. 
One/CD of/IN these/DT cleaved/VBN products/NNS (/( band/NN 1/CD pk/NN )/) correlates/VBZ with/IN RFX/NN activity/NN ./. 
A/DT similar/JJ comparison/NN with/IN protease-treated/JJ extracts/NNS prepared/VBN from/IN Jurkat/NN cells/NNS demonstrated/VBD the/DT presence/NN of/IN the/DT band/NN 1pk/NN activity/NN despite/IN an/DT absence/NN of/IN the/DT native/JJ RFX/NN activity/NN ./. 
In/IN contrast/NN ,/, protease/NN treatment/NN and/CC analysis/NN of/IN SJO/NN extracts/NNS showed/VBD no/DT detectable/JJ levels/NNS of/IN the/DT band/NN 1pk/NN activity/NN ./. 
These/DT results/NNS demonstrate/VBP that/IN multiple/JJ X1/NN box-specific/JJ DNA-binding/JJ activities/NNS exist/VBP in/IN all/DT lymphoid/JJ cells/NNS ,/, but/CC the/DT presence/NN of/IN an/DT actively/RB binding/NN RFX/NN species/NNS correlates/VBZ with/IN class/NN II/CD transcription/NN ./. 
UI/LS -/: 93124567/CD 
TI/LS -/: Human/JJ immunodeficiency/NN viruses/NNS containing/VBG heterologous/JJ enhancer/promoters/NNS are/VBP replication/NN competent/JJ and/CC exhibit/VBP different/JJ lymphocyte/NN tropisms/NNS ./. 
AB/LS -/: The/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) type/NN 1/CD long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) contains/VBZ binding/VBG sites/NNS for/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) and/CC the/DT constitutively/RB expressed/VBN transcription/NN factor/NN Sp1/NN ,/, both/DT of/IN which/WDT are/VBP highly/RB conserved/VBN in/IN HIV/NN and/CC simian/JJ immunodeficiency/NN virus/NN isolates/NNS ./. 
To/TO delineate/VB the/DT effects/NNS of/IN these/DT motifs/NNS on/IN the/DT replicative/JJ capacity/NN of/IN HIV/NN and/CC to/TO explore/VB the/DT possibility/NN of/IN extending/VBG the/DT virus/NN host/NN range/NN ,/, known/VBN heterologous/JJ enhancer/promoters/NNS were/VBD inserted/VBN into/IN the/DT HIV-1/NN LTR/NN in/IN place/NN of/IN the/DT NF-kappa/NN B/NN and/CC Sp1/NN binding/NN sites/NNS ./. 
The/DT effects/NNS of/IN these/DT substitutions/NNS on/IN viral/JJ replication/NN in/IN transfected/VBN HeLa/NN cells/NNS and/CC on/IN HIV/NN infection/NN of/IN human/JJ peripheral/JJ blood/NN lymphocytes/NNS or/CC continuous/JJ T-leukemia/NN cell/NN lines/NNS were/VBD evaluated/VBN ./. 
HIVs/NN in/IN which/WDT the/DT NF-/NN kappa/NN B/Sp1/NN enhancer/NN plus/CC the/DT downstream/JJ TATA/NN element/NN were/VBD replaced/VBN with/IN heterologous/JJ enhancer/promoters/NNS were/VBD also/RB constructed/VBN ./. 
Viruses/NNS containing/VBG the/DT human/JJ cytomegalovirus/NN immediate-early/JJ enhancer/NN exhibited/VBD infectious/JJ kinetics/NNS similar/JJ to/TO that/DT of/IN wild-type/JJ HIV/NN in/IN activated/VBN human/JJ peripheral/JJ blood/NN lymphocytes/NNS and/CC AA2/NN cells/NNS but/CC replicated/VBD less/RBR efficiently/RB in/IN H9/NN and/CC CEM/NN cells/NNS ./. 
These/DT studies/NNS indicate/VBP that/IN heterologous/JJ enhancer/NN elements/NNS are/VBP capable/JJ of/IN restoring/VBG Tat/NN responsiveness/NN to/TO the/DT HIV/NN LTR/NN in/IN the/DT context/NN of/IN directing/VBG reporter/NN gene/NN expression/NN as/RB well/RB as/IN in/IN the/DT production/NN of/IN infectious/JJ progeny/NN virions/NNS ./. 
UI/LS -/: 93126354/CD 
TI/LS -/: Tyrosine/NN phosphorylation/NN is/VBZ a/DT mandatory/JJ proximal/JJ step/NN in/IN radiation-induced/JJ activation/NN of/IN the/DT protein/NN kinase/NN C/NN signaling/NN pathway/NN in/IN human/JJ B-/NN lymphocyte/NN precursors/NNS [/( published/VBN erratum/NN appears/VBZ in/IN Proc/NNP Natl/NNP Acad/NNP Sci/NNP U/NNP S/NNP A/NNP 1993/CD Apr/NNP 15/CD ;/: 90/CD (/( 8/CD )/) :/: 3775/CD ]/) 
AB/LS -/: Ionizing/VBG radiation/NN triggers/VBZ a/DT signal/NN in/IN human/JJ B-lymphocyte/NN precursors/NNS that/WDT is/VBZ intimately/RB linked/VBN to/TO an/DT active/JJ protein-tyrosine/NN kinase/NN regulatory/JJ pathway/NN ./. 
We/PRP show/VBP that/IN in/IN B-lymphocyte/NN precursors/NNS ,/, irradiation/NN with/IN gamma-rays/NNS leads/VBZ to/TO (/( i/LS )/) stimulation/NN of/IN phosphatidylinositol/NN turnover/NN ;/: (/( ii/LS )/) downstream/JJ activation/NN by/IN covalent/JJ modification/NN of/IN multiple/JJ serine-specific/JJ protein/NN kinases/NNS ,/, including/VBG protein/NN kinase/NN C/NN ;/: and/CC (/( iii/LS )/) activation/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN ./. 
All/DT of/IN the/DT radiation-induced/JJ signals/NNS were/VBD effectively/RB prevented/VBN by/IN the/DT protein-tyrosine/NN kinase/NN inhibitors/NNS genistein/NN and/CC herbimycin/NN A/NN ./. 
Thus/RB ,/, tyrosine/NN phosphorylation/NN is/VBZ an/DT important/JJ and/CC perhaps/RB mandatory/JJ proximal/JJ step/NN in/IN the/DT activation/NN of/IN the/DT protein/NN kinase/NN C/NN signaling/NN cascade/NN in/IN human/JJ B-lymphocyte/NN precursors/NNS ./. 
Our/PRP$ report/VBP expands/NNS current/JJ knowledge/NN of/IN the/DT radiation-induced/JJ signaling/NN cascade/NN by/IN clarifying/VBG the/DT chronological/JJ sequence/NN of/IN biochemical/JJ events/NNS that/WDT follow/VBP irradiation/NN ./. 
UI/LS -/: 97218353/CD 
TI/LS -/: Detection/NN of/IN adenovirus/NN DNA/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS by/IN polymerase/NN chain/NN reaction/NN assay/NN ./. 
AB/LS -/: Adenovirus/NN can/MD establish/VB persistent/JJ infections/NNS which/WDT may/MD reactivate/VB and/CC cause/VB disease/NN in/IN immunocompromised/JJ hosts/NNS ./. 
Lymphocytes/NNS have/VBP been/VBN postulated/VBN to/TO serve/VB as/IN a/DT site/NN of/IN adenoviral/JJ persistence/NN based/VBN upon/IN the/DT ability/NN to/TO isolate/VB adenovirus/NN from/IN tonsils/NNS and/CC to/TO detect/VB adenovirus/NN DNA/NN by/IN Southern/NN blot/NN hybridization/NN in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS (/( PBMC/NN )/) ./. 
To/TO test/VB this/DT hypothesis/NN ,/, a/DT more/RBR sensitive/JJ and/CC specific/JJ polymerase/NN chain/NN reaction/NN (/( PCR/NN )/) assay/NN was/VBD developed/VBN to/TO detect/VB adenovirus/NN DNA/NN ./. 
Two/CD sets/NNS of/IN nested/VBD primers/NNS were/VBD designed/VBN to/TO conserved/VBN sequences/NNS in/IN the/DT adenovirus/NN E1A/NN and/CC hexon/NN genes/NNS ./. 
The/DT E1A/NN and/CC hexon/NN primers/NNS amplified/VBD DNA/NN from/IN representative/JJ adenoviral/JJ serotypes/NNS in/IN all/DT six/CD adenoviral/JJ groups/NNS (/( A-F/NNS )/) ./. 
Both/DT primers/NNS detected/VBD a/DT single/JJ copy/NN of/IN the/DT adenovirus/NN type/NN 2/CD genome/NN but/CC were/VBD less/RBR sensitive/JJ for/IN the/DT group/NN B/NN type/NN 35/CD ./. 
None/NN of/IN 33/CD PBMC/NN specimens/NNS from/IN healthy/JJ adults/NNS and/CC only/RB one/CD of/IN 40/CD pediatric/JJ samples/NNS was/VBD positive/JJ (/( at/IN a/DT low/JJ level/NN )/) for/IN adenovirus/NN DNA/NN by/IN nested/JJ PCR/NN assay/NN ./. 
In/IN comparison/NN ,/, PBMC/NN from/IN two/CD children/NNS with/IN fatal/JJ adenoviral/JJ infection/NN were/VBD both/RB strongly/RB positive/JJ for/IN adenovirus/NN DNA/NN ./. 
It/PRP is/VBZ concluded/VBN that/IN ,/, in/IN contrast/NN to/TO a/DT previous/JJ study/NN ,/, PBMC/NN are/VBP not/RB a/DT common/JJ site/NN of/IN persistent/JJ group/NN C/NN adenoviral/JJ infection/NN ./. 
In/IN addition/NN ,/, assay/NN of/IN PBMC/NN by/IN the/DT adenovirus-specific/JJ PCR/NN may/MD help/VB detect/VB early/JJ invasive/JJ disease/NN and/CC warrants/VBZ further/JJ evaluation/NN ./. 
UI/LS -/: 93363253/CD 
TI/LS -/: Tumor/NN necrosis/NN factor/NN receptor/NN expression/NN and/CC signal/NN transduction/NN in/IN HIV-1-infected/JJ cells/NNS ./. 
AB/LS -/: OBJECTIVE/NN :/: To/TO examine/VB the/DT inter-relationship/NN between/IN HIV-1/NN infection/NN and/CC the/DT cell/NN surface/NN receptors/NNS for/IN tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) -alpha/NN ,/, an/DT immunoregulatory/JJ cytokine/NN that/WDT can/MD enhance/VB HIV-1/NN replication/NN ./. 
DESIGN/NN :/: Infected/JJ promyelocytic/JJ and/CC promonocytic/JJ cells/NNS were/VBD examined/VBN because/IN they/PRP normally/RB express/VBP both/DT types/NNS of/IN TNF/NN receptors/NNS ./. 
METHODS/NNS :/: TNF/NN receptor/NN surface/NN expression/NN was/VBD determined/VBN by/IN specific/JJ monoclonal/JJ antibody/NN recognition/NN and/CC flow/NN cytometry/NN ,/, and/CC signal/NN transduction/NN was/VBD detected/VBN by/IN gel/NN shift/NN analysis/NN ./. 
HIV-1/NN activation/NN and/CC expression/NN was/VBD quantitated/VBN by/IN reverse/JJ transcriptase/NN assay/NN ./. 
RESULTS/NNS :/: In/IN the/DT OM-10.1/NN promyelocytic/JJ model/NN of/IN chronic/JJ infection/NN ,/, TNF-alpha-induced/JJ HIV-1/NN expression/NN also/RB resulted/VBD in/IN a/DT substantial/JJ increase/NN in/IN 75/CD kd/NN TNF/NN receptor/NN (/( TR75/NN )/) expression/NN although/IN 55/CD kD/NN TNF/NN receptor/NN (/( TR55/NN )/) levels/NNS were/VBD not/RB dramatically/RB altered/VBN ./. 
A/DT series/NN of/IN uninfected/JJ parental/JJ HL-60/NN subclones/NNS all/DT reduced/VBD TR75/NN surface/NN expression/NN in/IN response/NN to/TO TNF-alpha/NN treatment/NN ./. 
Enhanced/VBN TR75/NN expression/NN on/IN OM-10.1/NN cells/NNS followed/VBD the/DT same/JJ TNF-alpha-dose/NN dependency/NN as/IN that/WDT observed/VBN for/IN HIV-1/NN production/NN ./. 
An/DT increase/NN in/IN TR75/NN expression/NN was/VBD also/RB evident/JJ during/IN the/DT peak/NN of/IN an/DT acute/JJ HIV-1/NN infection/NN of/IN HL-60/NN promyelocytes/NNS ./. 
Although/IN TR55/NN expression/NN was/VBD unaltered/JJ during/IN TNF-alpha-induced/JJ HIV/NN activation/NN ,/, this/DT receptor/NN was/VBD still/RB involved/VBN in/IN the/DT viral/JJ activation/NN process/NN ./. 
Antibody/NN cross-linking/NN of/IN TR55/NN ,/, in/IN the/DT absence/NN of/IN exogenous/JJ TNF-alpha/NN ,/, induced/VBN maximal/JJ HIV-1/NN expression/NN ,/, an/DT up-modulation/NN of/IN surface/NN TR75/NN ,/, and/CC nuclear/JJ NF-kappa/NN B/NN activity/NN in/IN OM-10.1/NN cultures/NNS ./. 
Surprisingly/RB ,/, this/DT was/VBD the/DT case/NN even/RB when/WRB an/DT antagonistic/JJ anti-TR55/JJ antibody/NN was/VBD used/VBN ./. 
Anti-TR55/JJ antibody/NN cross-linking/NN in/IN chronically/RB infected/JJ U1/NN promonocytic/JJ cultures/NNS could/MD only/RB partially/RB substitute/VB for/IN TNF-alpha-induced/JJ HIV-1/NN expression/NN ./. 
CONCLUSIONS/NNS :/: Our/PRP$ results/NNS demonstrated/VBD that/IN HIV-1/NN infection/NN can/MD selectively/RB influence/VB the/DT surface/NN expression/NN of/IN TNF/NN receptors/NNS ,/, potentially/RB influencing/VBG its/PRP$ own/JJ expression/NN and/CC altering/VBG normal/JJ immunoregulatory/JJ signal/NN transduction/NN ./. 
UI/LS -/: 94191916/CD 
TI/LS -/: Comparative/JJ mapping/NN of/IN SRY/NN in/IN the/DT great/JJ apes/NNS ./. 
AB/LS -/: Cytogenetic/JJ studies/NNS of/IN the/DT primate/JJ Y/NN chromosomes/NNS have/VBP suggested/VBN that/IN extensive/JJ rearrangements/NNS have/VBP occurred/VBN during/IN evolution/NN of/IN the/DT great/JJ apes/NNS ./. 
We/PRP have/VBP used/VBN in/FW situ/FW hybridization/NN to/TO define/VB these/DT rearrangements/NNS at/IN the/DT molecular/JJ level/NN ./. 
pHU-14/NN ,/, a/DT probe/NN including/VBG sequences/NNS from/IN the/DT sex/NN determining/JJ gene/NN SRY/NN ,/, hybridizes/VBZ close/RB to/TO the/DT early/JJ replicating/VBG pseudoautosomal/JJ segment/NN in/IN a/DT telomeric/JJ or/CC subtelomeric/JJ position/NN of/IN the/DT Y/NN chromosomes/NNS of/IN all/DT great/JJ apes/NNS ./. 
The/DT low/JJ copy/NN repeat/NN detected/VBN by/IN the/DT probe/NN Fr35-II/NN is/VBZ obviously/RB included/VBN in/IN Y/NN chromosomal/NN rearrangements/NNS during/IN hominid/NN evolution/NN ./. 
These/DT results/NNS ,/, combined/VBN with/IN previous/JJ studies/NNS ,/, suggest/VBP that/IN the/DT Y/NN chromosome/NN in/IN great/JJ apes/NNS has/VBZ a/DT conserved/VBN region/NN including/VBG the/DT pseudoautosomal/JJ region/NN and/CC the/DT testis-determining/JJ region/NN ./. 
The/DT rest/NN of/IN the/DT Y/NN chromosome/NN has/VBZ undergone/VBN several/JJ rearrangements/NNS in/IN the/DT different/JJ great/JJ apes/NNS ./. 
UI/LS -/: 93272960/CD 
TI/LS -/: Calcium/NN dependent/JJ activation/NN of/IN the/DT NF-AT/NN transcription/NN factor/NN by/IN p59fyn/NN ./. 
AB/LS -/: A/DT reporter/NN gene/NN under/IN the/DT control/NN of/IN a/DT T-cell/NN antigen/NN receptor/NN element/NN was/VBD activated/VBN in/IN Jurkat/NN cells/NNS by/IN antigen/NN receptor/NN triggering/NN or/CC by/IN a/DT combination/NN of/IN phorbol/NN myristate/NN acetate/NN ,/, which/WDT activates/VBZ protein/NN kinase/NN C/NN ,/, and/CC a/DT calcium/NN ionophore/NN ./. 
Both/DT these/DT signals/NNS were/VBD necessary/JJ for/IN expression/NN of/IN the/DT reporter/NN gene/NN ./. 
When/WRB co-transfected/VBN with/IN a/DT construct/NN capable/JJ of/IN overexpressing/VBG the/DT tyrosine/NN kinase/NN p59fyn/NN ,/, the/DT reporter/NN gene/NN was/VBD activated/VBN by/IN PMA/NN alone/RB ./. 
Thus/RB p59fyn/NN could/MD replace/VB the/DT calcium/NN ionophore/NN but/CC not/RB activation/NN of/IN protein/NN kinase/NN C/NN ./. 
The/DT activation/NN by/IN p59fyn/NN plus/CC PMA/NN was/VBD blocked/VBN by/IN EGTA/NN and/CC by/IN the/DT immunosuppressant/JJ drug/NN cyclosporin/NN A/NN ./. 
UI/LS -/: 93292612/CD 
TI/LS -/: Dependence/NN for/IN the/DT proliferative/JJ response/NN to/TO erythropoietin/NN on/IN an/DT established/JJ erythroid/JJ differentiation/NN program/NN in/IN a/DT human/JJ hematopoietic/JJ cell/NN line/NN ,/, UT-7/NN ./. 
AB/LS -/: Erythroid/JJ differentiation/NN involves/VBZ the/DT activation/NN of/IN a/DT number/NN of/IN erythroid-specific/JJ genes/NNS ,/, most/JJS of/IN which/WDT ,/, including/VBG the/DT globin/NN genes/NNS and/CC the/DT erythropoietin/NN receptor/NN (/( Epo-R/NN )/) gene/NN ,/, are/VBP ,/, at/IN least/JJS in/IN part/NN ,/, regulated/VBN by/IN the/DT transcription/NN factor/NN GATA-1/NN ./. 
In/IN order/NN to/TO understand/VB the/DT relationship/NN ,/, if/IN any/DT ,/, between/IN expression/NN of/IN GATA-1/NN ,/, response/NN to/TO Epo/NN and/CC erythroid/JJ differentiation/NN ,/, we/PRP analyzed/VBD the/DT expression/NN of/IN GATA-1/NN ,/, Epo-R/NN and/CC globin/NN genes/NNS in/IN an/DT Epo-dependent/JJ human/JJ cell/NN line/NN ,/, UT-7/NN Epo/NN ./. 
The/DT results/NNS were/VBD compared/VBN to/TO those/DT obtained/VBN with/IN the/DT parental/JJ granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) -dependent/JJ cell/NN line/NN ,/, UT-7/NN ,/, which/WDT has/VBZ a/DT predominantly/RB megakaryoblastic/JJ phenotype/NN and/CC is/VBZ unable/JJ to/TO proliferate/VB continuously/RB in/IN the/DT presence/NN of/IN Epo/NN ./. 
UT-7/NN Epo/NN and/CC UT-7/NN expressed/VBD similar/JJ levels/NNS of/IN GATA-1/NN mRNA/NN and/CC binding/NN activity/NN ./. 
The/DT two/CD lines/NNS also/RB expressed/VBD comparable/JJ levels/NNS of/IN Epo-R/NN mRNA/NN while/IN the/DT number/NN of/IN Epo-binding/JJ sites/NNS on/IN UT-7/NN Epo/NN cells/NNS was/VBD one-sixth/CD the/DT number/NN of/IN UT-7/NN cells/NNS (/( 2400/CD +/-/CC 3/CD vs./CC 13/CD ,/, 800/CD +/-/CC 300/CD )/) ./. 
This/DT difference/NN in/IN the/DT number/NN of/IN binding/VBG sites/NNS could/MD be/VB due/JJ to/TO differences/NNS in/IN cell/NN surface/NN (/( UT-7/NN cells/NNS are/VBP 20/CD %/NN smaller/JJR than/IN the/DT parental/JJ UT-7/NN cells/NNS )/) or/CC in/IN receptor/NN turnover/NN ./. 
By/IN Northern/NN analysis/NN ,/, UT-7/NN cells/NNS expressed/VBD detectable/JJ levels/NNS of/IN beta-/NN and/CC gamma-globin/NN but/CC not/RB alpha-globin/NN ./. 
In/IN comparison/NN ,/, UT-7/NN Epo/NN cells/NNS expressed/VBD alpha-globin/NN and/CC higher/JJR levels/NNS of/IN gamma-globin/NN (/( 5-fold/JJ )/) and/CC beta-globin/NN (/( from/IN barely/RB to/TO clearly/RB detectable/JJ )/) ./. 
Globin/NN chains/NNS (/( alpha/NN ,/, beta/NN and/CC gamma/NN )/) were/VBD clearly/RB detectable/JJ by/IN affinity/NN chromatography/NN in/IN UT-7/NN Epo/NN but/CC not/RB in/IN UT-7/NN cells/NNS ./. 
The/DT frequency/NN of/IN the/DT cells/NNS which/WDT expressed/VBD beta-/NN and/CC gamma-globin/NN genes/NNS in/IN the/DT two/CD cell/NN populations/NNS was/VBD measured/VBN by/IN immunofluorescence/NN with/IN beta-/NN and/CC gamma-specific/JJ antibodies/NNS ./. 
The/DT number/NN of/IN gamma-positive/JJ cells/NNS and/CC their/PRP$ fluorescence/NN intensity/NN were/VBD higher/JJR in/IN UT-7/NN Epo/NN than/IN in/IN UT-7/NN cells/NNS (/( 0/CD to/TO 17/CD %/NN barely/RB positive/JJ cells/NNS and/CC 23/CD to/TO 40/CD %/NN clearly/RB positive/JJ cells/NNS ,/, respectively/RB )/) ,/, indicating/VBG that/IN the/DT increase/NN in/IN globin/NN mRNA/NN observed/VBN in/IN UT-7/NN Epo/NN is/VBZ due/JJ to/TO both/CC an/DT increase/NN of/IN gene/NN expression/NN per/IN cell/NN and/CC an/DT increase/NN in/IN numbers/NNS of/IN cells/NNS containing/VBG gamma-globin/NN ./. 
The/DT levels/NNS of/IN GATA-1/NN ,/, Epo-R/NN and/CC globin/NN mRNA/NN expressed/VBN were/VBD not/RB affected/VBN by/IN a/DT 24-hour/JJ incubation/NN of/IN either/CC cell/NN line/NN with/IN Epo/NN ,/, GM-CSF/NN or/CC interleukin-3/NN (/( IL-3/NN )/) ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 400/CD WORDS/NNS )/) 
UI/LS -/: 93216805/CD 
TI/LS -/: The/DT Sp1/NN transcription/NN factor/NN binds/VBZ the/DT CD11b/NN promoter/NN specifically/RB in/IN myeloid/JJ cells/NNS in/FW vivo/FW and/CC is/VBZ essential/JJ for/IN myeloid-specific/JJ promoter/NN activity/NN ./. 
AB/LS -/: The/DT myeloid/JJ integrin/NN CD11b/NN is/VBZ expressed/VBN selectively/RB on/IN the/DT surface/NN of/IN mature/JJ macrophages/NNS ,/, monocytes/NNS ,/, neutrophils/NNS ,/, and/CC natural/JJ killer/NN cells/NNS ./. 
Lineage-specific/JJ expression/NN is/VBZ controlled/VBN at/IN the/DT level/NN of/IN mRNA/NN transcription/NN ./. 
Recent/JJ isolation/NN of/IN the/DT CD11b/NN promoter/NN shows/VBZ that/IN 92/CD base/NN pairs/NNS (/( bp/NN )/) of/IN 5'-flanking/JJ DNA/NN are/VBP sufficient/JJ to/TO direct/VB myeloid-specific/JJ expression/NN of/IN a/DT reporter/NN gene/NN ./. 
To/TO characterize/VB regulatory/JJ sequences/NNS important/JJ for/IN promoter/NN activity/NN ,/, we/PRP performed/VBD linker/NN scanning/NN analysis/NN of/IN the/DT 92-bp/JJ CD11b/NN promoter/NN and/CC demonstrate/VB that/IN a/DT sequence/NN at/IN bp/NN -60/CD is/VBZ essential/JJ for/IN CD11b/NN promoter/NN activity/NN ./. 
We/PRP show/VBP that/IN this/DT sequence/NN binds/VBZ the/DT transcription/NN factor/NN Sp1/NN in/FW vitro/FW and/CC in/FW vivo/FW ./. 
In/FW vivo/FW the/DT Sp1/NN site/NN is/VBZ bound/VBN only/RB in/IN myeloid/JJ (/( U937/NN )/) cells/NNS ,/, not/RB in/IN cervical/JJ carcinoma/NN (/( HeLa/NN )/) cells/NNS ./. 
In/IN addition/NN ,/, the/DT macrophage/NN transcription/NN factor/NN PU.1/NN binds/VBZ the/DT CD11b/NN promoter/NN in/FW vitro/FW and/CC in/FW vivo/FW close/RB to/TO the/DT Sp1/NN site/NN ./. 
We/PRP propose/VBP a/DT model/NN in/IN which/WDT binding/NN of/IN a/DT myeloid-specific/JJ factor/NN (/( PU.1/NN )/) allows/VBZ a/DT general/JJ factor/NN (/( Sp1/NN )/) to/TO bind/VB in/IN a/DT tissue-specific/JJ fashion/NN thereby/RB contributing/VBG to/TO the/DT myeloid-specific/JJ expression/NN of/IN CD11b/NN ./. 
UI/LS -/: 93202345/CD 
TI/LS -/: Transcription/NN factor/NN jun-B/NN is/VBZ target/NN of/IN autoreactive/JJ T-cells/NNS in/IN IDDM/NN ./. 
AB/LS -/: Target/NN antigens/NNS defined/VBN by/IN autoantibodies/NNS in/IN IDDM/NN include/VBP insulin/NN ,/, a/DT putative/JJ glycolipid/NN that/WDT reacts/VBZ with/IN islet/NN cell/NN antibodies/NNS ,/, and/CC a/DT 64,000-M(r)/JJ protein/NN recently/RB identified/VBN as/IN glutamic/JJ acid/NN decarboxylase/NN ./. 
In/IN addition/NN ,/, some/DT IDDM/NN sera/NN that/WDT contain/VBP antibodies/NNS to/TO glutamic/JJ acid/NN decarboxylase/NN also/RB coprecipitate/VBP a/DT 38,000-M(r)/JJ protein/NN from/IN islets/NNS ./. 
This/DT study/NN used/VBD a/DT high/JJ titer/NN anti-38,000-M(r)/JJ serum/NN to/TO screen/VB bacteriophage/NN lambda/NN cDNA/NN expression/NN libraries/NNS and/CC identified/VBD human/JJ islet/NN and/CC placental/JJ clones/NNS encoding/VBG jun-B/NN ,/, the/DT nuclear/JJ transcription/NN protein/NN ,/, of/IN predicted/VBN 38,000/CD M(r)/NN ./. 
Peripheral/JJ blood/NN T-cells/NNS exhibited/VBD significant/JJ proliferation/NN in/IN response/NN to/TO a/DT recombinant/JJ fragment/NN of/IN jun-B/NN (/( amino/NN acids/NNS 1-180/CD )/) in/IN 12/CD of/IN 17/CD (/( 71/CD %/NN )/) recent-onset/JJ IDDM/NN subjects/NNS ,/, 8/CD of/IN 16/CD (/( 50/CD %/NN )/) ICA-positive/JJ first-degree/JJ relatives/NNS of/IN IDDM/NN subjects/NNS who/WP were/VBD at/IN risk/NN ,/, 3/CD of/IN 12/CD (/( 25/CD %/NN )/) other/JJ autoimmune/JJ disease/NN subjects/NNS ,/, and/CC 0/CD of/IN 10/CD healthy/JJ control/NN subjects/NNS ./. 
Proliferation/NN to/TO tetanus/NN toxoid/NN did/VBD not/RB differ/VB significantly/RB between/IN the/DT groups/NNS ./. 
Responses/NNS to/TO jun-B/NN were/VBD not/RB related/JJ to/TO age/NN ,/, sex/NN ,/, or/CC human/JJ leukocyte/NN antigen/NN status/NN ./. 
Thus/RB ,/, autoreactive/JJ T-cells/NNS identify/VBP a/DT novel/JJ antigen/NN ,/, p38/NN jun-B/NN ,/, in/IN IDDM/NN and/CC appear/VBP to/TO indicate/VB subjects/NNS at/IN risk/NN for/IN the/DT development/NN of/IN clinical/JJ disease/NN ./. 
UI/LS -/: 93194883/CD 
TI/LS -/: Stimulation/NN of/IN interleukin-1/NN alpha/NN and/CC interleukin-1/NN beta/NN production/NN in/IN human/JJ monocytes/NNS by/IN protein/NN phosphatase/NN 1/CD and/CC 2A/NN inhibitors/NNS ./. 
AB/LS -/: Protein/NN phosphatases/NNS 1/CD and/CC 2A/NN are/VBP important/JJ in/IN regulating/VBG cellular/JJ functions/NNS by/IN controlling/VBG the/DT phosphorylation/NN state/NN of/IN their/PRP$ substrates/NNS ./. 
In/IN human/JJ monocytes/NNS ,/, the/DT inhibitors/NNS of/IN these/DT phosphatases/NNS ,/, okadaic/JJ acid/NN and/CC calyculin/NN A/NN ,/, were/VBD found/VBN to/TO increase/VB the/DT mRNA/NN accumulation/NN and/CC cytokine/NN production/NN of/IN interleukin-1/NN beta/NN and/CC interleukin-1/NN alpha/NN ./. 
The/DT increased/VBN mRNA/NN accumulation/NN was/VBD found/VBN to/TO be/VB primarily/RB because/IN of/IN the/DT increase/NN in/IN the/DT transcription/NN rate/NN of/IN the/DT interleukin-1/NN genes/NNS ./. 
Stimulation/NN of/IN interleukin-1/NN gene/NN transcription/NN may/MD be/VB caused/VBN by/IN the/DT stimulation/NN of/IN transcription/NN factor/NN activities/NNS ,/, including/VBG those/DT of/IN AP-1/NN ,/, by/IN these/DT protein/NN phosphatase/NN inhibitors/NNS ./. 
Okadaic/JJ acid/NN increased/VBD the/DT synthesis/NN of/IN the/DT interleukin-1/NN beta/NN precursor/NN and/CC mature/JJ forms/NNS and/CC their/PRP$ secretion/NN ./. 
This/DT increased/VBD processing/NN and/CC secretion/NN correlated/VBN with/IN the/DT stimulation/NN of/IN IL-1/NN beta/NN convertase/NN mRNA/NN accumulation/NN ./. 
The/DT stimulation/NN of/IN interleukin-1/NN alpha/NN production/NN by/IN okadaic/JJ acid/NN was/VBD more/RBR modest/JJ than/IN that/DT of/IN interleukin-1/NN beta/NN ./. 
However/RB ,/, the/DT phosphorylation/NN of/IN the/DT precursor/NN interleukin-1/NN alpha/NN cytokine/NN was/VBD increased/VBN ./. 
These/DT results/NNS show/VBP that/IN protein/NN phosphatase/NN 1/CD and/CC 2A/NN inhibitors/NNS exert/VBP multiple/JJ effects/NNS on/IN cytokine/NN production/NN in/IN human/JJ monocytes/NNS and/CC suggest/VBP that/IN these/DT two/CD phosphatases/NNS play/VBP important/JJ roles/NNS in/IN regulating/VBG interleukin-1/NN production/NN ./. 
UI/LS -/: 93189564/CD 
TI/LS -/: The/DT interleukin/NN 2/CD CD28-responsive/JJ complex/NN contains/VBZ at/IN least/JJS three/CD members/NNS of/IN the/DT NF/NN kappa/NN B/NN family/NN :/: c-Rel/NN ,/, p50/NN ,/, and/CC p65/NN ./. 
AB/LS -/: Optimal/JJ activation/NN of/IN T/NN cells/NNS requires/VBZ at/IN least/JJS two/CD signals/NNS ./. 
One/CD signal/NN can/MD be/VB delivered/VBN by/IN the/DT antigen-specific/JJ T-cell/NN receptor/NN ,/, and/CC the/DT second/JJ signal/NN is/VBZ provided/VBN by/IN the/DT costimulatory/JJ molecule/NN (/( s/NNS )/) delivered/VBN by/IN the/DT antigen-presenting/JJ cell/NN ./. 
CD28/NN is/VBZ a/DT T-cell/NN surface/NN molecule/NN and/CC stimulation/NN through/IN this/DT protein/NN plays/VBZ an/DT important/JJ role/NN in/IN delivering/VBG the/DT second/JJ activation/NN signal/NN ./. 
In/IN this/DT report/NN ,/, we/PRP show/VBP that/IN in/IN human/JJ peripheral/JJ blood/NN T/NN cells/NNS ,/, CD28-mediated/JJ signal/NN transduction/NN involves/VBZ the/DT rel/NN family/NN proteins/NNS --/: c-Rel/NN ,/, p50/NN ,/, and/CC p65/NN ./. 
Treatment/NN of/IN peripheral/JJ blood/NN T/NN cells/NNS with/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) and/CC anti-CD28/JJ monoclonal/JJ antibody/NN (/( mAb/NN )/) results/VBZ in/IN augmentation/NN of/IN nuclear/JJ c-Rel/NN ,/, p50/NN ,/, and/CC p65/NN ,/, and/CC this/DT augmentation/NN can/MD occur/VB in/IN the/DT presence/NN of/IN the/DT immunosuppressant/JJ cyclosporin/NN A/NN ./. 
It/PRP is/VBZ also/RB shown/VBN in/IN this/DT report/NN that/IN ,/, in/IN response/NN to/TO PMA/anti-CD28/JJ mAb/NN or/CC anti-CD3/anti-CD28/JJ mAb/NN ,/, c-Rel/NN ,/, p50/NN ,/, and/CC p65/NN are/VBP associated/VBN with/IN CD28-responsive/JJ element/NN present/JJ in/IN the/DT promoter/NN of/IN the/DT human/JJ interleukin/NN 2/CD gene/NN ./. 
The/DT functional/JJ significance/NN of/IN c-Rel/NN involvement/NN in/IN the/DT CD28-responsive/JJ complex/NN is/VBZ demonstrated/VBN by/IN transient/JJ transfection/NN analysis/NN ,/, where/WRB cotransfection/NN of/IN c-Rel/NN augments/VBZ the/DT level/NN of/IN expression/NN of/IN a/DT chloramphenicol/JJ acetyltransferase/NN reporter/NN gene/NN linked/VBN to/TO the/DT CD28-responsive/JJ element/NN ./. 
UI/LS -/: 93152834/CD 
TI/LS -/: Expression/NN of/IN tal-1/NN and/CC GATA-binding/JJ proteins/NNS during/IN human/JJ hematopoiesis/NN ./. 
AB/LS -/: Tal-1/NN rearrangements/NNS are/VBP associated/VBN with/IN nearly/RB 30/CD %/NN of/IN human/JJ T/NN acute/JJ lymphoblastic/JJ leukemia/NN ./. 
Tal-1/NN gene/NN encodes/VBZ a/DT putative/JJ transcription/NN factor/NN with/IN a/DT basic/JJ helix-loop-helix/JJ domain/NN and/CC is/VBZ known/VBN to/TO be/VB predominantly/RB expressed/VBN in/IN hematopoietic/JJ cells/NNS ./. 
We/PRP investigated/VBD the/DT pattern/NN of/IN tal-1/NN expression/NN in/IN purified/VBN human/JJ hematopoietic/JJ cells/NNS by/IN in/FW situ/FW hybridization/NN and/CC reverse/JJ transcriptase/NN polymerase/NN chain/NN reaction/NN analysis/NN ./. 
Both/DT methods/NNS demonstrated/VBD that/IN the/DT tal-1/NN gene/NN is/VBZ expressed/VBN in/IN megakaryocytes/NNS and/CC erythroblasts/NNS as/RB well/RB as/IN in/IN basophilic/JJ granulocytes/NNS ./. 
In/IN addition/NN ,/, our/PRP$ results/NNS indicate/VBP that/IN the/DT tal-1/NN 1A/NN promoter/NN ,/, which/WDT contains/VBZ two/CD consensus/NN GATA-binding/JJ sites/NNS ,/, is/VBZ active/JJ mainly/RB in/IN these/DT lineages/NNS ./. 
Because/IN the/DT GATA-1/NN gene/NN is/VBZ known/VBN to/TO transactivate/VB several/JJ genes/NNS specific/JJ for/IN the/DT erythroid/JJ ,/, megakaryocytic/JJ ,/, and/CC mastocytic/basophilic/JJ lineages/NNS ,/, we/PRP studied/VBD GATA-1/NN expression/NN in/IN these/DT purified/VBN hematopoietic/JJ cells/NNS ./. 
We/PRP found/VBD that/IN GATA-1/NN and/CC tal-1/NN genes/NNS are/VBP coexpressed/VBN in/IN these/DT three/CD lineages/NNS ./. 
Remarkably/RB ,/, the/DT expression/NN of/IN both/DT genes/NNS is/VBZ downmodulated/VBN during/IN erythroid/JJ and/CC megakaryocytic/JJ terminal/JJ maturation/NN ./. 
In/IN immature/JJ hematopoietic/JJ cells/NNS ,/, tal-1/NN and/CC GATA-1/NN genes/NNS are/VBP coexpressed/VBN in/IN committed/VBN progenitors/NNS cells/NNS (/( CD34+/CD38(2+)/JJ )/) ,/, whereas/IN they/PRP are/VBP not/RB detectable/JJ in/IN the/DT most/RBS primitive/JJ cells/NNS (/( CD34(2+)/CD38-/JJ )/) ./. 
In/IN contrast/NN ,/, GATA-2/NN is/VBZ strongly/RB expressed/VBN in/IN both/CC most/RBS primitive/JJ and/CC committed/VBN progenitors/NNS cells/NNS ,/, whereas/IN GATA-3/NN is/VBZ mostly/RB detected/VBN in/IN most/RBS primitive/JJ ones/NNS ./. 
Altogether/RB our/PRP$ results/NNS strongly/RB suggest/VBP that/IN GATA-1/NN modulates/VBZ the/DT transcription/NN of/IN tal-1/NN during/IN the/DT differentiation/NN of/IN the/DT erythroid/JJ ,/, megakaryocytic/JJ ,/, and/CC basosophilic/JJ lineages/NNS ./. 
UI/LS -/: 93228445/CD 
TI/LS -/: The/DT lytic/JJ transition/NN of/IN Epstein-Barr/JJ virus/NN is/VBZ imitated/VBN by/IN recombinant/JJ B-cells/NNS ./. 
AB/LS -/: Lytic/JJ transition/NN of/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) is/VBZ initiated/VBN by/IN distinct/JJ immediate/JJ early/JJ regulators/NNS of/IN the/DT viral/JJ cycle/NN ,/, in/IN synchronization/NN to/TO temporary/JJ ,/, permissive/JJ conditions/NNS during/IN host/NN cell/NN differentiation/NN ./. 
We/PRP developed/VBD eukaryotic/JJ vectors/NNS suitable/JJ to/TO imitate/VB the/DT processes/NNS involved/VBN in/IN lytic/JJ transition/NN in/IN cell/NN culture/NN systems/NNS ./. 
Two/CD stable/JJ B/NN cell/NN lines/NNS were/VBD established/VBN :/: R59Z/NN activator/NN cells/NNS were/VBD used/VBN to/TO induce/VB lytic/JJ EBV/NN expression/NN in/IN a/DT constitutive/JJ manner/NN by/IN the/DT production/NN of/IN the/DT BZLF/NN 1/CD trans-activator/NN (/( Zta/NN )/) ./. 
R7-57/NN reporter/NN cells/NNS ,/, on/IN the/DT other/JJ hand/NN ,/, signaled/VBD induced/VBN activity/NN of/IN the/DT lytic/JJ origin/NN of/IN EBV/NN replication/NN (/( ori/NN Lyt/NN )/) ./. 
Different/JJ modes/NNS ,/, like/IN chemical/JJ induction/NN ,/, lytic/JJ superinfection/NN with/IN EBV/NN and/CC single/JJ gene/NN trans-activation/NN converted/VBD the/DT recombinant/JJ ori/NN Lyt/NN element/NN in/IN R7-57/NN reporter/NN cells/NNS ./. 
BZLF/NN 1/CD ,/, transiently/RB expressed/VBN in/IN R7-57/NN reporter/NN cells/NNS ,/, was/VBD the/DT only/JJ EBV/NN trans-activator/NN found/VBN ,/, sufficient/JJ in/NN inducing/VBG the/DT viral/JJ lytic/JJ cycle/NN ./. 
Basing/VBG on/IN these/DT experiments/NNS ,/, trans-cellular/JJ activation/NN of/IN EBV/NN was/VBD tested/VBN by/IN cocultivation/NN of/IN BZLF/NN 1-expressing/JJ R59Z/NN activator/NN cells/NNS with/IN the/DT R7-57/NN reporter/NN line/NN ./. 
No/DT lytic/JJ effect/NN on/IN the/DT reporter/NN cells/NNS could/MD be/VB measured/VBN ,/, neither/CC by/IN cocultivation/NN of/IN activator/NN cells/NNS nor/CC by/IN coincubation/NN of/IN BZLF/NN 1-containing/JJ cell/NN lysates/NNS ./. 
Latency/NN breaking/NN activity/NN ,/, however/RB ,/, was/VBD transferred/VBN from/IN activator/NN to/TO reporter/NN cells/NNS when/WRB active/JJ ,/, exogenous/JJ virus/NN was/VBD added/VBN ./. 
The/DT cell/NN system/NN described/VBN in/IN these/DT experiments/NNS provides/VBZ a/DT tool/NN for/IN the/DT detection/NN of/IN EBV/NN reactivation/NN and/CC demonstrates/VBZ the/DT potential/NN of/IN the/DT lytic/JJ regulatory/JJ gene/NN BZLF/NN 1/CD 
UI/LS -/: 93321228/CD 
TI/LS -/: Costimulation/NN of/IN cAMP/NN and/CC protein/NN kinase/NN C/NN pathways/NNS inhibits/VBZ the/DT CD3-dependent/JJ T/NN cell/NN activation/NN and/CC leads/VBZ to/TO a/DT persistent/JJ expression/NN of/IN the/DT AP-1/NN transcription/NN factor/NN ./. 
AB/LS -/: The/DT effects/NNS mediated/VBN by/IN a/DT combined/JJ stimulation/NN of/IN cAMP-/NN and/CC protein/NN kinase/NN C/NN (/( PKC/NN )/) -dependent/JJ pathways/NNS have/VBP been/VBN investigated/VBN in/IN different/JJ cellular/JJ systems/NNS ,/, and/CC it/PRP has/VBZ been/VBN shown/VBN that/IN they/PRP may/MD complement/VB each/DT other/JJ in/IN activating/VBG cell/NN proliferation/NN and/CC differentiation/NN ./. 
In/IN this/DT report/NN ,/, we/PRP show/VBP that/IN upon/IN the/DT stimulation/NN of/IN both/DT pathways/NNS T/NN lymphocytes/NNS became/VBD refractory/JJ to/TO activation/NN via/IN the/DT CD3/T/NN cell/NN receptor/NN (/( TcR/NN )/) complex/NN ./. 
T/NN cells/NNS preincubated/VBN with/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) and/CC dibutyryl/NN cAMP/NN (/( Bt2cAMP/NN )/) displayed/VBD a/DT deficient/JJ proliferative/JJ ability/NN in/IN response/NN to/TO anti-CD3/JJ mAb/NN stimulation/NN ,/, whereas/IN lymphocytes/NNS treated/VBN individually/RB with/IN either/CC Bt2cAMP/NN or/CC PMA/NN responded/VBD comparably/RB to/TO untreated/JJ samples/NNS ./. 
We/PRP detected/VBD an/DT association/NN between/IN the/DT reduced/VBN mitogenic/JJ response/NN and/CC low/JJ expression/NN of/IN both/CC interleukin-2/NN (/( IL-2/NN )/) and/CC the/DT alpha/NN chain/NN (/( CD25/NN )/) of/IN the/DT IL-2/NN receptor/NN (/( IL-2R/NN )/) ./. 
Analysis/NN of/IN intracellular/JJ Ca2+/NN mobilization/NN suggested/VBD that/IN the/DT CD3/TcR-dependent/JJ signal/NN transduction/NN was/VBD impaired/JJ in/IN PMA/Bt2cAMP-treated/JJ cells/NNS ./. 
Remarkably/RB ,/, we/PRP observed/VBD that/IN these/DT samples/NNS displayed/VBD a/DT persistent/JJ expression/NN of/IN the/DT c-fos/NN protooncogene/NN ,/, associated/VBN to/TO an/DT increased/VBN AP-1/NN DNA-binding/JJ activity/NN ,/, whereas/IN no/DT variations/NNS of/IN CREB/NN or/CC NF-kB/NN were/VBD detected/VBN ./. 
Neither/CC Bt2cAMP/NN nor/CC PMA/NN individually/RB mediated/VBD these/DT sustained/JJ effects/NNS ,/, which/WDT therefore/RB appear/VBP as/IN a/DT consequence/NN of/IN the/DT interplay/NN between/IN both/DT metabolic/JJ stimuli/NNS ./. 
Altogether/RB ,/, the/DT data/NNS provide/VBP the/DT evidence/NN that/IN both/DT pathways/NNS complement/VBP each/DT other/JJ in/IN regulating/VBG gene/NN expression/NN and/CC ,/, conversely/RB ,/, downregulate/VBP the/DT TcR/NN transduction/NN mechanisms/NNS ./. 
UI/LS -/: 94083530/CD 
TI/LS -/: The/DT lymphotoxin/NN promoter/NN is/VBZ stimulated/VBN by/IN HTLV-I/NN tax/NN activation/NN of/IN NF-kappa/NN B/NN in/IN human/JJ T-cell/NN lines/NNS ./. 
AB/LS -/: The/DT HTLV-I/NN transcriptional/JJ activator/NN tax/NN was/VBD used/VBN to/TO gain/VB insight/NN into/IN the/DT mechanism/NN of/IN lymphotoxin/NN (/( LT/NN ;/: TNF-beta/NN )/) gene/NN induction/NN ./. 
Tax-expressing/JJ cell/NN lines/NNS produce/VBP LT/NN biologic/JJ activity/NN ./. 
An/DT LT/NN promoter/NN (/( LT-293/NN )/) CAT/NN construct/NN that/WDT contained/VBD an/DT NF-kappa/NN B/NN site/NN was/VBD active/JJ in/IN the/DT LT-producing/JJ C81-66-45/NN cell/NN line/NN ,/, which/WDT contains/VBZ defective/JJ HTLV-I/NN but/CC expresses/VBZ tax/NN ./. 
The/DT observation/NN that/IN a/DT mutated/VBN LT-kappa/NN B/NN construct/NN (/( M1-CAT/NN )/) was/VBD inactive/JJ in/IN C81-66-45/NN ,/, confirmed/VBD the/DT importance/NN of/IN NF-kappa/NN B/NN in/IN LT/NN gene/NN expression/NN ./. 
Tax/NN was/VBD transfected/VBN into/IN HTLV-I-negative/JJ human/JJ T-cell/NN lines/NNS ./. 
Jurkat/NN T/NN cells/NNS stably/RB expressing/VBG tax/NN contained/VBD elevated/JJ levels/NNS of/IN NF-kappa/NN B/NN that/WDT directly/RB bound/VBD to/TO the/DT LT-kappa/NN B/NN site/NN ./. 
Tax/NN co-transfected/VBN with/IN reporter/NN constructs/NNS into/IN Jurkat/NN cells/NNS maximally/RB activated/VBD HTLV-I-LTR-CAT/NN and/CC kappa/NN B-fos-CAT/NN and/CC also/RB activated/VBD LT-293/NN to/TO a/DT lesser/JJR extent/NN ./. 
In/IN JM/NN T/NN cells/NNS ,/, tax/NN induced/JJ LT-293/NN activity/NN by/IN two-/CD to/TO four-fold/JJ ,/, though/IN there/EX was/VBD no/DT induction/NN of/IN M1-CAT/NN ./. 
The/DT increase/NN in/IN LT-293/NN CAT/NN activity/NN mirrored/VBD the/DT increase/NN in/IN LT/NN biologic/JJ activity/NN seen/VBN under/IN these/DT conditions/NNS ./. 
These/DT studies/NNS ,/, the/DT first/JJ to/TO demonstrate/VB induction/NN of/IN LT/NN promoter/NN activity/NN over/IN basal/JJ levels/NNS ,/, indicate/VBP that/IN HTLV-I/NN tax/NN causes/VBZ low-level/JJ activation/NN of/IN both/CC endogenous/JJ LT/NN and/CC the/DT LT/NN promoter/NN ,/, at/IN least/JJS in/IN part/NN through/IN activation/NN of/IN NF-kappa/NN B/NN ./. 
UI/LS -/: 93276575/CD 
TI/LS -/: A/DT concatenated/JJ form/NN of/IN Epstein-Barr/JJ viral/JJ DNA/NN in/IN lymphoblastoid/JJ cell/NN lines/NNS induced/VBN by/IN transfection/NN with/IN BZLF1/NN ./. 
AB/LS -/: The/DT replicative/JJ form/NN of/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) DNA/NN was/VBD studied/VBN using/VBG two/CD lymphoblastoid/JJ cell/NN lines/NNS ,/, X50-7/NN and/CC 6F11/NN ,/, which/WDT are/VBP latently/RB infected/VBN by/IN Epstein-Barr/JJ virus/NN ./. 
The/DT lytic/JJ cycle/NN of/IN EBV/NN infection/NN was/VBD induced/VBN by/IN transfection/NN of/IN the/DT cells/NNS with/IN the/DT BRLF1/BZLF1/NN coding/NN region/NN of/IN the/DT P3HR-1/NN defective/JJ genome/NN ./. 
We/PRP combined/VBD two/CD techniques/NNS to/TO identify/VB the/DT productive/JJ replicative/JJ form/NN of/IN Epstein-Barr/JJ viral/JJ DNA/NN in/IN the/DT lytic/JJ cycle-induced/JJ cells/NNS ./. 
Restriction/NN enzyme/NN analysis/NN followed/VBN by/IN Southern/NN blot/NN hybridization/NN identified/VBD a/DT significant/JJ increase/NN in/IN the/DT fused/VBN fragment/NN encompassing/VBG both/DT ends/NNS of/IN EBV/NN DNA/NN ./. 
This/DT indicates/VBZ an/DT increase/NN in/IN either/CC episomal/JJ DNA/NN or/CC concatameric/JJ linear/JJ DNA/NN ./. 
Southern/NN blot/NN analysis/NN of/IN in/FW situ/FW lysing/VBG gels/NNS revealed/VBD that/IN the/DT cellular/JJ content/NN of/IN linear/JJ EBV/NN DNA/NN was/VBD also/RB increased/VBN significantly/RB after/IN the/DT initiation/NN of/IN the/DT viral/JJ lytic/JJ cycle/NN ,/, while/IN the/DT amount/NN of/IN circular/JJ DNA/NN remained/VBD approximately/RB constant/JJ ./. 
We/PRP propose/VBP from/IN these/DT results/NNS that/IN the/DT source/NN of/IN the/DT fused/VBN fragment/NN encompassing/VBG both/DT ends/NNS of/IN EBV/NN DNA/NN is/VBZ a/DT concatenated/VBN linear/JJ EBV/NN DNA/NN molecule/NN ,/, and/CC that/IN such/PDT a/DT concatenated/VBN molecule/NN most/RBS likely/RB represents/VBZ a/DT replicative/JJ form/NN of/IN EBV/NN DNA/NN in/IN productively/RB infected/JJ cells/NNS ./. 
UI/LS -/: 93266777/CD 
TI/LS -/: Expression/NN levels/NNS of/IN the/DT thyrotropin/NN receptor/NN gene/NN in/IN autoimmune/JJ thyroid/NN disease/NN :/: coregulation/NN with/IN parameters/NNS of/IN thyroid/NN function/NN and/CC inverse/JJ relation/NN to/TO major/JJ histocompatibility/NN complex/NN classes/NNS I/CD and/CC II/CD ./. 
AB/LS -/: Using/VBG a/DT human/JJ TSH/NN receptor/NN (/( TSH-R/NN )/) cDNA/NN probe/NN ,/, we/PRP investigated/VBD TSH-R/NN transcript/NN levels/NNS in/IN 13/CD human/JJ thyroid/NN fragments/NNS by/IN Northern/NN blot/NN analysis/NN ;/: 7/CD Graves/NN '/POS disease/NN ,/, 2/CD Hashimoto/NN 's/POS disease/NN ,/, 3/CD endemic/JJ goiter/NN ,/, and/CC 1/CD healthy/JJ thyroid/NN gland/NN were/VBD studied/VBN ./. 
TSH-R/NN expression/NN levels/NNS were/VBD variable/JJ ,/, but/CC displayed/VBD a/DT close/JJ correlation/NN to/TO the/DT expression/NN of/IN thyroid/NN peroxidase/NN (/( r/NN =/JJ 0.703/CD ;/: P/NN </JJR 0.05/CD )/) ,/, thyroglobulin/NN (/( r/NN =/JJ 0.817/CD ;/: P/NN </JJR 0.01/CD )/) ,/, and/CC the/DT nuclear/JJ oncogene/NN c-fos/NN (/( r/NN =/JJ 0.935/CD ;/: P/NN </JJR 0.001/CD )/) ,/, but/CC not/RB c-myc/NN ./. 
Overall/RB ,/, TSH-R/NN transcript/NN levels/NNS were/VBD low/JJ or/CC absent/JJ in/IN those/DT thyroids/NNS in/IN which/WDT expression/NN of/IN the/DT major/JJ histocompatibility/NN complex/NN class/NN I/CD or/CC II/CD (/( MHC/NN I/CD or/CC II/CD )/) was/VBD high/JJ ,/, thus/RB establishing/VBG an/DT inverse/JJ relation/NN (/( MHC/NN I/NN ,/, r/NN =/JJ -0.791/CD ;/: P/NN </JJR 0.01/CD ;/: MHC/NN II/CD ,/, r/NN =/JJ -0.784/NN ;/: P/NN </JJR 0.01/CD )/) ./. 
In/FW situ/FW hybridization/NN showed/VBD that/IN apart/RB from/IN lymphocytes/NNS ,/, thyroid/NN cells/NNS themselves/PRP were/VBD the/DT source/NN of/IN MHC/NN II/CD transcripts/NNS ./. 
gamma-Interferon/NN expression/NN was/VBD only/RB detectable/JJ in/IN 1/CD Hashimoto/NN 's/POS goiter/NN ./. 
Our/PRP$ findings/NNS suggest/VBP that/IN next/JJ to/TO lymphocyte/NN infiltration/NN ,/, active/JJ regulatory/JJ events/NNS in/IN the/DT thyrocyte/NN are/VBP responsible/JJ for/IN the/DT inverse/JJ relation/NN between/IN functional/JJ parameters/NNS (/( TSH-R/NN ,/, thyroid/NN peroxidase/NN ,/, thyroglobulin/NN ,/, and/CC c-fos/NN )/) and/CC immunological/JJ markers/NNS (/( MHC/NN I/CD and/CC II/CD )/) ./. 
UI/LS -/: 93224755/CD 
TI/LS -/: Functional/JJ antagonism/NN between/IN vitamin/NN D3/NN and/CC retinoic/JJ acid/NN in/IN the/DT regulation/NN of/IN CD14/NN and/CC CD23/NN expression/NN during/IN monocytic/JJ differentiation/NN of/IN U-937/NN cells/NNS ./. 
AB/LS -/: 1,25/CD alpha-Dihydroxicholecalciferol/NN (/( VitD3/NN )/) and/CC retinoic/JJ acid/NN (/( RA/NN )/) are/VBP important/JJ regulators/NNS of/IN the/DT proliferation/NN and/CC differentiation/NN of/IN several/JJ cell/NN types/NNS ./. 
This/DT paper/NN describes/VBZ how/WRB the/DT expression/NN of/IN the/DT monocyte-macrophage/JJ Ag/NN ,/, CD14/NN ,/, and/CC the/DT low/JJ affinity/NN Fc/NN receptor/NN for/IN IgE/NN ,/, CD23/NN ,/, were/VBD inversely/RB regulated/VBN during/IN VitD3-/NN and/CC RA-induced/JJ monocytic/JJ differentiation/NN of/IN human/JJ U-937/NN monoblasts/NNS ./. 
PMA/NN induced/VBD the/DT expression/NN of/IN both/CC CD14/NN and/CC CD23/NN mRNA/NN and/CC protein/NN ./. 
Exposure/NN to/TO VitD3/NN rapidly/RB induced/VBD the/DT de/FW novo/FW expression/NN of/IN CD14/NN mRNA/NN and/CC protein/NN ./. 
The/DT addition/NN of/IN cycloheximide/NN completely/RB blocked/VBD the/DT VitD3/NN induction/NN of/IN CD14/NN mRNA/NN expression/NN ,/, indicating/VBG that/IN the/DT induction/NN was/VBD dependent/JJ on/IN ongoing/JJ protein/NN synthesis/NN ./. 
While/IN inducing/VBG CD14/NN expression/NN ,/, VitD3/NN concomitantly/RB suppressed/VBD the/DT basal/JJ ,/, PMA-/NN ,/, and/CC RA-inducible/JJ CD23/NN expression/NN in/IN a/DT dose-dependent/JJ manner/NN ./. 
In/IN contrast/NN ,/, U-937/NN cells/NNS induced/VBN by/IN RA/NN strongly/RB increased/VBD their/PRP$ expression/NN of/IN CD23/NN mRNA/NN and/CC protein/NN ,/, whereas/IN they/PRP completely/RB lacked/VBD detectable/JJ CD14/NN cell/NN surface/NN or/CC mRNA/NN expression/NN ./. 
Furthermore/RB ,/, the/DT VitD3-/NN and/CC the/DT PMA-induced/JJ CD14/NN expression/NN was/VBD inhibited/VBN as/IN a/DT temporal/JJ consequence/NN of/IN the/DT RA-induced/JJ differentiation/NN ./. 
The/DT results/NNS suggest/VBP that/IN there/EX exists/VBZ a/DT functional/JJ antagonism/NN between/IN VitD3/NN and/CC RA/NN that/WDT may/MD have/VB important/JJ implications/NNS for/IN the/DT regulation/NN of/IN certain/JJ immune/JJ and/CC inflammatory/JJ responses/NNS through/IN their/PRP$ inverse/JJ effects/NNS on/IN CD14/NN and/CC CD23/NN gene/NN expression/NN ./. 
UI/LS -/: 93275333/CD 
TI/LS -/: Cell-specific/JJ bifunctional/JJ role/NN of/IN Jun/NN oncogene/NN family/NN members/NNS on/IN glucocorticoid/NN receptor-dependent/JJ transcription/NN ./. 
AB/LS -/: Interaction/NN between/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) -/: and/CC glucocorticoid/NN receptor/NN (/( GR/NN )/) -mediated/JJ signaling/NN is/VBZ suggested/VBN by/IN the/DT ability/NN of/IN the/DT PKC/NN activating/NN phorbol/NN ester/NN 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) to/TO inhibit/VB GR-dependent/JJ transcription/NN of/IN the/DT mouse/NN mammary/JJ tumor/NN virus/NN (/( MMTV/NN )/) long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) ./. 
Here/RB we/PRP report/VBP that/IN this/DT interference/NN is/VBZ cell/NN specific/JJ ,/, as/IN TPA/NN augmented/VBD dexamethasone-induced/JJ transcriptional/JJ activation/NN of/IN the/DT MMTV/NN LTR/NN in/IN several/JJ T/NN cell/NN lines/NNS but/CC was/VBD inhibitory/JJ in/IN NIH-3T3/NN fibroblasts/NNS ./. 
TPA-GR/NN synergism/NN was/VBD determined/VBN to/TO have/VB occurred/VBN at/IN the/DT GR-responsive/JJ element/NN (/( GRE/NN )/) level/NN by/IN functional/JJ analysis/NN of/IN deletion/NN mutants/NNS or/CC synthetic/JJ GRE/NN oligonucleotides/NNS driving/VBG chloramphenicol/NN acetyl-transferase/NN expression/NN ./. 
Synergism/NN required/VBD an/DT intact/JJ GR/NN DNA-binding/JJ domain/NN ,/, whereas/IN amino-/NN or/CC carboxyl-terminal/JJ domains/NNS were/VBD dispensable/JJ ./. 
The/DT effect/NN was/VBD abrogated/VBN by/IN the/DT PKC/NN inhibitor/NN staurosporine/NN ,/, suggesting/VBG a/DT role/NN for/IN PKC/NN ./. 
Increased/VBN c-jun/NN ,/, jun-B/NN ,/, and/CC jun-D/NN expression/NN above/IN basal/JJ levels/NNS and/CC increased/VBN transcriptional/JJ activity/NN of/IN AP-1/TPA/NN responsive/JJ elements/NNS fused/VBN to/TO chloramphenicol/NN acetyl-transferase/NN vectors/NNS were/VBD observed/VBN in/IN T/NN cells/NNS treated/VBN with/IN TPA/NN alone/RB or/CC in/IN combination/NN with/IN dexamethasone/NN ./. 
The/DT ability/NN of/IN Jun/NN proteins/NNS to/TO cooperate/VB with/IN GR/NN in/IN T/NN cells/NNS has/VBZ been/VBN investigated/VBN after/IN transfection/NN of/IN c-jun/NN ,/, jun-B/NN ,/, or/CC jun-D/NN expression/NN vectors/NNS ,/, which/WDT augmented/VBD GR-dependent/JJ transcription/NN from/IN either/CC MMTV/NN LTR/NN or/CC GRE/NN ./. 
Conversely/RB ,/, c-jun/NN and/CC jun-B/NN transfection/NN blunted/VBD GR-dependent/JJ transcription/NN in/IN HeLa/NN cells/NNS ./. 
The/DT presence/NN of/IN c-fos/NN had/VBD a/DT negative/JJ influence/NN on/IN GR/NN function/NN and/CC correlated/VBD with/IN the/DT cell-specific/JJ synergistic/JJ or/CC antagonistic/JJ activity/NN of/IN Jun/NN with/IN respect/NN to/TO GR/NN ;/: high/JJ basal/JJ expression/NN of/IN c-fos/NN as/RB well/RB as/IN AP-1/NN DNA/NN binding/NN and/CC transcriptional/JJ activity/NN were/VBD observed/VBN in/IN HeLa/NN cells/NNS ,/, but/CC not/RB in/IN T/NN cells/NNS ./. 
Furthermore/RB overexpression/NN of/IN exogenous/JJ c-fos/NN has/VBZ an/DT inhibitory/JJ effect/NN on/IN GR-dependent/JJ transcription/NN from/IN GRE/NN in/IN T/NN cells/NNS ./. 
We/PRP propose/VBP that/IN Jun/NN plays/VBZ a/DT bifunctional/JJ role/NN on/IN GR-dependent/JJ transcriptional/JJ activation/NN of/IN GRE/NN ,/, selecting/VBG either/CC synergistic/JJ or/CC antagonistic/JJ activity/NN depending/VBG on/IN the/DT cell-specific/JJ microenvironment/NN ./. 
In/IN this/DT regard/NN ,/, intracellular/JJ levels/NNS of/IN c-fos/NN appear/VBP to/TO be/VB influential/JJ ./. 
UI/LS -/: 93194904/CD 
TI/LS -/: Cell/NN type-/NN and/CC stage-specific/JJ expression/NN of/IN the/DT CD20/B1/NN antigen/NN correlates/VBZ with/IN the/DT activity/NN of/IN a/DT diverged/JJ octamer/NN DNA/NN motif/NN present/JJ in/IN its/PRP$ promoter/NN ./. 
AB/LS -/: The/DT CD20/NN (/( B1/NN )/) gene/NN encodes/VBZ a/DT B/NN cell-specific/JJ protein/NN involved/VBN in/IN the/DT regulation/NN of/IN human/JJ B/NN cell/NN proliferation/NN and/CC differentiation/NN ./. 
Studies/NNS with/IN 5'/JJ deletion/NN CD20/NN promoter-CAT/NN constructs/NNS have/VBP previously/RB revealed/VBN two/CD regions/NNS of/IN the/DT promoter/NN between/IN bases/NNS -186/CD and/CC -280/CD and/CC between/IN bases/NNS -280/CD and/CC -454/CD which/WDT contained/VBD positive/JJ regulatory/JJ elements/NNS ./. 
In/IN this/DT study/NN we/PRP identified/VBD a/DT sequence/NN element/NN present/JJ in/IN the/DT most/RBS proximal/JJ region/NN located/JJ between/IN bases/NNS -214/CD and/CC -201/CD ,/, TTCTTCTAATTAA/NN ,/, which/WDT is/VBZ important/JJ in/IN the/DT high/JJ constitutive/JJ expression/NN of/IN CD20/NN in/IN mature/JJ B/NN cells/NNS and/CC the/DT induction/NN of/IN CD20/NN in/IN pre-B/JJ cells/NNS ./. 
This/DT sequence/NN element/NN was/VBD referred/VBN to/TO as/IN the/DT BAT/NN box/NN and/CC its/PRP$ deletion/NN significantly/RB reduced/VBD the/DT activity/NN of/IN a/DT CD20/NN promoter-CAT/JJ construct/NN in/IN B/NN cells/NNS ./. 
Mobility/NN shift/NN assays/NNS with/IN various/JJ mutant/JJ probes/NNS and/CC B/NN cell/NN nuclear/JJ extracts/NNS demonstrated/VBD that/IN the/DT core/NN sequence/NN TAAT/NN was/VBD essential/JJ for/IN binding/VBG to/TO this/DT site/NN ./. 
Cross/NN competition/NN experiments/NNS with/IN an/DT octamer/NN sequence/NN from/IN the/DT Ig/NN heavy/JJ chain/NN promoter/NN ,/, the/DT BAT/NN box/NN ,/, and/CC a/DT TA-rich/JJ sequence/NN present/JJ in/IN the/DT CD21/NN promoter/NN revealed/VBD that/IN all/DT three/CD sequences/NNS bound/VBD the/DT same/JJ nuclear/JJ proteins/NNS suggesting/VBG that/IN the/DT BAT/NN box/NN binding/NN proteins/NNS were/VBD Oct-1/NN and/CC Oct-2/NN ./. 
Southwestern/NN blotting/NN and/CC UV/NN cross-linking/NN studies/NNS confirmed/VBD that/IN the/DT BAT/NN box/NN binding/NN proteins/NNS were/VBD Oct-1/NN and/CC Oct-2/NN ./. 
The/DT affinity/NN of/IN the/DT BAT/NN box/NN binding/NN proteins/NNS for/IN the/DT BAT/NN box/NN was/VBD approximately/RB 25-fold/RB less/JJR than/IN for/IN the/DT octamer/NN sequence/NN and/CC the/DT BAT/NN box/NN binding/NN proteins/NNS dissociated/VBD from/IN the/DT BAT/NN box/NN 10-fold/RB more/RBR rapidly/RB than/IN from/IN the/DT octamer/NN sequence/NN ./. 
Despite/IN this/DT lower/JJR affinity/NN ,/, a/DT trimer/NN of/IN the/DT BAT/NN box/NN sequence/NN was/VBD as/IN efficiently/RB transactivated/VBN by/IN an/DT Oct-2/NN expression/NN vector/NN as/IN was/VBD a/DT trimer/NN of/IN the/DT octamer/NN sequence/NN in/IN HeLa/NN cells/NNS ./. 
The/DT BAT/NN box/NN and/CC Oct-2/NN were/VBD also/RB implicated/VBN in/IN the/DT induction/NN of/IN CD20/NN in/IN the/DT pre-B/JJ cell/NN line/NN ,/, PB-697/NN ,/, via/IN phorbol/NN esters/NNS ./. 
The/DT induction/NN of/IN CD20/NN mRNA/NN was/VBD temporally/RB associated/VBN with/IN induction/NN of/IN Oct-2/NN mRNA/NN and/CC a/DT BAT/NN box-deleted/JJ CD20-CAT/NN construct/NN ,/, in/IN contrast/NN to/TO the/DT wild/JJ type/NN ,/, was/VBD poorly/RB induced/VBN by/IN phorbol/NN esters/NNS ./. 
Together/RB these/DT results/NNS suggest/VBP that/IN the/DT BAT/NN box/NN binding/NN proteins/NNS are/VBP important/JJ in/IN the/DT B/NN cell/NN specific/JJ expression/NN of/IN CD20/NN and/CC perhaps/RB CD21/NN ./. 
UI/LS -/: 93184333/CD 
TI/LS -/: Human/JJ CD4/NN lymphocytes/NNS specifically/RB recognize/VBP a/DT peptide/NN representing/VBG the/DT fusion/NN region/NN of/IN the/DT hybrid/NN protein/NN pml/RAR/NN alpha/NN present/JJ in/IN acute/JJ promyelocytic/JJ leukemia/NN cells/NNS ./. 
AB/LS -/: Fusion/NN proteins/NNS present/JJ in/IN leukemic/JJ cells/NNS frequently/RB contain/VBP a/DT new/JJ amino/NN acid/NN at/IN the/DT fusion/NN point/NN ./. 
We/PRP tested/VBD whether/IN a/DT peptide/NN (/( BCR1/25/NN )/) encompassing/VBG the/DT fusion/NN region/NN of/IN the/DT hybrid/NN molecule/NN pml/RAR/NN alpha/NN ,/, which/WDT is/VBZ selectively/RB expressed/VBN by/IN acute/JJ promyelocytic/JJ leukemia/NN (/( APL/NN )/) cells/NNS ,/, can/MD be/VB recognized/VBN by/IN human/JJ T/NN lymphocytes/NNS in/FW vitro/FW ./. 
CD4+/JJ lymphocytes/NNS ,/, at/IN both/CC polyclonal/JJ and/CC clonal/JJ level/NN ,/, recognized/VBD peptide/NN BCR1/25/NN in/IN an/DT HLA-DR/NN --/: restricted/JJ fashion/NN on/IN presentation/NN by/IN autologous/JJ antigen-presenting/JJ cell/NN (/( APC/NN )/) or/CC by/IN APC/NN expressing/VBG the/DT HLA-DR11/NN restricting/NN molecule/NN ./. 
Control/NN peptides/NNS corresponding/VBG to/TO the/DT normal/JJ pml/NN and/CC RAR/NN alpha/NN proteins/NNS were/VBD not/RB recognized/VBN ./. 
One/CD clone/NN (/( DEG5/NN )/) also/RB exerted/VBD a/DT high/JJ and/CC specific/JJ cytotoxicity/NN against/IN autologous/JJ cells/NNS pulsed/VBN with/IN BCR1/25/NN ./. 
The/DT autologous/JJ DE/NN LCL/NN containing/VBG a/DT transduced/VBN pml/RAR/NN alpha/NN fusion/NN gene/NN and/CC expressing/VBG a/DT bcr1/NN type/NN of/IN the/DT pml/RAR/NN alpha/NN hybrid/NN protein/NN induced/VBD the/DT proliferation/NN of/IN DE/NN anti-BCR1/25/CD T/NN cell/NN clones/NNS ./. 
It/PRP is/VBZ concluded/VBN that/IN the/DT bcr1/NN type-pml/RAR/NN alpha/NN fusion/NN protein/NN of/IN APL/NN contains/VBZ an/DT antigenic/JJ site/NN ,/, absent/JJ from/IN the/DT normal/JJ parent/NN molecules/NNS and/CC recognized/VBN by/IN human/JJ CD4+/JJ lymphocytes/NNS ./. 
UI/LS -/: 93145322/CD 
TI/LS -/: The/DT zinc/NN finger/NN transcription/NN factor/NN Egr-1/NN is/VBZ essential/JJ for/IN and/CC restricts/VBZ differentiation/NN along/IN the/DT macrophage/NN lineage/NN ./. 
AB/LS -/: We/PRP have/VBP isolated/VBN cDNA/NN clones/NNS of/IN myeloid/JJ differentiation/NN primary/JJ response/NN (/( MyD/NN )/) genes/NNS ,/, activated/VBN in/IN the/DT absence/NN of/IN de/FW novo/FW protein/NN synthesis/NN following/VBG induction/NN for/IN differentiation/NN along/IN either/CC the/DT macrophage/NN or/CC granulocyte/NN lineage/NN in/IN human/JJ myeloblastic/JJ leukemia/NN HL-60/NN cells/NNS ./. 
One/CD cDNA/NN clone/NN of/IN a/DT primary/JJ response/NN gene/NN ,/, expressed/VBN upon/IN macrophage/NN differentiation/NN ,/, encoded/VBD for/IN Egr-1/NN ,/, a/DT zinc/NN finger/NN transcription/NN factor/NN ./. 
The/DT Egr-1/NN gene/NN was/VBD observed/VBN to/TO be/VB transcriptionally/RB silent/JJ in/IN HL-60/NN cells/NNS ,/, but/CC active/JJ in/IN U-937/NN and/CC M1/NN cells/NNS ,/, the/DT latter/JJ two/CD being/VBG predetermined/VBN for/IN macrophage/NN differentiation/NN ./. 
Egr-1/NN antisense/JJ oligomers/NNS in/IN the/DT culture/NN media/NNS blocked/VBD macrophage/NN differentiation/NN in/IN both/DT myeloid/JJ leukemia/NN cell/NN lines/NNS and/CC normal/JJ myeloblasts/NNS ./. 
HL-60/NN cells/NNS constitutively/RB expressing/VBG an/DT Egr-1/NN transgene/NN (/( HL-60Egr-1/NN )/) could/MD be/VB induced/VBN for/IN macrophage/NN ,/, but/CC not/RB granulocyte/NN ,/, differentiation/NN ./. 
These/DT observations/NNS indicate/VBP that/IN expression/NN of/IN Egr-1/NN is/VBZ essential/JJ for/IN and/CC restricts/VBZ differentiation/NN of/IN myeloblasts/NNS along/IN the/DT macrophage/NN lineage/NN ./. 
UI/LS -/: 93154317/CD 
TI/LS -/: The/DT Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD interacts/VBZ with/IN an/DT EBNA2/NN responsive/JJ cis-element/NN of/IN the/DT terminal/JJ protein/NN 1/CD gene/NN promoter/NN ./. 
AB/LS -/: The/DT Epstein-Barr/JJ virus/NN protein/NN EBNA2/NN acts/VBZ as/IN a/DT transcriptional/JJ activator/NN of/IN cellular/JJ and/CC viral/JJ genes/NNS and/CC plays/VBZ a/DT crucial/JJ role/NN in/IN the/DT immortalization/NN of/IN human/JJ primary/JJ B-cells/NNS by/IN EBV/NN ./. 
We/PRP have/VBP shown/VBN previously/RB that/IN EBNA2/NN transactivates/VBZ the/DT promoters/NNS of/IN the/DT latent/JJ membrane/NN antigens/NNS LMP/NN ,/, TP1/NN and/CC TP2/NN ./. 
The/DT promoter/NN of/IN the/DT TP1/NN gene/NN was/VBD chosen/VBN as/IN a/DT model/JJ system/NN to/TO study/VB the/DT molecular/JJ mechanism/NN of/IN EBNA2/NN mediated/JJ transactivation/NN ./. 
To/TO identify/VB an/DT EBNA2/NN dependent/JJ cis-acting/JJ element/NN ,/, various/JJ TP1/NN promoter-reporter/NN gene/NN constructs/NNS were/VBD transfected/VBN in/IN the/DT absence/NN and/CC presence/NN of/IN an/DT EBNA2/NN expression/NN vector/NN into/IN the/DT established/JJ B-cell/NN line/NN BL41-P3HR1/NN ./. 
We/PRP were/VBD able/JJ to/TO delineate/VB an/DT 81/CD bp/NN EBNA2/NN responsive/JJ region/NN between/IN -258/CD and/CC -177/CD relative/JJ to/TO the/DT TP1/NN RNA/NN start/NN site/NN ./. 
The/DT element/NN worked/VBD in/IN either/DT orientation/NN and/CC could/MD mediate/VB EBNA2/NN dependent/JJ transactivation/NN on/IN a/DT heterologous/JJ promoter/NN ./. 
Electrophoretic/JJ mobility/NN shift/NN assays/NNS revealed/VBD three/CD specific/JJ protein-DNA/NN complexes/NNS formed/VBN with/IN sequences/NNS of/IN the/DT EBNA2/NN responsive/JJ element/NN ./. 
Two/CD of/IN these/DT were/VBD not/RB cell/NN type/NN specific/JJ ,/, but/CC the/DT third/JJ was/VBD detected/VBN only/RB in/IN EBNA2/NN positive/JJ cell/NN extracts/NNS ./. 
Gel-shift/JJ analysis/NN in/IN the/DT presence/NN of/IN EBNA2/NN specific/JJ monoclonal/JJ antibodies/NNS revealed/VBD that/IN EBNA2/NN is/VBZ a/DT component/NN of/IN the/DT third/JJ complex/NN ./. 
Thus/RB ,/, these/DT experiments/NNS demonstrate/VBP that/IN EBNA2/NN interacts/VBZ with/IN an/DT EBNA2/NN responsive/JJ cis-element/NN of/IN the/DT TP1/NN promoter/NN 
UI/LS -/: 93315684/CD 
TI/LS -/: Minimally/RB modified/VBN low/JJ density/NN lipoprotein-induced/JJ inflammatory/JJ responses/NNS in/IN endothelial/JJ cells/NNS are/VBP mediated/VBN by/IN cyclic/JJ adenosine/NN monophosphate/NN ./. 
AB/LS -/: We/PRP have/VBP previously/RB shown/VBN that/IN minimally/RB oxidized/VBN LDL/NN (/( MM-LDL/NN )/) activated/VBD endothelial/JJ cells/NNS to/TO increase/VB their/PRP$ interaction/NN with/IN monocytes/NNS but/CC not/RB neutrophils/NNS ,/, inducing/VBG monocyte/NN but/CC not/RB neutrophil/NN binding/NN and/CC synthesis/NN of/IN monocyte/NN chemotactic/JJ protein-1/NN and/CC monocyte/NN colony-stimulating/JJ factor/NN (/( M-CSF/NN )/) ./. 
In/IN the/DT present/JJ studies/NNS we/PRP have/VBP examined/VBN the/DT signaling/NN pathways/NNS by/IN which/WDT this/DT monocyte-specific/JJ response/NN is/VBZ induced/VBN ./. 
Both/CC induction/NN of/IN monocyte/NN binding/NN and/CC mRNA/NN levels/NNS for/IN M-CSF/NN by/IN MM-LDL/NN were/VBD not/RB inhibited/VBN in/IN protein/NN kinase/NN C-depleted/JJ endothelial/JJ cells/NNS ./. 
A/DT number/NN of/IN our/PRP$ studies/NNS indicate/VBP that/IN cAMP/NN is/VBZ the/DT second/JJ messenger/NN for/IN the/DT effects/NNS of/IN MM-LDL/NN cited/VBN above/RB ./. 
Incubation/NN of/IN endothelial/JJ cells/NNS with/IN MM-LDL/NN caused/VBD a/DT 173/CD %/NN increase/NN in/IN intracellular/JJ cAMP/NN levels/NNS ./. 
Agents/NNS which/WDT increased/VBD cAMP/NN levels/NNS ,/, including/VBG cholera/NN toxin/NN ,/, pertussis/NN toxin/NN ,/, dibutyryl/NN cAMP/NN ,/, and/CC isoproterenol/NN mimicked/VBD the/DT actions/NNS of/IN MM-LDL/NN ./. 
Agents/NNS which/WDT elevated/VBD cAMP/NN were/VBD also/RB shown/VBN to/TO activate/VB NF/NN kappa/NN B/NN ,/, suggesting/VBG a/DT role/NN for/IN this/DT transcription/NN factor/NN in/IN activation/NN of/IN monocyte-endothelial/JJ interactions/NNS ./. 
Although/IN endothelial/JJ leukocyte/NN adhesion/NN molecule/NN (/( ELAM/NN )/) mRNA/NN synthesis/NN can/MD be/VB regulated/VBN by/IN NF/NN kappa/NN B/NN ,/, ELAM/NN was/VBD not/RB expressed/VBN and/CC ELAM/NN mRNA/NN was/VBD only/RB slightly/RB elevated/JJ in/IN response/NN to/TO MM-LDL/NN ./. 
We/PRP present/VBP evidence/NN that/IN induction/NN of/IN neutrophil/NN binding/NN by/IN LPS/NN is/VBZ actually/RB suppressed/VBN by/IN agents/NNS that/WDT elevated/VBD cAMP/NN levels/NNS ./. 
UI/LS -/: 93324366/CD 
TI/LS -/: Human/JJ T/NN cell/NN transcription/NN factor/NN GATA-3/NN stimulates/VBZ HIV-1/NN expression/NN ./. 
AB/LS -/: A/DT family/NN of/IN transcriptional/JJ activating/VBG proteins/NNS ,/, the/DT GATA/NN factors/NNS ,/, has/VBZ been/VBN shown/VBN to/TO bind/VB to/TO a/DT consensus/NN motif/NN through/IN a/DT highly/RB conserved/VBN C4/NN zinc/NN finger/NN DNA/NN binding/NN domain/NN ./. 
One/CD member/NN of/IN this/DT multigene/JJ family/NN ,/, GATA-3/NN ,/, is/VBZ most/RBS abundantly/RB expressed/VBN in/IN T/NN lymphocytes/NNS ,/, a/DT cellular/JJ target/NN for/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) infection/NN and/CC replication/NN ./. 
In/FW vitro/FW DNase/NN I/CD footprinting/NN analysis/NN revealed/VBD six/CD hGATA-3/NN binding/NN sites/NNS in/IN the/DT U3/NN region/NN (/( the/DT transcriptional/JJ regulatory/JJ domain/NN )/) of/IN the/DT HIV-1/NN LTR/NN ./. 
Cotransfection/NN of/IN an/DT hGATA-3/NN expression/NN plasmid/NN with/IN a/DT reporter/NN plasmid/NN whose/WP$ transcription/NN is/VBZ directed/VBN by/IN the/DT HIV-1/NN LTR/NN resulted/VBD in/IN 6-/CD to/TO 10-fold/JJ stimulation/NN of/IN LTR-mediated/JJ transcription/NN ,/, whereas/IN site/NN specific/JJ mutation/NN of/IN these/DT GATA/NN sites/NNS resulted/VBD in/IN virtual/JJ abrogation/NN of/IN the/DT activation/NN by/IN hGATA-3/NN ./. 
Further/RB ,/, deletion/NN of/IN the/DT hGATA-3/NN transcriptional/JJ activation/NN domain/NN abolished/VBD GATA-dependent/JJ HIV-1/NN trans-activation/NN ,/, showing/VBG that/IN the/DT stimulation/NN of/IN viral/JJ transcription/NN observed/VBN is/VBZ a/DT direct/JJ effect/NN of/IN cotransfected/VBN hGATA-3/NN ./. 
Introduction/NN of/IN the/DT HIV-1/NN plasmids/NNS in/IN which/WDT the/DT GATA/NN sites/NNS have/VBP been/VBN mutated/VBN into/IN human/JJ T/NN lymphocytes/NNS also/RB caused/VBD a/DT significant/JJ reduction/NN in/IN LTR-mediated/JJ transcription/NN at/IN both/CC the/DT basal/JJ level/NN and/CC in/IN (/( PHA-/NN plus/CC PMA-/NN )/) stimulated/JJ T/NN cells/NNS ./. 
These/DT observations/NNS suggest/VBP that/IN in/IN addition/NN to/TO its/PRP$ normal/JJ role/NN in/IN T/NN lymphocyte/NN gene/NN regulation/NN ,/, hGATA-3/NN may/MD also/RB play/VB a/DT significant/JJ role/NN in/IN HIV-1/NN transcriptional/JJ activation/NN ./. 
UI/LS -/: 93350203/CD 
TI/LS -/: Cytokine/NN modulation/NN of/IN HIV/NN expression/NN ./. 
AB/LS -/: Cytokines/NNS ,/, the/DT peptide/NN hormones/NNS which/WDT control/VBP the/DT homeostasis/NN of/IN the/DT immune/JJ system/NN and/CC also/RB play/VBP a/DT fundamental/JJ role/NN in/IN inflammatory/JJ and/CC immune/JJ mediated/JJ reactions/NNS ,/, have/VBP been/VBN involved/VBN at/IN multiple/JJ levels/NNS in/IN the/DT pathogenesis/NN of/IN the/DT acquired/VBN immune/JJ deficiency/NN syndrome/NN (/( AIDS/NN )/) ./. 
Infection/NN with/IN the/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) has/VBZ been/VBN shown/VBN to/TO induce/VB production/NN of/IN several/JJ cytokines/NNS both/CC in/FW vitro/FW and/CC in/FW vivo/FW ./. 
Conversely/RB ,/, several/JJ cytokines/NNS modulate/VBP the/DT levels/NNS of/IN HIV/NN expression/NN in/IN infected/JJ cells/NNS of/IN both/CC T/NN lymphocytic/JJ and/CC mononuclear/JJ phagocytic/JJ lineage/NN ./. 
Activated/VBN mononuclear/JJ cells/NNS ,/, particularly/RB B/NN cells/NNS which/WDT are/VBP in/IN a/DT state/NN of/IN chronic/JJ activation/NN in/IN HIV/NN infected/JJ individuals/NNS ,/, release/VBP HIV-inductive/JJ cytokines/NNS and/CC thus/RB play/VBP a/DT potentially/RB important/JJ role/NN in/IN the/DT pathogenesis/NN of/IN HIV/NN infection/NN ./. 
UI/LS -/: 93259462/CD 
TI/LS -/: Cloning/NN and/CC functional/JJ characterization/NN of/IN early/JJ B-cell/NN factor/NN ,/, a/DT regulator/NN of/IN lymphocyte-specific/JJ gene/NN expression/NN ./. 
AB/LS -/: Early/JJ B-cell/NN factor/NN (/( EBF/NN )/) was/VBD identified/VBN previously/RB as/IN a/DT tissue-specific/JJ and/CC differentiation/NN stage-specific/JJ DNA-binding/JJ protein/NN that/WDT participates/VBZ in/IN the/DT regulation/NN of/IN the/DT pre-B/JJ and/CC B/NN lymphocyte-specific/JJ mb-1/NN gene/NN ./. 
Partial/JJ amino/NN acid/NN sequences/NNS obtained/VBN from/IN purified/VBN EBF/NN were/VBD used/VBN to/TO isolate/VB cDNA/NN clones/NNS ,/, which/WDT by/IN multiple/JJ criteria/NNS encode/VB EBF/NN ./. 
The/DT recombinant/JJ polypeptide/NN formed/VBD sequence-specific/JJ complexes/NNS with/IN the/DT EBF-binding/NN site/NN in/IN the/DT mb-1/NN promoter/NN ./. 
The/DT cDNA/NN hybridized/VBD to/TO multiple/JJ transcripts/NNS in/IN pre-B/JJ and/CC B-cell/NN lines/NNS ,/, but/CC transcripts/NNS were/VBD not/RB detected/VBN at/IN significant/JJ levels/NNS in/IN plasmacytoma/NN ,/, T-cell/NN ,/, and/CC nonlymphoid/JJ cell/NN lines/NNS ./. 
Expression/NN of/IN recombinant/JJ EBF/NN in/IN transfected/VBN nonlymphoid/JJ cells/NNS strongly/RB activated/VBD transcription/NN from/IN reporter/NN plasmids/NNS containing/VBG functional/JJ EBF-binding/JJ sites/NNS ./. 
Analysis/NN of/IN DNA/NN binding/NN by/IN deletion/NN mutants/NNS of/IN EBF/NN identified/VBD an/DT amino-terminal/JJ cysteine-rich/JJ DNA-binding/JJ domain/NN lacking/VBG obvious/JJ sequence/NN similarity/NN to/TO known/JJ transcription/NN factors/NNS ./. 
DNA-binding/JJ assays/NNS with/IN cotranslated/VBN wild-type/JJ and/CC truncated/JJ forms/NNS of/IN EBF/NN indicated/VBD that/IN the/DT protein/NN interacts/VBZ with/IN its/PRP$ site/NN as/IN a/DT homodimer/NN ./. 
Deletions/NNS delineated/VBD a/DT carboxy-terminal/JJ dimerization/NN region/NN containing/VBG two/CD repeats/NNS of/IN 15/CD amino/NN acids/NNS that/WDT show/VBP similarity/NN with/IN the/DT dimerization/NN domains/NNS of/IN basic-helix-loop-helix/JJ proteins/NNS ./. 
Together/RB ,/, these/DT data/NNS suggest/VBP that/IN EBF/NN represents/VBZ a/DT novel/JJ regulator/NN of/IN B/NN lymphocyte-specific/JJ gene/NN expression/NN ./. 
UI/LS -/: 93241941/CD 
TI/LS -/: Cell-specific/JJ expression/NN of/IN helix-loop-helix/JJ transcription/NN factors/NNS encoded/VBN by/IN the/DT E2A/NN gene/NN ./. 
AB/LS -/: The/DT E2A/NN gene/NN encodes/VBZ transcription/NN factors/NNS of/IN the/DT helix-loop-helix/JJ family/NN that/WDT are/VBP implicated/VBN in/IN cell-specific/JJ gene/NN expression/NN as/IN part/NN of/IN dimeric/JJ complexes/NNS that/WDT interact/VBP with/IN E/NN box/NN enhancer/NN elements/NNS ./. 
It/PRP has/VBZ previously/RB been/VBN shown/VBN that/IN transcripts/NNS of/IN the/DT E2A/NN gene/NN can/MD be/VB detected/VBN in/IN a/DT wide/JJ range/NN of/IN cell/NN types/NNS ./. 
We/PRP have/VBP now/RB examined/VBN expression/NN of/IN the/DT mouse/NN E2A/NN gene/NN at/IN the/DT protein/NN level/NN using/VBG polyclonal/JJ antisera/NNS directed/VBN against/IN distinct/JJ portions/NNS of/IN the/DT E2A/NN protein/NN to/TO probe/NN blots/NNS of/IN cellular/JJ extracts/NNS ./. 
A/DT 73/CD kDa/NN protein/NN was/VBD identified/VBN by/IN this/DT analysis/NN :/: this/DT protein/NN is/VBZ highly/RB enriched/VBN in/IN cell/NN lines/NNS of/IN B/NN lymphoid/JJ origin/NN as/IN compared/VBN to/TO pancreatic/JJ beta-cells/NNS and/CC fibroblast/NN cells/NNS ./. 
The/DT detection/NN of/IN this/DT protein/NN selectively/RB in/IN extracts/NNS of/IN lymphoid/JJ cells/NNS correlates/VBZ with/IN the/DT presence/NN of/IN the/DT E/NN box-binding/JJ activity/NN LEF1/BCF1/NN in/IN these/DT cells/NNS ;/: this/DT binding/NN activity/NN was/VBD previously/RB shown/VBN to/TO be/VB efficiently/RB recognized/VBN by/IN antiserum/NN directed/VBN against/IN E2A/NN gene/NN products/NNS ./. 
Transfection/NN of/IN cells/NNS with/IN full/JJ length/NN E2A/NN cDNA/NN leads/VBZ to/TO appearance/NN of/IN protein/NN co-migrating/VBG with/IN the/DT 73/CD kDa/NN protein/NN on/IN SDS/NN gel/NN electrophoresis/NN and/CC co-migrating/VBG with/IN LEF1/BCF1/NN on/IN mobility/NN shift/NN analysis/NN ./. 
Our/PRP$ results/NNS are/VBP consistent/JJ with/IN the/DT view/NN that/IN the/DT DNA-binding/JJ activity/NN LEF1/BCF1/NN is/VBZ a/DT homodimer/NN of/IN E2A/NN proteins/NNS ;/: the/DT selective/JJ appearance/NN of/IN this/DT putative/JJ cell-specific/JJ transcription/NN factor/NN in/IN B/NN lymphoid/JJ cells/NNS seems/VBZ to/TO be/VB attributable/JJ ,/, at/IN least/JJS in/IN part/NN ,/, to/TO the/DT elevated/JJ E2A/NN protein/NN concentrations/NNS in/IN these/DT cells/NNS ./. 
UI/LS -/: 93244226/CD 
TI/LS -/: Hypertension/NN in/IN pregnancy/NN ./. 
AB/LS -/: Pregnancy-induced/JJ hypertension/NN (/( PIH/NN )/) is/VBZ a/DT frequent/JJ cause/NN of/IN maternal/JJ and/CC neonatal/JJ morbidity/NN and/CC mortality/NN ./. 
In/IN the/DT present/JJ study/NN we/PRP focused/VBD on/IN the/DT pathophysiology/NN of/IN PIH/NN ,/, mainly/RB on/IN the/DT role/NN of/IN mineralocorticoids/NNS ,/, reversed/VBN blood/NN pressure/NN patterns/NNS ,/, and/CC the/DT resulting/VBG necessity/NN of/IN continuous/JJ monitoring/NN of/IN the/DT preeclamptic/JJ mother/NN ./. 
Problems/NNS of/IN antihypertensive/JJ therapy/NN are/VBP discussed/VBN and/CC the/DT first/JJ results/NNS of/IN a/DT pilot/NN study/NN with/IN Urapidil/NN are/VBP presented/VBN ./. 
To/TO examine/VB the/DT role/NN of/IN mineralocorticoids/NNS in/IN the/DT pathophysiology/NN of/IN PIH/NN ,/, we/PRP studied/VBD plasma/NN aldosterone/NN and/CC 18-hydroxy-corticosterone/NN (/( 18-OH-B/NN )/) levels/NNS in/IN 25/CD women/NNS with/IN PIH/NN and/CC in/IN 25/CD healthy/JJ pregnant/JJ women/NNS ./. 
Furthermore/RB ,/, we/PRP evaluated/VBD the/DT mineralocorticoid/NN receptor/NN (/( MR/NN )/) count/NN in/IN mononuclear/JJ leukocytes/NNS in/IN the/DT 2/CD groups/NNS ./. 
The/DT MR-count/NN was/VBD significantly/RB decreased/VBN in/IN the/DT PIH-group/NN ./. 
The/DT values/NNS of/IN plasma/NN aldosterone/NN and/CC 18-OH-B/NN were/VBD also/RB low/JJ ./. 
These/DT results/NNS can/MD not/RB be/VB explained/VBN by/IN receptor/NN down-regulation/NN due/JJ to/TO higher/JJR level/NN of/IN mineralocorticoids/NNS of/IN the/DT zona/NN glomerulosa/NN ./. 
Perhaps/RB deoxycorticosterone/NN or/CC a/DT hitherto/RB unknown/JJ mineralocorticoid/NN is/VBZ responsible/JJ for/IN the/DT hypertension/NN and/CC altered/JJ MR-status/NN ./. 
The/DT first/JJ results/NNS of/IN continuous/JJ blood/NN pressure/NN measurements/NNS with/IN a/DT noninvasive/JJ ,/, real-time/JJ blood/NN pressure/NN monitor/NN (/( Finapres/NN )/) are/VBP presented/VBN ./. 
The/DT comparison/NN of/IN the/DT obtained/VBN values/NNS with/IN intraarterial/JJ measurements/NNS demonstrates/VBZ a/DT good/JJ correlation/NN between/IN the/DT two/CD methods/NNS ./. 
We/PRP also/RB report/VBP on/IN the/DT first/JJ experiences/NNS with/IN Urapidil/NN in/IN the/DT treatment/NN of/IN hypertension/NN in/IN severe/JJ preeclampsia/NN ./. 
The/DT data/NNS show/VBP that/IN hypertension/NN in/IN preeclamptic/JJ women/NNS can/MD be/VB treated/VBN by/IN Urapidil/NN without/IN side/JJ effects/NNS or/CC reflex-tachycardia/NN ./. 
Further/JJ studies/NNS will/MD have/VB to/TO prove/VB if/IN Urapidil/NN is/VBZ suited/VBN for/IN prepartal/JJ treatment/NN of/IN PIH/NN as/RB well/RB ./. 
UI/LS -/: 93186822/CD 
TI/LS -/: Suppression/NN of/IN a/DT cellular/JJ differentiation/NN program/NN by/IN phorbol/NN esters/NNS coincides/VBZ with/IN inhibition/NN of/IN binding/NN of/IN a/DT cell-specific/JJ transcription/NN factor/NN (/( NF-E2/NN )/) to/TO an/DT enhancer/NN element/NN required/VBN for/IN expression/NN of/IN an/DT erythroid-specific/JJ gene/NN ./. 
AB/LS -/: Induction/NN by/IN hemin/NN increases/VBZ ,/, while/IN induction/NN with/IN 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) represses/VBZ ,/, erythroid-specific/JJ gene/NN expression/NN in/IN the/DT human/JJ cell/NN line/NN K562/NN ./. 
We/PRP analyzed/VBD the/DT effects/NNS of/IN hemin/NN or/CC TPA/NN induction/NN on/IN the/DT binding/NN and/CC activity/NN of/IN transcription/NN factors/NNS at/IN a/DT regulatory/JJ element/NN found/VBN within/IN the/DT transcriptional/JJ regulatory/JJ sequences/NNS of/IN many/JJ erythroid-specific/JJ genes/NNS ./. 
TPA/NN induction/NN increases/VBZ the/DT binding/NN of/IN ubiquitous/JJ AP-1/NN factors/NNS to/TO this/DT element/NN ./. 
TPA/NN induction/NN inhibits/VBZ the/DT binding/NN of/IN the/DT lineage/NN limited/JJ transcription/NN factor/NN NF-E2/NN to/TO this/DT transcriptional/JJ control/NN element/NN ./. 
Hemin/NN induction/NN of/IN K562/NN cells/NNS does/VBZ not/RB facilitate/VB the/DT binding/NN of/IN NF-E2/NN to/TO its/PRP$ recognition/NN site/NN ./. 
Hemin/NN induction/NN appears/VBZ to/TO nonspecifically/RB increase/VB the/DT expression/NN of/IN transiently/RB transfected/VBN genes/NNS in/IN K562/NN cells/NNS ./. 
Beyond/IN this/DT nonspecific/JJ increase/NN in/IN gene/NN expression/NN ,/, hemin/NN induction/NN acts/VBZ to/TO increase/VB the/DT activity/NN of/IN the/DT lineage/NN limited/JJ transcription/NN factor/NN NF-E2/NN ./. 
The/DT divergent/JJ effects/NNS of/IN hemin/NN and/CC TPA/NN on/IN gene/NN expression/NN in/IN K562/NN cells/NNS are/VBP mediated/VBN ,/, in/IN part/NN ,/, by/IN their/PRP$ contrasting/JJ effects/NNS on/IN the/DT transcription/NN factor/NN NF-E2/NN ./. 
UI/LS -/: 93152894/CD 
TI/LS -/: Interleukin-3/NN expression/NN by/IN activated/VBN T/NN cells/NNS involves/VBZ an/DT inducible/JJ ,/, T-cell-specific/JJ factor/NN and/CC an/DT octamer/NN binding/NN protein/NN ./. 
AB/LS -/: Interleukin-3/NN (/( IL-3/NN )/) is/VBZ exclusively/RB expressed/VBN by/IN activated/VBN T/NN and/CC natural/JJ killer/NN cells/NNS ,/, a/DT function/NN that/WDT is/VBZ tightly/RB controlled/VBN both/CC in/IN a/DT lineage-specific/JJ and/CC in/IN a/DT stimulation-dependent/JJ manner/NN ./. 
We/PRP have/VBP investigated/VBN the/DT protein/NN binding/NN characteristics/NNS and/CC functional/JJ importance/NN of/IN the/DT ACT-1-activating/JJ region/NN of/IN the/DT IL-3/NN promoter/NN ./. 
This/DT region/NN binds/VBZ an/DT inducible/JJ ,/, T-cell-specific/JJ factor/NN over/IN its/PRP$ 5'/JJ end/NN ,/, a/DT site/NN that/WDT is/VBZ necessary/JJ for/IN the/DT expression/NN of/IN IL-3/NN in/IN the/DT absence/NN of/IN other/JJ upstream/JJ elements/NNS ./. 
Over/IN its/PRP$ 3'/JJ end/NN ,/, it/PRP binds/VBZ a/DT factor/NN that/WDT is/VBZ ubiquitously/RB and/CC constitutively/RB expressed/VBN ./. 
This/DT factor/NN is/VBZ Oct-1/NN or/CC an/DT immunologically/RB related/JJ octamer-binding/JJ protein/NN ,/, and/CC it/PRP plays/VBZ a/DT role/NN in/IN coordinating/VBG the/DT activity/NN of/IN several/JJ regulatory/JJ elements/NNS ./. 
These/DT characteristics/NNS make/VBP the/DT ACT-1/NN site/NN analogous/JJ to/TO the/DT activating/VBG ARRE-1/NN site/NN in/IN the/DT IL-2/NN promoter/NN ./. 
Furthermore/RB ,/, and/CC despite/IN a/DT lack/NN of/IN sequence/NN homology/NN ,/, the/DT promoters/NNS of/IN IL-3/NN and/CC IL-2/NN share/VBP an/DT organizational/JJ pattern/NN of/IN regulatory/JJ elements/NNS that/WDT is/VBZ likely/JJ to/TO be/VB important/JJ for/IN the/DT T-cell-specific/JJ expression/NN of/IN these/DT genes/NNS ./. 
UI/LS -/: 93136418/CD 
TI/LS -/: Interleukin-4/NN inhibits/VBZ the/DT lipopolysaccharide-induced/JJ expression/NN of/IN c-jun/NN and/CC c-fos/NN messenger/NN RNA/NN and/CC activator/NN protein-1/NN binding/NN activity/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: We/PRP studied/VBD the/DT effect/NN of/IN interleukin-4/NN (/( IL-4/NN )/) on/IN the/DT lipopolysaccharide/NN (/( LPS/NN )/) induction/NN of/IN two/CD immediate/JJ early/JJ genes/NNS c-fos/NN and/CC c-jun/NN ./. 
These/DT genes/NNS encode/VBP proteins/NNS that/WDT form/VBP the/DT dimeric/JJ complex/NN activator/NN protein-1/NN (/( AP-1/NN )/) ,/, which/WDT is/VBZ active/JJ as/IN a/DT transcriptional/JJ factor/NN ./. 
Maximal/JJ accumulation/NN of/IN either/CC c-fos/NN and/CC c-jun/NN messenger/NN RNA/NN (/( mRNA/NN )/) occurred/VBD 30/CD minutes/NNS after/IN LPS/NN addition/NN ./. 
When/WRB cells/NNS were/VBD treated/VBN with/IN IL-4/NN for/IN 5/CD hours/NNS before/IN LPS/NN activation/NN ,/, both/CC the/DT c-fos/NN and/CC the/DT c-jun/NN mRNA/NN expression/NN was/VBD decreased/VBN ./. 
The/DT inhibition/NN of/IN c-fos/NN and/CC c-jun/NN expression/NN by/IN IL-4/NN in/IN LPS-treated/JJ cells/NNS was/VBD shown/VBN to/TO be/VB due/JJ to/TO a/DT lower/JJR transcription/NN rate/NN of/IN the/DT c-fos/NN and/CC c-jun/NN genes/NNS ./. 
IL-4/NN did/VBD not/RB affect/VB the/DT stability/NN of/IN the/DT c-fos/NN and/CC c-jun/NN transcripts/NNS ./. 
Finally/RB ,/, using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, evidence/NN was/VBD obtained/VBN that/IN IL-4/NN inhibits/VBZ LPS-induced/JJ expression/NN of/IN AP-1/NN protein/NN ./. 
These/DT data/NNS indicate/VBP that/IN IL-4/NN suppresses/VBZ the/DT induction/NN of/IN transcription/NN factors/NNS in/IN human/JJ activated/VBN monocytes/NNS ./. 
UI/LS -/: 94085904/CD 
TI/LS -/: Transient/JJ pseudohypoaldosteronism/NN in/IN obstructive/JJ renal/JJ disease/NN with/IN transient/JJ reduction/NN of/IN lymphocytic/JJ aldosterone/NN receptors/NNS ./. 
Results/NNS in/IN two/CD affected/JJ infants/NNS ./. 
AB/LS -/: We/PRP report/VBP two/CD patients/NNS with/IN transient/JJ pseudohypoaldosteronism/NN due/JJ to/TO obstructive/JJ renal/JJ disease/NN ./. 
Both/DT patients/NNS presented/VBD with/IN a/DT salt-losing/JJ episode/NN simulating/VBG adrenal/JJ insufficiency/NN ./. 
In/IN one/CD patient/NN ,/, transient/JJ reduction/NN of/IN aldosterone/NN receptors/NNS could/MD be/VB documented/VBN ,/, while/IN in/IN the/DT second/JJ patient/NN the/DT clinical/JJ and/CC biochemical/JJ parameters/NNS were/VBD consistent/JJ with/IN transient/JJ pseudohypoaldosteronism/NN ./. 
Aldosterone/NN receptors/NNS were/VBD normal/JJ in/IN both/DT patients/NNS 
UI/LS -/: 93246027/CD 
TI/LS -/: Aldosterone-specific/JJ membrane/NN receptors/NNS and/CC rapid/JJ non-genomic/JJ actions/NNS of/IN mineralocorticoids/NNS ./. 
AB/LS -/: Functional/JJ studies/NNS in/IN extrarenal/JJ ,/, non-epithelial/JJ cells/NNS such/JJ as/IN smooth/JJ muscle/NN cells/NNS and/CC more/RBR recently/RB circulating/VBG human/JJ lymphocytes/NNS have/VBP provided/VBN increasing/VBG evidence/NN that/IN aldosterone/NN produces/VBZ not/RB only/RB classical/JJ genomic/JJ effects/NNS ,/, but/CC also/RB rapid/JJ ,/, non-genomic/JJ effects/NNS on/IN transmembrane/NN electrolyte/NN movements/NNS ./. 
These/DT involve/VBP activation/NN of/IN the/DT sodium/proton/NN exchanger/NN of/IN the/DT cell/NN membrane/NN at/IN very/RB low/JJ ,/, physiological/JJ concentrations/NNS of/IN aldosterone/NN with/IN an/DT acute/JJ onset/NN within/IN 1-2/CD min/NN ./. 
A/DT second/JJ messenger/NN cascade/NN involved/VBN is/VBZ the/DT inositol/NN 1,4,5-trisphosphate/calcium/NN pathway/NN which/WDT responds/VBZ over/IN the/DT same/JJ rapid/JJ time/NN course/NN ./. 
Such/JJ changes/NNS clearly/RB can/MD not/RB be/VB explained/VBN by/IN genomic/JJ mechanisms/NNS ,/, which/WDT are/VBP responsible/JJ for/IN later/JJ effects/NNS than/IN the/DT membrane/NN related/JJ rapid/JJ responses/NNS ./. 
The/DT mechanisms/NNS underlying/VBG these/DT rapid/JJ effects/NNS of/IN aldosterone/NN on/IN electrolytes/NNS have/VBP been/VBN extensively/RB studied/VBN in/IN human/JJ lymphocytes/NNS ,/, which/WDT thus/RB may/MD represent/VB valuable/JJ tools/NNS in/IN the/DT delineation/NN of/IN the/DT receptor-effector/JJ mechanisms/NNS involved/VBN ./. 
The/DT unique/JJ characteristics/NNS of/IN this/DT new/JJ pathway/NN for/IN steroid/NN action/NN include/VBP its/PRP$ rapid/JJ time/NN course/NN ,/, 10,000-fold/JJ selectivity/NN for/IN aldosterone/NN over/IN cortisol/NN and/CC the/DT ineffectiveness/NN of/IN spironolactones/NNS ,/, classical/JJ mineralocorticoid/NN antagonists/NNS ,/, as/IN antagonists/NNS of/IN the/DT response/NN ./. 
UI/LS -/: 92408021/CD 
TI/LS -/: Human/JJ immunodeficiency/NN virus/NN type/NN 1/CD Nef/NN protein/NN inhibits/VBZ NF-kappa/NN B/NN induction/NN in/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) can/MD establish/VB a/DT persistent/JJ and/CC latent/JJ infection/NN in/IN CD4+/JJ T/NN lymphocytes/NNS (/( W.C.Greene/NNP ,/, N.Engl.J./NNP Med.324/NNP :/: 308-317/CD ,/, 1991/CD ;/: S.M.Schnittman/NNP ,/, M.C.Psallidopoulos/NNP ,/, H.C./NNP Lane/NNP ,/, L.Thompson/NNP ,/, M.Baseler/NNP ,/, F.Massari/NNP ,/, C.H.Fox/NNP ,/, N.P.Salzman/NNP ,/, and/CC A.S.Fauci/NNP ,/, Science/NNP 245/CD :/: 305-308/CD ,/, 1989/CD )/) ./. 
Production/NN of/IN HIV-1/NN from/IN latently/RB infected/JJ cells/NNS requires/VBZ host/NN cell/NN activation/NN by/IN T-cell/NN mitogens/NNS (/( T.Folks/NNP ,/, D.M.Powell/NNP ,/, M.M.Lightfoote/NNP ,/, S.Benn/NNP ,/, M.A./NNP Martin/NNP ,/, and/CC A.S.Fauci/NNP ,/, Science/NNP 231/CD :/: 600-602/CD ,/, 1986/CD ;/: D.Zagury/NNP ,/, J./NNP Bernard/NNP ,/, R.Leonard/NNP ,/, R.Cheynier/NNP ,/, M.Feldman/NNP ,/, P.S.Sarin/NNP ,/, and/CC R.C./NNP Gallo/NNP ,/, Science/NNP 231/CD :/: 850-853/CD ,/, 1986/CD )/) ./. 
This/DT activation/NN is/VBZ mediated/VBN by/IN the/DT host/NN transcription/NN factor/NN NF-kappa/NN B/NN [/( G.Nabel/NNP and/CC D.Baltimore/NNP ,/, Nature/NNP (/( London/NNP )/) 326/CD :/: 711-717/CD ,/, 1987/CD ]/) ./. 
We/PRP report/VBP here/RB that/IN the/DT HIV-1-encoded/JJ Nef/NN protein/NN inhibits/VBZ the/DT induction/NN of/IN NF-kappa/NN B/NN DNA-binding/JJ activity/NN by/IN T- cell/NN mitogens/NNS ./. 
However/RB ,/, Nef/NN does/VBZ not/RB affect/VB the/DT DNA-binding/JJ activity/NN of/IN other/JJ transcription/NN factors/NNS implicated/VBN in/IN HIV-1/NN regulation/NN ,/, including/VBG SP-1/NN ,/, USF/NN ,/, URS/NN ,/, and/CC NF-AT/NN ./. 
Additionally/RB ,/, Nef/NN inhibits/VBZ the/DT induction/NN of/IN HIV-1-/NN and/CC interleukin/NN 2-directed/JJ gene/NN expression/NN ,/, and/CC the/DT effect/NN on/IN HIV-1/NN transcription/NN depends/VBZ on/IN an/DT intact/JJ NF-kappa/NN B-binding/JJ site/NN ./. 
These/DT results/NNS indicate/VBP that/IN defective/JJ recruitment/NN of/IN NF-kappa/NN B/NN may/MD underlie/VB Nef/NN 's/POS negative/JJ transcriptional/JJ effects/NNS on/IN the/DT HIV-1/NN and/CC interleukin/NN 2/CD promoters/NNS ./. 
Further/JJ evidence/NN suggests/VBZ that/IN Nef/NN inhibits/VBZ NF-kappa/NN B/NN induction/NN by/IN interfering/VBG with/IN a/DT signal/NN derived/VBN from/IN the/DT T-cell/NN receptor/NN complex/NN ./. 
UI/LS -/: 93061407/CD 
TI/LS -/: Expression/NN of/IN c-fos/NN ,/, c-jun/NN and/CC jun/NN B/NN in/IN peripheral/JJ blood/NN lymphocytes/NNS from/IN young/JJ and/CC elderly/JJ adults/NNS ./. 
AB/LS -/: The/DT expression/NN of/IN c-fos/NN ,/, c-jun/NN and/CC jun/NN B/NN proto-oncogenes/NNS was/VBD studied/VBN in/IN phytohemagglutinin/NN (/( PHA/NN )/) activated/VBN peripheral/JJ blood/NN lymphocytes/NNS (/( PBL/NN )/) from/IN young/JJ and/CC aged/JJ humans/NNS ./. 
Specific/JJ mRNAs/NNS for/IN c-fos/NN and/CC c-jun/NN were/VBD detectable/JJ within/IN 30/CD min/NN after/IN cell/NN activation/NN and/CC reached/VBD maximal/JJ levels/NNS within/IN 2/CD h/NN ./. 
Both/CC c-fos/NN and/CC jun/NN B/NN mRNAs/NNS decreased/VBD to/TO pre-activation/NN levels/NNS within/IN 6/CD h/NN ,/, while/IN c-jun/NN mRNA/NN remained/VBD elevated/JJ ./. 
In/IN PHA-activated/JJ PBL/NN ,/, no/DT age-related/JJ differences/NNS were/VBD observed/VBN in/IN c-fos/NN or/CC jun/NN B/NN mRNA/NN expression/NN ./. 
However/RB ,/, c-jun/NN mRNA/NN levels/NNS decreased/VBD significantly/RB (/( 1.73/CD +/-/CC 0.08/CD vs./CC 1.16/CD +/-/CC 0.09/CD arbitrary/JJ units/NNS ,/, P/NN </JJR 0.01/CD ,/, young/JJ vs./CC old/JJ )/) in/IN PBL/NN from/IN elderly/JJ individuals/NNS activated/VBN with/IN PHA/NN ./. 
Because/IN previous/JJ work/NN has/VBZ demonstrated/VBN that/IN T/NN cells/NNS from/IN elderly/JJ individuals/NNS may/MD display/VB normal/JJ proliferative/JJ responses/NNS when/WRB activated/VBN via/IN the/DT anti-CD2/JJ pathway/NN ,/, c-jun/NN and/CC jun/NN B/NN mRNA/NN expression/NN was/VBD also/RB studied/VBN in/IN anti-CD2-activated/JJ purified/VBN T/NN cells/NNS ./. 
No/DT age-related/JJ differences/NNS were/VBD found/VBN in/IN the/DT expression/NN of/IN either/DT of/IN these/DT two/CD proto-oncogenes/NNS by/IN anti-CD2/NN activated/JJ T/NN cells/NNS ./. 
These/DT results/NNS suggest/VBP that/IN the/DT decreased/VBN IL-2/NN production/NN and/CC proliferative/JJ response/NN displayed/VBN by/IN PHA-activated/JJ PBL/NN from/IN elderly/JJ adults/NNS may/MD be/VB related/JJ to/TO age-related/JJ changes/NNS in/IN c-jun/NN mRNA/NN expression/NN and/CC in/IN the/DT ratio/NN of/IN c-fos/NN to/TO c-jun/NN mRNA/NN ./. 
UI/LS -/: 92318928/CD 
TI/LS -/: Oct2/NN transactivation/NN from/IN a/DT remote/JJ enhancer/NN position/NN requires/VBZ a/DT B-cell-restricted/JJ activity/NN ./. 
AB/LS -/: Previous/JJ cotransfection/NN experiments/NNS had/VBD demonstrated/VBN that/IN ectopic/JJ expression/NN of/IN the/DT lymphocyte-specific/JJ transcription/NN factor/NN Oct2/NN could/MD efficiently/RB activate/VB a/DT promoter/NN containing/VBG an/DT octamer/NN motif/NN ./. 
Oct2/NN expression/NN was/VBD unable/JJ to/TO stimulate/VB a/DT multimerized/JJ octamer/NN enhancer/NN element/NN in/IN HeLa/NN cells/NNS ,/, however/RB ./. 
We/PRP have/VBP tested/VBN a/DT variety/NN of/IN Oct2/NN isoforms/VBZ generated/VBN by/IN alternative/JJ splicing/NN for/IN the/DT capability/NN to/TO activate/VB an/DT octamer/NN enhancer/NN in/IN nonlymphoid/JJ cells/NNS and/CC a/DT B-cell/NN line/NN ./. 
Our/PRP$ analyses/NNS show/VBP that/IN several/JJ Oct2/NN isoforms/NNS can/MD stimulate/VB from/IN a/DT remote/JJ position/NN but/CC that/IN this/DT stimulation/NN is/VBZ restricted/JJ to/TO B/NN cells/NNS ./. 
This/DT result/NN indicates/VBZ the/DT involvement/NN of/IN either/CC a/DT B-cell-specific/JJ cofactor/NN or/CC a/DT specific/JJ modification/NN of/IN a/DT cofactor/NN or/CC the/DT Oct2/NN protein/NN in/IN Oct2-mediated/JJ enhancer/NN activation/NN ./. 
Mutational/JJ analyses/NNS indicate/VBP that/IN the/DT carboxy-terminal/JJ domain/NN of/IN Oct2/NN is/VBZ critical/JJ for/IN enhancer/NN activation/NN ./. 
Moreover/RB ,/, this/DT domain/NN conferred/VBD enhancing/NN activity/NN when/WRB fused/VBN to/TO the/DT Oct1/NN protein/NN ,/, which/WDT by/IN itself/PRP was/VBD unable/JJ to/TO stimulate/VB from/IN a/DT remote/JJ position/NN ./. 
The/DT glutamine-rich/JJ activation/NN domain/NN present/JJ in/IN the/DT amino-terminal/JJ portion/NN of/IN Oct2/NN and/CC the/DT POU/NN domain/NN contribute/VBP only/RB marginally/RB to/TO the/DT transactivation/NN function/NN from/IN a/DT distal/JJ position/NN ./. 
UI/LS -/: 92269839/CD 
TI/LS -/: The/DT promoter/NN of/IN the/DT CD19/NN gene/NN is/VBZ a/DT target/NN for/IN the/DT B-cell-specific/JJ transcription/NN factor/NN BSAP/NN ./. 
AB/LS -/: The/DT CD19/NN protein/NN is/VBZ expressed/VBN on/IN the/DT surface/NN of/IN all/DT B-lymphoid/JJ cells/NNS with/IN the/DT exception/NN of/IN terminally/RB differentiated/VBN plasma/NN cells/NNS and/CC has/VBZ been/VBN implicated/VBN as/IN a/DT signal-transducing/JJ receptor/NN in/IN the/DT control/NN of/IN proliferation/NN and/CC differentiation/NN ./. 
Here/RB we/PRP demonstrate/VBP complete/JJ correlation/NN between/IN the/DT expression/NN pattern/NN of/IN the/DT CD19/NN gene/NN and/CC the/DT B-cell-specific/JJ transcription/NN factor/NN BSAP/NN in/IN a/DT large/JJ panel/NN of/IN B-lymphoid/JJ cell/NN lines/NNS ./. 
The/DT human/JJ CD19/NN gene/NN has/VBZ been/VBN cloned/VBN ,/, and/CC several/JJ BSAP-binding/JJ sites/NNS have/VBP been/VBN mapped/VBN by/IN in/FW vitro/FW protein-DNA/JJ binding/NN studies/NNS ./. 
In/IN particular/JJ ,/, a/DT high-affinity/JJ BSAP-binding/JJ site/NN instead/RB of/IN a/DT TATA/NN sequence/NN is/VBZ located/JJ in/IN the/DT -30/CD promoter/NN region/NN upstream/JJ of/IN a/DT cluster/NN of/IN heterogeneous/JJ transcription/NN start/NN sites/NNS ./. 
Moreover/RB ,/, this/DT site/NN is/VBZ occupied/VBN by/IN BSAP/NN in/FW vivo/FW in/IN a/DT CD19-expressing/JJ B-cell/NN line/NN but/CC not/RB in/IN plasma/NN or/CC HeLa/NN cells/NNS ./. 
This/DT high-affinity/JJ site/NN has/VBZ been/VBN conserved/VBN in/IN the/DT promoters/NNS of/IN both/CC human/JJ and/CC mouse/NN CD19/NN genes/NNS and/CC was/VBD furthermore/RB shown/VBN to/TO confer/VB B-cell/NN specificity/NN to/TO a/DT beta-globin/NN reporter/NN gene/NN in/IN transient/JJ transfection/NN experiments/NNS ./. 
In/IN addition/NN ,/, BSAP/NN was/VBD found/VBN to/TO be/VB the/DT only/RB abundant/JJ DNA-binding/JJ activity/NN of/IN B-cell/NN nuclear/JJ extracts/NNS that/WDT interacts/VBZ with/IN the/DT CD19/NN promoter/NN ./. 
Together/RB ,/, this/DT evidence/NN strongly/RB implicates/VBZ BSAP/NN in/IN the/DT regulation/NN of/IN the/DT CD19/NN gene/NN ./. 
UI/LS -/: 92294188/CD 
TI/LS -/: Eicosanoids/NNS in/IN breast/NN cancer/NN patients/NNS before/IN and/CC after/IN mastectomy/NN ./. 
AB/LS -/: In/IN 19/CD patients/NNS with/IN a/DT malignant/JJ breast/NN tumor/NN ,/, tumor/NN tissue/NN and/CC blood/NN were/VBD taken/VBN to/TO determine/VB the/DT eicosanoid/NN profile/NN and/CC platelet/NN aggregation/NN ./. 
Values/NNS were/VBD compared/VBN with/IN those/DT of/IN patients/NNS with/IN benign/JJ tumors/NNS (/( n/NN =/JJ 4/CD )/) ,/, or/CC undergoing/VBG a/DT mammary/JJ reduction/NN (/( n/NN =/JJ 7/CD )/) ./. 
Postoperatively/RB ,/, blood/NN was/VBD taken/VBN as/RB well/RB in/IN order/NN to/TO compare/VB pre-/JJ and/CC postoperative/JJ values/NNS ./. 
Eicosanoids/NNS were/VBD measured/VBN in/IN peripheral/JJ blood/NN monocytes/NNS and/CC mammary/JJ tissue/NN by/IN means/NNS of/IN HPLC/NN ;/: furthermore/RBR ,/, TXA2/NN ,/, 6-keto-PGF1/NN alpha/NN ,/, and/CC PGE2/NN were/VBD determined/VBN by/IN RIA/NN ./. 
Differences/NNS in/IN pre-/JJ and/CC postoperative/JJ values/NNS of/IN cancer/NN patients/NNS were/VBD seen/VBN in/IN plasma/NN RIA/NN values/NNS :/: PGE2/NN and/CC 6-k-PGF1/NN alpha/NN were/VBD significantly/RB higher/JJR preoperatively/RB when/WRB compared/VBN with/IN postoperatively/RB ,/, however/RB ,/, such/JJ differences/NNS were/VBD seen/VBN in/IN the/DT control/NN groups/NNS as/RB well/RB ./. 
Compared/VBN to/TO benign/JJ tumor/NN or/CC mammary/JJ reduction/NN test/NN material/NN the/DT eicosanoid/NN profile/NN of/IN tissue/NN obtained/VBN from/IN malignant/JJ mammary/JJ tumors/NNS showed/VBD important/JJ differences/NNS ./. 
Except/IN for/IN PGF2/NN alpha/NN ,/, HHT/NN and/CC 15-HETE/NN no/DT detectable/JJ quantities/NNS of/IN eicosanoids/NNS were/VBD found/VBN in/IN the/DT non-tumor/JJ material/NN ,/, whereas/IN in/IN the/DT malignant/JJ tumor/NN material/NN substantial/JJ quantities/NNS of/IN a/DT number/NN of/IN eicosanoid/NN metabolites/NNS were/VBD present/JJ ./. 
Statistically/RB significant/JJ correlations/NNS could/MD be/VB established/VBN between/IN patient/histopathology/NN data/NNS and/CC the/DT results/NNS of/IN the/DT platelet/NN aggregation/NN assays/NNS ,/, e.g./FW between/IN menopausal/JJ status/NN and/CC ADP/NN aggregation/NN ;/: oestrogen/NN receptor/NN (/( +/-/CC )/) and/CC collagen/NN and/CC arachidonic/JJ acid/NN aggregation/NN ,/, inflammatory/JJ cell/NN infiltration/NN score/NN and/CC arachidonic/JJ acid/NN aggregation/NN and/CC fibrosis/NN score/NN and/CC ADP/NN aggregation/NN ./. 
The/DT results/NNS show/VBP that/IN eicosanoid/NN synthesis/NN in/IN material/NN from/IN mammary/JJ cancer/NN patients/NNS is/VBZ different/JJ from/IN that/DT in/IN benign/JJ mammary/JJ tissue/NN ./. 
The/DT implications/NNS ,/, in/IN particular/JJ ,/, in/IN relation/NN to/TO future/JJ prognosis/NN of/IN the/DT patient/NN ,/, remain/VBP obscure/JJ ./. 
UI/LS -/: 92193465/CD 
TI/LS -/: Mineralocorticoids/NNPS and/CC mineralocorticoid/NN receptors/NNS in/IN mononuclear/JJ leukocytes/NNS in/IN patients/NNS with/IN pregnancy-induced/JJ hypertension/NN ./. 
AB/LS -/: To/TO examine/VB the/DT role/NN of/IN mineralocorticoids/NNS in/IN the/DT pathophysiology/NN of/IN pregnancy-induced/JJ hypertension/NN (/( PIH/NN )/) ,/, we/PRP studied/VBD plasma/NN aldosterone/NN and/CC 18-hydroxycorticosterone/NN levels/NNS in/IN 25/CD women/NNS with/IN PIH/NN and/CC 25/CD normal/JJ pregnant/JJ women/NNS ,/, as/IN controls/NNS ./. 
Furthermore/RB ,/, we/PRP evaluated/VBD the/DT mineralocorticoid/NN receptor/NN (/( MR/NN )/) status/NN in/IN mononuclear/JJ leukocytes/NNS in/IN the/DT 2/CD groups/NNS ./. 
MR/NN count/NN was/VBD significantly/RB (/( P/NN less/JJR than/IN 0.0005/CD )/) decreased/VBN in/IN the/DT PIH/NN group/NN (/( 148/CD +/-/CC 9/CD binding/VBG sites/cell/NNS )/) compared/VBN with/IN the/DT control/NN group/NN (/( 300/CD +/-/CC 17/CD binding/VBG sites/cell/NNS ;/: mean/NN +/-/CC SEM/NN )/) ./. 
Plasma/NN aldosterone/NN in/IN women/NNS with/IN PIH/NN was/VBD 281/CD +/-/CC 61/CD pmol/L/NN ;/: in/IN normal/JJ pregnant/JJ women/NNS it/PRP was/VBD 697/CD +/-/CC 172/CD pmol/L/NN (/( P/NN less/JJR than/IN 0.025/CD )/) ./. 
Plasma/NN 18-hydroxycorticosterone/NN was/VBD also/RB significantly/RB (/( P/NN less/JJR than/IN 0.025/CD )/) lower/JJR (/( PIH/NN ,/, 1071/CD +/-/CC 149/CD pmol/L/NN ;/: controls/NNS ,/, 1907/CD +/-/CC 318/CD pmol/L/NN )/) ./. 
These/DT values/NNS were/VBD determined/VBN at/IN the/DT onset/NN of/IN clinical/JJ symptoms/NNS of/IN PIH/NN ./. 
These/DT results/NNS can/MD not/RB be/VB explained/VBN by/IN receptor/NN down-regulation/NN due/JJ to/TO higher/JJR levels/NNS of/IN mineralocorticoids/NNS in/IN PIH/NN ;/: a/DT hitherto/RB unknown/JJ mineralocorticoid/NN may/MD ,/, thus/RB ,/, be/VB responsible/JJ for/IN the/DT hypertension/NN and/CC altered/JJ MR/NN status/NN ./. 
UI/LS -/: 92147648/CD 
TI/LS -/: Structure/NN function/NN analysis/NN of/IN vitamin/NN D/NN analogs/NNS with/IN C-ring/NN modifications/NNS ./. 
AB/LS -/: Analogs/NNS of/IN 1/CD alpha,25-dihydroxyvitamin/NN D3/NN (/( 1/CD alpha,25-(OH)/NN 2D3/NN )/) with/IN substitutions/NNS on/IN C-11/NN were/VBD synthesized/VBN ./. 
Small/JJ apolar/JJ substitutions/NNS (/( 11/CD alpha-methyl/NN ,/, 11/CD alpha-fluoromethyl/NN )/) did/VBD not/RB markedly/RB decrease/VB the/DT affinity/NN for/IN the/DT vitamin/NN D/NN receptor/NN ,/, but/CC larger/JJR (/( 11/CD alpha-chloromethyl/NN or/CC 11/CD alpha-/NN or/CC 11/CD beta-phenyl/NN )/) or/CC more/RBR polar/JJ substitutions/NNS (/( 11/CD alpha-hydroxymethyl/NN ,/, 11/CD alpha-(2-hydroxyethyl/NN ]/) decreased/VBD the/DT affinity/NN to/TO less/JJR than/IN 5/CD %/NN of/IN that/DT of/IN 1/CD alpha,25-OH)2D3/NN ./. 
Their/PRP$ affinity/NN for/IN the/DT vitamin/NN D-binding/JJ protein/NN ,/, however/RB ,/, increased/VBD up/RB to/TO 4-fold/RB ./. 
The/DT biological/JJ activity/NN of/IN 11/CD alpha-methyl-1/NN alpha,25-(OH)2D3/NN closely/RB resembled/VBD that/DT of/IN the/DT natural/JJ hormone/NN on/IN normal/JJ and/CC leukemic/JJ cell/NN proliferation/NN and/CC bone/NN resorption/NN ,/, whereas/IN its/PRP$ in/FW vivo/FW effect/NN on/IN calcium/NN metabolism/NN of/IN the/DT rachitic/JJ chick/NN was/VBD about/IN 50/CD %/NN of/IN that/DT of/IN 1/CD alpha,25-(OH)2D3/NN ./. 
The/DT 11/CD beta-methyl/NN analog/NN had/VBD a/DT greater/JJR than/IN 10-fold/RB lower/JJR activity/NN ./. 
The/DT differentiating/JJ effects/NNS of/IN the/DT other/JJ C-11/NN analogs/NNS on/IN human/JJ promyeloid/JJ leukemia/NN cells/NNS (/( HL-60/NN )/) agreed/VBD well/RB with/IN their/PRP$ bone-resorbing/JJ activity/NN and/CC receptor/NN affinity/NN ,/, but/CC they/PRP demonstrated/VBD lower/JJR calcemic/JJ effects/NNS in/FW vivo/FW ./. 
Large/JJ or/CC polar/JJ substitutions/NNS on/IN C-11/NN of/IN 1/CD alpha,25-(OH)2D3/NN thus/RB impair/VBP the/DT binding/NN of/IN the/DT vitamin/NN D/NN receptor/NN but/CC increase/VBP the/DT affinity/NN to/TO vitamin/NN D-binding/JJ protein/NN ./. 
The/DT effects/NNS of/IN many/JJ C-11-substituted/JJ 1/CD alpha,25-(OH)2D3/NN analogs/NNS on/IN HL-60/NN cell/NN differentiation/NN exceeded/VBD their/PRP$ activity/NN on/IN calcium/NN metabolism/NN ./. 
UI/LS -/: 92213189/CD 
TI/LS -/: Glucocorticoid/NN receptor/NN binding/NN in/IN three/CD different/JJ cell/NN types/NNS in/IN major/JJ depressive/JJ disorder/NN :/: lack/NN of/IN evidence/NN of/IN receptor/NN binding/NN defect/NN ./. 
AB/LS -/: 1/LS ./. 
In/IN order/NN to/TO further/RB understand/VB the/DT apparent/JJ glucocorticoid/NN resistance/NN in/IN major/JJ depressive/JJ disorder/NN ,/, circadian/JJ variation/NN in/IN cortisol/NN concentration/NN ,/, dexamethasone/NN suppression/NN and/CC glucocorticoid/NN receptor/NN binding/NN in/IN mononuclear/JJ leukocytes/NNS ,/, polymorphonuclear/JJ leukocytes/NNS and/CC cultured/VBN skin/NN fibroblasts/NNS were/VBD measured/VBN in/IN rigidly/RB defined/VBN major/JJ depressive/JJ disorder/NN patients/NNS and/CC non-depressed/JJ psychiatric/JJ controls/NNS ./. 
2/LS ./. 
Mononuclear/JJ leukocytes/NNS binding/VBG to/TO glucocorticoid/NN correlated/VBD significantly/RB with/IN polymorphonuclear/JJ leukocytes/NNS binding/VBG to/TO glucocorticoid/NN ,/, but/CC both/DT determinations/NNS failed/VBD to/TO differentiate/VB major/JJ depressive/JJ disorder/NN and/CC control/NN subjects/NNS ./. 
3/LS ./. 
Initial/JJ and/CC post-dexamethasone/JJ in/FW vitro/FW fibroblast/NN binding/VBG to/TO glucocorticoid/NN was/VBD not/RB different/JJ between/IN major/JJ depressive/JJ disorder/NN and/CC non-depressed/JJ control/NN subjects/NNS ./. 
4/CD ./. 
The/DT phenomenon/NN of/IN glucocorticoid/NN resistance/NN in/IN major/JJ depressive/JJ disorder/NN remains/VBZ unexplained/JJ ./. 
UI/LS -/: 92109743/CD 
TI/LS -/: High/JJ affinity/NN aldosterone/NN binding/VBG to/TO plasma/NN membrane/NN rich/JJ fractions/NNS from/IN mononuclear/JJ leukocytes/NNS :/: is/VBZ there/EX a/DT membrane/NN receptor/NN for/IN mineralocorticoids/NNS ?/. 
AB/LS -/: In/FW vitro/FW effects/NNS of/IN aldosterone/NN on/IN the/DT intracellular/JJ concentrations/NNS of/IN sodium/NN ,/, potassium/NN and/CC calcium/NN ,/, cell/NN volume/NN and/CC the/DT sodium-proton-antiport/NN have/VBP been/VBN described/VBN in/IN intact/JJ human/JJ mononuclear/JJ leukocytes/NNS (/( HML/NN )/) ./. 
In/IN the/DT present/JJ paper/NN ,/, the/DT binding/NN of/IN a/DT [125I]-labeled/JJ aldosterone/NN derivative/JJ to/TO plasma/NN membrane/NN rich/JJ fractions/NNS of/IN HML/NN was/VBD studied/VBN ./. 
High/JJ affinity/NN binding/NN of/IN the/DT radioligand/NN with/IN an/DT apparent/JJ Kd/NN of/IN approximately/RB 0.1/CD nM/NN was/VBD found/VBN ./. 
Aldosterone/NN displaced/VBD the/DT tracer/NN at/IN a/DT similar/JJ Kd/NN ./. 
Both/CC canrenone/NN and/CC cortisol/NN were/VBD inactive/JJ as/IN ligands/NNS up/RB to/TO concentrations/NNS of/IN 0.1/CD microM/NN ./. 
The/DT findings/NNS are/VBP the/DT first/JJ to/TO demonstrate/VB membrane/NN binding/NN sites/NNS with/IN a/DT high/JJ affinity/NN for/IN aldosterone/NN ,/, but/CC not/RB for/IN cortisol/NN ./. 
These/DT data/NNS are/VBP perfectly/RB compatible/JJ with/IN major/JJ properties/NNS of/IN steroidal/JJ effects/NNS on/IN the/DT sodium-proton-antiport/NN in/IN HML/NN and/CC thus/RB very/RB likely/RB represent/VBP membrane/NN receptors/NNS for/IN aldosterone/NN ./. 
UI/LS -/: 93079901/CD 
TI/LS -/: Natural/JJ variants/NNS of/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN :/: analysis/NN of/IN promoters/NNS with/IN duplicated/JJ DNA/NN regulatory/JJ motifs/NNS ./. 
AB/LS -/: Sequence/NN variation/NN in/IN the/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) region/NN of/IN HIV-1/NN was/VBD analyzed/VBN in/IN viral/JJ isolates/NNS of/IN 17/CD infected/JJ individuals/NNS ./. 
Two/CD classes/NNS of/IN LTR/NN size/NN variants/NNS were/VBD found/VBN ./. 
One/CD HIV-1/NN variant/NN was/VBD detected/VBN containing/VBG an/DT additional/JJ binding/VBG site/NN for/IN the/DT transcription/NN factor/NN Sp1/NN ./. 
Another/DT LTR/NN size/NN variation/NN was/VBD observed/VBN in/IN four/CD patients/NNS in/IN a/DT region/NN just/RB upstream/JJ of/IN the/DT NF-kappa/NN B/NN enhancer/NN ./. 
This/DT variation/NN was/VBD the/DT result/NN of/IN a/DT duplication/NN of/IN a/DT short/JJ DNA/NN sequence/NN (/( CTG-motif/NN )/) ./. 
Cell/NN culture/NN experiments/NNS demonstrated/VBD that/IN the/DT natural/JJ variant/NN with/IN four/CD Sp1/NN sites/NNS had/VBD a/DT slightly/RB higher/JJR promoter/NN activity/NN and/CC viral/JJ replication/NN rate/NN than/IN the/DT isogenic/JJ control/NN LTR/NN with/IN three/CD Sp1/NN sites/NNS ./. 
No/DT positive/JJ effect/NN of/IN the/DT duplicated/JJ CTG-motif/NN could/MD be/VB detected/VBN ./. 
In/IN order/NN to/TO measure/VB small/JJ differences/NNS in/IN virus/NN production/NN more/RBR accurately/RB ,/, equal/JJ amounts/NNS of/IN a/DT size/NN variant/NN and/CC the/DT wild-type/JJ plasmid/NN were/VBD cotransfected/VBN into/IN T-cells/NNS ./. 
The/DT virus/NN with/IN four/CD Sp1/NN sites/NNS did/VBD outgrow/VB the/DT three/CD Sp1/NN virus/NN in/IN 35/CD days/NNS of/IN culture/NN and/CC CTG-monomer/NN virus/NN outcompeted/VBD the/DT CTG-dimer/NN virus/NN in/IN 42/CD days/NNS ./. 
Based/VBN on/IN these/DT results/NNS we/PRP estimate/VBP a/DT 5-10/CD %/NN difference/NN in/IN virus/NN production/NN of/IN the/DT LTR/NN variants/NNS when/WRB compared/VBN to/TO that/DT of/IN wild-type/NN ./. 
UI/LS -/: 93046624/CD 
TI/LS -/: A/DT novel/JJ B/NN cell-derived/JJ coactivator/NN potentiates/VBZ the/DT activation/NN of/IN immunoglobulin/NN promoters/NNS by/IN octamer-binding/JJ transcription/NN factors/NNS ./. 
AB/LS -/: A/DT novel/JJ B/NN cell-restricted/JJ activity/NN ,/, required/VBN for/IN high/JJ levels/NNS of/IN octamer/Oct-dependent/JJ transcription/NN from/IN an/DT immunoglobulin/NN heavy/JJ chain/NN (/( IgH/NN )/) promoter/NN ,/, was/VBD detected/VBN in/IN an/DT in/FW vitro/FW system/NN consisting/VBG of/IN HeLa/NN cell-derived/JJ extracts/NNS complemented/VBN with/IN fractionated/VBN B/NN cell/NN nuclear/JJ proteins/NNS ./. 
The/DT factor/NN responsible/JJ for/IN this/DT activity/NN was/VBD designated/VBN Oct/NN coactivator/NN from/IN B/NN cells/NNS (/( OCA-B/NN )/) ./. 
OCA-B/NN stimulates/VBZ the/DT transcription/NN from/IN an/DT IgH/NN promoter/NN in/IN conjunction/NN with/IN either/CC Oct-1/NN or/CC Oct-2/NN but/CC shows/VBZ no/DT significant/JJ effect/NN on/IN the/DT octamer/Oct-dependent/JJ transcription/NN of/IN the/DT ubiquitously/RB expressed/VBN histone/NN H2B/NN promoter/NN and/CC the/DT transcription/NN of/IN USF-/NN and/CC Sp1-regulated/JJ promoters/NNS ./. 
Taken/VBN together/RB ,/, our/PRP$ results/NNS suggest/VBP that/IN OCA-B/NN is/VBZ a/DT tissue-/NN ,/, promoter-/NN ,/, and/CC factor-specific/JJ coactivator/NN and/CC that/IN OCA-B/NN may/MD be/VB a/DT major/JJ determinant/NN for/IN B/NN cell-specific/JJ activation/NN of/IN immunoglobulin/NN promoters/NNS ./. 
In/IN light/NN of/IN the/DT evidence/NN showing/VBG physical/JJ and/CC functional/JJ interactions/NNS between/IN Oct/NN factors/NNS and/CC OCA-B/NN ,/, we/PRP propose/VBP a/DT mechanism/NN of/IN action/NN for/IN OCA-B/NN and/CC discuss/VBP the/DT implications/NNS of/IN OCA-B/NN for/IN the/DT transcriptional/JJ regulation/NN of/IN other/JJ tissue-specific/JJ promoters/NNS ./. 
UI/LS -/: 93085167/CD 
TI/LS -/: SCL/NN and/CC related/JJ hemopoietic/JJ helix-loop-helix/JJ transcription/NN factors/NNS ./. 
AB/LS -/: The/DT helix-loop-helix/JJ (/( HLH/JJ )/) proteins/NNS are/VBP a/DT family/NN of/IN transcription/NN factors/NNS that/WDT include/VBP proteins/NNS critical/JJ to/TO differentiation/NN and/CC development/NN in/IN species/NNS ranging/VBG from/IN plants/NNS to/TO mammals/NNS ./. 
Five/CD members/NNS of/IN this/DT family/NN (/( MYC/NN ,/, SCL/NN ,/, TAL-2/NN ,/, LYL-1/NN and/CC E2A/NN )/) are/VBP implicated/VBN in/IN oncogenic/JJ events/NNS in/IN human/JJ lymphoid/JJ tumors/NNS because/IN of/IN their/PRP$ consistent/JJ involvement/NN in/IN chromosomal/JJ translocations/NNS ./. 
Although/IN activated/VBN in/IN T/NN cell/NN leukemias/NNS ,/, expression/NN of/IN SCL/NN and/CC LYL-1/NN is/VBZ low/JJ or/CC undetectable/JJ in/IN normal/JJ T/NN cell/NN populations/NNS ./. 
SCL/NN is/VBZ expressed/VBN in/IN erythroid/JJ ,/, megakaryocyte/NN and/CC mast/NN cell/NN populations/NNS (/( the/DT same/JJ cell/NN lineages/NNS as/IN GATA-1/NN ,/, a/DT zinc-finger/NN transcription/NN factor/NN )/) ./. 
In/IN addition/NN ,/, both/CC SCL/NN and/CC GATA-1/NN undergo/VBP coordinate/JJ modulation/NN during/IN chemically/RB induced/VBN erythroid/JJ differentiation/NN of/IN mouse/NN erythroleukemia/NN cells/NNS and/CC are/VBP down-modulated/VBN during/IN myeloid/JJ differentiation/NN of/IN human/JJ K562/NN cells/NNS ,/, thus/RB implying/VBG a/DT role/NN for/IN SCL/NN in/IN erythroid/JJ differentiation/NN events/NNS ./. 
However/RB ,/, in/IN contrast/NN to/TO GATA-1/NN ,/, SCL/NN is/VBZ expressed/VBN in/IN the/DT developing/VBG brain/NN ./. 
Studies/NNS of/IN the/DT function/NN of/IN SCL/NN suggest/VBP it/PRP is/VBZ also/RB important/JJ in/IN proliferation/NN and/CC self-renewal/JJ events/NNS in/IN erythroid/JJ cells/NNS ./. 
UI/LS -/: 92318932/CD 
TI/LS -/: Induction/NN of/IN the/DT POU/NN domain/NN transcription/NN factor/NN Oct-2/NN during/IN T-cell/NN activation/NN by/IN cognate/JJ antigen/NN ./. 
AB/LS -/: Oct-2/NN is/VBZ a/DT transcription/NN factor/NN that/WDT binds/VBZ specifically/RB to/TO octamer/NN DNA/NN motifs/NNS in/IN the/DT promoters/NNS of/IN immunoglobulin/NN and/CC interleukin-2/NN genes/NNS ./. 
All/DT tumor/NN cell/NN lines/NNS from/IN the/DT B-cell/NN lineage/NN and/CC a/DT few/JJ from/IN the/DT T-cell/NN lineage/NN express/VBP Oct-2/NN ./. 
To/TO address/VB the/DT role/NN of/IN Oct-2/NN in/IN the/DT T-cell/NN lineage/NN ,/, we/PRP studied/VBD the/DT expression/NN of/IN Oct-2/NN mRNA/NN and/CC protein/NN in/IN nontransformed/JJ human/JJ and/CC mouse/NN T/NN cells/NNS ./. 
Oct-2/NN was/VBD found/VBN in/IN CD4+/JJ and/CC CD8+/JJ T/NN cells/NNS prepared/VBN from/IN human/JJ peripheral/JJ blood/NN and/CC in/IN mouse/NN lymph/NN node/NN T/NN cells/NNS ./. 
In/IN a/DT T-cell/NN clone/NN specific/JJ for/IN pigeon/NN cytochrome/NN c/NN in/IN the/DT context/NN of/IN I-Ek/NN ,/, Oct-2/NN was/VBD induced/VBN by/IN antigen/NN stimulation/NN ,/, with/IN the/DT increase/NN in/IN Oct-2/NN protein/NN seen/VBN first/RB at/IN 3/CD h/NN after/IN activation/NN and/CC continuing/VBG for/IN at/IN least/JJS 24/CD h/NN ./. 
Oct-2/NN mRNA/NN induction/NN during/IN antigen-driven/JJ T-cell/NN activation/NN was/VBD blocked/VBN by/IN cyclosporin/NN A/NN ,/, as/RB well/RB as/IN by/IN protein/NN synthesis/NN inhibitors/NNS ./. 
These/DT results/NNS suggest/VBP that/IN Oct-2/NN participates/VBZ in/IN transcriptional/JJ regulation/NN during/IN T-cell/NN activation/NN ./. The/DT relatively/RB delayed/VBN kinetics/NNS of/IN Oct-2/NN induction/NN suggests/VBZ that/IN Oct-2/NN mediates/VBZ the/DT changes/NNS in/IN gene/NN expression/NN which/WDT occur/VBP many/JJ hours/NNS or/CC days/NNS following/VBG antigen/NN stimulation/NN of/IN T/NN lymphocytes/NNS ./. 
UI/LS -/: 93020778/CD 
TI/LS -/: Glucocorticoid/NN receptor/NN in/IN patients/NNS with/IN lupus/NN nephritis/NN :/: relationship/NN between/IN receptor/NN levels/NNS in/IN mononuclear/JJ leukocytes/NNS and/CC effect/NN of/IN glucocorticoid/NN therapy/NN ./. 
AB/LS -/: We/PRP investigated/VBD the/DT clinical/JJ significance/NN of/IN glucocorticoid/NN receptor/NN determination/NN in/IN 20/CD patients/NNS with/IN systemic/JJ lupus/NN erythematosus/NN (/( SLE/NN )/) who/WP afterwards/RB developed/VBD nephrotic/JJ syndrome/NN ./. 
Glucocorticoid/NN receptor/NN concentrations/NNS in/IN mononuclear/JJ leukocytes/NNS (/( MNL/NNS )/) in/IN these/DT patients/NNS were/VBD comparable/JJ with/IN those/DT in/IN both/CC other/JJ patients/NNS with/IN SLE/NN and/CC healthy/JJ persons/NNS ./. 
Improvement/NN in/IN urinary/JJ protein/NN excretion/NN and/CC in/IN disease/NN activity/NN ,/, which/WDT was/VBD scored/VBN according/VBG to/TO the/DT SLE/NNP Disease/NNP Activity/NNP Index/NNP system/NN of/IN the/DT University/NNP of/IN Toronto/NNP ,/, closely/RB related/JJ to/TO the/DT glucocorticoid/NN receptor/NN concentrations/NNS in/IN MNL/NN isolated/VBN from/IN the/DT corresponding/JJ patients/NNS ./. 
In/IN summary/NN ,/, glucocorticoid/NN receptor/NN determination/NN in/IN patients/NNS with/IN lupus/NN nephritis/NN may/MD be/VB a/DT predictive/JJ clue/NN for/IN assessing/VBG responsiveness/NN to/TO glucocorticoid/NN therapy/NN ./. 
UI/LS -/: 92320321/CD 
TI/LS -/: [/( Changes/NNS in/IN plasma/NN interleukin-1/NN and/CC their/PRP$ possible/JJ relationship/NN with/IN the/DT changes/NNS in/IN glucocorticoid/NN receptor/NN in/IN aged/JJ long-distance/JJ runner/NN ]/) 
AB/LS -/: For/IN the/DT study/NN of/IN the/DT changes/NNS in/IN plasma/NN interleukin-1/NN (/( IL-1/NN )/) and/CC their/PRP$ possible/JJ relationship/NN with/IN the/DT changes/NNS in/IN glucocorticoid/NN receptor/NN (/( GR/NN )/) ,/, plasma/NN IL-1/NN and/CC GR/NN in/IN peripheral/JJ blood/NN leukocytes/NNS in/IN aged/JJ long-distance/JJ runner/NN were/VBD measured/VBN simultaneously/RB ./. 
The/DT activity/NN of/IN IL-1/NN was/VBD expressed/VBN as/IN its/PRP$ ability/NN to/TO stimulate/VB 3H-TdR/NN incorporation/NN in/IN the/DT thymocytes/NNS of/IN C57/NN mice/NNS ./. 
GR/NN was/VBD determined/VBN by/IN whole/JJ cell/NN assay/NN with/IN 3H-Dex/NN ./. 
The/DT results/NNS showed/VBD that/IN the/DT activity/NN of/IN plasma/NN IL-1/NN in/IN aged/JJ long-distance/JJ runner/NN was/VBD 209/CD %/NN ,/, 223/CD %/NN and/CC 145/CD %/NN of/IN the/DT control/NN at/IN 14.7-18.7/CD ,/, 3.8-7.0/CD and/CC 1.5-2.6/CD KD/NN fractions/NNS ./. 
The/DT GR/NN in/IN peripheral/JJ blood/NN leukocytes/NNS in/IN aged/JJ runner/NN was/VBD 65/CD %/NN of/IN the/DT control/NN ./. 
Possible/JJ relationship/NN between/IN the/DT changes/NNS in/IN IL-1/NN and/CC GR/NN in/NN aged/JJ long-distance/JJ runner/NN and/CC its/PRP$ physiological/JJ significance/NN are/VBP discussed/VBN ./. 
UI/LS -/: 92193472/CD 
TI/LS -/: Mineralocorticoid/NN effector/NN mechanism/NN in/IN preeclampsia/NN ./. 
AB/LS -/: Mineralocorticoid/NN effector/NN mechanisms/NNS were/VBD evaluated/VBN in/IN 29/CD patients/NNS with/IN preeclampsia/NN and/CC in/IN 25/CD uncomplicated/JJ pregnancies/NNS by/IN measurement/NN of/IN plasma/NN aldosterone/NN ,/, levels/NNS of/IN mineralocorticoid/NN receptor/NN (/( MR/NN )/) in/IN mononuclear/JJ leucocytes/NNS ,/, and/CC subtraction/NN potential/NN difference/NN (/( SPD/NN ;/: rectal/JJ minus/CC oral/JJ values/NNS )/) ./. 
Mean/NN values/NNS for/IN plasma/NN aldosterone/NN were/VBD not/RB different/JJ between/IN the/DT two/CD groups/NNS ,/, but/CC significant/JJ differences/NNS were/VBD observed/VBN for/IN MR/NN (/( preeclampsia/NN ,/, 81/CD +/-/CC 44/CD receptors/cell/NNS ;/: controls/NNS ,/, 306/CD +/-/CC 168/CD )/) and/CC SPD/NN (/( preeclampsia/NN ,/, 65/CD +/-/CC 7/CD mV/NN ;/: controls/NNS ,/, 12/CD +/-/CC 5/CD mV/NN )/) ./. 
In/IN six/CD cases/NNS we/PRP determined/VBD MR/NN ,/, plasma/NN aldosterone/NN ,/, and/CC SPD/NN in/IN patients/NNS with/IN preeclampsia/NN before/IN and/CC 3/CD months/NNS after/IN delivery/NN ./. 
MR/NNS were/VBD reduced/VBN before/IN delivery/NN (/( 96/CD +/-/CC 27/CD receptors/cell/NNS )/) ,/, and/CC SPD/NN increased/VBD (/( 64/CD +/-/CC 8/CD mV/NN )/) ,/, with/IN both/DT parameters/NNS normalizing/VBG after/IN delivery/NN (/( MR/NN ,/, 242/CD +/-/CC 79/CD ;/: SPD/NN ,/, 14.0/CD +/-/CC 4/CD mV/NN )/) ./. 
Aldosterone/NN levels/NNS returned/VBD to/TO normal/JJ nonpregnant/JJ values/NNS after/IN delivery/NN ./. 
These/DT data/NNS suggest/VBP an/DT important/JJ role/NN for/IN abnormalities/NNS in/IN mineralocorticoid/NN effector/NN mechanisms/NNS in/IN the/DT etiology/NN of/IN preeclampsia/NN and/CC could/MD be/VB an/DT useful/JJ marker/NN for/IN diagnosis/NN ./. 
UI/LS -/: 92215726/CD 
TI/LS -/: Kinetics/NNS of/IN nuclear/JJ translocation/NN and/CC turnover/NN of/IN the/DT vitamin/NN D/NN receptor/NN in/IN human/JJ HL60/NN leukemia/NN cells/NNS and/CC peripheral/JJ blood/NN lymphocytes/NNS --/: coincident/JJ rise/NN of/IN DNA-relaxing/JJ activity/NN in/IN nuclear/JJ extracts/NNS ./. 
AB/LS -/: High/JJ affinity/NN receptors/NNS (/( VDR/NN )/) for/IN 1,25-dihydroxycholecalciferol/NN (/( calcitriol/NN )/) are/VBP expressed/VBN in/IN HL60/NN human/JJ leukemia/NN cells/NNS and/CC in/IN low/JJ numbers/NNS in/IN peripheral/JJ blood/NN lymphocytes/NNS (/( PBL/NN )/) ./. 
HL60/NN cells/NNS ,/, expressing/VBG some/DT characteristics/NNS of/IN promyelocytes/NNS ,/, can/MD be/VB induced/VBN to/TO monocytoid/NN differentiation/NN by/IN calcitriol/NN ./. 
Specific/JJ nuclear/JJ translocation/NN of/IN [3H]calcitriol/VDR/NN was/VBD examined/VBN after/IN exposure/NN of/IN whole/JJ cells/NNS to/TO 10/CD (/( -9/CD )/) M/l/NN calcitriol/NN in/IN the/DT presence/NN and/CC absence/NN of/IN a/DT 500-fold/JJ excess/NN of/IN unlabeled/JJ ligand/NN and/CC subsequent/JJ isolation/NN of/IN nuclei/NNS ./. 
Specific/JJ nuclear/JJ translocation/NN of/IN [3H]calcitriol/VDR/NN was/VBD found/VBN to/TO be/VB time/NN dependent/JJ reaching/VBG a/DT maximum/NN of/IN approximately/RB 2100/CD binding/VBG sites/nucleus/NNS after/IN 3/CD h/NN of/IN incubation/NN in/IN HL60/NN cells/NNS ,/, whereas/IN a/DT maximum/NN of/IN approximately/RB 310/CD binding/VBG sites/nucleus/NNS was/VBD found/VBN after/IN 3/CD h/NN in/IN PBL/NN ./. 
Pulse/NN exposure/NN of/IN HL60/NN to/TO radiolabeled/VBN hormone/NN for/IN 3/CD h/NN followed/VBN by/IN culture/NN in/IN medium/NN without/IN serum/NN and/CC calcitriol/NN lead/VBD to/TO nuclear/JJ retention/NN of/IN approximately/RB 1600/CD radiolabeled/VBN VDR/NN by/IN 8/CD h/NN and/CC approximately/RB 1000/CD VDR/NN by/IN 24/CD h/NN ./. 
Radiolabeled/VBN VDR/NN disappeared/VBD from/IN the/DT nuclear/JJ compartment/NN with/IN a/DT halflife/NN of/IN approximately/RB 30/CD min/NN if/IN cells/NNS were/VBD cultured/VBN with/IN identical/JJ concentrations/NNS of/IN unlabeled/JJ hormone/NN after/IN the/DT pulse/NN (/( pulse/chase-experiments/NNS )/) ./. 
No/DT difference/NN of/IN VDR/NN retention/NN in/IN pulse/NN and/CC pulse/chase-experiments/NNS was/VBD seen/VBN in/IN PBL/NN ,/, where/WRB VDR/NN halflife/NN was/VBD approximately/RB 30/CD min/NN ./. 
No/DT specific/JJ translocation/NN into/IN the/DT nuclear/JJ compartment/NN was/VBD seen/VBN when/WRB isolated/VBN nuclei/NNS were/VBD incubated/VBN in/IN [3H]calcitriol/NN ./. 
Radiolabeled/VBN hormone/receptor/NN complexes/NNS of/IN nuclei/NNS isolated/VBN from/IN cells/NNS exposed/VBN for/IN 3/CD h/NN to/TO radiolabeled/VBN hormone/NN --/: in/IN contrast/NN to/TO identical/JJ experiments/NNS with/IN intact/JJ cells/NNS --/: did/VBD not/RB disappear/VB from/IN the/DT nuclear/JJ compartment/NN upon/IN incubation/NN of/IN nuclei/NNS with/IN identical/JJ concentrations/NNS of/IN the/DT unlabeled/JJ compound/NN ./. 
The/DT activity/NN of/IN DNA/NN relaxing/NN enzymes/NNS (/( e.g./FW topoisomerases/NNS I/CD and/CC II/CD )/) in/IN nuclear/JJ extracts/NNS was/VBD measured/VBN using/VBG a/DT PBR/NN 322-relaxation-assay/NN ./. 
Enhanced/VBN overall/JJ enzyme/NN activity/NN was/VBD found/VBN in/IN nuclear/JJ extracts/NNS by/IN 1/CD h/NN after/IN incubation/NN with/IN calcitriol/NN (/( final/JJ ethanol/NN concentration/NN 0.0001/CD %/NN v/v/NN )/) in/IN HL60/NN and/CC PBL/NN ./. 
The/DT enhanced/VBN activity/NN disappeared/VBD after/IN 2/CD h/NN in/IN PBL/NN ,/, whereas/IN it/PRP was/VBD still/RB enhanced/VBN by/IN 4/CD h/NN in/IN HL60/NN ./. 
No/DT effect/NN was/VBD seen/VBN in/IN ethanol/NN treated/JJ controls/NNS ./. 
We/PRP conclude/VBP that/IN a/DT specific/JJ nuclear/JJ translocation/NN mechanism/NN exists/VBZ for/IN calcitriol/NN in/IN both/DT cell/NN types/NNS examined/VBN ,/, most/RBS likely/RB due/IN to/TO translocation/NN of/IN receptor/NN proteins/NNS after/IN hormone/NN binding/NN ./. 
Translocated/VBN hormone/receptor/NN complexes/NNS compete/VBP for/IN a/DT limited/JJ number/NN of/IN specific/JJ nuclear/JJ binding/VBG sites/NNS ./. 
Enhanced/VBN activity/NN of/IN topoisomerases/NNS in/IN nuclear/JJ extracts/NNS upon/IN translocation/NN of/IN VDR/NN might/MD reflect/VB interaction/NN of/IN both/DT within/IN the/DT nuclear/JJ compartment/NN ,/, thus/RB initiating/VBG DNA-unwinding/NN ,/, a/DT prerequisite/NN of/IN transcription/NN initiation/NN ./. 
UI/LS -/: 92135176/CD 
TI/LS -/: Influence/NN of/IN estradiol/NN and/CC tamoxifen/NN on/IN susceptibility/NN of/IN human/JJ breast/NN cancer/NN cell/NN lines/NNS to/TO lysis/NN by/IN lymphokine-activated/JJ killer/NN cells/NNS ./. 
AB/LS -/: The/DT design/NN of/IN combination/NN hormonal/JJ and/CC immunotherapeutic/JJ protocols/NNS for/IN breast/NN cancer/NN patients/NNS may/MD be/VB facilitated/VBN by/IN analysis/NN of/IN preclinical/JJ in/FW vitro/FW model/JJ systems/NNS ./. 
Estrogen/NN receptor/NN positive/JJ (/( ER+/JJ :/: MCF-7/NN )/) and/CC negative/JJ (/( ER-/JJ :/: MDA-MB-231/NN )/) human/JJ breast/NN cancer/NN cell/NN lines/NNS were/VBD utilized/VBN to/TO evaluate/VB the/DT effects/NNS of/IN tamoxifen/NN (/( TAM/NN )/) and/CC estradiol/NN (/( E2/NN )/) on/IN modulation/NN of/IN breast/NN cancer/NN target/NN susceptibility/NN to/TO lysis/NN by/IN lymphokine-activated/JJ killer/NN (/( LAK/NN )/) cells/NNS ./. 
E2-stimulated/JJ ER+/JJ cells/NNS were/VBD more/RBR susceptible/JJ to/TO lysis/NN by/IN LAK/NN cells/NNS than/IN corresponding/VBG TAM-treated/JJ or/CC control/NN cells/NNS ,/, while/IN treatment/NN of/IN ER- cells/NNS with/IN either/CC E2/NN or/CC TAM/NN alone/RB did/VBD not/RB alter/VB from/IN control/NN their/PRP$ susceptibility/NN to/TO this/DT immune-mediated/JJ lysis/NN ./. 
All/DT ER+/JJ and/CC ER-cells/NNS tested/VBN remained/VBD sensitive/JJ after/IN treatment/NN with/IN TAM/NN to/TO lysis/NN by/IN LAK/NN cells/NNS ./. 
In/IN addition/NN ,/, an/DT adenocarcinoma/NN reactive/JJ human-mouse/JJ chimeric/JJ monoclonal/JJ antibody/NN (/( ING-1/NN )/) was/VBD able/JJ to/TO significantly/RB boost/VB in/FW vivo/FW generated/VBN LAK/NN cell-mediated/JJ lysis/NN of/IN control/NN ,/, E2-treated/JJ ,/, and/CC TAM-treated/JJ ER+/JJ and/CC ER-cells/NNS ./. 
These/DT in/FW vitro/FW results/NNS provide/VBP a/DT preclinical/JJ rationale/NN for/IN in/FW vivo/FW testing/NN of/IN TAM/NN ,/, interleukin-2/NN (/( IL-2/NN )/) ,/, and/CC breast/NN cancer/NN reactive/JJ antibody-dependent/JJ cellular/JJ cytotoxicity/NN facilitating/VBG antibody/NN in/IN patients/NNS with/IN refractory/JJ or/CC high/JJ risk/NN breast/NN cancer/NN ./. 
UI/LS -/: 92107162/CD 
TI/LS -/: The/DT cellular/JJ oncogene/NN c-myb/NN can/MD interact/VB synergistically/RB with/IN the/DT Epstein-Barr/JJ virus/NN BZLF1/NN transactivator/NN in/IN lymphoid/JJ cells/NNS ./. 
AB/LS -/: Regulation/NN of/IN replicative/JJ functions/NNS in/IN the/DT Epstein-Barr/JJ virus/NN (/( EBV/NN )/) genome/NN is/VBZ mediated/VBN through/IN activation/NN of/IN a/DT virally/RB encoded/VBN transcription/NN factor/NN ,/, Z/NN (/( BZLF1/NN )/) ./. 
We/PRP have/VBP shown/VBN that/IN the/DT Z/NN gene/NN product/NN ,/, which/WDT binds/VBZ to/TO AP-1/NN sites/NNS as/IN a/DT homodimer/NN and/CC has/VBZ sequence/NN similarity/NN to/TO c-Fos/NN ,/, can/MD efficiently/RB activate/VB the/DT EBV/NN early/JJ promoter/NN ,/, BMRF1/NN ,/, in/IN certain/JJ cell/NN types/NNS (/( i.e./FW ,/, HeLa/NN cells/NNS )/) but/CC not/RB others/NNS (/( i.e./FW ,/, Jurkat/NN cells/NNS )/) ./. 
Here/RB we/PRP demonstrate/VBP that/IN the/DT c-myb/NN proto-oncogene/NN product/NN ,/, which/WDT is/VBZ itself/PRP a/DT DNA-binding/JJ protein/NN and/CC transcriptional/JJ transactivator/NN ,/, can/MD interact/VB synergistically/RB with/IN Z/NN in/IN activating/VBG the/DT BMRF1/NN promoter/NN in/IN Jurkat/NN cells/NNS (/( a/DT T-cell/NN line/NN )/) or/CC Raji/NN cells/NNS (/( an/DT EBV-positive/JJ B-cell/NN )/) ,/, whereas/IN the/DT c-myb/NN gene/NN product/NN by/IN itself/PRP has/VBZ little/JJ effect/NN ./. 
The/DT simian/JJ virus/NN 40/CD early/JJ promoter/NN is/VBZ also/RB synergistically/RB activated/VBN by/IN the/DT Z/c-myb/NN combination/NN ./. 
Synergistic/JJ transactivation/NN of/IN the/DT BMRF1/NN promoter/NN by/IN the/DT Z/c-myb/NN combination/NN appears/VBZ to/TO involve/VB direct/JJ binding/NN by/IN the/DT Z/NN protein/NN but/CC not/RB the/DT c-myb/NN protein/NN ./. 
A/DT 30-bp/JJ sequence/NN in/IN the/DT BMRF1/NN promoter/NN which/WDT contains/VBZ a/DT Z/NN binding/NN site/NN (/( a/DT consensus/NN AP-1/NN site/NN )/) is/VBZ sufficient/JJ to/TO transfer/VB high-level/JJ lymphoid-specific/JJ responsiveness/NN to/TO the/DT Z/c-myb/NN combination/NN to/TO a/DT heterologous/JJ promoter/NN ./. 
That/IN the/DT c-myb/NN oncogene/NN product/NN can/MD interact/VB synergistically/RB with/IN an/DT EBV-encoded/JJ member/NN of/IN the/DT leucine/NN zipper/NN protein/NN family/NN suggests/VBZ c-myb/NN is/VBZ likely/JJ to/TO engage/VB in/IN similar/JJ interactions/NNS with/IN cellularly/RB encoded/VBN transcription/NN factors/NNS ./. 
UI/LS -/: 93129248/CD 
TI/LS -/: Alpha-lipoic/JJ acid/NN is/VBZ a/DT potent/JJ inhibitor/NN of/IN NF-kappa/NN B/NN activation/NN in/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: Acquired/VBN immunodeficiency/NN syndrome/NN (/( AIDS/NN )/) results/VBZ from/IN infection/NN with/IN a/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) ./. 
The/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) region/NN of/IN HIV/NN proviral/JJ DNA/NN contains/VBZ binding/VBG sites/NNS for/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ,/, and/CC this/DT transcriptional/JJ activator/NN appears/VBZ to/TO regulate/VB HIV/NN activation/NN ./. 
Recent/JJ findings/NNS suggest/VBP an/DT involvement/NN of/IN reactive/JJ oxygen/NN species/NNS (/( ROS/NN )/) in/IN signal/NN transduction/NN pathways/NNS leading/VBG to/TO NF-kappa/NN B/NN activation/NN ./. 
The/DT present/JJ study/NN was/VBD based/VBN on/IN reports/NNS that/IN antioxidants/NNS which/WDT eliminate/VBP ROS/NN should/MD block/VB the/DT activation/NN of/IN NF-kappa/NN B/NN and/CC subsequently/RB HIV/NN transcription/NN ,/, and/CC thus/RB antioxidants/NNS can/MD be/VB used/VBN as/IN therapeutic/JJ agents/NNS for/IN AIDS/NN ./. 
Incubation/NN of/IN Jurkat/NN T/NN cells/NNS (/( 1/CD x/NN 10/CD (/( 6/CD )/) cells/ml/NNS )/) with/IN a/DT natural/JJ thiol/NN antioxidant/NN ,/, alpha-lipoic/JJ acid/NN ,/, prior/JJ to/TO the/DT stimulation/NN of/IN cells/NNS was/VBD found/VBN to/TO inhibit/VB NF-kappa/NN B/NN activation/NN induced/VBN by/IN tumor/NN necrosis/NN factor-alpha/NN (/( 25/CD ng/ml/NN )/) or/CC by/IN phorbol/NN 12-myristate/NN 13-acetate/NN (/( 50/CD ng/ml/NN )/) ./. 
The/DT inhibitory/JJ action/NN of/IN alpha-lipoic/JJ acid/NN was/VBD found/VBN to/TO be/VB very/RB potent/JJ as/IN only/RB 4/CD mM/NN was/VBD needed/VBN for/IN a/DT complete/JJ inhibition/NN ,/, whereas/IN 20/CD mM/NN was/VBD required/VBN for/IN N-acetylcysteine/NN ./. 
These/DT results/NNS indicate/VBP that/IN alpha-lipoic/JJ acid/NN may/MD be/VB effective/JJ in/IN AIDS/NN therapeutics/NNS ./. 
UI/LS -/: 93077034/CD 
TI/LS -/: Reticuloendotheliosis/NN virus/NN long/JJ terminal/JJ repeat/NN elements/NNS are/VBP efficient/JJ promoters/NNS in/IN cells/NNS of/IN various/JJ species/NNS and/CC tissue/NN origin/NN ,/, including/VBG human/JJ lymphoid/JJ cells/NNS ./. 
AB/LS -/: Promiscuous/JJ transcriptional/JJ activity/NN of/IN the/DT reticuloendotheliosis/NN virus/NN (/( REV/NN )/) long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) was/VBD detected/VBN in/IN transient/JJ expression/NN assays/NNS using/VBG LTR-chloramphenicol/NN acetyltransferase-encoding/JJ gene/NN chimeras/NNS ,/, and/CC cells/NNS of/IN diverse/JJ species/NNS and/CC tissue/NN type/NN ;/: levels/NNS of/IN expression/NN from/IN two/CD different/JJ REV/NN LTRs/NNS correlate/VBP with/IN reports/NNS of/IN pathogenicity/NN of/IN the/DT respective/JJ viruses/NNS in/FW vivo/FW ./. 
REVs/NNS do/VBP not/RB encode/VB a/DT transactivator/NN targeted/VBN to/TO the/DT viral/JJ LTR/NN ,/, and/CC cells/NNS infected/VBN with/IN Marek/NN 's/POS disease/NN virus/NN ,/, a/DT herpesvirus/NN with/IN an/DT overlapping/VBG host/NN range/NN ,/, do/VBP not/RB express/VB factors/NNS that/WDT preferentially/RB enhance/VBP expression/NN from/IN REV/NN or/CC avian/JJ sarcoma/leukemia/NN virus/NN LTRs/NNS ./. 
REV/NN LTRs/NNS work/VBP efficiently/RB in/IN human/JJ lymphoid/JJ cells/NNS ,/, and/CC are/VBP viable/JJ alternatives/NNS to/TO promoters/NNS commonly/RB used/VBN for/IN expression/NN of/IN cloned/VBN genes/NNS ./. 
They/PRP may/MD also/RB prove/VB useful/JJ in/IN the/DT identification/NN of/IN new/JJ ,/, ubiquitous/JJ cellular/JJ transcription/NN factors/NNS ./. 
UI/LS -/: 92407982/CD 
TI/LS -/: A/DT novel/JJ Ets-related/JJ transcription/NN factor/NN ,/, Elf-1/NN ,/, binds/VBZ to/TO human/JJ immunodeficiency/NN virus/NN type/NN 2/CD regulatory/JJ elements/NNS that/WDT are/VBP required/VBN for/IN inducible/JJ trans/JJ activation/NN in/IN T/NN cells/NNS ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) and/CC HIV-2/NN are/VBP structurally/RB related/JJ retroviruses/NNS which/WDT both/DT cause/VBP AIDS/NN in/IN humans/NNS ./. 
Although/IN both/DT viruses/NNS establish/VBP latency/NN in/IN quiescent/JJ human-peripheral-blood/JJ T/NN cells/NNS ,/, the/DT asymptomatic/JJ phase/NN of/IN HIV-2/NN infection/NN may/MD be/VB more/JJR prolonged/JJ than/IN that/DT of/IN HIV-1/NN ./. 
The/DT latent/JJ phases/NNS of/IN both/CC HIV-1/NN and/CC HIV-2/NN infection/NN have/VBP been/VBN shown/VBN to/TO be/VB disrupted/VBN by/IN T-cell/NN activation/NN ,/, a/DT process/NN that/WDT requires/VBZ host/NN cell/NN transcription/NN factors/NNS ./. 
In/IN the/DT case/NN of/IN HIV-1/NN ,/, the/DT transcription/NN factor/NN NF-kappa/NN B/NN is/VBZ sufficient/JJ for/IN inducible/JJ transcriptional/JJ activation/NN ./. 
In/IN contrast/NN ,/, factors/NNS in/IN addition/NN to/TO NF-kappa/NN B/NN are/VBP required/VBN to/TO activate/VB HIV-2/NN transcription/NN in/IN infected/JJ T/NN cells/NNS ./. 
In/IN this/DT report/NN ,/, we/PRP demonstrate/VBP that/IN a/DT novel/JJ Ets-related/JJ transcription/NN factor/NN ,/, Elf-1/NN ,/, binds/VBZ specifically/RB to/TO two/CD purine-rich/JJ motifs/NNS in/IN the/DT HIV-2/NN enhancer/NN ./. 
Mutagenesis/NN experiments/NNS demonstrated/VBD that/IN these/DT Elf-1/NN binding/NN sites/NNS are/VBP required/VBN for/IN induction/NN of/IN HIV-2/NN transcription/NN following/VBG T-cell-receptor-mediated/JJ T-cell/NN activation/NN ./. 
Moreover/RB ,/, Elf-1/NN is/VBZ the/DT only/JJ factor/NN present/JJ in/IN activated/VBN T-cell/NN nuclear/JJ extracts/NNS that/WDT binds/VBZ to/TO these/DT sites/NNS in/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ./. 
Thus/RB ,/, Elf-1/NN is/VBZ a/DT novel/JJ transcription/NN factor/NN that/WDT appears/VBZ to/TO be/VB required/VBN for/IN the/DT T-cell-receptor-mediated/JJ trans/JJ activation/NN of/IN HIV-2/NN gene/NN expression/NN ./. 
These/DT results/NNS may/MD explain/VB differences/NNS in/IN the/DT clinical/JJ spectra/NNS of/IN diseases/NNS caused/VBN by/IN HIV-1/NN and/CC HIV-2/NN and/CC may/MD also/RB have/VB implications/NNS for/IN the/DT design/NN of/IN therapeutic/JJ approaches/NNS to/TO HIV-2/NN infection/NN ./. 
UI/LS -/: 92392375/CD 
TI/LS -/: Okadaic/JJ acid/NN is/VBZ a/DT potent/JJ inducer/NN of/IN AP-1/NN ,/, NF-kappa/NN B/NN ,/, and/CC tumor/NN necrosis/NN factor-alpha/NN in/IN human/JJ B/NN lymphocytes/NNS ./. 
AB/LS -/: Treatment/NN of/IN human/JJ B/NN lymphocytes/NNS with/IN an/DT optimal/JJ concentration/NN of/IN okadaic/JJ acid/NN ,/, an/DT inhibitor/NN of/IN phosphatases/NNS 1/CD and/CC 2A/NN ,/, resulted/VBD in/IN the/DT induction/NN of/IN the/DT transcription/NN factor/NN ,/, AP-1/NN and/CC a/DT marked/JJ increase/NN in/IN NF-kappa/NN B/NN levels/NNS ./. 
In/IN contrast/NN ,/, no/DT effect/NN on/IN the/DT levels/NNS of/IN the/DT octamer/NN binding/NN proteins/NNS ,/, Oct-1/NN or/CC Oct-2/NN ,/, were/VBD found/VBN ./. 
Since/IN both/CC AP-1/NN and/CC NF-kappa/NN B/NN have/VBP been/VBN reported/VBN to/TO be/VB important/JJ in/IN the/DT induction/NN of/IN the/DT tumor/NN necrosis/NN factor-alpha/NN (/( TNF-alpha/NN )/) gene/NN we/PRP examined/VBD the/DT effects/NNS of/IN okadaic/JJ acid/NN on/IN TNF-alpha/NN mRNA/NN levels/NNS ./. 
Treatment/NN with/IN okadaic/JJ acid/NN resulted/VBD in/IN a/DT striking/JJ increase/NN in/IN TNF-alpha/NN mRNA/NN transcripts/NNS within/IN 1/CD h/NN of/IN stimulation/NN and/CC large/JJ amounts/NNS of/IN TNF-alpha/NN were/VBD released/VBN into/IN the/DT culture/NN media/NNS ./. 
Although/IN okadaic/JJ acid/NN provides/VBZ a/DT potent/JJ inductive/JJ signal/NN for/IN AP-1/NN and/CC NF-kappa/NN B/NN it/PRP did/VBD not/RB induce/VB either/CC B/NN cell/NN proliferation/NN or/CC immunoglobulin/NN secretion/NN ./. 
UI/LS -/: 92317168/CD 
TI/LS -/: Heterodimerization/NN and/CC transcriptional/JJ activation/NN in/FW vitro/FW by/IN NF-kappa/NN B/NN proteins/NNS ./. 
AB/LS -/: The/DT NF-kappa/NN B/NN family/NN of/IN transcription/NN proteins/NNS represents/VBZ multiple/JJ DNA/NN binding/NN ,/, rel/NN related/JJ polypeptides/NNS that/WDT contribute/VBP to/TO regulation/NN of/IN genes/NNS involved/VBN in/IN immune/JJ responsiveness/NN and/CC inflammation/NN ,/, as/RB well/RB as/IN activation/NN of/IN the/DT HIV/NN long/JJ terminal/JJ repeat/NN ./. 
In/IN this/DT study/NN multiple/JJ NF-kappa/NN B/NN related/JJ polypeptides/NNS ranging/VBG from/IN 85/CD to/TO 45/CD kDa/NN were/VBD examined/VBN for/IN their/PRP$ capacity/NN to/TO interact/VB with/IN the/DT PRDII/NN regulatory/JJ element/NN of/IN interferon/NN beta/NN and/CC were/VBD shown/VBN to/TO possess/VB distinct/JJ intrinsic/JJ DNA/NN binding/NN affinities/NNS for/IN this/DT NF-kappa/NN B/NN site/NN and/CC form/VB multiple/JJ DNA/NN binding/NN homo-/JJ and/CC heterodimer/NN complexes/NNS in/IN co-renaturation/NN experiments/NNS ./. 
Furthermore/RB ,/, using/VBG DNA/NN templates/NNS containing/VBG two/CD copies/NNS of/IN the/DT PRDII/NN domain/NN linked/VBN to/TO the/DT rabbit/NN beta/NN globin/NN gene/NN ,/, the/DT purified/VBN polypeptides/NNS specifically/RB stimulated/VBD NF-kappa/NN B/NN dependent/JJ transcription/NN in/IN an/DT in/FW vitro/FW reconstitution/NN assay/NN as/IN heterodimers/NNS but/CC not/RB as/IN p50/NN homodimers/NNS ./. 
These/DT experiments/NNS emphasize/VBP the/DT role/NN of/IN NF-kappa/NN B/NN dimerization/NN as/IN a/DT distinct/JJ level/NN of/IN transcriptional/JJ control/NN that/WDT may/MD permit/VB functional/JJ diversification/NN of/IN a/DT limited/JJ number/NN of/IN regulatory/JJ proteins/NNS ./. 
UI/LS -/: 92309248/CD 
TI/LS -/: c-myc/NN mRNA/NN expression/NN in/IN minor/JJ salivary/JJ glands/NNS of/IN patients/NNS with/IN Sjogren/NN 's/POS syndrome/NN ./. 
AB/LS -/: c-myc/NN protooncogene/NN is/VBZ implicated/VBN in/IN the/DT pathogenesis/NN of/IN B/NN cell/NN lymphoid/JJ malignancies/NNS and/CC high/JJ levels/NNS of/IN c-myc/NN mRNA/NN expression/NN are/VBP observed/VBN in/IN activated/VBN blood/NN mononuclear/JJ cells/NNS ./. 
Sjogren/NN 's/POS syndrome/NN (/( SS/NN )/) is/VBZ characterized/VBN by/IN lymphocytic/JJ infiltrates/NNS of/IN exocrine/JJ glands/NNS ,/, remarkable/JJ B/NN cell/NN hyperreactivity/NN and/CC a/DT strong/JJ predisposition/NN to/TO B/NN cell/NN neoplasia/NN ./. 
In/IN this/DT study/NN ,/, c-myc/NN protooncogene/NN mRNA/NN expression/NN in/IN 29/CD labial/JJ minor/JJ salivary/JJ gland/NN biopsies/NNS from/IN patients/NNS with/IN primary/JJ SS/NNS and/CC 15/CD controls/NNS was/VBD examined/VBN using/VBG in/FW situ/FW hybridization/NN histochemistry/NN ./. 
Two/CD 40mer/JJ oligonucleotides/NNS from/IN the/DT 1st/JJ and/CC the/DT 2nd/JJ exon/NN of/IN the/DT c-myc/NN gene/NN ,/, labeled/VBN with/IN 35S/NN ,/, were/VBD used/VBN as/IN probes/NNS ./. 
To/TO detect/VB the/DT origin/NN of/IN the/DT cell/NN hybridized/VBN with/IN a/DT c-myc/NN probe/NN ,/, a/DT combined/JJ immunochemistry/NN in/FW situ/FW hybridization/NN histochemistry/NN technique/NN was/VBD used/VBN ./. 
High/JJ c-myc/NN mRNA/NN expression/NN was/VBD detected/VBN on/IN acinar/JJ epithelial/JJ cells/NNS ./. 
c-myc/NN did/VBD not/RB correlate/VB with/IN c-fos/NN and/CC c-jun/NN protein/NN expression/NN ./. 
Stronger/JJR c-myc/NN mRNA/NN expression/NN was/VBD detected/VBN in/IN labial/JJ salivary/JJ glands/NNS of/IN patients/NNS with/IN longer/JJR disease/NN duration/NN (/( p/NN less/JJR than/IN or/CC equal/JJ to/TO 0.002/CD )/) and/CC more/RBR intense/JJ T/NN lymphocyte/NN infiltrates/NNS (/( p/NN less/JJR than/IN 0.05/CD )/) although/IN these/DT patients/NNS revealed/VBD no/DT hypergammaglobulinemia/NN ./. 
No/DT correlation/NN was/VBD observed/VBN between/IN c-myc/NN mRNA/NN and/CC B/NN lymphocyte/NN monoclonicity/NN or/CC lymphoma/NN ./. 
In/IN conclusion/NN ,/, strong/JJ c-myc/NN mRNA/NN expression/NN was/VBD observed/VBN on/IN epithelial/JJ cells/NNS of/IN labial/JJ salivary/JJ glands/NNS from/IN patients/NNS with/IN primary/JJ SS/NN ./. 
Our/PRP$ findings/NNS may/MD indicate/VB the/DT presence/NN of/IN a/DT reactivated/VBN virus/NN hosted/VBN in/IN these/DT cells/NNS ./. 
UI/LS -/: 92230800/CD 
TI/LS -/: Corticosteroid/NN receptors/NNS and/CC lymphocyte/NN subsets/NNS in/IN mononuclear/JJ leukocytes/NNS in/IN aging/NN ./. 
AB/LS -/: Plasma/NN cortisol/NN and/CC aldosterone/NN levels/NNS and/CC number/NN of/IN related/JJ receptors/NNS in/IN mononuclear/JJ leukocytes/NNS were/VBD measured/VBN in/IN 49/CD healthy/JJ aged/JJ subjects/NNS (/( 62-97/CD yr/NN )/) and/CC in/IN 21/CD adult/JJ controls/NNS (/( 21-50/CD yr/NN )/) ./. 
In/IN all/DT subjects/NNS ,/, in/IN addition/NN ,/, lymphocyte/NN subsets/NNS were/VBD determined/VBN as/IN an/DT index/NN of/IN corticosteroid/NN action/NN ./. 
The/DT mean/NN number/NN of/IN type/NN I/CD and/CC type/NN II/CD receptors/NNS was/VBD significantly/RB lower/JJR in/IN aged/JJ subjects/NNS than/IN in/IN controls/NNS (/( respectively/RB ,/, 198/CD +/-/CC 96/CD and/CC 272/CD +/-/CC 97/CD receptors/cell/NNS for/IN type/NN I/CD ,/, and/CC 1,794/CD +/-/CC 803/CD and/CC 3,339/CD +/-/CC 918/CD for/IN type/NN II/CD receptors/NNS )/) ./. 
Plasma/NN aldosterone/NN and/CC cortisol/NN and/CC lymphocyte/NN subsets/NNS were/VBD not/RB different/JJ in/IN the/DT two/CD groups/NNS ./. 
All/DT of/IN the/DT parameters/NNS were/VBD also/RB tested/VBN for/IN correlation/NN ,/, and/CC a/DT significant/JJ inverse/JJ correlation/NN was/VBD found/VBN between/IN age/NN and/CC type/NN I/CD and/CC type/NN II/CD receptors/NNS when/WRB all/DT subjects/NNS were/VBD plotted/VBN and/CC between/IN aged/JJ and/CC CD4/NN and/CC age/NN and/CC CD4/CD8/NN in/IN the/DT aged/JJ group/NN ./. 
These/DT data/NNS show/VBP that/IN aged/JJ subjects/NNS have/VBP reductions/NNS of/IN corticosteroid/NN receptors/NNS that/WDT are/VBP not/RB associated/VBN with/IN increase/NN of/IN related/JJ steroids/NNS and/CC that/IN this/DT situation/NN probably/RB represents/VBZ a/DT concomitant/NN of/IN the/DT normal/JJ aging/NN process/NN ./. 
UI/LS -/: 92176657/CD 
TI/LS -/: T/NN cell-specific/JJ negative/JJ regulation/NN of/IN transcription/NN of/IN the/DT human/JJ cytokine/NN IL-4/NN ./. 
AB/LS -/: IL-4/NN secreted/VBN by/IN activated/VBN T/NN cells/NNS is/VBZ a/DT pleiotropic/JJ cytokine/NN affecting/VBG growth/NN and/CC differentiation/NN of/IN diverse/JJ cell/NN types/NNS such/JJ as/IN T/NN cells/NNS ,/, B/NN cells/NNS ,/, and/CC mast/NN cells/NNS ./. 
We/PRP investigated/VBD the/DT upstream/JJ regulatory/JJ elements/NNS of/IN the/DT human/JJ IL-4/NN promoter/NN ./. 
A/DT novel/JJ T/NN cell-specific/JJ negative/JJ regulatory/JJ element/NN (/( NRE/NN )/) composed/VBN of/IN two/CD protein-binding/JJ sites/NNS were/VBD mapped/VBN in/IN the/DT 5'/JJ flanking/JJ region/NN of/IN the/DT IL-4/NN gene/NN :/: -311CTCCCTTCT-303/NN (/( NRE-I/NN )/) and/CC -288CTTTTTGCTT-TGC-300/NN (/( NRE-II/NN )/) ./. 
A/DT T/NN cell-specific/JJ protein/NN Neg-1/NN and/CC a/DT ubiquitous/JJ protein/NN Neg-2/NN binding/VBG to/TO NRE-I/NN and/CC NRE-II/NN ,/, respectively/RB ,/, were/VBD identified/VBN ./. 
Furthermore/RB ,/, a/DT positive/JJ regulatory/JJ element/NN was/VBD found/VBN 45/CD bp/NN downstream/RB of/IN the/DT NRE/NN ./. 
The/DT enhancer/NN activity/NN of/IN the/DT PRE/NN was/VBD completely/RB suppressed/VBN when/WRB the/DT NRE/NN was/VBD present/JJ ./. 
These/DT data/NNS suggest/VBP that/IN IL-4/NN promoter/NN activity/NN is/VBZ normally/RB down-regulated/VBN by/IN an/DT NRE/NN via/IN repression/NN of/IN the/DT enhancer/NN positive/JJ regulatory/JJ element/NN ./. 
These/DT data/NNS may/MD have/VB implications/NNS for/IN the/DT stringent/JJ control/NN of/IN IL-4/NN expression/NN in/IN T/NN cells/NNS ./. 
UI/LS -/: 92164748/CD 
TI/LS -/: Interleukin/NN 6-induced/JJ differentiation/NN of/IN a/DT human/JJ B/NN cell/NN line/NN into/IN IgM-secreting/JJ plasma/NN cells/NNS is/VBZ mediated/VBN by/IN c-fos/NN ./. 
AB/LS -/: The/DT role/NN of/IN the/DT protooncogene/NN c-fos/NN in/IN interleukin/NN (/( IL/NN )/) 6-induced/JJ B/NN cell/NN differentiation/NN was/VBD assessed/VBN ./. 
Treatment/NN of/IN SKW/NN 6.4/CD cells/NNS with/IN IL/NN 6/CD induced/VBD a/DT transient/JJ and/CC early/JJ stimulation/NN of/IN c-fos/NN sense/NN mRNA/NN expression/NN ./. 
The/DT effect/NN appeared/VBD within/IN 30/CD min/NN and/CC returned/VBD to/TO basal/JJ levels/NNS after/IN 2/CD h/NN ./. 
The/DT addition/NN of/IN antisense/JJ oligonucleotides/NNS to/TO c-fos/NN significantly/RB inhibited/VBD IL/NN 6-induced/JJ IgM/NN production/NN by/IN SKW/NN 6.4/CD cells/NNS (/( p/NN less/JJR than/IN 0.001/CD )/) ,/, whereas/IN control/NN oligonucleotides/NNS had/VBD no/DT inhibitory/JJ effect/NN ./. 
These/DT results/NNS indicate/VBP that/IN activation/NN of/IN c-fos/NN is/VBZ involved/VBN in/IN IL/NN 6-induced/JJ differentiation/NN of/IN SKW/NN 6.4/CD cells/NNS into/IN IgM-secreting/JJ cells/NNS ./. 
UI/LS -/: 92153263/CD 
TI/LS -/: Transcriptional/JJ regulation/NN during/IN T-cell/NN development/NN :/: the/DT alpha/NN TCR/NN gene/NN as/IN a/DT molecular/JJ model/NN ./. 
AB/LS -/: The/DT regulation/NN of/IN gene/NN expression/NN during/IN lymphocyte/NN differentiation/NN is/VBZ a/DT complex/JJ process/NN involving/VBG interactions/NNS between/IN multiple/JJ positive/JJ and/CC negative/JJ transcriptional/JJ regulatory/JJ elements/NNS ./. 
In/IN this/DT article/NN ,/, transcriptional/JJ regulation/NN of/IN the/DT archetypal/JJ T-cell-specific/JJ gene/NN ,/, alpha/NN TCR/NN ,/, is/VBZ discussed/VBN ./. 
Major/JJ recent/JJ developments/NNS ,/, including/VBG the/DT identification/NN of/IN novel/JJ families/NNS of/IN transcription/NN factors/NNS that/WDT regulate/VBP multiple/JJ T-cell/NN genes/NNS during/IN thymocyte/NN ontogeny/NN and/CC T-cell/NN activation/NN ,/, are/VBP described/VBN ./. 
UI/LS -/: 93129206/CD 
TI/LS -/: Photoaffinity/NN labeling/NN of/IN plasma/NN membrane/NN receptors/NNS for/IN aldosterone/NN from/IN human/JJ mononuclear/JJ leukocytes/NNS ./. 
AB/LS -/: Non-genomic/JJ effects/NNS of/IN aldosterone/NN on/IN the/DT sodium-proton-antiport/NN have/VBP been/VBN shown/VBN in/IN human/JJ mononuclear/JJ leukocytes/NNS which/WDT could/MD be/VB related/JJ to/TO a/DT new/JJ aldosterone/NN membrane/NN receptor/NN ./. 
In/IN the/DT present/JJ paper/NN plasma/NN membranes/NNS from/IN human/JJ mononuclear/JJ leukocytes/NNS were/VBD covalently/RB photolabeled/VBN with/IN a/DT [125I]-aldosterone/NN derivative/NN ./. 
Sodium/NN dodecyl/NN sulfate-polyacrylamide/JJ gel/NN electrophoresis/NN showed/VBD significant/JJ aldosterone/NN binding/NN at/IN a/DT molecular/JJ weight/NN of/IN approximately/RB 50000/CD Dalton/NN which/WDT was/VBD absent/JJ with/IN 1/CD microM/NN cold/JJ aldosterone/NN ,/, but/CC not/RB cortisol/NN in/IN the/DT binding/VBG media/NNS ./. 
The/DT presence/NN of/IN the/DT sulfhydryl/NN agent/NN dithiothreitol/NN did/VBD not/RB affect/VB results/NNS suggesting/VBG the/DT absence/NN of/IN disulfide/NN bridges/NNS in/IN the/DT steroid/NN binding/NN domain/NN of/IN the/DT receptor/NN ./. 
These/DT data/NNS are/VBP the/DT first/JJ to/TO define/VB the/DT molecular/JJ weight/NN of/IN the/DT membrane/NN receptor/NN for/IN aldosterone/NN ./. 
UI/LS -/: 93056505/CD 
TI/LS -/: Redox/NN status/NN of/IN cells/NNS influences/VBZ constitutive/JJ or/CC induced/VBN NF-kappa/NN B/NN translocation/NN and/CC HIV/NN long/JJ terminal/JJ repeat/NN activity/NN in/IN human/JJ T/NN and/CC monocytic/JJ cell/NN lines/NNS ./. 
AB/LS -/: We/PRP have/VBP tested/VBN the/DT hypothesis/NN that/IN cellular/JJ activation/NN events/NNS occurring/VBG in/IN T/NN lymphocytes/NNS and/CC monocytes/NNS and/CC mediated/VBN through/IN translocation/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN are/VBP dependent/JJ upon/IN the/DT constitutive/JJ redox/NN status/NN of/IN these/DT cells/NNS ./. 
We/PRP used/VBD phenolic/JJ ,/, lipid-soluble/JJ ,/, chain-breaking/JJ antioxidants/NNS (/( butylated/VBN hydroxyanisole/NN (/( BHA/NN )/) ,/, nordihydroquairetic/JJ acid/NN ,/, or/CC alpha-tocopherol/NN (/( vitamin/NN E/NN )/) to/TO show/VB that/IN peroxyl/JJ radical/JJ scavenging/NN in/IN unstimulated/JJ and/CC PMA-/NN or/CC TNF-stimulated/JJ cells/NNS blocks/VBZ the/DT functions/NNS depending/VBG on/IN NF-kappa/NN B/NN activation/NN ./. 
BHA/NN was/VBD found/VBN to/TO suppress/VB not/RB only/RB PMA-/NN or/CC TNF-induced/JJ ,/, but/CC also/RB constitutive/JJ ,/, HIV-enhancer/JJ activity/NN concomitant/JJ to/TO an/DT inhibition/NN of/IN NF-kappa/NN B/NN binding/NN activity/NN in/IN both/CC lymphoblastoid/JJ T/NN (/( J.Jhan/NN )/) and/CC monocytic/JJ (/( U937/NN )/) cell/NN lines/NNS ./. 
This/DT was/VBD also/RB true/JJ for/IN KBF/NN (/( p50/NN homodimer/NN )/) binding/NN activity/NN in/IN U937/NN cells/NNS ./. 
Secretion/NN of/IN TNF/NN ,/, the/DT product/NN of/IN another/DT NF-kappa/NN B-dependent/JJ gene/NN ,/, was/VBD abolished/VBN by/IN BHA/NN in/IN PMA-stimulated/JJ U937/NN cells/NNS ./. 
The/DT anti-oxidative/JJ effect/NN of/IN BHA/NN was/VBD accompanied/VBN by/IN an/DT increase/NN in/IN thiol/NN ,/, but/CC not/RB glutathione/NN ,/, content/NN in/IN stimulated/VBN and/CC unstimulated/JJ T/NN cell/NN ,/, whereas/IN TNF/NN stimulation/NN itself/PRP barely/RB modified/VBD the/DT cellular/JJ thiol/NN level/NN ./. 
Oxidative/JJ stress/NN obtained/VBN by/IN the/DT addition/NN of/IN H2O2/NN to/TO the/DT culture/NN medium/NN of/IN J.Jhan/NN or/CC U937/NN cells/NNS could/MD not/RB by/IN itself/PRP induce/VB NF-kappa/NN B/NN activation/NN ./. 
These/DT observations/NNS suggest/VBP that/IN TNF/NN and/CC PMA/NN do/VBP not/RB lead/VB to/TO NF-kappa/NN B/NN activation/NN through/IN induction/NN of/IN changes/NNS in/IN the/DT cell/NN redox/NN status/NN ./. 
Rather/RB ,/, TNF/NN and/CC PMA/NN can/MD exert/VB their/PRP$ effect/NN only/RB if/IN cells/NNS are/VBP in/IN an/DT appropriate/JJ redox/NN status/NN ,/, because/IN prior/JJ modification/NN toward/IN reduction/NN with/IN BHA/NN treatment/NN prevents/VBZ this/DT activation/NN ./. 
It/PRP appears/VBZ that/IN a/DT basal/JJ redox/NN equilibrium/NN tending/VBG toward/IN oxidation/NN is/VBZ a/DT prerequisite/NN for/IN full/JJ activation/NN of/IN transduction/NN pathways/NNS regulating/VBG the/DT activity/NN of/IN NF-kappa/NN B-dependent/JJ genes/NNS ./. 
UI/LS -/: 93024383/CD 
TI/LS -/: Selection/NN of/IN optimal/JJ kappa/NN B/Rel/NN DNA-binding/JJ motifs/NNS :/: interaction/NN of/IN both/DT subunits/NNS of/IN NF-kappa/NN B/NN with/IN DNA/NN is/VBZ required/VBN for/IN transcriptional/JJ activation/NN ./. 
AB/LS -/: Analysis/NN of/IN the/DT p50/NN and/CC p65/NN subunits/NNS of/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN complex/NN has/VBZ revealed/VBN that/IN both/DT proteins/NNS can/MD interact/VB with/IN related/JJ DNA/NN sequences/NNS through/IN either/CC homo-/JJ or/CC heterodimer/NN formation/NN ./. 
In/IN addition/NN ,/, the/DT product/NN of/IN the/DT proto-oncogene/NN c-rel/NN can/MD bind/VB to/TO similar/JJ DNA/NN motifs/NNS by/IN itself/PRP or/CC as/IN a/DT heterodimer/NN with/IN p50/NN or/CC p65/NN ./. 
However/RB ,/, these/DT studies/NNS have/VBP used/VBN a/DT limited/JJ number/NN of/IN known/JJ kappa/NN B/NN DNA/NN motifs/NNS ,/, and/CC the/DT question/NN of/IN the/DT optimal/JJ DNA/NN sequences/NNS preferred/VBN by/IN each/DT homodimer/NN has/VBZ not/RB been/VBN addressed/VBN ./. 
Using/VBG purified/VBN recombinant/JJ p50/NN ,/, p65/NN ,/, and/CC c-Rel/NN proteins/NNS ,/, optimal/JJ DNA-binding/JJ motifs/NNS were/VBD selected/VBN from/IN a/DT pool/NN of/IN random/JJ oligonucleotides/NNS ./. 
Alignment/NN of/IN the/DT selected/VBN sequences/NNS allowed/VBD us/PRP to/TO predict/VB a/DT consensus/NN sequence/NN for/IN binding/NN of/IN the/DT individual/JJ homodimeric/JJ Rel-related/JJ proteins/NNS ,/, and/CC DNA-protein/NN binding/NN analysis/NN of/IN the/DT selected/VBN DNA/NN sequences/VBZ revealed/VBD sequence/NN specificity/NN of/IN the/DT proteins/NNS ./. 
Contrary/JJ to/TO previous/JJ assumptions/NNS ,/, we/PRP observed/VBD that/IN p65/NN homodimers/NNS can/MD interact/VB with/IN a/DT subset/NN of/IN DNA/NN sequences/VBZ not/RB recognized/VBN by/IN p50/NN homodimers/NNS ./. 
Differential/JJ binding/NN affinities/NNS were/VBD also/RB obtained/VBN with/IN p50-/NN and/CC c-Rel-selected/JJ sequences/NNS ./. 
Using/VBG either/CC a/DT p50-/NN or/CC p65-selected/JJ kappa/NN B/NN motif/NN ,/, which/WDT displayed/VBD differential/JJ binding/NN with/IN respect/NN to/TO the/DT other/JJ protein/NN ,/, little/JJ to/TO no/DT binding/NN was/VBD observed/VBN with/IN the/DT heterodimeric/JJ NF-kappa/NN B/NN complex/NN ./. 
Similarly/RB ,/, in/IN transfection/NN experiments/NNS in/IN which/WDT the/DT selective/JJ kappa/NN B/NN binding/NN sites/NNS were/VBD used/VBN to/TO drive/VB the/DT expression/NN of/IN a/DT chloramphenicol/NN acetyltransferase/NN reporter/NN construct/NN ,/, the/DT p65-/NN and/CC p50-selected/JJ motifs/NNS were/VBD activated/VBN only/RB in/IN the/DT presence/NN of/IN p65/NN and/CC p50/65/NN (/( a/DT chimeric/JJ protein/NN with/IN the/DT p50/NN DNA/NN binding/NN domain/NN and/CC p65/NN activation/NN domain/NN )/) expression/NN vectors/NNS ,/, respectively/RB ,/, and/CC neither/DT demonstrated/VBD a/DT significant/JJ response/NN to/TO stimuli/NNS that/WDT induce/VBP NF-kappa/NN B/NN activity/NN ./. 
These/DT findings/NNS demonstrate/VBP that/IN interaction/NN of/IN both/DT subunits/NNS of/IN the/DT heterodimeric/JJ NF-kappa/NN B/NN complex/NN with/IN DNA/NN is/VBZ required/VBN for/IN DNA/NN binding/NN and/CC transcriptional/JJ activation/NN and/CC suggest/VBP that/IN transcriptional/JJ activation/NN mediated/VBN by/IN the/DT individual/JJ rel-related/JJ proteins/NNS will/MD differ/VB dramatically/RB ,/, depending/VBG on/IN the/DT specific/JJ kappa/NN B/NN motifs/NNS present/JJ ./. 
UI/LS -/: 92366555/CD 
TI/LS -/: NF-kappa/NN B-dependent/JJ induction/NN of/IN the/DT NF-kappa/NN B/NN p50/NN subunit/NN gene/NN promoter/NN underlies/VBZ self-perpetuation/NN of/IN human/JJ immunodeficiency/NN virus/NN transcription/NN in/IN monocytic/JJ cells/NNS ./. 
AB/LS -/: The/DT molecular/JJ mechanisms/NNS underlying/VBG the/DT sustained/JJ nuclear/JJ translocation/NN of/IN NF-kappa/NN B/NN observed/VBN in/IN U937/NN monocytic/JJ cells/NNS chronically/RB infected/VBN with/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) were/VBD studied/VBN ./. 
The/DT activity/NN of/IN the/DT promoter/NN regulating/VBG the/DT synthesis/NN of/IN the/DT p105/NN precursor/NN of/IN the/DT NF-kappa/NN B/NN p50/NN subunit/NN was/VBD enhanced/VBN in/IN these/DT cells/NNS ./. 
Deletions/NNS in/IN this/DT promoter/NN indicated/VBD that/IN this/DT upregulation/NN was/VBD mediated/VBN through/IN the/DT NF-kappa/NN B-/NN but/CC not/RB the/DT AP-1-binding/JJ motif/NN ,/, by/IN bona/FW fide/FW p50/p65/NN heterodimers/NNS ./. 
Analysis/NN of/IN cytosolic/JJ extracts/NNS indicated/VBD that/IN NF-kappa/NN B/NN levels/NNS were/VBD increased/VBN in/IN HIV-infected/JJ cells/NNS ./. 
In/IN contrast/NN to/TO the/DT transient/JJ NF-kappa/NN B/NN activation/NN induced/VBN by/IN phorbol/NN ester/NN ,/, the/DT permanent/JJ NF-kappa/NN B/NN translocation/NN induced/VBN by/IN HIV/NN infection/NN was/VBD not/RB dependent/JJ on/IN PKC/NN isoenzymes/NNS alpha/NN and/CC beta/NN as/IN shown/VBN by/IN the/DT use/NN of/IN a/DT specific/JJ inhibitor/NN (/( GF/NN 109203X/NN )/) ./. 
These/DT observations/NNS indicate/VBP that/IN during/IN chronic/JJ HIV/NN infection/NN of/IN U937/NN cells/NNS ,/, continuous/JJ NF-kappa/NN B/NN (/( p50/p65/NN )/) translocation/NN results/VBZ in/IN p105/NN promoter/NN upregulation/NN with/IN subsequent/JJ cytosolic/JJ NF-kappa/NN B/NN accumulation/NN ,/, ready/JJ for/IN further/JJ translocation/NN ./. 
This/DT HIV-mediated/JJ mechanism/NN results/VBZ in/IN a/DT self-perpetuating/JJ loop/NN of/IN NF-kappa/NN B/NN production/NN ./. 
UI/LS -/: 93041375/CD 
TI/LS -/: Activation/NN of/IN NF-kappa/NN B/NN by/IN interleukin/NN 2/CD in/IN human/JJ blood/NN monocytes/NNS ./. 
AB/LS -/: We/PRP report/VBP here/RB that/IN interleukin/NN 2/CD (/( IL-2/NN )/) acts/VBZ on/IN human/JJ blood/NN monocytes/NNS by/IN enhancing/VBG binding/NN activity/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN to/TO its/PRP$ consensus/NN sequence/NN in/IN the/DT 5'/JJ regulatory/JJ enhancer/NN region/NN of/IN the/DT IL-2/NN receptor/NN alpha/NN chain/NN (/( p55/NN )/) ./. 
Similarly/RB ,/, IL-2/NN activates/VBZ NF-kappa/NN B/NN in/IN the/DT human/JJ monocytic/JJ cell/NN line/NN U/NN 937/CD ,/, but/CC not/RB in/IN resting/VBG human/JJ T-cells/NNS ./. 
This/DT effect/NN is/VBZ detectable/JJ within/IN 15/CD min/NN and/CC peaks/VBZ 1/CD h/NN after/IN exposure/NN to/TO IL-2/NN ./. 
Enhanced/VBN NF-kappa/NN B/NN binding/NN activity/NN is/VBZ followed/VBN by/IN functional/JJ activation/NN in/IN that/IN inducibility/NN of/IN the/DT IL-2/NN receptor/NN alpha/NN chain/NN is/VBZ mediated/VBN by/IN enhanced/VBN NF-kappa/NN B/NN binding/NN and/CC that/IN a/DT heterologous/JJ promoter/NN containing/VBG the/DT NF-kappa/NN B/NN consensus/NN sequence/NN (/( -291/CD to/TO -245/CD )/) of/IN the/DT IL-2/NN receptor/NN alpha/NN chain/NN gene/NN is/VBZ activated/VBN ./. 
In/IN addition/NN ,/, IL-2/NN is/VBZ capable/JJ of/IN increasing/VBG transcript/NN levels/NNS of/IN the/DT p50/NN gene/NN coding/VBG for/IN the/DT p50/NN subunit/NN of/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN ,/, whereas/IN mRNA/NN levels/NNS of/IN the/DT p65/NN NF-kappa/NN B/NN gene/NN remained/VBD unchanged/JJ ./. 
UI/LS -/: 92235212/CD 
TI/LS -/: Studies/NNS on/IN the/DT biological/JJ activity/NN of/IN triiodothyronine/NN sulfate/NN ./. 
AB/LS -/: Hepatic/JJ microsomes/NNS and/CC isolated/VBN hepatocytes/NNS in/IN short/JJ term/NN culture/NN desulfate/VBP T3/NN sulfate/NN (/( T3SO4/NN )/) ./. 
We/PRP ,/, therefore/RB ,/, wished/VBD to/TO determine/VB whether/IN T3SO4/NN could/MD mimic/VB the/DT action/NN of/IN thyroid/NN hormone/NN in/FW vitro/FW ./. 
T3SO4/NN had/VBD no/DT thyromimetic/JJ effect/NN on/IN the/DT activity/NN of/IN Ca(2+)-ATPase/NN in/IN human/JJ erythrocyte/NN membranes/NNS at/IN doses/NNS up/RB to/TO 10,000/CD times/NNS the/DT maximally/RB effective/JJ dose/NN of/IN T3/NN (/( 10/CD (/( -10/CD )/) mol/L/NN )/) ./. 
In/IN GH4C1/NN pituitary/JJ cells/NNS ,/, T3SO4/NN failed/VBD to/TO displace/VB [125I]T3/NN from/IN nuclear/JJ receptors/NNS in/IN intact/JJ cells/NNS or/CC soluble/JJ preparations/NNS ./. 
Thus/RB ,/, T3SO4/NN was/VBD not/RB directly/RB thyromimetic/JJ in/IN either/CC an/DT isolated/VBN human/JJ membrane/NN system/NN or/CC a/DT pituitary/JJ cell/NN system/NN in/IN which/WDT nuclear/JJ receptor/NN occupancy/NN correlates/VBZ with/IN GH/NN synthesis/NN ./. 
Thyroid/NN hormones/NNS inhibit/VBP [3H]glycosaminoglycan/NN synthesis/NN by/IN cultured/VBN human/JJ dermal/JJ fibroblasts/NNS ,/, and/CC T3SO4/NN displayed/VBN about/IN 0.5/CD %/NN the/DT activity/NN of/IN T3/NN at/IN 72/CD h/NN ./. 
Human/JJ fibroblasts/NNS contained/VBD roughly/RB the/DT same/JJ level/NN of/IN microsomal/JJ p-nitrophenyl/NN sulfatase/NN activity/NN as/IN that/DT previously/RB observed/VBN in/IN hepatic/JJ microsomes/NNS ./. 
Propylthiouracil/NN (/( 50/CD mumol/L/NN )/) did/VBD not/RB affect/VB the/DT action/NN of/IN T3SO4/NN ,/, suggesting/VBG that/IN deiodination/NN was/VBD not/RB important/JJ for/IN this/DT activity/NN of/IN T3SO4/NN ./. 
Thus/RB ,/, it/PRP appears/VBZ T3SO4/NN has/VBZ no/DT intrinsic/JJ biological/JJ activity/NN ,/, but/CC ,/, under/IN certain/JJ circumstances/NNS ,/, may/MD be/VB reactivated/VBN by/IN desulfation/NN ./. 
UI/LS -/: 92185243/CD 
TI/LS -/: Human/JJ T/NN cell/NN activation/NN through/IN the/DT activation-inducer/JJ molecule/CD69/NN enhances/VBZ the/DT activity/NN of/IN transcription/NN factor/NN AP-1/NN ./. 
AB/LS -/: The/DT induction/NN of/IN the/DT AP-1/NN transcription/NN factor/NN has/VBZ been/VBN ascribed/VBN to/TO the/DT early/JJ events/NNS leading/VBG to/TO T/NN cell/NN differentiation/NN and/CC activation/NN ./. 
We/PRP have/VBP studied/VBN the/DT regulation/NN of/IN AP-1/NN activity/NN in/IN human/JJ peripheral/JJ blood/NN T/NN lymphocytes/NNS stimulated/VBN through/IN the/DT activation/NN inducer/NN molecule/NN (/( AIM/NN )/) /CD69/NN activation/NN pathway/NN ./. 
Phorbol/NN esters/NNS are/VBP required/VBN to/TO induce/VB AIM/CD69/NN cell-surface/JJ expression/NN as/RB well/RB as/IN for/IN triggering/VBG the/DT proliferation/NN of/IN T/NN cells/NNS in/IN conjunction/NN with/IN anti-AIM/JJ mAb/NN ./. 
Mobility/NN shift/NN assays/NNS showed/VBD that/IN addition/NN of/IN anti-AIM/JJ mAb/NN to/TO PMA-treated/JJ T/NN lymphocytes/NNS markedly/RB enhanced/VBD the/DT binding/NN activity/NN of/IN AP-1/NN to/TO its/PRP$ cognate/JJ sequence/NN ,/, the/DT phorbol/NN ester/NN response/NN element/NN ./. 
In/IN contrast/NN ,/, anti-AIM/NN mAb/NN did/VBD not/RB induce/VB any/DT change/NN in/IN the/DT binding/NN activity/NN of/IN NF-kappa/NN B/NN ,/, a/DT transcription/NN factor/NN whose/WP$ activity/NN is/VBZ also/RB regulated/VBN by/IN protein/NN kinase/NN C/NN ./. 
The/DT increase/NN in/IN AP-1-binding/JJ activity/NN was/VBD accompanied/VBN by/IN the/DT marked/JJ stimulation/NN of/IN the/DT transcription/NN of/IN c-fos/NN but/CC not/RB that/DT of/IN c-jun/NN ./. 
Blockade/NN of/IN the/DT DNA-binding/JJ complexes/NNS with/IN an/DT anti-Fos/JJ mAb/NN demonstrated/VBD a/DT direct/JJ participation/NN of/IN c-Fos/NN in/IN the/DT AP-1/NN complexes/NNS induced/VBN by/IN anti-AIM/NN mAb/NN ./. 
Most/JJS of/IN the/DT AP-1/NN activity/NN could/MD be/VB eliminated/VBN when/WRB the/DT anti-AIM/NN mAb/NN was/VBD added/VBN to/TO the/DT culture/NN medium/NN in/IN the/DT presence/NN of/IN cycloheximide/NN ,/, suggesting/VBG that/IN de/FW novo/FW protein/NN synthesis/NN is/VBZ crucial/JJ for/IN the/DT induction/NN of/IN AP-1-binding/JJ activity/NN ./. 
These/DT data/NNS provide/VBP the/DT evidence/NN that/IN activation/NN of/IN human/JJ peripheral/JJ blood/NN T/NN cells/NNS through/IN the/DT AIM/NN activation/NN pathway/NN regulate/VBP the/DT activity/NN of/IN AP-1/NN ./. 
Therefore/RB ,/, this/DT pathway/NN appears/VBZ as/IN a/DT crucial/JJ step/NN in/IN the/DT initiation/NN of/IN early/JJ T/NN cell/NN activation/NN events/NNS ./. 
UI/LS -/: 92176633/CD 
TI/LS -/: Gangliosides/NN suppress/VBP tumor/NN necrosis/NN factor/NN production/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: Both/CC normal/JJ and/CC malignant/JJ cells/NNS contain/VBP gangliosides/NNS as/IN important/JJ cell/NN membrane/NN constituents/NNS that/WDT ,/, after/IN being/VBG shed/VBN ,/, may/MD influence/VB cells/NNS of/IN the/DT immune/JJ system/NN ./. 
We/PRP have/VBP studied/VBN the/DT impact/NN of/IN gangliosides/NNS on/IN the/DT expression/NN of/IN TNF/NN in/IN blood/NN monocytes/NNS and/CC in/IN the/DT monocytic/JJ cell/NN line/NN Mono/NN Mac/NN 6/CD ./. 
Although/IN under/IN standard/JJ culture/NN conditions/NNS ,/, bovine/JJ brain/NN gangliosides/NNS (/( 100/CD micrograms/ml/NNS )/) suppressed/VBD LPS-stimulated/JJ TNF/NN production/NN 5-fold/RB in/IN PBMC/NN and/CC 10-fold/RB in/IN Mono/NN Mac/NN 6/CD cells/NNS ,/, suppression/NN was/VBD more/RBR efficient/JJ under/IN serum-free/JJ conditions/NNS ./. 
Looking/VBG at/IN highly/RB purified/VBN gangliosides/NNS ,/, GD3/NN ,/, GD1a/NN ,/, GM3/NN ,/, GM2/NN ,/, and/CC GM1/NN were/VBD all/DT effective/JJ in/IN reducing/VBG TNF/NN production/NN in/IN PBMC/NN ,/, and/CC in/IN Mono/NN Mac/NN 6/CD by/IN factor/NN 10/CD to/TO 50/CD ./. 
The/DT suppressive/JJ activity/NN was/VBD lost/VBN in/IN molecules/NNS ,/, lacking/VBG the/DT sugar/NN moiety/NN or/CC the/DT lipid/NN moiety/NN ./. 
Gangliosides/NNS appear/VBP to/TO act/VB at/IN an/DT early/JJ step/NN of/IN activation/NN in/IN that/IN TNF/NN transcripts/NNS were/VBD reduced/VBN and/CC the/DT mobilization/NN of/IN the/DT nuclear/JJ factor/NN kappa/NN B/NN was/VBD blocked/VBN ./. 
Furthermore/RB ,/, in/IN time/NN kinetics/NNS ,/, gangliosides/NNS were/VBD effective/JJ for/IN up/RB to/TO 30/CD min/NN after/IN addition/NN of/IN LPS/NN ,/, but/CC not/RB thereafter/RB ./. 
However/RB ,/, the/DT expression/NN of/IN the/DT CD14/NN Ag/NN ,/, a/DT receptor/NN molecule/NN for/IN LPS-LPS/NN binding/NN protein/NN complexes/NNS ,/, was/VBD unaffected/JJ by/IN gangliosides/NNS ./. 
Finally/RB ,/, when/WRB using/VBG Staphylococcus/FW aureus/FW or/CC platelet/NN activating/NN factor/NN as/IN a/DT stimulus/NN ,/, gangliosides/NNS were/VBD able/JJ to/TO suppress/VB TNF/NN production/NN in/IN Mono/NN Mac/NN 6/CD cells/NNS by/IN factor/NN 5/CD to/TO 10/CD ,/, as/RB well/RB ./. 
On/IN the/DT other/JJ hand/NN ,/, phorbol/NN ester-induced/JJ production/NN of/IN O2-/NN was/VBD similar/JJ in/IN cells/NNS treated/VBN with/IN and/CC without/IN gangliosides/NNS ./. 
Taken/VBN together/RB ,/, our/PRP$ data/NNS demonstrate/VBP that/IN TNF/NN gene/NN expression/NN in/IN monocytes/NNS induced/VBN by/IN different/JJ types/NNS of/IN stimuli/NNS can/MD be/VB blocked/VBN by/IN gangliosides/NNS at/IN an/DT early/JJ step/NN of/IN signal/JJ transduction/NN ./. 
UI/LS -/: 92123193/CD 
TI/LS -/: A/DT novel/JJ mitogen-inducible/JJ gene/NN product/NN related/JJ to/TO p50/p105-NF-kappa/NN B/NN participates/VBZ in/IN transactivation/NN through/IN a/DT kappa/NN B/NN site/NN ./. 
AB/LS -/: A/DT Rel-related/JJ ,/, mitogen-inducible/JJ ,/, kappa/NN B-binding/JJ protein/NN has/VBZ been/VBN cloned/VBN as/IN an/DT immediate-early/JJ activation/NN gene/NN of/IN human/JJ peripheral/JJ blood/NN T/NN cells/NNS ./. 
The/DT cDNA/NN has/VBZ an/DT open/JJ reading/NN frame/NN of/IN 900/CD amino/NN acids/NNS capable/JJ of/IN encoding/VBG a/DT 97-kDa/JJ protein/NN ./. 
This/DT protein/NN is/VBZ most/RBS similar/JJ to/TO the/DT 105-kDa/JJ precursor/NN polypeptide/NN of/IN p50-NF-kappa/NN B/NN ./. 
Like/IN the/DT 105-kDa/JJ precursor/NN ,/, it/PRP contains/VBZ an/DT amino-terminal/JJ Rel-related/JJ domain/NN of/IN about/IN 300/CD amino/NN acids/NNS and/CC a/DT carboxy-terminal/JJ domain/NN containing/VBG six/CD full/JJ cell/NN cycle/NN or/CC ankyrin/NN repeats/NNS ./. 
In/FW vitro-translated/JJ proteins/NNS ,/, truncated/VBN downstream/RB of/IN the/DT Rel/NN domain/NN and/CC excluding/VBG the/DT repeats/NNS ,/, bind/VBP kappa/NN B/NN sites/NNS ./. 
We/PRP refer/VBP to/TO the/DT kappa/NN B-binding/JJ ,/, truncated/VBN protein/NN as/IN p50B/NN by/IN analogy/NN with/IN p50-NF-kappa/NN B/NN and/CC to/TO the/DT full-length/JJ protein/NN as/IN p97/NN ./. 
p50B/NN is/VBZ able/JJ to/TO form/VB heteromeric/JJ kappa/NN B-binding/JJ complexes/NNS with/IN RelB/NN ,/, as/RB well/RB as/IN with/IN p65/NN and/CC p50/NN ,/, the/DT two/CD subunits/NNS of/IN NF-kappa/NN B/NN ./. 
Transient-transfection/NN experiments/NNS in/IN embryonal/JJ carcinoma/NN cells/NNS demonstrate/VBP a/DT functional/JJ cooperation/NN between/IN p50B/NN and/CC RelB/NN or/CC p65/NN in/IN transactivation/NN of/IN a/DT reporter/NN plasmid/NN dependent/JJ on/IN a/DT kappa/NN B/NN site/NN ./. 
The/DT data/NNS imply/VBP the/DT existence/NN of/IN a/DT complex/JJ family/NN of/IN NF-kappa/NN B-like/JJ transcription/NN factors/NNS ./. 
UI/LS -/: 93153207/CD 
TI/LS -/: Surrogate/NN thyroglobulin/NN receptors/NNS and/CC T/NN cell/NN proliferation/NN in/IN Hashimoto/NN 's/POS thyroiditis/NN ./. 
AB/LS -/: Immunoglobulin/NN molecules/NNS on/IN the/DT surface/NN of/IN a/DT B/NN lymphocyte/NN are/VBP the/DT endogenous/JJ "/`` receptors/NNS "/'' to/TO which/WDT specific/JJ antigens/NNS bind/VBP ./. 
Studies/NNS in/IN mice/NNS have/VBP shown/VBN that/IN a/DT monoclonal/JJ antibody/NN ,/, conjugated/VBN with/IN palmitate/NN to/TO provide/VB a/DT lipid/NN tail/NN ,/, can/MD be/VB inserted/VBN into/IN the/DT cell/NN membrane/NN to/TO provide/VB a/DT "/`` surrogate/JJ "/'' antigen/NN receptor/NN ./. 
We/PRP have/VBP investigated/VBN whether/IN a/DT palmitate/JJ conjugate/NN of/IN a/DT human/JJ monoclonal/JJ antibody/NN specific/JJ for/IN thyroglobulin/NN (/( TG/NN )/) could/MD function/VB as/IN a/DT surrogate/JJ TG/NN receptor/NN on/IN blood/NN mononuclear/JJ cells/NNS separated/VBN into/IN fractions/NNS enriched/VBN for/IN T/NN cells/NNS or/CC depleted/VBN of/IN T/NN cells/NNS (/( non-T/JJ cells/NNS )/) ./. 
Using/VBG flow/NN cytometry/NN ,/, we/PRP detected/VBD surrogate/JJ TG/NN receptors/NNS on/IN non-T/JJ (/( but/CC not/RB on/IN T/NN )/) cells/NNS from/IN 11/CD of/IN 11/CD individuals/NNS studied/VBN (/( 5/CD Hashimoto/NN patients/NNS and/CC 6/CD control/NN donors/NNS )/) ./. 
In/IN contrast/NN ,/, endogenous/JJ TG/NN receptors/NNS could/MD only/RB be/VB detected/VBN on/IN non-T/JJ cells/NNS from/IN 1/CD of/IN 3/CD Hashimoto/NN patients/NNS and/CC from/IN 0/CD of/IN 4/CD control/NN donors/NNS ./. 
Because/IN of/IN the/DT efficient/JJ binding/NN of/IN TG/NN by/IN surrogate/JJ receptors/NNS on/IN non-T/JJ cells/NNS ,/, we/PRP assessed/VBD the/DT ability/NN of/IN such/JJ cells/NNS to/TO present/VB TG/NN to/TO T/NN cells/NNS ./. 
Proliferation/NN in/IN response/NN to/TO TG/NN was/VBD observed/VBN in/IN T/NN cells/NNS from/IN only/RB 1/CD of/IN 5/CD Hashimoto/NN patients/NNS ./. 
This/DT low/JJ frequency/NN of/IN response/NN was/VBD no/RB different/JJ from/IN that/DT previously/RB detected/VBN using/VBG cultures/NNS of/IN T/NN cells/NNS and/CC autologous/JJ dendritic/JJ cells/NNS ./. 
Therefore/RB ,/, the/DT successful/JJ generation/NN of/IN surrogate/JJ receptors/NNS on/IN non-T/JJ cells/NNS is/VBZ not/RB associated/VBN with/IN more/RBR efficient/JJ TG/NN presentation/NN of/IN T/NN cells/NNS ./. 
Furthermore/RB ,/, the/DT significance/NN of/IN the/DT present/JJ study/NN is/VBZ that/IN the/DT T/NN cells/NNS ,/, not/RB the/DT antigen-presenting/JJ cells/NNS ,/, are/VBP likely/JJ to/TO be/VB the/DT limiting/VBG element/NN in/IN the/DT T/NN cell/NN proliferative/JJ response/NN to/TO TG/NN and/CC other/JJ thyroid/NN autoantigens/NNS ./. 
UI/LS -/: 93110357/CD 
TI/LS -/: Targeted/VBN degradation/NN of/IN c-Fos/NN ,/, but/CC not/RB v-Fos/NN ,/, by/IN a/DT phosphorylation-dependent/JJ signal/NN on/IN c-Jun/NN ./. 
AB/LS -/: The/DT proto-oncogene/NN products/NNS c-Fos/NN and/CC c-Jun/NN heterodimerize/VBP through/IN their/PRP$ leucine/NN zippers/NNS to/TO form/VB the/DT AP-1/NN transcription/NN factor/NN ./. 
The/DT transcriptional/JJ activity/NN of/IN the/DT heterodimer/NN is/VBZ regulated/VBN by/IN signal-dependent/JJ phosphorylation/NN and/CC dephosphorylation/NN events/NNS ./. 
The/DT stability/NN of/IN c-Fos/NN was/VBD found/VBN to/TO also/RB be/VB controlled/VBN by/IN intracellular/JJ signal/NN transduction/NN ./. 
In/IN transient/JJ expression/NN and/CC in/FW vitro/FW degradation/NN experiments/NNS ,/, the/DT stability/NN of/IN c-Fos/NN was/VBD decreased/VBN when/WRB the/DT protein/NN was/VBD dimerized/JJ with/IN phosphorylated/VBN c-Jun/NN ./. 
c-Jun/NN protein/NN isolated/VBN from/IN phorbol/NN ester-induced/JJ cells/NNS did/VBD not/RB target/VB c-Fos/NN for/IN degradation/NN ,/, which/WDT suggests/VBZ that/IN c-Fos/NN is/VBZ transiently/RB stabilized/VBN after/IN stimulation/NN of/IN cell/NN growth/NN ./. 
v-Fos/NN protein/NN ,/, the/DT retroviral/JJ counterpart/NN of/IN c-Fos/NN ,/, was/VBD not/RB susceptible/JJ to/TO degradation/NN targeted/VBN by/IN c-Jun/NN ./. 
UI/LS -/: 93054486/CD 
TI/LS -/: The/DT regulation/NN of/IN the/DT human/JJ tumor/NN necrosis/NN factor/NN alpha/NN promoter/NN region/NN in/IN macrophage/NN ,/, T/NN cell/NN ,/, and/CC B/NN cell/NN lines/NNS ./. 
AB/LS -/: The/DT 1311-base/JJ pair/NN human/JJ tumor/NN necrosis/NN factor/NN (/( TNF/NN )/) alpha/NN promoter/NN region/NN was/VBD fused/VBN to/TO the/DT luciferase/NN (/( Luc/NN )/) reporter/NN gene/NN and/CC studied/VBN in/IN a/DT transient/JJ transfection/NN system/NN in/IN three/CD TNF/NN producing/NN cell/NN lines/NNS ,/, the/DT U937/NN macrophage/NN cell/NN line/NN ,/, the/DT MLA/NN 144/CD T/NN cell/NN line/NN ,/, and/CC the/DT 729-6/CD B/NN cell/NN line/NN ./. 
This/DT full/JJ length/NN promoter/NN construct/NN can/MD be/VB induced/VBN by/IN phorbol/NN 13-myristate/NN acetate/NN (/( PMA/NN )/) in/IN each/DT of/IN these/DT cell/NN types/NNS ./. 
Analysis/NN of/IN a/DT series/NN of/IN 5'-truncations/NNS showed/VBD several/JJ peaks/NNS of/IN basal/JJ and/CC PMA/NN induced/JJ activity/NN suggesting/VBG the/DT presence/NN of/IN several/JJ positive/JJ and/CC negative/JJ regulatory/JJ elements/NNS ./. 
A/DT PMA/NN responsive/JJ element/NN was/VBD localized/JJ to/TO a/DT region/NN between/IN -95/CD and/CC -36/CD bp/NN relative/JJ to/TO the/DT transcription/NN start/NN site/NN ./. 
Within/IN this/DT region/NN ,/, single/JJ AP-2-/NN and/CC AP-1-like/JJ consensus/NN sequences/NNS were/VBD noted/VBN ./. 
These/DT AP-2/NN and/CC AP-1/NN sites/NNS were/VBD each/DT modified/VBN with/IN a/DT double/JJ point/NN mutation/NN ./. 
A/DT modest/JJ (/( 20-50/CD %/NN )/) reduction/NN in/IN TNF/NN promoter/NN activity/NN was/VBD observed/VBN with/IN the/DT AP-2/NN site/NN mutation/NN ./. 
However/RB ,/, mutation/NN of/IN the/DT AP-1/NN site/NN markedly/RB diminished/VBD both/CC the/DT basal/JJ and/CC PMA-activated/JJ promoter/NN activity/NN ./. 
Also/RB co-transfections/NNS of/IN the/DT wild-type/JJ promoter/NN construct/NN with/IN an/DT AP-1/c-jun/NN expression/NN vector/NN resulted/VBD in/IN augmented/JJ basal/JJ and/CC PMA-induced/JJ promoter/NN activity/NN ./. 
UI/LS -/: 93018835/CD 
TI/LS -/: Stable/JJ expression/NN of/IN transdominant/JJ Rev/NN protein/NN in/IN human/JJ T/NN cells/NNS inhibits/VBZ human/JJ immunodeficiency/NN virus/NN replication/NN ./. 
AB/LS -/: The/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) Rev/NN protein/NN is/VBZ essential/JJ for/IN viral/JJ structural/JJ protein/NN expression/NN (/( Gag/NN ,/, Pol/NN ,/, and/CC Env/NN )/) and/CC ,/, hence/RB ,/, for/IN viral/JJ replication/NN ./. 
In/IN transient/JJ transfection/NN assays/NNS ,/, mutant/JJ forms/NNS of/IN Rev/NN have/VBP been/VBN identified/VBN that/WDT inhibit/VBP wild-type/JJ Rev/NN activity/NN and/CC therefore/RB suppress/VBP viral/JJ replication/NN ./. 
To/TO determine/VB whether/IN such/JJ transdominant/JJ Rev/NN proteins/NNS could/MD provide/VB long-term/JJ protection/NN against/IN HIV/NN infection/NN without/IN affecting/VBG T/NN cell/NN function/NN ,/, T/NN leukemia/NN cell/NN lines/NNS were/VBD stably/RB transduced/VBN with/IN a/DT retroviral/JJ vector/NN encoding/VBG a/DT transdominant/JJ mutant/NN of/IN the/DT Rev/NN protein/NN ,/, M10/NN ./. 
While/IN all/PDT the/DT M10-expressing/JJ cell/NN lines/NNS remained/VBD infectable/JJ by/IN HIV-1/NN ,/, these/DT same/JJ cells/NNS failed/VBD to/TO support/VB a/DT productive/JJ replication/NN cycle/NN when/WRB infected/VBN with/IN a/DT cloned/VBN isolate/NN of/IN HIV-1/NN ./. 
In/IN addition/NN ,/, two/CD out/IN of/IN three/CD M10-expressing/JJ CEM/NN clones/NNS were/VBD also/RB resistant/JJ to/TO highly/RB productive/JJ infection/NN by/IN a/DT heterogeneous/JJ HIV-1/NN pool/NN ./. 
Expression/NN of/IN M10/NN did/VBD not/RB affect/VB induction/NN of/IN HIV/NN transcription/NN mediated/VBN by/IN the/DT kappa/NN B/NN regulatory/JJ element/NN or/CC Tat/NN ./. 
Importantly/RB ,/, constitutive/JJ expression/NN of/IN Rev/NN M10/NN did/VBD not/RB alter/VB the/DT secretion/NN of/IN interleukin/NN 2/CD in/IN response/NN to/TO mitogen/NN stimulation/NN of/IN EL-4/NN and/CC Jurkat/NN cells/NNS ./. 
The/DT inhibition/NN of/IN HIV/NN infection/NN in/IN cells/NNS stably/RB expressing/VBG a/DT transdominant/JJ Rev/NN protein/NN ,/, in/IN the/DT absence/NN of/IN any/DT deleterious/JJ effect/NN on/IN T/NN cell/NN function/NN ,/, suggests/VBZ that/IN such/PDT a/DT strategy/NN could/MD provide/VB a/DT therapeutic/JJ effect/NN in/IN the/DT T/NN lymphocytes/NNS of/IN acquired/VBN immunodeficiency/NN syndrome/NN patients/NNS ./. 
UI/LS -/: 92366521/CD 
TI/LS -/: Simple/JJ derivation/NN of/IN TFIID-dependent/JJ RNA/NN polymerase/NN II/CD transcription/NN systems/NNS from/IN Schizosaccharomyces/FW pombe/FW and/CC other/JJ organisms/NNS ,/, and/CC factors/NNS required/VBN for/IN transcriptional/JJ activation/NN ./. 
AB/LS -/: Resolution/NN of/IN whole/JJ cell/NN extract/NN through/IN two/CD chromatographic/JJ steps/NNS yields/VBZ a/DT single/JJ protein/NN fraction/NN requiring/VBG only/RB the/DT addition/NN of/IN TFIID/NN for/IN the/DT initiation/NN of/IN transcription/NN at/IN RNA/NN polymerase/NN II/CD promoters/NNS ./. 
This/DT approach/NN allows/VBZ the/DT convenient/JJ generation/NN of/IN RNA/NN polymerase/NN II/CD transcription/NN systems/NNS from/IN Saccharomyces/FW cerevisiae/FW ,/, human/JJ lymphocytes/NNS ,/, and/CC Schizosaccharomyces/FW pombe/FW ./. 
TFIIDs/NNS from/IN all/DT three/CD organisms/NNS are/VBP interchangeable/JJ among/IN all/DT three/CD systems/NNS ./. 
The/DT S./FW cerevisiae/FW and/CC Sch./FW pombe/FW systems/NNS support/VBP effects/NNS of/IN acidic/JJ activator/NN proteins/NNS ,/, provided/VBN a/DT further/JJ protein/NN fraction/NN from/IN S./FW cerevisiae/FW is/VBZ supplied/VBN ./. 
This/DT further/JJ fraction/NN is/VBZ distinct/JJ from/IN the/DT mediator/NN of/IN transcriptional/JJ activation/NN described/VBN previously/RB and/CC represents/VBZ a/DT second/JJ component/NN in/IN addition/NN to/TO general/JJ initiation/NN factors/NNS that/WDT may/MD facilitate/VB a/DT response/NN to/TO acidic/JJ activators/NNS ./. 
UI/LS -/: 93041372/CD 
TI/LS -/: Regulation/NN of/IN c-jun/NN expression/NN during/IN induction/NN of/IN monocytic/JJ differentiation/NN by/IN okadaic/JJ acid/NN ./. 
AB/LS -/: The/DT present/JJ work/NN has/VBZ examined/VBN the/DT effects/NNS of/IN okadaic/JJ acid/NN ,/, an/DT inhibitor/NN of/IN type/NN 1/CD and/CC 2A/NN protein/NN phosphatases/NNS ,/, on/IN the/DT regulation/NN of/IN c-jun/NN expression/NN during/IN monocytic/JJ differentiation/NN of/IN U-937/NN leukemia/NN cells/NNS ./. 
The/DT results/NNS demonstrate/VBP that/IN okadaic/JJ acid/NN treatment/NN is/VBZ associated/VBN with/IN induction/NN of/IN a/DT differentiated/VBN monocyte/NN phenotype/NN characterized/VBN by/IN :/: (/( a/LS )/) growth/NN arrest/NN ;/: (/( b/LS )/) increases/NNS in/IN Mac-1/NN cell/NN surface/NN antigen/NN expression/NN ;/: (/( c/LS )/) down-regulation/NN of/IN c-myc/NN transcripts/NNS ;/: and/CC (/( d/LS )/) induction/NN of/IN tumor/NN necrosis/NN factor/NN gene/NN expression/NN ./. 
This/DT induction/NN of/IN monocytic/JJ differentiation/NN was/VBD associated/VBN with/IN transient/JJ increases/NNS in/IN c-jun/NN mRNA/NN levels/NNS ,/, which/WDT were/VBD maximal/JJ at/IN 6/CD h/NN ./. 
Similar/JJ effects/NNS were/VBD obtained/VBN for/IN the/DT c-fos/NN gene/NN ./. 
Run-on/JJ analysis/NN demonstrated/VBD detectable/JJ levels/NNS of/IN c-jun/NN transcription/NN in/IN U-937/NN cells/NNS and/CC that/IN this/DT rate/NN is/VBZ increased/VBN approximately/RB 40-fold/RB following/VBG okadaic/JJ acid/NN exposure/NN ./. 
c-jun/NN mRNA/NN levels/NNS were/VBD superinduced/VBN in/IN cells/NNS treated/VBN with/IN both/CC okadaic/JJ acid/NN and/CC cycloheximide/NN ,/, whereas/IN inhibition/NN of/IN protein/NN synthesis/NN had/VBD little/JJ ,/, if/IN any/DT ,/, effect/NN on/IN okadaic/JJ acid-induced/JJ c-jun/NN transcription/NN ./. 
The/DT half-life/NN of/IN c-jun/NN mRNA/NN was/VBD similar/JJ (/( 45-50/CD min/NN )/) in/IN both/CC untreated/JJ and/CC okadaic/JJ acid-induced/JJ cells/NNS ./. 
In/IN contrast/NN ,/, treatment/NN with/IN both/DT okadaic/JJ acid/NN and/CC cycloheximide/NN was/VBD associated/VBN with/IN stabilization/NN (/( t/NN 1/2/CD =/JJ 90/CD min/NN )/) of/IN c-jun/NN transcripts/NNS ./. 
Taken/VBN together/RB ,/, these/DT findings/NNS indicate/VBP that/IN the/DT induction/NN of/IN c-jun/NN transcription/NN by/IN okadaic/JJ acid/NN is/VBZ controlled/VBN primarily/RB by/IN a/DT transcriptional/JJ mechanism/NN ./. 
Since/IN previous/JJ studies/NNS have/VBP demonstrated/VBN that/IN the/DT c-jun/NN gene/NN is/VBZ autoinduced/VBN by/IN Jun/AP-1/NN ,/, we/PRP also/RB studied/VBD transcription/NN of/IN c-jun/NN promoter/NN (/( positions/NNS -132/+170/CD )/) -reporter/JJ gene/NN constructs/NNS with/IN and/CC without/IN a/DT mutated/VBN AP-1/NN element/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 92378895/CD 
TI/LS -/: Mitogen/NN stimulation/NN of/IN T-cells/NNS increases/VBZ c-Fos/NN and/CC c-Jun/NN protein/NN levels/NNS ,/, AP-1/NN binding/NN and/CC AP-1/NN transcriptional/JJ activity/NN ./. 
AB/LS -/: We/PRP have/VBP analysed/VBN the/DT effect/NN of/IN mitogenic/JJ lectins/NNS on/IN c-Fos/NN and/CC c-Jun/NN protein/NN levels/NNS as/RB well/RB as/IN on/IN activator/NN protein-1/NN (/( AP-1/NN )/) binding/NN and/CC enhancer/NN activity/NN in/IN Jurkat/NN T-cells/NNS ./. 
Both/CC c-Fos/NN and/CC c-Jun/NN protein/NN levels/NNS were/VBD increased/VBN after/IN Con/NN A/NN and/CC PHA/NN stimulation/NN ./. 
Since/IN T-cell/NN stimulation/NN increases/VBZ both/CC intracellular/JJ Ca2+/NN and/CC cAMP/NN levels/NNS and/CC activates/VBZ protein/NN kinase/NN C/NN (/( PKC/NN )/) ,/, the/DT possible/JJ involvement/NN of/IN these/DT intracellular/JJ messengers/NNS in/IN c-Fos/NN and/CC c-Jun/NN induction/NN was/VBD tested/VBN ./. 
PMA/NN ,/, which/WDT directly/RB activates/VBZ PKC/NN ,/, mimicked/VBD the/DT effect/NN of/IN the/DT lectins/NNS on/IN c-Fos/NN and/CC c-Jun/NN ,/, but/CC elevation/NN of/IN either/CC intracellular/JJ Ca2+/NN or/CC cAMP/NN levels/NNS had/VBD little/JJ or/CC no/DT effect/NN ./. 
The/DT mitogen-induced/JJ increase/NN of/IN c-Fos/NN and/CC c-Jun/NN immunoreactivity/NN was/VBD inhibited/VBN by/IN H-7/NN ,/, a/DT kinase/NN inhibitor/NN with/IN relatively/RB high/JJ specificity/NN for/IN PKC/NN ,/, and/CC less/RBR efficiently/RB by/IN H-8/NN ,/, a/DT structurally/RB related/JJ kinase/NN inhibitor/NN less/RBR active/JJ on/IN PKC/NN ,/, but/CC more/RBR active/JJ on/IN cyclic/JJ nucleotide-dependent/JJ kinases/NNS ./. 
Con/NN A/NN stimulation/NN was/VBD found/VBN to/TO increase/VB both/CC binding/NN of/IN AP-1/NN to/TO the/DT AP-1/NN consensus/NN sequence/NN ,/, TRE/NN ,/, and/CC AP-1/NN enhancer/NN activity/NN ,/, in/IN Jurkat/NN cells/NNS ./. 
PMA/NN was/VBD also/RB found/VBN to/TO increase/VB the/DT AP-1/NN enhancer/NN activity/NN ,/, whereas/IN elevation/NN of/IN Ca2+/NN or/CC cAMP/NN had/VBD only/RB minor/JJ effects/NNS ./. 
We/PRP conclude/VBP that/IN stimulation/NN with/IN mitogenic/JJ lectins/NNS is/VBZ sufficient/JJ to/TO increase/VB both/CC c-Fos/NN and/CC c-Jun/NN protein/NN levels/NNS ,/, AP-1/NN binding/NN and/CC AP-1/NN enhancer/NN activity/NN in/IN Jurkat/NN cells/NNS and/CC that/IN they/PRP act/VBP via/IN mechanisms/NNS that/WDT could/MD involve/VB the/DT activation/NN of/IN PKC/NN ./. 
UI/LS -/: 92212930/CD 
TI/LS -/: An/DT 11-base-pair/JJ DNA/NN sequence/NN motif/NN apparently/RB unique/JJ to/TO the/DT human/JJ interleukin/NN 4/CD gene/NN confers/VBZ responsiveness/NN to/TO T-cell/NN activation/NN signals/NNS ./. 
AB/LS -/: We/PRP have/VBP identified/VBN a/DT DNA/NN segment/NN that/WDT confers/VBZ responsiveness/NN to/TO antigen/NN stimulation/NN signals/NNS on/IN the/DT human/JJ interleukin/NN (/( IL/NN )/) 4/CD gene/NN in/IN Jurkat/NN cells/NNS ./. 
The/DT human/JJ IL-4/NN gene/NN ,/, of/IN 10/CD kilobases/NNS ,/, is/VBZ composed/VBN of/IN four/CD exons/NNS and/CC three/CD introns/NNS ./. 
A/DT cis-acting/JJ element/NN (/( P/NN sequence/NN )/) resides/VBZ in/IN the/DT 5'/JJ upstream/JJ region/NN ;/: no/DT additional/JJ DNA/NN segments/NNS with/IN enhancer/NN activity/NN were/VBD identified/VBN in/IN the/DT human/JJ IL-4/NN gene/NN ./. 
For/IN further/JJ mapping/NN purposes/NNS ,/, a/DT fusion/NN promoter/NN was/VBD constructed/VBN with/IN the/DT granulocyte/macrophage/JJ colony-stimulating/JJ factor/NN basic/JJ promoter/NN containing/VBG 60/CD base/NN pairs/NNS of/IN sequence/NN upstream/JJ from/IN the/DT cap/NN site/NN of/IN the/DT mouse/NN granulocyte/macrophage/JJ colony-stimulating/JJ factor/NN gene/NN and/CC various/JJ lengths/NNS of/IN the/DT 5'/JJ upstream/JJ sequence/NN of/IN the/DT IL-4/NN gene/NN ./. 
The/DT P/NN sequence/NN was/VBD located/JJ between/IN positions/NNS -79/CD and/CC -69/CD relative/JJ to/TO the/DT transcription/NN start/NN site/NN of/IN the/DT human/JJ IL-4/NN gene/NN ,/, and/CC this/DT location/NN was/VBD confirmed/VBN by/IN base-substitution/NN mutations/NNS ./. 
The/DT plasmids/NNS carrying/VBG multiple/JJ copies/NNS of/IN the/DT P/NN sequence/NN showed/VBD higher/JJR responsiveness/NN to/TO the/DT stimulation/NN ./. 
The/DT binding/VBG protein/NN (/( s/NNS )/) that/WDT recognize/VBP the/DT P/NN sequence/NN of/IN the/DT IL-4/NN gene/NN were/VBD identified/VBN by/IN DNA-mobility-shift/JJ assays/NNS ./. 
The/DT binding/NN of/IN NF/NN (/( P/NN )/) (/( a/DT DNA/NN binding/NN protein/NN that/WDT specifically/RB recognizes/VBZ the/DT P/NN sequence/NN )/) to/TO the/DT P/NN sequence/NN was/VBD abolished/VBN when/WRB oligonucleotides/NNS carrying/VBG base/NN substitutions/NNS were/VBD used/VBN ,/, indicating/VBG that/IN the/DT NF/NN (/( P/NN )/) interaction/NN is/VBZ sequence-specific/JJ and/CC that/IN binding/NN specificity/NN of/IN the/DT protein/NN paralleled/VBD the/DT sequence/NN requirements/NNS for/IN IL-4/NN expression/NN in/FW vivo/FW ./. 
The/DT P/NN sequence/NN does/VBZ not/RB share/VB homology/NN with/IN the/DT 5'/JJ upstream/JJ sequence/NN of/IN the/DT IL-2/NN gene/NN ,/, even/RB though/IN surrounding/VBG sequences/NNS of/IN the/DT IL-4/NN gene/NN share/NN high/JJ homology/NN with/IN the/DT IL-2/NN gene/NN ./. 
We/PRP conclude/VBP that/IN a/DT different/JJ set/NN of/IN proteins/NNS recognize/VBP IL-2/NN and/CC IL-4/NN genes/NNS ./. 
UI/LS -/: 92207144/CD 
TI/LS -/: Leukotriene/NN B4/NN stimulates/VBZ c-fos/NN and/CC c-jun/NN gene/NN transcription/NN and/CC AP-1/NN binding/NN activity/NN in/IN human/JJ monocytes/NNS ./. 
AB/LS -/: We/PRP have/VBP examined/VBN the/DT effect/NN of/IN leukotriene/NN B4/NN (/( LTB4/NN )/) ,/, a/DT potent/JJ lipid/NN proinflammatory/JJ mediator/NN ,/, on/IN the/DT expression/NN of/IN the/DT proto-oncogenes/NNS c-jun/NN and/CC c-fos/NN ./. 
In/IN addition/NN ,/, we/PRP looked/VBD at/IN the/DT modulation/NN of/IN nuclear/JJ factors/NNS binding/VBG specifically/RB to/TO the/DT AP-1/NN element/NN after/IN LTB4/NN stimulation/NN ./. 
LTB4/NN increased/VBD the/DT expression/NN of/IN the/DT c-fos/NN gene/NN in/IN a/DT time-/NN and/CC concentration-dependent/JJ manner/NN ./. 
The/DT c-jun/NN mRNA/NN ,/, which/WDT is/VBZ constitutively/RB expressed/VBN in/IN human/JJ peripheral-blood/NN monocytes/NNS at/IN relatively/RB high/JJ levels/NNS ,/, was/VBD also/RB slightly/RB augmented/JJ by/IN LTB4/NN ,/, although/IN to/TO a/DT much/RB lower/JJR extent/NN than/IN c-fos/NN ./. 
The/DT kinetics/NNS of/IN expression/NN of/IN the/DT two/CD genes/NNS were/VBD also/RB slightly/RB different/JJ ,/, with/IN c-fos/NN mRNA/NN reaching/VBG a/DT peak/NN at/IN 15/CD min/NN after/IN stimulation/NN and/CC c-jun/NN at/IN 30/CD min/NN ./. 
Both/DT messages/NNS rapidly/RB declined/VBD thereafter/RB ./. 
Stability/NN of/IN the/DT c-fos/NN and/CC c-jun/NN mRNA/NN was/VBD not/RB affected/VBN by/IN LTB4/NN ,/, as/IN assessed/VBN after/IN actinomycin/NN D/NN treatment/NN ./. 
Nuclear/JJ transcription/NN studies/NNS in/FW vitro/FW showed/VBD that/IN LTB4/NN increased/VBD the/DT transcription/NN of/IN the/DT c-fos/NN gene/NN 7-fold/RB and/CC the/DT c-jun/NN gene/NN 1.4-fold/RB ./. 
Resting/VBG monocytes/NNS contained/VBD nuclear/JJ factors/NNS binding/VBG to/TO the/DT AP-1/NN element/NN ,/, but/CC stimulation/NN of/IN monocytes/NNS with/IN LTB4/NN induced/VBD greater/JJR AP-1-binding/JJ activity/NN of/IN nuclear/JJ proteins/NNS ./. 
These/DT results/NNS indicate/VBP that/IN LTB4/NN may/MD regulate/VB the/DT production/NN of/IN different/JJ cytokines/NNS by/IN modulating/VBG the/DT yield/NN and/or/CC the/DT function/NN of/IN transcription/NN factors/NNS such/JJ as/IN AP-1-binding/JJ proto-oncogene/NN products/NNS ./. 
UI/LS -/: 92195648/CD 
TI/LS -/: Modulation/NN of/IN normal/JJ erythroid/JJ differentiation/NN by/IN the/DT endogenous/JJ thyroid/NN hormone/NN and/CC retinoic/JJ acid/NN receptors/NNS :/: a/DT possible/JJ target/NN for/IN v-erbA/NN oncogene/NN action/NN ./. 
AB/LS -/: The/DT v-erbA/NN oncogene/NN ,/, a/DT mutated/VBN version/NN of/IN the/DT thyroid/NN hormone/NN receptor/NN alpha/NN (/( c-erbA/TR-alpha/NN )/) ,/, inhibits/VBZ erythroid/JJ differentiation/NN and/CC constitutively/RB represses/VBZ transcription/NN of/IN certain/JJ erythrocyte/NN genes/NNS ,/, suggesting/VBG a/DT normal/JJ function/NN of/IN the/DT proto-oncogene/NN c-erbA/NN in/IN erythropoiesis/NN ./. 
Here/RB we/PRP demonstrate/VBP that/IN the/DT endogenous/JJ thyroid/NN hormone/NN receptor/NN alpha/NN (/( c-erbA/TR-alpha/NN )/) and/CC the/DT closely/RB related/JJ retinoic/JJ acid/NN receptor/NN alpha/NN (/( RAR-alpha/NN )/) play/VBP a/DT role/NN in/IN the/DT regulation/NN of/IN normal/JJ erythroid/JJ differentiation/NN ./. 
Retinoic/JJ acid/NN (/( RA/NN )/) distinctly/RB modulated/VBD the/DT erythroid/JJ differentiation/NN program/NN of/IN normal/JJ erythroid/JJ progenitors/NNS and/CC erythroblasts/NNS reversibly/RB transformed/VBN by/IN a/DT conditional/JJ tyrosine/NN kinase/NN oncogene/NN ./. 
When/WRB added/VBN pulsewise/RB to/TO immature/JJ cells/NNS ,/, differentiation/NN was/VBD accelerated/VBN while/IN more/RBR mature/JJ cells/NNS underwent/VBD premature/JJ cell/NN death/NN ./. 
Thyroid/NN hormone/NN (/( T3/NN )/) alone/RB caused/VBD similar/JJ but/CC weaker/JJR effects/NNS ./. 
Interestingly/RB ,/, T3/NN strongly/RB enhanced/VBD the/DT action/NN of/IN RA/NN ,/, suggesting/VBG cooperative/JJ action/NN of/IN the/DT two/CD receptors/NNS in/IN modulating/VBG erythroid/JJ differentiation/NN ./. 
Expression/NN of/IN the/DT human/JJ RAR-alpha/NN in/IN receptor-negative/JJ erythroblasts/NNS conferred/VBD RA-induced/JJ regulation/NN of/IN differentiation/NN to/TO the/DT otherwise/RB unresponsive/JJ cells/NNS ,/, thus/RB showing/VBG that/IN the/DT RAR-alpha/NN is/VBZ essential/JJ for/IN the/DT RA/NN effect/NN ./. 
Likewise/RB ,/, enhanced/VBN expression/NN of/IN exogenous/JJ c-erbA/TR-alpha/NN in/IN erythroblasts/NNS rendered/VBD them/PRP susceptible/JJ to/TO modulation/NN of/IN differentiation/NN by/IN T3/NN ,/, suggesting/VBG a/DT similar/JJ function/NN of/IN both/DT receptors/NNS ./. 
UI/LS -/: 93150054/CD 
TI/LS -/: Activation/NN of/IN lymphokine/NN genes/NNS in/IN T/NN cells/NNS :/: role/NN of/IN cis-acting/JJ DNA/NN elements/NNS that/WDT respond/VBP to/TO T/NN cell/NN activation/NN signals/NNS ./. 
AB/LS -/: Activation/NN of/IN T/NN cells/NNS is/VBZ initiated/VBN by/IN the/DT recognition/NN of/IN antigen/NN on/IN antigen/NN presenting/NN cells/NNS to/TO exert/VB the/DT effector/NN functions/NNS in/IN immune/JJ and/CC inflammatory/JJ responses/NNS ./. 
Two/CD types/NNS of/IN helper/NN T/NN cell/NN (/( Th/NN )/) clones/NNS (/( Th1/NN and/CC Th2/NN )/) are/VBP defined/VBN on/IN the/DT basis/NN of/IN different/JJ patterns/NNS of/IN cytokine/NN (/( lymphokine/NN )/) secretion/NN ./. 
They/PRP determine/VBP the/DT outcome/NN of/IN an/DT antigenic/JJ response/NN toward/IN humoral/JJ or/CC cell-mediated/JJ immunity/NN ./. 
Although/IN lymphokine/NN genes/NNS are/VBP coordinately/RB regulated/VBN upon/IN antigen/NN stimulation/NN ,/, they/PRP are/VBP regulated/VBN by/IN the/DT mechanisms/NNS common/JJ to/TO all/DT as/RB well/RB as/IN those/DT which/WDT are/VBP unique/JJ to/TO each/DT gene/NN ./. 
For/IN most/JJS lymphokine/NN genes/NNS ,/, a/DT combination/NN of/IN phorbol/NN esters/NNS (/( phorbol/NN 12-myristate/NN 13/CD acetate/NN ,/, PMA/NN )/) and/CC calcium/NN ionophores/NNS (/( A23187/NN )/) is/VBZ required/VBN for/IN their/PRP$ maximal/JJ induction/NN ./. 
Yet/RB phorbol/NN ester/NN alone/RB or/CC calcium/NN ionophore/NN alone/RB produce/VBP several/JJ lymphokines/NNS ./. 
The/DT production/NN of/IN the/DT granulocyte-macrophage/JJ colony/NN stimulating/NN factor/NN (/( GM-CSF/NN )/) is/VBZ completely/RB dependent/JJ on/IN the/DT two/CD signals/NNS ./. 
We/PRP have/VBP previously/RB found/VBN a/DT cis-acting/JJ region/NN spanning/VBG the/DT GM-CSF/NN promoter/NN region/NN (/( positions/NNS -95/CD to/TO +27/CD )/) that/WDT confers/VBZ inducibility/NN to/TO reporter/NN genes/NNS in/IN transient/JJ transfection/NN assays/NNS ./. 
Further/JJ analysis/NN identified/VBD three/CD elements/NNS required/VBN for/IN efficient/JJ induction/NN ,/, referred/VBN to/TO as/IN GM2/NN ,/, GC-box/NN and/CC conserved/VBN lymphokine/NN element/NN (/( CLE0/NN )/) ./. 
GM2/NN defines/VBZ a/DT binding/VBG site/NN for/IN protein/NN (/( s/NNS )/) whose/WP$ binding/NN is/VBZ inducible/JJ by/IN PMA/NN ./. 
One/CD protein/NN ,/, NF-GM2/NN is/VBZ similar/JJ to/TO the/DT transcription/NN factor/NN NF-kB/NN ./. 
GC-box/NN is/VBZ a/DT binding/VBG site/NN for/IN constitutively/RB bound/VBN proteins/NNS ./. 
CLEO/NN defines/VBZ a/DT binding/VBG site/NN for/IN protein/NN (/( s/NNS )/) whose/WP$ optimum/NN binding/NN is/VBZ stimulated/VBN by/IN PMA/NN and/CC A23187/NN ./. 
Viral/JJ trans-activators/NNS such/JJ as/IN Tax/NN (/( human/JJ T/NN cell/NN leukemia/NN virus-1/NN ,/, HTLV-1/NN )/) and/CC E2/NN (/( bovine/JJ papilloma/NN virus/NN ,/, BPV/NN )/) proteins/NNS are/VBP other/JJ agents/NNS which/WDT activate/VBP lymphokine/NN gene/NN expression/NN by/IN bypassing/VBG T/NN cell/NN receptor/NN (/( TCR/NN )/) mediated/JJ signaling/NN ./. 
The/DT trans-activation/NN domain/NN of/IN E2/NN and/CC Tax/NN is/VBZ interchangeable/JJ although/IN they/PRP have/VBP no/DT obvious/JJ sequence/NN homology/NN between/IN them/PRP ./. 
The/DT viral/JJ trans-activators/NNS appear/VBP to/TO target/VB specific/JJ DNA/NN binding/NN protein/NN such/JJ as/IN NF-kB/NN and/CC Sp1/NN to/TO cis-acting/JJ DNA/NN site/NN and/CC promote/VB lymphokine/NN gene/NN expression/NN without/IN TCR-mediated/JJ stimulation/NN ./. 
UI/LS -/: 93112057/CD 
TI/LS -/: Mutations/NNS in/IN the/DT Pit-1/NN gene/NN in/IN children/NNS with/IN combined/JJ pituitary/JJ hormone/NN deficiency/NN ./. 
AB/LS -/: Pit-1/NN is/VBZ a/DT pituitary-specific/JJ transcription/NN factor/NN that/WDT binds/VBZ to/TO and/CC transactivates/VBZ promoters/NNS of/IN growth/NN hormone/NN and/CC prolactin/NN genes/NNS ./. 
In/IN three/CD unrelated/JJ Japanese/JJ children/NNS with/IN combined/JJ pituitary/JJ hormone/NN deficiency/NN ,/, we/PRP identified/VBD three/CD point/NN mutations/NNS in/IN the/DT Pit-1/NN gene/NN ,/, Pro24Leu/NN ,/, Arg143Gln/NN ,/, and/CC Arg271Trp/NN ,/, located/JJ on/IN the/DT major/JJ transactivation/NN region/NN ,/, POU-specific/JJ domain/NN ,/, and/CC POU-homeodomain/NN ,/, respectively/RB ./. 
UI/LS -/: 93114357/CD 
TI/LS -/: Activation/NN of/IN protein/NN kinase/NN C/NN and/CC elevation/NN of/IN cAMP/NN interact/VBP synergistically/RB to/TO raise/VB c-Fos/NN and/CC AP-1/NN activity/NN in/IN Jurkat/NN cells/NNS ./. 
AB/LS -/: We/PRP have/VBP earlier/RBR found/VBN that/IN in/IN Jurkat/NN cells/NNS activation/NN of/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) enhances/VBZ the/DT cyclic/JJ adenosine/NN monophosphate/NN (/( cAMP/NN )/) accumulation/NN induced/VBN by/IN adenosine/NN receptor/NN stimulation/NN or/CC activation/NN of/IN Gs/NN ./. 
Here/RB we/PRP have/VBP therefore/RB examined/VBN the/DT effect/NN of/IN the/DT phorbol/NN ester/NN PMA/NN (/( phorbol/NN 12-myristate/NN 13-acetate/NN )/) which/WDT stimulates/VBZ PKC/NN and/CC a/DT combination/NN of/IN the/DT adenosine/NN receptor/NN agonist/NN NECA/NN (/( 5'-(N-ethyl)-carboxamido/JJ|NN adenosine/NN )/) and/CC forskolin/NN to/TO raise/VB cAMP/NN ,/, on/IN the/DT levels/NNS of/IN c-Fos/NN and/CC Jun/NN and/CC on/IN the/DT binding/VBG and/CC transcriptional/JJ activity/NN of/IN the/DT transcription/NN factor/NN ,/, activator/NN protein-1/NN (/( AP-1/NN )/) ./. 
PMA/NN treatment/NN caused/VBD a/DT concentration-/NN and/CC time-dependent/JJ increase/NN in/IN both/CC c-Fos/NN and/CC Jun/NN immunoreactivity/NN in/IN contrast/NN to/TO cAMP/NN elevation/NN that/WDT had/VBD only/RB a/DT slight/JJ effect/NN ./. 
Both/CC PMA/NN and/CC the/DT combination/NN of/IN NECA/NN and/CC forskolin/NN acted/VBD together/RB either/CC to/TO increase/VB (/( c-Fos/NN )/) or/CC decrease/VB (/( Jun/NN )/) protein/NN levels/NNS as/RB well/RB as/IN increasing/VBG AP-1/NN binding/NN ,/, as/IN judged/VBN by/IN gel-shift/NN assay/NN ,/, and/CC AP-1/NN transcriptional/JJ activity/NN ./. 
Furthermore/RB there/EX was/VBD a/DT clear-cut/JJ synergy/NN between/IN the/DT PKC/NN stimulator/NN and/CC the/DT cAMP/NN elevating/NN agents/NNS ./. 
The/DT results/NNS demonstrate/VBP that/IN the/DT simultaneous/JJ activation/NN of/IN PKC/NN and/CC elevation/NN of/IN cAMP/NN leads/VBZ to/TO an/DT enhanced/VBN AP-1/NN transcriptional/JJ activity/NN in/IN a/DT T-leukemia/NN cell/NN line/NN ,/, suggesting/VBG that/IN the/DT previously/RB observed/VBN interaction/NN between/IN the/DT parallel/JJ signal/NN transduction/NN pathways/NNS may/MD have/VB functional/JJ consequences/NNS at/IN the/DT level/NN of/IN gene/NN transcription/NN ./. 
UI/LS -/: 93105477/CD 
TI/LS -/: Inhibition/NN of/IN anti-CD3/JJ monoclonal/JJ antibody-induced/JJ T-cell/NN proliferation/NN by/IN dexamethasone/NN ,/, isoproterenol/NN ,/, or/CC prostaglandin/NN E2/NN either/CC alone/RB or/CC in/IN combination/NN ./. 
AB/LS -/: 1/LS ./. 
The/DT purpose/NN of/IN these/DT studies/NNS was/VBD to/TO investigate/VB the/DT modulation/NN of/IN the/DT proliferation/NN of/IN human/JJ T/NN cells/NNS obtained/VBN from/IN peripheral/JJ blood/NN by/IN dexamethasone/NN (/( DEX/NN )/) ,/, isoproterenol/NN (/( ISO/NN )/) ,/, and/CC prostaglandin/NN E2/NN (/( PGE2/NN )/) ./. 
The/DT former/JJ two/CD substances/NNS interact/VBP with/IN T/NN cells/NNS via/IN the/DT glucocorticoid/NN and/CC beta-adrenergic/JJ receptors/NNS respectively/RB ./. 
When/WRB occupied/VBN by/IN their/PRP$ natural/JJ ligands/NNS ,/, glucocorticosteroids/NNS and/CC catecholamines/NNS ,/, these/DT receptors/NNS have/VBP a/DT role/NN in/IN modulating/VBG T-cell/NN function/NN during/IN stress/NN ./. 
During/IN the/DT inflammatory/JJ response/NN increased/VBN levels/NNS of/IN PGE2/NN bind/VBP to/TO their/PRP$ receptors/NNS on/IN T/NN cells/NNS and/CC thus/RB alter/VBP responsiveness/NN ./. 
Proliferation/NN of/IN T/NN cells/NNS was/VBD induced/VBN by/IN immobilized/VBN anti-CD3/JJ monoclonal/JJ antibody/NN (/( mAb/NN )/) in/IN the/DT presence/NN or/CC absence/NN of/IN an/DT additional/JJ costimulatory/JJ signal/NN delivered/VBN by/IN anti-CD28/JJ mAb/NN ./. 
2/LS ./. 
Various/JJ physiologic/JJ concentrations/NNS of/IN DEX/NN ,/, ISO/NN ,/, or/CC PGE2/NN were/VBD added/VBN at/IN the/DT time/NN of/IN initiation/NN of/IN the/DT cultures/NNS and/CC subsequent/JJ proliferation/NN of/IN the/DT unstimulated/JJ T/NN cells/NNS was/VBD determined/VBN ./. 
The/DT results/NNS demonstrate/VBP that/IN physiologic/JJ concentrations/NNS of/IN all/DT three/CD of/IN these/DT agents/NNS inhibit/VBP the/DT anti-CD3/JJ mAb-induced/JJ proliferation/NN of/IN T/NN cells/NNS ./. 
3/LS ./. 
Although/IN DEX/NN and/CC PGE2/NN were/VBD equipotent/JJ in/IN suppressing/JJ T-cell/NN proliferation/NN ,/, ISO/NN was/VBD much/RB less/RBR effective/JJ ./. 
4/LS ./. 
Because/IN concomitant/JJ elevations/NNS in/IN the/DT peripheral/JJ levels/NNS of/IN these/DT substances/NNS may/MD occur/VB ,/, experiments/NNS were/VBD performed/VBN to/TO determine/VB the/DT T-cell/NN inhibitory/JJ effects/NNS of/IN DEX/NN together/RB with/IN either/CC PGE2/NN or/CC ISO/NN ./. 
Synergistic/JJ suppression/NN of/IN T-cell/NN proliferation/NN was/VBD observed/VBN when/WRB various/JJ concentrations/NNS of/IN DEX/NN and/CC PGE2/NN ,/, but/CC not/RB DEX/NN and/CC ISO/NN ,/, were/VBD added/VBN to/TO cultures/NNS ./. 
This/DT synergistic/JJ suppression/NN could/MD not/RB be/VB explained/VBN by/IN an/DT increase/NN in/IN cAMP/NN accumulation/NN in/IN T/NN cells/NNS stimulated/VBN with/IN DEX/NN and/CC PGE2/NN ./. 
5/LS ./. 
Finally/RB ,/, the/DT addition/NN of/IN anti-CD28/JJ mAb/NN to/TO anti-CD3/JJ mAb-stimulated/JJ T/NN cells/NNS overcame/VBD much/JJ of/IN the/DT suppression/NN of/IN proliferation/NN induced/VBN by/IN PGE2/NN or/CC ISO/NN but/CC less/RBR so/RB than/IN that/DT induced/VBN by/IN DEX/NN ./. 
UI/LS -/: 92366509/CD 
TI/LS -/: In/FW vivo/FW footprint/NN analysis/NN of/IN the/DT HLA-DRA/NN gene/NN promoter/NN :/: cell-specific/JJ interaction/NN at/IN the/DT octamer/NN site/NN and/CC up-regulation/NN of/IN X/NN box/NN binding/NN by/IN interferon/NN gamma/NN ./. 
AB/LS -/: Analysis/NN of/IN the/DT major/JJ histocompatibility/NN complex/NN class/NN II/CD gene/NN promoter/NN DRA/NN has/VBZ previously/RB identified/VBN at/IN least/JJS five/CD cis-acting/JJ regions/NNS required/VBN for/IN maximal/JJ expression/NN ./. 
We/PRP have/VBP examined/VBN the/DT DRA/NN promoter/NN for/IN protein-DNA/JJ interactions/NNS in/IN the/DT intact/JJ cell/NN ,/, which/WDT may/MD mediate/VB transcriptional/JJ activation/NN ./. 
Using/VBG in/FW vivo/FW genomic/JJ footprinting/NN we/PRP identified/VBD interactions/NNS in/IN B-cell/NN lines/NNS at/IN the/DT octamer/NN site/NN and/CC the/DT Y/NN ,/, X1/NN ,/, and/CC X2/NN boxes/NNS ./. 
Class/NN II/CD antigen/NN expressing/VBG T-cell/NN lines/NNS maintained/VBD contacts/NNS identical/JJ to/TO B-cell/NN lines/NNS ,/, while/IN class/NN II-negative/JJ T-cell/NN lines/NNS exhibited/VBD no/DT interactions/NNS ./. 
In/IN lymphoid/JJ cell/NN lines/NNS ,/, the/DT octamer/NN site/NN is/VBZ occupied/VBN and/CC required/VBN for/IN maximal/JJ expression/NN ./. 
This/DT is/VBZ most/RBS likely/RB due/JJ to/TO the/DT presence/NN of/IN the/DT lymphoid-specific/JJ OTF-2/NN factor/NN ./. 
In/IN contrast/NN ,/, the/DT class/NN II-positive/JJ nonlymphoid/JJ glioblastoma/NN cell/NN line/NN does/VBZ not/RB exhibit/VB interactions/NNS at/IN the/DT octamer/NN site/NN despite/IN the/DT presence/NN of/IN the/DT ubiquitous/JJ OTF-1/NN factor/NN and/CC an/DT open/JJ binding/VBG site/NN ./. 
Thus/RB ,/, the/DT DRA/NN promoter/NN discriminates/VBZ against/IN OTF-1/NN activation/NN at/IN the/DT level/NN of/IN DNA/NN binding/NN in/IN the/DT glioblastoma/NN line/NN ./. 
Interferon/NN gamma/NN induces/VBZ class/NN II/CD expression/NN in/IN this/DT glioblastoma/NN cell/NN line/NN and/CC ,/, in/IN parallel/NN ,/, up-regulates/VBZ X1/NN and/CC X2/NN box/NN protein-DNA/JJ interactions/NNS ,/, while/IN all/DT other/JJ interactions/NNS remain/VBP unchanged/JJ ./. 
These/DT results/NNS suggest/VBP that/IN interferon/NN gamma/NN functions/VBZ on/IN a/DT poised/VBN promoter/NN by/IN altering/VBG weak/JJ ,/, nonproductive/JJ interactions/NNS at/IN the/DT X/NN boxes/NNS to/TO strong/JJ interactions/NNS ./. 
These/DT findings/NNS provide/VBP direct/JJ in/FW vivo/FW evidence/NN to/TO strongly/RB suggest/VB that/IN the/DT modulation/NN of/IN X1/NN and/CC X2/NN interactions/NNS is/VBZ an/DT important/JJ constituent/NN of/IN the/DT interferon/NN gamma/NN induction/NN pathway/NN ./. 
UI/LS -/: 93012816/CD 
TI/LS -/: Estrogen/NN binding/NN sites/NNS in/IN peripheral/JJ blood/NN monocytes/NNS and/CC effects/NNS of/IN danazol/NN on/IN their/PRP$ sites/NNS in/FW vitro/FW ./. 
AB/LS -/: 1/LS ./. 
This/DT study/NN was/VBD designed/VBN to/TO investigate/VB the/DT presence/NN of/IN estrogen/NN type/NN I/CD (/( high/JJ affinity/NN ,/, low/JJ capacity/NN )/) and/CC type/NN II/CD (/( low/JJ affinity/NN ,/, high/JJ capacity/NN )/) binding/NN sites/NNS in/IN human/JJ peripheral/JJ blood/NN monocytes/NNS and/CC the/DT effects/NNS of/IN danazol/NN on/IN these/DT sites/NNS ./. 
2/LS ./. 
These/DT two/CD types/NNS of/IN estrogen/NN binding/NN sites/NNS existed/VBD in/IN human/JJ peripheral/JJ blood/NN monocytes/NNS ./. 
3/LS ./. 
Danazol/NN bound/VBD to/TO these/DT sites/NNS in/IN high/JJ concentration/NN (/( 10/CD (/( -6/CD )/) M/NN ,/, clinical/JJ serum/NN concentration/NN during/IN danazol/NN therapy/NN )/) and/CC decreased/VBD the/DT number/NN of/IN both/DT sites/NNS ./. 
4/LS ./. 
It/PRP is/VBZ suggested/VBN that/IN danazol/NN has/VBZ an/DT anti-estrogenic/JJ action/NN to/TO the/DT monocytes/NNS through/IN the/DT competition/NN and/CC suppression/NN of/IN estrogen/NN binding/NN sites/NNS as/IN seen/VBN in/IN the/DT estrogen/NN target/NN organ/NN ./. 
UI/LS -/: 93030402/CD 
TI/LS -/: A/DT microtitre/NN assay/NN system/NN for/IN glucocorticoid/NN receptors/NNS :/: decreased/VBN receptor/NN concentration/NN in/IN myocardial/JJ infarction/NN ./. 
AB/LS -/: A/DT major/JJ difficulty/NN in/IN determination/NN of/IN glucocorticoid/NN receptor/NN sites/NNS is/VBZ the/DT very/RB complicated/JJ assay/NN procedure/NN ./. 
Therefore/RB ,/, we/PRP describe/VBP a/DT microtitre/NN assay/NN system/NN for/IN glucocorticoid/NN receptors/NNS which/WDT is/VBZ a/DT whole-cell/JJ competitive/JJ binding/NN radioassay/NN using/VBG [3H]-dexamethasone/NN as/IN radioligand/NN ./. 
This/DT modification/NN of/IN a/DT previously/RB described/VBN protocol/NN simplifies/VBZ and/CC reduces/VBZ laboratory/NN work/NN and/CC allows/VBZ assay/NN reproducibility/NN to/TO be/VB controlled/VBN more/RBR reliably/RB ./. 
Thus/RB enabled/VBN to/TO perform/VB the/DT test/NN on/IN multiple/JJ blood/NN samples/NNS in/IN parallel/NN ,/, we/PRP investigated/VBD cardiac/JJ infarction/NN patients/NNS over/IN a/DT 12-day/JJ period/NN to/TO test/VB if/IN glucocorticoid/NN receptor/NN binding/NN is/VBZ altered/VBN in/IN this/DT '/`` stressful/JJ '/'' disease/NN ./. 
On/IN the/DT first/JJ day/NN of/IN the/DT disease/NN ,/, glucocorticoid/NN receptor/NN capacity/NN was/VBD significantly/RB decreased/VBN without/IN alteration/NN of/IN the/DT receptor-ligand/JJ affinity/NN ,/, whereas/IN on/IN days/NNS 4/CD and/CC 12/CD the/DT number/NN of/IN receptor/NN sites/NNS was/VBD normal/JJ again/RB ./. 
This/DT result/NN fits/VBZ well/RB into/IN the/DT general/JJ observation/NN of/IN stress-induced/JJ down-regulation/NN of/IN immune/JJ responses/NNS ./. 
UI/LS -/: 92368408/CD 
TI/LS -/: SRC-related/JJ proto-oncogenes/NNS and/CC transcription/NN factors/NNS in/IN primary/JJ human/JJ T/NN cells/NNS :/: modulation/NN by/IN cyclosporin/NN A/NN and/CC FK506/NN ./. 
AB/LS -/: Activation/NN of/IN T/NN lymphocytes/NNS induces/VBZ transcription/NN of/IN genes/NNS encoding/VBG for/IN lymphokines/NNS ./. 
Interleukin-2/NN (/( IL-2/NN )/) gene/NN expression/NN is/VBZ controlled/VBN transcriptionally/RB by/IN the/DT cooperative/JJ activity/NN of/IN specific/JJ trans-activating/JJ factors/NNS that/WDT bind/VBP to/TO the/DT IL-2/NN enhancer/NN ./. 
Cyclosporin/NN A/NN (/( CsA/NN )/) and/CC FK506/NN inhibit/VBP the/DT production/NN of/IN IL-2/NN in/IN T/NN lymphocytes/NNS at/IN the/DT level/NN of/IN gene/NN transcription/NN ./. 
A/DT member/NN of/IN the/DT src/NN gene/NN family/NN ,/, the/DT lymphocyte-specific/JJ protein/NN tyrosine/NN kinase/NN ,/, p56lck/NN ,/, has/VBZ been/VBN implicated/VBN in/IN IL-2/NN production/NN ./. 
CsA/NN was/VBD found/VBN not/RB to/TO inhibit/VB lck/NN gene/NN expression/NN ,/, nor/CC the/DT activity/NN of/IN the/DT lck/NN gene/NN product/NN ./. 
However/RB ,/, CsA/NN and/CC FK506/NN inhibit/VBP the/DT appearance/NN of/IN DNA/NN binding/NN activity/NN of/IN factors/NNS that/WDT bind/VBP to/TO the/DT NF-AT/NN and/CC AP-1/NN sites/NNS in/IN the/DT IL-2/NN enhancer/NN ./. 
Since/IN the/DT induction/NN of/IN NF-AT/NN and/CC AP-1/NN is/VBZ induced/VBN by/IN the/DT same/JJ stimuli/NNS that/WDT stimulate/VBP IL-2/NN production/NN ,/, these/DT results/NNS indicate/VBP that/IN the/DT immunosuppressant/JJ action/NN of/IN CsA/NN and/CC FK506/NN is/VBZ exerted/VBN at/IN the/DT level/NN of/IN these/DT trans-activating/JJ factors/NNS ./. 
UI/LS -/: 92156807/CD 
TI/LS -/: The/DT AP-1/NN site/NN at/IN -150/CD bp/NN ,/, but/CC not/RB the/DT NF-kappa/NN B/NN site/NN ,/, is/VBZ likely/JJ to/TO represent/VB the/DT major/JJ target/NN of/IN protein/NN kinase/NN C/NN in/IN the/DT interleukin/NN 2/CD promoter/NN ./. 
AB/LS -/: Stimulation/NN of/IN T/NN cells/NNS with/IN antigen/NN results/VBZ in/IN activation/NN of/IN several/JJ kinases/NNS ,/, including/VBG protein/NN kinase/NN C/NN (/( PKC/NN )/) ,/, that/WDT may/MD mediate/VB the/DT later/JJ induction/NN of/IN activation-related/JJ genes/NNS ./. 
We/PRP have/VBP examined/VBN the/DT potential/JJ role/NN of/IN PKC/NN in/IN induction/NN of/IN the/DT interleukin/NN 2/CD (/( IL-2/NN )/) gene/NN in/IN T/NN cells/NNS stimulated/VBN through/IN the/DT T/NN cell/NN receptor/CD3/NN complex/NN ./. 
We/PRP have/VBP previously/RB shown/VBN that/IN prolonged/JJ treatment/NN of/IN the/DT untransformed/JJ T/NN cell/NN clone/NN Ar-5/NN with/IN phorbol/NN esters/NNS results/VBZ in/IN downmodulation/NN of/IN the/DT alpha/NN and/CC beta/NN isozymes/NNS of/IN PKC/NN ,/, and/CC abrogates/VBZ induction/NN of/IN IL-2/NN mRNA/NN and/CC protein/NN ./. 
Here/RB we/PRP show/VBP that/IN phorbol/NN ester/NN treatment/NN also/RB abolishes/VBZ induction/NN of/IN chloramphenicol/JJ acetyltransferase/NN activity/NN in/IN Ar-5/NN cells/NNS transfected/VBN with/IN a/DT plasmid/NN containing/VBG the/DT IL-2/NN promoter/NN linked/VBN to/TO this/DT reporter/NN gene/NN ./. 
The/DT IL-2/NN promoter/NN contains/VBZ binding/VBG sites/NNS for/IN nuclear/JJ factors/NNS including/VBG NFAT-1/NN ,/, Oct/NN ,/, NF-kappa/NN B/NN ,/, and/CC AP-1/NN ,/, which/WDT are/VBP all/DT potentially/RB sensitive/JJ to/TO activation/NN of/IN PKC/NN ./. 
We/PRP show/VBP that/IN induction/NN of/IN a/DT trimer/NN of/IN the/DT NFAT/NN and/CC Oct/NN sites/NNS is/VBZ not/RB sensitive/JJ to/TO phorbol/NN ester/NN treatment/NN ,/, and/CC that/IN mutations/NNS in/IN the/DT NF-kappa/NN B/NN site/NN have/VBP no/DT effect/NN on/IN inducibility/NN of/IN the/DT IL-2/NN promoter/NN ./. 
In/IN contrast/NN ,/, mutations/NNS in/IN the/DT AP-1/NN site/NN located/JJ at/IN -150/CD bp/NN almost/RB completely/RB abrogate/VBP induction/NN of/IN the/DT IL-2/NN promoter/NN ,/, and/CC appearance/NN of/IN an/DT inducible/JJ nuclear/JJ factor/NN binding/VBG to/TO this/DT site/NN is/VBZ sensitive/JJ to/TO PKC/NN depletion/NN ./. 
Moreover/RB ,/, cotransfections/NNS with/IN c-fos/NN and/CC c-jun/NN expression/NN plasmids/NNS markedly/RB enhance/VBP induction/NN of/IN the/DT IL-2/NN promoter/NN in/IN minimally/RB stimulated/VBN T/NN cells/NNS ./. 
Our/PRP$ results/NNS indicate/VBP that/IN the/DT AP-1/NN site/NN at/IN -150/CD bp/NN represents/VBZ a/DT major/JJ ,/, if/IN not/RB the/DT only/JJ ,/, site/NN of/IN PKC/NN responsiveness/NN in/IN the/DT IL-2/NN promoter/NN ./. 
UI/LS -/: 92408125/CD 
TI/LS -/: [/( Effect/NN of/IN antihypertensive/JJ therapy/NN with/IN captopril/NN on/IN gluco-/JJ and/CC mineralocorticoid/NN receptors/NNS of/IN peripheral/JJ blood/NN lymphocytes/NNS in/IN hypertensive/JJ patients/NNS of/IN various/JJ age/NN ]/) 
AB/LS -/: Binding/NN of/IN 3H-dexamethasone/NN and/CC 3H-aldosterone/NN by/IN peripheral/JJ lymphocyte/NN receptors/NNS was/VBD investigated/VBN in/IN healthy/JJ persons/NNS and/CC hypertensive/JJ patients/NNS before/IN and/CC after/IN 2-week/JJ captopril/NN treatment/NN ./. 
The/DT number/NN of/IN glucocorticoid/NN and/CC mineralocorticoid/NN binding/NN sites/NNS was/VBD increased/VBN in/IN hypertensives/NNS vs/CC normotensives/NNS ./. 
The/DT treatment/NN with/IN the/DT ACE/NN inhibitor/NN captopril/NN led/VBD to/TO activation/NN of/IN hormone-receptor/NN interactions/NNS ./. 
There/EX was/VBD a/DT more/RBR marked/JJ rise/NN of/IN the/DT number/NN of/IN receptors/NNS in/IN middle-aged/JJ (/( 44-55/CD years/NNS )/) hypertensives/NNS vs/CC elderly/JJ (/( 61-80/CD years/NNS )/) subjects/NNS after/IN captopril/NN treatment/NN ./. 
UI/LS -/: 93121695/CD 
TI/LS -/: The/DT use/NN of/IN interferon-gamma-treated/JJ U937/NN cells/NNS in/IN chemiluminescence/NN assays/NNS to/TO detect/VB red/JJ cell/NN ,/, platelet/NN and/CC granulocyte/NN antibodies/NNS of/IN potential/JJ clinical/JJ significance/NN ./. 
AB/LS -/: The/DT chemiluminescent/JJ (/( CL/JJ )/) response/NN of/IN interferon-gamma-treated/JJ U937/NN (/( IFN-U937/NN )/) cells/NNS to/TO sensitized/VBN target/NN cells/NNS has/VBZ been/VBN used/VBN to/TO detect/VB red/JJ cell/NN ,/, platelet/NN and/CC granulocyte/NN antibodies/NNS ./. 
A/DT clone/NN of/IN U937/NN cells/NNS was/VBD selected/VBN which/WDT expressed/VBD Fc/NN receptor/NN I/NN (/( Fc/NN gamma/NN RI/NN )/) and/CC which/WDT ,/, after/IN incubation/NN with/IN IFN-gamma/NN for/IN 72/CD h/NN ,/, was/VBD capable/JJ of/IN generating/VBG high/JJ levels/NNS of/IN lucigenin-enhanced/JJ CL/NN ./. 
The/DT CL/NN responses/NNS of/IN IFN-U937/NN cells/NNS and/CC peripheral/JJ blood/NN human/JJ monocytes/NNS to/TO sensitized/VBN red/JJ cells/NNS ,/, platelets/NNS or/CC granulocytes/NNS were/VBD then/RB compared/VBN ./. 
Assays/NNS using/VBG monocytes/NNS or/CC IFN-U937/NN cells/NNS were/VBD of/IN comparable/JJ sensitivity/NN for/IN detection/NN of/IN antibodies/NNS against/IN all/DT three/CD types/NNS of/IN target/NN cell/NN ./. 
In/IN addition/NN ,/, the/DT use/NN of/IN IFN-U937/NN cells/NNS reduced/VBD interassay/JJ variation/NN and/CC simplified/VBD|VBN assay/NN performance/NN ./. 
The/DT potential/JJ clinical/JJ usefulness/NN of/IN these/DT CL/NN assays/NNS was/VBD suggested/VBN by/IN the/DT ability/NN of/IN both/CC monocytes/NNS and/CC IFN-U937/NN cells/NNS to/TO respond/VB to/TO red/JJ cells/NNS ,/, platelets/NNS or/CC granulocytes/NNS sensitized/VBN with/IN sera/NN from/IN pregnant/JJ women/NNS whose/WP$ babies/NNS had/VBD either/CC haemolytic/JJ disease/NN of/IN the/DT newborn/JJ (/( HDN/NN )/) ,/, alloimmune/JJ thrombocytopenia/NN or/CC alloimmune/JJ neutropenia/NN respectively/RB ./. 
In/IN addition/NN ,/, monocytes/NNS and/CC IFN-U937/NN cells/NNS both/DT responded/VBD to/TO red/JJ cells/NNS sensitized/VBN with/IN antibodies/NNS against/IN a/DT variety/NN of/IN specificities/NNS of/IN assumed/VBN (/( although/IN not/RB documented/VBN )/) clinical/JJ significance/NN for/IN blood/NN transfusion/NN recipients/NNS ./. 
In/IN contrast/NN ,/, monocytes/NNS and/CC IFN-U937/NN cells/NNS responded/VBD only/RB weakly/RB to/TO red/JJ cells/NNS sensitized/VBN with/IN either/CC anti-D/JJ in/IN sera/NN from/IN mothers/NNS of/IN babies/NNS unaffected/JJ by/IN HDN/NN ,/, or/CC with/IN antisera/NNS containing/VBG high/JJ titre/NN antibodies/NNS with/IN specificities/NNS not/RB normally/RB associated/VBN with/IN significantly/RB reduced/VBN red/JJ cell/NN survival/NN ./. 
UI/LS -/: 93101981/CD 
TI/LS -/: Ablation/NN of/IN transplanted/VBN HTLV-I/NN Tax-transformed/JJ tumors/NNS in/IN mice/NNS by/IN antisense/JJ inhibition/NN of/IN NF-kappa/NN B/NN [/( published/VBN erratum/NN appears/VBZ in/IN Science/NNP 1993/CD Mar/NNP 12/CD ;/: 259/CD (/( 5101/CD )/) :/: 1523/CD ]/) 
AB/LS -/: Mice/NNS transgenic/JJ for/IN the/DT human/JJ T/NN cell/NN leukemia/NN virus/NN (/( HTLV-I/NN )/) Tax/NN gene/NN develop/VBP fibroblastic/JJ tumors/NNS that/WDT express/VBP NF-kappa/NN B-inducible/JJ early/JJ genes/NNS ./. 
In/FW vitro/FW inhibition/NN of/IN NF-kappa/NN B/NN expression/NN by/IN antisense/JJ oligodeoxynucleotides/NNS (/( ODNs/NNS )/) inhibited/VBD growth/NN of/IN these/DT culture-adapted/JJ Tax-transformed/JJ fibroblasts/NNS as/RB well/RB as/IN an/DT HTLV-I-transformed/JJ human/JJ lymphocyte/NN line/NN ./. 
In/IN contrast/NN ,/, antisense/JJ inhibition/NN of/IN Tax/NN itself/PRP had/VBD no/DT apparent/JJ effect/NN on/IN cell/NN growth/NN ./. 
Mice/NNS treated/VBN with/IN antisense/NN to/TO NF-kappa/NN B/NN ODNs/NNS showed/VBD rapid/JJ regression/NN of/IN transplanted/VBN fibrosarcomas/NNS ./. 
This/DT suggests/VBZ that/IN NF-kappa/NN B/NN expression/NN may/MD be/VB necessary/JJ for/IN the/DT maintenance/NN of/IN the/DT malignant/JJ phenotype/NN and/CC provides/VBZ a/DT therapeutic/JJ approach/NN for/IN HTLV-I-associated/JJ disease/NN ./. 
UI/LS -/: 93072349/CD 
TI/LS -/: Membrane/NN receptors/NNS for/IN aldosterone/NN :/: a/DT novel/JJ pathway/NN for/IN mineralocorticoid/NN action/NN ./. 
AB/LS -/: Rapid/JJ nongenomic/JJ in/FW vitro/FW effects/NNS of/IN aldosterone/NN on/IN intracellular/JJ electrolytes/NNS ,/, cell/NN volume/NN ,/, and/CC Na(+)-H+/JJ antiport/NN have/VBP been/VBN found/VBN in/IN human/JJ mononuclear/JJ leukocytes/NNS (/( HML/NN )/) ./. 
Binding/NN of/IN 125I-labeled/JJ aldosterone/NN to/TO plasma/NN membranes/NNS of/IN HML/NN shares/VBZ important/JJ features/NNS with/IN these/DT functional/JJ data/NNS ./. 
This/DT includes/VBZ a/DT very/RB low/JJ apparent/JJ dissociation/NN constant/NN (/( Kd/NN )/) of/IN 0.1/CD nM/NN for/IN both/CC aldosterone/NN and/CC the/DT effect/NN on/IN the/DT Na(+)-H(+)-antiport/NN ,/, a/DT high/JJ turnover/NN rate/NN ,/, and/CC the/DT almost/RB exclusive/JJ binding/NN selectivity/NN for/IN aldosterone/NN ./. 
Dexamethasone/NN ,/, RU/NN 26988/CD ,/, corticosterone/NN ,/, ouabain/NN ,/, amiloride/NN ,/, and/CC 18-hydroxyprogesterone/NN were/VBD inactive/JJ as/IN ligands/NNS ./. 
Deoxycorticosterone/NN acetate/NN had/VBD an/DT intermediate/JJ activity/NN with/IN an/DT apparent/JJ Kd/NN of/IN 100/CD nM/NN ./. 
These/DT findings/NNS are/VBP the/DT first/JJ to/TO demonstrate/VB membrane/NN binding/NN of/IN aldosterone/NN being/VBG compatible/JJ with/IN major/JJ aspects/NNS of/IN its/PRP$ nongenomic/JJ effects/NNS ./. 
UI/LS -/: 93011470/CD 
TI/LS -/: Leukotriene/NN B4/NN transcriptionally/RB activates/VBZ interleukin-6/NN expression/NN involving/VBG NK-chi/NN B/NN and/CC NF-IL6/NN ./. 
AB/LS -/: Leukotriene/NN B4/NN (/( LTB4/NN )/) is/VBZ a/DT notable/JJ participant/NN in/IN inflammation/NN and/CC chemotaxis/NN ./. 
It/PRP is/VBZ ,/, however/RB ,/, still/RB unclear/JJ whether/IN LTB4/NN acts/VBZ in/IN this/DT regard/NN directly/RB or/CC indirectly/RB by/IN stimulating/VBG the/DT release/NN of/IN chemotactic/JJ and/CC inflammatory/JJ cytokines/NNS ./. 
Here/RB we/PRP report/VBP that/IN LTB4/NN induces/VBZ synthesis/NN of/IN interleukin/NN (/( IL/NN )/) -6/CD by/IN human/JJ blood/NN monocytes/NNS through/IN transcriptional/JJ activation/NN of/IN the/DT IL-6/NN gene/NN ./. 
We/PRP furthermore/RB demonstrate/VBP that/IN this/DT process/NN involves/VBZ activation/NN of/IN the/DT transcription/NN factor/NN NF-chi/NN B/NN and/CC ,/, to/TO a/DT lesser/JJR extent/NN ,/, of/IN NF-IL6/NN ,/, while/IN the/DT activity/NN of/IN the/DT transcription/NN factor/NN AP-1/NN ,/, shown/VBN to/TO otherwise/RB confer/VB IL-6/NN inducibility/NN ,/, appeared/VBD to/TO be/VB unaffected/JJ by/IN LTB4/NN ./. 
Involvement/NN of/IN NF-chi/NN B/NN and/CC NF-IL6/NN in/IN induction/NN of/IN IL-6/NN transcription/NN by/IN monocytes/NNS was/VBD demonstrated/VBN using/VBG deleted/JJ forms/NNS of/IN the/DT IL-6/NN promoter/NN ./. 
Activation/NN of/IN the/DT IL-6/NN promoter/NN by/IN LTB4/NN was/VBD not/RB only/RB associated/VBN with/IN accumulation/NN of/IN the/DT respective/JJ transcripts/NNS but/CC resulted/VBD in/IN synthesis/NN of/IN functional/JJ IL-6/NN protein/NN as/RB well/RB ./. 
In/IN addition/NN ,/, LTB4/NN mediated/VBD transactivation/NN of/IN a/DT heterologous/JJ promoter/NN construct/NN containing/VBG the/DT NF-chi/NN B/NN or/CC the/DT NF-IL6/NN enhancer/NN ,/, but/CC not/RB the/DT AP-1/NN enhancer/NN ./. 
The/DT signaling/NN events/NNS mediating/VBG this/DT effect/NN appeared/VBD to/TO involve/VB the/DT release/NN of/IN H2O2/NN ,/, since/IN LTB4/NN failed/VBD to/TO induce/VB NF-chi/NN B/NN or/CC NF-IL6/NN in/IN the/DT presence/NN of/IN the/DT scavenger/NN of/IN H2O2/NN ,/, N-acetyl-L-cysteine/NN ./. 
UI/LS -/: 92378748/CD 
TI/LS -/: Bcl-2/NN :/: a/DT repressor/NN of/IN lymphocyte/NN death/NN ./. 
AB/LS -/: The/DT genes/NNS and/CC mechanisms/NNS that/WDT control/VBP programmed/VBN cell/NN death/NN are/VBP currently/RB the/DT subject/NN of/IN intense/JJ study/NN ./. 
The/DT bcl-2/NN gene/NN ,/, a/DT repressor/NN of/IN lymphocyte/NN death/NN ,/, is/VBZ perhaps/RB the/DT best/JJS understood/VBN of/IN the/DT programmed/VBN cell/NN death/NN associated/JJ genes/NNS ./. 
Here/RB ,/, Stanley/NNP Korsmeyer/NNP provides/VBZ a/DT brief/JJ overview/NN of/IN bcl-2/NN ,/, concentrating/VBG on/IN its/PRP$ roles/NNS in/IN B-/NN and/CC T-cell/NN development/NN and/CC in/IN oncogenesis/NN ./. 
UI/LS -/: 92311659/CD 
TI/LS -/: Cytoplasmic/JJ domain/NN heterogeneity/NN and/CC functions/NNS of/IN IgG/NN Fc/NN receptors/NNS in/IN B/NN lymphocytes/NNS ./. 
AB/LS -/: B/NN lymphocytes/NNS and/CC macrophages/NNS express/VBP closely/RB related/JJ immunoglobulin/NN G/NN (/( IgG/NN )/) Fc/NN receptors/NNS (/( Fc/NN gamma/NN RII/NN )/) that/WDT differ/VBP only/RB in/IN the/DT structures/NNS of/IN their/PRP$ cytoplasmic/JJ domains/NNS ./. 
Because/IN of/IN cell/NN type-specific/JJ alternative/JJ messenger/NN RNA/NN splicing/NN ,/, B-cell/NN Fc/NN gamma/NN RII/NN contains/VBZ an/DT insertion/NN of/IN 47/CD amino/NN acids/NNS that/WDT participates/VBZ in/IN determining/VBG receptor/NN function/NN in/IN these/DT cells/NNS ./. 
Transfection/NN of/IN an/DT Fc/NN gamma/NN RII-negative/JJ B-cell/NN line/NN with/IN complementary/JJ DNA/NN 's/POS encoding/VBG the/DT two/CD splice/NN products/NNS and/CC various/JJ receptor/NN mutants/NNS indicated/VBD that/IN the/DT insertion/NN was/VBD responsible/JJ for/IN preventing/VBG both/CC Fc/NN gamma/NN RII-mediated/JJ endocytosis/NN and/CC Fc/NN gamma/NN RII-mediated/JJ antigen/NN presentation/NN ./. 
The/DT insertion/NN was/VBD not/RB required/VBN for/IN Fc/NN gamma/NN RII/NN to/TO modulate/VB surface/NN immunoglobulin-triggered/JJ B-cell/NN activation/NN ./. 
Instead/RB ,/, regulation/NN of/IN activation/NN involved/VBD a/DT region/NN of/IN the/DT cytoplasmic/JJ domain/NN common/JJ to/TO both/CC the/DT lymphocyte/NN and/CC macrophage/NN receptor/NN isoforms/NNS ./. 
In/IN contrast/NN ,/, the/DT insertion/NN did/VBD contribute/VB to/TO the/DT formation/NN of/IN caps/NNS in/IN response/NN to/TO receptor/NN cross-linking/NN ,/, consistent/JJ with/IN suggestions/NNS that/IN the/DT lymphocyte/NN but/CC not/RB macrophage/NN form/NN of/IN the/DT receptor/NN can/MD associate/VB with/IN the/DT detergent-insoluble/JJ cytoskeleton/NN ./. 
UI/LS -/: 92362919/CD 
TI/LS -/: [/( Age-related/JJ changes/NNS in/IN glucocorticoid/NN and/CC mineralocorticoid/NN receptors/NNS in/IN lymphocytes/NNS of/IN healthy/JJ persons/NNS and/CC patients/NNS with/IN hypertension/NN ]/) 
AB/LS -/: It/PRP has/VBZ been/VBN found/VBN that/IN the/DT number/NN of/IN glucocorticoid/NN receptors/NNS in/IN lymphocytes/NNS of/IN the/DT peripheral/JJ blood/NN of/IN healthy/JJ elderly/JJ subjects/NNS increases/VBZ ,/, while/IN the/DT number/NN of/IN mineralocorticoid/NN receptors/NNS decreases/VBZ ./. 
The/DT mechanisms/NNS of/IN hormone-receptor/NN interactions/NNS in/IN hypertension/NN are/VBP activated/VBN :/: the/DT number/NN of/IN glucocorticoid/NN and/CC mineralocorticoid/NN binding/NN sites/NNS grows/VBZ in/IN hypertensive/JJ patients/NNS ./. 
Still/RB a/DT more/RBR essential/JJ rise/NN in/IN the/DT number/NN of/IN receptors/NNS is/VBZ observed/VBN in/IN mid-age/JJ hypertensive/NN patients/NNS than/IN in/IN elderly/JJ ones/NNS ./. 
UI/LS -/: 92255823/CD 
TI/LS -/: The/DT mechanism/NN of/IN action/NN of/IN cyclosporin/NN A/NN and/CC FK506/NN ./. 
AB/LS -/: CsA/NN and/CC FK506/NN are/VBP powerful/JJ suppressors/NNS of/IN the/DT immune/JJ system/NN ,/, most/RBS notably/RB of/IN T/NN cells/NNS ./. 
They/PRP act/VBP at/IN a/DT point/NN in/IN activation/NN that/WDT lies/VBZ between/IN receptor/NN ligation/NN and/CC the/DT transcription/NN of/IN early/JJ genes/NNS ./. 
Here/RB ,/, Stuart/NNP Schreiber/NNP and/CC Gerald/NNP Crabtree/NNP review/VBP recent/JJ findings/NNS that/WDT indicate/VBP CsA/NN and/CC FK506/NN operate/VBP as/IN prodrugs/NNS :/: they/PRP bind/VBP endogenous/JJ intracellular/JJ receptors/NNS ,/, the/DT immunophilins/NNS ,/, and/CC the/DT resulting/VBG complex/NN targets/VBZ the/DT protein/NN phosphatase/NN ,/, calcineurin/NN ,/, to/TO exert/VB the/DT immunosuppressive/JJ effect/NN ./. 
UI/LS -/: 92156797/CD 
TI/LS -/: Induction/NN of/IN monocytic/JJ differentiation/NN and/CC NF-kappa/NN B-like/JJ activities/NNS by/IN human/JJ immunodeficiency/NN virus/NN 1/CD infection/NN of/IN myelomonoblastic/JJ cells/NNS ./. 
AB/LS -/: The/DT effects/NNS of/IN human/JJ immunodeficiency/NN virus/NN 1/CD (/( HIV-1/NN )/) infection/NN on/IN cellular/JJ differentiation/NN and/CC NF-kappa/NN B/NN DNA/NN binding/NN activity/NN have/VBP been/VBN investigated/VBN in/IN a/DT new/JJ model/NN of/IN myeloid/JJ differentiation/NN ./. 
PLB-985/NN cells/NNS represent/VBP a/DT bipotential/JJ myelomonoblastic/JJ cell/NN population/NN capable/JJ of/IN either/CC granulocytic/JJ or/CC monocytic/JJ differentiation/NN after/IN induction/NN with/IN appropriate/JJ inducers/NNS ./. 
By/IN virtue/NN of/IN the/DT presence/NN of/IN CD4/NN on/IN the/DT cell/NN surface/NN ,/, PLB-985/NN cells/NNS were/VBD chronically/RB infected/VBN with/IN HIV-1/NN strain/NN IIIB/NN ./. 
PLB-IIIB/NN cells/NNS clearly/RB possessed/VBD a/DT more/RBR monocytic/JJ phenotype/NN than/IN the/DT parental/JJ myeloblasts/NNS ,/, as/IN determined/VBN by/IN differential/JJ staining/NN ,/, increased/VBN expression/NN of/IN the/DT myeloid-specific/JJ surface/NN markers/NNS ,/, and/CC transcription/NN of/IN the/DT c-fms/NN proto-oncogene/NN ./. 
NF-kappa/NN B/NN binding/NN activity/NN was/VBD inducible/JJ by/IN tumor/NN necrosis/NN factor/NN and/CC phorbol/NN myristate/NN acetate/NN in/IN PLB-985/NN ./. 
However/RB ,/, in/IN PLB-IIIB/NN cells/NNS ,/, constitutive/JJ expression/NN of/IN a/DT novel/JJ NF-kappa/NN B/NN complex/NN was/VBD detected/VBN ,/, composed/VBN of/IN proteins/NNS ranging/VBG between/IN 70/CD and/CC 110/CD kD/NN ./. 
These/DT proteins/NNS interacted/VBD specifically/RB with/IN the/DT symmetric/JJ NF-kappa/NN B/NN site/NN from/IN the/DT interferon/NN beta/NN (/( IFN-beta/NN )/) promoter/NN ./. 
Mutations/NNS affecting/VBG the/DT 5'/JJ guanine/JJ residues/NNS of/IN the/DT kappa/NN B/NN site/NN were/VBD unable/JJ to/TO compete/VB for/IN these/DT NF-kappa/NN B-related/JJ proteins/NNS ./. 
Inducibility/NN of/IN endogenous/JJ IFN-beta/NN and/CC IFN-alpha/NN RNA/NN was/VBD also/RB increased/VBN in/IN PLB-IIIB/NN cells/NNS ./. 
These/DT studies/NNS indicate/VBP that/IN HIV-1/NN infection/NN of/IN myelomonoblastic/JJ cells/NNS may/MD select/VB for/IN a/DT more/RBR mature/JJ monocytic/JJ phenotype/NN and/CC that/IN unique/JJ subunit/NN associations/NNS of/IN NF-kappa/NN B/NN DNA/NN binding/NN proteins/NNS may/MD contribute/VB to/TO differential/JJ NF-kappa/NN B-mediated/JJ gene/NN expression/NN ./. 
UI/LS -/: 92113075/CD 
TI/LS -/: Cortisol/NN receptor/NN resistance/NN :/: the/DT variability/NN of/IN its/PRP$ clinical/JJ presentation/NN and/CC response/NN to/TO treatment/NN ./. 
AB/LS -/: Primary/JJ (/( partial/JJ )/) cortisol/NN receptor/NN resistance/NN was/VBD previously/RB reported/VBN in/IN a/DT total/NN of/IN 7/CD patients/NNS and/CC 14/CD asymptomatic/JJ family/NN members/NNS ./. 
Its/PRP$ occurrence/NN is/VBZ considered/VBN to/TO be/VB extremely/RB rare/JJ ./. 
In/IN the/DT present/JJ study/NN we/PRP report/VBP on/IN 6/CD patients/NNS (/( 2/CD males/NNS and/CC 4/CD females/NNS )/) with/IN the/DT syndrome/NN ./. 
The/DT first/JJ male/JJ patient/NN presented/VBD with/IN mild/JJ hypertension/NN ./. 
Hydrochlorothiazide/NN therapy/NN resulted/VBD in/IN life-threatening/JJ hypokalemia/NN ./. 
The/DT second/JJ male/JJ patient/NN had/VBD slight/JJ hypertension/NN without/IN hypokalemia/NN ./. 
All/DT four/CD female/JJ patients/NNS presented/VBD between/IN the/DT age/NN of/IN 20-30/CD yr/NN with/IN acne/NN ,/, hirsutism/NN ,/, and/CC irregular/JJ menstruations/NNS ./. 
Low/JJ dose/NN dexamethasone/NN therapy/NN (/( 1-1.5/CD mg/day/NN )/) was/VBD of/IN clinical/JJ benefit/NN in/IN these/DT patients/NNS ./. 
All/DT patients/NNS showed/VBD insufficient/JJ suppression/NN of/IN serum/NN cortisol/NN concentrations/NNS in/IN the/DT overnight/JJ 1-mg/JJ dexamethasone/NN test/NN ./. 
The/DT diurnal/JJ rhythm/NN of/IN ACTH/NN and/CC cortisol/NN was/VBD intact/JJ ,/, albeit/IN at/IN an/DT elevated/JJ level/NN ./. 
There/EX was/VBD a/DT normal/JJ increase/NN in/IN ACTH/NN ,/, cortisol/NN ,/, and/CC GH/NN (/( except/IN in/IN one/CD obese/JJ patient/NN )/) in/IN response/NN to/TO insulin-induced/JJ hypoglycemia/NN ,/, while/IN cortisol/NN production/NN was/VBD elevated/JJ in/IN three/CD patients/NNS ./. 
Circulating/VBG adrenal/JJ androgen/NN levels/NNS were/VBD increased/VBN in/IN all/DT patients/NNS ./. 
Glucocorticoid/NN receptors/NNS were/VBD investigated/VBN in/IN a/DT whole/JJ cell/NN dexamethasone/NN binding/NN assay/NN in/IN mononuclear/JJ leukocytes/NNS ./. 
In/IN the/DT first/JJ male/JJ patient/NN ,/, the/DT number/NN of/IN receptors/NNS was/VBD very/RB low/JJ ,/, while/IN the/DT affinity/NN was/VBD lower/JJR than/IN that/DT in/IN controls/NNS ./. 
A/DT lowered/JJ affinity/NN to/TO dexamethasone/NN was/VBD found/VBN in/IN one/CD female/JJ patient/NN ,/, while/IN a/DT lowered/JJ number/NN of/IN receptors/NNS was/VBD found/VBN in/IN three/CD patients/NNS ./. 
In/IN the/DT second/JJ male/JJ patient/NN ,/, no/DT abnormalities/NNS were/VBD found/VBN ./. 
As/IN a/DT bioassay/NN for/IN glucocorticoid/NN action/NN we/PRP also/RB measured/VBD dexamethasone/NN suppressibility/NN of/IN mitogen-stimulated/JJ incorporation/NN of/IN [3H]thymidine/NN in/IN mononuclear/JJ leukocytes/NNS ./. 
In/IN the/DT male/JJ patient/NN with/IN normal/JJ receptor/NN status/NN ,/, dexamethasone/NN suppressibility/NN of/IN [3H]thymidine/NN incorporation/NN was/VBD significantly/RB lower/JJR than/IN that/DT in/IN healthy/JJ controls/NNS with/IN respect/NN to/TO both/CC maximal/JJ suppression/NN and/CC IC50/NN ./. 
Partial/JJ cortisol/NN receptor/NN resistance/NN might/MD be/VB less/RBR rare/JJ than/IN previously/RB thought/VBN ./. 
In/IN the/DT six/CD patients/NNS presented/VBN ,/, at/IN least/JJS three/CD different/JJ forms/NNS can/MD be/VB recognized/VBN ./. 
Therapy/NN with/IN dexamethasone/NN was/VBD successful/JJ in/IN female/JJ patients/NNS with/IN acne/NN and/CC hirsutism/NN ,/, as/IN the/DT secondary/JJ increase/NN in/IN the/DT production/NN of/IN adrenal/JJ androgens/NNS was/VBD effectively/RB controlled/VBN ./. 
UI/LS -/: 92367617/CD 
TI/LS -/: The/DT development/NN of/IN functionally/RB responsive/JJ T/NN cells/NNS ./. 
AB/LS -/: The/DT work/NN reviewed/VBN in/IN this/DT article/NN separates/VBZ T/NN cell/NN development/NN into/IN four/CD phases/NNS ./. 
First/JJ is/VBZ an/DT expansion/NN phase/NN prior/RB to/TO TCR/NN rearrangement/NN ,/, which/WDT appears/VBZ to/TO be/VB correlated/VBN with/IN programming/NN of/IN at/IN least/JJS some/DT response/NN genes/NNS for/IN inducibility/NN ./. 
This/DT phase/NN can/MD occur/VB to/TO some/DT extent/NN outside/IN of/IN the/DT thymus/NN ./. 
However/RB ,/, the/DT profound/JJ T/NN cell/NN deficit/NN of/IN nude/JJ mice/NNS indicates/VBZ that/IN the/DT thymus/NN is/VBZ by/IN far/RB the/DT most/RBS potent/JJ site/NN for/IN inducing/VBG the/DT expansion/NN per/FW se/FW ,/, even/RB if/IN other/JJ sites/NNS can/MD induce/VB some/DT response/NN acquisition/NN ./. 
Second/JJ is/VBZ a/DT controlled/JJ phase/NN of/IN TCR/NN gene/NN rearrangement/NN ./. 
The/DT details/NNS of/IN the/DT regulatory/JJ mechanism/NN that/WDT selects/VBZ particular/JJ loci/NNS for/IN rearrangement/NN are/VBP still/RB not/RB known/VBN ./. 
It/PRP seems/VBZ that/IN the/DT rearrangement/NN of/IN the/DT TCR/NN gamma/NN loci/NNS in/IN the/DT gamma/NN delta/NN lineage/NN may/MD not/RB always/RB take/VB place/NN at/IN a/DT developmental/JJ stage/NN strictly/RB equivalent/JJ to/TO the/DT rearrangement/NN of/IN TCR/NN beta/NN in/IN the/DT alpha/NN beta/NN lineage/NN ,/, and/CC it/PRP is/VBZ not/RB clear/JJ just/RB how/WRB early/RB the/DT two/CD lineages/NNS diverge/VBP ./. 
In/IN the/DT TCR/NN alpha/NN beta/NN lineage/NN ,/, however/RB ,/, the/DT final/JJ gene/NN rearrangement/NN events/NNS are/VBP accompanied/VBN by/IN rapid/JJ proliferation/NN and/CC an/DT interruption/NN in/IN cellular/JJ response/NN gene/NN inducibility/NN ./. 
The/DT loss/NN of/IN conventional/JJ responsiveness/NN is/VBZ probably/RB caused/VBN by/IN alterations/NNS at/IN the/DT level/NN of/IN signaling/NN ,/, and/CC may/MD be/VB a/DT manifestation/NN of/IN the/DT physiological/JJ state/NN that/WDT is/VBZ a/DT precondition/NN for/IN selection/NN ./. 
Third/JJ is/VBZ the/DT complex/JJ process/NN of/IN selection/NN ./. 
Whereas/IN peripheral/JJ T/NN cells/NNS can/MD undergo/VB forms/NNS of/IN positive/JJ selection/NN (/( by/IN antigen-driven/JJ clonal/JJ expansion/NN )/) and/CC negative/JJ selection/NN (/( by/IN abortive/JJ stimulation/NN leading/VBG to/TO anergy/NN or/CC death/NN )/) ,/, neither/DT is/VBZ exactly/RB the/DT same/JJ phenomenon/NN that/WDT occurs/VBZ in/IN the/DT thymic/JJ cortex/NN ./. 
Negative/JJ selection/NN in/IN the/DT cortex/NN appears/VBZ to/TO be/VB a/DT suicidal/JJ inversion/NN of/IN antigen/NN responsiveness/NN :/: instead/RB of/IN turning/VBG on/IN IL-2/NN expression/NN ,/, the/DT activated/VBN cell/NN destroys/VBZ its/PRP$ own/JJ chromatin/NN ./. 
The/DT genes/NNS that/WDT need/VBP to/TO be/VB induced/VBN for/IN this/DT response/NN are/VBP not/RB yet/RB identified/VBN ,/, but/CC it/PRP is/VBZ unquestionably/RB a/DT form/NN of/IN activation/NN ./. 
It/PRP is/VBZ interesting/JJ that/IN in/IN humans/NNS and/CC rats/NNS ,/, cortical/JJ thymocytes/NNS undergoing/VBG negative/JJ selection/NN can/MD still/RB induce/VB IL-2R/NN alpha/NN expression/NN and/CC even/RB be/VB rescued/VBN in/FW vitro/FW ,/, if/IN exogenous/JJ IL-2/NN is/VBZ provided/VBN ./. 
Perhaps/RB murine/JJ thymocytes/NNS are/VBP denied/VBN this/DT form/NN of/IN rescue/NN because/IN they/PRP shut/VBD off/RP IL-2R/NN beta/NN chain/NN expression/NN at/IN an/DT earlier/JJR stage/NN or/CC because/IN they/PRP may/MD be/VB uncommonly/RB Bcl-2/NN deficient/JJ (/( cf./VBP Sentman/NNP et/FW al./FW ,/, 1991/CD ;/: Strasser/NNP et/FW al./FW ,/, 1991/CD )/) ./. 
Even/RB so/RB ,/, medullary/JJ thymocytes/NNS remain/VBP at/IN least/JJS partially/RB susceptible/JJ to/TO negative/JJ selection/NN even/RB as/IN they/PRP continue/VBP to/TO mature/VB ./. 
UI/LS -/: 93153017/CD 
TI/LS -/: I/NN kappa/NN B/MAD-3/NN masks/VBZ the/DT nuclear/JJ localization/NN signal/NN of/IN NF-kappa/NN B/NN p65/NN and/CC requires/VBZ the/DT transactivation/NN domain/NN to/TO inhibit/VB NF-kappa/NN B/NN p65/NN DNA/NN binding/NN ./. 
AB/LS -/: The/DT active/JJ nuclear/JJ form/NN of/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN complex/NN is/VBZ composed/VBN of/IN two/CD DNA/NN binding/NN subunits/NNS ,/, NF-kappa/NN B/NN p65/NN and/CC NF-kappa/NN B/NN p50/NN ,/, both/DT of/IN which/WDT share/VBP extensive/JJ N-terminal/JJ sequence/NN homology/NN with/IN the/DT v-rel/NN oncogene/NN product/NN ./. 
The/DT NF-kappa/NN B/NN p65/NN subunit/NN provides/VBZ the/DT transactivation/NN activity/NN in/IN this/DT complex/JJ and/CC serves/VBZ as/IN an/DT intracellular/JJ receptor/NN for/IN a/DT cytoplasmic/JJ inhibitor/NN of/IN NF-kappa/NN B/NN ,/, termed/VBN I/NN kappa/NN B/NN ./. 
In/IN contrast/NN ,/, NF-kappa/NN B/NN p50/NN alone/RB fails/VBZ to/TO stimulate/VB kappa/NN B-directed/JJ transcription/NN ,/, and/CC based/VBN on/IN prior/JJ in/FW vitro/FW studies/NNS ,/, is/VBZ not/RB directly/RB regulated/VBN by/IN I/NN kappa/NN B/NN ./. 
To/TO investigate/VB the/DT molecular/JJ basis/NN for/IN the/DT critical/JJ regulatory/JJ interaction/NN between/IN NF-kappa/NN B/NN and/CC I/NN kappa/NN B/MAD-3/NN ,/, a/DT series/NN of/IN human/JJ NF-kappa/NN B/NN p65/NN mutants/NNS was/VBD identified/VBN that/WDT functionally/RB segregated/VBD DNA/NN binding/NN ,/, I/NN kappa/NN B-mediated/JJ inhibition/NN ,/, and/CC I/NN kappa/NN B-induced/JJ nuclear/JJ exclusion/NN of/IN this/DT transcription/NN factor/NN ./. 
Results/NNS from/IN in/FW vivo/FW expression/NN studies/NNS performed/VBN with/IN these/DT NF-kappa/NN B/NN p65/NN mutants/NNS revealed/VBD the/DT following/NN :/: 1/LS )/) I/NN kappa/NN B/MAD-3/NN completely/RB inhibits/VBZ NF-kappa/NN B/NN p65-dependent/JJ transcriptional/JJ activation/NN mediated/VBN through/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD kappa/NN B/NN enhancer/NN in/IN human/JJ T/NN lymphocytes/NNS ,/, 2/LS )/) the/DT binding/NN of/IN I/NN kappa/NN B/MAD-3/NN to/TO NF-kappa/NN B/NN p65/NN is/VBZ sufficient/JJ to/TO retarget/VB NF-kappa/NN B/NN p65/NN from/IN the/DT nucleus/NN to/TO the/DT cytoplasm/NN ,/, 3/LS )/) selective/JJ deletion/NN of/IN the/DT functional/JJ nuclear/JJ localization/NN signal/NN present/JJ in/IN the/DT Rel/NN homology/NN domain/NN of/IN NF-kappa/NN B/NN p65/NN disrupts/VBZ its/PRP$ ability/NN to/TO engage/VB I/NN kappa/NN B/MAD-3/NN ,/, and/CC 4/LS )/) the/DT unique/JJ C-terminus/NN of/IN NF-kappa/NN B/NN p65/NN attenuates/VBZ its/PRP$ own/JJ nuclear/JJ localization/NN and/CC contains/VBZ sequences/NNS that/WDT are/VBP required/VBN for/IN I/NN kappa/NN B-mediated/JJ inhibition/NN of/IN NF-kappa/NN B/NN p65/NN DNA/NN binding/NN activity/NN ./. 
Together/RB ,/, these/DT findings/NNS suggest/VBP that/IN the/DT nuclear/JJ localization/NN signal/NN and/CC transactivation/NN domain/NN of/IN NF-kappa/NN B/NN p65/NN constitute/VBP a/DT bipartite/JJ system/NN that/WDT is/VBZ critically/RB involved/VBN in/IN the/DT inhibitory/JJ function/NN of/IN I/NN kappa/NN B/MAD-3/NN ./. 
Unexpectedly/RB ,/, our/PRP$ in/FW vivo/FW studies/NNS also/RB demonstrate/VBP that/IN I/NN kappa/NN B/MAD-3/NN binds/VBZ directly/RB to/TO NF-kappa/NN B/NN p50/NN ./. 
This/DT interaction/NN is/VBZ functional/JJ as/IN it/PRP leads/VBZ to/TO retargeting/NN of/IN NF-kappa/NN B/NN p50/NN from/IN the/DT nucleus/NN to/TO the/DT cytoplasm/NN ./. 
However/RB ,/, no/DT loss/NN of/IN DNA/NN binding/NN activity/NN is/VBZ observed/VBN ,/, presumably/RB reflecting/VBG the/DT unique/JJ C-terminal/JJ domain/NN that/WDT is/VBZ distinct/JJ from/IN that/DT present/JJ in/IN NF-kappa/NN B/NN p65/NN ./. 
UI/LS -/: 93024468/CD 
TI/LS -/: Characterization/NN of/IN a/DT new/JJ tissue-specific/JJ transcription/NN factor/NN binding/VBG to/TO the/DT simian/JJ virus/NN 40/CD enhancer/NN TC-II/NN (/( NF-kappa/NN B/NN )/) element/NN ./. 
AB/LS -/: We/PRP have/VBP biochemically/RB and/CC functionally/RB characterized/VBN a/DT new/JJ transcription/NN factor/NN ,/, NP-TCII/NN ,/, which/WDT is/VBZ present/JJ in/IN nuclei/NNS from/IN unstimulated/JJ T/NN and/CC B/NN lymphocytes/NNS but/CC is/VBZ not/RB found/VBN in/IN nonhematopoietic/JJ cells/NNS ./. 
This/DT factor/NN has/VBZ a/DT DNA-binding/JJ specificity/NN similar/JJ to/TO that/DT of/IN NF-kappa/NN B/NN but/CC is/VBZ unrelated/JJ to/TO this/DT or/CC other/JJ Rel/NN proteins/NNS by/IN functional/JJ and/CC biochemical/JJ criteria/NNS ./. 
It/PRP can/MD also/RB be/VB distinguished/VBN from/IN other/JJ previously/RB described/VBN lymphocyte-specific/JJ DNA-binding/JJ proteins/NNS ./. 
UI/LS -/: 93024882/CD 
TI/LS -/: The/DT candidate/NN oncoprotein/NN Bcl-3/NN is/VBZ an/DT antagonist/NN of/IN p50/NF-kappa/NN B-mediated/JJ inhibition/NN ./. 
AB/LS -/: The/DT candidate/NN oncogene/NN bcl-3/NN was/VBD discovered/VBN as/IN a/DT translocation/NN into/IN the/DT immunoglobulin/NN alpha-locus/NN in/IN some/DT cases/NNS of/IN B-cell/NN chronic/JJ lymphocytic/JJ leukaemias/NNS ./. 
The/DT protein/NN Bcl-3/NN contains/VBZ seven/CD so-called/JJ ankyrin/NN repeats/NNS ./. 
Similar/JJ repeat/NN motifs/NNS are/VBP found/VBN in/IN a/DT number/NN of/IN diverse/JJ regulatory/JJ proteins/NNS but/CC the/DT motifs/NNS of/IN Bcl-3/NN are/VBP most/RBS closely/RB related/JJ to/TO those/DT found/VBN in/IN I/NN kappa/NN B/NN proteins/NNS in/IN which/WDT the/DT ankyrin/NN repeat/NN domain/NN is/VBZ thought/VBN to/TO be/VB directly/RB involved/VBN in/IN inhibition/NN of/IN NF-kappa/NN B/NN activity/NN ./. 
No/DT biological/JJ function/NN has/VBZ yet/RB been/VBN described/VBN for/IN Bcl-3/NN ,/, but/CC it/PRP was/VBD noted/VBN recently/RB that/IN Bcl-3/NN interferes/VBZ with/IN DNA-binding/NN of/IN the/DT p50/NN subunit/NN of/IN NF-kappa/NN B/NN in/FW vitro/FW ./. 
Here/RB we/PRP demonstrate/VBP that/IN Bcl-3/NN can/MD aid/VB kappa/NN B/NN site-dependent/JJ transcription/NN in/FW vivo/FW by/IN counteracting/VBG the/DT inhibitory/JJ effects/NNS of/IN p50/NF-kappa/NN B/NN homodimers/NNS ./. 
Bcl-3/NN may/MD therefore/RB aid/VB activation/NN of/IN select/JJ NF-kappa/NN B-regulated/JJ genes/NNS ,/, including/VBG those/DT of/IN the/DT human/JJ immunodeficiency/NN virus/NN ./. 
UI/LS -/: 93013114/CD 
TI/LS -/: [/( Mechanism/NN of/IN action/NN of/IN steroid/NN hormones/NNS ./. I/LS ./. Estrogens/NNS ]/) 
AB/LS -/: The/DT steroid/NN hormone/NN are/VBP very/RB versatile/JJ molecules/NNS :/: although/IN they/PRP are/VBP related/JJ among/IN them/PRP by/IN their/PRP$ chemical/JJ structure/NN ,/, they/PRP have/VBP very/RB diverse/JJ functions/NNS and/CC including/VBG antagonic/JJ ./. 
Their/PRP$ action/NN mechanism/NN is/VBZ not/RB completely/RB cleared/VBN ./. 
The/DT estrogens/NNS participate/VBP in/IN the/DT regulation/NN of/IN practically/RB all/PDT the/DT reproductive/JJ and/CC sexual/JJ events/NNS of/IN the/DT female/NN ,/, although/IN the/DT intracellular/JJ actions/NNS by/IN which/WDT they/PRP take/VBP place/NN are/VBP not/RB well/RB known/VBN and/CC the/DT proposed/JJ models/NNS do/VBP not/RB adequately/RB satisfy/VB the/DT questions/NNS ./. 
Currently/RB it/PRP is/VBZ accepted/VBN the/DT existence/NN of/IN a/DT cytoplasmic/JJ and/or/CC nuclear/JJ receptor/NN ,/, without/IN explaining/VBG satisfactorily/RB how/WRB the/DT hormones/NNS come/VBN to/TO the/DT nucleus/NN ./. 
The/DT endocrine/JJ events/NNS that/WDT are/VBP rapidly/RB expressed/VBN (/( seconds/NNS )/) are/VBP due/JJ to/TO a/DT possible/JJ interaction/NN with/IN cellular/JJ membrane/NN ./. 
The/DT purpose/NN of/IN this/DT review/NN is/VBZ to/TO analyze/VB and/CC concilliate/VB the/DT reported/VBN data/NNS on/IN the/DT mechanism/NN of/IN action/NN of/IN estrogens/NNS ./. 
UI/LS -/: 92291523/CD 
TI/LS -/: Reduced/VBN susceptibility/NN to/TO HIV-1/NN infection/NN of/IN ethyl-methanesulfonate-treated/JJ CEM/NN subclones/NNS correlates/VBZ with/IN a/DT blockade/NN in/IN their/PRP$ protein/NN kinase/NN C/NN signaling/NN pathway/NN ./. 
AB/LS -/: We/PRP have/VBP described/VBN the/DT isolation/NN of/IN chemically/RB induced/VBN CEM/NN subclones/NNS that/WDT express/VBP CD4/NN receptors/NNS and/CC bind/VBP soluble/JJ gp120/NN ,/, yet/RB show/VBP a/DT markedly/RB reduced/VBN susceptibility/NN to/TO infection/NN with/IN HIV-1/NN ./. 
Two/CD subclones/NNS were/VBD found/VBN to/TO have/VB an/DT abnormal/JJ response/NN to/TO the/DT protein/NN kinase/NN C/NN (/( PKC/NN )/) activator/NN PMA/NN ./. 
PMA/NN treatment/NN induced/VBD CD3/NN and/CC CD25/NN (/( IL-2R/NN )/) receptors/NNS on/IN the/DT parental/JJ line/NN and/CC on/IN other/JJ ethyl-methanesulfonate-derived/JJ subclones/NNS ,/, but/CC not/RB on/IN these/DT two/CD mutants/NNS ./. 
Direct/JJ assays/NNS of/IN PKC/NN activity/NN were/VBD conducted/VBN ./. 
Total/JJ cellular/JJ PKC/NN enzymatic/JJ activity/NN was/VBD found/VBN to/TO be/VB normal/JJ in/IN these/DT subclones/NNS ./. 
PMA-induced/JJ CD4/NN down-modulation/NN occurred/VBD normally/RB ./. 
In/IN addition/NN ,/, activation/NN of/IN c-raf/NN kinase/NN was/VBD normal/JJ ./. 
Since/IN HIV-1/NN long/JJ terminal/JJ repeat/NN contains/VBZ two/CD functional/JJ nuclear/JJ factor/NN kB/NN (/( NF-kB/NN )/) regulatory/JJ elements/NNS ,/, we/PRP studied/VBD the/DT ability/NN of/IN PMA/NN to/TO induce/VB NF-kB/NN binding/NN activity/NN by/IN different/JJ assays/NNS ./. 
Chloramphenicol/NN acetyl/NN transferase/NN (/( CAT/NN )/) assays/NNS using/VBG the/DT HIV-1/NN (/( -139/CD )/) long/JJ terminal/JJ repeat-CAT/JJ construct/NN showed/VBD no/DT PMA/NN induction/NN of/IN CAT/NN activity/NN in/IN these/DT subclones/NNS (/( unlike/IN the/DT parental/JJ line/NN and/CC other/JJ subclones/NNS )/) ./. 
Okadaic/JJ acid/NN ,/, an/DT inhibitor/NN of/IN phosphatases/NNS 1/CD and/CC 2A/NN ,/, did/VBD not/RB overcome/VB the/DT defect/NN in/IN these/DT subclones/NNS ./. 
Gel/NN retardation/NN assays/NNS ,/, using/VBG a/DT 32P-probe/NN containing/VBG the/DT HIV-1/NN NF-kB/NN probe/NN and/CC nuclear/JJ extracts/NNS from/IN PMA-treated/JJ cells/NNS ,/, showed/VBD significantly/RB reduced/VBN induction/NN of/IN nuclear/JJ NF-kB/NN binding/NN proteins/NNS in/IN these/DT two/CD subclones/NNS compared/VBN with/IN wild/JJ type/NN CEM/NN and/CC a/DT control/NN subclone/NN ./. 
Deoxycholate/JJ treatment/NN of/IN cytoplasmic/JJ extracts/NNS from/IN these/DT subclones/NNS released/VBD much/JJ reduced/VBN NF-kB/NN binding/NN proteins/NNS from/IN their/PRP$ cytoplasmic/JJ pools/NNS ./. 
Thus/RB ,/, reduced/JJ levels/NNS of/IN PKC-induced/JJ nuclear/JJ NF-kB/NN activity/NN in/IN two/CD T/NN cell/NN subclones/NNS did/VBD not/RB affect/VB their/PRP$ normal/JJ cell/NN growth/NN ,/, but/CC correlated/VBD with/IN a/DT pronounced/JJ reduction/NN in/IN their/PRP$ susceptibility/NN to/TO HIV-1/NN infection/NN ./. 
UI/LS -/: 92244343/CD 
TI/LS -/: Nuclear/JJ factor/NN of/IN activated/VBN T/NN cells/NNS contains/VBZ Fos/NN and/CC Jun/NN ./. 
AB/LS -/: The/DT nuclear/JJ factor/NN NF-AT/NN (/( ref./NN 1/CD )/) is/VBZ induced/VBN in/IN T/NN cells/NNS stimulated/VBN through/IN the/DT T-cell/NN receptor/CD3/NN complex/NN ,/, and/CC is/VBZ required/VBN for/IN interleukin-2/NN (/( IL-2/NN )/) gene/NN induction/NN ./. 
Although/IN NF-AT/NN has/VBZ not/RB been/VBN cloned/VBN or/CC purified/VBN ,/, there/EX is/VBZ evidence/NN that/IN it/PRP is/VBZ a/DT major/JJ target/NN for/IN immunosuppression/NN by/IN cyclosporin/NN A/NN (/( CsA/NN )/) and/CC FK506/NN (/( refs/NNS 2-7/CD )/) ./. 
NF-AT/NN induction/NN may/MD require/VB two/CD activation-dependent/JJ events/NNS :/: the/DT CsA-sensitive/JJ translocation/NN of/IN a/DT pre-existing/JJ component/NN and/CC the/DT CsA-resistant/JJ synthesis/NN of/IN a/DT nuclear/JJ component/NN ./. 
Here/RB we/PRP report/VBP that/IN the/DT newly/RB synthesized/VBN nuclear/JJ component/NN of/IN NF-AT/NN is/VBZ the/DT transcription/NN factor/NN AP-1/NN ./. 
We/PRP show/VBP that/IN the/DT inducible/JJ nuclear/JJ form/NN of/IN NF-AT/NN contains/VBZ Fos/NN and/CC Jun/NN proteins/NNS ./. 
Furthermore/RB ,/, we/PRP identify/VBP a/DT pre-existing/JJ NF-AT-binding/JJ factor/NN that/WDT is/VBZ present/JJ in/IN hypotonic/JJ extracts/NNS of/IN unstimulated/JJ T/NN cells/NNS ./. 
On/IN the/DT basis/NN of/IN binding/NN ,/, reconstitution/NN and/CC cotransfection/NN experiments/NNS ,/, we/PRP propose/VBP that/IN activation/NN of/IN NF-AT/NN occurs/VBZ in/IN at/IN least/JJS two/CD stages/NNS :/: a/DT CsA-sensitive/JJ stage/NN involving/VBG modification/NN and/or/CC translocation/NN of/IN the/DT pre-existing/JJ NF-AT/NN complex/NN ,/, and/CC a/DT CsA-insensitive/JJ stage/NN involving/VBG the/DT addition/NN of/IN newly/RB synthesized/VBN Fos/NN or/CC Fos/Jun/NN proteins/NNS to/TO the/DT pre-existing/JJ complex/NN ./. 
UI/LS -/: 92195320/CD 
TI/LS -/: A/DT lymphoid/JJ cell-specific/JJ nuclear/JJ factor/NN containing/VBG c-Rel-like/JJ proteins/NNS preferentially/RB interacts/VBZ with/IN interleukin-6/NN kappa/NN B-related/JJ motifs/NNS whose/WP$ activities/NNS are/VBP repressed/VBN in/IN lymphoid/JJ cells/NNS ./. 
AB/LS -/: The/DT proto-oncoprotein/NN c-Rel/NN is/VBZ a/DT member/NN of/IN the/DT nuclear/JJ factor/NN kappa/NN B/NN transcription/NN factor/NN family/NN ,/, which/WDT includes/VBZ the/DT p50/NN and/CC p65/NN subunits/NNS of/IN nuclear/JJ factor/NN kappa/NN B/NN ./. 
We/PRP show/VBP here/RB that/IN c-Rel/NN binds/VBZ to/TO kappa/NN B/NN sites/NNS as/IN homodimers/NNS as/RB well/RB as/IN heterodimers/NNS with/IN p50/NN ./. 
These/DT homodimers/NNS and/CC heterodimers/NNS show/VBP distinct/JJ DNA-binding/JJ specificities/NNS and/CC affinities/NNS for/IN various/JJ kappa/NN B/NN motifs/NNS ./. 
In/IN particular/JJ ,/, the/DT c-Rel/NN homodimer/NN has/VBZ a/DT high/JJ affinity/NN for/IN interleukin-6/NN (/( IL-6/NN )/) and/CC beta/NN interferon/NN kappa/NN B/NN sites/NNS ./. 
In/IN spite/NN of/IN its/PRP$ association/NN with/IN p50/NN in/FW vitro/FW ,/, however/RB ,/, we/PRP found/VBD a/DT lymphoid/JJ cell-specific/JJ nuclear/JJ factor/NN in/FW vivo/FW that/WDT contains/VBZ c-Rel/NN but/CC not/RB p50/NN epitopes/NNS ;/: this/DT factor/NN ,/, termed/VBN IL-6/NN kappa/NN B/NN binding/NN factor/NN II/CD ,/, appears/VBZ to/TO contain/VB the/DT c-Rel/NN homodimer/NN and/CC preferentially/RB recognizes/VBZ several/JJ IL-6/NN kappa/NN B-related/JJ kappa/NN B/NN motifs/NNS ./. 
Although/IN it/PRP has/VBZ been/VBN previously/RB shown/VBN that/IN the/DT IL-6/NN kappa/NN B/NN motif/NN functions/VBZ as/IN a/DT potent/JJ IL-1/tumor/NN necrosis/NN factor-responsive/JJ element/NN in/IN nonlymphoid/JJ cells/NNS ,/, its/PRP$ activity/NN was/VBD found/VBN to/TO be/VB repressed/VBN in/IN lymphoid/JJ cells/NNS such/JJ as/IN a/DT Jurkat/NN T-cell/NN line/NN ./. 
We/PRP also/RB present/VBP evidence/NN that/IN IL-6/NN kappa/NN B/NN binding/NN factor/NN II/CD functions/VBZ as/IN a/DT repressor/NN specific/JJ for/IN IL-6/NN kappa/NN B-related/JJ kappa/NN B/NN motifs/NNS in/IN lymphoid/JJ cells/NNS ./. 
UI/LS -/: 92156261/CD 
TI/LS -/: Cortisol/NN resistance/NN in/IN acquired/VBN immunodeficiency/NN syndrome/NN ./. 
AB/LS -/: This/DT study/NN concerns/VBZ 9/CD iv/NN drug/NN abusers/NNS with/IN acquired/VBN immunodeficiency/NN syndrome/NN (/( AIDS/NN )/) who/WP developed/VBD hypercortisolism/NN without/IN the/DT clinical/JJ signs/NNS or/CC metabolic/JJ consequences/NNS of/IN hypercortisolism/NN ./. 
All/DT patients/NNS were/VBD characterized/VBN by/IN an/DT Addisonian/JJ picture/NN (/( weakness/NN ,/, weight/NN loss/NN ,/, hypotension/NN ,/, hyponatremia/NN ,/, and/CC intense/JJ mucocutaneous/JJ melanosis/NN )/) ./. 
An/DT acquired/JJ form/NN of/IN peripheral/JJ resistance/NN to/TO glucocorticoids/NNS was/VBD suspected/VBN ./. 
We/PRP ,/, therefore/RB ,/, examined/VBD glucocorticoid/NN receptor/NN characteristics/NNS on/IN mononuclear/JJ leukocytes/NNS by/IN measuring/VBG [3H]dexamethasone/NN binding/NN and/CC the/DT effect/NN of/IN dexamethasone/NN on/IN [3H]thymidine/NN incorporation/NN ,/, which/WDT is/VBZ one/CD of/IN the/DT effects/NNS of/IN glucocorticoid/NN receptor/NN activation/NN ./. 
Glucocorticoid/NN receptor/NN density/NN was/VBD increased/VBN in/IN AIDS/NN patients/NNS with/IN an/DT Addisonian/JJ picture/NN (/( group/NN 1/CD ;/: 16.2/CD +/-/CC 9.4/CD fmol/million/NN cells/NNS )/) compared/VBN to/TO values/NNS in/IN 12/CD AIDS/NN patients/NNS without/IN an/DT Addisonian/JJ picture/NN (/( group/NN 2/CD ;/: 6.05/CD +/-/CC 2.6/CD fmol/million/NN cells/NNS ;/: P/NN less/JJR than/IN 0.01/CD )/) and/CC sex-/NN and/CC age-matched/JJ controls/NNS (/( 3.15/CD +/-/CC 2.3/CD fmol/million/NN cells/NNS ;/: P/NN less/JJR than/IN 0.01/CD )/) ./. 
The/DT affinity/NN of/IN glucocorticoid/NN receptors/NNS (/( Kd/NN )/) was/VBD strikingly/RB decreased/VBN (/( 9.36/CD +/-/CC 3.44/CD nM/NN in/IN group/NN 1/CD ;/: 3.2/CD +/-/CC 1.5/CD nM/NN in/IN group/NN 2/CD ;/: 2.0/CD +/-/CC 0.8/CD nM/NN in/IN controls/NNS ;/: P/NN less/JJR than/IN 0.01/CD )/) ./. 
[3H]Thymidine/NN incorporation/NN was/VBD decreased/VBN dose-dependently/RB by/IN dexamethasone/NN in/IN controls/NNS and/CC patients/NNS ;/: the/DT effect/NN was/VBD significantly/RB blunted/VBN (/( P/NN less/JJR than/IN 0.05/CD )/) in/IN group/NN 1/CD patients/NNS ,/, which/WDT suggests/VBZ that/IN activation/NN of/IN glucocorticoid/NN receptor/NN is/VBZ impaired/JJ as/IN a/DT result/NN of/IN the/DT glucocorticoid/NN receptor/NN abnormality/NN ./. 
In/IN conclusion/NN ,/, AIDS/NN patients/NNS with/IN hypercortisolism/NN and/CC clinical/JJ features/NNS of/IN peripheral/JJ resistance/NN to/TO glucocorticoids/NNS are/VBP characterized/VBN by/IN abnormal/JJ glucocorticoid/NN receptors/NNS on/IN lymphocytes/NNS ./. 
Resistance/NN to/TO glucocorticoids/NNS implies/VBZ a/DT complex/JJ change/NN in/IN immune-endocrine/JJ function/NN ,/, which/WDT may/MD be/VB important/JJ in/IN the/DT course/NN of/IN immunodeficiency/NN syndrome/NN ./. 
UI/LS -/: 92134262/CD 
TI/LS -/: A/DT novel/JJ primer/NN extension/NN method/NN to/TO detect/VB the/DT number/NN of/IN CAG/NN repeats/NNS in/IN the/DT androgen/NN receptor/NN gene/NN in/IN families/NNS with/IN X-linked/JJ spinal/JJ and/CC bulbar/JJ muscular/JJ atrophy/NN ./. 
AB/LS -/: X-linked/JJ spinal/JJ and/CC bulbar/JJ muscular/JJ atrophy/NN (/( SBMA/NN )/) ,/, an/DT adult-onset/JJ form/NN of/IN motor/NN neuron/NN disease/NN ,/, was/VBD recently/RB reported/VBN to/TO be/VB caused/VBN by/IN amplification/NN of/IN the/DT CAG/NN repeats/NNS in/IN the/DT androgen/NN receptor/NN gene/NN ./. 
We/PRP report/VBP here/RB a/DT simple/JJ and/CC rapid/JJ strategy/NN to/TO detect/VB the/DT precise/JJ number/NN of/IN the/DT CAGs/NNS ./. 
After/IN the/DT DNA/NN fragment/NN containing/VBG the/DT CAG/NN repeats/NNS is/VBZ amplified/VBN by/IN the/DT polymerase/NN chain/NN reaction/NN ,/, a/DT primer/NN extension/NN is/VBZ carried/VBN out/RP ;/: the/DT extension/NN of/IN the/DT end-labelled/JJ reverse/JJ primer/NN adjacent/JJ to/TO 3'/JJ end/NN of/IN CAG/NN repeats/NNS stops/VBZ at/IN the/DT first/JJ T/NN after/IN CAG/NN repeats/NNS with/IN the/DT incorporation/NN of/IN dideoxy/JJ ATP/NN in/IN the/DT reaction/NN mixture/NN ./. 
The/DT resultant/JJ primer/NN products/NNS are/VBP analysed/VBN by/IN denaturing/VBG polyacrylamide/NN gel/NN electrophoresis/NN and/CC autoradiography/NN ./. 
This/DT method/NN could/MD be/VB quite/RB useful/JJ to/TO detect/VB not/RB only/RB CAG/NN repeats/NNS in/IN SBMA/NN but/CC also/RB other/JJ polymorphic/JJ dinucleotide/JJ and/CC trinucleotide/JJ repeats/NNS ./. 
UI/LS -/: 94051535/CD 
TI/LS -/: Cellular/JJ immune/JJ and/CC cytokine/NN pathways/NNS resulting/VBG in/IN tissue/NN factor/NN expression/NN and/CC relevance/NN to/TO septic/JJ shock/NN ./. 
AB/LS -/: Cells/NNS of/IN monocyte/NN lineage/NN serve/VBP as/IN effector/NN cells/NNS in/IN the/DT cellular/JJ immune/JJ response/NN ./. 
In/IN addition/NN ,/, they/PRP respond/VBP to/TO LPS/NN and/CC cytokines/NNS with/IN activation/NN and/CC expression/NN of/IN inflammatory/JJ effector/NN gene/NN products/NNS similar/JJ to/TO those/DT elicited/VBN by/IN the/DT antigen/NN driven/JJ response/NN ./. 
The/DT response/NN to/TO antigen/NN proceeds/VBZ at/IN the/DT T/NN helper/NN cell/NN level/NN through/IN two/CD independent/JJ forms/NNS of/IN cellular/JJ collaboration/NN ,/, contact/NN and/CC lymphokine/NN ./. 
We/PRP review/VBP the/DT control/NN of/IN expression/NN of/IN the/DT Tissue/NN Factor/NN (/( TF/NN )/) gene/NN and/CC the/DT function/NN of/IN the/DT TF/NN protein/NN ./. 
The/DT enhanced/VBN initiation/NN of/IN transcription/NN of/IN the/DT TF/NN gene/NN appears/VBZ to/TO require/VB engagement/NN of/IN a/DT 56/CD bp/NN LPS/NN Response/NN Element/NN ,/, an/DT enhancer/NN that/WDT is/VBZ engaged/VBN by/IN both/DT AP-1/NN type/NN heterodimeric/JJ complexes/NNS as/RB well/RB as/IN NF/NN kappa/NN B/NN like/IN heterodimeric/JJ complexes/NNS ./. 
Dissociation/NN of/IN NF/NN kappa/NN B/NN from/IN Ig/NN kappa/NN B/NN by/IN cytokine/NN and/CC LPS/NN stimulation/NN ,/, and/CC possibly/RB activated/VBN T/NN cells/NNS ,/, may/MD represent/VB a/DT common/JJ pathway/NN to/TO induction/NN of/IN the/DT TF/NN and/CC other/JJ inflammatory/JJ genes/NNS ./. 
Enhancement/NN of/IN expression/NN of/IN TF/NN is/VBZ observed/VBN upon/IN adhesion/NN of/IN Mo/NN to/TO endothelial/JJ cells/NNS and/CC extracellular/JJ matrix/JJ proteins/NNS ,/, as/RB well/RB as/IN upon/IN engagement/NN of/IN leukocyte/NN integrins/NNS ./. 
The/DT biological/JJ effects/NNS that/WDT follow/VBP from/IN expression/NN of/IN TF/NN by/IN vascular/JJ cells/NNS have/VBP been/VBN resolved/VBN by/IN analysis/NN of/IN function/NN aided/VBN by/IN the/DT use/NN of/IN recombinant/JJ full/JJ length/NN TF/NN and/CC truncated/VBN surface/NN domain/NN of/IN TF/NN ./. 
The/DT rules/NNS of/IN assembly/NN of/IN the/DT cognate/JJ ligands/NNS of/IN TF/NN ,/, namely/RB the/DT zymogen/NN plasma/NN factors/NNS VII/NN and/CC the/DT serine/NN protease/NN factor/NN VIIa/NN ,/, with/IN the/DT soluble/JJ surface/NN domain/NN of/IN TF/NN in/IN free/JJ solution/NN ,/, in/IN the/DT presence/NN of/IN phospholipid/JJ surfaces/NNS and/CC cell/NN surface/NN and/CC of/IN the/DT anchored/VBN TF/NN molecule/NN have/VBP been/VBN described/VBN ./. 
It/PRP is/VBZ evident/JJ that/IN assembly/NN of/IN the/DT surface/NN domain/NN of/IN TF/NN with/IN VIIa/NN to/TO form/VB the/DT binary/JJ TF.VIIa/NN complex/NN induces/VBZ a/DT significant/JJ increase/NN in/IN the/DT Kcat/NN of/IN the/DT catalytic/JJ domain/NN of/IN VIIa/NN for/IN small/JJ peptidyl/JJ substrates/NNS and/CC more/JJR profoundly/RB for/IN protein/NN substrate/NN ./. 
This/DT provides/VBZ substantial/JJ evidence/NN for/IN an/DT allosteric/JJ effect/NN on/IN the/DT catalytic/JJ cleft/NN of/IN VIIa/NN that/WDT is/VBZ imparted/VBN by/IN binding/VBG to/TO TF/NN ,/, its/PRP$ cognate/JJ catalytic/JJ cofactor/NN ./. 
It/PRP is/VBZ also/RB evident/JJ that/IN the/DT TF.VIIa/NN complex/NN is/VBZ proteolytically/RB active/JJ and/CC can/MD activate/VB the/DT zymogen/NN plasma/NN factor/NN X/NN to/TO the/DT serine/NN protease/NN Xa/NN in/IN free/JJ solution/NN ,/, inferring/VBG that/IN extended/VBN substrate/NN recognition/NN by/IN induced/VBN structural/JJ loci/NNS of/IN the/DT TF.VIIa/NN complex/NN are/VBP created/VBN from/IN either/DT or/CC both/DT proteins/NNS to/TO constitute/VB a/DT new/JJ recognition/NN structure/NN ./. 
It/PRP is/VBZ also/RB evident/JJ that/IN association/NN of/IN X/NN with/IN charged/JJ phospholipid/JJ surfaces/NNS enhances/VBZ the/DT proteolytic/JJ activation/NN of/IN this/DT zymogen/NN by/IN increasing/VBG recognition/NN and/CC susceptibility/NN of/IN the/DT sessile/NN peptide/NN bond/NN deduced/VBN from/IN the/DT markedly/RB decreased/VBN Km/NN and/CC increased/VBN Kcat/NN ./. 
UI/LS -/: 93100507/CD 
TI/LS -/: Phorbol/NN ester/NN reduces/VBZ constitutive/JJ nuclear/JJ NF/NN kappa/NN B/NN and/CC inhibits/VBZ HIV-1/NN production/NN in/IN mature/JJ human/JJ monocytic/JJ cells/NNS ./. 
AB/LS -/: NF/NN kappa/NN B/NN is/VBZ a/DT potent/JJ mediator/NN of/IN specific/JJ gene/NN expression/NN in/IN human/JJ monocytes/NNS and/CC has/VBZ been/VBN shown/VBN to/TO play/VB a/DT role/NN in/IN transcription/NN of/IN the/DT HIV-1/NN genome/NN in/IN promonocytic/JJ leukemias/NNS ./. 
There/EX is/VBZ little/JJ information/NN available/JJ on/IN the/DT response/NN of/IN NF/NN kappa/NN B/NN to/TO cytokines/NNS in/IN normal/JJ human/JJ monocytes/NNS ./. 
We/PRP have/VBP used/VBN a/DT 32P-labeled/JJ oligonucleotide/NN derived/VBN from/IN human/JJ immunodeficiency/NN virus/NN (/( HIV-1/NN )/) long/JJ terminal/JJ repeat/NN ,/, which/WDT contains/VBZ a/DT tandem/JJ repeat/NN of/IN the/DT NF/NN kappa/NN B/NN binding/NN sequence/NN ,/, as/IN a/DT probe/NN in/IN a/DT gel/NN retardation/NN assay/NN to/TO study/VB this/DT transcription/NN factor/NN ./. 
Using/VBG this/DT assay/NN ,/, we/PRP have/VBP detected/VBN NF/NN kappa/NN B/NN in/IN extracts/NNS of/IN nuclei/NNS from/IN normal/JJ human/JJ monocytes/NNS ./. 
Treatment/NN of/IN normal/JJ monocytes/NNS with/IN 12-0-/NN tetradecanoyl/NN phorbol-13-acetate/NN (/( TPA/NN )/) for/IN 4-24/CD h/NN caused/VBD the/DT complete/JJ disappearance/NN of/IN NF/NN kappa/NN B/NN from/IN nuclear/JJ extracts/NNS of/IN monocytes/NNS ./. 
A/DT similar/JJ result/NN was/VBD obtained/VBN with/IN the/DT mature/JJ monocytic/JJ leukemia/NN cell/NN line/NN THP-1/NN ./. 
The/DT constitutive/JJ transcription/NN factor/NN SP1/NN was/VBD unaffected/JJ by/IN addition/NN of/IN TPA/NN ./. 
The/DT disappearance/NN of/IN NF/NN kappa/NN B/NN from/IN the/DT nucleus/NN was/VBD concentration/NN dependent/JJ between/IN 10/CD and/CC 50/CD ng/ml/NN of/IN phorbol/NN ester/NN ./. 
In/IN THP-1/NN cells/NNS ,/, TPA/NN also/RB induced/VBD a/DT new/JJ ,/, faster-migrating/JJ NF/NN kappa/NN B/NN species/NNS not/RB induced/VBN in/IN monocytes/NNS ./. 
Protein/NN kinase/NN C/NN inhibitor/NN staurosporine/NN ,/, but/CC not/RB cyclic/JJ nucleotide-dependent/JJ protein/NN kinase/NN inhibitor/NN HA-1004/NN ,/, also/RB dramatically/RB reduced/VBD constitutive/JJ levels/NNS of/IN nuclear/JJ NF/NN kappa/NN B/NN ./. 
Finally/RB ,/, TPA/NN addition/NN to/TO monocytes/NNS infected/VBN with/IN HIV-1/NN inhibited/VBD HIV-1/NN replication/NN ,/, as/IN determined/VBN by/IN reverse/JJ transcriptase/NN assays/NNS ,/, in/IN a/DT concentration-dependent/JJ manner/NN ./. 
These/DT results/NNS are/VBP in/IN striking/JJ contrast/NN to/TO the/DT increase/NN in/IN nuclear/JJ NF/NN kappa/NN B/NN and/CC HIV-1/NN replication/NN induced/VBN by/IN phorbol/NN esters/NNS in/IN promonocytic/JJ leukemia/NN cells/NNS U937/NN and/CC HL-60/NN ,/, and/CC emphasize/VBP the/DT importance/NN of/IN studying/VBG cytokine/NN regulation/NN of/IN HIV-1/NN in/IN normal/JJ monocytes/NNS ./. 
UI/LS -/: 93066282/CD 
TI/LS -/: A/DT mechanism/NN for/IN the/DT antiinflammatory/JJ effects/NNS of/IN corticosteroids/NNS :/: the/DT glucocorticoid/NN receptor/NN regulates/VBZ leukocyte/NN adhesion/NN to/TO endothelial/JJ cells/NNS and/CC expression/NN of/IN endothelial-leukocyte/JJ adhesion/NN molecule/NN 1/CD and/CC intercellular/JJ adhesion/NN molecule/NN 1/CD ./. 
AB/LS -/: Corticosteroids/NNS are/VBP the/DT preeminent/JJ antiinflammatory/JJ agents/NNS although/IN the/DT molecular/JJ mechanisms/NNS that/WDT impart/VBP their/PRP$ efficacy/NN have/VBP not/RB been/VBN defined/VBN ./. 
The/DT endothelium/NN plays/VBZ a/DT critical/JJ role/NN in/IN inflammation/NN by/IN directing/VBG circulating/VBG leukocytes/NNS into/IN extravascular/JJ tissues/NNS by/IN expressing/VBG adhesive/JJ molecules/NNS for/IN leukocytes/NNS [/( e.g./FW ,/, endothelial-leukocyte/JJ adhesion/NN molecule/NN 1/CD (/( ELAM-1/NN )/) and/CC intercellular/JJ adhesion/NN molecule/NN 1/CD (/( ICAM-1/NN )/) ]/) ./. 
We/PRP therefore/RB determined/VBD whether/IN corticosteroids/NNS suppress/VBP inflammation/NN by/IN inhibiting/VBG endothelial/JJ expression/NN of/IN adhesion/NN molecules/NNS for/IN neutrophils/NNS (/( polymorphonuclear/JJ leukocytes/NNS )/) ./. 
Preincubation/NN of/IN endothelial/JJ cells/NNS with/IN endotoxin/NN [/( lipopolysaccharide/NN (/( LPS/NN )/) ,/, 1/CD microgram/ml/NN ]/) led/VBD to/TO a/DT 4-fold/JJ increase/NN in/IN subsequent/JJ adherence/NN of/IN polymorphonuclear/JJ leukocytes/NNS (/( P/NN </JJR 0.0001/CD ,/, n/NN =/JJ 10/CD )/) to/TO endothelial/JJ cells/NNS ,/, an/DT increase/NN that/WDT was/VBD markedly/RB attenuated/VBN when/WRB endothelial/JJ cells/NNS were/VBD treated/VBN with/IN dexamethasone/NN (/( IC50/NN </JJR 1/CD nM/NN ,/, P/NN </JJR 0.0001/CD ,/, n/NN =/JJ 6/CD or/CC 7/CD )/) during/IN preincubation/NN with/IN LPS/NN ./. 
Moreover/RB ,/, the/DT steroid/NN receptor/NN agonist/NN cortisol/NN (/( 10/CD microM/NN )/) ,/, but/CC not/RB its/PRP$ inactive/JJ metabolite/NN tetrahydrocortisol/NN (/( 10/CD microM/NN )/) ,/, diminished/VBD LPS-induced/JJ endothelial/JJ cell/NN adhesiveness/NN ./. 
Further/JJ evidence/NN that/IN the/DT action/NN of/IN dexamethasone/NN was/VBD mediated/VBN through/IN ligation/NN of/IN corticosteroid/NN receptors/NNS [/( human/JJ glucocorticoid/NN receptors/NNS (/( hGRs/NNS )/) ]/) was/VBD provided/VBN by/IN experiments/NNS utilizing/VBG the/DT steroid/NN antagonist/NN RU-486/NN ./. 
RU-486/NN (/( 10/CD microM/NN )/) ,/, which/WDT prevents/VBZ translocation/NN of/IN ligated/VBN hGR/NN to/TO the/DT nucleus/NN by/IN inhibiting/VBG dissociation/NN of/IN hGR/NN from/IN heat/NN shock/NN protein/NN 90/CD ,/, completely/RB aborted/VBD the/DT effect/NN of/IN dexamethasone/NN on/IN adhesiveness/NN of/IN endothelial/JJ cells/NNS (/( P/NN </JJR 0.0005/CD ,/, n/NN =/JJ 3/CD )/) ./. 
Treatment/NN of/IN endothelial/JJ cells/NNS with/IN LPS/NN (/( 1/CD microgram/ml/NN )/) stimulated/VBD transcription/NN of/IN ELAM-1/NN ,/, as/IN shown/VBN by/IN Northern/NN blot/NN analysis/NN ,/, and/CC expression/NN of/IN membrane-associated/JJ ELAM-1/NN and/CC ICAM-1/NN ,/, as/IN shown/VBN by/IN quantitative/JJ immunofluorescence/NN (/( both/DT P/NN </JJR 0.001/CD ,/, n/NN =/JJ 9/CD )/) ./. 
Dexamethasone/NN markedly/RB inhibited/VBD LPS-stimulated/JJ accumulation/NN of/IN mRNA/NN for/IN ELAM-1/NN and/CC expression/NN of/IN ELAM-1/NN and/CC ICAM-1/NN (/( IC50/NN </JJR 10/CD nM/NN ,/, both/DT P/NN </JJR 0.001/CD ,/, n/NN =/JJ 4-9/CD )/) ;/: inhibition/NN of/IN expression/NN by/IN dexamethasone/NN was/VBD reversed/VBN by/IN RU-486/NN (/( both/DT P/NN </JJR 0.005/CD ,/, n/NN =/JJ 4-6/CD )/) ./. 
As/IN in/IN the/DT adhesion/NN studies/NNS ,/, cortisol/NN but/CC not/RB tetrahydrocortisol/NN inhibited/VBD expression/NN of/IN ELAM-1/NN and/CC ICAM-1/NN (/( both/DT P/NN </JJR 0.005/CD ,/, n/NN =/JJ 3/CD or/CC 4/CD )/) ./. 
In/IN contrast/NN ,/, sodium/NN salicylate/NN (/( 1/CD mM/NN )/) inhibited/VBD neither/CC adhesion/NN nor/CC expression/NN of/IN these/DT adhesion/NN molecules/NNS ./. 
These/DT studies/NNS suggest/VBP that/IN antagonism/NN by/IN dexamethasone/NN of/IN endotoxin-induced/JJ inflammation/NN is/VBZ a/DT specific/JJ instance/NN of/IN the/DT general/JJ biological/JJ principle/NN that/IN the/DT glucocorticoid/NN receptor/NN is/VBZ a/DT hormone-dependent/JJ regulator/NN of/IN transcription/NN ./. 
UI/LS -/: 92387536/CD 
TI/LS -/: Pax-5/NN encodes/VBZ the/DT transcription/NN factor/NN BSAP/NN and/CC is/VBZ expressed/VBN in/IN B/NN lymphocytes/NNS ,/, the/DT developing/VBG CNS/NNS ,/, and/CC adult/JJ testis/NN ./. 
AB/LS -/: BSAP/NN has/VBZ been/VBN identified/VBN previously/RB as/IN a/DT transcription/NN factor/NN that/WDT is/VBZ expressed/VBN at/IN early/JJ ,/, but/CC not/RB late/JJ ,/, stages/NNS of/IN B-cell/NN differentiation/NN ./. 
Biochemical/JJ purification/NN and/CC cDNA/NN cloning/NN has/VBZ now/RB revealed/VBN that/IN BSAP/NN belongs/VBZ to/TO the/DT family/NN of/IN paired/JJ domain/NN proteins/NNS ./. 
BSAP/NN is/VBZ encoded/VBN by/IN the/DT Pax-5/NN gene/NN and/CC has/VBZ been/VBN highly/RB conserved/VBN between/IN human/JJ and/CC mouse/NN ./. 
An/DT intact/JJ paired/JJ domain/NN was/VBD shown/VBN to/TO be/VB both/CC necessary/JJ and/CC sufficient/JJ for/IN DNA/NN binding/NN of/IN BSAP/NN ./. 
Binding/VBG studies/NNS with/IN several/JJ BSAP/NN recognition/NN sequences/NNS demonstrated/VBD that/IN the/DT sequence/NN specificity/NN of/IN BSAP/NN differs/VBZ from/IN that/DT of/IN the/DT distantly/RB related/JJ paired/JJ domain/NN protein/NN Pax-1/NN ./. 
During/IN embryogenesis/NN ,/, the/DT BSAP/NN gene/NN is/VBZ transiently/RB expressed/VBN in/IN the/DT mesencephalon/NN and/CC spinal/JJ cord/NN with/IN a/DT spatial/JJ and/CC temporal/JJ expression/NN pattern/NN that/WDT is/VBZ distinct/JJ from/IN that/DT of/IN other/JJ Pax/NN genes/NNS in/IN the/DT developing/VBG central/JJ nervous/JJ system/NN (/( CNS/NN )/) ./. 
Later/RB ,/, the/DT expression/NN of/IN the/DT BSAP/NN gene/NN shifts/VBZ to/TO the/DT fetal/JJ liver/NN where/WRB it/PRP correlates/VBZ with/IN the/DT onset/NN of/IN B/NN lymphopoiesis/NN ./. 
BSAP/NN expression/NN persists/VBZ in/IN B/NN lymphocytes/NNS and/CC is/VBZ also/RB seen/VBN in/IN the/DT testis/NN of/IN the/DT adult/JJ mouse/NN ./. 
All/DT of/IN this/DT evidence/NN indicates/VBZ that/IN the/DT transcription/NN factor/NN BSAP/NN may/MD not/RB only/RB play/VB an/DT important/JJ role/NN in/IN B-cell/NN differentiation/NN but/CC also/RB in/IN neural/JJ development/NN and/CC spermatogenesis/NN ./. 
UI/LS -/: 92335296/CD 
TI/LS -/: Cell/NN cycle-dependent/JJ initiation/NN and/CC lineage-dependent/JJ abrogation/NN of/IN GATA-1/NN expression/NN in/IN pure/JJ differentiating/VBG hematopoietic/JJ progenitors/NNS ./. 
AB/LS -/: The/DT programmed/VBN activation/repression/NN of/IN transcription/NN factors/NNS in/IN early/JJ hematopoietic/JJ differentiation/NN has/VBZ not/RB yet/RB been/VBN explored/VBN ./. 
The/DT DNA-binding/JJ protein/NN GATA-1/NN is/VBZ required/VBN for/IN normal/JJ erythroid/JJ development/NN and/CC regulates/VBZ erythroid-expressed/JJ genes/NNS in/IN maturing/VBG erythroblasts/NNS ./. 
We/PRP analyzed/VBD GATA-1/NN expression/NN in/IN early/JJ human/JJ adult/JJ hematopoiesis/NN by/IN using/VBG an/DT in/FW vitro/FW system/NN in/IN which/WDT "/`` pure/JJ "/'' early/JJ hematopoietic/JJ progenitors/NNS are/VBP induced/VBN to/TO gradual/JJ and/CC synchronized/VBD differentiation/NN selectively/RB along/IN the/DT erythroid/JJ or/CC granulocyte-macrophage/JJ pathway/NN by/IN differential/JJ treatment/NN with/IN hematopoietic/JJ growth/NN factors/NNS ./. 
The/DT GATA-1/NN gene/NN ,/, though/IN virtually/RB silent/JJ in/IN quiescent/JJ progenitors/NNS ,/, is/VBZ activated/VBN after/IN entrance/NN into/IN the/DT cell/NN cycle/NN upon/IN stimulation/NN with/IN hematopoietic/JJ growth/NN factors/NNS ./. 
Subsequently/RB ,/, increasing/VBG expression/NN along/IN the/DT erythroid/JJ pathway/NN contrasts/VBZ with/IN an/DT abrupt/JJ downregulation/NN in/IN the/DT granulocyte-macrophage/JJ lineage/NN ./. 
These/DT results/NNS suggest/VBP a/DT microenvironment-directed/JJ ,/, two-step/JJ model/NN for/IN GATA-1/NN expression/NN in/IN differentiating/VBG hematopoietic/JJ progenitors/NNS that/WDT involves/VBZ (/( i/LS )/) cycle-dependent/JJ initiation/NN and/CC (/( ii/LS )/) lineage-dependent/JJ maintenance/NN or/CC suppression/NN ./. 
Hypothetically/RB ,/, on/off/JJ switches/NNS of/IN lineage-restricted/JJ transactivators/NNS may/MD underlie/VB the/DT binary/JJ fate/NN decisions/NNS of/IN hematopoietic/JJ progenitors/NNS ./. 
UI/LS -/: 92260664/CD 
TI/LS -/: Specific/JJ NF-kappa/NN B/NN subunits/NNS act/VBP in/IN concert/NN with/IN Tat/NN to/TO stimulate/VB human/JJ immunodeficiency/NN virus/NN type/NN 1/CD transcription/NN ./. 
AB/LS -/: NF-kappa/NN B/NN is/VBZ a/DT protein/NN complex/NN which/WDT functions/VBZ in/IN concert/NN with/IN the/DT tat-I/NN gene/NN product/NN to/TO stimulate/VB human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) transcription/NN ./. 
To/TO determine/VB whether/IN specific/JJ members/NNS of/IN the/DT NF-kappa/NN B/NN family/NN contribute/VBP to/TO this/DT effect/NN ,/, we/PRP have/VBP examined/VBN the/DT abilities/NNS of/IN different/JJ NF-kappa/NN B/NN subunits/NNS to/TO act/VB with/IN Tat-I/NN to/TO stimulate/VB transcription/NN of/IN HIV/NN in/IN Jurkat/NN T-leukemia/NN cells/NNS ./. 
We/PRP have/VBP found/VBN that/IN the/DT p49/NN (/( 100/CD )/) DNA/NN binding/NN subunit/NN ,/, together/RB with/IN p65/NN ,/, can/MD act/VB in/IN concert/NN with/IN Tat-I/NN to/TO stimulate/VB the/DT expression/NN of/IN HIV-CAT/NN plasmid/NN ./. 
Little/JJ effect/NN was/VBD observed/VBN with/IN 50-kDa/JJ forms/NNS of/IN p105/NN NF-kappa/NN B/NN or/CC rel/NN ,/, in/IN combination/NN with/IN p65/NN or/CC full-length/JJ c-rel/NN ,/, which/WDT do/VBP not/RB stimulate/VB the/DT HIV/NN enhancer/NN in/IN these/DT cells/NNS ./. 
These/DT findings/NNS suggest/VBP that/IN the/DT combination/NN of/IN p49/NN (/( 100/CD )/) and/CC p65/NN NF-kappa/NN B/NN can/MD act/VB in/IN concert/NN with/IN the/DT tat-I/NN gene/NN product/NN to/TO stimulate/VB the/DT synthesis/NN of/IN HIV/NN RNA/NN ./. 
UI/LS -/: 92235036/CD 
TI/LS -/: Stable/JJ expression/NN of/IN HB24/NN ,/, a/DT diverged/JJ human/JJ homeobox/NN gene/NN ,/, in/IN T/NN lymphocytes/NNS induces/VBZ genes/NNS involved/VBN in/IN T/NN cell/NN activation/NN and/CC growth/NN ./. 
AB/LS -/: A/DT diverged/JJ homeobox/NN gene/NN ,/, HB24/NN ,/, which/WDT is/VBZ known/VBN to/TO be/VB induced/VBN following/VBG lymphocyte/NN activation/NN ,/, was/VBD introduced/VBN into/IN Jurkat/NN T/NN cells/NNS under/IN the/DT control/NN of/IN a/DT constitutive/JJ promoter/NN ./. 
Stable/JJ transfectants/NNS of/IN HB24/NN were/VBD established/VBN that/WDT expressed/VBD high/JJ levels/NNS of/IN HB24/NN mRNA/NN and/CC possessed/VBD an/DT altered/JJ phenotype/NN suggestive/JJ of/IN activated/VBN T/NN cells/NNS ./. 
A/DT number/NN of/IN genes/NNS known/VBN to/TO be/VB induced/VBN following/VBG T/NN cell/NN activation/NN and/CC associated/VBN with/IN cell/NN growth/NN were/VBD increased/VBN in/IN the/DT transfectants/NNS ,/, including/VBG c-fos/NN ,/, c-myc/NN ,/, c-myb/NN ,/, HLA-DR/NN ,/, lck/NN ,/, NF-kappa/NN B/NN ,/, interleukin-2/NN and/CC interleukin-2/NN receptor/NN alpha/NN (/( IL-2R/NN alpha/NN )/) ./. 
Analysis/NN of/IN IL-2R/NN alpha/NN expression/NN by/IN transient/JJ transfection/NN of/IN IL-2R/NN alpha/NN promoter/NN constructs/NNS into/IN the/DT HB24/NN transfectants/NNS revealed/VBD constitutive/JJ expression/NN (/( about/RB 60/CD %/NN of/IN phytohemagglutinin-/NN and/CC phorbol/NN ester-activated/JJ Jurkat/NN cells/NNS )/) that/WDT was/VBD dependent/JJ on/IN the/DT kappa/NN B/NN site/NN in/IN the/DT IL-2R/NN alpha/NN promoter/NN ./. 
Furthermore/RB ,/, as/IN a/DT consequence/NN of/IN the/DT increased/VBN HB24/NN mRNA/NN levels/NNS ,/, the/DT Jurkat/NN HB24/NN transfectants/NNS proliferated/VBD more/RBR rapidly/RB than/IN control/NN cell/NN lines/NNS ./. 
Thus/RB ,/, stable/JJ expression/NN of/IN HB24/NN confers/VBZ an/DT activation/NN phenotype/NN on/IN a/DT human/JJ T/NN cell/NN line/NN ,/, implicating/VBG this/DT gene/NN as/IN an/DT important/JJ transcriptional/JJ factor/NN during/IN T/NN cell/NN activation/NN and/CC growth/NN ./. 
UI/LS -/: 92385366/CD 
TI/LS -/: Functional/JJ interaction/NN between/IN the/DT two/CD zinc/NN finger/NN domains/NNS of/IN the/DT v-erb/NN A/NN oncoprotein/NN ./. 
AB/LS -/: The/DT v-erb/NN A/NN oncogene/NN of/IN avian/JJ erythroblastosis/NN virus/NN is/VBZ a/DT mutated/VBN and/CC virally/RB transduced/VBN copy/NN of/IN a/DT host/NN cell/NN gene/NN encoding/VBG a/DT thyroid/NN hormone/NN receptor/NN ./. 
The/DT protein/NN expressed/VBN by/IN the/DT v-erb/NN A/NN oncogene/NN binds/VBZ to/TO DNA/NN and/CC acts/VBZ as/IN a/DT dominant/JJ negative/JJ inhibitor/NN of/IN both/CC the/DT thyroid/NN hormone/NN receptor/NN and/CC the/DT closely/RB related/JJ retinoic/JJ acid/NN receptor/NN ./. 
The/DT v-erb/NN A/NN protein/NN has/VBZ sustained/VBN two/CD amino/NN acid/NN alterations/NNS within/IN its/PRP$ DNA-binding/JJ domain/NN relative/JJ to/TO that/DT of/IN c-erb/NN A/NN ,/, one/CD of/IN which/WDT ,/, at/IN serine/NN 61/CD ,/, is/VBZ known/VBN to/TO be/VB important/JJ for/IN v-erb/NN A/NN function/NN in/IN the/DT neoplastic/JJ cell/NN ./. 
We/PRP report/VBP here/RB that/IN the/DT second/JJ alteration/NN ,/, at/IN threonine/NN 78/CD ,/, also/RB plays/VBZ an/DT important/JJ ,/, although/IN more/RBR indirect/JJ ,/, role/NN :/: alteration/NN of/IN the/DT sequence/NN at/IN threonine/NN 78/CD such/JJ that/IN it/PRP resembles/VBZ that/DT of/IN c-erb/NN A/NN can/MD act/VB as/IN an/DT intragenic/JJ suppressor/NN and/CC can/MD partially/RB restore/VB function/NN to/TO a/DT v-erb/NN A/NN protein/NN rendered/VBN defective/JJ due/JJ to/TO a/DT mutation/NN at/IN position/NN 61/CD ./. 
Threonine/NN 78/CD lies/VBZ within/IN the/DT D-box/NN of/IN the/DT v-erb/NN A/NN protein/NN ,/, a/DT region/NN thought/VBN to/TO mediate/VB receptor-receptor/JJ dimerizations/NNS ,/, and/CC is/VBZ not/RB in/IN physical/JJ proximity/NN to/TO the/DT serine/NN at/IN position/NN 61/CD ./. 
It/PRP therefore/RB appears/VBZ that/IN an/DT indirect/JJ interaction/NN occurs/VBZ between/IN these/DT two/CD sites/NNS and/CC that/IN this/DT interaction/NN is/VBZ crucial/JJ for/IN v-erb/NN A/NN function/NN ./. 
UI/LS -/: 92186836/CD 
TI/LS -/: cis-acting/JJ sequences/NNS required/VBN for/IN inducible/JJ interleukin-2/NN enhancer/NN function/NN bind/VBP a/DT novel/JJ Ets-related/JJ protein/NN ,/, Elf-1/NN ./. 
AB/LS -/: The/DT recent/JJ definition/NN of/IN a/DT consensus/NN DNA/NN binding/NN sequence/NN for/IN the/DT Ets/NN family/NN of/IN transcription/NN factors/NNS has/VBZ allowed/VBN the/DT identification/NN of/IN potential/JJ Ets/NN binding/NN sites/NNS in/IN the/DT promoters/NNS and/CC enhancers/NNS of/IN many/JJ inducible/JJ T-cell/NN genes/NNS ./. 
In/IN the/DT studies/NNS described/VBN in/IN this/DT report/NN ,/, we/PRP have/VBP identified/VBN two/CD potential/JJ Ets/NNS binding/NN sites/NNS ,/, EBS1/NN and/CC EBS2/NN ,/, which/WDT are/VBP conserved/VBN in/IN both/CC the/DT human/JJ and/CC murine/JJ interleukin-2/NN enhancers/NNS ./. 
Within/IN the/DT human/JJ enhancer/NN ,/, these/DT two/CD sites/NNS are/VBP located/JJ within/IN the/DT previously/RB defined/VBN DNase/NN I/CD footprints/NNS ,/, NFAT-1/NN and/CC NFIL-2B/NN ,/, respectively/RB ./. 
Electrophoretic/JJ mobility/NN shift/NN and/CC methylation/NN interference/NN analyses/NNS demonstrated/VBD that/IN EBS1/NN and/CC EBS2/NN are/VBP essential/JJ for/IN the/DT formation/NN of/IN the/DT NFAT-1/NN and/CC NFIL-2B/NN nuclear/JJ protein/NN complexes/NNS ./. 
Furthermore/RB ,/, in/FW vitro/FW mutagenesis/NN experiments/NNS demonstrated/VBD that/IN inducible/JJ interleukin-2/NN enhancer/NN function/NN requires/VBZ the/DT presence/NN of/IN either/CC EBS1/NN or/CC EBS2/NN ./. 
Two/CD well-characterized/JJ Ets/NN family/NN members/NNS ,/, Ets-1/NN and/CC Ets-2/NN ,/, are/VBP reciprocally/RB expressed/VBN during/IN T-cell/NN activation/NN ./. 
Surprisingly/RB ,/, however/RB ,/, neither/DT of/IN these/DT proteins/NNS bound/VBD in/FW vitro/FW to/TO EBS1/NN or/CC EBS2/NN ./. 
We/PRP therefore/RB screened/VBD a/DT T-cell/NN cDNA/NN library/NN under/IN low-stringency/NN conditions/NNS with/IN a/DT probe/NN from/IN the/DT DNA/NN binding/NN domain/NN of/IN Ets-1/NN and/CC isolated/VBD a/DT novel/JJ Ets/NN family/NN member/NN ,/, Elf-1/NN ./. 
Elf-1/NN contains/VBZ a/DT DNA/NN binding/NN domain/NN that/WDT is/VBZ nearly/RB identical/JJ to/TO that/DT of/IN E74/NN ,/, the/DT ecdysone-inducible/JJ Drosophila/NN transcription/NN factor/NN required/VBN for/IN metamorphosis/NN (/( hence/RB the/DT name/NN Elf-1/NN ,/, for/IN E74-like/JJ factor/NN 1/CD )/) ./. 
Elf-1/NN bound/VBD specifically/RB to/TO both/CC EBS1/NN and/CC EBS2/NN in/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS ./. 
It/PRP also/RB bound/VBD to/TO the/DT purine-rich/JJ CD3R/NN element/NN from/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 2/CD long/JJ terminal/JJ repeat/NN ,/, which/WDT is/VBZ required/VBN for/IN inducible/JJ virus/NN expression/NN in/IN response/NN to/TO signalling/NN through/IN the/DT T-cell/NN receptor/NN ./. 
Taken/VBN together/RB ,/, these/DT results/NNS demonstrate/VBP that/IN multiple/JJ Ets/NN family/NN members/NNS with/IN apparently/RB distinct/JJ DNA/NN binding/NN specificities/NNS regulate/VBP differential/JJ gene/NN expression/NN in/IN resting/VBG and/CC activated/VBN T/NN cells/NNS ./. 
UI/LS -/: 92165059/CD 
TI/LS -/: Binding/NN of/IN erythroid/JJ and/CC non-erythroid/JJ nuclear/JJ proteins/NNS to/TO the/DT silencer/NN of/IN the/DT human/JJ epsilon-globin-encoding/JJ gene/NN ./. 
AB/LS -/: To/TO clarify/VB the/DT molecular/JJ mechanisms/NNS involved/VBN in/IN the/DT developmental/JJ control/NN of/IN hemoglobin-encoding/JJ genes/NNS we/PRP have/VBP been/VBN studying/VBG the/DT expression/NN of/IN these/DT genes/NNS in/IN human/JJ cells/NNS in/IN continuous/JJ culture/NN ./. 
We/PRP have/VBP previously/RB reported/VBN the/DT presence/NN of/IN a/DT transcriptional/JJ control/NN element/NN with/IN the/DT properties/NNS of/IN a/DT silencer/NN extending/VBG from/IN -392/CD to/TO -177/CD bp/NN relative/JJ to/TO the/DT cap/NN site/NN of/IN the/DT human/JJ epsilon-globin-encoding/JJ gene/NN [/( Cao/NNP et/FW al./FW ,/, Proc.Natl.Acad.Sci.USA/NNP 86/CD (/( 1989/CD )/) 5306-5309/CD ]/) ./. 
We/PRP also/RB showed/VBD that/IN this/DT silencer/NN has/VBZ stronger/JJR inhibitory/JJ activity/NN in/IN HeLa/NN cells/NNS ,/, as/IN compared/VBN to/TO K562/NN human/JJ erythroleukemia/NN cells/NNS ./. 
Using/VBG deletion/NN mutants/NNS and/CC cis-cloned/JJ synthetic/JJ oligodeoxyribonucleotides/NNS in/IN transient/JJ expression/NN assays/NNS ,/, nucleotide/NN sequences/NNS responsible/JJ for/IN this/DT effect/NN have/VBP now/RB been/VBN further/RBR delimited/VBN to/TO 44/CD bp/NN located/JJ from/IN -294/CD to/TO -251/CD bp/NN ./. 
Gel/NN electrophoresis/NN mobility/NN shift/NN assays/NNS and/CC DNaseI/NN footprinting/NN assays/NNS demonstrate/VBP that/IN these/DT negative/JJ regulatory/JJ sequences/NNS are/VBP recognized/VBN differently/RB by/IN proteins/NNS present/JJ in/IN nuclear/JJ extracts/NNS obtained/VBN from/IN HeLa/NN and/CC K562/NN cells/NNS ./. 
Two/CD binding/VBG proteins/NNS are/VBP detected/VBN in/IN K562/NN nuclear/JJ extracts/NNS ,/, while/IN only/RB one/CD is/VBZ found/VBN in/IN extracts/NNS from/IN HeLa/NN cells/NNS ./. 
Possible/JJ mechanisms/NNS by/IN which/WDT these/DT proteins/NNS may/MD regulate/VB transcription/NN of/IN the/DT epsilon-globin-encoding/JJ gene/NN in/IN erythroid/JJ and/CC non-erythroid/JJ cells/NNS are/VBP discussed/VBN ./. 
UI/LS -/: 93113611/CD 
TI/LS -/: Calcitriol/NN :/: a/DT hematolymphopoietrope/NN ?/. [/( editorial/NN ]/) 
AB/LS -/: A/DT MEDLINE/NN search/NN of/IN the/DT English-language/JJ literature/NN was/VBD conducted/VBN using/VBG the/DT indexing/NN terms/NNS '/`` immunology/NN ,/, calcitriol/NN and/CC vitamin/NN D/NN '/'' to/TO identify/VB studies/NNS indicating/VBG a/DT role/NN for/IN calcitriol/NN as/IN a/DT primary/JJ immunomodulator/NN ./. 
Sixty-six/CD papers/NNS published/VBN between/IN January/NNP 1956/CD and/CC June/NNP 1991/CD were/VBD identified/VBN ./. 
Forty-five/CD of/IN these/DT reports/NNS are/VBP cited/VBN in/IN this/DT review/NN ./. 
The/DT data/NNS strongly/RB suggest/VBP an/DT endocrine/NN ,/, autocrine/NN and/or/CC paracrine/NN role/NN for/IN calcitriol/NN in/IN immune/JJ regulation/NN ./. 
No/DT unifying/JJ hypothesis/NN has/VBZ yet/RB emerged/VBN explaining/VBG this/DT collection/NN of/IN data/NNS ./. 
This/DT paper/NN provides/VBZ a/DT brief/JJ review/NN of/IN immune/JJ properties/NNS currently/RB attributed/VBN to/TO calcitriol/NN ./. 
UI/LS -/: 93087498/CD 
TI/LS -/: Transcription/NN of/IN the/DT hypersensitive/JJ site/NN HS2/NN enhancer/NN in/IN erythroid/JJ cells/NNS ./. 
AB/LS -/: In/IN the/DT human/JJ genome/NN ,/, the/DT erythroid-specific/JJ hypersensitive/JJ site/NN HS2/NN enhancer/NN regulates/VBZ the/DT transcription/NN of/IN the/DT downstream/JJ beta-like/JJ globin/NN genes/NNS 10-50/CD kilobases/NNS away/RB ./. 
The/DT mechanism/NN of/IN HS2/NN enhancer/NN function/NN is/VBZ not/RB known/VBN ./. 
The/DT present/JJ study/NN employs/VBZ RNA/NN protection/NN assays/NNS to/TO analyze/VB the/DT transcriptional/JJ status/NN of/IN the/DT HS2/NN enhancer/NN in/IN transfected/VBN recombinant/JJ chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) plasmids/NNS ./. 
In/IN erythroid/JJ K562/NN cells/NNS in/IN which/WDT the/DT HS2/NN enhancer/NN is/VBZ active/JJ ,/, the/DT HS2/NN sequence/NN directs/VBZ the/DT synthesis/NN of/IN long/JJ enhancer/NN transcripts/NNS that/WDT are/VBP initiated/VBN apparently/RB from/IN within/IN the/DT enhancer/NN and/CC elongated/VBN through/IN the/DT intervening/VBG DNA/NN into/IN the/DT cis-linked/JJ CAT/NN gene/NN ./. 
In/IN nonerythroid/JJ HL-60/NN cells/NNS in/IN which/WDT the/DT HS2/NN enhancer/NN is/VBZ inactive/JJ ,/, long/JJ enhancer/NN transcripts/NNS are/VBP not/RB detectable/JJ ./. 
Splitting/VBG the/DT HS2/NN enhancer/NN between/IN two/CD tandem/JJ Ap1/NN sites/NNS abolishes/VBZ the/DT synthesis/NN of/IN a/DT group/NN of/IN long/JJ enhancer/NN transcripts/NNS and/CC results/VBZ in/IN loss/NN of/IN enhancer/NN function/NN and/CC transcriptional/JJ silencing/NN of/IN the/DT cis-linked/JJ CAT/NN gene/NN ./. 
In/IN directing/VBG the/DT synthesis/NN of/IN RNA/NN through/IN the/DT intervening/VBG DNA/NN and/CC the/DT gene/NN by/IN a/DT tracking/NN and/CC transcription/NN mechanism/NN ,/, the/DT HS2/NN enhancer/NN may/MD (/( i/LS )/) open/VB up/RP the/DT chromatin/NN structure/NN of/IN a/DT gene/NN domain/NN and/CC (/( ii/LS )/) deliver/VB enhancer/NN binding/NN proteins/NNS to/TO the/DT promoter/NN sequence/NN where/WRB they/PRP may/MD stimulate/VB the/DT transcription/NN of/IN the/DT gene/NN at/IN the/DT cap/NN site/NN ./. 
UI/LS -/: 93065212/CD 
TI/LS -/: Characterization/NN of/IN a/DT novel/JJ T/NN lymphocyte/NN protein/NN which/WDT binds/VBZ to/TO a/DT site/NN related/JJ to/TO steroid/thyroid/JJ hormone/NN receptor/NN response/NN elements/NNS in/IN the/DT negative/JJ regulatory/JJ sequence/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN long/JJ terminal/JJ repeat/NN ./. 
AB/LS -/: We/PRP have/VBP previously/RB identified/VBN a/DT T/NN lymphocyte/NN protein/NN which/WDT binds/VBZ to/TO a/DT site/NN within/IN the/DT LTR/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) and/CC exerts/VBZ an/DT inhibitory/JJ effect/NN on/IN virus/NN gene/NN expression/NN ./. 
The/DT palindromic/JJ site/NN (/( site/NN B/NN )/) recognized/VBN by/IN this/DT protein/NN is/VBZ related/JJ to/TO the/DT palindromic/JJ binding/VBG sites/NNS of/IN members/NNS of/IN the/DT steroid/thyroid/JJ hormone/NN receptor/NN family/NN ./. 
Here/RB we/PRP characterize/VBP the/DT T/NN cell/NN protein/NN binding/VBG to/TO this/DT site/NN as/IN a/DT 100/CD kD/NN protein/NN which/WDT is/VBZ most/RBS abundant/JJ in/IN T/NN cells/NNS and/CC which/WDT binds/VBZ to/TO site/NN B/NN as/IN a/DT 200/CD kD/NN complex/NN ./. 
This/DT protein/NN is/VBZ distinct/JJ from/IN other/JJ members/NNS of/IN the/DT steroid/thyroid/JJ hormone/NN receptor/NN family/NN including/VBG the/DT COUP/NN protein/NN which/WDT has/VBZ a/DT closely/RB related/JJ DNA/NN binding/NN specificity/NN ./. 
UI/LS -/: 92371447/CD 
TI/LS -/: TAR-independent/JJ transactivation/NN by/IN Tat/NN in/IN cells/NNS derived/VBN from/IN the/DT CNS/NN :/: a/DT novel/JJ mechanism/NN of/IN HIV-1/NN gene/NN regulation/NN ./. 
AB/LS -/: The/DT Tat/NN protein/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) is/VBZ essential/JJ for/IN productive/JJ infection/NN and/CC is/VBZ a/DT potential/JJ target/NN for/IN antiviral/JJ therapy/NN ./. 
Tat/NN ,/, a/DT potent/JJ activator/NN of/IN HIV-1/NN gene/NN expression/NN ,/, serves/VBZ to/TO greatly/RB increase/VB the/DT rate/NN of/IN transcription/NN directed/VBN by/IN the/DT viral/JJ promoter/NN ./. 
This/DT induction/NN ,/, which/WDT seems/VBZ to/TO be/VB an/DT important/JJ component/NN in/IN the/DT progression/NN of/IN acquired/VBN immune/JJ deficiency/NN syndrome/NN (/( AIDS/NN )/) ,/, may/MD be/VB due/JJ to/TO increased/VBN transcriptional/JJ initiation/NN ,/, increased/VBN transcriptional/JJ elongation/NN ,/, or/CC a/DT combination/NN of/IN these/DT processes/NNS ./. 
Much/JJ attention/NN has/VBZ been/VBN focused/VBN on/IN the/DT interaction/NN of/IN Tat/NN with/IN a/DT specific/JJ RNA/NN target/NN termed/VBN TAR/NN (/( transactivation/NN responsive/NN )/) which/WDT is/VBZ present/JJ in/IN the/DT leader/NN sequence/NN of/IN all/DT HIV-1/NN mRNAs/NNS ./. 
This/DT interaction/NN is/VBZ believed/VBN to/TO be/VB an/DT important/JJ component/NN of/IN the/DT mechanism/NN of/IN transactivation/NN ./. 
In/IN this/DT report/NN we/PRP demonstrate/VBP that/IN in/IN certain/JJ CNS-derived/JJ cells/NNS Tat/NN is/VBZ capable/JJ of/IN activating/VBG HIV-1/NN through/IN a/DT TAR-independent/JJ pathway/NN ./. 
A/DT Tat-responsive/JJ element/NN is/VBZ found/VBN upstream/RB within/IN the/DT viral/JJ promoter/NN that/WDT in/IN glial-derived/JJ cell/NN lines/NNS allows/VBZ transactivation/NN in/IN the/DT absence/NN of/IN TAR/NN ./. 
Deletion/NN mapping/NN and/CC hybrid/NN promoter/NN constructs/NNS demonstrate/VBP that/IN the/DT newly/RB identified/VBN Tat-responsive/JJ element/NN corresponds/VBZ to/TO a/DT sequence/NN within/IN the/DT viral/JJ long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) previously/RB identified/VBN as/IN the/DT HIV-1/NN enhancer/NN ,/, or/CC NF-kappa/NN B/NN domain/NN ./. 
DNA/NN band-shift/JJ analysis/NN reveals/VBZ NF-kappa/NN B/NN binding/NN activity/NN in/IN glial/JJ cells/NNS that/WDT differs/VBZ from/IN that/DT present/JJ in/IN T/NN lymphoid/JJ cells/NNS ./. 
Further/RB ,/, we/PRP observe/VBP that/IN TAR-deleted/JJ mutants/NNS of/IN HIV-1/NN demonstrate/VBP normal/JJ late/JJ gene/NN expression/NN in/IN glial/JJ cells/NNS as/IN evidenced/VBN by/IN syncytia/NN formation/NN and/CC production/NN of/IN viral/JJ p24/NN antigen/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 92331609/CD 
TI/LS -/: Transcription/NN factor/NN AP-2/NN activates/VBZ gene/NN expression/NN of/IN HTLV-I/NN ./. 
AB/LS -/: The/DT HTLV-I/NN LTR/NN contains/VBZ three/CD conserved/VBN regulatory/JJ elements/NNS known/VBN as/IN 21/CD base/NN pair/NN repeats/NNS which/WDT are/VBP required/VBN for/IN stimulation/NN of/IN gene/NN expression/NN by/IN the/DT transactivator/NN protein/NN tax/NN ./. 
Mutagenesis/NN indicates/VBZ that/IN the/DT 21/CD bp/NN repeats/NNS can/MD be/VB subdivided/VBN into/IN three/CD motifs/NNS ,/, A/NN ,/, B/NN and/CC C/NN ,/, each/DT of/IN which/WDT influences/VBZ the/DT level/NN of/IN tax/NN activation/NN ./. 
The/DT A/NN site/NN in/IN the/DT 21/CD bp/NN repeat/NN has/VBZ strong/JJ homology/NN with/IN previously/RB described/VBN binding/VBG sites/NNS for/IN the/DT transcription/NN factor/NN AP-2/NN ./. 
We/PRP demonstrated/VBD that/IN AP-2/NN mRNA/NN was/VBD present/JJ in/IN T-lymphocytes/NNS and/CC that/IN cellular/JJ factors/NNS from/IN both/CC non-transformed/JJ and/CC transformed/VBN T-lymphocytes/NNS specifically/RB bound/VBD to/TO the/DT consensus/NN motif/NN for/IN AP-2/NN in/IN each/DT 21/CD bp/NN ./. 
To/TO determine/VB the/DT role/NN of/IN AP-2/NN in/IN the/DT regulation/NN of/IN the/DT HTLV-I/NN LTR/NN gene/NN expression/NN ,/, we/PRP used/VBD an/DT AP-2/NN cDNA/NN in/IN DNA/NN binding/NN and/CC transient/JJ expression/NN assays/NNS ./. 
Gel/NN retardation/NN and/CC methylation/NN interference/NN studies/NNS revealed/VBD that/IN bacterially/RB produced/VBN AP-2/NN bound/VBD specifically/RB and/CC with/IN high/JJ affinity/NN to/TO all/DT three/CD 21/CD bp/NN repeats/NNS ,/, and/CC that/IN it/PRP required/VBD the/DT core/NN sequence/NN AGGC/NN for/IN specific/JJ binding/NN ./. 
Binding/NN of/IN AP-2/NN prevented/VBD the/DT subsequent/JJ binding/NN of/IN members/NNS of/IN the/DT CREB/ATF/NN family/NN to/TO an/DT adjacent/JJ regulatory/JJ motif/NN in/IN the/DT 21/CD bp/NN repeat/NN ./. 
Transfection/NN of/IN an/DT AP-2/NN expression/NN construct/NN into/IN T-lymphocytes/NNS activated/VBD gene/NN expression/NN from/IN the/DT HTLV-I/NN LTR/NN ./. 
At/IN least/JJS two/CD 21/CD bp/NN repeats/NNS were/VBD required/VBN for/IN high/JJ levels/NNS of/IN AP-2/NN activation/NN and/CC mutagenesis/NN of/IN the/DT AP-2/NN consensus/NN binding/NN sequences/NNS in/IN the/DT 21/CD bp/NN repeats/NNS eliminate/VBP this/DT activation/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 92260679/CD 
TI/LS -/: Activation/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD enhancer/NN is/VBZ not/RB dependent/JJ on/IN NFAT-1/NN ./. 
AB/LS -/: The/DT function/NN of/IN a/DT putative/JJ NFAT-1/NN site/NN in/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD enhancer/NN has/VBZ been/VBN analyzed/VBN ./. 
Activation/NN by/IN the/DT T-cell/NN antigen/NN receptor/NN is/VBZ minimal/JJ in/IN Jurkat/NN cells/NNS and/CC is/VBZ mediated/VBN by/IN the/DT kappa/NN B/NN sites/NNS ./. 
The/DT putative/JJ NFAT-1/NN region/NN is/VBZ not/RB required/VBN for/IN the/DT response/NN to/TO anti-CD3/NN or/CC to/TO mitogens/NNS in/IN T-cell/NN ,/, B-cell/NN ,/, or/CC monocyte/macrophage/NN leukemia/NN lines/NNS ,/, nor/CC is/VBZ it/PRP a/DT cis-acting/JJ negative/JJ regulatory/JJ element/NN ./. 
UI/LS -/: 92218428/CD 
TI/LS -/: The/DT B/NN cell-specific/JJ nuclear/JJ factor/NN OTF-2/NN positively/RB regulates/VBZ transcription/NN of/IN the/DT human/JJ class/NN II/CD transplantation/NN gene/NN ,/, DRA/NN ./. 
AB/LS -/: The/DT promoter/NN of/IN the/DT major/JJ histocompatibility/NN class/NN II/CD gene/NN DRA/NN contains/VBZ an/DT octamer/NN element/NN (/( ATTTGCAT/NN )/) that/WDT is/VBZ required/VBN for/IN efficient/JJ DRA/NN expression/NN in/IN B/NN cells/NNS ./. 
Several/JJ DNA-binding/JJ proteins/NNS are/VBP known/VBN to/TO bind/VB this/DT sequence/NN ./. 
The/DT best/RBS characterized/VBN are/VBP the/DT B/NN cell-specific/JJ OTF-2/NN and/CC the/DT ubiquitous/JJ OTF-1/NN ./. 
This/DT report/NN directly/RB demonstrates/VBZ that/IN OTF-2/NN but/CC not/RB OTF-1/NN regulates/VBZ the/DT DRA/NN gene/NN ./. 
In/FW vitro/FW transcription/NN analysis/NN using/VBG protein/NN fractions/NNS enriched/VBN for/IN the/DT octamer-binding/JJ protein/NN OTF-2/NN demonstrate/VBP a/DT positive/JJ functional/JJ role/NN for/IN OTF-2/NN in/IN DRA/NN gene/NN transcription/NN ./. 
In/IN contrast/NN ,/, OTF-1-enriched/JJ protein/NN fractions/NNS did/VBD not/RB affect/VB DRA/NN gene/NN transcription/NN although/IN it/PRP functionally/RB enhanced/VBD the/DT transcription/NN of/IN another/DT gene/NN ./. 
Recombinant/JJ OTF-2/NN protein/NN produced/VBN by/IN in/FW vitro/FW transcription/translation/NN could/MD also/RB enhance/VB DRA/NN gene/NN transcription/NN in/FW vitro/FW ./. 
In/FW vivo/FW transient/JJ transfection/NN studies/NNS utilizing/VBG an/DT OTF-2/NN expression/NN vector/NN resulted/VBD in/IN similar/JJ findings/NNS :/: that/IN OTF-2/NN protein/NN enhanced/VBD DRA/NN gene/NN transcription/NN ,/, and/CC that/IN this/DT effect/NN requires/VBZ an/DT intact/JJ octamer/NN element/NN ./. 
Together/RB these/DT results/NNS constitute/VBP the/DT first/JJ direct/JJ evidence/NN of/IN a/DT positive/JJ role/NN for/IN the/DT lymphoid-specific/JJ octamer-binding/JJ factor/NN in/IN DRA/NN gene/NN transcription/NN ./. 
UI/LS -/: 92251244/CD 
TI/LS -/: Interferon-gamma/NN potentiates/VBZ the/DT antiviral/JJ activity/NN and/CC the/DT expression/NN of/IN interferon-stimulated/JJ genes/NNS induced/VBN by/IN interferon-alpha/NN in/IN U937/NN cells/NNS ./. 
AB/LS -/: Binding/NN of/IN type/NN I/CD interferon/NN (/( IFN-alpha/beta/NN )/) to/TO specific/JJ receptors/NNS results/VBZ in/IN the/DT rapid/JJ transcriptional/JJ activation/NN ,/, independent/JJ of/IN protein/NN synthesis/NN ,/, of/IN IFN-alpha-stimulated/JJ genes/NNS (/( ISGs/NNS )/) in/IN human/JJ fibroblasts/NNS and/CC HeLa/NN and/CC Daudi/NN cell/NN lines/NNS ./. 
The/DT binding/NN of/IN ISGF3/NN (/( IFN-stimulated/JJ gene/NN factor/NN 3/CD )/) to/TO the/DT conserved/VBN IFN-stimulated/JJ response/NN element/NN (/( ISRE/NN )/) results/VBZ in/IN transcriptional/JJ activation/NN ./. 
This/DT factor/NN is/VBZ composed/VBN of/IN a/DT DNA-binding/JJ protein/NN (/( ISGF3/NN gamma/NN )/) ,/, which/WDT normally/RB is/VBZ present/JJ in/IN the/DT cytoplasm/NN ,/, and/CC other/JJ IFN-alpha-activated/JJ proteins/NNS which/WDT preexist/VBP as/IN latent/JJ cytoplasmic/JJ precursors/NNS (/( ISGF3/NN alpha/NN )/) ./. 
We/PRP have/VBP found/VBN that/IN ISG/NN expression/NN in/IN the/DT monocytic/JJ U937/NN cell/NN line/NN differs/VBZ from/IN most/JJS cell/NN lines/NNS previously/RB examined/VBN ./. 
U937/NN cells/NNS express/VBP both/CC type/NN I/CD and/CC type/NN II/CD IFN/NN receptors/NNS ,/, but/CC only/RB IFN-alpha/NN is/VBZ capable/JJ of/IN inducing/VBG antiviral/JJ protection/NN in/IN these/DT cells/NNS ./. 
Pretreatment/NN with/IN IFN-gamma/NN potentiates/VBZ the/DT IFN-alpha-induced/JJ protection/NN ,/, but/CC IFN-gamma/NN alone/RB does/VBZ not/RB have/VB any/DT antiviral/JJ activity/NN ./. 
ISG15/NN mRNA/NN accumulation/NN in/IN U937/NN cells/NNS is/VBZ not/RB detectable/JJ before/IN 6/CD h/NN of/IN IFN-alpha/NN treatment/NN ,/, peaks/VBZ at/IN 24/CD h/NN ,/, and/CC requires/VBZ protein/NN synthesis/NN ./. 
Although/IN IFN-gamma/NN alone/RB does/VBZ not/RB induce/VB ISG/NN expression/NN ,/, IFN-gamma/NN pretreatment/NN markedly/RB increases/VBZ and/CC hastens/VBZ ISG/NN expression/NN and/CC transcriptional/JJ induction/NN ./. 
Nuclear/JJ extracts/NNS assayed/VBN for/IN the/DT presence/NN of/IN ISRE/NN binding/NN factors/NNS by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS show/VBP that/IN ISGF3/NN is/VBZ induced/VBN by/IN IFN-alpha/NN within/IN 6/CD h/NN from/IN undetectable/JJ basal/JJ levels/NNS in/IN untreated/JJ U937/NN cells/NNS ./. 
Activation/NN of/IN ISGF3/NN alpha/NN ,/, the/DT latent/JJ component/NN of/IN ISGF3/NN ,/, occurs/VBZ rapidly/RB ./. 
However/RB ,/, the/DT increase/NN in/IN ISGF3/NN activity/NN ultimately/RB correlates/VBZ with/IN the/DT accumulation/NN of/IN ISGF3/NN gamma/NN induced/VBN by/IN IFN-alpha/NN or/CC IFN-gamma/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 93043110/CD 
TI/LS -/: Single/JJ point/NN estimation/NN of/IN glucocorticoid/NN receptors/NNS in/IN lymphocytes/NNS of/IN normal/JJ subjects/NNS and/CC of/IN children/NNS under/IN long/JJ term/NN glucocorticoid/NN treatment/NN ./. 
AB/LS -/: A/DT single/JJ point/NN assay/NN of/IN glucocorticoid/NN receptors/NNS (/( GR/NN )/) in/IN human/JJ lymphocytes/NNS based/VBN on/IN the/DT measurement/NN of/IN specific/JJ dexamethasone/NN binding/NN has/VBZ been/VBN developed/VBN and/CC compared/VBN with/IN a/DT common/JJ multi-point/JJ Scatchard/NN analysis/NN ./. 
The/DT assay/NN conditions-concentration/NN of/IN the/DT ligand/NN 20/CD nmol/l/NN ,/, incubation/NN time/NN 2/CD h/NN and/CC the/DT cell/NN count/NN 2-6/CD mil./CD 
cells/tube/NNS in/IN the/DT assay/NN volume/NN 0.25/CD ml/NN were/VBD found/VBN to/TO be/VB optimal/JJ ./. 
An/DT attempt/NN was/VBD also/RB undertaken/VBN to/TO use/VB a/DT cell/NN harvester/NN for/IN the/DT separation/NN of/IN cells/NNS from/IN unbound/JJ ligand/NN ./. 
Though/IN specifically/RB bound/VBN dexamethasone/NN measured/VBN by/IN whole-cell/JJ assay/NN and/CC that/DT using/VBG cell/NN harvester/NN correlated/VBD well/RB ,/, almost/RB by/IN one/CD order/NN lower/JJR values/NNS obtained/VBN with/IN the/DT latter/JJ method/NN render/VBP it/PRP non-applicable/JJ for/IN receptor/NN quantitation/NN ./. 
The/DT results/NNS from/IN 9/CD healthy/JJ volunteers/NNS (/( average/JJ GR/NN concentration/NN 7131/CD +/-/CC 1256/CD sites/cell/NNS )/) correlated/VBD excellently/RB with/IN those/DT obtained/VBN by/IN the/DT Scatchard/NN analysis/NN ./. 
The/DT single/JJ point/NN assay/NN has/VBZ been/VBN also/RB applied/VBN for/IN determination/NN of/IN GH/NN in/IN 10/CD children/NNS treated/VBN with/IN large/JJ doses/NNS of/IN prednisone/NN ./. 
The/DT average/JJ values/NNS from/IN healthy/JJ volunteers/NNS did/VBD not/RB differ/VB significantly/RB from/IN those/DT found/VBN in/IN these/DT children/NNS ,/, though/RB much/RB broader/JJR range/NN was/VBD found/VBN in/IN patients/NNS ./. 
UI/LS -/: 92142646/CD 
TI/LS -/: Glucocorticoid/NN receptor/NN and/CC inhibition/NN of/IN 3-O-methyl-D-glucose/NN uptake/NN by/IN glucocorticoids/NNS in/IN peripheral/JJ blood/NN leukocytes/NNS from/IN normal/JJ humans/NNS :/: correlation/NN between/IN receptor/NN level/NN and/CC hormone/NN effect/NN in/FW vitro/FW ./. 
AB/LS -/: We/PRP have/VBP measured/VBN the/DT glucocorticoid/NN receptor/NN concentration/NN in/IN mononuclear/JJ and/CC polymorphonuclear/JJ leukocytes/NNS ,/, both/DT of/IN which/WDT were/VBD isolated/VBN from/IN peripheral/JJ blood/NN from/IN ten/CD healthy/JJ male/JJ volunteers/NNS ./. 
In/IN parallel/NN ,/, the/DT inhibitory/JJ effect/NN of/IN dexamethasone/NN on/IN 3-O-methyl-D-glucose/NN uptake/NN was/VBD assayed/VBN in/IN the/DT corresponding/JJ mononuclear/JJ leukocytes/NNS ./. 
The/DT glucocorticoid/NN receptor/NN levels/NNS in/IN mononuclear/JJ leukocytes/NNS correlated/VBD with/IN those/DT in/IN polymorphonuclear/JJ leukocytes/NNS ,/, and/CC there/EX was/VBD a/DT linear/JJ relationship/NN between/IN the/DT cellular/JJ glucocorticoid/NN receptor/NN levels/NNS and/CC glucocorticoid-mediated/JJ inhibition/NN of/IN the/DT uptake/NN of/IN 3-O-methyl-D-glucose/NN in/IN mononuclear/JJ leukocytes/NNS ./. 
When/WRB mononuclear/JJ leukocytes/NNS were/VBD incubated/VBN in/IN the/DT presence/NN of/IN 8-bromo-cAMP/NN ,/, cellular/JJ glucocorticoid/NN receptor/NN levels/NNS increased/VBD and/CC a/DT more/RBR pronounced/JJ inhibitory/JJ effect/NN of/IN dexamethasone/NN was/VBD observed/VBN on/IN the/DT transport/NN of/IN 3-O-methyl-D-glucose/NN ./. 
We/PRP conclude/VBP that/IN the/DT cellular/JJ glucocorticoid/NN receptor/NN levels/NNS in/IN peripheral/JJ blood/NN leukocytes/NNS reflect/VBP in/FW vitro/FW responsiveness/NN to/TO glucocorticoids/NNS in/IN mononuclear/JJ leukocytes/NNS from/IN healthy/JJ males/NNS ,/, and/CC that/IN the/DT individual/JJ responsiveness/NN may/MD alter/VB upon/IN changes/NNS in/IN the/DT cellular/JJ levels/NNS of/IN glucocorticoid/NN receptor/NN ./. 
UI/LS -/: 92224250/CD 
TI/LS -/: Transcription/NN factor/NN activation/NN and/CC functional/JJ stimulation/NN of/IN human/JJ monocytes/NNS ./. 
AB/LS -/: Activation/NN of/IN expression/NN of/IN genes/NNS encoding/VBG transcription/NN factors/NNS :/: c-fos/NN and/CC c-jun/NN and/CC formation/NN of/IN AP1/NN transcriptional/JJ complex/NN in/IN human/JJ monocytes/NNS was/VBD investigated/VBN ./. 
It/PRP was/VBD found/VBN that/IN lipopolysaccharide/NN induced/VBD strongly/RB both/CC c-fos/NN and/CC c-jun/NN expression/NN as/RB well/RB as/IN AP1/NN formation/NN ./. 
Interferon/NN gamma/NN activated/VBD strongly/RB c-fos/NN and/CC weakly/RB c-jun/NN and/CC AP1/NN ./. 
Tumor/NN necrosis/NN factor/NN induced/VBD slightly/RB c-fos/NN and/CC had/VBD almost/RB no/DT effect/NN on/IN c-jun/NN and/CC AP1/NN ./. 
The/DT data/NNS suggest/VBP that/IN differences/NNS in/IN functional/JJ responses/NNS elicited/VBN in/IN monocytes/NNS by/IN all/DT three/CD factors/NNS may/MD be/VB dependent/JJ on/IN different/JJ routes/NNS on/IN nuclear/JJ signalling/NN employed/VBN by/IN the/DT factors/NNS ./. 
UI/LS -/: 92062170/CD 
TI/LS -/: Regulation/NN of/IN interleukin-1/NN beta/NN production/NN by/IN glucocorticoids/NNS in/IN human/JJ monocytes/NNS :/: the/DT mechanism/NN of/IN action/NN depends/VBZ on/IN the/DT activation/NN signal/NN ./. 
AB/LS -/: Glucocorticoids/NNS are/VBP known/VBN to/TO downregulate/VB interleukin-1/NN beta/NN production/NN in/IN monocytic/JJ cells/NNS by/IN two/CD different/JJ mechanims/NNS :/: direct/JJ inhibition/NN of/IN the/DT gene/NN transcription/NN and/CC destabilization/NN of/IN the/DT preformed/JJ interleukin-1/NN beta/NN mRNA/NN ./. 
Now/RB we/PRP have/VBP examined/VBN the/DT effect/NN of/IN the/DT nature/NN of/IN the/DT monocyte/NN activating/NN signal/NN on/IN these/DT two/CD inhibitory/JJ mechanims/NNS ./. 
When/WRB human/JJ monocytes/NNS were/VBD preincubated/VBN with/IN dexamethasone/NN for/IN 1/CD hour/NN and/CC then/RB stimulated/VBN either/CC with/IN bacterial/JJ lipopolysaccharide/NN or/CC phorbol/NN myristate/NN ,/, it/PRP was/VBD found/VBN that/IN dexamethasone/NN inhibited/VBD the/DT lipopolysaccharide-induced/JJ interleukin-1/NN beta/NN protein/NN production/NN ,/, but/CC the/DT phorbol/NN myristate-induced/JJ production/NN was/VBD increased/VBN 3-10/CD fold/RB ./. 
This/DT difference/NN was/VBD also/RB seen/VBN at/IN the/DT mRNA/NN level/NN ./. 
When/WRB dexamethasone/NN was/VBD added/VBN to/TO the/DT cultures/NNS 3/CD hours/NNS after/IN the/DT stimulators/NNS ,/, it/PRP clearly/RB decreased/VBD the/DT interleukin-1/NN beta/NN mRNA/NN levels/NNS regardless/RB of/IN the/DT stimulator/NN used/VBN (/( although/IN the/DT effect/NN was/VBD clearly/RB weaker/JJR on/IN the/DT PMA-induced/JJ mRNA/NN )/) ./. 
Thus/RB these/DT data/NNS suggest/VBP that/IN the/DT phorbol/NN myristate-induced/JJ signal/NN (/( prolonged/JJ protein/NN kinase/NN C/NN activation/NN ?/. )/) can/MD not/RB be/VB inhibited/VBN by/IN prior/JJ incubation/NN with/IN dexamethasone/NN and/CC it/PRP also/RB protects/VBZ the/DT induced/VBN mRNA/NN for/IN the/DT degradative/JJ action/NN of/IN dexamethasone/NN ./. 
UI/LS -/: 92013087/CD 
TI/LS -/: Nuclear/JJ transcription/NN factors/NNS that/WDT bind/VBP to/TO elements/NNS of/IN the/DT IL-2/NN promoter/NN ./. 
Induction/NN requirements/NNS in/IN primary/JJ human/JJ T/NN cells/NNS ./. 
AB/LS -/: Prior/JJ studies/NNS have/VBP identified/VBN several/JJ elements/NNS that/WDT contribute/VBP to/TO the/DT activity/NN of/IN the/DT IL-2/NN promoter/NN in/IN the/DT stimulated/VBN T/NN cell/NN line/NN ,/, Jurkat/NN ./. 
The/DT sites/NNS and/CC their/PRP$ corresponding/JJ nuclear/JJ binding/VBG factors/NNS include/VBP :/: NF-kappa/NN B/NN ,/, AP-1/NN ,/, AP-3/NN ,/, OCT-1/NN ,/, and/CC NF-AT/NN ./. 
The/DT latter/JJ "/`` nuclear/JJ factor/NN for/IN activated/VBN T/NN cells/NNS "/'' likely/RB contributes/VBZ to/TO the/DT tissue/NN specificity/NN of/IN IL-2/NN gene/NN expression/NN ./. 
Using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, we/PRP have/VBP studied/VBN these/DT transcription/NN factors/NNS in/IN primary/JJ T/NN cells/NNS from/IN human/JJ blood/NN to/TO verify/VB their/PRP$ presence/NN in/IN a/DT physiologic/JJ setting/NN and/CC to/TO identify/VB the/DT signals/NNS that/WDT stimulate/VBP factor/NN activity/NN ./. 
All/DT factors/NNS are/VBP induced/VBN in/IN the/DT nuclei/NNS of/IN T/NN cells/NNS upon/IN activation/NN with/IN mitogens/NNS but/CC not/RB with/IN exogenous/JJ IL-2/NN growth/NN factor/NN ./. 
However/RB ,/, the/DT signaling/NN requirements/NNS and/CC sensitivity/NN to/TO protein/NN synthesis/NN inhibitors/NNS differ/VBP considerably/RB ./. 
Only/RB the/DT activities/NNS for/IN NF-AT/NN and/CC AP-1/NN sites/NNS require/VBP two/CD signals/NNS for/IN optimal/JJ induction/NN ,/, i.e./FW ,/, PMA/NN plus/CC either/CC lectin/NN or/CC antibody/NN to/TO the/DT CD3/NN or/CC CD28/NN surface/NN molecules/NNS ./. 
Other/JJ factors/NNS are/VBP induced/VBN by/IN lectin/NN ,/, antibody/NN ,/, and/or/CC PMA/NN alone/RB ./. 
After/IN appropriate/JJ stimulation/NN ,/, both/CC NF-AT/NN and/CC AP-1/NN are/VBP peculiarly/RB sensitive/JJ to/TO the/DT protein/NN synthesis/NN inhibitor/NN anisomycin/NN ./. 
Our/PRP$ data/NNS correlate/VBP the/DT activity/NN of/IN NF-AT/NN and/CC AP-1/NN in/IN gel/NN shift/NN assays/NNS with/IN the/DT two/CD signals/NNS requirements/NNS for/IN IL-2/NN gene/NN expression/NN ./. 
UI/LS -/: 91361546/CD 
TI/LS -/: NF-kappa/NN B/NN activity/NN in/IN T/NN cells/NNS stably/RB expressing/VBG the/DT Tax/NN protein/NN of/IN human/JJ T/NN cell/NN lymphotropic/JJ virus/NN type/NN I/CD ./. 
AB/LS -/: The/DT effect/NN of/IN constitutive/JJ Tax/NN expression/NN on/IN the/DT interaction/NN of/IN NF-kappa/NN B/NN with/IN its/PRP$ recognition/NN sequence/NN and/CC on/IN NF-kappa/NN B-dependent/JJ gene/NN expression/NN was/VBD examined/VBN in/IN T/NN lymphoid/JJ Jurkat/NN cell/NN lines/NNS (/( 19D/NN and/CC 9J/NN )/) stably/RB transformed/VBN with/IN a/DT Tax/NN expression/NN vector/NN ./. 
Tax/NN expressing/NN T/NN cell/NN lines/NNS contained/VBD a/DT constitutive/JJ level/NN of/IN NF-kappa/NN B/NN binding/NN activity/NN ,/, detectable/JJ by/IN mobility/NN shift/NN assay/NN and/CC uv/NN cross-linking/NN using/VBG a/DT palindromic/JJ NF-kappa/NN B/NN probe/NN homologous/JJ to/TO the/DT interferon/NN beta/NN PRDII/NN site/NN ./. 
In/IN Jurkat/NN and/CC NC2.10/NN induction/NN with/IN phorbol/NN esters/NNS resulted/VBD in/IN the/DT appearance/NN of/IN new/JJ DNA/NN binding/NN proteins/NNS of/IN 85/CD ,/, 75/CD ,/, and/CC 54/CD kDa/NN ,/, whereas/IN in/IN Tax/NN expressing/NN cells/NNS the/DT 85-kDa/JJ protein/NN and/CC a/DT 92-kDa/JJ DNA/NN binding/NN protein/NN were/VBD constitutively/RB induced/VBN ./. 
Expression/NN of/IN Tax/NN protein/NN in/IN 19D/NN and/CC 9J/NN resulted/VBD in/IN transcription/NN of/IN the/DT endogenous/JJ NF-kappa/NN B-dependent/JJ granulocyte-macrophage/JJ colony/NN stimulating/NN factor/NN gene/NN and/CC increased/VBD basal/JJ level/NN expression/NN of/IN transfected/VBN NF-kappa/NN B-regulated/JJ promoters/NNS ./. 
Nonetheless/RB transcription/NN of/IN both/CC the/DT endogenous/JJ and/CC the/DT transfected/VBN gene/NN was/VBD inducible/JJ by/IN PMA/NN treatment/NN ./. 
Tax/NN expression/NN in/IN Jurkat/NN T/NN cells/NNS may/MD alter/VB the/DT stoichiometry/NN of/IN NF-kappa/NN B/NN DNA/NN binding/NN proteins/NNS and/CC thus/RB change/VB the/DT expression/NN of/IN NF-kappa/NN B-regulated/JJ promoters/NNS ./. 
UI/LS -/: 92001749/CD 
TI/LS -/: A/DT nuclear/JJ factor/NN NF-GM2/NN that/WDT interacts/VBZ with/IN a/DT regulatory/JJ region/NN of/IN the/DT GM-CSF/NN gene/NN essential/JJ for/IN its/PRP$ induction/NN in/IN responses/NNS to/TO T-cell/NN activation/NN :/: purification/NN from/IN human/JJ T-cell/NN leukemia/NN line/NN Jurkat/NN cells/NNS and/CC similarity/NN to/TO NF-kappa/NN B/NN ./. 
AB/LS -/: Activation/NN of/IN T/NN cells/NNS by/IN antigen/NN ,/, lectin/NN ,/, or/CC a/DT combination/NN of/IN phorbol-12-myristate/NN acetate/NN (/( PMA/NN )/) and/CC calcium/NN ionophore/NN (/( A23187/NN )/) leads/VBZ to/TO the/DT induction/NN of/IN genes/NNS for/IN a/DT set/NN of/IN lymphokines/NNS ,/, including/VBG granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN (/( GM-CSF/NN )/) ./. 
We/PRP demonstrated/VBD in/IN earlier/JJR studies/NNS that/IN the/DT upstream/JJ region/NN of/IN the/DT mouse/NN GM-CSF/NN promoter/NN at/IN positions/NNS between/IN -95/CD and/CC -73/CD is/VBZ essential/JJ for/IN transcriptional/JJ activation/NN in/IN response/NN to/TO PMA/A23187/NN ./. 
This/DT region/NN contains/VBZ two/CD DNA-binding/JJ motifs/NNS ,/, GM2/NN and/CC GC-box/NN ./. 
The/DT GM2/NN sequence/NN (/( GGTAGTTCCC/NN )/) is/VBZ recognized/VBN by/IN an/DT inducible/JJ factor/NN NF-GM2/NN ;/: the/DT other/JJ (/( CCGCCC/NN )/) by/IN constitutive/JJ factors/NNS A1/NN ,/, A2/NN ,/, and/CC B/NN ./. 
To/TO elucidate/VB the/DT mechanism/NN of/IN GM-CSF/NN gene/NN activation/NN ,/, we/PRP have/VBP purified/VBN the/DT inducible/JJ factor/NN NF-GM2/NN from/IN the/DT nuclear/JJ extract/NN of/IN stimulated/VBN Jurkat/NN cells/NNS on/IN the/DT basis/NN of/IN specific/JJ DNA-binding/JJ activity/NN ./. 
The/DT purified/VBN NF-GM2/NN consists/VBZ of/IN 50/CD (/( p50/NN )/) and/CC 65/CD kDa/NN (/( p65/NN )/) polypeptides/NNS and/CC has/VBZ a/DT binding/NN activity/NN specific/JJ for/IN both/CC the/DT GM-CSF/NN and/CC immunoglobulin/NN kappa/NN (/( GGAAAGTCCC/NN )/) enhancers/NNS ./. 
Electrophoretically/RB purified/VBN p50/NN alone/RB can/MD form/VB a/DT protein-DNA/JJ complex/NN ,/, but/CC in/IN the/DT mixture/NN ,/, p50/NN associates/VBZ preferentially/RB with/IN p65/NN to/TO form/VB the/DT NF-GM2/NN complex/NN ./. 
In/IN addition/NN ,/, p65/NN gave/VBD per/FW se/FW ,/, with/IN low/JJ affinity/NN ,/, a/DT protein-DNA/JJ complex/NN that/WDT migrated/VBD more/RBR slowly/RB than/IN native/JJ NF-GM2/NN complex/NN ./. 
Furthermore/RB ,/, an/DT antiserum/NN against/IN KBF1/NN (/( identical/JJ to/TO 50/CD kDa/NN NF-kappa/NN B/NN protein/NN )/) reacted/VBD with/IN the/DT p50/NN of/IN NF-GM2/NN ,/, indicating/VBG that/IN the/DT NF-GM2/NN polypeptide/NN can/MD not/RB be/VB immunologically/RB differentiated/VBN from/IN the/DT 50/CD kDa/NN subunit/NN of/IN NF-kappa/NN B/NN ./. 
The/DT purified/VBN NF-GM2/NN activated/VBD in/FW vitro/FW transcription/NN from/IN the/DT kappa/NN B/NN enhancer/NN ,/, while/IN it/PRP failed/VBD to/TO stimulate/VB transcription/NN from/IN the/DT GM-CSF/NN promoter/NN harboring/VBG the/DT GM2/NN sequence/NN ./. 
This/DT suggests/VBZ that/IN the/DT activation/NN mechanism/NN of/IN the/DT GM-CSF/NN gene/NN through/IN the/DT GM2/GC-box/JJ|NN sequence/NN is/VBZ different/JJ from/IN that/DT of/IN genes/NNS carrying/VBG the/DT kappa/NN B/NN enhancer/NN alone/RB ./. 
UI/LS -/: 91292530/CD 
TI/LS -/: Characterization/NN of/IN an/DT immediate-early/JJ gene/NN induced/VBN in/IN adherent/JJ monocytes/NNS that/WDT encodes/VBZ I/NN kappa/NN B-like/JJ activity/NN ./. 
AB/LS -/: We/PRP have/VBP cloned/VBN a/DT group/NN of/IN cDNAs/NNS representing/VBG mRNAs/NNS that/WDT are/VBP rapidly/RB induced/VBN following/VBG adherence/NN of/IN human/JJ monocytes/NNS ./. 
One/CD of/IN the/DT induced/VBN transcripts/NNS (/( MAD-3/NN )/) encodes/VBZ a/DT protein/NN of/IN 317/CD amino/NN acids/NNS with/IN one/CD domain/NN containing/VBG five/CD tandem/JJ repeats/NNS of/IN the/DT cdc10/ankyrin/JJ motif/NN ,/, which/WDT is/VBZ 60/CD %/NN similar/JJ (/( 46/CD %/NN identical/JJ )/) to/TO the/DT ankyrin/NN repeat/NN region/NN of/IN the/DT precursor/NN of/IN NF-kappa/NN B/KBF1/NN p50/NN ./. 
The/DT C-terminus/NN has/VBZ a/DT putative/JJ protein/NN kinase/NN C/NN phosphorylation/NN site/NN ./. 
In/FW vitro/FW translated/VBN MAD-3/NN protein/NN was/VBD found/VBN to/TO specifically/RB inhibit/VB the/DT DNA-binding/JJ activity/NN of/IN the/DT p50/p65/NN NF-kappa/NN B/NN complex/NN but/CC not/RB that/DT of/IN the/DT p50/p50/NN KBF1/NN factor/NN or/CC of/IN other/JJ DNA-binding/JJ proteins/NNS ./. 
The/DT MAD-3/NN cDNA/NN encodes/VBZ an/DT I/NN kappa/NN B-like/JJ protein/NN that/WDT is/VBZ likely/JJ to/TO be/VB involved/VBN in/IN regulation/NN of/IN transcriptional/JJ responses/NNS to/TO NF-kappa/NN B/NN ,/, including/VBG adhesion-dependent/JJ pathways/NNS of/IN monocyte/NN activation/NN ./. 
UI/LS -/: 91248763/CD 
TI/LS -/: Cortivazol/NN mediated/VBD induction/NN of/IN glucocorticoid/NN receptor/NN messenger/NN ribonucleic/JJ acid/NN in/IN wild-type/JJ and/CC dexamethasone-resistant/JJ human/JJ leukemic/NN (/( CEM/NN )/) cells/NNS ./. 
AB/LS -/: Cortivazol/NN is/VBZ a/DT phenylpyrazolo/JJ glucocorticoid/NN of/IN high/JJ potency/NN and/CC unusual/JJ structure/NN ./. 
In/IN both/CC wild-type/JJ and/CC highly/RB dexamethasone/NN (/( dex/NN )/) -resistant/JJ clones/NNS of/IN the/DT human/JJ leukemic/JJ cell/NN line/NN CEM/NN ,/, exposure/NN to/TO cortivazol/NN leads/VBZ to/TO cell/NN death/NN ./. 
It/PRP has/VBZ been/VBN shown/VBN recently/RB that/IN in/IN wild-type/JJ CEM/NN cells/NNS but/CC not/RB in/IN a/DT dex-resistant/JJ ,/, glucocorticoid/NN receptor/NN (/( GR/NN )/) -defective/JJ clone/NN ICR-27/NN TK-3/NN ,/, dex/NN induces/VBZ GR/NN mRNA/NN ./. 
To/TO test/VB the/DT hypothesis/NN that/IN cortivazol/NN acts/VBZ in/IN dex-resistant/JJ cells/NNS by/IN making/VBG use/NN of/IN the/DT residual/JJ GR/NN found/VBN there/RB ,/, wild-type/JJ and/CC dex-resistant/JJ clones/NNS were/VBD treated/VBN with/IN various/JJ concentrations/NNS of/IN cortivazol/NN and/CC induction/NN of/IN GR/NN mRNA/NN was/VBD studied/VBN ./. 
Cortivazol/NN significantly/RB induced/VBD GR/NN mRNA/NN in/IN the/DT normal/JJ CEM-C7/NN as/RB well/RB as/IN in/IN two/CD classes/NNS of/IN dex-resistant/JJ clones/NNS ,/, although/IN the/DT dex-resistant/JJ clones/NNS needed/VBD at/IN least/JJS 10/CD times/NNS more/JJR cortivazol/NN than/IN the/DT normal/JJ cells/NNS for/IN significant/JJ GR/NN mRNA/NN induction/NN ./. 
Increased/VBN levels/NNS of/IN GR/NN mRNA/NN were/VBD noticed/VBN as/RB early/RB as/IN 3/CD h/NN after/IN treatment/NN ./. 
A/DT general/JJ correlation/NN between/IN induction/NN of/IN GR/NN mRNA/NN and/CC lysis/NN of/IN the/DT normal/JJ and/CC dex-resistant/JJ cells/NNS was/VBD found/VBN ./. 
Positive/JJ induction/NN of/IN GR/NN mRNA/NN might/MD be/VB one/CD of/IN the/DT earliest/JJS crucial/JJ steps/NNS in/IN the/DT lysis/NN of/IN normal/JJ and/CC dex-resistant/JJ CEM/NN cells/NNS ,/, or/CC might/MD serve/VB as/IN a/DT marker/NN for/IN the/DT process/NN ./. 
However/RB ,/, the/DT lysis/NN pathway/NN in/IN the/DT dex-resistant/JJ cells/NNS is/VBZ defective/JJ in/IN that/IN dex-resistant/JJ clones/NNS needed/VBD significantly/RB more/JJR cortivazol/NN than/IN the/DT normal/JJ cells/NNS for/IN lysis/NN of/IN the/DT cells/NNS ./. 
UI/LS -/: 91218850/CD 
TI/LS -/: HIV/NN enhancer/NN activity/NN perpetuated/VBN by/IN NF-kappa/NN B/NN induction/NN on/IN infection/NN of/IN monocytes/NNS [/( see/VB comments/NNS ]/) 
AB/LS -/: Permissiveness/NN to/TO replication/NN of/IN human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) differs/VBZ in/IN T/NN lymphocytes/NNS and/CC macrophages/NNS ./. 
In/IN T/NN cells/NNS ,/, HIV/NN transcription/NN is/VBZ poorly/RB detected/VBN in/FW vivo/FW ./. 
Cloned/VBN ,/, normal/JJ T/NN lymphocytes/NNS show/VBP very/RB little/JJ ,/, if/IN any/DT ,/, basal/JJ activity/NN of/IN the/DT HIV/NN enhancer/NN and/CC low/JJ nuclear/JJ expression/NN of/IN NF-kappa/NN B/NN ,/, a/DT potent/JJ transcriptional/JJ activator/NN of/IN the/DT HIV/NN enhancer/NN ./. 
In/IN contrast/NN ,/, fixed/JJ tissue/NN macrophages/NNS express/VBP detectable/JJ HIV/NN proteins/NNS ,/, indicating/VBG permanent/JJ virus/NN transcription/NN ./. 
One/CD explanation/NN for/IN the/DT perpetuation/NN of/IN virus/NN infection/NN in/IN macrophages/NNS could/MD be/VB sustained/JJ nuclear/JJ NF-kappa/NN B/NN expression/NN ./. 
However/RB ,/, the/DT U937/NN monocytic/JJ cell/NN line/NN ,/, which/WDT is/VBZ fully/RB permissive/JJ to/TO HIV/NN replication/NN ,/, is/VBZ known/VBN to/TO express/VB only/RB low/JJ levels/NNS of/IN nuclear/JJ NF-kappa/NN B/NN ./. 
We/PRP show/VBP here/RB that/IN chronic/JJ HIV/VBP infection/NN results/VBZ in/IN both/CC induction/NN of/IN a/DT nuclear/JJ factor/NN with/IN antigenic/JJ properties/NNS indistinguishable/JJ from/IN those/DT of/IN NF-kappa/NN B/NN and/CC permanently/RB increased/VBN HIV/NN enhancer/NN activity/NN ./. 
This/DT phenomenon/NN ,/, which/WDT is/VBZ independent/JJ of/IN tumour/NN necrosis/NN factor/NN ,/, is/VBZ associated/VBN with/IN HIV/NN replication/NN ,/, and/CC is/VBZ thus/RB likely/JJ to/TO explain/VB at/IN least/JJS in/IN part/NN the/DT perpetuation/NN of/IN HIV/NN infection/NN in/IN monocytes/NNS ./. 
UI/LS -/: 91173312/CD 
TI/LS -/: Isolation/NN of/IN a/DT rel-related/JJ human/JJ cDNA/NN that/WDT potentially/RB encodes/VBZ the/DT 65-kD/JJ subunit/NN of/IN NF-kappa/NN B/NN [/( published/VBN erratum/NN appears/VBZ in/IN Science/NNP 1991/CD Oct/NNP 4/CD ;/: 254/CD (/( 5028/CD )/) :/: 11/CD ]/) 
AB/LS -/: A/DT DNA/NN probe/NN that/WDT spanned/VBD a/DT domain/NN conserved/VBN among/IN the/DT proto-oncogene/NN c-rel/NN ,/, the/DT Drosophila/NN morphogen/NN dorsal/NN ,/, and/CC the/DT p50/NN DNA/NN binding/NN subunit/NN of/IN NF-kappa/NN B/NN was/VBD generated/VBN from/IN Jurkat/NN T/NN cell/NN complementary/JJ DNA/NN with/IN the/DT polymerase/NN chain/NN reaction/NN (/( PCR/NN )/) and/CC degenerate/JJ oligonucleotides/NNS ./. 
This/DT probe/NN was/VBD used/VBN to/TO identify/VB a/DT rel-related/JJ complementary/JJ DNA/NN that/WDT hybridized/VBD to/TO a/DT 2.6-kilobase/JJ messenger/NN RNA/NN present/JJ in/IN human/JJ T/NN and/CC B/NN lymphocytes/NNS ./. 
In/FW vitro/FW transcription/NN and/CC translation/NN of/IN the/DT complementary/JJ DNA/NN resulted/VBD in/IN the/DT synthesis/NN of/IN a/DT protein/NN with/IN an/DT apparent/JJ molecular/JJ size/NN of/IN 65/CD kilodaltons/NNS (/( kD/NN )/) ./. 
The/DT translated/VBN protein/NN showed/VBD weak/JJ DNA/NN binding/NN with/IN a/DT specificity/NN for/IN the/DT kappa/NN B/NN binding/VBG motif/NN ./. 
This/DT protein-DNA/JJ complex/JJ comigrated/VBN with/IN the/DT complex/NN obtained/VBN with/IN the/DT purified/VBN human/JJ p65/NN NF-kappa/NN B/NN subunit/NN and/CC binding/NN was/VBD inhibited/VBN by/IN I/NN kappa/NN B-alpha/NN and/CC -beta/NN proteins/NNS ./. 
In/IN addition/NN ,/, the/DT 65-kD/JJ protein/NN associated/VBN with/IN the/DT p50/NN subunit/NN of/IN NF-kappa/NN B/NN and/CC the/DT kappa/NN B/NN probe/NN to/TO form/VB a/DT complex/NN with/IN the/DT same/JJ electrophoretic/JJ mobility/NN as/IN the/DT NF-kappa/NN B-DNA/JJ complex/NN ./. 
Therefore/RB the/DT rel-related/JJ 65-kD/JJ protein/NN may/MD represent/VB the/DT p65/NN subunit/NN of/IN the/DT active/JJ NF-kappa/NN B/NN transcription/NN factor/NN complex/NN ./. 
UI/LS -/: 91246215/CD 
TI/LS -/: The/DT human/JJ myelomonocytic/JJ cell/NN line/NN U-937/NN as/IN a/DT model/NN for/IN studying/VBG alterations/NNS in/IN steroid-induced/JJ monokine/NN gene/NN expression/NN :/: marked/JJ enhancement/NN of/IN lipopolysaccharide-stimulated/JJ interleukin-1/NN beta/NN messenger/NN RNA/NN levels/NNS by/IN 1,25-dihydroxyvitamin/NN D3/NN ./. 
AB/LS -/: The/DT active/JJ metabolite/NN of/IN vitamin/NN D/NN ,/, 1,25-dihydroxyvitamin/NN D3/NN [/( 1,25-(OH)2D3/NN ]/) ,/, is/VBZ a/DT potent/JJ regulator/NN of/IN human/JJ monocyte/macrophage/JJ function/NN in/FW vitro/FW ./. 
To/TO establish/VB a/DT model/NN for/IN 1,25-(OH)2D3/NN regulation/NN of/IN human/JJ monocyte/NN monokine/NN synthesis/NN ,/, three/CD human/JJ cell/NN lines/NNS (/( U-937/NN ,/, THP-1/NN ,/, and/CC HL-60/NN )/) were/VBD examined/VBN for/IN :/: 1/LS )/) the/DT presence/NN of/IN functional/JJ 1,25-(OH)2D3/NN receptors/NNS ;/: 2/LS )/) the/DT accumulation/NN of/IN interleukin-1/NN beta/NN (/( IL-1/NN beta/NN )/) mRNA/NN and/CC IL-1/NN beta/NN protein/NN in/IN response/NN to/TO lipopolysaccharide/NN (/( LPS/NN )/) ;/: and/CC 3/LS )/) the/DT regulation/NN of/IN this/DT response/NN by/IN 1,25-(OH)2D3/NN ./. 
All/DT three/CD cell/NN lines/NNS expressed/VBD vitamin/NN D/NN receptor/NN and/CC had/VBD increased/VBN levels/NNS of/IN IL-1/NN beta/NN mRNA/NN in/IN response/NN to/TO LPS/NN ./. 
Preincubation/NN of/IN cells/NNS with/IN 1,25-(OH)2D3/NN augmented/VBD IL-1/NN beta/NN mRNA/NN levels/NNS only/RB in/IN U-937/NN and/CC HL-60/NN cells/NNS ./. 
From/IN these/DT data/NNS ,/, and/CC taking/VBG into/IN consideration/NN their/PRP$ state/NN of/IN differentiation/NN and/CC relative/JJ ease/NN of/IN culture/NN ,/, U-937/NN was/VBD chosen/VBN over/IN HL-60/NN and/CC THP-1/NN as/IN the/DT cell/NN line/NN we/PRP further/RB characterized/VBD ./. 
In/IN U-937/NN cells/NNS ,/, optimum/JJ time/NN and/CC dose/NN of/IN pretreatment/NN with/IN 1,25-(OH)2D3/NN were/VBD determined/VBN to/TO be/VB 12-24/CD h/NN at/IN a/DT receptor/NN saturating/JJ concentration/NN of/IN 1,25-(OH)2D3/NN (/( 10/CD nM/NN )/) ./. 
Preincubation/NN of/IN cells/NNS with/IN 1,25-(OH)2D3/NN had/VBD no/DT effect/NN on/IN the/DT time/NN course/NN of/IN IL-1/NN beta/NN mRNA/NN appearance/NN in/IN response/NN to/TO LPS/NN ./. 
However/RB ,/, exposure/NN of/IN U-937/NN cells/NNS to/TO 1,25-(OH)2D3/NN increased/VBD by/IN 200/CD %/NN the/DT level/NN of/IN IL-1/NN beta/NN mRNA/NN detected/VBD and/CC decreased/VBD by/IN three/CD orders/NNS of/IN magnitude/NN the/DT concentration/NN of/IN LPS/NN required/VBN to/TO achieve/VB steady/JJ state/NN mRNA/NN levels/NNS equivalent/JJ to/TO those/DT observed/VBN in/IN U-937/NN cells/NNS not/RB preincubated/VBN with/IN the/DT hormone.2+o/NN 
UI/LS -/: 91354520/CD 
TI/LS -/: Regulation/NN of/IN M-CSF/NN expression/NN by/IN M-CSF/NN :/: role/NN of/IN protein/NN kinase/NN C/NN and/CC transcription/NN factor/NN NF/NN kappa/NN B/NN ./. 
AB/LS -/: Macrophage-colony-stimulating/JJ factor/NN (/( M-CSF/NN )/) ,/, also/RB referred/VBN to/TO as/IN CSF-1/NN ,/, regulates/VBZ the/DT survival/NN ,/, growth/NN ,/, differentiation/NN and/CC functional/JJ activity/NN of/IN monocytes/NNS by/IN binding/VBG to/TO a/DT single/JJ class/NN of/IN high-affinity/JJ cell/NN surface/NN receptors/NNS ,/, known/VBN to/TO be/VB the/DT product/NN of/IN the/DT c-fms/NN protooncogene/NN ./. 
The/DT detection/NN of/IN both/CC M-CSF/NN and/CC c-fms/NN expression/NN by/IN cells/NNS of/IN the/DT monocyte/NN lineage/NN has/VBZ suggested/VBN that/IN M-CSF/NN may/MD act/VB by/IN an/DT autocrine/JJ mechanism/NN ./. 
Interestingly/RB ,/, it/PRP has/VBZ been/VBN shown/VBN that/IN M-CSF/NN can/MD induce/VB the/DT expression/NN of/IN its/PRP$ own/JJ gene/NN ./. 
Although/IN sensitivity/NN to/TO M-CSF/NN can/MD be/VB modulated/VBN by/IN regulation/NN of/IN receptor/NN expression/NN and/CC function/NN ,/, M-CSF/NN responsiveness/NN is/VBZ largely/RB determined/VBN at/IN a/DT postreceptor/NN level/NN ./. 
To/TO date/NN ,/, little/JJ is/VBZ known/VBN about/IN the/DT intracellular/JJ pathway/NN of/IN M-CSF/NN signal/NN transduction/NN ./. 
We/PRP have/VBP therefore/RB investigated/VBN the/DT changes/NNS in/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) activity/NN upon/IN exposure/NN of/IN monocytes/NNS to/TO M-CSF/NN ./. 
We/PRP show/VBP that/IN M-CSF/NN activates/VBZ and/CC translocates/VBZ PKC/NN ./. 
Inhibition/NN of/IN PKC/NN by/IN the/DT isoquinoline/NN derivative/JJ H7/NN abolishes/VBZ induction/NN of/IN M-CSF/NN by/IN M-CSF/NN ./. 
Furthermore/RB ,/, activation/NN of/IN PKC/NN was/VBD pertussis-toxin-sensitive/JJ and/CC was/VBD associated/VBN with/IN the/DT detection/NN of/IN an/DT NF/NN kappa/NN B/NN protein/NN in/IN nuclear/JJ extracts/NNS of/IN M-CSF-induced/JJ blood/NN monocytes/NNS but/CC not/RB in/IN monocytes/NNS exposed/VBN to/TO medium/NN treatment/NN only/RB ./. 
The/DT results/NNS suggest/VBP that/IN M-CSF/NN induction/NN of/IN M-CSF/NN involves/VBZ G/NN proteins/NNS ,/, PKC/NN and/CC NF/NN kappa/NN B/NN ./. 
UI/LS -/: 92052214/CD 
TI/LS -/: Clone/NN pAT/NN 133/CD identifies/VBZ a/DT gene/NN that/WDT encodes/VBZ another/DT human/JJ member/NN of/IN a/DT class/NN of/IN growth/NN factor-induced/JJ genes/NNS with/IN almost/RB identical/JJ zinc-finger/NN domains/NNS ./. 
AB/LS -/: We/PRP report/VBP the/DT structure/NN and/CC regulation/NN of/IN a/DT gene/NN represented/VBN by/IN clone/NN pAT/NN 133/CD ,/, which/WDT is/VBZ induced/VBN upon/IN transition/NN from/IN a/DT resting/JJ state/NN (/( G0/NN )/) through/IN the/DT early/JJ phase/NN of/IN the/DT cell/NN cycle/NN (/( G1/NN )/) ./. 
The/DT pAT/NN 133/CD gene/NN is/VBZ immediately/RB induced/VBN ,/, with/IN FOS-like/JJ kinetics/NNS ,/, in/IN human/JJ T/NN cells/NNS and/CC in/IN fibroblasts/NNS ./. 
Primary/JJ structure/NN analysis/NN showed/VBD that/IN the/DT encoded/VBN protein/NN contains/VBZ three/CD tandem/JJ zinc-finger/NN sequences/NNS of/IN the/DT type/NN Cys2-Xaa12-His2/NN ./. 
This/DT zinc-finger/NN region/NN ,/, which/WDT is/VBZ thought/VBN to/TO bind/VB DNA/NN in/IN a/DT sequence-specific/JJ manner/NN ,/, is/VBZ similar/JJ (/( greater/JJR than/IN 80/CD %/NN on/IN the/DT amino/NN acid/NN level/NN )/) to/TO two/CD previously/RB described/VBN transcription/NN factors/NNS pAT/NN 225/EGR1/NN and/CC pAT/NN 591/EGR2/NN ./. 
Except/IN for/IN the/DT conserved/VBN zinc-finger/NN domains/NNS ,/, the/DT amino/NN acid/NN sequences/NNS of/IN the/DT three/CD proteins/NNS are/VBP distinct/JJ ./. 
This/DT structural/JJ similarity/NN suggests/VBZ that/IN the/DT pAT/NN 133/CD gene/NN encodes/VBZ a/DT transcription/NN factor/NN with/IN a/DT specific/JJ biological/JJ function/NN ./. 
Comparing/VBG the/DT regulation/NN of/IN these/DT related/JJ zinc-finger-encoding/JJ genes/NNS showed/VBD coordinate/JJ induction/NN upon/IN mitogenic/JJ stimulation/NN of/IN resting/VBG T/NN lymphocytes/NNS and/CC of/IN resting/VBG fibroblasts/NNS ./. 
However/RB ,/, upon/IN transition/NN from/IN a/DT proliferating/JJ (/( G1/NN )/) to/TO a/DT resting/JJ state/NN of/IN the/DT cell/NN cycle/NN the/DT three/CD genes/NNS were/VBD differently/RB regulated/VBN ./. 
In/IN human/JJ histiocytic/JJ U937/NN cells/NNS mRNA/NN of/IN clone/NN pAT/NN 133/CD was/VBD constitutively/RB expressed/VBN ,/, whereas/IN mRNA/NN of/IN pAT/NN 225/EGR1/NN was/VBD induced/VBN upon/IN induction/NN of/IN terminal/JJ differentiation/NN ./. 
In/IN contrast/NN mRNA/NN representing/VBG pAT/NN 591/EGR2/NN was/VBD not/RB expressed/VBN in/IN these/DT cells/NNS ./. 
This/DT difference/NN in/IN gene/NN regulation/NN suggests/VBZ distinct/JJ biological/JJ roles/NNS in/IN the/DT control/NN of/IN cell/NN proliferation/NN for/IN the/DT respective/JJ proteins/NNS ./. 
UI/LS -/: 92038993/CD 
TI/LS -/: v-erbA/NN overexpression/NN is/VBZ required/VBN to/TO extinguish/VB c-erbA/NN function/NN in/IN erythroid/JJ cell/NN differentiation/NN and/CC regulation/NN of/IN the/DT erbA/NN target/NN gene/NN CAII/NN ./. 
AB/LS -/: The/DT v-erbA/NN oncoprotein/NN represents/VBZ a/DT retrovirus-transduced/JJ oncogenic/JJ version/NN of/IN the/DT thyroid/NN hormone/NN (/( T3/T4/NN )/) receptor/NN c-erbA/NN (/( type/NN alpha/NN )/) ./. 
It/PRP contributes/VBZ to/TO virus-induced/JJ erythroleukemia/NN by/IN efficiently/RB arresting/VBG differentiation/NN of/IN red/JJ cell/NN progenitors/NNS and/CC by/IN suppressing/VBG transcription/NN of/IN erythrocyte-specific/JJ genes/NNS ./. 
Here/RB ,/, we/PRP show/VBP that/IN v-erbA/NN and/CC c-erbA/NN bind/VBP directly/RB to/TO sequences/NNS within/IN the/DT promoter/NN of/IN the/DT erythrocyte-specific/JJ carbonic/JJ anhydrase/NN II/CD (/( CAII/NN )/) ,/, a/DT gene/NN whose/WP$ transcription/NN is/VBZ efficiently/RB suppressed/VBN by/IN v-erbA/NN ./. 
This/DT erbA-binding/JJ site/NN confers/VBZ thyroid/NN hormone/NN responsiveness/NN to/TO a/DT heterologous/JJ promoter/NN in/IN transient/JJ expression/NN experiments/NNS and/CC is/VBZ a/DT target/NN for/IN efficient/JJ down-regulation/NN of/IN CAII/NN transcription/NN by/IN the/DT v-erbA/NN oncoprotein/NN ./. 
In/IN stably/RB transformed/VBN erythroblasts/NNS coexpressing/VBG the/DT v-erbA/NN oncoprotein/NN and/CC the/DT c-erbA/T3/NN receptor/NN at/IN an/DT approximately/RB equimolar/JJ ratio/NN ,/, c-erbA/NN activity/NN is/VBZ dominant/JJ over/IN v-erbA/NN ./. 
T3/NN efficiently/RB induced/VBD erythroid/JJ differentiation/NN in/IN these/DT cells/NNS ,/, thus/RB overcoming/VBG the/DT v-erbA-mediated/JJ differentiation/NN arrest/NN ./. 
Likewise/RB ,/, T3/NN activated/VBD CAII/NN transcription/NN as/RB well/RB as/IN transient/JJ expression/NN of/IN a/DT T3-responsive/JJ reporter/NN gene/NN containing/VBG the/DT CAII-specific/JJ erbA-binding/JJ site/NN ./. 
The/DT c-erbA-dependent/JJ activation/NN of/IN this/DT CAII/NN reporter/NN construct/NN could/MD only/RB be/VB suppressed/VBN by/IN very/RB high/JJ amounts/NNS of/IN v-erbA/NN ./. 
Our/PRP$ results/NNS suggest/VBP that/IN overexpression/NN of/IN v-erbA/NN is/VBZ required/VBN for/IN its/PRP$ function/NN as/IN an/DT oncoprotein/NN ./. 
UI/LS -/: 92013023/CD 
TI/LS -/: Anti-CD2/JJ receptor/NN antibodies/NNS activate/VBP the/DT HIV/NN long/JJ terminal/JJ repeat/NN in/IN T/NN lymphocytes/NNS ./. 
AB/LS -/: The/DT CD2/NN T/NN lymphocyte/NN glycoprotein/NN surface/NN molecule/NN mediates/VBZ both/CC cell/NN to/TO cell/NN adhesion/NN and/CC T/NN cell/NN activation/NN ,/, two/CD processes/NNS that/WDT are/VBP involved/VBN in/IN the/DT spread/NN of/IN HIV/NN infection/NN ./. 
Treatment/NN of/IN chronically/RB HIV-infected/JJ PBMC/NN with/IN anti-CD2/JJ mAb/NN has/VBZ been/VBN shown/VBN to/TO induce/VB the/DT expression/NN of/IN infectious/JJ virus/NN from/IN these/DT cultures/NNS ./. 
In/IN this/DT study/NN we/PRP investigated/VBD the/DT mechanisms/NNS whereby/WRB anti-CD2/JJ antibodies/NNS stimulate/VBP viral/JJ production/NN ./. 
We/PRP demonstrate/VBP that/IN treatment/NN of/IN transiently/RB transfected/VBN T/NN lymphocytes/NNS with/IN anti-CD2/JJ antibodies/NNS results/VBZ in/IN activation/NN of/IN the/DT HIV/NN long/JJ terminal/JJ repeat/NN ./. 
Furthermore/RB ,/, CAT/NN assays/NNS using/VBG mutated/VBN HIV/NN long/JJ terminal/JJ repeat-CAT/NN constructs/NNS and/CC gel/NN shift/NN assays/NNS demonstrate/VBP that/IN this/DT activation/NN is/VBZ dependent/JJ on/IN the/DT NF-kappa/NN B/NN enhancer/NN ./. 
These/DT studies/NNS suggest/VBP that/IN interaction/NN of/IN CD2/NN with/IN its/PRP$ natural/JJ ligand/NN ,/, LFA-3/NN ,/, may/MD play/VB a/DT role/NN in/IN regulation/NN of/IN HIV/NN expression/NN ./. 
UI/LS -/: 91293101/CD 
TI/LS -/: Reactive/JJ oxygen/NN intermediates/NNS as/IN apparently/RB widely/RB used/VBN messengers/NNS in/IN the/DT activation/NN of/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN and/CC HIV-1/NN ./. 
AB/LS -/: Hydrogen/NN peroxide/NN and/CC oxygen/NN radicals/NNS are/VBP agents/NNS commonly/RB produced/VBN during/IN inflammatory/JJ processes/NNS ./. 
In/IN this/DT study/NN ,/, we/PRP show/VBP that/IN micromolar/JJ concentrations/NNS of/IN H2O2/NN can/MD induce/VB the/DT expression/NN and/CC replication/NN of/IN HIV-1/NN in/IN a/DT human/JJ T/NN cell/NN line/NN ./. 
The/DT effect/NN is/VBZ mediated/VBN by/IN the/DT NF-kappa/NN B/NN transcription/NN factor/NN which/WDT is/VBZ potently/RB and/CC rapidly/RB activated/VBN by/IN an/DT H2O2/NN treatment/NN of/IN cells/NNS from/IN its/PRP$ inactive/JJ cytoplasmic/JJ form/NN ./. 
N-acetyl-L-cysteine/NN (/( NAC/NN )/) ,/, a/DT well/RB characterized/VBN antioxidant/NN which/WDT counteracts/VBZ the/DT effects/NNS of/IN reactive/JJ oxygen/NN intermediates/NNS (/( ROI/NN )/) in/IN living/VBG cells/NNS ,/, prevented/VBD the/DT activation/NN of/IN NF-kappa/NN B/NN by/IN H2O2/NN ./. 
NAC/NN and/CC other/JJ thiol/JJ compounds/NNS also/RB blocked/VBD the/DT activation/NN of/IN NF-kappa/NN B/NN by/IN cycloheximide/NN ,/, double-stranded/JJ RNA/NN ,/, calcium/NN ionophore/NN ,/, TNF-alpha/NN ,/, active/JJ phorbol/NN ester/NN ,/, interleukin-1/NN ,/, lipopolysaccharide/NN and/CC lectin/NN ./. 
This/DT suggests/VBZ that/IN diverse/JJ agents/NNS thought/VBN to/TO activate/VB NF-kappa/NN B/NN by/IN distinct/JJ intracellular/JJ pathways/NNS might/MD all/DT act/VB through/IN a/DT common/JJ mechanism/NN involving/VBG the/DT synthesis/NN of/IN ROI/NN ./. 
ROI/NN appear/VBP to/TO serve/VB as/IN messengers/NNS mediating/VBG directly/RB or/CC indirectly/RB the/DT release/NN of/IN the/DT inhibitory/JJ subunit/NN I/NN kappa/NN B/NN from/IN NF-kappa/NN B/NN ./. 
UI/LS -/: 91266912/CD 
TI/LS -/: Inhibition/NN of/IN transcription/NN factors/NNS belonging/VBG to/TO the/DT rel/NF-kappa/NN B/NN family/NN by/IN a/DT transdominant/JJ negative/JJ mutant/NN ./. 
AB/LS -/: The/DT KBF1/NN factor/NN ,/, which/WDT binds/VBZ to/TO the/DT enhancer/NN A/NN located/JJ in/IN the/DT promoter/NN of/IN the/DT mouse/NN MHC/NN class/NN I/CD gene/NN H-2Kb/NN ,/, is/VBZ indistinguishable/JJ from/IN the/DT p50/NN DNA/NN binding/NN subunit/NN of/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN ,/, which/WDT regulates/VBZ a/DT series/NN of/IN genes/NNS involved/VBN in/IN immune/JJ and/CC inflammatory/JJ responses/NNS ./. 
The/DT KBF1/p50/NN factor/NN binds/VBZ as/IN a/DT homodimer/NN but/CC can/MD also/RB form/VB heterodimers/NNS with/IN the/DT products/NNS of/IN other/JJ members/NNS of/IN the/DT same/JJ family/NN ,/, like/IN the/DT c-rel/NN and/CC v-rel/NN (/( proto/NN )/) oncogenes/NNS ./. 
The/DT dimerization/NN domain/NN of/IN KBF1/p50/NN is/VBZ contained/VBN between/IN amino/NN acids/NNS 201/CD and/CC 367/CD ./. 
A/DT mutant/NN of/IN KBF1/p50/NN (/( delta/NN SP/NN )/) ,/, unable/JJ to/TO bind/VB to/TO DNA/NN but/CC able/JJ to/TO form/VB homo-/JJ or/CC heterodimers/NNS ,/, has/VBZ been/VBN constructed/VBN ./. 
This/DT protein/NN reduces/VBZ or/CC abolishes/VBZ in/FW vitro/FW the/DT DNA/NN binding/NN activity/NN of/IN wild-type/JJ proteins/NNS of/IN the/DT same/JJ family/NN (/( KBF1/p50/NN ,/, c-/NN and/CC v-rel/NN )/) ./. 
This/DT mutant/JJ also/RB functions/NNS in/FW vivo/FW as/IN a/DT trans-acting/JJ dominant/JJ negative/JJ regulator/NN :/: the/DT transcriptional/JJ inducibility/NN of/IN the/DT HIV/NN long/JJ terminal/JJ repeat/NN (/( which/WDT contains/VBZ two/CD potential/JJ NF-kappa/NN B/NN binding/NN sites/NNS )/) by/IN phorbol/NN ester/NN (/( PMA/NN )/) is/VBZ inhibited/VBN when/WRB it/PRP is/VBZ co-transfected/VBN into/IN CD4+/JJ T/NN cells/NNS with/IN the/DT delta/NN SP/NN mutant/NN ./. 
Similarly/RB the/DT basal/JJ as/RB well/RB as/IN TNF/NN or/CC IL1-induced/JJ activity/NN of/IN the/DT MHC/NN class/NN I/CD H-2Kb/NN promoter/NN can/MD be/VB inhibited/VBN by/IN this/DT mutant/NN in/IN two/CD different/JJ cell/NN lines/NNS ./. 
These/DT results/NNS constitute/VBP the/DT first/JJ formal/JJ demonstration/NN that/IN these/DT genes/NNS are/VBP regulated/VBN by/IN members/NNS of/IN the/DT rel/NF-kappa/NN B/NN family/NN ./. 
UI/LS -/: 91224990/CD 
TI/LS -/: Tissue-specific/JJ expression/NN of/IN the/DT platelet/NN GPIIb/NN gene/NN ./. 
AB/LS -/: One/CD of/IN the/DT major/JJ objectives/NNS in/IN the/DT study/NN of/IN thrombogenesis/NN is/VBZ to/TO determine/VB the/DT mechanisms/NNS by/IN which/WDT a/DT hematopoietic/JJ progenitor/NN is/VBZ activated/VBN and/CC committed/VBN to/TO the/DT megakaryocytic/JJ lineage/NN ./. 
Recent/JJ development/NN of/IN primary/JJ cultures/NNS of/IN human/JJ megakaryocytes/NNS and/CC the/DT molecular/JJ cloning/NN of/IN genes/NNS that/WDT are/VBP specific/JJ to/TO this/DT lineage/NN offer/VBP the/DT possibility/NN of/IN getting/VBG some/DT insights/NNS into/IN the/DT genetic/JJ mechanisms/NNS that/WDT control/VBP megakaryocytopoiesis/NNS ./. 
One/CD gene/NN of/IN interest/NN is/VBZ the/DT glycoprotein/NN IIb/NN (/( GPIIb/NN )/) gene/NN ;/: GPIIb/NN ,/, the/DT alpha/NN subunit/NN of/IN the/DT platelet/NN cytoadhesin/NN GPIIb-IIIa/NN ,/, is/VBZ produced/VBN in/IN megakaryocytes/NNS at/IN an/DT early/JJ stage/NN of/IN the/DT differentiation/NN ,/, whereas/IN the/DT other/JJ subunit/NN of/IN this/DT complex/NN ,/, GPIIIa/NN ,/, is/VBZ expressed/VBN in/IN other/JJ cells/NNS ./. 
For/IN these/DT reasons/NNS ,/, the/DT 5'-flanking/JJ region/NN of/IN the/DT GPIIb/NN gene/NN was/VBD used/VBN to/TO identify/VB the/DT regions/NNS that/WDT interact/VBP with/IN DNA-binding/JJ nuclear/JJ factors/NNS ./. 
A/DT fragment/NN extending/VBG from/IN -643/CD to/TO +33/CD is/VBZ capable/JJ of/IN controlling/VBG the/DT tissue-specific/JJ expression/NN of/IN the/DT CAT/NN gene/NN in/IN transfection/NN experiments/NNS ./. 
Within/IN this/DT region/NN ,/, we/PRP have/VBP identified/VBN several/JJ sequences/NNS that/WDT are/VBP implicated/VBN in/IN DNA/NN protein/NN interactions/NNS as/IN shown/VBN in/IN DNAse/NN I/NN footprints/NNS and/CC gel/NN mobility/NN shift/NN assays/NNS ./. 
One/CD region/NN ,/, centered/VBN at/IN -54/CD ,/, is/VBZ similar/JJ to/TO a/DT nuclear/JJ factor/NN E1-binding/JJ site/NN ,/, and/CC a/DT region/NN located/JJ at/IN position/NN -233/CD contains/VBZ a/DT CCAAT/NN motif/NN ./. 
Two/CD domains/NNS centered/VBN at/IN positions/NNS -345/CD and/CC -540/CD ,/, respectively/RB ,/, bind/VBP proteins/NNS that/WDT are/VBP present/JJ in/IN megakaryocytic/JJ cells/NNS and/CC nonrelated/JJ cells/NNS as/RB well/RB ./. 
Finally/RB ,/, two/CD other/JJ domains/NNS ,/, located/JJ at/IN positions/NNS -460/CD and/CC -510/CD ,/, interact/VBP with/IN proteins/NNS that/WDT are/VBP only/RB present/JJ in/IN megakaryocytic/JJ cells/NNS ./. 
In/IN addition/NN ,/, deletion/NN of/IN the/DT region/NN containing/VBG these/DT two/CD domains/NNS results/VBZ in/IN a/DT significant/JJ decrease/NN of/IN the/DT promoter/NN activity/NN ./. 
It/PRP is/VBZ very/RB likely/JJ that/IN these/DT domains/NNS bind/VBP megakaryocyte-specific/JJ nuclear/JJ proteins/NNS acting/VBG as/IN positive/JJ transcription/NN factors/NNS ./. 
UI/LS -/: 91349414/CD 
TI/LS -/: Lymphocyte/NN glucocorticoid/NN receptor/NN binding/NN during/IN depression/NN and/CC after/IN clinical/JJ recovery/NN ./. 
AB/LS -/: Lymphocyte/NN glucocorticoid/NN receptor/NN binding/NN parameters/NNS were/VBD studied/VBN in/IN 15/CD severely/RB depressed/JJ patients/NNS during/IN depression/NN and/CC after/IN clinical/JJ recovery/NN ,/, and/CC in/IN 15/CD healthy/JJ controls/NNS ./. 
There/EX was/VBD no/DT difference/NN in/IN glucocorticoid/NN receptor/NN number/NN or/CC affinity/NN between/IN depressed/JJ patients/NNS and/CC recovered/JJ or/CC control/NN subjects/NNS ./. 
Afternoon/NN ACTH/NN and/CC cortisol/NN concentrations/NNS did/VBD not/RB differ/VB significantly/RB between/IN the/DT three/CD groups/NNS ./. 
No/DT relationship/NN could/MD be/VB established/VBN between/IN glucocorticoid/NN receptor/NN binding/NN and/CC antidepressant/JJ medication/NN ./. 
These/DT data/NNS support/VBP the/DT view/NN of/IN an/DT impaired/JJ ligand-induced/JJ plasticity/NN of/IN glucocorticoid/NN receptor/NN regulation/NN rather/RB than/IN the/DT hypothesis/NN of/IN decreased/VBN glucocorticoid/NN receptor/NN numbers/NNS during/IN depression/NN ./. 
UI/LS -/: 92314696/CD 
TI/LS -/: Every/DT enhancer/NN works/VBZ with/IN every/DT promoter/NN for/IN all/PDT the/DT combinations/NNS tested/VBN :/: could/MD new/JJ regulatory/JJ pathways/NNS evolve/VBP by/IN enhancer/NN shuffling/NN ?/. 
AB/LS -/: The/DT promoters/NNS and/CC enhancers/NNS of/IN cell/NN type-specific/JJ genes/NNS are/VBP often/RB conserved/VBN in/IN evolution/NN ,/, and/CC hence/RB one/NN might/MD expect/VB that/IN a/DT given/JJ enhancer/NN has/VBZ evolved/VBN to/TO work/VB best/RBS with/IN its/PRP$ own/JJ promoter/NN ./. 
While/IN this/DT expectation/NN may/MD be/VB realized/VBN in/IN some/DT cases/NNS ,/, we/PRP have/VBP not/RB found/VBN evidence/NN for/IN it/PRP ./. 
A/DT total/NN of/IN 27/CD combinations/NNS of/IN different/JJ promoters/NNS and/CC enhancers/NNS were/VBD tested/VBN by/IN transfection/NN into/IN cultured/VBN cells/NNS ./. 
We/PRP found/VBD that/IN the/DT relative/JJ efficiency/NN of/IN the/DT enhancers/NNS is/VBZ approximately/RB the/DT same/JJ ,/, irrespective/JJ of/IN the/DT type/NN of/IN promoter/NN used/VBN ,/, i.e./FW ,/, there/EX was/VBD no/DT strong/JJ preference/NN for/IN any/DT given/JJ enhancer/promoter/JJ combination/NN ./. 
Notably/RB ,/, we/PRP do/VBP not/RB see/VB particularly/RB strong/JJ transcription/NN when/WRB the/DT immunoglobulin/NN kappa/NN enhancer/NN (/( or/CC the/DT immunoglobulin/NN heavy/JJ chain/NN enhancer/NN )/) is/VBZ used/VBN to/TO activate/VB a/DT kappa/NN gene/NN promoter/NN ./. 
We/PRP propose/VBP that/IN a/DT generally/RB permissive/JJ enhancer/promoter/JJ interaction/NN is/VBZ of/IN evolutionary/JJ benefit/NN for/IN higher/JJR eukaryotes/NNS :/: by/IN enhancer/NN shuffling/NN ,/, genes/NNS could/MD be/VB easily/RB brought/VBN under/IN a/DT new/JJ type/NN of/IN inducibility/cell/NN type/NN specificity/NN ./. 
UI/LS -/: 91282927/CD 
TI/LS -/: Towards/IN a/DT molecular/JJ understanding/NN of/IN T-cell/NN differentiation/NN ./. 
AB/LS -/: Lymphoid/JJ differentiation/NN is/VBZ one/CD of/IN the/DT best/RBS studied/VBN examples/NNS of/IN mammalian/JJ development/NN ./. 
Here/RB Hans/NNP Clevers/NNP and/CC Michael/NNP Owen/NNP describe/VBP how/WRB the/DT cloning/NN of/IN the/DT genes/NNS that/WDT encode/VBP T-cell-specific/JJ membrane/NN proteins/NNS allows/VBZ the/DT identification/NN of/IN transcription/NN factors/NNS that/WDT control/VBP the/DT expression/NN of/IN these/DT T-cell/NN genes/NNS ./. 
Such/JJ transcription/NN factors/NNS play/VBP a/DT key/JJ role/NN in/IN the/DT development/NN of/IN the/DT mature/JJ T-cell/NN phenotype/NN by/IN functioning/VBG as/IN '/`` master/JJ regulators/NNS of/IN T-cell/NN differentiation/NN '/'' ./. 
UI/LS -/: 91187152/CD 
TI/LS -/: A/DT study/NN on/IN the/DT circadian/JJ rhythm/NN of/IN glucocorticoid/NN receptor/NN ./. 
AB/LS -/: Circadian/JJ rhythm/NN in/IN glucocorticoid/NN receptor/NN (/( GR/NN )/) was/VBD studied/VBN in/IN the/DT rat/NN liver/NN and/CC human/JJ peripheral/JJ leukocytes/NNS ./. 
For/IN rats/NNS exposed/VBN to/TO a/DT natural/JJ environmental/JJ photic/JJ cycle/NN or/CC a/DT 12L/NN :/: 12D/NN artificial/JJ light/NN regime/NN ,/, peak/JJ values/NNS of/IN hepatic/JJ GR/NN were/VBD detected/VBN between/IN 23/CD :/: 00/CD and/CC 02/CD :/: 00/CD h/NN ./. 
Except/IN for/IN a/DT 4-hour/JJ advancement/NN of/IN the/DT peak/NN ,/, a/DT similar/JJ circadian/JJ rhythm/NN of/IN hepatic/JJ GR/NN was/VBD detected/VBN in/IN rats/NNS reared/VBN under/IN a/DT reversed/VBN lighting/NN regimen/NNS (/( 12D/NN :/: 12L/NN ;/: lights/NNS on/IN between/IN 18/CD :/: 30/CD and/CC 06/CD :/: 30/CD h/NN )/) ./. 
In/IN human/JJ leukocytes/NNS ,/, the/DT peak/JJ value/NN of/IN GR/NN was/VBD found/VBN to/TO parallel/VB that/DT of/IN plasma/NN cortisol/NN with/IN high/JJ and/CC low/JJ values/NNS detected/VBN at/IN 04:00-08:00/CD h/NN and/CC 23:00-24:00/CD h/NN ,/, respectively/RB ./. 
In/IN patients/NNS suffering/VBG from/IN Cushing/NN 's/POS syndrome/NN ,/, the/DT circadian/JJ rhythm/NN of/IN plasma/NN cortisol/NN either/CC disappeared/VBD or/CC was/VBD inverted/VBN while/IN that/DT of/IN GR/NN did/VBD not/RB significantly/RB deviate/VB from/IN the/DT normal/JJ subjects/NNS ./. 
For/IN apoplexic/JJ patients/NNS with/IN lesions/NNS localized/JJ to/TO the/DT base/NN of/IN the/DT brain/NN as/IN indicated/VBN by/IN computerized/VBN tomography/NN ,/, the/DT diurnal/JJ variation/NN of/IN GR/NN was/VBD abolished/VBN ./. 
Conversely/RB ,/, diurnal/JJ rhythmicity/NN persisted/VBD in/IN apoplexy/NN patients/NNS whose/WP$ lesions/NNS were/VBD in/IN the/DT cerebral/JJ cortex/NN ./. 
Thus/RB ,/, we/PRP postulated/VBD that/IN the/DT circadian/JJ modification/NN of/IN GR/NN was/VBD independent/JJ of/IN the/DT diurnal/JJ fluctuations/NNS in/IN plasma/NN cortisol/NN level/NN or/CC the/DT circadian/JJ variations/NNS in/IN environmental/JJ lighting/NN and/CC that/IN the/DT rhythmicity/NN might/MD be/VB regulated/VBN by/IN the/DT '/`` circadian/JJ pacemaker/NN '/'' located/JJ in/IN the/DT human/JJ basal/JJ brain/NN ./. 
These/DT diurnal/JJ variations/NNS in/IN GR/NN might/MD serve/VB to/TO coordinate/VB the/DT reactivity/NN of/IN the/DT target/NN cells/NNS to/TO cortisol/NN because/IN the/DT diurnal/JJ rhythms/NNS of/IN a/DT GR-mediated/JJ response/NN ,/, the/DT fractional/JJ inhibition/NN of/IN chemotactic/JJ migration/NN rate/NN of/IN polymorphonuclear/JJ leukocytes/NNS by/IN cortisol/NN ,/, were/VBD found/VBN to/TO be/VB synchronous/JJ with/IN those/DT of/IN GR/NN ./. 
UI/LS -/: 92112059/CD 
TI/LS -/: Transcription/NN factor/NN requirements/NNS for/IN U2/NN snRNA-encoding/JJ gene/NN activation/NN in/IN B/NN lymphoid/JJ cells/NNS ./. 
AB/LS -/: Transcription/NN of/IN a/DT human/JJ U2/NN small/JJ nuclear/JJ RNA/NN (/( snRNA/NN )/) -encoding/JJ gene/NN in/IN HeLa/NN cells/NNS requires/VBZ a/DT distal/JJ enhancer/NN element/NN ,/, which/WDT is/VBZ composed/VBN of/IN one/CD octamer/NN motif/NN (/( Oct/NN )/) and/CC three/CD Sp/NN 1-binding/JJ sites/NNS ./. 
To/TO study/VB the/DT transcription/NN factor/NN requirement/NN in/IN B-cells/NNS ,/, different/JJ U2/NN enhancer/NN constructions/NNS were/VBD transfected/VBN into/IN the/DT lymphoid/JJ cell/NN line/NN ,/, BJA-B/NN ./. 
The/DT results/NNS showed/VBD that/IN the/DT activation/NN of/IN U2/NN snRNA/NN transcription/NN in/IN B-cells/NNS also/RB requires/VBZ an/DT enhancer/NN comprising/VBG both/CC the/DT Oct/NN and/CC at/IN least/JJS one/CD Sp/NN 1-binding/JJ site/NN ./. 
Deletion/NN of/IN all/PDT the/DT Sp/NN 1-binding/JJ sites/NNS from/IN the/DT enhancer/NN reduces/VBZ transcription/NN by/IN 80-90/CD %/NN in/IN HeLa/NN ,/, as/RB well/RB as/IN in/IN BJA-B/NN cells/NNS ,/, whereas/IN the/DT removal/NN of/IN the/DT octamer-binding/JJ site/NN reduces/VBZ transcription/NN to/TO levels/NNS below/IN detection/NN in/IN both/DT cell/NN types/NNS ./. 
Enhancers/NNS containing/VBG a/DT single/JJ Oct/NN have/VBP ,/, nevertheless/RB ,/, the/DT capacity/NN to/TO partially/RB activate/VB U2/NN snRNA/NN transcription/NN in/IN both/DT HeLa/NN cells/NNS ,/, in/IN which/WDT only/RB OTF-1/NN is/VBZ expressed/VBN ,/, and/CC in/IN BJA-B/NN cells/NNS in/IN which/WDT OTF-2/NN is/VBZ the/DT predominantly/RB expressed/VBN octamer-binding/JJ factor/NN ./. 
The/DT most/RBS likely/JJ interpretation/NN of/IN our/PRP$ results/NNS is/VBZ that/IN both/CC the/DT ubiquitous/JJ transcription/NN factor/NN ,/, OTF-1/NN ,/, and/CC the/DT B-cell-specific/JJ transcription/NN factor/NN ,/, OTF-2/NN ,/, can/MD activate/VB U2/NN snRNA/NN transcription/NN ./. 
The/DT results/NNS also/RB revealed/VBD a/DT similar/JJ functional/JJ cooperation/NN between/IN the/DT transcription/NN factors/NNS which/WDT bind/VBP to/TO the/DT Oct/NN and/CC the/DT adjacent/JJ Sp/NN 1-binding/JJ site/NN in/IN BJA-B/NN cells/NNS ,/, as/IN has/VBZ been/VBN observed/VBN in/IN HeLa/NN cells/NNS ,/, since/IN a/DT template/NN which/WDT contains/VBZ a/DT weak/JJ binding/VBG site/NN for/IN OTFs/NNS expresses/VBZ wild-type/JJ levels/NNS of/IN U2/NN snRNA/NN in/IN both/DT cell/NN types/NNS when/WRB the/DT weak/JJ octamer-binding/JJ site/NN is/VBZ combined/VBN with/IN a/DT Sp/NN 1-binding/JJ site/NN ./. 
UI/LS -/: 92051383/CD 
TI/LS -/: One/CD base/NN pair/NN change/NN abolishes/VBZ the/DT T/NN cell-restricted/JJ activity/NN of/IN a/DT kB-like/JJ proto-enhancer/NN element/NN from/IN the/DT interleukin/NN 2/CD promoter/NN ./. 
AB/LS -/: The/DT inducible/JJ ,/, T/NN cell-specific/JJ enhancers/NNS of/IN murine/JJ and/CC human/JJ Interleukin/NN 2/CD (/( Il-2/NN )/) genes/NNS contain/VBP the/DT kB-like/JJ sequence/NN GGGATTTCACC/NN as/IN an/DT essential/JJ cis-acting/JJ enhancer/NN motif/NN ./. 
When/WRB cloned/VBN in/IN multiple/JJ copies/NNS this/DT so-called/JJ TCEd/NN (/( distal/JJ T/NN cell/NN element/NN )/) acts/VBZ as/IN an/DT inducible/JJ proto-enhancer/NN element/NN in/IN E14/NN T/NN lymphoma/NN cells/NNS ,/, but/CC not/RB in/IN HeLa/NN cells/NNS ./. 
In/IN extracts/NNS of/IN induced/VBN ,/, Il-2/NN secreting/NN El4/NN cells/NNS three/CD individual/JJ protein/NN factors/NNS bind/VBP to/TO TCEd/NN DNA/NN ./. 
The/DT binding/NN of/IN the/DT most/RBS prominent/JJ factor/NN ,/, named/VBN TCF-1/NN (/( T/NN cell/NN factor/NN 1/CD )/) ,/, is/VBZ correlated/VBN with/IN the/DT proto-enhancer/NN activity/NN of/IN TCEd/NN ./. 
TCF-1/NN consists/VBZ of/IN two/CD polypeptides/NNS of/IN about/RB 50/CD kD/NN and/CC 105/CD kD/NN ;/: the/DT former/JJ seems/VBZ to/TO be/VB related/JJ to/TO the/DT 50/CD kD/NN polypeptide/NN of/IN NF-kB/NN ./. 
Purified/VBN NF-kB/NN is/VBZ also/RB able/JJ to/TO bind/VB to/TO the/DT TCEd/NN ,/, but/CC TCF-1/NN binds/VBZ stronger/JJR than/IN NF-kB/NN to/TO TCEd/NN DNA/NN ./. 
The/DT conversion/NN of/IN the/DT TCEd/NN to/TO a/DT '/`` perfect/JJ '/'' NF-kB/NN binding/NN site/NN leads/VBZ to/TO a/DT tighter/JJR binding/NN of/IN NF-kB/NN to/TO TCEd/NN DNA/NN and/CC ,/, as/IN a/DT functional/JJ consequence/NN ,/, to/TO the/DT activity/NN of/IN the/DT '/`` converted/VBN '/'' TCEd/NN motifs/NNS in/IN HeLa/NN cells/NNS ./. 
Thus/RB ,/, the/DT substitution/NN of/IN the/DT underlined/VBN A/NN residue/NN to/TO a/DT C/NN within/IN the/DT GGGATTTCACC/NN motif/NN abolishes/VBZ its/PRP$ T/NN cell-restricted/JJ activity/NN and/CC leads/VBZ to/TO its/PRP$ functioning/VBG in/IN both/CC El4/NN cells/NNS and/CC HeLa/NN cells/NNS ./. 
These/DT results/NNS indicate/VBP that/IN lymphocyte-specific/JJ factors/NNS binding/VBG to/TO the/DT TCEd/NN are/VBP involved/VBN in/IN the/DT control/NN of/IN T/NN cell/NN specific-transcription/NN of/IN the/DT Il-2/NN gene/NN ./. 
UI/LS -/: 92020218/CD 
TI/LS -/: An/DT erythroid/JJ specific/JJ enhancer/NN upstream/JJ to/TO the/DT gene/NN encoding/VBG the/DT cell-type/JJ specific/JJ transcription/NN factor/NN GATA-1/NN ./. 
AB/LS -/: The/DT transcription/NN factor/NN GATA-1/NN is/VBZ expressed/VBN in/IN a/DT subset/NN of/IN hemopoietic/JJ cells/NNS ,/, where/WRB it/PRP mediates/VBZ the/DT cell-type/JJ specific/JJ expression/NN of/IN several/JJ genes/NNS ./. 
We/PRP have/VBP cloned/VBN the/DT mouse/NN and/CC human/JJ GATA-1/NN genes/NNS ./. 
A/DT region/NN upstream/JJ to/TO the/DT first/JJ exon/NN ,/, and/CC highly/RB conserved/VBN between/IN mouse/NN and/CC man/NN ,/, acts/VBZ as/IN an/DT erythroid/JJ specific/JJ enhancer/NN in/IN transient/JJ assays/NNS ,/, if/IN linked/VBN to/TO the/DT GATA-1/NN or/CC to/TO the/DT SV40/NN promoter/NN ./. 
The/DT activity/NN of/IN the/DT enhancer/NN is/VBZ almost/RB completely/RB dependent/JJ on/IN the/DT integrity/NN of/IN a/DT dimeric/JJ GATA-1/NN binding/NN site/NN ./. 
UI/LS -/: 92020850/CD 
TI/LS -/: Demonstration/NN of/IN a/DT 1,25-dihydroxyvitamin/NN D3-responsive/JJ protein/NN in/IN human/JJ lymphocytes/NNS :/: immunologic/JJ crossreactivity/NN and/CC inverse/JJ regulation/NN with/IN the/DT vitamin/NN D/NN receptor/NN ./. 
AB/LS -/: Using/VBG Western/NN blot/NN analysis/NN with/IN a/DT monoclonal/JJ antibody/NN recognizing/VBG a/DT 17-amino/NN acid/NN epitope/NN of/IN the/DT 1,25-dihydroxyvitamin/NN D3/NN [/( 1,25(OH)2D3/NN ]/) receptor/NN ,/, we/PRP have/VBP detected/VBN two/CD crossreacting/VBG proteins/NNS in/IN activated/VBN normal/JJ human/JJ lymphocytes/NNS ./. 
The/DT smaller/JJR of/IN the/DT two/CD proteins/NNS (/( 50/CD kDa/NN )/) was/VBD indistinguishable/JJ from/IN the/DT classical/JJ 1,25(OH)2D3/NN receptor/NN and/CC ,/, similar/JJ to/TO the/DT classical/JJ 1,25(OH)2D3/NN receptor/NN ,/, was/VBD upregulated/VBN in/IN a/DT dose-dependent/JJ fashion/NN by/IN 1,25(OH)2D3/NN ./. 
The/DT larger/JJR crossreacting/VBG protein/NN exhibited/VBD an/DT electrophoretic/JJ mobility/NN of/IN 80/CD kDa/NN ,/, was/VBD localized/JJ in/IN the/DT cell/NN cytosol/NN ,/, and/CC appeared/VBD to/TO be/VB specific/JJ for/IN activated/VBN lymphocytes/NNS since/IN it/PRP was/VBD not/RB detected/VBN in/IN several/JJ other/JJ human/JJ cells/NNS including/VBG monocytes/NNS ./. 
More/RBR strikingly/RB ,/, the/DT 80-kDa/JJ protein/NN was/VBD downregulated/VBN in/IN a/DT dose-dependent/JJ fashion/NN by/IN 1,25(OH)2D3/NN ;/: this/DT effect/NN was/VBD independent/JJ of/IN the/DT mode/NN of/IN lymphocyte/NN activation/NN and/CC specific/JJ for/IN the/DT 1,25(OH)2D3/NN metabolite/NN of/IN vitamin/NN D3/NN ./. 
However/RB ,/, two/CD potent/JJ immunosuppressive/JJ agents/NNS ,/, glucocorticoids/NNS and/CC cyclosporin/NN A/DT ,/, also/RB inhibited/VBD the/DT 80-kDa/JJ protein/NN ./. 
UI/LS -/: 91363265/CD 
TI/LS -/: Regulation/NN of/IN glucocorticoid/NN receptors/NNS in/IN human/JJ mononuclear/JJ cells/NNS :/: effects/NNS of/IN glucocorticoid/NN treatment/NN ,/, Cushing/NN 's/POS disease/NN and/CC ketoconazole/NN ./. 
AB/LS -/: Glucocorticoid/NN receptors/NNS (/( GcR/NN )/) were/VBD determined/VBN by/IN a/DT whole/JJ cell/NN assay/NN in/IN human/JJ mononulear/JJ leukocytes/NNS (/( hMNL/NN )/) from/IN control/NN subjects/NNS ,/, patients/NNS receiving/VBG glucocorticoid/NN therapy/NN for/IN systemic/JJ diseases/NNS and/CC Cushing/NN 's/POS disease/NN patients/NNS with/IN or/CC without/IN ketoconazole/NN therapy/NN ./. 
Prolonged/JJ corticosteroid/NN treatment/NN resulted/VBD in/IN down-regulation/NN of/IN GcR/NN ,/, while/IN the/DT mean/NN level/NN of/IN GcR/NN in/IN Cushing/NN 's/POS disease/NN was/VBD normal/JJ ./. 
In/IN this/DT group/NN ,/, however/RB ,/, receptor/NN levels/NNS and/CC morning/NN plasma/NN cortisol/NN values/NNS showed/VBD a/DT negative/JJ correlation/NN ,/, indicating/VBG a/DT subtle/JJ down-regulatory/JJ effect/NN ./. 
Furthermore/RB ,/, GcR/NN were/VBD unaltered/JJ after/IN these/DT patients/NNS received/VBD ketoconazole/NN ,/, in/IN spite/NN of/IN a/DT marked/JJ reduction/NN in/IN morning/NN plasma/NN cortisol/NN and/CC urinary/JJ free/JJ cortisol/NN ./. 
We/PRP also/RB observed/VBD that/IN ketoconazole/NN was/VBD a/DT weak/JJ competitor/NN of/IN GcR/NN in/IN intact/JJ cells/NNS ,/, although/IN it/PRP significantly/RB inhibited/VBD [3H]/NN dexamethasone/NN binding/NN in/IN cytosolic/JJ preparations/NNS from/IN rat/NN tissues/NNS ./. 
The/DT results/NNS suggested/VBD that/IN GcR/NN in/IN hMNL/NN are/VBP down-regulated/VBN by/IN synthetic/JJ steroids/NNS given/VBN in/FW vivo/FW ,/, but/CC they/PRP showed/VBD very/RB mild/JJ down-regulation/NN in/IN hypercortisolemic/JJ patients/NNS suffering/VBG from/IN Cushing/NN 's/POS disease/NN ./. 
Finally/RB ,/, we/PRP did/VBD not/RB observed/VBN either/CC up-regulation/NN or/CC antagonism/NN of/IN GcR/NN by/IN ketoconazole/NN treatment/NN ,/, at/IN the/DT time/NN that/IN cortisol/NN levels/NNS of/IN patients/NNS with/IN Cushing/NN 's/POS disease/NN were/VBD reduced/VBN ./. 
This/DT indicates/VBZ that/IN the/DT beneficial/JJ effects/NNS of/IN ketoconazole/NN in/IN Cushing/NN 's/POS disease/NN are/VBP due/JJ to/TO adrenal/JJ cortisol/NN suppression/NN and/CC not/RB to/TO interaction/NN with/IN GcR/NN of/IN target/NN cells/NNS ,/, and/CC that/IN the/DT process/NN of/IN GcR/NN regulation/NN in/IN hMNL/NN is/VBZ a/DT complex/JJ phenomenon/NN awaiting/VBG further/RBR elucidation/NN ./. 
UI/LS -/: 91296379/CD 
TI/LS -/: HTLV-1/NN Tax/NN induces/VBZ expression/NN of/IN various/JJ immediate/JJ early/JJ serum/NN responsive/JJ genes/NNS ./. 
AB/LS -/: Human/JJ T-cell/NN leukemia/NN virus/NN type/NN 1/CD (/( HTLV-1/NN )/) is/VBZ an/DT etiological/JJ agent/NN of/IN adult/JJ T-cell/NN leukemia/NN (/( ATL/NN )/) ./. 
We/PRP showed/VBD here/RB by/IN mobility-shift/NN assay/NN that/IN T-cell/NN lines/NNS transformed/VBN with/IN the/DT virus/NN contained/VBD high/JJ levels/NNS of/IN AP-1/NN activities/NNS ./. 
Consistent/JJ with/IN this/DT result/NN ,/, these/DT cell/NN lines/NNS expressed/VBD increased/VBN levels/NNS of/IN mRNAs/NNS encoding/VBG the/DT AP-1/NN proteins/NNS ,/, c-Fos/NN ,/, Fra-1/NN ,/, c-Jun/NN ,/, JunB/NN ,/, and/CC JunD/NN ./. 
Previously/RB ,/, transcription/NN of/IN the/DT c-fos/NN gene/NN has/VBZ been/VBN reported/VBN to/TO be/VB transactivated/VBN by/IN the/DT viral/JJ transcription/NN factor/NN ,/, Tax1/NN ./. 
By/IN using/VBG the/DT human/JJ T-cell/NN line/NN (/( JPX-9/NN )/) ,/, in/IN which/WDT expression/NN of/IN the/DT Tax1/NN is/VBZ inducible/JJ ,/, we/PRP showed/VBD that/IN expression/NN of/IN mRNAs/NNS for/IN Fra-1/NN ,/, c-Jun/NN ,/, and/CC JunD/NN was/VBD also/RB transactivated/VBN by/IN Tax1/NN ./. 
Moreover/RB ,/, Tax1/NN activated/VBD expression/NN of/IN two/CD other/JJ transcription/NN factors/NNS having/VBG zinc/NN finger/NN motifs/NNS ,/, Egr-1/NN and/CC Egr-2/NN ,/, in/IN the/DT same/JJ cells/NNS ./. 
The/DT Tax1-inducible/JJ transcription/NN factors/NNS identified/VBN here/RB are/VBP encoded/VBN by/IN the/DT members/NNS of/IN immediate/JJ early/JJ genes/NNS under/IN the/DT control/NN of/IN growth/NN signals/NNS ./. 
Thus/RB ,/, Tax1/NN was/VBD suggested/VBN to/TO replace/VB growth/NN signals/NNS ,/, at/IN least/JJS in/IN part/NN ,/, by/IN this/DT mechanism/NN ./. 
UI/LS -/: 91221358/CD 
TI/LS -/: Glucocorticoid/NN receptor/NN characteristics/NNS in/IN monocytes/NNS of/IN patients/NNS with/IN corticosteroid-resistant/JJ bronchial/JJ asthma/NN ./. 
AB/LS -/: The/DT mechanism/NN of/IN corticosteroid/NN resistance/NN in/IN bronchial/JJ asthma/NN has/VBZ been/VBN studied/VBN by/IN determining/VBG the/DT rank/NN order/NN of/IN potency/NN for/IN different/JJ corticosteroids/NNS in/IN inhibiting/VBG the/DT generation/NN of/IN a/DT 3/CD kD/NN molecule/NN from/IN peripheral/JJ blood/NN monocytes/NNS isolated/VBN from/IN corticosteroid-sensitive/JJ (/( CS/JJ )/) and/CC corticosteroid-resistant/JJ (/( CR/JJ )/) asthmatic/JJ subjects/NNS ,/, which/WDT augments/VBZ leukotriene/NN B4/NN (/( LTB4/NN )/) generation/NN by/IN human/JJ neutrophils/NNS (/( PMN/NN )/) stimulated/VBN by/IN calcium/NN ionophore/NN ./. 
In/IN addition/NN ,/, binding/VBG studies/NNS with/IN (/( 3H/NN )/) dexamethasone/NN have/VBP been/VBN performed/VBN to/TO determine/VB the/DT dissociation/NN constant/NN (/( Kd/NN )/) and/CC receptor/NN numbers/NNS (/( Ro/NN )/) in/IN the/DT monocytes/NNS of/IN these/DT two/CD groups/NNS of/IN subjects/NNS ./. 
The/DT concentration/NN of/IN corticosteroid/NN producing/VBG 50/CD %/NN inhibition/NN (/( IC50/NN )/) was/VBD 600/CD nM/NN ,/, 70/CD nM/NN ,/, and/CC 0.5/CD nM/NN for/IN hydrocortisone/NN ,/, methylprednisolone/NN ,/, and/CC dexamethasone/NN ,/, respectively/RB ,/, in/IN monocytes/NNS from/IN CS/JJ individuals/NNS ./. 
There/EX was/VBD only/RB weak/JJ inhibition/NN of/IN the/DT generation/NN of/IN enhancing/NN activity/NN by/IN the/DT corticosteroids/NNS in/IN the/DT CR/JJ asthmatic/JJ individuals/NNS ./. 
The/DT dexamethasone/NN Kd/NN was/VBD 2.45/CD +/-/CC 0.58/CD nM/NN (/( mean/NN +/-/CC SEM/NN ,/, n/NN =/JJ 6/CD )/) in/IN the/DT CS/JJ group/NN and/CC 1.6/CD +/-/CC 0.35/CD nM/NN (/( mean/NN +/-/CC SEM/NN ,/, n/NN =/JJ 6/CD )/) in/IN the/DT CR/JJ group/NN of/IN patients/NNS (/( p/NN =/JJ 0.14/CD )/) ./. 
The/DT Ro/NN in/IN the/DT CS/JJ group/NN was/VBD 3,605/CD +/-/CC 984/CD binding/VBG sites/NNS per/IN nucleus/NN (/( mean/NN +/-/CC SEM/NN ,/, n/NN =/JJ 6/CD )/) and/CC 4,757/CD +/-/CC 692/CD binding/VBG sites/NNS per/IN nucleus/NN (/( mean/NN +/-/CC SEM/NN ,/, n/NN =/JJ 6/CD )/) in/IN the/DT CR/JJ group/NN (/( p/NN =/JJ 0.23/CD )/) ./. 
These/DT findings/NNS indicate/VBP that/IN corticosteroid/NN resistance/NN in/IN bronchial/JJ asthma/NN can/MD not/RB be/VB explained/VBN by/IN abnormalities/NNS in/IN corticosteroid/NN receptor/NN characteristics/NNS ./. 
UI/LS -/: 91210272/CD 
TI/LS -/: Vitamin/NN D/NN receptor/NN expression/NN in/IN human/JJ lymphocytes/NNS ./. 
Signal/NN requirements/NNS and/CC characterization/NN by/IN western/NN blots/NNS and/CC DNA/NN sequencing/NN ./. 
AB/LS -/: The/DT signals/NNS controlling/VBG the/DT expression/NN of/IN the/DT receptor/NN protein/NN for/IN 1/CD alpha,25-dihydroxyvitamin/NN D3/NN in/IN normal/JJ human/JJ lymphocytes/NNS and/CC the/DT relationship/NN of/IN this/DT protein/NN to/TO the/DT classical/JJ vitamin/NN D/NN receptor/NN were/VBD examined/VBN ./. 
Lymphocytes/NNS activated/VBN with/IN the/DT OKT3/NN antibody/NN to/TO the/DT T-cell/NN antigen/NN receptor/NN expressed/VBD fewer/JJR binding/VBG sites/NNS as/IN compared/VBN to/TO lymphocytes/NNS that/WDT were/VBD activated/VBN by/IN the/DT polyclonal/JJ activator/NN phytohemagglutinin/NN (/( PHA/NN )/) ./. 
However/RB ,/, combination/NN of/IN OKT3/NN and/CC phorbol/NN myristate/NN acetate/NN produced/VBD a/DT concentration/NN of/IN binding/VBG sites/NNS similar/JJ to/TO the/DT PHA-activated/JJ cells/NNS ./. 
The/DT receptor/NN from/IN OKT3/NN and/CC OKT3/NN +/CC phorbol/NN myristate/NN acetate-activated/JJ lymphocytes/NNS exhibited/VBD decreased/VBN binding/NN to/TO DNA-cellulose/NN compared/VBN to/TO PHA-activated/JJ lymphocytes/NNS ./. 
In/IN lymphocytes/NNS activated/VBN either/CC by/IN PHA/NN or/CC OKT3/NN (/( but/CC not/RB in/IN resting/VBG cells/NNS )/) ,/, a/DT 50-kDa/JJ species/NNS cross-reacting/VBG with/IN a/DT monoclonal/JJ antibody/NN against/IN the/DT intestinal/JJ vitamin/NN D/NN receptor/NN was/VBD detected/VBN ./. 
Finally/RB ,/, RNA/NN from/IN activated/VBN lymphocytes/NNS was/VBD amplified/VBN by/IN polymerase/NN chain/NN reaction/NN using/VBG oligonucleotide/NN primers/NNS flanking/VBG the/DT 196/CD base/NN pair/NN long/JJ region/NN encoding/VBG the/DT DNA-binding/JJ domain/NN of/IN the/DT human/JJ intestinal/JJ receptor/NN ./. 
The/DT amplified/VBN product/NN showed/VBD an/DT identical/JJ nucleotide/NN sequence/NN to/TO the/DT DNA-binding/JJ domain/NN of/IN the/DT human/JJ intestinal/JJ receptor/NN ./. 
These/DT findings/NNS suggest/VBP that/IN expression/NN of/IN the/DT 1,25-(OH)2D3/NN receptor/NN in/IN lymphocytes/NNS is/VBZ triggered/VBN by/IN distinct/JJ and/CC contingent/JJ signals/NNS ,/, and/CC that/IN the/DT protein/NN and/CC the/DT mRNA/NN encoding/VBG it/PRP are/VBP identical/JJ to/TO the/DT classical/JJ vitamin/NN D/NN receptor/NN ./. 
UI/LS -/: 91172768/CD 
TI/LS -/: Comparison/NN of/IN constitutive/JJ and/CC inducible/JJ transcriptional/JJ enhancement/NN mediated/VBN by/IN kappa/NN B-related/JJ sequences/NNS :/: modulation/NN of/IN activity/NN in/IN B/NN cells/NNS by/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD tax/NN gene/NN ./. 
AB/LS -/: The/DT kappa/NN B/NN sequence/NN (/( GGGACTTTCC/NN )/) binds/VBZ a/DT factor/NN ,/, NF-kappa/NN B/NN ,/, that/WDT is/VBZ constitutively/RB found/VBN in/IN its/PRP$ functional/JJ ,/, DNA/NN binding/NN form/NN only/RB in/IN B/NN lymphocytes/NNS ./. 
A/DT factor/NN with/IN apparently/RB indistinguishable/JJ sequence/NN specificity/NN can/MD be/VB induced/VBN in/IN many/JJ other/JJ cell/NN types/NNS ,/, where/WRB it/PRP is/VBZ used/VBN to/TO regulate/VB inducible/JJ gene/NN expression/NN ./. 
For/IN example/NN ,/, kappa/NN B-related/JJ sequences/NNS have/VBP been/VBN shown/VBN to/TO be/VB important/JJ for/IN the/DT transcription/NN of/IN a/DT few/JJ inducible/JJ genes/NNS ,/, such/JJ as/IN the/DT interleukin/NN 2/CD receptor/NN alpha-chain/NN gene/NN and/CC the/DT beta-interferon/NN gene/NN ./. 
However/RB ,/, these/DT genes/NNS are/VBP not/RB constitutively/RB active/JJ in/IN B/NN lymphocytes/NNS ,/, suggesting/VBG that/IN other/JJ regulatory/JJ mechanisms/NNS must/MD play/VB a/DT role/NN in/IN determining/VBG the/DT patterns/NNS of/IN expression/NN ./. 
We/PRP have/VBP investigated/VBN the/DT constitutive/JJ and/CC inducible/JJ transcriptional/JJ activity/NN mediated/VBN by/IN five/CD kappa/NN B-related/JJ sequence/NN elements/NNS in/IN two/CD different/JJ cell/NN types/NNS ./. 
We/PRP show/VBP that/IN in/IN S194/NN plasma/NN cells/NNS the/DT activity/NN of/IN each/DT element/NN correlates/VBZ well/RB with/IN the/DT relative/JJ affinity/NN of/IN B-cell-derived/JJ NF-kappa/NN B/NN for/IN that/DT element/NN ./. 
This/DT leads/VBZ to/TO significantly/RB lower/RBR transcription/NN enhancement/NN by/IN sites/NNS derived/VBN from/IN the/DT interleukin/NN 2/CD receptor/NN or/CC T-cell/NN receptor/NN genes/NNS in/IN S194/NN cells/NNS ./. 
However/RB ,/, in/IN either/CC EL-4/NN (/( T/NN )/) cells/NNS or/CC S194/NN cells/NNS ,/, both/DT lower-affinity/JJ sites/NNS can/MD be/VB significantly/RB induced/VBN by/IN the/DT tax/NN gene/NN product/NN of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD ,/, showing/VBG that/IN NF-kappa/NN B/NN activity/NN can/MD be/VB modulated/VBN even/RB in/IN a/DT B-cell/NN line/NN that/WDT constitutively/RB expresses/VBZ this/DT factor/NN ./. 
UI/LS -/: 91110562/CD 
TI/LS -/: Specific/JJ depletion/NN of/IN the/DT B-cell/NN population/NN induced/VBN by/IN aberrant/JJ expression/NN of/IN human/JJ interferon/NN regulatory/JJ factor/NN 1/CD gene/NN in/IN transgenic/JJ mice/NNS ./. 
AB/LS -/: Interferons/NNS (/( IFNs/NNS )/) are/VBP well/RB known/VBN both/CC as/IN antiviral/JJ proteins/NNS and/CC as/IN potent/JJ regulators/NNS of/IN cell/NN growth/NN and/CC differentiation/NN ./. 
In/IN fact/NN ,/, IFNs/NNS inhibit/VBP growth/NN of/IN various/JJ normal/JJ and/CC transformed/VBN cell/NN types/NNS ./. 
Previously/RB ,/, a/DT nuclear/JJ factor/NN ,/, IRF-1/NN (/( interferon/NN regulatory/JJ factor/NN 1/CD )/) ,/, which/WDT binds/VBZ to/TO type/NN I/CD IFN/NN and/CC some/DT IFN-inducible/JJ gene/NN promoters/NNS ,/, was/VBD identified/VBN and/CC cloned/VBN ./. 
Since/IN the/DT IRF-1/NN gene/NN is/VBZ both/CC virus/NN and/CC IFN/NN inducible/JJ ,/, an/DT intriguing/JJ issue/NN is/VBZ raised/VBN as/IN to/TO whether/IN the/DT IRF-1/NN gene/NN is/VBZ functioning/VBG in/IN IFN-mediated/JJ regulation/NN of/IN cell/NN growth/NN and/CC differentiation/NN ./. 
In/IN this/DT study/NN ,/, we/PRP generated/VBD transgenic/JJ mice/NNS carrying/VBG the/DT human/JJ IRF-1/NN gene/NN linked/VBN to/TO the/DT human/JJ immunoglobulin/NN heavy-chain/JJ enhancer/NN ./. 
In/IN the/DT transgenic/JJ mice/NNS ,/, all/PDT the/DT lymphoid/JJ tissues/NNS examined/VBN showed/VBD a/DT dramatic/JJ reduction/NN in/IN the/DT number/NN of/IN B/NN lymphocytes/NNS (/( B/NN cells/NNS )/) ./. 
Preparation/NN and/CC analysis/NN of/IN bone/NN marrow/NN cells/NNS from/IN the/DT chimeric/JJ mice/NNS indicated/VBD that/IN the/DT bone/NN marrow/NN is/VBZ the/DT effective/JJ site/NN for/IN specific/JJ depletion/NN of/IN the/DT B-cell/NN population/NN ./. 
In/IN fact/NN ,/, transgenic/JJ bone/NN marrow/NN cells/NNS cocultured/VBN with/IN a/DT bone/NN marrow-derived/JJ stromal/JJ cell/NN line/NN revealed/VBD an/DT altered/JJ B-cell/NN maturation/NN pattern/NN ./. 
UI/LS -/: 92108417/CD 
TI/LS -/: Characterization/NN of/IN a/DT cofactor/NN that/WDT regulates/VBZ dimerization/NN of/IN a/DT mammalian/JJ homeodomain/NN protein/NN ./. 
AB/LS -/: Dimerization/NN among/IN transcription/NN factors/NNS has/VBZ become/VBN a/DT recurrent/JJ theme/NN in/IN the/DT regulation/NN of/IN eukaryotic/JJ gene/NN expression/NN ./. 
Hepatocyte/NN nuclear/JJ factor-1/NN alpha/NN (/( HNF-1/NN alpha/NN )/) is/VBZ a/DT homeodomain-containing/JJ protein/NN that/WDT functions/VBZ as/IN a/DT dimer/NN ./. 
A/DT dimerization/NN cofactor/NN of/IN HNF-1/NN alpha/NN (/( DCoH/NN )/) was/VBD identified/VBN that/WDT displayed/VBD a/DT restricted/JJ tissue/NN distribution/NN and/CC did/VBD not/RB bind/VB to/TO DNA/NN ,/, but/CC ,/, rather/RB ,/, selectively/RB stabilized/VBD HNF-1/NN alpha/NN dimers/NNS ./. 
The/DT formation/NN of/IN a/DT stable/JJ tetrameric/JJ DCoH-HNF-1/NN alpha/NN complex/NN ,/, which/WDT required/VBD the/DT dimerization/NN domain/NN of/IN HNF-1/NN alpha/NN ,/, did/VBD not/RB change/VB the/DT DNA/NN binding/NN characteristics/NNS of/IN HNF-1/NN alpha/NN ,/, but/CC enhanced/VBD its/PRP$ transcriptional/JJ activity/NN ./. 
However/RB ,/, DCoH/NN did/VBD not/RB confer/VB transcriptional/JJ activation/NN to/TO the/DT GAL4/NN DNA/NN binding/NN domain/NN ./. 
These/DT results/NNS indicate/VBP that/IN DCoH/NN regulates/VBZ formation/NN of/IN transcriptionally/RB active/JJ tetrameric/JJ complexes/NNS and/CC may/MD contribute/VB to/TO the/DT developmental/JJ specificity/NN of/IN the/DT complex/NN ./. 
UI/LS -/: 92060325/CD 
TI/LS -/: Glucocorticoid/NN resistance/NN in/IN chronic/JJ asthma/NN ./. 
Glucocorticoid/NN pharmacokinetics/NNS ,/, glucocorticoid/NN receptor/NN characteristics/NNS ,/, and/CC inhibition/NN of/IN peripheral/JJ blood/NN T/NN cell/NN proliferation/NN by/IN glucocorticoids/NNS in/FW vitro/FW ./. 
AB/LS -/: A/DT total/NN of/IN 37/CD chronic/JJ ,/, severe/JJ ,/, nonsmoking/JJ asthmatic/JJ patients/NNS with/IN documented/JJ|VBN reversible/JJ airways/NNS obstruction/NN were/VBD classified/VBN as/IN glucocorticoid-sensitive/JJ or/CC -resistant/JJ on/IN the/DT basis/NN of/IN changes/NNS in/IN FEV1/NN ,/, FVC/NN ,/, and/CC peak/JJ expiratory/NN flow/NN (/( PEF/NN )/) after/IN oral/JJ prednisolone/NN ./. 
The/DT resistant/JJ patients/NNS showed/VBD no/DT significant/JJ improvements/NNS in/IN airflow/NN limitation/NN ./. 
Phytohemagglutinin/NN (/( PHA/NN )/) -induced/JJ proliferation/NN of/IN peripheral/JJ blood/NN T/NN lymphocytes/NNS from/IN the/DT sensitive/JJ but/CC not/RB the/DT resistant/JJ asthmatic/JJ patients/NNS was/VBD significantly/RB (/( p/NN less/JJR than/IN 0.01/CD )/) inhibited/VBN by/IN dexamethasone/NN (/( 10/CD (/( -7/CD )/) mol/L/NN )/) ,/, reflecting/VBG a/DT shift/NN of/IN the/DT dose-response/JJ curve/NN ./. 
When/WRB all/PDT the/DT asthmatic/JJ patients/NNS were/VBD analyzed/VBN together/RB ,/, there/EX was/VBD a/DT significant/JJ correlation/NN between/IN the/DT degree/NN of/IN sensitivity/NN of/IN T/NN cells/NNS to/TO dexamethasone/NN and/CC the/DT clinical/JJ responsiveness/NN to/TO prednisolone/JJ (/( p/NN less/RBR than/IN 0.01/CD )/) ./. 
No/DT differences/NNS were/VBD observed/VBN between/IN six/CD of/IN the/DT sensitive/JJ and/CC resistant/JJ patients/NNS in/IN the/DT clearance/NN of/IN plasma/NN prednisolone/JJ derived/VBN from/IN orally/RB administered/VBN prednisone/NN ./. 
Peripheral/JJ blood/NN mononuclear/JJ cell/NN glucocorticoid/NN receptors/NNS were/VBD also/RB characterized/VBN in/IN five/CD sensitive/JJ and/CC seven/CD resistant/JJ patients/NNS ./. 
The/DT numbers/NNS and/CC binding/NN affinities/NNS of/IN these/DT receptors/NNS could/MD not/RB account/VB for/IN the/DT observed/VBN difference/NN in/IN the/DT susceptibility/NN of/IN these/DT cells/NNS to/TO functional/JJ inhibition/NN by/IN dexamethasone/NN in/FW vitro/FW ./. 
These/DT results/NNS suggest/VBP that/IN clinical/JJ glucocorticoid/NN resistance/NN in/IN chronic/JJ asthma/NN does/VBZ not/RB reflect/VB abnormal/JJ glucocorticoid/NN clearance/NN but/CC may/MD be/VB due/JJ at/IN least/JJS partly/RB to/TO a/DT relative/JJ insensitivity/NN of/IN T/NN lymphocytes/NNS to/TO glucocorticoids/NNS ./. 
This/DT lack/NN of/IN sensitivity/NN is/VBZ unexplained/JJ but/CC is/VBZ not/RB attributable/JJ to/TO abnormalities/NNS of/IN cellular/JJ glucocorticoid/NN receptors/NNS ./. 
UI/LS -/: 92042309/CD 
TI/LS -/: Inhibition/NN of/IN phorbol/NN ester-induced/JJ monocytic/JJ differentiation/NN by/IN dexamethasone/NN is/VBZ associated/VBN with/IN down-regulation/NN of/IN c-fos/NN and/CC c-jun/NN (/( AP-1/NN )/) ./. 
AB/LS -/: Previous/JJ studies/NNS have/VBP shown/VBN that/IN treatment/NN of/IN human/JJ myeloid/JJ leukemia/NN cells/NNS with/IN 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) is/VBZ associated/VBN with/IN induction/NN of/IN monocytic/JJ differentiation/NN and/CC expression/NN of/IN the/DT c-jun/NN and/CC c-fos/NN early/JJ response/NN genes/NNS ./. 
The/DT present/JJ work/NN demonstrates/VBZ that/IN the/DT glucocorticoid/NN dexamethasone/NN inhibits/VBZ TPA-induced/JJ increases/NNS in/IN c-jun/NN and/CC c-fos/NN mRNA/NN levels/NNS in/IN U-937/NN leukemia/NN cells/NNS ./. 
These/DT findings/NNS were/VBD associated/VBN with/IN a/DT block/NN in/IN appearance/NN of/IN the/DT monocytic/JJ phenotype/NN ,/, including/VBG inhibition/NN of/IN TPA-induced/JJ increases/NNS in/IN lamin/NN A/NN ,/, lamin/NN C/NN ,/, and/CC vimentin/NN transcripts/NNS ./. 
Other/JJ studies/NNS have/VBP demonstrated/VBN that/IN TPA-induced/JJ monocytic/JJ differentiation/NN and/CC expression/NN of/IN the/DT c-jun/NN and/CC c-fos/NN genes/NNS in/IN myeloid/JJ leukemia/NN cells/NNS are/VBP regulated/VBN by/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) ./. 
The/DT finding/NN that/IN dexamethasone/NN has/VBZ no/DT effect/NN on/IN TPA-induced/JJ activation/NN of/IN PKC/NN suggests/VBZ that/IN this/DT glucocorticoid/NN inhibits/VBZ signals/NNS downstream/JJ or/CC parallel/JJ to/TO this/DT enzyme/NN ./. 
Nuclear/JJ run-on/JJ assays/NNS demonstrate/VBP that/IN :/: (/( 1/LS )/) induction/NN of/IN c-jun/NN and/CC c-fos/NN expression/NN by/IN TPA/NN is/VBZ regulated/VBN by/IN transcriptional/JJ mechanisms/NNS ,/, (/( 2/LS )/) TPA-induced/JJ expression/NN of/IN c-jun/NN and/CC c-fos/NN does/VBZ not/RB require/VB protein/NN synthesis/NN ,/, and/CC (/( 3/LS )/) TPA-induced/JJ expression/NN of/IN both/DT genes/NNS is/VBZ inhibited/VBN at/IN the/DT transcriptional/JJ level/NN by/IN dexamethasone/NN ./. 
To/TO further/RB define/VB the/DT effects/NNS of/IN dexamethasone/NN at/IN the/DT molecular/JJ level/NN ,/, we/PRP prepared/VBD a/DT series/NN of/IN deleted/VBN c-jun/NN promoter/NN fragments/NNS linked/VBN to/TO the/DT chloramphenicol/NN acetyltransferase/NN (/( CAT/NN )/) gene/NN ./. 
Increases/NNS in/IN CAT/NN activity/NN during/IN transient/JJ expression/NN of/IN these/DT constructs/NNS in/IN TPA-treated/JJ U-937/NN cells/NNS could/MD be/VB assigned/VBN to/TO the/DT region/NN (/( -97/CD to/TO -20/CD )/) of/IN the/DT promoter/NN that/WDT contains/VBZ the/DT AP-1/NN binding/NN site/NN ./. 
This/DT induction/NN of/IN CAT/NN activity/NN was/VBD sensitive/JJ to/TO dexamethasone/NN ./. 
These/DT findings/NNS suggest/VBP that/IN dexamethasone/NN down-regulates/VBZ TPA-induced/JJ transcription/NN of/IN the/DT c-jun/NN gene/NN during/IN monocytic/JJ differentiation/NN by/IN inhibiting/VBG activation/NN of/IN the/DT AP-1/NN site/NN ./. 
UI/LS -/: 91366165/CD 
TI/LS -/: Tumor/NN necrosis/NN factor-alpha/NN mRNA/NN accumulation/NN in/IN human/JJ myelomonocytic/JJ cell/NN lines/NNS ./. 
Role/NN of/IN transcriptional/JJ regulation/NN by/IN DNA/NN sequence/NN motifs/NNS and/CC mRNA/NN stabilization/NN ./. 
AB/LS -/: The/DT cytokine/NN TNF/NN mediates/VBZ many/JJ of/IN the/DT pathologic/JJ signs/NNS of/IN cachexia/NN ,/, inflammation/NN ,/, and/CC sepsis/NN ./. 
The/DT current/JJ work/NN describes/VBZ the/DT regulation/NN of/IN TNF/NN in/IN human/JJ myelomonocytic/JJ cell/NN lines/NNS after/IN PMA/NN stimulation/NN ./. 
The/DT cell/NN lines/NNS exhibit/VBP a/DT low/JJ level/NN of/IN constitutive/JJ TNF/NN mRNA/NN expression/NN ./. 
Within/IN 2/CD to/TO 4/CD h/NN of/IN PMA/NN exposure/NN ,/, steady/JJ state/NN levels/NNS of/IN TNF/NN mRNA/NN are/VBP markedly/RB elevated/JJ in/IN all/DT myelomonocytic/JJ cell/NN lines/NNS studied/VBN ./. 
This/DT rise/NN is/VBZ due/JJ to/TO increased/VBN mRNA/NN stability/NN ,/, which/WDT increased/VBD by/IN almost/RB twofold/RB ,/, and/CC to/TO an/DT overall/JJ increase/NN in/IN transcription/NN ,/, which/WDT rises/VBZ by/IN more/JJR than/IN sixfold/RB ./. 
At/IN the/DT level/NN of/IN the/DT genomic/JJ TNF/NN gene/NN ,/, a/DT DNase/NN I/CD hypersensitive/JJ site/NN is/VBZ detected/VBN within/IN the/DT TNF/NN promoter/NN between/IN -200/CD to/TO -100/CD bp/NN relative/JJ to/TO the/DT transcription/NN initiation/NN site/NN ./. 
Although/IN absent/JJ in/IN nonexpressing/VBG erythroleukemia/NN cell/NN lines/NNS ,/, the/DT DNase/NN I/CD site/NN is/VBZ present/JJ in/IN uninduced/JJ myelomonocytic/JJ cell/NN lines/NNS and/CC is/VBZ not/RB changed/VBN after/IN PMA/NN induction/NN ./. 
The/DT PMA/NN induction/NN of/IN c-fos/NN mRNA/NN correlated/VBD well/RB with/IN TNF/NN gene/NN induction/NN ;/: expression/NN of/IN genes/NNS encoding/VBG other/JJ proteins/NNS in/IN the/DT AP-1/NN complex/NN (/( junB/NN and/CC junD/NN )/) were/VBD also/RB induced/VBN by/IN PMA/NN ./. 
The/DT nuclear/JJ extracts/NNS from/IN resting/VBG and/CC induced/VBN ML-1/NN cells/NNS contain/VBP proteins/NNS binding/VBG specifically/RB to/TO the/DT AP-1/NN ,/, AP-2/NN ,/, and/CC NF/NN kappa/NN B/NN sequence/NN located/JJ within/IN the/DT TNF/NN promoter/NN ./. 
PMA/NN induction/NN increases/VBZ the/DT level/NN of/IN a/DT number/NN of/IN specific/JJ binding/VBG complexes/NNS relative/JJ to/TO the/DT resting/VBG cells/NNS ./. 
The/DT regulatory/JJ mechanisms/NNS of/IN the/DT human/JJ and/CC murine/JJ TNF/NN genes/NNS are/VBP discussed/VBN ./. 
UI/LS -/: 91319738/CD 
TI/LS -/: Enhancement/NN of/IN human/JJ immunodeficiency/NN virus/NN 1/CD replication/NN in/IN monocytes/NNS by/IN 1,25-dihydroxycholecalciferol/NN ./. 
AB/LS -/: Human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) expression/NN and/CC replication/NN are/VBP under/IN tight/JJ regulatory/JJ control/NN ./. 
We/PRP demonstrate/VBP that/IN 1,25-dihydroxycholecalciferol/NN [/( 1,25-(OH)2D3/NN ]/) enhances/VBZ the/DT replication/NN of/IN monocyte-/NN and/CC lymphocyte-tropic/JJ strains/NNS of/IN HIV-1/NN up/IN to/TO 10,000-fold/RB in/IN monocyte/NN cell/NN lines/NNS ,/, peripheral/JJ blood/NN monocytes/NNS ,/, and/CC unfractionated/JJ peripheral/JJ blood/NN mononuclear/JJ cells/NNS ./. 
1,25(OH)2D3/NN is/VBZ therefore/RB one/CD of/IN the/DT most/RBS potent/JJ regulators/NNS of/IN HIV-1/NN replication/NN described/VBN to/TO date/NN ./. 
Precursors/NNS of/IN 1,25(OH)2D3/NN enhance/VBP HIV-1/NN replication/NN in/IN proportion/NN to/TO their/PRP$ affinity/NN for/IN the/DT 1,25(OH)2D3/NN intracellular/JJ receptor/NN ,/, suggesting/VBG that/IN 1,25(OH)2D3/NN influences/VBZ HIV-1/NN replication/NN by/IN mechanisms/NNS involving/VBG this/DT receptor/NN ./. 
These/DT studies/NNS may/MD have/VB important/JJ implications/NNS for/IN the/DT design/NN of/IN effective/JJ therapy/NN of/IN HIV-1/NN infection/NN ./. 
UI/LS -/: 91237114/CD 
TI/LS -/: Transforming/VBG growth/NN factor-beta/NN suppresses/VBZ human/JJ B/NN lymphocyte/NN Ig/NN production/NN by/IN inhibiting/VBG synthesis/NN and/CC the/DT switch/NN from/IN the/DT membrane/NN form/NN to/TO the/DT secreted/JJ form/NN of/IN Ig/NN mRNA/NN ./. 
AB/LS -/: Transforming/VBG growth/NN factor-beta/NN (/( TGF-beta/NN )/) inhibits/VBZ B/NN cell/NN Ig/NN secretion/NN and/CC reduces/VBZ B/NN cell/NN membrane/NN Ig/NN expression/NN ./. 
The/DT addition/NN of/IN TGF-beta/NN to/TO human/JJ B/NN lymphocyte/NN cultures/NNS stimulated/VBN with/IN Staphylococcus/FW aureus/FW Cowan/NN strain/NN I/NN and/CC IL-2/NN completely/RB inhibited/VBD B/NN cell/NN Ig/NN secretion/NN (/( greater/JJR than/IN 90/CD %/NN )/) and/CC decreased/VBD B/NN cell/NN surface/NN IgM/NN ,/, IgD/NN ,/, kappa/NN L/NN chain/NN ,/, and/CC lambda/NN L/NN chain/NN expression/NN ./. 
In/IN contrast/NN ,/, TGF-beta/NN had/VBD only/RB minimal/JJ effects/NNS on/IN two/CD other/JJ B/NN cell/NN membrane/NN proteins/NNS ,/, HLA-DR/NN and/CC CD20/NN ./. 
Internal/JJ labeling/NN with/IN [35S]methionine/NN and/CC immunoprecipitation/NN with/IN anti-IgM/JJ ,/, anti-kappa/JJ ,/, and/CC anti-lambda/JJ antibodies/NNS revealed/VBD a/DT striking/JJ reduction/NN in/IN kappa/NN L/NN chain/NN in/IN the/DT presence/NN of/IN TGF-beta/NN ./. 
A/DT less/RBR pronounced/JJ reduction/NN in/IN lambda/NN L/NN chain/NN and/CC microH/NN chain/NN was/VBD also/RB noted/VBN ./. 
Northern/NN blot/NN analysis/NN of/IN RNA/NN purified/VBN from/IN B/NN cells/NNS treated/VBN with/IN TGF-beta/NN for/IN varying/VBG time/NN intervals/NNS revealed/VBD a/DT significant/JJ decrease/NN in/IN steady/JJ state/NN kappa/NN and/CC lambda/NN L/NN chain/NN mRNA/NN levels/NNS ./. 
Furthermore/RB ,/, a/DT significant/JJ decrease/NN in/IN the/DT switch/NN from/IN the/DT membrane/NN forms/NNS of/IN mu/NN and/CC gamma/NN to/TO their/PRP$ respective/JJ secreted/JJ forms/NNS was/VBD noted/VBN in/IN the/DT presence/NN of/IN TGF-beta/NN ./. 
Nuclear/JJ run-on/JJ experiments/NNS demonstrated/VBD decreased/VBN transcription/NN of/IN kappa/NN L/NN chain/NN ./. 
The/DT effects/NNS of/IN TGF-beta/NN on/IN two/CD transcriptional/JJ regulatory/JJ factors/NNS ,/, Oct-2/NN and/CC nuclear/JJ factor/NN (/( NF/NN )/) kappa/NN B/NN ,/, known/VBN to/TO be/VB important/JJ in/IN Ig/NN gene/NN transcription/NN were/VBD examined/VBN ./. 
Oct-2/NN mRNA/NN levels/NNS and/CC both/DT Oct-2/NN and/CC NF-kappa/NN B/NN proteins/NNS in/IN nuclear/JJ extracts/NNS were/VBD not/RB altered/VBN by/IN treatment/NN with/IN TGF-beta/NN ./. 
In/IN contrast/NN ,/, levels/NNS of/IN the/DT transcriptional/JJ factor/NN AP-1/NN ,/, which/WDT is/VBZ not/RB known/VBN to/TO be/VB important/JJ in/IN B/NN cell/NN Ig/NN production/NN ,/, were/VBD reduced/VBN by/IN TGF-beta/NN ./. 
These/DT findings/NNS demonstrate/VBP that/IN TGF-beta/NN decreases/VBZ B/NN lymphocyte/NN Ig/NN secretion/NN by/IN inhibiting/VBG the/DT synthesis/NN of/IN Ig/NN mRNA/NN and/CC inhibiting/VBG the/DT switch/NN from/IN the/DT membrane/NN form/NN to/TO the/DT secreted/JJ forms/NNS of/IN mu/NN and/CC gamma/NN mRNA/NN ./. 
The/DT mechanism/NN by/IN which/WDT TGF-beta/NN inhibits/VBZ Ig/NN chain/NN synthesis/NN is/VBZ unclear/JJ although/IN it/PRP does/VBZ not/RB involve/VB inhibition/NN of/IN the/DT binding/NN of/IN NF-kappa/NN B/NN or/CC Oct-2/NN to/TO their/PRP$ respective/JJ target/NN sequences/NNS ./. 
UI/LS -/: 91203899/CD 
TI/LS -/: Murine/JJ and/CC human/JJ T-lymphocyte/NN GATA-3/NN factors/NNS mediate/VBP transcription/NN through/IN a/DT cis-regulatory/JJ element/NN within/IN the/DT human/JJ T-cell/NN receptor/NN delta/NN gene/NN enhancer/NN ./. 
AB/LS -/: A/DT family/NN of/IN transcriptional/JJ activators/NNS has/VBZ recently/RB been/VBN identified/VBN in/IN chickens/NNS ;/: these/DT transcriptional/JJ activators/NNS recognize/VBP a/DT common/JJ consensus/NN motif/NN (/( WGATAR/NN )/) through/IN a/DT conserved/VBN C4/NN zinc/NN finger/NN DNA-binding/JJ domain/NN ./. 
One/CD of/IN the/DT members/NNS of/IN this/DT multigene/JJ family/NN ,/, cGATA-3/NN ,/, is/VBZ most/RBS abundantly/RB expressed/VBN in/IN the/DT T-lymphocyte/NN cell/NN lineage/NN ./. 
Analysis/NN of/IN human/JJ and/CC murine/JJ GATA-3/NN factors/NNS shows/VBZ a/DT striking/JJ degree/NN of/IN amino/NN acid/NN sequence/NN identity/NN and/CC similar/JJ patterns/NNS of/IN tissue/NN specificity/NN of/IN expression/NN in/IN these/DT three/CD organisms/NNS ./. 
The/DT murine/JJ and/CC human/JJ factors/NNS are/VBP abundantly/RB expressed/VBN in/IN a/DT variety/NN of/IN human/JJ and/CC murine/JJ T-cell/NN lines/NNS and/CC can/MD activate/VB transcription/NN through/IN a/DT tissue-specific/JJ GATA-binding/JJ site/NN identified/VBN within/IN the/DT human/JJ T-cell/NN receptor/NN delta/NN gene/NN enhancer/NN ./. 
We/PRP infer/VBP that/IN the/DT murine/JJ and/CC human/JJ GATA-3/NN proteins/NNS play/VBP a/DT central/JJ and/CC highly/RB conserved/VBN role/NN in/IN vertebrate/NN T-cell-specific/JJ transcriptional/JJ regulation/NN ./. 
UI/LS -/: 91204058/CD 
TI/LS -/: Processing/NN of/IN the/DT precursor/NN of/IN NF-kappa/NN B/NN by/IN the/DT HIV-1/NN protease/NN during/IN acute/JJ infection/NN ./. 
AB/LS -/: Transcription/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type-1/NN (/( HIV-1/NN )/) genome/NN is/VBZ regulated/VBN in/IN part/NN by/IN cellular/JJ factors/NNS and/CC is/VBZ stimulated/VBN by/IN activation/NN of/IN latently/RB infected/JJ T/NN cells/NNS ./. 
T-cell/NN activation/NN also/RB correlates/VBZ with/IN the/DT induction/NN of/IN the/DT factor/NN NF-kappa/NN B/NN which/WDT binds/VBZ to/TO two/CD adjacent/JJ sites/NNS in/IN the/DT HIV-1/NN long/JJ terminal/JJ repeat/NN ./. 
This/DT factor/NN consists/VBZ of/IN two/CD DNA-binding/JJ subunits/NNS of/IN relative/JJ molecular/JJ mass/NN 50,000/CD (/( 50K/CD )/) associated/VBN with/IN two/CD 65K/CD subunits/NNS ./. 
It/PRP is/VBZ located/JJ in/IN the/DT nucleus/NN in/IN mature/JJ B/NN cells/NNS ,/, but/CC is/VBZ present/JJ in/IN other/JJ cell/NN types/NNS as/IN an/DT inactive/JJ cytoplasmic/JJ complex/NN ./. 
External/JJ stimuli/NNS ,/, including/VBG those/DT that/WDT activate/VBP T/NN cells/NNS ,/, result/VBP in/IN nuclear/JJ translocation/NN of/IN active/JJ NF-kappa/NN B/NN ./. 
The/DT cloning/NN of/IN the/DT complementary/JJ DNA/NN for/IN the/DT 50K/CD subunit/NN helped/VBD to/TO identify/VB an/DT exclusively/RB cytoplasmic/JJ 105K/CD precursor/NN (/( p105/NN )/) (/( V.B./NNP ,/, P.K./NNP and/CC A.I./NNP ,/, manuscript/NN submitted/VBN )/) ./. 
The/DT expression/NN of/IN active/JJ NF-kappa/NN B/NN might/MD therefore/RB also/RB be/VB regulated/VBN by/IN the/DT extent/NN of/IN processing/NN of/IN p105/NN ./. 
Because/IN HIV-1/NN requires/VBZ active/JJ NF-kappa/NN B/NN for/IN efficient/JJ transcription/NN ,/, we/PRP tested/VBD the/DT effect/NN of/IN HIV-1/NN infection/NN on/IN the/DT processing/NN of/IN the/DT human/JJ 105K/CD precursor/NN ./. 
We/PRP show/VBP here/RB that/IN the/DT HIV-1/NN protease/NN can/MD process/VB p105/NN and/CC increases/VBZ levels/NNS of/IN active/JJ nuclear/JJ NF-kappa/NN B/NN complex/NN ./. 
UI/LS -/: 91159628/CD 
TI/LS -/: 1,25-Dihydroxyvitamin/NN D3/NN receptor/NN RNA/NN :/: expression/NN in/IN hematopoietic/JJ cells/NNS ./. 
AB/LS -/: 1,25-Dihydroxyvitamin/NN D3/NN [/( 1,25(OH)2D3/NN ]/) induces/VBZ differentiation/NN and/CC inhibits/VBZ proliferation/NN of/IN myeloid/JJ leukemic/JJ cells/NNS from/IN various/JJ lines/NNS and/CC patients/NNS ;/: these/DT effects/NNS are/VBP probably/RB mediated/VBN through/IN the/DT 1,25(OH)2D3/NN receptor/NN ./. 
Little/JJ is/VBZ known/VBN of/IN expression/NN of/IN 1,25(OH)2D3/NN receptor/NN RNA/NN in/IN hematopoietic/JJ cells/NNS ./. 
We/PRP examined/VBD the/DT expression/NN and/CC modulation/NN of/IN expression/NN of/IN 1,25(OH)2D3/NN receptor/NN RNA/NN in/IN various/JJ proliferating/VBG and/CC nonproliferating/JJ hematopoietic/JJ cells/NNS ./. 
Constitutive/JJ expression/NN of/IN 1,25(OH)2D3/NN receptor/NN RNA/NN was/VBD detected/VBN in/IN various/JJ kinds/NNS of/IN hematopoietic/JJ cells/NNS ,/, including/VBG macrophages/NNS and/CC activated/VBN T/NN lymphocytes/NNS ,/, as/RB well/RB as/IN in/IN cell/NN lines/NNS KG-1/NN (/( myeloblasts/NNS )/) ,/, HL-60/NN (/( promyelocytes/NNS )/) ,/, ML-3/NN (/( myelomonoblasts/NNS )/) ,/, U937/NN ,/, THP-1/NN (/( monoblasts/NNS )/) ,/, K562/NN (/( erythroblasts/NNS )/) ,/, and/CC S-LB1/NN (/( HTLV-1-transfected/JJ T/NN lymphocytes/NNS )/) ./. 
Receptor/NN transcripts/NNS were/VBD 4.6/CD kilobases/NNS (/( kb/NN )/) ,/, and/CC no/DT variant/JJ sizes/NNS were/VBD observed/VBN ./. 
All/DT cell/NN lines/NNS examined/VBN in/IN this/DT group/NN also/RB expressed/VBD 1,25(OH)2D3/NN receptors/NNS ./. 
Most/JJS B/NN lymphocyte/NN lines/NNS expressed/VBD negligible/JJ levels/NNS of/IN 1,25(OH)2D3/NN receptor/NN RNA/NN and/CC protein/NN ;/: however/RB ;/: analysis/NN of/IN a/DT lymphoid/myeloid/JJ somatic/JJ hybrid/NN suggested/VBD that/IN suppression/NN of/IN expression/NN of/IN 1,25(OH)2D3/NN receptor/NN RNA/NN in/IN B/NN lymphocytes/NNS may/MD be/VB a/DT dominant/JJ characteristic/NN ./. 
HL-60/NN cells/NNS were/VBD cultured/VBN with/IN 10/CD (/( -7/CD )/) mol/L/NN 1,25(OH)2D3/NN for/IN 24/CD to/TO 72/CD hours/NNS ,/, and/CC levels/NNS of/IN expression/NN of/IN 1,25(OH)2D3/NN receptor/NN and/CC its/PRP$ RNA/NN were/VBD examined/VBN ./. 
Levels/NNS of/IN RNA/NN coding/NN for/IN the/DT receptor/NN were/VBD not/RB modulated/VBN by/IN exposure/NN to/TO high/JJ levels/NNS of/IN ligand/NN ./. 
Levels/NNS of/IN occupied/VBN 1,25(OH)2D3/NN receptor/NN protein/NN increased/VBD in/IN these/DT HL-60/NN cells/NNS ;/: but/CC the/DT total/JJ number/NN of/IN 1,25(OH)2D3/NN receptors/NNS decreased/VBD about/RB 50/CD %/NN at/IN 24/CD hours/NNS and/CC returned/VBD toward/IN normal/JJ at/IN 72/CD hours/NNS ./. 
Steady-state/JJ levels/NNS of/IN 1,25(OH)2D3/NN receptor/NN RNA/NN were/VBD not/RB affected/VBN by/IN terminal/JJ differentiation/NN of/IN HL-60/NN toward/IN either/CC granulocytes/NNS or/CC macrophages/NNS ./. 
Nondividing/JJ macrophages/NNS from/IN normal/JJ individuals/NNS also/RB expressed/VBD 1,25(OH)2D3/NN receptor/NN RNA/NN ./. 
In/IN contrast/NN ,/, nondividing/JJ peripheral/JJ blood/NN lymphocytes/NNS from/IN normal/JJ individuals/NNS did/VBD not/RB express/VB 1,25(OH)2D3/NN receptor/NN RNA/NN ;/: with/IN stimulation/NN of/IN proliferation/NN of/IN these/DT cells/NNS ,/, accumulation/NN of/IN 1,25(OH)2D3/NN receptor/NN RNA/NN increased/VBD markedly/RB ./. 
Half-life/NN (/( t1/2/NN )/) of/IN 1,25(OH)2D3/NN receptor/NN RNA/NN in/IN T/NN lymphocytes/NNS was/VBD short/JJ (/( 1/CD hour/NN )/) as/IN determined/VBN by/IN measuring/VBG decay/NN of/IN the/DT message/NN after/IN addition/NN of/IN actinomycin/NN D/NN ./. 
Consistent/JJ with/IN this/DT short/JJ t1/2/NN ,/, accumulation/NN of/IN 1,25(OH)2D3/NN receptor/NN RNA/NN increased/VBD in/IN cells/NNS as/IN their/PRP$ protein/NN synthesis/NN was/VBD inhibited/VBN ./. 
Further/JJ studies/NNS are/VBP required/VBN to/TO understand/VB the/DT physiologic/JJ role/NN of/IN 1,25(OH)2D3/NN receptors/NNS in/IN myeloid/JJ cells/NNS and/CC proliferating/VBG T/NN lymphocytes/NNS ./. 
UI/LS -/: 91119580/CD 
TI/LS -/: Expression/NN of/IN c-jun/NN ,/, jun/NN B/NN and/CC jun/NN D/NN proto-oncogenes/NNS in/IN human/JJ peripheral-blood/JJ granulocytes/NNS ./. 
AB/LS -/: We/PRP have/VBP found/VBN that/IN purified/VBN human/JJ peripheral-blood/JJ granulocytes/NNS express/VBP constitutively/RB significant/JJ levels/NNS of/IN proto-oncogenes/NNS c-jun/NN ,/, jun/NN B/NN and/CC jun/NN D/NN mRNA/NN ./. 
Upon/IN functional/JJ activation/NN of/IN granulocytes/NNS by/IN 4/CD beta-phorbol/NN 12-myristate/NN 13-acetate/NN (/( PMA/NN )/) ,/, the/DT levels/NNS of/IN c-jun/NN ,/, jun/NN B/NN and/CC jun/NN D/NN transcripts/NNS were/VBD increased/VBN ./. 
The/DT three/CD jun/NN genes/NNS showed/VBD a/DT similar/JJ time/NN course/NN in/IN their/PRP$ induction/NN by/IN PMA/NN ,/, maximal/JJ mRNA/NN levels/NNS being/VBG reached/VBN after/IN 60/CD min/NN of/IN induction/NN ./. 
These/DT results/NNS suggest/VBP that/IN expression/NN of/IN c-jun/NN ,/, jun/NN B/NN and/CC jun/NN D/NN genes/NNS might/MD be/VB involved/VBN in/IN terminal/JJ granulocyte/NN differentiation/NN or/CC in/IN regulating/VBG granulocyte/NN functionality/NN ./. 
UI/LS -/: 92107919/CD 
TI/LS -/: The/DT 29-kDa/JJ proteins/NNS phosphorylated/VBN in/IN thrombin-activated/JJ human/JJ platelets/NNS are/VBP forms/NNS of/IN the/DT estrogen/NN receptor-related/JJ 27-kDa/JJ heat/NN shock/NN protein/NN ./. 
AB/LS -/: Thrombin/NN plays/VBZ a/DT critical/JJ role/NN in/IN platelet/NN activation/NN ,/, hemostasis/NN ,/, and/CC thrombosis/NN ./. 
Cellular/JJ activation/NN by/IN thrombin/NN leads/VBZ to/TO the/DT phosphorylation/NN of/IN multiple/JJ proteins/NNS ,/, most/JJS of/IN which/WDT are/VBP unidentified/JJ ./. 
We/PRP have/VBP characterized/VBN several/JJ 29-kDa/JJ proteins/NNS that/WDT are/VBP rapidly/RB phosphorylated/VBN following/VBG exposure/NN of/IN intact/JJ human/JJ platelets/NNS to/TO thrombin/NN ./. 
A/DT murine/JJ monoclonal/JJ antibody/NN raised/VBN to/TO an/DT unidentified/JJ estrogen/NN receptor-related/JJ 29-kDa/JJ protein/NN selectively/RB recognized/VBD these/DT proteins/NNS as/RB well/RB as/IN a/DT more/RBR basic/JJ ,/, unphosphorylated/JJ 27-kDa/JJ protein/NN ./. 
Cellular/JJ activation/NN by/IN thrombin/NN led/VBN to/TO a/DT marked/JJ shift/NN in/IN the/DT proportion/NN of/IN protein/NN from/IN the/DT 27-kDa/JJ unphosphorylated/JJ form/NN to/TO the/DT 29-kDa/JJ phosphoprotein/NN species/NNS ./. 
Using/VBG this/DT antibody/NN ,/, we/PRP isolated/VBD and/CC sequenced/VBD a/DT human/JJ cDNA/NN clone/NN encoding/VBG a/DT protein/NN that/WDT was/VBD identical/JJ to/TO the/DT mammalian/JJ 27-kDa/JJ heat/NN shock/NN protein/NN (/( HSP27/NN )/) ,/, a/DT protein/NN of/IN uncertain/JJ function/NN that/WDT is/VBZ known/VBN to/TO be/VB phosphorylated/VBN to/TO several/JJ forms/NNS and/CC to/TO be/VB transcriptionally/RB induced/VBN by/IN estrogen/NN ./. 
The/DT 29-kDa/JJ proteins/NNS were/VBD confirmed/VBN to/TO be/VB phosphorylated/VBN forms/NNS of/IN HSP27/NN by/IN immunoprecipitation/NN studies/NNS ./. 
Thus/RB ,/, the/DT "/`` estrogen/NN receptor-related/JJ protein/NN "/'' is/VBZ HSP27/NN ,/, and/CC the/DT three/CD major/JJ 29-kDa/JJ proteins/NNS phosphorylated/VBN in/IN thrombin-activated/JJ platelets/NNS are/VBP forms/NNS of/IN HSP27/NN ./. 
These/DT data/NNS suggest/VBP a/DT role/NN for/IN HSP27/NN in/IN the/DT signal/NN transduction/NN events/NNS of/IN platelet/NN activation/NN ./. 
UI/LS -/: 92052179/CD 
TI/LS -/: Isolation/NN of/IN a/DT candidate/NN repressor/activator/NN ,/, NF-E1/NN (/( YY-1/NN ,/, delta/NN )/) ,/, that/WDT binds/VBZ to/TO the/DT immunoglobulin/NN kappa/NN 3'/JJ enhancer/NN and/CC the/DT immunoglobulin/NN heavy-chain/NN mu/NN E1/NN site/NN ./. 
AB/LS -/: We/PRP have/VBP determined/VBN that/IN the/DT developmental/JJ control/NN of/IN immunoglobulin/NN kappa/NN 3'/JJ enhancer/NN (/( kappa/NN E3'/NN )/) activity/NN is/VBZ the/DT result/NN of/IN the/DT combined/JJ influence/NN of/IN positive-/JJ and/CC negative-acting/JJ elements/NNS ./. 
We/PRP show/VBP that/IN a/DT central/JJ core/NN in/IN the/DT kappa/NN E3'/NN enhancer/NN is/VBZ active/JJ at/IN the/DT pre-B-cell/JJ stage/NN but/CC is/VBZ repressed/VBN by/IN flanking/VBG negative-acting/JJ elements/NNS ./. 
The/DT negative-acting/JJ sequences/NNS repress/VBP enhancer/NN activity/NN in/IN a/DT position-/NN and/CC orientation-independent/JJ manner/NN at/IN the/DT pre-B-cell/JJ stage/NN ./. 
We/PRP have/VBP isolated/VBN a/DT human/JJ cDNA/NN clone/NN encoding/VBG a/DT zinc/NN finger/NN protein/NN (/( NF-E1/NN )/) that/WDT binds/VBZ to/TO the/DT negative-acting/JJ segment/NN of/IN the/DT kappa/NN E3'/NN enhancer/NN ./. 
This/DT protein/NN also/RB binds/VBZ to/TO the/DT immunoglobulin/NN heavy-chain/NN enhancer/NN mu/NN E1/NN site/NN ./. 
NF-E1/NN is/VBZ encoded/VBN by/IN the/DT same/JJ gene/NN as/IN the/DT YY-1/NN protein/NN ,/, which/WDT binds/VBZ to/TO the/DT adeno-associated/JJ virus/NN P5/NN promoter/NN ./. 
NF-E1/NN is/VBZ also/RB the/DT human/JJ homologue/NN of/IN the/DT mouse/NN delta/NN protein/NN ,/, which/WDT binds/VBZ to/TO ribosomal/JJ protein/NN gene/NN promoters/NNS ./. 
The/DT predicted/VBN amino/NN acid/NN sequence/NN of/IN this/DT protein/NN contains/VBZ features/NNS characteristic/JJ of/IN transcriptional/JJ activators/NNS as/RB well/RB as/IN transcriptional/JJ repressors/NNS ./. 
Cotransfection/NN studies/NNS with/IN this/DT cDNA/NN indicate/VBP that/IN it/PRP can/MD repress/VB basal/JJ promoter/NN activity/NN ./. 
The/DT apparent/JJ dual/JJ function/NN of/IN this/DT protein/NN is/VBZ discussed/VBN ./. 
UI/LS -/: 92029620/CD 
TI/LS -/: A/DT human/JJ putative/JJ lymphocyte/NN G0/G1/NN switch/NN gene/NN containing/VBG a/DT CpG-rich/JJ island/NN encodes/VBZ a/DT small/JJ basic/JJ protein/NN with/IN the/DT potential/NN to/TO be/VB phosphorylated/VBN ./. 
AB/LS -/: Genes/NNS actively/RB involved/VBN in/IN the/DT G0/G1/NN switch/NN (/( G0S/NN genes/NNS )/) may/MD be/VB differentially/RB expressed/VBN during/IN the/DT lectin-induced/JJ switch/NN of/IN lymphocytes/NNS from/IN the/DT G0/NN to/TO the/DT G1/NN phases/NNS of/IN the/DT cell/NN cycle/NN ./. 
This/DT paper/NN presents/VBZ studies/NNS of/IN G0S2/NN ,/, a/DT member/NN of/IN a/DT set/NN of/IN putative/JJ G0S/NN genes/NNS ,/, for/IN which/WDT cDNAs/NNS were/VBD cloned/VBN and/CC selected/VBN on/IN the/DT basis/NN of/IN differential/JJ cDNA/NN hybridization/NN ./. 
G0S2/NN mRNA/NN increases/VBZ transiently/RB within/IN 1-2/CD hr/NN of/IN the/DT addition/NN of/IN lectin/NN or/CC cycloheximide/NN to/TO cultured/VBN blood/NN mononuclear/JJ cells/NNS ./. 
Comparison/NN of/IN a/DT nearly/RB full-length/JJ cDNA/NN sequence/NN with/IN the/DT corresponding/JJ genomic/JJ sequence/NN reveals/VBZ one/CD small/JJ intron/NN and/CC an/DT open/JJ reading/NN frame/NN in/IN the/DT second/JJ exon/NN ./. 
The/DT derived/VBN 103-amino-acid/JJ basic/JJ protein/NN has/VBZ two/CD potential/JJ alpha-helical/JJ domains/NNS separated/VBN by/IN a/DT hydrophobic/JJ region/NN with/IN the/DT potential/NN to/TO generate/VB turns/NNS and/CC assume/VB a/DT beta-sheet/JJ conformation/NN ./. 
Consistent/JJ with/IN involvement/NN in/IN the/DT G0/G1/NN switch/NN ,/, the/DT protein/NN contains/VBZ potential/JJ sites/NNS for/IN phosphorylation/NN by/IN protein/NN kinase/NN C/NN and/CC casein/NN kinase/NN II/CD ./. 
The/DT gene/NN contains/VBZ a/DT CpG-rich/JJ island/NN suggesting/VBG expression/NN in/IN the/DT germ/NN line/NN ./. 
An/DT upstream/JJ segment/NN contains/VBZ tandem/JJ dinucleotide/NN repeats/NNS (CT)19/(CA)16/NN ./. 
There/EX is/VBZ a/DT suitably/RB located/JJ TATA/NN box/NN ,/, but/CC potential/JJ sites/NNS for/IN CCAAT-box/NN binding/NN factors/NNS are/VBP far/RB upstream/JJ ,/, embedded/JJ in/IN a/DT 42-nucleotide/JJ repeat/NN element/NN ./. 
Potential/JJ sites/NNS for/IN transcription/NN factors/NNS AP1/NN ,/, AP2/NN ,/, and/CC AP3/NN are/VBP consistent/JJ with/IN rapid/JJ transcriptional/JJ activation/NN in/IN response/NN to/TO inducing/VBG agents/NNS ./. 
UI/LS -/: 91367666/CD 
TI/LS -/: USF-related/JJ transcription/NN factor/NN ,/, HIV-TF1/NN ,/, stimulates/VBZ transcription/NN of/IN human/JJ immunodeficiency/NN virus-1/NN ./. 
AB/LS -/: The/DT transcription/NN factor/NN HIV-TF1/NN ,/, which/WDT binds/VBZ to/TO a/DT region/NN about/IN 60/CD bp/NN upstream/JJ from/IN the/DT enhancer/NN of/IN the/DT human/JJ immunodeficiency/NN virus-1/NN (/( HIV-1/NN )/) ,/, was/VBD purified/VBN from/IN human/JJ B/NN cells/NNS ./. 
HIV-TF1/NN had/VBD a/DT molecular/JJ weight/NN of/IN 39,000/CD ./. 
Binding/NN of/IN HIV-TF1/NN to/TO the/DT HIV/NN long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) activated/VBD transcription/NN from/IN the/DT HIV/NN promoter/NN in/FW vitro/FW ./. 
The/DT HIV-TF1-binding/JJ site/NN in/IN HIV/NN LTR/NN was/VBD similar/JJ to/TO the/DT site/NN recognized/VBN by/IN upstream/JJ stimulatory/JJ factor/NN (/( USF/NN )/) in/IN the/DT adenovirus/NN major/JJ late/JJ promoter/NN ./. 
DNA-binding/JJ properties/NNS of/IN HIV-TF1/NN suggested/VBD that/IN HIV-TF1/NN might/MD be/VB identical/JJ or/CC related/JJ to/TO USF/NN ./. 
Interestingly/RB ,/, treatment/NN of/IN purified/VBN HIV-TF1/NN by/IN phosphatase/NN greatly/RB reduced/VBD its/PRP$ DNA-binding/JJ activity/NN ,/, suggesting/VBG that/IN phosphorylation/NN of/IN HIV-TF1/NN was/VBD essential/JJ for/IN DNA/NN binding/NN ./. 
The/DT disruption/NN of/IN HIV-TF1-binding/JJ site/NN induced/VBD a/DT 60/CD %/NN decrease/NN in/IN the/DT level/NN of/IN transcription/NN from/IN the/DT HIV/NN promoter/NN in/FW vivo/FW ./. 
These/DT results/NNS suggest/VBP that/IN HIV-TF1/NN is/VBZ involved/VBN in/IN transcriptional/JJ regulation/NN of/IN HIV-1/NN ./. 
UI/LS -/: 91292396/CD 
TI/LS -/: Severe/JJ 5-fluorouracil/NN toxicity/NN secondary/JJ to/TO dihydropyrimidine/NN dehydrogenase/NN deficiency/NN ./. 
A/DT potentially/RB more/RBR common/JJ pharmacogenetic/JJ syndrome/NN ./. 
AB/LS -/: This/DT study/NN describes/VBZ the/DT inheritance/NN of/IN a/DT defect/NN in/IN pyrimidine/NN catabolism/NN and/CC its/PRP$ association/NN with/IN drug-induced/JJ toxicity/NN in/IN a/DT patient/NN receiving/VBG 5-fluorouracil/NN (/( FUra/NN )/) as/IN adjuvant/JJ chemotherapy/NN for/IN breast/NN carcinoma/NN ./. 
The/DT study/NN population/NN included/VBD the/DT affected/VBN patient/NN (/( proband/NN )/) ,/, nine/CD of/IN her/PRP$ blood/NN relatives/NNS ,/, and/CC seven/CD healthy/JJ volunteers/NNS ./. 
The/DT activity/NN of/IN dihydropyrimidine/NN dehydrogenase/NN (/( DPD/NN )/) ,/, the/DT initial/JJ enzyme/NN of/IN pyrimidine/NN (/( and/CC FUra/NN )/) catabolism/NN ,/, in/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS was/VBD measured/VBN in/IN each/DT subject/NN by/IN a/DT specific/JJ radiometric/JJ assay/NN using/VBG FUra/NN as/IN the/DT substrate/NN ./. 
The/DT proband/NN had/VBD no/DT detectable/JJ DPD/NN activity/NN ./. 
When/WRB enzyme/NN levels/NNS in/IN the/DT proband/NN and/CC relatives/NNS were/VBD compared/VBN with/IN that/DT in/NN controls/NNS ,/, an/DT autosomal/JJ recessive/JJ pattern/NN of/IN inheritance/NN was/VBD demonstrated/VBN ./. 
This/DT is/VBZ the/DT third/JJ patient/NN with/IN severe/JJ FUra/NN toxicity/NN secondary/JJ to/TO an/DT alteration/NN in/IN pyrimidine/NN catabolism/NN and/CC the/DT second/NN from/IN our/PRP$ clinic/NN population/NN suggesting/VBG that/IN the/DT frequency/NN of/IN this/DT genetic/JJ defect/NN may/MD be/VB greater/JJR than/IN previously/RB thought/VBN ./. 
Monitoring/VBG DPD/NN activity/NN may/MD be/VB important/JJ in/IN the/DT management/NN of/IN patients/NNS experiencing/VBG severe/JJ toxicity/NN secondary/JJ to/TO FUra/NN chemotherapy/NN ./. 
UI/LS -/: 91237803/CD 
TI/LS -/: Transactivation/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN promoter/NN by/IN human/JJ herpesvirus/NN 6/CD (/( HHV-6/NN )/) strains/VBZ GS/NN and/CC Z-29/NN in/IN primary/JJ human/JJ T/NN lymphocytes/NNS and/CC identification/NN of/IN transactivating/VBG HHV-6/NN (/( GS/NN )/) gene/NN fragments/NNS ./. 
AB/LS -/: Human/JJ herpesvirus/NN 6/CD (/( HHV-6/NN )/) can/MD activate/VB the/DT human/JJ immunodeficiency/NN virus/NN (/( HIV/NN )/) promoter/NN and/CC accelerate/VB cytopathic/JJ effects/NNS in/IN HIV-infected/JJ human/JJ T/NN cells/NNS ./. 
This/DT study/NN examines/VBZ the/DT regions/NNS of/IN the/DT HIV/NN promoter/NN required/VBN for/IN HHV-6/NN transactivation/NN in/IN a/DT heterogeneous/JJ population/NN of/IN primary/JJ human/JJ T/NN lymphocytes/NNS with/IN or/CC without/IN antigenic/JJ stimulation/NN ./. 
Two/CD different/JJ strains/NNS of/IN HHV-6/NN ,/, GS/NN and/CC Z29/NN ,/, transactivated/VBD the/DT HIV/NN promoter/NN ./. 
The/DT GS/NN strain/NN transactivated/VBD the/DT promoter/NN in/IN both/CC stimulated/VBN and/CC resting/VBG T/NN cells/NNS ,/, while/IN the/DT Z29/NN strain/NN increased/VBD HIV/NN promoter/NN activity/NN only/RB in/IN stimulated/VBN T/NN cells/NNS ./. 
Three/CD DNA/NN clones/NNS containing/VBG HHV-6/NN (/( GS/NN )/) genomic/JJ fragments/NNS transactivated/VBD the/DT HIV/NN promoter/NN in/IN cotransfected/VBN T/NN cells/NNS ./. 
A/DT 21.4-kb/JJ DNA/NN clone/NN ,/, pZVB70/NN ,/, showed/VBD the/DT highest/JJS transactivating/NN ability/NN ,/, while/IN two/CD other/JJ DNA/NN fragments/NNS ,/, pZVB10/NN (/( 6.2/CD kb/NN )/) and/CC pZVH14/NN (/( 8.7/CD kb/NN )/) ,/, showed/VBD lower/JJR activity/NN ./. 
One/CD of/IN these/DT clones/NNS ,/, pZVH14/NN ,/, activated/VBD the/DT HIV/NN promoter/NN construct/NN containing/VBG a/DT mutation/NN in/IN the/DT NF/NN kappa/NN B/NN site/NN ./. 
However/RB ,/, this/DT mutated/VBN NF/NN kappa/NN B/NN promoter/NN was/VBD not/RB transactivated/VBN during/IN HHV-6/NN (/( GS/NN )/) infection/NN or/CC after/IN cotransfection/NN with/IN pZVB70/NN or/CC pZVB10/NN ./. 
These/DT data/NNS indicate/VBP that/IN the/DT NF/NN kappa/NN B/NN sites/NNS of/IN the/DT HIV/NN promoter/NN are/VBP essential/JJ for/IN its/PRP$ transactivation/NN during/IN HHV-6/NN (/( GS/NN )/) infection/NN ./. 
By/IN increasing/VBG HIV/NN promoter/NN activity/NN in/IN primary/JJ T/NN lymphocytes/NNS ,/, HHV-6/NN may/MD consequently/RB increase/VB HIV/NN replication/NN ,/, leading/VBG to/TO an/DT increase/NN in/IN the/DT cytopathic/JJ effect/NN on/IN coinfected/VBN human/JJ T/NN cells/NNS ./. 
UI/LS -/: 91321794/CD 
TI/LS -/: Inhibition/NN of/IN HIV-1/NN replication/NN and/CC NF-kappa/NN B/NN activity/NN by/IN cysteine/NN and/CC cysteine/NN derivatives/NNS ./. 
AB/LS -/: HIV-1/NN proviral/JJ DNA/NN contains/VBZ two/CD binding/VBG sites/NNS for/IN the/DT transcription/NN factor/NN NF-kappa/NN B/NN ./. 
HIV-1-infected/JJ individuals/NNS have/VBP ,/, on/IN average/NN ,/, abnormally/RB high/JJ levels/NNS of/IN tumour/NN necrosis/NN factor/NN alpha/NN (/( TNF/NN alpha/NN )/) and/CC abnormally/RB low/JJ plasma/NN cysteine/NN levels/NNS ./. 
We/PRP therefore/RB investigated/VBD the/DT effects/NNS of/IN cysteine/NN and/CC related/JJ thiols/NNS on/IN HIV-1/NN replication/NN and/CC NF-kappa/NN B/NN expression/NN ./. 
The/DT experiments/NNS in/IN this/DT report/NN show/VBP that/IN cysteine/NN or/CC N-acetylcysteine/NN (/( NAC/NN )/) raise/VBP the/DT intracellular/JJ glutathione/NN (/( GSH/NN )/) level/NN and/CC inhibit/VBP HIV-1/NN replication/NN in/IN persistently/RB infected/JJ Molt-4/NN and/CC U937/NN cells/NNS ./. 
However/RB ,/, inhibition/NN of/IN HIV-1/NN replication/NN appears/VBZ not/RB to/TO be/VB directly/RB correlated/VBN with/IN GSH/NN levels/NNS ./. 
Cysteine/NN and/CC NAC/NN also/RB inhibit/VBP NF-kappa/NN B/NN activity/NN as/IN determined/VBN by/IN electrophoretic/JJ mobility/NN shift/NN assays/NNS and/CC chloramphenicol/NN acetyl-transferase/NN (/( CAT/NN )/) gene/NN expression/NN under/IN control/NN of/IN NF-kappa/NN B/NN binding/NN sites/NNS in/IN uninfected/JJ cells/NNS ./. 
This/DT suggests/VBZ that/IN the/DT cysteine/NN deficiency/NN in/IN HIV-1-infected/JJ individuals/NNS may/MD cause/VB an/DT over-expression/NN of/IN NF-kappa/NN B-dependent/JJ genes/NNS and/CC enhance/VB HIV-1/NN replication/NN ./. 
NAC/NN may/MD be/VB considered/VBN for/IN the/DT treatment/NN of/IN HIV-1-infected/JJ individuals/NNS ./. 
UI/LS -/: 91184620/CD 
TI/LS -/: A/DT thymus-specific/JJ member/NN of/IN the/DT HMG/NN protein/NN family/NN regulates/VBZ the/DT human/JJ T/NN cell/NN receptor/NN C/NN alpha/NN enhancer/NN ./. 
AB/LS -/: The/DT human/JJ T/NN cell-specific/JJ transcription/NN factor/NN TCF-1/NN alpha/NN plays/VBZ a/DT key/JJ role/NN in/IN the/DT tissue-specific/JJ activation/NN of/IN the/DT T/NN cell/NN receptor/NN (/( TCR/NN )/) C/NN alpha/NN enhancer/NN and/CC binds/VBZ to/TO pyrimidine-rich/JJ elements/NNS (/( 5'-PyCTTTG-3'/NN )/) present/JJ in/IN a/DT variety/NN of/IN other/JJ T/NN cell-specific/JJ control/NN regions/NNS ./. 
Using/VBG amino/NN acid/NN sequence/NN information/NN derived/VBN from/IN the/DT DNA/NN affinity-purified/JJ protein/NN ,/, we/PRP have/VBP now/RB isolated/VBN cDNA/NN clones/NNS encoding/VBG TCF-1/NN alpha/NN ./. 
The/DT TCF-1/NN alpha/NN cDNA/NN contains/VBZ a/DT single/JJ 68-amino-acid/JJ domain/NN that/WDT is/VBZ homologous/JJ to/TO a/DT region/NN conserved/VBN among/IN high-mobility/JJ group/NN (/( HMG/NN )/) and/CC nonhistone/JJ chromosomal/JJ proteins/NNS ./. 
Expression/NN of/IN full-length/JJ and/CC mutant/JJ cDNA/NN clones/NNS in/IN bacteria/NNS reveal/VBP that/IN the/DT single/JJ HMG/NN motif/NN ,/, which/WDT is/VBZ predicted/VBN to/TO contain/VB two/CD extended/VBN alpha-helical/JJ segments/NNS ,/, is/VBZ sufficient/JJ to/TO direct/VB the/DT sequence-specific/JJ binding/NN of/IN TCF-1/NN alpha/NN to/TO DNA/NN ./. 
Northern/NN blot/NN experiments/NNS demonstrate/VBP further/RBR that/IN TCF-1/NN alpha/NN mRNA/NN is/VBZ highly/RB tissue/NN specific/JJ ,/, found/VBN primarily/RB in/IN the/DT thymus/NN or/CC T/NN cell/NN lines/NNS ./. 
The/DT immature/JJ CEM/NN T/NN cell/NN line/NN expresses/VBZ relatively/RB low/JJ levels/NNS of/IN TCF-1/NN alpha/NN mRNA/NN ,/, which/WDT are/VBP increased/VBN upon/IN activation/NN of/IN these/DT cells/NNS by/IN phorbol/NN esters/NNS ./. 
Interestingly/RB ,/, the/DT cloned/VBN TCF-1/NN alpha/NN protein/NN is/VBZ a/DT potent/JJ transcriptional/JJ activator/NN of/IN the/DT human/JJ TCR/NN alpha/NN enhancer/NN in/IN nonlymphoid/JJ cell/NN lines/NNS ,/, whereas/IN the/DT activity/NN of/IN the/DT endogenous/JJ protein/NN in/IN T/NN cell/NN lines/NNS is/VBZ strongly/RB dependent/JJ on/IN an/DT additional/JJ T/NN cell-specific/JJ protein/NN that/WDT interacts/VBZ with/IN the/DT core/NN enhancer/NN ./. 
TCF-1/NN alpha/NN is/VBZ currently/RB unique/JJ among/IN the/DT newly/RB emerging/VBG family/NN of/IN DNA-binding/JJ regulatory/JJ proteins/NNS that/WDT share/VBP the/DT HMG/NN motif/NN in/IN that/IN it/PRP is/VBZ a/DT highly/RB tissue-specific/JJ RNA/NN polymerase/NN II/CD transcription/NN factor/NN ./. 
UI/LS -/: 91134976/CD 
TI/LS -/: A/DT novel/JJ HIV-1/NN isolate/JJ containing/VBG alterations/NNS affecting/VBG the/DT NF-kappa/NN B/NN element/NN ./. 
AB/LS -/: Three/CD molecular/JJ clones/NNS of/IN HIV-1/NN ,/, derived/VBN from/IN a/DT single/JJ isolate/NN (/( AL1/NN )/) ,/, exhibited/VBD distinct/JJ replicative/JJ and/CC cytopathic/JJ properties/NNS during/IN propagation/NN in/IN a/DT human/JJ T/NN cell/NN line/NN ./. 
The/DT phenotypic/JJ differences/NNS observed/VBN were/VBD attributable/JJ ,/, in/IN large/JJ part/NN ,/, to/TO changes/NNS affecting/VBG the/DT viral/JJ LTR/NN ./. 
Nucleotide/NN sequence/NN and/CC PCR/NN analyses/NNS demonstrated/VBD the/DT presence/NN of/IN novel/JJ duplications/NNS or/CC deletions/NNS involving/VBG the/DT NF-kappa/NN B/NN motif/NN ./. 
These/DT changes/NNS in/IN the/DT enhancer/NN element/NN were/VBD identified/VBN in/IN the/DT original/JJ AL1/NN virus/NN stock/NN ./. 
Subcloning/NN of/IN the/DT variant/JJ NF-kappa/NN B/NN segments/NNS into/IN LTR-driven/JJ CAT/NN expression/NN vectors/NNS confirmed/VBD a/DT correlation/NN between/IN promoter/JJ activity/NN and/CC replicative/cytopathic/JJ capacity/NN ./. 
UI/LS -/: 91187647/CD 
TI/LS -/: Multiple/JJ Oct2/NN isoforms/NNS are/VBP generated/VBN by/IN alternative/JJ splicing/NN ./. 
AB/LS -/: The/DT interaction/NN of/IN the/DT Oct2/NN transcription/NN factor/NN with/IN the/DT cognate/JJ octamer/NN motif/NN ATGCAAAT/NN is/VBZ a/DT critical/JJ determinant/NN of/IN the/DT lymphoid-specific/JJ expression/NN of/IN immunoglobulin/NN genes/NNS ./. 
Ectopic/JJ expression/NN of/IN cloned/VBN Oct2/NN cDNA/NN was/VBD shown/VBN to/TO be/VB sufficient/JJ to/TO reconstitute/VB at/IN least/JJS some/DT aspects/NNS of/IN this/DT regulation/NN in/IN non-lymphoid/JJ cells/NNS ./. 
We/PRP describe/VBP the/DT isolation/NN and/CC characterization/NN of/IN multiple/JJ cDNAs/NNS encoding/VBG mouse/NN Oct2/NN from/IN a/DT mature/JJ B-cell/NN line/NN and/CC we/PRP show/VBP that/IN a/DT variety/NN of/IN isoforms/NNS of/IN this/DT transcription/NN factor/NN is/VBZ generated/VBN from/IN a/DT single/JJ gene/NN by/IN an/DT alternative/JJ splicing/NN mechanism/NN ./. 
All/PDT the/DT isoforms/NNS retain/VBP the/DT previously/RB characterized/VBN POU-domain/NN and/CC are/VBP therefore/RB able/JJ to/TO bind/VB to/TO the/DT octamer/NN motif/NN ./. 
Different/JJ amounts/NNS of/IN the/DT various/JJ isoforms/NNS are/VBP present/JJ within/IN the/DT same/JJ B-cell/NN regardless/RB of/IN the/DT developmental/JJ stage/NN of/IN B-cell/NN differentiation/NN and/CC at/IN least/JJS some/DT of/IN the/DT isoforms/NNS are/VBP conserved/VBN between/IN mouse/NN and/CC humans/NNS ./. 
In/IN cotransfection/NN experiments/NNS we/PRP show/VBP that/IN all/PDT the/DT isoforms/NNS are/VBP able/JJ to/TO activate/VB an/DT octamer/NN containing/VBG promoter/NN element/NN in/IN fibroblasts/NNS revealing/VBG an/DT unexpected/JJ functional/JJ redundancy/NN ./. 
Finally/RB ,/, we/PRP show/VBP that/IN one/CD of/IN the/DT isoforms/NNS encodes/VBZ the/DT previously/RB described/VBN lymphoid-specific/JJ Oct2B/NN protein/NN which/WDT has/VBZ been/VBN suggested/VBN to/TO be/VB involved/VBN in/IN the/DT function/NN of/IN the/DT octamer/NN motif/NN in/IN the/DT context/NN of/IN the/DT immunoglobulin/NN heavy-chain/NN (/( IgH/NN )/) enhancer/NN ./. 
UI/LS -/: 92223210/CD 
TI/LS -/: [/( Regulation/NN of/IN intracellular/JJ cholesterol/NN synthesis/NN in/IN hypercholesterolemia/NN by/IN glucocorticoids/NNS ]/) 
AB/LS -/: The/DT rate/NN of/IN endogenous/JJ cholesterol/NN synthesis/NN in/IN blood/NN lymphocytes/NNS and/CC skin/NN fibroblasts/NNS from/IN patients/NNS with/IN type/NN IIa/NN hyperlipidemia/NN was/VBD found/VBN to/TO be/VB increased/VBN in/IN comparison/NN with/IN healthy/JJ donors/NNS ./. 
The/DT cells/NNS of/IN hyperlipidemic/JJ patients/NNS had/VBD lowered/JJ levels/NNS of/IN glucocorticoid/NN receptors/NNS concomitantly/RB with/IN a/DT partial/JJ loss/NN of/IN their/PRP$ sensitivity/NN to/TO glucocorticoids/NNS ./. 
In/IN fibroblasts/NNS from/IN patients/NNS with/IN hereditary/JJ hypercholesteremia/NN of/IN homozygous/JJ type/NN the/DT number/NN of/IN glucocorticoid/NN receptors/NNS did/VBD not/RB exceed/VB 10/CD %/NN of/IN their/PRP$ content/NN in/IN normal/JJ cells/NNS ./. 
The/DT decrease/NN of/IN the/DT number/NN of/IN glucocorticoid/NN receptors/NNS in/IN patients/NNS with/IN type/NN IIa/NN hyperlipidemia/NN seems/VBZ to/TO be/VB a/DT compensatory/JJ response/NN of/IN cells/NNS culminating/VBG in/IN activation/NN of/IN endogenous/JJ cholesterol/NN synthesis/NN ./. 
UI/LS -/: 92052106/CD 
TI/LS -/: Negative/JJ regulation/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD expression/NN in/IN monocytes/NNS :/: role/NN of/IN the/DT 65-kDa/JJ plus/CC 50-kDa/JJ NF-kappa/NN B/NN dimer/NN ./. 
AB/LS -/: Although/IN monocytic/JJ cells/NNS can/MD provide/VB a/DT reservoir/NN for/IN viral/JJ production/NN in/FW vivo/FW ,/, their/PRP$ regulation/NN of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) transcription/NN can/MD be/VB either/CC latent/JJ ,/, restricted/JJ ,/, or/CC productive/JJ ./. 
These/DT differences/NNS in/IN gene/NN expression/NN have/VBP not/RB been/VBN molecularly/RB defined/VBN ./. 
In/IN THP-1/NN cells/NNS with/IN restricted/JJ HIV/NN expression/NN ,/, there/EX is/VBZ an/DT absence/NN of/IN DNA-protein/JJ binding/NN complex/NN formation/NN with/IN the/DT HIV-1/NN promoter-enhancer/NN associated/VBN with/IN markedly/RB less/JJR viral/JJ RNA/NN production/NN ./. 
This/DT absence/NN of/IN binding/NN was/VBD localized/JJ to/TO the/DT NF-kappa/NN B/NN region/NN of/IN the/DT HIV-1/NN enhancer/NN ;/: the/DT 65-kDa/JJ plus/CC 50-kDa/JJ NF-kappa/NN B/NN heterodimer/NN was/VBD preferentially/RB lost/VBN ./. 
Adding/VBG purified/VBN NF-kappa/NN B/NN protein/NN to/TO nuclear/JJ extracts/NNS from/IN cells/NNS with/IN restricted/JJ expression/NN overcomes/VBZ this/DT lack/NN of/IN binding/NN ./. 
In/IN addition/NN ,/, treatment/NN of/IN these/DT nuclear/JJ extracts/NNS with/IN sodium/NN deoxycholate/NN restored/VBD their/PRP$ ability/NN to/TO form/VB the/DT heterodimer/NN ,/, suggesting/VBG the/DT presence/NN of/IN an/DT inhibitor/NN of/IN NF-kappa/NN B/NN activity/NN ./. 
Furthermore/RB ,/, treatment/NN of/IN nuclear/JJ extracts/NNS from/IN these/DT cells/NNS that/WDT had/VBD restricted/JJ expression/NN with/IN lipopolysaccharide/NN increased/VBD viral/JJ production/NN and/CC NF-kappa/NN B/NN activity/NN ./. 
Antiserum/NN specific/JJ for/IN NF-kappa/NN B/NN binding/NN proteins/NNS ,/, but/CC not/RB c-rel-specific/JJ antiserum/NN ,/, disrupted/VBD heterodimer/NN complex/NN formation/NN ./. 
Thus/RB ,/, both/DT NF-kappa/NN B-binding/JJ complexes/NNS are/VBP needed/VBN for/IN optimal/JJ viral/JJ transcription/NN ./. 
Binding/NN of/IN the/DT 65-kDa/JJ plus/CC 50-kDa/JJ heterodimer/NN to/TO the/DT HIV-1/NN enhancer/NN can/MD be/VB negatively/RB regulated/VBN in/IN monocytes/NNS ,/, providing/VBG one/CD mechanism/NN restricting/VBG HIV-1/NN gene/NN expression/NN ./. 
UI/LS -/: 92006162/CD 
TI/LS -/: Glucocorticoid/NN receptors/NNS in/IN normal/JJ leukocytes/NNS :/: effects/NNS of/IN age/NN ,/, gender/NN ,/, season/NN ,/, and/CC plasma/NN cortisol/NN concentrations/NNS ./. 
AB/LS -/: We/PRP measured/VBD glucocorticoid/NN receptors/NNS (/( GR/NN )/) in/IN mononuclear/JJ leukocytes/NNS (/( MNL/NN )/) isolated/VBN from/IN peripheral/JJ blood/NN of/IN 145/CD apparently/RB healthy/JJ volunteers/NNS (/( 86/CD men/NNS and/CC 59/CD women/NNS )/) ./. 
An/DT age-related/JJ decrease/NN in/IN the/DT number/NN of/IN GR/NN was/VBD suggested/VBN between/IN subjects/NNS younger/JJR than/IN 20/CD years/NNS and/CC elderly/JJ subjects/NNS ;/: there/EX was/VBD no/DT apparent/JJ seasonal/JJ variation/NN in/IN GR/NN ./. 
Gender/NN difference/NN in/IN the/DT number/NN of/IN GR/NN was/VBD not/RB significant/JJ ,/, although/IN women/NNS showed/VBD slightly/RB fewer/JJR GR/NN ./. 
Eight/CD patients/NNS with/IN dermatomyositis/polymyositis/NN were/VBD examined/VBN to/TO determine/VB whether/IN the/DT number/NN of/IN GR/NN in/IN MNL/NN could/MD be/VB down-regulated/VBN by/IN their/PRP$ cognate/JJ ligands/NNS ./. 
The/DT number/NN of/IN GR/NN in/IN MNL/NN from/IN these/DT patients/NNS was/VBD significantly/RB decreased/VBN one/CD month/NN after/IN the/DT initiation/NN of/IN prednisolone/NN therapy/NN ./. 
However/RB ,/, in/IN normal/JJ subjects/NNS ,/, the/DT GR/NN in/IN MNL/NN did/VBD not/RB demonstrate/VB circadian/JJ variation/NN ,/, in/IN contrast/NN to/TO concentrations/NNS of/IN plasma/NN cortisol/NN ./. 
UI/LS -/: 92031293/CD 
TI/LS -/: Synergism/NN between/IN two/CD distinct/JJ elements/NNS of/IN the/DT HTLV-I/NN enhancer/NN during/IN activation/NN by/IN the/DT trans-activator/NN of/IN HTLV-I/NN ./. 
AB/LS -/: We/PRP have/VBP conducted/VBN functional/JJ studies/NNS of/IN the/DT enhancer/NN elements/NNS of/IN human/JJ T-cell/NN leukemia/NN virus/NN type/NN I/CD (/( HTLV-I/NN )/) using/VBG the/DT human/JJ T-cell/NN lines/NNS Jurkat/NN and/CC MOLT/NN 4/CD ,/, which/WDT are/VBP negative/JJ for/IN HTLV-I/NN ,/, and/CC MT-2/NN and/CC TL-Mor/NN ,/, which/WDT carry/VBP the/DT proviral/JJ genome/NN of/IN HTLV-I/NN ./. 
Two/CD distinct/JJ elements/NNS have/VBP been/VBN implicated/VBN in/IN function/NN of/IN the/DT HTLV-I/NN enhancer/NN ./. 
One/CD is/VBZ the/DT 21-base-pair/JJ (/( bp/NN )/) core/NN element/NN that/WDT is/VBZ responsible/JJ for/IN trans-activation/NN by/IN the/DT HTLV-I/NN trans-activator/NN p40tax/NN and/CC that/WDT has/VBZ the/DT ability/NN to/TO bind/VB to/TO cyclic-AMP/NN responsive/JJ element/NN binding/NN factor/NN (/( CREB/NN )/) -like/JJ factor/NN (/( s/NNS )/) ./. 
The/DT other/JJ is/VBZ a/DT region/NN interposed/VBN between/IN the/DT 21-bp/JJ elements/NNS ./. 
In/IN this/DT study/NN we/PRP demonstrate/VBP that/IN a/DT subfragment/NN (/( C26/NN )/) in/IN the/DT region/NN between/IN the/DT 21-bp/JJ elements/NNS is/VBZ involved/VBN in/IN trans-activation/NN by/IN p40tax/NN ,/, possibly/RB through/IN binding/NN to/TO an/DT NF-kappa/NN B-like/JJ nuclear/JJ factor/NN or/CC factors/NNS ./. 
Formation/NN of/IN the/DT protein-DNA/JJ complex/NN with/IN the/DT C26/NN subfragment/NN was/VBD positively/RB affected/VBN by/IN p40tax/NN ./. 
The/DT C26/NN element/NN conferred/VBD partial/JJ responsiveness/NN to/TO p40tax/NN when/WRB linked/VBN to/TO one/CD copy/NN of/IN the/DT 21-bp/JJ element/NN that/WDT ,/, by/IN itself/PRP ,/, showed/VBD little/JJ activation/NN in/IN response/NN to/TO p40tax/NN ./. 
However/RB ,/, the/DT C26/NN element/NN alone/RB ,/, even/RB when/WRB repeated/VBN ,/, could/MD not/RB be/VB activated/VBN by/IN p40tax/NN ,/, unlike/IN other/JJ NF-kappa/NN B-binding/JJ elements/NNS ./. 
In/IN contrast/NN ,/, the/DT C26/NN element/NN itself/PRP was/VBD profoundly/RB activated/VBN upon/IN stimulation/NN with/IN 12-O-tetradecanoylphorbol-13-acetate/NN ./. 
These/DT findings/NNS therefore/RB suggest/VBP that/IN the/DT HTLV-I/NN enhancer/NN contains/VBZ multiple/JJ functional/JJ elements/NNS ,/, including/VBG binding/VBG sites/NNS for/IN at/IN least/JJS CREB-/NN and/CC NF-kappa/NN B-like/JJ factors/NNS ,/, which/WDT synergistically/RB cooperate/VBP in/IN activation/NN of/IN the/DT HTLV-I/NN enhancer/NN in/IN response/NN to/TO p40tax/NN ./. 
Our/PRP$ results/NNS also/RB demonstrate/VBP that/IN TPA-dependent/JJ activation/NN of/IN the/DT HTLV-I/NN enhancer/NN may/MD be/VB mediated/VBN through/IN the/DT C26/NN element/NN ./. 
UI/LS -/: 91277630/CD 
TI/LS -/: Human/JJ tumor/NN necrosis/NN factor/NN alpha/NN gene/NN regulation/NN in/IN phorbol/NN ester/NN stimulated/VBD T/NN and/CC B/NN cell/NN lines/NNS ./. 
AB/LS -/: The/DT minimal/JJ region/NN of/IN the/DT human/JJ tumor/NN necrosis/NN factor/NN alpha/NN (/( TNF-alpha/NN )/) gene/NN promoter/NN necessary/JJ for/IN its/PRP$ transcriptional/JJ induction/NN by/IN phorbol/NN esters/NNS (/( PMA/NN )/) in/IN human/JJ T/NN and/CC B/NN lymphocyte/NN cell/NN lines/NNS has/VBZ been/VBN localized/JJ between/IN -52/CD and/CC +89/CD nucleotides/NNS (/( nt/NN )/) relative/JJ to/TO the/DT gene/NN 's/POS transcriptional/JJ start/NN site/NN ./. 
Comparison/NN of/IN these/DT sequences/NNS to/TO those/DT required/VBN to/TO mediate/VB virus/NN or/CC lipopolysaccharide/NN (/( LPS/NN )/) induction/NN of/IN the/DT gene/NN reveal/VB significant/JJ differences/NNS ,/, and/CC thus/RB ,/, the/DT sequence/NN requirements/NNS for/IN PMA/NN induction/NN are/VBP distinct/JJ from/IN those/DT that/WDT mediate/VBP induction/NN by/IN virus/NN or/CC LPS/NN ./. 
Although/IN three/CD sites/NNS in/IN the/DT TNF-alpha/NN promoter/NN (/( kappa/NN 1/CD ,/, kappa/NN 2/CD ,/, and/CC kappa/NN 3/CD )/) specifically/RB bind/VBP the/DT transcription/NN factor/NN NF-kappa/NN B/NN in/IN lymphoid/JJ nuclear/JJ extracts/NNS ,/, TNF-alpha/NN mRNA/NN induction/NN by/IN PMA/NN does/VBZ not/RB correlate/VB with/IN NF-kappa/NN B/NN binding/NN activities/NNS displayed/VBN by/IN different/JJ T/NN and/CC B/NN cell/NN lines/NNS ./. 
Moreover/RB ,/, kappa/NN 1/CD -/: kappa/NN 3/CD can/MD each/DT be/VB deleted/VBN from/IN the/DT TNF-alpha/NN promoter/NN with/IN little/JJ effect/NN on/IN the/DT gene/NN 's/POS inducibility/NN by/IN PMA/NN ./. 
Therefore/RB ,/, TNF-alpha/NN mRNA/NN induction/NN by/IN PMA/NN ,/, like/IN its/PRP$ induction/NN by/IN virus/NN and/CC LPS/NN ,/, is/VBZ not/RB primarily/RB mediated/VBN by/IN NF-kappa/NN B/NN ,/, but/CC rather/RB is/VBZ mediated/VBN through/IN other/JJ sequences/NNS and/CC protein/NN factors/NNS ./. 
Surprisingly/RB ,/, multimers/NNS of/IN kappa/NN 1/CD -/: kappa/NN 3/CD can/MD confer/VB PMA/NN inducibility/NN on/IN a/DT heterologous/JJ promoter/NN in/IN a/DT B/NN (/( Raji/NN )/) ,/, but/CC not/RB a/DT T/NN (/( HUT78/NN )/) cell/NN line/NN ./. 
However/WRB they/PRP are/VBP not/RB functional/JJ on/IN a/DT truncated/VBN TNF-alpha/NN promoter/NN ,/, indicating/VBG that/IN promoter/NN context/NN and/CC cell/NN type/NN specificity/NN influence/VBP the/DT PMA/NN inducible/JJ function/NN of/IN these/DT NF-kappa/NN B/NN binding/NN sites/NNS ./. 
UI/LS -/: 91237800/CD 
TI/LS -/: Differentiation-associated/JJ expression/NN of/IN the/DT Epstein-Barr/JJ virus/NN BZLF1/NN transactivator/NN protein/NN in/IN oral/JJ hairy/JJ leukoplakia/NN ./. 
AB/LS -/: The/DT BZLF1/NN protein/NN of/IN Epstein-Barr/JJ virus/NN (/( EBV/NN )/) is/VBZ a/DT key/JJ immediate-early/JJ protein/NN which/WDT has/VBZ been/VBN shown/VBN to/TO disrupt/VB virus/NN latency/NN in/IN EBV-infected/JJ B/NN cells/NNS ./. 
We/PRP have/VBP generated/VBN a/DT monoclonal/JJ antibody/NN ,/, BZ1/NN ,/, to/TO BZLF1/NN which/WDT reacts/VBZ in/IN immunohistology/NN ,/, immunoblotting/NN ,/, and/CC immunoprecipitation/NN and/CC which/WDT recognizes/VBZ both/CC the/DT active/JJ ,/, dimeric/JJ form/NN and/CC the/DT inactive/JJ ,/, monomeric/JJ form/NN of/IN the/DT protein/NN ./. 
Biopsies/NNS of/IN oral/JJ hairy/JJ leukoplakia/NN ,/, an/DT AIDS-associated/JJ lesion/NN characterized/VBN by/IN high-level/JJ EBV/NN replication/NN ,/, were/VBD examined/VBN by/IN immunohistochemistry/NN using/VBG the/DT BZ1/NN monoclonal/JJ antibody/NN ./. 
A/DT differentiation-associated/JJ pattern/NN of/IN BZLF1/NN expression/NN was/VBD observed/VBN ,/, BZ1/NN reacting/VBG with/IN nuclei/NNS of/IN the/DT upper/JJ spinous/JJ layer/NN of/IN the/DT lesion/NN ./. 
This/DT finding/NN suggests/VBZ that/IN the/DT BZLF1/NN promoter/NN may/MD be/VB regulated/VBN by/IN the/DT degree/NN of/IN squamous/JJ differentiation/NN ./. 
A/DT comparison/NN of/IN in/FW situ/FW hybridization/NN to/TO EBV/NN DNA/NN and/CC viral/JJ capsid/NN antigen/NN staining/VBG with/IN BZ1/NN reactivity/NN suggested/VBD that/IN BZLF1/NN expression/NN precedes/VBZ rampant/JJ virus/NN replication/NN ./. 
The/DT inability/NN to/TO detect/VB EBV/NN in/IN the/DT lower/RBR epithelial/JJ layers/NNS of/IN oral/JJ hairy/JJ leukoplakia/NN raises/VBZ questions/NNS concerning/VBG the/DT nature/NN of/IN EBV/NN latency/NN and/CC persistence/NN in/IN stratified/JJ squamous/JJ epithelium/NN ./. 
UI/LS -/: 91347784/CD 
TI/LS -/: [/( Changes/NNS in/IN levels/NNS of/IN leucocytic/JJ estrogen/NN receptor/NN in/IN patients/NNS with/IN menopausal/JJ type/NN II/CD diabetes/NNS and/CC its/PRP$ significance/NN ]/) 
AB/LS -/: The/DT number/NN of/IN estrogen/NN receptors/NNS (/( ER/NN )/) in/IN human/JJ peripheral/JJ leucocytes/NNS in/IN 12/CD women/NNS with/IN menopausal/JJ type/NN II/CD diabetes/NNS was/VBD measured/VBN with/IN radio-ligand/JJ binding/NN method/NN ./. 
The/DT results/NNS were/VBD compared/VBN with/IN those/DT of/IN 12/CD menopausal/JJ women/NNS without/IN diabetes/NNS and/CC 12/CD normal/JJ women/NNS of/IN childbearing/JJ age/NN ./. 
It/PRP was/VBD found/VBN that/IN the/DT number/NN of/IN ER/NN in/IN the/DT patients/NNS was/VBD significantly/RB decreased/VBN ./. 
Our/PRP$ data/NNS indicate/VBP that/IN decrease/NN of/IN ER/NN level/NN in/IN leukocytes/NNS may/MD be/VB related/JJ to/TO the/DT pathogenesis/NN of/IN type/NN II/CD diabetes/NNS in/IN menopausal/JJ period/NN ./. 
UI/LS -/: 91174087/CD 
TI/LS -/: Lymphocyte/NN glucocorticoid/NN receptor/NN number/NN in/IN posttraumatic/JJ stress/NN disorder/NN ./. 
AB/LS -/: OBJECTIVE/NN :/: The/DT authors/NNS '/POS objective/NN was/VBD to/TO investigate/VB the/DT possibility/NN that/IN glucocorticoid/NN receptor/NN changes/NNS may/MD be/VB involved/VBN in/IN the/DT dysregulation/NN of/IN the/DT hypothalamic-pituitary-adrenal/JJ (/( HPA/JJ )/) axis/NN in/IN posttraumatic/JJ stress/NN disorder/NN (/( PTSD/NN )/) ./. 
METHOD/NN :/: They/PRP measured/VBD the/DT number/NN of/IN lymphocyte/NN cytosolic/JJ glucocorticoid/NN receptors/NNS and/CC plasma/NN cortisol/NN concentrations/NNS in/IN 15/CD consecutively/RB admitted/VBN male/JJ combat/NN Vietnam/NN veterans/NNS with/IN PTSD/NN and/CC in/IN a/DT normal/JJ comparison/NN group/NN of/IN 11/CD subjects/NNS ./. 
RESULTS/NNS :/: Both/CC the/DT patients/NNS and/CC the/DT normal/JJ comparison/NN subjects/NNS showed/VBD a/DT morning-to-afternoon/JJ decline/NN in/IN glucocorticoid/NN receptor/NN concentrations/NNS ,/, paralleling/VBG the/DT normal/JJ diurnal/JJ decline/NN in/IN cortisol/NN levels/NNS ./. 
The/DT number/NN of/IN glucocorticoid/NN receptors/NNS was/VBD 63/CD %/NN greater/JJR in/IN the/DT morning/NN and/CC 26/CD %/NN greater/JJR in/IN the/DT afternoon/NN in/IN the/DT patients/NNS with/IN PTSD/NN than/IN in/IN the/DT normal/JJ subjects/NNS ./. 
No/DT group/NN differences/NNS in/IN cortisol/NN levels/NNS were/VBD observed/VBN ,/, nor/CC were/VBD glucocorticoid/NN receptor/NN number/NN and/CC cortisol/NN levels/NNS correlated/VBD ./. 
The/DT number/NN of/IN morning/NN glucocorticoid/NN receptors/NNS was/VBD positively/RB correlated/VBN with/IN symptoms/NNS of/IN PTSD/NN and/CC anxiety/NN ./. 
CONCLUSIONS/NNS :/: These/DT results/NNS provide/VBP further/JJ evidence/NN for/IN a/DT dysregulation/NN of/IN the/DT HPA/JJ axis/NN in/IN PTSD/NN ./. 
The/DT finding/NN that/IN patients/NNS with/IN PTSD/NN had/VBD a/DT substantially/RB greater/JJR number/NN of/IN lymphocyte/NN glucocorticoid/NN receptors/NNS than/IN normal/JJ comparison/NN subjects/NNS is/VBZ consistent/JJ with/IN the/DT authors/NNS '/POS previous/JJ observations/NNS of/IN low/JJ 24-hour/JJ urinary/JJ cortisol/NN excretion/NN in/IN subjects/NNS with/IN PTSD/NN ./. 
Furthermore/RB ,/, the/DT receptor/NN changes/NNS observed/VBN are/VBP opposite/JJ of/IN those/DT reported/VBN in/IN major/JJ depressive/JJ disorder/NN ./. 
The/DT present/JJ data/NNS ,/, along/IN with/IN other/JJ findings/NNS of/IN HPA/JJ abnormalities/NNS in/IN PTSD/NN ,/, support/VBP the/DT possibility/NN of/IN a/DT greater/JJR negative/JJ feedback/NN sensitivity/NN at/IN one/CD or/CC more/JJR levels/NNS of/IN the/DT HPA/JJ axis/NN ./. 
UI/LS -/: 91376384/CD 
TI/LS -/: Induction/NN of/IN NF-kappa/NN B/NN during/IN monocyte/NN differentiation/NN is/VBZ associated/VBN with/IN activation/NN of/IN HIV-gene/JJ expression/NN ./. 
AB/LS -/: Cells/NNS of/IN the/DT monocyte-macrophage/JJ lineage/NN are/VBP important/JJ targets/NNS of/IN HIV/NN infection/NN ./. 
We/PRP report/VBP here/RB that/IN the/DT phenotypic/JJ differentiation/NN of/IN monocyte/NN cell/NN lines/NNS induced/VBN by/IN phorbol/NN esters/NNS or/CC tumour/NN necrosis/NN factor/NN alpha/NN (/( TNF/NN alpha/NN )/) is/VBZ associated/VBN with/IN expression/NN of/IN nuclear/JJ factor/NN kappa/NN B/NN (/( NF-kappa/NN B/NN )/) ./. 
In/IN parallel/NN with/IN such/JJ differentiation/NN ,/, HIV/NN transcription/NN ,/, monitored/VBN using/VBG an/DT HIV/NN long/JJ terminal/JJ repeat/NN reporter/NN gene/NN construct/NN ,/, is/VBZ activated/VBN in/IN such/JJ cells/NNS under/IN the/DT influence/NN of/IN enhanced/VBN NF-kappa/NN B/NN expression/NN ./. 
Also/RB ,/, in/IN a/DT promonocyte/JJ cell/NN line/NN chronically/RB infected/VBN with/IN HIV/NN ,/, NF-kappa/NN B/NN expression/NN and/CC HIV/NN transcription/NN were/VBD enhanced/VBN on/IN stimulation/NN with/IN phorbol/NN ester/NN or/CC TNF/NN alpha/NN ./. 
Thus/RB ,/, stimulation/NN of/IN monocyte/NN cell/NN lines/NNS by/IN phorbol/NN esters/NNS or/CC TNF/NN alpha/NN induces/VBZ cell/NN differentiation/NN and/CC activates/VBZ HIV/NN transcription/NN ./. 
Such/PDT a/DT process/NN may/MD have/VB fundamental/JJ implications/NNS in/IN AIDS/NN pathogenesis/NN in/FW vivo/FW and/CC may/MD be/VB important/JJ in/IN disease/NN progression/NN induced/VBN by/IN opportunistic/JJ infections/NNS directly/RB or/CC indirectly/RB involving/VBG macrophages/NNS ./. 
UI/LS -/: 91236793/CD 
TI/LS -/: Demonstration/NN of/IN estrogen/NN and/CC progesterone/NN receptors/NNS as/RB well/RB as/IN Ki-67/NN and/CC p-145/NN antigens/NNS in/IN single/JJ tumor/NN cells/NNS from/IN blood/NN and/CC pleural/JJ effusions/NNS using/VBG a/DT slide/NN assay/NN ./. 
AB/LS -/: We/PRP describe/VBP a/DT slide/NN assay/NN that/WDT allows/VBZ the/DT demonstration/NN of/IN antigens/NNS localized/JJ in/IN the/DT nucleus/NN from/IN isolated/VBN white/JJ blood/NN cells/NNS as/RB well/RB as/IN from/IN single/JJ tumor/NN cells/NNS derived/VBN from/IN malignant/JJ effusions/NNS ./. 
With/IN the/DT antibodies/NNS Ki-67/NN and/CC anti-p-145/NN an/DT increased/VBN rate/NN of/IN nuclear/JJ and/CC nucleolar/JJ staining/NN resulted/VBD in/IN cells/NNS from/IN highly/RB malignant/JJ lymphomas/NNS ./. 
An/DT almost/RB identical/JJ reaction/NN was/VBD obtained/VBN when/WRB tumor/NN cells/NNS from/IN malignant/JJ effusions/NNS were/VBD tested/VBN ./. 
Cells/NNS isolated/VBN from/IN the/DT blood/NN of/IN patients/NNS with/IN leukemic/JJ spread/NN of/IN lymphomas/NNS of/IN low/JJ malignancy/NN yielded/VBD a/DT weak/JJ staining/NN comparable/JJ to/TO that/DT of/IN normal/JJ mesothelial/JJ cells/NNS from/IN non-tumorous/JJ cavity/NN fluids/NNS ./. 
The/DT detection/NN of/IN estrogen/NN and/CC progesterone/NN receptors/NNS (/( ER/NN and/CC PR/NN )/) localized/JJ in/IN the/DT cell/NN nucleus/NN can/MD be/VB achieved/VBN by/IN the/DT same/JJ assay/NN ./. 
The/DT reaction/NN is/VBZ enhanced/VBN by/IN incubation/NN of/IN the/DT tumor/NN cells/NNS for/IN 30/CD min/NN at/IN 37/CD degrees/NNS C/NN prior/RB to/TO fixation/NN ./. 
Pleural/JJ effusions/NNS from/IN 20/CD patients/NNS with/IN breast/NN cancer/NN were/VBD tested/VBN ./. 
ER/NN was/VBD positive/JJ in/IN 13/CD and/CC PR/NN was/VBD positive/JJ in/IN 12/CD of/IN the/DT 20/CD samples/NNS ./. 
In/IN 5/CD cases/NNS there/EX was/VBD a/DT divergent/JJ reaction/NN with/IN ER/NN and/CC PR/NN antibody/NN ./. 
The/DT hormone/NN receptors/NNS of/IN the/DT primary/JJ tumor/NN were/VBD known/VBN in/IN 15/CD (/( ER/NN )/) and/CC 14/CD (/( PR/NN )/) patients/NNS ,/, respectively/RB ./. 
In/IN each/DT cohort/NN there/EX was/VBD only/RB one/CD case/NN with/IN a/DT negative/JJ reaction/NN of/IN the/DT primary/JJ tumor/NN and/CC a/DT positive/JJ reaction/NN with/IN the/DT isolated/VBN tumor/NN cells/NNS from/IN the/DT pleural/JJ effusions/NNS ./. 
These/DT results/NNS indicate/VBP that/IN the/DT demonstration/NN of/IN hormone/NN receptor/NN proteins/NNS in/IN cells/NNS from/IN malignant/JJ effusions/NNS is/VBZ possible/JJ and/CC that/IN there/EX is/VBZ a/DT correlation/NN with/IN the/DT status/NN of/IN the/DT primary/JJ site/NN of/IN cancer/NN ./. 
UI/LS -/: 92068245/CD 
TI/LS -/: Constitutive/JJ activation/NN of/IN NF-kB/NN in/IN human/JJ thymocytes/NNS ./. 
AB/LS -/: NF-kB/NN is/VBZ a/DT eukaryotic/JJ transcription/NN regulatory/JJ factor/NN ./. 
In/IN T/NN cells/NNS and/CC T/NN cell/NN lines/NNS ,/, NF-kB/NN is/VBZ bound/VBN to/TO a/DT cytoplasmic/JJ proteic/JJ inhibitor/NN ,/, the/DT IkB/NN ./. 
Treatment/NN of/IN T/NN cells/NNS with/IN mitogens/NNS (/( phorbol/NN esters/NNS )/) or/CC cytokines/NNS (/( TNF/NN alpha/NN )/) induces/VBZ NF-kB/NN nuclear/JJ translocation/NN and/CC the/DT subsequent/JJ expression/NN of/IN NF-kB/NN dependent/JJ T/NN cell/NN genes/NNS ./. 
Here/RB we/PRP examined/VBD the/DT activation/NN of/IN NF-kB/NN in/IN human/JJ T/NN cell/NN thymic/JJ progenitors/NNS ./. 
We/PRP report/VBP differences/NNS in/IN (Ca2+)i/NN requirement/NN for/IN NF-kB/NN activation/NN in/IN thymocytes/NNS as/IN compared/VBN to/TO mature/JJ T/NN cells/NNS ./. 
Furthermore/RB ,/, our/PRP$ results/NNS indicated/VBD that/IN thymocytes/NNS have/VBP a/DT constitutively/RB active/JJ form/NN of/IN NF-kB/NN ,/, suggesting/VBG that/IN they/PRP are/VBP activated/VBN in/FW vivo/FW ./. 
UI/LS -/: 92103005/CD 
TI/LS -/: TCF-1/NN ,/, a/DT T/NN cell-specific/JJ transcription/NN factor/NN of/IN the/DT HMG/NN box/NN family/NN ,/, interacts/VBZ with/IN sequence/NN motifs/NNS in/IN the/DT TCR/NN beta/NN and/CC TCR/NN delta/NN enhancers/NNS ./. 
AB/LS -/: We/PRP have/VBP recently/RB identified/VBN and/CC cloned/VBN TCF-1/NN ,/, a/DT T/NN cell-specific/JJ transcription/NN factor/NN with/IN specificity/NN for/IN the/DT AACAAAG/NN motif/NN in/IN the/DT CD3/NN epsilon/NN enhancer/NN and/CC for/IN the/DT TTCAAAG/NN motif/NN in/IN the/DT TCR/NN alpha/NN enhancer/NN ./. 
TCF-1/NN belongs/VBZ to/TO the/DT family/NN of/IN transcription-regulating/JJ proteins/NNS which/WDT share/VBP a/DT region/NN of/IN homology/NN termed/VBN the/DT HMG-box/NN ./. 
Here/RB ,/, we/PRP show/VBP by/IN gel/NN retardation/NN analysis/NN that/IN TCF-1/NN specifically/RB recognizes/VBZ the/DT T/NN beta/NN 5/CD element/NN of/IN the/DT TCR/NN beta/NN enhancer/NN and/CC the/DT T/NN delta/NN 7/CD element/NN of/IN the/DT TCR/NN delta/NN enhancer/NN ./. 
Comparison/NN of/IN the/DT sequences/NNS of/IN all/DT elements/NNS recognized/VBN by/IN TCF-1/NN defines/VBZ a/DT consensus/NN motif/NN A/T/NN A/T/NN C/NN A/NN A/G/NN A/NN G/NN ./. 
These/DT observations/NNS imply/VBP that/IN TCF-1/NN is/VBZ involved/VBN in/IN the/DT control/NN of/IN several/JJ T/NN cell-specific/JJ genes/NNS and/CC might/MD thus/RB play/VB an/DT important/JJ role/NN in/IN the/DT establishment/NN and/CC maintenance/NN of/IN the/DT mature/JJ T/NN cell/NN phenotype/NN ./. 
UI/LS -/: 92179751/CD 
TI/LS -/: [/( Regulatory/JJ effect/NN of/IN insulin/NN on/IN glucocorticoid/NN receptor/NN in/IN human/JJ peripheral/JJ leukocytes/NNS ]/) 
AB/LS -/: The/DT regulatory/JJ effect/NN of/IN insulin/NN on/IN the/DT specific/JJ binding/VBG power/NN of/IN glucocorticoid/NN receptor/NN (/( GR/NN )/) of/IN human/JJ leukocytes/NNS was/VBD assessed/VBN by/IN the/DT unoccupied/JJ receptor/NN sites/NNS capable/JJ of/IN combining/VBG with/IN [3H]/NN labelled/JJ dexamethasone/NN measured/VBN at/IN 3/CD and/CC 24/CD h/NN after/IN incubation/NN with/IN various/JJ concentrations/NNS of/IN insulin/NN added/VBN to/TO the/DT medium/NN ./. 
After/IN 3/CD h/NN incubation/NN the/DT specific/JJ binding/VBG power/NN with/IN [3H]/NN Dex/NN was/VBD decreased/VBN by/IN 23.3/CD +/-/CC 10.0/CD ,/, 32.2/CD +/-/CC 13.2/CD and/CC 54.3/CD +/-/CC 9.2/CD %/NN (/( P/NN greater/JJR than/IN 0.05/CD ,/, P/NN greater/JJR than/IN 0.05/CD and/CC P/NN less/JJR than/IN 0.01/CD as/IN compared/VBN with/IN the/DT control/NN value/NN of/IN 100/CD in/IN the/DT absence/NN of/IN insulin/NN )/) respectively/RB in/IN the/DT presence/NN of/IN 20/CD mU/L/NN (/( physiological/JJ testing/NN concentration/NN )/) ,/, 200/CD mU/L/NN (/( physiological/JJ upper/JJ limit/NN )/) and/CC 2,000/CD mU/L/NN (/( pharmacological/JJ concentration/NN )/) insulin/NN in/IN the/DT incubation/NN medium/NN ./. 
After/IN 24/CD h/NN incubation/NN the/DT decrease/NN of/IN these/DT values/NNS increased/VBD respectively/RB to/TO 43.5/CD +/-/CC 19.0/CD ,/, 56.1/CD +/-/CC 20.7/CD and/CC 80.2/CD +/-/CC 15.5/CD (/( P/NN less/JJR than/IN 0.05/CD ,/, P/NN less/JJR than/IN 0.01/CD and/CC P/NN less/JJR than/IN 0.01/CD compared/VBN with/IN control/NN )/) ./. 
Thus/RB the/DT inhibitory/JJ effect/NN of/IN insulin/NN on/IN the/DT GR/NN binding/NN power/NN is/VBZ both/CC dose-/NN and/CC time-dependent/JJ ,/, which/WDT strongly/RB suggests/VBZ that/IN GR/NN is/VBZ tonically/RB controlled/VBN by/IN insulin/NN concentration/NN change/NN under/IN physiological/JJ conditions/NNS ./. 
UI/LS -/: 91369589/CD 
TI/LS -/: The/DT effect/NN of/IN toremifene/NN therapy/NN on/IN serum/NN immunoglobulin/NN levels/NNS in/IN breast/NN cancer/NN ./. 
AB/LS -/: Estrogens/NNS and/CC anti-estrogens/NNS enhance/VBP the/DT number/NN of/IN immunoglobulin/NN (/( Ig/NN )/) -secreting/NN cells/NNS in/IN pokeweed/NN mitogen/NN (/( PWM/NN )/) -stimulated/JJ lymphocyte/NN cultures/NNS ./. 
Lymphocytes/NNS from/IN patients/NNS who/WP have/VBP received/VBN anti-estrogen/NN therapy/NN show/VBP similar/JJ enhancement/NN of/IN Ig-secreting/JJ cells/NNS after/IN PWM/NN stimulation/NN ./. 
In/IN this/DT study/NN the/DT effect/NN of/IN anti-estrogen/NN (/( toremifene/NN )/) therapy/NN on/IN serum/NN immunoglobulin/NN (/( IgA/NN ,/, IgM/NN ,/, IgG/NN )/) levels/NNS in/IN breast/NN cancer/NN patients/NNS was/VBD investigated/VBN ./. 
Serum/NN Ig/NN levels/NNS were/VBD followed/VBN up/RB to/TO two/CD years/NNS after/IN or/CC during/IN the/DT therapy/NN ./. 
An/DT unexpected/JJ finding/NN was/VBD that/IN the/DT Ig/NN levels/NNS decreased/VBD during/IN the/DT follow-up/JJ period/NN ./. 
This/DT decrease/NN was/VBD seen/VBN in/IN patients/NNS who/WP responded/VBD to/TO the/DT therapy/NN as/RB well/RB as/IN in/IN those/DT who/WP did/VBD not/RB ./. 
UI/LS -/: 91266919/CD 
TI/LS -/: Human/JJ erythroid/JJ 5-aminolevulinate/NN synthase/NN :/: promoter/NN analysis/NN and/CC identification/NN of/IN an/DT iron-responsive/JJ element/NN in/IN the/DT mRNA/NN ./. 
AB/LS -/: 5-Aminolevulinate/NN synthase/NN (/( ALAS/NN )/) catalyzes/VBZ the/DT first/JJ step/NN of/IN the/DT heme/NN biosynthetic/JJ pathway/NN ./. 
cDNA/NN clones/NNS for/IN the/DT human/JJ erythroid/JJ ALAS/NN isozyme/NN were/VBD isolated/VBN from/IN a/DT fetal/JJ liver/NN library/NN ./. 
It/PRP can/MD be/VB deduced/VBN that/IN the/DT erythroid/JJ ALAS/NN precursor/NN protein/NN has/VBZ a/DT molecular/JJ weight/NN of/IN 64.6/CD kd/NN ,/, and/CC is/VBZ similar/JJ in/IN size/NN to/TO the/DT previously/RB isolated/VBN human/JJ housekeeping/JJ ALAS/NN precursor/NN of/IN molecular/JJ weight/NN 70.6/CD kd/NN ./. 
The/DT mature/JJ mitochondrial/JJ forms/NNS of/IN the/DT erythroid/JJ and/CC housekeeping/JJ ALAS/NN isozymes/NNS are/VBP predicted/VBN to/TO have/VB molecular/JJ weights/NNS of/IN 59.5/CD kd/NN and/CC 64.6/CD kd/NN ,/, respectively/RB ./. 
The/DT two/CD isozymes/NNS show/VBP little/JJ amino/NN acid/NN identity/NN in/IN their/PRP$ N-terminal/JJ signal/NN sequences/NNS but/CC have/VBP considerable/JJ sequence/NN identity/NN in/IN the/DT C-terminal/JJ two-thirds/CD of/IN their/PRP$ proteins/NNS ./. 
An/DT analysis/NN of/IN the/DT immediate/JJ promoter/NN of/IN the/DT human/JJ erythroid/JJ ALAS/NN gene/NN revealed/VBD several/JJ putative/JJ erythroid-specific/JJ cis-acting/JJ elements/NNS including/VBG both/PDT a/DT GATA-1/NN and/CC an/DT NF-E2/NN binding/NN site/NN ./. 
An/DT iron-responsive/JJ element/NN (/( IRE/NN )/) motif/NN has/VBZ been/VBN identified/VBN in/IN the/DT 5'-untranslated/JJ region/NN of/IN the/DT human/JJ erythroid/JJ ALAS/NN mRNA/NN ,/, but/CC is/VBZ not/RB present/JJ in/IN the/DT housekeeping/JJ ALAS/NN mRNA/NN ./. 
Gel/NN retardation/NN experiments/NNS established/VBD that/IN this/DT IRE/NN motif/NN formed/VBD a/DT protein - RNA/JJ complex/NN with/IN cytosolic/JJ extracts/NNS from/IN human/JJ K562/NN cells/NNS and/CC this/DT binding/NN was/VBD strongly/RB competed/VBN with/IN IRE/NN transcripts/NNS from/IN ferritin/NN or/CC transferrin/NN receptor/NN mRNAs/NNS ./. 
A/DT transcript/NN of/IN the/DT ALAS/NN IRE/NN ,/, mutated/VBN in/IN the/DT conserved/VBN loop/NN of/IN the/DT IRE/NN ,/, did/VBD not/RB readily/RB form/VB this/DT protein - RNA/JJ complex/NN ./. 
These/DT results/NNS suggest/VBP that/IN the/DT IRE/NN motif/NN in/IN the/DT ALAS/NN mRNA/NN is/VBZ functional/JJ and/CC imply/VBP that/IN translation/NN of/IN the/DT mRNA/NN is/VBZ controlled/VBN by/IN cellular/JJ iron/NN availability/NN during/IN erythropoiesis/NN ./. 
UI/LS -/: 91291720/CD 
TI/LS -/: Regulation/NN of/IN jun/NN and/CC fos/NN gene/NN expression/NN in/IN human/JJ monocytes/NNS by/IN the/DT macrophage/NN colony-stimulating/JJ factor/NN ./. 
AB/LS -/: The/DT macrophage/NN colony-stimulating/JJ factor/NN (/( M-CSF/NN )/) is/VBZ required/VBN for/IN the/DT growth/NN and/CC differentiation/NN of/IN mononuclear/JJ phagocytes/NNS ./. 
However/RB ,/, the/DT signaling/NN events/NNS responsible/JJ for/IN these/DT effects/NNS remain/VBP unclear/JJ ./. 
The/DT present/JJ studies/NNS have/VBP examined/VBN the/DT effects/NNS of/IN M-CSF/NN on/IN potential/JJ signaling/NN pathways/NNS involving/VBG expression/NN of/IN the/DT jun/NN and/CC fos/NN early/JJ response/NN genes/NNS ./. 
Low/JJ levels/NNS of/IN c-jun/NN transcripts/NNS were/VBD detectable/JJ in/IN resting/VBG human/JJ peripheral/JJ blood/NN monocytes/NNS ./. 
Treatment/NN of/IN these/DT cells/NNS with/IN 10/CD (/( 3/CD )/) units/ml/NNS human/JJ recombinant/JJ M-CSF/NN was/VBD associated/VBN with/IN rapid/JJ and/CC transient/JJ increases/NNS in/IN c-jun/NN mRNA/NN levels/NNS ./. 
Nuclear/JJ run-on/JJ assays/NNS and/CC mRNA/NN stability/NN studies/NNS demonstrated/VBD that/IN M-CSF/NN regulates/VBZ c-jun/NN expression/NN by/IN both/CC an/DT increase/NN in/IN transcription/NN rate/NN and/CC a/DT prolongation/NN in/IN the/DT half-life/NN of/IN c-jun/NN transcripts/NNS ./. 
M-CSF/NN treatment/NN was/VBD also/RB associated/VBN with/IN a/DT rapid/JJ induction/NN of/IN the/DT jun-B/NN gene/NN ,/, although/IN expression/NN of/IN this/DT gene/NN was/VBD prolonged/JJ compared/VBN to/TO that/DT of/IN c-jun/NN ./. 
We/PRP further/RB demonstrate/VBP that/IN M-CSF/NN increases/VBZ c-fos/NN mRNA/NN levels/NNS in/IN human/JJ monocytes/NNS through/IN control/NN at/IN both/CC the/DT transcriptional/JJ and/CC posttranscriptional/JJ levels/NNS ./. 
Maximal/JJ induction/NN of/IN the/DT c-fos/NN gene/NN was/VBD followed/VBN by/IN that/DT for/IN the/DT fos-B/NN gene/NN ./. 
Moreover/RB ,/, M-CSF-induced/JJ expression/NN of/IN the/DT fos-related/JJ gene/NN ,/, fra-1/NN ,/, was/VBD delayed/VBN compared/VBN to/TO that/DT for/IN both/DT c-fos/NN and/CC fos-B/NN ./. 
Taken/VBN together/RB ,/, the/DT results/NNS indicate/VBP that/IN M-CSF/NN treatment/NN is/VBZ associated/VBN with/IN differential/JJ activation/NN of/IN multiple/JJ members/NNS of/IN the/DT jun/fos/NN family/NN and/CC that/IN expression/NN of/IN these/DT genes/NNS could/MD contribute/VB to/TO nuclear/JJ signaling/NN mechanisms/NNS that/WDT regulate/VBP a/DT specific/JJ program/NN of/IN monocyte/NN differentiation/NN ./. 
UI/LS -/: 91325181/CD 
TI/LS -/: Glucocorticoid/NN receptors/NNS in/IN systemic/JJ lupus/NN erythematosus/NN ./. 
AB/LS -/: Glucocorticosteroids/NNS remain/VBP the/DT major/JJ treatment/NN modality/NN for/IN systemic/JJ lupus/NN erythematosus/NN (/( SLE/NN )/) ,/, but/CC their/PRP$ mechanism/NN of/IN action/NN is/VBZ unclear/JJ ./. 
Over/IN the/DT past/JJ decade/NN it/PRP has/VBZ become/VBN clear/JJ that/IN glucocorticosteroid/NN receptors/NNS play/VBP a/DT significant/JJ role/NN in/IN the/DT mechanism/NN of/IN glucocorticosteroid/NN action/NN ./. 
We/PRP studied/VBD glucocorticosteroid/NN receptor/NN density/NN and/CC affinity/NN on/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS by/IN the/DT glucocorticosteroid/NN binding/NN assay/NN in/IN 33/CD patients/NNS with/IN SLE/NN who/WP had/VBD taken/VBN no/DT glucocorticosteroid/NN for/IN the/DT previous/JJ 6/CD months/NNS and/CC in/IN 32/CD healthy/JJ controls/NNS ./. 
Patients/NNS '/POS disease/NN activity/NN was/VBD measured/VBN by/IN the/DT SLE/NN Disease/NN Activity/NN Index/NN (/( SLEDAI/NN )/) ./. 
Glucocorticosteroid/NN receptors/NNS on/IN leukocytes/NNS of/IN patients/NNS with/IN SLE/NN were/VBD significantly/RB higher/JJR than/IN in/IN healthy/JJ controls/NNS (/( 4419/CD +/-/CC 306/CD vs/CC 3369/CD +/-/CC 196/CD ,/, p/NN less/JJR than/IN 0.005/CD )/) ./. 
The/DT binding/NN affinity/NN was/VBD not/RB different/JJ between/IN patients/NNS and/CC controls/NNS ./. 
There/EX was/VBD no/DT correlation/NN between/IN glucocorticosteroid/NN receptor/NN number/NN and/CC SLE/NN disease/NN activity/NN ./. 
UI/LS -/: 91170801/CD 
TI/LS -/: Kappa/NN B/NN binding/NN proteins/NNS are/VBP constitutively/RB expressed/VBN in/IN an/DT IL-2/NN autocrine/NN human/JJ T/NN cell/NN line/NN ./. 
AB/LS -/: The/DT IL-2/NN and/CC the/DT IL-2-R/NN alpha/NN genes/NNS are/VBP both/DT expressed/VBN transiently/RB in/IN normal/JJ T/NN lymphocytes/NNS after/IN Ag/NN or/CC mitogen/NN activation/NN ./. 
In/IN contrast/NN ,/, the/DT human/JJ T/NN cell/NN line/NN ,/, IARC/NN 301/CD ,/, expresses/VBZ these/DT two/CD genes/NNS constitutively/RB and/CC we/PRP have/VBP previously/RB demonstrated/VBN that/IN its/PRP$ growth/NN depends/VBZ on/IN the/DT autocrine/JJ production/NN of/IN this/DT T/NN cell/NN growth/NN factor/NN and/CC high/JJ affinity/NN IL-2R/NN ./. 
To/TO dissect/VB the/DT molecular/JJ basis/NN for/IN the/DT unusual/JJ persistent/JJ expression/NN of/IN the/DT IL-2/NN and/CC IL-2-R/NN alpha/NN genes/NNS in/IN these/DT IARC/NN 301/CD T/NN cells/NNS ,/, we/PRP have/VBP analyzed/VBN the/DT interactions/NNS of/IN constitutively/RB expressed/VBN nuclear/JJ proteins/NNS with/IN the/DT 5'/JJ flanking/JJ regions/NNS of/IN the/DT IL-2/NN and/CC IL-2-R/NN alpha/NN genes/NNS using/VBG both/DT DNase/NN I/CD footprinting/NN and/CC gel/NN retardation/NN techniques/NNS ./. 
We/PRP have/VBP found/VBN that/IN a/DT region/NN in/IN both/DT genes/NNS (/( -276/CD to/TO -250/CD for/IN IL-2-R/NN alpha/NN and/CC -203/CD to/TO -183/CD for/IN IL-2/NN )/) ,/, which/WDT corresponds/VBZ to/TO a/DT kappa/NN B/NN enhancer/NN element/NN ,/, is/VBZ specifically/RB protected/VBN by/IN nuclear/JJ proteins/NNS from/IN IARC/NN 301/CD ./. 
In/IN agreement/NN with/IN this/DT finding/NN ,/, both/CC the/DT IL-2/NN and/CC IL-2-R/NN alpha/NN promoters/NNS are/VBP active/JJ in/IN transient/JJ transfection/NN assays/NNS in/IN IARC/NN 301/CD cells/NNS ./. 
In/IN contrast/NN ,/, mutation/NN of/IN the/DT kappa/NN B/NN enhancer/NN results/VBZ in/IN markedly/RB attenuated/VBN activities/NNS of/IN both/DT promoters/NNS ./. 
Two/CD proteins/NNS binding/VBG the/DT kappa/NN B/NN sequence/NN ,/, NF-kappa/NN B/NN and/CC KBF1/NN ,/, are/VBP constitutively/RB expressed/VBN in/IN IARC/NN 301/CD nuclei/NNS and/CC induced/VBN by/IN PMA/NN and/CC PHA/NN in/IN Jurkat/NN ./. 
They/PRP bind/VBP to/TO the/DT kappa/NN B/NN motifs/NNS with/IN different/JJ relative/JJ affinities/NNS that/WDT may/MD reflect/VB their/PRP$ different/JJ contribution/NN in/IN the/DT expression/NN of/IN various/JJ promoters/NNS ./. 
UI/LS -/: 91376383/CD 
TI/LS -/: HIV1/NN infection/NN of/IN human/JJ monocytes/NNS and/CC macrophages/NNS promotes/VBZ induction/NN or/CC translocation/NN of/IN NF-KB-related/JJ factors/NNS ./. 
AB/LS -/: In/IN 1991/CD ,/, we/PRP demonstrated/VBD ,/, using/VBG electrophoretic/JJ mobility/NN shift/NN assays/NNS ,/, that/IN 3/CD different/JJ factors/NNS (/( termed/VBN B1/NN ,/, B2/NN and/CC B3/NN )/) with/IN affinity/NN for/IN the/DT KB-enhancer/JJ|NN target/NN sequence/NN were/VBD specifically/RB detected/VBN in/IN nuclear/JJ extracts/NNS from/IN HIV1-infected/JJ monocytes/NNS and/CC macrophages/NNS ./. 
The/DT B2/NN factor/NN was/VBD induced/VBN in/IN the/DT nuclei/NNS of/IN these/DT cells/NNS only/RB upon/IN HIV1/NN infection/NN ./. 
The/DT B3/NN factor/NN was/VBD only/RB slightly/RB evident/JJ in/IN nuclei/NNS of/IN uninfected/JJ cells/NNS but/CC was/VBD readily/RB detectable/JJ in/IN nuclei/NNS of/IN infected/JJ monocytes/NNS ./. 
Its/PRP$ expression/NN remained/VBD very/RB low/JJ in/IN nuclei/NNS of/IN HIV1-infected/JJ macrophages/NNS ./. 
In/IN this/DT paper/NN ,/, we/PRP demonstrate/VBP that/IN the/DT B2/NN factor/NN is/VBZ expressed/VBN in/IN the/DT cytosol/NN of/IN monocytes/NNS and/CC macrophages/NNS as/IN a/DT DNA-binding/JJ protein/NN ,/, indicating/VBG that/IN it/PRP is/VBZ not/RB associated/VBN with/IN an/DT inhibitor/NN (/( IKB/NN )/) ./. 
This/DT factor/NN remained/VBD clustered/VBN in/IN the/DT cytosol/NN and/CC was/VBD translocated/VBN to/TO the/DT nuclei/NNS only/RB after/IN HIV1/NN infection/NN ./. 
The/DT B3/NN factor/NN is/VBZ detected/VBN in/IN the/DT cytosol/NN only/RB when/WRB cells/NNS are/VBP HIV1-infected/JJ ./. 
The/DT role/NN of/IN HIV1/NN infection/NN in/IN the/DT expression/NN and/CC the/DT translocation/NN of/IN these/DT factors/NNS is/VBZ discussed/VBN ./. 
UI/LS -/: 91114695/CD 
TI/LS -/: Identification/NN and/CC cloning/NN of/IN TCF-1/NN ,/, a/DT T/NN lymphocyte-specific/JJ transcription/NN factor/NN containing/VBG a/DT sequence-specific/JJ HMG/NN box/NN ./. 
AB/LS -/: CD3-epsilon/NN expression/NN is/VBZ controlled/VBN by/IN a/DT downstream/JJ T/NN lymphocyte-specific/JJ enhancer/NN element/NN ./. 
We/PRP report/VBP the/DT identification/NN of/IN a/DT T/NN cell-specific/JJ transcription/NN factor/NN ,/, TCF-1/NN ,/, binding/VBG to/TO this/DT element/NN ./. 
The/DT multimerized/JJ recognition/NN motif/NN of/IN TCF-1/NN constituted/VBD a/DT T/NN cell-specific/JJ enhancer/NN ./. 
Subsequent/JJ cloning/NN of/IN TCF-1/NN identified/VBD three/CD splice/NN alternatives/NNS ./. 
TCF-1/NN contained/VBD a/DT single/JJ DNA-binding/JJ HMG/NN box/NN most/RBS closely/RB related/JJ to/TO similar/JJ boxes/NNS in/IN the/DT putative/JJ mammalian/JJ sex-determining/JJ gene/NN SRY/NN and/CC in/IN the/DT Schizosaccharomyces/FW pombe/FW Mc/NN mating/NN type/NN gene/NN ./. 
TCF-1/NN mRNA/NN was/VBD expressed/VBN uniquely/RB in/IN T/NN lymphocytes/NNS ./. 
Upon/IN cotransfection/NN into/IN non-T/JJ cells/NNS ,/, TCF-1/NN could/MD transactivate/VB through/IN its/PRP$ cognate/JJ motif/NN ./. 
These/DT results/NNS identify/VBP TCF-1/NN as/IN a/DT T/NN cell-specific/JJ transcription/NN factor/NN ,/, which/WDT might/MD play/VB a/DT role/NN in/IN the/DT establishment/NN of/IN the/DT mature/JJ T/NN cell/NN phenotype/NN ./. 
UI/LS -/: 92066454/CD 
TI/LS -/: Identification/NN of/IN transcriptional/JJ suppressor/NN proteins/NNS that/WDT bind/VBP to/TO the/DT negative/JJ regulatory/JJ element/NN of/IN the/DT human/JJ immunodeficiency/NN virus/NN type/NN 1/CD ./. 
AB/LS -/: Two/CD different/JJ proteins/NNS which/WDT independently/RB bound/VBD to/TO neighboring/VBG sequences/NNS within/IN the/DT negative/JJ regulatory/JJ element/NN (/( NRE/NN )/) of/IN human/JJ immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) were/VBD detected/VBN in/IN the/DT nuclear/JJ extract/NN of/IN a/DT virus-infected/JJ human/JJ T/NN cell/NN line/NN ./. 
One/CD of/IN the/DT factors/NNS bound/VBD to/TO a/DT novel/JJ dyad/NN symmetrical/JJ sequence/NN ./. 
This/DT sequence/NN is/VBZ well/RB conserved/VBN in/IN various/JJ HIV-1/NN isolates/NNS and/CC partial/JJ homology/NN was/VBD found/VBN with/IN the/DT promoter/JJ region/NN of/IN the/DT human/JJ retinoblastoma/NN gene/NN ./. 
Similar/JJ DNA/NN binding/NN activity/NN was/VBD detected/VBN in/IN a/DT variety/NN of/IN virus-uninfected/JJ human/JJ T/NN cell/NN lines/NNS and/CC HeLa/NN cells/NNS by/IN means/NNS of/IN a/DT gel/NN mobility/NN shift/NN assay/NN ./. 
The/DT other/JJ factor/NN bound/VBN to/TO a/DT putative/JJ AP-1/NN recognition/NN sequence/NN predicted/VBD for/IN the/DT HIV-1/NN NRE/NN ./. 
However/RB ,/, this/DT factor/NN did/VBD not/RB bind/VB to/TO a/DT typical/JJ AP-1/NN site/NN ./. 
The/DT insertion/NN of/IN multiple/JJ copies/NNS of/IN the/DT binding/VBG site/NN for/IN the/DT former/JJ or/CC latter/JJ factor/NN into/IN a/DT heterologous/JJ promoter/NN reduced/VBD the/DT promoter/NN activity/NN to/TO one-tenth/CD or/CC one-third/CD ,/, respectively/RB ./. 
Thus/RB ,/, each/DT factor/NN may/MD function/VB as/IN a/DT novel/JJ negative/JJ regulator/NN of/IN transcription/NN ./. 
UI/LS -/: 92265660/CD 
TI/LS -/: Protein/NN kinase/NN C/NN activation/NN and/CC protooncogene/NN expression/NN in/IN differentiation/retrodifferentiation/NN of/IN human/JJ U-937/NN leukemia/NN cells/NNS ./. 
AB/LS -/: Human/JJ U-937/NN leukemia/NN cells/NNS differentiate/VBP along/IN the/DT monocytic/JJ lineage/NN following/VBG 3-day/JJ exposures/NNS to/TO 12-O-tetradecanoylphorbol-13-acetate/NN (/( TPA/NN )/) ./. 
This/DT induction/NN of/IN differentiation/NN is/VBZ accompanied/VBN by/IN adherence/NN and/CC loss/NN of/IN proliferation/NN ,/, as/RB well/RB as/IN expression/repression/NN of/IN differentiation-associated/JJ genes/NNS ./. 
Long/JJ term/NN culture/NN of/IN TPA-differentiated/JJ U-937/NN cells/NNS in/IN the/DT absence/NN of/IN phorbol/NN ester/NN for/IN 32-36/CD days/NNS resulted/VBD in/IN a/DT process/NN of/IN retrodifferentiation/NN ./. 
The/DT retrodifferentiated/VBN cells/NNS detached/VBD from/IN the/DT substrate/NN and/CC reinitiated/VBD proliferation/NN ./. 
Other/JJ cellular/JJ parameters/NNS ,/, such/JJ as/IN glycosidase/NN activities/NNS ,/, cytokine/NN release/NN ,/, and/CC filament/NN expression/NN ,/, returned/VBD to/TO levels/NNS similar/JJ to/TO that/DT observed/VBN in/IN uninduced/JJ cells/NNS ./. 
Treatment/NN of/IN U-937/NN cells/NNS with/IN TPA/NN resulted/VBD in/IN a/DT rapid/JJ translocation/NN of/IN protein/NN kinase/NN C/NN (/( PKC/NN )/) from/IN the/DT cytosol/NN to/TO cell/NN membrane/NN fractions/NNS within/IN 2-8/CD min/NN ./. 
Increased/VBN levels/NNS of/IN membrane-associated/JJ PKC/NN activity/NN persisted/VBD until/IN 17-29/CD days/NNS ./. 
However/RB ,/, longer/JJR periods/NNS of/IN incubation/NN were/VBD associated/VBN with/IN a/DT return/NN to/TO the/DT distribution/NN of/IN PKC/NN in/IN control/NN cells/NNS ./. 
Activation/NN of/IN PKC/NN has/VBZ been/VBN implicated/VBN in/IN the/DT regulation/NN of/IN certain/JJ immediate/JJ early/JJ response/NN genes/NNS ,/, and/CC in/IN the/DT present/JJ studies/NNS ,/, TPA/NN rapidly/RB induced/VBD c-fos/NN and/CC c-jun/NN gene/NN expression/NN ./. 
Levels/NNS of/IN c-fos/NN and/CC c-jun/NN transcripts/NNS remained/VBD elevated/JJ during/IN periods/NNS of/IN PKC/NN activation/NN and/CC also/RB returned/VBD to/TO levels/NNS observed/VBN in/IN control/NN cells/NNS by/IN 30-36/CD days/NNS ,/, when/WRB the/DT cells/NNS entered/VBD retrodifferentiation/NN ./. 
Staurosporine/NN ,/, a/DT nonspecific/JJ inhibitor/NN of/IN PKC/NN ,/, partially/RB blocked/VBD TPA-induced/JJ adherence/NN and/CC growth/NN inhibition/NN and/CC concomitantly/RB prevented/VBD TPA-induced/JJ c-fos/NN and/CC c-jun/NN gene/NN expression/NN ./. 
(/( ABSTRACT/NN TRUNCATED/VBN AT/IN 250/CD WORDS/NNS )/) 
UI/LS -/: 92118719/CD 
TI/LS -/: Kappa/NN B-specific/JJ DNA/NN binding/NN proteins/NNS are/VBP differentially/RB inhibited/VBN by/IN enhancer/NN mutations/NNS and/CC biological/JJ oxidation/NN ./. 
AB/LS -/: Kappa/NN B/NN (/( kappa/NN B/NN )/) enhancer/NN binding/NN proteins/NNS isolated/VBN from/IN the/DT nuclei/NNS of/IN activated/VBN human/JJ T/NN cells/NNS produce/VBP two/CD distinct/JJ nucleoprotein/NN complexes/NNS when/WRB incubated/VBN with/IN the/DT kappa/NN B/NN element/NN from/IN the/DT interleukin-2/NN receptor-alpha/NN (/( IL-2R/NN alpha/NN )/) gene/NN ./. 
These/DT two/CD DNA-protein/JJ complexes/NNS are/VBP composed/VBN of/IN at/IN least/JJS four/CD host/NN proteins/NNS (/( p50/NN ,/, p55/NN ,/, p75/NN ,/, p85/NN )/) ,/, each/DT of/IN which/WDT shares/VBZ structural/JJ similarity/NN with/IN the/DT v-rel/NN oncogene/NN product/NN ./. 
Nuclear/JJ expression/NN of/IN these/DT proteins/NNS is/VBZ induced/VBN with/IN distinctly/RB biphasic/JJ kinetics/NNS following/VBG phorbol/NN ester/NN activation/NN of/IN T/NN cells/NNS (/( p55/p75/NN early/JJ and/CC p50/p85/NN late/JJ )/) ./. 
DNA-protein/JJ crosslinking/NN studies/NNS have/VBP revealed/VBN that/IN the/DT more/RBR rapidly/RB migrating/VBG B2/NN complex/NN contains/VBZ both/CC p50/NN and/CC p55/NN while/IN the/DT more/RBR slowly/RB migrating/VBG B1/NN complex/NN is/VBZ composed/VBN of/IN p50/NN ,/, p55/NN ,/, p75/NN ,/, and/CC p85/NN ./. 
Site-directed/JJ mutagenesis/NN of/IN the/DT wild-type/JJ IL-2R/NN alpha/NN kappa/NN B/NN enhancer/NN (/( GGGGAATCTCCC/NN )/) has/VBZ revealed/VBN that/IN the/DT binding/NN of/IN p50/NN and/CC p55/NN (/( B2/NN complex/NN )/) is/VBZ particularly/RB sensitive/JJ to/TO alteration/NN of/IN the/DT 5'/JJ triplet/NN of/IN deoxyguanosine/NN residues/NNS ./. 
In/IN contrast/NN ,/, formation/NN of/IN the/DT B1/NN complex/NN ,/, reflecting/VBG the/DT binding/NN of/IN p75/NN and/CC p85/NN ,/, critically/RB depends/VBZ upon/IN the/DT more/RBR 3'/JJ sequences/NNS of/IN this/DT enhancer/NN element/NN ./. 
DNA/NN binding/NN by/IN all/DT four/CD of/IN these/DT Rel-related/JJ factors/NNS is/VBZ blocked/VBN by/IN selective/JJ chemical/JJ modification/NN of/IN lysine/NN and/CC arginine/NN residues/NNS ,/, suggesting/VBG that/IN both/DT of/IN these/DT basic/JJ amino/NN acids/NNS are/VBP required/VBN for/IN binding/VBG to/TO the/DT kappa/NN B/NN element/NN ./. 
Similarly/RB ,/, covalent/JJ modification/NN of/IN free/JJ sulfhydryl/NN groups/NNS with/IN diamide/NN (/( reversible/JJ )/) or/CC N-ethylmaleimide/NN (/( irreversible/JJ )/) results/VBZ in/IN a/DT complete/JJ loss/NN of/IN DNA/NN binding/NN activity/NN ./. 
In/IN contrast/NN ,/, mild/JJ oxidation/NN with/IN glucose/NN oxidase/NN selectively/RB inhibits/VBZ p75/NN and/CC p85/NN binding/NN while/IN not/RB blocking/VBG p50/NN and/CC p55/NN interactions/NNS ./. 
These/DT findings/NNS suggest/VBP that/IN reduced/VBN cysteine/NN thiols/NNS play/VBP an/DT important/JJ role/NN in/IN the/DT DNA/NN binding/NN activity/NN of/IN this/DT family/NN of/IN Rel-related/JJ transcription/NN factors/NNS ./. 
UI/LS -/: 92127655/CD 
TI/LS -/: [/( Changes/NNS in/IN leucocytic/JJ estrogen/NN receptor/NN levels/NNS in/IN patients/NNS with/IN climacteric/JJ syndrome/NN and/CC therapeutic/JJ effect/NN of/IN liuwei/FW dihuang/FW pills/NNS ]/) 
AB/LS -/: The/DT numbers/NNS of/IN estrogen/NN receptor/NN (/( ER/NN )/) in/IN human/JJ peripheral/JJ leucocytes/NNS in/IN 22/CD women/NNS with/IN climacteric/JJ syndrome/NN were/VBD measured/VBN by/IN radioligand/NN method/NN ./. 
The/DT results/NNS were/VBD compared/VBN with/IN those/DT of/IN 12/CD normal/JJ child-bearing-age/JJ women/NNS ./. 
It/PRP wat/VBD found/VBN that/IN the/DT contents/NNS of/IN leucocytic/JJ ER/NN in/IN climacteric/JJ syndrome/NN patients/NNS were/VBD significantly/RB lower/JJR than/IN normal/JJ child-bearing-age/JJ women/NNS ./. 
The/DT authors/NNS used/VBD a/DT Chinese/JJ prescription/NN --/: Liuwei/FW Dihuang/FW Pills/NNS (/( LDP/NN )/) to/TO treat/VB the/DT patients/NNS for/IN 2/CD months/NNS ./. 
The/DT numbers/NNS of/IN leucocytic/JJ ER/NN were/VBD significantly/RB increased/VBN after/IN treatment/NN ./. 
The/DT data/NNS indicate/VBP that/IN decrease/NN of/IN ER/NN levels/NNS in/IN cell/NN may/MD involve/VB in/IN the/DT pathogenesis/NN of/IN climacteric/JJ syndrome/NN ./. 
LDP/NN not/RB only/RB increases/VBZ plasma/NN estradiol/NN levels/NNS ,/, but/CC also/RB increases/VBZ the/DT leucocytic/JJ ER/NN levels/NNS ./. 
This/DT may/MD be/VB the/DT basis/NN of/IN the/DT therapeutic/JJ effect/NN on/IN the/DT disease/NN ./. 
UI/LS -/: 92049367/CD 
TI/LS -/: Evaluation/NN of/IN the/DT role/NN of/IN ligand/NN and/CC thermal/JJ activation/NN of/IN specific/JJ DNA/NN binding/NN by/IN in/FW vitro/FW synthesized/VBN human/JJ glucocorticoid/NN receptor/NN ./. 
AB/LS -/: We/PRP have/VBP used/VBN a/DT DNA-binding/immunoprecipitation/JJ assay/NN to/TO analyze/VB the/DT capacity/NN of/IN human/JJ glucocorticoid/NN receptor/NN (/( hGR/NN )/) ,/, generated/VBN in/IN rabbit/NN reticulocyte/NN lysates/NNS ,/, to/TO bind/VB DNA/NN ./. 
In/FW vitro/FW translated/VBN hGR/NN was/VBD indistinguishable/JJ from/IN native/JJ hGR/NN ,/, as/IN determined/VBN by/IN migration/NN on/IN sodium/NN dodecyl/NN sulfate-polyacrylamide/JJ gels/NNS ,/, sedimentation/NN on/IN sucrose/NN density/NN gradients/NNS ,/, and/CC reactivity/NN with/IN antipeptide/JJ antibodies/NNS generated/VBN against/IN hGR/NN ./. 
In/IN addition/NN ,/, cell-free/JJ synthesized/VBN hGR/NN was/VBD capable/JJ of/IN specific/JJ binding/NN to/TO glucocorticoid/NN response/NN element/NN (/( GRE/NN )/) -containing/JJ DNA/NN fragments/NNS ./. 
Using/VBG this/DT assay/NN system/NN ,/, we/PRP have/VBP evaluated/VBN the/DT contributions/NNS of/IN ligand/NN binding/NN and/CC heat/NN activation/NN to/TO DNA/NN binding/NN by/IN these/DT glucocorticoid/NN receptors/NNS ./. 
In/FW vitro/FW translated/VBN hGR/NN was/VBD capable/JJ of/IN selective/JJ DNA/NN binding/NN even/RB in/IN the/DT absence/NN of/IN glucocorticoid/NN ./. 
Treatment/NN with/IN dexamethasone/NN or/CC the/DT antiglucocorticoid/JJ RU486/NN had/VBD no/DT additional/JJ effect/NN on/IN the/DT DNA-binding/JJ capacity/NN when/WRB receptor/NN preparations/NNS were/VBD maintained/VBN at/IN 0/CD C/NN (/( no/DT activation/NN )/) ./. 
In/IN contrast/NN ,/, addition/NN of/IN either/CC ligand/NN or/CC antagonist/NN in/IN combination/NN with/IN a/DT heat/NN activation/NN step/NN promoted/VBD DNA/NN binding/NN by/IN approximately/RB 3-fold/RB over/IN that/DT of/IN heat-activated/JJ unliganded/JJ receptors/NNS ./. 
Agonist/NN (/( dexamethasone/NN )/) was/VBD slightly/RB more/JJR effective/JJ in/IN supporting/VBG specific/JJ DNA/NN binding/NN than/IN antagonist/NN (/( RU486/NN )/) ./. 
DNA/NN binding/NN by/IN in/FW vitro/FW synthesized/VBN GR/NN was/VBD blocked/VBN by/IN the/DT addition/NN of/IN sodium/NN molybdate/NN to/TO the/DT receptor/NN preparations/NNS before/IN steroid/NN addition/NN and/CC thermal/JJ activation/NN ./. 
Addition/NN of/IN KCl/NN resulted/VBD in/IN less/RBR DNA/NN binding/NN either/CC due/JJ to/TO blockage/NN of/IN DNA-receptor/JJ complex/NN formation/NN or/CC disruption/NN of/IN the/DT complexes/NNS ./. 
The/DT specificity/NN of/IN DNA/NN binding/NN by/IN cell-free/JJ synthesized/VBN hGR/NN was/VBD analyzed/VBN further/RB by/IN examining/VBG the/DT abilities/NNS of/IN various/JJ DNAs/NNS to/TO compete/VB for/IN binding/VBG to/TO a/DT naturally/RB occurring/VBG GRE/NN found/VBD in/IN the/DT mouse/NN mammary/JJ tumor/NN virus-long/JJ terminal/JJ repeat/NN ./. 
Oligonucleotides/NNS containing/VBG the/DT consensus/NN GRE/NN were/VBD the/DT most/RBS efficient/JJ competitors/NNS ,/, and/CC fragments/NNS containing/VBG regulatory/JJ sequences/NNS from/IN glucocorticoid-repressible/JJ genes/NNS were/VBD somewhat/RB competitive/JJ ,/, whereas/IN single/JJ stranded/JJ oligonucleotides/NNS were/VBD unable/JJ to/TO compete/VB for/IN mouse/NN mammary/JJ tumor/NN virus-long/JJ terminal/JJ repeat/NN DNA/NN binding/NN ,/, except/IN when/WRB competitor/NN was/VBD present/JJ at/IN extremely/RB high/JJ concentrations/NNS ./. 
Together/RB these/DT studies/NNS indicate/VBP that/IN hGR/NN synthesized/VBN in/IN rabbit/NN reticulocyte/NN lysates/NNS displays/VBZ many/JJ of/IN the/DT same/JJ properties/NNS ,/, including/VBG GRE-specific/JJ DNA/NN binding/NN ,/, observed/VBN for/IN glucocorticoid/NN receptor/NN present/JJ in/IN cytosolic/JJ extracts/NNS of/IN mammalian/JJ cells/NNS and/CC tissues/NNS ./. 
Similarities/NNS between/IN the/DT effects/NNS of/IN dexamethasone/NN and/CC RU486/NN suggest/VBP that/IN the/DT antiglucocorticoid/JJ properties/NNS of/IN RU486/NN do/VBP not/RB occur/VB at/IN the/DT level/NN of/IN specific/JJ DNA/NN binding/NN ./. 
UI/LS -/: 91264362/CD 
TI/LS -/: Expression/NN of/IN 1,25(OH)2D3/NN receptors/NNS on/IN alveolar/JJ lymphocytes/NNS from/IN patients/NNS with/IN pulmonary/JJ granulomatous/JJ diseases/NNS ./. 
AB/LS -/: 1,25(OH)2D3/NN is/VBZ known/VBN to/TO be/VB produced/VBN at/IN sites/NNS of/IN granulomatous/JJ reactions/NNS ./. 
In/IN order/NN to/TO characterize/VB the/DT cell/NN types/NNS that/WDT are/VBP targets/NNS for/IN this/DT immunoregulatory/JJ hormone/NN ,/, we/PRP have/VBP evaluated/VBN the/DT expression/NN of/IN 1,25(OH)2D3/NN receptors/NNS on/IN peripheral/JJ blood/NN T-lymphocytes/NNS and/CC those/DT recovered/VBN from/IN the/DT lung/NN by/IN bronchoalveolar/JJ lavage/NN from/IN patients/NNS with/IN pulmonary/JJ granulomatous/JJ diseases/NNS (/( tuberculosis/NN and/CC sarcoidosis/NN )/) and/CC from/IN normal/JJ control/NN subjects/NNS using/VBG combined/JJ autoradiographic/JJ and/CC immunohistochemical/JJ techniques/NNS ./. 
Lavage/NN T-lymphocytes/NNS from/IN patients/NNS with/IN tuberculosis/NN or/CC with/IN sarcoidosis/NN ,/, but/CC not/RB those/DT from/IN normal/JJ control/NN subjects/NNS ,/, expressed/VBD 1,25(OH)2D3/NN receptors/NNS as/IN demonstrated/VBN by/IN binding/NN of/IN [3H]1,25(OH)2D3/NN ,/, which/WDT was/VBD inhibited/VBN by/IN the/DT presence/NN of/IN excess/JJ unlabeled/JJ 1,25(OH)2D3/NN ,/, but/CC not/RB by/IN the/DT presence/NN of/IN unlabeled/JJ 25/CD (/( OH/NN )/) D3/NN (/( receptor-positive/JJ lymphocytes/NNS :/: sarcoidosis/NN ,/, 20/CD +/-/CC 12/CD %/NN ;/: tuberculosis/NN ,/, 31/CD +/-/CC 17/CD %/NN )/) ./. 
In/IN contrast/NN ,/, blood/NN lymphocytes/NNS from/IN patients/NNS with/IN granulomatous/JJ diseases/NNS did/VBD not/RB express/VB detectable/JJ 1,25(OH)2D3/NN receptors/NNS ./. 
The/DT percentage/NN of/IN lavage/NN T-lymphocytes/NNS expressing/VBG 1,25(OH)2D3/NN receptors/NNS was/VBD significantly/RB greater/JJR for/IN patients/NNS with/IN tuberculosis/NN presenting/VBG with/IN isolated/VBN hilar/JJ adenopathy/JJ than/IN for/IN patients/NNS with/IN pulmonary/JJ infiltrates/NNS and/or/CC cavities/NNS ./. 
1,25(OH)2D3/NN receptors/NNS were/VBD expressed/VBN to/TO a/DT greater/JJR extent/NN on/IN CD8+/JJ T-lymphocytes/NNS than/IN on/IN CD4+/JJ T-lymphocytes/NNS in/IN sarcoidosis/NN ,/, whereas/IN a/DT greater/JJR proportion/NN of/IN CD4+/JJ than/IN of/IN CD8+/JJ T-lymphocytes/NNS from/IN patients/NNS with/IN tuberculosis/NN were/VBD receptor-positive/JJ ./. 
These/DT findings/NNS support/VBP the/DT conclusion/NN that/IN the/DT interaction/NN of/IN 1,25(OH)2D3/NN with/IN its/PRP$ receptor/NN on/IN T-lymphocytes/NNS may/MD play/VB an/DT important/JJ role/NN in/IN the/DT regulation/NN of/IN granulomatous/JJ reactions/NNS ,/, but/CC because/IN these/DT receptors/NNS are/VBP expressed/VBN on/IN different/JJ lymphocyte/NN populations/NNS ,/, the/DT net/JJ effect/NN of/IN this/DT potent/JJ immunoregulatory/JJ molecule/NN is/VBZ likely/RB different/JJ in/IN sarcoidosis/NN and/CC tuberculosis/NN ./. 
UI/LS -/: 91219488/CD 
TI/LS -/: Role/NN for/IN the/DT Epstein-Barr/JJ virus/NN nuclear/JJ antigen/NN 2/CD in/IN viral/JJ promoter/NN switching/VBG during/IN initial/JJ stages/NNS of/IN infection/NN ./. 
AB/LS -/: During/IN latent/JJ Epstein-Barr/JJ virus/NN (/( EBV/NN )/) infection/NN of/IN human/JJ B/NN lymphocytes/NNS ,/, six/CD viral/JJ nuclear/JJ antigen/NN (/( EBNAs/NNS )/) are/VBP expressed/VBN from/IN long/JJ primary/JJ transcripts/NNS by/IN means/NNS of/IN alternative/JJ splicing/NN and/CC alternative/JJ polyadenylylation/NN sites/NNS ./. 
These/DT transcripts/NNS initiate/VBP from/IN one/CD of/IN two/CD promoters/NNS ,/, Cp/NN or/CC Wp/NN ,/, that/WDT function/VBP in/IN a/DT mutually/RB exclusive/JJ fashion/NN ./. 
Wp/NN is/VBZ exclusively/RB utilized/VBN during/IN the/DT initial/JJ stages/NNS of/IN infection/NN of/IN primary/JJ B/NN lymphocytes/NNS ,/, followed/VBN by/IN a/DT switch/NN to/TO Cp/NN usage/NN ./. 
These/DT studies/NNS have/VBP been/VBN extended/VBN to/TO show/VB that/IN (/( i/LS )/) a/DT mutant/JJ EBV/NN strain/NN lacking/VBG the/DT gene/NN encoding/VBG EBNA/NN 2/CD fails/VBZ to/TO switch/VB from/IN Wp/NN to/TO Cp/NN usage/NN in/IN primary/JJ B/NN lymphocytes/NNS ,/, although/IN the/DT virus/NN contains/VBZ a/DT functional/JJ Cp/NN ;/: (/( ii/LS )/) a/DT region/NN from/IN -429/CD to/TO -245/CD base/NN pairs/NNS upstream/JJ of/IN Cp/NN is/VBZ essential/JJ for/IN Cp/NN activity/NN in/IN B/NN lymphocytes/NNS ,/, but/CC only/RB in/IN the/DT context/NN of/IN upstream/JJ and/CC downstream/JJ sequences/NNS ;/: (/( iii/LS )/) this/DT region/NN contains/VBZ an/DT EBNA/NN 2-dependent/JJ enhancer/NN ;/: and/CC (/( iv/LS )/) DNase/NN I/CD protection/NN employing/VBG nuclear/JJ extracts/NNS from/IN B/NN and/CC T/NN lymphocytes/NNS revealed/VBD a/DT B-cell-specific/JJ footprint/NN in/IN the/DT region/NN of/IN the/DT EBNA/NN 2-dependent/JJ enhancer/NN ./. 
These/DT results/NNS support/VBP a/DT model/NN for/IN viral/JJ promoter/NN switching/NN during/IN the/DT initial/JJ stages/NNS of/IN infection/NN in/IN which/WDT Wp/NN activity/NN leads/VBZ to/TO the/DT expression/NN of/IN EBNA/NN 2/CD ,/, followed/VBN by/IN activation/NN of/IN Cp/NN through/IN the/DT EBNA/NN 2-dependent/JJ enhancer/NN ./. 
UI/LS -/: 91184714/CD 
TI/LS -/: Immune/JJ response/NN of/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS to/TO HBx-antigen/NN of/IN hepatitis/NN B/NN virus/NN ./. 
AB/LS -/: The/DT hepatitis/NN B/NN virus/NN genome/NN encodes/VBZ a/DT transcriptional/JJ transactivator/NN protein/NN designated/VBN HBxAg/NN ./. 
We/PRP have/VBP investigated/VBN whether/IN this/DT antigen/NN is/VBZ a/DT target/NN structure/NN for/IN human/JJ T-lymphocytes/NNS ./. 
Using/VBG recombinant/JJ HBxAg/NN protein/NN ,/, we/PRP found/VBD HBxAg-specific/JJ stimulation/NN of/IN peripheral/JJ blood/NN mononuclear/JJ cells/NNS in/IN patients/NNS with/IN acute/JJ hepatitis/NN B/NN virus/NN infection/NN (/( 6/CD of/IN 6/CD )/) and/CC chronic/JJ hepatitis/NN B/NN virus/NN infection/NN (/( 6/CD of/IN 17/CD )/) but/CC not/RB in/IN healthy/JJ individuals/NNS ./. 
With/IN HBxAg-specific/JJ synthetic/JJ polypeptides/NNS ,/, several/JJ T-cell/NN epitopes/NNS were/VBD identified/VBN ./. 
Most/JJS were/VBD located/JJ in/IN the/DT carboxyterminal/JJ half/NN of/IN the/DT HBxAg/NN protein/NN ./. 
Five/CD T-cell/NN clones/NNS specific/JJ for/IN a/DT T-cell/NN epitope/NN located/JJ at/IN the/DT carboxyterminal/JJ region/NN of/IN HBxAg/NN were/VBD established/VBN and/CC found/VBN to/TO belong/VB to/TO the/DT CD2/CD4-positive/JJ ,/, CD8-negative/JJ subtype/NN ./. 
These/DT data/NNS establish/VBP for/IN the/DT first/JJ time/NN HBxAg/NN as/IN an/DT antigen/NN in/IN the/DT cellular/JJ immune/JJ response/NN ./. 
UI/LS -/: 91339573/CD 
TI/LS -/: [/( Changes/NNS in/IN leucocytic/JJ estrogen/NN receptor/NN levels/NNS in/IN patients/NNS with/IN gynecomastia/NN ]/) 
AB/LS -/: The/DT number/NN of/IN estrogen/NN receptor/NN (/( ER/NN )/) in/IN human/JJ peripheral/JJ leucocytes/NNS in/IN 13/CD men/NNS with/IN gynecomastia/NNS were/VBD measured/VBN by/IN radioligand/NN binding/NN method/NN ./. The/DT results/NNS were/VBD compared/VBN with/IN those/DT of/IN 13/CD sex-/NN and/CC age-matched/JJ healthy/JJ subjects/NNS ./. 
It/PRP was/VBD found/VBN that/IN the/DT number/NN of/IN ER/NN in/IN leucocytes/NNS was/VBD significantly/RB increased/VBN in/IN gynecomastia/NN (/( Rs/NN of/IN leucocytes/NNS were/VBD 1054/CD +/-/CC 254/CD sites/cell/NN )/) ./. 
It/PRP suggested/VBD that/IN increase/NN of/IN ER/NN levels/NNS play/VBP an/DT important/JJ role/NN in/IN the/DT pathogenesis/NN of/IN gynecomastia/NN ./. 
UI/LS -/: 91101115/CD 
TI/LS -/: The/DT NF/NN kappa/NN B/NN independent/JJ cis-acting/JJ sequences/NNS in/IN HIV-1/NN LTR/NN responsive/NN to/TO T-cell/NN activation/NN ./. 
AB/LS -/: The/DT rate/NN of/IN transcription/NN initiation/NN directed/VBN by/IN the/DT long/JJ terminal/JJ repeat/NN (/( LTR/NN )/) of/IN HIV-1/NN increases/VBZ in/IN response/NN to/TO mitogenic/JJ stimuli/NNS of/IN T/NN cells/NNS ./. 
Here/RB we/PRP show/VBP that/IN the/DT response/NN of/IN the/DT HIV-1/NN LTR/NN may/MD be/VB governed/VBN by/IN two/CD independent/JJ sequences/NNS located/JJ 5'/JJ to/TO the/DT site/NN of/IN transcription/NN initiation/NN sequences/NNS that/WDT bind/VBP either/CC NFAT-1/NN or/CC NF/NN kappa/NN B/NN ./. 
The/DT rate/NN of/IN LTR-directed/JJ gene/NN expression/NN increased/VBD in/IN response/NN to/TO treatment/NN with/IN either/CC a/DT phorbol/NN ester/NN or/CC tumor/NN necrosis/NN factor/NN alpha/NN if/IN either/CC the/DT NFAT-1/NN or/CC NF/NN kappa/NN B/NN binding/NN sites/NNS were/VBD deleted/VBN ,/, but/CC failed/VBD to/TO respond/VB to/TO these/DT mitogenic/JJ stimuli/NNS if/IN both/DT sequences/NNS were/VBD absent/JJ ./. 
The/DT HIV-1/NN mutant/JJ virus/NN containing/VBG both/CC NF/NN kappa/NN B/NN and/CC NFAT-1/NN deletion/NN was/VBD able/JJ to/TO replicate/VB although/IN at/IN a/DT much/JJ decreased/VBN growth/NN rate/NN ,/, while/IN the/DT deletion/NN of/IN NFAT-1/NN alone/RB increased/VBD the/DT viral/JJ growth/NN rate/NN in/IN Jurkat/NN cells/NNS ./. 
Neither/CC deletion/NN of/IN NF/NN kappa/NN B/NN nor/CC deletion/NN of/IN NFAT-1/NN decreased/VBD activation/NN of/IN viral/JJ replication/NN by/IN phorbol/NN ester/NN ./. 
UI/LS -/: 92052243/CD 
TI/LS -/: cAMP-dependent/JJ regulation/NN of/IN proenkephalin/NN by/IN JunD/NN and/CC JunB/NN :/: positive/JJ and/CC negative/JJ effects/NNS of/IN AP-1/NN proteins/NNS ./. 
AB/LS -/: We/PRP demonstrate/VBP that/IN JunD/NN ,/, a/DT component/NN of/IN the/DT AP-1/NN transcription/NN factor/NN complex/NN ,/, activates/VBZ transcription/NN of/IN the/DT human/JJ proenkephalin/NN gene/NN in/IN a/DT fashion/NN that/WDT is/VBZ completely/RB dependent/JJ upon/IN the/DT cAMP-dependent/JJ protein/NN kinase/NN ,/, protein/NN kinase/NN A/NN ./. 
Activation/NN of/IN proenkephalin/NN transcription/NN by/IN JunD/NN is/VBZ dependent/JJ upon/IN a/DT previously/RB characterized/VBN cAMP-/NN ,/, phorbol/NN ester-/NN ,/, and/CC Ca(2+)-inducible/JJ enhancer/NN ,/, and/CC JunD/NN is/VBZ shown/VBN to/TO bind/VB the/DT enhancer/NN as/IN a/DT homodimer/NN ./. 
Another/DT component/NN of/IN the/DT AP-1/NN transcription/NN complex/NN ,/, JunB/NN ,/, is/VBZ shown/VBN to/TO inhibit/VB activation/NN mediated/VBN by/IN JunD/NN ./. 
As/IN a/DT homodimer/NN JunB/NN is/VBZ unable/JJ to/TO bind/VB the/DT enhancer/NN ;/: however/RB in/IN the/DT presence/NN of/IN c-Fos/NN ,/, high-affinity/JJ binding/NN is/VBZ observed/VBN ./. 
Furthermore/RB ,/, JunD/NN is/VBZ shown/VBN to/TO activate/VB transcription/NN of/IN genes/NNS linked/VBN to/TO both/CC cAMP/NN and/CC phorbol/NN ester/NN response/NN elements/NNS in/IN a/DT protein/NN kinase/NN A-dependent/JJ fashion/NN ,/, further/RB blurring/VBG the/DT distinction/NN between/IN these/DT response/NN elements/NNS ./. 
These/DT results/NNS demonstrate/VBP that/IN the/DT transcriptional/JJ activity/NN of/IN an/DT AP-1-related/JJ protein/NN is/VBZ regulated/VBN by/IN the/DT cAMP-dependent/JJ second-messenger/NN pathway/NN and/CC suggest/VBP that/IN JunD/NN and/CC other/JJ AP-1-related/JJ proteins/NNS may/MD play/VB an/DT important/JJ role/NN in/IN the/DT regulation/NN of/IN gene/NN expression/NN by/IN cAMP-dependent/JJ intracellular/JJ signaling/NN pathways/NNS ./. 
UI/LS -/: 92257680/CD 
TI/LS -/: [/( Plasma/NN cortisol/NN concentration/NN and/CC blood/NN leukocyte/NN content/NN of/IN glucocorticoid/NN receptors/NNS in/IN patients/NNS with/IN deficiency-cold/JJ vs/CC deficiency-heat/JJ syndromes/NNS ]/) 
AB/LS -/: Plasma/NN cortisol/NN concentration/NN and/CC blood/NN leukocyte/NN content/NN of/IN glucocorticoid/NN receptors/NNS (/( GCR/NN )/) were/VBD assayed/VBN in/IN 20/CD patients/NNS with/IN deficiency/NN syndromes/NNS ,/, 10/CD cold/JJ in/IN property/NN (/( deficiency-cold/JJ )/) ,/, the/DT other/JJ 10/CD hot/JJ in/IN property/NN (/( deficiency-heat/JJ )/) ,/, and/CC also/RB in/IN 10/CD healthy/JJ individuals/NNS as/IN normal/JJ control/NN for/IN the/DT purpose/NN of/IN investigating/VBG the/DT nature/NN of/IN cold/NN and/CC heat/NN syndromes/NNS ./. 
As/IN a/DT result/NN ,/, the/DT cases/NNS of/IN deficiency-cold/JJ syndrome/NN (/( DCS/NN )/) had/VBD a/DT normal/JJ concentration/NN of/IN plasma/NN cortisol/NN but/CC a/DT lowered/JJ content/NN of/IN GCR/NN in/IN leukocytes/NNS when/WRB compared/VBN with/IN the/DT normal/JJ control/NN (/( P/NN less/JJR than/IN 0.05/CD )/) ;/: the/DT cases/NNS of/IN deficiency-heat/JJ syndrome/NN (/( DHS/NN )/) had/VBD a/DT higher/JJR concentration/NN of/IN plasma/NN cortisol/NN than/IN the/DT normal/JJ control/NN (/( P/NN less/JJR than/IN 0.05/CD )/) and/CC a/DT slightly/RB higher/JJR content/NN of/IN GCR/NN in/IN leukocytes/NNS ./. 
It/PRP was/VBD concluded/VBN that/IN the/DT DCS/NN is/VBZ characterized/VBN by/IN diminished/VBN biological/JJ effects/NNS of/IN adrenocortical/JJ activity/NN ,/, while/IN the/DT DHS/NN ,/, by/IN augmented/JJ biological/JJ effects/NNS of/IN adrenocortical/JJ activity/NN ./. 
UI/LS -/: 92088960/CD 
TI/LS -/: The/DT role/NN of/IN jun/NN and/CC fos/NN gene/NN family/NN members/NNS in/IN 12-O-tetradecanoylphorbol-13-acetate/NN induced/VBD hemopoietic/JJ differentiation/NN ./. 
AB/LS -/: Terminal/JJ differentiation/NN of/IN the/DT leukemic/JJ cell/NN lines/NNS U-937/NN and/CC HL-60/NN by/IN 12-O-tetradecanoylphorbol-13-acetate/NN is/VBZ accompanied/VBN by/IN marked/JJ changes/NNS in/IN gene/NN expression/NN ./. 
In/IN this/DT study/NN ,/, we/PRP demonstrate/VBP that/IN the/DT expression/NN of/IN jun/NN and/CC fos/NN gene/NN family/NN members/NNS is/VBZ induced/VBN with/IN variable/JJ kinetics/NNS during/IN 12-O-tetradecanoylphorbol-13-acetate/NN induced/VBD differentiation/NN ,/, with/IN c-jun/NN expression/NN best/RB paralleling/JJ differentiation/NN ./. 
The/DT generation/NN of/IN AP-1/NN complexes/NNS ,/, as/IN measured/VBN by/IN DNA/NN binding/NN activity/NN ,/, closely/RB parallels/VBZ morphological/JJ differentiation/NN ./. 
Furthermore/RB ,/, the/DT ability/NN of/IN these/DT complexes/NNS to/TO regulate/VB gene/NN expression/NN is/VBZ demonstrated/VBN by/IN increased/VBN transcription/NN from/IN an/DT AP-1/NN driven/VBN reporter/NN construct/NN and/CC marked/JJ increases/NNS in/IN the/DT expression/NN of/IN endogenous/JJ AP-1/NN regulated/JJ genes/NNS ./. 
Differentiation/NN assays/NNS using/VBG water/NN soluble/JJ phorbol/NN esters/NNS reveal/VBP that/IN differentiation/NN becomes/VBZ irreversible/JJ soon/RB after/IN AP-1/NN appears/VBZ ./. 
This/DT tight/JJ correlation/NN between/IN c-jun/NN expression/NN ,/, the/DT generation/NN of/IN AP-1/NN activity/NN ,/, and/CC differentiation/NN suggests/VBZ a/DT critical/JJ role/NN for/IN this/DT gene/NN and/CC transcriptional/JJ complex/NN during/IN this/DT process/NN ./. 
UI/LS -/: 91351285/CD 
TI/LS -/: Nuclear/JJ association/NN of/IN a/DT T-cell/NN transcription/NN factor/NN blocked/VBN by/IN FK-506/NN and/CC cyclosporin/NN A/NN [/( see/VB comments/NNS ]/) 
AB/LS -/: Cyclosporin/NN A/NN and/CC FK506/NN inhibit/VBP T-/NN and/CC B-cell/NN activation/NN and/CC other/JJ processes/NNS essential/JJ to/TO an/DT effective/JJ immune/JJ response/NN ./. 
In/IN T/NN lymphocytes/NNS these/DT drugs/NNS disrupt/VBP an/DT unknown/JJ step/NN in/IN the/DT transmission/NN of/IN signals/NNS from/IN the/DT T-cell/NN antigen/NN receptor/NN to/TO cytokine/NN genes/NNS that/WDT coordinate/VBP the/DT immune/JJ response/NN ./. 
The/DT putative/JJ intracellular/JJ receptors/NNS for/IN FK506/NN and/CC cyclosporin/NN are/VBP cis-trans/JJ prolyl/JJ isomerases/NNS ./. 
Binding/NN of/IN the/DT drug/NN inhibits/VBZ isomerase/NN activity/NN ,/, but/CC studies/NNS with/IN other/JJ prolyl/JJ isomerase/NN inhibitors/NNS and/CC analysis/NN of/IN cyclosporin-resistant/JJ mutants/NNS in/IN yeast/NN suggest/VBP that/IN the/DT effects/NNS of/IN the/DT drug/NN result/VBP from/IN the/DT formation/NN of/IN an/DT inhibitory/JJ complex/NN between/IN the/DT drug/NN and/CC isomerase/NN ,/, and/CC not/RB from/IN inhibition/NN of/IN isomerase/NN activity/NN ./. 
A/DT transcription/NN factor/NN ,/, NF-AT/NN ,/, which/WDT is/VBZ essential/JJ for/IN early/JJ T-cell/NN gene/NN activation/NN ,/, seems/VBZ to/TO be/VB a/DT specific/JJ target/NN of/IN cyclosporin/NN A/NN and/CC FK506/NN action/NN because/IN transcription/NN directed/VBN by/IN this/DT protein/NN is/VBZ blocked/VBN in/IN T/NN cells/NNS treated/VBN with/IN these/DT drugs/NNS ,/, with/IN little/JJ or/CC no/DT effect/NN on/IN other/JJ transcription/NN factors/NNS such/JJ as/IN AP-1/NN and/CC NF-kappa/NN B/NN ./. 
Here/RB we/PRP demonstrate/VBP that/IN NF-AT/NN is/VBZ formed/VBN when/WRB a/DT signal/NN from/IN the/DT antigen/NN receptor/NN induces/VBZ a/DT pre-existing/JJ cytoplasmic/JJ subunit/NN to/TO translocate/VB to/TO the/DT nucleus/NN and/CC combine/VB with/IN a/DT newly/RB synthesized/VBN nuclear/JJ subunit/NN of/IN NF-AT/NN ./. 
FK506/NN and/CC cyclosporin/NN A/NN block/VBP translocation/NN of/IN the/DT cytoplasmic/JJ component/NN without/IN affecting/VBG synthesis/NN of/IN the/DT nuclear/JJ subunit/NN ./. 
UI/LS -/: 91364264/CD 
TI/LS -/: Glucocorticoid/NN receptors/NNS in/IN lymphocytes/NNS in/IN anorexia/NN nervosa/NN ./. 
AB/LS -/: OBJECTIVE/NN :/: The/DT aim/NN was/VBD to/TO explore/VB the/DT down-regulation/NN of/IN the/DT glucocorticoid/NN receptors/NNS during/IN hypercortisolaemia/NN in/IN anorexia/NN nervosa/NN ./. 
DESIGN/NN :/: Urine/NN and/CC plasma/NN samples/NNS were/VBD obtained/VBN for/IN cortisol/NN determination/NN and/CC blood/NN lymphocytes/NNS were/VBD isolated/VBN for/IN receptor/NN binding/NN studies/NNS ./. 
PATIENTS/NNS :/: Sixteen/CD anorexic/JJ patients/NNS ,/, aged/JJ 16-27/CD years/NNS ,/, with/IN a/DT mean/NN +/-/CC SEM/NN body/NN mass/NN index/NN of/IN 14.2/CD +/-/CC 2.0/CD (/( ranging/VBG from/IN 11.1/CD to/TO 17.4/CD )/) ,/, and/CC 15/CD normal/JJ women/NNS were/VBD studied/VBN ./. 
Six/CD patients/NNS were/VBD reinvestigated/VBN after/IN a/DT significant/JJ weight/NN gain/NN ./. 
MEASUREMENTS/NNS :/: The/DT binding/NN capacity/NN and/CC affinity/NN of/IN the/DT glucocorticoid/NN receptors/NNS were/VBD measured/VBN with/IN dexamethasone/NN as/IN ligand/NN on/IN lymphocytes/NNS ./. 
RESULTS/NNS :/: In/IN patients/NNS ,/, both/DT total/JJ and/CC free/JJ plasma/NN cortisol/NN concentrations/NNS were/VBD higher/JJR than/IN in/IN the/DT normal/JJ women/NNS ,/, as/IN was/VBD their/PRP$ urinary/JJ free/JJ cortisol/NN ;/: the/DT number/NN of/IN glucocorticoid/NN receptors/NNS per/IN cell/NN (/( Ro/NN )/) and/CC the/DT binding/NN affinity/NN (/( Kd/NN )/) for/IN dexamethasone/NN were/VBD ,/, however/RB ,/, not/RB significantly/RB different/JJ (/( Ro/NN :/: 7687/CD +/-/CC 1750/CD vs/CC 7347/CD +/-/CC 1285/CD sites/cell/NN ;/: Kd/NN :/: 7.7/CD +/-/CC 2.4/CD vs/CC 7.4/CD +/-/CC 1.7/CD nM/NN at/IN 24/CD degrees/NNS C/NN )/) ./. 
After/IN weight/NN gain/NN (/( 14/CD +/-/CC 2/CD to/TO 16/CD +/-/CC 2/CD kg/m2/NN )/) ,/, receptor/NN numbers/NNS were/VBD 8421/CD +/-/CC 2126/CD (/( pre/JJ|RB )/) and/CC 9011/CD +/-/CC 500/CD (/( post/JJ|RB )/) sites/cell/NN ,/, which/WDT are/VBP not/RB significantly/RB different/JJ (/( P/NN greater/JJR than/IN 0.2/CD )/) ;/: the/DT Kd/NN was/VBD unchanged/JJ (/( 9.3/CD +/-/CC 2.6/CD vs/CC 9.2/CD +/-/CC 2.4/CD nM/NN )/) ./. 
CONCLUSIONS/NNS Hypercortisolaemia/NN does/VBZ not/RB down-regulate/VB the/DT lymphocyte/NN glucocorticoid/NN receptors/NNS in/IN anorexia/NN nervosa/NN and/CC a/DT post-receptor/JJ defect/NN might/MD be/VB involved/VBN in/IN peripheral/JJ tissue/NN resistance/NN to/TO the/DT effects/NNS of/IN glucocorticoid/NN hormones/NNS in/IN undernutrition/NN ./. 
UI/LS -/: 91236696/CD 
TI/LS -/: Inhibition/NN of/IN protein/NN phosphatases/NNS by/IN okadaic/JJ acid/NN induces/VBZ AP1/NN in/IN human/JJ T/NN cells/NNS ./. 
AB/LS -/: To/TO examine/VB the/DT role/NN of/IN protein/NN phosphatases/NNS in/IN T/NN cell/NN activation/NN ,/, Jurkat/NN cells/NNS were/VBD treated/VBN with/IN okadaic/JJ acid/NN ,/, an/DT inhibitor/NN of/IN type/NN 1/CD and/CC 2A/NN phosphatases/NNS ,/, and/CC nuclear/JJ extracts/NNS were/VBD examined/VBN for/IN the/DT presence/NN of/IN AP1/NN as/IN a/DT measure/NN of/IN early/JJ T/NN cell/NN activation/NN ./. 
Okadaic/JJ acid/NN was/VBD found/VBN to/TO be/VB a/DT potent/JJ inducer/NN of/IN AP1/NN ./. 
In/IN contrast/NN to/TO phorbol/NN esters/NNS such/JJ as/IN phorbol/NN myristate/NN acetate/NN (/( PMA/NN )/) ,/, the/DT induction/NN of/IN AP1/NN by/IN okadaic/JJ acid/NN occurs/VBZ predominantly/RB by/IN transcriptional/JJ activation/NN of/IN the/DT jun/NN and/CC fos/NN family/NN of/IN proto-oncogenes/NNS ./. 
Surprisingly/RB ,/, while/IN the/DT addition/NN of/IN phytohemagglutinin/NN further/RB enhanced/VBD the/DT induction/NN of/IN AP1/NN ,/, the/DT addition/NN of/IN PMA/NN inhibited/VBD it/PRP ./. 
Okadaic/JJ acid/NN treatment/NN was/VBD found/VBN to/TO dramatically/RB increase/VB mRNA/NN transcripts/NNS of/IN the/DT jun/NN family/NN of/IN proto-oncogenes/NNS including/VBG c-jun/NN ,/, junD/NN ,/, and/CC junB/NN and/CC to/TO a/DT lesser/JJR extent/NN the/DT fos/NN family/NN including/VBG c-fos/NN and/CC fra-1/NN ./. 
By/IN comparison/NN ,/, PMA/NN is/VBZ a/DT very/RB inefficient/JJ inducer/NN of/IN the/DT jun/NN gene/NN family/NN in/IN Jurkat/NN cells/NNS ./. 
Similar/JJ to/TO its/PRP$ effect/NN on/IN the/DT induction/NN of/IN AP1/NN by/IN okadaic/JJ acid/NN ,/, PMA/NN inhibits/VBZ the/DT induction/NN of/IN c-jun/NN mRNA/NN by/IN okadaic/JJ acid/NN ./. 
Transfection/NN of/IN c-jun/NN promoter/NN constructs/NNS confirmed/VBD the/DT marked/JJ difference/NN between/IN PMA/NN and/CC okadaic/JJ acid/NN in/IN inducing/VBG c-jun/NN transcription/NN ./. 
The/DT induction/NN of/IN AP1/NN by/IN okadaic/JJ acid/NN suggests/VBZ that/IN protein/NN phosphatases/NNS 1/CD and/CC 2A/NN (/( PP1/NN and/CC PP2A/NN )/) may/MD be/VB involved/VBN in/IN T/NN cell/NN activation/NN as/IN important/JJ negative/JJ regulators/NNS of/IN the/DT transcription/NN factor/NN AP1/NN ./. 
UI/LS -/: 91217625/CD 
TI/LS -/: Cloning/NN of/IN murine/JJ TCF-1/NN ,/, a/DT T/NN cell-specific/JJ transcription/NN factor/NN interacting/VBG with/IN functional/JJ motifs/NNS in/IN the/DT CD3-epsilon/NN and/CC T/NN cell/NN receptor/NN alpha/NN enhancers/NNS ./. 
AB/LS -/: CD3-epsilon/NN gene/NN expression/NN is/VBZ confined/VBN to/TO the/DT T/NN cell/NN lineage/NN ./. 
We/PRP have/VBP recently/RB identified/VBN and/CC cloned/VBN a/DT human/JJ transcription/NN factor/NN ,/, TCF-1/NN ,/, that/WDT binds/VBZ to/TO a/DT functional/JJ element/NN in/IN the/DT T/NN lymphocyte-specific/JJ enhancer/NN of/IN CD3-epsilon/NN ./. 
In/IN a/DT panel/NN of/IN human/JJ cell/NN lines/NNS ,/, TCF-1/NN expression/NN was/VBD restricted/JJ to/TO T/NN lineage/NN cells/NNS ./. 
TCF-1/NN belonged/VBD to/TO a/DT novel/JJ family/NN of/IN genes/NNS that/WDT contain/VBP the/DT so-called/JJ high/JJ mobility/NN group/NN 1/CD (/( HMG/NN )/) box/NN ./. 
Here/RB we/PRP report/VBP the/DT cloning/NN of/IN murine/JJ TCF-1/NN ./. 
Two/CD splice/NN alternatives/NNS were/VBD identified/VBN that/WDT were/VBD not/RB previously/RB observed/VBN in/IN human/JJ TCF-1/NN ./. 
Murine/JJ and/CC human/JJ TCF-1/NN displayed/VBD a/DT 95.5/CD %/NN overall/JJ amino/NN acid/NN homology/NN ./. 
Recombinant/JJ murine/JJ and/CC human/JJ TCF-1/NN recognized/VBD the/DT same/JJ sequence/NN motif/NN in/IN the/DT CD3-epsilon/NN enhancer/NN as/IN judged/VBN by/IN gel/NN retardation/NN and/CC methylation/NN interference/NN assays/NNS ./. 
With/IN the/DT murine/JJ cDNA/NN clones/NNS several/JJ aspects/NNS of/IN TCF-1/NN were/VBD analyzed/VBN ./. 
First/RB ,/, deletion/NN analysis/NN revealed/VBD that/IN a/DT region/NN of/IN TCF-1/NN containing/VBG the/DT HMG/NN box/NN was/VBD sufficient/JJ for/IN sequence-specific/JJ binding/NN ./. 
Second/RB ,/, by/IN high/JJ stringency/NN Northern/NN blotting/NN and/CC in/FW situ/FW hybridization/NN ,/, TCF-1/NN expression/NN was/VBD shown/VBN to/TO be/VB confined/VBN to/TO the/DT thymus/NN and/CC to/TO the/DT T/NN cell/NN areas/NNS of/IN the/DT spleen/NN ./. 
Third/RB ,/, TCF-1/NN bound/VBD specifically/RB to/TO a/DT functional/JJ T/NN cell-specific/JJ element/NN in/IN the/DT T/NN cell/NN receptor/NN alpha/NN (/( TCR-alpha/NN )/) enhancer/NN ./. 
The/DT T/NN lineage-specific/JJ expression/NN and/CC the/DT affinity/NN for/IN functional/JJ motifs/NNS in/IN the/DT TCR-alpha/NN and/CC CD3-epsilon/NN enhancers/NNS imply/VBP an/DT important/JJ role/NN for/IN TCF-1/NN in/IN the/DT establishment/NN of/IN the/DT mature/JJ T/NN cell/NN phenotype/NN ./. 
UI/LS -/: 91291757/CD 
TI/LS -/: Cloning/NN of/IN a/DT human/JJ homeobox/NN gene/NN that/WDT resembles/VBZ a/DT diverged/JJ Drosophila/NN homeobox/NN gene/NN and/CC is/VBZ expressed/VBN in/IN activated/VBN lymphocytes/NNS ./. 
AB/LS -/: A/DT new/JJ homeobox/NN gene/NN ,/, HB24/NN ,/, has/VBZ been/VBN isolated/VBN from/IN a/DT human/JJ B-lymphocyte/NN cDNA/NN library/NN ./. 
Northern/JJ|NN blot/NN analysis/NN of/IN polyadenylated/JJ RNA/NN purified/VBN from/IN activated/VBN human/JJ B/NN cells/NNS revealed/VBD a/DT single/JJ mRNA/NN transcript/NN of/IN approximately/RB 2.3/CD kb/NN ./. 
Two/CD cDNA/NN clones/NNS were/VBD sequenced/VBN and/CC provided/VBN 2,250/CD nucleotides/NNS (/( nt/NN )/) of/IN DNA/NN sequence/NN information/NN ./. 
There/EX is/VBZ a/DT single/JJ methionine/NN codon-initiated/JJ open/JJ reading/NN frame/NN of/IN 1,458/CD nt/NN in/IN frame/NN with/IN a/DT homeobox/NN and/CC a/DT CAX/NN repeat/NN ,/, and/CC the/DT open/JJ reading/NN frame/NN is/VBZ predicted/VBN to/TO encode/VB a/DT protein/NN of/IN 51,659/CD daltons/NNS ./. 
When/WRB the/DT homeodomain/NN from/IN HB24/NN was/VBD compared/VBN to/TO known/JJ mammalian/JJ and/CC Drosophila/NN homeodomains/NNS it/PRP was/VBD found/VBN to/TO be/VB only/RB moderately/RB conserved/VBN ,/, but/CC when/WRB it/PRP was/VBD compared/VBN to/TO a/DT highly/RB diverged/JJ Drosophila/FW homeodomain/NN ,/, H2.0/NN ,/, it/PRP was/VBD found/VBN to/TO be/VB 80/CD %/NN identical/JJ ./. 
The/DT HB24/NN mRNA/NN was/VBD absent/JJ or/CC present/JJ at/IN low/JJ levels/NNS in/IN normal/JJ B/NN and/CC T/NN lymphocytes/NNS ;/: however/RB ,/, with/IN the/DT appropriate/JJ activation/NN signal/NN HB24/NN mRNA/NN was/VBD induced/VBN within/IN several/JJ hours/NNS even/RB in/IN the/DT presence/NN of/IN cycloheximide/NN ./. 
Characterization/NN of/IN HB24/NN expression/NN in/IN lymphoid/JJ and/CC select/JJ developing/VBG tissues/NNS was/VBD performed/VBN by/IN in/FW situ/FW hybridization/NN ./. 
Positive/JJ hybridization/NN was/VBD found/VBN in/IN thymus/NN ,/, tonsil/NN ,/, bone/NN marrow/NN ,/, developing/VBG vessels/NNS ,/, and/CC in/IN fetal/JJ brain/NN ./. 
HB24/NN is/VBZ likely/JJ to/TO have/VB an/DT important/JJ role/NN in/IN lymphocytes/NNS as/RB well/RB as/IN in/IN certain/JJ developing/VBG tissues/NNS ./. 
UI/LS -/: 91132035/CD 
TI/LS -/: Platelet-activating/JJ factor/NN induces/VBZ phospholipid/JJ turnover/NN ,/, calcium/NN flux/NN ,/, arachidonic/JJ acid/NN liberation/NN ,/, eicosanoid/NN generation/NN ,/, and/CC oncogene/JJ expression/NN in/IN a/DT human/JJ B/NN cell/NN line/NN ./. 
AB/LS -/: Platelet-activating/JJ factor/NN is/VBZ a/DT potent/JJ mediator/NN of/IN the/DT inflammatory/JJ response/NN ./. 
Studies/NNS of/IN the/DT actions/NNS of/IN platelet-activating/JJ factor/NN have/VBP centered/VBN mainly/RB around/IN neutrophils/NNS ,/, monocytes/NNS ,/, and/CC platelets/NNS ./. 
In/IN this/DT report/NN we/PRP begin/VBP to/TO uncover/VB the/DT influence/NN of/IN platelet-activating/NN factor/NN on/IN B/NN lymphocytes/NNS ./. 
Employing/VBG the/DT EBV-transformed/JJ human/JJ B/NN cell/NN line/NN SKW6.4/NN ,/, we/PRP demonstrate/VBP that/IN platelet-activating/JJ factor/NN significantly/RB alters/VBZ membrane/NN phospholipid/JJ metabolism/NN indicated/VBN by/IN the/DT incorporation/NN of/IN 32P/NN into/IN phosphatidylcholine/NN ,/, phosphatidylinositol/NN ,/, and/CC phosphatidic/JJ acid/NN but/CC not/RB significantly/RB into/IN phosphatidylethanolamine/NN at/IN concentrations/NNS ranging/VBG from/IN 10/CD (/( -9/CD )/) to/TO 10/CD (/( -6/CD )/) M/NN ./. 
The/DT inactive/JJ precursor/NN ,/, lyso-platelet-activating/JJ factor/NN ,/, at/IN a/DT concentration/NN as/RB high/JJ as/IN 10/CD (/( -7/CD )/) M/NN had/VBD no/DT effect/NN on/IN any/DT of/IN the/DT membrane/NN phospholipids/NNS ./. 
We/PRP also/RB show/VBP that/IN platelet-activating/JJ factor/NN from/IN 10/CD (/( -12/CD )/) to/TO 10/CD (/( -6/CD )/) M/NN induced/VBD rapid/JJ and/CC significant/JJ elevation/NN in/IN intracellular/JJ calcium/NN levels/NNS ,/, whereas/IN lyso-platelet-activating/JJ factor/NN was/VBD again/RB ineffective/JJ ./. 
We/PRP further/RB demonstrate/VBP the/DT impact/NN of/IN platelet-activating/JJ factor/NN binding/VBG to/TO B/NN cells/NNS by/IN measuring/VBG platelet-activating/JJ factor/NN induced/JJ arachidonic/JJ acid/NN release/NN and/CC 5-hydroxyeicosatetraenoic/JJ acid/NN production/NN ./. 
Moreover/RB ,/, platelet-activating/JJ factor/NN was/VBD capable/JJ of/IN inducing/VBG transcription/NN of/IN the/DT nuclear/JJ proto-oncogenes/NNS c-fos/NN and/CC c-jun/NN ./. 
Finally/RB we/PRP explored/VBD the/DT possible/JJ role/NN of/IN 5-hydroxyeicosatetraenoic/JJ acid/NN as/IN a/DT regulator/NN of/IN arachidonic/JJ acid/NN liberation/NN demonstrating/VBG that/IN endogenous/JJ 5-lipoxygenase/NN activity/NN modulates/VBZ platelet-activating/JJ factor/NN induced/JJ arachidonic/JJ acid/NN release/NN perhaps/RB acting/VBG at/IN the/DT level/NN of/IN phospholipase/NN A2/NN ./. 
In/IN summary/NN ,/, platelet-activating/JJ factor/NN is/VBZ shown/VBN here/RB to/TO have/VB a/DT direct/JJ and/CC profound/JJ effect/NN on/IN a/DT pure/JJ B/NN cell/NN line/NN ./. 
UI/LS -/: 91094881/CD 
TI/LS -/: Positive/JJ and/CC negative/JJ regulation/NN of/IN immunoglobulin/NN gene/NN expression/NN by/IN a/DT novel/JJ B-cell-specific/JJ enhancer/NN element/NN ./. 
AB/LS -/: A/DT new/JJ B-cell-specific/JJ enhancer/NN element/NN has/VBZ been/VBN identified/VBN 3'/JJ of/IN E4/NN and/CC the/DT octamerlike/JJ motifs/NNS in/IN the/DT human/JJ immunoglobulin/NN heavy-chain/NN gene/NN enhancer/NN ./. 
Tandem/JJ copies/NNS of/IN this/DT 67-bp/JJ MnlI-AluI/NN fragment/NN ,/, when/WRB fused/VBN to/TO the/DT chloramphenicol/JJ acetyltransferase/NN gene/NN driven/VBN by/IN the/DT conalbumin/JJ promoter/NN ,/, stimulated/VBD transcription/NN in/IN B/NN cells/NNS but/CC not/RB in/IN Jurkat/NN T/NN cells/NNS or/CC HeLa/NN cells/NNS ./. 
Footprinting/NN analysis/NN revealed/VBD that/IN the/DT identical/JJ sequence/NN CCGAAACTGAAAAGG/NN ,/, designated/VBN E6/NN ,/, was/VBD protected/VBN by/IN nuclear/JJ extracts/NNS from/IN B/NN cells/NNS ,/, T/NN cells/NNS ,/, or/CC HeLa/NN cells/NNS ./. 
Gel/NN mobility/NN shift/NN assays/NNS using/VBG a/DT synthetic/JJ E6/NN motif/NN detected/VBD a/DT B-cell-specific/JJ complex/NN in/IN addition/NN to/TO a/DT ubiquitous/JJ band/NN found/VBN also/RB in/IN T/NN cells/NNS and/CC HeLa/NN cells/NNS ./. 
In/IN agreement/NN with/IN the/DT results/NNS of/IN gel/NN retardation/NN assays/NNS ,/, tandem/JJ copies/NNS of/IN the/DT E6/NN motif/NN stimulated/VBD transcription/NN in/IN ARH77/NN and/CC Raji/NN cells/NNS but/CC not/RB in/IN Jurkat/NN or/CC HeLa/NN cells/NNS ./. 
Furthermore/RB ,/, a/DT mutant/JJ E6/NN motif/NN lost/VBD both/CC in/FW vitro/FW binding/NN activity/NN and/CC in/FW vivo/FW enhancer/NN activity/NN ./. 
In/IN striking/JJ contrast/NN to/TO the/DT mouse/NN Ig/NN heavy-chain/JJ enhancer/NN ,/, in/IN which/WDT the/DT octamer/NN motif/NN acts/VBZ as/IN a/DT B-cell-specific/JJ enhancer/NN element/NN ,/, the/DT human/JJ enhancer/NN contains/VBZ an/DT octamerlike/JJ sequence/NN with/IN one/CD base/NN substitution/NN which/WDT bound/VBD octamer-binding/JJ proteins/NNS with/IN only/RB very/RB low/JJ affinity/NN and/CC showed/VBD no/DT enhancer/NN activity/NN of/IN its/PRP$ own/JJ ./. 
Interestingly/RB ,/, the/DT MnlI-AluI/NN fragment/NN could/MD suppress/VB the/DT basal-level/JJ activity/NN of/IN the/DT conalbumin/JJ promoter/NN in/IN both/CC Jurkat/NN and/CC HeLa/NN cells/NNS ./. 
Moreover/RB ,/, simian/JJ virus/NN 40/CD enhancer/NN activity/NN was/VBD blocked/VBN by/IN the/DT MnlI-AluI/NN fragment/NN in/IN HeLa/NN cells/NNS but/CC not/RB in/IN B/NN cells/NNS ./. 
Thus/RB ,/, the/DT novel/JJ enhancer/NN element/NN identified/VBN in/IN this/DT study/NN is/VBZ probably/RB a/DT target/NN site/NN for/IN both/CC positive/JJ and/CC negative/JJ factors/NNS ./. 
